FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Sonomoto, K
   Yamaoka, K
   Oshita, K
   Fukuyo, S
   Zhang, XM
   Nakano, K
   Okada, Y
   Tanaka, Y
AF Sonomoto, Koshiro
   Yamaoka, Kunihiro
   Oshita, Koichi
   Fukuyo, Shunsuke
   Zhang, Xiangmei
   Nakano, Kazuhisa
   Okada, Yosuke
   Tanaka, Yoshiya
TI Interleukin 1β induces differentiation of human mesenchymal stem cells
   into osteoblasts via the Wnt 5a/receptor tyrosine kinase like orphan
   receptor 2 pathway
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID NECROSIS FACTOR ALPHA; COLLAGEN INDUCED ARTHRITIS; VERSUS HOST DISEASE;
   RHEUMATOID ARTHRITIS; DOUBLE BLIND; EXPRESSION; CANCER; WNT5A; BONE;
   THERAPY
AB Objective Mesenchymal stem cells (MSCs) are considered to be a novel tool for the treatment of rheumatoid arthritis (RA) because of their multipotency to differentiate into osteoblasts and chondrocytes, their immunosuppressive effects, and availability. The aim of this study was to assess the mechanisms of human MSC differentiation into osteoblasts under inflammatory conditions. Methods Human MSCs were cultured in commercialized osteogenic induction medium with inflammatory cytokines for up to 10 days. Osteoblast differentiation was detected by alkaline phosphatase staining and messenger RNA (mRNA) expression of multiple osteoblast markers. Mineralization was assessed by alizarin red S staining. Results Among the various cytokines tested, interleukin 1 beta (IL 1 beta) induced differentiation of human MSCs into osteoblasts, which was confirmed by alkaline phosphatase activity, expression of RUNX2 mRNA, and strong alizarin red S staining. Among various molecules of the Wnt family, Wnt 5a and receptor tyrosine kinaselike orphan receptor 2 (Ror2), a major receptor of Wnt 5a, were significantly induced in human MSCs by IL 1 beta. Silencing of either WNT5A or ROR2 by small interfering RNA with 2 different sequences reduced alkaline phosphatase activity, RUNX2 expression, and alizarin red S staining of human MSCs induced by IL 1 beta. Conclusion IL 1 beta effectively and rapidly induced human MSC differentiation into osteoblasts and mineralization, mainly through the noncanonical Wnt 5a/Ror2 pathway. These results suggest potential benefits of IL 1 beta treated human MSCs in the treatment of damaged bone as well as in the induction of self renewal and self repair of damaged tissue, including osseous tissue.
C1 [Tanaka, Yoshiya] Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 1, Yahata Nishi Ku, Kitakyushu, Fukuoka 8078555, Japan.
C3 University of Occupational & Environmental Health   Japan
RP Tanaka, Y (通讯作者)，Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 1, Yahata Nishi Ku, 1 1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.
EM tanaka@med.uoeh u.ac.jp
RI Okada, Yosuke/AAT 3173 2020; zhang, xiangmei/HSD 0595 2023
FU Ministry of Health, Labor and Welfare of Japan; Ministry of Education,
   Culture, Sports, Science and Technology of Japan; University of
   Occupational and Environmental Health, Japan; Eisai; Takeda; Astellas;
   Abbott; Mitsubishi Tanabe; Chugai; Bristol Myers Squibb; MSD; Pfizer;
   Daiichi Sankyo
FX Supported in part by the Ministry of Health, Labor and Welfare of Japan
   (Research Grants In Aid for Scientific Research), by the Ministry of
   Education, Culture, Sports, Science and Technology of Japan, and by the
   University of Occupational and Environmental Health, Japan (UOEH Grant
   for Advanced Research). Dr. Tanaka has received consulting fees,
   speaking fees, and/or honoraria from Eisai, Takeda, Astellas, and Abbott
   (less than $10,000 each) and from Mitsubishi Tanabe and Chugai (more
   than $10,000 each) and has received research grants from Bristol Myers
   Squibb, Mitsubishi Tanabe, MSD, Takeda, Astellas, Eisai, Chugai, Pfizer,
   and Daiichi Sankyo.
CR Augello A, 2007, ARTHRITIS RHEUM US, V56, P1175, DOI 10.1002/art.22511
   Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Chen Y, 2009, J CELL BIOCHEM, V106, P353, DOI 10.1002/jcb.22020
   Meirelles LDS, 2006, J CELL SCI, V119, P2204, DOI 10.1242/jcs.02932
   Djouad F, 2005, ARTHRITIS RHEUM US, V52, P1595, DOI 10.1002/art.21012
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Gorman JD, 2002, NEW ENGL J MED, V346, P1349, DOI 10.1056/NEJMoa012664
   Guo CA, 2007, J BIOSCI BIOENG, V103, P547, DOI 10.1263/jbb.103.547
   Hare JM, 2009, J AM COLL CARDIOL, V54, P2277, DOI 10.1016/j.jacc.2009.06.055
   Hartmann C, 2000, DEVELOPMENT, V127, P3141
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   Huang CL, 2005, J CLIN ONCOL, V23, P8765, DOI 10.1200/JCO.2005.02.2871
   Hughes KR, 2011, INFLAMM BOWEL DIS, V17, P213, DOI 10.1002/ibd.21353
   Kanakaraj P, 1998, J EXP MED, V187, P2073, DOI 10.1084/jem.187.12.2073
   Katoh M, 2007, INT J MOL MED, V19, P273
   Klareskog L, 2004, LANCET, V363, P675, DOI 10.1016/S0140 6736(04)15640 7
   Kubota T, 2009, J BONE MINER METAB, V27, P265, DOI 10.1007/s00774 009 0064 8
   Kurayoshi M, 2006, CANCER RES, V66, P10439, DOI 10.1158/0008 5472.CAN 06 2359
   Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140 6736(04)16104 7
   LeBlanc K, 2008, LANCET, V371, P1579, DOI 10.1016/S0140 6736(08)60690 X
   Ling L, 2009, GENE, V433, P1, DOI 10.1016/j.gene.2008.12.008
   Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202
   Matsuguchi T, 2009, J BONE MINER RES, V24, P398, DOI 10.1359/JBMR.081107
   Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549
   Oshita K, 2011, ARTHRITIS RHEUM US, V63, P1658, DOI 10.1002/art.30309
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Saitoh T, 2002, INT J MOL MED, V10, P345
   Sen M, 2000, P NATL ACAD SCI USA, V97, P2791, DOI 10.1073/pnas.050574297
   TAICHMAN RS, 1992, INFLAMMATION, V16, P587, DOI 10.1007/BF00919342
   Takada I, 2007, NAT CELL BIOL, V9, P1273, DOI 10.1038/ncb1647
   Takada I, 2010, PPAR RES, V2010, DOI 10.1155/2010/341671
   Urbán VS, 2008, STEM CELLS, V26, P244, DOI 10.1634/stemcells.2007 0267
   Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535 6108(02)00045 4
   Zappia E, 2005, BLOOD, V106, P1755, DOI 10.1182/blood 2005 04 1496
NR 35
TC 133
Z9 150
U1 0
U2 15
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0004 3591
J9 ARTHRITIS RHEUM US
JI Arthritis Rheum.
PD OCT
PY 2012
VL 64
IS 10
BP 3355
EP 3363
DI 10.1002/art.34555
PG 9
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 014VE
UT WOS:000309403000033
PM 22674197
DA 2025 08 17
ER

PT J
AU Feng, J
   Liu, S
   Ma, S
   Zhao, J
   Zhang, W
   Qi, W
   Cao, PC
   Wang, Z
   Lei, W
AF Feng, Jing
   Liu, Shuai
   Ma, Sai
   Zhao, Jian
   Zhang, Wei
   Qi, Wei
   Cao, Pengchong
   Wang, Zheng
   Lei, Wei
TI Protective effects of resveratrol on postmenopausal osteoporosis:
   regulation of SIRT1 NF κB signaling pathway
SO ACTA BIOCHIMICA ET BIOPHYSICA SINICA
LA English
DT Article
DE resveratrol; osteoporosis; sirtuin 1
ID NF KAPPA B; BONE MINERAL DENSITY; OSTEOGENIC DIFFERENTIATION;
   STEM CELLS; SIRT1; INHIBITION; WOMEN; RATS; PREVENTION; OSTEOPENIA
AB Postmenopausal osteoporosis severely jeopardizes human health. Seeking for therapeutic drugs without side effects is of great necessity. Our study was designed to investigate whether resveratrol, an agonist of SIRT1, could have favorable effect on osteoporosis and to explore the underlying mechanisms. Rat osteoporosis model (ovariectomy group, OVX) was established by bilateral ovariectomy. Three different doses of resveratrol were used: 5 mg/kg/d (low dosed, RESLD), 25 mg/kg/d (medium dosed, RESMD), and 45 mg/kg/d (high dosed, RESHD). Results showed that RESLD did not show any significant effect on OVX alterations, while RESMD and RESHD significantly elevated the decreased bone mineral density induced by osteoporosis (RESMD 0.205 +/  0.023, RESHD 0.214 +/  0.053 vs. OVX 0.165 +/  0.050 g/cm(2) respectively; P < 0.05). Serum markers alkaline phosphatase (ALP) and osteocalcin were moderately restored by resveratrol. Moreover, resveratrol improved bone structure in OVX rats, demonstrated by hematoxylin eosin staining and micro computed tomographic results. In vitro results revealed that resveratrol promoted osteoblast differentiation of bone marrow mesenchymal stromal cells, evidenced by the increase of ALP generation and mRNA expression of collagen 1 (P < 0.05; RESMD, RESHD vs. control group). SIRT1 gene silencing by siRNA transfection blocked these beneficial effects of resveratrol (P < 0.05; RES + SIRT1(KD) vs. RESHD). Western blot results showed that resveratrol activated SIRT1 and subsequently suppressed the activity of NF kappa B with decreased expression level of p I kappa Ba and NF kappa B p65 (P < 0.05). Our findings verified the effects of specific dosed resveratrol on postmenopausal osteoporosis through osteoblast differentiation via SIRT1 NF kappa B signaling pathway. This study suggested the therapeutic potential of resveratrol against osteoporosis and stressed the importance of effective doses.
C1 [Feng, Jing; Liu, Shuai; Zhao, Jian; Zhang, Wei; Qi, Wei; Cao, Pengchong; Lei, Wei] Fourth Mil Med Univ, Dept Orthoped, Xijing Hosp, Xian 710032, Peoples R China.
   [Ma, Sai] Fourth Mil Med Univ, Xijing Hosp, Dept Cardiol, Xian 710032, Peoples R China.
   [Wang, Zheng] China PLA Gen Hosp, Dept Orthoped, Beijing 100853, Peoples R China.
C3 Air Force Medical University; Air Force Medical University
RP Wang, Z (通讯作者)，China PLA Gen Hosp, Dept Orthoped, Beijing 100853, Peoples R China.
EM Wangzheng301@163.com; leiwei@fmmu.edu.cn
RI Cao, Peng/GQP 3834 2022
FU National Natural Science Foundation of China [31170913]
FX This work was supported by a grant from the National Natural Science
   Foundation of China (No. 31170913).
CR Alles N, 2010, ENDOCRINOLOGY, V151, P4626, DOI 10.1210/en.2010 0399
   Andela VB, 2002, BIOCHEM BIOPH RES CO, V297, P237, DOI 10.1016/S0006 291X(02)02141 1
   Cho Peter, 2004, Implant Dent, V13, P79, DOI 10.1097/01.ID.0000116456.76235.BC
   Dosier CR, 2012, J MECH BEHAV BIOMED, V11, P112, DOI 10.1016/j.jmbbm.2011.08.014
   Eliseev RA, 2006, EXP CELL RES, V312, P40, DOI 10.1016/j.yexcr.2005.09.016
   Feng XM, 2013, CELL BIOL INT, V37, P1267, DOI 10.1002/cbin.10141
   French L, 2002, J FAM PRACTICE, V51, P875
   Guerrero RF, 2009, NAT PROD COMMUN, V4, P635
   He X, 2010, BIOCHEM BIOPH RES CO, V401, P356, DOI 10.1016/j.bbrc.2010.09.053
   Hou JL, 2010, CURR NEUROVASC RES, V7, P95, DOI 10.2174/156720210791184899
   Hsiao HB, 2013, OSTEOPOROSIS INT, V24, P1663, DOI 10.1007/s00198 012 2199 z
   KANIS JA, 1994, OSTEOPOROSIS INT, V4, P368, DOI 10.1007/BF01622200
   Kitada M, 2013, DIABETES METAB J, V37, P315, DOI 10.4093/dmj.2013.37.5.315
   Li DZ, 2014, J BONE MINER METAB, V32, P494, DOI 10.1007/s00774 013 0530 1
   Lin Qian, 2005, Int J Biomed Sci, V1, P76
   Liou SF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069468
   Mizutani K, 2000, J NUTR SCI VITAMINOL, V46, P78, DOI 10.3177/jnsv.46.78
   Mobasheri A, 2013, ANN NY ACAD SCI, V1290, P59, DOI 10.1111/nyas.12145
   Morris BJ, 2013, FREE RADICAL BIO MED, V56, P133, DOI 10.1016/j.freeradbiomed.2012.10.525
   Muir JM, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471 2474 14 253
   Noguchi Y, 2013, CLIN INTERV AGING, V8, P1313, DOI 10.2147/CIA.S49825
   Rahman I, 2012, PREV MED, V54, pS20, DOI 10.1016/j.ypmed.2011.11.014
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Selby Peter, 2004, Curr Osteoporos Rep, V2, P101, DOI 10.1007/s11914 004 0018 y
   Shakibaei M, 2011, J BIOL CHEM, V286, P11492, DOI 10.1074/jbc.M110.198713
   Silva I, 2012, ACTA REUMATOL PORT, V37, P302
   Vassiliou V, 2013, CLIN ONCOL UK, V25, P290, DOI 10.1016/j.clon.2013.01.008
   Yao HW, 2012, BIOCHEM PHARMACOL, V84, P1332, DOI 10.1016/j.bcp.2012.06.031
   Yao ZQ, 2014, J BONE MINER RES, V29, P866, DOI 10.1002/jbmr.2108
   Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244
   Yilmaz M, 2013, INDIAN J PHARMACOL, V45, P344, DOI 10.4103/0253 7613.115008
   Zhao HF, 2014, BRIT J NUTR, V111, P836, DOI 10.1017/S0007114513003115
NR 33
TC 79
Z9 107
U1 0
U2 41
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1672 9145
EI 1745 7270
J9 ACTA BIOCH BIOPH SIN
JI Acta Biochim. Biophys. Sin.
PD DEC
PY 2014
VL 46
IS 12
BP 1024
EP 1033
DI 10.1093/abbs/gmu103
PG 10
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA AU7KA
UT WOS:000345778200003
PM 25377437
DA 2025 08 17
ER

PT J
AU Wang, PP
   Perche, F
   Logeart Avramoglou, D
   Pichon, C
AF Wang, Pinpin
   Perche, Federico
   Logeart Avramoglou, Delphine
   Pichon, Chantal
TI RNA based therapy for osteogenesis
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article; Proceedings Paper
CT 5th Annual Meeting of the French Society of Nanomedicine on Nanomedicine
     From Particle Design to Applications (SFNano)
CY DEC 03 05, 2018
CL Montpellier, FRANCE
SP French Soc Nanomedicine
DE Osteogenesis; Gene therapy; RNA interference; mRNA; Protein replacement;
   Osteoporosis
ID MODIFIED MESSENGER RNA; BONE MORPHOGENETIC PROTEINS; PLURIPOTENT
   STEM CELLS; REVERSE CAP ANALOGS; KAPPA B LIGAND; IN VITRO;
   POSTMENOPAUSAL WOMEN; DELIVERY SYSTEM; OSTEOBLAST DIFFERENTIATION;
   BMP 2 INDUCED OSTEOGENESIS
AB Nucleic acid based therapy has shown great promise in accelerating bone regeneration as well as other diseases. Nucleic acids used in gene therapy mainly are either plasmid DNA (pDNA) or RNAs. Although pDNA therapy has been extensively studied for decades with encouraging preclinical and clinical results, side effects, and low efficiency associated with nuclear trafficking are hard to bypass. Unlike pDNA, RNAs (mRNA, siRNA, miRNA) exert their function in the cytoplasm, thereby being more efficient in hard to transfect cells such as primary osteoblasts. RNA interference based gene silencing represents a negative regulation which knockdown the expression of antagonists that impair osteogenesis process. In contrary, mRNA therapy for osteogenesis represents a positive regulation which delivers mRNA encoding growth factors to accelerate bone regeneration. This review presents a comprehensive summary of the mRNA and siRNA based therapies and the targets for bone regeneration in case of bone defect and osteoporosis.
C1 [Wang, Pinpin; Perche, Federico; Pichon, Chantal] CNRS, Ctr Biophys Mol UPR4301, Rue Charles Sadron, Orleans 02, France.
   [Logeart Avramoglou, Delphine] UMR CNRS 7052 INSERM U1271, Lab Osteoarticular Biol Bioengn & Bioimaging, 10 Ave Verdun, F 75010 Paris, France.
C3 Centre National de la Recherche Scientifique (CNRS); Institut National
   de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite
RP Pichon, C (通讯作者)，CNRS, Ctr Biophys Mol UPR4301, Rue Charles Sadron, Orleans 02, France.
EM pichon@cnrs.fr
RI WANG, Pinpin/AAT 2242 2020; Perche, Fédérico/A 4247 2017;
   Logeart Avramoglou, Delphine/N 7390 2017
OI Perche, Federico/0000 0002 7400 7219; WANG, Pinpin/0000 0002 9182 4704;
   PICHON, Chantal/0000 0003 3161 3937; Logeart Avramoglou,
   Delphine/0000 0002 2052 9425
FU CNRS; University of Orleans; China Scholarship Council
FX This work is supported by CNRS and University of Orleans. WANG Pinpin
   thanks the financial support from China Scholarship Council.
CR Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663
   Adams D, 2017, BMC NEUROL, V17, DOI 10.1186/s12883 017 0948 5
   Agrawal N, 2003, MICROBIOL MOL BIOL R, V67, P657, DOI 10.1128/MMBR.67.4.657 685.2003
   Alcamí A, 2000, J VIROL, V74, P11230, DOI 10.1128/JVI.74.23.11230 11239.2000
   Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560
   Amini Ami R., 2012, Critical Reviews in Biomedical Engineering, V40, P363
   Anderson BR, 2010, NUCLEIC ACIDS RES, V38, P5884, DOI 10.1093/nar/gkq347
   Andries O, 2015, J CONTROL RELEASE, V217, P337, DOI 10.1016/j.jconrel.2015.08.051
   [Anonymous], 2018, CELL DEATH AMP DIS, DOI DOI 10.1038/S41419 018 0881 6
   [Anonymous], 2017, ONCOTARGET
   [Anonymous], CELL MOL LIFE SCI
   [Anonymous], MOL THER
   [Anonymous], MOL CELL
   Arnaud Barbe N, 1998, NUCLEIC ACIDS RES, V26, P3550, DOI 10.1093/nar/26.15.3550
   Asrani KH, 2018, RNA BIOL, V15, P756, DOI 10.1080/15476286.2018.1450054
   Badieyan ZS, 2016, J CONTROL RELEASE, V239, P137, DOI 10.1016/j.jconrel.2016.08.037
   Balmayor ER, 2017, STEM CELLS DEV, V26, P25, DOI 10.1089/scd.2016.0171
   Balmayor ER, 2016, BIOMATERIALS, V87, P131, DOI 10.1016/j.biomaterials.2016.02.018
   BANERJEE AK, 1980, MICROBIOL REV, V44, P175, DOI 10.1128/MMBR.44.2.175 205.1980
   Bashirullah A, 2001, P NATL ACAD SCI USA, V98, P7025, DOI 10.1073/pnas.111145698
   Bilecen DS, 2019, TISSUE ENG PT A, V25, P34, DOI [10.1089/ten.tea.2017.0476, 10.1089/ten.TEA.2017.0476]
   BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032
   Brunger JM, 2017, ARTHRITIS RHEUMATOL, V69, P1111, DOI 10.1002/art.39982
   Cai A, 1999, BIOCHEMISTRY US, V38, P8538, DOI 10.1021/bi9830213
   CAMPBELL JM, 1990, J BIOCHEM BIOPH METH, V20, P259, DOI 10.1016/0165 022X(90)90084 P
   Cekaite L, 2007, J MOL BIOL, V365, P90, DOI 10.1016/j.jmb.2006.09.034
   Chaudhary A, 2011, BIOCHEM BIOPH RES CO, V404, P313, DOI 10.1016/j.bbrc.2010.11.114
   Chen C, 2012, J CELL BIOCHEM, V113, P3672, DOI 10.1002/jcb.24240
   Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092 8674(01)00578 5
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Choi BY, 2015, J MATER CHEM B, V3, P6448, DOI 10.1039/c5tb00843c
   Coller J, 2004, ANNU REV BIOCHEM, V73, P861, DOI 10.1146/annurev.biochem.73.011303.074032
   CONTRERAS R, 1982, NUCLEIC ACIDS RES, V10, P6353, DOI 10.1093/nar/10.20.6353
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Couttet P, 1997, P NATL ACAD SCI USA, V94, P5628, DOI 10.1073/pnas.94.11.5628
   Csobonyeiova M, 2017, J ADV RES, V8, P321, DOI 10.1016/j.jare.2017.02.004
   Cui ZK, 2015, J CONTROL RELEASE, V217, P42, DOI 10.1016/j.jconrel.2015.08.031
   Dan MX, 2012, MOL BIOL REP, V39, P7813, DOI 10.1007/s11033 012 1624 x
   de Fougerolles A, 2007, NAT REV DRUG DISCOV, V6, P443, DOI 10.1038/nrd2310
   des Rieux A, 2009, J CONTROL RELEASE, V136, P148, DOI 10.1016/j.jconrel.2009.02.004
   Devlin RD, 2003, ENDOCRINOLOGY, V144, P1972, DOI 10.1210/en.2002 220918
   Dimitriou R, 2005, INJURY, V36, P1392, DOI 10.1016/j.injury.2005.07.019
   Dorn G, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh044
   EDMONDS M, 1971, P NATL ACAD SCI USA, V68, P1336, DOI 10.1073/pnas.68.6.1336
   Egermann M, 2005, OSTEOPOROSIS INT, V16, pS120, DOI 10.1007/s00198 004 1817 9
   Elangovan S, 2015, J CONTROL RELEASE, V218, P22, DOI 10.1016/j.jconrel.2015.09.050
   Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Evans CH, 2015, NAT REV RHEUMATOL, V11, P234, DOI 10.1038/nrrheum.2015.28
   Fang JM, 1996, P NATL ACAD SCI USA, V93, P5753, DOI 10.1073/pnas.93.12.5753
   Ferizi M, 2016, SCI REP UK, V6, DOI 10.1038/srep39149
   Filleur S, 2003, CANCER RES, V63, P3919
   Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168 9525(99)01818 1
   Fischer L, 2002, J BIOL CHEM, V277, P30870, DOI 10.1074/jbc.M109330200
   Fisher S, 1999, NAT GENET, V23, P442, DOI 10.1038/70557
   Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131
   Freund I, 2019, GENES BASEL, V10, DOI 10.3390/genes10020092
   Gallie DR, 1998, GENE, V216, P1, DOI 10.1016/S0378 1119(98)00318 7
   Gazzerro E, 2007, J BIOL CHEM, V282, P31549, DOI 10.1074/jbc.M701317200
   Geall AJ, 2012, P NATL ACAD SCI USA, V109, P14604, DOI 10.1073/pnas.1209367109
   Genant HK, 1999, OSTEOPOROSIS INT, V10, P259, DOI 10.1007/s001980050224
   Ghadakzadeh S, 2016, J BONE MINER RES, V31, P475, DOI 10.1002/jbmr.2816
   Giannoudis PV, 2011, INJURY, V42, P591, DOI 10.1016/j.injury.2011.03.036
   GOLDBERG VM, 1987, CLIN ORTHOP RELAT R, P7
   Grier Alexandra E, 2016, Mol Ther Nucleic Acids, V5, pe306, DOI 10.1038/mtna.2016.21
   Grudzien Nogalska E, 2007, RNA, V13, P1745, DOI 10.1261/rna.701307
   Hankenson KD, 2015, ADV DRUG DELIVER REV, V94, P3, DOI 10.1016/j.addr.2015.09.008
   Hanna J, 2009, NATURE, V462, P595, DOI 10.1038/nature08592
   Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a
   Hausburg F, 2015, CELL PHYSIOL BIOCHEM, V35, P1360, DOI 10.1159/000373957
   Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620
   Hille F, 2018, CELL, V172, P1239, DOI 10.1016/j.cell.2017.11.032
   Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226
   Hollick Rosemary J, 2011, Menopause Int, V17, P66, DOI 10.1258/mi.2011.011014
   Holtkamp S, 2006, BLOOD, V108, P4009, DOI 10.1182/blood 2006 04 015024
   HORIKAMI SM, 1984, VIROLOGY, V138, P1, DOI 10.1016/0042 6822(84)90142 9
   Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097 2765(00)80067 2
   Hu KZ, 2017, MOL MED REP, V15, P2186, DOI 10.3892/mmr.2017.6253
   Huang JS, 2018, ACS APPL MATER INTER, V10, P28471, DOI 10.1021/acsami.8b10521
   Huang RL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.101
   Im GI, 2013, J BIOMED MATER RES A, V101, P3009, DOI 10.1002/jbm.a.34576
   Inada T, 2018, BIOMATER SCI UK, V6, P440, DOI 10.1039/c7bm01100h
   JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092 8674(93)90290 7
   Jansen RP, 2001, NAT REV MOL CELL BIO, V2, P247, DOI 10.1038/35067016
   Jemielity J, 2003, RNA, V9, P1108, DOI 10.1261/rna.5430403
   JIRIKOWSKI GF, 1992, SCIENCE, V255, P996, DOI 10.1126/science.1546298
   Jones E, 2011, INJURY, V42, P562, DOI 10.1016/j.injury.2011.03.030
   Karikó K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008
   Karikó K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200
   Karikó K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200
   Karikó K, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr695
   Khorsand B, 2017, AAPS J, V19, P438, DOI 10.1208/s12248 016 0034 8
   Khorsand B, 2017, J CONTROL RELEASE, V248, P53, DOI 10.1016/j.jconrel.2017.01.008
   Kim I, 2007, RNA, V13, P289, DOI 10.1261/rna.342607
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Koide M, 2010, PERIODONTOL 2000, V54, P235, DOI 10.1111/j.1600 0757.2010.00355.x
   KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092 8674(84)90268 X
   Kormann MSD, 2011, NAT BIOTECHNOL, V29, P154, DOI 10.1038/nbt.1733
   KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125
   Kozak M, 2005, GENE, V361, P13, DOI 10.1016/j.gene.2005.06.037
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kwong FNK, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2436
   Lam JKW, 2015, MOL THER NUCL ACIDS, V4, DOI 10.1038/mtna.2015.23
   LANGBERG SR, 1981, J BIOL CHEM, V256, P54
   Laursen MB, 2010, MOL BIOSYST, V6, P862, DOI 10.1039/b918869j
   Li B, 2016, BIOCONJUGATE CHEM, V27, P849, DOI 10.1021/acs.bioconjchem.6b00090
   Liang C, 2015, NAT MED, V21, P288, DOI 10.1038/nm.3791
   Liu XL, 2016, J BIOMED RES, V30, P264, DOI 10.7555/JBR.30.20150110
   Lo HJ, 1998, MOL CELL BIOL, V18, P665, DOI 10.1128/MCB.18.2.665
   Longo KA, 2002, J BIOL CHEM, V277, P38239, DOI 10.1074/jbc.M206402200
   LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485
   Ma ZW, 2014, J NANOBIOTECHNOL, V12, DOI 10.1186/1477 3155 12 23
   MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077
   Manaka T, 2011, BIOMATERIALS, V32, P9642, DOI 10.1016/j.biomaterials.2011.08.026
   Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756
   Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997 717
   Maxhimer JB, 2015, GENES DIS, V2, P57, DOI 10.1016/j.gendis.2014.12.004
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   McCormick C, 2017, NAT REV IMMUNOL, V17, P647, DOI 10.1038/nri.2017.63
   Mckay WF, 2007, INT ORTHOP, V31, P729, DOI 10.1007/s00264 007 0418 6
   McKenna SA, 2007, NAT PROTOC, V2, P3270, DOI 10.1038/nprot.2007.480
   MENDECKI J, 1972, BIOCHEMISTRY US, V11, P792, DOI 10.1021/bi00755a018
   Merino R, 1999, DEVELOPMENT, V126, P5515
   Mignone F, 2002, GENOME BIOL, V3, DOI 10.1186/gb 2002 3 3 reviews0004
   Miller VM, 2003, P NATL ACAD SCI USA, V100, P7195, DOI 10.1073/pnas.1231012100
   MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783
   Mockey M, 2006, BIOCHEM BIOPH RES CO, V340, P1062, DOI 10.1016/j.bbrc.2005.12.105
   Mu X, 2018, NUCLEIC ACIDS RES, V46, P5239, DOI 10.1093/nar/gky177
   Mukherjee D, 2002, EMBO J, V21, P165, DOI 10.1093/emboj/21.1.165
   Nacheva GA, 2003, EUR J BIOCHEM, V270, P1458, DOI 10.1046/j.1432 1033.2003.03510.x
   Naito Yuki, 2013, Methods Mol Biol, V942, P57, DOI 10.1007/978 1 62703 119 6_3
   Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379
   Negishi Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489
   Nguyen MK, 2018, ACTA BIOMATER, V75, P105, DOI 10.1016/j.actbio.2018.06.007
   Ozcan G, 2015, ADV DRUG DELIVER REV, V87, P108, DOI 10.1016/j.addr.2015.01.007
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243
   Pascolo Steve, 2008, V183, P221
   Pearce JJH, 1999, DEV BIOL, V209, P98, DOI 10.1006/dbio.1999.9240
   Peng Jing, 2008, V419, P215, DOI 10.1007/978 1 59745 033 1_15
   PERRIN DD, 1965, NATURE, V208, P787, DOI 10.1038/208787a0
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Phua KKL, 2017, BIOMATERIALS, V133, P29, DOI 10.1016/j.biomaterials.2017.04.009
   Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092 8674(00)80132 4
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Ríos CN, 2012, CLIN ORTHOP RELAT R, V470, P2541, DOI 10.1007/s11999 012 2475 4
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Roush K, 2011, AM J NURS, V111, P26, DOI 10.1097/01.NAJ.0000403358.44058.f7
   Rozbruch SR, 2006, J ORTHOP TRAUMA, V20, P197
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   SACHS AB, 1987, MOL CELL BIOL, V7, P3268, DOI 10.1128/MCB.7.9.3268
   Sahin U, 2014, NAT REV DRUG DISCOV, V13, P759, DOI 10.1038/nrd4278
   Schilcher J, 2011, NEW ENGL J MED, V364, P1728, DOI 10.1056/NEJMoa1010650
   Scott IC, 2000, DEV DYNAM, V217, P449, DOI 10.1002/(SICI)1097 0177(200004)217:4<449::AID DVDY12>3.0.CO;2 8
   Shimer AL, 2009, INJURY, V40, P32
   Shin J, 2016, SMALL, V12, P6266, DOI 10.1002/smll.201601868
   SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092 8674(92)90316 5
   Sorensen DR, 2003, J MOL BIOL, V327, P761, DOI 10.1016/S0022 2836(03)00181 5
   Stepinski J, 2001, RNA, V7, P1486
   Strenkowska M, 2010, NEW J CHEM, V34, P993, DOI 10.1039/b9nj00644c
   Suen PK, 2016, J ORTHOP TRANSL, V4, P1, DOI 10.1016/j.jot.2015.08.004
   Sun Y, 2016, ACS NANO, V10, P5759, DOI 10.1021/acsnano.5b07828
   Suzuki K, 2008, NAT IMMUNOL, V9, P17, DOI 10.1038/ni1553
   Svedbom A, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0137 0
   Svitkin YV, 2017, NUCLEIC ACIDS RES, V45, P6023, DOI 10.1093/nar/gkx135
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Takayama K, 2009, J BONE MINER METAB, V27, P402, DOI 10.1007/s00774 009 0054 x
   Tavernier G, 2011, J CONTROL RELEASE, V150, P238, DOI 10.1016/j.jconrel.2010.10.020
   Teng SS, 2014, TISSUE ENG PART B RE, V20, P328, DOI [10.1089/ten.teb.2013.0301, 10.1089/ten.TEB.2013.0301]
   Thess A, 2015, MOL THER, V23, P1456, DOI 10.1038/mt.2015.103
   Trepotec Z, 2019, TISSUE ENG PT A, V25, P69, DOI [10.1089/ten.tea.2017.0485, 10.1089/ten.TEA.2017.0485]
   TRIANAALONSO FJ, 1995, J BIOL CHEM, V270, P6298, DOI 10.1074/jbc.270.11.6298
   Uchida S, 2015, PHARMACEUTICS, V7, P137, DOI 10.3390/pharmaceutics7030137
   Urist MR, 2009, CLIN ORTHOP RELAT R, V467, P3051, DOI 10.1007/s11999 009 1068 3
   van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357 2725(98)00134 4
   Veedu RN, 2010, CHEM BIODIVERS, V7, P536, DOI 10.1002/cbdv.200900343
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wan DC, 2007, J BIOL CHEM, V282, P26450, DOI 10.1074/jbc.M703282200
   Wang CC, 2018, CAILIAO GONGCHENG, V46, P1, DOI 10.11868/j.issn.1001 4381.2017.001137
   Wang CD, 2018, CELL PHYSIOL BIOCHEM, V46, P133, DOI 10.1159/000488416
   Wang H, 2015, INT J NANOMED, V10, P5671, DOI 10.2147/IJN.S88798
   Wang S, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00379
   Wang YW, 2012, BIOMATERIALS, V33, P8540, DOI 10.1016/j.biomaterials.2012.07.039
   Wang YW, 2010, PHARM RES DORDR, V27, P1273, DOI 10.1007/s11095 010 0099 5
   Warren L, 2010, CELL STEM CELL, V7, P618, DOI 10.1016/j.stem.2010.08.012
   WEI CM, 1975, CELL, V4, P379, DOI 10.1016/0092 8674(75)90158 0
   Weissman Drew, 2013, Methods Mol Biol, V969, P43, DOI 10.1007/978 1 62703 260 5_3
   Wesselhoeft RA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05096 6
   WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918
   Wu XB, 2003, J CLIN INVEST, V112, P924, DOI 10.1172/JCI200315543
   Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101
   Yang E, 2003, GENOME RES, V13, P1863, DOI 10.1101/gr.1272403
   Yoshioka N, 2013, CELL STEM CELL, V13, P246, DOI 10.1016/j.stem.2013.06.001
   You ZB, 2002, J CELL BIOL, V157, P429, DOI 10.1083/jcb.200201110
   Yu YQ, 2017, ACTA BIOMATER, V49, P590, DOI 10.1016/j.actbio.2016.11.067
   Zangi L, 2013, NAT BIOTECHNOL, V31, P898, DOI 10.1038/nbt.2682
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhang L, 2019, ACTA BIOMATER, V84, P16, DOI 10.1016/j.actbio.2018.11.039
   Zhang W, 2019, TISSUE ENG PT A, V25, P131, DOI [10.1089/ten.TEA.2018.0112, 10.1089/ten.tea.2018.0112]
   Zhang Y, 2014, J DENT RES, V93, P1095, DOI 10.1177/0022034514552676
   Zhang YF, 2016, SCI REP UK, V6, DOI 10.1038/srep26925
   Zhang YF, 2015, J BONE MINER RES, V30, P286, DOI 10.1002/jbmr.2322
   Zhang Z, 2017, MOL THER NUCL ACIDS, V9, P230, DOI 10.1016/j.omtn.2017.09.009
   Zheng LZ, 2016, BONE, V83, P190, DOI 10.1016/j.bone.2015.11.010
   Zheng XF, 2004, RNA, V10, P1934, DOI 10.1261/rna.7150804
   Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092 8674(00)80133 6
   Zohra FT, 2007, BIOCHEM BIOPH RES CO, V358, P373, DOI 10.1016/j.bbrc.2007.04.059
NR 208
TC 29
Z9 29
U1 0
U2 39
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378 5173
EI 1873 3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD OCT 5
PY 2019
VL 569
AR 118594
DI 10.1016/j.ijpharm.2019.118594
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Pharmacology & Pharmacy
GA JA8TJ
UT WOS:000488123900068
PM 31394184
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Barbanente, A
   Ditaranto, N
   Laghezza, A
   Tortorella, P
   Intini, FP
   Pacifico, C
   Natile, G
   Margiotta, N
AF Barbanente, Alessandra
   Ditaranto, Nicoletta
   Laghezza, Antonio
   Tortorella, Paolo
   Intini, Francesco P. P.
   Pacifico, Concetta
   Natile, Giovanni
   Margiotta, Nicola
TI Cisplatin and zoledronic acid: two drugs combined in a Pt(ii) complex
   with potential antitumor activity towards bone tumors and metastases
SO DALTON TRANSACTIONS
LA English
DT Article
ID STRUCTURAL CHARACTERIZATION; LINKED PHOSPHONATES; PLATINUM COMPLEX;
   BISPHOSPHONATES; CANCER; MULTINUCLEAR; MECHANISM; OXIDATION; DELIVERY;
   SPECTRA
AB Treatment of primary bone malignancies comprises surgery, radiotherapy, chemotherapy, and analgesics. Platinum based chemotherapeutics, such as cisplatin, are commonly used for the treatment of bone cancer but, despite their success, outcomes are limited by toxicity and resistance. Recently, dinuclear Pt complexes with a bridging geminal bisphosphonate ligand proved to be endowed with selective accumulation in bone tumors or metastases leading to improved efficacy and reduced systemic toxicity. Further improvement could be expected by the use of a bisphosphonate ligand with intrinsic pharmacological activity such as zoledronic acid (ZL). In the present work is reported the synthesis and full characterization of the dinuclear Pt(ii) complex [{cis Pt(NH3)(2)}(2)(ZL)]HSO4 which combines two drugs with antitumor activity, cisplatin and zoledronic acid. Both drugs, individually, are already approved by the U.S. Food and Drug Administration and the European Medicinal Agency for clinical use. The in vitro cytotoxicity of the new Pt(ii) ZL complex has been tested against a panel of human tumor cell lines.
C1 [Barbanente, Alessandra; Ditaranto, Nicoletta; Intini, Francesco P. P.; Pacifico, Concetta; Natile, Giovanni; Margiotta, Nicola] Univ Bari Aldo Moro, Dipartimento Chim, Via E Orabona 4, I 70125 Bari, Italy.
   [Laghezza, Antonio; Tortorella, Paolo] Univ Bari Aldo Moro, Dipartimento Farm Sci Farmaco, Via E Orabona 4, I 70125 Bari, Italy.
C3 Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari
   Aldo Moro
RP Margiotta, N (通讯作者)，Univ Bari Aldo Moro, Dipartimento Chim, Via E Orabona 4, I 70125 Bari, Italy.
EM nicola.margiotta@uniba.it
RI Margiotta, Nicola/AAE 3975 2021; Ditaranto, Nicoletta/N 7067 2013;
   Laghezza, Antonio/F 7420 2014
OI Barbanente, Alessandra/0000 0002 9001 8719; Margiotta,
   Nicola/0000 0003 4034 875X; Ditaranto, Nicoletta/0000 0001 7529 9906
CR [Anonymous], 2000, KALEIDAGRAPH 3 5
   Anthony EJ, 2020, CHEM SCI, V11, DOI 10.1039/d0sc04082g
   APPLETON TG, 1986, INORG CHEM, V25, P726, DOI 10.1021/ic00226a005
   APPLETON TG, 1986, INORG CHEM, V25, P720, DOI 10.1021/ic00226a004
   Bandoli G, 1997, J AM CHEM SOC, V119, P10370, DOI 10.1021/ja964170g
   Barbanente A, 2021, MOLECULES, V26, DOI 10.3390/molecules26113417
   Carozzi VA, 2010, CURR CANCER DRUG TAR, V10, P670
   Clézardin P, 2005, CANCER RES, V65, P4971, DOI 10.1158/0008 5472.CAN 05 0264
   Corinti D, 2020, ANGEW CHEM INT EDIT, V59, P15595, DOI 10.1002/anie.202007597
   Curci A, 2017, INORG CHEM, V56, P7482, DOI 10.1021/acs.inorgchem.7b00931
   Dhara S.C., 1970, INDIAN J CHEM, V8, P193
   Dolmella A, 2002, POLYHEDRON, V21, P275, DOI 10.1016/S0277 5387(01)00992 5
   Drach J, 2000, J CANCER RES CLIN, V126, P441, DOI 10.1007/s004320050011
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   FELTHAM RD, 1964, J CHEM SOC, P4587, DOI 10.1039/jr9640004587
   Gabano E, 2009, CURR MED CHEM, V16, P4544, DOI 10.2174/092986709789760661
   Gibson D, 2016, DALTON T, V45, P12983, DOI 10.1039/c6dt01414c
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9 90004 3
   Iafisco M, 2009, J MATER CHEM, V19, P8385, DOI 10.1039/b914379c
   Jakupec MA, 2008, DALTON T, P183, DOI 10.1039/b712656p
   Johnstone TC, 2016, CHEM REV, V116, P3436, DOI 10.1021/acs.chemrev.5b00597
   KLENNER T, 1990, J CANCER RES CLIN, V116, P341, DOI 10.1007/BF01612916
   KLENNER T, 1990, J CANCER RES CLIN, V116, P453, DOI 10.1007/BF01612993
   KLENNER T, 1990, CANCER TREAT REV, V17, P253, DOI 10.1016/0305 7372(90)90056 L
   Lipton A, 2011, EXPERT OPIN PHARMACO, V12, P749, DOI 10.1517/14656566.2011.538384
   Macedo F, 2017, ONCOL REV, V11, P43, DOI 10.4081/oncol.2017.321
   Margiotta N, 2007, DALTON T, P3131, DOI 10.1039/b705239a
   Margiotta N, 2012, J MED CHEM, V55, P7182, DOI 10.1021/jm3006838
   Margiotta N, 2011, J INORG BIOCHEM, V105, P548, DOI 10.1016/j.jinorgbio.2010.12.011
   Margiotta N, 2009, DALTON T, P10904, DOI 10.1039/b919721d
   Margiotta N, 2008, J INORG BIOCHEM, V102, P2078, DOI 10.1016/j.jinorgbio.2008.07.008
   MATSUMOTO K, 1992, J AM CHEM SOC, V114, P8110, DOI 10.1021/ja00047a020
   Nadar RA, 2021, MATER TODAY BIO, V9, DOI 10.1016/j.mtbio.2020.100088
   Nadar RA, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 62039 2
   Naumkin A. V., 2012, NIST XRAY PHOTOELECT
   Piccinonna S, 2012, DALTON T, V41, P9689, DOI 10.1039/c2dt30712j
   Qiu L, 2017, EUR J PHARMACOL, V810, P120, DOI 10.1016/j.ejphar.2017.06.035
   Qiu L, 2015, J BIOL INORG CHEM, V20, P1263, DOI 10.1007/s00775 015 1305 z
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Savino S, 2018, EUR J MED CHEM, V158, P184, DOI 10.1016/j.ejmech.2018.08.044
   Thibaudeau L, 2014, CANCER METAST REV, V33, P721, DOI 10.1007/s10555 014 9499 z
   Todd RC, 2009, METALLOMICS, V1, P280, DOI 10.1039/b907567d
   Uchino H, 2005, BRIT J CANCER, V93, P678, DOI 10.1038/sj.bjc.6602772
   van Driel M, 2014, ARCH BIOCHEM BIOPHYS, V561, P159, DOI 10.1016/j.abb.2014.07.013
   Wang XY, 2013, CHEM SOC REV, V42, P202, DOI 10.1039/c2cs35259a
   WELKERLING H, 1991, VIRCHOWS ARCH A, V418, P419, DOI 10.1007/BF01605928
   Zhang ZQ, 2018, INORG CHEM, V57, P3315, DOI 10.1021/acs.inorgchem.7b03261
NR 48
TC 3
Z9 3
U1 6
U2 18
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1477 9226
EI 1477 9234
J9 DALTON T
JI Dalton Trans.
PD MAY 9
PY 2023
VL 52
IS 18
BP 6117
EP 6128
DI 10.1039/d3dt00734k
EA APR 2023
PG 12
WC Chemistry, Inorganic & Nuclear
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA F3EE2
UT WOS:000973346700001
PM 37066998
DA 2025 08 17
ER

PT J
AU Broom, RJ
   Hinder, V
   Sharples, K
   Proctor, J
   Duffey, S
   Pollard, S
   Fong, PCC
   Forgeson, G
   Harris, DL
   Jameson, MB
   O'Donnell, A
   North, RT
   Deva, S
   Hanning, FJ
   Grey, A
   Findlay, MPN
AF Broom, Reuben J.
   Hinder, Victoria
   Sharples, Katrina
   Proctor, Janie
   Duffey, Steven
   Pollard, Stephanie
   Fong, Peter C. C.
   Forgeson, Garry
   Harris, Dean L.
   Jameson, Michael B.
   O'Donnell, Anne
   North, Richard T.
   Deva, Sanjeev
   Hanning, Fritha J.
   Grey, Andrew
   Findlay, Michael P. N.
TI Everolimus and Zoledronic Acid in Patients With Renal Cell Carcinoma
   With Bone Metastases: A Randomized First Line Phase II Trial
SO CLINICAL GENITOURINARY CANCER
LA English
DT Article
DE Bisphosphonates; Neoplasm metastasis; Randomized controlled trial;
   Skeletal related events; Targeted therapy
ID INTERFERON ALPHA; CANCER PATIENTS; SOLID TUMORS; RESORPTION; SUNITINIB;
   SURVIVAL; BISPHOSPHONATES; MARKERS
AB This study prospectively evaluated the benefits of the addition of bone specific therapy to targeted therapy in patients with renal cell carcinoma metastatic to bone. Thirty patients were randomized to either everolimus alone or everolimus in combination with zoledronic acid. The study found that this combination approach suppressed bone turnover and suggested prolonged tumor control.
   Background: Bone metastases from renal cell carcinoma (RCC) are a major cause of morbidity. Post hoc analysis has suggested that bone turnover markers can identify patients at risk of skeletal related events (SREs) among those receiving zoledronic acid. This study sought to evaluate the effect on bone metastases of everolimus alone compared with everolimus plus zoledronic acid. Patients and Methods: Thirty treatment naive patients with RCC and >= 1 bone metastases were randomized 1: 1 to everolimus (10 mg daily) versus everolimus plus zoledronic acid (4 mg intravenously 4 weekly). Bone specific assessments were performed at baseline and at weeks 1, 4, 8, and 12. Treatment was continued on allocated arm until progression per RECIST 1.1 (Response Evaluation Criteria in Solid Tumors, version 1.1). The primary outcome measure was urine N telopeptide (uNTX) level, with secondary measures of plasma C telopeptide (CTX), quality of life (Functional Assessment of Cancer Therapy Bone Pain [FACT BP], Brief Pain Inventory [BPI]), progression free survival (PFS), SREs, and safety. Results: After 12 weeks, reduction in mean uNTX and CTX on everolimus plus zoledronic acid relative to everolimus was 68.4% (95% CI, 60.1% 74.9%; P < .0001) and 76.2% (95% CI, 67.3% 82.7%; P < .0001), respectively. There was no evidence of a difference for FACT BP (P = .5), but evidence was favorable for BPI Severity (P = .05) and BPI Interference (P = .06). Median PFS was 7.5 months (95% CI, 3.4 11.2) on everolimus plus zoledronic acid and 5.4 months (95% CI, 3.2 6.3) on everolimus (P = .009). Median time to first SRE was 9.6 months (95% CI, 4.3 15.5) on everolimus plus zoledronic acid and 5.2 months (95% CI, 1.6 8.2) on everolimus (P = .03). Conclusion: In this RCC population, the addition of zoledronic acid to everolimus significantly reduced bone resorption markers and may prolong tumor control.
C1 [Broom, Reuben J.; Fong, Peter C. C.; Deva, Sanjeev; Hanning, Fritha J.] Auckland City Hosp, Reg Canc & Blood Ctr, Auckland 1023, New Zealand.
   [Hinder, Victoria; Sharples, Katrina; Proctor, Janie; Duffey, Steven; Pollard, Stephanie; Findlay, Michael P. N.] Univ Auckland, Discipline Oncol, Auckland 1, New Zealand.
   [Sharples, Katrina] Univ Otago, Dunedin Sch Med, Dept Prevent & Social Med, Dunedin, New Zealand.
   [Forgeson, Garry] Palmerston North Hosp, Midcent Reg Canc Treatment Serv, Palmerston North, New Zealand.
   [Harris, Dean L.] Christchurch Hosp, Oncol Serv, Christchurch, New Zealand.
   [Jameson, Michael B.] Waikato Hosp, Reg Canc Ctr, Hamilton, New Zealand.
   [O'Donnell, Anne] Wellington Hosp, Wellington Blood & Canc Ctr, Wellington, New Zealand.
   [North, Richard T.] Tauranga Hosp, Tauranga, New Zealand.
   [Grey, Andrew] Univ Auckland, Dept Med, Auckland 1, New Zealand.
C3 Auckland City Hospital; University of Auckland; University of Otago;
   Christchurch Hospital New Zealand; Waikato Hospital; University of
   Auckland
RP Broom, RJ (通讯作者)，Auckland City Hosp, Room 1036,Bldg 7,Pk Rd, Auckland 1023, New Zealand.
EM ReubenB@adhb.govt.nz
RI ; Jameson, Michael/C 3423 2008
OI Jameson, Michael/0000 0001 7068 4311; 
FU Novartis (Sponsor: UniServices Ltd, University of Auckland)
FX Funding was provided by Novartis (Sponsor: UniServices Ltd, University
   of Auckland). All authors state that they have no conflicts of interest.
CR Beuselinck B, 2012, BRIT J CANCER, V107, P1665, DOI 10.1038/bjc.2012.385
   Broom R, 2007, PROG PALLIAT CARE, V15, P1, DOI 10.1179/096992607X177791
   Coleman RE, 2005, J CLIN ONCOL, V23, P4925, DOI 10.1200/JCO.2005.06.091
   Fehm T, 2012, BMC CANCER, V12, DOI 10.1186/1471 2407 12 308
   Ferlay J, 2010, EUR J CANCER, V46, P765, DOI 10.1016/j.ejca.2009.12.014
   Fleissig Y, 2012, OR SURG OR MED OR PA, V113, pE1, DOI 10.1016/j.tripleo.2011.06.023
   Grey A, 2009, J CLIN ENDOCR METAB, V94, P538, DOI 10.1210/jc.2008 2241
   Hoefert S, 2010, ORAL SURG ORAL MED O, V110, P463, DOI 10.1016/j.tripleo.2010.04.049
   Jensen AB, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.1023
   Keizman D, 2012, EUR J CANCER, V48, P1031, DOI 10.1016/j.ejca.2012.02.050
   Kneissel M, 2004, BONE, V35, P1144, DOI 10.1016/j.bone.2004.07.013
   Lipton A, 2008, CANCER AM CANCER SOC, V113, P193, DOI 10.1002/cncr.23529
   Motzer RJ, 1999, J CLIN ONCOL, V17, P2530, DOI 10.1200/JCO.1999.17.8.2530
   Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044
   Motzer RJ, 2013, J CLIN ONCOL, V31
   Patil S, 2009, J CLIN ONCOL, V27, p15s
   Riechelmann RP, 2008, AM J CLIN ONCOL CANC, V31, P182, DOI 10.1097/COC.0b013e3181574084
   Rini BI, 2008, J CLIN ONCOL, V26, P5422, DOI 10.1200/JCO.2008.16.9847
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Solomayer EF, 2012, ANN ONCOL, V23, P2271, DOI 10.1093/annonc/mdr612
   Tunn UW, 2012, CAN J UROL, V19, P6261
   Wolfe R, 1999, CONTROL CLIN TRIALS, V20, P547, DOI 10.1016/S0197 2456(99)00032 X
   Zekri J, 2001, INT J ONCOL, V19, P379
NR 23
TC 34
Z9 35
U1 3
U2 9
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219 3931 USA
SN 1558 7673
EI 1938 0682
J9 CLIN GENITOURIN CANC
JI Clin. Genitourin. Cancer
PD FEB
PY 2015
VL 13
IS 1
BP 50
EP 58
DI 10.1016/j.clgc.2014.07.002
PG 9
WC Oncology; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Urology & Nephrology
GA AY2HR
UT WOS:000347410100015
PM 25163397
DA 2025 08 17
ER

PT J
AU Wang, WZ
   Olson, D
   Cheng, B
   Guo, X
   Wang, KZ
AF Wang, Weizhuo
   Olson, Douglas
   Cheng, Bin
   Guo, Xiong
   Wang, Kunzheng
TI Sanguis Draconis resin stimulates osteoblast alkaline phosphatase
   activity and mineralization in MC3T3 E1 cells
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Sanguis Draconis; Osteoporosis; Bone; MC3T3 E1
ID DRAGONS BLOOD; GENE EXPRESSION; BONE FORMATION; DIFFERENTIATION;
   PROLIFERATION; OSTEOPOROSIS; SUPPRESSION; PHENOTYPE; DISEASE; HEALTH
AB Ethnopharmacological relevance: Sanguis Draconis (SD), "Dragon's Blood", is a resin that is obtained from Daemonorops draco (Palmae). Used in traditional medicine, it has shown activity in the prevention of osteoporosis as well as promoting the healing of bone fractures.
   Materials and methods: In this study, the effects of Sanguis Dranonis ethanol extract on beta glycerolphosphate and ascorbic acid induced differentiation using mouse calvaria origin MC3T3 E1 osteoblastic cells was examined. We looked at osteoblast differentiation, proliferation, and mineralization by measuring alkaline phosphatase (ALP) and specific bone marker activities. Osteoblast like MC3T3 E1 cells were cultured in various concentrations of SD ethanol extract (0.005 1 mg/mL) during the osteoblast differentiation period (I, 5, 15, and 25 days).
   Results: As measured by 3[4,5 dimethylthiazol 2 y] 2,5 diphenyltetrazolium bromide assay, SD extracts increased cell proliferation as compared to control. The most pronounced effect was observed at the concentration range between 0.01 and 0.1 mg/mL (P < 0.01). This SD stimulatory effect for cell proliferation was observed during the whole osteogenic period. Cellular (synthesized) ALP activity was increased during 15 days of culture, and was confirmed by the staining of ALP activity on cell matrix layers for matrix calcification. SD stimulatory effect for cell mineralization we observed in 14 and 21 days. Elevated mRNA or protein levels of bone morphogenetic protein 2(BMP 2), the differentiation marker osteocalcin, osteopontin, collgen I, and a master osteogenic transcription factor, Runx2, were observed in SD treated cells.
   Conclusions: These results suggest that SD may increase osteogenic effect by stimulating cell ALP activity and affect the BMP signaling pathway cascades in osteoblastic cells, then promotes osteoblast differentiation, mineralization, and bone formation. (C) 2012 Published by Elsevier Ireland Ltd.
C1 [Wang, Weizhuo; Cheng, Bin; Wang, Kunzheng] Xi An Jiao Tong Univ, Coll Med, Affiliated Hosp 2, Dept Orthoped Surg, Xian 710004, Shaanxi, Peoples R China.
   [Olson, Douglas] SUNY Buffalo, Sch Dent Med, Dept Oral Biol, Buffalo, NY 14214 USA.
   [Guo, Xiong] Xi An Jiao Tong Univ, Minist Educ, Key Lab Environm & Genes Related Dis, Dept Publ Hlth,Med Coll, Xian 710061, Shannxi, Peoples R China.
C3 Xi'an Jiaotong University; State University of New York (SUNY) System;
   University at Buffalo, SUNY; Xi'an Jiaotong University
RP Wang, WZ (通讯作者)，Xi An Jiao Tong Univ, Coll Med, Affiliated Hosp 2, Dept Orthoped Surg, Xian 710004, Shaanxi, Peoples R China.
EM wangweizhuo@mail.xjtu.edu.cn
RI ; 王, 志英/GZM 0958 2022
OI Wang, Kunzheng/0000 0002 1981 4237; 
FU Natural Scientific Fund of China [81001225]; Xian Jiaotong University,
   China; University at Buffalo, US [08143004]; Fundamental Research Funds
   for the Central Universities [08140003]
FX This project was supported by the Natural Scientific Fund of China
   (81001225), and the International Co operative Fund in Xian Jiaotong
   University, China and University at Buffalo, US (08143004), and the
   Fundamental Research Funds for the Central Universities (08140003).
CR Aglyamov SR, 2007, INT J BIOMED IMAGING, V2007, DOI 10.1155/2007/35830
   Ahn EM, 2004, BIOL PHARM BULL, V27, P548, DOI 10.1248/bpb.27.548
   ANDERSON HC, 1995, CLIN ORTHOP RELAT R, P266
   [Anonymous], 2010, INT J INTEGRATED CAR, V10, pe046
   Bahlous Afef, 2006, Tunis Med, V84, P751
   Balcerzak M, 2003, ACTA BIOCHIM POL, V50, P1019
   Bandyopadhyay A, 2006, PLOS GENET, V2, P2116, DOI 10.1371/journal.pgen.0020216
   BREMNER I, 1995, P NUTR SOC, V54, P489, DOI 10.1079/PNS19950017
   Briot K, 2005, Gynecol Obstet Fertil, V33, P1009, DOI 10.1016/j.gyobfe.2005.10.017
   Chen Su, 2006, Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, V23, P1172
   Cho YE, 2010, NUTR RES, V30, P501, DOI 10.1016/j.nutres.2010.06.011
   Choy CS, 2008, J ETHNOPHARMACOL, V115, P455, DOI 10.1016/j.jep.2007.10.012
   Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0
   Edwards HGM, 2004, ANALYST, V129, P134, DOI 10.1039/b311072a
   FARLEY JR, 1994, J BONE MINER RES, V9, P497
   Franceschi RT, 2009, CELLS TISSUES ORGANS, V189, P144, DOI 10.1159/000151747
   Gori F, 1999, J BONE MINER RES, V14, P1522, DOI 10.1359/jbmr.1999.14.9.1522
   Gupta D, 2008, J ETHNOPHARMACOL, V115, P361, DOI 10.1016/j.jep.2007.10.018
   Ichikawa K, 1997, PLANTA MED, V63, P540, DOI 10.1055/s 2006 957759
   Kwun IS, 2010, BONE, V46, P732, DOI 10.1016/j.bone.2009.11.003
   Leboime A, 2010, JOINT BONE SPINE, V77, pS107, DOI 10.1016/S1297 319X(10)70004 X
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Musial Kinga, 2008, Pol Merkur Lekarski, V24 Suppl 4, P25
   Ozeki K, 2008, J MATER SCI MATER M, V19, P1753, DOI 10.1007/s10856 007 3288 y
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Putnam SE, 2007, PHYTOTHER RES, V21, P99, DOI 10.1002/ptr.2030
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Saha S, 2011, J APPL MATH, P1, DOI 10.1155/2011/721349
   Schneider GB, 1999, BONE, V24, P321, DOI 10.1016/S8756 3282(99)00007 1
   STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157
   Thangakumaran S, 2009, Indian J Dent Res, V20, P7
   Tremollieres F, 2006, Gynecol Obstet Fertil, V34, P370, DOI 10.1016/j.gyobfe.2006.02.005
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   W W, 1999, Folia Morphol (Warsz), V58, P155
   W W C, 1881, Science, V2, P83
   W W C, 1883, Science, V2, P211
   Wang WZ, 2008, J RHEUMATOL, V35, P696
   Wu CWW, 2007, NMR BIOMED, V20, P643, DOI 10.1002/nbm.1116
   Yi T, 2011, J ETHNOPHARMACOL, V133, P796, DOI 10.1016/j.jep.2010.11.008
   Zhu YD, 2007, J NAT PROD, V70, P1570, DOI 10.1021/np070260v
NR 42
TC 35
Z9 40
U1 0
U2 52
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD JUN 26
PY 2012
VL 142
IS 1
BP 168
EP 174
DI 10.1016/j.jep.2012.04.033
PG 7
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA 966PS
UT WOS:000305850500024
PM 22543168
DA 2025 08 17
ER

PT J
AU Lin, YT
   Peng, SW
   Imtiyaz, Z
   Ho, CW
   Chiou, WF
   Lee, MH
AF Lin, Yi Tzu
   Peng, Shih Wen
   Imtiyaz, Zuha
   Ho, Chin Wen
   Chiou, Wen Fei
   Lee, Mei Hsien
TI In vivo and in vitro evaluation of the osteogenic
   potential of Davallia mariesii T. Moore ex Baker
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Osteoporosis; Davallia mariesii; Ovariectomy; Primary human osteoblasts;
   5 O beta D (6 O Vanilloylglucopyranosyl)gentisic acid
ID CHINESE MEDICINE; BONE; DIFFERENTIATION; MODEL
AB Ethnopharmacological relevance: Postmenopausal osteoporosis is a major bone health issue worldwide. There is an unmet medical need for osteoporosis treatments, a disease which disproportionately impacts women. Exploring botanicals to prevent or treat osteoporosis is currently an interest of investigations. Rhizomes of Davallia mariesii T. Moore ex Baker (Davalliacea) are used an indigenous herbal medicine in Asia for injuries due to fractures, contusions, and strains.
   Aim of the study: In the present study, we investigated the osteogenic effect of the water extract of rhizomes of D. mariesii (DMH) on bone loss induced by an ovariectomy (OVX) in mice and also its impact on osteogenesis in primary human osteoblasts (HObs). Additionally, we performed a quantitative analysis of compounds in the DMH extract.
   Materials and methods: OVX C57BL/6J mice were orally administrated DMH extract for 12 weeks, and microarchitecture parameters were examined by microcomputed tomography. DMH extract was fractionated in a bioguided manner, and fractions were isolated to obtain active compounds using HObs. Cell viability was evaluated by an MTT assay. Characteristics of early and late osteogenesis were analyzed by alkaline phosphatase activity and a mineralization assay. Molecular mechanisms were explored by a real time quantitative PCR. Compounds in the DMH extract were identified and quantified using liquid chromatography tandem mass spectroscopy (LC MS/MS).
   Results: DMH improved bone mineral densities of vertebrae and the femur. Through microarchitectural observations, DMH significantly decreased the bone surface/volume ratio and trabecular separation, and also increased the connectivity density in the OVX group. Additionally, DMH inhibited osteoclast differentiation in receptor activator of nuclear factor KB ligand induced osteoclasts and increased bone formation in HObs. After bio guided fractionation and isolation, we found that eriodictyol 7 O beta D glucuronide (2) significantly increased alkaline phosphatase activity, and 5 O beta D (6 O vanilloylglucopyranosyl)gentisic acid (3) substantially enhanced mineral deposition. In HObs, compound 3 was more potent in upregulating expressions of bone morphogenetic protein 2, bone sialoprotein, osteopontin, osterix, and estrogen receptor a. The amount of bioactive compound 3 in DMH was 5.68 + 0.64 mg/g of dry weight according to LC MS/MS.
   Conclusion: For the first time we report that D. mariesii and its isolated compounds demonstrated potent osteogenic activities. Quantitative results of D. mariesii could be a reference for phytochemical analyses.
C1 [Lin, Yi Tzu; Imtiyaz, Zuha; Lee, Mei Hsien] Taipei Med Univ, Coll Pharm, Clin Drug Dev Herbal Med, 250 Wuxing St, Taipei 11031, Taiwan.
   [Peng, Shih Wen; Lee, Mei Hsien] Taipei Med Univ, Coll Pharm, Grad Inst Pharmacognosy, 250 Wuxing St, Taipei 11031, Taiwan.
   [Ho, Chin Wen] Tatung Univ, Coll Engn, Dept Bioengn, 40 Zhongshan North Rd,Sect 3, Taipei 10452, Taiwan.
   [Chiou, Wen Fei] Minist Hlth & Welf, Natl Res Inst Chinese Med, 155 1 Linong St,Sect 2, Taipei 11221, Taiwan.
   [Lee, Mei Hsien] Taipei Med Univ Hosp, Ctr Reprod Med & Sci, 252 Wuxing St, Taipei 11031, Taiwan.
C3 Taipei Medical University; Taipei Medical University; Tatung University;
   National Research Institute of Chinese Medicine; Taipei Medical
   University Hospital; Taipei Medical University
RP Lee, MH (通讯作者)，Taipei Med Univ, Coll Pharm, Grad Inst Pharmacognosy, 250 Wuxing St, Taipei 11031, Taiwan.; Chiou, WF (通讯作者)，Minist Hlth & Welf, Natl Res Inst Chinese Med, 155 1 Linong St,Sect 2, Taipei 11221, Taiwan.
EM d339102003@tmu.edu.tw; erica200480@gmail.com; d339105004@tmu.edu.tw;
   cwho@ttu.edu.tw; wfchiou@nricm.edu.tw; lmh@tmu.edu.tw
OI Imtiyaz, Zuha/0000 0001 6927 8623
FU Ministry of Science and Technology, Taiwan [MOST104 2320 B 038 021 MY2]
FX The authors acknowledge the technical assistance provided by the
   Instrumentation Center of National Taiwan University and the Core
   Facility Center of Taipei Medical University. This work was supported by
   a grant from the Ministry of Science and Technology, Taiwan (grant no.
   MOST104 2320 B 038 021 MY2).
CR Almeida M, 2013, J CLIN INVEST, V123, P394, DOI 10.1172/JCI65910
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chinese Pharmacopoeia Commission, 2015, PHARMACOPOEIA PEOPLE, P256
   CUI CB, 1993, CHEM PHARM BULL, V41, P1491, DOI 10.1248/cpb.41.1491
   CUI CB, 1990, CHEM PHARM BULL, V38, P3218, DOI 10.1248/cpb.38.3218
   Czekanska EM, 2012, EUR CELLS MATER, V24, P1
   Do HJ, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/8701650
   Gasser JA., 2017, BONE TOXICOLOGY MOL, P27, DOI DOI 10.1007/978 3 319 56192 9
   Hagh MF, 2015, CELL J, V17, P71
   Han XW, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00103
   Hong GJ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00331
   Huang YC, 2013, EVID BASED COMPL ALT, V2013, P2013, DOI [DOI 10.1155/2013/409421, DOI 10.1155/2013/190281]
   Imtiyaz Z, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133119
   Kenkre JS, 2018, ANN CLIN BIOCHEM, V55, P308, DOI 10.1177/0004563218759371
   Kong LB, 2019, J CELL MOL MED, V23, P3077, DOI 10.1111/jcmm.14277
   Kuo TR, 2017, BIOMARK RES, V5, DOI 10.1186/s40364 017 0097 4
   Kushwaha P, 2019, J CELL PHYSIOL, V234, P23719, DOI 10.1002/jcp.28940
   LEE M, 1992, MAGN RESON CHEM, V30, P1035, DOI 10.1002/mrc.1260301102
   Leung Ping Chung, 2013, J Tradit Complement Med, V3, P82, DOI 10.4103/2225 4110.110407
   Lin TH, 2017, J VASC SURG, V66, P586, DOI 10.1016/j.jvs.2016.03.462
   Man XJ, 2019, MOL MED REP, V19, P4637, DOI 10.3892/mmr.2019.10125
   Mao YW, 2014, J AGR FOOD CHEM, V62, P5581, DOI 10.1021/jf5012177
   Martinkovich S, 2014, CLIN INTERV AGING, V9, P1437, DOI 10.2147/CIA.S66690
   Mielke M, 2018, ZOOL LETT, V4, DOI 10.1186/s40851 018 0093 z
   Mira Pascual L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020538
   Ni LJ, 2016, J ETHNOPHARMACOL, V179, P420, DOI 10.1016/j.jep.2015.12.052
   Orimo Hideo, 2010, Journal of Nippon Medical School, V77, P4
   Pang XG, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4178021
   Rufus P, 2013, CURR DRUG TARGETS, V14, P1689, DOI 10.2174/1389450114666131220160357
   Song SH, 2017, MOLECULES, V22, DOI 10.3390/molecules22071033
   Sophocleous Antonia, 2014, Bonekey Rep, V3, P614, DOI 10.1038/bonekey.2014.109
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Suvarna V, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00981
   Wang LB, 2018, J CHROMATOGR SCI, V56, P327, DOI 10.1093/chromsci/bmy002
   Wang RN, 2014, GENES DIS, V1, P87, DOI 10.1016/j.gendis.2014.07.005
   Wei WL, 2020, J ETHNOPHARMACOL, V251, DOI 10.1016/j.jep.2019.112490
   Wittkowske C, 2016, FRONT BIOENG BIOTECH, V4, DOI 10.3389/fbioe.2016.00087
   Wu CR, 2018, NUTRIENTS, V10, DOI 10.3390/nu10101449
   Wu CF, 2017, PHYTOTHER RES, V31, P1349, DOI 10.1002/ptr.5860
   Xiao WM, 2016, FRONT ORAL BIOL, V18, P9, DOI 10.1159/000351895
   Yang YS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10809 6
   Yeh CC, 2015, DRUG DES DEV THER, V9, P2285, DOI 10.2147/DDDT.S78277
   Yui PB, 2008, NAT CHEM BIOL, V4, P33, DOI 10.1038/nchembio.2007.54
   Zhang H, 2015, CELL MOL BIOL, V61, P96
   Zhang L., 2015, OPEN J STOMATOL, V5, P243
   Zhang Y., 2020, BIOSCI BIOTECH BIOCH, V21, P538, DOI [10.3390/ijms21020538, DOI 10.3390/IJMS21020538]
NR 47
TC 8
Z9 10
U1 1
U2 24
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD JAN 10
PY 2021
VL 264
AR 113126
DI 10.1016/j.jep.2020.113126
PG 12
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA OH5QM
UT WOS:000582639600008
PM 32763416
DA 2025 08 17
ER

PT J
AU Abrahamsen, B
   Einhorn, TA
AF Abrahamsen, Bo
   Einhorn, Thomas A.
TI Beyond a reasonable doubt? Bisphosphonates and atypical femur fractures
SO BONE
LA English
DT Article
DE Osteoporosis; Bisphosphonates; Atypical femur fractures;
   Pathophysiology; Epidemiology
ID FEMORAL SHAFT FRACTURES; DIAPHYSEAL FEMUR; ALENDRONATE THERAPY; NATIONAL
   COHORT; BONE TURNOVER; OSTEOPOROSIS; COMPLICATION; RISK
AB In May 2011, we were privileged to debate on behalf of the ECTS and the ASBMR in a Clinical Debate hosted by the IBMS and the ECTS with the motion "Atypical femoral shaft fractures are a consequence of bisphosphonate therapy". The evidence presented for and against the motion is summarized and discussed in this joint commentary. The hypothetical chain of evidence between bisphosphonates, decreased toughness of bone, microcrack accumulation in man and atypical fractures is plausible but unproven. However, the combination of consistent clinical features (which may include a stress reaction at the site of maximum tensile load), a significant statistical association and a feasible biological mechanism gives grounds for caution especially as regards long term treatment in patients at low or moderate risk of osteoporotic fractures. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Abrahamsen, Bo] Gentofte Univ Hosp, Dept Med F, DK 2900 Hellerup, Denmark.
   [Abrahamsen, Bo] Univ So Denmark, Inst Clin Res, OPEN, DK 5000 Odense C, Denmark.
   [Einhorn, Thomas A.] Boston Univ, Med Ctr, Dept Orthopaed Surg, Boston, MA USA.
C3 University of Copenhagen; Herlev & Gentofte Hospital; University of
   Southern Denmark; Boston University
RP Abrahamsen, B (通讯作者)，Gentofte Univ Hosp, Dept Med F, DK 2900 Hellerup, Denmark.
EM b.abrahamsen@physician.dk
RI ; Abrahamsen, Bo/B 8920 2008
OI Abrahamsen, Bo/0000 0002 2730 6080; Einhorn, Thomas/0000 0002 5075 4885
FU Novartis; Nycomed; Amgen; Amgen, Merck Speakers Bureau with Nycomed;
   Merck; Eli Lilly
FX BA: Grant/Research support from Novartis, Nycomed, Amgen, Merck Speakers
   Bureau with Nycomed, Merck, Eli Lilly. TAE: Consulting fees from
   Novartis and Eli Lilly.
CR Abrahamsen B, 2010, J CLIN ENDOCR METAB, V95, P5258, DOI 10.1210/jc.2010 1571
   Abrahamsen B, 2009, J BONE MINER RES, V24, P1095, DOI [10.1359/JBMR.081247, 10.1359/jbmr.081247]
   Black DM, 2010, NEW ENGL J MED, V362, P1761, DOI 10.1056/NEJMoa1001086
   Brennan O, 2011, J ORTHOP RES, V29, P419, DOI 10.1002/jor.21229
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Dell R, 2010, JBMR S, VS1, P1201
   Feldstein AC, 2012, J BONE MINER RES, V27, P977, DOI 10.1002/jbmr.1550
   Giusti A, 2011, BONE, V48, P966, DOI 10.1016/j.bone.2010.12.033
   Isaacs JD, 2010, CLIN ORTHOP RELAT R, V468, P3384, DOI 10.1007/s11999 010 1535 x
   Jamal SA, 2011, NEW ENGL J MED, V365, P1261, DOI 10.1056/NEJMc1107029
   Kim SY, 2011, J BONE MINER RES, V26, P993, DOI 10.1002/jbmr.288
   Koh JSB, 2011, SINGAP MED J, V52, P77
   Kwek EBK, 2008, INJURY, V39, P224, DOI 10.1016/j.injury.2007.08.036
   Morgan EF, 2008, OSTEOPOROSIS, VOLS I AND II, 3RD EDITION, P3
   Neviaser AS, 2008, J ORTHOP TRAUMA, V22, P346, DOI 10.1097/BOT.0b013e318172841c
   Nieves JW, 2010, OSTEOPOROSIS INT, V21, P399, DOI 10.1007/s00198 009 0962 6
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Park Wyllie LY, 2011, JAMA J AM MED ASSOC, V305, P783, DOI 10.1001/jama.2011.190
   Pauwels F, 1948, Z ANAT ENTWICKLUNGS, P129
   Schilcher J, 2011, NEW ENGL J MED, V364, P1728, DOI 10.1056/NEJMoa1010650
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Wang Z, 2011, J BONE MINER RES, V26, P553, DOI 10.1002/jbmr.233
   Wright JG, 2006, J BONE JOINT SURG BR, V88B, P1264, DOI 10.1302/0301 620X.88B9.18389
NR 23
TC 16
Z9 18
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
J9 BONE
JI Bone
PD MAY
PY 2012
VL 50
IS 5
BP 1196
EP 1200
DI 10.1016/j.bone.2012.02.009
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 932EY
UT WOS:000303274400024
PM 22366401
DA 2025 08 17
ER

PT J
AU Wang, X
   Jiang, W
   Pan, K
   Tao, L
   Zhu, Y
AF Wang, X.
   Jiang, W.
   Pan, K.
   Tao, L.
   Zhu, Y.
TI Melatonin induces RAW264.7 cell apoptosis via the BMAL1/ROS/ MAPK p38
   pathway to improve postmenopausal osteoporosis
SO BONE & JOINT RESEARCH
LA English
DT Article
DE Melatonin; Osteoporosis; BMAL1; ROS
ID GUT MICROBIOTA; BONE MARROW; DEFICIENCY; CONTRIBUTES; FRACTURE
AB Aims Currently, the effect of drug treatment for osteoporosis is relatively poor, and the side effects are numerous and serious. Melatonin is a potential drug to improve bone mass in postmenopausal women. Unfortunately, the mechanism by which melatonin improves bone metabolism remains unclear. The aim of this study was to further investigate the potential mechanism of melatonin in the treatment of osteoporosis. Methods The effects of melatonin on mitochondrial apoptosis protein, bmal1 gene, and related path way proteins of RAW264.7 (mouse mononuclear macrophage leukaemia cells) were analyzed by western blot. Cell Counting Kit  8 was used to evaluate the effect of melatonin on cell viability. Flow cytometry was used to evaluate the effect of melatonin on the apoptosis of RAW264.7 cells and mitochondrial membrane potential. A reactive oxygen species (ROS) detection kit was used to evaluate the level of ROS in osteoclast precursors. We used bmal1 small interfering RNAs (siRNAs) to downregulate the Bmal1 gene. We established a postmen opausal mouse model and verified the effect of melatonin on the bone mass of postmeno pausal osteoporosis in mice via micro  CT. Bmal1 lentiviral activation particles were used to establish an in vitro model of overexpression of the bmal1 gene. Results Melatonin promoted apoptosis of RAW264.7 cells and increased the expression of BMAL1 to inhibit the activation of ROS and phosphorylation of mitogen activated protein kinase (MAP  K)  p38. Silencing the bmal1 gene weakened the above effects of melatonin. After that, we used dehydrocorydaline (DHC) to enhance the activation of MAPK p38, and the effects of melatonin on reducing ROS levels and promoting apoptosis of RAW264.7 cells were also blocked. Then, we constructed a mouse model of postmenopausal osteoporosis and administered melatonin. The results showed that melatonin improves bone loss in ovariectomized mice. Finally, we estab lished a model of overexpression of the bmal1 gene, and these results suggest that the bmal1 gene can regulate ROS activity and change the level of the MAPK p38 signalling pathway. Conclusion Our study confirmed that melatonin promotes the apoptosis of RAW264.7 cells through BMAL1/ROS/MAPK p38, and revealed the therapeutic effect and mechanism of melatonin in postmenopausal osteoporosis. This finding enriches BMAL1 as a potential target for the treatment of osteoporosis and the pathogenesis of postmenopausal osteoporosis.
C1 [Wang, X.; Jiang, W.; Pan, K.; Tao, L.; Zhu, Y.] First Hosp China Med Univ, Shenyang, Liaoning, Peoples R China.
RP Zhu, Y (通讯作者)，First Hosp China Med Univ, Shenyang, Liaoning, Peoples R China.
EM zhuyuedr@163.com
RI ; JIANG, WEN/ABK 9900 2022; Lin, Tao/KRO 9146 2024
OI Tao, Lin/0000 0002 1702 9833; jiang, wen/0000 0001 5521 4792; Wang,
   Xiaochuan/0000 0001 8556 3301; 
FU National Natural Science Foundation of China [32200943, 82072387];
   Shenyang Young and Middle  aged Innovative Talents Project [RC210171]
FX The authors disclose receipt of the following financial or material
   support for the research, authorship, and/or publication of this
   article: the study was supported by the National Natural Science
   Foundation of China (grant no. 82072387) , National Natural Science
   Foundation of China (grant no. 32200943) , Shenyang Young and Middle 
   aged Innovative Talents Project (grant no. RC210171) .
CR Abe S, 2022, BONE JOINT OPEN, V3, P261, DOI 10.1302/2633 1462.33.BJO 2022 0004.R1
   Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Al Hourani K, 2021, BONE JOINT RES, V10, P840, DOI 10.1302/2046 3758.1012.BJR 2021 0452.R1
   Amstrup AK, 2013, OSTEOPOROSIS INT, V24, P2919, DOI 10.1007/s00198 013 2404 8
   Anderson ST, 2020, SCIENCE, V369, P1164, DOI 10.1126/science.abd4964
   Apel K, 2004, ANNU REV PLANT BIOL, V55, P373, DOI 10.1146/annurev.arplant.55.031903.141701
   Breen DP, 2014, JAMA NEUROL, V71, P589, DOI 10.1001/jamaneurol.2014.65
   Chen GJ, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117636
   Cheng B, 2021, BONE JOINT RES, V10, P734, DOI [10.1302/204<Gamma> 3758.1011.BJR 2021 0181.R1, 10.1302/2046 3758.1011.BJR 2021 0181.R1]
   Cipolla Neto J, 2018, ENDOCR REV, V39, P990, DOI 10.1210/er.2018 00084
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Conti A, 2000, J PINEAL RES, V28, P193, DOI 10.1034/j.1600 079X.2000.280401.x
   Cotts KG, 2018, JAMA J AM MED ASSOC, V319, P1040, DOI 10.1001/jama.2017.21995
   D'Autréaux B, 2007, NAT REV MOL CELL BIO, V8, P813, DOI 10.1038/nrm2256
   van Zuijdewijn CD, 2021, BRIT J CLIN PHARMACO, V87, P3485, DOI 10.1111/bcp.14780
   Dong W, 2022, BONE JOINT RES, V11, P528, DOI 10.1302/2046 3758.118.BJR 2021 0392.R1
   Dou C, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.69
   Dubocovich ML, 2005, ENDOCRINE, V27, P101, DOI 10.1385/ENDO:27:2:101
   Fink HA, 2019, ANN INTERN MED, V171, P37, DOI 10.7326/M19 0533
   Hao Y, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12869
   Hijikata Y, 2022, BONE JOINT J, V104B, P97, DOI 10.1302/0301 620X.104B1.BJJ 2021 0151.R3
   Hernandez Morante JJ, 2012, AGE, V34, P1369, DOI 10.1007/s11357 011 9309 2
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim MH, 2022, BONE JOINT RES, V11, P304, DOI 10.1302/2046 3758.115.BJR 2021 0380.R1
   Kondratov RV, 2009, AGING US, V1, P979, DOI 10.18632/aging.100113
   Li J, 2021, BONE JOINT RES, V10, P51, DOI 10.1302/2046 3758.101.BJR 2020 0273.R1
   Liu YD, 2022, BONE JOINT RES, V11, P200, DOI [10.1302/2046 3758.114.BJR 2020 0308.R2, 10.1302/2046 3758.114.BJR 2020 0308 R2]
   Marya S, 2022, BONE JOINT J, V104B, P915, DOI 10.1302/0301 620X.104B8.BJJ 2021 1638.R1
   McCadden L, 2018, J LARYNGOL OTOL, V132, P372, DOI 10.1017/S0022215118000324
   Montgomery S, 2021, BONE JOINT J, V103B, P1783, DOI 10.1302/0301 620X.103B12.BJJ 2021 0495.R2
   Munmun F, 2021, J PINEAL RES, V71, DOI 10.1111/jpi.12749
   Ott SM, 2022, J BONE MINER RES, V37, P1, DOI 10.1002/jbmr.4479
   Reiter RJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082439
   Sies H, 2020, NAT REV MOL CELL BIO, V21, P363, DOI 10.1038/s41580 020 0230 3
   Sim IW, 2020, J CLIN ONCOL, V38, P2971, DOI 10.1200/JCO.19.02192
   Sithole C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910544
   Sun XW, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101309
   Tan DX, 1999, BBA GEN SUBJECTS, V1472, P206, DOI 10.1016/S0304 4165(99)00125 7
   Tang ZH, 2020, MOL THER NUCL ACIDS, V19, P865, DOI 10.1016/j.omtn.2019.12.020
   Tu C, 2022, BONE JOINT RES, V11, P413, DOI 10.1302/2046 3758.117.BJR 2021 0554.R2
   Vasey C, 2021, NUTRIENTS, V13, DOI 10.3390/nu13103480
   Vatner SF, 2020, AGEING RES REV, V64, DOI 10.1016/j.arr.2020.101194
   Williamson TK, 2022, BONE JOINT J, V104B, P1249, DOI 10.1302/0301 620X.104B11.BJJ 2022 0574.R1
   Xia YY, 2019, J PINEAL RES, V66, DOI 10.1111/jpi.12547
   Xie MR, 2020, CIRC RES, V126, pE15, DOI 10.1161/CIRCRESAHA.119.315502
   Xin W, 2021, BONE JOINT RES, V10, P526, DOI 10.1302/2046 3758.108.BJR 2020 0127.R2
   Yang KD, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.975181
   Yue JC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072346
   Zhang Y, 2022, BONE JOINT RES, V11, P763, DOI 10.1302/2046 3758.1111.BJR 2022 0147.R2
   Zhao JJ, 2018, STEM CELL REP, V10, P180, DOI 10.1016/j.stemcr.2017.11.017
   Zhou MS, 2022, BONE JOINT RES, V11, P751, DOI 10.1302/2046 3758.1111.BJR 2022 0017.R2
   Zhou QZ, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/7067984
   Zhou X, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12470
NR 53
TC 15
Z9 17
U1 5
U2 15
PU BRITISH EDITORIAL SOC BONE & JOINT SURGERY
PI LONDON
PA 22 BUCKINGHAM STREET, LONDON WC2N 6ET, ENGLAND
SN 2046 3758
J9 BONE JOINT RES
JI Bone Jt. Res.
PD NOV
PY 2023
VL 12
IS 11
BP 677
EP 690
DI 10.1302/2046 3758.1211.BJR 2022 0425.R3
PG 14
WC Cell & Tissue Engineering; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Orthopedics
GA Z1TX5
UT WOS:001109987000001
PM 37907083
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Egli, RJ
   Schober, M
   Hempfing, A
   Ganz, R
   Hofstetter, W
   Leunig, M
AF Egli, Rainer J.
   Schober, Martin
   Hempfing, Axel
   Ganz, Reinhold
   Hofstetter, Willy
   Leunig, Michael
TI Sensitivity of osteoblasts, fibroblasts, bone marrow cells, and to
   5 aminolevulinic acid based photodynamic therapy
SO JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B BIOLOGY
LA English
DT Article
DE photodynamic therapy; 5 aminotevulinic acid; osteoblast; dendritic cell;
   mixed leukocyte reaction
ID OSTEOCHONDRAL ARTICULAR CARTILAGE; ALKALINE PHOSPHATASE;
   PROTOPORPHYRIN IX; IMMUNE RESPONSE; LEUKEMIC CELLS; ALLOGRAFTS;
   TRANSPLANTATION; ACCUMULATION; CHONDROCYTES; ACTIVATION
AB Introduction: Photodynamic therapy with 5 aminolevulinic acid (5 ALA PDT) exerts cell type specific effects on target cells. Since chondrocytes were found to be more resistant than osteoblasts to 5 ALA PDT, the pre treatment of osteochondral grafts with 5 ALA PDT may represent a means to devitalize the osseous portion while maintaining functional cartilage. The present study was designed to determine the effects of 5 ALA PDT in vitro on cell populations residing in skeletal tissues.
   Methods: Osteoblasts, fibroblasts, bone marrow cells, and dendritic cells were incubated with 0.5 mM 5 ALA for 4 h. Protoporphyrin IX (PpIX) accumulation and after exposure to light cellular functions were assessed for up to 6 days.
   Results: Accumulation of PpIX reached a plateau at 0.5 mM in osteoblasts, fibroblasts, and dendritic cells, and at 2.0 mM in bone marrow cells. At 0.5 mM 5 ALA, similar responses to illumination were observed in all cells with a survival rate of less than 12% at a light dose of 20 J/cm(2). The function of osteoblasts (proliferation, levels of mRNA encoding collagen type 1, alkaline phosphatase activity) and fibroblasts (proliferation, levels of mRNAs encoding collagens type I and III) was not affected, when the cells were treated with 5 ALA and light doses of <= 10 J/cm(2). Paralleling the reduction of viable cells after 5 ALA PDT, the capacity of dendritic cells to stim  ulate T cells in a mixed leukocyte reaction decreased to 4 +/  2% at 20 J/cm(2).
   Conclusion: The investigated cell types were sensitive to 5 ALA PDT and the residual cell debris did not elicit an allogenic response. These findings, together with the resistance of chondrocytes to 5 ALA PDT, encourage the further investigation of this protocol in the pretreatment of osteochondral allografts. (c) 2007 Elsevier B.V. All rights reserved.
C1 [Egli, Rainer J.; Schober, Martin; Hempfing, Axel; Hofstetter, Willy] Univ Oxford, Nuffield Orthopaed Ctr, Botnar Res Ctr, Inst Muscuskeletal Sci, Oxford OX1 2JD, England.
   [Ganz, Reinhold] Balgrist Univ Hosp, Dept Orthoped, CH 8008 Zurich, Switzerland.
   [Leunig, Michael] Schulthess Clin, CH 8008 Zurich, Switzerland.
C3 Nuffield Orthopaedic Centre; University of Oxford; University of Zurich;
   Schulthess Clinic
RP Egli, RJ (通讯作者)，Univ Oxford, Nuffield Orthopaed Ctr, Botnar Res Ctr, Inst Muscuskeletal Sci, Oxford OX1 2JD, England.
EM rainer.egli@ndos.ox.ac.uk; mschober@bluewin.ch; hempfing@yahoo.de;
   reinhold.ganz@balgrist.ch; hofstetter@dkf.unibe.ch;
   michael.leunig@kws.ch
RI ; Leunig, Michael/E 7951 2017
OI Tivchev, Peter/0000 0002 2936 9026; Hofstetter,
   Wilhelm/0000 0003 0126 8423; Egli, Rainer/0000 0003 4440 2338; 
CR BILLINGHAM RE, 1971, CELL IMMUNOL, V2, P1, DOI 10.1016/0008 8749(71)90022 0
   Bluestone JA, 1996, CLIN TRANSPLANT, V10, P104
   BRUN A, 1988, SCAND J CLIN LAB INV, V48, P261, DOI 10.3109/00365518809167493
   Bugbee WD, 1999, CLIN SPORT MED, V18, P67, DOI 10.1016/S0278 5919(05)70130 7
   Convery FR, 1996, J BONE JOINT SURG AM, V78A, P1082, DOI 10.2106/00004623 199607000 00013
   Corthay A, 2006, SCAND J IMMUNOL, V64, P93, DOI 10.1111/j.1365 3083.2006.01782.x
   EGLI RJ, 2006, SWISS MED FORUM, V6, pS13
   FELIX R, 1979, BIOCHEM J, V183, P73, DOI 10.1042/bj1830073
   FRIEDLAENDER GE, 1992, ORTHOPEDICS, V15, P1171
   Grebenová D, 1998, J PHOTOCH PHOTOBIO B, V47, P74, DOI 10.1016/S1011 1344(98)00206 1
   HANANIA J, 1992, CANCER LETT, V65, P127, DOI 10.1016/0304 3835(92)90156 P
   Horas U, 2003, J BONE JOINT SURG AM, V85A, P185, DOI 10.2106/00004623 200302000 00001
   HOROWITZ MC, 1991, J BONE JOINT SURG AM, V73A, P1157, DOI 10.2106/00004623 199173080 00004
   Hryhorenko EA, 1998, IMMUNOPHARMACOLOGY, V40, P231, DOI 10.1016/S0162 3109(98)00047 2
   Kubo T, 2001, J Orthop Sci, V6, P276, DOI 10.1007/s007760100047
   Lafferty K J, 1986, Prog Clin Biol Res, V224, P87
   Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022 1759(98)00204 X
   MIGNOTTE F, 1991, BIOL CELL, V71, P67, DOI 10.1016/0248 4900(91)90052 O
   Moan J, 1998, INT J CANCER, V75, P134, DOI 10.1002/(SICI)1097 0215(19980105)75:1<134::AID IJC20>3.0.CO;2 F
   Ohlendorf C, 1996, J ORTHOPAED RES, V14, P413, DOI 10.1002/jor.1100140311
   Poole AR, 2003, J BONE JOINT SURG AM, V85A, P40, DOI 10.2106/00004623 200300002 00006
   RODRIGO JJ, 1987, CLIN ORTHOP RELAT R, P268
   Rodrigo JJ, 1996, CLIN ORTHOP RELAT R, P96
   Sirlin CB, 2001, RADIOLOGY, V219, P35, DOI 10.1148/radiology.219.1.r01ap0435
   SKJODT H, 1989, IMMUNOLOGY, V68, P416
   Stevenson S, 1996, CLIN ORTHOP RELAT R, P66
   THOREN K, 1993, ACTA ORTHOP SCAND, V64, P44, DOI 10.3109/17453679308994526
   WHYTE MP, 1994, ENDOCR REV, V15, P439, DOI 10.1210/er.15.4.439
   Wingenfeld C, 2002, J BONE JOINT SURG AM, V84A, P1420, DOI 10.2106/00004623 200208000 00019
   WONG GL, 1980, ARTHRITIS RHEUM, V23, P1081, DOI 10.1002/art.1780231003
NR 30
TC 16
Z9 17
U1 1
U2 11
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1011 1344
J9 J PHOTOCH PHOTOBIO B
JI J. Photochem. Photobiol. B Biol.
PD DEC 14
PY 2007
VL 89
IS 2 3
BP 70
EP 77
DI 10.1016/j.jphotobiol.2007.09.005
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 243FH
UT WOS:000251780100002
PM 17945503
DA 2025 08 17
ER

PT J
AU Li, J
   He, ZX
   Liu, RG
   Ma, MX
   Yang, L
   Ye, C
AF Li, Jing
   He, Zhixu
   Liu, Riguang
   Ma, Minxian
   Yang, Long
   Ye, Chuan
TI Brg1 promotes osteogenic differentiation of mesenchymal stem cells by
   regulating Runx2 mediated Wnt and PI3K/AKT pathways
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Brahma related gene 1; osteoporosis; mesenchymal stem cells; osteogenic
   differentiation; Runt related transcription factor 2; Wnt and PI3K/AKT
   pathways
ID CHROMATIN REMODELING COMPLEXES; UMBILICAL CORD BLOOD; BONE MARROW;
   OSTEOBLAST DIFFERENTIATION; STROMAL CELLS; GENE THERAPY; IN VITRO;
   OSTEOPOROSIS; EXPRESSION; SENESCENCE
AB Objective: Brahma related gene 1 (Brg1) has been reported to be related with osteoblast differentiation; however, exact mechanism is unclear. We aimed to investigate the functional role of Brg1 in osteoblast differentiation of bone marrow derived mesenchymal stem cells (MSCs), as well as underlying mechanism. Methods: MSCs obtained from bone marrow of rats were transfected with pcDNA3.1 Brg1 or empty vector, and the transfection efficiency was confirmed. Thereafter, effects of Brg1 overexpression on osteogenesis markers Runt related transcription factor 2 (Runx2), special protein 7 (Sp7), collagen I and osteopontin (OPN) were investigated, as well as cell viability, adhesion ability and migration ability of MSCs. In addition, the interaction between Brg1 and Runx2 was explored by co immunoprecipitation (Co IP). Moreover, after transfection with pcDNA3.1 Brg1, MSCs were incubated with or without the inhibitor of Runx2, CADD522, and then the expression of Wnt and PI3K/AKT pathways key proteins was determined. Results: Brg1 expression vector was successfully transfected into MSCs. Overexpression of Brg1 significantly upregulated expression of Runx2, Sp7, collagen I and OPN, cell viability and adhesion ability (all P < 0.05), but had no effect on migration ability. Additionally, Runx2 was able to coprecipitate with Brg1 and was regulated by Brg1. The expressions of Wnt and PI3K/AKT pathways key proteins were statistically increased by overexpression of Brg1 (P < 0.05); however, administration of CADD522 markedly reversed the effects (P < 0.05 or P < 0.01). Conclusion: Brg1 promotes osteogenic differentiation of MSCs, and the effects might be by regulating Runx2 mediated downstream Wnt and PI3K/AKT pathways.
C1 [Li, Jing; He, Zhixu; Liu, Riguang; Ma, Minxian; Yang, Long; Ye, Chuan] Guizhou Med Univ, Guiyang, Peoples R China.
   [He, Zhixu] Guizhou Med Univ, Affiliated Hosp, Dept Pediat, Guiyang, Peoples R China.
   [Liu, Riguang; Yang, Long; Ye, Chuan] Guizhou Med Univ, Affiliated Hosp, Dept Orthopaed, 28 Guiyi St, Guiyang 550004, Peoples R China.
   [Ma, Minxian] Guizhou Med Univ, Affiliated Hosp, Dept Stomatol, Guiyang, Peoples R China.
C3 Guizhou Medical University; Guizhou Medical University; Guizhou Medical
   University; Guizhou Medical University
RP Ye, C (通讯作者)，Guizhou Med Univ, Affiliated Hosp, Dept Orthopaed, 28 Guiyi St, Guiyang 550004, Peoples R China.
EM yechuan0013@126.com
RI he, zeying/HCH 3380 2022; ye, chuan/ITT 0839 2023
FU National Natural Science Foundation of China [81360232]
FX This study was supported by National Natural Science Foundation of China
   (No. 81360232).
CR Aggarwal R, 2014, METHODS MOL BIOL, V1213, P209, DOI 10.1007/978 1 4939 1453 1_17
   Alessio N, 2010, ONCOGENE, V29, P5452, DOI 10.1038/onc.2010.285
   Antebi B, 2014, CURR OSTEOPOROS REP, V12, P41, DOI 10.1007/s11914 013 0184 x
   Asakura A, 2001, DIFFERENTIATION, V68, P245, DOI 10.1046/j.1432 0436.2001.680412.x
   Augello A, 2010, HUM GENE THER, V21, P1226, DOI 10.1089/hum.2010.173
   Bai J, 2012, J CANCER RES CLIN, V138, P991, DOI 10.1007/s00432 012 1172 8
   Baksh D, 2004, J CELL MOL MED, V8, P301, DOI 10.1111/j.1582 4934.2004.tb00320.x
   Bernardo ME, 2007, J CELL PHYSIOL, V211, P121, DOI 10.1002/jcp.20911
   Bultman SJ, 2005, GENE DEV, V19, P2849, DOI 10.1101/gad.1364105
   De Bari C, 2001, ARTHRITIS RHEUM, V44, P85, DOI 10.1002/1529 0131(200101)44:1<85::AID ANR12>3.0.CO;2 6
   De Bari C, 2001, ARTHRITIS RHEUM US, V44, P1928, DOI 10.1002/1529 0131(200108)44:8<1928::AID ART331>3.0.CO;2 P
   DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092 8674(94)90405 7
   Fakhry Maya, 2013, World J Stem Cells, V5, P136, DOI 10.4252/wjsc.v5.i4.136
   Fuerer C, 2008, EMBO REP, V9, P134, DOI 10.1038/sj.embor.7401159
   Glenn Justin D, 2014, World J Stem Cells, V6, P526, DOI 10.4252/wjsc.v6.i5.526
   Harjanto D, 2010, ORG BIOMOL CHEM, V8, P299, DOI 10.1039/b913064k
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Justesen J, 2001, Ugeskr Laeger, V163, P5491
   Kaeser MD, 2008, J BIOL CHEM, V283, P32254, DOI 10.1074/jbc.M806061200
   Kanis JA, 2000, BONE, V27, P585, DOI 10.1016/S8756 3282(00)00381 1
   Kim N, 2013, ANN HEMATOL, V92, P1295, DOI 10.1007/s00277 013 1796 z
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Lee OK, 2004, BLOOD, V103, P1669, DOI 10.1182/blood 2003 05 1670
   Li Chao, 2015, Med Sci Monit, V21, P845, DOI 10.12659/MSM.893144
   Limpert AS, 2013, J NEUROSCI, V33, P2388, DOI 10.1523/JNEUROSCI.3223 12.2013
   Lin X, 2015, CLIN INTERV AGING, V10, P1017, DOI 10.2147/CIA.S54613
   Looker AC, 1997, J BONE MINER RES, V12, P1761, DOI 10.1359/jbmr.1997.12.11.1761
   Lupsa BC, 2015, ENDOCRIN METAB CLIN, V44, P517, DOI 10.1016/j.ecl.2015.05.002
   Mareschi K, 2001, HAEMATOLOGICA, V86, P1099
   Pino AM, 2012, BIOL RES, V45, P279, DOI 10.4067/S0716 97602012000300009
   Napolitano MA, 2007, J CELL SCI, V120, P2904, DOI 10.1242/jcs.004002
   ONeill TW, 1996, J BONE MINER RES, V11, P1010
   Park JH, 2009, DNA REPAIR, V8, P29, DOI 10.1016/j.dnarep.2008.08.011
   Qin Y, 2016, ARCH BIOL SCI, V68, P551, DOI 10.2298/ABS150901045Q
   Squillaro T, 2015, CELL CYCLE, V14, P1315, DOI 10.4161/15384101.2014.995053
   Sui BD, 2016, STEM CELL TRANSL MED, V5, P1238, DOI 10.5966/sctm.2015 0347
   Wong AKC, 2000, CANCER RES, V60, P6171
   Yeatts AB, 2013, BBA GEN SUBJECTS, V1830, P2470, DOI 10.1016/j.bbagen.2012.06.007
   Young DW, 2005, J CELL BIOCHEM, V94, P720, DOI 10.1002/jcb.20332
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
NR 40
TC 1
Z9 1
U1 0
U2 6
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936 2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2016
VL 9
IS 11
BP 11074
EP 11082
PG 9
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pathology
GA EH8YU
UT WOS:000392059400022
DA 2025 08 17
ER

PT J
AU Gaudio, A
   Morabito, N
AF Gaudio, A
   Morabito, N
TI Pharmacological management of severe postmenopausal osteoporosis
SO DRUGS & AGING
LA English
DT Article
ID BONE MINERAL DENSITY; FRACTURE INTERVENTION TRIAL; RANDOMIZED
   CONTROLLED TRIAL; VITAMIN D SUPPLEMENTATION; ALENDRONATE 70 MG;
   VERTEBRAL FRACTURES; HIP FRACTURE; NONVERTEBRAL FRACTURES; RISEDRONATE
   PREVENTS; PARATHYROID HORMONE
AB The most devastating consequence of osteoporosis is bone fracture, particularly at the vertebral or femoral level. As defined by the WHO, patients with osteoporosis who have had one or more fragility fractures have severe osteoporosis. Those who sustain a vertebral fracture represent a particularly vulnerable group whose risk of another vertebral fracture within the following year is increased by a factor of 3 5. In addition, the presence of a vertebral fracture is associated with an increased risk of hip fracture. In light of these data, treatment of established osteoporosis is extremely important to prevent other fragility fractures. This review examines the therapies approved by the US FDA for the treatment of osteoporosis that have been shown to reduce the incidence of new fractures in patients with established osteoporosis. We evaluated the mechanisms of action, available formulations, efficacy in preventing fractures and increasing bone mineral density (BMD), duration of treatment, adverse effects and contraindications to use of alendronic acid (alendronate), risedronic acid (risedronate), calcitonin, raloxifene and teriparatide. All these drugs are able to prevent new vertebral fractures in patients with established osteoporosis. Only alendronic acid and risedronic acid have also been shown to reduce the risk of fracture at the femoral level, but they are contraindicated in patients with upper gastrointestinal diseases. Calcitonin is a good option in subjects with back pain because of its analgesic effect. Raloxifene is useful when patients have high plasma lipid levels or a family history of breast cancer. Teriparatide is indicated in subjects with very low BMD and multiple vertebral fractures. Patient characteristics should determine selection of therapy but the decision is always difficult and fraught with uncertainty.
C1 Univ Messina, Dept Internal Med, I 98100 Messina, Italy.
C3 University of Messina
RP Morabito, N (通讯作者)，Univ Messina, Dept Internal Med, Pad C3 Piano,AOU Viale Gazzi, I 98100 Messina, Italy.
EM nancynat@libero.it
RI ; Gaudio, Agostino/AAL 4380 2020
OI GAUDIO, Agostino/0000 0002 9958 9606; 
CR American Association of Clinical Endocrinologists Osteoporosis Task Force, 2001, Endocr Pract, V7, P293
   [Anonymous], AM BON HLTH STAT OST
   [Anonymous], 1994, ASS FRACT RISK ITS A
   Black DM, 1999, J BONE MINER RES, V14, P821, DOI 10.1359/jbmr.1999.14.5.821
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Boivin G, 2002, CONNECT TISSUE RES, V43, P535, DOI 10.1080/03008200290000934
   Boivin GY, 2000, BONE, V27, P687, DOI 10.1016/S8756 3282(00)00376 8
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Brown JP, 2002, CALCIFIED TISSUE INT, V71, P103, DOI 10.1007/s00223 002 2011 8
   Cauley JA, 2000, OSTEOPOROSIS INT, V11, P556, DOI 10.1007/s001980070075
   Center JR, 1999, LANCET, V353, P878, DOI 10.1016/S0140 6736(98)09075 8
   Chavassieux PM, 1997, J CLIN INVEST, V100, P1475, DOI 10.1172/JCI119668
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Chesnut CH III, 2000, AM J MED, V109, P267, DOI 10.1016/S0002 9343(00)00490 3
   CHESTNUT CH, 1995, AM J MED, V99, P144, DOI 10.1016/S0002 9343(99)80134 X
   COOPER C, 1992, J BONE MINER RES, V7, P221, DOI 10.1002/jbmr.5650070214
   Cumming RG, 1997, J BONE MINER RES, V12, P1321, DOI 10.1359/jbmr.1997.12.9.1321
   Cummings SR, 1999, JAMA J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   DAVIDSON M, 2002, CLIN REV, V12, P76
   DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003
   Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301
   Delmas PD, 1997, J CLIN ONCOL, V15, P955, DOI 10.1200/JCO.1997.15.3.955
   Donahue JG, 2002, ARCH INTERN MED, V162, P936, DOI 10.1001/archinte.162.8.936
   Draper MW, 1996, J BONE MINER RES, V11, P835
   Ensrud KE, 2004, J BONE MINER RES, V19, P1259, DOI 10.1359/JBMR.040326
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   European Medicines Agency, 2002, REGULATORY REQUIREME, P2
   Fleisch HA, 1997, ANN MED, V29, P55, DOI 10.3109/07853899708998743
   FORTEO L, 2001, PINK SHEET, V63, P3
   Goldstein SR, 1998, AM J OBSTET GYNECOL, V179, P1479, DOI 10.1016/S0002 9378(98)70012 2
   Greenspan SL, 2002, J BONE MINER RES, V17, P1988
   Harrington JT, 2004, CALCIFIED TISSUE INT, V74, P129, DOI 10.1007/s00223 003 0042 4
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Kado DM, 1999, ARCH INTERN MED, V159, P1215, DOI 10.1001/archinte.159.11.1215
   Kanis JA, 1999, QJM MON J ASSOC PHYS, V92, P143, DOI 10.1093/qjmed/92.3.143
   Kannus P, 2000, NEW ENGL J MED, V343, P1506, DOI 10.1056/NEJM200011233432101
   Khovidhunkit W, 1999, ANN INTERN MED, V130, P431, DOI 10.7326/0003 4819 130 5 199903020 00015
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Klotzbuecher CM, 2000, J BONE MINER RES, V15, P721, DOI 10.1359/jbmr.2000.15.4.721
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Lindsay R, 2001, JAMA J AM MED ASSOC, V285, P320, DOI 10.1001/jama.285.3.320
   Lips P, 1996, ANN INTERN MED, V124, P400, DOI 10.7326/0003 4819 124 4 199602150 00003
   Lyritis GP, 1999, CLIN J PAIN, V15, P284, DOI 10.1097/00002508 199912000 00004
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   Mellström DD, 2004, CALCIFIED TISSUE INT, V75, P462, DOI 10.1007/s00223 004 0286 7
   *MERCK CO, 2001, FOS AD SOD PACK INS
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Pols HAP, 1999, OSTEOPOROSIS INT, V9, P461, DOI 10.1007/PL00004171
   *PROCT GAMBL, 2002, ACT RIS SOD PACK INS
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   REID IR, 1995, AM J MED, V98, P331, DOI 10.1016/S0002 9343(99)80310 6
   Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807
   Reid IR, 1998, ENDOCRIN METAB CLIN, V27, P389, DOI 10.1016/S0889 8529(05)70011 6
   REPCHINSKY C, 2001, COMPENDIUM PHARM SPE, P236
   Roux C, 2004, CURR MED RES OPIN, V20, P433, DOI 10.1185/030079903125003125
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Schneider PF, 1999, J BONE MINER RES, V14, P1387, DOI 10.1359/jbmr.1999.14.8.1387
   Schnitzer T, 2000, AGING CLIN EXP RES, V12, P1
   Silverman SL, 2002, OSTEOPOROSIS INT, V13, P858, DOI 10.1007/s001980200118
   Sorensen OH, 2003, BONE, V32, P120, DOI 10.1016/S8756 3282(02)00946 8
   Walsh BW, 1998, JAMA J AM MED ASSOC, V279, P1445, DOI 10.1001/jama.279.18.1445
   Watts NB, 2003, J CLIN ENDOCR METAB, V88, P542, DOI 10.1210/jc.2002 020400
   Zuckerman JD, 1996, NEW ENGL J MED, V334, P1519, DOI 10.1056/NEJM199606063342307
NR 67
TC 7
Z9 10
U1 0
U2 4
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170 229X
EI 1179 1969
J9 DRUG AGING
JI Drugs Aging
PY 2005
VL 22
IS 5
BP 405
EP 417
DI 10.2165/00002512 200522050 00005
PG 13
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 944XL
UT WOS:000230464300005
PM 15903353
DA 2025 08 17
ER

PT J
AU Du, KW
   Li, ZQ
   Fang, XC
   Cao, TW
   Xu, YZ
AF Du, Kewei
   Li, Ziqiang
   Fang, Xuchen
   Cao, Tingwei
   Xu, Yaozeng
TI Ferulic acid promotes osteogenesis of bone marrow derived mesenchymal
   stem cells by inhibiting microRNA 340 to induce β catenin expression
   through hypoxia
SO EUROPEAN JOURNAL OF CELL BIOLOGY
LA English
DT Article
DE Osteogenesis; Mesenchymal stem cells; Hypoxia; MicroRNA; Ferulic acid
ID DIFFERENTIATION; PROLIFERATION; ANGIOGENESIS; METASTASIS; THERAPY;
   PATHWAY
AB Osteogenic differentiation is regulated through multiple signaling networks that may include responses to hypoxia. Antioxidant ferulic acid (FA) can promote hypoxia signaling by inducing hypoxic induced factor (HIF). However, whether FA could affect osteogenesis has not been explored. We examined human bone marrow derived mesenchymal stem cell (MSC) following FA treatment The expression of beta catenin was measured, and candidate microRNAs that target beta catenin were studied. The involvement of hypoxia was investigated in miR 340 5p that contains hypoxia response elements (HRE) in the promoter region. Further, the osteogenic potential of FA treated MSC was assessed by alkaline phosphatase (ALP) activity and alizarin red staining assays. Osteoblast marker gene expressions were also compared between controls and FA treated cells. FA induced beta catenin expression in MSC. This effect is likely mediated through a derepression of beta catenin 3' UTR inhibition by miR 340 5p. HIF 1 alpha, which suppressed miR 340 5p promoter activation through HRE motifs, was induced by FA. The induction of beta catenin signaling by FA was consistent with an enhancement in osteogenesis of FA treated MSC, which could be attenuated by miR 340 5p overexpression. Analysis of the signaling networks induced by FA reveals that hypoxia may promote the osteogenic program in mesenchymal stem cells via a novel microRNA pathway.
C1 [Du, Kewei; Xu, Yaozeng] Soochow Univ, Affiliated Hosp 1, Dept Orthopaed Surg, 188 Shizi Rd, Suzhou 215006, Peoples R China.
   [Du, Kewei; Li, Ziqiang; Fang, Xuchen; Cao, Tingwei] Shidong Hosp Yangpu Dist Shanghai, Dept Orthopaed Surg, 999 Shiguang Rd, Shanghai 200438, Peoples R China.
C3 Soochow University   China
RP Xu, YZ (通讯作者)，Soochow Univ, Affiliated Hosp 1, Dept Orthopaed Surg, 188 Shizi Rd, Suzhou 215006, Peoples R China.
EM xuyaozeng221@sina.com
CR Ameres SL, 2013, NAT REV MOL CELL BIO, V14, P475, DOI 10.1038/nrm3611
   Arnett TR, 2003, J CELL PHYSIOL, V196, P2, DOI 10.1002/jcp.10321
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Bartoszewska S, 2015, FASEB J, V29, P1467, DOI 10.1096/fj.14 267054
   Boxall SA, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/975871
   Bozec A, 2008, NATURE, V454, P221, DOI 10.1038/nature07019
   Cai HQ, 2014, INT J MOL SCI, V15, P560, DOI 10.3390/ijms15010560
   Chen Z, 2013, J CLIN INVEST, V123, P1057, DOI 10.1172/JCI65344
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Fan LH, 2015, BONE, V81, P544, DOI 10.1016/j.bone.2015.09.005
   Fernandez S, 2015, ONCOGENE, V34, P3240, DOI 10.1038/onc.2014.267
   Gong AGW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165486
   GRAF E, 1992, FREE RADICAL BIO MED, V13, P435, DOI 10.1016/0891 5849(92)90184 I
   Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838
   He M, 2013, CELL DEATH DIFFER, V20, P408, DOI 10.1038/cdd.2012.130
   Huang J, 2016, CELL PHYSIOL BIOCHEM, V39, P1177, DOI 10.1159/000447824
   Huang X, 2009, MOL CELL, V35, P856, DOI 10.1016/j.molcel.2009.09.006
   Lai YL, 2006, MOL CELL BIOCHEM, V292, P45, DOI 10.1007/s11010 006 9175 x
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Lian JB, 2012, NAT REV ENDOCRINOL, V8, P212, DOI 10.1038/nrendo.2011.234
   Lin CM, 2010, J NUTR BIOCHEM, V21, P627, DOI 10.1016/j.jnutbio.2009.04.001
   Liu CG, 2008, NAT PROTOC, V3, P563, DOI 10.1038/nprot.2008.14
   Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022
   Mathew S, 2004, CRIT REV BIOTECHNOL, V24, P59, DOI 10.1080/07388550490491467
   Mohammadi Yeganeh S, 2016, TUMOR BIOL, V37, P8993, DOI 10.1007/s13277 015 4513 9
   Oishi S, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00416
   Park KM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5075
   Sagar T, 2016, CYTOTECHNOLOGY, V68, P1963, DOI 10.1007/s10616 016 0009 8
   Sassa S, 2003, IN VIVO, V17, P277
   Saydam O, 2009, MOL CELL BIOL, V29, P5923, DOI 10.1128/MCB.00332 09
   Semenza GL, 1996, TRENDS CARDIOVAS MED, V6, P151, DOI 10.1016/1050 1738(96)00039 4
   Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021
   Semenza GL, 2009, PHYSIOLOGY, V24, P97, DOI 10.1152/physiol.00045.2008
   Sgarbossa A, 2015, NUTRIENTS, V7, P5764, DOI 10.3390/nu7075246
   SHARE JB, 1976, AM J MENT DEF, V80, P388
   Sultana R, 2012, BBA MOL BASIS DIS, V1822, P748, DOI 10.1016/j.bbadis.2011.10.015
   Sun JY, 2012, BIOCHEM BIOPH RES CO, V420, P787, DOI 10.1016/j.bbrc.2012.03.075
   Takeyama H, 2014, MOL CANCER THER, V13, P976, DOI 10.1158/1535 7163.MCT 13 0571
   Utting JC, 2006, EXP CELL RES, V312, P1693, DOI 10.1016/j.yexcr.2006.02.007
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581
   Wu ZS, 2011, CANCER AM CANCER SOC, V117, P2842, DOI 10.1002/cncr.25860
   Zhao ZH, 2008, FOOD CHEM, V109, P691, DOI 10.1016/j.foodchem.2008.02.039
NR 42
TC 37
Z9 42
U1 0
U2 29
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0171 9335
EI 1618 1298
J9 EUR J CELL BIOL
JI Eur. J. Cell Biol.
PD SEP
PY 2017
VL 96
IS 6
BP 496
EP 503
DI 10.1016/j.ejcb.2017.07.002
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA FL5KW
UT WOS:000414276700002
PM 28764862
DA 2025 08 17
ER

PT J
AU Meng, SL
   Zhang, X
   Yu, Y
   Tong, MH
   Yuan, YF
   Cao, YG
   Zhang, W
   Shi, XL
   Liu, K
AF Meng, Shilong
   Zhang, Xu
   Yu, Yang
   Tong, Minghao
   Yuan, Yifeng
   Cao, Yanguang
   Zhang, Wei
   Shi, Xiaolin
   Liu, Kang
TI New QiangGuYin Containing Serum Inhibits Osteoclast Derived Exosome
   Secretion and Down Regulates Notum to Promote Osteoblast Differentiation
SO ADVANCED BIOLOGY
LA English
DT Article
DE exosomes; new QiangGuYin; osteoclast; osteogenic differentiation;
   osteoporosis
ID MESENCHYMAL STEM CELLS; OSTEOPOROSIS; MICRORNAS
AB New QiangGuYin (N QGY), the addition of sea buckthorn on the basis of QGY formula, is herbal formula widely used clinically in China for the treatment of osteoporosis (OP), but its mechanism warrants further exploration. The mechanisms of QGY and N QGY in the treatment of OP are probed from the perspective of osteoclast osteoblast balance. Thirty Sprague Dawley rats are randomly divided into N QGY group, QGY group, and Control group. Beyond control rats that orally took normal saline, other rats are orally administered with isometric N QGY or QGY twice every day for 3 days. The drug containing serum and control serum are prepared and their effects on osteoclast derived exosome secretion are determined by bicinchoninic acid assay (BCA), nanoparticle tracking analysis, and Western blot. GW4869 and Interleukin 1 beta (IL 1 beta) are adopted as the exosome inhibitor and inducer, respectively. Exosome uptake, cell counting kit 8, alkaline phosphatase (ALP) staining, alizarin red staining, enzyme linked immunosorbent assay, quantitative real time polymerase chain reaction, and Western blot are performed to examine the effects of altered osteoclast exosome content on osteogenic differentiation of mesenchymal stem cells (MSCs). N QGY, QGY, and GW4869 inhibit osteoclast derived exosome secretion and exosome uptake by MSCs, whereas IL 1 beta exerted the opposite effects (p < 0.05). Different from IL 1 beta, N QGY, QGY, and GW4869 partially elevated MSC viability, osteocalcin secretion, ALP, RUNX Family Transcription Factor 2 (RUNX2) and Osteopontin (OPN) expressions, and calcium deposition in the osteoclast MSCs coculture system (p < 0.05). Mechanically, osteoclasts increased Notum protein level but decreased beta catenin level, which is enhanced by IL 1 beta but is reversed by GW4869, QGY, and N QGY (p < 0.05). And the effect of N QGY is more conspicuous than that of QGY (P<0.05). N QGY containing serum inhibits exosome levels in osteoclasts, thereby enhancing osteogenic differentiation of MSCs via inhibition of Notum protein and promotion of beta catenin protein.
C1 [Meng, Shilong; Zhang, Xu; Yu, Yang; Tong, Minghao] Zhejiang Chinese Med Univ, Clin Sch 2, Hangzhou 310053, Zhejiang, Peoples R China.
   [Yuan, Yifeng; Cao, Yanguang; Shi, Xiaolin; Liu, Kang] Zhejiang Chinese Med Univ, Affiliated Hosp 2, Hangzhou 310005, Zhejiang, Peoples R China.
   [Zhang, Wei] Zhejiang Chinese Med Univ, Affiliated Hosp 2, Xianju Branch, Taizhou 310006, Zhejiang, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang Chinese Medical
   University; Zhejiang Chinese Medical University
RP Liu, K (通讯作者)，Zhejiang Chinese Med Univ, Affiliated Hosp 2, Hangzhou 310005, Zhejiang, Peoples R China.
EM 20084011@ZCMU.edu.cn
RI Yuan, Yifeng/ABH 6910 2020; Tong, Minghao/LFS 7191 2024
FU National Natural Science Foundation of China [81973884, 82274272]; Key
   Research Project of Zhejiang Traditional Chinese Medicine [2022ZZ020];
   Zhejiang Provincial Education Department Project [Y202248737]
FX S.M. and X.Z contributed equally to this work. The authors thank all
   colleagues working in the Second School of Clinical Medicine, Zhejiang
   University of Traditional Chinese Medicine. This work was supported by
   the National Natural Science Foundation of China [81973884 & 82274272];
   the Key Research Project of Zhejiang Traditional Chinese Medicine
   [2022ZZ020]; the Zhejiang Provincial Education Department Project
   [Y202248737]. These funders had no role in the study design, data
   collection, and analysis, interpretation of data, and writing the
   manuscript.
CR Brommage R, 2019, BONE RES, V7, DOI 10.1038/s41413 018 0038 3
   Brown JP, 2021, ENDOCRINOL METAB, V36, P544, DOI 10.3803/EnM.2021.301
   Cheng M, 2011, J ETHNOPHARMACOL, V138, P279, DOI 10.1016/j.jep.2011.09.030
   Coughlan T, 2014, CLIN MED, V14, P187, DOI 10.7861/clinmedicine.14 2 187
   Crane JL, 2014, J CLIN INVEST, V124, P466, DOI 10.1172/JCI70050
   Gan DH, 2019, MED SCI MONITOR, V25, P5700, DOI 10.12659/MSM.915170
   He JB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01344
   Hu LF, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020360
   Hu YQ, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/2310025
   Huang YP, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/4170156
   Huo KL, 2023, WORLD J STEM CELLS, V15, P83, DOI 10.4252/wjsc.v15.i3.83
   Huynh N, 2016, J DENT RES, V95, P673, DOI 10.1177/0022034516633189
   Jian J, 2015, ACTA PHARM SIN B, V5, P454, DOI 10.1016/j.apsb.2015.06.005
   Jin H, 2022, BIOMED PHARMACOTHER, V153, DOI 10.1016/j.biopha.2022.113379
   Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Li L, 2019, AGING US, V11, P9348, DOI 10.18632/aging.102376
   Li QC, 2022, CURR PHARM DESIGN, V28, P899, DOI 10.2174/1381612828666220128104206
   Li XF, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/7114139
   Li Y, 2018, CURR STEM CELL RES T, V13, P185, DOI 10.2174/1574888X12666171012141908
   Liu M, 2018, J DENT RES, V97, P859, DOI 10.1177/0022034518764411
   Narayanan K, 2018, BIOMATERIALS, V182, P312, DOI 10.1016/j.biomaterials.2018.08.027
   Nilsson KH, 2021, AM J PHYSIOL ENDOC M, V320, pE967, DOI 10.1152/ajpendo.00565.2020
   Park KH, 2022, NUTRIENTS, V14, DOI 10.3390/nu14173604
   Peng ZC, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.911326
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Shao Y, 2022, MEDICINE, V101, DOI 10.1097/MD.0000000000029257
   Shi Jingli, 2008, J Tradit Chin Med, V28, P211
   Shi Z. Y., 2017, EVID BASED COMPL ALT, V2017, P1
   Wang JY, 2019, VIROL SIN, V34, P59, DOI 10.1007/s12250 019 00087 3
   Wang Y, 2023, Guidelines and Standards of Chinese Medicine, V1, P1, DOI DOI 10.1097/GSCM.0000000000000009
   Wen JY, 2023, BIOMED PHARMACOTHER, V158, DOI 10.1016/j.biopha.2022.114122
   Willis CM, 2017, FRONT NEUROSCI SWITZ, V11, DOI 10.3389/fnins.2017.00335
   Wu HS, 2022, J PHARMACEUT BIOMED, V221, DOI 10.1016/j.jpba.2022.115078
   Xiao J., 2023, EVID BASED COMPL ALT, V2023, P1
   Xie XD, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.594247
   Xie Y, 2017, J CELL MOL MED, V21, P1033, DOI 10.1111/jcmm.13039
   Yong EL, 2021, SINGAP MED J, V62, P159, DOI 10.11622/smedj.2021036
   Yu B, 2022, PERIODONTOL 2000, V89, P99, DOI 10.1111/prd.12422
   Yuan YF, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.994995
   Yuan YF, 2022, AGING US, V14, P892, DOI 10.18632/aging.203848
   Zhu SP, 2018, BIOL REV, V93, P469, DOI 10.1111/brv.12353
   Zhu Y, 2020, NANOSCALE, V12, P8720, DOI 10.1039/d0nr00867b
NR 44
TC 1
Z9 1
U1 9
U2 18
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 2701 0198
J9 ADV BIOL GER
JI Adv. Biol.
PD MAR
PY 2025
VL 9
IS 3
DI 10.1002/adbi.202400166
EA JUN 2024
PG 8
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA 0FW0O
UT WOS:001256526400001
PM 38935529
DA 2025 08 17
ER

PT J
AU Wang, WYJ
   Zheng, XL
   Wang, HH
   Zuo, B
   Chen, SS
   Li, J
AF Wang, Wanyuji
   Zheng, Xueling
   Wang, Hehe
   Zuo, Bin
   Chen, Sisi
   Li, Jiao
TI Mechanical Unloading Promotes Osteoclastic Differentiation and Bone
   Resorption by Modulating the MSC Secretome to Favor Inflammation
SO CELL TRANSPLANTATION
LA English
DT Article
DE mechanical loading; MSCs; osteoclasts; bone resorption; inflammation
ID HEMATOPOIETIC STEM; OSTEOCYTE; RANKL; MECHANOTRANSDUCTION; SKELETAL
AB Aging, space flight, and prolonged bed rest have all been linked to bone loss, and no effective treatments are clinically available at present. Here, with the rodent hindlimb unloading (HU) model, we report that the bone marrow (BM) microenvironment was significantly altered, with an increased number of myeloid cells and elevated inflammatory cytokines. In such inflammatory BM, the osteoclast mediated bone resorption was greatly enhanced, leading to a shifted bone remodeling balance that ultimately ends up with disuse induced osteoporosis. Using Piezo1 conditional knockout (KO) mice (Piezo1fl/fl;LepRCre), we proved that lack of mechanical stimuli on LepR+ mesenchymal stem cells (MSCs) is the main reason for the pathological BM inflammation. Mechanically, the secretome of MSCs was regulated by mechanical stimuli. Inadequate mechanical load leads to increased production of inflammatory cytokines, such as interleukin (IL) 1 alpha, IL 6, macrophage colony stimulating factor 1 (M CSF 1), and so on, which promotes monocyte proliferation and osteoclastic differentiation. Interestingly, transplantation of 10% cyclic mechanical stretch (CMS) treated MSCs into HU animals significantly alleviated the BM microenvironment and rebalanced bone remodeling. In summary, our research revealed a new mechanism underlying mechanical unloading induced bone loss and suggested a novel stem cell based therapy to potentially prevent disuse induced osteoporosis.
C1 [Wang, Wanyuji; Zheng, Xueling; Wang, Hehe; Li, Jiao] Zunyi Med Univ, Dept Cell Biol, Zunyi, Peoples R China.
   [Zuo, Bin; Chen, Sisi] Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Dept Orthoped Surg, Shanghai, Peoples R China.
   [Li, Jiao] Zunyi Med Univ, Dept Cell Biol, West Xuefu Rd, Zunyi 563000, Guizhou, Peoples R China.
C3 Zunyi Medical University; Shanghai Jiao Tong University; Zunyi Medical
   University
RP Li, J (通讯作者)，Zunyi Med Univ, Dept Cell Biol, West Xuefu Rd, Zunyi 563000, Guizhou, Peoples R China.
EM Jiaoli@zmu.edu.cn
RI ; chen, sisi/KMA 2807 2024
OI Wang, Wanyuji/0009 0002 9461 3520; 
FU National Natural Science Foundation of China [82060266]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This
   research was funded by grants from the National Natural Science
   Foundation of China (grant no. 82060266).
CR Ayaz Guner S, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964 020 00614 w
   Brylka LJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02182
   Bullock WA., 2019, Orthod Craniofac Res, V22
   Christen P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5855
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012 1026
   Delgado Calle J, 2022, PHYSIOL REV, V102, DOI 10.1152/physrev.00043.2020
   Driscoll J, 2019, J GASTROENTEROL, V54, P763, DOI 10.1007/s00535 019 01599 1
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   FROST HM, 1992, J BONE MINER RES, V7, P253
   Gnani D, 2019, AGING CELL, V18, DOI 10.1111/acel.12933
   Gortazar AR, 2013, J BIOL CHEM, V288, P8168, DOI 10.1074/jbc.M112.437921
   Gould NR, 2021, BONE, V149, DOI 10.1016/j.bone.2021.115971
   Greenbaum A, 2013, NATURE, V495, P227, DOI 10.1038/nature11926
   HATTNER R, 1965, NATURE, V206, P489, DOI 10.1038/206489a0
   Hu XB, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13095
   Huiskes R, 2000, NATURE, V405, P704, DOI 10.1038/35015116
   Kartsogiannis V, 1999, BONE, V25, P525, DOI 10.1016/S8756 3282(99)00214 8
   Kohli N, 2018, BONE, V110, P38, DOI 10.1016/j.bone.2018.01.015
   Kushioka J, 2023, INFLAMM REGEN, V43, DOI 10.1186/s41232 023 00279 1
   Lehmann J, 2022, CELL MOL LIFE SCI, V79, DOI 10.1007/s00018 021 04035 x
   Li J, 2016, AGING DIS, V7, P514, DOI 10.14336/AD.2015.1206
   Li XH, 2019, ELIFE, V8, DOI 10.7554/eLife.49631
   Liu FD, 2017, ACS BIOMATER SCI ENG, V3, P3292, DOI 10.1021/acsbiomaterials.7b00644
   Lloyd SA, 2014, J BONE MINER RES, V29, P275, DOI 10.1002/jbmr.2165
   Mitchell CA, 2023, NAT CELL BIOL, V25, P30, DOI 10.1038/s41556 022 01053 0
   O'Hagan Wong K, 2016, ONCOTARGET, V7, P13285, DOI 10.18632/oncotarget.7690
   Ozcivici E, 2010, NAT REV RHEUMATOL, V6, P50, DOI 10.1038/nrrheum.2009.239
   Plotkin LI, 2015, CURR OSTEOPOROS REP, V13, P67, DOI 10.1007/s11914 015 0255 2
   Sato T, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 17099 3
   Shen B, 2021, NATURE, V591, P438, DOI 10.1038/s41586 021 03298 5
   Shiau HJ, 2014, PERIODONTOL 2000, V64, P81, DOI 10.1111/prd.12033
   Spatz JM, 2015, J BIOL CHEM, V290, P16744, DOI 10.1074/jbc.M114.628313
   Sugimoto A, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 18089 0
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001
   Van Tol AF., 2020, Proc Natl Acad Sci U S A, V117
   Vilar A., 2023, Acta Biomater
   Wang LJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14146 6
   Wang YL, 2007, P NATL ACAD SCI USA, V104, P15941, DOI 10.1073/pnas.0707246104
   Xiao F, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm 21 1838
   Xiong JH, 2012, J BONE MINER RES, V27, P499, DOI 10.1002/jbmr.1547
   Zhao YN, 2023, ADV HEALTHC MATER, V12, DOI 10.1002/adhm.202203099
   Zheng X., 2023, Cytotherapy, V25
   Zheng XL, 2021, EXP GERONTOL, V148, DOI 10.1016/j.exger.2021.111313
NR 44
TC 2
Z9 2
U1 1
U2 7
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0963 6897
EI 1555 3892
J9 CELL TRANSPLANT
JI Cell Transplant.
PY 2024
VL 33
AR 09636897241236584
DI 10.1177/09636897241236584
PG 13
WC Cell & Tissue Engineering; Medicine, Research & Experimental;
   Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine; Transplantation
GA LO1Y6
UT WOS:001187664300001
PM 38501500
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Shigematsu, T
   Fukagawa, M
   Yokoyama, K
   Akiba, T
   Fujii, A
   Shinoda, A
   Akizawa, T
AF Shigematsu, Takashi
   Fukagawa, Masafumi
   Yokoyama, Keitaro
   Akiba, Takashi
   Fujii, Akifumi
   Shinoda, Atsushi
   Akizawa, Tadao
TI Influence of dialysate Ca concentrations on the therapeutic effects of
   etelcalcetide with concomitant drugs in patients with secondary
   hyperparathyroidism
SO NEPHROLOGY
LA English
DT Article
DE bone metabolism; calcimimetics; calcium dialysate; etelcalcetide;
   secondary hyperparathyroidism
ID PATIENTS RECEIVING HEMODIALYSIS; SERUM PARATHYROID HORMONE; METABOLISM;
   CALCIUM
AB Aim Secondary hyperparathyroidism (SHPT), a complication of haemodialysis, is commonly treated with calcimimetics. The impact of dialysates containing different calcium (Ca) concentrations on clinical efficacy of calcimimetics are unclear. We examined whether dialysate Ca concentrations influence the efficacy and dosing of etelcalcetide with concomitant drugs. Methods We performed post hoc analyses of a 52 week, open label, multicentre study of etelcalcetide in Japanese SHPT patients to determine whether dialysate Ca influences the therapeutic effects of etelcalcetide with concomitant drugs. We evaluated the differences in serum intact parathyroid hormone (iPTH), corrected Ca (cCa) and phosphate levels among three dialysate Ca concentration groups (2.5, 2.75 or 3.0 mEq/L Ca). Tartrate resistant acid phosphatase 5b (TRACP 5b) and bone alkaline phosphatase (BAP) levels were also compared. Since the dialysate Ca concentration may influence dose adjustment, we assessed the etelcalcetide and concomitant drug doses. Results There were no clinically meaningful differences in iPTH, cCa and phosphate levels among the 2.5, 2.75 and 3.0 mEq/L groups (n = 34, 64 and 35, respectively) over 52 weeks. At Week 52, more than 82%, 71% and 67% of patients had iPTH, cCa and phosphate levels within target ranges (60 240 pg/mL, 8.4 10.0 mg/dL and 3.5 6.0 mg/dL, respectively) across the three groups. TRACP 5b and BAP levels decreased by Week 52 regardless of dialysate Ca. Changes in etelcalcetide and concomitant drug doses were generally similar in each group. Conclusion The efficacy and dosing of etelcalcetide with concomitant drugs were essentially unaffected by the dialysate Ca concentration. Patients showed improvements in bone hypermetabolism during treatment.
C1 [Shigematsu, Takashi] Wakayama Med Univ, Dept Nephrol, 811 1 Kimiidera, Wakayama, Wakayama 6418509, Japan.
   [Fukagawa, Masafumi] Tokai Univ, Sch Med, Dept Internal Med, Div Nephrol Endocrinol & Metab, Isehara, Kanagawa, Japan.
   [Yokoyama, Keitaro] Jikei Univ, Sch Med, Dept Internal Med, Div Nephrol & Hypertens, Tokyo, Japan.
   [Akiba, Takashi] Tokyo Next Nephrol & Dialysis Clin, Tokyo, Japan.
   [Fujii, Akifumi] Ono Pharmaceut Co Ltd, Clin Dev Planning, Osaka, Japan.
   [Shinoda, Atsushi] Ono Pharmaceut Co Ltd, Med Affairs, Osaka, Japan.
   [Akizawa, Tadao] Showa Univ, Sch Med, Dept Med, Div Nephrol, Tokyo, Japan.
C3 Wakayama Medical University; Tokai University; Jikei University; Ono
   Pharmaceutical Co Ltd; Ono Pharmaceutical Co Ltd; Showa University
RP Shigematsu, T (通讯作者)，Wakayama Med Univ, Dept Nephrol, 811 1 Kimiidera, Wakayama, Wakayama 6418509, Japan.
EM taki@wakayama med.ac.jp
FU Ono Pharmaceutical Co., Ltd.
FX This study was funded and conducted by Ono Pharmaceutical Co., Ltd. The
   authors thank the Clinical Development Department, Ono Pharmaceutical
   Co., Ltd., for their assistance in preparing and writing this report,
   and Nicholas D. Smith (EMC K.K.) for medical writing support, which was
   funded by Ono Pharmaceutical Co. Ltd.
CR [Anonymous], 2017, Sci. Rep., V7, P1
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Block GA, 2017, JAMA J AM MED ASSOC, V317, P146, DOI 10.1001/jama.2016.19456
   Block GA, 2017, JAMA J AM MED ASSOC, V317, P156, DOI 10.1001/jama.2016.19468
   Cozzolino M, 2017, THER CLIN RISK MANAG, V13, P679, DOI 10.2147/TCRM.S108490
   Cunningham J, 2011, CLIN J AM SOC NEPHRO, V6, P913, DOI 10.2215/CJN.06040710
   Fukagawa M, 2013, THER APHER DIAL, V17, P247, DOI 10.1111/1744 9987.12058
   Halleen JM, 2002, CALCIFIED TISSUE INT, V71, P20, DOI 10.1007/s00223 001 2122 7
   Hamano N, 2017, EXPERT OPIN PHARMACO, V18, P529, DOI 10.1080/14656566.2017.1303482
   Hamano T, 2018, SEMIN DIALYSIS, V31, P592, DOI 10.1111/sdi.12729
   KLEEMAN CR, 1961, CALIF MED, V94, P335
   Pun PH, 2016, HEMODIAL INT, V20, P421, DOI 10.1111/hdi.12382
   Shigematsu T, 2018, CLIN THER, V40, P2099, DOI 10.1016/j.clinthera.2018.10.016
   Shigematsu T, 2018, CLIN EXP NEPHROL, V22, P426, DOI 10.1007/s10157 017 1442 5
   Silver J, 2002, AM J PHYSIOL RENAL, V283, pF367, DOI 10.1152/ajprenal.00061.2002
   Ueda M, 2005, LIFE SCI, V77, P1130, DOI 10.1016/j.lfs.2005.02.007
   van der Sande FM, 2019, BLOOD PURIFICAT, V47, P230, DOI 10.1159/000494584
   Yokoyama K, 2002, NEPHRON, V92, P86, DOI 10.1159/000064484
NR 18
TC 2
Z9 2
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1320 5358
EI 1440 1797
J9 NEPHROLOGY
JI Nephrology
PD AUG
PY 2020
VL 25
IS 8
BP 634
EP 643
DI 10.1111/nep.13682
EA DEC 2019
PG 10
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA MP9OV
UT WOS:000504539800001
PM 31765028
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Xing, J
   Lian, M
   Shen, QJ
   Feng, GJ
   Huang, D
   Lu, XH
   Gu, ZF
   Li, LR
   Zhang, JL
   Huang, S
   You, QS
   Wu, X
   Zhang, DM
   Feng, XM
AF Xing, Jing
   Lian, Min
   Shen, Qijie
   Feng, Guijuan
   Huang, Dan
   Lu, Xiaohui
   Gu, Zhifeng
   Li, Liren
   Zhang, Jinglong
   Huang, Shen
   You, Qingsheng
   Wu, Xiang
   Zhang, Dongmei
   Feng, Xingmei
TI AGS3 is involved in TNF α medicated osteogenic differentiation of human
   dental pulp stem cells
SO DIFFERENTIATION
LA English
DT Article
DE Activator of G protein signaling 3 (AGS3); Tumor necrosis factor alpha
   (TNE alpha); Dental pulp stem cells (DPSCs); Cyclic 3',5' adenosine
   monophosphate (cAMP); Protein kinase A (PKA); CAMP response element
   (CRE) binding protein (CREB); Osteogenic differentiation
ID NECROSIS FACTOR ALPHA; IN VITRO; CHRONIC PERIODONTITIS;
   RHEUMATOID ARTHRITIS; CLINICAL PARAMETERS; CYTOKINE PROFILES; RAT MODEL;
   BONE LOSS; EXPRESSION; ACTIVATOR
AB Dental pulp stem cells (DPSCs) are multipotent adult stem cells capable of differentiating along the osteoblast, adipocyte, and chondrocyte lineages. Regulating differentiation of DPSCs may be a useful tool for regenerative medicine and cell based therapy in oral diseases. Multisignaling pathways are involved in osteogenic differentiation of DPSCs. Recent studies show that cAMP/PKA/CREB signaling could stimulate the expression of genes such as bone morphogenic proteins 2 (BMP2), inhibitor of DNA binding 2 (ID2), bone sialoprotein, osteocalcin, and type XXIV collagen, which have been implicated in osteogenesis and bone formation. Activator of G protein signaling 3 (AGS3, gene name G protein signaling modulator 1, Gpsml), an accessory protein for G protein signaling, plays an important role in regulating the phosphorylation acyclic AMP response element binding protein (p CREB). However, the involvement of AGS3 in osteogenic differentiation of DPSCs has not been explored. Our data indicated that increased expression of AGS3 would inhibit osteogenic differentiation of DPSCs exposed to inflammatory cytokine tumor necrosis factor alpha (TNF alpha) via cAMP/PKA/CREB signaling. The negative role of AGS3 in osteogenic differentiation was further confirmed by knocking down and over expression of AGS3. Our findings may provide clinical implications for osteoporosis. (C) 2015 international Society of Differentiation. Published by Elsevier B.V. All rights reserved.
C1 [Xing, Jing; Lian, Min; Shen, Qijie; Feng, Guijuan; Huang, Dan; Lu, Xiaohui; Feng, Xingmei] Nantong Univ, Jiangsu Prov Key Lab Inflammat & Mol Drug Target, Affiliated Hosp, Dept Stomatol, Nantong, Peoples R China.
   [Gu, Zhifeng] Nantong Univ, Affiliated Hosp, Dept Rheumatol, Nantong, Peoples R China.
   [Li, Liren] Nantong Univ, Affiliated Hosp, Dept Hematol, Nantong, Peoples R China.
   [Zhang, Dongmei] Nantong Univ, Coll Med, Dept Pathogen Biol, Nantong, Peoples R China.
   [Zhang, Jinglong; Huang, Shen] Nantong Univ, Affiliated Hosp 2, Dept Spine Surg, Nantong, Peoples R China.
   [You, Qingsheng; Wu, Xiang] Nantong Univ, Affiliated Hosp, Dept Cardiothorac Surg, Nantong, Peoples R China.
C3 Nantong University; Nantong University; Nantong University; Nantong
   University; Nantong University; Nantong University
RP Zhang, DM (通讯作者)，Nantong Univ, Coll Med, Dept Immunol, Nantong, Peoples R China.
EM zdm060808@aliyun.com; fengxingmei1220@163.com
RI ; Gu, Zhifeng/AAP 9566 2021; Lu, Xiaohui/I 1937 2012; Chen,
   Hao/KXR 2271 2024
OI Feng, xingmei/0000 0001 8046 3336; 
FU Graduate Student Innovation of Science and Technology Project in Jiangsu
   Province [SJLX0588]; Graduate Student Innovation of Science and
   Technology Project in Nantong University [YKS14015]; "Top Six Types of
   Talents" Financial Assistance of Jiangsu Province Grant [10]; Jiangsu
   Provincial Natural Science Foundation [BK2011385]; Nantong City Social
   Development Projects funds [HS2012032]
FX This work was supported by Graduate Student Innovation of Science and
   Technology Projects in Jiangsu Province (Grant no. SJLX0588) and in
   Nantong University (Grant no. YKS14015); the "Top Six Types of Talents"
   Financial Assistance of Jiangsu Province Grant (No. 10); Jiangsu
   Provincial Natural Science Foundation (BK2011385); and the Nantong City
   Social Development Projects funds (HS2012032).
CR Alge DL, 2010, J TISSUE ENG REGEN M, V4, P73, DOI 10.1002/term.220
   Blumer JB, 2008, ENDOCRINOLOGY, V149, P3842, DOI 10.1210/en.2008 0050
   Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207
   D'Alimonte I, 2013, STEM CELL RES, V11, P611, DOI 10.1016/j.scr.2013.04.002
   Ding C, 2014, J CLIN PERIODONTOL, V41, P748, DOI 10.1111/jcpe.12279
   Engebretson S, 2007, J CLIN PERIODONTOL, V34, P18, DOI 10.1111/j.1600 051X.2006.01017.x
   Feng XM, 2013, CELL BIOL INT, V37, P1267, DOI 10.1002/cbin.10141
   Feng XM, 2013, CELL MOL NEUROBIOL, V33, P1023, DOI 10.1007/s10571 013 9965 0
   Górska R, 2003, J CLIN PERIODONTOL, V30, P1046, DOI 10.1046/j.0303 6979.2003.00425.x
   Gronthos S, 2002, J DENT RES, V81, P531, DOI 10.1177/154405910208100806
   Havemose Poulsen A, 2005, J PERIODONTOL, V76, P2276, DOI 10.1902/jop.2005.76.12.2276
   Huang H, 2011, CELL PROLIFERAT, V44, P420, DOI 10.1111/j.1365 2184.2011.00769.x
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   JANSSON L, 1995, J CLIN PERIODONTOL, V22, P729, DOI 10.1111/j.1600 051X.1995.tb00254.x
   Kim JM, 2013, J CELL PHYSIOL, V228, P617, DOI 10.1002/jcp.24171
   KJELDSEN M, 1993, J PERIODONTOL, V64, P1013, DOI 10.1902/jop.1993.64.11.1013
   Kong XW, 2013, BBA GEN SUBJECTS, V1830, P5119, DOI 10.1016/j.bbagen.2013.07.027
   Lisignoli G, 2004, EXP GERONTOL, V39, P659, DOI 10.1016/j.exger.2003.09.030
   Mareddy S, 2009, J CELL BIOCHEM, V106, P776, DOI 10.1002/jcb.22088
   Mori G, 2010, J BIOL REG HOMEOS AG, V24, P167
   Mori G, 2011, ANN NY ACAD SCI, V1237, P47, DOI 10.1111/j.1749 6632.2011.06234.x
   Mountziaris PM, 2013, J BIOMAT SCI POLYM E, V24, P1794, DOI 10.1080/09205063.2013.803455
   Özgören Ö, 2014, ADV CLIN EXP MED, V23, P559
   Pesevska S, 2012, LASER MED SCI, V27, P377, DOI 10.1007/s10103 011 0898 x
   Pierdomenico L, 2005, TRANSPLANTATION, V80, P836, DOI 10.1097/01.tp.0000173794.72151.88
   Purpura KA, 2004, STEM CELLS, V22, P39, DOI 10.1634/stemcells.22 1 39
   Rettori E, 2012, NEUROIMMUNOMODULAT, V19, P293, DOI 10.1159/000339113
   Rodríguez Lozano FJ, 2012, MED ORAL PATOL ORAL, V17, pE1062, DOI 10.4317/medoral.17925
   Shao S, 2014, INT J HEMATOL, V99, P57, DOI 10.1007/s12185 013 1484 8
   Siddappa R, 2008, P NATL ACAD SCI USA, V105, P7281, DOI 10.1073/pnas.0711190105
   Venkataramana NK, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/931902
   Wang W, 2013, J NEUROSCI RES, V91, P726, DOI 10.1002/jnr.23195
   Wang WW, 2010, MOL CELL BIOCHEM, V338, P115, DOI 10.1007/s11010 009 0344 6
   Xu XC, 2014, J TRANSL MED, V12, DOI 10.1186/s12967 014 0284 0
   Yang DC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001540
   Yang XC, 2012, J CELL BIOCHEM, V113, P669, DOI 10.1002/jcb.23396
   Zhang J., 2014, DIFFER RES BIOL DIVE, V88, P91
   Zhao BH, 2012, J EXP MED, V209, P319, DOI 10.1084/jem.20111566
   Zheng Y, 2009, J DENT RES, V88, P249, DOI 10.1177/0022034509333804
   Zhu WJ, 2013, ARCH ORAL BIOL, V58, P1791, DOI 10.1016/j.archoralbio.2013.09.012
NR 40
TC 22
Z9 24
U1 0
U2 12
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0301 4681
EI 1432 0436
J9 DIFFERENTIATION
JI Differentiation
PD JUN
PY 2015
VL 89
IS 5
BP 128
EP 136
DI 10.1016/j.diff.2015.06.001
PG 9
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA CR0JY
UT WOS:000361005900003
PM 26143356
DA 2025 08 17
ER

PT J
AU Kushwaha, AC
   Mohanbhai, SJ
   Sardoiwala, MN
   Jaganathan, M
   Karmakar, S
   Choudhury, SR
AF Kushwaha, Avinash Chandra
   Mohanbhai, Soni Jignesh
   Sardoiwala, Mohammed Nadim
   Jaganathan, Mahendran
   Karmakar, Surajit
   Choudhury, Subhasree Roy
TI Nanoemulsified Genistein and Vitamin D Mediated Epigenetic Regulation to
   Inhibit Osteoporosis
SO ACS BIOMATERIALS SCIENCE & ENGINEERING
LA English
DT Article
DE osteoporosis; NF kappa B; genistein; vitamin D; histone
   methyltransferases
ID CELLS
AB The imbalance in the bone remodeling process with more bone resorption by osteoclasts compared to bone formation by osteoblasts results in a metabolic bone disorder known as osteoporosis. This condition reduces the bone mineral density and increases the risk of fractures due to low bone mass and disrupted bone microarchitecture. Osteodastogenesis increases when the receptor activator NF kappa B ligand (RANKL) on the osteoblast surface binds to the receptor activator NF kappa B (RANK) on the osteoclast surface and the function of the decoy receptor of RANKL, osteoprotegrin, is compromised due to external stimuli such as heparin and lipopolysaccharides. The RANK/RANKL axis promotes the nuclear factor kappa B (NF kappa B) expression, which in turn increases the histone methyltransferase activity of EzH2 and EzH1 for the epigenetic regulation of osteoclastogenesis related genes. Genistein counteracts NFKB induced osteoclastogenesis and downstream signaling through the direct regulation of histone methyltransferase, EzH2 and EzH1, transcription. However, genistein possesses limitations like low bioavailability, low water solubility, high estrogen activity, and thyroid side effects, which obstruct its therapeutic usage. Here, the nanoemulsified formulation of genistein with vitamin D was utilized to circumvent the limitations of genistein so that it can be utilized for therapeutic purposes in osteoporosis management. The nanoemulsification of genistein and vitamin D was performed through the spontaneous emulsification using Tween 80 and medium chain triglyceride oil as an organic phase. The physiologically stable and biocompatible combination of the genistein and vitamin D nanoemulsion (GVNE) exhibited the controlled release pattern of genistein with Korsmeyer Peppas and Higuchi models under different pH conditions (7.4, 6.5, and 1.2). The GVNE potentially enhanced the therapeutic efficacy under in vitro osteoporosis models and helped restore disease parameters like alkaline phosphatase activity, tartrate resistant acid phosphatase activity, and the formation of multinuclear giant cells. Molecularly, the GVNE overturned the LPS induced osteoclastogenesis by downregulation of NF kappa B expression along with its binding on EzH2 and EzH1 promoters. GVNE effects on the osteoporosis model established it as an efficient antiosteoporotic therapy. This nanonutraceutical based formulation provides an epigenetic regulation of osteoporosis management and opens new avenues for alternate epigenetic therapies for osteoporosis.
C1 [Kushwaha, Avinash Chandra; Mohanbhai, Soni Jignesh; Sardoiwala, Mohammed Nadim; Jaganathan, Mahendran; Karmakar, Surajit; Choudhury, Subhasree Roy] Inst Nano Sci & Technol, Mohali 140306, Punjab, India.
C3 Department of Science & Technology (India); Institute of Nano Science &
   Technology (INST)
RP Karmakar, S; Choudhury, SR (通讯作者)，Inst Nano Sci & Technol, Mohali 140306, Punjab, India.
EM surajit@inst.ac.in; subhasreerc@inst.ac.in
RI ; Choudhury, Subhasree/AAY 7859 2020; Sardoiwala,
   Mohammed/AAY 8161 2020; Karamkar, Swastik/ACF 6764 2022
OI Karmakar, Surajit/0000 0001 6800 2457; Sardoiwala, Mohammed
   Nadim/0000 0001 8900 0813; Kushwaha, Avinash
   Chandra/0000 0002 9748 6371; 
FU ICMR [35/4/2020 Nano/BMS, R11013/09/2021 GIA/HR]; DBT
   [BT/PR40647/MED/31/436/2020]
FX The authors acknowledge ICMR (35/4/2020 Nano/BMS and
   R11013/09/2021 GIA/HR) and DBT (BT/PR40647/MED/31/436/2020) to the PIs
   for providing partial funding support.
CR Adamik J, 2020, J BONE MINER RES, V35, DOI 10.1002/jbmr.3863
   Akkawi Ibrahim, 2018, Joints, V6, P122, DOI 10.1055/s 0038 1660790
   AlQranei MS, 2021, BMC IMMUNOL, V22, DOI 10.1186/s12865 021 00409 9
   Awasthi H, 2018, MED RES REV, V38, P2024, DOI 10.1002/med.21504
   Chen WF, 2006, BRIT J NUTR, V95, P1039, DOI 10.1079/BJN20061735
   Dalmolin LF, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10040214
   Dev A, 2021, PHYTOMEDICINE, V80, DOI 10.1016/j.phymed.2020.153386
   Ferrari SL, 2005, WORLD REV NUTR DIET, V95, P35, DOI 10.1159/000088271
   Glowka E, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11070347
   Guttoff M, 2015, FOOD CHEM, V171, P117, DOI 10.1016/j.foodchem.2014.08.087
   Iannetti A, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004642
   Islam S, 2007, BIOCHEM BIOPH RES CO, V360, P346, DOI 10.1016/j.bbrc.2007.06.023
   Jagdale Swati C, 2018, Recent Pat Drug Deliv Formul, V12, P130, DOI 10.2174/1872211312666180227091059
   Ji Meng Xia, 2015, Chronic Dis Transl Med, V1, P9, DOI 10.1016/j.cdtm.2015.02.006
   Jia XS, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/6310560
   Jing H, 2016, MOL THER, V24, P217, DOI 10.1038/mt.2015.152
   Jolly JJ, 2018, IRAN J MED SCI, V43, P208
   Kadappan AS, 2018, MOL NUTR FOOD RES, V62, DOI 10.1002/mnfr.201700836
   Kelmann RG, 2007, INT J PHARMACEUT, V342, P231, DOI 10.1016/j.ijpharm.2007.05.004
   Lee SH, 2014, INT J MOL SCI, V15, P10605, DOI 10.3390/ijms150610605
   Lui JC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13685
   Morabito N, 2002, OSTEOPOROSIS INT, V13, P644, DOI 10.1007/s001980200087
   Osip SL, 2004, THROMB HAEMOSTASIS, V92, P803, DOI 10.1160/TH04 03 0199
   Panday K, 2014, THER ADV MUSCULOSKEL, V6, P185, DOI 10.1177/1759720X14546350
   Razavi R, 2021, BIOMED PHARMACOTHER, V138, DOI 10.1016/j.biopha.2021.111464
   Silva APC, 2009, PHARMAZIE, V64, P32, DOI 10.1691/ph.2008.8150
   Stern PH, 2014, J CELL BIOCHEM, V115, P2033, DOI 10.1002/jcb.24879
   Tu Kristie N, 2018, P T, V43, P92
   Walsh MC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00511
   Wang YQ, 2015, BBA MOL CELL RES, V1853, P1715, DOI 10.1016/j.bbamcr.2015.04.001
   Yu S, 2019, FOODS, V8, DOI 10.3390/foods8110553
   Zhang B, 2020, INT J PHARMACEUT, V583, DOI 10.1016/j.ijpharm.2020.119354
NR 32
TC 9
Z9 9
U1 0
U2 7
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2373 9878
J9 ACS BIOMATER SCI ENG
JI ACS Biomater. Sci. Eng.
PD SEP 12
PY 2022
VL 8
IS 9
BP 3810
EP 3818
DI 10.1021/acsbiomaterials.2c00165
EA AUG 2022
PG 9
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA 4Q4EK
UT WOS:000848467100001
PM 36005299
DA 2025 08 17
ER

PT J
AU Foer, D
   Zhu, M
   Cardone, RL
   Simpson, C
   Sullivan, R
   Nemiroff, S
   Lee, G
   Kibbey, RG
   Petersen, KF
   Insogna, KL
AF Foer, D.
   Zhu, M.
   Cardone, R. L.
   Simpson, C.
   Sullivan, R.
   Nemiroff, S.
   Lee, G.
   Kibbey, R. G.
   Petersen, K. F.
   Insogna, K. L.
TI Impact of gain of function mutations in the low density lipoprotein
   receptor related protein 5 (LRP5) on glucose and lipid homeostasis
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Glucose metabolism; Hemoglobin A1c; Insulin secretion; LDL; Lipid
   metabolism; LRP5
ID MUSCLE INSULIN RESISTANCE; DE NOVO LIPOGENESIS; MISSENSE MUTATIONS; MICE
   LACKING; ASSOCIATION; CHOLESTEROL; METABOLISM; GENE
AB LRP5 loss of function mutations have been shown to cause profound osteoporosis and have been associated with impaired insulin sensitivity and dysregulated lipid metabolism. We hypothesized that gain of function mutations in LRP5 would also affect these parameters. We therefore studied individuals with LRP5 gain of function mutations exhibiting high bone mass (HBM) phenotypes and found that while there was no detected change in insulin sensitivity, there was a significant reduction in serum LDL.
   Wnt signaling through LRP5 represents a newly appreciated metabolic pathway, which potentially represents a target for drug discovery in type 2 diabetes and hyperlipidemia. Studies in animal models suggest a physiologic link between LRP5 and glucose and lipid homeostasis; however, whether it plays a similar role in humans is unclear. As current literature links loss of function LRP5 to impaired glucose and lipid metabolism, we hypothesized that individuals with an HBM causing mutation in LRP5 would exhibit improved glucose and lipid homeostasis. Since studies in animal models have suggested that Wnt signaling augments insulin secretion, we also examined the effect of Wnt signaling on glucose stimulated insulin secretion on human pancreatic islets.
   This was a matched case control study. We used several methods to assess glucose and lipid metabolism in 11 individuals with HBM causing mutations in LRP5. Affected study participants were recruited from previously identified kindreds with HBM causing LRP5 mutations and included 9 males and 2 females. Two subjects that were being treated with insulin for type 2 diabetes were excluded from our analysis, as this would have obscured our ability to determine the impact of gain of function LRP5 mutations on glucose metabolism. The mean age of the evaluated study subjects was 55 +/  7 with a mean BMI of 27.2 +/  2.0. Control subjects were matched and recruited from the general community at an equivalent ratio, with 18 males and 4 females (mean age 56 +/  4; mean BMI 27.2 +/  1.0). Study testing was conducted at an academic medical center.
   There were no statistically significant differences between affected and matched control populations for HbA1c (p = 0.06), eAG (p = 0.06), insulin (p = 0.82), HOMA B (p = 0.34), or HOMA IR (p = 0.66). The mean Insulin Sensitivity Index (ISI) was also similar between control and affected individuals. Total cholesterol (p = 0.43), triglycerides (TG) (p = 0.56), and HDL (p = 0.32) were not different between the same two groups. In a small subset of studied subjects, intramyocellular and hepatic lipid content were similar in the affected individuals and controls when quantified by proton magnetic resonance spectroscopy (MRS). However, the mean value for serum LDL was significantly lower (p = 0.04) in affected individuals. In primary human islets, there were no differences between control and Wnt treatment groups for insulin secretion measured as area under the curve (AUC) for first phase (p = 0.17) or second phase (p = 0.33) insulin secretion.
   Although our sample size was small, our data do not support the hypothesis that HBM causing LRP5 mutations, associated with increased Wnt signaling, improve glucose metabolism in humans. However, it does appear that LRP5 variants may affect LDL metabolism, a major risk factor for coronary artery disease. The molecular mechanisms underpinning this effect warrant further study.
C1 [Foer, D.; Zhu, M.; Cardone, R. L.; Simpson, C.; Sullivan, R.; Nemiroff, S.; Lee, G.; Kibbey, R. G.; Petersen, K. F.; Insogna, K. L.] Yale Univ, Sch Med, Dept Internal Med, Endocrinol Sect, POB 208020,333 Cedar St, New Haven, CT 06520 USA.
   [Kibbey, R. G.] Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St, New Haven, CT 06520 USA.
   [Petersen, K. F.] Univ Copenhagen, Novo Nordisk Fdn Ctr Basic Metab Res, Copenhagen, Denmark.
C3 Yale University; Yale University; Novo Nordisk Foundation; University of
   Copenhagen
RP Insogna, KL (通讯作者)，Yale Univ, Sch Med, Dept Internal Med, Endocrinol Sect, POB 208020,333 Cedar St, New Haven, CT 06520 USA.
EM karl.insogna@yale.edu
OI Zhu, Meiling/0000 0002 6227 9858; Nemiroff, Samuel/0000 0002 0508 0711;
   Insogna, Karl/0000 0001 6973 5679
FU National Institutes of Health [NIH R01 DK092606, R01 AG 23686];
   Distinguished Clinical Investigator Award from the American Diabetes
   Association; Novo Nordisk Center for Basic Metabolic Research; National
   Center For Advancing Translational Sciences of the NIH [TL1TR000141];
   Yale Bone Center; NNF Center for Basic Metabolic Research [Gillum Group]
   Funding Source: researchfish
FX This study was supported by the National Institutes of Health Grants NIH
   R01 DK092606 (R.G.K.), R01 AG 23686 (K.F.P.), a Distinguished Clinical
   Investigator Award from the American Diabetes Association (K.F.P), the
   Novo Nordisk Center for Basic Metabolic Research (K.F.P.), the National
   Center For Advancing Translational Sciences of the NIH TL1TR000141
   (D.F.), and the Yale Bone Center (DF, KLI).
CR Ai M, 2005, MOL CELL BIOL, V25, P4946, DOI 10.1128/MCB.25.12.4946 4955.2005
   [Anonymous], NAT DIAB STAT REP ES
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Cabrera O, 2007, CELL TRANSPLANT, V16, P1039, DOI 10.3727/000000007783472408
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Flannery C, 2012, DIABETES, V61, P2711, DOI 10.2337/db12 0206
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   Fujino T, 2003, P NATL ACAD SCI USA, V100, P229, DOI 10.1073/pnas.0133792100
   Giusti B, 2009, EUR J VASC ENDOVASC, V38, P104, DOI 10.1016/j.ejvs.2009.01.020
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Hey PJ, 1998, GENE, V216, P103, DOI 10.1016/S0378 1119(98)00311 4
   ISHIBASHI S, 1994, P NATL ACAD SCI USA, V91, P4431, DOI 10.1073/pnas.91.10.4431
   Jiang XY, 2010, EXP CLIN ENDOCR DIAB, V118, P388, DOI 10.1055/s 0029 1225613
   Jurczak MJ, 2011, DIABETES, V60, P890, DOI 10.2337/db10 1328
   Kim DH, 1998, J BIOCHEM TOKYO, V124, P1072, DOI 10.1093/oxfordjournals.jbchem.a022223
   Krssak M, 1999, DIABETOLOGIA, V42, P113, DOI 10.1007/s001250051123
   Lappalainen S, 2009, CLIN ENDOCRINOL, V70, P725, DOI 10.1111/j.1365 2265.2008.03388.x
   Lee G.S., 2013, J Bone Miner Res
   Magoori K, 2003, J BIOL CHEM, V278, P11331, DOI 10.1074/jbc.M211987200
   Morino K, 2006, DIABETES, V55, pS9, DOI 10.2337/db06 S002
   Nathan DM, 2008, DIABETES CARE, V31, P1473, DOI 10.2337/dc08 0545
   Palsgaard J, 2012, J BIOL CHEM, V287, P12016, DOI 10.1074/jbc.M111.337048
   Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314
   Petersen KF, 2015, P NATL ACAD SCI USA, V112, P11330, DOI 10.1073/pnas.1514844112
   Pigeau GM, 2009, DIABETES, V58, P2084, DOI 10.2337/db08 1371
   Rabol R, 2011, P NATL ACAD SCI USA, V108, P13705, DOI 10.1073/pnas.1110105108
   Saarinen A, 2010, CLIN ENDOCRINOL, V72, P481, DOI 10.1111/j.1365 2265.2009.03680.x
   Steiner DJ, 2010, ISLETS, V2, P135, DOI 10.4161/isl.2.3.11815
   van Meurs JBJ, 2008, JAMA J AM MED ASSOC, V299, P1277, DOI 10.1001/jama.299.11.1277
   Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277
   Whyte MP, 2004, NEW ENGL J MED, V350, P2096
   Zenibayashi M, 2008, ENDOCR J, V55, P699, DOI 10.1507/endocrj.K08E 021
NR 32
TC 9
Z9 9
U1 0
U2 4
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD JUN
PY 2017
VL 28
IS 6
BP 2011
EP 2017
DI 10.1007/s00198 017 3977 4
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA EW9IP
UT WOS:000402832500025
PM 28283687
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Defranoux, NA
   Stokes, CL
   Young, DL
   Kahn, AJ
AF Defranoux, NA
   Stokes, CL
   Young, DL
   Kahn, AJ
TI In silico modeling and simulation of bone biology: A proposal
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE mathematical modeling; in silico simulation; bone remodeling; drug
   testing; osteoporosis
AB Contemporary, computer based mathematical modelling techniques make it possible to represent complex biological mechanisms in a manner that permits hypothesis testing in silico. This perspective shows how such approaches might be applied to bone remodelling and therapeutic research.
   Currently, the dominant conceptual model applied in bone research involves the dynamic balance between the continual build up and breakdown of bone matrix by two cell types, the osteoblasts and osteoclasts, acting together as a coordinated, remodeling unit. This conceptualization has served extraordinarily well as a focal point for understanding how mutations, chemical mediators, and mechanical force, as well as external influences (e.g., drugs, diet) affect bone structure and function. However, the need remains to better understand and predict the consequences of manipulating any single factor, or combination of factors, within the context of this complex system's multiple interacting pathways. Mathematical models are a natural extension of conceptual models, providing dynamic, quantitative descriptions of the relationships among interacting components. This formalization creates the ability to simulate the natural behavior of a system, as well as its modulation by therapeutic or dietetic interventions. A number of mathematical models have been developed to study complex bone functions, but most include only a limited set of biological components needed to address a few specific questions. However, it is possible to develop larger, multiscale models that capture the dynamic interactions of many biological components and relate them to important physiological or pathological outcomes that allow broader study. Examples of such models include Entelos' PhysioLab platforms. These models simulate the dynamic, quantitative interactions among a biological system's biochemicals, cells, tissues, and organs and how they give rise to key physiologic and pathophysiologic outcomes. We propose that a similar predictive, dynamical, multiscale mathematical model of bone remodeling and metabolism would provide a better understanding of the mechanisms governing these phenomena as well as serve as an in silico platform for testing pharmaceutical and clinical interventions on metabolic bone disease.
C1 Univ Calif San Francisco, Sch Dent, Dept Cell & Tissue Biol, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Sch Dent, Dept Growth & Dev, San Francisco, CA 94143 USA.
   Entelos Inc, Silico R&D Dept, Foster City, CA USA.
C3 University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   Entelos Inc.
RP Kahn, AJ (通讯作者)，Univ Calif San Francisco, Sch Dent, Dept Cell & Tissue Biol, 521 Parnassus Ave,Box 0640, San Francisco, CA 94143 USA.
EM olbones@itsa.ucsf.edu
CR [Anonymous], 2004, INN STAGN CHALL OPP
   FROST HM, 1987, BONE MINER, V2, P73
   FROST HM, 1973, ORTHOPEDIC LECT, V1, P214
   Helmick C G, 1995, Arthritis Care Res, V8, P203, DOI 10.1002/art.1790080403
   Hernandez CJ, 2003, OSTEOPOROSIS INT, V14, P843, DOI 10.1007/s00198 003 1454 8
   Huiskes R, 2000, NATURE, V405, P704, DOI 10.1038/35015116
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   *NAT OST FDN, 2004, OST FAST FACTS
   Paglia F, 2001, CLIN CHEM, V47, P1314
   Saag Kenneth G, 2004, South Med J, V97, P555, DOI 10.1097/00007611 200406000 00008
   Turner CH, 1999, CALCIFIED TISSUE INT, V65, P466, DOI 10.1007/s002239900734
   van der Linden JC, 2001, J BIOMECH, V34, P1573, DOI 10.1016/S0021 9290(01)00146 4
   Zippel H., 1992, Wolff's Law and Connective Tissue Regulation, P1, DOI DOI 10.1515/9783110875676.1
NR 13
TC 27
Z9 29
U1 0
U2 13
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUL
PY 2005
VL 20
IS 7
BP 1079
EP 1084
DI 10.1359/JBMR.050401
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 940HK
UT WOS:000230134100001
PM 15940360
DA 2025 08 17
ER

PT J
AU Ye, L
   Yu, CC
   Xia, JC
   Ni, KN
   Zhang, YJ
   Ying, XZ
   Xie, DQ
   Jin, Y
   Sun, RT
   Tang, RK
   Fan, SW
   Yao, SS
AF Ye, Lin
   Yu, Congcong
   Xia, Jiechao
   Ni, Kainan
   Zhang, Yejin
   Ying, Xiaozhang
   Xie, Dingqi
   Jin, Yang
   Sun, Rongtai
   Tang, Ruikang
   Fan, Shunwu
   Yao, Shasha
TI Multifunctional nanomaterials via cell cuproptosis and oxidative
   stress for treating osteosarcoma and OS induced bone destruction
SO MATERIALS TODAY BIO
LA English
DT Article
DE Cuproptosis; Responsive biomaterial; Neoplastic bone destruction;
   Reactive oxygen species; Mild photo  thermal therapy
ID PROTEIN
AB Reactive Oxygen Species (ROS) refers to a highly reactive class of oxidizing species that have the potential to induce cellular apoptosis and necrosis. Cuproptosis, a type of cell death, is primarily associated with the effects of copper ions. However, the specific relationship between ROS, cuproptosis, and osteosarcoma (OS) remains relatively unexplored. Additionally, there is limited research on the use of cuproptosis in conjunction with oxidative stress for treating OS and inhibiting tumor induced bone destruction. To address these gaps, a novel treatment approach has been developed for OS and neoplastic bone destruction. This approach involves the utilization of glutathione (GSH) and pH responsive organic inorganic mesoporous silica nanoparticles@Cu2S@oxidized Dextran (short for MCD). The MCD material demonstrates excellent cytocompatibility, osteogenesis, tumor suppression, and the ability to inhibit osteoclast formation. The specific mechanism of action involves the mitochondria of the MCD material inhibiting key proteins in the tricarboxylic acid (TCA) cycle. Simultaneously, the generation of ROS promotes this inhibition and leads to alterations in cellular energy metabolism. Moreover, the MCD biomaterial exhibits promising mild temperature photothermal therapy in the second near infrared (NIR II) range, effectively mitigating tumor growth and OS induced bone destruction in vivo.
C1 [Ye, Lin; Yu, Congcong; Xia, Jiechao; Ying, Xiaozhang; Xie, Dingqi; Jin, Yang; Sun, Rongtai; Fan, Shunwu; Yao, Shasha] Zhejiang Univ, Sir Run Run Shaw Hosp, Key Lab Musculoskeletal Syst Degenerat & Regenerat, Med Coll,Dept Orthopaed Surg, Hangzhou 310016, Peoples R China.
   [Ye, Lin; Yu, Congcong; Xia, Jiechao; Ying, Xiaozhang; Xie, Dingqi; Jin, Yang; Sun, Rongtai; Fan, Shunwu; Yao, Shasha] Key Lab Musculoskeletal Syst Degenerat & Regenerat, Hangzhou 310016, Zhejiang, Peoples R China.
   [Ni, Kainan; Zhang, Yejin] Wenzhou Univ, Zhejiang Univ, Affiliated Lishui Hosp, Dept Orthoped,Lishui Cent Hosp,Med Affiliated Hosp, Lishui 323600, Peoples R China.
   [Tang, Ruikang] Zhejiang Univ, Ctr Biomat & Biopathways, Dept Chem, Hangzhou 310027, Zhejiang, Peoples R China.
C3 Zhejiang University; Wenzhou University; Zhejiang University; Zhejiang
   University
RP Fan, SW; Yao, SS (通讯作者)，Zhejiang Univ, Sir Run Run Shaw Hosp, Key Lab Musculoskeletal Syst Degenerat & Regenerat, Med Coll,Dept Orthopaed Surg, Hangzhou 310016, Peoples R China.; Tang, RK (通讯作者)，Zhejiang Univ, Ctr Biomat & Biopathways, Dept Chem, Hangzhou 310027, Zhejiang, Peoples R China.
EM rtang@zju.edu.cn; shunwu_fan@zju.edu.cn; yaoshasha@zju.edu.cn
RI Zhang, Keyue/GXF 4304 2022; Jin, Yang/KCJ 9682 2024
FU National Natural Science Foundation of China [82002284]; Health
   Commission of Zhejiang Province [2021449373]; National Science and
   Technology Major Project [2020YFC1107100]
FX <BOLD>Acknowledgements</BOLD> The study was supported by the National
   Natural Science Foundation of China (Grant No. 82002284) , the Health
   Commission of Zhejiang Province (Grant No. 2021449373) , the National
   Science and Technology Major Project (Grant Nos. 2020YFC1107100) .
CR Chen PC, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045 017 0390 6
   Choi S, 2021, J TRANSL MED, V19, DOI 10.1186/s12967 021 03154 0
   Civitello DJ, 2020, P ROY SOC B BIOL SCI, V287, DOI 10.1098/rspb.2019.2446
   Dhandapani R, 2020, BIOACT MATER, V5, P458, DOI 10.1016/j.bioactmat.2020.03.009
   Du X, 2014, ADV FUNCT MATER, V24, P7627, DOI 10.1002/adfm.201402408
   He M, 2017, INT J ONCOL, V50, P1590, DOI 10.3892/ijo.2017.3928
   Huang JL, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030422
   Huang LT, 2019, INT J ONCOL, V54, P1969, DOI 10.3892/ijo.2019.4781
   Kalimeris K, 2016, J SURG RES, V206, P263, DOI 10.1016/j.jss.2016.08.049
   Kim H, 2020, BONE RES, V8, DOI 10.1038/s41413 019 0080 9
   LaCourse Kaitlyn D, 2022, Cell Rep, V41, P111625, DOI 10.1016/j.celrep.2022.111625
   Li B, 2018, INT J NANOMED, V13, P7289, DOI 10.2147/IJN.S175334
   Li JM, 2021, BIOACT MATER, V6, P3839, DOI 10.1016/j.bioactmat.2021.03.039
   Li MZ, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.992431
   Lin JT, 2017, MAT SCI ENG C MATER, V81, P478, DOI 10.1016/j.msec.2017.08.036
   Liu JJ, 2022, NUCLEIC ACIDS RES, V50, P704, DOI 10.1093/nar/gkab1236
   Liu L, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6661534
   Lopès A, 2020, INT J CANCER, V146, P3147, DOI 10.1002/ijc.32920
   Ma BJ, 2019, J AM CHEM SOC, V141, P849, DOI 10.1021/jacs.8b08714
   McNeill EP, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 1203 8
   Navet B, 2018, CANCERS, V10, DOI 10.3390/cancers10110398
   de Solorzano IO, 2016, ACS APPL MATER INTER, V8, P21545, DOI 10.1021/acsami.6b05727
   Park EM, 2022, NAT MED, V28, P690, DOI 10.1038/s41591 022 01779 2
   Pei YH, 2021, GREEN CHEM, V23, P6975, DOI 10.1039/d1gc01857d
   Qiao XR, 2020, INT J NANOMED, V15, P7185, DOI 10.2147/IJN.S239550
   Schafer JW, 2020, ACS CATAL, V10, P8476, DOI 10.1021/acscatal.0c01618
   Sharma M, 2018, AUTOPHAGY, V14, P1239, DOI 10.1080/15548627.2018.1474312
   Su TA, 2018, J AM CHEM SOC, V140, P13764, DOI 10.1021/jacs.8b08014
   Suvarnapathaki S, 2022, BIOACT MATER, V13, P64, DOI 10.1016/j.bioactmat.2021.11.002
   Swaidan A, 2021, NANOMATERIALS BASEL, V11, DOI 10.3390/nano11092156
   Takagi S, 2021, ONCOGENE, V40, P5548, DOI 10.1038/s41388 021 01956 6
   Tsuge M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030736
   Tsvetkov P, 2022, SCIENCE, V375, P1254, DOI 10.1126/science.abf0529
   Wang CG, 2019, THERANOSTICS, V9, P65, DOI 10.7150/thno.29766
   Wang X, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 14870 4
   Wei XA, 2022, EMBO MOL MED, V14, DOI 10.15252/emmm.202115373
   Wu ZW, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.934080
   Xu CJ, 2009, J AM CHEM SOC, V131, P15346, DOI 10.1021/ja905938a
   Xu DR, 2021, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.620629
   Xu Y, 2015, REDOX BIOL, V6, P446, DOI 10.1016/j.redox.2015.09.008
   Yamakawa Y, 2017, CANCER SCI, V108, P1870, DOI 10.1111/cas.13316
   Yang JL, 2015, INT J MOL SCI, V16, P28635, DOI 10.3390/ijms161226123
   Yang MY, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.919231
   Yang SP, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1323 9
   Yang ZM, 2020, INT J ONCOL, V57, P433, DOI 10.3892/ijo.2020.5067
   Ye GN, 2022, ACTA PHARM SIN B, V12, P1288, DOI 10.1016/j.apsb.2021.08.015
   Zhang LL, 2017, J MATER CHEM B, V5, P8013, DOI 10.1039/c7tb01526g
   Zheng X, 2018, INT J MOL MED, V41, P3137, DOI 10.3892/ijmm.2018.3515
   Zhou J, 2023, ANGEW CHEM INT EDIT, V62, DOI 10.1002/anie.202213922
   Zhou L, 2020, INT J BIOL SCI, V16, P309, DOI 10.7150/ijbs.37162
NR 50
TC 12
Z9 12
U1 9
U2 59
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2590 0064
J9 MATER TODAY BIO
JI Mater. Today Bio
PD APR
PY 2024
VL 25
AR 100996
DI 10.1016/j.mtbio.2024.100996
EA FEB 2024
PG 17
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA NS8A9
UT WOS:001202523400001
PM 38420143
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Turner, RT
   Wong, CP
   Iwaniec, UT
AF Turner, Russell T.
   Wong, Carmen P.
   Iwaniec, Urszula T.
TI Effect of Reduced c Kit Signaling on Bone Marrow Adiposity
SO ANATOMICAL RECORD ADVANCES IN INTEGRATIVE ANATOMY AND EVOLUTIONARY
   BIOLOGY
LA English
DT Article
DE hematopoietic stem cell; mesenchymal stem cell; adipocyte; mast cell;
   receptor tyrosine kinase; gleevec (imatinib mesilate)
ID STEM CELL FACTOR; MAST CELLS; ANOREXIA NERVOSA; TYROSINE KINASE; STROMAL
   CELLS; RECEPTOR; MOUSE; EXPRESSION; TISSUE; MICE
AB c Kit (CD117) is required for normal differentiation of osteoblasts from bone marrow stromal cells and for normal bone formation. Osteoblasts and adipocytes originate from a common progenitor cell, and a reciprocal relationship in differentiation of the two lineages is often observed. Therefore, the effects of abnormal c kit signaling on bone marrow adiposity and adipocyte precursor pool size were evaluated in mouse strains with loss of function mutations in kit receptor or kit ligand. Additionally, to determine whether short duration pharmacological disruption of kit signaling influences bone marrow adiposity, we administered the kit receptor antagonist gleevec (imatinib mesilate) for 1 week to middle aged (13 month old) male rats known to have high levels of bone marrow fat. Compared to wild type littermates, adipocytes were absent and adipocyte precursors greatly reduced in bone marrow from kit receptor deficient Kit(W/W v) mice. Administration of secreted kit ligand to membrane associated kit ligand deficient Kit(Sl/Sl d) mice was ineffective in inducing bone marrow adipogenesis. These findings suggest that activation of kit receptor by the membrane associated form of kit ligand is required for kit signaling to promote bone marrow adipogenesis in mice. Rats treated with gleevec had lower adipocyte density compared to age matched controls, suggesting that kit signaling is required to maintain normal bone marrow adiposity. Taken together, our results indicate that c Kit signaling plays an important but previously unsuspected role in regulating bone marrow adiposity. Anat Rec, 294:1126 1134, 2011. (C) 2011Wiley Liss, Inc.
C1 [Turner, Russell T.; Wong, Carmen P.; Iwaniec, Urszula T.] Oregon State Univ, Dept Nutr & Exercise Sci, Corvallis, OR 97331 USA.
C3 Oregon State University
RP Turner, RT (通讯作者)，Oregon State Univ, Dept Nutr & Exercise Sci, 107B Milam Hall, Corvallis, OR 97331 USA.
EM russell.turner@oregonstate.edu
CR Abella E, 2002, AM J CLIN PATHOL, V118, P582, DOI 10.1309/2Y7X YDXK 006B XLT2
   Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Aouadi M, 2006, DIABETES, V55, P281, DOI 10.2337/diabetes.55.02.06.db05 0963
   Ashman LK, 1999, INT J BIOCHEM CELL B, V31, P1037, DOI 10.1016/S1357 2725(99)00076 X
   Aubert J, 1999, CELL MOL LIFE SCI, V56, P538, DOI 10.1007/s000180050450
   BATHIJA A, 1979, AM J HEMATOL, V6, P191, DOI 10.1002/ajh.2830060303
   BATISTA JN, 1988, DRUG ALCOHOL DEPEN, V22, P27, DOI 10.1016/0376 8716(88)90033 6
   Berrozpe G, 1999, BLOOD, V94, P2658, DOI 10.1182/blood.V94.8.2658.420k23_2658_2666
   Böhm J, 2000, AM J SURG PATHOL, V24, P56, DOI 10.1097/00000478 200001000 00007
   Bredella MA, 2009, J CLIN ENDOCR METAB, V94, P2129, DOI 10.1210/jc.2008 2532
   Caserta F, 2001, AM J PHYSIOL ENDOC M, V280, pE238, DOI 10.1152/ajpendo.2001.280.2.E238
   Conrad C, 2008, STEM CELLS DEV, V17, P23, DOI 10.1089/scd.2007.0159
   COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092 8674(90)90298 S
   Cui QJ, 2006, J BONE JOINT SURG AM, V88A, P148, DOI 10.2106/JBJS.F.00534
   Dewar AL, 2005, BLOOD, V105, P3127, DOI 10.1182/blood 2004 10 3967
   Duque G, 2008, CURR OPIN RHEUMATOL, V20, P429, DOI 10.1097/BOR.0b013e3283025e9c
   Gattei V, 1996, CELL GROWTH DIFFER, V7, P753
   Gimble JM, 1996, BONE, V19, P421, DOI 10.1016/S8756 3282(96)00258 X
   Grimbaldeston MA, 2005, AM J PATHOL, V167, P835, DOI 10.1016/S0002 9440(10)62055 X
   HATANAKA K, 1986, BIOCHIM BIOPHYS ACTA, V878, P440, DOI 10.1016/0005 2760(86)90254 7
   Horny HP, 2007, PATHOBIOLOGY, V74, P121, DOI 10.1159/000101711
   Huss R, 2002, BRIT J HAEMATOL, V118, P305, DOI 10.1046/j.1365 2141.2002.03587.x
   IKUTA K, 1991, INT J CELL CLONING, V9, P451
   Iwaniec Urszula T., 2008, V447, P325, DOI 10.1007/978 1 59745 242 7_21
   Kilroy GE, 2007, J CELL PHYSIOL, V212, P702, DOI 10.1002/jcp.21068
   Koma Y, 2005, LAB INVEST, V85, P426, DOI 10.1038/labinvest.3700231
   LANGNER CA, 1989, J BIOL CHEM, V264, P7994
   Liu J, 2009, NAT MED, V15, P940, DOI 10.1038/nm.1994
   Lotinun S, 2005, J BONE MINER RES, V20, P644, DOI 10.1359/JBMR.041209
   Lowry MB, 2008, ENDOCRINOLOGY, V149, P5735, DOI 10.1210/en.2008 0134
   Marsicano G, 1997, VET IMMUNOL IMMUNOP, V55, P291, DOI 10.1016/S0165 2427(96)05599 7
   Mayack SR, 2008, BLOOD, V112, P519, DOI 10.1182/blood 2008 01 133710
   Menagh PJ, 2010, J BONE MINER RES, V25, P757, DOI 10.1359/jbmr.091015
   Morita Y, 2006, J OBSTET GYNAECOL RE, V32, P513, DOI 10.1111/j.1447 0756.2006.00437.x
   Nagayoshi K, 2006, J CELL PHYSIOL, V208, P188, DOI 10.1002/jcp.20652
   OTSUKA T, 1994, STEM CELLS, V12, P409, DOI 10.1002/stem.5530120408
   Pei LM, 2004, J CLIN INVEST, V113, P805, DOI 10.1172/JCI200421311
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460 2075.1988.tb02907.x
   Reber L, 2006, EUR J PHARMACOL, V533, P327, DOI 10.1016/j.ejphar.2005.12.067
   Shiozawa Y, 2008, ACTA HAEMATOL BASEL, V120, P134, DOI 10.1159/000178144
   TAVASSOL.M, 1974, EXPERIENTIA, V30, P424, DOI 10.1007/BF01921701
   Thalmeier K, 1996, EXP HEMATOL, V24, P1
   TRAN MA, 1981, J LIPID RES, V22, P1271
   Turner RT, 2010, J BONE MINER RES, V25, P1637, DOI 10.1002/jbmr.49
   Väänänen HK, 2005, ANN MED, V37, P469, DOI 10.1080/07853890500371957
   Valtieri M, 2008, J CELL PHYSIOL, V217, P296, DOI 10.1002/jcp.21521
   Yu WH, 2008, MOL CELL BIOCHEM, V310, P11, DOI 10.1007/s11010 007 9661 9
   ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092 8674(90)90302 U
NR 49
TC 10
Z9 10
U1 0
U2 4
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1932 8486
J9 ANAT REC
JI Anat. Rec.
PD JUL
PY 2011
VL 294
IS 7
BP 1126
EP 1134
DI 10.1002/ar.21409
PG 9
WC Anatomy & Morphology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Anatomy & Morphology
GA 781RS
UT WOS:000291951800005
PM 21634019
OA Bronze
DA 2025 08 17
ER

PT J
AU Epstein Barash, H
   Gutman, D
   Markovsky, E
   Mishan Eisenberg, G
   Koroukhov, N
   Szebeni, J
   Golomb, G
AF Epstein Barash, Hila
   Gutman, Dikla
   Markovsky, Ela
   Mishan Eisenberg, Galit
   Koroukhov, Nickolay
   Szebeni, Janos
   Golomb, Gershon
TI Physicochemical parameters affecting liposomal bisphosphonates
   bioactivity for restenosis therapy: Internalization, cell inhibition,
   activation of cytokines and complement, and mechanism of cell death
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article; Proceedings Paper
CT 7th International NanoDDS Meeting
CY OCT 05 06, 2009
CL Indianapolis, IN
DE Liposomes; Bisphosphonates; Monocytes/macrophages; Restenosis;
   Cytokines; Anti inflammation; Complement activation
ID REDUCES NEOINTIMAL FORMATION; NECROSIS FACTOR ALPHA; ACUTE PHASE
   RESPONSE; IN VITRO; MACROPHAGE LIKE; BONE RESORPTION; MEDIATED
   DEPLETION; MEVALONATE PATHWAY; GROWTH INHIBITION; STEALTH LIPOSOMES
AB Partial inactivation and transient depletion of monocytes/macrophages by liposomal bisphosphonates (LIP Bps) is widely experimented in various inflammatory disorders including restenosis. Previous studies on activation of cytokines by LIP Bps are limited to certain cell lines. Moreover, the correlation between in vitro and in vivo studies and complement (C) activation has not been reported. We report here a comprehensive study on the bioactivity of LIP Bps on various cells' internalization and proliferation, mechanism of cell death, cytokines (in vitro and in vivo) and C activation (in the rat, rabbit and pig). The role of the following parameters has been determined i) drug type (clodronate/alendronate); ii) vesicles size (60 800 nm); iii) charge (neutral/negative/positive); and iv) cell culture type (various cell lines and primary cultures). It was found that monocyte/macrophage inhibition and cytokine activation depend on the cell type, with a limited correlation to the bioactivity obtained in the rat and rabbit models of restenosis. Negatively charged liposomes (85 +/  20 nm) effectively depleted rabbit's monocytes (67% depletion), with a minor activation of cytokines and no C activation. It is concluded that cell culture studies are insufficient for assessing cytokine activation, and that by controlling LIP BP properties (size, charge and drug type) optimal bioactivity could be achieved. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Epstein Barash, Hila; Gutman, Dikla; Markovsky, Ela; Mishan Eisenberg, Galit; Koroukhov, Nickolay; Golomb, Gershon] Hebrew Univ Jerusalem, Sch Pharm, Fac Med, IL 91120 Jerusalem, Israel.
   [Szebeni, Janos] Seroscience Ltd, Budapest, Hungary.
C3 Hebrew University of Jerusalem
RP Golomb, G (通讯作者)，Hebrew Univ Jerusalem, Sch Pharm, Fac Med, 12065 Ein Kerem Med Ctr, IL 91120 Jerusalem, Israel.
EM gershong@ekmd.huji.ac.il
RI Golomb, Gershon/C 6342 2012
OI Golomb, Gershon/0000 0002 7369 9831
CR ADAMI S, 1987, CALCIFIED TISSUE INT, V41, P326, DOI 10.1007/BF02556671
   Afergan E, 2009, J DRUG DELIV SCI TEC, V19, P263, DOI 10.1016/S1773 2247(09)50050 0
   Afergan E, 2008, J CONTROL RELEASE, V132, P84, DOI 10.1016/j.jconrel.2008.08.017
   ALLEN TM, 1991, BIOCHIM BIOPHYS ACTA, V1068, P133, DOI 10.1016/0005 2736(91)90201 I
   Anderson Peter, 2006, Future Oncol, V2, P333, DOI 10.2217/14796694.2.3.333
   [Anonymous], 2007, CIRCULATION, DOI DOI 10.1161/CIRCULATIONAHA.106.666800
   Babensee JE, 2005, J BIOMED MATER RES A, V74A, P503, DOI 10.1002/jbm.a.30429
   BARTLETT GR, 1959, J BIOL CHEM, V234, P466
   Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   Bhatia V, 2006, J Assoc Physicians India, V54, P879
   Bodor Aron, 2003, Acta Pharm Hung, V73, P115
   Buiting AMJ, 1996, J IMMUNOL METHODS, V192, P55, DOI 10.1016/0022 1759(96)00034 8
   Butts C, 2005, J CLIN ONCOL, V23, P6674, DOI 10.1200/JCO.2005.13.011
   Camenzind E, 2007, CIRCULATION, V115, P1440, DOI 10.1161/CIRCULATIONAHA.106.666800
   Chanan Khan A, 2003, ANN ONCOL, V14, P1430, DOI 10.1093/annonc/mdg374
   Cockett MI, 1999, CURR OPIN MOL THER, V1, P279
   Cohen Sela E, 2006, J CONTROL RELEASE, V113, P23, DOI 10.1016/j.jconrel.2006.03.010
   Conwell CC, 2005, ADV GENET, V53, P3, DOI 10.1016/S0065 2660(05)53001 3
   Cooper N R, 1973, Contemp Top Mol Immunol, V2, P155
   Danenberg HD, 2003, CIRCULATION, V108, P2798, DOI 10.1161/01.CIR.0000097002.69209.CD
   Danenberg HD, 2003, J CARDIOVASC PHARM, V42, P671, DOI 10.1097/00005344 200311000 00014
   Danenberg HD, 2002, CIRCULATION, V106, P599, DOI 10.1161/01.CIR.0000023532.98469.48
   Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011
   Epstein H, 2007, J CONTROL RELEASE, V117, P322, DOI 10.1016/j.jconrel.2006.10.030
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Frith JC, 2003, J BONE MINER RES, V18, P204, DOI 10.1359/jbmr.2003.18.2.204
   Frith JC, 2001, ARTHRITIS RHEUM, V44, P2201, DOI 10.1002/1529 0131(200109)44:9<2201::AID ART374>3.0.CO;2 E
   Golomb G, 1996, ATHEROSCLEROSIS, V125, P171
   Haber E, 2009, HUM REPROD, V24, P398, DOI 10.1093/humrep/den375
   Haibel H, 2003, RHEUMATOLOGY, V42, DOI 10.1093/rheumatology/keg256
   Harrington KJ, 2000, CLIN ONCOL UK, V12, P16, DOI 10.1007/s001740050003
   Immordino ML, 2006, INT J NANOMED, V1, P297
   Jamshidi P, 2008, INT J CARDIOL, V130, pE111, DOI 10.1016/j.ijcard.2007.06.105
   Jensen LO, 2007, J AM COLL CARDIOL, V50, P463, DOI 10.1016/j.jacc.2007.06.002
   JULIANO RL, 1975, BIOCHEM BIOPH RES CO, V63, P651, DOI 10.1016/S0006 291X(75)80433 5
   King LE, 1996, J CHROMATOGR B, V678, P325, DOI 10.1016/0378 4347(95)00531 5
   LANG JK, 1990, J CHROMATOGR, V507, P157, DOI 10.1016/S0021 9673(01)84191 1
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   LIM HW, 1990, DERMATOL CLIN, V8, P609
   Majai G, 2007, EUR J IMMUNOL, V37, P1343, DOI 10.1002/eji.200636398
   Makkonen N, 1996, J PHARMACOL EXP THER, V277, P1097
   Makkonen N, 1999, EUR J PHARM SCI, V8, P109, DOI 10.1016/S0928 0987(98)00065 7
   MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545
   Moghimi SM, 1998, ADV DRUG DELIVER REV, V32, P45, DOI 10.1016/S0169 409X(97)00131 2
   Moghimi SM, 2003, PROG LIPID RES, V42, P463, DOI 10.1016/S0163 7827(03)00033 X
   Moghimi SM, 2001, PHARM RES DORDR, V18, P1, DOI 10.1023/A:1011054123304
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   MONKKONEN J, 1995, J CONTROL RELEASE, V35, P145, DOI 10.1016/0168 3659(95)00031 3
   MONKKONEN J, 1993, CALCIFIED TISSUE INT, V53, P139, DOI 10.1007/BF01321893
   MONKKONEN J, 1994, J DRUG TARGET, V2, P299, DOI 10.3109/10611869409015910
   Moses JW, 2003, NEW ENGL J MED, V349, P1315, DOI 10.1056/NEJMoa035071
   NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022 1759(91)90198 O
   PENNANEN N, 1995, PHARMACEUT RES, V12, P916, DOI 10.1023/A:1016281608773
   Petrovski G, 2007, AUTOPHAGY, V3, P509
   RANJIT GB, 1995, CLIN CANCER RES, V1, P223
   Reis ES, 2006, INFLAMM RES, V55, P179, DOI 10.1007/s00011 006 0068 y
   Richards PJ, 2001, RHEUMATOLOGY, V40, P978, DOI 10.1093/rheumatology/40.9.978
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Rogers MJ, 1996, J BONE MINER RES, V11, P1482
   Sacci John B Jr, 2002, Methods Mol Med, V72, P503, DOI 10.1385/1 59259 271 6:503
   Santini D, 2004, BIODRUGS, V18, P269, DOI 10.2165/00063030 200418040 00004
   Sauty A, 1996, BONE, V18, P133, DOI 10.1016/8756 3282(95)00448 3
   Selander KS, 1996, MOL PHARMACOL, V50, P1127
   Sioud M, 2005, J MOL BIOL, V348, P1079, DOI 10.1016/j.jmb.2005.03.013
   Skubitz KM, 2000, ANTI CANCER DRUG, V11, P555, DOI 10.1097/00001813 200008000 00006
   Slegers TPAM, 2000, CURR EYE RES, V20, P322, DOI 10.1076/0271 3683(200004)20:4;1 5;FT322
   Stone GW, 2004, NEW ENGL J MED, V350, P221, DOI 10.1056/NEJMoa032441
   Sugawara S, 1998, BRIT J PHARMACOL, V125, P735, DOI 10.1038/sj.bjp.0702151
   Szebeni J, 2006, AM J PHYSIOL HEART C, V290, pH1050, DOI 10.1152/ajpheart.00622.2005
   Szebeni J, 2005, TOXICOLOGY, V216, P106, DOI 10.1016/j.tox.2005.07.023
   Szebeni J, 1999, CIRCULATION, V99, P2302, DOI 10.1161/01.CIR.99.17.2302
   Szebeni J, 2000, AM J PHYSIOL HEART C, V279, pH1319, DOI 10.1152/ajpheart.2000.279.3.H1319
   SZOKA F, 1980, ANNU REV BIOPHYS BIO, V9, P467, DOI 10.1146/annurev.bb.09.060180.002343
   Thiebaud D, 1997, CALCIFIED TISSUE INT, V61, P386, DOI 10.1007/s002239900353
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   Toussirot É, 2007, CURR OPIN RHEUMATOL, V19, P340
   Töyräs A, 2003, EUR J PHARM SCI, V19, P223, DOI 10.1016/S0928 0987(03)00108 8
   van Etten EWM, 1998, ANTIMICROB AGENTS CH, V42, P1677, DOI 10.1128/AAC.42.7.1677
   van Rooijen N, 2002, J LIPOSOME RES, V12, P81, DOI 10.1081/LPR 120004780
   van Rooijen N, 2003, METHOD ENZYMOL, V373, P3
   vanRooijen N, 1997, TRENDS BIOTECHNOL, V15, P178, DOI 10.1016/S0167 7799(97)01019 6
   vanRooijen N, 1996, J IMMUNOL METHODS, V193, P93, DOI 10.1016/0022 1759(96)00056 7
   VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83
   VERWEIJ J, 1994, EUR J CANCER, V30A, P842, DOI 10.1016/0959 8049(94)90303 4
   VOGT W, 1983, AGENTS ACTIONS, V13, P391, DOI 10.1007/BF02176401
   Wernli G, 2009, BASIC RES CARDIOL, V104, P681, DOI 10.1007/s00395 009 0033 3
   Wirth T, 2006, CURR DRUG SAF, V1, P253, DOI 10.2174/157488606777934440
   Zeisberger SM, 2006, BRIT J CANCER, V95, P272, DOI 10.1038/sj.bjc.6603240
   Zito MA, 2001, BRAIN RES, V892, P13, DOI 10.1016/S0006 8993(00)03135 8
NR 89
TC 78
Z9 99
U1 0
U2 23
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168 3659
EI 1873 4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD SEP 1
PY 2010
VL 146
IS 2
SI SI
BP 182
EP 195
DI 10.1016/j.jconrel.2010.03.011
PG 14
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Chemistry; Pharmacology & Pharmacy
GA 642ZS
UT WOS:000281261900004
PM 20359513
DA 2025 08 17
ER

PT J
AU Moore, KN
   Gunderson, CC
   Sabbatini, P
   McMeekin, DS
   Mantia Smaldone, G
   Burger, RA
   Morgan, MA
   Kapoun, AM
   Brachmann, RK
   Stagg, R
   Farooki, A
   O'Cearbhaill, RE
AF Moore, Kathleen N.
   Gunderson, Camille C.
   Sabbatini, Paul
   McMeekin, D. Scott
   Mantia Smaldone, Gina
   Burger, Robert A.
   Morgan, Mark A.
   Kapoun, Ann M.
   Brachmann, Rainer Karl
   Stagg, Robert
   Farooki, Azeez
   O'Cearbhaill, Roisin E.
TI A phase 1b dose escalation study of ipafricept (OMP 54F28) in
   combination with paclitaxel and carboplatin in patients with recurrent
   platinum sensitive ovarian cancer
SO GYNECOLOGIC ONCOLOGY
LA English
DT Article
DE Ovarian cancer; Wnt signaling; Ipafricept; Platinum sensitive
ID DOUBLE BLIND; MAINTENANCE THERAPY; EPITHELIAL OVARIAN; STEM CELLS;
   CHEMOTHERAPY; BEVACIZUMAB; TRIAL; WNT5A
AB Objectives: The WNT pathway is an important oncologic driver of epithelial ovarian cancer (EOC). The first in class recombinant fusion protein ipafricept (IPA) blocks Wnt signaling through binding of Wnt ligands. This phase Ib trial was designed to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RPh2) for IPA in combination with taxane and platinum therapy (C/P).
   Methods: Dose escalation started with a standard 3 + 3 design for IPA/C/P with q3w intravenous IPA on Day 1, in cycles 1 to 6 with C (AUC = 5 mg/ml.min) and P (175 mg/m(2)). For enhanced bone safety the trial was revised to 6 patient cohorts with a q3w regimen of IPA on Day 1 and C/P on Day 3 (IPA  > C/P).
   Results: 37 patients have been treated; 30 of whom were treated following protocol revision to q3w IPA(D1)  > C/P(D3) (2 & 4 mg/kg). IPA related TEAEs that occurred in >= 15% included: fatigue (40%); nausea (35%); diarrhea and decreased appetite (22%) each; dysgeusia (19%); and vomiting (16.2%). 22% reported >= 1 IPA related TEAE Grade >= 3 the most common of which was neutropenia at 16%. There were no DLTs; the MTD was not reached. The maximum administered dose based on bone safety was 6 mg/kg. The overall response rate (ORR) was 75.7%. Median PFS was 10.3 months (95% CI 8.5 14.2) and OS 33 months (95% CI 23.4 NR).
   Conclusions: IPA is well tolerated in combination with sequential C/P. ORR, PFS and OS are comparable to historical data but bone toxicity at efficacy doses of this particular Wnt inhibitor limit further development in EOC. (C) 2019 Elsevier Inc. All rights reserved.
C1 [Moore, Kathleen N.; Gunderson, Camille C.; McMeekin, D. Scott] Univ Oklahoma, Stephenson Canc Ctr, 800 NE 10th St, Oklahoma City, OK 73104 USA.
   [Sabbatini, Paul; O'Cearbhaill, Roisin E.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
   [Sabbatini, Paul; O'Cearbhaill, Roisin E.] Weill Cornell Med Coll, New York, NY USA.
   [Mantia Smaldone, Gina] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.
   [Burger, Robert A.; Morgan, Mark A.] Univ Penn, Philadelphia, PA 19104 USA.
   [Kapoun, Ann M.; Brachmann, Rainer Karl; Stagg, Robert; Farooki, Azeez] OncoMed Pharmaceut Inc, Redwood City, CA USA.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center; Memorial Sloan Kettering Cancer Center; Cornell University;
   Weill Cornell Medicine; Fox Chase Cancer Center; University of
   Pennsylvania
RP Moore, KN (通讯作者)，800 NE 10th St, Oklahoma City, OK 73104 USA.
EM kathleen moore@ouhsc.edu; sabbatip@mskcc.org;
   Gina.Mantia Smaldone@fccc.edu; Robert.burger@uphs.upenn.edu;
   mark.morgan@uphs.upenn.edu; ann.kapoun@oncomed.com;
   rainer.brachmann@oncomed.com; Robert.stagg@oncomed.com;
   azeez.farooki@oncomed.com; ocearbhr@mskcc.org
OI Moore, Kathleen/0000 0002 5803 0718
FU NIH/NCI [P30 CA008748]
FX This study was funded in part through the NIH/NCI Support Grant P30
   CA008748 (Dr. O'Cearbhaill, Dr. Sabbatini).
CR Acebron SP, 2014, MOL CELL, V54, P663, DOI 10.1016/j.molcel.2014.04.014
   Aghajanian C, 2012, J CLIN ONCOL, V30, P2039, DOI 10.1200/JCO.2012.42.0505
   Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Bhalla KN, 2003, ONCOGENE, V22, P9075, DOI 10.1038/sj.onc.1207233
   Clarke MF, 2006, CELL, V124, P1111, DOI 10.1016/j.cell.2006.03.011
   Coleman RL, 2017, LANCET, V390, P1949, DOI 10.1016/S0140 6736(17)32440 6
   Coleman RL, 2017, LANCET ONCOL, V18, P779, DOI 10.1016/S1470 2045(17)30279 6
   Dylla SJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002428
   Fischer MM, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1700090
   Ford CE, 2016, GYNECOL ONCOL, V140, P345, DOI 10.1016/j.ygyno.2015.09.085
   Ford CE, 2014, GYNECOL ONCOL, V134, P338, DOI 10.1016/j.ygyno.2014.06.004
   Ford CE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054362
   GORE ME, 1989, BRIT J CANCER, V60, P767, DOI 10.1038/bjc.1989.356
   Jacob F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031885
   MARKMAN M, 1991, J CLIN ONCOL, V9, P389, DOI 10.1200/JCO.1991.9.3.389
   Mirza MR, 2016, NEW ENGL J MED, V375, P2154, DOI 10.1056/NEJMoa1611310
   Mita MM, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.2516
   Niehrs C, 2012, EMBO J, V31, P2705, DOI 10.1038/emboj.2012.124
   Parmar MK, 2003, LANCET, V361, P2099
   Peng CJ, 2011, INT J GYNECOL CANCER, V21, P280, DOI 10.1097/IGC.0b013e31820aaadb
   Pfisterer J, 2006, J CLIN ONCOL, V24, P4699, DOI 10.1200/JCO.2006.06.0913
   Pujade Lauraine E, 2017, LANCET ONCOL, V18, P1274, DOI 10.1016/S1470 2045(17)30469 2
   Pujade Lauraine E, 2010, J CLIN ONCOL, V28, P3323, DOI 10.1200/JCO.2009.25.7519
   Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008 5472.CAN 05 3153
NR 24
TC 75
Z9 85
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0090 8258
EI 1095 6859
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD AUG
PY 2019
VL 154
IS 2
BP 294
EP 301
DI 10.1016/j.ygyno.2019.04.001
PG 8
WC Oncology; Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Obstetrics & Gynecology
GA IN7KC
UT WOS:000478859300009
PM 31174889
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Deng, X
   Tan, SM
   Zhu, D
   Sun, YJ
   Yu, JH
   Meng, XL
   Zheng, LP
   Liu, YQ
AF Deng Xue
   Tan Suming
   Zhu Di
   Sun Yujiao
   Yu Jinghua
   Meng Xiangling
   Zheng Luping
   Liu Yanqiu
TI The combined effect of oleonuezhenide and wedelolactone on proliferation
   and osteoblastogenesis of bone marrow mesenchymal stem cells
SO PHYTOMEDICINE
LA English
DT Article
DE Osteoblastogenesis; Bone marrow mesenchymal stem cells; Wedelolactone;
   Oleonuezhenide
ID CHINESE HERBAL PREPARATION; BETA CATENIN; SIGNALING PATHWAY; WNT;
   MINERALIZATION
AB Background: Regulation of the survival and differentiation of bone marrow mesenchymal stem cells is an essential consideration in the development of targeted drugs for treatment of osteoporosis.
   Purpose: The present study aimed to evaluate the combined effect of wedelolactone and oleonuezhenide, two compounds from Chinese formula Er Zhi Wan, on osteoblastogenesis and the underlying molecular mechanisms.
   Methods: MIT assay was taken to evaluate cell proliferation. The alkaline phosphatase (ALP) activity assay was used to determine the activity of ALP. Alizarin red S (ARS) staining was taken to indicate the intensity of the calcium deposits. Quantitative real time PCR and Western blot were performed to the levels of Runx2, Osteocalcin, and Osterix expression in mouse bone marrow mesenchymal stem cells (BMSCs). Ovariectomized mouse model and bone histomorphometric analysis were also used to research the effects of wedelolactone and oleonuezhenide on bone loss caused by ovariectomy.
   Results: Wedelolactone combined with oleonuezhenide enhanced osteoblast differentiation and bone mineralization. Osteoblastogenesis related marker genes including osteocalcin, Runx2, and osteorix were upregulated in the presence of wedelolactone and oleonuezhenide. At the molecular level, oleonuezhenide did not affect GSK 3 beta phosphorylation induced by wedelolactone, but elevated casein kinase 2 alpha (CK2 alpha) expression, resulting in beta catenin and Runx2 nuclear translocation. In addition, 30 mu M wedelolactone induced cytotoxicity in bone marrow mesenchymal stem cells was relieved by 9 mu M oleonuezhenide. These cells were protected by oleonuezhenide and maintained osteoblastic activity. Oleonuezhenide increased Wnt5a and CK2 alpha expression. Wedelolactone reduced extracellular signal regulated kinase (ERK) phosphorylation was reversed by oleonuezhenide. In ovariectomized mice, administration of wedelolactone and oleonuezhenide prevented ovariectomy induced bone loss by enhancing osteoblastic activity.
   Conclusion: These results suggested that oleonuezhenide enhanced the effects of wedelolactone on osteoblastogenesis. These two compounds could be developed as a combined therapeutic agent for osteoporosis.
C1 [Deng Xue; Tan Suming; Zhu Di; Sun Yujiao; Zheng Luping; Liu Yanqiu] Dalian Med Univ, Inst Coll Integrat Med, 9 West Sect Lvshun South Rd, Dalian 116044, Peoples R China.
   [Yu Jinghua; Meng Xiangling] Jilin Univ, First Hosp Jilin Univ, Inst Virol & AIDS Res, Changchun 130000, Jilin, Peoples R China.
C3 Dalian Medical University; Jilin University
RP Liu, YQ (通讯作者)，Dalian Med Univ, Inst Coll Integrat Med, 9 West Sect Lvshun South Rd, Dalian 116044, Peoples R China.
EM yqliu@dmu.edu.cn
RI Yu, Jinghua/AAS 5660 2020
OI liu, Yan Qiu/0000 0002 1905 7168
FU National Natural Science Foundation of China [81473545]; Liaoning
   province plans to support innovative talents in Colleges and
   Universities [LR2017050]; Natural Science Foundation of Liaoning
   province [20180550417]; State Scholorship Fund [201808210086]
FX This study was supported by a grant from the National Natural Science
   Foundation of China (81473545), by Liaoning province plans to support
   innovative talents in Colleges and Universities (LR2017050), by Natural
   Science Foundation of Liaoning province (20180550417) and by the State
   Scholorship Fund (201808210086).
CR Arbon KS, 2012, FOOD CHEM TOXICOL, V50, P198, DOI 10.1016/j.fct.2011.10.031
   Arioka M, 2013, BIOCHEM BIOPH RES CO, V440, P677, DOI 10.1016/j.bbrc.2013.09.126
   Bek S, 2002, J CELL SCI, V115, P4743, DOI 10.1242/jcs.00154
   Chen BB, 2017, MOLECULES, V22, DOI 10.3390/molecules22091469
   Chen JR, 2005, J BIOL CHEM, V280, P4632, DOI 10.1074/jbc.M411530200
   Chen QF, 2013, PHYTOTHER RES, V27, P973, DOI 10.1002/ptr.4820
   Cheng M, 2011, J ETHNOPHARMACOL, V138, P279, DOI 10.1016/j.jep.2011.09.030
   Cheruvu HS, 2018, J CHROMATOGR B, V1081, P80, DOI 10.1016/j.jchromb.2018.01.035
   Dyer Jamie O, 2010, Small GTPases, V1, P44
   Egermann M, 2005, OSTEOPOROSIS INT, V16, pS129, DOI 10.1007/s00198 005 1859 7
   Haÿ E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008284
   Hayashi M, 2012, NATURE, V485, P69, DOI 10.1038/nature11000
   Hayashi M, 2010, BIOCHEM BIOPH RES CO, V393, P432, DOI 10.1016/j.bbrc.2010.02.013
   He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117
   Hoemann CD, 2009, PATHOL BIOL, V57, P318, DOI 10.1016/j.patbio.2008.06.004
   Hu K., 2017, MOD J INTEGR TRADIT, V4, P384
   Hum Julia M, 2017, Bone Rep, V6, P38, DOI 10.1016/j.bonr.2017.01.003
   Kiernan J, 2017, STEM CELL TRANSL MED, V6, P1930, DOI 10.1002/sctm.17 0054
   Kim DY, 2013, KOREAN J PHYSIOL PHA, V17, P447, DOI 10.4196/kjpp.2013.17.5.447
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kubota T, 2009, J BONE MINER METAB, V27, P265, DOI 10.1007/s00774 009 0064 8
   Lee YJ, 2012, EUR J MED CHEM, V56, P361, DOI 10.1016/j.ejmech.2012.07.041
   Lerner UH, 2015, J INTERN MED, V277, P630, DOI 10.1111/joim.12368
   Li L, 2016, PHYTOMEDICINE, V23, P340, DOI 10.1016/j.phymed.2016.01.007
   Lisberg A, 2017, CPT PHARMACOMET SYST, V6, P208, DOI 10.1002/psp4.12154
   Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092 8674(02)00685 2
   Liu YQ, 2014, J ETHNOPHARMACOL, V157, P206, DOI 10.1016/j.jep.2014.09.033
   Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549
   Nishio Y, 2006, GENE, V372, P62, DOI 10.1016/j.gene.2005.12.022
   Okamoto M, 2014, SCI REP UK, V4, DOI 10.1038/srep04493
   Ponce DP, 2011, MOL CELL BIOCHEM, V356, P127, DOI 10.1007/s11010 011 0965 4
   Syed SD, 2003, PHYTOTHER RES, V17, P420, DOI 10.1002/ptr.1153
   Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137
   van Tonder Alet, 2015, BMC Res Notes, V8, P47, DOI 10.1186/s13104 015 1000 8
   Wang L, 2008, P NATL ACAD SCI USA, V105, P4826, DOI 10.1073/pnas.0712365105
   Wang YP, 2014, FRONT BIOSCI LANDMRK, V19, P379, DOI 10.2741/4214
   Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611
   [杨光明 Yang Guangming], 2016, [中草药, Chinese Traditional and Herbal Drugs], V47, P760
   Yu Q. Y, 2009, STRAIT PHARM J, V11, P169
   Zhang H, 2008, MATURITAS, V61, P334, DOI 10.1016/j.maturitas.2008.09.023
   Zhang JF, 2010, MOL CELL ENDOCRINOL, V314, P70, DOI 10.1016/j.mce.2009.08.012
NR 41
TC 11
Z9 12
U1 1
U2 30
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944 7113
EI 1618 095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD DEC
PY 2019
VL 65
AR 153103
DI 10.1016/j.phymed.2019.153103
PG 13
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA JS8OQ
UT WOS:000500561700014
PM 31805425
DA 2025 08 17
ER

PT J
AU Gao, G
   Tian, Z
   Zhu, HY
   Ouyang, XY
AF Gao, Gan
   Tian, Zhen
   Zhu, Huan Ye
   Ouyang, Xun Yan
TI miRNA 133b targets FGFR1 and presents multiple tumor suppressor
   activities in osteosarcoma
SO CANCER CELL INTERNATIONAL
LA English
DT Article
DE Osteosarcoma; miR 133b; Fibroblast growth factor receptor 1; Tumor
   suppressor; Ras; MAPK signaling; PI3K; Akt signaling
ID EPITHELIAL MESENCHYMAL TRANSITION; THERAPEUTIC TARGETS; MIR 133B ACTS;
   EXPRESSION; MIGRATION; GROWTH; INVASION; PROLIFERATION; MICRORNA 133B;
   SURVIVAL
AB BackgroundOsteosarcoma (OS) is the most common bone malignancy prevalent in children and young adults. MicroRNA 133b (miR 133b), through directly targeting the fibroblast growth factor receptor 1 (FGFR1), is increasingly recognized as a tumor suppressor in different types of cancers. However, little is known on the biological and functional significance of miR 133b/FGFR1 regulation in osteosarcoma.MethodsThe expressions of miR 133b and FGFR1 were examined by RT qPCR and compared between 30 paired normal bone tissues and OS tissues, and also between normal osteoblasts and three OS cells lines, MG 63, U2OS, and SAOS 2. Using U2OS and MG 63 as the model system, the functional significance of miR 133b and FGFR1 was assessed on cell viability, proliferation, apoptosis, migration/invasion, and epithelial mesenchymal transition (EMT) by overexpressing miR 133b and down regulating FGFR1 expression, respectively. Furthermore, the signaling cascades controlled by miR 133b/FGFR1 were examined.ResultsmiR 133b was significantly down regulated while FGFR1 robustly up regulated in OS tissues and OS cell lines, when compared to normal bone tissues and normal osteoblasts, respectively. Low miR 133b expression and high FGFR1 expression were associated with location of the malignant lesion, advanced clinical stage, and distant metastasis. FGFR1 was a direct target of miR 133b. Overexpressing miRNA 133b or knocking down FGFR1 significantly reduced the viability, proliferation, migration/invasion, and EMT, but promoted apoptosis of both MG 63 and U2OS cells. Both the Ras/MAPK and PI3K/Akt intracellular signaling cascades were inhibited in response to overexpressing miRNA 133b or knocking down FGFR1 in OS cells.ConclusionmiR 133b, by targeting FGFR1, presents a plethora of tumor suppressor activities in OS cells. Boosting miR 133b expression or reducing FGFR1 expression may benefit OS therapy.
C1 [Gao, Gan; Tian, Zhen; Zhu, Huan Ye; Ouyang, Xun Yan] Guizhou Prov Peoples Hosp, Dept Orthoped, 83 East Zhongshan Rd, Guiyang 550002, Guizhou, Peoples R China.
RP Gao, G (通讯作者)，Guizhou Prov Peoples Hosp, Dept Orthoped, 83 East Zhongshan Rd, Guiyang 550002, Guizhou, Peoples R China.
EM gaogan615@163.com
FU Department of Science and Technology of Guizhou Province [5724 5]
FX This work was supported by funding from the Department of Science and
   Technology of Guizhou Province, [2017]5724 5.
CR Adamopoulos C, 2016, EXP BIOL MED, V241, P1296, DOI 10.1177/1535370216648806
   Akçakaya P, 2011, INT J ONCOL, V39, P311, DOI 10.3892/ijo.2011.1043
   Amary MF, 2014, CANCER MED US, V3, P980, DOI 10.1002/cam4.268
   Anninga JK, 2011, EUR J CANCER, V47, P2431, DOI 10.1016/j.ejca.2011.05.030
   [Anonymous], 2018, CANCERS BASEL, V10
   Baird K, 2005, CANCER RES, V65, P9226, DOI 10.1158/0008 5472.CAN 05 1699
   Cannell IG, 2008, BIOCHEM SOC T, V36, P1224, DOI 10.1042/BST0361224
   Chen XN, 2014, CANCER CELL INT, V14, DOI 10.1186/s12935 014 0070 3
   Cheng YS, 2017, ONCOL REP, V38, P3220, DOI 10.3892/or.2017.5944
   Crawford M, 2009, BIOCHEM BIOPH RES CO, V388, P483, DOI 10.1016/j.bbrc.2009.07.143
   Dai J, 2016, ONCOTARGET, V7, P87147, DOI 10.18632/oncotarget.13515
   Duan FT, 2013, MOL CANCER, V12, DOI 10.1186/1476 4598 12 164
   Gorlick R, 2009, CANC TREAT, V152, P467, DOI 10.1007/978 1 4419 0284 9_27
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hu G, 2010, CANCER BIOL THER, V10, P190, DOI 10.4161/cbt.10.2.12186
   Kano M, 2010, INT J CANCER, V127, P2804, DOI 10.1002/ijc.25284
   Karatas OF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098675
   Katoh M, 2014, MED RES REV, V34, P280, DOI 10.1002/med.21288
   Kumazaki M, 2015, ONCOTARGET, V6, P25828, DOI 10.18632/oncotarget.4558
   Li DJ, 2017, ONCOTARGET, V8, P50193, DOI 10.18632/oncotarget.16745
   Li X, 2014, CLIN CANCER RES, V20, P2312, DOI 10.1158/1078 0432.CCR 13 1588
   Lin C, 2018, INT J MOL MED, V41, P2050, DOI 10.3892/ijmm.2018.3382
   Lindsey BA, 2017, RHEUMATOL THER, V4, P25, DOI 10.1007/s40744 016 0050 2
   Liu G, 2016, ONCOL LETT, V11, P2903, DOI 10.3892/ol.2016.4316
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mitchelson Keith Richard, 2015, World J Biol Chem, V6, P162, DOI 10.4331/wjbc.v6.i3.162
   Moustakas A, 2017, MOL ONCOL, V11, P715, DOI 10.1002/1878 0261.12094
   Novello C, 2013, INT J ONCOL, V42, P667, DOI 10.3892/ijo.2012.1717
   Ornitz DM, 2015, WIRES DEV BIOL, V4, P215, DOI 10.1002/wdev.176
   Patron JP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035345
   Reddy KB, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935 015 0185 1
   Sannino G, 2017, CANCER RES, V77, P4556, DOI 10.1158/0008 5472.CAN 17 0032
   Saxena NK, 2007, CANCER RES, V67, P2497, DOI 10.1158/0008 5472.CAN 06 3075
   Tian ZJ, 2016, EXP CELL RES, V343, P135, DOI 10.1016/j.yexcr.2016.03.027
   Wan J, 2016, ONCOL LETT, V11, P511, DOI 10.3892/ol.2015.3962
   Wen DC, 2013, TUMOR BIOL, V34, P793, DOI 10.1007/s13277 012 0609 7
   Wu DY, 2014, MOL MED REP, V9, P2491, DOI 10.3892/mmr.2014.2116
   Yang L, 2017, EUR REV MED PHARMACO, V21, P5602, DOI 10.26355/eurrev_201712_14001
   Zhang C, 2014, INT J CLIN EXP PATHO, V7, P4194
   Zhao HF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083571
   Zhen Y, 2017, ONCOL RES, V25, P1109, DOI 10.3727/096504016X14800889609439
   Zhou WY, 2016, CANCER BIOL MED, V13, P260, DOI 10.20892/j.issn.2095 3941.2015.0102
   Zou YG, 2018, ONCOL LETT, V15, P1097, DOI 10.3892/ol.2017.7432
NR 43
TC 23
Z9 23
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1475 2867
J9 CANCER CELL INT
JI Cancer Cell Int.
PD DEC 18
PY 2018
VL 18
AR 210
DI 10.1186/s12935 018 0696 7
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA HE8YS
UT WOS:000453734500002
PM 30574019
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Pathi, SP
   Kowalczewski, C
   Tadipatri, R
   Fischbach, C
AF Pathi, Siddharth P.
   Kowalczewski, Christine
   Tadipatri, Ramya
   Fischbach, Claudia
TI A Novel 3 D Mineralized Tumor Model to Study Breast Cancer Bone
   Metastasis
SO PLOS ONE
LA English
DT Article
ID NF KAPPA B; GROWTH FACTOR; OSTEOBLAST ADHESION; CELL PROLIFERATION;
   SIGNALING PATHWAY; RAW264.7 CELLS; IN VIVO; EXPRESSION; HYDROXYAPATITE;
   OSTEOPONTIN
AB Background: Metastatic bone disease is a frequent cause of morbidity in patients with advanced breast cancer, but the role of the bone mineral hydroxyapatite (HA) in this process remains unclear. We have developed a novel mineralized 3 D tumor model and have employed this culture system to systematically investigate the pro metastatic role of HA under physiologically relevant conditions in vitro.
   Methodology/Principal Findings: MDA MB231 breast cancer cells were cultured within non mineralized or mineralized polymeric scaffolds fabricated by a gas foaming particulate leaching technique. Tumor cell adhesion, proliferation, and secretion of pro osteoclastic interleukin 8 (IL 8) was increased in mineralized tumor models as compared to non mineralized tumor models, and IL 8 secretion was more pronounced for bone specific MDA MB231 subpopulations relative to lung specific breast cancer cells. These differences were pathologically significant as conditioned media collected from mineralized tumor models promoted osteoclastogenesis in an IL 8 dependent manner. Finally, drug testing and signaling studies with transforming growth factor beta (TGF beta) confirmed the clinical relevance of our culture system and revealed that breast cancer cell behavior is broadly affected by HA.
   Conclusions/Significance: Our results indicate that HA promotes features associated with the neoplastic and metastatic growth of breast carcinoma cells in bone and that IL 8 may play an important role in this process. The developed mineralized tumor models may help to reveal the underlying cellular and molecular mechanisms that may ultimately enable more efficacious therapy of patients with advanced breast cancer.
C1 [Pathi, Siddharth P.; Kowalczewski, Christine; Tadipatri, Ramya; Fischbach, Claudia] Cornell Univ, Dept Biomed Engn, Ithaca, NY 14853 USA.
C3 Cornell University
RP Pathi, SP (通讯作者)，Cornell Univ, Dept Biomed Engn, Ithaca, NY 14853 USA.
EM cf99@cornell.edu
RI Fischbach, Claudia/C 8550 2009
OI Fischbach, Claudia/0000 0002 9368 0150
FU National Science Foundation (NSF); Musculoskeletal Repair and
   Regeneration Core Center at the Hospital for Special Surgery in New York
   [AR046121]
FX This work was supported by a National Science Foundation (NSF) graduate
   research fellowship (SPP) (nsfgrfp.org) and funding by the
   Musculoskeletal Repair and Regeneration Core Center at the Hospital for
   Special Surgery in New York (Grant AR046121)
   (http://www.hss.edu/repair regeneration center.asp). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Anselme K, 2000, BIOMATERIALS, V21, P667, DOI 10.1016/S0142 9612(99)00242 2
   Bachelder RE, 2001, CANCER RES, V61, P5736
   Bancroft CC, 2002, INT J CANCER, V99, P538, DOI 10.1002/ijc.10398
   Bendre M, 2003, CLIN ORTHOP RELAT R, pS39, DOI 10.1097/01.blo.0000093844.72468.f4
   Bendre MS, 2003, BONE, V33, P28, DOI 10.1016/S8756 3282(03)00086 3
   Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059
   BOSKEY AL, 1993, BONE MINER, V22, P147, DOI 10.1016/S0169 6009(08)80225 5
   Boskey AL, 2002, CALCIFIED TISSUE INT, V71, P145, DOI 10.1007/s00223 001 1121 z
   Boyan B. D., 2003, European Cells & Materials, V6, P22
   Butcher DT, 2009, NAT REV CANCER, V9, P108, DOI 10.1038/nrc2544
   Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005
   Chirgwin JM, 2000, CRIT REV EUKAR GENE, V10, P159, DOI 10.1615/CritRevEukarGeneExpr.v10.i2.50
   Deckers MML, 2000, ENDOCRINOLOGY, V141, P1667, DOI 10.1210/en.141.5.1667
   Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Fischbach C, 2007, NAT METHODS, V4, P855, DOI 10.1038/NMETH1085
   Fischbach C, 2009, P NATL ACAD SCI USA, V106, P399, DOI 10.1073/pnas.0808932106
   Fong YC, 2008, J BONE MINER RES, V23, P961, DOI 10.1359/JBMR.080206
   Gilbert M, 2000, J BIOL CHEM, V275, P16213, DOI 10.1074/jbc.M001773200
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Guise TA, 2003, CLIN ORTHOP RELAT R, pS32, DOI 10.1097/01.blo.0000093055.96273.69
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Guise TA, 2008, CANCER TREAT REV, V34, pS19, DOI 10.1016/j.ctrv.2008.03.006
   Hartley JW, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742 4690 5 1
   Hiraga T, 2001, CANCER RES, V61, P4418
   Iafisco M, 2008, LANGMUIR, V24, P4924, DOI 10.1021/la703381h
   Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Khalili P, 2006, MOL CANCER THER, V5, P2271, DOI 10.1158/1535 7163.MCT 06 0100
   Kim SS, 2006, BIOMATERIALS, V27, P1399, DOI 10.1016/j.biomaterials.2005.08.016
   Kindle L, 2006, J BONE MINER RES, V21, P193, DOI 10.1359/JBMR.051027
   Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535 7163.MCT 07 0234
   KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554
   Kostic A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006361
   Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911 005 5399 8
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Mailland M, 1997, ENDOCRINOLOGY, V138, P3601, DOI 10.1210/en.138.9.3601
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Mercer RR, 2004, CLIN EXP METASTAS, V21, P427, DOI 10.1007/s10585 004 1867 6
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320
   Mitsuyama H, 2004, J BONE MINER RES, V19, P671, DOI 10.1359/JBMR.0301256
   Mizukami Y, 2005, NAT MED, V11, P992, DOI 10.1038/nm1294
   Morgan MP, 2001, MOL CARCINOGEN, V32, P111, DOI 10.1002/mc.1070
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Mundy GR, 1997, CANCER AM CANCER SOC, V80, P1546, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1546::AID CNCR4>3.3.CO;2 R
   Nagano M, 1996, BIOMATERIALS, V17, P1771, DOI 10.1016/0142 9612(95)00357 6
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046
   Pampaloni F, 2007, NAT REV MOL CELL BIO, V8, P839, DOI 10.1038/nrm2236
   Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010
   Pezzatini S, 2007, BONE, V41, P523, DOI 10.1016/j.bone.2007.06.016
   Polek TC, 2003, J BIOL CHEM, V278, P32317, DOI 10.1074/jbc.M302518200
   Rao H, 2009, BONE, V44, pS141, DOI 10.1016/j.bone.2009.01.447
   Roderick HL, 2008, NAT REV CANCER, V8, P361, DOI 10.1038/nrc2374
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Singhal H, 1997, CLIN CANCER RES, V3, P605
   Suda T, 1997, J BONE MINER RES, V12, P869, DOI 10.1359/jbmr.1997.12.6.869
   Tanaka Y, 2007, CLIN CANCER RES, V13, P816, DOI 10.1158/1078 0432.CCR 06 2258
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Youngs SJ, 1997, INT J CANCER, V71, P257, DOI 10.1002/(SICI)1097 0215(19970410)71:2<257::AID IJC22>3.0.CO;2 D
NR 61
TC 88
Z9 106
U1 1
U2 32
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JAN 22
PY 2010
VL 5
IS 1
AR e8849
DI 10.1371/journal.pone.0008849
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 547NK
UT WOS:000273896100014
PM 20107512
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Hauser, M
   Siegrist, M
   Denzer, A
   Saulacic, N
   Grosjean, J
   Bohner, M
   Hofstetter, W
AF Hauser, Michel
   Siegrist, Mark
   Denzer, Alain
   Saulacic, Nikola
   Grosjean, Joel
   Bohner, Marc
   Hofstetter, Willy
TI Bisphosphonates reduce biomaterial turnover in healing of critical size
   rat femoral defects
SO JOURNAL OF ORTHOPAEDIC SURGERY
LA English
DT Article
DE bisphosphonate; BMP2; fracture healing; osteoporosis; beta tricalcium
   phosphate
ID ALENDRONATE TREATMENT; BONE; FRACTURE; ANTAGONISTS; INHIBITION;
   PROTEINS; PATHWAY; VARIANT; WOMEN; MODEL
AB Treatment of osteoporotic patients with bisphosphonates (BPs) preserves bone mass and microarchitecture. The high prescription rate of the drugs brings about increases in the numbers of fractures and bone defects requiring surgical interventions in these patients. Currently, critical size defects are filled with biomaterials and healing is supported with bone morphogenetic proteins (BMP). It is hypothesized that BPs interfere with biomaterial turnover during BMP supported repair of defects filled with beta tricalcium phosphate (beta TCP) ceramics. To test this hypothesis, retired breeder rats were ovariectomized (OVX). After 8 weeks, treatment with alendronate (ALN) commenced. Five weeks later, 6 mm diaphyseal femoral defects were applied and stabilized with locking plates. beta TCP cylinders loaded with 1 mu g and 10 mu g BMP2, 10 mu g L51P, an inhibitor of BMP antagonists and 1 mu g BMP2/10 beta g L51P were fitted into the defects. Femora were collected 16 weeks post implantation. In groups receiving calcium phosphate implants loaded with 10 mu g BMP2 and 1 mu g BMP2/10 mu g L51P, the volume of bone was increased and beta TCP was decreased compared to groups receiving implants with 1 mu g BMP2 and 10 mu g L51P. Treatment of animals with ALN caused a decrease in beta TCP turnover. The results corroborate the synergistic effects of BMP2 and L51P on bone augmentation. Administration of ALN caused a reduction in implant turnover, demonstrating the dependence of beta TCP removal on osteoclast activity, rather than on chemical solubility. Based on these data, it is suggested that in patients treated with BPs, healing of biomaterial filled bone defects may be impaired because of the failure to remove the implant and its replacement by authentic bone.
C1 [Hauser, Michel; Siegrist, Mark; Denzer, Alain; Hofstetter, Willy] Univ Bern, Dept BioMed Res DBMR, Bone Biol & Orthopaed Res, Murtenstr 35, CH 3008 Bern, Switzerland.
   [Hauser, Michel] Univ Bern, Grad Sch Cellular & Biomed Sci, Bern, Switzerland.
   [Saulacic, Nikola] Univ Bern, Dept BioMed Res DBMR, Clin Craniomaxillofacial Surg, Bern, Switzerland.
   [Grosjean, Joel] Univ Bern, Dept BioMed Res DBMR, Urol Res Grp, Bern, Switzerland.
   [Bohner, Marc] RMS Fdn, Bettlach, Switzerland.
C3 University of Bern; University of Bern; University of Bern; University
   of Bern
RP Hofstetter, W (通讯作者)，Univ Bern, Dept BioMed Res DBMR, Bone Biol & Orthopaed Res, Murtenstr 35, CH 3008 Bern, Switzerland.
EM hofstetter@dbmr.unibe.ch
RI Bohner, Marc/F 3828 2011
OI Bohner, Marc/0000 0002 5079 3286
FU Alfred & Anneliese Sutter Stottner Foundation
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This work
   was made possible by a grant from the Alfred & Anneliese Sutter Stottner
   Foundation to Willy Hofstetter.
CR Albers CE, 2012, BONE, V51, P401, DOI 10.1016/j.bone.2012.06.020
   Arganda Carreras I., 2014, NEUROSCI 2014 SHORT, P73
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Bone HG, 1997, J CLIN ENDOCR METAB, V82, P265, DOI 10.1210/jc.82.1.265
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002 0023
   Cao YP, 2002, J BONE MINER RES, V17, P2237, DOI 10.1359/jbmr.2002.17.12.2237
   CHESTNUT CH, 1995, AM J MED, V99, P144, DOI 10.1016/S0002 9343(99)80134 X
   Cranney A, 2002, ENDOCR REV, V23, P508, DOI 10.1210/er.2001 2002
   Dean DB, 2010, J ANAT, V216, P625, DOI 10.1111/j.1469 7580.2010.01214.x
   Fu LJ, 2013, ACTA PHARMACOL SIN, V34, P387, DOI 10.1038/aps.2012.170
   Gerstenfeld LC, 2009, J BONE MINER RES, V24, P196, DOI 10.1359/JBMR.081113
   Gröngröft I, 2009, J BIOMECH, V42, P2089, DOI 10.1016/j.jbiomech.2009.06.004
   Haque T, 2008, BONE, V42, P1144, DOI 10.1016/j.bone.2008.01.028
   Hosking D, 1998, NEW ENGL J MED, V338, P485, DOI 10.1056/NEJM199802193380801
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Keller S, 2004, NAT STRUCT MOL BIOL, V11, P481, DOI 10.1038/nsmb756
   Khattab HM, 2014, BONE, V69, P165, DOI 10.1016/j.bone.2014.09.011
   Khattab HM, 2018, J BONE MINER METAB, V1, P1
   Kirsch T, 2000, FEBS LETT, V468, P215, DOI 10.1016/S0014 5793(00)01214 X
   Kloen P, 2002, J BONE JOINT SURG AM, V84A, P1909, DOI 10.2106/00004623 200211000 00001
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   MacNeal WJ, 1922, JAMA, V78
   McClung M, 2013, AM J MED, V126, P13, DOI 10.1016/j.amjmed.2012.06.023
   Penney DP, 2002, BIOTECH HISTOCHEM, V77, P237, DOI 10.1080/714028210
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Ruppert R, 1996, EUR J BIOCHEM, V237, P295, DOI 10.1111/j.1432 1033.1996.0295n.x
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Sebald HJ, 2012, ACTA BIOMATER, V8, P3816, DOI 10.1016/j.actbio.2012.06.036
   URIST MR, 1979, P NATL ACAD SCI USA, V76, P1828, DOI 10.1073/pnas.76.4.1828
   Walsh DW, 2010, TRENDS CELL BIOL, V20, P244, DOI 10.1016/j.tcb.2010.01.008
   Wernike E, 2010, EUR CELLS MATER, V19, P30
NR 33
TC 10
Z9 10
U1 0
U2 10
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1022 5536
EI 2309 4990
J9 J ORTHOP SURG HONG K
JI J. Orthop. Surg.
PD SEP 30
PY 2018
VL 26
IS 3
AR 2309499018802487
DI 10.1177/2309499018802487
PG 10
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Surgery
GA GV4AQ
UT WOS:000446040100001
PM 30270749
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Fei, ZG
   Sun, CG
   Peng, XQ
   Han, M
   Zhou, QJ
AF Fei, Zhengguo
   Sun, Chunguang
   Peng, Xiaoqiang
   Han, Mu
   Zhou, Qijia
TI Kruppel like factor 4 promotes the proliferation and osteogenic
   differentiation of BMSCs through SOX2/IGF2 pathway
SO ACTA BIOCHIMICA POLONICA
LA English
DT Article
DE Kr?ppel like factor 4; human bone marrow mesenchymal stem cells; SOX2;
   IGF2; osteogenic differentiation
ID MESENCHYMAL STEM CELLS; SOX2; KLF4; OSTEOBLAST; COLLAGEN; OCT4
AB Objectives: Human bone marrow mesenchymal stem cells (BMSCs) have multi lineage differentiation potential and have been widely researched in regenerative medicine. The purpose of this research was to explore whether Kruppel like factor 4 (KLF4) can regulate the osteogenic differentiation of BMSCs. Methods: We transfected human BMSCs with KLF4 overexpression plasmid and si KLF4 to study the effects of KLF4. We performed cell proliferation assay, flow cytometry and Alizarin Red staining on BMSCs. Quantitative real time PCR and western blot was performed to determined mRNA and protein expression of osteogenic differentiation markers, KLF4, SOX2 and IGF2. Bone defect animal model was created and the adenovirus containing KLF4 overexpression or knockdown plasmid was injected. Finally, HE staining was performed on tibia to assess the new bone formation. Results: Our results showed that KLF4 promotes not only the growth of BMSCs, but also their osteogenic differentiation. Also, it mediated these effects through SOX2/IGF2 signaling pathway. In addition, KLF4 overexpression could increase the bone regeneration in in vivo model, whereas KLF4 knockdown decreased the bone regeneration. Conclusions: KLF4 regulates BMSC's osteogenic differentiation via SOX2/IGF2 pathway.
C1 [Fei, Zhengguo; Sun, Chunguang; Peng, Xiaoqiang; Han, Mu; Zhou, Qijia] Funing Peoples Hosp, Dept Orthopaed, Yancheng City, Jiangsu, Peoples R China.
RP Zhou, QJ (通讯作者)，Funing Peoples Hosp, Dept Orthopaed, Yancheng City, Jiangsu, Peoples R China.
EM zqj7966888@sina.com
FU Yancheng City Health Committeeand Yancheng City Science and Technology
   Bureau [YK2020089]
FX Yancheng City Health Committeeand Yancheng City Science and Technology
   Bureau (NO. YK2020089)
CR Akkouch A, 2019, HUM GENE THER, V30, P1405, DOI 10.1089/hum.2019.019
   Brydone AS, 2010, P I MECH ENG H, V224, P1329, DOI 10.1243/09544119JEIM770
   Chiu YF, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 65006 z
   Dimitriou R, 2011, INJURY, V42, pS3, DOI 10.1016/j.injury.2011.06.015
   Donzelli E, 2007, ARCH ORAL BIOL, V52, P64, DOI 10.1016/j.archoralbio.2006.07.007
   Feinberg MW, 2007, EMBO J, V26, P4138, DOI 10.1038/sj.emboj.7601824
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   Ghaleb AM, 2017, GENE, V611, P27, DOI 10.1016/j.gene.2017.02.025
   Griffin M, 2011, J BONE JOINT SURG BR, V93B, P427, DOI 10.1302/0301 620X.93B4.25249
   Hamidouche Z, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471 2121 11 44
   Huang Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.433
   Kaneda A, 2007, P NATL ACAD SCI USA, V104, P20926, DOI 10.1073/pnas.0710359105
   Kolf CM, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2116
   Majesky MW, 2017, CIRC RES, V120, P296, DOI 10.1161/CIRCRESAHA.116.309322
   Min SY, 2019, P NATL ACAD SCI USA, V116, P17970, DOI 10.1073/pnas.1906512116
   Mo MH, 2016, CELL MOL LIFE SCI, V73, P3311, DOI 10.1007/s00018 016 2229 7
   Müller P, 2008, J CELL MOL MED, V12, P281, DOI 10.1111/j.1582 4934.2007.00103.x
   Nishimura K, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229744
   Park SB, 2012, CELL DEATH DIFFER, V19, P534, DOI 10.1038/cdd.2011.137
   Qi H, 2007, CELL RES, V17, P578, DOI 10.1038/cr.2007.59
   Rady D, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/8837654
   Robert AW, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00561
   Sadatpoor SO, 2020, INT J STEM CELLS, V13, P24, DOI 10.15283/ijsc19031
   Seo E, 2013, CELL REP, V3, P2075, DOI 10.1016/j.celrep.2013.05.029
   Shi ST, 1996, J BONE MINER RES, V11, P1139, DOI 10.1002/jbmr.5650110813
   Tang JM, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389 018 0074 2
   Tompkins DH, 2011, AM J RESP CELL MOL, V45, P101, DOI 10.1165/rcmb.2010 0149OC
   Tsao YT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010159
   Wei Z, 2009, STEM CELLS, V27, P2969, DOI 10.1002/stem.231
   Xu LJ, 2018, MOL CELLS, V41, P575, DOI 10.14348/molcells.2018.2359
   Yourek G, 2010, REGEN MED, V5, P713, DOI 10.2217/RME.10.60
   Zheng H, 2009, AM J PHYSIOL GASTR L, V296, pG490, DOI 10.1152/ajpgi.90393.2008
NR 32
TC 4
Z9 5
U1 0
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1734 154X
J9 ACTA BIOCHIM POL
JI Acta Biochim. Pol.
PY 2022
VL 69
IS 2
BP 349
EP 355
DI 10.18388/abp.2020_5797
EA MAY 2022
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 2G8CA
UT WOS:000813579700001
PM 35617351
OA gold
DA 2025 08 17
ER

PT J
AU Zhou, YL
   Chen, X
   Zhu, ZM
   Bi, DC
   Ma, SY
AF Zhou, Youlong
   Chen, Xing
   Zhu, Zemin
   Bi, Daochi
   Ma, Shuyun
TI MiR 133a delivery to osteoblasts ameliorates mechanical
   unloading triggered osteopenia progression in vitro and in vivo
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Osteopenia; Mechanical unloading; miR 133a; Osteoblasts
ID DIFFERENTIATION; BONE; OSTEOPOROSIS; MICE; EXPRESSION; CELLS; RUNX2
AB Mechanical unloading induced bone loss is a clinical challenge, and deep understanding for this disease is necessary for developing novel and effective therapies. MicroRNAs (miRNAs) are small non coding RNAs, and involved in bone remodeling. In the study, we attempted to explore the potential of miR 133a in regulating osteoblast activation and its anti osteopenia function both in vitro and in vivo. Our in vitro studies at first showed that miR 133a could significantly promote the expression of osteocalcin (OCN), Collagen I, alkaline phosphatase (ALP), runt related transcription factor 2 (Runx2) and osterix (Osx), promoting the activation and mineralization of osteoblasts. Then, hindlimb unloading (HU) challenged mice were established with or without intravenous injection of agomir miR 133a using an osteoblast targeting delivery system. We found that miR 133a in osteoblasts significantly alleviated the bone loss, microstructural, and biomechanical property in mice with mechanical unloading, contributing to osteopenia alleviation. Furthermore, both in vitro and in vivo experiments showed that miR 133a could restrain osteoclastogenesis via tartrate resistant acid phosphatase (TRAP) staining. In conclusion, our results suggested that miR 133a may be a promising factor in mediating the occurrence and progression of osteopenia caused by mechanical unloading, and thus targeting miR 133a could be considered as an effective therapeutic strategy for the suppression of pathological osteopenia.
C1 [Zhou, Youlong; Chen, Xing; Zhu, Zemin; Bi, Daochi; Ma, Shuyun] Changxing Peoples Hosp, Dept Orthopaed, Huzhou 313100, Zhejiang, Peoples R China.
RP Zhou, YL (通讯作者)，Changxing Peoples Hosp, Dept Orthopaed, Huzhou 313100, Zhejiang, Peoples R China.
EM zhouyoulongex@foxmail.com
FU General Public Welfare Projects of Science and Technology Department of
   Zhejiang Province of China [N0.LGF 18H060002]
FX This work was supported by grants from General Public Welfare Projects
   of Science and Technology Department of Zhejiang Province of China
   (N0.LGF 18H060002) .
CR Ahmad N, 2019, MOL THER NUCL ACIDS, V14, P536, DOI 10.1016/j.omtn.2019.01.002
   Akkawi Ibrahim, 2018, Joints, V6, P122, DOI 10.1055/s 0038 1660790
   Alghazali KM, 2015, DRUG METAB REV, V47, P431, DOI 10.3109/03602532.2015.1115871
   Bhushan R, 2013, INT J BIOCHEM CELL B, V45, P696, DOI 10.1016/j.biocel.2012.12.008
   Boehrs Jessica, 2008, J Prosthodont, V17, P517, DOI 10.1111/j.1532 849X.2008.00330.x
   Castaño IM, 2016, SCI REP UK, V6, DOI 10.1038/srep27941
   Chen FJ, 2014, CELL PHYSIOL BIOCHEM, V33, P796, DOI 10.1159/000358653
   Chitu V, 2012, BLOOD, V120, P3126, DOI 10.1182/blood 2012 04 425595
   Chou LY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197210
   Deckard C, 2017, J BIOL PHYS, V43, P139, DOI 10.1007/s10867 016 9439 y
   Ding Y, 2019, J CELL BIOCHEM, V120, P16025, DOI 10.1002/jcb.28882
   Donaubauer AJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176377
   Fang M, 2018, J CELL BIOCHEM, V119, P5175, DOI 10.1002/jcb.26545
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Hao LY, 2016, CELL PHYSIOL BIOCHEM, V38, P1267, DOI 10.1159/000443074
   Hawse JR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019429
   Hayami T, 2011, MATRIX BIOL, V30, P281, DOI 10.1016/j.matbio.2011.04.003
   Kang Yun Seok, 2017, J Exerc Nutrition Biochem, V21, P48
   Kirk B, 2020, J CACHEXIA SARCOPENI, V11, P609, DOI 10.1002/jcsm.12567
   Komori T, 2018, HISTOCHEM CELL BIOL, V149, P313, DOI 10.1007/s00418 018 1640 6
   Kuosmanen SM, 2018, REDOX BIOL, V18, P77, DOI 10.1016/j.redox.2018.06.007
   Laurent M, 2013, BEST PRACT RES CL EN, V27, P527, DOI 10.1016/j.beem.2013.04.010
   Li J, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2159 z
   Li XL, 2019, FASEB J, V33, P8913, DOI 10.1096/fj.201802711R
   Li ZX, 2020, ENVIRON SCI POLLUT R, V27, P6628, DOI 10.1007/s11356 019 06648 z
   Liao XB, 2013, ENDOCRINOLOGY, V154, P3344, DOI 10.1210/en.2012 2236
   Nakajima A, 2009, J BONE MINER RES, V24, P1162, DOI [10.1359/jbmr.090205, 10.1359/JBMR.090205]
   Nakamura H, 2013, J BONE MINER RES, V28, P1457, DOI 10.1002/jbmr.1866
   Olivier BJ, 2008, HEPATOLOGY, V47, P259, DOI 10.1002/hep.21971
   Park Min KH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6418
   Peng H, 2018, EUR REV MED PHARMACO, V22, P2519, DOI 10.26355/eurrev_201805_14914
   Porwal K, 2017, J NUTR BIOCHEM, V44, P22, DOI 10.1016/j.jnutbio.2017.02.011
   Prasad J, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 42378 5
   Rodriguez JES, 2009, J BONE MINER RES, V24, P1917, DOI [10.1359/JBMR.090507, 10.1359/jbmr.090507]
   Roy E, 2020, VIRUSES BASEL, V12, DOI 10.3390/v12111207
   Sui BD, 2016, STEM CELL TRANSL MED, V5, P1238, DOI 10.5966/sctm.2015 0347
   Thakar T, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 16096 w
   Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187
   Uddin SMZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073914
   Wang LJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14146 6
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Wang Y, 2015, CELL MOL BIOL LETT, V20, P586, DOI 10.1515/cmble 2015 0034
   Wang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034641
   Wang YX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 1153 1
   Williamson Liam, 2017, Bone Rep, V6, P44, DOI 10.1016/j.bonr.2017.02.001
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Xia JW, 2020, ANN RHEUM DIS, V79, P1460, DOI 10.1136/annrheumdis 2020 217892
   Xu RY, 2018, AGING CELL, V17, DOI 10.1111/acel.12794
   Yang K, 2018, BONE, V114, P40, DOI 10.1016/j.bone.2018.06.003
   Yang Y, 2020, BIOL RES, V53, DOI 10.1186/s40659 020 00309 z
   Younes N, 2020, THORAX, V75, P556, DOI 10.1136/thoraxjnl 2019 213561
   Zhang LJ, 2020, BIOCHEM BIOPH RES CO, V522, P164, DOI 10.1016/j.bbrc.2019.11.057
   Zhang W, 2018, DNA CELL BIOL, V37, P199, DOI 10.1089/dna.2017.3936
   Zhang YQ, 2017, AM J TRANSL RES, V9, P126
NR 54
TC 4
Z9 7
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD AUG
PY 2021
VL 97
AR 107613
DI 10.1016/j.intimp.2021.107613
EA MAY 2021
PG 10
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA TR7TW
UT WOS:000679165100001
PM 33962226
DA 2025 08 17
ER

PT J
AU Baloglu, M
   Özkorkmaz, EG
AF Baloglu, M.
   Ozkorkmaz, E. Gokalp
TI Biochemical and immunohistochemical investigations on bone formation and
   remodelling in ovariectomised rats with tamoxifen citrate administration
SO FOLIA MORPHOLOGICA
LA English
DT Article
DE ovariectomy; bone remodelling; tamoxifen; osteonectin; osteopontin
ID MINERAL DENSITY; SERUM CHOLESTEROL; MODEL; OSTEOPONTIN; OSTEOPOROSIS;
   EXPRESSION; WOMEN; ANGIOGENESIS; RESORPTION; MELATONIN
AB Background: Osteoporosis results with the imbalance between osteoblastic formation and osteoclastic resorption, resulting in susceptibility to bone fractures. Ovariectomy leads to osteoporosis by triggering alterations in bone formation and structure. Tamoxifen as an anti oestrogen is used for adjuvant therapy especially in metastatic diseases and known to have a bone mass protective effect after ovariectomy.
   Materials and methods: An animal model of ovariectomy induced osteoporosis after tamoxifen citrate administration was studied via biochemical and immunohistochemical methods. Female Wistar albino rats (n = 45), selected according to their oestrous cycle, were divided into three groups; I   control, II   ovariectomy, III   ovariectomy + tamoxifen. Following ovariectomy, tamoxifen citrate (10 mg/kg) was given intraperitoneally daily for 8 weeks. At the end of the period, animals were sacrificed under anaesthesia, blood samples were taken to measure oestrogen, calcium, and alkaline phosphate. Tibia bone samples were fixed in formalin solution and decalcified with 5% ethylene diamine tetra acetic acid. After the routine histological follow up, samples were embedded in paraffin and cut with a microtome for semi thin sections. Primary antibodies osteonectin and osteopontin were applied to sections and examined under light microscope.
   Results: As a consequence, when oestrogen and calcium data were compared there was a decrease in ovariectomy group with an increase in alkaline phosphatase. In ovariectomy + tamoxifen group, these values were close to the control group. Osteonectin was observed to promote bone formation by influencing collagen fibre formation, extracellular matrix development, osteoblast differentiation and the capacity to affect osteoclast activity.
   Conclusions: It has been suggested that osteopontin, the cytokine and cell binding protein, stimulates cellular signalling pathways, induces bone remodelling and acts in osteoporosis.
C1 [Baloglu, M.] Diyarbakir Gazi Yasargil Educ & Res Hosp, Dept Physiotherapy, Diyarbakir, Turkey.
   [Ozkorkmaz, E. Gokalp] Dicle Univ, Sch Med, Dept Histol & Embryol, TR 21280 Diyarbakir, Turkey.
C3 Diyarbakir Training & Research Hospital; Dicle University
RP Özkorkmaz, EG (通讯作者)，Dicle Univ, Sch Med, Dept Histol & Embryol, TR 21280 Diyarbakir, Turkey.
EM egokalp62@hotmail.com
RI Baloğlu, Murat/JEO 5303 2023; GOKALP OZKORKMAZ, EBRU/Y 2382 2018
OI GOKALP OZKORKMAZ, EBRU/0000 0002 1967 4844
CR BLACK LJ, 1994, J CLIN INVEST, V93, P63, DOI 10.1172/JCI116985
   Bland R, 2000, CLIN SCI, V98, P217, DOI 10.1042/CS19990252
   Cao H, 2017, EXP THER MED, V13, P2399, DOI 10.3892/etm.2017.4233
   Cardinali DP, 2003, J PINEAL RES, V34, P81, DOI 10.1034/j.1600 079X.2003.00028.x
   Celik O, 2007, GYNECOL OBSTET REPRO, V13, P92
   Choi JS, 2014, EXP THER MED, V8, P957, DOI 10.3892/etm.2014.1793
   De Laet CEDH, 2002, J BONE MINER RES, V17, P2231, DOI 10.1359/jbmr.2002.17.12.2231
   Duvall CL, 2007, J BONE MINER RES, V22, P286, DOI 10.1359/JBMR.061103
   Erben RG, 1996, ANAT REC, V246, P39, DOI 10.1002/(SICI)1097 0185(199609)246:1<39::AID AR5>3.0.CO;2 A
   Fakkert IE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169673
   Frolik CA, 1996, BONE, V18, P621, DOI 10.1016/8756 3282(96)00085 3
   Gajdos Csaba, 2002, Clin Breast Cancer, V2, P272, DOI 10.3816/CBC.2002.n.002
   Jee W. S. S., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P193
   Jordan VC, 2001, ANN NY ACAD SCI, V949, P72
   JORDAN VC, 1987, BREAST CANCER RES TR, V10, P31, DOI 10.1007/BF01806132
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   KALU DN, 1991, BONE MINER, V14, P175, DOI 10.1016/0169 6009(91)90021 Q
   KELM RJ, 1994, J BIOL CHEM, V269, P30147
   KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092 8674(87)90193 0
   Koparal M, 2016, INT J MORPHOL, V34, P763, DOI 10.4067/S0717 95022016000200053
   Laçin N, 2019, FOLIA MORPHOL, V78, P545, DOI 10.5603/FM.a2018.0110
   Lelovas PP, 2008, COMPARATIVE MED, V58, P424
   Liu XL, 2015, CLIN ORAL IMPLAN RES, V26, P392, DOI 10.1111/clr.12360
   LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302
   LUCAS RC, 1989, J BONE MINER RES, V4, P901
   MARTIN TJ, 1989, ENDOCRIN METAB CLIN, V18, P833, DOI 10.1016/S0889 8529(18)30346 3
   Murat B, 2018, ANAL QUANT CYTOPATHO, V40, P213
   Ostrowska Z, 2009, POSTEP HIG MED DOSW, V63, P39
   Park SB, 2010, J KOREAN NEUROSURG S, V48, P309, DOI 10.3340/jkns.2010.48.4.309
   Perry MJ, 2005, ENDOCRINOLOGY, V146, P1060, DOI 10.1210/en.2004 1114
   Petrow PK, 2000, ARTHRITIS RHEUM, V43, P1597, DOI 10.1002/1529 0131(200007)43:7<1597::AID ANR25>3.0.CO;2 0
   Portal Núñez S, 2012, HISTOL HISTOPATHOL, V27, P559, DOI 10.14670/HH 27.559
   Sodek J, 2006, J DENT RES, V85, P404, DOI 10.1177/154405910608500503
   Standal T, 2004, EXP ONCOL, V26, P179
   Takayama B, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471 2474 9 164
   THOMAS T, 1989, CANCER RES, V49, P5852
   TURKEN S, 1989, JNCI J NATL CANCER I, V81, P1086, DOI 10.1093/jnci/81.14.1086
   Turner R T, 2001, Rev Endocr Metab Disord, V2, P117, DOI 10.1023/A:1010067326811
   TURNER RT, 1987, J BONE MINER RES, V2, P449
   TURNER RT, 1988, ENDOCRINOLOGY, V122, P1146, DOI 10.1210/endo 122 3 1146
   Vogel Victor G, 2002, Clin Breast Cancer, V3, P153, DOI 10.3816/CBC.2002.n.020
   WATERS DJ, 1991, ACTA ORTHOP SCAND, V62, P238, DOI 10.3109/17453679108993600
   WRONSKI TJ, 1989, CALCIFIED TISSUE INT, V45, P360, DOI 10.1007/BF02556007
   Yan Q, 1999, J HISTOCHEM CYTOCHEM, V47, P1495, DOI 10.1177/002215549904701201
   Zhang ZG, 2014, SCI WORLD J, DOI 10.1155/2014/645975
NR 45
TC 7
Z9 7
U1 0
U2 6
PU VIA MEDICA
PI GDANSK
PA UL SWIETOKRZYSKA 73, 80 180 GDANSK, POLAND
SN 0015 5659
EI 1644 3284
J9 FOLIA MORPHOL
JI Folia Morphol.
PY 2019
VL 78
IS 4
BP 789
EP 797
DI 10.5603/FM.a2019.0035
PG 9
WC Anatomy & Morphology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Anatomy & Morphology
GA KH2PR
UT WOS:000510490300015
PM 30949994
OA gold
DA 2025 08 17
ER

PT J
AU Fan, LY
   Fan, JF
   Liu, Y
   Li, TP
   Xu, HY
   Yang, YL
   Deng, LC
   Li, HL
   Zhao, RC
AF Fan, Linyuan
   Fan, Junfen
   Liu, Yan
   Li, Tangping
   Xu, Haoying
   Yang, Yanlei
   Deng, Luchan
   Li, Hongling
   Zhao, Robert Chunhua
TI miR 450b Promotes Osteogenic Differentiation In Vitro and Enhances Bone
   Formation In Vivo by Targeting BMP3
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
DE human adipose derived mesenchymal stem cells; osteogenic
   differentiation; bone formation; miR 450b; bone morphogenetic protein 3
ID MESENCHYMAL STEM CELLS; OSTEOBLAST DIFFERENTIATION; MICRORNA
   THERAPEUTICS; ADIPOSE TISSUE; MARROW; ANGIOGENESIS; SUPPRESSION;
   PROTEIN 3; MECHANISM; DELIVERY
AB Osteoporosis is characterized by deterioration of bone microarchitecture and low bone mass. One of the primary causes of osteoporosis is the decrease in the osteogenic differentiation of mesenchymal stem cells (MSCs). Tissue engineering therapy with genetically modified MSCs has attracted much attention in the study of bone regeneration. In this study, we found that the expression level of miR 450b was upregulated during osteogenic differentiation of human adipose derived mesenchymal stem cells (hADSCs). To explore the effect of miR 450b on the osteogenesis of hADSCs, we performed a series of gain  and loss of function analyses and demonstrated that miR 450b not only promoted the process of hADSC differentiation to osteoblasts in vitro but also enhanced ectopic bone formation in vivo. Bone morphogenetic protein 3 (BMP3), the most abundant BMP member in bone, was identified as a direct target of miR 450b. Downregulation of the endogenous expression of BMP3 could mimic the effect of miR 450b upregulation on the osteogenic differentiation of hADSCs. Overall, our study first demonstrated that a novel microRNA miR 450b was essential for hADSC differentiation, which could promote osteogenic differentiation in vitro and enhance bone formation in vivo by directly suppressing BMP3.
C1 [Fan, Linyuan; Fan, Junfen; Liu, Yan; Li, Tangping; Xu, Haoying; Yang, Yanlei; Deng, Luchan; Li, Hongling; Zhao, Robert Chunhua] Chinese Acad Med Sci, Ctr Excellence Tissue Engn, Peking Union Med Coll Hosp, Inst Basic Med Sci,Sch Basic Med,Peking Union Med, Beijing 100005, Peoples R China.
C3 Institute of Basic Medical Sciences   CAMS; Chinese Academy of Medical
   Sciences   Peking Union Medical College; Peking Union Medical College;
   Peking Union Medical College Hospital
RP Li, HL; Zhao, RC (通讯作者)，Chinese Acad Med Sci, Ctr Excellence Tissue Engn, Peking Union Med Coll Hosp, Inst Basic Med Sci,Sch Basic Med,Peking Union Med, Beijing 100005, Peoples R China.
EM lihongling2007@ibms.pumc.edu.cn; zhaochunhua@ibms.pumc.edu.cn
RI yang, yanlei/GQH 5514 2022; zhao, chunhua/MZR 1130 2025
OI Fan, Junfen/0000 0003 1892 5768; 
FU National Natural Science Foundation of China [81700782, 81370466,
   81370879, 81473450, 81672313]; National Key Research and Development
   Program of China [2016YFA0101000, 2016YFA0101003]; key technologies R &
   D program of Sichuan [2015SZ0020]; CAMS Innovation Fund for Medical
   Sciences [2017 I2M 3 007, 2017 I2M 3 006]; Beijing Key Laboratory of New
   Drug Development and Clinical Trial of Stem Cell Therapy [BZ0381];
   undertaken government transfer functions and public service
   demonstration projects [2017GGFZ001]
FX This work was supported by grants from the National Natural Science
   Foundation of China (no. 81700782, 81370466, 81370879, 81473450,
   81672313); the National Key Research and Development Program of China
   (2016YFA0101000, 2016YFA0101003); the key technologies R & D program of
   Sichuan (2015SZ0020); CAMS Innovation Fund for Medical Sciences
   (2017 I2M 3 007, 2017 I2M 3 006); the Beijing Key Laboratory of New Drug
   Development and Clinical Trial of Stem Cell Therapy (BZ0381); and
   undertaken government transfer functions and public service
   demonstration projects (2017GGFZ001).
CR Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Cao Y, 2005, BIOCHEM BIOPH RES CO, V332, P370, DOI 10.1016/j.bbrc.2005.04.135
   Carreira AC, 2014, J DENT RES, V93, P335, DOI 10.1177/0022034513518561
   Charles LF, 2015, EXP GERONTOL, V64, P62, DOI 10.1016/j.exger.2015.02.006
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Chen L, 2014, STEM CELLS, V32, P902, DOI 10.1002/stem.1615
   Chen Y, 2009, J CELL BIOCHEM, V106, P353, DOI 10.1002/jcb.22020
   Cheng CJ, 2015, NATURE, V518, P107, DOI 10.1038/nature13905
   Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003
   Daluiski A, 2001, NAT GENET, V27, P84, DOI 10.1038/83810
   Deschaseaux F, 2009, TRENDS MOL MED, V15, P417, DOI 10.1016/j.molmed.2009.07.002
   Ferguson VL, 2003, BONE, V33, P387, DOI 10.1016/S8756 3282(03)00199 6
   Gabriely G, 2011, CANCER RES, V71, P3563, DOI 10.1158/0008 5472.CAN 10 3568
   Gamer LW, 2009, DEV DYNAM, V238, P2374, DOI 10.1002/dvdy.22048
   García Gareta E, 2015, BONE, V81, P112, DOI 10.1016/j.bone.2015.07.007
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   Jin YH, 2016, DNA CELL BIOL, V35, P249, DOI 10.1089/dna.2015.3120
   Jo JY, 2015, INT J ORAL MAX SURG, V44, P921, DOI 10.1016/j.ijom.2015.02.015
   Kato T, 2018, STEM CELLS DEV, V27, P85, DOI 10.1089/scd.2017.0199
   Kim SE, 2015, COLLOID SURFACE B, V134, P453, DOI 10.1016/j.colsurfb.2015.05.003
   Klein Nulend J, 2015, J BIOMECH, V48, P855, DOI 10.1016/j.jbiomech.2014.12.007
   Kokabu S, 2012, MOL ENDOCRINOL, V26, P87, DOI 10.1210/me.2011 1168
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Li H, 2015, CELL DEATH DIFFER, V22, P1935, DOI 10.1038/cdd.2015.99
   Liao JY, 2017, CELL PHYSIOL BIOCHEM, V41, P1905, DOI 10.1159/000471945
   Lin CY, 2015, BIOMATERIALS, V50, P98, DOI 10.1016/j.biomaterials.2015.01.052
   Lin CY, 2013, BIOMATERIALS, V34, P9401, DOI 10.1016/j.biomaterials.2013.08.051
   Liu FB, 2016, INT J MOL MED, V38, P283, DOI 10.3892/ijmm.2016.2612
   Long HT, 2017, DNA CELL BIOL, V36, P715, DOI 10.1089/dna.2017.3657
   Ma JL, 2015, J BIOMED MATER RES A, V103, P439, DOI 10.1002/jbm.a.35192
   McMahon MS, 2012, ORTHOPEDICS, V35, P920, DOI 10.3928/01477447 20121023 02
   Montgomery RL, 2011, CIRCULATION, V124, P1537, DOI 10.1161/CIRCULATIONAHA.111.030932
   Pecot CV, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3427
   Pelled G, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/6530624
   Qi M, 2017, THERANOSTICS, V7, P4498, DOI 10.7150/thno.17949
   Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246
   Scheideler M, 2008, BMC GENOMICS, V9, DOI 10.1186/1471 2164 9 340
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Shalom Feuerstein R, 2012, STEM CELLS, V30, P898, DOI 10.1002/stem.1068
   Shirzeyli MH, 2017, MICROSC RES TECHNIQ, V80, P1151, DOI 10.1002/jemt.22880
   Sun MM, 2014, ONCOGENE, V33, P2075, DOI 10.1038/onc.2013.165
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Trang P, 2011, MOL THER, V19, P1116, DOI 10.1038/mt.2011.48
   Turgeman G, 2002, J CELL BIOCHEM, V86, P461, DOI 10.1002/jcb.10231
   van Rooij E, 2014, EMBO MOL MED, V6, P851, DOI 10.15252/emmm.201100899
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Wang Z, 2018, OSTEOPOROSIS INT, V29, P535, DOI 10.1007/s00198 017 4255 1
   Wei JW, 2012, J CELL BIOL, V197, P509, DOI 10.1083/jcb.201201057
   Weilner S, 2016, AGING CELL, V15, P744, DOI 10.1111/acel.12484
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Xie Q, 2017, SCI REP UK, V7, DOI 10.1038/srep42840
   Yu S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.363
NR 54
TC 39
Z9 42
U1 0
U2 20
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547 3287
EI 1557 8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD MAY
PY 2018
VL 27
IS 9
BP 600
EP 611
DI 10.1089/scd.2017.0276
EA APR 2018
PG 12
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA GE4JT
UT WOS:000430611100001
PM 29649414
DA 2025 08 17
ER

PT J
AU Hosseini, V
   Paryan, M
   Koochaki, A
   Cesaire, HM
   Mohammadi Yeganeh, S
AF Hosseini, Vahedeh
   Paryan, Mahdi
   Koochaki, Ameneh
   Cesaire, Henry Manuel
   Mohammadi Yeganeh, Samira
TI Mir 4699 promotes the osteogenic differentiation of mesenchymal stem
   cells
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Mesenchymal stem cell; miR 4699; Osteogenic differentiation; DKK1;
   TNFSF11
ID OSTEOBLAST DIFFERENTIATION; MICRORNAS; RANKL; DKK1; EXPRESSION; RUNX2
AB IntroductionMesenchymal stem cells (MSCs) are drawing considerable attention in the field of regenerative medicine due to their differentiation capabilities. The miRNAs are among the most important epigenetic regulators of MSC differentiation. Our previous study identified miR 4699 as a direct suppressor of the DKK1 and TNSF11 gene expression. However, the precise osteogenic related phenotype or mechanism caused by miR 4699 change has yet to be dealt with in depth.Material and MethodsIn the present study, miR 4699 mimics were transfected into human Adipose tissue derived mesenchymal stem cells (hAd MSCs) and osteoblast marker gene expression (RUNX2, ALP, and OCN), was analyzed to investigate whether miR 4699 promotes osteoblast differentiation of hAd MSCs through targeting the DKK 1 and TNFSF11. We further examined and compared the effects of recombinant human BMP2 with miR 4699 on cell differentiation. In addition to quantitative PCR, analysis of alkaline phosphatase activity, calcium content assay, and Alizarin red staining were used to explore osteogenic differentiation. To evaluate the effect of miR 4699 on its target gene (on protein level) we utilized the western blotting technique.ResultsThe overexpression of miR 4699 in hAd MSCs resulted in the stimulation of alkaline phosphatase activity, osteoblast mineralization, and the expression of RUNX2, ALP, and OCN osteoblast marker genes.ConclusionOur findings indicated that miR 4699 supported and synergized the BMP2 induced osteoblast differentiation of mesenchymal stem cells. We suggest, thereof, the utilization of hsa miR 4699 for further in vivo experimental investigation to reveal the potential therapeutic impact of regenerative medicine for different types of bone defects.
C1 [Hosseini, Vahedeh] Kurdistan Univ Med Sci, Res Inst Hlth Dev, Cellular & Mol Res Ctr, Sanandaj, Iran.
   [Hosseini, Vahedeh] Kurdistan Univ Med Sci, Fac Med, Dept Mol Med & Genet, Sanandaj, Iran.
   [Paryan, Mahdi] Pasteur Inst Iran, Prod & Res Complex, Dept Res & Dev, Tehran, Iran.
   [Koochaki, Ameneh] Shahid Beheshti Univ Med Sci, Cellular & Mol Biol Res Ctr, Tehran, Iran.
   [Cesaire, Henry Manuel] St Josephs Coll, Dept Nursing, Brooklyn, NY USA.
   [Mohammadi Yeganeh, Samira] Shahid Beheshti Univ Med Sci, Med Nanotechnol & Tissue Engn Res Ctr, Tehran, Iran.
   [Mohammadi Yeganeh, Samira] Shahid Beheshti Univ Med Sci, Sch Adv Technol Med, Dept Med Biotechnol, Tehran, Iran.
C3 Kurdistan University of Medical Sciences; Kurdistan University of
   Medical Sciences; Pasteur Network; Pasteur Institute of Iran; Shahid
   Beheshti University Medical Sciences; Shahid Beheshti University Medical
   Sciences; Shahid Beheshti University Medical Sciences
RP Paryan, M (通讯作者)，Pasteur Inst Iran, Prod & Res Complex, Dept Res & Dev, Tehran, Iran.; Mohammadi Yeganeh, S (通讯作者)，Shahid Beheshti Univ Med Sci, Med Nanotechnol & Tissue Engn Res Ctr, Tehran, Iran.; Mohammadi Yeganeh, S (通讯作者)，Shahid Beheshti Univ Med Sci, Sch Adv Technol Med, Dept Med Biotechnol, Tehran, Iran.
EM m_paryan@pasteur.ac.ir; s.mohammadiyeganeh@sbmu.ac.ir
RI paryan/R 3394 2018; Mohammadi Yeganeh, Samira/HDL 7640 2022
OI Mohammadi Yeganeh, Samira/0000 0003 0430 6325; 
FU Shahid Beheshti University of Medical Sciences, Tehran, Iran [32003]
FX This project was funded by Shahid Beheshti University of Medical
   Sciences, Tehran, Iran (Contact grant No: 32003). The funders had no
   role in the study design, data collection, analysis, decision to
   publish, or preparation of the manuscript.
CR Amankwah EK, 2020, ANTICANCER RES, V40, P3147, DOI 10.21873/anticanres.14296
   Awasthi H, 2018, MED RES REV, V38, P2024, DOI 10.1002/med.21504
   Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006 291X(02)02951 0
   Bajada S, 2009, BONE, V45, P726, DOI 10.1016/j.bone.2009.06.015
   Baron Roland, 2007, Curr Osteoporos Rep, V5, P73
   Butler JS, 2011, J ORTHOP RES, V29, P414, DOI 10.1002/jor.21260
   Cao X, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0040 9
   Danks L, 2013, J BIOCHEM, V154, P29, DOI 10.1093/jb/mvt049
   Frey JL, 2015, MOL CELL BIOL, V35, P1979, DOI 10.1128/MCB.01343 14
   Fung B, 2020, BONE JOINT J, V102B, P1723, DOI 10.1302/0301 620X.102B12.BJJ 2020 1125.R1
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Genda Y, 2013, INT J MOL MED, V31, P129, DOI 10.3892/ijmm.2012.1163
   Grünhagen J, 2015, J BONE MINER RES, V30, P796, DOI 10.1002/jbmr.2412
   Han Y, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080886
   Hosseini V, 2018, J CELL BIOCHEM, V119, P5960, DOI 10.1002/jcb.26791
   Hu CH, 2017, SCI REP UK, V7, DOI 10.1038/srep43191
   Iwamoto N, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1703 z
   Kapinas K, 2010, J BIOL CHEM, V285, P25221, DOI 10.1074/jbc.M110.116137
   Kobayashi Y, 2009, CRIT REV EUKAR GENE, V19, P61, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.30
   Li SN, 2015, J ORTHOP RES, V33, P1008, DOI 10.1002/jor.22830
   Li ZH, 2014, NAT REV DRUG DISCOV, V13, P622, DOI 10.1038/nrd4359
   Liu XY, 2016, MOL BIOL REP, V43, P939, DOI 10.1007/s11033 016 4030 y
   Mori K, 2006, J CELL BIOCHEM, V98, P1629, DOI 10.1002/jcb.20891
   Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36
   Pitari MR, 2015, ONCOTARGET, V6, P27343, DOI 10.18632/oncotarget.4398
   Presen DM, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00352
   Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Sui L, 2018, BIOMATERIALS, V177, P88, DOI 10.1016/j.biomaterials.2018.05.038
   Tang PF, 2014, RNA BIOL, V11, P1355, DOI 10.1080/15476286.2014.996462
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Untergasser A, 2021, BMC BIOINFORMATICS, V22, DOI 10.1186/s12859 021 04306 1
   Venegas KR, 2013, OMICS PERSONALIZED M, DOI [10.1007/978 81 322 1184 6_29, DOI 10.1007/978 81 322 1184 6_29]
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wei F, 2021, J CHIN PHYS, P1044
   Zhang J, 2011, J BONE MINER RES, V26, P1953, DOI 10.1002/jbmr.377
   Zhang XH, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15037674
   Zheng LL, 2017, J CELL PHYSIOL, V232, P182, DOI 10.1002/jcp.25406
NR 38
TC 2
Z9 2
U1 0
U2 2
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD JUL
PY 2023
VL 41
IS 4
BP 481
EP 491
DI 10.1007/s00774 023 01433 y
EA MAY 2023
PG 11
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA L5OY1
UT WOS:000997038300001
PM 37247112
DA 2025 08 17
ER

PT J
AU Dudakovic, A
   Camilleri, ET
   Riester, SM
   Paradise, CR
   Gluscevic, M
   O'Toole, TM
   Thaler, R
   Evans, JM
   Yan, H
   Subramaniam, M
   Hawse, JR
   Stein, GS
   Montecino, MA
   Mcgee Lawrence, ME
   Westendorf', JJ
   van Wijnen, AJ
AF Dudakovic, Amel
   Camilleri, Emily T.
   Riester, Scott M.
   Paradise, Christopher R.
   Gluscevic, Martina
   O'Toole, Thomas M.
   Thaler, Roman
   Evans, Jared M.
   Yan, Huihuang
   Subramaniam, Malayannan
   Hawse, John R.
   Stein, Gary S.
   Montecino, Martin A.
   Mcgee Lawrence, Meghan E.
   Westendorf', Jennifer J.
   van Wijnen, Andre J.
TI Enhancer of Zeste Homolog 2 Inhibition Stimulates Bone Formation and
   Mitigates Bone Loss Caused by Ovariectomy in Skeletally Mature Mice
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID MESENCHYMAL STEM CELLS; HISTONE METHYLTRANSFERASE EZH2; CHIP SEQ DATA;
   MUSCLE DIFFERENTIATION; INTEGRATIVE ANALYSIS; DEVELOPMENTAL GENES;
   DNA METHYLATION; TARGETING EZH2; SELF RENEWAL; OSTEOPOROSIS
AB Perturbations in skeletal development and bone degeneration may result in reduced bone mass and quality, leading to greater fracture risk. Bone loss is mitigated by bone protective therapies, but there is a clinical need for new bone anabolic agents. Previous work has demonstrated that Ezh2 (enhancer of zeste homolog 2), a histone 3 lysine 27 (H3K27) methyltransferase, suppressed differentiation of osteogenic progenitors. Here, we investigated whether inhibition of Ezh2 can be leveraged for bone stimulatory applications. Pharmacologic inhibition and siRNA knockdown of Ezh2 enhanced osteogenic commitment of MC3T3 preosteoblasts. Next generation RNA sequencing of mRNAs and real time quantitative PCR profiling established that Ezh2 inactivation promotes expression of bone related gene regulators and extracellular matrix proteins. Mechanistically, enhanced gene expression was linked to decreased H3K27 trimethylation (H3K27me3) near transcriptional start sites in genome wide sequencing of chromatin immunoprecipitations assays. Administration of an Ezh2 inhibitor modestly increases bone density parameters of adult mice. Furthermore, Ezh2 inhibition also alleviated bone loss in an estrogen deficient mammalian model for osteoporosis. Ezh2 inhibition enhanced expression of Wnt10B and Pth1r and increased the BMP dependent phosphorylation of Smad1/5. Thus, these data suggest that inhibition of Ezh2 promotes paracrine signaling in osteoblasts and has bone anabolic and osteoprotective potential in adults.
C1 [Dudakovic, Amel; Camilleri, Emily T.; Riester, Scott M.; Paradise, Christopher R.; O'Toole, Thomas M.; Thaler, Roman; Westendorf', Jennifer J.; van Wijnen, Andre J.] Mayo Clin, Dept Orthoped Surg, 200 First St SW, Rochester, MN 55905 USA.
   [Subramaniam, Malayannan; Hawse, John R.; Westendorf', Jennifer J.; van Wijnen, Andre J.] Mayo Clin, Dept Biochem & Mol Biol, 200 First St SW, Rochester, MN 55905 USA.
   [Gluscevic, Martina] Mayo Clin, Initiat Maximum Student Dev, Rochester, MN 55905 USA.
   [Evans, Jared M.; Yan, Huihuang] Mayo Clin, Stat & Informat, Rochester, MN 55905 USA.
   [Stein, Gary S.] Univ Vermont, Dept Biochem, Sch Med, Burlington, VT 05405 USA.
   [Montecino, Martin A.] Univ Andres Bello, Ctr Invest Biomed, Santiago 8370146, Chile.
   [Montecino, Martin A.] Univ Andres Bello, FONDAP Ctr Genome Regulat, Santiago 8370146, Chile.
   [Mcgee Lawrence, Meghan E.] Georgia Regents Univ, Dept Cellular Biol & Anat, Augusta, GA 30912 USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; University of
   Vermont; Universidad Andres Bello; Universidad Andres Bello; University
   System of Georgia; Augusta University
RP van Wijnen, AJ (通讯作者)，Mayo Clin, Dept Orthoped Surg, 200 First St SW, Rochester, MN 55905 USA.; van Wijnen, AJ (通讯作者)，Mayo Clin, Dept Biochem & Mol Biol, 200 First St SW, Rochester, MN 55905 USA.
EM vanwijnen.andre@mayo.edu
RI ; van Wijnen, Andre/AAG 3578 2019; Riester, Scott/K 7032 2015
OI van Wijnen, Andre J./0000 0002 4458 0946; Dudakovic,
   Amel/0000 0002 8850 3977; Paradise, Christopher/0000 0002 5882 709X;
   Camilleri, Emily/0000 0001 8982 6770; Montecino,
   Martin/0000 0002 6025 0023; O'Toole, Thomas/0000 0002 8487 448X
FU National Institutes of Health [F32 AR066508, R01 AR049069, R01 AR068103,
   R01 DE020194]; Fondo de Financiamiento de Centros de Investigation en
   Areas Prioritarias [15090007]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants F32 AR066508 (to A. D.), R01 AR049069 (to A. J. v. W.),
   R01 AR068103 (to J. J. W.), and R01 DE020194 (to J. J. W.), Fondo de
   Financiamiento de Centros de Investigation en Areas Prioritarias
   15090007 (to M. A. M.), and generous philanthropic support from William
   H. and Karen J. Eby and the charitable foundation in their names. The
   authors declare that they have no conflicts of interest with the
   contents of this article. The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   National Institutes of Health.
CR Arrowsmith CH, 2015, NAT CHEM BIOL, V11, P536, DOI 10.1038/nchembio.1867
   Bellido T, 2013, BONE, V54, P250, DOI 10.1016/j.bone.2012.09.016
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Cakouros D, 2012, MOL CELL BIOL, V32, P1433, DOI 10.1128/MCB.06315 11
   Canalis E, 2013, NAT REV ENDOCRINOL, V9, P575, DOI 10.1038/nrendo.2013.154
   Caretti G, 2004, GENE DEV, V18, P2627, DOI 10.1101/gad.1241904
   Chou RH, 2015, CELL TRANSPLANT, V24, P313, DOI 10.3727/096368915X686823
   de GorterDavid J., 2013, PRIMER METABOLIC BON, V8th, P15, DOI DOI 10.1002/9781118453926.CH2
   Dennison E, 2000, HORM RES, V54, P58, DOI 10.1159/000053299
   Dudakovic A, 2015, J BIOL CHEM, V290, P27604, DOI 10.1074/jbc.M115.672345
   Dudakovic A, 2014, J CELL BIOCHEM, V115, P1816, DOI 10.1002/jcb.24852
   Dudakovic A, 2013, J BIOL CHEM, V288, P28783, DOI 10.1074/jbc.M113.489732
   Ge K., 2012, BIOCHIM BIOPHYS ACTA, V7, P727
   GLAZER RI, 1986, BIOCHEM BIOPH RES CO, V135, P688, DOI 10.1016/0006 291X(86)90048 3
   Gordon JAR, 2015, BONE, V81, P739, DOI 10.1016/j.bone.2015.03.011
   Hemming S, 2014, STEM CELLS, V32, P802, DOI 10.1002/stem.1573
   Huang D, 2016, ONCOL REP, V35, P1083, DOI 10.3892/or.2015.4467
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Hui TQ, 2014, J ENDODONT, V40, P1132, DOI 10.1016/j.joen.2014.01.031
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Jing H, 2016, MOL THER, V24, P217, DOI 10.1038/mt.2015.152
   Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036
   Lee JS, 2010, CELL, V142, P682, DOI 10.1016/j.cell.2010.08.011
   Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352
   Lian JB, 2012, NAT REV ENDOCRINOL, V8, P212, DOI 10.1038/nrendo.2011.234
   MacLean C, 2008, ANN INTERN MED, V148, P197, DOI 10.7326/0003 4819 148 3 200802050 00198
   Marchesi I, 2014, CELL CYCLE, V13, P516, DOI 10.4161/cc.27921
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Margueron R, 2008, MOL CELL, V32, P503, DOI 10.1016/j.molcel.2008.11.004
   McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606
   McGee Lawrence ME, 2011, BONE, V48, P1117, DOI 10.1016/j.bone.2011.01.007
   Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535 7163.MCT 09 0013
   PECK WA, 1993, AM J MED, V94, P646
   Pereira JD, 2010, P NATL ACAD SCI USA, V107, P15957, DOI 10.1073/pnas.1002530107
   Pike JW, 2011, J BONE MINER RES, V26, P1155, DOI 10.1002/jbmr.317
   Rosen V, 2009, CYTOKINE GROWTH F R, V20, P475, DOI 10.1016/j.cytogfr.2009.10.018
   Sánchez Duffhues G, 2015, BONE, V80, P43, DOI 10.1016/j.bone.2015.05.025
   Schellenberg A, 2011, AGING US, V3, P873, DOI 10.18632/aging.100391
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Shen L, 2014, BMC GENOMICS, V15, DOI 10.1186/1471 2164 15 284
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   van Wijnen AJ, 2013, CURR OSTEOPOROS REP, V11, P72, DOI 10.1007/s11914 013 0143 6
   Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   Wang LF, 2010, P NATL ACAD SCI USA, V107, P7317, DOI 10.1073/pnas.1000031107
   Wei YK, 2011, NAT CELL BIOL, V13, P87, DOI 10.1038/ncb2139
   Wu H, 2014, GENOME BIOL, V15, DOI 10.1186/gb 2014 15 3 r52
   Yan HH, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471 2105 15 280
   Zang CZ, 2009, BIOINFORMATICS, V25, P1952, DOI 10.1093/bioinformatics/btp340
   Zhu L, 2013, BIOCHEM BIOPH RES CO, V432, P612, DOI 10.1016/j.bbrc.2013.02.036
NR 52
TC 79
Z9 87
U1 0
U2 15
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD NOV 18
PY 2016
VL 291
IS 47
BP 24594
EP 24606
DI 10.1074/jbc.M116.740571
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA ED5EX
UT WOS:000388875500021
PM 27758858
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Inokuchi, S
   Shimamoto, K
AF Inokuchi, Shoichiro
   Shimamoto, Koji
TI Wnt/β catenin pathway as a potential target for Parkinson's disease: a
   cohort study of romosozumab using routinely collected health data in
   Japan
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE osteoporosis; electronic health records; drug repositioning; Wnt
   signaling pathway; Parkinson disease
ID MOUSE MODEL; SCLEROSTIN; DIFFERENTIATION; WOMEN
AB Introduction Romosozumab is a monoclonal antibody approved for osteoporosis which targets sclerostin, an endogenous inhibitor of Wnt/beta catenin pathway. Given the essential roles of the Wnt/beta catenin pathway in various tissues, we hypothesized romosozumab treatment may influence other conditions.Methods This cohort study included patients prescribed romosozumab or parathyroid receptor (PTHR) agonists after 1 January 2019, using a Japanese electronic medical record database. The outcomes of interest included autoimmune disease, interstitial pneumonia, cardiovascular outcome, Alzheimer's disease, Parkinson's disease (PD), serious infections, and malignancies. A stabilized inverse probability weighted Cox proportional hazard model was used to estimate the hazard ratios. Age  and gender based subgroup analyses were conducted. Exploratory outcomes based on three digit International Classification of Diseases 10th Revision based were also examined.Results In total, 2,673 patients treated with romosozumab and 5,980 treated with PTHR agonists were identified, respectively. While most outcomes of interest showed no association with romosozumab, the risk of PD decreased with romosozumab (hazard ratio [95% confidence interval], 0.37 [0.14 0.94]) compared with PTHR agonist. Regarding the cardiovascular outcome, no notable association was identified overall; however, gender based subgroup analysis suggested that male sex may be a potential risk factor with romosozumab treatment. Only 16 of 903 exploratory outcomes were potentially influenced by romosozumab.Conclusion Romosozumab lowered the risk of PD development compared with PTHR agonist. The study also highlights the utility of routinely collected health data for drug repositioning. While further validation is warranted, the findings suggest that the Wnt beta catenin pathway holds promise as a therapeutic target for PD.
C1 [Inokuchi, Shoichiro; Shimamoto, Koji] Real World Data Co Ltd, Res & Analyt Dept, Kyoto, Japan.
RP Inokuchi, S (通讯作者)，Real World Data Co Ltd, Res & Analyt Dept, Kyoto, Japan.
EM shoichiro.inokuchi.nhy@jmdc.co.jp
RI Inokuchi, Shoichiro/LWI 2059 2024
OI Inokuchi, Shoichiro/0000 0002 5501 8852
FU Real World Data Co., Ltd.; JMDC Inc.
FX The author(s) declare that financial support was received for the
   research, authorship, and/or publication of this article. This study was
   supported by Real World Data Co., Ltd. and JMDC Inc.
CR Abbas MM, 2018, MOV DISORD CLIN PRAC, V5, P14, DOI 10.1002/mdc3.12568
   Amgen Inc. EVENITY, 2019, U.S. Food and drug administration website
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Bastakoty D, 2016, FASEB J, V30, P3271, DOI 10.1096/fj.201600502R
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Cao HH, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 28968 9
   Chilosi M, 2003, AM J PATHOL, V162, P1495, DOI 10.1016/S0002 9440(10)64282 4
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Esfandiari F, 2012, STEM CELLS DEV, V21, P3233, DOI 10.1089/scd.2011.0678
   Fixen C, 2021, CURR OSTEOPOROS REP, V19, P15, DOI 10.1007/s11914 020 00652 w
   Gattinoni L, 2009, NAT MED, V15, P808, DOI 10.1038/nm.1982
   Gupta Sandeep K, 2011, Perspect Clin Res, V2, P109, DOI 10.4103/2229 3485.83221
   Hayashida K, 2021, J EPIDEMIOL, V31, P1, DOI 10.2188/jea.JE20200288
   Hua Y, 2022, EUR J MED CHEM, V234, DOI 10.1016/j.ejmech.2022.114239
   Jourdan JP, 2020, J PHARM PHARMACOL, V72, P1145, DOI 10.1111/jphp.13273
   Kvist AV, 2021, J CLIN MED, V10, DOI 10.3390/jcm10081660
   L'Episcopo F, 2014, STEM CELLS, V32, P2147, DOI 10.1002/stem.1708
   L'Episcopo F, 2013, J NEUROSCI, V33, P1462, DOI 10.1523/JNEUROSCI.3206 12.2013
   L'Episcopo F, 2012, J NEUROSCI, V32, P2062, DOI 10.1523/JNEUROSCI.5259 11.2012
   Langan Sinead M, 2018, BMJ, V363, pk3532, DOI 10.1136/bmj.k3532
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Lim SY, 2022, WOMENS HEALTH, V18, DOI 10.1177/17455057221125577
   Liu JQ, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 021 00762 6
   Mahlknecht P, 2015, J PARKINSON DIS, V5, P681, DOI 10.3233/JPD 150685
   Marchetti B, 2020, AGING CELL, V19, DOI 10.1111/acel.13101
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83
   Qureshi AR, 2015, KIDNEY INT, V88, P1356, DOI 10.1038/ki.2015.194
   Ramakrishna K, 2023, DISEASES BASEL, V11, DOI 10.3390/diseases11030089
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Schneeweiss S, 2009, EPIDEMIOLOGY, V20, P512, DOI 10.1097/EDE.0b013e3181a663cc
   Schurman Charles A, 2023, J Bone Metab, V30, P1, DOI 10.11005/jbm.2023.30.1.1
   Shi TS, 2024, NAT METAB, V6, DOI 10.1038/s42255 024 00989 x
   Singh S, 2018, MOL NEUROBIOL, V55, P6500, DOI 10.1007/s12035 017 0860 4
   Stefanis L, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a009399
   Stokar J, 2024, J CLIN ENDOCR METAB, V110, pe861, DOI 10.1210/clinem/dgae173
   Sun MH, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.602330
   Tanjore H, 2013, AM J RESP CRIT CARE, V187, P630, DOI 10.1164/rccm.201205 0972OC
   van Loosdregt J, 2018, J IMMUNOL, V201, P2193, DOI 10.4049/jimmunol.1800633
   Wang K, 2010, J MED SYST, V34, P95, DOI 10.1007/s10916 008 9220 2
   Xie J, 2005, STAT MED, V24, P3089, DOI 10.1002/sim.2174
   Xu S, 2010, VALUE HEALTH, V13, P273, DOI 10.1111/j.1524 4733.2009.00671.x
   Yarom N, 2019, J CLIN ONCOL, V37, P2270, DOI 10.1200/JCO.19.01186
   Yu FY, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392 021 00701 5
   Yuan J, 2023, NPJ AGING, V9, DOI 10.1038/s41514 023 00114 4
   Yuan J, 2019, J ALZHEIMERS DIS, V69, P59, DOI 10.3233/JAD 181249
   Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304
   Zhang Y, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045 020 00990 3
NR 48
TC 2
Z9 3
U1 1
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUL 22
PY 2024
VL 15
AR 1411285
DI 10.3389/fphar.2024.1411285
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA A6I5S
UT WOS:001283553600001
PM 39104397
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Sorensen, MG
   Henriksen, K
   Dziegiel, MH
   Tankó, LB
   Karsdal, MA
AF Sorensen, M. G.
   Henriksen, K.
   Dziegiel, M. H.
   Tanko, L. B.
   Karsdal, M. A.
TI Estrogen directly attenuates human osteoclastogenesis, but has no effect
   on resorption by mature osteoclasts
SO DNA AND CELL BIOLOGY
LA English
DT Article
ID IN SITU HYBRIDIZATION; BONE RESORPTION; RECEPTOR ALPHA; RANK LIGAND;
   OVARIECTOMIZED RATS; OSTEOPROTEGERIN OPG; GENE EXPRESSION; TARGET CELLS;
   SEX STEROIDS; CATHEPSIN K
AB Estrogen deficiency arising with the menopause promotes marked acceleration of bone resorption, which can be restored by hormone replacement therapy. The inhibitory effects of estrogen seem to involve indirect cytokinemediated effects via supporting bone marrow cells, but direct estrogen receptor mediated effects on the bone resorbing osteoclasts have also been proposed. Little information is available on whether estrogens modulate human osteoclastogenesis or merely inhibit the functional activity of osteoclasts. To clarify whether estrogens directly modulate osteoclastic activities human CD14(+) monocytes were cultured in the presence of M CSF and RANKL to induce osteoclast differentiation. Addition of 0.1 10 nM 17 beta estradiol to differentiating osteoclasts resulted in a dose dependent reduction in tartrate resistant acid phosphatase (TRACP) activity reaching 60% at 0.1 nM. In addition, 17 beta estradiol inhibited bone resorption, as measured by the release of the C terminal crosslinked telopeptide (CTX), by 60% at 0.1 nM, but had no effect on the overall cell viability. In contrast to the results obtained with differentiating osteoclasts, addition of 17 beta  estradiol (0.001 10 nM) to mature osteoclasts did not affect bone resorption or TRACP activity. We investigated expression of the estrogen receptors, using immunocytochemistry and Western blotting. We found that ER alpha is expressed in osteoclast precursors, whereas ER alpha is expressed at all stages, indicating that the inhibitory effect of estrogen on osteoclastogenesis is mediated by ER alpha for the major part. In conclusion, these results suggest that the in vivo effects of estrogen are mediated by reduction of osteoclastogenesis rather than direct inhibition of the resorptive activity of mature osteoclasts.
C1 Nordic Biosci AS, DK 2730 Herlev, Denmark.
   Copenhagen Univ Hosp, HS Blodbank, Copenhagen, Denmark.
C3 University of Copenhagen; Copenhagen University Hospital
RP Karsdal, MA (通讯作者)，Nordic Biosci AS, Herlev Hovedgade 207, DK 2730 Herlev, Denmark.
EM mk@Nordicbioscience.com
OI Karsdal, Morten/0000 0001 5026 8740; Dziegiel, Morten
   Hanefeld/0000 0001 8034 1523
CR Batra GS, 2003, J PATHOL, V200, P65, DOI 10.1002/path.1332
   Bord S, 2001, J CLIN ENDOCR METAB, V86, P2309, DOI 10.1210/jc.86.5.2309
   Braidman IP, 2001, J BONE MINER RES, V16, P214, DOI 10.1359/jbmr.2001.16.2.214
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   Cao YP, 2002, J BONE MINER RES, V17, P2237, DOI 10.1359/jbmr.2002.17.12.2237
   Compston JE, 2001, PHYSIOL REV, V81, P419, DOI 10.1152/physrev.2001.81.1.419
   Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511
   Henriksen K, 2006, J BONE MINER RES, V21, P58, DOI 10.1359/JBMR.050905
   Henriksen K, 2004, AM J PATHOL, V164, P1537, DOI 10.1016/S0002 9440(10)63712 1
   Huang WH, 1998, J MOL ENDOCRINOL, V20, P211, DOI 10.1677/jme.0.0200211
   Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096 1132
   Karsdal MA, 2005, AM J PATHOL, V166, P467, DOI 10.1016/S0002 9440(10)62269 9
   Karsdal MA, 2003, J BIOL CHEM, V278, P44975, DOI 10.1074/jbc.M303905200
   Khosla S, 2002, J CLIN ENDOCR METAB, V87, P1443, DOI 10.1210/jc.87.4.1443
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kitazawa R, 1999, BBA GENE STRUCT EXPR, V1445, P134, DOI 10.1016/S0167 4781(99)00032 9
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kostenuik PJ, 2001, ENDOCRINOLOGY, V142, P4295, DOI 10.1210/en.142.10.4295
   KREMER M, 1995, J CELL BIOCHEM, V57, P271, DOI 10.1002/jcb.240570211
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Levi G, 2002, EMBO REP, V3, P22, DOI 10.1093/embo reports/kvf003
   LittlewoodEvans A, 1997, BONE, V20, P81, DOI 10.1016/S8756 3282(96)00351 1
   Massey HM, 1999, BRIT J HAEMATOL, V106, P167
   Michael H, 2005, J BONE MINER RES, V20, P2224, DOI 10.1359/JBMR.050803
   Nicholson GC, 2000, CLIN SCI, V99, P133, DOI 10.1042/CS19990355
   Oreffo ROC, 1999, HISTOCHEM CELL BIOL, V111, P125, DOI 10.1007/s004180050342
   OURSLER MJ, 1991, P NATL ACAD SCI USA, V88, P6613, DOI 10.1073/pnas.88.15.6613
   OURSLER MJ, 1994, P NATL ACAD SCI USA, V91, P5227, DOI 10.1073/pnas.91.12.5227
   OURSLER MJ, 1993, ENDOCRINOLOGY, V132, P1373, DOI 10.1210/en.132.3.1373
   Parikka V, 2001, ENDOCRINOLOGY, V142, P5371, DOI 10.1210/en.142.12.5371
   Ramalho AC, 2002, EUR CYTOKINE NETW, V13, P39
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Riggs BL, 2000, J CLIN INVEST, V106, P1203, DOI 10.1172/JCI11468
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Russell G, 2001, Novartis Found Symp, V232, P251
   Schlöndorff J, 2001, J BIOL CHEM, V276, P14665, DOI 10.1074/jbc.M010741200
   Schoppet M, 2002, ARTERIOSCL THROM VAS, V22, P549, DOI 10.1161/01.ATV.0000012303.37971.DA
   Shevde NK, 2000, P NATL ACAD SCI USA, V97, P7829, DOI 10.1073/pnas.130200197
   Srivastava S, 2001, J BIOL CHEM, V276, P8836, DOI 10.1074/jbc.M010764200
   Sunyer T, 1999, J CLIN INVEST, V103, P1409, DOI 10.1172/JCI4682
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Thirunavukkarasu K, 2001, J BIOL CHEM, V276, P36241, DOI 10.1074/jbc.M104319200
   Udagawa N, 2000, ENDOCRINOLOGY, V141, P3478, DOI 10.1210/en.141.9.3478
   Vanderschueren D, 2004, ENDOCR REV, V25, P389, DOI 10.1210/er.2003 0003
   Vidal O, 1999, J BONE MINER RES, V14, P923, DOI 10.1359/jbmr.1999.14.6.923
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
NR 47
TC 35
Z9 43
U1 0
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1044 5498
EI 1557 7430
J9 DNA CELL BIOL
JI DNA Cell Biol.
PD AUG
PY 2006
VL 25
IS 8
BP 475
EP 483
DI 10.1089/dna.2006.25.475
PG 9
WC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
GA 074ME
UT WOS:000239815700006
PM 16907645
DA 2025 08 17
ER

PT J
AU Linares, J
   Matesanz, MC
   Vila, M
   Feito, MJ
   Gonçalves, G
   Vallet Regí, M
   Marques, PAAP
   Portolés, MT
AF Linares, Javier
   Concepcion Matesanz, M.
   Vila, Mercedes
   Jose Feito, M.
   Goncalves, Gil
   Vallet Regi, Maria
   Marques, Paula A. A. P.
   Teresa Portoles, M.
TI Endocytic Mechanisms of Graphene Oxide Nanosheets in Osteoblasts,
   Hepatocytes and Macrophages
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE endocytosis; graphene oxide; hepatocyte; macrophage; nanoparticle;
   osteoblast
ID CELL; MACROPINOCYTOSIS; NANOPARTICLES; PATHWAYS; DELIVERY
AB Nano graphene oxide (GO) has attracted great interest in nanomedicine due to its own intrinsic properties and its possible biomedical applications such as drug delivery, tissue engineering and hyperthermia cancer therapy. However, the toxicity of GO nanosheets is not yet well known and it is necessary to understand its entry mechanisms into mammalian cells in order to avoid cell damage and human toxicity. In the present study, the cellular uptake of pegylated GO nanosheets of ca. 100 nm labeled with fluorescein isothiocyanate (FITC PEG GOs) has been evaluated in the presence of eight inhibitors (colchicine, wortmannin, amiloride, cytochalasin B, cytochalasin D, genistein, phenylarsine oxide and chlorpromazine) that specifically affect different endocytosis mechanisms. Three cell types were chosen for this study: human Saos 2 osteoblasts, human HepG2 hepatocytes and murine RAW 264.7 macrophages. The results show that different mechanisms take part in FITC PEG GOs uptake, depending on the characteristics of each cell type. However, macropinocytosis seems to be a general internalization process in the three cell lines analyzed. Besides macropinocytosis, FITC PEG GOs can enter through pathways dependent on microtubules in Saos 2 osteoblasts, and through clathrin dependent mechanisms in HepG2 hepatocytes and RAW 264.7 macrophages. HepG2 cells can also phagocytize FITC PEG GOs. These findings help to understand the interactions at the interface of GO nanosheets and mammalian cells and must be considered in further studies focused on their use for biomedical applications.
C1 [Linares, Javier; Concepcion Matesanz, M.; Jose Feito, M.; Teresa Portoles, M.] Univ Complutense, Fac Chem, Dept Biochem & Mol Biol 1, E 28040 Madrid, Spain.
   [Vila, Mercedes; Vallet Regi, Maria] Univ Complutense, Fac Pharm, Dept Inorgan & Bioinorgan Chem, Inst Invest Sanitaria Hosp Octubre i 12 12, E 28040 Madrid, Spain.
   [Vila, Mercedes; Vallet Regi, Maria] CIBER BBN, Networking Res Ctr Bioengn Biomat & Nanomed, Aragon 50018, Spain.
   [Vila, Mercedes; Goncalves, Gil; Marques, Paula A. A. P.] Univ Aveiro, Dept Mech Engn, TEMA NRD, P 3810193 Aveiro, Portugal.
C3 Complutense University of Madrid; Complutense University of Madrid;
   CIBER   Centro de Investigacion Biomedica en Red; CIBERBBN; Universidade
   de Aveiro
RP Portolés, MT (通讯作者)，Univ Complutense, Fac Chem, Dept Biochem & Mol Biol 1, E 28040 Madrid, Spain.
EM portoles@quim.ucm.es
RI Gonçalves, Gil/M 7640 2013; Goncalves, Gil/M 7640 2013; Feito,
   Maria/AAE 7813 2020; Marques, Paula/A 7371 2008; Vallet Regí,
   Maria/M 3378 2014; Portolés, María/U 1678 2017; Vallet Regi,
   Maria/M 3378 2014; PORTOLES PEREZ, MARIA TERESA/U 1678 2017
OI Ceron, Ester/0000 0003 1449 1018; Goncalves, Gil/0000 0002 2302 9661;
   Marques, Paula/0000 0002 7498 452X; Vallet Regi,
   Maria/0000 0002 6104 4889; Linares, Javier/0000 0001 6877 0827; FEITO
   CASTELLANO, MARIA JOSE/0000 0001 8623 4913; Vila,
   Mercedes/0000 0002 8473 0881; PORTOLES PEREZ, MARIA
   TERESA/0000 0002 9681 0184
FU Comunidad de Madrid [S2009/MAT 1472]; Ministerio de Ciencia e Innovacion
   (MICINN) [MAT2012 35556, CSO2010 11384 E]; CIBER BBN; MEC; Ministry for
   the RyC grant; Fundacao para a Ciencia e Tecnologia (FCT) Investigator
   Program; European Union; QREN; FEDER; COMPETE [PEst C/EME/UI0481/2013];
   FCT [SFRH/BDP/84419/2012]; QREN, programme Mais Centro Programa
   Operacional Regional do Centro and Uniao Europeia/Fundo Europeu de
   Desenvolvimento Regional, project Biomaterials for Regenerative Medicine
   [CENTRO 07 ST24 FEDER 002030]; FCT
FX This study was supported by research grants from Comunidad de Madrid
   (project S2009/MAT 1472) and the Ministerio de Ciencia e Innovacion
   (MICINN) (projects MAT2012 35556 and CSO2010 11384 E Agening Network of
   Excellence). J. Linares and M. C. Matesanz are greatly indebted to
   CIBER BBN and MEC, respectively, for predoctoral fellowships. M. Vila
   thanks the Spanish Ministry for the RyC grant and the Fundacao para a
   Ciencia e Tecnologia (FCT) Investigator Program 2012. We thank FCT, the
   European Union, QREN, FEDER, COMPETE, for funding the TEMA research unit
   (PEst C/EME/UI0481/2013). Gil Goncalves thanks the FCT for a PostDoc
   grant (SFRH/BDP/84419/2012). Paula Marques thanks QREN, programme Mais
   Centro Programa Operacional Regional do Centro and Uniao Europeia/Fundo
   Europeu de Desenvolvimento Regional, project Biomaterials for
   Regenerative Medicine (CENTRO 07 ST24 FEDER 002030) and the FCT
   Investigator Program 2013. The authors also thank the staff of the
   Cytometry and Fluorescence Microscopy Center of the Universidad
   Complutense de Madrid (Spain) for assistance in the flow cytometry and
   confocal microscopy studies.
CR Bandmann V, 2012, FEBS LETT, V586, P3626, DOI 10.1016/j.febslet.2012.08.008
   Bhowmick T, 2012, J CONTROL RELEASE, V157, P485, DOI 10.1016/j.jconrel.2011.09.067
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655
   Chen JG, 1997, LIFE SCI, V61, P29, DOI 10.1016/S0024 3205(97)00354 8
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   Depan D, 2011, ACTA BIOMATER, V7, P3432, DOI 10.1016/j.actbio.2011.05.019
   Fan HL, 2010, BIOMACROMOLECULES, V11, P2345, DOI 10.1021/bm100470q
   Fujimoto T, 2000, J CELL SCI, V113, P3509
   Gonçalves G, 2013, ADV HEALTHC MATER, V2, P1072, DOI 10.1002/adhm.201300023
   Goncalves G, 2009, CHEM MATER, V21, P4796, DOI 10.1021/cm901052s
   Hou CH, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4151
   Jokerst JV, 2011, NANOMEDICINE UK, V6, P715, DOI [10.2217/NNM.11.19, 10.2217/nnm.11.19]
   Jones AT, 2007, J CELL MOL MED, V11, P670, DOI 10.1111/j.1582 4934.2007.00062.x
   Kiyoshima D, 2011, J CELL SCI, V124, P3859, DOI 10.1242/jcs.088559
   Koivusalo M, 2010, J CELL BIOL, V188, P547, DOI 10.1083/jcb.200908086
   Kruth HS, 2005, J BIOL CHEM, V280, P2352, DOI 10.1074/jbc.M407167200
   Liu XS, 2013, LANGMUIR, V29, P9138, DOI 10.1021/la401556k
   Liu Z, 2008, J AM CHEM SOC, V130, P10876, DOI 10.1021/ja803688x
   Mäger I, 2012, BBA BIOMEMBRANES, V1818, P502, DOI 10.1016/j.bbamem.2011.11.020
   Matesanz MC, 2013, BIOMATERIALS, V34, P1562, DOI 10.1016/j.biomaterials.2012.11.001
   Mayor S, 2007, NAT REV MOL CELL BIO, V8, P603, DOI 10.1038/nrm2216
   Mu QX, 2012, ACS APPL MATER INTER, V4, P2259, DOI 10.1021/am300253c
   Novoselov KS, 2012, NATURE, V490, P192, DOI 10.1038/nature11458
   Sahay G, 2010, J CONTROL RELEASE, V145, P182, DOI 10.1016/j.jconrel.2010.01.036
   Sato K, 2009, LIFE SCI, V85, P800, DOI 10.1016/j.lfs.2009.10.012
   Schulz WL, 2012, J VIROL, V86, P12665, DOI 10.1128/JVI.01861 12
   SOJI T, 1992, ANAT REC, V233, P543, DOI 10.1002/ar.1092330408
   Sun XM, 2008, NANO RES, V1, P203, DOI 10.1007/s12274 008 8021 8
   Tuma PL, 1999, J CELL BIOL, V145, P1089, DOI 10.1083/jcb.145.5.1089
   Vila M, 2014, NANOTECHNOLOGY, V25, DOI 10.1088/0957 4484/25/3/035101
   Vila M, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957 4484/23/46/465103
   Yang CT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021971
   Yang K, 2010, NANO LETT, V10, P3318, DOI 10.1021/nl100996u
   Yue H, 2012, BIOMATERIALS, V33, P4013, DOI 10.1016/j.biomaterials.2012.02.021
   Zhang LM, 2010, SMALL, V6, P537, DOI 10.1002/smll.200901680
   Zolnik BS, 2010, ENDOCRINOLOGY, V151, P458, DOI 10.1210/en.2009 1082
NR 36
TC 143
Z9 150
U1 6
U2 168
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
EI 1944 8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD AUG 27
PY 2014
VL 6
IS 16
BP 13697
EP 13706
DI 10.1021/am5031598
PG 10
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA AO2CB
UT WOS:000341122000048
PM 24979758
DA 2025 08 17
ER

PT J
AU Kang, Q
   Song, WX
   Luo, Q
   Tang, N
   Luo, JY
   Luo, XJ
   Chen, J
   Bi, Y
   He, BC
   Park, JK
   Jiang, W
   Tang, Y
   Huang, JY
   Su, YX
   Zhu, GH
   He, Y
   Yin, H
   Hu, ZM
   Wang, Y
   Chen, L
   Zuo, GW
   Pan, XC
   Shen, JK
   Vokes, T
   Reid, RR
   Haydon, RC
   Luu, HH
   He, TC
AF Kang, Quan
   Song, Wen Xin
   Luo, Qing
   Tang, Ni
   Luo, Jinyong
   Luo, Xiaoji
   Chen, Jin
   Bi, Yang
   He, Bai Cheng
   Park, Jong Kyung
   Jiang, Wei
   Tang, Yi
   Huang, Jiayi
   Su, Yuxi
   Zhu, Gao Hui
   He, Yun
   Yin, Hong
   Hu, Zhenming
   Wang, Yi
   Chen, Liang
   Zuo, Guo Wei
   Pan, Xiaochuan
   Shen, Jikun
   Vokes, Tamara
   Reid, Russell R.
   Haydon, Rex C.
   Luu, Hue H.
   He, Tong Chuan
TI A Comprehensive Analysis of the Dual Roles of BMPs in Regulating
   Adipogenic and Osteogenic Differentiation of Mesenchymal Progenitor
   Cells
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
ID BONE MORPHOGENETIC PROTEINS; STEM CELLS; OSTEOBLAST DIFFERENTIATION;
   ADIPOCYTE DIFFERENTIATION; MULTILINEAGE DIFFERENTIATION; C3H10T1/2
   CELLS; MARROW; WNT; TISSUE; EXPRESSION
AB Pluripotent mesenchymal stem cells (MSCs) are bone marrow stromal progenitor cells that can differentiate into osteogenic, chondrogenic, adipogenic, and myogenic lineages. Several signaling pathways have been shown to regulate the lineage commitment and terminal differentiation of MSCs. Here, we conducted a comprehensive analysis of the 14 types of bone morphogenetic protein (BMPs) for their abilities to regulate multilineage specific differentiation of MSCs. We found that most BMPs exhibited distinct abilities to regulate the expression of Runx2, Sox9, MyoD, and PPAR gamma 2. Further analysis indicated that BMP 2, BMP 4, BMP 6, BMP 7, and BMP 9 effectively induced both adipogenic and osteogenic differentiation in vitro and in vivo. BMP induced commitment to osteogenic or adipogenic lineage was shown to be mutually exclusive. Overexpression of Runx2 enhanced BMP induced osteogenic differentiation, whereas knockdown of Runx2 expression diminished BMP induced bone formation with a decrease in adipocyte accumulation in vivo. Interestingly, overexpression of PPAR gamma 2 not only promoted adipogenic differentiation, but also enhanced osteogenic differentiation upon BMP 2, BMP 6, and BMP 9 stimulation. Conversely, MSCs with PPAR gamma 2 knockdown or mouse embryonic fibroblasts derived from PPAR gamma 2( / ) mice exhibited a marked decrease in adipogenic differentiation, coupled with reduced osteogenic differentiation and diminished mineralization upon BMP 9 stimulation, suggesting that PPAR gamma 2 may play a role in BMP induced osteogenic and adipogenic differentiation. Thus, it is important to understand the molecular mechanism behind BMP regulated lineage divergence during MSC differentiation, as this knowledge could help us to understand the pathogenesis of skeletal diseases and may lead to the development of strategies for regenerative medicine.
C1 [Kang, Quan; Song, Wen Xin; Luo, Qing; Tang, Ni; Luo, Jinyong; Luo, Xiaoji; Chen, Jin; Bi, Yang; He, Bai Cheng; Jiang, Wei; Huang, Jiayi; Su, Yuxi; Zhu, Gao Hui; He, Yun; Yin, Hong; Wang, Yi; Chen, Liang; Zuo, Guo Wei; Shen, Jikun; Reid, Russell R.; Haydon, Rex C.; Luu, Hue H.; He, Tong Chuan] Univ Chicago, Med Ctr, Mol Oncol Lab, Dept Surg, Chicago, IL 60637 USA.
   [Kang, Quan; Song, Wen Xin; Luo, Qing; Tang, Ni; Luo, Jinyong; Luo, Xiaoji; Chen, Jin; Bi, Yang; He, Bai Cheng; Park, Jong Kyung; Huang, Jiayi; Su, Yuxi; Zhu, Gao Hui; He, Yun; Hu, Zhenming; Wang, Yi; Chen, Liang; Zuo, Guo Wei; He, Tong Chuan] Chinese Minist Educ, Key Lab Diagnost Med, Chongqing, Peoples R China.
   [Kang, Quan; Song, Wen Xin; Luo, Qing; Tang, Ni; Luo, Jinyong; Luo, Xiaoji; Chen, Jin; Bi, Yang; He, Bai Cheng; Park, Jong Kyung; Huang, Jiayi; Su, Yuxi; Zhu, Gao Hui; He, Yun; Hu, Zhenming; Wang, Yi; Chen, Liang; Zuo, Guo Wei; He, Tong Chuan] Chongqing Med Univ, Childrens Hosp, Chongqing, Peoples R China.
   [Tang, Ni; Chen, Liang] Chongqing Med Univ, Affiliated Hosp 2, Chongqing, Peoples R China.
   [Park, Jong Kyung] Catholic Univ Korea, St Pauls Hosp, Coll Med, Dept Surg, Seoul, South Korea.
   [Tang, Yi] Northwestern Univ, Childrens Mem Hosp, Dept Pathol, Chicago, IL 60614 USA.
   [Pan, Xiaochuan] Univ Chicago, Dept Radiol, Chicago, IL 60637 USA.
   [Vokes, Tamara] Univ Chicago, Endocrinol Sect, Chicago, IL 60637 USA.
C3 University of Chicago; University of Chicago Medical Center; Chongqing
   Medical University; Chongqing Medical University; Catholic University of
   Korea; Northwestern University; Ann & Robert H. Lurie Children's
   Hospital of Chicago; University of Chicago; University of Chicago
RP He, TC (通讯作者)，Univ Chicago, Med Ctr, Mol Oncol Lab, Dept Surg, 5841 S Maryland Ave,MC3079, Chicago, IL 60637 USA.
EM hluu@surgery.bsd.uchicago.edu; tche@surgery.bsd.uchicago.edu
RI Tang, Ni/Z 5133 2019; Reid, Russell/LIF 6227 2024; huang,
   jiayi/AAR 3913 2021; Hu, Zhenming/ABA 5860 2021
OI Tang, Ni/0000 0001 5830 8786; 
FU American Cancer Society; Brinson Foundation; Natural Science Foundation
   of China; Chinese Ministry of Science and Technology [30500602,
   30600625]; Chinese Ministry of Science and Technology; Orthopaedic
   Research and Education Foundation; National Institutes of Health
FX We thank Bruce M. Spiegelman of Dana Farber Cancer Institute, Boston,
   MA, for providing the PPAR gamma 2 null mouse embryo fibroblasts (MEFs).
   We also thank Parke Davis/Pfizer for generously providing Troglitazone.
   The reported work was supported, in part, by research grants from the
   American Cancer Society ( H. H. L. and T. C. H.), The Brinson Foundation
   ( T. C. H.), the Natural Science Foundation of China and the Chinese
   Ministry of Science and Technology (QL, # 30500602; QK, # 30600625;
   Z.L.D. and T. C. H.), the 863 Project Grant from the Chinese Ministry of
   Science and Technology (Z.L.D., T. C. H., Q. K., and Q. L.), the
   Orthopaedic Research and Education Foundation ( R. C. H. and H. H. L.),
   and the National Institutes of Health ( Q. K., R. C. H., T. C. H., and
   H. H. L.).
CR AHRENS M, 1993, DNA CELL BIOL, V12, P871, DOI 10.1089/dna.1993.12.871
   Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Ali AA, 2005, ENDOCRINOLOGY, V146, P1226, DOI 10.1210/en.2004 0735
   Asahina I, 1996, EXP CELL RES, V222, P38, DOI 10.1006/excr.1996.0005
   Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809
   Aubin JE, 1998, J CELL BIOCHEM, P73, DOI 10.1002/(SICI)1097 4644(1998)72:30/31+<73::AID JCB11>3.0.CO;2 L
   Baksh D, 2004, J CELL MOL MED, V8, P301, DOI 10.1111/j.1582 4934.2004.tb00320.x
   Barry FP, 2004, INT J BIOCHEM CELL B, V36, P568, DOI 10.1016/j.biocel.2003.11.001
   Bowers RR, 2006, P NATL ACAD SCI USA, V103, P13022, DOI 10.1073/pnas.0605789103
   BURKHARDT R, 1987, BONE, V8, P157, DOI 10.1016/8756 3282(87)90015 9
   Burns JS, 2005, CANCER RES, V65, P3126, DOI 10.1158/0008 5472.CAN 04 2218
   Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471 4914(01)02016 0
   Chen TL, 2001, J CELL BIOCHEM, V82, P187, DOI 10.1002/jcb.1145
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Daluiski A, 2001, NAT GENET, V27, P84, DOI 10.1038/83810
   Deng ZL, 2008, FRONT BIOSCI LANDMRK, V13, P2001, DOI 10.2741/2819
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Ducy P, 2000, KIDNEY INT, V57, P2207, DOI 10.1046/j.1523 1755.2000.00081.x
   FRIEDENSTEIN AJ, 1966, J EMBRYOL EXP MORPH, V16, P381
   Fux C, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh001
   GIMBLE JM, 1995, J CELL BIOCHEM, V58, P393, DOI 10.1002/jcb.240580312
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092 8674(00)81664 5
   Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580
   Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955
   Ji XH, 2000, J BONE MINER METAB, V18, P132, DOI 10.1007/s007740050103
   Jin WZ, 2006, DEV CELL, V10, P461, DOI 10.1016/j.devcel.2006.02.016
   Justesen J, 2001, BIOGERONTOLOGY, V2, P165, DOI 10.1023/A:1011513223894
   Kajkenova O, 1997, J BONE MINER RES, V12, P1772, DOI 10.1359/jbmr.1997.12.11.1772
   Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   Kaplan FS, 2000, J BONE MINER RES, V15, P2084, DOI 10.1359/jbmr.2000.15.11.2084
   Kléber M, 2004, CURR OPIN CELL BIOL, V16, P681, DOI 10.1016/j.ceb.2004.08.006
   Kobayashi H, 2000, BIOCHEM BIOPH RES CO, V273, P630, DOI 10.1006/bbrc.2000.2981
   Li JZ, 2003, GENE THER, V10, P1735, DOI 10.1038/sj.gt.3302075
   Luo J, 2005, CURR GENE THER, V5, P167, DOI 10.2174/1566523053544218
   Luo J, 2007, NAT PROTOC, V2, P1236, DOI 10.1038/nprot.2007.135
   Luo JY, 2007, LAB INVEST, V87, P97, DOI 10.1038/labinvest.3700509
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Luo Q, 2007, GENE, V395, P160, DOI 10.1016/j.gene.2007.02.030
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   MEUNIER P, 1971, CLIN ORTHOP RELAT R, P147, DOI 10.1097/00003086 197110000 00021
   Mie M, 2000, TISSUE ENG, V6, P9, DOI 10.1089/107632700320847
   Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474 9728.2004.00127.x
   Molofsky AV, 2004, CURR OPIN CELL BIOL, V16, P700, DOI 10.1016/j.ceb.2004.09.004
   Muraglia A, 2000, J CELL SCI, V113, P1161
   Nuttall ME, 2004, CURR OPIN PHARMACOL, V4, P290, DOI 10.1016/j.coph.2004.03.002
   Osyczka AM, 2002, CALCIFIED TISSUE INT, V71, P447, DOI 10.1007/s00223 001 1090 2
   Peng Y, 2004, J BIOL CHEM, V279, P32941, DOI 10.1074/jbc.M403344200
   Peng Y, 2003, J CELL BIOCHEM, V90, P1149, DOI 10.1002/jcb.10744
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Reddi AH, 1998, NAT BIOTECHNOL, V16, P247, DOI 10.1038/nbt0398 247
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   REZNIKOFF CA, 1973, CANCER RES, V33, P3231
   ROZMAN C, 1990, BLOOD, V76, P892
   Rubio D, 2005, CANCER RES, V65, P3035, DOI 10.1158/0008 5472.CAN 04 4194
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092 8674(03)00432 X
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   Sorocéanu MA, 2004, J ENDOCRINOL, V183, P203, DOI 10.1677/joe.1.05723
   Sottile V, 2000, FEBS LETT, V475, P201, DOI 10.1016/S0014 5793(00)01655 0
   Taha MF, 2006, ANAT HISTOL EMBRYOL, V35, P271, DOI 10.1111/j.1439 0264.2006.00680.x
   Tang MK, 2000, DEV BIOL, V218, P89, DOI 10.1006/dbio.1999.9578
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   Varga AC, 2005, ONCOGENE, V24, P5713, DOI 10.1038/sj.onc.1208919
   Verma S, 2002, J CLIN PATHOL, V55, P693, DOI 10.1136/jcp.55.9.693
   WANG EA, 1993, GROWTH FACTORS, V9, P57, DOI 10.3109/08977199308991582
   Wang JB, 2004, CURR OPIN GENET DEV, V14, P533, DOI 10.1016/j.gde.2004.07.013
   Zhang JW, 2005, DEV BIOL, V284, P1, DOI 10.1016/j.ydbio.2005.05.009
   Zhao GQ, 2003, GENESIS, V35, P43, DOI 10.1002/gene.10167
   zur Nieden NI, 2005, BMC DEV BIOL, V5, DOI 10.1186/1471 213X 5 1
NR 71
TC 336
Z9 385
U1 1
U2 56
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547 3287
EI 1557 8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD MAY
PY 2009
VL 18
IS 4
BP 545
EP U33
DI 10.1089/scd.2008.0130
PG 15
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA 444QV
UT WOS:000265996400003
PM 18616389
OA Green Published
DA 2025 08 17
ER

PT J
AU Iguchi, K
   Tatsuda, Y
   Usui, S
   Hirano, K
AF Iguchi, Kazuhiro
   Tatsuda, Yoshiki
   Usui, Shigeyuki
   Hirano, Kazuyuki
TI Pamidronate inhibits antiapoptotic bcl 2 expression through inhibition
   of the mevalonate pathway in prostate cancer PC 3 cells
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Bcl 2; Pamidronate; Bisphosphonate; Prostate cancer; Mevalonate pathway;
   Rap1
ID BISPHOSPHONATES INDUCE APOPTOSIS; ZOLEDRONIC ACID; BONE METASTASIS;
   GENE EXPRESSION; FAMILY PROTEINS; BREAST CANCER; THERAPY; ALENDRONATE;
   KINASE; GROWTH
AB Bisphosphonates are expected to be efficacious to prevent the growth of metastatic cancer in bone tissue. Bone metastases often occur in patients with various cancers, such as breast, lung and prostate cancer. Bcl 2 is a potent antiapoptotic protein and its expression is known to be closely related to its function. In this study, to investigate the effect of bisphosphonates on cancer cells, we focused on bcl 2 expression in bisphosphonate treated prostate cancer cells. First, we observed that bcl 2 mRNA expression in PC 3 was significantly inhibited to 12% of the control level by treatment with 100 mu M pamidronate for 12 h. Inhibition was seen in cells treated with nitrogen containing bisphosphonates, which have the ability to inhibit isoprenoid biosynthesis via the mevalonate pathway, but not in non nitrogen containing etidronate. Simultaneous treatment with geranylgeraniol, an intermediate of the mevalonate pathway, significantly blocked inhibition by pamidronate, and treatment with geranylgeranyl transferase inhibitor GGTI 286 also suppressed bcl 2 mRNA expression. Furthermore, pamidronate inhibited the translocation of Rap1 protein to the membrane fraction, suggesting that a change in posttranslational modification of Rap1 occurred in treated cells. Finally, knockdown of Rap1 by siRNA resulted in the inhibition of bcl 2 expression. These results strongly indicate that bcl 2 reduction in bisphosphonate treated PC 3 cells is dependent on inhibition of the mevalonate pathway. The inhibitory effect of bisphosphonates on bcl 2 expression shown in prostate cancer cell line should be tested in animal experiments and clinical studies. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Iguchi, Kazuhiro; Tatsuda, Yoshiki; Usui, Shigeyuki; Hirano, Kazuyuki] Gifu Pharmaceut Univ, Lab Pharmaceut, Gifu 5011196, Japan.
C3 Gifu Pharmaceutical University
RP Hirano, K (通讯作者)，Gifu Pharmaceut Univ, Lab Pharmaceut, 1 25 4 Daigaku Nishi, Gifu 5011196, Japan.
EM hirano@gifu pu.ac.jp
FU Ministry of Education, Culture, Sports, Science, and Technology of Japan
   [18791130]; Grants in Aid for Scientific Research [18791130] Funding
   Source: KAKEN
FX This study was supported by a grant in aid for young scientists (no.
   18791130) from the Ministry of Education, Culture, Sports, Science, and
   Technology of Japan.
CR Asahi H, 2003, J UROLOGY, V169, P281, DOI 10.1016/S0022 5347(05)64093 1
   Asahi H, 2006, INT J UROL, V13, P593, DOI 10.1111/j.1442 2042.2006.01360.x
   Azad N, 2006, J BIOL CHEM, V281, P34124, DOI 10.1074/jbc.M602551200
   Boissier S, 2000, CANCER RES, V60, P2949
   Bradley DA, 2008, CANCER J, V14, P15, DOI 10.1097/PPO.0b013e31816220b7
   COLOMBEL M, 1993, AM J PATHOL, V143, P390
   Fabbri F, 2008, J TRANSL MED, V6, DOI 10.1186/1479 5876 6 43
   FLEISCH H, 1969, SCIENCE, V165, P1262, DOI 10.1126/science.165.3899.1262
   Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Iguchi K, 2007, ANTICANCER RES, V27, P3843
   Iguchi K, 2006, ANTICANCER RES, V26, P2977
   Iguchi K, 2006, CANCER LETT, V237, P223, DOI 10.1016/j.canlet.2005.06.006
   Inoue R, 2005, BRIT J PHARMACOL, V146, P633, DOI 10.1038/sj.bjp.0706373
   Kang MH, 2009, CLIN CANCER RES, V15, P1126, DOI 10.1158/1078 0432.CCR 08 0144
   Kim SJ, 2005, CANCER RES, V65, P3707, DOI 10.1158/0008 5472.CAN 04 3601
   Lee MV, 2001, CANCER RES, V61, P2602
   Li DC, 2004, CANCER SCI, V95, P644, DOI 10.1111/j.1349 7006.2004.tb03323.x
   Liu G, 2009, CLIN CANCER RES, V15, P3172, DOI 10.1158/1078 0432.CCR 08 2985
   Lu S, 2008, ONCOL REP, V20, P581, DOI 10.3892/or_00000045
   Mazzocca A, 2003, MOL PHARMACOL, V63, P159, DOI 10.1124/mol.63.1.159
   MCDONNELL TJ, 1992, CANCER RES, V52, P6940
   Nishida S, 2003, LIFE SCI, V73, P2655, DOI 10.1016/S0024 3205(03)00664 7
   Oades GM, 2003, J UROLOGY, V170, P246, DOI 10.1097/01.ju.0000070685.34760.5f
   Ory B, 2007, MOL PHARMACOL, V71, P333, DOI 10.1124/mol.106.028837
   Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761
   Raaijmakers JH, 2009, J BIOL CHEM, V284, P10995, DOI 10.1074/jbc.R800061200
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Smith MR, 2001, NEW ENGL J MED, V345, P948, DOI 10.1056/NEJMoa010845
   Tatsuda Y, 2010, EUR J PHARMACOL, V627, P348, DOI 10.1016/j.ejphar.2009.10.067
   Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732
   Valenti MT, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 49
   Virtanen SS, 2002, CANCER RES, V62, P2708
   Walker K, 2005, CURR OPIN GENET DEV, V15, P62, DOI 10.1016/j.gde.2004.11.001
   Wang CX, 2006, CELL DEATH DIFFER, V13, P1203, DOI 10.1038/sj.cdd.4401804
   Wang L, 2001, J BIOL CHEM, V276, P37242, DOI 10.1074/jbc.M105089200
   Wang LY, 2008, CANCER RES, V68, P4377, DOI 10.1158/0008 5472.CAN 07 6590
   Yip KW, 2008, ONCOGENE, V27, P6398, DOI 10.1038/onc.2008.307
NR 40
TC 12
Z9 12
U1 1
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD SEP 1
PY 2010
VL 641
IS 1
BP 35
EP 40
DI 10.1016/j.ejphar.2010.05.010
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 623MX
UT WOS:000279746000006
PM 20519142
DA 2025 08 17
ER

PT J
AU Ren, YM
   Lee, MY
   Schliffke, S
   Paavola, J
   Amos, PJ
   Ge, X
   Ye, MY
   Zhu, SJ
   Senyei, G
   Lum, L
   Ehrlich, BE
   Qyang, YB
AF Ren, Yongming
   Lee, Min Young
   Schliffke, Simon
   Paavola, Jere
   Amos, Peter J.
   Ge, Xin
   Ye, Mingyu
   Zhu, Shenjun
   Senyei, Grant
   Lum, Lawrence
   Ehrlich, Barbara E.
   Qyang, Yibing
TI Small molecule Wnt inhibitors enhance the efficiency of BMP 4 directed
   cardiac differentiation of human pluripotent stem cells
SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
LA English
DT Article
DE Cardiomyocyte; Embryonic stem cell; Induced pluripotent stem cell;
   Cardiac differentiation; Optical recording
ID CARDIOMYOCYTES; HEART; FIBROBLASTS; INDUCTION; MYOCYTES; RENEWAL;
   DEVELOP; MODELS
AB Human induced pluripotent stem (iPS) cells potentially provide a unique resource for generating patient specific cardiomyocytes to study cardiac disease mechanisms and treatments. However, existing approaches to cardiomyocyte production from human iPS cells are inefficient, limiting the application of iPS cells in basic and translational cardiac research. Furthermore, strategies to accurately record changes in iPS cell derived cardiomyocyte action potential duration (APD) are needed to monitor APD related cardiac disease and for rapid drug screening. We examined whether modulation of the bone morphogenetic protein 4 (BMP 4) and Wnt/beta catenin signaling pathways could induce efficient cardiac differentiation of human iPS cells. We found that early treatment of human iPS cells with BMP 4 followed by late treatment with small molecule Wnt inhibitors led to a marked increase in production of cardiomyocytes compared to existing differentiation strategies. Using immunocytochemical staining and real time intracellular calcium imaging, we showed that these induced cardiomyocytes expressed typical sarcomeric markers, exhibited normal rhythmic Ca2+ transients, and responded to both beta adrenergic and electric stimulation. Furthermore, human iPS cell derived cardiomyocytes demonstrated characteristic changes in action potential duration in response to cardioactive drugs procainamide and verapamil using voltage sensitive dye based optical recording. Thus, modulation of the BMP 4 and Wnt signaling pathways in human iPS cells leads to highly efficient production of cardiomyocytes with typical electrophysiological function and pharmacologic responsiveness. The use of human iPS cell derived cardiomyocytes and the application of calcium and voltage sensitive dyes for the direct, rapid measurement of iPS cell derived cardiomyocyte activity promise to offer attractive platforms for studying cardiac disease mechanisms and therapeutics. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Ren, Yongming; Lee, Min Young; Amos, Peter J.; Ge, Xin; Senyei, Grant; Qyang, Yibing] Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT 06520 USA.
   [Schliffke, Simon; Paavola, Jere; Ehrlich, Barbara E.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA.
   [Schliffke, Simon] Univ Med Ctr Hamburg Eppendorf, Dept Anat Expt Morphol 2, Hamburg, Germany.
   [Paavola, Jere] Minerva Fdn, Inst Med Res, Helsinki 00290, Finland.
   [Ye, Mingyu] Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA.
   [Zhu, Shenjun] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA.
   [Lum, Lawrence] Univ Texas SW Med Ctr Dallas, Dept Cell Biol, Dallas, TX 75390 USA.
   [Qyang, Yibing] Yale Univ, Yale Stem Cell Ctr, New Haven, CT 06520 USA.
C3 Yale University; Yale University; University of Hamburg; University
   Medical Center Hamburg Eppendorf; Yale University; Harvard University;
   Harvard University Medical Affiliates; Massachusetts General Hospital;
   University of Texas System; University of Texas Southwestern Medical
   Center; Yale University
RP Qyang, YB (通讯作者)，Yale Univ, Sch Med, Yale Stem Cell Ctr, Sect Cardiovasc Med, 300 George St,Room 773A, New Haven, CT 06510 USA.
EM yibing.qyang@yale.edu
RI Lee, Hye/D 9081 2016; Senyei, Grant/GQZ 4020 2022; Ye,
   Mingyu/R 6778 2017; Paavola, Jere/GRF 6451 2022
OI Ye, Mingyu/0000 0001 8560 4345; Ehrlich, Barbara/0000 0001 9657 9704;
   Qyang, Yibing/0000 0002 0332 2449
FU Yale startup fund; Connecticut Stem Cell [09SCAYALE10]; NIH
   [1K02HL101990 01, UL1 RR024139, 5 T32 HL007950, 1R01GM076398 01,
   DK57751, DK061747]; Finnish Foundation for Cardiovascular Research;
   Welch Foundation [I 1665]
FX This work was supported by the Yale startup fund, the Connecticut Stem
   Cell 09SCAYALE10, NIH 1K02HL101990 01 and UL1 RR024139 (YQ), NIH 5 T32
   HL007950 (PJ), the Finnish Foundation for Cardiovascular Research (JP),
   Welch Foundation I 1665 and NIH 1R01GM076398 01 (LL), and NIH DK57751
   and DK061747 (BEE).
CR Akar FG, 2003, CIRC RES, V93, P638, DOI 10.1161/01.RES.0000092248.59479.AE
   Braam SR, 2010, STEM CELL RES, V4, P107, DOI 10.1016/j.scr.2009.11.004
   Carvajal Vergara X, 2010, NATURE, V465, P808, DOI 10.1038/nature09005
   Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137
   Chen SB, 2006, P NATL ACAD SCI USA, V103, P17266, DOI 10.1073/pnas.0608156103
   Cheng Hsien C., 2006, Journal of Pharmacological and Toxicological Methods, V54, P278, DOI 10.1016/j.vascn.2006.01.002
   Fu JD, 2010, STEM CELLS DEV, V19, P773, DOI 10.1089/scd.2009.0184
   Fukuda K, 2006, CIRC RES, V98, P1002, DOI 10.1161/01.RES.0000218272.18669.6e
   Hardy M. E. L., 2006, Journal of Pharmacological and Toxicological Methods, V54, P173, DOI 10.1016/j.vascn.2006.02.013
   He JQ, 2003, CIRC RES, V93, P32, DOI 10.1161/01.RES.0000080317.92718.99
   Huber I, 2007, FASEB J, V21, P2551, DOI 10.1096/fj.05 5711com
   Itzhaki I, 2011, NATURE, V471, P225, DOI 10.1038/nature09747
   Jia FJ, 2010, NAT METHODS, V7, P197, DOI [10.1038/NMETH.1426, 10.1038/nmeth.1426]
   Kehat I, 2001, J CLIN INVEST, V108, P407, DOI 10.1172/JCI200112131
   Kim D, 2009, CELL STEM CELL, V4, P472, DOI 10.1016/j.stem.2009.05.005
   Laflamme MA, 2007, NAT BIOTECHNOL, V25, P1015, DOI 10.1038/nbt1327
   Leschik J, 2008, NAT PROTOC, V3, P1381, DOI 10.1038/nprot.2008.116
   Lieu DK, 2009, STEM CELLS DEV, V18, P1493, DOI 10.1089/scd.2009.0052
   Maherali N, 2007, CELL STEM CELL, V1, P55, DOI 10.1016/j.stem.2007.05.014
   Marvin MJ, 2001, GENE DEV, V15, P316, DOI 10.1101/gad.855501
   Moon Randall T, 2004, Nat Rev Genet, V5, P691, DOI 10.1038/nrg1427
   Moretti A, 2010, NEW ENGL J MED, V363, P1397, DOI 10.1056/NEJMoa0908679
   Mummery C, 2003, CIRCULATION, V107, P2733, DOI 10.1161/01.CIR.0000068356.38592.68
   Panáková D, 2010, NATURE, V466, P874, DOI 10.1038/nature09249
   Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]
   Qyang Y, 2007, CELL STEM CELL, V1, P165, DOI 10.1016/j.stem.2007.05.018
   Ridley JM, 2003, BIOCHEM BIOPH RES CO, V306, P388, DOI 10.1016/S0006 291X(03)00980 X
   Schneider VA, 2001, GENE DEV, V15, P304, DOI 10.1101/gad.855601
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takei S, 2009, AM J PHYSIOL HEART C, V296, pH1793, DOI 10.1152/ajpheart.01288.2008
   Tanaka T, 2009, BIOCHEM BIOPH RES CO, V385, P497, DOI 10.1016/j.bbrc.2009.05.073
   Tran TH, 2009, STEM CELLS, V27, P1869, DOI 10.1002/stem.95
   Ueno S, 2007, P NATL ACAD SCI USA, V104, P9685, DOI 10.1073/pnas.0702859104
   Warren L, 2010, CELL STEM CELL, V7, P618, DOI 10.1016/j.stem.2010.08.012
   Xu CH, 2002, CIRC RES, V91, P501, DOI 10.1161/01.RES.0000035254.80718.91
   Yang L, 2008, NATURE, V453, P524, DOI 10.1038/nature06894
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Zhang JH, 2009, CIRC RES, V104, pE30, DOI 10.1161/CIRCRESAHA.108.192237
   Zwi L, 2009, CIRCULATION, V120, P1513, DOI 10.1161/CIRCULATIONAHA.109.868885
NR 39
TC 118
Z9 145
U1 0
U2 37
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0022 2828
EI 1095 8584
J9 J MOL CELL CARDIOL
JI J. Mol. Cell. Cardiol.
PD SEP
PY 2011
VL 51
IS 3
BP 280
EP 287
DI 10.1016/j.yjmcc.2011.04.012
PG 8
WC Cardiac & Cardiovascular Systems; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cardiovascular System & Cardiology; Cell Biology
GA 812TI
UT WOS:000294315400002
PM 21569778
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Matsushima, N
   Nakamichi, N
   Kambe, Y
   Takano, K
   Moriguchi, N
   Yoneda, Y
AF Matsushima, Nobuyuki
   Nakamichi, Noritaka
   Kambe, Yuki
   Takano, Katsura
   Moriguchi, Nobuaki
   Yoneda, Yukio
TI Cytoprotective properties of phenolic antidiarrheic ingredients in
   cultured astrocytes and neurons of rat brains
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE antidiarrheic; astrocyte; neuron; hydrogen peroxide; glutamate
ID CELL DEATH; CALVARIAL OSTEOBLASTS; OLIVE OIL; BONE LOSS; POLYPHENOL;
   PYRUVATE; CYTOTOXICITY; MECHANISM; TOXICITY; EXPOSURE
AB We have previously shown that particular phenolic antidiarrheic ingredients, including 2 methoxy 4 methylphenol (2M4MP) and 2 methoxy 4 ethyphenol (2M4EP), but not 2 methoxyphenol (2MP), significantly inhibit cellular maturation and differentiation of the bone resorbing osteoclasts with concomitant protection of the bone forming osteoblasts against oxidative stress by hydrogen peroxide (H2O2). In the present study, we evaluated the pharmacological actions of these three major phenolic antidiarrheic ingredients on the cellular viability in cultured astrocytes and neurons of the rat brain in vitro. Both 2M4MP and 2M4EP induced more efficient prevention of cell death induced by the brief exposure to 0.1 mM H2O2 for 2 h than 2MP upon simultaneous exposure in cultured rat cortical astrocytes. Similarly, both 2M4MP and 2M4EP were more effective than 2MP in significantly protecting the cytotoxicity by brief exposure to 0.1 mM H2O2 for 6 h in cultured rat hippocampal neurons, with concomitant suppression of the generation of intracellular reactive oxygen species in neurons exposed to H2O2. Moreover, the three ingredients not only significantly prevented cell death in hippocampal neurons exposed to 0.1 mM glutamate for 1 h when determined 48 h after the brief exposure, but also inhibited the generation of intracellular reactive oxygen species and the elevation of intracellular Ca2+ ions in neurons exposed to glutamate. These results suggest that particular phenolic antidiarrheic ingredients may prevent cell death through a mechanism related to diminution of the neurotoxicity of glutamate in neurons, in addition to eliciting cytoprotection against oxidative stress in astrocytes and neurons, in the rat brain. (c) 2007 Elsevier B.V. All rights reserved.
C1 Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Pharmaceut Sci, Mol Pharmacol Lab, Kanazawa, Ishikawa 920, Japan.
   Taiko Pharmaceut Co Ltd, Suita, Osaka 564, Japan.
C3 Kanazawa University
RP Yoneda, Y (通讯作者)，Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Pharmaceut Sci, Mol Pharmacol Lab, Kanazawa, Ishikawa 920, Japan.
EM yyoneda@p.kanazawa u.ac.jp
RI Nakamichi, Noritaka/AAB 7388 2020; Takano Kawabe, Katsura/JDW 6520 2023;
   Yoneda, Yukio/ABI 1864 2020
OI Nakamichi, Noritaka/0000 0002 0283 3546; Yoneda,
   Yukio/0000 0002 4624 177X
CR DELAISSE JM, 1986, BIOCHEM PHARMACOL, V35, P3091, DOI 10.1016/0006 2952(86)90391 6
   Desagher S, 1996, J NEUROSCI, V16, P2553
   DIPORZIO U, 1980, NATURE, V288, P370, DOI 10.1038/288370a0
   Hinoi E, 2002, BIOCHEM BIOPH RES CO, V294, P1177, DOI 10.1016/S0006 291X(02)00578 8
   Hinoi E, 2006, MOL PHARMACOL, V70, P925, DOI 10.1124/mol.106.024398
   Hirai T, 2005, J NEUROSCI RES, V80, P491, DOI 10.1002/jnr.20497
   Horcajada Molteni MN, 2000, J BONE MINER RES, V15, P2251, DOI 10.1359/jbmr.2000.15.11.2251
   Manna C, 1997, J NUTR, V127, P286, DOI 10.1093/jn/127.2.286
   Mimura T, 2005, BIOMED RES TOKYO, V26, P139, DOI 10.2220/biomedres.26.139
   Moriguchi N, 2006, HISTOL HISTOPATHOL, V21, P969, DOI 10.14670/HH 21.969
   MORIGUCHI N, 2006, BIOCHEM PHARMACOL, V73, P385
   Mronga T, 2004, GLIA, V46, P446, DOI 10.1002/glia.20022
   Murakami K, 2003, NEUROSCIENCE, V117, P37, DOI 10.1016/S0306 4522(02)00804 7
   Nakamichi N, 2002, J NEUROSCI RES, V67, P275, DOI 10.1002/jnr.10096
   Nakamura O., 2002, Eur. J. Sport Sci, V2, P1, DOI [10.1080/17461390200072203, DOI 10.1080/17461390200072203]
   Park YH, 2003, CELL BIOL TOXICOL, V19, P325, DOI 10.1023/B:CBTO.0000004986.51081.c5
   Puel C, 2004, BRIT J NUTR, V92, P119, DOI 10.1079/BJN20041181
   Puel C, 2005, CALCIFIED TISSUE INT, V77, P311, DOI 10.1007/s00223 005 0060 5
   Raicevic N, 2005, NEUROPHARMACOLOGY, V48, P720, DOI 10.1016/j.neuropharm.2004.12.003
   Savolainen KM, 1998, TOXICOL LETT, V103, P363, DOI 10.1016/S0378 4274(98)00233 1
   WHITTEMORE ER, 1994, NEUROREPORT, V5, P1485, DOI 10.1097/00001756 199407000 00019
   Yazaki Kinya, 1993, Bulletin of Tokyo Dental College, V34, P141
NR 22
TC 8
Z9 8
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD JUL 12
PY 2007
VL 567
IS 1 2
BP 59
EP 66
DI 10.1016/j.ejphar.2007.03.034
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 179HZ
UT WOS:000247281700008
PM 17475240
DA 2025 08 17
ER

PT J
AU Roberts, BM
   Geddis, AV
   Sczuroski, CE
   Reynoso, M
   Hughes, JM
   Gwin, JA
   Staab, JS
AF Roberts, Brandon M.
   Geddis, Alyssa V.
   Sczuroski, Cara E.
   Reynoso, Marinaliz
   Hughes, Julie M.
   Gwin, Jess A.
   Staab, Jeffery S.
TI A single, maximal dose of celecoxib, ibuprofen, or flurbiprofen does not
   reduce the muscle signalling response to plyometric exercise in young
   healthy adults
SO EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY
LA English
DT Article
DE Nonsteroidal anti inflammatory drugs; Resistance exercise; Ribosome
   biogenesis; Satellite cells; Skeletal muscle; mTOR; Prostaglandins;
   Protein synthesis
ID HUMAN SKELETAL MUSCLE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SATELLITE
   CELL PROLIFERATION; ACUTE RESISTANCE EXERCISE; COX INHIBITING DRUGS;
   CYCLOOXYGENASE 1 AND 2; INTERSTITIAL FLUID; PROTEIN SYNTHESIS;
   HYPERTROPHY; PHOSPHORYLATION
AB Background Non steroidal anti inflammatory drugs (NSAIDs) possess analgesic and anti inflammatory properties by inhibiting cyclooxygenase (COX) enzymes. Conflicting evidence exists on whether NSAIDs influence signaling related to muscle adaptations and exercise with some research finding a reduction in muscle protein synthesis signaling via the AKT mTOR pathway, changes in satellite cell signaling, reductions in muscle protein degradation, and reductions in cell proliferation. In this study, we determined if a single maximal dose of flurbiprofen (FLU), celecoxib (CEL), ibuprofen (IBU), or a placebo (PLA) affects the short term muscle signaling responses to plyometric exercise. Methods This was a block randomized, double masked, crossover design, where 12 participants performed four plyometric exercise bouts consisting of 10 sets of 10 plyometric jumps at 40% 1RM. Two hours before exercise, participants consumed a single dose of celecoxib (CEL 200 mg), IBU (800 mg), FLU (100 mg) or PLA with food. Muscle biopsy samples were collected before and 3 h after exercise from the vastus lateralis. Data were analyzed using a repeated measures (RM) ANOVA, ANOVA, or a Friedman test. Significance was considered at p < 0.05. Results We found no treatment effects on the mRNA expression of PTSG1, PTSG2, MYC, TBP, RPLOP, MYOD1, Pax7, MYOG, Atrogin 1, or MURF1 (all, p > 0.05). We also found no treatment effects on AKT mTOR signaling or MAPK signaling measured through the phosphorylation status of mTORS2441, mTORS2448, RPS6 235/236, RPS 240/244, 4EBP1, ERK1/2, p38 T180/182 normalized to their respective total abundance (all, p > 0.05). However, we did find a significant difference between MNK1 T197/202 in PLA compared to FLU (p < .05). Conclusion A single, maximal dose of IBU, CEL, or FLU taken prior to exercise did not affect the signaling of muscle protein synthesis, protein degradation, or ribosome biogenesis three hours after a plyometric training bout.
C1 [Roberts, Brandon M.; Geddis, Alyssa V.; Sczuroski, Cara E.; Reynoso, Marinaliz; Hughes, Julie M.; Staab, Jeffery S.] US Army Res Inst Environm Med, Mil Performance Div, 10 Gen Greene Ave, Bldg 42, Natick, MA 01760 USA.
   [Gwin, Jess A.] US Army Res Inst Environm Med, Mil Nutr Div, 10 Gen Greene Ave, Bldg 42, Natick, MA 01760 USA.
C3 United States Department of Defense; United States Army; United States
   Department of Defense; United States Army
RP Roberts, BM (通讯作者)，US Army Res Inst Environm Med, Mil Performance Div, 10 Gen Greene Ave, Bldg 42, Natick, MA 01760 USA.
EM Brandon.m.roberts38.mil@health.mil
RI Staab, Jeffery/MNP 9286 2025; Roberts, Brandon/H 4504 2019; Hughes,
   Julie/MFH 7731 2025
OI Roberts, Brandon M./0000 0003 0395 6967; 
FU Military Operational Medicine Research Program
FX No Statement Available
CR Alaranta A, 2008, SPORTS MED, V38, P449, DOI 10.2165/00007256 200838060 00002
   Baar K, 1999, AM J PHYSIOL CELL PH, V276, pC120, DOI 10.1152/ajpcell.1999.276.1.C120
   Bamman MM, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a029751
   Bolster DR, 2003, J PHYSIOL LONDON, V553, P213, DOI 10.1113/jphysiol.2003.047019
   Bondesen BA, 2004, AM J PHYSIOL CELL PH, V287, pC475, DOI 10.1152/ajpcell.00088.2004
   Brewer CB, 2014, J STRENGTH COND RES, V28, P74, DOI 10.1519/JSC.0b013e318291ba98
   Buford TW, 2009, APPL PHYSIOL NUTR ME, V34, P745, DOI 10.1139/H09 067
   Burd NA, 2010, AM J PHYSIOL ENDOC M, V298, pE354, DOI 10.1152/ajpendo.00423.2009
   Carroll CC, 2013, AM J PHYSIOL REG I, V305, pR24, DOI 10.1152/ajpregu.00593.2012
   Cashman JN, 1996, DRUGS, V52, P13, DOI 10.2165/00003495 199600525 00004
   Chaillou T, 2014, J CELL PHYSIOL, V229, P1584, DOI 10.1002/jcp.24604
   Davis JS, 2017, OPEN HEART, V4, DOI 10.1136/openhrt 2016 000550
   Deldicque L, 2008, EUR J APPL PHYSIOL, V104, P57, DOI 10.1007/s00421 008 0786 7
   Drummond MJ, 2009, J APPL PHYSIOL, V106, P1374, DOI 10.1152/japplphysiol.91397.2008
   Egerman MA, 2014, CRIT REV BIOCHEM MOL, V49, P59, DOI 10.3109/10409238.2013.857291
   Galpin AJ, 2012, APPL PHYSIOL NUTR ME, V37, P80, DOI [10.1139/H11 131, 10.1139/h11 131]
   Gehlert S, 2015, PFLUG ARCH EUR J PHY, V467, P1343, DOI 10.1007/s00424 014 1579 y
   Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550
   Haddad F, 2004, J APPL PHYSIOL, V96, P203, DOI 10.1152/japplphysiol.00856.2003
   Krentz JR, 2008, APPL PHYSIOL NUTR ME, V33, P470, DOI 10.1139/H08 019
   Langenbach R, 1999, BIOCHEM PHARMACOL, V58, P1237, DOI 10.1016/S0006 2952(99)00158 6
   Lilja M, 2018, ACTA PHYSIOL, V222, DOI 10.1111/apha.12948
   Lilja M, 2023, J APPL PHYSIOL, V134, P753, DOI 10.1152/japplphysiol.00698.2022
   Lim C, 2022, MED SCI SPORT EXER, V54, P1546, DOI 10.1249/MSS.0000000000002929
   Lundberg TR, 2018, SCAND J MED SCI SPOR, V28, P2252, DOI 10.1111/sms.13275
   Mackey AL, 2007, J APPL PHYSIOL, V103, P425, DOI 10.1152/japplphysiol.00157.2007
   Mackey AL, 2016, FASEB J, V30, P2266, DOI 10.1096/fj.201500198R
   Mackey AL, 2013, J APPL PHYSIOL, V115, P900, DOI 10.1152/japplphysiol.00044.2013
   Markworth JF, 2014, J APPL PHYSIOL, V117, P20, DOI 10.1152/japplphysiol.01299.2013
   Markworth JF, 2011, AM J PHYSIOL CELL PH, V300, pC671, DOI 10.1152/ajpcell.00549.2009
   Matheny RW, 2022, PHYSIOL REP, V10, DOI 10.14814/phy2.15481
   Mendias CL, 2004, MUSCLE NERVE, V30, P497, DOI 10.1002/mus.20102
   Mikkelsen UR, 2009, J APPL PHYSIOL, V107, P1600, DOI 10.1152/japplphysiol.00707.2009
   Nindl BC, 2012, AM J PHYSIOL REG I, V303, pR1080, DOI 10.1152/ajpregu.00275.2012
   Novak ML, 2009, AM J PHYSIOL REG I, V296, pR1132, DOI 10.1152/ajpregu.90874.2008
   Prisk V, 2003, HISTOL HISTOPATHOL, V18, P1243, DOI 10.14670/HH 18.1243
   Roberts BM, 2024, J SCI MED SPORT, V27, P287, DOI 10.1016/j.jsams.2024.02.002
   Roberts BM, 2024, J INT SOC SPORT NUTR, V21, DOI 10.1080/15502783.2024.2302046
   Roberts BM, 2023, J INT SOC SPORT NUTR, V20, DOI 10.1080/15502783.2022.2164209
   Roberts MD, 2023, PHYSIOL REV, V103, P2679, DOI 10.1152/physrev.00039.2022
   Schoenfeld BJ, 2012, SPORTS MED, V42, P1017, DOI 10.2165/11635190 000000000 00000
   Shi H, 2009, AM J PHYSIOL CELL PH, V296, pC1040, DOI 10.1152/ajpcell.00475.2008
   Smyth EM, 2009, J LIPID RES, V50, pS423, DOI 10.1194/jlr.R800094 JLR200
   Sostres C, 2010, BEST PRACT RES CL GA, V24, P121, DOI 10.1016/j.bpg.2009.11.005
   Sterczala AJ, 2022, J APPL PHYSIOL, V133, P170, DOI 10.1152/japplphysiol.00592.2021
   Taylor LW, 2012, J STRENGTH COND RES, V26, P599, DOI 10.1519/JSC.0b013e318242f92d
   Trappe RA, 2002, AM J PHYSIOL ENDOC M, V282, pE551, DOI 10.1152/ajpendo.00352.2001
   Trappe TA, 2001, J CLIN ENDOCR METAB, V86, P5067, DOI 10.1210/jc.86.10.5067
   Trappe TA, 2013, J APPL PHYSIOL, V115, P909, DOI 10.1152/japplphysiol.00061.2013
   Urso ML, 2013, J APPL PHYSIOL, V115, P920, DOI 10.1152/japplphysiol.00036.2013
   VANE JR, 1995, INFLAMM RES, V44, P1, DOI 10.1007/BF01630479
   Walker LA, 2017, MIL MED, V182, pE1709, DOI 10.7205/MILMED D 16 00183
   Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563
   Weinheimer EM, 2007, AM J PHYSIOL REG I, V292, pR2241, DOI 10.1152/ajpregu.00718.2006
   Zhou YJ, 2014, PHARMACOEPIDEM DR S, V23, P43, DOI 10.1002/pds.3463
   Ziltener J.  L., 2010, Annals of Physical and Rehabilitation Medicine, V53, P278, DOI 10.1016/j.rehab.2010.03.001
NR 56
TC 0
Z9 0
U1 1
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1439 6319
EI 1439 6327
J9 EUR J APPL PHYSIOL
JI Eur. J. Appl. Physiol.
PD DEC
PY 2024
VL 124
IS 12
BP 3607
EP 3617
DI 10.1007/s00421 024 05565 5
EA JUL 2024
PG 11
WC Physiology; Sport Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology; Sport Sciences
GA M3A1Q
UT WOS:001275220200001
PM 39044030
DA 2025 08 17
ER

PT J
AU Fan, SH
   Cai, YL
   Wei, YQ
   Yang, J
   Gao, JM
   Yang, Y
AF Fan, Shangheng
   Cai, Yulan
   Wei, Yunqin
   Yang, Jia
   Gao, Jianmei
   Yang, Yan
TI Sarcopenic obesity and osteoporosis: Research progress and hot spots
SO EXPERIMENTAL GERONTOLOGY
LA English
DT Article
DE Sarcopenic obesity; Osteoporosis; Metabolic disorder; Holistic treatment
ID WHOLE BODY VIBRATION; BONE MINERAL DENSITY; IMPROVES INSULIN
   SENSITIVITY; BETA AMINOISOBUTYRIC ACID; MESENCHYMAL STEM CELLS;
   POSTMENOPAUSAL WOMEN; SKELETAL MUSCLE; OSTEOCLAST FORMATION;
   ADIPOSE TISSUE; OLDER ADULTS
AB Sarcopenic obesity (SO) and osteoporosis (OP) are associated with aging and obesity. The pathogenesis of SO is complex, including glucolipid and skeletal muscle metabolic disorders caused by inflammation, insulin resistance, and other factors. Growing evidence links muscle damage to bone loss. Muscle lipid metabolism disorders of SO disrupt the balance between bone formation and bone resorption, increasing the risk of OP. Conversely, bones also play a role in fat and muscle metabolism. In the context of aging and obesity, the comprehensive review focuses on the effects of mechanical stimulation, mesenchymal stem cells (MSCs), chronic inflammation, myokines, and adipokines on musculoskeletal, at the same time, the impact of osteokines on muscle lipid metabolism were also analyzed. So far, exercise combined with diet therapy is the most effective strategy for increasing musculoskeletal mass. A holistic treatment of musculoskeletal diseases is still in the preliminary exploration stage. Therefore, this article aims to improve the understanding of musculoskeletal  fat interactions in SO and OP, explores targets that can provide holistic treatment for SO combined with OP, and discusses current limitations and challenges. We hope to provide relevant ideas for developing specific therapies and improving disease prognosis in the future.
C1 [Fan, Shangheng; Cai, Yulan; Wei, Yunqin; Yang, Jia; Yang, Yan] Zunyi Med Univ, Affiliated Hosp 2, Dept Endocrinol & Metab, Zunyi, Peoples R China.
   [Fan, Shangheng; Gao, Jianmei] Zunyi Med Univ, Key Lab Basic Pharmacol, Minist Educ, Zunyi, Peoples R China.
   [Fan, Shangheng; Gao, Jianmei] Zunyi Med Univ, Joint Int Res Lab Ethnomed, Minist Educ, Zunyi, Peoples R China.
   [Fan, Shangheng; Gao, Jianmei] Zunyi Med Univ, Sch Pharm, Key Lab Basic Pharmacol, Zunyi, Peoples R China.
   [Fan, Shangheng; Gao, Jianmei] Zunyi Med Univ, Sch Pharm, Zunyi 563000, Peoples R China.
C3 Zunyi Medical University; Zunyi Medical University; Zunyi Medical
   University; Zunyi Medical University; Zunyi Medical University
RP Gao, JM (通讯作者)，Zunyi Med Univ, Sch Pharm, Zunyi 563000, Peoples R China.; Gao, JM (通讯作者)，Zunyi Med Univ, Dept Pharmacol, Key Lab Basic Pharmacol,Minist Educ, Key Lab Basic Pharmacol Guizhou Prov, Zunyi 563000, Peoples R China.; Gao, JM (通讯作者)，Zunyi Med Univ, Dept Pharmacol, Joint Int Res Lab Ethnomed, Minist Educ, Zunyi 563000, Peoples R China.; Yang, Y (通讯作者)，Zunyi Med Univ, Dept Endocrinol & Metab, Affiliated Hosp 2, Zunyi 563000, Guizhou, Peoples R China.
EM gaojianmei@zmu.edu.cn; 2006yangyan80@163.com
FU National Natural Science Foundation of China [82060159, 82260167];
   Natural Science Foundation of Guiz hou Province [[2020] 1Y314]; Science
   and Technology Program of Guizhou Province [[2020] Y010]; Scientific
   research project of Guizhou Dendrobium Industry Development Research
   Center [2019003013]; Science and Technology Department Planning Project
   of Guizhou Province [ZK [2022] General 639]; Zunyi City Joint Fund
   project [Zunyi department combine HZ word] [332]
FX This work was supported by the National Natural Science Foundation of
   China [82060159, 82260167] , Natural Science Foundation of Guizhou
   Province [ [2020] 1Y314] , Science and Technology Program of Guizhou
   Province [ [2020] Y010] , Scientific research project of Guizhou
   Dendrobium Industry Development Research Center [2019003013] , Science
   and Technology Department Planning Project of Guizhou Province [ZK
   [2022] General 639] , and Zunyi City Joint Fund project [Zunyi
   department combine HZ word [2022] No. 332] .
CR Abbenhardt C, 2013, J INTERN MED, V274, P163, DOI 10.1111/joim.12062
   Aggarwal R, 2022, CRIT REV FOOD SCI, V62, P2548, DOI 10.1080/10408398.2020.1855101
   Ahmed S, 2023, ROY SOC OPEN SCI, V10, DOI 10.1098/rsos.231023
   Pahlavani HA, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.811751
   Almodóvar J, 2014, BIOMATERIALS, V35, P3975, DOI 10.1016/j.biomaterials.2014.01.012
   Amartuvshin O, 2020, AGING CELL, V19, DOI 10.1111/acel.13191
   Ambati S, 2010, ENDOCRINE, V37, P115, DOI 10.1007/s12020 009 9274 z
   Avellaneda J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22058 7
   Axelrod CL, 2023, METABOLISM, V146, DOI 10.1016/j.metabol.2023.155639
   Axmann R, 2009, ARTHRITIS RHEUM US, V60, P2747, DOI 10.1002/art.24781
   Bernkopf DB, 2018, J CELL BIOL, V217, P1383, DOI 10.1083/jcb.201708191
   Blaschke M, 2018, ADV CLIN EXP MED, V27, P45, DOI 10.17219/acem/67561
   Bocelli Tyndall C, 2015, ANN RHEUM DIS, V74, P260, DOI 10.1136/annrheumdis 2013 204235
   Bonnet N, 2019, J CLIN INVEST, V129, P3214, DOI 10.1172/JCI125915
   Boström P, 2012, NATURE, V481, P463, DOI 10.1038/nature10777
   Bouchonville M, 2014, INT J OBESITY, V38, P423, DOI 10.1038/ijo.2013.122
   Brack AS, 2008, CELL STEM CELL, V2, P50, DOI 10.1016/j.stem.2007.10.006
   Brack AS, 2007, SCIENCE, V317, P807, DOI 10.1126/science.1144090
   Bressan E, 2019, MATERIALS, V12, DOI 10.3390/ma12122036
   Cacciatore S, 2023, ANN GERIATR MED RES, V27, P87, DOI 10.4235/agmr.22.0158
   Camporez JPG, 2016, P NATL ACAD SCI USA, V113, P2212, DOI 10.1073/pnas.1525795113
   Candow DG, 2022, BONE, V162, DOI 10.1016/j.bone.2022.116467
   Candow DG, 2021, NUTRIENTS, V13, DOI 10.3390/nu13030745
   Cawthorn WP, 2012, BONE, V50, P477, DOI 10.1016/j.bone.2011.08.010
   Chen LK, 2020, J AM MED DIR ASSOC, V21, P300, DOI 10.1016/j.jamda.2019.12.012
   Chen YX, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01487
   Cho ES, 2012, MOL CELLS, V33, P173, DOI 10.1007/s10059 012 2240 z
   Chung JH, 2016, ANN NUTR METAB, V68, P77, DOI 10.1159/000442004
   Colaianni G, 2015, P NATL ACAD SCI USA, V112, P12157, DOI 10.1073/pnas.1516622112
   Conte C, 2018, ACTA DIABETOL, V55, P305, DOI 10.1007/s00592 018 1101 7
   Dankbar B, 2015, NAT MED, V21, P1085, DOI 10.1038/nm.3917
   de Castro LF, 2023, NEW ENGL J MED, V388, P766, DOI 10.1056/NEJMc2214862
   Deng MY, 2011, INT ORTHOP, V35, P1099, DOI 10.1007/s00264 010 1141 2
   Deutz NEP, 2014, CLIN NUTR, V33, P929, DOI 10.1016/j.clnu.2014.04.007
   Dodd GT, 2015, CELL, V160, P88, DOI 10.1016/j.cell.2014.12.022
   Dong J, 2016, INT J OBESITY, V40, P434, DOI 10.1038/ijo.2015.200
   Donini LM, 2022, CLIN NUTR, V41, P990, DOI 10.1016/j.clnu.2021.11.014
   Dufresne SS, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478 018 0533 1
   Dufresne SS, 2016, AM J PHYSIOL CELL PH, V310, pC663, DOI 10.1152/ajpcell.00285.2015
   Dungan CM, 2020, FASEB J, V34, P7018, DOI 10.1096/fj.202000111RR
   Feng JP, 2022, FRONT PHYSIOL, V13, DOI 10.3389/fphys.2022.882151
   Frechette DM, 2017, ANN NY ACAD SCI, V1409, P33, DOI 10.1111/nyas.13442
   Fu LN, 2005, CELL, V122, P803, DOI 10.1016/j.cell.2005.06.028
   Fusaro M, 2020, NUTRIENTS, V12, DOI 10.3390/nu12123625
   Gandham A, 2021, OBES REV, V22, DOI 10.1111/obr.13187
   Gao QQ, 2021, CLIN NUTR, V40, P4633, DOI 10.1016/j.clnu.2021.06.009
   Ghiotto L, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.913953
   Giannoulis MG, 2012, ENDOCR REV, V33, P314, DOI 10.1210/er.2012 1002
   Gielen E, 2023, METABOLISM, V145, DOI 10.1016/j.metabol.2023.155638
   Goldspink Geoffrey, 2012, J Aging Res, V2012, P158279, DOI 10.1155/2012/158279
   Goodman CA, 2015, BONE, V80, P24, DOI 10.1016/j.bone.2015.04.014
   Gries KJ, 2022, SEMIN CELL DEV BIOL, V123, P57, DOI 10.1016/j.semcdb.2021.10.009
   Hamoudi D, 2020, HUM MOL GENET, V29, P483, DOI 10.1093/hmg/ddz312
   He C, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.585644
   He H, 2016, OSTEOPOROSIS INT, V27, P473, DOI 10.1007/s00198 015 3241 8
   Heng MWY, 2023, BMC GERIATR, V23, DOI 10.1186/s12877 023 04500 1
   Herrmann M, 2019, CURR STEM CELL RES T, V14, P305, DOI 10.2174/1574888X14666190123161447
   Homer Bouthiette C, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 90565 0
   Hong XT, 2022, CELL STEM CELL, V29, P1298, DOI 10.1016/j.stem.2022.07.009
   Huang HS, 2023, ACTA BIOMATER, V157, P609, DOI 10.1016/j.actbio.2022.12.019
   Huang R, 2022, J ORTHOP RES, V40, P2510, DOI 10.1002/jor.25286
   Ilich JZ, 2024, AGEING RES REV, V98, DOI 10.1016/j.arr.2024.102326
   Ilich JZ, 2014, AGEING RES REV, V15, P51, DOI 10.1016/j.arr.2014.02.007
   Imerb N, 2020, MECH AGEING DEV, V191, DOI 10.1016/j.mad.2020.111335
   Infante M, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 018 1001 2
   Ji T, 2022, AGING DIS, V13, P379, DOI 10.14336/AD.2021.1006
   Ji YA, 2022, ANTIOXIDANTS BASEL, V11, DOI 10.3390/antiox11091686
   Jiang F, 2023, BIOACT MATER, V25, P307, DOI 10.1016/j.bioactmat.2023.02.001
   Juffer P, 2012, AM J PHYSIOL ENDOC M, V302, pE389, DOI 10.1152/ajpendo.00320.2011
   Jung TW, 2018, EXP MOL MED, V50, DOI 10.1038/s12276 018 0147 5
   Jung TW, 2015, DIABETOLOGIA, V58, P2096, DOI 10.1007/s00125 015 3663 z
   Kakehi S, 2022, WORLD J MENS HEALTH, V40, P1, DOI 10.5534/wjmh.200190
   Kalinkovich A, 2017, AGEING RES REV, V35, P200, DOI 10.1016/j.arr.2016.09.008
   Kelly OJ, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040747
   Kim H, 2018, CELL, V175, P1756, DOI 10.1016/j.cell.2018.10.025
   Kim M, 2017, J TISSUE ENG REGEN M, V11, P1524, DOI 10.1002/term.2050
   Kim YC, 2023, NUTRIENTS, V15, DOI 10.3390/nu15173854
   Kindler JM, 2016, J CLIN ENDOCR METAB, V101, P198, DOI 10.1210/jc.2015 3451
   Kirk B, 2023, CALCIFIED TISSUE INT, V112, P297, DOI 10.1007/s00223 022 01044 1
   Kirk Ben, 2019, Aging Med (Milton), V2, P147, DOI 10.1002/agm2.12080
   Kitase Y, 2018, CELL REP, V22, P1531, DOI 10.1016/j.celrep.2018.01.041
   Komrakova M, 2022, J ENDOCRINOL INVEST, V45, P2299, DOI 10.1007/s40618 022 01865 9
   Lacour F, 2017, CELL REP, V18, P2320, DOI 10.1016/j.celrep.2017.02.036
   Levinger I, 2014, BONE, V64, P8, DOI 10.1016/j.bone.2014.03.008
   Li HF, 2021, MOL METAB, V54, DOI 10.1016/j.molmet.2021.101358
   Li X, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154677
   Li ZY, 2015, DIABETES, V64, P4011, DOI 10.2337/db15 0274
   Lin YH, 2022, ARCH OSTEOPOROS, V17, DOI 10.1007/s11657 022 01107 8
   Liu HH, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.13035
   Liu HF, 2015, TRIALS, V16, DOI 10.1186/s13063 015 0780 4
   Locatelli V, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/235060
   Ma XY, 2022, AGING US, V14, P5681, DOI 10.18632/aging.204145
   Maeda K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225525
   Marie PJ, 2008, ARCH BIOCHEM BIOPHYS, V473, P98, DOI 10.1016/j.abb.2008.02.030
   Mera P, 2016, MOL METAB, V5, P1042, DOI 10.1016/j.molmet.2016.07.002
   Mera P, 2016, CELL METAB, V23, P1078, DOI 10.1016/j.cmet.2016.05.004
   Muñoz Cánoves P, 2020, FEBS J, V287, P406, DOI 10.1111/febs.15182
   Nishikawa A, 2016, CLIN INTERV AGING, V11, P913, DOI 10.2147/CIA.S107285
   Nunan E, 2022, GEROSCIENCE, V44, P1393, DOI 10.1007/s11357 022 00567 7
   Omosule CL, 2022, J BONE MINER RES, V37, P938, DOI 10.1002/jbmr.4529
   Ono T, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00225 w
   Ormsbee MJ, 2014, J CACHEXIA SARCOPENI, V5, P183, DOI 10.1007/s13539 014 0146 x
   Ozkok S, 2022, CLIN NUTR, V41, P2509, DOI 10.1016/j.clnu.2022.09.005
   Papadopoulou SK, 2021, NUTRIENTS, V13, DOI 10.3390/nu13124499
   Park MJ, 2023, METABOLISM, V144, DOI 10.1016/j.metabol.2023.155577
   Patel VS, 2017, OBESITY, V25, P1745, DOI 10.1002/oby.21958
   Perry RJ, 2016, DIABETOLOGIA, V59, P933, DOI 10.1007/s00125 016 3909 4
   Piao LM, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 02895 z
   Poggiogalle E, 2021, CURR OPIN CLIN NUTR, V24, P33, DOI 10.1097/MCO.0000000000000714
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Rajapakse CS, 2021, J BONE MINER RES, V36, P673, DOI 10.1002/jbmr.4229
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Roberts LD, 2014, CELL METAB, V19, P96, DOI 10.1016/j.cmet.2013.12.003
   Sarabon N, 2020, J CLIN MED, V9, DOI 10.3390/jcm9092902
   Sawakami K, 2006, J BIOL CHEM, V281, P23698, DOI 10.1074/jbc.M601000200
   Sayenko DG, 2010, NEUROSCI LETT, V482, P66, DOI 10.1016/j.neulet.2010.07.009
   Schiaffino S, 2013, FEBS J, V280, P4294, DOI 10.1111/febs.12253
   Scott D, 2017, J BONE MINER RES, V32, P575, DOI 10.1002/jbmr.3016
   Shree N, 2019, INT J OBESITY, V43, P2107, DOI 10.1038/s41366 019 0438 5
   Slatkovska L, 2011, ANN INTERN MED, V155, P668, DOI 10.7326/0003 4819 155 10 201111150 00005
   Stevens JR, 2010, J BONE MINER RES, V25, P2138, DOI 10.1002/jbmr.118
   Suh Joonho, 2020, J Bone Metab, V27, P151
   Tanjaya J, 2022, BIOMATERIALS, V287, DOI 10.1016/j.biomaterials.2022.121609
   Trajanoska K, 2019, CURR OSTEOPOROS REP, V17, P86, DOI 10.1007/s11914 019 00505 1
   Verzola D, 2019, KIDNEY INT, V95, P506, DOI 10.1016/j.kint.2018.10.010
   Villareal DT, 2006, AM J CLIN NUTR, V84, P1317, DOI 10.1093/ajcn/84.6.1317
   von Maltzahn J, 2012, TRENDS CELL BIOL, V22, P602, DOI 10.1016/j.tcb.2012.07.008
   Wallner C, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 10404 z
   Wang BYH, 2023, J CACHEXIA SARCOPENI, V14, P1349, DOI 10.1002/jcsm.13228
   Wang C, 2023, CELL DEATH DIS, V14, DOI 10.1038/s41419 023 05843 8
   Wang FS, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10091394
   Wang JQ, 2023, NPJ REGEN MED, V8, DOI 10.1038/s41536 023 00279 2
   Wu FZ, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.771336
   Wu Q, 2017, CELL PHYSIOL BIOCHEM, V41, P1360, DOI 10.1159/000465455
   Wysocki A, 2011, ANN INTERN MED, V155, P680, DOI 10.7326/0003 4819 155 10 201111150 00006
   Xu WJ, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms241914484
   Yang JM, 2022, ARCH OSTEOPOROS, V17, DOI 10.1007/s11657 022 01120 x
   Yang M, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 53522 6
   Yang YJ, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052604
   Yoo TK, 2013, YONSEI MED J, V54, P1321, DOI 10.3349/ymj.2013.54.6.1321
   Yoshida T, 2020, CELLS BASEL, V9, DOI 10.3390/cells9091970
   Yoshimura N, 2017, OSTEOPOROSIS INT, V28, P189, DOI 10.1007/s00198 016 3823 0
   You YH, 2023, CELL DEATH DIS, V14, DOI 10.1038/s41419 023 05565 x
   Yu LM, 2015, STEM CELLS, V33, P240, DOI 10.1002/stem.1844
   Yue R, 2016, CELL STEM CELL, V18, P782, DOI 10.1016/j.stem.2016.02.015
   Zhang MM, 2023, FRONT PHYSIOL, V14, DOI 10.3389/fphys.2023.1127474
   Zhang Y, 2014, DIABETES, V63, P514, DOI 10.2337/db13 1106
   Zhao P, 2018, EUR REV MED PHARMACO, V22, P3962, DOI 10.26355/eurrev_201806_15280
   Zheng SL, 2023, ACTA PHARM SIN B, V13, P1568, DOI 10.1016/j.apsb.2022.12.008
   Zhou S, 2008, AGING CELL, V7, P335, DOI 10.1111/j.1474 9726.2008.00377.x
   Zhu YQ, 2019, EUR J AGEING, V16, P273, DOI 10.1007/s10433 019 00498 x
   Zoch ML, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.4
NR 152
TC 5
Z9 5
U1 6
U2 18
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0531 5565
EI 1873 6815
J9 EXP GERONTOL
JI Exp. Gerontol.
PD OCT 1
PY 2024
VL 195
AR 112544
DI 10.1016/j.exger.2024.112544
EA AUG 2024
PG 13
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Geriatrics & Gerontology
GA E2F4D
UT WOS:001301210000001
PM 39147076
OA hybrid
DA 2025 08 17
ER

PT J
AU Chu, WX
   Peng, WL
   Lu, YY
   Liu, YS
   Li, QS
   Wang, HB
   Wang, L
   Zhang, BK
   Liu, ZX
   Han, L
   Ma, HD
   Yang, HS
   Han, CF
   Lu, XH
AF Chu, Wenxiang
   Peng, Weilin
   Lu, Yingying
   Liu, Yishan
   Li, Qisheng
   Wang, Haibin
   Wang, Liang
   Zhang, Bangke
   Liu, Zhixiao
   Han, Lin
   Ma, Hongdao
   Yang, Haisong
   Han, Chaofeng
   Lu, Xuhua
TI PRMT6 Epigenetically Drives Metabolic Switch from Fatty Acid Oxidation
   toward Glycolysis and Promotes Osteoclast Differentiation During
   Osteoporosis
SO ADVANCED SCIENCE
LA English
DT Article
DE fatty acids oxidation; glycolysis; metabolic reprogramming;
   osteoclastogenesis; PRMT6
ID ARGININE METHYLATION; HYPOXIA; EXPRESSION; SUPPRESSION; REPRESSION;
   COMPLEX; CANCER; CELLS
AB Epigenetic regulation of metabolism profoundly influences cell fate commitment. During osteoclast differentiation, the activation of RANK signaling is accompanied by metabolic reprogramming, but the epigenetic mechanisms by which RANK signaling induces this reprogramming remain elusive. By transcriptional sequence and ATAC analysis, this study identifies that activation of RANK signaling upregulates PRMT6 by epigenetic modification, triggering a metabolic switching from fatty acids oxidation toward glycolysis. Conversely, Prmt6 deficiency reverses this shift, markedly reducing HIF 1 alpha mediated glycolysis and enhancing fatty acid oxidation. Consequently, PRMT6 deficiency or inhibitor impedes osteoclast differentiation and alleviates bone loss in ovariectomized (OVX) mice. At the molecular level, Prmt6 deficiency reduces asymmetric dimethylation of H3R2 at the promoters of genes including Ppard, Acox3, and Cpt1a, enhancing genomic accessibility for fatty acid oxidation. PRMT6 thus emerges as a metabolic checkpoint, mediating metabolic switch from fatty acid oxidation to glycolysis, thereby supporting osteoclastogenesis. Unveiling PRMT6's critical role in epigenetically orchestrating metabolic shifts in osteoclastogenesis offers a promising target for anti resorptive therapy.
   RANKL induced PRMT6 catalyzes asymmetric dimethylation of H3R2 at key FAO gene promoters (Ppard, Acox3, and Cpt1a), inhibiting FAO. This alleviates FAO's suppressive effect on glycolysis, synergizing with PRMT6's promotion of HIF alpha dependent glycolysis, thus mediating the metabolic shift from FAO to glycolysis and promoting osteoclastogenesis initiation. RANKL: the receptor activator of nuclear factor kappa B ligand. FAO: fatty acids oxidation. image
C1 [Chu, Wenxiang; Peng, Weilin; Liu, Yishan; Li, Qisheng; Wang, Haibin; Wang, Liang; Zhang, Bangke; Ma, Hongdao; Yang, Haisong; Lu, Xuhua] Naval Med Univ, Changzheng Hosp, Dept Orthopaed, Shanghai 200003, Peoples R China.
   [Lu, Yingying] Fudan Univ, Obstet & Gynecol Hosp, Shanghai 200011, Peoples R China.
   [Liu, Zhixiao; Han, Chaofeng] Naval Med Univ, Histol & Embryol Dept, Shanghai 200433, Peoples R China.
   [Liu, Zhixiao; Han, Chaofeng] Naval Med Univ, Shanghai Key Lab Cell Engn, Shanghai 200433, Peoples R China.
   [Han, Lin] Naval Med Univ, Affiliated Hosp 3, Dept Orthopaed, Shanghai 201805, Peoples R China.
   [Han, Chaofeng] Naval Med Univ, Inst Immunol, Natl Key Lab Immun & Inflammat, Shanghai 200433, Peoples R China.
C3 Naval Medical University; Fudan University; Naval Medical University;
   Naval Medical University; Naval Medical University; Naval Medical
   University
RP Lu, XH (通讯作者)，Naval Med Univ, Changzheng Hosp, Dept Orthopaed, Shanghai 200003, Peoples R China.; Han, CF (通讯作者)，Naval Med Univ, Histol & Embryol Dept, Shanghai 200433, Peoples R China.; Han, CF (通讯作者)，Naval Med Univ, Shanghai Key Lab Cell Engn, Shanghai 200433, Peoples R China.; Han, CF (通讯作者)，Naval Med Univ, Inst Immunol, Natl Key Lab Immun & Inflammat, Shanghai 200433, Peoples R China.
EM hcf@immunol.org; luxuhua@smmu.edu.cn
RI wang, haibin/HPC 4457 2023; liu, zhixiao/F 8809 2015; Ma,
   Hongdao/KCK 5384 2024; Liu, Yang/S 4770 2018; Han, Lin/ABC 9111 2021
OI Liu, Yishan/0009 0007 0156 2354; peng, weilin/0009 0007 7186 3080; Chu,
   Wenxiang/0009 0007 8890 0300; , zhixiao/0000 0003 0794 8462; Han,
   Chaofeng/0000 0002 8489 6478; Han, Lin/0000 0002 3492 8822
FU National Natural Science Foundation of China [81572201, 81802185,
   32170878, 31970853]; Research Projects of Shanghai Changzheng Hospital
   [0901, 2020YCXYJ ZD06]
FX This work was supported by grants from the National Natural Science
   Foundation of China (81572201, 81802185, 32170878 and 31970853) and the
   Research Projects of Shanghai Changzheng Hospital (0901 and
   2020YCXYJ ZD06).
CR Adamik J, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 32849 1
   Ahn H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153886
   Al Hadi H, 2015, ACTA ORTHOP, V86, P264, DOI 10.3109/17453674.2014.964621
   Al Hadi H, 2013, J ORTHOP RES, V31, P1839, DOI 10.1002/jor.22443
   Baba M, 2018, J BONE MINER RES, V33, P1785, DOI 10.1002/jbmr.3477
   Blanc RS, 2017, MOL CELL, V65, P8, DOI 10.1016/j.molcel.2016.11.003
   Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010 1502
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/nmeth.2688, 10.1038/NMETH.2688]
   Crotta S, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 36352 z
   DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002
   Dhawan S, 2011, DEV CELL, V20, P419, DOI 10.1016/j.devcel.2011.03.012
   Di Lorenzo A, 2014, NUCLEIC ACIDS RES, V42, P8297, DOI 10.1093/nar/gku530
   Doi K, 2022, ARTHRITIS RHEUMATOL, V74, P948, DOI 10.1002/art.42074
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   El Andaloussi N, 2006, MOL CELL, V22, P51, DOI 10.1016/j.molcel.2006.02.013
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Friscic J, 2021, IMMUNITY, V54, P1002, DOI 10.1016/j.immuni.2021.03.003
   Fulcher AJ, 2016, BBA MOL CELL RES, V1863, P254, DOI 10.1016/j.bbamcr.2015.11.019
   Gao ZH, 2014, NATURE, V516, P349, DOI 10.1038/nature13921
   Guccione E, 2007, NATURE, V449, P933, DOI 10.1038/nature06166
   Gupta S, 2021, LIFE BASEL, V11, DOI 10.3390/life11090951
   Hiraga T, 2007, CANCER RES, V67, P4157, DOI 10.1158/0008 5472.CAN 06 2355
   Hochrein SM, 2022, CELL METAB, V34, P516, DOI 10.1016/j.cmet.2022.02.015
   Hua T, 2024, BRAIN BEHAV IMMUN, V118, P101, DOI 10.1016/j.bbi.2024.02.027
   Huang D, 2014, CELL REP, V8, P1930, DOI 10.1016/j.celrep.2014.08.028
   Huang TZ, 2021, MOL CELL, V81, DOI 10.1016/j.molcel.2021.01.015
   Indo Y, 2013, J BONE MINER RES, V28, P2392, DOI 10.1002/jbmr.1976
   Jung J, 2019, NAT CELL BIOL, V21, P85, DOI 10.1038/s41556 018 0217 x
   Kasonga AE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125145
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 14511 w
   Lamy O, 2017, J CLIN ENDOCR METAB, V102, P354, DOI 10.1210/jc.2016 3170
   Lee YH, 2012, STEM CELLS DEV, V21, P2613, DOI 10.1089/scd.2011.0330
   Li BE, 2020, FASEB J, V34, P11058, DOI 10.1096/fj.202000771R
   Li X, 2023, NATURE, V622, P619, DOI 10.1038/s41586 023 06585 5
   Li ZF, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03869 4
   Liu HD, 2023, SCI ADV, V9, DOI 10.1126/sciadv.adg0731
   Lucas S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02490 4
   Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054
   Luo YH, 2019, GASTROENTEROLOGY, V157, P744, DOI 10.1053/j.gastro.2019.05.057
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002
   Murata K, 2017, IMMUNITY, V47, P66, DOI 10.1016/j.immuni.2017.06.018
   Nishikawa K, 2015, NAT MED, V21, P281, DOI 10.1038/nm.3774
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   Novotny A, 2023, NUCLEIC ACIDS RES, V51, P2602, DOI 10.1093/nar/gkad117
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012
   Park SH, 2023, METABOLISM, V145, DOI 10.1016/j.metabol.2023.155591
   Park Min KH, 2019, SEMIN IMMUNOPATHOL, V41, P565, DOI 10.1007/s00281 019 00757 0
   Philippe C, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201600219
   Pouysségur J, 2022, SEMIN CANCER BIOL, V86, P334, DOI 10.1016/j.semcancer.2022.07.004
   Qiang LH, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 37148 x
   Ryall JG, 2015, CELL STEM CELL, V17, P651, DOI 10.1016/j.stem.2015.11.012
   Scaramuzzino C, 2015, NEURON, V85, P88, DOI 10.1016/j.neuron.2014.12.031
   Stein C, 2012, NUCLEIC ACIDS RES, V40, P9522, DOI 10.1093/nar/gks767
   Taira TM, 2023, J DENT RES, V102, P440, DOI 10.1177/00220345221141043
   Talkowski ME, 2012, CELL, V149, DOI 10.1016/j.cell.2012.03.028
   Tannahill GM, 2013, NATURE, V496, P238, DOI 10.1038/nature11986
   Taubmann J, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 77892 4
   Tsai KD, 2018, J CELL BIOCHEM, V119, P3404, DOI 10.1002/jcb.26511
   Veis DJ, 2023, ANNU REV PATHOL MECH, V18, P257, DOI 10.1146/annurev pathmechdis 031521 040919
   Wagner A, 2021, CELL, V184, P4168, DOI 10.1016/j.cell.2021.05.045
   Wang HF, 2021, NAT REV MOL CELL BIO, V22, P410, DOI 10.1038/s41580 021 00335 z
   Wickramasinghe NM, 2022, CELL STEM CELL, V29, P559, DOI 10.1016/j.stem.2022.02.011
   Xu C, 2023, METABOLISM, V145, DOI 10.1016/j.metabol.2023.155592
   Yoshimatsu M, 2011, INT J CANCER, V128, P562, DOI 10.1002/ijc.25366
   Zhang H, 2019, CELL MOL IMMUNOL, V16, P800, DOI 10.1038/s41423 018 0057 4
   Zhang YS, 2024, CELL METAB, V36, DOI 10.1016/j.cmet.2023.12.003
   Zhao XX, 2016, J BIOL CHEM, V291, P402, DOI 10.1074/jbc.M115.666347
   Zhu LX, 2023, EMBO J, V42, DOI 10.15252/embj.2022111148
NR 71
TC 6
Z9 7
U1 5
U2 28
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 2198 3844
J9 ADV SCI
JI Adv. Sci.
PD OCT
PY 2024
VL 11
IS 40
DI 10.1002/advs.202403177
EA AUG 2024
PG 19
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA U1N4V
UT WOS:001286654600001
PM 39120025
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Deng, J
   Feng, ZP
   Li, Y
   Pan, TT
   Li, QF
   Zhao, CH
AF Deng, Jing
   Feng, Zhengping
   Li, Yue
   Pan, Tingting
   Li, Qifu
   Zhao, Changhong
TI Efficacy and safety of recombinant human parathyroid hormone (1 34) are
   similar to those of alendronate in the treatment of postmenopausal
   osteoporosis
SO MEDICINE
LA English
DT Article
DE alendronate; bone mineral density; postmenopausal osteoporosis;
   recombinant human parathyroid hormone
ID ENDOTHELIAL GROWTH FACTOR; BONE MINERAL DENSITY; DOUBLE BLIND;
   TERIPARATIDE; WOMEN; MECHANISMS; RESORPTION; THERAPIES; BISPHOSPHONATES;
   ANGIOGENESIS
AB The study evaluates efficacy and safety of recombinant human parathyroid hormone (1 34) [rhPTH (1 34)] and alendronate (ALN) in the treatment of postmenopausal osteoporosis.
   Totally 65 postmenopausal women with osteoporosis were divided into 2 groups. PTH group received daily subcutaneous injection of rhPTH (1 34), and ALN group were treated orally with ALN per week. Bone mineral density (BMD) of lumbar spine (1 4), femoral neck, and total hip, serum levels of calcium, phosphorus, total cholesterol, triglyceride, alkaline phosphatase (ALP), N terminal propeptide of type I collagen (PINP), and C telopeptide of type I collagen (CTX) were tested before treatment and at week 24 and 48 after treatment. Serum levels of vascular endothelial growth factor (VEGF) and platelet derived growth factor BB (PDGF BB) were measured before treatment and at week 48 after treatment.
   The rhPTH (1 34) increased BMD of lumbar spine (1 4), but decreased BMD of femoral neck and total hip at week 48 after treatment. By contrast, ALN enhanced BMD of lumbar spine (1 4) and femoral neck, but reduced BMD of total hip at week 48 after treatment. In PTH group, serum levels of PINP, ALP, and beta CTX were significantly elevated above baseline at week 24 and 48 after treatment. Treatment with ALN decreased levels of PINP, ALP, and beta CTX compared with baseline at week 24 and 48 after treatment. rhPTH (1 34) and ALN significantly decreased levels of PDGF BB, but not levels of VEGF. rhPTH (1 34) increased levels of calcium, phosphorus and triglyceride, but decreased levels of total cholesterol. ALN increased levels of calcium and triglyceride, but reduced levels of phosphorus and total cholesterol. rhPTH (1 34) and ALN were safe in the treatment of postmenopausal osteoporosis.
   The study demonstrates that efficacy of rhPTH (1 34) on BMD of lumbar spine (1 4) is similar to that of alendronate in the treatment of postmenopausal osteoporosis. The effect of rhPTH (1 34) on BMD of femoral neck or total hip is weaker than that of ALN. In addition, rhPTH (1 34) increases BMD of lumbar spine (1 4) maybe by raising serum levels of VEGF, but reduces BMD of femoral neck and total hip maybe by decreasing serum levels of PDGF BB.
C1 [Deng, Jing; Feng, Zhengping; Li, Yue; Pan, Tingting; Li, Qifu; Zhao, Changhong] Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrinol, 1 Youyi Rd, Chongqing 400016, Peoples R China.
C3 Chongqing Medical University
RP Feng, ZP (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrinol, 1 Youyi Rd, Chongqing 400016, Peoples R China.
EM fengzhengping@sina.com
FU National Key Clinical Specialties Construction Program of China; Science
   Foundation of Chongqing Municipal Heath Bureau [2012 2 041]
FX The study was supported by the National Key Clinical Specialties
   Construction Program of China and the Science Foundation of Chongqing
   Municipal Heath Bureau (no: 2012 2 041).
CR Alonso V, 2008, J CELL PHYSIOL, V217, P717, DOI 10.1002/jcp.21547
   Augustine M, 2013, CURR OSTEOPOROS REP, V11, P400, DOI 10.1007/s11914 013 0171 2
   Body JJ, 2002, J CLIN ENDOCR METAB, V87, P4528, DOI 10.1210/jc.2002 020334
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Costa N, 2009, CYTOKINE, V46, P376, DOI 10.1016/j.cyto.2009.03.012
   Drake MT, 2011, BONE, V49, P349, DOI 10.1016/j.bone.2011.05.003
   Esbrit P, 2000, J AM SOC NEPHROL, V11, P1085, DOI 10.1681/ASN.V1161085
   Gatti Davide, 2015, Expert Opin Pharmacother, V16, P2409, DOI 10.1517/14656566.2015.1087506
   Giusti A, 2015, CLIN INTERV AGING, V10, P105, DOI 10.2147/CIA.S44057
   Hintze Gerhard, 2016, Med Monatsschr Pharm, V39, P228
   Horner A, 2001, BONE, V28, P65, DOI 10.1016/S8756 3282(00)00422 1
   Hu K, 2016, BONE, V91, P30, DOI 10.1016/j.bone.2016.06.013
   Hu K, 2016, J CLIN INVEST, V126, P509, DOI 10.1172/JCI82585
   Huang HC, 2016, AM J ORTHOD DENTOFAC, V149, P366, DOI 10.1016/j.ajodo.2015.09.021
   Huang TW, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003626
   Isogai Y, 2015, CALCIFIED TISSUE INT, V97, P412, DOI 10.1007/s00223 015 0026 1
   Iwamoto Jun, 2015, English, V1, P63, DOI 10.1016/j.afos.2015.07.004
   Jabalee J, 2015, DEV BIOL, V406, P52, DOI 10.1016/j.ydbio.2015.07.014
   Jackson RD, 2014, SEMIN REPROD MED, V32, P454, DOI 10.1055/s 0034 1384629
   Li Jun, 2015, Zhongguo Gu Shang, V28, P446
   McClung MR, 2005, ARCH INTERN MED, V165, P1762, DOI 10.1001/archinte.165.15.1762
   Migliore A, 2012, CURR MED RES OPIN, V28, P467, DOI 10.1185/03007995.2012.659724
   Miyauchi A, 2010, BONE, V47, P493, DOI 10.1016/j.bone.2010.05.022
   Passeri E, 2015, J BIOL REG HOMEOS AG, V29, P931
   Ponnapakkam T, 2014, DRUG DISCOV TODAY, V19, P204, DOI 10.1016/j.drudis.2013.07.015
   Rahman MM, 2015, BIOCHEM BIOPH RES CO, V462, P159, DOI 10.1016/j.bbrc.2015.04.115
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Rossini M, 2015, ENDOCRINE, V49, P620, DOI 10.1007/s12020 014 0506 5
   Schafer AL, 2011, J CLIN ENDOCR METAB, V96, pE1982, DOI 10.1210/jc.2011 0587
   Shen L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022494
   SISSONS HA, 1984, CALCIFIED TISSUE INT, V36, P711, DOI 10.1007/BF02405394
   Song JF, 2014, MED SCI MONITOR, V20, P2624, DOI 10.12659/MSM.892581
   STAUFFER M, 1973, AM J PHYSIOL, V225, P269, DOI 10.1152/ajplegacy.1973.225.2.269
   Sugiyama T, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00006
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Xu ZG, 2017, AM J THER, V24, pE130, DOI 10.1097/MJT.0000000000000446
   Yang Y, 2015, ASIAN PAC J TROP MED, V8, P79, DOI 10.1016/S1995 7645(14)60192 9
   Yu TS, 2016, DIS MODEL MECH, V9, P155, DOI 10.1242/dmm.019091
NR 38
TC 10
Z9 13
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025 7974
EI 1536 5964
J9 MEDICINE
JI Medicine (Baltimore)
PD NOV
PY 2018
VL 97
IS 47
AR e13341
DI 10.1097/MD.0000000000013341
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA HD3ZK
UT WOS:000452464700055
PM 30461654
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Peng, JF
   Zhao, JJ
   Tang, QM
   Wang, JY
   Song, WC
   Lu, XF
   Huang, XF
   Chen, GJ
   Zheng, WH
   Zhang, LY
   Han, YY
   Yan, CZ
   Wan, Q
   Chen, LL
AF Peng, Jinfeng
   Zhao, Jiajia
   Tang, Qingming
   Wang, Jinyu
   Song, Wencheng
   Lu, Xiaofeng
   Huang, Xiaofei
   Chen, Guangjin
   Zheng, Wenhao
   Zhang, Luoying
   Han, Yunyun
   Yan, Chunze
   Wan, Qian
   Chen, Lili
TI Low intensity near infrared light promotes bone regeneration via
   circadian clock protein cryptochrome 1
SO INTERNATIONAL JOURNAL OF ORAL SCIENCE
LA English
DT Article
ID LEVEL LASER THERAPY; MESENCHYMAL STEM CELLS; MAMMALIAN CRY1; EXPRESSION;
   ATHEROSCLEROSIS; OSTEOGENESIS; RADIATION; GENES
AB Bone regeneration remains a great clinical challenge. Low intensity near infrared (NIR) light showed strong potential to promote tissue regeneration, offering a promising strategy for bone defect regeneration. However, the effect and underlying mechanism of NIR on bone regeneration remain unclear. We demonstrated that bone regeneration in the rat skull defect model was significantly accelerated with low intensity NIR stimulation. In vitro studies showed that NIR stimulation could promote the osteoblast differentiation in bone mesenchymal stem cells (BMSCs) and MC3T3 E1 cells, which was associated with increased ubiquitination of the core circadian clock protein Cryptochrome 1 (CRY1) in the nucleus. We found that the reduction of CRY1 induced by NIR light activated the bone morphogenetic protein (BMP) signaling pathways, promoting SMAD1/5/9 phosphorylation and increasing the expression levels of Runx2 and Osterix. NIR light treatment may act through sodium voltage gated channel Scn4a, which may be a potential responder of NIR light to accelerate bone regeneration. Together, these findings suggest that low intensity NIR light may promote in situ bone regeneration in a CRY1 dependent manner, providing a novel, efficient and non invasive strategy to promote bone regeneration for clinical bone defects.
C1 [Peng, Jinfeng; Zhao, Jiajia; Tang, Qingming; Song, Wencheng; Lu, Xiaofeng; Huang, Xiaofei; Chen, Guangjin; Zheng, Wenhao; Chen, Lili] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Stomatol, Wuhan, Peoples R China.
   [Peng, Jinfeng; Zhao, Jiajia; Tang, Qingming; Wang, Jinyu; Song, Wencheng; Lu, Xiaofeng; Huang, Xiaofei; Chen, Guangjin; Zheng, Wenhao; Chen, Lili] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Stomatol, Wuhan, Peoples R China.
   [Peng, Jinfeng; Zhao, Jiajia; Tang, Qingming; Wang, Jinyu; Song, Wencheng; Lu, Xiaofeng; Huang, Xiaofei; Chen, Guangjin; Zheng, Wenhao; Chen, Lili] Hubei Prov Key Lab Oral & Maxillofacial Dev & Reg, Wuhan, Peoples R China.
   [Zhang, Luoying] Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Key Lab Mol Biophys, Minist Educ, Wuhan, Peoples R China.
   [Han, Yunyun] Huazhong Univ Sci & Technol, Dept Neurobiol, Sch Basic Med, Wuhan, Peoples R China.
   [Han, Yunyun] Huazhong Univ Sci & Technol, Tongji Med Coll, Wuhan, Peoples R China.
   [Yan, Chunze] Huazhong Univ Sci & Technol, Sch Mat Sci & Engn, State Key Lab Mat Proc & Die & Mould Technol, Wuhan, Peoples R China.
   [Wan, Qian] Huazhong Univ Sci & Technol, Sch Pharm, Hubei Key Lab Nat Med Chem & Resource Evaluat, Wuhan, Peoples R China.
C3 Huazhong University of Science & Technology; Huazhong University of
   Science & Technology; Huazhong University of Science & Technology;
   Huazhong University of Science & Technology; Huazhong University of
   Science & Technology; Huazhong University of Science & Technology;
   Huazhong University of Science & Technology
RP Chen, LL (通讯作者)，Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Stomatol, Wuhan, Peoples R China.; Chen, LL (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Stomatol, Wuhan, Peoples R China.; Chen, LL (通讯作者)，Hubei Prov Key Lab Oral & Maxillofacial Dev & Reg, Wuhan, Peoples R China.
EM chenlili1030@hust.edu.cn
RI Yan, Chunze/IAQ 2618 2023; Chen, Lili/HJY 7871 2023; Zheng,
   Wenhao/KBR 3871 2024; Han, Yunyun/O 2092 2013; Wan, Qian/O 5515 2014
OI Chen, Lili/0000 0002 9965 8990; Peng, Jinfeng/0000 0002 7438 3337; Chen,
   Guangjin/0009 0006 1551 0996; Han, Yunyun/0000 0003 2336 167X; 
FU National Key Research and Development Program of China [2021YFC2400404];
   Key Program of National Natural Science of China [82030070]; National
   Science Foundation for Excellent Young Scholars of China [31725011];
   Youth Clinical Research Fund of Chinese Stomatological Association
   [CSA O2020 10]
FX This work was funded by the National Key Research and Development
   Program of China (2021YFC2400404, to L.C.), the Key Program of National
   Natural Science of China (82030070, to L.C.), the National Science
   Foundation for Excellent Young Scholars of China (31725011, to L.C.),
   and the Youth Clinical Research Fund of Chinese Stomatological
   Association (CSA O2020 10, to Q.T.).
CR Agas D, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22147586
   Al Shammari AM, 2019, EGYPT J NEUROL PSYCH, V55, DOI 10.1186/s41983 018 0047 6
   Allada R, 2021, NEW ENGL J MED, V384, P550, DOI 10.1056/NEJMra1802337
   Antebi YE, 2017, CELL, V170, P1184, DOI 10.1016/j.cell.2017.08.015
   Bai J, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02493 5
   Bass J, 2016, SCIENCE, V354, P994, DOI 10.1126/science.aah4965
   Busino L, 2007, SCIENCE, V316, P900, DOI 10.1126/science.1141194
   Campana V, 2014, J MATER SCI MATER M, V25, P2445, DOI 10.1007/s10856 014 5240 2
   Campbell SS, 1998, SCIENCE, V279, P396, DOI 10.1126/science.279.5349.396
   Chaves I, 2006, MOL CELL BIOL, V26, P1743, DOI 10.1128/MCB.26.5.1743 1753.2006
   Chen L, 2019, NAT GENET, V51, P777, DOI 10.1038/s41588 019 0384 0
   Chen Q, 2019, ADV MATER, V31, DOI 10.1002/adma.201900192
   Chiou YY, 2016, P NATL ACAD SCI USA, V113, pE6072, DOI 10.1073/pnas.1612917113
   Cho S, 2009, J INVEST DERM SYMP P, V14, P15, DOI 10.1038/jidsymp.2009.7
   Choi K, 2013, J BIOMED MATER RES B, V101B, P919, DOI 10.1002/jbm.b.32897
   Chow Renee Wei Yan, 2017, F1000Res, V6, DOI 10.12688/f1000research.10617.1
   Cipitria A, 2017, ACTA BIOMATER, V60, P50, DOI 10.1016/j.actbio.2017.07.032
   Czarna A, 2013, CELL, V153, P1394, DOI 10.1016/j.cell.2013.05.011
   De Santis R, 2009, WOODHEAD PUBL MATER, P252
   Diamantino AG, 2017, LASER MED SCI, V32, P1041, DOI 10.1007/s10103 017 2205 y
   Dibner C, 2010, ANNU REV PHYSIOL, V72, P517, DOI 10.1146/annurev physiol 021909 135821
   dos Santos KW, 2022, LASER MED SCI, V37, P1727, DOI 10.1007/s10103 021 03423 w
   Fu LN, 2005, CELL, V122, P803, DOI 10.1016/j.cell.2005.06.028
   Gaharwar AK, 2020, NAT REV MATER, V5, P686, DOI 10.1038/s41578 020 0209 x
   Glavas H, 2018, J COSMET LASER THER, V20, P269, DOI 10.1080/14764172.2017.1406607
   Grimm C, 2000, INVEST OPHTH VIS SCI, V41, P3984
   Gunji H, 2018, LASER SURG MED, V50, P772, DOI 10.1002/lsm.22797
   Guntur AR, 2011, ANN NY ACAD SCI, V1237, P58, DOI 10.1111/j.1749 6632.2011.06213.x
   Haltaufderhyde K, 2015, PHOTOCHEM PHOTOBIOL, V91, P117, DOI 10.1111/php.12354
   Hashmi JT, 2010, PM&R, V2, pS292, DOI 10.1016/j.pmrj.2010.10.013
   Hatori M, 2010, CELL RES, V20, P1285, DOI 10.1038/cr.2010.152
   He Y, 2013, CELL PROLIFERAT, V46, P644, DOI 10.1111/cpr.12075
   Hirano A, 2017, CELL REP, V19, P255, DOI 10.1016/j.celrep.2017.03.041
   Hirota T, 2012, SCIENCE, V337, P1094, DOI 10.1126/science.1223710
   Holt BD, 2017, WIRES NANOMED NANOBI, V9, DOI 10.1002/wnan.1437
   Huang YY, 2011, DOSE RESPONSE, V9, P602, DOI 10.2203/dose response.11 009.Hamblin
   Huang ZF, 2020, MOL MED REP, V21, P1590, DOI 10.3892/mmr.2020.10954
   Ip D, 2015, CLIN INTERV AGING, V10, P1255, DOI 10.2147/CIA.S86907
   Jaitovich A, 2010, BBA MOL BASIS DIS, V1802, P1140, DOI 10.1016/j.bbadis.2010.03.009
   Katakawa Y, 2016, J CELL BIOCHEM, V117, P1788, DOI 10.1002/jcb.25478
   Kim YY, 2022, DIABETES, V71, P1373, DOI 10.2337/db21 0649
   Kim YJ, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10101590
   Levraut J, 2001, CRIT CARE MED, V29, P1033, DOI 10.1097/00003246 200105000 00032
   Lieben Liesbet, 2016, Nat Rev Rheumatol, V12, P132, DOI 10.1038/nrrheum.2016.10
   Liu Y, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201703771
   Ma L, 2020, MATER TODAY, V36, P48, DOI 10.1016/j.mattod.2019.12.005
   Mao WB, 2022, PHARMACOL RES, V179, DOI 10.1016/j.phrs.2022.106205
   McElderry JDP, 2013, J BONE MINER RES, V28, P1846, DOI 10.1002/jbmr.1924
   Melo MD, 2015, CLIN REHABIL, V29, P570, DOI 10.1177/0269215514552082
   Metin R, 2018, LASER MED SCI, V33, P1699, DOI 10.1007/s10103 018 2523 8
   Mohamad SA, 2021, PHOTOCH PHOTOBIO SCI, V20, P699, DOI 10.1007/s43630 021 00047 5
   Nagata MJH, 2013, J PHOTOCH PHOTOBIO B, V121, P6, DOI 10.1016/j.jphotobiol.2013.01.013
   Nagel G, 2003, P NATL ACAD SCI USA, V100, P13940, DOI 10.1073/pnas.1936192100
   Nam D, 2015, J CELL SCI, V128, P1835, DOI 10.1242/jcs.167643
   Narasimamurthy R, 2012, P NATL ACAD SCI USA, V109, P12662, DOI 10.1073/pnas.1209965109
   Nelidova D, 2020, SCIENCE, V368, P1108, DOI 10.1126/science.aaz5887
   Nemoto E, 2012, BIOCHEM BIOPH RES CO, V422, P627, DOI 10.1016/j.bbrc.2012.05.039
   Okano S, 2009, NEUROSCI LETT, V451, P246, DOI 10.1016/j.neulet.2009.01.014
   OKUNO T, 1994, ANN OCCUP HYG, V38, P351
   Paoletti P, 2019, NAT REV NEUROSCI, V20, P514, DOI 10.1038/s41583 019 0197 2
   Parico GCG, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964 020 00665 z
   Park IS, 2014, BIOMATERIALS, V35, P9280, DOI 10.1016/j.biomaterials.2014.07.061
   Park JH, 2021, LASER MED SCI, V36, P843, DOI 10.1007/s10103 020 03123 x
   Prabhakar S.S., 2012, MED SECRETS, V5
   Salehpour F, 2019, PHOTOBIOMOD PHOTOMED, V37, P581, DOI 10.1089/photob.2019.4676
   Sanders DW, 2014, J ORTHOP TRAUMA, V28, P632, DOI 10.1097/BOT.0000000000000194
   St John PC, 2014, P NATL ACAD SCI USA, V111, P2040, DOI 10.1073/pnas.1323618111
   Stolzing A, 2008, MECH AGEING DEV, V129, P163, DOI 10.1016/j.mad.2007.12.002
   Sun H, 2022, BIOMATERIALS, V280, DOI 10.1016/j.biomaterials.2021.121243
   Tan L, 2018, ADV MATER, V30, DOI 10.1002/adma.201801808
   Tsukamoto H, 2021, ADV EXP MED BIOL, V1293, P73, DOI 10.1007/978 981 15 8763 4_5
   Tsukamoto Yamauchi N, 2015, BIOCHEM BIOPH RES CO, V459, P172, DOI 10.1016/j.bbrc.2015.02.100
   Ukon Y, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.845716
   van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323
   Van Heest A, 1999, LANCET, V353, pSL28
   Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114
   Walmsley GG, 2015, NANOMED NANOTECHNOL, V11, P1253, DOI 10.1016/j.nano.2015.02.013
   Wang C, 2016, ACS APPL MATER INTER, V8, P11262, DOI 10.1021/acsami.6b01103
   Wang CZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103348
   Wu ZR, 2022, ADV HEALTHC MATER, V11, DOI 10.1002/adhm.202200298
   Xie YL, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00682
   Xu C, 2016, J BONE MINER RES, V31, P1344, DOI 10.1002/jbmr.2803
   Xue XF, 2018, NAT MATER, V17, P633, DOI 10.1038/s41563 018 0082 9
   Yang CC, 2016, J TISSUE ENG REGEN M, V10, P120, DOI 10.1002/term.1714
   Yang L, 2015, INT IMMUNOPHARMACOL, V28, P525, DOI 10.1016/j.intimp.2015.07.001
   Yasuda S, 2020, NATURE, V578, P296, DOI 10.1038/s41586 020 1982 9
   Yu LN, 2021, WORLD J HEPATOL, V13, P1378, DOI 10.4254/wjh.v13.i10.1378
   Yu SL, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12727
   Yu XG, 2022, CHEM ENG J, V433, DOI 10.1016/j.cej.2021.132799
   Yumimoto K, 2013, J BIOL CHEM, V288, P32766, DOI 10.1074/jbc.M113.511303
   Zhao JJ, 2018, STEM CELL REP, V10, P180, DOI 10.1016/j.stemcr.2017.11.017
   Zhou L, 2019, CELL REPROGRAM, V21, P141, DOI 10.1089/cell.2018.0054
   Zhou W, 2017, CELL PHYSIOL BIOCHEM, V42, P551, DOI 10.1159/000477605
   Zhou X, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12470
   Zhu MJ, 2018, AM J TRANSL RES, V10, P3150
NR 95
TC 23
Z9 24
U1 7
U2 61
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1674 2818
EI 2049 3169
J9 INT J ORAL SCI
JI Int. J. Oral Sci.
PD DEC
PY 2022
VL 14
IS 1
AR 53
DI 10.1038/s41368 022 00207 y
PG 11
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 6E7GY
UT WOS:000883545600001
PM 36376275
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Vimalraj, S
   Rajalakshmi, S
   Saravanan, S
   Preeth, DR
   Vasanthi, RLA
   Shairam, M
   Chatterjee, S
AF Vimalraj, Selvaraj
   Rajalakshmi, Subramaniyam
   Saravanan, Sekaran
   Preeth, Desingh Raj
   Vasanthi, Rajkumar L. A.
   Shairam, Manickaraj
   Chatterjee, Suvro
TI Synthesis and characterization of zinc silibinin complexes: A potential
   bioactive compound with angiogenic, and antibacterial activity for bone
   tissue engineering
SO COLLOIDS AND SURFACES B BIOINTERFACES
LA English
DT Article
DE Silibinin; Zinc(II); Phenanthroline; Osteoblast differentiation;
   miR 590/smad7
ID PROMOTES OSTEOBLAST DIFFERENTIATION; STEM CELL PROLIFERATION; COPPER(II)
   COMPLEXES; EXPRESSION; ANGIOPOIETIN 1; MICRORNA 15B; PROTEINS; EFFICACY;
   SILYBIN; GROWTH
AB Zinc silibinin complex [Zn(sil)(H2O)(2)] and mixed ligand zinc complexes such as Zn(silibinin)(phenanthroline) [Zn(sil)(phen)], and Zn(silibinin)(neocuproine) [Zn(sil)(neo)] have been synthesized and characterized. The UV vis spectra of the Zn(II) complexes showed a considerable shift in the intra ligand transition. From the IR spectra, it is clear that carbonyl group in the C ring is involved in the metal chelation besides A/C ring hydroxyl group. Thermal gravimetric analysis showed that [Zn(sil)(neo)] has higher thermal stability compared to the other two Zn(II) complexes. The potential biological activities of the synthesized complexes were studied systematically. In osteoblast differentiation, silibinin and Zn silibinin complexes enhanced osteoblast differentiation at the cellular level by increasing calcium deposition and ALP activity, and at molecular level increased osteoblast markers include Runx2, type 1 col, ALP and OC mRNAs expression. Additionally, Zn silibinin complexes showed promising effects on osteoblast differentiation by regulating miR 590/Smad7 signaling pathway. Among the complexes, Zn(sil)(phen) showed more stimulatory effect on osteoblastic differentiation. These complexes also exhibited angiogenic property by increasing VEGF and Ang 1 expression in mouse MSC5 and antibacterial activity against E. coli (Gram negative) and S. aureus (Gram positive) strains. Thus, the present study demonstrated that the Zn silibinin complexes exhibit great potential as a pharmacological agent for bone tissue engineering. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Vimalraj, Selvaraj; Chatterjee, Suvro] Anna Univ, Vasc Biol Lab, Dept Biotechnol, MIT Campus, Madras 600044, Tamil Nadu, India.
   [Vimalraj, Selvaraj; Chatterjee, Suvro] Anna Univ, AU KBC Res Ctr, MIT Campus, Madras 600044, Tamil Nadu, India.
   [Rajalakshmi, Subramaniyam; Preeth, Desingh Raj; Shairam, Manickaraj] Anna Univ, AU KBC Res Ctr, Chem Biol & Nanobiotechnol Lab, MIT Campus, Madras 600044, Tamil Nadu, India.
   [Saravanan, Sekaran] SASTRA Univ, Sch Chem & Biotechnol, Dept Bioengn, Ctr Nanotechnol &Advanced Biomat CeNTAB, Thanjavur 613401, Tamil Nadu, India.
   [Vasanthi, Rajkumar L. A.] Alagappa Univ, Dept Anim Hlth & Management, Karaikkudi 630003, Tamil Nadu, India.
C3 Anna University; Anna University Chennai; Anna University; Anna
   University Chennai; Anna University; Anna University Chennai; Shanmugha
   Arts, Science, Technology & Research Academy (SASTRA); Alagappa
   University
RP Vimalraj, S (通讯作者)，Anna Univ, Vasc Biol Lab, Dept Biotechnol, MIT Campus, Madras 600044, Tamil Nadu, India.; Vimalraj, S (通讯作者)，Anna Univ, AU KBC Res Ctr, MIT Campus, Madras 600044, Tamil Nadu, India.; Rajalakshmi, S (通讯作者)，Anna Univ, AU KBC Res Ctr, Chem Biol & Nanobiotechnol Lab, MIT Campus, Madras 600044, Tamil Nadu, India.
EM vimalr50@gmail.com; rajimaniyam@gmail.com
RI Sekaran, Saravanan/AFP 5431 2022; Subramaniyam, Rajalakshmi/F 3030 2011;
   selvaraj, vimalraj/ADS 2441 2022; selvaraj, vimalraj/KDO 0834 2024
OI Lourduraj, Vasanthi/0000 0001 9487 1787; Subramaniyam,
   Rajalakshmi/0000 0003 0608 1959; selvaraj, vimalraj/0000 0001 6951 4569;
   Sekaran, Saravanan/0000 0002 2212 0180
FU Department of Science and Technology (DST), Inspire Faculty Program,
   Government of India [DST/INSPIRE/04/2017/002913]; Science and
   Engineering Research Board (SERB) [PDF/2015/000133]; DST Inspire Faculty
   program [DST/INSPIRE/04/2015/001945]; University Grant
   Commission Faculty Research Program (UGC FRP), Government of India
FX This work was supported by research grants to Dr. S. Vimlaraj from
   Department of Science and Technology (DST), Inspire Faculty Program,
   Government of India (grant no. DST/INSPIRE/04/2017/002913) and Science
   and Engineering Research Board (SERB), (grant no. PDF/2015/000133). Dr.
   Rajalakshmi thank DST Inspire Faculty (DST/INSPIRE/04/2015/001945)
   program for the research grant. This work was also partially supported
   by a grant from the University Grant Commission Faculty Research Program
   (UGC FRP), Government of India to Dr. SC.
CR Anderson HC, 2004, AM J PATHOL, V164, P841, DOI 10.1016/S0002 9440(10)63172 0
   [Anonymous], 2013, SCI WORLD J
   Azeena S, 2017, MAT SCI ENG C MATER, V71, P1156, DOI 10.1016/j.msec.2016.11.118
   Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097 4644(19970701)66:1<1::AID JCB1>3.0.CO;2 V
   Borsari M, 2001, J INORG BIOCHEM, V85, P123, DOI 10.1016/S0162 0134(01)00198 2
   Carmeliet P, 2005, ONCOLOGY BASEL, V69, P4, DOI 10.1159/000088478
   Chinoy MR, 2002, AM J PHYSIOL LUNG C, V283, pL60, DOI 10.1152/ajplung.00317.2001
   Cho JK, 2012, J PHARM SCI US, V101, P2382, DOI 10.1002/jps.23137
   Davies D, 2003, NAT REV DRUG DISCOV, V2, P114, DOI 10.1038/nrd1008
   de Oliveira DR, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/292797
   Feric NT, 2014, BIOMATER SCI UK, V2, P1384, DOI 10.1039/c4bm00073k
   Ferrer EG, 2006, J BIOL INORG CHEM, V11, P791, DOI 10.1007/s00775 006 0122 9
   Haddad Y, 2011, EVID BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep164
   HARRIS WR, 1979, J AM CHEM SOC, V101, P6534, DOI 10.1021/ja00516a011
   Jia LJ, 2010, COLLOID SURFACE B, V80, P213, DOI 10.1016/j.colsurfb.2010.06.008
   Kasprzak MM, 2015, RSC ADV, V5, P45853, DOI 10.1039/c5ra05069c
   Kim JL, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/919374
   Kim JL, 2012, J CELL BIOCHEM, V113, P247, DOI 10.1002/jcb.23351
   Lee Y. S., 2012, BIOMED RES INT, V2011
   Leena RS, 2017, COLLOID SURFACE B, V158, P308, DOI 10.1016/j.colsurfb.2017.06.048
   Lin ZW, 2014, EXP THER MED, V7, P625, DOI 10.3892/etm.2013.1464
   Mannelli LD, 2012, J PAIN, V13, P276, DOI 10.1016/j.jpain.2011.11.009
   Miranda PJ, 2015, INT J BIOL MACROMOL, V72, P145, DOI 10.1016/j.ijbiomac.2014.07.051
   Moorthi A, 2013, INT J BIOL MACROMOL, V56, P181, DOI 10.1016/j.ijbiomac.2013.02.017
   Naso LG, 2011, J BIOL INORG CHEM, V16, P653, DOI 10.1007/s00775 011 0769 8
   Rajalakshmi S., 2016, ADV CENT SCI, V1, P13
   Rajalakshmi S, 2014, EUR J MED CHEM, V80, P393, DOI 10.1016/j.ejmech.2014.04.064
   Rajalakshmi S, 2012, J INORG BIOCHEM, V117, P48, DOI 10.1016/j.jinorgbio.2012.08.010
   Saravanan S, 2015, J BIOMED NANOTECHNOL, V11, P1124, DOI 10.1166/jbn.2015.2057
   Selvaraj S, 2014, MED RES REV, V34, P677, DOI 10.1002/med.21301
   Singh RP, 2006, J NATL CANCER I, V98, P846, DOI 10.1093/jnci/djj231
   Singh RP, 2005, EUR J CANCER, V41, P1969, DOI 10.1016/j.ejca.2005.03.033
   Surai PF, 2015, ANTIOXIDANTS BASEL, V4, P204, DOI 10.3390/antiox4010204
   Vimalraj S, 2016, INT J BIOL MACROMOL, V93, P1457, DOI 10.1016/j.ijbiomac.2015.12.083
   Vimalraj S, 2015, INT J BIOL MACROMOL, V79, P490, DOI 10.1016/j.ijbiomac.2015.05.017
   Vimalraj S, 2015, INT J BIOL MACROMOL, V78, P202, DOI 10.1016/j.ijbiomac.2015.04.008
   Vimalraj S, 2014, J CELL PHYSIOL, V229, P1236, DOI 10.1002/jcp.24557
   Vimalraj S, 2014, INT J BIOL MACROMOL, V66, P194, DOI 10.1016/j.ijbiomac.2014.02.030
   Vimalraj S, 2013, DIS MARKERS, V2013, DOI 10.1155/2013/451248
   Vimalraj S, 2013, CURR ISSUES MOL BIOL, V15, P7
   Vimalraj S, 2017, ADV BIOCHEM HEALTH D, V6, P495, DOI 10.1007/978 3 319 61115 0_22
   Vimalraj S, 2018, MAT SCI ENG C MATER, V83, P187, DOI 10.1016/j.msec.2017.09.005
   Vimalraj S, 2017, REPROD TOXICOL, V70, P30, DOI 10.1016/j.reprotox.2017.02.014
   Vimbela GV, 2017, INT J NANOMED, V12, P3941, DOI 10.2147/IJN.S134526
   Vishal M, 2017, J CELL PHYSIOL, V232, P371, DOI 10.1002/jcp.25434
   Wang JX, 2017, ACS APPL MATER INTER, V9, P33609, DOI 10.1021/acsami.7b08864
   Ying XZ, 2013, EUR J PHARMACOL, V721, P225, DOI 10.1016/j.ejphar.2013.09.031
   Young MF, 2003, OSTEOPOROSIS INT, V14, pS35, DOI 10.1007/s00198 002 1342 7
   Zhang LF, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0099946, 10.1371/journal.pone.0084950]
   Zhao L, 2010, J BONE MINER RES, V25, P1246, DOI 10.1002/jbmr.28
   Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200
   Zhu XX, 2016, EXPERT REV CLIN PHAR, V9, P1323, DOI 10.1080/17512433.2016.1208563
NR 52
TC 34
Z9 34
U1 0
U2 23
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927 7765
EI 1873 4367
J9 COLLOID SURFACE B
JI Colloid Surf. B Biointerfaces
PD JUL 1
PY 2018
VL 167
BP 134
EP 143
DI 10.1016/j.colsurfb.2018.04.007
PG 10
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Chemistry; Materials Science
GA GI8BQ
UT WOS:000434747200015
PM 29635136
DA 2025 08 17
ER

PT J
AU Zhuang, JL
   Li, X
   Zhang, Y
   Shi, RX
   Shi, C
   Yu, DS
   Bao, XF
   Hu, M
AF Zhuang, Jinliang
   Li, Xun
   Zhang, Yi
   Shi, Ruixin
   Shi, Ce
   Yu, Dongsheng
   Bao, Xingfu
   Hu, Min
TI Sema6A plexin A2 axis stimulates RANKL induced osteoclastogenesis
   through PLCγ mediated NFATc1 activation
SO LIFE SCIENCES
LA English
DT Article
DE Sema6A; Plexin A2; Osteoclastogenesis; PLC gamma; NFATc1
ID LAMINA RESTRICTED PROJECTION; BONE; DIFFERENTIATION; PLEXIN A2;
   SEMAPHORINS; EXPRESSION
AB Recently, several plexins and semaphorins have been associated with osteoclastogenesis, a vital process for bone remodeling. Plexin A2 is implicated in bone homeostasis, however, whether it plays a role in osteoclastogenesis and the underlying mechanism remain unknown. We show that plexin A2 expression is upregulated during RANKL induced osteoclastogenesis. In addition, the soluble Sema6A fused with IgG1 Fc region (Fc Sema6A) interacts with plexin A2 from cell lysates of osteoclasts, suggesting that plexin A2 acts as a receptor of Sema6A in osteoclasts. Moreover, Sema6A treatment stimulates RANKL induced osteoclastogenesis, and this effect is abolished when plexin A2 is neutralized, which illustrates an indispensable role of plexin A2 in mediating Sema6A effect on osteoclastogenesis. Mechanistically, Sema6A plexin A2 axis enhances RANKL induced activation of PLC gamma as well as downstream target NFATc1, one master transcriptional factor of osteoclastogenesis. Lastly, inhibition of PLC gamma by pharmacological inhibitor U73122 abrogates Sema6A stimulated NFATc1 activation and RANKL induced osteoclastogenesis, thus demonstrating that the PLC gamma mediated NFATc1 activation accounts for the promotive role of Sema6A plexin A2 axis in RANKL induced osteoclastogenesis. Taken together, this study uncovers a novel role of Sema6A and plexin A2 in osteoclastogenesis, and also offers them as possible therapeutic targets in the intervention of osteolytic diseases.
C1 [Zhuang, Jinliang; Zhang, Yi; Shi, Ruixin; Yu, Dongsheng; Bao, Xingfu; Hu, Min] Jilin Univ, Sch & Hosp Stomatol, Dept Orthodont, 1500 Qinghua Rd, Changchun 130021, Jilin, Peoples R China.
   [Zhuang, Jinliang; Zhang, Yi; Shi, Ce; Hu, Min] Jilin Prov Key Lab Tooth Dev & Bone Remodeling, Changchun, Jilin, Peoples R China.
   [Li, Xun] Jilin Univ, Sch & Hosp Stomatol, Dept Endodont, Changchun 130021, Jilin, Peoples R China.
   [Shi, Ce] Jilin Univ, Sch & Hosp Stomatol, Dept Pathol, Changchun 130021, Jilin, Peoples R China.
C3 Jilin University; Jilin University; Jilin University
RP Hu, M (通讯作者)，Jilin Univ, Sch & Hosp Stomatol, Dept Orthodont, 1500 Qinghua Rd, Changchun 130021, Jilin, Peoples R China.
EM humjlu159@163.com
RI bao, xingfu/D 9619 2017; Wang, Yukun/GRJ 5930 2022
CR Abramoff M.D., 2004, J. Biophot. Int., V11, P36, DOI DOI 10.1201/9781420005615.AX4
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756
   Boyce BF, 2012, EUR J CLIN INVEST, V42, P1332, DOI 10.1111/j.1365 2362.2012.02717.x
   Feng HT, 2009, J BIOL CHEM, V284, P14667, DOI 10.1074/jbc.M901670200
   Harre U, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7651
   Hwang JY, 2006, OSTEOPOROSIS INT, V17, P1592, DOI 10.1007/s00198 006 0126 x
   Irie N, 2009, J BIOL CHEM, V284, P14637, DOI 10.1074/jbc.M807598200
   Isaacs JD, 2010, CLIN ORTHOP RELAT R, V468, P3384, DOI 10.1007/s11999 010 1535 x
   Kang SJ, 2013, SEMIN CELL DEV BIOL, V24, P163, DOI 10.1016/j.semcdb.2012.09.008
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kawauchi T, 2006, NAT CELL BIOL, V8, P17, DOI 10.1038/ncb1338
   Kitazawa R, 2018, HISTOCHEM CELL BIOL, V149, P405, DOI 10.1007/s00418 018 1639 z
   Kuroda Y, 2008, P NATL ACAD SCI USA, V105, P8643, DOI 10.1073/pnas.0800642105
   Leitner MG, 2016, BRIT J PHARMACOL, V173, P2555, DOI 10.1111/bph.13538
   Li YY, 2016, METHODS MOL BIOL, V1406, P73, DOI 10.1007/978 1 4939 3444 7_6
   Lian JB, 2006, REV ENDOCR METAB DIS, V7, P1, DOI 10.1007/s11154 006 9001 5
   Lorenzo J, 2017, J CLIN INVEST, V127, P2530, DOI 10.1172/JCI94606
   Luchin A, 2000, J BONE MINER RES, V15, P451, DOI 10.1359/jbmr.2000.15.3.451
   Maier V, 2011, MOL CELL NEUROSCI, V46, P419, DOI 10.1016/j.mcn.2010.11.005
   Negishi Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489
   Oh JE, 2012, PLEXINA2 MEDIATES OS
   Oh JE, 2012, J BONE MINER RES, V27, P552, DOI 10.1002/jbmr.1471
   Parker LH, 2004, NATURE, V428, P754, DOI 10.1038/nature02416
   Renaud J, 2008, NAT NEUROSCI, V11, P440, DOI 10.1038/nn2064
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Sasaki Y, 2002, NEURON, V35, P907, DOI 10.1016/S0896 6273(02)00857 7
   Seuk KM, 2010, RANKL MEDIATED REACT, V285, P6913
   Shinohara M, 2008, CELL, V132, P794, DOI 10.1016/j.cell.2007.12.037
   Song I, 2009, FEBS LETT, V583, P2435, DOI 10.1016/j.febslet.2009.06.047
   Suto F, 2007, NEURON, V53, P535, DOI 10.1016/j.neuron.2007.01.028
   Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092 8674(00)80063 X
   Tawarayama H, 2010, J NEUROSCI, V30, P7049, DOI 10.1523/JNEUROSCI.0073 10.2010
   Xiao WM, 2016, FRONT ORAL BIOL, V18, P17, DOI 10.1159/000351896
   Xiao WM, 2016, FRONT ORAL BIOL, V18, P9, DOI 10.1159/000351895
   Xie ZG, 2006, CEREB CORTEX, V16, pI64, DOI 10.1093/cercor/bhj170
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
   Zhao QX, 2010, INT J BIOCHEM CELL B, V42, P576, DOI 10.1016/j.biocel.2009.12.018
   Zhou YP, 2008, TRENDS BIOCHEM SCI, V33, P161, DOI 10.1016/j.tibs.2008.01.006
NR 39
TC 4
Z9 6
U1 0
U2 13
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024 3205
EI 1879 0631
J9 LIFE SCI
JI Life Sci.
PD APR 1
PY 2019
VL 222
BP 29
EP 35
DI 10.1016/j.lfs.2019.01.060
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA HP1IU
UT WOS:000461421000004
PM 30826495
DA 2025 08 17
ER

PT J
AU Hong, L
   Yang, C
AF Hong, Liu
   Yang, Chao
TI Eupatilin ameliorates postmenopausal osteoporosis via elevating
   microRNA 211 5p and repressing JAK2/STAT3 pathway
SO ENVIRONMENTAL TOXICOLOGY
LA English
DT Article
DE Eupatilin; JAK2/STAT3; micro CT; microRNA 211 5p; postmenopausal
   osteoporosis
ID CELL PROLIFERATION; BONE; DIFFERENTIATION; OSTEOCLASTOGENESIS;
   INFLAMMATION; METASTASIS; EXPRESSION; FRACTURES; CANCER
AB Postmenopausal osteoporosis (PMOP) poses a significant threat to women's health worldwide. Eupatilin is a key bioactive component of the Chinese herbal medicine Artemisia asiatica Nakai. Recent research reports have proved the inhibitory function of Eupatilin in many diseases. MicroRNAs (miRNAs) are 21 23 nucleotide long, single stranded, noncoding RNA molecules generated endogenously, and many studies have indicated that miRNAs are involved in the development of osteoporosis. This study explored the role and potential mechanism of Eupatilin underlying PMOP. First, rats were given intragastric administration of Eupatilin every day and subcutaneous injections of oligonucleotides or plasmids that interfered with miR 211 5p or janus kinase 2 (JAK2) once a week. After 4 weeks, the PMOP rat model was established. Then, serum alkaline phosphatase, calcium, and phosphorus levels, as well as femur bone mineral density and biomechanical parameters, were detected. Hematoxylin eosin staining and Masson staining were applied for detecting the pathological condition of femur, and immunohistochemical staining was for detecting osteocalcin. MC3T3 E1 cells were transfected with plasmid vectors interfering with miR 211 5p or JAK2; and cell viability, lactate dehydrogenase cytotoxicity, and cell mineralization were subsequently examined. The relationship between miR 211 5p and JAK2/signal transducer and activator of transcription 3 (STAT3) pathway was analyzed. The targeting relation between miR 211 5p and JAK2 was also verified. The experimental results revealed that Eupatilin improved the pathological conditions of PMOP rats by promoting the proliferation and mineralization of osteoblasts. MiR 211 5p was down regulated and JAK2/STAT3 was upregulated in PMOP rats. Upregulation of miR 211 5p further improved the pathological conditions of PMOP rats based on Eupatilin treatment. MiR 211 5p inhibited the JAK2/STAT3 pathway. JAK2 offset the effects of elevated miR 211 5p on PMOP rats. Overall, Eupatilin attenuates PMOP through elevating miR 211 5p and repressing JAK2/STAT3 pathway, which suggests the utility of Eupatilin as a potential drug for POMP treatment.
C1 [Hong, Liu; Yang, Chao] Maternal & Child Hlth Hosp Hubei Prov, Dept Orthoped, Wuhan, Hubei, Peoples R China.
   [Yang, Chao] Maternal & Child Hlth Hosp Hubei Prov, Dept Orthoped, 745 Wuluo Rd, Wuhan 430070, Hubei, Peoples R China.
RP Yang, C (通讯作者)，Maternal & Child Hlth Hosp Hubei Prov, Dept Orthoped, 745 Wuluo Rd, Wuhan 430070, Hubei, Peoples R China.
EM yangchao585@outlook.com
CR ACOG Committee on Clinical Practice Guidelines Gynecology, 2022, Obstet Gynecol, V139, P698, DOI 10.1097/AOG.0000000000004730
   Aili D, 2021, EXP THER MED, V21, DOI 10.3892/etm.2021.9886
   An Q, 2021, BIOENGINEERED, V12, P2702, DOI 10.1080/21655979.2021.1930925
   Bellavia D, 2019, CELL MOL LIFE SCI, V76, P3723, DOI 10.1007/s00018 019 03162 w
   Black DM, 2020, NEW ENGL J MED, V383, P743, DOI 10.1056/NEJMoa1916525
   Brown JP, 2021, ENDOCRINOL METAB, V36, P544, DOI 10.3803/EnM.2021.301
   Burr D. B., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P184
   Chen ZH, 2020, THERANOSTICS, V10, P12263, DOI 10.7150/thno.53009
   Cheung Ralph K. H., 2007, Hong Kong Medical Journal, V13, P485
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cui Q, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1428 1
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Ensrud Kristine E, 2021, JAMA, V325, P96, DOI 10.1001/jama.2020.2923
   Fu Y, 2020, REJUV RES, V23, P313, DOI 10.1089/rej.2019.2239
   Hollick Rosemary J, 2011, Menopause Int, V17, P66, DOI 10.1258/mi.2011.011014
   Hong Y, 2023, J BIOCHEM MOL TOXIC, V37, DOI 10.1002/jbt.23317
   Huang CQ, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 05362 y
   Ji Y, 2014, DENT MATER, V30, P1263, DOI 10.1016/j.dental.2014.08.381
   Jin Y, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 022 00872 9
   Kim Ju Young, 2015, Bone Rep, V3, P83, DOI 10.1016/j.bonr.2015.10.003
   Kim J, 2015, J KOREAN MED SCI, V30, P233, DOI 10.3346/jkms.2015.30.3.233
   Kourtis LC, 2014, ANN BIOMED ENG, V42, P1773, DOI 10.1007/s10439 014 1027 3
   Krzeszinski JY, 2014, NATURE, V512, P431, DOI 10.1038/nature13375
   Lee S, 2008, FOOD CHEM TOXICOL, V46, P2865, DOI 10.1016/j.fct.2008.05.026
   Lenart BA, 2008, NEW ENGL J MED, V358, P1304, DOI 10.1056/NEJMc0707493
   Li CH, 2012, BIOCHEM BIOPH RES CO, V429, P156, DOI 10.1016/j.bbrc.2012.10.122
   Moura SR, 2020, BONE, V134, DOI 10.1016/j.bone.2020.115303
   Murshed M, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031229
   Nawata H, 2005, J BONE MINER METAB, V23, P105, DOI 10.1007/s00774 004 0596 x
   Pala E, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190667
   Peng Z, 2020, BIOCHEM PHARMACOL, V177, DOI 10.1016/j.bcp.2020.113983
   Qi XY, 2019, PHYTOMEDICINE, V53, P286, DOI 10.1016/j.phymed.2018.09.014
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rahnama M, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/416929
   Reginster JY, 2006, OSTEOPOROSIS INT, V17, P159, DOI 10.1007/s00198 005 1957 6
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Roy S, 2017, J HEPATOL, V67, P966, DOI 10.1016/j.jhep.2017.06.007
   Seol SY, 2004, WORLD J GASTROENTERO, V10, P2379
   Son JE, 2013, PLANTA MED, V79, P1009, DOI 10.1055/s 0033 1350621
   Sonda N, 2013, IMMUNITY, V38, P1236, DOI 10.1016/j.immuni.2013.06.004
   Sun CR, 2022, FRONT MED LAUSANNE, V9, DOI 10.3389/fmed.2022.935961
   Wang CL, 2016, INFLAMMATION, V39, P807, DOI 10.1007/s10753 016 0309 3
   Wang G, 2021, DIABET METAB SYND OB, V14, P671, DOI 10.2147/DMSO.S288338
   Wang H, 2022, BIOENGINEERED, V13, P5709, DOI 10.1080/21655979.2021.2017626
   Wang W, 2022, CLIN EXP PHARMACOL P, V49, P113, DOI 10.1111/1440 1681.13591
   Wang X, 2018, J CELL PHYSIOL, V233, P9447, DOI 10.1002/jcp.26833
   Weaver CM, 2011, ADV NUTR, V2, P290, DOI 10.3945/an.111.000463
   Wu Z, 2020, CELL BIOCHEM FUNCT, V38, P428, DOI 10.1002/cbf.3493
   Xiao YY, 2022, CANCER RES, V82, P4191, DOI 10.1158/0008 5472.CAN 22 1203
   Yamaguchi M, 2007, MOL CELL BIOCHEM, V303, P83, DOI 10.1007/s11010 007 9458 x
   Yu K, 2015, INT J CLIN EXP MED, V8, P22191
   Zhang L, 2020, J BONE MINER METAB, V38, P794, DOI 10.1007/s00774 020 01123 z
   Zhang YL, 2016, INT J BIOL SCI, V12, P347, DOI 10.7150/ijbs.13269
   Zhang ZD, 2016, BIOMED PHARMACOTHER, V84, P438, DOI 10.1016/j.biopha.2016.09.045
   Zhao FJ, 2021, AGING US, V13, P6945, DOI 10.18632/aging.202552
   Zhong Y, 2021, EXP NEUROL, V341, DOI 10.1016/j.expneurol.2021.113690
   Zhu J, 2019, J CELL PHYSIOL, V234, P21182, DOI 10.1002/jcp.28721
NR 57
TC 3
Z9 3
U1 2
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1520 4081
EI 1522 7278
J9 ENVIRON TOXICOL
JI Environ. Toxicol.
PD APR
PY 2024
VL 39
IS 4
BP 2218
EP 2228
DI 10.1002/tox.24069
EA DEC 2023
PG 11
WC Environmental Sciences; Toxicology; Water Resources
WE Science Citation Index Expanded (SCI EXPANDED)
SC Environmental Sciences & Ecology; Toxicology; Water Resources
GA KJ5X9
UT WOS:001129398800001
PM 38130072
DA 2025 08 17
ER

PT J
AU Wang, P
   Wang, M
   Zhuo, TL
   Li, Y
   Lin, WP
   Ding, LL
   Zhang, M
   Zhou, C
   Zhang, JF
   Li, G
   Wang, HB
   Xu, LL
AF Wang, Peng
   Wang, Min
   Zhuo, Tingling
   Li, Ying
   Lin, Weiping
   Ding, Lingli
   Zhang, Meng
   Zhou, Chi
   Zhang, Jinfang
   Li, Gang
   Wang, Haibin
   Xu, Liangliang
TI Hydroxysafflor yellow A promotes osteogenesis and bone development via
   epigenetically regulating β catenin and prevents ovariectomy induced
   bone loss
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE Hydroxysafflor yellow A; osteoporosis; KDM7A; beta catenin
ID DIFFERENTIATION; OSTEOBLAST; EXPRESSION; MIGRATION
AB In clinical treatment, there is increasingly prevalent that traditional Chinese medicine treats common bone diseases including osteoporosis. Hydroxysafflor yellow A (HSYA), one of the essential compounds of Safflower, has been used as the therapy for thrombus, myocardial ischemia, and inflammation, but its effect on osteogenesis through epigenetic control and ovariectomy induced bone loss in vivo has not been explored. Therefore, the study aimed to explore the function and mechanism of HSYA on bone formation and development. We found HSYA could enhance the cell viability and promote osteogenesis of hBMSCs in vitro. Mechanistically, HSYA could increase the expression of beta catenin leading to its accumulation in the nucleus and activation of downstream targets to promote osteogenesis. Besides, RNA seq and quantitative RT PCR and western blot showed KDM7A was significantly increased by HSYA. The occupancy of H3K27me2 on beta catenin promoter was significantly decreased by HSYA, which could be reversed by silencing endogenous KDM7A. More importantly, HSYA promoted bone development in chick embryos and prevented ovariectomy (OVX) induced bone loss in SD rats. Taken together, our study has shown convincing evidence that HSYA could promote osteogenesis and bone development via epigenetically regulating beta catenin and prevent ovariectomy induced bone loss.
C1 [Wang, Peng; Wang, Min; Zhuo, Tingling; Li, Ying; Ding, Lingli; Zhang, Meng] Guangzhou Univ Chinese Med, Jichang Rd, Guangzhou, Peoples R China.
   [Wang, Peng] Radboud Univ Nijmegen, Expt Rheumatol, Med Ctr, Nijmegen, Netherlands.
   [Lin, Weiping; Li, Gang] Chinese Univ Hong Kong, Prince Wales Hosp, Fac Med, Dept Orthopaed & Traumatol,Shatin, Hong Kong, Peoples R China.
   [Zhou, Chi; Wang, Haibin; Xu, Liangliang] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Joint Orthopaed, Guangzhou, Guangdong, Peoples R China.
   [Zhou, Chi; Zhang, Jinfang; Wang, Haibin; Xu, Liangliang] Guangzhou Univ Chinese Med, Lingnan Med Res Ctr, Lab Orthopaed & Traumatol, Guangzhou, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Radboud University Nijmegen;
   Chinese University of Hong Kong; Prince of Wales Hospital; Guangzhou
   University of Chinese Medicine; Guangzhou University of Chinese Medicine
RP Wang, HB (通讯作者)，Guangzhou Univ Chinese Med, Jichang Rd, Guangzhou, Peoples R China.; Xu, LL (通讯作者)，Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Peoples R China.
EM hipknee@163.com; xull 2016@gzucm.edu.cn
RI Lin, Weiping/JZE 4461 2024; XU, LIANGLIANG/AAZ 7935 2020
OI Xu, Liangliang/0000 0002 5249 7480
CR Ao H, 2018, EVID BASED COMPL ALT, V2018, DOI 10.1155/2018/8259280
   Chen R, 2017, STEM CELL REP, V8, P743, DOI 10.1016/j.stemcr.2017.01.016
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Cohen MM, 2006, AM J MED GENET A, V140A, P2646, DOI 10.1002/ajmg.a.31368
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Fang B, 2019, J ETHNOPHARMACOL, V238, DOI 10.1016/j.jep.2019.111862
   Fang B, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 018 1112 x
   HAMBURGER V, 1992, DEV DYNAM, V195, P231, DOI 10.1002/dvdy.1001950404
   Hu ZhiChao Hu ZhiChao, 2018, Food and Function, V9, P4443, DOI [10.1039/c8fo00732b, 10.1039/C8FO00732B]
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   Jiang CY, 2018, BIOCHEM BIOPH RES CO, V502, P382, DOI 10.1016/j.bbrc.2018.05.176
   Kim JH, 2019, FOOD FUNCT, V10, P3650, DOI 10.1039/c9fo00615j
   Ko JY, 2013, BONE, V57, P468, DOI 10.1016/j.bone.2013.09.019
   Lerner UH, 2015, J INTERN MED, V277, P630, DOI 10.1111/joim.12368
   Li CJ, 2015, J CLIN INVEST, V125, P1509, DOI 10.1172/JCI77716
   Liang WC, 2016, SCI REP UK, V6, DOI 10.1038/srep20121
   Lv MY, 2019, J CELL BIOCHEM, V120, P17273, DOI 10.1002/jcb.28989
   Ma L, 2017, BIOL PHARM BULL, V40, P1706, DOI 10.1248/bpb.b17 00281
   Molagoda IMN, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110711
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Orimo Hideo, 2010, Journal of Nippon Medical School, V77, P4
   Pan MR, 2015, SCI REP UK, V5, DOI 10.1038/srep18709
   Schmitz N, 2010, OSTEOARTHR CARTILAGE, V18, pS113, DOI 10.1016/j.joca.2010.05.026
   Sen B, 2020, J BONE MINER RES, V35, P1149, DOI 10.1002/jbmr.3975
   Takada I, 2009, EXPERT OPIN THER TAR, V13, P593, DOI [10.1517/14728220902915310 , 10.1517/14728220902915310]
   Tsukada YI, 2010, GENE DEV, V24, P432, DOI 10.1101/gad.1864410
   Wang LF, 2013, EMBO J, V32, P45, DOI 10.1038/emboj.2012.306
   Wang P, 2018, INT J MED SCI, V15, P1480, DOI 10.7150/ijms.27333
   Wei QS, 2019, J ORTHOP TRANSL, V18, P65, DOI 10.1016/j.jot.2018.11.002
   Xu LL, 2015, FASEB J, V29, P1143, DOI 10.1096/fj.14 254169
   Yousefi AM, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/6180487
   Zhu HJ, 2015, CYTOTECHNOLOGY, V67, P885, DOI 10.1007/s10616 014 9783 3
NR 32
TC 12
Z9 15
U1 0
U2 23
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357 2725
EI 1878 5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD AUG
PY 2021
VL 137
AR 106033
DI 10.1016/j.biocel.2021.106033
EA JUL 2021
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA XP4VG
UT WOS:000730864000001
PM 34216755
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Chen, YX
   Yu, JQ
   Ke, QF
   Gao, YS
   Zhang, CQ
   Guo, YP
AF Chen, Yixuan
   Yu, Jianqing
   Ke, Qinfei
   Gao, Youshui
   Zhang, Changqing
   Guo, Yaping
TI Bioinspired fabrication of carbonated hydroxyapatite/chitosan nanohybrid
   scaffolds loaded with TWS119 for bone regeneration
SO CHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE Carbonated hydroxyapatite; Chitosan; Therapeutic scaffold; Bone
   regeneration
ID CATENIN SIGNALING PATHWAY; MESENCHYMAL STEM CELLS; DRUG DELIVERY;
   IN VITRO; OSTEOBLAST DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION; POROUS
   SCAFFOLDS; WNT; INHIBITOR; CHITOSAN
AB Effective repair of bone defects mainly depends on the osteoinductivity and biocompatibility of implants. Herein, we for the first time reported the bioinspired fabrication of carbonated hydroxyapatite/chitosan (CHA/CS) nanohybrid scaffolds using CaCO3/CS porous scaffolds as sacrificial templates, followed by loading TWS119 drugs (CHA/CS/TWS119). After treatment with phosphate buffer solutions, the CaCO3/CS porous scaffolds were in situ converted into CHA/CS nanohybrid scaffolds via the dissolution precipitation reaction. The as formed CHA nanoplates with thicknesses of similar to 20 nm and widths of 1.0 2.0 mu m were perpendicular to the scaffold surfaces. The three dimensional interconnected macropores supported the adhesion and spreading of bone mesenchymal stem cells (BMSCs), and the mesopores within the CHA nanoplates as drug delivery channels improved the drug loading release properties. The controlled drug release of the CHA/CS/TWS119 nanohybrid scaffolds significantly enhanced the osteogenic differentiation of BMSCs by the activated GSK3 beta/beta catenin pathway. Moreover, rat cranial defect models revealed the enhancing effects of the CHA/CS/TWS119 scaffold on bone tissue regeneration. The micro CT, haematoxylin and eosin (H&E) staining, Van Gieson (VG) staining, Masson staining and double fluorochrome labelling results demonstrated that more new bone tissues were formed in the CHA/CS/TWS119 nanohybrid scaffolds than the control group without loading TWS119. Therefore, the CHA/CS/TWS119 nanohybrid scaffold is a promising therapeutic material for bone tissue regeneration.
C1 [Yu, Jianqing; Ke, Qinfei; Guo, Yaping] Shanghai Normal Univ, Key Lab Resource Chem, Educ Minist, Shanghai 200234, Peoples R China.
   [Yu, Jianqing; Ke, Qinfei; Guo, Yaping] Shanghai Normal Univ, Shanghai Key Lab Rare Earth Funct Mat, Shanghai 200234, Peoples R China.
   [Chen, Yixuan; Gao, Youshui; Zhang, Changqing] Shanghai Jiao Tong Univ, Dept Orthoped Surg, Affiliated Peoples Hosp 6, Shanghai 200233, Peoples R China.
C3 Shanghai Normal University; Shanghai Normal University; Shanghai Jiao
   Tong University
RP Guo, YP (通讯作者)，Shanghai Normal Univ, Key Lab Resource Chem, Educ Minist, Shanghai 200234, Peoples R China.; Guo, YP (通讯作者)，Shanghai Normal Univ, Shanghai Key Lab Rare Earth Funct Mat, Shanghai 200234, Peoples R China.; Zhang, CQ (通讯作者)，Shanghai Jiao Tong Univ, Dept Orthoped Surg, Affiliated Peoples Hosp 6, Shanghai 200233, Peoples R China.
EM hangcq@sjtu.edu.cn; ypguo@shnu.edu.cn
RI chen, yixuan/KVC 2060 2024; GAO, YOUSHUI/U 8349 2019
OI zhang, changqing/0000 0002 7408 4126; chen, yixuan/0000 0001 7390 0622;
   Guo, Ya Ping/0000 0002 5450 2968
FU Natural Science Foundation of China [51372152]; Innovation Foundation of
   Shanghai Education Committee [14ZZ124]; Key Disciplines of Shanghai
   Municipal Education Commission [J50206]; National High Technology
   Research and Development Program of China [2012AA020506]; "Priority
   Among Priorities" Clinical Medical Center Construction Project of the
   Science and Technology Commission of Shanghai Municipality [12JC1405600]
FX This research was supported by Natural Science Foundation of China (No.
   51372152), Innovation Foundation of Shanghai Education Committee (No.
   14ZZ124), Key Disciplines of Shanghai Municipal Education Commission
   (No. J50206), National High Technology Research and Development Program
   of China (2012AA020506), "Priority Among Priorities" Clinical Medical
   Center Construction Project of the Science and Technology Commission of
   Shanghai Municipality (No. 12JC1405600).
CR Alberti S, 2015, CHEM COMMUN, V51, P6050, DOI 10.1039/c4cc10414e
   Baek S, 2015, NANOSCALE, V7, P14191, DOI 10.1039/c5nr02730f
   Baron Roland, 2007, Curr Osteoporos Rep, V5, P73
   Beier EE, 2015, J BIOL CHEM, V290, P18216, DOI 10.1074/jbc.M114.629204
   Chen W, 2016, MAT SCI ENG C MATER, V67, P395, DOI 10.1016/j.msec.2016.04.106
   Chen W, 2014, J MATER CHEM B, V2, P1653, DOI 10.1039/c3tb21769h
   Chen YX, 2017, NANOSCALE, V9, P6765, DOI 10.1039/c7nr00601b
   Chen Y, 2010, ACS NANO, V4, P6001, DOI 10.1021/nn1015117
   Cheng PW, 2015, DIABETES, V64, P3413, DOI 10.2337/db14 1439
   Cook DA, 2014, STEM CELL RES, V12, P415, DOI 10.1016/j.scr.2013.10.002
   Ding S, 2003, P NATL ACAD SCI USA, V100, P7632, DOI 10.1073/pnas.0732087100
   Fuentes RG, 2015, NAT PROD REP, V32, P1622, DOI 10.1039/c5np00074b
   Fujisaki K, 2012, J MECH BEHAV BIOMED, V10, P176, DOI 10.1016/j.jmbbm.2012.02.025
   Georgiou KR, 2012, BONE, V50, P1223, DOI 10.1016/j.bone.2012.03.027
   Gillespie JR, 2013, ENDOCRINOLOGY, V154, P3702, DOI 10.1210/en.2013 1155
   Guan JJ, 2015, J MATER CHEM B, V3, P1655, DOI 10.1039/c4tb02085e
   Guillaume O, 2017, ACTA BIOMATER, V54, P386, DOI 10.1016/j.actbio.2017.03.006
   Guo YP, 2015, J MATER CHEM B, V3, P4679, DOI 10.1039/c5tb00175g
   Hashemi M, 2016, RSC ADV, V6, P74072, DOI 10.1039/c6ra13822e
   Hashemi M, 2017, BIOTECHNOL APPL BIOC, V64, P433, DOI 10.1002/bab.1487
   Hunziker EB, 2012, BONE, V51, P98, DOI 10.1016/j.bone.2012.04.004
   Iafisco M, 2015, CRYSTENGCOMM, V17, P507, DOI 10.1039/c4ce01415d
   Karner CM, 2017, CELL MOL LIFE SCI, V74, P1649, DOI 10.1007/s00018 016 2425 5
   Kim HY, 2015, CELL DEATH DIFFER, V22, P912, DOI 10.1038/cdd.2014.238
   Kim H, 2010, ACTA BIOMATER, V6, P3234, DOI 10.1016/j.actbio.2010.02.031
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kulkarni NH, 2006, J BONE MINER RES, V21, P910, DOI 10.1359/JBMR.060316
   Kumar J, 2011, BONE, V49, P343, DOI 10.1016/j.bone.2011.05.018
   Le Henaff C, 2015, J BIOL CHEM, V290, P18009, DOI 10.1074/jbc.M115.646208
   Lerner UH, 2015, J INTERN MED, V277, P630, DOI 10.1111/joim.12368
   Liu Y, 2016, SMALL, V12, P4611, DOI 10.1002/smll.201600626
   Loiselle AE, 2013, TISSUE ENG PT A, V19, P1704, DOI [10.1089/ten.tea.2012.0560, 10.1089/ten.TEA.2012.0560]
   Marsell R, 2012, BONE, V50, P619, DOI 10.1016/j.bone.2011.11.007
   Nakamura M, 2016, ACS BIOMATER SCI ENG, V2, P259, DOI 10.1021/acsbiomaterials.5b00509
   Olszta MJ, 2007, MAT SCI ENG R, V58, P77, DOI 10.1016/j.mser.2007.05.001
   Ono M, 2011, PLATELETS, V22, P196, DOI 10.3109/09537104.2010.541959
   Palmer LC, 2008, CHEM REV, V108, P4754, DOI 10.1021/cr8004422
   Qiu JJ, 2017, CARBON, V125, P227, DOI 10.1016/j.carbon.2017.09.064
   Qu X, 2016, J MATER CHEM B, V4, P4901, DOI 10.1039/c6tb01262k
   Quarto N, 2010, J BONE MINER RES, V25, P1680, DOI 10.1359/jbmr.091116
   Roh HS, 2017, MAT SCI ENG C MATER, V74, P525, DOI 10.1016/j.msec.2016.12.054
   Sabatino M, 2016, BLOOD, V128, P519, DOI 10.1182/blood 2015 11 683847
   Sadat Shojai M, 2016, CHEM ENG J, V289, P38, DOI 10.1016/j.cej.2015.12.079
   Schmidt SM, 2006, MICROPOR MESOPOR MAT, V94, P330, DOI 10.1016/j.micromeso.2006.04.006
   Scholz G, 2016, EBIOMEDICINE, V4, P50, DOI 10.1016/j.ebiom.2016.01.019
   Shen SB, 2017, CHEM ENG J, V309, P278, DOI 10.1016/j.cej.2016.10.043
   SING KSW, 1985, PURE APPL CHEM, V57, P603, DOI 10.1351/pac198557040603
   Tamer TM, 2017, CARBOHYD POLYM, V169, P441, DOI 10.1016/j.carbpol.2017.04.027
   Tang XJ, 2017, MATER LETT, V198, P121, DOI 10.1016/j.matlet.2017.04.006
   Vallet Regí M, 2007, ANGEW CHEM INT EDIT, V46, P7548, DOI 10.1002/anie.200604488
   Walsh D, 2001, BIOMATERIALS, V22, P1205, DOI 10.1016/S0142 9612(00)00268 4
   Wang W, 2016, MOL NEUROBIOL, V53, P7028, DOI 10.1007/s12035 015 9607 2
   Wang Y, 2013, J AM CHEM SOC, V135, P4799, DOI 10.1021/ja312221g
   Wen X, 2016, RSC ADV, V6, P113940, DOI 10.1039/c6ra20448a
   Wenk HR, 1999, BONE, V24, P361, DOI 10.1016/S8756 3282(98)00192 6
   Wu SL, 2014, MAT SCI ENG R, V80, P1, DOI 10.1016/j.mser.2014.04.001
   Xu ZL, 2016, J MATER CHEM B, V4, P7919, DOI 10.1039/c6tb01282e
   Zhang W, 2016, FUND CLIN PHARMACOL, V30, P596, DOI 10.1111/fcp.12225
   Zhang W, 2013, BIOMATERIALS, V34, P713, DOI 10.1016/j.biomaterials.2012.10.027
   Zhao YF, 2005, MICROPOR MESOPOR MAT, V87, P110, DOI 10.1016/j.micromeso.2005.07.046
   Zhu Y, 2017, ACS NANO, V11, P3690, DOI 10.1021/acsnano.6b08193
NR 61
TC 43
Z9 44
U1 4
U2 126
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1385 8947
EI 1873 3212
J9 CHEM ENG J
JI Chem. Eng. J.
PD JUN 1
PY 2018
VL 341
BP 112
EP 125
DI 10.1016/j.cej.2018.02.010
PG 14
WC Engineering, Environmental; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA GU8CL
UT WOS:000445561100012
DA 2025 08 17
ER

PT J
AU Zheng, Y
   Yu, WW
   Li, HY
   Lin, HB
   Chen, Z
   Chen, HS
   Zhang, PP
   Tian, Y
   Xu, XW
   Shen, YQ
AF Zheng, Yi
   Yu, Wenwen
   Li, Hongyan
   Lin, Hongbing
   Chen, Zhen
   Chen, Huishan
   Zhang, Peipei
   Tian, Yue
   Xu, Xiaowei
   Shen, Yuqin
TI CpG oligodeoxynucleotides inhibit the proliferation and osteoclastic
   differentiation of RAW264.7 cells
SO RSC ADVANCES
LA English
DT Article
ID TUMOR NECROSIS FACTOR; DNA; OLIGONUCLEOTIDES; OSTEOBLASTS; INDUCTION;
   ADJUVANT; ODN
AB Clinical prevention and treatment of periodontitis induced bone absorption remains a challenge. The anti infection role of CpG oligodeoxynucleotides (CpG ODNs) is well known; however, their effect on osteoclasts is still unclear. Here, we show that some CpG ODNs can regulate osteoclastogenesis of RAW264.7 cells. The phosphorothioate CpG ODN was efficiently taken up by the cells within 1 h and distributed in the cytoplasm. BW006, YW001, YW002, and FC004 CpG ODNs significantly repressed cell proliferation by targeting several cyclin proteins to arrest the cells in the G2 phase and to further initiate cell apoptosis. Regarding differentiation, we selected six CpG ODNs (FC002, BW006, YW002, YW001, FC004, and MT01) that markedly inhibited the gene expression levels of Nfatc, c fos, RANK, and MMP9. TRAP staining showed that only YW002, YW001, and FC004 suppressed osteoclast generation and maturation. These three CpG ODNs dramatically declined the protein levels of osteoclastogenic proteins by elevating the ratio of OPG/RANKL and also downregulating the inflammatory factors (TNF alpha, IL 1 beta, IL 6, and IL 17) at different stages. Thus, the selected CpG ODNs may be a potential molecular therapy for the prevention and treatment of periodontitis mediated bone resorption.
C1 [Zheng, Yi; Li, Hongyan; Lin, Hongbing; Chen, Zhen; Chen, Huishan; Zhang, Peipei; Tian, Yue; Xu, Xiaowei; Shen, Yuqin] Jilin Univ, Hosp Stomatol, Dept Periodont, 1500 Qinghua Rd, Changchun 130021, Jilin, Peoples R China.
   [Zheng, Yi; Lin, Hongbing; Shen, Yuqin] First Hosp Jilin Univ, Key Lab Organ Regenerat & Transplantat, Minist Educ, Changchun 130061, Jilin, Peoples R China.
   [Yu, Wenwen] Jilin Univ, Hosp Stomatol, Dept Orthodont, 1500 Qinghua Rd, Changchun 130021, Peoples R China.
   [Yu, Wenwen] Nankai Univ, Tianjin Stomatol Hosp, Dept Orthodont, Tianjin 300041, Peoples R China.
C3 Jilin University; Jilin University; Jilin University; Tianjin Medical
   University; Nankai University
RP Shen, YQ (通讯作者)，Jilin Univ, Hosp Stomatol, Dept Periodont, 1500 Qinghua Rd, Changchun 130021, Jilin, Peoples R China.; Shen, YQ (通讯作者)，First Hosp Jilin Univ, Key Lab Organ Regenerat & Transplantat, Minist Educ, Changchun 130061, Jilin, Peoples R China.
EM shenyqjlu@126.com
RI Yu, Wenwen/LCE 3187 2024; Xu, Xiaowei/I 6687 2018
FU Medical Support Program of the Jilin university [470110000423]; National
   Natural Science Foundation of China [81371153]; Medical Support Program
   of the Jilin province [20170311032YY]; Jilin Natural Science Research
   Foundation [20160101335JC]; Jilin province Education Department project
   [485]
FX This research was supported by grants from the Medical Support Program
   of the Jilin university (No. 470110000423), National Natural Science
   Foundation of China (No. 81371153), Medical Support Program of the Jilin
   province (No. 20170311032YY), Jilin Natural Science Research Foundation
   (No. 20160101335JC), and Jilin province Education Department project (Ji
   Jiao Ke He Zhi [2016] No. 485).
CR Agrawal S, 1998, CURR OPIN CHEM BIOL, V2, P519, DOI 10.1016/S1367 5931(98)80129 4
   Amcheslavsky A, 2005, J BONE MINER RES, V20, P1692, DOI 10.1359/JBMR.050515
   Amcheslavsky A, 2007, J BONE MINER RES, V22, P1301, DOI 10.1359/JBMR.070501
   Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858
   Barros SP, 2016, PERIODONTOL 2000, V70, P53, DOI 10.1111/prd.12107
   Chan JHP, 2006, CLIN EXP PHARMACOL P, V33, P533, DOI 10.1111/j.1440 1681.2006.04403.x
   Darveau RP, 2010, NAT REV MICROBIOL, V8, P481, DOI 10.1038/nrmicro2337
   Eckstein F, 2014, NUCLEIC ACID THER, V24, P374, DOI 10.1089/nat.2014.0506
   Gérard C, 2014, INTERFACE FOCUS, V4, DOI 10.1098/rsfs.2013.0075
   Graves DT, 2003, J PERIODONTOL, V74, P391, DOI 10.1902/jop.2003.74.3.391
   Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785
   Hanagata N, 2017, INT J NANOMED, V12, P515, DOI 10.2147/IJN.S114477
   Hayman AR, 2008, AUTOIMMUNITY, V41, P218, DOI 10.1080/08916930701694667
   Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123
   Hienz SA, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/615486
   Hou X, 2012, INT J MOL SCI, V13, P7902, DOI 10.3390/ijms13077902
   How KY, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00053
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Klinman D, 2008, J LEUKOCYTE BIOL, V84, P958, DOI 10.1189/jlb.1107775
   Klinman DM, 2004, NAT REV IMMUNOL, V4, P248, DOI 10.1038/nri1329
   Krieg AM, 2003, NAT MED, V9, P831, DOI 10.1038/nm0703 831
   Krisher T, 2014, J CELL BIOCHEM, V115, P2146, DOI 10.1002/jcb.24891
   Kudo O, 2002, J PATHOL, V198, P220, DOI 10.1002/path.1190
   Kudo O, 2003, BONE, V32, P1, DOI 10.1016/S8756 3282(02)00915 8
   Kurreck J, 2003, EUR J BIOCHEM, V270, P1628, DOI 10.1046/j.1432 1033.2003.03555.x
   Lambert G, 2001, ADV DRUG DELIVER REV, V47, P99, DOI 10.1016/S0169 409X(00)00116 2
   Liu C, 2010, MOL ORAL MICROBIOL, V25, P178, DOI 10.1111/j.2041 1014.2009.00560.x
   Miyajima S, 2014, SCI REP UK, V4, DOI 10.1038/srep05171
   Mutwiri GK, 2004, J CONTROL RELEASE, V97, P1, DOI 10.1016/j.jcornel.2004.02.022
   Ni C, 2019, BIOMATERIALS, V206, P115, DOI 10.1016/j.biomaterials.2019.03.039
   Nonnenmacher C, 2003, INFECT IMMUN, V71, P850, DOI 10.1128/IAI.71.2.850 856.2003
   Pereira M, 2018, J CELL SCI, V131, DOI 10.1242/jcs.216267
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   PUTNEY SD, 1981, P NATL ACAD SCI BIOL, V78, P7350, DOI 10.1073/pnas.78.12.7350
   Ripamonti U, 2009, CYTOKINE GROWTH F R, V20, P489, DOI 10.1016/j.cytogfr.2009.10.016
   Roberts TL, 2011, MOL IMMUNOL, V48, P1027, DOI 10.1016/j.molimm.2011.01.011
   Ronaghy A, 2002, J IMMUNOL, V168, P51, DOI 10.4049/jimmunol.168.1.51
   Rudnicka W, 2009, EUR J IMMUNOL, V39, P1211, DOI 10.1002/eji.200838617
   Shirota H, 2014, EXPERT REV VACCINES, V13, P299, DOI 10.1586/14760584.2014.863715
   Yang M, 2012, INT IMMUNOPHARMACOL, V13, P408, DOI 10.1016/j.intimp.2012.05.003
   Yu XQ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165862
   Zhang HJ, 2017, MAT SCI ENG C MATER, V73, P144, DOI 10.1016/j.msec.2016.12.072
   Zheng Y, 2017, RSC ADV, V7, P27121, DOI 10.1039/c6ra27182k
   Zou W, 2003, J BIOL CHEM, V278, P16732, DOI 10.1074/jbc.M212473200
   Zou W, 2002, FASEB J, V16, P274, DOI 10.1096/fj.01 0586com
NR 45
TC 6
Z9 6
U1 0
U2 21
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046 2069
J9 RSC ADV
JI RSC Adv.
PD APR 15
PY 2020
VL 10
IS 25
BP 14885
EP 14891
DI 10.1039/c9ra11036d
PG 7
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA LH4FJ
UT WOS:000528740900050
PM 35497169
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Sun, MX
   Clayton, N
   Alam, S
   Asmussen, N
   Wong, AD
   Kim, JH
   Luong, G
   Mokhtari, S
   Pellei, D
   Carrico, CK
   Schwartz, Z
   Boyan, BD
   Giannobile, WV
   Sahingur, SE
   Lin, Z
AF Sun, Mingxu
   Clayton, Nicholas
   Alam, Sheikh
   Asmussen, Niels
   Wong, Andrew
   Kim, Jin Ha
   Luong, Gary
   Mokhtari, Sasan
   Pellei, David
   Carrico, Caroline K.
   Schwartz, Zvi
   Boyan, Barbara D.
   Giannobile, William V.
   Sahingur, Sinem Esra
   Lin, Zhao
TI Selective BET inhibitor RVX 208 ameliorates periodontal inflammation and
   bone loss
SO JOURNAL OF CLINICAL PERIODONTOLOGY
LA English
DT Article
DE BET inhibitor; histone acetylation; osteoclast; periodontitis; RVX 208
ID BROMODOMAIN INHIBITOR; IN VITRO; APABETALONE; EXPRESSION; PROTEINS;
   BRD2; GENE
AB Aim: To determine the effects of RVX 208, a selective bromodomain and extra terminal domain (BET) inhibitor targeting bromodomain 2 (BD2), on periodontal inflammation and bone loss.Materials and Methods: Macrophage like cells (RAW264.7) and human gingival epithelial cells were challenged by Porphyromonas gingivalis (Pg) with or without RVX 208. Inflammatory gene expression and cytokine production were measured by reverse transcription polymerase chain reaction and enzyme linked immunosorbent assay, respectively. RAW264.7 cells were induced to osteoclast differentiation. After RVX 208 treatment, osteoclast differentiation was evaluated by histology, tartrate resistant acid phosphatase (TRAP) activity and the expression of osteoclast specific genes. The effect of RVX 208 on osteoclast transcriptome was studied by RNA sequencing. Periodontitis was induced in rats by ligature and local RVX 208 treatment was administered every other day. Alveolar bone loss was measured by micro computed tomography.Results: RVX 208 inhibited inflammatory gene expression and cytokine production in Pg infected cells. Osteoclast differentiation was inhibited by RVX 208, as evidenced by reduced osteoclast number, TRAP activity and osteoclast specific gene expression. RVX 208 displayed a more selective and less profound suppressive impact on transcriptome compared with pan BET inhibitor, JQ1. RVX 208 administration prevented the alveolar bone loss in vivo.Conclusions: RVX 208 regulated both upstream (inflammatory cytokine production) and downstream (osteoclast differentiation) events that lead to periodontal tissue destruction, suggesting that it may be a promising 'epi drug' for the prevention of periodontitis.
C1 [Sun, Mingxu; Clayton, Nicholas; Alam, Sheikh; Wong, Andrew; Kim, Jin Ha; Luong, Gary; Mokhtari, Sasan; Pellei, David; Lin, Zhao] Virginia Commonwealth Univ, Sch Dent, Dept Periodont, Richmond, VA USA.
   [Sun, Mingxu] Jianbo Dent Clin, Qingdao, Peoples R China.
   [Asmussen, Niels; Schwartz, Zvi; Boyan, Barbara D.] Virginia Commonwealth Univ, Dept Biomed Engn, Richmond, VA USA.
   [Carrico, Caroline K.] Virginia Commonwealth Univ, Sch Dent, Dept Dent Publ Hlth & Policy, Richmond, VA USA.
   [Giannobile, William V.] Harvard Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA USA.
   [Sahingur, Sinem Esra] Univ Penn, Sch Dent Med, Dept Periodont, Philadelphia, PA USA.
   [Lin, Zhao] VCU Sch Dent, Dept Periodont, 521 North 11th St, Richmond, VA 23298 USA.
C3 Virginia Commonwealth University; Virginia Commonwealth University;
   Virginia Commonwealth University; Harvard University; Harvard School of
   Dental Medicine; University of Pennsylvania; Virginia Commonwealth
   University
RP Lin, Z (通讯作者)，VCU Sch Dent, Dept Periodont, 521 North 11th St, Richmond, VA 23298 USA.
EM zlin@vcu.edu
OI Wong, Andrew/0000 0002 0902 3159
FU This work was supported by National Institutes of Health grant
   R01DE028915 and a start up fund from Virginia Commonwealth University
   School of Dentistry to Zhao Lin. We thank David J Cohen, Chongxia Yue,
   Jie Cao, Noorpreet Kaur, Sheriz Chisley Strickler, S [R01DE028915];
   National Institutes of Health; Virginia Commonwealth University School
   of Dentistry
FX This work was supported by National Institutes of Health grant
   R01DE028915 and a start up fund from Virginia Commonwealth University
   School of Dentistry to Zhao Lin. We thank David J Cohen, Chongxia Yue,
   Jie Cao, Noorpreet Kaur, Sheriz Chisley Strickler, Simrah Ansari and
   Shreya Dalal for their excellent technical assistance.
CR Bailey D, 2010, J AM COLL CARDIOL, V55, P2580, DOI 10.1016/j.jacc.2010.02.035
   Baud'huin M, 2017, BONE, V94, P10, DOI 10.1016/j.bone.2016.09.020
   Belkina AC, 2013, J IMMUNOL, V190, P3670, DOI 10.4049/jimmunol.1202838
   Berthon C, 2016, LANCET HAEMATOL, V3, pE186, DOI 10.1016/S2352 3026(15)00247 1
   Caputo VS, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2020.101989
   Cheung KL, 2017, MOL CELL, V65, P1068, DOI 10.1016/j.molcel.2016.12.022
   Chiang Cheng Ming, 2009, F1000 Biol Rep, V1, P98, DOI 10.3410/B1 98
   Crump KE, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00814 16
   Gacias M, 2014, CHEM BIOL, V21, P841, DOI 10.1016/j.chembiol.2014.05.009
   Gamsjaeger R, 2011, MOL CELL BIOL, V31, P2632, DOI 10.1128/MCB.05413 11
   Gilan O, 2020, SCIENCE, V368, P387, DOI 10.1126/science.aaz8455
   Grauballe MB, 2017, CLIN EXP DENT RES, V3, P25, DOI 10.1002/cre2.54
   Haffajee AD, 2006, PERIODONTOL 2000, V42, P7, DOI 10.1111/j.1600 0757.2006.00190.x
   O'Connor MH, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.856966
   Imai K, 2012, BIOCHIMIE, V94, P839, DOI 10.1016/j.biochi.2011.12.001
   Jacques C, 2020, EPIGENOMICS UK, V12, P127, DOI 10.2217/epi 2019 0172
   Jahagirdar R, 2014, ATHEROSCLEROSIS, V236, P91, DOI 10.1016/j.atherosclerosis.2014.06.008
   Larsson L, 2022, PERIODONTOL 2000, V90, P125, DOI 10.1111/prd.12453
   Lee CT, 2016, J IMMUNOL, V197, P2796, DOI 10.4049/jimmunol.1600859
   Lee DU, 2016, TOXICOL APPL PHARM, V300, P47, DOI 10.1016/j.taap.2016.03.013
   Maksylewicz A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00933
   Martins MD, 2016, J DENT RES, V95, P215, DOI 10.1177/0022034515611876
   McLure KG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083190
   Meng S, 2014, J DENT RES, V93, P657, DOI 10.1177/0022034514534261
   Moffatt Jauregui CE, 2013, J PERIODONTAL RES, V48, P713, DOI 10.1111/jre.12059
   Nicholls SJ, 2021, CARDIOVASC DIABETOL, V20, DOI 10.1186/s12933 020 01199 x
   Nicholls SJ, 2018, AM J CARDIOVASC DRUG, V18, P109, DOI 10.1007/s40256 017 0250 3
   Nicholls SJ, 2016, AM J CARDIOVASC DRUG, V16, P55, DOI 10.1007/s40256 015 0146 z
   Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589
   Park Min KH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6418
   Picaud S, 2013, P NATL ACAD SCI USA, V110, P19754, DOI 10.1073/pnas.1310658110
   Schröder S, 2012, J BIOL CHEM, V287, P1090, DOI 10.1074/jbc.M111.282855
   Siebel AL, 2016, METABOLISM, V65, P904, DOI 10.1016/j.metabol.2016.03.002
   Sullivan JM, 2015, J EXP MED, V212, P1771, DOI 10.1084/jem.20151271
   Van Dyke TE, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00511
   Wasiak S, 2017, J CARDIOVASC TRANSL, V10, P337, DOI 10.1007/s12265 017 9755 z
   Wasiak S, 2016, DATA BRIEF, V8, P1280, DOI 10.1016/j.dib.2016.07.047
   Xiao E, 2017, CELL HOST MICROBE, V22, P120, DOI 10.1016/j.chom.2017.06.014
   Yin L, 2011, MUCOSAL IMMUNOL, V4, P409, DOI 10.1038/mi.2010.83
NR 39
TC 6
Z9 7
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0303 6979
EI 1600 051X
J9 J CLIN PERIODONTOL
JI J. Clin. Periodontol.
PD DEC
PY 2023
VL 50
IS 12
BP 1658
EP 1669
DI 10.1111/jcpe.13887
EA OCT 2023
PG 12
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA Y4YF0
UT WOS:001086427200001
PM 37855275
DA 2025 08 17
ER

PT J
AU Cultrara, CN
   Kozuch, SD
   Ramasundaram, P
   Heller, CJ
   Shah, S
   Beck, AE
   Sabatino, D
   Zilberberg, J
AF Cultrara, Christopher N.
   Kozuch, Stephen D.
   Ramasundaram, Poornema
   Heller, Claudia J.
   Shah, Sunil
   Beck, Adah E.
   Sabatino, David
   Zilberberg, Jenny
TI GRP78 modulates cell adhesion markers in prostate Cancer and multiple
   myeloma cell lines
SO BMC CANCER
LA English
DT Article
DE GRP78; Gene knockdown; Epithelia mesenchymal transition (EMT); Cell
   adhesion
ID UNFOLDED PROTEIN RESPONSE; TGF BETA; N CADHERIN; DRUG RESISTANCE;
   STEM CELLS; ROLES; IDENTIFICATION; SUBPOPULATION; INACTIVATION;
   METASTASIS
AB BackgroundGlucose regulated protein 78 (GRP78) is a resident chaperone of the endoplasmic reticulum and a master regulator of the unfolded protein response under physiological and pathological cell stress conditions. GRP78 is overexpressed in many cancers, regulating a variety of signaling pathways associated with tumor initiation, proliferation, adhesion and invasion which contributes to metastatic spread. GRP78 can also regulate cell survival and apoptotic pathways to alter responsiveness to anticancer drugs. Tumors that reside in or metastasize to the bone and bone marrow (BM) space can develop pro survival signals through their direct adhesive interactions with stromal elements of this niche thereby resisting the cytotoxic effects of drug treatment. In this study, we report a direct correlation between GRP78 and the adhesion molecule N cadherin (N cad), known to play a critical role in the adhesive interactions of multiple myeloma and metastatic prostate cancer with the bone microenvironment.MethodsN cad expression levels (transcription and protein) were evaluated upon siRNA mediated silencing of GRP78 in the MM.1S multiple myeloma and the PC3 metastatic prostate cancer cell lines. Furthermore, we evaluated the effects of GRP78 knockdown (KD) on epithelial mesenchymal (EMT) transition markers, morphological changes and adhesion of PC3 cells.ResultsGRP78 KD led to concomitant downregulation of N cad in both tumors types. In PC3 cells, GRP78 KD significantly decreased E cadherin (E cad) expression likely associated with the induction in TGF 1 expression. Furthermore, GRP78 KD also triggered drastic changes in PC3 cells morphology and decreased their adhesion to osteoblasts (OSB) dependent, in part, to the reduced N cad expression.ConclusionThis work implicates GRP78 as a modulator of cell adhesion markers in MM and PCa. Our results may have clinical implications underscoring GRP78 as a potential therapeutic target to reduce the adhesive nature of metastatic tumors to the bone niche.
C1 [Cultrara, Christopher N.; Kozuch, Stephen D.; Heller, Claudia J.; Shah, Sunil; Beck, Adah E.; Sabatino, David] Dept Chem & Biochem, 400 South Orange Ave, S Orange, NJ 07079 USA.
   [Ramasundaram, Poornema; Zilberberg, Jenny] Hackensack Univ, Med Ctr, Ctr Discovery & Innovat, 340 Kingsland St,Bldg 102, Nutley, NJ 07110 USA.
C3 Hackensack University Medical Center
RP Zilberberg, J (通讯作者)，Hackensack Univ, Med Ctr, Ctr Discovery & Innovat, 340 Kingsland St,Bldg 102, Nutley, NJ 07110 USA.
EM Jenny.Zilberberg@hackensackmeridian.org
RI ; shah, sunil/K 5948 2019; Shah, Sunil/K 5948 2019
OI Heller, Claudia/0000 0001 8895 9221; Zilberberg,
   Jenny/0000 0002 4139 2616; shah, sunil/0000 0001 7084 1399; Sabatino,
   David/0000 0002 9797 0833
FU Emerald Foundation, Inc.
FX This research was supported in part by a grant from the Emerald
   Foundation, Inc. to JZ.
CR Adomako A, 2015, BMC CANCER, V15, DOI 10.1186/s12885 015 1460 1
   [Anonymous], BIOMED RES INT
   Bao X, 2017, INT J ONCOL, V50, P477, DOI 10.3892/ijo.2016.3806
   Bartkowiak K, 2015, CANCER RES, V75, P5367, DOI 10.1158/0008 5472.CAN 14 3728
   Brennan SK, 2009, J MOL MED, V87, P1079, DOI 10.1007/s00109 009 0531 7
   Brook N, 2018, INT J BIOCHEM CELL B, V96, P63, DOI 10.1016/j.biocel.2018.01.003
   Busch EL, 2016, CLIN EXP METASTAS, V33, P53, DOI 10.1007/s10585 015 9757 7
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Cao Z, 2017, ONCOTARGET, V8, P78507, DOI 10.18632/oncotarget.19659
   Chhabra S, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045 015 0177 6
   Coughlin TR, 2017, CURR DRUG TARGETS, V18, P1281, DOI 10.2174/1389450117666161226121650
   Croft DR, 2008, CANCER CELL, V14, P349, DOI 10.1016/j.ccr.2008.10.009
   Cui YX, 2016, ANTICANCER RES, V36, P1193
   Damiano JS, 2002, CURR CANCER DRUG TAR, V2, P37, DOI 10.2174/1568009023334033
   de Castro NP, 2010, FUTURE ONCOL, V6, P1127, DOI 10.2217/FON.10.68
   Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013
   Esposito M, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031252
   Fournier PGJ, 2015, CANCER CELL, V27, P809, DOI 10.1016/j.ccell.2015.04.009
   Gass JN, 2004, TRENDS IMMUNOL, V25, P17, DOI 10.1016/j.it.2003.11.004
   Ghosh N, 2009, CANCER LETT, V277, P1, DOI 10.1016/j.canlet.2008.08.005
   Gray PC, 2012, FEBS LETT, V586, P1836, DOI 10.1016/j.febslet.2012.01.051
   Heerboth S, 2015, CLIN TRANSL MED, V4, DOI 10.1186/s40169 015 0048 3
   Hua YP, 2013, CLIN CANCER RES, V19, P6242, DOI 10.1158/1078 0432.CCR 13 2083
   Huang CF, 2010, CANCER RES, V70, P4580, DOI 10.1158/0008 5472.CAN 09 3016
   Jones A, 2014, J BIOL CHEM, V289, P35326, DOI 10.1074/jbc.M114.611962
   Jones E, 2009, EXPERT OPIN THER TAR, V13, P227, DOI [10.1517/14728220802705696 , 10.1517/14728220802705696]
   Klauzinska M, 2015, CONNECT TISSUE RES, V56, P364, DOI 10.3109/03008207.2015.1077239
   Lee AS, 2014, NAT REV CANCER, V14, P263, DOI 10.1038/nrc3701
   Li ZW, 2006, BLOOD REV, V20, P333, DOI 10.1016/j.blre.2005.08.003
   Li ZW, 2014, ONCOTARGET, V5, P5369, DOI 10.18632/oncotarget.2105
   Lu Y, 2011, ONCOGENE, V30, P4567, DOI 10.1038/onc.2011.164
   Ma Jie, 2015, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V23, P1044, DOI 10.7534/j.issn.1009 2137.2015.04.027
   Malek MAYA, 2015, ONCOTARGET, V6, P3098
   Mandelin J, 2015, P NATL ACAD SCI USA, V112, P3776, DOI 10.1073/pnas.1500128112
   Mishra A, 2012, MOL CANCER RES, V10, P703, DOI 10.1158/1541 7786.MCR 11 0569
   Misra UK, 2009, MOL CANCER THER, V8, P1350, DOI 10.1158/1535 7163.MCT 08 0990
   Morgenroth A, 2014, MOL CANCER THER, V13, P144, DOI 10.1158/1535 7163.MCT 13 0240
   Mrozik KM, 2015, BRIT J HAEMATOL, V171, P387, DOI 10.1111/bjh.13596
   Nakamura M, 2006, LEUKEMIA LYMPHOMA, V47, P531, DOI 10.1080/10428190500312196
   Neri P, 2012, CURR CANCER DRUG TAR, V12, P776, DOI 10.2174/156800912802429337
   Obeng EA, 2006, BLOOD, V107, P4907, DOI 10.1182/blood 2005 08 3531
   Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316
   Pedersen EA, 2012, ASIAN J ANDROL, V14, P423, DOI 10.1038/aja.2011.164
   Pfaffenbach KT, 2011, CURR OPIN CELL BIOL, V23, P150, DOI 10.1016/j.ceb.2010.09.007
   Puch S, 2001, J CELL SCI, V114, P1567
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476 5586(04)80047 2
   Sheng LF, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478 811X 11 94
   Shiirevnyamba A, 2011, BRIT J CANCER, V104, P505, DOI 10.1038/sj.bjc.6606070
   Shiozawa Y, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.57
   Steinbrunn T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097443
   Tanaka H, 2010, NAT MED, V16, P1414, DOI 10.1038/nm.2236
   Thulin MH, 2016, MOL CELL ENDOCRINOL, V422, P182, DOI 10.1016/j.mce.2015.11.013
   Tomita K, 2000, CANCER RES, V60, P3650
   Vandyke K, 2013, BRIT J HAEMATOL, V161, P499, DOI 10.1111/bjh.12280
   Villarejo A, 2014, J BIOL CHEM, V289, P930, DOI 10.1074/jbc.M113.528026
   Vincenz L, 2013, MOL CANCER THER, V12, P831, DOI 10.1158/1535 7163.MCT 12 0782
   Wang M, 2009, ANTIOXID REDOX SIGN, V11, P2307, DOI [10.1089/ars.2009.2485, 10.1089/ARS.2009.2485]
   Wang M, 2016, INT J ONCOL, V48, P595, DOI 10.3892/ijo.2015.3270
   Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5
   Yun SP, 2017, BIOMOL THER SEOUL
   Zhang L, 2015, INT J BIOCHEM CELL B, P202
   Zhang LH, 2010, J CELL BIOCHEM, V110, P1299, DOI 10.1002/jcb.22679
   Zhang WT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125995
   Zhang XX, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/917296
   Zhang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080071
   Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328
   Zhu GY, 2015, J CELL PHYSIOL, V230, P1413, DOI 10.1002/jcp.24923
   Zoni E, 2017, ONCOGENE, V36, P4739, DOI 10.1038/onc.2017.87
NR 68
TC 31
Z9 34
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471 2407
J9 BMC CANCER
JI BMC Cancer
PD DEC 18
PY 2018
VL 18
AR 1263
DI 10.1186/s12885 018 5178 8
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA HE8HO
UT WOS:000453687000003
PM 30563499
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Varela, A
   Chouinard, L
   Lesage, E
   Guldberg, R
   Smith, SY
   Kostenuik, PJ
   Hattersley, G
AF Varela, Aurore
   Chouinard, Luc
   Lesage, Elisabeth
   Guldberg, Robert
   Smith, Susan Y.
   Kostenuik, Paul J.
   Hattersley, Gary
TI One year of abaloparatide, a selective peptide activator of the PTH1
   receptor, increased bone mass and strength in ovariectomized rats
SO BONE
LA English
DT Article
DE Abaloparatide; PTH1 receptor; Anabolic agents; Bone strength;
   Osteoporosis
ID PARATHYROID HORMONE 1 34; MINERAL DENSITY; CORTICAL BONE; POSTMENOPAUSAL
   WOMEN; VERTEBRAL FRACTURES; OSTEOPOROSIS; FLUORIDE; THERAPY; QUALITY;
   ANALOG
AB Abaloparatide is a novel 34 amino acid peptide selected to be a potent and selective activator of the parathyroid hormone receptor 1 (PTHR1) signaling pathway. The effects of 12 months of abaloparatide treatment on bone mass, bone strength and bone quality was assessed in osteopenic ovariectomized (OVX) rats. SD rats were subjected to OVX or sham surgery at 6 months of age and left untreated for 3 months to allow OVX induced bone loss. Eighteen OVX rats were sacrificed after this bone depletion period, and the remaining OVX rats received daily s.c. injections of vehicle (n = 18) or abaloparatide at 1, 5 or 25 mu g/kg/d (n = 18/dose level) for 12 months. Sham controls (n = 18) received vehicle daily. Bone changes were assessed by DXA and pQCT after 0, 3, 6 or 12 months of treatment, and destructive biomechanical testing was conducted at month 12 to assess bone strength and bone quality. Abaloparatide dose dependently increased bone mass at the lumbar spine and at the proximal and diaphyseal regions of the tibia and femur. pQCT revealed that increased cortical bone volume at the tibia was a result of periosteal expansion and endocortical bone apposition. Abaloparatide dose dependently increased structural strength of L4 L5 vertebral bodies, the femur diaphysis, and the femur neck. Increments in peak load for lumbar spine and the femur diaphysis of abaloparatide treated rats persisted even after adjusting for treatment related increments in BMC, and estimated material properties were maintained or increased at the femur diaphysis with abaloparatide. The abaloparatide groups also exhibited significant and positive correlations between bone mass and bone strength at these sites. These data indicate that gains in cortical and trabecular bone mass with abaloparatide are accompanied by and correlated with improvements in bone strength, resulting in maintenance or improvement in bone quality. Thus, this study demonstrated that long term daily administration of abaloparatide to osteopenic OVX rats led to dose dependent improvements in bone mass, geometry and strength. (C) 2016 Published by Elsevier Inc.
C1 [Varela, Aurore; Chouinard, Luc; Lesage, Elisabeth; Smith, Susan Y.] Charles River Labs, Montreal, PQ, Canada.
   [Guldberg, Robert] Georgia Inst Technol, Petit Inst Bioengn, Biosci, Atlanta, GA 30332 USA.
   [Guldberg, Robert] Georgia Inst Technol, Woodruff Sch Mech Engn, Atlanta, GA 30332 USA.
   [Kostenuik, Paul J.] Univ Michigan, Ann Arbor, MI 48109 USA.
   [Kostenuik, Paul J.] Phylon Pharma Serv, Newbury Pk, CA USA.
   [Hattersley, Gary] Radius Hlth, 950 Winter St, Waltham, MA 02451 USA.
C3 University System of Georgia; Georgia Institute of Technology;
   University System of Georgia; Georgia Institute of Technology;
   University of Michigan System; University of Michigan; Radius Health,
   Inc.
RP Hattersley, G (通讯作者)，Radius Hlth, 950 Winter St, Waltham, MA 02451 USA.
EM ghattersley@radiuspharm.com
FU Radius Health, Inc.
FX This study was sponsored by Radius Health, Inc.
CR Allen MR, 2008, OSTEOPOROSIS INT, V19, P95, DOI 10.1007/s00198 007 0451 8
   [Anonymous], use of laboratory animals
   Augat P, 1998, J ORTHOPAED RES, V16, P629, DOI 10.1002/jor.1100160517
   Austin M, 2012, J BONE MINER RES, V27, P687, DOI 10.1002/jbmr.1472
   Bahar H, 2016, CALCIFIED TISSUE INT, V99, P489, DOI 10.1007/s00223 016 0171 1
   Bouxsein ML, 1999, BONE, V25, P49, DOI 10.1016/S8756 3282(99)00093 9
   CHAN MM, 1977, J NUTR, V107, P1747, DOI 10.1093/jn/107.9.1747
   Chen PQ, 2007, J BONE MINER RES, V22, P841, DOI 10.1359/JBMR.070310
   CHMP, 2005, GUID EV NEW MED PROD, P1
   ClinicalTrials.gov, 24 MONTH EXT STUD BA
   Doyle N, 2014, J BONE MINER RES, V29, pS319
   Ejersted C, 1995, BONE, V17, P507, DOI 10.1016/8756 3282(95)00371 1
   FDA, 1994, FDA DRAFT GUD PRECL
   Fox J, 2006, CALCIFIED TISSUE INT, V79, P262, DOI 10.1007/s00223 006 0108 1
   Hernandez CJ, 2006, BONE, V39, P1173, DOI 10.1016/j.bone.2006.06.001
   Hochberg MC, 1999, ARTHRITIS RHEUM US, V42, P1246, DOI 10.1002/1529 0131(199906)42:6<1246::AID ANR22>3.0.CO;2 U
   Hochberg MC, 2002, J CLIN ENDOCR METAB, V87, P1586, DOI 10.1210/jc.87.4.1586
   Iida Klein A, 2006, J BONE MINER RES, V21, P274, DOI 10.1359/JBMR.051017
   Kostenuik P., 2013, Marcus and Feldmans Osteoporosis. Two Vol. Set Vol. 1, V4th ed., P873
   LAFAGE MH, 1995, J CLIN INVEST, V95, P2127, DOI 10.1172/JCI117901
   Leder BZ, 2015, J CLIN ENDOCR METAB, V100, P697, DOI 10.1210/jc.2014 3718
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   Ominsky MS, 2008, J BONE MINER RES, V23, P672, DOI 10.1359/JBMR.080109
   Ominsky MS, 2011, BONE, V49, P162, DOI 10.1016/j.bone.2011.04.001
   Ominsky MS, 2009, J BONE MINER RES, V24, P1234, DOI [10.1359/JBMR.090215, 10.1359/jbmr.090215]
   Sato M, 1997, ENDOCRINOLOGY, V138, P4330, DOI 10.1210/en.138.10.4330
   SOGAARD CH, 1994, BONE, V15, P393, DOI 10.1016/8756 3282(94)90815 X
   SOGAARD CH, 1994, ENDOCRINOLOGY, V134, P650, DOI 10.1210/en.134.2.650
   SOGAARD CH, 1995, BONE, V16, P163, DOI 10.1016/S8756 3282(94)00025 5
   Stewart AF, 2000, J BONE MINER RES, V15, P1517, DOI 10.1359/jbmr.2000.15.8.1517
   Thomsen JS, 1999, BONE, V25, P561, DOI 10.1016/S8756 3282(99)00212 4
   Varela A., 2016, J BONE MINER RES
   Xu J, 2013, CALCIFIED TISSUE INT, V93, P276, DOI 10.1007/s00223 013 9755 1
NR 33
TC 44
Z9 46
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD FEB
PY 2017
VL 95
BP 143
EP 150
DI 10.1016/j.bone.2016.11.027
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA EI0LD
UT WOS:000392165100019
PM 27894941
OA hybrid
DA 2025 08 17
ER

PT J
AU Cantley, MD
   Fairlie, DP
   Bartold, PM
   Marino, V
   Gupta, PK
   Haynes, DR
AF Cantley, Melissa D.
   Fairlie, David P.
   Bartold, P. Mark
   Marino, Victor
   Gupta, Praveer K.
   Haynes, David R.
TI Inhibiting histone deacetylase 1 suppresses both inflammation and bone
   loss in arthritis
SO RHEUMATOLOGY
LA English
DT Article
DE histone deacetylase 1; inflammation; osteoclasts; bone loss; collagen
   antibody induced arthritis
ID OSTEOCLAST LIKE CELLS; RHEUMATOID ARTHRITIS; IN VITRO; RECEPTOR
   ACTIVATOR; HDAC INHIBITORS; MOUSE MODEL; DESTRUCTION; EXPRESSION;
   MACROPHAGES; RESORPTION
AB Objective. Histone deacetylase 1 (HDAC1) is highly expressed in the synovium of RA patients. Thus we aimed to investigate a novel HDAC inhibitor (HDACi), NW 21, designed to target HDAC1. The effect of NW 21 on osteoclast formation and activity, cytokine and chemokine expression in vitro and arthritis in mice was assessed.
   Methods. The effects on human osteoclast formation and activity derived from human blood monocytes stimulated with receptor activator of nuclear factor kB ligand (RANKL) and M CSF were assessed. The anti inflammatory activity of NW 21 was assessed using human monocytes stimulated with either TNF alpha or lipopolysaccharide for 24 h. mRNA expression of monocyte chemotactic protein 1 (MCP 1), TNF alpha, macrophage inflammatory protein 1 alpha (MIP 1 alpha), IL 1 and RANTES (regulated on activation, normal T cell expressed and secreted) was assessed. The effect of NW 21 in the collagen antibody induced arthritis model was assessed following daily oral administration at 5 mg/kg/day. The HDAC1 inhibitors NW 21 and MS 275 were compared with a broad acting HDACi, 1179.4b. Effects on inflammation and bone were assessed using paw inflammation scoring, histology and live animal micro CT.
   Results. NW 21 suppressed osteoclast formation and activity as well as significantly reducing mRNA expression of MCP 1 and MIP 1 alpha in monocytes stimulated by lipopolysaccharide or TNF alpha (P<0.05) in vitro. Only inhibitors that targeted HDAC1 (NW 21 and MS 275) reduced inflammation and bone loss in the arthritis model.
   Conclusion. The results indicate that inhibitors targeting HDAC1, such as NW 21 and MS 275, may be useful for treating RA, as such drugs can simultaneously target both inflammation and bone resorption.
C1 [Cantley, Melissa D.; Haynes, David R.] Univ Adelaide, Sch Med Sci, Discipline Anat & Pathol, Adelaide, SA 5005, Australia.
   [Fairlie, David P.; Gupta, Praveer K.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia.
   [Bartold, P. Mark; Marino, Victor] Univ Adelaide, Sch Dent, Colgate Australian Clin Dent Res Ctr, Adelaide, SA, Australia.
C3 University of Adelaide; University of Queensland; University of Adelaide
RP Cantley, MD (通讯作者)，Univ Adelaide, Sch Med Sci, Discipline Anat & Pathol, Adelaide, SA 5005, Australia.
EM melissa.cantley@adelaide.edu.au
RI ; Cantley, Melissa/V 4674 2019; Fairlie, David/F 8865 2014; Bartold,
   Mark/H 8122 2019
OI Fairlie, David/0000 0002 7856 8566; Bartold, Peter/0000 0002 5695 3877;
   Cantley, Melissa/0000 0002 7188 0928; 
FU Australian Dental Research Foundation [73/2011]
FX This work was supported by Australian Dental Research Foundation grant
   (73/2011).
CR Alias E, 2012, ACTA BIOMATER, V8, P3104, DOI 10.1016/j.actbio.2012.04.037
   [Anonymous], BIOCH J
   Cantley MD, 2011, J PERIODONTAL RES, V46, P697, DOI 10.1111/j.1600 0765.2011.01392.x
   Cantley MD, 2011, J CELL PHYSIOL, V226, P3233, DOI 10.1002/jcp.22684
   Cantley MD, 2011, J CLIN PERIODONTOL, V38, P532, DOI 10.1111/j.1600 051X.2011.01714.x
   Culley KL, 2013, ARTHRITIS RHEUM US, V65, P1822, DOI 10.1002/art.37965
   de Vries F, 2007, ARTHRITIS RHEUM US, V56, P208, DOI 10.1002/art.22294
   Dinarello CA, 2011, MOL MED, V17, P333, DOI 10.2119/molmed.2011.00116
   Fischle W, 2001, J BIOL CHEM, V276, P35826, DOI 10.1074/jbc.M104935200
   Franssen MEJ, 2005, J INVEST DERMATOL, V124, P373, DOI 10.1111/j.0022 202X.2004.23612.x
   Fujikawa Y, 1996, ANN RHEUM DIS, V55, P816, DOI 10.1136/ard.55.11.816
   Granfar RMS, 2005, MOL CELL PROBE, V19, P119, DOI 10.1016/j.mcp.2004.10.003
   Gupta P, 2012, CURR TOP MED CHEM, V12, P1479, DOI 10.2174/156802612802652420
   HAYNES DR, 1990, IMMUNOL CELL BIOL, V68, P225, DOI 10.1038/icb.1990.31
   Haynes DR, 2001, RHEUMATOLOGY, V40, P623, DOI 10.1093/rheumatology/40.6.623
   Horiuchi M, 2009, J RHEUMATOL, V36, P1580, DOI 10.3899/jrheum.081115
   Hsieh IN, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.133
   Joosten LAB, 2011, MOL MED, V17, P391, DOI 10.2119/molmed.2011.00058
   Kahnberg P, 2006, J MED CHEM, V49, P7611, DOI 10.1021/jm050214x
   Kawabata Tomoko, 2010, Arthritis Res Ther, V12, pR133, DOI 10.1186/ar3071
   Kelly RDW, 2013, BIOCHEM SOC T, V41, P741, DOI 10.1042/BST20130010
   Keystone E, 2009, CURR OPIN RHEUMATOL, V21, P231, DOI 10.1097/BOR.0b013e328329f84f
   Kim HN, 2009, EUR J PHARMACOL, V623, P22, DOI 10.1016/j.ejphar.2009.09.025
   Kim MS, 2006, J BIOL CHEM, V281, P1274, DOI 10.1074/jbc.M510156200
   KOCH AE, 1994, J CLIN INVEST, V93, P921, DOI 10.1172/JCI117097
   KOCH AE, 1992, J CLIN INVEST, V90, P772, DOI 10.1172/JCI115950
   Kristensen LE, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2084
   Leoni F, 2005, MOL MED, V11, P1, DOI 10.2119/2006 00005.Dinarello
   Lin HS, 2007, BRIT J PHARMACOL, V150, P862, DOI 10.1038/sj.bjp.0707165
   Miyamoto K, 2009, BIOCHEM BIOPH RES CO, V383, P373, DOI 10.1016/j.bbrc.2009.04.020
   Mohan N, 2001, ARTHRITIS RHEUM US, V44, P2862, DOI 10.1002/1529 0131(200112)44:12<2862::AID ART474>3.0.CO;2 W
   Nakamura T, 2005, J IMMUNOL, V175, P5809, DOI 10.4049/jimmunol.175.9.5809
   Nasu Y, 2008, OSTEOARTHR CARTILAGE, V16, P723, DOI 10.1016/j.joca.2007.10.014
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Ryu OH, 2007, J PERIODONTOL, V78, P1627, DOI 10.1902/jop.2007.070066
   Schett G, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2166
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Slingerland M, 2014, ANTI CANCER DRUG, V25, P140, DOI 10.1097/CAD.0000000000000040
   Suzuki Y, 2001, RHEUMATOLOGY, V40, P673, DOI 10.1093/rheumatology/40.6.673
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Tavares R, 2012, J RHEUMATOL, V39, P2088, DOI 10.3899/jrheum.120100
   Toritsuka Y, 1997, J RHEUMATOL, V24, P1690
   UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo 125 4 1805
   Vojinovic J, 2011, ARTHRITIS RHEUM US, V63, P1452, DOI 10.1002/art.30238
   Wheatley NC, 2010, BIOORG MED CHEM LETT, V20, P7080, DOI 10.1016/j.bmcl.2010.09.096
   WOLPE SD, 1988, J EXP MED, V167, P570, DOI 10.1084/jem.167.2.570
   Yang XJ, 2008, NAT REV MOL CELL BIO, V9, P206, DOI 10.1038/nrm2346
NR 48
TC 64
Z9 71
U1 0
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462 0324
EI 1462 0332
J9 RHEUMATOLOGY
JI RHEUMATOLOGY
PD SEP
PY 2015
VL 54
IS 9
BP 1713
EP 1723
DI 10.1093/rheumatology/kev022
PG 11
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA CT5KL
UT WOS:000362848500025
PM 25832610
DA 2025 08 17
ER

PT J
AU Ravosa, MJ
   Ning, J
   Liu, YY
   Stack, MS
AF Ravosa, Matthew J.
   Ning, Jie
   Liu, Yueying
   Stack, M. Sharon
TI Bisphosphonate effects on the behaviour of oral epithelial cells and
   oral fibroblasts
SO ARCHIVES OF ORAL BIOLOGY
LA English
DT Article
DE Bisphosphonates (BPs); Osteonecrosis of the jaw (ONJ); Fibroblasts;
   Epithelium; Oral cavity; Wound healing; Proliferation; Apoptosis;
   Migration; Collagen
ID ZOLEDRONIC ACID; OSTEOBLAST DIFFERENTIATION; CANCER PATIENTS;
   OSTEONECROSIS; JAW; PROLIFERATION; PHARMACODYNAMICS; PHARMACOKINETICS;
   MATURATION; INHIBITION
AB Objective: Bisphosphonates (BPs) like Zometa (ZA) are widely used to treat complications of bony metastases in cancer patients. A serious adverse event occurs in 1 12% of patients on BP therapy, osteonecrosis of the jaw (BPONJ). BPONJ develops after oral trauma and is manifested by poor wound healing and soft tissue breakdown followed by exposure and necrosis of intra oral bone. Currently, there is no effective clinical treatment for BPONJ.
   Design: We evaluated the effect of ZA on the proliferation, apoptosis and migratory capacity of the cell lines CRL 7408, an oral fibroblast culture and OKF/6, an oral epithelial cell line.
   Results: In both oral epithelium and fibroblasts, ZA exposure inhibited proliferation and elevated apoptosis; however oral fibroblasts were differentially influenced versus oral epithelial cells. In oral fibroblasts, ZA treatment significantly inhibited motility. Further, quantitative real time PCR demonstrated that ZA treatment of oral fibroblasts inhibits expression of both the COL1A1 and COL1A2 chains of type I collagen, consistent with a loss of collagen immunofluorescent staining.
   Conclusions: These data support a model wherein ZA treatment impedes oral wound healing by blocking the growth and migratory capacity of oral fibroblasts as well as downregulating the transcription of type I collagen, functions necessary to deposit the granulation tissue needed for re epithelization. Therefore, BP released from bone following tooth extraction may delay wound healing of the oral mucosal barrier and contribute to BPONJ pathogenesis. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Ravosa, Matthew J.; Ning, Jie; Liu, Yueying; Stack, M. Sharon] Univ Missouri, Sch Med, Dept Pathol & Anat Sci, Columbia, MO 65212 USA.
C3 University of Missouri System; University of Missouri Columbia
RP Ravosa, MJ (通讯作者)，Univ Missouri, Sch Med, Dept Pathol & Anat Sci, M263 Med Sci Bldg,1 Hosp Dr DC055 07, Columbia, MO 65212 USA.
EM ravosam@missouri.edu
FU University of Missouri Research Board, Department of Pathology and
   Anatomical Sciences, University of Missouri School of Medicine;
   Department of Pathology and Anatomical Sciences at the University of
   Missouri School of Medicine; University of Missouri Research Board
FX University of Missouri Research Board, Department of Pathology and
   Anatomical Sciences, University of Missouri School of Medicine.Supported
   by the Department of Pathology and Anatomical Sciences at the University
   of Missouri School of Medicine as well as the University of Missouri
   Research Board (MJR). Dr. James Rheinwald of Harvard University is
   thanked for access to the OKF/6 cells used in this research. Dr. Robert
   Zitsch III, Department of Otolaryngology at the University of Missouri
   School of Medicine, Dr. Thomas Southard, Department of Orthodontics at
   the University of Iowa School of Dentistry, and two anonymous reviewers
   are thanked for helpful discussion.
CR Allen MR, 2009, CELLS TISSUES ORGANS, V189, P289, DOI 10.1159/000151371
   Bedogni A, 2008, ORAL SURG ORAL MED O, V105, P358, DOI 10.1016/j.tripleo.2007.08.040
   Bilezikian JP, 2006, NEW ENGL J MED, V355, P2278, DOI 10.1056/NEJMp068157
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   D'Aoust P, 2000, CELL TISSUE RES, V302, P353, DOI 10.1007/s004419900165
   Fleisch HA, 1997, ANN MED, V29, P55, DOI 10.3109/07853899708998743
   Frediani B, 2004, BONE, V35, P859, DOI 10.1016/j.bone.2004.06.001
   Fromigué O, 2002, J ENDOCRINOL INVEST, V25, P539, DOI 10.1007/BF03345497
   Gerharz M, 2007, WOUND REPAIR REGEN, V15, P105, DOI 10.1111/j.1524 475X.2006.00191.x
   Green J, 2010, SEMIN ONCOL, V37, pS3, DOI 10.1053/j.seminoncol.2010.06.003
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Kobayashi Y, 2010, J BONE MINER METAB, V28, P165, DOI 10.1007/s00774 009 0128 9
   Lam DK, 2007, J CAN DENT ASSOC, V73, P417
   Landesberg R, 2008, J ORAL MAXIL SURG, V66, P839, DOI 10.1016/j.joms.2008.01.026
   Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092 8674(00)81280 5
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Midwood KS, 2004, INT J BIOCHEM CELL B, V36, P1031, DOI 10.1016/j.biocel.2003.12.003
   Munshi HG, 2002, METHOD CELL BIOL, V69, P195, DOI 10.1016/S0091 679X(02)69013 2
   Nguyen DT, 2009, WOODHEAD PUBL MATER, P25, DOI 10.1533/9781845695545.1.25
   Novince CM, 2009, CELLS TISSUES ORGANS, V189, P275, DOI 10.1159/000152915
   Orriss IR, 2009, J CELL BIOCHEM, V106, P109, DOI 10.1002/jcb.21983
   Ravosa MJ, 2010, ANAT REC, V293, P557, DOI 10.1002/ar.21133
   RAWLINSON SCF, 1995, J BONE MINER RES, V10, P1225
   Reid IR, 2007, BONE, V41, P318, DOI 10.1016/j.bone.2007.04.196
   Reid IR, 2009, BONE, V44, P4, DOI 10.1016/j.bone.2008.09.012
   Ruggiero SL, 2009, ANNU REV MED, V60, P85, DOI 10.1146/annurev.med.60.063007.134350
   Scheper MA, 2009, BRIT J HAEMATOL, V144, P667, DOI 10.1111/j.1365 2141.2008.07504.x
   Silverman SL, 2009, AM J MED, V122, P33, DOI 10.1016/j.amjmed.2008.12.005
   Skerjanec A, 2003, J CLIN PHARMACOL, V43, P154, DOI 10.1177/0091270002239824
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
NR 31
TC 77
Z9 79
U1 0
U2 15
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0003 9969
EI 1879 1506
J9 ARCH ORAL BIOL
JI Arch. Oral Biol.
PD MAY
PY 2011
VL 56
IS 5
BP 491
EP 498
DI 10.1016/j.archoralbio.2010.11.003
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 758CP
UT WOS:000290138000010
PM 21146154
DA 2025 08 17
ER

PT J
AU Petrova, NL
   Edmonds, ME
AF Petrova, Nina L.
   Edmonds, Michael E.
TI Conservative and Pharmacologic Treatments for the Diabetic Charcot Foot
SO CLINICS IN PODIATRIC MEDICINE AND SURGERY
LA English
DT Article
DE Charcot neuroarthropathy; Diabetes mellitus; MRI; Casting therapy;
   Disease activity
ID ARTHROPATHY; OSTEOARTHROPATHY; NEUROARTHROPATHY; MANAGEMENT;
   BISPHOSPHONATES; MORTALITY; DISEASE; MARKERS; START
AB Charcot neuroarthropathy is a disabling complication of diabetic neuropathy. Prolonged immobilization in a total contact cast (TCC) is among the main treatments. Education of health care professionals in the application of TCC together with well conducted clinical trials are required to overcome its frequent underuse. There are no established pharmacologic therapies to treat this condition; however, there is an overwhelming need for a new therapeutic approach. Novel targeted drug delivery systems are required to prevent the pathologic bone and joint destruction of the Charcot neuroarthropathy and this may lead to an improved outcome in diabetic patients with this condition.
C1 [Petrova, Nina L.; Edmonds, Michael E.] Kings Coll Hosp NHS Fdn Trust, Diabet Foot Clin, Denmark Hill, London SE5 9RS, England.
C3 King's College Hospital NHS Foundation Trust
RP Petrova, NL (通讯作者)，Kings Coll Hosp NHS Fdn Trust, Diabet Foot Clin, Denmark Hill, London SE5 9RS, England.
EM petrovanl@yahoo.com
OI Petrova, Nina/0000 0001 6937 6565
CR Armstrong DG, 1997, J REHABIL RES DEV, V34, P317
   Armstrong DG, 1997, DIABETIC MED, V14, P357, DOI 10.1002/(SICI)1096 9136(199705)14:5<357::AID DIA341>3.0.CO;2 8
   Bates M, 2015, DIABETIC MED, V32, P149
   Bem R, 2006, DIABETES CARE, V29, P1392, DOI 10.2337/dc06 0376
   Chantelau E, 2006, EXP CLIN ENDOCR DIAB, V114, P428, DOI 10.1055/s 2006 924229
   Chantelau E, 2005, DIABETIC MED, V22, P1707, DOI 10.1111/j.1464 5491.2005.01677.x
   Chantelau EA, 2012, BMJ BRIT MED J, V344, DOI 10.1136/bmj.e2765
   de Souza LJ, 2008, J BONE JOINT SURG AM, V90A, P754, DOI 10.2106/JBJS.F.01523
   Dhawan V, 2005, FOOT ANKLE INT, V26, P717, DOI 10.1177/107110070502600910
   Ertugrul BM, 2013, DIABET FOOT ANKLE, V4, DOI 10.3402/dfa.v4i0.21855
   Fabrin J, 2000, DIABETES CARE, V23, P796, DOI 10.2337/diacare.23.6.796
   Folestad A, 2015, J FOOT ANKLE RES, V8, DOI 10.1186/s13047 015 0129 y
   Game FL, 2012, DIABETOLOGIA, V55, P32, DOI 10.1007/s00125 011 2354 7
   Gazis A, 2004, DIABETIC MED, V21, P1243, DOI 10.1111/j.1464 5491.2004.01215.x
   Gough A, 1997, DIABETIC MED, V14, P527, DOI 10.1002/(SICI)1096 9136(199707)14:7<527::AID DIA404>3.3.CO;2 H
   Hastings MK, 2013, J BONE JOINT SURG AM, V95A, P1206, DOI 10.2106/JBJS.L.00250
   Jude EB, 2001, DIABETOLOGIA, V44, P2032, DOI 10.1007/s001250100008
   Katoulis EC, 1997, DIABETES CARE, V20, P1904, DOI 10.2337/diacare.20.12.1904
   La Fontaine Javier, 2016, Foot (Edinb), V26, P7, DOI 10.1016/j.foot.2015.11.001
   Labovitz JM, 2016, J DIABETES COMPLICAT, V30, P710, DOI 10.1016/j.jdiacomp.2016.01.004
   Larsen K, 2001, J Wound Care, V10, P323
   Mabilleau G, 2010, J MUSCULOSKEL NEURON, V10, P84
   McCrory JL., 1998, FOOT, V8, P158, DOI 10.1016/s0958 2592(98)90052 9
   Moura Neto A, 2012, DIABETES RES CLIN PR, V96, pE11, DOI 10.1016/j.diabres.2011.12.029
   Pakarinen TK, 2011, DIABETES CARE, V34, P1514, DOI 10.2337/dc11 0396
   Petrova NL, 2008, DIABETES METAB RES, V24, pS58, DOI 10.1002/dmrr.846
   Petrova NL, 2016, DIABETES METAB RES, V32, P281, DOI 10.1002/dmrr.2734
   Petrova NL, 2015, DIABETIC MED, V32, P267, DOI 10.1111/dme.12590
   Petrova NL, 2013, DIABETES OBES METAB, V15, P193, DOI 10.1111/j.1463 1326.2012.01671.x
   Petrova NL, 2007, DIABETES CARE, V30, P997, DOI 10.2337/dc06 2168
   Pinzur MS, 2000, FOOT ANKLE INT, V21, P916, DOI 10.1177/107110070002101105
   Pinzur MS, 2006, FOOT ANKLE INT, V27, P324, DOI 10.1177/107110070602700503
   Pitocco D, 2005, DIABETES CARE, V28, P1214, DOI 10.2337/diacare.28.5.1214
   Richard JL, 2012, DIABETOLOGIA, V55, P1258, DOI 10.1007/s00125 012 2507 3
   Rogers LC, 2011, DIABETES CARE, V34, P2123, DOI 10.2337/dc11 0844
   Saiz E, 2013, DENT MATER, V29, P103, DOI 10.1016/j.dental.2012.08.001
   Sanders L J., 2001, Levin and O'Neals the Diabetic Foot, V6th, P439
   Sinacore DR, 1998, J DIABETES COMPLICAT, V12, P287, DOI 10.1016/S1056 8727(98)00006 3
   Sinacore DR, 1999, J ORTHOP SPORT PHYS, V29, P736, DOI 10.2519/jospt.1999.29.12.736
   Sohn MW, 2010, DIABETES CARE, V33, P98, DOI 10.2337/dc09 1497
   Uccioli L, 2010, DIABETES CARE, V33, P350, DOI 10.2337/dc09 1141
   Valabhji Jonathan, 2011, Diabetes Care, V34, pe135, DOI 10.2337/dc11 0960
   van Baal J, 2010, DIABETES CARE, V33, P1086, DOI 10.2337/dc09 1428
   Wu T, 2012, J BONE JOINT SURG BR, V94B, P344, DOI 10.1302/0301 620X.94B3.27122
   Wukich DK, 2004, FOOT ANKLE INT, V25, P556, DOI 10.1177/107110070402500808
   Zampa V, 2011, SKELETAL RADIOL, V40, P991, DOI 10.1007/s00256 010 1092 0
NR 46
TC 15
Z9 18
U1 0
U2 11
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0891 8422
EI 1558 2302
J9 CLIN PODIATR MED SUR
JI Clin. Podiatr. Med. Surg.
PD JAN
PY 2017
VL 34
IS 1
BP 15
EP +
DI 10.1016/j.cpm.2016.07.003
PG 11
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA EG5IY
UT WOS:000391078700004
PM 27865311
DA 2025 08 17
ER

PT J
AU Reinholz, MM
   Zinnen, SP
   Dueck, AC
   Dingli, D
   Reinholz, GG
   Jonart, LA
   Kitzmann, KA
   Bruzek, AK
   Negron, V
   Abdalla, AK
   Arendt, BK
   Croatt, AJ
   Sanchez Perez, L
   Sebesta, DP
   Lönnberg, H
   Yoneda, T
   Nath, KA
   Jelinek, DF
   Russell, SJ
   Ingle, JN
   Spelsberg, TC
   Dixon, HBF
   Karpeisky, A
   Lingle, WL
AF Reinholz, Monica M.
   Zinnen, Shawn P.
   Dueck, Amylou C.
   Dingli, David
   Reinholz, Gregory G.
   Jonart, Leslie A.
   Kitzmann, Kathleen A.
   Bruzek, Amy K.
   Negron, Vivian
   Abdalla, Abdalla K.
   Arendt, Bonnie K.
   Croatt, Anthony J.
   Sanchez Perez, Luis
   Sebesta, David P.
   Lonnberg, Harri
   Yoneda, Toshiyuki
   Nath, Karl A.
   Jelinek, Diane F.
   Russell, Stephen J.
   Ingle, James N.
   Spelsberg, Thomas C.
   Dixon, Henry B. F. (Hal)
   Karpeisky, Alexander
   Lingle, Wilma L.
TI A promising approach for treatment of tumor induced bone diseases:
   Utilizing bisphosphonate derivatives of nucleoside antimetabolites
SO BONE
LA English
DT Article
DE Bone cancer; Bisphosphonates; Chemotherapeutics; Drug conjugation;
   Targeting
ID BREAST CANCER PATIENTS; HUMAN MYELOMA CELLS; ZOLEDRONIC ACID;
   ANTITUMOR ACTIVITY; DELIVERY SYSTEMS; DRUG DELIVERY; FOLLOW UP;
   METASTASIS; RESORPTION; POTENT
AB Despite palliative treatments, tumor induced bone disease (TIBD) remains highly debilitating for many cancer patients and progression typically results in death within two years. Therefore, more effective therapies with enhanced anti resorptive and cytotoxic characteristics are needed. We developed bisphosphonate chemotherapeutic conjugates designed to bind bone and hydrolyze, releasing both compounds, thereby targeting both osteoclasts and tumor cells. This study examined the effects of our lead compound, MBC 11 (the anhydride formed between arabinocytidine (AraC) 5' phosphate and etidronate), on bone tumor burden, bone volume, femur bone mineral density (BMD), and overall survival using two distinct mouse models of TIBD, the 4T1/luc breast cancer and the KAS 6/1 MIP1 alpha multiple myeloma models. In mice orthotopically inoculated with 4T1/luc mouse mammary cells, MBC 11 (0.04 mu g/day: s.c.) reduced the incidence of bone metastases to 40% (4 / 10), compared to 90% (9 / 10; p = 0.057) and 100% (5 / 5; p = 0.04) of PBS  or similarly dosed, zoledronate treated mice, respectively. MBC 11 also significantly decreased bone tumor burden compared to PBS  or zoledronate treated mice (p = 0.021, p = 0.017, respectively). MBC 11 and zoledronate (0.04 mu g/day) significantly increased bone volume by two  and four fold, respectively, compared to PBS treated mice (p = 0.005, p<0.001, respectively). In mice systemically injected with human multiple myeloma KAS 6/1 MIP1 alpha cells, 0.04 and 4.0 mu g/day MBC 11 improved femur BMD by 13% and 16%, respectively, compared to PBS (p = 0.025,p = 0.017, respectively) at 10 weeks post tumor cell injection and increased mean survival to 95 days compared to 77 days in mice treated with PBS (p = 0.047). Similar doses of zoledronate also improved femur BMD (p <= 0.01 vs PBS) and increased mean survival to 86 days, but this was not significantly different than in PBS treated mice (p = 0.53). These results demonstrate that MBC 11 decreases bone tumor burden, maintains bone structure, and may increase overall survival, warranting further investigation as a treatment for TIBD. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Reinholz, Monica M.; Jonart, Leslie A.; Kitzmann, Kathleen A.; Bruzek, Amy K.; Negron, Vivian; Abdalla, Abdalla K.; Lingle, Wilma L.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55906 USA.
   [Reinholz, Gregory G.] Mayo Clin, Dept Orthoped Surg, Rochester, MN 55906 USA.
   [Dingli, David; Sanchez Perez, Luis; Russell, Stephen J.] Mayo Clin, Dept Mol Med, Rochester, MN 55906 USA.
   [Arendt, Bonnie K.; Jelinek, Diane F.] Mayo Clin, Dept Immunol, Rochester, MN 55906 USA.
   [Croatt, Anthony J.; Nath, Karl A.] Mayo Clin, Dept Nephrol, Rochester, MN 55906 USA.
   [Ingle, James N.] Mayo Clin, Dept Med Oncol, Rochester, MN 55906 USA.
   [Spelsberg, Thomas C.] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55906 USA.
   [Zinnen, Shawn P.; Sebesta, David P.; Dixon, Henry B. F. (Hal); Karpeisky, Alexander] MBC Pharma Inc, Aurora, CO USA.
   [Dueck, Amylou C.] Mayo Clin Scottsdale, Biostat Sect, Scottsdale, AZ USA.
   [Lonnberg, Harri] Univ Turku, Dept Chem, Turku, Finland.
   [Yoneda, Toshiyuki] Univ Texas Hlth Sci Ctr San Antonio, Dept Med Endocrinol, San Antonio, TX 78229 USA.
   [Yoneda, Toshiyuki] Osaka Univ, Dept Biochem, Grad Sch Dent, Osaka, Japan.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo
   Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic Phoenix; University of
   Turku; University of Texas System; University of Texas Health Science
   Center at San Antonio; University of Osaka
RP Reinholz, MM (通讯作者)，Mayo Clin, Dept Lab Med & Pathol, Stabile 12 12, Rochester, MN 55906 USA.
EM reinholz.monica@mayo.edu; szinnen@mbcpharma.com; dueck.amylou@mayo.edu;
   dingli.david@mayo.edu; reinholz.gregory@mayo.edu;
   lesliejonart@yahoo.com; kitzmann.kathleen@mayo.edu; amybruzek@gmail.com;
   negron.vivian@mayo.edu; abdalla.sen@gmail.com; arendt.bonnie@mayo.edu;
   croatt.anthony@mayo.edu; luis.sanchez perez@duke.edu;
   David.sebesta@gmail.com; Harlon@utu.fi; tyoneda@dent.osaka u.ac.jp;
   nath.karl@mayo.edu; jelinek.diane@mayo.edu; russell.stephen@mayo.edu;
   ingle.james@mayo.edu; spelsberg.thomas@mayo.edu;
   akarpeisky@mbcpharma.com; lingle.wilma@mayo.edu
OI Russell, Stephen/0000 0002 0799 6432; Karpeisky,
   Alexander/0000 0002 9226 8789; Jelinek, Diane F/0009 0003 2055 5011
FU United States National Institutes of Health [P01CA062242, 1R41CA097577,
   1R41CA105583]; MBC Pharma Inc. [RRF31J, 3X1127]
FX This work was supported by United States National Institutes of Health
   grants, P01CA062242 (PI: DF Jelinek), 1R41CA097577 and 1R41CA105583 (PI:
   MM Reinholz), MBC Pharma research grants RRF31J and 3X1127 (PI: MM
   Reinholz), and MBC Pharma Inc. We thank Drs. Nelly Paduykova, Sergei
   Mikhailov (Engelhardt Institute of Molecular Biology, Russian Academy of
   Sciences, Moscow, Russia), and Dr. Andrei Guzaev (AM Chemicals,
   Oceanside CA) for the synthesis of the conjugates. We thank Mr. Darren
   Riehle for making digital images of the bone histology and Dr. Kara
   Lukasiewicz for critical review of this manuscript.
CR Aapro M, 2008, ANN ONCOL, V19, P420, DOI 10.1093/annonc/mdm442
   Abe M, 2002, BLOOD, V100, P2195, DOI 10.1182/blood.V100.6.2195.h81802002195_2195_2202
   Ali SM, 2003, CLIN ORTHOP RELAT R, pS132, DOI 10.1097/01.blo.0000092981.12414.7b
   Body JJ, 2006, SUPPORT CARE CANCER, V14, P408, DOI 10.1007/s00520 005 0913 5
   Brown Sue A, 2007, Curr Opin Endocrinol Diabetes Obes, V14, P436, DOI 10.1097/MED.0b013e3282f15419
   Buijs JT, 2009, BONE, V44, P380, DOI 10.1016/j.bone.2008.10.047
   Clézardin P, 2005, CANCER RES, V65, P4971, DOI 10.1158/0008 5472.CAN 05 0264
   Clézardin P, 2002, SEMIN ONCOL, V29, P33, DOI 10.1053/sonc.2002.37420
   Clézardin P, 2003, CURR MED CHEM, V10, P173, DOI 10.2174/0929867033368529
   Coleman RE, 2007, SEMIN ONCOL, V34, pS11, DOI 10.1053/j.seminoncol.2007.10.003
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Costa L, 2007, BREAST, V16, pS16, DOI 10.1016/j.breast.2007.10.005
   Croucher PI, 2003, J BONE MINER RES, V18, P482, DOI 10.1359/jbmr.2003.18.3.482
   Daubiné F, 2007, J NATL CANCER I, V99, P322, DOI 10.1093/jnci/djk054
   Ezra A, 2000, ADV DRUG DELIVER REV, V42, P175, DOI 10.1016/S0169 409X(00)00061 2
   Fabulet O, 1995, PHOSPHORUS SULFUR, V101, P225, DOI 10.1080/10426509508042521
   Fleisch H., 2000, BISPHOSPHONATES BONE
   Gnant M, 2008, LANCET ONCOL, V9, P840, DOI 10.1016/S1470 2045(08)70204 3
   GREEN JR, 1994, J BONE MINER RES, V9, P745
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9 90004 3
   Hillner BE, 2003, J CLIN ONCOL, V21, P4042, DOI 10.1200/JCO.2003.08.017
   Hirabayashi H, 2003, CLIN PHARMACOKINET, V42, P1319, DOI 10.2165/00003088 200342150 00002
   Hiraga T, 2004, CLIN CANCER RES, V10, P4559, DOI 10.1158/1078 0432.CCR 03 0325
   Hortobagyi GN, 2001, SEMIN ONCOL, V28, P1, DOI [10.1053/sonc.2001.24153, 10.1053/sonc.2001.30704]
   Hosain F, 1996, J NUCL MED, V37, P105
   Jelinek DF, 1997, J IMMUNOL, V159, P487
   KARPEISKY MY, 2004, Patent No. 6750340
   KARPEISKY MY, 2001, Patent No. 6214812
   Lelekakis M, 1999, CLIN EXP METASTAS, V17, P163, DOI 10.1023/A:1006689719505
   Lipton A, 2006, CLIN CANCER RES, V12, p6209S, DOI 10.1158/1078 0432.CCR 06 1213
   Lyseng Williamson KA, 2008, DRUGS, V68, P2661, DOI 10.2165/0003495 200868180 00010
   Mundy G, 2001, SEMIN ONCOL, V28, P2, DOI 10.1053/sonc.2001.25441
   Ora M, 2008, J ORG CHEM, V73, P4123, DOI 10.1021/jo800317e
   Petrut B, 2008, CURR ONCOL, V15, pS50, DOI 10.3747/co.2008.176
   Pittock ST, 2005, KIDNEY INT, V68, P611, DOI 10.1111/j.1523 1755.2005.00439.x
   Powles T, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1384
   Reinholz GG, 2002, BREAST CANCER RES TR, V71, P257, DOI 10.1023/A:1014418017382
   Saarto T, 2004, ACTA ONCOL, V43, P650, DOI 10.1080/02841860410032885
   Senaratne SG, 2002, BREAST CANCER RES, V4, P18, DOI 10.1186/bcr412
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Shipman CM, 1998, LEUKEMIA LYMPHOMA, V32, P129, DOI 10.3109/10428199809059253
   Stepensky D, 2003, CLIN PHARMACOKINET, V42, P863, DOI 10.2165/00003088 200342100 00001
   STURTZ G, 1993, EUR J MED CHEM, V28, P899, DOI 10.1016/0223 5234(93)90043 E
   Takahashi R, 2001, LEUKEMIA RES, V25, P77, DOI 10.1016/S0145 2126(00)00087 4
   Uludag H, 2002, CURR PHARM DESIGN, V8, P1929, DOI 10.2174/1381612023393585
   Westendorf JJ, 1996, LEUKEMIA, V10, P866
   WINGEN F, 1986, J CANCER RES CLIN, V111, P209, DOI 10.1007/BF00389236
   Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070
   Yoneda Toshiyuki, 2000, Cancer, V88, P2979, DOI 10.1002/1097 0142(20000615)88:12+<2979::AID CNCR13>3.0.CO;2 U
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
   Zheng Y, 2007, BONE, V40, P471, DOI 10.1016/j.bone.2006.09.016
NR 51
TC 32
Z9 38
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUL
PY 2010
VL 47
IS 1
BP 12
EP 22
DI 10.1016/j.bone.2010.03.006
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 615QN
UT WOS:000279150400002
PM 20233612
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Xie, H
   Liu, M
   Jin, YF
   Lin, HQ
   Zhang, YS
   Zheng, S
AF Xie, Hui
   Liu, Ming
   Jin, Yaofeng
   Lin, Haiqing
   Zhang, Yushan
   Zheng, Song
TI miR 1323 suppresses bone mesenchymal stromal cell osteogenesis and
   fracture healing via inhibiting BMP4/SMAD4 signaling
SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
LA English
DT Article
DE Fracture; Atrophic non union; BMP4; SMAD4; miR 1323
ID STEM CELLS; IN VITRO; DIFFERENTIATION; EXPRESSION; OSTEOBLAST;
   INDUCTION; CARTILAGE; PATHWAY
AB Background Atrophic non union fractures show no radiological evidence of callus formation within 3 months of fracture. microRNA dysregulation may underlie the dysfunctional osteogenesis in atrophic non union fractures. Here, we aimed to analyze miR 1323 expression in human atrophic non union fractures and examine miR 1323's underlying mechanism of action in human mesenchymal stromal cells. Methods Human atrophic non union and standard healing fracture specimens were examined using H&E and Alcian Blue staining, immunohistochemistry, qRT PCR, immunoblotting, and ALP activity assays. The effects of miR 1323 mimics or inhibition on BMP4, SMAD4, osteogenesis related proteins, ALP activity, and bone mineralization were analyzed in human mesenchymal stromal cells. Luciferase reporter assays were utilized to assay miR 1323's binding to the 3'UTRs of BMP4 and SMAD4. The effects of miR 1323, BMP4, and SMAD4 were analyzed by siRNA and overexpression vectors. A rat femur fracture model was established to analyze the in vivo effects of antagomiR 1323 treatment. Results miR 1323 was upregulated in human atrophic non union fractures. Atrophic non union was associated with downregulation of BMP4 and SMAD4 as well as the osteogenic markers ALP, collagen I, and RUNX2. In vitro, miR 1323 suppressed BMP4 and SMAD4 expression by binding to the 3'UTRs of BMP4 and SMAD4. Moreover, miR 1323's inhibition of BMP4 and SMAD4 inhibited mesenchymal stromal cell osteogenic differentiation via modulating the nuclear translocation of the transcriptional co activator TAZ. In vivo, antagomiR 1323 therapy facilitated the healing of fractures in a rat model of femoral fracture. Conclusions This evidence supports the miR 1323/BMP4 and miR 1323/SMAD4 axes as novel therapeutic targets for atrophic non union fractures.
C1 [Xie, Hui; Liu, Ming; Jin, Yaofeng; Lin, Haiqing; Zhang, Yushan; Zheng, Song] Jiaxing Univ, Affiliated Hosp 2, Dept Orthoped, 1518 Huanchengbei Rd, Jiaxing 314299, Zhejiang, Peoples R China.
C3 Jiaxing University
RP Zheng, S (通讯作者)，Jiaxing Univ, Affiliated Hosp 2, Dept Orthoped, 1518 Huanchengbei Rd, Jiaxing 314299, Zhejiang, Peoples R China.
EM jxeyzhengsong@163.com
CR Abe T, 2001, J CELL PHYSIOL, V189, P144, DOI 10.1002/jcp.10011
   Bonneau E, 2019, EJIFCC, V30, P114
   Chen S, 2014, MOL MED REP, V9, P1820, DOI 10.3892/mmr.2014.2024
   CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277
   Cleveland KB, 2013, DELAYED UNION NONUNI, P3
   Dumic Cule I, 2018, INT ORTHOP, V42, P2619, DOI 10.1007/s00264 018 4153 y
   Franceschi RT, 1999, CRIT REV ORAL BIOL M, V10, P40, DOI 10.1177/10454411990100010201
   Gaston MS, 2007, J BONE JOINT SURG BR, V89B, P1553, DOI 10.1302/0301 620X.89B12
   Hamidouche Z, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471 2121 11 44
   Hu R, 2010, EXPERT OPIN THER TAR, V14, P1109, DOI 10.1517/14728222.2010.512916
   Huang J, 2010, STEM CELLS, V28, P357, DOI 10.1002/stem.288
   Kassem M, 2004, CLONING STEM CELLS, V6, P369, DOI 10.1089/clo.2004.6.369
   Kloen P, 2002, J BONE JOINT SURG AM, V84A, P1909, DOI 10.2106/00004623 200211000 00001
   Kloen P, 2012, BONE, V51, P59, DOI 10.1016/j.bone.2012.03.032
   Lian CJ, 2016, J PINEAL RES, V61, P317, DOI 10.1111/jpi.12349
   Lian JB, 2012, NAT REV ENDOCRINOL, V8, P212, DOI 10.1038/nrendo.2011.234
   Lian JB, 2004, CRITICAL REV EUKARYO, V14
   Liu DB, 2018, MED SCI MONITOR, V24, P4363, DOI 10.12659/MSM.905958
   Long HT, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1693 z
   Long HT, 2017, DNA CELL BIOL, V36, P715, DOI 10.1089/dna.2017.3657
   Lu Q, 2016, CALCIFIED TISSUE INT, V99, P500, DOI 10.1007/s00223 016 0173 z
   Luzi E, 2008, J BONE MINER RES, V23, P287, DOI 10.1359/JBMR.071011
   Martín F, 2019, METHODS MOL BIOL, V1937, P267, DOI 10.1007/978 1 4939 9065 8_17
   Mason DE, 2019, J CELL BIOL, V218, P1369, DOI 10.1083/jcb.201806065
   Mathieu M, 2013, BONE, V53, P391, DOI 10.1016/j.bone.2013.01.005
   Mauney JR, 2005, BIOMATERIALS, V26, P3173, DOI 10.1016/j.biomaterials.2004.08.020
   Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148
   Murata K, 2014, J BONE MINER RES, V29, P316, DOI 10.1002/jbmr.2040
   Nishimura R, 2012, J BIOCHEM, V151, P247, DOI 10.1093/jb/mvs004
   Oda T, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891 019 2970 9
   Park JS, 2019, STEM CELLS, V37, P368, DOI 10.1002/stem.2949
   Scarfì S, 2016, WORLD J STEM CELLS, V8, P1, DOI 10.4252/wjsc.v8.i1.1
   Talele NP, 2015, STEM CELL REP, V4, P1016, DOI 10.1016/j.stemcr.2015.05.004
   Trohatou O, 2014, STEM CELL TRANSL MED, V3, P54, DOI 10.5966/sctm.2013 0081
   Wagner JM, 2019, J TRANSL MED, V17, DOI 10.1186/s12967 019 02171 4
   Wang LQ, 2019, J BONE MINER RES, V34, P520, DOI 10.1002/jbmr.3626
   Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982 7992.2002
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Zhao RB, 2016, BIOCHEM BIOPH RES CO, V477, P749, DOI 10.1016/j.bbrc.2016.06.130
   Zhuang WZ, 2015, STEM CELLS, V33, P1985, DOI 10.1002/stem.1989
NR 40
TC 12
Z9 16
U1 1
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 799X
J9 J ORTHOP SURG RES
JI J. Orthop. Surg. Res.
PD JUN 29
PY 2020
VL 15
IS 1
AR 237
DI 10.1186/s13018 020 01685 8
PG 13
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA MG6PN
UT WOS:000546151600001
PM 32600409
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Qiao, MN
   Wu, D
   Carey, M
   Zhou, XB
   Zhang, L
AF Qiao, Minna
   Wu, Dan
   Carey, Michelle
   Zhou, Xiaobo
   Zhang, Le
TI Multi Scale Agent Based Multiple Myeloma Cancer Modeling and the Related
   Study of the Balance between Osteoclasts and Osteoblasts
SO PLOS ONE
LA English
DT Article
ID BONE MARROW; STEM CELL; GLUCOCORTICOIDS; PATHOGENESIS; MECHANISMS;
   CYTOKINES; PROTEIN; RNA
AB Research Background
   Currently, multiple myeloma is the second most common hematological malignancy in the U.S., constituting 1% of all cancers. With conventional treatment, the median survival time is typically 3 4 years, although it can be extended to 5 7 years or longer with advanced treatments. Recent research indicated that an increase in osteoclast (OC) activity is often associated withmultiple myeloma (MM) and that a decrease inosteoblast (OB) activity contributesto the osteolytic lesions in MM. Normally, the populations of OCs and OBs are inequilibrium, and an imbalance in this statecontributes to the development of lesions.
   Research procedures
   A multi scale agent based multiple myeloma model was developed to simulate the proliferation, migration and death of OBs and OCs. Subsequently, this model was employed to investigate the efficacy of thethree most commonly used drugs for MM treatment under the following two premises: the reduction in the progression of MM and the re establishment of the equilibrium between OCs and OBs.
   Research purposes
   The simulated results not only demonstrated the capacity of the model to choose optimal combinations of the drugs but also showed that the optimal use of the three drugs can restore the balance between OCs and OBs as well as kill MMs. Furthermore, the drug synergism analysis function of the model revealed that restoring the balance between OBs and OCs can significantly increase the efficacy of drugs against tumor cells.
C1 [Qiao, Minna; Zhang, Le] Southwest Univ, Coll Comp & Informat Sci, Chongqing, Peoples R China.
   [Wu, Dan; Zhou, Xiaobo] Wake Forest Univ, Sch Med, Dept Radiol, Winston Salem, NC 27109 USA.
   [Carey, Michelle] Univ Rochester, Dept Biostat & Computat Biol, Rochester, NY 14627 USA.
C3 Southwest University   China; Wake Forest University; University of
   Rochester
RP Zhou, XB (通讯作者)，Wake Forest Univ, Sch Med, Dept Radiol, Winston Salem, NC 27109 USA.
EM xizhou@wakehealth.edu; zhanglcq@swu.edu.cn
RI ; Zhang, Le/AAD 9104 2019
OI Carey, Michelle/0000 0002 5603 4264; Zhang, Le/0000 0002 3708 1727
FU  [U01 CA166886 01];  [P30AI078498];  [HHSN272201000055C];  [61372138]
FX This work was supported by http://grants.nih.gov/grants/oer.htm: U01
   CA166886 01, P30AI078498, HHSN272201000055C; and www.nsfc.gov.cn: No.
   61372138.
CR ALEXANIAN R, 1969, J AMER MED ASSOC, V208, P1680, DOI 10.1001/jama.208.9.1680
   BATAILLE R, 1991, J CLIN INVEST, V88, P62, DOI 10.1172/JCI115305
   Filella X, 1996, CANCER DETECT PREV, V20, P52
   Fitzgerald JB, 2006, NAT CHEM BIOL, V2, P458, DOI 10.1038/nchembio817
   Fulciniti M, 2009, BLOOD, V114, pS151
   GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247
   Guo J, 2004, CLIN CANCER RES, V10, P3333, DOI 10.1158/1078 0432.CCR 03 0366
   Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952
   Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189
   Hiroshi T, 2003, NATURE, V423, P337
   ISHIKAWA H, 1990, BLOOD, V75, P715
   Jian Ming Hou, 2012, Acta Pharmacologica Sinica, V33, P1277
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Maria Victoria M, 2006, BLOOD, V108, P2165
   Meletios D, 2007, NEW ENGL J MED, V357, P2123
   MOALLI PA, 1993, CANCER RES, V53, P3877
   MOALLI PA, 1992, BLOOD, V79, P213
   Nicola G, 2006, BLOOD, V108, P3992
   Oftedal S, 1921, J AMER MED ASSOC, V77, P1547
   Politou MC, 2006, INT J CANCER, V119, P1728, DOI 10.1002/ijc.22033
   Richardson PG, 2005, NEW ENGL J MED, V352, P2487, DOI 10.1056/NEJMoa043445
   Rongrong Z, 2013, BONE, V52, P145, DOI [10.1016/j.bone.2012.09.029, DOI 10.1016/J.BONE.2012.09.029]
   Roodman GD, 2010, J BONE MINER METAB, V28, P244, DOI 10.1007/s00774 009 0154 7
   Straetemans R, 2005, BIOMETRICAL J, V47, P299, DOI 10.1002/bimj.200410124
   Sun XQ, 2012, BIOMATERIALS, V33, P8265, DOI 10.1016/j.biomaterials.2012.07.041
   Sundar J, 2005, BRIT J HAEMATOL, V129, P776
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Yaccoby S, 2002, BRIT J HAEMATOL, V116, P278, DOI 10.1046/j.1365 2141.2002.03257.x
   Yong Zhan Z, 2009, ACTA PHARMACOL SIN, V7, P1025
   ZAR JH, 1972, J AM STAT ASSOC, V67, P578, DOI 10.2307/2284441
   ZHANG XG, 1994, BLOOD, V83, P3654
   Zhen YZ, 2009, INT J HEMATOL, V90, P44, DOI 10.1007/s12185 009 0340 3
NR 32
TC 17
Z9 20
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD DEC 11
PY 2015
VL 10
IS 12
AR e0143206
DI 10.1371/journal.pone.0143206
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CZ1ZA
UT WOS:000366903600009
PM 26659358
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Wang, XN
   Liao, XL
   Zhang, YM
   Wei, LY
   Pang, YZ
AF Wang, Xueni
   Liao, Xiuling
   Zhang, Yimin
   Wei, Linyao
   Pang, Yuzhou
TI Schisandrin B regulates MC3T3 E1 subclone 14 cells proliferation and
   differentiation through BMP2 SMADs RUNX2 SP7 signaling axis
SO SCIENTIFIC REPORTS
LA English
DT Article
AB Schisandrin B (SchB) is the highest content of biphenyl cyclooctene lignans in Schisandra chinensis. It has been reported to have a variety of pharmacological effects, including anti inflammatory, anti oxidant, anti cancer, heart protection, liver protection. In this study, we found that SchB can promote the proliferation of MC3T3 E1 subclone 14 cells. Meanwhile, we found that SchB can regulate the BMP2 SMADs signaling pathway by increasing gene and protein expression of those relative biomolecules. Furthermore, SchB can raise the RUNX2 and SP7 expression in both mRNA and protein levels. Since the role of BMP2 SMADs RUNX2 SP7 signaling axis in osteoblast proliferation and differentiation has been well documented. The present experimental findings indicate that SchB could promote the proliferation and differentiation of osteoblasts through BMP2 SMADs RUNX2 SP7 signaling axis.
C1 [Wang, Xueni; Liao, Xiuling; Zhang, Yimin; Pang, Yuzhou] Guangxi Univ Chinese Med, Guangxi Zhuang Yao Med Ctr Engn & Technol, 13 Wuhe Rd, Nanning 530200, Peoples R China.
   [Wang, Xueni] Guangxi Univ Chinese Med, Guangxi Key Lab Zhuang & Yao Ethn Med, Nanning 530200, Peoples R China.
   [Liao, Xiuling] Guangxi Univ Chinese Med, Fac Pharm, 13 Wuhe Rd, Nanning 530200, Peoples R China.
   [Wei, Linyao] Guangxi Univ Chinese Med, Guangxi Key Lab Efficacy Study Chinese Mat Med, 13 Wuhe Rd, Nanning 530200, Peoples R China.
C3 Guangxi University of Chinese Medicine; Guangxi University of Chinese
   Medicine; Guangxi University of Chinese Medicine; Guangxi University of
   Chinese Medicine
RP Wang, XN (通讯作者)，Guangxi Univ Chinese Med, Guangxi Zhuang Yao Med Ctr Engn & Technol, 13 Wuhe Rd, Nanning 530200, Peoples R China.; Wang, XN (通讯作者)，Guangxi Univ Chinese Med, Guangxi Key Lab Zhuang & Yao Ethn Med, Nanning 530200, Peoples R China.
EM wangxueni@yeah.net
RI Wang, Xueni/AFV 2278 2022; zhang, yimin/AAI 1487 2020
OI Wang, Xueni/0000 0001 9884 994X; 
FU National Natural Science Foundation of China [81973976]; Initial
   Scientific Research Fund of Guangxi University of Chinese Medicine
   [2017BS040]
FX This work was supported by the National Natural Science Foundation of
   China (81973976), the Initial Scientific Research Fund of Guangxi
   University of Chinese Medicine (2017BS040).
CR Brunner M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196021
   Chen ZJ, 2019, J BIOSCIENCES, V44, DOI 10.1007/s12038 019 9948 5
   Chiu PY, 2011, FITOTERAPIA, V82, P682, DOI 10.1016/j.fitote.2011.02.010
   Dai ZS, 2019, J SEP SCI, V42, P2444, DOI 10.1002/jssc.201900222
   Ji ZR, 2019, INFLAMMATION, V42, P731, DOI 10.1007/s10753 018 0931 3
   Karner CM, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00253 16
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   Komori T, 2018, HISTOCHEM CELL BIOL, V149, P313, DOI 10.1007/s00418 018 1640 6
   Liu Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040480
   Ran JS, 2018, DRUG DES DEV THER, V12, P1195, DOI 10.2147/DDDT.S162014
   Shen MJ, 2018, CELL PHYSIOL BIOCHEM, V50, P1522, DOI 10.1159/000494651
   Sun KH, 2019, CHEM BIOL INTERACT, V303, P7, DOI 10.1016/j.cbi.2019.01.039
   Titorencu I, 2014, CELL TISSUE RES, V355, P23, DOI 10.1007/s00441 013 1750 3
   Wu ZD, 2017, BIOMED PHARMACOTHER, V94, P1, DOI 10.1016/j.biopha.2017.07.071
   Xiang SS, 2014, MOLECULES, V19, P13235, DOI 10.3390/molecules190913235
NR 15
TC 9
Z9 11
U1 1
U2 14
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD SEP 2
PY 2020
VL 10
IS 1
AR 14476
DI 10.1038/s41598 020 71564 z
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA PT4JX
UT WOS:000608582500012
PM 32879393
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Cravens, EM
   Kirkwood, JS
   Wolfe, LM
   Packer, RA
   Whalen, LR
   Wojda, SJ
   Prenni, JE
   Florant, GL
   Donahue, SW
AF Cravens, Emily M.
   Kirkwood, Jay S.
   Wolfe, Lisa M.
   Packer, Rebecca A.
   Whalen, Lawrence R.
   Wojda, Samantha J.
   Prenni, Jessica E.
   Florant, Gregory L.
   Donahue, Seth W.
TI The effects of neurectomy and hibernation on bone properties and the
   endocannabinoid system in marmots (Marmota flaviventris)
SO COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY A MOLECULAR & INTEGRATIVE
   PHYSIOLOGY
LA English
DT Article
DE Endocannabinoid; Hibernation; Neurectomy; Bone remodeling
ID CANNABINOID RECEPTOR; GROUND SQUIRRELS; OSTEOCLAST FUNCTION; MASS;
   DIFFERENTIATION; OVARIECTOMY; STRENGTH; MICROSTRUCTURE; METABOLISM;
   OSTEOBLAST
AB Hibernators have adapted a physiological mechanism allowing them to undergo long periods of inactivity without experiencing bone loss. However, the biological mechanisms that prevent bone loss are unknown. Previous studies found meaningful changes, between active and hibernating marmots, in the endocannabinoid system of many tissues, including bone. Cannabinoid receptors (CB1 and CB2) have divergent localization in bone. CB1 is predominately found on sympathetic nerve terminals, while CB2 is more abundant on bone cells and their progenitors. This study aimed to determine the contribution of innervation on endocannabinoid regulation of bone properties in hibernating (during torpor) and non hibernating yellow bellied marmots. Neurectomy, a model for disuse osteoporosis, was performed unilaterally in both hibernating and active marmots. Endocannabinoid concentrations were measured in bone marrow, cortical, and trabecular regions from fourth metatarsals of both hindlimbs using microflow chromatography tandem quadrupole mass spectrometry. Trabecular bone architectural properties of fifth metatarsals were evaluated using micro computed tomography. There were ligand specific increases with neurectomy in active, but not hibernating, marmots. Trabecular bone architectural properties were not affected by neurectomy during hibernation, but did show some minor negative changes in active marmots. These findings suggest protection from bone loss in hibernating rodents is peripherally rather than centrally regulated. Furthermore, findings suggest even active marmots with normal metabolism are partially protected from disuse induced bone loss compared to laboratory rodents. Understanding the mechanism hibernators use to maintain bone density may guide development for novel bone loss prevention therapies.
C1 [Cravens, Emily M.; Donahue, Seth W.] Colorado State Univ, Sch Bioengn, Ft Collins, CO 80523 USA.
   [Kirkwood, Jay S.; Wolfe, Lisa M.; Prenni, Jessica E.] Colorado State Univ, Prote & Metabol Facil, Ft Collins, CO 80523 USA.
   [Packer, Rebecca A.] Colorado State Univ, Dept Clin Sci, Ft Collins, CO 80523 USA.
   [Whalen, Lawrence R.] Colorado State Univ, Dept Biomed Sci, Ft Collins, CO 80523 USA.
   [Wojda, Samantha J.] Colorado State Univ, Dept Mech Engn, Ft Collins, CO 80523 USA.
   [Florant, Gregory L.] Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA.
   [Cravens, Emily M.; Wojda, Samantha J.; Donahue, Seth W.] Univ Massachusetts, Dept Biomed Engn, 130 Nat Resources Rd, Amherst, MA 01003 USA.
   [Kirkwood, Jay S.] Univ Calif Riverside, Metabol Core Facil, Riverside, CA 92521 USA.
C3 Colorado State University System; Colorado State University Fort
   Collins; Colorado State University System; Colorado State University
   Fort Collins; Colorado State University System; Colorado State
   University Fort Collins; Colorado State University System; Colorado
   State University Fort Collins; Colorado State University System;
   Colorado State University Fort Collins; Colorado State University
   System; Colorado State University Fort Collins; University of
   Massachusetts System; University of Massachusetts Amherst; University of
   California System; University of California Riverside
RP Donahue, SW (通讯作者)，Univ Massachusetts, Dept Biomed Engn, 130 Nat Resources Rd, Amherst, MA 01003 USA.
EM swdonahue@umass.edu
OI Prenni, Jessica/0000 0002 0337 8450
FU National Science Foundation, United States [1555196]; Direct For
   Biological Sciences; Division Of Integrative Organismal Systems
   [1555196] Funding Source: National Science Foundation
FX This work was supported by the National Science Foundation, United
   States, [grant number 1555196].
CR Armitage KB, 2003, COMP BIOCHEM PHYS A, V134, P103
   Bab I, 2008, BRIT J PHARMACOL, V153, P182, DOI 10.1038/sj.bjp.0707593
   Battista N, 2012, FRONT BEHAV NEUROSCI, V6, DOI 10.3389/fnbeh.2012.00009
   Bogren LK, 2016, PHYSIOL REP, V4, DOI 10.14814/phy2.12771
   Borand L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090350
   Broccardo CJ, 2013, J CHROMATOGR B, V934, P16, DOI 10.1016/j.jchromb.2013.06.031
   Brown AJ, 2007, BRIT J PHARMACOL, V152, P567, DOI 10.1038/sj.bjp.0707481
   Carey HV, 2003, PHYSIOL REV, V83, P1153, DOI 10.1152/physrev.00008.2003
   Chan BY, 2007, BONE, V40, P149, DOI 10.1016/j.bone.2006.07.029
   David V, 2006, AM J PHYSIOL ENDOC M, V290, pE440, DOI 10.1152/ajpendo.00293.2004
   Di Marzo V, 2012, PHILOS T R SOC B, V367, P3216, DOI 10.1098/rstb.2011.0382
   Doherty AH, 2016, PHYSIOL BIOCHEM ZOOL, V89, P364, DOI 10.1086/687413
   Doherty AH, 2012, J MORPHOL, V273, P604, DOI 10.1002/jmor.20007
   Donahue SW, 2001, AM J PHYSIOL CELL PH, V281, pC1635, DOI 10.1152/ajpcell.2001.281.5.C1635
   Feng B, 2016, BIOMED REP, V4, P589, DOI 10.3892/br.2016.637
   FLORANT GL, 1977, AM J PHYSIOL, V232, pR203, DOI 10.1152/ajpregu.1977.232.5.R203
   Godlewski G, 2009, PROSTAG OTH LIPID M, V89, P105, DOI 10.1016/j.prostaglandins.2009.07.001
   Grabner GF, 2017, PHARMACOL THERAPEUT, V175, P35, DOI 10.1016/j.pharmthera.2017.02.033
   Idris AI, 2008, ENDOCRINOLOGY, V149, P5619, DOI 10.1210/en.2008 0150
   Idris Aymen I, 2012, Front Endocrinol (Lausanne), V3, P136, DOI 10.3389/fendo.2012.00136
   Idris AI, 2009, CELL METAB, V10, P139, DOI 10.1016/j.cmet.2009.07.006
   Ito M, 2002, BONE, V30, P594, DOI 10.1016/S8756 3282(02)00684 1
   KEILA S, 1994, J BONE MINER RES, V9, P321
   Kim HJ, 2019, J CELL PHYSIOL, V234, P11490, DOI 10.1002/jcp.27805
   Kimura J., 2001, Electrodiagnosis in Diseases of Nerve and Muscle, Principles and Practice, V3rd, P91, DOI DOI 10.1093/MED/9780199738687.003.0005
   Kimura J., 2013, Electrodiagnosis in diseases of nerve and muscle principles and practice, V4th, P361
   Kirkwood JS, 2016, J CHROMATOGR B, V1033, P271, DOI 10.1016/j.jchromb.2016.08.035
   Komori T, 2015, EUR J PHARMACOL, V759, P287, DOI 10.1016/j.ejphar.2015.03.028
   Lau RYC, 2011, J OSTEOPOROS, V2011, DOI 10.4061/2011/293808
   Lecka Czernik Beata, 2010, Curr Osteoporos Rep, V8, P84, DOI 10.1007/s11914 010 0016 1
   Ma XL, 2016, SCI REP UK, V6, DOI 10.1038/srep24562
   MacLean B, 2010, BIOINFORMATICS, V26, P966, DOI 10.1093/bioinformatics/btq054
   Marie PJ, 2006, PPAR RES, V2006, DOI 10.1155/PPAR/2006/64807
   McGee Lawrence M, 2015, J EXP BIOL, V218, P2067, DOI 10.1242/jeb.120725
   McGee Lawrence ME, 2011, J EXP BIOL, V214, P1240, DOI 10.1242/jeb053520
   McGee Lawrence ME, 2009, BONE, V45, P1186, DOI 10.1016/j.bone.2009.08.011
   McGee Lawrence ME, 2009, J BIOMECH, V42, P1378, DOI 10.1016/j.jbiomech.2008.11.039
   McGee Lawrence ME, 2008, AM J PHYSIOL REG I, V295, pR1999, DOI 10.1152/ajpregu.90648.2008
   Miller PD, 2016, EXPERT OPIN PHARMACO, V17, P473, DOI 10.1517/14656566.2016.1124856
   Moriya S, 2016, J CELL PHYSIOL, V231, P1163, DOI 10.1002/jcp.25214
   Mulawa EA, 2018, J BIOL RHYTHM, V33, P388, DOI 10.1177/0748730418777660
   O'Sullivan SE, 2016, BRIT J PHARMACOL, V173, P1899, DOI 10.1111/bph.13497
   Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103
   Pisani P, 2016, WORLD J ORTHOP, V7, P171, DOI 10.5312/wjo.v7.i3.171
   Sophocleous A, 2011, ENDOCRINOLOGY, V152, P2141, DOI 10.1210/en.2010 0930
   Stunes AK, 2011, BMC ENDOCR DISORD, V11, DOI 10.1186/1472 6823 11 11
   Sun XD, 2015, INT J MED SCI, V12, P270, DOI 10.7150/ijms.11078
   Sun Y, 2007, PPAR RES, V2007, DOI 10.1155/2007/23513
   Takano M, 2012, MOL CELL ENDOCRINOL, V348, P224, DOI 10.1016/j.mce.2011.08.027
   Tam J, 2008, FASEB J, V22, P285, DOI 10.1096/fj.06 7957com
   Tamaki H, 2013, J MUSCULOSKEL NEURON, V13, P289
   TURNER CH, 1995, J BONE MINER RES, V10, P1544
   Utz JC, 2009, J EXP BIOL, V212, P2746, DOI 10.1242/jeb.032854
   Whyte LS, 2009, P NATL ACAD SCI USA, V106, P16511, DOI 10.1073/pnas.0902743106
   Wojda SJ, 2016, PHYSIOL BIOCHEM ZOOL, V89, P72, DOI 10.1086/684619
   Wojda SJ, 2012, BONE, V50, P182, DOI 10.1016/j.bone.2011.10.013
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   ZIMMERMAN GD, 1976, CRYOBIOLOGY, V13, P84, DOI 10.1016/0011 2240(76)90163 2
   Zoerner AA, 2011, BBA MOL CELL BIOL L, V1811, P706, DOI 10.1016/j.bbalip.2011.08.004
NR 59
TC 6
Z9 6
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1095 6433
EI 1531 4332
J9 COMP BIOCHEM PHYS A
JI Comp. Biochem. Physiol. A Mol. Integr. Physiol.
PD MAR
PY 2020
VL 241
AR 110621
DI 10.1016/j.cbpa.2019.110621
PG 9
WC Biochemistry & Molecular Biology; Physiology; Zoology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Physiology; Zoology
GA KM6JR
UT WOS:000514244900001
PM 31783174
DA 2025 08 17
ER

PT J
AU Orecchini, E
   Mondanelli, G
   Orabona, C
   Volpi, C
   Adorisio, S
   Calvitti, M
   Thuy, TT
   Delfino, DV
   Belladonna, ML
AF Orecchini, Elena
   Mondanelli, Giada
   Orabona, Ciriana
   Volpi, Claudia
   Adorisio, Sabrina
   Calvitti, Mario
   Trinh Thi Thuy
   Delfino, Domenico, V
   Belladonna, Maria Laura
TI Artocarpus tonkinensis Extract Inhibits LPS Triggered
   Inflammation Markers and Suppresses RANKL Induced Osteoclastogenesis in
   RAW264.7
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE Artocarpus tonkinensis; osteoclastogenesis; rheumatoid arthritis; hmong
   ethnic minority; vietnam traditional medicine
ID COLLAGEN INDUCED ARTHRITIS; T CELLS; KAPPA B; C SRC; LEAVES; GLYCOSIDES;
   TOLERANCE; COMPOUND; IL 17; MICE
AB Artocarpus tonkinensis (At) leaf decoction, a traditional remedy prepared in North Vietnam by the Hmong ethnic group, is a tea extract rich in bioactive compounds that may have therapeutic effects in arthritis and backache. Indeed, it has been demonstrated that At is able to inhibit Th17 lymphocytes development and to protect mice in an experimental model of collagen induced arthritis. By resorting to macrophage in vitro models of inflammation and osteoclastogenesis, we showed that At extract significantly reduced nitric oxide synthase 2 (NOS2) activity and IL 6 production by RAW 264.7 murine cells. Moreover, At demonstrated an anti osteoclastogenic effect, as revealed by complete inhibition of TRAP positive osteoclast formation and decreased expression of key osteoclast related genes. This At activity likely relies on the inhibition of RANK downstream signaling pathway, as the activation of non receptor tyrosine kinase Src is reduced upon RANKL At exposure. Protective effect of At against bone loss was also enlightened in vivo by collagen induced arthritis (CIA) experiment demonstrating that, although paw edema was only weakly opposed by drinking At decoction, bone and cartilage were well preserved in CIA+At mice and joint tissue expressed decreased levels of osteoclast marker genes respect to CIA control group. Maesopsin 4 O beta D glucoside (i.e., TAT 2, one of the main decoction bioactive components) was capable to contrast NOS2 activity, IL 6 expression and osteoclast formation, too, albeit to a lesser extent when compared to At decoction. Overall, this study enlightens another At cell target, macrophages, beside Th17 lymphocytes, and suggests that the anti arthritic beneficial effects of At decoction largely derives from its ability to counteract not only inflammation, but also osteoclastogenesis.
C1 [Orecchini, Elena; Mondanelli, Giada; Orabona, Ciriana; Volpi, Claudia; Calvitti, Mario; Delfino, Domenico, V; Belladonna, Maria Laura] Univ Perugia, Dept Med & Surg, Perugia, Italy.
   [Adorisio, Sabrina] Univ Perugia, Foligno Nursing Sch, Dept Med & Surg, Perugia, Italy.
   [Trinh Thi Thuy] Vietnam Acad Sci & Technol, Inst Chem, Hanoi, Vietnam.
C3 University of Perugia; University of Perugia; Vietnam Academy of Science
   & Technology (VAST)
RP Belladonna, ML (通讯作者)，Univ Perugia, Dept Med & Surg, Perugia, Italy.
EM marialaura.belladonna@unipg.it
RI Delfino, Domenico/AAB 5124 2020; Belladonna, Maria Laura/LZG 9042 2025;
   Mondanelli, Giada/H 7899 2018; Orabona, Ciriana/L 8725 2015
OI Orecchini, Elena/0000 0003 1872 4042; 
FU Italian Ministry of Education, Universities and Research
   [PRIN2017 2017BA9LM5, PRIN2017 20173EAZ2Z]; Vietnam Academy of Science
   and Technology [VAST.04.08/20 21]; Fondo Ricerca di Base 2019,
   Universita degli Studi di Perugia
FX This work was supported by the Italian Ministry of Education,
   Universities and Research (PRIN2017 2017BA9LM5 to CO;
   PRIN2017 20173EAZ2Z to CV), by Vietnam Academy of Science and Technology
   (project VAST.04.08/20 21 to TTT) and by "Fondo Ricerca di Base 2019,
   Universita degli Studi di Perugia" (project entitled "Studio sul
   processo di preparazione e validazione degli effetti biologici di
   sostanze naturali selezionate della medicina tradizionale Vietnamita" to
   DVD).
CR Adorisio S, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00503
   Adorisio S, 2016, NAT PROD COMMUN, V11, P1409
   BARKER SC, 1995, BIOCHEMISTRY US, V34, P14843, DOI 10.1021/bi00045a027
   Bessede A, 2014, NATURE, V511, P184, DOI 10.1038/nature13323
   Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   Dang DTN, 2009, SCAND J IMMUNOL, V69, P110, DOI 10.1111/j.1365 3083.2008.02205.x
   Destaing O, 2008, MOL BIOL CELL, V19, P394, DOI 10.1091/mbc.E07 03 0227
   Fan H, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00864
   Kim S, 2019, J MICROBIOL BIOTECHN, V29, P11, DOI 10.4014/jmb.1810.10005
   Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703
   Manni G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00292
   MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252
   Mondanelli G, 2020, J AUTOIMMUN, V115, DOI 10.1016/j.jaut.2020.102509
   Mondanelli G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00428
   Mondanelli G, 2017, IMMUNITY, V46, P233, DOI 10.1016/j.immuni.2017.01.005
   Nakae S, 2003, P NATL ACAD SCI USA, V100, P5986, DOI 10.1073/pnas.1035999100
   Ngoc DDT, 2005, SCAND J IMMUNOL, V61, P234, DOI 10.1111/j.1365 3083.2005.01560.x
   Ohsugi Y, 2020, J TRANSL AUTOIMMUN, V3, DOI 10.1016/j.jtauto.2019.100030
   Pozzesi N, 2011, J CHEMOTHERAPY, V23, P150, DOI 10.1179/joc.2011.23.3.150
   Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308
   Roskoski R, 2015, PHARMACOL RES, V94, P9, DOI 10.1016/j.phrs.2015.01.003
   Scherer HU, 2020, J AUTOIMMUN, V110, DOI 10.1016/j.jaut.2019.102400
   Siouti E, 2019, BIOCHEM PHARMACOL, V165, P152, DOI 10.1016/j.bcp.2019.03.029
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Takayanagi H, 2000, ARTHRITIS RHEUM US, V43, P259, DOI 10.1002/1529 0131(200002)43:2<259::AID ANR4>3.0.CO;2 W
   Thuy TT, 2004, PHARMAZIE, V59, P297
   Tran CN, 2007, ARTHRITIS RHEUM, V56, P1497, DOI 10.1002/art.22573
   Thuy TT, 2017, CHEM NAT COMPD+, V53, P759, DOI 10.1007/s10600 017 2113 1
   Thuy TT, 2016, ASIAN PAC J TROP MED, V9, P343, DOI 10.1016/j.apjtm.2016.03.012
   Udalova IA, 2016, NAT REV RHEUMATOL, V12, P472, DOI 10.1038/nrrheum.2016.91
   Visagie A, 2015, INT J ENV RES PUB HE, V12, P13779, DOI 10.3390/ijerph121113779
   Volpi C, 2016, NEUROPHARMACOLOGY, V102, P59, DOI 10.1016/j.neuropharm.2015.10.036
   Wu B, 2020, INT IMMUNOPHARMACOL, V80, DOI 10.1016/j.intimp.2020.106187
   Zhi X, 2020, J CELL MOL MED, V24, P5122, DOI 10.1111/jcmm.15153
NR 34
TC 7
Z9 7
U1 0
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JAN 22
PY 2021
VL 11
AR 593829
DI 10.3389/fphar.2020.593829
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA QC1XB
UT WOS:000614627500001
PM 33551802
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU PosthumaDeBoer, J
   Piersma, SR
   Pham, TV
   van Egmond, PW
   Knol, JC
   Cleton Jansen, AM
   van Geer, MA
   van Beusechem, VW
   Kaspers, GJL
   van Royen, BJ
   Jiménez, CR
   Helder, MN
AF PosthumaDeBoer, J.
   Piersma, S. R.
   Pham, T. V.
   van Egmond, P. W.
   Knol, J. C.
   Cleton Jansen, A. M.
   van Geer, M. A.
   van Beusechem, V. W.
   Kaspers, G. J. L.
   van Royen, B. J.
   Jimenez, C. R.
   Helder, M. N.
TI Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor
   for targeted drug delivery
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE osteosarcoma; proteomics; targeted therapy; drug delivery; EPHA2
ID SPECTROMETRY BASED PROTEOMICS; PLASMA MEMBRANE PROTEINS; OSTEOBLASTIC
   CELL LINES; MASS SPECTROMETRY; LABEL FREE; IN VIVO; CARCINOMA
   PROGRESSION; BIOMARKER DISCOVERY; OSTEOGENIC SARCOMA; PANCREATIC CANCER
AB Background: Osteosarcoma (OS) is the most common bone tumour in children and adolescents. Despite aggressive therapy regimens, treatment outcomes are unsatisfactory. Targeted delivery of drugs can provide higher effective doses at the site of the tumour, ultimately improving the efficacy of existing therapy. Identification of suitable receptors for drug targeting is an essential step in the design of targeted therapy for OS.
   Methods: We conducted a comparative analysis of the surface proteome of human OS cells and osteoblasts using cell surface biotinylation combined with nano liquid chromatography   tandem mass spectrometry based proteomics to identify surface proteins specifically upregulated on OS cells. This approach generated an extensive data set from which we selected a candidate to study for its suitability as receptor for targeted treatment delivery to OS. First, surface expression of the ephrin type A receptor 2 (EPHA2) receptor was confirmed using FACS analysis. Ephrin type A receptor 2 expression in human tumour tissue was tested using immunohistochemistry. Receptor targeting and internalisation studies were conducted to assess intracellular uptake of targeted modalities via EPHA2. Finally, tissue micro arrays containing cores of human OS tissue were stained using immunohistochemistry and EPHA2 staining was correlated to clinical outcome measures.
   Results: Using mass spectrometry, a total of 2841 proteins were identified of which 156 were surface proteins significantly upregulated on OS cells compared with human primary osteoblasts. Ephrin type A receptor 2 was highly upregulated and the most abundant surface protein on OS cells. In addition, EPHA2 was expressed in a vast majority of human OS samples. Ephrin type A receptor 2 effectively mediates internalisation of targeted adenoviral vectors into OS cells. Patients with EPHA2 positive tumours showed a trend toward inferior overall survival.
   Conclusion: The results presented here suggest that the EPHA2 receptor can be considered an attractive candidate receptor for targeted delivery of therapeutics to OS.
C1 [PosthumaDeBoer, J.; van Egmond, P. W.; van Royen, B. J.; Helder, M. N.] Vrije Univ Amsterdam Med Ctr, Dept Orthopaed Surg, NL 1007 MB Amsterdam, Netherlands.
   [Piersma, S. R.; Pham, T. V.; Knol, J. C.; Jimenez, C. R.] Vrije Univ Amsterdam Med Ctr, OncoProte Lab, Dept Med Oncol, NL 1007 MB Amsterdam, Netherlands.
   [Cleton Jansen, A. M.] Leiden Univ Med Ctr, Dept Pathol, NL 2300 RC Leiden, Netherlands.
   [van Geer, M. A.] Acad Med Ctr, Tytgat Inst Liver & Intestinal Res, NL 1105 BK Amsterdam, Netherlands.
   [van Beusechem, V. W.] Vrije Univ Amsterdam Med Ctr, Dept Med Oncol, NL 1007 MB Amsterdam, Netherlands.
   [Kaspers, G. J. L.] Vrije Univ Amsterdam Med Ctr, NL 1007 MB Amsterdam, Netherlands.
   [van Royen, B. J.; Helder, M. N.] Skeletal Tissue Engn Grp Amsterdam, Res Inst MOVE, NL 1007 MB Amsterdam, Netherlands.
C3 Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije
   Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Leiden University;
   Leiden University Medical Center (LUMC); University of Amsterdam;
   Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; VU
   UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY
   MEDICAL CENTER
RP Helder, MN (通讯作者)，Vrije Univ Amsterdam Med Ctr, Dept Orthopaed Surg, POB 7057, NL 1007 MB Amsterdam, Netherlands.
EM c.jimenez@vumc.nl; m.helder@vumc.nl
RI van Royen, Barend/W 4864 2019; Kaspers, Gertjan/ABC 5334 2020; Jimenez,
   Connie/AAI 3763 2020
OI Van Royen, Barend/0000 0002 6548 7214; Jimenez, Connie
   R/0000 0002 3103 4508; Kaspers, Gertjan/0000 0001 7716 8475; 
FU Individualised Musculoskeletal Regeneration and Reconstruction Network
   (Danish Research Council), Aarhus, Denmark; VONK: VUmc Onderzoek naar
   Kinderkanker, Amsterdam, The Netherlands
FX We kindly acknowledge Meike de Wit for her advice and guidance on cell
   surface protein isolation and Silvina Fratantoni for her technical
   assistance. JP is supported by the Individualised Musculoskeletal
   Regeneration and Reconstruction Network (Danish Research Council),
   Aarhus, Denmark; and by VONK: VUmc Onderzoek naar Kinderkanker,
   Amsterdam, The Netherlands. TVP, CRJ and the proteomics infrastructure
   were supported by the VUmc Cancer Center Amsterdam.
CR Abdou AG, 2010, INDIAN J CANCER, V47, P46, DOI 10.4103/0019 509X.58859
   Albrethsen J, 2010, MOL CELL PROTEOMICS, V9, P988, DOI 10.1074/mcp.M900546 MCP200
   Altman DG., 1991, PRACTICAL STAT MED R
   Avnet S, 2009, CANCER RES, V69, P2443, DOI 10.1158/0008 5472.CAN 08 2645
   Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
   Cai YP, 2010, J PATHOL, V220, P24, DOI 10.1002/path.2628
   Chen K, 2008, PEDIATR BLOOD CANCER, V51, P349, DOI 10.1002/pbc.21595
   Cox J, 2007, CELL, V130, P395, DOI 10.1016/j.cell.2007.07.032
   De Boer JP, 2012, ONCOTARGET, V3, P1169
   de Wit M, 2012, GUT, V61, P855, DOI 10.1136/gutjnl 2011 300511
   Dickerson EB, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 10
   Folio C, 2009, J PROTEOME RES, V8, P3882, DOI 10.1021/pr900113w
   Fritsche Guenther R, 2010, HISTOPATHOLOGY, V57, P836, DOI 10.1111/j.1365 2559.2010.03713.x
   Gorlick R, 2003, CLIN CANCER RES, V9, P5442
   Guo QC, 2007, ACTA PHARMACOL SIN, V28, P850, DOI 10.1111/j.1745 7254.2007.00603.x
   Guo Y, 2008, CLIN ORTHOP RELAT R, V466, P2039, DOI 10.1007/s11999 008 0344 y
   Guo Y, 2007, J ORTHOP RES, V25, P964, DOI 10.1002/jor.20356
   Hammond SA, 2007, CANCER RES, V67, P3927, DOI 10.1158/0008 5472.CAN 06 2760
   Hua YQ, 2011, TUMOR BIOL, V32, P1013, DOI 10.1007/s13277 011 0203 4
   Hughes DPM, 2009, EXPERT OPIN DRUG DEL, V6, P1311, DOI 10.1517/17425240903280422
   Jia SF, 1999, CLIN EXP METASTAS, V17, P501, DOI 10.1023/A:1006623001465
   Kansara M, 2007, DNA CELL BIOL, V26, P1, DOI 10.1089/dna.2006.0505
   Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982
   Kim SY, 2008, CLIN EXP METASTAS, V25, P201, DOI 10.1007/s10585 007 9133 3
   Kolb EA, 2010, PEDIATR BLOOD CANCER, V55, P67, DOI 10.1002/pbc.22479
   Krishnan K, 2005, CANCER J, V11, P306, DOI 10.1097/00130404 200507000 00006
   Landen CN Jr, 2005, CANCER RES, V65, P6910, DOI 10.1158/0008 5472.CAN 05 0530
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lee JW, 2010, CLIN CANCER RES, V16, P2562, DOI 10.1158/1078 0432.CCR 10 0017
   Liu XD, 2009, CANCER INVEST, V27, P345, DOI 10.1080/07357900802438577
   Lund R, 2009, J PROTEOME RES, V8, P3078, DOI 10.1021/pr801091k
   Mansky PJ, 2002, J PEDIAT HEMATOL ONC, V24, P440, DOI 10.1097/00043426 200208000 00007
   Marco RAW, 2003, J CELL BIOCHEM, V88, P1038, DOI 10.1002/jcb.10465
   McQueen P, 2011, EXPERT REV ANTICANC, V11, P1223, DOI [10.1586/era.11.94, 10.1586/ERA.11.94]
   Mitra S, 2010, BIOCHEMISTRY US, V49, P6687, DOI 10.1021/bi1006223
   Mohseny AB, 2009, J PATHOL, V219, P294, DOI 10.1002/path.2603
   Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806
   Pham TV, 2012, EXPERT REV MOL DIAGN, V12, P343, DOI [10.1586/erm.12.31, 10.1586/ERM.12.31]
   Pham TV, 2010, BIOINFORMATICS, V26, P363, DOI 10.1093/bioinformatics/btp677
   Piersma SR, 2010, J PROTEOME RES, V9, P1913, DOI 10.1021/pr901072h
   Rochet N, 1999, INT J CANCER, V82, P282, DOI 10.1002/(SICI)1097 0215(19990719)82:2<282::AID IJC20>3.0.CO;2 R
   ROSEN G, 1982, CANCER AM CANCER SOC, V49, P1221, DOI 10.1002/1097 0142(19820315)49:6<1221::AID CNCR2820490625>3.0.CO;2 E
   Rubin EM, 2010, MOL CANCER THER, V9, P731, DOI 10.1158/1535 7163.MCT 09 0147
   Scarberry KE, 2008, J AM CHEM SOC, V130, P10258, DOI 10.1021/ja801969b
   Scheurer SB, 2005, PROTEOMICS, V5, P2718, DOI 10.1002/pmic.200401163
   Stevens TJ, 2000, PROTEINS, V39, P417, DOI 10.1002/(SICI)1097 0134(20000601)39:4<417::AID PROT140>3.0.CO;2 Y
   Tandon M, 2011, EXPERT OPIN THER TAR, V15, P31, DOI 10.1517/14728222.2011.538682
   Udayakumar D, 2011, ONCOGENE, V30, P4921, DOI 10.1038/onc.2011.210
   Van Geer MA, 2010, INT J ONCOL, V36, P233, DOI 10.3892/ijo_00000494
   van Geer MA, 2009, WORLD J GASTROENTERO, V15, P2754, DOI 10.3748/wjg.15.2754
   Varelias A, 2002, CANCER, V95, P862, DOI 10.1002/cncr.10749
   Wan X, 2009, ONCOGENE, V28, P3401, DOI 10.1038/onc.2009.206
   Wu CC, 2003, NAT BIOTECHNOL, V21, P262, DOI 10.1038/nbt0303 262
   Zhang YK, 2009, ANTI CANCER DRUG, V20, P702, DOI 10.1097/CAD.0b013e32832e89c7
   Zhang ZY, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 206
NR 55
TC 48
Z9 51
U1 1
U2 19
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007 0920
EI 1532 1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD OCT 15
PY 2013
VL 109
IS 8
BP 2142
EP 2154
DI 10.1038/bjc.2013.578
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 236KN
UT WOS:000325795000015
PM 24064975
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Beattie, JR
   Towler, MR
AF Beattie, J. Renwick
   Towler, Mark R.
TI Raman spectroscopy as a tool for monitoring osteoporosis therapy in
   postmenopausal osteoporosis
SO JOURNAL OF RAMAN SPECTROSCOPY
LA English
DT Article
DE bisphosphonate; bone; fracture risk; osteoporosis; Raman spectroscopy
ID FRACTURE RISK REDUCTION; BONE MINERAL DENSITY; CATHEPSIN K;
   MULTIVARIATE ANALYSIS; COLLAGEN; WOMEN; MODEL; FINGERNAILS;
   BISPHOSPHONATES; OSTEONECROSIS
AB Bisphosphonate based pharmacological therapy of osteoporosis reduces risk of fracture, but modulation of bone mineral density does not solely explain this. Additional bone quality aspects affecting fragility need to be better understood, alongside methods to monitor them. Systemic factors that influence bone collagen remodelling also remodel keratin in parallel processes. In this study, human fingernail clippings from subjects with and without bone active pharmaceutical intervention are compared. A discriminant model was able to distinguish between the nails from patients that were treatment naive and treated with an area under the curve of 71% in the test set. A time series of changes relative to baseline revealed that after 1 year, the scores of the treated group (95 confidence interval 37% to 377% change) differed from both the 12 week measurements ( 198% to 34%) and scores from untreated subjects ( 92% to  674%). Analysis of the spectral differences and model coefficients revealed features that were inverse to those observed in three previous osteoporosis models, indicating that treatment was reverting damaged protein structure. This study provides preliminary evidence that bone active medication systemically influences keratin structure in humans and provides some discussion on the underlying mechanism. The study demonstrates that bisphosphonates have a direct influence on protein structure, warranting further investigation of these effects.
   Bone active medication systemically influences keratin structure in humans. Model based on Raman spectra of human fingernails can discriminate between treated and untreated individuals. Model is correlated with previous models of osteoporosis. Over time, untreated individuals show a trend suggestive of increasing osteoporosis risk, whereas treated individuals show a reversal suggesting lowering of risk.image
C1 [Beattie, J. Renwick] Causeway Enterprise Agcy, J Renwick Beattie Consulting, Ballycastle, North Ireland.
   [Towler, Mark R.] Missouri Univ Sci & Technol, Dept Chem & Biochem Engn, Rolla, MO USA.
   [Towler, Mark R.] Missouri Univ Sci & Technol, Dept Chem & Biochem Engn, Rolla, MO 65401 USA.
C3 University of Missouri System; Missouri University of Science &
   Technology; University of Missouri System; Missouri University of
   Science & Technology
RP Towler, MR (通讯作者)，Missouri Univ Sci & Technol, Dept Chem & Biochem Engn, Rolla, MO 65401 USA.
EM mtowler@mst.edu
RI Beattie, Rene/I 4506 2015
OI Beattie, Rene/0000 0002 0205 717X
FU The authors would like to acknowledge the TRIO team at the University of
   Sheffield (R. Eastell, N.A. Peel, J. Walsh, E.V. McCloskey, and M.
   Paggiosi) for sample collection and reference measurements recorded as
   part of the TRIO study.
FX The authors would like to acknowledge the TRIO team at the University of
   Sheffield (R. Eastell, N.A. Peel, J. Walsh, E.V. McCloskey, and M.
   Paggiosi) for sample collection and reference measurements recorded as
   part of the TRIO study.
CR Allen MR., 2007, IBMS BoneKEy, V4, P49, DOI [10.1138/20060248, DOI 10.1138/20060248]
   ANDERLE G, 1987, BIOPHYS J, V52, P69, DOI 10.1016/S0006 3495(87)83189 2
   [Anonymous], 1986, Biological applications of Raman spectroscopy
   ASTM International, 1997, E399901997 ASTM
   Beattie JR, 2017, J RAMAN SPECTROSC, V48, P813, DOI 10.1002/jrs.5123
   Beattie JR, 2014, OIL GAS SCI TECHNOL, V69, P207, DOI 10.2516/ogst/2013185
   Beattie JR, 2019, J MATER SCI MATER M, V30, DOI 10.1007/s10856 019 6226 x
   Beattie JR, 2018, CLIN MED INSIGHTS AR, V11, P1, DOI 10.1177/1179544117754050
   Beattie JR, 2013, J RAMAN SPECTROSC, V44, P329, DOI 10.1002/jrs.4178
   Beattie JR, 2011, J RAMAN SPECTROSC, V42, P1419, DOI 10.1002/jrs.2851
   Beattie JR, 2009, J RAMAN SPECTROSC, V40, P429, DOI 10.1002/jrs.2146
   Beattie JR, 2016, CLIN MED INSIGHTS AR, V9, P109, DOI 10.4137/CMAMD.S38493
   BEATTIE JR, 2021, APPL SPECTROSC, P1
   Black DM, 2020, LANCET DIABETES ENDO, V8, P672, DOI 10.1016/S2213 8587(20)30159 5
   Boonen S, 2012, CURR OSTEOPOROS REP, V10, P73, DOI 10.1007/s11914 011 0085 9
   Brömme D, 2009, EXPERT OPIN INV DRUG, V18, P585, DOI [10.1517/13543780902832661, 10.1517/13543780902832661 ]
   CAMACHO CJ, 1995, PROTEINS, V22, P27, DOI 10.1002/prot.340220105
   Caraher MC, 2018, BBA MOL BASIS DIS, V1864, P398, DOI 10.1016/j.bbadis.2017.10.020
   Chen PQ, 2006, J BONE MINER RES, V21, P1785, DOI 10.1359/JBMR.060802
   Cummings SR, 2002, AM J MED, V112, P281, DOI 10.1016/S0002 9343(01)01124 X
   Cummins NM, 2010, SPECTROSC INT J, V24, P517, DOI 10.1155/2010/820580
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Eckhart L., 1833, BIOCH BIOPHYS ACTA M, V2013, P3471
   HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708
   Hansen T, 2006, VIRCHOWS ARCH, V449, P448, DOI 10.1007/s00428 006 0261 y
   Hernández B, 2016, J RAMAN SPECTROSC, V47, P210, DOI 10.1002/jrs.4776
   Hernández B, 2014, J RAMAN SPECTROSC, V45, P657, DOI 10.1002/jrs.4521
   Kim S, 2017, J BONE MINER RES, V32, P309, DOI 10.1002/jbmr.2985
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Koch FP, 2010, HEAD FACE MED, V6, DOI 10.1186/1746 160X 6 12
   Kumar S, 2007, BONE, V40, P122, DOI 10.1016/j.bone.2006.07.015
   Leeming DJ, 2009, OSTEOPOROSIS INT, V20, P1461, DOI 10.1007/s00198 009 0904 3
   Lehmann HJ, 2002, ANN RHEUM DIS, V61, P530, DOI 10.1136/ard.61.6.530
   Martin TJ., 2000, Aust Prescriber, V23, P130
   Moran P, 2007, J MATER SCI MATER M, V18, P969, DOI [10.1007/s10856 006 0037 6, 10.1007/S10856 006 0037 6]
   Ochi Y, 2011, BONE, V49, P1351, DOI 10.1016/j.bone.2011.09.041
   Palacky J, 2011, J RAMAN SPECTROSC, V42, P1528, DOI 10.1002/jrs.2896
   Parker SF, 2013, CHEM PHYS, V424, P75, DOI 10.1016/j.chemphys.2013.04.020
   Pillay I, 2005, J WOMENS HEALTH, V14, P339, DOI 10.1089/jwh.2005.14.339
   Rogers MJ, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115493
   Schmidt FN, 2017, BONE, V97, P243, DOI 10.1016/j.bone.2017.01.015
   Schuit SCE, 2004, BONE, V34, P195, DOI 10.1016/j.bone.2003.10.001
   SHURVELL HF, 1989, J RAMAN SPECTROSC, V20, P163, DOI 10.1002/jrs.1250200307
   Takeuchi H, 2003, BIOPOLYMERS, V72, P305, DOI 10.1002/bip.10440
   Tang SY, 2009, OSTEOPOROSIS INT, V20, P887, DOI 10.1007/s00198 008 0754 4
   Towler MR, 2007, J MATER SCI MATER M, V18, P759, DOI 10.1007/s10856 006 0018 9
   Tu A.T, 1982, Raman Spectroscopy in Biology: Principles and Applications
   VANBREUKELEN FJM, 1979, LANCET, V1, P803
   Viguet Carrin S, 2006, OSTEOPOROSIS INT, V17, P319, DOI 10.1007/s00198 005 2035 9
   Wang XD, 2000, CLIN ORTHOP RELAT R, P228
   Willett TL, 2019, BONE, V120, P187, DOI 10.1016/j.bone.2018.10.024
   YU NT, 1972, J MOL BIOL, V70, P117, DOI 10.1016/0022 2836(72)90167 2
NR 52
TC 0
Z9 0
U1 1
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0377 0486
EI 1097 4555
J9 J RAMAN SPECTROSC
JI J. Raman Spectrosc.
PD DEC
PY 2023
VL 54
IS 12
BP 1399
EP 1407
DI 10.1002/jrs.6602
EA OCT 2023
PG 9
WC Spectroscopy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Spectroscopy
GA LZ2Y5
UT WOS:001075790500001
DA 2025 08 17
ER

PT J
AU Dragomir, A
   Rocha, J
   Vanhuyse, M
   Cury, FL
   Kassouf, W
   Hu, J
   Aprikian, AG
AF Dragomir, A.
   Rocha, J.
   Vanhuyse, M.
   Cury, F. L.
   Kassouf, W.
   Hu, J.
   Aprikian, A. G.
TI Treatment patterns and trends in patients dying of prostate cancer in
   Quebec: a population based study
SO CURRENT ONCOLOGY
LA English
DT Article
DE Metastatic castration resistant prostate cancer; treatments for advanced
   prostate cancer; health care resource utilization; management of
   metastatic castration resistant prostate cancer in Quebec; treatment
   patterns and trends
ID MITOXANTRONE PLUS PREDNISONE; CUA CUOG GUIDELINES; LHRH ANTAGONISTS;
   INCREASED SURVIVAL; BONE METASTASIS; DOUBLE BLIND; CASTRATION;
   DOCETAXEL; THERAPY; MEN
AB Introduction Since just after the year 2000 in Quebec, the management of metastatic castration resistant prostate cancer (mCRPC) has evolved considerably, with the inclusion of docetaxel based chemotherapy, bone targeted therapies (zoledronic acid and denosumab), and more recently, abiraterone, enzalutamide, and cabazitaxel for docetaxel refractory patients. In the present study, we aimed to analyze contemporary mcrpc management patterns and therapy utilization trends in Quebec.
   Methods The study cohort consisted of patients dying of prostate cancer (pca) between January 2001 and December 2013, selected from Quebec public health care insurance databases. Patient selection was based on death from a pca related cause or therapy used according to the Canadian Urological Association guidelines on mcrpc management. Treatments included chemotherapy (mitoxantrone before 2005 and docetaxel after 2005), abiraterone, bone targeted therapy (zoledronic acid or denosumab, or both), and palliative radiation therapy (RT). During the study period, neither enzalutamide nor cabazitaxel was publicly reimbursed in Quebec, and as a result, no capture of their use was possible for this study. Multivariate logistic regression was used to identify factors associated with the probability of receiving chemotherapy, bone targeted therapies, and palliative RT before death from pca.
   Results Overall, the database search identified 3106 patients who died of pca between January 2001 and December 2013. Median age of death was 78 years. Of those 3106 patients, just 2568 (83%) received mCRPC specific treatments: chemotherapy, abiraterone, palliative RT, or bone targeted therapy; the other 17% of the patients were managed solely with maximum androgen blockade (androgen deprivation therapy plus anti androgens) despite a record of pca related death. Logistic regression analyses indicate that patients dying after 2005 were more likely to have received chemotherapy [odds ratio (OR): 1.51; 95% CI: 1.22 to 1.85] and bone targeted therapy (OR: 1.97; 95% CI: 1.64 to 2.37). Age was a significant predictor for the use of chemotherapy, bone targeted therapy, and palliative rt (ors in the range 0.96 0.98, p < 0.05).
   Conclusions Patient age seems to be a strong determinant in the of selection mcrpc therapy, affecting the probability of the use of chemotherapy, bone targeted therapy, or palliative rt. Although chemotherapy is still used only in a small percentage of patients, the introduction of new therapies such as bone targeted therapy, docetaxel, and abiraterone affected treatment selection over time. The availability of enzalutamide since February 2014 will likely produce additional changes in mcrpc management.
C1 [Dragomir, A.; Rocha, J.; Kassouf, W.; Hu, J.; Aprikian, A. G.] McGill Univ, Dept Surg, Urol, Montreal, PQ, Canada.
   [Dragomir, A.; Rocha, J.; Hu, J.] McGill Univ, Hlth Ctr, Res Inst, Montreal, PQ, Canada.
   [Vanhuyse, M.] McGill Univ, Div Med Oncol, Dept Oncol, Montreal, PQ, Canada.
   [Vanhuyse, M.; Cury, F. L.; Kassouf, W.; Aprikian, A. G.] McGill Univ, Hlth Ctr, Montreal, PQ, Canada.
   [Cury, F. L.] McGill Univ, Div Radiat Oncol, Dept Oncol, Montreal, PQ, Canada.
C3 McGill University; McGill University; McGill University; McGill
   University; McGill University
RP Dragomir, A (通讯作者)，5252 de Maisonneuve Blvd West,Second Floor,2B 45, Montreal, PQ H4A 3S5, Canada.
EM alice.dragomir@muhc.mcgill.ca
RI Cury, Fabio/AAW 5633 2020
CR [Anonymous], 1997, INT CLASSIFICATION D
   [Anonymous], 2019, NCCN CLIN PRACTICE G
   Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095
   Berthold DR, 2008, J CLIN ONCOL, V26, P242, DOI 10.1200/JCO.2007.12.4008
   Carter JA, 2012, EXPERT REV PHARM OUT, V12, P425, DOI [10.1586/ERP.12.31, 10.1586/erp.12.31]
   Cook T, 2000, Oncologist, V5, P162, DOI 10.1634/theoncologist.5 2 162
   Crawford ED, 2009, ONCOLOGY NY, V23, P626
   De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618
   de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140 6736(10)61389 X
   de Jong IJ, 2007, CURR MED RES OPIN, V23, P1077, DOI 10.1185/030079907X187973
   Dragomir A, 2010, MED CARE, V48, P418, DOI 10.1097/MLR.0b013e3181d567bd
   Engel Nitz Nicole M, 2011, Cancer Manag Res, V3, P233, DOI 10.2147/CMR.S21033
   Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470 2045(12)70379 0
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Hagiwara M, 2014, SUPPORT CARE CANCER, V22, P103, DOI 10.1007/s00520 013 1951 z
   Harris V, 2011, CLIN ONCOL UK, V23, P706, DOI 10.1016/j.clon.2011.04.014
   Harris WP, 2009, NAT CLIN PRACT UROL, V6, P76, DOI 10.1038/ncpuro1296
   Heidenreich A, 2011, EUR UROL, V59, P61, DOI 10.1016/j.eururo.2010.10.039
   Huggins C, 1972, CA Cancer J Clin, V22, P232, DOI 10.3322/canjclin.22.4.232
   Huggins C, 2002, J UROLOGY, V168, P9, DOI 10.1016/S0022 5347(05)64820 3
   Humphreys MR, 2013, J CANCER, V4, P304, DOI 10.7150/jca.4192
   Ribal MJ, 2015, PROSTATE CANCER US, V2015, DOI 10.1155/2015/186740
   Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294
   Keizman D, 2009, ONCOLOGY NY, V23, P631
   Kirby M, 2011, INT J CLIN PRACT, V65, P1180, DOI 10.1111/j.1742 1241.2011.02799.x
   Konski A, 2004, INT J RADIAT ONCOL, V60, P1373, DOI 10.1016/j.ijrobp.2004.05.053
   Labrie F, 2004, J ANDROL, V25, P305
   Lafeuille MH, 2013, AM HEALTH DRUG BENEF, V6, P307
   Lissbrant IF, 2013, ACTA ONCOL, V52, P1593, DOI 10.3109/0284186X.2013.770164
   Manikandan R, 2005, UROL INT, V75, P217, DOI 10.1159/000087797
   Mottet N, 2011, EUR UROL, V59, P572, DOI 10.1016/j.eururo.2011.01.025
   Moul JW, 2012, NAT REV UROL, V9, P125, DOI 10.1038/nrurol.2012.5
   Nakabayashi M, 2013, CANCER AM CANCER SOC, V119, P2990, DOI 10.1002/cncr.28102
   Parker C., 2012, Journal of Clinical Oncology, V30
   Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318
   Saad F, 2015, CUAJ CAN UROL ASSOC, V9, P90, DOI 10.5489/cuaj.2526
   Saad F, 2013, CUAJ CAN UROL ASSOC, V7, P231, DOI 10.5489/cuaj.1542
   Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506
   Schröder F, 2012, BJU INT, V109, P1, DOI 10.1111/j.1464 410X.2012.11215.x
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   *STAT CAN, 1986, CAN CLASS DIAGN THER
   Tannock IF, 1996, J CLIN ONCOL, V14, P1756, DOI 10.1200/JCO.1996.14.6.1756
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   Usami M, 2007, PROSTATE CANCER P D, V10, P194, DOI 10.1038/sj.pcan.4500934
   Weston P, 2005, EUR UROL, V47, P422, DOI 10.1016/j.eururo.2004.11.015
   Zielinski RR, 2014, CUAJ CAN UROL ASSOC, V8, pE520, DOI 10.5489/cuaj.2076
NR 46
TC 6
Z9 8
U1 0
U2 0
PU MULTIMED INC
PI TORONTO
PA 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA
SN 1198 0052
J9 CURR ONCOL
JI Curr. Oncol.
PD AUG
PY 2017
VL 24
IS 4
BP 240
EP 248
DI 10.3747/co.24.3598
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA FF3CD
UT WOS:000408772200018
PM 28874892
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Koike, T
   Mikami, T
   Shida, M
   Habuchi, O
   Kitagawa, H
AF Koike, Toshiyasu
   Mikami, Tadahisa
   Shida, Miharu
   Habuchi, Osami
   Kitagawa, Hiroshi
TI Chondroitin sulfate E mediates estrogen induced osteoanabolism
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OSTEOBLAST DIFFERENTIATION; CELL DIVISION; BONE HEALTH; N CADHERIN;
   GROWTH; GLUCURONOSYLTRANSFERASE; GLYCOSAMINOGLYCANS; IDENTIFICATION;
   PROTEOGLYCANS; BIOSYNTHESIS
AB Osteoporosis is an age related disorder of bone remodeling in which bone resorption outstrips bone matrix deposition. Although anticatabolic agents are frequently used as first line therapies for osteoporosis, alternative anabolic strategies that can enhance anabolic, osteogenic potential are actively sought. Sex steroid hormones, particularly estrogens, are bidirectional regulators for bone homeostasis; therefore, estrogen mediated events are important potential targets for such anabolic therapies. Here, we show that estrogen induced, osteoanabolic effects were mediated via enhanced production of chondroitin sulfate E (CS E), which could act as an osteogenic stimulant in our cell based system. Conversely, estrogen deficiency caused reduced expression of CS E synthesizing enzymes, including GalNAc4S 6ST, and led to decreased CS E production in cultures of bone marrow cells derived from ovariectomized mice. Moreover, Galnac4s6st deficient mice had abnormally low bone mass that resulted from impaired osteoblast differentiation. These results indicated that strategies aimed at boosting CS E biosynthesis are promising alternative therapies for osteoporosis.
C1 [Koike, Toshiyasu; Mikami, Tadahisa; Shida, Miharu; Kitagawa, Hiroshi] Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan.
   [Habuchi, Osami] Aichi Med Univ, Res Complex Med Frontiers, Nagakute, Aichi 4801195, Japan.
C3 Kobe Pharmaceutical University; Aichi Medical University
RP Kitagawa, H (通讯作者)，Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan.
EM kitagawa@kobepharma u.ac.jp
RI Kitagawa, Hiroshi/AAJ 1344 2020
OI Kitagawa, Hiroshi/0000 0002 9307 7079; Koike,
   Toshiyasu/0000 0001 6930 0317
FU Ministry of Education, Culture, Sports, Science and Technology
   (MEXT) Supported Program for the Strategic Research Foundation at
   Private Universities; MEXT of Japan [23110003, 25293014, 24590132];
   Grants in Aid for Scientific Research [25293014, 24590132] Funding
   Source: KAKEN
FX This work was supported in part by the Ministry of Education, Culture,
   Sports, Science and Technology (MEXT) Supported Program for the
   Strategic Research Foundation at Private Universities, 2012 2017 (to
   H.K.) and Grants in aid for Scientific Research on Innovative Areas (No.
   23110003 to H.K., Deciphering sugar chain based signals regulating
   integrative neuronal functions), for Scientific Research B (No. 25293014
   to H.K.), and for Scientific Research C (No. 24590132 to T.M.) from MEXT
   of Japan. We thank Yu Tazuma for technical assistance.
CR Bi YM, 2005, J BIOL CHEM, V280, P30481, DOI 10.1074/jbc.M500573200
   Carrino DA, 2011, GLYCOBIOLOGY, V21, P257, DOI 10.1093/glycob/cwq162
   Cheng SL, 2000, J BONE MINER RES, V15, P2362, DOI 10.1359/jbmr.2000.15.12.2362
   Di Benedetto A, 2010, J CELL SCI, V123, P2640, DOI 10.1242/jcs.067777
   Izumikawa T, 2008, J BIOL CHEM, V283, P11396, DOI 10.1074/jbc.M707549200
   Izumikawa T, 2014, SCI REP UK, V4, DOI 10.1038/srep03701
   Izumikawa T, 2012, BIOCHEM J, V441, P697, DOI 10.1042/BJ20111472
   Izumikawa T, 2011, BIOCHEM J, V434, P321, DOI 10.1042/BJ20101456
   Izumikawa T, 2010, J BIOL CHEM, V285, P12190, DOI 10.1074/jbc.M110.100941
   Kanno S, 2004, TOXICOLOGY, V196, P137, DOI 10.1016/j.tox.2003.12.002
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   Kii I, 2004, J BONE MINER RES, V19, P1840, DOI 10.1359/JBMR.040812
   Klüppel M, 2005, DEVELOPMENT, V132, P3989, DOI 10.1242/dev.01948
   Koike T, 2012, BIOCHEM BIOPH RES CO, V420, P523, DOI 10.1016/j.bbrc.2012.03.024
   Komosinska Vassev KB, 2008, CLIN CHEM LAB MED, V46, P219, DOI 10.1515/CCLM.2008.048
   Labrie F, 2007, NAT CLIN PRACT ENDOC, V3, P584, DOI 10.1038/ncpendmet0559
   Li BJ, 2011, J CELL BIOCHEM, V112, P1229, DOI 10.1002/jcb.23049
   Li Y, 2013, SCI REP UK, V3, DOI 10.1038/srep02422
   Lustberg MB, 2012, J CLIN ONCOL, V30, P3665, DOI 10.1200/JCO.2012.42.2097
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Mikami T, 2013, BBA GEN SUBJECTS, V1830, P4719, DOI 10.1016/j.bbagen.2013.06.006
   Mikami T, 2012, J BIOL CHEM, V287, P38531, DOI 10.1074/jbc.M111.336925
   Mikami T, 2009, J BIOL CHEM, V284, P4494, DOI 10.1074/jbc.M809227200
   Miyata S, 2012, NAT NEUROSCI, V15, P414, DOI 10.1038/nn.3023
   Mizuguchi S, 2003, NATURE, V423, P443, DOI 10.1038/nature01635
   Mochizuki A, 2006, J IMMUNOL, V177, P4360, DOI 10.4049/jimmunol.177.7.4360
   Nadanaka S, 2011, J BIOL CHEM, V286, P4199, DOI 10.1074/jbc.M110.155093
   Ohtake Niimi S, 2010, J BIOL CHEM, V285, P20793, DOI 10.1074/jbc.M109.084749
   Plaas AHK, 1997, J BIOL CHEM, V272, P20603, DOI 10.1074/jbc.272.33.20603
   PRINCE CW, 1983, J NUTR, V113, P1576, DOI 10.1093/jn/113.8.1576
   Riggs BL, 2000, J CLIN INVEST, V106, P1203, DOI 10.1172/JCI11468
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011
   Takeuchi K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3740
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Thiele H, 2004, P NATL ACAD SCI USA, V101, P10155, DOI 10.1073/pnas.0400334101
   Vandenput L, 2009, NAT REV ENDOCRINOL, V5, P437, DOI 10.1038/nrendo.2009.112
   VEJLENS L, 1971, CALC TISS RES, V7, P175, DOI 10.1007/BF02062605
   Watanabe Y, 2010, BIOCHEM J, V432, P47, DOI 10.1042/BJ20100847
   Zhu H, 2010, NAT PROTOC, V5, P550, DOI 10.1038/nprot.2009.238
NR 42
TC 27
Z9 27
U1 1
U2 22
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD MAR 11
PY 2015
VL 5
AR 8994
DI 10.1038/srep08994
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CD5OS
UT WOS:000351138300009
PM 25759206
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Hu, JP
   Nishishita, K
   Sakai, E
   Yoshida, H
   Kato, Y
   Tsukuba, T
   Okamoto, K
AF Hu, Jin Ping
   Nishishita, Kazuhisa
   Sakai, Eiko
   Yoshida, Hajime
   Kato, Yuzo
   Tsukuba, Takayuki
   Okamoto, Kuniaki
TI Berberine inhibits RANKL induced osteoclast formation and survival
   through suppressing the NF κB and Akt pathways
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE berberine; RANKL; osteoclast; Akt; NF kappa B; apoptosis
ID COLONY STIMULATING FACTOR; RECEPTOR ACTIVATOR; HL 60 CELLS; IN VITRO;
   APOPTOSIS; DIFFERENTIATION; KINASE; INDUCTION; ALPHA; EXPRESSION
AB Berberine, an isoquinoline alkaloid isolated from several medicinal plants, has been reported to possess anti bacterial, anti inflammatory and antitumor properties. Although berberine also inhibits osteoclastogenesis and bone resorption, the molecular machinery for its inhibitory effects remains unknown. This study focused on the suppressive effects of berberine on receptor activator of nuclear factor kappa B (NF kappa B) ligand (RANKL)induced osteoclastogenesis and survival. Berberine inhibited RANKL mediated osteoclast fort nation and survival while having no cytotoxic effects on bone marrow macrophages or osteoblastic cells. Berberine attenuated RANKL induced activation of NF kappa B through inhibiting phosphorylation at the activation loop of I kappa B alpha kinase, phosphorylation and degradation of I kappa B alpha, and NF kappa B p65 nuclear translocation. RANKL induced Akt phosphorylation was strongly inhibited by berberine; however, neither monocyte/macrophage colony stimulating factor (M CSF) induced nor insulin induced Akt activation was inhibited by the drug. Under M CSF  and RANKL deprived condition, berberine increased the active form of caspase 3 in osteoclasts. By contrast, berberine did not potentiate the activation of caspase 3 in M CSF deprived bone marrow macrophages. These findings indicate that berberine inhibits osteoclast formation and survival through suppression of NF kappa B and Akt activation and that both pathways in the osteoclast lineage are highly sensitive to berberine treatment. (C) 2007 Elsevier B.V. All rights reserved.
C1 [Hu, Jin Ping; Nishishita, Kazuhisa; Sakai, Eiko; Kato, Yuzo; Tsukuba, Takayuki; Okamoto, Kuniaki] Nagasaki Univ, Grad Sch Biomed Sci, Div Oral Pathopharmacol, Nagasaki 8528588, Japan.
   [Hu, Jin Ping] Jilin Univ, Stomatol Hosp, Changchun 130041, Peoples R China.
   [Yoshida, Hajime] Nagasaki Univ, Grad Sch Biomed Sci, Div Oral & Maxillofacial Surg, Nagasaki 8528588, Japan.
C3 Nagasaki University; Jilin University; Nagasaki University
RP Nishishita, K (通讯作者)，Nagasaki Univ, Grad Sch Biomed Sci, Div Oral Pathopharmacol, Sakamoto 1 7 1, Nagasaki 8528588, Japan.
EM kazu@nagasaki u.ac.jp
RI Tsukuba, Takayuki/I 9542 2018
CR Anis KV, 2001, J PHARM PHARMACOL, V53, P763, DOI 10.1211/0022357011775901
   Bhatt NY, 2002, J IMMUNOL, V169, P6427, DOI 10.4049/jimmunol.169.11.6427
   Birdsall T. C., 1997, Alternative Medicine Review, V2, P94
   Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309
   Dvorák Z, 2006, CHEM BIOL INTERACT, V159, P117, DOI 10.1016/j.cbi.2005.10.105
   Enk R, 2007, J ETHNOPHARMACOL, V109, P170, DOI 10.1016/j.jep.2006.07.013
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   FULLER K, 1993, J EXP MED, V178, P1733, DOI 10.1084/jem.178.5.1733
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200
   Hsiang CY, 2005, J BIOMED SCI, V12, P791, DOI 10.1007/s11373 005 9003 4
   Hu JP, 2000, ORAL DIS, V6, P297, DOI 10.1111/j.1601 0825.2000.tb00142.x
   Hwang JM, 2006, ARCH TOXICOL, V80, P62, DOI 10.1007/s00204 005 0014 8
   Iwamoto T, 2001, J BIOL CHEM, V276, P46031, DOI 10.1074/jbc.M104464200
   Jantova S, 2007, TOXICOL IN VITRO, V21, P25, DOI 10.1016/j.tiv.2006.07.015
   Kang BY, 2002, BIOCHEM PHARMACOL, V63, P1901, DOI 10.1016/S0006 2952(02)00982 6
   Kawaida R, 2003, J EXP MED, V197, P1029, DOI 10.1084/jem.20021321
   Kim SK, 2007, PHARMACOL THERAPEUT, V113, P88, DOI 10.1016/j.pharmthera.2006.07.004
   Kong WJ, 2004, NAT MED, V10, P1344, DOI 10.1038/nm1135
   KUO CL, 1995, CANCER LETT, V93, P193, DOI 10.1016/0304 3835(95)03809 B
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Letasiová S, 2006, CANCER LETT, V239, P254, DOI 10.1016/j.canlet.2005.08.024
   Li HY, 1999, BIOL PHARM BULL, V22, P391, DOI 10.1248/bpb.22.391
   Mantena SK, 2006, MOL CANCER THER, V5, P296, DOI 10.1158/1535 7163.MCT 05 0448
   Nishida S, 2003, AM J CHINESE MED, V31, P551, DOI 10.1142/S0192415X03001211
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081
   Stern PH, 2007, J CELL BIOCHEM, V101, P1087, DOI 10.1002/jcb.21311
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Wartenberg M, 2003, LAB INVEST, V83, P87, DOI 10.1097/01.LAB.0000049348.51663.2F
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Yoshida H, 2006, J BIOCHEM, V139, P583, DOI 10.1093/jb/mvj066
   Zeng XJ, 1999, BIOMED CHROMATOGR, V13, P442, DOI 10.1002/(SICI)1099 0801(199911)13:7<442::AID BMC908>3.3.CO;2 1
NR 33
TC 129
Z9 141
U1 1
U2 24
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD FEB 2
PY 2008
VL 580
IS 1 2
BP 70
EP 79
DI 10.1016/j.ejphar.2007.11.013
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 260AU
UT WOS:000252983100010
PM 18083161
DA 2025 08 17
ER

PT J
AU Cui, MC
   Qu, JQ
   Chen, SJ
   Chen, HJ
   Zhou, HB
AF Cui, Ming chao
   Qu, Jian qi
   Chen, Shao jun
   Chen, Hong jiang
   Zhou, Hai bin
TI Daucosterol Protects MC3T3 E1 Cells against
   H2O2 induced Injury via Regulating IGF 1
   Pathway
SO LATIN AMERICAN JOURNAL OF PHARMACY
LA English
DT Article
DE daucosterol; IGF 1 signal pathway; MC3T3 E1 Cells
ID D GLUCOSIDE; OSTEOPOROSIS; BONE; LIPOPOLYSACCHARIDE; PROLIFERATION;
   MANAGEMENT; AUTOPHAGY; DENSITY; STRESS; DAMAGE
AB Daucosterol has been considered as a promising anti osteoporosis drug due to its capacity of facilitating osteoblast like cell proliferation. However, its mechanism remains obscure. In this thesis, the protective effects of daucosterol on MC3T3 E1 cells subjected to H2O2 were evaluated by cell viability assay with CCK 8, by cell apoptosis analysis with Annexin V FITC/PI double staining and flow cytometry, and by caspase 3 activity assay with colorimetry. The mechanism of protection was also studied by IGF 1 protein quantitation with ELISA and picropodophyllin (PPP, IGF 1 receptor chemical inhibitor) inhibition test with CCK 8. Results indicated that daucosterol dose groups of 10,20, and 40 mu M all significantly increased the cell viability, respectively. And 10 mu M was the optimal dose of them. Daucosterol in the dose of 10 mu M reduced caspase 3 activity and apoptotic rate. It was also found that daucosterol (10 mu M) increased the expression level of IGF 1 protein, and the protection of daucosterol was inhibited in the presence of PPP (200 mu M). These results thus suggested that daucosterol might protect MC3T3 E1 cells against H2O2 induced injury via regulating IGF 1 pathway which played an essential role in keeping normal bone metabolism.
C1 [Cui, Ming chao; Chen, Shao jun; Chen, Hong jiang] Zhejiang Pharmaceut Coll, Sch Tradit Chinese Med, Ningbo 315100, Zhejiang, Peoples R China.
   [Cui, Ming chao; Chen, Hong jiang] Nanjing Univ Chinese Med, Sch Pharm, Nanjing 210046, Jiangsu, Peoples R China.
   [Qu, Jian qi] Second Peoples Hosp Liaocheng, Linqing 252600, Shandong, Peoples R China.
   [Zhou, Hai bin] Ningbo Liwah Pharmaceut Co Ltd, Ningbo 315174, Zhejiang, Peoples R China.
C3 Nanjing University of Chinese Medicine
RP Cui, MC (通讯作者)，Zhejiang Pharmaceut Coll, Sch Tradit Chinese Med, Ningbo 315100, Zhejiang, Peoples R China.; Cui, MC (通讯作者)，Nanjing Univ Chinese Med, Sch Pharm, Nanjing 210046, Jiangsu, Peoples R China.
EM cuimc@139.com
RI zhou, haibin/N 4597 2014
FU Zhejiang Provincial Natural Science Foundation of China [LY15H280009];
   Ningbo Natural Science Foundation [2015A610290]; Scientific Research
   Project of Zhejiang Pharmaceutical College [ZPCSR2010007]
FX Programs Supported by Zhejiang Provincial Natural Science Foundation of
   China (LY15H280009), Ningbo Natural Science Foundation (2015A610290),
   Scientific Research Project of Zhejiang Pharmaceutical College
   (ZPCSR2010007).
CR Addison WN, 2015, BONE, V71, P244, DOI 10.1016/j.bone.2014.11.003
   Anitua E, 2013, J PERIODONTOL, V84, P1180, DOI 10.1902/jop.2012.120292
   AYLWARD F, 1958, NATURE, V181, P1064, DOI 10.1038/1811064a0
   Benford HL, 2001, BONE, V28, P465, DOI 10.1016/S8756 3282(01)00412 4
   Choi JN, 2012, NAT PROD RES, V26, P2340, DOI 10.1080/14786419.2012.654608
   Economou MA, 2008, ACTA OPHTHALMOL, V86, P930, DOI [10.1111/j.1755 3768.2008.01188.x, 10.1111/j.1755 3768.2008.01182.x, 10.1111/j.1755 3768.2008.01185.x, 10.1111/j.1755 3768.2008.01184.x]
   Fatokun AA, 2006, BONE, V39, P542, DOI 10.1016/j.bone.2006.02.062
   Golob AL, 2015, MED CLIN N AM, V99, P587, DOI 10.1016/j.mcna.2015.01.010
   Huang YL, 2015, J FUNCT FOODS, V15, P487, DOI 10.1016/j.jff.2015.03.056
   Jiang LH, 2014, J STEROID BIOCHEM, V140, P90, DOI 10.1016/j.jsbmb.2013.12.002
   Kim KA, 2014, MOL NUTR FOOD RES, V58, P963, DOI 10.1002/mnfr.201300433
   Laviola L, 2007, CURR PHARM DESIGN, V13, P663, DOI 10.2174/138161207780249146
   Lee JH, 2007, VACCINE, V25, P3834, DOI 10.1016/j.vaccine.2007.01.108
   Li BX, 2013, ENDOCRINE, V43, P136, DOI 10.1007/s12020 012 9757 1
   Li YK, 2014, PAK J MED SCI, V30, P131, DOI 10.12669/pjms.301.4264
   Lin X, 2015, CLIN INTERV AGING, V10, P1017, DOI 10.2147/CIA.S54613
   Pan YL, 2012, CHEM COMMUN, V48, P997, DOI 10.1039/c1cc15407a
   Power FB, 1913, J CHEM SOC, V103, P399, DOI 10.1039/ct9130300399
   Saeidnia S., 2014, European Journal of Medicinal Plants, V4, P590
   Stockert JC, 2012, ACTA HISTOCHEM, V114, P785, DOI 10.1016/j.acthis.2012.01.006
   Tian X., 2015, International Journal of Caring Sciences, V8, P152
   Wang YM, 2006, J BONE MINER RES, V21, P1350, DOI 10.1359/JBMR.060610
   Wauquier F, 2009, TRENDS MOL MED, V15, P468, DOI 10.1016/j.molmed.2009.08.004
   Wu XP, 2003, BRIT J RADIOL, V76, P452, DOI 10.1259/bjr/36670654
   Xie WL, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/312901
   Yakar S, 2002, J CLIN INVEST, V110, P771, DOI 10.1172/JCI200215463
   Yang YH, 2014, FREE RADICAL BIO MED, V77, P10, DOI 10.1016/j.freeradbiomed.2014.08.028
   Zhao CK, 2015, LIFE SCI, V137, P37, DOI 10.1016/j.lfs.2015.07.019
NR 28
TC 0
Z9 0
U1 0
U2 8
PU COLEGIO FARMACEUTICOS PROVINCIA DE BUENOS AIRES
PI LA PLATA
PA DEPT CIENTIFICO, CALLE 5 NO 966, LA PLATA, 00000, ARGENTINA
SN 0326 2383
J9 LAT AM J PHARM
JI Lat. Am. J. Pharm.
PD APR
PY 2016
VL 35
IS 3
BP 564
EP 569
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA DL9MU
UT WOS:000375968200020
DA 2025 08 17
ER

PT J
AU Bose, S
   Sarkar, N
   Majumdar, U
AF Bose, Susmita
   Sarkar, Naboneeta
   Majumdar, Ujjayan
TI Micelle encapsulated curcumin and piperine laden 3D printed calcium
   phosphate scaffolds enhance in vitro biological properties
SO COLLOIDS AND SURFACES B BIOINTERFACES
LA English
DT Article
DE Curcumin; Micelle; 3D printing; Bone tissue engineering; Multifunctional
   bone Scaffold
ID BLOCK COPOLYMER MICELLES; OSTEOBLAST DIFFERENTIATION; CANCER CELLS;
   ANGIOGENESIS; BIOAVAILABILITY; OSTEOSARCOMA; APOPTOSIS; RELEASE; MATRIX
AB Limitations in the current clinical management of critical sized osseous defects have driven the need for multifunctional bone constructs. The ideal bone scaffold should possess advanced microarchitecture, well defined pore interconnectivity, and supply biological signals, which actively guide and control tissue regeneration while simultaneously preventing post implantation complications. Here, a natural medicine based localized drug delivery from 3D printed scaffold is presented, which offers controlled release of curcumin, piperine from nano sized polymeric micelles, and burst release of antibacterial carvacrol from the coating endowing the scaffold with their distinct, individual biological properties. This functionalized scaffold exhibits improved osteoblast (hFOB) cell attachment, 4 folds higher hFOB proliferation, and 73% increased hFOB differentiation while simultaneously providing cytotoxicity towards osteosarcoma cells with 61% lesser viability compared to control. In vitro, early tube formation (p < 0.001) indicates that the scaffolds can modulate the endothelial cellular network, critical for faster wound healing. The scaffold also exhibits 94% enhanced antibacterial efficacy (p < 0.001) against gram positive Staphylococcus aureus, the main causative bacteria for osteomyelitis. Together, the multifunctional scaffolds provide controlled delivery of natural biomolecules from the nano sized micelle  loaded 3D printed matrix for significant improvement in osteoblast proliferation, endothelial formation, osteosarcoma, and bacterial inhibition, guiding better bone regeneration for post traumatic defect repair.
C1 [Bose, Susmita; Sarkar, Naboneeta; Majumdar, Ujjayan] Washington State Univ, Sch Mech & Mat Engn, WM Keck Biomed Mat Res Lab, Pullman, WA 99164 USA.
C3 Washington State University
RP Bose, S (通讯作者)，Washington State Univ, Sch Mech & Mat Engn, WM Keck Biomed Mat Res Lab, Pullman, WA 99164 USA.
EM sbose@wsu.edu
RI Majumdar, Ujjayan/MTA 4447 2025
FU National Institute of Dental and Craniofacial Research (NIDCR) of the
   NIH [R01 DE029204 01]; National Institute of Arthritis and
   Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of
   Health (NIH) [R01 AR066361]
FX Authors would like to acknowledge financial support from the National
   Institute of Dental and Craniofacial Research (NIDCR) of the NIH under
   Award number R01 DE029204 01 and National Institute of Arthritis and
   Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of
   Health (NIH) under Award number R01 AR066361. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institute of Health.
CR Aggarwal BB, 2003, ANTICANCER RES, V23, P363
   Ahmed Farid OAH, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929 017 0373 5
   Ak T, 2008, CHEM BIOL INTERACT, V174, P27, DOI 10.1016/j.cbi.2008.05.003
   Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r
   Anderson ME, 2016, ORTHOP CLIN N AM, V47, P283, DOI 10.1016/j.ocl.2015.08.022
   Bansal SS, 2011, CANCER PREV RES, V4, P1158, DOI 10.1158/1940 6207.CAPR 10 0006
   Ben Arfa A, 2006, LETT APPL MICROBIOL, V43, P149, DOI 10.1111/j.1472 765X.2006.01938.x
   Bose S, 2018, MATER TODAY CHEM, V8, P110, DOI 10.1016/j.mtchem.2018.03.005
   Bose Susmita, 2022, Binder Jet Additive Manufacturing of Biomaterials, P77
   Cacciatore I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120937
   Carpentier G, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 67289 8
   Chang R, 2014, INT J NANOMED, V9, P461, DOI 10.2147/IJN.S55505
   Chen BJ, 2021, THERANOSTICS, V11, P5911, DOI 10.7150/thno.56266
   Chen SF, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.634650
   Chen ZG, 2016, INT J MOL MED, V37, P329, DOI 10.3892/ijmm.2015.2432
   DeCicco Skinner KL, 2014, JOVE J VIS EXP, DOI 10.3791/51312
   Deng Y, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 05196 1
   Dhillon N, 2008, CLIN CANCER RES, V14, P4491, DOI 10.1158/1078 0432.CCR 08 0024
   Dorai T, 2001, PROSTATE, V47, P293, DOI 10.1002/pros.1074
   Durfee RA, 2016, RHEUMATOL THER, V3, P221, DOI 10.1007/s40744 016 0046 y
   Fielding G, 2013, ACTA BIOMATER, V9, P9137, DOI 10.1016/j.actbio.2013.07.009
   Gu QL, 2012, PHARMACOGN MAG, V8, P202, DOI 10.4103/0973 1296.99285
   Guarda A, 2011, INT J FOOD MICROBIOL, V146, P144, DOI 10.1016/j.ijfoodmicro.2011.02.011
   Harrison DJ, 2018, EXPERT REV ANTICANC, V18, P39, DOI 10.1080/14737140.2018.1413939
   Heras C, 2020, ACTA BIOMATER, V114, P395, DOI 10.1016/j.actbio.2020.07.044
   Hosseini S, 2019, COLLOID SURFACE B, V173, P662, DOI 10.1016/j.colsurfb.2018.10.035
   Hussan F, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/174916
   Jo Y, 2023, J MATER CHEM B, V11, P5503, DOI 10.1039/d2tb02210a
   Jordan SC, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 05382 w
   KATAOKA K, 1993, J CONTROL RELEASE, V24, P119
   Ke DX, 2018, ADDIT MANUF, V22, P111, DOI 10.1016/j.addma.2018.04.020
   Kim DY, 2018, BIOCHEM BIOPH RES CO, V495, P1497, DOI 10.1016/j.bbrc.2017.11.200
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Kumar S, 2007, EUR J PHARMACOL, V575, P177, DOI 10.1016/j.ejphar.2007.07.056
   Lei D, 2019, MATER HORIZ, V6, P1197, DOI 10.1039/c9mh00174c
   Leung MHM, 2008, LANGMUIR, V24, P5672, DOI 10.1021/la800780w
   Li XM, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00625
   Liu R, 2018, DENT MATER, V34, P1112, DOI 10.1016/j.dental.2018.04.007
   Liu WD, 2016, J DRUG TARGET, V24, P694, DOI 10.3109/1061186X.2016.1157883
   Liu WJ, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0029 4
   Magi G, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00165
   Majeed M., 1998, US Patent, Patent No. [5744161, 005744161A, 005744161]
   MUJUMDAR AM, 1990, JPN J MED SCI BIOL, V43, P95, DOI 10.7883/yoken1952.43.95
   Nandi SK, 2018, J BIOMED MATER RES B, V106, P1073, DOI 10.1002/jbm.b.33910
   Nostro Antonia, 2012, Recent Pat Antiinfect Drug Discov, V7, P28
   Novosel EC, 2011, ADV DRUG DELIVER REV, V63, P300, DOI 10.1016/j.addr.2011.03.004
   Pillai GR, 2004, CANCER LETT, V208, P163, DOI 10.1016/j.canlet.2004.01.008
   Rapoport N, 2007, PROG POLYM SCI, V32, P962, DOI 10.1016/j.progpolymsci.2007.05.009
   Rather RA, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00010
   Sahu A, 2011, J BIOMATER APPL, V25, P619, DOI 10.1177/0885328209357110
   Samiei M, 2021, STEM CELLS INT, V2021, DOI 10.1155/2021/9980137
   Sarkar N, 2020, ACS APPL MATER INTER, V12, P13644, DOI 10.1021/acsami.9b22474
   Sarkar N, 2019, ACS APPL MATER INTER, V11, P17184, DOI 10.1021/acsami.9b01218
   Sharma AV, 2012, ANTIOXID REDOX SIGN, V16, P351, DOI 10.1089/ars.2011.4232
   Shishodia S, 2005, ANN NY ACAD SCI, V1056, P206, DOI 10.1196/annals.1352.010
   Shoba G, 1998, PLANTA MED, V64, P353, DOI 10.1055/s 2006 957450
   Singh Sarvjeet, 2006, Anti Cancer Agents in Medicinal Chemistry, V6, P259, DOI 10.2174/187152006776930918
   Son HE, 2018, LIFE SCI, V193, P34, DOI 10.1016/j.lfs.2017.12.008
   Subbiah V, 2023, NAT MED, V29, P49, DOI 10.1038/s41591 022 02160 z
   Tan B., 2021, ACS Appl. Mater. Interfaces
   Teow SY, 2016, J TROP MED US, V2016, DOI 10.1155/2016/2853045
   Vu AA, 2019, ACTA BIOMATER, V92, P325, DOI 10.1016/j.actbio.2019.05.020
   Wang RX, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/7569127
   Wang TY, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/1390795
   Wang YW, 2016, JALA J LAB AUTOM, V21, P723, DOI 10.1177/2211068216655524
   Xiao J, 2016, CURR OPIN MICROBIOL, V34, P90, DOI 10.1016/j.mib.2016.08.008
NR 66
TC 8
Z9 8
U1 5
U2 34
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0927 7765
EI 1873 4367
J9 COLLOID SURFACE B
JI Colloid Surf. B Biointerfaces
PD NOV
PY 2023
VL 231
AR 113563
DI 10.1016/j.colsurfb.2023.113563
EA OCT 2023
PG 16
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Chemistry; Materials Science
GA X5AR8
UT WOS:001098580300001
PM 37832173
DA 2025 08 17
ER

PT J
AU Hirozane, T
   Masuda, M
   Sugano, T
   Sekita, T
   Goto, N
   Aoyama, T
   Sakagami, T
   Uno, Y
   Moriyama, H
   Sawa, M
   Asano, N
   Nakamura, M
   Matsumoto, M
   Nakayama, R
   Kondo, T
   Kawai, A
   Kobayashi, E
   Yamada, T
AF Hirozane, Toru
   Masuda, Mari
   Sugano, Teppei
   Sekita, Tetsuya
   Goto, Naoko
   Aoyama, Toru
   Sakagami, Takato
   Uno, Yuko
   Moriyama, Hideki
   Sawa, Masaaki
   Asano, Naofumi
   Nakamura, Masaya
   Matsumoto, Morio
   Nakayama, Robert
   Kondo, Tadashi
   Kawai, Akira
   Kobayashi, Eisuke
   Yamada, Tesshi
TI Direct conversion of osteosarcoma to adipocytes by targeting TNIK
SO JCI INSIGHT
LA English
DT Article
ID NCK INTERACTING KINASE; STEM CELLS; TRANSCRIPTIONAL REGULATION;
   NEOADJUVANT CHEMOTHERAPY; PROGNOSTIC FACTORS; GENE EXPRESSION; C MYC;
   WNT; METASTASIS; OSTEOBLASTOGENESIS
AB Osteosarcoma (OS) is an aggressive mesenchymal tumor for which no molecularly targeted therapies are available. We have previously identified TRAF2  and NCK interacting protein kinase (TNIK) as an essential factor for the transactivation of Wnt signal target genes and shown that its inhibition leads to eradication of colorectal cancer stem cells. The involvement of Wnt signaling in the pathogenesis of OS has been implicated. The aim of the present study was to examine the potential of TNIK as a therapeutic target in OS. RNA interference or pharmacological inhibition of TNIK suppressed the proliferation of OS cells. Transcriptome analysis suggested that a small molecule inhibitor of TNIK upregulated the expression of genes involved in OS cell metabolism and down regulated transcription factors essential for maintaining the stem cell phenotype. Metabolome analysis revealed that this TNIK inhibitor redirected the metabolic network from carbon flux toward lipid accumulation in OS cells. Using in vitro and in vivo OS models, we confirmed that TNIK inhibition abrogated the OS stem cell phenotype, simultaneously driving conversion of OS cells to adipocyte li Ice cells through induction of PPAR gamma. In relation to potential therapeutic targeting in clinical practice, TNIK was confirmed to be in an active state in OS cell lines and clinical specimens. From these findings, we conclude that TNIK is applicable as a potential target for treatment of OS, affecting cell fate determination.
C1 [Hirozane, Toru; Masuda, Mari; Sugano, Teppei; Sekita, Tetsuya; Goto, Naoko; Aoyama, Toru; Sakagami, Takato; Yamada, Tesshi] Natl Canc Ctr, Div Cellular Signaling, Tokyo, Japan.
   [Hirozane, Toru; Sekita, Tetsuya; Asano, Naofumi; Nakamura, Masaya; Matsumoto, Morio; Nakayama, Robert] Keio Univ, Dept Orthoped Surg, Sch Med, Tokyo, Japan.
   [Sugano, Teppei] Nippon Med Sch, Grad Sch Med, Dept Pulm Med & Oncol, Tokyo, Japan.
   [Aoyama, Toru; Sakagami, Takato] Keio Univ, Sch Med, Tokyo, Japan.
   [Uno, Yuko; Moriyama, Hideki; Sawa, Masaaki] Carna Biosci Inc, Kobe, Hyogo, Japan.
   [Asano, Naofumi; Kondo, Tadashi] Natl Canc Ctr, Div Rare Canc Res, Tokyo, Japan.
   [Kawai, Akira; Kobayashi, Eisuke] Natl Canc Ctr, Div Musculoskeletal Oncol, Tokyo, Japan.
   [Yamada, Tesshi] Tokyo Med Univ, Dept Gastrointestinal & Pediat Surg, Tokyo, Japan.
C3 National Cancer Center   Japan; Keio University; Nippon Medical School;
   Keio University; National Cancer Center   Japan; National Cancer Center
     Japan; Tokyo Medical University
RP Hirozane, T (通讯作者)，Keio Univ, Dept Orthoped Surg, Sch Med, Shinjyuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM t.hirozane@gmail.com
RI ; hirozane, toru/AHC 2952 2022; Nakamura, Masaya/K 4111 2013
OI Kondo, Tadashi/0000 0001 6405 7792; Aoyama, Toru/0000 0001 8466 1612;
   Hirozane, Toru/0000 0002 3645 961X; 
FU Orthopedic Oncology Division of Keio University; National Cancer Center
   Research and Development Fund [26 A 13, 26 A 5]; Japan Agency for
   Medical Research and Development (AMED) [16im0210804h0001]; Kobayashi
   Foundation for Cancer Research; KAKENHI [16K14627, 17H03603, 18K15249,
   20K18040, 20K20474]; Japan Society for the Promotion of Science;
   Foundation for Promotion of Cancer Research in Japan; Project Mirai
   Cancer Research Grants from the Japan Cancer Society; Princess Takamatsu
   Cancer Research Fund; Grants in Aid for Scientific Research [18K15249,
   16K14627, 17H03603, 20K20474, 20K18040, 20K07690, 21H03062] Funding
   Source: KAKEN
FX We are grateful to Toshio Imai and Naoaki Uchiya (National Cancer Center
   Research Institute) for their help with the animal experiments and
   preparation of paraffin embedded tissue sections. We thank all members
   of the Yamada Laboratory at the National Cancer Center, the Orthopedic
   Oncology Division of Keio University, and affiliated hospitals for
   editing the manuscript and other helpful suggestions. This study was
   supported by the National Cancer Center Research and Development Fund
   (26 A 13 and 26 A 5 to TY), the Acceleration Transformative Research for
   Medical Innovation program of the Japan Agency for Medical Research and
   Development (AMED) (16im0210804h0001 to TY), the Kobayashi Foundation
   for Cancer Research (to TY), a KAKENHI Grant in Aid for Challenging
   Exploratory Research (16K14627 to M. Masuda), a Grant in Aid for
   Scientific Research (B) (17H03603 to M. Masuda), a Grant in Aid for
   Early Career Scientists (18K15249 and 20K18040 to TH), a Grant in Aid
   for Challenging Research (Pioneering) (20K20474 to TY) of the Japan
   Society for the Promotion of Science, a Cancer Research Grant from the
   Foundation for Promotion of Cancer Research in Japan (to M. Masuda),
   Project Mirai Cancer Research Grants from the Japan Cancer Society (to
   M. Masuda), and a Research Grant from the Princess Takamatsu Cancer
   Research Fund (to M. Masuda).
CR Banks AS, 2015, NATURE, V517, P391, DOI 10.1038/nature13887
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Basu Roy U, 2012, ONCOGENE, V31, P2270, DOI 10.1038/onc.2011.405
   Basu Roy U, 2016, ONCOTARGET, V7, P60954, DOI 10.18632/oncotarget.11273
   Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
   Burns KA, 2007, BBA MOL CELL BIOL L, V1771, P952, DOI 10.1016/j.bbalip.2007.04.018
   Cai Y, 2014, J CELL BIOCHEM, V115, P625, DOI 10.1002/jcb.24708
   Carrle D, 2006, INT ORTHOP, V30, P445, DOI 10.1007/s00264 006 0192 x
   Choi JH, 2011, NATURE, V477, P477, DOI 10.1038/nature10383
   Cole MF, 2008, GENE DEV, V22, P746, DOI 10.1101/gad.1642408
   Dieudonné FX, 2012, J BONE MINER RES, V27, P2118, DOI 10.1002/jbmr.1650
   Fleuren EDG, 2016, NAT REV CANCER, V16, P83, DOI 10.1038/nrc.2015.18
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008 5472.CAN 03 1952
   Honda K, 2005, GASTROENTEROLOGY, V128, P51, DOI 10.1053/j.gastro.2004.10.004
   Huang DW, 2007, NUCLEIC ACIDS RES, V35, pW169, DOI 10.1093/nar/gkm415
   Iwamoto Y, 2009, J ORTHOP SCI, V14, P397, DOI 10.1007/s00776 009 1347 6
   James AW, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/684736
   Janeway KA, 2010, LANCET ONCOL, V11, P670, DOI 10.1016/S1470 2045(10)70062 0
   Jin J, 2014, PATHOL RES PRACT, V210, P621, DOI 10.1016/j.prp.2013.10.007
   Kang S, 2007, J BIOL CHEM, V282, P14515, DOI 10.1074/jbc.M700030200
   Kansara M, 2007, DNA CELL BIOL, V26, P1, DOI 10.1089/dna.2006.0505
   Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002
   Kim W, 2018, J SURG ONCOL, V117, P1223, DOI 10.1002/jso.24963
   Knoepfler PS, 2007, CANCER RES, V67, P5061, DOI 10.1158/0008 5472.CAN 07 0426
   Kovac M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9940
   Kuijjer ML, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755 8794 7 4
   Mahmoudi T, 2009, EMBO J, V28, P3329, DOI 10.1038/emboj.2009.285
   Martins Neves SR, 2016, J CELL PHYSIOL, V231, P876, DOI 10.1002/jcp.25179
   Masuda M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12586
   Mehlem A, 2013, NAT PROTOC, V8, P1149, DOI 10.1038/nprot.2013.055
   Mir O, 2008, LANCET ONCOL, V9, P1198, DOI 10.1016/S1470 2045(08)70309 7
   Mirabello L, 2015, CANCER DISCOV, V5, P920, DOI 10.1158/2159 8290.CD 15 0125
   Ohashi Y, 2008, MOL BIOSYST, V4, P135, DOI 10.1039/b714176a
   Okamura M, 2009, P NATL ACAD SCI USA, V106, P5819, DOI 10.1073/pnas.0901676106
   Ooga T, 2011, MOL BIOSYST, V7, P1217, DOI 10.1039/c0mb00141d
   Pereira L, 2006, MOL CELL BIOL, V26, P7479, DOI 10.1128/MCB.00368 06
   Perry JA, 2014, P NATL ACAD SCI USA, V111, pE5564, DOI 10.1073/pnas.1419260111
   Qiu Bo, 2016, Bio Protoc, V6, DOI 10.21769/BioProtoc.1912
   Rosen ED, 2000, GENE DEV, V14, P1293
   Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950
   Sabò A, 2014, NATURE, V511, P488, DOI 10.1038/nature13537
   Sakaue H, 2002, GENE DEV, V16, P908, DOI 10.1101/gad.983202
   Schürch C, 2012, J CLIN INVEST, V122, P624, DOI 10.1172/JCI45977
   Sekita T, 2020, CANCERS, V12, DOI 10.3390/cancers12051258
   Sethi JK, 2010, BIOCHEM J, V427, P1, DOI 10.1042/BJ20091866
   Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658
   Shitashige M, 2008, GASTROENTEROLOGY, V134, P1961, DOI 10.1053/j.gastro.2008.03.010
   Shitashige M, 2010, CANCER RES, V70, P5024, DOI 10.1158/0008 5472.CAN 10 0306
   Sugano T, 2021, BRIT J CANCER, V124, P228, DOI 10.1038/s41416 020 01162 3
   Sugimoto M, 2010, METABOLOMICS, V6, P78, DOI 10.1007/s11306 009 0178 y
   Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137
   Takahashi H, 2015, BMC CANCER, V15, DOI 10.1186/s12885 015 1783 y
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi N, 2019, CANCER RES, V79, P3088, DOI 10.1158/0008 5472.CAN 18 2693
   Tawbi HA, 2017, LANCET ONCOL, V18, P1493, DOI 10.1016/S1470 2045(17)30624 1
   Techavichit P, 2016, BMC CANCER, V16, DOI 10.1186/s12885 016 2909 6
   Thompson CB, 2014, EMBO J, V33, P1420, DOI 10.15252/embj.201488785
   Tong Q, 2000, SCIENCE, V290, P134, DOI 10.1126/science.290.5489.134
   Van Raay TJ, 2005, NEURON, V46, P23, DOI 10.1016/j.neuron.2005.02.023
   Vijayakumar S, 2011, CANCER CELL, V19, P601, DOI 10.1016/j.ccr.2011.03.010
   Wang H, 2016, CELL STEM CELL, V18, P495, DOI 10.1016/j.stem.2016.03.005
   Xia JG, 2015, NUCLEIC ACIDS RES, V43, pW251, DOI 10.1093/nar/gkv380
   Yamada T, 2017, CANCER SCI, V108, P818, DOI 10.1111/cas.13203
   Yamaguchi U, 2008, J CLIN ONCOL, V26, P4100, DOI 10.1200/JCO.2007.14.2331
   Yan GN, 2016, CANCER LETT, V370, P268, DOI 10.1016/j.canlet.2015.11.003
   Yi XJ, 2015, MOL MED REP, V12, P5042, DOI 10.3892/mmr.2015.4025
   Yu DH, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.9
   Zhang Y, 2016, TUMOR BIOL, V37, P1035, DOI 10.1007/s13277 015 3881 5
   Zhao S, 2015, ONCOGENE, V34, P5069, DOI 10.1038/onc.2014.429
NR 71
TC 16
Z9 20
U1 1
U2 8
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
EI 2379 3708
J9 JCI INSIGHT
JI JCI Insight
PD FEB 8
PY 2021
VL 6
IS 3
AR e137245
DI 10.1172/jci.insight.137245
PG 17
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA QF8ON
UT WOS:000617149800006
PM 33400690
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Shima, WN
   Ali, AM
   Subramani, T
   Alitheen, NBM
   Hamid, M
   Samsudin, AR
   Yeap, SK
AF Shima, Wan Nazatul
   Ali, Abdul Manaf
   Subramani, Tamilselvan
   Alitheen, Noorjahan Banu Mohamed
   Hamid, Muhajir
   Samsudin, Abdul Rani
   Yeap, Swee Keong
TI Rapid growth and osteogenic differentiation of mesenchymal stem cells
   isolated from human bone marrow
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE bone marrow; cell differentiation; mesenchymal stem cell; osteoblast
ID EXPRESSION; BLOOD
AB Mesenchymal stem cells (MSCs) are involved in bone formation in the embryo, bone repair and remodeling. The differentiation of these cells is a complex multistep pathway that involves discrete cellular transitions and is similar to that which occurs during hematopoiesis. MSCs have self renewal capacity without differentiation in long term culture. In the present study, MSCs were isolated from human bone marrow and characterized by the presence of cluster of differentiation 105 marker using the labeled streptavidin biotin method. The MSCs were cultured in Dulbecco's modified Eagle's medium supplemented with fetal bovine serum, ascorbic acid, beta glycerol phosphate and dexamethasone to differentiate into osteoblasts. Biological in vitro analysis showed the rapid proliferation of the MSCs. Further evaluation of specific osteogenic markers using von Kossa staining and the alkaline phosphate assay demonstrated that the MSCs were stimulated to differentiate into osteoblast lineage cells. This mesengenic potential indicated that the bone marrow derived cells were multipotent MSCs. The findings of this study show that bone marrow can be a legitimate source of MSCs for the production of osteoblasts for utilization in bone replacement therapy.
C1 [Shima, Wan Nazatul; Subramani, Tamilselvan; Alitheen, Noorjahan Banu Mohamed] Univ Putra Malaysia, Fac Biotechnol & Biomol Sci, Dept Cell & Mol Biol, Serdang 43400, Selangor, Malaysia.
   [Shima, Wan Nazatul; Samsudin, Abdul Rani] Univ Sains Malaysia Hlth Campus, Sch Dent Sci, Kubang Kerian 16150, Kelantan, Malaysia.
   [Ali, Abdul Manaf] Univ Zainal Abidin, Fac Agr & Biotechnol, Kuala Terengganu 20400, Terengganu, Malaysia.
   [Hamid, Muhajir] Univ Putra Malaysia, Fac Biotechnol & Biomol Sci, Dept Microbiol, Serdang 43400, Selangor, Malaysia.
   [Yeap, Swee Keong] Univ Putra Malaysia, Inst Biosci, Serdang 43400, Selangor, Malaysia.
C3 Universiti Putra Malaysia; Universiti Sains Malaysia; Universiti Sultan
   Zainal Abidin; Universiti Putra Malaysia; Universiti Putra Malaysia
RP Alitheen, NBM (通讯作者)，Univ Putra Malaysia, Fac Biotechnol & Biomol Sci, Dept Cell & Mol Biol, Serdang 43400, Selangor, Malaysia.
EM noorjahan@biotech.upm.edu.my
RI shahidan, wan nazatul shima/P 5608 2016; shahidan, wan/ABG 1621 2020;
   Alitheen, Noorjahan/AAL 3713 2020; Yeap, Swee Keong/H 9285 2013; Ali,
   Irfan/JVO 2044 2024; Yeap, Swee/H 9285 2013; Subramani,
   Tamilselvan/G 4304 2011
OI shahidan, wan nazatul shima/0000 0002 1702 2973; Hamid,
   Muhajir/0000 0002 2475 7628; Alitheen, Noorjahan
   Banu/0000 0003 1966 8580; Yeap, Swee Keong/0000 0002 4736 0674; 
CR Carinci F, 2005, ARCH ORAL BIOL, V50, P481, DOI 10.1016/j.archoralbio.2004.11.006
   FRIEDENSTEIN AJ, 1982, EXP HEMATOL, V10, P217
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   Hung SC, 2002, STEM CELLS, V20, P249, DOI 10.1634/stemcells.20 3 249
   Koç ON, 2000, J CLIN ONCOL, V18, P307, DOI 10.1200/JCO.2000.18.2.307
   Li Z, 1999, BONE, V25, P661, DOI 10.1016/S8756 3282(99)00227 6
   Minguell JJ, 2001, EXP BIOL MED, V226, P507, DOI 10.1177/153537020122600603
   Ohgushi Hajime, 2003, Novartis Found Symp, V249, P118
   Petite H, 2000, NAT BIOTECHNOL, V18, P959, DOI 10.1038/79449
   PRICE JS, 1994, EUR J CLIN NUTR, V48, pS131
   Sanchez Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389
   Shin H, 2005, BIOMATERIALS, V26, P3645, DOI 10.1016/j.biomaterials.2004.09.050
   Wexler SA, 2003, BRIT J HAEMATOL, V121, P368, DOI 10.1046/j.1365 2141.2003.04284.x
NR 13
TC 10
Z9 13
U1 0
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD JUN
PY 2015
VL 9
IS 6
BP 2202
EP 2206
DI 10.3892/etm.2015.2381
PG 5
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA CJ4ZI
UT WOS:000355496800026
PM 26136960
OA Green Published, Green Accepted, gold
DA 2025 08 17
ER

PT J
AU Gao, XQ
   Usas, A
   Proto, JD
   Lu, AP
   Cummins, JH
   Proctor, A
   Chen, CW
   Huard, J
AF Gao, Xueqin
   Usas, Arvydas
   Proto, Jonathan D.
   Lu, Aiping
   Cummins, James H.
   Proctor, Alexander
   Chen, Chien Wen
   Huard, Johnny
TI Role of donor and host cells in muscle derived stem cell mediated bone
   repair: differentiation vs. paracrine effects
SO FASEB JOURNAL
LA English
DT Article
DE bone morphogenetic protein 4; inflammation; angiogenesis; monocyte
   chemotactic protein 1; cyclooxygenase 2
ID VIVO GENE THERAPY; MONOCYTE CHEMOATTRACTANT PROTEIN 1; MESENCHYMAL
   STEM/STROMAL CELLS; SKELETAL MUSCLE; REGENERATIVE MECHANISMS;
   MORPHOGENETIC PROTEIN 2; STEM/PROGENITOR CELLS; ENGINEERED BONE;
   ANGIOGENESIS; RECRUITMENT
AB Murine muscle derived stem cells (MDSCs) have been shown capable of regenerating bone in a critical size calvarial defect model when transduced with BMP 2 or 4; however, the contribution of the donor cells and their interactions with the host cells during the bone healing process have not been fully elucidated. To address this question, C57/BL/6J mice were divided into MDSC/BMP4/GFP, MDSC/GFP, and scaffold groups. After transplanting MDSCs into the critical size calvarial defects created in normal mice, we found that mice transplanted with BMP4GFP transduced MDSCs healed the bone defect in 4 wk, while the control groups (MDSC GFP and scaffold) demonstrated no bone healing. The newly formed trabecular bone displayed similar biomechanical properties as the native bone, and the donor cells directly participated in endochondral bone formation via their differentiation into chondrocytes, osteoblasts, and osteocytes via the BMP4 pSMAD5 and COX 2 PGE2 signaling pathways. In contrast to the scaffold group, the MDSC groups attracted more inflammatory cells initially and incurred faster inflammation resolution, enhanced angiogenesis, and suppressed initial immune responses in the host mice. MDSCs were shown to attract macrophages via the secretion of monocyte chemotactic protein 1 and promote endothelial cell proliferation by secreting multiple growth factors. Our findings indicated that BMP4GFP transduced MDSCs not only regenerated bone by direct differentiation, but also positively influenced the host cells to coordinate and promote bone tissue repair through paracrine effects. Gao, X., Usas, A., Proto, J. D., Lu, A., Cummins, J. H., Proctor, A., Chen, C. W., Huard, J. Role of donor and host cells in muscle derived stem cell mediated bone repair: differentiation vs. paracrine effects.
C1 [Gao, Xueqin; Usas, Arvydas; Proto, Jonathan D.; Lu, Aiping; Cummins, James H.; Chen, Chien Wen; Huard, Johnny] Univ Pittsburgh, Dept Orthopaed Surg, Stem Cell Res Ctr, Pittsburgh, PA 15219 USA.
   [Proctor, Alexander] Act Life Sci, Santa Barbara, CA USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Huard, J (通讯作者)，Univ Pittsburgh, Dept Orthopaed Surg, Stem Cell Res Ctr, Bridgeside Point 2,450 Technol Dr, Pittsburgh, PA 15219 USA.
EM jhuard@pitt.edu
RI ; LU, Aiping/JDX 0577 2023; Usas, Arvydas/AGO 1702 2022
OI Chen, William CW/0000 0002 6891 3557; Gao, Xueqin/0000 0001 5833 1548; ,
   Jonathan Proto/0009 0005 9950 4720
FU U.S. National Institutes of Health [5RO1 DE13420 09]; Henry J. Mankin
   endowed chair at the University of Pittsburgh
FX The authors thank Jessica C. Tebbets, Ying Tang, and Minakshi Poddar for
   their assistance in producing the retro BMP4/GFP and retro GFP viruses
   utilized in this study and Mathieu Huard for his assistance in paraffin
   sectioning. The authors also thank Allison Logar (Children's Hospital of
   Pittsburgh, Pittsburgh, PA, USA) for the FACS sorting of GFP and
   BMP4GFP transduced MDSCs. The authors also thank Dr. Burhan Gharaibeh
   for assistance in formatting the references and Bria King and Adam
   Kozemchak for their editorial assistance. This project was supported, in
   part, by a U.S. National Institutes of Health grant (5RO1 DE13420 09)
   awarded to J. H. and the Henry J. Mankin endowed chair at the University
   of Pittsburgh. J. H. receives remuneration as a consultant and royalties
   from Cook MyoSite, Inc. (Pittsburgh, PA, USA). The other authors declare
   no conflicts of interest. The experiments performed for this study
   comply with the current laws of the United States of America.
CR Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood 2004 04 1559
   Akiyama H, 2005, P NATL ACAD SCI USA, V102, P14665, DOI 10.1073/pnas.0504750102
   Akiyama H., 2002, GENE DEV, V16, P2183
   Alhag M, 2011, ORAL MAXILLOFAC SURG, V15, P31, DOI 10.1007/s10006 010 0241 x
   Ando Y, 2014, BONE, V61, P82, DOI 10.1016/j.bone.2013.12.029
   Behr B, 2011, STEM CELLS, V29, P286, DOI 10.1002/stem.581
   Ben Mordechai T, 2013, J AM COLL CARDIOL, V62, P1890, DOI 10.1016/j.jacc.2013.07.057
   Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Duran JM, 2013, CIRC RES, V113, P539, DOI 10.1161/CIRCRESAHA.113.301202
   Gao XQ, 2013, CELL TRANSPLANT, V22, P2393, DOI 10.3727/096368912X658854
   Gehmert S, 2011, CLIN HEMORHEOL MICRO, V48, P5, DOI 10.3233/CH 2011 1397
   Gharaibeh B, 2008, NAT PROTOC, V3, P1501, DOI 10.1038/nprot.2008.142
   Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05 5211com
   Hsiao STF, 2012, STEM CELLS DEV, V21, P2189, DOI 10.1089/scd.2011.0674
   Kanczler JM, 2008, EUR CELLS MATER, V15, P100, DOI 10.22203/eCM.v015a08
   Lau KHW, 2013, BONE, V53, P369, DOI 10.1016/j.bone.2013.01.003
   Lee JY, 2002, HUM GENE THER, V13, P1201, DOI 10.1089/104303402320138989
   Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601
   Mastrogiacomo M, 2005, J CELL PHYSIOL, V204, P594, DOI 10.1002/jcp.20325
   Misener Stephen., 2000, Bioinformatics: Methods and Protocols
   Murnaghan M, 2006, J BONE JOINT SURG AM, V88A, P140, DOI 10.2106/JBJS.F.00454
   Musgrave DS, 2002, J BONE JOINT SURG BR, V84B, P120, DOI 10.1302/0301 620X.84B1.11708
   Németh K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905
   Peng HR, 2005, J BONE MINER RES, V20, P2017, DOI 10.1359/JBMR.050708
   Peng HR, 2002, J CLIN INVEST, V110, P751, DOI 10.1172/JCI200215153
   Posner LJ, 1997, BONE, V21, P321, DOI 10.1016/S8756 3282(97)00154 3
   Prockop DJ, 2013, STEM CELLS, V31, P2042, DOI 10.1002/stem.1400
   Prockop DJ, 2012, MOL THER, V20, P14, DOI 10.1038/mt.2011.211
   Qu D, 2011, J BIOMED MATER RES A, V96A, P543, DOI 10.1002/jbm.a.33009
   Roddy GW, 2011, STEM CELLS, V29, P1572, DOI 10.1002/stem.708
   Sanberg PR, 2010, J CELL MOL MED, V14, P553, DOI 10.1111/j.1582 4934.2009.00903.x
   Shen HC, 2004, BONE, V34, P982, DOI 10.1016/j.bone.2004.01.028
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Stich S, 2008, EUR J CELL BIOL, V87, P365, DOI 10.1016/j.ejcb.2008.03.009
   Tamasi JA, 2013, J BONE MINER RES, V28, P1975, DOI 10.1002/jbmr.1933
   Tasso R, 2012, BIOMATERIALS, V33, P2086, DOI 10.1016/j.biomaterials.2011.11.043
   Tasso R, 2010, BIOMATERIALS, V31, P2121, DOI 10.1016/j.biomaterials.2009.11.064
   Tasso R, 2009, TISSUE ENG PT A, V15, P2203, DOI 10.1089/ten.tea.2008.0269
   Tatebe M, 2005, CYTOTHERAPY, V7, P520, DOI 10.1080/14653240500361350
   Tortelli F, 2010, BIOMATERIALS, V31, P242, DOI 10.1016/j.biomaterials.2009.09.038
   Turner NJ, 2013, J TISSUE ENG REGEN M, V7, P139, DOI 10.1002/term.508
   Usas A, 2009, TISSUE ENG PT A, V15, P285, DOI 10.1089/ten.tea.2008.0130
   Wright VJ, 2002, MOL THER, V6, P169, DOI 10.1006/mthe.2002.0654
   Xie C, 2009, AM J PATHOL, V175, P772, DOI 10.2353/ajpath.2009.081099
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
   Zou DH, 2011, STEM CELLS, V29, P1380, DOI 10.1002/stem.693
NR 47
TC 53
Z9 58
U1 1
U2 16
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3998 USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD AUG
PY 2014
VL 28
IS 8
BP 3792
EP 3809
DI 10.1096/fj.13 247965
PG 18
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA AN0HM
UT WOS:000340265400044
PM 24843069
OA Green Published
DA 2025 08 17
ER

PT J
AU Oliveira, FA
   Matos, AA
   Santesso, MR
   Tokuhara, CK
   Leite, AL
   Bagnato, VS
   Machado, MAAM
   Peres Buzalaf, C
   Oliveira, RC
AF Oliveira, Flavia A.
   Matos, Adriana A.
   Santesso, Mariana R.
   Tokuhara, Cintia K.
   Leite, Aline L.
   Bagnato, Vanderley S.
   Machado, Maria A. A. M.
   Peres Buzalaf, Camila
   Oliveira, Rodrigo C.
TI Low intensity lasers differently induce primary human osteoblast
   proliferation and differentiation
SO JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B BIOLOGY
LA English
DT Article
DE LLLT; LLL; LED; Phototherapy; Human osteoblasts; ERK
ID MATRICELLULAR PROTEIN; GROWTH FACTOR; THERAPY; IRRADIATION; SPARC;
   CELLS; NM; PHOSPHORYLATION; EXPRESSION; PROMOTES
AB Among various compounds used in research and clinic for degenerative bone diseases, low level laser therapy (LLLT), comprising low level lasers (LLL) and light emitting diodes (LEDs), has been investigated regarding its effects on bone metabolism. They have specific wavelengths but in general act as a cellular biomodulator, and as a therapeutic agent, rebalancing and normalizing their activity. However, they are not standardized yet, since their parameters of use are relevant for the effects and mechanisms of action. Therefore, the aim of this study was to compare the influence of two spectrums of LLL and LED phototherapy, at the same energy densities (10 and 50 J/cm(2)), on human osteoblasts proliferation and differentiation. The involvement of ERK signaling on proliferation was also investigated by evaluating its activation during proliferation under different phototherapies by western blotting and CFSE based osteoblast proliferation was measured in a presence or absence of the ERIC specific inhibitor. Osteogenic differentiation was evaluated through in vitro mineralization and gene expression of type I collagen (COL1A1) and osteonectin (SPARC) by Real Time  PCR. Increases in viable cells and proliferation were obtained after irradiation, regardless of LLLT type. However, only red at 10 J/cm2 and infrared at both doses, but not LED, induced ERK1/2 activation. In the presence of ERK inhibitor, the LLL induced proliferation was prevented. In addition, while COL1A1 gene expression was upregulated by red laser, SPARC does so by infrared stimulation. However, LED, at both doses, increased both COL1A1 and SPARC expression. All LLLT increased mineralization, dependent on the dose and time. Thus, LLL and LED differently modulated the metabolism of human osteoblasts, increasing proliferation by mechanism dependent or not of ERK signaling activation and osteogenic differentiation markers. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Oliveira, Flavia A.; Matos, Adriana A.; Santesso, Mariana R.; Tokuhara, Cintia K.; Leite, Aline L.; Machado, Maria A. A. M.; Oliveira, Rodrigo C.] Univ Sao Paulo, Bauru Sch Dent, Dept Biol Sci, Bauru, SP, Brazil.
   [Bagnato, Vanderley S.] Univ Sao Paulo, Inst Fis Sao Carlos, Dept Fis & Ciencia Mat, Sao Carlos, SP, Brazil.
   [Peres Buzalaf, Camila] Univ Sagrado Coracao, Proreitoria Pesquisa & Posgrad, Bauru, SP, Brazil.
C3 Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade do
   Sagrado Coracao
RP Oliveira, RC (通讯作者)，Alameda Octavio Pinheiro Brisolla 9 75, BR 17012901 Bauru, SP, Brazil.
EM rodrigocardoso@usp.br
RI ; Arruda Matos, Adriana/F 4188 2018; Oliveira, Flavia Amadeu
   de/M 9680 2013; Amadeu de Oliveira, Flavia/M 9680 2013; Bagnato,
   Vanderlei/C 3133 2012; Matos, Adriana/F 4188 2018; Leite,
   Aline/J 9748 2012; Machado, Maria Aparecida de Andrade
   Moreira/D 8224 2012; Peres Buzalaf, Camila/C 5109 2012; Oliveira,
   Rodrigo/E 2551 2012; Tokuhara, Cintia/P 8385 2017; Machado, Maria
   Aparecida Andrade/D 8224 2012; Santesso, Mariana/AAD 6422 2020
OI Rodrigues Santesso, Mariana/0000 0001 9740 1780; Arruda Matos,
   Adriana/0000 0002 2823 7769; Bagnato, Vanderlei
   Salvador/0000 0003 4833 239X; Oliveira, Flavia Amadeu
   de/0000 0003 3063 6694; Machado, Maria Aparecida de Andrade
   Moreira/0000 0003 3778 7444; De Lima Leite, Aline/0000 0002 2112 1309;
   Oliveira, Rodrigo/0000 0003 3070 5960; Tokuhara,
   Cintia/0000 0002 1852 5986; 
FU Sao Paulo State Research Support Foundation (FAPESP) [2007/08367 0,
   2008/11261 1, 2008/11391 2]; Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [07/08367 0, 08/11391 2] Funding Source: FAPESP
FX Prof. Dr. Jose Mauro Granjeiro, who kindly donated the primary human
   osteoblasts for this research and Profa. Dra. Ana Paula Campanelli for
   acquiring cells in the flow cytometry experiments. This work was
   supported by Sao Paulo State Research Support Foundation (FAPESP)
   (grants #2007/08367 0; #2008/11261 1; #2008/11391 2).
CR Akgul T, 2014, LASER MED SCI, V29, P351, DOI 10.1007/s10103 013 1355 9
   Aleksic V, 2010, LASER MED SCI, V25, P559, DOI 10.1007/s10103 010 0761 5
   Amid R, 2014, J LASERS MED SCI, V5, P163
   [Anonymous], J PHOTOCHEM PHOTOB B
   Basso FG, 2013, LASER MED SCI, V28, P367, DOI 10.1007/s10103 012 1057 8
   Bloise N, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.12.128006
   Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939
   Brekken RA, 2000, MATRIX BIOL, V19, P569, DOI 10.1016/S0945 053X(00)00105 0
   Chung H, 2012, ANN BIOMED ENG, V40, P516, DOI 10.1007/s10439 011 0454 7
   da Rosa AS, 2012, PHOTOCHEM PHOTOBIOL, V88, P161, DOI 10.1111/j.1751 1097.2011.01032.x
   Fukuda TY, 2013, LASER MED SCI, V28, P1305, DOI 10.1007/s10103 012 1231 z
   Fukuhara E, 2006, CALCIFIED TISSUE INT, V79, P443, DOI 10.1007/s00223 006 0072 9
   Serafim KGG, 2012, LASER MED SCI, V27, P113, DOI 10.1007/s10103 011 0923 0
   Ge CX, 2012, J BONE MINER RES, V27, P538, DOI 10.1002/jbmr.561
   Ginani F, 2015, LASER MED SCI, V30, P2189, DOI 10.1007/s10103 015 1730 9
   Góralczyk K, 2015, LASER MED SCI, V30, P273, DOI 10.1007/s10103 014 1650 0
   Grassi FR, 2011, J BIOL REG HOMEOS AG, V25, P603
   Huang JH, 2011, LASER MED SCI, V26, P381, DOI 10.1007/s10103 010 0870 1
   Hunzelmann N, 1998, J INVEST DERMATOL, V110, P122, DOI 10.1046/j.1523 1747.1998.00094.x
   Jansen JHW, 2004, J CELL BIOCHEM, V93, P542, DOI 10.1002/jcb.20162
   Jawad MM, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.12.128001
   KAMIHAGI K, 1994, BIOCHEM BIOPH RES CO, V200, P423, DOI 10.1006/bbrc.1994.1466
   Kiyosaki T, 2010, PHOTOMED LASER SURG, V28, pS167, DOI 10.1089/pho.2009.2693
   Lin GQ, 2015, EXP THER MED, V9, P1807, DOI 10.3892/etm.2015.2353
   Lubart R, 2005, PHOTOMED LASER SURG, V23, P3, DOI 10.1089/pho.2005.23.3
   Martignago CCS, 2015, LASER MED SCI, V30, P203, DOI 10.1007/s10103 014 1644 y
   Pacheco PS, 2013, PHOTOMED LASER SURG, V31, P225, DOI 10.1089/pho.2012.3434
   Petri Alice Dias, 2010, Braz. Dent. J., V21, P491, DOI 10.1590/S0103 64402010000600003
   Pyo SJ, 2013, LASER MED SCI, V28, P543, DOI 10.1007/s10103 012 1109 0
   RAINES EW, 1992, P NATL ACAD SCI USA, V89, P1281, DOI 10.1073/pnas.89.4.1281
   Volpato LER, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3602850
   Rodríguez Carballo E, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00040
   Roskoski R, 2012, PHARMACOL RES, V66, P105, DOI 10.1016/j.phrs.2012.04.005
   Schwartz HO, 2011, LASER MED SCI, V26, P539, DOI 10.1007/s10103 011 0902 5
   Shefer G, 2001, J CELL PHYSIOL, V187, P73, DOI 10.1002/1097 4652(2001)9999:9999<::AID JCP1053>3.0.CO;2 9
   Stadler I, 2004, PHOTOMED LASER SURG, V22, P227, DOI 10.1089/1549541041438560
   Stein E, 2008, WIEN KLIN WOCHENSCHR, V120, P112, DOI 10.1007/s00508 008 0932 6
   TREMBLE PM, 1993, J CELL BIOL, V121, P1433, DOI 10.1083/jcb.121.6.1433
NR 38
TC 49
Z9 51
U1 0
U2 15
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1011 1344
EI 1873 2682
J9 J PHOTOCH PHOTOBIO B
JI J. Photochem. Photobiol. B Biol.
PD OCT
PY 2016
VL 163
BP 14
EP 21
DI 10.1016/j.jphotobiol.2016.08.006
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA DY1JT
UT WOS:000384852000002
PM 27521889
DA 2025 08 17
ER

PT J
AU Mamtani, M
   Kulkarni, H
AF Mamtani, M.
   Kulkarni, H.
TI Bone recovery after zoledronate therapy in thalassemia induced
   osteoporosis: a meta analysis and systematic review
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Osteoclasts; Thalassemia; Zoledronate
ID MINERAL DENSITY; ACID; BISPHOSPHONATES; IMPROVEMENT; METABOLISM; MARKERS
AB Zoledronate is a promising bisphosphonate that improves the bone mineral density by 0.69 standard deviations in thalassemia induced osteoporosis, but the entire range of its actions and side effects is currently not fully understood.
   Zoledronate is a promising bisphosphonate for the treatment of thalassemia induced osteoporosis; however, a quantitative summary of its beneficial effect and its effects on the markers of bone turnover are not established.
   We conducted a meta analysis of the published randomized controlled trials using standardized mean difference and a random effects model for improvement in bone mineral density (BMD). We also conducted a systematic review for the influence of zoledronate on markers of bone turnover and bone pain.
   We found that zoledronate improves the baseline BMD by 0.69 (95% confidence interval 0.47 0.90) standard deviations an effect that was more pronounced when BMD was measured at the lumbar spine. However, the mechanistic interpretations of the effects on the markers of bone turnover are not completely clear.
   Sufficient evidence exists to demonstrate that 4 mg zoledronate given every 3 months markedly improves the BMD; however, more qualitative and quantitative evidence is required to understand the mechanisms of its action and the potential side effects.
C1 [Mamtani, M.; Kulkarni, H.] Lata Med Res Fdn, Nagpur, Maharashtra, India.
RP Kulkarni, H (通讯作者)，12023 Waterway Rdg, San Antonio, TX 78249 USA.
EM hemant_kulkarnius@yahoo.com
RI Kulkarni, Hemant/AEM 5750 2022
CR Angelopoulos NG, 2007, PEDIATR HEMAT ONCOL, V24, P481, DOI 10.1080/08880010701533611
   Angelopoulos NG, 2007, J BONE MINER METAB, V25, P60, DOI 10.1007/s00774 006 0728 6
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Borgna Pignatti C, 2005, ANN NY ACAD SCI, V1054, P40, DOI 10.1196/annals.1345.006
   Brown JE, 2007, CLIN CANCER RES, V13, P5406, DOI 10.1158/1078 0432.CCR 07 0247
   DERCHI G, 1992, EUR HEART J, V13, P1368, DOI 10.1093/oxfordjournals.eurheartj.a060068
   Fleisch HA, 1997, ANN MED, V29, P55, DOI 10.3109/07853899708998743
   Gaudio A, 2008, J ENDOCRINOL INVEST, V31, P181, DOI 10.1007/BF03345587
   Gilfillan CP, 2006, CALCIFIED TISSUE INT, V79, P138, DOI 10.1007/s00223 006 0314 x
   Gurevitch O, 2006, MED HYPOTHESES, V67, P729, DOI 10.1016/j.mehy.2006.03.051
   Jensen CE, 1998, J PEDIATR ENDOCR MET, V11, P975
   Jensen CE, 1998, BRIT J HAEMATOL, V103, P911
   JOHANSON NA, 1990, ORTHOP CLIN N AM, V21, P191
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Mahachoklertwattana Pat, 2006, Haematologica, V91, p1155A
   Mamtani M, 2008, BRIT J HAEMATOL, V141, P882, DOI 10.1111/j.1365 2141.2008.07122.x
   Michelson J, 1988, J Orthop Trauma, V2, P29, DOI 10.1097/00005131 198802000 00007
   Morabito N, 2002, OSTEOPOROSIS INT, V13, P644, DOI 10.1007/s001980200087
   Otrock ZK, 2008, ANN HEMATOL, V87, P947, DOI 10.1007/s00277 008 0497 5
   Otrock ZK, 2006, ANN HEMATOL, V85, P605, DOI 10.1007/s00277 006 0136 y
   Patanè S, 2010, INT J CARDIOL, V138, pE24, DOI 10.1016/j.ijcard.2008.06.039
   Pennisi P, 2003, J BONE MINER METAB, V21, P402, DOI 10.1007/s00774 003 0435 5
   Perifanis V, 2004, BRIT J HAEMATOL, V125, P91, DOI 10.1111/j.1365 2141.2004.04871.x
   Perifanis V, 2007, ANN HEMATOL, V86, P23, DOI 10.1007/s00277 006 0180 7
   POOTRAKUL P, 1981, NEW ENGL J MED, V304, P1470, DOI 10.1056/NEJM198106113042406
   Reginster JY, 2007, DRUG AGING, V24, P351, DOI 10.2165/00002512 200724050 00001
   Shamshirsaz Alireza Abdollah, 2003, BMC Endocr Disord, V3, P4
   Toumba Meropi, 2007, Pediatr Endocrinol Rev, V5, P642
   *USFDA, 2008, EARL COMM ONG SAF RE
   *USFDA, 2008, INF HEALTHC PROF
   Voskaridou E, 2004, BRIT J HAEMATOL, V127, P127, DOI 10.1111/j.1365 2141.2004.05143.x
   Voskaridou E, 2003, BRIT J HAEMATOL, V123, P730, DOI 10.1046/j.1365 2141.2003.04657.x
   Voskaridou E, 2008, HAEMATOL HEMATOL J, V93, P1588, DOI 10.3324/haematol.12849
   Voskaridou E, 2008, ACTA HAEMATOL BASEL, V119, P40, DOI 10.1159/000114869
   Voskaridou E, 2006, HAEMATOLOGICA, V91, P1193
   Voskaridou E, 2006, HAEMATOLOGICA, V91, P813
   Wonke B, 1998, J PEDIATR ENDOCR MET, V11, P795
NR 37
TC 19
Z9 19
U1 0
U2 4
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD JAN
PY 2010
VL 21
IS 1
BP 183
EP 187
DI 10.1007/s00198 009 0875 4
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 527LB
UT WOS:000272367500020
PM 19242634
DA 2025 08 17
ER

PT J
AU Hamamura, K
   Zhao, LM
   Jiang, C
   Tanjung, N
   Swarnkar, G
   Yokota, H
AF Hamamura, Kazunori
   Zhao, Liming
   Jiang, Chang
   Tanjung, Nancy
   Swarnkar, Gaurav
   Yokota, Hiroki
TI Hydroxyapatite Modulates mRNA Expression Profiles in Cultured Osteocytes
SO CELLULAR AND MOLECULAR BIOENGINEERING
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the Biomedical Engineering Society (BMES)
CY OCT 12 15, 2011
CL Hartford, CT
SP Biomed Engn Soc
DE Osteocytes; Hydroxyapatite; Microarray; Signaling pathway; FGF23; Wnt;
   PI3K
ID MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; PHOSPHATE HOMEOSTASIS;
   IN VIVO; BONE; PROTEINS; FGF23; SCLEROSTIN; OSTEOBLAST; 3 KINASE
AB Osteocytes in vivo present a unique pattern of gene expression necessary for bone remodeling and mineral metabolism. Genes expressed in osteocytes such as Sost and fibroblast growth factor 23 (FGF23) are essential for load driven bone formation and regulation of phosphate in the serum, respectively. However, their expression levels in standard cell cultures are significantly low and the mechanism of their transcriptional regulation is hardly examined. Since osteocytes reside in hydroxyapatite (HA) surrounded lacunae, in this in vitro study we addressed a question whether they would exhibit mRNA expression profiles close to in vivo in the presence of HA. Our hypothesis was that HA would provide a three dimensional (3D) growth environment important for the regulation of many of the osteocyte characteristic genes. To test this hypothesis, we grew MLO A5 cells in a 3D collagen matrix with and without HA deposition and conducted a genome wide expression analysis. The results revealed that deposition of HA markedly elevated the mRNA levels of Sost, dentin matrix protein 1 (DMP1), and FGF23. The microarray derived data indicated potential involvements of Wnt and PI3K signaling. Protein and mRNA expression analysis using pharmacological inhibitors such as LY294002 and pertussis toxin showed that HA driven gene regulation was in part mediated by Akt in a PI3K pathway and G protein linked receptors. In summary, we demonstrated herein that HA provided a growth environment that enabled osteocytes to stimulate their characteristic genes such as Sost, DMP1, and FGF23.
C1 [Zhao, Liming; Tanjung, Nancy; Swarnkar, Gaurav; Yokota, Hiroki] Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA.
   [Hamamura, Kazunori] Univ So Calif, Sch Dent, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA.
   [Jiang, Chang] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15219 USA.
   [Yokota, Hiroki] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
C3 Purdue University System; Purdue University; Purdue University in
   Indianapolis; University of Southern California; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Indiana University System; Indiana University Bloomington
RP Yokota, H (通讯作者)，Indiana Univ Purdue Univ, Dept Biomed Engn, SL220C,723 W Michigan St, Indianapolis, IN 46202 USA.
EM hyokota@iupui.edu
RI SWARNKAR, GAURAV/AAE 3223 2021
OI Jiang, Chang/0000 0001 6417 2096; Hamamura, Kazunori/0000 0002 8143 338X
CR AARDEN EM, 1994, J CELL BIOCHEM, V55, P287, DOI 10.1002/jcb.240550304
   Bonewald LF, 2007, ANN NY ACAD SCI, V1116, P281, DOI 10.1196/annals.1402.018
   Boukhechba F, 2009, J BONE MINER RES, V24, P1927, DOI [10.1359/JBMR.090517, 10.1359/jbmr.090517]
   Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655
   Feng JQ, 2006, NAT GENET, V38, P1310, DOI 10.1038/ng1905
   Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   Kato Y, 2001, J BONE MINER RES, V16, P1622, DOI 10.1359/jbmr.2001.16.9.1622
   Kost CK, 1999, CLIN EXP PHARMACOL P, V26, P449
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Ling YF, 2005, J BONE MINER RES, V20, P2169, DOI 10.1359/JBMR.050815
   Liu SG, 2007, CURR OPIN NEPHROL HY, V16, P329, DOI 10.1097/MNH.0b013e3281ca6ffd
   Martin A, 2011, FASEB J, V25, P2551, DOI 10.1096/fj.10 177816
   Nampei A, 2004, J BONE MINER METAB, V22, P176, DOI 10.1007/s00774 003 0468 9
   Noble BS, 2000, MOL CELL ENDOCRINOL, V159, P7, DOI 10.1016/S0303 7207(99)00174 4
   Papanicolaou SE, 2009, BIORHEOLOGY, V46, P389, DOI 10.3233/BIR 2009 0550
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Raheja LF, 2008, BIOCHEM BIOPH RES CO, V366, P1061, DOI 10.1016/j.bbrc.2007.12.076
   Robinson JA, 2006, J BIOL CHEM, V281, P31720, DOI 10.1074/jbc.M602308200
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Sawakami K, 2006, J BIOL CHEM, V281, P23698, DOI 10.1074/jbc.M601000200
   Schmidmaier G, 2002, BONE, V31, P165, DOI 10.1016/S8756 3282(02)00798 6
   Schneider P, 2010, BONE, V47, P848, DOI 10.1016/j.bone.2010.07.026
   Shimada T, 2004, J BONE MINER RES, V19, P429, DOI 10.1359/JBMR.0301264
   Tanaka SM, 2005, CALCIFIED TISSUE INT, V76, P261, DOI 10.1007/s00223 004 0238 2
   Ubaidus S, 2009, J ELECTRON MICROSC, V58, P381, DOI 10.1093/jmicro/dfp032
   VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241
   Warden SJ, 2005, ENDOCRINOLOGY, V146, P685, DOI 10.1210/en.2004 1259
   White KE, 2006, ENDOCR REV, V27, P221, DOI 10.1210/er.2005 0019
   Xia XC, 2010, MOL CELL BIOL, V30, P206, DOI 10.1128/MCB.01844 08
   Yu XJ, 2005, CYTOKINE GROWTH F R, V16, P221, DOI 10.1016/j.cytogfr.2005.01.002
   Zhang P, 2009, BONE, V44, P989, DOI 10.1016/j.bone.2009.01.367
NR 33
TC 3
Z9 4
U1 0
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1865 5025
EI 1865 5033
J9 CELL MOL BIOENG
JI Cell. Mol. Bioeng.
PD JUN
PY 2012
VL 5
IS 2
BP 217
EP 226
DI 10.1007/s12195 012 0228 9
PG 10
WC Cell & Tissue Engineering; Biophysics; Cell Biology; Engineering,
   Biomedical
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Cell Biology; Biophysics; Engineering
GA 940EM
UT WOS:000303872800010
DA 2025 08 17
ER

PT J
AU Da Silva, D
   Crous, A
   Abrahamse, H
AF Da Silva, Daniella
   Crous, Anine
   Abrahamse, Heidi
TI Photobiomodulation Dose Response on Adipose Derived Stem Cell
   Osteogenesis in 3D Cultures
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE adipose derived mesenchymal stem cells; differentiation inducers;
   three dimensional cell culture; photobiomodulation; osteoblasts;
   osteoporosis regenerative therapy
AB Osteoporosis and other degenerative bone diseases pose significant challenges to global healthcare systems due to their prevalence and impact on quality of life. Current treatments often alleviate symptoms without fully restoring damaged bone tissue, highlighting the need for innovative approaches like stem cell therapy. Adipose derived mesenchymal stem cells (ADMSCs) are particularly promising due to their accessibility, abundant supply, and strong differentiation potential. However, ADMSCs tend to favor adipogenic pathways, necessitating the use of differentiation inducers (DIs), three dimensional (3D) hydrogel environments, and photobiomodulation (PBM) to achieve targeted osteogenic differentiation. This study investigated the combined effects of osteogenic DIs, a fast dextran hydrogel matrix, and PBM at specific wavelengths and fluences on the proliferation and differentiation of immortalized ADMSCs into osteoblasts. Near infrared (NIR) and green (G) light, as well as their combination, were used with fluences of 3 J/cm2, 5 J/cm2, and 7 J/cm2. The results showed statistically significant increases in alkaline phosphatase levels, a marker of osteogenic differentiation, with G light at 7 J/cm2 demonstrating the most substantial impact on ADMSC differentiation. Calcium deposits, visualized by Alizarin red S staining, appeared as early as 24 h post treatment in PBM groups, suggesting accelerated osteogenic differentiation. ATP luminescence assays indicated increased proliferation in all experimental groups, particularly with NIR and NIR G light at 3 J/cm2 and 5 J/cm2. MTT viability and LDH membrane permeability assays confirmed enhanced cell viability and stable cell health, respectively. In conclusion, PBM significantly influences the differentiation and proliferation of hydrogel embedded immortalized ADMSCs into osteoblast like cells, with G light at 7 J/cm2 being particularly effective. These findings support the combined use of 3D hydrogel matrices and PBM as a promising approach in regenerative medicine, potentially leading to innovative treatments for degenerative bone diseases.
C1 [Da Silva, Daniella; Crous, Anine; Abrahamse, Heidi] Univ Johannesburg, Fac Hlth Sci, Laser Res Ctr, POB 17011, ZA 2028 Johannesburg, South Africa.
C3 University of Johannesburg
RP Abrahamse, H (通讯作者)，Univ Johannesburg, Fac Hlth Sci, Laser Res Ctr, POB 17011, ZA 2028 Johannesburg, South Africa.
EM 216040611@student.uj.ac.za; acrous@uj.ac.za; habrahamse@uj.ac.za
RI Crous, Anine/AAM 8015 2020; Abrahamse, Heidi/U 7763 2019; Da Silva,
   Daniella/AAL 5075 2020; Crous, Anine/AAL 6476 2020
OI Crous, Anine/0000 0002 7581 7731; Abrahamse, Heidi/0000 0001 5002 827X;
   Da Silva, Daniella/0000 0002 1588 2697; 
FU National Research Foundation of South Africa Thuthuka Instrument;
   Department of Science and Innovation (DSI)   African Laser Centre (ALC)
   [HLHA23X, ALC R007]; University Research Council [2022URC00513];
   Department of Science and Innovation South African Research Chairs
   Initiative [DSI NRF/SARChI, 146290]; University of Johannesburg Faculty
   of Health Sciences;  [TTK2205035996]
FX This work was supported by the National Research Foundation of South
   Africa Thuthuka Instrument (grant number TTK2205035996); the Department
   of Science and Innovation (DSI), which was funded by the African Laser
   Centre (ALC) (grant number HLHA23X, task ALC R007); the University
   Research Council (grant number 2022URC00513); the Department of Science
   and Innovation South African Research Chairs Initiative (DSI NRF/SARChI)
   (grant number 146290); and the APC was funded by the University of
   Johannesburg Faculty of Health Sciences.
CR Adolpho LF, 2023, J FUNCT BIOMATER, V14, DOI 10.3390/jfb14060306
   Aibar Almazán A, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23169465
   [Anonymous], 2007, EN 60825 1
   Barnsley J, 2021, AGING CLIN EXP RES, V33, P759, DOI 10.1007/s40520 021 01817 y
   Biniazan F, 2024, INT J MOL SCI, V25, DOI 10.3390/ijms25042356
   Çevik ZBY, 2023, J PHOTOCH PHOTOBIO B, V238, DOI 10.1016/j.jphotobiol.2022.112615
   Chang So Young, 2020, MEDICAL LASERS, V9, P134, DOI 10.25289/ML.2020.9.2.134
   Da Silva D, 2024, CURR ISSUES MOL BIOL, V46, P6346, DOI 10.3390/cimb46070379
   Da Silva D, 2025, NEURAL REGEN RES, V20, P598, DOI 10.4103/NRR.NRR D 23 01219
   Da Silva D, 2023, REGEN THER, V24, P602, DOI 10.1016/j.reth.2023.11.003
   Da Silva D, 2021, STEM CELLS INT, V2021, DOI 10.1155/2021/8843179
   Deana AM, 2018, LASER MED SCI, V33, P1147, DOI 10.1007/s10103 018 2486 9
   Diniz IMA, 2018, J CELL PHYSIOL, V233, P4907, DOI 10.1002/jcp.26309
   Dompe C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061724
   Dungel P, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24065895
   Felician MCP., 2023, J. Photochem. Photobiol, V17, P100197, DOI DOI 10.1016/J.JPAP.2023.100197
   Ghasemi M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222312827
   Hoang DM, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 022 01134 4
   Hunsberger J, 2020, STEM CELL TRANSL MED, V9, P728, DOI 10.1002/sctm.19 0389
   Jiang YX, 2020, SMALL METHODS, V4, DOI 10.1002/smtd.201900879
   Karnas E, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1120175
   Klein Robert, 2020, Veterinary Medicine International, V2020, P5346483, DOI 10.1155/2020/5346483
   LeBoff MS, 2022, OSTEOPOROSIS INT, V33, P2049, DOI 10.1007/s00198 021 05900 y
   Li HL, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22105404
   Maji S, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23052662
   de Andrade ALM, 2019, LASER MED SCI, V34, P677, DOI 10.1007/s10103 018 2642 2
   Mazini L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102523
   Norahan MH, 2023, BIOACT MATER, V24, P197, DOI 10.1016/j.bioactmat.2022.11.019
   Oliveira NK, 2019, DENT MATER, V35, P1740, DOI 10.1016/j.dental.2019.08.109
   Peng JF, 2022, INT J ORAL SCI, V14, DOI 10.1038/s41368 022 00207 y
   Qin Y, 2023, ADV SCI, V10, DOI 10.1002/advs.202207334
   Roets B, 2024, JOVE J VIS EXP, DOI 10.3791/66616
   Son S, 2015, SCI REP UK, V5, DOI 10.1038/srep17401
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Tsai G. Y., 2024, J. Photochem. Photobiol., V20
   Urzì O, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms241512046
   Wang YG, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 07525 w
   Wang YG, 2016, SCI REP UK, V6, DOI 10.1038/srep33719
   Yoo Shin Hyuk, 2020, MEDICAL LASERS, V9, P119, DOI 10.25289/ML.2020.9.2.119
   Zaccara IM, 2018, J BIOMED OPT, V23, DOI 10.1117/1.JBO.23.9.095001
   Zakrzewski W, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1165 5
   Zhang JX, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/8810813
   Zhu JJ, 2019, NAT REV MOL CELL BIO, V20, P436, DOI 10.1038/s41580 019 0123 5
NR 43
TC 1
Z9 1
U1 2
U2 7
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD SEP
PY 2024
VL 25
IS 17
AR 9176
DI 10.3390/ijms25179176
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA F6Y5I
UT WOS:001311252800001
PM 39273125
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Uddin, SMZ
   Hadjiargyrou, M
   Cheng, JQ
   Zhang, S
   Hu, MY
   Qin, YX
AF Uddin, Sardar M. Z.
   Hadjiargyrou, Michael
   Cheng, Jiqi
   Zhang, Shu
   Hu, Minyi
   Qin, Yi Xian
TI REVERSAL OF THE DETRIMENTAL EFFECTS OF SIMULATED MICROGRAVITY ON HUMAN
   OSTEOBLASTS BY MODIFIED LOW INTENSITY PULSED ULTRASOUND
SO ULTRASOUND IN MEDICINE AND BIOLOGY
LA English
DT Article
DE Simulated microgravity; Mechano transduction; Countermeasure; Bone loss;
   LIPUS; Acoustic streaming; Osteoporosis
ID OSTEOGENIC DIFFERENTIATION; EXTRACELLULAR MATRIX; MECHANICAL FORCE; AKT
   PATHWAY; I COLLAGEN; BONE CELLS; EXPRESSION; ACTIVATION;
   MECHANOTRANSDUCTION; ADHESION
AB Microgravity (MG) is known to induce bone loss in astronauts during long duration space mission because of a lack of sufficient mechanical stimulation under MG. It has been demonstrated that mechanical signals are essential for maintaining cell viability and motility, and they possibly serve as a countermeasure to the catabolic effects of MG. The objective of this study was to examine the effects of high frequency acoustic wave signals on osteoblasts in a simulated microgravity (SMG) environment (created using 1 D clinostat bioreactor) using a modified low intensity pulsed ultrasound (mLIPUS). Specifically, we evaluated the hypothesis that osteoblasts (human fetal osteoblastic cell line) exposure to mLIPUS for 20 min/d at 30 mW/cm(2) will significantly reduce the detrimental effects of SMG. Effects of SMG with mLIPUS were analyzed using the MTS proliferation assay for proliferation, phalloidin for F actin staining, Sirius red stain for collagen, and Alizarin red for mineralization. Our data showed that osteoblast exposure to SMG results in significant decreases in proliferation (similar to  38% and similar to  44% on days 4 and 6, respectively; p < 0.01), collagen content (similar to  22%; p < 0.05) and mineralization (similar to  37%; p < 0.05) and actin stress fibers. In contrast, mLIPUS stimulation in SMG condition significantly increases the rate of proliferation (similar to 24% by day 6; p < 0.05), collagen content (similar to 52%; p < 0.05) and matrix mineralization (similar to 25%; p < 0.001) along with restoring formation of actin stress fibers in the SMG exposed osteoblasts. These data suggest that the acoustic wave can potentially be used as a countermeasure for disuse osteopenia. (E mail: yi xian.qin@stonybrook.edu) (C) 2013 World Federation for Ultrasound in Medicine & Biology.
C1 [Uddin, Sardar M. Z.; Hadjiargyrou, Michael; Cheng, Jiqi; Zhang, Shu; Hu, Minyi; Qin, Yi Xian] SUNY Stony Brook, Dept Biomed Engn, Orthopaed Bioengn Res Lab, Stony Brook, NY 11794 USA.
C3 State University of New York (SUNY) System; Stony Brook University
RP Qin, YX (通讯作者)，SUNY Stony Brook, Dept Biomed Engn, 215 Bioengn Bldg, Stony Brook, NY 11794 USA.
EM yi xian.qin@stonybrook.edu
RI hu, minyi/HZL 5959 2023; Hadjiargyrou, Michael/H 7191 2018; Uddin,
   Sardar/AAO 9222 2020
OI Hadjiargyrou, Michael/0000 0001 8927 2333; Zhang,
   Shu/0000 0002 4380 1268
FU National Space Biomedical Research Institute through National
   Aeronautics and Space Administration [NCC 9 58 (SMST01603)]; National
   Institutes of Health [AR49286, AR60621, AR52379]; New York State
   Foundation for Science, Technology and Innovation (NYSTAR)
FX This work was supported by the National Space Biomedical Research
   Institute through National Aeronautics and Space Administration
   Cooperative Agreement NCC 9 58 (SMST01603, to YXQ), National Institutes
   of Health (AR49286, AR60621 and AR52379, to YXQ.), and New York State
   Foundation for Science, Technology and Innovation (NYSTAR). The authors
   thank Yunkai Huang and other members in the Orthopaedic Bioengineering
   Research Laboratory at Stony Brook University for their kind assistance
   and technical support for the study.
CR Alvarenga ÉC, 2010, BONE, V46, P355, DOI 10.1016/j.bone.2009.09.017
   BINDERMAN I, 1988, CALCIFIED TISSUE INT, V42, P261, DOI 10.1007/BF02553753
   BINDERMAN I, 1984, CALCIFIED TISSUE INT, V36, pS82, DOI 10.1007/BF02406139
   Boyd JL, 2002, J CLIN DENSITOM, V5, P375, DOI 10.1385/JCD:5:4:375
   de Gusmao CVB, 2010, CLIN ORTHOP RELAT R, V468, P1149, DOI 10.1007/s11999 009 1146 6
   Carvalho DCL, 2004, ARTIF ORGANS, V28, P114, DOI 10.1111/j.1525 1594.2004.07091.x
   CHAPMAN IV, 1980, ULTRASOUND MED BIOL, V6, P47, DOI 10.1016/0301 5629(80)90063 0
   Chen SH, 2007, P ANN INT IEEE EMBS, P5834
   Cheung WH, 2012, J ORTHOP RES, V30, P129, DOI 10.1002/jor.21487
   Cheung WH, 2011, ULTRASOUND MED BIOL, V37, P231, DOI 10.1016/j.ultrasmedbio.2010.11.016
   Ferreri SL, 2011, BONE, V48, P1095, DOI 10.1016/j.bone.2011.01.002
   Gadaleta SJ, 1996, CONNECT TISSUE RES, V34, P203, DOI 10.3109/03008209609000699
   Geiger B, 2002, CELL, V110, P139, DOI 10.1016/S0092 8674(02)00831 0
   Hoson T, 1997, PLANTA, V203, pS187, DOI 10.1007/PL00008108
   Hou CH, 2009, J CELL PHYSIOL, V220, P196, DOI 10.1002/jcp.21751
   Huang CY, 2010, FASEB J, V24, P3625, DOI 10.1096/fj.10 157370
   Hughes Fulford M, 2003, ADV SPACE RES SERIES, V32, P1585, DOI 10.1016/S0273 1177(03)90399 1
   Hughes Fulford M, 1998, Gravit Space Biol Bull, V11, P51
   Hughes Fulford M, 2006, J CELL BIOCHEM, V99, P435, DOI 10.1002/jcb.20883
   Hughes Fulford Millie, 2002, Adv Space Biol Med, V8, P129
   HughesFulford M, 1996, EXP CELL RES, V224, P103, DOI 10.1006/excr.1996.0116
   Huijser R., 2000, Fokker Space, V1
   Ingber DE, 2006, FASEB J, V20, P811, DOI 10.1096/fj.05 5424rev
   Kaneko T, 2002, PANCREATOLOGY, V2, P61, DOI 10.1159/000049450
   Kook SH, 2009, J CELL BIOCHEM, V106, P1060, DOI 10.1002/jcb.22085
   Landis WJ, 1996, J STRUCT BIOL, V117, P24, DOI 10.1006/jsbi.1996.0066
   Landis WJ, 1996, MICROSC RES TECHNIQ, V33, P192
   Li JK, 2003, BIOMATERIALS, V24, P2379, DOI 10.1016/S0142 9612(03)00033 4
   Li J, 2008, MOL CELL BIOCHEM, V309, P41, DOI 10.1007/s11010 007 9641 0
   LYNCH MP, 1995, EXP CELL RES, V216, P35, DOI 10.1006/excr.1995.1005
   Marie PJ, 2000, CALCIFIED TISSUE INT, V67, P2, DOI 10.1007/s00223001088
   Nabavi N, 2011, BONE, V49, P965, DOI 10.1016/j.bone.2011.07.036
   Naruse K, 2003, J BONE MINER RES, V18, P360, DOI 10.1359/jbmr.2003.18.2.360
   Nolte PA, 2001, J ORTHOP RES, V19, P301, DOI 10.1016/S0736 0266(00)00027 9
   Papachroni KK, 2009, TRENDS MOL MED, V15, P208, DOI 10.1016/j.molmed.2009.03.001
   Pavalko FM, 2003, J CELL BIOCHEM, V88, P104, DOI 10.1002/jcb.10284
   Prè D, 2009, TISSUE ENG PART C ME, V15, P669, DOI [10.1089/ten.tec.2008.0599, 10.1089/ten.TEC.2008.0599]
   Qin Y. X., 2010, Journal of Cosmology, V12, P3778
   Raucci A, 2008, J CELL PHYSIOL, V215, P442, DOI 10.1002/jcp.21323
   Rubin J, 1997, J CELL PHYSIOL, V170, P81, DOI 10.1002/(SICI)1097 4652(199701)170:1<81::AID JCP9>3.0.CO;2 H
   Schwarz R P, 1992, J Tissue Cult Methods, V14, P51, DOI 10.1007/BF01404744
   Shapiro J. R., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P322
   Sheyn D, 2010, TISSUE ENG PT A, V16, P3403, DOI 10.1089/ten.tea.2009.0834
   SILVER IL, 1976, J THEOR BIOL, V61, P353
   Suzuki A, 2009, ACTA BIOCH BIOPH SIN, V41, P108, DOI 10.1093/abbs/gmn012
   Takeuchi R, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2451
   Tang CH, 2007, J BIOL CHEM, V282, P25406, DOI 10.1074/jbc.M701001200
   Tang CH, 2006, MOL PHARMACOL, V69, P2047, DOI 10.1124/mol.105.022160
   Uddin SMZ, 2011, CELL MOL BIOENG, V4, P81, DOI 10.1007/s12195 010 0153 8
   VANLOON JJWA, 1995, J BONE MINER RES, V10, P550
   Vico L, 2001, CALCIFIED TISSUE INT, V68, P1, DOI 10.1007/BF02684996
   Yang KH, 1996, J ORTHOP RES, V14, P802, DOI 10.1002/jor.1100140518
   Yang RS, 2005, BONE, V36, P276, DOI 10.1016/j.bone.2004.10.009
NR 53
TC 14
Z9 15
U1 0
U2 28
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0301 5629
EI 1879 291X
J9 ULTRASOUND MED BIOL
JI Ultrasound Med. Biol.
PD MAY
PY 2013
VL 39
IS 5
BP 804
EP 812
DI 10.1016/j.ultrasmedbio.2012.11.016
PG 9
WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
GA 123OZ
UT WOS:000317401000008
PM 23453382
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Ottewell, PD
   Wang, N
   Brown, HK
   Fowles, CA
   Croucher, PI
   Eaton, CL
   Holen, I
AF Ottewell, Penelope D.
   Wang, Ning
   Brown, Hannah K.
   Fowles, C. Anne
   Croucher, Peter I.
   Eaton, Colby L.
   Holen, Ingunn
TI OPG Fc inhibits ovariectomy induced growth of disseminated breast cancer
   cells in bone
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE breast cancer; OPG; metastasis; bone
ID SKELETAL TUMOR BURDEN; ZOLEDRONIC ACID; MOUSE MODEL; RANK LIGAND;
   IN VIVO; MULTIPLE MYELOMA; ADJUVANT THERAPY; PROSTATE CANCER;
   METASTASIS; OSTEOPROTEGERIN
AB Dormant disseminated tumour cells can be detected in the bone marrow of breast cancer patients several years after resection of the primary tumour. The majority of these patients will remain asymptomatic, however, similar to 15% will go on to develop overt bone metastases and this condition is currently incurable. The reason why these dormant cells are stimulated to proliferate and form bone tumours in some patients and not others remains to be elucidated. We have recently shown that in an in vivo model, increasing bone turnover by ovariectomy stimulated proliferation of disseminated tumour cells, resulting in formation of bone metastasis. We now show for the first time that osteoclast mediated mechanisms induce growth of tumours from dormant MDA MB 231 cells disseminated in the bone. We also show that disruption of RANK RANKL interactions following administration of OPG Fc inhibits growth of these dormant tumour cells in vivo. Our data support early intervention with anti resorptive therapy in a low oestrogen environment to prevent development of bone metastases.
C1 [Ottewell, Penelope D.; Brown, Hannah K.; Holen, Ingunn] Univ Sheffield, Dept Oncol, Acad Unit Clin Oncol, Sheffield S10 2RX, S Yorkshire, England.
   [Wang, Ning; Fowles, C. Anne; Eaton, Colby L.] Univ Sheffield, Dept Human Metab, Acad Unit Bone Biol, Sheffield S10 2RX, S Yorkshire, England.
   [Croucher, Peter I.] Garvan Inst Med Res, Musculoskeletal Med Div, Sydney, NSW, Australia.
C3 University of Sheffield; University of Sheffield; Garvan Institute of
   Medical Research
RP Ottewell, PD (通讯作者)，Univ Sheffield, Sch Med, Acad Unit Clin Oncol, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.
EM p.d.ottewell@sheffield.ac.uk
RI Wang, Ning/HKO 8446 2023
OI WANG, NING/0000 0002 2663 7515; Holen, Ingunn/0000 0002 8759 6913;
   Ottewell, Penelope/0000 0002 4826 0771; Croucher,
   Peter/0000 0002 7102 2413
FU Cancer Research UK; Mrs Janice Gibson and the Ernest Heine Family
   Foundation; Cancer Research UK [11991] Funding Source: researchfish
FX Grant sponsor: Cancer Research UK; Mrs Janice Gibson and the Ernest
   Heine Family Foundation.
CR Aguirre Ghiso JA, 2013, NAT MED, V19, P276, DOI 10.1038/nm.3120
   Armstrong AP, 2008, PROSTATE, V68, P92, DOI 10.1002/pros.20678
   Bellahcène A, 2007, BREAST CANCER RES TR, V101, P135, DOI 10.1007/s10549 006 9279 8
   Body JJ, 2013, B CANCER, V100, P1207, DOI 10.1684/bdc.2013.1835
   Canon J, 2012, BREAST CANCER RES TR, V135, P771, DOI 10.1007/s10549 012 2222 2
   Canon J, 2010, BONE, V46, P1613, DOI 10.1016/j.bone.2010.03.001
   Canon JR, 2008, CLIN EXP METASTAS, V25, P119, DOI 10.1007/s10585 007 9127 1
   Casas A, 2013, BREAST, V22, P585, DOI 10.1016/j.breast.2013.05.007
   Chen YC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2781
   Clézardin P, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2835
   COLE AA, 1987, J HISTOCHEM CYTOCHEM, V35, P203, DOI 10.1177/35.2.3540104
   Coleman RE, 2013, NAT REV RHEUMATOL, V9, P365, DOI 10.1038/nrrheum.2013.36
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Figueroa Magalhaes MC, 2012, ONCOLOGY NY, V26, P955
   Gnant M, 2011, LANCET ONCOL, V12, P631, DOI 10.1016/S1470 2045(11)70122 X
   Haider MT, 2014, BONE, V66, P240, DOI 10.1016/j.bone.2014.06.023
   Lee SK, 2006, J BONE MINER RES, V21, P1704, DOI 10.1359/JBMR.060726
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   Liu XL, 2015, CLIN ORAL IMPLAN RES, V26, P392, DOI 10.1111/clr.12360
   Miller RE, 2014, J THORAC ONCOL, V9, P345, DOI 10.1097/JTO.0000000000000070
   Morony S, 2005, ENDOCRINOLOGY, V146, P3235, DOI 10.1210/en.2004 1583
   Morony S, 2001, CANCER RES, V61, P4432
   Mucowski SJ, 2014, FERTIL STERIL, V101, P1117, DOI 10.1016/j.fertnstert.2013.12.055
   Ottewell PD, 2008, JNCI J NATL CANCER I, V100, P1167, DOI 10.1093/jnci/djn240
   Ottewell PD, 2008, CLIN CANCER RES, V14, P4658, DOI 10.1158/1078 0432.CCR 07 1545
   Ottewell PD, 2014, ENDOCR RELAT CANCER, V21, P769, DOI 10.1530/ERC 14 0199
   Ottewell PD, 2014, CLIN CANCER RES, V20, P2922, DOI 10.1158/1078 0432.CCR 13 1246
   Park HR, 2003, J KOREAN MED SCI, V18, P541, DOI 10.3346/jkms.2003.18.4.541
   Roodman GD, 2008, CANCER TREAT REV, V34, P92, DOI 10.1016/j.ctrv.2007.09.002
   Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451
   Townson JL, 2006, CELL CYCLE, V5, P1744, DOI 10.4161/cc.5.16.2864
   van der Horst G, 2011, NEOPLASIA, V13, P516, DOI 10.1593/neo.11122
   Vanderkerken K, 2003, CANCER RES, V63, P287
   Zauli G, 2009, CELL MOL LIFE SCI, V66, P841, DOI 10.1007/s00018 008 8536 x
   Zhao H, 2014, CELL BIOCHEM BIOPHYS, V70, P1097, DOI 10.1007/s12013 014 0028 z
   Zinonos I, 2014, INT J ONCOL, V45, P532, DOI 10.3892/ijo.2014.2468
NR 36
TC 47
Z9 51
U1 1
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0020 7136
EI 1097 0215
J9 INT J CANCER
JI Int. J. Cancer
PD AUG 15
PY 2015
VL 137
IS 4
BP 968
EP 977
DI 10.1002/ijc.29439
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA CK7QY
UT WOS:000356428400023
PM 25603921
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Tardoski, S
   Gineyts, E
   Ngo, J
   Kocot, A
   Clézardin, P
   Melodelima, D
AF Tardoski, Sophie
   Gineyts, Evelyne
   Ngo, Jacqueline
   Kocot, Anthony
   Clezardin, Philippe
   Melodelima, David
TI LOW INTENSITY ULTRASOUND PROMOTES CLATHRIN DEPENDENT ENDOCYTOSIS FOR
   DRUG PENETRATION INTO TUMOR CELLS
SO ULTRASOUND IN MEDICINE AND BIOLOGY
LA English
DT Article
DE Ultrasound; Drug delivery; Bisphosphonate; Zoledronic acid; Bone
   metastasis; Breast cancer
ID PULSED ULTRASOUND; ATP ANALOG; IN VIVO; ISOPENTENYL PYROPHOSPHATE;
   FOCUSED ULTRASOUND; TARGETED DELIVERY; SHEAR STRESS; BREAST;
   BISPHOSPHONATES; DIFFERENTIATION
AB Ultrasound mediated drug delivery is a field of research with promising results, although the exact mechanisms underlying intracellular delivery of therapeutic compounds remain to be elucidated. Many studies use drug carriers and cavitation to enhance drug uptake into tumor cells. However, cavitation could induce cell lysis and remain difficult to control and predict in vivo. In this study, low intensity ultrasound was delivered using two transducers working at 2.9 and 1.3 MHz. The maximal peak negative pressure was 0.29 MPa to avoid cavitation. Low intensity ultrasound induced clathrin mediated endocytosis and forced the penetration of a bisphosphonate (zoledronic acid) into MCF 7 human breast cancer cells potentially as a result of mechanical stresses. When sonication parameters were adjusted to create mild hyperthermia in addition to the mechanical stress, further significant accumulation of ZOL was observed. These results provide better insight into the role of acoustic parameters in drug uptake. (E mail: sophie.tardoski@inserm.fr) (C) 2015 World Federation for Ultrasound in Medicine & Biology.
C1 [Tardoski, Sophie; Ngo, Jacqueline; Kocot, Anthony] INSERM, UMR 1032, LabTAU, F 69424 Lyon, France.
   [Tardoski, Sophie; Gineyts, Evelyne] INSERM, U1033, F 69424 Lyon, France.
   [Tardoski, Sophie; Gineyts, Evelyne; Ngo, Jacqueline; Kocot, Anthony; Clezardin, Philippe; Melodelima, David] Univ Lyon, Lyon, France.
   [Tardoski, Sophie; Clezardin, Philippe; Melodelima, David] LabEx DEVweCAN, Lyon, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Claude Bernard Lyon 1; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Universite Claude Bernard Lyon 1
RP Tardoski, S (通讯作者)，INSERM, UMR 1032, LabEx DEVweCAN, 151 Cours Albert Thomas, F 69424 Lyon, France.
EM sophie.tardoski@inserm.fr
RI Melodelima, David/AAR 7183 2020; Clezardin, Philippe/M 8071 2014
OI Gineyts, Evelyne/0000 0003 3868 5810; Clezardin,
   Philippe/0000 0003 0149 4463; Melodelima, David/0000 0003 3913 1270
FU French National Research Agency [ANR BLANC 2010 1508 01]; Institut
   Federatif de Recherche [IFR62]; LabEX DEVweCAN of Universite de Lyon
   [ANR 10 LABX 61]; program "Investissements d'Avenir" [ANR 11 IDEX 0007]
FX This work was supported by the French National Research Agency (ANR
   BLANC 2010 1508 01) (PC and DM) and the Institut Federatif de Recherche
   IFR62 (DM). Additional funding was obtained from the LabEX DEVweCAN
   (ANR 10 LABX 61) of Universite de Lyon, within the program
   "Investissements d'Avenir" (ANR 11 IDEX 0007) operated by the French
   National Research Agency (PC and DM). The authors thank Christelle
   Cassin and Elisabeth Errazuriz Cerda (CIQLE SFR Sante Lyon Est) for
   their help during transmission electron microscopy.
CR Afadzi M, 2013, IEEE T ULTRASON FERR, V60, P21, DOI 10.1109/TUFFC.2013.2534
   Angle SR, 2011, ULTRASONICS, V51, P281, DOI 10.1016/j.ultras.2010.09.004
   APFEL RE, 1982, BRIT J CANCER, V45, P140
   Apodaca G, 2002, AM J PHYSIOL RENAL, V282, pF179, DOI 10.1152/ajprenal.2002.282.2.F179
   de Paula DMB, 2011, J GENE MED, V13, P392, DOI 10.1002/jgm.1586
   Benzaïd I, 2011, CANCER RES, V71, P4562, DOI 10.1158/0008 5472.CAN 10 3862
   Boissier S, 2000, CANCER RES, V60, P2949
   Clézardin P, 2011, BONE, V48, P71, DOI 10.1016/j.bone.2010.07.016
   Dayton P, 1999, ULTRASOUND MED BIOL, V25, P1195, DOI 10.1016/S0301 5629(99)00062 9
   DRAPER DO, 1995, J ORTHOP SPORT PHYS, V21, P153, DOI 10.2519/jospt.1995.21.3.153
   Escoffre JM, 2013, PHYS MED BIOL, V58, P8135, DOI 10.1088/0031 9155/58/22/8135
   Evergren E, 2004, J NEUROSCI METH, V135, P169, DOI 10.1016/j.jneumeth.2003.12.010
   Evjen TJ, 2013, EUR J PHARM BIOPHARM, V84, P526, DOI 10.1016/j.ejpb.2012.12.007
   FELIX R, 1984, CALCIFIED TISSUE INT, V36, P108, DOI 10.1007/BF02405302
   Feril LB, 2003, ULTRASOUND MED BIOL, V29, P331, DOI 10.1016/S0301 5629(02)00700 7
   Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
   Gleizal A, 2010, REV STOMATOL CHIR, V111, P280, DOI 10.1016/j.stomax.2009.07.013
   Goertz DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052307
   Goldberg MW, 2010, METHODS MOL BIOL, V657, P297, DOI 10.1007/978 1 60761 783 9_24
   Green JR, 2003, CANCER, V97, P840, DOI 10.1002/cncr.11128
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hancock HA, 2009, ULTRASOUND MED BIOL, V35, P1722, DOI 10.1016/j.ultrasmedbio.2009.04.020
   Hashimoto K, 2007, BIOCHEM BIOPH RES CO, V354, P478, DOI 10.1016/j.bbrc.2007.01.014
   Horsman MR, 1997, INT J HYPERTHER, V13, P141, DOI 10.3109/02656739709012378
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   HYNYNEN K, 1991, ULTRASOUND MED BIOL, V17, P157, DOI 10.1016/0301 5629(91)90123 E
   Jauhiainen M, 2009, J CHROMATOGR B, V877, P2967, DOI 10.1016/j.jchromb.2009.07.010
   Jin LF, 2013, INT J MOL SCI, V14, P9737, DOI 10.3390/ijms14059737
   Komarova Y, 2010, ANNU REV PHYSIOL, V72, P463, DOI 10.1146/annurev physiol 021909 135833
   Kong G, 2001, CANCER RES, V61, P3027
   Larkin JO, 2008, ULTRASOUND MED BIOL, V34, P406, DOI 10.1016/j.ultrasmedbio.2007.09.005
   Lawrie A, 2000, GENE THER, V7, P2023, DOI 10.1038/sj.gt.3301339
   Leskinen JJ, 2012, ULTRASOUND MED BIOL, V38, P777, DOI 10.1016/j.ultrasmedbio.2012.01.019
   Li L, 2012, BIOCHEM BIOPH RES CO, V418, P296, DOI 10.1016/j.bbrc.2012.01.014
   Lu HB, 2009, BIOCHEM BIOPH RES CO, V378, P569, DOI 10.1016/j.bbrc.2008.11.074
   Lum AFH, 2006, J CONTROL RELEASE, V111, P128, DOI 10.1016/j.jconrel.2005.11.006
   Lusini L, 2001, INT J CANCER, V91, P55, DOI 10.1002/1097 0215(20010101)91:1<55::AID IJC1006>3.0.CO;2 4
   Meijering BDM, 2009, CIRC RES, V104, P679, DOI 10.1161/CIRCRESAHA.108.183806
   Melodelima D, 2002, PHYS MED BIOL, V47, P4191, DOI 10.1088/0031 9155/47/23/306
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   Moonen CTW, 2007, CLIN CANCER RES, V13, P3482, DOI 10.1158/1078 0432.CCR 07 0204
   Padilla F, 2014, ULTRASONICS, V54, P1125, DOI 10.1016/j.ultras.2014.01.004
   Paparel P, 2008, PROSTATE CANCER P D, V11, P181, DOI 10.1038/sj.pcan.4501005
   Ponce AM, 2006, INT J HYPERTHER, V22, P205, DOI 10.1080/02656730600582956
   Räikkönen J, 2010, BIOCHEM PHARMACOL, V79, P777, DOI 10.1016/j.bcp.2009.10.003
   Räikkönen J, 2009, BRIT J PHARMACOL, V157, P427, DOI 10.1111/j.1476 5381.2009.00160.x
   Rifai B, 2010, J ACOUST SOC AM, V128, pEL310, DOI 10.1121/1.3496388
   Rogers MJ, 1997, PHARMACEUT RES, V14, P625, DOI 10.1023/A:1012157212793
   Rychak JJ, 2005, IEEE T ULTRASON FERR, V52, P421, DOI 10.1109/TUFFC.2005.1417264
   Sadowski Cheryl A, 2011, Can J Hosp Pharm, V64, P36
   Shervington A, 2008, CANCER INVEST, V26, P535, DOI 10.1080/07357900801904140
   Song CW, 2009, INT J HYPERTHER, V25, P91, DOI 10.1080/02656730902744171
   SONG CW, 1984, CANCER RES, V44, P4721
   SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409
   Suzuki A, 2009, ACTA BIOCH BIOPH SIN, V41, P108, DOI 10.1093/abbs/gmn012
   Suzuki R, 2007, J DRUG TARGET, V15, P531, DOI 10.1080/10611860701499789
   Tachibana K, 1999, LANCET, V353, P1409, DOI 10.1016/S0140 6736(99)01244 1
   Tajali SB, 2012, AM J PHYS MED REHAB, V91, P349, DOI 10.1097/PHM.0b013e31822419ba
   Tang XD, 2010, INT J CANCER, V126, P90, DOI 10.1002/ijc.24710
   ter Haar G, 2011, ULTRASOUND MED BIOL, V37, P177, DOI 10.1016/j.ultrasmedbio.2010.10.021
   Tugnoli V, 2001, BIOPOLYMERS, V62, P297, DOI 10.1002/bip.10005
   Unsworth J, 2007, ULTRASOUND MED BIOL, V33, P1468, DOI 10.1016/j.ultrasmedbio.2006.12.003
   VanBavel E, 2007, PROG BIOPHYS MOL BIO, V93, P374, DOI 10.1016/j.pbiomolbio.2006.07.017
   Vincenot J, 2013, ULTRASOUND MED BIOL, V39, P1241, DOI 10.1016/j.ultrasmedbio.2013.01.019
   Wada A, 2006, J HEPATOL, V44, P142, DOI 10.1016/j.jhep.2005.09.022
   WANG SJ, 1994, J ORTHOP RES, V12, P40, DOI 10.1002/jor.1100120106
   Watson KD, 2012, CANCER RES, V72, P1485, DOI 10.1158/0008 5472.CAN 11 3232
   Yang RS, 2005, BONE, V36, P276, DOI 10.1016/j.bone.2004.10.009
   Yoshie O, 2000, SPRINGER SEMIN IMMUN, V22, P371, DOI 10.1007/s002810000051
   Yuh EL, 2005, RADIOLOGY, V234, P431, DOI 10.1148/radiol.2342030889
   Zaragoza C, 2012, CURR OPIN LIPIDOL, V23, P446, DOI 10.1097/MOL.0b013e328357e837
   Zhang CB, 2013, ULTRASOUND MED BIOL, V39, P161, DOI 10.1016/j.ultrasmedbio.2012.08.025
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
   Zhou SX, 2004, J BIOL CHEM, V279, P54463, DOI 10.1074/jbc.M404786200
   Zhou Y, 2012, J CONTROL RELEASE, V157, P103, DOI 10.1016/j.jconrel.2011.09.068
   Zhou Y, 2009, ULTRASOUND MED BIOL, V35, P1756, DOI 10.1016/j.ultrasmedbio.2009.05.012
NR 76
TC 27
Z9 28
U1 2
U2 29
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0301 5629
EI 1879 291X
J9 ULTRASOUND MED BIOL
JI Ultrasound Med. Biol.
PD OCT
PY 2015
VL 41
IS 10
BP 2740
EP 2754
DI 10.1016/j.ultrasmedbio.2015.06.006
PG 15
WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
GA CY5TM
UT WOS:000366470400020
PM 26213291
DA 2025 08 17
ER

PT J
AU Ironside, MS
   Duer, MJ
   Reid, DG
   Byard, S
AF Ironside, Matthew S.
   Duer, Melinda J.
   Reid, David G.
   Byard, Stephen
TI Bisphosphonate protonation states, conformations, and dynamics on bone
   mineral probed by solid state NMR without isotope enrichment
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Article
DE Drug targeting; Biomaterials; Chemical shift anisotropy; REDOR;
   Molecular dynamics; Osteoporosis
ID NITROGEN CONTAINING BISPHOSPHONATES; FARNESYL PYROPHOSPHATE SYNTHASE;
   CHEMICAL SHIFT TENSOR; IN VITRO; ANTIRESORPTIVE PROPERTIES;
   CLINICAL EFFICACY; SIDE BAND; HYDROXYAPATITE; DISSOCIATION; PAMIDRONATE
AB Recognition of bone mineral by bisphosphonates is crucial to their targeting, efficacy, therapeutic and diagnostic applications, and pharmacokinetics. In a search for rapid and simple NMR approaches to assessing the bone recognition characteristics of bisphosphonates, we have studied alendronate, pamidronate, neridronate, zoledronate and tiludronate, in crystalline form and bound to the surface of pure bone mineral stripped of its organic matrix by a simple chemical process. P 31 NMR chemical shift anisotropies and asymmetries in the crystalline compounds cluster strongly into groupings corresponding to fully protonated, monoprotonated, and deprotonated phosphonate states. All the mineral bound bisphosphonates cluster in the same anisotropy asymmetry space as the deprotonated phosphonates. In C 13{P 31} rotational echo double resonance (REDOR) experiments, which are sensitive to carbon phosphorus inter atomic distances, the strongly mineral bound alendronate displays very similar conformational and side chain dynamics to its crystalline state. Pamidronate and neridronate, with shorter and longer sidechains, respectively, and generally weaker mineral binding, display more dynamical sidechains in the mineral bound state. The REDOR experiment provides a simple rationalization of bisphosphonate mineral affinity in terms of molecular structure and dynamics, consistent with findings from much more labour  and time intensive isotope labelling approaches. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Ironside, Matthew S.; Duer, Melinda J.; Reid, David G.] Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England.
   [Byard, Stephen] Sanofi Aventis, Dept Analyt Sci, Northumberland, England.
C3 University of Cambridge; Sanofi Aventis; Sanofi United Kingdom
RP Duer, MJ (通讯作者)，Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.
EM Matt.Ironside@cantab.net; Mjd13@cam.ac.uk; Dgr30@cam.ac.uk;
   Stephen.Byard@sanofi aventis.com
OI Duer, Melinda/0000 0002 9196 5072
FU UK EPSRC (MSI); BBSRC (DGR)
FX Dr. Rachel Murray (Animal Health Trust, UK) for equine bone, Dr.
   Jonathan Green (Novartis Pharma AG, Basel, Switzerland) for a gift of
   disodium zoledronate, the UK EPSRC (MSI) and BBSRC (DGR) for funding.
   The electron micrograph used in the graphical abstract was downloaded
   from the Bone Research Society website
   (http://www.brsoc.org.uk/gallery).
CR BRELIERE JC, 1984, Patent No. 1984100718
   Cho GY, 2003, SCIENCE, V300, P1123, DOI 10.1126/science.1078470
   COIRO VM, 1989, ACTA CRYSTALLOGR C, V45, P446, DOI 10.1107/S0108270188011576
   Duer M. J., 2004, INTRO SOLID STATE NM
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   FENZKE D, 1990, J MAGN RESON, V88, P172, DOI 10.1016/0022 2364(90)90122 P
   Grossmann G, 2000, MAGN RESON CHEM, V38, P11, DOI 10.1002/(SICI)1097 458X(200001)38:1<11::AID MRC597>3.0.CO;2 V
   HERZFELD J, 1980, J CHEM PHYS, V73, P6021, DOI 10.1063/1.440136
   Ironside MS, 2008, MAGN RESON CHEM, V46, P913, DOI 10.1002/mrc.2262
   Levitt MH, 2002, J MAGN RESON, V155, P300, DOI 10.1006/jmre.2002.2520
   Maltsev S, 2007, J MATER SCI, V42, P8804, DOI 10.1007/s10853 007 1916 z
   Mao JH, 2006, J AM CHEM SOC, V128, P14485, DOI 10.1021/ja061737c
   MARICQ MM, 1979, J CHEM PHYS, V70, P3300, DOI 10.1063/1.437915
   Mukherjee S, 2008, J AM CHEM SOC, V130, P1264, DOI 10.1021/ja0759949
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Olivieri AC, 1996, J MAGN RESON SER A, V123, P207, DOI 10.1006/jmra.1996.0237
   PAN Y, 1990, J MAGN RESON, V90, P330, DOI 10.1016/0022 2364(90)90138 Y
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2006, BONE, V39, P443, DOI 10.1016/j.bone.2006.02.060
   Raghunathan V, 2006, J PHYS CHEM B, V110, P9324, DOI 10.1021/jp056644g
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   Sanders JM, 2003, J MED CHEM, V46, P5171, DOI 10.1021/jm0302344
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V255, P491, DOI 10.1006/bbrc.1999.0224
   van Beek ER, 1998, BONE, V23, P437, DOI 10.1016/S8756 3282(98)00120 3
   VANBEEK E, 1994, J BONE MINER RES, V9, P1875, DOI 10.1002/jbmr.5650091206
   vanBeek E, 1996, J BONE MINER RES, V11, P1492
   Vega D, 2002, ACTA CRYSTALLOGR C, V58, pM77, DOI 10.1107/S0108270101019655
   Vega D, 1996, ACTA CRYSTALLOGR C, V52, P2198, DOI 10.1107/S0108270196006105
   Widler L, 2002, J MED CHEM, V45, P3721, DOI 10.1021/jm020819i
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
NR 32
TC 24
Z9 24
U1 0
U2 28
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0939 6411
EI 1873 3441
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD SEP
PY 2010
VL 76
IS 1
BP 120
EP 126
DI 10.1016/j.ejpb.2010.05.013
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 650YY
UT WOS:000281892000014
PM 20554022
DA 2025 08 17
ER

PT J
AU Chang, HR
   Zhang, D
   Xin, Z
   Zhang, PF
   Ding, WY
   Chang, YZ
AF Chang, Hengrui
   Zhang, Dong
   Xin, Zhen
   Zhang, Pengfei
   Ding, Wenyuan
   Chang, Yan Zhong
TI Influence of prazosin on systemic iron levels and the associated iron
   metabolic alterations in spontaneously hypertensive rats
SO PHARMACOLOGY RESEARCH & PERSPECTIVES
LA English
DT Article
DE bone tissue; hepatic; hypertension; iron metabolism; Prazosin
ID FERRITIN; FERROPORTIN; ABSORPTION; CHANNEL; DISEASE; ZINC
AB The relationship between cardiovascular diseases and iron disorders has gained increasing attention; however, the effects of hypotensive drugs on iron metabolic alterations in hypertension are not well understood. The purpose of this study was to investigate iron metabolic changes after prazosin treatment of spontaneously hypertensive rats (SHRs) and Wistar Kyoto (WKY) rats. Our second objective was to examine the effects of hypertension and anti hypertensive drugs on bone formation and resorption. SHRs and WKY rats were randomized into either prazosin treated groups (WKY+ PZ and SHR + PZ) or untreated groups (WKY and SHR). After 7days of intragastric prazosin administration, the rats were sacrificed for analysis; blood samples and organs (the duodenum, liver, kidneys, spleen, and femur) were collected. Both WKY+ PZ and SHR groups exhibited iron deficiency in the serum and liver. Prazosin increased the iron levels in the bone tissue of SHRs. Prazosin stimulated the expression of hepcidin mRNA in the liver of SHRs and inhibited the expression of this iron regulatory hormone in WKY rats. FPN1 expression in the duodenum was increased significantly in SHRs, however markedly decreased after prazosin treatment. The expression of TLR4 and Ctsk was enhanced in the bone tissue of SHRs, whereas CLC 7 expression was inhibited. Both hypotension and hypertension can lead to iron deficiency. Treatment with prazosin restored iron homeostasis in SHRs. The inverse impacts of prazosin on hepatic hepcidin expression in SHRs versus WKY rats indicates differing iron regulatory mechanisms between hypertensive and normal animals. The osteoclast activity was found to be enhanced in SHRs. Further study is needed to address whether the changes in osteoblast and osteoclast activity in SHRs correlates with the effects on iron metabolism.
C1 [Chang, Hengrui; Ding, Wenyuan] Hebei Med Univ, Dept Spinal Surg, Hosp 3, Shijiazhuang, Hebei, Peoples R China.
   [Chang, Hengrui; Zhang, Dong; Xin, Zhen; Zhang, Pengfei; Chang, Yan Zhong] Hebei Normal Univ, Coll Life Sci, Shijiazhuang, Hebei, Peoples R China.
C3 Hebei Medical University; Hebei Normal University
RP Ding, WY (通讯作者)，Hebei Med Univ, Dept Spinal Surg, Hosp 3, Shijiazhuang, Hebei, Peoples R China.; Chang, YZ (通讯作者)，Hebei Normal Univ, Coll Life Sci, Shijiazhuang, Hebei, Peoples R China.
EM chang7676@163.com; drdingwy@163.com; yzchang@hebtu.edu.cn
RI Chang, Yan Zhong/AAB 5676 2020; Zhang, Pengfei/E 6883 2012
OI Chang, Yan Zhong/0000 0002 6386 9649; 
FU National Natural Science Foundation of China [31340064]
FX National Natural Science Foundation of China, Grant/Award Number:
   31340064
CR Arezes J, 2020, BLOOD, V135, P547, DOI 10.1182/blood.2019003140
   Bastos Marta Ferreira, 2010, Braz. oral res., V24, P170, DOI 10.1590/S1806 83242010000200008
   Braun LA, 2013, INT J CLIN PRACT, V67, P717, DOI 10.1111/ijcp.12040
   Cappuccio FP, 1999, LANCET, V354, P971, DOI 10.1016/S0140 6736(99)01437 3
   Chang YZ, 2005, J CELL PHYSIOL, V204, P623, DOI 10.1002/jcp.20321
   Chow CK, 2013, JAMA J AM MED ASSOC, V310, P959, DOI 10.1001/jama.2013.184182
   CUTLER JA, 1993, CLIN EXP HYPERTENS, V15, P1193, DOI 10.3109/10641969309037105
   de Souza A, 2018, INT J PHARMACEUT, V547, P421, DOI 10.1016/j.ijpharm.2018.06.018
   Dosh SA, 2002, J FAM PRACTICE, V51, P74
   Duck KA, 2016, BIOMETALS, V29, P573, DOI 10.1007/s10534 016 9952 2
   Frank MK, 2012, BIOL TRACE ELEM RES, V145, P222, DOI 10.1007/s12011 011 9188 5
   Kasper D, 2005, EMBO J, V24, P1079, DOI 10.1038/sj.emboj.7600576
   Kong WN, 2018, J CELL BIOCHEM, V119, P5517, DOI 10.1002/jcb.26715
   Koori K, 2014, CELL TISSUE RES, V357, P707, DOI 10.1007/s00441 014 1918 5
   Li GF, 2012, OSTEOPOROSIS INT, V23, P2403, DOI 10.1007/s00198 012 1982 1
   LOYKE HF, 1990, BIOL TRACE ELEM RES, V25, P47, DOI 10.1007/BF02990263
   Machado I, 2016, FOOD CHEM, V194, P373, DOI 10.1016/j.foodchem.2015.08.027
   McKie AT, 2001, SCIENCE, V291, P1755, DOI 10.1126/science.1057206
   Mitchell S, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003299
   Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742
   Oh CK, 2016, J BIOL CHEM, V291, P19858, DOI 10.1074/jbc.M116.722520
   Piperno A, 2002, J HYPERTENS, V20, P1513, DOI 10.1097/00004872 200208000 00013
   Ramakrishnan L, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00641
   Seravalle G, 2020, HYPERTENSION, V76, P1444, DOI 10.1161/HYPERTENSIONAHA.120.15511
   Shi ZH, 2010, ANTIOXID REDOX SIGN, V13, P783, DOI 10.1089/ars.2009.3018
   STANASZEK WF, 1983, DRUGS, V25, P339, DOI 10.2165/00003495 198325040 00002
   Suliburska J, 2014, EUR J PHARMACOL, V738, P326, DOI 10.1016/j.ejphar.2014.06.003
   SULLIVAN JL, 1981, LANCET, V1, P1293
   Tiyasatkulkovit W, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 48797 8
   Tsay J, 2010, BLOOD, V116, P2582, DOI 10.1182/blood 2009 12 260083
   Valenti L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134635
   Varenna M, 2013, CALCIFIED TISSUE INT, V93, P86, DOI 10.1007/s00223 013 9731 9
   Xu YJ, 2011, REGUL PEPTIDES, V172, P58, DOI 10.1016/j.regpep.2011.08.009
   Yamasaki K, 2009, TOXICOL LETT, V191, P211, DOI 10.1016/j.toxlet.2009.08.023
   Zarjou A, 2010, J BONE MINER RES, V25, P164, DOI 10.1359/jbmr.091002
NR 35
TC 0
Z9 0
U1 0
U2 3
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 2052 1707
J9 PHARMACOL RES PERSPE
JI Pharmacol. Res. Perspect.
PD AUG
PY 2022
VL 10
IS 4
AR e00991
DI 10.1002/prp2.991
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 3F0HM
UT WOS:000830355400001
PM 35892277
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lin, Z
   Pavlos, NJ
   Cake, MA
   Wood, DJ
   Xu, J
   Zheng, MH
AF Lin, Z.
   Pavlos, N. J.
   Cake, M. A.
   Wood, D. J.
   Xu, J.
   Zheng, M. H.
TI Evidence that human cartilage and chondrocytes do not express calcitonin
   receptor
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article
DE calcitonin; cartilage; chondrocyte; subchondral bone; osteoarthritis
ID SALMON CALCITONIN; PARATHYROID HORMONE; ARTICULAR CHONDROCYTES;
   GENE EXPRESSION; II DEGRADATION; BONE; OSTEOARTHRITIS; GROWTH;
   METABOLISM; CULTURE
AB Objective: Calcitonin (CT) has been recently shown to exhibit direct protective effects on articular cartilage against joint degenerative disease. It has been proposed that CT might act via the CT receptor (CTR) to activate the cyclic AMP (cAMP) pathway and protect type II collagen degradation. In this study, we investigated the existence of CTR in human articular cartilage and chondrocytes, and examined the potential pharmacological effects and transduction pathway of salmon CT (sCT) in human chondrocytes.
   Methods: Five human articular cartilage samples were examined for the expression of the CTR by polymerase chain reaction (PCR), immuno staining and Western blot analysis. cAMP levels in human chondrocyte stimulated with sCT were assessed by ELISA. The effect of sCT on the gene expression profiles, including aggrecan, type II collagen, MMP 1, MMP 3 and MMP 13, of human chondrocytes was also examined by relative quantitative Real time PCR.
   Results: We failed to detect the CTR at both the transcriptional and protein levels in human chondrocytes and cartilage tissue by PCR, immunostaining and Western blotting. cAMP levels were significantly elevated in human chondrocytes by forskolin (100 mu M) to more than 10 fold (P < 0.001), however, were not induced by sCT (10( 7) M, 10( 8) M, 10( 9) M). Real time PCR analysis demonstrated that sCT slightly reduced the gene expression of MMPs, although this effect was not statistically significant.
   Conclusion: In contrary to previous reports, our data indicate that human cartilage and chondrocytes do not express CTR. Furthermore, sCT does not appear to have direct effects on human chondrocytes. We propose that the chondroprotective effect of CT observed in vivo may be indirect via its impact on subchondral bone resorptive activity of osteoclasts. (C) 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
C1 [Lin, Z.; Pavlos, N. J.; Wood, D. J.; Xu, J.; Zheng, M. H.] Univ Western Australia, Ctr Orthopaed Res, QEII Med Ctr, Sch Surg & Pathol, Nedlands, WA 6009, Australia.
   [Cake, M. A.] Murdoch Univ, Sch Vet & Biomed Sci, Murdoch, WA 6150, Australia.
C3 University of Western Australia; Queen Elizabeth II Medical Centre;
   Murdoch University
RP Zheng, MH (通讯作者)，Univ Western Australia, Ctr Orthopaed Res, QEII Med Ctr, Sch Surg & Pathol, M block,Monash Ave, Nedlands, WA 6009, Australia.
EM minghao.zheng@uwa.edu.au
RI Cake, Martin/B 5935 2013
OI Cake, Martin/0000 0002 0072 9024; Xu, Jiake/0000 0003 2021 8309; Pavlos,
   Nathan/0000 0001 7003 188X; Zheng, Minghao/0000 0003 1185 4768
CR Badurski J, 1995, Pol Tyg Lek, V50, P37
   BADURSKI JE, 1991, CALCIFIED TISSUE INT, V49, P27, DOI 10.1007/BF02555899
   Bagger YZ, 2005, BONE, V37, P425, DOI 10.1016/j.bone.2005.04.032
   Behets C, 2004, J BONE MINER RES, V19, P1821, DOI 10.1359/JBMR.040609
   BURCH WM, 1985, ENDOCRINOLOGY, V116, P1724, DOI 10.1210/endo 116 5 1724
   BURCH WM, 1984, ENDOCRINOLOGY, V114, P1196, DOI 10.1210/endo 114 4 1196
   DESHMUKH K, 1977, BIOCHIM BIOPHYS ACTA, V499, P28, DOI 10.1016/0304 4165(77)90225 2
   Di Nino DL, 2003, ENDOCRINOLOGY, V144, P1979, DOI 10.1210/en.2002 220905
   Felson DT, 2004, ARTHRITIS RHEUM US, V50, P341, DOI 10.1002/art.20051
   FRANCHIMONT P, 1989, J CLIN ENDOCR METAB, V69, P259, DOI 10.1210/jcem 69 2 259
   FRIEDMAN J, 1965, SCIENCE, V150, P1465, DOI 10.1126/science.150.3702.1465
   GORN AH, 1992, J CLIN INVEST, V90, P1726, DOI 10.1172/JCI116046
   Hajjaji HE, 2004, OSTEOARTHR CARTILAGE, V12, P904, DOI 10.1016/j.joca.2004.08.005
   Hellio MP, 1997, OSTEOARTHR CARTILAGE, V5, P121, DOI 10.1016/S1063 4584(97)80005 2
   Huang L, 2000, AM J PATHOL, V156, P761, DOI 10.1016/S0002 9440(10)64942 5
   Ishikawa Y, 1997, J BONE MINER RES, V12, P356, DOI 10.1359/jbmr.1997.12.3.356
   JONES DG, 1990, J ORTHOP RES, V8, P227, DOI 10.1002/jor.1100080211
   Karsdal MA, 2006, OSTEOARTHR CARTILAGE, V14, P617, DOI 10.1016/j.joca.2006.03.014
   KUESTNER RE, 1994, MOL PHARMACOL, V46, P246
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lyritis G. P., 2001, Journal of Musculoskeletal & Neuronal Interactions, V2, P137
   Manicourt D. H., 2005, Journal of Musculoskeletal & Neuronal Interactions, V5, P285
   Manicourt DH, 2006, ARTHRITIS RHEUM, V54, P3205, DOI 10.1002/art.22075
   Manicourt DH, 1999, ARTHRITIS RHEUM US, V42, P1159, DOI 10.1002/1529 0131(199906)42:6<1159::AID ANR12>3.0.CO;2 Q
   McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666
   Papaioannou NA, 2007, OSTEOARTHR CARTILAGE, V15, P386, DOI 10.1016/j.joca.2006.10.012
   Pondel M, 2000, INT J EXP PATHOL, V81, P405, DOI 10.1046/j.1365 2613.2000.00176.x
   PUNZI L, 1989, CLIN EXP RHEUMATOL, V7, P247
   RAISZ LG, 1967, NATURE, V214, P486, DOI 10.1038/214486a0
   Sondergaard BC, 2006, OSTEOARTHR CARTILAGE, V14, P759, DOI 10.1016/j.joca.2006.01.014
   WARSHAWSKY H, 1980, J CELL BIOL, V85, P682, DOI 10.1083/jcb.85.3.682
   Xu JK, 2005, J CELL PHYSIOL, V202, P554, DOI 10.1002/jcp.20159
NR 32
TC 12
Z9 13
U1 0
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1063 4584
EI 1522 9653
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD APR
PY 2008
VL 16
IS 4
BP 450
EP 457
DI 10.1016/j.joca.2007.08.003
PG 8
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA 291JV
UT WOS:000255194100008
PM 17890110
OA Bronze
DA 2025 08 17
ER

PT J
AU Wang, Y
   Zhang, T
   Xu, Y
   Chen, R
   Qu, N
   Zhang, B
   Xia, C
AF Wang, Yue
   Zhang, Tongen
   Xu, Yang
   Chen, Rui
   Qu, Ning
   Zhang, Bing
   Xia, Chun
TI Suppressing phosphoinositide specific phospholipases Cγ1 promotes
   mineralization of osteoarthritic subchondral bone osteoblasts via
   increasing autophagy, thereby ameliorating articular cartilage
   degeneration
SO BONE
LA English
DT Article
DE Osteoarthritis subchondral bone osteoblasts; Autophagy; PLC gamma 1
   signaling; Endoplasmic reticulum stress; Mineralization; Articular
   cartilage degeneration
ID ENDOPLASMIC RETICULUM STRESS; INHIBITION; EXPRESSION; CELLS
AB Introduction: Phosphoinositide specific phospholipases C gamma 1 (PLC gamma 1) signaling has been shown to modulate osteoarthritis (OA) chondrocyte metabolism. However, the role of PLC gamma 1 in OA osteoblasts remains unclear. Herein, whether and how PLC gamma 1 was involved in mineralization in OA subchondral bone osteoblasts were investigated.
   Methods: Primary non OA and OA osteoblasts of human and rat isolated from the subchondral bone or the calvaria were cultured in vitro, as well as mouse pre osteoblastic cell line MC3T3 E1 cells. Rat knee OA model was induced by anterior cruciate ligament transection (ACLT), in which bone canal was carried out from the surface of lateral epicondyle of femur using micro electric drill. Morphological characteristics of subchondral bone structure and articular cartilage were assessed using CT, micro CT, and Safranin O/Fast green staining, respectively. Mineralization was measured by alizarin red staining. The expression and production of genes involved in osteoblastic phenotype and mineralization were evaluated by qPCR, western blotting, and immunohistochemistry assays, respectively. The inhibitions were performed using inhibitors and ShRNAs.
   Results: The decreased relative bone density and thickness in the early stage of OA and the increased one in the late stage of OA were observed in subchondral bone of ACLT rat model. Decreased ALP and OCN levels and absorbance values of ARS content were observed in in vitro osteoblasts isolated from 2 w post ACLT rat model, as well as IL 1 beta treated (for maintaining and mimicking inflammatory status) human OA and rat osteoblasts. Decreased Atg7 level and LC3BII/I ratio in combination with an increase in the P62 level, was concomitant with decreased ALP and OCN mRNA levels and absorbance values of ARS content in OA or IL 1 beta treated osteoblasts. Specific inhibition of PLC gamma 1 by ShRNAs or inhibitor (U73122) elevated ALP and OCN mRNA levels and absorbance values of ARS content accompanied with increased Atg7 level and LC3BII/I ratio in combination with a decrease in the P62 level in OA osteoblasts. Furthermore, the promoting effect of PLC gamma 1 inhibition on ALP and OCN mRNA levels and absorbance values of ARS content was reversed by endoplasmic reticulum (ER) stress activator HA15, as well as autophagic inhibitors CQ and 3MA. Injection with PLC gamma 1 inhibitor U73122 from the surface of lateral epicondyle of femur reduced aberrant subchondral bone formation and attenuated articular cartilage degeneration in ACLT rat.
   Conclusion: Aberrant changes of OA subchondral bone structure were concomitant with altered osteoblastic phenotype and mineralization. Impaired autophagy contributed to decreased osteoblastic mineralization in the early stage of OA. PLC gamma 1 inhibition promoted osteoblastic mineralization through increasing autophagy in OA osteoblasts, which was partially attributed to suppression of ER stress. Targeting PLC gamma 1 in subchondral bone osteoblasts could be more efficacious for OA therapy through treating the bone and cartilage at the same time. In summary, we hypothesize that suppressing PLC gamma 1 promotes mineralization of osteoarthritic subchondral bone osteoblasts via increasing autophagy, thereby ameliorating articular cartilage degeneration.
C1 [Wang, Yue; Zhang, Tongen; Xu, Yang; Xia, Chun] Xiamen Univ, Zhongshan Hosp, Bone & Joint Res Inst, Xiamen 361004, Fujian, Peoples R China.
   [Chen, Rui; Qu, Ning; Zhang, Bing] Xiamen Univ, Sch Med, Xiamen 361102, Fujian, Peoples R China.
C3 Xiamen University; Xiamen University
RP Xia, C (通讯作者)，Xiamen Univ, Zhongshan Hosp, Bone & Joint Res Inst, Xiamen 361004, Fujian, Peoples R China.; Zhang, B (通讯作者)，Xiamen Univ, Sch Med, Xiamen 361102, Fujian, Peoples R China.
EM cristal66@xmu.edu.cn; chunxia@xmu.edu.cn
OI chen, rui/0009 0003 7080 6093
FU National Natural Science Foundation of China [81572189, 81972091]
FX This study was supported by the National Natural Science Foundation of
   China (No. 81572189 and 81972091).
CR Ansari MY, 2018, OSTEOARTHR CARTILAGE, V26, P1087, DOI 10.1016/j.joca.2017.07.020
   Bartolomé A, 2013, BIOCHEM J, V455, P329, DOI 10.1042/BJ20130562
   Behets C, 2004, J BONE MINER RES, V19, P1821, DOI 10.1359/JBMR.040609
   Bettica P, 2002, ARTHRITIS RHEUM, V46, P3178, DOI 10.1002/art.10630
   Chen XL, 2021, J CELL MOL MED, V25, P1531, DOI 10.1111/jcmm.16245
   Chen XL, 2020, BIOCHEM BIOPH RES CO, V532, P292, DOI 10.1016/j.bbrc.2020.08.049
   Choi JH, 2007, ADV ENZYME REGUL, V47, P104, DOI 10.1016/j.advenzreg.2006.12.010
   Couchourel D, 2009, ARTHRITIS RHEUM US, V60, P1438, DOI 10.1002/art.24489
   Dai LZ, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 13334 y
   Darcy A, 2012, BONE, V50, P1294, DOI 10.1016/j.bone.2012.03.001
   Ding M, 2010, ACTA ORTHOP, V81, P5, DOI 10.3109/17453671003619037
   Goldring SR, 2016, NAT REV RHEUMATOL, V12, P632, DOI 10.1038/nrrheum.2016.148
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034
   Hu WH, 2021, ANN RHEUM DIS, V80, P413, DOI 10.1136/annrheumdis 2020 218089
   Intema F, 2010, OSTEOARTHR CARTILAGE, V18, P691, DOI 10.1016/j.joca.2010.01.004
   Karsdal MA, 2014, ANN RHEUM DIS, V73, P336, DOI 10.1136/annrheumdis 2013 204111
   Kumarasinghe DD, 2012, OSTEOARTHR CARTILAGE, V20, P1357, DOI 10.1016/j.joca.2012.07.005
   Li GY, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4405
   Li HX, 2018, AUTOPHAGY, V14, P1726, DOI 10.1080/15548627.2018.1483807
   Liu F, 2013, J BONE MINER RES, V28, P2414, DOI 10.1002/jbmr.1971
   Liu ZJ, 2015, INT J MOL SCI, V16, P17857, DOI 10.3390/ijms160817857
   Massicotte F, 2006, BONE, V38, P333, DOI 10.1016/j.bone.2005.09.007
   Moskowitz RW, 2006, OSTEOARTHR CARTILAGE, V14, P1, DOI 10.1016/j.joca.2005.08.015
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Parys JB, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478 811X 10 17
   Samadi N, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 64796 6
   Sanchez C, 2005, OSTEOARTHR CARTILAGE, V13, P988, DOI 10.1016/j.joca.2005.07.012
   Sanchez C, 2005, OSTEOARTHR CARTILAGE, V13, P979, DOI 10.1016/j.joca.2005.03.008
   Sanduja S, 2016, ONCOGENE, V35, P5295, DOI 10.1038/onc.2016.70
   Shahnazari S, 2010, CELL HOST MICROBE, V8, P137, DOI 10.1016/j.chom.2010.07.002
   Shapiro IM, 2014, AUTOPHAGY, V10, P7, DOI 10.4161/auto.26679
   Strassle BW, 2010, OSTEOARTHR CARTILAGE, V18, P1319, DOI 10.1016/j.joca.2010.06.007
   Tat SK, 2008, CLIN EXP RHEUMATOL, V26, P295
   Vicencio JM, 2009, CELL DEATH DIFFER, V16, P1006, DOI 10.1038/cdd.2009.34
   Wang F, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075 019 1952 5
   Whitehouse CA, 2010, P NATL ACAD SCI USA, V107, P12913, DOI 10.1073/pnas.0913058107
   Yang L, 2010, CELL METAB, V11, P467, DOI 10.1016/j.cmet.2010.04.005
   Yin JJ, 2016, MOL MED REP, V14, P3999, DOI 10.3892/mmr.2016.5708
   Zhang RK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032356
   Zhen GH, 2013, NAT MED, V19, P704, DOI 10.1038/nm.3143
   Zheng WW, 2019, FASEB J, V33, P4077, DOI 10.1096/fj.201801851R
   Zini N, 2005, HISTOCHEM CELL BIOL, V124, P131, DOI 10.1007/s00418 005 0022 z
NR 43
TC 10
Z9 14
U1 1
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JAN
PY 2022
VL 154
AR 116262
DI 10.1016/j.bone.2021.116262
EA NOV 2021
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA XC6RP
UT WOS:000722138500010
PM 34813965
OA hybrid
DA 2025 08 17
ER

PT J
AU Trincavelli, ML
   Daniele, S
   Giacomelli, C
   Taliani, S
   Da Settimo, F
   Cosimelli, B
   Greco, G
   Novellino, E
   Martini, C
AF Trincavelli, Maria Letizia
   Daniele, Simona
   Giacomelli, Chiara
   Taliani, Sabrina
   Da Settimo, Federico
   Cosimelli, Barbara
   Greco, Giovanni
   Novellino, Ettore
   Martini, Claudia
TI Osteoblast differentiation and survival: A role for A2B
   adenosine receptor allosteric modulators
SO BIOCHIMICA ET BIOPHYSICA ACTA MOLECULAR CELL RESEARCH
LA English
DT Article
DE A(2B) adenosine receptor; Receptor allosteric modulators; Mesenchymal
   stem cells; Osteoblast differentiation; Osteoblast survival; IL 6
ID MESENCHYMAL STEM CELLS; BONE FORMATION; INTERLEUKIN 6 SECRETION; IL 6;
   TRANSCRIPTION; ACTIVATION; EXPRESSION; CYTOKINES; STIMULATION; A(2A)
AB The A(2B) adenosine receptor (A(2B) AR), activated in response to high levels of endogenous adenosine, is the major AR subtype involved in mesenchymal stem cell (MSC) differentiation to osteoblasts and bone formation. For this reason, targeting of A(2B) AR with selective allosteric modulators may represent a promising pharmacological approach to the treatment of bone diseases.
   Herein, we report the characterization of a 3 keto indole derivative, 2 (1 benzy1 1H indol 3 yl) 2 oxo N phenylacetamide (KI 7), as A(2B) AR positive allosteric modulator in MSCs, demonstrating that this compound is able to potentiate the effects of either adenosine and synthetic orthosteric A(2B) AR agonists in mediating osteoblast differentiation in vitro. In detail, we observed that MSC treatment with KI 7 determined an increase in the expression of osteoblast related genes (Runx2 and osterix) and osteoblast marker proteins (phosphatase alkaline and osteocalcin), associated with a stimulation of osteoblast mineralization.
   In the early phase of differentiation programme, KI 7 significantly potentiated physiological and A(2B) AR agonist mediated down regulation of IL 6 release. Conversely, during the late stage of differentiation, when most of the cells have an osteoblast phenotype, KI 7 caused a sustained raise in IL 6 levels and an improvement in osteoblast viability. These data suggest that a positive allosteric modulation of A(2B) AR not only favours MSC commitment to osteoblasts, but also ensures a greater survival of mature osteoblasts. Our study paves the way for a therapeutic use of selective positive allosteric modulators of A(2B) AR in the control of osteoblast differentiation, bone formation and fracture repair. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Trincavelli, Maria Letizia; Daniele, Simona; Giacomelli, Chiara; Taliani, Sabrina; Da Settimo, Federico; Martini, Claudia] Univ Pisa, Dept Pharm, I 56126 Pisa, Italy.
   [Cosimelli, Barbara; Greco, Giovanni; Novellino, Ettore] Univ Naples Federico II, Dept Pharm, I 80131 Naples, Italy.
C3 University of Pisa; University of Naples Federico II
RP Martini, C (通讯作者)，Univ Pisa, Dept Pharm, Via Bonanno 6, I 56126 Pisa, Italy.
EM claudia.martini@unipi.it
RI TALIANI, SABRINA/AAO 7850 2020; Daniele, Simona/AAB 8888 2019;
   Trincavelli, Maria Letizia/M 1921 2015; DA SETTIMO PASSETTI,
   FEDERICO/M 1451 2015; Da Settimo, Federico/JFJ 2192 2023; Martini,
   Claudia/AAC 4089 2019; Giacomelli, Chiara/K 4954 2016
OI Trincavelli, Maria Letizia/0000 0001 8124 977X; DA SETTIMO PASSETTI,
   FEDERICO/0000 0002 7897 7917; Martini, Claudia/0000 0001 9379 3027;
   Novellino, Ettore/0000 0002 2181 2142; TALIANI,
   SABRINA/0000 0001 8675 939X; Giacomelli, Chiara/0000 0002 6244 602X
FU Italian Ministry of Education (Project of National Research Interest
   PRIN) [20122ATMNJ]
FX This work was supported by a grant funded by the Italian Ministry of
   Education (Project of National Research Interest PRIN 2012, 20122ATMNJ).
   The Italian Ministry had no further role in the study design, analysis
   or interpretation of the data, the writing of the report or the decision
   to submit the paper for publication.
CR Costa MA, 2011, J CELL PHYSIOL, V226, P1353, DOI 10.1002/jcp.22458
   Alexander D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081674
   Angeli A, 2002, ANN NY ACAD SCI, V966, P97, DOI 10.1111/j.1749 6632.2002.tb04207.x
   Aurelio L, 2011, BIOORG MED CHEM LETT, V21, P3704, DOI 10.1016/j.bmcl.2011.04.080
   Beil FT, 2008, EUR J TRAUMA EMERG S, V34, P527, DOI 10.1007/s00068 008 8201 y
   Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137
   Boguslawski G, 2000, J BIOL CHEM, V275, P999, DOI 10.1074/jbc.275.2.999
   Carroll SH, 2013, EXPERT REV MOL MED, V15, DOI 10.1017/erm.2013.2
   Carroll SH, 2012, J BIOL CHEM, V287, P15718, DOI 10.1074/jbc.M112.344994
   Ebara S, 2002, SPINE, V27, pS10, DOI 10.1097/00007632 200208151 00004
   Evans BAJ, 2006, J BONE MINER RES, V21, P228, DOI 10.1359/JBMR.051021
   Feng W, 2010, BRIT J PHARMACOL, V159, P1598, DOI 10.1111/j.1476 5381.2009.00558.x
   Gao ZG, 2006, DRUG DISCOV TODAY, V11, P191, DOI 10.1016/S1359 6446(05)03689 5
   Gao Zhan Guo, 2013, Drug Discov Today Technol, V10, pe237, DOI 10.1016/j.ddtec.2012.08.004
   Gao ZG, 2011, BIOCHEM PHARMACOL, V82, P658, DOI 10.1016/j.bcp.2011.06.017
   Gharibi B, 2011, J BONE MINER RES, V26, P2112, DOI 10.1002/jbmr.424
   Ham Jack, 2012, Front Endocrinol (Lausanne), V3, P113
   He WJ, 2013, FASEB J, V27, P3446, DOI 10.1096/fj.13 231233
   Hilaire CS, 2008, BIOCHEM BIOPH RES CO, V375, P292, DOI 10.1016/j.bbrc.2008.07.059
   Hoebertz A, 2003, TRENDS PHARMACOL SCI, V24, P290, DOI 10.1016/S0165 6147(03)00123 8
   Honig S, 2013, BULL HOSP JT DIS, V71, P184
   Hughes FJ, 2006, PERIODONTOL 2000, V41, P48, DOI 10.1111/j.1600 0757.2006.00161.x
   HUGHES FJ, 1993, BONE MINER, V21, P21, DOI 10.1016/S0169 6009(08)80117 1
   Hyde RJ, 2001, MOL MEMBR BIOL, V18, P53, DOI 10.1080/09687680110033765
   ISHIMI Y, 1990, J IMMUNOL, V145, P3297
   Jacobson KA, 2011, ADV PHARMACOL, V61, P187, DOI 10.1016/B978 0 12 385526 8.00007 2
   Kao R, 2012, ENDOCRINE, V42, P622, DOI 10.1007/s12020 012 9717 9
   Katebi M, 2009, J LEUKOCYTE BIOL, V85, P438, DOI 10.1189/jlb.0908520
   Kim JM, 2013, J CELL PHYSIOL, V228, P617, DOI 10.1002/jcp.24171
   Kimatrai Salvador Maria, 2013, Drug Discov Today Technol, V10, pe285, DOI 10.1016/j.ddtec.2012.08.005
   KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243
   Kolachala V, 2005, CELL MOL LIFE SCI, V62, P2647, DOI 10.1007/s00018 005 5328 4
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Latini S, 2001, J NEUROCHEM, V79, P463, DOI 10.1046/j.1471 4159.2001.00607.x
   Lee J, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4470
   Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775
   Luhmann T, 2012, J CONTROL RELEASE, V161, P198, DOI 10.1016/j.jconrel.2011.10.001
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Mediero A, 2013, TRENDS ENDOCRIN MET, V24, P290, DOI 10.1016/j.tem.2013.02.001
   Montesinos MC, 2002, AM J PATHOL, V160, P2009, DOI 10.1016/S0002 9440(10)61151 0
   NORDSTEDT C, 1990, ANAL BIOCHEM, V189, P231, DOI 10.1016/0003 2697(90)90113 N
   Pastor Anglada M, 2001, MOL MEMBR BIOL, V18, P81, DOI 10.1080/09687680117464
   Peruzzi B, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1651
   Portal Nunez Sergio, 2012, Rev Esp Geriatr Gerontol, V47, P125, DOI 10.1016/j.regg.2011.09.003
   Pricola KL, 2009, J CELL BIOCHEM, V108, P577, DOI 10.1002/jcb.22289
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rees DA, 2003, BRIT J PHARMACOL, V140, P764, DOI 10.1038/sj.bjp.0705488
   Roth JA, 1999, J BIOL CHEM, V274, P22041, DOI 10.1074/jbc.274.31.22041
   Schwaninger M, 1997, J NEUROCHEM, V69, P1145
   Siddappa R, 2008, P NATL ACAD SCI USA, V105, P7281, DOI 10.1073/pnas.0711190105
   Sitaraman SV, 2001, J CLIN INVEST, V107, P861, DOI 10.1172/JCI11783
   Suda T, 2003, J CELL BIOCHEM, V88, P259, DOI 10.1002/jcb.10331
   Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378 1119(01)00798 3
   Taliani S, 2013, EUR J MED CHEM, V69, P331, DOI 10.1016/j.ejmech.2013.09.001
   Trincavelli ML, 2014, BBA GEN SUBJECTS, V1840, P1194, DOI 10.1016/j.bbagen.2013.12.021
   Trincavelli ML, 2004, J NEUROCHEM, V91, P1180, DOI 10.1111/j.1471 4159.2004.02793.x
   Valant C, 2012, J MED CHEM, V55, P2367, DOI 10.1021/jm201600e
   Vandesompele J, 2002, ANAL BIOCHEM, V303, P95, DOI 10.1006/abio.2001.5564
   Vazquez JF, 2008, J NEUROCHEM, V105, P904, DOI 10.1111/j.1471 4159.2007.05191.x
   Wei W, 2013, J IMMUNOL, V190, P138, DOI 10.4049/jimmunol.1103721
   Zhang C, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749 799X 5 37
NR 62
TC 38
Z9 43
U1 0
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167 4889
EI 1879 2596
J9 BBA MOL CELL RES
JI Biochim. Biophys. Acta Mol. Cell Res.
PD DEC
PY 2014
VL 1843
IS 12
BP 2957
EP 2966
DI 10.1016/j.bbamcr.2014.09.013
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA AR7UR
UT WOS:000343785700015
PM 25241343
OA Bronze
DA 2025 08 17
ER

PT J
AU Korczak, M
   Roszkowski, P
   Skowronska, W
   Zoldak, KM
   Popowski, D
   Granica, S
   Piwowarski, JP
AF Korczak, Maciej
   Roszkowski, Piotr
   Skowronska, Weronika
   Zoldak, Klaudia M.
   Popowski, Dominik
   Granica, Sebastian
   Piwowarski, Jakub P.
TI Urolithin A conjugation with NSAIDs inhibits its glucuronidation and
   maintains improvement of Caco 2 monolayers' barrier function
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Urolithin A; NSAIDs; Glucuronidation; TEER; Tight junction proteins;
   Next generation sequencing
ID TIGHT JUNCTION; IN VITRO; ELLAGIC ACID; CELL MODELS; PERMEABILITY;
   METABOLISM; CYTOCHROME P450; AUTOPHAGY; TRANSPORT; PATHWAY
AB Urolithin A (UA) is an ellagitannin derived postbiotic metabolite which emerged as a promising health boosting agent, promoting mitophagy, improving skeletal muscle function, and suppressing the inflammatory response. However, phase II intestinal metabolism severely limits its biopotency, leading to the formation of nonactive glucuronides. To address this constraint, a set of new UA derivatives (UADs), conjugated with nonsteroidal antiinflammatory drugs (NSAIDs), was synthesized. The bioavailability and inhibitory activity of UADs against UAglucuronidation were evaluated using differentiated Caco 2 cell monolayers. Parallelly, after the administration of tested substances, the transepithelial electrical resistance (TEER) of the cell monolayers was continuously monitored using the CellZscope device. Though investigated UADs did not penetrate Caco 2 monolayers, all of them significantly suppressed the glucuronidation rate of UA, while conjugates with diclofenac increased the concentration of free molecule on the basolateral side. Moreover, esters of UA with diclofenac (DicloUA) and aspirin (AspUA) positively influenced cell membrane integrity. Western blot analysis revealed that some UADs, including DicloUA, increased the expression of pore sealing tight junction proteins and decreased the level of pore forming claudin 2, which may contribute to their beneficial activity towards the barrier function. To provide comprehensive insight into the mechanism of action of DicloUA, Caco 2 cells were subjected to transcriptomic analysis. Next generation sequencing (NGS) uncovered substantial changes in the expression of genes involved, for instance, in multivesicular body organization and zinc ion homeostasis. The results presented in this study offer new perspectives on the beneficial effects of modifying UA's structure on its intestinal metabolism and bioactivity in vitro.
C1 [Korczak, Maciej; Zoldak, Klaudia M.; Popowski, Dominik; Piwowarski, Jakub P.] Med Univ Warsaw, Microbiota Lab, Warsaw, Poland.
   [Roszkowski, Piotr] Univ Warsaw, Fac Chem, Warsaw, Poland.
   [Skowronska, Weronika; Granica, Sebastian] Med Univ Warsaw, Dept Pharmaceut Microbiol, Warsaw, Poland.
   [Popowski, Dominik] Prof Waclaw Dabrowski Inst Agr & Food Biotechnol S, Dept Food Safety & Chem Anal, Warsaw, Poland.
C3 Medical University of Warsaw; University of Warsaw; Medical University
   of Warsaw
RP Piwowarski, JP (通讯作者)，Med Univ Warsaw, Microbiota Lab, Warsaw, Poland.
EM jakub.piwowarski@wum.edu.pl
RI ; Popowski, Dominik/GLT 5369 2022; Skowrońska, Weronika/JQV 9937 2023
OI Piwowarski, Jakub/0000 0002 5011 0983; Popowski,
   Dominik/0000 0002 4514 4193; Granica, Sebastian/0000 0002 1876 1321;
   Skowronska, Weronika/0000 0002 6960 2152; Korczak,
   Maciej/0000 0002 3594 8673
FU Polish National Science Centre [UMO 2019/35/O/NZ7/00619]
FX Project financially supported by Polish National Science Centre research
   grant Preludium Bis No. UMO 2019/35/O/NZ7/00619.
CR Ahsan A, 2021, ACTA PHARM SIN B, V11, P1708, DOI 10.1016/j.apsb.2020.10.018
   Aleksander SA, 2023, GENETICS, V224, DOI 10.1093/genetics/iyad031
   Avila Gálvez MA, 2018, J AGR FOOD CHEM, V66, P8547, DOI 10.1021/acs.jafc.8b03100
   Giménez Bastida JA, 2020, FOOD CHEM TOXICOL, V139, DOI 10.1016/j.fct.2020.111260
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Bateman A, 2023, NUCLEIC ACIDS RES, V51, pD523, DOI 10.1093/nar/gkac1052
   Bialonska D, 2009, J AGR FOOD CHEM, V57, P10181, DOI 10.1021/jf9025794
   Bjarnason I, 2009, J GASTROENTEROL, V44, P23, DOI 10.1007/s00535 008 2266 6
   Bobowska A, 2021, EUR J NUTR, V60, P1957, DOI 10.1007/s00394 020 02386 y
   Brandon EFA, 2006, TOXICOL APPL PHARM, V211, P1, DOI 10.1016/j.taap.2005.05.004
   Chao GQ, 2021, INFLAMMATION, V44, P1396, DOI 10.1007/s10753 021 01424 z
   Chelakkot C, 2018, EXP MOL MED, V50, DOI 10.1038/s12276 018 0126 x
   Chen SS, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.622744
   Cortés Martín A, 2018, FOOD FUNCT, V9, P4100, DOI [10.1039/c8fo00956b, 10.1039/C8FO00956B]
   D'Amico D, 2021, TRENDS MOL MED, V27, P687, DOI 10.1016/j.molmed.2021.04.009
   Ding XM, 2021, TRENDS FOOD SCI TECH, V107, P455, DOI 10.1016/j.tifs.2020.11.015
   Feng YH, 2018, CELL PHYSIOL BIOCHEM, V49, P190, DOI 10.1159/000492853
   García Villalba R, 2022, MOL NUTR FOOD RES, V66, DOI 10.1002/mnfr.202101019
   Ge SX, 2020, BIOINFORMATICS, V36, P2628, DOI 10.1093/bioinformatics/btz931
   Ghosh S, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.1004603
   Gohari IM, 2019, TOXINS, V11, DOI 10.3390/toxins11100582
   Gong QY, 2022, NEURAL REGEN RES, V17, P2007, DOI 10.4103/1673 5374.335163
   González Sarrías A, 2014, EUR J NUTR, V53, P853, DOI 10.1007/s00394 013 0589 4
   González Sarrías A, 2009, J AGR FOOD CHEM, V57, P5623, DOI 10.1021/jf900725e
   González Sarrías A, 2009, MOL NUTR FOOD RES, V53, P686, DOI 10.1002/mnfr.200800150
   Greene C, 2019, FLUIDS BARRIERS CNS, V16, DOI 10.1186/s12987 019 0123 z
   Groestlinger J, 2022, FRONT NUTR, V9, DOI 10.3389/fnut.2022.882222
   Guo ZR, 2017, ACTA PHARM SIN B, V7, P119, DOI 10.1016/j.apsb.2016.06.003
   Han QA, 2016, MOL NUTR FOOD RES, V60, P1933, DOI 10.1002/mnfr.201500827
   Hasan M, 2018, PHARMACOL RES PERSPE, V6, DOI 10.1002/prp2.417
   He YY, 2021, TOXINS, V13, DOI 10.3390/toxins13020167
   Hering NA, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.610164
   Huo JY, 2023, FOODS, V12, DOI 10.3390/foods12030450
   Huo JY, 2022, FOOD RES INT, V162, DOI 10.1016/j.foodres.2022.112175
   Jarrar YB, 2020, PROSTAG LEUKOTR ESS, V153, DOI 10.1016/j.plefa.2020.102055
   Joo J, 2015, BIOPHARM DRUG DISPOS, V36, P258, DOI 10.1002/bdd.1933
   Komatsu W, 2018, EUR J PHARMACOL, V833, P411, DOI 10.1016/j.ejphar.2018.06.023
   Konsoula R, 2005, TOXICOL IN VITRO, V19, P675, DOI 10.1016/j.tiv.2005.03.006
   Korczak M, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 15870 8
   Koziel MJ, 2021, TOXINS, V13, DOI 10.3390/toxins13110758
   Krug SM, 2014, SEMIN CELL DEV BIOL, V36, P166, DOI 10.1016/j.semcdb.2014.09.002
   Kuo WT, 2022, ANN NY ACAD SCI, V1514, P21, DOI 10.1111/nyas.14798
   Lavis LD, 2008, ACS CHEM BIOL, V3, P203, DOI 10.1021/cb800065s
   Li N, 2004, AM J PHYSIOL GASTR L, V287, pG726, DOI 10.1152/ajpgi.00012.2004
   Lin D, 2022, NAT PRODUCT BIOPROSP, V12, DOI 10.1007/s13659 022 00331 6
   Mazerska Z, 2016, PHARMACOL THERAPEUT, V159, P35, DOI 10.1016/j.pharmthera.2016.01.009
   Monaco A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22147677
   Narai A, 1997, TOXICOL IN VITRO, V11, P347, DOI 10.1016/S0887 2333(97)00026 X
   Newman DJ, 2020, J NAT PROD, V83, P770, DOI 10.1021/acs.jnatprod.9b01285
   Nighot PK, 2015, J BIOL CHEM, V290, P7234, DOI 10.1074/jbc.M114.597492
   Palomo L, 2018, HEPATOL COMMUN, V2, P1064, DOI 10.1002/hep4.1210
   Piwowarski JP, 2014, J ETHNOPHARMACOL, V155, P801, DOI 10.1016/j.jep.2014.06.032
   Popowski D, 2021, J ETHNOPHARMACOL, V274, DOI 10.1016/j.jep.2021.114053
   Prot Bertoye C, 2020, GENES BASEL, V11, DOI 10.3390/genes11030290
   Ryu D, 2016, NAT MED, V22, P879, DOI 10.1038/nm.4132
   Saha K, 2023, J CROHNS COLITIS, V17, P433, DOI 10.1093/ecco jcc/jjac148
   Sahashi H, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.963314
   Seo GS, 2014, BIOCHEM PHARMACOL, V90, P115, DOI 10.1016/j.bcp.2014.05.006
   Shao YX, 2017, J NUTR, V147, P1282, DOI 10.3945/jn.116.243238
   Shao YX, 2017, J NUTR BIOCHEM, V43, P18, DOI 10.1016/j.jnutbio.2017.01.013
   Singh R, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 018 07859 7
   Srinivasan B, 2015, JALA J LAB AUTOM, V20, P107, DOI 10.1177/2211068214561025
   Tantishaiyakul V, 2002, PHARMACEUT RES, V19, P1013, DOI 10.1023/A:1016470523923
   Tu HJ, 2023, J FOOD DRUG ANAL, V31, P358, DOI 10.38212/2224 6614.3462
   Van Itallie CM, 2014, SEMIN CELL DEV BIOL, V36, P157, DOI 10.1016/j.semcdb.2014.08.011
   Venugopal S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225655
   Wang DW, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.1051497
   Wang XL, 2023, REDOX BIOL, V59, DOI 10.1016/j.redox.2022.102590
   Xiao Y, 2022, MOL NUTR FOOD RES, V66, DOI 10.1002/mnfr.202100863
   Youhanna S, 2021, J PHARM SCI US, V110, P50, DOI 10.1016/j.xphs.2020.07.001
   Zaal EA, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00500
   Zhang MW, 2023, CRIT REV FOOD SCI, V63, P6900, DOI 10.1080/10408398.2022.2036693
NR 72
TC 1
Z9 1
U1 1
U2 8
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD DEC 31
PY 2023
VL 169
AR 115932
DI 10.1016/j.biopha.2023.115932
EA NOV 2023
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA CL1W6
UT WOS:001125325900001
PM 38000358
OA gold
DA 2025 08 17
ER

PT J
AU Xu, Q
   Zhang, XM
   Duan, KZ
   Gu, XY
   Han, M
   Liu, BL
   Zhao, ZQ
   Zhang, YQ
AF Xu, Qian
   Zhang, Xiao Meng
   Duan, Kai Zheng
   Gu, Xi Yao
   Han, Mei
   Liu, Ben Long
   Zhao, Zhi Qi
   Zhang, Yu Qiu
TI Peripheral TGF β1 Signaling Is a Critical Event in Bone Cancer Induced
   Hyperalgesia in Rodents
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE bone cancer pain; dorsal root ganglion; patch clamp; thermal
   hyperalgesia; TGF beta; TRPV1
ID GROWTH FACTOR BETA; PRIMARY SENSORY NEURONS; ROOT GANGLION NEURONS;
   PROTEIN KINASE C; GENE RELATED PEPTIDE; TGF BETA; CAPSAICIN RECEPTOR;
   TRANSFORMING GROWTH FACTOR BETA 1; PKC EPSILON; RAT MODEL
AB Pain is the most common symptom of bone cancer. TGF beta, a major bone derived growth factor, is largely released by osteoclast bone resorption during the progression of bone cancer and contributes to proliferation, angiogenesis, immunosuppression, invasion, and metastasis. Here, we further show that TGF beta 1 is critical for bone cancer induced pain sensitization. We found that, after the progression of bone cancer, TGF beta 1 was highly expressed in tumor bearing bone, and the expression of its receptors, TGF beta RI and TGF beta RII, was significantly increased in the DRG in a rat model of bone cancer pain that is based on intratibia inoculation of Walker 256 mammary gland carcinoma cells. The blockade of TGF beta receptors by the TGF beta RI antagonist SD 208 robustly suppressed bone cancer induced thermal hyperalgesia on post tumor day 14 (PTD 14). Peripheral injection of TGF beta 1 directly induced thermal hyperalgesia in intact rats and wide type mice, but not in Trpv1( / ) mice. Whole cell patch clamp recordings from DRG neurons showed that transient receptor potential vanilloid (TRPV1) sensitivity was significantly enhanced on PTD 14. Extracellular application of TGF beta 1 significantly potentiated TRPV1 currents and increased [Ca2+](i) in DRG neurons. Pharmacological studies revealed that the TGF beta 1 sensitization of TRPV1 and the induction of thermal hyperalgesia required the TGF beta R mediated Smad independent PKC epsilon and TGF beta activating kinase 1 p38 pathways. These findings suggest that TGF beta 1 signaling contributes to bone cancer pain via the upregulation and sensitization of TRPV1 in primary sensory neurons and that therapeutic targeting of TGF beta 1 may ameliorate the bone cancer pain in advanced cancer.
C1 Fudan Univ, Inst Neurobiol, Inst Brain Sci, Shanghai 200032, Peoples R China.
   Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China.
C3 Fudan University; Fudan University
RP Zhang, YQ (通讯作者)，Fudan Univ, Inst Neurobiol, 1202 Mingdao Bldg,131 Dong An Rd, Shanghai 200032, Peoples R China.
EM yuqiuzhang@fudan.edu.cn
RI ; Gu, xiyao/ADA 0821 2022; Zhang, Xuegong/ABG 9911 2022
OI Gu, xiyao/0000 0003 1203 9298; Duan, Kaizheng/0000 0003 3248 6722
FU National Basic Research Program of China [2013CB531900]; National
   Natural Science Foundation of China [31121061, 31271183, 31070973]
FX This work was supported by the National Basic Research Program of China
   (2013CB531900) and the National Natural Science Foundation of China
   (31121061, 31271183, and 31070973).
CR Adami S, 1997, CANCER, V80, P1674, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1674::AID CNCR18>3.0.CO;2 X
   Ai XB, 1999, MOL CELL NEUROSCI, V14, P506, DOI 10.1006/mcne.1999.0798
   Ananth S, 1999, CANCER RES, V59, P2210
   Bandyopadhyay A, 2006, CANCER RES, V66, P6714, DOI 10.1158/0008 5472.CAN 05 3565
   Bhave G, 2003, P NATL ACAD SCI USA, V100, P12480, DOI 10.1073/pnas.2032100100
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807
   Cesare P, 1999, NEURON, V23, P617, DOI 10.1016/S0896 6273(00)80813 2
   Dallas SL, 2002, J BIOL CHEM, V277, P21352, DOI 10.1074/jbc.M111663200
   de Caestecker M, 2004, CYTOKINE GROWTH F R, V15, P1, DOI 10.1016/j.cytogfr.2003.10.004
   Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006
   Duan KZ, 2012, PAIN, V153, P562, DOI 10.1016/j.pain.2011.11.020
   Echeverry S, 2009, MOL PAIN, V5, DOI 10.1186/1744 8069 5 16
   Ghilardi JR, 2005, J NEUROSCI, V25, P3126, DOI 10.1523/JNEUROSCI.3815 04.2005
   GRIFFITHS JR, 1991, BRIT J CANCER, V64, P425, DOI 10.1038/bjc.1991.326
   Hamamoto DT, 2008, J NEUROPHYSIOL, V100, P2300, DOI 10.1152/jn.01337.2007
   Han Y, 2012, NEUROSCI BULL, V28, P165, DOI 10.1007/s12264 012 1211 0
   Hering S, 2001, EXP CLIN ENDOCR DIAB, V109, P217, DOI 10.1055/s 2001 15109
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   Juárez P, 2011, BONE, V48, P23, DOI 10.1016/j.bone.2010.08.004
   Kawamata T, 2010, J ANESTH, V24, P328, DOI 10.1007/s00540 010 0919 0
   Krieglstein K, 2011, TRENDS NEUROSCI, V34, P421, DOI 10.1016/j.tins.2011.06.002
   Lantero A, 2012, MOL NEUROBIOL, V45, P76, DOI 10.1007/s12035 011 8221 1
   Massagué J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Mohammad KS, 2011, CANCER RES, V71, P175, DOI 10.1158/0008 5472.CAN 10 2651
   Mu YB, 2012, CELL TISSUE RES, V347, P11, DOI 10.1007/s00441 011 1201 y
   Mulsow JJW, 2005, ANN SURG, V242, P880, DOI 10.1097/01.sla.0000189606.58343.cd
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234
   Nagaraj NS, 2010, EXPERT OPIN INV DRUG, V19, P77, DOI 10.1517/13543780903382609
   Niiyama Y, 2007, NEUROSCIENCE, V148, P560, DOI 10.1016/j.neuroscience.2007.05.049
   Niiyama Y, 2009, BRIT J ANAESTH, V102, P251, DOI 10.1093/bja/aen347
   Numazaki M, 2002, J BIOL CHEM, V277, P13375, DOI 10.1074/jbc.C200104200
   Pan HL, 2010, MOL PAIN, V6, DOI 10.1186/1744 8069 6 85
   Rowland Goldsmith MA, 2002, MOL CANCER THER, V1, P161
   Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896 6273(00)80564 4
   Tramullas M, 2010, J NEUROSCI, V30, P1502, DOI 10.1523/JNEUROSCI.2584 09.2010
   Utreras E, 2012, J BIOL CHEM, V287, P16917, DOI 10.1074/jbc.M111.329979
   Vulchanova L, 2010, MOL PAIN, V6, DOI 10.1186/1744 8069 6 31
   Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765
   Xu P, 2005, J NEUROSCI, V25, P9227, DOI 10.1523/JNEUROSCI.3051 05.2005
   Zhang H, 2007, J NEUROSCI, V27, P12067, DOI 10.1523/JNEUROSCI.0496 07.2007
   Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328
   Zhou Y, 2003, J NEUROCHEM, V85, P571, DOI 10.1046/j.1471 4159.2003.01675.x
   Zhu WG, 2007, J NEUROSCI, V27, P13770, DOI 10.1523/JNEUROSCI.3822 07.2007
   Zhu WG, 2007, MOL CELL NEUROSCI, V34, P689, DOI 10.1016/j.mcn.2007.01.005
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304 3959(83)90201 4
NR 47
TC 62
Z9 65
U1 0
U2 22
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270 6474
J9 J NEUROSCI
JI J. Neurosci.
PD DEC 4
PY 2013
VL 33
IS 49
BP 19099
EP 19111
DI 10.1523/JNEUROSCI.4852 12.2013
PG 13
WC Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA 267PO
UT WOS:000328110100007
PM 24305807
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Wang, XD
   Yu, YY
   Lieu, S
   Yang, F
   Lang, J
   Lu, CY
   Werb, Z
   Hu, D
   Miclau, T
   Marcucio, R
   Colnot, C
AF Wang, Xiaodong
   Yu, Yan Yiu
   Lieu, Shirley
   Yang, Frank
   Lang, Jeffrey
   Lu, Chuanyong
   Werb, Zena
   Hu, Diane
   Miclau, Theodore
   Marcucio, Ralph
   Colnot, Celine
TI MMP9 regulates the cellular response to inflammation after skeletal
   injury
SO BONE
LA English
DT Article
DE Fracture repair; Periosteum; Macrophage; Matrix metalloproteinase;
   Mechanical environment; Mouse models
ID MESENCHYMAL STEM CELLS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS;
   BONE FORMATION; FRACTURE REPAIR; INTRAMEMBRANOUS OSSIFICATION; MATRIX
   METALLOPROTEINASE 2; GENE EXPRESSION; HOST ORIGIN; MARROW; ABSENCE
AB Like other tissue injuries, bone fracture triggers an inflammatory response, which plays an important role in skeletal repair. Inflammation is believed to have both positive and negative effects on bone repair, but the underlying cellular mechanisms are not well understood. To assess the role of inflammation on skeletal cell differentiation, we used mouse models of fracture repair that stimulate either intramembranous or endochondral ossification. In the first model, fractures are rigidly stabilized leading to direct bone formation, while in the second model, fracture instability causes cartilage and bone formation. We compared the inflammatory response in these two mechanical environments and found changes in the expression patterns of inflammatory genes and in the recruitment of inflammatory cells and osteoclasts. These results suggested that the inflammatory response could influence skeletal cell differentiation after fracture. We then exploited matrix metalloproteinase 9 (MMP9) that is expressed in inflammatory cells and osteoclasts, and which we previously showed is a potential regulator of cell fate decisions during fracture repair. Mnip9( / ) mice heal stabilized fractures via endochondral ossification, while wild type mice heal via intramembranous ossification. In parallel, we observed increases in macrophages and T cells in the callus of Mmp9( / ) compared to wild type mice. To assess the link between the profile of inflammatory cells and skeletal cell fate functionally, we transplanted Mnip9( / ) mice with wild type bone marrow, to reconstitute a wild type hematopoietic lineage in interaction with the Mnip9( / ) stroma and periosteum. Following transplantation, Mmp9( / ) mice healed stabilized fractures via intramembranous ossification and exhibited a normal profile of inflammatory cells. Moreover, Mmp9( / ) periosteal grafts healed via intramembranous ossification in wild type hosts, but healed via endochondral ossification in Mmp9( / ) hosts. We observed that macrophages accumulated at the periosteal surface in Mmp9( / ) mice, suggesting that cell differentiation in the periosteum is influenced by factors such as BMP2 that are produced locally by inflammatory cells. Taken together, these results show that MMP9 mediates indirect effects on skeletal cell differentiation by regulating the inflammatory response and the distribution of inflammatory cells, leading to the local regulation of periosteal cell differentiation. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Colnot, Celine] Univ Paris Descartes Sorbonne Paris Cite, INSERM U781, Inst Imagine, Hop Necker Enfants Malad, F 75015 Paris, France.
   [Wang, Xiaodong; Yu, Yan Yiu; Lieu, Shirley; Yang, Frank; Lang, Jeffrey; Lu, Chuanyong; Hu, Diane; Miclau, Theodore; Marcucio, Ralph; Colnot, Celine] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA USA.
   [Werb, Zena] Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Necker Enfants Malades   APHP; University of
   California System; University of California San Francisco; University of
   California System; University of California San Francisco
RP Colnot, C (通讯作者)，Univ Paris Descartes Sorbonne Paris Cite, INSERM U781, Inst Imagine, Hop Necker Enfants Malad, Tour Lavoisier 2Eme Etage,149 Rue Sevres, F 75015 Paris, France.
EM celine.colnot@inserm.fr
RI ; Colnot, Celine/D 4997 2017
OI Marcucio, Ralph/0000 0002 0537 818X; colnot, celine/0000 0001 8423 8718
FU NIH NIAMS [R01 AR053645, R01 AR057344]; INSERM; ATIP AVENIR; Marie Curie
   International Reintegration grant [R01 AR046238, R01 CA057621]
FX This work was funded by NIH NIAMS R01 AR053645 to TM, R01 AR057344 to CC
   and TM, INSERM ATIP AVENIR and Marie Curie International Reintegration
   grant to CC, R01 AR046238 and R01 CA057621 to ZW. Microarray analysis
   was performed at the UCSF Lung Biology Microarray Core Facility. We
   thank Jesse Shantz for help with statistical analyses.
CR Abdul Hadi O, 2009, J BONE JOINT SURG AM, V91A, P2020
   Alblowi J, 2009, AM J PATHOL, V175, P1574, DOI 10.2353/ajpath.2009.090148
   Alexander KA, 2011, J BONE MINER RES, V26, P1517, DOI 10.1002/jbmr.354
   Behonick DJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001150
   Chang JK, 2006, TOXICOLOGY, V228, P111, DOI 10.1016/j.tox.2006.08.028
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Cho TJ, 2002, J BONE MINER RES, V17, P513, DOI 10.1359/jbmr.2002.17.3.513
   Claes L, 2012, NAT REV RHEUMATOL, V8, P133, DOI 10.1038/nrrheum.2012.1
   Claes L, 2011, ACTA ORTHOP, V82, P223, DOI 10.3109/17453674.2011.570677
   Colburn NT, 2009, ARTHRITIS RHEUM US, V60, P1694, DOI 10.1002/art.24520
   Colnot C, 2006, BIOCHEM BIOPH RES CO, V350, P557, DOI 10.1016/j.bbrc.2006.09.079
   Colnot C, 2003, DEVELOPMENT, V130, P4123, DOI 10.1242/dev.00559
   Colnot C, 2012, J ORTHOP RES
   Colnot C, 2009, J BONE MINER RES, V24, P274, DOI 10.1359/JBMR.081003
   Colnot CI, 2001, MECH DEVELOP, V100, P245, DOI 10.1016/S0925 4773(00)00532 3
   Corry DB, 2004, FASEB J, V18, P995, DOI 10.1096/fj.03 1412fje
   Dan H, 2009, J ANIM SCI, V87, P3544, DOI 10.2527/jas.2009 2068
   Einhorn TA, 1998, CLIN ORTHOP RELAT R, pS7
   EINHORN TA, 1995, J BONE MINER RES, V10, P1272
   Esparza J, 2004, FASEB J, V18, P1682, DOI 10.1096/fj.04 2445com
   Gerstenfeld LC, 2003, J BONE MINER RES, V18, P1584, DOI 10.1359/jbmr.2003.18.9.1584
   Gerstenfeld LC, 2001, CELLS TISSUES ORGANS, V169, P285, DOI 10.1159/000047893
   Giordano A, 2007, J CELL PHYSIOL, V211, P27, DOI 10.1002/jcp.20959
   Granero Moltó F, 2009, STEM CELLS, V27, P1887, DOI 10.1002/stem.103
   Greenlee KJ, 2006, J IMMUNOL, V177, P7312, DOI 10.4049/jimmunol.177.10.7312
   Gutiérrez Fernández A, 2007, FASEB J, V21, P2580, DOI 10.1096/fj.06 7860com
   Hankemeier S, 2001, J ORTHOP RES, V19, P531, DOI 10.1016/S0736 0266(00)00044 9
   Heiner DE, 2006, J ORTHOP TRAUMA, V20, P27, DOI 10.1097/01.bot.0000184143.90448.aa
   Hsu JYC, 2006, J NEUROSCI, V26, P9841, DOI 10.1523/JNEUROSCI.1993 06.2006
   Huang CY, 2010, FASEB J, V24, P3625, DOI 10.1096/fj.10 157370
   Huang Y, 2012, J ORTHOP RES, V30, P304, DOI 10.1002/jor.21505
   Kan LX, 2009, STEM CELLS, V27, P150, DOI 10.1634/stemcells.2008 0576
   Karamichos D, 2008, J TISSUE ENG REGEN M, V2, P97, DOI 10.1002/term.69
   Le AX, 2001, J ORTHOPAED RES, V19, P78, DOI 10.1016/S0736 0266(00)00006 1
   Lieu S, 2011, DIS MODEL MECH, V4, P203, DOI 10.1242/dmm.006304
   Lu CY, 2011, J ORTHOP TRAUMA, V25, P494, DOI 10.1097/BOT.0b013e31822511e0
   Lu CY, 2005, J ORTHOP RES, V23, P1300, DOI 10.1016/j.orthres.2005.04.003
   McBride SH, 2011, ANN BIOMED ENG, V39, P1570, DOI 10.1007/s10439 010 0242 9
   Miclau T, 2007, J ORTHOP RES, V25, P1552, DOI 10.1002/jor.20435
   Mountziaris PM, 2011, TISSUE ENG PART B RE, V17, P393, DOI [10.1089/ten.teb.2011.0182, 10.1089/ten.TEB.2011.0182]
   Ortega N, 2010, DIS MODEL MECH, V3, P224, DOI 10.1242/dmm.004226
   Palomares KTS, 2009, J ORTHOP RES, V27, P1123, DOI 10.1002/jor.20863
   Pape HC, 2010, J ORTHOP TRAUMA, V24, P522, DOI 10.1097/BOT.0b013e3181ed1361
   Radi ZA, 2009, TOXICOL PATHOL, V37, P34, DOI 10.1177/0192623308329474
   Recknagel S, 2011, J ORTHOP RES, V29, P734, DOI 10.1002/jor.21299
   Reif S, 2005, DIGESTION, V71, P124, DOI 10.1159/000084626
   Rieger K, 2005, EXP HEMATOL, V33, P605, DOI 10.1016/j.exphem.2005.02.004
   Rosen V, 2011, TISSUE ENG PART B RE, V17, P475, DOI [10.1089/ten.teb.2011.0265, 10.1089/ten.TEB.2011.0265]
   Rundle CH, 2006, BONE, V38, P521, DOI 10.1016/j.bone.2005.09.015
   Satija NK, 2009, J CELL MOL MED, V13, P4385, DOI 10.1111/j.1582 4934.2009.00857.x
   Sibai T, 2011, CLIN ORTHOP RELAT R, V469, P2215, DOI 10.1007/s11999 010 1722 9
   SIMMONS PJ, 1987, NATURE, V328, P429, DOI 10.1038/328429a0
   Simon AM, 2007, J BONE JOINT SURG AM, V89A, P500, DOI 10.2106/JBJS.F.00127
   Stickens D, 2004, DEVELOPMENT, V131, P5883, DOI 10.1242/dev.01461
   Thompson Z, 2002, J ORTHOPAED RES, V20, P1091, DOI 10.1016/S0736 0266(02)00017 7
   Toben D, 2011, J BONE MINER RES, V26, P113, DOI 10.1002/jbmr.185
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Ulivi V, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3367
   Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400
   Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092 8674(00)81169 1
   Wang Q, 2011, BONE, V48, P524, DOI 10.1016/j.bone.2010.10.178
   Wang Q, 2010, AM J PATHOL, V177, P3100, DOI 10.2353/ajpath.2010.100060
   Wixted JJ, 2009, J CELL PHYSIOL, V221, P31, DOI 10.1002/jcp.21809
   Xie C, 2008, BONE, V43, P1075, DOI 10.1016/j.bone.2008.08.109
   Xing ZQ, 2010, J ORTHOP RES, V28, P1000, DOI 10.1002/jor.21087
   Xing ZQ, 2010, DIS MODEL MECH, V3, P451, DOI 10.1242/dmm.003186
   Yu YY, 2010, BONE, V47, P65, DOI 10.1016/j.bone.2010.03.012
   Yu YY, 2010, BONE, V46, P841, DOI 10.1016/j.bone.2009.11.005
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 69
TC 88
Z9 100
U1 0
U2 22
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JAN
PY 2013
VL 52
IS 1
BP 111
EP 119
DI 10.1016/j.bone.2012.09.018
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 060BK
UT WOS:000312750700013
PM 23010105
OA Green Accepted, Green Published
DA 2025 08 17
ER

PT J
AU Wang, N
   Li, JY
   Song, H
   Liu, C
   Hu, HG
   Liao, HL
   Cong, W
AF Wang, Nan
   Li, Jingyang
   Song, Hui
   Liu, Chao
   Hu, Honggang
   Liao, Hongli
   Cong, Wei
TI Synthesis and anti osteoporosis activity of novel Teriparatide
   glycosylation derivatives
SO RSC ADVANCES
LA English
DT Article
ID ANTIBACTERIAL ACTIVITIES; GLYCOPEPTIDE; TYROCIDINE; THERAPY
AB Osteoporosis is a metabolic bone disease that is characterized by low bone mass and micro architectural deterioration of bones. The mechanism underlying this disease implicates an imbalance between bone resorption and bone remodeling. In 2002, the US Food and Drug Administration (FDA) approved Teriparatide for the treatment of osteoporosis, and so far, this compound is the only permitted osteoanabolic. However, as a structurally flexible linear peptide, this drug may be further optimized. In this study, we develop a series of novelN acetyl glucosamine glycosylation derivatives of Teriparatide and examine their characteristics. Of the analyzed compounds, PTHG 9 exhibits enhanced helicity, greater protease stability, and increased osteoblast differentiation promoting ability compared with the original Teriparatide. Accordingly, PTHG 9 is suggested as a therapeutic candidate for postmenopausal osteoporosis (PMOP) and other related diseases. The successful development of an enhanced osteoporosis drug proves that the method proposed herein can be used to effectively enhance the chemical and biological properties of linear peptides with various biological functions.
C1 [Wang, Nan; Song, Hui; Liu, Chao; Hu, Honggang; Cong, Wei] Shanghai Univ, Inst Translat Med, Shanghai, Peoples R China.
   [Li, Jingyang] Shanghai Jiaa Tong Univ, Xinhua Hosp, Dept Pediat Resp Med, Sch Med, Shanghai, Peoples R China.
   [Liao, Hongli] Chengdu Med Coll, Sch Pharm, Chengdu, Peoples R China.
C3 Shanghai University; Chengdu Medical College
RP Cong, W (通讯作者)，Shanghai Univ, Inst Translat Med, Shanghai, Peoples R China.; Liao, HL (通讯作者)，Chengdu Med Coll, Sch Pharm, Chengdu, Peoples R China.
EM liaohl213@126.com; viviencong@shu.edu.cn
OI Hu, Hong Gang/0000 0003 0577 3021; Wang, Nan/0000 0002 1011 4509
FU Key R & D Projects of Science and Technology Department of Sichuan
   Province [2019YFS0097]; Science and Technology Project of Nantong, China
   [MS22019026]; National Natural Science Foundation of China [91849129,
   81703526, 41806088]
FX We thank LetPub for its linguistic assistance during the preparation of
   this manuscript. We are grateful to the Key R & D Projects of Science
   and Technology Department of Sichuan Province (2019YFS0097), the Science
   and Technology Project of Nantong, China (MS22019026), the National
   Natural Science Foundation of China (No. 91849129, No. 81703526 and No.
   41806088) and instrumental analysis centre of Second Military Medical
   University for NMR spectroscopic and mass spectrometric analyses.
CR Baron R, 2012, NAT REV ENDOCRINOL, V8, P76, DOI 10.1038/nrendo.2011.207
   Chen JS, 2012, NAT REV ENDOCRINOL, V8, P81, DOI 10.1038/nrendo.2011.146
   Chtioui H, 2011, NEW ENGL J MED, V364, P1081, DOI 10.1056/NEJMc1100730
   Diaz R., 2012, NAT REV ENDOCRINOL, V8, P255
   Ding LL, 2020, OSTEOPOROSIS INT, V31, P961, DOI 10.1007/s00198 019 05183 4
   Farooki A, 2007, NEW ENGL J MED, V357, P2410, DOI 10.1056/NEJMc076405
   Greenfield NJ, 2006, NAT PROTOC, V1, P2876, DOI 10.1038/nprot.2006.202
   Heath V., 2010, NEW ENGL J MED, V363, P2396
   Hu HG, 2009, J MED CHEM, V52, P2052, DOI 10.1021/jm801577r
   Kraenzlin ME, 2011, NAT REV ENDOCRINOL, V7, P647, DOI 10.1038/nrendo.2011.108
   Li YL, 2019, ACS CHEM BIOL, V14, P516, DOI 10.1021/acschembio.9b00046
   Liu C, 2018, EUR J MED CHEM, V145, P661, DOI 10.1016/j.ejmech.2018.01.022
   Mourtada R, 2019, NAT BIOTECHNOL, V37, P1186, DOI 10.1038/s41587 019 0222 z
   Premdjee B, 2011, BIOORG MED CHEM LETT, V21, P4973, DOI 10.1016/j.bmcl.2011.05.059
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Silva BC, 2011, ANNU REV MED, V62, P307, DOI 10.1146/annurev med 061709 145401
   Sun P, 2020, BIOCHEM BIOPH RES CO, V525, P850, DOI 10.1016/j.bbrc.2020.02.177
   Tan YS, 2016, DRUG DISCOV TODAY, V21, P1642, DOI 10.1016/j.drudis.2016.06.012
   Tegola Luciana La, 2018, J Frailty Sarcopenia Falls, V3, P138, DOI 10.22540/JFSF 03 138
   Toonstra C, 2016, J ORG CHEM, V81, P6176, DOI 10.1021/acs.joc.6b01044
   Wang D, 2006, J AM CHEM SOC, V128, P9248, DOI 10.1021/ja062710w
   Wu Q., 2020, J CLIN MED, V9, P1
   Wysocki A, 2011, ANN INTERN MED, V155, P680, DOI 10.7326/0003 4819 155 10 201111150 00006
   Zamani M, 2018, ARCH OSTEOPOROS, V13, DOI 10.1007/s11657 018 0540 7
   Zou Y, 2015, J PEPT SCI, V21, P586, DOI 10.1002/psc.2774
NR 25
TC 9
Z9 10
U1 1
U2 32
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046 2069
J9 RSC ADV
JI RSC Adv.
PD JUL 8
PY 2020
VL 10
IS 43
BP 25730
EP 25735
DI 10.1039/d0ra05136e
PG 6
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA MQ4CV
UT WOS:000552843400036
PM 35518599
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wong, AK
   Schönmeyr, BH
   Soares, MA
   Li, S
   Mehrara, BJ
AF Wong, Alex K.
   Schonmeyr, Bjoern H.
   Soares, Marc A.
   Li, Sen
   Mehrara, Babak J.
TI Hyperbaric oxygen inhibits growth but not differentiation of normal and
   irradiated osteoblasts
SO JOURNAL OF CRANIOFACIAL SURGERY
LA English
DT Article
DE osteoblast; hyperbaric oxygen; ionizing radiation; osteoradionecrosis;
   cell cycle; apoptosis; differentiation; microarray
ID IONIZING RADIATION; IN VITRO; VEGF EXPRESSION; CANCER CELLS; BONE;
   THERAPY; APOPTOSIS; PROLIFERATION; TRIAL; LINE
AB Hyperbaric oxygen (HBO) therapy is used in the treatment of osteoradionecrosis. Although HBO is thought to improve radiation induced hypocellularity and bone tissue hypoxia, the precise effects of HBO on bone cells such as osteoblasts have not been described. In this study, our goal was to assess the effect of HBO on irradiated and nonirradiated primary osteoblast cultures and assess for changes in growth, apoptosis, cell cycle profile, differentiation, and gene expression. We found that daily HBO treatments caused a 24% decrease in cell growth after 9 days in culture. Hyperbaric oxygen negatively affects growth by inducing osteoblast apoptosis and cell cycle arrest Hyperbaric oxygen leads to G1/S cell cycle arrest in unirradiated osteoblasts where as it causes G2/M arrest in cells that were previously irradiated with either 7 or 12 Gy of ionizing radiation. Although radiation was shown to have a dose dependent inhibitory effect on early osteoblast differentiation as measured by alkaline phosphatase activity, HBO did not have a significant effect on osteoblast differentiation. Microarray analysis revealed that exposure to HBO leads to a differential expression of a variety of gene families including stress response pathways. In summary, although successive daily HBO treatments resulted in growth delay, osteoblast function as measured by the ability to produce alkaline phosphatase was not significantly affected. These data suggest that HBO does not have any positive effects on either normal or radiation damaged osteoblasts in vitro.
C1 [Wong, Alex K.] Univ Pittsburgh, Sch Med, Div Plast & Reconstruct Surg, Pittsburgh, PA USA.
   [Schonmeyr, Bjoern H.; Soares, Marc A.; Li, Sen; Mehrara, Babak J.] Mem Sloan Kettering Canc Ctr, Dept Surg, Plast & Reconstruct Serv, New York, NY 10021 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Memorial Sloan Kettering Cancer Center
RP Mehrara, BJ (通讯作者)，1275 York Ave,Room MRI 1006, New York, NY 10021 USA.
EM mehrarab@mskcc.org
CR Annane D, 2004, J CLIN ONCOL, V22, P4893, DOI 10.1200/JCO.2004.09.006
   Calvert JW, 2002, BRAIN RES, V951, P1, DOI 10.1016/S0006 8993(02)03094 9
   Chae HU, 1999, J RADIAT RES, V40, P323, DOI 10.1269/jrr.40.323
   Chen YC, 2007, LEUKEMIA RES, V31, P805, DOI 10.1016/j.leukres.2006.09.016
   Conconi MT, 2003, J INVEST MED, V51, P227, DOI 10.1136/jim 51 04 24
   Dare A, 1997, J DENT RES, V76, P658, DOI 10.1177/00220345970760020601
   Dimitrijevich SD, 1999, WOUND REPAIR REGEN, V7, P53
   Dudziak ME, 2000, PLAST RECONSTR SURG, V106, P1049, DOI 10.1097/00006534 200010000 00015
   Fujii J, 2002, REDOX REP, V7, P123, DOI 10.1179/135100002125000352
   Ganguly BJ, 2002, APOPTOSIS, V7, P499, DOI 10.1023/A:1020686908831
   Granowitz EV, 2005, ANTICANCER RES, V25, P3833
   Hollander Dirk A., 2000, Cell and Tissue Banking, V1, P261, DOI 10.1023/A:1010145312698
   Jereczek Fossa BA, 2002, CANCER TREAT REV, V28, P65, DOI 10.1053/ctrv.2002.0254
   Kalns JE, 1999, IN VITRO CELL DEV AN, V35, P98
   Kang Thomas S, 2004, Arch Facial Plast Surg, V6, P31, DOI 10.1001/archfaci.6.1.31
   MARX RE, 1990, AM J SURG, V160, P519, DOI 10.1016/S0002 9610(05)81019 0
   MARX RE, 1985, J AM DENT ASSOC, V111, P49, DOI 10.14219/jada.archive.1985.0074
   Mehrara BJ, 1999, J BONE MINER RES, V14, P1290, DOI 10.1359/jbmr.1999.14.8.1290
   Mody N, 2001, FREE RADICAL BIO MED, V31, P509, DOI 10.1016/S0891 5849(01)00610 4
   Muhonen A, 2004, INT J ORAL MAX SURG, V33, P173, DOI 10.1054/ijom.2003.0489
   NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022 1759(91)90198 O
   Park JH, 2002, MOL CELL ENDOCRINOL, V192, P197, DOI 10.1016/S0303 7207(02)00036 9
   Pasquier D, 2004, RADIOTHER ONCOL, V72, P1, DOI 10.1016/j.radonc.2004.04.005
   Ratisoontorn C, 2005, BONE, V36, P627, DOI 10.1016/j.bone.2005.01.010
   ROBERTS GP, 1994, BRIT J DERMATOL, V131, P630, DOI 10.1111/j.1365 2133.1994.tb04973.x
   Salim A, 2004, J BIOL CHEM, V279, P40007, DOI 10.1074/jbc.M403715200
   Sawai T, 1996, J ORAL MAXIL SURG, V54, P975, DOI 10.1016/S0278 2391(96)90396 1
   Steinbrech DS, 1999, PLAST RECONSTR SURG, V104, P738, DOI 10.1097/00006534 199909030 00019
   Steinbrech DS, 2000, AM J PHYSIOL CELL PH, V278, pC853, DOI 10.1152/ajpcell.2000.278.4.C853
   Szymczyk KH, 2004, BONE, V34, P148, DOI 10.1016/j.bone.2003.09.003
   Tibbles PM, 1996, NEW ENGL J MED, V334, P1642, DOI 10.1056/NEJM199606203342506
   Tompach PC, 1997, INT J ORAL MAX SURG, V26, P82, DOI 10.1016/S0901 5027(05)80632 0
   TUNCAY OC, 1994, AM J ORTHOD DENTOFAC, V105, P457, DOI 10.1016/S0889 5406(94)70006 0
   Utting JC, 2006, EXP CELL RES, V312, P1693, DOI 10.1016/j.yexcr.2006.02.007
   Wang X, 1998, INT J RADIAT ONCOL, V40, P189
   Warren SM, 2001, J SURG RES, V99, P147, DOI 10.1006/jsre.2001.6128
NR 36
TC 13
Z9 15
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106 3621 USA
SN 1049 2275
J9 J CRANIOFAC SURG
JI J. Craniofac. Surg.
PD MAY
PY 2008
VL 19
IS 3
BP 757
EP 765
DI 10.1097/SCS.0b013e31816aac19
PG 9
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery
GA 306JV
UT WOS:000256245100034
PM 18520395
DA 2025 08 17
ER

PT J
AU Zhao, HY
   Cai, WS
   Li, S
   Da, ZK
   Sun, HX
   Ma, L
   Lin, YX
   Zhi, DB
AF Zhao, Hongyu
   Cai, Weisong
   Li, Shuai
   Da, Zuke
   Sun, Hanxue
   Ma, Liang
   Lin, Yaoxin
   Zhi, Debao
TI Characterization of neuroblastoma bone invasion/metastasis in
   established bone metastatic model of SY5Y and KCNR cell lines
SO CHILDS NERVOUS SYSTEM
LA English
DT Article
DE Neuroblastoma; Bone invasion/metastasis; Osteolytic response;
   Invasion/metastasis related factors
ID PROGNOSTIC VALUE; MECHANISMS; TUMOR; INVASION; BIOLOGY; SYSTEM; ACID
AB To determine the mechanism of neuroblastoma (NB) bone invasion/metastasis, it is necessary to investigate the bone invasion/metastasis related factors in the bone invasion/metastasis process. Some evidence has suggested that various proteins were involved in bone osteolytic response. The invasion/metastasis property and gene expression of NB, however, are still unknown.
   Single cell suspensions of SY5Y and KCNR cells were injected directly into the femur of nude mice. Radiological and histological analyses, immunohistochemistry analyses, and western blot assay were performed to characterize bone metastasis mechanism in these bone metastasis models.
   SY5Y and KCNR NB cells result in osteolytic responses in bone metastasis model. Osteoprotegerin (OPG), receptor activator of NF kappaB ligand (RANKL), parathyroid hormone related peptide (PTHrP), endothelin 1 (ET 1), and CXCR4 were examined and compared among in vitro, in vivo, and normal bone, respectively. PTHrP, OPG, RANKL, and ET 1 except CXCR4 in SY5Y and KCNR NB cells xenografts were strikingly upregulated compared with normal bone and NB cells. However, significantly stronger expression of PTHrP and RANKL was presented than ET 1 and OPG; furthermore, the ratios of expression of PTHrP, RANKL to OPG, and ET 1 were also markedly increased in vivo versus in vitro.
   Our study provided evidence that NB cell may enhance bone invasion through PTHrP, OPG, RANKL, and ET 1, especially PTHrP and RANKL which may display stronger effects. CXCR4 appeared not participating in bone invasion, but in tumor growth, and homing to bone. Targeting PTHrP, OPG, ET 1, and RANKL may provide a new insight and method for patient therapy by inhibiting NB bone metastasis and invasiveness.
C1 [Zhao, Hongyu; Li, Shuai; Da, Zuke; Ma, Liang; Lin, Yaoxin; Zhi, Debao] China Med Univ, Shengjing Hosp, Dept Neurosurg, Shenyang, Peoples R China.
   [Cai, Weisong] China Med Univ, Shengjing Hosp, Dept Oncol, Shenyang, Peoples R China.
   [Sun, Hanxue] China Med Univ, Shengjing Hosp, Dept Pathol, Shenyang, Peoples R China.
C3 China Medical University; China Medical University; China Medical
   University
RP Zhao, HY (通讯作者)，China Med Univ, Shengjing Hosp, Dept Neurosurg, Shenyang, Peoples R China.
EM zhaocmu1974@yahoo.com.cn
RI Linden, Rafael/F 2275 2011
FU National Natural Science Foundation grant from the China National
   Science Foundation Committee [81172410]
FX This work was supported by National Natural Science Foundation grant
   from the China National Science Foundation Committee (project code
   81172410).
CR Ara T, 2006, CANCER METAST REV, V25, P645, DOI 10.1007/s10555 006 9028 9
   Armstrong JL, 2012, ONCOL REP, V27, P293, DOI 10.3892/or.2011.1479
   Bilir A, 2010, J NEURO ONCOL, V100, P385, DOI 10.1007/s11060 010 0209 6
   Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014
   Carlisle AJ, 2009, MOL CANCER, V8, DOI 10.1186/1476 4598 8 126
   Chappard D., 2011, Morphologie, V95, P65, DOI 10.1016/j.morpho.2011.02.004
   Chawla M, 2010, INDIAN J NUCL MED, V25, P147, DOI 10.4103/0972 3919.78249
   Davidoff AM, 2012, SEMIN PEDIATR SURG, V21, P2, DOI 10.1053/j.sempedsurg.2011.10.009
   Dickey A, 2011, J NEURO ONCOL, V104, P145, DOI 10.1007/s11060 010 0491 3
   Enjuanes A, 2010, ENDOCRINE, V37, P180, DOI 10.1007/s12020 009 9285 9
   Granchi D, 2011, BONE, V48, P152, DOI 10.1016/j.bone.2010.06.028
   Gulenchyn KY, 2012, CLIN ONCOL UK, V24, P294, DOI 10.1016/j.clon.2011.12.003
   Ishola TA, 2007, SURG ONCOL, V16, P149, DOI 10.1016/j.suronc.2007.09.005
   Jabbar S, 2011, J CLIN PATHOL, V64, P354, DOI 10.1136/jcp.2010.086595
   Klymenko T, 2011, MOL CANCER THER, V10, P2373, DOI 10.1158/1535 7163.MCT 11 0326
   Ma M, 2011, CANCER LETT, V312, P1, DOI 10.1016/j.canlet.2011.06.028
   Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140 6736(07)60983 0
   Matthay KK, 2010, BRIT J CANCER, V102, P1319, DOI 10.1038/sj.bjc.6605621
   Meier R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001016
   Ostrowska Z, 2012, BONE, V50, P156, DOI 10.1016/j.bone.2011.09.054
   Park JR, 2008, PEDIATR CLIN N AM, V55, P97, DOI 10.1016/j.pcl.2007.10.014
   Park JR, 2011, J CLIN ONCOL, V29, P4351, DOI 10.1200/JCO.2010.34.3293
   Peng HJ, 2007, CANCER RES, V67, P9346, DOI 10.1158/0008 5472.CAN 06 4508
   Poretti A, 2012, DEV MED CHILD NEUROL, V54, P297, DOI 10.1111/j.1469 8749.2011.04174.x
   Roodman GD, 2004, NEW ENGL J MED, V350, P655
   Sartelet H, 2012, IN VIVO, V26, P19
   Seeger RC, 2011, SEMIN CANCER BIOL, V21, P229, DOI 10.1016/j.semcancer.2011.09.012
   Sharp SE, 2011, SEMIN NUCL MED, V41, P345, DOI 10.1053/j.semnuclmed.2011.05.001
   Sohara Y, 2005, CANCER LETT, V228, P203, DOI 10.1016/j.canlet.2005.01.059
   Sohara Y, 2003, CANCER RES, V63, P3026
   Suva LJ, 2011, NAT REV ENDOCRINOL, V7, P208, DOI 10.1038/nrendo.2010.227
   Taggart DR, 2011, J CLIN ONCOL, V29, P4358, DOI 10.1200/JCO.2011.35.9570
NR 32
TC 6
Z9 6
U1 0
U2 18
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0256 7040
EI 1433 0350
J9 CHILD NERV SYST
JI Childs Nerv. Syst.
PD JUL
PY 2013
VL 29
IS 7
BP 1097
EP 1105
DI 10.1007/s00381 013 2086 8
PG 9
WC Clinical Neurology; Pediatrics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology; Pediatrics; Surgery
GA 163YO
UT WOS:000320374800008
PM 23559392
DA 2025 08 17
ER

PT J
AU Eun, SY
   Cheon, YH
   Park, GD
   Chung, CH
   Lee, CH
   Kim, JY
   Lee, MS
AF Eun, So Young
   Cheon, Yoon Hee
   Park, Gyeong Do
   Chung, Chong Hyuk
   Lee, Chang Hoon
   Kim, Ju Young
   Lee, Myeung Su
TI Anti Osteoporosis Effects of the Eleutherococcus senticosus,
   Achyranthes japonica, and Atractylodes japonica Mixed
   Extract Fermented with Nuruk
SO NUTRIENTS
LA English
DT Article
DE Vigeo; nuruk fermentation; osteoclasts; bone resorption; osteoporosis
ID LACTOBACILLUS PLANTARUM; KAPPA B; GINSENG; BARK
AB Vigeo is a mixture of fermented extracts of Eleutherococcus senticosus Maxim (ESM), Achyranthes japonica (Miq.) Nakai (AJN), and Atractylodes japonica Koidzumi (AJK) manufactured using the traditional Korean nuruk fermentation method. Although the bioactive effects of ESM, AJN, and AJK have already been reported, the pharmacological effects of Vigeo have not been proven. Therefore, in this study, we investigated whether Vigeo had inhivitory effects on lipopolysaccharide (LPS) induced inflammatory bone loss in vivo and receptor activator of nuclear factor B ligand (RANKL) induced osteoclastogenesis and the related mechanism in vitro. Vigeo administration conferred effective protection against bone loss induced by excessive inflammatory response and activity of osteoclasts in LPS induced inflammatory osteoporosis mouse model. In addition, Vigeo significantly suppressed the formation of tartrate resistant acid phosphatase positive osteoclasts induced by RANKL and inhibited F actin formation and bone resorbing activity without any cytotoxicity. Moreover, Vigeo significantly inhibited RANKL induced phosphorylation of p38, ERK, JNK, I kappa B, and AKT and degradation of IkB. Additionally, Vigeo strongly inhibited the mRNA and protein expression of c FOS and NFATc1 and subsequently attenuated the expression of osteoclast specific marker genes induced by RANKL. We demonstrated for the first time the anti osteoporosis effect of Vigeo, suggesting that it could be a potential therapeutic candidate for the treatment of osteoclast mediated inflammatory bone diseases.
C1 [Eun, So Young; Cheon, Yoon Hee; Park, Gyeong Do; Chung, Chong Hyuk; Lee, Chang Hoon; Kim, Ju Young; Lee, Myeung Su] Wonkwang Univ, Sch Med, Musculoskeletal & Immune Dis Res Inst, 460 Iksandae Ro, Iksan 54538, South Korea.
   [Chung, Chong Hyuk; Lee, Chang Hoon; Lee, Myeung Su] Wonkwang Univ Hosp, Dept Internal Med, Div Rheumatol, 460 Iksandae Ro, Iksan 54538, South Korea.
C3 Wonkwang University; Wonkwang University
RP Kim, JY; Lee, MS (通讯作者)，Wonkwang Univ, Sch Med, Musculoskeletal & Immune Dis Res Inst, 460 Iksandae Ro, Iksan 54538, South Korea.; Lee, MS (通讯作者)，Wonkwang Univ Hosp, Dept Internal Med, Div Rheumatol, 460 Iksandae Ro, Iksan 54538, South Korea.
EM eunsoyg@hanmail.net; hanleuni@naver.com; rudeh2508@naver.com;
   taylorchung@hanmail.net; lch110@wku.ac.kr; kimjy1014@gmail.com;
   ckhlms@wku.ac.kr
RI ; Lee, Sang Hoon/ABH 6210 2020
OI chung, chong hyuk/0000 0001 5806 0733; Kim,
   Ju Young/0000 0002 4493 0264; 
FU Korea Health Technology R&D Project through the Korea Health Industry
   Development Institute (KHIDI)   Ministry of Health & Welfare, Republic
   of Korea [HI20C1951]
FX FundingThis research was supported by a grant from the Korea Health
   Technology R&D Project through the Korea Health Industry Development
   Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic
   of Korea (grant number: HI20C1951).
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bae EA, 2004, ARCH PHARM RES, V27, P1136, DOI 10.1007/BF02975119
   Cheon YH, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906 015 0801 6
   Han Y, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472 6882 12 154
   Hong MH, 2010, ARCH PHARM RES, V33, P843, DOI 10.1007/s12272 010 0606 6
   Hwang YC, 2009, J BONE MINER METAB, V27, P584, DOI 10.1007/s00774 009 0093 3
   Joo SS, 2009, PHYTOTHER RES, V23, P913, DOI 10.1002/ptr.2758
   Jung J, 2003, PLANTA MED, V69, P610, DOI 10.1055/s 2003 41127
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   Kim D, 2011, J ETHNOPHARMACOL, V133, P803, DOI 10.1016/j.jep.2010.11.007
   Kim JE, 2008, J MICROBIOL BIOTECHN, V18, P1423
   Kim JY, 2014, J BONE MINER RES, V29, P1541, DOI 10.1002/jbmr.2183
   Kimura Y, 2004, J ETHNOPHARMACOL, V95, P447, DOI 10.1016/j.jep.2004.08.027
   Kropotov AV, 2002, B EXP BIOL MED+, V133, P252, DOI 10.1023/A:1015834717178
   Lee DY, 2009, J MICROBIOL BIOTECHN, V19, P1328, DOI 10.4014/jmb.0902.0072
   Lee JE, 2017, J MICROBIOL BIOTECHN, V27, P896
   Lee SO, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906 018 2310 x
   Lee SG, 2012, J ETHNOPHARMACOL, V142, P634, DOI 10.1016/j.jep.2012.05.020
   Lei V, 1999, INT J FOOD MICROBIOL, V53, P169, DOI 10.1016/S0168 1605(99)00156 7
   Lim DW, 2013, MOLECULES, V18, P7998, DOI 10.3390/molecules18077998
   Ng CC, 2011, J BIOSCI BIOENG, V111, P289, DOI 10.1016/j.jbiosc.2010.11.011
   Oh YC, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472 6882 12 17
   Park JH, 2013, ASIAN AUSTRAL J ANIM, V26, P287, DOI 10.5713/ajas.2012.12438
   Park SH, 2006, ARCH PHARM RES, V29, P768, DOI 10.1007/BF02974078
   Parvez S, 2006, J APPL MICROBIOL, V100, P1171, DOI 10.1111/j.1365 2672.2006.02963.x
   Rizzello CG, 2013, MICROB CELL FACT, V12, DOI [10.1186/1475 2859 12 44, 10.1186/1475 2859 12 105]
   Rousseau S, 2020, CRIT REV FOOD SCI, V60, P826, DOI 10.1080/10408398.2018.1552243
   Wang KT, 2011, EVID BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq006
   Woo YM, 2019, DATA BRIEF, V25, DOI 10.1016/j.dib.2019.104088
   Xutian S, 2009, AM J CHINESE MED, V37, P411, DOI 10.1142/S0192415X09006941
   Yang XB, 2017, INT J CLIN EXP PATHO, V10, P4514
   Yoon TJ, 2004, J ETHNOPHARMACOL, V93, P247, DOI 10.1016/j.jep.2004.03.052
   Zhao X, 2021, PHARMACEUTICALS BASE, V14, DOI 10.3390/ph14080776
NR 33
TC 11
Z9 11
U1 0
U2 8
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6643
J9 NUTRIENTS
JI Nutrients
PD NOV
PY 2021
VL 13
IS 11
AR 3904
DI 10.3390/nu13113904
PG 12
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA XJ6WN
UT WOS:000726925600001
PM 34836159
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Erlandson, KM
   O'Riordan, M
   Hileman, CO
   Rapaport, E
   Labbato, D
   Campbell, TB
   McComsey, GA
AF Erlandson, Kristine M.
   O'Riordan, MaryAnn
   Hileman, Corrilynn O.
   Rapaport, Eric
   Labbato, Danielle
   Campbell, Thomas B.
   McComsey, Grace A.
TI Plasma Sclerostin in HIV Infected Adults on Effective Antiretroviral
   Therapy
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN; OSTEOCLAST DIFFERENTIATION;
   CIRCULATING SCLEROSTIN; VASCULAR CALCIFICATION; MONOCYTE ACTIVATION;
   ARTERIAL STIFFNESS; RISK FACTORS; DISEASE; WNT
AB Sclerostin is linked to bone physiology and cardiovascular disease through the Wnt/beta catenin signaling pathway. The goal of this study was to determine if sclerostin is related to bone physiology and cardiovascular disease during antiretroviral treatment in HIV infected persons. This was a cross sectional analysis from study entry into the Stopping Atherosclerosis and Treating Unhealthy bone with RosuvastatiN in HIV (SATURN) trial, an ongoing randomized trial comparing rosuvastatin to placebo in HIV infected adults on antiretroviral therapy. Plasma sclerostin was measured at study entry by ELISA from participants with available samples. Spearman correlation and multivariable linear regression were used to test relationships between sclerostin and bone density or bone turnover and cardiovascular disease. Among 139 HIV infected participants (median age 46 years, CD4 lymphocyte count 614 cells/mu l), the median plasma sclerostin level was 444.1 (IQR 330.3, 570.1) pg/ml. Correlations were detected between sclerostin and age (r = 0.26), lumbar spine Z score (r = 0.31), RANKL (r =  0.21), carotid intima media thickness (CIMT, r = 0.19), and sVCAM 1 (r = 0.27), p < 0.05. No significant correlations were detected between sclerostin and current (r = 0.006) or nadir CD4 count (r = 0.11). While associations between sclerostin, lumbar spine Z score, and sVCAM 1 were robust to covariate adjustment (p < 0.01), association with CIMT was no longer significant (p = 0.08). Our findings provide preliminary support for a relationship between sclerostin and bone mineral density in HIV infected persons. The Wnt/beta catenin pathway should be investigated as a potential mechanism for loss of bone mineral density in treated HIV infection.
C1 [Erlandson, Kristine M.; Rapaport, Eric; Campbell, Thomas B.] Univ Colorado, 12700 East 19th Ave,Mail Stop B168, Aurora, CO 80111 USA.
   [O'Riordan, MaryAnn; Labbato, Danielle; McComsey, Grace A.] Case Western Reserve Univ, Cleveland, OH 44106 USA.
   [Hileman, Corrilynn O.] MetroHlth Med Ctr, Cleveland, OH USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus; University System of Ohio; Case Western Reserve University;
   MetroHealth System
RP Erlandson, KM (通讯作者)，Univ Colorado, 12700 East 19th Ave,Mail Stop B168, Aurora, CO 80111 USA.
EM kristine.erlandson@ucdenver.edu
FU National Institutes of Health [NR012642, K23AG050260, K23HL116209]
FX This study was supported by funding through the National Institutes of
   Health (NR012642 to G.A.M., K23AG050260 to K.M.E., and K23HL116209 to
   C.O.H.). The contents are the authors' sole responsibility and do not
   necessarily represent official NIH views.
CR Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bhattoa HP, 2013, J BONE MINER METAB, V31, P579, DOI 10.1007/s00774 013 0451 z
   Brown TT, 2009, JAIDS J ACQ IMM DEF, V51, P554, DOI 10.1097/QAI.0b013e3181adce44
   Carano RAD, 2003, DRUG DISCOV TODAY, V8, P980, DOI 10.1016/S1359 6446(03)02866 6
   Cejka D, 2014, J CLIN ENDOCR METAB, V99, P248, DOI 10.1210/jc.2013 2786
   Cejka D, 2012, NEPHROL DIAL TRANSPL, V27, P226, DOI 10.1093/ndt/gfr270
   Claes KJ, 2013, J CLIN ENDOCR METAB, V98, P3221, DOI 10.1210/jc.2013 1521
   COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580
   Costa AG, 2014, OSTEOPOROSIS INT, V25, P1547, DOI 10.1007/s00198 014 2635 3
   Drake MT, 2010, J CLIN ENDOCR METAB, V95, P5056, DOI 10.1210/jc.2010 0720
   Duvivier C, 2009, AIDS, V23, P817, DOI 10.1097/QAD.0b013e328328f789
   Eckard AR, 2014, J INFECT DIS, V209, P1156, DOI 10.1093/infdis/jiu012
   Erlandson KM, 2014, JAIDS J ACQ IMM DEF, V65, P290, DOI 10.1097/QAI.0000000000000005
   Erlandson KM, 2012, JAIDS J ACQ IMM DEF, V61, P484, DOI 10.1097/QAI.0b013e3182716e38
   Funderburg NT, 2014, CLIN INFECT DIS, V58, P588, DOI 10.1093/cid/cit748
   Garnero P, 2013, OSTEOPOROSIS INT, V24, P489, DOI 10.1007/s00198 012 1978 x
   Gaudio A, 2014, DIABETES VASC DIS RE, V11, P48, DOI 10.1177/1479164113510923
   Gaudio A, 2010, J CLIN ENDOCR METAB, V95, P2248, DOI 10.1210/jc.2010 0067
   Hampson G, 2013, BONE, V56, P42, DOI 10.1016/j.bone.2013.05.010
   Il Mödder U, 2011, J BONE MINER RES, V26, P27, DOI 10.1002/jbmr.128
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Longenecker CT, 2013, HIV MED, V14, P385, DOI 10.1111/hiv.12013
   Longenecker CT, 2014, AIDS, V28, P969, DOI 10.1097/QAD.0000000000000158
   Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105
   Malhotra S, 2009, EXP HEMATOL, V37, P19, DOI 10.1016/j.exphem.2008.08.008
   Mani A, 2007, SCIENCE, V315, P1278, DOI 10.1126/science.1136370
   Manolagas SC, 2007, MOL ENDOCRINOL, V21, P2605, DOI 10.1210/me.2007 0259
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   McComsey GA, 2007, AIDS, V21, P2473, DOI 10.1097/QAD.0b013e3282ef961d
   McComsey GA, 2011, J INFECT DIS, V203, P1791, DOI 10.1093/infdis/jir188
   McComsey GA, 2010, CLIN INFECT DIS, V51, P937, DOI 10.1086/656412
   Modarresi R, 2009, AM J PATHOL, V174, P123, DOI 10.2353/ajpath.2009.080484
   Mödder UI, 2011, J BONE MINER RES, V26, P373, DOI 10.1002/jbmr.217
   Morales Santana S, 2013, DIABETES CARE, V36, P1667, DOI 10.2337/dc12 1691
   Negredo E, 2015, J ANTIMICROB CHEMOTH
   Okada Y, 2002, ENDOCR J, V49, P483, DOI 10.1507/endocrj.49.483
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Polyzos SA, 2012, OSTEOPOROSIS INT, V23, P1171, DOI 10.1007/s00198 010 1525 6
   Post WS, 2014, ANN INTERN MED, V160, P458, DOI 10.7326/M13 1754
   Prieto Alhambra D, 2014, JAIDS J ACQ IMM DEF, V66, P90, DOI 10.1097/QAI.0000000000000112
   Register TC, 2014, J CLIN ENDOCR METAB, V99, P315, DOI 10.1210/jc.2013 3168
   Santiago F, 2012, BIOCHEM BIOPH RES CO, V417, P223, DOI 10.1016/j.bbrc.2011.11.089
   Schäfer A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014060
   STREETEN EA, 1990, BONE MINER, V10, P85, DOI 10.1016/0169 6009(90)90084 S
   Szulc P, 2013, J BONE MINER RES, V28, P1760, DOI 10.1002/jbmr.1888
   TANAKA Y, 1995, J BONE MINER RES, V10, P1462
   Thambiah S, 2012, CALCIFIED TISSUE INT, V90, P473, DOI 10.1007/s00223 012 9595 4
   van Bezooijen RL, 2007, J BONE MINER RES, V22, P19, DOI 10.1359/JBMR.061002
NR 50
TC 8
Z9 8
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889 2229
EI 1931 8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD JUL
PY 2015
VL 31
IS 7
BP 731
EP 738
DI 10.1089/aid.2015.0052
PG 8
WC Immunology; Infectious Diseases; Virology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Infectious Diseases; Virology
GA DD4IJ
UT WOS:000369885400011
PM 25919636
OA Green Published
DA 2025 08 17
ER

PT J
AU Penolazzi, L
   Lampronti, I
   Borgatti, M
   Khan, MTH
   Zennaro, M
   Piva, R
   Gambari, R
AF Penolazzi, Letizia
   Lampronti, Ilaria
   Borgatti, Monica
   Khan, Mahmud Tareq Hassan
   Zennaro, Margherita
   Piva, Roberta
   Gambari, Roberto
TI Induction of apoptosis of human primary osteoclasts treated with
   extracts from the medicinal plant Emblica officinalis
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID NF KAPPA B; PROLIFERATION STIMULATING ACTIVITY; TRANSCRIPTION FACTORS;
   IN VITRO; RHEUMATOID ARTHRITIS; DECOY MIMICKING; PROMOTER REGION; BONE
   METASTASIS; RANKL; DIFFERENTIATION
AB Background: Osteoclasts (OCs) are involved in rheumatoid arthritis and in several pathologies associated with bone loss. Recent results support the concept that some medicinal plants and derived natural products are of great interest for developing therapeutic strategies against bone disorders, including rheumatoid arthritis and osteoporosis. In this study we determined whether extracts of Emblica officinalis fruits display activity of possible interest for the treatment of rheumatoid arthritis and osteoporosis by activating programmed cell death of human primary osteoclasts.
   Methods: The effects of extracts from Emblica officinalis on differentiation and survival of human primary OCs cultures obtained from peripheral blood were determined by tartrate acid resistant acid phosphatase (TRAP) positivity and colorimetric MTT assay. The effects of Emblica officinalis extracts on induction of OCs apoptosis were studied using TUNEL and immunocytochemical analysis of FAS receptor expression. Finally, in vitro effects of Emblica officinalis extracts on NF kB transcription factor activity were determined by gel shift experiments.
   Results: Extracts of Emblica officinalis were able to induce programmed cell death of mature OCs, without altering, at the concentrations employed in our study, the process of osteoclastogenesis. Emblica officinalis increased the expression levels of Fas, a critical member of the apoptotic pathway. Gel shift experiments demonstrated that Emblica officinalis extracts act by interfering with NF kB activity, a transcription factor involved in osteoclast biology. The data obtained demonstrate that Emblica officinalis extracts selectively compete with the binding of transcription factor NF kB to its specific target DNA sequences. This effect might explain the observed effects of Emblica officinalis on the expression levels of interleukin 6, a NF kB specific target gene.
   Conclusion: Induction of apoptosis of osteoclasts could be an important strategy both in interfering with rheumatoid arthritis complications of the bone skeleton leading to joint destruction, and preventing and reducing osteoporosis. Accordingly, we suggest the application of Emblica officinalis extracts as an alternative tool for therapy applied to bone diseases.
C1 [Penolazzi, Letizia; Lampronti, Ilaria; Borgatti, Monica; Zennaro, Margherita; Piva, Roberta; Gambari, Roberto] Univ Ferrara, Dept Biochem & Mol Biol, ER GenTech, BioPharmaNet, I 44100 Ferrara, Italy.
   [Khan, Mahmud Tareq Hassan] Univ Tromso, Inst Med Biol, Dept Pharmacol, N 9001 Tromso, Norway.
   [Khan, Mahmud Tareq Hassan] Univ Karachi, HEJ Res Inst Chem, Int Ctr Chem Sci, Karachi 32, Pakistan.
   [Gambari, Roberto] Univ Ferrara, Ctr Biotechnol, I 44100 Ferrara, Italy.
C3 University of Ferrara; UiT The Arctic University of Tromso; University
   of Karachi; University of Ferrara
RP Gambari, R (通讯作者)，Univ Ferrara, Dept Biochem & Mol Biol, ER GenTech, BioPharmaNet, I 44100 Ferrara, Italy.
EM pnlmlt@unife.it; lmi@unife.it; brgmnc@unife.it;
   mahmud.khan@fagmed.int.no; znnmgh@unife.it; piv@unife.it; gam@unife.it
RI Lampronti, Ilaria/F 5522 2016; Gambari, Roberto/F 9555 2015; Khan,
   Mahmud/V 9572 2019; Borgatti, Monica/G 2611 2015
OI Lampronti, Ilaria/0000 0002 1972 7766; Gambari,
   Roberto/0000 0001 9205 6033; Penolazzi, Letizia/0000 0002 1293 5087;
   Borgatti, Monica/0000 0001 8470 2496; Piva, Roberta/0000 0003 2663 6210
FU CIB (Consorzio Interuniversitario di Biotecnologie, Italy); AIRC
   (Associazione Italiana Ricerca sul Cancro), AVTL ( Associazione Veneta
   per la Lotta alla Talassemia, Italy)
FX R. G. is funded by CIB (Consorzio Interuniversitario di Biotecnologie,
   Italy), AIRC (Associazione Italiana Ricerca sul Cancro), AVTL (
   Associazione Veneta per la Lotta alla Talassemia, Italy), SPINNER e
   PRIITT (EU, Obiettivo 2), Fondazione Cassa di Risparmio di Padova e
   Rovigo, STAMINA Project of Ferrara University and UE ITHANET Project. We
   would like to thank Dr. Amanda J. Neville ( Department of Experimental
   and Diagnostic Medicine, Section of Medical Genetics) for her
   contribution in revising the text.
CR Ahmad I, 1998, J ETHNOPHARMACOL, V62, P183, DOI 10.1016/S0378 8741(98)00055 5
   Ameye LG, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2016
   Anila L, 2002, J ETHNOPHARMACOL, V79, P81, DOI 10.1016/S0378 8741(01)00361 0
   ASMAWI MZ, 1993, J PHARM PHARMACOL, V45, P581, DOI 10.1111/j.2042 7158.1993.tb05605.x
   Bagi CM, 2005, ADV DRUG DELIVER REV, V57, P995, DOI 10.1016/j.addr.2004.12.014
   Bhattacharya A, 2000, PHYTOMEDICINE, V7, P173, DOI 10.1016/S0944 7113(00)80091 4
   Blair HC, 2006, REV ENDOCR METAB DIS, V7, P23, DOI 10.1007/s11154 006 9010 4
   Borgatti M, 2003, J BIOL CHEM, V278, P7500, DOI 10.1074/jbc.M206780200
   Boyce BF, 2006, CURR OPIN RHEUMATOL, V18, P427, DOI 10.1097/01.bor.0000231913.32364.32
   Chapurlat RD, 2006, NAT CLIN PRACT ENDOC, V2, P211, DOI 10.1038/ncpendmet0121
   Cicek M, 2006, CANCER METAST REV, V25, P635, DOI 10.1007/s10555 006 9035 x
   Colucci S, 2007, J PATHOL, V212, P47, DOI 10.1002/path.2153
   Croom KF, 2006, DRUGS, V66, P1593, DOI 10.2165/00003495 200666120 00005
   DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022 1759(86)90368 6
   Do SH, 2008, MENOPAUSE, V15, P676, DOI 10.1097/gme.0b013e31815bb687
   Domingo Domenech J, 2006, CLIN CANCER RES, V12, P5578, DOI 10.1158/1078 0432.CCR 05 2767
   Faloni APS, 2007, J PERIODONTAL RES, V42, P193, DOI 10.1111/j.1600 0765.2006.00932.x
   Funk JL, 2006, J NAT PROD, V69, P351, DOI 10.1021/np050327j
   Gillespie MT, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2141
   Giuliani N, 2006, CURR PHARM BIOTECHNO, V7, P423, DOI 10.2174/138920106779116955
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Haynes D. R., 2006, Inflammopharmacology, V14, P193, DOI 10.1007/s10787 006 0006 1
   Hidaka S, 1999, PHYTOTHER RES, V13, P14, DOI 10.1002/(SICI)1099 1573(199902)13:1<14::AID PTR375>3.0.CO;2 V
   Idris A, 2008, BIOCHEM BIOPH RES CO, V371, P94, DOI 10.1016/j.bbrc.2008.04.014
   Jose JK, 2001, J ETHNOPHARMACOL, V75, P65, DOI 10.1016/S0378 8741(00)00378 0
   Kanakis I, 2005, IN VIVO, V19, P311
   Khan MTH, 2002, INT J ONCOL, V21, P187
   Kim KW, 2007, IMMUNOL LETT, V110, P54, DOI 10.1016/j.imlet.2007.03.004
   Kitahara K, 2007, CURR OPIN RHEUMATOL, V19, P238, DOI 10.1097/BOR.0b013e328099af80
   Lampronti I, 2003, PHYTOMEDICINE, V10, P300, DOI 10.1078/094471103322004794
   LAMPRONTI I, 2007, EVINDENCE BASED COMP
   Lipton A, 2006, CLIN CANCER RES, V12, p6305S, DOI 10.1158/1078 0432.CCR 06 1157
   Manette C, 2006, CURR MED CHEM, V13, P1585, DOI 10.2174/092986706777442057
   Matsuzaki K, 1999, ENDOCRINOLOGY, V140, P925, DOI 10.1210/en.140.2.925
   Meng F, 2004, PHARMAZIE, V59, P643
   New SA, 2003, P NUTR SOC, V62, P889, DOI 10.1079/PNS2003310
   Ochi S, 2007, P NATL ACAD SCI USA, V104, P11394, DOI 10.1073/pnas.0701971104
   Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519
   Penolazzi L, 2003, BIOCHEM PHARMACOL, V66, P1189, DOI 10.1016/S0006 2952(03)00470 2
   Penolazzi L, 2006, APOPTOSIS, V11, P1653, DOI 10.1007/s10495 006 8763 2
   Piva R, 2005, APOPTOSIS, V10, P1079, DOI 10.1007/s10495 005 0618 8
   Piva R, 2006, ANN NY ACAD SCI, V1091, P509, DOI 10.1196/annals.1378.092
   Pritts T, 2002, AM J SURG, V183, P372, DOI 10.1016/S0002 9610(02)00812 7
   Putnam SE, 2007, PHYTOTHER RES, V21, P99, DOI 10.1002/ptr.2030
   Ramprasath VR, 2006, CHEM BIOL INTERACT, V160, P183, DOI 10.1016/j.cbi.2005.11.009
   Sánchez Conde M, 2005, HIV CLIN TRIALS, V6, P197, DOI 10.1310/ED57 EU48 RK6A E5U0
   Sato K, 2006, CURR OPIN RHEUMATOL, V18, P419, DOI 10.1097/01.bor.0000231912.24740.a5
   Scartezzini P, 2006, J ETHNOPHARMACOL, V104, P113, DOI 10.1016/j.jep.2005.08.065
   Schett G, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2110
   Shu Goukei, 2006, Mod Rheumatol, V16, P343
   Sohail MT, 2005, PHYTOTHER RES, V19, P365, DOI 10.1002/ptr.1680
   Suematsu Ayako, 2007, Mod Rheumatol, V17, P17
   Sultana Sarwat, 2005, Indian Journal of Experimental Biology, V43, P430
   Szekanecz Z, 2007, CURR OPIN RHEUMATOL, V19, P289, DOI 10.1097/BOR.0b013e32805e87ae
   Tanishima Shinji, 2007, Mod Rheumatol, V17, P198, DOI 10.1007/s10165 007 0566 y
   Teitelbaum SL, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1857
   THAKUR CP, 1984, INDIAN J MED RES, V79, P142
   Tremoulet AH, 2006, EXPERT OPIN INV DRUG, V15, P1427, DOI 10.1517/13543784.15.11.1427
   Uchiyama S, 2007, J CELL BIOCHEM, V101, P529, DOI 10.1002/jcb.21208
   Verdrengh M, 2007, J ORTHOP RES, V25, P304, DOI 10.1002/jor.20317
   Villanova I, 1999, J BONE MINER RES, V14, P1867, DOI 10.1359/jbmr.1999.14.11.1867
   Wang DW, 2001, PLANTA MED, V67, P748, DOI 10.1055/s 2001 18343
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yin J, 2004, BIOL PHARM BULL, V27, P583, DOI 10.1248/bpb.27.583
NR 64
TC 40
Z9 46
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1472 6882
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD OCT 30
PY 2008
VL 8
AR 59
DI 10.1186/1472 6882 8 59
PG 11
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA 399ND
UT WOS:000262805700001
PM 18973662
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Hu, H
   Chen, Y
   Zou, ZY
   Li, LP
   Wei, FX
   Liu, C
   Ling, ZM
   Zou, XN
AF Hu, Hao
   Chen, Yan
   Zou, Zhiyuan
   Li, Liangping
   Wei, Fuxin
   Liu, Chun
   Ling, Zemin
   Zou, Xuenong
TI Panax Notoginseng Saponins Prevent Bone Loss by Promoting Angiogenesis
   in an Osteoporotic Mouse Model
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID MARROW STROMAL CELLS; OSTEOGENESIS; ANTIOXIDANT; MECHANISM; APOPTOSIS;
   EXTRACTS; ROOTS; CHINA; MAPK
AB With the aging of the population and the extension of life expectancy, osteoporosis is becoming a global epidemic. Although there are several drugs used to treat osteoporosis in clinical practice, such as parathyroid hormone or bisphosphonates, they all have some serious side effects. Therefore, a safer drug is called for osteoporosis, especially for the prevention in the early stage of the disease, not only the treatment in the later stage. Panax notoginseng saponin (PNS), a traditional Chinese herb, has been used as anti ischemic drug due to its function on improving vascular circulation. In order to verify whether Panax notoginseng saponins (PNS) could be used to prevent osteoporosis, ovariectomy (OVX) was induced in female C57BL/C6J mice, followed by orally administration with 40 mg/kg/d, 80 mg/kg/d, and 160 mg/kg/d of three different dosages of PNS for 9 weeks. Serum biochemical analysis, micro CT, histological evaluation, and immunostaining of markers of osteogenesis and angiogenesis were performed in the sham, osteoporotic (OVX), and treatment (OVX+PNS) groups. Micro CT and histological evaluation showed that compared to sham group, the bone mass of OVX group reduced significantly, while it was significantly restored in the moderate dose PNS (40 mg/kg and 80 mg/kg) treatment groups. The expression of CD31 and osteocalcin (OCN) in the bone tissue of treatment group also increased, suggesting that PNS activated osteogenesis and angiogenesis, which subsequently increased the bone mass. These results confirmed the potential function of PNS on the prevention of osteoporosis. However, in the high dose of PNS (160 mg/kg) group, the antiosteoportic effect had been eliminated, which also suggested the importance of proper dose of PNS for the prevention and treatment of osteoporosis in postmenopausal women.
C1 [Hu, Hao; Chen, Yan; Zou, Zhiyuan; Li, Liangping; Ling, Zemin; Zou, Xuenong] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Spinal Surg, Guangdong Prov Key Lab Orthoped & Traumatol, Guangzhou 510080, Peoples R China.
   [Wei, Fuxin] Sun Yat Sen Univ, Affiliated Hosp 7, Dept Orthopaed Surg, Shenzhen 518107, Peoples R China.
   [Wei, Fuxin] Sun Yat Sen Univ, Orthoped Res Inst, Shenzhen 518107, Peoples R China.
   [Liu, Chun] Sun Yat Sen Univ, Affiliated Hosp 1, Precis Med Inst, Guangzhou 510080, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University;
   Sun Yat Sen University
RP Ling, ZM; Zou, XN (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 1, Dept Spinal Surg, Guangdong Prov Key Lab Orthoped & Traumatol, Guangzhou 510080, Peoples R China.
EM huhao7@mail2.sysu.edu.cn; cheny585@mail2.sysu.edu.cn;
   medzhiyuan@163.com; lliangp2018@zju.edu.cn; suifeng720@163.com;
   liuch393@mail.sysu.edu.cn; lingzm@mail2.sysu.edu.cn;
   zouxuen@mail.sysu.edu.cn
RI ; Ling, Zemin/ABF 3060 2021; li, liangping/LVR 1411 2024; Liu,
   Chun/KPA 2480 2024; D'Este, Matteo/AAB 2835 2022; Hu, Hao/JTV 6417 2023
OI Hu, Hao/0000 0002 1127 0589; Ling, Zemin/0000 0002 2742 6429; 
FU Science and Technology Program of Guangzhou [201704030082,
   201804020011]; National Natural Science Foundation of Guangdong
   Province Major Fundamental Research Fostering Program, China
   [2017A030308004]; Key Project of NSFC Guangdong Joint Program [U1601220]
FX This work was supported by research grants from Science and Technology
   Program of Guangzhou (201704030082 and 201804020011), the National
   Natural Science Foundation of Guangdong Province Major Fundamental
   Research Fostering Program, China (2017A030308004), and Key Project of
   NSFC Guangdong Joint Program (U1601220).
CR Cagnetta V, 2012, CLIN CASES MINER BON, V9, P85
   Chan RYK, 2002, J CLIN ENDOCR METAB, V87, P3691, DOI 10.1210/jc.87.8.3691
   Chen P, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889 016 3712 7
   Chen SX, 2011, J ETHNOPHARMACOL, V137, P263, DOI 10.1016/j.jep.2011.05.011
   Cosman F, 2015, OSTEOPOROSIS INT, V26, P2045, DOI 10.1007/s00198 015 3037 x
   Dong TTX, 2003, J AGR FOOD CHEM, V51, P4617, DOI 10.1021/jf034229k
   Fan JZ, 2015, MENOPAUSE, V22, P1343, DOI 10.1097/GME.0000000000000471
   He NW, 2012, J MED FOOD, V15, P350, DOI 10.1089/jmf.2011.1801
   Hong SJ, 2009, PHYTOTHER RES, V23, P677, DOI 10.1002/ptr.2705
   Jang YJ, 2011, ARCH ORAL BIOL, V56, P1319, DOI 10.1016/j.archoralbio.2011.05.010
   Jha S, 2015, J BONE MINER RES, V30, P2179, DOI 10.1002/jbmr.2565
   Ji Z, 2015, IN VITRO CELL DEV AN, V51, P950, DOI 10.1007/s11626 015 9915 x
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Khosla S, 2015, J BONE MINER RES, V30, P1134, DOI 10.1002/jbmr.2529
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Li XD, 2011, CELL PHYSIOL BIOCHEM, V28, P367, DOI 10.1159/000331753
   Li XD, 2010, CELL PHYSIOL BIOCHEM, V26, P1081, DOI 10.1159/000323986
   Liu HF, 2009, DRUG METAB DISPOS, V37, P2290, DOI 10.1124/dmd.109.029819
   Meng X, 2014, FREE RADICAL RES, V48, P445, DOI 10.3109/10715762.2014.885117
   Negri S, 2020, STEM CELL TRANSL MED, V9, P1617, DOI 10.1002/sctm.20 0152
   Ng TB, 2006, J PHARM PHARMACOL, V58, P1007, DOI 10.1211/jpp.58.8.0001
   Ng TB, 2004, J ETHNOPHARMACOL, V93, P285, DOI 10.1016/j.jep.2004.03.040
   Qiang H, 2010, CHIN J INTEGR MED, V16, P525, DOI 10.1007/s11655 010 0566 1
   Shen Y, 2010, J NAT MED TOKYO, V64, P336, DOI 10.1007/s11418 010 0416 7
   Towler DA, 2003, OSTEOPOROSIS INT, V14, pS46, DOI 10.1007/s00198 003 1473 5
   Wang Y, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906 016 1304 9
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Yang M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16003
   Zhang YG, 2008, CLIN EXP PHARMACOL P, V35, P1238, DOI 10.1111/j.1440 1681.2008.04997.x
   Zhao GR, 2006, FOOD CHEM, V99, P767, DOI 10.1016/j.foodchem.2005.09.002
   Zheng HZ, 2013, J ETHNOPHARMACOL, V147, P595, DOI 10.1016/j.jep.2013.03.043
NR 31
TC 14
Z9 18
U1 1
U2 24
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314 6133
EI 2314 6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD DEC 14
PY 2020
VL 2020
AR 8412468
DI 10.1155/2020/8412468
PG 8
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA PM1PB
UT WOS:000603579200005
PM 33415157
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Lee, PH
   Yew, TL
   Lai, YL
   Lee, SY
   Chen, HL
AF Lee, Po Hui
   Yew, Tu Lai
   Lai, Yu Lin
   Lee, Shyh Yuan
   Chen, Hen Li
TI Parathyroid hormone gene activated matrix with DFDBA/collagen composite
   matrix enhances bone regeneration in rat calvarial bone defects
SO JOURNAL OF THE CHINESE MEDICAL ASSOCIATION
LA English
DT Article
DE Allografts; Bone morphogenetic proteins; Bone regeneration; Gene
   therapy; Parathyroid hormone
ID DELIVERY IN VIVO; POSTMENOPAUSAL WOMEN; PROTEIN KINASE; GROWTH FACTOR;
   ALLOGRAFT; PTH; OSTEOPOROSIS; INTERMITTENT; COLLAGEN; CELLS
AB Background: Gene activated matrix (GAM) induces sustained local production of growth factors to promote tissue regeneration. GAM contains a plasmid DNA (pDNA) encoding target proteins that is physically entrapped within a biodegradable matrix carrier. GAM with a pDNA encoding the first 34 amino acids of parathyroid hormone (PTH 1 34) and a collagen matrix enhances bone regeneration in long bone defects. Demineralized freeze dried bone allograft (DFDBA) is a widely used osteoinductive bone graft. The present study determined the osteogenic effects of PTH GAM with a collagen or DFDBA/collagen composite (D/C) matrix for treating craniofacial bone defects.
   Methods: We constructed a pDNA encoding human PTH 1 34 and performed cyclic AMP ELISA to verify the bioactivity of PTH 1 34. Next, we generated a D/C matrix and PTH GAMs containing a collagen matrix (PTH C GAM) or D/C matrix (PTH D/C GAM). Rats with critical sized calvarial bone defects were divided into four groups, namely, untreated rats (sham group) and rats grafted with D/C matrix, PTH C GAM, or PTH D/C GAM (D/C, PTH C GAM, or PTH D/C GAM groups, respectively). PTH expression was determined by performing immunohistochemical staining after 4 and 8 weeks. New bone formation was evaluated by performing radiography, dual energy X ray absorptiometry, microcomputed tomography, and histological examination.
   Results: PTH pDNA transfected cells secreted bioactive PTH 1 34. Moreover, PTH was expressed at 4 and 8 weeks after the surgery in rats in the PTH C GAM group but not in rats in the D/C group. New bone formation in the calvarial bone defects, from more to less, was in the order of PTH D/C GAM, PTH C GAM, D/C, and sham groups.
   Conclusion: Our results indicate that PTH GAM with a collagen matrix promotes local PTH production for at least 8 weeks and bone regeneration in craniofacial bone defect. Moreover, our results indicate that replacement of the collagen matrix with the D/C matrix improves the osteogenic effects of PTH GAM. Copyright (C) 2018, the Chinese Medical Association. Published by Elsevier Taiwan LLC.
C1 [Lee, Po Hui; Chen, Hen Li] Natl Yang Ming Univ, Inst Oral Biol, Taipei, Taiwan.
   [Yew, Tu Lai] Natl Yang Ming Univ, Dept Biotechnol, Taipei, Taiwan.
   [Yew, Tu Lai] Natl Yang Ming Univ, Lab Sci Med, Taipei, Taiwan.
   [Lai, Yu Lin; Lee, Shyh Yuan; Chen, Hen Li] Taipei Vet Gen Hosp, Dept Stomatol, Taipei, Taiwan.
   [Lai, Yu Lin; Lee, Shyh Yuan; Chen, Hen Li] Natl Yang Ming Univ, Dept Dent, 155,Sect 2,Linong St, Taipei 112, Taiwan.
C3 National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung
   University; National Yang Ming Chiao Tung University; Taipei Veterans
   General Hospital; National Yang Ming Chiao Tung University
RP Chen, HL (通讯作者)，Natl Yang Ming Univ, Dept Dent, 155,Sect 2,Linong St, Taipei 112, Taiwan.
EM hlchen2@ym.edu.tw
RI Liu, Liqun/HRE 2145 2023; Lee, Shyh Yuan/F 8295 2012
OI Lee, Shyh Yuan/0000 0002 9880 2372
FU Taipei Veterans General Hospital, Taiwan [VGH94365 6]; National Health
   Research Institutes, Taiwan [NHRI EX94 9305SC]; National Research
   Program for Biopharmaceuticals (NRPB) at the Ministry of Science and
   Technology (MOST) of Taiwan [MOST 105 2325 B 001 010]
FX This study was funded primarily by the Taipei Veterans General Hospital,
   Taiwan [grant number VGH94365 6] and the National Health Research
   Institutes, Taiwan [grant number NHRI EX94 9305SC]. We thank the Taiwan
   Mouse Clinic [grant number MOST 105 2325 B 001 010] which is funded by
   the National Research Program for Biopharmaceuticals (NRPB) at the
   Ministry of Science and Technology (MOST) of Taiwan for mu CT technical
   support in the rat calvarial defect experiment.
CR Bonadio J, 1999, NAT MED, V5, P753, DOI 10.1038/10473
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Bright C, 2006, SPINE, V31, P2163, DOI 10.1097/01.brs.0000232721.59901.45
   Chen DC, 2007, J BIOMED MATER RES A, V80A, P399, DOI 10.1002/jbm.a.30932
   Chen H, 2003, CLIN ORTHOP RELAT R, P291, DOI 10.1097/01.blo.0000079443.64912.18
   D'Mello S, 2017, AAPS J, V19, P43, DOI 10.1208/s12248 016 9982 2
   Dobnig H, 2004, EXPERT OPIN PHARMACO, V5, P1153, DOI 10.1517/eoph.5.5.1153.31088
   Elangovan S, 2014, BIOMATERIALS, V35, P737, DOI 10.1016/j.biomaterials.2013.10.021
   Erclik MS, 2002, AM J PHYSIOL ENDOC M, V282, pE534, DOI 10.1152/ajpendo.00417.2001
   Evans CH, 2012, ADV DRUG DELIVER REV, V64, P1331, DOI 10.1016/j.addr.2012.03.013
   Fang JM, 1996, P NATL ACAD SCI USA, V93, P5753, DOI 10.1073/pnas.93.12.5753
   Huang YC, 2005, GENE THER, V12, P418, DOI 10.1038/sj.gt.3302439
   Jang JH, 2005, MOL THER, V12, P475, DOI 10.1016/j.ymthe.2005.03.036
   Kaito Takashi, 2016, Bone Rep, V5, P173, DOI 10.1016/j.bonr.2016.07.003
   KANO J, 1994, BIOCHEM BIOPH RES CO, V199, P271, DOI 10.1006/bbrc.1994.1224
   Kempen DHR, 2010, TISSUE ENG PT A, V16, P3769, DOI [10.1089/ten.tea.2010.0173, 10.1089/ten.TEA.2010.0173]
   Khan SN, 2004, EXPERT OPIN BIOL TH, V4, P741
   Kohles SS, 2000, CALCIFIED TISSUE INT, V67, P156, DOI 10.1007/s00223001127
   Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140 6736(97)02342 8
   Lohmann CH, 2001, ARCH ORTHOP TRAUM SU, V121, P583, DOI 10.1007/s004020100291
   Lu CH, 2013, BIOTECHNOL ADV, V31, P1695, DOI 10.1016/j.biotechadv.2013.08.015
   Missana LR, 2014, J BIOMED MATER RES A, V102, P4358, DOI 10.1002/jbm.a.35114
   Mohan S, 2000, BONE, V27, P471, DOI 10.1016/S8756 3282(00)00355 0
   Morgan EF, 2008, BONE, V43, P1031, DOI 10.1016/j.bone.2008.07.251
   MOSEKILDE L, 1991, ENDOCRINOLOGY, V129, P421, DOI 10.1210/endo 129 1 421
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nevins M, 2005, J PERIODONTOL, V76, P2205, DOI 10.1902/jop.2005.76.12.2205
   OXLUND H, 1993, CALCIFIED TISSUE INT, V53, P394
   POLSON AM, 1978, J CLIN PERIODONTOL, V5, P13, DOI 10.1111/j.1600 051X.1978.tb01902.x
   Schwartz Z, 1996, J PERIODONTOL, V67, P918, DOI 10.1902/jop.1996.67.9.918
   Schwartz Z, 1998, J PERIODONTOL, V69, P470, DOI 10.1902/jop.1998.69.4.470
   Shea LD, 1999, NAT BIOTECHNOL, V17, P551, DOI 10.1038/9853
   Shen V, 2000, J BONE MINER RES, V15, P740, DOI 10.1359/jbmr.2000.15.4.740
   Sheyn D, 2013, MOL PHARMACEUT, V10, P4462, DOI 10.1021/mp400292p
   SHIGEYAMA Y, 1995, J PERIODONTOL, V66, P478, DOI 10.1902/jop.1995.66.6.478
   Silva ED, 2015, MED ORAL PATOL ORAL, V20, pE489, DOI 10.4317/medoral.20412
   TAKAGI K, 1982, ANN SURG, V196, P100, DOI 10.1097/00000658 198207000 00020
   Tsai CH, 2002, J BIOMED MATER RES, V63, P65, DOI 10.1002/jbm.10089
   UZAWA T, 1995, BONE, V16, P477
   Valderrama P, 2010, J PERIODONTOL, V81, P737, DOI 10.1902/jop.2010.090562
   Wildemann B., 2007, Cell and Tissue Banking, V8, P107, DOI 10.1007/s10561 006 9021 0
   Winn S R, 2005, Orthod Craniofac Res, V8, P183, DOI 10.1111/j.1601 6343.2005.00332.x
   Yang D, 2007, BONE, V40, P1453, DOI 10.1016/j.bone.2007.02.001
NR 43
TC 5
Z9 7
U1 0
U2 9
PU ELSEVIER TAIWAN
PI TAIPEI
PA RM N 412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2,
   TAIPEI, 10449, TAIWAN
SN 1726 4901
EI 1728 7731
J9 J CHIN MED ASSOC
JI J. Chin. Med. Assoc.
PD AUG
PY 2018
VL 81
IS 8
BP 699
EP 707
DI 10.1016/j.jcma.2017.12.004
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA GO1BV
UT WOS:000439681300007
PM 29551486
OA hybrid
DA 2025 08 17
ER

PT J
AU Jamieson, WL
   Shimizu, S
   DAmbrosio, JA
   Meucci, O
   Fatatis, A
AF Jamieson, Whitney L.
   Shimizu, Saori
   DAmbrosio, Julia A.
   Meucci, Olimpia
   Fatatis, Alessandro
TI CX3CR1 is expressed by prostate epithelial cells and androgens regulate
   the levels of CX3CL1/fractalkine in the bone marrow: Potential role in
   prostate cancer bone tropism
SO CANCER RESEARCH
LA English
DT Article
ID HEMATOPOIETIC PROGENITOR CELLS; ENDOTHELIAL CELLS; CHEMOKINE
   FRACTALKINE; FUNCTIONAL EXPRESSION; ADHESION; RECEPTOR; METASTASIS;
   INTEGRIN; DIHYDROTESTOSTERONE; LOCALIZATION
AB We have previously shown that the chemokine fractalkine promotes the adhesion of human prostate cancer cells to bone marrow endothelial cells as well as their migration toward human ostcoblasts in vitro. Thus, the interaction of fractalkine with its receptor CX3CR1 could play a crucial role in vivo by directing circulating prostate cancer cells to the bone. We found that although CX3CR1 is minimally detectable in epithelial cells of normal prostate glands, it is overexpressed upon malignant transformation. Interestingly, osteoblasts, stromal and mesenchymal cells derived from human bone marrow aspirates express the cell bound form of fractalkine, whereas the soluble form of the chemokine is detected in bone marrow supernatants. To investigate the mechanisms regulating the levels of soluble fractalkine in the bone marrow, we focused on androgens, which play a critical role in both prostate cancer progression and skeletal metastasis. Here, we show that dihydrotestosterone dramatically increases the cleavage of fractalkine from the plasma membrane of bone cells and its action is reversed by nilutamide an antagonist of the androgen receptor as well as the wide spectrum inhibitor of matrix metalloproteases, GM6001. However, dihydrotestosterone was unable to induce fractalkine cleavage from human bone marrow endothelial cells. Thus, androgens could promote the extravasation of CX3CR1 bearing cancer cells on a fractalkine concentration gradient, while leaving unaltered their ability to adhere to the bone marrow endothelium. In conclusion, our results indicate that CX3CR1, fractalkine, and the enzymes responsible for its cleavage might represent suitable targets for therapies aiming to counteract skeletal secondary tumors from prostate adenocarcinoma.
C1 [Jamieson, Whitney L.; Shimizu, Saori; DAmbrosio, Julia A.; Meucci, Olimpia; Fatatis, Alessandro] Drexel Univ, Coll Med, Dept Physiol & Pharmacol, Philadelphia, PA 19102 USA.
   [Fatatis, Alessandro] Drexel Univ, Coll Med, Dept Pathol, Philadelphia, PA 19102 USA.
   [Fatatis, Alessandro] Drexel Univ, Coll Med, Dept Lab Med, Philadelphia, PA 19102 USA.
C3 Drexel University; Drexel University; Drexel University
RP Fatatis, A (通讯作者)，Drexel Univ, Coll Med, Dept Physiol & Pharmacol, Philadelphia, PA 19102 USA.
EM afatatis@drexelmed.edu
FU NIDA NIH HHS [R37 DA015014, R01 DA019808, DA19808, DA15014, R01
   DA015014] Funding Source: Medline; NIGMS NIH HHS [GM067892, R01
   GM067892] Funding Source: Medline
CR Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388
   Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0
   Burger M, 2003, ONCOGENE, V22, P8093, DOI 10.1038/sj.onc.1207097
   Cardones AR, 2003, CANCER RES, V63, P6751
   Chapman GA, 2000, EUR J PHARMACOL, V392, P189, DOI 10.1016/S0014 2999(00)00117 5
   Chipman S.F., 1985, THINKING LEARNING SK, V1, P1
   Combadiere C, 1998, BIOCHEM BIOPH RES CO, V253, P728, DOI 10.1006/bbrc.1998.9849
   Compston JE, 2001, PHYSIOL REV, V81, P419, DOI 10.1152/physrev.2001.81.1.419
   Dole EJ, 1997, ANN PHARMACOTHER, V31, P65, DOI 10.1177/106002809703100112
   Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413
   GALARDY RE, 1994, ANN NY ACAD SCI, V732, P315, DOI 10.1111/j.1749 6632.1994.tb24746.x
   Garton KJ, 2001, J BIOL CHEM, V276, P37993
   Goda S, 2000, J IMMUNOL, V164, P4313, DOI 10.4049/jimmunol.164.8.4313
   Hoogewerf AJ, 1997, BIOCHEMISTRY US, V36, P13570, DOI 10.1021/bi971125s
   Imai K, 1999, BRIT J HAEMATOL, V106, P905, DOI 10.1046/j.1365 2141.1999.01644.x
   Karan D, 2003, INT J ONCOL, V23, P1365
   Kawano H, 2003, P NATL ACAD SCI USA, V100, P9416, DOI 10.1073/pnas.1533500100
   Lehr JE, 1998, J NATL CANCER I, V90, P118, DOI 10.1093/jnci/90.2.118
   Liu GY, 2005, J BIOL CHEM, V280, P19858, DOI 10.1074/jbc.M413073200
   Lucas AD, 2003, CIRCULATION, V108, P2498, DOI 10.1161/01.CIR.0000097119.57756.EF
   Mantalaris A, 2001, J PATHOL, V193, P361, DOI 10.1002/1096 9896(0000)9999:9999<::AID PATH803>3.0.CO;2 W
   McCulloch DR, 2004, CLIN CANCER RES, V10, P314, DOI 10.1158/1078 0432.CCR 0846 3
   McCulloch DR, 2000, MOL CELL ENDOCRINOL, V167, P11, DOI 10.1016/S0303 7207(00)00305 1
   Moore MAS, 2001, BIOESSAYS, V23, P674, DOI 10.1002/bies.1095
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Netelenbos T, 2003, LEUKEMIA, V17, P175, DOI 10.1038/sj.leu.2402738
   Orr FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096 9896(200002)190:3<310::AID PATH525>3.0.CO;2 P
   Schlöndorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264 6021:3470131
   See WA, 2002, J UROLOGY, V168, P429, DOI 10.1016/S0022 5347(05)64652 6
   Shulby SA, 2004, CANCER RES, V64, P4693, DOI 10.1158/0008 5472.CAN 03 3437
   Taichman RS, 2002, CANCER RES, V62, P1832
   Tsou CL, 2001, J BIOL CHEM, V276, P44622, DOI 10.1074/jbc.M107327200
   Verrier S, 2004, BONE, V35, P34, DOI 10.1016/j.bone.2003.12.029
   Vicari AP, 2002, CYTOKINE GROWTH F R, V13, P143, DOI 10.1016/S1359 6101(01)00033 8
NR 34
TC 94
Z9 116
U1 0
U2 11
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 0008 5472
J9 CANCER RES
JI Cancer Res.
PD MAR 15
PY 2008
VL 68
IS 6
BP 1715
EP 1722
DI 10.1158/0008 5472.CAN 07 1315
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 274TO
UT WOS:000254024400015
PM 18339851
OA Green Accepted, Green Submitted, Bronze
DA 2025 08 17
ER

PT J
AU Aoi, N
   Inoue, K
   Chikanishi, T
   Fujiki, R
   Yamamoto, H
   Kato, H
   Eto, H
   Doi, K
   Itami, S
   Kato, S
   Yoshimura, K
AF Aoi, Noriyuki
   Inoue, Keita
   Chikanishi, Toshihiro
   Fujiki, Ryoji
   Yamamoto, Hanako
   Kato, Harunosuke
   Eto, Hitomi
   Doi, Kentaro
   Itami, Satoshi
   Kato, Shigeaki
   Yoshimura, Kotaro
TI 1α,25 Dihydroxyvitamin D3 Modulates the Hair Inductive
   Capacity of Dermal Papilla Cells: Therapeutic Potential for Hair
   Regeneration
SO STEM CELLS TRANSLATIONAL MEDICINE
LA English
DT Article
ID VITAMIN D RECEPTOR; FOLLICLE DEVELOPMENT; MOLECULAR MECHANISM;
   ANTAGONISTIC ACTION; EAR WOUNDS; HUMAN SKIN; IN VIVO; GROWTH; GENE;
   EXPRESSION
AB Dermal papilla cells (DPCs) have the potential to induce differentiation of epithelial stem cells into hair, and Wnt signaling is deeply involved in the initiation process. The functional limitation of expanded adult DPCs has been a difficult challenge for cell based hair regrowth therapy. We previously reported that 1 alpha,25 dihydroxyvitamin D 3 (VD3) upregulates expression of transforming growth factor (TGF) beta 2 and alkaline phosphatase (ALP) activity, both features of hair inducing human DPCs (hDPCs). In this study, we further examined the effects and signaling pathways associated with VD3 actions on DPCs. VD3 suppressed hDPC proliferation in a dose dependent, noncytotoxic manner. Among the Wnt related genes investigated, Wnt10b expression was significantly upregulated by VD3 in hDPCs. Wnt10b upregulation, as well as upregulation of ALPL (ALP, liver/bone/kidney) and TGF beta 2, by VD, was specific in hDPCs and not detected in human dermal fibroblasts. Screening of paracrine or endocrine factors in the skin indicated that all trans retinoic acid (atRA) upregulated Wnt10b gene expression, although synergistic upregulation (combined atRA and VD3) was not seen. RNA interference with vitamin D receptor (VDR) revealed that VD3 upregulation of Wnt10b, ALPL, and TGF beta 2 was mediated through the genomic VDR pathway. In a rat model of de novo hair regeneration by murine DPC transplantation, pretreatment with VD3 significantly enhanced hair folliculogenesis. Specifically, a greater number of outgrowing hair shafts and higher maturation of regenerated follicles were observed. Together, these data suggest that VD3 may promote functional differentiation of DPCs and be useful in preserving the hair follicle inductive capacity of cultured DPCs for hair regeneration therapies. STEM CELLS TRANSLATIONAL MEDICINE 2012;1:615 626
C1 [Yoshimura, Kotaro] Univ Tokyo, Sch Med, Dept Plast Surg, Bunkyo Ku, Tokyo 1138655, Japan.
   [Yamamoto, Hanako] Univ Tokyo, Sch Med, Dept Biochem & Mol Biol, Tokyo 1138655, Japan.
   [Chikanishi, Toshihiro; Kato, Shigeaki] Japan Sci & Technol Agcy, ERATO, Saitama, Japan.
   [Chikanishi, Toshihiro; Fujiki, Ryoji; Kato, Shigeaki] Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1138655, Japan.
   [Itami, Satoshi] Osaka Univ, Grad Sch Med, Dept Regenerat Dermatol, Suita, Osaka, Japan.
C3 University of Tokyo; University of Tokyo; Japan Science & Technology
   Agency (JST); University of Tokyo; University of Osaka
RP Yoshimura, K (通讯作者)，Univ Tokyo, Sch Med, Dept Plast Surg, Bunkyo Ku, 7 3 1 Hongo, Tokyo 1138655, Japan.
EM yoshimura@umin.ac.jp
RI Yoshimura, Kotaro/C 8524 2009
OI Yoshimura, Kotaro/0000 0002 7152 5475
FU Japanese Ministry of Education, Culture, Sports, Science, and Technology
   [18591964, 21791738]; Japanese Society of Anti Aging Medicine;
   Grants in Aid for Scientific Research [21791738, 18591964] Funding
   Source: KAKEN
FX We thank Dr. Eiji Ochiai (Teijin Pharma Ltd., Tokyo, Japan) for
   technical supervision of the pVDR experiment and Ayako Kurata for
   technical assistance. This work was supported by Grants 18591964 and
   21791738 from the Japanese Ministry of Education, Culture, Sports,
   Science, and Technology and by the second Annual Research Award Grant of
   the Japanese Society of Anti Aging Medicine.
CR Aoi N, 2012, J TISSUE ENG REGEN M, V6, P85, DOI 10.1002/term.400
   Bikle DD, 2011, EXP DERMATOL, V20, P7, DOI 10.1111/j.1600 0625.2010.01202.x
   Bikle DD, 2010, J BONE MINER METAB, V28, P117, DOI 10.1007/s00774 009 0153 8
   Bouillon R, 2008, ENDOCR REV, V29, P726, DOI 10.1210/er.2008 0004
   Darwish Hisham, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P89
   DasGupta R, 1999, DEVELOPMENT, V126, P4557
   Driskell RR, 2011, J CELL SCI, V124, P1179, DOI 10.1242/jcs.082446
   Ellison TI, 2005, MOL ENDOCRINOL, V19, P2309, DOI 10.1210/me.2004 0382
   Foitzik K, 1999, DEV BIOL, V212, P278, DOI 10.1006/dbio.1999.9325
   Havlickova B, 2009, J INVEST DERMATOL, V129, P972, DOI 10.1038/jid.2008.315
   Higgins CA, 2010, EXP DERMATOL, V19, P546, DOI 10.1111/j.1600 0625.2009.01007.x
   HORNE KA, 1986, J EMBRYOL EXP MORPH, V97, P111
   Iida M, 2007, DEV GROWTH DIFFER, V49, P185, DOI 10.1111/j.1440 169x.2007.00907.x
   Inamatsu M, 1998, J INVEST DERMATOL, V111, P767, DOI 10.1046/j.1523 1747.1998.00382.x
   Inoue K, 2009, J CELL MOL MED, V13, P4643, DOI 10.1111/j.1582 4934.2009.00739.x
   Ito M, 2007, NATURE, V447, P316, DOI 10.1038/nature05766
   JAHODA CAB, 1993, J INVEST DERMATOL, V101, P584, DOI 10.1111/1523 1747.ep12366039
   JAHODA CAB, 1992, DEVELOPMENT, V115, P1103
   Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193
   Kang SW, 1997, J INVEST DERMATOL, V108, P513, DOI 10.1111/1523 1747.ep12289736
   Kennel KA, 2010, MAYO CLIN PROC, V85, P752, DOI 10.4065/mcp.2010.0138
   Kishimoto J, 2000, GENE DEV, V14, P1181
   Kratochwil K, 1996, GENE DEV, V10, P1382, DOI 10.1101/gad.10.11.1382
   Lehmann B, 2003, ARCH DERMATOL RES, V295, P24, DOI 10.1007/s00403 003 0387 6
   Lemon BD, 1996, MOL CELL BIOL, V16, P1006
   Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831
   LICHTI U, 1993, J INVEST DERMATOL, V101, pS124, DOI 10.1111/1523 1747.ep12363165
   Mamede AC, 2011, NUTR CANCER, V63, P479, DOI 10.1080/01635581.2011.539315
   McCullough ML, 2009, ANNU REV NUTR, V29, P111, DOI 10.1146/annurev nutr 080508 141248
   McElwee KJ, 2003, J INVEST DERMATOL, V121, P1267, DOI 10.1111/j.1523 1747.2003.12568.x
   Menegaz D, 2010, J STEROID BIOCHEM, V119, P127, DOI 10.1016/j.jsbmb.2010.01.011
   Millar SE, 2002, J INVEST DERMATOL, V118, P216, DOI 10.1046/j.0022 202x.2001.01670.x
   Miller J, 2001, J INVEST DERMATOL, V117, P612, DOI 10.1046/j.0022 202x.2001.01438.x
   Miura D, 1999, J BIOL CHEM, V274, P16392, DOI 10.1074/jbc.274.23.16392
   Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950
   Ochiai E, 2005, MOL ENDOCRINOL, V19, P1147, DOI 10.1210/me.2004 0234
   Osada A, 2007, TISSUE ENG, V13, P975, DOI 10.1089/ten.2006.0304
   Oshimori N, 2012, CELL STEM CELL, V10, P63, DOI 10.1016/j.stem.2011.11.005
   Ouji Y, 2006, BIOCHEM BIOPH RES CO, V345, P581, DOI 10.1016/j.bbrc.2006.04.142
   Ouji Y, 2007, BIOCHEM BIOPH RES CO, V359, P516, DOI 10.1016/j.bbrc.2007.05.135
   Ozono K, 1999, J BIOL CHEM, V274, P32376, DOI 10.1074/jbc.274.45.32376
   Paus R, 1999, J INVEST DERMATOL, V113, P523, DOI 10.1046/j.1523 1747.1999.00740.x
   Paus R, 1996, CANCER RES, V56, P4438
   Qiao J, 2008, EXP DERMATOL, V17, P512, DOI 10.1111/j.1600 0625.2007.00661.x
   Qiao JZ, 2009, REGEN MED, V4, P667, DOI 10.2217/RME.09.50
   Reddy S, 2001, MECH DEVELOP, V107, P69, DOI 10.1016/S0925 4773(01)00452 X
   Rendl M, 2008, GENE DEV, V22, P543, DOI 10.1101/gad.1614408
   REYNOLDS AJ, 1992, DEVELOPMENT, V115, P587
   RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092 8674(75)80001 8
   Sakai Y, 2001, J CLIN INVEST, V107, P961, DOI 10.1172/JCI11676
   Sutton ALM, 2003, MOL ENDOCRINOL, V17, P777, DOI 10.1210/me.2002 0363
   WEINBERG WC, 1993, J INVEST DERMATOL, V100, P229, DOI 10.1111/1523 1747.ep12468971
   Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897 391
   Zanello LP, 2006, STEROIDS, V71, P291, DOI 10.1016/j.steroids.2005.09.012
   Zhang YH, 2009, DEV CELL, V17, P49, DOI 10.1016/j.devcel.2009.05.011
   Zhou YL, 2009, J BONE MINER RES, V24, P643, DOI 10.1359/JBMR.081216
NR 56
TC 31
Z9 37
U1 1
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2157 6564
EI 2157 6580
J9 STEM CELL TRANSL MED
JI Stem Cells Transl. Med.
PD AUG
PY 2012
VL 1
IS 8
BP 615
EP 626
DI 10.5966/sctm.2012 0032
PG 12
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 057OE
UT WOS:000312572100010
PM 23197867
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zanardi, I
   Zifarelli, G
   Pusch, M
AF Zanardi, Ilaria
   Zifarelli, Giovanni
   Pusch, Michael
TI An optical assay of the transport activity of ClC 7
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CHLORIDE CHANNEL; BONE RESORPTION; PROKARYOTIC HOMOLOG; REQUIRES OSTM1;
   OSTEOPETROSIS; OSTEOPOROSIS; PATHOLOGY; BINDING; PROTEIN; CIC 7
AB Osteoporosis, characterized by excessive osteoclast mediated bone resorption, affects millions of people worldwide representing a major public health problem. ClC 7 is a chloride proton exchanger localized in lysosomes and in the resorption lacuna in osteoclasts where it is essential for bone resorption. Thus, drugs targeted at ClC 7 have been proposed for ameliorating osteoporosis. However, functional assays suited for high throughput screening (HTS) of ClC 7 function are lacking. Here we describe two complementary variants of purely optical assays of the transport activity of ClC 7, redirected to the plasma membrane employing a genetically encoded fluorescent Cl /pH indicator fused to the ClC 7 protein. These simple and robust functional assays of ClC 7 transport are well suited to be applied in HTS of small molecule inhibitors and may help to develop drugs suited for the treatment of osteoporosis.
C1 [Zanardi, Ilaria; Zifarelli, Giovanni; Pusch, Michael] CNR, Ist Biofis, I 16149 Genoa, Italy.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica
   (IBF CNR)
RP Pusch, M (通讯作者)，CNR, Ist Biofis, Via De Marini 6, I 16149 Genoa, Italy.
EM pusch@ge.ibf.cnr.it
RI ; Pusch, Michael/ACU 0378 2022
OI Pusch, Michael/0000 0002 8644 8847; Zanardi, Ilaria/0000 0002 5254 7433;
   
FU Italian Institute of Technology (progetto SEED); Telethon Italy
   [GGP12008]; Italian Ministry of Education (progetto PRIN); Compagnia San
   Paolo
FX We thank D. Arosio for the E<SUP>2</SUP>GFP/DsRed clone, T.J. Jentsch
   for the WT clones of ClC 7 and Ostm1, E. Lingueglia for the FaNaCh
   clone, A. Gradogna and S. De Stefano for help with the oocyte injection,
   A. Liantonio and D. Conte Camerino for sharing chloride channel
   blockers, and F. Quartino, A. Barbin, and D. Magliozzi for technical
   assistance. The financial support by the Italian Institute of Technology
   (progetto SEED), Telethon Italy (grant GGP12008), the Italian Ministry
   of Education (progetto PRIN), and the Compagnia San Paolo is gratefully
   acknowledged.
CR Accardi A, 2004, J GEN PHYSIOL, V123, P109, DOI 10.1085/jgp.200308935
   Accardi A, 2004, NATURE, V427, P803, DOI 10.1038/nature02314
   Arosio D, 2010, NAT METHODS, V7, P516, DOI [10.1038/NMETH.1471, 10.1038/nmeth.1471]
   BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210
   Chalhoub N, 2003, NAT MED, V9, P399, DOI 10.1038/nm842
   Costa A, 2012, J PHYSIOL LONDON, V590, P3421, DOI 10.1113/jphysiol.2012.230227
   De Angeli A, 2006, NATURE, V442, P939, DOI 10.1038/nature05013
   Eggermont J, 2001, CELL BIOCHEM BIOPHYS, V35, P263, DOI 10.1385/CBB:35:3:263
   Estévez R, 2003, NEURON, V38, P47, DOI 10.1016/S0896 6273(03)00168 5
   Jensen VK, 2011, ASSAY DRUG DEV TECHN, V9, P157, DOI 10.1089/adt.2010.0272
   Jentsch TJ, 2008, CRIT REV BIOCHEM MOL, V43, P3, DOI [10.1080/10409230701829110, 10.1080/10409230701829110 ]
   Kasper D, 2005, EMBO J, V24, P1079, DOI 10.1038/sj.emboj.7600576
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092 8674(01)00206 9
   Lange PF, 2006, NATURE, V440, P220, DOI 10.1038/nature04535
   Leisle L, 2011, EMBO J, V30, P2140, DOI 10.1038/emboj.2011.137
   Liantonio A, 2002, MOL PHARMACOL, V62, P265, DOI 10.1124/mol.62.2.265
   Liantonio A, 2008, P NATL ACAD SCI USA, V105, P1369, DOI 10.1073/pnas.0708977105
   LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0
   Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362
   Picollo A, 2005, NATURE, V436, P420, DOI 10.1038/nature03720
   Pressey S. N., J NEUROPATHOL EXP NE, V69, P1228
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Schaller S, 2004, J BONE MINER RES, V19, P1144, DOI 10.1359/JBMR.040302
   Scheel O, 2005, NATURE, V436, P424, DOI [10.1038/nature03860, 10.1038/nature0386O]
   Silverman S, 2012, OSTEOPOROSIS INT, V23, P797, DOI 10.1007/s00198 011 1775 y
   Stauber T, 2010, J BIOL CHEM, V285, P34537, DOI 10.1074/jbc.M110.162545
   STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Trichas G, 2008, BMC BIOL, V6, DOI 10.1186/1741 7007 6 40
   Weinert S, 2010, SCIENCE, V328, P1401, DOI 10.1126/science.1188072
   Woolf AD, 2003, B WORLD HEALTH ORGAN, V81, P646
   Zifarelli G, 2007, REV PHYSIOL BIOCH P, V158, P23, DOI 10.1007/112_2006_0605
NR 33
TC 9
Z9 10
U1 0
U2 10
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD FEB 6
PY 2013
VL 3
AR 1231
DI 10.1038/srep01231
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 086SD
UT WOS:000314706300006
PM 23390581
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kwan, KKL
   Dong, TNTX
   Tsim, KWK
AF Kwan, Kenneth Kin Leung
   Dong, Tina Ting Xia
   Tsim, Karl Wah Keung
TI Danggui Buxue Tang, a Chinese herbal decoction containing Astragali
   Radix and Angelicae Sinensis Radix, improves mitochrondial bioenergetics
   in osteoblast
SO PHYTOMEDICINE
LA English
DT Article
DE Osteoporosis; Mitochondria; Bioenergetics; Bone proliferation and
   differentiation; Herbal medicine
ID DIFFERENTIATION; EXPRESSION; PHOSPHORYLATION; MITOCHONDRIA; BONE
AB Osteoporosis is the process of bone loss, particular after menopause, when the production of estrogen in women is decreaing. Bioenergetic function is one of the critical roles in bone remodeling. Danggui Buxue Tang (DBT) is an herbal mixture containing Astragali Radix (AR) and Angelicae Sinensis Radix (ASR), and which is consumed for "Qi invigorating", i.e., stimulating energy metabolism, as a traditional Chinese medicine (TCM). However, the role of DBT in metabolism of osteoblast has not been examined. Here, we employed a metabolic flux to examine the mitochondrial functions of cultured osteoblast in the presence of herbal extracts, including DBT, ASR, AR, AR + ASR (single mixing of two herbal extracts), as well as DBT.cal (a DBT extract depeleting calycosin), to examine their roles in osteoblastic metabolism, e.g. glycolysis and energy kinetics. By revealing the rates of oxygen consumption and extracellular acidification of mitochrondia, the DBT treated osteoblasts were markedly strengthened with increases of maximal respiration, spare capacity, glycolysis capacity and glycolysis reserve, in comparing to other herbal extracts. In addition, the bioenergetic metabolism was modulated by DBT via the signaling of cellular Ca2+ and reactive oxgen species (ROS). Furthermore, DBT affected the morphology of mitochondria, as well as mitochondrial dynamic. Here, we propose that DBT can be regarded as benefit herbal extract in improving osteoblastic metabolism for bone disorders via central energy metabolism and mitochondrial bioenergetics.
C1 [Kwan, Kenneth Kin Leung; Dong, Tina Ting Xia; Tsim, Karl Wah Keung] Shenzhen Res Inst, Shenzhen Key Lab Edible & Med Bioresources, Hitech Pk, Shenzhen 518000, Peoples R China.
   [Kwan, Kenneth Kin Leung; Dong, Tina Ting Xia; Tsim, Karl Wah Keung] Hong Kong Univ Sci & Technol, Div Life Sci, Clear Water Bay, Hong Kong, Peoples R China.
   [Kwan, Kenneth Kin Leung; Dong, Tina Ting Xia; Tsim, Karl Wah Keung] Hong Kong Univ Sci & Technol, Ctr Chinese Med, Clear Water Bay, Hong Kong, Peoples R China.
C3 Hong Kong University of Science & Technology; Hong Kong University of
   Science & Technology
RP Kwan, KKL (通讯作者)，Hong Kong Univ Sci & Technol, Div Life Sci, Clear Water Bay, Hong Kong, Peoples R China.; Kwan, KKL (通讯作者)，Hong Kong Univ Sci & Technol, Ctr Chinese Med, Clear Water Bay, Hong Kong, Peoples R China.
EM botsim@ust.hk
FU Foshan University of Science and Technology [FSUST19 SRI10]; Key Area
   Research and Development Program of Guangdong Province
   [2020B1111110006]; Shenzhen Science and Technology Innovation Committee
   [ZDSYS201707281432317, JCYJ2017 0413173747440, JCYJ2018030 6174903174];
   Zhongshan Municipal Bureau of Science and Technology [ZSST20SC03];
   Guangzhou Science and Technology Committee Research Grant [GZSTI16SC02,
   GZSTI17SC02]; Hong Kong RGC Theme based Research Scheme [T13 605/18 W];
   Hong Kong Innovation Technology Fund [ITS/500/18FP, TCPD/17 9]; 
   [TUYF19SC02];  [PD18SC01];  [HMRF18SC06];  [HMRF20SC07];  [AFD20SC01]
FX The authors appreciate Mr. W. S. Lee (Electron Microscope Unit, The
   University of Hong Kong) for his demonstration of TEM. This work is
   supported by Special project of Foshan University of Science and
   Technology in 2019 (FSUST19 SRI10); The Key Area Research and
   Development Program of Guangdong Province (2020B1111110006); Shenzhen
   Science and Technology Innovation Committee (ZDSYS201707281432317;
   JCYJ2017 0413173747440; JCYJ2018030 6174903174), Zhongshan Municipal
   Bureau of Science and Technology (ZSST20SC03); Guangzhou Science and
   Technology Committee Research Grant (GZSTI16SC02; GZSTI17SC02); Hong
   Kong RGC Theme based Research Scheme (T13 605/18 W); Hong Kong
   Innovation Technology Fund (ITS/500/18FP; TCPD/17 9); TUYF19SC02,
   PD18SC01 and HMRF18SC06; HMRF20SC07; AFD20SC01.
CR Arakaki N, 2013, BIOMED RES TOKYO, V34, P161, DOI 10.2220/biomedres.34.161
   Bok J, 2007, MOL CELL NEUROSCI, V36, P13, DOI 10.1016/j.mcn.2007.05.008
   Choi RCY, 2011, EVID BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nen085
   Chung Y., 2018, OSTEOPOROSIS SARCOPE, V4, DOI [10.1016/j.afos.2018.11.012.S3 S4, DOI 10.1016/J.AFOS.2018.11.012.S3 S4]
   Conley KE, 2016, J EXP BIOL, V219, P243, DOI 10.1242/jeb.126623
   Davis G., 2003, CURR HEPATITIS REP, V2, P40, DOI [10.1007/s11901 003 0013 2, DOI 10.1007/S11901 003 0013 2]
   Dobson PF, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 68566 2
   Dong TTX, 2006, J AGR FOOD CHEM, V54, P2767, DOI 10.1021/jf053163l
   Gao QT, 2008, PLANTA MED, V74, P392, DOI 10.1055/s 2008 1034322
   Gao QT, 2007, FEBS LETT, V581, P233, DOI 10.1016/j.febslet.2006.12.018
   GERSTENFELD LC, 1987, DEV BIOL, V122, P49, DOI 10.1016/0012 1606(87)90331 9
   Gong AGW, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00036
   Gong AGW, 2016, PLANTA MED, V82, P418, DOI 10.1055/s 0035 1558332
   Gong AGW, 2015, J ETHNOPHARMACOL, V168, P150, DOI 10.1016/j.jep.2015.03.033
   Gong GW, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/3648685
   Kwan KKL, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00614
   Langenbach F, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt328
   Lee N, 2012, BONE, V50, pS62, DOI 10.1016/j.bone.2012.02.173
   Li JH, 2019, NAT COMMUN, V10
   Lin HQ, 2017, J ETHNOPHARMACOL, V199, P205, DOI 10.1016/j.jep.2017.01.044
   Lindsay R., 1996, OSTEOPOROS INT, V6, P305, DOI [10.1007/bf02500739, DOI 10.1007/BF02500739]
   Ooi CG, 1999, BONE, V24, p27S, DOI 10.1016/S8756 3282(99)00036 8
   Osellame LD, 2012, BEST PRACT RES CL EN, V26, P711, DOI 10.1016/j.beem.2012.05.003
   Park J, 2019, BONE, V124, P22, DOI 10.1016/j.bone.2019.04.009
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rossi A, 2019, BBA MOL CELL RES, V1866, P1068, DOI 10.1016/j.bbamcr.2018.10.016
   SALVADOR RA, 1973, ARCH BIOCHEM BIOPHYS, V154, P583, DOI 10.1016/0003 9861(73)90012 X
   Smith RL, 2018, ENDOCR REV, V39, P489, DOI 10.1210/er.2017 00211
   Sun N, 2016, MOL CELL, V61, P654, DOI 10.1016/j.molcel.2016.01.028
   Valente AJ, 2017, ACTA HISTOCHEM, V119, P315, DOI 10.1016/j.acthis.2017.03.001
   Warriner AH, 2009, CURR OPIN RHEUMATOL, V21, P356, DOI 10.1097/BOR.0b013e32832c6aa4
   Wu QY, 2020, FASEB J, V34, P8941, DOI 10.1096/fj.202000708R
   Xu ML, 2016, CHEM BIOL INTERACT, V259, P295, DOI 10.1016/j.cbi.2016.03.025
   Yavropoulou Maria P, 2007, Hormones (Athens), V6, P279
   Yu AXD, 2020, FASEB J, V34, P4311, DOI 10.1096/fj.201902319RRR
   Zhou T, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/8928934
NR 36
TC 19
Z9 23
U1 4
U2 37
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944 7113
EI 1618 095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD JUL 15
PY 2021
VL 88
AR 153605
DI 10.1016/j.phymed.2021.153605
EA JUN 2021
PG 8
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA SS4OC
UT WOS:000661732400015
PM 34107409
DA 2025 08 17
ER

PT J
AU Gao, Y
   Li, YF
   Xue, J
   Jia, YQA
   Hu, J
AF Gao, Ying
   Li, Yunfeng
   Xue, Jing
   Jia, Yongqian
   Hu, Jing
TI Effect of the anti diabetic drug metformin on bone mass in
   ovariectomized rats
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Metformin; Ovariectomy; Bone density; Bone quality; Osteoblast markers
ID OSTEOBLAST DIFFERENTIATION; MC3T3 E1 CELLS; EXPRESSION; PPAR GAMMA 2;
   OSF2/CBFA1; INSULIN; GENES
AB Recent studies have reported bone loss in the patients with diabetes and a direct osteogenic effect of metformin on osteoblast like cells in culture. In this study, we investigated the action of metformin on bone mass in ovariectomized (OVX) rats. Three months after either a sham surgery or bilateral ovariectomy, thirty two female Sprague Dawley rats were randomly assigned into four groups: (1) Sham group; (2) OVX group; (3) OVX + metformin (50 mg/kg/day) group; and (4) OVX + metformin (100 mg/kg/day) group. After 2 months of oral administration with or without metformin, tibiae were harvested for dual energy X ray absorptiometry, micro computed tomography (micro CT) and histology analysis, while the bone marrow cells from tibiae were collected for measurement of the mRNAs expressions for three osteoblast genes and estrogen receptors alpha by the use of real time RT PCR. We found that the impaired bone density and quality induced by bilateral ovariectomy were significantly improved by the treatment of metformin (both 50 and 100 mg/kg/day), and this action could be partly mediated by regulating bone marrow cells development through induction of mechanisms regulating osteoblast markers core binding factor a1 and LDL receptor related protein 5. These findings provide new evidence that the anti diabetic drug metformin has a direct inhibition effect on bone loss in OVX rats, in addition to its well documented osteogenic potency in vitro. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Gao, Ying; Li, Yunfeng; Xue, Jing; Hu, Jing] Sichuan Univ, State Key Lab Oral Dis, Chengdu 610041, Peoples R China.
   [Gao, Ying] Shanxi Med Univ, Hosp 1, Dept Stomatol, Taiyuan 030001, Peoples R China.
   [Jia, Yongqian] Sichuan Univ, W China Sch Med, Dept Internal Med, Chengdu 610041, Peoples R China.
C3 Sichuan University; Shanxi Medical University; Sichuan University
RP Hu, J (通讯作者)，Sichuan Univ, State Key Lab Oral Dis, Chengdu 610041, Peoples R China.
EM drhu@vip.sohu.com
RI ; wang, meng/GWZ 9558 2022
OI Li, Yunfeng/0000 0003 2659 8074; 
CR Allen KV, 2004, EUR J PHARMACOL, V490, P169, DOI 10.1016/j.ejphar.2004.02.054
   Blagosklonny MV, 2007, DRUG DISCOV TODAY, V12, P218, DOI 10.1016/j.drudis.2007.01.004
   Carnevale V, 2004, DIABETES METAB RES, V20, P196, DOI 10.1002/dmrr.449
   Chau Diane L, 2003, Curr Diab Rep, V3, P37, DOI 10.1007/s11892 003 0051 8
   Cortizo AM, 2006, EUR J PHARMACOL, V536, P38, DOI 10.1016/j.ejphar.2006.02.030
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Duque G, 2004, EXP GERONTOL, V39, P333, DOI 10.1016/j.exger.2003.11.008
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   GIUGLIANO D, 1993, DIABETES CARE, V16, P1387, DOI 10.2337/diacare.16.10.1387
   Hanson NA, 2004, BONE, V35, P326, DOI 10.1016/j.bone.2004.02.019
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Itoh F, 2003, EUR J PHARMACOL, V477, P9, DOI 10.1016/j.ejphar.2003.08.011
   Kanazawa I, 2008, BIOCHEM BIOPH RES CO, V375, P414, DOI 10.1016/j.bbrc.2008.08.034
   Katayama Y, 1996, J BONE MINER RES, V11, P931, DOI 10.1002/jbmr.5650110709
   Kneissel M, 2004, BONE, V35, P1144, DOI 10.1016/j.bone.2004.07.013
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Lecka Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097 4644(19990901)74:3<357::AID JCB5>3.0.CO;2 7
   Levasseur R, 2005, JOINT BONE SPINE, V72, P207, DOI 10.1016/j.jbspin.2004.10.008
   Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385
   McCarthy AD, 1997, MOL CELL BIOCHEM, V170, P43, DOI 10.1023/A:1006816223292
   Paolisso G, 2001, EXP GERONTOL, V37, P149, DOI 10.1016/S0531 5565(01)00148 6
   Tang ZH, 2006, BONE, V38, P181, DOI 10.1016/j.bone.2005.08.010
   VAN HD, 2005, AGING CELL, V4, P79
   Vestergaard P, 2005, DIABETOLOGIA, V48, P1292, DOI 10.1007/s00125 005 1786 3
   Wang FS, 2005, ENDOCRINOLOGY, V146, P2415, DOI 10.1210/en.2004 1050
NR 26
TC 89
Z9 104
U1 0
U2 22
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD JUN 10
PY 2010
VL 635
IS 1 3
BP 231
EP 236
DI 10.1016/j.ejphar.2010.02.051
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 602ZR
UT WOS:000278178200035
PM 20307532
DA 2025 08 17
ER

PT J
AU Yang, JD
   Cong, N
   Shi, DN
   Chen, S
   Zhang, ZY
   Zhao, PW
AF Yang, Jiadi
   Cong, Nan
   Shi, Danning
   Chen, Si
   Zhang, Zeye
   Zhao, Piwen
TI Siwu decoction exerts a phytoestrogenic osteoprotective effect on
   postmenopausal osteoporosis via the estrogen receptor/
   phosphatidylinositol 3 kinase/serine/threonine protein kinase pathway
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Siwu decoction; Postmenopausal osteoporosis; Estrogen receptor; PI3K/AKT
   pathway; Network pharmacology
ID ER ALPHA; BONE; INHIBITION; CELLS; BETA; JNK
AB Ethnopharmacological relevance: Siwu decoction (SWD) is widely used in gynecological diseases, such as peripheral menopause syndrome, premature ovarian failure, and menstrual disorder. However, the mechanism of SWD on postmenopausal osteoporosis (PMOP) remains unclear. Aim of the study: To discover the phytoestrogenic osteoprotective effect of SWD on PMOP. Materials and methods: The potential mechanism of SWD on PMOP was filtered through network pharmacology research. The potential mechanism was verified in MC3T3 E1 cell lines in vitro. CCK8 assay was conducted to assess cell proliferation and the expressions of ER/PI3K/AKT pathway were analyzed using Western blot. Female F 344 rats were chosen to set up the PMOP model. The osteoprotective effect of SWD in vivo was evaluated using Hematoxylin eosin staining, TRAP staining, Goldner staining and DXA. The potential mechanism was verified in vivo through Western blot and immunohistochemistry. RT qPCR was conducted to unveil the expressions of osteogenesis genes. Results: Network pharmacology research showed that ER/PI3K/AKT pathway may be the potential mechanism of SWD on PMOP. SWD promoted the proliferation of osteoblasts and regulated the protein expressions of ER/PI3K/ AKT pathway in vitro. SWD improved the morphological structure, bone mineralization and bone mineral density of femurs and suppressed osteoclastogenesis in PMOP rat model via ER/PI3K/AKT pathway in vivo. In addition, SWD regulated the mRNA expressions of osteogenesis related genes. Conclusions: SWD exerts a phytoestrogenic osteoprotective on PMOP by regulating ER/PI3K/AKT pathway, which marks it as a valuable medicine or supplement of PMOP.
C1 [Yang, Jiadi; Cong, Nan; Shi, Danning; Chen, Si; Zhang, Zeye; Zhao, Piwen] Beijing Univ Chinese Med, Sch Life Sci, 11 East Rd,North 3rd Ring Rd, Beijing 100029, Peoples R China.
   [Cong, Nan] Jinzhou Med Univ, Affiliated Hosp 1, Dept Gynecol, 2,Sect 5,Renmin St, Jinzhou 121000, Peoples R China.
C3 Beijing University of Chinese Medicine; Jinzhou Medical University
RP Zhao, PW (通讯作者)，Beijing Univ Chinese Med, Sch Life Sci, 11 East Rd,North 3rd Ring Rd, Beijing 100029, Peoples R China.
EM yjdi666@sina.com; congn@jzmu.edu.cn; shidanning@bucm.edu.cn;
   sissy2009@126.com; 20210941110@bucm.edu.cn; pzhao@bucm.edu.cn
RI Zhao, Piwen/JCT 7728 2023
FU National Natural Science Foundation of China [81673764]
FX This work was supported by the National Natural Science Foundation of
   China (grant numbers 81673764) .
CR Agas D, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22147586
   Arumugam Somasundaram., 2017, Japanese Kampo Medicines for the Treatment of Common Diseases: Focus on Inflammation
   Chang IC, 2010, OSTEOPOROSIS INT, V21, P1401, DOI 10.1007/s00198 009 1107 7
   Changizi Z, 2021, J BIOCHEM MOL TOXIC, V35, DOI 10.1002/jbt.22642
   Choi EM, 2011, FOOD CHEM TOXICOL, V49, P1800, DOI 10.1016/j.fct.2011.04.031
   Cui JR, 2022, AGEING RES REV, V77, DOI 10.1016/j.arr.2022.101608
   Dong C, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2019.109796
   Ediriweera MK, 2019, SEMIN CANCER BIOL, V59, P147, DOI 10.1016/j.semcancer.2019.05.012
   Guo W, 2022, J ORTHOP SURG RES, V17, DOI 10.1186/s13018 022 02965 1
   Guo YZ, 2017, INT J MOL MED, V39, P71, DOI 10.3892/ijmm.2016.2826
   He JB, 2023, J ADV RES, V53, P235, DOI 10.1016/j.jare.2023.01.003
   Hwang JH, 2023, J CONTROL RELEASE, V355, P184, DOI 10.1016/j.jconrel.2023.01.071
   Jones BC, 2023, RADIOLOGY, V307, DOI 10.1148/radiol.221810
   Kusuyama J, 2019, FASEB J, V33, P7331, DOI 10.1096/fj.201802465R
   Liedert A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218301
   Lindberg MK, 2003, MOL ENDOCRINOL, V17, P203, DOI 10.1210/me.2002 0206
   Liu XL, 2023, SCI ADV, V9, DOI 10.1126/sciadv.adf3329
   Ma L, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0050 2
   McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002
   Melville KM, 2014, J BONE MINER RES, V29, P370, DOI 10.1002/jbmr.2082
   Meng QH, 2020, BIOCHEM PHARMACOL, V180, DOI 10.1016/j.bcp.2020.114134
   Mills EG, 2021, ENDOCR REV, V42, P691, DOI 10.1210/endrev/bnab015
   Noah MLN, 2023, CELL COMMUN SIGNAL, V21, DOI 10.1186/s12964 023 01052 0
   Ni XM, 2023, PHYTOMEDICINE, V108, DOI 10.1016/j.phymed.2022.154509
   Sabapathy K, 2019, J MOL CELL BIOL, V11, P317, DOI 10.1093/jmcb/mjz010
   Schüler Toprak S, 2023, CANCERS, V15, DOI 10.3390/cancers15102845
   Suthon S, 2022, HUM GENET, V141, P1849, DOI 10.1007/s00439 022 02463 8
   Vimalraj S, 2020, GENE, V754, DOI 10.1016/j.gene.2020.144855
   Wang J., 1998, Sichuan Traditional Chinese Medicine, P11
   Wang LJ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00190 4
   Wang YM, 2018, BIOCHEM BIOPH RES CO, V498, P981, DOI 10.1016/j.bbrc.2018.03.093
   Wang YX, 2016, ARCH MED RES, V47, P255, DOI 10.1016/j.arcmed.2016.07.002
   Wei HD, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 40087 2
   Whelan E, 2022, CANCERS, V14, DOI 10.3390/cancers14112708
   Wu CM, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472 6882 13 277
   Xu XY, 2023, J BONE MINER RES, V38, P186, DOI 10.1002/jbmr.4731
   Xue JF, 2017, BIOMED PHARMACOTHER, V89, P1252, DOI 10.1016/j.biopha.2017.01.130
   Yang DS, 2020, BIOCHEM BIOPH RES CO, V533, P510, DOI 10.1016/j.bbrc.2020.09.054
   Zaldivar V, 2009, NEUROENDOCRINOLOGY, V90, P292, DOI 10.1159/000235618
   Zhan JD, 2020, FOOD FUNCT, V11, P7830, DOI [10.1039/d0fo00837k, 10.1039/D0FO00837K]
   Zhang H, 2023, ACTA PHARMACOL SIN, V44, P446, DOI 10.1038/s41401 022 00954 y
   Zhang W.Y., 1990, Tianjin Pharmacy, P17
   Zhang Ze Ye, 2022, Zhongguo Zhong Yao Za Zhi, V47, P2750, DOI 10.19540/j.cnki.cjcmm.20211216.704
   Zhang ZY, 2021, J ETHNOPHARMACOL, V269, DOI 10.1016/j.jep.2020.113696
   Zhao BK, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.615191
   Zhou FR, 2021, J ETHNOPHARMACOL, V280, DOI 10.1016/j.jep.2021.114431
NR 46
TC 2
Z9 2
U1 10
U2 29
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD OCT 5
PY 2024
VL 332
AR 118366
DI 10.1016/j.jep.2024.118366
EA MAY 2024
PG 13
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA TZ2T6
UT WOS:001245022300001
PM 38763371
DA 2025 08 17
ER

PT J
AU Neri, T
   Muggeo, S
   Paulis, M
   Caldana, ME
   Crisafulli, L
   Strina, D
   Focarelli, ML
   Faggioli, F
   Recordati, C
   Scaramuzza, S
   Scanziani, E
   Mantero, S
   Buracchi, C
   Sobacchi, C
   Lombardo, A
   Naldini, L
   Vezzoni, P
   Villa, A
   Ficara, F
AF Neri, Tui
   Muggeo, Sharon
   Paulis, Marianna
   Caldana, Maria Elena
   Crisafulli, Laura
   Strina, Dario
   Focarelli, Maria Luisa
   Faggioli, Francesca
   Recordati, Camilla
   Scaramuzza, Samantha
   Scanziani, Eugenio
   Mantero, Stefano
   Buracchi, Chiara
   Sobacchi, Cristina
   Lombardo, Angelo
   Naldini, Luigi
   Vezzoni, Paolo
   Villa, Anna
   Ficara, Francesca
TI Targeted Gene Correction in Osteopetrotic Induced Pluripotent Stem Cells
   for the Generation of Functional Osteoclasts
SO STEM CELL REPORTS
LA English
DT Article
ID AUTOSOMAL RECESSIVE OSTEOPETROSIS; MOUSE MODEL; IPS CELLS; THERAPY;
   IMMUNODEFICIENCY; SUBUNIT
AB Autosomal recessive osteopetrosis is a human bone disease mainly caused by TCIRG1 gene mutations that prevent osteoclasts resorbing activity, recapitulated by the oc/oc mouse model. Bone marrow transplantation is the only available treatment, limited by the need for a matched donor. The use of induced pluripotent stem cells (iPSCs) as an unlimited source of autologous cells to generate gene corrected osteoclasts might represent a powerful alternative. We generated iPSCs from oc/oc mice, corrected the mutation using a BAC carrying the entire Tcirg1 gene locus as a template for homologous recombination, and induced hematopoietic differentiation. Similarly to physiologic fetal hematopoiesis, iPSC derived CD41(+) cells gradually gave rise to CD45(+) cells, which comprised both mature myeloid cells and high proliferative potential colony forming cells. Finally, we differentiated the gene corrected iPSC derived myeloid cells into osteoclasts with rescued bone resorbing activity. These results are promising for a future translation into the human clinical setting.
C1 [Neri, Tui; Muggeo, Sharon; Paulis, Marianna; Caldana, Maria Elena; Crisafulli, Laura; Strina, Dario; Focarelli, Maria Luisa; Faggioli, Francesca; Scaramuzza, Samantha; Mantero, Stefano; Sobacchi, Cristina; Vezzoni, Paolo; Villa, Anna; Ficara, Francesca] CNR, Milan Unit, Ist Ric Genet & Biomed, I 20138 Milan, Italy.
   [Neri, Tui; Muggeo, Sharon; Paulis, Marianna; Caldana, Maria Elena; Crisafulli, Laura; Strina, Dario; Focarelli, Maria Luisa; Faggioli, Francesca; Scaramuzza, Samantha; Mantero, Stefano; Buracchi, Chiara; Sobacchi, Cristina; Vezzoni, Paolo; Villa, Anna; Ficara, Francesca] Humanitas Clin & Res Ctr, I 20089 Rozzano, MI, Italy.
   [Recordati, Camilla; Scanziani, Eugenio] Fdn Filarete, Mouse & Anim Pathol Lab, I 20139 Milan, Italy.
   [Scanziani, Eugenio] Univ Milan, Dept Vet Sci & Publ Hlth, I 20133 Milan, Italy.
   [Lombardo, Angelo; Naldini, Luigi] Ist Sci San Raffaele, San Raffaele Telethon Inst Gene Therapy TIGET, I 20132 Milan, Italy.
   [Lombardo, Angelo; Naldini, Luigi] Univ Vita Salute San Raffaele, I 20132 Milan, Italy.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto di Ricerca Genetica e
   Biomedica (IRGB CNR); IRCCS Humanitas Research Hospital; University of
   Milan; Vita Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy
   (Sr Tiget); Vita Salute San Raffaele University
RP Villa, A (通讯作者)，CNR, Milan Unit, Ist Ric Genet & Biomed, I 20138 Milan, Italy.
EM anna.villa@humanitasresearch.it
RI PAULIS, Marianna/R 8113 2018; Muggeo, Sharon/J 3651 2018; Recordati,
   Camilla/GLR 1552 2022; Crisafulli, Laura/Q 2271 2018; BURACCHI,
   CHIARA/HNC 4333 2023; Faggioli, Francesca/K 1592 2016; Mantero,
   Stefano/AAE 5515 2021; Vezzoni, Paolo/R 3416 2019; Scanziani,
   Eugenio/G 8046 2017; Scaramuzza, Samantha/AAN 2204 2020; Sobacchi,
   Cristina/J 9345 2018; SOBACCHI, CRISTINA/J 9345 2018; Crisafulli,
   Laura/ABI 1447 2020; muggeo, sharon/J 3651 2018; Paulis,
   Marianna/R 8113 2018; Ficara, Francesca/M 4624 2016; lombardo,
   angelo/J 6241 2016; strina, dario/LSK 2865 2024
OI PAULIS, Marianna/0000 0001 7803 9982; Muggeo,
   Sharon/0000 0001 7135 9780; Recordati, Camilla/0000 0002 7172 9662;
   NALDINI, Luigi/0000 0002 7835 527X; Vezzoni, Paolo/0000 0002 6382 3923;
   LOMBARDO, Angelo Leone/0000 0001 8262 042X; Crisafulli,
   Laura/0000 0002 1393 5652; Villa, Anna/0000 0003 4428 9013; Faggioli,
   Francesca/0000 0001 8030 3674; strina, dario/0000 0002 0628 5997;
   Scanziani, Eugenio/0000 0003 3996 5048; BURACCHI,
   CHIARA/0000 0002 5345 7448; Sobacchi, Cristina/0000 0002 2684 7184;
   Mantero, Stefano/0000 0003 0608 2724; scaramuzza,
   samantha/0000 0003 2903 3650; Ficara, Francesca/0000 0003 1873 1189; 
FU European Community's Seventh Framework Programme [602300]; PRIN Project
   [20102M7T8X_003]; Ricerca Finalizzata from Ministero della salute
   [RF 2009 1499, 542]; Programma Nazionale per la Ricerca Consiglio
   Nazionale delle Ricerche [PE 2011 02347329]; Lombardia Region   National
   Research Council of Italy [16/7/2012]; Telethon (TIGET) EU [D2, FP7
   601958 SUPERSIST, 249845]; Italian Ministry of Health; Marie Curie
   International Reintegration Grant [PIRG6 GA 2009 256452]
FX The research leading to these results has received funding from the
   European Community's Seventh Framework Programme under grant agreement
   n. 602300 (SYBIL) to A.V., PRIN Project 20102M7T8X_003 to A.V., Ricerca
   Finalizzata from Ministero della salute RF 2009 1499,542 to A.V.,
   Programma Nazionale per la Ricerca Consiglio Nazionale delle Ricerche
   "Aging Program 2012 2014" to A.V. and P.V., PE 2011 02347329 to P.V.,
   Lombardia Region   National Research Council of Italy (16/7/2012)
   Project "MbMM   Basic methodologies for innovation in the diagnosis and
   therapy of multi factorial diseases" (signed 25/7/2013) to P.V.,
   Telethon (TIGET grant D2) EU (FP7 601958 SUPERSIST, ERC Advanced Grant
   249845 TARGETINGGENETHERAPY) and the Italian Ministry of Health to L.N.
   F. Ficara was supported by a Marie Curie International Reintegration
   Grant (grant number PIRG6 GA 2009 256452). We thank Barbara Tondelli for
   the generation of the oc/oc mouse strain in the Ly5.1 genetic
   background.
CR Aiuti A, 2013, SCIENCE, V341, P865, DOI 10.1126/science.1233151
   Aiuti A, 2009, NEW ENGL J MED, V360, P447, DOI 10.1056/NEJMoa0805817
   Anchan RM, 2011, HUM MOL GENET, V20, P962, DOI 10.1093/hmg/ddq542
   Biffi A, 2013, SCIENCE, V341, P864, DOI 10.1126/science.1233158
   Cappariello A, 2010, J BONE MINER RES, V25, P106, DOI 10.1359/jbmr.090715
   Cavazzana Calvo M, 2010, NATURE, V467, P318, DOI 10.1038/nature09328
   Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131
   Genovese P, 2014, NATURE, V510, P235, DOI 10.1038/nature13420
   Hacein Bey Abina S, 2010, NEW ENGL J MED, V363, P355, DOI 10.1056/NEJMoa1000164
   Hanna J, 2007, SCIENCE, V318, P1920, DOI 10.1126/science.1152092
   Hanna JH, 2010, CELL, V143, P508, DOI 10.1016/j.cell.2010.10.008
   Howden SE, 2011, P NATL ACAD SCI USA, V108, P6537, DOI 10.1073/pnas.1103388108
   Nienhuis AW, 2013, BLOOD, V122, P1556, DOI 10.1182/blood 2013 04 453209
   Orchard PJ, 2015, BLOOD, V126, P270, DOI 10.1182/blood 2015 01 625541
   Robin C, 2011, BLOOD, V117, P5088, DOI 10.1182/blood 2011 01 329516
   Robinton DA, 2012, NATURE, V481, P295, DOI 10.1038/nature10761
   Scimeca JC, 2000, BONE, V26, P207, DOI 10.1016/S8756 3282(99)00278 1
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
NR 20
TC 20
Z9 20
U1 0
U2 2
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2213 6711
J9 STEM CELL REP
JI Stem Cell Rep.
PD OCT 13
PY 2015
VL 5
IS 4
BP 558
EP 568
DI 10.1016/j.stemcr.2015.08.005
PG 11
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA CW4UL
UT WOS:000364990900010
PM 26344905
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wu, SM
   Chen, F
   Yang, XY
   Wu, TF
   Sun, W
   Yu, L
AF Wu, Shi Ming
   Chen, Feng
   Yang, Xiao Yan
   Wu, Teng Fei
   Sun, Wei
   Yu, Ling
TI Probing the interaction between metastatic breast cancer cells and
   osteoblasts in a thread based breast bone co culture device
SO LAB ON A CHIP
LA English
DT Article
ID ANTIBODY BASED IMMUNOTHERAPY; OSTEOGENIC NICHE; DIFFERENTIATION; TARGET;
   CSPG4; MODEL
AB Breast cancer metastasis to bone is a leading killer in breast cancer patients. A type I collagen modified thread (Col I@thread) was prepared for 3 dimensional cell culture and breast cancer bone metastasis co culture device assembly. First, the coating of Col I on nylon threads for promoting cell adhesion and growth was studied. Through SEM, XPS, and protein concentration measurements, it was found that the lyophilization method remarkably preserved the Col I activity and the internal structure of the thread, thereby promoting cell attachment and proliferation. RNA sequencing (RNA Seq) and quantitative PCR analysis showed that osteoblast cells (MC3T3 E1) grown on Col I@thread had elevated RUNX2, ALP, OPN, and Col I gene expression to promote osteoblast differentiation. Single cell analysis found that osteoblast MC3T3 E1 cells growing on Col I@thread had higher Ca2+ secretion activity and mineralized nodules, suggesting robust cell activity and bone matrix formation than cells growing on 2D culture plates. Col I@threads were knotted in an interdigital cross finger frame to assemble the breast cancer bone co culture model. Confocal microscopy and flow cytometry tests quantified the invasive breast cancer cells. Moreover, the thread based co culture devices allowed us to isolate the invasive and non invasive breast cancer cells to compare their molecular characteristics. qPCR results showed that expression of CX43, CXCR5, and CSPG4 genes was significantly increased in breast cancer cells with bone metastasis. Meanwhile, the expression of RUNX2 and OPG genes in osteoblasts was inhibited. The co culture model based on the Col I@thread mimics the bone tissue microenvironment to reveal the cross talk between cancer cells and bone tissue. Moreover, the thread based co culture device is easy to fabricate and operate, providing a platform for exploring the cellular and molecular mechanisms of breast cancer bone metastasis, and holds potential for high throughput screening of anti breast cancer bone metastasis drugs.
C1 [Wu, Shi Ming; Chen, Feng; Yang, Xiao Yan; Yu, Ling] Southwest Univ, Inst Clean Energy & Adv Mat, Key Lab Luminescent & Real Time Analyt Chem, Fac Mat & Energy,Minist Educ, Chongqing 400715, Peoples R China.
   [Wu, Teng Fei] Southwest Univ, Sch Life Sci, Key Lab Freshwater Fish Reprod & Dev, Key Lab Aquat Sci Chongqing,Minist Educ, Chongqing 400715, Peoples R China.
   [Sun, Wei] Hainan Normal Univ, Coll Chem & Chem Engn, Haikou 571158, Peoples R China.
C3 Southwest University   China; Southwest University   China; Hainan
   Normal University
RP Yu, L (通讯作者)，Southwest Univ, Inst Clean Energy & Adv Mat, Key Lab Luminescent & Real Time Analyt Chem, Fac Mat & Energy,Minist Educ, Chongqing 400715, Peoples R China.
EM lingyu12@swu.edu.cn
RI wu, shiming/KJL 1658 2024; Chen, Feng/AFH 2421 2022; Sun,
   Wei/KOC 5094 2024
FU National Natural Science Foundation of China [32171401]; Natural Science
   Foundation of Chongqing [CSTB2022NSCQ MSX0808]; Innovation Platform for
   Academicians of Hainan Province [YSPTZX202126]
FX This work was financially supported by the National Natural Science
   Foundation of China (No. 32171401), the Natural Science Foundation of
   Chongqing (CSTB2022NSCQ MSX0808), and the specific research fund of The
   Innovation Platform for Academicians of Hainan Province (YSPTZX202126).
CR Baker CE, 2018, CLIN REV BONE MINER, V16, P142, DOI 10.1007/s12018 018 9256 x
   Bäuerle T, 2005, INT J CANCER, V115, P177, DOI 10.1002/ijc.20840
   BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605
   Bersini S, 2014, BIOMATERIALS, V35, P2454, DOI 10.1016/j.biomaterials.2013.11.050
   Bunse M, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 020 20488 3
   Croucher PI, 2016, NAT REV CANCER, V16, P373, DOI 10.1038/nrc.2016.44
   Ell B, 2012, CELL, V151, DOI 10.1016/j.cell.2012.10.005
   Gawrzak S, 2018, NAT CELL BIOL, V20, P211, DOI 10.1038/s41556 017 0021 z
   Gericke A, 2005, CALCIFIED TISSUE INT, V77, P45, DOI 10.1007/s00223 004 1288 1
   Guy J. B., 2017, JOVE J VIS EXP, V549, P7670
   GUZZO CE, 1969, CANCER, V24, P382, DOI 10.1002/1097 0142(196908)24:2<382::AID CNCR2820240221>3.0.CO;2 S
   Huang B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13885
   Jeon JS, 2015, P NATL ACAD SCI USA, V112, P214, DOI 10.1073/pnas.1417115112
   Komori T., 2022, INT J MOL SCI, V23
   Krzeszinski JY, 2015, TRENDS PHARMACOL SCI, V36, P360, DOI [10.1016/J.tips.2015.04.006, 10.1016/j.tips.2015.04.006]
   Lee MN, 2018, EXP MOL MED, V50, DOI 10.1038/s12276 018 0170 6
   Liu YL, 2022, J ANAL TEST, V6, P178, DOI 10.1007/s41664 022 00223 1
   Maji S, 2018, CARBOHYD POLYM, V189, P115, DOI 10.1016/j.carbpol.2018.01.104
   Marturano Kruik A, 2018, P NATL ACAD SCI USA, V115, P1256, DOI 10.1073/pnas.1714282115
   McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002
   Mei XT, 2019, INTEGR BIOL UK, V11, P119, DOI 10.1093/intbio/zyz008
   Mostafalu P, 2016, MICROSYST NANOENG, V2, DOI 10.1038/micronano.2016.39
   Murakami MA, 2017, NATURE, V549, P39, DOI 10.1038/nature23545
   Nilghaz A, 2012, LAB CHIP, V12, P209, DOI 10.1039/c1lc20764d
   Noori A, 2017, INT J NANOMED, V12, P4937, DOI 10.2147/IJN.S124671
   PAGET S, 1989, CANCER METAST REV, V8, P98
   Ramesan S, 2016, LAB CHIP, V16, P2820, DOI 10.1039/c5lc00937e
   Rivera Z, 2012, CLIN CANCER RES, V18, P5352, DOI 10.1158/1078 0432.CCR 12 0628
   Romero Moreno R, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 12108 6
   Shah KR, 2022, CELL CALCIUM, V104, DOI 10.1016/j.ceca.2022.102594
   Shakiba M, 2021, POLYM ADVAN TECHNOL, V32, P3368, DOI 10.1002/pat.5372
   Sritharan S, 2018, J CRANIO MAXILL SURG, V46, P1361, DOI 10.1016/j.jcms.2018.05.002
   Stewart E, 2017, NATURE, V549, P96, DOI 10.1038/nature23647
   Sung H, 2021, CA CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Ulum MF, 2016, LAB CHIP, V16, P1492, DOI 10.1039/c6lc00175k
   Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024
   Viti F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148173
   Wang H, 2018, CANCER CELL, V34, P823, DOI 10.1016/j.ccell.2018.10.002
   Wang H, 2015, CANCER CELL, V27, P193, DOI 10.1016/j.ccell.2014.11.017
   Wang XC, 2021, BIOENGINEERED, V12, P1126, DOI 10.1080/21655979.2021.1905259
   Wang XH, 2010, JNCI J NATL CANCER I, V102, P1496, DOI 10.1093/jnci/djq343
   Whitesides GM, 2006, NATURE, V442, P368, DOI 10.1038/nature05058
   Xiao LG, 2020, BONE, V134, DOI 10.1016/j.bone.2020.115291
   Xing SY, 2013, LAB CHIP, V13, P1937, DOI 10.1039/c3lc41255e
   Xiong ZC, 2018, CANCER MANAG RES, V10, P287, DOI 10.2147/CMAR.S155524
   Yao J, 2012, J HAND SURG AM, V37A, P1639, DOI 10.1016/j.jhsa.2012.04.038
   Zhang JF, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368 019 0046 1
   Zheng HQ, 2017, CANCER CELL, V32, P731, DOI 10.1016/j.ccell.2017.11.002
NR 48
TC 8
Z9 9
U1 6
U2 21
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1473 0197
EI 1473 0189
J9 LAB CHIP
JI Lab Chip
PD JUN 13
PY 2023
VL 23
IS 12
BP 2838
EP 2853
DI 10.1039/d3lc00106g
EA MAY 2023
PG 16
WC Biochemical Research Methods; Chemistry, Multidisciplinary; Chemistry,
   Analytical; Nanoscience & Nanotechnology; Instruments & Instrumentation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Science & Technology  
   Other Topics; Instruments & Instrumentation
GA I5GA0
UT WOS:000998994100001
PM 37255012
DA 2025 08 17
ER

PT J
AU Ryu, TK
   Kang, RH
   Jeong, KY
   Jun, DR
   Koh, JM
   Kim, D
   Bae, SK
   Choi, SW
AF Ryu, Tae Kyung
   Kang, Rae Hyoung
   Jeong, Ki Young
   Jun, Dae Ryong
   Koh, Jung Min
   Kim, Doyun
   Bae, Soo Kyung
   Choi, Sung Wook
TI Bone targeted delivery of nanodiamond based drug carriers conjugated
   with alendronate for potential osteoporosis treatment
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Nanodiamond; Alendronate; Bone targeting; Osteoporosis
ID NANOPARTICLES; INHIBITION; MECHANISM; HYDROXYAPATITE; CONNEXIN 43;
   CELLS; SHAPE; ACID; SIZE
AB This paper describes the design of alendronate conjugated nanodiamonds (Alen NDs) and evaluation of their feasibility for bone targeted delivery. Alen NDs exhibited a high affinity to hydroxyapatite (HAp, the mineral component of bone) due to the presence of Alen. Unlike NDs (without Alen), Alen NDs were preferentially taken up by MC3T3 E1 osteoblast like cells, compared to NIH3T3 and HepG2 cells, suggesting their cellular specificity. In addition, NDs itself increased ALP activity of MC3T3 E1 cells, compared to control group (osteogenic medium) and Alen NDs exhibited more enhanced ALP activity. In addition, an in vivo study revealed that Alen NDs effectively accumulated in bone tissues after intravenous tail vein injection. These results confirm the superior properties of Alen NDs with advantages of high HAp affinity, specific uptake for MC3T3 E1 cells, positive synergistic effect for ALP activity, and in vivo bone targeting ability. The Alen NDs can potentially be employed for osteoporosis treatment by delivering both NDs and Alen to bone tissue. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Ryu, Tae Kyung; Kang, Rae Hyoung; Jeong, Ki Young; Jun, Dae Ryong; Choi, Sung Wook] Catholic Univ Korea, Dept Biotechnol, 43 Jibong Ro, Bucheon Si 420743, Gyeonggi Do, South Korea.
   [Koh, Jung Min] Univ Ulsan, Coll Med, Asan Med Ctr, Div Endocrinol & Metab, 88 Olymp Ro 43 Gil, Seoul 138736, South Korea.
   [Kim, Doyun; Bae, Soo Kyung] Catholic Univ Korea, Coll Pharm, 43 Jibong Ro, Bucheon Si 420743, Gyeonggi Do, South Korea.
C3 Catholic University of Korea; University of Ulsan; Asan Medical Center;
   Catholic University of Korea
RP Choi, SW (通讯作者)，Catholic Univ Korea, Dept Biotechnol, 43 Jibong Ro, Bucheon Si 420743, Gyeonggi Do, South Korea.
EM choisw@catholic.ac.kr
RI ; kim, juhee/HKV 6163 2023
OI Kang, Rae Hyung/0000 0001 9380 6553; 
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Science, ICT & Future Planning
   [NRF 2014R1A1A1005826, NRF 2015R1A4A1042350]; Korea Health Technology
   R&D Project, Ministry of Health & Welfare, Republic of Korea [HI13C1634]
FX This study was supported by Basic Science Research Program through the
   National Research Foundation of Korea (NRF) funded by the Ministry of
   Science, ICT & Future Planning (NRF 2014R1A1A1005826 and
   NRF 2015R1A4A1042350) and a grant from the Korea Health Technology R&D
   Project, Ministry of Health & Welfare, Republic of Korea (project no.
   HI13C1634).
CR Araujo L, 1999, J DRUG TARGET, V6, P373, DOI 10.3109/10611869908996844
   Branson BT, 2013, ACS NANO, V7, P3183, DOI 10.1021/nn305664x
   Chen MX, 2012, ANAL BIOANAL CHEM, V402, P791, DOI 10.1007/s00216 011 5467 4
   Choi SW, 2007, J CONTROL RELEASE, V122, P24, DOI 10.1016/j.jconrel.2007.06.003
   Chow EK, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001713
   Coughlin AJ, 2014, SMALL, V10, P556, DOI 10.1002/smll.201302217
   Csapo J, 1997, ANAL CHIM ACTA, V339, P99, DOI 10.1016/S0003 2670(96)00452 7
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Fu LJ, 2008, BONE, V43, P40, DOI 10.1016/j.bone.2008.03.008
   Ganta S, 2008, J CONTROL RELEASE, V126, P187, DOI 10.1016/j.jconrel.2007.12.017
   Guan B, 2010, SMALL, V6, P1514, DOI 10.1002/smll.200902305
   Kasugai S, 2000, J BONE MINER RES, V15, P936, DOI 10.1359/jbmr.2000.15.5.936
   Komatsu K, 2013, J ENDOCRINOL, V219, P145, DOI 10.1530/JOE 13 0040
   Lee CS, 2013, BIOMATERIALS, V34, P9227, DOI 10.1016/j.biomaterials.2013.08.037
   Lee GJ, 2012, J NANOSCI NANOTECHNO, V12, P5995, DOI 10.1166/jnn.2012.6345
   Lee SM, 2009, LAB CHIP, V9, P2683, DOI 10.1039/b902922b
   Lezcano V, 2014, EXP CELL RES, V324, P30, DOI 10.1016/j.yexcr.2014.03.016
   Lezcano V, 2012, ARCH BIOCHEM BIOPHYS, V518, P95, DOI 10.1016/j.abb.2011.12.022
   Liao MH, 2002, J MATER CHEM, V12, P3654, DOI 10.1039/b207158d
   Luo XL, 2006, ELECTROANAL, V18, P319, DOI 10.1002/elan.200503415
   Mochalin VN, 2012, NAT NANOTECHNOL, V7, P11, DOI [10.1038/nnano.2011.209, 10.1038/NNANO.2011.209]
   Morelli S, 2011, ARCH BIOCHEM BIOPHYS, V507, P248, DOI 10.1016/j.abb.2010.12.013
   Muro S, 2008, MOL THER, V16, P1450, DOI 10.1038/mt.2008.127
   Nakashima K, 2005, J LUMIN, V111, P113, DOI 10.1016/j.jlumin.2004.07.002
   ORME MW, 1994, BIOORG MED CHEM LETT, V4, P1375, DOI 10.1016/S0960 894X(01)80365 6
   Ozawa S, 1996, BIOMATERIALS, V17, P23, DOI 10.1016/0142 9612(96)80751 4
   Paolino D, 2015, J MATER CHEM B, V3, P250, DOI 10.1039/c4tb00955j
   Park H, 2013, BIOMATERIALS, V34, P6992, DOI 10.1016/j.biomaterials.2013.05.070
   Ryu TK, 2015, MACROMOL BIOSCI, V15, P1469, DOI 10.1002/mabi.201500176
   Strom G., 1995, ADV DRUG DELIV REV, P31
   Sun J, 2012, ARCH ORAL BIOL, V57, P728, DOI 10.1016/j.archoralbio.2011.12.007
   Tan JF, 2013, MICROFLUID NANOFLUID, V14, P77, DOI 10.1007/s10404 012 1024 5
   Torii S, 2009, J HEAT TRANS T ASME, V131, DOI 10.1115/1.3072923
   Tye CE, 2003, J BIOL CHEM, V278, P7949, DOI 10.1074/jbc.M211915200
   Wang D, 2003, BIOCONJUGATE CHEM, V14, P853, DOI 10.1021/bc034090j
   Xie HQ, 2009, J PHYS D APPL PHYS, V42, DOI 10.1088/0022 3727/42/9/095413
   Yokogawa K, 2001, ENDOCRINOLOGY, V142, P1228, DOI 10.1210/en.142.3.1228
   Yoo H, 2013, LANGMUIR, V29, P5962, DOI 10.1021/la3051302
   Zhang BT, 2013, ANAL CHIM ACTA, V784, P1, DOI 10.1016/j.aca.2013.03.054
   Zhang QW, 2011, BIOMATERIALS, V32, P87, DOI 10.1016/j.biomaterials.2010.08.090
   Zhang XY, 2012, POLYMER, V53, P3178, DOI 10.1016/j.polymer.2012.05.029
NR 41
TC 75
Z9 81
U1 1
U2 85
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168 3659
EI 1873 4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD JUN 28
PY 2016
VL 232
BP 152
EP 160
DI 10.1016/j.jconrel.2016.04.025
PG 9
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA DN9LL
UT WOS:000377401000016
PM 27094604
DA 2025 08 17
ER

PT J
AU Tahir, A
   Kampleitner, C
   Wirglauer, T
   Grienke, U
   Hoffmann, O
   Rollinger, JM
AF Tahir, Ammar
   Kampleitner, Carina
   Wirglauer, Theresa
   Grienke, Ulrike
   Hoffmann, Oskar
   Rollinger, Judith M.
TI Biochemometry Based Discovery of Phenylpropanoids from Azadirachta
   indica Fruits as Inhibitors of In Vitro Osteoclast Formation
SO MOLECULES
LA English
DT Article
DE Azadirachta indica; phenylpropanoids; biochemometry; osteoporosis;
   inhibition of osteoclast differentiation
ID NF KAPPA B; DIFFERENTIATION; ESTROGEN; CONSTITUENTS; ACTIVATION;
   MECHANISMS; PRECURSORS
AB (1) Background: Inhibition of osteoclast differentiation is the key approach in treating osteoporosis. However, using state of the art treatments such as bisphosphonates and estrogen based therapy is usually accompanied by many side effects. As opposed to this, the use of natural products as an osteoporotic remedy delivers promising outcomes with minimal side effects. (2) Methods: In the present study, we implemented a biochemometric workflow comprising (i) chemometric approaches using NMR and mass spectrometry and (ii) cell biological approaches using an osteoclast cytochemical marker (TRAP). The workflow serves as a screening tool to pursue potential in vitro osteoclast inhibitors. (3) Results: The workflow allowed for the selective isolation of two phenylpropanoids (coniferyl alcohol and sinapyl alcohol) from the fruits of neem tree (Azadirachta indica). These two isolated phenylpropanoids showed a very promising dose dependent inhibition of osteoclast differentiation with negligible effects in terms of cell viability. (4) Conclusion: The presented workflow is an effective tool in the discovery of potential candidates for osteoclast inhibition from complex extracts. The used biochemometric approach saves time, effort and costs while delivering precise hints to selectively isolate bioactive constituents.
C1 [Tahir, Ammar; Grienke, Ulrike; Rollinger, Judith M.] Univ Vienna, Dept Pharmaceut Sci, Div Pharmacognosy, Josef Holaubek Pl 2, A 1090 Vienna, Austria.
   [Kampleitner, Carina; Wirglauer, Theresa; Hoffmann, Oskar] Univ Vienna, Dept Pharmaceut Sci, Div Pharmacol & Toxicol, Josef Holaubek Pl 2, A 1090 Vienna, Austria.
C3 University of Vienna; University of Vienna
RP Rollinger, JM (通讯作者)，Univ Vienna, Dept Pharmaceut Sci, Div Pharmacognosy, Josef Holaubek Pl 2, A 1090 Vienna, Austria.
EM ammar.tahir@univie.ac.at; carina.kampleitner@univie.ac.at;
   a1202312@unet.univie.ac.at; ulrike.grienke@univie.ac.at;
   oskar.hoffmann@univie.ac.at; judith.rollinger@univie.ac.at
RI ; Rollinger, Judith/Q 5996 2019; Grienke, Ulrike/H 2585 2017
OI Rollinger, Judith/0000 0001 6581 0774; Kampleitner,
   Carina/0000 0003 3072 5072; Grienke, Ulrike/0000 0003 0305 9270; Tahir,
   Ammar/0000 0003 3682 5680
FU University of Vienna
FX Open Access Funding by the University of Vienna.
CR Aehle E, 2011, PHYTOCHEMISTRY, V72, P2396, DOI 10.1016/j.phytochem.2011.08.013
   Akhila A, 1999, PROG CH ORG NAT PROD, V78, P47
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Ballanti P, 1997, OSTEOPOROSIS INT, V7, P39, DOI 10.1007/BF01623458
   BARON R, 1986, AM J PATHOL, V122, P363
   Bharti AC, 2004, J IMMUNOL, V172, P5940, DOI 10.4049/jimmunol.172.10.5940
   Biswas K, 2002, CURR SCI INDIA, V82, P1336
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cappariello A, 2014, ARCH BIOCHEM BIOPHYS, V558, P70, DOI 10.1016/j.abb.2014.06.017
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Islas JF, 2020, J FUNCT FOODS, V74, DOI 10.1016/j.jff.2020.104171
   Grienke U, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 47434 8
   Gupta SC, 2017, PHYTOMEDICINE, V34, P14, DOI 10.1016/j.phymed.2017.07.001
   Hu JP, 2008, EUR J PHARMACOL, V580, P70, DOI 10.1016/j.ejphar.2007.11.013
   Kampleitner C, 2018, JOVE J VIS EXP, DOI 10.3791/58077
   Kartika IGAA, 2020, MOLECULES, V25, DOI 10.3390/molecules25214914
   Kimira Y, 2015, PHYTOMEDICINE, V22, P1120, DOI 10.1016/j.phymed.2015.08.013
   Kirtikar KR., 1991, The Indian Medicinal plants, V2nd edn
   Kushwaha P, 2019, J CELL PHYSIOL, V234, P23719, DOI 10.1002/jcp.28940
   Kushwaha P, 2016, BIOORG MED CHEM LETT, V26, P3719, DOI 10.1016/j.bmcl.2016.05.076
   Lancefield CS, 2015, GREEN CHEM, V17, P4980, DOI [10.1039/c5gc01334h, 10.1039/C5GC01334H]
   Lee W, 2018, BIOCHEM BIOPH RES CO, V495, P2242, DOI 10.1016/j.bbrc.2017.12.079
   Levin VA, 2018, OSTEOPOROSIS INT, V29, P1049, DOI 10.1007/s00198 018 4414 z
   Li H, 1998, BIOL PHARM BULL, V21, P1322, DOI 10.1248/bpb.21.1322
   Li HY, 1998, BIOL PHARM BULL, V21, P594, DOI 10.1248/bpb.21.594
   Liu JJ, 2018, PHYTOMEDICINE, V42, P43, DOI 10.1016/j.phymed.2018.03.020
   Liu YX, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005467.pub2
   Lv YD, 2015, EXP THER MED, V9, P143, DOI 10.3892/etm.2014.2071
   Nagini Siddavaram, 2014, Enzymes, V36, P131, DOI 10.1016/B978 0 12 802215 3.00007 0
   Park KR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249579
   Puri H.S., 1999, Neem: The Divine Tree. Azadirachta indica
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Ruggiero SL, 2006, ORAL SURG ORAL MED O, V102, P433, DOI 10.1016/j.tripleo.2006.06.004
   Sakakibara N, 2007, ORG BIOMOL CHEM, V5, P802, DOI 10.1039/b616705e
   Sethi G, 2007, CHEM BIOL, V14, P738, DOI 10.1016/j.chembiol.2007.07.002
   Sushma Drabu Sushma Drabu, 2012, Research Journal of Pharmaceutical, Biological and Chemical Sciences, V3, P120
   TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo 123 5 2600
   Thummuri D, 2019, J CELL PHYSIOL, V234, P443, DOI 10.1002/jcp.26575
   Wang XL, 2010, NAT PROD RES, V24, P1206, DOI 10.1080/14786410902991860
   Wisutsitthiwong C, 2011, BIOCHEM BIOPH RES CO, V415, P361, DOI 10.1016/j.bbrc.2011.10.073
   Zwirchmayr J, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10050679
NR 42
TC 0
Z9 0
U1 0
U2 5
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 1420 3049
J9 MOLECULES
JI Molecules
PD JUN
PY 2022
VL 27
IS 11
AR 3611
DI 10.3390/molecules27113611
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 1Z9DE
UT WOS:000809114800001
PM 35684547
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Koski, C
   Vu, AA
   Bose, S
AF Koski, Caitlin
   Vu, Ashley A.
   Bose, Susmita
TI Effects of chitosan loaded hydroxyapatite on osteoblasts and
   osteosarcoma for chemopreventative applications
SO MATERIALS SCIENCE & ENGINEERING C MATERIALS FOR BIOLOGICAL APPLICATIONS
LA English
DT Article
DE Chitosan; Osteosarcoma; Osteoblast; Bone scaffolds
ID TUMOR; PH; NANOPARTICLES; DELIVERY; RELEASE; ANTIBACTERIAL; COATINGS;
   MATRIX; GROWTH; BCL 2
AB Osteosarcoma remains one of the most common malignant primary bone tumors. Post surgical defect repair combined with tumor suppression remains a major clinical challenge. Investigations of alternative treatments for osteosarcoma, while promising, have led to multi drug resistance. These constraints of common treatment strategies have triggered the need for new therapeutic candidates in bone cancer treatment. Chitosan, a common biopolymer utilized in bone and tissue engineering applications, has recently been studied as a pro apoptotic agent in metastatic cell lines like breast cancer, but has not been utilized in bone cancer applications. In this study, chitosan was directly loaded onto HA disks to evaluate its in vitro release and effects on human fetal osteoblast (hFOB) and human osteosarcoma (MG 63) cell lines. It is hypothesized that the sustained release of chitosan will decrease osteosarcoma cell proliferation and enhance proliferation of osteoblast cells. Through morphological characterization and MTT assay analysis, chitosan showed no toxicity to human fetal osteoblast (hFOB) cells. Chitosan was also shown to decrease human osteosarcoma cell viability by up to 96% compared to control samples. This suggests a pro apoptotic mechanism against osteosarcoma as well as the potential clinical application of chitosan as a drug candidate in ceramic scaffolds at tumor resected sites.
C1 [Koski, Caitlin; Vu, Ashley A.; Bose, Susmita] Washington State Univ, Sch Mech & Mat Engn, WM Keck Biomed Mat Res Lab, Pullman, WA 99164 USA.
C3 Washington State University
RP Bose, S (通讯作者)，Washington State Univ, Sch Mech & Mat Engn, WM Keck Biomed Mat Res Lab, Pullman, WA 99164 USA.
EM sbose@wsu.edu
OI Vu, Ashley/0000 0003 4336 8342
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
   (NIAMS) of the U.S. National Institutes of Health (NIH) [R01 AR066361]
FX Authors would like to acknowledge financial support from the National
   Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of
   the U.S. National Institutes of Health (NIH) under grant numbers R01
   AR066361. The content is solely the responsibility of the authors and
   does not necessarily represent the official views of the National
   Institutes of Health.
CR Adhikari HS, 2018, INT J BIOMATER, V2018, DOI 10.1155/2018/2952085
   Babu A, 2017, MAR DRUGS, V15, DOI 10.3390/md15040096
   Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
   Bose S, 2018, MATER TODAY CHEM, V8, P110, DOI 10.1016/j.mtchem.2018.03.005
   Bose S, 2012, ACTA BIOMATER, V8, P1401, DOI 10.1016/j.actbio.2011.11.017
   BUCHOLZ RW, 1989, CLIN ORTHOP RELAT R, P53
   CarrenoGomez B, 1997, INT J PHARM, V148, P231, DOI 10.1016/S0378 5173(96)04847 8
   Deng XW, 2014, BIOMATERIALS, V35, P4333, DOI 10.1016/j.biomaterials.2014.02.006
   Ferrari S, 2004, CANCER, V100, P1936, DOI 10.1002/cncr.20151
   Fielding GA, 2012, ACTA BIOMATER, V8, P3144, DOI 10.1016/j.actbio.2012.04.004
   Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478
   GILLIES RJ, 1994, AM J PHYSIOL, V267, pC195, DOI 10.1152/ajpcell.1994.267.1.C195
   Gillies RJ, 2008, J NUCL MED, V49, p24S, DOI 10.2967/jnumed.107.047258
   Hasegawa M, 2001, JPN J CANCER RES, V92, P459, DOI 10.1111/j.1349 7006.2001.tb01116.x
   Izumi H, 2003, CANCER TREAT REV, V29, P541, DOI 10.1016/S0305 7372(03)00106 3
   Mahoney BP, 2003, BIOCHEM PHARMACOL, V66, P1207, DOI 10.1016/S0006 2952(03)00467 2
   Ordikhani F, 2014, MAT SCI ENG C MATER, V41, P240, DOI 10.1016/j.msec.2014.04.036
   Perut F, 2014, EXP CELL RES, V320, P21, DOI 10.1016/j.yexcr.2013.10.011
   Pillé JY, 2006, HUM GENE THER, V17, P1019, DOI 10.1089/hum.2006.17.1019
   Riemann A, 2016, ADV EXP MED BIOL, V876, P215, DOI 10.1007/978 1 4939 3023 4_27
   Roy M, 2011, SURF COAT TECH, V205, P2785, DOI 10.1016/j.surfcoat.2010.10.042
   Saravanabhavan SS, 2019, MAT SCI ENG C MATER, V99, P1459, DOI 10.1016/j.msec.2019.02.047
   Sarkar N, 2019, ACS APPL MATER INTER, V11, P17184, DOI 10.1021/acsami.9b01218
   Shen KT, 2009, FOOD CHEM TOXICOL, V47, P1864, DOI 10.1016/j.fct.2009.04.044
   Song B, 2009, ONCOGENE, V28, P4065, DOI 10.1038/onc.2009.274
   Song B, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 96
   Sumathra M, 2018, ACS OMEGA, V3, P14620, DOI 10.1021/acsomega.8b02090
   Tan ML, 2014, BIOMATERIALS, V35, P7828, DOI 10.1016/j.biomaterials.2014.05.087
   Tan ML, 2010, BIOMATERIALS, V31, P541, DOI 10.1016/j.biomaterials.2009.09.069
   Tarafder S, 2013, MAT SCI ENG C MATER, V33, P3121, DOI 10.1016/j.msec.2013.02.049
   Tarafder S, 2010, LANGMUIR, V26, P16625, DOI 10.1021/la101851f
   Taylor S., 2005, ADV FOOD NUTR RES, V49, P94
   VAUPEL P, 1989, CANCER RES, V49, P6449
   Vu AA, 2019, ACTA BIOMATER, V92, P325, DOI 10.1016/j.actbio.2019.05.020
   Warburg O., J GEN PHYSL, V8, P319
   Winterowd Jack G., 1995, V67, P441
   Zeltinger J, 2001, TISSUE ENG, V7, P557, DOI 10.1089/107632701753213183
   Zhao Y, 2009, BIOCHEM BIOPH RES CO, V390, P642, DOI 10.1016/j.bbrc.2009.10.020
NR 38
TC 21
Z9 22
U1 0
U2 93
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928 4931
EI 1873 0191
J9 MAT SCI ENG C MATER
JI Mater. Sci. Eng. C Mater. Biol. Appl.
PD OCT
PY 2020
VL 115
AR 111041
DI 10.1016/j.msec.2020.111041
PG 9
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA ME1ST
UT WOS:000544442100007
PM 32600681
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Wilson, EL
   Garton, M
   Fuller, HR
AF Wilson, Emma L.
   Garton, Mark
   Fuller, Heidi R.
TI Anti epileptic drugs and bone loss: Phenytoin reduces pro collagen I and
   alters the electrophoretic mobility of osteonectin in cultured bone
   cells
SO EPILEPSY RESEARCH
LA English
DT Article
DE Phenytoin; Valproate; Collagen; Osteonectin; SPARC; AEDs; Anti epileptic
   drugs; Bone
ID OSTEOGENESIS IMPERFECTA; MINERAL DENSITY; GLYCOSYLATION; VARIABILITY;
   VALPROATE
AB Phenytoin is an antiepileptic drug used in the management of partial and tonic clonic seizures. In previous studies we have shown that valproate, another antiepileptic drug, reduced the amount of two key bone proteins, pro collagen I and osteonectin (SPARC, BM 40), in both skin fibroblasts and cultured osteoblast like cells. Here we show that phenytoin also reduces pro collagen I production in osteoblast like cells, but does not appear to cause a decrease in osteonectin message or protein production. Instead, a 24 h exposure to a clinically relevant concentration of phenytoin resulted in a dose dependent change in electrophoretic mobility of osteonectin, which was suggestive of a change in post translational modification status. The perturbation of these important bone proteins could be one of the mechanisms to explain the bone loss that has been reported following long term treatment with phenytoin. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Wilson, Emma L.; Fuller, Heidi R.] RJAH Orthopaed Hosp, Wolfson Ctr Inherited Neuromuscular Dis, Oswestry SY10 7AG, Shrops, England.
   [Garton, Mark] RJAH Orthopaed NHS Fdn Trust, Dept Rheumatol, Oswestry SY10 7AG, Shrops, England.
   [Fuller, Heidi R.] Keele Univ, Inst Sci & Technol Med, Keele, Staffs, England.
C3 Keele University; Keele University
RP Fuller, HR (通讯作者)，Keele Univ, Inst Sci & Technol Med, Keele, Staffs, England.
EM h.r.fuller@keele.ac.uk
OI Fuller, Heidi/0000 0002 2858 869X; Wilson, Emma/0000 0001 5064 2966
FU RJAH charitable funds
FX This work was funded by the RJAH charitable funds. Authors' roles: Study
   design: ELH, MG and HRF; conduct of experiments: ELH; drafting
   manuscript: ELH, MG and HRF. HRF takes responsibility for the integrity
   of the data analysis. The authors are grateful to Professor Glenn Morris
   for providing access to laboratory facilities.
CR Bobustuc GC, 2010, NEURO ONCOLOGY, V12, P917, DOI 10.1093/neuonc/noq044
   Delany AM, 2003, ENDOCRINOLOGY, V144, P2588, DOI 10.1210/en.2002 221044
   Fuller HR, 2010, J PROTEOME RES, V9, P4228, DOI 10.1021/pr1005263
   Gallagher EP, 2001, TOXICOL SCI, V59, P118, DOI 10.1093/toxsci/59.1.118
   Gao X.M., 1991, NEUROSCI LETT, V135, P159
   Huh HJ, 2013, THER DRUG MONIT, V35, P177, DOI 10.1097/FTD.0b013e31827efe1d
   Humphrey EL, 2013, EPILEPSY RES, V106, P446, DOI 10.1016/j.eplepsyres.2013.06.011
   Johannessen SI, 2006, CLIN PHARMACOKINET, V45, P1061, DOI 10.2165/00003088 200645110 00002
   Kaufmann B, 2004, GLYCOBIOLOGY, V14, P609, DOI 10.1093/glycob/cwh063
   KELM RJ, 1991, J BIOL CHEM, V266, P9632
   Lee RH, 2010, AM J GERIATR PHARMAC, V8, P34, DOI 10.1016/j.amjopharm.2010.02.003
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mendoza Londono R, 2015, AM J HUM GENET, V96, P979, DOI 10.1016/j.ajhg.2015.04.021
   Nakken KO, 2010, EXPERT OPIN DRUG SAF, V9, P561, DOI 10.1517/14740331003636475
   Pack Alison M., 2003, Epilepsy Curr, V3, P91, DOI 10.1046/j.1535 7597.2003.03306.x
   Rauch F, 2004, LANCET, V363, P1377, DOI 10.1016/S0140 6736(04)16051 0
   VALIMAKI MJ, 1994, J BONE MINER RES, V9, P631
   WEINSTEIN RS, 1984, J CLIN ENDOCR METAB, V58, P1003, DOI 10.1210/jcem 58 6 1003
NR 18
TC 4
Z9 6
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920 1211
EI 1872 6844
J9 EPILEPSY RES
JI Epilepsy Res.
PD MAY
PY 2016
VL 122
BP 97
EP 101
DI 10.1016/j.eplepsyres.2016.03.002
PG 5
WC Clinical Neurology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA DK3GM
UT WOS:000374805100015
PM 26999801
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Marupanthorn, K
   Tantrawatpan, C
   Kheolamai, P
   Tantikanlayaporn, D
   Manochantr, S
AF Marupanthorn, Kulisara
   Tantrawatpan, Chairat
   Kheolamai, Pakpoom
   Tantikanlayaporn, Duangrat
   Manochantr, Sirikul
TI Bone morphogenetic protein 2 enhances the osteogenic differentiation
   capacity of mesenchymal stromal cells derived from human bone marrow and
   umbilical cord
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE mesenchymal stromal cells; osteogenic differentiation; umbilical cord;
   bone marrow; bone morphogenetic protein 2
ID STEM CELLS; GROWTH; TISSUE; EXPRESSION; CARTILAGE; PLACENTA; DELIVERY;
   DEFECTS; THERAPY; PATHWAY
AB Mesenchymal stromal cells (MSCs) are multipotent cells that can give rise to different cell types of the mesodermal lineages. They are powerful sources for cell therapy in regenerative medicine as they can be isolated from various tissues, and can be expanded and induced to differentiate into multiple lineages. Recently, the umbilical cord has been suggested as an alternative source of MSCs. Although MSCs derived from the umbilical cord can be induced to differentiate into osteoblasts with a phenotypic similarity to that of bone marrow derived MSCs, the differentiation ability is not consistent. In addition, MSCs from the umbilical cord require a longer period of time to differentiate into osteoblasts. Previous studies have demonstrated the benefits of bone morphogenetic protein 2 (BMP 2) in bone tissue regeneration. In addition, several studies have supported the use of BMP 2 in periodontal regeneration, sinus lift bone grafting and non unions in oral surgery. Although the use of BMP 2 for bone tissue regeneration has been extensively investigated, the BMP 2 induced osteogenic differentiation of MSCs derived from the umbilical cord has not yet been fully examined. Therefore, in this study, we aimed to examine the effects of BMP 2 on the osteogenic differentiation of MSCs derived from umbilical cord compared to that of MSCs derived from bone marrow. The degree of osteogenic differentiation following BMP 2 treatment was determined by assessing alkaline phosphatase (ALP) activity, and the expression profiles of osteogenic differentiation marker genes, osterix (Osx), Runt related transcription factor 2 (Runx2) and osteocalcin (Ocn). The results revealed that BMP 2 enhanced the osteogenic differentiation capacity of MSCs derived from both bone marrow and umbilical cord as demonstrated by increased ALP activity and the upregulation of osteogenic differentiation marker genes. The enhancement of the osteogenic differentiation capacity of MSCs by BMP 2 suggests that these MSCs may be used as alternative sources for bone engineering or cell therapy in regenerative medicine.
C1 [Marupanthorn, Kulisara; Tantrawatpan, Chairat; Kheolamai, Pakpoom; Tantikanlayaporn, Duangrat; Manochantr, Sirikul] Thammasat Univ, Fac Med, Dept Preclin Sci, Div Cell Biol, Paholyotin Rd, Pathum Thani 12120, Thailand.
   [Tantrawatpan, Chairat; Kheolamai, Pakpoom; Tantikanlayaporn, Duangrat; Manochantr, Sirikul] Thammasat Univ, Ctr Excellence Stem Cell Res, Pathum Thani 12120, Thailand.
C3 Thammasat University; Thammasat University
RP Manochantr, S (通讯作者)，Thammasat Univ, Fac Med, Dept Preclin Sci, Div Cell Biol, Paholyotin Rd, Pathum Thani 12120, Thailand.
EM bsirikul@gmail.com
RI Kheolamai, Pakpoom/R 8575 2019; Manochantr, Sirikul/AAX 7324 2021;
   Marupanthorn, Kulisara/JPA 3856 2023; Tantikanlayaporn,
   Duangrat/AAB 3358 2021
OI Tantikanlayaporn, Duangrat/0000 0002 1197 4957; Marupanthorn,
   Kulisara/0000 0002 4647 6237; Manochantr, Sirikul/0000 0003 0565 3441
FU Thailand Research Fund and Thammasat University [RSA5980042]; Center of
   Excellence in Stem Cell Research, Thammasat University
FX The authors would like to thank the staff at the delivery room,
   Thammasat University Hospital, for facilitating specimen collection and
   all the volunteers for kindly donating the tissues for this study. This
   study was supported by grants from Thailand Research Fund and Thammasat
   University (RSA5980042) and Center of Excellence in Stem Cell Research,
   Thammasat University.
CR Arinzeh TL, 2003, J BONE JOINT SURG AM, V85A, P1927, DOI 10.2106/00004623 200310000 00010
   Bais MV, 2009, BONE, V45, P254, DOI 10.1016/j.bone.2009.04.239
   Cheng YH, 2016, BIOMATERIALS, V103, P207, DOI 10.1016/j.biomaterials.2016.06.060
   Dang PN, 2016, STEM CELL TRANSL MED, V5, P206, DOI 10.5966/sctm.2015 0115
   De Biase P, 2005, INJURY, V36, P43, DOI 10.1016/j.injury.2005.07.034
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Hernigou P, 2005, J BONE JOINT SURG BR, V87B, P896, DOI 10.1302/0301 620X.87B7.16289
   Hsiao HY, 2016, PRS GLOB OPEN, V4, DOI 10.1097/GOX.0000000000000817
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Kim HJ, 2003, J BIOL CHEM, V278, P319, DOI 10.1074/jbc.M203750200
   Kim YJ, 2004, J BIOL CHEM, V279, P50773, DOI 10.1074/jbc.M404145200
   Koç ON, 2001, BONE MARROW TRANSPL, V27, P235, DOI 10.1038/sj.bmt.1702791
   Krampera M, 2007, BONE, V40, P382, DOI 10.1016/j.bone.2006.09.006
   Krampera M, 2006, BONE, V39, P678, DOI 10.1016/j.bone.2006.04.020
   Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Li X, 2011, STEM CELLS, V29, P263, DOI 10.1002/stem.572
   Lieberman JR, 1999, J BONE JOINT SURG AM, V81A, P905, DOI 10.2106/00004623 199907000 00002
   Lin ZW, 2014, EXP THER MED, V7, P625, DOI 10.3892/etm.2013.1464
   Loeser RF, 2010, CLIN GERIATR MED, V26, P371, DOI 10.1016/j.cger.2010.03.002
   Lu LL, 2006, HAEMATOLOGICA, V91, P1017
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   Manochantr S, 2013, INTERN MED J, V43, P430, DOI 10.1111/imj.12044
   Mikami Y, 2016, J BONE MINER METAB, V34, P627, DOI 10.1007/s00774 015 0719 6
   Na K, 2007, BIOMATERIALS, V28, P2631, DOI 10.1016/j.biomaterials.2007.02.008
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nishimura R, 2008, J BONE MINER METAB, V26, P203, DOI 10.1007/s00774 007 0824 2
   Osyczka AM, 2005, ENDOCRINOLOGY, V146, P3428, DOI 10.1210/en.2005 0303
   Osyczka AM, 2009, CONNECT TISSUE RES, V50, P270, DOI 10.1080/03008200902846262
   Petite H, 2000, NAT BIOTECHNOL, V18, P959, DOI 10.1038/79449
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Ryoo HM, 2006, GENE, V366, P51, DOI 10.1016/j.gene.2005.10.011
   Scarfì S, 2016, WORLD J STEM CELLS, V8, P1, DOI 10.4252/wjsc.v8.i1.1
   Stock UA, 2001, ANNU REV MED, V52, P443, DOI 10.1146/annurev.med.52.1.443
   Tsao YT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010159
   Tseng SS, 2008, J BONE JOINT SURG AM, V90A, P92, DOI 10.2106/JBJS.G.01192
   Viateau V, 2007, J ORTHOP RES, V25, P741, DOI 10.1002/jor.20352
   Wagner W, 2005, EXP HEMATOL, V33, P1402, DOI 10.1016/j.exphem.2005.07.003
   Wang XF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157214
   Yi H, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.50
NR 40
TC 67
Z9 82
U1 0
U2 18
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
EI 1791 244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD MAR
PY 2017
VL 39
IS 3
BP 654
EP 662
DI 10.3892/ijmm.2017.2872
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA EP1VU
UT WOS:000397173200019
PM 28204808
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Court, H
   Amoyel, M
   Hackman, M
   Lee, KE
   Xu, RL
   Miller, G
   Bar Sagi, D
   Bach, EA
   Bergo, MÖ
   Philips, MR
AF Court, Helen
   Amoyel, Marc
   Hackman, Michael
   Lee, Kyoung Eun
   Xu, Ruliang
   Miller, George
   Bar Sagi, Dafna
   Bach, Erika A.
   Bergo, Martin O.
   Philips, Mark R.
TI Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates
   KRAS driven pancreatic neoplasia via Notch suppression
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID K RAS; CARBOXYL METHYLTRANSFERASE; INTRAEPITHELIAL NEOPLASIA; DUCTAL
   ADENOCARCINOMA; CANCER; PROGRESSION; EXPRESSION; CELLS; TRANSFORMATION;
   MICE
AB RAS is the most frequently mutated oncogene in human cancers. Despite decades of effort, anti RAS therapies have remained elusive. Isoprenylcysteine carboxylmethyltransferase (ICMT) methylates RAS and other CaaX containing proteins, but its potential as a target for cancer therapy has not been fully evaluated. We crossed a Pdxl Cre;LSL Kras(G12D) mouse, which is a model of pancreatic ductal adenocarcinoma.(PDA), with a mouse harboring afloxed allele of Icmt. Surprisingly, we found that ICMT deficiency dramatically accelerated the development and progression of neoplasia. ICMT deficient pancreatic ductal epithelial cells had a slight growth advantage and were resistant to premature senescence by a mechanism that involved suppression of cyclin dependent kinase inhibitor 2A (p16(INK4A)) expression. ICMT deficiency precisely phenocopied. Notchl deficiency in the Pdx1 Cre;LSL Kras(G12D) model by exacerbating pancreatic intraepithelial neoplasias, promoting facial papillomas, and derepressing Wnt signaling. Silencing ICMT in human.osteosarcoma cells decreased Notchl signaling in response to stimulation with cell surface ligands. Additionally, targeted. silencing of Ste14, the Drosophila homolog of Icmt, resulted in defects in wing development, consistent with Notch loss of function. Our data suggest that ICMT behaves like a tumor suppressor in PDA because it is required for Notchl signaling.
C1 [Court, Helen; Philips, Mark R.] NYU, Sch Med, Dept Med, New York, NY USA.
   [Court, Helen; Philips, Mark R.] NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA.
   [Court, Helen; Amoyel, Marc; Lee, Kyoung Eun; Bar Sagi, Dafna; Bach, Erika A.; Philips, Mark R.] NYU, Sch Med, Dept Biochem & Mol Pharmacol, New York, NY USA.
   [Court, Helen; Bar Sagi, Dafna; Philips, Mark R.] NYU, Sch Med, Inst Canc, New York, NY USA.
   [Hackman, Michael; Miller, George] NYU, Sch Med, Dept Surg, New York, NY USA.
   [Xu, Ruliang] NYU, Sch Med, Dept Pathol, New York, NY USA.
   [Bergo, Martin O.] Sahlgrens Univ Hosp, Inst Med, S 41345 Gothenburg, Sweden.
C3 New York University; New York University; New York University; New York
   University; New York University; New York University; Sahlgrenska
   University Hospital
RP Philips, MR (通讯作者)，NYU, Sch Med, Inst Canc, Srnilow 1207,522 1st Ave, New York, NY USA.
EM philim01@med.nyu.edu
RI Amoyel, Marc/GLR 0962 2022
OI xu, ruliang/0000 0002 9165 4610; Mark, Philips/0000 0002 1179 8156;
   Amoyel, Marc/0000 0002 2691 2097; Lee, Kyoung Eun/0000 0002 3955 7389;
   Bach, Erika/0000 0002 5997 4489; Bar Sagi, Dafna/0000 0003 2597 8948
FU NIH [CA118495, CA116034, GM055279, DK085278, CA155649, 5R01CA55360,
   5R01GM078266]; Jeffrey Rosenzweig Foundation for Pancreatic Cancer
   Research; NCI [5P30CA016087 32]
FX We thank Stephen Blacklow for providing expert advice as well as cell
   lines and reagents for the Notchl luciferase assay. We thank Jonathan
   Court for statistical analysis of data. We thank Cynthia Loomis, Luis
   Chiriboga, and the NYU Langone Medical Center Histopathology and
   Immunohistochemistry Core Facilities for their assistance with specimen
   preparation and histology. We thank Jessica Treisman and Ramanuj
   DasGupta for fly stocks and discussions. We thank Rebecca Zuckerman and
   Christopher Graffeo for technical assistance. This work was supported by
   NIH Grants CA118495, CA116034, and GM055279 and by funding from the
   Jeffrey Rosenzweig Foundation for Pancreatic Cancer Research (to M.R.
   Philips). Support was also provided by NIH Awards DK085278 and CA155649
   (to G. Miller) and 5R01CA55360 and 5R01GM078266 (to D. Bar Sagi). This
   work was also supported in part by NCI grant 5P30CA016087 32.
CR Agbunag C, 2006, METHOD ENZYMOL, V407, P703, DOI 10.1016/S0076 6879(05)07055 2
   Ahearn IM, 2012, NAT REV MOL CELL BIO, V13, P39, DOI 10.1038/nrm3255
   Ahearn IM, 2011, MOL CELL, V41, P173, DOI 10.1016/j.molcel.2011.01.001
   ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092 8674(88)90571 5
   [Anonymous], 2012, R LANG ENV STAT COMP
   Ashar HR, 2000, J BIOL CHEM, V275, P30451, DOI 10.1074/jbc.M003469200
   Aste Amézaga M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009094
   Bachem MG, 2005, GASTROENTEROLOGY, V128, P907, DOI 10.1053/j.gastro.2004.12.036
   BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023
   Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103
   Bedrosian AS, 2011, GASTROENTEROLOGY, V141, P1915, DOI 10.1053/j.gastro.2011.07.033
   Bergo MO, 2004, J CLIN INVEST, V113, P539, DOI 10.1172/JCI200418829
   Bergo MO, 2000, J BIOL CHEM, V275, P17605, DOI 10.1074/jbc.C000079200
   Bergo MO, 2001, J BIOL CHEM, V276, P5841, DOI 10.1074/jbc.C000831200
   BOS JL, 1989, CANCER RES, V49, P4682
   Carrière C, 2009, BIOCHEM BIOPH RES CO, V382, P561, DOI 10.1016/j.bbrc.2009.03.068
   Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783
   Choy E, 2000, METHOD ENZYMOL, V325, P101
   Chu GC, 2007, J CELL BIOCHEM, V101, P887, DOI 10.1002/jcb.21209
   Cox AD, 2002, CURR OPIN PHARMACOL, V2, P388, DOI 10.1016/S1471 4892(02)00181 9
   Demehri S, 2009, CANCER CELL, V16, P55, DOI 10.1016/j.ccr.2009.05.016
   deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005
   Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969
   Fiordalis JJ, 2002, J BIOL CHEM, V277, P10813, DOI 10.1074/jbc.M107684200
   Gannon M, 2000, GENESIS, V26, P143, DOI 10.1002/(SICI)1526 968X(200002)26:2<143::AID GENE13>3.0.CO;2 L
   Grosshans BL, 2006, P NATL ACAD SCI USA, V103, P11821, DOI 10.1073/pnas.0601617103
   Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012
   Hanlon L, 2010, CANCER RES, V70, P4280, DOI 10.1158/0008 5472.CAN 09 4645
   Heikkinen S., 2007, Curr Protoc Mol Biol, DOI [10. 1002/0471142727.mb29b03s77, DOI 10.1002/0471142727.MB29B03S77, 10.1002/0471142727.mb29b03s77]
   Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535 6108(03)00309 X
   Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023
   Hruban RH, 2007, MODERN PATHOL, V20, pS61, DOI 10.1038/modpathol.3800685
   Hruban RH, 2004, AM J SURG PATHOL, V28, P977, DOI 10.1097/01.pas.0000126675.59108.80
   Ijichi H, 2006, GENE DEV, V20, P3147, DOI 10.1101/gad.1475506
   Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001
   Judd WR, 2011, J MED CHEM, V54, P5031, DOI 10.1021/jm200249a
   LAMPEL M, 1977, VIRCHOWS ARCH A, V373, P97, DOI 10.1007/BF00432156
   Le Borgne R, 2005, DEVELOPMENT, V132, P1751, DOI 10.1242/dev.01789
   Lee KE, 2010, CANCER CELL, V18, P448, DOI 10.1016/j.ccr.2010.10.020
   Lin X, 2002, GASTROENTEROLOGY, V123, P345, DOI 10.1053/gast.2002.34279
   Lowenfels AB, 1999, GASTROENTEROL CLIN N, V28, P673, DOI 10.1016/S0889 8553(05)70080 7
   Maurer Stroh S, 2007, PLOS COMPUT BIOL, V3, P634, DOI 10.1371/journal.pcbi.0030066
   Mazur PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013578
   Mazur PK, 2010, P NATL ACAD SCI USA, V107, P13438, DOI 10.1073/pnas.1002423107
   Micchelli CA, 1997, DEVELOPMENT, V124, P1485
   Michaelson D, 2005, MOL BIOL CELL, V16, P1606, DOI 10.1091/mbc.e04 11 0960
   Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099
   Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004
   PARODY TR, 1993, GENETICS, V135, P527
   Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186
   Reid TS, 2004, J MOL BIOL, V343, P417, DOI 10.1016/j.jmb.2004.08.056
   Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092 8674(03)01075 4
   Shi CJ, 2009, MOL CANCER RES, V7, P230, DOI 10.1158/1541 7786.MCR 08 0206
   Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007
   Vigil D, 2010, NAT REV CANCER, V10, P842, DOI 10.1038/nrc2960
   Wahlstrom AM, 2008, BLOOD, V112, P1357, DOI 10.1182/blood 2007 06 094060
   WATANABE O, 1984, AM J PHYSIOL, V246, pG457, DOI 10.1152/ajpgi.1984.246.4.G457
   Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459
   WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0
   Winter Vann AM, 2005, P NATL ACAD SCI USA, V102, P4336, DOI 10.1073/pnas.0408107102
   Wright LP, 2006, J LIPID RES, V47, P883, DOI 10.1194/jlr.R600004 JLR200
   Yonezawa S, 2008, GUT LIVER, V2, P137, DOI 10.5009/gnl.2008.2.3.137
   Zhu LQ, 2007, AM J PATHOL, V171, P263, DOI 10.2353/ajpath.2007.061176
NR 63
TC 41
Z9 57
U1 0
U2 14
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021 9738
EI 1558 8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD NOV
PY 2013
VL 123
IS 11
BP 4681
EP 4694
DI 10.1172/JCI65764
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 247IU
UT WOS:000326611900017
PM 24216479
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Wang, L
   Lu, WG
   Shi, J
   Zhang, HY
   Xu, XL
   Gao, B
   Huang, Q
   Li, XJ
   Hu, YQ
   Jie, Q
   Luo, ZJ
   Yang, L
AF Wang, Long
   Lu, Wei Guang
   Shi, Jun
   Zhang, Hong Yang
   Xu, Xiao Long
   Gao, Bo
   Huang, Qiang
   Li, Xiao Jie
   Hu, Ya Qian
   Jie, Qiang
   Luo, Zhuo Jing
   Yang, Liu
TI Anti osteoporotic effects of tetramethylpyrazine via promoting
   osteogenic differentiation and inhibiting osteoclast formation
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE tetramethylpyrazine; glucocorticoids; osteoporosis; mesenchymal stem
   cells; osteoclasts
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; INDUCED APOPTOSIS; OSTEOBLAST
   DIFFERENTIATION; BONE FORMATION; PROTECTS; EXPRESSION; AUTOPHAGY;
   INDUCE; INJURY; CELLS
AB Long term glucocorticoid therapy results in various side effects, including a high incidence of glucocorticoid induced osteoporosis (GIOP), which is the most common form of secondary osteoporosis. Excess glucocorticoids reduce the viability of bone marrow derived mesenchymal stem cells (BMSCs) and prolong osteoclast survival. These two types of cell are essential in the balance between bone formation and resorption. Tetramethylpyrazine (TMP), the pharmacologically active component extracted from Chuanxiong, has been reported to protect BMSCs from glucocorticoid induced apoptosis. In the present study, the protective effects of TMP on BMSC differentiation and osteoclasts maturation in GIOP were investigated in vivo and in vitro. The immunostaining of osterix (OSX) and tartrate resistant acid phosphatase (TRAP) staining indicated that TMP promoted osteogenesis and inhibited osteoclastogenesis in a rat model of GIOP. Treatment with 10( 6) M dexamethasone (Dex) significantly inhibited BMSC differentiation and increased TRAP positive cells in vitro. However, different concentrations of TMP (50, 100 and 200 mu M) ameliorated the negative effects of Dex by promoting the activity of alkaline phosphatase (ALP) and the calcium mineralization of BMSCs following osteogenic induction, which increased the expression levels of osteogenic genes, including ALP, collagen type I alpha 1, osteocalcin and OSX, and decreased osteoclastogenesis related genes, including TRAP, nuclear factor of T cells cytoplasmic 1 and cathepsin K. In addition, it was found that the inhibition of receptor activator of nuclear factor kappa B ligand and intereleukin 6 in BMSCs may be a possible mechanism for the protective effects of TMP against glucocorticoid induced osteoclastogenesis. These results are the first, to the best of our knowledge, to demonstrate that TMP promotes BMSC differentiation and inhibits osteoclastogenesis to ameliorate bone mass change in GIOP.
C1 [Wang, Long; Lu, Wei Guang; Shi, Jun; Zhang, Hong Yang; Xu, Xiao Long; Gao, Bo; Huang, Qiang; Li, Xiao Jie; Hu, Ya Qian; Jie, Qiang; Luo, Zhuo Jing; Yang, Liu] Fourth Mil Med Univ, Xijing Hosp, Inst Orthoped Surg, 15 Changle West Rd, Xian 710032, Shaanxi, Peoples R China.
C3 Air Force Medical University
RP Luo, ZJ; Yang, L (通讯作者)，Fourth Mil Med Univ, Xijing Hosp, Inst Orthoped Surg, 15 Changle West Rd, Xian 710032, Shaanxi, Peoples R China.
EM zjluofmmu@hotmail.com; yangliu@fmmu.edu.cn
RI Lu, Weiguang/HJA 2546 2022; Zhang, Hongyang/IAR 1565 2023
OI Lu, Weiguang/0000 0002 3920 9667; Hu, Yaqian/0000 0002 1936 5478
FU National Natural Science Foundation of China [81572192, 81472043];
   Program for Changjiang Scholars and Innovative Research Team in
   University [IRT13051]
FX This study was supported by the National Natural Science Foundation of
   China (grant nos. 81572192 and 81472043) and the Program for Changjiang
   Scholars and Innovative Research Team in University (grant no.
   IRT13051).
CR ASH P, 1980, NATURE, V283, P669, DOI 10.1038/283669a0
   Bonyadi M, 2003, P NATL ACAD SCI USA, V100, P5840, DOI 10.1073/pnas.1036475100
   Bouffi C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014247
   Boyce BF, 2013, J BONE MINER RES, V28, P711, DOI 10.1002/jbmr.1885
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Chen JJ, 2013, FOOD CHEM TOXICOL, V62, P499, DOI 10.1016/j.fct.2013.09.019
   Chen L, 2014, NEUROCHEM INT, V66, P27, DOI 10.1016/j.neuint.2014.01.006
   Chen TL, 2004, BONE, V35, P83, DOI 10.1016/j.bone.2004.03.019
   Cui L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034647
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Gao B, 2015, STEM CELLS DEV, V24, P781, DOI 10.1089/scd.2014.0367
   Gong XZ, 2015, ARCH TOXICOL, V89, P1057, DOI 10.1007/s00204 014 1302 y
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hofbauer LC, 2010, EUR J ENDOCRINOL, V162, P1009, DOI 10.1530/EJE 10 0015
   Hu JZ, 2016, SPINE, V41, P1272, DOI 10.1097/BRS.0000000000001546
   Huang Q, 2015, BONE, V73, P132, DOI 10.1016/j.bone.2014.12.059
   Jia D, 2006, ENDOCRINOLOGY, V147, P5592, DOI 10.1210/en.2006 0459
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kim HJ, 2006, J CLIN INVEST, V116, P2152, DOI 10.1172/JCI28084
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lagasse E, 1997, CELL, V89, P1021, DOI 10.1016/S0092 8674(00)80290 1
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu C, 2014, INT J BIOL SCI, V10, P350, DOI 10.7150/ijbs.8366
   Miura M, 2004, J CLIN INVEST, V114, P1704, DOI 10.1172/JCI200420427
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Papanicolaou DA, 2000, J CLIN ENDOCR METAB, V85, P1331, DOI 10.1210/jc.85.3.1331
   Rizzoli R, 2015, NAT REV RHEUMATOL, V11, P98, DOI 10.1038/nrrheum.2014.188
   Shi J, 2015, BONE, V79, P222, DOI 10.1016/j.bone.2015.06.014
   Tanaka Yoshiya, 2013, Clin Calcium, V23, P229, DOI CliCa1302229235
   Wang KK, 2011, J MOL CELL BIOL, V3, P360, DOI 10.1093/jmcb/mjr021
   Wang L, 2017, STEM CELLS DEV, V26, P419, DOI 10.1089/scd.2016.0233
   Wang L, 2015, MOL MED REP, V11, P2711, DOI 10.3892/mmr.2014.3099
   Wang XY, 2011, J BONE MINER RES, V26, P1964, DOI 10.1002/jbmr.394
   Xiu Y, 2014, J CLIN INVEST, V124, P297, DOI 10.1172/JCI66947
   Yu N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133055
NR 35
TC 13
Z9 14
U1 1
U2 19
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD DEC
PY 2017
VL 16
IS 6
BP 8307
EP 8314
DI 10.3892/mmr.2017.7610
PG 8
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA FQ3AM
UT WOS:000418229200053
PM 28983593
OA Bronze
DA 2025 08 17
ER

PT J
AU Teramachi, J
   Tenshin, H
   Hiasa, M
   Oda, A
   Bat Erdene, A
   Harada, T
   Nakamura, S
   Ashtar, M
   Shimizu, S
   Iwasa, M
   Sogabe, K
   Oura, M
   Fujii, S
   Kagawa, K
   Miki, H
   Endo, I
   Haneji, T
   Matsumoto, T
   Abe, M
AF Teramachi, Jumpei
   Tenshin, Hirofumi
   Hiasa, Masahiro
   Oda, Asuka
   Bat Erdene, Ariunzaya
   Harada, Takeshi
   Nakamura, Shingen
   Ashtar, Mohannad
   Shimizu, So
   Iwasa, Masami
   Sogabe, Kimiko
   Oura, Masahiro
   Fujii, Shiro
   Kagawa, Kumiko
   Miki, Hirokazu
   Endo, Itsuro
   Haneji, Tatsuji
   Matsumoto, Toshio
   Abe, Masahiro
TI TAK1 is a pivotal therapeutic target for tumor progression and bone
   destruction in myeloma
SO HAEMATOLOGICA
LA English
DT Article
ID MARROW STROMAL CELLS; NF KAPPA B; ENDOTHELIAL GROWTH FACTOR; RESISTANCE
   CAM DR; MULTIPLE MYELOMA; OSTEOBLAST DIFFERENTIATION; SIGNALING
   CASCADES; PIM 2 KINASE; INHIBITION; ADHESION
AB Along with tumor progression, the bone marrow microenvironment is skewed in multiple myeloma (MM), which underlies the unique pathophysiology of MM and confers aggressiveness and drug resistance in MM cells. TGF b activated kinase 1 (TAK1) mediates a wide range of intracellular signaling pathways. We demonstrate here that TAK1 is constitutively overexpressed and phosphorylated in MM cells, and that TAK1 inhibition suppresses the activation of NF KB, p38MAPK, ERK and STAT3 in order to decrease the expression of critical mediators for MM growth and survival, including PIM2, MYC, Mcl1, IRF4, and Sp1, along with a substantial reduction in the angiogenic factor VEGF in MM cells. Intriguingly, TAK1 phosphorylation was also induced along with upregulation of vascular cell adhesion molecule 1 (VCAM 1) in bone marrow stromal cells (BMSC) in cocultures with MM cells, which facilitated MM cell BMSC adhesion while inducing IL 6 production and receptor activator of nuclear factor K B ligand (RANKL) expression by BMSC. TAK1 inhibition effectively impaired MM cell adhesion to BMSC to disrupt the support of MM cell growth and survival by BMSC. Furthermore, TAK1 inhibition suppressed osteoclastogenesis enhanced by RANKL in cocultures of bone marrow cells with MM cells, and restored osteoblastic differentiation suppressed by MM cells or inhibitory factors for osteoblastogenesis overproduced in MM. Finally, treatment with the TAK1 inhibitor LLZ1640 2 markedly suppressed MM tumor growth and prevented bone destruction and loss in mouse MM models. Therefore, TAK1 inhibition may be a promising therapeutic option targeting not only MM cells but also the skewed bone marrow microenvironment in MM.
C1 [Teramachi, Jumpei; Haneji, Tatsuji] Tokushima Univ, Grad Sch, Dept Histol Oral Histol, Tokushima, Japan.
   [Teramachi, Jumpei; Tenshin, Hirofumi; Hiasa, Masahiro; Oda, Asuka; Bat Erdene, Ariunzaya; Harada, Takeshi; Nakamura, Shingen; Ashtar, Mohannad; Shimizu, So; Iwasa, Masami; Sogabe, Kimiko; Oura, Masahiro; Fujii, Shiro; Kagawa, Kumiko; Abe, Masahiro] Tokushima Univ, Grad Sch, Dept Hematol Endocrinol & Metab, Tokushima, Japan.
   [Tenshin, Hirofumi; Hiasa, Masahiro; Ashtar, Mohannad; Shimizu, So] Tokushima Univ, Grad Sch, Dept Orthodont & Dentofacial Orthoped, Tokushima, Japan.
   [Bat Erdene, Ariunzaya] Mongolian Natl Univ Med Sci, Sch Biomed, Dept Immunol & Lab Med, Ulaanbaatar, Mongolia.
   [Miki, Hirokazu] Tokushima Univ Hosp, Div Transfus Med & Cell Therapy, Tokushima, Japan.
   [Endo, Itsuro] Tokushima Univ, Grad Sch, Inst Biomed Sci, Dept Chronomed, Tokushima, Japan.
   [Matsumoto, Toshio] Tokushima Univ, Fujii Mem Inst Med Sci, Tokushima, Japan.
C3 Tokushima University; Tokushima University; Tokushima University;
   Mongolian National University of Medical Sciences; Tokushima University;
   Tokushima University; Tokushima University
RP Teramachi, J (通讯作者)，Tokushima Univ, Grad Sch, Dept Histol Oral Histol, Tokushima, Japan.; Teramachi, J; Abe, M (通讯作者)，Tokushima Univ, Grad Sch, Dept Hematol Endocrinol & Metab, Tokushima, Japan.
EM jumptera@okayama u.ac.jp; masabe@tokushima u.ac.jp
RI Nakamura, Shingen/GPX 5438 2022; HIASA, MASAHIRO/ABB 3885 2021
OI Bat Erdene, Ariunzaya/0000 0003 1852 0584; HIASA,
   MASAHIRO/0000 0002 4830 6274
FU JSPS KAKENHI [JP18K08329, JP16K11504, JP17KK0169, JP18H06294]; Aki
   Horinouchi Research Grant; Japan Leukemia Research Fund; Yasuda Memorial
   Medical Foundation; Ichiro Kanehara Foundation; Research Clusters
   program of Tokushima University
FX !This work was supported in part by JSPS KAKENHI Grant Numbers
   JP18K08329, JP16K11504, JP17KK0169, JP18H06294; and Aki Horinouchi
   Research Grant; Japan Leukemia Research Fund; Yasuda Memorial Medical
   Foundation; the Ichiro Kanehara Foundation; and the Research Clusters
   program of Tokushima University. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abe M, 2009, J BONE MINER METAB, V27, P16, DOI 10.1007/s00774 008 0012 z
   Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254
   Asano J, 2011, LEUKEMIA, V25, P1182, DOI 10.1038/leu.2011.60
   Bat Erdene A, 2016, ONCOTARGET, V7, P79050, DOI 10.18632/oncotarget.12594
   Beishline K, 2015, FEBS J, V282, P224, DOI 10.1111/febs.13148
   Bellamy WT, 2001, SEMIN ONCOL, V28, P551, DOI 10.1053/sonc.2001.28606
   Buglio D, 2012, BLOOD, V120, P347, DOI 10.1182/blood 2011 07 369397
   Cackowski FC, 2010, BLOOD, V115, P140, DOI 10.1182/blood 2009 08 237628
   Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104
   D'Souza S, 2011, BLOOD, V118, P6871, DOI 10.1182/blood 2011 04 346775
   Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658
   Ehrlich LA, 2005, BLOOD, V106, P1407, DOI 10.1182/blood 2005 03 1080
   Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801
   Fulciniti M, 2011, CLIN CANCER RES, V17, P6500, DOI 10.1158/1078 0432.CCR 11 1036
   Giuliani N, 2005, BLOOD, V106, P2472, DOI 10.1182/blood 2004 12 4986
   Giuliani N, 2004, HAEMATOLOGICA, V89, P1118
   Giuliani N, 2004, LEUKEMIA, V18, P628, DOI 10.1038/sj.leu.2403269
   Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782
   Hiasa M, 2015, LEUKEMIA, V29, P207, DOI 10.1038/leu.2014.147
   Hiruma Y, 2009, BLOOD, V113, P4894, DOI 10.1182/blood 2008 08 173948
   Jöhrer K, 2012, J MOL MED, V90, P681, DOI 10.1007/s00109 011 0848 x
   Kikuchi J, 2010, BLOOD, V116, P406, DOI 10.1182/blood 2009 07 235663
   Landowski TH, 2003, ONCOGENE, V22, P2417, DOI 10.1038/sj.onc.1206315
   Lu AL, 2016, AM J PATHOL, V186, P678, DOI 10.1016/j.ajpath.2015.11.003
   Lu J, 2013, BLOOD, V122, P1610, DOI 10.1182/blood 2013 01 481457
   Maeda S, 2004, EMBO J, V23, P552, DOI 10.1038/sj.emboj.7600067
   Matsumoto T, 2011, BONE, V48, P129, DOI 10.1016/j.bone.2010.05.036
   Michigami T, 2000, BLOOD, V96, P1953, DOI 10.1182/blood.V96.5.1953.h8001953_1953_1960
   Mihaly SR, 2014, CELL DEATH DIFFER, V21, P1667, DOI 10.1038/cdd.2014.123
   Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359 6101(99)00025 8
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Nyman JS, 2016, BONE, V91, P81, DOI 10.1016/j.bone.2016.07.007
   Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428
   Raje N, 2011, CLIN CANCER RES, V17, P1278, DOI 10.1158/1078 0432.CCR 10 1804
   Safina A, 2008, ONCOGENE, V27, P1198, DOI 10.1038/sj.onc.1210768
   Sakurai H, 2012, TRENDS PHARMACOL SCI, V33, P522, DOI 10.1016/j.tips.2012.06.007
   Silbermann R, 2013, J BONE ONCOL, V2, P59, DOI 10.1016/j.jbo.2013.04.001
   Singh A, 2012, CELL, V148, P639, DOI 10.1016/j.cell.2011.12.033
   Spinella Jaegle S, 2001, BONE, V29, P323, DOI 10.1016/S8756 3282(01)00580 4
   Takeuchi K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009870
   Tanaka Y, 2007, CLIN CANCER RES, V13, P816, DOI 10.1158/1078 0432.CCR 06 2258
   Tang SS, 2018, EXP CELL RES, V363, P196, DOI 10.1016/j.yexcr.2018.01.005
   Tenshin H, 2017, BLOOD ADV, V1, P2124, DOI 10.1182/bloodadvances.2017008813
   Teramachi J, 2016, LEUKEMIA, V30, P390, DOI 10.1038/leu.2015.229
   Teramachi J, 2018, BRIT J HAEMATOL, V180, P581, DOI 10.1111/bjh.14388
   Tornin J, 2016, ONCOTARGET, V7, P30935, DOI 10.18632/oncotarget.8817
   Vallet S, 2010, P NATL ACAD SCI USA, V107, P5124, DOI 10.1073/pnas.0911929107
   Wang LH, 2007, BLOOD, V110, P4373, DOI 10.1182/blood 2006 07 038026
   Yasui H, 2006, BRIT J HAEMATOL, V132, P385, DOI 10.1111/j.1365 2141.2005.05860.x
   Zhu YX, 2014, BLOOD, V124, P536, DOI 10.1182/blood 2014 02 557819
NR 50
TC 17
Z9 20
U1 0
U2 6
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390 6078
J9 HAEMATOLOGICA
JI Haematologica
PD MAY
PY 2021
VL 106
IS 5
BP 1401
EP 1413
DI 10.3324/haematol.2019.234476
PG 13
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA RX0IM
UT WOS:000646903300020
PM 32273474
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Klauzen, P
   Semenova, D
   Kostina, D
   Uspenskiy, V
   Malashicheva, A
AF Klauzen, Polina
   Semenova, Daria
   Kostina, Daria
   Uspenskiy, Vladimir
   Malashicheva, Anna
TI Purinergic Signaling in Pathologic Osteogenic Differentiation of Aortic
   Valve Interstitial Cells from Patients with Aortic Valve Calcification
SO BIOMEDICINES
LA English
DT Article
DE aortic valve; calcification; purinergic signaling; osteogenic
   differentiation
ID URIDINE ADENOSINE TETRAPHOSPHATE; IN VITRO; MINERALIZATION; RECEPTOR;
   ACTS
AB Purinergic signaling is associated with a vast spectrum of physiological processes, including cardiovascular system function and, in particular, its pathological calcifications, such as aortic valve stenosis. Aortic valve stenosis (AS) is a degenerative disease for which there is no cure other than surgical replacement of the affected valve. Purinergic signaling is known to be involved in the pathologic osteogenic differentiation of valve interstitial cells (VIC) into osteoblast like cells, which underlies the pathogenesis of AS. ATP, its metabolites and related nucleotides also act as signaling molecules in normal osteogenic differentiation, which is observed in pro osteoblasts and leads to bone tissue development. We show that stenotic and non stenotic valve interstitial cells significantly differ from each other, especially under osteogenic stimuli. In osteogenic conditions, the expression of the ecto nucleotidases ENTPD1 and ENPP1, as well as ADORA2b, is increased in AS VICs compared to normal VICs. In addition, AS VICs after osteogenic stimulation look more similar to osteoblasts than non stenotic VICs in terms of purinergic signaling, which suggests the stronger osteogenic differentiation potential of AS VICs. Thus, purinergic signaling is impaired in stenotic aortic valves and might be used as a potential target in the search for an anti calcification therapy.
C1 [Klauzen, Polina; Semenova, Daria; Kostina, Daria; Malashicheva, Anna] Russian Acad Sci, Lab Regenerat Biomed, Inst Cytol, Tikhoretskiy Ave 4, St Petersburg 194064, Russia.
   [Uspenskiy, Vladimir] Almazov Natl Med Res Ctr, Akkuratova St 2, St Petersburg 197341, Russia.
C3 Russian Academy of Sciences; St. Petersburg Scientific Centre of the
   Russian Academy of Sciences; Institute of Cytology RAS; Almazov National
   Medical Research Centre
RP Malashicheva, A (通讯作者)，Russian Acad Sci, Lab Regenerat Biomed, Inst Cytol, Tikhoretskiy Ave 4, St Petersburg 194064, Russia.
EM malashicheva@incras.ru
RI Kostina, Daria/H 2212 2016; Malashicheva, Anna/K 2649 2014
OI Kostina, Daria/0000 0003 0641 8101; 
CR Ahmadi A, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 03204 4
   Bogdanova M, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.835825
   Burnstock G, 2017, CIRC RES, V120, P207, DOI 10.1161/CIRCRESAHA.116.309726
   Côté N, 2012, J MOL CELL CARDIOL, V52, P1191, DOI 10.1016/j.yjmcc.2012.02.003
   Eltzschig HK, 2013, J MOL MED, V91, P141, DOI 10.1007/s00109 013 0999 z
   Jankowski V, 2005, NAT MED, V11, P223, DOI 10.1038/nm1188
   Johnson K, 2001, ARTHRITIS RHEUM, V44, P1071, DOI 10.1002/1529 0131(200105)44:5<1071::AID ANR187>3.0.CO;2 3
   Kawano A, 2012, BIOCHEM BIOPH RES CO, V419, P374, DOI 10.1016/j.bbrc.2012.01.156
   Kostina D, 2022, CELLS BASEL, V11, DOI 10.3390/cells11213356
   Kudryavtsev I, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00604
   Kutryb Zajac B, 2020, MOLECULES, V25, DOI 10.3390/molecules25204652
   Kutryb Zajac B, 2020, CLIN RES CARDIOL, V109, P137, DOI 10.1007/s00392 019 01495 x
   Lobov Arseniy, 2022, Biological Communications, V67, P32, DOI 10.21638/spbu03.2022.104
   Lobov AA, 2022, FRONT CARDIOVASC MED, V9, DOI 10.3389/fcvm.2022.969096
   Patel JJ, 2018, J CELL PHYSIOL, V233, P3230, DOI 10.1002/jcp.26166
   Proudfoot D, 2000, CIRC RES, V87, P1055, DOI 10.1161/01.RES.87.11.1055
   Qian SM, 2017, ATHEROSCLEROSIS, V257, P38, DOI 10.1016/j.atherosclerosis.2016.12.014
   Schuchardt M, 2012, KIDNEY INT, V81, P256, DOI 10.1038/ki.2011.326
   Tanase DM, 2022, CELLS BASEL, V11, DOI 10.3390/cells11172663
   Weber A., 2018, EUR HEART J, V39, pehy566.P5089, DOI [10.1093/eurheartj/ehy566.P5089, DOI 10.1093/EURHEARTJ/EHY566.P5089]
   Weber A, 2018, FASEB J, V32, P4356, DOI 10.1096/fj.201701326R
   Yang JS, 2019, MOL MED REP, V20, P5084, DOI 10.3892/mmr.2019.10790
   Zhou ZC, 2016, AM J PHYSIOL HEART C, V311, pH299, DOI 10.1152/ajpheart.00578.2015
NR 23
TC 5
Z9 5
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2227 9059
J9 BIOMEDICINES
JI Biomedicines
PD FEB
PY 2023
VL 11
IS 2
AR 307
DI 10.3390/biomedicines11020307
PG 11
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA 9G8JA
UT WOS:000938391100001
PM 36830843
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Yu, H
   Herbert, BA
   Valerio, M
   Yarborough, L
   Hsu, LC
   Argraves, KM
AF Yu, Hong
   Herbert, Bethany A.
   Valerio, Michael
   Yarborough, Leigh
   Hsu, Li Chien
   Argraves, Kelley M.
TI FTY720 inhibited proinflammatory cytokine release and osteoclastogenesis
   induced by Aggregatibacter actinomycetemcomitans
SO LIPIDS IN HEALTH AND DISEASE
LA English
DT Article
DE FTY720; Sphingosine 1 phosphate; Periodontitis; Cytokine;
   Osteoclastogenesis; Aggregatibacter actinomycetemcomitans
ID SPHINGOSINE 1 PHOSPHATE; THERAPEUTIC TARGETS; MULTIPLE SCLEROSIS; BONE
   HOMEOSTASIS; SPHINGOSINE 1 PHOSPHATE; FINGOLIMOD; RECEPTORS;
   IMMUNOSUPPRESSANT; OSTEOIMMUNOLOGY; INFLAMMATION
AB Background: Periodontitis is a bacteria driven inflammatory bone loss disease. Previous studies showed that the oral pathogen Aggregatibacter actinomycetemcomitans (A. actinomycetemcomitans) stimulated the generation of sphingosine 1 phosphate (S1P). In addition, S1P signaling regulated the migration of osteoclast precursors and affected osteoclastogenesis. Furthermore, treatment with FTY720 (also called fingolimod, a modulator of multiple S1P receptors) alleviated osteoporosis and suppressed arthritis in animals. This study determined the effect of FTY720 on proinflammatory cytokine production and osteoclastogenesis in murine bone marrow cells with or without A. actinomycetemcomitans stimulation.
   Methods: Murine bone marrow derived monocytes and macrophages (BMMs) were treated with vehicle ethanol or FTY720, and were either unstimulated or stimulated for 0.5 to 6 h with A. actinomycetemcomitans. The protein levels of interleukin (IL) 1 beta, IL 6, and tumor necrosis factor (TNF) alpha in the media of BMMs were quantified by enzyme linked immunosorbent assay (ELISA). Protein expressions, including phosphorylated phosphoinositide 3 kinase (p PI3K), p Akt, p extracellular signal regulated kinase (p ERK), PI3K, Akt, and ERK were evaluated by Western blot. In addition, murine bone marrow derived pre osteoclasts were treated with macrophage colony stimulating factor (M CSF) and receptor activator of nuclear factor kappa B ligand (RANKL) for three days. Then the cells were treated with either vehicle or FTY720 and were either unstimulated or stimulated with A. actinomycetemcomitans for 4 to 24 h. Control cells were treated with M CSF alone with or without bacterial stimulation. Osteoclasts were stained by tartrate resistant acid phosphatase (TRAP) staining. The mRNA levels of osteoclastogenic factors, including nuclear factor of activated T cells cytoplasmic calcineurin dependent 1 (Nfatc1), cathepsin K (Ctsk), acid phosphatase 5 (Acp5), osteoclast associated receptor (Oscar), and RANKL were quantified by quantitative real time polymerase chain reaction (PCR).
   Results: FTY720 dose dependently inhibited IL 1 beta, IL 6, and TNF alpha protein levels induced by A. actinomycetemcomitans in BMMs compared with controls. Additionally, FTY720 attenuated p PI3K, p Akt, and p ERK expressions induced by A. actinomycetemcomitans. Furthermore, FTY720 suppressed osteoclastogenesis in bone marrow derived pre osteoclasts with or without bacterial stimulation and reduced the mRNA levels of Nfatc1, Ctsk, Acp5, and Oscar, but not RANKL in bone marrow derived pre osteoclasts.
   Conclusion: FTY720 inhibited proinflammatory cytokine production and suppressed osteoclastogenesis, supporting FTY720 as a potential therapy for inflammatory bone loss diseases.
C1 [Yu, Hong; Herbert, Bethany A.; Valerio, Michael] Med Univ S Carolina, Dept Oral Hlth Sci, Charleston, SC 29425 USA.
   [Yu, Hong; Herbert, Bethany A.; Valerio, Michael] Med Univ S Carolina, Ctr Oral Hlth Res, Charleston, SC 29425 USA.
   [Yarborough, Leigh; Hsu, Li Chien] Clemson Univ, Clemson, SC 29634 USA.
   [Argraves, Kelley M.] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA.
C3 Medical University of South Carolina; Medical University of South
   Carolina; Clemson University; Medical University of South Carolina
RP Yu, H (通讯作者)，Med Univ S Carolina, Dept Oral Hlth Sci, 173 Ashley Ave, Charleston, SC 29425 USA.
EM yuho@musc.edu
RI ; Valerio, Michael/JKB 7726 2023
OI Valerio, Michael/0000 0003 1261 7078; 
FU National Institutes of Health [P30 GM103339, R03 DE025026]; National
   Institute of General Medicine [P30 GM103331]
FX This study was supported by grant P30 GM103339, R03 DE025026 from the
   National Institutes of Health. In addition, this project utilized the
   facility and resources of the Laboratory of the Center for Oral Health
   Research (L COHR), which is supported by the National Institute of
   General Medicine grant P30 GM103331. We thank the Writing Center at
   Medical University of South Carolina for manuscript review and
   assistance. The authors declare no potential conflicts of interest with
   respect to the authorship and/or publication of this article.
CR Aarthi JJ, 2011, J DENT RES, V90, P841, DOI 10.1177/0022034510389178
   Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200
   Chiba K, 1998, J IMMUNOL, V160, P5037
   Chiba K, 2012, FUTURE MED CHEM, V4, P771, DOI [10.4155/FMC.12.25, 10.4155/fmc.12.25]
   Feng W, 2014, FRONT BIOSCI LANDMRK, V19, P758, DOI 10.2741/4242
   FUJITA T, 1994, J ANTIBIOT, V47, P208, DOI 10.7164/antibiotics.47.208
   Gräler MH, 2004, FASEB J, V18, P551, DOI 10.1096/fj.03 0910fje
   Graves D, 2008, J PERIODONTOL, V79, P1585, DOI 10.1902/jop.2008.080183
   Hoitsma AJ, 2011, NEPHROL DIAL TRANSPL, V26, P3802, DOI 10.1093/ndt/gfr503
   Ishii M, 2013, BBA MOL CELL BIOL L, V1831, P223, DOI 10.1016/j.bbalip.2012.06.002
   Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713
   Kikuta J, 2011, RHEUMATOL INT, V31, P967, DOI 10.1007/s00296 010 1634 8
   Kim J., 2014, J. Nanomater, V2014, P1, DOI DOI 10.1155/2014/532043
   Kunkel GT, 2013, NAT REV DRUG DISCOV, V12, P688, DOI 10.1038/nrd4099
   Lai WQ, 2012, FUTURE MED CHEM, V4, P727, DOI [10.4155/FMC.12.28, 10.4155/fmc.12.28]
   Lee SH, 2012, J CLIN ENDOCR METAB, V97, pE1421, DOI 10.1210/jc.2012 1044
   Maceyka M, 2012, TRENDS CELL BIOL, V22, P50, DOI 10.1016/j.tcb.2011.09.003
   Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238
   Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284
   Matsuo Koichi, 2005, Nihon Rinsho, V63, P1541
   Montalban X, 2011, MULT SCLER J, V17, P1341, DOI 10.1177/1352458511411061
   Müller H, 2005, EUR J IMMUNOL, V35, P533, DOI 10.1002/eji.200425556
   Nemeth K, 2011, J IMMUNOL, V186, P13, DOI 10.4049/jimmunol.1002483
   Ngkelo A, 2012, J INFLAMM LOND, V9, DOI 10.1186/1476 9255 9 1
   Noda H, 2013, J NEUROIMMUNOL, V256, P13, DOI 10.1016/j.jneuroim.2012.12.005
   Oikawa T, 2013, CELL MOL LIFE SCI, V70, P3341, DOI 10.1007/s00018 012 1238 4
   Ryu J, 2006, EMBO J, V25, P5840, DOI 10.1038/sj.emboj.7601430
   Shi Lin D, 2015, BIOCHEM BIOPH RES CO, V458, P667
   Snider AJ, 2010, BIOCHIMIE, V92, P707, DOI 10.1016/j.biochi.2010.02.008
   Spiegel S, 2011, NAT REV IMMUNOL, V11, P403, DOI 10.1038/nri2974
   Takabe K, 2008, PHARMACOL REV, V60, P181, DOI 10.1124/pr.107.07113
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Väänänen HK, 2008, ARCH BIOCHEM BIOPHYS, V473, P132, DOI 10.1016/j.abb.2008.03.037
   Xia P, 2011, CYTOKINE GROWTH F R, V22, P45, DOI 10.1016/j.cytogfr.2010.09.004
   Yu H, 2011, GENE THER, V18, P344, DOI 10.1038/gt.2010.139
   Yu H, 2013, J LIPID RES, V54, P189, DOI 10.1194/jlr.M031427
   Zhao QX, 2010, INT J BIOCHEM CELL B, V42, P576, DOI 10.1016/j.biocel.2009.12.018
NR 37
TC 23
Z9 25
U1 0
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476 511X
J9 LIPIDS HEALTH DIS
JI Lipids Health Dis.
PD JUL 4
PY 2015
VL 14
AR 66
DI 10.1186/s12944 015 0057 7
PG 11
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA CM1OQ
UT WOS:000357450600001
PM 26138336
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Scullen, T
   Santo, L
   Vallet, S
   Fulciniti, M
   Eda, H
   Cirstea, D
   Patel, K
   Nemani, N
   Yee, A
   Mahindra, A
   Raje, N
AF Scullen, T.
   Santo, L.
   Vallet, S.
   Fulciniti, M.
   Eda, H.
   Cirstea, D.
   Patel, K.
   Nemani, N.
   Yee, A.
   Mahindra, A.
   Raje, N.
TI Lenalidomide in combination with an activin A neutralizing antibody:
   preclinical rationale for a novel anti myeloma strategy
SO LEUKEMIA
LA English
DT Article
DE lenalidomide; activin A; myeloma
ID IMMUNOMODULATORY THALIDOMIDE ANALOGS; DEPENDENT KINASE INHIBITOR; HUMAN
   MULTIPLE MYELOMA; OSTEOBLAST DIFFERENTIATION; PLUS DEXAMETHASONE;
   BONE DISEASE; CELLS; DLX5; OSTEOCLASTOGENESIS; PATHOPHYSIOLOGY
AB Given the prevalence of osteolytic bone disease in multiple myeloma (MM), novel therapies targeting bone microenvironment are essential. Previous studies have identified activin A to be of critical importance in MM induced osteolysis. Lenalidomide is a known and approved treatment strategy for relapsed MM. Our findings demonstrate that lenalidomide acts directly on bone marrow stromal cells via an Akt mediated increase in Jun N terminal kinase dependent signaling resulting in activin A secretion, with consequent inhibition of osteoblastogenesis. Here, we attempted to augment the antitumor benefits of lenalidomide while overcoming its effects on osteoblastogenesis by combining it with a neutralizing antibody to activin A. Increased activin A secretion induced by lenalidomide was abrogated by the addition of activin A neutralizing antibody, which effectively restored osteoblast function and inhibited MM induced osteolysis without negating the cytotoxic effects of lenalidomide on malignant cells. This provides the rationale for an ongoing clinical trial (NCT01562405) combining lenalidomide with an anti activin A strategy.
C1 [Scullen, T.; Santo, L.; Vallet, S.; Eda, H.; Cirstea, D.; Patel, K.; Nemani, N.; Yee, A.; Mahindra, A.; Raje, N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc,Div Hematol & Oncol, Boston, MA 02114 USA.
   [Fulciniti, M.; Cirstea, D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
C3 Harvard University; Harvard Medical School; Harvard University Medical
   Affiliates; Massachusetts General Hospital; Harvard University; Harvard
   University Medical Affiliates; Dana Farber Cancer Institute; Harvard
   Medical School
RP Raje, N (通讯作者)，Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc,Div Hematol & Oncol, 55 Fruit St, Boston, MA 02114 USA.
EM nraje@partners.org
RI Vallet, Sonia/AHE 3935 2022; Scullen, Tyler/ADD 3280 2022
OI Patel, Kishan/0000 0002 5526 2900; Vallet, Sonia/0000 0003 0146 8089
FU LLS; MMRF
FX NR is supported by LLS and MMRF.
CR Abdulkadyrov KM, 2009, BLOOD, V114, P312, DOI 10.1182/blood.V114.22.749.749
   BATAILLE R, 1989, J CLIN ONCOL, V7, P1909, DOI 10.1200/JCO.1989.7.12.1909
   Breitkreutz I, 2008, LEUKEMIA, V22, P1925, DOI 10.1038/leu.2008.174
   CLEMENTS M, 2011, TLS TIMES LIT S 0325, P21
   De Matteo M, 2010, LEUKEMIA RES, V34, P243, DOI 10.1016/j.leukres.2009.07.017
   Dimopoulos M, 2007, NEW ENGL J MED, V357, P2123, DOI 10.1056/NEJMoa070594
   Eijken M, 2007, FASEB J, V21, P2949, DOI 10.1096/fj.07 8080com
   Giuliani N, 2005, BLOOD, V106, P2472, DOI 10.1182/blood 2004 12 4986
   Giuliani N, 2006, BLOOD, V108, P3992, DOI 10.1182/blood 2006 05 026112
   Gupta D, 2001, LEUKEMIA, V15, P1950, DOI 10.1038/sj.leu.2402295
   Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623
   Holleville N, 2003, DEV BIOL, V257, P177, DOI 10.1016/S0012 1606(03)00059 9
   Ikenoue T, 1999, J CELL BIOCHEM, V75, P206, DOI 10.1002/(SICI)1097 4644(19991101)75:2<206::AID JCB3>3.3.CO;2 K
   Kotla V, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756 8722 2 36
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Matsuo Y, 2000, BRIT J HAEMATOL, V109, P54, DOI 10.1046/j.1365 2141.2000.01985.x
   Mitsiades N, 2002, BLOOD, V99, P4525, DOI 10.1182/blood.V99.12.4525
   Mukherjee S, 2008, J CLIN INVEST, V118, P491, DOI [10.1172/JCI33102, 10.1172/JC133102]
   Mulivor AW, 2008, BONE S2, V44, pS221
   Munemasa S, 2008, INT J ONCOL, V33, P129
   Pearsall RS, 2008, P NATL ACAD SCI USA, V105, P7082, DOI 10.1073/pnas.0711263105
   Pozzi S, 2009, CLIN CANCER RES, V15, P5829, DOI 10.1158/1078 0432.CCR 09 0426
   Raje N, 2009, LEUKEMIA, V23, P961, DOI 10.1038/leu.2008.378
   Raje N, 2011, CLIN CANCER RES, V17, P1278, DOI 10.1158/1078 0432.CCR 10 1804
   Raje N, 2010, CURR OPIN MOL THER, V12, P586
   Richardson P, 2009, BLOOD, V114, P772, DOI 10.1182/blood 2008 12 196238
   Richardson PG, 2006, BLOOD, V108, P3458, DOI 10.1182/blood 2006 04 015909
   Roodman GD, 2010, J CELL BIOCHEM, V109, P283, DOI 10.1002/jcb.22403
   Ruckle J, 2009, J BONE MINER RES, V24, P744, DOI 10.1359/JBMR.081208
   Samee N, 2008, AM J PATHOL, V173, P773, DOI 10.2353/ajpath.2008.080243
   Santo L, 2010, ONCOGENE, V29, P2325, DOI 10.1038/onc.2009.510
   SHAO LE, 1992, BLOOD, V79, P773
   SHIOZAKI M, 1992, P NATL ACAD SCI USA, V89, P1553, DOI 10.1073/pnas.89.5.1553
   Tanimoto K, 1996, J BIOL CHEM, V271, P32760, DOI 10.1074/jbc.271.51.32760
   Terpos E, 2007, LEUKEMIA, V21, P1875, DOI 10.1038/sj.leu.2404843
   Vallet S, 2008, LEUKEMIA LYMPHOMA, V49, P1238, DOI 10.1080/10428190802005191
   Vallet S, 2007, BLOOD, V110, P3744, DOI 10.1182/blood 2007 05 093294
   Vallet S, 2010, P NATL ACAD SCI USA, V107, P5124, DOI 10.1073/pnas.0911929107
   Weber DM, 2007, NEW ENGL J MED, V357, P2133, DOI 10.1056/NEJMoa070596
NR 39
TC 36
Z9 39
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887 6924
EI 1476 5551
J9 LEUKEMIA
JI Leukemia
PD AUG
PY 2013
VL 27
IS 8
BP 1715
EP 1721
DI 10.1038/leu.2013.50
PG 7
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Hematology
GA 197BP
UT WOS:000322823200012
PM 23417027
DA 2025 08 17
ER

PT J
AU Dos Santos, MP
   De Farias, CB
   Roesler, R
   Brunetto, AL
   Abujamra, AL
AF Dos Santos, Michel Pinheiro
   De Farias, Caroline Brunetto
   Roesler, Rafael
   Brunetto, Algemir Lunardi
   Abujamra, Ana Lucia
TI In vitro antitumor effect of sodium butyrate and zoledronic acid
   combined with traditional chemotherapeutic drugs: A paradigm of
   synergistic molecular targeting in the treatment of Ewing sarcoma
SO ONCOLOGY REPORTS
LA English
DT Article
DE Ewing sarcoma; sodium butyrate; zoledronic acid; adjuvant therapy;
   chemotherapy; synergistic effect
ID HISTONE DEACETYLASE INHIBITORS; TUMOR GROWTH; BONE; BISPHOSPHONATES;
   OSTEOSARCOMA; FAMILY; CELLS; COMBINATION
AB Histone deacetylase inhibitors and bisphosphonates have a promising future in the treatment of cancer as targeted anticancer drugs, particularly when used together or in combination with other cytotoxic agents. However, the effects of these combined treatments have not yet been systematically evaluated in Ewing sarcoma. The in vitro effects on cellular proliferation, viability and survival were investigated in two Ewing sarcoma cell lines, SK ES 1 and RD ES. The cell lines were treated with sodium butyrate, a histone deacetylase inhibitor and zoledronic acid, a bisphosphonate, alone, together or in combination with chemotherapeutic drugs recommended for clinical treatment of Ewing sarcoma. The data demonstrated that the combination of sodium butyrate and zoledronic acid had a synergistic cytotoxic effect at 72 h following treatment, persisting for 10 14 days post treatment, in both cell lines tested. All combinations between sodium butyrate or zoledronic acid and the traditional antineoplastic drugs (doxorubicin, etoposide and vincristine) demonstrated a synergistic cytotoxic effect at 72 h in SK ES 1 and RD ES cells, except for the combinations of sodium butyrate with vincristine and of zoledronic acid with doxorubicin, which showed only an additive effect in RD ES cell lines as compared to each agent alone. These acute effects observed in both Ewing sarcoma cell lines were confirmed by the clonogenic assay. The present data suggest that combining histone deacetylase inhibitors and bisphosphonates with traditional chemotherapeutic drugs is a promising therapeutic strategy for the treatment of Ewing sarcoma, and provides a basis for further studies in this field.
C1 [Dos Santos, Michel Pinheiro; De Farias, Caroline Brunetto; Roesler, Rafael; Brunetto, Algemir Lunardi; Abujamra, Ana Lucia] Univ Fed Rio Grande do Sul, Univ Hosp Res Ctr CPE HCPA, Canc Res Lab, Porto Alegre, RS, Brazil.
   [De Farias, Caroline Brunetto; Brunetto, Algemir Lunardi; Abujamra, Ana Lucia] Fed Univ Hosp HCPA, Childrens Canc Inst, BR 90035903 Porto Alegre, RS, Brazil.
   [De Farias, Caroline Brunetto; Brunetto, Algemir Lunardi; Abujamra, Ana Lucia] Fed Univ Hosp HCPA, Pediat Oncol Unit, BR 90035903 Porto Alegre, RS, Brazil.
   [Dos Santos, Michel Pinheiro; Abujamra, Ana Lucia] Univ Fed Rio Grande do Sul, Sch Med, Med Sci Program, Porto Alegre, RS, Brazil.
   [De Farias, Caroline Brunetto; Roesler, Rafael; Brunetto, Algemir Lunardi; Abujamra, Ana Lucia] Natl Inst Translat Med INCT TM, Porto Alegre, RS, Brazil.
   [Roesler, Rafael] Univ Fed Rio Grande do Sul, Inst Basic Hlth Sci, Dept Pharmacol, Lab Neuropharmacol & Neural Tumor Biol, Porto Alegre, RS, Brazil.
C3 Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio
   Grande do Sul; Universidade Federal do Rio Grande do Sul
RP Abujamra, AL (通讯作者)，Fed Univ Hosp HCPA, Childrens Canc Inst, Rua Ramiro Barcelos 2350,3 Leste, BR 90035903 Porto Alegre, RS, Brazil.
EM aabujamra@hcpa.ufrgs.br
RI Abujamra, Ana Lucia/D 4903 2013; Abujamra, Ana/D 4903 2013; de Farias,
   Caroline/F 5078 2016; Roesler, Rafael/U 9261 2019
OI Abujamra, Ana Lucia/0000 0002 4899 4644; de farias,
   Caroline/0000 0002 6435 6626; Roesler, Rafael/0000 0001 6016 2261
FU Rafael Koff Acordi Project (Children's Cancer Institute, Porto Alegre,
   Brazil); Academic Research Hospital Fund (HCPA FIPE, Porto Alegre,
   Brazil) [10 0362]
FX The present study was supported by the Rafael Koff Acordi Project
   (Children's Cancer Institute, Porto Alegre, Brazil) and the Academic
   Research Hospital Fund 10 0362 (HCPA FIPE, Porto Alegre, Brazil). We are
   grateful to Mr. Eduardo Monteiro for his help with elaboration of the
   images presented herein, OncosinoS and Libbs for the antineoplastic
   agents and zoledronic acid, respectively, and to all members of the
   Cancer Research Laboratory.
CR Abujamra AL, 2010, LEUKEMIA RES, V34, P687, DOI 10.1016/j.leukres.2009.08.021
   Battaglia S, 2011, J BONE MINER RES, V26, P2439, DOI 10.1002/jbmr.453
   Bayrak OF, 2011, J NEUROSURG SPINE, V15, P620, DOI 10.3171/2011.7.SPINE10798
   Bernstein M, 2006, ONCOLOGIST, V11, P503, DOI 10.1634/theoncologist.11 5 503
   Blanchard F, 2005, DRUG DISCOV TODAY, V10, P197, DOI 10.1016/S1359 6446(04)03309 4
   Cai ZL, 2011, INT J RADIAT BIOL, V87, P1135, DOI 10.3109/09553002.2011.622033
   Caraglia M, 2006, ENDOCR RELAT CANCER, V13, P7, DOI 10.1677/erc.1.01094
   Carvajal R, 2005, HEMATOL ONCOL CLIN N, V19, P501, DOI 10.1016/j.hoc.2005.03.004
   Chauvin C, 2008, CANCER RES, V68, P9433, DOI 10.1158/0008 5472.CAN 08 0104
   Chou T.C., 1991, MEDIAN EFFECT PRINCI
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065 2571(84)90007 4
   Clézardin P, 2011, BONE, V48, P71, DOI 10.1016/j.bone.2010.07.016
   de Farias CB, 2010, ONCOLOGY BASEL, V79, P430, DOI 10.1159/000326564
   de Oliveira MS, 2009, J NEURO ONCOL, V93, P191, DOI 10.1007/s11060 008 9775 2
   dos Santos MP, 2009, LEUKEMIA RES, V33, P218, DOI 10.1016/j.leukres.2008.07.003
   Flores DG, 2008, CURR NEUROVASC RES, V5, P99, DOI 10.2174/156720208784310240
   Frew AJ, 2009, CANCER LETT, V280, P125, DOI 10.1016/j.canlet.2009.02.042
   Gaspar Nathalie, 2012, Sarcoma, V2012, P301975, DOI 10.1155/2012/301975
   Giuliani N, 1998, SCAND J RHEUMATOL, V27, P38
   Hande KR, 1998, EUR J CANCER, V34, P1514, DOI 10.1016/S0959 8049(98)00228 7
   Hirbe AC, 2009, BONE, V44, P908, DOI 10.1016/j.bone.2009.01.010
   Hoshino I, 2010, SURG TODAY, V40, P809, DOI 10.1007/s00595 010 4300 6
   Iwamoto Y, 2007, JPN J CLIN ONCOL, V37, P79, DOI 10.1093/jjco/hyl142
   JOHNSON IS, 1963, CANCER RES, V23, P1390
   Jürgens H, 2011, EUR J CANCER, V47, pS366, DOI 10.1016/S0959 8049(11)70206 4
   Karosas AO, 2010, AM J HEALTH SYST PH, V67, P1599, DOI 10.2146/ajhp090526
   Kovar H, 2012, FRONT ONCOL, V2, P1, DOI 10.3389/fonc.2012.00054
   Li Y, 2012, CANCER LETT, V320, P14, DOI 10.1016/j.canlet.2012.01.018
   Marks PA, 2010, BBA GENE REGUL MECH, V1799, P717, DOI 10.1016/j.bbagrm.2010.05.008
   Marks PA, 2010, EXPERT OPIN INV DRUG, V19, P1049, DOI 10.1517/13543784.2010.510514
   McGee Lawrence ME, 2011, GENE, V474, P1, DOI 10.1016/j.gene.2010.12.003
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Muraro M, 2008, CELL IMMUNOL, V253, P71, DOI 10.1016/j.cellimm.2008.05.002
   Odri GA, 2010, CANCER RES, V70, P7610, DOI 10.1158/0008 5472.CAN 09 4272
   Ottewell PD, 2009, MOL CANCER THER, V8, P2821, DOI 10.1158/1535 7163.MCT 09 0462
   Pili R, 2012, BRIT J CANCER, V106, P77, DOI 10.1038/bjc.2011.527
   Pratap J, 2010, MOL CANCER THER, V9, P3210, DOI 10.1158/1535 7163.MCT 10 0572
   Ricchetti ET, 2005, CLIN ORTHOP RELAT R, P248, DOI 10.1097/01.blo.0000128641.53637.c9
   Riggi N, 2007, CANCER LETT, V254, P1, DOI 10.1016/j.canlet.2006.12.009
   Sakimura R, 2005, INT J CANCER, V116, P784, DOI 10.1002/ijc.21069
   Schimmel KJM, 2004, CANCER TREAT REV, V30, P181, DOI 10.1016/j.ctrv.2003.07.003
   Schlottmann S, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00107
   Schmidt AL, 2010, J MOL NEUROSCI, V40, P303, DOI 10.1007/s12031 009 9221 8
   Siddiqui Tariq, 2010, Clin Adv Hematol Oncol, V8, P499
   Sonnemann J, 2003, ANTI CANCER DRUG, V14, P767, DOI 10.1097/01.cad.0000094848.34612.41
   Sonnemann J, 2007, MOL CANCER THER, V6, P2976, DOI 10.1158/1535 7163.MCT 07 0221
   Sonnemann J, 2007, J CANCER RES CLIN, V133, P847, DOI 10.1007/s00432 007 0227 8
   Stresing V, 2007, CANCER LETT, V257, P16, DOI 10.1016/j.canlet.2007.07.007
   Tenta R, 2006, ANTICANCER RES, V26, P283
   Winter MC, 2008, CANCER TREAT REV, V34, P453, DOI 10.1016/j.ctrv.2008.02.004
   ZALUPSKI M, 1988, J NATL CANCER I, V80, P556, DOI 10.1093/jnci/80.8.556
   Zhao M, 2012, CANCER SCI, V103, P58, DOI 10.1111/j.1349 7006.2011.02113.x
   Zhou ZC, 2005, CANCER AM CANCER SOC, V104, P1713, DOI 10.1002/cncr.21383
NR 53
TC 20
Z9 20
U1 0
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021 335X
EI 1791 2431
J9 ONCOL REP
JI Oncol. Rep.
PD FEB
PY 2014
VL 31
IS 2
BP 955
EP 968
DI 10.3892/or.2013.2907
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AC7FX
UT WOS:000332694400057
PM 24316794
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Jones, MD
   Liu, JC
   Barthel, TK
   Hussain, S
   Lovria, E
   Cheng, DF
   Schoonmaker, JA
   Mulay, S
   Ayers, DC
   Bouxsein, ML
   Stein, GS
   Mukherjee, S
   Lian, JB
AF Jones, Marci D.
   Liu, Julie C.
   Barthel, Thomas K.
   Hussain, Sadiq
   Lovria, Erik
   Cheng, Dengfeng
   Schoonmaker, Jesse A.
   Mulay, Sudhanshu
   Ayers, David C.
   Bouxsein, Mary L.
   Stein, Gary S.
   Mukherjee, Siddhartha
   Lian, Jane B.
TI A Proteasome Inhibitor, Bortezomib, Inhibits Breast Cancer Growth and
   Reduces Osteolysis by Downregulating Metastatic Genes
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID MYELOMA BONE DISEASE; MULTIPLE MYELOMA; IN VIVO; OSTEOBLAST
   DIFFERENTIATION; OSTEOCLAST FUNCTION; CELLS; ACTIVATION; THERAPY;
   PATHWAY; MICE
AB Purpose: The incidence of bone metastasis in advanced breast cancer (BrCa) exceeds 70%. Bortezomib, a proteasome inhibitor used for the treatment of multiple myeloma, also promotes bone formation. We tested the hypothesis that proteasome inhibitors can ameliorate BrCa osteolytic disease.
   Experimental Design: To address the potentially beneficial effect of bortezomib in reducing tumor growth in the skeleton and counteracting bone osteolysis, human MDA MB 231 BrCa cells were injected into the tibia of mice to model bone tumor growth for in vivo assessment of treatment regimens before and after tumor growth.
   Results: Controls exhibited tumor growth, destroying trabecular and cortical bone and invading muscle. Bortezomib treatment initiated following inoculation of tumor cells strikingly reduced tumor growth, restricted tumor cells mainly to the marrow cavity, and almost completely inhibited osteolysis in the bone micro environment over a 3 to 4 week period as shown by [F 18] fluorodeoxyglucose positron emission tomography, micro computed tomography scanning, radiography, and histology. Thus, proteasome inhibition is effective in killing tumor cells within the bone. Pretreatment with bortezomib for 3 weeks before inoculation of tumor cells was also effective in reducing osteolysis. Our in vitro and in vivo studies indicate that mechanisms by which bortezomib inhibits tumor growth and reduces osteolysis result from inhibited cell proliferation, necrosis, and decreased expression of factors that promote BrCa tumor progression in bone.
   Conclusion: These findings provide a basis for a novel strategy to treat patients with BrCa osteolytic lesions, and represent an approach for protecting the entire skeleton from metastatic bone disease. Clin Cancer Res; 16(20); 4978 89. (C) 2010 AACR.
C1 [Jones, Marci D.; Liu, Julie C.; Hussain, Sadiq; Stein, Gary S.; Lian, Jane B.] Univ Massachusetts, Dept Cell Biol, Sch Med, Worcester, MA 01655 USA.
   [Jones, Marci D.; Liu, Julie C.; Hussain, Sadiq; Stein, Gary S.; Lian, Jane B.] Univ Massachusetts, Ctr Canc, Sch Med, Worcester, MA 01655 USA.
   [Jones, Marci D.; Barthel, Thomas K.; Lovria, Erik; Ayers, David C.] Univ Massachusetts, Dept Orthoped & Phys Rehabil, Sch Med, Worcester, MA 01655 USA.
   [Cheng, Dengfeng] Univ Massachusetts, Div Nucl Med, Sch Med, Dept Radiol, Worcester, MA 01655 USA.
   [Bouxsein, Mary L.] Beth Israel Deaconess Med Ctr, Ctr Adv Orthoped Studies, Boston, MA 02215 USA.
   [Schoonmaker, Jesse A.; Mulay, Sudhanshu; Mukherjee, Siddhartha] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
   [Mukherjee, Siddhartha] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA.
C3 University of Massachusetts System; University of Massachusetts
   Worcester; University of Massachusetts System; University of
   Massachusetts Worcester; University of Massachusetts System; University
   of Massachusetts Worcester; University of Massachusetts System;
   University of Massachusetts Worcester; Harvard University; Harvard
   University Medical Affiliates; Beth Israel Deaconess Medical Center;
   Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Columbia University
RP Lian, JB (通讯作者)，Univ Massachusetts, Dept Cell Biol, Sch Med, 55 Lake Ave N, Worcester, MA 01655 USA.
EM jane.lian@umassmed.edu
RI Liu, Julie/H 7496 2013
OI Liu, Julie/0000 0003 0784 2529
FU Zimmer, Inc.; Musculoskeletal Transplant Foundation (MTF); NIH
   [P01CA082834, S10RR023540, F32AR055030]; Diabetes Endocrinology Research
   Center [DK32520]
FX D.C. Ayers: commercial research grant, Zimmer, Inc.; other commercial
   research support, Musculoskeletal Transplant Foundation (MTF).Studies
   reported were in part supported by NIH grants P01CA082834, S10RR023540,
   and F32AR055030. Core resources supported by the Diabetes Endocrinology
   Research Center grant DK32520 were also used. J.B. Lian is a member of
   the University of Massachusetts Diabetes and Endocrinology Resource
   Center (DK32520). The contents of this manuscript are solely the
   responsibility of the authors and do not necessarily represent the
   official views of the NIH.
CR Adams J, 1999, CANCER RES, V59, P2615
   Ahn KS, 2007, BLOOD, V110, P2286, DOI 10.1182/blood 2007 04 084996
   Ande SR, 2009, EUR J PHARMACOL, V625, P199, DOI 10.1016/j.ejphar.2009.08.042
   Barnes GL, 2003, CANCER RES, V63, P2631
   Boissy P, 2008, LEUKEMIA RES, V32, P1661, DOI 10.1016/j.leukres.2008.02.019
   Bouxsein ML, 2005, J BONE MINER RES, V20, P1085, DOI 10.1359/JBMR.050307
   Costa L, 2007, BREAST, V16, pS16, DOI 10.1016/j.breast.2007.10.005
   Cresta S, 2008, EUR J CANCER, V44, P1829, DOI 10.1016/j.ejca.2008.05.022
   Diel Ingo J, 2007, J Support Oncol, V5, P475
   Edwards CM, 2009, AM J HEMATOL, V84, P268, DOI 10.1002/ajh.21374
   Engel RH, 2007, CANCER INVEST, V25, P733, DOI 10.1080/07357900701506573
   Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198
   Giuliani N, 2007, BLOOD, V110, P334, DOI 10.1182/blood 2006 11 059188
   Glatt V, 2007, J BONE MINER RES, V22, P1197, DOI 10.1359/JBMR.070507
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Greenberg JI, 2009, EXPERT OPIN BIOL TH, V9, P1347, DOI 10.1517/14712590903208883
   Heider U, 2006, EUR J HAEMATOL, V77, P233, DOI 10.1111/j.1600 0609.2006.00692.x
   Heider U, 2009, EUR J HAEMATOL, V82, P31, DOI 10.1111/j.1600 0609.2008.01164.x
   Huang HM, 2009, LEUKEMIA RES, V33, P115, DOI 10.1016/j.leukres.2008.07.028
   King AE, 2008, PHARMACOTHERAPY, V28, P667, DOI 10.1592/phco.28.5.667
   López Knowles E, 2010, CANCER EPIDEM BIOMAR, V19, P301, DOI 10.1158/1055 9965.EPI 09 0741
   Mukherjee S, 2008, J CLIN INVEST, V118, P491, DOI [10.1172/JCI33102, 10.1172/JC133102]
   Oyajobi BO, 2007, BRIT J HAEMATOL, V139, P434, DOI 10.1111/j.1365 2141.2007.06829.x
   Pennisi A, 2009, AM J HEMATOL, V84, P6, DOI 10.1002/ajh.21310
   Pratap J, 2005, MOL CELL BIOL, V25, P8581, DOI 10.1128/MCB.25.19.8581 8591.2005
   PRATAP J, 2010, BONE
   Pratap J, 2008, CANCER RES, V68, P7795, DOI 10.1158/0008 5472.CAN 08 1078
   Pratap J, 2009, CANCER RES, V69, P6807, DOI 10.1158/0008 5472.CAN 09 1471
   Previdi S, 2010, EUR J CANCER, V46, P1679, DOI 10.1016/j.ejca.2010.02.036
   Qiang YW, 2009, BLOOD, V113, P4319, DOI 10.1182/blood 2008 08 174300
   Rajagopalan S, 2005, J BIOMED MATER RES A, V75A, P877, DOI 10.1002/jbm.a.30498
   Roland CL, 2009, MOL CANCER THER, V8, P1761, DOI 10.1158/1535 7163.MCT 09 0280
   Roodman GD, 2009, LEUKEMIA, V23, P435, DOI 10.1038/leu.2008.336
   Schmid P, 2008, ANN ONCOL, V19, P871, DOI 10.1093/annonc/mdm569
   Shimazaki C, 2005, LEUKEMIA, V19, P1102, DOI 10.1038/sj.leu.2403758
   Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71
   Terpos E, 2008, LEUKEMIA RES, V32, P1646, DOI 10.1016/j.leukres.2008.06.017
   Terpos E, 2007, BLOOD, V110, P1098, DOI 10.1182/blood 2007 03 067710
   Terpos E, 2006, BRIT J HAEMATOL, V135, P688, DOI 10.1111/j.1365 2141.2006.06356.x
   Uy GL, 2007, CLIN LYMPHOMA MYELOM, V7, P587, DOI 10.3816/CLM.2007.n.045
   Valachis A, 2010, GYNECOL ONCOL, V117, P139, DOI 10.1016/j.ygyno.2009.12.001
   von Metzler I, 2007, LEUKEMIA, V21, P2025, DOI 10.1038/sj.leu.2404806
   Whang PG, 2005, PROSTATE CANCER P D, V8, P327, DOI 10.1038/sj.pcan.4500823
   Yang CH, 2006, ANN ONCOL, V17, P813, DOI 10.1093/annonc/mdj131
   Zangari M, 2005, BRIT J HAEMATOL, V131, P71, DOI 10.1111/j.1365 2141.2005.05733.x
   Zavrski I, 2005, BIOCHEM BIOPH RES CO, V333, P200, DOI 10.1016/j.bbrc.2005.05.098
   Zhou XL, 2010, ACTA PHARMACOL SIN, V31, P202, DOI 10.1038/aps.2009.200
NR 47
TC 57
Z9 62
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1078 0432
EI 1557 3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD OCT 15
PY 2010
VL 16
IS 20
BP 4978
EP 4989
DI 10.1158/1078 0432.CCR 09 3293
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 663IT
UT WOS:000282877700010
PM 20843837
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Jia, XQ
   Hong, Q
   Lei, L
   Li, DQ
   Li, JW
   Mo, M
   Wang, YJ
   Shao, ZM
   Shen, ZZ
   Cheng, JY
   Liu, GY
AF Jia, Xiaoqing
   Hong, Qi
   Lei, Li
   Li, Daqiang
   Li, Jianwei
   Mo, Miao
   Wang, Yujie
   Shao, Zhimin
   Shen, Zhenzhou
   Cheng, Jingyi
   Liu, Guangyu
TI Basal and therapy driven hypoxia inducible factor 1α confers resistance
   to endocrine therapy in estrogen receptor positive breast cancer
SO ONCOTARGET
LA English
DT Article
DE HIF 1 alpha; endocrine resistance; zoledronic acid; estrogen receptor;
   breast cancer
ID ZOLEDRONIC ACID; TUMOR PROGRESSION; ANGIOGENESIS INHIBITORS;
   POSTMENOPAUSAL WOMEN; SIGNAL TRANSDUCTION; RANDOMIZED TRIAL;
   GROWTH FACTOR; IN VITRO; BISPHOSPHONATES; CELLS
AB Resistance is an obstacle to endocrine therapy for breast cancer. We measured levels of hypoxia inducible factor (HIF) 1 alpha in 52 primary breast cancer patients before and after receiving neoadjuvant endocrine therapy with letrozole for at least 3 months. Pre treatment levels of HIF 1 alpha were associated with negative clinical outcome. Furthermore, levels of HIF 1 alpha were increased in post treatment residual tumors compared with those in pre treatment biopsy samples. In animal studies, xenografts stably expressing HIF 1 alpha were resistant to endocrine therapy with fulvestrant compared with the effects in control xenografts. Additionally, HIF 1 alpha transcription was inhibited by zoledronic acid, a conventional drug for the treatment of postmenopausal osteoporosis, and was accompanied by a marked inhibition of the RAS/MAPK/ERK1/2 pathway. HIF 1 alpha is a determinant of resistance to endocrine therapy and should be considered as a potential therapeutic target for overcoming endocrine resistance in estrogen receptor (ER) positive breast cancer. In addition, zoledronic acid may overcome endocrine resistance in ER positive human breast cancer by targeting HIF 1 alpha transcription through inhibition of the RAS/MAPK/ERK1/2 pathway. Clinical studies on the administration of zoledronic acid as a second line treatment in patients who failed endocrine therapy should be considered to improve therapeutic outcomes in breast cancer patients.
C1 [Jia, Xiaoqing; Hong, Qi; Li, Daqiang; Li, Jianwei; Wang, Yujie; Shao, Zhimin; Shen, Zhenzhou; Liu, Guangyu] Fudan Univ, Shanghai Med Coll, Key Lab Breast Canc Shanghai, Dept Breast Surg,Shanghai Canc Ctr,Dept Oncol, Shanghai 200433, Peoples R China.
   [Lei, Li] First Peoples Hosp Kunming, Dept Breast Surg, Kunming, Peoples R China.
   [Mo, Miao] Fudan Univ, Shanghai Med Coll, Dept Oncol, Clin Stat Ctr,Shanghai Canc Ctr, Shanghai 200433, Peoples R China.
   [Cheng, Jingyi] Fudan Univ, Shanghai Canc Ctr, Dept Oncol, Dept Nucl Med,Shanghai Med Coll, Shanghai, Peoples R China.
C3 Fudan University; Fudan University; Fudan University
RP Liu, GY (通讯作者)，Fudan Univ, Shanghai Med Coll, Key Lab Breast Canc Shanghai, Dept Breast Surg,Shanghai Canc Ctr,Dept Oncol, Shanghai 200433, Peoples R China.
EM ququmail@126.com; liugy123@yahoo.com
FU National Natural Science Foundation of China [NSFC30600725,
   NSFC81301246]; Shanghai United Developing Technology Project of
   Municipal Hospitals [SHDC12010116]; Key Clinical Program of the Ministry
   of Health; Novartis; AstraZeneca
FX This research is supported by grants from the National Natural Science
   Foundation of China (NSFC30600725 and NSFC81301246), the Shanghai United
   Developing Technology Project of Municipal Hospitals (SHDC12010116), the
   Key Clinical Program of the Ministry of Health (2010 2012), and a grant
   from Novartis and AstraZeneca. This research is supported by the funders
   that had no role in study design, data collection and analysis, decision
   to publish, or preparation of the manuscript.
CR Aebersold DM, 2001, CANCER RES, V61, P2911
   Aft R, 2010, LANCET ONCOL, V11, P421, DOI 10.1016/S1470 2045(10)70054 1
   Bachtiary B, 2003, CLIN CANCER RES, V9, P2234
   Blagosklonny MV, 2004, CANCER CELL, V5, P13, DOI 10.1016/S1535 6108(03)00336 2
   Bos R, 2003, CANCER, V97, P1573, DOI 10.1002/cncr.11246
   Bottaro DP, 2003, NATURE, V423, P593, DOI 10.1038/423593a
   Cheng JY, 2013, J NUCL MED, V54, P333, DOI 10.2967/jnumed.112.111963
   Clézardin P, 2003, CURR MED CHEM, V10, P173, DOI 10.2174/0929867033368529
   Coleman R, 2013, ANN ONCOL, V24, P398, DOI 10.1093/annonc/mds277
   Coombes RC, 2004, NEW ENGL J MED, V350, P1081, DOI 10.1056/NEJMoa040331
   Cooper C, 2004, CLIN CANCER RES, V10, P8720, DOI 10.1158/1078 0432.CCR 04 1235
   Ellis M, 2004, ONCOLOGIST, V9, P20, DOI 10.1634/theoncologist.9 suppl_3 20
   Generali D, 2006, CLIN CANCER RES, V12, P4562, DOI 10.1158/1078 0432.CCR 05 2690
   Generali D, 2009, J CLIN ONCOL, V27, P227, DOI 10.1200/JCO.2007.13.7083
   Gnant M, 2012, CANCER TREAT REV, V38, P407, DOI 10.1016/j.ctrv.2011.09.003
   Gnant M, 2011, LANCET ONCOL, V12, P631, DOI 10.1016/S1470 2045(11)70122 X
   Gordan JD, 2007, CURR OPIN GENET DEV, V17, P71, DOI 10.1016/j.gde.2006.12.006
   Green JR, 2011, CRIT REV ONCOL HEMAT, V77, pS3, DOI 10.1016/S1040 8428(11)70003 8
   Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092 8674(00)80108 7
   Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474
   Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Ke QD, 2006, MOL PHARMACOL, V70, P1469, DOI 10.1124/mol.106.027029
   Kieran MW, 2003, NAT MED, V9, P1104, DOI 10.1038/nm0903 1104a
   Kurebayashi J, 2005, CANCER CHEMOTH PHARM, V56, pS39, DOI 10.1007/s00280 005 0099 z
   Kurebayashi J, 2001, JPN J CANCER RES, V92, P1093, DOI 10.1111/j.1349 7006.2001.tb01064.x
   Laderoute KR, 2000, CLIN CANCER RES, V6, P2941
   Lim JH, 2004, ONCOGENE, V23, P9427, DOI 10.1038/sj.onc.1208003
   MASOOD S, 1992, DIAGN CYTOPATHOL, V8, P475, DOI 10.1002/dc.2840080508
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Neville Webbe HL, 2010, BRIT J CANCER, V102, P1010, DOI 10.1038/sj.bjc.6605579
   Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535 6108(03)00085 0
   Polascik Thomas J, 2008, Ther Clin Risk Manag, V4, P261
   Rack B, 2010, ANTICANCER RES, V30, P1807
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471 4914(02)02317 1
   Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Steeg PS, 2003, NAT MED, V9, P822, DOI 10.1038/nm0703 822
   Tang XD, 2010, INT J CANCER, V126, P90, DOI 10.1002/ijc.24710
   Tsui L, 2013, MOL VIS, V19, P2260
   Yang XM, 2009, INVEST OPHTH VIS SCI, V50, P1873, DOI 10.1167/iovs.08 2591
   Zhao T, ONCOTARGET IN PRESS
   Zhong H, 1999, CANCER RES, V59, P5830
NR 45
TC 38
Z9 40
U1 1
U2 9
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD APR 20
PY 2015
VL 6
IS 11
BP 8648
EP 8662
DI 10.18632/oncotarget.3257
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA CN9NB
UT WOS:000358774600016
PM 25929338
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Chen, JS
   Shen, J
   Yang, XL
   Tan, HT
   Yang, RH
   Mo, CY
   Wang, Y
   Luan, XJ
   Huang, WH
   Chen, GQ
   Xu, XJ
AF Chen, Jingsong
   Shen, Jie
   Yang, Xili
   Tan, Huiting
   Yang, Ronghua
   Mo, Cuiying
   Wang, Ying
   Luan, Xiaojun
   Huang, Wenhua
   Chen, Guoqiang
   Xu, Xuejuan
TI 被撤回的出版物: Exploring the Temporal Correlation of Sarcopenia with Bone
   Mineral Density and the Effects of Osteoblast Derived Exosomes on
   Myoblasts through an Oxidative Stress Related Gene (Retracted Article)
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article; Retracted Publication
ID TSH SUPPRESSIVE THERAPY; MUSCLE; DIFFERENTIATION; CARCINOMA; CANCER;
   PROLIFERATION; ASSOCIATION; APOPTOSIS; PROMOTE; HEALTH
AB Sarcopenia is an age related accelerated loss of muscle strength and mass. Bone and muscle are closely related as they are physically adjacent, and bone can influence muscle. However, the temporal association between bone mineral density (BMD) and muscle mass in different regions of the body after adjustment for potential indicators and the mechanisms by which bone influences muscle in sarcopenia remain unclear. Therefore, this study aimed to explore the temporal association between muscle mass and BMD in different regions of the body and mechanisms by which bone regulates muscle in sarcopenia. Here, cross lagged models were utilized to analyze the temporal association between BMD and muscle mass. We found that low density lipoprotein (LDL C) positively predicted appendicular lean mass. Mean whole body BMD (WBTOT BMD), lumbar spine BMD (LS BMD), and pelvic BMD (PELV BMD) temporally and positively predicted appendicular lean mass, and appendicular lean mass temporally and positively predicted WBTOT BMD, LS BMD, and PELV BMD. Moreover, this study revealed that primary mice femur osteoblasts, but not primary mice skull osteoblasts, induced differentiation of C2C12 myoblasts through exosomes. Furthermore, the level of long noncoding RNA (lncRNA) taurine upregulated 1 (TUG1) was decreased, and the level of lncRNA differentiation antagonizing nonprotein coding RNA (DANCR) was increased in skull osteoblast derived exosomes, the opposite of femur osteoblast secreted exosomes. In addition, lncRNA TUG1 enhanced and lncRNA DANCR suppressed the differentiation of myoblasts through regulating the transcription of oxidative stress related myogenin (Myog) gene by modifying the binding of myogenic factor 5 (MyfS) to the Myog gene promoter via affecting the nuclear translocation of MyfS. The results of the present study may provide novel diagnostic biomarkers and therapeutic targets for sarcopenia.
C1 [Chen, Jingsong; Tan, Huiting; Mo, Cuiying; Luan, Xiaojun; Xu, Xuejuan] First Peoples Hosp Foshan, Dept Endocrinol, Foshan 528000, Guangdong, Peoples R China.
   [Shen, Jie] Southern Med Univ, Peoples Hosp Shunde 1, Dept Endocrinol, Shunde Hosp, Foshan 528399, Guangdong, Peoples R China.
   [Yang, Xili] First Peoples Hosp Foshan, Dept Cardiol, Foshan 528000, Guangdong, Peoples R China.
   [Yang, Ronghua] South China Univ Technol, Guangzhou Peoples Hosp 1, Dept Burn & Plast Surg, Guangzhou, Guangdong, Peoples R China.
   [Wang, Ying] First Peoples Hosp Foshan, Dept Nucl Med, Foshan 528000, Guangdong, Peoples R China.
   [Huang, Wenhua] Southern Med Univ, Guangdong Engn Res Ctr Translat Med 3D Printing A, Sch Basic Med Sci, Guangdong Prov Key Lab Med Biomech,Natl Key Disc, Guangzhou 510515, Guangdong, Peoples R China.
   [Huang, Wenhua] Southern Med Univ, Guangdong Med Innovat Platform Translat 3D Print, Affiliated Hosp 3, Guangzhou 510000, Guangdong, Peoples R China.
   [Chen, Guoqiang] First Peoples Hosp Foshan, Dept Rheumatol, Foshan 528000, Guangdong, Peoples R China.
C3 Southern Medical University   China; South China University of
   Technology; Southern Medical University   China; Southern Medical
   University   China
RP Xu, XJ (通讯作者)，First Peoples Hosp Foshan, Dept Endocrinol, Foshan 528000, Guangdong, Peoples R China.; Huang, WH (通讯作者)，Southern Med Univ, Guangdong Engn Res Ctr Translat Med 3D Printing A, Sch Basic Med Sci, Guangdong Prov Key Lab Med Biomech,Natl Key Disc, Guangzhou 510515, Guangdong, Peoples R China.; Huang, WH (通讯作者)，Southern Med Univ, Guangdong Med Innovat Platform Translat 3D Print, Affiliated Hosp 3, Guangzhou 510000, Guangdong, Peoples R China.; Chen, GQ (通讯作者)，First Peoples Hosp Foshan, Dept Rheumatol, Foshan 528000, Guangdong, Peoples R China.
EM cjsfsyyy@126.com; sjiesy@smu.edu.cn; 634411146@qq.com; 419755885@qq.com;
   21720091@qq.com; 2037454795@qq.com; wangy@fsyyy.com; 149879447@qq.com;
   huangwenhua2009@139.com; 13929981788@139.com; snowcaressyou@163.com
RI shen, jie/JJF 0994 2023; huang, wenhua/AAO 5990 2020; Chen,
   Guo Qiang/AGP 7651 2022
OI huang, wenhua/0000 0003 2382 9180; 
FU GuangDong Basic and Applied Basic Research Foundation; National Natural
   Science Foundation of China; Foshan 14th Fifth High Level Key Specialty
   Construction Project;  [2019A1515110463];  [82102526];  [21773199]; 
   [31972915]
FX AcknowledgmentsThis work was supported by the GuangDong Basic and
   Applied Basic Research Foundation (2019A1515110463), the National
   Natural Science Foundation of China (82102526, 21773199, and 31972915),
   and the Foshan 14th Fifth High Level Key Specialty Construction Project.
CR Brancatella A, 2020, ENDOCR CONNECT, V9, pR158, DOI 10.1530/EC 20 0167
   Chen CH, 2020, J CLIN INVEST, V130, P404, DOI 10.1172/JCI130892
   Chen LL, 2020, EXP CELL RES, V387, DOI 10.1016/j.yexcr.2019.111751
   Chen X, 2017, TOXICOL SCI, V158, P275, DOI 10.1093/toxsci/kfx096
   Cruz Jentoft AJ, 2019, LANCET, V393, P2636, DOI 10.1016/S0140 6736(19)31138 9
   Cruz Jentoft AJ, 2019, AGE AGEING, V48, P16, DOI 10.1093/ageing/afy169
   Davis DD, 2022, EMS TRACTION SPLINT
   Deng SJ, 2018, ONCOGENE, V37, P5811, DOI 10.1038/s41388 018 0382 1
   dos Santos VR, 2017, DIABETES METAB SYND, V11, pS115, DOI 10.1016/j.dsx.2016.12.019
   Ozer FF, 2021, DYSPHAGIA, V36, P140, DOI 10.1007/s00455 020 10120 3
   Gan L, 2020, CIRCULATION, V141, P968, DOI 10.1161/CIRCULATIONAHA.119.042640
   Ham DJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 18140 1
   Huang MD, 2015, MOL CANCER, V14, DOI 10.1186/s12943 015 0431 0
   Ida S, 2019, J DIABETES RES, V2019, DOI 10.1155/2019/1365189
   Isaacson J, 2014, CLIN REV BONE MINER, V12, P77, DOI 10.1007/s12018 013 9152 3
   Jiang SY, 2019, EUR REV MED PHARMACO, V23, P5558, DOI 10.26355/eurrev_201907_18289
   Kapustin AN, 2015, CIRC RES, V116, P1312, DOI 10.1161/CIRCRESAHA.116.305012
   Lei L, 2020, CANCER BIOL THER, V21, P717, DOI 10.1080/15384047.2020.1764318
   Li GHY, 2020, INT J EPIDEMIOL, V49, P1221, DOI 10.1093/ije/dyz145
   Liu SC, 2019, EUR REV MED PHARMACO, V23, P4584, DOI 10.26355/eurrev_201906_18035
   Lu Q, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/5576023
   Marty E, 2017, BONE, V105, P276, DOI 10.1016/j.bone.2017.09.008
   Matee Karabo R, 2022, Endocr Regul, V56, P126, DOI 10.2478/enr 2022 0014
   Movérare Skrtic S, 2019, FASEB J, V33, P11163, DOI 10.1096/fj.201900707R
   Patil R, 2013, OSTEOPOROSIS INT, V24, P787, DOI 10.1007/s00198 012 2046 2
   Qi HM, 2019, AGING CLIN EXP RES, V31, P1549, DOI 10.1007/s40520 019 01266 8
   Reginster JY, 2016, CURR OPIN CLIN NUTR, V19, P31, DOI 10.1097/MCO.0000000000000230
   Reijnierse EM, 2015, AGE, V37, DOI 10.1007/s11357 015 9825 6
   Ren J, 2018, THERANOSTICS, V8, P3932, DOI 10.7150/thno.25541
   Ristow M, 2009, P NATL ACAD SCI USA, V106, P8665, DOI 10.1073/pnas.0903485106
   Rong YD, 2018, BMC GERIATR, V18, DOI 10.1186/s12877 018 1007 9
   Scott D, 2017, J BONE MINER RES, V32, P575, DOI 10.1002/jbmr.3016
   Shen H, 2015, J BONE MINER RES, V30, P596, DOI 10.1002/jbmr.2389
   Sieber CC, 2019, AGING CLIN EXP RES, V31, P793, DOI 10.1007/s40520 019 01170 1
   Smith RC, 2013, CURR OPIN SUPPORT PA, V7, P352, DOI 10.1097/SPC.0000000000000013
   Szlejf C, 2020, J AM GERIATR SOC, V68, P1545, DOI 10.1111/jgs.16416
   Troyer RM, 2017, EXP CELL RES, V358, P369, DOI 10.1016/j.yexcr.2017.07.011
   van Niel G, 2018, NAT REV MOL CELL BIO, V19, P213, DOI 10.1038/nrm.2017.125
   Wang MY, 2020, EUR REV MED PHARMACO, V24, P922, DOI 10.26355/eurrev_202001_20077
   Wang XC, 2022, CERAM INT, V48, P13695, DOI 10.1016/j.ceramint.2022.01.251
   Woo J, 2017, CLIN GERIATR MED, V33, P305, DOI 10.1016/j.cger.2017.02.003
   Xu Q, 2018, BIOCHEM BIOPH RES CO, V498, P32, DOI 10.1016/j.bbrc.2018.02.144
   Xu XJ, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.653724
   Xu XJ, 2021, PEERJ, V9, DOI 10.7717/peerj.10753
   Xue YN, 2019, J CELL BIOCHEM, V120, P19087, DOI 10.1002/jcb.29232
   Zhang B, 2019, J CELL PHYSIOL, V234, P16692, DOI 10.1002/jcp.28354
   Zhang Q, 2020, CLIN INTERV AGING, V15, P1649, DOI 10.2147/CIA.S266722
   Zhang Y, 2020, THERANOSTICS, V10, P10823, DOI 10.7150/thno.47830
   Zhao X, 2019, EXP CLIN ENDOCR DIAB, V127, P50, DOI 10.1055/a 0762 0341
   Zhong JX, 2014, CELL DEATH DIFFER, V21, P1013, DOI 10.1038/cdd.2014.22
   Zhou X, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194781
NR 51
TC 3
Z9 6
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1942 0900
EI 1942 0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PD SEP 15
PY 2022
VL 2022
AR 9774570
DI 10.1155/2022/9774570
PG 18
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 4Y2IW
UT WOS:000861354900003
PM 36160702
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Charpidou, A
   Tsagouli, S
   Gkiozos, I
   Grapsa, D
   Moutsos, M
   Kiagia, M
   Syrigos, K
AF Charpidou, Andriani
   Tsagouli, Sofia
   Gkiozos, Ioannis
   Grapsa, Dimitra
   Moutsos, Michalis
   Kiagia, Maria
   Syrigos, Konstantinos
TI Bone metastases in patients with small cell lung carcinoma: rate of
   development, early versus late onset, modality of treatment, and their
   impact on survival. A single institution retrospective cohort study
SO CLINICAL & EXPERIMENTAL METASTASIS
LA English
DT Article
DE Bone metastases; Overall survival; Prognosis; Small cell lung carcinoma
ID SKELETAL RELATED EVENTS; ZOLEDRONIC ACID; CANCER PATIENTS; SOLID TUMORS;
   PROSTATE CANCER; TARGETED AGENTS; DISEASE; MARKERS; THERAPY; DENOSUMAB
AB The aim of the present study was to further explore the impact of bone metastases (BMs) and their therapeutic management on the overall prognosis of patients with small cell lung carcinoma (SCLC). We performed a retrospective analysis of medical records of 363 patients with histologically or cytologically confirmed SCLC, diagnosed and treated in the Oncology Unit of Sotiria Athens General Hospital, between January 2003 and December 2012. Demographic and clinicopathological features, including BMs, their time point of development (early onset/at diagnosis versus late onset/at a subsequent time point), treatment modality for BMs (radiotherapy, bisphosphonates or both) and the presence of skeletal related events (SREs), were correlated with overall survival (OS). Survival analysis was performed using the Kaplan Meier method, log rank tests and Cox regression analysis. Overall, 130/363 patients (35.8 %) were diagnosed with either early onset (97/363 cases, 26.7 %) or late onset BMs (33/363 cases, 9.1 %). Patients with early onset BMs had a reduced OS as compared to those with late onset BMs [Hazard ratio (HR) 0.61; 95 % Confidence interval (CI) 0.41 0.91; p = 0.015) or those without BMs (HR 0.76; 95 % CI 0.6 0.96; p = 0.024). SREs and treatment modality of BMs had no impact on OS. Multiple Cox regression analysis showed that increased age, poor performance status (PS), presence of BMs and early onset BMs were independently associated with reduced OS. The results of our single institution study suggest that the development of early onset BMs may represent an independent predictor of a worse prognosis among patients with SCLC, in addition to well established adverse prognostic factors such as poor PS.
C1 [Charpidou, Andriani; Tsagouli, Sofia; Gkiozos, Ioannis; Grapsa, Dimitra; Moutsos, Michalis; Kiagia, Maria; Syrigos, Konstantinos] Univ Athens, Sch Med, Sotiria Gen Hosp, Oncol Unit,Dept Med 3, Mesogion 152, GR 11527 Athens, Greece.
C3 National & Kapodistrian University of Athens
RP Syrigos, K (通讯作者)，Univ Athens, Sch Med, Sotiria Gen Hosp, Oncol Unit,Dept Med 3, Mesogion 152, GR 11527 Athens, Greece.
EM ksyrigos@med.uoa.gr
RI Syrigos, Kostas/AAE 8045 2019
CR Arinc S, 2010, MED ONCOL, V27, P237, DOI 10.1007/s12032 009 9198 8
   Brown JE, 2005, JNCI J NATL CANCER I, V97, P59, DOI 10.1093/jnci/dji002
   Calderone R, 2011, EUR J CANCER, V47, P1603, DOI 10.1016/j.ejca.2011.05.008
   Clemons M, 2012, CURR ONCOL, V19, P259, DOI 10.3747/co.19.1011
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Coleman R, 2012, JNCI J NATL CANCER I, V104, P1059, DOI 10.1093/jnci/djs263
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Costa L, 2002, J CLIN ONCOL, V20, P850, DOI 10.1200/JCO.20.3.850
   Demers Laurence M., 2000, Cancer, V88, P2919, DOI 10.1002/1097 0142(20000615)88:12+<2919::AID CNCR7>3.0.CO;2 Z
   Govindan R, 2006, J CLIN ONCOL, V24, P4539, DOI 10.1200/JCO.2005.04.4859
   Gül G, 2016, CURR MED RES OPIN, V32, P133, DOI 10.1185/03007995.2015.1105795
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hirsh V, 2008, J THORAC ONCOL, V3, P228, DOI 10.1097/JTO.0b013e3181651c0e
   Hirsh Vera, 2004, Clin Lung Cancer, V6, P170, DOI 10.3816/CLC.2004.n.030
   Jahanzeb M, 2010, SEMIN ONCOL, V37, pS45, DOI 10.1053/j.seminoncol.2010.06.004
   Karim Syed Mustafa, 2013, Clin Adv Hematol Oncol, V11, P281
   Kuchuk M, 2013, J BONE ONCOL, V2, P22, DOI 10.1016/j.jbo.2012.12.004
   Lipton A, 2001, CANCER TREAT REV, V27, P181, DOI 10.1053/ctrv.2000.0212
   Lipton A, 2001, SEMIN ONCOL, V28, P54, DOI 10.1016/S0093 7754(01)90233 7
   Lipton A, 2008, CANCER AM CANCER SOC, V113, P193, DOI 10.1002/cncr.23529
   Lopez Olivo MA, 2012, SUPPORT CARE CANCER, V20, P2985, DOI 10.1007/s00520 012 1563 z
   Mahtani R, 2011, CLIN LUNG CANCER, V12, P26, DOI 10.3816/CLC.2011.n.003
   Masters GA., 2010, Principles and practice of lung cancer, V4th, P341
   Matsumoto S, 2005, LUNG CANCER, V47, P31, DOI 10.1016/j.lungcan.2004.06.003
   Nakazawa K, 2012, ONCOL LETT, V4, P617, DOI 10.3892/ol.2012.792
   Niho S, 2011, J THORAC ONCOL, V6, P796, DOI 10.1097/JTO.0b013e318208ec77
   Oster G, 2013, SUPPORT CARE CANCER, V21, P3279, DOI 10.1007/s00520 013 1887 3
   Rolfo C, 2014, EXPERT OPIN BIOL TH, V14, P15, DOI 10.1517/14712598.2013.843667
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   SAGMAN U, 1991, J CLIN ONCOL, V9, P1639, DOI 10.1200/JCO.1991.9.9.1639
   Scagliotti GV, 2012, J THORAC ONCOL, V7, P1823, DOI 10.1097/JTO.0b013e31826aec2b
   Sehouli J, 2013, ANN ONCOL, V24, P3024, DOI 10.1093/annonc/mdt398
   Spizzo G, 2009, ANTICANCER RES, V29, P5245
   STUARTHARRIS R, 1993, EUR J CANCER, V29A, P1601, DOI 10.1016/0959 8049(93)90304 X
   Tan Jessica, 2012, World J Oncol, V3, P42, DOI 10.4021/wjon266w
   Tchekmedyian NS, 2010, CANCER INVEST, V28, P849, DOI 10.3109/07357907.2010.483508
   Tsuya A, 2007, LUNG CANCER, V57, P229, DOI 10.1016/j.lungcan.2007.03.013
   Zarogoulidis K, 2009, INT J CANCER, V125, P1705, DOI 10.1002/ijc.24470
NR 38
TC 7
Z9 8
U1 1
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0262 0898
EI 1573 7276
J9 CLIN EXP METASTAS
JI Clin. Exp. Metastasis
PD JUN
PY 2016
VL 33
IS 5
BP 453
EP 460
DI 10.1007/s10585 016 9789 7
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA DN4GE
UT WOS:000377020900005
PM 27209468
DA 2025 08 17
ER

PT J
AU Placencio, VR
   Li, XH
   Sherrill, TP
   Fritz, G
   Bhowmick, NA
AF Placencio, Veronica R.
   Li, Xiaohong
   Sherrill, Taylor P.
   Fritz, Gloria
   Bhowmick, Neil A.
TI Bone Marrow Derived Mesenchymal Stem Cells Incorporate into the Prostate
   during Regrowth
SO PLOS ONE
LA English
DT Article
ID CANCER METASTASIS; BETA CATENIN; DIFFERENTIATION; ANDROGEN; FUSION;
   GROWTH; MODEL; TUMOR; LIVER; TRANSPLANTATION
AB Background: Prostate cancer recurrence involves increased growth of cancer epithelial cells, as androgen dependent prostate cancer progresses to castrate resistant prostate cancer (CRPC) following initial therapy. Understanding CRPC prostate regrowth will provide opportunities for new cancer therapies to treat advanced disease.
   Methodology/Principal Findings: Elevated chemokine expression in the prostate stroma of a castrate resistant mouse model, Tgfbr2(fspKO), prompted us to look at the involvement of bone marrow derived cells (BMDCs) in prostate regrowth. We identified bone marrow cells recruited to the prostate in GFP chimeric mice. A dramatic increase in BMDC recruitment for prostate regrowth occurred three days after exogenous testosterone implantation. Recruitment led to incorporation of BMDCs within the prostate epithelia. Immunofluorescence staining suggested BMDCs in the prostate coexpressed androgen receptor; p63, a basal epithelial marker; and cytokeratin 8, a luminal epithelial marker. A subset of the BMDC population, mesenchymal stem cells (MSCs), were specifically found to be incorporated in the prostate at its greatest time of remodeling. Rosa26 expressing MSCs injected into GFP mice supported MSC fusion with resident prostate epithelial cells through co localization of beta galactosidase and GFP during regrowth. In a human C4 2B xenograft model of CRPC, MSCs were specifically recruited. Injection of GFP labeled MSCs supported C4 2B tumor progression by potentiating canonical Wnt signaling. The use of MSCs as a targeted delivery vector for the exogenously expressed Wnt antagonist, secreted frizzled related protein 2 (SFRP2), reduced tumor growth, increased apoptosis and potentiated tumor necrosis.
   Conclusions/Significance: Mesenchymal stem cells fuse with prostate epithelia during the process of prostate regrowth. MSCs recruited to the regrowing prostate can be used as a vehicle for transporting genetic information with potential therapeutic effects on castrate resistant prostate cancer, for instance by antagonizing Wnt signaling through SFRP2.
C1 [Placencio, Veronica R.; Li, Xiaohong; Bhowmick, Neil A.] Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA.
   [Li, Xiaohong; Fritz, Gloria; Bhowmick, Neil A.] Vanderbilt Univ, Dept Urol Surg, Nashville, TN USA.
   [Sherrill, Taylor P.] Vanderbilt Univ, Dept Pulm & Crit Care Med, Nashville, TN USA.
   [Bhowmick, Neil A.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA.
C3 Vanderbilt University; Vanderbilt University; Vanderbilt University;
   Cedars Sinai Medical Center
RP Placencio, VR (通讯作者)，Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA.
EM bhowmickn@cshs.org
RI ; Bhowmick, Neil/AAA 7302 2019
OI , Xiaohong/0000 0001 5074 193X; 
FU National Institute of Health/National Cancer Institute [CA108646,
   CA126505]; Department of Defense Prostate Cancer Research [PC081246];
   National Institute of Health/NRSA [GM079879]; NIH [CA68485, DK20593,
   DK58404, HD15052, DK59637, EY08126]
FX The work was supported by the National Institute of Health/National
   Cancer Institute (CA108646 and CA126505 to NAB), the Department of
   Defense Prostate Cancer Research Program (PC081246 to NAB), and National
   Institute of Health/NRSA (GM079879 to VRP). Immunofluorescence and
   confocal images were taken in part through the VUMC Cell Imaging Shared
   Resource (supported by NIH grants CA68485, DK20593, DK58404, HD15052,
   DK59637, and EY08126). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Alfaro MP, 2008, P NATL ACAD SCI USA, V105, P18366, DOI 10.1073/pnas.0803437105
   Alison MR, 2009, CURR OPIN ONCOL, V21, P77, DOI 10.1097/CCO.0b013e32831de4cf
   Ammirante M, 2010, NATURE, V464, P302, DOI 10.1038/nature08782
   Anumanthan G, 2008, J UROLOGY, V180, P1778, DOI 10.1016/j.juro.2008.04.076
   Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922
   Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002
   Bisson I, 2009, CELL RES, V19, P683, DOI 10.1038/cr.2009.43
   Boomershine CS, 2009, GUT, V58, P1267, DOI 10.1136/gut.2008.170779
   Chytil A, 2002, GENESIS, V32, P73, DOI 10.1002/gene.10046
   Dan YY, 2008, J GASTROEN HEPATOL, V23, P687, DOI 10.1111/j.1440 1746.2008.05383.x
   DasGupta R, 1999, DEVELOPMENT, V126, P4557
   Davies PS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006530
   Dittmar T, 2009, MED HYPOTHESES, V73, P542, DOI 10.1016/j.mehy.2009.05.044
   Everhart MB, 2005, J LEUKOCYTE BIOL, V77, P173, DOI 10.1189/jlb.1203647
   Fritz V, 2008, CURR STEM CELL RES T, V3, P32, DOI 10.2174/157488808783489462
   Fritz V, 2008, STEM CELLS, V26, P2981, DOI 10.1634/stemcells.2008 0139
   Li HC, 2006, WORLD J GASTROENTERO, V12, P363, DOI 10.3748/wjg.v12.i3.363
   Houghton J, 2004, SCIENCE, V306, P1568, DOI 10.1126/science.1099513
   Houghton J, 2007, SEMIN CANCER BIOL, V17, P191, DOI 10.1016/j.semcancer.2006.04.003
   Ichim TE, 2010, CELL IMMUNOL, V260, P75, DOI 10.1016/j.cellimm.2009.10.006
   Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Kasper S, 1998, LAB INVEST, V78, P319
   Kawada H, 2004, BLOOD, V104, P3581, DOI 10.1182/blood 2004 04 1488
   Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092 8674(01)00328 2
   Lee KD, 2004, HEPATOLOGY, V40, P1275, DOI 10.1002/hep.20469
   LI X, 2008, PROSTATE TUMOR PROGR
   Liu CF, 2006, NEOPLASIA, V8, P716, DOI 10.1593/neo.06253
   Luo JL, 2007, NATURE, V446, P690, DOI 10.1038/nature05656
   Palapattu GS, 2006, J UROLOGY, V176, P813, DOI 10.1016/j.juro.2006.03.077
   Phinney DG, 1999, J CELL BIOCHEM, V72, P570
   Placencio VR, 2008, CANCER RES, V68, P4709, DOI 10.1158/0008 5472.CAN 07 6289
   Reinders MEJ, 2010, NEPHROL DIAL TRANSPL, V25, P17, DOI 10.1093/ndt/gfp552
   Rizvi AZ, 2006, P NATL ACAD SCI USA, V103, P6321, DOI 10.1073/pnas.0508593103
   Song H, 2010, EXPERT OPIN BIOL TH, V10, P309, DOI 10.1517/14712590903455997
   Spagnoli A, 2005, ENDOCRIN DEV, V9, P17, DOI 10.1159/000085719
   Terry S, 2006, J CELL BIOCHEM, V99, P402, DOI 10.1002/jcb.20983
   THALMANN GN, 1994, CANCER RES, V54, P2577
   Tsujimura A, 2002, J CELL BIOL, V157, P1257, DOI 10.1083/jcb.200202067
   Vaday GG, 2006, PROSTATE, V66, P124, DOI 10.1002/pros.20306
   Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539
   Verras M, 2006, CANCER LETT, V237, P22, DOI 10.1016/j.canlet.2005.06.004
   Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531
   Wang X, 2009, NATURE, V461, P495, DOI 10.1038/nature08361
   Xu WT, 2009, CANCER LETT, V281, P32, DOI 10.1016/j.canlet.2009.02.022
   Yu XP, 2009, PROSTATE, V69, P249, DOI 10.1002/pros.20877
NR 46
TC 44
Z9 46
U1 1
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD SEP 23
PY 2010
VL 5
IS 9
AR e12920
DI 10.1371/journal.pone.0012920
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 653KV
UT WOS:000282091100024
PM 20886110
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Alothman, M
   Althobaity, W
   Asiri, Y
   Alreshoodi, S
   Alismail, K
   Alshaalan, M
AF Alothman, Maram
   Althobaity, Waleed
   Asiri, Yasser
   Alreshoodi, Saleh
   Alismail, Khalid
   Alshaalan, Meshal
TI Giant cell tumor of bone following denosumab treatment: assessment of
   tumor response using various imaging modalities
SO INSIGHTS INTO IMAGING
LA English
DT Article
DE Giant cell tumor; Denosumab; Magnetic resonance imaging
AB Background Giant cell tumor (GCT) is a nonmalignant neoplasm composed of multinucleated giant and mononuclear stromal cells. This study aimed to compare imaging findings of GCT pre  and post denosumab treatment, including lesion size, percentage of signal intensity/density change, and time of initial objective tumor response. This will have a great impact on selection of most appropriate imaging technique to accurately measure therapy response and its related complications, which would influence the physicians to tailor the treatment regimen to suit each patient. Results As per inverse Choi density/size (ICDS), 16 patients (84.2%) had an objective tumor response and 15 (78.9%) had an increase in density or decrease in signal intensity, and the mean of signal intensity decrease in the treated lesions was 32.4% (95% CI, 18 46.7). Only seven patients (36.8%) had tumors demonstrating >= 10% decrease in size, all of which showed a positive change in signal/density except for one. Moreover, 17 patients (89.4%) showed a clear demarcation/low signal intensity margin surrounding >= two third of the lesion periphery. The median time to first objective tumor response was approximately 23 weeks. Conclusion Based on the ICDS criteria, most patients with giant cell tumor of bone show objective tumor response to denosumab. Modification of ICDS to include marginal sclerosis or clear demarcation of the lesions might be considered as a separate response criterion to accurately assess the treatment response in patients with GCT.
C1 [Alothman, Maram; Althobaity, Waleed; Asiri, Yasser; Alreshoodi, Saleh; Alismail, Khalid; Alshaalan, Meshal] King Faisal Specialist Hosp & Res Ctr, Dept Med Imaging, Riyadh, Saudi Arabia.
C3 King Faisal Specialist Hospital & Research Center
RP Alothman, M; Althobaity, W (通讯作者)，King Faisal Specialist Hosp & Res Ctr, Dept Med Imaging, Riyadh, Saudi Arabia.
EM Alothman.maram@gmail.com
RI Al Ismail, khalid/G 2599 2015
CR [Anonymous], ECR 2014 C 1095 IM G
   Bertoni F, 2003, CANCER, V97, P2520, DOI 10.1002/cncr.11359
   Branstetter DG, 2012, CLIN CANCER RES, V18, P4415, DOI 10.1158/1078 0432.CCR 12 0578
   CAMPANACCI M, 1987, J BONE JOINT SURG AM, V69A, P106, DOI 10.2106/00004623 198769010 00018
   Chakarun CJ, 2013, RADIOGRAPHICS, V33, P197, DOI 10.1148/rg.331125089
   Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470 2045(13)70277 8
   Choi H, 2007, J CLIN ONCOL, V25, P1753, DOI 10.1200/JCO.2006.07.3049
   Engellau J, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957 018 1478 3
   He AN, 2013, INT J CLIN ONCOL, V18, P498, DOI [10.1007/s10147 012 0409 5, 10.1007/s10147 013 0561 6]
   Luengo Alonso G, 2019, ARCH ORTHOP TRAUM SU, V139, P1339, DOI 10.1007/s00402 019 03167 x
   MCGRATH P J, 1972, Journal of Bone and Joint Surgery British Volume, V54, P216
   ROCK MG, 1986, J BONE JOINT SURG AM, V68A, P1073, DOI 10.2106/00004623 198668070 00016
   SUNG HW, 1982, J BONE JOINT SURG AM, V64, P755, DOI 10.2106/00004623 198264050 00015
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   Turcotte RE, 2002, CLIN ORTHOP RELAT R, P248
   Ueda T, 2015, ANN ONCOL, V26, P2149, DOI 10.1093/annonc/mdv307
   Xu SF, 2013, CURR ONCOL, V20, pE442, DOI 10.3747/co.20.1497
NR 17
TC 6
Z9 7
U1 0
U2 1
PU SPRINGEROPEN
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1869 4101
J9 INSIGHTS IMAGING
JI Insights Imaging
PD FEB 27
PY 2020
VL 11
IS 1
AR 41
DI 10.1186/s13244 020 00845 y
PG 6
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA KW2BM
UT WOS:000520974700001
PM 32108273
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Abraham, AK
   Mager, DE
   Gao, X
   Li, M
   Healy, DR
   Maurer, TS
AF Abraham, Anson K.
   Mager, Donald E.
   Gao, Xiang
   Li, Mei
   Healy, David R.
   Maurer, Tristan S.
TI Mechanism Based Pharmacokinetic/Pharmacodynamic Model of Parathyroid
   Hormone Calcium Homeostasis in Rats and Humans
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN; IONIZED CALCIUM;
   PHARMACODYNAMIC MODELS; SENSING RECEPTOR; PLASMA CALCIUM; SECRETION;
   OSTEOPOROSIS; HYPOCALCEMIA; PHYSIOLOGY
AB The purpose of this study was to develop a mechanism based pharmacokinetic/pharmacodynamic model that describes the regulation of the parathyroid hormone (PTH) Ca2+ system in rats and humans. Temporal concentration data for endogenous PTH and Ca2+ were extracted from literature for rats (normal adult males) and humans. In addition, exogenous PTH was administered subcutaneously to male Sprague Dawley rats with jugular vein catheters, and plasma concentrations were measured over time. A mathematical model was developed and fitted simultaneously to endogenous PTH, Ca2+, and exogenous PTH concentrations in rats. Ca2+ concentrations were described using a turnover model, with its depletion being induced by a chelating agent, and PTH concentrations were characterized using a precursor dependent indirect response model. The same structural model was used for fitting data obtained in humans. PTH stimulation was driven by occupancy of the Ca2+ sensing receptor, and lowering of physiological Ca2+ concentrations increased PTH secretion, with PTH profiles being adequately described by the model. PTH stimulatory capacity was baseline dependent in rats [S max_rats = 34.8 x PTHo] and humans [S max_humans = 392/PTHo]. Modeling results suggest that normal rats are twice as sensitive to Ca2+ induced PTH stimulation compared with humans. In conclusion, the developed model adequately characterizes the PTH Ca2+ regulation across species and may be useful in the development of therapeutic drugs targeting this system.
C1 [Maurer, Tristan S.] Pfizer Global Res & Dev, Dept Pharmacokinet Pharmadynam & Metab, Groton, CT 06340 USA.
   [Li, Mei; Healy, David R.] Pfizer Global Res & Dev, Pfizer Healthy Aging Translat Pharmacol, Dept Biol, Groton, CT 06340 USA.
   [Gao, Xiang] Pfizer Global Res & Dev, Dept Clin Pharmacol, Groton, CT 06340 USA.
   [Abraham, Anson K.; Mager, Donald E.] SUNY Buffalo, Dept Pharmaceut Sci, Amherst, NY USA.
C3 Pfizer; Pfizer USA; Pfizer; Pfizer USA; Pfizer; Pfizer USA; State
   University of New York (SUNY) System; University at Buffalo, SUNY
RP Maurer, TS (通讯作者)，Pfizer Global Res & Dev, Dept Pharmacokinet Pharmadynam & Metab, Eastern Point Rd, Groton, CT 06340 USA.
EM s.maurer@pfizer.com
OI Abraham, Anson/0000 0002 9579 7483; Maurer, Tristan/0009 0007 2994 1954
FU University at Buffalo Pfizer Strategic Alliance
FX This study was funded in part by the University at Buffalo Pfizer
   Strategic Alliance.
CR Bieglmayer C, 2002, CLIN CHEM, V48, P1731
   Body JJ, 2002, J CLIN ENDOCR METAB, V87, P4528, DOI 10.1210/jc.2002 020334
   Brixen KT, 2004, BASIC CLIN PHARMACOL, V94, P260
   BROWN EM, 1983, J CLIN ENDOCR METAB, V56, P572, DOI 10.1210/jcem 56 3 572
   Chattopadhyay N, 2000, INT J BIOCHEM CELL B, V32, P789, DOI 10.1016/S1357 2725(00)00031 5
   Chen RA, 2004, AM J PHYSIOL RENAL, V286, pF1005, DOI 10.1152/ajprenal.00013.2004
   Cosman F, 1999, CALCIFIED TISSUE INT, V65, P257, DOI 10.1007/s002239900694
   Cosman F, 1998, J CLIN ENDOCR METAB, V83, P788, DOI 10.1210/jc.83.3.788
   D'Argenio DZ., 1997, ADAPT II user's guide, DOI DOI 10.1182/blood 2004 02 0414
   DAMOUR P, 1992, J CLIN ENDOCR METAB, V74, P525, DOI 10.1210/jc.74.3.525
   Fox J, 1997, BONE, V21, P163, DOI 10.1016/S8756 3282(97)00108 7
   FOX J, 1991, AM J PHYSIOL, V260, pE220, DOI 10.1152/ajpendo.1991.260.2.E220
   FOX J, 1981, AM J PHYSIOL, V240, pE649, DOI 10.1152/ajpendo.1981.240.6.E649
   Friedman PA, 2006, AM J PHYSIOL RENAL, V290, pF975, DOI 10.1152/ajprenal.00336.2005
   FRIEDMAN PA, 2006, AGENTS AFFECTING MIN
   Greenspan SL, 2007, ANN INTERN MED, V146, P326, DOI 10.7326/0003 4819 146 5 200703060 00005
   HABENER JF, 1975, ENDOCRINOLOGY, V97, P431, DOI 10.1210/endo 97 2 431
   Hamann KL, 2006, RHEUM DIS CLIN N AM, V32, P703, DOI 10.1016/j.rdc.2006.07.005
   Hodsman AB, 2003, J CLIN ENDOCR METAB, V88, P5212, DOI 10.1210/jc.2003 030768
   Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   JUPPNER HW, 2001, ENDOCRINOLOGY, P969
   KAO PC, 1992, MAYO CLIN PROC, V67, P637, DOI 10.1016/S0025 6196(12)60717 4
   Lalonde RL, 2007, CLIN PHARMACOL THER, V82, P21, DOI 10.1038/sj.clpt.6100235
   Lewin E, 1995, Curr Opin Nephrol Hypertens, V4, P324, DOI 10.1097/00041552 199507000 00007
   Libutti SK, 1999, SURGERY, V126, P1145, DOI 10.1067/msy.2099.101835
   Mager DE, 2008, CLIN PHARMACOL THER, V83, P909, DOI 10.1038/clpt.2008.52
   Mager DE, 2003, DRUG METAB DISPOS, V31, P510, DOI 10.1124/dmd.31.5.510
   MAYER GP, 1979, ENDOCRINOLOGY, V104, P1778, DOI 10.1210/endo 104 6 1778
   Momsen G, 1997, SCAND J CLIN LAB INV, V57, P381, DOI 10.3109/00365519709084585
   Nemeth EF, 2002, CURR PHARM DESIGN, V8, P2077, DOI 10.2174/1381612023393387
   Porter CJH, 2000, J PHARM SCI US, V89, P297, DOI 10.1002/(SICI)1520 6017(200003)89:3<297::AID JPS2>3.0.CO;2 P
   Ramakrishnan R, 2003, J PHARMACOL EXP THER, V306, P324, DOI 10.1124/jpet.102.047191
   Raposo JF, 2002, J CLIN ENDOCR METAB, V87, P4330, DOI 10.1210/jc.2002 011870
   Schmitt CP, 1996, J CLIN ENDOCR METAB, V81, P4236, DOI 10.1210/jc.81.12.4236
   Sharma A, 1998, J PHARM SCI, V87, P1577, DOI 10.1021/js980171q
NR 36
TC 19
Z9 21
U1 0
U2 2
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3995 USA
SN 0022 3565
EI 1521 0103
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD JUL
PY 2009
VL 330
IS 1
BP 169
EP 178
DI 10.1124/jpet.109.152033
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 461PL
UT WOS:000267280300019
PM 19386792
DA 2025 08 17
ER

PT J
AU Staines, KA
   Myers, K
   Little, K
   Ralston, SH
   Farquharson, C
AF Staines, Katherine A.
   Myers, Katherine
   Little, Kirsty
   Ralston, Stuart H.
   Farquharson, Colin
TI Proton Pump Inhibitors Inhibit PHOSPHO1 Activity and Matrix
   Mineralisation In Vitro
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE PHOSPHO1; Proton pump inhibitors; Histamine 2 receptor antagonists;
   Mineralisation; TNAP
ID TERM OMEPRAZOLE TREATMENT; SKELETAL MINERALIZATION; CALCIUM CARBONATE;
   GROWTH PLATE; BONE; RISK; VESICLES; FRACTURE; MEDICATIONS; ABSORPTION
AB Proton pump inhibitors (PPIs) have been associated with an increased risk of fragility fractures in pharmaco epidemiological studies. The mechanism is unclear, but it has been speculated that by neutralising gastric acid, they may reduce intestinal calcium absorption, causing secondary hyperparathyroidism and bone loss. Here we investigated that hypothesis that the skeletal effects of PPI might be mediated by inhibitory effects on the bone specific phosphatase PHOSPHO1. We found that the all PPIs tested inhibited the activity of PHOSPHO1 with IC50 ranging between 0.73 mu M for esomeprazole to 19.27 mu M for pantoprazole. In contrast, these PPIs did not inhibit TNAP activity. We also found that mineralisation of bone matrix in primary osteoblast cultures was inhibited by several PPIs in a concentration dependent manner. In contrast, the histamine 2 receptor antagonists (H2RA) nizatidine, famotidine, cimetidine and ranitidine had no inhibitory effects on PHOSPHO1 activity. Our experiments show for the first time that PPIs inhibit PHOSPHO1 activity and matrix mineralisation in vitro revealing a potential mechanism by which these widely used drugs are associated with the risk of fractures.
C1 [Staines, Katherine A.] Univ Brighton, Sch Pharm & Biomol Sci, Lewes Rd, Brighton BN2 4GJ, E Sussex, England.
   [Myers, Katherine; Little, Kirsty; Farquharson, Colin] Univ Edinburgh, Roslin Inst, Edinburgh, Midlothian, Scotland.
   [Ralston, Stuart H.] Univ Edinburgh, Inst Genet & Canc, Ctr Genom & Expt Med, Edinburgh, Midlothian, Scotland.
C3 University of Brighton; UK Research & Innovation (UKRI); Biotechnology
   and Biological Sciences Research Council (BBSRC); Roslin Institute;
   University of Edinburgh; University of Edinburgh
RP Staines, KA (通讯作者)，Univ Brighton, Sch Pharm & Biomol Sci, Lewes Rd, Brighton BN2 4GJ, E Sussex, England.
EM k.staines@brighton.ac.uk
RI ; Staines, Katherine/AAF 6823 2020; farquharson, colin/C 2956 2011
OI farquharson, colin/0000 0002 4970 4039; Staines,
   Katherine/0000 0002 8492 9778; 
FU Medical Research Scotland; Society for Endocrinology; Biotechnology and
   Biological Sciences Research Council (BBSRC) [BB/J004316/1]; BBSRC
   [BBS/E/D/10002071, BBS/E/R/00003741] Funding Source: UKRI; Biotechnology
   and Biological Sciences Research Council [BBS/E/D/10002071,
   BBS/E/R/00003741] Funding Source: researchfish
FX We are grateful to Medical Research Scotland for a Vacation Scholarship
   (KM) and the Society for Endocrinology for a Summer Studentship (KL). We
   are also grateful to the Biotechnology and Biological Sciences Research
   Council (BBSRC) for Institute Strategic Programme Grant Funding
   BB/J004316/1.
CR Anderson H Clarke, 2003, Curr Rheumatol Rep, V5, P222, DOI 10.1007/s11926 003 0071 z
   Anderson HC, 2004, AM J PATHOL, V164, P841, DOI 10.1016/S0002 9440(10)63172 0
   Ciancaglini P, 2010, J BONE MINER RES, V25, P716, DOI 10.1359/jbmr.091023
   Costa Rodrigues J, 2013, FEBS J, V280, P5052, DOI 10.1111/febs.12478
   Cui GL, 2001, SCAND J GASTROENTERO, V36, P1011
   Cui L, 2016, BONE, V87, P147, DOI 10.1016/j.bone.2016.04.007
   de Vries F, 2009, OSTEOPOROSIS INT, V20, P1989, DOI 10.1007/s00198 009 0891 4
   Dillon S, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10202
   GagnemoPersson R, 1997, CALCIFIED TISSUE INT, V61, P210, DOI 10.1007/s002239900325
   Graham DY, 2018, CLIN GASTROENTEROL H, V16, P800, DOI 10.1016/j.cgh.2017.09.033
   Gray SL, 2010, ARCH INTERN MED, V170, P765, DOI 10.1001/archinternmed.2010.94
   Hansen KE, 2010, J BONE MINER RES, V25, P2510, DOI 10.1002/jbmr.166
   Hardy P, 1998, ARTIF ORGANS, V22, P569, DOI 10.1046/j.1525 1594.1998.06200.x
   Hollingworth S, 2010, PHARMACOEPIDEM DR S, V19, P1019, DOI 10.1002/pds.1969
   Houston B, 1999, BBA MOL CELL RES, V1448, P500, DOI 10.1016/S0167 4889(98)00153 0
   Houston B, 2004, BONE, V34, P629, DOI 10.1016/j.bone.2003.12.023
   Huesa Carmen, 2015, Biochem Biophys Rep, V4, P196
   Insogna KL, 2009, AM J GASTROENTEROL, V104, pS2, DOI 10.1038/ajg.2009.44
   Javaheri B, 2015, BONE, V81, P277, DOI 10.1016/j.bone.2015.07.035
   Kirchheiner J, 2009, EUR J CLIN PHARMACOL, V65, P19, DOI 10.1007/s00228 008 0576 5
   Lyu B, 2020, AM J NEPHROL, V51, P433, DOI 10.1159/000507470
   MacRae VE, 2010, BONE, V46, P1146, DOI 10.1016/j.bone.2009.12.018
   McKee MD, 2013, J DENT RES, V92, P721, DOI 10.1177/0022034513490958
   Mebarek S., 2009, ACTA BIOCHIM POL, DOI DOI 10.18388/ABP.2009_2462
   Millán JL, 2013, CALCIFIED TISSUE INT, V93, P299, DOI 10.1007/s00223 012 9672 8
   MIZUNASHI K, 1993, CALCIFIED TISSUE INT, V53, P21, DOI 10.1007/BF01352010
   O'Connell MB, 2005, AM J MED, V118, P778, DOI 10.1016/j.amjmed.2005.02.007
   Park JH, 2020, BMC GERIATR, V20, DOI 10.1186/s12877 020 01794 3
   Poly TN, 2019, OSTEOPOROSIS INT, V30, P103, DOI 10.1007/s00198 018 4788 y
   Roberts S, 2007, J BONE MINER RES, V22, P617, DOI 10.1359/JBMR.070108
   Roberts SJ, 2004, BIOCHEM J, V382, P59, DOI 10.1042/BJ20040511
   Robison R, 1923, BIOCHEM J, V17, P286, DOI 10.1042/bj0170286
   Sachs George, 2010, Curr Gastroenterol Rep, V12, P437, DOI 10.1007/s11894 010 0149 5
   SERFATYLACROSNIERE C, 1995, J AM COLL NUTR, V14, P364
   Stewart AJ, 2003, PROTEIN ENG, V16, P889, DOI 10.1093/protein/gzg126
   Stewart AJ, 2006, BONE, V39, P1000, DOI 10.1016/j.bone.2006.05.014
   Targownik LE, 2008, CAN MED ASSOC J, V179, P319, DOI 10.1503/cmaj.071330
   Vestergaard P, 2006, CALCIFIED TISSUE INT, V79, P76, DOI 10.1007/s00223 006 0021 7
   Yadav MC, 2016, J BONE MINER RES, V31, P1275, DOI 10.1002/jbmr.2790
   Yadav MC, 2011, J BONE MINER RES, V26, P286, DOI 10.1002/jbmr.195
   Yanagihara Gabriela Rezende, 2015, Rev. bras. ortop., V50, P232, DOI 10.1016/j.rboe.2015.03.002
   Yang YX, 2006, JAMA J AM MED ASSOC, V296, P2947, DOI 10.1001/jama.296.24.2947
   Yu EW, 2008, CALCIFIED TISSUE INT, V83, P251, DOI 10.1007/s00223 008 9170 1
   Zhou B, 2016, OSTEOPOROSIS INT, V27, P339, DOI 10.1007/s00198 015 3365 x
NR 44
TC 8
Z9 9
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD DEC
PY 2021
VL 109
IS 6
BP 696
EP 705
DI 10.1007/s00223 021 00882 9
EA JUL 2021
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA WK6BZ
UT WOS:000669189000001
PM 34213594
OA Green Submitted, Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Xu, Y
   Qi, JQ
   Sun, W
   Zhong, W
   Wu, HW
AF Xu, Yan
   Qi, Jingqi
   Sun, Wei
   Zhong, Wu
   Wu, Hongwei
TI Therapeutic Effects of Zoledronic Acid Loaded Hyaluronic
   Acid/Polyethylene Glycol/Nano Hydroxyapatite Nanoparticles on
   Osteosarcoma
SO FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
LA English
DT Article
DE nanoparticle; osteosarcoma; zoledronic acid; tumor therapy; targeted
   therapy
ID DRUG DELIVERY; BISPHOSPHONATES; CHEMOTHERAPY; MECHANISMS; EXPRESSION;
   APOPTOSIS; SURVIVAL
AB Zoledronic acid (ZOL) has been approved as the only bisphosphonate for the prevention and treatment of metastatic bone diseases with acceptable safety and tolerability. However, systemic or direct injection of ZOL often causes severe side effects, which limits its clinical application. Here, an innovative nano drug delivery system, ZOL loaded hyaluronic acid/polyethylene glycol/nano hydroxyapatite nanoparticles (HA PEG nHA ZOL NPs), has been found to effectively inhibit the proliferation of three types of human osteosarcoma cell lines (143b, HOS, and MG63) at 1 10 mu mol/L, while with low cell cytotoxicity on normal cells. The NPs significantly enhanced the apoptosis related protein expression and tumor cell apoptosis rate. The NPs could also inhibit the proliferation of osteosarcoma cells by blocking the S phase of the cell cycle. In the orthotopic osteosarcoma nude mice model, local injection of the HA PEG nHA ZOL NPs stimulated tumor necrosis, apoptosis, and granulocyte infiltration in the blood vessels. Altogether, the ZOL nano delivery system possesses great potential for local treatment to prevent local tumor recurrence and can be applied in clinical osteosarcoma therapy.
C1 [Xu, Yan; Zhong, Wu; Wu, Hongwei] Cent South Univ, Hunan Canc Hosp, Changsha, Peoples R China.
   [Xu, Yan; Zhong, Wu; Wu, Hongwei] Cent South Univ, Affiliated Canc Hosp Xiangya, Sch Med, Changsha, Peoples R China.
   [Qi, Jingqi; Sun, Wei] Zhejiang Univ, Univ Edinburgh Inst, Hangzhou, Peoples R China.
C3 Central South University; Central South University; Zhejiang University
RP Wu, HW (通讯作者)，Cent South Univ, Hunan Canc Hosp, Changsha, Peoples R China.; Wu, HW (通讯作者)，Cent South Univ, Affiliated Canc Hosp Xiangya, Sch Med, Changsha, Peoples R China.
EM wuhongwei@hnca.org.cn
RI Sun, Wei/AAC 7024 2019
FU Hunan Cancer Hospital Climb Plan [YF2020007]; Key Projects of Platform
   and the Talent Plan of Changsha Science and Technology Bureau
   [kh1801129]; Natural Science Foundation of Hunan Province [2017JJ3109]
FX The study was supported by the Hunan Cancer Hospital Climb Plan
   (YF2020007) and Key Projects of Platform and the Talent Plan of Changsha
   Science and Technology Bureau (No. kh1801129) and Natural Science
   Foundation of Hunan Province (NO. 2017JJ3109).
CR Anderson ME, 2016, ORTHOP CLIN N AM, V47, P283, DOI 10.1016/j.ocl.2015.08.022
   Arcaute K, 2006, ANN BIOMED ENG, V34, P1429, DOI 10.1007/s10439 006 9156 y
   Bahrami B, 2017, IMMUNOL LETT, V190, P64, DOI 10.1016/j.imlet.2017.07.015
   Blanco E, 2015, NAT BIOTECHNOL, V33, P941, DOI 10.1038/nbt.3330
   Burns J, 2020, SEMIN CANCER BIOL, V61, P56, DOI 10.1016/j.semcancer.2019.11.003
   Chang J, 2012, ONCOL LETT, V4, P299, DOI 10.3892/ol.2012.723
   Dai CF, 2015, COLLOID SURFACE B, V136, P262, DOI 10.1016/j.colsurfb.2015.09.015
   Dhillon S, 2016, DRUGS, V76, P1683, DOI 10.1007/s40265 016 0662 4
   Gao SY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179248
   Garbayo E, 2020, WIRES NANOMED NANOBI, V12, DOI 10.1002/wnan.1637
   Giger EV, 2013, J CONTROL RELEASE, V167, P175, DOI 10.1016/j.jconrel.2013.01.032
   GREF R, 1995, ADV DRUG DELIVER REV, V16, P215, DOI 10.1016/0169 409X(95)00026 4
   HERNIGOU P, 1989, J BONE JOINT SURG BR, V71, P804, DOI 10.1302/0301 620X.71B5.2584251
   Iguchi T, 2007, INT J ONCOL, V31, P285
   Katagiri H, 1997, ARCH ORTHOP TRAUM SU, V116, P329
   Labrinidis A, 2009, CLIN CANCER RES, V15, P3451, DOI 10.1158/1078 0432.CCR 08 1616
   Letaief F, 2020, J ORTHOP SURG HONG K, V28, DOI 10.1177/2309499020974501
   Li K, 2020, BIOACT MATER, V5, P721, DOI 10.1016/j.bioactmat.2020.04.010
   Li X, 2019, ACS APPL MATER INTER, V11, P7311, DOI 10.1021/acsami.8b16588
   Lin H, 2020, INT J MED SCI, V17, P2248, DOI 10.7150/ijms.47405
   Liu H, 2015, BIOMATERIALS, V49, P103, DOI 10.1016/j.biomaterials.2015.01.017
   Liu J, 2014, BIOTECHNOL ADV, V32, P693, DOI 10.1016/j.biotechadv.2013.11.009
   Longmire M, 2008, NANOMEDICINE UK, V3, P703, DOI 10.2217/17435889.3.5.703
   Ma MX, 2020, INT IMMUNOPHARMACOL, V83, DOI 10.1016/j.intimp.2020.106388
   MacMillan AK, 2014, INT J NANOMED, V9, P5627, DOI 10.2147/IJN.S66852
   Meazza C, 2016, EXPERT REV ANTICANC, V16, P543, DOI 10.1586/14737140.2016.1168697
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   Nadar RA, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201601119
   Nikezic AVV, 2020, EUR J PHARM SCI, V151, DOI 10.1016/j.ejps.2020.105412
   Oertel S, 2010, TUMORI, V96, P582, DOI 10.1177/030089161009600411
   Ohba T, 2014, J BONE MINER RES, V29, P1431, DOI 10.1002/jbmr.2182
   Ohba T, 2014, BONE, V63, P110, DOI 10.1016/j.bone.2014.03.005
   Ouyang ZX, 2018, CURR DRUG TARGETS, V19, P409, DOI 10.2174/1573399811666150615145409
   Piperno Neumann S, 2016, LANCET ONCOL, V17, P1070, DOI 10.1016/S1470 2045(16)30096 1
   Proskuryakov SY, 2010, CURR PHARM DESIGN, V16, P56, DOI 10.2174/138161210789941793
   Reyes C, 2016, J CELL BIOCHEM, V117, P20, DOI 10.1002/jcb.25266
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Shmeeda H, 2013, J CONTROL RELEASE, V167, P265, DOI 10.1016/j.jconrel.2013.02.003
   Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630
   Valentin R, 2018, BLOOD, V132, P1248, DOI 10.1182/blood 2018 02 791350
   Wang LW, 2020, BMC CANCER, V20, DOI 10.1186/s12885 020 07568 9
   Wolfe TD, 2011, CLIN EXP METASTAS, V28, P377, DOI 10.1007/s10585 011 9377 9
   Wu HW, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.690409
   Wu J, 2021, J PERS MED, V11, DOI 10.3390/jpm11080771
   Wu X, 2021, ACS APPL MATER INTER, V13, P27920, DOI 10.1021/acsami.1c06059
   Xiao Z, 2018, CELL PHYSIOL BIOCHEM, V51, P1879, DOI 10.1159/000495714
   Xu Y, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.629928
   Yu SB, 2017, BMC CANCER, V17, DOI 10.1186/s12885 017 3047 5
NR 48
TC 19
Z9 20
U1 4
U2 33
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 4185
J9 FRONT BIOENG BIOTECH
JI Front. Bioeng. Biotechnol.
PD MAY 26
PY 2022
VL 10
AR 897641
DI 10.3389/fbioe.2022.897641
PG 14
WC Biotechnology & Applied Microbiology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering
GA 1Y6ZH
UT WOS:000808289800001
PM 35694235
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yao, Y
   Kauffmann, F
   Maekawa, S
   Sarment, LV
   Sugai, JV
   Schmiedeler, CA
   Doherty, EJ
   Holdsworth, G
   Kostenuik, PJ
   Giannobile, WV
AF Yao, Yao
   Kauffmann, Frederic
   Maekawa, Shogo
   Sarment, Lea V.
   Sugai, James V.
   Schmiedeler, Caroline A.
   Doherty, Edward J.
   Holdsworth, Gill
   Kostenuik, Paul J.
   Giannobile, William V.
TI Sclerostin antibody stimulates periodontal regeneration in large
   alveolar bone defects
SO SCIENTIFIC REPORTS
LA English
DT Article
ID IN VIVO; PARATHYROID HORMONE; GENE; BIODEGRADATION; ROMOSOZUMAB;
   BIOCOMPATIBILITY; MICROSPHERES; OSTEOCYTES; DELIVERY; CARRIERS
AB Destruction of the alveolar bone in the jaws can occur due to periodontitis, trauma or following tumor resection. Common reconstructive therapy can include the use of bone grafts with limited predictability and efficacy. Romosozumab, approved by the FDA in 2019, is a humanized sclerostin neutralizing antibody (Scl Ab) indicated in postmenopausal women with osteoporosis at high risk for fracture. Preclinical models show that Scl Ab administration preserves bone volume during periodontal disease, repairs bone defects surrounding dental implants, and reverses alveolar bone loss following extraction socket remodeling. To date, there are no studies evaluating Scl Ab to repair osseous defects around teeth or to identify the efficacy of locally delivered Scl Ab for targeted drug delivery. In this investigation, the use of systemically delivered versus low dose locally delivered Scl Ab via poly(lactic co glycolic) acid (PLGA) microspheres (MSs) was compared at experimentally created alveolar bone defects in rats. Systemic Scl Ab administration improved bone regeneration and tended to increase cementogenesis measured by histology and microcomputed tomography, while Scl Ab delivered by MSs did not result in enhancements in bone or cemental repair compared to MSs alone or control. In conclusion, systemic administration of Scl Ab promotes bone and cemental regeneration while local, low dose delivery did not heal periodontal osseous defects in this study.
C1 [Yao, Yao; Kauffmann, Frederic; Maekawa, Shogo; Sarment, Lea V.; Sugai, James V.; Schmiedeler, Caroline A.; Kostenuik, Paul J.; Giannobile, William V.] Univ Michigan, Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA.
   [Yao, Yao; Kauffmann, Frederic; Maekawa, Shogo; Sarment, Lea V.; Sugai, James V.; Schmiedeler, Caroline A.; Giannobile, William V.] Univ Michigan, Biointerfaces Inst, Ann Arbor, MI 48109 USA.
   [Giannobile, William V.] Univ Michigan, Coll Engn, Dept Biomed Engn, Ann Arbor, MI 48019 USA.
   [Kauffmann, Frederic] Univ Med Ctr Freiburg, Dept Oral & Craniomaxillofacial Surg, Ctr Dent Med, D 79110 Freiburg, Germany.
   [Maekawa, Shogo] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Periodontol, Tokyo 1138510, Japan.
   [Doherty, Edward J.] Harvard Univ, Wyss Inst Biol Inspired Engn, Boston, MA 02115 USA.
   [Holdsworth, Gill] UCB Pharma, Slough SL1 3WE, Berks, England.
   [Giannobile, William V.] Harvard Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan; University of Freiburg; Institute of Science
   Tokyo; Tokyo Medical & Dental University (TMDU); Harvard University; UCB
   Pharma SA; Harvard University; Harvard School of Dental Medicine
RP Giannobile, WV (通讯作者)，Univ Michigan, Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA.; Giannobile, WV (通讯作者)，Univ Michigan, Biointerfaces Inst, Ann Arbor, MI 48109 USA.; Giannobile, WV (通讯作者)，Univ Michigan, Coll Engn, Dept Biomed Engn, Ann Arbor, MI 48019 USA.; Giannobile, WV (通讯作者)，Harvard Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
EM William_Giannobile@hsdm.harvard.edu
RI Maekawa, Shogo/AAX 6288 2021; Yao, Yao/HZI 6533 2023
OI MAEKAWA, SHOGO/0000 0002 6207 7826; Yao, Yao/0000 0001 6713 874X
FU NIH/NIDCR [U24 DE026915]; UCB Pharma/Amgen Inc.; National Institute of
   Dental and Craniofacial Research [U24DE029462] Funding Source: NIH
   RePORTER
FX This study was supported by the NIH/NIDCR U24 DE026915 and UCB
   Pharma/Amgen Inc.
CR Anderson JM, 2012, ADV DRUG DELIVER REV, V64, P72, DOI 10.1016/j.addr.2012.09.004
   Axelrad TW, 2007, INJURY, V38, pS49, DOI 10.1016/j.injury.2007.02.010
   Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91
   Boyce Rogely Waite, 2018, Bone Rep, V8, P90, DOI 10.1016/j.bonr.2018.03.001
   Chang PC, 2012, J BIOMED MATER RES A, V100A, P2970, DOI 10.1002/jbm.a.34244
   Cirelli JA, 2009, GENE THER, V16, P426, DOI 10.1038/gt.2008.174
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Esposito M, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003607.pub3
   Hadaya D, 2019, J BONE MINER RES, V34, P171, DOI 10.1002/jbmr.3581
   Hansson Stig, 2012, J Dent Biomech, V3, p1758736012456543, DOI 10.1177/1758736012456543
   Hens JR, 2005, J BONE MINER RES, V20, P1103, DOI 10.1359/JBMR.050210
   Herford AS, 2011, ORAL MAXIL SURG CLIN, V23, P433, DOI 10.1016/j.coms.2011.04.004
   Hu ZA, 2018, ACS APPL MATER INTER, V10, P2377, DOI 10.1021/acsami.7b18458
   Jain A, 2016, ADV DRUG DELIVER REV, V107, P213, DOI 10.1016/j.addr.2016.07.002
   JEFFCOAT MK, 1993, J BONE MINER RES, V8, pS467
   Jin QM, 2003, J PERIODONTOL, V74, P202, DOI 10.1902/jop.2003.74.2.202
   Ke HZ, 2012, ENDOCR REV, V33, P747, DOI 10.1210/er.2011 1060
   Kim SW, 2017, J BONE MINER RES, V32, P892, DOI 10.1002/jbmr.3038
   Larsson L, 2016, J DENT RES, V95, P255, DOI 10.1177/0022034515618887
   Leupin O, 2011, J BIOL CHEM, V286, P19489, DOI 10.1074/jbc.M110.190330
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Liu M, 2018, J DENT RES, V97, P1031, DOI 10.1177/0022034518766874
   Lü JM, 2009, EXPERT REV MOL DIAGN, V9, P325, DOI 10.1586/ERM.09.15
   Markham A, 2019, DRUGS, V79, P471, DOI 10.1007/s40265 019 01072 6
   Minisola S, 2014, EXPERT OPIN BIOL TH, V14, P1225, DOI 10.1517/14712598.2014.920815
   Ominsky MS, 2015, BONE, V81, P380, DOI 10.1016/j.bone.2015.08.007
   Ominsky MS, 2014, J BONE MINER RES, V29, P1424, DOI 10.1002/jbmr.2152
   Ominsky MS, 2017, BONE, V96, P63, DOI 10.1016/j.bone.2016.10.019
   Padial Molina M, 2015, NAT PROTOC, V10, P1038, DOI 10.1038/nprot.2015.063
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Pritchard EM, 2011, EXPERT OPIN DRUG DEL, V8, P797, DOI 10.1517/17425247.2011.568936
   Qu XH, 2006, BIOMATERIALS, V27, P3540, DOI 10.1016/j.biomaterials.2006.02.015
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Santoro M, 2014, J CONTROL RELEASE, V190, P210, DOI 10.1016/j.jconrel.2014.04.014
   Tan WL, 2012, CLIN ORAL IMPLAN RES, V23, P1, DOI 10.1111/j.1600 0501.2011.02375.x
   Taut AD, 2013, J BONE MINER RES, V28, P2347, DOI 10.1002/jbmr.1984
   Tu XL, 2015, P NATL ACAD SCI USA, V112, pE478, DOI 10.1073/pnas.1409857112
   van Lierop AH, 2011, J BONE MINER RES, V26, P2804, DOI 10.1002/jbmr.474
   Vaquette C, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201800457
   Versypt ANF, 2013, J CONTROL RELEASE, V165, P29, DOI 10.1016/j.jconrel.2012.10.015
   Virdi AS, 2012, J BONE JOINT SURG AM, V94A, P1670, DOI 10.2106/JBJS.K.00344
   Virk MS, 2013, J BONE JOINT SURG AM, V95A, P694, DOI 10.2106/JBJS.L.00285
   VISSCHER GE, 1985, J BIOMED MATER RES, V19, P349, DOI 10.1002/jbm.820190315
   Washington MA, 2018, ACTA BIOMATER, V65, P259, DOI 10.1016/j.actbio.2017.10.043
   Wei GB, 2004, BIOMATERIALS, V25, P345, DOI 10.1016/S0142 9612(03)00528 3
   Yu SH, 2018, TISSUE ENG PT A, V24, P1672, DOI [10.1089/ten.tea.2018.0013, 10.1089/ten.TEA.2018.0013]
NR 46
TC 34
Z9 37
U1 1
U2 17
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD OCT 1
PY 2020
VL 10
IS 1
AR 16217
DI 10.1038/s41598 020 73026 y
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA NZ5KZ
UT WOS:000577142600029
PM 33004873
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Mills, LJ
   Spector, LG
   Largaespada, DA
   Williams, LA
AF Mills, Lauren J.
   Spector, Logan G.
   Largaespada, David A.
   Williams, Lindsay A.
TI Sex differences in expression of immune elements emerge in children,
   young adults and mice with osteosarcoma
SO BIOLOGY OF SEX DIFFERENCES
LA English
DT Article
DE Osteosarcoma; Sex differences; Gene expression; Survival disparities;
   Pediatric and young adult cancer; Mouse osteosarcoma
ID PATHWAY; REARRANGEMENT; PROGRESSION; SURVIVAL; BIOLOGY
AB BackgroundMales < 40years old are more likely to be diagnosed with and die from osteosarcoma (OS). The underlying mechanisms may depend on sex differences in immune response.MethodsWe used SEER data to estimate survival differences between males and females aged < 40years at OS diagnosis. In NCI TARGET OS cases, we determined sex differences in gene expression, conducted Gene Set Enrichment Analysis (GSEA), and applied the LM22 signature to identify biologic sex differences. We compared sex differences in gene expression profiles in TARGET OS to those observed in Sleeping Beauty (SB) transposon mutagenesis accelerated Trp53(R270H) mutant mouse OS and healthy adult osteoblasts.ResultsMales had worse 17 year overall survival than females (SEER p < 0.0001). From 87 TARGET OS cases, we observed 1018 genes and 69 pathways that differed significantly by sex (adjusted p < 0.05). Pathway and gene lists overlapped with those from mice (p = 0.03) and healthy osteoblasts (p = 0.017), respectively. Pathways that differed significantly by sex were largely immune based and included the PD 1/PD L1 immunotherapy pathway. We observed sex differences in M2 macrophages (LM22; p = 0.056) and M1 M2 macrophage transition (GSEA; p = 0.037) in TARGET OS. LM22 trends were similar in mice. Twenty four genes differentially expressed by sex in TARGET OS had existing cancer therapies.ConclusionsSex differences in OS gene expression were similar across species and centered on immune pathways. Identified sex specific therapeutic targets may improve outcomes in young individuals with OS.
C1 [Mills, Lauren J.; Spector, Logan G.; Largaespada, David A.; Williams, Lindsay A.] Univ Minnesota, Sch Med, Dept Pediat, Minneapolis, MN 55455 USA.
   [Mills, Lauren J.; Spector, Logan G.; Largaespada, David A.; Williams, Lindsay A.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA.
   [Spector, Logan G.; Williams, Lindsay A.] Univ Minnesota, Dept Pediat, Div Epidemiol & Clin Res, Minneapolis, MN 55455 USA.
   [Largaespada, David A.; Williams, Lindsay A.] Univ Minnesota, Brain Tumor Program, Minneapolis, MN 55455 USA.
   [Largaespada, David A.] Univ Minnesota, Sch Med, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA.
   [Largaespada, David A.] Univ Minnesota, Ctr Genome Engn, Minneapolis, MN USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities
RP Williams, LA (通讯作者)，Univ Minnesota, Sch Med, Dept Pediat, Minneapolis, MN 55455 USA.; Williams, LA (通讯作者)，Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA.; Williams, LA (通讯作者)，Univ Minnesota, Dept Pediat, Div Epidemiol & Clin Res, Minneapolis, MN 55455 USA.; Williams, LA (通讯作者)，Univ Minnesota, Brain Tumor Program, Minneapolis, MN 55455 USA.
EM lawilliams@umn.edu
RI ; Mills, Lauren/HTM 1052 2023; Largaespada, David/C 9832 2014
OI Williams, Lindsay/0000 0003 3842 4629; Mills,
   Lauren/0000 0002 8914 2587; Spector, Logan/0000 0003 2516 0222
FU Zach Sobiech Osteosarcoma Fund; American Cancer Society; Children's
   Cancer Research Fund
FX This work was supported by the Zach Sobiech Osteosarcoma Fund (LJM), the
   American Cancer Society Research Professorship (DAL), and the Children's
   Cancer Research Fund (LAW).
CR Aras S, 2017, BRIT J CANCER, V117, P1583, DOI 10.1038/bjc.2017.356
   Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI [10.1093/nar/gkt1102, 10.1093/nar/gkz1031]
   Diessner BJ, 2019, CANCER MED US, V8, P3216, DOI 10.1002/cam4.2177
   Dumars C, 2016, ONCOTARGET, V7, P78343, DOI 10.18632/oncotarget.13055
   FREBOURG T, 1995, AM J HUM GENET, V56, P608
   Gianferante DM, 2017, NAT REV ENDOCRINOL, V13, P480, DOI 10.1038/nrendo.2017.16
   Goldman MJ, 2020, NAT BIOTECHNOL, V38, P675, DOI 10.1038/s41587 020 0546 8
   Granados A, 2015, J CLIN RES PEDIATR E, V7, P235, DOI 10.4274/jcrpe.2007
   Gröbner SN, 2018, NATURE, V555, P321, DOI 10.1038/nature25480
   Grundberg E, 2009, GENOME RES, V19, P1942, DOI 10.1101/gr.095224.109
   Guo Z, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1618 x
   Heymann MF, 2019, CELL IMMUNOL, V343, DOI 10.1016/j.cellimm.2017.10.011
   Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895
   Kamitaki N, 2020, NATURE, V582, P577, DOI 10.1038/s41586 020 2277 x
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838
   Kim JY, 2016, CANCER RES TREAT, V48, P1338, DOI 10.4143/crt.2015.430
   Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90
   Lau CC, 2004, GENE CHROMOSOME CANC, V39, P11, DOI 10.1002/gcc.10291
   Lee J, 2019, THORAC CANCER, V10, P103, DOI 10.1111/1759 7714.12917
   Li XY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0474 4
   Libert C, 2010, NAT REV IMMUNOL, V10, P594, DOI 10.1038/nri2815
   Liu XQ, 2019, ENVIRON HEALTH PREV, V24, DOI 10.1186/s12199 019 0835 3
   Lussier DM, 2015, J IMMUNOTHER, V38, P96, DOI 10.1097/CJI.0000000000000065
   Mirabello L, 2020, JAMA ONCOL, V6, P724, DOI 10.1001/jamaoncol.2020.0197
   Mirabello L, 2015, JNCI J NATL CANCER I, V107, DOI 10.1093/jnci/djv101
   Mirabello L, 2011, CANCER CAUSE CONTROL, V22, P899, DOI 10.1007/s10552 011 9763 2
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   Moriarity BS, 2015, NAT GENET, V47, P615, DOI 10.1038/ng.3293
   Mutsaers AJ, 2014, BONE, V62, P56, DOI 10.1016/j.bone.2014.02.003
   Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]
   Perry JA, 2014, P NATL ACAD SCI USA, V111, pE5564, DOI 10.1073/pnas.1419260111
   Piccini P, 2018, ITAL J PEDIATR, V44, DOI 10.1186/s13052 017 0437 x
   Roberts SS, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00181
   Scott MC, 2018, CANCER RES, V78, P326, DOI 10.1158/0008 5472.CAN 17 0576
   Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Wang S, 2019, MOLECULES, V24, DOI 10.3390/molecules24010075
   WASHBURN TC, 1965, PEDIATRICS, V35, P57
   Williams LA, 2019, JNCI CANCER SPECT, V3, DOI 10.1093/jncics/pkz032
   Williams LA, 2019, PEDIATR BLOOD CANCER, V66, DOI 10.1002/pbc.27620
   Wu CC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 14646 w
   Ye YQ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 15679 x
   Zhu ZH, 2017, ONCOTARGET, V8, P59570, DOI 10.18632/oncotarget.19168
NR 43
TC 11
Z9 11
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2042 6410
J9 BIOL SEX DIFFER
JI Biol. Sex Differ.
PD JAN 6
PY 2021
VL 12
IS 1
AR 5
DI 10.1186/s13293 020 00347 y
PG 12
WC Endocrinology & Metabolism; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Genetics & Heredity
GA PS9JB
UT WOS:000608236900003
PM 33407928
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Jorgensen, NR
   Teilmann, SC
   Henriksen, Z
   Meier, E
   Hansen, SS
   Jensen, JEB
   Sorensen, OH
   Petersen, JS
AF Jorgensen, NR
   Teilmann, SC
   Henriksen, Z
   Meier, E
   Hansen, SS
   Jensen, JEB
   Sorensen, OH
   Petersen, JS
TI The antiarrhythmic peptide analog rotigaptide (ZP123) stimulates gap
   junction intercellular communication in human osteoblasts and prevents
   decrease in femoral trabecular bone strength in ovariectomized rats
SO ENDOCRINOLOGY
LA English
DT Article
ID CONNEXIN43; DDT; CONDUCTANCE; EXPRESSION; ISCHEMIA
AB Gap junctions play an important role in bone development and function, but the lack of pharmacological tools has hampered the gap junction research. The antiarrhythmic peptides stimulate gap junction communication between cardiomyocytes, but effects in noncardiac tissue are unknown. The purpose of this study was to examine whether antiarrhythmic peptides, which are small peptides increasing gap junctional conductivity, show specific binding to osteoblasts and investigate the effect of the stable analog rotigaptide ( ZP123) on gap junctional intercellular communication in vitro and on bone mass and strength in vivo. Cell coupling and calcium signaling were assessed in vitro on human, primary, osteoblastic cells. In vivo effects of rotigaptide on bone strength and density were determined 4 wk after ovariectomy in rats treated with either vehicle, sc injection twice daily ( 300 nmol per kilogram body weight) or by continuous ip infusion ( 158 nmol per kilogram body weight per day). During metabolic stress, a high affinity  binding site ( K D = 0.1 nM) with low density ( 15 fmol/ mg protein) for [ I 125] di  I  AAP10 was demonstrated. During physiological conditions, specific binding sites for [I 125] AAP10 could not be shown. Studies of the effects of rotigaptide on propagation of intercellular calcium waves and cell  to  cell coupling demonstrated that 10 nM rotigaptide produced a small increase in intercellular communication during physiological conditions ( + 4.5 +/  1.6% vs. vehicle; P < 0.05). During conditions with metabolic stress, 10 nM rotigaptide produced an increase in coupling measured by both methods. Four weeks after ovariectomy, bone strength of the femoral head was reduced by 20% in vehicle  treated ovariectomized rats, which was completely prevented in both rotigaptide  treated groups. Rotigaptide also prevented decreases in bone mineral. We conclude that the stable analog rotigaptide increases gap junctional communication in osteoblasts in vitro and preferably during conditions with metabolic stress. Rotigaptide further prevents ovariectomy  induced bone loss in vivo. Thus, gap junction modulation may be a promising new target for osteoporosis therapy.
C1 Univ Copenhagen, Dept Endocrinol & Clin Biochem, Osteoporosis & Metab Bone Unit, DK 2650 Hvidovre, Denmark.
   Zealand Pharma AS, DK 2600 Glostrup, Denmark.
C3 University of Copenhagen; Zealand Pharma A/S
RP Jorgensen, NR (通讯作者)，Univ Copenhagen, Hvidovre Hosp, Dept 545, Osteoporosis Res Clin, Kettegaard Alle 30, DK 2650 Hvidovre, Denmark.
EM niklas@dadlnet.dk
RI Jørgensen, Niklas/B 6003 2012
OI Jorgensen, Niklas Rye/0000 0001 9624 5210; Jensen, Jens Erik
   Beck/0000 0003 4290 0480
CR AONUMA S, 1980, CHEM PHARM BULL, V28, P3332
   CHIBA H, 1993, CELL STRUCT FUNCT, V18, P419, DOI 10.1247/csf.18.419
   CIVITELLI R, 1993, J CLIN INVEST, V91, P1888, DOI 10.1172/JCI116406
   Daleau P, 1998, J PHARMACOL EXP THER, V284, P1174
   DAndrea P, 1996, CELL CALCIUM, V20, P389, DOI 10.1016/S0143 4160(96)90001 9
   DELMAR M, 2000, CARDIAC ELECTROPHYSI
   DHEIN S, 1994, N S ARCH PHARMACOL, V350, P174
   DONAHUE HJ, 1995, J BONE MINER RES, V10, P1359
   Donahue HJ, 1998, CALCIFIED TISSUE INT, V62, P85, DOI 10.1007/s002239900398
   Donahue HJ, 2000, BONE, V26, P417, DOI 10.1016/S8756 3282(00)00245 3
   Duffy HS, 2002, J BIOL CHEM, V277, P36706, DOI 10.1074/jbc.M207016200
   Eloff BC, 2003, CIRCULATION, V108, P3157, DOI 10.1161/01.CIR.0000101926.43759.10
   GOLDBERG GS, 1995, BIOTECHNIQUES, V18, P490
   Guan XJ, 1996, CARCINOGENESIS, V17, P1791, DOI 10.1093/carcin/17.9.1791
   Jorgensen NR, 1997, J CELL BIOL, V139, P497, DOI 10.1083/jcb.139.2.497
   Jorgensen NR, 2000, J BONE MINER RES, V15, P1024, DOI 10.1359/jbmr.2000.15.6.1024
   Kjolbye AL, 2003, J PHARMACOL EXP THER, V306, P1191, DOI 10.1124/jpet.103.052258
   Koenig Jennifer A., 1999, V106, P89
   Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092 8674(00)81282 9
   Lecanda F, 1998, MOL BIOL CELL, V9, P2249, DOI 10.1091/mbc.9.8.2249
   Lecanda F, 2000, J CELL BIOL, V151, P931, DOI 10.1083/jcb.151.4.931
   Lerner DL, 2001, CARDIOVASC RES, V50, P263, DOI 10.1016/S0008 6363(00)00301 1
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MADHUKAR BV, 1983, CANCER LETT, V18, P251, DOI 10.1016/0304 3835(83)90233 1
   Muller A, 1997, EUR J PHARMACOL, V327, P65, DOI 10.1016/S0014 2999(97)89679 3
   Nielsen M, 2000, BIOCHEM BIOPH RES CO, V275, P804, DOI 10.1006/bbrc.2000.3378
   RUCH RJ, 1994, CARCINOGENESIS, V15, P301, DOI 10.1093/carcin/15.2.301
   STEINBERG TH, 1994, EMBO J, V13, P744, DOI 10.1002/j.1460 2075.1994.tb06316.x
   Tiemann U, 1998, REPROD TOXICOL, V12, P551, DOI 10.1016/S0890 6238(98)00034 3
   TUNCAY OC, 1994, AM J ORTHOD DENTOFAC, V105, P457, DOI 10.1016/S0889 5406(94)70006 0
   Turusov V, 2002, ENVIRON HEALTH PERSP, V110, P125, DOI 10.1289/ehp.02110125
   Xing DZ, 2003, J CARDIOVASC ELECTR, V14, P510, DOI 10.1046/j.1540 8167.2003.02329.x
   Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199
   Ziambaras K, 1998, J BONE MINER RES, V13, P218, DOI 10.1359/jbmr.1998.13.2.218
NR 34
TC 30
Z9 33
U1 0
U2 2
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD NOV
PY 2005
VL 146
IS 11
BP 4745
EP 4754
DI 10.1210/en.2004 1414
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 974IP
UT WOS:000232585200021
PM 16109789
OA Bronze
DA 2025 08 17
ER

PT J
AU Chen, M
   Zhou, SQ
   Sun, K
   Hu, YJ
   Wen, HY
   Ren, GL
AF Chen, Ming
   Zhou, Siqi
   Sun, Kai
   Hu, Yongjun
   Wen, Haiyan
   Ren, Geliang
TI Andrographolide protects BMSCs from dexamethasone induced cellular
   dysfunction and promotes bone formation via the PI3K/AKT pathway
SO JOURNAL OF FUNCTIONAL FOODS
LA English
DT Article
DE Osteoporosis; Andrographolide; Dexamethasone; PI3K/AKT; Bone marrow
   mesenchymal cells
ID MESENCHYMAL STEM CELLS; DIFFERENTIATION; APOPTOSIS; OSTEOCLASTOGENESIS;
   OSTEOPOROSIS; OSTEOGENESIS; OSTEOBLAST
AB Osteoporosis is a common metabolic disease with high morbidity and mortality in the elderly, bringing a heavy socioeconomic burden. Excess use of glucocorticoid is the main cause of secondary Osteoporosis, and there are limited therapies for glucocorticoid induced osteoporosis (GIOP) treatment. In this study, we explored the protective effect of andrographolide (AGP) on dexamethasone (DEX) induced dysfunction and osteogenic inhibition in vitro and in vivo. The results showed that AGP could alleviate DEX induced cytotoxicity, apoptosis and senescence in BMSCs. AGP also increased the level of calcium nodules, RUNX2, COL1A1, OCN and ALP in DEXtreated BMSCs, suggesting that AGP promoted osteogenic differentiation. We found that AGP activated PI3K/ AKT signaling pathways and the PI3K inhibitor LY294002 reversed the protective effects of AGP. Additionally, in the GIOP mice model, AGP alleviated bone loss in vivo. In conclusion, these results demonstrated that AGP has a protective effect and promoted bone formation against GIOP through PI3K/AKT pathway.
C1 [Chen, Ming; Hu, Yongjun; Ren, Geliang] Anhui Univ Sci & Technol, Hosp 1, Dept Orthoped, Huainan 232000, Peoples R China.
   [Chen, Ming; Zhou, Siqi; Sun, Kai] Wuhan Univ, Renmin Hosp, Dept Orthoped, Wuhan 430060, Peoples R China.
   [Wen, Haiyan] Wuhan Univ, Renmin Hosp, Dept Pharm, Wuhan 430060, Peoples R China.
C3 Anhui University of Science & Technology; Wuhan University; Wuhan
   University
RP Ren, GL (通讯作者)，Anhui Univ Sci & Technol, Hosp 1, Dept Orthoped, Huainan 232000, Peoples R China.; Wen, HY (通讯作者)，Wuhan Univ, Renmin Hosp, Dept Pharm, Wuhan 430060, Peoples R China.
EM why123@whu.edu.cn; rengeliang 1983@163.com
RI Sun, Kai/GXM 4359 2022
FU Fundamental Research Funds for the Central Universities [2042023kf0034,
   2042023kf0049]; Science and Technology Bureau Project of Huainan City,
   Anhui Province [2021148, 2020033]
FX Acknowledgments This research was supported by the Fundamental Research
   Funds for the Central Universities (No. 2042023kf0034 and 2042023kf0049)
   and the Science and Technology Bureau Project of Huainan City, Anhui
   Province under Grant (No. 2021148 and 2020033) .
CR Adami G, 2019, OSTEOPOROSIS INT, V30, P1145, DOI 10.1007/s00198 019 04906 x
   Adler RA, 2016, J BONE MINER RES, V31, P16, DOI 10.1002/jbmr.2708
   Almalki SG, 2016, DIFFERENTIATION, V92, P41, DOI 10.1016/j.diff.2016.02.005
   Binkley N, 2018, OSTEOPOROSIS INT, V29, P999, DOI 10.1007/s00198 018 4385 0
   Buehring B, 2013, J ALLERGY CLIN IMMUN, V132, P1019, DOI 10.1016/j.jaci.2013.08.040
   Chan WCW, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115445
   Chang YY, 2019, J ORTHOP TRANSL, V19, P47, DOI 10.1016/j.jot.2019.02.001
   Chen M, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/6821170
   Chen X, 2021, BONE JOINT RES, V10, P237, DOI 10.1302/2046 3758.104.BJR 2020 0255.R2
   Chotiyarnwong P, 2020, NAT REV ENDOCRINOL, V16, P437, DOI 10.1038/s41574 020 0341 0
   Compston J, 2018, ENDOCRINE, V61, P7, DOI 10.1007/s12020 018 1588 2
   Ebeling PR, 2022, ENDOCR REV, V43, P240, DOI 10.1210/endrev/bnab028
   Hu YJ, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.680127
   Huang TL, 2021, BRIT J PHARMACOL, V178, P4352, DOI 10.1111/bph.15614
   Jayakumar T, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/846740
   Kaewkittikhun M, 2021, J AGR FOOD CHEM, V69, P9259, DOI 10.1021/acs.jafc.1c02724
   Kondo T, 2008, J CELL BIOCHEM, V103, P335, DOI 10.1002/jcb.21414
   Kong YH, 2022, BIOENGINEERED, V13, P10640, DOI 10.1080/21655979.2022.2065753
   Lai WX, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.722175
   Luo SS, 2020, CHEM BIOL INTERACT, V319, DOI 10.1016/j.cbi.2020.108984
   Lv WX, 2021, MOL MED REP, V23, DOI 10.3892/mmr.2021.11984
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Pan JM, 2019, J RECEPT SIG TRANSD, V39, P80, DOI 10.1080/10799893.2019.1625061
   Phunikom N, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02312 x
   Qiao LC, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111932
   Ramirez Perez S, 2022, ISCIENCE, V25, DOI 10.1016/j.isci.2022.105548
   Samakova A, 2019, PHYSIOL RES, V68, pS131, DOI 10.33549/physiolres.934345
   Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221
   Talaber G, 2011, REJUV RES, V14, P241, DOI 10.1089/rej.2010.1110
   Vandewalle J, 2018, TRENDS ENDOCRIN MET, V29, P42, DOI 10.1016/j.tem.2017.10.010
   Wang J, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.899775
   Wang TT, 2020, APOPTOSIS, V25, P157, DOI 10.1007/s10495 020 01599 0
   Wang Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 19360 1
   Wen L, 2014, EUR J PHARMACOL, V740, P421, DOI 10.1016/j.ejphar.2014.06.053
   Xie XD, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.826023
   Xu WN, 2020, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00922
   Yang KD, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.829830
   Yao Q, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392 023 01330 w
   Zeng B, 2022, PHYTOTHER RES, V36, P336, DOI 10.1002/ptr.7324
   Zhan JD, 2020, FOOD FUNCT, V11, P7830, DOI [10.1039/d0fo00837k, 10.1039/D0FO00837K]
   Zhang LM, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.744647
   Zhang Y, 2020, J CELL PHYSIOL, V235, P5511, DOI 10.1002/jcp.29261
   Zhou PY, 2019, ARTIF CELL NANOMED B, V47, P3720, DOI 10.1080/21691401.2019.1664563
NR 44
TC 2
Z9 2
U1 4
U2 36
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1756 4646
EI 2214 9414
J9 J FUNCT FOODS
JI J. Funct. Food.
PD JUN
PY 2023
VL 105
AR 105576
DI 10.1016/j.jff.2023.105576
EA MAY 2023
PG 11
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA J9XU1
UT WOS:001013090500001
OA gold
DA 2025 08 17
ER

PT J
AU Grey, A
   Bolland, M
   Gamble, G
   Wattie, D
   Horne, A
   Davidson, J
   Reid, IR
AF Grey, Andrew
   Bolland, Mark
   Gamble, Greg
   Wattie, Diana
   Horne, Anne
   Davidson, James
   Reid, Ian R.
TI The peroxisome proliferator activated receptor γ agonist rosiglitazone
   decreases bone formation and bone mineral density in healthy
   postmenopausal women:: A randomized, controlled trial
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID TYPE 2 DIABETES MELLITUS; IMPAIRED FASTING GLUCOSE; FRACTURE RISK;
   OSTEOBLAST DIFFERENTIATION; BODY COMPOSITION; OLDER WHITE; IN VITRO;
   THIAZOLIDINEDIONES; TURNOVER; MICE
AB Context: Thiazolidinediones, which are peroxisome proliferator activated receptor gamma agonists, are widely prescribed to patients with disorders characterized by insulin resistance. Preclinical studies suggest that peroxisome proliferator activated receptor gamma signaling negatively regulates bone formation and bone density. Human data on the skeletal effects of thiazolidinediones are currently available only from observational studies.
   Objective: The objective of the study was to determine whether rosiglitazone, a thiazolidinedione, inhibits bone formation.
   Design: The study was a 14 wk randomized, double blind, placebo controlled trial.
   Setting: The study was conducted in the general community.
   Patients: Fifty healthy, postmenopausal women participated in the study.
   Intervention: Intervention was rosiglitazone 8 mg/d.
   Main Outcome Measures: The primary end point was biochemical markers of bone formation, and secondary end points were a bone resorption marker and bone mineral density.
   Results: The osteoblast markers procollagen type I N terminal propeptide and osteocalcin declined by 13% (P < 0.005 vs. placebo) and 10% (P = 0.04 vs. placebo), respectively, in the rosiglitazone group. These changes were evident by 4 wk and persisted for the duration of the study. There was no change in the serum beta C terminal telopeptide of type I collagen, a marker of bone resorption (P = 0.9 vs. placebo). Total hip bone density fell in the rosiglitazone group (mean change from baseline rosiglitazone  1.9%, placebo  0.2%; between group difference 1.7%, 95% confidence interval 0.6 2.7, P < 0.01); lumbar spine bone density fell significantly from baseline values in the rosiglitazone group (P = 0.02 vs. baseline) but was not significantly different between groups (mean change from baseline rosiglitazone  1.2%, placebo  0.2%; between group difference 1.0%, 95% confidence interval  0.2 2.3, P = 0.13).
   Conclusions: Short term therapy with rosiglitazone exerts detrimental skeletal effects by inhibiting bone formation. Skeletal end points should be included in future long term studies of thiazolidinedione use.
C1 Univ Auckland, Dept Med, Auckland 1020, New Zealand.
   Auckland City Hosp, LabPlus, Auckland 1020, New Zealand.
C3 University of Auckland; Auckland City Hospital
RP Grey, A (通讯作者)，Univ Auckland, Dept Med, Private Bag 92019, Auckland 1020, New Zealand.
EM a.grey@auckland.ac.nz
RI ; Bolland, Mark/A 7554 2008
OI Horne, Anne/0000 0003 2783 7452; Bolland, Mark/0000 0003 0465 2674;
   Reid, Ian/0000 0001 6021 5458
CR Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Ali AA, 2005, ENDOCRINOLOGY, V146, P1226, DOI 10.1210/en.2004 0735
   Bonds DE, 2006, J CLIN ENDOCR METAB, V91, P3404, DOI 10.1210/jc.2006 0614
   Cornish J, 1998, AM J PHYSIOL ENDOC M, V275, pE694, DOI 10.1152/ajpendo.1998.275.4.E694
   Cornish J, 1996, CALCIFIED TISSUE INT, V59, P492, DOI 10.1007/BF00369216
   Cornish J, 2002, J ENDOCRINOL, V175, P405, DOI 10.1677/joe.0.1750405
   de Liefde II, 2005, OSTEOPOROSIS INT, V16, P1713, DOI 10.1007/s00198 005 1909 1
   Dormandy JA, 2005, LANCET, V366, P1279, DOI 10.1016/S0140 6736(05)67528 9
   Ehrmann DA, 2005, NEW ENGL J MED, V352, P1223, DOI 10.1056/NEJMra041536
   Gerstein HC, 2006, LANCET, V368, P1096, DOI 10.1016/S0140 6736(06)69420 8
   Gimble JM, 1996, MOL PHARMACOL, V50, P1087
   JENNERMANN C, 1995, J BONE MINER RES, V10, pS241
   Justesen J, 2004, ENDOCRINOLOGY, V145, P1916, DOI 10.1210/en.2003 1427
   Kahn SE, 2006, NEW ENGL J MED, V355, P2427, DOI 10.1056/NEJMoa066224
   Kawaguchi H, 2005, J BONE MINER METAB, V23, P275, DOI 10.1007/s00774 005 0599 2
   Kendall DM, 2006, DIABETES CARE, V29, P154, DOI 10.2337/diacare.29.1.154
   Khan E, 2003, J LAB CLIN MED, V142, P29, DOI 10.1016/S0022 2143(03)00058 1
   Lazarenko OP, 2006, BONE, V38, P74, DOI 10.1016/j.bone.2005.07.008
   Lecka Czernik B, 2002, ENDOCRINOLOGY, V143, P2376, DOI 10.1210/en.143.6.2376
   Lecka Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097 4644(19990901)74:3<357::AID JCB5>3.0.CO;2 7
   Li M, 2006, BONE, V39, P796, DOI 10.1016/j.bone.2006.04.008
   Mbalaviele G, 2000, J BIOL CHEM, V275, P14388, DOI 10.1074/jbc.275.19.14388
   Nicodemus KK, 2001, DIABETES CARE, V24, P1192, DOI 10.2337/diacare.24.7.1192
   Okazaki R, 1997, J CLIN ENDOCR METAB, V82, P2915, DOI 10.1210/jc.82.9.2915
   Okazaki R, 1999, ENDOCR J, V46, P795, DOI 10.1507/endocrj.46.795
   Okazaki R, 1999, ENDOCRINOLOGY, V140, P5060, DOI 10.1210/en.140.11.5060
   Pei LM, 2004, J CLIN INVEST, V113, P805, DOI 10.1172/JCI200421311
   Reid IR, 1997, EUR J ENDOCRINOL, V137, P209, DOI 10.1530/eje.0.1370209
   Reid IR, 2005, J CLIN ENDOCR METAB, V90, P5212, DOI 10.1210/jc.2005 0573
   Reid IR, 2004, BONE, V35, P224, DOI 10.1016/j.bone.2004.03.023
   Rzonca SO, 2004, ENDOCRINOLOGY, V145, P401, DOI 10.1210/en.2003 0746
   Schwartz AV, 2006, J CLIN ENDOCR METAB, V91, P3349, DOI 10.1210/jc.2005 2226
   Sorocéanu MA, 2004, J ENDOCRINOL, V183, P203, DOI 10.1677/joe.1.05723
   Staels B, 2005, DIABETES, V54, P2460, DOI 10.2337/diabetes.54.8.2460
   Strotmeyer ES, 2005, ARCH INTERN MED, V165, P1612, DOI 10.1001/archinte.165.14.1612
   Strotmeyer ES, 2004, J BONE MINER RES, V19, P1084, DOI 10.1359/JBMR.040311
   Syversen U, 2003, J BONE MINER RES, V18, pS42
   Taylor BC, 2004, J AM GERIATR SOC, V52, P1479, DOI 10.1111/j.1532 5415.2004.52410.x
   Ton FN, 2005, J BONE MINER RES, V20, P464, DOI 10.1359/JBMR.041125
   Truxillo C., 2005, SAS US GROUP INT C P
   Vestergaard P, 2005, DIABETOLOGIA, V48, P1292, DOI 10.1007/s00125 005 1786 3
   Watanabe S, 2003, J BONE MINER METAB, V21, P166, DOI 10.1007/s007740300026
   Yki Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001
   Yki Järvinen H, 2005, LANCET, V366, P1241, DOI 10.1016/S0140 6736(05)67504 6
NR 44
TC 335
Z9 361
U1 0
U2 8
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815 5817 USA
SN 0021 972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD APR
PY 2007
VL 92
IS 4
BP 1305
EP 1310
DI 10.1210/jc.2006 2646
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 153WH
UT WOS:000245466600020
PM 17264176
OA Bronze
DA 2025 08 17
ER

PT J
AU Bondar, C
   Mucci, J
   Crivaro, A
   Ormazabal, M
   Ceci, R
   Oliveri, B
   González, D
   Rozenfeld, P
AF Bondar, C.
   Mucci, J.
   Crivaro, A.
   Ormazabal, M.
   Ceci, R.
   Oliveri, B.
   Gonzalez, D.
   Rozenfeld, P.
TI In vitro osteoclastogenesis from Gaucher patients' cells
   correlates with bone mineral density but not with Chitotriosidase
SO BONE
LA English
DT Article
DE Gaucher disease; Bone pathology; Osteoclasts; Chitotriosidase; Bone
   mineral density
ID ENZYME REPLACEMENT THERAPY; MARROW BURDEN SCORE; VELAGLUCERASE ALPHA;
   DISEASE TYPE 1; ADULT PATIENTS; IMMUNE SYSTEM; T CELLS; MANIFESTATIONS;
   INVOLVEMENT; MACROPHAGES
AB Gaucher disease (GD) is caused by mutations on the gene encoding for the lysosomal enzyme glucocerebrosidase. Type I GD (GD1) patients present anemia, hepatosplenomegaly and bone alterations. In spite of treatment, bone alterations in GD patients persist, including poor bone mineral density (BMD). Mechanisms leading to bone damage are not completely understood, but previous reports suggest that osteoclasts are involved. Chitotriosidase (CHIT) is the most reliable biomarker used in the follow up of patients, although its correlation with bone status is unknown. The aim of this work was to study the pro osteoclastogenic potential in patients and to evaluate its correlation with CHIT activity levels and clinical parameters. PBMC5 from treated patients and healthy controls were cultured in the presence of M CSF, and mature osteoclasts were counted. BMD, blood CHIT activity and serum levels of CTX, BAP, and cytokines were evaluated in patients. We found that blood CHIT activity and osteoclast differentiation were significantly increased in patients, but no correlation between them was observed. Interestingly, osteoclast numbers but not CHIT, presented a negative correlation with BMD expressed as Z score. CTX, BAP and serum cytokines involved in bone remodeling were found altered in GD1 patients. These results show for the first time a correlation between osteoclast differentiation and BMD in GD1 patients, supporting the involvement of osteoclasts in the bone pathology of GD1. Our results also suggest that an altered immune response may play an important role in bone damage. (C) 2017 Elsevier Inc All rights reserved.
C1 [Bondar, C.; Mucci, J.; Crivaro, A.; Ormazabal, M.; Ceci, R.; Rozenfeld, P.] Univ Nacl La Plata, CONICET, Fac Ciencias Exactas, IIFP,Dept Ciencias Biol, 47 & 115, RA 1900 La Plata, Buenos Aires, Argentina.
   [Oliveri, B.] UBA Hosp Clin, CONICET, Inst Inmunol Genet & Metab INIGEM, Lab Osteoporosis & Enfermedades Metabol Oseas, Buenos Aires, DF, Argentina.
   [Gonzalez, D.] Mautalen Salud & Invest, Bs As, Argentina.
C3 Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET);
   National University of La Plata; Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET)
RP Rozenfeld, P (通讯作者)，Univ Nacl La Plata, CONICET, CCTLa Plata, Fac Ciencias Exactas,IIFP,Dept Ciencias Biol, 47 & 115, RA 1900 La Plata, Buenos Aires, Argentina.
EM paurozen@biol.unlp.edu.ar
OI Ormazabal, Maximiliano Emanuel/0000 0003 0455 5532; Oliveri,
   Beatriz/0000 0002 6694 4341
FU Agencia Nacional de Promocion Cientifica y Tecnologica, Argentina
   [PICT1179 2013]; Universidad Nacional de La Plata [X679]
FX This work was supported by the Agencia Nacional de Promocion Cientifica
   y Tecnologica, Argentina [PICT1179 2013 to PR], and Universidad Nacional
   de La Plata [X679 to PR]. None of the funders was involved in the study
   design, data collection, data analysis, data interpretation, writing of
   the report, or decision to submit for publication.
CR Aflaki E, 2016, AGING CELL, V15, P77, DOI 10.1111/acel.12409
   Algate K, 2016, J PERIODONTAL RES, V51, P549, DOI 10.1111/jre.12339
   Andersson H, 2008, PEDIATRICS, V122, P1182, DOI 10.1542/peds.2007 2144
   Dahl SV, 2006, CURR MED RES OPIN, V22, P1045, DOI 10.1185/030079906X104623
   Deegan PB, 2011, MEDICINE, V90, P52, DOI 10.1097/MD.0b013e3182057be4
   Di Rosa M, 2014, BONE, V61, P55, DOI 10.1016/j.bone.2014.01.005
   El Jawhari JJ, 2016, INJURY, V47, P2399, DOI 10.1016/j.injury.2016.10.008
   Elstein D, 2014, BLOOD CELL MOL DIS, V53, P56, DOI 10.1016/j.bcmd.2014.02.006
   Evans KE, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471 2121 8 4
   Gervas Arruga J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126153
   Giuffrida G, 2014, ADV THER, V31, P1197, DOI 10.1007/s12325 014 0174 0
   Giuffrida G, 2012, HEMATOL REP, V4, P70, DOI 10.4081/hr.2012.e21
   Khan A, 2012, J BONE MINER RES, V27, P1839, DOI 10.1002/jbmr.1680
   Laudemann K, 2016, BLOOD CELL MOL DIS, V57, P35, DOI 10.1016/j.bcmd.2015.11.003
   Maas M, 2003, RADIOLOGY, V229, P554, DOI 10.1148/radiol.2292020296
   Marcucci G, 2014, CALCIFIED TISSUE INT, V95, P477, DOI 10.1007/s00223 014 9923 y
   Mariani G, 2016, AM J ROENTGENOL, V206, P1245, DOI 10.2214/AJR.15.15294
   Meguid MHA, 2013, RHEUMATOL INT, V33, P697, DOI 10.1007/s00296 012 2375 7
   Mikosch P, 2010, WIEN MED WOCHENSCHR, V160, P609, DOI 10.1007/s10354 010 0841 y
   Mistry PK, 2011, BLOOD CELL MOL DIS, V46, P66, DOI 10.1016/j.bcmd.2010.10.011
   Mistry PK, 2010, P NATL ACAD SCI USA, V107, P19473, DOI 10.1073/pnas.1003308107
   Mucci JM, 2015, BLOOD CELL MOL DIS, V55, P134, DOI 10.1016/j.bcmd.2015.05.009
   Mucci JM, 2012, GENE, V509, P51, DOI 10.1016/j.gene.2012.07.071
   Okamoto K, 2011, INT IMMUNOPHARMACOL, V11, P543, DOI 10.1016/j.intimp.2010.11.010
   Pandey Manoj Kumar, 2013, Critical Reviews in Oncogenesis, V18, P197
   Panicker LM, 2014, STEM CELLS, V32, P2338, DOI 10.1002/stem.1732
   Pavlova EV, 2011, BLOOD CELL MOL DIS, V46, P27, DOI 10.1016/j.bcmd.2010.10.010
   Reed M, 2013, BLOOD CELL MOL DIS, V51, P185, DOI 10.1016/j.bcmd.2013.04.006
   Robertson PL, 2007, AM J ROENTGENOL, V188, P1521, DOI 10.2214/AJR.06.1410
   Roca M, 2007, EUR J RADIOL, V62, P132, DOI 10.1016/j.ejrad.2006.11.024
   Sims KB, 2008, CLIN GENET, V73, P430, DOI 10.1111/j.1399 0004.2008.00978.x
   Sims NA, 2016, INT J BIOCHEM CELL B, V79, P14, DOI 10.1016/j.biocel.2016.08.003
   van Breemen MJ, 2007, BBA MOL BASIS DIS, V1772, P788, DOI 10.1016/j.bbadis.2007.04.002
   van Dussen L, 2014, J INHERIT METAB DIS, V37, P991, DOI 10.1007/s10545 014 9711 x
   Weitzmann MN, 2016, NAT REV ENDOCRINOL, V12, P518, DOI 10.1038/nrendo.2016.91
   Wenstrup RJ, 2002, BRIT J RADIOL, V75, pA2, DOI 10.1259/bjr.75.suppl_1.750002
   Yoshino M, 2007, PEDIATR INT, V49, P959, DOI 10.1111/j.1442 200X.2007.02502.x
   Yuan FL, 2010, BIOCHEM BIOPH RES CO, V402, P173, DOI 10.1016/j.bbrc.2010.09.120
   Zaiss MM, 2007, ARTHRITIS RHEUM, V56, P4104, DOI 10.1002/art.23138
NR 39
TC 12
Z9 12
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD OCT
PY 2017
VL 103
BP 262
EP 269
DI 10.1016/j.bone.2017.07.020
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FF0NY
UT WOS:000408599600031
PM 28736246
OA Green Accepted, Green Published
DA 2025 08 17
ER

PT J
AU Zhou, YD
   Lewis, TL
   Robinson, LJ
   Brundage, KM
   Schafer, R
   Martin, KH
   Blair, HC
   Soboloff, J
   Barnett, JB
AF Zhou, Yandong
   Lewis, Tricia L.
   Robinson, Lisa J.
   Brundage, Kathy M.
   Schafer, Rosana
   Martin, Karen H.
   Blair, Harry C.
   Soboloff, Jonathan
   Barnett, John B.
TI The Role of Calcium Release Activated Calcium Channels in Osteoclast
   Differentiation
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID TERMINAL DIFFERENTIATION; STIM1; RECEPTOR; RANKL; ORAI1; DEFICIENCY;
   EXPRESSION; INITIATION; ALPHA; CELLS
AB Osteoclasts are specialized macrophage derivatives that secrete acid and proteinases to mobilize bone for mineral homeostasis, growth, and replacement or repair. Osteoclast differentiation generally requires the monocyte growth factor m CSF and the TNF family cytokine RANKL, although differentiation is regulated by many other cytokines and by intracellular signals, including Ca2+. Studies of osteoclast differentiation in vitro were performed using human monocytic precursors stimulated with m CSF and RANKL, revealing significant loss in both the expression and function of the required components of store operated Ca2+ entry over the course of osteoclast differentiation. However, inhibition of CRAC using either the pharmacological agent 3,4 dichloropropioanilide (DCPA) or by knockdown of Orai1 severely inhibited formation of multinucleated osteoclasts. In contrast, no effect of CRAC channel inhibition was observed on expression of the osteoclast protein tartrate resistant acid phosphatase (TRAP). Our findings suggest that despite the fact that they are down regulated during osteoclast differentiation, CRAC channels are required for cell fusion, a late event in osteoclast differentiation. Since osteoclasts cannot function properly without multinucleation, selective CRAC inhibitors may have utility in management of hyperresorptive states. J. Cell. Physiol. J. Cell. Physiol. 226: 1082 1089, 2011. (C) 2010 Wiley Liss, Inc.
C1 [Zhou, Yandong; Soboloff, Jonathan] Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA.
   [Lewis, Tricia L.; Brundage, Kathy M.; Schafer, Rosana; Martin, Karen H.; Barnett, John B.] W Virginia Univ, Sch Med, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA.
   [Robinson, Lisa J.; Blair, Harry C.] Univ Pittsburgh, Sch Med, Vet Affairs Med Ctr, Dept Pathol & Physiol & Cell Biol, Pittsburgh, PA USA.
   [Brundage, Kathy M.; Schafer, Rosana; Martin, Karen H.; Barnett, John B.] W Virginia Univ, Sch Med, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple
   University; West Virginia University; Pennsylvania Commonwealth System
   of Higher Education (PCSHE); University of Pittsburgh; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); West Virginia
   University
RP Soboloff, J (通讯作者)，Temple Univ, Sch Med, Dept Biochem, 3440 N Broad St, Philadelphia, PA 19140 USA.
EM soboloff@temple.edu; jbarnett@hsc.wvu.edu
RI ; Soboloff, Jonathan/I 6995 2012; Barnett, John/AAW 6642 2020
OI Martin, Karen/0000 0001 8916 4092; Soboloff,
   Jonathan/0000 0001 5192 1297; 
FU National Institutes of Health (USA) [ES011311, AG12951, AR053566];
   Department of Veteran's Affairs (USA)
FX Contract grant sponsor: National Institutes of Health (USA);Contract
   grant numbers: ES011311, AG12951, AR053566.Contract grant sponsor:
   Department of Veteran's Affairs (USA).
CR Blair H. C., 2007, V45, P539
   Blair HC, 2009, LAB INVEST, V89, P1007, DOI 10.1038/labinvest.2009.58
   Chang EJ, 2008, J CELL SCI, V121, P2555, DOI 10.1242/jcs.028217
   Day CJ, 2005, J CELL BIOCHEM, V95, P17, DOI 10.1002/jcb.20410
   Deng XX, 2009, J BIOL CHEM, V284, P22501, DOI 10.1074/jbc.R109.018655
   Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702
   Feske S, 2009, IMMUNOL REV, V231, P189, DOI 10.1111/j.1600 065X.2009.00818.x
   Ikeda F, 2006, J IMMUNOL, V177, P2384, DOI 10.4049/jimmunol.177.4.2384
   Kim K, 2005, J BIOL CHEM, V280, P35209, DOI 10.1074/jbc.M505815200
   Kim MH, 2010, ARCH PHARM RES, V33, P457, DOI 10.1007/s12272 010 0316 0
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Lewis TL, 2008, TOXICOL SCI, V103, P97, DOI 10.1093/toxsci/kfn031
   Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055
   Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647
   Masuyama R, 2008, CELL METAB, V8, P257, DOI 10.1016/j.cmet.2008.08.002
   Muik M, 2009, J BIOL CHEM, V284, P8421, DOI 10.1074/jbc.C800229200
   Park CY, 2009, CELL, V136, P876, DOI 10.1016/j.cell.2009.02.014
   Robinson LJ, 2009, EXP CELL RES, V315, P1287, DOI 10.1016/j.yexcr.2009.01.014
   Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019
   Stathopulos PB, 2008, CELL, V135, P110, DOI 10.1016/j.cell.2008.08.006
   Stathopulos PB, 2006, J BIOL CHEM, V281, P35855, DOI 10.1074/jbc.M608247200
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Ustyugova IV, 2007, TOXICOL SCI, V97, P364, DOI 10.1093/toxsci/kfm048
   Vig M, 2006, CURR BIOL, V16, P2073, DOI 10.1016/j.cub.2006.08.085
   Wang YJ, 2009, P NATL ACAD SCI USA, V106, P7391, DOI 10.1073/pnas.0900293106
   Wu MM, 2006, J CELL BIOL, V174, P803, DOI 10.1083/jcb.200604014
   Xie YC, 1997, TOXICOL APPL PHARM, V145, P184, DOI 10.1006/taap.1997.8179
   Yaroslavskiy BB, 2005, J CELL SCI, V118, P5479, DOI 10.1242/jcs.02655
   Yuan JP, 2009, CHANNELS, V3, P221, DOI 10.4161/chan.3.4.9198
   Zhou YD, 2009, J BIOL CHEM, V284, P19164, DOI 10.1074/jbc.C109.010900
NR 30
TC 42
Z9 50
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD APR
PY 2011
VL 226
IS 4
BP 1082
EP 1089
DI 10.1002/jcp.22423
PG 8
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA 720CW
UT WOS:000287258800025
PM 20839232
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Kumar, S
   Mulia, GE
   Figueiredo, ML
AF Kumar, Shreya
   Mulia, Grace E.
   Figueiredo, Marxa L.
TI Cabozantinib and IL 27 combinatorial therapy for bone metastatic
   prostate cancer
SO FRONTIERS IN MOLECULAR BIOSCIENCES
LA English
DT Article
DE prostate cancer; bone metastasis; immunotherapy; chemotherapy;
   interleukin 27; cabozantinib
ID GENE EXPRESSION; TUMOR; INTERLEUKIN 27; DELIVERY; TRANSCRIPTOME;
   ANGIOGENESIS; PATHWAYS; MET
AB Introduction: Prostate cancer is the second leading cause of cancer related death among American men. Prostate tumor cells exhibit significant tropism for the bone and once metastasis occurs, survival rates fall significantly. Current treatment options are not curative and focus on symptom management. Immunotherapies are rapidly emerging as a possible therapeutic option for a variety of cancers including prostate cancer, however, variable patient response remains a concern. Chemotherapies, like cabozantinib, can have immune priming effects which sensitize tumors to immunotherapies. Additionally, lower doses of chemotherapy can be used in this context which can reduce patient side effects. We hypothesized that a combination of chemotherapy (cabozantinib) and immunotherapy [Interleukin 27 (IL 27)] could be used to treat bone metastatic prostate cancer and exert pro osteogenic effects. IL 27 is a multi functional cytokine, which promotes immune cell recruitment to tumors, while also promoting bone repair.Methods: To test this hypothesis, in vivo experiments were performed where syngeneic C57BL/6J mice were implanted intratibially with TRAMP C2ras Luc cells that are able to form tumors in bone. Immunotherapy was administered in the form of intramuscular gene therapy, delivering plasmid DNA encoding a reporter gene (Lucia), and/or a therapeutic gene (IL 27). Sonoporation was used to aid gene delivery. Following immunotherapy, the animals received either cabozantinib or a vehicle control by oral gavage. Bioluminescence imaging was used to monitor tumor size over time.Results: Combinatorial therapy inhibited tumor growth and improved survival. Further, RNA sequencing was used to investigate the mechanisms involved. Microcomputed tomography and differentiation assays indicated that the combination therapy improved bone quality by enhancing osteoblast differentiation and inhibiting osteoclast differentiation.Discussion: Our conclusion is that a chemo immunotherapy approach such as the one examined in this work has potential to emerge as a novel therapeutic strategy for treating bone metastatic prostate cancer. This approach will enable a significant reduction in chemotherapy associated toxicity, enhance sensitivity to immunotherapy, and improve bone quality.
C1 [Kumar, Shreya; Mulia, Grace E.; Figueiredo, Marxa L.] Purdue Univ, Coll Vet Med, Dept Basic Med Sci, W Lafayette, IN 47907 USA.
C3 Purdue University System; Purdue University
RP Figueiredo, ML (通讯作者)，Purdue Univ, Coll Vet Med, Dept Basic Med Sci, W Lafayette, IN 47907 USA.
EM mlfiguei@purdue.edu
OI Kumar, Shreya/0000 0002 8480 9493; Mulia, Grace/0000 0003 4880 4342
FU The authors declare financial support was received for the research,
   authorship, and/or publication of this article. This project was funded
   by CA196947 and partially by AR069079. We acknowledge support from the
   Basic Medical Sciences department at Purdue [CA196947, AR069079]; Basic
   Medical Sciences department at Purdue University [P30 CA023168];
   Institute for Cancer Research, NIH; Purdue Imaging Facility   Purdue
   University Libraries Open Access Publishing Fund
FX The authors declare financial support was received for the research,
   authorship, and/or publication of this article. This project was funded
   by CA196947 and partially by AR069079. We acknowledge support from the
   Basic Medical Sciences department at Purdue University. The authors
   gratefully acknowledge the support of the Collaborative Core for Cancer
   Bioinformatics (C<SUP>3</SUP>B) from the Institute for Cancer Research,
   NIH grant P30 CA023168, and the Purdue Imaging Facility. The publication
   of this article was funded by the Purdue University Libraries Open
   Access Publishing Fund.
CR Atkins MB, 2018, CANCER TREAT REV, V70, P127, DOI 10.1016/j.ctrv.2018.07.009
   Bergerot P, 2019, MOL CANCER THER, V18, P2185, DOI 10.1158/1535 7163.MCT 18 1399
   Bhaumik S, 2002, P NATL ACAD SCI USA, V99, P377, DOI 10.1073/pnas.012611099
   Dai JL, 2014, CLIN CANCER RES, V20, P617, DOI 10.1158/1078 0432.CCR 13 0839
   Di Carlo E, 2014, ONCOTARGET, V5, P10332, DOI 10.18632/oncotarget.1425
   Donnelly RP, 2009, ANN NY ACAD SCI, V1182, P1, DOI 10.1111/j.1749 6632.2009.05382.x
   Escoffre JM, 2013, CURR GENE THER, V13, P2, DOI 10.2174/156652313804806606
   Figueiredo ML, 2020, MOL THER METH CLIN D, V17, P739, DOI 10.1016/j.omtm.2020.03.022
   Gillespie M, 2022, NUCLEIC ACIDS RES, V50, pD687, DOI 10.1093/nar/gkab1028
   Grüllich C, 2014, RECENT RESULTS CANC, V201, P207, DOI 10.1007/978 3 642 54490 3_12
   Haider MT, 2015, BONE, V81, P581, DOI 10.1016/j.bone.2015.08.003
   Hisada M, 2004, CANCER RES, V64, P1152, DOI 10.1158/0008 5472.CAN 03 2084
   Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]
   Kwilas AR, 2014, J TRANSL MED, V12, DOI 10.1186/s12967 014 0294 y
   Li LQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045115
   Li TW, 2020, NUCLEIC ACIDS RES, V48, pW509, DOI 10.1093/nar/gkaa407
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Ma ZF, 2018, CENT EUR J IMMUNOL, V43, P1, DOI 10.5114/ceji.2018.74867
   Mahon KL, 2011, ENDOCR RELAT CANCER, V18, pR103, DOI 10.1530/ERC 10 0343
   Manandhar S, 2018, BMB REP, V51, P174, DOI 10.5483/BMBRep.2018.51.4.033
   Martin M., 2011, EMBNET J, V17, P10, DOI DOI 10.14806/EJ.17.1.200
   Mayer DCG, 1997, J CELL BIOL, V139, P1477, DOI 10.1083/jcb.139.6.1477
   Owen KL, 2020, EMBO REP, V21, DOI 10.15252/embr.202050162
   Pertea M, 2015, NAT BIOTECHNOL, V33, P290, DOI 10.1038/nbt.3122
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Scirocchi F, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.755433
   Shalapour S, 2015, NATURE, V521, P94, DOI 10.1038/nature14395
   Shen H, 2004, AM J PHYSIOL CELL PH, V286, pC840, DOI 10.1152/ajpcell.00335.2003
   Shimizu M, 2006, J IMMUNOL, V176, P7317, DOI 10.4049/jimmunol.176.12.7317
   Shinozaki Y, 2009, INT J CANCER, V124, P1372, DOI 10.1002/ijc.24107
   Song ZS, 2019, J CANCER, V10, P1398, DOI 10.7150/jca.29571
   Sturm G, 2019, BIOINFORMATICS, V35, pI436, DOI 10.1093/bioinformatics/btz363
   Su JL, 2005, CANCER RES, V65, P4827, DOI 10.1158/0008 5472.CAN 05 0188
   Sun J, 2019, BMC MED GENET, V20, DOI 10.1186/s12881 019 0923 7
   Wei J, 2013, J IMMUNOL, V191, P500, DOI 10.4049/jimmunol.1300328
   Xie ZR, 2021, CURR PROTOC, V1, DOI 10.1002/cpz1.90
   Yakes FM, 2011, MOL CANCER THER, V10, P2298, DOI 10.1158/1535 7163.MCT 11 0264
   Zhang J, 2012, FEBS LETT, V586, P3255, DOI 10.1016/j.febslet.2012.06.047
   Zhang LQ, 2002, MOL THER, V5, P223, DOI 10.1006/mthe.2002.0551
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09234 6
   Zhu JM, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98745
   Zitvogel L, 2008, NAT REV IMMUNOL, V8, P59, DOI 10.1038/nri2216
   Zolochevska O, 2013, HUM GENE THER, V24, P970, DOI 10.1089/hum.2013.091
   Zolochevska O, 2013, J CELL PHYSIOL, V228, P1127, DOI 10.1002/jcp.24265
NR 44
TC 3
Z9 3
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 2296 889X
J9 FRONT MOL BIOSCI
JI Front. Mol. Biosci.
PD SEP 28
PY 2023
VL 10
AR 1259336
DI 10.3389/fmolb.2023.1259336
PG 17
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA T6WR0
UT WOS:001079372400001
PM 37842640
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Silver, K
   Desormaux, A
   Freeman, LC
   Lillich, JD
AF Silver, Kristopher
   Desormaux, Alejandra
   Freeman, Lisa C.
   Lillich, James D.
TI Expression of pleiotrophin, an important regulator of cell migration, is
   inhibited in intestinal epithelial cells by treatment with non steroidal
   anti inflammatory drugs
SO GROWTH FACTORS
LA English
DT Article
DE Pleitrophin; NSAID; cell migration; epithelia
ID GROWTH FACTOR; CYCLOOXYGENASE INHIBITION; GASTROINTESTINAL TOXICITY; K+
   CHANNELS; INDOMETHACIN; CALPAIN; ACTIVATION; PROLIFERATION; MECHANISMS;
   PEPTIDE
AB Non steroidal anti inflammatory drugs (NSAIDs) are among the most widely used drugs for the suppression of inflammation and pain. However, the analgesic properties of NSAIDs are also associated with significant negative side effects, most notably in the gastrointestinal (GI) tract. Increasingly, evidence indicates that the ulcerogenic properties of some NSAIDs are not exclusively the result of inhibition of cyclooxygenase isoforms in the GI tract, and other mechanisms, including inhibition of cell migration and epithelial restitution, are being explored. Recently, microarray analysis was used to identify potential novel targets of NSAID activity in intestinal epithelial cells. Treated cells exhibited significant reductions in the gene expression of pleiotrophin (PTN), a cytokine and growth factor known to participate in angiogenesis and bone growth. This report aimed to confirm the microarray results reported previously, and to measure protein expression of PTN in intestinal epithelial cells. Furthermore, we also examined the effects of exogenous PTN on cell migration in the presence and absence of either NSAIDs with variable ulcerogenic potential or PTN specific siRNA. Our results demonstrated that indomethacin and NS 398, two NSAIDs with ulcerogenic potential significantly decrease both gene and protein expressions of PTN in IEC 6 cells and protein expression in IEC 6 Cdx2 cells. Additionally, cell migration experiments with PTN siRNA showed that PTN is an important mediator of IEC 6 cell migration, and addition of exogenous PTN partially restores the deficits in cell migration caused by treatment with indomethacin and NS 398. Finally, measurement of PTN protein expression in the GI tract of horses treated with phenylbutazone showed that PTN expression is reduced by NSAIDs in vivo. Our results show that PTN is an important mediator of cell migration in IEC 6 cells, and PTN is a potential target through which NSAIDs may inhibit cell migration, epithelial restitution, and wound healing in the GI tract.
C1 [Desormaux, Alejandra; Lillich, James D.] Kansas State Univ, Coll Vet Med, Dept Clin Sci, Manhattan, KS 66506 USA.
   [Silver, Kristopher] ARS, USDA, Ctr Grain & Anim Hlth Res, Manhattan, KS 66502 USA.
   [Freeman, Lisa C.] Kansas State Univ, Dept Anat & Physiol, Coll Vet Med, Manhattan, KS 66506 USA.
C3 Kansas State University; United States Department of Agriculture (USDA);
   Kansas State University
RP Lillich, JD (通讯作者)，Kansas State Univ, Coll Vet Med, Dept Clin Sci, Manhattan, KS 66506 USA.
EM lillich@vet.k state.edu
OI Silver, Kristopher/0000 0002 8140 2786
FU National Institutes of Health Center of Biological Research
   Excellence/COBRE Mentoring Grant [NIH1P20RR017686]
FX This work was supported by National Institutes of Health Center of
   Biological Research Excellence/COBRE Mentoring Grant No. NIH1P20RR017686
   (Core A and B). The USDA is an equal opportunity provider and employer.
   Mention of trade names or commercial products in this publication is
   solely for the purpose of providing specific information and does not
   imply recommendation or endorsement by the U.S. Department of
   Agriculture.
CR Ashton M, 2002, BRIT J PHARMACOL, V135, P407, DOI 10.1038/sj.bjp.0704497
   Cryer B, 2005, AM J GASTROENTEROL, V100, P1694, DOI 10.1111/j.1572 0241.2005.50565.x
   Delcò F, 2004, DIGESTION, V69, P10, DOI 10.1159/000076542
   Deuel TF, 2002, ARCH BIOCHEM BIOPHYS, V397, P162, DOI 10.1006/abbi.2001.2705
   Dignass AU, 2001, INFLAMM BOWEL DIS, V7, P68, DOI 10.1097/00054725 200102000 00014
   Dineen SP, 2008, CANCER RES, V68, P4340, DOI 10.1158/0008 5472.CAN 07 6705
   Fendrick A Mark, 2009, Osteopath Med Prim Care, V3, P1, DOI 10.1186/1750 4732 3 1
   Freeman LC, 2007, BIOCHEM PHARMACOL, V74, P74, DOI 10.1016/j.bcp.2007.03.030
   FREY HH, 1977, ARCH INT PHARMACOD T, V230, P300
   Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390
   Glading A, 2004, MOL CELL BIOL, V24, P2499, DOI 10.1128/MCB.24.6.2499 2512.2004
   Glading A, 2001, J BIOL CHEM, V276, P23341, DOI 10.1074/jbc.M008847200
   Israel LH, 2001, DIS COLON RECTUM, V44, P1362, DOI 10.1007/BF02234797
   KARCHER LF, 1990, J VET INTERN MED, V4, P247, DOI 10.1111/j.1939 1676.1990.tb03117.x
   Kato M, 2001, J PHARM PHARMACOL, V53, P1679, DOI 10.1211/0022357011778070
   Kokoska ER, 1998, AM J PHYSIOL GASTR L, V275, pG620, DOI 10.1152/ajpgi.1998.275.4.G620
   Lichtenberger LM, 2001, BIOCHEM PHARMACOL, V61, P631, DOI 10.1016/S0006 2952(00)00576 1
   MACALLISTER CG, 1993, J AM VET MED ASSOC, V202, P71
   Mahmud T, 1996, ARTHRITIS RHEUM, V39, P1998, DOI 10.1002/art.1780391208
   Mikelis C, 2009, FASEB J, V23, P1459, DOI 10.1096/fj.08 117564
   Pai R, 2001, LIFE SCI, V69, P3055, DOI 10.1016/S0024 3205(01)01412 6
   Papadimitriou E, 2004, CURR CANCER DRUG TAR, V4, P471, DOI 10.2174/1568009043332835
   Penney AG, 1995, DIGEST DIS SCI, V40, P2684, DOI 10.1007/BF02220461
   Perez Pinera P, 2008, CURR OPIN HEMATOL, V15, P210, DOI 10.1097/MOH.0b013e3282fdc69e
   Peskar BM, 2001, LIFE SCI, V69, P2993, DOI 10.1016/S0024 3205(01)01407 2
   Polykratis A, 2005, J BIOL CHEM, V280, P22454, DOI 10.1074/jbc.M414407200
   Polytarchou C, 2009, INT J CANCER, V124, P1785, DOI 10.1002/ijc.24084
   Pufe T, 2007, OSTEOARTHR CARTILAGE, V15, P155, DOI 10.1016/j.joca.2006.07.005
   QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248
   Radi ZA, 2009, TOXICOL PATHOL, V37, P34, DOI 10.1177/0192623308329474
   Rahgozar M, 2001, J GASTROEN HEPATOL, V16, P290, DOI 10.1046/j.1440 1746.2001.02433.x
   Rao JN, 2002, AM J PHYSIOL CELL PH, V282, pC885, DOI 10.1152/ajpcell.00361.2001
   Raveendran NN, 2008, J PHARMACOL EXP THER, V325, P389, DOI 10.1124/jpet.107.127720
   SCHMASSMANN A, 1995, AM J PHYSIOL GASTR L, V268, pG276, DOI 10.1152/ajpgi.1995.268.2.G276
   Silver K, 2010, INT J BIOCHEM CELL B, V42, P2030, DOI 10.1016/j.biocel.2010.09.007
   Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313
   Somasundaram S, 2000, ALIMENT PHARM THER, V14, P639
   Suh E, 1996, MOL CELL BIOL, V16, P619
   Suzuki T, 1997, BIOL PHARM BULL, V20, P438
   Tanaka A, 2001, J PHYSIOLOGY PARIS, V95, P21, DOI 10.1016/S0928 4257(01)00005 5
   Tavares IA, 2000, ALIMENT PHARM THERAP, V14, P795
   Tomisato W, 2004, BIOCHEM PHARMACOL, V67, P575, DOI 10.1016/j.bcp.2003.09.020
   Ulbricht U, 2006, J NEUROCHEM, V98, P1497, DOI 10.1111/j.1471 4159.2006.04022.x
   Wallace JL, 2008, CURR OPIN INVEST DR, V9, P1151
   Whittle BJR, 2003, FUND CLIN PHARMACOL, V17, P301, DOI 10.1046/j.1472 8206.2003.00135.x
   Wolfe MM, 1999, NEW ENGL J MED, V341, P1398
NR 46
TC 20
Z9 21
U1 0
U2 13
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0897 7194
EI 1029 2292
J9 GROWTH FACTORS
JI Growth Factors
PD AUG
PY 2012
VL 30
IS 4
BP 258
EP 266
DI 10.3109/08977194.2012.693920
PG 9
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA 996UC
UT WOS:000308119300005
PM 22691166
DA 2025 08 17
ER

PT J
AU Yamamoto, K
   Isogai, Y
   Ishida, T
   Hagihara, K
AF Yamamoto, Kouichi
   Isogai, Yukihiro
   Ishida, Takayuki
   Hagihara, Keisuke
TI Enhancement of ghrelin signaling system by Rikkunshi To attenuates
   teriparatide induced pica in rats
SO JOURNAL OF PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Ghrelin; Nausea; Pica; Rikkunshi To; Teriparatide
ID PARATHYROID HORMONE; GASTRIC MOTILITY; FEMALE RATS; OSTEOPOROSIS;
   ANTAGONISM; DOPAMINE; MEDICINE
AB Teriparatide is clinically used for the treatment of osteoporosis; however, nausea is often observed in patients. Its insufficient control affects the ability to continue teriparatide therapy. Rikkunshi To (RKT), a traditional Japanese herbal medicine, improves the gastrointestinal function via activation of the ghrelin signaling system. We investigated the therapeutic effects of RKT on teriparatide induced nausea in rats and the involvement of ghrelin in these effects. We previously reported that ovariectomized rats showed pica (kaolin ingestion), a behavior that can be used to assess nausea in rats, after the subcutaneous administration of teriparatide; thus, the behavior was used as an index of nausea. Ovariectomized rats were fed diets with or without RKT (1%) for 2 weeks, and then they received the subcutaneous injection of teriparatide (400 mg/kg). Teriparatide significantly increased the incidence of pica, while suppressing intestinal motility and plasma ghrelin levels in rats fed normal diets; however, rats fed diets with RKT showed improvements in all of the teriparatide induced adverse reactions. These therapeutic effects were antagonized by a ghrelin receptor antagonist ([D Lys3] GHRP 6; 200 nmol/rat). These findings suggest that the enhancement of ghrelin signaling is involved in RKT's therapeutic effect, and that RKT is a potentially useful treatment for teriparatide induced nausea. (c) 2018 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.
C1 [Yamamoto, Kouichi; Ishida, Takayuki] Osaka Univ, Grad Sch Med, Div Hlth Sci, Dept Med Sci & Technol, Yamadaoka 1 7, Suita, Osaka 5650871, Japan.
   [Isogai, Yukihiro] Asahi Kasei Pharma Corp, Med Affairs Dept, Pharmaceut Business Adm Div, Chiyoda Ku, 1 105 Kanda Jinbocho, Tokyo 1018101, Japan.
   [Hagihara, Keisuke] Osaka Univ, Grad Sch Med, Dept Adv Hybrid Med, Yamadaoka 2 2, Suita, Osaka 5650871, Japan.
C3 University of Osaka; Asahi Kasei Pharma Corporation; University of Osaka
RP Yamamoto, K (通讯作者)，Osaka Univ, Grad Sch Med, Div Hlth Sci, Dept Med Sci & Technol, Yamadaoka 1 7, Suita, Osaka 5650871, Japan.
EM kouichi@sahs.med.osaka u.ac.jp
RI Yamamoto, Kouichi/AAN 1586 2021
OI Yamamoto, Kouichi/0000 0002 8073 2871
CR Abdel Hakim S M, 2014, Endocr Regul, V48, P126
   BODEN SD, 1990, ORTHOP CLIN N AM, V21, P31
   Brixen KT, 2004, BASIC CLIN PHARMACOL, V94, P260
   Carroll MF, 2003, AM FAM PHYSICIAN, V67, P1959
   Caughey GE, 2010, PHARMACOEPIDEM DR S, V19, P977, DOI 10.1002/pds.2009
   Cheung CK, 2013, GUT LIVER, V7, P505, DOI 10.5009/gnl.2013.7.5.505
   Clegg DJ, 2007, DIABETES, V56, P1051, DOI 10.2337/db06 0015
   Engelstoft MS, 2013, MOL METAB, V2, P376, DOI 10.1016/j.molmet.2013.08.006
   Kido T, 2005, J PHARMACOL SCI, V98, P161, DOI 10.1254/jphs.FPJ04056X
   Matsumura T, 2010, J GASTROENTEROL, V45, P300, DOI 10.1007/s00535 009 0166 z
   MITCHELSON F, 1992, DRUGS, V43, P295, DOI 10.2165/00003495 199243030 00002
   Mittelstadt S. W., 2005, Journal of Pharmacological and Toxicological Methods, V52, P154, DOI 10.1016/j.vascn.2005.04.017
   MOK LLS, 1987, J BONE MINER RES, V2, P329
   NAGAHATA Y, 1995, SCAND J GASTROENTERO, V30, P880, DOI 10.3109/00365529509101595
   NAGAHATA Y, 1992, GASTROENTEROL JPN, V27, P482
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976 0105.177703
   Peeters TL, 2005, GUT, V54, P1638, DOI 10.1136/gut.2004.062604
   Rizzoli Rene, 2011, Expert Rev Clin Pharmacol, V4, P593
   Shiraki M, 2016, OSTEOPOROSIS INT, V27, P3057, DOI 10.1007/s00198 016 3640 5
   Sugimoto T, 2014, OSTEOPOROSIS INT, V25, P1173, DOI 10.1007/s00198 013 2516 1
   Takeda H, 2008, GASTROENTEROLOGY, V134, P2004, DOI 10.1053/j.gastro.2008.02.078
   Takeda H, 2012, CURR PHARM DESIGN, V18, P4827, DOI 10.2174/138161212803216933
   Tominaga K, 2011, EVID BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep173
   Tominaga K, 2014, J GASTROENTEROL, V49, P1392, DOI 10.1007/s00535 013 0896 9
   Weiss Guillet EM, 2003, BEST PRACT RES CL EN, V17, P623, DOI 10.1016/S1521 690X(03)00056 3
   Yamamoto K, 2016, J PHARMACOL SCI, V131, P68, DOI 10.1016/j.jphs.2016.03.015
   Yamamoto K, 2015, EUR J PHARMACOL, V764, P457, DOI 10.1016/j.ejphar.2015.07.039
   Yamamoto K, 2011, J PHARMACOL TOX MET, V63, P30, DOI 10.1016/j.vascn.2010.04.011
   Yamamotoa K, 2018, J PHARMACOL TOX MET, V91, P66, DOI 10.1016/j.vascn.2018.01.559
NR 29
TC 5
Z9 6
U1 1
U2 3
PU JAPANESE PHARMACOLOGICAL SOC
PI KYOTO
PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI EBISUGAWA NAKAGYO KU, KYOTO, 604,
   JAPAN
SN 1347 8613
EI 1347 8648
J9 J PHARMACOL SCI
JI J. Pharmacol. Sci.
PD JUN
PY 2018
VL 137
IS 2
BP 137
EP 145
DI 10.1016/j.jphs.2018.05.003
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GO9UA
UT WOS:000440452000006
PM 29914799
OA gold
DA 2025 08 17
ER

PT J
AU Falcai, MJ
   Zamarioli, A
   Okubo, R
   de Paula, FJA
   Volpon, JB
AF Falcai, M. J.
   Zamarioli, A.
   Okubo, R.
   de Paula, F. J. A.
   Volpon, J. B.
TI The osteogenic effects of swimming, jumping, and vibration on the
   protection of bone quality from disuse bone loss
SO SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS
LA English
DT Article
DE Osteoporosis; osteogenesis; tail suspension; exercise therapy; bone
   tissue; osteoblasts; osteoclasts
ID MAGNITUDE MECHANICAL SIGNALS; YOUNG GROWING RATS; DAILY EXPOSURE;
   HIGH FREQUENCY; ADULT RATS; IGF I; EXERCISE; WOMEN; METAANALYSIS;
   ALENDRONATE
AB We assessed and compared the effects of swimming, jumping, and vibration therapies on the prevention of bone loss because of unloading. Eighty Wistar rats were randomly divided into eight groups: S, permanent hind limb suspended rats; CON, control rats; S+Swim, unloading interrupted by swimming exercise; S+C Swim, suspension interrupted by regular weight bearing with the same duration as in the S+Swim protocol; S+Jump, unloading interrupted by jumping exercise; S+C Jump, suspension interrupted for regular weight bearing as in the S+Jump group; S+Vibr, unloading interrupted by vibration; and S+C Vibr, suspension with interruptions for regular weight bearing with the same protocol as that used for the S+Vibr rats. At the end of the experiment, the bone mineral density, bone strength, histomorphometric parameters, and serum levels of the bone markers were analyzed. The hind limb suspended rats exhibited bone quality loss. In contrast, the trained rats showed a significant increase in bone mass, bone strength, bone formation, and serum levels of bone markers compared with the respective controls. Although we did not find a significant difference among the three physical exercises, the osteogenic effect of vibration was slightly lower than that of swimming and jumping. Thus, all physical exercises were efficient in preventing bone loss because of unloading and preserving bone quality.
C1 [Falcai, M. J.; Zamarioli, A.; Okubo, R.] Univ Sao Paulo, Sch Med Ribeirao Preto, Lab Bioengn, Sao Paulo, Brazil.
   [de Paula, F. J. A.] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Internal Med, Sao Paulo, Brazil.
   [Volpon, J. B.] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Biomech Med & Rehabil Locomotor Syst, Sao Paulo, Brazil.
C3 Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de
   Sao Paulo
RP Falcai, MJ (通讯作者)，Univ Sao Paulo, Sch Med Ribeirao Preto, Lab Bioengn, Sao Paulo, Brazil.
EM mfalcai@gmail.com
RI Zamarioli, Ariane/K 7001 2012; Volpon, Jose/D 3041 2012; Okubo,
   Rodrigo/J 9194 2013; de Paula, Francisco/D 5026 2012
OI Zamarioli, Ariane/0000 0002 7939 0528; Okubo,
   Rodrigo/0000 0003 3450 2183; de Paula, Francisco/0000 0003 1262 3486
FU State of Sao Paulo Research Foundation (FAPESP); Coordination for the
   Improvement of Higher Education Personnel (CAPES)
FX This study was financially supported by the State of Sao Paulo Research
   Foundation (FAPESP) and by the Coordination for the Improvement of
   Higher Education Personnel (CAPES). We also thank Geraldo Cassio dos
   Reis for performing the statistical analysis and Vanda Jorgetti for the
   histological preparation.
CR Abrahamsen B, 2010, CALCIFIED TISSUE INT, V86, P421, DOI 10.1007/s00223 010 9364 1
   AERSSENS J, 1993, CALCIFIED TISSUE INT, V53, P269, DOI 10.1007/BF01320913
   Bakker AD, 2003, AM J PHYSIOL ENDOC M, V285, pE608, DOI 10.1152/ajpendo.00501.2002
   Bala Y, 2011, EUR J ENDOCRINOL, V165, P647, DOI 10.1530/EJE 11 0333
   Bone Henry G, 2004, Curr Osteoporos Rep, V2, P24, DOI 10.1007/s11914 004 0011 5
   BOURRIN S, 1992, CALCIFIED TISSUE INT, V51, P137, DOI 10.1007/BF00298502
   Bravo G, 1997, ARCH PHYS MED REHAB, V78, P1375, DOI 10.1016/S0003 9993(97)90313 0
   Burr DB, 2002, BONE, V30, P781, DOI 10.1016/S8756 3282(02)00707 X
   Chan ME, 2012, FASEB J, V26, P4855, DOI 10.1096/fj.12 209841
   Cochrane DJ, 2011, INT J SPORTS MED, V32, P75, DOI 10.1055/s 0030 1268010
   Dargent Molina Patricia, 1998, Current Opinion in Rheumatology, V10, P357, DOI 10.1097/00002281 199807000 00014
   De Palo EF, 2008, CLIN CHIM ACTA, V387, P71, DOI 10.1016/j.cca.2007.09.005
   Flieger J, 1998, CALCIFIED TISSUE INT, V63, P510, DOI 10.1007/s002239900566
   Gallagher JC, 2002, MENOPAUSE, V9, P84
   Honda A, 2008, J APPL PHYSIOL, V105, P849, DOI 10.1152/japplphysiol.00902.2007
   Huang TH, 2003, J APPL PHYSIOL, V95, P300, DOI 10.1152/japplphysiol.01076.2002
   Iwamoto J, 2004, J BONE MINER METAB, V22, P26, DOI 10.1007/s00774 003 0443 5
   Joo YI, 2003, BONE, V33, P485, DOI 10.1016/S8756 3282(03)00212 6
   Ju YI, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193 1801 2 35
   Ju YI, 2012, J APPL PHYSIOL, V112, P766, DOI 10.1152/japplphysiol.01219.2011
   Kelley GA, 2000, J APPL PHYSIOL, V88, P1730, DOI 10.1152/jappl.2000.88.5.1730
   Luu Yen K, 2009, Bonekey Osteovision, V6, P132
   Morey Holton ER, 2002, J APPL PHYSIOL, V92, P1367, DOI 10.1152/japplphysiol.00969.2001
   Nolen R Scott, 2011, J Am Vet Med Assoc, V239, P1269
   NORDIN BEC, 1983, ACTA ORTHOP SCAND, V54, P482
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Ozcivici E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011178
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Rubin CT, 2007, P NATL ACAD SCI USA, V104, P17879, DOI 10.1073/pnas.0708467104
   Rubin CT, 2001, DRUG DISCOV TODAY, V6, P848, DOI 10.1016/S1359 6446(01)01872 4
   Ruff C, 2006, AM J PHYS ANTHROPOL, V129, P484, DOI 10.1002/ajpa.20371
   Shiguemoto GE, 2012, SCAND J MED SCI SPOR, V22, P607, DOI 10.1111/j.1600 0838.2010.01284.x
   Shin HK, 2010, ORTHOPEDICS, V33, DOI 10.3928/01477447 20101021 02
   Snow Harter C, 1991, Exerc Sport Sci Rev, V19, P351
   SWISSASIVAN A, 1990, CALCIFIED TISSUE INT, V47, P173, DOI 10.1007/BF02555984
   Turner CH, 2006, ANN NY ACAD SCI, V1068, P429, DOI 10.1196/annals.1346.039
   Umemura Y, 2008, J APPL PHYSIOL, V104, P1116, DOI 10.1152/japplphysiol.00937.2007
   Wolff I, 1999, OSTEOPOROSIS INT, V9, P1, DOI 10.1007/s001980050109
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   Xie LQ, 2006, BONE, V39, P1059, DOI 10.1016/j.bone.2006.05.012
   Yang P, 2009, AVIAT SPACE ENVIR MD, V80, P88, DOI 10.3357/ASEM.2368.2009
NR 41
TC 20
Z9 25
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0905 7188
EI 1600 0838
J9 SCAND J MED SCI SPOR
JI Scand. J. Med. Sci. Sports
PD JUN
PY 2015
VL 25
IS 3
BP 390
EP 397
DI 10.1111/sms.12240
PG 8
WC Sport Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Sport Sciences
GA CI2ID
UT WOS:000354568800023
PM 24779886
DA 2025 08 17
ER

PT J
AU Takayama, Y
   Mizumachi, K
AF Takayama, Yoshiharu
   Mizumachi, Koko
TI Effect of lactoferrin embedded collagen membrane on osteogenic
   differentiation of human osteoblast like cells
SO JOURNAL OF BIOSCIENCE AND BIOENGINEERING
LA English
DT Article
DE Lactoferrin; Collagen membrane; Drug delivery system; Osteoblasts;
   Differentiation
ID BONE FORMATION; DRUG DELIVERY; BOVINE LACTOFERRIN; GROWTH; BMP 2;
   ANGIOGENESIS; REGENERATION; ADHESION; HEPARIN; BINDING
AB Lactoferrin (LF) has the ability to promote the proliferation and differentiation of osteoblasts, suggesting its potential utility as an osteogenic growth factor in bone tissue engineering. However, this type of application requires improved drug delivery system (DDS) technology at the target site. In this study, we report enhanced calcium deposition and alkaline phosphatase (ALP) activity using the type I collagen membrane during osteogenic differentiation of MG63 human osteoblast like cells, indicating that type I collagen not only acts as a site for calcification but also promotes the expression of differentiated phenotypes. We also used this membrane as a drug delivery carrier for bovine LE Approximately 27% of LF embedded on the type I collagen membrane was released within the first hour in cell free condition. This initial burst release of LF was followed by a slower release from the collagen membrane. Bovine LF embedded in the type I collagen membrane promoted its calcification during osteogenic differentiation of MG63 cells without the loss of LF bioactivity. Taken together, ALP activity and osteocalcin production were enhanced in the MG63 cells plated on the LF embedded collagen membrane, suggesting that LF incorporated in the collagen membrane promoted bone like tissue formation by MG63 cells. These observations suggest that the type I collagen membrane is useful as a drug delivery carrier for LF in bone tissue engineering. (C) 2008, The Society for Biotechnology, Japan. All rights reserved.
C1 [Takayama, Yoshiharu; Mizumachi, Koko] Natl Inst Livestock & Grassland Sci, Funct Biomol Res Team, Tsukuba, Ibaraki 3050901, Japan.
C3 National Agriculture & Food Research Organization   Japan
RP Takayama, Y (通讯作者)，Natl Inst Livestock & Grassland Sci, Funct Biomol Res Team, 2 Ikenodai, Tsukuba, Ibaraki 3050901, Japan.
EM takay@affrc.go.jp
RI Takayama, Yoshiharu/M 8826 2019; Takayama, Yoshiharu/E 3662 2010
OI Takayama, Yoshiharu/0000 0003 4532 7114
FU Ministry of Education, Culture, Sports, Science, and Technology of Japan
   [18780253]; Grants in Aid for Scientific Research [18780253] Funding
   Source: KAKEN
FX This study was supported by a Grant in Aid for Young Scientists B (No.
   18780253) to YT from the Ministry of Education, Culture, Sports,
   Science, and Technology of Japan.
CR Andreadis ST, 2006, TRENDS BIOTECHNOL, V24, P331, DOI 10.1016/j.tibtech.2006.05.001
   BILLIAU A, 1977, ANTIMICROB AGENTS CH, V12, P11, DOI 10.1128/AAC.12.1.11
   BONEWALD LF, 1992, J BIOL CHEM, V267, P8943
   Brock JH, 2002, BIOCHEM CELL BIOL, V80, P1, DOI 10.1139/o01 212
   CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277
   Cornish J, 2006, BIOCHEM CELL BIOL, V84, P297, DOI 10.1139/O06 057
   García AJ, 2005, J DENT RES, V84, P407, DOI 10.1177/154405910508400502
   Gundberg CM, 2000, CLIN LAB MED, V20, P489
   Hirata K, 2007, J BONE MINER METAB, V25, P6, DOI 10.1007/s00774 006 0721 0
   Jikko A, 1999, J BONE MINER RES, V14, P1075, DOI 10.1359/jbmr.1999.14.7.1075
   Kimoto T, 1998, J DENT RES, V77, P1965, DOI 10.1177/00220345980770120301
   King Gaston N., 2001, Current Pharmaceutical Biotechnology, V2, P131, DOI 10.2174/1389201013378716
   Kofron MD, 2004, CURR OPIN BIOTECH, V15, P399, DOI 10.1016/j.copbio.2004.07.004
   Lee CH, 2001, INT J PHARMACEUT, V221, P1, DOI 10.1016/S0378 5173(01)00691 3
   LYNCH MP, 1995, EXP CELL RES, V216, P35, DOI 10.1006/excr.1995.1005
   Mackie EJ, 2003, INT J BIOCHEM CELL B, V35, P1301, DOI 10.1016/S1357 2725(03)00107 9
   Matsumoto A, 2001, J PERIODONTAL RES, V36, P175, DOI 10.1034/j.1600 0765.2001.360306.x
   Murata M, 2000, CLIN ORAL IMPLAN RES, V11, P289, DOI 10.1034/j.1600 0501.2000.011004289.x
   Muschler GE, 2004, J BONE JOINT SURG AM, V86A, P1541, DOI 10.2106/00004623 200407000 00029
   Nakagawa T, 2000, ORAL DIS, V6, P172
   Rose FRAJ, 2002, BIOCHEM BIOPH RES CO, V292, P1, DOI 10.1006/bbrc.2002.6519
   Salasznyk RM, 2004, J BIOMED BIOTECHNOL, P24, DOI 10.1155/S1110724304306017
   Saltzman WM, 2002, NAT REV DRUG DISCOV, V1, P177, DOI 10.1038/nrd744
   Sato H, 1996, PHARMACEUT RES, V13, P1565, DOI 10.1023/A:1016096016642
   Shimazaki K, 1998, J DAIRY SCI, V81, P2841, DOI 10.3168/jds.S0022 0302(98)75843 6
   Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099
   Takagishi Y, 2006, TISSUE ENG, V12, P927, DOI 10.1089/ten.2006.12.927
   Takayama S, 2001, J DENT RES, V80, P2075, DOI 10.1177/00220345010800121001
   Takayama Y, 2008, BIOSCI BIOTECH BIOCH, V72, P226, DOI 10.1271/bbb.70465
   Takezawa T, 2007, J BIOTECHNOL, V131, P76, DOI 10.1016/j.jbiotec.2007.05.033
   Thomas LL, 2002, J IMMUNOL, V169, P993, DOI 10.4049/jimmunol.169.2.993
   Trif M, 2001, EXP BIOL MED, V226, P559, DOI 10.1177/153537020122600608
   vanBerkel PHC, 1997, BIOCHEM J, V328, P145, DOI 10.1042/bj3280145
   Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI13662
   Yamamoto M, 2001, J BIOMAT SCI POLYM E, V12, P77, DOI 10.1163/156856201744461
NR 35
TC 41
Z9 46
U1 0
U2 27
PU SOC BIOSCIENCE BIOENGINEERING JAPAN
PI OSAKA
PA OSAKA UNIV, FACULTY ENGINEERING, 2 1 YAMADAOKA, SUITA, OSAKA, 565 0871,
   JAPAN
SN 1389 1723
J9 J BIOSCI BIOENG
JI J. Biosci. Bioeng.
PD FEB
PY 2009
VL 107
IS 2
BP 191
EP 195
DI 10.1016/j.jbiosc.2008.09.018
PG 5
WC Biotechnology & Applied Microbiology; Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA 425XM
UT WOS:000264671200017
PM 19217559
DA 2025 08 17
ER

PT J
AU Sun, X
   Wei, B
   Peng, ZH
   Fu, QL
   Wang, CJ
   Zhen, JC
   Sun, JC
AF Sun, Xin
   Wei, Bo
   Peng, Zhiheng
   Fu, Qinglong
   Wang, Chaojun
   Zhen, Jinchang
   Sun, Jiecong
TI Protective effects of Dipsacus asper polysaccharide on
   osteoporosis in vivo by regulating RANKL/RANK/OPG/VEGF and PI3K/Akt/eNOS
   pathway
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Dipsacus asper polysaccahride
ID INDUCED BONE LOSS; RADIX DIPSACI; ESTROGEN RECEPTOR; ENDOTHELIAL CELLS;
   EXTRACT; OVARIECTOMY; RAT; DIFFERENTIATION; ANGIOGENESIS; OSTEOCLAST
AB A homogenous polysaccharide (DAP), with a molecular weight of 2.61 x 10(4) Da, was isolated from the roots of Dipsacus asper Wall. Gas chromatography (GC) indicated that DAP was composed of galactose and mannose with a molar ratio of 1:1. The purpose of this study was to evaluate the effect of DAP on the progress of bone loss in the ovariectomized (OVX) rat model of osteoporosis. Administration of DAP (50 and 200 mg/kg/body wt. day) for 12 weeks significantly prevented OVX induced bone loss, biomechanical reduction, the body weight gain, the loss of the uterus weight, as well as increased U Ca/Cr, U P/Cr, ALP, TRAP, OC and DPD/Cr levels in rats, which was further supported by the histopathological examinations. Furthermore, we found that the mechanism by which DAP elicited anti osteoporotic effects was mediated by up regulation of VEGF and OPG, but down regulation of RANK and RANKL in both protein and mRNA expression in OVX rats, as well as the activation of PI3K/Akt/eNOS signaling pathway, indicating that DAP can be clinically used as a potential alternative medicine for the prevention and treatment of postmenopausal osteoporosis. (C) 2019 Elsevier B.V. All rights reserved.
C1 [Sun, Xin; Wei, Bo; Peng, Zhiheng; Fu, Qinglong; Wang, Chaojun; Zhen, Jinchang; Sun, Jiecong] Guangdong Med Univ, Dept Orthopaed Surg, Affiliated Hosp, Zhanjiang 524001, Guangdong, Peoples R China.
C3 Guangdong Medical University
RP Sun, X (通讯作者)，Guangdong Med Univ, Dept Orthopaed Surg, Affiliated Hosp, Zhanjiang 524001, Guangdong, Peoples R China.
EM xinsun@mail.com
RI Fu, Qing Long/HJI 4852 2023
FU Science and Technology Planning Project of Guangdong Province
   [2017ZC0311]
FX This work was supported by Science and Technology Planning Project of
   Guangdong Province (No. 2017ZC0311).
CR Ahsan A, 2015, APOPTOSIS, V20, P1563, DOI 10.1007/s10495 015 1175 4
   Bahlous Afef, 2006, Tunis Med, V84, P751
   Bahram H.A., 1996, J NUTR, V126, P161
   BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003 2697(73)90377 1
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Costa N, 2009, CYTOKINE, V46, P376, DOI 10.1016/j.cyto.2009.03.012
   Desai S, 2017, J ETHNOPHARMACOL, V199, P1, DOI 10.1016/j.jep.2017.01.031
   DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1038/168167a0
   Epstein S, 2006, CLIN THER, V28, P151, DOI 10.1016/j.clinthera.2006.02.007
   Feigin VL, 2007, STROKE, V38, P1734, DOI 10.1161/STROKEAHA.107.487132
   GENANT HK, 1989, AM J OBSTET GYNECOL, V161, P1842, DOI 10.1016/S0002 9378(89)80004 3
   Hertrampf T, 2008, MOL CELL ENDOCRINOL, V291, P104, DOI 10.1016/j.mce.2008.03.003
   Hofbauer L. C., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P268
   Hung TM, 2006, J ETHNOPHARMACOL, V108, P188, DOI 10.1016/j.jep.2006.04.029
   Kim SW, 2004, J UROLOGY, V172, P1538, DOI 10.1097/01.ju.0000137744.12814.2e
   Kohli Sarvraj Singh, 2011, Indian J Endocrinol Metab, V15, P175, DOI 10.4103/2230 8210.83401
   Kurasawa Kentaro, 2005, Clin Calcium, V15, P959
   Lee SJ, 2006, AM J PHYSIOL HEART C, V291, pH2836, DOI 10.1152/ajpheart.00113.2006
   Lelovas PP, 2008, COMPARATIVE MED, V58, P424
   Li WL, 2017, INT J CLIN EXP PATHO, V10, P11438
   Liu JC, 2012, CARBOHYD POLYM, V87, P1236, DOI 10.1016/j.carbpol.2011.09.007
   Liu ZG, 2009, J ETHNOPHARMACOL, V123, P74, DOI 10.1016/j.jep.2009.02.025
   Mandelin J, 2003, J BONE JOINT SURG BR, V85B, P1196, DOI 10.1302/0301 620X.85B8.13311
   Marsden J, 2002, J STEROID BIOCHEM, V83, P123, DOI 10.1016/S0960 0760(02)00258 3
   McNamara LM, 2010, J R SOC INTERFACE, V7, P353, DOI 10.1098/rsif.2009.0282
   Namba T, 1993, ENCY WAKAN YAKU TRAD, P185
   Nian H, 2009, PHYTOMEDICINE, V16, P320, DOI 10.1016/j.phymed.2008.12.006
   Niu YB, 2012, OSTEOPOROSIS INT, V23, P2649, DOI 10.1007/s00198 012 1932 y
   Niu YB, 2015, PHARM BIOL, V53, P110, DOI 10.3109/13880209.2014.911920
   Niu YB, 2011, PHYTOTHER RES, V25, P1700, DOI 10.1002/ptr.3414
   Notomi T, 2003, J BONE MINER RES, V18, P140, DOI 10.1359/jbmr.2003.18.1.140
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   Park JA, 2008, LIFE SCI, V82, P1217, DOI 10.1016/j.lfs.2008.03.021
   Santollo J, 2007, AM J PHYSIOL REG I, V293, pR2194, DOI 10.1152/ajpregu.00385.2007
   Saran U, 2014, ARCH BIOCHEM BIOPHYS, V561, P109, DOI 10.1016/j.abb.2014.07.006
   Shih CC, 2001, J ETHNOPHARMACOL, V77, P233, DOI 10.1016/S0378 8741(01)00302 6
   Shuid AN, 2011, J ETHNOPHARMACOL, V133, P538, DOI 10.1016/j.jep.2010.10.033
   Soucacos PN, 2001, CLIN ORTHOP RELAT R, P120
   Steven L., 2000, SCIENCE, V289, P1504
   Stevenson JC, 2005, MATURITAS, V51, P113, DOI 10.1016/j.maturitas.2005.01.012
   Swaminathan R, 2001, CLIN CHIM ACTA, V313, P95, DOI 10.1016/S0009 8981(01)00656 8
   Tanaka Yoshiya, 2005, Current Drug Targets   Inflammation and Allergy, V4, P325, DOI 10.2174/1568010054022015
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Termine JD, 1998, MATURITAS, V30, P241, DOI 10.1016/S0378 5122(98)00092 9
   Trouvin AP, 2010, CLIN INTERV AGING, V5, P345, DOI 10.2147/CIA.S10153
   Wensel TM, 2011, PHARMACOTHERAPY, V31, P510, DOI 10.1592/phco.31.5.510
   Wong RWK, 2007, PHYTOTHER RES, V21, P596, DOI 10.1002/ptr.2126
   WRONSKI TJ, 1989, CALCIFIED TISSUE INT, V45, P360, DOI 10.1007/BF02556007
   Xu H, 2005, AM J CHINESE MED, V33, P299, DOI 10.1142/S0192415X05002916
   Yang HH, 2017, CELL PHYSIOL BIOCHEM, V42, P506, DOI 10.1159/000477597
   Zhang YZ, 2006, J ETHNOPHARMACOL, V105, P274, DOI 10.1016/j.jep.2005.12.013
   Zhao X, 2011, J ETHNOPHARMACOL, V137, P1083, DOI 10.1016/j.jep.2011.07.017
   Zhao YM, 2011, CHEM BIODIVERS, V8, P414, DOI 10.1002/cbdv.201000022
   2012, J CEREB BLOOD FLOW M, V32, P884, DOI DOI 10.1038/JCBFM.2012.2
NR 55
TC 46
Z9 59
U1 2
U2 53
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0141 8130
EI 1879 0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD MAY 15
PY 2019
VL 129
BP 579
EP 587
DI 10.1016/j.ijbiomac.2019.02.022
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA HW3VQ
UT WOS:000466621200060
PM 30735778
DA 2025 08 17
ER

PT J
AU Ma, J
   Ren, J
   Thorikay, M
   van Dinther, M
   Sanchez Duffhues, G
   Caradec, J
   Benderitter, P
   Hoflack, J
   ten Dijke, P
AF Ma, Jin
   Ren, Jiang
   Thorikay, Midory
   van Dinther, Maarten
   Sanchez Duffhues, Gonzalo
   Caradec, Josselin
   Benderitter, Pascal
   Hoflack, Jan
   ten Dijke, Peter
TI Inhibiting Endothelial Cell Function in Normal and Tumor Angiogenesis
   Using BMP Type I Receptor Macrocyclic Kinase Inhibitors
SO CANCERS
LA English
DT Article
DE activin receptor like kinase; angiogenesis; bone morphogenetic protein;
   endothelial cell; macrocyclic kinase inhibitor
ID BONE MORPHOGENETIC PROTEIN; VEGF; EXPRESSION; GROWTH; ALK1;
   NORMALIZATION; VASCULATURE; OSTEOBLAST; STRATEGIES; CANCER
AB Simple Summary Anti angiogenesis agents have shown anti cancer activity by preventing blood vessel ingrowth, thereby limiting tumour growth and metastasis. Although these molecules lead to prolonged overall survival of cancer patients, therapy resistance is easily acquired. Therefore, novel inhibitors against other signaling pathways mediating angiogenesis are needed to achieve more efficient and sustainable targeting of the angiogenesis process. Here, we synthesized and identified two compounds belonging to a new class of small molecules termed macrocyclics that selectively inhibit bone morphogenetic protein receptor kinase activity. One compound also inhibits vascular endothelial growth factor induced signalling. Treatment studies using in vitro cultured cells and zebrafish embryos revealed that both compounds impaired endothelial cell function and decreased normal and tumour induced angiogenesis. Both compounds might provide a steppingstone for the development of novel angiogenesis therapeutic agents. Angiogenesis, i.e., the formation of new blood vessels from pre existing endothelial cell (EC) lined vessels, is critical for tissue development and also contributes to neovascularization related diseases, such as cancer. Vascular endothelial growth factor (VEGF) and bone morphogenetic proteins (BMPs) are among many secreted cytokines that regulate EC function. While several pharmacological anti angiogenic agents have reached the clinic, further improvement is needed to increase clinical efficacy and to overcome acquired therapy resistance. More insights into the functional consequences of targeting specific pathways that modulate blood vessel formation may lead to new therapeutic approaches. Here, we synthesized and identified two macrocyclic small molecular compounds termed OD16 and OD29 that inhibit BMP type I receptor (BMPRI) induced SMAD1/5 phosphorylation and downstream gene expression in ECs. Of note, OD16 and OD29 demonstrated higher specificity against BMPRI activin receptor like kinase 1/2 (ALK1/2) than the commonly used small molecule BMPRI kinase inhibitor LDN 193189. OD29, but not OD16, also potently inhibited VEGF induced extracellular regulated kinase MAP kinase phosphorylation in ECs. In vitro, OD16 and OD29 exerted strong inhibition of BMP9 and VEGF induced ECs migration, invasion and cord formation. Using Tg (fli:EGFP) zebrafish embryos, we found that OD16 and OD29 potently antagonized dorsal longitudinal anastomotic vessel (DLAV), intra segmental vessel (ISV), and subintestinal vessel (SIV) formation during embryonic development. Moreover, the MDA MB 231 breast cancer cell induced tumor angiogenesis in zebrafish embryos was significantly decreased by OD16 and OD29. Both macrocyclic compounds might provide a steppingstone for the development of novel anti angiogenesis therapeutic agents.
C1 [Ma, Jin; Ren, Jiang; Thorikay, Midory; van Dinther, Maarten; Sanchez Duffhues, Gonzalo; ten Dijke, Peter] Leiden Univ, Dept Cell & Chem Biol, Med Ctr, NL 2333 ZC Leiden, Netherlands.
   [Ma, Jin; Thorikay, Midory; van Dinther, Maarten; ten Dijke, Peter] Leiden Univ, Oncode Inst, Med Ctr, NL 2333 ZC Leiden, Netherlands.
   [Caradec, Josselin; Benderitter, Pascal; Hoflack, Jan] Oncodesign SA, F 21000 Dijon, France.
C3 Leiden University; Leiden University Medical Center (LUMC); Leiden
   University   Excl LUMC; Leiden University   Excl LUMC; Leiden
   University; Leiden University Medical Center (LUMC)
RP ten Dijke, P (通讯作者)，Leiden Univ, Dept Cell & Chem Biol, Med Ctr, NL 2333 ZC Leiden, Netherlands.; ten Dijke, P (通讯作者)，Leiden Univ, Oncode Inst, Med Ctr, NL 2333 ZC Leiden, Netherlands.
EM J.Ma@lumc.nl; ren jiang@outlook.com; M.Thorikay@lumc.nl;
   M.A.H.van_Dinther@lumc.nl; G.Sanchez_Duffhues@lumc.nl;
   JCARADEC@oncodesign.com; PBENDERITTER@oncodesign.com;
   JHOFLACK@oncodesign.com; P.ten_Dijke@lumc.nl
RI Sanchez Duffhues, Gonzalo/AAH 1152 2020; Dijke, Peter/AAG 4660 2021; ten
   Dijke, Peter/AAG 4660 2021; Sanchez Duffhues, Gonzalo/D 2201 2017
OI ten Dijke, Peter/0000 0002 7234 342X; Ma, Jin/0000 0002 5343 1352;
   Sanchez Duffhues, Gonzalo/0000 0002 3205 0710; Hoflack,
   Jan/0009 0003 8300 7450
FU CGC.NL; Netherlands Cardio Vascular Research Initiative: the Dutch Heart
   Foundation; Dutch Federation of University Medical Centers; Netherlands
   Organization for Health Research and Development; Royal Netherlands
   Academy of Sciences; Chinese Scholarship Council; FOP Italia; La
   Marato TV3 [202038]
FX Work in our laboratory on the role of BMPs in angiogenesis was supported
   by CGC.NL and the Netherlands Cardio Vascular Research Initiative: the
   Dutch Heart Foundation, the Dutch Federation of University Medical
   Centers, the Netherlands Organization for Health Research and
   Development, and the Royal Netherlands Academy of Sciences Grant awarded
   to the Phaedra Impact and the Reconnect consortia. J.M. was supported by
   the Chinese Scholarship Council. G.S. D. was sponsored by FOP Italia and
   a grant from La Marato TV3 (#202038).
CR Alsamarah A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132221
   Benn A, 2017, FASEB J, V31, P4720, DOI 10.1096/fj.201700193RR
   Bertolino P, 2005, CHEST, V128, p585S, DOI 10.1378/chest.128.6_suppl.585S
   Bodnar RJ, 2006, CIRC RES, V98, P617, DOI 10.1161/01.RES.0000209968.66606.10
   Brown MA, 2005, J BIOL CHEM, V280, P25111, DOI 10.1074/jbc.M503328200
   Burger RA, 2011, NEW ENGL J MED, V365, P2473, DOI 10.1056/NEJMoa1104390
   Cannon JE, 2010, BRIT J PHARMACOL, V161, P140, DOI 10.1111/j.1476 5381.2010.00871.x
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Cook KM, 2010, CA CANCER J CLIN, V60, P222, DOI 10.3322/caac.20075
   Coultas L, 2005, NATURE, V438, P937, DOI 10.1038/nature04479
   Cunha SI, 2010, J EXP MED, V207, P85, DOI 10.1084/jem.20091309
   David L, 2007, BLOOD, V109, P1953, DOI 10.1182/blood 2006 07 034124
   David L, 2009, CYTOKINE GROWTH F R, V20, P203, DOI 10.1016/j.cytogfr.2009.05.001
   Draut H, 2017, CHEM BIODIVERS, V14, DOI 10.1002/cbdv.201600302
   Dyer LA, 2014, TRENDS ENDOCRIN MET, V25, P472, DOI 10.1016/j.tem.2014.05.003
   Ebisawa T, 1999, J CELL SCI, V112, P3519
   Eichmann A, 2012, CURR OPIN CELL BIOL, V24, P188, DOI 10.1016/j.ceb.2012.02.002
   Ferrara N, 2009, EUR CYTOKINE NETW, V20, P158, DOI 10.1684/ecn.2009.0170
   Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801
   Gangopahyay A, 2011, J BIOL CHEM, V286, P33134, DOI 10.1074/jbc.M111.274100
   Hao J, 2010, ACS CHEM BIOL, V5, P245, DOI 10.1021/cb9002865
   Hen G, 2015, DEVELOPMENT, V142, P4266, DOI 10.1242/dev.129247
   Herbert SP, 2011, NAT REV MOL CELL BIO, V12, P551, DOI 10.1038/nrm3176
   Horbelt D, 2015, J BIOL CHEM, V290, P3390, DOI 10.1074/jbc.M114.604397
   Jain RK, 2014, CANCER CELL, V26, P605, DOI 10.1016/j.ccell.2014.10.006
   Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901 987
   Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819
   Kang JI, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 41115 2
   Kelly RJ, 2009, TARGET ONCOL, V4, P297, DOI 10.1007/s11523 009 0126 9
   Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596
   Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200
   Larrivée B, 2012, DEV CELL, V22, P489, DOI 10.1016/j.devcel.2012.02.005
   Lee HW, 2017, ARTERIOSCL THROM VAS, V37, P657, DOI 10.1161/ATVBAHA.116.308422
   Li YY, 2020, J MOL CELL CARDIOL, V147, P92, DOI 10.1016/j.yjmcc.2020.07.010
   Mäkinen K, 2003, ACTA CHIR BELG, V103, P470
   Mallinson J, 2012, FUTURE MED CHEM, V4, P1409, DOI [10.4155/FMC.12.93, 10.4155/fmc.12.93]
   Morikawa M, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021873
   Moya IM, 2012, DEV CELL, V22, P501, DOI 10.1016/j.devcel.2012.01.007
   Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626
   Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014 5793(98)00954 5
   Ren J, 2017, JOVE J VIS EXP, DOI 10.3791/55459
   Roelen BAJ, 1997, DEV DYNAM, V209, P418, DOI 10.1002/(SICI)1097 0177(199708)209:4<418::AID AJA9>3.0.CO;2 L
   Rosen Jonathan N, 2009, J Vis Exp, DOI 10.3791/1115
   Roskoski R, 2007, BIOCHEM BIOPH RES CO, V356, P323, DOI 10.1016/j.bbrc.2007.02.156
   Roukens MG, 2010, NAT CELL BIOL, V12, P933, DOI 10.1038/ncb2096
   Sánchez Duffhues G, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10230
   Scharpfenecker M, 2007, J CELL SCI, V120, P964, DOI 10.1242/jcs.002949
   Seki T, 2003, CIRC RES, V93, P682, DOI 10.1161/01.RES.0000095246.40391.3B
   Simms V. A., 2017, VASCULAR CELL, V9, P2, DOI 10.24238/13221 9 1 172
   Valdimarsdottir G, 2002, CIRCULATION, V106, P2263, DOI 10.1161/01.CIR.0000033830.36431.46
   van Meeteren LA, 2012, J BIOL CHEM, V287, P18551, DOI 10.1074/jbc.M111.338103
   Viallard C, 2020, ONCOGENE, V39, P2996, DOI 10.1038/s41388 020 1200 0
   Viallard C, 2017, ANGIOGENESIS, V20, P409, DOI 10.1007/s10456 017 9562 9
   Voss MH, 2019, CANCER AM CANCER SOC, V125, P2400, DOI 10.1002/cncr.32061
   Wang XZ, 2017, MOL MED REP, V16, P8937, DOI 10.3892/mmr.2017.7730
   Wheatley Price P, 2016, J THORAC ONCOL, V11, P2018, DOI 10.1016/j.jtho.2016.06.024
   Ye L, 2016, CANCER LETT, V380, P586, DOI 10.1016/j.canlet.2015.10.036
   Yoo SY, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/127170
   Zakarija A, 2005, CURR OPIN ONCOL, V17, P578, DOI 10.1097/01.cco.0000183672.15133.ab
NR 59
TC 7
Z9 8
U1 1
U2 6
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6694
J9 CANCERS
JI Cancers
PD JUN
PY 2021
VL 13
IS 12
AR 2951
DI 10.3390/cancers13122951
PG 25
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA SY7VX
UT WOS:000666092000001
PM 34204675
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Li, ZL
   Li, XT
   Hao, RC
   Wang, FY
   Wang, YX
   Zhao, ZD
   Li, PL
   Yin, BF
   Mao, N
   Ding, L
   Zhu, H
AF Li, Zhi Ling
   Li, Xiao Tong
   Hao, Rui Cong
   Wang, Fei Yan
   Wang, Yu Xing
   Zhao, Zhi Dong
   Li, Pei Lin
   Yin, Bo Feng
   Mao, Ning
   Ding, Li
   Zhu, Heng
TI Human osteoarthritic articular cartilage stem cells suppress osteoclasts
   and improve subchondral bone remodeling in experimental knee
   osteoarthritis partially by releasing TNFAIP3
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Cell isolation; Articular cartilage stem cells; Osteoclasts; Subchondral
   bone remodeling; Diseased microenvironments
ID CHONDROGENIC PROGENITOR CELLS; REPAIR; TISSUE; POPULATION; REVEAL;
   MARROW
AB BackgroundThough articular cartilage stem cell (ACSC) based therapies have been demonstrated to be a promising option in the treatment of diseased joints, the wide variety of cell isolation, the unknown therapeutic targets, and the incomplete understanding of the interactions of ACSCs with diseased microenvironments have limited the applications of ACSCs.MethodsIn this study, the human ACSCs have been isolated from osteoarthritic articular cartilage by advantage of selection of anatomical location, the migratory property of the cells, and the combination of traumatic injury, mechanical stimuli and enzymatic digestion. The protective effects of ACSC infusion into osteoarthritis (OA) rat knees on osteochondral tissues were evaluated using micro CT and pathological analyses. Moreover, the regulation of ACSCs on osteoarthritic osteoclasts and the underlying mechanisms in vivo and in vitro were explored by RNA sequencing, pathological analyses and functional gain and loss experiments. The one way ANOVA was used in multiple group data analysis.ResultsThe ACSCs showed typical stem cell like characteristics including colony formation and committed osteo chondrogenic capacity. In addition, intra articular injection into knee joints yielded significant improvement on the abnormal subchondral bone remodeling of osteoarthritic rats. Bioinformatic and functional analysis showed that ACSCs suppressed osteoarthritic osteoclasts formation, and inflammatory joint microenvironment augmented the inhibitory effects. Further explorations demonstrated that ACSC derived tumor necrosis factor alpha induced protein 3 (TNFAIP3) remarkably contributed to the inhibition on osteoarhtritic osteoclasts and the improvement of abnormal subchondral bone remodeling.ConclusionIn summary, we have reported an easy and reproducible human ACSC isolation strategy and revealed their effects on subchondral bone remodeling in OA rats by releasing TNFAIP3 and suppressing osteoclasts in a diseased microenvironment responsive manner.
C1 [Li, Zhi Ling; Li, Xiao Tong; Hao, Rui Cong; Wang, Fei Yan; Wang, Yu Xing; Zhao, Zhi Dong; Li, Pei Lin; Yin, Bo Feng; Zhu, Heng] Beijing Inst Radiat Med, Dept Stem Cells & Regenerat Med, Rd Taiping 27, Beijing 100850, Peoples R China.
   [Hao, Rui Cong; Wang, Fei Yan; Zhu, Heng] Anhui Med Univ, Basic Med Coll, Hefei 230032, Anhui, Peoples R China.
   [Wang, Yu Xing; Zhao, Zhi Dong] Peoples Liberat Army Gen Hosp, Fuxing Rd 28, Beijing 100853, Peoples R China.
   [Mao, Ning] Beijing Inst Basic Med Sci, Rd Taiping 27, Beijing 100850, Peoples R China.
   [Ding, Li] Air Force Med Ctr, PLA, Rd Fucheng 30, Beijing 100142, Peoples R China.
C3 Anhui Medical University; Chinese People's Liberation Army General
   Hospital
RP Zhu, H (通讯作者)，Beijing Inst Radiat Med, Dept Stem Cells & Regenerat Med, Rd Taiping 27, Beijing 100850, Peoples R China.; Zhu, H (通讯作者)，Anhui Med Univ, Basic Med Coll, Hefei 230032, Anhui, Peoples R China.; Ding, L (通讯作者)，Air Force Med Ctr, PLA, Rd Fucheng 30, Beijing 100142, Peoples R China.
EM dingli7578@163.com; zhudingdingabc@163.com
RI zhu, dingdingabc/AAZ 7892 2020; li, peilin/R 4460 2019; Wang,
   Yuxing/F 3195 2017
OI Zhu, Heng/0000 0002 8408 3821; 
FU No.
FX No.
CR Arden NK, 2021, NAT REV RHEUMATOL, V17, P59, DOI 10.1038/s41584 020 00523 9
   Bannuru RR, 2019, OSTEOARTHR CARTILAGE, V27, P1578, DOI 10.1016/j.joca.2019.06.011
   Berenbaum F, 2018, NAT REV RHEUMATOL, V14, P674, DOI 10.1038/s41584 018 0073 x
   Duarte Joao H, 2014, Nat Rev Rheumatol, V10, P446, DOI 10.1038/nrrheum.2014.107
   Goldring SR, 2016, NAT REV RHEUMATOL, V12, P632, DOI 10.1038/nrrheum.2016.148
   He J, 2021, CELL RES, V31, P742, DOI 10.1038/s41422 021 00467 z
   Hong JY, 2016, J PERIODONTAL RES, V51, P529, DOI 10.1111/jre.12332
   Hu WH, 2021, ANN RHEUM DIS, V80, P413, DOI 10.1136/annrheumdis 2020 218089
   Hunter DJ, 2019, LANCET, V393, P1745, DOI 10.1016/S0140 6736(19)30417 9
   Jensen EC, 2013, ANAT REC, V296, P378, DOI 10.1002/ar.22641
   Jiang WH, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00201 4
   Jiang YZ, 2016, STEM CELL TRANSL MED, V5, P733, DOI 10.5966/sctm.2015 0192
   Jiang YZ, 2015, NAT REV RHEUMATOL, V11, P206, DOI 10.1038/nrrheum.2014.200
   Katz JN, 2021, JAMA J AM MED ASSOC, V325, P568, DOI 10.1001/jama.2020.22171
   Kim JE, 2014, INT J NANOMED, V9, P141, DOI 10.2147/IJN.S54114
   Koelling S, 2009, CELL STEM CELL, V4, P324, DOI 10.1016/j.stem.2009.01.015
   Le Blanc K, 2012, NAT REV IMMUNOL, V12, P383, DOI 10.1038/nri3209
   Li PL, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02353 2
   Li X, 2020, STEM CELL TRANSL MED, V9, P261, DOI 10.1002/sctm.19 0300
   Mantripragada VP, 2018, J BONE JOINT SURG AM, V100, P1771, DOI 10.2106/JBJS.18.00005
   Martens A, 2022, EMBO REP, V23, DOI 10.15252/embr.202255233
   Ng J, 2020, STEM CELLS, V38, P477, DOI 10.1002/stem.3139
   OFNER D, 1992, PATHOL RES PRACT, V188, P742
   Pan J, 2009, J ORTHOP RES, V27, P1347, DOI 10.1002/jor.20883
   Pippenger BE, 2015, OSTEOARTHR CARTILAGE, V23, P1865, DOI 10.1016/j.joca.2015.07.021
   Pretzel D, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3320
   Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014
   Rikkers M, 2022, NPJ REGEN MED, V7, DOI 10.1038/s41536 021 00203 6
   Shang FQ, 2021, BIOACT MATER, V6, P666, DOI 10.1016/j.bioactmat.2020.08.014
   Sharma L, 2021, NEW ENGL J MED, V384, P51, DOI 10.1056/NEJMcp1903768
   Su XL, 2015, J ORTHOP RES, V33, P84, DOI 10.1002/jor.22731
   Sui BD, 2019, BIOMATERIALS, V196, P18, DOI 10.1016/j.biomaterials.2017.10.046
   Tao TQ, 2018, TISSUE ENG PT A, V24, P1112, DOI [10.1089/ten.tea.2017.0322, 10.1089/ten.TEA.2017.0322]
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Wang KT, 2019, AM J SPORT MED, V47, P2200, DOI 10.1177/0363546519854219
   Wang YX, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 2144 z
   Ward LSC, 2019, J CELL SCI, V132, DOI 10.1242/jcs.222067
   Wu MJM, 2022, AM J SPORT MED, V50, P3090, DOI 10.1177/03635465221113325
   Wu YY, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 02281 1
   Xie XT, 2012, BIOMATERIALS, V33, P7008, DOI 10.1016/j.biomaterials.2012.06.058
   Xu CC, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 03178 3
   Yan K, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12778
   Yu Y, 2014, OSTEOARTHR CARTILAGE, V22, P1318, DOI 10.1016/j.joca.2014.07.002
   Zelinka A, 2022, Osteoarthritis Cartilage, V20
   Zhou C, 2016, OSTEOARTHR CARTILAGE, V24, P1648, DOI 10.1016/j.joca.2016.04.016
   Zhou C, 2014, J ORTHOP RES, V32, P981, DOI 10.1002/jor.22641
   Zhu H, 2015, BIOMATERIALS, V53, P688, DOI 10.1016/j.biomaterials.2015.03.005
   Zhu H, 2010, NAT PROTOC, V5, P550, DOI 10.1038/nprot.2009.238
NR 48
TC 8
Z9 9
U1 2
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD SEP 27
PY 2023
VL 14
IS 1
AR 253
DI 10.1186/s13287 023 03411 7
PG 18
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA S4VW1
UT WOS:001071170000001
PM 37752608
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Yan, WL
   Shen, M
   Sun, KN
   Li, SM
   Miao, JY
   Wang, J
   Xu, JY
   Wen, PC
   Zhang, Q
AF Yan, Wenliang
   Shen, Meng
   Sun, Kainong
   Li, Shiming
   Miao, Jingyuan
   Wang, Jun
   Xu, Jiayang
   Wen, Pengcheng
   Zhang, Qian
TI Norisoboldine, a Natural Isoquinoline Alkaloid, Inhibits Diaphyseal
   Fracture Healing in Mice by Alleviating Cartilage Formation
SO BIOMEDICINES
LA English
DT Article
DE norisoboldine; fracture healing; BMP2; endochondral ossification
ID COLLAGEN INDUCED ARTHRITIS; RADIX LINDERAE; DIFFERENTIATION; REPAIR;
   ACTIVATION; CELLS; RATS; BMP2
AB Norisoboldine (NOR), the major isoquinoline alkaloid constituent of a Chinese traditional medicine Radix Linderae, has been demonstrated to inhibit osteoclast differentiation and improve arthritis. The aim of this study is to examine the effect of NOR on bone fracture healing and the underlying mechanisms correlated with bone marrow stromal cells (BMSCs) differentiation to chondrocytes. Our results showed that NOR inhibits the tibia fracture healing process by suppressing cartilage formation, which leads to less endochondral ossification, indicated by less osterix and collage I signaling at the fracture site. Moreover, NOR significantly reduced the differentiation of primary BMSCs to chondrocytes in vitro by reducing the bone morphogenetic protein 2 (BMP2) signaling. These findings imply that NOR negatively regulates the healing of the tibial midshaft fracture, which might delay the union of the fractures and should be noticed when used in other treatments.
C1 [Yan, Wenliang; Miao, Jingyuan; Wen, Pengcheng] Gansu Agr Univ, Coll Food Sci & Engn, Lanzhou 730070, Peoples R China.
   [Yan, Wenliang; Shen, Meng; Sun, Kainong; Li, Shiming; Miao, Jingyuan; Wang, Jun; Xu, Jiayang; Zhang, Qian] China Agr Univ, Dept Nutr & Hlth, Beijing 100193, Peoples R China.
   [Sun, Kainong; Zhang, Qian] Food Lab Zhongyuan, Luohe 462300, Peoples R China.
C3 Gansu Agricultural University; China Agricultural University
RP Wen, PC (通讯作者)，Gansu Agr Univ, Coll Food Sci & Engn, Lanzhou 730070, Peoples R China.; Zhang, Q (通讯作者)，China Agr Univ, Dept Nutr & Hlth, Beijing 100193, Peoples R China.; Zhang, Q (通讯作者)，Food Lab Zhongyuan, Luohe 462300, Peoples R China.
EM wenpch@126.com; qianzhang@cau.edu.cn
RI ; Zhang, Qian/B 5047 2019
OI Wen, Pengcheng/0000 0002 4521 4067; Li, Shi ming/0000 0003 0116 2493; 
FU National Natural Science Foundation of China [82272566]; Beijing Nova
   Program [20220484144]; 111 Project from the Education Ministry of China
   [B18053]; FUXI Talents Program of Gansu Agricultural University
   [Gaufx 02Y01]
FX Please add: This work was supported by the National Natural Science
   Foundation of China Grant 82272566 (to Q.Z.), Beijing Nova Program
   20220484144 (to Q.Z.), the 111 Project from the Education Ministry of
   China B18053 (to Q.Z.), and the FUXI Talents Program of Gansu
   Agricultural University Gaufx 02Y01 (to P.W.).
CR Bahney CS, 2019, J ORTHOP RES, V37, P35, DOI 10.1002/jor.24170
   Chen Q, 2021, BIOL PHARM BULL, V44, P1536, DOI 10.1248/bpb.b21 00457
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Gao S, 2016, IMMUNOPHARM IMMUNOT, V38, P327, DOI 10.1080/08923973.2016.1202961
   Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435
   Gerstenfeld LC, 2003, J BONE MINER RES, V18, P1584, DOI 10.1359/jbmr.2003.18.9.1584
   Hu DP, 2017, DEVELOPMENT, V144, P221, DOI 10.1242/dev.130807
   Kayal R, 2009, BONE, V44, P357, DOI 10.1016/j.bone.2008.10.042
   Kitaori T, 2009, ARTHRITIS RHEUM US, V60, P813, DOI 10.1002/art.24330
   Kodama J, 2022, BONE REP, V17, DOI 10.1016/j.bonr.2022.101616
   Legendre F, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03579 y
   Li X, 2011, ORTHOPEDICS, V34, P450, DOI 10.3928/01477447 20110427 19
   Lu DA, 2012, EXP BIOL MED, V237, P919, DOI 10.1258/ebm.2012.011416
   Lu Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081220
   Luo Y, 2010, PHYTOMEDICINE, V17, P726, DOI 10.1016/j.phymed.2010.01.013
   Lv Q, 2018, CHIN J NAT MEDICINES, V16, P161, DOI 10.1016/S1875 5364(18)30044 X
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Ogasawara A, 2008, BONE, V43, P832, DOI 10.1016/j.bone.2008.07.246
   Shao R, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00148 y
   Shu B, 2011, J CELL SCI, V124, P3428, DOI 10.1242/jcs.083659
   Song JH, 2022, TISSUE ENG REGEN MED, V19, P565, DOI 10.1007/s13770 021 00412 6
   Tong B, 2015, TOXICOL APPL PHARM, V282, P90, DOI 10.1016/j.taap.2014.11.008
   Tu JW, 2014, BONE, V69, P12, DOI 10.1016/j.bone.2014.08.016
   Wang CC, 2016, J CLIN INVEST, V126, P1471, DOI 10.1172/JCI80672
   Wang JY, 2022, J ORTHOP SURG RES, V17, DOI 10.1186/s13018 022 03364 2
   Wei ZF, 2015, INT J BIOL SCI, V11, P1113, DOI 10.7150/ijbs.12152
   Wei ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059171
   Wei ZF, 2012, J CELL BIOCHEM, V113, P2785, DOI 10.1002/jcb.24156
   Xing DD, 2022, J BIOCHEM MOL TOXIC, V36, DOI 10.1002/jbt.22937
   Zhang CT, 2019, J BONE MINER RES, V34, P547, DOI 10.1002/jbmr.3610
   Zhao C, 2017, GENES DIS, V4, P229, DOI 10.1016/j.gendis.2017.10.004
   Zhou N, 2016, CELL TISSUE RES, V366, P101, DOI 10.1007/s00441 016 2403 0
NR 32
TC 4
Z9 4
U1 2
U2 18
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2227 9059
J9 BIOMEDICINES
JI Biomedicines
PD JUL
PY 2023
VL 11
IS 7
AR 2031
DI 10.3390/biomedicines11072031
PG 9
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA N1VP7
UT WOS:001034975500001
PM 37509670
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Rundle, CH
   Strong, DD
   Chen, ST
   Linkhart, TA
   Sheng, MHC
   Wergedal, JE
   Lau, KHW
   Baylink, DJ
AF Rundle, Charles H.
   Strong, Donna D.
   Chen, Shin Tai
   Linkhart, Thomas A.
   Sheng, Matilda H.  C.
   Wergedal, Jon E.
   Lau, K.  H. William
   Baylink, David J.
TI Retroviral based gene therapy with cyclooxygenase 2 promotes the union
   of bony callus tissues and accelerates fracture heating in the rat
SO JOURNAL OF GENE MEDICINE
LA English
DT Article
DE bone; cyclooxygenase 2; fracture healing; gene therapy; prostaglandins;
   retroviral vectors
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROSTAGLANDIN E 2; GROWTH FACTORS;
   IN VIVO; CALVARIAL OSTEOBLASTS; MECHANICAL PROPERTIES; STROMAL CELLS;
   EXPRESSION; REPAIR; ENHANCEMENT
AB Background An in vivo gene therapy strategy was developed to accelerate bone fracture repair.
   Methods Direct injection of a murine leukemia virus based vector targeted transgene expression to the proliferating periosteal cells arising shortly after fracture. Cyclooxygenase 2 (Cox 2) was selected because the transgene for its prostaglandin products that promote angiogenesis, bone formation and bone resorption, are all required for fracture healing. The human (h) Cox 2 transgene was modified to remove AU rich elements in the T untranslated region and to improve protein translation.
   Results In vitro studies revealed robust and sustained Cox 2 protein expression, prostaglandin E 2 and alkaline phosphatase production in rat bone marrow stromal cells and osteoblasts transgenic for the hCox 2 gene. In vivo studies in the rat femur fracture revealed that Cox 2 transgene expression produced bony union of the fracture by 21 days post fracture, a time when cartilage persisted within the fracture tissues of control animals and approximately 1 week earlier than the healing normally observed in this model. None of the ectopic bone formation associated with bone morphogenetic protein gene therapy was observed.
   Conclusions This study represents the first demonstration that a single local application of a retroviral vector expressing a single osteoinductive transgene consistently accelerated fracture repair. Copyright (C) 2007 John Wiley & Sons, Ltd.
C1 [Sheng, Matilda H.  C.; Lau, K.  H. William] Jerry L Pettis Mem Vet Adm Med Ctr, Musculoskeletal Dis Ctr 151, Loma Linda, CA 92357 USA.
   [Rundle, Charles H.; Strong, Donna D.; Chen, Shin Tai; Linkhart, Thomas A.; Sheng, Matilda H.  C.; Wergedal, Jon E.; Lau, K.  H. William; Baylink, David J.] Loma Linda Univ, Dept Med, Loma Linda, CA 92350 USA.
   [Strong, Donna D.; Chen, Shin Tai; Wergedal, Jon E.; Lau, K.  H. William; Baylink, David J.] Loma Linda Univ, Dept Biochem & Microbiol, Loma Linda, CA 92350 USA.
   [Linkhart, Thomas A.] Loma Linda Univ, Dept Pediat, Loma Linda, CA 92350 USA.
C3 Loma Linda University; Loma Linda University; Loma Linda University
RP Lau, KHW (通讯作者)，Jerry L Pettis Mem Vet Adm Med Ctr, Musculoskeletal Dis Ctr 151, 11201 Benton St, Loma Linda, CA 92357 USA.
EM william.lau@med.va.gov
RI Weston, Wendy/J 3653 2015
OI Weston, Wendy/0000 0002 6748 6653; Lau, Kin Hing/0000 0003 1109 5052
CR Alkhiary YM, 2005, J BONE JOINT SURG AM, V87A, P731, DOI 10.2106/JBJS.D.02115
   Beasley Leslie S., 2000, P311
   Bhattacharyya T, 2005, ARTHRIT RHEUM ARTHR, V53, P364, DOI 10.1002/art.21170
   BOLANDER ME, 1992, P SOC EXP BIOL MED, V200, P165
   BORMARENS F, 1984, J ORTHOP RES, V2, P97
   Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200
   Eckardt H, 2005, J BONE JOINT SURG BR, V87B, P1434, DOI 10.1302/0301 620X.87B10
   Einhorn TA, 2003, J BONE JOINT SURG AM, V85A, P1425, DOI 10.2106/00004623 200308000 00002
   EINHORN TA, 1995, J BONE JOINT SURG AM, V77A, P940, DOI 10.2106/00004623 199506000 00016
   EKELAND A, 1982, ACTA ORTHOP SCAND, V53, P527, DOI 10.3109/17453678208992252
   Futagami A, 2002, LAB INVEST, V82, P1503, DOI 10.1097/01.LAB.0000035024.75914.39
   Gerstenfeld L. C., 2003, Journal of Musculoskeletal & Neuronal Interactions, V3, P297
   Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435
   Gerstenfeld LC, 2003, J ORTHOP RES, V21, P670, DOI 10.1016/S0736 0266(03)00003 2
   González L, 2001, J COMP PATHOL, V125, P41, DOI 10.1053/jcpa.2001.0475
   Gysin R, 2002, GENE THER, V9, P991, DOI 10.1038/sj.gt.3301772
   Hannouche D, 2001, J BONE JOINT SURG BR, V83B, P157, DOI 10.1302/0301 620X.83B2.12106
   HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384
   Iwaki A, 1997, J BONE MINER RES, V12, P96, DOI 10.1359/jbmr.1997.12.1.96
   JINGUSHI S, 1990, J ORTHOP RES, V8, P364, DOI 10.1002/jor.1100080308
   JOYCE ME, 1990, ORTHOP CLIN N AM, V21, P199
   Kaneki H, 1999, J CELL BIOCHEM, V73, P36, DOI 10.1002/(SICI)1097 4644(19990401)73:1<36::AID JCB5>3.3.CO;2 6
   Kawaguchi H, 2001, J CLIN ENDOCR METAB, V86, P875, DOI 10.1210/jc.86.2.875
   KAWAGUCHI H, 1995, CLIN ORTHOP RELAT R, P36
   Keila S, 2001, J ENDOCRINOL, V168, P131, DOI 10.1677/joe.0.1680131
   Keller J, 1996, DAN MED BULL, V43, P317
   KELLER J, 1993, ACTA ORTHOP SCAND, V64, P59, DOI 10.3109/17453679308994530
   KYEYUNENYOMBI E, 1995, CALCIFIED TISSUE INT, V56, P154, DOI 10.1007/BF00296348
   LIDA Y, 1995, NUCL ACIDS S SER, V34, P103
   Lieberman JR, 2002, J BONE JOINT SURG AM, V84A, P1032, DOI 10.2106/00004623 200206000 00022
   MCCARTHY TL, 1994, J CELL PHYSIOL, V160, P163, DOI 10.1002/jcp.1041600119
   McCormack JE, 1997, HUM GENE THER, V8, P1263, DOI 10.1089/hum.1997.8.10 1263
   Meyer RA, 2003, J BONE JOINT SURG AM, V85A, P1243, DOI 10.2106/00004623 200307000 00010
   Meyer RA, 2001, J ORTHOP RES, V19, P428, DOI 10.1016/S0736 0266(00)90034 2
   Moalic S, 2001, INT J ONCOL, V18, P533
   MOSKALEWSKI S, 1983, AM J ANAT, V167, P249, DOI 10.1002/aja.1001670210
   NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.bi.55.070186.000441
   Panagiotis M, 2005, INJURY, V36, pS30, DOI 10.1016/j.injury.2005.10.008
   Paralkar VM, 2003, P NATL ACAD SCI USA, V100, P6736, DOI 10.1073/pnas.1037343100
   Paralkar VM, 2002, J CELL PHYSIOL, V190, P207, DOI 10.1002/JCP.10048
   Peng HR, 2001, MOL THER, V4, P95, DOI 10.1006/mthe.2001.0423
   RAISZ LG, 1993, ENDOCRINOLOGY, V133, P1504, DOI 10.1210/en.133.4.1504
   ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460 2075.1993.tb05858.x
   Rundle CH, 2006, BONE, V38, P521, DOI 10.1016/j.bone.2005.09.015
   Rundle CH, 2003, BONE, V32, P591, DOI 10.1016/S8756 3282(03)00096 6
   Samoto H, 2003, J BIOL CHEM, V278, P28659, DOI 10.1074/jbc.M300671200
   Shamir D, 2004, BONE, V34, P157, DOI 10.1016/j.bone.2003.09.008
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   von Rahden BHA, 2005, CANCER RES, V65, P5038, DOI 10.1158/0008 5472.CAN 04 1107
   YASKO AW, 1992, J BONE JOINT SURG AM, V74A, P659, DOI 10.2106/00004623 199274050 00005
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 51
TC 42
Z9 47
U1 0
U2 1
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 1099 498X
J9 J GENE MED
JI J. Gene. Med.
PD MAR
PY 2008
VL 10
IS 3
BP 229
EP 241
DI 10.1002/jgm.1148
PG 13
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 283YP
UT WOS:000254672700001
PM 18088065
DA 2025 08 17
ER

PT J
AU Xu, JC
   Ji, J
   Wang, Z
   Xu, T
AF Xu, Jiancheng
   Ji, Jing
   Wang, Zhan
   Xu, Tao
TI Mechanism of Bazedoxifene/conjugated estrogens drugs therapy and its
   Clinical effect on osteoporosis
SO PROGRESS IN NUTRITION
LA English
DT Article
DE Estrogen; Bazedoxifene; Osteoporosis; Clinical effect
ID OSTEOCLAST DIFFERENTIATION; OSTEOPROTEGERIN; FRACTURE; LIGAND; ALPHA;
   CELLS
AB Objective: To observe the clinical effects and explore the mechanism of Bazedoxifene/conjugated estrogens upon bone targeting in the treatment of postmenopausal osteoporosis Methods: The study group was inclusive of 211 postmenopausal osteoporotic patients who were under treatment with Bazedoxifene/conjugated estrogens drugs in the study hospital during the period January and December 2018. The control group contained 56 patients and were treated only with calcium. The researchers analyzed the risks involved in the adverse events such as bone mineral density, osteoprotegerin (OPG) and insulin like growth factor (IGF) and fracture prior to and after the treatment. Results: The study results inferred that the clinical treatment effective rate was 88.39% in Study group whereas it was 23.21% in the control group and were statistically significant (P<0.05). Prior to treatment, the researchers identified no significant difference in mean lumbar positive position (L2 4) and right femoral neck bone density IL 1 beta in between the groups (P>0.05). However, after the treatment, the study group data showed high mean lumbar positive position (L2 4) and heavy right femoral neck bone density in comparison with the control group (P<0.05). When compared to the control group (P<0.05), the Study group experienced less number of adverse events after 12 months of treatment. Conclusion: Bazedoxifene/conjugated estrogen is proved in the current study as an efficient drug to treat postmenopausal osteoporosis. It has the ability to arrest the rapid loss of bone mass, enhance the bone density, mitigate fracture risks and effectively reduce the symptoms of menopause.
C1 [Xu, Jiancheng; Ji, Jing; Xu, Tao] Gansu Prov Hosp Tradit Chinese Med, Dept Rehabil Med, Lanzhou, Gansu, Peoples R China.
   [Wang, Zhan] Lanzhou Univ, Dept Orthopaed, Peoples Clin Med Coll, Gansu Prov Hosp, Lanzhou, Gansu, Peoples R China.
C3 Lanzhou University
RP Xu, T (通讯作者)，Gansu Prov Hosp Tradit Chinese Med, Dept Rehabil Med, Lanzhou, Gansu, Peoples R China.
EM bv856632@126.com
CR Chen LR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092213
   Coughlan T, 2014, CLIN MED, V14, P187, DOI 10.7861/clinmedicine.14 2 187
   Ferretti C, 2014, TISSUE ENG PT A, V20, P2473, DOI [10.1089/ten.tea.2013.0453, 10.1089/ten.TEA.2013.0453]
   Figliomeni A, 2018, CLIN EXP RHEUMATOL, V36, P948
   Hofbauer LC, 1997, EUR J ENDOCRINOL, V137, P345, DOI 10.1530/eje.0.1370345
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4367, DOI 10.1210/en.140.9.4367
   Jehle Peter M., 2003, Eur J Intern Med, V14, P32, DOI 10.1016/S0953 6205(02)00183 8
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Levin VA, 2018, OSTEOPOROSIS INT, V29, P1049, DOI 10.1007/s00198 018 4414 z
   Li ZN, 2019, BIOCHEM PHARMACOL, V163, P279, DOI 10.1016/j.bcp.2019.02.002
   Mano H, 2001, CYTOTECHNOLOGY, V35, P17, DOI 10.1023/A:1008188120766
   Mesalic L, 2008, BOSNIAN J BASIC MED, V8, P188, DOI 10.17305/bjbms.2008.2980
   Orimo H, 2001, J BONE MINER METAB, V19, P331, DOI 10.1007/s007740170001
   Sang CL, 2016, BONE, V84, P78, DOI 10.1016/j.bone.2015.12.012
   Schnitzer Thomas J, 2003, Curr Rheumatol Rep, V5, P43, DOI 10.1007/s11926 003 0082 9
   Sun MQ, 2016, CYTOKINE, V80, P35, DOI 10.1016/j.cyto.2016.01.011
   WIGNALL FS, 1992, J MED VIROL, V38, P44, DOI 10.1002/jmv.1890380110
   Xiang D, 2018, EUR REV MED PHARMACO, V22, P8084, DOI 10.26355/eurrev_201812_16498
   Xing Q, 2015, BIOMED RES INT, V2015
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 20
TC 0
Z9 0
U1 0
U2 0
PU MATTIOLI 1885
PI FIDENZA
PA VIA DELLA LODESANA 649 SX, FIDENZA, 43046 PR, ITALY
SN 1129 8723
J9 PROG NUTR
JI Prog. Nutr.
PY 2021
VL 23
IS 2
AR e2021069
DI 10.23751/pn.v23i2.10101
PG 7
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA TD8CT
UT WOS:000669548500062
DA 2025 08 17
ER

PT J
AU Huk, DJ
   Austin, BF
   Horne, TE
   Hinton, RB
   Ray, WC
   Heistad, DD
   Lincoln, J
AF Huk, Danielle J.
   Austin, Blair F.
   Horne, Tori E.
   Hinton, Robert B.
   Ray, William C.
   Heistad, Donald D.
   Lincoln, Joy
TI Valve Endothelial Cell Derived Tgfβ1 Signaling Promotes Nuclear
   Localization of Sox9 in Interstitial Cells Associated With Attenuated
   Calcification
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE animal model cardiovascular disease; aortic valve; endothelial cell;
   heart valve; signaling pathways
ID AUTOSOMAL SEX REVERSAL; MOUSE MODEL; TRANSFORMING GROWTH FACTOR BETA 1;
   CAMPOMELIC DYSPLASIA; II COLLAGEN; HEART; BETA; STENOSIS; DISEASE;
   PROGRESSION
AB Objective Aortic valve disease, including calcification, affects >2% of the human population and is caused by complex interactions between multiple risk factors, including genetic mutations, the environment, and biomechanics. At present, there are no effective treatments other than surgery, and this is because of the limited understanding of the mechanisms that underlie the condition. Previous work has shown that valve interstitial cells within the aortic valve cusps differentiate toward an osteoblast like cell and deposit bone like matrix that leads to leaflet stiffening and calcific aortic valve stenosis. However, the mechanisms that promote pathological phenotypes in valve interstitial cells are unknown.
   Approach and Results Using a combination of in vitro and in vivo tools with mouse, porcine, and human tissue, we show that in valve interstitial cells, reduced Sox9 expression and nuclear localization precedes the onset of calcification. In vitro, Sox9 nuclear export and calcific nodule formation is prevented by valve endothelial cells. However, in vivo, loss of Tgf1 in the endothelium leads to reduced Sox9 expression and calcific aortic valve disease.
   Conclusions Together, these findings suggest that reduced nuclear localization of Sox9 in valve interstitial cells is an early indicator of calcification, and therefore, pharmacological targeting to prevent nuclear export could serve as a novel therapeutic tool in the prevention of calcification and stenosis.
C1 [Huk, Danielle J.] Leonard M Miller Sch Med, Mol & Cellular Pharmacol Grad Program, Miami, FL USA.
   [Huk, Danielle J.; Austin, Blair F.; Horne, Tori E.; Lincoln, Joy] Nationwide Childrens Hosp Res Inst, Ctr Cardiovasc Res, 575 Childrens Crossroad,WB4239, Columbus, OH 43215 USA.
   [Huk, Danielle J.; Austin, Blair F.; Horne, Tori E.; Lincoln, Joy] Nationwide Childrens Hosp Res Inst, Ctr Heart, Columbus, OH USA.
   [Hinton, Robert B.] Cincinnati Childrens Hosp Med Ctr, Inst Heart, Div Cardiol, Cincinnati, OH 45229 USA.
   [Ray, William C.] Nationwide Childrens Hosp Res Inst, Battelle Ctr Math Med, Columbus, OH USA.
   [Ray, William C.] Ohio State Univ, Interdisciplinary Grad Program Biophys, Columbus, OH 43210 USA.
   [Ray, William C.; Lincoln, Joy] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA.
   [Heistad, Donald D.] Univ Iowa, Carver Coll Med, Div Cardiovasc Med, Iowa City, IA USA.
   [Heistad, Donald D.] Univ Iowa, Dept Pharmacol, Carver Coll Med, Iowa City, IA 52242 USA.
C3 University System of Ohio; Ohio State University; Nationwide Childrens
   Hospital; Research Institute at Nationwide Children's Hospital;
   University System of Ohio; Ohio State University; Nationwide Childrens
   Hospital; Research Institute at Nationwide Children's Hospital; Center
   for Cardiovascular & Pulmonary Research; Cincinnati Children's Hospital
   Medical Center; University System of Ohio; Ohio State University;
   Nationwide Childrens Hospital; Research Institute at Nationwide
   Children's Hospital; University System of Ohio; Ohio State University;
   University of Iowa; University of Iowa
RP Lincoln, J (通讯作者)，Nationwide Childrens Hosp Res Inst, Ctr Cardiovasc Res, 575 Childrens Crossroad,WB4239, Columbus, OH 43215 USA.
EM joy.lincoln@nationwidechildrens.org
RI ; Ray, William/E 3930 2011
OI Ray, William/0000 0002 4207 250X; Lincoln, Joy/0000 0003 1517 6888; 
FU National Institutes of Health (NIH) [HL091878, HL127033]; NIH [HL62984];
   American Heart Association [14GRNT19630003];  [13PRE13930008]; American
   Heart Association (AHA) [14GRNT19630003] Funding Source: American Heart
   Association (AHA)
FX National Institutes of Health (NIH) HL091878, HL127033 (J. Lincoln), NIH
   HL62984 (D.D. Heistad), American Heart Association Grant in Aid
   (14GRNT19630003, J. Lincoln), and Predoctoral Fellowship Awards
   (13PRE13930008, D.J. Huk).
CR Acharya A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027743
   Arjunon S, 2013, ANN BIOMED ENG, V41, P1331, DOI 10.1007/s10439 013 0785 7
   Barnette DN, 2013, J MOL CELL CARDIOL, V65, P137, DOI 10.1016/j.yjmcc.2013.10.007
   Beckmann E, 2010, J HEART VALVE DIS, V19, P441
   Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697 174
   Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792
   Bosse K, 2013, J MOL CELL CARDIOL, V60, P27, DOI 10.1016/j.yjmcc.2013.04.001
   Bowen CJ, 2015, DEV BIOL, V407, P145, DOI 10.1016/j.ydbio.2015.07.012
   Butcher JT, 2006, TISSUE ENG, V12, P905, DOI 10.1089/ten.2006.12.905
   Cavalca V, 2013, INTERACT CARDIOV TH, V17, P923, DOI 10.1093/icvts/ivt386
   Cheng AX, 2010, J BONE MINER RES, V25, P2404, DOI 10.1002/jbmr.174
   Chester Adrian H, 2014, Glob Cardiol Sci Pract, V2014, P52, DOI 10.5339/gcsp.2014.11
   Clark Greuel JN, 2007, ANN THORAC SURG, V83, P946, DOI 10.1016/j.athoracsur.2006.10.026
   Dasu D, 2013, J HEART VALVE DIS, V22, P621
   Fang M, 2014, ARTERIOSCL THROM VAS, V34, P2601, DOI 10.1161/ATVBAHA.114.304579
   FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0
   Freeman RV, 2005, CIRCULATION, V111, P3316, DOI 10.1161/CIRCULATIONAHA.104.486738
   Garg V, 2005, NATURE, V437, P270, DOI 10.1038/nature03940
   GLAGOV S, 1988, ARCH PATHOL LAB MED, V112, P1018
   Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80
   Gould Russell A, 2010, J Vis Exp, DOI 10.3791/2158
   Gould ST, 2014, BIOMATERIALS, V35, P3596, DOI 10.1016/j.biomaterials.2014.01.005
   Gu XX, 2011, AM J PHYSIOL HEART C, V300, pH448, DOI 10.1152/ajpheart.01178.2009
   Hagler MA, 2013, CARDIOVASC RES, V99, P175, DOI 10.1093/cvr/cvt083
   Haudenschild DR, 2010, ARTHRITIS RHEUM US, V62, P191, DOI 10.1002/art.25051
   Hinton RB, 2006, CIRC RES, V98, P1431, DOI 10.1161/01.RES.0000224114.65109.4e
   Honda S, 2014, ARTERIOSCL THROM VAS, V34, P270, DOI 10.1161/ATVBAHA.113.302610
   Hulin A, 2012, CARDIOVASC RES, V93, P480, DOI 10.1093/cvr/cvr337
   Hutcheson JD, 2014, NAT REV CARDIOL, V11, P218, DOI 10.1038/nrcardio.2014.1
   Jian B, 2003, ANN THORAC SURG, V75, P457, DOI 10.1016/S0003 4975(02)04312 6
   Kim L, 2008, J KOREAN MED SCI, V23, P41, DOI 10.3346/jkms.2008.23.1.41
   Kou I, 2004, J BIOL CHEM, V279, P50942, DOI 10.1074/jbc.M406786200
   Lincoln J, 2007, DEV BIOL, V305, P120, DOI 10.1016/j.ydbio.2007.02.002
   Lincoln J, 2014, CIRC J, V78, P1801, DOI 10.1253/circj.CJ 14 0510
   Lincoln J, 2006, DEV BIOL, V294, P292, DOI 10.1016/j.ydbio.2006.03.027
   Miller JD, 2009, CIRCULATION, V119, P2693, DOI 10.1161/CIRCULATIONAHA.108.834614
   Molin DGM, 2003, DEV DYNAM, V227, P431, DOI 10.1002/dvdy.10314
   Munjal C, 2014, DIS MODEL MECH, V7, P987, DOI 10.1242/dmm.015255
   Ng CM, 2004, J CLIN INVEST, V114, P1586, DOI 10.1172/JCI22715
   Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487
   Osman L, 2006, CIRCULATION, V114, pI547, DOI 10.1161/CIRCULATIONAHA.105.001115
   Paruchuri S, 2006, CIRC RES, V99, P861, DOI 10.1161/01.RES.0000245188.41002.2c
   Peacock JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026769
   Peacock JD, 2010, CIRC RES, V106, P712, DOI 10.1161/CIRCRESAHA.109.213702
   Pho M, 2008, AM J PHYSIOL HEART C, V294, pH1767, DOI 10.1152/ajpheart.01305.2007
   Rajamannan NM, 2011, CIRCULATION, V124, P1783, DOI 10.1161/CIRCULATIONAHA.110.006767
   Richards J, 2013, AM J PATHOL, V182, P1922, DOI 10.1016/j.ajpath.2013.01.037
   Sekiya I, 2000, J BIOL CHEM, V275, P10738, DOI 10.1074/jbc.275.15.10738
   Sobczak Magdalena, 2010, J Vis Exp, DOI 10.3791/2316
   WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092 8674(94)90041 8
   Walker GA, 2004, CIRC RES, V95, P253, DOI 10.1161/01.RES.0000136520.07995.aa
   Weiss RM, 2006, CIRCULATION, V114, P2065, DOI 10.1161/CIRCULATIONAHA.106.634139
   Wu BR, 2011, CIRC RES, V109, P183, DOI 10.1161/CIRCRESAHA.111.245035
   Zhou G, 2006, P NATL ACAD SCI USA, V103, P19004, DOI 10.1073/pnas.0605170103
NR 54
TC 54
Z9 65
U1 0
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1079 5642
EI 1524 4636
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD FEB
PY 2016
VL 36
IS 2
BP 328
EP 338
DI 10.1161/ATVBAHA.115.306091
PG 11
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology; Cardiovascular System & Cardiology
GA DC8PX
UT WOS:000369483200018
PM 26634652
OA Green Accepted
DA 2025 08 17
ER

PT J
AU de Gusmao, CVB
   Batista, NA
   Lemes, VTV
   Neto, WLM
   de Faria, LD
   Alves, JM
   Belangero, WD
AF Buarque de Gusmao, Carlos Vinicius
   Batista, Nilza Alzira
   Vidotto Lemes, Valeria Trombini
   Maia Neto, Wilson Leite
   de Faria, Lidia Dornelas
   Alves, Jose Marcos
   Belangero, William Dias
TI EFFECT OF LOW INTENSITY PULSED ULTRASOUND STIMULATION, EXTRACORPOREAL
   SHOCKWAVES AND RADIAL PRESSURE WAVES ON AKT, BMP 2, ERK 2, FAK AND
   TGF β1 DURING BONE HEALING IN RAT TIBIAL DEFECTS
SO ULTRASOUND IN MEDICINE AND BIOLOGY
LA English
DT Article
DE Bone morphogenetic protein; Bone; ERK; ESWT; Focal adhesion kinase;
   Fracture; LIPUS; Osteogenesis; Radial pressure waves; Transforming
   growth factor
ID FOCAL ADHESION KINASE; MESENCHYMAL STEM CELLS; OSTEOBLAST
   DIFFERENTIATION; DISTRACTION OSTEOGENESIS; OSTEOPOROTIC FRACTURE;
   ACOUSTIC FIELD; EXPRESSION; THERAPY; GROWTH; REGENERATION
AB An experimental study was conducted to determine whether low intensity pulsed ultrasound stimulation (LIPUS), extracorporeal shockwave treatment (ESWT) and radial pressure wave treatment (RPWT) modulate Akt, bone morphogenetic protein 2 (BMP 2), extracellular signal regulated kinase 2 (ERK 2), focal adhesion kinase (FAK) and transforming growth factor beta 1 (TGF beta 1) during bone healing in rat tibial defects. Rat tibial defects were exposed to 500 shots of ESWT delivered at 0.12 mJ/mm(2), 500 impulses of RPWT operated at 2.0 bar or to daily 20 min 30 mW/cm(2) LIPUS. Following 1, 3 and 6 wk, bones were harvested to determine the expression and activity of Akt, BMP 2, ERK 2, FAK and TGF beta 1. Animals exposed to ultrasound were followed up to 3 wk. Protein expression and activity were unchanged following LIPUS treatment. ESWT increased Akt activity 2.11 fold (p = 0.043) and TGF beta 1 expression 9.11 fold (p = 0.016) at 1 wk and increased FAK activity 2.16 fold (p = 0.047) at 3 wk. RPWT increased FAK activity 2.6 fold (p = 0.028) at 3 wk and decreased Akt expression 0.52 fold (p = 0.05) at 6 wk. In conclusion, the protocols employed for ESWT and RPWT modulated distinct signaling pathways during fracture healing, while LIPUS standard protocol did not change the usual signaling pathways of the proteins investigated. Future studies are required to monitor osteogenesis so that the biologic meaning of our results can be clarified. (C) 2019 World Federation for Ultrasound in Medicine & Biology. All rights reserved.
C1 [Buarque de Gusmao, Carlos Vinicius; Batista, Nilza Alzira; Vidotto Lemes, Valeria Trombini; Maia Neto, Wilson Leite; de Faria, Lidia Dornelas; Belangero, William Dias] State Univ Campinas UNICAMP, Fac Med Sci, Dept Orthoped & Traumatol, Campinas, SP, Brazil.
   [Alves, Jose Marcos] Univ Sao Paulo, Coll Engn Sao Carlos, Elect Engn Dept, Sao Carlos, SP, Brazil.
C3 Universidade Estadual de Campinas; Universidade de Sao Paulo
RP de Gusmao, CVB (通讯作者)，Rua Tessalia Vieira de Camargo 126,Cidade Univ, BR 13083887 Campinas, SP, Brazil.
EM vigusmao@yahoo.com
RI Alves, José/M 1441 2017; belangero, william dias/B 7685 2012
OI belangero, william dias/0000 0003 1838 1473
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2014/26729 0]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES) [02 P 3369/2017]; Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [14/26729 0] Funding Source: FAPESP
FX The authors thank Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP), which funded the research (process number 2014/26729 0);
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES),
   which granted a PhD scholarship to the main author (C.V.B.G)(process
   number 02 P 3369/2017); and Professor Orlando Petrucci Junior who kindly
   allowed the use of his laboratory facilities.
CR Allori AC, 2008, TISSUE ENG PART B RE, V14, P259, DOI 10.1089/ten.teb.2008.0082
   Alvarez RG, 2011, FOOT ANKLE INT, V32, P746, DOI 10.3113/FAI.2011.0746
   [Anonymous], 2010, BMC MUSCULOSKEL DIS, DOI DOI 10.1186/1471 2474 11 229
   Barque de Gusmao C.V., 2016, ADV TECHNIQUES BONE
   de Gusmao CVB, 2010, CLIN ORTHOP RELAT R, V468, P1149, DOI 10.1007/s11999 009 1146 6
   Chen YJ, 2004, J ORTHOP RES, V22, P526, DOI 10.1016/j.orthres.2003.10.005
   Cheung WH, 2012, J ORTHOP RES, V30, P129, DOI 10.1002/jor.21487
   Cheung WH, 2011, ULTRASOUND MED BIOL, V37, P231, DOI 10.1016/j.ultrasmedbio.2010.11.016
   Cho TJ, 2002, J BONE MINER RES, V17, P513, DOI 10.1359/jbmr.2002.17.3.513
   Cleveland RO, 2007, ULTRASOUND MED BIOL, V33, P1327, DOI 10.1016/j.ultrasmedbio.2007.02.014
   Császár NBM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140541
   de Faria LD, 2015, THESIS
   de Gusmao CV, 2018, THESIS
   Dos Santos PRD, 2015, INT J SURG, V24, P120, DOI 10.1016/j.ijsu.2015.09.065
   Dimitriou R, 2005, INJURY, V36, P1392, DOI 10.1016/j.injury.2005.07.019
   Esteki A, 2010, J ORTHOP TRAUMA, V24, P170, DOI 10.1097/BOT.0b013e3181b778e8
   Fávaro Pípi E, 2010, ULTRASOUND MED BIOL, V36, P2057, DOI 10.1016/j.ultrasmedbio.2010.07.012
   Ganzorig K, 2015, ARCH ORAL BIOL, V60, P902, DOI 10.1016/j.archoralbio.2015.02.014
   Gertsen G I, 2016, Klin Khir, P54
   Gollwitzer H, 2013, ULTRASOUND MED BIOL, V39, P126, DOI 10.1016/j.ultrasmedbio.2012.08.026
   Griffin XL, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008579.pub3
   HECKMAN JD, 1994, J BONE JOINT SURG AM, V76A, P26, DOI 10.2106/00004623 199401000 00004
   Hou CH, 2009, J CELL BIOCHEM, V106, P7, DOI 10.1002/jcb.21934
   Hu J, 2016, SCI REP UK, V6, DOI 10.1038/srep20875
   Huang HM, 2016, CHINESE MED J PEKING, V129, P2567, DOI 10.4103/0366 6999.192776
   Kertzman P, 2017, J ORTHOP SURG RES, V12, DOI 10.1186/s13018 017 0667 z
   Kim JB, 2007, BONE, V41, P39, DOI 10.1016/j.bone.2007.01.024
   Kinami Y, 2013, J ORTHOP SCI, V18, P410, DOI 10.1007/s00776 013 0358 5
   Koolen MKE, 2018, J ORTHOP RES, V36, P76, DOI 10.1002/jor.23615
   Lai JP, 2010, J TRAUMA, V69, P1252, DOI 10.1097/TA.0b013e3181cbc7ac
   Leighton R, 2017, INJURY, V48, P1339, DOI 10.1016/j.injury.2017.05.016
   Lu HB, 2009, BIOCHEM BIOPH RES CO, V378, P569, DOI 10.1016/j.bbrc.2008.11.074
   Lubbert PHW, 2008, INJURY, V39, P1444, DOI 10.1016/j.injury.2008.04.004
   Maeda S, 2004, EMBO J, V23, P552, DOI 10.1038/sj.emboj.7600067
   Marsell R, 2011, INJURY, V42, P551, DOI 10.1016/j.injury.2011.03.031
   Martini L, 2003, ARTIF CELL BLOOD SUB, V31, P449, DOI 10.1081/BIO 120025415
   Martini L, 2006, J TRAUMA, V61, P1198, DOI 10.1097/01.ta.0000203575.96896.34
   Mehrara BJ, 1999, PLAST RECONSTR SURG, V103, P536, DOI 10.1097/00006534 199902000 00026
   Mukherjee A, 2009, J CELL SCI, V122, P716, DOI 10.1242/jcs.042770
   Narasaki Kazuto, 2003, J Orthop Sci, V8, P474, DOI 10.1007/s00776 003 0664 4
   Naruse K, 2010, ULTRASOUND MED BIOL, V36, P1098, DOI 10.1016/j.ultrasmedbio.2010.04.011
   Notarnicola Angela, 2012, Musculoskelet Surg, V96, P183, DOI 10.1007/s12306 012 0213 4
   Perez C, 2013, J ACOUST SOC AM, V134, P1663, DOI 10.1121/1.4812885
   Ray BJ, 2012, J LEUKOCYTE BIOL, V92, P1021, DOI 10.1189/jlb.0512259
   Sarahrudi K, 2011, INJURY, V42, P833, DOI 10.1016/j.injury.2011.03.055
   Suzawa M, 2002, J BONE MINER RES, V17, P240, DOI 10.1359/jbmr.2002.17.2.240
   Suzuki Akito, 2009, J Oral Sci, V51, P29
   Tam KF, 2005, CLIN ORTHOP RELAT R, P260, DOI 10.1097/01.blo.0000169080.23281.f5
   Tamma R, 2009, ULTRASOUND MED BIOL, V35, P2093, DOI 10.1016/j.ultrasmedbio.2009.05.022
   Tamura Y, 2001, J BONE MINER RES, V16, P1772, DOI 10.1359/jbmr.2001.16.10.1772
   Tang CH, 2006, MOL PHARMACOL, V69, P2047, DOI 10.1124/mol.105.022160
   Tanzer M, 2001, J ORTHOP RES, V19, P195, DOI 10.1016/S0736 0266(00)00034 6
   Uchida S, 2000, BONE, V27, P81, DOI 10.1016/S8756 3282(00)00293 3
   Uusitalo H, 2001, BONE, V28, P423, DOI 10.1016/S8756 3282(01)00406 9
   van der Jagt OP, 2011, J BONE JOINT SURG AM, V93A, P38, DOI 10.2106/JBJS.I.01535
   Vidotto VT, 2017, ACTA ORTOP BRAS, V25, P71, DOI 10.1590/1413 785220172502164015
   Wang CJ, 2008, ARCH ORTHOP TRAUM SU, V128, P879, DOI 10.1007/s00402 008 0663 1
   Wang CJ, 2007, ARCH ORTHOP TRAUM SU, V127, P137, DOI 10.1007/s00402 006 0236 0
   Wang CJ, 2004, BONE, V34, P225, DOI 10.1016/j.bone.2003.08.005
   Wang CJ., 2012, BIOMED J, V35, P481, DOI [10.4103/2319 4170.104413, DOI 10.4103/2319 4170.104413]
   Wang FS, 2003, BONE, V32, P387, DOI 10.1016/S8756 3282(03)00029 2
   Wang T, 2017, J CELL PHYSIOL, V232, P913, DOI 10.1002/jcp.25641
   Xu JK, 2012, J BIOL CHEM, V287, P26200, DOI 10.1074/jbc.M112.349811
   Xu ZH, 2009, INT ORTHOP, V33, P789, DOI 10.1007/s00264 008 0553 8
   Zhao GS, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007589
NR 65
TC 12
Z9 12
U1 1
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0301 5629
EI 1879 291X
J9 ULTRASOUND MED BIOL
JI Ultrasound Med. Biol.
PD AUG
PY 2019
VL 45
IS 8
BP 2140
EP 2161
DI 10.1016/j.ultrasmedbio.2019.04.011
PG 22
WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
GA IE6MV
UT WOS:000472491200028
PM 31101448
DA 2025 08 17
ER

PT J
AU Haroutunian, GG
   Tsaghikian, A
   Fedorova, E
   Chaurasia, P
   Gusella, GL
   Mosoian, A
AF Haroutunian, Gagik Greg
   Tsaghikian, Ashot
   Fedorova, Elena
   Chaurasia, Pratima
   Gusella, Gabriele Luca
   Mosoian, Arevik
TI Electromagnetic Fields Generated by the IteraCoil Device Differentiate
   Mesenchymal Stem Progenitor Cells Into the Osteogenic Lineage
SO BIOELECTROMAGNETICS
LA English
DT Article
DE mesenchymal stem progenitor cells (MSPCs); alternating electromagnetic
   field (EMF); alternating current (AC); osteogenic differentiation;
   chondrogenic differentiation
ID ELECTRICAL STIMULATION; IN VITRO; BONE; FREQUENCY; GROWTH;
   OSTEODIFFERENTIATION; OSTEOBLASTOGENESIS; BIOELECTRICITY; BEHAVIOR;
   CALCIUM
AB Rapid advances in mesenchymal stem progenitor cells (MSPCs) have rendered impetus into the area of cell therapy and regenerative medicine. The main promise of future stem cell therapies is their reliance on autologous stem cells derived from adipose tissue, which also includes treatments of bone fractures and degeneration. The effectiveness of different electric devices utilized to reprogram MSPCs toward osteogenic differentiation has provided varying degrees of effectiveness for clinical use. Adipose tissue derived MSPCs were flow cytometrically characterized and further differentiated into osteoblasts by culturing either in growth medium with pro osteogenic supplements or without supplements with alternating electromagnetic field (EMF) generated by IteraCoil. IteraCoil is a multi solenoid coil with a specific complex geometry that creates a 3D EMF with desired parameters without directly applying electrodes to the cells and tissues. The flow cytometric analysis of highly enriched (>= 95%) adipose derived MSPCs (CD34( ), CD73(+), CD90(+), and CD105(+)) was utilized for the study. Osteoblasts and chondrocyte differentiations were then assessed by specific staining and quantified using ImageJ (National Institutes of Health). The osteoblastic differentiation of MSPCs cultured in regular medium and exposed to EMF at 0.05 and 1 kHz frequencies was compared with MSPCs cultured in a pro osteogenic supplemented medium. In this study, we demonstrated that EMF from IteraCoil might have affected the signaling pathways that induce the osteogenic differentiation of human adipose derived MSPCs in the absence of exogenous osteogenic factors. Therefore, EMF generated osteogenic differentiation of reprogrammed adipose derived autologous MSPCs may treat the loss of osteoblasts and osteoporosis and open new avenues for the development of regenerative cellular therapy. (c) 2022 Bioelectromagnetics Society.
C1 [Haroutunian, Gagik Greg] USC, Keck Sch Med, Childrens Hosp Los Angeles, Los Angeles, CA USA.
   [Tsaghikian, Ashot] Data Proc & Field Engn Corp, Glendale, CA USA.
   [Fedorova, Elena; Gusella, Gabriele Luca; Mosoian, Arevik] SkinAxis LLC, 140 East Hanover Ave, Cedar Knolls, NJ 07927 USA.
   [Chaurasia, Pratima] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
C3 Children's Hospital Los Angeles; University of Southern California;
   University of Southern California Keck Hospital; Icahn School of
   Medicine at Mount Sinai
RP Mosoian, A (通讯作者)，SkinAxis LLC, 140 East Hanover Ave, Cedar Knolls, NJ 07927 USA.
EM arevik.mosoian@skinaxis.com
FU SkinAxis LLC
FX SkinAxis LLC.
CR Arzouni AA, 2017, CLIN SCI, V131, P2835, DOI 10.1042/CS20171251
   Ashrafi M, 2019, WOUND REPAIR REGEN, V27, P5, DOI 10.1111/wrr.12679
   Bai LH, 2009, GLIA, V57, P1192, DOI 10.1002/glia.20841
   Bai XH, 2009, CELL MOL LIFE SCI, V66, P667, DOI 10.1007/s00018 008 8633 x
   Bicer M, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 020 02094 8
   Boquest AC, 2005, MOL BIOL CELL, V16, P1131, DOI 10.1091/mbc.E04 10 0949
   Boregowda SV, 2018, STEM CELLS, V36, P7, DOI 10.1002/stem.2713
   Cai SB, 2017, FASEB J, V31, P346, DOI 10.1096/fj.201600560R
   Çakmak AS, 2016, J ORTHOP RES, V34, P581, DOI 10.1002/jor.23059
   Chun SY, 2019, TISSUE ENG REGEN MED, V16, P385, DOI 10.1007/s13770 019 00199 7
   Creecy CM, 2013, TISSUE ENG PT A, V19, P467, DOI [10.1089/ten.tea.2012.0091, 10.1089/ten.TEA.2012.0091]
   Di Summa PG, 2018, ANAT REC, V301, P1714, DOI 10.1002/ar.23841
   Domenis R, 2015, STEM CELL RES THER, V6, DOI 10.1186/scrt536
   Dubus M, 2019, COLLOID SURFACE B, V181, P671, DOI 10.1016/j.colsurfb.2019.06.021
   Eischen Loges M, 2018, PEERJ, V6, DOI 10.7717/peerj.4959
   Goganau I, 2018, EXP NEUROL, V300, P247, DOI 10.1016/j.expneurol.2017.11.011
   Guasti L, 2012, STEM CELL TRANSL MED, V1, P384, DOI 10.5966/sctm.2012 0009
   Hakim R, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1218 9
   Hernández Bule ML, 2014, CELL PHYSIOL BIOCHEM, V34, P1741, DOI 10.1159/000366375
   Holm JS, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0887 0
   Hronik Tupaj M, 2012, TISSUE ENG PART B RE, V18, P167, DOI [10.1089/ten.teb.2011.0244, 10.1089/ten.TEB.2011.0244]
   Hronik Tupaj M, 2011, BIOMED ENG ONLINE, V10, DOI 10.1186/1475 925X 10 9
   Hu WW, 2019, J BIOMED MATER RES B, V107, P1607, DOI 10.1002/jbm.b.34253
   Isaacson BM, 2010, J BIOMED MATER RES A, V95A, P1270, DOI 10.1002/jbm.a.32905
   Jamal D, 2017, INT J BIOMATER, V2017, DOI 10.1155/2017/3684812
   Kammerer PW., 2020, SCAND J IMMUNOL, V8, P1
   Kang S, 2007, J BIOL CHEM, V282, P14515, DOI 10.1074/jbc.M700030200
   Kim IS, 2009, TISSUE ENG PT A, V15, P2411, DOI 10.1089/ten.tea.2008.0554
   Kim YS, 2021, J CONTROL RELEASE, V330, P565, DOI 10.1016/j.jconrel.2020.12.055
   Kwon HJ, 2016, SCI REP UK, V6, DOI 10.1038/srep39302
   Lalu MM, 2018, STEM CELL TRANSL MED, V7, P857, DOI 10.1002/sctm.18 0120
   Levin M, 2021, CELL, V184, P1971, DOI 10.1016/j.cell.2021.02.034
   Levin M, 2017, ANNU REV BIOMED ENG, V19, P353, DOI [10.1146/annurev bioeng 071114 040647, 10.1146/annurev bioeng 071114040647]
   Levin M, 2014, MOL BIOL CELL, V25, P3835, DOI 10.1091/mbc.E13 12 0708
   Levin M, 2013, WIRES SYST BIOL MED, V5, P657, DOI 10.1002/wsbm.1236
   Levin M, 2012, ANNU REV BIOMED ENG, V14, P295, DOI [10.1146/annurev bioeng 071811 150114, 10.1146/annurev.bioeng 071811 150114]
   Liau LL, 2018, CYTOTECHNOLOGY, V70, P1221, DOI 10.1007/s10616 018 0214 8
   Lo Furno D, 2018, J CELL PHYSIOL, V233, P3982, DOI 10.1002/jcp.26192
   Luo F, 2012, ORTHOPEDICS, V35, pE526, DOI 10.3928/01477447 20120327 11
   Mayer Wagner S, 2011, BIOELECTROMAGNETICS, V32, P283, DOI 10.1002/bem.20633
   McCullen SD, 2010, TISSUE ENG PART C ME, V16, P1377, DOI 10.1089/ten.TEC.2009.0751
   Meyer J, 2015, AESTHET SURG J, V35, P1030, DOI 10.1093/asj/sjv075
   Mussano F, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051454
   Oliva Anthony A, 2019, Aging Med (Milton), V2, P142, DOI 10.1002/agm2.12079
   Parate D, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 09892 w
   Petersen MBK, 2018, CURR TOP DEV BIOL, V129, P143, DOI 10.1016/bs.ctdb.2018.02.009
   Phinney DG, 2007, CELL CYCLE, V6, P2884, DOI 10.4161/cc.6.23.5095
   Pini J, 2018, J BONE MINER RES, V33, P1826, DOI 10.1002/jbmr.3474
   Ross CL, 2015, STEM CELL RES, V15, P96, DOI 10.1016/j.scr.2015.04.009
   Saria MG, 2016, CLIN J ONCOL NURS, V20, P9, DOI 10.1188/16.CJON.S1.9 13
   Sun S, 2007, FASEB J, V21, P1472, DOI 10.1096/fj.06 7153com
   Takada I, 2009, EXPERT OPIN THER TAR, V13, P593, DOI [10.1517/14728220902915310 , 10.1517/14728220902915310]
   Tang W, 2008, SCIENCE, V322, P583, DOI 10.1126/science.1156232
   Tsuchiya A, 2019, INFLAMM REGEN, V39, DOI 10.1186/s41232 019 0107 z
   Wagner SK, 2017, BMJ OPEN OPHTHALMOL, V2, DOI 10.1136/bmjophth 2017 000096
   Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672
   Whited JL, 2019, CURR OPIN GENET DEV, V57, P61, DOI 10.1016/j.gde.2019.06.014
   Wu SY, 2018, BIOCHEM BIOPH RES CO, V503, P715, DOI 10.1016/j.bbrc.2018.06.066
   Zeighami A, 2019, BIOELECTROMAGNETICS, V40, P128, DOI 10.1002/bem.22173
   Zhang JY, 2016, ACTA BIOMATER, V32, P46, DOI 10.1016/j.actbio.2015.12.024
   Zhang YT, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.598607
NR 61
TC 2
Z9 2
U1 2
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0197 8462
EI 1521 186X
J9 BIOELECTROMAGNETICS
JI Bioelectromagnetics
PD MAY
PY 2022
VL 43
IS 4
BP 245
EP 256
DI 10.1002/bem.22401
EA APR 2022
PG 12
WC Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Biophysics
GA 1A8AF
UT WOS:000779117500001
PM 35391494
OA Green Published
DA 2025 08 17
ER

PT J
AU Lee, LCY
   Gadegaard, N
   de Andrés, MC
   Turner, LA
   Burgess, KV
   Yarwood, SJ
   Wells, J
   Salmeron Sanchez, M
   Meek, D
   Oreffo, ROC
   Dalby, MJ
AF Lee, Louisa C. Y.
   Gadegaard, Nikolaj
   de Andres, Maria C.
   Turner, Lesley Anne
   Burgess, Karl V.
   Yarwood, Stephen J.
   Wells, Julia
   Salmeron Sanchez, Manuel
   Meek, Dominic
   Oreffo, Richard O. C.
   Dalby, Matthew J.
TI Nanotopography controls cell cycle changes involved with skeletal stem
   cell self renewal and multipotency
SO BIOMATERIALS
LA English
DT Article
DE Nanotopography; Skeletal stem cells; Mesenchymal stem cells; Cell cycle
ID OSTEOBLAST DIFFERENTIATION; PROTEIN EXPRESSION; HUMAN BONE; MAINTENANCE;
   PHENOTYPE; MARROW; SHAPE; PLURIPOTENCY; OSTEOGENESIS; REGENERATION
AB In culture isolated bone marrow mesenchymal stem cells (more precisely termed skeletal stem cells, SSCs) spontaneously differentiate into fibroblasts, preventing the growth of large numbers of multi potent SSCs for use in regenerative medicine. However, the mechanisms that regulate the expansion of SSCs, while maintaining multipotency and preventing fibroblastic differentiation are poorly understood. Major hurdles to understanding how the maintenance of SSCs is regulated are (a) SSCs isolated from bone marrow are heterogeneous populations with different proliferative characteristics and (b) a lack of tools to investigate SSC number expansion and multipotency. Here, a nanotopographical surface is used as a tool that permits SSC proliferation while maintaining multipotency. It is demonstrated that retention of SSC phenotype in culture requires adjustments to the cell cycle that are linked to changes in the activation of the mitogen activated protein kinases. This demonstrates that biomaterials can offer cross SSC culture tools and that the biological processes that determine whether SSCs retain multipotency or differentiate into fibroblasts are subtle, in terms of biochemical control, but are profound in terms of determining cell fate. (C) 2016 The Authors. Published by Elsevier Ltd.
C1 [Lee, Louisa C. Y.; Turner, Lesley Anne; Dalby, Matthew J.] Univ Glasgow, Ctr Cell Engn, Inst Mol Cell & Syst Biol, Coll Med Vet & Life Sci, Joseph Black Bldg, Glasgow G12 8QQ, Lanark, Scotland.
   [Gadegaard, Nikolaj; Salmeron Sanchez, Manuel] Univ Glasgow, Sch Engn, Div Biomed Engn, Rankine Bldg, Glasgow G12 8LT, Lanark, Scotland.
   [de Andres, Maria C.; Wells, Julia; Oreffo, Richard O. C.] Univ Southampton, Inst Dev Sci, Ctr Human Dev Stem Cells & Regenerat, Bone & Joint Res Grp, Southampton SO16 6YD, Hants, England.
   [Burgess, Karl V.] Univ Glasgow, Wolfson Wohl Canc Res Ctr, Coll Med Vet & Life Sci, Glasgow Poly Facil, Garsube Campus, Bearsden G61 1QH, Scotland.
   [Yarwood, Stephen J.] Heriot Watt Univ, Inst Biol Chem Biophys & Bioengn, William Perkin Bldg, Edinburgh EH14 4AS, Midlothian, Scotland.
   [Meek, Dominic] Queen Elizabeth Univ Hosp, Dept Orthopaed, Glasgow G51 4TF, Lanark, Scotland.
C3 University of Glasgow; University of Glasgow; University of Southampton;
   University of Glasgow; Heriot Watt University; Queen Elizabeth
   University Hospital (QEUH)
EM matthew.dalby@glasgow.ac.uk
RI Dalby, Matthew/G 2426 2012; Gadegaard, Nikolaj/E 9243 2010; de+Andrés,
   María/AAP 1473 2020; Meek, Dominic/AAF 5057 2020; Oreffo,
   Richard/A 4615 2011; Salmeron Sanchez, Manuel/E 4680 2010
OI Burgess, Karl/0000 0002 0881 715X; Yarwood, Stephen/0000 0001 9489 9253;
   Oreffo, Richard/0000 0001 5995 6726; Salmeron Sanchez,
   Manuel/0000 0002 8112 2100; Dalby, Matthew/0000 0002 0528 3359; de
   Andres, Maria C./0000 0003 2260 6356
FU MVLS scholarship; BBSRC [BB/L023814/1, BB/L021072/1, BB/K011235/1];
   BBSRC [BB/L021072/1, BB/K011235/1, BB/L023814/1, BB/D015324/1] Funding
   Source: UKRI; Biotechnology and Biological Sciences Research Council
   [BB/K011235/1, BB/D015324/1, BB/L023814/1, BB/L021072/1] Funding Source:
   researchfish; British Heart Foundation [PG/10/26/28303, FS/17/12/32703,
   PG/15/15/31316] Funding Source: researchfish
FX We thank Dr Marco Cantini and Elie Mpoyi for help with AFM, orthopaedic
   surgeons at Southampton General Hospital for provision of femoral head
   samples and thank Mrs Carol Anne Smith for technical assistance. We also
   thank Glasgow Polyomics Facility for help with RNAseq and metabolomics
   experiments and JWNC technical staff. LCYL was funded by an MVLS
   scholarship. Dalby, Gadegaard and Oreffo are supported by BBSRC grants
   BB/L023814/1, BB/L021072/1 and BB/K011235/1.
CR Benoit DSW, 2008, NAT MATER, V7, P816, DOI 10.1038/nmat2269
   Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028
   Bianco P, 2011, BLOOD, V117, P5281, DOI 10.1182/blood 2011 01 315069
   Chong JL, 2009, NATURE, V462, P930, DOI 10.1038/nature08677
   Churchman SM, 2012, ARTHRITIS RHEUM US, V64, P2632, DOI 10.1002/art.34434
   Cortés F, 1999, MECH DEVELOP, V83, P161, DOI 10.1016/S0925 4773(99)00030 1
   Curran JM, 2006, BIOMATERIALS, V27, P4783, DOI 10.1016/j.biomaterials.2006.05.001
   Curran JM, 2010, LAB CHIP, V10, P1662, DOI 10.1039/c004149a
   Dalby MJ, 2007, NAT MATER, V6, P997, DOI 10.1038/nmat2013
   Dalby MJ, 2014, NAT MATER, V13, P558, DOI [10.1038/NMAT3980, 10.1038/nmat3980]
   Dawson JI, 2014, STEM CELLS, V32, P35, DOI 10.1002/stem.1559
   Docheva D, 2008, J CELL MOL MED, V12, P537, DOI 10.1111/j.1582 4934.2007.00138.x
   Engler A, 2004, BIOPHYS J, V86, P617, DOI 10.1016/S0006 3495(04)74140 5
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   FRIEDENSTEIN AJ, 1976, INT REV CYTOL, V47, P327, DOI 10.1016/S0074 7696(08)60092 3
   FRIEDENSTEIN AJ, 1995, CALCIFIED TISSUE INT, V56, pS17, DOI 10.1007/BF03354643
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Howard D, 2002, BIOCHEM BIOPH RES CO, V299, P208, DOI 10.1016/S0006 291X(02)02561 5
   JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0
   Kamentsky L, 2011, BIOINFORMATICS, V27, P1179, DOI 10.1093/bioinformatics/btr095
   Kilian KA, 2010, P NATL ACAD SCI USA, V107, P4872, DOI 10.1073/pnas.0903269107
   Laurenti E, 2015, CELL STEM CELL, V16, P302, DOI 10.1016/j.stem.2015.01.017
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   McMurray RJ, 2011, NAT MATER, V10, P637, DOI [10.1038/NMAT3058, 10.1038/nmat3058]
   Menchón C, 2011, CELL CYCLE, V10, P1435, DOI 10.4161/cc.10.9.15421
   Neganova I, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.464
   Ogasawara T, 2004, MOL CELL BIOL, V24, P6560, DOI 10.1128/mcb.24.15.6560 6568.2004
   Pauldin S., 2013, CELL, V155, P135
   Rosner M, 2013, NAT PROTOC, V8, P602, DOI 10.1038/nprot.2013.011
   SAVATIER P, 1994, ONCOGENE, V9, P809
   Seras Franzoso J, 2014, NANOMEDICINE UK, V9, P207, DOI 10.2217/nnm.13.43
   SIMMONS PJ, 1991, BLOOD, V78, P55
   Solmesky L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012689
   STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424
   Stewart K, 1999, J BONE MINER RES, V14, P1345, DOI 10.1359/jbmr.1999.14.8.1345
   Tare RS, 2008, MOL CELL ENDOCRINOL, V288, P11, DOI 10.1016/j.mce.2008.02.017
   Trappmann B, 2012, NAT MATER, V11, P642, DOI [10.1038/NMAT3339, 10.1038/nmat3339]
   Tsimbouri PM, 2012, ACS NANO, V6, P10239, DOI 10.1021/nn304046m
   Van Horn RD, 2010, J BIOL CHEM, V285, P21849, DOI 10.1074/jbc.M110.141010
   Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427
   Wen JH, 2014, NAT MATER, V13, P979, DOI [10.1038/NMAT4051, 10.1038/nmat4051]
   White J, 2005, MOL BIOL CELL, V16, P2018, DOI 10.1091/mbc.E04 12 1056
   Yang JL, 2014, ACS NANO, V8, P9941, DOI 10.1021/nn504767g
   Yourek G, 2007, ASAIO J, V53, P219, DOI 10.1097/MAT.0b013e31802deb2d
   Zhang D, 2013, BIOMATERIALS, V34, P3962, DOI 10.1016/j.biomaterials.2013.02.029
NR 45
TC 49
Z9 52
U1 0
U2 36
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD FEB
PY 2017
VL 116
BP 10
EP 20
DI 10.1016/j.biomaterials.2016.11.032
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA EI7MC
UT WOS:000392681100002
PM 27914982
OA Green Published, Green Accepted, hybrid
DA 2025 08 17
ER

PT J
AU Pioletti, DP
AF Pioletti, Dominique P.
TI Integration of mechanotransduction concepts in bone tissue engineering
SO COMPUTER METHODS IN BIOMECHANICS AND BIOMEDICAL ENGINEERING
LA English
DT Article
DE bone scaffold; total knee implant revision; mechanical loading; in vivo;
   finite element method; translational medicine
ID REINFORCED PLA SCAFFOLDS; IN VIVO; COMPOSITE SCAFFOLDS; MECHANICAL
   SIGNALS; CELLS; INCREASES; FLUID; OSTEOBLASTS; BIOREACTOR; RESORPTION
AB Mechanical stimulus has been identified for a long time as a key player in the adaptation of the musculo skeletal tissues to their function. Mechanical loading is then an intrinsic variable to be considered when new developments are proposed in bone tissue engineering. By combining structural biomechanics and mechanotransduction aspects, a new paradigm is presented for bone tissue engineering. It is proposed that in vivo mechanical loading be used to increased bone formation in the scaffold instead of pre seeding the scaffold with cells or delivering growth factors. In this article, we demonstrated the feasibility of this approach and compared it to the classical tissue engineering strategy. In particular, we showed that bone formation could be increased in the scaffold that underwent mechanical loading during an in vivo study in rats. A model of bone formation was then proposed to translate the in vivo results into a possible clinical application where the loading of the scaffold would be transmitted by the sharing of the load between an implant and the bone scaffold.
C1 Ecole Polytech Fed Lausanne, LBO, IBI, STI,Stn 19, CH 1015 Lausanne, Switzerland.
C3 Swiss Federal Institutes of Technology Domain; Ecole Polytechnique
   Federale de Lausanne
RP Pioletti, DP (通讯作者)，Ecole Polytech Fed Lausanne, LBO, IBI, STI,Stn 19, CH 1015 Lausanne, Switzerland.
EM dominique.pioletti@epfl.ch
RI Pioletti, Dominique/C 5697 2008
OI Pioletti, Dominique/0000 0001 5535 5296
FU SNSF [205320 121893, 32003B 108386, 404640 101114]; Inter Institutional
   Center for Translational Biomechanics EPFL CHUV DAL; Swiss National
   Science Foundation (SNF) [205320_121893] Funding Source: Swiss National
   Science Foundation (SNF)
FX This project was supported by SNSF Grants (Nos 205320 121893,
   32003B 108386 and 404640 101114) and the Inter Institutional Center for
   Translational Biomechanics EPFL CHUV DAL. The author would like to thank
   Guillaume Pioletti for his drawings of craniums in Figure 1.
CR Anselme K, 1999, BONE, V25, p51S, DOI 10.1016/S8756 3282(99)00133 7
   Blecha L. D., 2005, Computer Methods in Biomechanics and Biomedical Engineering, V8, P307, DOI 10.1080/10255840500322433
   Blecha LD, 2010, J BIOMECH, V43, P933, DOI 10.1016/j.jbiomech.2009.11.004
   Blecha LD, 2009, J ORTHOP RES, V27, P1082, DOI 10.1002/jor.20836
   Boerckel JD, 2009, J BIOMECH ENG T ASME, V131, DOI 10.1115/1.3148472
   Burr DB, 1996, BONE, V18, P405, DOI 10.1016/8756 3282(96)00028 2
   Checa S, 2010, J BIOMECH, V43, P961, DOI 10.1016/j.jbiomech.2009.10.044
   Duty AO, 2007, J BIOMECH ENG T ASME, V129, P531, DOI 10.1115/1.2746375
   FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488
   Genetos DC, 2005, J BONE MINER RES, V20, P41, DOI 10.1359/jbmr.041009
   Goodship AE, 2009, J ORTHOP RES, V27, P922, DOI 10.1002/jor.20824
   Han YF, 2004, P NATL ACAD SCI USA, V101, P16689, DOI 10.1073/pnas.0407429101
   Handschel J, 2002, BIOMATERIALS, V23, P1689, DOI 10.1016/S0142 9612(01)00296 4
   Hollister SJ, 2011, TISSUE ENG PART B RE, V17, P459, DOI [10.1089/ten.TEB.2011.0251, 10.1089/ten.teb.2011.0251]
   HUISKES R, 1992, CLIN ORTHOP RELAT R, P124
   Malone AMD, 2007, P NATL ACAD SCI USA, V104, P13325, DOI 10.1073/pnas.0700636104
   Mathieu LM, 2006, BIOMATERIALS, V27, P905, DOI 10.1016/j.biomaterials.2005.07.015
   McCoy RJ, 2012, BIOTECHNOL BIOENG, V109, P1583, DOI 10.1002/bit.24424
   Montjovent MO, 2008, BONE, V42, P554, DOI 10.1016/j.bone.2007.10.018
   Montjovent MO, 2007, J BIOMED MATER RES A, V83A, P41, DOI 10.1002/jbm.a.31208
   Montjovent MO, 2005, TISSUE ENG, V11, P1640, DOI 10.1089/ten.2005.11.1640
   Ozcivici E, 2010, NAT REV RHEUMATOL, V6, P50, DOI 10.1038/nrrheum.2009.239
   Pioletti DP, 2006, SWISS MED WKLY, V136, P557
   Pioletti DP, 2010, COMPUT METHOD BIOMEC, V13, P837, DOI 10.1080/10255841003630660
   Roshan Ghias A, COMPUT METHODS BIOME, DOI 10. 1080/10255842. 2012. 719607
   Roshan Ghias A, 2011, BONE, V49, P1357, DOI 10.1016/j.bone.2011.09.040
   Roshan Ghias A, 2011, BIOMATERIALS, V32, P7006, DOI 10.1016/j.biomaterials.2011.05.085
   Roshan Ghias A, 2010, EUR CELLS MATER, V19, P41, DOI 10.22203/eCM.v019a05
   RUBIN CT, 1985, CALCIFIED TISSUE INT, V37, P411, DOI 10.1007/BF02553711
   Schulte FA, 2011, BONE, V48, P433, DOI 10.1016/j.bone.2010.10.007
   Sikavitsas VI, 2003, P NATL ACAD SCI USA, V100, P14683, DOI 10.1073/pnas.2434367100
   Stadelmann VA, 2008, BONE, V42, P358, DOI 10.1016/j.bone.2007.09.055
   Stevens MM, 2005, P NATL ACAD SCI USA, V102, P11450, DOI 10.1073/pnas.0504705102
   Terrier A, 2009, COMPUT METHOD BIOMEC, V12, P333, DOI 10.1080/10255840802603589
   van der Pol U, 2010, ACTA BIOMATER, V6, P3755, DOI 10.1016/j.actbio.2010.03.028
NR 35
TC 13
Z9 16
U1 0
U2 28
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1025 5842
EI 1476 8259
J9 COMPUT METHOD BIOMEC
JI Comput. Methods Biomech. Biomed. Eng.
PD OCT 1
PY 2013
VL 16
IS 10
SI SI
BP 1050
EP 1055
DI 10.1080/10255842.2013.780602
PG 6
WC Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Computer Science; Engineering
GA 237CA
UT WOS:000325844600003
PM 23531231
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Du, YY
   Chen, H
   Zhou, L
   Guo, QF
   Gong, SM
   Feng, SY
   Guan, QJ
   Shi, PL
   Lv, TX
   Guo, YL
   Yang, C
   Sun, P
   Li, K
   Xu, SG
   Li, L
AF Du, Yingying
   Chen, Hui
   Zhou, Lei
   Guo, Qunfeng
   Gong, Shuangming
   Feng, Siyuan
   Guan, Qiujing
   Shi, Peilin
   Lv, Tongxin
   Guo, Yilan
   Yang, Cheng
   Sun, Peng
   Li, Kun
   Xu, Shuogui
   Li, Lei
TI REGγ is essential to maintain bone homeostasis by degrading TRAF6,
   preventing osteoporosis
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE independent degradation; REG gamma; TRAF6; NIP30; osteoporosis
ID OSTEOCLAST; RANKL; WOMEN
AB Primary osteoporosis, manifesting as decreased bone mass and increased bone fragility, is a "silent disease" that is often ignored until a bone breaks. Accordingly, it is urgent to develop reliable biomarkers and novel therapeutic strategies for osteoporosis treatment. Here, we identified REG gamma as a potential biomarker of osteoporotic populations through proteomics analysis. Next, we demonstrated that REG gamma deficiency increased osteoclast activity and triggered bone mass loss in REG gamma knockout (KO) and bone marrow  derive macrophage (BMM)  conditional REG gamma KO mice. However, the osteoclast activity decreased in BMM  conditional REG gamma overexpression mice. Mechanistically, we defined that REG gamma 20S proteasome directly degraded TRAF6 to inhibit bone absorption in a ubiquitin  independent pathway. More importantly, BMM  conditional Traf6KO with REG gamma KO mice could "rescue" the osteoporosis phenotypes. Based on NIP30 (a REG gamma "inhibitor") dephosphorylation by CKII inhibition activated the ubiquitin  independent degradation of TRAF6, we selected TTP22, an inhibitor of CKII, and defined that TTP22 could alleviate osteoporosis in vitro and in vivo. Overall, our study reveals a unique function of NIP30/REG gamma/TRAF6 axis in osteoporosis and provides a potential therapeutic drug TTP22 for osteoporosis.
C1 [Du, Yingying; Zhou, Lei; Gong, Shuangming; Feng, Siyuan; Guan, Qiujing; Shi, Peilin; Lv, Tongxin] East China Normal Univ, Shanghai Key Lab Regulatory Biol, Inst Biomed Sci, Sch Life Sci, Shanghai 200241, Peoples R China.
   [Chen, Hui] Fudan Univ, Shanghai Fifth Peoples Hosp, Dept Trauma Emergency & Crit Care Med, Shanghai 200240, Peoples R China.
   [Chen, Hui; Li, Lei] East China Normal Univ, Shanghai Fifth Peoples Hosp, Joint Ctr Translat Med, Shanghai 200241, Peoples R China.
   [Chen, Hui; Li, Lei] East China Normal Univ, Sch Life Sci, Shanghai, Peoples R China.
   [Zhou, Lei] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Orthoped, Shanghai 200080, Peoples R China.
   [Yang, Cheng] Naval Med Univ, Changzheng Hosp, Dept Orthoped, Shanghai 200003, Peoples R China.
   [Guo, Yilan; Sun, Peng] East China Normal Univ, Key Lab Adolescent Hlth Assessment & Exercise Inte, Minist Educ, Shanghai 200241, Peoples R China.
   [Li, Kun] East China Normal Univ, Hlth Sci Ctr, Shanghai 200241, Peoples R China.
   [Xu, Shuogui] Naval Med Univ, Changhai Hosp, Affiliated Hosp 1, Shanghai 200433, Peoples R China.
   [Li, Lei] East China Normal Univ, Chongqing Key Lab Precis Opt, Chongqing Inst, Chongqing 401120, Peoples R China.
   [Li, Lei] East China Normal Univ, Shanghai Frontiers Sci Ctr Genome Editing & Cell, Shanghai, Peoples R China.
C3 East China Normal University; Fudan University; East China Normal
   University; East China Normal University; Shanghai Jiao Tong University;
   Naval Medical University; East China Normal University; East China
   Normal University; Naval Medical University; East China Normal
   University; East China Normal University
RP Li, L (通讯作者)，East China Normal Univ, Shanghai Fifth Peoples Hosp, Joint Ctr Translat Med, Shanghai 200241, Peoples R China.; Li, L (通讯作者)，East China Normal Univ, Sch Life Sci, Shanghai, Peoples R China.; Li, K (通讯作者)，East China Normal Univ, Hlth Sci Ctr, Shanghai 200241, Peoples R China.; Xu, SG (通讯作者)，Naval Med Univ, Changhai Hosp, Affiliated Hosp 1, Shanghai 200433, Peoples R China.; Li, L (通讯作者)，East China Normal Univ, Chongqing Key Lab Precis Opt, Chongqing Inst, Chongqing 401120, Peoples R China.; Li, L (通讯作者)，East China Normal Univ, Shanghai Frontiers Sci Ctr Genome Editing & Cell, Shanghai, Peoples R China.
EM kunli12345@163.com; shuogui_xu@smmu.edu.cn; lli@bio.ecnu.edu.cn
RI Feng, Siyuan/AAA 1320 2022
FU National Natural Science Foundation of China [82022051, 32171130];
   Science and Technology Commission of Shanghai Municipality
   [23ZR1452000]; Shanghai Pilot Program for Basic Research [TQ20240208];
   Natural Science Foundation of Chongqing [CSTB2024NSCQ  JQX0009]; Naval
   Medical University Research Foundation [2021 MS14]; East China Normal
   University Multifunctional Platform for Innovation [001, 011]; 
   [82372456]
FX We thank Prof. Bert W O'Malley and Prof. Xiaotao Li (Department of
   Molecular and Cellular Biology, Baylor College of Medicine, Baylor
   College of Medicine) for their support of and suggestions on this study.
   This work was funded by the National Natural Science Foundation of China
   (NO. 82022051, 82372456, and 32171130) , the Science and Technology
   Commission of Shanghai Municipality (NO. 23ZR1452000) , Shanghai Pilot
   Program for Basic Research (TQ20240208) , Natural Science Foundation of
   Chongqing (CSTB2024NSCQ JQX0009) , and the Naval Medical University
   Research Foundation (NO. 2021 MS14) . We also thank the support of East
   China Normal University Multifunctional Platform for Innovation (001 and
   011) . Schematic illustrations were created using BioRender.com . We
   also thank the Instruments Sharing Platform of School of Life Sciences,
   East China Normal University.
CR Barton LF, 2004, J IMMUNOL, V172, P3948, DOI 10.4049/jimmunol.172.6.3948
   Brenke JK, 2018, J BIOL CHEM, V293, P13191, DOI 10.1074/jbc.RA118.002649
   Chellaiah MA, 2021, CELLS BASEL, V10, DOI 10.3390/cells10092432
   Chen XY, 2007, MOL CELL, V26, P843, DOI 10.1016/j.molcel.2007.05.022
   Chen YJ, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.803880
   CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092 8674(94)90396 4
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Deardorff WJ, 2022, JAMA INTERN MED, V182, P33, DOI 10.1001/jamainternmed.2021.6745
   Deepak V, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2201490119
   Delgado Calle J, 2022, PHYSIOL REV, V102, DOI 10.1152/physrev.00043.2020
   Du YY, 2024, P NATL ACAD SCI USA, V121, DOI 10.1073/pnas.2405265121
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Fricker LD, 2020, ANNU REV PHARMACOL, V60, P457, DOI 10.1146/annurev pharmtox 010919 023603
   Gao X, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 18767 0
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Inomata M, 2012, CELL MOL LIFE SCI, V69, P963, DOI 10.1007/s00018 011 0819 y
   Jang HD, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658 019 0156 y
   Jonik Nowak B, 2018, P NATL ACAD SCI USA, V115, pE6477, DOI 10.1073/pnas.1722299115
   Kanis JA, 2002, LANCET, V359, P1929, DOI 10.1016/S0140 6736(02)08761 5
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   König D, 2018, NUTRIENTS, V10, DOI 10.3390/nu10010097
   Kuo TR, 2017, BIOMARK RES, V5, DOI 10.1186/s40364 017 0097 4
   Lai PL, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.249
   Lau EMC, 2015, J CLIN DENSITOM, V18, P519, DOI 10.1016/j.jocd.2014.11.001
   Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814
   Li CW, 2022, CELL DEATH DIFFER, V29, P1123, DOI 10.1038/s41418 021 00904 x
   Li L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7875
   Li L, 2013, P NATL ACAD SCI USA, V110, P11005, DOI 10.1073/pnas.1308497110
   Li XT, 2007, MOL CELL, V26, P831, DOI 10.1016/j.molcel.2007.05.028
   Li XT, 2006, CELL, V124, P381, DOI 10.1016/j.cell.2005.11.037
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076
   Ma QY, 2021, BONE RES, V9, DOI 10.1038/s41413 020 00121 1
   Mao I, 2008, Cell Mol Life Sci, V65, P3971, DOI 10.1007/s00018 008 8291 z
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Migliorini F, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02474 7
   Murata S, 1999, J BIOL CHEM, V274, P38211, DOI 10.1074/jbc.274.53.38211
   NIKAIDO T, 1990, CLIN EXP IMMUNOL, V79, P209
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Reid IR, 2020, NAT REV ENDOCRINOL, V16, P333, DOI 10.1038/s41574 020 0339 7
   Sambrook PN, 1996, MED J AUSTRALIA, V165, P332, DOI 10.5694/j.1326 5377.1996.tb124996.x
   Sattui SE, 2014, NAT REV ENDOCRINOL, V10, P592, DOI 10.1038/nrendo.2014.125
   Seriolo B, 2013, AGING CLIN EXP RES, V25, pS27, DOI 10.1007/s40520 013 0107 9
   Song SS, 2022, PHARMACOL THERAPEUT, V237, DOI 10.1016/j.pharmthera.2022.108168
   Strickson S, 2017, P NATL ACAD SCI USA, V114, pE3481, DOI 10.1073/pnas.1702367114
   Sun KQ, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.629968
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Takegahara N, 2022, BONE, V159, DOI 10.1016/j.bone.2022.116353
   Tan EM, 2017, J BONE MINER RES, V32, P846, DOI 10.1002/jbmr.3031
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Thibaudeau TA, 2019, PHARMACOL REV, V71, P170, DOI 10.1124/pr.117.015370
   Tong L, 2020, CELL DEATH DIFFER, V27, P1795, DOI 10.1038/s41418 019 0459 6
   Tu JL, 2022, J BIOL CHEM, V298, DOI 10.1016/j.jbc.2022.102571
   Vitaca T, 2022, LANCET DIABETES ENDO, V10, P273, DOI 10.1016/S2213 8587(22)00012 2
   Wang JH, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111595
   Wang LJ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00190 4
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Wu CL, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 02073 3
   Wu H, 2003, BIOESSAYS, V25, P1096, DOI 10.1002/bies.10352
   Xiao PL, 2022, OSTEOPOROSIS INT, V33, P2137, DOI 10.1007/s00198 022 06454 3
   Yoon K, 2008, CELL DEATH DIFFER, V15, P730, DOI 10.1038/sj.cdd.4402304
   Zhu XZ, 2022, SCI CHINA LIFE SCI, V65, P1608, DOI 10.1007/s11427 021 2018 7
NR 64
TC 2
Z9 2
U1 6
U2 10
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
EI 1091 6490
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 19
PY 2024
VL 121
IS 47
AR e2405265121
DI 10.1073/pnas.2405265121
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA O1E3G
UT WOS:001368638000001
PM 39536082
OA hybrid
DA 2025 08 17
ER

PT J
AU Szajnman, SH
   Ravaschino, EL
   Docampo, R
   Rodriguez, JB
AF Szajnman, SH
   Ravaschino, EL
   Docampo, R
   Rodriguez, JB
TI Synthesis and biological evaluation of 1 amino 1,1 bisphosphonates
   derived from fatty acids against Trypanosoma cruzi targeting
   farnesyl pyrophosphate synthase
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Chagas' disease; Trypanosoma cruzi; bisphosphonates; farnesyl
   pyrophosphate synthase.
ID NITROGEN CONTAINING BISPHOSPHONATES; IN VITRO; POTENT INHIBITORS;
   1 PHENYL 1 HYDROXYMETHYLENE BISPHOSPHONATE; DIPHOSPHATE SYNTHASE;
   GROWTH INHIBITORS; CHELATING AGENTS; CHAGAS DISEASE; CHEMOTHERAPY; VIVO
AB We have investigated the effect of a series of 1 amino 1,1 bisphosphonates derived from fatty acids against proliferation of the clinically more relevant form of Trypanosoma cruzi, the causative agent of American trypanosomiasis (Chagas' disease). Some of these drugs were potent inhibitors against the intracellular form of the parasite, exhibiting IC50 values at low micromolar level. Cellular activity was associated with the inhibition of enzymatic activity of T cruzi farnesyl pyrophosphate synthase. As bisphosphonate containing drugs are FDA approved for the treatment of bone resorption disorders, their potential innocuousness makes them good candidates to control tropical diseases. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Organ, Buenos Aires, DF, Argentina.
   Univ Georgia, Ctr Global & Emerging Dis, Athens, GA 30602 USA.
   Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA.
C3 University of Buenos Aires; University System of Georgia; University of
   Georgia; University System of Georgia; University of Georgia
RP Rodriguez, JB (通讯作者)，Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Organ, Pabellon 2,Ciudad Univ,C1428EHA, Buenos Aires, DF, Argentina.
EM jbr@qo.fcen.uba.ar
RI ; Szajnman, Sergio/AFM 1606 2022
OI Rodriguez, Juan Bautista/0000 0002 5180 096X; Szajnman, Sergio
   Hernan/0000 0001 6989 4768; 
CR Augustyns K, 2001, CURR PHARM DESIGN, V7, P1117, DOI 10.2174/1381612013397564
   BRENER Z, 1973, ANNU REV MICROBIOL, V27, P347, DOI 10.1146/annurev.mi.27.100173.002023
   BRENER Z, 1979, PHARMACOL THERAPEUT, V7, P71, DOI 10.1016/0163 7258(79)90025 1
   Cazzulo JJ, 2001, CURR PHARM DESIGN, V7, P1143, DOI 10.2174/1381612013397528
   Cinque GM, 1998, J MED CHEM, V41, P1540, DOI 10.1021/jm970860z
   Docampo R, 1997, PARASITOL TODAY, V13, P129, DOI 10.1016/S0169 4758(97)01021 1
   Docampo R, 2001, CURR PHARM DESIGN, V7, P1157, DOI 10.2174/1381612013397546
   Docampo Roberto, 2001, Current Drug Targets   Infectious Disorders, V1, P51, DOI 10.2174/1568005013343191
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Ebetino FH, 2005, J ORGANOMET CHEM, V690, P2679, DOI 10.1016/j.jorganchem.2005.03.005
   Galel SA, 1996, TRANSFUSION, V36, P227, DOI 10.1046/j.1537 2995.1996.36396182140.x
   Garzoni LR, 2004, INT J ANTIMICROB AG, V23, P286, DOI 10.1016/j.ijantimicag.2003.07.019
   Ghosh S, 2004, J MED CHEM, V47, P175, DOI 10.1021/jm030084x
   Griffiths DV, 1997, TETRAHEDRON, V53, P17815, DOI 10.1016/S0040 4020(97)10245 9
   Gumienna Kontecka E, 2002, INORG CHIM ACTA, V339, P111, DOI 10.1016/S0020 1693(02)00918 0
   Gumienna Kontecka E, 2002, J INORG BIOCHEM, V89, P13, DOI 10.1016/S0162 0134(01)00412 3
   HOSFIELD DJ, 2006, J BIOL CHEM, V278, P18401
   KIRCHHOFF LV, 1993, NEW ENGL J MED, V329, P639, DOI 10.1056/NEJM199308263290909
   Leonard DM, 1997, J MED CHEM, V40, P2971, DOI 10.1021/jm970226l
   Ling Y, 2005, J MED CHEM, V48, P3130, DOI 10.1021/jm040132t
   Martin MB, 1999, BIOCHEM BIOPH RES CO, V263, P754, DOI 10.1006/bbrc.1999.1404
   Martin MB, 2002, J MED CHEM, V45, P2904, DOI 10.1021/jm0102809
   Martin MB, 2001, J MED CHEM, V44, P909, DOI 10.1021/jm0002578
   Matczak Jon E, 2002, POLYHEDRON, V21, P321, DOI 10.1016/S0277 5387(01)00996 2
   Montalvetti A, 2001, J BIOL CHEM, V276, P33930, DOI 10.1074/jbc.M103950200
   Montalvetti A, 2003, J BIOL CHEM, V278, P17075, DOI 10.1074/jbc.M210467200
   OGURA K, 1985, METHOD ENZYMOL, V110, P167
   Olive G, 2000, SYNTHETIC COMMUN, V30, P619, DOI 10.1080/00397910008087363
   PAPAPOULOS S, Patent No. 0753523
   Reszka AA, 2004, MINI REV MED CHEM, V4, P711
   Reszka Alfred A, 2003, Curr Rheumatol Rep, V5, P65, DOI 10.1007/s11926 003 0085 6
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rodriguez JB, 2001, CURR PHARM DESIGN, V7, P1105, DOI 10.2174/1381612013397555
   Rodriguez JB, 1995, CURR MED CHEM, V2, P723
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Szajnman SH, 2003, BIOORG MED CHEM LETT, V13, P3231, DOI 10.1016/S0960 894X(03)00663 2
   Szajnman SH, 2001, BIOORG MED CHEM LETT, V11, P789, DOI 10.1016/S0960 894X(01)00057 9
   Szajnman SH, 2000, J MED CHEM, V43, P1826, DOI 10.1021/jm9905007
   TARSHIS LC, 1994, BIOCHEMISTRY US, V33, P10871, DOI 10.1021/bi00202a004
   Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018
   Urbina JA, 1999, J BIOL CHEM, V274, P33609, DOI 10.1074/jbc.274.47.33609
   Urbina JA, 2003, TRENDS PARASITOL, V19, P495, DOI 10.1016/j.pt.2003.09.001
   Watts AG, 2003, J AM CHEM SOC, V125, P7532, DOI 10.1021/ja0344967
   Widler L, 2002, J MED CHEM, V45, P3721, DOI 10.1021/jm020819i
   Yokoyama K, 1998, MOL BIOCHEM PARASIT, V94, P87, DOI 10.1016/S0166 6851(98)00053 X
   Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325
NR 47
TC 75
Z9 85
U1 1
U2 8
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960 894X
EI 1464 3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD NOV 1
PY 2005
VL 15
IS 21
BP 4685
EP 4690
DI 10.1016/j.bmcl.2005.07.060
PG 6
WC Chemistry, Medicinal; Chemistry, Organic
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Chemistry
GA 972PO
UT WOS:000232465900007
PM 16143525
OA Green Published
DA 2025 08 17
ER

PT J
AU Li, G
   Liu, HF
   Zhang, XG
   Liu, XC
   Zhang, GD
   Liu, QH
AF Li, Gang
   Liu, Haifeng
   Zhang, Xiaogang
   Liu, Xingchao
   Zhang, Guodong
   Liu, Qinghe
TI The protective effects of microRNA 26a in steroid induced osteonecrosis
   of the femoral head by repressing EZH2 (Publication with Expression of
   Concern)
SO CELL CYCLE
LA English
DT Article; Publication with Expression of Concern
DE Steroid induced osteonecrosis of the femoral head; microRNA 26a;
   enhancer of zeste homologue 2; apoptosis; osteoblast; osteoclast
ID NASOPHARYNGEAL CARCINOMA; INDUCED NECROSIS; CELL GROWTH; PPAR GAMMA;
   MIR 26A; OSTEOSARCOMA; INHIBITION; GENES; TUMORIGENESIS; EXPRESSION
AB Recently, the role of microRNAs (miRs) in human diseases has been verified. This study was determined to explore the protective effects of microRNA 26a (miR 26a) in steroid induced osteonecrosis of the femoral head (SONFH) with the involvement of enhancer of zeste homologue 2 (EZH2). Femoral head (FH) samples from SONFH patients and patients with femoral neck fracture were collected, and rat SONFH models were established by Escherichia coli endotoxin combining with large dose steroid pulse assay. The hemorheology, blood lipid, inflammatory factors, and pathologic changes were measured by a series of experiments. Moreover, the detection of osteoblasts, osteoclasts, miR 26a expression, EZH2 expression, osteoprotegerin (OPG) and osteoprotegerin ligand (OPGL), and the apoptosis of osteocytes were conducted. The target relation between miR 26a and EZH2 was clarified by bioinformatics and dual luciferase reporter gene assay. MiR 26a was poorly expressed, while EZH2 was highly expressed in SONFH, and the elevation of miR 26a could repress EZH2 expression. Elevated miR 26a and reduced EZH2 were able to decelerate the apoptosis of osteocytes, increase osteoblasts, and decrease osteoclasts, resulting in a repression of SONFH progression. Additionally, EZH2 was a target gene of miR 26a. Furthermore, the elevation of EZH2 could reverse the repression of SONFH progression that is induced by elevated miR 26a. We found that up regulation of miR 26a and knockdown of EZH2 could suppress the development of SONFH, which would contribute to the therapy of SONFH.
C1 [Li, Gang; Liu, Haifeng; Zhang, Xiaogang; Liu, Xingchao; Zhang, Guodong] Hebei Med Univ, Hebei Yanda Hosp, Dept Orthped, Sanhe, Peoples R China.
   [Liu, Qinghe] Capital Med Univ, Beijing Chaoyang Hosp, Dept Orthped, Beijing, Peoples R China.
C3 Hebei Medical University; Capital Medical University
RP Liu, QH (通讯作者)，Capital Med Univ, Beijing Chaoyang Hosp, Dept Orthped, Beijing, Peoples R China.
EM Liuqinghe2019@163.com
RI Li, Gang/GWM 7351 2022; Liu, Haifeng/ITU 7594 2023
FU Key scientific and technological research programs of HeBei Province
   [20180897]
FX This work was supported by The Key scientific and technological research
   programs of HeBei Province, Grant/Award Number: 20180897; The Key
   scientific and technological research programs of HeBei Province
   [20180897].
CR Adamik J, 2017, MOL CANCER RES, V15, P405, DOI 10.1158/1541 7786.MCR 16 0242 T
   Aimaiti A, 2011, MED HYPOTHESES, V77, P282, DOI 10.1016/j.mehy.2011.04.036
   Bai R, 2015, EXP THER MED, V10, P591, DOI 10.3892/etm.2015.2521
   Dong Yu lei, 2015, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V37, P152, DOI 10.3881/j.issn.1000 503X.2015.02.004
   Ge X, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 1176 7
   Gu CX, 2016, SCI REP UK, V6, DOI 10.1038/srep38491
   Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838
   Hao C, 2016, SCI REP UK, V6, DOI 10.1038/srep22599
   Huo YQ, 2017, ONCOTARGET, V8, P46993, DOI 10.18632/oncotarget.16551
   Jiang LD, 2020, J CELL PHYSIOL, V235, P979, DOI 10.1002/jcp.29013
   Li F, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20181635
   Li Z, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12418
   Li Z, 2017, EXP THER MED, V14, P5069, DOI 10.3892/etm.2017.5183
   Liang H, 2019, INFLAMM RES, V68, P325, DOI 10.1007/s00011 019 01221 3
   Lin Z, 2017, GENE, V627, P322, DOI 10.1016/j.gene.2017.05.026
   Liu JY, 2018, ONCOL LETT, V15, P8303, DOI 10.3892/ol.2018.8359
   Lu JA, 2011, CANCER RES, V71, P225, DOI 10.1158/0008 5472.CAN 10 1850
   McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606
   Mohammadi Torbati Peyman, 2019, Asian Pac J Cancer Prev, V20, P1453
   Shen HJ, 2018, ACTA BIOCH BIOPH SIN, V50, P191, DOI 10.1093/abbs/gmx141
   Song Y, 2017, BONE, V101, P104, DOI 10.1016/j.bone.2017.05.002
   Sun RR, 2016, ONCOTARGET, V7, P38333, DOI 10.18632/oncotarget.9518
   TAHERIAZAM A, 2015, DIAGN PATHOL, V10
   Tian Y, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/8298193
   Vella S, 2013, INT J MOL SCI, V14, P24154, DOI 10.3390/ijms141224154
   Wang ZW, 2018, BIOMED PHARMACOTHER, V107, P598, DOI 10.1016/j.biopha.2018.08.025
   Xie QY, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150071
   Xu BY, 2018, EUR REV MED PHARMACO, V22, P486, DOI 10.26355/eurrev_201801_14199
   Xu XX, 2014, J MOL HISTOL, V45, P473, DOI 10.1007/s10735 014 9571 6
   Yang IP, 2012, CARCINOGENESIS, V33, P1522, DOI 10.1093/carcin/bgs166
   Yu M, 2019, CHEM BIOL INTERACT, V307, P51, DOI 10.1016/j.cbi.2019.04.028
   Zhao DW, 2012, BONE, V50, P325, DOI 10.1016/j.bone.2011.11.002
   Zhao Z, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20182025
   Zhuang CB, 2016, INT J ONCOL, V48, P1195, DOI 10.3892/ijo.2016.3336
   Zingg D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7051
NR 35
TC 29
Z9 32
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538 4101
EI 1551 4005
J9 CELL CYCLE
JI Cell Cycle
PD MAR 3
PY 2020
VL 19
IS 5
BP 551
EP 566
DI 10.1080/15384101.2020.1717043
EA FEB 2020
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA KQ4EV
UT WOS:000513977000001
PM 32054404
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Zehra, S
   Ghouri, M
   Jafari, H
   Saleem, S
   Fatima, S
   Azhar, A
AF Zehra, Sitwat
   Ghouri, Maham
   Jafari, Halima
   Saleem, Saima
   Fatima, Sehrish
   Azhar, Abid
TI Single nucleotide polymorphisms (rs3736228 and rs4988321)
   in low density lipoprotein receptor related protein 5 gene with
   predisposition to rheumatoid arthritis
SO GENE
LA English
DT Article
DE Linkage disequilibrium; T ARMS PCR; ACR; EULAR 2010 criteria; Single
   nucleotide polymorphism(s)
ID WNT SIGNALING PATHWAY; A1330V POLYMORPHISM; RISK; ASSOCIATION
AB Background: LRP5 (Lipoprotein Receptor 5) is one of the representatives of the low density lipoprotein receptors family that play a crucial role in the process of bone homeostasis and bone remodeling. The role of LRP5 single nucleotide polymorphisms (SNPs) rs3736228 and rs4988321 has been associated with the susceptibility to osteoporosis and bone fracture. The frequency of mentioned LRP5 SNPs is unknown among RA (Rheumatoid Arthritis) patients. The case control study was designed to determine the association of targeted SNPs among RA patients.Methodology: Patients were selected by ACR/EULAR 2010 criteria. After ethical approval blood samples of pa tients and healthy individuals were collected. DNA was extracted from the whole blood followed by amplification of the targeted region by T ARMS PCR (Tetra primer Amplification Refractory Mutation System) obtained product was observed on agarose gel electrophoresis. The data were analyzed by statistical and bioinformatic tools.Results: It was observed that the SNPs rs3736228 and rs4988321 showed significant association with the risk of RA [chi 2 = 44, p =< 0.001, O.R 95 % CI = 2.495, (1.865  3.337), p =< 0.001] and [chi 2 = 85, p =< 0.001, O.R 95 % CI = 2.05, (1.571  2.69), p =< 0.001] respectively. Haplotypes AT, GC, and GT were found to be signifi cantly associated with the risk of RA. Furthermore, both SNPs were in 40 % LD (Linkage Disequilibrium).Conclusions: The study revealed that SNPs rs3736228 and rs4988321 were significantly associated with the increased susceptibility to RA. The study serves as the baseline data considering targeted SNPs and their asso ciation with the progression of the disease. The study might be utilized for the development of potential biomarker for diagnostic purposes and in the precision medicine approach.
C1 [Zehra, Sitwat; Ghouri, Maham; Jafari, Halima; Saleem, Saima; Fatima, Sehrish; Azhar, Abid] Univ Karachi, Karachi Inst Biotechnol & Genet Engn KIBGE, Karachi, Pakistan.
   [Zehra, Sitwat] Univ Karachi, Karachi Inst Biotechnol & Genet Engn KIBGE, Karachi 75270, Pakistan.
C3 University of Karachi; University of Karachi
RP Zehra, S (通讯作者)，Univ Karachi, Karachi Inst Biotechnol & Genet Engn KIBGE, Karachi 75270, Pakistan.
EM sitwat.zehra@kibge.edu.pk; maham.ghouri@kibge.edu.pk;
   halima.jaffari@kibge.edu.pk; saima.saleem@kibge.edu.pk;
   sehrish.fatima@kibge.edu.pk; abid.azhar@kibge.edu.pk
RI ; Ghouri, Maham/GXH 1754 2022
OI Ghouri, Maham/0000 0003 3586 5947; 
CR Aletaha D, 2010, ARTHRITIS RHEUM US, V62, P2569, DOI 10.1002/art.27584
   [Anonymous], 2022, DAWN VISUAL CALCULAT
   [Anonymous], 2020, MedCalc Software bv
   [Anonymous], US NATL LIB MED BRAN
   [Anonymous], 2022, ENSEMBL GRCH37 RELEA
   Ayers R., 2022, PLAST SURG PRINC PRA, P919, DOI [10.1016/B978 0 323 65381 7.00059 9, DOI 10.1016/B978 0 323 65381 7.00059 9]
   Bremander A, 2019, ARTHRIT CARE RES, V71, P166, DOI 10.1002/acr.23764
   Brown Z, 2020, ACR OPEN RHEUMATOL, V2, P371, DOI 10.1002/acr2.11132
   Cai PA, 2020, J CELL PHYSIOL, V235, P1746, DOI 10.1002/jcp.29093
   Corp I, 2017, IBM SPSS STAT WINDOW
   de Rooy DPC, 2013, ANN RHEUM DIS, V72, P769, DOI 10.1136/annrheumdis 2012 202184
   de Souza KSC, 2018, ARCH ENDOCRIN METAB, V62, P480, DOI [10.20945/2359 3997000000057, 10.20945/2359 399700000005]
   El Gazzar A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020625
   Fernández Torres J, 2020, RHEUMATOLOGY, V59, P418, DOI 10.1093/rheumatology/kez269
   Funakoshi Yayoi, 2011, Environmental Health and Preventive Medicine, V16, P106, DOI 10.1007/s12199 010 0172 z
   Furuya T, 2009, MOD RHEUMATOL, V19, P140, DOI 10.1007/s10165 008 0138 9
   Haseeb M, 2019, CELLS BASEL, V8, DOI 10.3390/cells8111380
   Holdren M, 2021, ARTHRITIS RHEUMATOL, V73, P53, DOI 10.1002/art.41499
   Kane B.S., 2020, WORLD J CARDIOVASCUL, V10, P1
   Kelmenson LB, 2020, ARTHRITIS RHEUMATOL, V72, P251, DOI 10.1002/art.41091
   Meissner Y, 2021, ANN RHEUM DIS, V80, P49, DOI 10.1136/annrheumdis 2020 218356
   Mellado M, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00384
   Miao CG, 2013, CELL SIGNAL, V25, P2069, DOI 10.1016/j.cellsig.2013.04.002
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Mohsin Z, 2018, CUREUS J MED SCIENCE, V10, DOI 10.7759/cureus.2858
   Mukhtar M, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/8326246
   Ntusi NAB, 2019, HELL J CARDIOL, V60, P28, DOI 10.1016/j.hjc.2018.01.008
   Pikwer M, 2014, ANN RHEUM DIS, V73, P573, DOI 10.1136/annrheumdis 2012 202781
   Ponchel F, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 60314 w
   Poole JA, 2019, J BONE MINER RES, V34, P1733, DOI 10.1002/jbmr.3745
   Rabelo FD, 2010, AUTOIMMUN REV, V9, P207, DOI 10.1016/j.autrev.2009.08.003
   Rodríguez Carrio J, 2017, ARTHRITIS RHEUMATOL, V69, P70, DOI 10.1002/art.39811
   Roetzer KM, 2018, BONE, V107, P154, DOI 10.1016/j.bone.2017.12.002
   Rohrich DC, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075 020 02384 9
   Roy H.S., 2019, OPEN MED IMAGING J, V11
   Schiavone ML, 2020, J CELL PHYSIOL, V235, P6808, DOI 10.1002/jcp.29575
   Shi YY, 2005, CELL RES, V15, P97, DOI 10.1038/sj.cr.7290272
   Son KM, 2021, KOREAN J INTERN MED, V36, P214, DOI 10.3904/kjim.2019.006
   Suwazono Y, 2006, BLOOD PRESSURE, V15, P80, DOI 10.1080/08037050600650191
   Swafford D, 2015, DISCOV MED, V19, P303
   Takeuchi T, 2021, MOD RHEUMATOL, V31, P53, DOI 10.1080/14397595.2020.1733214
   Targonska Stepniak B, 2019, CLIN RHEUMATOL, V38, P1131, DOI 10.1007/s10067 018 4369 7
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
   Zhou YC, 2017, CURR RHEUMATOL REP, V19, DOI 10.1007/s11926 017 0679 z
   Zlatkovic Svenda MI, 2019, SRP ARK CELOK LEK, V147, P235, DOI 10.2298/SARH180110009Z
NR 45
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378 1119
EI 1879 0038
J9 GENE
JI Gene
PD JAN 30
PY 2023
VL 851
AR 147025
DI 10.1016/j.gene.2022.147025
EA NOV 2022
PG 6
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA 6D8VW
UT WOS:000882963800003
PM 36328193
DA 2025 08 17
ER

PT J
AU Nakano, C
   Kitabatake, Y
   Takeyari, S
   Ohata, Y
   Kubota, T
   Taketani, K
   Kogo, M
   Ozono, K
AF Nakano, Chiho
   Kitabatake, Yasuji
   Takeyari, Shinji
   Ohata, Yasuhisa
   Kubota, Takuo
   Taketani, Ken
   Kogo, Mikihiko
   Ozono, Keiichi
TI Genetic correction of induced pluripotent stem cells mediated by
   transcription activator like effector nucleases targeting ALPL
   recovers enzyme activity and calcification in vitro
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Article
DE Genome editing; Metabolic bone disease; Inborn error; Alkaline
   phosphatase; Gene therapy
ID NONSPECIFIC ALKALINE PHOSPHATASE; REPLACEMENT THERAPY; HYPOPHOSPHATASIA;
   JAPANESE; TRANSPLANTATION
AB Hypophosphatasia (HPP) is an inheritable disease affecting both skeletal systems and extra skeletal organs due to mutations of the gene ALPL, which encodes tissue nonspecific alkaline phosphatase. Recently, an enzyme replacement therapy using asfotase alfa was developed to ameliorate the complications of HPP. However, it requires frequent injections and is expensive to maintain. As an alternative, cell and gene therapy using human induced pluripotent stem cells (iPSCs) after precise correction of the mutation is feasible due to advances in genome editing technology. In the study, we examined the alkaline phosphatase (ALP) activity and calcification in vitro of two childhood HPP patient derived iPSCs after the correction of the c.1559delT mutation, which is the most frequent mutation in Japanese patients with HPP, using transcription activator like effector nucleases (TALENs). The gene correction targeting vector was designed for site directed mutagenesis using TALEN. After selection with antibiotics, some clones with the selection cassette were obtained. Gene correction was confirmed by Sanger sequencing. The mutation was corrected in one allele of ALPL in homozygous patients and compound heterozygous patients. The correction of ALPL did not result in an increase in ALP when the selection cassette remained. Conversely, iPSCs exhibited ALP activity after the elimination of the cassette using Cre/LoxP. The quantitative analysis showed the half ALP activity in corrected iPSCs of that of control iPSCs, corresponding to heterozygous correction of the mutation. In addition, osteoblasts differentiated from the corrected iPSCs exhibited high ALP activity and some calcification in vitro. Moreover, the osteoblast like phenotype was confirmed by increased expression of osteoblast specific genes such as COL1A1 and osteocalcin. These results suggest that gene correction in iPSCs may be a candidate treatment for HPP patients.
C1 [Nakano, Chiho; Kitabatake, Yasuji; Takeyari, Shinji; Ohata, Yasuhisa; Kubota, Takuo; Ozono, Keiichi] Osaka Univ, Grad Sch Med, Dept Pediat, Osaka, Japan.
   [Nakano, Chiho] Osaka Univ Hosp, Unit Dent, Osaka, Japan.
   [Kogo, Mikihiko] Osaka Univ, Grad Sch Dent, Dept Oral & Maxillofacial Surg, Osaka, Japan.
   [Taketani, Ken] Shimane Univ, Dept Pediat, Osaka, Japan.
C3 University of Osaka; University of Osaka; University of Osaka; Shimane
   University
RP Ozono, K (通讯作者)，2 2 Yamada Oka, Suita, Osaka 5650871, Japan.
EM keioz@ped.med.osaka u.ac.jp
RI Ohata, Yasuhisa/AAJ 4615 2020; Kogo, Mikihiko/ABD 7080 2020
OI Kitabatake, Yasuji/0000 0002 2907 9512; Ohata,
   Yasuhisa/0000 0001 6084 6620; 
FU Japan Agency for Medical Research and Development [JP17ek0109135]; Novo
   Nordisk Study Award for Growth and Development
FX The authors thank Takashi Yamamoto, Department of Mathematical and Life
   Sciences Graduate School of Science, Hiroshima University for the
   technical advices. We also thank Toshimi Michigami, Department of Bone
   and Mineral Research, Osaka Medical Center and Research Institute for
   Maternal and Child Health, for the useful discussion. We thank the
   patients with hypophosphatasia for providing skin fibroblasts. This work
   was supported in part by Japan Agency for Medical Research and
   Development [grant number JP17ek0109135] and Novo Nordisk Study Award
   for Growth and Development.
CR Banno K, 2016, CELL REP, V15, P1228, DOI 10.1016/j.celrep.2016.04.031
   Bedell VM, 2012, NATURE, V491, P114, DOI 10.1038/nature11537
   Bishop N, 2016, ARCH DIS CHILD, V101, P514, DOI 10.1136/archdischild 2015 309579
   Chambers DC, 2017, STEM CELL TRANSL MED, V6, P1152, DOI 10.1002/sctm.16 0372
   Doyle EL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082120
   Dunbar CE, 2018, SCIENCE, V359, P175, DOI 10.1126/science.aan4672
   Fukuta M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112291
   Hotta A, 2015, ANNU REV GENET, V49, P47, DOI 10.1146/annurev genet 112414 054926
   Iijima O, 2015, HUM GENE THER, V26, P801, DOI 10.1089/hum.2015.078
   Inada E, 2017, J INVESTIG CLIN DENT, V8, DOI 10.1111/jicd.12236
   Kishnani PS, 2017, MOL GENET METAB, V122, P4, DOI 10.1016/j.ymgme.2017.07.010
   Kitaoka T, 2017, CLIN ENDOCRINOL, V87, P10, DOI 10.1111/cen.13343
   Lechanteur C, 2016, J TRANSL MED, V14, DOI 10.1186/s12967 016 0892 y
   Lo Furno D, 2018, J CELL PHYSIOL, V233, P3982, DOI 10.1002/jcp.26192
   MACGREGOR GR, 1995, DEVELOPMENT, V121, P1487
   Michigami T, 2005, EUR J PEDIATR, V164, P277, DOI 10.1007/s00431 004 1612 9
   Millán JL, 2016, CALCIFIED TISSUE INT, V98, P398, DOI 10.1007/s00223 015 0079 1
   Mornet E., GENEREVIEWS
   Müller HL, 2000, J CLIN ENDOCR METAB, V85, P743, DOI 10.1210/jc.85.2.743
   Nishimura K, 2017, STEM CELL RES, V23, P13, DOI 10.1016/j.scr.2017.06.011
   Okazaki Y, 2016, EUR J PEDIATR, V175, P433, DOI 10.1007/s00431 015 2641 2
   Ozono K, 2011, J HUM GENET, V56, P174, DOI 10.1038/jhg.2011.6
   Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726
   Shi YF, 2010, CELL RES, V20, P510, DOI 10.1038/cr.2010.44
   Singh AK, 2016, CANCER RES, V76, P6445, DOI 10.1158/0008 5472.CAN 16 1311
   Suzuki K, 2014, CELL STEM CELL, V15, P31, DOI 10.1016/j.stem.2014.06.016
   Taketani T, 2015, CELL TRANSPLANT, V24, P1931, DOI 10.3727/096368914X685410
   Taketani T, 2014, ARCH DIS CHILD, V99, P211, DOI 10.1136/archdischild 2013 305037
   Tenorio J, 2017, AM J MED GENET A, V173, P601, DOI 10.1002/ajmg.a.37991
   Watanabe A, 2011, J HUM GENET, V56, P166, DOI 10.1038/jhg.2010.161
   Whyte MP, 2017, J BONE MINER RES, V32, P667, DOI 10.1002/jbmr.3075
   Whyte MP, 2016, NAT REV ENDOCRINOL, V12, P233, DOI 10.1038/nrendo.2016.14
   Whyte MP, 2016, J CLIN ENDOCR METAB, V101, P333, DOI 10.1210/jc.2015 3462
   Whyte MP, 2012, NEW ENGL J MED, V366, P904, DOI 10.1056/NEJMoa1106173
   Yu KR, 2016, HUM GENE THER, V27, P729, DOI 10.1089/hum.2016.107
NR 35
TC 14
Z9 15
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 1096 7192
EI 1096 7206
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD JUN
PY 2019
VL 127
IS 2
BP 158
EP 165
DI 10.1016/j.ymgme.2019.05.014
PG 8
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental
   Medicine
GA IG1MK
UT WOS:000473555500007
PM 31178256
DA 2025 08 17
ER

PT J
AU Hain, BA
   Jude, B
   Xu, HF
   Smuin, DM
   Fox, EJ
   Elfar, JC
   Waning, DL
AF Hain, Brian A.
   Jude, Baptiste
   Xu, Haifang
   Smuin, Dallas M.
   Fox, Edward J.
   Elfar, John C.
   Waning, David L.
TI Zoledronic Acid Improves Muscle Function in Healthy Mice Treated with
   Chemotherapy
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE BISPHOSPHONATE; BONE LOSS; CACHEXIA; CHEMOTHERAPY; MUSCLE WEAKNESS
ID VITAMIN D; BREAST CANCER; BONE LOSS; PALLIATIVE CHEMOTHERAPY;
   MECHANISMS; CACHEXIA; BISPHOSPHONATES; DISEASE; QUALITY; OSTEOPOROSIS
AB Carboplatin is a chemotherapy drug used to treat solid tumors but also causes bone loss and muscle atrophy and weakness. Bone loss contributes to muscle weakness through bone muscle crosstalk, which is prevented with the bisphosphonate zoledronic acid (ZA). We treated mice with carboplatin in the presence or absence of ZA to assess the impact of bone resorption on muscle. Carboplatin caused loss of body weight, muscle mass, and bone mass, and also led to muscle weakness as early as 7 days after treatment. Mice treated with carboplatin and ZA lost body weight and muscle mass but did not lose bone mass. In addition, muscle function in mice treated with ZA was similar to control animals. We also used the anti TGF beta antibody (1D11) to prevent carboplatin induced bone loss and showed similar results to ZA treated mice. We found that atrogin 1 mRNA expression was increased in muscle from mice treated with carboplatin, which explained muscle atrophy. In mice treated with carboplatin for 1 or 3 days, we did not observe any bone or muscle loss, or muscle weakness. In addition, reduced caloric intake in the carboplatin treated mice did not cause loss of bone or muscle mass, or muscle weakness. Our results show that blocking carboplatin induced bone resorption is sufficient to prevent skeletal muscle weakness and suggests another benefit to bone therapy beyond bone in patients receiving chemotherapy. (c) 2019 American Society for Bone and Mineral Research.
C1 [Hain, Brian A.; Jude, Baptiste; Xu, Haifang; Waning, David L.] Penn State Coll Med, Dept Cellular & Mol Physiol, Hershey, PA USA.
   [Smuin, Dallas M.; Fox, Edward J.; Elfar, John C.] Penn State Coll Med, Dept Orthopaed & Rehabil, Hershey, PA USA.
   [Fox, Edward J.; Elfar, John C.; Waning, David L.] Ctr Orthopaed Res & Translat Sci, Hershey, PA USA.
   [Waning, David L.] Penn State Canc Inst, Hershey, PA USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); Pennsylvania State
   University; Penn State Health; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); Pennsylvania State University; Penn State
   Health
RP Waning, DL (通讯作者)，500 Univ Dr,H166,Rm C4718E, Hershey, PA 17033 USA.
EM ciswaning@psu.eciu
RI Elfar, John/Q 7371 2017; Jude, Baptiste/IUO 3201 2023; Jude,
   Baptiste/ABA 1731 2020
OI Jude, Baptiste/0000 0002 5506 2482; Fox, Edward/0000 0003 0347 1839
CR Albadawi H, 2013, J SURG RES, V182, P339, DOI 10.1016/j.jss.2012.10.033
   Alonso N, 2017, CLIN REV BONE MINER, V15, P37, DOI 10.1007/s12018 016 9226 0
   Anderson LJ, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912 017 0562 0
   [Anonymous], OXID MED CELL LONGEV
   [Anonymous], AM J KIDNEY DIS
   Aono Y, 2011, J BONE MINER RES, V26, P803, DOI 10.1002/jbmr.275
   Axelsen CT, 2018, MOL CLIN ONCOL, V8, P767, DOI 10.3892/mco.2018.1615
   Barreto R, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 15040 1
   Belizário JE, 2001, BRIT J CANCER, V84, P1135, DOI 10.1054/bjoc.2001.1700
   Bentzinger CF, 2013, SKELET MUSCLE, V3, DOI 10.1186/2044 5040 3 6
   Berenson JR, 2005, ONCOLOGIST, V10, P52, DOI 10.1634/theoncologist.10 1 52
   Bischoff Ferrari Heike A, 2011, Curr Osteoporos Rep, V9, P116, DOI 10.1007/s11914 011 0059 y
   Bonetto A, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.101
   Brabec V, 2005, DRUG RESIST UPDATE, V8, P131, DOI 10.1016/j.drup.2005.04.006
   Cavaletti G, 1998, ANN ONCOL, V9, P443, DOI 10.1023/A:1008231925889
   Cersosimo RJ, 2005, ANN PHARMACOTHER, V39, P128, DOI 10.1345/aph.1E319
   Clezardin Philippe, 2013, Bonekey Rep, V2, P267, DOI 10.1038/bonekey.2013.1
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Conte E, 2017, J CACHEXIA SARCOPENI, V8, P386, DOI 10.1002/jcsm.12185
   Damrauer JS, 2018, EUR J TRANSL MYOL, V28, P139, DOI 10.4081/ejtm.2018.7590
   Dawson Hughes B, 2017, J STEROID BIOCHEM, V173, P313, DOI 10.1016/j.jsbmb.2017.03.018
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Edwards JR, 2010, J BONE MINER RES, V25, P2419, DOI 10.1002/jbmr.139
   Fan CM, 2016, J BONE MINER METAB, V34, P277, DOI 10.1007/s00774 015 0679 x
   Fanzani A, 2011, TOXICOL APPL PHARM, V250, P312, DOI 10.1016/j.taap.2010.11.003
   Fearon K, 2011, LANCET ONCOL, V12, P489, DOI 10.1016/S1470 2045(10)70218 7
   FLEISCH HA, 1970, EUR J CLIN INVEST, V1, P12, DOI 10.1111/j.1365 2362.1970.tb00591.x
   Gangadharan A, 2017, ONCOTARGET, V8, P24009, DOI 10.18632/oncotarget.15103
   Girgis CM, 2019, J CACHEXIA SARCOPENI, V10, P1228, DOI 10.1002/jcsm.12460
   Gordon BS, 2013, INT J BIOCHEM CELL B, V45, P2147, DOI 10.1016/j.biocel.2013.05.039
   Guise TA, 2006, ONCOLOGIST, V11, P1121, DOI 10.1634/theoncologist.11 10 1121
   Hain B.A., 2019, JCSM RAPID COMMUN, V2, P1
   Holick MF, 2017, REV ENDOCR METAB DIS, V18, P153, DOI 10.1007/s11154 017 9424 1
   Jean G, 2017, NUTRIENTS, V9, DOI 10.3390/nu9040328
   Kotler DP, 2000, ANN INTERN MED, V133, P622, DOI 10.7326/0003 4819 133 8 200010170 00015
   Lips P, 2011, BEST PRACT RES CL EN, V25, P585, DOI 10.1016/j.beem.2011.05.002
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Matheus HR, 2018, J CLIN PERIODONTOL, V45, P241, DOI 10.1111/jcpe.12824
   Molina P, 2017, J CACHEXIA SARCOPENI, V8, P686, DOI 10.1002/jcsm.12218
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Oun R, 2018, DALTON T, V47, P6645, DOI 10.1039/c8dt00838h
   Pfeilschifter J, 2000, J CLIN ONCOL, V18, P1570, DOI 10.1200/JCO.2000.18.7.1570
   Poggio F, 2018, ANN ONCOL, V29, P1497, DOI 10.1093/annonc/mdy127
   Quasthoff S, 2002, J NEUROL, V249, P9, DOI 10.1007/PL00007853
   Räkel A, 2011, CLIN INTERV AGING, V6, P89, DOI 10.2147/CIA.S7282
   Rana T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078043
   Rapoport BL, 2014, CURR TREAT OPTION ON, V15, P86, DOI 10.1007/s11864 013 0266 0
   Remels AHV, 2013, J APPL PHYSIOL, V114, P1253, DOI 10.1152/japplphysiol.00790.2012
   Rha SY, 2017, SUPPORT CARE CANCER, V25, P1519, DOI 10.1007/s00520 016 3545 z
   Roodman GD, 2012, CANCER METAST REV, V31, P569, DOI 10.1007/s10555 012 9372 x
   Sakai H, 2017, PFLUG ARCH EUR J PHY, V469, P1495, DOI 10.1007/s00424 017 2045 4
   Sakai H, 2014, TOXICOL APPL PHARM, V278, P190, DOI 10.1016/j.taap.2014.05.001
   Sakai R, 2001, MOL CELL ENDOCRINOL, V180, P183, DOI 10.1016/S0303 7207(01)00496 8
   Sandri M, 2001, J NEUROPATH EXP NEUR, V60, P302, DOI 10.1093/jnen/60.3.302
   Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092 8674(04)00400 3
   Scicchitano Bianca Maria, 2015, Recent Adv DNA Gene Seq, V9, P26
   Shandala T, 2012, J CELL PHYSIOL, V227, P2889, DOI 10.1002/jcp.23034
   Sharma P, 2017, CLIN CANCER RES, V23, P649, DOI 10.1158/1078 0432.CCR 16 0162
   Sieber P, 2013, CLIN DRUG INVEST, V33, P117, DOI 10.1007/s40261 012 0041 1
   Stene GB, 2015, ACTA ONCOL, V54, P340, DOI 10.3109/0284186X.2014.953259
   Stine KC, 2014, J ORTHOP RES, V32, P464, DOI 10.1002/jor.22527
   Sun QA, 2011, P NATL ACAD SCI USA, V108, P16098, DOI 10.1073/pnas.1109546108
   Vagnildhaug OM, 2018, SUPPORT CARE CANCER, V26, P1871, DOI 10.1007/s00520 017 4022 z
   VANHENNIK MB, 1987, CANCER RES, V47, P6297
   von Haehling S, 2017, NAT REV CARDIOL, V14, P323, DOI 10.1038/nrcardio.2017.51
   von Haehling S, 2016, J CACHEXIA SARCOPENI, V7, P507, DOI 10.1002/jcsm.12167
   VONROENN JH, 1992, ONCOLOGY, V49, P50, DOI 10.1159/000227129
   Waning DL, 2015, NAT MED, V21, P1262, DOI 10.1038/nm.3961
   Waning DL, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.59
   Wen Y, 2018, J APPL PHYSIOL, V124, P40, DOI 10.1152/japplphysiol.00762.2017
   White JP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024650
   Willemse PM, 2014, J CLIN ENDOCR METAB, V99, P4101, DOI 10.1210/jc.2014 1722
   Wright JD, 2015, CANCER INVEST, V33, P331, DOI 10.3109/07357907.2015.1047506
   Yamada T, 2009, ARTHRITIS RHEUM US, V60, P3280, DOI 10.1002/art.24907
   Yee AJ, 2018, FUTURE ONCOL, V14, P195, DOI 10.2217/fon 2017 0403
   Yoon MS, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00788
   Zheng GZ, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12541
NR 77
TC 32
Z9 34
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD FEB
PY 2020
VL 35
IS 2
BP 368
EP 381
DI 10.1002/jbmr.3890
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA KJ7HG
UT WOS:000512228400018
PM 31614017
OA Bronze
DA 2025 08 17
ER

PT J
AU Shono, Y
   Ueha, S
   Wang, Y
   Abe, J
   Kurachi, M
   Matsuno, Y
   Sugiyama, T
   Nagasawa, T
   Imamura, M
   Matsushima, K
AF Shono, Yusuke
   Ueha, Satoshi
   Wang, Yong
   Abe, Jun
   Kurachi, Makoto
   Matsuno, Yoshihiro
   Sugiyama, Tatsuki
   Nagasawa, Takashi
   Imamura, Masahiro
   Matsushima, Kouji
TI Bone marrow graft versus host disease: early destruction of
   hematopoietic niche after MHC mismatched hematopoietic stem cell
   transplantation
SO BLOOD
LA English
DT Article
ID IMMUNE RECONSTITUTION; PROGENITOR CELLS; T CELLS; MICE; REQUIRE;
   ANTIGEN; LIPOPOLYSACCHARIDE; DIFFERENTIATION; LYMPHOPOIESIS; MACROPHAGES
AB Disrupted hematopoiesis and delayed immune reconstitution are life threatening complications of allogeneic hematopoietic stem cell transplantation (allo HSCT). Although graft versus host disease (GVHD) is a major risk factor for the bone marrow (BM) insufficiency, how GVHD impairs BM hematopoiesis has been largely unknown. We hypothesized that BM stromal niche could be a target of GVHD. In major histocompatibility complex (MHC) mismatched murine models of GVHD, we have demonstrated the early destruction of osteoblasts that especially affected B cell lineages. The defective B lymphopoiesis was due to the impaired ability of BM stroma and osteoblasts to support the hematopoiesis, as evidenced by the failure of GVHD affected BM to reconstitute the hematopoietic cells. The administration of anti CD4 monoclonal antibody (mAb) ameliorated these effects and improved B lymphopoiesis while preserving graft versus tumor effects. Genetic ablation of Fas Fas ligand signaling also partially restored B lymphopoiesis. Our present study provided evidence of BM GVHD, with the identification of osteoblasts as the main target for GVHD in BM. Moreover, our data showed the potential for mAb therapies to enhance immune reconstitution in vivo for patients undergoing allo HSCT. (Blood. 2010; 115(26):5401 5411)
C1 [Matsushima, Kouji] Univ Tokyo, Dept Mol Prevent Med, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan.
   [Shono, Yusuke; Imamura, Masahiro] Hokkaido Univ, Grad Sch Med, Dept Hematol & Oncol, Sapporo, Hokkaido, Japan.
   [Matsuno, Yoshihiro] Hokkaido Univ Hosp, Dept Surg Pathol, Sapporo, Hokkaido 060, Japan.
   [Sugiyama, Tatsuki; Nagasawa, Takashi] Kyoto Univ, Inst Frontier Med Sci, Dept Immunobiol & Hematol, Kyoto, Japan.
C3 University of Tokyo; Hokkaido University; Hokkaido University; Kyoto
   University
RP Matsushima, K (通讯作者)，Univ Tokyo, Dept Mol Prevent Med, Grad Sch Med, Bunkyo Ku, 7 3 1 Hongo, Tokyo 1130033, Japan.
EM koujim@m.u tokyo.ac.jp
RI ; Matsuno, Yoshihiro/F 6891 2012
OI Abe, Jun/0000 0001 7511 4502; Nagasawa, Takashi/0000 0002 1085 0960;
   Ueha, Satoshi/0000 0002 3871 9921; Sugiyama, Tatsuki/0000 0002 9349 0824
FU Grants in Aid for Scientific Research [19059004] Funding Source: KAKEN
CR Abrahamsen IW, 2005, HAEMATOLOGICA, V90, P86
   Adams GB, 2006, NAT IMMUNOL, V7, P333, DOI 10.1038/ni1331
   Akadegawa K, 2005, J IMMUNOL, V174, P5499, DOI 10.4049/jimmunol.174.9.5499
   Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599
   André Schmutz I, 2005, CYTOTHERAPY, V7, P102, DOI 10.1080/14653240510027118
   Ara T, 2003, IMMUNITY, V19, P257, DOI 10.1016/S1074 7613(03)00201 2
   Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004
   Baker MB, 1997, P NATL ACAD SCI USA, V94, P1366, DOI 10.1073/pnas.94.4.1366
   Busslinger M, 2004, ANNU REV IMMUNOL, V22, P55, DOI 10.1146/annurev.immunol.22.012703.104807
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Chang MK, 2008, J IMMUNOL, V181, P1232, DOI 10.4049/jimmunol.181.2.1232
   Cooke KR, 1996, BLOOD, V88, P3230, DOI 10.1182/blood.V88.8.3230.bloodjournal8883230
   Crooks GM, 2006, BIOL BLOOD MARROW TR, V12, P42, DOI 10.1016/j.bbmt.2005.10.015
   Egawa T, 2001, IMMUNITY, V15, P323, DOI 10.1016/S1074 7613(01)00185 6
   ERB P, 1990, J IMMUNOL, V144, P790
   Falzarano G, 1996, BLOOD, V87, P2853, DOI 10.1182/blood.V87.7.2853.bloodjournal8772853
   GARVY BA, 1993, BLOOD, V82, P2758
   GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890 197410000 00001
   Hale GA, 2005, BIOL BLOOD MARROW TR, V11, P912, DOI 10.1016/j.bbmt.2005.07.012
   Hardy RR, 2001, ANNU REV IMMUNOL, V19, P595, DOI 10.1146/annurev.immunol.19.1.595
   Imamura M, 2002, INT J HEMATOL, V76, P191, DOI 10.1007/BF03165243
   Iwasaki T, 1999, CELL IMMUNOL, V197, P30, DOI 10.1006/cimm.1999.1553
   *JAP SOC HEM CELL, 2003, ANN REP NAT SURV
   Kamath AF, 2006, BLOOD, V107, P591, DOI 10.1182/blood 2005 06 2506
   Karsunky H, 2008, BLOOD, V111, P5562, DOI 10.1182/blood 2007 11 126219
   Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026
   Lin MI, 2007, CANCER RES, V67, P2849, DOI 10.1158/0008 5472.CAN 06 4082
   Lo Celso C, 2009, NATURE, V457, P92, DOI 10.1038/nature07434
   Miller DL, 2000, P NATL ACAD SCI USA, V97, P10179, DOI 10.1073/pnas.180294397
   Mori T, 1998, BLOOD, V92, P101, DOI 10.1182/blood.V92.1.101.413k14_101_107
   Nagasawa T, 2006, NAT REV IMMUNOL, V6, P107, DOI 10.1038/nri1780
   Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0
   Novitzky N, 2001, CYTOTHERAPY, V3, P211, DOI 10.1080/146532401753174043
   Nurnberger W, 1997, ANN HEMATOL, V74, P221, DOI 10.1007/s002770050288
   Peggs KS, 2004, LEUKEMIA LYMPHOMA, V45, P1093, DOI 10.1080/10428190310001641260
   Pettit AR, 2008, BONE, V43, P976, DOI 10.1016/j.bone.2008.08.128
   Reutershan J, 2007, J IMMUNOL, V179, P1254, DOI 10.4049/jimmunol.179.2.1254
   Richardson P, 2001, ACTA HAEMATOL BASEL, V106, P57, DOI 10.1159/000046590
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Shlomchik WD, 2007, NAT REV IMMUNOL, V7, P340, DOI 10.1038/nri2000
   Socolovsky M, 2001, BLOOD, V98, P3261, DOI 10.1182/blood.V98.12.3261
   STALDER T, 1994, J IMMUNOL, V152, P1127
   Storek J, 2001, BLOOD, V98, P489, DOI 10.1182/blood.V98.2.489
   Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016
   Teshima T, 2002, NAT MED, V8, P575, DOI 10.1038/nm0602 575
   Tokoyoda K, 2004, IMMUNITY, V20, P707, DOI 10.1016/j.immuni.2004.05.001
   Ueha S, 2007, J LEUKOCYTE BIOL, V81, P176, DOI 10.1189/jlb.0306231
   Visnjic D, 2004, BLOOD, V103, P3258, DOI 10.1182/blood 2003 11 4011
   Wilson A, 2006, NAT REV IMMUNOL, V6, P93, DOI 10.1038/nri1779
   Wu JY, 2009, J BONE MINER RES, V24, P759, DOI [10.1359/JBMR.090225, 10.1359/jbmr.090225]
   XENOCOSTAS A, 1991, TRANSPLANTATION, V51, P1089, DOI 10.1097/00007890 199105000 00031
   Xie YC, 2009, NATURE, V457, P97, DOI 10.1038/nature07639
   Yanik G, 2006, SEMIN HEMATOL, V43, P42, DOI 10.1053/j.seminhematol.2005.09.004
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
   Zhu J, 2007, BLOOD, V109, P3706, DOI 10.1182/blood 2006 08 041384
NR 55
TC 146
Z9 161
U1 0
U2 7
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006 4971
EI 1528 0020
J9 BLOOD
JI Blood
PD JUL 1
PY 2010
VL 115
IS 26
BP 5401
EP 5411
DI 10.1182/blood 2009 11 253559
PG 11
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 619MV
UT WOS:000279435200018
PM 20354171
OA Bronze
DA 2025 08 17
ER

PT J
AU Wu, MT
   Qiu, QZ
   Zhou, Q
   Li, J
   Yang, JZ
   Zheng, CC
   Luo, AR
   Li, XF
   Zhang, HH
   Cheng, XD
   Lu, WG
   Liu, PY
   Lu, BJ
   Lu, Y
AF Wu, Mengting
   Qiu, Qiongzi
   Zhou, Qing
   Li, Jia
   Yang, Juze
   Zheng, Chengcai
   Luo, Aoran
   Li, Xufan
   Zhang, Honghe
   Cheng, Xiaodong
   Lu, Weiguo
   Liu, Pengyuan
   Lu, Bingjian
   Lu, Yan
TI circFBXO7/miR 96 5p/MTSS1 axis is an important regulator in the Wnt
   signaling pathway in ovarian cancer
SO MOLECULAR CANCER
LA English
DT Article
DE circFBXO7; Ovarian cancer; miR 96 5p; MTSS1; Wnt/beta catenin signaling
ID BETA CATENIN; CIRCULAR RNA; METASTASIS; EXPRESSION; ACTIVATION;
   SUPPRESSOR; SRC; PROLIFERATION; TRANSCRIPTION; DEGRADATION
AB Background: CircRNAs are a novel class of evolutionarily conserved noncoding RNA molecules that form covalently closed continuous loop structures without 5 ' caps and 3 ' poly(A) tails. Accumulating evidence suggests that circRNAs play important regulatory roles in cancer and are promising biomarkers for cancer diagnosis and prognosis, as well as targets for cancer therapy. In this study, we identify and explore the role of a novel circRNA, circFBXO7, in ovarian cancer.
   Methods: rRNA depleted RNA sequencing was performed to identify differentially expressed circRNAs between ovarian cancerous and normal tissues. qRT PCR and single molecule RNA in situ hybridization was used to quantify circFBXO7 expression in tumor tissues. The association of circFBXO7 expression with patient prognosis was evaluated by Kaplan Meier survival analysis. The biological function of circFBXO7 was also investigated using loss of function and gain of function assays in vivo and in vitro. Luciferase reporter and TOP/FOP Flash reporter assays were then conducted together with RNA immunoprecipitation and western blot to assess the circFBXO7/miR 96 5p/MTSS1/Wnt/beta catenin axis.
   Results: circFBXO7 was downregulated in ovarian cancer which was associated with poor prognosis. Biologically, circFBXO7 overexpression significantly suppressed ovarian cancer cell proliferation, migration, and invasion in vitro, and inhibited tumor growth and metastasis in vivo, whereas its knockdown exerted an opposite role. Mechanistically, circFBXO7 functioned as a competing endogenous RNA for miR 96 5p to regulate the expression of MTSS1. Consequently, downregulation of MTSS1 led to excessive accumulation of beta catenin and increased phosphorylation of GSK3 beta, leading to the translocation of beta catenin to the nucleus, thereby activating the Wnt/beta catenin signaling pathway and ultimately promoting ovarian cancer progression.
   Conclusions: Our findings indicate that circFBXO7 acts as a bone fide tumor suppressor in ovarian cancer and that the circFBXO7/miR 96 5p/MTSS1 axis is an important regulator in the Wnt/beta catenin signaling pathway which may provide a promising target for ovarian cancer therapy.
C1 [Wu, Mengting; Qiu, Qiongzi; Zhou, Qing; Zheng, Chengcai; Luo, Aoran; Cheng, Xiaodong; Lu, Bingjian; Lu, Yan] Zhejiang Univ, Zhejiang Prov Key Lab Precis Diag & Therapy Major, Womens Hosp, Sch Med, Hangzhou 310006, Zhejiang, Peoples R China.
   [Wu, Mengting; Qiu, Qiongzi; Zhou, Qing; Li, Jia; Yang, Juze; Zheng, Chengcai; Luo, Aoran; Li, Xufan; Cheng, Xiaodong; Liu, Pengyuan; Lu, Bingjian; Lu, Yan] Zhejiang Univ, Sch Med, Inst Translat Med, Hangzhou 310006, Zhejiang, Peoples R China.
   [Li, Jia; Yang, Juze; Li, Xufan; Liu, Pengyuan] Zhejiang Univ, Key Lab Precis Med Diag & Monitoring Res Zhejiang, Sir Run Run Shaw Hosp, Sch Med, Hangzhou 310016, Zhejiang, Peoples R China.
   [Zhang, Honghe] Zhejiang Univ, Res Unit Intelligence Classificat Tumor Pathol &, Chinese Acad Med Sci, Dept Pathol,Sch Med, Hangzhou 310058, Zhejiang, Peoples R China.
   [Zhang, Honghe; Cheng, Xiaodong; Lu, Weiguo; Liu, Pengyuan; Lu, Bingjian; Lu, Yan] Zhejiang Univ, Canc Ctr, Hangzhou 310013, Zhejiang, Peoples R China.
   [Lu, Weiguo] Zhejiang Univ, Womens Hosp, Womens Reprod Hlth Key Lab Zhejiang Prov, Sch Med, Hangzhou 310006, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University; Zhejiang University; Chinese
   Academy of Medical Sciences   Peking Union Medical College; Zhejiang
   University; Zhejiang University; Zhejiang University
RP Lu, BJ; Lu, Y (通讯作者)，Zhejiang Univ, Zhejiang Prov Key Lab Precis Diag & Therapy Major, Womens Hosp, Sch Med, Hangzhou 310006, Zhejiang, Peoples R China.; Liu, PY; Lu, BJ; Lu, Y (通讯作者)，Zhejiang Univ, Sch Med, Inst Translat Med, Hangzhou 310006, Zhejiang, Peoples R China.; Liu, PY (通讯作者)，Zhejiang Univ, Key Lab Precis Med Diag & Monitoring Res Zhejiang, Sir Run Run Shaw Hosp, Sch Med, Hangzhou 310016, Zhejiang, Peoples R China.; Liu, PY; Lu, BJ; Lu, Y (通讯作者)，Zhejiang Univ, Canc Ctr, Hangzhou 310013, Zhejiang, Peoples R China.
EM pyliu@zju.edu.cn; lbj@zju.edu.cn; yanIu76@zju.edu.cn
RI Liu, Pengyuan/ITV 9407 2023; Lu, Yan/HLV 7168 2023
FU Key R&D Program of Zhejiang Province [2021C03126, 2020C04003,
   2019C03010]; National Natural Science Foundation of China [82072857,
   81872112]; Key Program of Zhejiang Provincial Natural Science Foundation
   of China [LZ20H160001]; Medical Health Science and Technology Key
   Project of Zhejiang Provincial Health Commission [WKJ ZJ 2007]; CAMS
   Innovation Fund for Medical Sciences (CIFMS) [2019 I2M 5 044]; Leading
   Innovative and Entrepreneur Team Introduction Program of Zhejiang of
   China [2019R01001]
FX This work has been supported in part by the Key R&D Program of Zhejiang
   Province (2021C03126, 2020C04003 and 2019C03010), National Natural
   Science Foundation of China (82072857 and 81872112), the Key Program of
   Zhejiang Provincial Natural Science Foundation of China (LZ20H160001),
   Medical Health Science and Technology Key Project of Zhejiang Provincial
   Health Commission (WKJ ZJ 2007), the CAMS Innovation Fund for Medical
   Sciences (CIFMS, 2019 I2M 5 044), and the Leading Innovative and
   Entrepreneur Team Introduction Program of Zhejiang of China
   (2019R01001).
CR Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005
   Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   Arnaiz E, 2019, SEMIN CANCER BIOL, V58, P90, DOI 10.1016/j.semcancer.2018.12.002
   Ashwal Fluss R, 2014, MOL CELL, V56, P55, DOI 10.1016/j.molcel.2014.08.019
   Baker AM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 02295 5
   Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644
   Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166
   Bershteyn M, 2010, DEV CELL, V19, P270, DOI 10.1016/j.devcel.2010.07.009
   Bompard G, 2005, J CELL SCI, V118, P5393, DOI 10.1242/jcs.02640
   Bounoutas A, 2009, GENETICS, V183, P607, DOI 10.1534/genetics.109.105726
   Chen LL, 2016, NAT REV MOL CELL BIO, V17, P205, DOI 10.1038/nrm.2015.32
   Chen M, 2022, CELL MOL LIFE SCI, V79, DOI 10.1007/s00018 022 04147 y
   Chen Q, 2014, EMBO REP, V15, P1254, DOI 10.15252/embr.201439644
   Chen YH, 2020, NUCLEIC ACIDS RES, V48, pD127, DOI 10.1093/nar/gkz757
   Cheng ZA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 11162 4
   Condello S, 2013, FASEB J, V27, P3100, DOI 10.1096/fj.12 222620
   Conedera S, 2016, NEUROBIOL AGING, V40, DOI 10.1016/j.neurobiolaging.2016.01.003
   Cui C, 2018, TRENDS BIOCHEM SCI, V43, P623, DOI 10.1016/j.tibs.2018.06.003
   Galbraith KK, 2018, CELL REP, V24, P95, DOI 10.1016/j.celrep.2018.06.013
   Haraguchi K, 2004, BIOCHEM BIOPH RES CO, V313, P841, DOI 10.1016/j.bbrc.2003.12.021
   Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552
   Herath NI, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2013.67
   Huang HY, 2020, NUCLEIC ACIDS RES, V48, pD148, DOI 10.1093/nar/gkz896
   Huang XY, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046 016 0361 8
   Karni R, 2005, MOL CELL BIOL, V25, P5031, DOI 10.1128/MCB.25.12.5031 5039.2005
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb 2013 14 4 r36
   Kim WY, 2003, P NATL ACAD SCI USA, V100, P4933, DOI 10.1073/pnas.0736949100
   Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389
   Kovaka S, 2019, GENOME BIOL, V20, DOI 10.1186/s13059 019 1910 1
   Laman H, 2005, EMBO J, V24, P3104, DOI 10.1038/sj.emboj.7600775
   Lee SH, 2007, STRUCTURE, V15, P145, DOI 10.1016/j.str.2006.12.005
   Legnini I, 2017, MOL CELL, V66, P22, DOI 10.1016/j.molcel.2017.02.017
   Li Q, 2019, HEPATOLOGY, V70, P1298, DOI 10.1002/hep.30671
   Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002
   Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959
   Liu B, 2019, J OVARIAN RES, V12, DOI 10.1186/s13048 019 0533 1
   Liu R, 2015, INT J ONCOL, V47, P1429, DOI 10.3892/ijo.2015.3121
   Ma S, 2007, HUM PATHOL, V38, P1201, DOI 10.1016/j.humpath.2007.01.004
   Matamala N, 2015, CLIN CHEM, V61, P1098, DOI 10.1373/clinchem.2015.238691
   Mattila PK, 2007, J CELL BIOL, V176, P953, DOI 10.1083/jcb.200609176
   Meng SJ, 2017, MOL CANCER, V16, DOI 10.1186/s12943 017 0663 2
   Mertz KD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4465
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Pamudurti NR, 2017, MOL CELL, V66, P9, DOI 10.1016/j.molcel.2017.02.021
   Parr C, 2009, EUR J CANCER, V45, P1673, DOI 10.1016/j.ejca.2009.02.019
   Quinones GA, 2010, J CELL BIOL, V189, P353, DOI 10.1083/jcb.200910136
   Schemionek M, 2016, LEUKEMIA, V30, P823, DOI 10.1038/leu.2015.329
   Sengal AT, 2020, CLIN CANCER RES, V26, P4569, DOI 10.1158/1078 0432.CCR 19 4088
   Shen T, 2015, PROTEIN CELL, V6, P871, DOI 10.1007/s13238 015 0202 0
   Siegel RL, 2020, CA CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Soutto M, 2015, GUT, V64, P1028, DOI 10.1136/gutjnl 2014 307191
   Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20
   Trapnell C, 2013, NAT BIOTECHNOL, V31, P46, DOI 10.1038/nbt.2450
   Vahabi M, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 019 1119 x
   Vo JN, 2019, CELL, V176, P869, DOI 10.1016/j.cell.2018.12.021
   Wei SL, 2019, EBIOMEDICINE, V44, P182, DOI 10.1016/j.ebiom.2019.05.032
   Wilusz JE, 2018, WIRES RNA, V9, DOI 10.1002/wrna.1478
   Wilusz JE, 2013, SCIENCE, V340, P440, DOI 10.1126/science.1238522
   Wu DQ, 2010, TRENDS BIOCHEM SCI, V35, P161, DOI 10.1016/j.tibs.2009.10.002
   Wu XJ, 2021, GENOME BIOL, V22, DOI 10.1186/s13059 020 02250 6
   Xie W, 2018, ONCOL LETT, V15, P3464, DOI 10.3892/ol.2018.7728
   Yang F, 2019, MOL CANCER, V18, DOI 10.1186/s12943 019 1094 z
   Yin XL, 2020, EXP THER MED, V19, P2757, DOI 10.3892/etm.2020.8502
   Yokoyama N, 2009, J CELL SCI, V122, P4439, DOI 10.1242/jcs.051847
   Zhang L, 2019, MOL CANCER, V18, DOI 10.1186/s12943 019 1080 5
   Zhang XO, 2016, GENOME RES, V26, P1277, DOI 10.1101/gr.202895.115
   Zhou WY, 2020, MOL CANCER, V19, DOI 10.1186/s12943 020 01286 3
NR 67
TC 34
Z9 37
U1 3
U2 30
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1476 4598
J9 MOL CANCER
JI Mol. Cancer
PD JUN 29
PY 2022
VL 21
IS 1
AR 137
DI 10.1186/s12943 022 01611 y
PG 19
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 2O1IH
UT WOS:000818819800002
PM 35768865
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ishimoto, K
   Hayano, S
   Yanagita, T
   Kurosaka, H
   Kawanabe, N
   Itoh, S
   Ono, M
   Kuboki, T
   Kamioka, H
   Yamashiro, T
AF Ishimoto, Kazuya
   Hayano, Satoru
   Yanagita, Takeshi
   Kurosaka, Hiroshi
   Kawanabe, Noriaki
   Itoh, Shinsuke
   Ono, Mitsuaki
   Kuboki, Takuo
   Kamioka, Hiroshi
   Yamashiro, Takashi
TI Topical Application of Lithium Chloride on the Pulp Induces Dentin
   Regeneration
SO PLOS ONE
LA English
DT Article
ID MESSENGER RNA EXPRESSION; ONYCHO DERMAL DYSPLASIA; STEM CELLS;
   ODONTOBLAST DIFFERENTIATION; IN VIVO; TOOTH; DSPP; DENTINOGENESIS;
   MUTATION; THERAPY
AB We herein describe a novel procedure for dentin regeneration that mimics the biological processes of tooth development in nature. The canonical Wnt signaling pathway is an important regulator of the Dentin sialophosphoprotein (Dspp) expression. Our approach mimics the biological processes underlying tooth development in nature and focuses on the activation of canonical Wnt signaling to trigger the natural process of dentinogenesis. The coronal portion of the dentin and the underlying pulp was removed from the first molars. We applied lithium chloride (LiCl), an activator of canonical Wnt signaling, on the amputated pulp surface to achieve transdifferentiation toward odontoblasts from the surrounding pulpal cells. MicroCT and microscopic analyses demonstrated that the topical application of LiCl induced dentin repair, including the formation of a complete dentin bridge. LiCl induced dentin is a tubular dentin in which the pulp cells are not embedded within the matrix, as in primary dentin. In contrast, a dentin bridge was not induced in the control group treated with pulp capping with material carriers alone, although osteodentin without tubular formation was induced at a comparatively deeper position from the pulp exposure site. We also evaluated the influence of LiCl on differentiation toward odontoblasts in vitro. In the mDP odontoblast cell line, LiCl activated the mRNA expression of Dspp, Axin2 and Kallikrein 4 (Klk4) and downregulated the Osteopontin (Osp) expression. These results provide a scientific basis for the biomimetic regeneration of dentin using LiCl as a new capping material to activate dentine regeneration.
C1 [Ishimoto, Kazuya; Hayano, Satoru; Kurosaka, Hiroshi; Kawanabe, Noriaki; Itoh, Shinsuke; Kamioka, Hiroshi; Yamashiro, Takashi] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Orthodont, Okayama, Japan.
   [Yanagita, Takeshi] Okayama Univ Hosp, Dept Orthodont, Okayama, Japan.
   [Ono, Mitsuaki; Kuboki, Takuo] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Oral Rehabil & Regenerat Med, Okayama, Japan.
C3 Okayama University; Okayama University; Okayama University
RP Yamashiro, T (通讯作者)，Osaka Univ, Grad Sch Dent, Dept Orthodont & Dentofacial Orthoped, Osaka, Japan.
EM yamashiro@dent.osaka u.ac.jp
RI Yamashiro, Takashi/S 6010 2019; Kamioka, Hiroshi/B 2476 2011; Kuboki,
   Takuo/A 5955 2010
OI Yamashiro, Takashi/0000 0002 4419 9643; Kurosaka,
   Hiroshi/0000 0002 8956 5467; Kuboki, Takuo/0000 0003 3756 2835
FU Japan Society for the Promotion of Science (JSPS) [19390529, 24249093];
   Grants in Aid for Scientific Research [19390529, 26253088, 25242041,
   25862014, 15K20587, 26463093] Funding Source: KAKEN
FX This work was supported by Grant in Aid for Scientific Research
   (KAKENHI) 19390529 and 24249093 from the Japan Society for the Promotion
   of Science (JSPS). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Adaimy L, 2007, AM J HUM GENET, V81, P821, DOI 10.1086/520064
   Aguilar P, 2011, J ENDODONT, V37, P581, DOI 10.1016/j.joen.2010.12.004
   Cox CF, 1996, OPER DENT, V21, P4
   Cruz EV, 2002, INT ENDOD J, V35, P330, DOI 10.1046/j.1365 2591.2002.00482.x
   Dong F, 2012, CURR OPIN ORGAN TRAN, V17, P670, DOI 10.1097/MOT.0b013e328359a617
   DSouza RN, 1997, J BONE MINER RES, V12, P2040, DOI 10.1359/jbmr.1997.12.12.2040
   Feng JQ, 1998, J BIOL CHEM, V273, P9457, DOI 10.1074/jbc.273.16.9457
   Goldberg M, 2003, AM J DENT, V16, P66
   Goldberg M, 2008, PHARMACOL RES, V58, P137, DOI 10.1016/j.phrs.2008.05.013
   Gomes JE, 2012, J ENDODONT, V38, P91, DOI 10.1016/j.joen.2011.09.020
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Han NN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088890
   Hayano S, 2012, J BIOL CHEM, V287, P12217, DOI 10.1074/jbc.M111.332924
   Hosoya A, 2006, J ORAL BIOSCI, V48, P132, DOI 10.2330/joralbiosci.48.132
   Hu JCC, 2002, EUR J ORAL SCI, V110, P307, DOI 10.1034/j.1600 0722.2002.21301.x
   Huang George T J, 2011, Front Biosci (Elite Ed), V3, P788, DOI 10.2741/e286
   Ji YM, 2010, TISSUE ENG PT A, V16, P1823, DOI 10.1089/ten.TEA.2009.0054
   Kawanabe N, 2012, EXP CELL RES, V318, P453, DOI 10.1016/j.yexcr.2012.01.008
   Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455
   Lammi L, 2004, AM J HUM GENET, V74, P1043, DOI 10.1086/386293
   Li ST, 2011, BIOCHEM BIOPH RES CO, V410, P698, DOI 10.1016/j.bbrc.2011.06.065
   Lim WH, 2014, J BONE MINER RES, V29, P892, DOI 10.1002/jbmr.2088
   Linde Anders, 1993, Critical Reviews in Oral Biology and Medicine, V4, P679
   Lohi M, 2010, DEV DYNAM, V239, P160, DOI 10.1002/dvdy.22047
   McGee Lawrence ME, 2013, J BIOL CHEM, V288, P5291, DOI 10.1074/jbc.M112.414995
   Nagano T, 2003, J DENT RES, V82, P982, DOI 10.1177/154405910308201209
   Nakashima M, 2011, Adv Dent Res, V23, P313, DOI 10.1177/0022034511405323
   Nakatomi M, 2013, J ENDODONT, V39, P612, DOI 10.1016/j.joen.2012.12.016
   Nawaz S, 2009, EUR J HUM GENET, V17, P1600, DOI 10.1038/ejhg.2009.81
   Parirokh M, 2010, J ENDODONT, V36, P400, DOI 10.1016/j.joen.2009.09.009
   Qin C, 2002, J DENT RES, V81, P392, DOI 10.1177/154405910208100607
   Sreenath T, 2003, J BIOL CHEM, V278, P24874, DOI 10.1074/jbc.M303908200
   Suomalainen M, 2010, DEV DYNAM, V239, P364, DOI 10.1002/dvdy.22106
   Takushige T, 2004, INT ENDOD J, V37, P132, DOI 10.1111/j.0143 2885.2004.00771.x
   Tziafas D, 2000, J DENT, V28, P77, DOI 10.1016/S0300 5712(99)00047 0
   Tziafas D, 2004, CARIES RES, V38, P314, DOI 10.1159/000077771
   Wang YP, 2013, ARCH ORAL BIOL, V58, P1709, DOI 10.1016/j.archoralbio.2013.09.001
   Wu N, 2010, ARCH ORAL BIOL, V55, P426, DOI 10.1016/j.archoralbio.2010.03.011
   Xiao SX, 2001, NAT GENET, V27, P201, DOI 10.1038/84848
   Yamashiro T, 2007, DIFFERENTIATION, V75, P452, DOI 10.1111/j.1432 0436.2006.00150.x
   Yamashiro T, 2002, MECH DEVELOP, V119, pS107, DOI 10.1016/S0925 4773(03)00101 1
   Zhang XH, 2001, NAT GENET, V27, P151, DOI 10.1038/84765
NR 42
TC 40
Z9 42
U1 0
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAR 26
PY 2015
VL 10
IS 3
AR e0121938
DI 10.1371/journal.pone.0121938
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CK6QW
UT WOS:000356353700161
PM 25812134
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Medina, OP
   Medina, TP
   Humbert, J
   Qi, B
   Baum, WG
   Will, O
   Damm, T
   Glüer, C
AF Medina, Oula Penate
   Medina, Tuula Penate
   Humbert, Jana
   Qi, Bao
   Baum, Wolfgang
   Will, Olga
   Damm, Timo
   Glueer, Claus
TI Using Alendronic Acid Coupled Fluorescently Labelled SM Liposomes as a
   Vehicle for Bone Targeting
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Alendronic acid; liposomes; multimodal imaging; ICG; sphingomyelin; bone
   targeting
ID NITROGEN CONTAINING BISPHOSPHONATES; IN VIVO; NANOPARTICLES; DELIVERY;
   ANGIOGENESIS; OSTEOPOROSIS; APOPTOSIS; SYSTEM
AB Background: We recently developed a liposomal nanoparticle system that can be used for drug delivery and simultaneously be monitored by optical or photoacoustic imaging devices. Here we tested the efficacy of alendronate as a homing molecule in SM liposomes for bone targeting.
   Methods: Alendronate was immobilized covalently on the liposomal surface and the fluorescent dye indocyanine green was used as a payload in the liposomes. The indocyanine green delivery was analyzed by 3D optical tomography, optical fluorescence scanner, photoacoustic imaging, and by ex vivo biodistribution studies.
   Results: The results show that the alendronate, coupled to the liposomal surface, increases sphingomyelin containing liposome targeting up to several folds.
   Conclusion: The alendronate targeted liposomes open possibilities for an application in active bone targeting.
C1 [Medina, Oula Penate; Medina, Tuula Penate; Humbert, Jana; Qi, Bao; Will, Olga; Damm, Timo; Glueer, Claus] Univ Kiel, Univ Med Ctr Schleswig Holstein UKSH, Dept Radiol & Neuroradiol, Sect Biomed Imaging, Kiel, Germany.
   [Baum, Wolfgang] Univ Kiel, MOIN CC, Bot Garten 14, D 24118 Kiel, Germany.
   [Medina, Oula Penate; Medina, Tuula Penate; Humbert, Jana; Qi, Bao; Will, Olga; Damm, Timo; Glueer, Claus] Christian Albrechts Univ CAU, Med Fak, Inst Expt Tumorforsch, Kiel, Germany.
   [Baum, Wolfgang] Univ Klinikum Erlangen, Med Klin 3, Inst Klin Immunol, Gluckstr 4A, D 91054 Erlangen, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital; University
   of Kiel; University of Erlangen Nuremberg
RP Medina, OP; Medina, TP (通讯作者)，Univ Kiel, Univ Med Ctr Schleswig Holstein UKSH, Dept Radiol & Neuroradiol, Sect Biomed Imaging, Kiel, Germany.
EM oula.penate@rad.uni kiel.de; Tuula.penate@rad.uni kiel.de
RI Glüer, Claus Christian/C 9752 2010; Penate Medina, oula/ABB 8198 2021;
   Damm, Timo/HGA 8541 2022; penate medina, oula/G 5136 2012
OI Penate Medina, Tuula/0000 0002 5899 7005; penate medina,
   oula/0000 0001 9878 5309
FU Damp Foundation; state of Schleswig Holstein; European Union
   ERDF European Regional Development Fund [122 09 053]
FX This study was supported in part by the Damp Foundation, a research
   grant from the state of Schleswig Holstein and the European Union
   ERDF European Regional Development Fund (122 09 053) (MOIN CC,
   Zukunftsprogramm Wirtschaft), as well as intramural grants for Oula
   Penate Medina (FoFo 2012) and Tuula Penate Medina (FoFo 2014).
CR Allsopp BJ, 2016, CLIN ORTHOP RELAT R, V474, P1319, DOI 10.1007/s11999 016 4769 4
   Anada T, 2009, BIOORG MED CHEM LETT, V19, P4148, DOI 10.1016/j.bmcl.2009.05.117
   Bell A, 2016, ORTHOP CLIN N AM, V47, P365, DOI 10.1016/j.ocl.2015.09.010
   Braza MS, 2013, BRIT J HAEMATOL, V160, P123, DOI 10.1111/bjh.12090
   Chaudhari KR, 2012, J CONTROL RELEASE, V158, P470, DOI 10.1016/j.jconrel.2011.11.020
   Cook Gillian E, 2015, J Orthop Trauma, V29 Suppl 12, pS57, DOI 10.1097/BOT.0000000000000470
   D'Oronzo S, 2019, J BONE ONCOL, V15, DOI 10.1016/j.jbo.2018.10.004
   Farrell Kristen B, 2018, Bone Rep, V9, P47, DOI 10.1016/j.bonr.2018.06.007
   Feng SS, 2019, ACS APPL MATER INTER, V11, P7357, DOI 10.1021/acsami.8b18820
   Ferreira DD, 2015, INT J NANOMED, V10, P2441, DOI 10.2147/IJN.S76168
   Gutman D, 2012, J CONTROL RELEASE, V161, P619, DOI 10.1016/j.jconrel.2011.11.037
   Hodgins NO, 2017, ADV DRUG DELIVER REV, V114, P143, DOI 10.1016/j.addr.2017.07.003
   Jafari S, 2016, EUR J PHARM SCI, V91, P225, DOI 10.1016/j.ejps.2016.05.014
   Jordan KM, 2003, ANN RHEUM DIS, V62, P1145, DOI 10.1136/ard.2003.011742
   Katsumi H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135966
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   MUHLBAUER RC, 1971, EUR J CLIN INVEST, V1, P336, DOI 10.1111/j.1365 2362.1971.tb00640.x
   Cattalini J, 2012, TISSUE ENG PART B RE, V18, P323, DOI 10.1089/ten.teb.2011.0737
   Peng KT, 2010, BIOMATERIALS, V31, P5227, DOI 10.1016/j.biomaterials.2010.03.027
   Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967
   Rogers TL, 2011, J TRANSL MED, V9, DOI 10.1186/1479 5876 9 177
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Salerno M, 2010, CURR CANCER DRUG TAR, V10, P649, DOI 10.2174/156800910793605767
   Santini D, 2006, RECENT PAT ANTI CANC, V1, P383, DOI 10.2174/157489206778776989
   Singh JA, 2016, ARTHRIT CARE RES, V68, P1, DOI 10.1002/acr.22783
   Stresing V, 2011, BONE, V48, P259, DOI 10.1016/j.bone.2010.09.035
   Swami A, 2014, P NATL ACAD SCI USA, V111, P10287, DOI 10.1073/pnas.1401337111
   Tamura T, 2011, ONCOL REP, V25, P1139, DOI 10.3892/or.2011.1152
   Van Acker HH, 2016, PHARMACOL THERAPEUT, V158, P24, DOI 10.1016/j.pharmthera.2015.11.008
   van Griensven M, 2015, ADV DRUG DELIVER REV, V94, P151, DOI 10.1016/j.addr.2015.07.006
   van Rooijen N, 2002, J LIPOSOME RES, V12, P81, DOI 10.1081/LPR 120004780
   Walter G, 2012, DTSCH ARZTEBL INT, V109, P257, DOI [10.3238/arztebl.012.0257, 10.3238/arztebl.2012.0257]
   Whitmire RE, 2012, BIOMATERIALS, V33, P7665, DOI 10.1016/j.biomaterials.2012.06.101
   WU D, 2018, NANOSCALE, P38
   Ye WL, 2015, SCI REP UK, V5, DOI 10.1038/srep14614
   Yue B, 2015, ANN ROY COLL SURG, V97, P333, DOI 10.1308/003588415X14181254789321
NR 36
TC 3
Z9 3
U1 0
U2 24
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381 6128
EI 1873 4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2020
VL 26
IS 46
BP 6021
EP 6027
DI 10.2174/1381612826666200614175905
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA PN6JN
UT WOS:000604583400011
PM 32534563
DA 2025 08 17
ER

PT J
AU Wu, SN
   Huang, YM
   Liao, YK
AF Wu, Sheng Nan
   Huang, Yan Ming
   Liao, Yu Kai
TI Effects of Ibandronate Sodium, a Nitrogen Containing Bisphosphonate, on
   Intermediate Conductance Calcium Activated Potassium Channels in
   Osteoclast Precursor Cells (RAW 264.7)
SO JOURNAL OF MEMBRANE BIOLOGY
LA English
DT Article
DE Osteoclast; Ibandronate; Bisphosphonate; K+ current;
   Intermediate conductance Ca2+ activated K+ channel; Membrane potential;
   Cell migration
ID CA2+ ACTIVATED K+ CHANNEL; IN VITRO; INHIBITION; PROLIFERATION; GROWTH;
   OSTEOPOROSIS; CONTRIBUTES; KINASE; TARGET; AGENTS
AB Ibanonate sodium (Iban), a nitrogen containing bisphosphonate, is recognized to reduce skeletal complications through an inhibition of osteoclast mediated bone resorption. However, how this drug interacts with ion channels in osteoclasts and creates anti osteoclastic activity remains largely unclear. In this study, we investigated the possible effects of Iban and other related compounds on ionic currents in the osteoclast precursor RAW 264.7 cells. Iban suppressed the amplitude of whole cell K+ currents (I (K)) in a concentration dependent manner with an IC50 value of 28.9 mu M. The I (K) amplitude was sensitive to block by TRAM 34 and Iban mediated inhibition of I (K) was reversed by further addition of DCEBIO, an activator of intermediate conductance Ca2+ activated K+ (IKCa) channels. Intracellular dialysis with Iban diminished I (K) amplitude and further addition of ionomycin reversed its inhibition. In 17 beta estradiol treated cells, Iban mediated inhibition of I (K) remained effective. In cell attached current recordings, Iban applied to bath did not modify single channel conductance of IKCa channels; however, it did reduce channel activity. Iban induced inhibition of IKCa channels was voltage dependent. As IKCa channel activity was suppressed by KN 93, subsequent addition of Iban did not further decrease the channel open probability. Iban could not exert any effect on inwardly rectifying K+ current in RAW 264.7 cells. Under current clamp recordings, Iban depolarized the membrane of RAW 264.7 cells and DCEBIO reversed Iban induced depolarization. Iban also suppressed lipopolysaccharide stimulated migration of RAW 264.7 cells in a concentration dependent manner. Therefore, the inhibition by Iban of IKCa channels would be an important mechanism underlying its actions on the functional activity of osteoclasts occurring in vivo.
C1 [Wu, Sheng Nan; Huang, Yan Ming; Liao, Yu Kai] Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 70101, Taiwan.
   [Wu, Sheng Nan] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 70101, Taiwan.
C3 National Cheng Kung University; National Cheng Kung University
RP Wu, SN (通讯作者)，Natl Cheng Kung Univ, Coll Med, Dept Physiol, 1 Univ Rd, Tainan 70101, Taiwan.
EM snwu@mail.ncku.edu.tw
RI Wu, Sheng Nan/B 9224 2009
OI Wu, Sheng Nan/0000 0002 5208 3253
FU National Science Council, Taiwan [NSC 101 2320 B 006 009]; Aim for the
   Top University Project, National Cheng Kung University, Tainan City,
   Taiwan
FX Part of the research leading to the present results was aided by a grant
   from the National Science Council (NSC 101 2320 B 006 009), Taiwan,
   through a contract awarded to S.N.W. and from the Aim for the Top
   University Project, National Cheng Kung University, Tainan City, Taiwan.
   The authors are grateful to Ming Chun Hsu for her technical assistance
   in this work.
CR Anderson ME, 1998, J PHARMACOL EXP THER, V287, P996
   Begenisich T, 2004, J BIOL CHEM, V279, P47681, DOI 10.1074/jbc.M409627200
   CLARK RB, 1995, BRIT J PHARMACOL, V115, P335, DOI 10.1111/j.1476 5381.1995.tb15882.x
   Díaz P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090961
   Dunn PM, 1998, J MEMBRANE BIOL, V165, P133, DOI 10.1007/s002329900427
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Espinosa L, 2002, J CELL SCI, V115, P3837, DOI 10.1242/jcs.00062
   Fisher JE, 2013, CALCIFIED TISSUE INT, V92, P531, DOI 10.1007/s00223 013 9711 0
   Gallagher JC, 2013, CLIN OBSTET GYNECOL, V56, P749, DOI 10.1097/GRF.0b013e3182a982c2
   Grössinger EM, 2014, LEUKEMIA, V28, P954, DOI 10.1038/leu.2014.37
   He CG, 2013, IEEE T BIO MED ENG, V60, P230, DOI 10.1109/TBME.2012.2222404
   Islam S, 2007, BIOCHEM BIOPH RES CO, V360, P346, DOI 10.1016/j.bbrc.2007.06.023
   Jensen BS, 2001, CURR DRUG TARGETS, V2, P401, DOI 10.2174/1389450013348173
   Jones H, 2014, FASEB J, V28
   Journé F, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1845
   Kaushal V, 2007, J NEUROSCI, V27, P234, DOI 10.1523/JNEUROSCI.3593 06.2007
   Kemmer G, 2010, NAT PROTOC, V5, P267, DOI 10.1038/nprot.2009.182
   Komarova SV, 2001, CURR PHARM DESIGN, V7, P637, DOI 10.2174/1381612013397799
   Lallet Daher H, 2009, ONCOGENE, V28, P1792, DOI 10.1038/onc.2009.25
   Liu SI, 1998, BBA BIOMEMBRANES, V1368, P256, DOI 10.1016/S0005 2736(97)00183 1
   Marathe DD, 2011, BIOPHARM DRUG DISPOS, V32, P471, DOI 10.1002/bdd.770
   McFerrin MB, 2012, AM J PHYSIOL CELL PH, V303, pC1070, DOI 10.1152/ajpcell.00040.2012
   Morales P, 2013, J GEN PHYSIOL, V142, P37, DOI 10.1085/jgp.201210933
   Mosekilde L, 2013, DRUGS, V73, P15, DOI 10.1007/s40265 012 0003 1
   Ohya S, 2011, J PHARMACOL EXP THER, V338, P528, DOI 10.1124/jpet.111.182782
   Pazianas M, 2011, JNCI J NATL CANCER I, V103, P232, DOI 10.1093/jnci/djq516
   Prokopenko Volodymyr, 2014, Curr Drug Discov Technol, V11, P133
   Shao WJ, 2005, AM J PHYSIOL CELL PH, V289, pC248, DOI 10.1152/ajpcell.00393.2004
   Shen AY, 2007, J PHARM PHARMACOL, V59, P679, DOI 10.1211/jpp.59.5.0008
   Shin WJ, 2011, TRANSPL P, V43, P170, DOI 10.1016/j.transproceed.2010.12.002
   So EC, 2011, LIFE SCI, V89, P691, DOI 10.1016/j.lfs.2011.08.013
   Suzuki S, 2008, INT J ORAL MED SCI, V7, P45
   Toyama K, 2008, J CLIN INVEST, V118, P3025, DOI 10.1172/JCI30836
   Tsai KL, 2013, CELL PHYSIOL BIOCHEM, V31, P938, DOI 10.1159/000350112
   Valverde P, 2005, J DENT RES, V84, P488, DOI 10.1177/154405910508400603
   Wang CL, 2012, CELL PHYSIOL BIOCHEM, V30, P687, DOI 10.1159/000341449
   Wu SN, 2011, J MEMBRANE BIOL, V241, P11, DOI 10.1007/s00232 011 9358 6
   Wu SN, 1998, LIFE SCI, V62, P2283, DOI 10.1016/S0024 3205(98)00209 4
   Wulff H, 2000, P NATL ACAD SCI USA, V97, P8151, DOI 10.1073/pnas.97.14.8151
   Wulff H, 2007, CURR MED CHEM, V14, P1437, DOI 10.2174/092986707780831186
   Yang DM, 2004, ANTICANCER RES, V24, P1617
   Zhang W, 2013, CHINESE MED J PEKING, V126, P751, DOI 10.3760/cma.j.issn.0366 6999.20112327
NR 42
TC 9
Z9 9
U1 1
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0022 2631
EI 1432 1424
J9 J MEMBRANE BIOL
JI J. Membr. Biol.
PD FEB
PY 2015
VL 248
IS 1
BP 103
EP 115
DI 10.1007/s00232 014 9747 8
PG 13
WC Biochemistry & Molecular Biology; Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Physiology
GA AZ5SF
UT WOS:000348279300012
PM 25362532
DA 2025 08 17
ER

PT J
AU Takeyama, M
   Sai, K
   Imatoh, T
   Segawa, K
   Hirasawa, N
   Saito, Y
AF Takeyama, Mayu
   Sai, Kimie
   Imatoh, Takuya
   Segawa, Katsunori
   Hirasawa, Noriyasu
   Saito, Yoshiro
TI Influence of Japanese Regulatory Action on Denosumab Related
   Hypocalcemia Using Japanese Adverse Drug Event Report Database
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article
DE denosumab; regulatory action; Japanese Adverse Drug Event Report
   database; hypocalcemia; osteonecrosis of the jaw; zoledronic acid
ID CANCER PATIENTS; SYSTEM; IMPACT; OSTEONECROSIS; RISK; JAW
AB The anti receptor activator of nuclear factor kappa B ligand (RANKL) antibody, Denosumab (DEN), was approved in April 2012 in Japan, but a Dear Healthcare Professional Letter of Rapid Safety Communication was released in September, 2012 by the regulatory authority because of the severe hypocalcemia risks. Currently, the effectiveness of this regulatory action has not been evaluated and, therefore, this study aimed to assess its impact on DEN induced hypocalcemia using the Japanese Adverse Drug Event Report database (JADER). The case reports from April 2012 to September 2014 were collected from the JADER, which included 151642 adverse events for the primary suspected drugs. The reporting odds ratio (ROR) of hypocalcemia as a signal of the target adverse event was analyzed for DEN and zoledronic acid (ZOL, a reference drug). Changes in RORs were compared between the pre  (Pre, April 2012 to September 2012) and post  (Post 1, October 2012 to September 2013 and Post 2, October 2013 to September 2014) periods of the regulatory action. A decrease in the hypocalcemia ROR was observed for DEN in the post periods, especially Post 2. Multivariate logistic regression analysis showed a significant decrease in hypocalcemia signal in Post 1 (p=0.0306 vs. Pre) and Post 2 (p=0.0054 vs. Pre). ZOL caused no significant changes in ROR of hypocalcemia, and none of the drugs caused ROR changes in jaw osteonecrosis (a reference adverse event). This study suggests that the regulatory action against hypocalcemia in DEN effectively decreased hypocalcemia signal. Further studies using medical information databases are needed to confirm this result.
C1 [Takeyama, Mayu; Hirasawa, Noriyasu; Saito, Yoshiro] Tohoku Univ, Grad Sch Pharmaceut Sci, Aoba Ku, 6 3 Aramaki Aza Aoba, Sendai, Miyagi 9808578, Japan.
   [Takeyama, Mayu; Sai, Kimie; Imatoh, Takuya; Segawa, Katsunori; Saito, Yoshiro] Natl Inst Hlth Sci, Div Med Safety Sci, Setagaya Ku, 1 18 1 Kamiyoga, Tokyo 1588501, Japan.
C3 Tohoku University; National Institute of Health Sciences   Japan
RP Sai, K (通讯作者)，Natl Inst Hlth Sci, Div Med Safety Sci, Setagaya Ku, 1 18 1 Kamiyoga, Tokyo 1588501, Japan.
EM sai@nihs.go.jp
RI ; Imatoh, Takuya/AAX 5251 2020
OI Hirasawa, Noriyasu/0000 0002 8062 4838; 
FU Research on Regulatory Science of Pharmaceuticals and Medical Devices
   from Japan Agency for Medical Research and Development, AMED
FX This research was partially supported by the Research on Regulatory
   Science of Pharmaceuticals and Medical Devices from Japan Agency for
   Medical Research and Development, AMED.
CR Abe J, 2016, J PHARM HEALTH CARE, V2, DOI 10.1186/s40780 016 0048 5
   [Anonymous], SAF INF
   Body JJ, 2015, EUR J CANCER, V51, P1812, DOI 10.1016/j.ejca.2015.05.016
   Campisi G, 2014, FUTURE ONCOL, V10, P257, DOI [10.2217/FON.13.211, 10.2217/fon.13.211]
   Domschke C, 2014, BREAST CARE, V9, P332, DOI 10.1159/000368844
   Fujiwara M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154425
   Hanatani T, 2014, J CLIN PHARM THER, V39, P361, DOI 10.1111/jcpt.12153
   Hanatani T, 2015, INT J CLIN PHARM NET, V37, P537, DOI 10.1007/s11096 015 0097 0
   Hauben M, 2007, DRUG SAFETY, V30, P143, DOI 10.2165/00002018 200730020 00004
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hoffman KB, 2016, DRUG SAFETY, V39, P561, DOI 10.1007/s40264 016 0409 x
   Matsuda S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126413
   Medicines and Healthcare products Regulatory Agency (MHRA), DEN UPD REC
   Nakamura M, 2015, J PHARM HEALTH CARE, V1, DOI 10.1186/s40780 015 0035 2
   Narushima D, 2016, PEERJ, V4, DOI 10.7717/peerj.1753
   Ooba N, 2011, DRUG SAFETY, V34, P329, DOI 10.2165/11588230 000000000 00000
   Pariente A, 2007, DRUG SAFETY, V30, P891, DOI 10.2165/00002018 200730100 00007
   Pharmaceuticals and Medical Devices Agency, DEAR HEALTHC PROF LE
   Qi WX, 2013, CURR MED RES OPIN, V29, P1067, DOI 10.1185/03007995.2013.813840
   Sakaeda T, 2013, INT J MED SCI, V10, P796, DOI 10.7150/ijms.6048
   van Puijenbroek EP, 2003, DRUG SAFETY, V26, P293, DOI 10.2165/00002018 200326050 00001
NR 21
TC 14
Z9 14
U1 0
U2 4
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2 12 15 SHIBUYA, SHIBUYA KU, TOKYO, 150 0002, JAPAN
SN 0918 6158
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD SEP
PY 2017
VL 40
IS 9
BP 1447
EP 1453
DI 10.1248/bpb.b17 00266
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA FF6WB
UT WOS:000409156600015
PM 28867727
OA gold
DA 2025 08 17
ER

PT J
AU Hasegawa, Y
   Franks, JM
   Tanaka, Y
   Uehara, Y
   Read, DF
   Williams, C
   Srivatsan, S
   Pitstick, LB
   Nikolaidis, NM
   Shaver, CM
   Kropski, J
   Ware, LB
   Taylor, CJ
   Banovich, NE
   Wu, HX
   Gardner, JC
   Osterburg, AR
   Yu, JJ
   Kopras, EJ
   Teitelbaum, SL
   Wikenheiser Brokamp, KA
   Trapnell, C
   Mccormack, FX
AF Hasegawa, Yoshihiro
   Franks, Jennifer M.
   Tanaka, Yusuke
   Uehara, Yasuaki
   Read, David F.
   Williams, Claire
   Srivatsan, Sanjay
   Pitstick, Lori B.
   Nikolaidis, Nikolaos M.
   Shaver, Ciara M.
   Kropski, Jonathan
   Ware, Lorraine B.
   Taylor, Chase J.
   Banovich, Nicholas E.
   Wu, Huixing
   Gardner, Jason C.
   Osterburg, Andrew R.
   Yu, Jane J.
   Kopras, Elizabeth J.
   Teitelbaum, Steven L.
   Wikenheiser Brokamp, Kathryn A.
   Trapnell, Cole
   Mccormack, Francis X.
TI Pulmonary osteoclast like cells in silica induced pulmonary fibrosis
SO SCIENCE ADVANCES
LA English
DT Article
ID RESISTANT ACID PHOSPHATASE; BONE LOSS; II CELLS; RANKL; DIFFERENTIATION;
   PATHOGENESIS; MACROPHAGES; HOMEOSTASIS; MECHANISMS; ASBESTOSIS
AB The pathophysiology of silicosis is poorly understood, limiting development of therapies for those who have been exposed to the respirable particle. We explored mechanisms of silica induced pulmonary fibrosis in human lung samples collected from patients with occupational exposure to silica and in a longitudinal mouse model of silicosis using multiple modalities including whole lung single cell RNA sequencing and histological, biochemical, and physiologic assessments. In addition to pulmonary inflammation and fibrosis, intratracheal silica challenge induced osteoclast like differentiation of alveolar macrophages and recruited monocytes, driven by induction of the osteoclastogenic cytokine, receptor activator of nuclear factor kappa Beta ligand (RANKL) in pulmonary lymphocytes, and alveolar type II cells. Anti RANKL monoclonal antibody treatment suppressed silica induced osteoclast like differentiation in the lung and attenuated pulmonary fibrosis. We conclude that silica induces differentiation of pulmonary osteoclast like cells leading to progressive lung injury, likely due to sustained elaboration of bone resorbing proteases and hydrochloric acid. Interrupting osteoclast like differentiation may therefore constitute a promising avenue for moderating lung damage in silicosis.
C1 [Hasegawa, Yoshihiro; Tanaka, Yusuke; Uehara, Yasuaki; Pitstick, Lori B.; Nikolaidis, Nikolaos M.; Wu, Huixing; Gardner, Jason C.; Osterburg, Andrew R.; Yu, Jane J.; Kopras, Elizabeth J.; Mccormack, Francis X.] Univ Cincinnati, Dept Internal Med, Div Pulm Crit Care & Sleep Med, Cincinnati, OH 45221 USA.
   [Franks, Jennifer M.; Read, David F.; Williams, Claire; Srivatsan, Sanjay; Trapnell, Cole] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.
   [Shaver, Ciara M.; Kropski, Jonathan; Ware, Lorraine B.; Taylor, Chase J.; Banovich, Nicholas E.] Vanderbilt Univ Sch Med, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN USA.
   [Teitelbaum, Steven L.] Washington Univ, Sch Med, Dept Pathol & Immunol, Dept Med, St Louis, MO USA.
   [Teitelbaum, Steven L.] Washington Univ, Sch Med, Div Bone & Mineral Dis, St Louis, MO USA.
   [Wikenheiser Brokamp, Kathryn A.] Cincinnati Childrens Hosp Med Ctr, Div Pulm Biol, Div Pathol & Lab Med, Cincinnati, OH USA.
   [Wikenheiser Brokamp, Kathryn A.] Cincinnati Childrens Hosp Med Ctr, Perinatal Inst, Cincinnati, OH USA.
   [Wikenheiser Brokamp, Kathryn A.] Univ Cincinnati, Dept Pathol & Lab Med, Cincinnati, OH USA.
C3 University System of Ohio; University of Cincinnati; University of
   Washington; University of Washington Seattle; Vanderbilt University;
   Washington University (WUSTL); Washington University (WUSTL); Cincinnati
   Children's Hospital Medical Center; Cincinnati Children's Hospital
   Medical Center; University System of Ohio; University of Cincinnati
RP Hasegawa, Y; Mccormack, FX (通讯作者)，Univ Cincinnati, Dept Internal Med, Div Pulm Crit Care & Sleep Med, Cincinnati, OH 45221 USA.; Franks, JM; Trapnell, C (通讯作者)，Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.
EM y hasegawa@sapmed.ac.jp; jmfranks@uw.edu; coletrap@uw.edu;
   frank.mccormack@uc.edu
RI ; Ware, Lorraine/KPB 7924 2024; McCormack, Francis/ABE 8398 2020;
   Shaver, Ciara/MBH 7213 2025; Kropski, Jonathan/LXU 9640 2024
OI Srivatsan, Sanjay/0000 0001 7282 0487; Franks,
   Jennifer/0000 0003 2400 5431; Gardner, Jason/0000 0002 5924 9201; Ware,
   Lorraine/0000 0002 9429 4702; Shaver, Ciara/0000 0002 5677 0288;
   Hasegawa, Yoshihiro/0000 0001 7014 1472; 
FU Center of Environmental Genetic Pilot [P30 ES006096]; Department of
   Internal Medicine, University of Cincinnati; Chan Zuckerberg Initiative
   [DAF2020 217687]; CZI [DAF2020 218446]; Chan Zuckerberg Initiative DAF
   of Silicon Valley Community Foundation; Japan Society for the Promotion
   of Science [20K22880]; GSK Japan Research Grant [AS2021A000090017]; 
   [R01HL127455];  [R01HL145372];  [W81XWH1910415];  [K08HL136888]; 
   [R01HL126176];  [R01HL158906];  [R01HL118342]
FX This work was supported by R01HL127455 (F.X.M.), Center of Environmental
   Genetic Pilot supported P30 ES006096 (F.X.M.), a pilot award from the
   Department of Internal Medicine, University of Cincinnati (F.X.M.),
   R01HL145372 (J.K. and N.E.B.), W81XWH1910415 (J.K. and N.E.B.),
   K08HL136888 (C.M.S.), R01HL126176 (L.B.W.), R01HL158906 (L.B.W.), and
   Chan Zuckerberg Initiative (DAF2020 217687) (C.T.), and R01HL118342
   (C.T.). This publication has been made possible in part by CZI Grant
   DAF2020 218446, Grant DOI https://doi.org/10.37921/721772ELJWZB from the
   Chan Zuckerberg Initiative DAF, an advised fund of Silicon Valley
   Community Foundation (Funder DOI 10.13039/100014989), Japan Society for
   the Promotion of Science (20K22880) (Y.H.), and GSK Japan Research Grant
   2021 (AS2021A000090017) (Y.H.).
CR Adamopoulos IE, 2015, NAT REV RHEUMATOL, V11, P189, DOI 10.1038/nrrheum.2014.198
   Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059 017 1349 1
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Beers MF, 2017, AM J RESP CELL MOL, V57, P18, DOI 10.1165/rcmb.2016 0426PS
   Borges VM, 2001, J EXP MED, V194, P155, DOI 10.1084/jem.194.2.155
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Branchfield K, 2016, SCIENCE, V351, P707, DOI 10.1126/science.aad7969
   Cao JY, 2017, SCIENCE, V357, P661, DOI 10.1126/science.aam8940
   Cassel SL, 2008, P NATL ACAD SCI USA, V105, P9035, DOI 10.1073/pnas.0803933105
   Chen WH, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001206
   Cheng ML, 2014, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00329
   Chiu WSM, 2004, GENESIS, V39, P178, DOI 10.1002/gene.20041
   Cohen RA, 2022, ANN AM THORAC SOC, V19, P1469, DOI 10.1513/AnnalsATS.202109 1064OC
   Cruz FF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147005
   DOBBS LG, 1979, J CLIN INVEST, V63, P378, DOI 10.1172/JCI109313
   Ehrlich RI, 2011, OCCUP ENVIRON MED, V68, P96, DOI 10.1136/oem.2009.048827
   EKRYLANDER B, 1994, J BIOL CHEM, V269, P14853
   Gao YH, 2007, J CLIN INVEST, V117, P122, DOI 10.1172/JCI30074
   Habermann AC, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba1972
   Halleen JM, 1999, J BIOL CHEM, V274, P22907, DOI 10.1074/jbc.274.33.22907
   Halleen JM, 2000, J BONE MINER RES, V15, P1337, DOI 10.1359/jbmr.2000.15.7.1337
   Hussell T, 2014, NAT REV IMMUNOL, V14, P81, DOI 10.1038/nri3600
   Janckila AJ, 2002, CLIN CHIM ACTA, V320, P49, DOI 10.1016/S0009 8981(02)00026 8
   Jin FY, 2021, J INFLAMM RES, V14, P1647, DOI 10.2147/JIR.S306883
   Kamijo S, 2006, BIOCHEM BIOPH RES CO, V347, P124, DOI 10.1016/j.bbrc.2006.06.098
   Kawai T, 2006, AM J PATHOL, V169, P987, DOI 10.2353/ajpath.2006.060180
   Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092 8674(01)00206 9
   Leung CC, 2012, LANCET, V379, P2008, DOI 10.1016/S0140 6736(12)60235 9
   Lézot F, 2015, BONE, V73, P51, DOI 10.1016/j.bone.2014.12.011
   Li C, 2017, THERANOSTICS, V7, P4255, DOI 10.7150/thno.20270
   Li CG, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86629
   Lopes Pacheco M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109982
   Maciejewska A, 2008, INT J OCCUP MED ENV, V21, P1, DOI 10.2478/v10001 008 0010 3
   Madala SK, 2012, RESP RES, V13, DOI 10.1186/1465 9921 13 51
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Mbalaviele G, 2017, J CLIN INVEST, V127, P2030, DOI 10.1172/JCI93356
   Metzger TC, 2013, CELL REP, V5, P166, DOI 10.1016/j.celrep.2013.08.038
   Mijanovic O, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232213762
   Mossman BT, 1998, AM J RESP CRIT CARE, V157, P1666, DOI 10.1164/ajrccm.157.5.9707141
   Palaniyar N, 2002, J BIOL CHEM, V277, P26971, DOI 10.1074/jbc.M110080200
   Park JH, 2017, MOL CELLS, V40, P706
   Ramsgaard L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009604
   Read D. F., bioRxiv
   Rees D, 2007, INT J TUBERC LUNG D, V11, P474
   RICHARDS RJ, 1987, LUNG, V165, P143, DOI 10.1007/BF02714430
   Rosenberg N, 2012, RAMBAM MAIMONIDES ME, V3, DOI 10.5041/RMMJ.10080
   Rosendahl S, 2021, J BIOL CHEM, V296, DOI 10.1074/jbc.RA120.015571
   Saito A, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac8577
   Sato T, 2018, LUNG CANCER TARGETS, V9, P91, DOI 10.2147/LCTT.S156376
   Sherlock JP, 2012, NAT MED, V18, P1069, DOI 10.1038/nm.2817
   Steenland K, 2014, CA CANCER J CLIN, V64, P63, DOI 10.3322/caac.21214
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Thakur SA, 2009, TOXICOL SCI, V107, P238, DOI 10.1093/toxsci/kfn210
   Totsuka T, 2009, J IMMUNOL, V182, P6079, DOI 10.4049/jimmunol.0711823
   Trapnell C, 2014, NAT BIOTECHNOL, V32, P381, DOI 10.1038/nbt.2859
   Uehara Y, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 36810 8
   Wagner GR, 1997, LANCET, V349, P1311, DOI 10.1016/S0140 6736(96)07336 9
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   Wang B., 2020, PREPRINT, DOI [10.1101/2020.03.14.20024141, DOI 10.1101/2020.03.14.20024141]
   Wolock SL, 2019, CELL SYST, V8, P281, DOI 10.1016/j.cels.2018.11.005
   Wu HP, 2009, J BONE MINER RES, V24, P871, DOI [10.1359/JBMR.081239, 10.1359/jbmr.081239]
   Yu JJ, 2009, P NATL ACAD SCI USA, V106, P2635, DOI 10.1073/pnas.0810790106
   Zelko IN, 2016, RESP RES, V17, DOI 10.1186/s12931 016 0478 5
   Zou W, 2012, J BONE MINER RES, V27, P2490, DOI 10.1002/jbmr.1706
NR 67
TC 3
Z9 3
U1 2
U2 10
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2375 2548
J9 SCI ADV
JI Sci. Adv.
PD JUL 10
PY 2024
VL 10
IS 28
AR eadl4913
DI 10.1126/sciadv.adl4913
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA A1J2I
UT WOS:001280159000020
PM 38985878
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Mbese, Z
   Choene, M
   Morifi, E
   Nwamadi, M
   Adeyemi, S
   Oyebamiji, AK
   Adeyinka, AS
   George, B
   Aderibigbe, BA
AF Mbese, Zintle
   Choene, Mpho
   Morifi, Eric
   Nwamadi, M.
   Adeyemi, Samson
   Oyebamiji, Abel Kolawole
   Adeyinka, Adedapo S.
   George, Blassan
   Aderibigbe, Blessing Atim
TI Hybrid Molecules Containing Methotrexate, Vitamin D, and Platinum
   Derivatives: Synthesis, Characterization, In Vitro Cytotoxicity,
   In Silico ADME Docking, Molecular Docking and Dynamics
SO CHEMISTRY & BIODIVERSITY
LA English
DT Article
DE Cytotoxicity; Methotrexate; In Silico ADME; Vitamin D; Molecular docking
ID BONE METASTASIS; BIOLOGICAL EVALUATION; COLORECTAL CANCER; DRUG; TARGET;
   MECHANISMS; INTERPLAY
AB Designing hybrid based drugs is one promising strategy for developing effective anticancer drugs that explore combination therapy to enhance treatment efficacy, overcome the development of drug resistance, and lower treatment duration. Bisphosphonates and Vitamin D are commonly administered drugs for the treatment of bone diseases and the prevention of bone metastases. Platinum based and methotrexate are widely used anticancer drugs in clinics. However, their use is hampered by adverse side effects. Hybrid based compounds containing either bisphosphonate, vitamin D, platinum based, or methotrexate were synthesized and characterized using FTIR, H 1 ,P 31, C 13 NMR, and UHPLC HRMS which confirmed their successful synthesis. The hydroxyapatite bone binding assay revealed a promising percentage binding affinity of the bisphosphonate hybrid compounds. In vitro cytotoxicity assays on MCF 7 and HT 29cell lines revealed a promising cytotoxic effect of hybrid 19 at 50 and 100 mu g/mL on HT 29 and hybrid 15 on MCF 7 at 100 mu g/mL. Molecular docking and dynamics simulation analysis revealed a binding affinity of  9.70kcal/mol for hybrid 15 against Human 3 alpha hydroxysteroid dehydrogenase type 3, showing its capability to inhibit Human 3 alpha hydroxysteroid dehydrogenase type 3. The Swiss ADME, ProTox II, GUSAR (General Unrestricted Structure Activity Relationships), and molecular docking and dynamics studies revealed that these compounds are promising anticancer compounds.
C1 [Mbese, Zintle; Aderibigbe, Blessing Atim] Univ Ft Hare, Dept Chem, Alice Campus, ZA 5700 Alice, Eastern Cape, South Africa.
   [Choene, Mpho] Univ Johannesburg, Dept Biochem, Kingsway Campus, ZA 2006 Auckland Pk, South Africa.
   [Morifi, Eric] Univ Witwatersrand, Sch Chem, Mass Spectrometry Div, ZA 2050 Johannesburg, South Africa.
   [Nwamadi, M.] Univ Johannesburg, Dept Chem, Auckland Pk Campus, ZA 2006 Auckland Pk, South Africa.
   [Adeyemi, Samson] Univ Witwatersrand, Wits Adv Drug Delivery Platform Res Unit, Dept Pharm & Pharmacol, Sch Therapeut Sci,Fac Hlth Sci, Johannesburg, South Africa.
   [Oyebamiji, Abel Kolawole] Bowen Univ, Dept Chem & Ind Chem, Iwo, Osun State, Nigeria.
   [Adeyinka, Adedapo S.] Univ Johannesburg, Res Ctr Synth & Catalysis, Dept Chem Sci, Auckland Pk, ZA 2006 Johannesburg, South Africa.
   [George, Blassan] Univ Johannesburg, Laser Res Ctr, Fac Hlth Sci, Doornfontein Campus, ZA 2028 Johannesburg, South Africa.
C3 University of Fort Hare; University of Johannesburg; University of
   Witwatersrand; University of Johannesburg; University of Witwatersrand;
   University of Johannesburg; University of Johannesburg
RP Aderibigbe, BA (通讯作者)，Univ Ft Hare, Dept Chem, Alice Campus, ZA 5700 Alice, Eastern Cape, South Africa.
EM blessingaderibigbe@gmail.com
RI Aderibigbe, Blessing/ITV 6685 2023; Adeyinka, Adedapo
   Sunday/GQQ 5725 2022; Adeyinka, Adedapo/GQQ 5725 2022; Morifi,
   Eric/IQU 7806 2023; Oyebamiji, Abel/ABI 1570 2020; Adeyemi,
   Samson/ABE 4356 2021; George, Blassan/U 8844 2019
OI Adeyinka, Adedapo Sunday/0000 0002 2318 8208; Aderibigbe,
   Blessing/0000 0003 1157 7481; 
FU University of Fort Hare, Govan Mbeki Research and Development Center,
   South African Medical Research Council; National Research Foundation
FX The financial support from the University of Fort Hare, Govan Mbeki
   Research and Development Center, South African Medical Research Council,
   and National Research Foundation towards this research is hereby
   acknowledged.
CR Aderibigbe BA, 2020, J INORG ORGANOMET P, V30, P1503, DOI 10.1007/s10904 019 01325 7
   Aft R, 2012, CRIT REV ONCOL HEMAT, V82, P233, DOI 10.1016/j.critrevonc.2011.05.009
   Akinnusi PA, 2023, BIOINFORM BIOL INSIG, V17, DOI 10.1177/11779322231167970
   Alvarez Valdes A., 2019, J. Inorg. Biochem, V191, P112
   Ameji PJ, 2023, J TAIBAH UNIV MED SC, V18, P1417, DOI 10.1016/j.jtumed.2023.05.021
   Anusionwu CG, 2022, BIOORGAN MED CHEM, V58, DOI 10.1016/j.bmc.2022.116652
   Bonzi G, 2015, BIOCONJUGATE CHEM, V26, P489, DOI 10.1021/bc500614b
   Braga RC, 2015, MOL INFORM, V34, P698, DOI 10.1002/minf.201500040
   Cai B, 2016, STEROIDS, V116, P45, DOI 10.1016/j.steroids.2016.10.006
   Cathomas R, 2014, UROL INT, V92, P377, DOI 10.1159/000358258
   Cevik U. A., 2022, J. Mol. Struct, V15, P1252
   Chen C, 2018, CHINESE CHEM LETT, V29, P1609, DOI 10.1016/j.cclet.2018.02.010
   Delou JMA, 2019, CELLS BASEL, V8, DOI 10.3390/cells8091013
   Desai SA, 2021, J EGYPT NATL CANCER, V33, DOI 10.1186/s43046 021 00059 3
   Dewanjee S, 2017, MOLECULES, V22, DOI 10.3390/molecules22060871
   Dlamini NL, 2018, ARTIF CELL NANOMED B, V46, pS287, DOI 10.1080/21691401.2018.1491481
   El Megharbel SM, 2019, APPL ORGANOMET CHEM, V33, DOI 10.1002/aoc.4892
   Fernandes R, 2016, J BONE ONCOL, V5, P57, DOI 10.1016/j.jbo.2016.02.004
   Finch A. J., 2014, AUST PRESCR, V37, P137, DOI [10.18773/austprescr.2014.050, DOI 10.18773/AUSTPRESCR.2014.050]
   Garrido A, 2020, EUR J MED CHEM, V195, DOI 10.1016/j.ejmech.2020.112290
   Guo ZJ, 2018, CANCER METAST REV, V37, P409, DOI 10.1007/s10555 018 9749 6
   Gupta D, 2009, MOL PHARMACEUT, V6, P1604, DOI 10.1021/mp900084v
   ul Hassan SS, 2022, J BIOMOL STRUCT DYN, V40, P484, DOI 10.1080/07391102.2020.1815579
   Hermawan A., 2022, Egypt. J. Med. Hum. Genet, V23, P1
   Holladay L, 2023, CANCER TREAT RES COM, V37, DOI 10.1016/j.ctarc.2023.100763
   Jahnke W, 2010, CHEMMEDCHEM, V5, P770, DOI 10.1002/cmdc.201000016
   Janicka M, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232415887
   Kalev P, 2011, ANTI CANCER AGENT ME, V11, P38, DOI 10.2174/187152011794941172
   Kalyaanamoorthy S, 2018, MED RES REV, V38, P525, DOI 10.1002/med.21445
   Karacivi M, 2017, MOL PHARMACEUT, V14, P1373, DOI 10.1021/acs.molpharmaceut.6b01173
   Khwaza V, 2023, CHEM BIODIVERS, V20, DOI 10.1002/cbdv.202300034
   Kmiecik SW, 2017, POSTEP HIG MED DOSW, V71, P618
   Kozminski P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103483
   Krger K., 2015, Biochim. Biophys. Acta (BBA) Mol. Cell. Res, V1853, P685
   Laha JK, 2018, ACS OMEGA, V3, P8787, DOI 10.1021/acsomega.8b00894
   Lawal A., 2012, J. Pharm. Biomed. Sci, V24, P6
   Li YC, 2019, J CHEM INF MODEL, V59, P4063, DOI 10.1021/acs.jcim.9b00314
   Liu FQ, 2016, TUMOR BIOL, V37, P16127, DOI 10.1007/s13277 016 5465 4
   lvarezGonzlez B., 2020, Molecules, V25, P6049
   Maestro MA, 2019, J MED CHEM, V62, P6854, DOI 10.1021/acs.jmedchem.9b00208
   Majidzadeh H, 2021, PHARM SCI IRAN, V27, P536, DOI 10.34172/PS.2021.12
   Mason SD, 2011, TRENDS CELL BIOL, V21, P228, DOI 10.1016/j.tcb.2010.12.002
   Mbese Zintle, 2022, Recent Adv Antiinfect Drug Discov, V17, P54, DOI 10.2174/1574891X16666220124122445
   Morak Mlodawska B, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24086970
   Mukaya HE, 2017, POLYM BULL, V74, P3161, DOI 10.1007/s00289 016 1886 x
   Munnik BL, 2023, DALTON T, V52, P15786, DOI 10.1039/d3dt02254d
   Na SY, 2022, J CANCER PREV, V27, P147, DOI 10.15430/JCP.2022.27.3.147
   Nadar R. A., 2020, Sci. Rep, V10, P1
   Nadhum S. A., 2015, Iraqi. J. Pharm. Sci, V24, P74
   Nakatake H, 2011, CHEM PHARM BULL, V59, P710, DOI 10.1248/cpb.59.710
   Nemat A, 2022, J BIOMOL STRUCT DYN, V40, P2865, DOI 10.1080/07391102.2020.1844053
   Ng TL, 2021, SUPPORT CARE CANCER, V29, P925, DOI 10.1007/s00520 020 05556 0
   Njogu PM, 2013, ACS MED CHEM LETT, V4, P72, DOI 10.1021/ml400164t
   Oyebamiji AK, 2020, J CHEM NY, V2020, DOI 10.1155/2020/6735232
   Pasqua L, 2019, NANOSCALE ADV, V1, P3269, DOI 10.1039/c9na00249a
   Pietraszek A, 2013, STEROIDS, V78, P1003, DOI 10.1016/j.steroids.2013.06.001
   Pucci S, 2016, ONCOTARGET, V7, P19982, DOI 10.18632/oncotarget.6964
   Qiu L, 2015, J BIOL INORG CHEM, V20, P1263, DOI 10.1007/s00775 015 1305 z
   Ray S, 2014, PROG REACT KINET MEC, V39, P122, DOI 10.3184/146867814X13981545064892
   Ren GW, 2015, J MOL MED, V93, P1203, DOI 10.1007/s00109 015 1329 4
   Rodriguez Aller M, 2015, J DRUG DELIV SCI TEC, V30, P342, DOI 10.1016/j.jddst.2015.05.009
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Samuels ER, 2018, MOL PHARMACEUT, V15, P279, DOI 10.1021/acs.molpharmaceut.7b00957
   Semenenko OM, 2024, STEROIDS, V201, DOI 10.1016/j.steroids.2023.109332
   Shultz MD, 2019, J MED CHEM, V62, P1701, DOI 10.1021/acs.jmedchem.8b00686
   Tang LY, 2023, MOLECULES, V28, DOI 10.3390/molecules28031414
   Tsaioun K, 2016, ALTEX ALTERN ANIM EX, V33, P343, DOI 10.14573/altex.1610101
   Villa F, 2005, J BIOL CHEM, V280, P8180, DOI 10.1074/jbc.M412211200
   Welsh J, 2012, ARCH BIOCHEM BIOPHYS, V523, P107, DOI 10.1016/j.abb.2011.10.019
   Wu CW, 2017, ONCOL REP, V37, P2177, DOI 10.3892/or.2017.5439
   Xu J, 2013, CURR MED CHEM, V20, P4109
   Yang CM, 2010, CLIN EXP METASTAS, V27, P341, DOI 10.1007/s10585 010 9331 2
   Zhang B, 2016, BIOCHEM J, V473, P1037, DOI 10.1042/BCJ20160083
   Zhang KJ, 2018, J MED CHEM, V61, P6983, DOI [10.1021/acsjmedchem.8b00124, 10.1021/acs.jmedchem.8b00124]
NR 74
TC 1
Z9 1
U1 4
U2 7
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1612 1872
EI 1612 1880
J9 CHEM BIODIVERS
JI Chem. Biodivers.
PD JAN
PY 2025
VL 22
IS 1
AR e202400373
DI 10.1002/cbdv.202400373
EA NOV 2024
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA U1T0W
UT WOS:001357626100001
PM 39278836
OA hybrid
DA 2025 08 17
ER

PT J
AU Behera, J
   Ison, J
   Rai, H
   Tyagi, N
AF Behera, Jyotirmaya
   Ison, Jessica
   Rai, Hitesh
   Tyagi, Neetu
TI Allyl sul fi de promotes osteoblast differentiation and bone density via
   reducing mitochondrial DNA release mediated Kdm6b/H3K27me3 epigenetic
   mechanism
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Mitochondrial biogenesis; Osteoclastogenesis; BMMSCs mineralization;
   mtDNA release
ID SULFIDE; JMJD3
AB Age associated bone loss or osteoporosis is a common clinical manifestation during aging (AG). The mechanism underlying age associated osteoblast dysfunction induced by oxidative damage in the mitochondria and loss of bone density remains elusive. Here, we demonstrated the effect of allyl sulfide (AS), a natural organosulfur compound, on mitochondrial (mt) function in bone marrow derived mesenchymal stem cells (BMMSCs) and bone density in AG mice. The data demonstrate that AS treatment in AG mice promotes BMMSCs differentiation and mineralization via inhibition of mitochondrial oxidative damage. The data also indicate that AG related mito damage was associated with reduced mitochondrial biogenesis and oxidative phosphorylation, and release of a greater concentration of mtDNA. Furthermore, the data showed that mtDNA caused histone H3K27 demethylase inhibition, KDM6B, and subsequent inflammation by unbalancing mitochondrial redox homeostasis. KDM6B overexpression in AG BMMSCs or AS administration in AG mice restores osteogenesis and bone density in vitro and in vivo. Mechanistically, AS or the mitochondrial specific antioxidant Mito TEMPO increased KDM6B expression and upregulated the expression of Runx2 in BMMSCs, probably via epigenetic inhibition of H3K27me3 methylation at the promoter. These data uncover the previously undefined role of AS mediated prevention of mtDNA release, promoting osteogenesis and bone density via an epigenetic mechanism. Therefore, AS could be a potential drug target for the treatment of aging associated osteoporosis. (c) 2021 Elsevier Inc. All rights reserved.
C1 [Behera, Jyotirmaya; Ison, Jessica; Rai, Hitesh; Tyagi, Neetu] Univ Louisville, Sch Med, Dept Physiol, Bone Biol Lab, Louisville, KY 40292 USA.
C3 University of Louisville
RP Tyagi, N (通讯作者)，Univ Louisville, Hlth Sci Ctr, Dept Physiol, Bone Biol Lab A 1201, Louisville, KY 40202 USA.
EM neetu.tyagi@louisville.edu
RI ; Tyagi, Neetu/AFZ 1370 2022; Behera, Jyotirmaya/GNM 9046 2022
OI Behera, Ph.D., Jyotirmaya/0000 0003 2023 9900; Rai,
   Hitesh/0009 0009 0210 566X; 
FU National Institute of Health (NIH), USA [AR 067667]
FX This research study was supported, in part, by National Institute of
   Health (NIH), USA grant AR 067667 to NT.
CR An JH, 2010, BONE, V47, P140, DOI 10.1016/j.bone.2010.04.593
   Behera J, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 33149 9
   Behera J, 2018, BONE, V114, P90, DOI 10.1016/j.bone.2018.06.009
   Burchfield JS, 2015, INT J BIOCHEM CELL B, V67, P148, DOI 10.1016/j.biocel.2015.07.006
   Calixio J.B., 2004, PLANTA MED, V70
   COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184
   Dobson PF, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 68566 2
   Farr JN, 2017, NAT MED, V23, P1072, DOI 10.1038/nm.4385
   Fasolino I, 2015, MOL NUTR FOOD RES, V59, P434, DOI 10.1002/mnfr.201400347
   Lee HS, 2009, OSTEOARTHR CARTILAGE, V17, P91, DOI 10.1016/j.joca.2008.05.010
   Mody N, 2001, FREE RADICAL BIO MED, V31, P509, DOI 10.1016/S0891 5849(01)00610 4
   Mukherjee M, 2004, PHYTOTHER RES, V18, P389, DOI 10.1002/ptr.1448
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nam M, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 26322 7
   PARFITT AM, 1984, CALCIFIED TISSUE INT, V36, pS123, DOI 10.1007/BF02406145
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Shang A, 2019, FOODS, V8, DOI 10.3390/foods8070246
   She F, 2014, MOL MED REP, V9, P493, DOI 10.3892/mmr.2013.1832
   Swigut T, 2007, CELL, V131, P29, DOI 10.1016/j.cell.2007.09.026
   van Meurs JBJ, 2004, NEW ENGL J MED, V350, P2033, DOI 10.1056/NEJMoa032546
   Xiao ZS, 2005, DEV BIOL, V283, P345, DOI 10.1016/j.ydbio.2005.04.028
   Yang D, 2013, J BIOL CHEM, V288, P33530, DOI 10.1074/jbc.M113.497040
NR 22
TC 15
Z9 18
U1 0
U2 16
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAR 5
PY 2021
VL 543
BP 87
EP 94
DI 10.1016/j.bbrc.2021.01.016
EA FEB 2021
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA QL5HI
UT WOS:000621107500013
PM 33556823
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Sun, Y
   Wang, XQ
   Chen, R
   Zhu, D
   Shen, ZQ
   Zhao, HB
   Lee, WH
AF Sun Yan
   Wang Xiaoqi
   Chen Ran
   Zhu Di
   Shen Zhiqiang
   Zhao Hongbin
   Lee Wenhui
TI Osteoking downregulates Mgp in an osteoporotic fracture rat model
SO JOURNAL OF TRADITIONAL CHINESE MEDICINE
LA English
DT Article
DE Osteoporosis; Osteoporotic fractures; Matrix Gla protein; Osteoking
ID MATRIX GLA PROTEIN; BONE MORPHOGENETIC PROTEIN 2; VITAMIN K;
   OSTEOCALCIN; CALCIFICATION; EPIDEMIOLOGY; BINDING; MICE; MEN
AB OBJECTIVE: To investigate the effectiveness of osteoking, a Traditional Chinese Medicine originating from Yi nationality, against osteoporosis (OP) and osteoporotic fracture (OPF), and to elucidate its mechanism of action.
   METHODS: An osteoporotic fracture rat model was established; animals were divided into three treatment groups: parathyroid hormone, osteoking and 0.9%NaCI. After 4, 8 and 12 weeks of treatment, serum and bone tissues were collected. Enzyme linked immuno sorbent assay, x ray, histopathological evaluation and proteomics were used. Proteomics and GO annotation were performed based on identified peptides. The relative network was obtained from the STRING database and verified by polymerase chain reaction and Western blotting.
   RESULTS: After osteoking treatment, the bone mineral density (BMD) increased with time in the osteoking group. At week 12, the BMD and bone mineral salt content of the osteoking group were 4.5% and 20.6% higher than those of the negative control group, respectively. Furthermore, the body weight followed the order of positive control group > osteoking group > negative control group, with significant differences among the groups (P < 0.05). Micro CT analysis of femur sections revealed that the bone surface/volume ratio was significantly higher in the osteoking group than that in the negative control group. X ray images demonstrated that the osteoking group showed clear callus. Moreover, high voltage micro CT demonstrated a massive cortical bone accumulation in the osteoking group. The gray values of callus in the osteoking group were higher than those in the negative group. From week 4 to 12, the serum bone alkaline phosphatase level increased by 49.6% in the osteoking group and the serum propeptide of type I procollagen level decreased by 80.6%. Alizarin red staining demonstrated that the calcium deposition in the osteoking group was higher than that in the negative control group. Notably, the expression of Mgp, a key osteogenesis inhibitor, was lower in the osteoking group compared with the negative control group. Moreover, Sparc, bone morphogenetic protein 2 and Bglap expression was higher in the osteoking group through activation of the transforming growth factor receptor activator of nuclear factor kappa B Ligand pathway.
   CONCLUSION: Osteoking treatment increased bone quality and promoted calcium deposition. The results suggest that osteoking inhibits Mgp through the TGF beta/RANKL pathway to improve OP/OPF. (C) 2020 JTCM. All rights reserved.
C1 [Sun Yan; Wang Xiaoqi; Zhu Di; Shen Zhiqiang] Kunming Med Univ, Pharmaceut Coll, Kunming 650500, Yunnan, Peoples R China.
   [Sun Yan; Zhu Di; Shen Zhiqiang] Kunming Med Univ, Key Lab Pharmacol Nat Prod Yunnan Prov, Kunming 650500, Yunnan, Peoples R China.
   [Sun Yan; Wang Xiaoqi; Zhu Di; Lee Wenhui] Chinese Acad Sci, Kunming Inst Zool, Key Lab Anim Models & Human Dis Mech, Key Lab Bioact Peptides Yunnan Prov, Kunming 650032, Yunnan, Peoples R China.
   [Sun Yan; Zhu Di; Zhao Hongbin] Kunming Univ Sci & Technol, Affiliated Hosp, Peoples Hosp Yunnan Prov 1, Traumatol Emergency Dept, Kunming 650032, Yunnan, Peoples R China.
   [Chen Ran] Kunming Med Univ, Affiliated Hosp 2, Lab Dept, Kunming 650000, Yunnan, Peoples R China.
C3 Kunming Medical University; Kunming Medical University; Chinese Academy
   of Sciences; Kunming Institute of Zoology, CAS; Kunming University of
   Science & Technology; Kunming Medical University
RP Shen, ZQ (通讯作者)，Kunming Med Univ, Pharmaceut Coll, Kunming 650500, Yunnan, Peoples R China.; Shen, ZQ (通讯作者)，Kunming Med Univ, Key Lab Pharmacol Nat Prod Yunnan Prov, Kunming 650500, Yunnan, Peoples R China.; Zhao, HB (通讯作者)，Kunming Univ Sci & Technol, Affiliated Hosp, Peoples Hosp Yunnan Prov 1, Traumatol Emergency Dept, Kunming 650032, Yunnan, Peoples R China.
EM szq21cn@hotmall.com; zhb3279@163.com
RI Zhao, Hongbin/I 3783 2016
FU National Science Foundation of China Yunnan Province Joint Fund
   [U1502227]
FX Supported by the National Science Foundation of China Yunnan Province
   Joint Fund (The mechanisms of the Osteoking for promoting bone formation
   in OP and OPF, No. U1502227)
CR Ahlquist RP, 2010, J PHARM SCI, V59, P728, DOI DOI 10.1002/jps.2600590543
   Bensimon Brito A, 2012, BMC DEV BIOL, V12, DOI 10.1186/1471 213X 12 28
   Bliuc D, 2009, JAMA J AM MED ASSOC, V301, P513, DOI 10.1001/jama.2009.50
   Bostrom K, 2001, J BIOL CHEM, V276, P14044, DOI 10.1074/jbc.M008103200
   Cancela ML, 2014, ARCH BIOCHEM BIOPHYS, V561, P56, DOI 10.1016/j.abb.2014.07.020
   Clayton A, 2005, J CELL SCI, V118, P3631, DOI 10.1242/jcs.02494
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Dahlberg S, 2018, NUTRIENTS, V10, DOI 10.3390/nu10010046
   Dempster David W, 2011, Am J Manag Care, V17 Suppl 6, pS164
   Deryugina EI, 2015, MATRIX BIOL, V44 46, P94, DOI 10.1016/j.matbio.2015.04.004
   Diab DL, 2013, CURR OPIN ENDOCRINOL, V20, P501, DOI 10.1097/01.med.0000436194.10599.94
   Dore RK, 2013, PATIENT PREFER ADHER, V7, P435, DOI 10.2147/PPA.S31067
   Dowd TL, 2003, BIOCHEMISTRY US, V42, P7769, DOI 10.1021/bi034470s
   Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0
   Faienza MF, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/575936
   Fusaro M, 2017, CLIN CASES MINER BON, V14, P200, DOI 10.11138/ccmbm/2017.14.1.200
   Gheorghe Simona Roxana, 2016, Clujul Med, V89, P319, DOI 10.15386/cjmed 579
   Guo XL, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003 019 0304 y
   Hannafon F, 2014, J GERONTOL NURS, V40, P10, DOI 10.3928/00989134 20140204 01
   Hu M, 2006, ZHONG GUO ZHONG XI Y, V26, P1003
   Hu Min, 2005, Zhongguo Zhong Xi Yi Jie He Za Zhi, V25, P160
   Huo J, 2016, GENET MOL RES, V15, P150
   Hur DJ, 2005, AM J MED GENET A, V135A, P36, DOI 10.1002/ajmg.a.30680
   Indran IR, 2016, PHARMACOL THERAPEUT, V162, P188, DOI 10.1016/j.pharmthera.2016.01.015
   Jackson RD, 2014, SEMIN REPROD MED, V32, P454, DOI 10.1055/s 0034 1384629
   Kehler Tatjana, 2014, Reumatizam, V61, P60
   Lim DW, 2014, MOLECULES, V19, P783, DOI 10.3390/molecules19010783
   Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0
   Nanda A, 2006, AM J MED GENET A, V140A, P1487, DOI 10.1002/ajmg.a.31234
   PRICE PA, 1985, J BIOL CHEM, V260, P4971
   Qi W, 2011, BIOL TRACE ELEM RES, V143, P302, DOI 10.1007/s12011 010 8829 4
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Scott LJ, 2014, DRUG AGING, V31, P555, DOI 10.1007/s40266 014 0191 3
   Siddiqi MH, 2013, J GINSENG RES, V37, P261, DOI 10.5142/jgr.2013.37.261
   Subbiah V, 2010, OSTEOPOROSIS INT, V21, P1041, DOI 10.1007/s00198 009 1004 0
   Sun Y., 2016, ZHONG GUO GU ZHI SU, V12, P21
   Sweatt A, 2003, J THROMB HAEMOST, V1, P178, DOI 10.1046/j.1538 7836.2003.00023.x
   Wallin R, 2000, THROMB HAEMOSTASIS, V84, P1039
   Xue W, 2006, INVEST OPHTH VIS SCI, V47, P997, DOI 10.1167/iovs.05 1106
   Yagami K, 1999, J CELL BIOL, V147, P1097, DOI 10.1083/jcb.147.5.1097
   Yao YC, 2008, CIRC RES, V102, P1065, DOI 10.1161/CIRCRESAHA.107.166124
   Yin J, 2005, BIOL PHARM BULL, V28, P275, DOI 10.1248/bpb.28.275
   Zebboudj AF, 2002, J BIOL CHEM, V277, P4388, DOI 10.1074/jbc.M109683200
NR 43
TC 9
Z9 9
U1 0
U2 7
PU JOURNAL TRADITIONAL CHINESE MED
PI BEIJING
PA 16 NANXIAOJIE, DONGZHIMEN NEI, BEIJING, 100700, PEOPLES R CHINA
SN 0255 2922
EI 1577 7014
J9 J TRADIT CHIN MED
JI J. Tradit. Chin. Med.
PD JUN
PY 2020
VL 40
IS 3
BP 422
EP 431
PG 10
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA LV4DZ
UT WOS:000538389300010
PM 32506856
DA 2025 08 17
ER

PT J
AU Wang, L
   Jin, FL
   Wang, PY
   Hou, SQ
   Jin, T
   Chang, XS
   Zhao, LP
AF Wang, Li
   Jin, Fulu
   Wang, Peiyu
   Hou, Shiqiang
   Jin, Tao
   Chang, Xiansong
   Zhao, Liangping
TI 被撤回的出版物: Adropin Inhibits Vascular Smooth Muscle Cell Osteogenic
   Differentiation to Alleviate Vascular Calcification via the JAK2/ STAT3
   Signaling Pathway (Retracted Article)
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article; Retracted Publication
AB Vascular calcification is characterized as the deposition of hydroxyapatite mineral in the form of calcium phosphate complexes in the vasculature. Transdifferentiation between vascular smooth muscle cells (VSMCs) and osteoblast like cells is considered essential in the progression of vascular calcification. The pathophysiological mechanisms underlying vascular calcification and VSMC osteogenic differentiation remain to be fully elucidated, and the development of novel therapies is required. In the present study, PCR and western blot analysis were conducted to quantify the mRNA and protein expression levels of calcification associated markers (bone morphogenetic protein 2, alkaline phosphatase, osteoprotegerin, osteocalcin, and runtrelated transcription factor 2) and adropin in VSMCs and rat vascular tissues. The calcification of VSMCs was assessed using alizarin red staining. Moreover, adropin expression levels in VSMCs were analyzed using immunofluorescence. Lentiviral transfection and small interfering RNA were used for overexpression and knockdown of adropin in VSMCs, respectively. The results demonstrated that adropin alleviated vascular calcification in vivo. Moreover, adropin also inhibited osteogenic differentiation and the calcification of VSMCs in vitro. Notably, results of the present study revealed that the tyrosine protein kinase JAK2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathway played a key role in the aforementioned inhibition. In conclusion, the results of the present study demonstrated that adropin inhibited VSMC osteogenic differentiation to alleviate vascular calcification via the JAK2/STAT3 signaling pathway.
C1 [Wang, Li; Jin, Fulu; Wang, Peiyu; Jin, Tao; Chang, Xiansong; Zhao, Liangping] Soochow Univ, Affiliated Hosp 2, Dept Cardiol, Suzhou 215004, Jiangsu, Peoples R China.
   [Wang, Li; Chang, Xiansong] Soochow Univ, Affiliated Hosp 2, Emergency Dept, Suzhou 215004, Jiangsu, Peoples R China.
   [Hou, Shiqiang] Fudan Univ, Zhongshan Hosp, Shanghai Inst Cardiovasc Dis, Dept Cardiol, Shanghai 200032, Peoples R China.
C3 Soochow University   China; Soochow University   China; Fudan University
RP Zhao, LP (通讯作者)，Soochow Univ, Affiliated Hosp 2, Dept Cardiol, Suzhou 215004, Jiangsu, Peoples R China.
EM zhaoliangping1234@outlook.com
RI Zhao, Liang Ping/GQH 8688 2022
FU Suzhou Science and Technology Development Program Guidance Project Fund
   [SYSD2013093]; Xinxin Heart (SIP) Foundation [2019 CCA ACCESS 058];
   Postgraduate Research & Practice Innovation Program of Jiangsu Province
   [SJCX22 1510]; Trust Research Project [HX201902]
FX This study was supported by the Suzhou Science and Technology
   Development Program Guidance Project Fund (grant number SYSD2013093),
   Xinxin Heart (SIP) Foundation (2019 CCA ACCESS 058), Postgraduate
   Research & Practice Innovation Program of Jiangsu Province
   (SJCX22 1510), and Trust Research Project (HX201902).
CR Altamimi TR, 2019, METABOLISM, V98, P37, DOI 10.1016/j.metabol.2019.06.005
   Durham AL, 2018, CARDIOVASC RES, V114, P590, DOI 10.1093/cvr/cvy010
   Han JH, 2021, BRIT J PHARMACOL, V178, P4533, DOI 10.1111/bph.15631
   He J, 2019, CLIN EXP NEPHROL, V23, P501, DOI 10.1007/s10157 018 1666 z
   Hossain E, 2021, CAN J PHYSIOL PHARM, V99, P237, DOI 10.1139/cjpp 2020 0415
   Hou YC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030980
   Jaminon A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225694
   Kumar KG, 2008, CELL METAB, V8, P468, DOI 10.1016/j.cmet.2008.10.011
   Kuo FY, 2020, DIABET METAB SYND OB, V13, P2269, DOI 10.2147/DMSO.S243755
   Li L, 2022, J CARDIOVASC TRANSL, V15, P1256, DOI 10.1007/s12265 022 10248 7
   Li L, 2016, CLIN CHIM ACTA, V453, P107, DOI 10.1016/j.cca.2015.12.010
   Liu XH, 2016, PROG BIOPHYS MOL BIO, V122, P156, DOI 10.1016/j.pbiomolbio.2016.02.002
   Lu Y, 2019, J BIOSCIENCES, V44, DOI 10.1007/s12038 019 9895 1
   Mushala BAS, 2021, AM J PHYSIOL HEART C, V320, pH238, DOI 10.1152/ajpheart.00449.2020
   Nurnberg ST, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008538
   Rocha Singh KJ, 2014, CATHETER CARDIO INTE, V83, pE212, DOI 10.1002/ccd.25387
   Singh A, 2021, MOL BIOL REP, V48, P887, DOI 10.1007/s11033 020 06086 y
   Thapa D, 2019, J MOL CELL CARDIOL, V129, P174, DOI 10.1016/j.yjmcc.2019.02.012
   Villa Bellosta R, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222413536
   Wang L, 2021, EXP THER MED, V21, DOI 10.3892/etm.2021.9992
   Wang LY, 2017, BIOMED PHARMACOTHER, V95, P599, DOI 10.1016/j.biopha.2017.08.087
   Xu DC, 2022, J CANCER, V13, P2050, DOI 10.7150/jca.65875
   Yosaee S, 2016, IRAN J PUBLIC HEALTH, V45, P1568
NR 23
TC 7
Z9 7
U1 1
U2 4
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314 6133
EI 2314 6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD JUL 27
PY 2022
VL 2022
AR 9122264
DI 10.1155/2022/9122264
PG 10
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA VN4VY
UT WOS:001153393100007
PM 35937397
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Ríhová, K
   Lapcik, P
   Veselá, B
   Knopfová, L
   Potesil, D
   Pokludová, J
   Smarda, J
   Matalová, E
   Bouchal, P
   Benes, P
AF Rihova, Kamila
   Lapcik, Petr
   Vesela, Barbora
   Knopfova, Lucia
   Potesil, David
   Pokludova, Jana
   Smarda, Jan
   Matalova, Eva
   Bouchal, Pavel
   Benes, Petr
TI Caspase 9 Is a Positive Regulator of Osteoblastic Cell Migration
   Identified by diaPASEF Proteomics
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE ABHD2; Caspase 9; diaPASEF; migration; osteoblasts; proteomics
ID DOMAIN; ACTIVATION; INVASION; DATABASE; ENZYMES; DIFFERENTIATION;
   PROLIFERATION; ACCUMULATION; INFLAMMATION; MECHANISMS
AB Caspase 9 is traditionally considered the initiator caspase of the intrinsic apoptotic pathway. In the past decade, however, other functions beyond initiation/execution of cell death have been described including cell type dependent regulation of proliferation, differentiation/maturation, mitochondrial, and endosomal/lysosomal homeostasis. As previous studies revealed nonapoptotic functions of caspases in osteogenesis and bone homeostasis, this study was performed to identify proteins and pathways deregulated by knockout of caspase 9 in mouse MC3T3 E1 osteoblasts. Data independent acquisition parallel accumulation serial fragmentation (diaPASEF) proteomics was used to compare protein profiles of control and caspase 9 knockout cells. A total of 7669 protein groups were quantified, and 283 upregulated/141 downregulated protein groups were associated with the caspase 9 knockout phenotype. The deregulated proteins were mainly enriched for those associated with cell migration and motility and DNA replication/repair. Altered migration was confirmed in MC3T3 E1 cells with the genetic and pharmacological inhibition of caspase 9. ABHD2, an established regulator of cell migration, was identified as a possible substrate of caspase 9. We conclude that caspase 9 acts as a modulator of osteoblastic MC3T3 E1 cell migration and, therefore, may be involved in bone remodeling and fracture repair.
C1 [Rihova, Kamila; Knopfova, Lucia; Pokludova, Jana; Smarda, Jan; Benes, Petr] Masaryk Univ, Fac Sci, Dept Expt Biol, Brno 62500, Czech Republic.
   [Rihova, Kamila; Knopfova, Lucia; Pokludova, Jana; Benes, Petr] St Annes Univ Hosp, Int Clin Res Ctr, Brno 60200, Czech Republic.
   [Lapcik, Petr; Bouchal, Pavel] Masaryk Univ, Fac Sci, Dept Biochem, Brno 62500, Czech Republic.
   [Vesela, Barbora; Matalova, Eva] Czech Acad Sci, Inst Anim Physiol & Genet, Lab Odontogenesis & Osteogenesis, Brno 60200, Czech Republic.
   [Potesil, David] Masaryk Univ, Cent European Inst Technol, Prote Core Facil, Brno 62500, Czech Republic.
   [Matalova, Eva] Univ Vet Sci, Fac Vet Med, Dept Physiol, Brno 61242, Czech Republic.
C3 Masaryk University Brno; St. Anne's University Hospital Brno (FNUSA);
   St. Anne's University Hospital Brno (FNUSA ICRC); Masaryk University
   Brno; Czech Academy of Sciences; Institute of Animal Physiology &
   Genetics of the Czech Academy of Sciences; Masaryk University Brno;
   University of Veterinary Sciences Brno
RP Benes, P (通讯作者)，Masaryk Univ, Fac Sci, Dept Expt Biol, Brno 62500, Czech Republic.; Benes, P (通讯作者)，St Annes Univ Hosp, Int Clin Res Ctr, Brno 60200, Czech Republic.
EM pbenes@sci.muni.cz
RI Potesil, David/D 9696 2012; Benes, Petr/K 6369 2016; Bouchal,
   Pavel/H 6834 2013
OI Lapcik, Petr/0009 0009 4957 6645; Benes, Petr/0000 0002 8297 9675;
   Bouchal, Pavel/0000 0002 7118 4113
FU Czech Science Foundation [21 21409S]; National Institute for Cancer
   Research (Programme EXCELES)   European Union   Next Generation EU
   [LX22NPO5102]; MEYS CR [LM2023042]; European Regional Development
   Fund Project, UP CIISB [CZ.02.1.01/0.0/0.0/18_046/0015974]
FX The research was supported by the Czech Science Foundation (project
   21 21409S) and project National Institute for Cancer Research (Programme
   EXCELES, ID Project No. LX22NPO5102)   Funded by the European Union  
   Next Generation EU. CIISB, Instruct CZ Centre of Instruct ERIC EU
   consortium, funded by MEYS CR infrastructure project LM2023042 and
   European Regional Development Fund Project, UP CIISB" (No.
   CZ.02.1.01/0.0/0.0/18_046/0015974), is gratefully acknowledged for the
   financial support of the measurements at the CEITEC Proteomics Core
   Facility.
CR An HK, 2020, AUTOPHAGY, V16, P1598, DOI 10.1080/15548627.2019.1695398
   Antonopoulos H, 2001, J IMMUNOL, V166, P3672, DOI 10.4049/jimmunol.166.6.3672
   Araya LE, 2021, ACS CHEM BIOL, V16, P2280, DOI 10.1021/acschembio.1c00456
   Benes P, 2012, ENVIRON MOL MUTAGEN, V53, P515, DOI 10.1002/em.21712
   Bononi G, 2021, J MED CHEM, V64, P9759, DOI 10.1021/acs.jmedchem.1c00624
   Boonyarat C, 2021, BIOL PHARM BULL, V44, P494, DOI 10.1248/bpb.b20 00718
   Bratton SB, 2010, J CELL SCI, V123, P3209, DOI 10.1242/jcs.073643
   Bulatovic I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120176
   Campano P., 2023, ANN VASC MED RES, DOI [10.47739/2378 9344/1154, DOI 10.47739/2378 9344/1154]
   Campbell DS, 2013, J CELL BIOL, V203, P657, DOI 10.1083/jcb.201303072
   Concordet JP, 2018, NUCLEIC ACIDS RES, V46, pW242, DOI 10.1093/nar/gky354
   Dawar S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.406
   Fortelny N, 2015, NUCLEIC ACIDS RES, V43, pD290, DOI 10.1093/nar/gku1012
   Freimuth J, 2013, HEPATOLOGY, V58, P1779, DOI 10.1002/hep.26538
   Geisbrecht ER, 2004, CELL, V118, P111, DOI 10.1016/j.cell.2004.06.020
   Ghosh S, 2020, BIORXIV, DOI DOI 10.1101/548529
   Gorelick Ashkenazi A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05204 6
   Han J, 2021, AUTOPHAGY, V17, P1393, DOI 10.1080/15548627.2020.1761742
   Hollville E, 2018, SEMIN CELL DEV BIOL, V82, P127, DOI 10.1016/j.semcdb.2017.11.037
   Hu B, 2010, P NATL ACAD SCI USA, V107, P21635, DOI 10.1073/pnas.1016814108
   Janecková E, 2018, J HISTOCHEM CYTOCHEM, V66, P47, DOI 10.1369/0022155417739283
   Janzen V, 2008, CELL STEM CELL, V2, P584, DOI 10.1016/j.stem.2008.03.012
   Jones PH, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742 4690 9 10
   Keller N, 2018, SEMIN CELL DEV BIOL, V82, P105, DOI 10.1016/j.semcdb.2018.01.009
   Knopfová L, 2018, ONCOGENE, V37, P1020, DOI 10.1038/onc.2017.392
   Krajewska M, 2005, CLIN CANCER RES, V11, P5462, DOI 10.1158/1078 0432.CCR 04 2527
   Kratochvílová A, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 64294 9
   Kuo CT, 2006, NEURON, V51, P283, DOI 10.1016/j.neuron.2006.07.014
   Kuranaga E, 2012, GENES CELLS, V17, P83, DOI 10.1111/j.1365 2443.2011.01579.x
   Lamy L, 2013, CANCER CELL, V23, P435, DOI 10.1016/j.ccr.2013.02.017
   Lapcik P, 2023, PROTEOMICS, V23, DOI 10.1002/pmic.202200408
   Li JY, 2007, NAT CELL BIOL, V9, P276, DOI 10.1038/ncb1541
   Li P, 2017, ONCOTARGET, V8, P23996, DOI 10.18632/oncotarget.15098
   Li SX, 2016, SCI REP UK, V6, DOI 10.1038/srep20425
   Li Z, 2010, CELL, V141, P859, DOI 10.1016/j.cell.2010.03.053
   Liao YX, 2019, NUCLEIC ACIDS RES, V47, pW199, DOI 10.1093/nar/gkz401
   Lopez Cruzan M, 2013, BIOGERONTOLOGY, V14, P121, DOI 10.1007/s10522 013 9415 x
   Lord CC, 2013, BBA MOL CELL BIOL L, V1831, P792, DOI 10.1016/j.bbalip.2013.01.002
   Mahauad Fernandez WD, 2016, IMMUN INFLAMM DIS, V4, P4, DOI 10.1002/iid3.92
   Matalova E, 2013, DEV GROWTH DIFFER, V55, P615, DOI 10.1111/dgd.12066
   Meier F, 2020, NAT METHODS, V17, P1229, DOI 10.1038/s41592 020 00998 0
   Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984
   Miller MR, 2016, SCIENCE, V352, P555, DOI 10.1126/science.aad6887
   Miura M, 2004, J CLIN INVEST, V114, P1704, DOI 10.1172/JCI200420427
   Miyata K, 2005, BIOCHEM BIOPH RES CO, V329, P296, DOI 10.1016/j.bbrc.2005.01.127
   Mogi M, 2003, J BIOL CHEM, V278, P47477, DOI 10.1074/jbc.M307055200
   Murray TVA, 2008, J CELL SCI, V121, P3786, DOI 10.1242/jcs.024547
   Ohsawa S, 2010, P NATL ACAD SCI USA, V107, P13366, DOI 10.1073/pnas.0910488107
   Oliveros J. C., VENNY INTERACTIVE TO
   Oomman S, 2006, BRAIN RES, V1078, P19, DOI 10.1016/j.brainres.2006.01.041
   Pastén Hidalgo K, 2008, REPRODUCTION, V136, P41, DOI 10.1530/REP 07 0300
   Perez Riverol Y, 2022, NUCLEIC ACIDS RES, V50, pD543, DOI 10.1093/nar/gkab1038
   Poghosyan Z, 2002, J BIOL CHEM, V277, P4999, DOI 10.1074/jbc.M107430200
   Puhl JG, 2012, J NEUROSCI, V32, P17646, DOI 10.1523/JNEUROSCI.2249 12.2012
   Ramesova A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179576
   Raudvere U, 2019, NUCLEIC ACIDS RES, V47, pW191, DOI 10.1093/nar/gkz369
   Rawlings ND, 2018, NUCLEIC ACIDS RES, V46, pD624, DOI 10.1093/nar/gkx1134
   Ríhová K, 2022, CLIN EXP METASTAS, V39, P375, DOI 10.1007/s10585 021 10145 4
   Shalini S, 2015, CELL DEATH DIFFER, V22, P526, DOI 10.1038/cdd.2014.216
   Shalini S, 2012, CELL DEATH DIFFER, V19, P1370, DOI 10.1038/cdd.2012.13
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Su TT, 2020, OPEN BIOL, V10, DOI 10.1098/rsob.200130
   Sun GG, 2014, TUMOR BIOL, V35, P3455, DOI 10.1007/s13277 013 1456 x
   Sun LB, 2019, BMC CANCER, V19, DOI 10.1186/s12885 019 5425 7
   Svandova E, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.330
   Swiecki M, 2012, J IMMUNOL, V188, P2488, DOI 10.4049/jimmunol.1103145
   Tang D, 2021, BIOENGINEERED, V12, P4100, DOI 10.1080/21655979.2021.1953213
   Thiel A, 2018, BIOL REV, V93, P350, DOI 10.1111/brv.12345
   Tyanova S, 2016, NAT METHODS, V13, P731, DOI [10.1038/NMETH.3901, 10.1038/nmeth.3901]
   Van Opdenbosch N, 2019, IMMUNITY, V50, P1352, DOI 10.1016/j.immuni.2019.05.020
   Vesela B, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.794407
   Vesela B, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.589136
   WebGestalt, About us
   Westphal D, 2010, J BIOL CHEM, V285, P42046, DOI 10.1074/jbc.M110.177147
   Wickham H., 2016, ggplot2: Elegant Graphics for Data Analysis, DOI [10.1007/978 3 319 24277 4, DOI 10.1007/978 3 319 24277 4]
   Williams DW, 2006, NAT NEUROSCI, V9, P1234, DOI 10.1038/nn1774
   Zhang XY, 2020, ONCOL LETT, V20, DOI 10.3892/ol.2020.12174
   Zhang YP, 2007, MECH AGEING DEV, V128, P213, DOI 10.1016/j.mad.2006.11.030
   Zhou M, 2018, INT J CANCER, V143, P921, DOI 10.1002/ijc.31374
NR 79
TC 3
Z9 3
U1 7
U2 23
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535 3893
EI 1535 3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD MAR 18
PY 2024
VL 23
IS 8
BP 2999
EP 3011
DI 10.1021/acs.jproteome.3c00641
EA MAR 2024
PG 13
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA A6D1K
UT WOS:001187677300001
PM 38498986
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Jin, YL
   Kim, D
   Choi, YJ
   Song, I
   Chung, YS
AF Jin, Yilan
   Kim, Dowan
   Choi, Yong Jun
   Song, Insun
   Chung, Yoon Sok
TI Gene Network Analysis for Osteoporosis, Sarcopenia, Diabetes, and
   Obesity in Human Mesenchymal Stromal Cells
SO GENES
LA English
DT Article
DE osteoporosis; gene network analysis; mesenchymal stromal cells
ID STEM CELLS; RNA SEQ; BONE; RISK; DIFFERENTIATION; EXPRESSION; ADIPOCYTE;
   MELLITUS; THERAPY; TYPE 1
AB The systemic gene interactions that occur during osteoporosis and their underlying mechanisms remain to be determined. To this end, mesenchymal stromal cells (MSCs) were analyzed from bone marrow samples collected from healthy individuals (n = 5) and patients with osteoporosis (n = 5). A total of 120 osteoporosis related genes were identified using RNA sequencing (RNA seq) and Ingenuity Pathway Analysis (IPA) software. In order to analyze these genes, we constructed a heatmap of one way hierarchical clustering and grouped the gene expression patterns of the samples. The MSCs from one control participant showed a similar expression pattern to that observed in the MSCs of three patients with osteoporosis, suggesting that the differentiating genes might be important genetic determinants of osteoporosis. Then, we selected the top 38 genes based on fold change and expression, excluding osteoporosis related genes from the control participant. We identified a network among the top 38 genes related to osteoblast and osteoclast differentiation, bone remodeling, osteoporosis, and sarcopenia using the Molecule Activity Predictor program. Among them, 25 genes were essential systemic genes involved in osteoporosis. Furthermore, we identified 24 genes also associated with diabetes and obesity, among which 10 genes were involved in a network related to bone and energy metabolism. The study findings may have implications for the treatment and prevention of osteoporosis.
C1 [Jin, Yilan; Choi, Yong Jun; Song, Insun; Chung, Yoon Sok] Ajou Univ, Dept Endocrinol & Metab, Sch Med, Suwon 16499, South Korea.
   [Jin, Yilan; Choi, Yong Jun; Song, Insun; Chung, Yoon Sok] Ajou Univ, Ajou Inst Aging, Med Ctr, Suwon 16499, South Korea.
   [Kim, Dowan] Ajou Univ, Ajou Translat OMICS Ctr, Sch Med, Suwon 16499, South Korea.
   [Kim, Dowan] Ajou Univ, Dept Med Sci, Grad Sch Med, Suwon 16499, South Korea.
C3 Ajou University; Ajou University; Ajou University; Ajou University
RP Chung, YS (通讯作者)，Ajou Univ, Dept Endocrinol & Metab, Sch Med, Suwon 16499, South Korea.; Chung, YS (通讯作者)，Ajou Univ, Ajou Inst Aging, Med Ctr, Suwon 16499, South Korea.
EM jinyilan520@hanmail.net; kdowan@ajou.ac.kr; colsmile@hanmail.net;
   song1009@gmail.com; yschung@ajou.ac.kr
RI ; JIN, YILAN/JCP 4239 2023
OI Kim, Dowan/0000 0003 4243 8476; Choi, Yong Jun/0000 0003 3960 8470;
   Song, Insun/0000 0001 6418 6359; JIN, YILAN/0000 0003 2488 5061; Chung,
   Yoon Sok/0000 0003 0179 4386
FU National Research Foundation, Korea [NRF 2017R1D1A1B04030746,
   NRF 2019R1F1A1063188]
FX This study was supported by grants from the National Research
   Foundation, Korea (NRF 2017R1D1A1B04030746; NRF 2019R1F1A1063188).
CR Akkawi Ibrahim, 2018, Joints, V6, P122, DOI 10.1055/s 0038 1660790
   Al Anouti F, 2019, BONE REP, V11, DOI 10.1016/j.bonr.2019.100216
   Angelopoulou M, 2003, EXP HEMATOL, V31, P413, DOI 10.1016/S0301 472X(03)00042 0
   Ardawi MSM, 2013, BONE, V56, P355, DOI 10.1016/j.bone.2013.06.029
   Ascenzi F, 2019, AGING CELL, V18, DOI 10.1111/acel.12954
   Benisch P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045142
   Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007 0197
   Choi Y, 2017, GENE, V632, P7, DOI 10.1016/j.gene.2017.08.015
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Ellervik C, 2011, DIABETES CARE, V34, P2256, DOI 10.2337/dc11 0416
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Frank GR, 2013, MOL GENET METAB, V110, P191, DOI 10.1016/j.ymgme.2013.04.005
   Gao J, 2018, CELL DEATH DIFFER, V25, P229, DOI 10.1038/cdd.2017.144
   Gathercole LL, 2010, J STEROID BIOCHEM, V122, P21, DOI 10.1016/j.jsbmb.2010.03.060
   Golpanian S, 2016, PHYSIOL REV, V96, P1127, DOI 10.1152/physrev.00019.2015
   Grey A, 1999, ENDOCRINOLOGY, V140, P4683, DOI 10.1210/en.140.10.4683
   Ha J, 2010, J IMMUNOL, V184, P4717, DOI 10.4049/jimmunol.0902444
   Hatim B., 2019, GENES BASEL, V10, P706
   Hegele RA, 2002, DIABETES, V51, P3586, DOI 10.2337/diabetes.51.12.3586
   Hwang JY, 2009, BONE, V45, P1098, DOI 10.1016/j.bone.2009.07.080
   Inzerillo AM, 2004, REV ENDOCR METAB DIS, V5, P261, DOI 10.1023/B:REMD.0000032415.83124.20
   James AW, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/684736
   Kim H, 2017, J BONE MINER RES, V32, P397, DOI 10.1002/jbmr.2974
   Lee KG, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9010046
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Leidig Bruckner G, 2001, EXP CLIN ENDOCR DIAB, V109, pS493, DOI 10.1055/s 2001 18605
   Li BX, 2013, ENDOCRINE, V43, P136, DOI 10.1007/s12020 012 9757 1
   Lin JT, 2004, CLIN ORTHOP RELAT R, P126, DOI 10.1097/01.blo.0000132404.30139.f2
   Madkour MI, 2019, DIABETES RES CLIN PR, V155, DOI 10.1016/j.diabres.2019.107801
   Mani A, 2007, SCIENCE, V315, P1278, DOI 10.1126/science.1136370
   Marioni JC, 2008, GENOME RES, V18, P1509, DOI 10.1101/gr.079558.108
   Martin JA, 2011, NAT REV GENET, V12, P671, DOI 10.1038/nrg3068
   Matsunaga H, 2018, BIOCHEM BIOPH RES CO, V495, P740, DOI 10.1016/j.bbrc.2017.11.069
   Mediero A, 2015, J BONE MINER RES, V30, P837, DOI 10.1002/jbmr.2421
   Moyer Mileur LJ, 2008, J BONE MINER RES, V23, P1884, DOI 10.1359/JBMR.080713
   Nair S, 2004, DIABETOLOGIA, V47, P1088, DOI 10.1007/s00125 004 1407 6
   Oh SW, 2004, OBES RES, V12, P2031, DOI 10.1038/oby.2004.254
   Ortega FJ, 2011, EUR J ENDOCRINOL, V165, P639, DOI 10.1530/EJE 11 0384
   Ozsolak F, 2011, NAT REV GENET, V12, P87, DOI 10.1038/nrg2934
   Ridderstråle M, 2006, DIABETOLOGIA, V49, P496, DOI 10.1007/s00125 005 0129 8
   Rosen CJ, 2009, AM J MED, V122, P409, DOI 10.1016/j.amjmed.2008.11.027
   Rouault C, 2013, ENDOCRINOLOGY, V154, P1069, DOI 10.1210/en.2012 1415
   Salem HK, 2010, STEM CELLS, V28, P585, DOI 10.1002/stem.269
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Sato T, 2017, IN VIVO, V31, P321, DOI 10.21873/invivo.11062
   Schwartz AV, 2003, CALCIFIED TISSUE INT, V73, P515, DOI 10.1007/s00223 003 0023 7
   Seeliger C, 2014, J BONE MINER RES, V29, P1718, DOI 10.1002/jbmr.2175
   Shangguan YF, 2018, AM J PATHOL, V188, P2863, DOI 10.1016/j.ajpath.2018.08.008
   Sun L, 2019, PAK J MED SCI, V35, P691, DOI 10.12669/pjms.35.3.84
   Thrailkill KM, 2005, AM J PHYSIOL ENDOC M, V289, pE735, DOI 10.1152/ajpendo.00159.2005
   Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621
   Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120
   Vincent AM, 2007, EXP NEUROL, V208, P216, DOI 10.1016/j.expneurol.2007.07.017
   Wallenius V, 2002, NAT MED, V8, P75, DOI 10.1038/nm0102 75
   Wang J, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/748435
   Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484
   Yang Q, 2011, J BONE MINER RES, V26, P1188, DOI 10.1002/jbmr.337
   Yang Y, 2019, J CELL SCI, V132, DOI 10.1242/jcs.230490
NR 58
TC 0
Z9 0
U1 1
U2 21
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4425
J9 GENES BASEL
JI Genes
PD MAR
PY 2022
VL 13
IS 3
AR 459
DI 10.3390/genes13030459
PG 14
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA 0C4OW
UT WOS:000775295600001
PM 35328013
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Benyettou, F
   Lalatonne, Y
   Sainte Catherine, O
   Monteil, M
   Motte, L
AF Benyettou, Farah
   Lalatonne, Yoann
   Sainte Catherine, Odile
   Monteil, Maelle
   Motte, Laurence
TI Superparamagnetic nanovector with anti cancer properties:
   γFe2O3@Zoledronate
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Drug nanoparticle; Magnetic nanoparticle; Bisphosphonate; Cancer drugs;
   Drug targeting; Cell internalization
ID BONE METASTASES; ZOLEDRONIC ACID; BISPHOSPHONATES; THERAPY; RESORPTION;
   BREAST
AB We elaborate a magnetic nanovector to vectorize Zoledronate, an anti cancer interest molecule of the hydroxmethylenebisphosphonate's family. In fact, Zoledronate is a powerful adjuvant in the treatment of bone diseases such as osteoporosis and Paget's disease. But, recent studies have shown that in addition to anti osteoclastic properties, it presents antitumour properties notably in the case of breast and prostate cancer. However, these properties cannot be exploited due to their very high affinity to divalent cations and their preferentially accumulation in bone. To overcome this problem, one strategy is the vectorization trough maghemite nanocrystal functionalization. The specific surface coating permits to consider gamma Fe2O3@Zoledronate as a drug delivery vehicle for therapeutic activity. The anchoring to the nanoparticle's surface allowed to increase their hydrophobicity and also to change the therapeutic target, increasing the Zoledronate intestinal absorption instead of their accumulation in bone. We show that Zoledronate link the nanoparticle surface through phosphonate groups. The biological in vitro tests performed on breast cancer cell line, MDA MB 231, showed that gamma Fe2O3@Zoledronate have anti proliferative activity. In addition, the gamma Fe2O3 core could be used as MRI contrast agent for a good therapeutic evaluation. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Benyettou, Farah; Lalatonne, Yoann; Sainte Catherine, Odile; Monteil, Maelle; Motte, Laurence] Univ Paris 13, Lab CSPBAT FRE 3043, CNRS, F 93017 Bobigny, France.
   [Lalatonne, Yoann] Hop Avicenne, Nucl Med Serv, F 93009 Bobigny, France.
C3 Centre National de la Recherche Scientifique (CNRS); Universite Paris
   13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Avicenne   APHP; Universite Paris 13
RP Motte, L (通讯作者)，Univ Paris 13, Lab CSPBAT FRE 3043, CNRS, 74 Rue Marcel Cachin, F 93017 Bobigny, France.
EM laurence.motte@smbh.univ paris13.fr
RI ; Lalatonne, Yoann/AAQ 3764 2020; motte, laurence/AAD 8647 2022
OI Lalatonne, Yoann/0000 0003 2235 6561; motte,
   laurence/0000 0001 6129 539X; 
CR Boissier S, 2000, CANCER RES, V60, P2949
   Green JR, 2003, CANCER, V97, P840, DOI 10.1002/cncr.11128
   Green JR, 2002, DRUG DEVELOP RES, V55, P210, DOI 10.1002/ddr.10071
   Lalatonne Y, 2004, J PHYS CHEM B, V108, P1848, DOI 10.1021/jp035665c
   Lalatonne Y, 2008, CHEM COMMUN, P2553, DOI 10.1039/b801911h
   Lipton Allan, 2000, Cancer, V88, P3033, DOI 10.1002/1097 0142(20000615)88:12+<3033::AID CNCR20>3.3.CO;2 3
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Rosen LS, 2004, CANCER, V100, P36, DOI 10.1002/cncr.11892
   Russell RGG, 2007, BONE, V40, pS21, DOI 10.1016/j.bone.2007.03.002
   Scherer F, 2002, GENE THER, V9, P102, DOI 10.1038/sj.gt.3301624
   Stresing V, 2007, CANCER LETT, V257, P16, DOI 10.1016/j.canlet.2007.07.007
   Takeuchi M, 1998, CHEM PHARM BULL, V46, P1703
   Zeisberger SM, 2006, BRIT J CANCER, V95, P272, DOI 10.1038/sj.bjc.6603240
NR 13
TC 48
Z9 51
U1 1
U2 23
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378 5173
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD SEP 11
PY 2009
VL 379
IS 2
SI SI
BP 324
EP 327
DI 10.1016/j.ijpharm.2009.04.010
PG 4
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 499WE
UT WOS:000270256400019
PM 19457625
DA 2025 08 17
ER

PT J
AU Zhao, FJ
   Zhang, CG
   Liu, J
   Liu, L
   Cao, XD
   Chen, XF
   Lei, B
   Shao, LQ
AF Zhao, Fujian
   Zhang, Chenguang
   Liu, Jia
   Liu, Lu
   Cao, Xiaodong
   Chen, Xiaofeng
   Lei, Bo
   Shao, Longquan
TI Periosteum structure/function mimicking bioactive scaffolds with
   piezoelectric/chem/nano signals for critical sized bone regeneration
SO CHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE Periosteum biomimetic biomaterials; Piezoelectric scaffolds; Bioactive
   glass; Bone tissue engineering
ID CALCIUM SENSING RECEPTOR; EXTRACELLULAR CALCIUM; IN VITRO;
   DIFFERENTIATION; CASR; MEMBRANES; GLASS
AB The critical sized bone regeneration is still a challenge in regenerative medicine. Periosteum possesses excellent osteogenic capacity because it can provide osteogenic cells and growth factors and guide bone healing. Herein, inspired by the nanostructure/piezoelectric property of bone and the structure/function of periosteum, we report a periosteum structure/function mimicking scaffolds with piezoelectric signal bioactive ion nanofibrous surface for critical sized bone regeneration. The biomimetic scaffolds have a gradient structure including the piezoelectric polymer layer and bioactive glass nanofibrous surface. The bioactive multifunctional scaffolds could remarkably improve the proliferation, adhesion, osteogenesis differentiation of bone marrow stem cells (BMSCs), significantly enhance the formation of periosteum like tissue and the critical sized bone regeneration at the center of bone defect. Further studies of the molecular mechanism showed that the bioactive piezoelectric nanostructure scaffolds could activate the calcium sensing receptor of osteoblasts by accumulating Ca2+. Our study provides a synergistically piezoelectricity bioactive ion nanostructure strategy to design bioactive biomaterials for critical sized bone regeneration.
C1 [Zhao, Fujian; Zhang, Chenguang; Liu, Jia; Shao, Longquan] Southern Med Univ, Stomatol Hosp, Guangzhou 510280, Peoples R China.
   [Lei, Bo] Xi An Jiao Tong Univ, Coll Stomatol, Key Lab Shaanxi Prov Craniofacial Precis Med Res, Xian 710000, Peoples R China.
   [Lei, Bo] Xi An Jiao Tong Univ, Frontier Inst Sci & Technol, Xian 710000, Peoples R China.
   [Lei, Bo] Xi An Jiao Tong Univ, Instrument Anal Ctr, Xian 710054, Peoples R China.
   [Liu, Lu; Cao, Xiaodong; Chen, Xiaofeng] South China Univ Technol, Sch Mat Sci & Engn, Dept Biomed Engn, Guangzhou 510641, Peoples R China.
   [Liu, Lu; Cao, Xiaodong; Chen, Xiaofeng] South China Univ Technol, Natl Engn Res Ctr Tissue Restorat & Reconstruct, Guangzhou 510006, Peoples R China.
   [Shao, Longquan] Guangdong Prov Key Lab Construct & Detect Tissue, Guangzhou 510515, Peoples R China.
C3 Southern Medical University   China; Xi'an Jiaotong University; Xi'an
   Jiaotong University; Xi'an Jiaotong University; South China University
   of Technology; South China University of Technology
RP Shao, LQ (通讯作者)，Southern Med Univ, Stomatol Hosp, Guangzhou 510280, Peoples R China.; Lei, B (通讯作者)，Xi An Jiao Tong Univ, Coll Stomatol, Key Lab Shaanxi Prov Craniofacial Precis Med Res, Xian 710000, Peoples R China.; Lei, B (通讯作者)，Xi An Jiao Tong Univ, Frontier Inst Sci & Technol, Xian 710000, Peoples R China.; Lei, B (通讯作者)，Xi An Jiao Tong Univ, Instrument Anal Ctr, Xian 710054, Peoples R China.; Chen, XF (通讯作者)，South China Univ Technol, Sch Mat Sci & Engn, Dept Biomed Engn, Guangzhou 510641, Peoples R China.; Chen, XF (通讯作者)，South China Univ Technol, Natl Engn Res Ctr Tissue Restorat & Reconstruct, Guangzhou 510006, Peoples R China.; Shao, LQ (通讯作者)，Guangdong Prov Key Lab Construct & Detect Tissue, Guangzhou 510515, Peoples R China.
EM chenxf@scut.edu.cn; rayboo@xjtu.edu.cn; shaolongquan@smu.edu.cn
RI ; Zhao, Fujian/MGW 4715 2025; chenguang, Zhang/JED 7350 2023; Lei,
   Bo/B 9463 2009; Cao, Xiaodong/D 6045 2011
OI Shao, Longquan/0000 0002 3770 0815; Chen, Xiaofeng/0000 0002 3591 8001; 
FU National Key Research and Development Program of China [2018YFC1106300];
   National Natural Science Foundation of China [51672088, 51872224,
   81870786]; Natural Science Foundation of Guangdong Province
   [2019A1515110480]; Medical Scientific Research Foundation of Guangdong
   Province of China [A2020107]; Science Research Cultivation Program of
   Stomatological Hospital, Southern Medical University [PY2019007]
FX This study was financially supported by the National Key Research and
   Development Program of China (grant no. 2018YFC1106300), the National
   Natural Science Foundation of China (grant no. 51672088, 51872224,
   81870786), the Natural Science Foundation of Guangdong Province (grant
   no. 2019A1515110480), the Medical Scientific Research Foundation of
   Guangdong Province of China (grant no. A2020107) and the Science
   Research Cultivation Program of Stomatological Hospital, Southern
   Medical University (grant no. PY2019007).
CR Aguirre A, 2010, BIOCHEM BIOPH RES CO, V393, P156, DOI 10.1016/j.bbrc.2010.01.109
   Bagur R, 2017, MOL CELL, V66, P780, DOI 10.1016/j.molcel.2017.05.028
   Baldwin JG, 2017, BIOMATERIALS, V121, P193, DOI 10.1016/j.biomaterials.2016.11.016
   Brown EM, 2013, BEST PRACT RES CL EN, V27, P333, DOI 10.1016/j.beem.2013.02.006
   Chattopadhyay N, 2004, ENDOCRINOLOGY, V145, P3451, DOI 10.1210/en.2003 1127
   Chernozem RV, 2019, ACS APPL MATER INTER, V11, P19522, DOI 10.1021/acsami.9b04936
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Debnath S, 2018, NATURE, V562, P133, DOI 10.1038/s41586 018 0554 8
   Dvorak MM, 2004, P NATL ACAD SCI USA, V101, P5140, DOI 10.1073/pnas.0306141101
   Dvorak Ewell MM, 2011, J BONE MINER RES, V26, P2935, DOI 10.1002/jbmr.520
   Fernandes HR, 2018, MATERIALS, V11, DOI 10.3390/ma11122530
   Fiume E, 2018, J FUNCT BIOMATER, V9, DOI 10.3390/jfb9010024
   Galli C, 2019, BIOELECTROMAGNETICS, V40, P211, DOI 10.1002/bem.22187
   Gong M, 2019, NANOMED NANOTECHNOL, V17, P124, DOI 10.1016/j.nano.2019.01.002
   González Vázquez A, 2014, ACTA BIOMATER, V10, P2824, DOI 10.1016/j.actbio.2014.02.004
   Hoppe A, 2011, BIOMATERIALS, V32, P2757, DOI 10.1016/j.biomaterials.2011.01.004
   Hosoyama K, 2019, BIOTECHNOL ADV, V37, P444, DOI 10.1016/j.biotechadv.2019.02.011
   Hu C, 2019, BIOMATERIALS, V219, DOI 10.1016/j.biomaterials.2019.119366
   Jia WT, 2015, ADV HEALTHC MATER, V4, P2842, DOI 10.1002/adhm.201500447
   Jin GR, 2014, MAT SCI ENG C MATER, V45, P671, DOI 10.1016/j.msec.2014.06.004
   Jones JR, 2013, ACTA BIOMATER, V9, P4457, DOI 10.1016/j.actbio.2012.08.023
   Jung H, 2018, J TISSUE ENG REGEN M, V12, pE1349, DOI 10.1002/term.2518
   Kapat K, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201909045
   Koffler J, 2019, NAT MED, V25, P263, DOI 10.1038/s41591 018 0296 z
   Koori K, 2014, CELL TISSUE RES, V357, P707, DOI 10.1007/s00441 014 1918 5
   Maeno S, 2005, BIOMATERIALS, V26, P4847, DOI 10.1016/j.biomaterials.2005.01.006
   Maria CS, 2016, SEMIN CELL DEV BIOL, V49, P11, DOI 10.1016/j.semcdb.2015.12.004
   Marie PJ, 2010, BONE, V46, P571, DOI 10.1016/j.bone.2009.07.082
   Marino A, 2017, ACS APPL MATER INTER, V9, P17663, DOI 10.1021/acsami.7b04323
   Mattioli Belmonte M, 2017, J TISSUE ENG REGEN M, V11, P1986, DOI 10.1002/term.2095
   Metwally S, 2019, MAT SCI ENG C MATER, V104, DOI 10.1016/j.msec.2019.109883
   Mizumachi H, 2017, BONE, V101, P191, DOI 10.1016/j.bone.2017.05.012
   More N, 2017, MED HYPOTHESES, V108, P10, DOI 10.1016/j.mehy.2017.07.021
   Ortiz Capisano MC, 2013, AM J PHYSIOL RENAL, V304, pF248, DOI 10.1152/ajprenal.00451.2012
   Przekora A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020435
   Qiu PC, 2020, BIOMATERIALS, V227, DOI 10.1016/j.biomaterials.2019.119552
   Sheikh Z, 2015, MATERIALS, V8, P7913, DOI 10.3390/ma8115430
   Sun FH, 2019, J MATER CHEM B, V7, P665, DOI 10.1039/c8tb02435a
   Tang Q, 2019, THERANOSTICS, V9, P1125, DOI 10.7150/thno.29566
   Tharmalingam S, 2011, J BIOL CHEM, V286, P40922, DOI 10.1074/jbc.M111.265454
   Vichery C, 2016, MATERIALS, V9, DOI 10.3390/ma9040288
   Wu L, 2020, BIOMATERIALS, V227, DOI 10.1016/j.biomaterials.2019.119555
   Xia Y, 2018, BIOMATERIALS, V183, P151, DOI 10.1016/j.biomaterials.2018.08.040
   Yamauchi M, 2005, AM J PHYSIOL ENDOC M, V288, pE608, DOI 10.1152/ajpendo.00229.2004
   Yang BG, 2016, ADV HEALTHC MATER, V5, P474, DOI 10.1002/adhm.201500520
   Zayzafoon M, 2006, J CELL BIOCHEM, V97, P56, DOI 10.1002/jcb.20675
   Zhang CG, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201701466
   Zhang K, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0032 9
   Zhang XH, 2016, ACS NANO, V10, P7279, DOI 10.1021/acsnano.6b02247
   Zhao FJ, 2018, BIOMATERIALS, V178, P36, DOI 10.1016/j.biomaterials.2018.06.004
NR 50
TC 56
Z9 56
U1 14
U2 315
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1385 8947
EI 1873 3212
J9 CHEM ENG J
JI Chem. Eng. J.
PD DEC 15
PY 2020
VL 402
AR 126203
DI 10.1016/j.cej.2020.126203
PG 11
WC Engineering, Environmental; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA NU2YN
UT WOS:000573509100004
DA 2025 08 17
ER

PT J
AU Yang, KD
   Pei, L
   Zhou, SM
   Tao, L
   Zhu, Y
AF Yang, Keda
   Pei, Lei
   Zhou, Siming
   Tao, Lin
   Zhu, Yue
TI Metformin attenuates H2O2 induced osteoblast
   apoptosis by regulating SIRT3 via the PI3K/AKT pathway
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE osteoporosis; metformin; mitochondria; SIRT3; PI3K; AKT
ID OSTEOPOROSIS; METABOLISM; INHIBITION; OXIDATION; SIRTUINS; ESTROGEN; P53
AB Osteoporosis is a common metabolic disease that has a high incidence in postmenopausal women. Studies have indicated that oxidative damage plays an important role in the development of postmenopausal osteoporosis. Metformin has been showed to have the ability to relieve excessive oxidation. The aim of the present was to determine the therapeutic effect and potential mechanism of metformin in postmenopausal osteoporosis. Oxidative damage was stimulated in vitro by the addition of H2O2 to MC3T3 E1 cells and a mouse menopausal model was also constructed. Cell viability and flow cytometry experiments were performed to determine the effects of H2O2 and metformin treatment on apoptosis. Mitochondrial membrane potential was tested by JC 1 assays. Western blotting was used to detect the expression of mitochondrial apoptosis markers and antioxidant enzymes. Small interfering RNA was used to knockdown sirtuin3 (SIRT3), which was verified at the mRNA and protein levels. Bilateral ovariectomy was used to prepare menopausal mice, which were analyzed using micro computed tomography. The results indicated that metformin is able to repair mitochondrial damage and inhibit the apoptosis of osteoblasts induced by H2O2, and also reverse bone mass loss in ovariectomized mice. Western blotting results demonstrated the involvement of SIRT3 in the production of antioxidant enzymes that are essential in protecting against mitochondrial injury. In addition, experiments with SIRT3 knockdown indicated that metformin reverses H2O2 induced osteoblast apoptosis by upregulating the expression of SIRT3 via the PI3K/AKT pathway. The results of the present reveal the pathogenesis of oxidative damage and the therapeutic effect of metformin in postmenopausal osteoporosis. They also suggest that SIRT3 is a potential drug target in the treatment of osteoporosis, with metformin being a candidate drug for modification and/or clinical application.
C1 [Yang, Keda; Pei, Lei; Zhou, Siming; Tao, Lin; Zhu, Yue] China Med Univ, Dept Orthoped, Hosp 1, 155 Nanjing North St, Shenyang 110001, Liaoning, Peoples R China.
C3 China Medical University
RP Tao, L; Zhu, Y (通讯作者)，China Med Univ, Dept Orthoped, Hosp 1, 155 Nanjing North St, Shenyang 110001, Liaoning, Peoples R China.
EM taolindr@163.com; zhuyuedr@163.com
RI Lin, Tao/KRO 9146 2024
FU National Natural Science Foundation of China [81472044]; Construction of
   Clinical Medical Research Center of Orthopaedics and Sports
   Rehabilitation Diseases in Liaoning Province [2019416030]
FX The study was supported by the National Natural Science Foundation of
   China (grant no. 81472044), Construction of Clinical Medical Research
   Center of Orthopaedics and Sports Rehabilitation Diseases in Liaoning
   Province (grant no. 2019416030).
CR Chiu HC, 2018, J CACHEXIA SARCOPENI, V9, P585, DOI 10.1002/jcsm.12289
   Dahmani Z, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240982
   Fathi E, 2020, TISSUE CELL, V67, DOI 10.1016/j.tice.2020.101429
   Fathi E, 2020, ADV PHARM BULL, V10, P307, DOI 10.34172/apb.2020.037
   Ghribi O, 2002, J NEUROCHEM, V82, P137, DOI 10.1046/j.1471 4159.2002.00957.x
   Glaser DL, 1997, SPINE, V22, p12S, DOI 10.1097/00007632 199712151 00003
   Govindarajulu M, 2021, NEUROCHEM INT, V144, DOI 10.1016/j.neuint.2021.104958
   Guetta V, 1997, CIRCULATION, V96, P2795, DOI 10.1161/01.CIR.96.9.2795
   Hirschey MD, 2010, NATURE, V464, P121, DOI 10.1038/nature08778
   Houtkooper RH, 2012, NAT REV MOL CELL BIO, V13, P225, DOI 10.1038/nrm3293
   Hu JP, 2021, EXP THER MED, V21, DOI 10.3892/etm.2021.9917
   Jehan S, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.555283
   Jing XZ, 2019, J CELL PHYSIOL, V234, P10123, DOI 10.1002/jcp.27678
   Khaled S, 2020, LIFE SCI, V260, DOI 10.1016/j.lfs.2020.118426
   Kim HS, 2010, CANCER CELL, V17, P41, DOI 10.1016/j.ccr.2009.11.023
   Kim Y, 2021, CANCER IMMUNOL IMMUN, V70, P961, DOI 10.1007/s00262 020 02703 8
   Krishnaswamy VKD, 2020, LIFE SCI, V263, DOI 10.1016/j.lfs.2020.118545
   Kushi LH, 1996, NEW ENGL J MED, V334, P1156, DOI 10.1056/NEJM199605023341803
   Li ML, 2020, REDOX BIOL, V36, DOI 10.1016/j.redox.2020.101632
   Li P, 2021, EXP THER MED, V21, DOI 10.3892/etm.2021.9669
   Liu SW, 2020, NEUROCHEM RES, V45, P2499, DOI 10.1007/s11064 020 03108 w
   Luo XJ, 2021, ANGEW CHEM INT EDIT, V60, P1403, DOI 10.1002/anie.202012237
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Oryan A, 2021, LIFE SCI, V264, DOI 10.1016/j.lfs.2020.118681
   Park JS, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9100978
   Perovic A, 2018, FREE RADICAL RES, V52, P188, DOI 10.1080/10715762.2017.1422211
   Pryor R, 2019, CELL, V178, P1299, DOI 10.1016/j.cell.2019.08.003
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rahimi G, 2021, NUTR METAB, V18, DOI 10.1186/s12986 021 00543 6
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   SACK MN, 1994, LANCET, V343, P269, DOI 10.1016/S0140 6736(94)91117 7
   Saha PC, 2021, BIOCONJUGATE CHEM, V32, P833, DOI 10.1021/acs.bioconjchem.1c00106
   Satapati S, 2015, J CLIN INVEST, V125, P4447, DOI 10.1172/JCI82204
   Schumacker PT, 2010, CANCER CELL, V17, P5, DOI 10.1016/j.ccr.2009.12.032
   Schurman L, 2008, EXP CLIN ENDOCR DIAB, V116, P333, DOI 10.1055/s 2007 992786
   Shen CL, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 29063 9
   Shukla S, 2016, TOXICOL APPL PHARM, V291, P70, DOI 10.1016/j.taap.2015.12.006
   Sies H, 2020, NAT REV MOL CELL BIO, V21, P363, DOI 10.1038/s41580 020 0230 3
   Sim IW, 2020, J CLIN ONCOL, V38, P2971, DOI 10.1200/JCO.19.02192
   Styrkarsdottir U, 2003, PLOS BIOL, V1, P351, DOI 10.1371/journal.pbio.0000069
   Tremblay BP, 2020, NATURE, V579, P348, DOI 10.1038/d41586 020 00552 0
   Vatner SF, 2020, AGEING RES REV, V64, DOI 10.1016/j.arr.2020.101194
   Wang L, 2020, IUBMB LIFE, V72, P749, DOI 10.1002/iub.2174
   Wang Y, 2020, CANCER MANAG RES, V12, P1079, DOI 10.2147/CMAR.S232388
   Yang W, 2016, CELL, V167, P985, DOI 10.1016/j.cell.2016.10.016
   Zhang DY, 2020, REJUV RES, V23, P453, DOI 10.1089/rej.2019.2260
   Zhou QZ, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/7067984
   Zhou W, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/4019619
NR 48
TC 29
Z9 34
U1 3
U2 42
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD NOV
PY 2021
VL 22
IS 5
AR 1316
DI 10.3892/etm.2021.10751
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA WD0WF
UT WOS:000704667300001
PM 34630670
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Chebbi, I
   Migianu Griffoni, E
   Sainte Catherine, O
   Lecouvey, M
   Seksek, O
AF Chebbi, Imene
   Migianu Griffoni, Evelyne
   Sainte Catherine, Odile
   Lecouvey, Marc
   Seksek, Olivier
TI In vitro assessment of liposomal neridronate on MDA MB 231 human
   breast cancer cells
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Bisphosphonates; Neridronate; Liposome; Human breast cancer cells
ID INHIBITS ANGIOGENESIS; DELIVERY SYSTEMS; BISPHOSPHONATES; GROWTH; ACID;
   VIVO; PROLIFERATION; ACTIVATION; MECHANISM; PATHWAY
AB Bisphosphonates have been used for decades in the standard therapy of bone related diseases, including bone metastasis of various malignancies, and they might as well be toxic on early cancer cells themselves. In order to allow a better delivery of neridronate (a N containing bisphosphonate with relatively poor activity), liposomes were evaluated in vitro on cancer cell lines (MDA MB 231, U87 MG and Caco2). After chemical synthesis, this water soluble molecule was encapsulated into liposomes containing DOPC:DOPG:Chol (72:27:1 molar ratio). The influence of neridronate (free or liposomal) on cell viability or proliferation after treatment was evaluated using the MTT method, as well as cell migration and invasion assays; these techniques showed a drastic improvement of the action of neridronate on MDA MB 231 cells with an EC50 50 times lower when neridronate was encapsulated. Internalization of liposomes was followed by flow cytometry and fluorescence microscopy, demonstrating internalization via the endocytic pathway. Furthermore, since overexpression of matrix metalloproteinases (particularly MMP 2 and MMP 9) has been correlated to poor prognosis in many cancer types, detection of MMP expression is a satisfactory indication of the therapy efficiency and was then performed on treated cells. On MDA MB 231 cells, MPPs expression was also significantly reduced by neridronate while entrapped in liposomes. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Chebbi, Imene; Seksek, Olivier] Univ Paris 06, CNRS, ANBioPhy, FRE 3207, Evry, France.
   [Migianu Griffoni, Evelyne; Sainte Catherine, Odile; Lecouvey, Marc] Univ Paris 13, CNRS, Equipe C2B, CSPBAT,FRE 3043, Bobigny, France.
C3 Centre National de la Recherche Scientifique (CNRS); Sorbonne
   Universite; Universite Paris 13; Centre National de la Recherche
   Scientifique (CNRS)
RP Seksek, O (通讯作者)，Univ Paris 06, CNRS, ANBioPhy, FRE 3207, Genopole Campus 1, Evry, France.
EM olivier.seksek@upmc.fr
RI ; Seksek, Olivier/AAO 1837 2020; Lecouvey, Marc/ADO 6272 2022
OI Seksek, Olivier/0000 0002 3053 3022; 
CR Aapro M, 2008, ANN ONCOL, V19, P420, DOI 10.1093/annonc/mdm442
   Arum SM, 2008, CURR OPIN ENDOCRINOL, V15, P508, DOI 10.1097/MED.0b013e3283184017
   Corrado A, 2005, CLIN RHEUMATOL, V24, P527, DOI 10.1007/s10067 005 1100 2
   Denoyelle C, 2003, BRIT J CANCER, V88, P1631, DOI 10.1038/sj.bjc.6600925
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Felnerova D, 2004, CURR OPIN BIOTECH, V15, P518, DOI 10.1016/j.copbio.2004.10.005
   Fenske DB, 2008, EXPERT OPIN DRUG DEL, V5, P25, DOI 10.1517/17425247.5.1.25
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Hamma Kourbali Y, 2003, BIOCHEM BIOPH RES CO, V310, P816, DOI 10.1016/j.bbrc.2003.09.083
   Journé F, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1845
   Kato K, 2005, J CANCER RES CLIN, V131, P340, DOI 10.1007/s00432 004 0654 8
   Kieczykowski GR, 1995, J ORG CHEM, V60, P8310, DOI 10.1021/jo00130a036
   Kleinman H K, 2001, Curr Protoc Cell Biol, VChapter 12, DOI 10.1002/0471143030.cb1202s00
   Layman R, 2007, HEMATOL ONCOL CLIN N, V21, P341, DOI 10.1016/j.hoc.2007.03.004
   Ledoux D, 2006, ANTI CANCER DRUG, V17, P479, DOI 10.1097/01.cad.0000198909.52701.0f
   Liu EB, 2000, CANCER RES, V60, P2361
   Merlotti D, 2007, J BONE MINER RES, V22, P1510, DOI 10.1359/JBMR.070704
   Merrell MA, 2007, EUR J PHARMACOL, V570, P27, DOI 10.1016/j.ejphar.2007.05.075
   Mönkkönen H, 2008, ANTI CANCER DRUG, V19, P391, DOI 10.1097/CAD.0b013e3282f632bf
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Muller S, 2005, ANTICANCER RES, V25, P2655
   Neves M, 2002, NUCL MED BIOL, V29, P329, DOI 10.1016/S0969 8051(01)00305 5
   Nicolin V, 2007, ACTA HISTOCHEM, V109, P397, DOI 10.1016/j.acthis.2007.04.002
   OLSON F, 1979, BIOCHIM BIOPHYS ACTA, V557, P9, DOI 10.1016/0005 2736(79)90085 3
   OROURKE NP, 1994, BRIT J CANCER, V69, P914, DOI 10.1038/bjc.1994.176
   Pittari Gianfranco, 2006, Acta Biomed, V77, P81
   Ribatti D, 2007, CLIN RHEUMATOL, V26, P1094, DOI 10.1007/s10067 006 0455 3
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Samad Abdus, 2007, Current Drug Delivery, V4, P297, DOI 10.2174/156720107782151269
   Seksek Olivier, 2004, Methods Mol Biol, V252, P545
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Shaw NJ, 2005, ARCH DIS CHILD, V90, P494, DOI 10.1136/adc.2003.036590
   Sprague JE, 2006, NUCL MED BIOL, V33, P227, DOI 10.1016/j.nucmedbio.2005.10.011
   Tanvetyanon T, 2006, ANN ONCOL, V17, P897, DOI 10.1093/annonc/mdj105
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   van Rooijen N, 2002, J LIPOSOME RES, V12, P81, DOI 10.1081/LPR 120004780
   van Rooijen N, 2003, METHOD ENZYMOL, V373, P3
   VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83
   Veerareddy PR, 2004, DRUG TODAY, V40, P133, DOI 10.1358/dot.2004.40.2.799425
   Waterhouse Dawn N., 2001, Drug Safety, V24, P903, DOI 10.2165/00002018 200124120 00004
   Wu Shenhong, 2007, Acta Oncol, V46, P581
   Zacharis CK, 2008, J PHARMACEUT BIOMED, V48, P483, DOI 10.1016/j.jpba.2008.05.028
NR 42
TC 22
Z9 27
U1 0
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378 5173
EI 1873 3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD JAN 4
PY 2010
VL 383
IS 1 2
BP 116
EP 122
DI 10.1016/j.ijpharm.2009.09.011
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 533FT
UT WOS:000272809800016
PM 19748562
DA 2025 08 17
ER

PT J
AU Chen, SH
   Lin, SW
   Lin, SR
   Liang, PH
   Yang, JM
AF Chen, Shih Hsun
   Lin, Sheng Wei
   Lin, Shen Rong
   Liang, Po Huang
   Yang, Jinn Moon
TI Moiety Linkage Map Reveals Selective Nonbisphosphonate Inhibitors of
   Human Geranylgeranyl Diphosphate Synthase
SO JOURNAL OF CHEMICAL INFORMATION AND MODELING
LA English
DT Article
ID NITROGEN CONTAINING BISPHOSPHONATES; CHAIN LENGTH DETERMINATION;
   PYROPHOSPHATE SYNTHASE; MOLECULAR DOCKING; CRYSTAL STRUCTURE;
   SACCHAROMYCES CEREVISIAE; ZOLEDRONIC ACID; IN VIVO; MECHANISM;
   BIOSYNTHESIS
AB Bisphosphonates are potent inhibitors of farnesyl pyrophosphate synthase (FPPS) and geranylgeranyl diphosphate synthase (GGPPS). Current bisphosphonate drugs (e.g., Fosamax and Zometa) are highly efficacious in the treatment of bone diseases such as osteoporosis, Paget's disease, and tumor induced osteolysis, but they are often less potent in blood and soft tissue due to their phosphate moieties. The discovery of nonbisphosphonate inhibitors of FPPS and/or GGPPS for the treatment of bone diseases and cancers is, therefore, a current goal. Here, we propose a moiety linkage based method, combining a site moiety map with chemical structure rules. (CSRs), to discover nonbisphosphonate inhibitors from thousands of commercially available compounds and known crystal structures. Our moiety linkage map reveals the binding mechanisms and inhibitory efficacies of 51 human GGPPS (hGGPPS) inhibitors. To the best of our knowledge, we are the first team to discover two novel selective nonbisphosphonate inhibitors, which bind to the inhibitory site of hGGPPS, using CSRs and site moiety maps. These two compounds can be considered as a novel lead for the potent inhibitors of hGGPPS for the treatment of cancers and mevalonate pathway diseases. Moreover, based on our moiety linkage map, we identified two key residues of hGGPPS, K202, and K212, which play an important role for the inhibitory effect of zoledronate (IC50 = 3.4 mu M and 2.4 mu M, respectively). This result suggests that our method can discover specific hGGPPS inhibitors across multiple prenyltransferases. These results show that the compounds that highly fit our moiety linkage map often inhibit hGGPPS activity and induce tumor cell apoptosis. We believe that our method is useful for discovering potential inhibitors and binding mechanisms for pharmaceutical targets.
C1 [Chen, Shih Hsun; Yang, Jinn Moon] Natl Chiao Tung Univ, Dept Biol Sci & Technol, Hsinchu 30050, Taiwan.
   [Lin, Sheng Wei; Liang, Po Huang] Acad Sinica, Inst Biol Chem, Taipei 11529, Taiwan.
   [Lin, Shen Rong; Yang, Jinn Moon] Natl Chiao Tung Univ, Inst Bioinformat & Syst Biol, Hsinchu 30050, Taiwan.
C3 National Yang Ming Chiao Tung University; Academia Sinica   Taiwan;
   National Yang Ming Chiao Tung University
RP Liang, PH (通讯作者)，Acad Sinica, Inst Biol Chem, Taipei 11529, Taiwan.
EM phliang@gate.sinica.edu.tw; moon@faculty.nctu.edu.tw
RI Liang, Po Huang/H 6610 2015; Lin, Sheng Wei/G 8142 2015; Yang,
   Jinn Moon/AAU 4400 2021
OI Liang, Po Huang/0000 0003 1207 5256; Yang,
   Jinn Moon/0000 0002 3205 4391; Lin, Sheng Wei/0000 0001 7777 2090; 
FU National Science Council; Ministry of Education; National Health
   Research Institutes [NHRI EX100 10009PI]
FX The authors are grateful to the Core Facility for Protein Structural
   Analysis supported by the National Core Facility Program for
   Biotechnology. Dr. Yang was supported by the National Science Council
   and partially supported by the Ministry of Education and National Health
   Research Institutes (NHRI EX100 10009PI).
CR ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022 2836(05)80360 2
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Chang KM, 2012, BIOCHEMISTRY US, V51, P3412, DOI 10.1021/bi300069j
   Chang TH, 2006, J BIOL CHEM, V281, P14991, DOI 10.1074/jbc.M512886200
   Chen YF, 2010, NUCLEIC ACIDS RES, V38, pW424, DOI 10.1093/nar/gkq480
   Chin KH, 2010, J MOL BIOL, V396, P646, DOI 10.1016/j.jmb.2009.11.076
   Davignon J, 2005, VASC HEALTH RISK MAN, V1, P29, DOI 10.2147/vhrm.1.1.29.58937
   Docampo Roberto, 2001, Current Drug Targets   Infectious Disorders, V1, P51, DOI 10.2174/1568005013343191
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Ewing TJA, 2001, J COMPUT AID MOL DES, V15, P411, DOI 10.1023/A:1011115820450
   Gabelli SB, 2006, PROTEINS, V62, P80, DOI 10.1002/prot.20754
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Goffinet M, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 60
   Guo RT, 2007, P NATL ACAD SCI USA, V104, P10022, DOI 10.1073/pnas.0702254104
   Guo RT, 2004, J BIOL CHEM, V279, P4903, DOI 10.1074/jbc.M310161200
   Hosfield DJ, 2004, J BIOL CHEM, V279, P8526, DOI 10.1074/jbc.C300511200
   Houten SM, 2003, J BIOL CHEM, V278, P5736, DOI 10.1074/jbc.M206564200
   Hsu KC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032142
   Hsu KC, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471 2105 12 S1 S33
   Hudock M. P., 2008, J MED CHEM, V51, P5594
   Hung HC, 2009, ANTIVIR RES, V81, P123, DOI 10.1016/j.antiviral.2008.10.006
   Jahnke W, 2010, NAT CHEM BIOL, V6, P660, DOI [10.1038/NCHEMBIO.421, 10.1038/nchembio.421]
   JIANG Y, 1995, J BIOL CHEM, V270, P21793, DOI 10.1074/jbc.270.37.21793
   Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kavanagh KL, 2006, J BIOL CHEM, V281, P22004, DOI 10.1074/jbc.M602603200
   Kloer DP, 2006, BIOCHEMISTRY US, V45, P15197, DOI 10.1021/bi061572k
   Kramer B, 1999, PROTEINS, V37, P228, DOI 10.1002/(SICI)1097 0134(19991101)37:2<228::AID PROT8>3.0.CO;2 8
   Liang PH, 2002, EUR J BIOCHEM, V269, P3339, DOI 10.1046/j.1432 1033.2002.03014.x
   Morris GM, 1996, J COMPUT AID MOL DES, V10, P293, DOI 10.1007/BF00124499
   Ogura K, 1998, CHEM REV, V98, P1263, DOI 10.1021/cr9600464
   Olszewski N, 2002, PLANT CELL, V14, pS61, DOI 10.1105/tpc.010476
   Pan JJ, 2000, BIOCHEMISTRY US, V39, P10936, DOI 10.1021/bi000992l
   Pan YP, 2003, J CHEM INF COMP SCI, V43, P267, DOI 10.1021/ci020055f
   POULTER CD, 1976, BIOCHEMISTRY US, V15, P1079, DOI 10.1021/bi00650a019
   RUDIGER W, 1980, EUR J BIOCHEM, V109, P193, DOI 10.1111/j.1432 1033.1980.tb04784.x
   Sacchettini JC, 1997, SCIENCE, V277, P1788, DOI 10.1126/science.277.5333.1788
   Sawatdichaikul O, 2012, J MOL MODEL, V18, P1241, DOI 10.1007/s00894 011 1135 z
   Simoni D, 2008, J MED CHEM, V51, P6800, DOI 10.1021/jm801003y
   Stresing V, 2007, CANCER LETT, V257, P16, DOI 10.1016/j.canlet.2007.07.007
   Sun HY, 2005, J BACTERIOL, V187, P8137, DOI 10.1128/JB.187.23.8137 8148.2005
   Szabo CM, 2002, J MED CHEM, V45, P2185, DOI 10.1021/jm010412y
   Thomsen R, 2006, J MED CHEM, V49, P3315, DOI 10.1021/jm051197e
   Wang RX, 2003, J MED CHEM, V46, P2287, DOI 10.1021/jm0203783
   Yang JM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000428
   Yang JM, 2005, J CHEM INF MODEL, V45, P1134, DOI 10.1021/ci050034w
   Yang JM, 2005, PROTEINS, V59, P205, DOI 10.1002/prot.20387
   Yang JM, 2004, PROTEINS, V55, P288, DOI 10.1002/prot.20035
   Yang L, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002016
   Yang MC, 2008, CRYST GROWTH DES, V8, P4268, DOI 10.1021/cg800697s
   Zhang YH, 2009, J AM CHEM SOC, V131, P5153, DOI 10.1021/ja808285e
NR 51
TC 5
Z9 8
U1 0
U2 18
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1549 9596
EI 1549 960X
J9 J CHEM INF MODEL
JI J. Chem Inf. Model.
PD SEP
PY 2013
VL 53
IS 9
BP 2299
EP 2311
DI 10.1021/ci400227r
PG 13
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Computer Science,
   Information Systems; Computer Science, Interdisciplinary Applications
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Chemistry; Computer Science
GA 295DQ
UT WOS:000330097200009
PM 23919676
DA 2025 08 17
ER

PT J
AU Karsdal, MA
   Henriksen, K
   Arnold, M
   Christiansen, C
AF Karsdal, Morten A.
   Henriksen, Kim
   Arnold, Michel
   Christiansen, Claus
TI Calcitonin   A drug of the past or for the future? Physiologic
   inhibition of bone resorption while sustaining osteoclast numbers
   improves bone quality
SO BIODRUGS
LA English
DT Article
ID VERTEBRAL FRACTURE RISK; SPRAY SALMON CALCITONIN; POSTMENOPAUSAL WOMEN;
   ESTABLISHED OSTEOPOROSIS; MINERAL DENSITY; ALENDRONATE TREATMENT; ORAL
   DELIVERY; ANTIRESORPTIVE THERAPIES; ANTINOCICEPTIVE ACTIVITY;
   BIOCHEMICAL MARKERS
AB Postmenopausal osteoporosis results from a continuous imbalance between bone resorption and bone formation, favoring bone resorption. An increasing, number of treatments for osteoporosis are in development and on the market. A range of differences and similarities are found between these treatment options, and these need to be carefully evaluated before the initiation of treatment. This article summarizes data from in vitro and animal studies, as well as clinical trials, on the effect of calcitonin on bone turnover.
   Calcitonin was found to exert its antiresorptive effects via directly reducing osteoclastic resorption, and thus leads to an increase in bone mineral density and bone strength. Furthermore, calcitonin appears to mainly target the most active osteoclasts, and in contrast to most other antiresorptive agents it does not reduce the number of osteoclasts. Finally, in humans, while attenuating resorption, calcitonin treatment does not interfere markedly with bone formation, in contrast to other currently available antiresorptive agents. Thus, we speculate that calcitonin treatment will lead to a continuously positive bone balance in contrast with other antiresorptive agents currently on the market and thereby, in a physiologic manner, result in improved bone quality.
   Calcitonin is currently only available in injectable and nasal formulations. An oral formulation may, however, improve patient acceptance and compliance. Currently, several different routes are being pursued to identify an optimal oral formulation, of which the technology based on 5 CNAC is the most advanced. There are promising clinical data available for this formulation from both osteoarthritis and osteoporosis clinical trials, although the antifracture efficacy is not yet known.
C1 [Karsdal, Morten A.; Henriksen, Kim; Christiansen, Claus] Nord Biosci AS, Dept Pharmacol, DK 2730 Herlev, Denmark.
   [Arnold, Michel] Novartis, Basel, Switzerland.
C3 Nordic Bioscience
RP Karsdal, MA (通讯作者)，Nord Biosci AS, Dept Pharmacol, Herlev Hovedgade 207, DK 2730 Herlev, Denmark.
EM mk@nordicbioscience.com
OI Karsdal, Morten/0000 0001 5026 8740
CR Azria M, 2002, BONE, V30, p80S
   AZRIA M, 1989, PHYSL PHARMA, P2
   Bagger YZ, 2005, BONE, V37, P425, DOI 10.1016/j.bone.2005.04.032
   Bernkop Schnurch Andreas, 2004, Expert Opin Drug Deliv, V1, P87, DOI 10.1517/17425247.1.1.87
   Bjarnason NH, 2001, OSTEOPOROSIS INT, V12, P922, DOI 10.1007/s001980170020
   Bjarnason NH, 2002, BONE, V30, P307, DOI 10.1016/S8756 3282(01)00662 7
   Blau LA, 2003, ANN PHARMACOTHER, V37, P564, DOI 10.1345/aph.1C350
   BRAGA P, 1978, LIFE SCI, V22, P971, DOI 10.1016/0024 3205(78)90362 4
   BRAGA PC, 1994, AGENTS ACTIONS, V41, P121, DOI 10.1007/BF02001904
   Buclin T, 2002, J BONE MINER RES, V17, P1478, DOI 10.1359/jbmr.2002.17.8.1478
   Byrjalsen I, 2008, OSTEOPOROSIS INT, V19, P339, DOI 10.1007/s00198 007 0462 5
   CHAMBERS TJ, 1983, J CLIN ENDOCR METAB, V57, P819, DOI 10.1210/jcem 57 4 819
   Chesnut CH, 2005, J BONE MINER RES, V20, P1548, DOI 10.1359/JBMR.050411
   Chesnut CH III, 2000, AM J MED, V109, P267, DOI 10.1016/S0002 9343(00)00490 3
   Christgau S, 2000, CLIN CHEM, V46, P431
   COPP DH, 1962, ENDOCRINOLOGY, V70
   Cranney A, 2002, ENDOCR REV, V23, P540, DOI 10.1210/er.2001 6002
   Cummings SR, 2000, AM J MED, V109, P330, DOI 10.1016/S0002 9343(00)00539 8
   Cummings SR, 2002, AM J MED, V112, P281, DOI 10.1016/S0002 9343(01)01124 X
   Deftos LJ., 2006, PRIMER METABOLIC BON, P115
   Dempster DW., 2006, PRIMER METABOLIC BON, V6th, P7
   Durie BGM, 2005, NEW ENGL J MED, V353, P99
   Eastell R., 2006, PRIMER METABOLIC BON, P259
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   Garcia Fuentes M, 2005, INT J PHARMACEUT, V296, P122, DOI 10.1016/j.ijpharm.2004.12.030
   GENNARI C, 1994, BRIT J CLIN PRACT, V48, P196
   Gennari C, 2002, BONE, V30, p67S
   Gertz BJ, 1998, CALCIFIED TISSUE INT, V63, P102, DOI 10.1007/s002239900497
   GONZALEZ D, 1986, CALCIFIED TISSUE INT, V38, P71, DOI 10.1007/BF02556832
   Guggi D, 2003, PHARM RES DORDR, V20, P1989, DOI 10.1023/B:PHAM.0000008047.82334.7d
   Harvey N., 2006, PRIMER, V6, P244
   HATTNER R, 1965, NATURE, V206, P489, DOI 10.1038/206489a0
   HEERSCHE JNM, 1992, BONE MINER, V16, P174, DOI 10.1016/0169 6009(92)90895 K
   Henriksen DB, 2004, BONE, V34, P140, DOI 10.1016/j.bone.2003.09.009
   Henriksen K, 2007, OSTEOPOROSIS INT, V18, P681, DOI 10.1007/s00198 006 0286 8
   Hwang JS, 2006, OSTEOPOROSIS INT, V17, P373, DOI 10.1007/s00198 005 2002 5
   Ikegame M, 2004, BONE, V35, P27, DOI 10.1016/j.bone.2004.03.018
   Jiang YB, 2005, J BONE MINER RES, V20, P125, DOI 10.1359/JBMR.041008
   Kanis JA, 1999, QJM MON J ASSOC PHYS, V92, P143, DOI 10.1093/qjmed/92.3.143
   Karsdal MA, 2006, OSTEOARTHR CARTILAGE, V14, P617, DOI 10.1016/j.joca.2006.03.014
   KARSDAL MA, 2007, J BONE MINER RES  S1, V22, pW478
   KARSDAL MA, 2007, BONEKEY OSTEOVISION, V4, P19
   Karsdal MA, 2007, ANN NY ACAD SCI, V1117, P181, DOI 10.1196/annals.1402.041
   Karsdal MA, 2007, J BONE MINER RES, V22, P487, DOI 10.1359/JBMR.070109
   Karsdal MA, 2006, DRUGS, V66, P1909, DOI 10.2165/00003495 200666150 00002
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Knopp JA, 2005, OSTEOPOROSIS INT, V16, P1281, DOI 10.1007/s00198 004 1798 8
   KUMAR MA, 1963, LANCET, V35, P480
   Kung AWC, 2006, CURR MED RES OPIN, V22, P929, DOI 10.1185/030079906X104768
   Lamprecht A, 2004, J CONTROL RELEASE, V98, P1, DOI 10.1016/j.jconrel.2004.02.001
   Lee YH, 2000, ADV DRUG DELIVER REV, V42, P225, DOI 10.1016/S0169 409X(00)00063 6
   Lyritis G. P., 2001, Journal of Musculoskeletal & Neuronal Interactions, V2, P137
   Lyritis GP, 2002, BONE, V30, p71S
   Malkov Dmitry, 2005, Current Drug Delivery, V2, P191, DOI 10.2174/1567201053586001
   Mancini L, 2007, AM J PATHOL, V170, P1018, DOI 10.2353/ajpath.2007.060830
   Manicourt DH, 2006, ARTHRITIS RHEUM, V54, P3205, DOI 10.1002/art.22075
   MARTIN MI, 1995, GEN PHARMACOL, V26, P641, DOI 10.1016/0306 3623(94)00210 E
   Martin TJ, 2007, CLIN SCI, V112, P77, DOI 10.1042/CS20060046
   Martin TJ., 2001, OSTEOPOROSIS, V1, P361
   McClung Michael R, 2006, Curr Osteoporos Rep, V4, P28, DOI 10.1007/s11914 006 0012 7
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Mehta N. M., 2003, Current Pharmaceutical Design, V9, P2659, DOI 10.2174/1381612033453622
   OVERGAARD K, 1992, BRIT MED J, V305, P556, DOI 10.1136/bmj.305.6853.556
   OVERGAARD K, 1991, CALCIFIED TISSUE INT, V49, pS60, DOI 10.1007/BF02555091
   Plosker GL, 1996, DRUG AGING, V8, P378, DOI 10.2165/00002512 199608050 00006
   Ravn P, 1999, BONE, V24, P237, DOI 10.1016/S8756 3282(98)00183 5
   Ravn P, 1999, J CLIN ENDOCR METAB, V84, P2363, DOI 10.1210/jc.84.7.2363
   RICO H, 1992, BONE MINER, V16, P131, DOI 10.1016/0169 6009(92)90883 F
   RICO H, 1995, CALCIFIED TISSUE INT, V56, P181, DOI 10.1007/BF00298606
   ROHNER J, 1985, CLIN RHEUMATOL, V4, P218, DOI 10.1007/BF02032297
   Sakuma S, 2002, INT J PHARM, V239, P185, DOI 10.1016/S0378 5173(02)00113 8
   Sarkar S, 2002, J BONE MINER RES, V17, P1, DOI 10.1359/jbmr.2002.17.1.1
   SARNSETHSIRI P, 1971, CLIN ORTHOP RELAT R, P301, DOI 10.1097/00003086 197101000 00035
   SCHLEMMER A, 1992, J CLIN ENDOCR METAB, V74, P476, DOI 10.1210/jc.74.3.476
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Sexton PM, 1999, CURR MED CHEM, V6, P1067
   Shareef M Ajmal, 2003, AAPS PharmSci, V5, pE17, DOI 10.1208/ps050217
   Shyu JF, 2007, BONE, V40, P1329, DOI 10.1016/j.bone.2007.01.014
   Silverman SL, 2002, OSTEOPOROSIS INT, V13, P858, DOI 10.1007/s001980200118
   Smoum R, 2006, BIOCONJUGATE CHEM, V17, P1000, DOI 10.1021/bc050357y
   Sondergaard BC, 2006, OSTEOARTHR CARTILAGE, V14, P759, DOI 10.1016/j.joca.2006.01.014
   Sorensen MG, 2007, J BONE MINER METAB, V25, P36, DOI 10.1007/s00774 006 0725 9
   Streubel Alexander, 2006, Expert Opin Drug Deliv, V3, P217, DOI 10.1517/17425247.3.2.217
   Suzuki H, 1996, ENDOCRINOLOGY, V137, P4685, DOI 10.1210/en.137.11.4685
   TAKAHASHI H, 1964, Surg Forum, V15, P437
   Tankó LB, 2004, J BONE MINER RES, V19, P1531, DOI 10.1359/JBMR.040715
   Torres Lugo M, 2000, BIOMATERIALS, V21, P1191, DOI 10.1016/S0142 9612(00)00011 9
   Trovas GP, 2002, J BONE MINER RES, V17, P521, DOI 10.1359/jbmr.2002.17.3.521
   Väänänen K, 2005, ADV DRUG DELIVER REV, V57, P959, DOI 10.1016/j.addr.2004.12.018
   van Laere M, 1992, Acta Orthop Belg, V58 Suppl 1, P259
   VANDEN MG, 2006, EXPERT OPIN DRUG DEL, V3, P111
   Wallach S, 1999, BONE, V25, P509, DOI 10.1016/S8756 3282(99)00200 8
   Wang J, 2003, J CONTROL RELEASE, V88, P369, DOI 10.1016/S0168 3659(03)00008 7
   Watts NB, 2004, J CLIN DENSITOM, V7, P255, DOI 10.1385/JCD:7:3:255
   WELCH SP, 1986, J PHARMACOL EXP THER, V237, P54
   YAMAMOTO M, 1982, PHARMACOLOGY, V24, P337, DOI 10.1159/000137616
   Zaidi M, 2002, BONE, V30, P655, DOI 10.1016/S8756 3282(02)00688 9
NR 97
TC 63
Z9 74
U1 0
U2 6
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1173 8804
EI 1179 190X
J9 BIODRUGS
JI Biodrugs
PY 2008
VL 22
IS 3
BP 137
EP 144
DI 10.2165/00063030 200822030 00001
PG 8
WC Oncology; Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Immunology; Pharmacology & Pharmacy
GA 313RI
UT WOS:000256757300001
PM 18481897
DA 2025 08 17
ER

PT J
AU Rao, SH
   Evans, KD
   Oberbauer, AM
   Martin, RB
AF Rao, S. H.
   Evans, K. D.
   Oberbauer, A. M.
   Martin, R. B.
TI Bisphosphonate treatment in the oim mouse model alters bone
   modeling during growth
SO JOURNAL OF BIOMECHANICS
LA English
DT Article
DE Osteogenesis imperfecta; Bisphosphonate; Pamic ronate; Oim mouse; Bone
ID NITROGEN CONTAINING BISPHOSPHONATES; INTRAVENOUS PAMIDRONATE TREATMENT;
   SEVERE OSTEOGENESIS IMPERFECTA; ALENDRONATE TREATMENT; IN VITRO;
   CHILDREN; MECHANISMS; MICE; DISCONTINUATION; MACROPHAGES
AB Osteogenesis imperfecta (OI) is a heritable disease, which results from an abnormal amount Or Structure of Type I collagen. Bisphosphonates, a class of synthetic antiresorptive drugs. Used in osteoporosis management, are also used to decrease fracture incidence and improve quality of life in children with OI. In this study, we used the Oim mouse to test the hypotheses that pamidronate treatment during active growth (1) produces larger, stronger, stiffer long bone diaphyses without altering bone material properties, and (2) negatively impacts longitudinal bone growth. Our results indicate that femoral cross sectional moment of inertia in the distal metaphysis tended to increase with pamidronate treatment and that the treated bones are thicker and structurally stiffer. but shorter than their control dose counterparts. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Rao, S. H.; Martin, R. B.] Univ Calif Davis, Med Ctr, Orthopaed Res Labs, Sacramento, CA 95817 USA.
   [Evans, K. D.; Oberbauer, A. M.] Univ Calif Davis, Dept Anim Sci, Davis, CA 95616 USA.
C3 University of California System; University of California Davis;
   University of California System; University of California Davis
EM sheilahrao@gmail.com
FU NIH [AR4720501]
FX The authors wish to acknowledge NIH grant AR4720501 for funding this
   research.
CR ALMAN B, 1987, J ORTHOP RES, V5, P139, DOI 10.1002/jor.1100050118
   Åström E, 2002, ARCH DIS CHILD, V86, P356, DOI 10.1136/adc.86.5.356
   Bagi CM, 2006, BONE, V38, P136, DOI 10.1016/j.bone.2005.07.028
   Bembi B, 1997, J PEDIATR US, V131, P622, DOI 10.1016/S0022 3476(97)70074 X
   BURR DB, 1995, BONE, V17, P431, DOI 10.1016/S8756 3282(95)00241 3
   Byers Peter H., 1993, P317
   Camacho NP, 1999, J BONE MINER RES, V14, P264, DOI 10.1359/jbmr.1999.14.2.264
   Camacho NP, 2001, CALCIFIED TISSUE INT, V69, P94, DOI 10.1007/s002230010045
   Chevrel G, 2001, JOINT BONE SPINE, V68, P125, DOI 10.1016/S1297 319X(01)00256 1
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Fratzl P, 1996, J CLIN INVEST, V97, P396, DOI 10.1172/JCI118428
   Frith JC, 2003, J BONE MINER RES, V18, P204, DOI 10.1359/jbmr.2003.18.2.204
   Garn S., 1970, EARLIER GAIN LATER L
   Glorieux FH, 1998, NEW ENGL J MED, V339, P947, DOI 10.1056/NEJM199810013391402
   Land C, 2006, J BONE MINER RES, V21, P374, DOI 10.1359/JBMR.051207
   LANDMAN JO, 1995, J CLIN ENDOCR METAB, V80, P3465, DOI 10.1210/jc.80.12.3465
   LandsmeerBeker EA, 1997, EUR J PEDIATR, V156, P792, DOI 10.1007/s004310050715
   Licata AA, 2005, ANN PHARMACOTHER, V39, P668, DOI 10.1345/aph.1E357
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   LIN JH, 1992, DRUG METAB DISPOS, V20, P473
   Lindsay R, 2002, J CLIN INVEST, V110, P1239, DOI 10.1172/JCI200217051
   Lopez M. J., 2000, MECH TESTING BONE BO, P207
   Martin R. B., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P209
   McBride DJ, 1998, CALCIFIED TISSUE INT, V62, P172, DOI 10.1007/s002239900412
   McCarthy EA, 2002, PEDIATR RES, V52, P660, DOI 10.1203/01.PDR.0000032068.76811.0D
   Miller E, 2007, CALCIFIED TISSUE INT, V81, P206, DOI 10.1007/s00223 007 9045 x
   Misof BM, 2005, BONE, V36, P150, DOI 10.1016/j.bone.2004.10.006
   Paterson CR, 1997, BAILLIERE CLIN ENDOC, V11, P195, DOI 10.1016/S0950 351X(97)80601 5
   Plotkin H, 2000, J CLIN ENDOCR METAB, V85, P1846, DOI 10.1210/jc.85.5.1846
   POMP D, 1991, MOUSE GENOME, V89, P279
   Primorac D, 2001, CROAT MED J, V42, P393
   Rauch F, 2003, J CLIN ENDOCR METAB, V88, P986, DOI 10.1210/jc.2002 021371
   Rauch F, 2007, BONE, V40, P821, DOI 10.1016/j.bone.2006.11.020
   Rogers MJ, 2004, CALCIFIED TISSUE INT, V75, P451, DOI 10.1007/s00223 004 0024 1
   Saban J, 1996, BONE, V19, P575, DOI 10.1016/S8756 3282(96)00305 5
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   SHOENFELD Y, 1975, AM J DIS CHILD, V129, P679, DOI 10.1001/archpedi.1975.02120430019007
   SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101
   Sims NA, 2006, AM J PHYSIOL ENDOC M, V290, pE456, DOI 10.1152/ajpendo.00311.2005
   Syed F, 2005, BIOCHEM BIOPH RES CO, V328, P688, DOI 10.1016/j.bbrc.2004.11.097
   van Beek ER, 2003, BONE, V33, P805, DOI 10.1016/j.bone.2003.07.007
   Wang XD, 2000, CLIN ORTHOP RELAT R, P228
NR 42
TC 27
Z9 35
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0021 9290
EI 1873 2380
J9 J BIOMECH
JI J. Biomech.
PD DEC 5
PY 2008
VL 41
IS 16
BP 3371
EP 3376
DI 10.1016/j.jbiomech.2008.09.028
PG 6
WC Biophysics; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Engineering
GA 387PY
UT WOS:000261965300012
PM 19022450
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Jin, P
   Wu, HY
   Xu, GJ
   Zheng, L
   Zhao, JM
AF Jin, Pan
   Wu, Huayu
   Xu, Guojie
   Zheng, Li
   Zhao, Jinmin
TI 被撤回的出版物: Epigallocatechin 3 gallate (EGCG) as a pro osteogenic agent to
   enhance osteogenic differentiation of mesenchymal stem cells from human
   bone marrow: an in vitro study (Retracted Article)
SO CELL AND TISSUE RESEARCH
LA English
DT Article; Retracted Publication
DE Epigallocatechin 3 gallate; Green tea; Human bone marrow; Mesenchymal
   stem cells; Osteoporosis; Osteogenic inducer
ID POLYPHENOL ( ) EPIGALLOCATECHIN GALLATE; INDUCED OXIDATIVE STRESS;
   MINERAL DENSITY; MORPHOGENETIC PROTEIN 2; HIP FRACTURE; RISK FACTORS;
   OSTEOBLASTS; WOMEN; TRANSCRIPTION; OSTEOPOROSIS
AB The proliferation and osteogenic capacity of mesenchymal stem cells (MSCs) needs to be improved for their use in cell based therapy for osteoporosis. ( ) Epigallocatechin 3 gallate (EGCG), one of the green tea catechins, has been widely investigated in studies of osteoblasts and osteoclasts. However, no consensus on its role as an osteogenic inducer has been reached, possibly because of the various types of cell lines examined and the range of concentrations of EGCG used. In this study, the osteogenic effects of EGCG are studied in primary human bone marrow derived MSCs (hBMSCs) by detecting cell proliferation, alkaline phosphatase (ALP) activity and the expression of relevant osteogenic markers. Our results show that EGCG has a strong stimulatory effect on hBMSCs developing towards the osteogenic lineage, especially at a concentration of 5 mu M, as evidenced by an increased ALP activity, the up regulated expression of osteogenic genes and the formation of bone like nodules. Further exploration has indicated that EGCG directes osteogenic differentiation via the continuous up regulation of Runx2. The underlying mechanism might involve EGCG affects on osteogenic differentiation through the modulation of bone morphogenetic protein 2 expression. EGCG has also been found to promote the proliferation of hBMSCs in a dose dependent manner. This might be associated with its antioxidative effect leading to favorable amounts of reactive oxygen species in the cellular environment. Our study thus indicates that EGCG can be used as a pro osteogenic agent for the stem cell based therapy of osteoporosis.
C1 [Jin, Pan; Xu, Guojie; Zhao, Jinmin] Guangxi Med Univ, Affiliated Hosp 1, Dept Orthopaed Trauma & Hand Surg, Nanning 530021, Guangxi, Peoples R China.
   [Wu, Huayu] Guangxi Med Univ, Dept Cell Biol & Genet, Sch Premed Sci, Nanning 530021, Guangxi, Peoples R China.
   [Zheng, Li] Guangxi Med Univ, Med & Sci Res Ctr, Nanning 530021, Guangxi, Peoples R China.
   [Jin, Pan; Xu, Guojie; Zhao, Jinmin] Guangxi Med Univ, Res Ctr Regenerat Med, Nanning 530021, Guangxi, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University; Guangxi Medical
   University; Guangxi Medical University
RP Zhao, JM (通讯作者)，Guangxi Med Univ, Affiliated Hosp 1, Dept Orthopaed Trauma & Hand Surg, Nanning 530021, Guangxi, Peoples R China.
EM zhengli224@163.com; zhaojinmin@126.com
RI ; Jin, Pan/W 6434 2019; zhao, jin/LBH 0351 2024
OI Zhao, Jinmin/0000 0002 1047 8820; 
FU National Science & Technology Pillar Program of China [2012BAI42G00];
   National Natural Science Foundation of China [81101156]; Guangxi Natural
   Science Foundation Program of China [2013GXNSFAA019246]
FX This work was financially supported by the National Science & Technology
   Pillar Program of China (grant no. 2012BAI42G00), the National Natural
   Science Foundation of China (grant no. 81101156) and the Guangxi Natural
   Science Foundation Program of China (grant no. 2013GXNSFAA019246).
CR Aubin J E, 2001, Rev Endocr Metab Disord, V2, P81, DOI 10.1023/A:1010011209064
   Aubin JE, 1998, BIOCHEM CELL BIOL, V76, P899, DOI 10.1139/bcb 76 6 899
   Benisch P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045142
   Caplan AI, 2007, J CELL PHYSIOL, V213, P341, DOI 10.1002/jcp.21200
   Chen CH, 2005, OSTEOPOROSIS INT, V16, P2039, DOI 10.1007/s00198 005 1995 0
   Chen Z, 2003, AM J EPIDEMIOL, V158, P772, DOI 10.1093/aje/kwg214
   Cobb J, 2006, P NATL ACAD SCI USA, V103, P4511, DOI 10.1073/pnas.0510544103
   Devine A, 2007, AM J CLIN NUTR, V86, P1243, DOI 10.1093/ajcn/86.4.1243
   Fehrer C, 2005, EXP GERONTOL, V40, P926, DOI 10.1016/j.exger.2005.07.006
   Gangji V, 2004, J BONE JOINT SURG AM, V86A, P1153, DOI 10.2106/00004623 200406000 00006
   Han DW, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/850684
   Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577
   Harborne JB, 2000, PHYTOCHEMISTRY, V55, P481, DOI 10.1016/S0031 9422(00)00235 1
   HARRIS SE, 1994, J BONE MINER RES, V9, P855
   Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580
   Hoover PA, 1996, CAN J PHYSIOL PHARM, V74, P911, DOI 10.1139/cjpp 74 8 911
   Javed A, 2001, MOL CELL BIOL, V21, P2891, DOI 10.1128/MCB.21.8.2891 2905.2001
   JOHNELL O, 1995, J BONE MINER RES, V10, P1802, DOI 10.1002/jbmr.5650101125
   Juffroy O, 2009, DIFFERENTIATION, V78, P223, DOI 10.1016/j.diff.2009.07.005
   Kamon M, 2010, CELL BIOL INT, V34, P109, DOI 10.1042/CBI20090011
   Kanis J, 1999, OSTEOPOROSIS INT, V9, P45, DOI 10.1007/s001980050115
   Kastrinaki MC, 2008, TISSUE ENG PART C ME, V14, P333, DOI 10.1089/ten.tec.2008.0173
   Lee SH, 2012, CALCIFIED TISSUE INT, V90, P404, DOI 10.1007/s00223 012 9584 7
   Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052
   Mauney JR, 2005, TISSUE ENG, V11, P787, DOI 10.1089/ten.2005.11.787
   Muraki S, 2007, J ORTHOP SCI, V12, P317, DOI 10.1007/s00776 007 1143 0
   Na K, 2007, BIOMATERIALS, V28, P2631, DOI 10.1016/j.biomaterials.2007.02.008
   Nakagawa H, 2002, BIOCHEM BIOPH RES CO, V292, P94, DOI 10.1006/bbrc.2002.6622
   Nishimura R, 2002, BONE, V31, P303, DOI 10.1016/S8756 3282(02)00826 8
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   REDDI AH, 1994, CURR OPIN GENET DEV, V4, P737, DOI 10.1016/0959 437X(94)90141 O
   Rodriguez RM, 2011, REVIEW, P98
   Schroeder Tania M., 2005, Birth Defects Research, V75, P213, DOI 10.1002/bdrc.20043
   Sugisawa A, 2002, J NUTR, V132, P1836, DOI 10.1093/jn/132.7.1836
   Tielens S, 2008, IN VITRO CELL DEV AN, V44, P368, DOI 10.1007/s11626 008 9126 9
   Vacanti V, 2005, J CELL PHYSIOL, V205, P194, DOI 10.1002/jcp.20376
   Vali B, 2007, J NUTR BIOCHEM, V18, P341, DOI 10.1016/j.jnutbio.2006.06.005
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   WOZNEY JM, 1992, MOL REPROD DEV, V32, P160, DOI 10.1002/mrd.1080320212
   Wu CH, 2002, ARCH INTERN MED, V162, P1001, DOI 10.1001/archinte.162.9.1001
   Yagi H, 2013, J CELL BIOCHEM, V114, P1163, DOI 10.1002/jcb.24459
   YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681
   Yang CH, 2009, CHINESE J PHYSIOL, V52, P151, DOI 10.4077/CJP.2009.AMH022
   Yun JH, 2004, J PERIODONTAL RES, V39, P300, DOI 10.1111/j.1600 0765.2004.00743.x
   zur Nieden NI, 2003, DIFFERENTIATION, V71, P18, DOI 10.1046/j.1432 0436.2003.700602.x
NR 45
TC 72
Z9 77
U1 0
U2 54
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0302 766X
EI 1432 0878
J9 CELL TISSUE RES
JI Cell Tissue Res.
PD MAY
PY 2014
VL 356
IS 2
BP 381
EP 390
DI 10.1007/s00441 014 1797 9
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA AG8LB
UT WOS:000335668800010
PM 24682582
DA 2025 08 17
ER

PT J
AU Xu, W
   Neill, T
   Yang, Y
   Hu, Z
   Cleveland, E
   Wu, Y
   Hutten, R
   Xiao, X
   Stock, SR
   Shevrin, D
   Kaul, K
   Brendler, C
   Iozzo Renato, V
   Seth, P
AF Xu, W.
   Neill, T.
   Yang, Y.
   Hu, Z.
   Cleveland, E.
   Wu, Y.
   Hutten, R.
   Xiao, X.
   Stock, S. R.
   Shevrin, D.
   Kaul, K.
   Brendler, C.
   Iozzo Renato, V.
   Seth, P.
TI The systemic delivery of an oncolytic adenovirus expressing decorin
   inhibits bone metastasis in a mouse model of human prostate cancer
SO GENE THERAPY
LA English
DT Article
ID SKELETAL RELATED EVENTS; BETA RECEPTOR II; MET; SUPPRESSION; ACTIVATION;
   MITOPHAGY; THERAPY; DISEASE; MATRIX; CELLS
AB In an effort to develop a new therapy for prostate cancer (PCa) bone metastases, we have created Ad.dcn, a recombinant oncolytic adenovirus carrying the human decorin gene. Infection of PC 3 and DU 145, the human prostate tumor cells, with Ad.dcn or a non replicating adenovirus Ad(E1 ).dcn resulted in decorin expression; Ad.dcn produced high viral titers and cytotoxicity in human prostate tumor cells. Adenoviral mediated decorin expression inhibited Met, the Wnt/beta catenin signaling axis, vascular endothelial growth factor A, reduced mitochondrial DNA levels and inhibited tumor cell migration. To examine the antitumor response of Ad. dcn, PC 3 luc cells were inoculated in the left heart ventricle to establish bone metastases in nude mice. Ad.dcn, in conjunction with control replicating and non replicating vectors were injected via tail vein. The real time monitoring of mice, once a week, by bioluminescence imaging and X ray radiography showed that Ad.dcn produced significant inhibition of skeletal metastases. Analyses of the mice at the terminal time point indicated a significant reduction in the tumor burden, osteoclast number, serum tartrate resistant acid phosphatase 5b levels, osteocalcin levels, hypercalcemia, inhibition of cancer cachexia and an increase in the animal survival. Based on these studies, we believe that Ad.dcn can be developed as a potential new therapy for PCa bone metastasis.
C1 [Xu, W.; Yang, Y.; Seth, P.] Univ Chicago, NorthShore Res Inst, Dept Med, Gene Therapy Program, Evanston, IL 60201 USA.
   [Neill, T.; Iozzo Renato, V.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA.
   [Neill, T.; Iozzo Renato, V.] Thomas Jefferson Univ, Kimmel Canc Ctr, Canc Cell Biol & Signaling Program, Philadelphia, PA 19107 USA.
   [Hu, Z.] Natl Inst Food & Drug Control, Div In Vitro Diagnost Reagents 1, Beijing, Peoples R China.
   [Cleveland, E.; Kaul, K.] NorthShore Res Inst, Dept Pathol, Evanston, IL USA.
   [Wu, Y.] NorthShore Res Inst, Dept Radiol, Image Proc Lab, Evanston, IL USA.
   [Hutten, R.] Argonne Natl Lab, Adv Photon Source, Lemont, IL USA.
   [Stock, S. R.] Northwestern Univ, Dept Cell & Mol Biol, Chicago, IL 60611 USA.
   [Shevrin, D.] NorthShore Res Inst, Dept Med, Evanston, IL USA.
   [Brendler, C.] NorthShore Univ HealthSytem, Dept Surg, Evanston, IL USA.
C3 NorthShore University Health System; University of Chicago; Thomas
   Jefferson University; Thomas Jefferson University; National Institute of
   Food & Drug Control   China; NorthShore University Health System;
   NorthShore University Health System; United States Department of Energy
   (DOE); Argonne National Laboratory; Northwestern University; NorthShore
   University Health System
RP Seth, P (通讯作者)，Univ Chicago, Evanston Hosp, NorthShore Res Inst, Gene Therapy Program,Dept Med, 2650 Ridge Ave,Room B 652, Evanston, IL 60201 USA.
EM pseth@northshore.org
RI ; Iozzo, Renato/AAS 1980 2020
OI Stock, Stuart R./0000 0002 8886 4035; Iozzo, Renato/0000 0002 5908 5112
FU National Institutes of Health [R01CA12738, R01CA39481]; John and Carol
   Walter Center for Urological Health, NorthShore University HealthSystem;
   US Department of Energy, Office of Science, Office of Basic Energy
   Sciences [DE AC02 06CH11357]
FX The work was funded in part by the National Institutes of Health grant #
   R01CA12738 (PS), grant # R01CA39481 (RVI), and philanthropic support
   through John and Carol Walter Center for Urological Health, NorthShore
   University HealthSystem. Use of the Advanced Photon Source was supported
   by the US Department of Energy, Office of Science, Office of Basic
   Energy Sciences, under Contract No. DE AC02 06CH11357. We are thankful
   to Janardan Khandekar, Theodore Mazzone, Bruce Brockstein and Michael
   Caplan for their continuous support.
CR Aftab DT, 2011, CLIN TRANSL ONCOL, V13, P703, DOI 10.1007/s12094 011 0719 5
   Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373
   Buraschi Simone, 2010, J Biol Chem, V285, P42075, DOI 10.1074/jbc.M110.172841
   Camacho DF, 2014, CANCER METAST REV, V33, P545, DOI 10.1007/s10555 013 9476 y
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Choi IK, 2013, CANCER GENE THER, V20, P70, DOI 10.1038/cgt.2012.95
   Choi IK, 2010, GENE THER, V17, P190, DOI 10.1038/gt.2009.142
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Cook LM, 2014, CANCER METAST REV, V33, P511, DOI 10.1007/s10555 014 9494 4
   Cory G, 2011, METHODS MOL BIOL, V769, P25, DOI 10.1007/978 1 61779 207 6_2
   Dagda RK, 2009, J BIOL CHEM, V284, P13843, DOI 10.1074/jbc.M808515200
   Deng XY, 2014, CANCER TREAT REV, V40, P730, DOI 10.1016/j.ctrv.2014.04.003
   Edwards IJ, 2012, NAT REV UROL, V9, P196, DOI 10.1038/nrurol.2012.19
   Feugaing DDS, 2013, EUR J CELL BIOL, V92, P1, DOI 10.1016/j.ejcb.2012.08.004
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Gartrell BA, 2014, NAT REV CLIN ONCOL, V11, P335, DOI 10.1038/nrclinonc.2014.70
   Goldoni S, 2008, AM J PATHOL, V173, P844, DOI 10.2353/ajpath.2008.080275
   Goldoni S, 2009, J CELL BIOL, V185, P743, DOI 10.1083/jcb.200901129
   Guise T, 2010, SEMIN ONCOL, V37, pS2, DOI 10.1053/j.seminoncol.2010.10.007
   Henke A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042516
   Hu Z, 2010, CANCER GENE THER, V17, P235, DOI 10.1038/cgt.2009.72
   Hu ZB, 2012, HUM GENE THER, V23, P871, DOI 10.1089/hum.2012.040
   Hu ZB, 2011, MOL THER, V19, P1609, DOI 10.1038/mt.2011.114
   Hu ZB, 2010, HUM GENE THER, V21, P1623, DOI 10.1089/hum.2010.018
   Katayose D, 1995, CLIN CANCER RES, V1, P889
   Kypta RM, 2012, NAT REV UROL, V9, P418, DOI 10.1038/nrurol.2012.116
   Lee RJ, 2013, CANCER J, V19, P90, DOI 10.1097/PPO.0b013e318281e280
   Li X, 2008, BLOOD, V112, P159, DOI 10.1182/blood 2007 11 124164
   Li X, 2012, J BONE MINER RES, V27, P1635, DOI 10.1002/jbmr.1620
   Lipton A, 2012, EXPERT REV CLIN PHAR, V5, P359, DOI [10.1586/ecp.12.35, 10.1586/ECP.12.35]
   Ma YT, 2013, IMMUNITY, V39, P211, DOI 10.1016/j.immuni.2013.07.017
   Munesue S, 2007, J BIOL CHEM, V282, P28164, DOI 10.1074/jbc.M609812200
   Neill T, 2014, J BIOL CHEM, V289, P4952, DOI 10.1074/jbc.M113.512566
   Neill T, 2012, AM J PATHOL, V181, P380, DOI 10.1016/j.ajpath.2012.04.029
   Neill T, 2012, J BIOL CHEM, V287, P5492, DOI 10.1074/jbc.M111.283499
   Reed CC, 2002, ONCOGENE, V21, P3688, DOI 10.1038/sj.onc.1205470
   Schenk E, 2010, HUM GENE THER, V21, P807, DOI 10.1089/hum.2009.206
   Schneider A, 2005, ENDOCRINOLOGY, V146, P1727, DOI 10.1210/en.2004 1211
   Seth P., 1999, ADENOVIRUSES BASIC B
   Seth P, 2006, HUM GENE THER, V17, P1152, DOI 10.1089/hum.2006.17.1152
   Sturge J, 2011, NAT REV CLIN ONCOL, V8, P357, DOI 10.1038/nrclinonc.2011.67
   Suzman DL, 2014, CANCER METAST REV, V33, P619, DOI 10.1007/s10555 013 9480 2
   Varkaris A, 2011, EXPERT OPIN INV DRUG, V20, P1677, DOI 10.1517/13543784.2011.631523
   Wang YX, 2001, REV SCI INSTRUM, V72, P2062, DOI 10.1063/1.1355270
   Xu WD, 2014, MOL THER, V22, P1504, DOI 10.1038/mt.2014.80
   Yamamoto M, 2010, MOL THER, V18, P243, DOI 10.1038/mt.2009.266
   Zeng YP, 2006, CANCER RES, V66, P9566, DOI 10.1158/0008 5472.CAN 06 1488
   Zhang Z, 2012, CANCER GENE THER, V19, P630, DOI 10.1038/cgt.2012.41
   Zhang ZW, 2011, HUM GENE THER, V22, P1137, DOI 10.1089/hum.2011.003
NR 49
TC 75
Z9 83
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969 7128
EI 1476 5462
J9 GENE THER
JI Gene Ther.
PD MAR
PY 2015
VL 22
IS 3
BP 247
EP 256
DI 10.1038/gt.2014.110
PG 10
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Research & Experimental Medicine
GA CE9QX
UT WOS:000352179600004
PM 25503693
OA Bronze, Green Accepted, Green Submitted
DA 2025 08 17
ER

PT J
AU Liedtke, RK
AF Liedtke, Rainer K.
TI A Model on the Induction of Adverse Vascular Long Term Effects of NSAIDs
SO MEDICINAL CHEMISTRY
LA English
DT Article
DE NSAID; metastatic calcification; arteriosclerosis; hypertension; chronic
   kidney disease; biochemical model
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; BONE LIKE APATITE; SELECTIVE
   CYCLOOXYGENASE 2 INHIBITORS; CORONARY ARTERY CALCIFICATION; ASPIRIN
   INDUCES APOPTOSIS; STAGE RENAL DISEASE; LOW DOSE ASPIRIN;
   PLASMA MEMBRANE; IN VITRO; HEMODIALYSIS PATIENTS
AB The causes of increased rates of myocardial infarctions and strokes by application of non steroidal anti inflammatory agents ( NSAIDs) are unclear. Here we present a biochemical model that the long term vascular effects of NSAIDs can be consequences of their antiproliferative cellular mechanism. The analysis of the model suggests that the in tramitochondrial uncoupling of oxidative phosphorylation induced by NSAIDs increases, through a reduced activity of ATP dependent ionic pumps, the intra cellular calcium x phosphate product with a consecutively increased formation and export of various calcium phosphate compounds. The latter cause, by chemical replication mechanisms of arterial hydroxyapatite deposits, a metatstatic calcifying vascular process. This sclerogenic vascular mineralization corresponds to an early arteriosclerotic development resembling the Monckeberg's media calcification. The mechanism shows direct analogies to the accelerated and metastatic calcification of coronary arteries seen in chronic kidney disease and dialysis. This appears an extra cellular time lapse version of the protracted cell model. The induction of this degenerative mechanism may explain the increased number of adverse cardiovascular, renovascular and cerebrovascular effects of NSAIDs as they are observed in long term therapies.
C1 [Liedtke, Rainer K.] Pharmed Inst Cybernet, Munich, Germany.
RP Liedtke, RK (通讯作者)，Pharmed, POB 1306, D 82031 Grunwald Munich, Germany.
EM liedtke@pharmed.de
CR Bellinghieri G, 2007, EXPERT OPIN EMERG DR, V12, P355, DOI 10.1517/14728214.12.3.355
   Block GA, 2007, KIDNEY INT, V71, P438, DOI 10.1038/sj.ki.5002059
   Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176
   Block GA, 2005, KIDNEY INT, V68, P1815, DOI 10.1111/j.1523 1755.2005.00600.x
   Bolland MJ, 2008, BMJ BRIT MED J, V336, P262, DOI 10.1136/bmj.39440.525752.BE
   Chertow GM, 2004, NEPHROL DIAL TRANSPL, V19, P1489, DOI 10.1093/ndt/gfh125
   Cozzolino M, 2007, EXPERT OPIN EMERG DR, V12, P341, DOI 10.1517/14728214.12.3.341
   Dedier J, 2002, HYPERTENSION, V40, P604, DOI 10.1161/01.HYP.0000035856.77718.DA
   Dikshit P, 2006, J BIOL CHEM, V281, P29228, DOI 10.1074/jbc.M602629200
   Duchen MR, 2000, J PHYSIOL LONDON, V529, P57, DOI 10.1111/j.1469 7793.2000.00057.x
   Ferramosca E, 2005, AM HEART J, V149, P820, DOI 10.1016/j.ahj.2004.07.023
   Forman JP, 2007, ARCH INTERN MED, V167, P394, DOI 10.1001/archinte.167.4.394
   Forman JP, 2005, HYPERTENSION, V46, P500, DOI 10.1161/01.HYP.0000177437.07240.70
   Gislason GH, 2006, CIRCULATION, V113, P2906, DOI 10.1161/CIRCULATIONAHA.106.616219
   Gross ML, 2007, CLIN J AM SOC NEPHRO, V2, P121, DOI 10.2215/CJN.01760506
   Gu YW, 2004, BIOMATERIALS, V25, P4127, DOI 10.1016/j.biomaterials.2003.11.030
   Hanahisa Y, 2001, INT J MOL MED, V7, P407
   Hart RG, 2000, ARCH NEUROL CHICAGO, V57, P326, DOI 10.1001/archneur.57.3.326
   He G, 2003, NAT MATER, V2, P552, DOI 10.1038/nmat945
   He J, 1998, JAMA J AM MED ASSOC, V280, P1930, DOI 10.1001/jama.280.22.1930
   Heindl B, 2001, N S ARCH PHARMACOL, V363, P233, DOI 10.1007/s002100000349
   Honda Y, 2007, J BIOMED MATER RES B, V80B, P281, DOI 10.1002/jbm.b.30595
   Ifrim Silvi, 2004, Rom J Intern Med, V42, P343
   Jiang HD, 2005, J BIOL CHEM, V280, P42061, DOI 10.1074/jbc.M412280200
   Johnson AJ, 2002, BIOCHEM J, V366, P831, DOI 10.1042/BJ20020279
   Kearney PM, 2006, BMJ BRIT MED J, V332, P1302, DOI 10.1136/bmj.332.7553.1302
   Kikuchi M, 2001, BIOMATERIALS, V22, P1705, DOI 10.1016/S0142 9612(00)00305 7
   Kim HM, 2004, J ROY SOC INTERFACE, V1, P17, DOI 10.1098/rsif.2004.0003
   KIM KM, 1984, IN VITRO SCAN ELECT, P1809
   Krause MM, 2003, ARTHRITIS RHEUM, V48, P1438, DOI 10.1002/art.10969
   Kronmal RA, 1998, STROKE, V29, P887, DOI 10.1161/01.STR.29.5.887
   London GM, 2003, NEPHROL DIAL TRANSPL, V18, P1731, DOI 10.1093/ndt/gfg414
   MANSON JE, 1990, AM J MED, V89, P772, DOI 10.1016/0002 9343(90)90220 8
   MARTENS ME, 1984, BIOCHEM PHARMACOL, V33, P2869, DOI 10.1016/0006 2952(84)90209 0
   McGettigan P, 2006, JAMA J AM MED ASSOC, V296, P1633, DOI 10.1001/jama.296.13.jrv60011
   Mingatto FE, 1996, ARCH BIOCHEM BIOPHYS, V334, P303, DOI 10.1006/abbi.1996.0459
   Mohr W, 2002, Z KARDIOL, V91, P557, DOI 10.1007/s00392 002 0812 4
   Moreno Sánchez R, 1999, BIOCHEM PHARMACOL, V57, P743, DOI 10.1016/S0006 2952(98)00330 X
   Nulton Persson AC, 2004, J CARDIOVASC PHARM, V44, P591, DOI 10.1097/00005344 200411000 00012
   Oh KW, 2003, TOXICOL SCI, V73, P44, DOI 10.1093/toxsci/kfg045
   OMER B, 1990, POL J PHARMACOL PHAR, V42, P441
   Patsalas S, 2007, RENAL FAILURE, V29, P623, DOI 10.1080/08860220701395010
   Petrescu I, 1997, BBA BIOENERGETICS, V1318, P385, DOI 10.1016/S0005 2728(96)00109 0
   Piqué M, 2000, FEBS LETT, V480, P193, DOI 10.1016/S0014 5793(00)01922 0
   Raggi P, 2002, J AM COLL CARDIOL, V39, P695, DOI 10.1016/S0735 1097(01)01781 8
   RIDKER PM, 1991, ANN INTERN MED, V114, P835, DOI 10.7326/0003 4819 114 10 835
   RIDKER PM, 1991, AM HEART J, V122, P1588, DOI 10.1016/0002 8703(91)90275 M
   Salgueiro Pagadigorria CL, 2004, CHEM BIOL INTERACT, V147, P49, DOI 10.1016/j.cbi.2003.10.004
   Schneeweiss S, 2006, ARTHRITIS RHEUM US, V54, P3390, DOI 10.1002/art.22219
   Schwarz U, 2000, NEPHROL DIAL TRANSPL, V15, P218, DOI 10.1093/ndt/15.2.218
   Shull GE, 2003, ANN NY ACAD SCI, V986, P453, DOI 10.1111/j.1749 6632.2003.tb07229.x
   Sigrist MK, 2007, CLIN J AM SOC NEPHRO, V2, P1241, DOI 10.2215/CJN.02190507
   Szücs G, 2007, RHEUMATOLOGY, V46, P759, DOI 10.1093/rheumatology/kel426
   Tanaka K, 2005, J BIOL CHEM, V280, P31059, DOI 10.1074/jbc.M502956200
   TOMODA T, 1994, LIVER, V14, P103
   Trost LC, 1997, TOXICOL APPL PHARM, V147, P431, DOI 10.1006/taap.1997.8313
   Vokó Z, 2001, NEUROEPIDEMIOLOGY, V20, P40, DOI 10.1159/000054756
   Wang JL, 2004, BIOCHEM PHARMACOL, V67, P1123, DOI 10.1016/j.bcp.2003.11.004
   Zhang W, 2003, CHEM MATER, V15, P3221, DOI 10.1021/cm030080g
NR 59
TC 2
Z9 3
U1 0
U2 5
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1573 4064
EI 1875 6638
J9 MED CHEM
JI Med. Chem.
PD JAN
PY 2009
VL 5
IS 1
BP 23
EP 28
DI 10.2174/157340609787049235
PG 6
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 415XX
UT WOS:000263970900004
PM 19149647
DA 2025 08 17
ER

PT J
AU Casarrubios, L
   Gómez Cerezo, N
   Feito, MJ
   Vallet Regí, M
   Arcos, D
   Portolés, MT
AF Casarrubios, Laura
   Gomez Cerezo, Natividad
   Feito, Maria Jose
   Vallet Regi, Maria
   Arcos, Daniel
   Portoles, Maria Teresa
TI Ipriflavone Loaded Mesoporous Nanospheres with Potential Applications
   for Periodontal Treatment
SO NANOMATERIALS
LA English
DT Article
DE endocytosis; ipriflavone; mesoporous nanospheres; nanoparticles;
   oxidative stress; pre osteoblasts
ID GRAPHENE OXIDE NANOSHEETS; BIOACTIVE GLASS; DIFFERENTIATION;
   NANOPARTICLES; OSTEOBLASTS; DELIVERY; SOL; ENDOCYTOSIS; OSTEOCLASTS;
   MECHANISMS
AB The incorporation and effects of hollow mesoporous nanospheres in the system SiO2 CaO (nanoMBGs) containing ipriflavone (IP), a synthetic isoflavone that prevents osteoporosis, were evaluated. Due to their superior porosity and capability to host drugs, these nanoparticles are designed as a potential alternative to conventional bioactive glasses for the treatment of periodontal defects. To identify the endocytic mechanisms by which these nanospheres are incorporated within the MC3T3 E1 cells, five inhibitors (cytochalasin B, cytochalasin D, chlorpromazine, genistein and wortmannin) were used before the addition of these nanoparticles labeled with fluorescein isothiocyanate (FITC nanoMBGs). The results indicate that nanoMBGs enter the pre osteoblasts mainly through clathrin dependent mechanisms and in a lower proportion by macropinocytosis. The present study evidences the active incorporation of nanoMBG IPs by MC3T3 E1 osteoprogenitor cells that stimulate their differentiation into mature osteoblast phenotype with increased alkaline phosphatase activity. The final aim of this study is to demonstrate the biocompatibility and osteogenic behavior of IP loaded bioactive nanoparticles to be used for periodontal augmentation purposes and to shed light on internalization mechanisms that determine the incorporation of these nanoparticles into the cells.
C1 [Casarrubios, Laura; Feito, Maria Jose; Portoles, Maria Teresa] Univ Complutense Madrid, Hosp Clin San Carlos IdISSC, Inst Invest Sanit, Dept Bioquim & Biol Mol,Fac Ciencias Quim, Madrid 28040, Spain.
   [Gomez Cerezo, Natividad; Vallet Regi, Maria; Arcos, Daniel] Univ Complutense Madrid, Fac Farm, Hosp Octubre i 12 12, Dept Quim Ciencias Farmaceut,Inst Invest Sanit, Plaza Ramon y Cajal S N, Madrid 28040, Spain.
   [Gomez Cerezo, Natividad; Vallet Regi, Maria; Arcos, Daniel; Portoles, Maria Teresa] CIBER BBN, CIBER Bioingn Biomat & Nanomed, Madrid 28040, Spain.
C3 Complutense University of Madrid; Hospital Clinico San Carlos;
   Complutense University of Madrid; Hospital Universitario 12 de Octubre;
   CIBER   Centro de Investigacion Biomedica en Red; CIBERBBN
RP Portolés, MT (通讯作者)，Univ Complutense Madrid, Hosp Clin San Carlos IdISSC, Inst Invest Sanit, Dept Bioquim & Biol Mol,Fac Ciencias Quim, Madrid 28040, Spain.; Vallet Regí, M; Arcos, D (通讯作者)，Univ Complutense Madrid, Fac Farm, Hosp Octubre i 12 12, Dept Quim Ciencias Farmaceut,Inst Invest Sanit, Plaza Ramon y Cajal S N, Madrid 28040, Spain.; Vallet Regí, M; Arcos, D; Portolés, MT (通讯作者)，CIBER BBN, CIBER Bioingn Biomat & Nanomed, Madrid 28040, Spain.
EM laura.casarrubios.molina@gmail.com; magome21@ucm.es; mjfeito@ucm.es;
   vallet@ucm.es; arcosd@ucm.es; portoles@quim.ucm.es
RI ; Vallet Regi, Maria/M 3378 2014; Vallet Regí, Maria/M 3378 2014;
   Portolés, María/U 1678 2017; PORTOLES PEREZ, MARIA TERESA/U 1678 2017;
   Arcos, Daniel/L 6167 2014; Feito, Maria/AAE 7813 2020; Cerezo,
   Maria/AAA 4410 2020
OI Gomez Cerezo, Natividad/0000 0001 9708 1000; Vallet Regi,
   Maria/0000 0002 6104 4889; FEITO CASTELLANO, MARIA
   JOSE/0000 0001 8623 4913; Casarrubios Molina, Laura/0000 0002 5835 8342;
   PORTOLES PEREZ, MARIA TERESA/0000 0002 9681 0184; Ceron,
   Ester/0000 0003 1449 1018; 
FU Ministerio de Economia y Competitividad; Agencia Estatal de
   Investigacion (AEI); Fondo Europeo de Desarrollo Regional (FEDER)
   [MAT2016 75611 R AEI/FEDER, UE]; European Research Council [694160]
FX This research was funded by Ministerio de Economia y Competitividad,
   Agencia Estatal de Investigacion (AEI) and Fondo Europeo de Desarrollo
   Regional (FEDER) (MAT2016 75611 R AEI/FEDER, UE to D.A. and M.T.P.);
   European Research Council (Advanced Grant VERDI; ERC 2015 AdG Proposal
   No. 694160 to M.V. R.).
CR Addison WN, 2015, BONE, V71, P244, DOI 10.1016/j.bone.2014.11.003
   Ara T, 2010, EUR J CANCER, V46, P1223, DOI 10.1016/j.ejca.2010.02.026
   Arcos D, 2010, ACTA BIOMATER, V6, P2874, DOI 10.1016/j.actbio.2010.02.012
   Bandmann V, 2012, FEBS LETT, V586, P3626, DOI 10.1016/j.febslet.2012.08.008
   Bapat RA, 2020, INT J PHARMACEUT, V586, DOI 10.1016/j.ijpharm.2020.119596
   Bapat RA, 2019, DRUG DISCOV TODAY, V24, P85, DOI 10.1016/j.drudis.2018.08.012
   Beck GR, 2012, NANOMED NANOTECHNOL, V8, P793, DOI 10.1016/j.nano.2011.11.003
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655
   Casarrubios L, 2018, EUR J PHARM BIOPHARM, V133, P258, DOI 10.1016/j.ejpb.2018.10.019
   Cicuéndez M, 2017, COLLOID SURFACE B, V158, P33, DOI 10.1016/j.colsurfb.2017.06.019
   Duan HB, 2016, MATER LETT, V167, P201, DOI 10.1016/j.matlet.2015.12.162
   Gera S, 2017, CURR DRUG DELIV, V14, P904, DOI 10.2174/1567201813666161230142123
   Gómez Cerezo N, 2019, ACTA BIOMATER, V90, P393, DOI 10.1016/j.actbio.2019.04.019
   Gómez Cerezo N, 2018, J COLLOID INTERF SCI, V528, P309, DOI 10.1016/j.jcis.2018.05.099
   Greenspan D.C., 2020, BIOGLASS BIOACTIVITY
   Hannig C, 2010, MED HYPOTHESES, V74, P670, DOI 10.1016/j.mehy.2009.11.007
   Horwood NJ, 1998, ENDOCRINOLOGY, V139, P4743, DOI 10.1210/en.139.11.4743
   Huang WY, 2020, FRONT MATER, V7, DOI 10.3389/fmats.2020.00241
   Kuroyanagi G, 2018, BONE, V116, P221, DOI 10.1016/j.bone.2018.08.011
   Lee JH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150727
   LI R, 1991, J APPL BIOMATER, V2, P231, DOI 10.1002/jab.770020403
   Li YQ, 2015, CHEM EUR J, V21, P8038, DOI 10.1002/chem.201406570
   Linares J, 2014, ACS APPL MATER INTER, V6, P13697, DOI 10.1021/am5031598
   Lopez Noriega A, 2010, CHEM EUR J, V16, P10879, DOI 10.1002/chem.201000137
   Luhmann T, 2012, J CONTROL RELEASE, V161, P198, DOI 10.1016/j.jconrel.2011.10.001
   Mäger I, 2012, BBA BIOMEMBRANES, V1818, P502, DOI 10.1016/j.bbamem.2011.11.020
   Manzano M, 2006, CHEM MATER, V18, P5696, DOI 10.1021/cm0615370
   Mao LX, 2017, ACTA BIOMATER, V61, P217, DOI 10.1016/j.actbio.2017.08.015
   Mariani E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030636
   Matesanz MC, 2013, BIOMATERIALS, V34, P1562, DOI 10.1016/j.biomaterials.2012.11.001
   MAZZUOLI G, 1992, BONE MINER, V19, pS27, DOI 10.1016/0169 6009(92)90863 9
   Gómez Cerezo MN, 2020, MAT SCI ENG C MATER, V109, DOI 10.1016/j.msec.2019.110572
   Nescáková Z, 2019, BIOACT MATER, V4, P312, DOI 10.1016/j.bioactmat.2019.10.002
   Oh N, 2014, INT J NANOMED, V9, P51, DOI 10.2147/IJN.S26592
   Polo L, 2018, CHEM EUR J, V24, P18944, DOI 10.1002/chem.201803301
   Portal Núñez S, 2017, TRENDS ENDOCRIN MET, V28, P695, DOI 10.1016/j.tem.2017.06.003
   Priyadarsini Subhashree, 2018, J Oral Biol Craniofac Res, V8, P58, DOI 10.1016/j.jobcr.2017.12.004
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   REGINSTER JYL, 1993, BONE MINER, V23, P223, DOI 10.1016/S0169 6009(08)80099 2
   Sato K, 2009, LIFE SCI, V85, P800, DOI 10.1016/j.lfs.2009.10.012
   Schulz WL, 2012, J VIROL, V86, P12665, DOI 10.1128/JVI.01861 12
   Shang LL, 2021, BIOACT MATER, V6, P1175, DOI 10.1016/j.bioactmat.2020.10.010
   Skallevold HE, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235960
   STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424
   UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461
   Udall J N, 1987, Adv Exp Med Biol, V216A, P821
   Wu CT, 2014, J CONTROL RELEASE, V193, P282, DOI 10.1016/j.jconrel.2014.04.026
   Wu CT, 2012, INTERFACE FOCUS, V2, P292, DOI 10.1098/rsfs.2011.0121
   Yan XX, 2004, ANGEW CHEM INT EDIT, V43, P5980, DOI 10.1002/anie.200460598
   Zakrzewski W, 2020, NANOMATERIALS BASEL, V10, DOI 10.3390/nano10061216
   Zhang XD, 2016, SCI REP UK, V6, DOI 10.1038/srep19361
   Zheng K, 2019, MAT SCI ENG C MATER, V103, DOI 10.1016/j.msec.2019.109764
NR 52
TC 27
Z9 28
U1 5
U2 19
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2079 4991
J9 NANOMATERIALS BASEL
JI Nanomaterials
PD DEC
PY 2020
VL 10
IS 12
AR 2573
DI 10.3390/nano10122573
PG 17
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA PL4KJ
UT WOS:000603092500001
PM 33371499
OA Green Accepted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Shen, GY
   Shang, Q
   Zhang, ZD
   Zhao, WH
   Chen, HL
   Mijiti, I
   Chen, GF
   Yu, X
   Yu, FY
   Zhang, P
   He, JH
   Zhang, XL
   Tang, JJ
   Cui, JC
   Liang, D
   Zeng, LF
   Ren, H
   Jiang, XB
AF Shen, Gengyang
   Shang, Qi
   Zhang, Zhida
   Zhao, Wenhua
   Chen, Honglin
   Mijiti, Ibrayinjan
   Chen, Guifeng
   Yu, Xiang
   Yu, Fuyong
   Zhang, Peng
   He, Jiahui
   Zhang, Xuelai
   Tang, Jingjing
   Cui, Jianchao
   Liang, De
   Zeng, Lingfeng
   Ren, Hui
   Jiang, Xiaobing
TI Zuo Gui Wan Aqueous Extract Ameliorates Glucocorticoid Induced Spinal
   Osteoporosis of Rats by Regulating let 7f and Autophagy
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE ZGW aqueous extract; GIOP; let 7f; autophagy; Chinese medicine
ID OSTEOBLAST DIFFERENTIATION; BONE LOSS
AB ObjectiveThis study proposes to explore the protective effect of Zuo Gui Wan (ZGW) aqueous extract on spinal glucocorticoid induced osteoporosis (GIOP) in vivo and in vitro, and the underlying mechanisms of ZGW in GIOP and osteogenic differentiation of bone marrow derived mesenchymal stem cells (BMSCs) were conducted. MethodsIn vivo, SD rats were randomly divided into three groups: control group (CON), dexamethasone (DEXM) group, and ZGW group, which were given vehicle, DEXM injection, and ZGW intragastric administration at the same time. Vertebral bone microarchitecture, biomechanics, histomorphology, serum AKP activity, and the autophagosome of osteoblasts were examined. The mRNA expressions of let 7f, autophagy associated genes (mTORC1, Beclin 1, ATG12, ATG5, and LC3), Runx2, and CTSK were examined. In vitro, the let 7f overexpression/silencing vector was constructed and transfected to evaluate the osteogenic differentiation of BMSCs. Western blot was employed to detect the expression of autophagy associated proteins (ULK2, ATG5, ATG12, Beclin 1, LC3). ResultsIn vivo, ZGW promoted the bone quantity, quality, and strength; alleviated histological damage; increased the serum AKP activity; and reduced the autophagosome number in osteoblasts. Moreover, ZGW increased the let 7f, mTORC1, and Runx2 mRNA expressions and reduced the Beclin 1, ATG12, ATG5, LC3, and CTSK mRNA expressions. In vitro, bioinformatics prediction and dual luciferase reporter gene assay verified that let 7f targeted the binding to ULK2 and negatively regulated the ULK2 expression. Furthermore, by let 7f overexpression/silencing, ZGW may promote osteoblast differentiation of BMSCs by regulating let 7f and autophagy as evidenced by Western blot (ULK2, ATG5, ATG12, Beclin 1, LC3). ConclusionsZGW may ameliorate GC induced spinal osteoporosis by promoting osteoblast differentiation of BMSCs by activation of let 7f and suppression of autophagy.
C1 [Shen, Gengyang; Zhang, Zhida; Yu, Xiang; Zhang, Xuelai; Tang, Jingjing; Cui, Jianchao; Liang, De; Ren, Hui; Jiang, Xiaobing] Guangzhou Univ Chinese Med, Dept Spinal Surg, Affiliated Hosp 1, Guangzhou, Peoples R China.
   [Shen, Gengyang; Shang, Qi; Zhang, Zhida; Zhao, Wenhua; Chen, Honglin; Chen, Guifeng; Yu, Xiang; Yu, Fuyong; Zhang, Peng; He, Jiahui; Zhang, Xuelai; Tang, Jingjing; Cui, Jianchao; Liang, De; Ren, Hui; Jiang, Xiaobing] Guangzhou Univ Chinese Med, Lingnan Med Res Ctr, Guangzhou, Peoples R China.
   [Shen, Gengyang] Guangzhou Univ Chinese Med, Nanshan Hosp, Shenzhen Nanshan Hosp Chinese Med, Dept Spinal Surg,Affiliated Hosp 1, Guangzhou, Peoples R China.
   [Shang, Qi; Zhao, Wenhua; Chen, Honglin; Chen, Guifeng; Yu, Fuyong; Zhang, Peng; He, Jiahui] Guangzhou Univ Chinese Med, Clin Coll 1, Guangzhou, Peoples R China.
   [Mijiti, Ibrayinjan] First Peoples Hosp Kashgar, Dept Spinal Surg, Kashgar, Peoples R China.
   [Zeng, Lingfeng] Guangzhou Univ Chinese Med, Dept Orthoped, Affiliated Hosp 2, Guangzhou, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou
   University of Chinese Medicine; Guangzhou University of Chinese Medicine
RP Ren, H; Jiang, XB (通讯作者)，Guangzhou Univ Chinese Med, Dept Spinal Surg, Affiliated Hosp 1, Guangzhou, Peoples R China.; Ren, H; Jiang, XB (通讯作者)，Guangzhou Univ Chinese Med, Lingnan Med Res Ctr, Guangzhou, Peoples R China.; Zeng, LF (通讯作者)，Guangzhou Univ Chinese Med, Dept Orthoped, Affiliated Hosp 2, Guangzhou, Peoples R China.
EM 1347301175@qq.com; renhuispine@163.com; spinedrjxb@sina.com
RI ; Zhida, Zhang/HME 3183 2023; Zhang, Peng/IZP 9286 2023; zhong,
   feng/G 4623 2015
OI Cui, Jianchao/0000 0003 4358 1450; Shen, Gengyang/0000 0001 8940 7912;
   Zhang, Peng/0000 0003 1777 3790
FU National Natural Science Foundation of China [81904225, 81774338];
   Innovation Team project of Guangdong Education Department
   [2021KCXTD017]; Guangdong Natural Science Foundation [2020A1515110322,
   2021A1515011247]; High Level University Collaborative Innovation Team of
   GZUCM [2021xk57]; Natural Science Foundation of Xinjiang Autonomous
   Region [2019D01C013]
FX Funding This research was funded by the National Natural Science
   Foundation of China (81904225 and 81774338), Innovation Team project of
   Guangdong Education Department (2021KCXTD017), Guangdong Natural Science
   Foundation (2020A1515110322 and 2021A1515011247), High Level University
   Collaborative Innovation Team of GZUCM (2021xk57), and Natural Science
   Foundation of Xinjiang Autonomous Region (2019D01C013). The funding
   institutions had not any role in study design, data collection, data
   analysis, interpretation, or writing of the report in this study.
CR Blanchard OL, 2015, FASEB J, V29, P1629, DOI 10.1096/fj.14 269043
   Bodemann BO, 2011, CELL, V144, P253, DOI 10.1016/j.cell.2010.12.018
   Chotiyarnwong P, 2020, NAT REV ENDOCRINOL, V16, P437, DOI 10.1038/s41574 020 0341 0
   Deng P, 2021, CELL STEM CELL, V28, P1057, DOI 10.1016/j.stem.2021.01.010
   Fassio A, 2017, CURR PHARM DESIGN, V23, P6241, DOI 10.2174/1381612823666170713104431
   Fleseriu M, 2021, LANCET DIABETES ENDO, V9, P847, DOI 10.1016/S2213 8587(21)00235 7
   Hill SM, 2021, NAT CHEM BIOL, V17, P448, DOI 10.1038/s41589 020 00726 x
   Lai NN, 2015, J ETHNOPHARMACOL, V166, P228, DOI 10.1016/j.jep.2015.03.011
   Lee SY, 2022, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.815386
   Li HF, 2021, ACS APPL MATER INTER, V13, P25290, DOI 10.1021/acsami.1c05437
   Li HX, 2018, AUTOPHAGY, V14, P1726, DOI 10.1080/15548627.2018.1483807
   Li WX, 2018, J TRADIT CHIN MED, V38, P33
   Liang D, 2016, BIOMED PHARMACOTHER, V82, P151, DOI 10.1016/j.biopha.2016.04.068
   Lin NY, 2016, ANN RHEUM DIS, V75, P1203, DOI 10.1136/annrheumdis 2015 207240
   Lin WL, 2020, AM J CHINESE MED, V48, P1749, DOI 10.1142/S0192415X20500871
   Liu FX, 2021, J TRADIT CHIN MED, V41, P927, DOI 10.19852/j.cnki.jtcm.20210903.001
   Liu FX, 2018, BIOMED PHARMACOTHER, V103, P1052, DOI 10.1016/j.biopha.2018.04.102
   Radoshevich L, 2010, CELL, V142, P590, DOI 10.1016/j.cell.2010.07.018
   Ren H, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 10614 5
   Ren H, 2015, STEROIDS, V102, P65, DOI 10.1016/j.steroids.2015.07.006
   Seidel T, 2019, BASIC RES CARDIOL, V114, DOI 10.1007/s00395 019 0758 6
   Shang Q, 2021, J CELL PHYSIOL, V236, P4231, DOI 10.1002/jcp.30179
   Shang Q, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/1517596
   Shang Q, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/6815620
   Shen GY, 2019, INT J BIOL SCI, V15, P2182, DOI 10.7150/ijbs.33490
   Shen GY, 2020, EBIOMEDICINE, V52, DOI 10.1016/j.ebiom.2020.102626
   Shen GY, 2018, CELL MOL LIFE SCI, V75, P2683, DOI 10.1007/s00018 018 2776 1
   Shen GY, 2016, CALCIFIED TISSUE INT, V99, P1, DOI 10.1007/s00223 016 0122 x
   Wang LF, 2019, J CELL PHYSIOL, V234, P3207, DOI 10.1002/jcp.27335
   Wei JW, 2015, CELL, V161, P1576, DOI 10.1016/j.cell.2015.05.029
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Xu K, 2021, ENVIRON TOXICOL, V36, P2123, DOI 10.1002/tox.23327
   Zhang Jian Hua, 2017, Zhongguo Zhong Yao Za Zhi, V42, P3983, DOI 10.19540/j.cnki.cjcmm.20170907.002
NR 33
TC 11
Z9 14
U1 1
U2 18
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD MAY 3
PY 2022
VL 13
AR 878963
DI 10.3389/fendo.2022.878963
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 1I1FE
UT WOS:000796981200001
PM 35592785
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Han, J
   Ren, GW
   Xu, ZW
   Qi, W
   Shang, YZ
   Wen, SB
   Luo, YA
AF Han, Jie
   Ren, Guowu
   Xu, Zhiwei
   Qi, Wen
   Shang, Yuzhi
   Wen, Shuaibo
   Luo, Yehao
TI Exploring the relationship between systemic lupus erythematosus and
   osteoporosis based on bioinformatics
SO LUPUS
LA English
DT Article
DE Systemic lupus erythematosus; osteoporosis; bioinformatics; signaling
   pathway; GEO database
ID DIFFERENTIATION; SLE; ASSOCIATION
AB Objective This study aimed to explore the relationship between systemic lupus erythematosus (SLE) and osteoporosis (OP) based on bioinformatics. Methods The expression profiles of SLE and OP gene chips were searched through the GEO database, and the differentially expressed genes (DEGs) were screened out to obtain the intersection. Then, the Funrich software was used to predict the upstream miRNAs of the intersection genes, and the miRNA mRNA relationship network was constructed. Afterward, the String database and Cytoscape software were used to construct the protein interaction network of the intersection genes to screen out the key genes. Finally, the functions and related pathways of key genes were analyzed by using the DAVID database. Results ①A total of 140 intersection genes of SLE and OP were obtained; ②There were 217 miRNAs regulating the intersection genes; ③IL 4, FOS, TLR1, TLR6, CD40LG, CCR1 were the key genes in the protein interaction network; ④The DAVID enrichment analysis mainly covered the positive regulation of cytokine production, the regulation of osteoclast differentiation, macrophage activation and other biological processes, involving Toll like receptor signaling pathway, T cell receptor signaling pathway, Th1, Th2, and Th17 cells Differentiation, IL 17 signaling pathway. Conclusions SLE and OP still have some highly overlapping differential gene expressions under the background of complex gene networks. The gene functions and signaling pathways involved can simultaneously regulate the two diseases, suggesting that there is a close relationship between the molecular mechanisms of the two diseases, and that it may be a target of drugs that interfere with two diseases at the same time.
C1 [Han, Jie; Xu, Zhiwei; Shang, Yuzhi] Guangxi Univ Tradit Chinese Med, Ruikang Hosp, Nanning, Peoples R China.
   [Ren, Guowu; Qi, Wen; Wen, Shuaibo; Luo, Yehao] Guangxi Univ Tradit Chinese Med, Nanning, Peoples R China.
C3 Guangxi University of Chinese Medicine; Guangxi University of Chinese
   Medicine
RP Ren, GW (通讯作者)，Guangxi Univ Tradit Chinese Med, Guangxi Zhuang Autonomous Reg, Nanning 530299, Peoples R China.
EM rgw1997@163.com
OI Han, Jie/0000 0003 1750 4400; ren, guowu/0000 0001 7017 2391
FU Guangxi Traditional Chinese Medicine Appropriate Technology Development
   and Promotion Project [GZSY21 30]; Guangxi Medical And Health
   Appropriate Technology Development and Promotion Application Project
   [S2019070]; Guangxi University Young and middle aged Teachers scientific
   Research Basic Ability Enhancement Project [2020KY07017]; Graduate
   Education Innovation Program [GZZJ202011]; Hospital Preparation quality
   improvement project of Chinese Zhuang Yao medicine [GZZJ202011]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This project
   was supported by Guangxi Traditional Chinese Medicine Appropriate
   Technology Development and Promotion Project (GZSY21 30); Guangxi
   Medical And Health Appropriate Technology Development and Promotion
   Application Project (S2019070); Guangxi University Young and middle aged
   Teachers scientific Research Basic Ability Enhancement Project
   (2020KY07017); Hospital Preparation quality improvement project of
   Chinese Zhuang Yao medicine (GZZJ202011); Graduate Education Innovation
   Program(GZZJ202011).
CR Ali R, 2019, LUPUS, V28, P1233, DOI 10.1177/0961203319867129
   Azizieh F, 2017, MENOPAUSE, V24, P1057, DOI 10.1097/GME.0000000000000885
   Azizieh FY, 2019, J INFLAMM RES, V12, P99, DOI 10.2147/JIR.S203590
   Bignon A, 2014, J IMMUNOL, V192, P886, DOI 10.4049/jimmunol.1300123
   Bultink IEM, 2018, CALCIFIED TISSUE INT, V102, P575, DOI 10.1007/s00223 017 0322 z
   Caielli S, 2019, NAT MED, V25, P75, DOI 10.1038/s41591 018 0254 9
   Carter EE, 2016, NAT REV RHEUMATOL, V12, P605, DOI 10.1038/nrrheum.2016.137
   Chen SY, 2019, CLIN RHEUMATOL, V38, P1361, DOI 10.1007/s10067 019 04467 8
   Chinese Rheumatology Association, 2020, Zhonghua Nei Ke Za Zhi, V59, P172, DOI 10.3760/cma.j.issn.0578 1426.2020.03.002
   Collins FL, 2017, BONE, V97, P94, DOI 10.1016/j.bone.2017.01.002
   Dai H, 2017, J IMMUNOL, V199, P903, DOI 10.4049/jimmunol.1700418
   Das A, 2015, AM J PATHOL, V185, P2596, DOI 10.1016/j.ajpath.2015.06.001
   de Sales Lima Marco Vinicius, 2018, J Oral Maxillofac Res, V9, pe5, DOI 10.5037/jomr.2018.9405
   Dou C, 2018, J BONE MINER RES, V33, P899, DOI 10.1002/jbmr.3364
   Feng XJ, 2020, J CELL PHYSIOL, V235, P5111, DOI 10.1002/jcp.29379
   Gu CY, 2019, ARCH OSTEOPOROS, V15, DOI 10.1007/s11657 019 0667 1
   He J, 2020, ANN RHEUM DIS, V79, P141, DOI 10.1136/annrheumdis 2019 215396
   Houssen ME, 2016, INT J RHEUM DIS, V19, P685, DOI 10.1111/1756 185X.12452
   Huang YK, 2020, SCI CHINA LIFE SCI, V63, P429, DOI 10.1007/s11427 019 1555 9
   Jung JY, 2020, OSTEOPORO SARCOPENIA, V6, P173, DOI 10.1016/j.afos.2020.11.001
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P801, DOI [10.1007/s00198 018 4704 5, 10.1007/s00198 020 05303 5, 10.1007/s00223 018 00512 x]
   Kassem A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156708
   Katsuyama T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01088
   Koga T, 2019, EXPERT REV CLIN IMMU, V15, P629, DOI 10.1080/1744666X.2019.1593141
   Kong J, 2019, INFLAMMATION, V42, P255, DOI 10.1007/s10753 018 0889 1
   Kono M, 2018, ARTHRITIS RHEUMATOL, V70, P2046, DOI 10.1002/art.40585
   Kuwabara T, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/3908061
   Liang CL, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.683249
   Mao ZX, 2019, IUBMB LIFE, V71, P1916, DOI 10.1002/iub.2131
   Marques CPC, 2016, CLIN EXP IMMUNOL, V183, P187, DOI 10.1111/cei.12708
   Mohammadoo khorasani M, 2016, INDIAN J MED RES, V143, P591, DOI 10.4103/0971 5916.187107
   Panach L, 2016, BONE, V83, P94, DOI 10.1016/j.bone.2015.11.002
   Patop IL, 2019, EMBO J, V38, DOI 10.15252/embj.2018100836
   Pérez Ferro M, 2016, J RHEUMATOL, V43, P1444, DOI 10.3899/jrheum.151386
   Ramanujam M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102668
   Rasmussen TK, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0660 z
   Read KA, 2019, METHODS MOL BIOL, V1960, P75, DOI 10.1007/978 1 4939 9167 9_6
   Su XP, 2019, CHEM BIOL INTERACT, V306, P110, DOI 10.1016/j.cbi.2019.04.015
   Sucur A, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1337 6
   Sun Y, 2015, J RECEPT SIG TRANSD, V35, P600, DOI 10.3109/10799893.2015.1030412
   Talaat RM, 2015, CYTOKINE, V72, P146, DOI 10.1016/j.cyto.2014.12.027
   Tanaka Y, 2022, ARTHRIT CARE RES, V74, P187, DOI 10.1002/acr.24431
   Uzrail AH, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/1703842
   Walana W, 2018, HUM IMMUNOL, V79, P809, DOI 10.1016/j.humimm.2018.08.007
   Wan H, 2018, BALK MED J, V35, P320, DOI 10.4274/balkanmedj.2017.1165
   Wang DR, 2019, J CELL BIOCHEM, V120, P18667, DOI 10.1002/jcb.29153
   Wang X, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1618 8
   Wang YH, 2020, EXP THER MED, V20, P3185, DOI 10.3892/etm.2020.9045
   Wu JC, 2021, BIOCHEM J, V478, P721, DOI 10.1042/BCJ20200314
   Xia T, 2020, INT J MOL MED, V46, P709, DOI 10.3892/ijmm.2020.4615
   Xu CL, 2018, CLIN IMMUNOL, V197, P179, DOI 10.1016/j.clim.2018.10.001
   Xu Q, 2019, P NATL ACAD SCI USA, V116, P982, DOI 10.1073/pnas.1807484116
   Xue YL, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20201227
   Yamamoto K, 2019, INTERNAL MED, V58, P1049, DOI 10.2169/internalmedicine.1271 18
   Yang DH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092093
   Yim Mijung, 2020, J Bone Metab, V27, P227, DOI 10.11005/jbm.2020.27.4.227
   Yin ZQ, 2019, EUR J PHARMACOL, V859, DOI 10.1016/j.ejphar.2019.172550
   Yu L, 2019, BIOCHEM BIOPH RES CO, V516, P546, DOI 10.1016/j.bbrc.2019.06.087
   Yuan SW, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/9827574
   Zeng Q, 2019, J BONE MINER RES, V34, P1789, DOI 10.1002/jbmr.3757
   Zhang JK, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12907
   Zhao L, 2019, EUR J PHARMACOL, V853, P145, DOI 10.1016/j.ejphar.2019.03.030
   Zhou HY, 2018, CLIN RHEUMATOL, V37, P2405, DOI 10.1007/s10067 018 4124 0
NR 63
TC 3
Z9 4
U1 1
U2 15
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0961 2033
EI 1477 0962
J9 LUPUS
JI Lupus
PD FEB
PY 2022
VL 31
IS 2
BP 163
EP 177
AR 09612033211073909
DI 10.1177/09612033211073909
EA JAN 2022
PG 15
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA YW0AM
UT WOS:000748900000001
PM 35067074
DA 2025 08 17
ER

PT J
AU Li, T
   Yuan, JH
   Xu, PC
   Jia, JY
   Zhao, JMH
   Zhang, J
   Ding, R
   Zhao, XK
   He, DW
   Wu, TL
   Cheng, XG
AF Li, Tao
   Yuan, Jinghong
   Xu, Peichuan
   Jia, Jingyu
   Zhao, Jiangminghao
   Zhang, Jian
   Ding, Rui
   Zhao, Xiaokun
   He, Dingwen
   Wu, Tianlong
   Cheng, Xigao
TI PMAIP1, a novel diagnostic and potential therapeutic biomarker in
   osteoporosis
SO AGING US
LA English
DT Article
DE osteoporosis; transcription factors; BMSC; ceRNA; diagnosis
ID ALKALINE PHOSPHATASE ACTIVITY; L HISTIDINATO ZINC; EXTRACELLULAR
   CALCIUM; BONE MARROW; ESTROGEN DEFICIENCY; MOLECULAR MECHANISM;
   BIOCHEMICAL MARKERS; ENRICHMENT ANALYSIS; CELL PROLIFERATION; OSTEOBLAST
AB Background: Osteoporosis is a common endocrine metabolic bone disease, which may lead to severe consequences. However, the unknown molecular mechanism of osteoporosis, the observable side effects of present treatments and the inability to fundamentally improve bone metabolism seriously restrict the impact of prevention and treatment. The study aims to identify potential biomarkers from osteoclast progenitors, specifically peripheral blood monocytes on predicting the osteoporotic phenotype. Methods: Datasets were obtained from Gene Expression Omnibus (GEO). Based on the differentially expressed genes (DEGs) and GSEA results, GO and KEGG analyses were performed using the DAVID database and Metascape database. PPI network, TF network, drug gene interaction network, and ceRNA network were established to determine the hub genes. Its osteogenesis, migration, and proliferation abilities in bone marrow mesenchymal stem cells (BMSCs) were validated through RT qPCR, WB, ALP staining, VK staining, wound healing assay, transwell assay, and CCK 8 assay. Results: A total of 63 significant DEGs were screened. Functional and pathway enrichment analysis discovered that the functions of the significant DEGs (SDEGs) are mainly related to immunity and metal ions. A comprehensive evaluation of all the network analyses, PMAIP1 was defined as osteoporosis's core gene. This conclusion was further confirmed in clinical cohort data. A series of experiments demonstrated that the PMAIP1 gene can promote the osteogenesis, migration and proliferation of BMSC cells. Conclusions: All of these outcomes showed a new theoretical basis for further research in the treatment of osteoporosis, and PMAIP1 was identified as a potential biomarker for osteoporosis diagnosis and treatment.
C1 [Li, Tao; Yuan, Jinghong; Xu, Peichuan; Jia, Jingyu; Zhang, Jian; Ding, Rui; He, Dingwen; Wu, Tianlong; Cheng, Xigao] Inst Orthopaed Jiangxi Prov, Nanchang, Jiangxi, Peoples R China.
   [Yuan, Jinghong; Jia, Jingyu; Zhao, Jiangminghao; Zhang, Jian; Zhao, Xiaokun; Cheng, Xigao] Nanchang Univ, Affiliated Hosp 2, Dept Osteoporosis, Nanchang, Peoples R China.
   [Ding, Rui; Wu, Tianlong; Cheng, Xigao] Nanchang Univ, Affiliated Hosp 2, Dept Orthopaed, Nanchang, Peoples R China.
C3 Nanchang University; Nanchang University
RP Cheng, XG (通讯作者)，Inst Orthopaed Jiangxi Prov, Nanchang, Jiangxi, Peoples R China.; Cheng, XG (通讯作者)，Nanchang Univ, Affiliated Hosp 2, Dept Osteoporosis, Nanchang, Peoples R China.; Cheng, XG (通讯作者)，Nanchang Univ, Affiliated Hosp 2, Dept Orthopaed, Nanchang, Peoples R China.
EM xigaocheng@hotmail.com
RI Zhang, Jian/AAT 4540 2021; Ding, Rui/AAL 7714 2021; LI,
   TAO/AAL 5932 2020
FU Key Project of International Science and Technology Cooperation
   [20232BBH80001]
FX This research is supported by The Key Project of International Science
   and Technology Cooperation (No. 20232BBH80001 to Xigao Cheng) .
CR Ahmadian M, 2013, NAT MED, V19, P557, DOI 10.1038/nm.3159
   Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Backes C, 2016, NUCLEIC ACIDS RES, V44, pW110, DOI 10.1093/nar/gkw345
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Center JR, 1999, LANCET, V353, P878, DOI 10.1016/S0140 6736(98)09075 8
   Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030
   Christakos S, 2016, PHYSIOL REV, V96, P365, DOI 10.1152/physrev.00014.2015
   Cotto Kelsy C, 2018, Nucleic Acids Res, V46, pD1068, DOI 10.1093/nar/gkx1143
   Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb 2003 4 9 r60
   de Barboza GD, 2015, WORLD J GASTROENTERO, V21, P7142, DOI 10.3748/wjg.v21.i23.7142
   Do H, 2019, BIOL RES, V52, DOI 10.1186/s40659 019 0244 5
   Doherty DA, 2001, OSTEOPOROSIS INT, V12, P16, DOI 10.1007/s001980170152
   Dvorak MM, 2004, P NATL ACAD SCI USA, V101, P5140, DOI 10.1073/pnas.0306141101
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Fulton DL, 2009, GENOME BIOL, V10, DOI 10.1186/gb 2009 10 3 r29
   Garvie CW, 2001, MOL CELL, V8, P937, DOI 10.1016/S1097 2765(01)00392 6
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Genant HK, 1999, OSTEOPOROSIS INT, V10, P259, DOI 10.1007/s001980050224
   Halford SE, 2004, NUCLEIC ACIDS RES, V32, P3040, DOI 10.1093/nar/gkh624
   HASHIZUME M, 1994, MOL CELL BIOCHEM, V131, P19, DOI 10.1007/BF01075720
   HASHIZUME M, 1993, MOL CELL BIOCHEM, V122, P59, DOI 10.1007/BF00925737
   Hu CH, 2017, SCI REP UK, V7, DOI 10.1038/srep43191
   Huang ZM, 2001, J BIOL CHEM, V276, P21351, DOI 10.1074/jbc.M010921200
   Idrus E, 2011, BIOCHEM BIOPH RES CO, V410, P620, DOI 10.1016/j.bbrc.2011.06.040
   Igarashi A, 2001, INT J MOL MED, V8, P433
   Janky R, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003731
   Jilka RL, 1998, BONE, V23, P75, DOI 10.1016/S8756 3282(98)00077 5
   Jin S, 2020, CLIN CANCER RES, V26, P3371, DOI 10.1158/1078 0432.CCR 19 1900
   Johnell O, 2005, J BONE MINER RES, V20, P1185, DOI 10.1359/JBMR.050304
   Khosla S, 1997, J CLIN ENDOCR METAB, V82, P1522, DOI 10.1210/jc.82.5.1522
   Khosla S, 1998, J CLIN ENDOCR METAB, V83, P2266, DOI 10.1210/jc.83.7.2266
   Khundmiri SJ, 2016, COMPR PHYSIOL, V6, P561, DOI 10.1002/cphy.c140071
   Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499
   Kim JH, 2014, CELL DEATH DIFFER, V21, P1613, DOI 10.1038/cdd.2014.71
   Kim YH, 2019, BIOCHEM BIOPH RES CO, V520, P459, DOI 10.1016/j.bbrc.2019.10.048
   Lambert SA, 2018, CELL, V172, P650, DOI 10.1016/j.cell.2018.01.029
   Li CJ, 2015, J CLIN INVEST, V125, P1509, DOI 10.1172/JCI77716
   Lim KHC, 2013, NUTRIENTS, V5, P3184, DOI 10.3390/nu5083184
   Liu XQ, 2003, IMMUNITY, V19, P341, DOI 10.1016/S1074 7613(03)00234 6
   Lorentzon M, 2015, J INTERN MED, V277, P650, DOI 10.1111/joim.12369
   Lorget F, 2000, BIOCHEM BIOPH RES CO, V268, P899, DOI 10.1006/bbrc.2000.2229
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Marahleh A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02925
   Maraka S, 2015, BMJ BRIT MED J, V351, DOI 10.1136/bmj.h3783
   Martín Merino E, 2018, OSTEOPOROSIS INT, V29, P467, DOI 10.1007/s00198 017 4308 5
   MIYAUCHI A, 1990, J CELL BIOL, V111, P2543, DOI 10.1083/jcb.111.6.2543
   Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474 9728.2004.00127.x
   Mostafavi S, 2008, GENOME BIOL, V9, DOI 10.1186/gb 2008 9 s1 s4
   Nuti R, 2019, INTERN EMERG MED, V14, P85, DOI 10.1007/s11739 018 1874 2
   Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053
   Park KH, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478 811X 11 74
   Peacock M, 2010, CLIN J AM SOC NEPHRO, V5, pS23, DOI 10.2215/CJN.05910809
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   RELEA P, 1995, AGE AGEING, V24, P303, DOI 10.1093/ageing/24.4.303
   Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806
   Sadighi A, 2008, SAUDI MED J, V29, P1276
   Scholtysek C, 2013, NAT MED, V19, P608, DOI 10.1038/nm.3146
   Seo YW, 2003, J BIOL CHEM, V278, P48292, DOI 10.1074/jbc.M308785200
   Sitara D, 2010, IMMUNOL REV, V233, P286, DOI 10.1111/j.0105 2896.2009.00849.x
   Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675
   Soysa NS, 2009, BIOCHEM BIOPH RES CO, V378, P1, DOI 10.1016/j.bbrc.2008.10.146
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Takeda S, 1999, ENDOCRINOLOGY, V140, P1005, DOI 10.1210/en.140.2.1005
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   Vaananen HK, 1996, MATURITAS, V23, pS65
   Veldurthy V, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.41
   Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672
   Weber A, 2013, APOPTOSIS, V18, P1093, DOI 10.1007/s10495 013 0868 9
   Wen J, 2020, INT J BIOCHEM CELL B, V122, DOI 10.1016/j.biocel.2020.105719
   Yamakawa T, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115494
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Ye J, 2021, ACS NANO, V15, P13692, DOI 10.1021/acsnano.1c04974
   Yin C, 2019, J CELL PHYSIOL, V234, P11524, DOI 10.1002/jcp.27815
   ZAIDI M, 1993, CELL CALCIUM, V14, P271, DOI 10.1016/0143 4160(93)90048 B
   Zhang ND, 2019, BIOCHEM BIOPH RES CO, V519, P790, DOI 10.1016/j.bbrc.2019.09.058
   Zhao XF, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756 9966 33 3
   Zheng YJ, 2019, MOL THER NUCL ACIDS, V18, P485, DOI 10.1016/j.omtn.2019.07.026
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09234 6
   Zofková I, 2013, CLIN CHEM LAB MED, V51, P1555, DOI 10.1515/cclm 2012 0868
NR 87
TC 0
Z9 0
U1 0
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945 4589
J9 AGING US
JI Aging US
PD FEB 28
PY 2024
VL 16
IS 4
PG 22
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA KI6G7
UT WOS:001179364200015
DA 2025 08 17
ER

PT J
AU Cheng, YD
   Cao, FD
   Wu, J
   Zhan, JL
   Liu, MY
   Ou, LL
   Chen, XF
   Lai, RF
AF Cheng, Yaodong
   Cao, Fengdi
   Wu, Jian
   Zhan, Jialin
   Liu, Minyi
   Ou, Lingling
   Chen, Xufeng
   Lai, Renfa
TI MicroRNA 374a promotes osteogenic differentiation of periodontal
   ligament stem cells through directly targeting APC/Wnt/β catenin
   signaling pathway
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Periodontal ligament stem cells; osteogenic differentiation;
   microRNA 374a; APC; Wnt/beta catenin signaling pathway
ID MIR 374A PROMOTES; PROLIFERATION; ADIPOGENESIS; OSTEOBLASTS; EXPRESSION;
   MIGRATION; CANCER; ROLES; AXIN2
AB MicroRNAs (miRNAs) have a significant regulatory effect on the differentiation of human stem cells, such as human adipose tissue derived stem cells (hADSCs), human mesenchymal stem cells (hMSCs) and embryonic stem cells (ESCs). However, little is known about the role of miRNAs in osteogenic differentiation of periodontal ligament stem cells (PDLSCs). Therefore, the aim of the present study is to determine the role of miRNAs and to elucidate its regulatory mechanism in osteogenic differentiation of PDLSCs. The miRNA expression profile before and after the osteoblastic differentiation of PDLSCs was assessed by microarray analysis and selected miRNAs were validated by quantitative RT PCR (qRT PCR). The gain and loss of function experiments were performed to investigate the underlying function of selected miRNA in osteogenic differentiation of PDLSCs. Regulation of putative selected miRNA targets was determined by dual luciferase reporter assays. In addition, the effects of selected miRNA on the Wnt/beta catenin signaling pathway were investigated by TOP/FOP flash luciferase assays and Western blot. Based on the miRNA expression profiling, we identified that 50 miRNAs were deregulated during the osteoblastic differentiation. Among these miRNAs, miR 374a was chosen for further study because miR 374a was significantly upregulated during osteogenic differentiation. Gain and loss of function studies showed that overexpression of miR 374a significantly enhanced osteogenic differentiation of PDLSCs whereas miR 374a inhibition attenuated cell differentiation. Mechanically, we identified that adenomatous polyposis coli (APC), an antagonist of Wnt/beta catenin signaling, was the target gene of miR 374a. Furthermore, down regulation of miR 374a led to inhibition of Wnt/beta catenin signaling pathway during differentiation. Our results demonstrate that miR 374a promoted osteogenic differentiation of PDLSCs by targeting APC through Wnt/beta catenin signaling pathway and highlighted the potential of forward miRNA based therapy to promote periodontal ligament regeneration of humans.
C1 [Cheng, Yaodong; Cao, Fengdi; Liu, Minyi; Ou, Lingling; Chen, Xufeng; Lai, Renfa] Jinan Univ, Affiliated Hosp 1, Dept Stomatol, 613 Huangpu Ave West, Guangzhou 510630, Guangdong, Peoples R China.
   [Wu, Jian] Hebei Med Univ, Coll Stomatol, Shijiazhuang, Peoples R China.
   [Zhan, Jialin] Guangxi Med Univ, Nanning, Peoples R China.
C3 Jinan University; Hebei Medical University; Guangxi Medical University
RP Cao, FD; Lai, RF (通讯作者)，Jinan Univ, Affiliated Hosp 1, Dept Stomatol, 613 Huangpu Ave West, Guangzhou 510630, Guangdong, Peoples R China.
EM fengdicaouu@yeah.net; renfalaier@163.com
RI 敬亮, 许/AHA 5467 2022; Cao, Fengdi/Z 3904 2019; Chen, Jiahao/KPA 0985 2024
OI Cao, Fengdi/0000 0002 9909 1568; 
FU Guangdong Provincial Medical Research Foundation [A2016360]
FX This study was supported by Guangdong Provincial Medical Research
   Foundation (No.: A2016360).
CR [Anonymous], ACS BIOMATER SCI ENG
   Baron Roland, 2007, Curr Osteoporos Rep, V5, P73
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Castoldi M, 2008, NAT PROTOC, V3, P321, DOI 10.1038/nprot.2008.4
   Du FY, 2015, EXP THER MED, V10, P207, DOI 10.3892/etm.2015.2477
   Gangaraju VK, 2009, NAT REV MOL CELL BIO, V10, P116, DOI 10.1038/nrm2621
   Gay I, 2014, J PERIODONTAL RES, V49, P110, DOI 10.1111/jre.12086
   Harris ES, 2010, MOL BIOL CELL, V21, P2611, DOI 10.1091/mbc.E10 03 0235
   Hartmann C, 2000, DEVELOPMENT, V127, P3141
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   Hong L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160915
   Jia Q, 2015, ARCH ORAL BIOL, V60, P234, DOI 10.1016/j.archoralbio.2014.10.007
   Kapinas K, 2010, J BIOL CHEM, V285, P25221, DOI 10.1074/jbc.M110.116137
   Lu T, 2015, INT J CLIN EXP PATHO, V8, P10776
   Luzi E, 2008, J BONE MINER RES, V23, P287, DOI 10.1359/JBMR.071011
   Mizuno Y, 2008, BIOCHEM BIOPH RES CO, V368, P267, DOI 10.1016/j.bbrc.2008.01.073
   Nohutcu RM, 1997, J PERIODONTOL, V68, P320, DOI 10.1902/jop.1997.68.4.320
   NOJIMA N, 1990, J PERIODONTAL RES, V25, P179, DOI 10.1111/j.1600 0765.1990.tb01041.x
   Pan S, 2013, HORM METAB RES, V45, P518, DOI 10.1055/s 0033 1334896
   Park SJ, 2010, BONE, V46, P1498, DOI 10.1016/j.bone.2010.02.027
   Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Shang YC, 2007, CYTOTHERAPY, V9, P667, DOI 10.1080/14653240701508437
   SOMERMAN MJ, 1990, ARCH ORAL BIOL, V35, P241, DOI 10.1016/0003 9969(90)90062 F
   Wang T, 2010, BIOCHEM BIOPH RES CO, V402, P186, DOI 10.1016/j.bbrc.2010.08.031
   Wang Y, 2015, ONCOL REP, V34, P1988, DOI 10.3892/or.2015.4182
   Wei FL, 2015, STEM CELLS DEV, V24, P312, DOI 10.1089/scd.2014.0191
   Xu XY, 2015, FEBS LETT, V589, P407, DOI 10.1016/j.febslet.2014.12.027
   Zhang WB, 2014, BONE, V58, P59, DOI 10.1016/j.bone.2013.09.015
   Zhang YL, 2012, HEPATOLOGY, V56, P1631, DOI 10.1002/hep.25849
   Zhou QA, 2011, BIOCHEM BIOPH RES CO, V404, P127, DOI 10.1016/j.bbrc.2010.11.079
NR 31
TC 2
Z9 2
U1 0
U2 5
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936 2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2017
VL 10
IS 6
BP 6444
EP 6452
PG 9
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pathology
GA EZ2NL
UT WOS:000404545900027
DA 2025 08 17
ER

PT J
AU Eastell, R
   Krege, JH
   Chen, PQ
   Glass, EV
   Reginster, JY
AF Eastell, R
   Krege, JH
   Chen, PQ
   Glass, EV
   Reginster, JY
TI Development of an algorithm for using PINP to monitor treatment of
   patients with teriparatide
SO CURRENT MEDICAL RESEARCH AND OPINION
LA English
DT Article; Proceedings Paper
CT 5th Congress on Clinical and Economic Aspects of Osteoporosis and
   Osteoarthritis
CY MAR 16 19, 2005
CL Rome, ITALY
DE osteoporosis; parathyroid hormone; PINP; teriparatide
ID BONE TURNOVER MARKERS; PARATHYROID HORMONE; POSTMENOPAUSAL WOMEN;
   BIOCHEMICAL MARKERS; MINERAL DENSITY; OSTEOPOROSIS; RALOXIFENE; THERAPY;
   IMPACT; BMD
AB Introduction: Teriparatide effects are mediated via the preferential stimulation of osteoblastic activity over osteoclastic activity. Amino terminal propeptide of type I procollagen (PINP) is an indicator of osteoblastic activity.
   Objective: Develop an algorithm using PINP as an aid in the management of patients with postmenopausal osteoporosis treated with teriparatide.
   Research design and methods: For inclusion in this post hoc analysis, trials had to be investigations of teriparatide 20 mu g/day in postmenopausal women with osteoporosis having measurements of PINP at 3 months and bone mineral density (BMD) at 12 months. Signal to noise ratio was calculated for a series of markers of bone turnover in the Fracture Prevention Trial. An algorithm was developed to monitor patients treated with teriparatide using PINP.
   Results:Three trials met inclusion criteria and included the Fracture Prevention, Forteo Alendronate Comparator and Anabolic After Antiresorptive trials. PINP had the highest signal to noise ratio of all bone turnover markers. Positive PINP responses defined as increases > 10 mu g/L were observed in 77 97% of teriparatide  and in 6% of placebo treated patients after 3 months of study drug. Mean lumbar spine BMD increases after 12 months of teriparatide in patients having PINP changes > 10 mu g/L ranged from 8.3% to 9.5% and in patients with PINP changes <= 10 mu g/L ranged from 5.9% to 7.6%.
   In the algorithm, PINP is measured at baseline and after 1 3 months of therapy. Patients with PINP increases > 10 mu g/L are given a positive message. Patients with PINP increases <= 10 mu g/L are assessed for adherence, teriparatide administration and storage techniques, and for the presence of medical conditions that might limit their therapeutic response, and these issues are addressed as appropriate. Patients without these issues and with PINP increases <= 10 mu g/L should be given a neutral message because BMD may significantly increase with continued therapy.
   Conclusions: The PINP algorithm provides information regarding the anabolic response to teriparatide therapy and has the potential to identify patients requiring help with issues of adherence, injection technique, teriparatide storage, and medical problems limiting therapeutic responsiveness to teriparatide treatment, Data assessing the relationship of changes in PINP to fracture risk reduction are not available. We recommend physicians audit the use of the algorithm in practice so that improvements can be made.
C1 Univ Sheffield, No Gen Hosp, Ctr Clin Sci, Sheffield S5 7AU, S Yorkshire, England.
   Lilly Res Labs, Indianapolis, IN USA.
   Univ Liege, B 4000 Liege, Belgium.
C3 University of Sheffield; Northern General Hospital; Eli Lilly; Lilly
   Research Laboratories; University of Liege
RP Univ Sheffield, No Gen Hosp, Ctr Clin Sci, Herries Rd, Sheffield S5 7AU, S Yorkshire, England.
EM r.eastell@sheffield.ac.uk
RI Reginster, Jean Yves/AGC 6097 2022; Eastell, Richard/G 5851 2011
CR Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Blumsohn A, 2005, J BONE MINER RES, V20, pS411
   Chen PQ, 2005, J BONE MINER RES, V20, P962, DOI 10.1359/JBMR.050105
   Chenery Winthrop Holt, 1905, PMLA, VXX, P1
   Clowes JA, 2004, J CLIN ENDOCR METAB, V89, P1117, DOI 10.1210/jc.2003 030501
   Clowes JA, 2002, BONE, V30, P886, DOI 10.1016/S8756 3282(02)00728 7
   CLOWES JA, 2003, J BONE MINER RES S2, V18, pSU373
   Cosman F, 2005, NEW ENGL J MED, V353, P566, DOI 10.1056/NEJMoa050157
   Deal C, 2005, J BONE MINER RES, V20, P1905, DOI 10.1359/JBMR.050714
   Delmas PD, 2003, J BONE MINER RES, V18, pS374
   EFRON B, 1981, ANN STAT, V9, P586, DOI 10.1214/aos/1176345462
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   FINKELSTEIN JS, 1994, NEW ENGL J MED, V331, P1618, DOI 10.1056/NEJM199412153312404
   Hannon R, 1998, J BONE MINER RES, V13, P1124, DOI 10.1359/jbmr.1998.13.7.1124
   Lane NE, 2000, OSTEOPOROSIS INT, V11, P434, DOI 10.1007/s001980070111
   Lomeo A, 2000, CLIN CHEM, V46, P1200
   Machado ABD, 1999, J BONE MINER RES, V14, P602
   McClung MR, 2005, ARCH INTERN MED, V165, P1762, DOI 10.1001/archinte.165.15.1762
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Reginster JY, 2004, BONE, V34, P344, DOI 10.1016/j.bone.2003.10.004
   STEMARIE LG, 2005, IN PRESS J BONE MINE
NR 21
TC 101
Z9 104
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0300 7995
EI 1473 4877
J9 CURR MED RES OPIN
JI Curr. Med. Res. Opin.
PD JAN
PY 2006
VL 22
IS 1
BP 61
EP 66
DI 10.1185/030079905X75096
PG 6
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC General & Internal Medicine; Research & Experimental Medicine
GA 004KJ
UT WOS:000234751400007
PM 16393431
DA 2025 08 17
ER

PT J
AU Kolf, CM
   Song, L
   Helm, J
   Tuan, RS
AF Kolf, Catherine M.
   Song, Lin
   Helm, Jeannine
   Tuan, Rocky S.
TI Nascent osteoblast matrix inhibits osteogenesis of human mesenchymal
   stem cells in vitro
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Mesenchymal stem cells; Osteoblasts; Extracellular matrix; Osteogenesis;
   Stem cell niche
ID HUMAN BONE MARROW; HEMATOPOIETIC PROGENITOR CELLS; EXTRACELLULAR MATRIX;
   EX VIVO; DIFFERENTIATION; EXPANSION; COLLAGEN; TISSUE; MINERALIZATION;
   PROLIFERATION
AB Introduction: Adult mesenchymal stem cells (MSCs) are considered promising candidates for cell based therapies. Their potential utility derives primarily from their immunomodulatory activity, multi lineage differentiation potential, and likely progenitor cell function in wound healing and repair of connective tissues. However, in vitro, MSCs often senesce and spontaneously differentiate into osteoblasts after prolonged expansion, likely because of lack of regulatory microenvironmental signals. In vivo, osteoblasts that line the endosteal bone marrow surface are in close proximity to MSCs in the marrow stroma and thus may help to regulate MSC fate.
   Methods: We examined here how osteogenic differentiation of MSCs in vitro is affected by exposure to osteoblastic cells (OBCs). Human bone marrow MSCs were exposed to OBCs, derived by induced osteogenic differentiation of MSCs, either directly in contact co cultures, or indirectly to OBC conditioned medium or decellularized OBC extracellular matrix (ECM).
   Results: Our results showed that OBCs can act as negative regulators of MSC osteogenesis. mRNA expression profiling revealed that OBCs did not affect MSC osteogenesis in direct contact cultures or via secreted factors. However, seeding MSCs on decellularized OBC ECM significantly decreased expression of several osteogenic genes and maintained their fibroblastic morphologies. Proteomic analysis identified some of the candidate protein regulators of MSC osteogenesis.
   Conclusions: These findings provide the basis for future studies to elucidate the signaling mechanisms responsible for osteoblast matrix mediated regulation of MSC osteogenesis and to better manipulate MSC fate in vitro to minimize their spontaneous differentiation.
C1 [Kolf, Catherine M.; Song, Lin; Helm, Jeannine; Tuan, Rocky S.] NIAMSD, NIH, Cartilage Biol & Orthopaed Branch, Dept Hlth & Human Serv, Bethesda, MD USA.
   [Song, Lin] Johns Hopkins Univ, Dept Biol, Baltimore, MD USA.
   [Tuan, Rocky S.] Univ Pittsburgh, Sch Med, Ctr Cellular & Mol Engn, Dept Orthopaed Surg, Pittsburgh, PA 15219 USA.
   [Kolf, Catherine M.] Johns Hopkins Med Media Relat & Publ Affairs, Baltimore, MD 21231 USA.
   [Song, Lin] Stryker Orthoped, Mahwah, NJ 07430 USA.
   [Helm, Jeannine] Natl Inst Dent & Craniofacial Res, NIH, Translat Gen Res Branch, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH)   USA; NIH National Institute of
   Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Johns Hopkins
   University; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Johns Hopkins University; Johns
   Hopkins Medicine; National Institutes of Health (NIH)   USA; NIH
   National Institute of Dental & Craniofacial Research (NIDCR)
RP Tuan, RS (通讯作者)，NIAMSD, NIH, Cartilage Biol & Orthopaed Branch, Dept Hlth & Human Serv, Bethesda, MD USA.
EM rst13@pitt.edu
FU NIH Intramural Research Program [Z01 AR41131]; Commonwealth of
   Pennsylvania Department of Health [SAP 4100050913]
FX We sincerely thank Dr. Paul Manner (University of Washington) for
   providing femoral head tissue samples, and Jim Simone (NIAMS Flow
   Cytometry Facility), Dr. Lewis Pannell (Proteomics and Mass Spectrometry
   Laboratory, University of South Alabama), and Roberto Diaz (GE) for
   countless hours of sample processing and procedural advice. Supported by
   the NIH Intramural Research Program (Z01 AR41131) and the Commonwealth
   of Pennsylvania Department of Health (SAP 4100050913).
CR Antebi B, 2015, TISSUE ENG PART C ME, V21, P171, DOI [10.1089/ten.tec.2014.0092, 10.1089/ten.TEC.2014.0092]
   Arikawa E., SABIOSCIENCES TECHNI
   Becerra J, 1996, J BONE MINER RES, V11, P1703
   Bendall SC, 2007, NATURE, V448, P1015, DOI 10.1038/nature06027
   Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097 4644(199702)64:2<278::AID JCB11>3.0.CO;2 F
   Buhr N, 2007, ELECTROPHORESIS, V28, P1615, DOI 10.1002/elps.200600497
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Chen X, 2006, IMMUNOL CELL BIOL, V84, P413, DOI 10.1111/j.1440 1711.2006.01458.x
   Chen XD, 2007, J BONE MINER RES, V22, P1943, DOI 10.1359/JBMR.070725
   Cool SM, 2005, STEM CELLS DEV, V14, P632, DOI 10.1089/scd.2005.14.632
   Csaki C, 2009, HISTOCHEM CELL BIOL, V131, P251, DOI 10.1007/s00418 008 0524 6
   Dimitriou R, 2005, INJURY, V36, P1392, DOI 10.1016/j.injury.2005.07.019
   Einhorn TA, 1998, CLIN ORTHOP RELAT R, pS7
   Gan OI, 1997, BLOOD, V90, P641, DOI 10.1182/blood.V90.2.641.641_641_650
   Gerstenfeld LC, 2002, J BONE MINER RES, V17, P221, DOI 10.1359/jbmr.2002.17.2.221
   Gronthos S, 2003, J BONE MINER RES, V18, P716, DOI 10.1359/jbmr.2003.18.4.716
   Hadfield KD, 2008, J BIOL CHEM, V283, P5928, DOI 10.1074/jbc.M709299200
   Hashimoto K, 1997, BBA MOL CELL RES, V1355, P303, DOI 10.1016/S0167 4889(96)00147 4
   Heckmann L, 2006, CELLS TISSUES ORGANS, V182, P143, DOI 10.1159/000093964
   Heng BC, 2004, J BONE MINER RES, V19, P1379, DOI 10.1359/JBMR.040714
   Herzog EL, 2003, BLOOD, V102, P3483, DOI 10.1182/blood 2003 05 1664
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   King MW, 2009, INT J DEV BIOL, V53, P955, DOI 10.1387/ijdb.082719mk
   KIRK MD, 1995, J BONE MINER RES, V10, P1203
   Lai YL, 2010, STEM CELLS DEV, V19, P1095, DOI 10.1089/scd.2009.0217
   Lin H, 2012, BIOMATERIALS, V33, P4480, DOI 10.1016/j.biomaterials.2012.03.012
   Lozito TP, 2009, J CELL BIOCHEM, V107, P706, DOI 10.1002/jcb.22166
   Lozito Thomas P., 2009, P185, DOI 10.1007/978 1 60327 227 8_17
   Mizuno D, 2010, GROWTH FACTORS, V28, P34, DOI 10.3109/08977190903326362
   Ohno S, 2002, J DENT RES, V81, P822, DOI 10.1177/154405910208101205
   Pei M, 2011, TISSUE ENG PT A, V17, P3067, DOI [10.1089/ten.tea.2011.0158, 10.1089/ten.TEA.2011.0158]
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Reyes M, 2001, BLOOD, V98, P2615, DOI 10.1182/blood.V98.9.2615
   Salasznyk RM, 2004, J BIOMED BIOTECHNOL, P24, DOI 10.1155/S1110724304306017
   Sethe S, 2006, AGEING RES REV, V5, P91, DOI 10.1016/j.arr.2005.10.001
   Shi S, 2003, J BONE MINER RES, V18, P696, DOI 10.1359/jbmr.2003.18.4.696
   Shi ST, 1996, J BONE MINER RES, V11, P1139, DOI 10.1002/jbmr.5650110813
   Song L, 2004, FASEB J, V18, P980, DOI 10.1096/fj.03 1100fje
   Sun Y, 2011, FASEB J, V25, P1474, DOI 10.1096/fj.10 161497
   Taichman RS, 1996, BLOOD, V87, P518, DOI 10.1182/blood.V87.2.518.bloodjournal872518
   Tiaden AN, 2012, STEM CELLS, V30, P2271, DOI 10.1002/stem.1190
   Tsai MT, 2012, INT ORTHOP, V36, P199, DOI 10.1007/s00264 011 1259 x
   Tuan RS, 2003, ARTHRITIS RES THER, V5, P32, DOI 10.1186/ar614
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   URIST MR, 1979, P NATL ACAD SCI USA, V76, P1828, DOI 10.1073/pnas.76.4.1828
   Volloch V, 2013, MATRIX BIOL, V32, P365, DOI 10.1016/j.matbio.2013.06.001
   Wagner W, 2007, EXP HEMATOL, V35, P314, DOI 10.1016/j.exphem.2006.10.003
   Wang Y, 2007, J TISSUE ENG REGEN M, V1, P39, DOI 10.1002/term.6
   Xie T, 1998, CELL, V94, P251, DOI 10.1016/S0092 8674(00)81424 5
   Ye CP, 2007, CELL BIOCHEM FUNCT, V25, P267, DOI 10.1002/cbf.1330
   Zacchigna L, 2006, CELL, V124, P929, DOI 10.1016/j.cell.2005.12.035
NR 51
TC 13
Z9 17
U1 0
U2 23
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD DEC 22
PY 2015
VL 6
AR 258
DI 10.1186/s13287 015 0223 x
PG 16
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA CZ1VU
UT WOS:000366894600002
PM 26696301
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Keshishi, D
   Makunts, T
   Abagyan, R
AF Keshishi, Dro
   Makunts, Tigran
   Abagyan, Ruben
TI Common osteoporosis drug associated with increased rates of depression
   and anxiety
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MANAGEMENT; BISPHOSPHONATES; TERIPARATIDE; MECHANISM; BRAIN
AB Osteoporosis affects over 10 million Americans over 50. Bisphosphonate therapy, mainly alendronate, is amongst the most prescribed treatments for the disease. The use of alendronate and other bisphosphonates has been associated with depressive symptoms in recent case reports. In this study we quantified this association by analyzing over 100,000 adverse events reports from the Food and Drug Administration Adverse Events Reporting System (FAERS) and the World Health Organization's (WHO) global database for adverse drug reactions, ADRs, VigiAccess. We found that alendronate therapy is significantly associated with depression and anxiety when compared to other first line osteoporosis treatments. The reported risk of depressive ADRs was found to be over 14 fold greater in patients taking alendronate under the age of 65 and over fourfold greater for patients over 65 compared to the control. Several hypotheses concerning the molecular mechanism of the observed association of alendronate and depressive symptoms were discussed.
C1 [Keshishi, Dro; Makunts, Tigran; Abagyan, Ruben] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, San Diego, CA 92103 USA.
   [Makunts, Tigran] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA.
C3 University of California System; University of California San Diego; US
   Food & Drug Administration (FDA)
RP Abagyan, R (通讯作者)，Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, San Diego, CA 92103 USA.
EM rabagyan@health.ucsd.edu
OI Makunts, Tigran/0000 0001 5536 1266
FU NIH NIGSMS [R35 GM131881]
FX The authors thank Dr. Da Shi for the help with data preparation and
   analysis and Dr. Isaac V. Cohen for help with study design. We also
   thank Dr. Rabia S. Atayee, Dr. Kelly C. Lee, Dr. Linda Awdishu, and Dr.
   Ila Saunders, for fruitful discussions. The study was funded in part by
   NIH NIGSMS R35 GM131881 to R.A.
CR [Anonymous], MILL AM AFF OST LOW
   Barrett J, 2004, J CLIN PHARMACOL, V44, P951, DOI 10.1177/0091270004267594
   Bodenner D, 2007, CLIN INTERV AGING, V2, P499
   Brown EG, 1999, DRUG SAFETY, V20, P109, DOI 10.2165/00002018 199920020 00002
   Cibicková L, 2007, PHYSIOL RES, V56, P765, DOI 10.33549/physiolres.931121
   Cizza G, 2009, TRENDS ENDOCRIN MET, V20, P367, DOI 10.1016/j.tem.2009.05.003
   Cohen IV, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 85389 x
   Cohen IV, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 76258 0
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Eastell R, 2019, J CLIN ENDOCR METAB, V104, P1595, DOI 10.1210/jc.2019 00221
   Hanley DA, 2012, INT J CLIN PRACT, V66, P1139, DOI 10.1111/ijcp.12022
   Jeremiah MP, 2015, AM FAM PHYSICIAN, V92, P261
   Kelly RR, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00200
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Loeb JA, 2006, J NEUROL SCI, V243, P77, DOI 10.1016/j.jns.2005.11.033
   Makunts T, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 69773 7
   Martino G, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18158144
   Muglia P, 2010, MOL PSYCHIATR, V15, P589, DOI 10.1038/mp.2008.131
   Oliveira JRM, 2016, SCI REP UK, V6, DOI 10.1038/srep22961
   Porras AG, 1999, CLIN PHARMACOKINET, V36, P315, DOI 10.2165/00003088 199936050 00002
   Reszka Alfred A, 2003, Curr Osteoporos Rep, V1, P45, DOI 10.1007/s11914 003 0008 5
   Schmidt A, 1996, P NATL ACAD SCI USA, V93, P3068, DOI 10.1073/pnas.93.7.3068
   Stroup J, 2008, AM J HEALTH SYST PH, V65, P532, DOI 10.2146/ajhp070171
   Tu Kristie N, 2018, P T, V43, P92
   Wallace MJ, 1999, NAT GENET, V21, P334, DOI 10.1038/6866
   Wolffenbuttel B H R, 2003, Ned Tijdschr Geneeskd, V147, P35
NR 27
TC 20
Z9 21
U1 1
U2 10
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD DEC 14
PY 2021
VL 11
IS 1
AR 23956
DI 10.1038/s41598 021 03214 x
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA XP3OZ
UT WOS:000730779300063
PM 34907232
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Su, S
   Wu, LQ
   Zhou, GB
   Peng, LL
   Zhao, HZ
   Wang, X
   Li, K
AF Su, Si
   Wu, Liuqing
   Zhou, Guibao
   Peng, Lingling
   Zhao, Huanzhe
   Wang, Xiao
   Li, Kuan
TI Indication and adverse event profiles of denosumab and zoledronic acid:
   based on US FDA adverse event reporting system (FAERS)
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE denosumab; zoledronic acid; adverse events; off label use;
   pharmacovigilance
ID BONE MINERAL DENSITY; EARLY BREAST CANCER; NONMETASTATIC
   PROSTATE CANCER; ANDROGEN DEPRIVATION THERAPY; FRACTURE RISK;
   DISPROPORTIONALITY ANALYSIS; POSTMENOPAUSAL WOMEN; ADJUVANT LETROZOLE;
   DOUBLE BLIND; TAMOXIFEN
AB Objective: To investigate adverse events (AEs) associated with denosumab (Dmab) and zoledronic acid (ZA), compare their association strengths, and explore potential applications to provide clinical reference.Methods: We collected data from FAERS from January 2004 to November 2022 and mined AE signals for Dmab and ZA using ROR values. We compared signal intensity for same AEs and investigated off label use. We also examined their AEs in adjuvant therapy for breast and prostate cancer.Results: 154,735 reports of primary suspect drugs were analyzed in the FAERS database (Dmab: 117,857; ZA: 36,878). Dmab and ZA had 333 and 1,379 AE signals, with 189 overlaps. The AEs of Dmab included death (ROR:3.478), osteonecrosis of jaw (ROR:53.025), back pain (ROR:2.432), tooth disorder (ROR:16.18), bone pain (ROR:6.523). For ZA, the AEs included osteonecrosis (ROR:104.866), death (ROR: 3.645), pain (ROR:3.963), osteonecrosis of jaw (ROR: 91.744), tooth extraction (ROR: 142.143). Among overlap signals, Dmab showed higher strength in exostosis of the jaw (ROR: 182.66 vs. 5.769), atypical fractures (ROR: 55.589 vs. 9.123), and atypical femur fractures (ROR:49.824 vs. 4.968). And ZA exhibited stronger associations in abscess jaw (ROR: 84.119 vs. 11.12), gingival ulceration (ROR: 74.125 vs. 4.827), increased bone formation (ROR: 69.344 vs. 3.218). Additionally, we identified 528 off label uses for Dmab and 206 for ZA, with Dmab mainly used in prostate cancer (1.04%), breast cancer (1.03%), and arthritis (0.42%), while ZA in breast cancer (3.21%), prostate cancer (2.48%), and neoplasm malignant (0.52%). For Dmab in breast cancer treatment, AEs included death (11.6%), disease progression (3.3%), and neutropenia (2.7%), while for ZA included death (19.8%), emotional disorder (12.9%), osteomyelitis (11.7%). For prostate cancer treatment, Dmab`s AEs were death (8.9%), prostate cancer metastatic (1.6%), renal impairment (1.7%), while ZA`s included death (34.4%), general physical health deterioration (19.9%), and hemoglobin decreased (18.9%).Conclusion: Our analysis of FAERS database provided postmarketing surveillance data and revealed different strengths of reported AE signals between Dmab and ZA in some of their common AEs. It's also worth noting that both drugs have potential off label applications, which could introduce new AEs. This highlights the necessity for safety monitoring when using Dmab and ZA off label.
C1 [Su, Si; Wang, Xiao] Guangdong Med Univ, Sch Pharm, Zhanjiang, Peoples R China.
   [Su, Si; Zhou, Guibao; Peng, Lingling; Zhao, Huanzhe; Wang, Xiao; Li, Kuan] Southern Univ Sci & Technol, Jinan Univ, Affiliated Hosp 1, Dept Pharm,Clin Med Coll 2,Shenzhen Peoples Hosp, Shenzhen, Guangdong, Peoples R China.
   [Wu, Liuqing] Longgang Cent Hosp Shenzhen, Shenzhen, Guangdong, Peoples R China.
C3 Guangdong Medical University; Southern University of Science &
   Technology; Jinan University; Longgang District Central Hospital of
   Shenzhen
RP Wang, X (通讯作者)，Guangdong Med Univ, Sch Pharm, Zhanjiang, Peoples R China.; Wang, X; Li, K (通讯作者)，Southern Univ Sci & Technol, Jinan Univ, Affiliated Hosp 1, Dept Pharm,Clin Med Coll 2,Shenzhen Peoples Hosp, Shenzhen, Guangdong, Peoples R China.
EM wangxiao0719@163.com; li_kuan1989@126.com
OI Li, Kuan/0000 0002 5253 5811
FU This work was supported by grants from the National Natural Science
   Foundation of China (Grant NO. 81903581), Shenzhen Science and
   Technology Program (Grant NOs JCYJ20190807150005699 and
   RCBS20200714115000009), Shenzhen Key Medical Discipline Construction
   [81903581]; National Natural Science Foundation of China
   [JCYJ20190807150005699, RCBS20200714115000009]; Shenzhen Science and
   Technology Program [SZXK059]; Shenzhen Key Medical Discipline
   Construction Fund [ZDSYS20200811142804014]; Shenzhen Key Laboratory of
   Prevention and Treatment of Severe Infections
FX This work was supported by grants from the National Natural Science
   Foundation of China (Grant NO. 81903581), Shenzhen Science and
   Technology Program (Grant NOs JCYJ20190807150005699 and
   RCBS20200714115000009), Shenzhen Key Medical Discipline Construction
   Fund (Grant NO. SZXK059), Shenzhen Key Laboratory of Prevention and
   Treatment of Severe Infections (ZDSYS20200811142804014).
CR Abe J, 2015, INT J MED SCI, V12, P312, DOI 10.7150/ijms.10703
   Aihara T, 2010, ONCOLOGY BASEL, V79, P376, DOI 10.1159/000323489
   Aitken D, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891 018 2143 2
   Alatawi YM, 2017, EXPERT OPIN DRUG SAF, V16, P761, DOI 10.1080/14740338.2017.1323867
   Alibhai SMH, 2018, ANN INTERN MED, V168, P459, DOI 10.7326/L17 0702
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Bian SN, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.767999
   Bingham CO, 2006, ARTHRITIS RHEUM US, V54, P3494, DOI 10.1002/art.22160
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Bohm R., 2018, Primer on disproportionality analysis
   Boquete Castro A, 2016, CLIN ORAL IMPLAN RES, V27, P367, DOI 10.1111/clr.12556
   Brufsky AM, 2009, CLIN BREAST CANCER, V9, P77, DOI 10.3816/CBC.2009.n.015
   Chen Z, 2009, OSTEOPOROSIS INT, V20, P527, DOI 10.1007/s00198 008 0721 0
   Chhabra P, 2013, DRUG SAFETY, V36, P1117, DOI 10.1007/s40264 013 0115 x
   Coleman R, 2020, LANCET ONCOL, V21, P60, DOI 10.1016/S1470 2045(19)30687 4
   Crisafulli S, 2023, EXPERT OPIN DRUG SAF, V22, P373, DOI 10.1080/14740338.2023.2219892
   de Groot AF, 2018, CANCER TREAT REV, V62, P18, DOI 10.1016/j.ctrv.2017.10.010
   Dedes PG, 2012, BBA GEN SUBJECTS, V1820, P1926, DOI 10.1016/j.bbagen.2012.07.013
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Gnant M, 2015, ANN ONCOL, V26, P313, DOI 10.1093/annonc/mdu544
   Gralow JR, 2009, J NATL COMPR CANC NE, V7, pS1, DOI 10.6004/jnccn.2009.0076
   Greear E. L., 2022, Zoledronate. StatPearls. Treasure island (FL)
   Guise TA, 2006, ONCOLOGIST, V11, P1121, DOI 10.1634/theoncologist.11 10 1121
   Hauben M, 2003, ANN PHARMACOTHER, V37, P1117, DOI 10.1345/aph.1C515
   Hildebrand G.K., 2022, DENOSUMAB
   Hoffman KB, 2014, DRUG SAFETY, V37, P283, DOI 10.1007/s40264 014 0150 2
   Hu QW, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.799575
   Jamal SA, 2011, J BONE MINER RES, V26, P1829, DOI 10.1002/jbmr.403
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Khouri C, 2021, J CLIN EPIDEMIOL, V134, P14, DOI 10.1016/j.jclinepi.2021.01.015
   Klotz LH, 2013, EUR UROL, V63, P927, DOI 10.1016/j.eururo.2012.09.007
   Lin KF, 2015, GEN HOSP PSYCHIAT, V37, DOI 10.1016/j.genhosppsych.2015.01.007
   Marwitz KK, 2022, EXPLOR RES CLIN SOC, V5, DOI 10.1016/j.rcsop.2022.100130
   Michel C, 2017, CLIN DRUG INVEST, V37, P415, DOI 10.1007/s40261 017 0503 6
   Montastruc JL, 2011, BRIT J CLIN PHARMACO, V72, P905, DOI 10.1111/j.1365 2125.2011.04037.x
   Moore TJ, 2007, ARCH INTERN MED, V167, P1752, DOI 10.1001/archinte.167.16.1752
   Nicolatou Galitis O, 2019, OR SURG OR MED OR PA, V127, P117, DOI 10.1016/j.oooo.2018.09.008
   Noguchi Y, 2021, BRIEF BIOINFORM, V22, DOI 10.1093/bib/bbab347
   Omar NE, 2021, ESMO OPEN, V6, DOI 10.1016/j.esmoop.2021.100315
   Pang KL, 2020, DRUG DES DEV THER, V14, P4029, DOI 10.2147/DDDT.S270829
   Pariente A, 2007, DRUG SAFETY, V30, P891, DOI 10.2165/00002018 200730100 00007
   Powles T, 1996, J CLIN ONCOL, V14, P78, DOI 10.1200/JCO.1996.14.1.78
   Raje N, 2018, LANCET ONCOL, V19, P370, DOI 10.1016/S1470 2045(18)30072 X
   Rubin KH, 2020, BONE, V134, DOI 10.1016/j.bone.2020.115296
   Shao QH, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.750108
   Shapiro CL, 2020, CANCERS, V12, DOI 10.3390/cancers12113094
   She GR, 2017, EXP THER MED, V14, P4901, DOI 10.3892/etm.2017.5135
   Smith MR, 2003, J UROLOGY, V169, P2008, DOI 10.1097/01.ju.0000063820.94994.95
   Smith MR, 2001, NEW ENGL J MED, V345, P948, DOI 10.1056/NEJMoa010845
   Sverrisdóttir A, 2004, J CLIN ONCOL, V22, P3694, DOI 10.1200/JCO.2004.08.148
   Tanaka Y, 2021, J RHEUMATOL, V48, P1663, DOI 10.3899/jrheum.201376
   Tang S, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.970066
   Tseng OL, 2018, THER ADV MUSCULOSKEL, V10, P71, DOI 10.1177/1759720X18759291
   Ubellacker JM, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058 017 0815 8
   van Puijenbroek EP, 2002, PHARMACOEPIDEM DR S, V11, P3, DOI 10.1002/pds.668
   Verden A, 2018, DRUG SAFETY, V41, P357, DOI 10.1007/s40264 017 0622 2
   Waqas K, 2021, J BONE ONCOL, V28, DOI 10.1016/j.jbo.2021.100355
   Wilson C, 2018, EUR J CANCER, V94, P70, DOI 10.1016/j.ejca.2018.02.004
   Zaman K, 2012, ANN ONCOL, V23, P1474, DOI 10.1093/annonc/mdr448
NR 59
TC 7
Z9 7
U1 3
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 1
PY 2023
VL 14
AR 1225919
DI 10.3389/fphar.2023.1225919
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA X8VV5
UT WOS:001101171800001
PM 38027014
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lu, YF
   Liu, Y
   Fu, WM
   Xu, J
   Wang, B
   Sun, YX
   Wu, TY
   Xu, LL
   Chan, KM
   Zhang, JF
   Li, G
AF Lu, Ying Fei
   Liu, Yang
   Fu, Wei Ming
   Xu, Jia
   Wang, Bin
   Sun, Yu Xin
   Wu, Tian Yi
   Xu, Liang Liang
   Chan, Kai Ming
   Zhang, Jin Fang
   Li, Gang
TI Long noncoding RNA H19 accelerates tenogenic differentiation and
   promotes tendon healing through targeting miR 29b 3p and activating
   TGF β1 signaling
SO FASEB JOURNAL
LA English
DT Article
DE tendon differentiation; pathway; lncRNA; miRNA
ID MESENCHYMAL STEM CELLS; OSTEOBLAST DIFFERENTIATION;
   EXTRACELLULAR MATRIX; CANCER METASTASIS; ACHILLES TENDON; EXPRESSION;
   REPAIR; FIBROSIS; FIBROBLASTS; BIOLOGY
AB Tendon injures are common orthopedic conditions, but tendon development and the pathogenesis of tendon injures, such as tendinopathy, remain largely unknown and have limited the development of clinical therapy. Studies on tenogenic differentiation at the molecular level may help in developing novel therapeutic strategies. As novel regulators, long noncoding RNAs (lncRNAs) have been found to have widespread biological functions, and emerging evidence demonstrates that lncRNAs may play important regulatory roles in cell differentiation and tissue regeneration. In this study, we found that lncRNA H19 stimulated tenogenesis of human tendon derived stem cells. Stable overexpression of H19 significantly accelerated TGF beta 1 induced tenogenic differentiation in vitro and accelerated tendon healing in a mouse tendon defect model. H19 directly targeted miR 29b 3p, which is considered to be a negative regulator of tenogenesis. Furthermore, miR 29b 3p directly suppressed the expression of TGF beta 1 and type I collagen, thereby forming a novel regulatory feedback loop between H19 and TGF beta 1 to mediate tenogenic differentiation. Our study demonstrated that H19 promotes tenogenic differentiation both in vitro and in vivo by targeting miR 29b 3p and activating TGF beta 1 signaling. Regulation of the TGF beta 1/H19/miR 29b 3p regulatory loop may be a new strategy for treating tendon injury. Lu, Y. F., Liu, Y., Fu, W. M., Xu, J., Wang, B., Sun, Y. X., Wu, T. Y., Xu, L. L, Chan, K. M., Zhang, J. F., Li, G. Long noncoding RNA H19 accelerates tenogenic differentiation and promotes tendon healing through targeting miR 29b 3p and activating TGF beta 1 signaling.
C1 [Lu, Ying Fei; Liu, Yang; Xu, Jia; Wang, Bin; Sun, Yu Xin; Wu, Tian Yi; Xu, Liang Liang; Chan, Kai Ming; Zhang, Jin Fang; Li, Gang] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Orthoped & Traumatol, Hong Kong, Hong Kong, Peoples R China.
   [Chan, Kai Ming; Zhang, Jin Fang; Li, Gang] Chinese Univ Hong Kong, Lui Che Woo Inst Innovat Med, Hong Kong, Hong Kong, Peoples R China.
   [Chan, Kai Ming; Zhang, Jin Fang; Li, Gang] Chinese Univ Hong Kong, Fac Med, Li Ka Shing Inst Hlth Sci, Stem Cells & Regenerat Med Lab, Hong Kong, Hong Kong, Peoples R China.
   [Fu, Wei Ming] Southern Med Univ, Sch Pharmaceut Sci, Guangzhouv, Peoples R China.
   [Xu, Jia] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Orthopaed Surg, Shanghai, Peoples R China.
C3 Chinese University of Hong Kong; Prince of Wales Hospital; Chinese
   University of Hong Kong; Chinese University of Hong Kong; Southern
   Medical University   China; Shanghai Jiao Tong University
RP Zhang, JF; Li, G (通讯作者)，Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci, Room 904,9 F, Shatin, Hong Kong, Peoples R China.
EM zhangjf06@cuhk.edu.hk; gangli@cuhk.edu.hk
RI Liangliang, XU/K 9185 2019; WANG, BIN/O 2346 2019; SUN,
   Yuxin/B 5440 2016; Li, Gang/J 7830 2018
OI WANG, BIN/0000 0002 1348 1494; Xu, Liangliang/0000 0002 5249 7480; Li,
   Gang/0000 0002 3981 2239
FU Young Scientist Mentorship and Research Training (SMART) program; Lui
   Che Woo Institute of Innovation Medicine (The Chinese University of Hong
   Kong)
FX This work is partially supported by the Young Scientist Mentorship and
   Research Training (SMART) program and the Lui Che Woo Institute of
   Innovation Medicine (The Chinese University of Hong Kong). The authors
   declare no conflicts of interest.
CR Andres BM, 2008, CLIN ORTHOP RELAT R, V466, P1539, DOI 10.1007/s11999 008 0260 1
   Bi YM, 2007, NAT MED, V13, P1219, DOI 10.1038/nm1630
   Chen Q, 2014, INT J CLIN EXP PATHO, V7, P8462
   Cheng J, 2013, AM J MED SCI, V346, P98, DOI 10.1097/MAJ.0b013e318267680d
   Clayton RAE, 2008, INJURY, V39, P1338, DOI 10.1016/j.injury.2008.06.021
   Cushing L, 2015, BIOCHEM CELL BIOL, V93, P109, DOI 10.1139/bcb 2014 0095
   Dey BK, 2014, GENE DEV, V28, P491, DOI 10.1101/gad.234419.113
   Farhat YM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051411
   GOSHEN R, 1993, MOL REPROD DEV, V34, P374, DOI 10.1002/mrd.1080340405
   Guerquin MJ, 2013, J CLIN INVEST, V123, P3564, DOI 10.1172/JCI67521
   Guo J, 2016, EXP CELL RES, V341, P1, DOI 10.1016/j.yexcr.2016.01.007
   HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0
   Havis E, 2014, DEVELOPMENT, V141, P3683, DOI 10.1242/dev.108654
   He Y, 2013, BIOCHIMIE, V95, P1355, DOI 10.1016/j.biochi.2013.03.010
   Huang YP, 2015, STEM CELLS, V33, P3481, DOI 10.1002/stem.2225
   Isfort RJ, 1997, MOL CARCINOGEN, V20, P189, DOI 10.1002/(SICI)1098 2744(199710)20:2<189::AID MC5>3.0.CO;2 I
   Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027
   Keniry A, 2012, NAT CELL BIOL, V14, P659, DOI 10.1038/ncb2521
   KVIST M, 1994, SPORTS MED, V18, P173, DOI 10.2165/00007256 199418030 00004
   Li H, 2014, ONCOTARGET, V5, P2318, DOI 10.18632/oncotarget.1913
   Li JX, 2016, MOL MED REP, V13, P4229, DOI 10.3892/mmr.2016.5062
   Li JX, 2016, REPROD SCI, V23, P386, DOI 10.1177/1933719115602768
   Liang WC, 2016, SCI REP UK, V6, DOI 10.1038/srep20121
   Loewer S, 2010, NAT GENET, V42, P1113, DOI 10.1038/ng.710
   Luo M, 2013, CANCER LETT, V333, P213, DOI 10.1016/j.canlet.2013.01.033
   LUSTIG O, 1994, MOL REPROD DEV, V38, P239, DOI 10.1002/mrd.1080380302
   Ma CC, 2014, TUMOR BIOL, V35, P9163, DOI 10.1007/s13277 014 2185 5
   Ni M, 2012, J ORTHOP RES, V30, P613, DOI 10.1002/jor.21559
   Nourissat G, 2015, NAT REV RHEUMATOL, V11, P223, DOI 10.1038/nrrheum.2015.26
   Pathak S, 2010, REPROD FERT DEVELOP, V22, P939, DOI 10.1071/RD09154
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144
   Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159 8290.CD 11 0209
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Pryce BA, 2009, DEVELOPMENT, V136, P1351, DOI 10.1242/dev.027342
   Qin W, 2011, J AM SOC NEPHROL, V22, P1462, DOI 10.1681/ASN.2010121308
   Qiu YW, 2013, CELLS TISSUES ORGANS, V197, P27, DOI 10.1159/000341426
   Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev biochem 051410 092902
   Rui YF, 2010, TISSUE ENG PT A, V16, P1549, DOI [10.1089/ten.tea.2009.0529, 10.1089/ten.TEA.2009.0529]
   Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014
   Schweitzer R, 2010, DEVELOPMENT, V137, P2807, DOI 10.1242/dev.047498
   Sharma P, 2005, J BONE JOINT SURG AM, V87A, P187, DOI 10.2106/JBJS.D.01850
   Tsang WP, 2010, CARCINOGENESIS, V31, P350, DOI 10.1093/carcin/bgp181
   Wang B, 2016, EXP CELL RES, V347, P360, DOI 10.1016/j.yexcr.2016.08.018
   Wang Y, 2013, DEV CELL, V25, P69, DOI 10.1016/j.devcel.2013.03.002
   Winbanks CE, 2011, J BIOL CHEM, V286, P13805, DOI 10.1074/jbc.M110.192625
   Yang T, 2013, J CELL BIOCHEM, V114, P1336, DOI 10.1002/jcb.24474
   Yin Z, 2016, STEM CELL TRANSL MED, V5, P1106, DOI 10.5966/sctm.2015 0215
   Zhang Y, 2014, MOL THER, V22, P974, DOI 10.1038/mt.2014.25
   Zhu L, 2013, BIOCHEM BIOPH RES CO, V432, P612, DOI 10.1016/j.bbrc.2013.02.036
   Zhu ZJ, 2015, INT J CLIN EXP PATHO, V8, P10082
   Zuo CQ, 2013, MOL MED REP, V8, P463, DOI 10.3892/mmr.2013.1540
NR 52
TC 76
Z9 82
U1 0
U2 34
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3998 USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD MAR
PY 2017
VL 31
IS 3
BP 954
EP 964
DI 10.1096/fj.201600722R
PG 11
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA EM9ZX
UT WOS:000395671200012
PM 27895107
DA 2025 08 17
ER

PT J
AU Hutchison, MR
   White, PC
AF Hutchison, Michele R.
   White, Perrin C.
TI Prostacyclin Regulates Bone Growth via the Epac/Rap1 Pathway
SO ENDOCRINOLOGY
LA English
DT Article
ID HUMAN ARTICULAR CHONDROCYTES; ACTIVATED PROTEIN KINASE; NONSTEROIDAL
   ANTIINFLAMMATORY DRUGS; JUVENILE IDIOPATHIC ARTHRITIS; PROSTAGLANDIN
   E 2; IN VITRO; IGF I; CELL PROLIFERATION; INFLAMMATORY RESPONSE;
   PROSTANOID RECEPTORS
AB Prostaglandins, particularly PGE(2), are important to adult bone and joint health, but how prostaglandins act on growth plate cartilage to affect bone growth is unclear. We show that growth plate cartilage is distinct from articular cartilage with respect to cyclooxygenase (COX) 2 mRNA expression; although articular chondrocytes express very little COX 2, COX 2 expression is high in growth plate chondrocytes and is increased by IGF I. In bovine primary growth plate chondrocytes, ATDC5 cells, and human metatarsal explants, inhibition of COX activity with nonsteroidal antiinflammatory drugs (NSAIDs) inhibits chondrocyte proliferation and ERK activation by IGF I. This inhibition is reversed by prostaglandin E 2 and prostacyclin (PGI(2)) but not by prostaglandin D 2 or thromboxane B 2. Inhibition of COX activity in young mice by ip injections of NSAIDs causes dwarfism. In growth plate chondrocytes, inhibition of proliferation and ERK activation by NSAIDs is reversed by forskolin, 8 bromoadenosine, 3',5' cAMP and a prostacyclin analog, iloprost. The inhibition of proliferation and ERK activation by celecoxib is also reversed by 8CPT 2Me cAMP, an activator of Epac, implicating the small G protein Rap1 in the pathway activated by iloprost. These results imply that prostacyclin is required for proper growth plate development and bone growth.
C1 [Hutchison, Michele R.; White, Perrin C.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center
RP Hutchison, MR (通讯作者)，5323 Harry Hines Blvd,RM G2 236, Dallas, TX 75390 USA.
EM michele.hutchison@utsouthwestern.edu
FU NIH Grants from the National Institute of Diabetes and Digestive and
   Kidney Diseases [K08DK073447, R03DK089151]
FX This work was supported by NIH Grants K08DK073447 and R03DK089151 from
   the National Institute of Diabetes and Digestive and Kidney Diseases (to
   M.R.H.).
CR Abramovitz M, 2000, BBA MOL CELL BIOL L, V1483, P285, DOI 10.1016/S1388 1981(99)00164 X
   Adams SS, 1970, RHEUMATOL PHYS M S10, V10, P19
   Adebajo A, 2012, BMC FAM PRACT, V13, DOI 10.1186/1471 2296 13 23
   Alvarez Soria MA, 2008, OSTEOARTHR CARTILAGE, V16, P1484, DOI 10.1016/j.joca.2008.04.022
   Bassleer C, 1997, PHARMACOLOGY, V54, P49, DOI 10.1159/000139469
   Beharry KDA, 2006, INVEST OPHTH VIS SCI, V47, P3036, DOI 10.1167/iovs.06 0057
   Bishop Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042
   Blanco FJ, 1999, J RHEUMATOL, V26, P1366
   Bos JL, 2006, TRENDS BIOCHEM SCI, V31, P680, DOI 10.1016/j.tibs.2006.10.002
   Brochhausen C, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1948
   BROWN RD, 1992, J CLIN PHARMACOL, V32, P231, DOI 10.1002/j.1552 4604.1992.tb03831.x
   BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460 2075.1993.tb06105.x
   Chagin AS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4673
   Chang JK, 2006, TOXICOLOGY, V228, P111, DOI 10.1016/j.tox.2006.08.028
   Ciarmatori S, 2007, J MOL ENDOCRINOL, V38, P493, DOI 10.1677/jme.1.02179
   COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367
   Dewitt EM, 2012, ARTHRIT CARE RES, V64, P1001, DOI 10.1002/acr.21625
   DiBattista JA, 1996, MOL CELL ENDOCRINOL, V123, P27, DOI 10.1016/0303 7207(96)03887 7
   DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0
   Dingle JT, 1999, Z RHEUMATOL, V58, P125, DOI 10.1007/s003930050161
   DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998
   Dueckers G, 2012, CLIN IMMUNOL, V142, P176, DOI 10.1016/j.clim.2011.10.003
   Espinosa M, 2012, PEDIATR REV, V33, P303, DOI 10.1542/pir.33 7 303
   FLANAGAN AM, 1992, ENDOCRINOLOGY, V130, P443, DOI 10.1210/en.130.1.443
   FLETCHER BS, 1992, J BIOL CHEM, V267, P4338
   FONTAGNE J, 1984, INT J TISSUE REACT, V6, P233
   Fortier I, 2001, PROSTAG LEUKOTR ESS, V65, P79, DOI 10.1054/plef.2001.0292
   FRODIN M, 1994, J BIOL CHEM, V269, P6207
   Gerits N, 2008, CELL SIGNAL, V20, P1592, DOI 10.1016/j.cellsig.2008.02.022
   GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300
   Heinecke LF, 2010, OSTEOARTHR CARTILAGE, V18, P220, DOI 10.1016/j.joca.2009.08.015
   HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384
   Hutchison MR, 2007, ENDOCRINOLOGY, V148, P3122, DOI 10.1210/en.2006 1264
   Hutchison MR, 2012, MOL ENDOCRINOL, V26, P1406, DOI 10.1210/me.2012 1063
   Hutchison MR, 2010, MOL ENDOCRINOL, V24, P193, DOI 10.1210/me.2009 0228
   IGARASHI K, 1994, PROSTAG LEUKOTR ESS, V50, P169, DOI 10.1016/0952 3278(94)90140 6
   Iimoto S, 2005, INT J MOL MED, V16, P1083
   Jeffrey JE, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2346
   Ji P, 2012, J PHARM SCI US, V101, P2621, DOI 10.1002/jps.23184
   Kiely PDW, 2009, RHEUMATOLOGY, V48, P765, DOI 10.1093/rheumatology/kep073
   Kiriyama M, 1997, BRIT J PHARMACOL, V122, P217, DOI 10.1038/sj.bjp.0701367
   Krysan K, 2005, CANCER RES, V65, P6275, DOI 10.1158/0008 5472.CAN 05 0216
   LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092 8674(95)90126 4
   Li TF, 2004, EXP CELL RES, V300, P159, DOI 10.1016/j.yexcr.2004.06.019
   Lim H, 2002, ENDOCRINOLOGY, V143, P3207, DOI 10.1210/en.2002 220159
   Linglart A, 2012, J CLIN ENDOCR METAB, V97, pE2328, DOI 10.1210/jc.2012 2326
   Lowe GN, 1996, ENDOCRINOLOGY, V137, P2208, DOI 10.1210/en.137.6.2208
   MacRae VE, 2007, GROWTH HORM IGF RES, V17, P435, DOI 10.1016/j.ghir.2007.05.002
   MARCELON G, 1976, AGENTS ACTIONS, V6, P191, DOI 10.1007/BF01972207
   McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272
   Moreno Rubio J, 2010, ARTHRITIS RHEUM US, V62, P478, DOI 10.1002/art.27204
   MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092 8674(95)90125 6
   Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780
   Olney RC, 2004, BIOCHEM BIOPH RES CO, V317, P1171, DOI 10.1016/j.bbrc.2004.03.170
   Olney RC, 1999, MOL CELL ENDOCRINOL, V156, P63, DOI 10.1016/S0303 7207(99)00144 6
   Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q
   Pozzi A, 2004, J BIOL CHEM, V279, P29797, DOI 10.1074/jbc.M313989200
   Reginato MJ, 1998, J BIOL CHEM, V273, P1855, DOI 10.1074/jbc.273.4.1855
   Sasaki E, 2003, DIGEST DIS SCI, V48, P2257, DOI 10.1023/B:DDAS.0000007860.87503.09
   Schwartz Z, 1998, ENDOCRINOLOGY, V139, P1825, DOI 10.1210/en.139.4.1825
   SCHWARTZ Z, 1992, BONE, V13, P395, DOI 10.1016/8756 3282(92)90456 7
   Sims NA, 2000, J CLIN INVEST, V106, P1095, DOI 10.1172/JCI10753
   Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145
   Sörgel F, 2005, INT J CLIN PHARM TH, V43, P140
   Sylvia VL, 2001, J STEROID BIOCHEM, V78, P261, DOI 10.1016/S0960 0760(01)00099 1
   van Ryn J, 1997, Expert Opin Investig Drugs, V6, P609
   Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97
   Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092 8674(00)80184 1
   Wang X, 2010, BIOCHEM BIOPH RES CO, V402, P23, DOI 10.1016/j.bbrc.2010.09.095
   Weinreb M, 1997, BONE, V20, P521, DOI 10.1016/S8756 3282(97)00033 1
   Welting T J M, 2011, Eur Cell Mater, V22, P420
   Welting TJ, 2011, EUR CELLS MATER, V22, P436
   Yao H, 1998, J BIOL CHEM, V273, P8240, DOI 10.1074/jbc.273.14.8240
   Yonekura A, 1999, ENDOCR J, V46, P545, DOI 10.1507/endocrj.46.545
   Zhang L, 2007, MOL CELL BIOCHEM, V305, P19, DOI 10.1007/s11010 007 9523 5
NR 75
TC 9
Z9 9
U1 1
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD FEB
PY 2015
VL 156
IS 2
BP 499
EP 510
DI 10.1210/en.2014 1348
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CG2UV
UT WOS:000353131800011
PM 25406016
OA Bronze, Green Accepted, Green Published
DA 2025 08 17
ER

PT J
AU Gherardelli, C
   Cisternas, P
   Inestrosa, NC
AF Gherardelli, Camila
   Cisternas, Pedro
   Inestrosa, Nibaldo C.
TI Lithium Enhances Hippocampal Glucose Metabolism in an In Vitro Mice
   Model of Alzheimer's Disease
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE lithium; glucose; metabolism; Alzheimer's disease
ID MILD COGNITIVE IMPAIRMENT; PENTOSE PHOSPHATE PATHWAY; WNT SIGNALING
   PATHWAY; GLYCOGEN SYNTHASE; FDG PET; MOLECULAR MECHANISM; BRAIN;
   INSULIN; ACTIVATION; INHIBITION
AB Impaired cerebral glucose metabolism is an early event that contributes to the pathogenesis of Alzheimer's disease (AD). Importantly, restoring glucose availability by pharmacological agents or genetic manipulation has been shown to protect against A beta toxicity, ameliorate AD pathology, and increase lifespan. Lithium, a therapeutic agent widely used as a treatment for mood disorders, has been shown to attenuate AD pathology and promote glucose metabolism in skeletal muscle. However, despite its widespread use in neuropsychiatric disorders, lithium's effects on the brain have been poorly characterized. Here we evaluated the effect of lithium on glucose metabolism in hippocampal neurons from wild type (WT) and APPSwe/PS1 Delta E9 (APP/PS1) mice. Our results showed that lithium significantly stimulates glucose uptake and replenishes ATP levels by preferential oxidation of glucose through glycolysis in neurons from WT mice. This increase was also accompanied by a strong increase in glucose transporter 3 (Glut3), the major carrier responsible for glucose uptake in neurons. Similarly, using hippocampal slices from APP PS1 mice, we demonstrate that lithium increases glucose uptake, glycolytic rate, and the ATP:ADP ratio in a process that also involves the activation of AMPK. Together, our findings indicate that lithium stimulates glucose metabolism and can act as a potential therapeutic agent in AD.
C1 [Gherardelli, Camila; Inestrosa, Nibaldo C.] Pontificia Univ Catolica Chile, Fac Ciencias Biol, Ctr Envejecimiento & Regenerac CARE UC, Dept Biol Celular & Mol, Santiago 8331150, Chile.
   [Cisternas, Pedro] Univ OHiggins, Inst Ciencias Salud, Rancagua 2820000, Chile.
   [Inestrosa, Nibaldo C.] Univ Magallanes, Ctr Excelencia Biomed Magallanes CEBIMA, Punta Arenas 6210427, Chile.
C3 Pontificia Universidad Catolica de Chile; Universidad de O'Higgins;
   Universidad de Magallanes
RP Inestrosa, NC (通讯作者)，Pontificia Univ Catolica Chile, Fac Ciencias Biol, Ctr Envejecimiento & Regenerac CARE UC, Dept Biol Celular & Mol, Santiago 8331150, Chile.; Inestrosa, NC (通讯作者)，Univ Magallanes, Ctr Excelencia Biomed Magallanes CEBIMA, Punta Arenas 6210427, Chile.
EM ninestrosa@bio.puc.cl
OI CISTERNAS, PEDRO/0000 0001 7796 8982
FU Basal Center of Excellence in Aging and Regeneration [ACE210009];
   Sociedad Quimica y Minera de Chile (SQM)
FX This research was funded by Basal Center of Excellence in Aging and
   Regeneration (ACE210009). We also thank the Sociedad Quimica y Minera de
   Chile (SQM) for the special grant "The role of Lithium in Human Health
   and Disease".
CR Asano R., 2021, ALZHEIMERS DEMENT, V17, P54807, DOI [10.1002/alz.054807, DOI 10.1002/ALZ.054807]
   BAASTRUP PC, 1970, LANCET, V2, P326
   Bai SP, 2017, ENVIRON TOXICOL PHAR, V54, P191, DOI 10.1016/j.etap.2017.07.011
   Bolaños JP, 2008, BBA BIOENERGETICS, V1777, P789, DOI 10.1016/j.bbabio.2008.04.011
   Bomfim TR, 2012, J CLIN INVEST, V122, P1339, DOI 10.1172/JCI57256
   BOSCH F, 1986, J BIOL CHEM, V261, P6927
   Briggs KT, 2016, BIOPHYS J, V111, P294, DOI 10.1016/j.bpj.2016.06.015
   Cerpa W, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750 1326 5 3
   Chen ZC, 2013, PROG NEUROBIOL, V108, P21, DOI 10.1016/j.pneurobio.2013.06.004
   CHENG K, 1983, MOL CELL BIOCHEM, V56, P177
   Chuang DM, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00015
   Cisternas P, 2021, FRONT INTEGR NEUROSC, V15, DOI 10.3389/fnint.2021.733007
   Cisternas P, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00295
   Cisternas P, 2019, J NEUROCHEM, V149, P54, DOI 10.1111/jnc.14608
   Cisternas P, 2016, J BIOL CHEM, V291, P25950, DOI 10.1074/jbc.M116.735373
   Cisternas P, 2014, J NEUROCHEM, V129, P663, DOI 10.1111/jnc.12663
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Crippa S, 2017, EMBO MOL MED, V9, P1589, DOI 10.15252/emmm.201707814
   Daneman R, 2009, P NATL ACAD SCI USA, V106, P641, DOI 10.1073/pnas.0805165106
   de Cristóbal J, 2014, CURR ALZHEIMER RES, V11, P175, DOI 10.2174/156720501102140313145704
   DeTure MA, 2019, MOL NEURODEGENER, V14, DOI 10.1186/s13024 019 0333 5
   DIXIT PK, 1988, P SOC EXP BIOL MED, V187, P2
   Drummond E, 2017, ACTA NEUROPATHOL, V133, P155, DOI 10.1007/s00401 016 1662 x
   Dudev T, 2017, SCI REP UK, V7, DOI 10.1038/srep42377
   Dukart J, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002987
   Fjell AM, 2010, J NEUROSCI, V30, P2088, DOI 10.1523/JNEUROSCI.3785 09.2010
   Forlenza OV, 2014, ACS CHEM NEUROSCI, V5, P443, DOI 10.1021/cn5000309
   Forlenza OV, 2014, ACS CHEM NEUROSCI, V5, P484, DOI 10.1021/cn5000315
   Forlenza OV, 2011, BRIT J PSYCHIAT, V198, P351, DOI 10.1192/bjp.bp.110.080044
   Furnsinn C, 1997, AM J PHYSIOL ENDOC M, V273, pE514, DOI 10.1152/ajpendo.1997.273.3.E514
   Gejl M, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 17718 y
   Gejl M, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00108
   Gherardelli C, 2022, J ALZHEIMERS DIS, V87, P901, DOI 10.3233/JAD 215273
   Gherardelli C, 2021, J NEUROCHEM, V157, P1222, DOI 10.1111/jnc.15229
   Gordon BA, 2018, LANCET NEUROL, V17, P241, DOI 10.1016/S1474 4422(18)30028 0
   Hampel H, 2009, J CLIN PSYCHIAT, V70, P922, DOI 10.4088/JCP.08m04606
   HAUGAARD ES, 1974, BIOCHEM PHARMACOL, V23, P1675, DOI 10.1016/0006 2952(74)90394 3
   Haussmann R, 2021, NEUROSCI LETT, V760, DOI 10.1016/j.neulet.2021.136044
   Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552
   Herrero Mendez A, 2009, NAT CELL BIOL, V11, P747, DOI 10.1038/ncb1881
   Herzig S, 2018, NAT REV MOL CELL BIO, V19, P121, DOI 10.1038/nrm.2017.95
   Hollander E, 2008, NEUROPSYCHOBIOLOGY, V58, P37, DOI 10.1159/000154478
   Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326
   Hooper C, 2008, J NEUROCHEM, V104, P1433, DOI 10.1111/j.1471 4159.2007.05194.x
   Hou LL, 2015, BMC NEUROSCI, V16, DOI 10.1186/s12868 015 0222 y
   Inestrosa NC, 2008, MOL NEURODEGENER, V3, DOI 10.1186/1750 1326 3 9
   Jope RS, 2003, TRENDS PHARMACOL SCI, V24, P441, DOI 10.1016/S0165 6147(03)00206 2
   Jung S, 2017, J NUTR SCI VITAMINOL, V63, P365, DOI 10.3177/jnsv.63.365
   Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455
   Kohno T, 2007, J CLIN PSYCHOPHARM, V27, P698, DOI 10.1097/jcp.0b013e31815a23c2
   Leroy C, 2011, NEUROBIOL DIS, V43, P588, DOI 10.1016/j.nbd.2011.05.007
   Li XF, 2012, P NATL ACAD SCI USA, V109, P11402, DOI 10.1073/pnas.1205015109
   Macdonald A, 2008, INT J GERIATR PSYCH, V23, P704, DOI 10.1002/gps.1964
   Macko Antoni R., 2008, Archives of Physiology and Biochemistry, V114, P331, DOI [10.1080/13813450802536067, 10.1080/13813450802536067 ]
   MAHER F, 1994, MOL CELL NEUROSCI, V5, P369, DOI 10.1006/mcne.1994.1044
   Malhi GS, 2013, CNS DRUGS, V27, P135, DOI 10.1007/s40263 013 0039 0
   Martinez M, 2020, MOL NEUROBIOL, V57, P1389, DOI 10.1007/s12035 019 01785 5
   Matsunaga S, 2015, J ALZHEIMERS DIS, V48, P403, DOI 10.3233/JAD 150437
   Maurer IC, 2009, BIPOLAR DISORD, V11, P515, DOI 10.1111/j.1399 5618.2009.00729.x
   Mertens J, 2015, NATURE, V527, P95, DOI 10.1038/nature15526
   Mosconi L, 2008, NEUROBIOL AGING, V29, P676, DOI 10.1016/j.neurobiolaging.2006.12.008
   Mosconi Lisa, 2005, Eur J Nucl Med Mol Imaging, V32, P486, DOI 10.1007/s00259 005 1762 7
   Mosconi L, 2013, CLIN TRANSL IMAGING, V1, P217, DOI 10.1007/s40336 013 0026 y
   Mosconi L, 2009, EUR J NUCL MED MOL I, V36, P811, DOI [10.1007/s00259 008 1039 z, 10.1007/s00259 005 1762 7]
   MunozMontano JR, 1997, FEBS LETT, V411, P183, DOI 10.1016/S0014 5793(97)00688 1
   Nakashima H, 2005, ACTA NEUROPATHOL, V110, P547, DOI 10.1007/s00401 005 1087 4
   Niccoli T, 2016, CURR BIOL, V26, P2291, DOI [10.1016/j.cub.2016.07.017, 10.1016/j.cub.2016.09.018]
   Noble W, 2005, P NATL ACAD SCI USA, V102, P6990, DOI 10.1073/pnas.0500466102
   Nunes MA, 2013, CURR ALZHEIMER RES, V10, P104
   Osete JR, 2021, MOL PSYCHIATR, V26, P6789, DOI 10.1038/s41380 021 01164 4
   Pajak B, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010234
   Papadopoli D, 2021, BBA MOL CELL RES, V1868, DOI 10.1016/j.bbamcr.2021.119059
   PLENGE P, 1982, PSYCHOPHARMACOLOGY, V77, P348, DOI 10.1007/BF00432769
   PLENGE P, 1976, INT PHARMACOPSYCHIAT, V11, P84, DOI 10.1159/000468216
   Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142
   Rios JA, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964 018 0227 0
   Rizak J, 2014, ANN PSYCHIAT MENT HL, P1014
   Rydström J, 2006, BBA BIOENERGETICS, V1757, P721, DOI 10.1016/j.bbabio.2006.03.010
   Salimi A, 2017, J BIOCHEM MOL TOXIC, V31, DOI 10.1002/jbt.21836
   Serrano Pozo A, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a006189
   Shimada K, 2012, NEUROBIOL DIS, V46, P101, DOI 10.1016/j.nbd.2011.12.050
   Shorter E, 2009, BIPOLAR DISORD, V11, P4, DOI 10.1111/j.1399 5618.2009.00706.x
   Small GW, 2000, P NATL ACAD SCI USA, V97, P6037, DOI 10.1073/pnas.090106797
   Stampone E, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21031169
   Struewing IT, 2007, FEBS J, V274, P2749, DOI 10.1111/j.1742 4658.2007.05809.x
   Summers SA, 1999, J BIOL CHEM, V274, P17934, DOI 10.1074/jbc.274.25.17934
   Sun SS, 2017, REDOX BIOL, V11, P577, DOI 10.1016/j.redox.2016.12.029
   Suzuki T, 2013, MOL CELL, V50, P407, DOI 10.1016/j.molcel.2013.03.022
   Szablewski L, 2017, J ALZHEIMERS DIS, V55, P1307, DOI 10.3233/JAD 160841
   TABATA I, 1994, DIABETES, V43, P903, DOI 10.2337/diabetes.43.7.903
   Tanzi RE, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006296
   Tapia Rojas C, 2018, J NEUROCHEM, V144, P443, DOI 10.1111/jnc.14278
   Tapia Rojas C, 2015, BIOCHEM J, V466, P415, DOI 10.1042/BJ20140207
   Toledo EM, 2010, MOL PSYCHIATR, V15, P272, DOI 10.1038/mp.2009.72
   Toppala S, 2021, DIABETES CARE, V44, P2435, DOI 10.2337/dc21 0042
   Tsai CS, 1998, BIOCHEM CELL BIOL, V76, P637
   Valvezan AJ, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00001
   Van Cauwenberghe C, 2016, GENET MED, V18, P421, DOI 10.1038/gim.2015.117
   Wilson EN, 2020, J ALZHEIMERS DIS, V73, P723, DOI 10.3233/JAD 190862
   Winkler EA, 2015, NAT NEUROSCI, V18, P521, DOI 10.1038/nn.3966
   Wu DQ, 2010, TRENDS BIOCHEM SCI, V35, P161, DOI 10.1016/j.tibs.2009.10.002
   Xia MY, 2017, FEBS OPEN BIO, V7, P759, DOI 10.1002/2211 5463.12220
NR 102
TC 9
Z9 9
U1 3
U2 11
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2022
VL 23
IS 15
AR 8733
DI 10.3390/ijms23158733
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 3S1LF
UT WOS:000839363500001
PM 35955868
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Liu, XC
   Hou, YB
   Yang, MX
   Xin, XR
   Deng, Y
   Fu, RB
   Xiang, XC
   Cao, NB
   Liu, XM
   Yu, WX
   Yang, B
   Zhou, YM
AF Liu, Xinchan
   Hou, Yubo
   Yang, Mingxi
   Xin, Xirui
   Deng, Yu
   Fu, Ruobing
   Xiang, Xingchen
   Cao, Niuben
   Liu, Xiaomeng
   Yu, Weixian
   Yang, Bai
   Zhou, Yanmin
TI N Acetyl l cysteine Derived Carbonized Polymer Dots with ROS
   Scavenging via Keap1 Nrf2 Pathway Regulate Alveolar Bone Homeostasis in
   Periodontitis
SO ADVANCED HEALTHCARE MATERIALS
LA English
DT Article
DE antioxidants; carbonized polymer dots; kelch like ECH associated protein
   1; nuclear factor erythroid 2 related factor 2 pathways; periodontitis;
   reactive oxygen species
ID OXIDATIVE STRESS; OSTEOBLAST DIFFERENTIATION; CELLS; ACETYLCYSTEINE;
   DESTRUCTION; REDUCTION; DISEASE; INJURY; ROLES; NRF2
AB Periodontitis is a type of chronic inflammatory oral disease characterized by the destruction of periodontal connective tissue and progressive alveolar bone resorption. As oxidative stress is the key cause of periodontitis in the early periodontal microenvironment, antioxidative therapy has been considered a viable treatment for periodontitis. However, more stable and effective reactive oxygen species (ROS) scavenging nanomedicines are still highly needed due to the instability of traditional antioxidants. Herein, a new type of N acetyl l cysteine (NAC) derived red fluorescent carbonized polymer dots (CPDs) has been synthesized with excellent biocompatibility, which can serve as an extracellular antioxidant to scavenge ROS effectively. Moreover, NAC CPDs can promote osteogenic differentiation in human periodontal ligament cells (hPDLCs) under H2O2 stimulation. In addition, NAC CPDs are capable of targeted accumulation in alveolar bone in vivo, reducing the level of alveolar bone resorption in periodontitis mice, as well as performing fluorescence imaging in vitro and in vivo. In terms of mechanism, NAC CPDs may regulate redox homeostasis and promote bone formation in the periodontitis microenvironment by modulating the kelch like ECH associated protein l (Keap1)/nuclear factor erythroid 2 related factor 2 (Nrf2) pathway. This study provides a new strategy for the application of CPDs theranostic nanoplatform for periodontitis.
C1 [Liu, Xinchan; Zhou, Yanmin] Jilin Univ, Hosp Stomatol, Dept Oral Implantol, Changchun 130021, Peoples R China.
   [Liu, Xinchan; Hou, Yubo; Xin, Xirui; Deng, Yu; Fu, Ruobing; Xiang, Xingchen; Cao, Niuben; Liu, Xiaomeng; Yu, Weixian; Zhou, Yanmin] Jilin Univ, Hosp Stomatol, Jilin Prov Key Lab Tooth Dev & Bone Remodeling, Changchun 130021, Peoples R China.
   [Hou, Yubo; Xin, Xirui; Xiang, Xingchen; Yu, Weixian] Jilin Univ, Hosp Stomatol, Dept Periodontol, Changchun 130021, Peoples R China.
   [Yang, Mingxi; Yang, Bai] Jilin Univ, Coll Chem, State Key Lab Supramol Struct & Mat, Changchun 130012, Peoples R China.
   [Yang, Mingxi; Yang, Bai] First Hosp Jilin Univ, Joint Lab Opto Funct Theranost Med & Chem, Changchun 130021, Peoples R China.
C3 Jilin University; Jilin University; Jilin University; Jilin University;
   Jilin University
RP Zhou, YM (通讯作者)，Jilin Univ, Hosp Stomatol, Dept Oral Implantol, Changchun 130021, Peoples R China.; Yu, WX; Zhou, YM (通讯作者)，Jilin Univ, Hosp Stomatol, Jilin Prov Key Lab Tooth Dev & Bone Remodeling, Changchun 130021, Peoples R China.; Yu, WX (通讯作者)，Jilin Univ, Hosp Stomatol, Dept Periodontol, Changchun 130021, Peoples R China.; Yang, B (通讯作者)，Jilin Univ, Coll Chem, State Key Lab Supramol Struct & Mat, Changchun 130012, Peoples R China.; Yang, B (通讯作者)，First Hosp Jilin Univ, Joint Lab Opto Funct Theranost Med & Chem, Changchun 130021, Peoples R China.
EM ywx@jlu.edu.cn; byangchem@jlu.edu.cn; zhouym@jlu.edu.cn
OI Yang, Mingxi/0009 0009 5871 2282
FU National Natural Science Foundation of China [82071152, 82101454,
   22035001, 21774041]; Jilin Provincial Development and Reform Commission
   [2021C042 1]; Jilin Provincial Science and Technology International
   Co operation Project [20220402069GH]; JLU Science and Technology
   Innovative Research Team [2017TD 06]
FX & nbsp;The research was supported by the National Natural Science
   Foundation of China (82071152, 82101454, 22035001, 21774041), the Jilin
   Provincial Development and Reform Commission (2021C042 1), the Jilin
   Provincial Science and Technology International Co operation Project
   (20220402069GH), and the JLU Science and Technology Innovative Research
   Team (2017TD 06).
CR Aldini G, 2018, FREE RADICAL RES, V52, P751, DOI 10.1080/10715762.2018.1468564
   Alkadasi B, 2017, J ORAL SCI, V59, P519, DOI 10.2334/josnusd.16 0701
   Auluck A, 2007, MED ORAL PATOL ORAL, V12, pE360
   Bellezza I, 2018, BBA MOL CELL RES, V1865, P721, DOI 10.1016/j.bbamcr.2018.02.010
   Blair HC, 2017, TISSUE ENG PART B RE, V23, P268, DOI [10.1089/ten.teb.2016.0454, 10.1089/ten.TEB.2016.0454]
   Sczepanik FSC, 2020, PERIODONTOL 2000, V84, P45, DOI 10.1111/prd.12342
   Charupinijkul A, 2022, CLIN ORAL INVEST, V26, P535, DOI 10.1007/s00784 021 04031 2
   Choi S, 2019, J AM GERIATR SOC, V67, P1234, DOI 10.1111/jgs.15828
   Ciesielska A, 2021, CELL MOL LIFE SCI, V78, P1233, DOI 10.1007/s00018 020 03656 y
   Crous A, 2021, STEM CELL REV REP, V17, P1570, DOI 10.1007/s12015 021 10142 w
   de Molon RS, 2018, MICROSC RES TECHNIQ, V81, P1412, DOI 10.1002/jemt.23101
   Deandra FA, 2023, HELIYON, V9, DOI 10.1016/j.heliyon.2023.e13475
   Gou HQ, 2022, FREE RADICAL BIO MED, V190, P62, DOI 10.1016/j.freeradbiomed.2022.08.001
   Greabu M, 2020, MOLECULES, V25, DOI 10.3390/molecules25184338
   Hernández Ríos P, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00869
   Hernansanz Agustín P, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10030415
   Huang HT, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9111136
   Huang XF, 2020, J TRANSL MED, V18, DOI 10.1186/s12967 020 02664 7
   Kang WY, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/1681972
   Karaca B, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12050729
   Kim HM, 2017, MOLECULES, V22, DOI 10.3390/molecules22010042
   Kuang YC, 2020, BIOGERONTOLOGY, V21, P13, DOI 10.1007/s10522 019 09838 x
   Li X, 2021, DRUG DISCOV TODAY, V26, P1226, DOI 10.1016/j.drudis.2021.03.002
   Li Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.691013
   Liang Y, 2018, J AGR FOOD CHEM, V66, P440, DOI 10.1021/acs.jafc.7b04036
   Liu JJ, 2017, NANOSCALE, V9, P7135, DOI 10.1039/c7nr02128c
   Lorencini M, 2009, TISSUE CELL, V41, P43, DOI 10.1016/j.tice.2008.07.001
   Mitchell MJ, 2021, NAT REV DRUG DISCOV, V20, P101, DOI 10.1038/s41573 020 0090 8
   Okanobu A, 2017, J IMMUNOL METHODS, V445, P31, DOI 10.1016/j.jim.2017.03.003
   Pedre B, 2021, PHARMACOL THERAPEUT, V228, DOI 10.1016/j.pharmthera.2021.107916
   Preshaw PM, 2012, DIABETOLOGIA, V55, P21, DOI 10.1007/s00125 011 2342 y
   Raftos JE, 2007, INT J BIOCHEM CELL B, V39, P1698, DOI 10.1016/j.biocel.2007.04.014
   Raittio E, 2022, J CLIN PERIODONTOL, V49, P84, DOI 10.1111/jcpe.13569
   Rajput SA, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10081268
   Ren JK, 2021, C J CARBON RES, V7, DOI 10.3390/c7010002
   SHEFFNER AL, 1963, ANN NY ACAD SCI, V106, P298
   Shi WP, 2021, ARCH ORAL BIOL, V121, DOI 10.1016/j.archoralbio.2020.104958
   Soeroso Y, 2017, THER CLIN RISK MANAG, V13, P307, DOI 10.2147/TCRM.S130257
   Song X, 2022, PEERJ, V10, DOI 10.7717/peerj.13442
   Tao SY, 2019, J PHYS CHEM LETT, V10, P5182, DOI 10.1021/acs.jpclett.9b01384
   Toczewska J, 2023, ORAL DIS, V29, P3559, DOI 10.1111/odi.14287
   Tonetti MS, 2017, J CLIN PERIODONTOL, V44, P456, DOI 10.1111/jcpe.12732
   Ulasov AV, 2022, LIFE SCI, V291, DOI 10.1016/j.lfs.2021.120111
   Vimalraj S, 2020, GENE, V754, DOI 10.1016/j.gene.2020.144855
   Wang HB, 2020, ACS APPL MATER INTER, V12, P41088, DOI 10.1021/acsami.0c11735
   Wang YY, 2021, INT IMMUNOPHARMACOL, V90, DOI 10.1016/j.intimp.2020.107129
   Wang Y, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00910
   Wei Y, 2021, DRUG DES DEV THER, V15, P3509, DOI 10.2147/DDDT.S315249
   Xia CL, 2019, ADV SCI, V6, DOI 10.1002/advs.201901316
   Xin LJ, 2022, INT J ORAL SCI, V14, DOI 10.1038/s41368 022 00177 1
   Xue S, 2021, SMALL, V17, DOI 10.1002/smll.202102178
   Ye ZL, 2022, COCHRANE DB SYST REV, DOI 10.1002/14551858.CD009197.pub5
   Yu YJ, 2022, NANOSCALE, V14, P2628, DOI 10.1039/d1nr06043k
   Zhao XH, 2019, NANOSCALE, V11, P9526, DOI 10.1039/c9nr01118h
   Zheng QY, 2021, CHEM SOC REV, V50, P5086, DOI 10.1039/d1cs00056j
   Zhou H, 2020, CRYSTENGCOMM, V22, P1368, DOI 10.1039/c9ce01960j
   Zhou MJ, 2022, J CLIN PERIODONTOL, V49, P1052, DOI 10.1111/jcpe.13667
   Zou SQ, 2020, NANOTECHNOLOGY, V31, DOI 10.1088/1361 6528/ab5b40
NR 58
TC 18
Z9 18
U1 13
U2 138
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2192 2640
EI 2192 2659
J9 ADV HEALTHC MATER
JI Adv. Healthc. Mater.
PD OCT
PY 2023
VL 12
IS 26
DI 10.1002/adhm.202300890
EA JUN 2023
PG 15
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Science & Technology   Other Topics; Materials Science
GA U7ZD7
UT WOS:001014299000001
PM 37279380
DA 2025 08 17
ER

PT J
AU Zhang, Q
   Fong, CC
   Zhang, Y
   Tzang, CH
   Fong, WF
   Yang, MS
AF Zhang, Qi
   Fong, Chi Chun
   Zhang, Yaou
   Tzang, Chi Hung
   Fong, Wang Fun
   Yang, Mengsu
TI cDNA microarray analysis of the differentially expressed genes involved
   in murine pre osteoclast RAW264.7 cells proliferation stimulated by
   dexamethasone
SO LIFE SCIENCES
LA English
DT Article
DE dexamethasone; pre osteoclast RAW264.7; proliferation; cDNA microarray
ID PROTEIN KINASE C; NF KAPPA B; CORTICOSTEROIDS; INFLAMMATION;
   GLUCOCORTICOIDS; HORMONE; GTPASES; METALLOTHIONEIN; MODULATION;
   ACTIVATION
AB Glucocorticoids (GCs) are hormones with anti inflammatory and immuno suppressive effects. The use of hormonal medicine like GCs may cause systemic adverse effects. In the present study, the cellular response of murine pre osteoclast cell line RAW264.7 to dexamethasone (DEX) was investigated and the result demonstrated that DEX may stimulate RAW264.7 cells proliferation. Changes in gene expression involved in RAW264.7 cells proliferation stimulated by dexamethasone were investigated using cDNA microarrays containing 1000 cDNAs. It was found that 67 genes were regulated by DEX and could be grouped into 8 functional categories, including cell cycle regulation, cell survival, metabolism, pro inflammatory effect, cytoskeleton, proteasome, signaling transduction and transcription factors. Moreover, some signaling pathways that involve in modulation of DEX on RAW264.7 cells functions were identified, including p53, 14 3 3 gamma, MAPK, Elk 1, I kappa B and Ifn related pathways. (c) 2007 Elsevier Inc. All rights reserved.
C1 [Zhang, Qi; Fong, Chi Chun; Zhang, Yaou; Tzang, Chi Hung; Fong, Wang Fun; Yang, Mengsu] City Univ Hong Kong, Dept Biol & Chem, Kowloon, Hong Kong, Peoples R China.
C3 City University of Hong Kong
RP Yang, MS (通讯作者)，City Univ Hong Kong, Dept Biol & Chem, 83 Tat Chee Ave, Kowloon, Hong Kong, Peoples R China.
EM bhmyang@cityu.edu.hk
RI Qi, Zhihong/HIZ 8633 2022; Yang, Mengsu/I 5750 2015
OI Yang, Mengsu/0000 0003 2083 2296
CR Allen DB, 1996, ENDOCRIN METAB CLIN, V25, P699, DOI 10.1016/S0889 8529(05)70348 0
   Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309
   Balasubramanian S, 1999, INT J ONCOL, V15, P387
   Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649
   BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460 2075.1994.tb06609.x
   Barnes PJ, 2006, BRIT J PHARMACOL, V148, P245, DOI 10.1038/sj.bjp.0706736
   Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456
   Bereziat Gilbert, 1996, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V190, P409
   Blanchard JM, 2000, PATHOL BIOL, V48, P318
   BREMNER I, 1990, ANNU REV NUTR, V10, P63, DOI 10.1146/annurev.nu.10.070190.000431
   Brenner RE, 2001, PEDIATR PULM, V32, P1, DOI 10.1002/ppul.1081
   Brunner R, 2006, ANN NY ACAD SCI, V1071, P434, DOI 10.1196/annals.1364.037
   CLARK AF, 1994, INVEST OPHTH VIS SCI, V35, P281
   DALE DC, 1973, MED CLIN N AM, V57, P1277, DOI 10.1016/S0025 7125(16)32228 3
   DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455
   DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0
   DISILVESTRO RA, 1992, TOXICOL LETT, V60, P175, DOI 10.1016/0378 4274(92)90272 L
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476
   Flavell RA, 2002, CURR TOP MICROBIOL, V266, P1
   Fukui Y, 1999, CELL MOTIL CYTOSKEL, V42, P204, DOI 10.1002/(SICI)1097 0169(1999)42:3<204::AID CM4>3.0.CO;2 L
   GURWITZ JH, 1994, ARCH INTERN MED, V154, P97, DOI 10.1001/archinte.154.1.97
   Hamilton JA, 2002, TRENDS IMMUNOL, V23, P403, DOI 10.1016/S1471 4906(02)02260 3
   Han YL, 1996, J BIOL CHEM, V271, P5947, DOI 10.1074/jbc.271.10.5947
   Hegde P, 2000, BIOTECHNIQUES, V29, P548, DOI 10.2144/00293bi01
   HELMREICH JME, 2000, BIOCH CELL SIGNALING
   Hirayama T, 2002, J ENDOCRINOL, V175, P155, DOI 10.1677/joe.0.1750155
   Hirsch C, 2000, TRENDS CELL BIOL, V10, P268, DOI 10.1016/S0962 8924(00)01768 2
   Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901
   Hofmann J, 2001, REV PHYSIOL BIOCH P, V142, P1, DOI 10.1007/BFb0117491
   Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093
   Ismaili N, 2004, ANN NY ACAD SCI, V1024, P86, DOI 10.1196/annals.1321.007
   Jin B, 2004, TOXICOL IN VITRO, V18, P659, DOI 10.1016/j.tiv.2004.02.006
   JOOSS K, 1995, ONCOGENE, V10, P1529
   Kaji H, 1997, J BONE MINER RES, V12, P734, DOI 10.1359/jbmr.1997.12.5.734
   Kamberi M, 2002, CYTOKINE, V19, P14, DOI 10.1006/cyto.2002.1049
   Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339
   Kim DS, 2002, METABOLISM, V51, P589, DOI 10.1053/meta.2002.31985
   Kim HJ, 2006, J CLIN INVEST, V116, P2152, DOI 10.1172/JCI28084
   Kodaira K, 1999, GENE, V230, P121, DOI 10.1016/S0378 1119(99)00025 6
   KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0
   Krecicki T, 2006, MED SCI MONITOR, V12, pCR351
   Kumagai A, 1998, MOL BIOL CELL, V9, P345, DOI 10.1091/mbc.9.2.345
   Kuo YC, 2001, INFLAMM RES, V50, P73, DOI 10.1007/s000110050727
   Leclerc N, 2004, J MOL ENDOCRINOL, V33, P175, DOI 10.1677/jme.0.0330175
   Mazziotti G, 2006, TRENDS ENDOCRIN MET, V17, P144, DOI 10.1016/j.tem.2006.03.009
   Melcangi RC, 2000, NEUROREPORT, V11, P3969, DOI 10.1097/00001756 200012180 00013
   Mocchegiani E, 2000, BIOGERONTOLOGY, V1, P133, DOI 10.1023/A:1010095930854
   Moggs JG, 2003, TOXICOL LETT, V140, P149, DOI 10.1016/S0378 4274(02)00501 5
   Naor Z, 1995, CELL MOL NEUROBIOL, V15, P527, DOI 10.1007/BF02071315
   NOLLEN EA, 2005, J CELL SCI, V115, P2809
   OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376
   OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575
   Orphanides G, 2003, TOXICOL LETT, V140, P145, DOI 10.1016/S0378 4274(02)00500 3
   Pattenden SG, 2002, EMBO J, V21, P1978, DOI 10.1093/emboj/21.8.1978
   PECHAN PM, 1991, FEBS LETT, V280, P1, DOI 10.1016/0014 5793(91)80190 E
   Quackenbush J, 2001, NAT REV GENET, V2, P418, DOI 10.1038/35076576
   ROTH D, 1995, FEBS LETT, V374, P77, DOI 10.1016/0014 5793(95)01080 X
   Rozsa FW, 2006, MOL VIS, V12, P125
   RUSSOMARIE F, 1992, J NEUROIMMUNOL, V40, P281, DOI 10.1016/0165 5728(92)90144 A
   Shibli Rahhal A, 2006, CLIN DERMATOL, V24, P260, DOI 10.1016/j.clindermatol.2006.04.012
   Sorensen TS, 1996, MOL CELL BIOL, V16, P5888
   Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/0968 0004(96)10022 0
   Takuma A, 2003, J BIOL CHEM, V278, P44667, DOI 10.1074/jbc.M300213200
   Tanaka K, 2001, BIOCHIMIE, V83, P351, DOI 10.1016/S0300 9084(01)01237 8
   TOWNSEND HB, 1992, J NEUROIMMUNOL, V40, P281
   Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542
   WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092 8674(95)90385 2
   WHITWORTH JA, 1987, KIDNEY INT, V31, P1213, DOI 10.1038/ki.1987.131
   Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0
   Woodgett J:., 2000, Protein kinase function, V2nd
   Zhu XY, 2004, J STEROID BIOCHEM, V92, P375, DOI 10.1016/j.jsbmb.2004.07.010
NR 72
TC 8
Z9 9
U1 1
U2 9
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024 3205
EI 1879 0631
J9 LIFE SCI
JI Life Sci.
PD JAN 16
PY 2008
VL 82
IS 3 4
BP 135
EP 148
DI 10.1016/j.lfs.2007.10.012
PG 14
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 259WV
UT WOS:000252972500002
PM 18083200
DA 2025 08 17
ER

PT J
AU Chen, G
   Sun, J
   Lascau Coman, V
   Chevrier, A
   Marchand, C
   Hoemann, CD
AF Chen, G.
   Sun, J.
   Lascau Coman, V.
   Chevrier, A.
   Marchand, C.
   Hoemann, Caroline D.
TI Acute Osteoclast Activity following Subchondral Drilling Is Promoted by
   Chitosan and Associated with Improved Cartilage Repair Tissue
   Integration
SO CARTILAGE
LA English
DT Article
DE animal model; marrow stimulation; osteoclast; osteochondral repair;
   chitosan
ID AUTOLOGOUS CHONDROCYTE IMPLANTATION; ARTICULAR CARTILAGE; LINK PROTEIN;
   BONE; MICROFRACTURE; DEFECTS; KNEE; RECRUITMENT; NEUTROPHILS; RANKL
AB Objective: Cartilage bone integration is an important functional end point of cartilage repair therapy, but little is known about how to promote integration. We tested the hypothesis that chitosan stabilized blood clot implant elicits osteoclasts to drilled cartilage defects and promotes repair and cartilage bone integration. Design: Bilateral trochlear defects in 15 skeletally mature rabbit knees were microdrilled and then treated with chitosan glycerol phosphate (GP)/blood implant with fluorescent chitosan tracer and thrombin to accelerate in situ solidification or with thrombin alone. Chitosan clearance, osteoclast density, and osteochondral repair were evaluated at 1, 2, and 8 weeks at the outside, edge, and through the proximal microdrill holes. Results: Chitosan was retained at the top of the drill holes at 1 week as extracellular particles became internalized by granulation tissue cells at 2 weeks and was completely cleared by 8 weeks. Osteoclasts burst accumulated at microdrill hole edges at 1 week, in new woven bone at the base of the drill holes at 2 weeks, and below endochondral cartilage repair at 8 weeks. Implants elicited 2 fold more osteoclasts relative to controls (P < 0.001), a more complete drill hole bone repair, and improved cartilage bone integration and histological tissue quality. Treated and control 8 week cartilage repair tissues contained 85% collagen type II. After 8 weeks of repair, subchondral osteoclast density correlated positively with bone cartilage repair tissue integration (P < 0.0005). Conclusions: Chitosan GP/ blood implant amplified the acute influx of subchondral osteoclasts through indirect mechanisms, leading to significantly improved repair and cartilage bone integration without inducing net bone resorption. Osteoclasts are cellular mediators of marrow derived cartilage repair integration.
C1 [Chen, G.; Lascau Coman, V.; Chevrier, A.; Hoemann, Caroline D.] Ecole Polytech, Dept Chem Engn, Montreal, PQ H3C 3A7, Canada.
   [Sun, J.] BioSyntech Canada Inc, Laval, PQ, Canada.
   [Marchand, C.; Hoemann, Caroline D.] Ecole Polytech, Inst Biomed Engn, Montreal, PQ H3C 3A7, Canada.
C3 Universite de Montreal; Polytechnique Montreal; Universite de Montreal;
   Polytechnique Montreal
RP Hoemann, CD (通讯作者)，Ecole Polytech, Dept Chem Engn, 2900 Edouard Montpetit, Montreal, PQ H3C 3A7, Canada.
EM caroline.hoemann@polymtl.ca
RI HOEMANN, CAROLINE/J 4972 2012
OI Hoemann, Caroline/0000 0003 3750 7879
FU Canadian Institutes of Health Research (MOP) [185810]; Canadian
   Arthritis Network; Fonds de la Recherche en Sante du Quebec
FX Operating funds for this project were from the Canadian Institutes of
   Health Research (MOP 185810; principal investigator: C.D.H.) and the
   Canadian Arthritis Network. Salary support was provided by the Fonds de
   la Recherche en Sante du Quebec to C.D.H. (Bourse de Carriere Senior),
   C.M. (PhD fellowship), and V.L. (Groupe de Recherche en Sciences et
   Technologies Bio medicales). The authors thank G. Picard for excellent
   histology contributions.
CR Aguirre JI, 2006, J BONE MINER RES, V21, P605, DOI 10.1359/JBMR.060107
   Bolton MC, 1999, BIOCHEM J, V337, P77, DOI 10.1042/0264 6021:3370077
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Breinan HA, 2000, J ORTHOPAED RES, V18, P781, DOI 10.1002/jor.1100180516
   Breinan HA, 1997, J BONE JOINT SURG AM, V79A, P1439, DOI 10.2106/00004623 199710000 00001
   Breuil V, 2003, FASEB J, V17, P1751, DOI 10.1096/fj.02 1188fje
   Buschmann MD, 2006, CARTILAGE REPAIR ANA, P83
   Cackowski FC, 2010, BLOOD, V115, P140, DOI 10.1182/blood 2009 08 237628
   Chakravarti A, 2009, BLOOD, V114, P1633, DOI 10.1182/blood 2008 09 178301
   Chen HM, 2009, J ORTHOP RES, V27, P1432, DOI 10.1002/jor.20905
   Chevrier A, 2007, OSTEOARTHR CARTILAGE, V15, P316, DOI 10.1016/j.joca.2006.08.007
   Chevrier A, 2005, J HISTOTECHNOL, V28, P165
   Clark RAF., 1995, MOL CELLULAR BIOL WO, P3
   Davies J.E., 2000, BONE ENG, P1
   EVANS RA, 1979, MINER ELECTROL METAB, V2, P179
   Everts V, 2002, J BONE MINER RES, V17, P77, DOI 10.1359/jbmr.2002.17.1.77
   Herman S, 2008, TRENDS MOL MED, V14, P245, DOI 10.1016/j.molmed.2008.04.001
   Hoemann CD, 2007, OSTEOARTHR CARTILAGE, V15, P78, DOI 10.1016/j.joca.2006.06.015
   Hoemann CD, 2005, J BONE JOINT SURG AM, V87A, P2671, DOI 10.2106/JBJS.D.02536
   Hoemann CD, 2010, AM J SPORTS MED
   Insall J N, 1967, J Bone Joint Surg Br, V49, P211
   Knutsen G, 2004, J BONE JOINT SURG AM, V86A, P455, DOI 10.2106/00004623 200403000 00001
   Knutsen G, 2007, J BONE JOINT SURG AM, V89A, P2105, DOI 10.2106/JBJS.G.00003
   Kreja L, 2010, J CELL BIOCHEM, V109, P347, DOI 10.1002/jcb.22406
   Lascau Coman V, 2008, J BONE MINER RES, V23, pS408
   de Amorim FPLG, 2008, J MOL HISTOL, V39, P401, DOI 10.1007/s10735 008 9178 x
   Luna L.G., 1992, HISTOPATHOLOGIC METH
   Ma O, 2008, CARBOHYD POLYM, V72, P616, DOI 10.1016/j.carbpol.2007.10.004
   Marchand C, 2009, OSTEOARTHR CARTILAGE, V17, P953, DOI 10.1016/j.joca.2008.12.002
   Martin JA, 2003, J BONE JOINT SURG AM, V85A, P106, DOI 10.2106/00004623 200300002 00014
   Miao DS, 2002, J CLIN INVEST, V109, P1173, DOI 10.1172/JCI200214817
   Miao DS, 2002, BMC MUSCULOSKELET DI, V3, DOI 10.1186/1471 2474 3 16
   MITCHELL N, 1976, J BONE JOINT SURG AM, V58, P230, DOI 10.2106/00004623 197658020 00012
   Mithoefer K, 2005, J BONE JOINT SURG AM, V87A, P1911, DOI 10.2106/JBJS.D.02846
   Mosheimer BA, 2004, ARTHRITIS RHEUM US, V50, P2309, DOI 10.1002/art.20352
   Nehrer S, 1999, CLIN ORTHOP RELAT R, P149, DOI 10.1097/00003086 199908000 00020
   ODRISCOLL SW, 1988, J BONE JOINT SURG AM, V70A, P595, DOI 10.2106/00004623 198870040 00017
   Okamoto Y, 2003, MACROMOL BIOSCI, V3, P587, DOI 10.1002/mabi.200350026
   PELUSO G, 1994, BIOMATERIALS, V15, P1215, DOI 10.1016/0142 9612(94)90272 0
   PINEDA S, 1992, ACTA ANAT, V143, P335
   Robertson A, 2008, TECHNIQUES KNEE SURG, V7, P191
   Saris DBF, 2008, AM J SPORT MED, V36, P235, DOI 10.1177/0363546507311095
   Schell H, 2006, BONE, V38, P547, DOI 10.1016/j.bone.2005.09.018
   SHAMIS LD, 1989, AM J VET RES, V50, P290
   Shive MS, 2006, OPER TECH ORTHOP, V16, P271, DOI 10.1053/j.oto.2006.08.001
   Simard P, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2703
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Steadman JR, 1997, Oper Tech Orthop, V7, P300
   Tang LH, 1996, J ORTHOP RES, V14, P334, DOI 10.1002/jor.1100140225
   Temple Wong MM, 2009, OSTEOARTHR CARTILAGE, V17, P1469, DOI 10.1016/j.joca.2009.04.017
   Tran Khanh N, 2005, J ORTHOP RES, V23, P1354, DOI 10.1016/j.orthres.2005.05.009
   Ueno H, 2001, BIOMATERIALS, V22, P2125, DOI 10.1016/S0142 9612(00)00401 4
   USAMI Y, 1994, J VET MED SCI, V56, P1215, DOI 10.1292/jvms.56.1215
   Wei XC, 1999, J BIOMED MATER RES, V46, P539, DOI 10.1002/(SICI)1097 4636(19990915)46:4<539::AID JBM12>3.0.CO;2 S
NR 54
TC 28
Z9 36
U1 0
U2 9
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1947 6035
EI 1947 6043
J9 CARTILAGE
JI Cartilage
PD APR
PY 2011
VL 2
IS 2
BP 173
EP 185
DI 10.1177/1947603510381096
PG 13
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA V36NB
UT WOS:000209217400006
PM 26069578
OA Green Published
DA 2025 08 17
ER

PT J
AU Gu, MH
   Pan, BQ
   Chen, WS
   Xu, H
   Wu, XY
   Hu, XT
   Zheng, LL
   Ye, YY
   Meng, Q
   Xian, GY
   Zhang, ZJ
   Sheng, PY
AF Gu, Minghui
   Pan, Baiqi
   Chen, Weishen
   Xu, Hai
   Wu, Xiaoyu
   Hu, Xuantao
   Zheng, Linli
   Ye, Yongyu
   Meng, Qing
   Xian, Guoyan
   Zhang, Ziji
   Sheng, Puyi
TI SPHK Inhibitors and Zoledronic Acid Suppress Osteoclastogenesis and Wear
   Particle Induced Osteolysis
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE SPHKs; osteoclast; aseptic prosthetic loosening; periprosthetic
   osteolysis; inflammation
ID HIP; ARTHROPLASTY; REPLACEMENT; DEGRADATION; DISEASE
AB Background: Inflammatory osteolysis induced by wear particles is the major cause of prosthetic loosening after artificial joint replacement, and its prevention and treatment are difficult worldwide. Our previous study confirmed that sphingosine kinases (SPHKs) are important mediators regulating the wear particle induced macrophage inflammatory response. However, it is unclear whether SPHKs can modulate chronic inflammation and alleviate osteolysis. Zoledronic acid (ZA), an imidazole containing bisphosphonate, directly affects osteoclasts and prevents bone mineral related diseases. However, the effects of SPHK inhibitors and ZA used to treat periprosthetic osteolysis are unknown.Methods: We applied tartrate resistant acid phosphatase (TRAP) staining to evaluate bone destruction in the interface membranes of patients with aseptic loosening and a control group. A murine calvarial osteolysis model was used to examine the preventative effect of SPHK inhibitors and ZA on osteolysis. Micro CT scanning, immunohistochemistry (IHC), and histomorphometric analysis were conducted to determine the variations in inflammatory osteolysis. The effects of different drug concentrations on cell viability were evaluated using the Cell Counting Kit 8 (CCK 8) assay. Real time quantitative polymerase chain reaction (RT qPCR) analysis was performed to confirm the reduced expression of osteoclast specific genes after drug and titanium treatment. The osteoclast formation and functions of the drugs were analyzed using TRAP staining in vivo and in vitro. The effect of SPHKs/S1P TRAF2 BECN1 signaling pathways was verified via RT qPCR and tissue IHC.Results: In this study, we found that SPHK inhibitors (ABC294640 and FTY720) combined with ZA decreased the degree of inflammatory osteolysis in vivo. However, ABC294640 and ZA suppressed osteoclast differentiation and osteoclast specific genes in vitro. SPHKs regulate the inflammatory osteolysis induced by wear particles by increasing the expression of SPHKs/S1P TRAF2 BECN1.Conclusion: Our study revealed that wear particles could induce inflammatory osteolysis by upregulating SPHKs/S1P TRAF2 BECN1 and SPHK inhibitors/ZA inhibit osteoclastogenesis in vitro and prevent inflammatory osteolysis in vivo, suggesting that SPHK inhibitors and ZA can be a new perspective and scientific basis for the prevention and treatment of prosthesis loosening.
C1 [Gu, Minghui; Pan, Baiqi; Chen, Weishen; Wu, Xiaoyu; Hu, Xuantao; Zheng, Linli; Meng, Qing; Xian, Guoyan; Zhang, Ziji; Sheng, Puyi] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Joint Surg, Guangzhou, Peoples R China.
   [Gu, Minghui; Pan, Baiqi; Chen, Weishen; Wu, Xiaoyu; Hu, Xuantao; Zheng, Linli; Xian, Guoyan; Zhang, Ziji; Sheng, Puyi] Sun Yat Sen Univ, Affiliated Hosp 1, Guangdong Prov Key Lab Orthopaed & Traumatol, Guangzhou, Peoples R China.
   [Xu, Hai] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Radiol, Guangzhou, Peoples R China.
   [Ye, Yongyu] Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Orthopaed, Guangzhou, Peoples R China.
   [Meng, Qing] Guizhou Orthoped Hosp, Dept Orthoped, Guiyang, Peoples R China.
   [Xian, Guoyan] Univ Paris, CNRS, INSERM, B3OA, Paris, France.
C3 Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University;
   Guangdong Academy of Medical Sciences & Guangdong General Hospital;
   Southern Medical University   China; Centre National de la Recherche
   Scientifique (CNRS); Institut National de la Sante et de la Recherche
   Medicale (Inserm); Universite Paris Cite
RP Xian, GY; Zhang, ZJ; Sheng, PY (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 1, Dept Joint Surg, Guangzhou, Peoples R China.; Xian, GY; Zhang, ZJ; Sheng, PY (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 1, Guangdong Prov Key Lab Orthopaed & Traumatol, Guangzhou, Peoples R China.; Xian, GY (通讯作者)，Univ Paris, CNRS, INSERM, B3OA, Paris, France.
EM shengpy@mail.sysu.edu.cn; zhangziji@mail.sysu.edu.cn;
   guoyan.xian@etu.u paris.fr
RI Zhang, Ziji/MDT 9723 2025; wu, 晓煜/HIK 3475 2022
OI Chen, Weishen/0000 0003 3469 842X; 
CR Camuzard O, 2019, J BONE JOINT SURG AM, V101, P466, DOI 10.2106/JBJS.18.00479
   Chen WS, 2021, BIOMATER SCI UK, V9, P4922, DOI 10.1039/d1bm00691f
   Chung YH, 2014, J CELL PHYSIOL, V229, P1963, DOI 10.1002/jcp.24646
   Croucher PI, 2003, J BONE MINER RES, V18, P482, DOI 10.1359/jbmr.2003.18.3.482
   Edwards JP, 2006, J LEUKOCYTE BIOL, V80, P1298, DOI 10.1189/jlb.0406249
   Ferguson RJ, 2018, LANCET, V392, P1662, DOI 10.1016/S0140 6736(18)31777 X
   French KJ, 2010, J PHARMACOL EXP THER, V333, P129, DOI 10.1124/jpet.109.163444
   Fu GT, 2019, ORTHOP SURG, V11, P653, DOI 10.1111/os.12513
   Gallo J, 2014, ACTA BIOMATER, V10, P2354, DOI 10.1016/j.actbio.2014.02.003
   Gao MH, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0039 2
   Goodman SB, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2013.0962
   Goodman SB, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122091
   Gu MH, 2015, J ARTHROPLASTY, V30, P2219, DOI 10.1016/j.arth.2015.06.027
   Hait NC, 2009, SCIENCE, V325, P1254, DOI 10.1126/science.1176709
   Hu YH, 2011, MOL CELL NEUROSCI, V48, P72, DOI 10.1016/j.mcn.2011.06.007
   Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713
   Learmonth ID, 2007, LANCET, V370, P1508, DOI 10.1016/S0140 6736(07)60457 7
   Liang SX, 2020, AUTOPHAGY, V16, P1453, DOI 10.1080/15548627.2019.1687214
   Liu H, 2017, AUTOPHAGY, V13, P900, DOI 10.1080/15548627.2017.1291479
   Mbalaviele G, 2017, J CLIN INVEST, V127, P2030, DOI 10.1172/JCI93356
   McEvoy A, 2002, BONE, V30, P171, DOI 10.1016/S8756 3282(01)00658 5
   Pajarinen Jukka, 2014, J Long Term Eff Med Implants, V24, P283
   Purdue PE, 2007, CLIN ORTHOP RELAT R, P251, DOI 10.1097/01.blo.0000238813.95035.1b
   Pyne NJ, 2017, TRENDS PHARMACOL SCI, V38, P581, DOI 10.1016/j.tips.2017.04.003
   Ruspi G, 2014, CELL SIGNAL, V26, P683, DOI 10.1016/j.cellsig.2013.12.009
   Sarode Gargi S, 2016, J Contemp Dent Pract, V17, P513
   Schenten V, 2011, J LEUKOCYTE BIOL, V89, P587, DOI 10.1189/jlb.0510304
   Shao HG, 2015, BIOMATERIALS, V60, P92, DOI 10.1016/j.biomaterials.2015.04.048
   Shin BJ, 2020, J BONE MINER RES, V35, P789, DOI 10.1002/jbmr.3945
   Wang ZH, 2017, ACTA BIOMATER, V48, P489, DOI 10.1016/j.actbio.2016.11.020
   Wang ZH, 2015, AUTOPHAGY, V11, P2358, DOI 10.1080/15548627.2015.1106779
   Xian GY, 2020, J BIOMED MATER RES A, V108, P1792, DOI 10.1002/jbm.a.36938
   Yang GP, 2018, INFLAMMATION, V41, P1498, DOI 10.1007/s10753 018 0795 6
NR 33
TC 6
Z9 8
U1 1
U2 25
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD FEB 14
PY 2022
VL 12
AR 794429
DI 10.3389/fphar.2021.794429
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA ZK0XC
UT WOS:000762719600001
PM 35237148
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Hayashi, Y
   Kawakubo Yasukochi, T
   Mizokami, A
   Takeuchi, H
   Nakamura, S
   Hirata, M
AF Hayashi, Yoshikazu
   Kawakubo Yasukochi, Tomoyo
   Mizokami, Akiko
   Takeuchi, Hiroshi
   Nakamura, Seiji
   Hirata, Masato
TI Differential Roles of Carboxylated and Uncarboxylated Osteocalcin in
   Prostate Cancer Growth
SO JOURNAL OF CANCER
LA English
DT Article
DE osteocalcin; prostate cancer
ID RECEPTOR TYROSINE KINASE; METASTATIC PROGRESSION; SIGNALING PATHWAY;
   EXPRESSION; CELLS; THERAPY; TUMORS; RISK
AB Serum levels of osteocalcin (OC), a bone matrix non collagenous protein secreted by osteoblasts, are correlated with pathological bone remodeling such as the bone metastasis of cancer, as well as physiological bone turnover. The pathological roles in prostate cancer growth of the two existing types of serum OC, gamma carboxylated (GlaOC) and lower  (or un ) carboxylated (GluOC), have not yet been discriminatively examined. In the present study, we demonstrate that normal prostate epithelial cell growth was promoted by both types of OC, while growth of cancer cells in the prostate was accelerated by GlaOC but suppressed by GluOC. We suggest that OC regulates prostate cancer growth depending on the gamma carboxylation, in part by triggering reduced phosphorylation of receptor tyrosine kinases.
C1 [Hayashi, Yoshikazu; Kawakubo Yasukochi, Tomoyo; Mizokami, Akiko; Hirata, Masato] Kyushu Univ, Fac Dent Sci, Lab Mol & Cellular Biochem, Fukuoka 8128582, Japan.
   [Hayashi, Yoshikazu; Nakamura, Seiji] Kyushu Univ, Fac Dent Sci, Sect Oral & Maxillofacial Oncol, Fukuoka 8128582, Japan.
   [Mizokami, Akiko] Kyushu Univ, Fac Dent Sci, OBT Res Ctr, Fukuoka 8128582, Japan.
   [Kawakubo Yasukochi, Tomoyo] Fukuoka Univ, Fac Pharmaceut Sci, Dept Immunol & Mol Pharmacol, Fukuoka 8140180, Japan.
   [Takeuchi, Hiroshi] Kyushu Dent Univ, Div Appl Pharmacol, Kitakyushu, Fukuoka 8038580, Japan.
C3 Kyushu University; Kyushu University; Kyushu University; Fukuoka
   University; Kyushu Dental University
RP Hirata, M (通讯作者)，Kyushu Univ, Fac Dent Sci, Lab Mol & Cellular Biochem, Fukuoka 8128582, Japan.
EM hirata1@dent.kyushu u.ac.jp
RI Mizokami, Akiko/ABC 5448 2021; Takeuchi, Hiroshi/I 8849 2019
OI Takeuchi, Hiroshi/0000 0003 0033 2913; Mizokami,
   Akiko/0000 0002 7490 5190; Hayashi, Yoshikazu/0000 0001 8834 7946; 
FU Japan Society for the Promotion of Science (KAKENHI grants) [24229009,
   26861554, 16K11496, 26861553, 16K20421]; Grants in Aid for Scientific
   Research [26861554, 16K20421, 26861553, 16K11496] Funding Source: KAKEN
FX This work was supported by the Japan Society for the Promotion of
   Science (KAKENHI grants 24229009 to M.H., 26861554 and 16K11496 to
   T.K Y., and 26861553 and 16K20421 to A.M.).
CR Barreca A, 2011, J MOL ENDOCRINOL, V47, pR11, DOI 10.1530/JME 11 0004
   Batson J, 2014, BIOL OPEN, V3, P453, DOI 10.1242/bio.20146601
   Cecchi F, 2012, EXPERT OPIN THER TAR, V16, P553, DOI 10.1517/14728222.2012.680957
   Dawson DM, 1998, J NATL CANCER I, V90, P519, DOI 10.1093/jnci/90.7.519
   Festuccia C, 2009, PROSTATE, V69, P337, DOI 10.1002/pros.20884
   Gardner TA, 2009, ONCOL REP, V21, P903, DOI 10.3892/or_00000302
   Goodyear SM, 2009, PROSTATE, V69, P982, DOI 10.1002/pros.20945
   Guan M, 2009, INT J CANCER, V124, P88, DOI 10.1002/ijc.23890
   Hernández S, 2009, MODERN PATHOL, V22, P848, DOI 10.1038/modpathol.2009.46
   Huang YQ, 2015, J BIOL CHEM, V290, P17753, DOI 10.1074/jbc.M115.661066
   Kawakubo Yasukochi T, 2016, OBESITY, V24, P895, DOI 10.1002/oby.21447
   Kittles RA, 2006, J MED GENET, V43, P507, DOI 10.1136/jmg.2005.035790
   Koizumi M, 2002, J UROLOGY, V167, P1863, DOI 10.1016/S0022 5347(05)65250 0
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011
   Leung YK, 2006, NEOPLASIA, V8, P242, DOI 10.1593/neo.05853
   Lisle JE, 2013, BBA REV CANCER, V1835, P243, DOI 10.1016/j.bbcan.2013.01.003
   Lui Q, 2011, CHIN J CANCER, V30, P612
   Mertens Walker I, 2015, BMC CANCER, V15, DOI 10.1186/s12885 015 1164 6
   Mizokami A, 2014, BONE, V69, P68, DOI 10.1016/j.bone.2014.09.006
   Mizokami A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057375
   Mohamed ER, 2015, ONCOL LETT, V9, P1672, DOI 10.3892/ol.2015.2925
   Morrissey C, 2010, PROSTATE, V70, P1799, DOI 10.1002/pros.21216
   Nagano K, 2014, BIOCHEM BIOPH RES CO, V450, P545, DOI 10.1016/j.bbrc.2014.06.007
   Nimptsch K, 2009, CANCER EPIDEM BIOMAR, V18, P49, DOI 10.1158/1055 9965.EPI 08 0554
   Otani T, 2015, CELL SIGNAL, V27, P532, DOI 10.1016/j.cellsig.2014.12.018
   Paccez JD, 2014, INT J CANCER, V134, P1024, DOI 10.1002/ijc.28246
   Pi M, 2012, PROSTATE, V72, P399, DOI 10.1002/pros.21442
   Rebagay G, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00034
   Thulin MH, 2014, CLIN EXP METASTAS, V31, P269, DOI 10.1007/s10585 013 9626 1
   Valiathan RR, 2012, CANCER METAST REV, V31, P295, DOI 10.1007/s10555 012 9346 z
   Yang F, 2013, CANCER RES, V73, P3716, DOI 10.1158/0008 5472.CAN 12 3274
NR 32
TC 13
Z9 13
U1 0
U2 2
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1837 9664
J9 J CANCER
JI J. Cancer
PY 2016
VL 7
IS 12
BP 1605
EP 1609
DI 10.7150/jca.15523
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA EJ2YB
UT WOS:000393076400004
PM 27698897
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Wcislo, G
AF Wcislo, Gabriel
TI Pathophysiological basis for utility of zoledronic acid in patients with
   prostate cancer
SO WSPOLCZESNA ONKOLOGIA CONTEMPORARY ONCOLOGY
LA English
DT Article
DE prostate cancer; osteosclerotic bone metastasis; zoledronic acid; cancer
   bone loss
ID ANDROGEN DEPRIVATION THERAPY; RANDOMIZED CONTROLLED TRIAL;
   DELTA T CELLS; BONE METASTASIS; PLASMA LEVELS; IN VITRO; GROWTH; LEPTIN;
   BISPHOSPHONATES; PROGRESSION
AB Prostate cancer still appears to be a very important malignant disease in Western societies. It can be said that prostate cancer morbidity rises with age in old men. The natural history of prostate cancer is rather simple. The majority of patients who are diagnosed with localized prostate cancer are treated with curative intent with either radiation or surgery. Patients in whom treatment with curative intent is unsuccessful and those who present with metastasis are candidates for androgen suppression. Skeletal related events are defined by the existence of changes in antineoplastic therapy to treat bone pain, pathological bone fractures, radiation therapy to bone, spinal cord compression, and surgery to bone. Bone pathology correlates with cancer course and has been shown to influence survival. Pathobiology provides new insights into mechanisms responsible for bone metastases related to prostate cancer. Several studies have evaluated risk factors for bone loss and fractures in prostate cancer patients receiving androgen deprivation therapy. The three risk factors that have been reliably identified in patients with locally advanced disease are older age, low body mass index and a long duration of androgen deprivation therapy. In metastatic prostate cancer, the sole reliable risk factor is elevated levels of deoxypyridinoline. Zoledronic acid has a crucial impact on combined therapy with hormones, then with chemotherapy, and additionally can be used in the prevention of osteoporosis/osteopenia related to cancer treatment.
C1 Mil Inst Med, Dept Oncol, PL 00909 Warsaw, Poland.
C3 Military Institute of Aviation Medicine
RP Wcislo, G (通讯作者)，Mil Inst Med, Dept Oncol, 128 Szaserow St, PL 00909 Warsaw, Poland.
EM gabrielwcislo@yahoo.pl
OI Wcislo, Gabriel/0000 0002 8887 7688
CR ACHBAROU A, 1994, CANCER RES, V54, P2372
   Banerjee S, 2007, CANCER RES, V67, P3818, DOI 10.1158/0008 5472.CAN 06 3879
   Berenson JR, 2005, ONCOLOGIST, V10, P52, DOI 10.1634/theoncologist.10 1 52
   Bertucci F, 2001, LANCET ONCOL, V2, P674, DOI 10.1016/S1470 2045(01)00557 5
   Bruder JM, 2006, UROLOGY, V67, P152, DOI 10.1016/j.urology.2005.07.017
   Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408
   Cao C, 2006, CANCER RES, V66, P10040, DOI 10.1158/0008 5472.CAN 06 0802
   CARDUCCI MA, 2006, CLIN CANCER RES, V12, P1221
   Carles J, 2004, CLIN CANCER RES, V10, P4742, DOI 10.1158/1078 0432.CCR 04 0115
   Clézardin P, 2005, CANCER RES, V65, P4971, DOI 10.1158/0008 5472.CAN 05 0264
   Clines GA, 2007, MOL ENDOCRINOL, V21, P486, DOI 10.1210/me.2006 0346
   Corey E, 2005, CANCER RES, V65, P1710, DOI 10.1158/0008 5472.CAN 04 2033
   Corey E, 2003, CLIN CANCER RES, V9, P295
   Coxon FP, 2003, CALCIFIED TISSUE INT, V72, P80, DOI 10.1007/s00223 002 2017 2
   Coxon JP, 2004, BJU INT, V94, P164, DOI 10.1111/j.1464 4096.2004.04831.x
   Cramer SD, 1996, J UROLOGY, V156, P526, DOI 10.1016/S0022 5347(01)65919 6
   Dai JL, 2005, CANCER RES, V65, P8274, DOI 10.1158/0008 5472.CAN 05 1891
   Deo DD, 2008, J BIOMED BIOTECHNOL, DOI 10.1155/2008/163902
   Di Cristofano Antonio, 2001, Nature Genetics, V27, P222
   Diaz Michael, 2004, Cancer Control, V11, P364
   Dieli F, 2007, CANCER RES, V67, P7450, DOI 10.1158/0008 5472.CAN 07 0199
   Djavan B, 2002, J CLIN ONCOL, V20, P921, DOI 10.1200/JCO.20.4.921
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   Elefteriou F, 2004, P NATL ACAD SCI USA, V101, P3258, DOI 10.1073/pnas.0308744101
   Fizazi K, 2003, CLIN CANCER RES, V9, P2587
   FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275
   Fournier P, 2002, CANCER RES, V62, P6538
   Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376
   George DJ, 2001, CLIN CANCER RES, V7, P1932
   Goblirsch MJ, 2006, CLIN CANCER RES, V12, p6231S, DOI 10.1158/1078 0432.CCR 06 0682
   Goffinet M, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 60
   Goktas S, 1999, SEMIN ONCOL, V26, P162
   Hall CL, 2006, J CELL BIOCHEM, V97, P661, DOI 10.1002/jcb.20735
   Hayes R B, 1992, Eur J Cancer Prev, V1, P239, DOI 10.1097/00008469 199204000 00005
   Hofbauer LC, 1999, EUR J ENDOCRINOL, V140, P271, DOI 10.1530/eje.0.1400271
   Holcomb IN, 2008, CANCER RES, V68, P5599, DOI 10.1158/0008 5472.CAN 08 0812
   Huggins C, 1941, CANCER RES, V1, P293
   Hussain SA, 2003, BJU INT, V92, P690, DOI 10.1046/j.1464 410X.2003.04471.x
   Ioannidis JPA, 2007, ONCOLOGIST, V12, P301, DOI 10.1634/theoncologist.12 3 301
   Iwaniec UT, 2007, PEPTIDES, V28, P1012, DOI 10.1016/j.peptides.2007.02.001
   Jerónimo C, 2004, CLIN CANCER RES, V10, P8472, DOI 10.1158/1078 0432.CCR 04 0894
   Kabelitz D, 2007, CANCER RES, V67, P5, DOI 10.1158/0008 5472.CAN 06 3069
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Kaufmann SHE, 1996, P NATL ACAD SCI USA, V93, P2272, DOI 10.1073/pnas.93.6.2272
   Kitagawa Y, 2005, CANCER RES, V65, P10921, DOI 10.1158/0008 5472.CAN 05 1809
   Klezovitch O, 2004, CANCER CELL, V6, P185, DOI 10.1016/j.ccr.2004.07.008
   KRUPSKI TL, 2004, P AM SOC CLIN ONCO S, V22, P726
   Lam MGEH, 2008, EUR J NUCL MED MOL I, V35, P756, DOI 10.1007/s00259 007 0659 z
   Leder BZ, 2003, J CLIN ENDOCR METAB, V88, P204, DOI 10.1210/jc.2002 021036
   Lipton A, 2008, CANCER TREAT REV, V34, pS25, DOI 10.1016/j.ctrv.2008.03.008
   Lipton A, 2008, CANCER AM CANCER SOC, V113, P193, DOI 10.1002/cncr.23529
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Marx J, 2007, SCIENCE, V317, P1029, DOI 10.1126/science.317.5841.1029
   Michaelson MD, 2007, J CLIN ONCOL, V25, P1038, DOI 10.1200/JCO.2006.07.3361
   Michaelson MD, 2006, CANCER AM CANCER SOC, V107, P530, DOI 10.1002/cncr.22043
   MONTIE JE, 1994, UROLOGY, V43, P892, DOI 10.1016/0090 4295(94)90163 5
   Morgan TM, 2008, PROSTATE, V68, P861, DOI 10.1002/pros.20752
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Neville Webbe HL, 2005, INT J CANCER, V113, P364, DOI 10.1002/ijc.20602
   Nogawa M, 2005, ONCOL RES, V15, P1
   Onuma M, 2003, J BIOL CHEM, V278, P42660, DOI 10.1074/jbc.M304984200
   Oudes AJ, 2005, BMC CANCER, V5, DOI 10.1186/1471 2407 5 86
   PAGET S, 1989, CANCER METAST REV, V8, P98
   Polascik TJ, 2008, PROSTATE CANCER P D, V11, P13, DOI 10.1038/sj.pcan.4501019
   Punglia RS, 2003, NEW ENGL J MED, V349, P335, DOI 10.1056/NEJMoa021659
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Saad F, 2007, CANCER AM CANCER SOC, V110, P1860, DOI 10.1002/cncr.22991
   Saad F, 2006, CLIN GENITOURIN CANC, V4, P257, DOI 10.3816/CGC.2006.n.004
   Santini D, 2003, CLIN CANCER RES, V9, P2893
   SANTINI D, 2008, CANC IMMUNO IN PRESS
   Santomaggio A, 2007, ANN ONCOL, V18, P7
   Schneider A, 2005, ENDOCRINOLOGY, V146, P1727, DOI 10.1210/en.2004 1211
   Shaffer DR, 2005, P NATL ACAD SCI USA, V102, P210, DOI 10.1073/pnas.0407362102
   Shahinian VB, 2005, NEW ENGL J MED, V352, P154, DOI 10.1056/NEJMoa041943
   Shariat SF, 2001, J CLIN ONCOL, V19, P2856, DOI 10.1200/JCO.2001.19.11.2856
   Shariat SF, 2001, UROLOGY, V58, P1008, DOI 10.1016/S0090 4295(01)01405 4
   Smid M, 2006, J CLIN ONCOL, V24, P2261, DOI 10.1200/JCO.2005.03.8802
   Smith MR, 2006, CLIN CANCER RES, V12, p6315S, DOI 10.1158/1078 0432.CCR 06 0846
   Smith MR, 2003, J UROLOGY, V169, P2008, DOI 10.1097/01.ju.0000063820.94994.95
   Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469
   STERN PH, 1995, J NUTR, V125, pS2028, DOI 10.1093/jn/125.suppl_7.2028S
   Sullivan PW, 2006, QUAL LIFE RES, V15, P1297, DOI 10.1007/s11136 006 0003 2
   Thudi NK, 2008, PROSTATE, V68, P1116, DOI 10.1002/pros.20776
   Valta MP, 2006, ENDOCRINOLOGY, V147, P2171, DOI 10.1210/en.2005 1502
   Van Sant C, 2007, MOL CANCER THER, V6, P253, DOI 10.1158/1535 7163.MCT 06 0574
   Wang YZ., 2001, J Urol, V165, P1320
   WCISLO G, 2004, WSPOLCZESNA ONKOL, V8, P415
   WCISLO G, 2008, ACTA POL PH IN PRESS
   Wcislo G, 2005, WSPOLCZESNA ONKOL, V9, P143
   Wcislo G, 2006, WSPOLCZESNA ONKOL, V10, P103
   Wcislo G, 2006, WSPOLCZESNA ONKOL, V10, P34
   Xin L, 2005, P NATL ACAD SCI USA, V102, P6942, DOI 10.1073/pnas.0502320102
   Yi B, 2002, CANCER RES, V62, P917
   Yin JJ, 2003, P NATL ACAD SCI USA, V100, P10954, DOI 10.1073/pnas.1830978100
   Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070
   YU M, 1993, LAB INVEST, V68, P33
NR 97
TC 0
Z9 0
U1 0
U2 1
PU TERMEDIA PUBLISHING HOUSE LTD
PI POZNAN
PA KLEEBERGA 2, POZNAN, 61 615, POLAND
SN 1428 2526
EI 1897 4309
J9 WSPOLCZESNA ONKOL
JI Wspolczesna Onkol.
PD NOV
PY 2008
VL 12
IS 7
BP 324
EP 332
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 462ZN
UT WOS:000267397800006
DA 2025 08 17
ER

PT J
AU Zhang, ZC
   Liu, JC
   Li, YJ
   Wang, YS
   Zheng, X
   Wang, F
   Tong, T
   Miao, DC
   Chen, L
   Wang, LF
AF Zhang, Zhanchi
   Liu, Junchuan
   Li, Yijun
   Wang, Yunsheng
   Zheng, Xiao
   Wang, Feng
   Tong, Tong
   Miao, Dechao
   Chen, Lei
   Wang, Linfeng
TI 4 Hydroxyphenylacetic Acid, a microbial derived metabolite of
   Polyphenols, inhibits osteoclastogenesis by inhibiting ROS production
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Osteoclast; Osteoporosis; 4 Hydroxyphenylacetic acid; Reactive oxygen
   species
ID NF KAPPA B; INDUCED BONE LOSS; DIFFERENTIATION FACTOR; OXIDATIVE STRESS;
   CRUCIAL ROLE; RANKL; BIOAVAILABILITY; RECEPTOR; DEFENSE; LIGAND
AB Intracellular reactive oxygen species (ROS) accumulation is key to osteoclast differentiation. Plant derived polyphenols that have reduced ROS production have been widely studied for the treatment of osteoporosis. However, these compounds are rarely absorbed in the small intestine and are instead converted to phenolic acids by the microbiota in the colon. These large quantities of low molecular weight phenolic acids can then be absorbed by the body. 4 Hydroxyphenylacetic acid (4 HPA) is an important metabolite of these polyphenols that is generated by the human intestinal microbiota. However, its potential mechanism is not fully understood. In this study, we aimed to elucidate the role of 4 HPA on osteoclastogenesis and treating osteoporosis. Our study showed that 4 HPA inhibited osteoclast differentiation and function and downregulated osteoclast specific genes, including NFATc1, Atp6v0d2, MMP9, CTSK, Acp5, and c Fos. As for further mechanism exploration, 4 HPA reduced ROS accumulation by regulating nuclear factor erythroid 2 related factor (Nrf2) and subsequently inhibited the nuclear factor kappa B (NF kappa B) and mitogen activated protein kinase (MAPK) pathways. To evaluate the effect of 4 HPA on postmenopausal osteoporosis, an ovariectomized (OVX) mouse model was used. The Micro CT and histomorphometry analyses showed that 4 HPA effectively prevents bone loss. Encouragingly, 4HPA demonstrated efficacy in treating osteoporosis induced by OVX. In conclusion, our study revealed that 4 HPA, a polyphenol metabolite produced by intestinal microorganisms, also inhibits osteoclast formation and treats osteoporosis, which provides a new experimental basis and candidate drug for the treatment of osteoporosis.
C1 [Liu, Junchuan; Wang, Yunsheng; Zheng, Xiao; Wang, Feng; Tong, Tong; Miao, Dechao; Wang, Linfeng] Third Hosp Hebei Med Univ, Dept Orthopaed Surg, Shijiazhuang 050051, Peoples R China.
   [Liu, Junchuan; Wang, Yunsheng; Zheng, Xiao; Wang, Feng; Tong, Tong; Miao, Dechao; Wang, Linfeng] Third Hosp Hebei Med Univ, Key Lab Orthoped Biomech Hebei Prov, Shijiazhuang 050051, Peoples R China.
   [Zhang, Zhanchi] Hebei Med Univ, Dept Human Anat, Shijiazhuang 050017, Peoples R China.
   [Chen, Lei] Hebei Med Univ, Affiliated Hosp 4, Intens Care Ctr, Shijiazhuang 050011, Peoples R China.
   [Li, Yijun] Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou 325035, Peoples R China.
C3 Hebei Medical University; Hebei Medical University; Wenzhou Medical
   University
RP Wang, LF (通讯作者)，Third Hosp Hebei Med Univ, Dept Orthopaed Surg, Shijiazhuang 050051, Peoples R China.; Chen, L (通讯作者)，Hebei Med Univ, Affiliated Hosp 4, Intens Care Ctr, Shijiazhuang 050011, Peoples R China.
EM aj.chen@163.com; wanglinfenglaoshi@163.com
RI Wang, Linfeng/KEE 9655 2024
FU Hebei Provincial Central Guidance Local Science and Technology
   Development Project [236Z7742G]; Hebei Natural Science Foundation
   [H2020206382]
FX This research was supported by grants from the Hebei Provincial Central
   Guidance Local Science and Technology Development Project (236Z7742G)
   and the Hebei Natural Science Foundation (H2020206382) .
CR Aspray Terry J, 2019, Subcell Biochem, V91, P453, DOI 10.1007/978 981 13 3681 2_16
   Black DM, 2012, NEW ENGL J MED, V366, P2051, DOI 10.1056/NEJMp1202623
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cai X, 2013, CURR MED CHEM, V20, P2572, DOI 10.2174/09298673113209990120
   Cao X, 2011, NAT MED, V17, P1344, DOI 10.1038/nm.2499
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Clynes MA, 2020, BRIT MED BULL, V133, P105, DOI 10.1093/bmb/ldaa005
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cuadrado A, 2019, NAT REV DRUG DISCOV, V18, P295, DOI 10.1038/s41573 018 0008 x
   Cui LJ, 2021, ARCH OSTEOPOROS, V16, DOI 10.1007/s11657 021 00958 x
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Déprez S, 2000, J NUTR, V130, P2733, DOI 10.1093/jn/130.11.2733
   Diplock AT, 1998, BRIT J NUTR, V80, pS77, DOI 10.1079/BJN19980106
   Dröge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Förstermann U, 2008, NAT CLIN PRACT CARD, V5, P338, DOI 10.1038/ncpcardio1211
   Ge YW, 2020, J CELL MOL MED, V24, P3203, DOI 10.1111/jcmm.14995
   Goettsch C, 2013, J CLIN INVEST, V123, P4731, DOI 10.1172/JCI67603
   Guo W, 2021, J ORTHOP TRANSL, V28, P148, DOI 10.1016/j.jot.2021.01.005
   Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005
   Jiang YX, 2020, LIFE SCI, V246, DOI 10.1016/j.lfs.2020.117422
   Jung YY, 2008, J BIOL CHEM, V283, P23863, DOI 10.1074/jbc.M803072200
   Kim HS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01527 y
   Kim H, 2013, CELL METAB, V17, P249, DOI 10.1016/j.cmet.2013.01.002
   Landete JM, 2012, CRIT REV FOOD SCI, V52, P936, DOI 10.1080/10408398.2010.513779
   Lean JM, 2003, J CLIN INVEST, V112, P915, DOI 10.1172/JCI200318859
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Lee SE, 2001, J BIOL CHEM, V276, P49343, DOI 10.1074/jbc.M103642200
   Li AN, 2014, NUTRIENTS, V6, P6020, DOI 10.3390/nu6126020
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Luo SY, 2016, J ORTHOP TRANSL, V4, P35, DOI 10.1016/j.jot.2015.07.002
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   Ni S, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12882
   Park E, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/4122253
   Prior RL, 2010, J AGR FOOD CHEM, V58, P3940, DOI 10.1021/jf9028392
   Retraction, 2015, Crit Rev Food Sci Nutr, V55, P1792, DOI [10.1080/10408398.2015.1016371, DOI 10.1080/10408398.2015.1016371]
   Russell LA, 2018, BEST PRACT RES CL RH, V32, P835, DOI 10.1016/j.berh.2019.04.002
   Sun XW, 2019, FASEB J, V33, P12929, DOI 10.1096/fj.201900887RR
   Tian HS, 2023, NANO LETT, V23, P4101, DOI 10.1021/acs.nanolett.2c04295
   Wang QQ, 2022, SCI ADV, V8, DOI 10.1126/sciadv.abn3333
   Wang SY, 2021, J BONE MINER RES, V36, P1850, DOI 10.1002/jbmr.4328
   Wang XB, 2023, J ORTHOP TRANSL, V39, P135, DOI 10.1016/j.jot.2023.01.002
   Xu DW, 2020, INT IMMUNOPHARMACOL, V78, DOI 10.1016/j.intimp.2019.105983
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   You TM, 2015, OR SURG OR MED OR PA, V120, P548, DOI 10.1016/j.oooo.2015.07.017
   Zalli D, 2016, J BONE MINER RES, V31, P1701, DOI 10.1002/jbmr.2851
   Zebic L, 2019, BMJ BRIT MED J, V365, DOI 10.1136/bmj.l1733
   Zhao HQ, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00653
   Zhou QL, 2022, MICROBIOME, V10, DOI 10.1186/s40168 022 01271 6
NR 53
TC 2
Z9 2
U1 11
U2 18
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD DEC 25
PY 2024
VL 143
AR 113571
DI 10.1016/j.intimp.2024.113571
EA NOV 2024
PN 3
PG 12
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA M1K0A
UT WOS:001355186300001
PM 39520963
DA 2025 08 17
ER

PT J
AU Tang, ZR
   Chen, SY
   Ni, YL
   Zhao, R
   Zhu, XD
   Yang, X
   Zhang, XD
AF Tang, Zhurong
   Chen, Siyu
   Ni, Yilu
   Zhao, Rui
   Zhu, Xiangdong
   Yang, Xiao
   Zhang, Xingdong
TI Role of Na<SUP>+</SUP>, K<SUP>+</SUP> ATPase ion pump in osteoinduction
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Na+, K+ ATPase; Calcium phosphate bioceramic; Mesenchymal stem cells;
   Osteoinduction; Osteoporosis
ID BONE MORPHOGENETIC PROTEIN 2; INDUCE OSTEOGENIC DIFFERENTIATION;
   CALCIUM PHOSPHATE; NA/K ATPASE; MOLECULAR MECHANISMS; SIGNALING
   PATHWAYS; MINERAL DENSITY; STEM CELLS; C PEPTIDE; EXPRESSION
AB Porous biphasic calcium phosphate bioceramic (BCP) possesses osteoinductivity to induce the osteoblastic commitment of mesenchymal stem cells (MSCs) and ectopic bone formation. However, the underlying mechanism remains enigmatic. We performed a gene array analysis of MSCs cocultured with BCP to screen for candidate osteoinductive modulators. Na+, K+ ATPase (NKA), an ion transporter, therefore was identified as a crucial ion transporter in regulating the osteogenesis of the cells. NKA activator, a polyclonal antibody, enriched the cytomembrane abundance of NKA and lead to an enhanced osteogenic effect of BCP. As indicated in gene array analysis and suggested by co immunoprecipitation assay, protein phosphatase 2A (PP2A) was elevated by BCP to dephosphorylate NKA and prevent its endocytosis. The inhibition of NKA by ouabain resulted in an adverse effect on osteoinductivity of BCP. We further altered NKA activity in mice implanted with BCP and found that the intensity and incidence of osteoinduction was increased by the NKA activator. We went one step further by investigating the potential of targeting NKA in osteoporotic bone regeneration. Activating NKA upregulated osteogenic gene expression and calcium deposition ability of osteoporotic osteoblasts. Furthermore, activation of NKA in mice ameliorated estrogen deficiency induced bone loss, in terms of increased bone mass and improved bending strength. With this osteoinductive bioceramic derived ion transporter target, we demonstrate that the activation of NKA has significant potential to revolutionize the regeneration of bone.
   Statement of significance
   In this study, we identified an important role of Na+, K+ ATPase (NKA) have played in osteoinductivity of biphasic calcium phosphate bioceramic (BCP). Furthermore, we demonstrated the therapeutic potential of targeting NKA in osteoporotic bone regeneration. Numerous gene and protein targets to treat osteoporosis were discovered every year, mainly obtained by genomic and proteomic screenings of a large population. In contrast, our study identified an unrevealed bone regenerating target from the upregulated genes induced by an osteoinductive biomaterial. The approach was cost saving since it did not require a large sample pool. Furthermore, the target derived from this approach was proven to be anabolic. Identification of an anabolic agent holds significant value since most of the current anti osteoporotic therapies are antiresorptive. (C) 2021 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Tang, Zhurong; Chen, Siyu; Ni, Yilu; Zhao, Rui; Zhu, Xiangdong; Yang, Xiao; Zhang, Xingdong] Sichuan Univ, Natl Engn Res Ctr Biomat, 29 Wangjiang Rd, Chengdu 610064, Peoples R China.
   [Tang, Zhurong] Chongqing Med Univ, Inst Life Sci, Chongqing 400016, Peoples R China.
   [Ni, Yilu] Chongqing Med Univ, Coll Lab Med, Chongqing 400016, Peoples R China.
C3 Sichuan University; Chongqing Medical University; Chongqing Medical
   University
RP Yang, X (通讯作者)，Sichuan Univ, Natl Engn Res Ctr Biomat, 29 Wangjiang Rd, Chengdu 610064, Peoples R China.
EM xiaoyang114@scu.edu.cn
RI Yang, Xiaoyong/C 5920 2019
FU National Natural Science Foundation of China [81971755]; Sichuan Science
   and Technology Program [2020YFS0038]; Sichuan Science and Technology
   Innovation Team of China [2019JDTD0008, AA17204085 2]; Young Elite
   Scientist Sponsorship Program by CAST [2019QNRC001]; Fundamental
   Research Funds for the Central Universities; "111" ProjectofChina
   [B16033]
FX This work was supported by National Natural Science Foundation of China
   [grant number 81971755], Sichuan Science and Technology Program [grant
   number 2020YFS0038], Sichuan Science and Technology Innovation Team of
   China [grant number 2019JDTD0008], Guike [grant number AA17204085 2],
   Young Elite Scientist Sponsorship Program by CAST [grant number
   2019QNRC001], Fundamental Research Funds for the Central Universities,
   and the "111" ProjectofChina[grant number B16033].
CR Akimova OA, 2015, APOPTOSIS, V20, P1200, DOI 10.1007/s10495 015 1144 y
   Barradas AMC, 2013, INTEGR BIOL UK, V5, P920, DOI 10.1039/c3ib40027a
   Barradas AMC, 2011, EUR CELLS MATER, V21, P407, DOI 10.22203/eCM.v021a31
   Bohner M, 2019, MATER TODAY, V22, P132, DOI 10.1016/j.mattod.2018.10.036
   Boonrungsiman S, 2012, P NATL ACAD SCI USA, V109, P14170, DOI 10.1073/pnas.1208916109
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   CARAFOLI E, 1991, ANNU REV PHYSIOL, V53, P531, DOI 10.1146/annurev.ph.53.030191.002531
   Chai YC, 2012, BIOMATERIALS, V33, P3127, DOI 10.1016/j.biomaterials.2012.01.015
   Chen XN, 2016, J MATER CHEM B, V4, P2280, DOI 10.1039/c6tb00349d
   COLLINS EM, 1992, AM J PHYSIOL, V262, pH754, DOI 10.1152/ajpheart.1992.262.3.H754
   Dahl JP, 2000, BIOCHEMISTRY US, V39, P14877, DOI 10.1021/bi001073y
   DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968 0004(94)90038 8
   Deng WB, 2013, THERIOGENOLOGY, V79, P1196, DOI 10.1016/j.theriogenology.2013.02.018
   Edreira ERU, 2016, BIOFABRICATION, V8, DOI 10.1088/1758 5090/8/2/025006
   Fini M, 2001, BIOMED PHARMACOTHER, V55, P213, DOI 10.1016/S0753 3322(01)00054 3
   Francis MJO, 2002, INT J BIOCHEM CELL B, V34, P459, DOI 10.1016/S1357 2725(01)00142 X
   Fujibayashi S, 2004, BIOMATERIALS, V25, P443, DOI 10.1016/S0142 9612(03)00551 9
   Fukuda A, 2011, ACTA BIOMATER, V7, P2327, DOI 10.1016/j.actbio.2011.01.037
   Geering K, 2005, J BIOENERG BIOMEMBR, V37, P387, DOI 10.1007/s10863 005 9476 x
   Gracelli JB, 2012, CELL PHYSIOL BIOCHEM, V30, P160, DOI 10.1159/000339055
   Habibovic P, 2006, J ORTHOP RES, V24, P867, DOI 10.1002/jor.20115
   Hakki SS, 2014, J BIOMED MATER RES B, V102, P119, DOI 10.1002/jbm.b.32988
   HALL TJ, 1994, CELL BIOL INT, V18, P189, DOI 10.1006/cbir.1994.1060
   Kishore V, 2012, BIOMATERIALS, V33, P2137, DOI 10.1016/j.biomaterials.2011.11.066
   Koricanac G, 2011, EUR J PHARMACOL, V655, P23, DOI 10.1016/j.ejphar.2011.01.016
   KYTE J, 1971, J BIOL CHEM, V246, P4157
   Lai FF, 2013, J BIOL CHEM, V288, P13295, DOI 10.1074/jbc.M113.467381
   Lecuona E, 2006, FASEB J, V20, P2618, DOI 10.1096/fj.06 6503fje
   Lee DI, 2009, MOL PHARMACOL, V75, P774, DOI 10.1124/mol.108.052597
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Li XM, 2012, BIOMATERIALS, V33, P4818, DOI 10.1016/j.biomaterials.2012.03.045
   Li Y, 2011, J BIOL CHEM, V286, P32289, DOI 10.1074/jbc.M111.247825
   Locklin RM, 2001, J BONE MINER RES, V16, P2192, DOI 10.1359/jbmr.2001.16.12.2192
   Lucas S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02490 4
   LUCCHESI PA, 1991, J BIOL CHEM, V266, P9327
   Ma BJ, 2018, ACTA BIOMATER, V71, P108, DOI 10.1016/j.actbio.2018.02.033
   Montalcini T, 2015, OSTEOPOROSIS INT, V26, P1639, DOI 10.1007/s00198 015 3040 2
   Müller P, 2008, J CELL MOL MED, V12, P281, DOI 10.1111/j.1582 4934.2007.00103.x
   OBRIEN WJ, 1994, ARCH BIOCHEM BIOPHYS, V310, P32, DOI 10.1006/abbi.1994.1136
   Ohtomo Y, 1996, DIABETOLOGIA, V39, P199, DOI 10.1007/BF00403963
   Oryan A, 2014, BIOFACTORS, V40, P459, DOI 10.1002/biof.1177
   Palacios J, 2004, AM J PHYSIOL HEART C, V286, pH1793, DOI 10.1152/ajpheart.00990.2003
   Perinpanayagam H, 2001, J ORTHOPAED RES, V19, P993, DOI 10.1016/S0736 0266(01)00045 6
   Qing FZ, 2016, J ORTHOP RES, V34, P1147, DOI 10.1002/jor.23128
   Rejnmark L, 2007, OSTEOPOROSIS INT, V18, P409, DOI 10.1007/s00198 006 0250 7
   Ripamonti U, 1999, S AFR J SCI, V95, P335
   Rissanen JP, 2010, EXPERT OPIN DRUG DIS, V5, P1163, DOI 10.1517/17460441.2010.532484
   Sabik OL, 2017, TRANSL RES, V181, P15, DOI 10.1016/j.trsl.2016.10.009
   Shields LBE, 2006, SPINE, V31, P542, DOI 10.1097/01.brs.0000201424.27509.72
   Shih YRV, 2014, P NATL ACAD SCI USA, V111, P990, DOI 10.1073/pnas.1321717111
   Silva E, 2012, INT REV CEL MOL BIO, V294, P99, DOI 10.1016/B978 0 12 394305 7.00002 1
   Staines KA, 2014, J BONE MINER METAB, V32, P240, DOI 10.1007/s00774 013 0493 2
   Sun Q, 2019, J DENT, V82, P91, DOI 10.1016/j.jdent.2019.01.015
   Tang ZR, 2017, MAT SCI ENG C MATER, V70, P1000, DOI 10.1016/j.msec.2016.06.097
   Tang ZR, 2015, J BIOMED MATER RES A, V103, P1001, DOI 10.1002/jbm.a.35242
   VELDMAN CM, 1995, PFLUG ARCH EUR J PHY, V430, P64, DOI 10.1007/BF00373840
   Wang J, 2014, J BIOMED MATER RES A, V102, P4234, DOI 10.1002/jbm.a.35102
   Woo EJ, 2013, CLIN ORTHOP RELAT R, V471, P1707, DOI 10.1007/s11999 012 2684 x
   Xie PF, 2016, J MECH BEHAV BIOMED, V53, P341, DOI 10.1016/j.jmbbm.2015.08.040
   Xie ZJ, 2003, ANN NY ACAD SCI, V986, P497, DOI 10.1111/j.1749 6632.2003.tb07234.x
   Xiong SP, 2018, BIOCHEM PHARMACOL, V156, P281, DOI 10.1016/j.bcp.2018.08.024
   Xu KY, 2006, BIOCHEM BIOPH RES CO, V349, P582, DOI 10.1016/j.bbrc.2006.08.070
   Xu KY, 2011, BIOCHEM BIOPH RES CO, V406, P200, DOI 10.1016/j.bbrc.2011.02.013
   Xu KY, 2005, BIOCHEM BIOPH RES CO, V338, P1669, DOI 10.1016/j.bbrc.2005.10.067
   Yamasaki H., 1990, Jpan J Oral Biol, V32, P190, DOI DOI 10.2330/JORALBIOSCI1965.32.190
   Yang X, 2013, J MECH BEHAV BIOMED, V22, P51, DOI 10.1016/j.jmbbm.2013.03.009
   Yang X, 2013, BONE, V52, P308, DOI 10.1016/j.bone.2012.09.039
   Yang X, 2011, BONE, V48, P1154, DOI 10.1016/j.bone.2011.02.007
   Yu YX, 2017, FRONT MATER SCI, V11, P93, DOI 10.1007/s11706 017 0373 0
   Yuan HP, 2010, P NATL ACAD SCI USA, V107, P13614, DOI 10.1073/pnas.1003600107
   Zainabadi K, 2019, PHARMACOL RES, V143, P97, DOI 10.1016/j.phrs.2019.03.007
   Zayzafoon M, 2006, J CELL BIOCHEM, V97, P56, DOI 10.1002/jcb.20675
   Zhang BJ, 2020, ACTA BIOMATER, V114, P431, DOI 10.1016/j.actbio.2020.07.024
   Zhang X., 1991, Bioceramics and the Human Body, P408
   Zhao R, 2019, NANOSCALE, V11, P2721, DOI 10.1039/c8nr09417a
   Zhao R, 2017, ACTA BIOMATER, V59, P338, DOI 10.1016/j.actbio.2017.07.009
   Zheng J, 2011, CARDIOVASC RES, V89, P51, DOI 10.1093/cvr/cvq263
NR 77
TC 12
Z9 12
U1 4
U2 36
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD JUN 15
PY 2021
VL 129
BP 293
EP 308
DI 10.1016/j.actbio.2021.05.026
EA JUL 2021
PG 16
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA TG6EI
UT WOS:000671495400001
PM 34087440
DA 2025 08 17
ER

PT J
AU Miyazaki Asato, Y
   Koi, K
   Fujimoto, H
   Kakura, K
   Kido, H
   Yanagi, T
   Yamashita, J
AF Miyazaki Asato, Yoko
   Koi, Kiyono
   Fujimoto, Hiroki
   Kakura, Kae
   Kido, Hirofumi
   Yanagi, Tsukasa
   Yamashita, Junro
TI ! Intramedullary injury combined with osteoporosis therapeutics
   regulates targeted local osteogenesis
SO SCIENTIFIC REPORTS
LA English
DT Article
AB Bone marrow ablation prompts transient bone formation in nearly the entire medullary cavity before marrow regeneration occurs. Here, we establish a procedure to direct bone formation in a desired particular site within the medullary cavity for support of biomedical devices. Local intramedullary injury was performed in the tibiae of rats and parathyroid hormone (PTH), alendronate, or saline was administered. Newly generated bone in the medulla was assessed by micro CT and histology. To evaluate the function of newly generated bone, animals received intramedullary injury in tibiae followed by daily PTH. At day 14, implants were placed in the endocortical bone and the bone response to the implants was assessed. The fate of newly generated bone was compared with and without implants. We found that neither intramedullary injury nor medication alone resulted in bone formation. However, when combined, substantial bone was generated locally inside the diaphyseal medulla. Newly formed bone disappeared without implant placement but was retained with implants. Bone was especially retained around and between the implants. This study found that local bone marrow disruption followed by PTH or alendronate generated substantial cancellous bone locally in the diaphyseal medulla. This approach offers promise as a tissue engineering tool in medicine and dentistry.
C1 [Miyazaki Asato, Yoko; Kakura, Kae; Kido, Hirofumi; Yanagi, Tsukasa] Fukuoka Dent Coll, Dept Oral Rehabil, Oral Implantol, Fukuoka, Japan.
   [Koi, Kiyono] Oregon Hlth & Sci Univ, Sch Dent, Dept Restorat Dent, Portland, OR 97201 USA.
   [Fujimoto, Hiroki; Yamashita, Junro] Fukuoka Dent Coll, Dept Oral Rehabil, Fukuoka, Japan.
   [Yamashita, Junro] Fukuoka Dent Coll, Ctr Regenerat Med, Sawara Ku Tamura 2 15 1, Fukuoka 8140193, Japan.
C3 Fukuoka Dental College (FDC); Oregon Health & Science University;
   Fukuoka Dental College (FDC); Fukuoka Dental College (FDC)
RP Yamashita, J (通讯作者)，Fukuoka Dent Coll, Dept Oral Rehabil, Fukuoka, Japan.; Yamashita, J (通讯作者)，Fukuoka Dent Coll, Ctr Regenerat Med, Sawara Ku Tamura 2 15 1, Fukuoka 8140193, Japan.
EM yamashit@umich.edu
RI Koi, Kiyono/IUO 1847 2023; Yamashita, Junro/D 4787 2019
OI Yamashita, Junro/0000 0002 5486 1362
CR Adler RA, 2016, J BONE MINER RES, V31, P16, DOI 10.1002/jbmr.2708
   AMSEL S, 1969, ANAT RECORD, V164, P101, DOI 10.1002/ar.1091640107
   Andreassen TT, 2004, CALCIFIED TISSUE INT, V74, P351, DOI 10.1007/s00223 003 0093 6
   BAB IA, 1995, BONE, V17, pS437, DOI 10.1016/8756 3282(95)00323 6
   Buser D, 1999, PERIODONTOL 2000, V19, P151, DOI 10.1111/j.1600 0757.1999.tb00153.x
   Cleveland K, 2013, CAMPBELLS OPERATIVE, VIII, P2981
   Colón Emeric C, 2011, OSTEOPOROSIS INT, V22, P2329, DOI 10.1007/s00198 010 1473 1
   Duong LT, 2016, CALCIFIED TISSUE INT, V98, P381, DOI 10.1007/s00223 015 0051 0
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Gong HS, 2012, J BONE JOINT SURG AM, V94A, P1729, DOI 10.2106/JBJS.K.01434
   Hailer NP, 2010, ACTA ORTHOP, V81, P34, DOI 10.3109/17453671003685400
   Harding AK, 2011, ACTA ORTHOP, V82, P465, DOI 10.3109/17453674.2011.594231
   Jiang SY, 2015, MOL MED REP, V12, P7877, DOI 10.3892/mmr.2015.4421
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   JUDET R, 1972, CLIN ORTHOP RELAT R, P74
   Justesen J, 2001, BIOGERONTOLOGY, V2, P165, DOI 10.1023/A:1011513223894
   Kimmel DB, 2007, J DENT RES, V86, P1022, DOI 10.1177/154405910708601102
   Komatsu K, 2013, J ENDOCRINOL, V219, P145, DOI 10.1530/JOE 13 0040
   Kuroda S, 2005, CALCIFIED TISSUE INT, V77, P212, DOI 10.1007/s00223 004 0267 x
   Kuroshima S, 2014, OSTEOPOROSIS INT, V25, P1141, DOI 10.1007/s00198 013 2570 8
   Kuroshima S, 2013, J DENT RES, V92, P553, DOI 10.1177/0022034513487558
   Larsson L, 2016, J DENT RES, V95, P255, DOI 10.1177/0022034515618887
   Liu Ximeng, 2013, Curr Protoc Mol Biol, VChapter 4, DOI 10.1002/0471142727.mb0416s103
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Moran MM, 2016, BONEKEY REP, V5, DOI 10.1038/bonekey.2016.61
   Nakajima A, 2002, J BONE MINER RES, V17, P2038, DOI 10.1359/jbmr.2002.17.11.2038
   Nakazawa T, 2005, BONE, V37, P711, DOI 10.1016/j.bone.2005.06.013
   Qiu Z, 2013, OSTEOPOROSIS INT, V24, P2693, DOI 10.1007/s00198 013 2385 7
   Roberts SJ, 2015, BONE, V70, P10, DOI 10.1016/j.bone.2014.08.007
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Selye H, 1932, ENDOCRINOLOGY, V16, P547, DOI 10.1210/endo 16 5 547
   STEINBERG B, 1946, P SOC EXP BIOL MED, V61, P428, DOI 10.3181/00379727 61 15342
   SUVA LJ, 1993, J BONE MINER RES, V8, P379
   Tanoue R, 2015, J DENT RES, V94, P1251, DOI 10.1177/0022034515592867
   Uchiyama S, 2013, BONE JOINT J, V95B, P1544, DOI 10.1302/0301 620X.95B11.31652
   Ulrich SD, 2008, INT ORTHOP, V32, P597, DOI 10.1007/s00264 007 0364 3
   Yamashita J, 2008, J BONE MINER RES, V23, P621, DOI 10.1359/JBMR.071211
   Yamashita J, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10250
   Yamashita Junro, 2012, J Evid Based Dent Pract, V12, P233, DOI 10.1016/S1532 3382(12)70046 5
   Yamashita J, 2011, CLIN CANCER RES, V17, P1405, DOI 10.1158/1078 0432.CCR 10 1614
NR 40
TC 0
Z9 0
U1 0
U2 1
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD JAN 12
PY 2021
VL 11
IS 1
AR 205
DI 10.1038/s41598 020 80316 y
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA QM6YH
UT WOS:000621922200001
PM 33436871
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Kazemzadeh Narbat, M
   Noordin, S
   Masri, BA
   Garbuz, DS
   Duncan, CP
   Hancock, REW
   Wang, RZ
AF Kazemzadeh Narbat, Mehdi
   Noordin, Shahryar
   Masri, Bassam A.
   Garbuz, Donald S.
   Duncan, Clive P.
   Hancock, Robert E. W.
   Wang, Rizhi
TI Drug release and bone growth studies of antimicrobial peptide loaded
   calcium phosphate coating on titanium
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B APPLIED BIOMATERIALS
LA English
DT Article
DE peri implant infection; calcium phosphate coating; antimicrobial
   peptide; bone growth; titanium; orthopedic implants
ID RESISTANT STAPHYLOCOCCUS AUREUS; ANTIBACTERIAL PEPTIDES; BACTERIAL
   BIOFILMS; CATIONIC PEPTIDES; HYDROXYAPATITE; INFECTIONS; GENTAMICIN;
   MECHANISMS; PREVENTION
AB Preventing infection is one of the major challenges in total hip and joint arthroplasty. The main concerns of local drug delivery as a solution have been the evolution of antibiotic resistant bacteria and the potential inhibition of osseointegration caused by the delivery systems. This work investigated the in vitro drug release, antimicrobial performance, and cytotoxicity, as well as the in vivo bone growth of an antimicrobial peptide loaded into calcium phosphate coated Ti implants in a rabbit model. Two potent AMP candidates (HHC36: KRWWKWWRR, Tet213: KRWWKWWRRC) were first investigated through an in vitro cytotoxicity assay. MTT absorbance values revealed that HHC36 showed much lower cytotoxicity (minimal cytotoxic concentration 200 mu g/mL) than Tet 213 (50 mu g/mL). The AMP HHC36 loaded onto CaP (34.7 +/  4.2 mu g/cm2) had a burst release during the first few hours followed by a slow and steady release for 7 days as measured spectrophotometrically. The CaP AMP coatings were antimicrobial against Staphylococcus aureus and Pseudomonas aeruginosa strains in colony forming units (CFU) in vitro assays. No cytotoxicity was observed on CaP AMP samples against MG 63 osteoblast like cells after 5 days in vitro. In a trabecular bone growth in vivo study using cylindrical implants, loading of AMP HHC36 did not impair bone growth onto the implants. Significant bone on growth was observed on CaP coated Ti with or without HHC36 loading, as compared with Ti alone. The current AMP CaP coating thus offers in vivo osteoconductivity to orthopedic implants. It also offers in vitro antimicrobial property, with its in vivo performance to be confirmed in future animal infection models. (c) 2012 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2012.
C1 [Kazemzadeh Narbat, Mehdi; Wang, Rizhi] Univ British Columbia, Dept Mat Engn, Vancouver, BC V5Z 1M9, Canada.
   [Noordin, Shahryar; Masri, Bassam A.; Garbuz, Donald S.; Duncan, Clive P.] Univ British Columbia, Dept Orthopaed, Vancouver, BC V5Z 1M9, Canada.
   [Hancock, Robert E. W.] Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V5Z 1M9, Canada.
C3 University of British Columbia; University of British Columbia;
   University of British Columbia
RP Wang, RZ (通讯作者)，Univ British Columbia, Dept Mat Engn, Vancouver, BC V5Z 1M9, Canada.
EM rzwang@mail.ubc.ca
RI Masri, Bassam/AAI 6618 2020; Hancock, Robert/E 1145 2013
OI Masri, Bassam/0000 0001 6362 2120; 
FU Natural Sciences and Engineering Research Council of Canada; Canadian
   Institutes of Health Research
FX Contract grant sponsors: Natural Sciences and Engineering Research
   Council of Canada; the Canadian Institutes of Health Research
CR Brogden KA, 2005, NAT REV MICROBIOL, V3, P238, DOI 10.1038/nrmicro1098
   Brown K, 2011, J BONE JOINT SURG BR, V93, P100
   Chang YL, 1999, INT J ORAL MAX IMPL, V14, P239
   Cherkasov A, 2009, ACS CHEM BIOL, V4, P65, DOI 10.1021/cb800240j
   Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318
   Costerton JW, 2005, INT J ARTIF ORGANS, V28, P1062, DOI 10.1177/039139880502801103
   Darouiche RO, 2004, NEW ENGL J MED, V350, P1422, DOI 10.1056/NEJMra035415
   DELHAYE S, 1986, ANAL BIOCHEM, V159, P175, DOI 10.1016/0003 2697(86)90324 6
   Deligianni DD, 2001, BIOMATERIALS, V22, P87, DOI 10.1016/S0142 9612(00)00174 5
   Donlan RM, 2002, CLIN MICROBIOL REV, V15, P167, DOI 10.1128/CMR.15.2.167 193.2002
   Faber C, 2005, ANTIMICROB AGENTS CH, V49, P2438, DOI 10.1128/AAC.49.6.2438 2444.2005
   Fan YW, 2005, BIOMATERIALS, V26, P1623, DOI 10.1016/j.biomaterials.2004.06.019
   Fjell CD, 2009, J MED CHEM, V52, P2006, DOI 10.1021/jm8015365
   Francolini I, 2010, FEMS IMMUNOL MED MIC, V59, P227, DOI 10.1111/j.1574 695X.2010.00665.x
   Gao GZ, 2011, BIOMATERIALS, V32, P3899, DOI 10.1016/j.biomaterials.2011.02.013
   Garbuz DS, 2008, J BONE JOINT SURG AM, V90A, P1090, DOI 10.2106/JBJS.G.00415
   GERHART TN, 1988, J ORTHOP RES, V6, P585, DOI 10.1002/jor.1100060417
   Gidalevitz D, 2003, P NATL ACAD SCI USA, V100, P6302, DOI 10.1073/pnas.0934731100
   Glukhov E, 2005, J BIOL CHEM, V280, P33960, DOI 10.1074/jbc.M507042200
   Gough M, 1996, INFECT IMMUN, V64, P4922, DOI 10.1128/IAI.64.12.4922 4927.1996
   Hancock R E, 2001, Lancet Infect Dis, V1, P156, DOI 10.1016/S1473 3099(01)00092 5
   Hancock REW, 1998, TRENDS BIOTECHNOL, V16, P82, DOI 10.1016/S0167 7799(97)01156 6
   Hilpert K, 2005, NAT BIOTECHNOL, V23, P1008, DOI 10.1038/nbt1113
   Hilpert K, 2009, CHEM BIOL, V16, P58, DOI 10.1016/j.chembiol.2008.11.006
   Jenssen H, 2006, CLIN MICROBIOL REV, V19, P491, DOI 10.1128/CMR.00056 05
   Joosten U, 2005, BIOMATERIALS, V26, P5251, DOI 10.1016/j.biomaterials.2005.01.001
   Kazemzadeh Narbat M, 2010, BIOMATERIALS, V31, P9519, DOI 10.1016/j.biomaterials.2010.08.035
   Lauderdale KJ, 2010, J ORTHOP RES, V28, P55, DOI 10.1002/jor.20943
   Liu S, 2011, ACTA PHARMACOL SIN, V32, P79, DOI 10.1038/aps.2010.162
   Lyczak JB, 2000, MICROBES INFECT, V2, P1051, DOI 10.1016/S1286 4579(00)01259 4
   Madera L, 2011, IMMUNE RESPONSE TO INFECTION, P57
   Mello Charlene M, 2008, ACS SYM SER, V984, P52
   PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120
   Rao NL, 2011, PLAST RECONSTR SURG, V127, p177S, DOI 10.1097/PRS.0b013e3182001f0f
   Rathbone CR, 2011, J ORTHOP RES, V29, P1070, DOI 10.1002/jor.21343
   Rogers SS, 2008, LANGMUIR, V24, P13549, DOI 10.1021/la802442d
   Rotem S, 2009, BBA BIOMEMBRANES, V1788, P1582, DOI 10.1016/j.bbamem.2008.10.020
   Schnieders J, 2006, BIOMATERIALS, V27, P4239, DOI 10.1016/j.biomaterials.2006.03.032
   Stallmann HP, 2008, J ORTHOP RES, V26, P531, DOI 10.1002/jor.20511
   Thomas W, 2003, HDB HISTOLOGY METHOD
   Trampuz A, 2006, DRUGS, V66, P1089, DOI 10.2165/00003495 200666080 00005
   Trampuz A, 2006, CURR OPIN INFECT DIS, V19, P349, DOI 10.1097/01.qco.0000235161.85925.e8
   Woods AS, 2005, J PROTEOME RES, V4, P1397, DOI 10.1021/pr050077s
   Wu P, 2006, BIOMATERIALS, V27, P2450, DOI 10.1016/j.biomaterials.2005.11.031
   Yeaman MR, 2003, PHARMACOL REV, V55, P27, DOI 10.1124/pr.55.1.2
   Zhao LZ, 2009, J BIOMED MATER RES B, V91B, P470, DOI 10.1002/jbm.b.31463
   Zimmerli W, 2004, NEW ENGL J MED, V351, P1645, DOI 10.1056/NEJMra040181
NR 47
TC 95
Z9 107
U1 0
U2 146
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1552 4973
EI 1552 4981
J9 J BIOMED MATER RES B
JI J. Biomed. Mater. Res. Part B
PD JUL
PY 2012
VL 100B
IS 5
BP 1344
EP 1352
DI 10.1002/jbm.b.32701
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 953JX
UT WOS:000304864500019
PM 22566395
OA Bronze
DA 2025 08 17
ER

PT J
AU Tan, CO
   Battaglino, RA
   Doherty, AL
   Gupta, R
   Lazzari, AA
   Garshick, E
   Zafonte, R
   Morse, LR
AF Tan, C. O.
   Battaglino, R. A.
   Doherty, A. L.
   Gupta, R.
   Lazzari, A. A.
   Garshick, E.
   Zafonte, R.
   Morse, L. R.
TI Adiponectin is associated with bone strength and fracture history in
   paralyzed men with spinal cord injury
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Adiponectin; Biomarker; Finite element analysis; Fracture;
   Rehabilitation medicine; Spinal cord injury
ID MAPK SIGNALING PATHWAY; LOWER EXTREMITY BONE; MINERAL DENSITY; SERUM
   ADIPONECTIN; POSTMENOPAUSAL WOMEN; CANDIDATE BIOMARKER; PLASMA
   ADIPONECTIN; HUMAN OSTEOBLASTS; ELDERLY MEN; FAT MASS
AB We explored the association between adiponectin levels and bone strength in paralyzed men with spinal cord injury. We found that bone strength was inversely associated with circulating adiponectin levels. Thus, strength estimates and adiponectin levels may improve fracture risk prediction and detection of response to osteogenic therapies following spinal cord injury.
   Previous research has demonstrated an inverse relationship between circulating adiponectin and bone mineral density, suggesting that adiponectin may be used as a biomarker for bone health. However, this relationship may reflect indirect effects on bone metabolism via adipose mediated mechanical pathways rather than the direct effects of adipokines on bone metabolism. Thus, we explored the association between circulating adiponectin levels and bone strength in 27 men with spinal cord injury.
   Plasma adiponectin levels were quantified by ELISA assay. Axial stiffness and maximal load to fracture of the distal femur were quantified via finite element analysis using reconstructed 3D models of volumetric CT scans. We also collected information on timing, location, and cause of previous fractures.
   Axial stiffness and maximal load were inversely associated with circulating adiponectin levels (R (2) = 0.44, p = 0.01; R (2) = 0.58, p = 0.05) after adjusting for injury duration and lower extremity lean mass. In individuals with post SCI osteoporotic fractures, distal femur stiffness (p = 0.01) and maximal load (p = 0.005) were lower, and adiponectin was higher (p = 0.04) than those with no fracture history.
   Based on these findings, strength estimates may improve fracture risk prediction and detection of response to osteogenic therapies following spinal cord injury. Furthermore, our findings suggest that circulating adiponectin may indeed be a feasible biomarker for bone health and osteoporotic fracture risk in paralyzed individuals with spinal cord injury.
C1 [Tan, C. O.; Doherty, A. L.; Zafonte, R.; Morse, L. R.] Spaulding Rehabil Hosp, Spaulding Harvard SCI Model Syst, Boston, MA USA.
   [Tan, C. O.; Zafonte, R.; Morse, L. R.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA.
   [Morse, L. R.] Forsyth Inst, Cambridge, MA 02115 USA.
   [Battaglino, R. A.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
   [Gupta, R.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
   [Lazzari, A. A.] Boston Univ Sch Med, Primary Care Sect, VA Boston Healthcare Syst, Boston, MA USA.
   [Lazzari, A. A.] Boston Univ Sch Med, Rheumatol Sect, VA Boston Healthcare Syst, Boston, MA USA.
   [Garshick, E.] VA Boston Healthcare Syst, Pulm & Crit Care Med Sect, Med Serv, Boston, MA USA.
   [Garshick, E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Div Network Med, Boston, MA 02115 USA.
C3 Harvard University; Harvard Medical School; Harvard University Medical
   Affiliates; Spaulding Rehabilitation Hospital; Harvard University;
   Harvard Medical School; Harvard University; Harvard University Medical
   Affiliates; Forsyth Institute; Harvard University; Harvard School of
   Dental Medicine; Harvard University; Harvard University Medical
   Affiliates; Massachusetts General Hospital; Harvard University; Harvard
   University Medical Affiliates; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); VA Boston Healthcare System;
   Boston University; Boston University; Harvard University; Harvard
   University Medical Affiliates; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); VA Boston Healthcare System;
   Harvard University; Harvard University Medical Affiliates; US Department
   of Veterans Affairs; Veterans Health Administration (VHA); VA Boston
   Healthcare System; Harvard University; Harvard University Medical
   Affiliates; Brigham & Women's Hospital; Harvard Medical School
RP Morse, LR (通讯作者)，Forsyth Inst, Cambridge, MA 02115 USA.
EM Leslie.morse@mgh.harvard.edu
RI ; Morse, Leslie/AAU 5608 2020; Garshick, Eric/Y 6509 2019; Gupta,
   Radhey'Shyam/LKK 6909 2024; battaglino, ricardo/D 2892 2015; Tan, Can
   Ozan/E 2598 2016
OI S, R/0000 0003 1031 8621; Lazzari, Antonio/0000 0003 0256 4742; Tan, Can
   Ozan/0000 0001 9673 9907; 
FU Department of Defense [W81XWH 10 1 1043]; National Institute of
   Arthritis and Musculoskeletal and Skin Diseases [1R01AR059270 01];
   Department of Education, National Institute on Disability and
   Rehabilitation Research [H133N110010]
FX We thank Sam Davis, clinical research coordinator and technician, Boston
   VA Healthcare System, for assisting with bone density scans; and Rachael
   Burns and Kara Loo, research assistants, Boston VA Healthcare System,
   for collection of anthropometric data. This study received support from
   the Department of Defense (W81XWH 10 1 1043), the National Institute of
   Arthritis and Musculoskeletal and Skin Diseases (1R01AR059270 01), and
   the Department of Education, National Institute on Disability and
   Rehabilitation Research (H133N110010).
CR Agbaht K, 2009, ENDOCRINE, V35, P371, DOI 10.1007/s12020 009 9158 2
   Baldock P, 2011, HORM RES PAEDIAT, V76, P7, DOI 10.1159/000329134
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Barbour KE, 2012, OSTEOPOROSIS INT, V23, P1699, DOI 10.1007/s00198 011 1768 x
   Barbour KE, 2011, J BONE MINER RES, V26, P1568, DOI 10.1002/jbmr.361
   Basurto L, 2009, EUR J ENDOCRINOL, V160, P289, DOI 10.1530/EJE 08 0569
   Bauman WA, 2006, AM J PHYSIOL ENDOC M, V290, pE1098, DOI 10.1152/ajpendo.00250.2005
   Berner HS, 2004, BONE, V35, P842, DOI 10.1016/j.bone.2004.06.008
   Cody DD, 1999, J BIOMECH, V32, P1013, DOI 10.1016/S0021 9290(99)00099 8
   Dauty M, 2000, BONE, V27, P305, DOI 10.1016/S8756 3282(00)00326 4
   Doherty AL, 2014, J BONE MINER RES, V29, P251, DOI 10.1002/jbmr.2020
   Dreiseitl S, 1999, J AM MED INFORM ASSN, P246
   Fang QQ, 2009, I S BIOMED IMAGING, P1142, DOI 10.1109/ISBI.2009.5193259
   Friedman AW, 2006, JCR J CLIN RHEUMATOL, V12, P70, DOI 10.1097/01.rhu.0000208612.33819.8c
   GARLAND DE, 1992, J ORTHOPAED RES, V10, P371, DOI 10.1002/jor.1100100309
   Huang KC, 2004, CLIN ENDOCRINOL, V61, P204, DOI 10.1111/j.1365 2265.2004.02081.x
   HUISKES R, 1983, J BIOMECH, V16, P385, DOI 10.1016/0021 9290(83)90072 6
   Iacobellis G, 2011, J ENDOCRINOL INVEST, V34, pE12, DOI [10.1007/BF03346703, 10.3275/7170]
   Johansson H, 2012, J BONE MINER RES, V27, P1390, DOI 10.1002/jbmr.1591
   Jürimäe J, 2007, OSTEOPOROSIS INT, V18, P1253, DOI 10.1007/s00198 007 0365 5
   Jürimäe J, 2009, EUR J ENDOCRINOL, V160, P381, DOI 10.1530/EJE 08 0673
   Jürimäe J, 2008, J BONE MINER METAB, V26, P618, DOI 10.1007/s00774 008 0861 5
   Jürimäe J, 2007, AM J PHYSIOL ENDOC M, V293, pE42, DOI 10.1152/ajpendo.00610.2006
   Kanazawa I, 2009, EUR J ENDOCRINOL, V160, P265, DOI 10.1530/EJE 08 0642
   Keyak JH, 1998, J BIOMECH, V31, P125, DOI 10.1016/S0021 9290(97)00123 1
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Luo XH, 2005, EXP CELL RES, V309, P99, DOI 10.1016/j.yexcr.2005.05.021
   Luo XH, 2006, J BONE MINER RES, V21, P1648, DOI 10.1359/JBMR.060707
   MARTIN RB, 1991, J BIOMECH, V24, P79, DOI 10.1016/0021 9290(91)90379 2
   Misra Madhusmita, 2013, Pediatr Endocrinol Rev, V11, P21
   Morse LR, 2013, OSTEOPOROSIS INT, V24, P961, DOI 10.1007/s00198 012 2072 0
   Morse LR, 2009, ARCH PHYS MED REHAB, V90, P827, DOI 10.1016/j.apmr.2008.12.004
   Peng XD, 2008, CLIN CHIM ACTA, V387, P31, DOI 10.1016/j.cca.2007.08.012
   Reid IR, 2008, OSTEOPOROSIS INT, V19, P595, DOI 10.1007/s00198 007 0492 z
   Richards JB, 2007, J CLIN ENDOCR METAB, V92, P1517, DOI 10.1210/jc.2006 2097
   Schafer AL, 2011, J CLIN ENDOCR METAB, V96, pE1982, DOI 10.1210/jc.2011 0587
   Shapiro L., 2001, Computer vision
   Steyerberg EW, 1999, J CLIN EPIDEMIOL, V52, P935, DOI 10.1016/S0895 4356(99)00103 1
   Tuukkanen J, 2000, J BONE MINER RES, V15, P1905, DOI 10.1359/jbmr.2000.15.10.1905
   Vestergaard P, 1998, SPINAL CORD, V36, P790, DOI 10.1038/sj.sc.3100648
   Wheater G, 2013, J TRANSL MED, V11, DOI 10.1186/1479 5876 11 201
   Yokota T, 2002, J CLIN INVEST, V109, P1303, DOI 10.1172/JCI200214506
   Zhang YJ, 2012, BIOCHEM CELL BIOL, V90, P613, DOI [10.1139/o2012 022, 10.1139/O2012 022]
NR 43
TC 22
Z9 24
U1 0
U2 11
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD NOV
PY 2014
VL 25
IS 11
BP 2599
EP 2607
DI 10.1007/s00198 014 2786 2
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AS3HE
UT WOS:000344167500010
PM 24980185
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Chen, YQ
   Hu, WH
   Wang, YR
   Li, YH
   Li, XM
   Li, HB
   Tang, Y
   Zhang, LC
   Dong, YT
   Yang, XC
   Wei, Y
   Dong, SW
AF Chen, Yueqi
   Hu, Wenhui
   Wang, Yiran
   Li, Yuheng
   Li, Xiaoming
   Li, Haibo
   Tang, Yong
   Zhang, Lincheng
   Dong, Yutong
   Yang, Xiaochao
   Wei, Ye
   Dong, Shiwu
TI A selected small molecule prevents inflammatory osteolysis through
   restraining osteoclastogenesis by modulating PTEN activity
SO CLINICAL AND TRANSLATIONAL MEDICINE
LA English
DT Article
DE inflammatory osteolysis; osteoclastogenesis; PTEN; small molecule
ID RANKL INDUCED OSTEOCLASTOGENESIS; KAPPA B; DIFFERENTIATION; POLARIZATION
AB Background Inflammatory osteolysis is a severe infectious bone disorder that occurs during orthopaedic surgery and is caused by disruptions in the dynamic balance of bone matrix homeostasis, which makes this condition a burden on surgical procedures. Developing novel therapeutic drugs about inhibiting excessive osteoclastogenesis acts as an efficient approach to preventing inflammatory bone destruction.
   Methods To study this, we explored the potential effects and mechanisms of compound 17 on inflammatory osteolysis in vitro. Meanwhile, a lipopolysaccharide (LPS) induced calvarial osteolysis mouse model was used to evaluate the protective effect of compound 17 on inflammatory bone destruction in vivo.
   Results In our study, we found that compound 17 could inhibit osteoclast (OC) differentiation and bone resorption during RANKL and LPS stimulation in a time  and dose dependent manner, while compounds 5 and 13 did not have the same effects. Mechanistically, compound 17 promoted phosphatase and tensin homologue (PTEN) activity by reducing PTEN ubiquitination, thereby restraining the RANKL induced NF kappa B pathway, resulting in the inhibition of the expression of osteoclastogenesis related genes and the formation of the NLRP3 inflammasome. Additionally, we also investigated whether compound 17 could negatively modulate macrophage polarization and repolarization due to its anti inflammatory effects. Moreover, compound 17 also plays an important role in osteoblast differentiation and mineralization. In vivo experiments showed that compound 17 could effectively protect mice from LPS induced inflammatory bone destruction by inhibiting osteoclastogenesis and inflammation.
   Conclusions Taken together, these results show that compound 17 might play protective role in inflammatory bone destruction through inhibiting osteoclastogenesis and inflammation. These findings imply a possible role of compound 17 in inflammatory osteolysis related diseases.
C1 [Chen, Yueqi; Hu, Wenhui; Wang, Yiran; Li, Yuheng; Li, Xiaoming; Zhang, Lincheng; Dong, Yutong; Yang, Xiaochao; Dong, Shiwu] Army Med Univ, Third Mil Med Univ, Dept Biomed Mat Sci, Chongqing 400038, Peoples R China.
   [Chen, Yueqi; Tang, Yong; Dong, Shiwu] Army Med Univ, Third Mil Med Univ, Dept Orthopaed, Southwest Hosp, Chongqing, Peoples R China.
   [Li, Haibo] Army Med Univ, Third Mil Med Univ, Natl Engn Res Ctr Immunol Prod, Coll Pharm, Chongqing, Peoples R China.
   [Li, Haibo] Army Med Univ, Third Mil Med Univ, Dept Microbiol & Biochem Pharm, Coll Pharm, Chongqing, Peoples R China.
   [Wei, Ye] Southwest Univ, Sch Chem & Chem Engn, Chongqing 400715, Peoples R China.
   [Dong, Shiwu] Army Med Univ, Third Mil Med Univ, State Key Lab Trauma Burns & Combined Injury, Chongqing, Peoples R China.
C3 Army Medical University; Army Medical University; Army Medical
   University; Army Medical University; Southwest University   China; Army
   Medical University
RP Dong, SW (通讯作者)，Army Med Univ, Third Mil Med Univ, Dept Biomed Mat Sci, Chongqing 400038, Peoples R China.; Wei, Y (通讯作者)，Southwest Univ, Sch Chem & Chem Engn, Chongqing 400715, Peoples R China.
EM weiye712@swu.edu.cn; dongshiwu@tmmu.edu.cn
RI Chen, Yueqi/AAU 1724 2020; Yang, Xiaochao/AAM 8083 2021; Dong,
   Yutong/I 8654 2016; xiaoming, li/AAP 3567 2021; li, yuheng/LPQ 3255 2024
OI Chen, Yueqi/0000 0001 6975 2874; 
FU Key Program of Natural Science Foundation of China [81930067]; Nature
   Science Foundation of China [31870962]; Medical Science and Technology
   Youth Cultivation Project of PLA [20QNPY022]; Medical innovation of
   graduate students in Chongqing [CYS19360]
FX Key Program of Natural Science Foundation of China, Grant/Award Number:
   81930067; Nature Science Foundation of China, Grant/Award Number:
   31870962; Medical Science and Technology Youth Cultivation Project of
   PLA, Grant/Award Number: 20QNPY022; Medical innovation of graduate
   students in Chongqing, Grant/Award Number: CYS19360
CR Alippe Y., 2017, SCI REP, V7, P1
   Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Cassat JE, 2013, CELL HOST MICROBE, V13, P759, DOI 10.1016/j.chom.2013.05.003
   Center JR, 2020, BONE, V141, DOI 10.1016/j.bone.2020.115566
   Chen HW, 2020, J CELL MOL MED, V24, P9067, DOI 10.1111/jcmm.15543
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Chen YM, 2021, IEEE T SYST MAN CY S, V51, P4160, DOI 10.1109/TSMC.2019.2931484
   Chen YY, 2016, BMC MOL BIOL, V17, DOI 10.1186/s12867 016 0055 y
   Chen YQ, 2020, AGING US, V12, P11698, DOI 10.18632/aging.103337
   Chen YQ, 2018, LIFE SCI, V208, P305, DOI 10.1016/j.lfs.2018.07.048
   Cohen MM, 2006, AM J MED GENET A, V140A, P2646, DOI 10.1002/ajmg.a.31368
   Deng MY, 2018, J CELL PHYSIOL, V233, P5792, DOI 10.1002/jcp.26342
   Dong YT, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.110010
   Dove KK, 2017, J MOL BIOL, V429, P3363, DOI 10.1016/j.jmb.2017.08.008
   Dym Harry, 2017, Dent Clin North Am, V61, P271, DOI 10.1016/j.cden.2016.12.001
   Fotouhi L, 2018, CHEM REC, V18, P1633, DOI 10.1002/tcr.201800022
   Fu LM, 2018, BIOMED PHARMACOTHER, V107, P703, DOI 10.1016/j.biopha.2018.08.040
   Guo YC, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/3712083
   He Y, 2016, TRENDS BIOCHEM SCI, V41, P1012, DOI 10.1016/j.tibs.2016.09.002
   Hu WH, 2021, ANN RHEUM DIS, V80, P413, DOI 10.1136/annrheumdis 2020 218089
   Hu WH, 2020, CELL MOL LIFE SCI, V77, P5149, DOI 10.1007/s00018 020 03572 1
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Leslie NR, 2016, BIOCHEM SOC T, V44, P273, DOI 10.1042/BST20150224
   Lew DP, 1997, NEW ENGL J MED, V336, P999, DOI 10.1056/NEJM199704033361406
   Li SF, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 02947 3
   Li ZK, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00599
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Meng JH, 2020, BIOCHEM PHARMACOL, V171, DOI 10.1016/j.bcp.2019.113715
   Mund T, 2014, P NATL ACAD SCI USA, V111, P16736, DOI 10.1073/pnas.1412152111
   Nishimura T, 2012, J AM CHEM SOC, V134, P5056, DOI 10.1021/ja300697c
   Pajarinen J, 2019, BIOMATERIALS, V196, P80, DOI 10.1016/j.biomaterials.2017.12.025
   Perera AP, 2017, CURR PHARM DESIGN, V23, P2321, DOI 10.2174/1381612823666170201162414
   Qu XH, 2018, BIOCHEM BIOPH RES CO, V501, P547, DOI 10.1016/j.bbrc.2018.05.035
   Rocha FRG, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 64685 y
   Scheffner M, 2007, BMC BIOCHEM, V8, DOI 10.1186/1471 2091 8 S1 S6
   Shalev M, 2019, BBA MOL CELL RES, V1866, P114, DOI 10.1016/j.bbamcr.2018.07.005
   Sugatani T, 2003, J BIOL CHEM, V278, P5001, DOI 10.1074/jbc.M209299200
   Sun XW, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101309
   Tang DE, 2020, AGING US, V12, P13297, DOI 10.18632/aging.103434
   Thapa B, 2019, BMB REP, V52, P360, DOI 10.5483/BMBRep.2019.52.6.140
   van Bon L, 2011, CURR OPIN RHEUMATOL, V23, P505, DOI 10.1097/BOR.0b013e32834b0dac
   WALDVOGEL FA, 1970, NEW ENGL J MED, V282, P198, DOI 10.1056/NEJM197001222820406
   Wang LP, 2020, DRUG DISCOV TODAY, V25, P1919, DOI 10.1016/j.drudis.2020.09.001
   Xie JW, 2019, CYTOKINE GROWTH F R, V46, P36, DOI 10.1016/j.cytogfr.2019.03.004
   Xie Z, 2018, J BONE MINER RES, V33, P667, DOI 10.1002/jbmr.3334
   Xu LJ, 2018, CALCIFIED TISSUE INT, V103, P400, DOI 10.1007/s00223 018 0428 y
   Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035
   Yang DB, 2019, SEMIN IMMUNOPATHOL, V41, P551, DOI 10.1007/s00281 019 00754 3
   Zhang CC, 2014, J CELL PHYSIOL, V229, P1330, DOI 10.1002/jcp.24553
   Zhang LC, 2020, J CELL MOL MED, V24, P4389, DOI 10.1111/jcmm.15155
   Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200
   Zheng N, 2017, ANNU REV BIOCHEM, V86, P129, DOI 10.1146/annurev biochem 060815 014922
   Zhu LN, 2015, INT REV IMMUNOL, V34, P82, DOI 10.3109/08830185.2014.969421
NR 54
TC 12
Z9 13
U1 0
U2 14
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 2001 1326
J9 CLIN TRANSL MED
JI Clin. Transl. Med.
PD DEC
PY 2020
VL 10
IS 8
AR e240
DI 10.1002/ctm2.240
PG 22
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA PM2YM
UT WOS:000603671400017
PM 33377656
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Mannino, F
   D'Angelo, T
   Pallio, G
   Ieni, A
   Pirrotta, I
   Giorgi, DA
   Scarfone, A
   Mazziotti, S
   Booz, C
   Bitto, A
   Squadrito, F
   Irrera, N
AF Mannino, Federica
   D'Angelo, Tommaso
   Pallio, Giovanni
   Ieni, Antonio
   Pirrotta, Igor
   Giorgi, Domenico Antonio
   Scarfone, Alessandro
   Mazziotti, Silvio
   Booz, Christian
   Bitto, Alessandra
   Squadrito, Francesco
   Irrera, Natasha
TI The Nutraceutical Genistein Lycopene Combination Improves Bone Damage
   Induced by Glucocorticoids by Stimulating the Osteoblast Formation
   Process
SO NUTRIENTS
LA English
DT Article
DE osteoporosis; GIO; genistein; lycopene; nutraceuticals
ID OXIDATIVE STRESS; RATS; DIFFERENTIATION
AB Chronic glucocorticoid (GC) therapy is the most common cause of iatrogenic osteoporosis and represents an important risk factor for osteoporosis and bone fractures. New therapeutic approaches are required in order to treat osteoporosis and reduce the side effects related to the use of anti osteoporotic drugs. In this context, previous studies reported the efficacy of some isoflavones and carotenoids, such as lycopene and genistein, on the reduction of the risk of fracture related to osteoporosis. The aim of this study was to investigate the effects of a combined oral treatment, consisting of genistein and lycopene, in an experimental model of glucocorticoid induced osteoporosis (GIO). GIO was induced by subcutaneous injection of methylprednisolone (MP, 30 mg/kg) for 60 days, whereas the control group (Sham) received saline solution only. Following induction, MP animals randomly were assigned to receive alendronate, genistein, lycopene, or the association of genistein and lycopene or saline solution for additional 60 days together with MP. Femurs obtained from the Sham group were used for osteoblasts extraction; they were then incubated with dexamethasone (DEX) for 24 h to be then treated with lycopene or genistein or the association of lycopene and genistein for an additional 24 h. Treatments with lycopene and genistein restored the impaired mineralization of cells observed following DEX treatment and stimulated osteoblast differentiation by increasing the depressed expression of bALP and RUNX2 (p < 0.0001). Wnt5a, beta catenin, and Nrf 2 expression were significantly increased following genistein and lycopene treatment (p < 0.0001), thus confirming their antioxidant activity as well as their ability in stimulating osteoblast function, mostly when genistein and lycopene were used in association. The combined treatment of genistein and lycopene improved the bone damage induced by glucocorticoids and significantly restored the normal architecture of bones as well as adequate interconnectivity of bone trabeculae, thus increasing bone mineral density parameters. The obtained data demonstrated that genistein and lycopene but in particular their association might prevent GC's adverse effects, thus stimulating bone formation and reducing bone resorption, improving bone structure and microarchitecture, through different molecular pathways, such as the Wnt/beta catenin and the Nrf 2 signaling.
C1 [Mannino, Federica; Pallio, Giovanni; Pirrotta, Igor; Giorgi, Domenico Antonio; Scarfone, Alessandro; Bitto, Alessandra; Squadrito, Francesco; Irrera, Natasha] Univ Messina, Dept Clin & Expt Med, Via C Valeria Gazzi, I 98125 Messina, Italy.
   [D'Angelo, Tommaso; Mazziotti, Silvio] Univ Messina, Dept Biomed Dent Morphol & Funct Imaging Sci, Via C Valeria Gazzi, I 98125 Messina, Italy.
   [D'Angelo, Tommaso] Erasmus MC, Dept Radiol & Nucl Med, Dr Molewaterpl 40, NL 3015 GD Rotterdam, Netherlands.
   [Ieni, Antonio] Univ Messina, Dept Human Pathol Adult & Dev Age Gaetano Barresi, Via C Valeria Gazzi, I 98125 Messina, Italy.
   [Booz, Christian] Univ Hosp Frankfurt, Dept Diagnost & Intervent Radiol, Div Expt Imaging, Theodor Stern Kai 7, D 60590 Frankfurt, Germany.
C3 University of Messina; University of Messina; Erasmus University
   Rotterdam; Erasmus MC; University of Messina; Goethe University
   Frankfurt; Goethe University Frankfurt Hospital
RP Squadrito, F (通讯作者)，Univ Messina, Dept Clin & Expt Med, Via C Valeria Gazzi, I 98125 Messina, Italy.
EM fsquadrito@unime.it
RI Ieni, Antonio/AAC 7265 2019; D'Angelo, Tommaso/AAY 7285 2020; Mannino,
   Federica/AAC 6434 2022; Pallio, Giovanni/AAC 2420 2019; Bitto,
   Alessandra/K 8942 2016; Scarfone, Alessandro/HFZ 9851 2022; Irrera,
   Natasha/K 5411 2018
OI IENI, ANTONIO/0000 0003 2878 3572; Pallio, Giovanni/0000 0002 4187 2265;
   Irrera, Natasha/0000 0002 1134 7080; 
FU Ministry of Economic Development [F/050359/01 03/X32]
FX This work was supported by a grant from the Ministry of Economic
   Development assigned to Prof. Domenica Altavilla entitled: "Nutraceutici
   innovativi per il management dell'obesita e dell'osteoporosi" code:
   F/050359/01 03/X32.
CR Arcoraci V, 2017, NUTRIENTS, V9, DOI 10.3390/nu9020179
   Bachagol D, 2018, J NUTR BIOCHEM, V52, P18, DOI 10.1016/j.jnutbio.2017.09.023
   Benvenga S, 2020, NUTRIENTS, V12, DOI 10.3390/nu12051222
   Bitto A, 2009, BRIT J PHARMACOL, V156, P1287, DOI 10.1111/j.1476 5381.2008.00100.x
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Callaway DA, 2015, J BONE MINER METAB, V33, P359, DOI 10.1007/s00774 015 0656 4
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Demontiero O, 2012, THER ADV MUSCULOSKEL, V4, P61, DOI 10.1177/1759720X11430858
   Erben RG, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00082
   Erfanian A, 2017, FOOD CHEM, V214, P606, DOI 10.1016/j.foodchem.2016.07.116
   Harahap IA, 2021, FOODS, V10, DOI 10.3390/foods10112685
   Hayhoe RPG, 2017, BRIT J NUTR, V117, P1439, DOI 10.1017/S0007114517001180
   Hofbauer LC, 2009, MOL ENDOCRINOL, V23, P1525, DOI 10.1210/me.2009 0069
   Hsu PY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154367
   Humphrey EL, 2006, BONE, V38, P652, DOI 10.1016/j.bone.2005.10.004
   Jain S K, 2011, Mymensingh Med J, V20, P501
   Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI [10.1038/jcbfm.2010.220, 10.1111/j.1476 5381.2010.00872.x]
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Li XJ, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018 018 0944 5
   Li YQ, 2012, ACTA PHARMACOL SIN, V33, P66, DOI 10.1038/aps.2011.136
   Lv HC, 2022, EXP THER MED, V23, DOI 10.3892/etm.2021.11050
   Mackinnon ES, 2011, J NUTR HEALTH AGING, V15, P133, DOI 10.1007/s12603 011 0026 4
   Martiniakova M, 2020, J PHYSIOL PHARMACOL, V71, P307, DOI 10.26402/jpp.2020.3.01
   Meyer MB, 2014, J BIOL CHEM, V289, P16016, DOI 10.1074/jbc.M114.552216
   Papapoulos SE, 2011, ANN RHEUM DIS, V70, pI119, DOI 10.1136/ard.2010.141150
   Picciolo G, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8060164
   Rodríguez Carballo E, 2011, J BONE MINER RES, V26, P718, DOI 10.1002/jbmr.260
   Russo C, 2020, J TRANSL MED, V18, DOI 10.1186/s12967 020 02238 7
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   Semeghini MS, 2022, J ANAT, V241, P729, DOI 10.1111/joa.13672
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Walallawita US, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197119
   Wattanapenpaiboon N, 2003, ASIA PAC J CLIN NUTR, V12, P467
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
NR 34
TC 13
Z9 13
U1 2
U2 11
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6643
J9 NUTRIENTS
JI Nutrients
PD OCT
PY 2022
VL 14
IS 20
AR 4296
DI 10.3390/nu14204296
PG 12
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA 5Q5AW
UT WOS:000873845400001
PM 36296984
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Barkin, RL
AF Barkin, Robert L.
TI Extended release tramadol (ULTRAM®ER):: A pharmacotherapeutic,
   pharmacokinetic, and pharmacodynamic focus on effectiveness and safety
   in patients with chronic/persistent pain
SO AMERICAN JOURNAL OF THERAPEUTICS
LA English
DT Article
DE tramadol ER; safety and efficacy; pharmacokinetics; mechanism of action;
   drug interactions
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; IMMEDIATE RELEASE; CLINICAL TRIAL;
   MANAGEMENT; OSTEOARTHRITIS; RAT; HCL; HYDROCHLORIDE; WITHDRAWAL;
   EFFICACY
AB Tramadol is a centrally acting synthetic opioid analgesic that has a dual mechanism of action, binding to mu opioid receptors and weakly inhibiting the neuronal reuptake of norepinephrine and serotonin. Extended release (ER) tramadol tablets (ULTRAM(R)ER) are indicated for the management of moderate to moderately severe chronic (also referred to as persistent) pain in adults who require around the clock treatment of pain for an extended period of time. Because once daily tramadol ER results in less frequent fluctuations in plasma concentrations than equivalent daily doses of short acting tramadol, it may benefit patients experiencing pain throughout the dosing interval. On the basis of computer generated pharmacokinetic models, one can easily transition patients who are receiving short acting tramadol for chronic/persistent pain to tramadol ER, by calculating the current total daily close of short acting tramadol and starting tramadol ER at the nearest lower 100 mg close increment. In clinical studies, tramadol ER significantly reduced pain in patients with chronic pain from osteoarthritis and improved pain related sleep parameters, joint stiffness, and physical function. Tramadol ER has been shown to be safe and well tolerated and may be a suitable alternative for patients with inadequate analgesic response or contraindications (eg, cardiovascular disease, gastrointestinal ulcer) to use of nonsteroidal anti inflammatory drugs (NSAIDs) or cyclooxygenase 2 (COX 2) inhibitors. The proven efficacy and safety profile and the low potential for abuse make tramadol ER a viable therapeutic option for the management of chronic/persistent nonmalignant pain in some patients. This article reviews the pharmacology, pharmacokinetics, pharmacodynamics, dosage, delivery system, administration, analgesic efficacy, and safety and tolerability profile of tramadol ER.
C1 [Barkin, Robert L.] Rush Univ, Med Ctr, Dept Anesthesiol, Rush Pain Ctr, Chicago, IL 60601 USA.
   [Barkin, Robert L.] Rush Univ, Med Ctr, Dept Family Med, Rush Pain Ctr, Chicago, IL 60601 USA.
   [Barkin, Robert L.] Rush Univ, Med Ctr, Dept Pharmacol, Rush Pain Ctr, Chicago, IL 60601 USA.
   [Barkin, Robert L.] N Shore Pain Ctr, Skokie, IL USA.
C3 Rush University; Rush University; Rush University
RP Barkin, RL (通讯作者)，Rush Univ, Med Ctr, Dept Anesthesiol, Rush Pain Ctr, 1765 W Congress Pkwy, Chicago, IL 60601 USA.
CR Adams EH, 2006, J PAIN SYMPTOM MANAG, V31, P465, DOI 10.1016/j.jpainsymman.2005.10.006
   Antman EM, 2007, CIRCULATION, V115, P1634, DOI 10.1161/CIRCULATIONAHA.106.181424
   Babul N, 2004, J PAIN SYMPTOM MANAG, V28, P59, DOI 10.1016/j.jpainsymman.2003.11.006
   Barkin R L, 2000, Am J Ther, V7, P205, DOI 10.1097/00045391 200007030 00008
   Barkin R L, 2000, Am J Ther, V7, P31, DOI 10.1097/00045391 200007010 00006
   Barkin RL, 2005, CLIN GERIATR MED, V21, P465, DOI 10.1016/j.cger.2005.02.006
   Barkin RL, 2001, SOUTH MED J, V94, P756
   Barkin RL, 1996, DM DIS MON, V42, P389
   BARKIN RL, 2006, PAIN MED NETWORK, V21
   Barkin Robert L, 2006, Am J Ther, V13, P534, DOI 10.1097/01.mjt.0000253850.86480.fb
   Barkin Robert L, 2005, Am J Ther, V12, P431, DOI 10.1097/01.mjt.0000162011.58990.94
   Barkin Robert L, 2004, Am J Ther, V11, P124, DOI 10.1097/00045391 200403000 00007
   CARLSSON KH, 1987, EUR J PHARMACOL, V139, P1, DOI 10.1016/0014 2999(87)90491 2
   Cicero TJ, 2005, PHARMACOEPIDEM DR S, V14, P851, DOI 10.1002/pds.1113
   Claxton AJ, 2001, CLIN THER, V23, P1296, DOI 10.1016/S0149 2918(01)80109 0
   DANYLUK AP, 2006, 17 ANN M AM AC PAIN
   DRIESSEN B, 1992, BRIT J PHARMACOL, V105, P147, DOI 10.1111/j.1476 5381.1992.tb14226.x
   ERADIRI O, 2006, J CLIN PHARM, V46, P1091
   Gana TJ, 2006, CURR MED RES OPIN, V22, P1391, DOI 10.1185/030079906X115595
   Grond S, 2004, CLIN PHARMACOKINET, V43, P879, DOI 10.2165/00003088 200443130 00004
   Hair PI, 2006, DRUGS, V66, P2017, DOI 10.2165/00003495 200666150 00014
   HENNIES HH, 1988, ARZNEIMITTELFORSCH, V38 2, P877
   Inciardi JA, 2006, J ADDICT DIS, V25, P53, DOI 10.1300/J069v25n02_08
   JANAGAP C, 2006, 17 ANN CLIN M AM AC, P47
   KAYSER V, 1992, EUR J PHARMACOL, V224, P83, DOI 10.1016/0014 2999(92)94822 D
   Klotz U, 2003, ARZNEIMITTELFORSCH, V53, P681
   LAI JCK, 2003, AAPS PHARM SCI TECH, V5
   McCarberg B H, 2001, Am J Ther, V8, P181, DOI 10.1097/00045391 200105000 00006
   Mikus Gerd, 2005, Current Pharmacogenomics, V3, P43, DOI 10.2174/1570160053175018
   Murthy BP, 2007, CURR MED RES OPIN, V23, P275, DOI 10.1185/030079906X162773
   *ORTH MCNEIL INC, 2006, ULTRAM ER ULTRAM ER
   *ORTH MCNEIL PHARM, 2004, ULTRAM ULTRAM PRESC
   Pascual MLG, 2007, CURR MED RES OPIN, V23, P2531, DOI 10.1185/030079907X233179
   Poulsen L, 1996, CLIN PHARMACOL THER, V60, P636, DOI 10.1016/S0009 9236(96)90211 8
   RAFFA RB, 1992, J PHARMACOL EXP THER, V260, P275
   Roth SH, 1998, J RHEUMATOL, V25, P1358
   Senay EC, 2003, DRUG ALCOHOL DEPEN, V69, P233, DOI 10.1016/S0376 8716(02)00321 6
   Tatro D.S., 2007, DRUG INTERACTION FAC
   *TRAM BIOV CORP, 2004, DRUGS R&D, V5, P182
   VORSANGER G, 2006, 17 ANN CLIN M AM AC, P57
   VORSANGER G, SAFETY EFFICACY EXTE
   Whelton A, 2000, Am J Ther, V7, P63, DOI 10.1097/00045391 200007020 00004
   Wolfe MM, 1999, NEW ENGL J MED, V340, P1888, DOI 10.1056/NEJM199906173402407
   Woody GE, 2003, DRUG ALCOHOL DEPEN, V72, P163, DOI 10.1016/S0376 8716(03)00198 4
   2004, WORLD MED J, V103, P13
   2006, FORMULARY S, V41, P1
NR 46
TC 35
Z9 40
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106 3621 USA
SN 1075 2765
J9 AM J THER
JI Am. J. Ther.
PD MAR APR
PY 2008
VL 15
IS 2
BP 157
EP 166
DI 10.1097/MJT.0b013e31815b035b
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 306WD
UT WOS:000256277700011
PM 18356636
DA 2025 08 17
ER

PT J
AU Sucur, A
   Jajic, Z
   Artukovic, M
   Matijasevic, MI
   Anic, B
   Flegar, D
   Markotic, A
   Kelava, T
   Ivcevic, S
   Kovacic, N
   Katavic, V
   Grcevic, D
AF Sucur, Alan
   Jajic, Zrinka
   Artukovic, Marinko
   Matijasevic, Marina Ikic
   Anic, Branimir
   Flegar, Darja
   Markotic, Antonio
   Kelava, Tomislav
   Ivcevic, Sanja
   Kovacic, Natasa
   Katavic, Vedran
   Grcevic, Danka
TI Chemokine signals are crucial for enhanced homing and differentiation of
   circulating osteoclast progenitor cells
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
DE Osteoclast progenitor cells; Chemokines; Chemokine receptors;
   Osteoclasts; Rheumatoid arthritis; Peripheral blood; Synovial fluid;
   Cytokines; Inflammation; Bone loss
ID DISEASE ACTIVITY; CHEMOTACTIC RECRUITMENT; AMERICAN COLLEGE; PRECURSOR
   CELLS; RECEPTOR CXCR4; BONE LOSS; EXPRESSION; INDUCTION; RANKL;
   OSTEOIMMUNOLOGY
AB Background: The peripheral blood (PB) monocyte pool contains osteoclast progenitors (OCPs), which contribute to osteoresorption in inflammatory arthritides and are influenced by the cytokine and chemokine milieu. We aimed to define the importance of chemokine signals for migration and activation of OCPs in rheumatoid arthritis (RA) and psoriatic arthritis (PsA).
   Methods: PB and, when applicable, synovial fluid (SF) samples were collected from 129 patients with RA, 53 patients with PsA, and 110 control patients in parallel to clinical parameters of disease activity, autoantibody levels, and applied therapy. Receptors for osteoclastogenic factors (CD115 and receptor activator of nuclear factor kappa B [RANK]) and selected chemokines (CC chemokine receptor 1 [CCR1], CCR2, CCR4, CXC chemokine receptor 3 [CXCR3], CXCR4) were determined in an OCP rich subpopulation (CD3 CD19 CD56 CD11b(+)CD14(+)) by flow cytometry. In parallel, levels of CC chemokine ligand 2 (CCL2), CCL3, CCL4, CCL5, CXC chemokine ligand 9 (CXCL9), CXCL10, and CXCL12 were measured using cytometric bead array or enzyme linked immunosorbent assay. Sorted OCPs were stimulated in culture by macrophage colony stimulating factor and receptor activator of nuclear factor kappa B ligand, and they were differentiated into mature osteoclasts that resorb bone. Selected chemokines (CCL2, CCL5, CXCL10, and CXCL12) were tested for their osteoclastogenic and chemotactic effects on circulatory OCPs in vitro.
   Results: The OCP population was moderately enlarged among PB cells in RA and correlated with levels of tumor necrosis factor alpha (TNF alpha), rheumatoid factor, CCL2, and CCL5. Compared with PB, the RANK(+) subpopulation was expanded in SF and correlated with the number of tender joints. Patients with PsA could be distinguished by increased RANK expression rather than total OCP population. OCPs from patients with arthritis had higher expression of CCR1, CCR2, CCR4, CXCR3, and CXCR4. In parallel, patients with RA had increased levels of CCL2, CCL3, CCL4, CCL5, CXCL9, and CXCL10, with significant elevation in SF vs PB for CXCL10. The subset expressing CXCR4 positively correlated with TNF alpha, bone resorption marker, and rheumatoid factor, and it was reduced in patients treated with disease modifying antirheumatic drugs. The CCR4(+) subset showed a significant negative trend during anti TNF treatment. CCL2, CCL5, and CXCL10 had similar osteoclastogenic effects, with CCL5 showing the greatest chemotactic action on OCPs.
   Conclusions: In our study, we identified distinct effects of selected chemokines on stimulation of OCP mobilization, tissue homing, and maturation. Novel insights into migratory behaviors and functional properties of circulatory OCPs in response to chemotactic signals could open ways to new therapeutic targets in RA.
C1 [Sucur, Alan; Flegar, Darja; Markotic, Antonio; Kelava, Tomislav; Ivcevic, Sanja; Kovacic, Natasa; Katavic, Vedran; Grcevic, Danka] Univ Zagreb, Sch Med, Croatian Inst Brain Res, Salata 12, HR 10000 Zagreb, Croatia.
   [Sucur, Alan; Flegar, Darja; Markotic, Antonio; Kelava, Tomislav; Ivcevic, Sanja; Grcevic, Danka] Univ Zagreb, Sch Med, Dept Physiol & Immunol, Salata 3b, HR 10000 Zagreb, Croatia.
   [Jajic, Zrinka] Univ Zagreb, Sch Med, Phys Med & Rehabil, Dept Rheumatol,Clin Hosp Ctr Sestre Milosrdnice, Vinogradska Cesta 29, HR 10000 Zagreb, Croatia.
   [Artukovic, Marinko; Matijasevic, Marina Ikic] Clin Hosp Sveti Duh, Dept Clin Immunol & Pulmonol, Sveti Duh 64, HR 10000 Zagreb, Croatia.
   [Anic, Branimir] Clin Hosp Ctr Zagreb, Dept Clin Immunol & Rheumatol, Kispaticeva 12, HR 10000 Zagreb, Croatia.
   [Kovacic, Natasa] Univ Zagreb, Sch Med, Dept Anat, Salata 11, HR 10000 Zagreb, Croatia.
C3 University of Zagreb; University of Zagreb; University of Zagreb;
   University of Zagreb; UNIVERSITY ZAGREB HOSPITAL; University of Zagreb
RP Grcevic, D (通讯作者)，Univ Zagreb, Sch Med, Croatian Inst Brain Res, Salata 12, HR 10000 Zagreb, Croatia.; Grcevic, D (通讯作者)，Univ Zagreb, Sch Med, Dept Physiol & Immunol, Salata 3b, HR 10000 Zagreb, Croatia.
EM danka.grcevic@mef.hr
RI ; Grcevic, Danka/AAS 1666 2021; Markotic, Antonio/AAB 1086 2020;
   Matijašević, Marina/AAC 1982 2019; Sucur, Alan/AAB 9952 2021; Katavic,
   Vedran/E 8405 2011; Flegar, Darja/GWV 3374 2022; Kovacic,
   Natasa/AAA 4598 2021
OI Anic, Branimir/0000 0003 4940 0577; Markotic,
   Antonio/0000 0002 0410 542X; Kelava, Tomislav/0000 0002 6665 116X; Ikic
   Matijasevic, Marina/0000 0003 1511 0336; Grcevic,
   Danka/0000 0002 2365 8249; Katavic, Vedran/0000 0003 2900 1974; Sucur,
   Alan/0000 0001 7523 1047; Kovacic, Natasa/0000 0001 6042 2107
FU Croatian Science Foundation [5699, 7406]
FX This work was supported by grants from the Croatian Science Foundation
   (project numbers 5699 and 7406).
CR Adamopoulos Iannis E, 2015, Int J Clin Rheumtol, V10, P5
   Adamopoulos IE, 2015, NAT REV RHEUMATOL, V11, P189, DOI 10.1038/nrrheum.2014.198
   Aletaha D, 2010, ARTHRITIS RHEUM US, V62, P2569, DOI 10.1002/art.27584
   Anderson J, 2012, ARTHRIT CARE RES, V64, P640, DOI 10.1002/acr.21649
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Braun T, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3380
   Brühl H, 2007, ARTHRITIS RHEUM, V56, P2975, DOI 10.1002/art.22854
   Cross M, 2014, ANN RHEUM DIS, V73, P1316, DOI 10.1136/annrheumdis 2013 204627
   Deal C, 2012, CURR RHEUMATOL REP, V14, P231, DOI 10.1007/s11926 012 0253 7
   Del Fattore Andrea, 2012, Front Biosci (Elite Ed), V4, P2302
   Flytlie HA, 2010, CYTOKINE, V49, P24, DOI 10.1016/j.cyto.2009.10.005
   Fransen J, 2009, RHEUM DIS CLIN N AM, V35, P745, DOI 10.1016/j.rdc.2009.10.001
   Galliera E, 2008, INT J IMMUNOPATH PH, V21, P485, DOI 10.1177/039463200802100301
   Goldring SR, 2013, ANN RHEUM DIS, V72, P52, DOI 10.1136/annrheumdis 2012 202199
   Hoshino A, 2013, J CELL SCI, V126, P1032, DOI 10.1242/jcs.113910
   Hui AY, 2012, WIRES SYST BIOL MED, V4, P15, DOI 10.1002/wsbm.157
   Ikic M, 2014, INT ORTHOP, V38, P183, DOI 10.1007/s00264 013 2121 0
   Ivashkiv LB, 2011, ANN NY ACAD SCI, V1237, P88, DOI 10.1111/j.1749 6632.2011.06217.x
   Jajic I, 2008, DEV RHEUMATOLOGY 2 M
   Jung SM, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/263625
   Kanbe K, 2016, MOD RHEUMATOL, V26, P46, DOI 10.3109/14397595.2015.1054088
   Khan UA, 2014, J CELL BIOCHEM, V115, P1290, DOI 10.1002/jcb.24781
   Kim HR, 2014, ARTHRITIS RHEUMATOL, V66, P538, DOI 10.1002/art.38286
   Kim MS, 2006, J CELL BIOCHEM, V97, P512, DOI 10.1002/jcb.20649
   Krishnamurthy A, 2016, ANN RHEUM DIS, V75, P721, DOI 10.1136/annrheumdis 2015 208093
   Lebre MC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021772
   Matijasevic MI, 2016, CLIN EXP IMMUNOL, V186, P321, DOI 10.1111/cei.12862
   Matthys P, 2001, J IMMUNOL, V167, P4686, DOI 10.4049/jimmunol.167.8.4686
   Miyamoto K, 2009, BIOCHEM BIOPH RES CO, V383, P373, DOI 10.1016/j.bbrc.2009.04.020
   MOLL J M H, 1973, Seminars in Arthritis and Rheumatism, V3, P55, DOI 10.1016/0049 0172(73)90035 8
   Nagafuchi Y, 2016, SCI REP UK, V6, DOI 10.1038/srep29338
   Oberoi R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160145
   Pandya JM, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1224 1
   Sandblad KG, 2015, CLIN IMMUNOL, V161, P348, DOI 10.1016/j.clim.2015.09.012
   Schett G, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2571
   Souza PPC, 2013, IMMUNOL INVEST, V42, P555, DOI 10.3109/08820139.2013.822766
   Sucur A, 2014, INT ORTHOP, V38, P1893, DOI 10.1007/s00264 014 2386 y
   Szekanecz Z, 2016, NAT REV RHEUMATOL, V12, P5, DOI 10.1038/nrrheum.2015.157
   Takayanagi H, 2009, NAT REV RHEUMATOL, V5, P667, DOI 10.1038/nrrheum.2009.217
   Talbot J, 2015, ARTHRITIS RHEUMATOL, V67, P1751, DOI 10.1002/art.39117
   Wislowska M, 2009, RHEUMATOL INT, V29, P1403, DOI 10.1007/s00296 009 0867 x
   Wright LM, 2005, BONE, V36, P840, DOI 10.1016/j.bone.2005.01.021
   Yu XF, 2004, J BONE MINER RES, V19, P2065, DOI 10.1359/JBMR.040910
   Zhang Q, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2391
NR 44
TC 60
Z9 66
U1 1
U2 18
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1478 6354
EI 1478 6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PD JUN 15
PY 2017
VL 19
AR 142
DI 10.1186/s13075 017 1337 6
PG 16
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA EY4LK
UT WOS:000403949300005
PM 28619088
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhao, D
   Kang, W
   Wang, YW
   Ge, JY
   Huang, JF
   Yang, J
   Yang, WD
   Tang, XA
   Xie, SJ
AF Zhao, Dan
   Kang, Wen
   Wang, Yiwen
   Ge, Jiuyu
   Huang, Jianfeng
   Yang, Jie
   Yang, Weidong
   Tang, Xuna
   Xie, Sijing
TI SIRT1 Promotes Osteogenic Differentiation in Human Dental Pulp Stem
   Cells through Counteracting the Activation of STAT3
SO COATINGS
LA English
DT Article
DE dental pulp stem cells; SIRT1; STAT3; histone acetylation modulator
   proteins; osteogenic differentiation
ID GENE EXPRESSION; EPIGENETICS; INHIBITION
AB Human dental pulp stem cells (hDPSCs), which are characterized by self renewal capacity and the ability of multilineage differentiation, have gained increased attention in regenerative medicine recently. Histone acetylation modulator proteins (HAMPs) are a protein family that mediates the modification and identification of histone acetylation and participates in various critical cellular processes. Here, we comprehensively surveyed the expression profile of HAMPs during osteoblast differentiation of hDPSCs and found that the HDAC class III pathway was upregulated, whereas the signal transducer and activator of transcription 3 (STAT3) signaling was downregulated during osteogenesis. Further laboratory research demonstrated that Sirtuin 1 (SIRT1), a class III HDAC, was upregulated and STAT3 activation was downregulated during osteogenic differentiation. SIRT1 counteracted the activation of STAT3 to promote osteogenic differentiation of hDPSCs at 7 and 21 days in both Western blot assay and chemical staining, which highlights the promising utility of SIRT1 activators in hDPSCs based therapies for bone augmentation strategies and provides clinical insights that may lead to the development of osteogenic agents.
C1 [Zhao, Dan; Kang, Wen; Wang, Yiwen; Ge, Jiuyu; Huang, Jianfeng; Yang, Weidong; Tang, Xuna; Xie, Sijing] Nanjing Univ, Nanjing Stomatol Hosp, Dept Endodont, Sch Med, Nanjing 210008, Peoples R China.
   [Yang, Jie] Nanjing Univ, Nanjing Stomatol Hosp, Dept Periodont, Sch Med, Nanjing 210008, Peoples R China.
C3 Nanjing University; Nanjing University
RP Xie, SJ (通讯作者)，Nanjing Univ, Nanjing Stomatol Hosp, Dept Endodont, Sch Med, Nanjing 210008, Peoples R China.
EM freeyixi@163.com; kangwendoc@163.com; eavanwang84@gmail.com;
   jyge@nju.edu.cn; 121232004@smail.nju.edu.cn; dorothy0314@sina.com;
   ywdong2001@163.com; xunatang@126.com; xiesj@nju.edu.cn
RI ; WANG, Yiwen/KFB 4982 2024; YANG, Weidong/H 3390 2011; Huang,
   Jianfeng/F 8634 2011; Tang, xuna/KWU 1692 2024
OI Tang, Xuna/0000 0001 7819 7198; Zhao, Dan/0000 0002 5306 9840; 
FU National Natural Science Foundation of China [81801401, 82001111];
   Jiangsu Provincial Medical Youth Talent [QNRC2016119]
FX FundingThis work was supported by the National Natural Science
   Foundation of China (Grant Nos. 81801401, 82001111), and Jiangsu
   Provincial Medical Youth Talent (QNRC2016119).
CR Alves Fernandes DK, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133153
   Arrowsmith CH, 2012, NAT REV DRUG DISCOV, V11, P384, DOI 10.1038/nrd3674
   Awais S, 2020, OPEN LIFE SCI, V15, P229, DOI 10.1515/biol 2020 0023
   Aydin S, 2019, ADV EXP MED BIOL, V1144, P123, DOI 10.1007/5584_2018_333
   Berman AY, 2017, NPJ PRECIS ONCOL, V1, DOI 10.1038/s41698 017 0038 6
   Chen C, 2020, MECH AGEING DEV, V187, DOI 10.1016/j.mad.2020.111215
   Chen YS, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21144923
   Dernowsek JA, 2017, J CELL BIOCHEM, V118, P4045, DOI 10.1002/jcb.26060
   Duncan HF, 2016, INT ENDOD J, V49, P431, DOI 10.1111/iej.12475
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Gu SS, 2013, FRONT BIOSCI LANDMRK, V18, P1072, DOI 10.2741/4163
   Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313
   Hu ZY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 08554 x
   Huynh Nam Cong Nhat, 2017, Bone Rep, V7, P33, DOI 10.1016/j.bonr.2017.08.001
   Javaid N, 2017, GENES BASEL, V8, DOI 10.3390/genes8080196
   La Noce M, 2014, J DENT, V42, P761, DOI 10.1016/j.jdent.2014.02.018
   Luo Z, 2018, INT ENDOD J, V51, P767, DOI 10.1111/iej.12779
   Man K, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22105224
   Nie YZ, 2009, NAT CELL BIOL, V11, P492, DOI 10.1038/ncb1857
   Ozkul Y, 2016, J CELL PHYSIOL, V231, P2393, DOI 10.1002/jcp.25371
   Paino F, 2014, STEM CELLS, V32, P279, DOI 10.1002/stem.1544
   Pasquariello R, 2020, MOLECULES, V25, DOI 10.3390/molecules25194554
   Sabari BR, 2017, NAT REV MOL CELL BIO, V18, P90, DOI 10.1038/nrm.2016.140
   Sarubbo F, 2018, CURR NEUROPHARMACOL, V16, P126, DOI 10.2174/1570159X15666170703113212
   Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0 387 29362 0_23
   Song M, 2017, CELL TRANSPLANT, V26, P1001, DOI 10.3727/096368916X694391
   Stanko P, 2014, BIOMED PAP, V158, P373, DOI 10.5507/bp.2013.078
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Wang WH, 2018, J BIOL CHEM, V293, P11067, DOI 10.1074/jbc.RA117.001387
   Watroba M, 2017, AGEING RES REV, V40, P11, DOI 10.1016/j.arr.2017.08.001
   Xu Fengli, 2019, Redox Rep, V24, P70, DOI 10.1080/13510002.2019.1658377
   Xu JY, 2018, PHARMACOL RES, V136, P62, DOI 10.1016/j.phrs.2018.08.018
   Yamada Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051132
   Yamauchi Y, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00001
   Zhang H, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.560117
   Zhang S, 2019, J CELL PHYSIOL, V234, P15395, DOI 10.1002/jcp.28186
   Zhang Y, 2020, J CELL MOL MED, V24, P9041, DOI 10.1111/jcmm.15538
   Zhou D, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/8876265
NR 38
TC 0
Z9 0
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2079 6412
J9 COATINGS
JI Coatings
PD NOV
PY 2021
VL 11
IS 11
AR 1353
DI 10.3390/coatings11111353
PG 10
WC Materials Science, Multidisciplinary; Materials Science, Coatings &
   Films; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science; Physics
GA XG0FJ
UT WOS:000724437400001
OA gold
DA 2025 08 17
ER

PT J
AU Talukdar, S
   Kundu, SC
AF Talukdar, Sarmistha
   Kundu, Subhas C.
TI Engineered 3D Silk Based Metastasis Models: Interactions Between Human
   Breast Adenocarcinoma, Mesenchymal Stem Cells and Osteoblast Like Cells
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article
DE silk; fibroin; metastasis; tumor; 3D culture; bone microenvironment
ID CALCIUM SENSING RECEPTOR; CANCER CELLS; GROWTH FACTOR; ALPHA 3 BETA 1
   INTEGRIN; DRUG RESISTANCE; TUMOR MODEL; BONE; MIGRATION; SCAFFOLDS;
   INVASION
AB Bone metastasis occurs in 70% of breast cancer patients and is a frequent cause of morbidity in cancer patients. A delicate balance exists in the bone microenvironment, but the functional dynamics underlying the tumor cell microenvironment interactions remain poorly understood. 3D in vitro model systems of metastasis can throw new light on this phenomenon. Silk protein fibroin scaffolds, are cytocompatible for 3D cancer cell culture. They are structurally more resistant to protease degradation than other native biomaterials making these matrices suitable for cancer modeling. In this report, human breast adenocarcinoma cells, human osteoblast like cells and mesenchymal stem cells are co cultered. Cancer cells and osteoblast like cells are found to interact through secreted products. Decreased population of osteoblast like cells and mineralization of extracellular matrix are observed as a result of co culture. Significantly increased migration of breast cancer cells is observed in the bone like constructs than in non seeded scaffolds. The co culture constructs show significant increase in drug resistance, invasiveness and angiogenicity. Co culture of breast cancer cells with osteoblast like cells and mesenchymal stem cells also indicate that the interaction of cancer cells with bone microenvironment varies with spatial organization, presence of osteogenic factors as well as stromal cell type. Here, results show that 3D in vitro co culture models is possibly a better system to study and target cancer progression.
C1 [Talukdar, Sarmistha; Kundu, Subhas C.] Indian Inst Technol, Dept Biotechnol, Kharagpur 721302, W Bengal, India.
C3 Indian Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT)   Kharagpur
RP Talukdar, S (通讯作者)，Indian Inst Technol, Dept Biotechnol, Kharagpur 721302, W Bengal, India.
EM kundu@hijli.iitkgp.ernet.in
RI Kundu, Subhas C/AAC 1317 2020; Talukdar, Sarmistha/ABH 8480 2020
OI Kundu, Subhas C./0000 0002 7170 2291
FU Department of Biotechnology and its Bioinformatics facilities,
   Department of Science and Technology, Government of India
FX This work is supported by Department of Biotechnology and its
   Bioinformatics facilities, Department of Science and Technology,
   Government of India. We are also thankful to the subject experts of
   Indian Council of Medical Research, New Delhi for helpful discussions
   and suggestions during the initiation of the work.
CR Baker EL, 2010, BIOPHYS J, V99, P2048, DOI 10.1016/j.bpj.2010.07.051
   BERGHUIS HM, 1994, EUR J ORTHODONT, V16, P130, DOI 10.1093/ejo/16.2.130
   Burdett E, 2010, TISSUE ENG PART B RE, V16, P351, DOI 10.1089/ten.TEB.2009.0676
   Bussard KM, 2008, CANCER METAST REV, V27, P41, DOI 10.1007/s10555 007 9109 4
   Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865
   Clézardin P, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2835
   Corcoran KE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002563
   Datta A., 2001, COMP BIOCH PHYSL B, V129, P204
   Dazzi F, 2006, BLOOD REV, V20, P161, DOI 10.1016/j.blre.2005.11.002
   Erler JT, 2009, CLIN EXP METASTAS, V26, P35, DOI 10.1007/s10585 008 9209 8
   Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008 5472.CAN 05 1343
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   Gassmann Peter, 2008, V11, P21, DOI 10.1007/978 1 4020 6729 7_3
   Giannelli G, 2001, LAB INVEST, V81, P613, DOI 10.1038/labinvest.3780270
   Guise T.A., 2002, BoneKEy Osteovision, DOI 10.1138/2002052
   Guise TA, 2008, CANCER TREAT REV, V34, pS19, DOI 10.1016/j.ctrv.2008.03.006
   Hutmacher DW, 2010, TRENDS BIOTECHNOL, V28, P125, DOI 10.1016/j.tibtech.2009.12.001
   Hutmacher DW, 2010, NAT MATER, V9, P90, DOI 10.1038/nmat2619
   Jackson JG, 2001, ONCOGENE, V20, P7318, DOI 10.1038/sj.onc.1204920
   Jacob K, 1999, CANCER RES, V59, P4453
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   Joyce JA, 2005, CANCER CELL, V7, P513, DOI 10.1016/j.ccr.2005.05.024
   Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618
   Karsdal MA, 2001, J BIOL CHEM, V276, P39350, DOI 10.1074/jbc.M008738200
   Khamis ZI, 2012, INT J BREAST CANCER, V2012, DOI 10.1155/2012/574025
   Lacroix M, 1996, BREAST CANCER RES TR, V38, P209, DOI 10.1007/BF01806675
   Leibbrandt A, 2008, ANN NY ACAD SCI, V1143, P123, DOI 10.1196/annals.1443.016
   Leonhardt H, 2008, J PHYSIOL PHARMACOL, V59, P59
   Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027
   Levina V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003077
   Li ZW, 2006, BLOOD REV, V20, P333, DOI 10.1016/j.blre.2005.08.003
   Lin EY, 2002, J MAMMARY GLAND BIOL, V7, P147, DOI 10.1023/A:1020399802795
   Ma J., 2011, TISSUE ENG PART C ME, V17, P57
   Mandal BB, 2008, MACROMOL BIOSCI, V8, P807, DOI 10.1002/mabi.200800113
   Mandal BB, 2008, BIOTECHNOL BIOENG, V100, P1237, DOI 10.1002/bit.21835
   Mandal BB, 2009, ACTA BIOMATER, V5, P2579, DOI 10.1016/j.actbio.2009.02.033
   Mandal BB, 2009, BIOMATERIALS, V30, P2956, DOI 10.1016/j.biomaterials.2009.02.006
   Marinucci L, 2010, ANN BIOMED ENG, V38, P640, DOI 10.1007/s10439 009 9898 4
   Marzioni D, 2009, INT J IMMUNOPATH PH, V22, P627, DOI 10.1177/039463200902200308
   Mastro AM, 2004, J CELL BIOCHEM, V91, P265, DOI 10.1002/jcb.10746
   McKnight A. L., 2002, AJR, V178, P1417
   Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714
   Meinel L, 2005, BIOMATERIALS, V26, P147, DOI 10.1016/j.biomaterials.2004.02.047
   Mihai R, 2008, ANN ROY COLL SURG, V90, P271, DOI 10.1308/003588408X286044
   Moore MAS, 2001, BIOESSAYS, V23, P674, DOI 10.1002/bies.1095
   Moreau JE, 2007, CANCER RES, V67, P10304, DOI 10.1158/0008 5472.CAN 07 2483
   Morini M, 2000, INT J CANCER, V87, P336, DOI 10.1002/1097 0215(20000801)87:3<336::AID IJC5>3.3.CO;2 V
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Mundy GR, 2007, NUTR REV, V65, pS147, DOI [10.1111/j.1753 4887.2007.tb00353.x, 10.1301/nr.2007.dec.S147 S151]
   Nazarov R, 2004, BIOMACROMOLECULES, V5, P718, DOI 10.1021/bm034327e
   NICHOLSON R, 1989, BIOCHEMISTRY US, V28, P5195, DOI 10.1021/bi00438a042
   Ohshiba T, 2003, BRIT J CANCER, V88, P1318, DOI 10.1038/sj.bjc.6600858
   Patel S. A., 2008, J ONCOL, V425895, P7
   Pathi SP, 2011, BIOMATERIALS, V32, P5112, DOI 10.1016/j.biomaterials.2011.03.055
   Pathi SP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008849
   Qiao L, 2008, CELL RES, V18, P500, DOI 10.1038/cr.2008.40
   Rice J, 2012, NATURE, V485, pS55, DOI 10.1038/485S55a
   Saidak Z, 2009, EXP CELL RES, V315, P2072, DOI 10.1016/j.yexcr.2009.03.003
   Sanders JL, 2000, ENDOCRINOLOGY, V141, P4357, DOI 10.1210/en.141.12.4357
   Sapir Koren R., 2011, IBMS BONEKEY, V8, P86
   Secondini C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016078
   Sosnoski DM, 2012, INT J BREAST CANCER, V2012, DOI 10.1155/2012/160265
   Talukdar S, 2012, ADV FUNCT MATER, V22, P4778, DOI 10.1002/adfm.201200375
   Talukdar S, 2011, BIOMATERIALS, V32, P8927, DOI 10.1016/j.biomaterials.2011.08.027
   Talukdar S, 2011, BIOMATERIALS, V32, P2149, DOI 10.1016/j.biomaterials.2010.11.052
   Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451
   Verbridge SS, 2010, TISSUE ENG PT A, V16, P2147, DOI [10.1089/ten.tea.2009.0668, 10.1089/ten.TEA.2009.0668]
   Zhang YQ, 2005, J BIOTECHNOL, V120, P315, DOI 10.1016/j.jbiotec.2005.06.027
   Zlotnik A, 2004, SEMIN CANCER BIOL, V14, P181, DOI 10.1016/j.semcancer.2003.10.004
NR 70
TC 45
Z9 54
U1 2
U2 83
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616 301X
EI 1616 3028
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
PD NOV 13
PY 2013
VL 23
IS 42
BP 5249
EP 5260
DI 10.1002/adfm.201300312
PG 12
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA 258TF
UT WOS:000327480900004
DA 2025 08 17
ER

PT J
AU Chipoy, C
   Brounais, B
   Trichet, V
   Battaglia, S
   Berreur, M
   Oliver, L
   Juin, P
   Rédini, F
   Heymann, D
   Blanchard, F
AF Chipoy, C.
   Brounais, B.
   Trichet, V.
   Battaglia, S.
   Berreur, M.
   Oliver, L.
   Juin, P.
   Redini, F.
   Heymann, D.
   Blanchard, F.
TI Sensitization of osteosarcoma cells to apoptosis by oncostatin M depends
   on STAT5 and p53
SO ONCOGENE
LA English
DT Article
DE osteosarcoma; osteoblast; oncostatin M; STAT5; p53; apoptosis
ID SIGNAL TRANSDUCER; OSTEOBLAST DIFFERENTIATION; MITOCHONDRIAL MEMBRANE;
   HEMATOPOIETIC CELLS; GROWTH HORMONE; DNA DAMAGE; T CELLS; GENE; PROTEIN;
   BAX
AB Oncostatin M ( OSM), a cytokine of the interleukin  6 family, induces growth arrest and differentiation of osteoblastic cells into glial  like/ osteocytic cells. Here, we asked whether OSM regulates apoptosis of normal or transformed ( osteosarcoma) osteoblasts. We show that OSM sensitizes cells to apoptosis induced by various death inducers such as staurosporine, ultraviolet or tumor necrosis factor alpha. Apoptosis is mediated by the mitochondrial pathway, with release of cytochrome c from the mitochondria to the cytosol and activation of caspases  9 and   3. DNA micro arrays revealed that OSM modulates the expression of Bax, Bad, Bnip3, Bcl  2 and Mcl  1. Pharmacological inhibitors, dominant  negative signal transducer and activator of transcriptions ( STATs), stable RNA interference and knockout cells indicated that the transcription factors p53 and STAT5, which are activated by OSM, are implicated in the sensitization to apoptosis, being responsible for Bax induction and Bcl  2 reduction, respectively. These results indicate that, in addition to growth arrest and induced differentiation, OSM also sensitizes normal and transformed osteoblasts to apoptosis by a mechanism implicating ( i) activation and nuclear translocation of STAT5 and p53 and ( ii) an increased Bax/ Bcl  2 ratio. Therefore, association of OSM with kinase inhibitors such as Sts represents new therapeutic opportunities for wild  type p53 osteosarcoma.
C1 Univ Nantes, Fac Med, Lab Physiopathol Resorpt Osseuse & Therapie Tumeu, EA3822, F 44035 Nantes 1, France.
   INSERM, ER17, Nantes, France.
   INSERM, U601, Nantes, France.
C3 Nantes Universite; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Institut National de la Sante et de la Recherche
   Medicale (Inserm)
RP Chipoy, C (通讯作者)，Univ Nantes, Fac Med, Lab Physiopathol Resorpt Osseuse & Therapie Tumeu, EA3822, 1 Rue Gaston Veil, F 44035 Nantes 1, France.
EM celine.chipoy@univ nantes.fr
RI Blanchard, Frederic/K 8018 2015; Heymann, Dominique/AAC 6014 2019;
   Trichet, Valérie/L 1553 2015; ROYER, Bénédicte/AAY 8894 2020; Blanchard,
   Frederic/AAS 1930 2021; JUIN, Philippe/Q 1338 2019; Oliver,
   Lisa/L 3070 2015
OI Blanchard, Frederic/0000 0003 1055 2573; Trichet,
   Valerie/0000 0003 4183 9032; Heymann, Dominique/0000 0001 7777 0669;
   Juin, Philippe/0000 0002 4997 3888; Oliver, Lisa/0000 0002 5588 7564
CR Auernhammer CJ, 2004, J ENDOCRINOL, V180, P479, DOI 10.1677/joe.0.1800479
   Auguste P, 1997, J BIOL CHEM, V272, P15760, DOI 10.1074/jbc.272.25.15760
   Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456
   Baumann H, 2000, J BIOL CHEM, V275, P22014, DOI 10.1074/jbc.M002830200
   Bellido T, 1997, ENDOCRINOLOGY, V138, P3666, DOI 10.1210/en.138.9.3666
   Bellini MH, 1998, J ENDOCRINOL INVEST, V21, P1
   Buitenhuis M, 2004, INT J BIOCHEM CELL B, V36, P2120, DOI 10.1016/j.biocel.2003.11.008
   Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497
   CASEY G, 1991, ONCOGENE, V6, P1791
   CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43
   Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604
   Chen SH, 2004, CYTOKINE GROWTH F R, V15, P379, DOI 10.1016/j.cytogfr.2004.06.002
   Chipoy C, 2004, J BONE MINER RES, V19, P1850, DOI 10.1359/JBMR.040817
   Debierre Grockiego F, 2004, APOPTOSIS, V9, P717, DOI 10.1023/B:APPT.0000045785.65546.a2
   DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772
   Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929 935.2000
   FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297
   Fuchs B, 2002, CLIN ORTHOP RELAT R, P40
   Grant SL, 1999, MOL MED TODAY, V5, P406, DOI 10.1016/S1357 4310(99)01540 3
   Haupt S, 2003, J CELL SCI, V116, P4077, DOI 10.1242/jcs.00739
   Heath C, 2004, J BIOL CHEM, V279, P6666, DOI 10.1074/jbc.M308743200
   Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793
   Kamiya A, 1999, EMBO J, V18, P2127, DOI 10.1093/emboj/18.8.2127
   Kashkar H, 2005, J BIOL CHEM, V280, P20804, DOI 10.1074/jbc.M410869200
   Le Meur N, 2004, NUCLEIC ACIDS RES, V32, P5349, DOI 10.1093/nar/gkh870
   Lengner CJ, 2006, J CELL BIOL, V172, P909, DOI 10.1083/jcb.200508130
   Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754
   Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183
   Qin XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI 10.1073/pnas.232688199
   Sims NA, 2000, J CLIN INVEST, V106, P1095, DOI 10.1172/JCI10753
   Stephanou A, 2000, CELL DEATH DIFFER, V7, P329, DOI 10.1038/sj.cdd.4400656
   Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001
   Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747
   Townsend PA, 2004, J BIOL CHEM, V279, P5811, DOI 10.1074/jbc.M302637200
   Trichet V, 2006, J IMMUNOL, V177, P6129, DOI 10.4049/jimmunol.177.9.6129
   WADAYAMA B, 1994, CANCER RES, V54, P3042
   Wang XY, 2006, J CELL BIOL, V172, P115, DOI 10.1083/jcb.200507106
   Wei QZ, 2005, J BIOL CHEM, V280, P37790, DOI 10.1074/jbc.M502974200
NR 38
TC 43
Z9 49
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950 9232
J9 ONCOGENE
JI Oncogene
PD OCT 11
PY 2007
VL 26
IS 46
BP 6653
EP 6664
DI 10.1038/sj.onc.1210492
PG 12
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 219JT
UT WOS:000250081500007
PM 17471233
DA 2025 08 17
ER

PT J
AU Le Henaff, C
   Haÿ, E
   Velard, F
   Marty, C
   Tabary, O
   Marie, PJ
   Jacquot, JP
AF Le Henaff, Carole
   Hay, Eric
   Velard, Frederic
   Marty, Caroline
   Tabary, Olivier
   Marie, Pierre J.
   Jacquot, Jacky P.
TI Enhanced F508del CFTR Channel Activity Ameliorates Bone Pathology in
   Murine Cystic Fibrosis
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID MINERAL DENSITY; MIGLUSTAT; CHILDREN; DISEASE; ADULTS; HISTOMORPHOMETRY;
   FRACTURES; CFTR; OSTEOPENIA; MUTATION
AB In patients with cystic fibrosis (CF), rib and thoracic vertebral fractures can have adverse effects on Lung health because the resulting pain and debilitation can impair airway clearance. The F508del mutation in the CF transmembrane conductance regulator (Cftr) gene induces an osteopenic phenotype in humans and mice. N butyldeoxynojyrimicin (miglustat), an approved drug for treating type 1 Gaucher disease, was found to normalize CFTR dependent chloride transport in human F508del CFTR Lung cells and in nasal mucosa of F508del CF mice. Herein, we investigated whether targeting F508del CFTR may rescue the skeletal osteopenic phenotype in murine CF. We found that oral administration of low dose miglustat (120 mg/kg once a day for 28 days) improved bone mass and microarchitecture in the lumbar spine and femur in F508del mice. The increased bone density was associated with an increased bone formation rate and reduced bone resorption. This effect was associated with increased 17 beta estradiol but not with insulin Like growth factor 1 serum Levels in miglustat treated F508del. mice. Exposure of primary F508del osteoblasts to miglustat partially restored the deficient CFTR dependent chloride transport in these bone forming cells. This study provides evidence that reversal of CFTR dependent chloride transport in osteoblasts normalizes bone mass and microarchitecture in murine CF. These findings may provide a potential therapeutic strategy to prevent or correct the bone disease in patients with CF.
C1 [Le Henaff, Carole; Velard, Frederic; Jacquot, Jacky P.] SFR CAP Sante FED 4231, EA Biomat & Inflammat Site Osseux 4691, Reims, France.
   [Le Henaff, Carole; Velard, Frederic; Jacquot, Jacky P.] Univ Reims, F 51095 Reims, France.
   INSERM, UMR 606, Paris, France.
   [Hay, Eric; Marty, Caroline; Marie, Pierre J.] Univ Paris Diderot, Sorbonne Paris Cite, Paris, France.
   [Tabary, Olivier] INSERM, U938, Paris, France.
   [Tabary, Olivier] Univ Paris 06, Paris, France.
C3 Universite de Reims Champagne Ardenne; Institut National de la Sante et
   de la Recherche Medicale (Inserm); Universite Paris Cite; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Sorbonne
   Universite
RP Jacquot, JP (通讯作者)，Univ Reims, EA Biomat & Inflammat Site Osseux 4691, SFR CAP Sante FED 4231, 1 Rue Marechal Juin, F 51095 Reims, France.
EM pierre.marie@inserm.fr; jacky.jacquot@inserm.fr
RI Jacquot, Jacky/L 9060 2018; Tabary, Olivier/J 5931 2017; Velard,
   Frédéric/AAG 6783 2020; Haÿ, Eric/HNS 9912 2023
OI VELARD, Frederic/0000 0002 4826 2160; Tabary,
   Olivier/0000 0003 1997 2400; Hay, Eric/0000 0002 0131 9983; 
FU French Association Vaincre La Mucoviscidose [RF20110600482,
   RF20120600625]; Inserm/Region Champagne Ardenne Research Program
   [D200911226]
FX Supported in part by the French Association Vaincre La Mucoviscidose
   (grants RF20110600482 and RF20120600625 to J.P.J.) and an Inserm/Region
   Champagne Ardenne Research Program (convention D200911226 to J.P.J.).
CR [Anonymous], COCHRANE DATABASE SY
   [Anonymous], JOURNAL OF OSTEOPORO, DOI DOI 10.4061/2011/926045
   Aris RM, 2005, J CLIN ENDOCR METAB, V90, P1888, DOI 10.1210/jc.2004 1629
   Aris RM, 1998, ANN INTERN MED, V128, P186, DOI 10.7326/0003 4819 128 3 199802010 00004
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Chen H, 2012, J CLIN ENDOCR METAB, V97, P923, DOI 10.1210/jc.2011 1363
   Cottart CH, 2007, PEDIATR RES, V62, P528, DOI 10.1203/PDR.0b013e318155a61d
   Dorozhkin SV, 2002, ANGEW CHEM INT EDIT, V41, P3130, DOI 10.1002/1521 3773(20020902)41:17<3130::AID ANIE3130>3.0.CO;2 1
   Egan ME, 2004, SCIENCE, V304, P600, DOI 10.1126/science.1093941
   Elkin SL, 2002, AM J RESP CRIT CARE, V166, P1470, DOI 10.1164/rccm.200206 578OC
   Fanellli T, 2008, BIOL CELL, V100, P399, DOI 10.1042/BC20070095
   Festini F, 2005, J PEDIATR US, V147, P316, DOI 10.1016/j.jpeds.2005.04.031
   Galanaud D, 2009, MOL GENET METAB, V96, P55, DOI 10.1016/j.ymgme.2008.10.002
   Gimenez Maitre A, 2012, EUR RESPIR J, V39, P780, DOI 10.1183/09031936.00104111
   Giustina A, 2008, ENDOCR REV, V29, P535, DOI 10.1210/er.2007 0036
   Goss CH, 2013, AM J RESP CRIT CARE, V187, P915, DOI 10.1164/rccm.201301 0184UP
   Gronowitz E, 2006, BRIT J NUTR, V95, P1159, DOI 10.1079/BJN20061778
   Guilbault C, 2008, AM J RESP CELL MOL, V38, P47, DOI 10.1165/rcmb.2007 0036OC
   Haston CK, 2008, AM J RESP CRIT CARE, V177, P309, DOI 10.1164/rccm.200705 659OC
   Haworth CS, 2010, CURR OPIN PULM MED, V16, P616, DOI 10.1097/MCP.0b013e32833e2e94
   Haworth CS, 2000, CHEST, V118, P434, DOI 10.1378/chest.118.2.434
   Haworth CS, 1999, EUR RESPIR J, V14, P478, DOI 10.1034/j.1399 3003.1999.14b39.x
   Hillman LS, 2008, PEDIATR PULM, V43, P772, DOI 10.1002/ppul.20863
   Imai Y, 2010, MOL ENDOCRINOL, V24, P877, DOI 10.1210/me.2009 0238
   Jenkins BA, 2013, J CYST FIBROS, V12, P88, DOI 10.1016/j.jcf.2012.06.003
   KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460
   King SJ, 2005, EUR RESPIR J, V25, P54, DOI 10.1183/09031936.04.00050204
   Le Henaff C, 2012, AM J PATHOL, V180, P2068, DOI 10.1016/j.ajpath.2012.01.039
   Leonard A, 2012, J CYST FIBROS, V11, P231, DOI 10.1016/j.jcf.2011.12.004
   Lubamba B, 2009, AM J RESP CRIT CARE, V179, P1022, DOI 10.1164/rccm.200901 0049OC
   Noël S, 2008, J PHARMACOL EXP THER, V325, P1016, DOI 10.1124/jpet.107.135582
   Norez C, 2006, FEBS LETT, V580, P2081, DOI 10.1016/j.febslet.2006.03.010
   Norez C, 2009, AM J RESP CELL MOL, V41, P217, DOI 10.1165/rcmb.2008 0285OC
   Paccou J, 2010, CALCIFIED TISSUE INT, V86, P1, DOI 10.1007/s00223 009 9316 9
   Paradis J, 2010, J CYST FIBROS, V9, P239, DOI 10.1016/j.jcf.2010.05.001
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Pastores GM, 2007, CLIN THER, V29, P1645, DOI 10.1016/j.clinthera.2007.08.006
   PLATT FM, 1994, J BIOL CHEM, V269, P27108
   Quon BS, 2012, PAEDIATR RESPIR REV, V13, P206, DOI 10.1016/j.prrv.2012.03.005
   Ramsey BW, 2012, AM J RESP CRIT CARE, V185, P887, DOI 10.1164/rccm.201111 2068WS
   Rogan MP, 2010, P NATL ACAD SCI USA, V107, P20571, DOI 10.1073/pnas.1015281107
   Rossini M, 2004, BONE, V35, P771, DOI 10.1016/j.bone.2004.05.009
   Saint Criq V, 2011, ANTIMICROB AGENTS CH, V55, P1792, DOI 10.1128/AAC.01403 10
   Sermet Gaudelus I, 2007, AM J RESP CRIT CARE, V175, P951, DOI 10.1164/rccm.200606 776OC
   Sermet Gaudelus I, 2011, J CYST FIBROS, V10, pS16, DOI 10.1016/S1569 1993(11)60004 0
   Shane E, 1996, AM J MED, V101, P262, DOI 10.1016/S0002 9343(96)00155 6
   Shead EF, 2007, THORAX, V62, P650, DOI 10.1136/thx.2006.075887
   Shead EF, 2006, AM J RESP CRIT CARE, V174, P306, DOI 10.1164/rccm.200512 1943OC
   Sparks AA, 2009, CURR OPIN ENDOCRINOL, V16, P407, DOI 10.1097/MED.0b013e3283329b16
   Stalvey MS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080098
   Switzer M, 2009, J PEDIATR ENDOCR MET, V22, P417
   Treiber A, 2007, XENOBIOTICA, V37, P298, DOI 10.1080/00498250601094543
   VANDOORNINCK JH, 1995, EMBO J, V14, P4403, DOI 10.1002/j.1460 2075.1995.tb00119.x
   Venier RE, 2012, J MED GENET, V49, P591, DOI 10.1136/jmedgenet 2012 101070
   Whyte MP, 2008, J BONE MINER RES, V23, P1698, DOI 10.1359/JBMR.080511
NR 55
TC 25
Z9 26
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002 9440
EI 1525 2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD APR
PY 2014
VL 184
IS 4
BP 1132
EP 1141
DI 10.1016/j.ajpath.2013.12.027
PG 10
WC Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology
GA AD8XI
UT WOS:000333548600024
PM 24529904
DA 2025 08 17
ER

PT J
AU Koh, AJ
   Sinder, BP
   Entezami, P
   Nilsson, L
   McCauley, LK
AF Koh, A. J.
   Sinder, B. P.
   Entezami, P.
   Nilsson, L.
   McCauley, L. K.
TI The skeletal impact of the chemotherapeutic agent etoposide
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Bisphosphonate; Bone; Chemotherapy; Efferocytosis; Etoposide; Macrophage
ID ZOLEDRONIC ACID; ANABOLIC ACTIONS; BONE; MACROPHAGES; CANCER;
   MACROSIALIN; OSTEOCLASTS; ANTICANCER; SURVIVORS; RECEPTOR
AB The Summary Effects of the chemotherapeutic agent etoposide on the skeleton were determined in mice. Numbers of bone marrow cells were reduced and myeloid cells were increased. Bone volume was significantly decreased with signs of inhibition of bone formation. Etoposide after pre treatment with zoledronic acid still reduced bone but overall bone volume was higher than with etoposide alone.
   Introduction Chemotherapeutics target rapidly dividing tumor cells yet also impact hematopoietic and immune cells in an off target manner. A wide array of therapies have negative side effects on the skeleton rendering patients osteopenic and prone to fracture. This study focused on the pro apoptotic chemotherapeutic agent etoposide and its short and long term treatment effects in the bone marrow and skeleton.
   Methods Six to 16 week old mice were treated with etoposide (20 25 mg/kg) or vehicle control in short term (daily for 5 9 days) or long term(3x/week for 17 days or 6 weeks) regimens. Bone marrow cell populations and their phagocytic/efferocytic functions were analyzed by flow cytometry. Blood cell populations were assessed by CBC analysis. Bone volume and area compartments and osteoclast numbers were measured by microCT, histomorphometry, and TRAP staining. Biomarkers of bone formation (P1NP) and resorption TRAcP5b) were assayed from serum. Gene expression in bone marrow was assessed using qPCR.
   Results Flow cytometric analysis of the bone marrow revealed short term etoposide reduced overall cell numbers and B220(+) cells, with increased marrow apoptotic (AnnexinV(+)PI( )) cells, mesenchymal stem like cells, and CD68(+), CD45(+), and CD11b(+) monocyte/myeloid cells (as a percent of the total marrow). After 6 weeks, the CD68+, Gr1(+), CD11b(+), and CD45(+) cell populations were still relatively increased in etoposide treated bone marrow. Skeletal phenotyping revealed etoposide decreased bone volume, trabecular thickness, and cortical bone volume. Gene expression in the marrow for the leptin receptor and CXCL12 were reduced with short term etoposide, and an increased ratio of RANKL/OPG mRNA was observed. In whole bone, Runx2 and osteocalcin gene expressions were reduced, and in serum, P1NP was significantly reduced with etoposide. Treatment with the antiresorptive agent zoledronic acid prior to etoposide increased bone volume and improved the etoposide induced decrease in skeletal parameters.
   Conclusions These data suggest that etoposide induces apoptosis in the bone marrow and significantly reduces parameters of bone formation with rapid reduction in bone volume. Pre treatment with an antiresorptive agent results in a preservation of bone mass. Preventive approaches to preserving the skeleton should be considered in human clinical studies.
C1 [Koh, A. J.; Sinder, B. P.; Entezami, P.; Nilsson, L.; McCauley, L. K.] Univ Michigan, Sch Dent, Periodont & Oral Med, Ann Arbor, MI 48109 USA.
   [McCauley, L. K.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.
   [McCauley, L. K.] Univ Michigan, Sch Dent, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan
RP McCauley, LK (通讯作者)，Univ Michigan, Sch Dent, Periodont & Oral Med, Ann Arbor, MI 48109 USA.; McCauley, LK (通讯作者)，Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.; McCauley, LK (通讯作者)，Univ Michigan, Sch Dent, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.
EM mccauley@umich.edu
RI McCauley, Laurie/G 4041 2012
FU NIH [DK053904, CA093900]; National Cancer Institute [P01CA093900]
   Funding Source: NIH RePORTER; National Institute of Arthritis and
   Musculoskeletal and Skin Diseases [P30AR069620] Funding Source: NIH
   RePORTER
FX This work was supported in part by the NIH DK053904 and CA093900. We
   appreciate technical assistance by Chris Strayhorn (tissue preparation),
   Michelle Lynch (microCT), Stephanie Daignult Newton (statistics), Anna
   Seydel, James Rhee, and Megan Michalski for bone preparation and
   analyses, and the Flow Cytometry Core at the University of Michigan.
CR Alexander KA, 2011, J BONE MINER RES, V26, P1517, DOI 10.1002/jbmr.354
   Baldwin E. L., 2005, Current Medicinal Chemistry   Anti Cancer Agents, V5, P363, DOI 10.2174/1568011054222364
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Cegiela U, 2004, POL J PHARMACOL, V56, P327
   Chang MK, 2008, J IMMUNOL, V181, P1232, DOI 10.4049/jimmunol.181.2.1232
   Cho SW, 2013, J BIOL CHEM, V288, P6814, DOI 10.1074/jbc.M112.393363
   Colpo A, 2012, ONCOLOGIST, V17, P80, DOI 10.1634/theoncologist.2011 0177
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317
   Ganguly S, 2012, CLIN TRANSPLANT, V26, P447, DOI 10.1111/j.1399 0012.2011.01527.x
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Harre U, 2012, AUTOIMMUNITY, V45, P612, DOI 10.3109/08916934.2012.719950
   Hudson MM, 2013, JAMA J AM MED ASSOC, V309, P2371, DOI 10.1001/jama.2013.6296
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Koh AJ, 2011, ENDOCRINOLOGY, V152, P4525, DOI 10.1210/en.2011 1515
   Korns D, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00057
   Lézot F, 2015, BONE, V73, P51, DOI 10.1016/j.bone.2014.12.011
   Michalski MN, 2016, J CELL BIOCHEM, V117, P2697, DOI 10.1002/jcb.25567
   Montecucco A, 2007, CANCER LETT, V252, P9, DOI 10.1016/j.canlet.2006.11.005
   Montecucco A, 2015, EXCLI J, V14, P95, DOI 10.17179/excli2015 561
   Morikawa S, 2009, J EXP MED, V206, P2483, DOI 10.1084/jem.20091046
   Nicolay NH, 2016, CANCER LETT, V374, P75, DOI 10.1016/j.canlet.2016.02.007
   Orlikova B, 2014, CANCER TREAT RES, V159, P123, DOI 10.1007/978 3 642 38007 5_8
   Ottewell PD, 2014, CLIN CANCER RES, V20, P2922, DOI 10.1158/1078 0432.CCR 13 1246
   Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845
   Petropoulou AD, 2010, TRANSPLANTATION, V89, P1354, DOI 10.1097/TP.0b013e3181d84c8e
   Pettway GJ, 2005, BONE, V36, P959, DOI 10.1016/j.bone.2005.02.015
   Pierroz DD, 2010, J BIOL CHEM, V285, P28164, DOI 10.1074/jbc.M110.101964
   Pommier Y, 2010, CHEM BIOL, V17, P421, DOI 10.1016/j.chembiol.2010.04.012
   Quach JM, 2015, J BONE MINER RES, V30, P886, DOI 10.1002/jbmr.2415
   RABINOWITZ SS, 1991, J EXP MED, V174, P827, DOI 10.1084/jem.174.4.827
   Ramprasad MP, 1996, P NATL ACAD SCI USA, V93, P14833, DOI 10.1073/pnas.93.25.14833
   Rellick SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030758
   Remichkova M, 2008, INFLAMMATION, V31, P57, DOI 10.1007/s10753 007 9049 8
   Rissanen JP, 2008, CALCIFIED TISSUE INT, V82, P108, DOI 10.1007/s00223 007 9091 4
   Rizzoli R, 2013, OSTEOPOROSIS INT, V24, P2929, DOI 10.1007/s00198 013 2530 3
   Schimmer AD, 2001, BONE MARROW TRANSPL, V28, P387, DOI 10.1038/sj.bmt.1703149
   Schündeln MM, 2015, PEDIATR HEMAT ONCOL, V32, P455, DOI 10.3109/08880018.2015.1048912
   Sinder BP, 2015, J BONE MINER RES, V30, P2140, DOI 10.1002/jbmr.2735
   Soki FN, 2014, J BIOL CHEM, V289, P24560, DOI 10.1074/jbc.M114.571620
   Soki FN, 2013, J CELL BIOCHEM, V114, P67, DOI 10.1002/jcb.24301
   Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25
   Taichman RS, 2005, BLOOD, V105, P2631, DOI 10.1182/blood 2004 06 2480
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Wilson CL, 2013, CURR OSTEOPOROS REP, V11, P329, DOI 10.1007/s11914 013 0165 0
   Xian CJ, 2007, CANCER BIOL THER, V6, P170, DOI 10.4161/cbt.6.2.3576
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
NR 47
TC 10
Z9 11
U1 0
U2 6
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD AUG
PY 2017
VL 28
IS 8
BP 2321
EP 2333
DI 10.1007/s00198 017 4032 1
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FB6TN
UT WOS:000406275400008
PM 28429052
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Xu, Z
   Choudhary, S
   Okada, Y
   Voznesensky, O
   Alander, C
   Raisz, L
   Pilbeam, C
AF Xu, Zheng
   Choudhary, Shilpa
   Okada, Yosuke
   Voznesensky, Olga
   Alander, Cynthia
   Raisz, Lawrence
   Pilbeam, Carol
TI Cyclooxygenase 2 gene disruption promotes proliferation of murine
   calvarial osteoblasts in vitro
SO BONE
LA English
DT Article
DE prostaglandins; apoptosis; nonsteroidal anti inflammatory drugs; marrow
   stromal cells; mitogenesis
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; BONE BIOMECHANICAL PROPERTIES;
   PROSTAGLANDIN E 2; PARATHYROID HORMONE; MC3T3 E1 CELLS; KNOCKOUT MICE;
   PROSTANOID RECEPTORS; ANABOLIC ACTIONS; GROWTH; MECHANISMS
AB Cyclooxygenase 2 (COX 2) is highly expressed in osteoblasts, and COX 2 produced prostaglandins (PGs) can increase osteoblastic differentiation in vitro. The goal of this study was to examine effects of COX 2 expression on calvarial osteoblastic proliferation and apoptosis. Primary osteoblasts (POBs) were cultured from calvariae of COX 2 wild type (WT) and knockout (KO) mice. POB proliferation was evaluated by H 3 thymidine incorporation and analysis of cell replication and cell cycle distribution by flow cytometry. POB apoptosis was evaluated by annexin and PI staining on flow cytometry. As expected, PGE(2) production and alkaline phosphatase (ALP) activity were increased in WT cultures compared to KO cultures. In contrast, cell numbers were decreased in WT compared to KO cells by day 4 Of Culture. Proliferation, measured on days 3 7 of culture, was 2 fold greater in KO than in WT POBs and associated with decreased Go/Gl and increased S cell cycle distribution. There was no significant effect of COX 2 genotype on apoptosis under basal culture conditions on day 5 of culture. Cell growth was decreased in KO POBs by the addition of PGE(2) or a protein kinase A agonist and increased in WT POBs by the addition of NS398, a selective COX 2 inhibitor. In contrast, differentiation and cell growth in marrow stromal cell (MSC) cultures, evaluated by ALP and crystal violet staining respectively, were increased in MSCs from WT mice compared to MSCs from KO mice, and exogenous PGE, increased cell growth in KO MSC cultures. We conclude that PGs secondary to COX 2 expression decrease osteoblastic proliferation in cultured calvarial cells but increase growth of osteoblastic precursors in MSC cultures. (c) 2007 Elsevier Inc. All rights reserved.
C1 Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT 06030 USA.
   Univ Occupat & Environm Hlth, Dept Internal Med 1, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan.
C3 University of Connecticut; University of Occupational & Environmental
   Health   Japan
RP Pilbeam, C (通讯作者)，Univ Connecticut, Ctr Hlth, Dept Med, Room N4051,MARB,MC5456,263 Farmington Ave, Farmington, CT 06030 USA.
EM Pilbeam@nso.uchc.edu
RI Okada, Yosuke/AAT 3173 2020
FU NIDDK NIH HHS [R01DK48361, R01 DK048361] Funding Source: Medline
CR Akhter MP, 2006, CALCIFIED TISSUE INT, V78, P357, DOI 10.1007/s00223 005 0186 5
   Akhter MP, 2001, BONE, V29, P121, DOI 10.1016/S8756 3282(01)00486 0
   [Anonymous], 2002, PRINCIPLES BONE BIOL
   Aubin JE, 1998, BIOCHEM CELL BIOL, V76, P899, DOI 10.1139/bcb 76 6 899
   Backlund MG, 2005, ONCOLOGY BASEL, V69, P28, DOI 10.1159/000086629
   Barnes PJ, 2006, J CLIN INVEST, V116, P1210, DOI 10.1172/JCI28535
   Baylink TM, 1996, J BONE MINER RES, V11, P1413
   Bodine PVN, 2005, J CELL BIOCHEM, V96, P1212, DOI 10.1002/jcb.20599
   Brown G, 2003, EXP CELL RES, V291, P282, DOI 10.1016/S0014 4827(03)00393 8
   Brown KM, 2004, J BONE JOINT SURG AM, V86A, P116, DOI 10.2106/00004623 200401000 00017
   CENTRELLA M, 1994, ENDOCRINOLOGY, V135, P1611, DOI 10.1210/en.135.4.1611
   Chang JK, 2005, CONNECT TISSUE RES, V46, P200, DOI 10.1080/03008200500344025
   Chen Q, 2003, CALCIFIED TISSUE INT, V73, P387, DOI 10.1007/s00223 002 0009 x
   Chikazu D, 2002, J BONE MINER RES, V17, P1430, DOI 10.1359/jbmr.2002.17.8.1430
   Choudhary S, 2003, J BONE MINER RES, V18, P1813, DOI 10.1359/jbmr.2003.18.10.1813
   CHYUN YS, 1984, PROSTAG OTH LIPID M, V27, P97, DOI 10.1016/0090 6980(84)90223 5
   Drissi H, 1999, CANCER RES, V59, P3705
   FANG MA, 1992, ENDOCRINOLOGY, V131, P2113, DOI 10.1210/en.131.5.2113
   FayePetersen OM, 1996, PEDIATR PATHOL LAB M, V16, P489, DOI 10.1080/15513819609168686
   FEYEN JHM, 1985, PROSTAG OTH LIPID M, V30, P827, DOI 10.1016/0090 6980(85)90011 5
   FLANAGAN AM, 1992, ENDOCRINOLOGY, V130, P443, DOI 10.1210/en.130.1.443
   FUJIMORI A, 1989, J BONE MINER RES, V4, P697
   FUJIMORI A, 1989, CALCIFIED TISSUE INT, V44, P186, DOI 10.1007/BF02556563
   Fujino H, 2003, J BIOL CHEM, V278, P12151, DOI 10.1074/jbc.M212665200
   Gerstenfeld LC, 2003, J ORTHOP RES, V21, P670, DOI 10.1016/S0736 0266(03)00003 2
   Gobeil F, 2003, CAN J PHYSIOL PHARM, V81, P196, DOI 10.1139/Y02 163
   HAKEDA Y, 1986, J CELL PHYSIOL, V128, P155, DOI 10.1002/jcp.1041280204
   HERSCHMAN HR, 1995, BIOESSAYS, V17, P1031, DOI 10.1002/bies.950171207
   Ho ML, 1999, BIOCHEM PHARMACOL, V58, P983, DOI 10.1016/S0006 2952(99)00186 0
   Jang TJ, 2004, CARCINOGENESIS, V25, P1853, DOI 10.1093/carcin/bgh199
   Jee WSS, 1997, BONE, V21, P297, DOI 10.1016/S8756 3282(97)00147 6
   Kaneki H, 1999, J CELL BIOCHEM, V73, P36, DOI 10.1002/(SICI)1097 4644(19990401)73:1<36::AID JCB5>3.3.CO;2 6
   Ke HZ, 2006, J BONE MINER RES, V21, P565, DOI 10.1359/JBMR.051110
   Kobayashi T, 2002, PROSTAG OTH LIPID M, V68 9, P557, DOI 10.1016/S0090 6980(02)00055 2
   LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092 8674(95)90126 4
   Li M, 2003, J BONE MINER RES, V18, P2033, DOI 10.1359/jbmr.2003.18.11.2033
   Li XD, 2000, ENDOCRINOLOGY, V141, P2054, DOI 10.1210/en.141.6.2054
   Miyaura C, 2000, J BIOL CHEM, V275, P19819, DOI 10.1074/jbc.M002079200
   MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092 8674(95)90125 6
   Myers LK, 2006, BONE, V39, P1048, DOI 10.1016/j.bone.2006.05.015
   NAGATA T, 1994, CALCIFIED TISSUE INT, V55, P451, DOI 10.1007/BF00298559
   NORRDIN RW, 1988, CALCIFIED TISSUE INT, V42, P363, DOI 10.1007/BF02556354
   Okada Y, 2000, J BONE MINER RES, V15, pS217
   Okada Y, 2000, J CLIN INVEST, V105, P823, DOI 10.1172/JCI8195
   PILBEAM CC, 1995, J BONE MINER RES, V10, P406
   PILBEAM CC, 1993, J BIOL CHEM, V268, P25643
   Qin L, 2005, J BIOL CHEM, V280, P3104, DOI 10.1074/jbc.M409846200
   RAISZ LG, 1985, ENDOCR RES, V11, P59, DOI 10.3109/07435808509035425
   REN W, 1991, CALCIFIED TISSUE INT, V49, P197, DOI 10.1007/BF02556118
   Robertson G, 2006, BONE, V39, P767, DOI 10.1016/j.bone.2006.04.006
   SCUTT A, 1995, J BONE MINER RES, V10, P474
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Smith WL, 2002, PROSTAG OTH LIPID M, V68 9, P115, DOI 10.1016/S0090 6980(02)00025 4
   STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424
   Suda M, 1998, CALCIFIED TISSUE INT, V62, P327, DOI 10.1007/s002239900440
   Suda M, 1996, ENDOCRINOLOGY, V137, P1698, DOI 10.1210/en.137.5.1698
   Trifan OC, 2003, J CELL MOL MED, V7, P207, DOI 10.1111/j.1582 4934.2003.tb00222.x
   UEDA K, 1980, J PEDIATR US, V97, P834, DOI 10.1016/S0022 3476(80)80282 4
   Weinreb M, 1997, BONE, V20, P521, DOI 10.1016/S8756 3282(97)00033 1
   Xu MS, 2005, ENDOCRINOLOGY, V146, P1843, DOI 10.1210/en.2004 0734
   Xu Z, 2006, CANCER RES, V66, P6657, DOI 10.1158/0008 5472.CAN 05 3624
   Yoshida K, 2002, P NATL ACAD SCI USA, V99, P4580, DOI 10.1073/pnas.062053399
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 63
TC 23
Z9 34
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
J9 BONE
JI Bone
PD JUL
PY 2007
VL 41
IS 1
BP 68
EP 76
DI 10.1016/j.bone.2007.03.009
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 187NN
UT WOS:000247854900009
PM 17467356
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Sabatelli, S
   Scarpa, ES
   Giuliani, A
   Giordani, C
   Sabbatinelli, J
   Rippo, MR
   Cabodi, S
   Petrini, B
   Balercia, G
   Giacchetti, G
AF Sabatelli, Sofia
   Scarpa, Emanuele Salvatore
   Giuliani, Angelica
   Giordani, Chiara
   Sabbatinelli, Jacopo
   Rippo, Maria Rita
   Cabodi, Sara
   Petrini, Barbara
   Balercia, Giancarlo
   Giacchetti, Gilberta
TI Pro Osteogenic Effect of the Nutraceutical BlastiMin Complex® in Women
   with Osteoporosis or Osteopenia: An Open Intervention Clinical Trial
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE osteoporosis; nutraceuticals; osteoblasts; P1NP; CTX; BMD; CRP
ID SIGNALING PATHWAYS; BONE; MANAGEMENT; DIFFERENTIATION; DIAGNOSIS;
   MARKERS; DENSITY
AB Osteoporosis is a chronic disease that affects millions of patients worldwide and is characterized by low bone mineral density (BMD) and increased risk of fractures. Notably, natural molecules can increase BMD and exert pro osteogenic effects. Noteworthily, the nutraceutical BlastiMin Complex (R) (Mivell, Italy, European Patent Application EP4205733A1) can induce differentiation of human bone marrow mesenchymal stem cells (BM MSCs) in osteoblasts and can exert in vitro pro osteogenic and anti inflammatory effects. Thus, the purpose of this study was to verify the effects of BlastiMin Complex (R) on bone turnover markers (BTMs) and BMD in patients with senile and postmenopausal osteopenia or osteoporosis. The efficacy of BlastiMin Complex (R) on BTMs in serum was evaluated through biochemical assays. BMD values were analyzed by dual energy X ray absorptiometry (DXA) and Radiofrequency Echographic Multi Spectrometry (R.E.M.S.) techniques, and the SNPs with a role in osteoporosis development were evaluated by PCR. Clinical data obtained after 12 months of treatment showed an increase in bone turnover index, a decrease in C reactive protein levels, and a remarkable increase in P1NP levels, indicating the induction of osteoblast proliferation and activity in the cohort of 100% female patients recruited for the study. These findings show that the nutraceutical BlastiMin Complex (R) could be used as an adjuvant in combination with synthetic drugs for the treatment of osteoporosis pathology.
C1 [Sabatelli, Sofia; Giacchetti, Gilberta] Univ Politecn Marche, Dept Clin & Mol Sci, Clin Endocrinol & Metab Dis, I 60126 Ancona, Italy.
   [Scarpa, Emanuele Salvatore] Mivell Srls, R&D Dept, I 61032 Fano, Italy.
   [Giuliani, Angelica; Sabbatinelli, Jacopo; Rippo, Maria Rita] Univ Politecn Marche, Dept Clin & Mol Sci DISCLIMO, I 60126 Ancona, Italy.
   [Giordani, Chiara; Sabbatinelli, Jacopo] IRCCS Ist Nazl Ricovero & Cura Anziani INRCA, Clin Lab & Precis Med, I 60126 Ancona, Italy.
   [Cabodi, Sara; Petrini, Barbara] Diatech Pharmacogenet Srl, R&D Dept, I 60035 Jesi, Italy.
   [Balercia, Giancarlo] Univ Politecn Marche, Dept Clin & Mol Sci, Div Endocrinol, I 60126 Ancona, Italy.
C3 Marche Polytechnic University; Marche Polytechnic University; Marche
   Polytechnic University
RP Giacchetti, G (通讯作者)，Univ Politecn Marche, Dept Clin & Mol Sci, Clin Endocrinol & Metab Dis, I 60126 Ancona, Italy.
EM s.sabatelli@pm.univpm.it; e.scarpa@mivell.com;
   angelica.giuliani@staff.univpm.it; j.sabbatinelli@staff.univpm.it;
   m.r.rippo@staff.univpm.it; sara.cabodi@diatechpharmacogenetics.com;
   barbara.petrini@diatechpharmacogenetics.com;
   giancarlo.balercia@ospedaliriuniti.marche.it;
   gilberta.giacchetti@ospedaliriuniti.marche.it
RI Giuliani, Angelica/AAB 9024 2019; Sabbatinelli, Jacopo/U 1851 2018
FU European Union POR MARCHE FESR 2014/2020 [MARCHE FESR 2014/2020,
   I34I19007170007]; European Union POR
FX This research was funded by the European Union POR MARCHE FESR 2014/2020
   (Grant code: I34I19007170007) Asse 1, OS 2, Azione 2.1 Intervento
   2.1.1 Development of a collaborative platform in the field of
   personalized medicine, drugs, and new therapeutic approaches. Project
   acronym: Marche BioBank, www.marchebiobank.it. The content of the paper
   is the sole responsibility of the authors and can under no circumstances
   be regarded as reflecting the position of the European Union and/or
   Marche Region authorities.
CR Akkawi Ibrahim, 2018, Joints, V6, P122, DOI 10.1055/s 0038 1660790
   [Anonymous], European Patent Application, Patent No. [EP4205733A1, 4205733, 4205733A1]
   Bi JM, 2024, J AUTOIMMUN, V143, DOI 10.1016/j.jaut.2024.103169
   Camacho PM, 2016, ENDOCR PRACT, V22, P1, DOI 10.4158/EP161435.GL
   Casas Avila L, 2019, GYNECOL ENDOCRINOL, V35, P981, DOI 10.1080/09513590.2019.1613641
   Chau JFL, 2009, HISTOL HISTOPATHOL, V24, P1593, DOI 10.14670/HH 24.1593
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Genant HK, 1999, OSTEOPOROSIS INT, V10, P259, DOI 10.1007/s001980050224
   Gioia A, 2014, J ENDOCRINOL INVEST, V37, P1225, DOI 10.1007/s40618 014 0187 1
   Giordani C, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24108820
   Giovanni A, 2024, AGING CLIN EXP RES, V36, DOI 10.1007/s40520 024 02728 4
   Greenblatt MB, 2017, CLIN CHEM, V63, P464, DOI 10.1373/clinchem.2016.259085
   Han YJ, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0019 6
   Henriksen K, 2011, ENDOCR REV, V32, P31, DOI 10.1210/er.2010 0006
   Infante A, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0995 x
   Josse AR, 2020, PEDIATR RES, V88, P910, DOI 10.1038/s41390 020 0834 5
   Joung YH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159891
   Jówko E, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24043373
   Kanis JA, 2008, OSTEOPOROSIS INT, V19, P399, DOI 10.1007/s00198 008 0560 z
   Karimi SM, 2024, J TRADIT COMPL MED, V14, P1, DOI 10.1016/j.jtcme.2023.08.001
   Kim B, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10815
   Kuo TR, 2017, BIOMARK RES, V5, DOI 10.1186/s40364 017 0097 4
   Kurotaki D, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115471
   Langdahl BL, 2021, BRIT J PHARMACOL, V178, P1891, DOI 10.1111/bph.15024
   Li HX, 2021, CURR MED CHEM, V28, P1489, DOI 10.2174/0929867327666200330142432
   Li X, 2014, YONSEI MED J, V55, P912, DOI 10.3349/ymj.2014.55.4.912
   Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287
   Mansournia MA, 2017, EPIDEMIOLOGY, V28, P54, DOI 10.1097/EDE.0000000000000564
   Moradifard S, 2020, MUTAT RES REV MUTAT, V786, DOI 10.1016/j.mrrev.2020.108339
   Mun H, 2021, OSTEOPOROSIS INT, V32, P425, DOI 10.1007/s00198 020 05623 6
   Noh JY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207623
   Nuti R, 2019, INTERN EMERG MED, V14, P85, DOI 10.1007/s11739 018 1874 2
   Park JH, 2017, MOL CELLS, V40, P706
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Qaseem A, 2008, ANN INTERN MED, V149, P404, DOI 10.7326/0003 4819 149 6 200809160 00007
   Rucci N, 2008, CLIN CASES MINER BON, V5, P49
   Snpedia, SNPedia Database
   Szulc P, 2008, OSTEOPOROSIS INT, V19, P1683, DOI 10.1007/s00198 008 0660 9
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tu Kristie N, 2018, P T, V43, P92
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   Urano T, 2014, BIOCHEM BIOPH RES CO, V452, P287, DOI 10.1016/j.bbrc.2014.07.141
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Weaver Connie M., 2012, Journal of Nutrition in Gerontology and Geriatrics, V31, P239, DOI 10.1080/21551197.2012.698220
   Wong RHX, 2020, J BONE MINER RES, V35, P2121, DOI 10.1002/jbmr.4115
   Wu J, 2016, BIOMED REP, V5, P233, DOI 10.3892/br.2016.697
   Yunaini L., 2018, OnLine J. Biol. Sci, V18, P358, DOI [10.3844/ojbsci.2018.358.364, DOI 10.3844/OJBSCI.2018.358.364]
   Zhou H., 2020, Marcus and Feldmans Osteoporosis, VVolume 76, P1835
   Zmuda J. M., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P3
NR 49
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2024
VL 25
IS 16
AR 8565
DI 10.3390/ijms25168565
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA F0W1O
UT WOS:001307099100001
PM 39201253
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Johnston, S
   Andrews, S
   Shen, V
   Cosman, F
   Lindsay, R
   Dempster, DW
   Iida Klein, A
AF Johnston, Sara
   Andrews, Sharon
   Shen, Victor
   Cosman, Felicia
   Lindsay, Robert
   Dempster, David W.
   Iida Klein, Akiko
TI The effects of combination of alendronate and human parathyroid
   hormone(1 34) on bone strength are synergistic in the lumbar vertebra
   and additive in the femur of C57BL/6J mice
SO ENDOCRINOLOGY
LA English
DT Article
ID POSTMENOPAUSAL WOMEN; IN VIVO; OSTEOPOROSIS; BISPHOSPHONATES;
   TERIPARATIDE; RESORPTION; PERIOSTEAL; ESTROGEN; FRACTURE; THERAPY
AB Acyclic PTH regimen is as effective as a daily regimen on bone density gain in humans and in improving bone quality in mice. Our previous murine study evaluated the effects of a cyclic PTH regimen in the absence of a bisphosphonate, whereas our human study addressed the effects of a cyclic PTH regimen in the presence of ongoing alendronate (ALN) treatment. Accordingly, the current study examined the effects of cyclic or daily PTH regimens in combination with ALN on bone quality and bone density in mice. Twenty week old, female C57BL/6J mice were treated with the following sc injections (n = 10): 1) vehicle for 5 d/wk ( control); 2) ALN ( 20 mu g/kg.d) 3 d/wk ( ALN); 3) human PTH( 1 34) ( 40 mu g/kg.d) 5 d/wk ( daily PTH); 4) daily PTH in addition to ALN ( daily PTH plus ALN); 5) PTH 5 d/wk and vehicle 5 d/wk alternating weekly ( cyclic PTH); 6) cyclic PTH in addition to ALN(cyclic PTH plus ALN); and 7) PTH and ALN alternating weekly (alt PTH and ALN). Bone mineral density was measured weekly by dual energy x ray absorptiometry, and at 7 wk, bone markers, bone structure, and bone strength were evaluated by biochemical assays, peripheral quantitative computed tomography and mechanical testing, respectively. At 7 wk, all treatments significantly increased femoral and vertebral bone mineral density. ALN slightly decreased endosteal circumference, whereas PTH increased periosteal circumference, resulting in significant increases in femoral cortical thickness in all groups. PTH and ALN enhanced bone strength synergistically in the lumbar vertebrae and additively in the femur. Combined therapy, however, had no effects on bone markers. The results show that combinations of ALN and PTH, in both daily and cyclic regimens, produce more beneficial effects than treatment with either agent alone, suggesting that the mechanisms of actions of ALN and PTH on bone quality may be complementary.
C1 Helen Hayes Hosp, Reg Bone Ctr, W Haverstraw, NY 10993 USA.
   Helen Hayes Hosp, Clin Res Ctr, W Haverstraw, NY 10993 USA.
   MDS Pharma Serv Inc, Bothell, WA 98021 USA.
   Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA.
   Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA.
C3 Columbia University; Columbia University
RP Iida Klein, A (通讯作者)，Helen Hayes Hosp, Reg Bone Ctr, 51 N Route 9W, W Haverstraw, NY 10993 USA.
EM iida kleina@helenhayeshosp.org
CR Allen MR, 2006, CALCIFIED TISSUE INT, V79, P255, DOI 10.1007/s00223 006 0031 5
   Aultman CD, 2004, SPINE, V29, pE304, DOI 10.1097/01.BRS.0000132515.21703.38
   Bare S, 2005, J BONE MINER RES, V20, pS274
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   BONE CM, 2005, AGING SPINE, P8
   BORG U, 2004, P 21 INT C THEOR APP
   Chapurlat RD, 2006, NAT CLIN PRACT ENDOC, V2, P211, DOI 10.1038/ncpendmet0121
   Cosman F, 2005, NEW ENGL J MED, V353, P566, DOI 10.1056/NEJMoa050157
   Cosman F, 2001, J BONE MINER RES, V16, P925, DOI 10.1359/jbmr.2001.16.5.925
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   DELMAS PD, 1995, BONE, V16, P603, DOI 10.1016/8756 3282(95)00113 R
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   Finkelstein JS, 2006, J CLIN ENDOCR METAB, V91, P2882, DOI 10.1210/jc.2006 0190
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Fisher JE, 2000, ENDOCRINOLOGY, V141, P4793, DOI 10.1210/en.141.12.4793
   Gardiner EM, 2000, FASEB J, V14, P1908, DOI 10.1096/fj.99 1075com
   Gasser J. A., 2000, Journal of Musculoskeletal & Neuronal Interactions, V1, P53
   Girotra M, 2006, REV ENDOCR METAB DIS, V7, P113, DOI 10.1007/s11154 006 9007 z
   HODSMAN AB, 1993, BONE, V14, P523, DOI 10.1016/8756 3282(93)90190 L
   Iida Klein A, 2005, J ENDOCRINOL, V186, P549, DOI 10.1677/joe.1.06270
   Iida Klein A, 2003, J CLIN DENSITOM, V6, P25, DOI 10.1385/JCD:6:1:25
   Iida Klein A, 2002, J BONE MINER RES, V17, P808, DOI 10.1359/jbmr.2002.17.5.808
   Iida Klein A, 2006, J BONE MINER RES, V21, P274, DOI 10.1359/JBMR.051017
   Iida Klein A, 2007, BONE, V40, P391, DOI 10.1016/j.bone.2006.09.010
   Ishizuya T, 1997, J CLIN INVEST, V99, P2961, DOI 10.1172/JCI119491
   Iwata K, 2006, BONE, V39, P1053, DOI 10.1016/j.bone.2006.05.006
   Jerome CP, 1999, BONE, V25, P301, DOI 10.1016/S8756 3282(99)00166 0
   Kim YH, 2002, EXP MOL MED, V34, P145, DOI 10.1038/emm.2002.21
   Li Mei, 2005, Zhonghua Yi Xue Za Zhi, V85, P335
   Lindsay R, 2006, J BONE MINER RES, V21, P366, DOI 10.1359/JBMR.051109
   Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140 6736(97)02342 8
   Lindsay R, 2007, J BONE MINER RES, V22, P495, DOI 10.1359/JBMR.070104
   Ma YFL, 2006, J BONE MINER RES, V21, P855, DOI 10.1359/JBMR.060314
   Ma YFL, 2003, ENDOCRINOLOGY, V144, P2008, DOI 10.1210/en.2002 221061
   Martin TJ, 2007, CLIN SCI, V112, P77, DOI 10.1042/CS20060046
   Mitlak BH, 1996, J BONE MINER RES, V11, P430
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Pettway GJ, 2006, J BONE MINER RES, V21, pS114
   Porras AG, 1999, CLIN PHARMACOKINET, V36, P315, DOI 10.2165/00003088 199936050 00002
   REEVE J, 1990, BMJ BRIT MED J, V301, P314, DOI 10.1136/bmj.301.6747.314
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Samadfam R, 2007, ENDOCRINOLOGY, V148, P2778, DOI 10.1210/en.2006 1475
   Samadfam R, 2007, J BONE MINER RES, V22, P55, DOI 10.1359/JBMR.060915
   Turner RT, 2007, J BONE MINER RES, V22, P64, DOI 10.1359/JBMR.061006
   YATES AJP, 1988, J CLIN INVEST, V81, P932, DOI 10.1172/JCI113406
NR 46
TC 29
Z9 33
U1 0
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD SEP
PY 2007
VL 148
IS 9
BP 4466
EP 4474
DI 10.1210/en.2007 0229
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 200UX
UT WOS:000248789400041
PM 17569757
OA Bronze
DA 2025 08 17
ER

PT J
AU Filik, Y
   Bauer, K
   Hadzijusufovic, E
   Haider, P
   Greiner, G
   Witzeneder, N
   Hoermann, G
   Hohensinner, PJ
   Gleixner, KV
   Wojta, J
   Sperr, WR
   Valent, P
AF Filik, Yuksel
   Bauer, Karin
   Hadzijusufovic, Emir
   Haider, Patrick
   Greiner, Georg
   Witzeneder, Nadine
   Hoermann, Gregor
   Hohensinner, Philipp J.
   Gleixner, Karoline, V
   Wojta, Johann
   Sperr, Wolfgang R.
   Valent, Peter
TI PI3 kinase inhibition as a strategy to suppress the leukemic stem cell
   niche in Ph plus chronic myeloid leukemia
SO AMERICAN JOURNAL OF CANCER RESEARCH
LA English
DT Article
DE CML; BCR ABL1 inhibitors; leukemic stem cells; drug resistance; stem
   cell niche; PI3 kinase; mTOR; precision medicine
ID BONE MARROW MICROENVIRONMENT; ABL TYROSINE KINASE; BCR ABL; SELECTIVE
   INHIBITOR; IMATINIB; MECHANISMS; RESISTANCE; BIOLOGY; EXPRESSION;
   NILOTINIB
AB Recent data suggest that the disease associated microenvironment, known as the leukemic stem cell (LSC) niche, is substantially involved in drug resistance of LSC in BCR ABL1(+) chronic myeloid leukemia (CML). Attacking the LSC niche in CML may thus be an effective approach to overcome drug resistance. We have recently shown that osteoblasts are a major site of niche mediated LSC resistance against second  and third generation tyrosine kinase inhibitors (TKI) in CML. In the present study, we screened for drugs that are capable of suppressing the growth and viability of osteoblasts and/or other niche cells and can thereby overcome TKI resistance of CML LSC. Proliferation was analyzed by determining H 3 thymidine uptake in niche related cells, and apoptosis was measured by Annexin V/DAPI staining and flow cytometry. We found that the dual PI3 kinase (PI3K) and mTOR inhibitor BEZ235 and the selective pan PI3K inhibitor copanlisib suppress proliferation of primary osteoblasts (BEZ235 IC50 : 0.05 mu M; copanlisib IC50 : 0.05 mu M), the osteoblast cell line CAL 72 (BEZ235 IC50 : 0.5 mu M; copanlisib IC50 : 1 mu M), primary umbilical vein derived endothelial cells (BEZ235 IC50 : 0.5 mu M; copanlisib IC50 : 0.5 mu M), and the vascular endothelial cell line H MEC 1 (BEZ235 IC50 : 1 mu M; copanlisib IC50 : 1 mu M), whereas no comparable effects were seen with the mTOR inhibitor rapamycin. Furthermore, we show that BEZ235 and copanlisib cooperate with nilotinib and ponatinib in suppressing proliferation and survival of osteoblasts and endothelial cells. Finally, BEZ235 and copanlisib were found to overcome osteoblast mediated resistance against nilotinib and ponatinib in K562 cells, KU812 cells and primary CD34(+)/CD38( ) CML LSC. Together, targeting osteoblastic niche cells through PI3K inhibition may be a new effective approach to overcome niche induced TKI resistance in CML. Whether this approach can be translated into clinical application and can counteract drug resistance of LSC in patients with CML remains to be determined in clinical trials.
C1 [Filik, Yuksel; Bauer, Karin; Hadzijusufovic, Emir; Greiner, Georg; Witzeneder, Nadine; Hoermann, Gregor; Gleixner, Karoline, V; Sperr, Wolfgang R.; Valent, Peter] Med Univ Vienna, Ludwig Boltzmann Inst Hematol & Oncol, Waehringer Guertel 18 20, A 1090 Vienna, Austria.
   [Filik, Yuksel; Bauer, Karin; Hadzijusufovic, Emir; Gleixner, Karoline, V; Sperr, Wolfgang R.; Valent, Peter] Med Univ Vienna, Div Hematol & Hemostaseol, Dept Internal Med 1, Waehringer Guertel 18 20, A 1090 Vienna, Austria.
   [Hadzijusufovic, Emir] Univ Vet Med Vienna, Clin Unit Internal Med, Clin Small Anim, Dept Clin Compan Anim & Horses, Vienna, Austria.
   [Haider, Patrick; Hohensinner, Philipp J.; Wojta, Johann] Med Univ Vienna, Div Cardiol, Dept Internal Med 2, Vienna, Austria.
   [Greiner, Georg; Witzeneder, Nadine; Hoermann, Gregor] Med Univ Vienna, Dept Lab Med, Vienna, Austria.
   [Greiner, Georg] Med Diagnost Labs, Ihr Lab, Vienna, Austria.
   [Hoermann, Gregor] MLL Munich Leukemia Lab, Munich, Germany.
   [Wojta, Johann] Med Univ Vienna, Ludwig Boltzmann Inst Cardiovasc Res, Vienna, Austria.
C3 Ludwig Boltzmann Institute; Medical University of Vienna; Medical
   University of Vienna; University of Veterinary Medicine Vienna; Medical
   University of Vienna; Medical University of Vienna; MLL Munich Leukemia
   Laboratory; Medical University of Vienna; Ludwig Boltzmann Institute
RP Valent, P (通讯作者)，Med Univ Vienna, Ludwig Boltzmann Inst Hematol & Oncol, Waehringer Guertel 18 20, A 1090 Vienna, Austria.; Valent, P (通讯作者)，Med Univ Vienna, Div Hematol & Hemostaseol, Dept Internal Med 1, Waehringer Guertel 18 20, A 1090 Vienna, Austria.
EM peter.valent@meduniwien.ac.at
RI ; Haider, Patrick/CAI 2389 2022; Hoermann, Gregor/B 8832 2016; Wojta,
   Johann/AAC 8433 2020
OI Hohensinner, Philipp/0000 0003 4819 3190; Hoermann,
   Gregor/0000 0002 7374 4380; Sperr, Wolfgang/0000 0003 3288 8027
FU Austrian Science Fund (FWF) [F4704 B20, P30625 B28]; Austrian Science
   Fund (FWF) [P30625] Funding Source: Austrian Science Fund (FWF)
FX We would like to thank Christina Schewzik, Anna Katharina Schruef,
   Christian Milosits and Gabriele Stefanzl for excellent technical
   assistance. This study was supported by the Austrian Science Fund (FWF),
   grants No. F4704 B20 and P30625 B28.
CR ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523 1747.ep12613748
   Agarwal P, 2019, CELL STEM CELL, V24, P769, DOI 10.1016/j.stem.2019.02.018
   Agarwal P, 2015, ADV CANCER RES, V127, P227, DOI 10.1016/bs.acr.2015.04.007
   Aguayo A, 2000, BLOOD, V96, P2240, DOI 10.1182/blood.V96.6.2240.h8002240_2240_2245
   Airiau K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.309
   Arlinghaus Ralph, 2004, Cancer Treat Res, V119, P239
   Arrigoni E, 2018, STEM CELL TRANSL MED, V7, P305, DOI 10.1002/sctm.17 0175
   Barnes DJ, 2006, CELL CYCLE, V5, P2862, DOI 10.4161/cc.5.24.3573
   Bhatia Ravi, 2019, Trans Am Clin Climatol Assoc, V130, P246
   Branford S, 2011, CURR OPIN HEMATOL, V18, P111, DOI 10.1097/MOH.0b013e32834399ef
   Busch C, 2019, BIOCHEM SOC T, V47, P1307, DOI 10.1042/BST20190221
   Chen JQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130627
   Corbin AS, 2011, J CLIN INVEST, V121, P396, DOI 10.1172/JCI35721
   Cortes J, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045 021 01055 9
   Cortes JE, 2018, BLOOD, V132, P393, DOI 10.1182/blood 2016 09 739086
   Covarrubias AJ, 2015, SEMIN IMMUNOL, V27, P286, DOI 10.1016/j.smim.2015.08.001
   Deininger Michael, 2008, J Natl Compr Canc Netw, V6 Suppl 2, pS11
   Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343
   Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596 561
   Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401
   Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867
   Eisenwort G, 2019, LEUKEMIA, V33, P2673, DOI 10.1038/s41375 019 0460 6
   Elrick LJ, 2005, BLOOD, V105, P1862, DOI 10.1182/blood 2004 08 3373
   Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306
   Ghosh J, 2016, CURR STEM CELL REP, V2, P368, DOI 10.1007/s40778 016 0067 z
   Gleixner KV, 2019, LEUKEMIA RES, V78, P36, DOI 10.1016/j.leukres.2018.12.013
   Gover Proaktor A, 2017, LEUKEMIA LYMPHOMA, V58, P1455, DOI 10.1080/10428194.2016.1239258
   Guerrouahen BS, 2011, STEM CELLS INT, V2011, DOI 10.4061/2011/375857
   Hadzijusufovic E, 2017, LEUKEMIA, V31, P2388, DOI 10.1038/leu.2017.245
   Hadzijusufovic E, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.1883.1883
   Haguet H, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01007
   Herrmann H, 2014, BLOOD, V123, P3951, DOI 10.1182/blood 2013 10 536078
   Hochhaus A, 2020, LEUKEMIA, V34, P1495, DOI 10.1038/s41375 020 0842 9
   Hohensinner PJ, 2017, ARTERIOSCL THROM VAS, V37, P1913, DOI 10.1161/ATVBAHA.117.309383
   Huang WS, 2010, J MED CHEM, V53, P4701, DOI 10.1021/jm100395q
   Hughes TP, 2019, NEW ENGL J MED, V381, P2315, DOI 10.1056/NEJMoa1902328
   Jabbour E, 2018, AM J HEMATOL, V93, P442, DOI 10.1002/ajh.25011
   Jabbour E, 2015, CL LYMPH MYELOM LEUK, V15, P323, DOI 10.1016/j.clml.2015.03.006
   Jiang X, 2007, LEUKEMIA, V21, P926, DOI 10.1038/sj.leu.2404609
   Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573
   Kantarjian H, 2006, NEW ENGL J MED, V354, P2542, DOI 10.1056/NEJMoa055104
   Kantarjian Hagop, 2008, J Natl Compr Canc Netw, V6 Suppl 2, pS37
   Karar J, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00051
   Karp JE, 2004, CLIN CANCER RES, V10, P3577, DOI 10.1158/1078 0432.CCR 03 0627
   Konopleva MY, 2011, J CLIN ONCOL, V29, P591, DOI 10.1200/JCO.2010.31.0904
   Korkolopoulou P, 2003, LEUKEMIA, V17, P89, DOI 10.1038/sj.leu.2402769
   Martelli AM, 2010, BBA MOL CELL RES, V1803, P991, DOI 10.1016/j.bbamcr.2010.04.005
   Melo JV, 2004, HEMATOL ONCOL CLIN N, V18, P545, DOI 10.1016/j.hoc.2004.03.008
   Nair RR, 2010, BIOCHEM PHARMACOL, V80, P602, DOI 10.1016/j.bcp.2010.04.003
   O'Hare T, 2007, BLOOD, V110, P2242, DOI 10.1182/blood 2007 03 066936
   Osman AEG, 2021, BLOOD REV, V49, DOI 10.1016/j.blre.2021.100825
   Patel AB, 2017, HEMATOL ONCOL CLIN N, V31, P589, DOI 10.1016/j.hoc.2017.04.007
   Peter B, 2018, BLOOD, V132, DOI 10.1182/blood 2018 99 111126
   Rix U, 2007, BLOOD, V110, P4055, DOI 10.1182/blood 2007 07 102061
   Romero D, 2020, NAT REV CLIN ONCOL, V17, P135, DOI 10.1038/s41571 019 0324 z
   Sattler M, 1996, ONCOGENE, V12, P839
   Schepers K, 2015, CELL STEM CELL, V16, P254, DOI 10.1016/j.stem.2015.02.014
   Shah M, 2018, ADV EXP MED BIOL, V1100, P97, DOI 10.1007/978 3 319 97746 1_6
   Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480
   Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118
   Sillaber C, 2004, EUR J CLIN INVEST, V34, P2, DOI 10.1111/j.0960 135X.2004.01365.x
   Singh P, 2021, MED ONCOL, V38, DOI 10.1007/s12032 021 01462 5
   Soverini S, 2015, CL LYMPH MYELOM LEUK, V15, pS120, DOI 10.1016/j.clml.2015.02.035
   Sugimoto K, 2016, SCI REP UK, V6, DOI 10.1038/srep30779
   Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMoa055229
   Toofan P, 2014, BIOCHEM SOC T, V42, P809, DOI 10.1042/BST20140037
   Valent P, 2011, CURR CANCER DRUG TAR, V11, P56, DOI 10.2174/156800911793743655
   Valent P, 2008, BRIT J HAEMATOL, V142, P361, DOI 10.1111/j.1365 2141.2008.07197.x
   Valent P, 2020, SEMIN CANCER BIOL, V60, P191, DOI 10.1016/j.semcancer.2019.07.025
   Valent P, 2017, LEUKEMIA RES, V59, P47, DOI 10.1016/j.leukres.2017.05.008
   Valent P, 2015, BLOOD, V125, P901, DOI 10.1182/blood 2014 09 594432
   Weisberg E, 2005, CANCER CELL, V7, P129, DOI 10.1016/j.ccr.2005.01.007
   Weisberg E, 2007, NAT REV CANCER, V7, P345, DOI 10.1038/nrc2126
   Wylie AA, 2017, NATURE, V543, P733, DOI 10.1038/nature21702
   Zahiragic L, 2007, LEUKEMIA, V21, P1310, DOI 10.1038/sj.leu.2404632
   Zhou HS, 2016, CANCER BIOL MED, V13, P248, DOI 10.20892/j.issn.2095 3941.2016.0023
NR 76
TC 5
Z9 5
U1 0
U2 2
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 2156 6976
J9 AM J CANCER RES
JI Am. J. Cancer Res.
PY 2021
VL 11
IS 12
BP 6042
EP +
PG 28
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA YA5CR
UT WOS:000738351400018
PM 35018241
DA 2025 08 17
ER

PT J
AU Ketteler, M
   Block, GA
   Evenepoel, P
   Fukagawa, M
   Herzog, CA
   McCann, L
   Moe, SM
   Shroff, R
   Tonelli, MA
   Toussaint, ND
   Vervloet, MG
   Leonard, MB
AF Ketteler, Markus
   Block, Geoffrey A.
   Evenepoel, Pieter
   Fukagawa, Masafumi
   Herzog, Charles A.
   McCann, Linda
   Moe, Sharon M.
   Shroff, Rukshana
   Tonelli, Marcello A.
   Toussaint, Nigel D.
   Vervloet, Marc G.
   Leonard, Mary B.
TI Executive summary of the 2017 KDIGO Chronic Kidney Disease Mineral and
   Bone Disorder (CKD MBD) Guideline Update: what's changed and why it
   matters
SO KIDNEY INTERNATIONAL
LA English
DT Article
DE bone mineral density; calcium; dialysis; hyperparathyroidism;
   hyperphosphatemia; KDIGO CKD MBD Guideline; kidney transplantation
AB The KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of CKD MBD represents a selective update of the prior CKD MBD Guideline published in 2009. This update, along with the 2009 publication, is intended to assist the practitioner caring for adults and children with chronic kidney disease (CKD), those on chronic dialysis therapy, or individuals with a kidney transplant. This review highlights key aspects of the 2017 CKD MBD Guideline Update, with an emphasis on the rationale for the changes made to the original guideline document. Topic areas encompassing updated recommendations include diagnosis of bone abnormalities in CKD mineral and bone disorder (MBD), treatment of CKD MBD by targeting phosphate lowering and calcium maintenance, treatment of abnormalities in parathyroid hormone in CKD MBD, treatment of bone abnormalities by antiresorptives and other osteoporosis therapies, and evaluation and treatment of kidney transplant bone disease.
C1 [Ketteler, Markus] Klinikum Coburg, Coburg, Germany.
   [Block, Geoffrey A.] Denver Nephrol, Denver, CO USA.
   [Evenepoel, Pieter] Univ Hosp Leuven, Leuven, Belgium.
   [Fukagawa, Masafumi] Tokai Univ, Sch Med, Isehara, Kanagawa, Japan.
   [Herzog, Charles A.] Hennepin Cty Med Ctr, Minneapolis, MN USA.
   [Moe, Sharon M.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
   [Moe, Sharon M.] Roudebush Vet Affairs Med Ctr, Indianapolis, IN USA.
   [Shroff, Rukshana] Great Ormond St Hosp Children NHS Fdn Trust, London, England.
   [Tonelli, Marcello A.] Univ Calgary, Calgary, AB, Canada.
   [Toussaint, Nigel D.] Univ Melbourne, Royal Melbourne Hosp, Melbourne, Vic, Australia.
   [Vervloet, Marc G.] VU Univ Med Ctr Amsterdam, Amsterdam, Netherlands.
   [Leonard, Mary B.] Stanford Univ, Sch Med, Stanford, CA USA.
C3 Klinikum Coburg; KU Leuven; University Hospital Leuven; Tokai
   University; Hennepin County Medical Center; Indiana University System;
   Indiana University Bloomington; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); Richard L. Roudebush VA Medical
   Center; University of London; University College London; Great Ormond
   Street Hospital for Children NHS Foundation Trust; University of
   Calgary; Melbourne Health; Royal Melbourne Hospital; University of
   Melbourne; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER;
   Stanford University
RP Ketteler, M (通讯作者)，Klinikum Coburg GmbH, Div Nephrol, Ketschendorfer St 33, D 96450 Coburg, Germany.; Leonard, MB (通讯作者)，Stanford Univ, Sch Med, 300 Pasteur Dr,Room G 306, Stanford, CA 94305 USA.
EM markus.ketteler@klinikum coburg.de; leonard5@stanford.edu
RI ; Tonelli, Marcello/B 3028 2009; Block, Geoffrey/AAV 8070 2021;
   Vervoort, G.M.M./L 4718 2015; Meijers, Bjorn/D 6169 2018; P,
   Evenepoel/D 9597 2018; Shroff, Rukshana/AAG 5383 2019; Shroff,
   Rukshana/C 7347 2008
OI Fukagawa, Masafumi/0000 0002 7832 2339; Tonelli,
   Marcello/0000 0002 0846 3187; Vervloet, Marc/0000 0003 4607 9415;
   Meijers, Bjorn/0000 0002 2846 2026; Leonard, Mary/0000 0002 8972 6582;
   Shroff, Rukshana/0000 0001 8501 1072
FU Kidney Research UK [RP39/2013] Funding Source: researchfish; National
   Institute for Health Research [CDF 2016 09 038] Funding Source:
   researchfish; Department of Health [CDF 2016 09 038] Funding Source:
   Medline
CR Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017
   Ketteler M, 2015, KIDNEY INT, V87, P502, DOI 10.1038/ki.2014.425
   Kidney Dis Improving Global, 2017, KIDNEY INT SUPPL, V7, P1, DOI 10.1016/j.kisu.2017.04.001
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
NR 4
TC 714
Z9 772
U1 6
U2 58
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0085 2538
EI 1523 1755
J9 KIDNEY INT
JI Kidney Int.
PD JUL
PY 2017
VL 92
IS 1
BP 26
EP 36
DI 10.1016/j.kint.2017.04.006
PG 11
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA EY2UH
UT WOS:000403827000010
PM 28646995
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Journé, F
   Kheddoumi, N
   Chaboteaux, C
   Duvillier, H
   Laurent, G
   Body, JJ
AF Journe, Fabrice
   Kheddoumi, Naima
   Chaboteaux, Carole
   Duvillier, Hugues
   Laurent, Guy
   Body, Jean Jacques
TI Extracellular calcium increases bisphosphonate induced growth inhibition
   of breast cancer cells
SO BREAST CANCER RESEARCH
LA English
DT Article
ID IN VITRO; BONE METASTASES; MACROPHAGES; OSTEOCLASTS; APOPTOSIS; LINES;
   MAGNESIUM(II); IBANDRONATE; ALENDRONATE; MECHANISMS
AB Introduction Bisphosphonates have become standard therapy for the treatment of skeletal complications related to breast cancer. Although their therapeutic effects mainly result from an inhibition of osteoclastic bone resorption, in vitro data indicate that they also act directly on breast cancer cells, inhibiting proliferation and inducing apoptosis.
   Methods The present study examined the effects of calcium (from 0.6 to 2.0 mmol/l) on the antitumour activity of the bisphosphonate ibandronate (1 to 1,000 nmol/l) on MDA MB231 and MCF 7 breast cancer cells. Cell culture densities were determined using crystal violet staining assay. Apoptotic cell death was assessed by annexin V phycoerythrin and 7 aminoactinomycin double staining.
   Results At low calcium concentration, 30 mu mol/l ibandronate had no effect on MDA MB 231 cells growth and only slightly inhibited MCF 7 cells growth. Higher calcium levels significantly increased growth inhibition as well as cell apoptosis induced by ibandronate. We observed similar effects with zoledronic acid. Of note, enhancement of ibandronate induced growth inhibition was also observed in other breast cancer cell lines (T 47D, ZR75, Hs 578T and BT 549 cells). The growth inhibitory effect of ibandronate in the presence of high concentrations of calcium was partly suppressed by the calcium chelator EGTA (ethylene glycol tetra acetic acid). In addition, in the presence of calcium at high concentrations, cells accumulated more [(14)C] ibandronate than at low calcium concentrations. We obtained further evidence of enhancement of cellular ibandronate accumulation by calcium by demonstrating that high calcium levels increased the inhibition of protein prenylation induced by the bisphosphonate.
   Conclusion Altogether, our data suggest that extracellular calcium, probably through its binding to ibandronate, markedly increased its cellular accumulation and its inhibitory activity on breast tumour cells. Thus, calcium released during the process of tumour induced osteolysis might enhance the antitumour effects of bisphosphonates and contribute to their therapeutic efficacy.
C1 [Journe, Fabrice; Kheddoumi, Naima; Chaboteaux, Carole; Body, Jean Jacques] Univ Libre Bruxelles, Inst Jules Bordet, Lab Endocrinol & Bone Dis, B 1000 Brussels, Belgium.
   [Duvillier, Hugues] Univ Libre Bruxelles, Inst Jules Bordet, Lab Expt Hematol, B 1000 Brussels, Belgium.
   [Laurent, Guy] Univ Mons, Fac Med & Pharm, Histol Lab, B 7000 Mons, Belgium.
C3 Universite Libre de Bruxelles; Institut Jules Bordet; Institut Jules
   Bordet; Universite Libre de Bruxelles; University of Mons
RP Journé, F (通讯作者)，Univ Libre Bruxelles, Inst Jules Bordet, Lab Endocrinol & Bone Dis, Rue Heger Bordet, B 1000 Brussels, Belgium.
EM fabrice.journe@bordet.be
RI ; Body, Jean Jacques/G 9785 2015; Laurent, Guy/B 6278 2009
OI JOURNE, Fabrice/0000 0001 5051 231X; 
CR Body JJ, 2006, CLIN CANCER RES, V12, p6258S, DOI 10.1158/1078 0432.CCR 06 0840
   Body JJ, 2000, TUMOR BONE DIS OSTEO
   Coxon FP, 2001, J BIOL CHEM, V276, P48213, DOI 10.1074/jbc.M106473200
   Daubiné F, 2007, J NATL CANCER I, V99, P322, DOI 10.1093/jnci/djk054
   Derenne S, 1999, J BONE MINER RES, V14, P2048, DOI 10.1359/jbmr.1999.14.12.2048
   Frith JC, 2003, J BONE MINER RES, V18, P204, DOI 10.1359/jbmr.2003.18.2.204
   Frith JC, 1997, J BONE MINER RES, V12, P1358, DOI 10.1359/jbmr.1997.12.9.1358
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Fromigue O, 2003, BRIT J CANCER, V89, P178, DOI 10.1038/sj.bjc.6601009
   Hiraga T, 2001, CANCER RES, V61, P4418
   Hosfield DJ, 2004, J BIOL CHEM, V279, P8526, DOI 10.1074/jbc.C300511200
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Journe F, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1363
   Journe F, 2004, BRIT J CANCER, V91, P1703, DOI 10.1038/sj.bjc.6602181
   Lacroix M, 1998, CANCER LETT, V127, P29, DOI 10.1016/S0304 3835(97)00542 9
   LAMSON ML, 1984, INT J PHARMACEUT, V21, P143, DOI 10.1016/0378 5173(84)90089 9
   Masarachia P, 1996, BONE, V19, P281, DOI 10.1016/8756 3282(96)00182 2
   Matczak Jon E, 2002, POLYHEDRON, V21, P321, DOI 10.1016/S0277 5387(01)00996 2
   Matczak Jon E, 2006, J INORG BIOCHEM, V100, P1155, DOI 10.1016/j.jinorgbio.2006.01.005
   Merrell M, 2003, BREAST CANCER RES TR, V81, P231, DOI 10.1023/A:1026126430905
   Merrell MA, 2007, EUR J PHARMACOL, V559, P21, DOI 10.1016/j.ejphar.2006.11.064
   MONKKONEN J, 1994, J DRUG TARGET, V2, P299, DOI 10.3109/10611869409015910
   Reinholz GG, 2002, BREAST CANCER RES TR, V71, P257, DOI 10.1023/A:1014418017382
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Rogers MJ, 2004, CALCIFIED TISSUE INT, V75, P451, DOI 10.1007/s00223 004 0024 1
   Sanders JL, 2000, ENDOCRINOLOGY, V141, P4357, DOI 10.1210/en.141.12.4357
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014 4827(88)90191 7
   Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776
   Twiss IM, 1999, J BONE MINER RES, V14, P784, DOI 10.1359/jbmr.1999.14.5.784
   Yin JJ, 2003, P NATL ACAD SCI USA, V100, P10954, DOI 10.1073/pnas.1830978100
   Yu SP, 2001, CURR OPIN CELL BIOL, V13, P405, DOI 10.1016/S0955 0674(00)00228 3
NR 33
TC 12
Z9 12
U1 1
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1465 5411
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2008
VL 10
IS 1
AR R4
DI 10.1186/bcr1845
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 285YF
UT WOS:000254811400011
PM 18190680
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yamashita, S
   Katsumi, H
   Hibino, N
   Isobe, Y
   Yagi, Y
   Tanaka, Y
   Yamada, S
   Naito, C
   Yamamoto, A
AF Yamashita, Shugo
   Katsumi, Hidemasa
   Hibino, Nozomi
   Isobe, Yugo
   Yagi, Yumiko
   Tanaka, Yuka
   Yamada, Saki
   Naito, Chihiro
   Yamamoto, Akira
TI Development of PEGylated aspartic acid modified liposome as a
   bone targeting carrier for the delivery of paclitaxel and treatment of
   bone metastasis
SO BIOMATERIALS
LA English
DT Article
DE Drug delivery; Liposome; Aspartic acid; Bone targeting; Bone metastasis
ID IN VIVO; DRUG DELIVERY; CANCER CELLS; STEM CELLS; OSTEOCLASTS;
   MECHANISMS; RESORPTION; CALCIUM; MARROW; BREAST
AB To prevent bone metastasis, we developed polyethylene glycol (PEG) conjugated aspartic acid (Asp) modified liposomes (PEG Asp Lipo) as a bone targeting carrier of paclitaxel (PTX) by using Asp modified 1,2 dipalmitoyl sn glycero 3 phosphoethanolamine (DPPE Asp). The affinity of Asp modified liposomes to hydroxyapatite increased as the concentration of DPPE Asp increased. The bone accumulation of [H 3] labeled PEG(2) Asp(33) Lipo was approximately 24.6% 360 min after intravenous injection in mice, in contrast to 5.4% and 6.7% of [H 3] labeled normal Lipo and PEG(2) Lipo, respectively. Similarly, [C 14] labeled PTX encapsulated into PEG(2) Asp(33) Lipo predominantly accumulated in the bone. Furthermore, using an in situ imaging experiment, we observed that near infrared fluorescence labeled PEG(2) Asp(33) Lipo selectively accumulated in the bone near the joint after intravenous injection in mice. We also found that FITC labeled PEG(2) Asp(33) Lipo predominantly accumulated on eroded and quiescent bone surfaces. In a bone metastatic tumor mouse model, in which B16 BL6/Luc cells were injected into the left ventricle of female C57BL/6 mice, metastatic bone tumor growth was significantly inhibited by an intravenous injection of PEG(2) Asp(33) liposomal PTX. In contrast, PEGylated liposomal PTX hardly affected the growth of metastatic bone tumors. These findings indicate that PEG(2) Asp(33) Lipo is a promising bone targeting carrier for the delivery of PTX and treatment of bone metastasis. (c) 2017 Elsevier Ltd. All rights reserved.
C1 [Yamashita, Shugo; Katsumi, Hidemasa; Hibino, Nozomi; Isobe, Yugo; Yagi, Yumiko; Tanaka, Yuka; Yamada, Saki; Naito, Chihiro; Yamamoto, Akira] Kyoto Pharmaceut Univ, Dept Biopharmaceut, Yamashina Ku, Kyoto 6078414, Japan.
C3 Kyoto Pharmaceutical University
RP Katsumi, H (通讯作者)，Kyoto Pharmaceut Univ, Dept Biopharmaceut, Yamashina Ku, Kyoto 6078414, Japan.
EM hkatsumi@mb.kyoto phu.ac.jp
FU Kyoto Pharmaceutical University Fund for the Promotion of Scientific
   Research; MEXT Supported Program for the Strategic Research Foundation
   at Private Universities
FX This work was supported by the Kyoto Pharmaceutical University Fund for
   the Promotion of Scientific Research (H.K.) and MEXT Supported Program
   for the Strategic Research Foundation at Private Universities. The
   authors are grateful to Dr.Y. Hattori, Kyoto Pharmaceutical University,
   for his kind help and useful suggestions on MALDI TOF mass spectrometry.
CR Ajabnoor GMA, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.139
   Ames B.N, 1966, Meth. Enzymol, P115, DOI DOI 10.1016/0076 6879(66)08014 5
   Anada T, 2009, BIOORG MED CHEM LETT, V19, P4148, DOI 10.1016/j.bmcl.2009.05.117
   Ang ESM, 2012, J CELL BIOCHEM, V113, P946, DOI 10.1002/jcb.23423
   ARGUELLO F, 1988, CANCER RES, V48, P6876
   Berenson JR, 2001, CANCER, V91, P1191, DOI 10.1002/1097 0142(20010401)91:7<1191::AID CNCR1119>3.0.CO;2 0
   Boissier S, 2000, CANCER RES, V60, P2949
   Choi SW, 2007, J CONTROL RELEASE, V122, P24, DOI 10.1016/j.jconrel.2007.06.003
   COHLAN SQ, 1963, AM J DIS CHILD, V105, P453, DOI 10.1001/archpedi.1963.02080040455005
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Cool SK, 2013, J FLUORESC, V23, P909, DOI 10.1007/s10895 013 1215 9
   Dallas SL, 2002, J BIOL CHEM, V277, P21352, DOI 10.1074/jbc.M111663200
   El Mabhouh A, 2004, CANCER BIOTHER RADIO, V19, P627, DOI 10.1089/cbr.2004.19.627
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   HALL TJ, 1995, CALCIFIED TISSUE INT, V57, P463, DOI 10.1007/BF00301951
   Harrison JS, 2002, BLOOD, V99, P394, DOI 10.1182/blood.V99.1.394
   Hirose M, 2003, KEY ENG MAT, V240 2, P715, DOI 10.4028/www.scientific.net/KEM.240 242.715
   Hoang QQ, 2003, NATURE, V425, P977, DOI 10.1038/nature02079
   Hyoudou K, 2004, CLIN CANCER RES, V10, P7685, DOI 10.1158/1078 0432.CCR 04 1020
   ISHIKAWA Y, 1988, EUR J HAEMATOL, V40, P126
   Karau MJ, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193 1801 2 329
   Katsumi H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135966
   Kawamoto T, 2003, ARCH HISTOL CYTOL, V66, P123, DOI 10.1679/aohc.66.123
   Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911 005 5399 8
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   McCarthy I, 2006, J BONE JOINT SURG AM, V88A, P4, DOI 10.2106/JBJS.F.00890
   Miki T, 2000, ONCOL RES, V12, P209
   Ogawa K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084335
   PEZOA R, 1987, RES COMMUN CHEM PATH, V55, P133
   PORTER CJH, 1992, FEBS LETT, V305, P62, DOI 10.1016/0014 5793(92)80655 Z
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Sánchez AR, 2004, INT J DERMATOL, V43, P709, DOI 10.1111/j.1365 4632.2004.02108.x
   SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014 4827(88)90191 7
   Song SX, 2008, INT J PHARMACEUT, V363, P155, DOI 10.1016/j.ijpharm.2008.07.012
   Takai H, 1998, J BIOL CHEM, V273, P27091, DOI 10.1074/jbc.273.42.27091
   Takegami S, 2008, CHEM PHARM BULL, V56, P1097, DOI 10.1248/cpb.56.1097
   TALMAGE RV, 1970, AM J ANAT, V129, P467, DOI 10.1002/aja.1001290408
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Van Poznak CH, 2011, J CLIN ONCOL, V29, P1221, DOI 10.1200/JCO.2010.32.5209
   Wang D, 2007, BIOCONJUGATE CHEM, V18, P1375, DOI 10.1021/bc7002132
   Xu JK, 2005, J CELL PHYSIOL, V202, P554, DOI 10.1002/jcp.20159
   YAMAOKA K, 1981, J PHARMACOBIO DYNAM, V4, P879, DOI 10.1248/bpb1978.4.879
   Yamashita S, 2017, J CONTROL RELEASE, V262, P10, DOI 10.1016/j.jconrel.2017.07.018
   Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070
   Yoshizawa Y, 2011, INT J PHARMACEUT, V412, P132, DOI 10.1016/j.ijpharm.2011.04.008
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zheng YL, 2012, J PHARM SCI US, V101, P552, DOI 10.1002/jps.22773
NR 47
TC 58
Z9 59
U1 0
U2 132
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD FEB
PY 2018
VL 154
BP 74
EP 85
DI 10.1016/j.biomaterials.2017.10.053
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA FS1MA
UT WOS:000419538900007
PM 29120820
DA 2025 08 17
ER

PT J
AU Gao, B
   Chen, W
   Hao, L
   Zhu, G
   Feng, S
   Ci, H
   Zhou, X
   Stashenko, P
   Li, YP
AF Gao, B.
   Chen, W.
   Hao, L.
   Zhu, G.
   Feng, S.
   Ci, H.
   Zhou, X.
   Stashenko, P.
   Li, Y. P.
TI Inhibiting Periapical Lesions through AAV RNAi Silencing of Cathepsin K
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE endodontic disease; inflammation; bone resorption; dental caries;
   osteoclast; gene therapy
ID PERIODONTAL LIGAMENT CELLS; APICAL PERIODONTITIS; BONE RESORPTION;
   DENTAL PULP; DISEASE; RANKL; GENE; PYCNODYSOSTOSIS; PATHOGENESIS;
   EXPRESSION
AB Dental caries, one of the most prevalent infectious diseases worldwide, affects approximately 80% of children and the majority of adults. Dental caries may result in endodontic disease, leading to dental pulp necrosis, periapical inflammation and bone resorption, severe pain, and tooth loss. Periapical inflammation may also increase inflammation in other parts of the body. Although many studies have attempted to develop therapies for this disease, there is still an urgent need for effective treatments. In this study, we applied a novel gene therapeutic approach using recombinant adeno associated virus (AAV) mediated RNAi knockdown of Cathepsin K (Ctsk) gene expression, to target osteoclasts and periapical bone resorption in a mouse model. We found that AAV sh Cathepsin K (AAV sh Ctsk) impaired osteoclast function in vivo and furthermore reduced bacterial infection stimulated bone resorption by 88%. Reduced periapical lesion size was accompanied by decreases in mononuclear leukocyte infiltration and inflammatory cytokine expression. Our study shows that AAV RNAi silencing of Cathepsin K in periapical tissues can significantly reduce endodontic disease development, bone destruction, and inflammation in the periapical lesion. This is the first demonstration that AAV mediated RNAi knockdown gene therapy may significantly reduce the severity of endodontic disease.
C1 [Gao, B.; Hao, L.; Zhou, X.] Sichuan Univ, W China Coll Stomatol, State Key Lab Oral Dis, Chengdu, Sichuan, Peoples R China.
   [Gao, B.; Chen, W.; Hao, L.; Zhu, G.; Feng, S.; Ci, H.; Li, Y. P.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   [Stashenko, P.] Forsyth Inst, Dept Immunol & Infect Dis, Cambridge, MA USA.
C3 Sichuan University; University of Alabama System; University of Alabama
   Birmingham; Harvard University; Harvard University Medical Affiliates;
   Forsyth Institute
RP Chen, W (通讯作者)，Univ Alabama Birmingham, Dept Pathol, SHEL 810,1825 Univ Blvd, Birmingham, AL 35294 USA.
EM wechen@uab.edu; ypli@uab.edu
RI ; Zhou, Xuedong/LSL 0410 2024
OI Zhou, Xuedong/0000 0002 9319 7302; Hao, Liang/0000 0003 2071 7044; 
FU NIH [RC1 DE 020533 01]
FX We thank Ms. Christie Paulson and Mr. Zach Nolen for their excellent
   assistance with the manuscript. We also thank Drs. Sergei Musatov and
   Sonoko Ogawa for kindly providing the AAV H1 shRNA luc YFP and AAV H1
   vectors and for helpful suggestions. We appreciate the assistance of the
   Center for Metabolic Bone Disease at the University of Alabama at
   Birmingham (P30 AR046031). We are also grateful for the assistance of
   the Small Animal Phenotyping Core, Metabolism Core, and Neuroscience
   Molecular Detection Core Laboratory at the University of Alabama at
   Birmingham (P30 NS0474666). This work was supported by NIH grant
   RC1 DE 020533 01 (Y.P.L.). The authors declare no potential conflicts of
   interest with respect to the authorship and/or publication of this
   article.
CR Alexander B, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001079
   Asagiri M, 2008, SCIENCE, V319, P624, DOI 10.1126/science.1150110
   Buff SM, 2010, GENE THER, V17, P567, DOI 10.1038/gt.2010.28
   Carter BJ, 2005, HUM GENE THER, V16, P541, DOI 10.1089/hum.2005.16.541
   Chen W, 2007, HUM MOL GENET, V16, P410, DOI 10.1093/hmg/ddl474
   Cirelli JA, 2009, GENE THER, V16, P426, DOI 10.1038/gt.2008.174
   Cottard V, 2000, GENE THER, V7, P1930, DOI 10.1038/sj.gt.3301324
   Feng SM, 2009, BIOCHEM J, V417, P195, DOI 10.1042/BJ20081073
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Hommel JD, 2003, NAT MED, V9, P1539, DOI 10.1038/nm964
   KAKEHASHI S, 1965, ORAL SURG ORAL MED O, V20, P340, DOI 10.1016/0030 4220(65)90166 0
   Kamolmatyakul S, 2004, J DENT RES, V83, P791, DOI 10.1177/154405910408301011
   Kaplitt MG, 2007, LANCET, V369, P2097, DOI 10.1016/S0140 6736(07)60982 9
   Kawai T, 2006, AM J PATHOL, V169, P987, DOI 10.2353/ajpath.2006.060180
   Kojima T, 2006, INFLAMM RES, V55, P78, DOI 10.1007/s00011 005 0013 5
   Lin XP, 2011, INFECT IMMUN, V79, P911, DOI 10.1128/IAI.00944 10
   Musatov S, 2006, P NATL ACAD SCI USA, V103, P10456, DOI 10.1073/pnas.0603045103
   Nair PNR, 1997, PERIODONTOL 2000, V13, P121, DOI 10.1111/j.1600 0757.1997.tb00098.x
   Nair PNR, 2004, CRIT REV ORAL BIOL M, V15, P348, DOI 10.1177/154411130401500604
   Oseko F, 2009, MICROBIOL IMMUNOL, V53, P287, DOI 10.1111/j.1348 0421.2009.00123.x
   Ramamurthy HS, 2005, J PERIODONTOL, V76, P229, DOI 10.1902/jop.2005.76.2.229
   Sasaki H, 2000, J IMMUNOL, V165, P3626, DOI 10.4049/jimmunol.165.7.3626
   STASHENKO P, 1990, ENDOD DENT TRAUMATOL, V6, P89
   Uchiyama M, 2009, J DENT RES, V88, P609, DOI 10.1177/0022034509340008
   Ulrich Vinther M, 2007, ACTA ORTHOP, V78, P5
   WANG CY, 1993, J ENDODONT, V19, P107, DOI 10.1016/S0099 2399(06)80503 0
   Yamaguchi M, 2006, J DENT RES, V85, P751, DOI 10.1177/154405910608500812
   Yang SY, 2007, GENE DEV, V21, P1803, DOI 10.1101/gad.1544107
   Yu H, 2011, GENE THER, V18, P344, DOI 10.1038/gt.2010.139
   Zhang L, 2010, GENE THER, V17, P1262, DOI 10.1038/gt.2010.64
NR 30
TC 46
Z9 51
U1 0
U2 22
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD FEB
PY 2013
VL 92
IS 2
BP 180
EP 186
DI 10.1177/0022034512468757
PG 7
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 071XE
UT WOS:000313629700014
PM 23166044
OA Green Published
DA 2025 08 17
ER

PT J
AU Yamashita, S
   Katsumi, H
   Sakane, T
   Yamamoto, A
AF Yamashita, Shugo
   Katsumi, Hidemasa
   Sakane, Toshiyasu
   Yamamoto, Akira
TI Bone targeting dendrimer for the delivery of methotrexate and treatment
   of bone metastasis
SO JOURNAL OF DRUG TARGETING
LA English
DT Article
DE Dendrimer; bone targeting; alendronate; methotrexate; bone metastasis
ID POLYAMIDOAMINE PAMAM DENDRIMERS; BIOLOGICAL EVALUATION; CANCER THERAPY;
   HUMAN TUMORS; BLOOD FLOW; IN VITRO; MICROENVIRONMENT; BISPHOSPHONATES;
   CELLS; DRUG
AB We developed a bone targeting dendrimer for the delivery of anti tumour agents and effective treatment of bone metastasis, in which alendronate (ALN), a bone targeting moiety, is covalently bonded to a polyethylene glycol (PEG) conjugated polyamidoamine (PAMAM) dendrimer (PEG PAMAM ALN). Approximately 7.0 and 21.9% of the administered doses of [In 111]PAMAM and PEG PAMAM ALN accumulated in the bones within 180min after intravenous injection in mice, respectively. [H 3] labelled methotrexate (MTX) rapidly disappeared from the blood, and bone distribution was found to be only 1.1% of the administered dose at 180min. In contrast, 21.5% of the administered dose of [H 3]MTX loaded PEG PAMAM ALN accumulated in the bones at 180min after intravenous injection in mice, which was approximately 20 fold higher than that of [H 3]MTX. In a bone metastatic tumour mouse model, in which B16 BL6/Luc cells were injected into the left ventricle of female C57BL/6 mice, the growth of metastatic tumour in the bones was significantly inhibited by intravenous injection of MTX loaded PEG PAMAM ALN. These findings indicate that PEG PAMAM ALN is a promising bone targeting carrier for the delivery of anti tumour agents and treatment of bone metastasis.
C1 [Yamashita, Shugo; Katsumi, Hidemasa; Sakane, Toshiyasu; Yamamoto, Akira] Kyoto Pharmaceut Univ, Dept Biopharmaceut, Yamashina Ku, Kyoto 6078414, Japan.
   [Sakane, Toshiyasu] Kobe Pharmaceut Univ, Dept Pharmaceut Technol, Higashinada Ku, Kobe, Hyogo, Japan.
C3 Kyoto Pharmaceutical University; Kobe Pharmaceutical University
RP Katsumi, H (通讯作者)，Kyoto Pharmaceut Univ, Dept Biopharmaceut, Yamashina Ku, Kyoto 6078414, Japan.
EM hkatsumi@mb.kyoto phu.ac.jp
CR Ames B.N, 1966, Meth. Enzymol, P115, DOI DOI 10.1016/0076 6879(66)08014 5
   ARGUELLO F, 1988, CANCER RES, V48, P6876
   Cheng YY, 2007, EUR J MED CHEM, V42, P1032, DOI 10.1016/j.ejmech.2006.12.035
   COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Cremers SCLM, 2005, CLIN PHARMACOKINET, V44, P551, DOI 10.2165/00003088 200544060 00001
   DELANGE GL, 1990, J BIOMED MATER RES, V24, P829, DOI 10.1002/jbm.820240704
   Disibio G, 2008, ARCH PATHOL LAB MED, V132, P931, DOI 10.1043/1543 2165(2008)132[931:MPOCRF]2.0.CO;2
   Dong ZQ, 2010, INT J PHARMACEUT, V393, P244, DOI 10.1016/j.ijpharm.2010.04.021
   El Mabhouh A, 2004, CANCER BIOTHER RADIO, V19, P627, DOI 10.1089/cbr.2004.19.627
   ENGIN K, 1995, INT J HYPERTHER, V11, P211, DOI 10.3109/02656739509022457
   FLEISCH H, 1987, BONE, V8, pS23
   HARADA M, 1992, ADV EXP MED BIOL, V324, P173
   Hirabayashi H, 2003, CLIN PHARMACOKINET, V42, P1319, DOI 10.2165/00003088 200342150 00002
   Hirabayashi H, 2001, J CONTROL RELEASE, V70, P183, DOI 10.1016/S0168 3659(00)00355 2
   Hironaka Shu Ichi, 2000, Gastric Cancer, V3, P19, DOI 10.1007/PL00011684
   HNATOWICH DJ, 1982, INT J APPL RADIAT IS, V33, P327, DOI 10.1016/0020 708X(82)90144 2
   Höckel M, 2001, JNCI J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266
   Katsumi H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135966
   Lai PS, 2007, J CONTROL RELEASE, V122, P39, DOI 10.1016/j.jconrel.2007.06.012
   Majoros IJ, 2006, BIOMACROMOLECULES, V7, P572, DOI 10.1021/bm0506142
   McCarthy I, 2006, J BONE JOINT SURG AM, V88A, P4, DOI 10.2106/JBJS.F.00890
   Mizoshita T, 2008, INT J CLIN ONCOL, V13, P373, DOI 10.1007/s10147 007 0750 2
   Morioka M, 2010, BIOORGAN MED CHEM, V18, P1143, DOI 10.1016/j.bmc.2009.12.041
   Navarro G, 2010, J CONTROL RELEASE, V146, P99, DOI 10.1016/j.jconrel.2010.04.030
   Peppicelli S, 2014, CANCER METAST REV, V33, P823, DOI 10.1007/s10555 014 9506 4
   PORTER CJH, 1992, FEBS LETT, V305, P62, DOI 10.1016/0014 5793(92)80655 Z
   POSTE G, 1980, CANCER RES, V40, P1636
   Pratap J, 2005, MOL CELL BIOL, V25, P8581, DOI 10.1128/MCB.25.19.8581 8591.2005
   Roberts JC, 1996, J BIOMED MATER RES, V30, P53, DOI 10.1002/(SICI)1097 4636(199601)30:1<53::AID JBM8>3.0.CO;2 Q
   SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014 4827(88)90191 7
   Sochanik A, 2010, ARCH IMMUNOL THER EX, V58, P235, DOI 10.1007/s00005 010 0077 y
   TALMAGE RV, 1970, AM J ANAT, V129, P467, DOI 10.1002/aja.1001290408
   TETI A, 1989, J CLIN INVEST, V83, P227, DOI 10.1172/JCI113863
   Thomas TP, 2010, BIOORG MED CHEM LETT, V20, P5191, DOI 10.1016/j.bmcl.2010.07.005
   VAUPEL P, 1989, CANCER RES, V49, P6449
   YAMAOKA K, 1981, J PHARMACOBIO DYNAM, V4, P879, DOI 10.1248/bpb1978.4.879
   Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070
NR 38
TC 22
Z9 24
U1 2
U2 36
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1061 186X
EI 1029 2330
J9 J DRUG TARGET
JI J. Drug Target.
PY 2018
VL 26
IS 9
BP 818
EP 828
DI 10.1080/1061186X.2018.1434659
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GS7QT
UT WOS:000443898500007
PM 29376757
DA 2025 08 17
ER

PT J
AU Luciani, P
   Fibbi, B
   Mazzanti, B
   Deledda, C
   Ballerini, L
   Aldinucci, A
   Benvenuti, S
   Saccardi, R
   Peri, A
AF Luciani, Paola
   Fibbi, Benedetta
   Mazzanti, Benedetta
   Deledda, Cristiana
   Ballerini, Lara
   Aldinucci, Alessandra
   Benvenuti, Susanna
   Saccardi, Riccardo
   Peri, Alessandro
TI The effects of Exendin 4 on bone marrow derived mesenchymal cells
SO ENDOCRINE
LA English
DT Article
DE Diabetes; Bone marrow; GLP 1 agonists; Bone quality
ID PEPTIDE 1 RECEPTOR AGONISTS; STEM CELLS; OSTEOGENIC DIFFERENTIATION;
   MINERAL DENSITY; GLP 1 RECEPTOR; RISK; FRACTURES; PROLIFERATION;
   METAANALYSIS; OLDER
AB GLP 1 receptor agonists are antidiabetic drugs currently used in the therapy of type 2 diabetes. Despite several in vitro and in vivo animal studies suggesting a beneficial effect of GLP 1 analogues on bone, in humans their skeletal effects are not clear and clinical studies report conflicting results.
   We differentiated human mesenchymal stromal cells (hMSC) toward the adipogenic and the osteoblastic lineages, analysing the effect of Exendin 4 (EXE) before, during and after specific differentiations.
   We showed EXE ability to act selectively on a sub population of hMSC characterised by a more stem potential, shifting them from G1 to S/M phase of cell cycle. We observed that EXE pre treatment promotes both adipogenic and osteoblastic differentiations, possibly determined by an increased number of uncommitted progenitors. In fully differentiated cells, EXE affects mature adipocytes by increasing lipolysis, otherwise not altering osteoblasts metabolic activity. Moreover, the increased expression of osteoprotegerin, a modulator of the RANK/RANKL system, observed during osteogenic induction in presence of EXE, could negatively modulate osteoclastogenesis.
   Our data suggest a complex action of EXE on bone, targeting the proliferation of mesenchymal progenitors, the metabolism of mature adipocytes and the modulation of osteoclastogenesis. Thus, an overall positive effect of this molecule on bone quality might be hypothesised.
C1 [Luciani, Paola; Fibbi, Benedetta; Deledda, Cristiana; Benvenuti, Susanna; Peri, Alessandro] Univ Florence, Dept Expt & Clin Biomed Sci Mario Serio, Endocrine Unit, Florence, Italy.
   [Fibbi, Benedetta; Ballerini, Lara; Saccardi, Riccardo] Univ Florence, Dept Expt & Clin Med, Haematol Unit, Florence, Italy.
   [Aldinucci, Alessandra] Univ Florence, Dept NEUROFARBA, Florence, Italy.
C3 University of Florence; University of Florence; University of Florence
RP Peri, A (通讯作者)，Univ Florence, Dept Expt & Clin Biomed Sci Mario Serio, Endocrine Unit, Florence, Italy.
EM alessandro.peri@unifi.it
RI Peri, Alessandro/AAR 9664 2021; Fibbi, Benedetta/JVN 0164 2024; Deledda,
   Cristiana/AAB 8976 2019; Saccardi, Riccardo/IWE 0966 2023
OI Saccardi, Riccardo/0000 0002 5763 5467; fibbi,
   benedetta/0000 0002 7417 3874; 
FU Ente Cassa di Risparmio di Firenze
FX This study was supported by grants from Ente Cassa di Risparmio di
   Firenze.
CR Baksh D, 2004, J CELL MOL MED, V8, P301, DOI 10.1111/j.1582 4934.2004.tb00320.x
   Bartelt A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061264
   Benvenuti S, 2007, J ENDOCRINOL INVEST, V30, pRC26, DOI 10.1007/BF03350807
   Bollag RJ, 2000, ENDOCRINOLOGY, V141, P1228, DOI 10.1210/en.141.3.1228
   Botolin S, 2007, ENDOCRINOLOGY, V148, P198, DOI 10.1210/en.2006 1006
   Coin A, 2000, OSTEOPOROSIS INT, V11, P1043, DOI 10.1007/s001980070026
   Devlin MJ, 2014, ENDOCRINOLOGY, V155, P3806, DOI 10.1210/en.2014 1041
   Driessen JHM, 2017, BRIT J CLIN PHARMACO, V83, P923, DOI 10.1111/bcp.13167
   FELSON DT, 1993, J BONE MINER RES, V8, P567, DOI 10.1002/jbmr.5650080507
   Feng YY, 2016, J MOL ENDOCRINOL, V56, P189, DOI 10.1530/JME 15 0264
   Hess R, 2005, J CELL BIOCHEM, V94, P50, DOI 10.1002/jcb.20330
   Holloway WR, 2002, J BONE MINER RES, V17, P200, DOI 10.1359/jbmr.2002.17.2.200
   Ivers RQ, 2001, DIABETES CARE, V24, P1198, DOI 10.2337/diacare.24.7.1198
   Kang YM, 2016, ENDOCRINOL METAB, V31, P258, DOI 10.3803/EnM.2016.31.2.258
   Krings A, 2012, BONE, V50, P546, DOI 10.1016/j.bone.2011.06.016
   Lecka Czernik B, 2014, ARCH BIOCHEM BIOPHYS, V561, P124, DOI 10.1016/j.abb.2014.06.010
   Lee Hye Min, 2015, J Menopausal Med, V21, P93, DOI 10.6118/jmm.2015.21.2.93
   Li J, 2016, AGING DIS, V7, P514, DOI 10.14336/AD.2015.1206
   Lipscombe LL, 2007, DIABETES CARE, V30, P835, DOI 10.2337/dc06 1851
   Luetters CM, 2004, OSTEOPOROSIS INT, V15, P957, DOI 10.1007/s00198 004 1625 2
   Ma X, 2013, J BONE MINER RES, V28, P1641, DOI 10.1002/jbmr.1898
   Mabilleau G, 2014, J DIABETES, V6, P260, DOI 10.1111/1753 0407.12102
   Martin TJ, 2008, BEST PRACT RES CL EN, V22, P701, DOI 10.1016/j.beem.2008.07.006
   Meng JR, 2016, STEM CELL REP, V6, P579, DOI 10.1016/j.stemcr.2016.02.002
   Monami M., 2014, DIABETES CARE, V37, P2474
   Moura DS, 2016, SCI REP UK, V6, DOI 10.1038/srep28532
   Niu CC, 2015, J ORTHOP SURG RES, V10, DOI 10.1186/s13018 015 0236 2
   Nuche Berenguer B, 2010, J CELL PHYSIOL, V225, P585, DOI 10.1002/jcp.22243
   Nuche Berenguer B, 2009, CALCIFIED TISSUE INT, V84, P453, DOI 10.1007/s00223 009 9220 3
   Pacheco Pantoja Elda L., 2011, BMC Physiology, V11, P12, DOI 10.1186/1472 6793 11 12
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Sancho V, 2006, INT J MOL MED, V17, P1133
   Sanz C, 2010, AM J PHYSIOL ENDOC M, V298, pE634, DOI 10.1152/ajpendo.00460.2009
   Schwartz AV, 2011, JAMA J AM MED ASSOC, V305, P2184, DOI 10.1001/jama.2011.715
   Su B, 2015, ENDOCRINE, V48, P107, DOI 10.1007/s12020 014 0361 4
   Takikawa S, 2003, J BIOMED MATER RES A, V65A, P37, DOI 10.1002/jbm.a.10345
   Thomas T, 1999, ENDOCRINOLOGY, V140, P1630, DOI 10.1210/en.140.4.1630
   Villanueva Peñacarrillo ML, 2001, ENDOCRINE, V15, P241, DOI 10.1385/ENDO:15:2:241
   Wang CX, 2015, CELL PHYSIOL BIOCHEM, V35, P2223, DOI 10.1159/000374027
   Zhou H, 2015, SCI REP UK, V5, DOI 10.1038/srep12898
NR 40
TC 11
Z9 13
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1355 008X
EI 1559 0100
J9 ENDOCRINE
JI Endocrine
PD JUN
PY 2018
VL 60
IS 3
BP 423
EP 434
DI 10.1007/s12020 017 1430 2
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA GE9LE
UT WOS:000431550400007
PM 29094257
DA 2025 08 17
ER

PT J
AU Luo, SY
   Yang, YJ
   Chen, JF
   Zhong, ZG
   Huang, HX
   Zhang, JJ
   Cui, L
AF Luo, Shiying
   Yang, Yajun
   Chen, Jingfeng
   Zhong, Zhiguo
   Huang, Hongxin
   Zhang, Jingjing
   Cui, Liao
TI Tanshinol stimulates bone formation and attenuates dexamethasone induced
   inhibition of osteogenesis in larval zebrafish
SO JOURNAL OF ORTHOPAEDIC TRANSLATION
LA English
DT Article
DE glucocorticoid; osteogenesis; polyphenol; tanshinol; zebrafish
ID SALVIA MILTIORRHIZA; OXIDATIVE STRESS; DANSHENSU; ACID; CELLS;
   OSTEOPOROSIS; MODEL
AB Background/Objective: Tanshinol is the main active component of Salvia miltiorrhiza Bunge, a significant Traditional Chinese Medicine used to treat cardiovascular disease. We have shown that tanshinol exerts an antiosteoporostic effect via the enhancement of bone formation in vivo and in vitro. However, the mechanism remains unclear. Based on the polyphenol group in the structure of tanshinol, we speculate the protective action on skeletal tissue is related to antioxidative capacity. Our in vitro evidence indicated that tanshinol stimulated osteoblastic differentiation by its antioxidaive capacity. In this study, we aim to further confirm the effect of tanshinol on bone formation and the underlying mechanism in zebrafish in vivo.
   Methods: We used a Danio rerio (zebrafish) model, which has a bone formation process similar to humans, and evaluated the relationship between the dose and the effect of tanshinol on bone formation determined using alizarin red S staining or fluorescence intensity analysis in normal and glucocorticoid (GC) induced inhibition of an osteogenesis model using wild type zebrafish and cortical bone transgenic zebrafish tg(sp7: egfp). The expression of osteoblast specific genes and reactive oxygen species (ROS) were tested.
   Results: Our data showed that dexamethasone exerts a series of consequences, including the inhibition of bone formation, decrease of bone mass, downregulation of expression of osteoblast specific genes (runx2a, ALP, osteocalcin, and sp7), as well as the accumulation of ROS generation and decreased capacity of antioxidants. Tanshinol showed a protective effect on promoting bone formation and bone mass both in wild type larval zebrafish and transgenic zebrafish. Furthermore, tanshinol attenuated the inhibition of osteogenesis elicited by oxidative stress in the zebrafish exposed to dexamethasone.
   Conclusion: The present findings suggest that tanshinol prevented decreased osteogenesis in GC treated larval zebrafish via scavenging ROS and stimulated the expression of osteoblast specific genes. Tanshinol treatment may be developed as a novel therapeutic approach under recent recognised conditions of GC induced osteoporosis. Copyright (C) 2015, The Authors. Published by Elsevier (Singapore) Pte Ltd.
C1 [Luo, Shiying; Yang, Yajun; Chen, Jingfeng; Cui, Liao] Guangdong Med Univ, Guangdong Key Lab R&D Nat Drug, Dept Pharmacol, 2 East Wenming Rd, Zhanjiang 524023, Guangdong, Peoples R China.
   [Zhong, Zhiguo; Huang, Hongxin; Zhang, Jingjing] Guangdong Med Univ, Affiliated Hosp, Clin Res Ctr, 57 South Renmin Rd, Zhanjiang 524001, Guangdong, Peoples R China.
C3 Guangdong Medical University; Guangdong Medical University
RP Cui, L (通讯作者)，Guangdong Med Univ, Guangdong Key Lab R&D Nat Drug, Dept Pharmacol, 2 East Wenming Rd, Zhanjiang 524023, Guangdong, Peoples R China.; Zhang, JJ (通讯作者)，Guangdong Med Univ, Affiliated Hosp, Clin Res Ctr, 57 South Renmin Rd, Zhanjiang 524001, Guangdong, Peoples R China.
EM gdmccrc@163.com; cuiliao@163.com
RI Huang, HongXin/GSI 9716 2022
FU National Natural Science Foundation of China [81273518]; Science and
   Technology Planning Project of Guangdong Province [2012B060300027];
   Scientific Research Subject of Traditional Chinese Medicine Bureau of
   Guangdong Province, China [20152152]
FX This research was supported with grants from the National Natural
   Science Foundation of China (81273518), the Science and Technology
   Planning Project of Guangdong Province (2012B060300027), and Scientific
   Research Subject of Traditional Chinese Medicine Bureau of Guangdong
   Province (20152152), China.
CR Adams James David, 2006, Chin Med, V1, P3, DOI 10.1186/1749 8546 1 3
   Almeida M, 2011, J BIOL CHEM, V286, P44326, DOI 10.1074/jbc.M111.283481
   [Anonymous], FRONT ENDOCRINOL
   [Anonymous], 2000, GENOME RES
   Barrett Ruth, 2006, Biotechnology Journal, V1, P651, DOI 10.1002/biot.200600043
   Barut BA, 2000, PHYSIOL GENOMICS, V2, P49, DOI 10.1152/physiolgenomics.2000.2.2.49
   Camm EJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021142
   Canalis Ernesto, 2005, Curr Osteoporos Rep, V3, P98, DOI 10.1007/s11914 005 0017 7
   Chen B, 2014, CALCIFIED TISSUE INT, V94, P353, DOI 10.1007/s00223 013 9817 4
   Chong CM, 2013, NEUROSCI LETT, V543, P121, DOI 10.1016/j.neulet.2013.02.069
   Cui L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034647
   Cui L, 2009, ACTA PHARMACOL SIN, V30, P321, DOI 10.1038/aps.2009.9
   DeLaurier A, 2010, GENESIS, V48, P505, DOI 10.1002/dvg.20639
   Fleming A, 2005, J BIOMOL SCREEN, V10, P823, DOI 10.1177/1087057105279952
   Goldsmith P, 2004, CURR OPIN PHARMACOL, V4, P504, DOI 10.1016/j.coph.2004.04.005
   Haga Y, 2009, TRANSGENIC RES, V18, P669, DOI 10.1007/s11248 009 9259 y
   Hu J, 2012, INT J MOL SCI, V13, P14565, DOI 10.3390/ijms131114565
   Hurson CJ, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471 2474 8 12
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Li H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048872
   Li N, 2009, DEV DYNAM, V238, P459, DOI 10.1002/dvdy.21838
   Lin SE, 2014, CALCIFIED TISSUE INT, V95, P362, DOI 10.1007/s00223 014 9899 7
   Liu J, 1999, FREE RADICAL RES, V31, P559, DOI 10.1080/10715769900301131
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Matsuo Koichi, 2014, Clin Calcium, V24, P1337, DOI CliCa140913371342
   Parhami F, 1997, ARTERIOSCL THROM VAS, V17, P680, DOI 10.1161/01.ATV.17.4.680
   Tang YQ, 2011, PHYTOMEDICINE, V18, P1024, DOI 10.1016/j.phymed.2011.05.007
   Tankó LB, 2005, J BONE MINER RES, V20, P1912, DOI 10.1359/JBMR.050711
   Walker MB, 2007, BIOTECH HISTOCHEM, V82, P23, DOI 10.1080/10520290701333558
   Wauquier F, 2009, TRENDS MOL MED, V15, P468, DOI 10.1016/j.molmed.2009.08.004
   Weinstein RS, 2010, BONE, V46, P564, DOI 10.1016/j.bone.2009.06.030
   WESTERFIELD M, 2000, ZEBRAFISH BOOK
   Witten PE, 2001, J MORPHOL, V250, P197, DOI 10.1002/jmor.1065
   Wu L, 2007, PHYTOMEDICINE, V14, P652, DOI 10.1016/j.phymed.2007.07.060
   Yamagishi Sho Ichi, 2014, Clin Calcium, V24, P85, DOI CliCa140710531059
   Yang YJ, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/351895
   Yui PB, 2008, NAT CHEM BIOL, V4, P33, DOI 10.1038/nchembio.2007.54
   Zhang H, 2012, J INT MED RES, V40, P943, DOI 10.1177/147323001204000313
   Zhao BL, 1996, BIOCHEM MOL BIOL INT, V38, P1171
   Zhou XL, 2015, J PHARM PHARMACOL, V67, P980, DOI 10.1111/jphp.12381
NR 40
TC 59
Z9 67
U1 0
U2 29
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2214 031X
J9 J ORTHOP TRANSL
JI J. Orthop. Transl.
PD JAN
PY 2016
VL 4
BP 35
EP 45
DI 10.1016/j.jot.2015.07.002
PG 11
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA DQ5PO
UT WOS:000379257500004
PM 30035064
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Huang, LK
   Zeng, XS
   Jiang, ZW
   Peng, H
   Sun, F
AF Huang, Liang Kun
   Zeng, Xiao Shuang
   Jiang, Ze Wen
   Peng, Hao
   Sun, Fei
TI Echinacoside alleviates glucocorticoid induce osteonecrosis of femoral
   head in rats through PI3K/AKT/FOXO1 pathway
SO CHEMICO BIOLOGICAL INTERACTIONS
LA English
DT Article
DE SONFH; Dexamethasone; Echinacoside; Osteoblast; Apoptosis;
   PI3K/AKT/FOXO1
ID AVASCULAR NECROSIS; APOPTOSIS; PROMOTES; FOXO1
AB Steroid induced osteonecrosis of the femoral head (SONFH), caused by glucocorticoid (GC) administration, is known to exhibit a high incidence worldwide. Although osteoblast apoptosis has been reported as an important cytological basis of SONFH, the precise mechanism remains elusive. Echinacoside (Ech), a natural phenylethanoid glycoside, exerts multiple beneficial effects, such as facilitation of cell proliferation and antiinflammatory and anticancer activities. Herein, we aimed to explore the regulatory mechanism underlying glucocorticoid induced osteoblast apoptosis and determine the protective efficacy of Ech against SONFH. We comprehensively surveyed multiple public databases to identify SONFH related genes. Using bioinformatics analysis, we identified that the PI3K/AKT/FOXO1 signaling pathway was most strongly associated with SONFH. We examined the protective effect of Ech against SONFH using in vivo and in vitro experiments. Specifically, dexamethasone (Dex) decreased p PI3K and p AKT levels, which were reversed following Ech addition. Validation of the PI3K inhibitor (LY294002) and molecular docking of Ech and PI3K/AKT further indicated that Ech could directly enhance PI3K/AKT activity to alleviate Dex induced inhibition. Interestingly, Dex upregulated the expression of FOXO1, Bax, cleaved caspase 9, and cleaved caspase 3 and enhanced MC3T3 E1 apoptosis; application of Ech and siRNA FOXO1 reversed these effects. In vitro, Ech decreased the number of empty osteocytic lacunae, reduced TUNEL and FOXO1 positive cells, and improved bone microarchitecture. Our results provide robust evidence that PI3K/AKT/FOXO1 plays a crucial role in the development of SONFH. Moreover, Ech may be a promising candidate drug for the treatment of SONFH.
C1 [Huang, Liang Kun; Zeng, Xiao Shuang; Jiang, Ze Wen; Peng, Hao; Sun, Fei] Wuhan Univ, Dept Orthoped, Renmin Hosp, Wuhan 430060, Peoples R China.
C3 Wuhan University
RP Sun, F (通讯作者)，Wuhan Univ, Dept Orthoped, Renmin Hosp, Wuhan 430060, Peoples R China.
EM 631824582@qq.com
FU National tion of China [81672154]
FX Funding statement This study was supported by the National tion of China
   (No. 81672154) .
CR Al Omari AA, 2020, EUR J ORTHOP SURG TR, V30, P193, DOI 10.1007/s00590 019 02555 8
   Arbab D, 2016, DTSCH ARZTEBL INT, V113, P31, DOI 10.3238/arztebl.2016.0031
   Brommage R, 2021, BONE, V145, DOI 10.1016/j.bone.2019.115040
   Caplan A, 2017, J AM ACAD DERMATOL, V76, P1, DOI 10.1016/j.jaad.2016.01.062
   Chang C, 2020, J AUTOIMMUN, V110, DOI 10.1016/j.jaut.2020.102460
   Chen YX, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.581673
   Deng S, 2019, BIOMED PHARMACOTHER, V110, P602, DOI 10.1016/j.biopha.2018.11.103
   Gauthier J, 2019, BRIEF BIOINFORM, V20, P1981, DOI 10.1093/bib/bby063
   Goldbraikh D, 2020, EMBO REP, V21, DOI 10.15252/embr.201948791
   Han DD, 2019, FREE RADICAL BIO MED, V137, P1, DOI 10.1016/j.freeradbiomed.2019.04.014
   Han YJ, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0019 6
   Jafari M, 2019, J CELL PHYSIOL, V234, P2373, DOI 10.1002/jcp.27262
   Kaiser G, 2013, DIABETOLOGIA, V56, P1587, DOI 10.1007/s00125 013 2863 7
   Kim HK, 2021, MAR DRUGS, V19, DOI 10.3390/md19080412
   Larson E, 2018, INT ORTHOP, V42, P1723, DOI 10.1007/s00264 018 3917 8
   Li KQ, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01643 5
   Li L, 2018, BIOMED PHARMACOTHER, V104, P622, DOI 10.1016/j.biopha.2018.05.072
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Peng PJ, 2021, FEBS OPEN BIO, V11, P312, DOI 10.1002/2211 5463.13037
   Peng SM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9010184
   Sawa N, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 50236 7
   Schäll D, 2015, EUR J IMMUNOL, V45, P3087, DOI 10.1002/eji.201545609
   Seijas R, 2019, J INVEST SURG, V32, P218, DOI 10.1080/08941939.2017.1398282
   Sun F, 2021, DIS MARKERS, V2021, DOI 10.1155/2021/9911184
   Thompson AR, 2020, AM J PHYS MED REHAB, V99, pE54, DOI 10.1097/PHM.0000000000001202
   Wang Y, 2020, THERANOSTICS, V10, P11535, DOI 10.7150/thno.45261
   Weinstein RS, 2012, ENDOCRIN METAB CLIN, V41, P595, DOI 10.1016/j.ecl.2012.04.004
   Weinstein RS, 2012, ENDOCRINE, V41, P183, DOI 10.1007/s12020 011 9580 0
   Xing YQ, 2018, LIFE SCI, V193, P124, DOI 10.1016/j.lfs.2017.11.030
   Yoon BH, 2019, J ARTHROPLASTY, V34, P163, DOI 10.1016/j.arth.2018.09.005
   Zeng KW, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392 020 00447 6
   Zhao GF, 2022, REPROD SCI, V29, P1586, DOI 10.1007/s43032 021 00707 y
NR 32
TC 4
Z9 5
U1 8
U2 15
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009 2797
EI 1872 7786
J9 CHEM BIOL INTERACT
JI Chem. Biol. Interact.
PD MAR 1
PY 2024
VL 391
AR 110893
DI 10.1016/j.cbi.2024.110893
EA FEB 2024
PG 9
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA MX9L6
UT WOS:001197052300001
PM 38336255
DA 2025 08 17
ER

PT J
AU Mongerard Coulanges, M
   Migianu Griffoni, E
   Lecouvey, M
   Jolles, B
AF Mongerard Coulanges, Medge
   Migianu Griffoni, Evelyne
   Lecouvey, Marc
   Jolles, Beatrice
TI Impact of alendronate and VEGF antisense combined treatment on highly
   VEGF expressing A431 cells
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Alendronate; VEGF expression; TGF alpha; PI3K pathway; VEGF antisense;
   Proliferation
ID EPIDERMAL GROWTH FACTOR; VASCULAR PERMEABILITY FACTOR; IN VITRO;
   ZOLEDRONIC ACID; FACTOR RECEPTOR; BISPHOSPHONATES; ANGIOGENESIS;
   ACTIVATION; THERAPY; CONSEQUENCES
AB Bisphosphonates, and more specially nitrogen containing bisphosphonates, which are in current use for the treatment of bone diseases, demonstrate proapoptotic, antiproliferative, antiangiogenic and anti invasive properties on tumor cells. The amino bisphosphonate alendronate is considered as a potential anticancer drug. In the case of A431 cells, which express high levels of VEGF, it had a two step effect. At 24 h, the antitumor properties of alendronate were counterbalanced by a survival process, which consisted of an enhancement of VEGF expression (mRNA and protein secretion) and TGF alpha secretion. It was only at 48 h that alendronate displayed the expected anti proliferative and antiangiogenic properties. The first step, in which the PI3K pathway was engaged, could be prevented by the use of a VEGF antisense oligonucleotide. The combination of such an antisense with small concentrations of alendronate (similar to 2 mu M), which is of the order of clinically used concentrations, was shown to have an antiangiogenic effect as soon as 12 h. (c) 2009 Elsevier Inc. All rights reserved.
C1 [Mongerard Coulanges, Medge; Migianu Griffoni, Evelyne; Lecouvey, Marc; Jolles, Beatrice] Univ Paris 06, F 75005 Paris, France.
   [Mongerard Coulanges, Medge; Migianu Griffoni, Evelyne; Lecouvey, Marc; Jolles, Beatrice] CNRS, Lab Biophys Mol Cellulaire & Tissulaire, UMR 7033, F 75700 Paris, France.
   [Mongerard Coulanges, Medge; Migianu Griffoni, Evelyne; Lecouvey, Marc; Jolles, Beatrice] Univ Paris 13, F 93017 Bobigny, France.
C3 Sorbonne Universite; Centre National de la Recherche Scientifique
   (CNRS); Universite Paris 13
RP Jolles, B (通讯作者)，Univ Paris 06, Bat C 5eme Etage,Case 265,9 Quai St Bernard, F 75005 Paris, France.
EM beatrice.jolles@upmc.fr
RI Lecouvey, Marc/ADO 6272 2022
FU Ligue contre le cancer (comite de Seine Saint Denis)
FX This work was supported by the "Ligue contre le cancer (comite de
   Seine Saint Denis)".
CR Claffey KP, 1996, CANCER METAST REV, V15, P165, DOI 10.1007/BF00437469
   Diaz A., 2007, BIOTECNOL APL, V24, P10
   Farese JP, 2004, IN VITRO CELL DEV AN, V40, P113, DOI 10.1290/1543 706X(2004)040<0113:TEOTBA>2.0.CO;2
   Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
   Fournier P, 2002, CANCER RES, V62, P6538
   Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750
   Graeven U, 2001, CANCER RES, V61, P7282
   Hamma Kourbali Y, 2003, BRIT J CANCER, V89, P215, DOI 10.1038/sj.bjc.6601029
   Hashimoto K, 2007, BIOCHEM BIOPH RES CO, V354, P478, DOI 10.1016/j.bbrc.2007.01.014
   Heino TJ, 2008, BONE, V42, P702, DOI 10.1016/j.bone.2008.01.001
   Lecouvey M, 2000, HETEROATOM CHEM, V11, P556, DOI 10.1002/1098 1071(2000)11:7<556::AID HC15>3.0.CO;2 N
   Li MF, 2002, CLIN CANCER RES, V8, P3570
   LI S, 1996, BIOMED PHARMACOTHER, V50, P394
   Masood R, 1997, P NATL ACAD SCI USA, V94, P979, DOI 10.1073/pnas.94.3.979
   Matsuda M, 2001, J CELL BIOL, V153, P599, DOI 10.1083/jcb.153.3.599
   Millauer B, 1996, CANCER RES, V56, P1615
   Petit AMV, 1997, AM J PATHOL, V151, P1523
   Reddy K., 1996, Apoptosis, V1, P33, DOI 10.1007/BF00142076
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Santini D, 2003, ANN ONCOL, V14, P1468, DOI 10.1093/annonc/mdg401
   Senaratne SG, 2002, BREAST CANCER RES, V4, P18, DOI 10.1186/bcr412
   Stresing V, 2007, CANCER LETT, V257, P16, DOI 10.1016/j.canlet.2007.07.007
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   Van Poznak Catherine H, 2002, Cancer Control, V9, P480
   VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503
   White FC, 1995, GROWTH FACTORS, V12, P289, DOI 10.3109/08977199509028967
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Yuasa T, 2007, CURR MED CHEM, V14, P2126
   Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325
NR 29
TC 6
Z9 6
U1 0
U2 1
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD MAY 15
PY 2009
VL 77
IS 10
BP 1580
EP 1585
DI 10.1016/j.bcp.2009.02.016
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 436VW
UT WOS:000265445200003
PM 19426694
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Tokito, T
   Shukuya, T
   Akamatsu, H
   Taira, T
   Ono, A
   Kenmotsu, H
   Naito, T
   Murakami, H
   Takahashi, T
   Endo, M
   Yamamoto, N
AF Tokito, Takaaki
   Shukuya, Takehito
   Akamatsu, Hiroaki
   Taira, Tetsuhiko
   Ono, Akira
   Kenmotsu, Hirotsugu
   Naito, Tateaki
   Murakami, Haruyasu
   Takahashi, Toshiaki
   Endo, Masahiro
   Yamamoto, Nobuyuki
TI Efficacy of bevacizumab containing chemotherapy for non squamous
   non small cell lung cancer with bone metastases
SO CANCER CHEMOTHERAPY AND PHARMACOLOGY
LA English
DT Article
DE Bone metastases; Skeletal related event; Bevacizumab; Chemotherapy
ID SKELETAL METASTASES; ZOLEDRONIC ACID; PROSTATE CANCER; BREAST CANCER;
   SOLID TUMORS; PHASE III; THERAPY; BISPHOSPHONATES; CARBOPLATIN;
   PACLITAXEL
AB Skeletal related events (SREs) negatively affect the quality of life of patients with cancer. Vascular endothelial growth factor receptor (VEGFR) targeted therapy is effective against bone metastasis in animal models, but the clinical efficacy of anti VEGFR inhibitors against bone metastases remains unclear. Therefore, we aimed to investigate the efficacy of chemotherapy with bevacizumab, an anti VEGF antibody, against bone metastases.
   We retrospectively reviewed consecutive patients with non squamous non small cell lung cancer who received first line platinum based chemotherapy with zoledronic acid at Shizuoka Cancer Center between 2007 and 2011.
   Of 25 patients, 13 received bevacizumab based chemotherapy (BEV group) and 12 received chemotherapy without bevacizumab (non BEV group). The overall response (54 vs. 8 %, p = 0.01) and disease control (100 vs. 50 %, p = 0.01) rates were higher in the BEV group than in the non BEV group. The bone specific response (23 vs. 0 %, p = 0.038) and disease control (100 vs. 67 %, p = 0.01) rates were also higher in the BEV group. The median time to progression (TTP) for bone metastases was higher in the BEV group (13.7 vs. 4.3 months, p = 0.06), whereas that for overall disease was similar between the groups (5.7 vs. 2.6 months, p = 0.17). The proportions of patients with SREs were 23 and 50 % in the BEV and non BEV groups, respectively (p = 0.16).
   Bevacizumab might potentiate the antitumor activity of chemotherapy against systemic disease and bone metastases, prolonging bone specific TTP and reducing the incidence of SRE.
C1 [Tokito, Takaaki; Shukuya, Takehito; Akamatsu, Hiroaki; Taira, Tetsuhiko; Ono, Akira; Kenmotsu, Hirotsugu; Naito, Tateaki; Murakami, Haruyasu; Takahashi, Toshiaki; Yamamoto, Nobuyuki] Shizuoka Canc Ctr Hosp, Div Thorac Oncol, Nagaizumi, Shizuoka 4118777, Japan.
   [Endo, Masahiro] Shizuoka Canc Ctr, Div Diagnost Radiol, Nagaizumi, Shizuoka, Japan.
C3 Shizuoka Cancer Center; Shizuoka Cancer Center
RP Tokito, T (通讯作者)，Shizuoka Canc Ctr Hosp, Div Thorac Oncol, 1007 Shimonagakubo, Nagaizumi, Shizuoka 4118777, Japan.
EM t.tokito@scchr.jp
RI Naito, Tateaki/K 4703 2019; Akamatsu, Hiroaki/AFB 1852 2022
OI Naito, Tateaki/0000 0003 4047 2929; Akamatsu,
   Hiroaki/0000 0001 5856 5512; 
CR Bäuerle T, 2008, NEOPLASIA, V10, P511, DOI 10.1593/neo.08220
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Coleman RE, 2004, ONCOLOGIST, V9, P14, DOI 10.1634/theoncologist.9 90004 14
   Cook RJ, 2001, J NATL CANCER I, V93, P534, DOI 10.1093/jnci/93.7.534
   Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901 987
   Keizman D, 2012, EUR J CANCER, V48, P1031, DOI 10.1016/j.ejca.2012.02.050
   Kosteva J, 2004, LUNG CANCER J IASLC, V46, pS45
   Kosteva J, 2008, CURR OPIN ONCOL, V20, P155, DOI 10.1097/CCO.0b013e3282f54cf2
   Nagengast WB, 2007, J NUCL MED, V48, P1313, DOI 10.2967/jnumed.107.041301
   Niho S, 2012, LUNG CANCER, V76, P362, DOI 10.1016/j.lungcan.2011.12.005
   Paule B, 2010, ANTICANCER RES, V30, P5165
   Reck M, 2009, J CLIN ONCOL, V27, P1227, DOI 10.1200/JCO.2007.14.5466
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Rosen LS, 2003, CANCER, V12, P2613
   Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884
   Solares SS, 2009, CLIN TRANSL ONCOL, V11, P851, DOI 10.1007/s12094 009 0455 2
   Sone S, 2007, CANCER METAST REV, V26, P685, DOI 10.1007/s10555 007 9081 z
   Tsuya A, 2007, LUNG CANCER, V57, P229, DOI 10.1016/j.lungcan.2007.03.013
   Vogel CL, 2004, ONCOLOGIST, V9, P687, DOI 10.1634/theoncologist.9 6 687
   Weinfurt KP, 2005, ANN ONCOL, V16, P579, DOI 10.1093/annonc/mdi122
   Yano S, 2005, CLIN CANCER RES, V11, P8789, DOI 10.1158/1078 0432.CCR 05 0674
NR 24
TC 10
Z9 12
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0344 5704
J9 CANCER CHEMOTH PHARM
JI Cancer Chemother. Pharmacol.
PD JUN
PY 2013
VL 71
IS 6
BP 1493
EP 1498
DI 10.1007/s00280 013 2148 3
PG 6
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 155MD
UT WOS:000319751400012
PM 23532208
DA 2025 08 17
ER

PT J
AU Erkhembaatar, M
   Choi, EJ
   Lee, HY
   Lee, CH
   Lee, YR
   Kim, MS
AF Erkhembaatar, Munkhsoyol
   Choi, Eun Joo
   Lee, Hak Yong
   Lee, Choong Hun
   Lee, Young Rae
   Kim, Min Seuk
TI Attenuated RANKL induced cytotoxicity by Portulaca oleracea
   ethanol extract enhances RANKL mediated osteoclastogenesis
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
DE Portulaca oleracea; Receptor activator of NF kappa B ligand; Bone
   marrow derived macrophage; Osteoclastogenesis
ID NF KAPPA B; ACTIVATION; DIFFERENTIATION; RECEPTORS; APOPTOSIS; PATHWAY
AB Background: Portulaca oleracea (PO) has been widely used as traditional medicine because of its pharmacological activities. However, the effects of PO on osteoclasts that modulate bone homeostasis are still elusive.
   Methods: In this study, we examined the effects of PO ethanol extract (POEE) on receptor activator of nuclear factor kappa B ligand (RANKL) mediated Ca2+ mobilization, nuclear factor of activated T cell c1 (NFATc1) amplification, tartrate resistant acid phosphatase positive (TRAP+) multinucleated cell (MNC) formation, and cytotoxicity.
   Results: Our results demonstrated that POEE suppressed RANKL induced Ca2+ oscillations by inhibition of Ca2+ release from internal Ca2+ stores, resulting in reduction of NFATc1 amplification. Notably, POEE attenuated RANKL mediated cytotoxicity and cleavage of polyadenosine 5' diphosphate ribose polymerase (PARP), resulted in enhanced formation of TRAP+ MNCs.
   Conclusions: These results present in vitro effects of POEE on RANKL mediated osteoclastogenesis and suggest the possible use of PO in treating bone disorders, such as osteopetrosis.
C1 [Erkhembaatar, Munkhsoyol; Kim, Min Seuk] Wonkwang Univ, Coll Dent, Dept Oral Physiol, Iksan 570749, Jeonbuk, South Korea.
   [Erkhembaatar, Munkhsoyol; Lee, Young Rae; Kim, Min Seuk] Wonkwang Univ, Coll Dent, Inst Biomat Implant, Iksan 570749, Jeonbuk, South Korea.
   [Choi, Eun Joo] Wonkwang Univ, Coll Dent, Dept Oral & Maxillofacial Surg, Iksan 570749, Jeonbuk, South Korea.
   [Lee, Hak Yong] Huvet Inc, Iksan 570979, Jeonbuk, South Korea.
   [Lee, Choong Hun] Wonkwang Univ, Ctr PV Human Resource Dev, Next Generat Ind Radiat Technol RIC, Microelect & Display Technol, Iksan 570749, South Korea.
   [Lee, Young Rae] Wonkwang Univ, Sch Med, Ctr Metab Funct Regulat, Iksan 570749, Jeonbuk, South Korea.
   [Lee, Young Rae] Wonkwang Univ, Coll Dent, Dept Oral Biochem, Iksan 570749, South Korea.
C3 Wonkwang University; Wonkwang University; Wonkwang University; Wonkwang
   University; Wonkwang University; Wonkwang University
RP Kim, MS (通讯作者)，Wonkwang Univ, Coll Dent, Dept Oral Physiol, Iksan 570749, Jeonbuk, South Korea.
EM happy1487@wku.ac.kr
OI Erkhembaatar, Munkhsoyol/0009 0006 0855 9636
FU Wonkwang University
FX This research was supported by Wonkwang University in 2014.
CR Bharti AC, 2004, J BIOL CHEM, V279, P6065, DOI 10.1074/jbc.M308062200
   Farshori NN, 2014, ASIAN PAC J CANCER P, V15, P6633, DOI 10.7314/APJCP.2014.15.16.6633
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   Hwang JK, 2014, J DENT RES, V93, P685, DOI 10.1177/0022034514536579
   Kim MS, 2010, J BIOL CHEM, V285, P6913, DOI 10.1074/jbc.M109.051557
   Kim MS, 2009, J BIOL CHEM, V284, P9733, DOI 10.1074/jbc.M808097200
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Korcok J, 2004, J BONE MINER RES, V19, P642, DOI 10.1359/JBMR.040108
   Lee S, 2014, EXP DERMATOL, V23, P13, DOI 10.1111/exd.12396
   Miyamoto Takeshi, 2011, Keio Journal of Medicine, V60, P101
   Nuñez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581
   Park B, 2013, KOREAN J PHYSIOL PHA, V17, P427, DOI 10.4196/kjpp.2013.17.5.427
   Sugatani T, 2003, J BIOL CHEM, V278, P5001, DOI 10.1074/jbc.M209299200
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Wang CQ, 2010, PHYTOMEDICINE, V17, P527, DOI 10.1016/j.phymed.2009.09.006
   Weidema AF, 2001, AM J PHYSIOL CELL PH, V280, pC1531, DOI 10.1152/ajpcell.2001.280.6.C1531
   Xu ZX, 2014, INDIAN J BIOCHEM BIO, V51, P321
   Yang YM, 2013, KOREAN J PHYSIOL PHA, V17, P65, DOI 10.4196/kjpp.2013.17.1.65
   Yang YM, 2009, J BONE MINER RES, V24, P1763, DOI [10.1359/JBMR.090420, 10.1359/jbmr.090420]
NR 19
TC 4
Z9 4
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472 6882
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD JUL 14
PY 2015
VL 15
AR 226
DI 10.1186/s12906 015 0770 9
PG 7
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA CM7DW
UT WOS:000357851600003
PM 26169673
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Gandillet, A
   Park, S
   Lassailly, F
   Griessinger, E
   Vargaftig, J
   Filby, A
   Lister, TA
   Bonnet, D
AF Gandillet, A.
   Park, S.
   Lassailly, F.
   Griessinger, E.
   Vargaftig, J.
   Filby, A.
   Lister, T. A.
   Bonnet, D.
TI Heterogeneous sensitivity of human acute myeloid leukemia to β catenin
   down modulation
SO LEUKEMIA
LA English
DT Article
DE leukemic stem cell; acute myeloid leukemia; xenotransplantation;
   Wnt/beta catenin; leukemic culture initiating cells; whole body imaging
ID HEMATOPOIETIC STEM CELL; WNT SIGNALING PATHWAY; GENE EXPRESSION;
   SELF RENEWAL; PROGENITORS; GROWTH; ACTIVATION; COOPERATION; ENGRAFTMENT;
   EXPANSION
AB Dysregulation of the Wnt/beta catenin pathway has been observed in various malignancies, including acute myeloid leukemia (AML), where the overexpression of beta catenin is an independent adverse prognostic factor. beta catenin was found upregulated in the vast majority of AML samples and more frequently localized in the nucleus of leukemic stem cells compared with normal bone marrow CD34(+) cells. The knockdown of beta catenin, using a short hairpin RNA (shRNA) lentiviral approach, accelerates all trans retinoic acid induced differentiation and impairs the proliferation of HL60 leukemic cell line. Using in vivo quantitative tracking of these cells, we observed a reduced engraftment potential after xenotransplantation when beta catenin was silenced. However, when studying primary AML cells, despite effective downregulation of beta catenin we did not observe any impairment of their in vitro long term maintenance on MS 5 stroma nor of their engraftment potential in vivo. Altogether, these results show that despite a frequent beta catenin upregulation in AML, leukemia initiating cells might not be 'addicted' to this pathway and thus targeted therapy against beta catenin might not be successful in all patients. Leukemia (2011) 25, 770 780; doi: 10.1038/leu.2011.17; published online 22 February 2011
C1 [Gandillet, A.; Park, S.; Lassailly, F.; Griessinger, E.; Vargaftig, J.; Bonnet, D.] Canc Res UK, CRUK Haematopoiet Stem Cell Grp, London Res Inst, London WC2A 3LY, England.
   [Filby, A.] Canc Res UK, Flow Cytometry Core Facil, London Res Inst, London WC2A 3LY, England.
   [Lister, T. A.] Queen Mary Univ London, St Bartholomews Hosp, Dept Med Oncol, London, England.
C3 Cancer Research UK; Cancer Research UK; University of London; Queen Mary
   University London
RP Bonnet, D (通讯作者)，Canc Res UK, CRUK Haematopoiet Stem Cell Grp, London Res Inst, 44 Lincolns Inn Fields, London WC2A 3LY, England.
EM dominique.bonnet@cancer.org.uk
RI VARGAFTIG, Jacques/HSE 7525 2023; PARK, Sophie/M 6597 2014; Griessinger,
   Emmanuel/G 5574 2018
OI GRIESSINGER, Emmanuel/0000 0001 7529 4187; Filby,
   Andrew/0000 0001 9078 4360; PARK, Sophie/0000 0003 0514 5789; 
FU Cancer Research UK; European grant [037632]; London Research Institute
   Cancer Research UK
FX We thank all members of the London Research Institute Flow Cytometry and
   Equipment Park facilities and Christopher Ridler for technical
   assistance; Stuart Horswell for statistical analysis; Katie Foster and
   Yasmin Reyal for proof reading of the final paper and David Taussig for
   helpful discussions. We are grateful to R De Maria for kindly providing
   us with the TWR Luc<SUP> </SUP>Fluc<SUP>+</SUP> RFP plasmid construct
   and to Fernando Anjos Afonso for providing us with some of the qPCR
   primers used here. This work was funded by Cancer Research UK (DB) and
   by European grant (contract No. 037632) to DB. AG, SP, EG and JV are
   supported by London Research Institute Cancer Research UK fellowships.
CR Abrahamsson AE, 2009, P NATL ACAD SCI USA, V106, P3925, DOI 10.1073/pnas.0900189106
   Ailles LE, 1999, BLOOD, V94, P1761, DOI 10.1182/blood.V94.5.1761.417k23_1761_1772
   Ailles LE, 1999, EXP HEMATOL, V27, P1609, DOI 10.1016/S0301 472X(99)00099 5
   Baba Y, 2006, J IMMUNOL, V177, P2294, DOI 10.4049/jimmunol.177.4.2294
   Bansal D, 2006, P NATL ACAD SCI USA, V103, P16924, DOI 10.1073/pnas.0604579103
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797 730
   Brandts CH, 2005, CANCER RES, V65, P9643, DOI 10.1158/0008 5472.CAN 05 0422
   Dash AB, 2002, P NATL ACAD SCI USA, V99, P7622, DOI 10.1073/pnas.102583199
   Feuring Buske M, 2003, LEUKEMIA, V17, P760, DOI 10.1038/sj.leu.2402882
   Gilliland D Gary, 2004, Hematology Am Soc Hematol Educ Program, P80
   Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258
   Kirstetter P, 2006, NAT IMMUNOL, V7, P1048, DOI 10.1038/ni1381
   LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0
   Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024
   Majetl R, 2009, P NATL ACAD SCI USA, V106, P3396, DOI 10.1073/pnas.0900089106
   Matkovic K, 2006, LEUKEMIA, V20, P941, DOI 10.1038/sj.leu.2404204
   Mikesch JH, 2007, LEUKEMIA, V21, P1638, DOI 10.1038/sj.leu.2404732
   Müller Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890 2904.2004
   Nusse R., WNT
   Ortyn WE, 2006, CYTOM PART A, V69A, P852, DOI 10.1002/cyto.a.20306
   Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593
   Rizo A, 2008, BLOOD, V111, P2621, DOI 10.1182/blood 2007 08 106666
   Román Gómez J, 2007, BLOOD, V109, P3462, DOI 10.1182/blood 2006 09 047043
   Scheller M, 2006, NAT IMMUNOL, V7, P1037, DOI 10.1038/ni1387
   Schuringa Jan Jacob, 2009, V538, P287, DOI 10.1007/978 1 59745 418 6_14
   Sengupta A, 2007, LEUKEMIA, V21, P949, DOI 10.1038/sj.leu.2404657
   Siapati EK, 2011, BRIT J HAEMATOL, V152, P164, DOI 10.1111/j.1365 2141.2010.08471.x
   Sloma I, 2010, LEUKEMIA, V24, P1823, DOI 10.1038/leu.2010.159
   Taussig DC, 2008, BLOOD, V112, P568, DOI 10.1182/blood 2007 10 118331
   Taussig DC, 2010, BLOOD, V115, P1976, DOI 10.1182/blood 2009 02 206565
   Tickenbrock L, 2005, BLOOD, V105, P3699, DOI 10.1182/blood 2004 07 2924
   Valencia A, 2009, LEUKEMIA, V23, P1658, DOI 10.1038/leu.2009.86
   Wang XL, 2003, BLOOD, V102, P3478, DOI 10.1182/blood 2003 05 1432
   Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611
   Yeung J, 2010, CANCER CELL, V18, P606, DOI 10.1016/j.ccr.2010.10.032
   Ysebaert L, 2006, LEUKEMIA, V20, P1211, DOI 10.1038/sj.leu.2404239
   Zhao C, 2007, CANCER CELL, V12, P528, DOI 10.1016/j.ccr.2007.11.003
NR 37
TC 51
Z9 55
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887 6924
EI 1476 5551
J9 LEUKEMIA
JI Leukemia
PD MAY
PY 2011
VL 25
IS 5
BP 770
EP 780
DI 10.1038/leu.2011.17
PG 11
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Hematology
GA 762IZ
UT WOS:000290471100004
PM 21339756
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Atesok, K
   Matsumoto, T
   Karlsson, J
   Asahara, T
   Atala, A
   Doral, MN
   Verdonk, R
   Li, R
   Schemitsch, E
AF Atesok, Kivanc
   Matsumoto, Tomoyuki
   Karlsson, Jon
   Asahara, Takayuki
   Atala, Anthony
   Doral, M. Nedim
   Verdonk, Rene
   Li, Ru
   Schemitsch, Emil
TI An emerging cell based strategy in orthopaedics: endothelial progenitor
   cells
SO KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY
LA English
DT Article
DE Endothelial progenitor cell (EPC); Bone tissue engineering; Cell based
   therapy; Fracture healing
ID ENHANCES COLLATERAL PERFUSION; ACUTE MYOCARDIAL INFARCTION; BLOOD
   CD34 POSITIVE CELLS; MESENCHYMAL STEM CELLS; NITRIC OXIDE SYNTHASE;
   REGENERATION ENHANCEMENT; ULTRASTRUCTURAL CHANGES; ISCHEMIC MYOCARDIUM;
   REGIONAL FUNCTION; PRECURSOR CELLS
AB The purpose of this article was to analyze the results of studies in the literature, which evaluated the use of endothelial progenitor cells (EPCs) as a cell based tissue engineering strategy.
   EPCs have been successfully used in regenerative medicine to augment neovascularization in patients after myocardial infarction and limb ischemia. EPCs' important role as vasculogenic progenitors presents them as a potential source for cell based therapies to promote bone healing.
   EPCs have been shown to have prominent effects in promoting bone regeneration in several animal models. Evidence indicates that EPCs promote bone regeneration by stimulating both angiogenesis and osteogenesis through a differentiation process toward endothelial cell lineage and formation of osteoblasts. Moreover, EPCs increase vascularization and osteogenesis by increased secretion of growth factors and cytokines through paracrine mechanisms.
   EPCs offer the potential to emerge as a new strategy among other cell based therapies to promote bone regeneration. Further investigations and human trials are required to address current questions with regard to biology and mechanisms of action of EPCs in bone tissue engineering.
C1 [Atesok, Kivanc; Schemitsch, Emil] Univ Toronto, St Michaels Hosp, Div Orthopaed Surg, Musculoskeletal Res Lab, 55 Queen St E,Suite 800, Toronto, ON M5C 1R6, Canada.
   [Matsumoto, Tomoyuki] Kobe Univ, Grad Sch Med, Dept Orthopaed Surg, Chuo Ku, Kobe, Hyogo 6500017, Japan.
   [Karlsson, Jon] Gothenburg Univ, Sahlgrenska Acad, Sahlgrenska Univ Hosp, Dept Orthopaed, S 43180 Molndal, Sweden.
   [Asahara, Takayuki] Tokai Univ, Sch Med, Isehara, Kanagawa 2591193, Japan.
   [Asahara, Takayuki] Inst Biomed Res & Innovat, Vasc Regenerat Res Grp, Kobe, Hyogo 6500047, Japan.
   [Atala, Anthony] Wake Forest Univ, Bowman Gray Sch Med, Wake Forest Inst Regenerat Med, Winston Salem, NC 27157 USA.
   [Doral, M. Nedim] Hacettepe Univ, Dept Orthopaed & Traumatol, TR 06100 Ankara, Turkey.
   [Doral, M. Nedim] Hacettepe Univ, Dept Sports Med, TR 06100 Ankara, Turkey.
   [Verdonk, Rene] Gent State Univ Hosp, Dept Orthopaed Surg & Traumatol, B 9000 Ghent, Belgium.
C3 University of Toronto; Saint Michaels Hospital Toronto; Kobe University;
   University of Gothenburg; Sahlgrenska University Hospital; Tokai
   University; Institute for Biomedical Research & Innovation (IBRI); Wake
   Forest University; Wake Forest Baptist Medical Center; Hacettepe
   University; Hacettepe University; Ghent University; Ghent University
   Hospital
RP Atesok, K (通讯作者)，Univ Toronto, St Michaels Hosp, Div Orthopaed Surg, Musculoskeletal Res Lab, 55 Queen St E,Suite 800, Toronto, ON M5C 1R6, Canada.
EM Kivanc.Atesok@utoronto.ca; SchemitschE@smh.ca
RI Atala, Anthony/J 3052 2013; Schemitsch, Emil/G 5706 2017
OI Matsumoto, Tomoyuki/0000 0003 4587 0029; Atala,
   Anthony/0000 0001 8186 2160
CR Aguirre A, 2010, BIOCHEM BIOPH RES CO, V400, P284, DOI 10.1016/j.bbrc.2010.08.073
   Aicher A, 2003, CIRCULATION, V107, P2134, DOI 10.1161/01.CIR.0000062649.63838.C9
   Aicher A, 2003, NAT MED, V9, P1370, DOI 10.1038/nm948
   Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD
   Atesok K, 2011, THESIS U TORONTO, P83
   Atesok K, 2010, J ORTHOP RES, V28, P1007, DOI 10.1002/jor.21083
   Bahlmann FH, 2004, BLOOD, V103, P921, DOI 10.1182/blood 2003 04 1284
   BRIGHTON CT, 1991, J BONE JOINT SURG AM, V73A, P832, DOI 10.2106/00004623 199173060 00006
   Brighton CT, 1997, J ORTHOP TRAUMA, V11, P244, DOI 10.1097/00005131 199705000 00002
   Bueno EM, 2009, NAT REV RHEUMATOL, V5, P685, DOI 10.1038/nrrheum.2009.228
   Caplice Noel M, 2006, Nat Clin Pract Cardiovasc Med, V3 Suppl 1, pS129, DOI 10.1038/ncpcardio0432
   Capobianco S, 2010, WORLD J CARDIOL, V2, P411, DOI 10.4330/wjc.v2.i12.411
   Carano RAD, 2003, DRUG DISCOV TODAY, V8, P980, DOI 10.1016/S1359 6446(03)02866 6
   CARLINI RG, 1993, KIDNEY INT, V43, P1010, DOI 10.1038/ki.1993.142
   Dickson K F, 1995, Contemp Orthop, V30, P489
   Doyle B, 2006, ENDOTHELIUM J ENDOTH, V13, P403, DOI 10.1080/10623320601061656
   Einhorn T A, 2001, J Am Acad Orthop Surg, V9, P157
   EINHORN TA, 1995, J BONE JOINT SURG AM, V77A, P940, DOI 10.2106/00004623 199506000 00016
   Fedorovich NE, 2010, TISSUE ENG PT A, V16, P2355, DOI [10.1089/ten.tea.2009.0603, 10.1089/ten.TEA.2009.0603]
   Fuchs S, 2001, J AM COLL CARDIOL, V37, P1726, DOI 10.1016/S0735 1097(01)01200 1
   Gao YS, 2010, INT ORTHOP, V34, P779, DOI 10.1007/s00264 010 1009 5
   Geiger F, 2005, J BONE MINER RES, V20, P2028, DOI 10.1359/JBMR.050701
   Giannoudis PV, 2007, INJURY, V38, pS3, DOI 10.1016/S0020 1383(08)70003 2
   Gill M, 2001, CIRC RES, V88, P167
   Glowacki J, 1998, CLIN ORTHOP RELAT R, pS82, DOI 10.1097/00003086 199810001 00010
   Haller A., 1763, OPERA MINORA, V2, P400
   Haller H, 1996, KIDNEY INT, V50, P481, DOI 10.1038/ki.1996.339
   Hendrikx PJ, 1996, EXP HEMATOL, V24, P129
   Holstein JH, 2007, LIFE SCI, V80, P893, DOI 10.1016/j.lfs.2006.11.023
   Hristov M, 2004, J CELL MOL MED, V8, P498, DOI 10.1111/j.1582 4934.2004.tb00474.x
   HULTH ANDERS, 1964, ACTA ORTHOPAED SCAND, V34, P1
   Jaquet K, 2002, MICROVASC RES, V64, P326, DOI 10.1006/mvre.2002.2426
   Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397
   Kamihata H, 2001, CIRCULATION, V104, P1046, DOI 10.1161/hc3501.093817
   Kato S, 2010, J PHARMACOL SCI, V112, P167, DOI 10.1254/jphs.09262FP
   Kawamoto A, 2003, CIRCULATION, V107, P461, DOI 10.1161/01.CIR.0000046450.89986.50
   Keith A., 1928, P ROY SOC MED, V21, P301
   Keramaris NC, 2008, INJURY, V39, pS45, DOI 10.1016/S0020 1383(08)70015 9
   Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498
   Kuroda R, 2011, CELL TRANSPLANT, V20, P1491, DOI 10.3727/096368910X550189
   Laing AJ, 2007, J ORTHOP RES, V25, P44, DOI 10.1002/jor.20228
   Lee DY, 2008, BONE, V42, P932, DOI 10.1016/j.bone.2008.01.007
   Li R, 2011, J ORTHOP TRAUMA, V25, P467, DOI 10.1097/BOT.0b013e31821ad4ec
   Li R, 2009, J ORTHOP RES, V27, P8, DOI 10.1002/jor.20658
   Li ZH, 2011, INT J MED SCI, V8, P74, DOI 10.7150/ijms.8.74
   Logan ELB, 2006, THESIS U TORONTO, P4
   Lu CY, 2007, J ORTHOP RES, V25, P51, DOI 10.1002/jor.20264
   Matsumoto T, 2008, BONE, V43, P434, DOI 10.1016/j.bone.2008.05.001
   Matsumoto T, 2008, J CELL PHYSIOL, V215, P234, DOI 10.1002/jcp.21309
   Matsumoto T, 2006, AM J PATHOL, V169, P1440, DOI 10.2353/ajpath.2006.060064
   Matsumoto T, 2012, STEM CELLS DEV, V21, P859, DOI 10.1089/scd.2010.0528
   Meng QY, 2010, CHINESE MED J PEKING, V123, P471, DOI 10.3760/cma.j.issn.0366 6999.2010.04.016
   Mund JA, 2009, CYTOTHERAPY, V11, P103, DOI 10.1080/14653240802714827
   Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560
   Murohara T, 2000, J CLIN INVEST, V105, P1527, DOI 10.1172/JCI8296
   Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868
   Poh CK, 2010, BIOMATERIALS, V31, P1578, DOI 10.1016/j.biomaterials.2009.11.042
   Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603 702
   Rouwkema J, 2008, TRENDS BIOTECHNOL, V26, P434, DOI 10.1016/j.tibtech.2008.04.009
   Rozen N, 2009, BONE, V45, P918, DOI 10.1016/j.bone.2009.07.085
   Schächinger V, 2004, J AM COLL CARDIOL, V44, P1690, DOI 10.1016/j.jacc.2004.08.014
   Schuster MD, 2004, AM J PHYSIOL HEART C, V287, pH525, DOI 10.1152/ajpheart.00058.2004
   Seebach C, 2010, TISSUE ENG PT A, V16, P1961, DOI 10.1089/ten.TEA.2009.0715
   Shintani S, 2001, CIRCULATION, V103, P2776, DOI 10.1161/hc2301.092122
   Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C
   Tei K, 2008, STEM CELLS, V26, P819, DOI 10.1634/stemcells.2007 0671
   Teng Y.D., 2008, Principles of Regenerative Medicine, P300
   Timmermans F, 2009, J CELL MOL MED, V13, P87, DOI 10.1111/j.1582 4934.2008.00598.x
   TRUETA J, 1963, J BONE JOINT SURG BR, V45, P402, DOI 10.1302/0301 620X.45B2.402
   Urbich C, 2004, CIRC RES, V95, P343, DOI 10.1161/01.RES.0000137877.89448.78
   Zampetaki A, 2008, CARDIOVASC RES, V78, P413, DOI 10.1093/cvr/cvn081
   ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557
NR 73
TC 14
Z9 15
U1 0
U2 21
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0942 2056
EI 1433 7347
J9 KNEE SURG SPORT TR A
JI Knee Surg. Sports Traumatol. Arthrosc.
PD JUL
PY 2012
VL 20
IS 7
BP 1366
EP 1377
DI 10.1007/s00167 012 1940 7
PG 12
WC Orthopedics; Sport Sciences; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Sport Sciences; Surgery
GA 962FP
UT WOS:000305527400019
PM 22402606
DA 2025 08 17
ER

PT J
AU Coleman, RE
   Croucher, PI
   Padhani, AR
   Clézardin, P
   Chow, E
   Fallon, M
   Guise, T
   Colangeli, S
   Capanna, R
   Costa, L
AF Coleman, Robert E.
   Croucher, Peter I.
   Padhani, Anwar R.
   Clezardin, Philippe
   Chow, Edward
   Fallon, Marie
   Guise, Theresa
   Colangeli, Simone
   Capanna, Rodolfo
   Costa, Luis
TI Bone metastases
SO NATURE REVIEWS DISEASE PRIMERS
LA English
DT Article
ID PROGRESSION FREE SURVIVAL; SKELETAL RELATED EVENTS; ADVANCED
   BREAST CANCER; KAPPA B LIGAND; STEREOTACTIC BODY RADIOTHERAPY; ADVANCED
   MULTIPLE MYELOMA; SPINAL CORD COMPRESSION; LONG TERM EFFICACY;
   QUALITY OF LIFE; PROSTATE CANCER
AB Bone is the most frequent site for metastasis for many cancers, notably for tumours originating in the breast and the prostate. Tumour cells can escape from the primary tumour site and colonize the bone microenvironment. Within the bone, these disseminated tumour cells, as well as those arising in the context of multiple myeloma, may assume a state of dormancy, remaining quiescent for years before resuming proliferation and causing overt metastasis, which causes bone destruction via activation of osteoclast mediated osteolysis. This structural damage can lead to considerable morbidity, including pain, fractures and impaired quality of life. Although treatment of bone metastases and myeloma bone disease is rarely curative, disease control is often possible for many years through the use of systemic anticancer treatments on a background of multidisciplinary supportive care. This care should include bone targeted agents to inhibit tumour associated osteolysis and prevent skeletal morbidity as well as use of appropriate local treatments such as radiation therapy, orthopaedic surgery and specialist palliative care to minimize the impact of metastatic bone disease on physical functioning. In this Primer, we provide an overview of the clinical features, the pathophysiology and the specific treatment approaches to prevent and treat bone metastases from solid tumours as well as myeloma bone disease.
   The majority of individuals with cancer, notably those with breast or prostate cancer, will develop bone metastases. In this Primer, Coleman and colleagues discuss the epidemiology, pathophysiology and diagnosis of metastatic bone disease and highlight the specific treatment strategies to prevent disease progression and to manage skeletal morbidities.
C1 [Coleman, Robert E.; Clezardin, Philippe] Univ Sheffield, Dept Oncol & Metab, Sheffield, S Yorkshire, England.
   [Croucher, Peter I.] Garvan Inst Med Res, Darlinghurst, NSW, Australia.
   [Croucher, Peter I.] UNSW Sydney, St Vincents Clin Sch, Fac Med, Sydney, NSW, Australia.
   [Padhani, Anwar R.] Mt Vernon Canc Ctr, Paul Strickland Scanner Ctr, Northwood, Middx, England.
   [Clezardin, Philippe] Univ Lyon, Fac Med Lyon Est, INSERM, Res Unit UMR S1033,LyOS, Lyon, France.
   [Chow, Edward] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada.
   [Fallon, Marie] Univ Edinburgh, Edinburgh Canc Res Ctr IGMM, Edinburgh, Midlothian, Scotland.
   [Guise, Theresa] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA.
   [Colangeli, Simone; Capanna, Rodolfo] Univ Pisa, Dept Translat Res New Surg & Med Technol, Pisa, Italy.
   [Costa, Luis] Ctr Hosp Lisboa Norte, Fac Med, Hosp Santa Maria, Lisbon, Portugal.
   [Costa, Luis] Ctr Hosp Lisboa Norte, Fac Med, Inst Med Mol, Lisbon, Portugal.
C3 University of Sheffield; Garvan Institute of Medical Research;
   University of New South Wales Sydney; Mount Vernon Cancer Centre;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Claude Bernard Lyon 1; University of Toronto; University of
   Edinburgh; Indiana University System; Indiana University Bloomington;
   University of Pisa; Universidade de Lisboa; Hospital Santa Maria;
   Universidade de Lisboa
RP Coleman, RE (通讯作者)，Univ Sheffield, Dept Oncol & Metab, Sheffield, S Yorkshire, England.
EM r.e.coleman@sheffield.ac.uk
RI COLANGELI, Simone/K 2517 2018; Costa, Luis/E 5117 2015; Padhani,
   Anwar/KIA 9850 2024; COLANGELI, Simone/P 5644 2019; Clezardin,
   Philippe/M 8071 2014
OI COLANGELI, Simone/0000 0003 3861 4932; Fallon,
   Marie/0000 0001 9214 0091; Costa, Luis/0000 0002 4782 7318; Croucher,
   Peter/0000 0002 7102 2413; Clezardin, Philippe/0000 0003 0149 4463
FU J. Gibson and the Ernest Heine Family Foundation; Kay Stubbs Cancer
   Research Grant; Cancer Council New South Wales; Leukaemia Foundation;
   Prostate Cancer Foundation of Australia; Movember Foundation; National
   Health and Medical Research Council; INSERM, 'Appel a Projets LIA/LEA
   2016' [ASC17018CSA]; Weston Park Cancer Charity [CA163]; LabEX DEVweCAN
   from Universite de Lyon, within the programme 'Investissements d'Avenir'
   [ANR 10 LABX 61, ANR 11 IDEX 0007]
FX P.I.C. acknowledges J. Gibson and the Ernest Heine Family Foundation,
   the Kay Stubbs Cancer Research Grant, the Cancer Council New South
   Wales, the Leukaemia Foundation, the Prostate Cancer Foundation of
   Australia, The Movember Foundation and the National Health and Medical
   Research Council for supporting his research. P.C. acknowledges INSERM,
   'Appel a Projets LIA/LEA 2016' (grant no.: ASC17018CSA), Weston Park
   Cancer Charity (grant no.: CA163) and the LabEX DEVweCAN
   (ANR 10 LABX 61) from Universite de Lyon, within the programme
   'Investissements d'Avenir' (ANR 11 IDEX 0007) operated by the French
   National Research Agency (ANR), for funding his research.
CR Achrol AS, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572 018 0055 y
   Adamik J, 2018, J BONE ONCOL, V13, P62, DOI 10.1016/j.jbo.2018.09.001
   Aiello F, 2016, CHEMMEDCHEM, V11, P1686, DOI 10.1002/cmdc.201600111
   Alghamdi M, 2017, CHIN CLIN ONCOL, V6, DOI 10.21037/cco.2017.06.27
   [Anonymous], 2019, J CLIN ONCOL S
   Armstrong AJ, 2019, JAMA ONCOL, V6, P217
   Ballinger JR, 2018, BRIT J RADIOL, V91, DOI 10.1259/bjr.20170969
   Bennett MI, 2010, J PAIN, V11, P351, DOI 10.1016/j.jpain.2009.08.002
   Berenson JR, 1998, J CLIN ONCOL, V16, P593, DOI 10.1200/JCO.1998.16.2.593
   Berish RB, 2018, NAT REV UROL, V15, P403, DOI 10.1038/s41585 018 0020 2
   Bhattacharya IS, 2015, CLIN ONCOL UK, V27, P298, DOI 10.1016/j.clon.2015.01.030
   Body JJ, 2015, EUR J CANCER, V51, P1812, DOI 10.1016/j.ejca.2015.05.016
   Body JJ, 2001, SEMIN ONCOL, V28, P49, DOI 10.1016/S0093 7754(01)90232 5
   Body JJ, 2004, BRIT J CANCER, V90, P1133, DOI 10.1038/sj.bjc.6601663
   Body JJ, 2003, ANN ONCOL, V14, P1399, DOI 10.1093/annonc/mdg367
   BOXER DI, 1989, J NUCL MED, V30, P1318
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Braun S, 2005, NEW ENGL J MED, V353, P793, DOI 10.1056/NEJMoa050434
   Brown JE, 2005, JNCI J NATL CANCER I, V97, P59, DOI 10.1093/jnci/dji002
   Bruel BM, 2016, PAIN MED, V17, P2404, DOI 10.1093/pm/pnw060
   Brunetti G, 2020, J BONE MINER RES, V35, P671, DOI 10.1002/jbmr.3942
   Brylka LJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02182
   Buijs Jeroen T, 2012, Bonekey Rep, V1, P96, DOI 10.1038/bonekey.2012.96
   Calais J, 2019, LANCET ONCOL, V2045, P1
   Campbell JP, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001363
   Casimiro S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063153
   Chantry AD, 2010, J BONE MINER RES, V25, P2357, DOI 10.1002/jbmr.142
   Chen WG, 2019, CLIN EXP METASTAS, V36, P39, DOI 10.1007/s10585 018 9951 5
   Chen Z, 2014, BLOOD, V123, P2204, DOI 10.1182/blood 2013 07 517136
   Cher ML, 2006, AM J PATHOL, V168, P1405, DOI 10.2353/ajpath.2006.050874
   Choi SJ, 2000, BLOOD, V96, P671
   Chow E, 2012, CLIN ONCOL UK, V24, P112, DOI 10.1016/j.clon.2011.11.004
   Chow E, 2015, LANCET ONCOL, V16, P1463, DOI 10.1016/S1470 2045(15)00199 0
   Chow E, 2014, J CLIN ONCOL, V32, P3867, DOI 10.1200/JCO.2014.57.6264
   Chow E, 2014, LANCET ONCOL, V15, P164, DOI 10.1016/S1470 2045(13)70556 4
   Chu TQ, 2014, BIOCHEM BIOPH RES CO, V443, P962, DOI 10.1016/j.bbrc.2013.12.076
   Cleeland CS, 2006, CLIN CANCER RES, V12, p6236S, DOI 10.1158/1078 0432.CCR 06 0988
   Coleman R, 2015, LANCET, V386, P1353, DOI 10.1016/S0140 6736(15)60908 4
   Coleman R, 2014, ANN ONCOL, V25, P124, DOI 10.1093/annonc/mdu103
   Coleman RE, 2018, J BONE ONCOL, V13, P123, DOI 10.1016/j.jbo.2018.09.008
   Coleman R E, 1990, Clin Oncol (R Coll Radiol), V2, P328, DOI 10.1016/S0936 6555(05)80995 1
   COLEMAN RE, 1988, J NUCL MED, V29, P1354
   Coleman RE., 2019, Clinical Oncology, V51, P809
   Coleman R, 2020, LANCET ONCOL, V21, P60, DOI 10.1016/S1470 2045(19)30687 4
   Coleman R, 2019, BREAST, V48, pS92, DOI 10.1016/S0960 9776(19)31133 6
   Coleman R, 2017, LANCET ONCOL, V18, P1543, DOI 10.1016/S1470 2045(17)30603 4
   Coleman R, 2011, CRIT REV ONCOL HEMAT, V80, P411, DOI 10.1016/j.critrevonc.2011.02.005
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Coleman RE, 2013, NAT REV RHEUMATOL, V9, P365, DOI 10.1038/nrrheum.2013.36
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Contartese D, 2020, CELL MOL LIFE SCI, V77, P3913, DOI 10.1007/s00018 020 03513 y
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Cox TR, 2015, NATURE, V522, P106, DOI 10.1038/nature14492
   Crawford ED, 2019, J UROLOGY, V201, P682, DOI 10.1016/j.juro.2018.05.164
   Croucher PI, 2016, NAT REV CANCER, V16, P373, DOI 10.1038/nrc.2016.44
   Croucher PI, 2001, BLOOD, V98, P3534, DOI 10.1182/blood.V98.13.3534
   D'Oronzo S, 2019, J BONE ONCOL, V15, DOI 10.1016/j.jbo.2018.10.004
   Damron TA, 2020, J ORTHOP RES, V38, P1175, DOI 10.1002/jor.24660
   Danson S, 2019, J BONE ONCOL, V19, DOI 10.1016/j.jbo.2019.100261
   Delgado Calle J, 2017, LEUKEMIA, V31, P2686, DOI 10.1038/leu.2017.152
   Delgado Calle J, 2016, CANCER RES, V76, P1089, DOI 10.1158/0008 5472.CAN 15 1703
   Dennis K, 2011, CLIN ONCOL UK, V23, P709, DOI 10.1016/j.clon.2011.05.004
   Disch AC, 2020, EJSO EUR J SURG ONC, V46, P89, DOI 10.1016/j.ejso.2019.08.019
   Drost L, 2017, RADIOTHER ONCOL, V124, P45, DOI 10.1016/j.radonc.2017.05.010
   Dudley AC, 2008, CANCER CELL, V14, P201, DOI 10.1016/j.ccr.2008.06.017
   Eda H, 2016, J BONE MINER RES, V31, P1225, DOI 10.1002/jbmr.2789
   Ell B, 2013, CANCER CELL, V24, P542, DOI 10.1016/j.ccr.2013.09.008
   Escudier B, 2018, J CLIN ONCOL, V36, P765, DOI 10.1200/JCO.2017.74.7352
   Eyre R, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 12807 0
   Fallon MT, 2013, BRIT J ANAESTH, V111, P105, DOI 10.1093/bja/aet208
   Fallon M, 2016, J CLIN ONCOL, V34, P550, DOI 10.1200/JCO.2015.63.8221
   Fanti S, 2017, EUR J NUCL MED MOL I, V44, P1622, DOI 10.1007/s00259 017 3725 1
   Albiach CF, 2019, J PAIN RES, V12, P2125, DOI 10.2147/JPR.S194881
   Fisher CG, 2010, SPINE, V35, pE1221, DOI 10.1097/BRS.0b013e3181e16ae2
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fornetti J, 2018, J BONE MINER RES, V33, P2099, DOI 10.1002/jbmr.3618
   Futamura N, 2013, CLIN EXP METASTAS, V30, P595, DOI 10.1007/s10585 012 9563 4
   Gardner K, 2019, CRIT REV ONCOL HEMAT, V133, P33, DOI 10.1016/j.critrevonc.2018.10.008
   Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767
   Giuliani N, 2002, BLOOD, V100, P4615, DOI 10.1182/blood 2002 04 1121
   Giuliani N, 2007, CANCER RES, V67, P7665, DOI 10.1158/0008 5472.CAN 06 4666
   Gnant M, 2019, LANCET ONCOL, V20, P339, DOI 10.1016/S1470 2045(18)30862 3
   Gnant M, 2011, LANCET ONCOL, V12, P631, DOI 10.1016/S1470 2045(11)70122 X
   Gnoni Antonio, 2020, Oncotarget, V11, P480, DOI 10.18632/oncotarget.27439
   Gordon Williams Richard M, 2007, Curr Opin Support Palliat Care, V1, P6, DOI 10.1097/SPC.0b013e328133f5e9
   Gralow J.R., 2019, J NATL CANC I, V112, P698
   Grubmüller B, 2019, EUR J NUCL MED MOL I, V46, P1063, DOI 10.1007/s00259 018 4236 4
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Hadji P, 2013, CRIT REV ONCOL HEMAT, V87, P101, DOI 10.1016/j.critrevonc.2013.05.015
   Hahn C, 2014, PRACT RADIAT ONCOL, V4, P349, DOI 10.1016/j.prro.2014.06.003
   Harris K, 2009, EUR J CANCER, V45, P2510, DOI 10.1016/j.ejca.2009.05.024
   Health Quality Ontario, 2016, Ont Health Technol Assess Ser, V16, P1
   Heath DJ, 2009, J BONE MINER RES, V24, P425, DOI 10.1359/JBMR.081104
   Heider U, 2003, CLIN CANCER RES, V9, P1436
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Herbst RS, 2018, NATURE, V553, P446, DOI 10.1038/nature25183
   Hernández I, 2010, ONCOGENE, V29, P3758, DOI 10.1038/onc.2010.130
   Hesse E, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125543
   Himelstein AL, 2017, JAMA J AM MED ASSOC, V317, P48, DOI 10.1001/jama.2016.19425
   Hird A, 2009, INT J RADIAT ONCOL, V75, P193, DOI 10.1016/j.ijrobp.2008.10.044
   Hjertner O, 1999, BLOOD, V94, P3883
   Hofbauer LC, 2014, LANCET DIABETES ENDO, V2, P500, DOI 10.1016/S2213 8587(13)70203 1
   Hofman MS, 2018, LANCET ONCOL, V19, P825, DOI 10.1016/S1470 2045(18)30198 0
   Hortobagyi GN, 2017, JAMA ONCOL, V3, P906, DOI 10.1001/jamaoncol.2016.6316
   Hortobagyi GN, 2015, NEOPLASIA, V17, P279, DOI 10.1016/j.neo.2015.01.005
   Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401
   Hoskin P, 2015, JNCI J NATL CANCER I, V107, DOI 10.1093/jnci/djv197
   Hoskin PJ, 2019, JAMA J AM MED ASSOC, V322, P2084, DOI 10.1001/jama.2019.17913
   Hosseini H, 2016, NATURE, V540, P552, DOI 10.1038/nature20785
   Ibrahim T, 2010, CANCER AM CANCER SOC, V116, P1406, DOI 10.1002/cncr.24896
   Iuliani M, 2015, ONCOTARGET, V6, P12520, DOI 10.18632/oncotarget.3724
   Jambor I, 2016, ACTA ONCOL, V55, P59, DOI 10.3109/0284186X.2015.1027411
   Jensen AB, 2010, CLIN BREAST CANCER, V10, P452, DOI 10.3816/CBC.2010.n.059
   Joeckel E, 2014, MOL CANCER, V13, DOI 10.1186/1476 4598 13 42
   Johnson RW, 2014, CLIN EXP METASTAS, V31, P945, DOI 10.1007/s10585 014 9682 1
   Johnston EW, 2019, EUR RADIOL, V29, P3159, DOI 10.1007/s00330 018 5813 4
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Keller L, 2019, NAT REV CANCER, V19, P553, DOI 10.1038/s41568 019 0180 2
   Khoo WH, 2019, BLOOD, V134, P30, DOI 10.1182/blood.2018880930
   Kinnane N, 2007, EUR J ONCOL NURS, V11, pS28, DOI 10.1016/j.ejon.2007.07.002
   Kohno N., 2005, J CLIN ONCOL, V20, P3299
   Koreckij T, 2009, BRIT J CANCER, V101, P263, DOI 10.1038/sj.bjc.6605178
   Kumar S, 2016, LANCET ONCOL, V17, pE328, DOI 10.1016/S1470 2045(16)30206 6
   LAHTINEN R, 1992, LANCET, V340, P1049, DOI 10.1016/0140 6736(92)93075 X
   Laird BJA, 2011, SUPPORT CARE CANCER, V19, P1393, DOI 10.1007/s00520 010 0961 3
   Lamy O, 2019, CURR OSTEOPOROS REP, V17, P8, DOI 10.1007/s11914 019 00502 4
   Lang JL, 2018, BIOMARKERS, V23, P518, DOI 10.1080/1354750X.2018.1463566
   Lara Castillo N, 2020, CURR OSTEOPOROS REP, V18, P408, DOI 10.1007/s11914 020 00602 6
   Lawson MA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9983
   Lee RJ, 2013, CANCER J, V19, P90, DOI 10.1097/PPO.0b013e318281e280
   Liang WP, 2019, J CANCER RES CLIN, V145, P1999, DOI 10.1007/s00432 019 02950 y
   Lin SC, 2018, CURR OSTEOPOROS REP, V16, P642, DOI 10.1007/s11914 018 0480 6
   Lin SC, 2017, DEV CELL, V41, P467, DOI 10.1016/j.devcel.2017.05.005
   Liu AY, 2004, AM J PATHOL, V165, P1543, DOI 10.1016/S0002 9440(10)63412 8
   Luis Ravelo D, 2014, ONCOGENE, V33, P5090, DOI 10.1038/onc.2013.440
   Lutz S, 2011, INT J RADIAT ONCOL, V79, P965, DOI 10.1016/j.ijrobp.2010.11.026
   Maranzano E, 2005, J CLIN ONCOL, V23, P3358, DOI 10.1200/JCO.2005.08.193
   Marino S, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031286
   Mateo J, 2019, EUR UROL, V75, P285, DOI 10.1016/j.eururo.2018.07.035
   McDonald MM, 2017, BLOOD, V129, P3452, DOI 10.1182/blood 2017 03 773341
   McDonald R, 2017, JAMA ONCOL, V3, P953, DOI 10.1001/jamaoncol.2016.6770
   McWilliams K, 2013, QJM INT J MED, V106, P887, DOI 10.1093/qjmed/hct092
   Melton LJ, 2005, J BONE MINER RES, V20, P487, DOI 10.1359/JBMR.041131
   Melton LJ, 2004, J BONE MINER RES, V19, P25, DOI 10.1359/JBMR.0301212
   Middlemiss T, 2011, CLIN ONCOL UK, V23, P387, DOI 10.1016/j.clon.2011.03.003
   Miller RE, 2014, J THORAC ONCOL, V9, P345, DOI 10.1097/JTO.0000000000000070
   Miller S, 2017, BMJ SUPPORT PALLIAT, V7, pA46
   MIRELS H, 1989, CLIN ORTHOP RELAT R, P256
   Mishra A, 2011, CANCER MICROENVIRON, V4, P221, DOI 10.1007/s12307 011 0083 6
   Morgan GJ, 2013, CLIN CANCER RES, V19, P6030, DOI 10.1158/1078 0432.CCR 12 3211
   Morris MJ, 2015, J CLIN ONCOL, V33, P1356, DOI 10.1200/JCO.2014.55.3875
   Morrissey C, 2013, J BONE MINER RES, V28, P333, DOI 10.1002/jbmr.1749
   Mottet N, 2019, EAU EANM ESTRO ESUR, V53
   Nakata E, 2017, J ORTHOP SCI, V22, P946, DOI 10.1016/j.jos.2017.04.011
   NELSON JB, 1995, NAT MED, V1, P944, DOI 10.1038/nm0995 944
   Nicolatou Galitis O, 2019, OR SURG OR MED OR PA, V127, P117, DOI 10.1016/j.oooo.2018.09.008
   Ost P, 2018, J CLIN ONCOL, V36, P446, DOI 10.1200/JCO.2017.75.4853
   Oster G, 2013, SUPPORT CARE CANCER, V21, P3279, DOI 10.1007/s00520 013 1887 3
   Ottewell PD, 2014, CLIN CANCER RES, V20, P2922, DOI 10.1158/1078 0432.CCR 13 1246
   Owen KL, 2020, EMBO REP, V21, DOI 10.15252/embr.202050162
   Oyajobi BO, 2007, BRIT J HAEMATOL, V139, P434, DOI 10.1111/j.1365 2141.2007.06829.x
   Oyajobi BO, 2003, BLOOD, V102, P311, DOI 10.1182/blood 2002 12 3905
   Padhani AR, 2017, EUR UROL FOCUS, V3, P223, DOI 10.1016/j.euf.2016.06.018
   Padhani AR, 2017, EUR UROL, V71, P81, DOI 10.1016/j.eururo.2016.05.033
   Paget S., LANCET, V1, P571, DOI DOI 10.1016/S0140 6736(00)49915 0
   Pang HL, 2017, ONCOL RES, V25, P35, DOI 10.3727/096504016X14719078133249
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Parker C, 2018, JAMA ONCOL, V4, P1765, DOI 10.1001/jamaoncol.2018.4044
   Patchell RA, 2005, LANCET, V366, P643, DOI 10.1016/S0140 6736(05)66954 1
   PATERSON AHG, 1993, J CLIN ONCOL, V11, P59, DOI 10.1200/JCO.1993.11.1.59
   Paton Hough J, 2019, J BONE MINER RES, V34, P783, DOI 10.1002/jbmr.3606
   Patrick DL, 2015, SUPPORT CARE CANCER, V23, P1157, DOI 10.1007/s00520 014 2525 4
   Pavlovic M, 2015, JNCI J NATL CANCER I, V107, DOI 10.1093/jnci/djv256
   Pearse RN, 2001, P NATL ACAD SCI USA, V98, P11581, DOI 10.1073/pnas.201394498
   Perera M, 2020, EUR UROL, V77, P403, DOI 10.1016/j.eururo.2019.01.049
   Perez Lopez R, 2018, INVEST RADIOL, V53, P96, DOI 10.1097/RLI.0000000000000415
   Peters S, 2018, ANN ONCOL, V29, pviii493
   Phan TG, 2020, NAT REV CANCER, V20, P398, DOI 10.1038/s41568 020 0263 0
   Politou MC, 2006, INT J CANCER, V119, P1728, DOI 10.1002/ijc.22033
   Nguyen QN, 2019, JAMA ONCOL, V5, P872, DOI 10.1001/jamaoncol.2019.0192
   Raje N, 2018, LANCET ONCOL, V19, P370, DOI 10.1016/S1470 2045(18)30072 X
   Rajkumar S Vincent, 2016, Am Soc Clin Oncol Educ Book, V35, pe418, DOI 10.14694/EDBK_159009
   Rich SE, 2018, RADIOTHER ONCOL, V126, P547, DOI 10.1016/j.radonc.2018.01.003
   Rizzo S, 2017, CRIT REV ONCOL HEMAT, V120, P227, DOI 10.1016/j.critrevonc.2017.09.008
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Rosanò L, 2013, NAT REV CANCER, V13, P637, DOI 10.1038/nrc3546
   Rosen LS, 2001, CANCER J, V7, P377
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Rosen LS, 2004, CANCER, V100, P2613, DOI 10.1002/cncr.20308
   Roudier Martine P, 2004, Cancer Treat Res, V118, P311
   Ruhlmann CH, 2017, SUPPORT CARE CANCER, V25, P309, DOI 10.1007/s00520 016 3407 8
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Sartor O, 2013, CANCER TREAT REV, V39, P18, DOI 10.1016/j.ctrv.2012.03.006
   Scagliotti GV, 2012, ANN ONCOL, V23, P2082, DOI 10.1093/annonc/mds128
   Scher HI, 2016, J CLIN ONCOL, V34, P1402, DOI 10.1200/JCO.2015.64.2702
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Sethi N, 2011, NAT REV CANCER, V11, P735, DOI 10.1038/nrc3125
   Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022
   Shen GH, 2014, SKELETAL RADIOL, V43, P1503, DOI 10.1007/s00256 014 1903 9
   Shiozawa Y, 2011, CLIN CANCER RES, V17, P5553, DOI 10.1158/1078 0432.CCR 10 2505
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Siravegna G, 2017, NAT REV CLIN ONCOL, V14, P531, DOI 10.1038/nrclinonc.2017.14
   Smith DC, 2013, J CLIN ONCOL, V31, P412, DOI 10.1200/JCO.2012.45.0494
   Smith M, 2019, LANCET ONCOL, V20, P408, DOI 10.1016/S1470 2045(18)30860 X
   Smith M, 2016, J CLIN ONCOL, V34, P3005, DOI 10.1200/JCO.2015.65.5597
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   Song HL, 2020, BMC CANCER, V20, DOI 10.1186/s12885 020 06739 y
   Sottnik JL, 2015, CANCER RES, V75, P2151, DOI 10.1158/0008 5472.CAN 14 2493
   Sousa S, 2018, CALCIFIED TISSUE INT, V102, P227, DOI 10.1007/s00223 017 0353 5
   Sprave T, 2018, BMC CANCER, V18, DOI 10.1186/s12885 018 4777 8
   Sprave T, 2018, ANTICANCER RES, V38, P4961, DOI 10.21873/anticanres.12814
   Sprave T, 2018, RADIOTHER ONCOL, V128, P274, DOI 10.1016/j.radonc.2018.04.030
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Thang SP, 2019, EUR UROL ONCOL, V2, P670, DOI 10.1016/j.euo.2018.11.007
   Sung H, 2021, CA CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tahara RK, 2019, ADV EXP MED BIOL, V1152, P105, DOI 10.1007/978 3 030 20301 6_7
   Tateishi U, 2010, ANN NUCL MED, V24, P523, DOI 10.1007/s12149 010 0393 7
   Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078 0432.CCR 09 2329
   Terpos E, 2003, BLOOD, V102, P1064, DOI 10.1182/blood 2003 02 0380
   Theriault RL, 1999, J CLIN ONCOL, V17, P846, DOI 10.1200/JCO.1999.17.3.846
   Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Todenhöfer T, 2015, INT J ENDOCRINOL, V2015, DOI 10.1155/2015/838202
   TOWNSEND PW, 1995, INT J RADIAT ONCOL, V31, P43, DOI 10.1016/0360 3016(94)E0310 G
   Tsourdi E, 2017, BONE, V105, P11, DOI 10.1016/j.bone.2017.08.003
   Uehara S, 2019, J ORAL BIOSCI, V61, P135, DOI 10.1016/j.job.2019.07.002
   Urch C, 2004, PALLIATIVE MED, V18, P267, DOI 10.1191/0269216304pm887ra
   Vallet S, 2010, P NATL ACAD SCI USA, V107, P5124, DOI 10.1073/pnas.0911929107
   Van der Linden YM, 2004, J BONE JOINT SURG BR, V86B, P566, DOI 10.1302/0301 620X.86B4.14703
   van der Linden YM, 2003, RADIOTHER ONCOL, V69, P21, DOI 10.1016/S0167 8140(03)00232 9
   Vicent S, 2008, CANCER RES, V68, P2275, DOI 10.1158/0008 5472.CAN 07 6493
   Virgolini I, 2018, EUR J NUCL MED MOL I, V45, P471, DOI 10.1007/s00259 017 3882 2
   von Eyben FE, 2014, NUCL MED COMMUN, V35, P221, DOI 10.1097/MNM.0000000000000040
   von Moos R, 2019, CANCER TREAT REV, V76, P57, DOI 10.1016/j.ctrv.2019.05.003
   von Moos R, 2016, SUPPORT CARE CANCER, V24, P1327, DOI 10.1007/s00520 015 2908 1
   Wahl RL, 2009, J NUCL MED, V50, p122S, DOI 10.2967/jnumed.108.057307
   Wan XH, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009332
   Wang H, 2018, CANCER CELL, V34, P823, DOI 10.1016/j.ccell.2018.10.002
   Wang H, 2015, CANCER CELL, V27, P193, DOI 10.1016/j.ccell.2014.11.017
   Wang S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10379 7
   Wang WC, 2019, ONCOGENE, V38, P4540, DOI 10.1038/s41388 019 0736 3
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Weiss KR, 2011, J BONE JOINT SURG BR, V93B, P1093, DOI 10.1302/0301 620X.93B8.26194
   Westbrook JA, 2016, JNCI J NATL CANCER I, V108, DOI 10.1093/jnci/djv360
   Willeumier JJ, 2016, EFORT OPEN REV, V1, P136, DOI 10.1302/2058 5241.1.000008
   Wilson C, 2016, JAMA ONCOL, V2, P423, DOI 10.1001/jamaoncol.2015.5768
   Wirth M, 2015, EUR UROL, V67, P482, DOI 10.1016/j.eururo.2014.02.014
   Wondergem M, 2013, NUCL MED COMMUN, V34, P935, DOI 10.1097/MNM.0b013e328364918a
   Woodward JKL, 2007, BONE, V41, P912, DOI 10.1016/j.bone.2007.07.024
   Wright LE, 2017, ONCOTARGET, V8, P8406, DOI 10.18632/oncotarget.14139
   Wüstemann T, 2019, MED RES REV, V39, P40, DOI 10.1002/med.21508
   Yaccoby S, 2002, BRIT J HAEMATOL, V116, P278, DOI 10.1046/j.1365 2141.2002.03257.x
   Yaccoby S, 2007, BLOOD, V109, P2106, DOI 10.1182/blood 2006 09 047712
   Yang HL, 2011, EUR RADIOL, V21, P2604, DOI 10.1007/s00330 011 2221 4
   Yang M, 2020, SUPPORT CARE CANCER, V28, P2533, DOI 10.1007/s00520 020 05355 7
   Yin JJ, 2003, P NATL ACAD SCI USA, V100, P10954, DOI 10.1073/pnas.1830978100
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Yu EY, 2015, J NUCL MED, V56, P354, DOI 10.2967/jnumed.114.146936
   Zajaczkowska R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236047
   Zhang XHF, 2013, CELL, V154, P1060, DOI 10.1016/j.cell.2013.07.036
   Zoni E, 2016, J BONE ONCOL, V5, P104, DOI 10.1016/j.jbo.2016.04.002
NR 262
TC 368
Z9 391
U1 23
U2 168
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2056 676X
J9 NAT REV DIS PRIMERS
JI Nat. Rev. Dis. Primers
PD OCT 15
PY 2020
VL 6
IS 1
AR 83
DI 10.1038/s41572 020 00216 3
PG 28
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA OG8JR
UT WOS:000582123800001
PM 33060614
DA 2025 08 17
ER

PT J
AU Chen, SC
   Brooks, R
   Houskeeper, J
   Bremner, SK
   Dunlop, J
   Viollet, B
   Logan, PJ
   Salt, IP
   Ahmed, SF
   Yarwood, SJ
AF Chen, Suet Ching
   Brooks, Rebecca
   Houskeeper, Jessica
   Bremner, Shaun K.
   Dunlop, Julia
   Viollet, Benoit
   Logan, Pamela J.
   Salt, Ian P.
   Ahmed, S. Faisal
   Yarwood, Stephen J.
TI Metformin suppresses adipogenesis through both AMP activated protein
   kinase (AMPK) dependent and AMPK independent mechanisms
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE Adipogenesis; Osteogenesis; Metformin; Diabetes; AMPK; Mesenchymal stem
   cells
ID MESENCHYMAL STEM CELLS; ANTIDIABETIC DRUG METFORMIN; ADIPOCYTE
   DIFFERENTIATION; OSTEOBLAST DIFFERENTIATION; DIABETES MELLITUS;
   MAMMALIAN TARGET; UPSTREAM KINASE; 3T3 L1 CELLS; PPAR GAMMA; CROSS TALK
AB People with Type 2 diabetes mellitus (T2DM) have reduced bone mineral density and an increased risk of fractures due to altered mesenchymal stem cell (MSC) differentiation in the bone marrow. This leads to a shift in the balance of differentiation away from bone formation (osteogenesis) in favour of fat cell development (adipogenesis). The commonly used anti diabetic drug, metformin, activates the osteogenic transcription factor Runt related transcription factor 2 (Runx2), which may suppress adipogenesis, leading to improved bone health. Here we investigate the involvement of the metabolic enzyme, AMP activated protein kinase (AMPK), in these protective actions of metformin. The anti adipogenic actions of metformin were observed in multipotent C3H10T1/2 MSCs, in which metformin exerted reciprocal control over the activities of Runx2 and the adipogenic transcription factor, PPAR gamma, leading to suppression of adipogenesis. These effects appeared to be independent of AMPK activation but rather through the suppression of the mTOR/p70(S6K) signalling pathway. Basal AMPK and mTOR/p70(S6K) activity did appear to be required for adipogenesis, as demonstrated by the use of the AMPK inhibitor, compound C. This observation was further supported by using AMPK knockout mouse embryo fibroblasts (MEFs) where adipogenesis, as assessed by reduced lipid accumulation and expression of the adipogeneic transcription factor, C/EBP beta, was found to display an absolute requirement for AMPK. Further activation of AMPK in wild type MEFS, with either metformin or the AMPK specific activator, A769662, was also associated with suppression of adipogenesis. It appears, therefore, that basal AMPK activity is required for adipogenesis and that metformin can inhibit adipogenesis through AMPK dependent or independent mechanisms, depending on the cellular context. (C) 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license.
C1 [Chen, Suet Ching; Brooks, Rebecca; Ahmed, S. Faisal] Univ Glasgow, Sch Med, Dev Endocrinol Res Grp, Glasgow G51 4TF, Lanark, Scotland.
   [Chen, Suet Ching; Houskeeper, Jessica; Bremner, Shaun K.; Dunlop, Julia] Univ Glasgow, Inst Mol Cell & Syst Biol, Univ Ave, Glasgow G12 8QQ, Lanark, Scotland.
   [Logan, Pamela J.; Salt, Ian P.] Univ Glasgow, Inst Cardiovasc & Med Sci, Univ Ave, Glasgow G12 8QQ, Lanark, Scotland.
   [Viollet, Benoit] Inst Cochin, U1016, INSERM, Paris, France.
   [Viollet, Benoit] CNRS, UMR8104, Paris, France.
   [Viollet, Benoit] Univ Paris 05, Sorbonne Paris Cite, Paris, France.
   [Yarwood, Stephen J.] Heriot Watt Univ, Inst Biol Chem Biophys & Bioengn, Edinburgh Campus, Edinburgh EH14 4AS, Midlothian, Scotland.
C3 University of Glasgow; University of Glasgow; University of Glasgow;
   Universite Paris Cite; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS);
   CNRS   National Institute for Biology (INSB); Universite Paris Cite;
   Universite Paris Cite; Heriot Watt University
RP Yarwood, SJ (通讯作者)，Heriot Watt Univ, Inst Biol Chem Biophys & Bioengn, Edinburgh Campus, Edinburgh EH14 4AS, Midlothian, Scotland.
EM S.Yarwood@hw.ac.uk
RI Viollet, Benoit/O 6927 2017; Ahmed, Sk. Faisal/AGY 3981 2022
OI Viollet, Benoit/0000 0002 0121 0224; Bremner Hart,
   Shaun/0000 0002 8429 5154; Salt, Ian/0000 0003 0055 3724; Yarwood,
   Stephen/0000 0001 9489 9253
FU Tenovus Scotland [S13/15]; Diabetes UK Equipment Grant [BDA:
   11/0004309]; British Heart Foundation Project Grant [PG/15/15/31316];
   BBSRC [BB/D015324/1] Funding Source: UKRI; MRC [MR/N003403/1] Funding
   Source: UKRI; Biotechnology and Biological Sciences Research Council
   [BB/D015324/1] Funding Source: researchfish; British Heart Foundation
   [PG/15/15/31316, PG/10/26/28303, FS/17/12/32703] Funding Source:
   researchfish; Medical Research Council [MR/N003403/1] Funding Source:
   researchfish
FX This work was funded by a research project grant from Tenovus Scotland
   (grant number S13/15), awarded to SJY, IPS and SFA, a Diabetes UK
   Equipment Grant (grant number BDA: 11/0004309), awarded to SJY and IPS,
   and a British Heart Foundation Project Grant (grant number
   PG/15/15/31316) awarded to SJY.
CR Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097 4644(19970701)66:1<1::AID JCB1>3.0.CO;2 V
   Bang S, 2014, MOL ENDOCRINOL, V28, P1186, DOI 10.1210/me.2014 1134
   Bergeron R, 2001, AM J PHYSIOL ENDOC M, V281, pE1340, DOI 10.1152/ajpendo.2001.281.6.E1340
   CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Cool B, 2006, CELL METAB, V3, P403, DOI 10.1016/j.cmet.2006.05.005
   Cortizo AM, 2006, EUR J PHARMACOL, V536, P38, DOI 10.1016/j.ejphar.2006.02.030
   Cusi K, 1996, J CLIN ENDOCR METAB, V81, P4059, DOI 10.1210/jc.81.11.4059
   Day C., 2007, COMPREHENSIVE PHARM, P1
   Dowling RJO, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 33
   El Mir MY, 2000, J BIOL CHEM, V275, P223, DOI 10.1074/jbc.275.1.223
   Foretz M, 2010, J CLIN INVEST, V120, P2355, DOI 10.1172/JCI40671
   Fulco M, 2008, DEV CELL, V14, P661, DOI 10.1016/j.devcel.2008.02.004
   Grey A, 2007, J CLIN ENDOCR METAB, V92, P1305, DOI 10.1210/jc.2006 2646
   Habinowski SA, 2001, BIOCHEM BIOPH RES CO, V286, P852, DOI 10.1006/bbrc.2001.5484
   Hardie DG, 2015, CURR OPIN CELL BIOL, V33, P1, DOI 10.1016/j.ceb.2014.09.004
   Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009
   Hothersall E.J., 2013, J BONE MIN RES
   Jang WG, 2011, BONE, V48, P885, DOI 10.1016/j.bone.2010.12.003
   Janghorbani M, 2007, AM J EPIDEMIOL, V166, P495, DOI 10.1093/aje/kwm106
   Jeon MJ, 2003, J BIOL CHEM, V278, P23270, DOI 10.1074/jbc.M211610200
   Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027
   Kanazawa I, 2008, BIOCHEM BIOPH RES CO, V375, P414, DOI 10.1016/j.bbrc.2008.08.034
   Kilpadi KL, 2014, J IMMIGR MINOR HEALT, V16, P440, DOI 10.1007/s10903 013 9833 5
   Kim EK, 2012, J CELL PHYSIOL, V227, P1680, DOI 10.1002/jcp.22892
   Kobashigawa LC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104888
   Lantier L, 2014, FASEB J, V28, P3211, DOI 10.1096/fj.14 250449
   Lecka Czernik B, 2007, ENDOCRINOLOGY, V148, P903, DOI 10.1210/en.2006 1121
   Lecka Czernik B, 2009, CURR OPIN INVEST DR, V10, P1085
   Lee H, 2011, INT J MOL MED, V28, P65, DOI 10.3892/ijmm.2011.674
   Lee JO, 2012, J BIOL CHEM, V287, P44121, DOI 10.1074/jbc.M112.361386
   Lee S, 2014, BMC CELL BIOL, V15, DOI 10.1186/s12860 014 0042 4
   Longnus SL, 2005, DIABETOLOGIA, V48, P2591, DOI 10.1007/s00125 005 0016 3
   Moreno Navarrete JM, 2011, DIABETES, V60, P168, DOI 10.2337/db10 0805
   Morrow VA, 2003, J BIOL CHEM, V278, P31629, DOI 10.1074/jbc.M212831200
   Muruganandan S, 2009, CELL MOL LIFE SCI, V66, P236, DOI 10.1007/s00018 008 8429 z
   Nam M, 2008, ARCH BIOCHEM BIOPHYS, V479, P74, DOI 10.1016/j.abb.2008.07.029
   Pantovic A, 2013, BONE, V52, P524, DOI 10.1016/j.bone.2012.10.024
   Reihill JA, 2007, BIOCHEM BIOPH RES CO, V354, P1084, DOI 10.1016/j.bbrc.2007.01.110
   Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145
   Saitoh M, 2002, J BIOL CHEM, V277, P20104, DOI 10.1074/jbc.M201745200
   Salminen A, 2011, J MOL MED, V89, P667, DOI 10.1007/s00109 011 0748 0
   Salt IP, 2012, EXPERT OPIN INV DRUG, V21, P1155, DOI 10.1517/13543784.2012.696609
   Schwartz AV, 2006, J CLIN ENDOCR METAB, V91, P3349, DOI 10.1210/jc.2005 2226
   Shea CM, 2003, J CELL BIOCHEM, V90, P1112, DOI 10.1002/jcb.10734
   Shockley KR, 2009, J CELL BIOCHEM, V106, P232, DOI 10.1002/jcb.21994
   Sun HL, 2013, STEM CELLS, V31, P2183, DOI 10.1002/stem.1455
   TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224
   TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092 8674(94)90006 X
   Vazquez Martin A, 2009, CELL CYCLE, V8, P88, DOI 10.4161/cc.8.1.7499
   Vila Bedmar R, 2010, ENDOCRINOLOGY, V151, P980, DOI 10.1210/en.2009 0810
   Viollet B, 2012, CLIN SCI, V122, P253, DOI 10.1042/CS20110386
   Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031
   Yarwood SJ, 1999, J BIOL CHEM, V274, P8662, DOI 10.1074/jbc.274.13.8662
   YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168
   Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505
NR 56
TC 114
Z9 122
U1 1
U2 54
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303 7207
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD JAN 15
PY 2017
VL 440
IS C
BP 57
EP 68
DI 10.1016/j.mce.2016.11.011
PG 12
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA EI8WF
UT WOS:000392788200007
PM 27856330
OA Green Accepted, Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Ren, SJ
   Xing, GL
   Hu, NW
   Xu, WM
   Wang, YQ
   Dong, QP
   Jiang, YC
AF Ren, Shu Jun
   Xing, Guo Li
   Hu, Nai Wu
   Xu, Wei Ming
   Wang, Yong Qi
   Dong, Qing Ping
   Jiang, Yi Chang
TI Bu Shen Jian Pi Yi Qi Therapy Prevents Alcohol Induced Osteoporosis in
   Rats
SO AMERICAN JOURNAL OF THERAPEUTICS
LA English
DT Article
DE traditional Chinese medicine; Bu Shen Jian Pi Yi Qi; JIAN GU LING;
   alcohol induced osteoporosis; bone mineral density; bone mineral
   content; biomechanical properties; vitamin D receptor
ID TRADITIONAL CHINESE MEDICINE; VITAMIN D; BONE LOSS; HERBAL PREPARATION;
   ECONOMIC BURDEN; OSTEOBLASTS; EPIDEMIOLOGY; MECHANISMS; PROTECTS;
   EXTRACT
AB Bu Shen Jian Pi Yi Qi therapy, which refers to reinforcing kidney, regulating qi, and invigorating spleen, is a traditional Chinese medicine, and we investigated its efficacy in treatment of alcohol induced osteoporosis and its underlying mechanism. Forty adult male Sprague Dawley rats were randomly assigned into alcohol supplemented group, JIAN GU LING (JGL) group, calcium D3 + alfacalcidol group, and sham treated group. Bone mineral density (BMD), bone mineral content (BMC), and bone biomechanical properties were assessed. Biochemical analyses of serum and urine specimens were detected. Reverse transcription polymerase chain reaction was used to detect the mRNA level of vitamin D receptor (VDR). There were markedly lower bone metabolic markers and biomechanical properties in alcohol supplemented group compared with sham treated group (all P < 0.05). BMD, BMC, 25(OH)D 3, and 1,25(OH)(2)D 3 were elevated in JGL group relative to calcium D3 + alfacalcidol group (all P < 0.05). U Ca/Cr and U P/Cr in JGL group were higher than those in the calcium D3 + alfacalcidol group (all P < 0.05). VDR mRNA level in the JGL group was elevated markedly in comparison with alcohol + calcium D3 + alfacalcidol group (P < 0.05). Based on our results, Bu Shen Jian Pi Yi Qi therapy inhibits bone loss, promotes bone formation, and effectively improves bone metabolism in rats with experimental alcoholic osteoporosis. The disease reversal is evidenced by increased BMD and BMC, improved biomechanical properties, elevated VDR mRNA level, enhanced response sensitivity of 1, 25(OH)(2)D 3, and reduced S Ca/P.
C1 [Ren, Shu Jun; Xu, Wei Ming; Dong, Qing Ping; Jiang, Yi Chang] Heilongjiang Univ Chinese Med, Dept Orthoped & Traumatol, Affiliated Hosp 1, Heping Rd 26, Harbin 150040, Peoples R China.
   [Xing, Guo Li] Heilongjiang Univ Chinese Med, Clin Med Sch, Harbin, Peoples R China.
   [Hu, Nai Wu] Harbin Med Univ, Dept Orthoped Surg, Hosp 4, Harbin, Peoples R China.
   [Wang, Yong Qi] Heilongjiang Univ Chinese Med, Grad Sch, Harbin, Peoples R China.
C3 Heilongjiang University of Chinese Medicine; Heilongjiang University of
   Chinese Medicine; Harbin Medical University; Heilongjiang University of
   Chinese Medicine
RP Jiang, YC (通讯作者)，Heilongjiang Univ Chinese Med, Dept Orthoped & Traumatol, Affiliated Hosp 1, Heping Rd 26, Harbin 150040, Peoples R China.
EM jiangyichang532@126.com
OI ren, shu jun/0000 0002 9652 7450
FU Heilongjiang Administrative Bureau of Traditional Chinese Medicine
   [ZHY10 W22]
FX This work was funded by Heilongjiang Administrative Bureau of
   Traditional Chinese Medicine (ZHY10 W22), and we acknowledge the helpful
   comments on this article received from our reviewers.
CR Abukhadir SS, 2013, CURR DRUG TARGETS, V14, P1601, DOI 10.2174/13894501113146660231
   Atkins GJ, 2007, BONE, V40, P1517, DOI 10.1016/j.bone.2007.02.024
   Chakkalakal DA, 2005, ALCOHOL CLIN EXP RES, V29, P2077, DOI 10.1097/01.alc.0000192039.21305.55
   Chen Wei Heng, 2011, Zhongguo Gu Shang, V24, P352
   Cheng M, 2011, J ETHNOPHARMACOL, V138, P279, DOI 10.1016/j.jep.2011.09.030
   Cranney Ann, 2007, Evid Rep Technol Assess (Full Rep), P1
   Duan Heng, 2010, Zhong Yao Cai, V33, P243
   Ha H, 2013, MOLECULES, V18, P7376, DOI 10.3390/molecules18077376
   He JS, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/961926
   Holick MF, 2004, AM J CLIN NUTR, V79, P362
   Jia ZH, 2015, MOL MED REP, V12, P2082, DOI 10.3892/mmr.2015.3568
   Ju DH, 2014, FRONT MED PRC, V8, P389, DOI 10.1007/s11684 014 0362 y
   Leslie WD, 2014, CURR OPIN RHEUMATOL, V26, P440, DOI 10.1097/BOR.0000000000000064
   Leung Ping Chung, 2013, J Tradit Complement Med, V3, P82, DOI 10.4103/2225 4110.110407
   Liu He di, 2003, Zhongguo Zhongyao Zazhi, V28, P262
   Liu JC, 2014, BIOMED ENVIRON SCI, V27, P779, DOI 10.3967/bes2014.113
   Maddalozzo GF, 2009, OSTEOPOROSIS INT, V20, P1529, DOI 10.1007/s00198 009 0836 y
   Maurel DB, 2012, OSTEOPOROSIS INT, V23, P1, DOI 10.1007/s00198 011 1787 7
   Mercer KE, 2012, J PHARMACOL EXP THER, V343, P401, DOI 10.1124/jpet.112.197038
   Mingyue Wang, 2005, J Tradit Chin Med, V25, P132
   MITIUSHOVA NM, 1976, DOKL AKAD NAUK SSSR+, V230, P992
   Qu B, 2014, OSTEOPOROSIS INT, V25, P1853, DOI 10.1007/s00198 014 2699 0
   Shen Y, 2010, J NAT MED TOKYO, V64, P336, DOI 10.1007/s11418 010 0416 7
   SU KW, 1988, MINER ELECTROL METAB, V14, P229
   Svedbom A, 2014, ARCH OSTEOPOROS, V9, DOI 10.1007/s11657 014 0187 y
   Svedbom A, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0137 0
   Xie YM, 2011, CHIN J INTEGR MED, V17, P52, DOI 10.1007/s11655 011 0613 6
   Yang Xiao Chen, 2013, Zhongguo Zhong Yao Za Zhi, V38, P4015
   Yu LQ, 2013, J TRADIT CHIN MED, V33, P287, DOI 10.1016/S0254 6272(13)60166 1
   Zhang H, 2008, MATURITAS, V61, P334, DOI 10.1016/j.maturitas.2008.09.023
   Zhang R, 2009, BONE, V45, P553, DOI 10.1016/j.bone.2008.08.127
   Zhao Xiao guang, 2012, Zhongguo Zhen Jiu, V32, P485
   Zhao Y, 2007, J PHARM PHARMACOL, V59, P1167, DOI 10.1211/jpp.59.8.0016
NR 33
TC 1
Z9 4
U1 0
U2 17
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1075 2765
EI 1536 3686
J9 AM J THER
JI Am. J. Ther.
PD SEP OCT
PY 2016
VL 23
IS 5
BP E1135
EP E1142
DI 10.1097/MJT.0000000000000298
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA DX5TY
UT WOS:000384446400003
PM 26291589
DA 2025 08 17
ER

PT J
AU Toya, M
   Kushioka, J
   Shen, H
   Utsunomiya, T
   Hirata, H
   Tsubosaka, M
   Gao, Q
   Chow, SKH
   Zhang, N
   Goodman, SB
AF Toya, M.
   Kushioka, J.
   Shen, H.
   Utsunomiya, T.
   Hirata, H.
   Tsubosaka, M.
   Gao, Q.
   Chow, S. K H.
   Zhang, N.
   Goodman, S. B.
TI Sex differences of NF KB targeted therapy for mitigating osteoporosis
   associated with chronic inflammation of bone
SO BONE & JOINT RESEARCH
LA English
DT Article
ID KAPPA B KINASE; RHEUMATOID ARTHRITIS; RESORPTION; FEMALE;
   OSTEOARTHRITIS; OSTEONECROSIS; PREVENTION; INHIBITOR; PARTICLES;
   MEDIATOR
AB Aims Transcription factor nuclear factor kappa B (NF  KB) plays a major role in the pathogenesis of chronic inflammatory diseases in all organ systems. Despite its importance, NF  KB targeted drug therapy to mitigate chronic inflammation has had limited success in preclinical studies. We hypothesized that sex differences affect the response to NF  KB treatment during chronic inflammation in bone. This study investigated the therapeutic effects of NF  KB decoy oligodeoxynucleotides (ODN) during chronic inflammation in male and female mice. Methods We used a murine model of chronic inflammation induced by continuous intramedullary delivery of lipopolysaccharide contaminated polyethylene particles (cPE) using an osmotic pump. Specimens were evaluated using micro CT and histomorphometric analyses. Sex specific osteogenic and osteoclastic differentiation potentials were also investigated in vitro, including alkaline phosphatase, Alizarin Red, tartrate resistant acid phosphatase staining, and gene expression using reverse transcription polymerase chain reaction (RT PCR). Results Local delivery of NF  KB decoy ODN in vivo increased osteogenesis in males, but not females, in the presence of chronic inflammation induced by cPE. Bone resorption activity was decreased in both sexes. In vitro osteogenic and osteoclastic differentiation assays during inflammatory conditions did not reveal differences among the groups. Receptor activator of nuclear factor kappa B ligand (Rankl) gene expression by osteoblasts was significantly decreased only in males when treated with ODN. Conclusion We demonstrated that NF  KB decoy ODN increased osteogenesis in male mice and decreased bone resorption activity in both sexes in preclinical models of chronic inflammation. NF  KB signalling could be a therapeutic target for chronic inflammatory diseases involving bone, especially in males.
C1 [Toya, M.; Kushioka, J.; Shen, H.; Utsunomiya, T.; Hirata, H.; Tsubosaka, M.; Gao, Q.; Chow, S. K H.; Zhang, N.; Goodman, S. B.] Stanford Univ, Sch Med, Dept Orthopaed Surg, Stanford, CA 94305 USA.
   [Utsunomiya, T.] Kyushu Univ, Dept Orthopaed Surg, Fukuoka, Japan.
   [Goodman, S. B.] Stanford Univ, Dept Bioengn, Stanford, CA USA.
C3 Stanford University; Kyushu University; Stanford University
RP Goodman, SB (通讯作者)，Stanford Univ, Sch Med, Dept Orthopaed Surg, Stanford, CA 94305 USA.
EM goodbone@stanford.edu
RI Goodman, Stuart/AAZ 7499 2020; Zhang, Ning/AHA 3443 2022; Chow,
   Simon/AAG 7330 2020; Kushioka, Junichi/ABH 8046 2020; Shen,
   Huaishuang/GLV 4432 2022; Chow, Simon Kwoon ho/J 1554 2018; Utsunomiya,
   Takeshi/JXN 5914 2024
OI , Qi/0000 0003 0175 566X; Goodman, Stuart/0000 0002 1919 3717;
   Utsunomiya, Takeshi/0000 0002 9770 9803; HIRATA,
   HIROHITO/0000 0003 3114 1685; Zhang, Ning/0000 0002 9513 9288; Chow,
   Simon Kwoon ho/0000 0003 1742 980X; Toya, Masakazu/0000 0002 1244 8326;
   Kushioka, Junichi/0000 0002 0738 1569; 
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
   [R01AR073145, R01AR063717]
FX The authors disclose receipt of the following financial or material
   support for the research, authorship, and/or publication of this
   article: this work was supported by the National Institute of Arthritis
   and Musculoskeletal and Skin Diseases, Grant/Award Numbers: R01AR073145,
   R01AR063717.
CR Ando W, 2021, J ORTHOP SCI, V26, P46, DOI 10.1016/j.jos.2020.06.013
   Bankhead P, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 17204 5
   Beery AK, 2011, NEUROSCI BIOBEHAV R, V35, P565, DOI 10.1016/j.neubiorev.2010.07.002
   Bouman A, 2005, HUM REPROD UPDATE, V11, P411, DOI 10.1093/humupd/dmi008
   Brooks PJ, 2019, AM J PATHOL, V189, P1145, DOI 10.1016/j.ajpath.2019.02.006
   Callewaert F, 2010, J ENDOCRINOL, V207, P127, DOI 10.1677/JOE 10 0209
   Clayton JA, 2016, FASEB J, V30, P519, DOI 10.1096/fj.15 279554
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Fish EN, 2008, NAT REV IMMUNOL, V8, P737, DOI 10.1038/nri2394
   Fujihara SM, 2000, J IMMUNOL, V165, P1004, DOI 10.4049/jimmunol.165.2.1004
   Gerosa M, 2008, WOMENS HEALTH, V4, P195, DOI 10.2217/17455057.4.2.195
   Glatt V, 2007, J BONE MINER RES, V22, P1197, DOI 10.1359/JBMR.070507
   Goodman SB, 2020, J INFLAMM RES, V13, P913, DOI 10.2147/JIR.S281941
   Greenfield EM, 2010, J BIOL CHEM, V285, P32378, DOI 10.1074/jbc.M110.136895
   Grzelecki D, 2021, BONE JOINT J, V103B, P46, DOI 10.1302/0301 620X.103B1.BJJ 2020 0953.R1
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Ishida M, 2018, ENDOCRINOLOGY, V159, P3775, DOI 10.1210/en.2018 00639
   Ji M, 2021, BONE JOINT RES, V10, P285, DOI 10.1302/2046 3758.104.BJR 2020 0331.R1
   Jordan KM, 2002, BEST PRACT RES CL RH, V16, P795, DOI 10.1053/berh.2002.0264
   Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703
   Kim MH, 2022, BONE JOINT RES, V11, P304, DOI 10.1302/2046 3758.115.BJR 2021 0380.R1
   Klein SL, 2015, P NATL ACAD SCI USA, V112, P5257, DOI 10.1073/pnas.1502843112
   Kushioka J, 2023, J ORTHOP RES, V41, P1004, DOI 10.1002/jor.25434
   Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651
   Li SF, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00450
   Lin TH, 2017, ADV PROTEIN CHEM STR, V107, P117, DOI 10.1016/bs.apcsb.2016.11.002
   Lin TH, 2016, ACTA BIOMATER, V41, P273, DOI 10.1016/j.actbio.2016.05.038
   Lin TH, 2015, TISSUE ENG PT A, V21, P875, DOI [10.1089/ten.tea.2014.0144, 10.1089/ten.TEA.2014.0144]
   Lin T, 2018, J BIOMED MATER RES A, V106, P2744, DOI 10.1002/jbm.a.36504
   Liu YD, 2022, BONE JOINT RES, V11, P200, DOI [10.1302/2046 3758.114.BJR 2020 0308.R2, 10.1302/2046 3758.114.BJR 2020 0308 R2]
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020
   Lu R, 2023, BONE JOINT RES, V12, P259, DOI 10.1302/2046 3758.124.BJR 2022 0384.R1
   Martel Pelletier J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.72
   Mauro D, 2021, NAT REV RHEUMATOL, V17, P387, DOI 10.1038/s41584 021 00625 y
   McIntyre KW, 2003, ARTHRITIS RHEUM US, V48, P2652, DOI 10.1002/art.11131
   Miron RJ, 2016, ACTA BIOMATER, V46, P15, DOI 10.1016/j.actbio.2016.09.029
   Mitchell JP, 2018, INT REV CEL MOL BIO, V335, P41, DOI 10.1016/bs.ircmb.2017.07.007
   Nabeshima A, 2017, BIOMATERIALS, V117, P1, DOI 10.1016/j.biomaterials.2016.11.039
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Nathan K, 2019, BONE JOINT RES, V8, P481, DOI 10.1302/2046 3758.810.BJR 2018 0231.R2
   Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116
   Olsen Nancy J, 2002, J Gend Specif Med, V5, P28
   Pajarinen J, 2017, TISSUE ENG PART C ME, V23, P1003, DOI [10.1089/ten.tec.2017.0166, 10.1089/ten.TEC.2017.0166]
   Robinson WH, 2016, NAT REV RHEUMATOL, V12, P580, DOI 10.1038/nrrheum.2016.136
   Roman Blas JA, 2006, OSTEOARTHR CARTILAGE, V14, P839, DOI 10.1016/j.joca.2006.04.008
   Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081
   Shansky RM, 2021, NAT NEUROSCI, V24, P457, DOI 10.1038/s41593 021 00806 8
   Shansky RM, 2019, SCIENCE, V364, P825, DOI 10.1126/science.aaw7570
   Shiau HJ, 2010, J PERIODONTOL, V81, P1379, DOI 10.1902/jop.2010.100044
   Shimizu H, 2009, ANTIOXID REDOX SIGN, V11, P2065, DOI [10.1089/ars.2008.2355, 10.1089/ARS.2008.2355]
   Soldin OP, 2009, CLIN PHARMACOKINET, V48, P143, DOI 10.2165/00003088 200948030 00001
   Utsunomiya T, 2021, J BIOMED MATER RES A, V109, P1828, DOI 10.1002/jbm.a.37175
   Yao Q, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392 023 01330 w
   Yip KHM, 2004, J BONE MINER RES, V19, P1905, DOI 10.1359/JBMR.040919
   Yoon DY, 2014, SURGERY, V156, P508, DOI 10.1016/j.surg.2014.07.001
   Zanotti S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086757
   Zawawi MSF, 2015, J BIOMED MATER RES A, V103, P3572, DOI 10.1002/jbm.a.35484
   Zhang N, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 020 02086 8
   Zhong ZDA, 2017, J BONE MINER RES, V32, P1841, DOI 10.1002/jbmr.3186
   Zhou Y, 2022, BONE JOINT RES, V11, P594, DOI 10.1302/2046 3758.118.BJR 2021 0188.R1
   Zink A, 2000, J RHEUMATOL, V27, P613
NR 61
TC 4
Z9 4
U1 1
U2 5
PU BRITISH EDITORIAL SOC BONE & JOINT SURGERY
PI LONDON
PA 22 BUCKINGHAM STREET, LONDON WC2N 6ET, ENGLAND
SN 2046 3758
J9 BONE JOINT RES
JI Bone Jt. Res.
PD JAN
PY 2024
VL 13
IS 1
BP 28
EP 39
DI 10.1302/2046 3758.131.BJR 2023 0040.R3
PG 12
WC Cell & Tissue Engineering; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Orthopedics
GA FN0A8
UT WOS:001146374600001
PM 38194999
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Liu, L
   Zhao, GH
   Gao, QQ
   Chen, YJ
   Chen, ZP
   Xu, ZS
   Li, WD
AF Liu, L.
   Zhao, G. H.
   Gao, Q. Q.
   Chen, Y. J.
   Chen, Z. P.
   Xu, Z. S.
   Li, W. D.
TI Changes of mineralogical characteristics and osteoblast activities of
   raw and processed pyrites
SO RSC ADVANCES
LA English
DT Article
ID BONE FORMATION; IRON; DECREASES; CELLS
AB Pyrite, a commonly used mineral medicine in traditional Chinese medicine (TCM), is normally prescribed in the form of calcined or processed pyrite to ensure clinical safety and efficacy. We herein compared the changes of mineral phase characteristics of raw and processed pyrites and their effects on osteoblast proliferation. Processed pyrite was fragile and crispy compared to the raw one. Its main component changed from FeS2 to Fe7S8. After calcination and quenching in vinegar, the concentrations of Fe and Zn increased in the decoction of processed pyrite, whereas that of As decreased. Serum containing processed pyrite enhanced the alkaline phosphatase activity of osteoblasts compared to blank serum, and serum containing raw pyrite also increased such activity. The osteogenesis enhancing function of processed pyrite was manifested as increased numbers and areas of formed mineralized nodules. The findings are helpful to unveil the clinical mechanism of processed pyrite which has commonly been used to treat bone fracture in TCM practice.
C1 [Liu, L.; Zhao, G. H.; Gao, Q. Q.; Chen, Z. P.; Li, W. D.] Nanjing Univ Chinese Med, Coll Pharm, 138 Xianlin Ave, Nanjing, Jiangsu, Peoples R China.
   [Chen, Z. P.; Li, W. D.] Nanjing Univ Chinese Med, Engn Ctr, State Minist Educ Standardizat Chinese Med Proc, Nanjing, Jiangsu, Peoples R China.
   [Chen, Y. J.] Nanjing Univ, Modern Anal Ctr, Nanjing, Jiangsu, Peoples R China.
   [Xu, Z. S.] Wuhu Pure Sunshine Nat Med Co Ltd, Wuhu, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese
   Medicine; Nanjing University
RP Li, WD (通讯作者)，Nanjing Univ Chinese Med, Coll Pharm, 138 Xianlin Ave, Nanjing, Jiangsu, Peoples R China.; Li, WD (通讯作者)，Nanjing Univ Chinese Med, Engn Ctr, State Minist Educ Standardizat Chinese Med Proc, Nanjing, Jiangsu, Peoples R China.; Xu, ZS (通讯作者)，Wuhu Pure Sunshine Nat Med Co Ltd, Wuhu, Peoples R China.
EM xuzisheng@hotmail.com; liweidong0801@163.com
RI Gao, Qianqian/AAW 1689 2020
FU NSFC [81373970]; Jiangsu Qinglan Project
FX This research was supported by NSFC (grant number 81373970) and Jiangsu
   Qinglan Project (2014).
CR Abraham R, 2006, OSTEOPOROSIS INT, V17, P1165, DOI 10.1007/s00198 005 0033 6
   Baschant U, 2016, HAEMATOLOGICA, V101, P1499, DOI 10.3324/haematol.2016.144808
   Doyard M, 2012, OSTEOPOROSIS INT, V23, P2435, DOI 10.1007/s00198 011 1871 z
   Gao C., 2009, J TRADIT CHIN MED, V16, P47
   Gao C, 2009, NANJING ZHONG YI YAO, V25, P75
   He X., 1998, CHINESE MAT MED, P3
   He YF, 2013, BIOL TRACE ELEM RES, V152, P292, DOI 10.1007/s12011 013 9605 z
   Hwang J, 2004, AM J CHINESE MED, V32, P907, DOI 10.1142/S0192415X0400251X
   Jia T. Z., 2008, PROCESSING CHINESE H, P220
   Jin S.Y., 2004, STUDIES PROCESSING C, P276
   Katsumata SI, 2009, J NUTR, V139, P238, DOI 10.3945/jn.108.093757
   Lei Yu Lei Yu, 2011, Zhongcaoyao = Chinese Traditional and Herbal Drugs, V42, P275
   Li G. F., 2015, J BONE MINER RES, V02, P143
   Messer JG, 2009, BONE, V45, P972, DOI 10.1016/j.bone.2009.07.073
   Nagata M, 2011, J NUTR BIOCHEM, V22, P172, DOI 10.1016/j.jnutbio.2010.01.003
   National Pharmacopoeia Committee, 2015, PHARM PEOPL REP CHIN, P141
   Pountos I, 2010, INT ORTHOP, V34, P3, DOI 10.1007/s00264 009 0892 0
   Quan Zhengxiang, 2011, Zhongguo Zhong Yao Za Zhi, V36, P691
   Schindeler A, 2008, SEMIN CELL DEV BIOL, V19, P459, DOI 10.1016/j.semcdb.2008.07.004
   Seo HJ, 2010, NUTR RES PRACT, V4, P356, DOI 10.4162/nrp.2010.4.5.356
   Tie B. R., 1991, J CHIN MAT MED, V16, P341
   Wu H., 2012, PROCESSING CHINESE M, P225
   Xu A., 2009, THESIS
   Yu SB, 2013, BONE, V56, P234, DOI 10.1016/j.bone.2013.06.019
   Zhao GY, 2012, BIOL TRACE ELEM RES, V150, P487, DOI 10.1007/s12011 012 9511 9
NR 25
TC 19
Z9 23
U1 2
U2 18
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046 2069
J9 RSC ADV
JI RSC Adv.
PY 2017
VL 7
IS 45
BP 28373
EP 28382
DI 10.1039/c7ra03970k
PG 10
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA EX1QE
UT WOS:000402999300050
OA gold
DA 2025 08 17
ER

PT J
AU Samir, SM
   Malek, HA
AF Samir, S. M.
   Malek, H. A.
TI EFFECT OF CANNABINOID RECEPTORS 1 MODULATION ON OSTEOPOROSIS IN A RAT
   MODEL OF DIFFERENT AGES
SO JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
LA English
DT Article
DE osteoporosis; cannabinoids; methylprednisolone; rimonabant;
   osteoprotegrin; receptor activator of nuclear factor kappa B ligand;
   osteoporosis; cortical bone thickness; trabecular bone density
ID BONE MINERAL DENSITY; GLUCOCORTICOID RECEPTOR; MASS; OSTEOPROTEGERIN;
   OSTEOBLAST; TISSUE; ADIPOGENESIS; TOMOGRAPHY; OSTEOCLAST; RIMONABANT
AB Osteoporosis is a common health problem. The endocannabinoid pathway has been implicated as an important regulator of bone turnover. Rimonabant is a potent cannabinoid receptor1 (CBI) receptor antagonist with wide therapeutic use as an antiobesity drug that has been withdrawn due to side effects in the form of depression and suicidal attacks. This study investigated whether glucocorticoid induced bone loss is linked to CBl signaling and whether modulation of CB1 function affects the deleterious effects of glucocorticoid treatment on bone remodeling in rats. Sixty four rats were divided into two main groups: group 1 (G1) consisted of 12 14 month old rats and group 2 (G2) consisted of 3 4 month old rats. Each main group subdivided into four subgroups as follows: (NC1) and (NC2), the negative control groups, (MP1) and (MP2), received methylprednisolone (glucocorticoid), (RIM1) and (R1M2), received rimonabant, (MP + RIM1) and (MP + RIM2) received methylprednisolone with rimonabant. There was a significant decrease in bone mineral density (BMD) and bone mineral content (BMC) of the tibia bones together with a decrease in osteoprotegrin (OPG) expression but with a significant increase in receptor activator of nuclear factor kappa B ligand (RANKL) expression in osteoporotic rats. These parameters were reversed with co administration of rimonabant with methylprednisolone in young rats, though it increased the severity of osteoporosis in older rats. Image analysis technique revealed that there was a significant improvement in cortical bone thickness (CBT) and mean trabecular bone density (TBD) in young group only after rimonabant either alone or with glucocorticoid. CB1 receptors play age related different roles in bone turnover. So, CB1 antagonist can be used to prevent corticosteroid induced osteoporosis in young age but should be avoided in old age.
C1 Mansoura Univ, Fac Med, Dept Med Physiol, Mansoura, Egypt.
   [Malek, H. A.] Mansoura Univ, Fac Med, Dept Clin Pharmacol, Mansoura, Egypt.
C3 Egyptian Knowledge Bank (EKB); Mansoura University; Egyptian Knowledge
   Bank (EKB); Mansoura University
RP Malek, HA (通讯作者)，Mansoura Univ, Fac Med, Dept Clin Pharmacol, Mansoura, Egypt.
EM halamalek@live.com
RI samir, shereen/AAW 5915 2020; malek, hala/N 5355 2018
OI Malek, Hala/0000 0002 8590 9461; 
CR Bab I, 2008, J NEUROENDOCRINOL, V20, P69, DOI 10.1111/j.1365 2826.2008.01675.x
   Buettner C, 2008, NAT MED, V14, P667, DOI 10.1038/nm1775
   Deif MM, 2007, B ALEX FM, V43, P399
   Elshal MF, 2013, AFR J TRADIT COMPLEM, V10, P267, DOI 10.4314/ajtcam.v10i5.8
   Faulkner W. R., 1982, SELECTED METHODS SMA, P126
   Ferrari S, 2009, REV MED SUISSE, V10, P1325
   Fichna M, 2012, J PHYSIOL PHARMACOL, V63, P677
   Gimble JM, 2006, J CELL BIOCHEM, V98, P251, DOI 10.1002/jcb.20777
   Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255
   Idris AI, 2011, IBMS BONEKEY, V8, P84
   Idris Aymen I, 2012, Bonekey Rep, V1, P224, DOI 10.1038/bonekey.2012.224
   Idris AI, 2009, CELL METAB, V10, P139, DOI 10.1016/j.cmet.2009.07.006
   Jee W. S. S., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P193
   Kashani I. R., 2009, Acta Medica Iranica, V47, P251
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kim HJ, 2006, J CLIN INVEST, V116, P2152, DOI 10.1172/JCI28084
   Ko JY, 2012, ARTHRITIS RHEUM US, V64, P1204, DOI 10.1002/art.33457
   Leite CE, 2009, PHARMACOL REP, V61, P217, DOI 10.1016/S1734 1140(09)70025 8
   Lelovas PP, 2008, COMPARATIVE MED, V58, P424
   Lu NZ, 2007, MOL CELL BIOL, V27, P7143, DOI 10.1128/MCB.00253 07
   Malcher Lopes R, 2006, J NEUROSCI, V26, P6643, DOI 10.1523/JNEUROSCI.5126 05.2006
   McLaughlin F, 2002, BONE, V30, P924, DOI 10.1016/S8756 3282(02)00737 8
   Migliaccio Silvia, 2007, Aging Clin Exp Res, V19, P5
   Nakamichi Yuko, 2006, Clin Calcium, V16, P1463
   Netto CC, 2012, ARQ BRAS ENDOCRINOL, V56, P259, DOI 10.1590/S0004 27302012000400007
   O'Brien EA, 2001, BONE, V28, P208, DOI 10.1016/S8756 3282(00)00431 2
   Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103
   Patel MS, 2007, CALCIFIED TISSUE INT, V80, P337, DOI 10.1007/s00223 007 9015 3
   Perez Castrillon JL, 2009, CALCIFIED TISSUE INT, V85, P113, DOI 10.1007/s00223 009 9256 4
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Sosa M, 2008, EUR J INTERN MED, V19, P51, DOI 10.1016/j.ejim.2007.08.005
   Surve VV, 2001, ACTA ORTHOP SCAND, V72, P525, DOI 10.1080/000164701753532880
   Tallett AJ, 2007, PSYCHOPHARMACOLOGY, V195, P27, DOI 10.1007/s00213 007 0880 2
   Tam J, 2008, FASEB J, V22, P285, DOI 10.1096/fj.06 7957com
   Tam J, 2006, MOL PHARMACOL, V70, P786, DOI 10.1124/mol.106.026435
   Teng YTA, 2000, J CLIN INVEST, V106, pR59, DOI 10.1172/JCI10763
   Tomaszewska E, 2012, J PHYSIOL PHARMACOL, V63, P547
   Tsirella E, 2012, J PHYSIOL PHARMACOL, V63, P201
   VASILIADES J, 1976, CLIN CHEM, V22, P1664
   Wang FS, 2008, ENDOCRINOLOGY, V149, P1793, DOI 10.1210/en.2007 0910
   Wang FS, 2009, LIFE SCI, V85, P685, DOI 10.1016/j.lfs.2009.09.009
   Weinstein RS, 2010, ENDOCRINOLOGY, V151, P2641, DOI 10.1210/en.2009 1488
   Yao W, 2008, ARTHRITIS RHEUM, V58, P1674, DOI 10.1002/art.23454
NR 43
TC 24
Z9 28
U1 0
U2 6
PU POLISH PHYSIOLOGICAL SOC
PI GRZEGORZECKA
PA JAGIELLONIAN UNIV SCHOOL MED, INST PHYSIOLOGY, 31 531 KRAKOW, 16
   GRZEGORZECKA, POLAND
SN 0867 5910
J9 J PHYSIOL PHARMACOL
JI J. Physiol. Pharmacol.
PD OCT
PY 2014
VL 65
IS 5
BP 687
EP 694
PG 8
WC Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology
GA AU4CG
UT WOS:000345555900010
PM 25371528
DA 2025 08 17
ER

PT J
AU Hong, C
   Song, D
   Lee, DK
   Lin, L
   Pan, HC
   Lee, D
   Deng, P
   Liu, ZQ
   Hadaya, D
   Lee, HL
   Mohammad, A
   Zhang, XL
   Lee, M
   Wang, CY
   Ho, D
AF Hong, Christine
   Song, Dayoung
   Lee, Dong Keun
   Lin, Lawrence
   Pan, Hsin Chuan
   Lee, Deborah
   Deng, Peng
   Liu, Zhenqing
   Hadaya, Danny
   Lee, Hye Lim
   Mohammad, Abdulaziz
   Zhang, Xinli
   Lee, Min
   Wang, Cun Yu
   Ho, Dean
TI Reducing posttreatment relapse in cleft lip palatal expansion using an
   injectable estrogen nanodiamond hydrogel
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE nanomedicine; cleft palate; craniofacial medicine; nanodiamond; drug
   delivery
ID DOSE MICRONIZED 17 BETA ESTRADIOL; MESENCHYMAL STEM CELLS; REPLACEMENT
   THERAPY; DRUG DELIVERY; CHITOSAN HYDROGELS; BONE FORMATION; OLDER WOMEN;
   LONG TERM; DETONATION NANODIAMOND; ORTHODONTIC TREATMENT
AB Patients with cleft lip and/or palate (CLP), who undergo numerous medical interventions from infancy, can suffer from lifelong debilitation caused by underdeveloped maxillae. Conventional treatment approaches use maxillary expansion techniques to develop normal speech, achieve functional occlusion for nutrition intake, and improve esthetics. However, as patients with CLP congenitally lack bone in the cleft site with diminished capacity for bone formation in the expanded palate, more than 80% of the patient population experiences significant postexpansion relapse. While such relapse has been a long standing battle in craniofacial care of patients, currently there are no available strategies to address this pervasive problem. Estrogen, 17 beta estradiol (E2), is a powerful therapeutic agent that plays a critical role in bone homeostasis. However, E2's clinical application is less appreciated due to several limitations, including its pleiotropic effects and short half life. Here, we developed a treatment strategy using an injectable system with photo cross linkable hydrogel (G) and nanodiamond (ND) technology to facilitate the targeted and sustained delivery of E2 to promote bone formation. In a preclinical expansion/relapse model, this functionalized E2/ND/G complex substantially reduced postexpansion relapse by nearly threefold through enhancements in sutural remodeling compared with unmodified E2 administration. The E2/ND/G group demonstrated greater bone volume by twofold and higher osteoblast number by threefold, compared with the control group. The E2/ND/G platform maximized the beneficial effects of E2 through its extended release with superior efficacy and safety at the local level. This broadly applicable E2 delivery platform shows promise as an adjuvant therapy in craniofacial care of patients.
C1 [Hong, Christine; Song, Dayoung; Lin, Lawrence; Pan, Hsin Chuan; Lee, Deborah; Mohammad, Abdulaziz; Zhang, Xinli] Univ Calif Los Angeles, Sch Dent, Div Growth & Dev, Sect Orthodont, Los Angeles, CA 90095 USA.
   [Lee, Dong Keun; Lee, Min; Ho, Dean] Univ Calif Los Angeles, Sch Dent, Div Adv Prosthodont, Los Angeles, CA 90095 USA.
   [Deng, Peng; Liu, Zhenqing; Wang, Cun Yu; Ho, Dean] Univ Calif Los Angeles, Sch Dent, Div Oral Biol & Med, Los Angeles, CA 90095 USA.
   [Hadaya, Danny] Univ Calif Los Angeles, Sch Dent, Div Diagnost & Surg Sci, Los Angeles, CA 90095 USA.
   [Lee, Hye Lim] Univ Calif Irvine, Sue & Bill Gross Stem Cell Res Ctr, Irvine, CA 92697 USA.
   [Ho, Dean] Univ Calif Los Angeles, Henry Samueli Sch Engn & Appl Sci, Dept Bioengn, Los Angeles, CA 90095 USA.
   [Ho, Dean] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
   [Ho, Dean] Univ Calif Los Angeles, Calif NanoSyst Inst, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   University of California System; University of California Irvine;
   University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   UCLA Jonsson Comprehensive Cancer Center; University of California
   System; University of California Los Angeles
RP Hong, C (通讯作者)，Univ Calif Los Angeles, Sch Dent, Div Growth & Dev, Sect Orthodont, Los Angeles, CA 90095 USA.
EM chong@dentistry.ucla.edu
RI Zhang, Xinli/MIN 9371 2025; Pan, Hsin/D 1485 2019; Lee,
   Kee Joon/AAA 4090 2022
FU American Association of Orthodontists Foundation Biomedical Research
   Award; National Institutes of Health/National Institute of Dental and
   Craniofacial Research (NIH/NIDCR) K08 Award [K08DE024603]; National
   Science Foundation CAREER Award [CMMI 1350197]; Center for Scalable and
   Integrated NanoManufacturing [DMI 0327077, CMMI 0856492, DMR 1343991,
   OISE 1444100]; V Foundation for Cancer Research Scholars Award; Wallace
   H. Coulter Foundation Translational Research Award; National Cancer
   Institute Grant [U54CA151880]; Society for Laboratory Automation and
   Screening Endowed Fellowship; Beckman Coulter Life Sciences; American
   Academy of Implant Dentistry Research Foundation [20150460]; National
   Institute of Dental and Craniofacial Research [R01DE019412, R01DE024828]
   Funding Source: NIH RePORTER
FX We thank Dr. Kang Ting and his laboratory for generously providing the
   micro CT machine and technical assistance and Dr. Jeff Gornbein for
   performing statistical analysis. We also thank Tania Ohebsion, Jaime
   Tran, Alex Lee, Tim Yu, Steven Kim, Michelle Wong, Armin Miresmaili, and
   Delano Hankins for their assistance during the surgeries. C.H.
   gratefully acknowledges support from the American Association of
   Orthodontists Foundation Biomedical Research Award and the National
   Institutes of Health/National Institute of Dental and Craniofacial
   Research (NIH/NIDCR) K08 Award (K08DE024603). D.H. gratefully
   acknowledges support from the National Science Foundation CAREER Award
   (CMMI 1350197), the Center for Scalable and Integrated NanoManufacturing
   (DMI 0327077), CMMI 0856492, DMR 1343991, OISE 1444100, the V Foundation
   for Cancer Research Scholars Award, the Wallace H. Coulter Foundation
   Translational Research Award, National Cancer Institute Grant
   U54CA151880 (the content is solely the responsibility of the authors and
   does not necessarily represent the official views of the National Cancer
   Institute or the National Institutes of Health), the Society for
   Laboratory Automation and Screening Endowed Fellowship, Beckman Coulter
   Life Sciences, and the American Academy of Implant Dentistry Research
   Foundation under Grant 20150460.
CR Adnan A, 2011, MOL PHARMACEUT, V8, P368, DOI 10.1021/mp1002398
   Amini Fariborz, 2015, J Orthod Sci, V4, P65, DOI 10.4103/2278 0203.160237
   Arosarena OA, 2007, OTOLARYNG CLIN N AM, V40, P27, DOI 10.1016/j.otc.2006.10.011
   Barnard AS, 2008, J MATER CHEM, V18, P4038, DOI 10.1039/b809188a
   Barnard AS, 2009, ANALYST, V134, P1751, DOI 10.1039/b908532g
   BERGLAND O, 1986, CLEFT PALATE J, V23, P175
   Brandl F, 2007, BIOMATERIALS, V28, P134, DOI 10.1016/j.biomaterials.2006.09.017
   CARUSONICOLETTI M, 1985, J CLIN ENDOCR METAB, V61, P896, DOI 10.1210/jcem 61 5 896
   CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003 4819 122 1 199501010 00002
   Choi B, 2015, ACTA BIOMATER, V12, P30, DOI 10.1016/j.actbio.2014.10.013
   Choi B, 2014, ACS APPL MATER INTER, V6, P20110, DOI 10.1021/am505723k
   Chow EK, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001713
   Chow EKH, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005872
   Cowan CM, 2006, BONE, V38, P48, DOI 10.1016/j.bone.2005.06.023
   DeCesare GE, 2011, PLAST RECONSTR SURG, V127, P588, DOI 10.1097/PRS.0b013e3181fed5c5
   Drury JL, 2003, BIOMATERIALS, V24, P4337, DOI 10.1016/S0142 9612(03)00340 5
   Ekizer A, 2015, ANGLE ORTHOD, V85, P394, DOI 10.2319/031114 177.1
   ERNST M, 1988, P NATL ACAD SCI USA, V85, P2307, DOI 10.1073/pnas.85.7.2307
   Gomes MPV, 2004, ARCH INTERN MED, V164, P1965, DOI 10.1001/archinte.164.18.1965
   Grover GN, 2015, ADV HEALTHC MATER, V4, P1327, DOI 10.1002/adhm.201500167
   HARRISON RF, 1980, PHARMACOL THERAPEUT, V11, P451, DOI 10.1016/0163 7258(80)90037 6
   Ho DA, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500439
   Hoare TR, 2008, POLYMER, V49, P1993, DOI 10.1016/j.polymer.2008.01.027
   Hu JL, 2012, ACTA BIOMATER, V8, P1730, DOI 10.1016/j.actbio.2012.01.029
   Huang H, 2007, NANO LETT, V7, P3305, DOI 10.1021/nl071521o
   Kim S, 2016, J MATER CHEM B, V4, P5289, DOI [10.1039/C6TB01154C, 10.1039/c6tb01154c]
   Krüger A, 2005, CARBON, V43, P1722, DOI 10.1016/j.carbon.2005.02.020
   Lindahl SH, 2014, INT J WOMENS HEALTH, V6, P307, DOI 10.2147/IJWH.S52555
   Linder Aronson S, 1979, Br J Orthod, V6, P25
   Liu Z, 2009, NANO RES, V2, P85, DOI 10.1007/s12274 009 9009 8
   Long RE, 2000, CLEFT PALATE CRAN J, V37, P533, DOI 10.1597/1545 1569(2000)037<0533:OTOTPW>2.0.CO;2
   Man HB, 2012, PHYS STATUS SOLIDI A, V209, P1811, DOI 10.1002/pssa.201200073
   MEW J, 1983, AM J ORTHOD DENTOFAC, V83, P56, DOI 10.1016/0002 9416(83)90272 5
   Mochalin VN, 2013, MOL PHARMACEUT, V10, P3728, DOI 10.1021/mp400213z
   Mochalin VN, 2012, NAT NANOTECHNOL, V7, P11, DOI [10.1038/nnano.2011.209, 10.1038/NNANO.2011.209]
   Mohan N, 2010, NANO LETT, V10, P3692, DOI 10.1021/nl1021909
   Moore L, 2016, ACS NANO, V10, P7385, DOI 10.1021/acsnano.6b00839
   MOUSSA R, 1995, AM J ORTHOD DENTOFAC, V108, P478, DOI 10.1016/S0889 5406(95)70048 X
   Mueller A, 2005, EUR J ENDOCRINOL, V153, P107, DOI 10.1530/eje.1.01943
   NICHOLSON PT, 1989, EUR J ORTHODONT, V11, P186, DOI 10.1093/oxfordjournals.ejo.a035982
   Ohlsson C, 2009, EUR J ENDOCRINOL, V160, P883, DOI 10.1530/EJE 09 0118
   Okazaki R, 2002, ENDOCRINOLOGY, V143, P2349, DOI 10.1210/en.143.6.2349
   Park H, 2013, ACTA BIOMATER, V9, P4779, DOI 10.1016/j.actbio.2012.08.033
   Prestwood KM, 2003, JAMA J AM MED ASSOC, V290, P1042, DOI 10.1001/jama.290.8.1042
   Prestwood KM, 2000, J CLIN ENDOCR METAB, V85, P4462, DOI 10.1210/jc.85.12.4462
   Ramstad T, 1997, J ORAL REHABIL, V24, P658, DOI 10.1046/j.1365 2842.1997.00551.x
   Rochira V, 2001, MOL CELL ENDOCRINOL, V178, P215, DOI 10.1016/S0303 7207(01)00446 4
   Rochira V, 2015, INT J ENDOCRINOL, V2015, DOI 10.1155/2015/165215
   Ruggiero RJ, 2002, J MIDWIFERY WOM HEAL, V47, P130, DOI 10.1016/S1526 9523(02)00233 7
   Santen RJ, 2010, J CLIN ENDOCR METAB, V95, pS7, DOI 10.1210/jc.2009 2509
   Sawada M, 1996, EUR J ORTHODONT, V18, P169
   Scarabin PY, 2003, LANCET, V362, P428, DOI 10.1016/S0140 6736(03)14066 4
   SLAUGHTER WB, 1954, PLAST RECONSTR SURG, V13, P341, DOI 10.1097/00006534 195405000 00002
   Smith AH, 2011, NANOSCALE, V3, P2844, DOI 10.1039/c1nr10278h
   STEINICHE T, 1989, BONE, V10, P313, DOI 10.1016/8756 3282(89)90126 9
   Stockfisch H, 1969, REP C EUR ORTHOD SOC, V1969, P469
   Stoll C, 2000, CLEFT PALATE CRAN J, V37, P41, DOI 10.1597/1545 1569(2000)037<0041:AMICWO>2.3.CO;2
   SUBTELNY JD, 1954, AM J ORTHOD DENTOFAC, V40, P686, DOI 10.1016/0002 9416(54)90057 3
   TURNER RT, 1994, ENDOCR REV, V15, P275, DOI 10.1210/er.15.3.275
   Uysal Tancan, 2009, Eur J Dent, V3, P165
   Wang X, 2014, ACS NANO, V8, P12151, DOI 10.1021/nn503491e
   Wassenaar JW, 2016, J AM COLL CARDIOL, V67, P1074, DOI 10.1016/j.jacc.2015.12.035
   Watson BM, 2015, BIOMATERIALS, V67, P286, DOI 10.1016/j.biomaterials.2015.07.016
   Weisberg E, 2005, CLIMACTERIC, V8, P83, DOI 10.1080/13697130500087016
   WEISSBERGER AJ, 1991, J CLIN ENDOCR METAB, V72, P374, DOI 10.1210/jcem 72 2 374
   Xavier JR, 2015, ACS NANO, V9, P3109, DOI 10.1021/nn507488s
   Xi GF, 2014, NANOMED NANOTECHNOL, V10, P381, DOI 10.1016/j.nano.2013.07.013
   ZAHROWSKI JJ, 1992, ANGLE ORTHOD, V62, P197
   Zhang QW, 2011, BIOMATERIALS, V32, P87, DOI 10.1016/j.biomaterials.2010.08.090
NR 69
TC 25
Z9 28
U1 1
U2 42
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
EI 1091 6490
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 29
PY 2017
VL 114
IS 35
BP E7218
EP E7225
DI 10.1073/pnas.1704027114
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA FE9PQ
UT WOS:000408536000003
PM 28808036
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU MohanaSundaram, A
   Gohil, NV
   Etekochay, MO
   Patel, P
   Gurajala, S
   Sathanantham, ST
   Nsengiyumva, M
   Kumar, S
   Bin Emran, T
AF MohanaSundaram, ArunSundar
   Gohil, Namra Vinay
   Etekochay, Maudlyn O.
   Patel, Premalkumar
   Gurajala, Swathi
   Sathanantham, Shanmugarajan Thukani
   Nsengiyumva, Mugisha
   Kumar, Santosh
   Bin Emran, Talha
TI Mycobacterium tuberculosis: a new hitchhiker in the
   etiopathogenesis of periodontitis
SO INTERNATIONAL JOURNAL OF SURGERY
LA English
DT Article
DE extrapulmonary infection; inflammation; mycobacterium tuberculosis;
   periodontitis
ID DIABETES MELLITUS; PATHOGENESIS; INFLAMMATION; DISEASES; THERAPY;
   SMOKING; MARKERS
AB Periodontitis, a chronic inflammatory disease of the gums affects both the ligament and alveolar bone. A severe form of periodontal disease affects a strikingly high number of one billion adults globally. The disease permutes both the soft and hard tissues of the oral cavity leading to localized and systemic diseases. Periodontitis has a deleterious impact on systemic health causing diabetes, cardiovascular diseases (CVD), and other disease. The cause of the enhanced inflammatory process is due to dysbiosis and an unregulated immune response. Innate immune response and T cells trigger uninhibited cytokine release causing an unwarranted inflammatory response. The RANK  RANKL interaction between osteoblasts, immune cells, and progenitor osteoclasts results in the maturation of osteoclasts, which promote bone resorption. It is well established that dysbiosis of the oral cavity has been implicated in periodontitis. But emerging reports suggest that the pulmonary pathogen, Mycobacterium tuberculosis (Mtb), causes extrapulmonary diseases such as periodontitis. Many clinical case reports advocate the involvement of Mtb in periodontitis, which poses a threat with the surge of tuberculosis in HIV and other immunocompromised individuals. Fostering a better understanding of the mechanism, causative agents and control on inflammatory response is imperative in the prevention and treatment of periodontitis.
C1 [MohanaSundaram, ArunSundar] Sathyabama Inst Sci & Technol, Sch Pharm, Chennai, Tamilnadu, India.
   [Gohil, Namra Vinay] Med Coll Baroda & SSG Hosp Vadodara, Vadodara, Gujarat, India.
   [Sathanantham, Shanmugarajan Thukani] Vels Inst Sci Technol & Adv Studies VISTAS, Sch Pharmaceut Sci, Chennai, Tamilnadu, India.
   [Kumar, Santosh] Karnavati Univ, Karnavati Sch Dent, Gandhinagar, Gujarat, India.
   [Gurajala, Swathi] Imam Abdulrahman Bin Faisal Univ, Coll Appl Med Sci Jubail, Dammam, Saudi Arabia.
   [Etekochay, Maudlyn O.] Winterset Edge, Ingham Rd, Owings Mills, MD USA.
   [Patel, Premalkumar] Mt Sinai Med Ctr, Alton Rd, Miami Beach, FL USA.
   [Nsengiyumva, Mugisha] Publ Hlth & Sci Res Ctr, Kigali, Rwanda.
   [Bin Emran, Talha] BGC Trust Univ Bangladesh, Dept Pharm, Chittagong 4381, Bangladesh.
   [Bin Emran, Talha] Daffodil Int Univ, Fac Allied Hlth Sci, Dept Pharm, Dhaka, Bangladesh.
C3 Sathyabama Institute of Science & Technology; Vels Institute of Science,
   Technology & Advanced Studies; Imam Abdulrahman Bin Faisal University;
   Mount Sinai Medical Center; Daffodil International University
RP MohanaSundaram, A (通讯作者)，Sathyabama Inst Sci & Technol, Sch Pharm, Chennai, Tamilnadu, India.; Bin Emran, T (通讯作者)，BGC Trust Univ Bangladesh, Dept Pharm, Chittagong 4381, Bangladesh.; Bin Emran, T (通讯作者)，Daffodil Int Univ, Fac Allied Hlth Sci, Dept Pharm, Dhaka, Bangladesh.
EM arun.laureate@gmail.com; namragohil1996@gmail.com; maudetek@gmail.com;
   premal.patel29@yahoo.com; dr.gurajalaswathi@gmail.com;
   shanmuga5@yahoo.com; mnsengiyumva16@gmail.com;
   santoshkumar@karnavatiuniversity.edu.in; talhabmb@bgctub.ac.bd
RI Girdhar, DrGaurav/KIC 5802 2024; Gurajala, Dr.Swathi/AGW 2676 2022;
   Emran, Talha Bin/P 9184 2016; MohanaSundaram, ArunSundar/ABC 2659 2021
OI Emran, Talha Bin/0000 0003 3188 2272; GURAJALA,
   SWATHI/0000 0001 8178 4916; Nsengiyumva, Mugisha/0009 0005 9606 7908; 
CR Aarabi G, 2017, J DENT RES, V96, P610, DOI 10.1177/0022034517699786
   Abusleme L, 2021, PERIODONTOL 2000, V86, P57, DOI 10.1111/prd.12362
   Akinkugbe AA, 2017, J DENT RES, V96, P1392, DOI 10.1177/0022034517720924
   Alsayed SSR, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24065202
   Andrade NN, 2012, J ORAL MAXIL SURG, V70, pE12, DOI 10.1016/j.joms.2011.07.020
   [Anonymous], 2022, Oral health
   Bartold PM, 2019, J CLIN PERIODONTOL, V46, P6, DOI 10.1111/jcpe.13046
   Barutta F, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10010178
   Belibasakis GN, 2012, J CLIN PERIODONTOL, V39, P239, DOI 10.1111/j.1600 051X.2011.01810.x
   Blasco Baque V, 2017, GUT, V66, P872, DOI 10.1136/gutjnl 2015 309897
   Bunte K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143394
   CDC, 2013, Periodontal disease
   Cecoro G, 2020, MEDICINA LITHUANIA, V56, DOI 10.3390/medicina56060272
   Cekici A, 2014, PERIODONTOL 2000, V64, P57, DOI 10.1111/prd.12002
   Chai QY, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00158
   Chen TT, 2019, J DENT RES, V98, P157, DOI 10.1177/0022034518805745
   Curtis MA, 2020, PERIODONTOL 2000, V83, P14, DOI 10.1111/prd.12296
   Darveau RP, 2010, NAT REV MICROBIOL, V8, P481, DOI 10.1038/nrmicro2337
   Das Abhaya C, 2019, J Contemp Dent Pract, V20, P1417
   de Lima AFM, 2004, J CLIN PERIODONTOL, V31, P648, DOI 10.1111/j.1600 051X.2004.00576.x
   Dewhirst FE, 2010, J BACTERIOL, V192, P5002, DOI 10.1128/JB.00542 10
   Dominy SS, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau3333
   Dutzan N, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat0797
   Eke PI, 2020, PERIODONTOL 2000, V82, P257, DOI 10.1111/prd.12323
   Eke PI, 2012, J PERIODONTOL, V83, P1337, DOI 10.1902/jop.2012.110676
   El Sharkawy HM, 2016, J PERIODONTOL, V87, P1418, DOI 10.1902/jop.2016.150694
   Fischer LA, 2019, AM J OBSTET GYNECOL, V221, P383, DOI 10.1016/j.ajog.2019.04.029
   FLEMMIG TF, 1995, J CLIN PERIODONTOL, V22, P427, DOI 10.1111/j.1600 051X.1995.tb00173.x
   Franco C, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020440
   Gabriel AD, 2023, ORAL DIS, V29, P2483, DOI 10.1111/odi.14290
   Garg AK, 2014, AUST DENT J, V59, P258, DOI 10.1111/adj.12179
   Genco RJ, 2020, PERIODONTOL 2000, V83, P7, DOI 10.1111/prd.12344
   Graves D, 2008, J PERIODONTOL, V79, P1585, DOI 10.1902/jop.2008.080183
   Gregory, 1980, J Oral Maxillofac Surg, V53, P1334
   Gulati Minkle, 2014, J Indian Soc Periodontol, V18, P282, DOI 10.4103/0972 124X.134559
   Hajishengallis G, 2021, NAT REV IMMUNOL, V21, P426, DOI 10.1038/s41577 020 00488 6
   Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785
   Hajishengallis G, 2014, TRENDS IMMUNOL, V35, P3, DOI 10.1016/j.it.2013.09.001
   Hajishengallis G, 2012, NAT REV MICROBIOL, V10, P717, DOI 10.1038/nrmicro2873
   Hamid Rizwan, 2020, J Oral Maxillofac Pathol, V24, P332, DOI 10.4103/jomfp.JOMFP_174_19
   Herrera D, 2018, J PERIODONTOL, V89, pS85, DOI 10.1002/JPER.16 0642
   Holmstrup P, 2017, J ORAL MICROBIOL, V9, DOI 10.1080/20002297.2017.1332710
   Issa SA, 2020, IDCASES, V21, DOI 10.1016/j.idcr.2020.e00825
   Iype EM, 2001, BRIT J ORAL MAX SURG, V39, P402, DOI 10.1054/bjom.2000.0663
   Joshi V, 2014, J CLIN PERIODONTOL, V41, P1037, DOI 10.1111/jcpe.12300
   Kassebaum NJ, 2014, J DENT RES, V93, P1045, DOI 10.1177/0022034514552491
   Kilian M, 2016, BRIT DENT J, V221, P657, DOI 10.1038/sj.bdj.2016.865
   Kim OS, 2022, J CLIN PERIODONTOL, V49, P706, DOI 10.1111/jcpe.13648
   Kinane DF, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.38
   Kinane DF, 2005, PERIODONTOL 2000, V39, P91, DOI 10.1111/j.1600 0757.2005.00118.x
   Kinane DF, 2000, CRIT REV ORAL BIOL M, V11, P356, DOI 10.1177/10454411000110030501
   Kouanda B, 2021, PULM MED, V2021, DOI 10.1155/2021/4712406
   Lamont RJ, 2018, NAT REV MICROBIOL, V16, P745, DOI 10.1038/s41579 018 0089 x
   Li XY, 2022, FRONT MICROBIOL, V13, DOI 10.3389/fmicb.2022.895537
   Méheust R, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 12171 z
   Minty M, 2019, REV ENDOCR METAB DIS, V20, P449, DOI 10.1007/s11154 019 09526 8
   Mumtaz S, 2020, BRIT DENT J, V229, P571, DOI 10.1038/s41415 020 2368 y
   Munoz JE, 2020, Perverse Modernities, P1, DOI 10.1109/imbioc.2019.8777845
   Nascimento G.G., 2017, Current Oral Health Reports, P301, DOI DOI 10.1007/S40496 017 0158 7
   Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577 020 0285 6
   Nocini R., 2020, J. Public Health Emerg, V4, DOI [10.21037/jphe.2020.03.01, DOI 10.21037/JPHE.2020.03.01]
   Offenbacher S, 1996, J PERIODONTOL, V67, P1103, DOI 10.1902/jop.1996.67.10s.1103
   Pan WY, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368 019 0064 z
   Paster BJ, 2006, PERIODONTOL 2000, V42, P80, DOI 10.1111/j.1600 0757.2006.00174.x
   Petrescu N, 2022, MEMBRANES BASEL, V12, DOI 10.3390/membranes12090895
   Pradeep AR, 2010, J PERIODONTOL, V81, P214, DOI 10.1902/jop.2009.090429
   Qasim SSB, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113829
   Ramadan Doaa Elsayed, 2020, Eur J Dent, V14, P483, DOI 10.1055/s 0040 1712718
   Ramseier CA, 2017, J CLIN PERIODONTOL, V44, P1182, DOI 10.1111/jcpe.12782
   Rastogi Tanushree, 2019, J Indian Soc Periodontol, V23, P269, DOI 10.4103/jisp.jisp_435_18
   Rosier BT, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00092
   Silva IL, 2021, J MOL BIOL, V433, DOI 10.1016/j.jmb.2021.166836
   Singhal S, 2016, J ORAL SCI, V58, P547, DOI 10.2334/josnusd.16 0017
   Su Y, 2023, INT J ORAL SCI, V15, DOI 10.1038/s41368 023 00227 2
   Sultan AS, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006719
   Tamashiro NS, 2016, J DENT RES, V95, P829, DOI 10.1177/0022034516639274
   Tang BY, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.885029
   Vitkov L, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24054544
   Zhou XY, 2019, J PERIODONTOL, V90, P1032, DOI 10.1002/JPER.18 0528
NR 79
TC 3
Z9 3
U1 3
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1743 9191
EI 1743 9159
J9 INT J SURG
JI Int. J. Surg.
PD JUN
PY 2024
VL 110
IS 6
BP 3606
EP 3616
DI 10.1097/JS9.0000000000001122
PG 11
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery
GA UL4X2
UT WOS:001248212000063
PM 38231241
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ferreira, D
   Vilayur, E
   Gao, M
   Sankoorikal, C
   Bendinelli, C
AF Ferreira, David
   Vilayur, Eswari
   Gao, Michael
   Sankoorikal, Christy
   Bendinelli, Cino
TI Calcitriol loading before total parathyroidectomy with autotransplant in
   patients with end stage kidney disease: does it prevent postoperative
   hypocalcaemia?
SO INTERNAL MEDICINE JOURNAL
LA English
DT Article
DE calcimimetic agents; hyperparathyroidism; hypocalcaemia; kidney failure;
   chronic; parathyroidectomy
ID HUNGRY BONE SYNDROME; HEMODIALYSIS PATIENTS; HEART FAILURE;
   HYPERPARATHYROIDISM; CALCIUM; PREDICTORS
AB Background Hungry bone syndrome (HBS) is one of the most serious complications following parathyroidectomy for severe hyperparathyroidism. There is a lack of literature informing the treatment and risk factors for this condition and the ideal pre operative strategy for prevention. Aims The primary aims were to examine the incidence of HBS with pre operative calcitriol loading for 10 days and to determine the risk factors for HBS. The secondary aims were to determine the rate of intravenous calcium replacement in those with HBS and to assess whether cinacalcet removal has increased rates of parathyroidectomy in the end stage kidney disease population. Methods We performed a retrospective study from 2011 to 2018 on 45 patients with end stage kidney disease undergoing total parathyroidectomy with autotransplantation for severe hyperparathyroidism. This was based at the John Hunter and Newcastle Private Hospitals in New South Wales. Results 28.3% of patients with calcitriol loading undergoing parathyroidectomy fulfilled criteria for HBS. Pre operative variables that were associated with HBS were elevated parathyroid hormone (P = 0.028) and longer duration of renal replacement therapy (P = 0.033). Rates of total parathyroidectomy were higher after the removal of calcimimetics from the Pharmaceutical Benefits Scheme (P = 0.0024). Conclusions HBS remains a common complication of parathyroidectomy, even with prolonged high dose calcitriol loading. This emphasises the need for further trials investigating other targeted therapies, such as bisphosphonates, to prevent HBS. Those most at risk of HBS are patients with high bone turnover and prolonged renal replacement therapy.
C1 [Ferreira, David] Univ New South Wales, John Hunter Hosp, Sch Med, Dept Nephrol Med & Intervent Serv, Sydney, NSW, Australia.
   [Vilayur, Eswari] Univ Newcastle, Sch Epidemiol & Publ Hlth, Newcastle, NSW, Australia.
   [Gao, Michael] John Hunter Hosp, Dept Nephrol Med & Intervent Serv, Newcastle, NSW, Australia.
   [Sankoorikal, Christy] John Hunter Hosp, Endocrinol Dept, Med & Intervent Serv, Newcastle, NSW, Australia.
   [Bendinelli, Cino] John Hunter Hosp, Endocrine & Gen Surg, Dept Surg, Newcastle, NSW, Australia.
   [Bendinelli, Cino] Newcastle Private Hosp, Newcastle, NSW, Australia.
C3 University of New South Wales Sydney; John Hunter Hospital; University
   of Newcastle; John Hunter Hospital; John Hunter Hospital; John Hunter
   Hospital
RP Ferreira, D (通讯作者)，John Hunter Hosp, Dept Nephrol, Lookout Rd, Newcastle, NSW 2305, Australia.
EM dave_7@live.com.au
RI Ferreira, David/AAL 5552 2021
OI Ferreira, David/0000 0003 3142 4503
CR Bleyer AJ, 2005, AM J KIDNEY DIS, V46, P464, DOI 10.1053/j.ajkd.2005.04.035
   BRASIER AR, 1988, AM J MED, V84, P654, DOI 10.1016/0002 9343(88)90100 3
   Chen L, 2016, RENAL FAILURE, V38, P1050, DOI 10.1080/0886022X.2016.1184924
   CLAIR F, 1987, NEPHRON, V46, P18, DOI 10.1159/000184289
   Cruz DN, 1997, AM J KIDNEY DIS, V29, P759, DOI 10.1016/S0272 6386(97)90131 1
   Davenport A, 2007, NEPHROLOGY, V12, P386, DOI 10.1111/j.1440 1797.2007.00806.x
   FALKO JM, 1976, AM J MED SCI, V271, P85, DOI 10.1097/00000441 197601000 00012
   Foley RN, 2005, J AM SOC NEPHROL, V16, P210, DOI 10.1681/ASN.2004020138
   Goldfarb M, 2012, WORLD J SURG, V36, P1314, DOI 10.1007/s00268 012 1560 x
   Grzela T, 2006, INT J MOL MED, V17, P779
   Ho LY, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882 016 0421 5
   Jain N, 2017, CURR OPIN NEPHROL HY, V26, P250, DOI 10.1097/MNH.0000000000000327
   Konturek A, 2016, LANGENBECK ARCH SURG, V401, P965, DOI 10.1007/s00423 016 1447 7
   Kroll MH, 2000, B MATH BIOL, V62, P163, DOI 10.1006/bulm.1999.0146
   Kumar A, 1996, NEPHRON, V74, P729, DOI 10.1159/000189483
   Latus J, 2013, INT J NEPHROL RENOV, V6, P131, DOI 10.2147/IJNRD.S47179
   Li WD, 2016, NEPHROLOGY, V21, P133, DOI 10.1111/nep.12564
   Nieves JW, 2005, J BONE MINER RES, V20, P529, DOI 10.1359/JBMR.041005
   Rajaram YS, 2017, NEPHROL THER, V22, P51
   Riccardi D, 2008, CLIN KIDNEY J, V1, pI7, DOI 10.1093/ndtplus/sfm038
   Scuderi C, 2017, SENSIPAR INSTEAD SUR
   SHINODA T, 1992, NEPHRON, V60, P482, DOI 10.1159/000186813
   Torer N, 2009, TRANSPL P, V41, P3642, DOI 10.1016/j.transproceed.2009.06.207
   Viaene L, 2008, NEPHRON CLIN PRACT, V110, pC80, DOI 10.1159/000151722
   Witteveen JE, 2013, EUR J ENDOCRINOL, V168, pR45, DOI 10.1530/EJE 12 0528
   Zheng CM, 2012, TOHOKU J EXP MED, V226, P19, DOI 10.1620/tjem.226.19
NR 26
TC 10
Z9 10
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1444 0903
EI 1445 5994
J9 INTERN MED J
JI Intern. Med. J.
PD JUL
PY 2019
VL 49
IS 7
BP 886
EP 893
DI 10.1111/imj.14209
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA IJ1RR
UT WOS:000475676500012
PM 30552793
DA 2025 08 17
ER

PT J
AU Paradise, CR
   Galvan, ML
   Kubrova, E
   Bowden, S
   Liu, E
   Carstens, MF
   Thaler, R
   Stein, GS
   van Wijnen, AJ
   Dudakovic, A
AF Paradise, Christopher R.
   Galvan, M. Lizeth
   Kubrova, Eva
   Bowden, Sierra
   Liu, Esther
   Carstens, Mason F.
   Thaler, Roman
   Stein, Gary S.
   van Wijnen, Andre J.
   Dudakovic, Amel
TI The epigenetic reader Brd4 is required for osteoblast differentiation
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE bone; Brd4; bromodomain; epigenetics; osteoblast
ID BONE FORMATION; TRANSCRIPTIONAL CONTROL; HISTONE DEACETYLASES;
   SELECTIVE INHIBITION; IN VITRO; GENE; RUNX2; ACETYLATION; CELLS;
   DISRUPTION
AB Transcription networks and epigenetic mechanisms including DNA methylation, histone modifications, and noncoding RNAs control lineage commitment of multipotent mesenchymal progenitor cells. Proteins that read, write, and erase histone tail modifications curate and interpret the highly intricate histone code. Epigenetic reader proteins that recognize and bind histone marks provide a crucial link between histone modifications and their downstream biological effects. Here, we investigate the role of bromodomain containing (BRD) proteins, which recognize acetylated histones, during osteogenic differentiation. Using RNA sequencing (RNA seq) analysis, we screened for BRD proteins (n = 40) that are robustly expressed in MC3T3 osteoblasts. We focused functional follow up studies on Brd2 and Brd4 which are highly expressed in MC3T3 preosteoblasts and represent "bromodomain and extra terminal domain" (BET) proteins that are sensitive to pharmacological agents (BET inhibitors). We show that small interfering RNA depletion of Brd4 has stronger inhibitory effects on osteoblast differentiation than Brd2 loss as measured by osteoblast related gene expression, extracellular matrix deposition, and alkaline phosphatase activity. Similar effects on osteoblast differentiation are seen with the BET inhibitor +JQ1, and this effect is reversible upon its removal indicating that this small molecule has no lasting effects on the differentiation capacity of MC3T3 cells. Mechanistically, we find that Brd4 binds at known Runx2 binding sites in promoters of bone related genes. Collectively, these findings suggest that Brd4 is recruited to osteoblast specific genes and may cooperate with bone related transcription factors to promote osteoblast lineage commitment and maturation.
C1 [Paradise, Christopher R.] Mayo Clin, Grad Sch Biomed Sci, Rochester, MN 55905 USA.
   [Paradise, Christopher R.; van Wijnen, Andre J.] Mayo Clin, Ctr Regenerat Med, Rochester, MN 55905 USA.
   [Paradise, Christopher R.; Galvan, M. Lizeth; Kubrova, Eva; Bowden, Sierra; Liu, Esther; Carstens, Mason F.; Thaler, Roman; van Wijnen, Andre J.; Dudakovic, Amel] Mayo Clin, Dept Orthoped Surg, Rochester, MN 55905 USA.
   [Kubrova, Eva] Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN 55905 USA.
   [Stein, Gary S.] Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA.
   [van Wijnen, Andre J.; Dudakovic, Amel] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; University of
   Vermont; Mayo Clinic
RP van Wijnen, AJ; Dudakovic, A (通讯作者)，Mayo Clin, 200 First St SW, Rochester, MN 55905 USA.
EM vanWijnen.Andre@mayo.edu; Dudakovic.Amel@mayo.edu
RI ; van Wijnen, Andre/AAG 3578 2019
OI Bowden, Sierra/0000 0002 6862 7913; Dudakovic, Amel/0000 0002 8850 3977;
   Stein, Gary/0000 0001 8762 5422; van Wijnen, Andre
   J./0000 0002 4458 0946; Paradise, Christopher/0000 0002 5882 709X
FU Mayo Clinic Career Development Award in Orthopedics; National Institute
   of Arthritis and Musculoskeletal and Skin Diseases [R01 AR069049]
FX Mayo Clinic Career Development Award in Orthopedics, Grant/Award Number:
   to AD; National Institute of Arthritis and Musculoskeletal and Skin
   Diseases, Grant/Award Number: R01 AR069049 to AvW
CR Allis CD, 2016, NAT REV GENET, V17, P487, DOI 10.1038/nrg.2016.59
   Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Baud'huin M, 2017, BONE, V94, P10, DOI 10.1016/j.bone.2016.09.020
   Berendsen AD, 2015, BONE, V80, P14, DOI 10.1016/j.bone.2015.04.035
   Bradley EW, 2015, PHYSIOL REV, V95, P1359, DOI 10.1152/physrev.00004.2015
   Cantley MD, 2017, BONE, V95, P162, DOI 10.1016/j.bone.2016.11.028
   Devaiah BN, 2016, J LEUKOCYTE BIOL, V100, P679, DOI 10.1189/jlb.2RI0616 250R
   Di Bernardo G, 2009, STEM CELLS DEV, V18, P573, DOI 10.1089/scd.2008.0172
   Doroshow DB, 2017, ANN ONCOL, V28, P1776, DOI 10.1093/annonc/mdx157
   Dudakovic, 2017, CURRENT MOL BIOL REP, V3, P94, DOI [DOI 10.1007/S40610 017 0064 8, DOI 10.1007/s40610 017 0064 8]
   Dudakovic A, 2017, GENE, V609, P28, DOI 10.1016/j.gene.2017.01.019
   Dudakovic A, 2016, J BIOL CHEM, V291, P24594, DOI 10.1074/jbc.M116.740571
   Dudakovic A, 2015, J BIOL CHEM, V290, P27604, DOI 10.1074/jbc.M115.672345
   Dudakovic A, 2015, J CELL PHYSIOL, V230, P52, DOI 10.1002/jcp.24680
   Dudakovic A, 2013, J BIOL CHEM, V288, P28783, DOI 10.1074/jbc.M113.489732
   Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504
   Gibney ER, 2010, HEREDITY, V105, P4, DOI 10.1038/hdy.2010.54
   Gilmour J, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 28506 7
   Gordon JAR, 2015, BONE, V81, P739, DOI 10.1016/j.bone.2015.03.011
   Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   IWAMI K, 1993, INT J BIOCHEM, V25, P1631, DOI 10.1016/0020 711X(93)90522 G
   Jensen ED, 2008, J BONE MINER RES, V23, P361, DOI 10.1359/JBMR.071104
   Kalari KR, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471 2105 15 224
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb 2013 14 4 r36
   Kobayashi T, 2014, METHODS MOL BIOL, V1130, P3, DOI 10.1007/978 1 62703 989 5_1
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Lamoureux F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4511
   Lee HW, 2006, MOL ENDOCRINOL, V20, P2432, DOI 10.1210/me.2006 0061
   Lee JE, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 02403 5
   Lee S, 2009, CELL PROLIFERAT, V42, P711, DOI 10.1111/j.1365 2184.2009.00633.x
   Lian JB, 2006, REV ENDOCR METAB DIS, V7, P1, DOI 10.1007/s11154 006 9001 5
   Lovén J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036
   Maes C, 2010, DEV CELL, V19, P329, DOI 10.1016/j.devcel.2010.07.010
   McGee Lawrence ME, 2011, BONE, V48, P1117, DOI 10.1016/j.bone.2011.01.007
   McGee Lawrence ME, 2011, GENE, V474, P1, DOI 10.1016/j.gene.2010.12.003
   Meyer MB, 2014, J BIOL CHEM, V289, P16016, DOI 10.1074/jbc.M114.552216
   Mortada I, 2018, EUR J MED GENET, V61, P114, DOI 10.1016/j.ejmg.2017.10.015
   Najafova Z, 2017, NUCLEIC ACIDS RES, V45, P127, DOI 10.1093/nar/gkw826
   Nissen Meyer LSH, 2007, EPILEPSIA, V48, P1850, DOI 10.1111/j.1528 1167.2007.01176.x
   Pratap J, 2010, MOL CANCER THER, V9, P3210, DOI 10.1158/1535 7163.MCT 10 0572
   Razidlo DF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011492
   Sabari BR, 2017, NAT REV MOL CELL BIO, V18, P90, DOI 10.1038/nrm.2016.140
   Sakurai N, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 12342 2
   Sanchez R, 2009, CURR OPIN DRUG DISC, V12, P659
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Schroeder Tania M., 2005, Birth Defects Research, V75, P213, DOI 10.1002/bdrc.20043
   Schroeder TM, 2005, J BONE MINER RES, V20, P2254, DOI 10.1359/JBMR.050813
   Schroeder TM, 2004, J BIOL CHEM, V279, P41998, DOI 10.1074/jbc.M403702200
   Senn SM, 2010, EPILEPSIA, V51, P984, DOI 10.1111/j.1528 1167.2009.02516.x
   Shen J, 2003, MOL ENDOCRINOL, V17, P743, DOI 10.1210/me.2002 0122
   Shen JL, 2002, J BIOL CHEM, V277, P20284, DOI 10.1074/jbc.M112440200
   Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593
   Stein GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676
   Taniguchi Y, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111849
   van Wijnen AJ, 2019, J ORTHOP RES, V37, P1465, DOI 10.1002/jor.24305
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   Wu H, 2017, BBA GENE REGUL MECH, V1860, P438, DOI 10.1016/j.bbagrm.2017.01.003
   Wu H, 2014, GENOME BIOL, V15, DOI 10.1186/gb 2014 15 3 r52
   Xu S, 2013, ACTA PHARMACOL SIN, V34, P699, DOI 10.1038/aps.2012.182
NR 60
TC 22
Z9 24
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JUN
PY 2020
VL 235
IS 6
BP 5293
EP 5304
DI 10.1002/jcp.29415
EA DEC 2019
PG 12
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA KR5BZ
UT WOS:000503887100001
PM 31868237
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Lumachi, F
   Cappelletti, P
   Tozzoli, R
   Basso, SMM
   Luisetto, G
   Camozzi, V
AF Lumachi, Franco
   Cappelletti, Piero
   Tozzoli, Renato
   Basso, Stafano M. M.
   Luisetto, Giovanni
   Camozzi, Valentina
TI Diagnosis of Alterations of Serum Calcium Metabolism
SO MEDICINAL CHEMISTRY
LA English
DT Article
DE Calcium metabolism; hypercalcemia; calciuria; PTH; vitamin D; PTHrP
ID ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM; 3RD INTERNATIONAL WORKSHOP;
   PARATHYROID HORMONE; HEMODIALYSIS PATIENTS; IONIZED CALCIUM; VITAMIN D;
   HYPERCALCEMIA; OSTEOPOROSIS; STATEMENT; MARKERS
AB Calcium is essential to homeostasis and functioning of multiple organ systems. Its circulating concentration is maintained within a very tight physiologic range: 2.25 and 2.50 mmol/L. Under physiological conditions, the ionized calcium concentration is regulated by the parathyroid hormone (PTH), and 1,25(OH)(2) vitamin D through interactions on target organs such as kidney, bone and intestine. In mild, moderate, and severe hypercalcemia, laboratory findings are essential in assessing and monitoring disease course and therapy. The main tools are specific standard biochemical tests able to assess calcium balance and renal function, and some specific biochemical tests, such as PTH, 25(OH) vitamin D, and genetic sequencing, used to clarify the cause of hypercalcemia and, subsequently, to determine appropriate therapy. Once hypercalcemia is confirmed by ionized calcium measurement, the intact PTH assay plays a crucial role to differentiate PTH mediated from non PTH mediated hypercalcemia. Mild hypercalcemia is also present in up to 10 20% of patients treated with lithium for bipolar disorders, in 7 8% of those treated with thiazide diuretics, and in patients with prolonged immobilization, while very high (>3.5 mmol/L) serum calcium levels, together with low PTH, and a rapid increase of hypercalcemia, usually suggest a malignancy associated hypercalcemic syndrome. The measurement of PTH related protein, a tumor product that mimics certain action of PTH, is useful only in selected cases. The role of biochemical markers of bone turnover for predicting metastatic bone disease, and monitoring bone metabolic changes, and their usefulness as a predictive mean of the likelihood of bone loss or fractures risk is still unclear.
C1 [Lumachi, Franco] Univ Padua, Sch Med, Dept Surg Oncol & Gastroenterol Sci DiSCOG, I 35128 Padua, Italy.
   [Cappelletti, Piero] IRCCS, Ctr Oncol Reg CRO, I 33081 Aviano, PN, Italy.
   [Tozzoli, Renato] S Maria degli Angeli Hosp, Dept Clin Pathol, I 33170 Pordenone, Italy.
   [Luisetto, Giovanni; Camozzi, Valentina] Univ Padua, Sch Med, Dept Med & Surg Sci, I 35128 Padua, Italy.
C3 University of Padua; IRCCS Aviano (CRO); University of Padua
RP Lumachi, F (通讯作者)，Univ Padua, Sch Med, Dept Surg Oncol & Gastroenterol Sci DiSCOG, I 35128 Padua, Italy.
EM flumachi@unipd.it
RI Tozzoli, Renato/AAG 4067 2020; Lumachi, Franco/K 9501 2015; Camozzi,
   Valentina/Q 9833 2016; Cappelletti, Piero/GNW 6738 2022
OI Lumachi, Franco/0000 0001 8349 631X; Camozzi,
   Valentina/0000 0002 1634 951X; Basso, Stefano Maria
   Massimiliano/0000 0003 3155 1772
CR Bilezikian JP, 2009, J CLIN ENDOCR METAB, V94, P335, DOI 10.1210/jc.2008 1763
   Bilezikian JP, 2002, J CLIN ENDOCR METAB, V87, P5353, DOI 10.1210/jc.2002 021370
   Bischoff Ferrari HA, 2008, ADV EXP MED BIOL, V624, P55, DOI 10.1007/978 0 387 77574 6_5
   Calvi LM, 2008, J AM SOC NEPHROL, V19, P1257, DOI 10.1681/ASN.2007121327
   Cappelletti P, 2010, HYPERCALCEMIA PATHOPHYSIOLOGY & TREATMENT, P45
   Clase CM, 2000, NEPHROL DIAL TRANSPL, V15, P1841, DOI 10.1093/ndt/15.11.1841
   CLSI, 2005, INT TEST CLIN CHEM A
   Cole DEC, 2007, CLIN BIOCHEM, V40, P585, DOI 10.1016/j.clinbiochem.2007.03.019
   D'Amour P, 2006, KIDNEY INT, V70, pS29, DOI 10.1038/sj.ki.5001599
   Dawson Hughes B, 2005, OSTEOPOROSIS INT, V16, P713, DOI 10.1007/s00198 005 1867 7
   Eastell R, 2009, J CLIN ENDOCR METAB, V94, P340, DOI 10.1210/jc.2008 1758
   Friedman PA, 2006, AM J PHYSIOL RENAL, V290, pF975, DOI 10.1152/ajprenal.00336.2005
   Fritchie K, 2009, CLIN CHIM ACTA, V402, P146, DOI 10.1016/j.cca.2008.12.040
   Joly D, 2008, AM J KIDNEY DIS, V51, P987, DOI 10.1053/j.ajkd.2008.01.017
   LANDENSON JH, 1978, J CLIN ENDOCR METAB, V46, P986
   Lewiecki E Michael, 2010, Curr Osteoporos Rep, V8, P15, DOI 10.1007/s11914 010 0004 5
   Lumachi F, 2004, BRIT J RADIOL, V77, P100, DOI 10.1259/bjr/44399050
   Lumachi F, 2006, ANTICANCER RES, V26, P4803
   Lumachi F, 2009, ANN NY ACAD SCI, V1173, pE60, DOI 10.1111/j.1749 6632.2009.04953.x
   Lumachi F, 2009, ANTICANCER RES, V29, P1551
   Okamoto T, 2009, WORLD J SURG, V33, P2343, DOI 10.1007/s00268 009 9999 0
   Phinney KW, 2008, AM J CLIN NUTR, V88, p511S, DOI 10.1093/ajcn/88.2.511S
   Reginster JY, 2008, BONE, V42, P832, DOI 10.1016/j.bone.2008.01.021
   Slomp J, 2003, CRIT CARE MED, V31, P1389, DOI 10.1097/01.CCM.0000063044.55669.3C
   Toffaletti J. G., 2009, BLOOD GASES ELECTROL
   Toke J, 2009, WIEN KLIN WOCHENSCHR, V121, P236, DOI 10.1007/s00508 009 1149 z
   Viljoen A, 2008, CLIN CHEM LAB MED, V46, P1438, DOI 10.1515/CCLM.2008.275
   Wu AHB, 2006, Tietz clinical guide to laboratory tests, V4th
   Younes NA, 2005, CLIN CHIM ACTA, V353, P1, DOI 10.1016/j.cccn.2004.10.003
NR 29
TC 8
Z9 9
U1 1
U2 14
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1573 4064
J9 MED CHEM
JI Med. Chem.
PD JUL
PY 2012
VL 8
IS 4
BP 551
EP 555
DI 10.2174/157340612801216139
PG 5
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 016NC
UT WOS:000309524600007
PM 22571194
DA 2025 08 17
ER

PT J
AU Wang, L
   O'Leary, H
   Fortney, J
   Gibson, LF
AF Wang, Lin
   O'Leary, Heather
   Fortney, James
   Gibson, Laura F.
TI Ph<SUP>+</SUP>/VE cadfletin<SUP>+</SUP> identifies a stem cell like
   population of acute lymphoblastic leukemia sustained by bone matTow
   niche cells
SO BLOOD
LA English
DT Article
ID HEMATOPOIETIC STEM; BETA CATENIN; TYROSINE PHOSPHORYLATION; VASCULAR
   ENDOTHELIUM; MYELOID LEUKEMIA; PROGENITOR CELLS; VE CADHERIN;
   ACTIVATION; PATHWAY; CANCER
AB Although leukemic stem cells (LSCs) show a symbiotic relationship with bone marrow microenvironmental niches, the mechanism by which the marrow microenvironment contributes to self renewal and proliferation of LSCs remains elusive. In the present study, we identified a unique subpopulation of Philadelphia chromosome positive (Ph(+)) acute lymphoblastic leukemia (ALL) cells coexpressing markers of endothelial cells (including VE cadherin, PECAM 1, and Flk 1) and committed B lineage progenitors. After long term coculture with bone marrow stromal cells, tumor cells formed hematopoietic colonies and cords, expressed early stem  cell markers, and showed endothelial sprouting. Gene expression profiles of LSCs were altered in the presence of stromal cell contact. Stromal cell contact promoted leukemic cell VE cadherin expression, stabilized beta catenin, and up regulated Bcr abl fusion gene expression. Our study indicates that these specific tumor cells are uniquely positioned to respond to microenvironment derived self renewing and proliferative cues. Ph(+)/VE cadherin(+) tumarrow stromal cells, tumor cells formed hematopoietic colonies and cords, expressed early stem  cell markers, and showed endothelial sprouting. Gene expression profiles of LSCs were altered in the presence of stromal cell contact. Stromal cell contact promoted leukemic cell VE cadherin expression, stabilized beta catenin, and up regulated Bcr abl fusion gene expression. Our study indicates that these specific tumor cells are uniquely positioned to respond to microenvironment derived self renewing and proliferative cues. Ph(+)/VE cadherin(+) tumor subpopulation circumvents the requirement of exogenous Wnt signaling for self renewal through stromal cell support of leukemic cell VE cadherin expression and up regulated Bcr abl tyrosine kinase activity. These data suggest that strategies targeting signals in the marrow microenvironment that amplify the Bcr abl/VE cadherin/beta catenin axis may have utility in sensitizing drug resistant leukemic stem cells.
C1 W Virginia Univ, Sch Med, Dept Pediat, Morgantown, WV 26506 USA.
   W Virginia Univ, Sch Med, Dept Microbiol & Immunol, Morgantown, WV 26506 USA.
   W Virginia Univ, Sch Med, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA.
C3 West Virginia University; West Virginia University; West Virginia
   University
RP Wang, L (通讯作者)，W Virginia Univ, Sch Med, Dept Pediat, POB 9214, Morgantown, WV 26506 USA.
OI O'Leary, Heather/0000 0003 1321 1520; Gibson, Laura/0000 0002 7291 9046
FU NCI NIH HHS [R01 CA134573] Funding Source: Medline; NCRR NIH HHS [P20
   RR016440, RR 16440] Funding Source: Medline; NHLBI NIH HHS [R01
   HL056888, R01 HL 056888] Funding Source: Medline
CR Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004
   Bailey AS, 2006, P NATL ACAD SCI USA, V103, P13156, DOI 10.1073/pnas.0604203103
   Castor A, 2005, NAT MED, V11, P630, DOI 10.1038/nm1253
   Cobaleda C, 2000, BLOOD, V95, P1007, DOI 10.1182/blood.V95.3.1007.003k35_1007_1013
   Coluccia AML, 2007, EMBO J, V26, P1456, DOI 10.1038/sj.emboj.7601485
   Cox CV, 2004, BLOOD, V104, P2919, DOI 10.1182/blood 2004 03 0901
   Gunsilius E, 2000, LANCET, V355, P1688, DOI 10.1016/S0140 6736(00)02241 8
   Hendrix MJC, 2001, P NATL ACAD SCI USA, V98, P8018, DOI 10.1073/pnas.131209798
   Hotfilder M, 2005, CANCER RES, V65, P1442, DOI 10.1158/0008 5472.CAN 04 1356
   Hu YG, 2006, P NATL ACAD SCI USA, V103, P16870, DOI 10.1073/pnas.0606509103
   Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674
   Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258
   Khuntia D, 2006, J CLIN ONCOL, V24, P1295, DOI 10.1200/JCO.2005.04.6185
   Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026
   Kirstetter P, 2006, NAT IMMUNOL, V7, P1048, DOI 10.1038/ni1381
   Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226
   Li LH, 2006, CANCER RES, V66, P4553, DOI 10.1158/0008 5472.CAN 05 3986
   Maupas Schwalm F, 2005, CANCER RES, V65, P526
   MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768
   Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291
   Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287 2297.2003
   Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008 5472.CAN 05 0626
   Potter MD, 2005, J BIOL CHEM, V280, P31906, DOI 10.1074/jbc.M505568200
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   RUSTIN GJS, 1989, J CLIN ONCOL, V7, P900, DOI 10.1200/JCO.1989.7.7.900
   Scheller M, 2006, NAT IMMUNOL, V7, P1037, DOI 10.1038/ni1387
   Somervaille TCP, 2006, CANCER CELL, V10, P257, DOI 10.1016/j.ccr.2006.08.020
   Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040
   Vescovi AL, 2006, NAT REV CANCER, V6, P425, DOI 10.1038/nrc1889
   Wang L, 2005, STEM CELLS, V23, P1122, DOI 10.1634/stemcells.2004 0354
   Wang L, 2005, LEUKEMIA, V19, P344, DOI 10.1038/sj.leu.2403643
   Yin T, 2006, J CLIN INVEST, V116, P1195, DOI 10.1172/JCI28568
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
   Zhou Y, 1997, J CLIN INVEST, V99, P2139, DOI 10.1172/JCI119387
NR 37
TC 52
Z9 60
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006 4971
J9 BLOOD
JI Blood
PD NOV 1
PY 2007
VL 110
IS 9
BP 3334
EP 3344
DI 10.1182/blood 2007 01 068122
PG 11
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 230UJ
UT WOS:000250901200037
PM 17638851
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Fukui, T
   Oe, K
   Kawamoto, T
   Morishita, M
   Fujita, I
   Takahara, S
   Sakurai, A
   Iwakura, T
   Yoshida, K
   Ito, K
   Shoda, E
   Hiranaka, T
   Tsunoda, M
   Kuroda, R
   Niikura, T
AF Fukui, Tomoaki
   Oe, Keisuke
   Kawamoto, Teruya
   Morishita, Masayuki
   Fujita, Ikuo
   Takahara, Shunsuke
   Sakurai, Atsushi
   Iwakura, Takashi
   Yoshida, Keiji
   Ito, Kenjiro
   Shoda, Etsuo
   Hiranaka, Takafumi
   Tsunoda, Masaya
   Kuroda, Ryosuke
   Niikura, Takahiro
TI Multicenter study on atypical femoral fractures in patients with bone
   metastases taking bone  modifying agents
SO JOURNAL OF BONE ONCOLOGY
LA English
DT Article
DE Atypical femoral fracture; Bone metastasis; Zoledronic acid; Denosumab;
   Bone modifying agent; Bisphosphonate
ID ZOLEDRONIC ACID; BREAST CANCER; POSTMENOPAUSAL WOMEN; FEMUR FRACTURES;
   BISPHOSPHONATE USE; TARGETED AGENTS; DENOSUMAB; PREVENTION; TRIAL;
   COMPLICATIONS
AB Bone modifying agents (BMAs), with bone resorptive inhibitory effects, such as zoledronic acid and denosumab, are widely used at higher doses for bone related events caused by bone metastasis of malignant tumors. These drugs have been suggested to be associated with atypical femoral fractures (AFFs), and the relationship between BMAs and AFFs has attracted attention. To investigate the clinical features including bone union time of AFFs in patients administered BMA for bone metastasis, we conducted a retrospective multicenter study. Thirty AFFs from 19 patients were enrolled in this study. Thirteen patients had bilateral AFFs, and nineteen AFFs had pro dromal symptoms. Eighteen AFFs underwent surgery after complete fracture, three failed to achieve bone union and required nonunion surgery, and 11 AFFs that achieved bone union had an average period until bone union of 16.2 months, which was much longer than that previously reported for ordinary AFFs. Seven patients dis continued the BMAs, but not due to AFFs. Stopping BMAs in patients with bone metastasis would make it difficult to secure their performance of activities of daily living, and AFF with BMA administration might require a longer time for union. Therefore, it would be important to prevent incomplete AFF from becoming complete AFF via prophylactic internal fixation.
C1 [Fukui, Tomoaki; Oe, Keisuke; Kawamoto, Teruya; Kuroda, Ryosuke; Niikura, Takahiro] Kobe Univ, Dept Orthopaed Surg, Grad Sch Med, Kobe, Japan.
   [Morishita, Masayuki; Fujita, Ikuo] Hyogo Canc Ctr, Dept Orthopaed Surg, Akashi, Japan.
   [Takahara, Shunsuke] Kakogawa Med Ctr, Dept Orthopaed Surg, Kakogawa, Japan.
   [Sakurai, Atsushi; Iwakura, Takashi] Awaji Med Ctr, Dept Orthopaed Surg, Sumoto, Japan.
   [Yoshida, Keiji] Kobe City Nishi Kobe Med Ctr, Dept Orthopaed Surg, Kobe, Japan.
   [Ito, Kenjiro] Akashi Med Ctr, Dept Orthopaed Surg, Akashi, Japan.
   [Shoda, Etsuo; Niikura, Takahiro] Hyogo Prefectural Nishinomiya Hosp, Dept Orthopaed Surg, Nishinomiya, Japan.
   [Hiranaka, Takafumi] Takatsuki Hosp, Dept Orthopaed Surg, Takatsuki, Japan.
   [Iwakura, Takashi; Tsunoda, Masaya] Sanda City Hosp, Dept Orthopaed Surg, Sanda, Japan.
C3 Kobe University; Hyogo Cancer Center; Kobe City Medical Center General
   Hospital
RP Niikura, T (通讯作者)，Kobe Univ, Dept Orthopaed Surg, Grad Sch Med, Kobe, Japan.
EM niikura@tj8.so net.ne.jp
RI Kawamoto, Teruya/JUE 9670 2023; Oe, Keisuke/MIO 9342 2025; Hiranaka,
   Takafumi/J 7460 2019; Sakurai, Atsushi/HKO 2947 2023
OI Fukui, Tomoaki/0000 0001 9795 9549; 
CR Ahn SG, 2014, J BREAST CANCER, V17, P350, DOI 10.4048/jbc.2014.17.4.350
   Amadori D, 2013, LANCET ONCOL, V14, P663, DOI 10.1016/S1470 2045(13)70174 8
   Aspenberg P, 2010, J BONE MINER RES, V25, P404, DOI 10.1359/jbmr.090731
   Black DM, 2020, NEW ENGL J MED, V383, P743, DOI 10.1056/NEJMoa1916525
   Bogdan Y, 2016, J ORTHOP TRAUMA, V30, P177, DOI 10.1097/BOT.0000000000000516
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Cadieux B, 2022, J BONE ONCOL, V33, DOI 10.1016/j.jbo.2022.100416
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Chang ST, 2012, BONE, V51, P524, DOI 10.1016/j.bone.2012.05.010
   Chiang CY, 2013, BONE, V52, P360, DOI 10.1016/j.bone.2012.10.006
   Clemons M, 2021, EUR J CANCER, V142, P132, DOI 10.1016/j.ejca.2020.08.019
   Coleman RE, 2010, CANCER TREAT REV, V36, P615, DOI 10.1016/j.ctrv.2010.04.003
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dell RM, 2012, J BONE MINER RES, V27, P2544, DOI 10.1002/jbmr.1719
   Edwards BJ, 2016, J BONE MINER RES, V31, P1569, DOI 10.1002/jbmr.2818
   Gani L, 2021, JBMR PLUS, V5, DOI 10.1002/jbm4.10515
   Himelstein AL, 2017, JAMA J AM MED ASSOC, V317, P48, DOI 10.1001/jama.2016.19425
   Hortobagyi GN, 2017, JAMA ONCOL, V3, P906, DOI 10.1001/jamaoncol.2016.6316
   Khow KSF, 2015, J BONE MINER METAB, V33, P355, DOI 10.1007/s00774 014 0606 6
   Kim SJ, 2019, INJURY, V50, P1364, DOI 10.1016/j.injury.2019.06.002
   Koh A, 2017, BONE JOINT J, V99B, P295, DOI 10.1302/0301 620X.99B3.BJJ 2016 0276.R2
   Koizumi M, 2017, CLIN NUCL MED, V42, P463, DOI 10.1097/RLU.0000000000001592
   Lenart BA, 2009, OSTEOPOROSIS INT, V20, P1353, DOI 10.1007/s00198 008 0805 x
   Lenart BA, 2008, NEW ENGL J MED, V358, P1304, DOI 10.1056/NEJMc0707493
   Lin Tsung Li, 2013, BMC Res Notes, V6, P11, DOI 10.1186/1756 0500 6 11
   Martin M, 2012, CLIN CANCER RES, V18, P4841, DOI 10.1158/1078 0432.CCR 11 3310
   Meier RPH, 2012, ARCH INTERN MED, V172, P930, DOI 10.1001/archinternmed.2012.1796
   Paparodis R, 2013, ENDOCR PRACT, V19, pE64, DOI 10.4158/EP12367.CR
   Peichl P, 2011, J BONE JOINT SURG AM, V93A, P1583, DOI 10.2106/JBJS.J.01379
   Puhaindran ME, 2011, J BONE JOINT SURG AM, V93A, P1235, DOI 10.2106/JBJS.J.01199
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rosen LS, 2004, CANCER, V100, P36, DOI 10.1002/cncr.11892
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Schilcher J, 2011, NEW ENGL J MED, V364, P1728, DOI 10.1056/NEJMoa1010650
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033 2909.86.2.420
   Takahashi M, 2019, BMC CANCER, V19, DOI 10.1186/s12885 019 6236 6
   Thompson RN, 2014, BONE, V61, P44, DOI 10.1016/j.bone.2013.12.027
   Wang ZY, 2015, ONCOLOGIST, V20, P440, DOI 10.1634/theoncologist.2014 0328
   Wong MHF, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003474.pub3
   Yang SP, 2017, ONCOLOGIST, V22, P438, DOI 10.1634/theoncologist.2016 0192
NR 42
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2212 1374
J9 J BONE ONCOL
JI J. Bone Oncol.
PD JUN
PY 2023
VL 40
AR 100478
DI 10.1016/j.jbo.2023.100478
EA APR 2023
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA O1TQ3
UT WOS:001041718100001
PM 37180736
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Lin, CC
   Chang, WHS
   Cheng, TM
   Chiu, LH
   Wang, YH
   Lin, CAJ
   Ho, YS
   Zuo, CS
   Wang, YM
   Lai, WFT
AF Lin, Chien Chou
   Chang, Walter Hong Shong
   Cheng, Tsai Mu
   Chiu, Li Hsuan
   Wang, Yen Hsun
   Lin, Cheng An J.
   Ho, Yuan Soon
   Zuo, Chun S.
   Wang, Yun Ming
   Lai, Wen Fu Thomas
TI Two new, near infrared, fluorescent probes as potential tools for
   imaging bone repair
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MESENCHYMAL STEM CELLS; GOLD NANOPARTICLES; INTEGRIN; DIFFERENTIATION;
   OSTEOBLASTS; COMPARTMENT; ALENDRONATE; EXPRESSION; DIAGNOSIS; DELIVERY
AB A precise imaging technique to evaluate osteogenesis, osteodifferentiation, and osseointegration following peri implant surgery is in high clinical demand. Herein, we report the generation of two new, near infrared (NIR) fluorescent probes for use in the molecular imaging of bone repair. The first probe aims to monitor the in vitro differentiation of human mesenchymal stem cells (MSCs) into osteoblasts. A NIR fluorochrome was conjugated to a cyclic peptide that binds to integrin alpha 5 beta 1, a factor that promotes osteogenesis in MSCs and therefore functioned as an osteoblast specific marker. The second probe aims to monitor osteogenesis, and was generated by conjugating the drug pamidronate to a NIR fluorescent gold nanocluster. Pamidronate specifically binds to hydroxyapatite (HA), a mineral present in bone that is produced by osteoblasts, and therefore provides a functional marker for new bone formation. Our results show that both probes bind to their specific targets in vitro differentiated osteoblasts, and not to undifferentiated MSCs, and emit NIR fluorescence for functional detection. This in vitro work demonstrates the ability of these probes to bind to active osteoblasts and their mineral deposits and highlight their potential utility as clinical tools for the imaging of the osseointegration process at the molecular level.
C1 [Lin, Chien Chou; Ho, Yuan Soon] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei, Taiwan.
   [Chang, Walter Hong Shong; Lin, Cheng An J.] Chung Yuan Christian Univ, Dept Biomed Engn, Chungli, Taiwan.
   [Cheng, Tsai Mu] Taipei Med Univ, Coll Med & Technol, PhD Program Translat Med, Taipei, Taiwan.
   [Wang, Yen Hsun; Wang, Yun Ming] Natl Chiao Tung Univ, Ctr Intelligent Drug Syst & Smart Biodevices IDS2, Inst Mol Med & Bioengn, Dept Biol Sci & Technol, Hsinchu, Taiwan.
   [Chiu, Li Hsuan; Zuo, Chun S.; Lai, Wen Fu Thomas] Harvard Med Sch, McLean Imaging Ctr, McLean Hosp, Belmont, MA 02478 USA.
   [Lai, Wen Fu Thomas] Taipei Med Univ, Inst Grad Clin Med, Taipei, Taiwan.
   [Chiu, Li Hsuan; Lai, Wen Fu Thomas] Taipei Med Univ, Shuang Ho Hosp, Dept Res, New Taipei, Taiwan.
   [Chiu, Li Hsuan; Lai, Wen Fu Thomas] Taipei Med Univ, Shuang Ho Hosp, Dept Dent, New Taipei, Taiwan.
C3 Taipei Medical University; Chung Yuan Christian University; Taipei
   Medical University; National Yang Ming Chiao Tung University; Harvard
   University; Harvard University Medical Affiliates; McLean Hospital;
   Taipei Medical University; Taipei Medical University; Shuang Ho
   Hospital; Taipei Medical University; Shuang Ho Hospital
RP Wang, YM (通讯作者)，Natl Chiao Tung Univ, Ctr Intelligent Drug Syst & Smart Biodevices IDS2, Inst Mol Med & Bioengn, Dept Biol Sci & Technol, Hsinchu, Taiwan.; Lai, WFT (通讯作者)，Harvard Med Sch, McLean Imaging Ctr, McLean Hosp, Belmont, MA 02478 USA.; Lai, WFT (通讯作者)，Taipei Med Univ, Inst Grad Clin Med, Taipei, Taiwan.; Lai, WFT (通讯作者)，Taipei Med Univ, Shuang Ho Hosp, Dept Res, New Taipei, Taiwan.; Lai, WFT (通讯作者)，Taipei Med Univ, Shuang Ho Hosp, Dept Dent, New Taipei, Taiwan.
EM ymwang@mail.nctu.edu.tw; laitw@tmu.edu.tw
RI Lin, Cheng An/AAS 6532 2021; Chang, Wen Hao/C 4906 2013; Lin,
   Chien chung/B 6166 2012
OI Ho, Yuan SOON/0000 0002 3649 6680; /0000 0003 3636 5506; Lin,
   Cheng An/0000 0002 0452 1132; Chang, Wen Hao/0000 0003 4880 6006; 
FU National Science Council of Taiwan [NSC 101 2120 M 038 001,
   MOST 104 2514 S 038 001, NSC 104 2917 I 564 006,
   MOST 104 2622 B 038 006 CC1]
FX This study was supported in part by National Science Council of Taiwan
   grants NSC 101 2120 M 038 001, MOST 104 2514 S 038 001,
   NSC 104 2917 I 564 006, and MOST 104 2622 B 038 006 CC1.
CR [Anonymous], 2007, INT J ORAL MAX IMPL
   [Anonymous], 2004, CLONING STEM CELLS
   [Anonymous], 2009, EUR SPINE J S1, DOI DOI 10.1007/S00586 009 0998 5
   [Anonymous], 1998, NEW ENGL J MED
   [Anonymous], 2009, ACS NANO, DOI DOI 10.1021/NN800632J
   [Anonymous], 2003, NAT MED, DOI DOI 10.1038/NM0103 123
   [Anonymous], 2001, NAT BIOTECHNOL
   [Anonymous], 2011, J AM CHEM SOC, DOI DOI 10.1021/JA2064582
   [Anonymous], 2011, ANGEW CHEM INT EDIT, DOI DOI 10.1002/ANIE.201102892
   [Anonymous], 2010, CHEMMEDCHEM, DOI DOI 10.1002/CMDC.201000016
   [Anonymous], 2013, NANOMED NANOTECHNOL, DOI DOI 10.1016/J.NANO.2012.08.007
   [Anonymous], 1991, J CLIN INVEST
   [Anonymous], 2010, CLIN CANCER RES, DOI DOI 10.1158/1078 0432.CCR 10 0059
   [Anonymous], 2003, PROSTATE, DOI DOI 10.1002/PROS.10193
   [Anonymous], 2007, FRONT BIOSCI, DOI DOI 10.2741/2440
   [Anonymous], 2005, LANGMUIR, DOI DOI 10.1021/LA0513712
   [Anonymous], 2003, EUR RADIOL, DOI DOI 10.1007/S00330 002 1524 X
   [Anonymous], 2009, BONE, DOI DOI 10.1016/J.BONE.2008.08.118
   [Anonymous], 2011, FARADAY DISCUSS, DOI DOI 10.1039/C005286H
   [Anonymous], 2006, DEV DYNAM, DOI DOI 10.1002/DVDY.20603
   [Anonymous], 2007, CIRCULATION, DOI DOI 10.1161/CIRCULATIONAHA.106.654913
   [Anonymous], 1998, J BIOL CHEM
   [Anonymous], 2004, BIOPOLYMERS, DOI DOI 10.1002/BIP.20139
   [Anonymous], 1999, BONE
   [Anonymous], 1994, J CELL BIOL
   [Anonymous], 2007, ANESTH ANALG, DOI DOI 10.1213/01.ANE.0000256097.61730.CC
   [Anonymous], 2010, J BONE MINER RES, DOI DOI 10.1002/JBMR.141
   [Anonymous], 2005, BIOMATERIALS, DOI DOI 10.1016/J.BIOMATERIALS.2004.03.020
   [Anonymous], 2006, RADIOGRAPHICS, DOI DOI 10.1148/RG.26SI065512
   [Anonymous], 2003, P NATL ACAD SCI U S1, DOI DOI 10.1073/PNAS.1834138100
   [Anonymous], 2011, EUR J PHARM BIOPHARM, DOI DOI 10.1016/J.EJPB.2010.11.010
   [Anonymous], 2001, NAT BIOTECHNOL
   [Anonymous], 1996, BONE
   [Anonymous], 2010, J BONE MINER RES, DOI DOI 10.1002/JBMR.66
   [Anonymous], 2004, OSTEOARTHR CARTILAGE, DOI DOI 10.1016/J.JOCA.2003.11.005
   [Anonymous], 2007, J BONE MINER RES, DOI DOI 10.1359/JBMR.070504
   [Anonymous], 2004, CHEM REV, DOI DOI 10.1021/CR030698+
   [Anonymous], 2010, BMC CELL BIOL, DOI DOI 10.1186/1471 2121 11 44
   [Anonymous], 2008, NEOPLASIA, DOI DOI 10.1593/NEO.07856
   [Anonymous], 2001, ARCH ORAL BIOL
   [Anonymous], 2011, AM J ROENTGENOL, DOI DOI 10.2214/AJR.10.5416
   [Anonymous], 2006, BIOTECHNOL BIOENG, DOI DOI 10.1002/BIT.20939
   [Anonymous], 2016, ACS CHEM NEUROSCI, DOI DOI 10.1021/ACSCHEMNEURO.6B00174
   [Anonymous], 2011, FARADAY DISCUSS, DOI DOI 10.1039/C005286H
   Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i12.10
   Maruotti N., 2012, EUR J CLIN PHARM
   Olivia Fromigue O., 2010, BMC CELL BIOL, V11, pBR54
   Zhang Y N, 2017, J HEALTHCARE ENG, V2017, P2017
NR 48
TC 7
Z9 7
U1 1
U2 24
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD FEB 13
PY 2020
VL 10
IS 1
AR 2580
DI 10.1038/s41598 020 59522 1
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA NE8XO
UT WOS:000562888700014
PM 32054952
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Choi, SW
   Moon, SH
   Yang, HJ
   Kwon, DY
   Son, YJ
   Yu, R
   Kim, YS
   Kim, SI
   Chae, EJ
   Park, SJ
   Kim, SH
AF Choi, Sik Won
   Moon, Seong Hee
   Yang, Hye Jeong
   Kwon, Dae Young
   Son, Young Jin
   Yu, Ri
   Kim, Young Su
   Kim, So I.
   Chae, Eun Jeong
   Park, Sang Joon
   Kim, Seong Hwan
TI Antiresorptive Activity of Bacillus Fermented Antler Extracts:
   Inhibition of Osteoclast Differentiation
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID DC STAMP; BONE; RANKL; THERAPY; FUSION; NFAT2
AB Antlers have been traditionally used for thousands of years as a natural product with medicinal and pharmaceutical properties. In developing healthy foods, Bacillus mediated fermentation is widely used to enhance the biological activity of nutrients in foods. Recently, fermentation was shown to enhance the osteogenic activity of antlers. This study aimed to elucidate the antiresorptive activity of Bacillus fermented antler and its mode of action. We found that Bacillus fermented antler extract strongly inhibited osteoclast differentiation by downregulating the expression and activity of nuclear factor of activated T cells, cytoplasmic 1 (NFATc1). This extract also inhibited the activation of phospholipase C gamma 2 (PLC gamma 2), a signaling molecule that could regulate NFATc1 transcriptional activity. This suggested that Bacillus fermented antler extract could inhibit PLC gamma 2 NFATc1 signaling required for bone resorption and cell fusion. Consequently, Bacillus fermented antler extract might benefit osteoclast related disorders, including osteoporosis; furthermore, it may improve gastrointestinal activity.
C1 [Choi, Sik Won; Moon, Seong Hee; Kim, Seong Hwan] Korea Res Inst Chem Technol, Pharmacol Res Ctr, Lab Translat Therapeut, Bioorgan Sci Div, Taejon 305600, South Korea.
   [Yang, Hye Jeong; Kwon, Dae Young] Korean Food Res Inst, Food Funct Res Div, Songnam 463746, South Korea.
   [Son, Young Jin] Sunchon Natl Univ, Dept Pharm, Sunchon 540742, South Korea.
   [Yu, Ri; Park, Sang Joon] Kyungpook Natl Univ, Coll Vet Med, Dept Histol, Taegu 702701, South Korea.
   [Kim, Young Su; Kim, So I.; Chae, Eun Jeong] Korean Med Biofermentat Co Ltd, Seoul 137894, South Korea.
C3 Korea Research Institute of Chemical Technology (KRICT); Korea Food
   Research Institute (KFRI); Sunchon National University; Kyungpook
   National University (KNU)
RP Park, SJ (通讯作者)，Kyungpook Natl Univ, Coll Vet Med, Dept Histol, Taegu 702701, South Korea.
EM psj26@knu.ac.kr
RI Jin Ho, Seo/B 3621 2014; Kwon, Dae Young/IXD 9511 2023; Kim,
   Seong/AAA 6086 2021; chen, jiahong/GYR 2917 2022
OI Choi, Sik Won/0000 0003 1726 2536; 
FU Ministry of Food, Agriculture, Forestry, and Fisheries, Republic of
   Korea; KRICT's project [SI 1205]; Ministry of Knowledge Economy,
   Republic of Korea
FX This work was supported by the "Food Functionality Evaluation Program"
   under the Ministry of Food, Agriculture, Forestry, and Fisheries,
   Republic of Korea and KRICT's project, (SI 1205) funded by the Ministry
   of Knowledge Economy, Republic of Korea.
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Balkan W, 2009, GENE, V446, P90, DOI 10.1016/j.gene.2009.06.013
   Choi SW, 2012, FEBS LETT, V586, P263, DOI 10.1016/j.febslet.2011.12.033
   Dannemann C, 2007, BONE, V40, P828, DOI 10.1016/j.bone.2006.11.023
   Feng J, 2007, DIGEST DIS SCI, V52, P1845, DOI 10.1007/s10620 006 9705 0
   Hong HA, 2005, FEMS MICROBIOL REV, V29, P813, DOI 10.1016/j.femsre.2004.12.001
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Kukita T, 2004, J EXP MED, V200, P941, DOI 10.1084/jem.20040518
   Lee HS, 2011, J ETHNOPHARMACOL, V133, P710, DOI 10.1016/j.jep.2010.10.047
   Li YJ, 2007, J ETHNOPHARMACOL, V113, P191, DOI 10.1016/j.jep.2007.04.020
   Li Yinqing, 2010, Zhongguo Zhong Yao Za Zhi, V35, P759
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mao DL, 2006, J CLIN INVEST, V116, P2869, DOI 10.1172/JCI28775
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Meier RPH, 2012, ARCH INTERN MED, V172, P930, DOI 10.1001/archinternmed.2012.1796
   Meng Hai yan, 2009, Zhong Yao Cai, V32, P179
   Morabito N, 2002, J BONE MINER RES, V17, P1904, DOI 10.1359/jbmr.2002.17.10.1904
   Pothacharoen P, 2011, GLYCOCONJUGATE J, V28, P473, DOI 10.1007/s10719 011 9346 1
   Rassi CM, 2002, J BONE MINER RES, V17, P630, DOI 10.1359/jbmr.2002.17.4.630
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yang JH, 2010, INDIAN J EXP BIOL, V48, P554
NR 27
TC 14
Z9 16
U1 0
U2 16
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PY 2013
VL 2013
AR 748687
DI 10.1155/2013/748687
PG 9
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA 093WH
UT WOS:000315223300001
PM 23509596
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Liang, CX
   Liang, GY
   Zheng, XQ
   Huang, YX
   Huang, SH
   Yin, D
AF Liang, Changxiang
   Liang, Guoyan
   Zheng, Xiaoqing
   Huang, Yongxiong
   Huang, Shuaihao
   Yin, Dong
TI RSP5 Positively Regulates the Osteogenic Differentiation of Mesenchymal
   Stem Cells by Activating the K63 Linked Ubiquitination of Akt
SO STEM CELLS INTERNATIONAL
LA English
DT Article
ID NF KAPPA B; LIGASE; OSTEOBLAST; RUNX2; FATE; DEGRADATION; SMURF1
AB Mesenchymal stem cells (MSCs) are multipotent stem cells that have a strong osteogenic differentiation capacity. However, the molecular mechanism underlying the osteogenic differentiation of MSCs remains largely unknown and thus hinders further development of MSC based cell therapies for bone repair in the clinic. RSP5, also called NEDD4L (NEDD4 like E3 ubiquitin protein ligase), belongs to the HECT (homologous to E6 AP carboxyl terminus) domain containing E3 ligase family. Nevertheless, although many studies have been conducted to elucidate the role of RSP5 in various biological processes, its effect on osteogenesis remains elusive. In this study, we demonstrated that the expression of RSP5 was elevated during the osteogenesis of MSCs and positively regulated the osteogenic capacity of MSCs by inducing K63 linked polyubiquitination and activation of the Akt pathway. Taken together, our findings suggest that RSP5 may be a promising target to improve therapeutic efficiency by using MSCs for bone regeneration and repair.
C1 [Liang, Changxiang; Liang, Guoyan; Zheng, Xiaoqing; Huang, Yongxiong; Huang, Shuaihao; Yin, Dong] Guangdong Prov Peoples Hosp, Dept Spinal Surg, Guangzhou 510080, Peoples R China.
C3 Guangdong Academy of Medical Sciences & Guangdong General Hospital
RP Yin, D (通讯作者)，Guangdong Prov Peoples Hosp, Dept Spinal Surg, Guangzhou 510080, Peoples R China.
EM lcxspine@qq.com; paul2241@foxmail.com; 81686957@qq.com;
   gdhyx2012@163.com; 15800039832@163.com; tony inn@163.com
RI Liang, Guoyan/AEL 4482 2022; YIN, DONG/AAF 2883 2020
OI YIN, DONG/0000 0003 4581 5011
CR Ashraf S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040880
   Belgareh Touzé N, 2017, AUTOPHAGY, V13, P114, DOI 10.1080/15548627.2016.1252889
   Byon CH, 2008, J BIOL CHEM, V283, P15319, DOI 10.1074/jbc.M800021200
   Chan CH, 2012, CELL, V149, P1098, DOI 10.1016/j.cell.2012.02.065
   Chang J, 2013, P NATL ACAD SCI USA, V110, P9469, DOI 10.1073/pnas.1300532110
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Choi YH, 2014, FEBS J, V281, P3656, DOI 10.1111/febs.12887
   Dai JL, 2005, CANCER RES, V65, P8274, DOI 10.1158/0008 5472.CAN 05 1891
   Deng LL, 2015, BONE, V79, P37, DOI 10.1016/j.bone.2015.05.022
   Domanska A, 2015, RNA BIOL, V12, P1265, DOI 10.1080/15476286.2015.1094604
   Fang NN, 2014, NAT CELL BIOL, V16, P1227, DOI 10.1038/ncb3054
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   García García P, 2019, STEM CELL TRANSL MED, V8, P1306, DOI 10.1002/sctm.19 0145
   Goel P, 2015, GENE, V557, P1, DOI 10.1016/j.gene.2014.11.051
   Jeon SA, 2018, BONE, V116, P248, DOI 10.1016/j.bone.2018.08.012
   Jiang YP, 2019, LIFE SCI, V228, P208, DOI 10.1016/j.lfs.2019.05.002
   Kaminska J, 2011, EUR J CELL BIOL, V90, P1016, DOI 10.1016/j.ejcb.2011.08.002
   Kaneki H, 2006, J BIOL CHEM, V281, P4326, DOI 10.1074/jbc.M509430200
   Li W, 2013, CANCER RES, V73, P6938, DOI 10.1158/0008 5472.CAN 13 0913
   Liu XZ, 2017, EUR J PHARMACOL, V810, P156, DOI 10.1016/j.ejphar.2017.07.013
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001
   Manunta P, 2008, HYPERTENSION, V52, P366, DOI 10.1161/HYPERTENSIONAHA.108.113977
   Park D, 2012, CELL STEM CELL, V10, P259, DOI 10.1016/j.stem.2012.02.003
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Qu MH, 2016, TUMOR BIOL, V37, P5645, DOI 10.1007/s13277 015 4328 8
   Spees JL, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0363 7
   Tang Y, 2013, STEM CELLS DEV, V22, P668, DOI 10.1089/scd.2012.0226
   Ullah I, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150025
   Wang GH, 2019, NAT CELL BIOL, V21, P214, DOI 10.1038/s41556 018 0266 1
   Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065
   Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200
   Zhao YY, 2013, ELIFE, V2, DOI 10.7554/eLife.00459
NR 33
TC 15
Z9 15
U1 4
U2 12
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687 966X
EI 1687 9678
J9 STEM CELLS INT
JI Stem Cells Int.
PD APR 6
PY 2020
VL 2020
AR 7073805
DI 10.1155/2020/7073805
PG 13
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA LH8KB
UT WOS:000529030500001
PM 32322280
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Liu, Q
   Hu, CH
   Zhou, CH
   Cui, XX
   Yang, K
   Deng, C
   Xia, JJ
   Wu, Y
   Liu, LC
   Jin, Y
AF Liu, Qi
   Hu, Cheng Hu
   Zhou, Cui Hong
   Cui, Xiao Xia
   Yang, Kun
   Deng, Chao
   Xia, Jia Jia
   Wu, Yan
   Liu, Lu Chuan
   Jin, Yan
TI DKK1 rescues osteogenic differentiation of mesenchymal stem cells
   isolated from periodontal ligaments of patients with diabetes mellitus
   induced periodontitis
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GLYCATION END PRODUCTS; FACTOR KAPPA B; EXPRESSION; RECEPTOR; DISEASE;
   RAGE; AGES; PATHWAY; TISSUE; GENE
AB Multiple studies have shown that diabetes mellitus is an established risk factor for periodontitis. Recently mesenchymal stem cells derived from periodontal ligament (PDLSCs) have been utilized to reconstruct tissues destroyed by chronic inflammation. However, impact of periodontitis with diabetes mellitus on PDLSCs and mechanisms mediating effects of complex microenvironments remain poorly understood. In this study, we found multiple differentiation potential of PDLSCs from chronic periodontitis with diabetes mellitus donors (D PDLSCs) was damaged significantly. Inhibition of NF kappa B signaling could rescue osteogenic potential of PDLSCs from simple chronic periodontitis patients (P PDLSCs), whereas did not promote D PDLSCs osteogenesis. In addition, we found expression of DKK1 in D PDLSCs did not respond to osteogenic signal and decreased osteogenic potential of D PDLSCs treated with DKK1 could be reversed. To further elucidate different character between P PDLSCs and D PDLSCs, we treated PDLSCs with TNF alpha and advanced glycation end products (AGEs), and find out AGEs which enhance effect of TNF alpha in PDLSCs might mediate special personality of D PDLSCs. The adverse effect of AGEs in PDLSCs could be reversed when PDLSCs were treated with DKK1. These results suggested DKK1 mediating WNT signaling might be a therapy target to rescue potential of PDLSCs in periodontitis with diabetes mellitus.
C1 [Liu, Qi; Liu, Lu Chuan] Third Mil Med Univ, Res Inst Field Surg, Daping Hosp, Dept Stomatol, Chongqing 400042, Peoples R China.
   [Liu, Qi; Hu, Cheng Hu; Zhou, Cui Hong; Jin, Yan] Fourth Mil Med Univ, Ctr Tissue Engn, Sch Stomatol, State Key Lab Mil Stomatol, Xian 710032, Shaanxi, Peoples R China.
   [Jin, Yan] Fourth Mil Med Univ, Res & Dev Ctr Tissue Engn, Xian 710032, Shaanxi, Peoples R China.
   [Liu, Qi; Cui, Xiao Xia; Yang, Kun; Deng, Chao; Xia, Jia Jia; Wu, Yan] Zunyi Med Coll, Stomatol Hosp, Dept Periodontol, Zunyi 563003, Guizhou, Peoples R China.
   [Hu, Cheng Hu; Zhou, Cui Hong] Xian Inst Tissue Engn & Regenerat Med, Xian 710032, Shaanxi, Peoples R China.
   [Jin, Yan] Fourth Mil Med Univ, Sch Stomatol, Dept Oral Histol & Pathol, Xian 710032, Shaanxi, Peoples R China.
C3 Army Medical University; Air Force Medical University; Air Force Medical
   University; Zunyi Medical University; Air Force Medical University
RP Jin, Y (通讯作者)，Fourth Mil Med Univ, Ctr Tissue Engn, Sch Stomatol, State Key Lab Mil Stomatol, Xian 710032, Shaanxi, Peoples R China.
EM liuluchuan1957@126.com; yanjin@fmmu.edu.cn
RI Hu, Cheng Hu/I 4210 2013; 周, 翠红/ACA 7979 2022; Jin, Yan/I 4204 2013
OI Hu, Cheng Hu/0000 0003 2443 6485; yang, kun/0000 0002 7720 8681; 
FU National Major Scientific Research Program of China (973 Program)
   [2011CB964700, 2010CB944802]; Nature Science Foundation of China
   [31030033, 81020108019]; National Natural Science Area Foundation of
   China [81360168]
FX This research was supported by grants from the National Major Scientific
   Research Program of China (973 Program) (2011CB964700 and 2010CB944802),
   the Nature Science Foundation of China (31030033 and 81020108019), and
   the National Natural Science Area Foundation of China (81360168).
CR Abbass MM, 2012, ARCH ORAL BIOL, V57, P1342, DOI 10.1016/j.archoralbio.2012.06.007
   Boj SF, 2012, CELL, V151, P1595, DOI 10.1016/j.cell.2012.10.053
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Byun MR, 2014, CELL DEATH DIFFER, V21, P854, DOI 10.1038/cdd.2014.8
   Chang PC, 2013, J PERIODONTOL, V84, P379, DOI 10.1902/jop.2012.120076
   Chen FM, 2012, BIOMATERIALS, V33, P6320, DOI 10.1016/j.biomaterials.2012.05.048
   Chen FM, 2010, BIOMATERIALS, V31, P7892, DOI 10.1016/j.biomaterials.2010.07.019
   Chen X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.14
   Crabtree M, 2008, J ENDODONT, V34, P689, DOI 10.1016/j.joen.2008.02.013
   de Boer J, 2004, BONE, V34, P818, DOI 10.1016/j.bone.2004.01.016
   Ding G, 2010, STEM CELLS, V28, P1829, DOI 10.1002/stem.512
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   He L, 2010, DIABETES RES CLIN PR, V90, P73, DOI 10.1016/j.diabres.2010.06.016
   Kong XW, 2013, BBA GEN SUBJECTS, V1830, P5119, DOI 10.1016/j.bbagen.2013.07.027
   Koulmanda M, 2012, P NATL ACAD SCI USA, V109, P15443, DOI 10.1073/pnas.1018366109
   Kume S, 2005, J BONE MINER RES, V20, P1647, DOI 10.1359/JBMR.050514
   Lalla E, 2000, J CLIN INVEST, V105, P1117, DOI 10.1172/JCI8942
   Lalla E, 2011, NAT REV ENDOCRINOL, V7, P738, DOI 10.1038/nrendo.2011.106
   Lee K, 2012, DIABETES, V61, P2948, DOI 10.2337/db11 0300
   Li XF, 2012, P NATL ACAD SCI USA, V109, P11402, DOI 10.1073/pnas.1205015109
   Liu GZ, 2009, J CELL BIOL, V185, P67, DOI 10.1083/jcb.200810137
   Liu N, 2011, J BONE MINER RES, V26, P2082, DOI 10.1002/jbmr.440
   Liu W, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.65
   Liu WJ, 2014, BBA GEN SUBJECTS, V1840, P1125, DOI 10.1016/j.bbagen.2013.11.003
   Liu YL, 2011, STEM CELLS, V29, P1804, DOI 10.1002/stem.728
   Liu Y, 2008, STEM CELLS, V26, P1065, DOI 10.1634/stemcells.2007 0734
   Liu ZY, 2010, ADV EXP MED BIOL, V654, P391, DOI 10.1007/978 90 481 3271 3_17
   LOE H, 1993, DIABETES CARE, V16, P329, DOI 10.2337/diacare.16.1.329
   Morales Santana S, 2013, DIABETES CARE, V36, P1667, DOI 10.2337/dc12 1691
   Ortis F, 2012, FEBS LETT, V586, P984, DOI 10.1016/j.febslet.2012.02.021
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Takenaka K, 2006, CURR NEUROVASC RES, V3, P73, DOI 10.2174/156720206775541804
   Tobón Velasco JC, 2014, CNS NEUROL DISORD DR, V13, P1615, DOI 10.2174/1871527313666140806144831
   Yang F, 2011, STEM CELLS, V29, P981, DOI 10.1002/stem.646
   Yekollu SK, 2011, DIABETES, V60, P2928, DOI 10.2337/db11 0275
   Yu SJ, 2012, J PERIODONTOL, V83, P119, DOI 10.1902/jop.2011.100754
NR 36
TC 45
Z9 50
U1 1
U2 20
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD AUG 17
PY 2015
VL 5
AR 13142
DI 10.1038/srep13142
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CO9XV
UT WOS:000359531000001
PM 26278788
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Campbell, GM
   Tiwari, S
   Hofbauer, C
   Picke, AK
   Rauner, M
   Huber, G
   Peña, JA
   Damm, T
   Barkmann, R
   Morlock, MM
   Hofbauer, LC
   Glüer, CC
AF Campbell, G. M.
   Tiwari, S.
   Hofbauer, C.
   Picke, A.  K.
   Rauner, M.
   Huber, G.
   Pena, J. A.
   Damm, T.
   Barkmann, R.
   Morlock, M. M.
   Hofbauer, L. C.
   Glueer, C.  C.
TI Effects of parathyroid hormone on cortical porosity, non enzymatic
   glycation and bone tissue mechanics in rats with type 2 diabetes
   mellitus
SO BONE
LA English
DT Article
DE Bone anabolics; Biomechanics; Diabetes; Collagen; Non enzymatic
   glycation; Preclinical studies
ID POSTMENOPAUSAL WOMEN; END PRODUCTS; RODENT MODELS; I COLLAGEN;
   PENTOSIDINE; MASS; REGENERATION; FRAGILITY; MINERALIZATION; OSTEOPOROSIS
AB Type 2 diabetes mellitus increases skeletal fragility; however, the contributing mechanisms and the efficacy of bone forming agents are unclear. We studied diabetes and parathyroid hormone (PIT I) treatment effects on cortical porosity (Ct.Po), non enzymatic glycation (NEG) and bone mechanics in Zucker diabetic fatty (ZDF) rats. Eleven week old ZDF diabetic (DB) and non diabetic (ND) rats were given 75 mu g/kg PTH (1 84) or vehicle 5 days per week over 12 weeks. The right femora and L4 vertebrae were excised, micro CT scanned, and tested in 3 point bending and uniaxial compression, respectively. NEG of the samples was determined using fluorescence. Diabetes increased Ct.Po (vertebra (vert): +40.6%, femur (fern): +15.5% vs. ND group, p<0.05) but had no effect on NEG. PTH therapy reduced vertebral NEG in the ND animals only ( 73% vs untreated group, p <0.05), and increased femoral NEG in the DB vs. ND groups ( +63%, p <0.05). PTH therapy had no effect on Ct.Po. Diabetes negatively affected bone tissue mechanics where reductions in vertebral maximum strain ( 22%) and toughness (42%) were observed in the DB vs. ND group (p <0.05). PTH improved maximum strain in the vertebra of the ND animals (+21%, p <0.05) but did not have an effect in the DB group. PTH increased femoral maximum strain ( +21%) and toughness (+28%) in ND and decreased femoral maximum stress ( 13%) and toughness ( 27%) in the DB animals (treated vs. untreated, p <0.05). Ct.Po correlated negatively with maximum stress (fern: R =  0.35, p < 0.05, vert: R =  0.57, p <0.01), maximum strain (fern: R =  0.35, p < 0.05, vert: R =  0.43, p <0.05) and toughness (fern: R =  0.34, p <0.05, vert: R =  0.55, p <0.01), and NEG correlated negatively with toughness at the femur (R = 034, p <0.05) and maximum strain at the vertebra (R =  0.49, p < 0.05).
   Diabetes increased cortical porosity and reduced bone mechanics, which were not improved with PTH treatment. PTH therapy alone may worsen diabetic bone mechanics through formation of new bone with high AGEs cross linking. Optimal treatment regimens must address both improvements of bone mass and glycemic control in order to successfully reduce diabetic bone fragility. This article is part of a Special Issue entitled "Bone and diabetes". (C) 2015 Elsevier Inc. All rights reserved.
C1 [Campbell, G. M.; Huber, G.; Morlock, M. M.] TUHH Hamburg Univ Technol, Inst Biomech, Hamburg, Germany.
   [Campbell, G. M.; Tiwari, S.; Pena, J. A.; Damm, T.; Barkmann, R.; Glueer, C.  C.] Univ Hosp Schleswig Holstein, Dept Radiol & Neuroradiol, Sect Biomed Imaging, Kiel, Germany.
   [Hofbauer, C.] Tech Univ Dresden, Med Ctr, Dept Orthoped, D 01062 Dresden, Germany.
   [Picke, A.  K.; Rauner, M.; Hofbauer, L. C.] Tech Univ Dresden, Med Ctr, Dept Med 3, D 01062 Dresden, Germany.
   [Hofbauer, L. C.] Ctr Regenerat Therapies Dresden, Dresden, Germany.
C3 Hamburg University of Technology; University of Kiel; Schleswig Holstein
   University Hospital; Technische Universitat Dresden; Technische
   Universitat Dresden; Technische Universitat Dresden
RP Campbell, GM (通讯作者)，Hamburg Univ Technol, Inst Biomech, Denickestr 15, D 21073 Hamburg, Germany.
EM graeme.campbell@tuhh.de
RI Hofbauer, Lorenz C./G 2490 2010; peña, jaime/HTR 8894 2023; Rauner,
   Martina/A 1665 2015; Hofbauer, Lorenz/G 2490 2010; Campbell,
   Graeme/JPX 2238 2023; Bloch, Michael/O 7845 2017; Tiwari,
   Sanjay/Q 1853 2016; Huber, Gerd/AAB 5789 2021; Glüer,
   Claus Christian/C 9752 2010
OI Hofbauer, Lorenz C./0000 0002 8691 8423; Tiwari,
   Sanjay/0000 0002 3804 3300; Rauner, Martina/0000 0002 4067 6799; Huber,
   Gerd/0000 0002 9883 3953; Morlock, Michael/0000 0002 5330 2454
FU Deutsche Forschungsgemeinschaft (DFG) Forschergruppe 1586 SKELMET [GL
   289/9 1, Transregio 67]; state of Schleswig Holstein; European Union
   ERDF European Regional Development Fund [122 09 053]
FX The authors are grateful to Gabriele Mielke and Kay Sellenschloh from
   the TUHH for their assistance with the sample preparation and operation
   of the mechanical testing. Financial support was provided by the
   Deutsche Forschungsgemeinschaft (DFG) through the Forschergruppe 1586
   SKELMET (GL 289/9 1) (LCH, ST and CCG) and Transregio 67, project B2
   (CH, LCH) and by the research grant from the state of Schleswig Holstein
   and the European Union ERDF European Regional Development Fund (122 09
   053) (MOIN CC, Zukunftsprogramm Wirtschaft).
CR Beer F.P., 2004, Mechanics of materials
   Buie HR, 2007, BONE, V41, P505, DOI 10.1016/j.bone.2007.07.007
   Campbell GM, 2011, BONE, V49, P225, DOI 10.1016/j.bone.2011.04.008
   Dempster DW, 2001, J BONE MINER RES, V16, P1846, DOI 10.1359/jbmr.2001.16.10.1846
   Fajardo RJ, 2014, J BONE MINER RES, V29, P1025, DOI 10.1002/jbmr.2210
   Farr JN, 2014, J BONE MINER RES, V29, P787, DOI 10.1002/jbmr.2106
   Hamann C, 2014, ENDOCRINOLOGY, V155, P1197, DOI 10.1210/en.2013 1960
   Hamann C, 2013, J BONE MINER RES, V28, P627, DOI 10.1002/jbmr.1803
   Hamann C, 2011, AM J PHYSIOL ENDOC M, V301, pE1220, DOI 10.1152/ajpendo.00378.2011
   Hodsman AB, 2000, BONE, V27, P311, DOI 10.1016/S8756 3282(00)00316 1
   Katayama Y, 1996, J BONE MINER RES, V11, P931, DOI 10.1002/jbmr.5650110709
   Kimura S, 2012, J VET MED SCI, V74, P103, DOI 10.1292/jvms.11 0328
   Liu ZD, 2007, ACTA ORTHOP, V78, P46, DOI 10.1080/17453670610013411
   Mercer N, 2007, MOL CELL BIOCHEM, V306, P87, DOI 10.1007/s11010 007 9557 8
   Odetti P, 2005, ANN NY ACAD SCI, V1043, P710, DOI 10.1196/annals.1333.082
   Ogawa N, 2007, HORM METAB RES, V39, P871, DOI 10.1055/s 2007 991157
   OXLUND H, 1993, CALCIFIED TISSUE INT, V53, P394
   Patsch JM, 2013, J BONE MINER RES, V28, P313, DOI 10.1002/jbmr.1763
   Prisby RD, 2008, J ENDOCRINOL, V199, P379, DOI 10.1677/JOE 08 0046
   Reinwald S, 2009, AM J PHYSIOL ENDOC M, V296, pE765, DOI 10.1152/ajpendo.90937.2008
   Saito M, 2006, OSTEOPOROSIS INT, V17, P1514, DOI 10.1007/s00198 006 0155 5
   Saito M, 2011, OSTEOPOROSIS INT, V22, P2373, DOI 10.1007/s00198 010 1454 4
   Saito M, 2010, OSTEOPOROSIS INT, V21, P195, DOI 10.1007/s00198 009 1066 z
   Schwartz AV, 2009, J CLIN ENDOCR METAB, V94, P2380, DOI 10.1210/jc.2008 2498
   Schwartz AV, 2003, CALCIFIED TISSUE INT, V73, P515, DOI 10.1007/s00223 003 0023 7
   SELL DR, 1989, CONNECT TISSUE RES, V19, P77, DOI 10.3109/03008208909016816
   Sugiyama S, 1998, J AM SOC NEPHROL, V9, P1681
   TAKAHASHI M, 1993, DIABETOLOGIA, V36, P664, DOI 10.1007/BF00404078
   Tang SY, 2007, BONE, V40, P1144, DOI 10.1016/j.bone.2006.12.056
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   UZAWA T, 1995, BONE, V16, P477
   Viguet Carrin S, 2006, BONE, V39, P1073, DOI 10.1016/j.bone.2006.05.013
   Wihler C, 2005, DIABETOLOGIA, V48, P1645, DOI 10.1007/s00125 005 1837 9
   Yamamoto M, 2008, J CLIN ENDOCR METAB, V93, P1013, DOI 10.1210/jc.2007 1270
NR 34
TC 13
Z9 14
U1 1
U2 23
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JAN
PY 2016
VL 82
SI SI
BP 116
EP 121
DI 10.1016/j.bone.2015.04.049
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CY5HG
UT WOS:000366438100017
PM 25952971
DA 2025 08 17
ER

PT J
AU Thiagarajan, L
   Abu Awwad, HADM
   Dixon, JE
AF Thiagarajan, Lalitha
   Abu Awwad, Hosam Al Deen M.
   Dixon, James E.
TI Osteogenic Programming of Human Mesenchymal Stem Cells with Highly
   Efficient Intracellular Delivery of RUNX2
SO STEM CELLS TRANSLATIONAL MEDICINE
LA English
DT Article
DE Intracellular transduction; Glycosaminoglycan binding enhanced
   transduction; Cell penetrating peptide; Osteogenesis; RUNX2
ID HUMAN BONE MARROW; STROMAL CELLS; CHONDROGENIC DIFFERENTIATION; TISSUE;
   HETEROGENEITY; DEXAMETHASONE; INFLAMMATION; CHONDROCYTES; OSTEOBLASTS;
   MATURATION
AB Mesenchymal stem cells (MSCs) are being exploited in regenerative medicine due to their tri lineage differentiation and immunomodulation activity. Currently, there are two major challenges when directing the differentiation of MSCs for therapeutic applications. First, chemical and growth factor strategies to direct osteogenesis in vivo lack specificity for targeted delivery with desired effects. Second, MSC differentiation by gene therapy is difficult as transfection with existing approaches is clinically impractical (viral transfection) or have low efficacy (lipid mediated transfection). These challenges can be avoided by directly delivering nonvirally derived recombinant protein transcription factors with the glycosaminoglycan binding enhanced transduction (GET) delivery system (P21 and 8R peptides). We used the osteogenic master regulator, RUNX2 as a programming factor due to its stage specific role in osteochondral differentiation pathways. Herein, we engineered GET fusion proteins and compared sequential osteogenic changes in MSCs, induced by exposure to GET fusion proteins or conventional stimulation methods (dexamethasone and Bone morphogenetic protein 2). By assessing loss of stem cell surface markers, upregulation of osteogenic genes and matrix mineralization, we demonstrate that GET RUNX2 efficiently transduces MSCs and triggers osteogenesis by enhancing target gene expression directly. The high transduction efficiency of GET system holds great promise for stem cell therapies by allowing reproducible transcriptional control in stem cells, potentially bypassing problems observed with high concentration growth factor or pleiotropic steroid therapies.
C1 [Thiagarajan, Lalitha; Abu Awwad, Hosam Al Deen M.; Dixon, James E.] Univ Nottingham, Sch Pharm, Ctr Biomol Sci, Wolfson Ctr Stem Cells Tissue Engn & Modelling ST, Univ Pk, Nottingham NG7 2RD, England.
C3 University of Nottingham
RP Dixon, JE (通讯作者)，Univ Nottingham, Sch Pharm, Ctr Biomol Sci, Wolfson Ctr Stem Cells Tissue Engn & Modelling ST, Univ Pk, Nottingham NG7 2RD, England.
EM james.dixon@nottingham.ac.uk
OI Dixon, James/0000 0003 1225 3825
FU European Research Council under the European Community's Seventh
   Framework Programme/ERC [227845]; Medical Research Council
   [MR/K026682/1]; Engineering and Physical Sciences Research Council;
   Biotechnology and Biological Sciences Research Council; MRC
   [MR/K026682/1] Funding Source: UKRI; Medical Research Council
   [MR/K026682/1] Funding Source: researchfish
FX The study was funded by the European Research Council under the European
   Community's Seventh Framework Programme (FP7/2007 2013)/ERC grant
   agreement 227845. This work was supported by the Medical Research
   Council [grant number MR/K026682/1]; the Engineering and Physical
   Sciences Research Council; and the Biotechnology and Biological Sciences
   Research Council, acknowledged by L.T. and J.E.D. for the UK
   Regenerative Medicine Platform Hub "Acellular Approaches for Therapeutic
   Delivery".
CR Ando W, 2012, INFLAMM RES, V61, P599, DOI 10.1007/s00011 012 0450 x
   Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581
   Barbosa I, 2003, GLYCOBIOLOGY, V13, P647, DOI 10.1093/glycob/cwg082
   Birmingham E, 2012, EUR CELLS MATER, V23, P13, DOI 10.22203/eCM.v023a02
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Bruderer M, 2014, EUR CELLS MATER, V28, P269, DOI 10.22203/eCM.v028a19
   Carbone E.J., 2014, ADV REGENERATIVE BIO, V1, P25276, DOI DOI 10.3402/ARB.V1.25276
   Carter TG, 2008, J ORAL MAXIL SURG, V66, P1417, DOI 10.1016/j.joms.2008.01.058
   Chameettachal S, 2016, ACS BIOMATER SCI ENG, V2, P1450, DOI 10.1021/acsbiomaterials.6b00152
   DEJONG JGN, 1994, ANN CLIN BIOCHEM, V31, P267, DOI 10.1177/000456329403100309
   Dixon JE, 2016, P NATL ACAD SCI USA, V113, pE291, DOI 10.1073/pnas.1518634113
   Dixon JE, 2011, MOL THER, V19, P1695, DOI 10.1038/mt.2011.125
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Eltaher HM, 2016, ACTA BIOMATER, V41, P181, DOI 10.1016/j.actbio.2016.06.004
   Eyckmans J, 2014, NAT MATER, V13, P542, DOI 10.1038/nmat3989
   Fakhry Maya, 2013, World J Stem Cells, V5, P136, DOI 10.4252/wjsc.v5.i4.136
   Feng R, 2008, P NATL ACAD SCI USA, V105, P6057, DOI 10.1073/pnas.0711961105
   Fukunaga J, 2013, RNA, V19, P927, DOI 10.1261/rna.037879.112
   Glied AN, 2009, N Y STATE DENT J, V76, P32
   Glueck M, 2015, BIORESEARCH OPEN ACC, V4, P121, DOI 10.1089/biores.2015.0002
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Gronthos S, 2003, J CELL SCI, V116, P1827, DOI 10.1242/jcs.00369
   Haijun Zhang YP, 2012, CANCER RES, V71, P3257
   Hart DA., 2014, STEM CELLS INT, V7, P526
   Hattori T, 2010, DEVELOPMENT, V137, P901, DOI 10.1242/dev.045203
   Hayrapetyan A, 2015, TISSUE ENG PART B RE, V21, P75, DOI [10.1089/ten.teb.2014.0119, 10.1089/ten.TEB.2014.0119]
   He N, 2011, J CELL BIOCHEM, V112, P653, DOI 10.1002/jcb.22968
   Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200
   Ho AD, 2008, CYTOTHERAPY, V10, P320, DOI 10.1080/14653240802217011
   Jäger M, 2008, J ORTHOP RES, V26, P1440, DOI 10.1002/jor.20565
   Khan SN, 2004, EXPERT OPIN BIOL TH, V4, P741
   Kwon A, 2016, SCI REP UK, V6, DOI 10.1038/srep23544
   Kwon SH, 2013, TISSUE ENG PT A, V19, P49, DOI [10.1089/ten.tea.2012.0245, 10.1089/ten.TEA.2012.0245]
   Langenbach F, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt328
   Lee KB, 2012, J ORTHOP RES, V30, P1985, DOI 10.1002/jor.22160
   Li SC, 2011, P NATL ACAD SCI USA, V108, P12793, DOI 10.1073/pnas.1100509108
   Li ZJ, 2013, BIOTECHNOL ADV, V31, P312, DOI 10.1016/j.biotechadv.2012.12.003
   Liu TM, 2013, TISSUE ENG PART B RE, V19, P254, DOI [10.1089/ten.TEB.2012.0527, 10.1089/ten.teb.2012.0527]
   Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052
   Loebel C, 2015, TISSUE ENG PT A, V21, P115, DOI [10.1089/ten.tea.2014.0096, 10.1089/ten.TEA.2014.0096]
   Mark P, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/698076
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Ode A, 2013, EUR CELLS MATER, V25, P37, DOI 10.22203/eCM.v025a03
   Okamoto T, 2002, BIOCHEM BIOPH RES CO, V295, P354, DOI 10.1016/S0006 291X(02)00661 7
   Penick KJ, 2005, BIOTECHNIQUES, V105, P12170
   Phillips JE, 2008, P NATL ACAD SCI USA, V105, P12170, DOI [10.1073/pnas.0801988105, 10.1073/pnas.0B019BB105]
   Phinney DG, 2007, CELL CYCLE, V6, P2884, DOI 10.4161/cc.6.23.5095
   Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5
   Roudsari JM, 2012, CASP J INTERN MED, V3, P478
   Schagemann JC, 2013, J BIOMED MATER RES A, V101, P1620, DOI 10.1002/jbm.a.34457
   Schmitt B, 2003, DIFFERENTIATION, V71, P567, DOI 10.1111/j.1432 0436.2003.07109003.x
   Sisti KE, 2016, BIOCHEM BIOPH RES CO, V473, P719, DOI 10.1016/j.bbrc.2015.10.013
   Sivasubramaniyan K, 2012, ANN NY ACAD SCI, V1266, P94, DOI 10.1111/j.1749 6632.2012.06551.x
   Smits P, 2004, J CELL BIOL, V164, P747, DOI 10.1083/jcb.200312045
   Song L, 2006, STEM CELLS, V24, P1707, DOI 10.1634/stemcells.2005 0604
   Suh JS, 2014, INT J NANOMED, V9, P1153, DOI 10.2147/IJN.S55433
   Takács R, 2013, INT J MOL SCI, V14, P16141, DOI 10.3390/ijms140816141
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Tew SR, 2008, METHODS, V45, P2, DOI 10.1016/j.ymeth.2008.01.006
   Tolar J, 2010, STEM CELLS, V28, P1446, DOI 10.1002/stem.459
   Wagner W, 2005, EXP HEMATOL, V33, P1402, DOI 10.1016/j.exphem.2005.07.003
   Walsh S, 2001, RHEUMATOLOGY, V40, P74, DOI 10.1093/rheumatology/40.1.74
   Wechsler ME, 2016, TISSUE ENG PART C ME, V22, P155, DOI 10.1089/ten.tec.2015.0324
   Wernig M, 2008, NAT BIOTECHNOL, V26, P916, DOI 10.1038/nbt1483
   Wiesmann Anne, 2006, Head Face Med, V2, P8, DOI 10.1186/1746 160X 2 8
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   zur Nieden NI, 2005, BMC DEV BIOL, V5, DOI 10.1186/1471 213X 5 1
NR 67
TC 74
Z9 76
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2157 6564
EI 2157 6580
J9 STEM CELL TRANSL MED
JI Stem Cells Transl. Med.
PD DEC
PY 2017
VL 6
IS 12
BP 2146
EP 2159
DI 10.1002/sctm.17 0137
PG 14
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA FQ7ZP
UT WOS:000418582600010
PM 29090533
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Qiu, S
   Tao, ZB
   Tao, L
   Zhu, Y
AF Qiu, Shui
   Tao, Zheng Bo
   Tao, Lin
   Zhu, Yue
TI Melatonin induces mitochondrial apoptosis in osteoblasts by regulating
   the STIM1/cytosolic calcium elevation/ERK pathway
SO LIFE SCIENCES
LA English
DT Article
DE Melatonin; Osteoblast; STIM1; Cytosolic calcium elevation; ERK
ID OPERATED CA2+ ENTRY; ENDOPLASMIC RETICULUM; CELL DEATH; SCOLIOSIS;
   RELEASE; PROLIFERATION; HOMEOSTASIS; EXPRESSION; ORAI1; SOCE
AB Aims: Idiopathic scoliosis is a common deformity of the spine that has an especially high incidence rate in adolescents. Some studies have demonstrated a close relationship between idiopathic scoliosis and melatonin deficiency. Our team's previous research showed that melatonin can inhibit the proliferation of osteoblasts, but the mechanism remains unclear. This study aimed to determine the mechanism by which melatonin inhibits the proliferation of osteoblasts.
   Main methods: Cell viability experiment, DNA fragment detection and alkaline phosphatase (ALP) activity assays were performed to determine the effects of melatonin on the proliferation, apoptosis and differentiation of osteoblasts. We used immunofluorescence to detect the expression of STIM1 in melatonin treated osteoblasts. STIM1 interference was achieved using a specific siRNA, and a TRPC inhibitor was used to block the influx of Ca2+. The mRNA expression was determined by RT qPCR, and protein levels were measured by Western blot.
   Key findings: In this study, we found that melatonin inhibited the proliferation, differentiation and apoptosis of osteoblasts in a concentration dependent manner. Additional studies showed that melatonin elevated cytosolic calcium levels by upregulation of STIM1, leading to osteoblast apoptosis via the mitochondrial pathway. Finally, we demonstrated that the STIM1 mediated increase in cytosolic calcium levels induced apoptosis through the ERK pathway.
   Significance: Melatonin induces mitochondrial apoptosis in osteoblasts by regulating the STIM1/cytosolic calcium elevation/ERK pathway. These basic findings provide a basis for further clinical studies on melatonin as a drug therapeutic for idiopathic scoliosis.
C1 [Qiu, Shui; Tao, Zheng Bo; Tao, Lin; Zhu, Yue] China Med Univ, Dept Orthopaed, Hosp 1, 155 North Nanjing St, Shenyang 110001, Peoples R China.
C3 China Medical University
RP Zhu, Y (通讯作者)，China Med Univ, Dept Orthopaed, Hosp 1, 155 North Nanjing St, Shenyang 110001, Peoples R China.
EM taolindr@163.com; zhuyuedr@163.com
RI ; Lin, Tao/KRO 9146 2024
OI Tao, Lin/0000 0002 1702 9833; 
FU National Natural Science Foundation of China [81472044]; Construction of
   Clinical Medical Research Center of Orthopaedics and Sports
   Rehabilitation Diseases in Liaoning Province [2019416030]
FX This work was supported by National Natural Science Foundation of China
   (No. 81472044), and Construction of Clinical Medical Research Center of
   Orthopaedics and Sports Rehabilitation Diseases in Liaoning Province
   (No. 2019416030).
CR Bagnall K, 1999, J BONE JOINT SURG AM, V81A, P191, DOI 10.2106/00004623 199902000 00006
   Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155
   Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094
   Calvo Rodríguez M, 2016, BBA MOL CELL RES, V1863, P2637, DOI 10.1016/j.bbamcr.2016.08.001
   Chiu CK, 2016, SPINE, V41, pE566, DOI 10.1097/BRS.0000000000001304
   Clapham DE, 2007, CELL, V131, P1047, DOI 10.1016/j.cell.2007.11.028
   Das R, 2008, APOPTOSIS, V13, P867, DOI 10.1007/s10495 008 0224 7
   Elsamadicy AA, 2019, J NEUROSURG PEDIATR, V24, P722, DOI 10.3171/2019.7.PEDS19223
   Feng MY, 2010, CELL, V143, P84, DOI 10.1016/j.cell.2010.08.040
   Florea AM, 2009, NEUROTOXICOLOGY, V30, P803, DOI 10.1016/j.neuro.2009.04.014
   Ge CT, 2019, P NATL ACAD SCI USA, V116, P19635, DOI 10.1073/pnas.1908998116
   Gregory RB, 2004, BIOCHEM J, V381, P519, DOI 10.1042/BJ20040637
   Henke N, 2012, J BIOL CHEM, V287, P42042, DOI 10.1074/jbc.M112.417212
   Hu F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107217
   Jin X, 2017, NUTR RES, V42, P20, DOI 10.1016/j.nutres.2017.04.009
   Kouwenhoven JWM, 2008, SPINE, V33, P2898, DOI 10.1097/BRS.0b013e3181891751
   LERNER AB, 1959, NATURE, V183, P1821, DOI 10.1038/1831821a0
   Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055
   Liu H, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 42467 5
   Liu HM, 2012, TOXICOL LETT, V208, P254, DOI 10.1016/j.toxlet.2011.11.007
   Liu LF, 2011, J PINEAL RES, V50, P222, DOI 10.1111/j.1600 079X.2010.00832.x
   MACHIDA M, 1995, J BONE JOINT SURG BR, V77B, P134, DOI 10.1302/0301 620X.77B1.7822371
   Machida M, 2009, J PINEAL RES, V46, P344, DOI 10.1111/j.1600 079X.2009.00669.x
   Murphy KM, 1999, ONCOGENE, V18, P5991, DOI 10.1038/sj.onc.1203001
   Ong HL, 2019, BBA MOL CELL RES, V1866, P1037, DOI 10.1016/j.bbamcr.2018.11.018
   Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690
   Prevarskaya N, 2011, NAT REV CANCER, V11, P609, DOI 10.1038/nrc3105
   REITER RJ, 1991, MOL CELL ENDOCRINOL, V79, pC153, DOI 10.1016/0303 7207(91)90087 9
   Roberts Thomson SJ, 2010, PHARMACOL THERAPEUT, V127, P121, DOI 10.1016/j.pharmthera.2010.04.016
   Rushton PRP, 2016, EUR SPINE J, V25, P3324, DOI 10.1007/s00586 015 4335 x
   Salido GM, 2009, CELL SIGNAL, V21, P457, DOI 10.1016/j.cellsig.2008.11.005
   Stagno MJ, 2017, CELL PHYSIOL BIOCHEM, V42, P1366, DOI 10.1159/000479200
   Stevenson L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020276
   Targos B, 2005, ACTA BIOCHIM POL, V52, P397, DOI 10.18388/abp.2005_3452
   Wertz IE, 2000, J BIOL CHEM, V275, P11470, DOI 10.1074/jbc.275.15.11470
   Xiang MX, 2009, J ZHEJIANG UNIV SC B, V10, P619, DOI 10.1631/jzus.B0920153
   Xu ZK, 2016, CHEM BIOL INTERACT, V254, P63, DOI 10.1016/j.cbi.2016.05.025
   Yan J, 2016, CELL PHYSIOL BIOCHEM, V38, P1643, DOI 10.1159/000443104
   Yang S, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1500 x
   Yang ZY, 2018, CANCER SCI, V109, P2792, DOI 10.1111/cas.13718
   Zhang CF, 2016, NEUROCHEM INT, V97, P137, DOI 10.1016/j.neuint.2016.04.002
   Zhivotovsky B, 2011, CELL CALCIUM, V50, P211, DOI 10.1016/j.ceca.2011.03.003
NR 42
TC 20
Z9 23
U1 0
U2 13
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024 3205
EI 1879 0631
J9 LIFE SCI
JI Life Sci.
PD MAY 1
PY 2020
VL 248
AR 117455
DI 10.1016/j.lfs.2020.117455
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA LB2LN
UT WOS:000524467100008
PM 32088216
DA 2025 08 17
ER

PT J
AU Nagashima, M
   Takahashi, H
   Shimane, K
   Nagase, Y
   Wauke, K
AF Nagashima, Masakazu
   Takahashi, Hiroshi
   Shimane, Kenichi
   Nagase, Yuichi
   Wauke, Koichi
TI Osteogenesis and osteoclast inhibition in rheumatoid arthritis patients
   treated with bisphosphonates alone or in combination with pitavastatin
   over an 18 month follow up after more than 4 years of treatment with
   bisphosphonates
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
ID ACID PHOSPHATASE ISOFORMS; NECROSIS FACTOR ALPHA; BONE RESORPTION;
   IN VITRO; KAPPA B; POSTMENOPAUSAL OSTEOPOROSIS; TERMINAL PROPEPTIDE;
   ETIDRONATE THERAPY; MEVALONATE PATHWAY; VERTEBRAL FRACTURE
AB Introduction: To investigate the effects of bisphosphonates (Bis) (etidronate, alendronate, and risedronate), alone and in combination with statin, on the BMD (bone mineral density) and bone metabolism of rheumatoid arthritis (RA) patients.
   Methods: Seventy seven RA patients who had been receiving prednisolone (PSL) and Bis for over 4 years were divided into two groups: Bis and Bis + statin (n = 42 and 35; average age, 66.4 and 65.3 years; average disease duration, 24.9 and 20.8 years; average PSL dose, 2.4 and 2.7 mg, respectively). Serum levels of NTX (N terminal telopeptide of type I collagen), TRACP 5b (tartrate resistant acid phosphate 5b), PICP (C terminal propeptide of type I procollagen), and RANKL (receptor activator of NF kappa B ligand) were measured over an 18 month period of treatment and follow up. The BMD levels of the two groups at the radius, lumbar spine, and femoral neck were compared using DXA (dual energy x ray absorptiometry).
   Results: A significant increase was only observed in the BMD of the lumbar spine at 18 months, but the BMDs of the radius and femoral neck decreased during the follow up period in the Bis group. Meanwhile, a significant increase was observed in the BMD of the lumbar spine in the Bis + statin group during administration and the BMDs of the radius and femoral neck stayed at baseline. Among the markers of bone metabolism, serum NTX was up regulated after 6 months in the Bis + statin group. Serum TRACP 5b was significantly increased during the follow up period in the Bis + statin group, but only at 18 months in the Bis group. Serum PICP recovered to base line in the Bis + statin group, whereas that in the Bis group did not observably recover during the post administration follow up, but rather decreased.
   Conclusion: Our findings suggest that both bone resorption and bone formation were inhibited by long term administration of Bis alone, whereas combination therapy with Bis + statin may be associated with a less marked inhibition of bone metabolism. Cardiovascular disease is highly prevalent in RA patients and some patients are prescribed statins and bisphosphonate. Bis + statin may confer more benefit to the bone metabolism of these patients compared to Bis alone.
C1 [Nagashima, Masakazu; Takahashi, Hiroshi; Shimane, Kenichi; Nagase, Yuichi] Tokyo Metropolitan Bokutoh Hosp, Dept Rheumatol, Sumida Ku, Tokyo 1308575, Japan.
   [Wauke, Koichi] Hospitality Care Garden Seisei Rehabil Hosp, Aoi Ku, Shizuoka 4200823, Japan.
RP Nagashima, M (通讯作者)，Tokyo Metropolitan Bokutoh Hosp, Dept Rheumatol, Sumida Ku, Kohtohbashi 4 23 15, Tokyo 1308575, Japan.
EM m_nagashima@bokutoh hp.metro.tokyo.jp
CR ARNETT FC, 1988, ARTHRITIS RHEUM US, V31, P315, DOI 10.1002/art.1780310302
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   BROMLEY M, 1984, ARTHRITIS RHEUM US, V27, P968, DOI 10.1002/art.1780270902
   Chung YS, 2000, J CLIN ENDOCR METAB, V85, P1137, DOI 10.1210/jc.85.3.1137
   Eastell R, 2000, OSTEOPOROSIS INT, V11, P331, DOI 10.1007/s001980070122
   Eastell R, 2003, J BONE MINER RES, V18, P1051, DOI 10.1359/jbmr.2003.18.6.1051
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Gravallese EM, 1998, AM J PATHOL, V152, P943
   Hara K, 2002, BONE, V31, P575, DOI 10.1016/S8756 3282(02)00874 8
   Hasegawa J, 2003, J RHEUMATOL, V30, P474
   Janckila AJ, 2002, CLIN CHIM ACTA, V320, P49, DOI 10.1016/S0009 8981(02)00026 8
   Janckila AJ, 2001, CLIN CHEM, V47, P74
   Jimi E, 1998, J BIOL CHEM, V273, P8799, DOI 10.1074/jbc.273.15.8799
   Kananen K, 2006, OSTEOPOROSIS INT, V17, P724, DOI 10.1007/s00198 005 0040 7
   Kobayashi A, 2005, SCAND J RHEUMATOL, V34, P480, DOI 10.1080/03009740510026788
   KONIG A, 1988, J BONE MINER RES, V3, P621
   Koshihara Y, 2003, J ENDOCRINOL, V176, P339, DOI 10.1677/joe.0.1760339
   Kotake S, 2001, ARTHRITIS RHEUM, V44, P1003, DOI 10.1002/1529 0131(200105)44:5<1003::AID ANR179>3.3.CO;2 R
   Kushida K, 2004, J BONE MINER METAB, V22, P469, DOI 10.1007/s00774 004 0509 z
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   Maeda T, 2004, J CELL BIOCHEM, V92, P458, DOI 10.1002/jcb.20074
   Morishita M, 2008, J RHEUMATOL, V35, P407
   Mostaza JM, 2001, CLIN CHIM ACTA, V308, P133, DOI 10.1016/S0009 8981(01)00476 4
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Ste Marie LG, 2004, CALCIFIED TISSUE INT, V75, P469, DOI 10.1007/s00223 004 0039 7
   Sugiyama M, 2000, BIOCHEM BIOPH RES CO, V271, P688, DOI 10.1006/bbrc.2000.2697
   Tähtelä R, 2005, OSTEOPOROSIS INT, V16, P1109, DOI 10.1007/s00198 004 1819 7
   Takahashi K, 2000, CLIN CHIM ACTA, V301, P147, DOI 10.1016/S0009 8981(00)00338 7
   Takayanagi H, 2000, ARTHRITIS RHEUM US, V43, P259, DOI 10.1002/1529 0131(200002)43:2<259::AID ANR4>3.0.CO;2 W
   Wallach S, 2000, CALCIFIED TISSUE INT, V67, P277, DOI 10.1007/s002230001146
   Watanabe S, 2001, AM J MED, V110, P584, DOI 10.1016/S0002 9343(01)00679 9
   Yamamoto K, 2006, RHEUMATOL INT, V26, P627, DOI 10.1007/s00296 005 0042 y
   Zou W, 2001, J CELL BIOCHEM, V83, P70, DOI 10.1002/jcb.1202
NR 36
TC 6
Z9 6
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1478 6354
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PY 2012
VL 14
IS 5
AR R224
DI 10.1186/ar4063
PG 8
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 097QN
UT WOS:000315488700036
PM 23079134
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Hoque, J
   Shih, YRV
   Zeng, YZ
   Newman, H
   Sangaj, N
   Arjunji, N
   Varghese, S
AF Hoque, Jiaul
   Shih, Yu Ru V.
   Zeng, Yuze
   Newman, Hunter
   Sangaj, Nivedita
   Arjunji, Neha
   Varghese, Shyni
TI Bone targeting nanocarrier assisted delivery of adenosine to combat
   osteoporotic bone loss
SO BIOMATERIALS
LA English
DT Article
DE Adenosine; Osteogenesis; Nanocarrier; Drug delivery; Osteoporosis
ID MESENCHYMAL STEM CELLS; ENGINEERED NANOMEDICINE; RECEPTORS;
   DIFFERENTIATION; NANOPARTICLE; OSTEOBLAST; PROGRESS; THERAPY; AGENTS
AB Extracellular adenosine has been shown to play a key role in maintaining bone health and could potentially be used to treat bone loss. However, systemic administration of exogenous adenosine to treat bone disorders remains a challenge due to the ubiquitous presence of adenosine receptors in different organs and the short half life of adenosine in circulation. Towards this, we have developed a bone targeting nanocarrier and determined its potential for systemic administration of adenosine. The nanocarrier, synthesized via emulsion suspension photopolymerization, is comprised of hyaluronic acid (HA) copolymerized with phenylboronic acid (PBA), a moiety that can form reversible bonds with adenosine. The bone binding affinity of the nanocarrier was achieved by alendronate (Aln) conjugation. Nanocarriers functionalized with the alendronate (Aln NC) showed a 45% higher accumulation in the mice vertebrae in vivo compared to those lacking alendronate molecules (NCs). Systemic administration of adenosine via bone targeting nanocarriers (Aln NC) attenuated bone loss in ovariectomized (OVX) mice. Furthermore, bone tissue of mice treated with adenosine loaded Aln NC displayed trabecular bone characteristics comparable to healthy controls as shown by microcomputed tomography, histochemical staining, bone labeling, and mechanical strength. Overall, our results demonstrate the use of a bone targeting nanocarrier towards systemic administration of adenosine and its application in treating bone degenerative diseases such as osteoporosis.
C1 [Hoque, Jiaul; Shih, Yu Ru V.; Zeng, Yuze; Sangaj, Nivedita; Arjunji, Neha; Varghese, Shyni] Duke Univ, Sch Med, Dept Orthopaed Surg, Durham, NC 27710 USA.
   [Zeng, Yuze; Newman, Hunter; Varghese, Shyni] Duke Univ, Dept Mech Engn & Mat Sci, Durham, NC 27710 USA.
   [Varghese, Shyni] Duke Univ, Dept Biomed Engn, Durham, NC 27710 USA.
C3 Duke University; Duke University; Duke University
RP Varghese, S (通讯作者)，Duke Univ, Sch Med, Dept Orthopaed Surg, Durham, NC 27710 USA.
EM shyni.varghese@duke.edu
OI Newman, Hunter/0000 0003 0264 9957
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases of
   the National Institutes of Health [NIH R01 AR071552]; National Institute
   of Arthritis and Musculoskeletal and Skin Diseases [R01AR071552] Funding
   Source: NIH RePORTER
FX The authors acknowledge the financial support from National Institute of
   Arthritis and Musculoskeletal and Skin Diseases of the National
   Institutes of Health under Award Number NIH R01 AR071552. The authors
   would like to thank Gavin Gonzales for assistance with dynamic light
   scattering and zeta potential measurements. The authors would also like
   to thank Anna Gilpin for her constructive comments on the manuscript.
CR Alexis F, 2008, MOL PHARMACEUT, V5, P505, DOI 10.1021/mp800051m
   [Anonymous], 2014, PLOS ONE
   Burdick JA, 2005, BIOMACROMOLECULES, V6, P386, DOI 10.1021/bm049508a
   Carroll SH, 2012, J BIOL CHEM, V287, P15718, DOI 10.1074/jbc.M112.344994
   Cenni E, 2008, BIOMATERIALS, V29, P1400, DOI 10.1016/j.biomaterials.2007.12.022
   Cheng H, 2017, DRUG DISCOV TODAY, V22, P1336, DOI 10.1016/j.drudis.2017.04.021
   Cole LE, 2016, ADV DRUG DELIVER REV, V99, P12, DOI 10.1016/j.addr.2015.10.005
   Corral DA, 1998, P NATL ACAD SCI USA, V95, P13835, DOI 10.1073/pnas.95.23.13835
   Cosman F, 2019, CURR OPIN RHEUMATOL, V31, P376, DOI 10.1097/BOR.0000000000000616
   Drescher D, 2011, ANAL BIOANAL CHEM, V400, P1367, DOI 10.1007/s00216 011 4893 7
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Gaudin A, 2014, NAT NANOTECHNOL, V9, P1054, DOI [10.1038/NNANO.2014.274, 10.1038/nnano.2014.274]
   Geng Y, 2007, NAT NANOTECHNOL, V2, P249, DOI 10.1038/nnano.2007.70
   Gharibi B, 2011, J BONE MINER RES, V26, P2112, DOI 10.1002/jbmr.424
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Haas AV, 2018, J ENDOCR SOC, V2, P922, DOI 10.1210/js.2018 00118
   Heller DA, 2013, ADV MATER, V25, P1449, DOI 10.1002/adma.201202881
   Hu CMJ, 2015, NATURE, V526, P118, DOI 10.1038/nature15373
   Huang R, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.129144
   Jacobson KA, 2006, NAT REV DRUG DISCOV, V5, P247, DOI 10.1038/nrd1983
   Järvinen TAH, 2010, P NATL ACAD SCI USA, V107, P21671, DOI 10.1073/pnas.1016233107
   Kang HM, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600691
   Kang H, 2015, BIOMACROMOLECULES, V16, P1050, DOI 10.1021/acs.biomac.5b00099
   Kara FM, 2010, ARTHRITIS RHEUM US, V62, P534, DOI 10.1002/art.27219
   Katebi M, 2009, J LEUKOCYTE BIOL, V85, P438, DOI 10.1189/jlb.0908520
   Khosla S, 2012, J CLIN ENDOCR METAB, V97, P2272, DOI 10.1210/jc.2012 1027
   Lavrador P, 2018, J CONTROL RELEASE, V273, P51, DOI 10.1016/j.jconrel.2018.01.021
   Lawson MA, 2010, J BIOMED MATER RES B, V92B, P149, DOI 10.1002/jbm.b.31500
   Lindsay R, 2016, OSTEOPOROSIS INT, V27, P2395, DOI 10.1007/s00198 016 3534 6
   Mediero A, 2016, FASEB J, V30, P3887, DOI 10.1096/fj.201600616R
   Mediero A, 2013, TRENDS ENDOCRIN MET, V24, P290, DOI 10.1016/j.tem.2013.02.001
   Mediero A, 2012, AM J PATHOL, V180, P775, DOI 10.1016/j.ajpath.2011.10.017
   Merkel TJ, 2011, P NATL ACAD SCI USA, V108, P586, DOI 10.1073/pnas.1010013108
   Merlotti D, 2019, EXPERT OPIN PHARMACO, V20, P805, DOI 10.1080/14656566.2019.1583208
   MOSER GH, 1989, AM J PHYSIOL, V256, pC799, DOI 10.1152/ajpcell.1989.256.4.C799
   Mukherjee S, 2008, J AM CHEM SOC, V130, P1264, DOI 10.1021/ja0759949
   Raemdonck K, 2009, ADV FUNCT MATER, V19, P1406, DOI 10.1002/adfm.200801795
   Rosenblum D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03705 y
   Rotman SG, 2018, J CONTROL RELEASE, V269, P88, DOI 10.1016/j.jconrel.2017.11.009
   Ryu JH, 2019, CURR MED CHEM, V26, P6797, DOI 10.2174/0929867325666181008144436
   Shih YRV, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax1387
   Solling ASK, 2018, THER ADV MUSCULOSKEL, V10, P105, DOI 10.1177/1759720X18775936
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Sun Y, 2016, ACS NANO, V10, P5759, DOI 10.1021/acsnano.5b07828
   Swami A, 2014, P NATL ACAD SCI USA, V111, P10287, DOI 10.1073/pnas.1401337111
   Takahama H, 2009, J AM COLL CARDIOL, V53, P709, DOI 10.1016/j.jacc.2008.11.014
   Nguyen TDT, 2016, SCI REP UK, V6, DOI 10.1038/srep36707
   Vanderburgh J, 2020, ACS NANO, V14, P311, DOI 10.1021/acsnano.9b04571
   Varghese S, 2010, STEM CELLS, V28, P765, DOI 10.1002/stem.325
   Villa Jordan C, 2016, HSS J, V12, P66, DOI 10.1007/s11420 015 9469 1
   Yang YS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10809 6
   Yin Q, 2016, P NATL ACAD SCI USA, V113, pE4601, DOI 10.1073/pnas.1603316113
   Zeng Y, 2020, ADV MATER, V32, DOI 10.1002/adma.201906022
   Zeng YZ, 2019, ACTA BIOMATER, V93, P152, DOI 10.1016/j.actbio.2019.01.060
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
NR 55
TC 34
Z9 38
U1 4
U2 104
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD JUN
PY 2021
VL 273
AR 120819
DI 10.1016/j.biomaterials.2021.120819
EA APR 2021
PG 14
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA SB0CS
UT WOS:000649670900001
PM 33892345
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Kanazawa, I
   Yamaguchi, T
   Yano, S
   Yamauchi, M
   Yamamoto, M
   Sugimoto, T
AF Kanazawa, Ippei
   Yamaguchi, Toru
   Yano, Shozo
   Yamauchi, Mika
   Yamamoto, Masahiro
   Sugimoto, Toshitsugu
TI Adiponectin and AMP kinase activator stimulate proliferation,
   differentiation, and mineralization of osteoblastic MC3T3 E1 cells
SO BMC CELL BIOLOGY
LA English
DT Article
ID FATTY ACID OXIDATION; BONE MARROW CULTURES; PROTEIN KINASE;
   GLUCOSE TRANSPORT; BODY COMPOSITION; TRANSCRIPTION FACTOR;
   SKELETAL MUSCLE; IN VITRO; RECEPTORS; EXPRESSION
AB Background: Adiponectin is a key mediator of the metabolic syndrome that is caused by visceral fat accumulation. Adiponectin and its receptors are known to be expressed in osteoblasts, but their actions with regard to bone metabolism are still unclear. In this study, we investigated the effects of adiponectin on the proliferation, differentiation, and mineralization of osteoblastic MC3T3 E1 cells.
   Results: Adiponectin receptor type 1 (AdipoR1) mRNA was detected in the cells by RT PCR. The adenosine monophosphate activated protein kinase ( AMP kinase) was phosphorylated by both adiponectin and a pharmacological AMP kinase activator, 5 amino imidazole 4 carboxamideriboside ( AICAR), in the cells. AdipoR1 small interfering RNA ( siRNA) transfection potently knocked down the receptor mRNA, and the effect of this knockdown persisted for as long as 10 days after the transfection. The transfected cells showed decreased expressions of type I collagen and osteocalcin mRNA, as determined by real time PCR, and reduced ALP activity and mineralization, as determined by von Kossa and Alizarin red stainings. In contrast, AMP kinase activation by AICAR (0.01 0.5 mM) in wild  type MC3T3 E1 cells augmented their proliferation, differentiation, and mineralization. BrdU assay showed that the addition of adiponectin (0.01 1.0 mu g/ml) also promoted their proliferation. Osterix, but not Runx 2, appeared to be involved in these processes because AdipoR1 siRNA transfection and AICAR treatments suppressed and enhanced osterix mRNA expression, respectively.
   Conclusion: Taken together, this study suggests that adiponectin stimulates the proliferation, differentiation, and mineralization of osteoblasts via the AdipoR1 and AMP kinase signaling pathways in autocrine and/or paracrine fashions.
C1 [Kanazawa, Ippei; Yamaguchi, Toru; Yano, Shozo; Yamauchi, Mika; Yamamoto, Masahiro; Sugimoto, Toshitsugu] Shimane Univ, Sch Med, Dept Internal Med 1, Izumo, Shimane, Japan.
C3 Shimane University
RP Yamaguchi, T (通讯作者)，Shimane Univ, Sch Med, Dept Internal Med 1, Izumo, Shimane, Japan.
EM ippei.k@med.shimane u.ac.jp; yamaguch@med.shimane u.ac.jp;
   syano@med.shimane u.ac.jp; yamauchi@med.shimane u.ac.jp;
   masa ya@med.shimaneu; sugimoto@med.shimane u.ac.jp
RI Yano, Shozo/HJG 6965 2022; Kanazawa, Ippei/F 8609 2010
CR Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255
   Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992
   Berner HS, 2004, BONE, V35, P842, DOI 10.1016/j.bone.2004.06.008
   Cheng SL, 2003, J BIOL CHEM, V278, P45969, DOI 10.1074/jbc.M306972200
   Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120
   CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432 1033.1995.tb20498.x
   Fasshauer M, 2004, FEBS LETT, V558, P27, DOI 10.1016/S0014 5793(03)01525 4
   FELSON DT, 1993, J BONE MINER RES, V8, P567, DOI 10.1002/jbmr.5650080507
   Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798
   Fryer LGD, 2002, BIOCHEM J, V363, P167, DOI 10.1042/0264 6021:3630167
   Garrett IR, 2002, ARTHRITIS RES, V4, P237, DOI 10.1186/ar413
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Giri S, 2004, J NEUROSCI, V24, P479, DOI 10.1523/JNEUROSCI.4288 03.2004
   GLAUBER HS, 1995, J CLIN ENDOCR METAB, V80, P1118, DOI 10.1210/jc.80.4.1118
   GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0
   Hara K, 2005, DIABETOLOGIA, V48, P1307, DOI 10.1007/s00125 005 1806 3
   Kadowaki T, 2005, ENDOCR REV, V26, P439, DOI 10.1210/er.2005 0005
   Kefas BA, 2003, DIABETOLOGIA, V46, P250, DOI 10.1007/s00125 002 1030 3
   Kefas BA, 2003, J MOL ENDOCRINOL, V30, P151, DOI 10.1677/jme.0.0300151
   Khosla S, 1996, J BONE MINER RES, V11, P857
   Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058
   Lim S, 2004, BONE, V35, P792, DOI 10.1016/j.bone.2004.05.016
   LINDSAY R, 1992, J BONE MINER RES, V7, P55
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   LOWRY OH, 1954, J BIOL CHEM, V207, P19
   Luo XH, 2005, EXP CELL RES, V309, P99, DOI 10.1016/j.yexcr.2005.05.021
   Maeda K, 1997, GENE, V190, P227, DOI 10.1016/S0378 1119(96)00730 5
   Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a
   Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097 2765(01)00251 9
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Oshima K, 2005, BIOCHEM BIOPH RES CO, V331, P520, DOI 10.1016/j.bbrc.2005.03.210
   Ruderman NB, 1999, AM J PHYSIOL ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1
   Shinoda Y, 2006, J CELL BIOCHEM, V99, P196, DOI 10.1002/jcb.20890
   Sowa H, 2002, J BONE MINER RES, V17, P1190, DOI 10.1359/jbmr.2002.17.7.1190
   Stewart KJ, 2002, J INTERN MED, V252, P381, DOI 10.1046/j.1365 2796.2002.01050.x
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499
   Winder WW, 2001, J APPL PHYSIOL, V91, P1017, DOI 10.1152/jappl.2001.91.3.1017
   Winzell MS, 2004, BIOCHEM BIOPH RES CO, V321, P154, DOI 10.1016/j.bbrc.2004.06.130
   Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200
   Yamauchi M, 2005, AM J PHYSIOL ENDOC M, V288, pE608, DOI 10.1152/ajpendo.00229.2004
   Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705
   Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788
   Yang SY, 2003, J BONE MINER RES, V18, P705, DOI 10.1359/jbmr.2003.18.4.705
   Yano S, 2005, ENDOCRINOLOGY, V146, P2324, DOI 10.1210/en.2005 0065
   Yokota T, 2003, J IMMUNOL, V171, P5091, DOI 10.4049/jimmunol.171.10.5091
   Yokota T, 2002, J CLIN INVEST, V109, P1303, DOI 10.1172/JCI200214506
NR 47
TC 156
Z9 172
U1 0
U2 20
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471 2121
J9 BMC CELL BIOL
JI BMC Cell Biol.
PD NOV 29
PY 2007
VL 8
AR 51
DI 10.1186/1471 2121 8 51
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 262PZ
UT WOS:000253161800001
PM 18047638
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Huang, EY
   Zhu, GH
   Jiang, W
   Yang, K
   Gao, YH
   Luo, Q
   Gao, JL
   Kim, SH
   Liu, X
   Li, M
   Shi, Q
   Hu, N
   Wang, LY
   Liu, H
   Cui, J
   Zhang, WW
   Li, RD
   Chen, X
   Kong, YH
   Zhang, JY
   Wang, JH
   Shen, JK
   Bi, Y
   Statz, J
   He, BC
   Luo, JY
   Wang, HC
   Xiong, F
   Luu, HH
   Haydon, RC
   Yang, L
   He, TC
AF Huang, Enyi
   Zhu, Gaohui
   Jiang, Wei
   Yang, Ke
   Gao, Yanhong
   Luo, Qing
   Gao, Jian Li
   Kim, Stephanie H.
   Liu, Xing
   Li, Mi
   Shi, Qiong
   Hu, Ning
   Wang, Linyuan
   Liu, Hong
   Cui, Jing
   Zhang, Wenwen
   Li, Ruidong
   Chen, Xiang
   Kong, Yu Han
   Zhang, Jiye
   Wang, Jinhua
   Shen, Jikun
   Bi, Yang
   Statz, Joseph
   He, Bai Cheng
   Luo, Jinyong
   Wang, Huicong
   Xiong, Feng
   Luu, Hue H.
   Haydon, Rex C.
   Yang, Li
   He, Tong Chuan
TI Growth hormone synergizes with BMP9 in osteogenic differentiation by
   activating the JAK/STAT/IGF1 pathway in murine multilineage cells
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE BMP9 SIGNALING; EXTRAPITUITARY GROWTH HORMONE; JAK; STAT; IGF1 PATHWAY;
   MESENCHYMAL STEM CELLS; OSTEOGENIC DIFFERENTIATION
ID MESENCHYMAL STEM CELLS; BONE MORPHOGENETIC PROTEINS; HEPATIC PROGENITOR
   CELLS; IDIOPATHIC SHORT STATURE; OSTEOBLAST DIFFERENTIATION; RECOMBINANT
   ADENOVIRUSES; HUMAN OSTEOSARCOMA; TUMOR GROWTH; I AXIS; SYSTEM
AB Growth hormone (GH) is usually released by somatotrophs in the anterior pituitary in response to the GH releasing hormone and plays an important role in skeleton development and postnatal growth. However, it is unclear if extrapituitary GH exerts any effect on murine multilineage cells (MMCs). MMCs are multipotent progenitors that give rise to several lineages, including bone, cartilage, and fat. We have identified bone morphogenic protein 9 (BMP9) as one of the most osteogenic BMPs in MMCs by regulating a distinct set of downstream mediators. In this study, we find that GH is one of the most significantly upregulated genes by BMP9 in mouse MMCs through expression profiling analysis. We confirm that GH is a direct early target of and upregulated by BMP9 signaling. Exogenous GH synergizes with BMP9 on inducing early and late osteogenic markers in MMCs. Furthermore, BMP9 and GH costimulation leads to a significant expansion of growth plate in cultured limb explants. Although GH alone does not induce de novo bone formation in an ectopic bone formation model, BMP9 and GH costimulated MMCs form more mature bone, which can be inhibited by silencing GH expression. The synergistic osteogenic activity between BMP9 and GH can be significantly blunted by JAK/STAT inhibitors, leading to a decrease in GH regulated insulin like growth factor 1 (IGF1) expression in MMCs. Our results strongly suggest that BMP9 may effectively regulate extrapituitary GH expression in MMCs. Thus, it is conceivable that the BMP9 GH IGF axis may be exploited as an innovative strategy to enhance osteogenesis in regenerative medicine. (c) 2012 American Society for Bone and Mineral Research.
C1 [Huang, Enyi; Zhu, Gaohui; Jiang, Wei; Yang, Ke; Gao, Yanhong; Luo, Qing; Gao, Jian Li; Kim, Stephanie H.; Liu, Xing; Li, Mi; Shi, Qiong; Hu, Ning; Wang, Linyuan; Liu, Hong; Cui, Jing; Zhang, Wenwen; Li, Ruidong; Chen, Xiang; Kong, Yu Han; Zhang, Jiye; Wang, Jinhua; Shen, Jikun; Bi, Yang; Statz, Joseph; He, Bai Cheng; Luo, Jinyong; Luu, Hue H.; Haydon, Rex C.; He, Tong Chuan] Univ Chicago, Med Ctr, Mol Oncol Lab, Dept Surg, Chicago, IL 60637 USA.
   [Huang, Enyi; Wang, Huicong; Yang, Li] Chongqing Univ, Sch Bioengn, Chongqing 630044, Peoples R China.
   [Zhu, Gaohui; Luo, Qing; Liu, Xing; Li, Mi; Bi, Yang; Xiong, Feng; He, Tong Chuan] Chongqing Med Univ, Childrens Hosp, Stem Cell Biol & Therapy Lab, Key Lab Pediat Codesignated Chinese Minist Educ, Chongqing, Peoples R China.
   [Zhu, Gaohui; Luo, Qing; Liu, Xing; Li, Mi; Bi, Yang; Xiong, Feng; He, Tong Chuan] Chongqing Med Univ, Childrens Hosp, Chongqing Bur Educ, Chongqing, Peoples R China.
   [Yang, Ke] Third Mil Med Univ, Dept Cell Biol, Chongqing, Peoples R China.
   [Gao, Yanhong] Shanghai Jiao Tong Univ, Dept Geriatr, Xinhua Hosp, Shanghai 200030, Peoples R China.
   [Gao, Jian Li] Zhejiang Chinese Med Univ, Inst Mat Med, Hangzhou, Zhejiang, Peoples R China.
   [Shi, Qiong; Hu, Ning; Liu, Hong; Cui, Jing; Zhang, Wenwen; Li, Ruidong; Kong, Yu Han; Zhang, Jiye; Wang, Jinhua; He, Bai Cheng; Luo, Jinyong] Chongqing Med Univ, Chinese Minist Educ, Key Lab Diagnost Med Designated, Chongqing, Peoples R China.
   [Chen, Xiang] Fourth Mil Med Univ, Dept Orthopaed Surg, Affiliated Tangdu Hosp, Xian 710032, Peoples R China.
C3 University of Chicago; University of Chicago Medical Center; Chongqing
   University; Chongqing Medical University; Chongqing Medical University;
   Army Medical University; Shanghai Jiao Tong University; Zhejiang Chinese
   Medical University; Chongqing Medical University; Air Force Medical
   University
RP He, TC (通讯作者)，Univ Chicago, Med Ctr, Mol Oncol Lab, Dept Surg, 5841 S Maryland Ave,MC 3079, Chicago, IL 60637 USA.
EM yangli@cqu.edu.cn; tche@surgery.bsd.uchicago.edu
RI Chen, Xiangdong/KCX 7707 2024; GAO, Jian Li/J 4997 2017; Zhang,
   Jiye/LSJ 2675 2024; GAO, JianLi/J 4997 2017
OI Chen, Xiang/0000 0001 7628 516X; HUANG, ENYI/0000 0003 1163 5282; GAO,
   JianLi/0000 0002 5977 0021; Statz, Joseph/0000 0003 1091 4212
FU Orthopaedic Research and Education Foundation; National Institutes of
   Health; Natural Science Foundation of China and Shanghai Education
   Commission [81101360, 12YZ053]; China Scholarship Council
FX We thank Dr. Chad Hanley of the Department of Radiology at The
   University of Chicago for his assistance and advice on mCT scanning and
   imaging analysis. This work was supported in part by research grants
   from the Orthopaedic Research and Education Foundation (RCH and HHL),
   the National Institutes of Health (RCH, TCH, and HHL), and the Natural
   Science Foundation of China and Shanghai Education Commission (81101360
   and 12YZ053 to YG). EH was a recipient of the Predoctoral Fellowship
   from the China Scholarship Council.
CR Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809
   Aubin JE, 1998, BIOCHEM CELL BIOL, V76, P899, DOI 10.1139/bcb 76 6 899
   Bi Y, 2009, J CELL BIOCHEM, V108, P295, DOI 10.1002/jcb.22254
   Blair JC, 2002, TRENDS ENDOCRIN MET, V13, P325, DOI 10.1016/S1043 2760(02)00631 8
   Brooks AJ, 2010, NAT REV ENDOCRINOL, V6, P515, DOI 10.1038/nrendo.2010.123
   Canalis E, 2009, J CELL BIOCHEM, V108, P769, DOI 10.1002/jcb.22322
   Chen C, 2003, NAT BIOTECHNOL, V21, P294, DOI 10.1038/nbt795
   Chen LA, 2010, J BONE MINER RES, V25, P2447, DOI 10.1002/jbmr.133
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Deng ZL, 2008, FRONT BIOSCI LANDMRK, V13, P2001, DOI 10.2741/2819
   Dupont Joelle, 2003, Birth Defects Research, V69, P257, DOI 10.1002/bdrc.10022
   Harvey S, 1997, ENDOCRINE, V7, P267, DOI 10.1007/BF02801319
   Harvey S, 2010, ENDOCRINE, V38, P335, DOI 10.1007/s12020 010 9403 8
   He BC, 2010, CLIN CANCER RES, V16, P2235, DOI 10.1158/1078 0432.CCR 09 2499
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092 8674(00)81664 5
   Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580
   Huang JY, 2009, LIVER INT, V29, P1569, DOI 10.1111/j.1478 3231.2009.02111.x
   Hull KL, 2000, REV REPROD, V5, P175, DOI 10.1530/ror.0.0050175
   Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   Kang Q, 2009, STEM CELLS DEV, V18, P545, DOI 10.1089/scd.2008.0130
   Kasukawa Y, 2004, CURR PHARM DESIGN, V10, P2577, DOI 10.2174/1381612043383764
   Kawai M, 2010, J CELL BIOCHEM, V111, P14, DOI 10.1002/jcb.22678
   Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098
   Linkhart TA, 1996, BONE, V19, P1
   López Coviella I, 2000, SCIENCE, V289, P313, DOI 10.1126/science.289.5477.313
   Luo J, 2007, NAT PROTOC, V2, P1236, DOI 10.1038/nprot.2007.135
   Luo JY, 2010, J BIOL CHEM, V285, P29588, DOI 10.1074/jbc.M110.130518
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Luo Q, 2007, GENE, V395, P160, DOI 10.1016/j.gene.2007.02.030
   Luo XJ, 2008, LAB INVEST, V88, P1264, DOI 10.1038/labinvest.2008.98
   Luther G, 2011, CURR GENE THER, V11, P229
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191
   Park P, 2005, GROWTH HORM IGF RES, V15, pS13, DOI 10.1016/j.ghir.2005.06.011
   Peng Y, 2004, J BIOL CHEM, V279, P32941, DOI 10.1074/jbc.M403344200
   Peng Y, 2003, J CELL BIOCHEM, V90, P1149, DOI 10.1002/jcb.10744
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Rastegar F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014182
   Rosen CJ, 2007, HORM RES, V68, P2, DOI 10.1159/000110461
   Sharff KA, 2009, J BIOL CHEM, V284, P649, DOI 10.1074/jbc.M806389200
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092 8674(03)00432 X
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   SONG JJ, 1995, ENDOCRINOLOGY, V136, P4293, DOI 10.1210/en.136.10.4293
   Su Y, 2011, ONCOGENE, V30, P3907, DOI 10.1038/onc.2011.97
   Tanaka H, 1998, ENDOCR J, V45, pS47, DOI 10.1507/endocrj.45.Suppl_S47
   Tang N, 2009, J CELL MOL MED, V13, P2448, DOI 10.1111/j.1582 4934.2008.00569.x
   Thomas MJ, 1998, GROWTH HORM IGF RES, V8, P3, DOI 10.1016/S1096 6374(98)80316 X
   Truksa J, 2006, P NATL ACAD SCI USA, V103, P10289, DOI 10.1073/pnas.0603124103
   Varga AC, 2005, ONCOGENE, V24, P5713, DOI 10.1038/sj.onc.1208919
   Zhang JW, 2005, DEV BIOL, V284, P1, DOI 10.1016/j.ydbio.2005.05.009
   Zhang WL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011917
   Zhao GQ, 2003, GENESIS, V35, P43, DOI 10.1002/gene.10167
   Zhu GH, 2009, DIFFERENTIATION, V78, P195, DOI 10.1016/j.diff.2009.06.001
NR 56
TC 107
Z9 115
U1 0
U2 38
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUL
PY 2012
VL 27
IS 7
BP 1566
EP 1575
DI 10.1002/jbmr.1622
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 959EZ
UT WOS:000305297000016
PM 22467218
OA Bronze
DA 2025 08 17
ER

PT J
AU Zhang, Y
   Weng, QY
   Chen, JM
   Li, M
   Han, JM
AF Zhang, Yong
   Weng, Qiuyan
   Chen, Jianming
   Li, Ming
   Han, Jinming
TI Oroxylin A attenuates IL 1β induced inflammatory reaction via inhibiting
   the activation of the ERK and PI3K/AKT signaling pathways in
   osteoarthritis chondrocytes
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE Oroxylin A; interleukin 1&#946; osteoarthritis; extracellular
   signal regulated kinase 1; 2; phosphatidylinositol 3 kinase; protein
   kinase B
ID NF KAPPA B; GENE EXPRESSION; CARTILAGE DEGRADATION; AGGRECAN
   DEGRADATION; DOWN REGULATION; NITRIC OXIDE; TNF ALPHA; AUTOPHAGY;
   COLLAGEN; CELLS
AB Osteoarthritis (OA) is characterized by degradation of the articular cartilage, synovium inflammation, subchondral bone sclerosis and osteophyte formation. OA is the most common degenerative joint disorder among the elderly population. In particular, currently available therapeutic strategies, such as non steroidal anti inflammatory drugs (NSAIDs) may cause severe side effects. Therefore, novel candidate targets for OA therapy are urgently needed. Oroxylin A (OrA) is a natural mono flavonoid that can be extracted from Scutellariae radix. The present study aimed to investigate the potential effects of OrA on interleukin (IL) 1 beta induced chondrocytes inflammatory reactions. The current study performed quantitative PCR, western blotting and cell immunofluorescence to evaluate the effect of Oroxylin A in chondrocyte inflammation. The results demonstrated that OrA significantly attenuated the upregulation of inducible nitric oxide synthase and cyclooxygenase 2 by IL 1 beta at both protein and mRNA levels. IL 1 beta stimulated upregulation of matrix metalloproteinase (MMP) 3 and MMP 13 expression, in addition to disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) 4 and ADAMTS 5 expression, were all inhibited by OrA. Treatment with OrA significantly reversed the degradation of type II collagen and aggrecan by IL 1 beta. Mechanistically, OrA suppressed the IL 1 beta induced activation of ERK1/2 and PI3K/AKT signaling pathways. In conclusion, these findings suggest that OrA can serve as a potential therapeutic agent for the treatment of OA.
C1 [Zhang, Yong; Chen, Jianming; Li, Ming] Ningbo 6 Hosp, Dept Trauma Orthoped, Ningbo, Peoples R China.
   [Weng, Qiuyan] Ningbo Univ, Dept Neurol, Med Sch, Affiliated Hosp, Ningbo, Peoples R China.
   [Han, Jinming] Ningbo 6 Hosp, Dept Spine, 1059 Zhongshan East Rd, Ningbo 315000, Zhejiang, Peoples R China.
C3 Ningbo University
RP Han, JM (通讯作者)，Ningbo 6 Hosp, Dept Spine, 1059 Zhongshan East Rd, Ningbo 315000, Zhejiang, Peoples R China.
EM hanjinming83@163.com
RI Chen, Jianming/F 4980 2012; Li, Ming/ACU 5300 2022
FU Medical and Health Technology Project of Zhejiang Province [2019PY073];
   Science and Technology Research on Public Welfare Project of Ningbo,
   Zhejiang Province [2019C50050]; Scientific Technology Project of
   Agriculture and Social Development of Yinzhou, Ningbo, Zhejiang Province
   [20180137]
FX The present study was supported by the Medical and Health Technology
   Project of Zhejiang Province (grant no. 2019PY073); Science and
   Technology Research on Public Welfare Project of Ningbo, Zhejiang
   Province (grant no. 2019C50050) and the Scientific Technology Project of
   Agriculture and Social Development of Yinzhou, Ningbo, Zhejiang Province
   (grant no. 20180137).
CR Abramson SB, 2004, J RHEUMATOL, V31, P70, DOI 10.1097/BOR.0b013e328349c2b1
   Ashford Susan, 2014, Nurse Pract, V39, P1, DOI 10.1097/01.NPR.0000445886.71205.c4
   Bonassar LJ, 1997, ARCH BIOCHEM BIOPHYS, V344, P404, DOI 10.1006/abbi.1997.0205
   Chen YF, 2008, HEALTH TECHNOL ASSES, V12, P1, DOI 10.3310/hta12110
   Chen YC, 2000, BIOCHEM PHARMACOL, V59, P1445, DOI 10.1016/S0006 2952(00)00255 0
   Cheng CC, 2009, J CELL PHYSIOL, V221, P668, DOI 10.1002/jcp.21904
   Choi HW, 2018, INT J MOL MED, V41, P1103, DOI 10.3892/ijmm.2017.3309
   Chow YY, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/8293921
   Clark J. Derrell, 1997, ILAR J, V38, P41
   Ding J, 2009, LIFE SCI, V84, P499, DOI 10.1016/j.lfs.2009.01.013
   Felson DT, 2004, CLIN ORTHOP RELAT R, pS16, DOI 10.1097/01.blo.0000144971.12731.a2
   Gao Shi Chao, 2014, Zhongguo Gu Shang, V27, P441
   Gao Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/648459
   GIERCKSKY KE, 1989, SCAND J GASTROENTERO, V24, P3, DOI 10.3109/00365528909091168
   Glasson SS, 2005, NATURE, V434, P644, DOI 10.1038/nature03369
   Glyn Jones S, 2015, LANCET, V386, P376, DOI 10.1016/S0140 6736(14)60802 3
   Han QH, 2017, NAT PROD RES, V31, P1339, DOI 10.1080/14786419.2016.1244193
   Hashizume M, 2010, BIOCHEM BIOPH RES CO, V403, P184, DOI 10.1016/j.bbrc.2010.10.135
   Hungin A. P. S., 2001, American Journal of Medicine, V110, p8S, DOI 10.1016/S0002 9343(00)00628 8
   Ji QB, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 018 08277 5
   Kubota E, 1997, J ORAL MAXIL SURG, V55, P20, DOI 10.1016/S0278 2391(97)90438 9
   Lane NE, 1997, J RHEUMATOL, V24, P20
   Lee JH, 2015, J GINSENG RES, V39, P54, DOI 10.1016/j.jgr.2014.06.006
   Li JH, 2016, INT IMMUNOPHARMACOL, V40, P524, DOI 10.1016/j.intimp.2016.10.011
   Lichtenberger LM, 2006, J PHARM PHARMACOL, V58, P1421, DOI 10.1211/jpp.58.10.0001
   Liu ZJ, 2015, INT J MOL SCI, V16, P17857, DOI 10.3390/ijms160817857
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luo YY, 2017, PROTEIN CELL, V8, P560, DOI 10.1007/s13238 017 0377 7
   Mokuda S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10177 1
   More AS, 2013, PHARMACOL BIOCHEM BE, V103, P764, DOI 10.1016/j.pbb.2012.12.013
   Needleman P, 1999, OSTEOARTHR CARTILAGE, V7, P367, DOI 10.1053/joca.1998.0237
   Pattoli MA, 2005, J PHARMACOL EXP THER, V315, P382, DOI 10.1124/jpet.105.087569
   Poole AR, 2002, ANN RHEUM DIS, V61, P78, DOI 10.1136/ard.61.suppl_2.ii78
   Rahmati M, 2017, AGEING RES REV, V40, P20, DOI 10.1016/j.arr.2017.07.004
   Roos EM, 2016, NAT REV RHEUMATOL, V12, P92, DOI 10.1038/nrrheum.2015.135
   Sarzi Puttini P, 2005, SEMIN ARTHRITIS RHEU, V35, P1, DOI 10.1016/j.semarthrit.2005.01.013
   Sherwin CM, 2003, APPL ANIM BEHAV SCI, V81, P291, DOI 10.1016/S0168 1591(02)00288 5
   Shi J, 2016, IUBMB LIFE, V68, P293, DOI 10.1002/iub.1482
   Smith R. Lane, 1999, Frontiers in Bioscience, V4, pd704
   Song RH, 2007, ARTHRITIS RHEUM US, V56, P575, DOI 10.1002/art.22334
   Song XM, 2012, PHARMACOL REP, V64, P1189, DOI 10.1016/S1734 1140(12)70915 5
   Stanton H, 2005, NATURE, V434, P648, DOI 10.1038/nature03417
   Studer R, 1999, OSTEOARTHR CARTILAGE, V7, P377, DOI 10.1053/joca.1998.0216
   Sun XH, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/9241769
   Sun Y, 2009, EUR J PHARMACOL, V603, P22, DOI 10.1016/j.ejphar.2008.12.008
   Tchetina EV, 2005, J RHEUMATOL, V32, P876
   VERTEL BM, 1995, TRENDS CELL BIOL, V5, P458, DOI 10.1016/S0962 8924(00)89115 1
   Wang JR, 2011, J BIOL CHEM, V286, P39738, DOI 10.1074/jbc.M111.264549
   Wang MN, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4133
   Watson DJ, 2000, ARCH INTERN MED, V160, P2998, DOI 10.1001/archinte.160.19.2998
   Wong M, 2003, BONE, V33, P1, DOI 10.1016/S8756 3282(03)00083 8
   Xue JF, 2017, BIOMED PHARMACOTHER, V89, P1252, DOI 10.1016/j.biopha.2017.01.130
   Yao J, 2014, MOL CARCINOGEN, V53, P145, DOI 10.1002/mc.21958
   Ye M, 2014, BIOCHEM CELL BIOL, V92, P337, DOI 10.1139/bcb 2014 0030
   Zhang YQ, 2010, CLIN GERIATR MED, V26, P355, DOI [10.1016/j.rdc.2012.10.004, 10.1016/j.cger.2010.03.001]
   Zou MJ, 2015, MOL CARCINOGEN, V54, P1363, DOI 10.1002/mc.22212
   Zou MJ, 2012, CELL SIGNAL, V24, P1722, DOI 10.1016/j.cellsig.2012.04.009
NR 57
TC 14
Z9 16
U1 0
U2 12
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD APR
PY 2021
VL 21
IS 4
AR 388
DI 10.3892/etm.2021.9819
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA QP6HA
UT WOS:000623934600001
PM 33680110
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ulbrich, W
   Lamprecht, A
AF Ulbrich, Wiebke
   Lamprecht, Alf
TI Fluorimetric quantification of clodronate and alendronate in aqueous
   samples and in serum
SO TALANTA
LA English
DT Article
DE Clodronate; Alendronate; Bisphosphonates; Fluorimetric quantification;
   Plasma; Serum
ID POSTCOLUMN DERIVATIZATION; CHROMATOGRAPHIC ANALYSIS; ION CHROMATOGRAPHY;
   IN VITRO; BISPHOSPHONATES; MACROPHAGES; PLASMA; PHARMACEUTICALS;
   FLUORESCENCE; DEPLETION
AB The bisphosphonates clodronate and alendronate are drugs in the therapy of osteoporosis or Paget's disease. They are highly hydrophilic and therefore of low oral bioavailability. Determination methods for bisphosphonates are often laborious and expensive equipment is needed. The presented quantification method based on kinetic measurement of the fluorescence decrease of an Al3+ morin complex can be used to determine the bisphosphonate content in aqueous and plasma samples. The intra  and inter assay accuracies were found to be within 98.8% and 102.3% of the target samples for clodronate and within 97.2% and 105.0% of the target samples for alendronate. The LOQ was defined as 15.6 ng/ml for clodronate and 62.5 ng/ml for alendronate. In serum samples. intra  and inter assay accuracy was found to be within 99.0% and 101.6% of the target samples for clodronate and within 97.8% and 102.6% of the target samples for alendronate. In serum samples, the LOQ was defined as 1.55 mg/ml for clodronate and 0.39 mg/ml for alendronate. Though less sensitive in serum, the presented method could support research on the development of drug delivery systems in vitro and in vivo for the investigated and other structurally related bisphosphonates. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Ulbrich, Wiebke; Lamprecht, Alf] Univ Bonn, Lab Pharmaceut Technol & Biopharmaceut, D 5300 Bonn, Germany.
   [Lamprecht, Alf] Univ Franche Comte, Lab Pharmaceut Engn, F 25030 Besancon, France.
   [Lamprecht, Alf] Inst Univ France, Paris, France.
C3 University of Bonn; Universite Marie et Louis Pasteur; Institut
   Universitaire de France
RP Lamprecht, A (通讯作者)，Gerhard Domagk Str 3, D 53121 Bonn, Germany.
EM alf.lamprecht@uni bonn.de
CR BISAZ S, 1975, CLIN CHIM ACTA, V65, P299, DOI 10.1016/0009 8981(75)90255 7
   BLANCHARD J, 1981, J CHROMATOGR, V226, P455, DOI 10.1016/S0378 4347(00)86080 6
   Ceponis A, 2001, ARTHRITIS RHEUM, V44, P1908
   Danenberg HD, 2003, J CARDIOVASC PHARM, V42, P671, DOI 10.1097/00005344 200311000 00014
   Ezra A, 2000, ADV DRUG DELIVER REV, V42, P175, DOI 10.1016/S0169 409X(00)00061 2
   FITCHETT AW, 1993, LC, V1
   Haber E, 2009, HUM REPROD, V24, P398, DOI 10.1093/humrep/den375
   KOSONEN JP, 1992, J PHARMACEUT BIOMED, V10, P881, DOI 10.1016/0731 7085(91)80095 Q
   LIGGETT SJ, 1973, BIOCHEM MED METAB B, V7, P68, DOI 10.1016/0006 2944(73)90100 2
   Lovdahl MJ, 1999, J CHROMATOGR A, V850, P143, DOI 10.1016/S0021 9673(99)00622 6
   PENNANEN N, 1995, PHARMACEUT RES, V12, P916, DOI 10.1023/A:1016281608773
   Quashie NB, 2006, MALARIA J, V5, DOI 10.1186/1475 2875 5 95
   Shikama Y, 2010, TOXICOL LETT, V199, P123, DOI 10.1016/j.toxlet.2010.08.013
   Sparidans RW, 1999, PHARM WORLD SCI, V21, P1, DOI 10.1023/A:1008646810555
   STRAHLE J, 1995, LEHRBUCH ANAL PRAPAR
   TSAI EW, 1994, J PHARMACEUT BIOMED, V12, P983, DOI 10.1016/0731 7085(94)00047 6
   VIRTANEN V, 1993, J CHROMATOGR BIOMED, V617, P291, DOI 10.1016/0378 4347(93)80501 T
   VIRTANEN V, 1993, TALANTA, V40, P661, DOI 10.1016/0039 9140(93)80275 V
   Watanabe N, 2003, DIGEST DIS SCI, V48, P408, DOI 10.1023/A:1021960401290
   WELCHER FJ, 1948, ORG ANAL REAGENTS, V4, P193
   Yun MH, 2006, J PHARMACEUT BIOMED, V40, P168, DOI 10.1016/j.jpba.2005.06.025
   Zacharis CK, 2008, J PHARMACEUT BIOMED, V48, P483, DOI 10.1016/j.jpba.2008.05.028
NR 22
TC 15
Z9 15
U1 0
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0039 9140
EI 1873 3573
J9 TALANTA
JI Talanta
PD APR 15
PY 2011
VL 84
IS 2
BP 437
EP 442
DI 10.1016/j.talanta.2011.01.049
PG 6
WC Chemistry, Analytical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA 745CM
UT WOS:000289141500029
PM 21376970
DA 2025 08 17
ER

PT S
AU Piva, R
   Penolazzi, L
   Zennaro, M
   Bianchini, E
   Magri, E
   Borgatti, M
   Lampronti, I
   Lambertini, E
   Tavanti, E
   Gambari, R
AF Piva, Roberta
   Penolazzi, Letizia
   Zennaro, Margherita
   Bianchini, Ercolina
   Magri, Eros
   Borgatti, Monica
   Lampronti, Ilaria
   Lambertini, Elisabetta
   Tavanti, Elisa
   Gambari, Roberto
BE Diederich, M
TI Induction of apoptosis of osteoclasts by targeting transcription factors
   with decoy molecules
SO SIGNAL TRANSDUCTION PATHWAYS, PT B: STRESS SIGNALING AND TRANSCRIPTIONAL
   CONTROL
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT Cell Signaling World 2006 Conference
CY JAN 25 28, 2006
CL Luxembourg, LUXEMBOURG
DE NF kappa B; estrogen receptor; PNA; gene therapy; transcription;
   osteoclast
ID NF KAPPA B; ACIDS (PNA) DNA CHIMERAS; ESTROGEN RECEPTOR ALPHA;
   CIS ELEMENT DECOY; PNA DNA CHIMERAS; TFD PHARMACOTHERAPY; ORTHODONTIC
   FORCES; PROMOTER REGION; BINDING SITES; RAT TEETH
AB We review the effects of two transcription factor decoy oligonucleotides on apoptosis of human osteoclasts (OCs). The first decoy molecule was designed to inhibit nuclear factor kappa B (NF kappa B) binding to target sequence, the second to increase estrogen receptor (ER) alpha expression. We found that both decoy molecules are potent inducers of apoptosis of human OCs, associated with increase of caspase 3 activity and decrease of interleukin 6 expression. In addition, we provide evidence indicating that these oligonucleotides are active in vivo in inducing OCs apoptosis. Because OCs are essential for skeletal development and remodeling throughout the life of animal and man, the approach described is of potential clinical importance.
C1 Univ Ferrara, Dept Biochem & Mol Biol, Mol Biol Sect, I 44100 Ferrara, Italy.
   Univ Ferrara, ER Gentech, I 44100 Ferrara, Italy.
   Univ Ferrara, Dept Expt & Diagnost Med, Sect Pathol Anat, I 44100 Ferrara, Italy.
C3 University of Ferrara; University of Ferrara; University of Ferrara
RP Gambari, R (通讯作者)，Univ Ferrara, Dept Biochem & Mol Biol, Mol Biol Sect, Via Fossato di Mortara 74, I 44100 Ferrara, Italy.
EM gam@unife.it
RI Lampronti, Ilaria/F 5522 2016; Borgatti, Monica/G 2611 2015; Gambari,
   Roberto/F 9555 2015
OI Lampronti, Ilaria/0000 0002 1972 7766; Borgatti,
   Monica/0000 0001 8470 2496; Piva, Roberta/0000 0003 2663 6210;
   Penolazzi, Letizia/0000 0002 1293 5087; Gambari,
   Roberto/0000 0001 9205 6033
CR Borgatti M, 2004, CURR DRUG TARGETS, V5, P735, DOI 10.2174/1389450043345155
   Borgatti M, 2003, ONCOL RES, V13, P279, DOI 10.3727/096504003108748339
   Borgatti M, 2003, J BIOL CHEM, V278, P7500, DOI 10.1074/jbc.M206780200
   Borgatti M, 2002, BIOCHEM PHARMACOL, V64, P609, DOI 10.1016/S0006 2952(02)01188 7
   Boyce BF, 2005, J BONE MINER METAB, V23, P11, DOI 10.1007/BF03026317
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chaisson ML, 2004, J BIOL CHEM, V279, P54841, DOI 10.1074/jbc.M406392200
   EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0
   Gambari R, 2004, CURR DRUG TARGETS, V5, P419, DOI 10.2174/1389450043345416
   Gambari R, 2004, CURR MED CHEM, V11, P1253, DOI 10.2174/0929867043365242
   KRASSAS GE, 2001, NEUROANAL INTERACT, V2, P143
   Mann MJ, 2000, J CLIN INVEST, V106, P1071, DOI 10.1172/JCI11459
   Mischiati C, 1999, J BIOL CHEM, V274, P33114, DOI 10.1074/jbc.274.46.33114
   Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897 894
   Nielsen P E, 1999, Curr Issues Mol Biol, V1, P89
   NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210
   Nielsen PE, 2004, MOL BIOTECHNOL, V26, P233, DOI 10.1385/MB:26:3:233
   Penolazzi L, 2004, INT J MOL MED, V14, P145
   Penolazzi L, 2003, BIOCHEM PHARMACOL, V66, P1189, DOI 10.1016/S0006 2952(03)00470 2
   Penolazzi L, 2006, INT J MOL MED, V18, P807
   Penolazzi L, 2006, APOPTOSIS, V11, P1653, DOI 10.1007/s10495 006 8763 2
   Piva R, 2005, APOPTOSIS, V10, P1079, DOI 10.1007/s10495 005 0618 8
   Romanelli A, 2001, EUR J BIOCHEM, V268, P6066, DOI 10.1046/j.0014 2956.2001.02549.x
   Syed F, 2005, BIOCHEM BIOPH RES CO, V328, P688, DOI 10.1016/j.bbrc.2004.11.097
   Tomita T, 2000, RHEUMATOLOGY, V39, P749, DOI 10.1093/rheumatology/39.7.749
NR 25
TC 16
Z9 18
U1 0
U2 3
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA
SN 0077 8923
BN 978 1 57331 647 7
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2006
VL 1091
BP 509
EP 516
DI 10.1196/annals.1378.092
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Multidisciplinary
   Sciences
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Science & Technology  
   Other Topics
GA BFZ68
UT WOS:000245661600044
PM 17341640
DA 2025 08 17
ER

PT J
AU Bayat, M
   Jalalifirouzkouhi, A
AF Bayat, Mohammad
   Jalalifirouzkouhi, Ali
TI Presenting a Method to Improve Bone Quality Through Stimulation of
   Osteoporotic Mesenchymal Stem Cells by Low Level Laser Therapy
SO PHOTOMEDICINE AND LASER SURGERY
LA English
DT Article
DE low level laser therapy; osteoporosis; fracture; mesenchymal stem cells;
   regenerative medicine
ID IN VITRO; REGENERATIVE MEDICINE; CLINICAL APPLICATIONS; GROWTH FACTORS;
   PROLIFERATION; DIFFERENTIATION; MARROW; IRRADIATION; BISPHOSPHONATE;
   OSTEOINDUCTION
AB Objective: This review aims to present a method to improve bone quality through stimulation of osteoporotic mesenchymal stem cells (MSCs) by low level laser therapy (LLLT). Background: Osteoporosis (OP) is characterized by decreased bone mass and bone strength, which results in an increased incidence of bone fractures. These fractures often lead to additional disability and mortality. Osteoporotic MSCs have reduced osteogenic differentiation when cultured in their standard differentiation media. LLLT has a biostimulatory effect on fibroblasts and osteoblasts. MSCs have the ability to generate cells of connective tissue lineages, which includes the bones. Recently, transplantation of in vitro cultured bone marrow (BM) MSCs into sites at risk for development of osteoporotic bone has resulted in improved bone structure. Methods: Comprehensive research was performed using PubMed, and biostimulatory effect of LLLT on bony cells and MSCs were studied. Results: LLLT can stimulate growth, proliferation, and differentiation of SCs in vitro and in vivo. This ability of LLLT is an essential prerequisite for performing experiments related to disease control in humans. Thus, laser treated osteoporotic autologous BMMSCs may represent a promising therapeutic method to protect the bones in patients with OP and prevent fractures in these patients. Therefore, researchers hypothesize that transplantation of in vitro laser treated autologous cultured osteoporotic BMMSCs that have the appropriate osteogenic phenotype into sites at risk for development of osteoporotic bone may result in improved bone structure. In this respect, investigators have successfully used LLLT to restore autologous osteoporotic MSCs in vitro. Subsequently, these cells have been differentiated into osteoblast cell lines with the use of laser treatment after which they were transplanted into osteoporotic animal models. Conclusions: This technique might improve bone quality and structure. However, additional research must be undertaken to understand the underlying mechanisms of this treatment, validate its effectiveness, and assess the feasibility for clinical application of LLLT to treat MSCs in regeneration of osteoporotic bone.
C1 [Bayat, Mohammad] Shahid Beheshti Univ Med Sci, Cellular & Mol Biol Res Ctr, POB 19395 4719, Tehran, Iran.
   [Bayat, Mohammad] Shahid Beheshti Univ Med Sci, Biol & Anat Sci Dept, POB 19395 4719, Tehran, Iran.
   [Jalalifirouzkouhi, Ali] Shahid Beheshti Univ Med Sci, Sch Med, Tehran, Iran.
C3 Shahid Beheshti University Medical Sciences; Shahid Beheshti University
   Medical Sciences; Shahid Beheshti University Medical Sciences
RP Bayat, M (通讯作者)，Shahid Beheshti Univ Med Sci, Cellular & Mol Biol Res Ctr, POB 19395 4719, Tehran, Iran.; Bayat, M (通讯作者)，Shahid Beheshti Univ Med Sci, Biol & Anat Sci Dept, POB 19395 4719, Tehran, Iran.
EM mohbayat@sbmu.ac.ir
RI Bayat, Mohammad/AAG 5367 2020
OI bayat, mohammad/0000 0001 5214 4223
CR Abrahamse H, 2012, PHOTOMED LASER SURG, V30, P681, DOI 10.1089/pho.2012.9881
   Abramovitch Gottlib L, 2005, LASER MED SCI, V20, P138, DOI 10.1007/s10103 005 0355 9
   AlGhamdi KM, 2012, LASER MED SCI, V27, P237, DOI 10.1007/s10103 011 0885 2
   Archibald PRT, 2015, REGEN MED, V10, P959, DOI 10.2217/rme.15.59
   Barry FP, 2004, INT J BIOCHEM CELL B, V36, P568, DOI 10.1016/j.biocel.2003.11.001
   Bouvet Gerbettaz S, 2009, LASER SURG MED, V41, P291, DOI 10.1002/lsm.20759
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Choi K, 2013, J BIOMED MATER RES B, V101B, P919, DOI 10.1002/jbm.b.32897
   de Oliveira TS, 2015, LASER MED SCI, V30, P217, DOI 10.1007/s10103 014 1646 9
   Edwards JH, 2015, WORLD J STEM CELLS, V7, P568, DOI 10.4252/wjsc.v7.i3.568
   Fallahnezhad S, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.9.098002
   Fekrazad R, 2015, J PHOTOCH PHOTOBIO B, V151, P180, DOI 10.1016/j.jphotobiol.2015.08.002
   Barboza CAG, 2014, EINSTEIN SAO PAULO, V12, P75, DOI 10.1590/S1679 45082014AO2824
   Ginani F, 2015, LASER MED SCI, V30, P2189, DOI 10.1007/s10103 015 1730 9
   Gomiero C, 2016, VET RES COMMUN, V40, P39, DOI 10.1007/s11259 016 9652 y
   Griffin MD, 2010, HUM GENE THER, V21, P1641, DOI 10.1089/hum.2010.156
   Haasters F, 2014, BIOCHEM BIOPH RES CO, V452, P118, DOI 10.1016/j.bbrc.2014.08.055
   Herberts CA, 2011, J TRANSL MED, V9, DOI 10.1186/1479 5876 9 29
   Hou JF, 2008, LASER SURG MED, V40, P726, DOI 10.1002/lsm.20709
   Hsu YC, 2016, SEMIN CELL DEV BIOL, V52, P119, DOI 10.1016/j.semcdb.2016.02.011
   Huang YY, 2009, DOSE RESPONSE, V7, P358, DOI 10.2203/dose response.09 027.Hamblin
   Jakob F, 2005, INTERNIST, V46, pS24, DOI 10.1007/s00108 005 1417 6
   KARU T, 1989, Journal of Photochemistry and Photobiology B Biology, V3, P638, DOI 10.1016/1011 1344(89)80088 0
   Khajuria DK, 2011, REV BRAS REUMATOL, V51, P365
   Kim H, 2012, J DERMATOL SCI, V68, P149, DOI 10.1016/j.jdermsci.2012.09.013
   Kim HK, 2009, LASER MED SCI, V24, P214, DOI 10.1007/s10103 008 0550 6
   Koh MBC, 2012, BIOLOGICALS, V40, P214, DOI 10.1016/j.biologicals.2011.12.002
   Kushibiki T, 2009, PHOTOMED LASER SURG, V27, P493, DOI 10.1089/pho.2008.2343
   Leonida A, 2013, LASER MED SCI, V28, P125, DOI 10.1007/s10103 012 1067 6
   Li WT, 2010, PHOTOMED LASER SURG, V28, pS157, DOI 10.1089/pho.2009.2540
   Li Y, 2015, MOL THER, V23, P1349, DOI 10.1038/mt.2015.101
   Pino AM, 2012, BIOL RES, V45, P279, DOI 10.4067/S0716 97602012000300009
   Mason C, 2009, REGEN MED, V4, P835, DOI 10.2217/RME.09.64
   Nurkovic J., 2016, Lasers in Medical Science, V32, P151
   Oliveira FA, 2016, J PHOTOCH PHOTOBIO B, V163, P14, DOI 10.1016/j.jphotobiol.2016.08.006
   Parenti SI, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.10.108002
   Peng YL, 2014, OSTEOPOROSIS INT, V25, P1617, DOI 10.1007/s00198 014 2647 z
   Prall WC, 2013, BIOCHEM BIOPH RES CO, V440, P617, DOI 10.1016/j.bbrc.2013.09.114
   Sellmeyer DE, 2010, JAMA J AM MED ASSOC, V304, P1480, DOI 10.1001/jama.2010.1360
   Shen J, 2013, TISSUE ENG PT A, V19, P2390, DOI [10.1089/ten.tea.2012.0519, 10.1089/ten.TEA.2012.0519]
   Shi GX, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030564
   Soleimani M, 2012, LASER MED SCI, V27, P423, DOI 10.1007/s10103 011 0930 1
   Spanou A, 2015, ORAL DIS, V21, P927, DOI 10.1111/odi.12333
   Takeuchi Yasuhiro, 2009, Clin Calcium, V19, P85, DOI CliCa09018590
   Tewari D, 2015, STEM CELL REV REP, V11, P309, DOI 10.1007/s12015 014 9573 5
   Thompson WR, 2014, CURR OPIN ENDOCRINOL, V21, P447, DOI 10.1097/MED.0000000000000111
   Tong W, 2017, TRANSL RES, V181, P49, DOI 10.1016/j.trsl.2016.11.008
   Tuby H, 2011, LASER SURG MED, V43, P401, DOI 10.1002/lsm.21063
   Wang J, 2012, STEM CELLS DEV, V21, P2508, DOI 10.1089/scd.2011.0695
   Wang Z, 2006, TISSUE ENG, V12, P1753, DOI 10.1089/ten.2006.12.1753
   Watts NB, 2003, CLIN GERIATR MED, V19, P395, DOI 10.1016/S0749 0690(02)00069 1
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
   Wu JY, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0044027, 10.1371/journal.pone.0046393]
   Yang CC, 2016, J TISSUE ENG REGEN M, V10, P120, DOI 10.1002/term.1714
NR 54
TC 5
Z9 5
U1 0
U2 12
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1549 5418
EI 1557 8550
J9 PHOTOMED LASER SURG
JI Photomed. Laser Surg.
PD NOV
PY 2017
VL 35
IS 11
SI SI
BP 622
EP 628
DI 10.1089/pho.2016.4245
PG 7
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery
GA FL9RK
UT WOS:000414594700007
PM 28621568
DA 2025 08 17
ER

PT J
AU Heino, TJ
   Chagin, AS
   Takigawa, M
   Sävendahl, L
AF Heino, Terhi J.
   Chagin, Andrei S.
   Takigawa, Masaharu
   Savendahl, Lars
TI Effects of alendronate and pamidronate on cultured rat metatarsal
   bones:: Failure to prevent dexamethasone induced growth retardation
SO BONE
LA English
DT Article
DE bisphosphonates; glucocorticoids; bone growth; chondrocytes;
   proliferation
ID CYCLICAL INTRAVENOUS PAMIDRONATE; OSTEOGENESIS IMPERFECTA; ORAL
   ALENDRONATE; MOUSE MODEL; PLATE CHONDROCYTES; IN VITRO; BISPHOSPHONATES;
   CHILDREN; APOPTOSIS; ADOLESCENTS
AB Bisphosphonates are widely used anti resorptive drugs in the adult population. In children, their use has mainly been limited to patients with osteogenesis imperfecta. However, the powerful effects of bisphosphonates on bone turnover have raised concern about their long term effects on the growing skeleton.
   We aimed to study the effects of two commonly used bisphosphonates, alendronate (Aln) and pamidronate (Pam) on normal bone growth as well as their potential to prevent glucocorticoid induced growth retardation.
   Effects on bone growth were studied in fetal rat metatarsal bones (day E20) that were cultured for 5 47 days and measured every 2 7 days. Cellular mechanisms were investigated in metatarsal bones and also in the human chondrocytic cell line HCS 2/8. Chondrocyte viability (WST 1), proliferation (BrdU incorporation), differentiation (collagen type X immunohistochemistry) and apoptosis (TUNEL and Cell Death ELISA) were determined.
   At a clinically relevant concentration of bisphosphonates (1 mu M), metatarsal bone growth was stimulated by both Aln (p<0.001 for length and p < 0.05 for width) and Pam (p < 0.05 for both length and width) from day 19 of culture. The growth stimulatory effect was associated with increased chondrocyte proliferation (+21% with Aln and +24% with Pam), while cell differentiation and apoptosis were not affected. Despite the finding that both Aln and Pam (1 mu M) rescued HCS 2/8 cells from undergoing dexamethasone induced apoptosis, neither of them was able to prevent dexamethasone induced growth retardation of fetal rat metatarsal bones.
   Aln and Pam have the capacity to stimulate the growth of cultured fetal rat metatarsal bones; an effect associated with increased proliferation of growth plate chondrocytes. Our experimental data suggest that bisphosphonates are ineffective in preventing glucocorticoid induced growth retardation. Nevertheless, based on our in vitro data, both Aln and Pam appear safe to use in growing children, at least with regard to their effects on linear bone growth. (c) 2008 Elsevier Inc. All rights reserved.
C1 [Heino, Terhi J.; Chagin, Andrei S.; Savendahl, Lars] Karolinska Inst, Dept Woman & Child Hlth, Pediat Endocrinol Unit, Stockholm, Sweden.
   [Takigawa, Masaharu] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Biochem & Mol Dent, Okayama, Japan.
C3 Karolinska Institutet; Okayama University
RP Sävendahl, L (通讯作者)，Astrid Lindgren Childrens Hosp, Karolinska Inst, Q2 08, SE 17176 Stockholm, Sweden.
EM terhij.heino@utu.fi
RI ; Chagin, Andrei/F 4080 2014; Heino, Terhi/H 6866 2012
OI Heino, Terhi/0000 0003 2274 6834; Chagin, Andrei/0000 0002 2696 5850;
   Savendahl, Lars/0000 0003 1067 4976
CR Acott PD, 2005, PEDIATR NEPHROL, V20, P368, DOI 10.1007/s00467 004 1790 8
   Allen DB, 1996, ENDOCRIN METAB CLIN, V25, P699, DOI 10.1016/S0889 8529(05)70348 0
   Amin S, 2002, J BONE MINER RES, V17, P1512, DOI 10.1359/jbmr.2002.17.8.1512
   Bianchi ML, 2000, ARTHRITIS RHEUM US, V43, P1960, DOI 10.1002/1529 0131(200009)43:9<1960::AID ANR6>3.0.CO;2 J
   Brumsen C, 1997, MEDICINE, V76, P266, DOI 10.1097/00005792 199707000 00005
   Camacho NP, 2001, CALCIFIED TISSUE INT, V69, P94, DOI 10.1007/s002230010045
   Chagin AS, 2007, BONE, V40, P1415, DOI 10.1016/j.bone.2006.12.066
   Chagin AS, 2006, J ENDOCRINOL, V188, P193, DOI 10.1677/joe.1.06364
   Chrysis D, 2005, ENDOCRINOLOGY, V146, P1391, DOI 10.1210/en.2004 1152
   Chrysis D, 2003, J ENDOCRINOL, V176, P331, DOI 10.1677/joe.0.1760331
   De Luca F, 2001, ENDOCRINOLOGY, V142, P430, DOI 10.1210/en.142.1.430
   DiMeglio LA, 2006, J BONE MINER RES, V21, P132, DOI 10.1359/JBMR.051006
   Evans KD, 2003, BONE, V32, P268, DOI 10.1016/S8756 3282(02)00974 2
   Glorieux FH, 2000, J PEDIATR ENDOCR MET, V13, P989
   Heikkilä P, 2002, ANTI CANCER DRUG, V13, P245, DOI 10.1097/00001813 200203000 00006
   Itoh F, 2003, EUR J PHARMACOL, V477, P9, DOI 10.1016/j.ejphar.2003.08.011
   Land C, 2006, J BONE MINER RES, V21, P374, DOI 10.1359/JBMR.051207
   Land C, 2006, BONE, V39, P901, DOI 10.1016/j.bone.2006.04.004
   LOWIK CWGM, 1988, J BONE MINER RES, V3, P185
   Mansfield K, 2001, BONE, V28, P1, DOI 10.1016/S8756 3282(00)00409 9
   Mårtensson K, 2004, J BONE MINER RES, V19, P1805, DOI 10.1359/JBMR.040805
   McCarthy EA, 2002, PEDIATR RES, V52, P660, DOI 10.1203/01.PDR.0000032068.76811.0D
   Picherit C, 2000, BIOL NEONATE, V77, P181, DOI 10.1159/000014214
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2005, J BIOL CHEM, V280, P7317, DOI 10.1074/jbc.M412817200
   Plotkin LI, 2006, BONE, V39, P443, DOI 10.1016/j.bone.2006.02.060
   Rauch F, 2006, J CLIN ENDOCR METAB, V91, P1268, DOI 10.1210/jc.2005 2413
   Rauch F, 2007, BONE, V40, P821, DOI 10.1016/j.bone.2006.11.020
   Rodan GA, 1998, ANNU REV PHARMACOL, V38, P375, DOI 10.1146/annurev.pharmtox.38.1.375
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Rudge S, 2005, RHEUMATOLOGY, V44, P813, DOI 10.1093/rheumatology/keh538
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   Seikaly MG, 2005, J PEDIATR ORTHOPED, V25, P786, DOI 10.1097/01.bpo.0000176162.78980.ed
   TAKIGAWA M, 1989, CANCER RES, V49, P3996
   Twiss IM, 1999, J BONE MINER RES, V14, P784, DOI 10.1359/jbmr.1999.14.5.784
   Unal E, 2006, J PEDIATR ENDOCR MET, V19, P523
   Vaisman DN, 2005, BIOL TRACE ELEM RES, V104, P131, DOI 10.1385/BTER:104:2:131
   Van Offel JF, 2002, ANN RHEUM DIS, V61, P925, DOI 10.1136/ard.61.10.925
   Waterhouse KM, 2007, PEDIATR NEPHROL, V22, P282, DOI 10.1007/s00467 006 0306 0d
   Widler L, 2002, J MED CHEM, V45, P3721, DOI 10.1021/jm020819i
   Wiernikowski J T, 2005, J Oncol Pharm Pract, V11, P51, DOI 10.1191/1078155205jp145oa
   Wu SF, 2004, FASEB J, V18, P143, DOI 10.1096/fj.03 0294fje
   Zeitlin L, 2003, PEDIATRICS, V111, P1030, DOI 10.1542/peds.111.5.1030
NR 43
TC 16
Z9 18
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD APR
PY 2008
VL 42
IS 4
BP 702
EP 709
DI 10.1016/j.bone.2008.01.001
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 283NQ
UT WOS:000254643500011
PM 18276203
DA 2025 08 17
ER

PT J
AU Ghorab, MM
   Alsaisd, MS
   Nissan, YM
AF Ghorab, Mostafa M.
   Alsaisd, Mansour S.
   Nissan, Yassin M.
TI NOVEL PYRROLOPYRIMIDINES AND TRIAZOLOPYRROLOPYRIMIDINES CARRYING A
   BIOLOGICALLY ACTIVE SULFONAMIDE MOIETIES AS ANTICANCER AGENTS
SO ACTA POLONIAE PHARMACEUTICA
LA English
DT Article
DE anticancer; pyrrolopyrimidines; triazolopyrrolopyrimidines; sulfonamides
ID BONE RESORPTION; IN VITRO; C SRC; INHIBITORS; ANTITUMOR; DERIVATIVES;
   PYRIMIDINES; OSTEOCLAST; PYRROLE; TRANCE
AB A new series of pyrroles 5, 6, pyrrolopyrimidines 8, 11 14, 16 29, triazolo pyrrolopyrimidines 9, 10 and 15 carrying a biologically active sulfonamide moities wee synthesized using 2 amino 3 cyano 4 (4 bromophenyl)pyrrole 5 as a strategic starting material. The structures of the prepared compounds were confirmed by elemental analyses, IR, H 1 NMR and C 13 NMR data. All of the synthesized compounds showed promising anticancer activity against breast cancer cell line (MCF7) compared to doxorubicin as reference drug, especially compounds 5 17, 21 24 and 28 with better IC50 than that of doxorubicin. In order to suggest the mechanism of action of their cytotoxic activities, molecular docking on the active site of c Src was done and good results were obtained.
C1 [Ghorab, Mostafa M.; Alsaisd, Mansour S.] King Saud Univ, Coll Pharm, Dept Pharmacognosy, Riyadh 11451, Saudi Arabia.
   [Nissan, Yassin M.] Cairo Univ, Fac Pharm, Dept Pharmaceut Chem, Cairo, Egypt.
C3 King Saud University; Egyptian Knowledge Bank (EKB); Cairo University
RP Ghorab, MM (通讯作者)，King Saud Univ, Coll Pharm, Dept Pharmacognosy, POB 2457, Riyadh 11451, Saudi Arabia.
EM mmsghorab@gmail.com
RI Nissan, Yassin/L 1204 2017
OI Nissan, Yassin/0000 0002 6470 3392
FU Deanship of Scientific Research at King Saud University [RGP VPP 302]
FX The authors would like to extend their sincere appreciation to the
   Deanship of Scientific Research at King Saud University for its funding
   of this research through the Research Group Project no. RGP VPP 302.
CR Azas Nadine, 2003, Farmaco (Lausanne), V58, P1263, DOI 10.1016/j.farmac.2003.07.009
   Blake JF, 2010, BIOORG MED CHEM LETT, V20, P5607, DOI 10.1016/j.bmcl.2010.08.053
   Casini A, 2002, CURR CANCER DRUG TAR, V2, P55, DOI 10.2174/1568009023334060
   Deshmukh MB, 2009, EUR J MED CHEM, V44, P2651, DOI 10.1016/j.ejmech.2008.10.018
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   El Ella DAA, 2008, BIOORGAN MED CHEM, V16, P2391, DOI 10.1016/j.bmc.2007.11.072
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   Gholap AR, 2008, TETRAHEDRON, V64, P10214, DOI 10.1016/j.tet.2008.08.033
   Ghorab M., 2007, PHOSPHORUS SULFUR, V183, P1
   Ghorab MM, 2010, BIOORG MED CHEM LETT, V20, P6316, DOI 10.1016/j.bmcl.2010.08.005
   Ghorab MM, 2006, ARZNEIMITTELFORSCH, V56, P405
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Ismail MMF, 2006, ARZNEIMITTEL FORSCH, V56, P301
   Kawakita Y, 2012, BIOORGAN MED CHEM, V20, P6171, DOI 10.1016/j.bmc.2012.08.002
   Missbach M, 2000, BIOORG MED CHEM LETT, V10, P945, DOI 10.1016/S0960 894X(00)00131 1
   Missbach M, 1999, BONE, V24, P437, DOI 10.1016/S8756 3282(99)00020 4
   Mohamed MS, 2009, ACTA PHARMACEUT, V59, P145, DOI 10.2478/v10007 009 0016 9
   Owa T, 1999, J MED CHEM, V42, P3789, DOI 10.1021/jm9902638
   Recchi I, 2003, EUR J CANCER, V39, P1927, DOI 10.1016/S0959 8049(03)00394 0
   Rostom SAF, 2006, BIOORGAN MED CHEM, V14, P6475, DOI 10.1016/j.bmc.2006.06.020
   Said SA, 2009, EUR J MED CHEM, V44, P4787, DOI 10.1016/j.ejmech.2009.07.013
   Shih C, 1998, ADV ENZYME REGUL, V38, P135, DOI 10.1016/S0065 2571(97)00017 4
   SKEHAN P, 1990, JNCI J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   Susa M, 2000, PROTEIN EXPRES PURIF, V19, P99, DOI 10.1006/prep.2000.1221
   Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513
   Wong BR, 1999, J LEUKOCYTE BIOL, V65, P715, DOI 10.1002/jlb.65.6.715
NR 26
TC 4
Z9 4
U1 0
U2 6
PU POLSKIE TOWARZYSTWO FARMACEUTYCZNE
PI WARSAW
PA DLUGA 16, 00 238 WARSAW, POLAND
SN 0001 6837
EI 2353 5288
J9 ACTA POL PHARM
JI ACTA POL. PHARM.
PD JAN FEB
PY 2015
VL 72
IS 1
BP 65
EP 78
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA CC2RJ
UT WOS:000350192000008
PM 25850202
DA 2025 08 17
ER

PT J
AU Liu, XD
   Zheng, J
   Song, S
   Chen, ZJ
   Wang, YX
   Zhang, SJ
   Zhang, GH
   Lu, Q
   Song, YL
AF Liu, Xiang Dong
   Zheng, Jian
   Song, Shuang
   Chen, Zi Jun
   Wang, Yu Xi
   Zhang, Si Jia
   Zhang, Guan Hua
   Lu, Qun
   Song, Ying Liang
TI TRAF6 promotes osteogenesis in ADSCs through Raf Erk Merk Hif1 a pathway
SO ADIPOCYTE
LA English
DT Article
DE ADSCs; TRAF6; Hif1a; Osteogenesis
ID ADIPOSE TISSUE; STEM CELLS; INDUCED OSTEOCLASTOGENESIS; BONE;
   DIFFERENTIATION; PROLIFERATION; REPAIR; RANK; RATS
AB Critical size defects (CSDs) are challenging oral clinical issues that need to be solved. Adipose derived mesenchymal stem cells (ADSCs) and gene therapy offer a new target to solve these issues. Consequently, ADSCs attract more and more attention because of advantages such as easy obtainability and no ethical concerns. TNF receptor associated factor 6 (TRAF6) is a significant binding protein both of tumour necrosis factor superfamily and of the toll/interleukin 1 receptor superfamily. Evidence is accumulating that TRAF6 inhibited osteoclast formation and promoted the proliferation of multiple myeloma cell lines and bone resorption. Here, we reported that overexpression of TRAF6 enhanced the proliferation, migration and osteogenesis of ADSCs through Raf Erk Merk Hif1a pathway. Cell sheet of ADSCs combined with TRAF6 accelerated the healing of CSDs. In a word, TRAF6 enhanced osteogenesis, migration and proliferation through Raf Erk Merk Hif1a pathway.
C1 [Liu, Xiang Dong; Zheng, Jian; Chen, Zi Jun; Wang, Yu Xi; Zhang, Si Jia; Zhang, Guan Hua; Song, Ying Liang] Fourth Mil Med Univ, State Key Lab Mil Stomatol, Sch Stomatol, Dept Implant Dent, Xian, Peoples R China.
   [Liu, Xiang Dong; Zheng, Jian; Chen, Zi Jun; Wang, Yu Xi; Zhang, Si Jia; Zhang, Guan Hua; Song, Ying Liang] Fourth Mil Med Univ, Natl Clin Res Ctr Oral Dis, Sch Stomatol, Xian, Peoples R China.
   [Liu, Xiang Dong; Zheng, Jian; Chen, Zi Jun; Wang, Yu Xi; Zhang, Si Jia; Zhang, Guan Hua; Song, Ying Liang] Fourth Mil Med Univ, Shaanxi Engn Res Ctr Dent Mat & Adv Manufacture, Sch Stomatol, Xian, Peoples R China.
   [Song, Shuang] Xi An Jiao Tong Univ, Coll Stomatol, Dept Implant Dent, Xian, Peoples R China.
   [Lu, Qun] Fourth Mil Med Univ, State Key Lab Mil Stomatol, Sch Stomatol, Dept Operat Dent & Endodont, Xian, Peoples R China.
   [Lu, Qun] Fourth Mil Med Univ, Natl Clin Res Ctr Oral Dis, Sch Stomatol, Xian, Peoples R China.
   [Lu, Qun] Fourth Mil Med Univ, Sch Stomatol, Dept Operat Dent & Endodont, Shaanxi Key Lab Oral Dis, Xian, Peoples R China.
   [Lu, Qun] Fourth Mil Med Univ, State Key Lab Mil Stomatol, Sch Stomatol, Dept Operat Dent & Endodont, 169, Xian 710032, Shaanxi, Peoples R China.
   [Lu, Qun] Fourth Mil Med Univ, Natl Clin Res Ctr Oral Dis, Sch Stomatol, 169, Xian 710032, Shaanxi, Peoples R China.
   [Lu, Qun] Fourth Mil Med Univ, Sch Stomatol, Dept Operat Dent & Endodont, Shaanxi Key Lab Oral Dis, 169, Xian 710032, Shaanxi, Peoples R China.
   [Song, Ying Liang] Air Force Med Univ AFMU, Mil Med Univ 4, State Key Lab Mil Stomatol, Dept Implant Dent, 169 Changle West Rd, Xian, Shaanxi, Peoples R China.
   [Song, Ying Liang] Air Force Med Univ AFMU, Mil Med Univ 4, Natl Clin Res Ctr Oral Dis, Sch Stomatol, 169 Changle West Rd, Xian, Shaanxi, Peoples R China.
   [Song, Ying Liang] Air Force Med Univ AFMU, Mil Med Univ 4, Shaanxi Engn Res Ctr Dent Mat & Adv Manufacture, Sch Stomatol, 169 Changle West Rd, Xian, Shaanxi, Peoples R China.
C3 Air Force Medical University; Air Force Medical University; Air Force
   Medical University; Xi'an Jiaotong University; Air Force Medical
   University; Air Force Medical University; Air Force Medical University;
   Air Force Medical University; Air Force Medical University; Air Force
   Medical University; Air Force Medical University; Air Force Medical
   University; Air Force Medical University
RP Lu, Q (通讯作者)，Fourth Mil Med Univ, State Key Lab Mil Stomatol, Sch Stomatol, Dept Operat Dent & Endodont, 169, Xian 710032, Shaanxi, Peoples R China.; Lu, Q (通讯作者)，Fourth Mil Med Univ, Natl Clin Res Ctr Oral Dis, Sch Stomatol, 169, Xian 710032, Shaanxi, Peoples R China.; Lu, Q (通讯作者)，Fourth Mil Med Univ, Sch Stomatol, Dept Operat Dent & Endodont, Shaanxi Key Lab Oral Dis, 169, Xian 710032, Shaanxi, Peoples R China.; Song, YL (通讯作者)，Air Force Med Univ AFMU, Mil Med Univ 4, State Key Lab Mil Stomatol, Dept Implant Dent, 169 Changle West Rd, Xian, Shaanxi, Peoples R China.; Song, YL (通讯作者)，Air Force Med Univ AFMU, Mil Med Univ 4, Natl Clin Res Ctr Oral Dis, Sch Stomatol, 169 Changle West Rd, Xian, Shaanxi, Peoples R China.; Song, YL (通讯作者)，Air Force Med Univ AFMU, Mil Med Univ 4, Shaanxi Engn Res Ctr Dent Mat & Adv Manufacture, Sch Stomatol, 169 Changle West Rd, Xian, Shaanxi, Peoples R China.
EM luqun22@hotmail.com; songyingliang@163.com
RI Wang, Yuxi/AAL 8943 2020
FU National Natural Science Foundation of China [82170991]
FX This work was supported by the National Natural Science Foundation of
   China (82170991).
CR Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609
   Bacakova L, 2018, BIOTECHNOL ADV, V36, P1111, DOI 10.1016/j.biotechadv.2018.03.011
   Bartold M, 2019, J CLIN PERIODONTOL, V46, P12, DOI 10.1111/jcpe.13053
   Chen HM, 2017, MOL CANCER RES, V15, P598, DOI 10.1158/1541 7786.MCR 16 0293
   Darnay BG, 2007, ADV EXP MED BIOL, V597, P152
   Dou Y, 2018, CURR NEUROPHARMACOL, V16, P1306, DOI 10.2174/1570159X16666180412094655
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Georg I, 2020, CELL MOL IMMUNOL, V17, P954, DOI 10.1038/s41423 019 0254 9
   Harasymiak Krzyzanowska I, 2013, CELL MOL BIOL LETT, V18, P479, DOI 10.2478/s11658 013 0101 4
   He LG, 2016, EUR J PHARMACOL, V779, P66, DOI 10.1016/j.ejphar.2016.03.014
   Huang HM, 2017, ONCOL LETT, V14, P1464, DOI 10.3892/ol.2017.6322
   Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745
   Li KC, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 16547 3
   Li Y, 2020, MOL CELL ENDOCRINOL, V515, DOI 10.1016/j.mce.2020.110921
   Liang LH, 2014, J PERIODONTOL, V85, P601, DOI 10.1902/jop.2013.120652
   Liu XD, 2019, IN VITRO CELL DEV AN, V55, P189, DOI 10.1007/s11626 019 00318 7
   Lo SC, 2017, BIOMATERIALS, V124, P1, DOI 10.1016/j.biomaterials.2017.01.033
   Mazini L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102523
   Merceron C, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0045 z
   Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365 2443.1999.00265.x
   Pereira DD, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.554565
   Rada T, 2009, TISSUE ENG PART B RE, V15, P113, DOI 10.1089/ten.teb.2008.0423
   Raphael Mizrahi B, 2020, CURR OSTEOPOROS REP, V18, P433, DOI 10.1007/s11914 020 00607 1
   Sivaraj KK, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109352
   Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753
   Tsukasaki M, 2021, J BONE MINER METAB, V39, P82, DOI 10.1007/s00774 020 01165 3
   Vajgel A, 2014, CLIN ORAL IMPLAN RES, V25, P879, DOI 10.1111/clr.12194
   Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641
   Walsh MC, 2015, IMMUNOL REV, V266, P72, DOI 10.1111/imr.12302
   Walsh MC, 2003, CYTOKINE GROWTH F R, V14, P251, DOI 10.1016/S1359 6101(03)00027 3
   Wang K, 2018, BONE, V114, P257, DOI 10.1016/j.bone.2018.06.015
   Wang L, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/5245294
   Wikesjö UME, 2006, J CLIN PERIODONTOL, V33, P846, DOI 10.1111/j.1600 051X.2006.00985.x
   WIKESJO UME, 1991, J CLIN PERIODONTOL, V18, P49, DOI 10.1111/j.1600 051X.1991.tb01119.x
   Xu WN, 2020, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00922
   Xu XR, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/2506463
   Xue K, 2021, ADIPOCYTE, V10, P322, DOI 10.1080/21623945.2021.1945210
   Ye F, 2017, MOL MED REP, V16, P6228, DOI 10.3892/mmr.2017.7338
   Zakrzewski W, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1165 5
   Zhang DD, 2021, CELL DEATH DIFFER, V28, P283, DOI 10.1038/s41418 020 0600 6
   Zhang SP, 2018, BIOMATERIALS, V156, P16, DOI 10.1016/j.biomaterials.2017.11.028
   Zhang Y, 2010, ONCOGENE, V29, P5404, DOI 10.1038/onc.2010.270
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 43
TC 7
Z9 7
U1 0
U2 11
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2162 3945
EI 2162 397X
J9 ADIPOCYTE
JI Adipocyte
PD DEC 31
PY 2023
VL 12
IS 1
AR 2193280
DI 10.1080/21623945.2023.2193280
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA C5BA0
UT WOS:000962053400001
PM 37005742
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Moller, AMJ
   Delaissé, JM
   Olesen, JB
   Canto, LM
   Rogatto, SR
   Madsen, JS
   Soe, K
AF Moller, Anais M. J.
   Delaisse, Jean Marie
   Olesen, Jacob B.
   Canto, Luisa M.
   Rogatto, Silvia R.
   Madsen, Jonna S.
   Soe, Kent
TI Fusion Potential of Human Osteoclasts In Vitro Reflects Age, Menopause,
   and In Vivo Bone Resorption Levels of Their Donors A Possible
   Involvement of DC STAMP
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE osteoclast; multinucleation; osteoclastogenesis; cell fusion; DC STAMP;
   CTX; aging; menopause; DNA methylation; epigenetics
ID HORMONE REPLACEMENT THERAPY; DNA METHYLATION; PAGETS DISEASE; REFERENCE
   INTERVALS; TURNOVER MARKERS; WIDE ASSOCIATION; RANKL; BLOOD;
   PREMENOPAUSAL; OSTEOPOROSIS
AB It is well established that multinucleation is central for osteoclastic bone resorption. However, our knowledge on the mechanisms regulating how many nuclei an osteoclast will have is limited. The objective of this study was to investigate donor related variations in the fusion potential of in vitro generated osteoclasts. Therefore, CD14(+)monocytes were isolated from 49 healthy female donors. Donor demographics were compared to the in vivo bone biomarker levels and their monocytes' ability to differentiate into osteoclasts, showing that: (1) C terminal telopeptide of type I collagen (CTX) and procollagen type I N terminal propeptide (PINP) levels increase with age, (2) the number of nuclei per osteoclast in vitro increases with age, and (3) there is a positive correlation between the number of nuclei per osteoclast in vitro and CTX levels in vivo. Furthermore, the expression levels of the gene encoding dendritic cell specific transmembrane protein (DCSTAMP) of osteoclasts in vitro correlated positively with the number of nuclei per osteoclast, CTX levels in vivo, and donor age. Our results furthermore suggest that these changes in gene expression may be mediated through age related changes in DNA methylation levels. We conclude that both intrinsic factors and age induced increase in fusion potential of osteoclasts could be contributing factors for the enhanced bone resorption in vivo, possibly caused by increased expression levels ofDCSTAMP.
C1 [Moller, Anais M. J.; Delaisse, Jean Marie; Olesen, Jacob B.; Soe, Kent] Univ Hosp Southern Denmark, Lillebaelt Hosp, Clin Cell Biol, DK 7100 Vejle, Denmark.
   [Moller, Anais M. J.; Delaisse, Jean Marie; Rogatto, Silvia R.; Madsen, Jonna S.; Soe, Kent] Univ Southern Denmark, Dept Reg Hlth Res, DK 5230 Odense M, Denmark.
   [Moller, Anais M. J.; Madsen, Jonna S.] Univ Hosp Southern Denmark, Lillebaelt Hosp, Dept Clin Biochem & Immunol, DK 7100 Vejle, Denmark.
   [Delaisse, Jean Marie; Olesen, Jacob B.; Soe, Kent] Odense Univ Hosp, Dept Pathol, Clin Cell Biol, DK 5000 Odense C, Denmark.
   [Delaisse, Jean Marie; Soe, Kent] Univ Southern Denmark, Dept Clin Res, DK 5230 Odense M, Denmark.
   [Delaisse, Jean Marie; Soe, Kent] Univ Southern Denmark, Dept Mol Med, DK 5230 Odense M, Denmark.
   [Canto, Luisa M.; Rogatto, Silvia R.] Univ Hosp Southern Denmark, Lillebaelt Hosp, Dept Clin Genet, DK 7100 Vejle, Denmark.
   [Soe, Kent] Odense Univ Hosp, Odense Patient Data Explorat Network, OPEN, DK 5000 Odense C, Denmark.
C3 University of Southern Denmark; Lillebaelt Hospital; University of
   Southern Denmark; University of Southern Denmark; Lillebaelt Hospital;
   University of Southern Denmark; Odense University Hospital; University
   of Southern Denmark; University of Southern Denmark; University of
   Southern Denmark; Lillebaelt Hospital; University of Southern Denmark;
   Odense University Hospital
RP Moller, AMJ; Soe, K (通讯作者)，Univ Hosp Southern Denmark, Lillebaelt Hosp, Clin Cell Biol, DK 7100 Vejle, Denmark.; Moller, AMJ; Soe, K (通讯作者)，Univ Southern Denmark, Dept Reg Hlth Res, DK 5230 Odense M, Denmark.; Moller, AMJ (通讯作者)，Univ Hosp Southern Denmark, Lillebaelt Hosp, Dept Clin Biochem & Immunol, DK 7100 Vejle, Denmark.; Soe, K (通讯作者)，Odense Univ Hosp, Dept Pathol, Clin Cell Biol, DK 5000 Odense C, Denmark.; Soe, K (通讯作者)，Univ Southern Denmark, Dept Clin Res, DK 5230 Odense M, Denmark.; Soe, K (通讯作者)，Univ Southern Denmark, Dept Mol Med, DK 5230 Odense M, Denmark.; Soe, K (通讯作者)，Odense Univ Hosp, Odense Patient Data Explorat Network, OPEN, DK 5000 Odense C, Denmark.
EM anais.marie.moeller@gmail.com; Jean Marie.Delaisse@rsyd.dk;
   Jacob.Bastholm.Olesen@rsyd.dk; Luisa.Matos.Do.Canto.Alvim@rsyd.dk;
   silvia.regina.rogatto@rsyd.dk; Jonna.Skov.Madsen@rsyd.dk;
   kent.soee@rsyd.dk
RI Madsen, Jonna/AAF 7054 2019; Rogatto, Silvia/E 6535 2012; Matos do
   Canto, Luisa/M 6142 2013; Madsen, Jonna Skov/AAF 7054 2019; Soe,
   Kent/N 3618 2017
OI Delaisse, Jean Marie/0000 0001 7370 1500; Matos do Canto,
   Luisa/0000 0001 9095 9431; Madsen, Jonna Skov/0000 0001 6668 4714;
   Moller, Anais Marie Julie/0000 0001 7942 2780; Soe,
   Kent/0000 0001 7402 314X; Rogatto, Silvia/0000 0003 4637 5687
FU Research Council of Lillebaelt Hospital; Region of Southern Denmark
   [15/24819]; Institute of Regional Health Research, University of
   Southern Denmark; Aase & Ejnar Danielsen foundation [10 001835]; Fru
   Astrid Thaysens foundation [ATL 16/02]
FX This research was funded by: the Research Council of Lillebaelt
   Hospital; the Region of Southern Denmark, grant number 15/24819; The
   Institute of Regional Health Research, University of Southern Denmark;
   the Aase & Ejnar Danielsen foundation, grant number 10 001835; and the
   Fru Astrid Thaysens foundation, grant number ATL 16/02.
CR ADDISON WC, 1980, J ANAT, V130, P479
   Albagha OME, 2011, NAT GENET, V43, P685, DOI 10.1038/ng.845
   Appelman Dijkstra NM, 2018, BEST PRACT RES CL EN, V32, P657, DOI 10.1016/j.beem.2018.05.005
   Ardawi MSM, 2010, BONE, V47, P804, DOI 10.1016/j.bone.2010.07.017
   Bahl A, 2015, TWIN RES HUM GENET, V18, P647, DOI 10.1017/thg.2015.82
   Baird J, 2011, OSTEOPOROSIS INT, V22, P1323, DOI 10.1007/s00198 010 1344 9
   Boissy P, 2002, ENDOCRINOLOGY, V143, P1913, DOI 10.1210/en.143.5.1913
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cao J, 2003, J BONE MINER RES, V18, P270, DOI 10.1359/jbmr.2003.18.2.270
   Cao JJ, 2005, J BONE MINER RES, V20, P1659, DOI 10.1359/JBMR.050503
   Chin KY, 2018, INT J MED SCI, V15, P1373, DOI 10.7150/ijms.26571
   Chiu YH, 2012, J BONE MINER RES, V27, P79, DOI 10.1002/jbmr.531
   Chung PL, 2014, J CELL BIOCHEM, V115, P1412, DOI 10.1002/jcb.24792
   Coleman R, 2014, LANCET ONCOL, V15, P997, DOI 10.1016/S1470 2045(14)70302 X
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cundy T, 2018, METABOLISM, V80, P5, DOI 10.1016/j.metabol.2017.06.010
   Eastell R, 2008, P NUTR SOC, V67, P157, DOI 10.1017/S002966510800699X
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Garnero P, 1996, J BONE MINER RES, V11, P337, DOI 10.1002/jbmr.5650110307
   Ghayor C, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091446
   Glover SJ, 2009, J BONE MINER RES, V24, P389, DOI 10.1359/JBMR.080703
   Guo Y, 2016, SCI REP UK, V6, DOI 10.1038/srep30558
   Hobolt Pedersen AS, 2014, CALCIFIED TISSUE INT, V95, P73, DOI 10.1007/s00223 014 9864 5
   Jenkins N, 2013, BONE, V55, P271, DOI 10.1016/j.bone.2013.04.003
   Jevon M, 2002, J ENDOCRINOL, V172, P673, DOI 10.1677/joe.0.1720673
   JONES SJ, 1986, ANAT EMBRYOL, V174, P265, DOI 10.1007/BF00824342
   Jorgensen NR, 2017, OSTEOPOROSIS INT, V28, P2103, DOI 10.1007/s00198 017 4026 z
   Katsimbri P, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12740
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   Kukita T, 2004, J EXP MED, V200, P941, DOI 10.1084/jem.20040518
   KUSHIDA K, 1995, J CLIN ENDOCR METAB, V80, P2447, DOI 10.1210/jc.80.8.2447
   Laurier E, 2017, BMC MED GENET, V18, DOI 10.1186/s12881 017 0495 3
   Levaot N, 2015, BONE, V79, P21, DOI 10.1016/j.bone.2015.05.021
   Li M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103841
   Mensah KA, 2010, J CELL PHYSIOL, V223, P76, DOI 10.1002/jcp.22012
   Michelsen J, 2013, BONE, V57, P399, DOI 10.1016/j.bone.2013.09.010
   Moller AMJ, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 31159 1
   Moller AMJ, 2020, BONE RES, V8, DOI 10.1038/s41413 020 0102 7
   Moller AMJ, 2017, J CELL PHYSIOL, V232, P1396, DOI 10.1002/jcp.25633
   Morris JA, 2017, J BONE MINER RES, V32, P1644, DOI 10.1002/jbmr.3148
   Mouritzen U, 2003, ANN RHEUM DIS, V62, P332, DOI 10.1136/ard.62.4.332
   Mullin BH, 2019, SCI REP UK, V9, DOI 10.1038/s41598 018 37609 0
   Mundy G.R., 1995, BONE REMODELLING ITS, P12
   Pal S, 2016, SCI ADV, V2, DOI [10.1126/sciadv.1600584, 10.1016/j.exger.2009.12.007]
   PARFITT AM, 1983, J CLIN INVEST, V72, P1396, DOI 10.1172/JCI111096
   PIPER K, 1992, ANAT EMBRYOL, V186, P291
   Pivetta E, 2015, ONCOTARGET, V6, P31889, DOI 10.18632/oncotarget.5575
   Randolph JF, 2011, J CLIN ENDOCR METAB, V96, P746, DOI 10.1210/jc.2010 1746
   Ravn P, 1996, BONE, V19, P291, DOI 10.1016/8756 3282(96)00201 3
   Reppe S, 2017, EPIGENETICS US, V12, P674, DOI 10.1080/15592294.2017.1345832
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Riggs BL, 2000, J CLIN INVEST, V106, P1203, DOI 10.1172/JCI11468
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Roodman GD, 1996, BONE, V19, P209, DOI 10.1016/8756 3282(96)00211 6
   Sadeghi HM, 1999, EXP GERONTOL, V34, P959, DOI 10.1016/S0531 5565(99)00065 0
   Salamanna F, 2015, AGE, V37, DOI 10.1007/s11357 015 9819 4
   Seidler S, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471 2172 11 30
   Soe K, 2021, SEMIN CELL DEV BIOL, V112, P8, DOI 10.1016/j.semcdb.2020.05.016
   Soe K, 2015, BONE, V73, P181, DOI 10.1016/j.bone.2014.12.010
   Soe K, 2011, BONE, V48, P837, DOI 10.1016/j.bone.2010.11.011
   Soe K, 2010, J BONE MINER RES, V25, P2184, DOI 10.1002/jbmr.113
   Wang J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134986
   WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828
   Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190
   Wood CL, 2015, CURR GENOMICS, V16, P411, DOI 10.2174/1389202916666150817202217
   Xing LP, 2012, WORLD J ORTHOP, V3, P212, DOI 10.5312/wjo.v3.i12.212
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yagi M, 2006, J BONE MINER METAB, V24, P355, DOI 10.1007/s00774 006 0697 9
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zampieri M, 2015, MECH AGEING DEV, V151, P60, DOI 10.1016/j.mad.2015.02.002
   Zhang CC, 2014, J CELL PHYSIOL, V229, P1330, DOI 10.1002/jcp.24553
NR 71
TC 25
Z9 28
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD SEP
PY 2020
VL 21
IS 17
AR 6368
DI 10.3390/ijms21176368
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA NP1XE
UT WOS:000569973200001
PM 32887359
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Hawley, CM
   Holt, SG
AF Hawley, Carmel M.
   Holt, Stephen G.
TI Parathyroid hormone targets in chronic kidney disease and managing
   severe hyperparathyroidism
SO NEPHROLOGY
LA English
DT Article
DE calcimimetics; parathyroidectomy; vitamin D
ID HEMODIALYSIS PATIENTS; FRACTURES; OUTCOMES; HIP; SURVIVAL
AB Appropriate targets for parathyroid hormone (PTH) in patients with chronic kidney disease (CKD) stages 3 5D are controversial, as are the means by which these targets might be achieved. Secondary hyperparathyroidism is linked to symptoms like bone pain and itch, in addition to less clinically overt issues like bone fragility as well as vascular and soft tissue calcification which may lead to adverse hard endpoints, particularly fracture and death. Recognized therapies for managing a rising PTH include vitamin D analogues, with or without calcimimetic (where available), in addition to management of serum mineral concentrations with diet, binders and dialysis. Despite these interventions, many patients eventually develop refractory metabolic abnormalities of severe hyperparathyroidism (HPT). Treatment decisions in severe HPT in Australia previously centred around whether to perform parathyroidectomy or use calcimimetics in combination with calcitriol (or its analogues) with goals of symptom relief, fracture reduction and reducing vascular risk. The decision to remove Pharmaceutical Benefits Scheme reimbursement for the calcimimetic cinacalcet during 2015, means that parathyroidectomy has now become the only treatment likely to benefit most patients with severe HPT who are medically fit for operative intervention. Although improvements in care are apparent for patients with CKD, there remains an urgent need for basic science and large international trials to inform better ways to manage HPT.
C1 [Hawley, Carmel M.] Princess Alexandra Hosp, Dept Renal Med, Brisbane, Qld, Australia.
   [Hawley, Carmel M.] Univ Queensland, Dept Renal Med, Brisbane, Qld, Australia.
   [Hawley, Carmel M.] Univ Queensland, Australasian Kidney Trials Network, Brisbane, Qld, Australia.
   [Hawley, Carmel M.] Translat Res Inst, Brisbane, Qld, Australia.
   [Holt, Stephen G.] Royal Melbourne Hosp, Dept Nephrol, Melbourne, Vic, Australia.
   [Holt, Stephen G.] Univ Melbourne, Dept Med, Melbourne, Vic, Australia.
C3 Princess Alexandra Hospital; University of Queensland; University of
   Queensland; University of Queensland; Melbourne Health; Royal Melbourne
   Hospital; University of Melbourne
RP Hawley, CM (通讯作者)，Princess Alexandra Hosp, Dept Renal Med, Brisbane, Qld, Australia.
EM carmel.hawley@health.qld.gov.au
RI ; Hawley, Carmel/C 4905 2011; Holt, Stephen/AAU 7808 2020
OI Holt, Stephen/0000 0001 5004 5539; Hawley, Carmel/0000 0002 1392 5649; 
CR Belozeroff V, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472 6963 13 248
   Bleyer AJ, 2005, AM J KIDNEY DIS, V46, P464, DOI 10.1053/j.ajkd.2005.04.035
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Chertow GM, 2012, NEW ENGL J MED, V367, P2482, DOI 10.1056/NEJMoa1205624
   Coco M, 2000, AM J KIDNEY DIS, V36, P1115, DOI 10.1053/ajkd.2000.19812
   Danese MD, 2006, AM J KIDNEY DIS, V47, P149, DOI 10.1053/j.ajkd.2005.09.024
   Hawley Carmel, 2006, Nephrology (Carlton), V11 Suppl 1, pS198, DOI 10.1111/j.1440 1797.2006.00643.x
   Ishani A, 2014, CLIN J AM SOC NEPHRO, V16, P1
   Ishani A, 2015, CLIN J AM SOC NEPHRO, V10, P90, DOI 10.2215/CJN.03520414
   Jadoul M, 2006, KIDNEY INT, V70, P1358, DOI 10.1038/sj.ki.5001754
   Kestenbaum B, 2004, KIDNEY INT, V66, P2010, DOI 10.1111/j.1523 1755.2004.00972.x
   Ketteler M, 2015, KIDNEY INT, V87, P502, DOI 10.1038/ki.2014.425
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Konturek A, 2016, LANGENBECK ARCH SURG, V401, P965, DOI 10.1007/s00423 016 1447 7
   Mitterbauer C, 2007, BONE, V40, P516, DOI 10.1016/j.bone.2006.09.017
   Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
   Moldovan D, 2015, INT UROL NEPHROL, V47, P1871, DOI 10.1007/s11255 015 1106 x
   Molvarec A, 2009, HYPERTENS RES, V32, P665, DOI 10.1038/hr.2009.79
   Parfrey PS, 2015, TRIAL, P791
   Raggi P, 2011, NEPHROL DIAL TRANSPL, V26, P1327, DOI 10.1093/ndt/gfq725
   Sharma AK, 2016, NEPHROLOGY, V21, P801, DOI 10.1111/nep.12790
   Thadhani R, 2012, JAMA J AM MED ASSOC, V307, P674, DOI 10.1001/jama.2012.120
   Wang AYM, 2014, J AM SOC NEPHROL, V25, P175, DOI 10.1681/ASN.2013010103
NR 23
TC 8
Z9 12
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1320 5358
EI 1440 1797
J9 NEPHROLOGY
JI Nephrology
PD MAR
PY 2017
VL 22
SU S2
BP 47
EP 50
DI 10.1111/nep.13029
PG 4
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA ES9NT
UT WOS:000399886500012
PM 28429550
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Haffner Luntzer, M
   Lackner, I
   Liedert, A
   Fischer, V
   Ignatius, A
AF Haffner Luntzer, M.
   Lackner, I.
   Liedert, A.
   Fischer, V.
   Ignatius, A.
TI Effects of low magnitude high frequency vibration on osteoblasts are
   dependent on estrogen receptor α signaling and cytoskeletal remodeling
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Vibration; Mechanostimulation; Osteoblasts; Fracture healing
ID WHOLE BODY VIBRATION; MESENCHYMAL STEM CELLS; FLUID SHEAR STRESS;
   PRIMARY CILIA; GENE EXPRESSION; POSTMENOPAUSAL WOMEN; BONE;
   MECHANOTRANSDUCTION; DIFFERENTIATION; PROLIFERATION
AB Clinical and experimental studies demonstrate the potential of low magnitude high frequency vibration (LMHFV) to enhance bone formation in the intact skeleton and during fracture healing. Moreover, it was shown that the effects of vibration therapy during fracture healing are highly dependent on the estrogen status of the vibrated individual and that estrogen receptor (ER) alpha signaling plays a major role in mechanotransduction of LMHFV. Because it is known that LMHFV can directly act on osteogenic cells, we hypothesize that the differential effects of LMHFV in the presence and absence of estrogen are mediated by ER alpha signaling in osteoblasts. To prove this hypothesis, we subjected preosteoblastic MC3T3 E1 cells and primary osteoblasts to LMHFV in vitro. We found increased Cox2 gene expression, cell metabolic activity and cell proliferation after LMHFV in the absence of estrogen, whereas the effects were contrary in the presence of estrogen. Blocking of ER alpha signaling by Esr1 siRNA knockdown or adding the selective ER alpha antagonist MPP dihydrochloride abolished the effects of LMHFV on osteoblast proliferation and Cox2 expression. Furthermore, primary osteoblasts isolated from ER alpha knockout mice did not show a response towards LMHFV in the presence of estrogen. Additionally, blocking of actin cytoskeletal remodeling by adding the p160ROCK inhibitor Y 27632 abolished the effects of LMHFV. In contrast, expression of primary cilium was not necessary for mechanotransduction of LMHFV. These results suggest that direct effects of LMHFV on osteoblasts are dependent on ER alpha signaling and cytoskeletal remodeling. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Haffner Luntzer, M.; Lackner, I.; Liedert, A.; Fischer, V.; Ignatius, A.] Ulm Univ, Inst Orthopaed Res & Biomech, Ulm, Germany.
C3 Ulm University
RP Haffner Luntzer, M (通讯作者)，Ulm Univ, Inst Orthopaed Res & Biomech, Ulm, Germany.
EM Melanie.haffner luntzer@uni ulm.de
RI ; Ignatius, Anita/M 6012 2013; Fischer, Verena/GVU 3636 2022;
   Haffner Luntzer, Melanie/L 3562 2019
OI Haffner Luntzer, Melanie/0000 0002 3333 2613; Fischer,
   Verena/0000 0001 7039 8008; Lackner, Ina/0000 0001 6410 9222; 
FU Collaborative Research Centre 1149 (CRC1149)   German Research
   Foundation (DFG)
FX The study was conducted in the context of the Collaborative Research
   Centre 1149 (CRC1149) funded by the German Research Foundation (DFG).
CR Armstrong VJ, 2007, J BIOL CHEM, V282, P20715, DOI 10.1074/jbc.M703224200
   Bacabac RG, 2006, FASEB J, V20, P858, DOI 10.1096/fj.05 4966.com
   Bemben DA, 2010, BONE, V47, P650, DOI 10.1016/j.bone.2010.06.019
   Castillo AB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043291
   Chen BL, 2016, INT J MOL MED, V38, P1531, DOI 10.3892/ijmm.2016.2757
   Chung SL, 2014, J ORTHOP RES, V32, P1572, DOI 10.1002/jor.22715
   Delaine Smith RM, 2014, FASEB J, V28, P430, DOI 10.1096/fj.13 231894
   Dong J, 2006, J BIOL CHEM, V281, P18825, DOI 10.1074/jbc.M512826200
   Edwards JH, 2015, WORLD J STEM CELLS, V7, P568, DOI 10.4252/wjsc.v7.i3.568
   Ehnert S, 2017, J MOL MED, V95, P653, DOI 10.1007/s00109 017 1526 4
   FROST HM, 1987, ANAT RECORD, V219, P1, DOI 10.1002/ar.1092190104
   Haffner Luntzer M, 2018, FASEB J, V32, P1957, DOI 10.1096/fj.201700871R
   Haffner Luntzer M, 2018, BONE, V110, P11, DOI 10.1016/j.bone.2018.01.017
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   Lau E, 2010, BONE, V46, P1508, DOI 10.1016/j.bone.2010.02.031
   Lee EJ, 2007, EXP MOL MED, V39, P469, DOI 10.1038/emm.2007.51
   Leucht P, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000390
   Li CJ, 2011, BONE, V48, P286, DOI 10.1016/j.bone.2010.09.020
   Liedert A, 2010, BIOCHEM BIOPH RES CO, V394, P755, DOI 10.1016/j.bbrc.2010.03.065
   Malone AMD, 2007, P NATL ACAD SCI USA, V104, P13325, DOI 10.1073/pnas.0700636104
   Matsumoto K., 2017, J CELL BIOCH
   Nakamura K, 2014, J PERIODONTAL RES, V49, P363, DOI 10.1111/jre.12114
   Naruse K, 2003, J BONE MINER RES, V18, P360, DOI 10.1359/jbmr.2003.18.2.360
   Phua SC, 2017, CELL, V168, P264, DOI 10.1016/j.cell.2016.12.032
   Shang ZZ, 2014, INT J ORAL SCI, V6, P142, DOI 10.1038/ijos.2014.2
   Stuermer EK, 2010, CALCIFIED TISSUE INT, V87, P168, DOI 10.1007/s00223 010 9381 0
   Toma CD, 1997, J BONE MINER RES, V12, P1626, DOI 10.1359/jbmr.1997.12.10.1626
   Uzer G, 2015, STEM CELLS, V33, P2063, DOI 10.1002/stem.2004
   von Stengel S, 2011, OSTEOPOROSIS INT, V22, P317, DOI 10.1007/s00198 010 1215 4
   Wadhwa S, 2002, J BONE MINER RES, V17, P266, DOI 10.1359/jbmr.2002.17.2.266
   Wehrle E, 2015, DIS MODEL MECH, V8, P93, DOI 10.1242/dmm.018622
   Wehrle E, 2014, J ORTHOP RES, V32, P1006, DOI 10.1002/jor.22629
   Wozniak MA, 2004, BBA MOL CELL RES, V1692, P103, DOI 10.1016/j.bbamcr.2004.04.007
   Xie LQ, 2006, BONE, V39, P1059, DOI 10.1016/j.bone.2006.05.012
   Young SRL, 2009, J BONE MINER RES, V24, P411, DOI 10.1359/JBMR.081102
   Zhang M, 2012, CELLS TISSUES ORGANS, V195, P400, DOI 10.1159/000328003
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
   Zhao Y, 2016, ANN BIOMED ENG, V44, P2971, DOI 10.1007/s10439 016 1631 5
NR 38
TC 22
Z9 24
U1 1
U2 18
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 18
PY 2018
VL 503
IS 4
BP 2678
EP 2684
DI 10.1016/j.bbrc.2018.08.023
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA GT8MM
UT WOS:000444791600072
PM 30093109
DA 2025 08 17
ER

PT J
AU Wan, DQ
   Wang, CD
   Qu, XH
   Ai, ST
   Dai, KR
AF Wan Daqian
   Wang Chuandong
   Qu Xinhua
   Ai Songtao
   Dai Kerong
TI Chimaphilin inhibits proliferation and induces apoptosis in multidrug
   resistant osteosarcoma cell lines through insulin like growth factor I
   receptor (IGF IR) signaling
SO CHEMICO BIOLOGICAL INTERACTIONS
LA English
DT Article
DE Chimaphilin; Human osteosarcoma cell lines; IGF IR; Apoptosis
ID CANCER; MITOGENESIS; EXPRESSION; CHILDHOOD; PATHWAY
AB Chimaphilin, an active compound separated from pyrola, possesses the highly efficient antitumor activities. Insulin like growth factor I receptor (IGF IR) plays an important role in tumor cell survival. To look for effective strategies for interrupting IGF IR signaling pathway, we found that chimaphilin can inhibit the receptor tyrosine kinase activity of IGF IR. Chimaphilin inhibited the growth of both drug sensitive and drug resistant osteosarcoma cell lines in a time and dose dependent manner; however, it showed relatively little toxicity in normal osteoblast cell lines. Chimaphilin can increase the sensitivity of doxorubicin in doxorubicin resistant osteosarcoma cell lines. Additionally, small interfering RNA downregulation of IGF IR expression in drug resistant cell lines also caused resensitization to doxorubicin. Above all, we conclude that chimaphilin represents a valuable natural source and may potentially be applicable for reversing the drug resistant phenotype in osteosarcoma therapy. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Wan Daqian; Qu Xinhua; Dai Kerong] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Shanghai Key Lab Orthopaed Implants,Dept Orthopae, Shanghai 200011, Peoples R China.
   [Ai Songtao] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Radiol, Shanghai 200011, Peoples R China.
   [Wang Chuandong] Shanghai Jiao Tong Univ, Sch Med, Inst Hlth Sci, Key Lab Stem Cell Biol, Shanghai 200011, Peoples R China.
   [Wang Chuandong] Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai 200011, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University; Chinese Academy of Sciences
RP Ai, ST (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Radiol, Shanghai 200011, Peoples R China.
EM draisongtao@126.com; drdaikerong@126.com
RI Wan, Daqian/HKF 0584 2023; Qu, Xinhua/Q 3950 2016
OI wan, daqian/0000 0002 6999 4707; 
FU Shanghai Jiao Tong University Affiliated Sixth People's Hospital
FX The authors gratefully acknowledge the financial supports by Shanghai
   Jiao Tong University Affiliated Sixth People's Hospital.
CR Anninga JK, 2011, EUR J CANCER, V47, P2431, DOI 10.1016/j.ejca.2011.05.030
   Bielack S, 2009, ANN ONCOL, V20, P137, DOI 10.1093/annonc/mdp154
   Butler AA, 1998, CANCER RES, V58, P3021
   Chalhoub N, 2009, GENE DEV, V23, P1619, DOI 10.1101/gad.1799609
   Chitnis MM, 2008, CLIN CANCER RES, V14, P6364, DOI 10.1158/1078 0432.CCR 07 4879
   Doer M., 1996, J BIOL CHEM, V271, P243
   Galván IJ, 2008, PHYTOCHEMISTRY, V69, P738, DOI 10.1016/j.phytochem.2007.09.007
   García Echeverría C, 2004, CANCER CELL, V5, P231, DOI 10.1016/S1535 6108(04)00051 0
   Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929
   KAPPEL CC, 1994, CANCER RES, V54, P2803
   Kim SY, 2009, ONCOLOGIST, V14, P83, DOI 10.1634/theoncologist.2008 0189
   Kramarova E, 1996, INT J CANCER, V68, P759
   Le A.V., 1995, BIOMED PHARMACOTHER, V49, P415
   Ma WD, 2014, FOOD CHEM TOXICOL, V70, P1, DOI 10.1016/j.fct.2014.04.014
   MCKENNA RJ, 1966, J BONE JOINT SURG AM, VA 48, P1
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   NEUENSCHWANDER S, 1995, ENDOCRINOLOGY, V136, P4298, DOI 10.1210/en.136.10.4298
   Pinkerton CR, 1997, EUR J CANCER, V33, P895, DOI 10.1016/S0959 8049(97)00157 3
   Reiss K, 1998, EXP CELL RES, V242, P361, DOI 10.1006/excr.1998.4113
   Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089
   Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430
   Yao XH, 2015, FOOD CHEM, V169, P270, DOI 10.1016/j.foodchem.2014.07.115
NR 22
TC 18
Z9 23
U1 0
U2 19
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009 2797
EI 1872 7786
J9 CHEM BIOL INTERACT
JI Chem. Biol. Interact.
PD JUL 25
PY 2015
VL 237
BP 25
EP 30
DI 10.1016/j.cbi.2015.05.008
PG 6
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA CN2QZ
UT WOS:000358268300004
PM 25980584
DA 2025 08 17
ER

PT J
AU Nozawa, S
   Inubushi, T
   Irie, F
   Takigami, I
   Matsumoto, K
   Shimizu, K
   Akiyama, H
   Yamaguchi, Y
AF Nozawa, Satoshi
   Inubushi, Toshihiro
   Irie, Fumitoshi
   Takigami, Iori
   Matsumoto, Kazu
   Shimizu, Katsuji
   Akiyama, Haruhiko
   Yamaguchi, Yu
TI Osteoblastic heparan sulfate regulates osteoprotegerin function and bone
   mass
SO JCI INSIGHT
LA English
DT Article
ID RECEPTOR ACTIVATOR; GROWTH FACTOR; ALKALINE PHOSPHATASE; LIGAND RANKL;
   OSTEOCLASTOGENESIS; BINDING; EXPRESSION; MUTATION; REVEALS; CELLS
AB Bone remodeling is a highly coordinated process involving bone formation and resorption, and imbalance of this process results in osteoporosis. It has long been recognized that long term heparin therapy often causes osteoporosis, suggesting that heparan sulfate (HS), the physiological counterpart of heparin, is somehow involved in bone mass regulation. The role of endogenous HS in adult bone, however, remains unclear. To determine the role of HS in bone homeostasis, we conditionally ablated Ext1, which encodes an essential glycosyltransferase for HS biosynthesis, in osteoblasts. Resultant conditional mutant mice developed severe osteopenia. Surprisingly, this phenotype is not due to impairment in bone formation but to enhancement of bone resorption. We show that osteoprotegerin (OPG), which is known as a soluble decoy receptor for RANKL, needs to be associated with the osteoblast surface in order to efficiently inhibit RANKL/RANK signaling and that HS serves as a cell surface binding partner for OPG in this context. We also show that bone mineral density is reduced in patients with multiple hereditary exostoses, a genetic bone disorder caused by heterozygous mutations of Ext1, suggesting that the mechanism revealed in this study may be relevant to low bone mass conditions in humans.
C1 [Nozawa, Satoshi; Inubushi, Toshihiro; Irie, Fumitoshi; Yamaguchi, Yu] Sanford Burnham Prebys Med Discovery Inst, Human Genet Program, La Jolla, CA USA.
   [Nozawa, Satoshi; Takigami, Iori; Matsumoto, Kazu; Shimizu, Katsuji; Akiyama, Haruhiko] Gifu Univ, Dept Orthoped Surg, Gifu, Japan.
C3 Sanford Burnham Prebys Medical Discovery Institute; Gifu University
RP Yamaguchi, Y (通讯作者)，Sanford Burnham Prebys Med Discovery Inst, 10901 North Torrey Pines Rd, La Jolla, CA 92037 USA.
EM yyamaguchi@sbpdiscovery.org
OI Inubushi, Toshihiro/0000 0001 5303 4763; Nozawa,
   Satoshi/0000 0001 7293 023X
FU NIH [R01 AR055670]; Uehara Memorial Foundation Fellowship; Japan Society
   for the Promotion of Science; MHE Research Foundation
FX This work was supported by NIH grant R01 AR055670 (to YY). SN was the
   recipient of the Uehara Memorial Foundation Fellowship. TI was the
   recipient of the Postdoctoral Fellowship for Research Abroad from Japan
   Society for the Promotion of Science. We thank Thomas Clemens for
   providing Oc Cre mice and the MHE Research Foundation for support and
   encouragement.
CR [Anonymous], 2003, World Health Organ Tech Rep Ser, V921, P1
   Arima Y, 2012, CELL, V148, P447, DOI 10.1016/j.cell.2012.01.022
   Ariyoshi W, 2008, J CELL BIOCHEM, V103, P1707, DOI 10.1002/jcb.21559
   Avioli L V, 1975, Adv Exp Med Biol, V52, P375
   Baud'huin M, 2013, CYTOKINE GROWTH F R, V24, P401, DOI 10.1016/j.cytogfr.2013.06.001
   Bono F, 1997, BIOCHEM J, V326, P661, DOI 10.1042/bj3260661
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Fannon M, 2000, BIOCHEMISTRY US, V39, P1434, DOI 10.1021/bi991895z
   FULLER K, 1991, J CELL PHYSIOL, V147, P208, DOI 10.1002/jcp.1041470204
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Grzesik WJ, 2002, J BIOL CHEM, V277, P43638, DOI 10.1074/jbc.M202124200
   Harada S, 2012, J BONE MINER RES, V27, P461, DOI 10.1002/jbmr.555
   HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744
   Haynes DR, 2001, RHEUMATOLOGY, V40, P623, DOI 10.1093/rheumatology/40.6.623
   Hessle L, 2002, P NATL ACAD SCI USA, V99, P9445, DOI 10.1073/pnas.142063399
   Hikita A, 2006, J BIOL CHEM, V281, P36846, DOI 10.1074/jbc.M606656200
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Inatani M, 2003, SCIENCE, V302, P1044, DOI 10.1126/science.1090497
   Inubushi T, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90049
   Irie A, 2007, BONE, V41, P165, DOI 10.1016/j.bone.2007.04.190
   Irie F, 2008, P NATL ACAD SCI USA, V105, P12307, DOI 10.1073/pnas.0801302105
   JAFFE MD, 1965, J AMER MED ASSOC, V193, P158, DOI 10.1001/jama.1965.03090020072024
   Kamiya N, 2011, BIOCHEM BIOPH RES CO, V414, P326, DOI 10.1016/j.bbrc.2011.09.060
   Kamiya N, 2008, J BONE MINER RES, V23, P2007, DOI 10.1359/JBMR.080809
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kasza Z, 2013, J BIOL CHEM, V288, P25956, DOI 10.1074/jbc.M113.484360
   Kawamoto T, 2003, ARCH HISTOL CYTOL, V66, P123, DOI 10.1679/aohc.66.123
   Lemos MC, 2005, J CLIN ENDOCR METAB, V90, P5386, DOI 10.1210/jc.2004 2520
   Li MM, 2016, J BIOL CHEM, V291, P24160, DOI 10.1074/jbc.M116.751974
   LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267
   Lin XH, 2004, DEVELOPMENT, V131, P6009, DOI 10.1242/dev.01522
   Ling L, 2010, J CELL BIOCHEM, V109, P1222, DOI 10.1002/jcb.22506
   Pino AM, 2010, J BONE MINER RES, V25, P492, DOI 10.1359/jbmr.090802
   Matsumoto K, 2010, P NATL ACAD SCI USA, V107, P10932, DOI 10.1073/pnas.0914642107
   Matsumoto Y, 2010, J BIOL CHEM, V285, P19227, DOI 10.1074/jbc.M110.105338
   Metcalf JA, 2009, MOL GENET METAB, V97, P202, DOI 10.1016/j.ymgme.2009.03.005
   Miao DS, 2004, EXP CELL RES, V294, P210, DOI 10.1016/j.yexcr.2003.10.021
   Mishina Y, 2004, J BIOL CHEM, V279, P27560, DOI 10.1074/jbc.M404222200
   Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697
   MURPHY MS, 1992, LANCET, V340, P1098
   Nakamura H, 2002, J HISTOCHEM CYTOCHEM, V50, P945, DOI 10.1177/002215540205000708
   NAKAMURA H, 1994, J BONE MINER RES, V9, P1289, DOI 10.1002/jbmr.5650090819
   Narisawa S, 2007, J BONE MINER RES, V22, P1700, DOI 10.1359/JBMR.070714
   Nelson CA, 2012, STRUCTURE, V20, P1971, DOI 10.1016/j.str.2012.08.030
   O'Brien CA, 2010, BONE, V46, P911, DOI 10.1016/j.bone.2009.08.050
   Ono N, 2014, NAT CELL BIOL, V16, P1157, DOI 10.1038/ncb3067
   Orimo H, 2001, J BONE MINER METAB, V19, P331, DOI 10.1007/s007740170001
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Riddle RC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063323
   Seeliger C, 2014, J BONE MINER RES, V29, P1718, DOI 10.1002/jbmr.2175
   Sgariglia F, 2013, BONE, V57, P220, DOI 10.1016/j.bone.2013.08.012
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007
   Stieber JR, 2005, J AM ACAD ORTHOP SUR, V13, P110, DOI 10.5435/00124635 200503000 00004
   Tallquist MD, 2000, GENESIS, V26, P113, DOI 10.1002/(SICI)1526 968X(200002)26:2<113::AID GENE3>3.0.CO;2 2
   Théoleyre S, 2006, BIOCHEM BIOPH RES CO, V347, P460, DOI 10.1016/j.bbrc.2006.06.120
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   VIGNERY A, 1980, ANAT RECORD, V196, P191, DOI 10.1002/ar.1091960210
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Yamaguchi K, 1998, J BIOL CHEM, V273, P5117, DOI 10.1074/jbc.273.9.5117
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
   Yeo HJ, 2007, J BIOL CHEM, V282, P35318, DOI 10.1074/jbc.M702435200
   Yu K, 2003, DEVELOPMENT, V130, P3063, DOI 10.1242/dev.00491
   Yuan B, 2008, J CLIN INVEST, V118, P722, DOI 10.1172/JCI32702
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200
NR 66
TC 21
Z9 24
U1 0
U2 8
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
EI 2379 3708
J9 JCI INSIGHT
JI JCI Insight
PD FEB 8
PY 2018
VL 3
IS 3
AR e89624
DI 10.1172/jci.insight.89624
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA FW4DX
UT WOS:000425263900001
PM 29415886
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Coppolino, G
   Bolignano, D
   De Paola, L
   Giulino, C
   Mannella, A
   Riccio, M
   Mascaro, MA
   Lombardi, G
   Fuiano, G
   Lombardi, L
   Buemi, M
AF Coppolino, Giuseppe
   Bolignano, Davide
   De Paola, Luciano
   Giulino, Crispino
   Mannella, Ada
   Riccio, Mara
   Mascaro, Maria Antonietta
   Lombardi, Gianmarco
   Fuiano, Giorgio
   Lombardi, Luigi
   Buemi, Michele
TI Parathyroid Hormone and Mobilization of Circulating Bone Marrow Derived
   Cells in Uremic Patients
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Article
DE parathyroid hormone; uremia; endothelial progenitor cells; bone marrow
ID ENDOTHELIAL PROGENITOR CELLS; MIGRATORY ACTIVITY; HEMODIALYSIS; NUMBER;
   HYPERPARATHYROIDISM; THERAPY; RISK
AB Background: Parathyroid hormone (PTH) revealed a positive action on progenitor cells released from bone marrow, and many mechanisms supported PTH as a tool to improve stem cell based therapy in experimental models of ischemia. Elevated PTH resulted in increased mobilization of progenitors into the peripheral blood of patients affected by untreated primary hyperparathyroidism. A frequent finding in uremic patients is a higher PTH level, and different therapeutic strategies are adopted and implemented to achieve an intermediary PTH level. On the contrary, the amount of progenitors commonly results to be extremely reduced.
   Objective: In the present study, we investigated, in a cohort of uremic patients, the effect of different levels of PTH on mobilization of progenitor cell populations.
   Methods: Eighty patients (26 women, 54 men) were enrolled. Following the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines, patients were divided in 3 groups for PTH levels: low PTH group with a PTH level lower than 150 pg/mL (n = 25), KDOQI PTH group with a PTH level between 150 and 300 pg/mL (n = 37), and high PTH group with a PTH level higher than 300 pg/mL (n = 18). Patients with high levels of PTH were treated differently to achieve KDOQI targets: 5 received intravenous calcitriol and P binders, 3 received intravenous paracalcitriol, and 10 received cinacalcet. We quantified, by the combination of surfacemarkers (CD45(+), CD34(+), CD31(+), and c kit(+)), the number of hematopoietic and endothelial progenitor cells.
   Results: High PTH group demonstrated a significantly higher level of CD45(+)/CD34(+)/c kit(+) with respect to low PTH and KDOQI PTH groups (1.02 [SD, 0.12] vs. 0.56 [SD, 0.14] cells/uL, P < 0.01; and 1.02 [SD, 0.12] vs. 0.46 [SD, 0.20] cells/uL, P < 0.05). CD45(+)/CD34(+)/CD31(+) levels resulted significantly increased in the KDOQI PTH group compared with those observed in the low (1.83 [SD, 0.72] vs 1.26 [SD, 0.83] cells/KL, P = 0.04) and high PTH groups (1.83 [SD, 0.72] vs 1.20 [SD, 1.15] cells/KL, P = 0.04). Receiver operating characteristic analyses were performed to define the ability of CD45(+)/34(+)/31(+) to identify the presence of an optimal PTH status (9150 but G300 pg/mL) among all hemodialysis patients. The area under the curve of CD45(+)/34(+)/31(+) was 0.674 (95% confidence interval [CI], 0.501 0.819) with a best cutoff level of 1.36 cells/KL (sensitivity, 80.0; specificity, 59.1; P < 0.05). After 4 months, we demonstrated an increase in endothelial progenitor cell number in 13 patients with secondary hyperparathyroidism that achieved KDOQI targets in PTH levels after pharmacological treatment.
   Conclusions: Our data confirm, with acknowledged limitations due to the low number of patients, the effect of PTH on bone marrow derived progenitor cells emphasizing that, in our cohort, an intermediary PTH level, achieved following specific guidelines, results in an equilibrate balance between different subsets of progenitor cells.
C1 [Coppolino, Giuseppe; De Paola, Luciano; Lombardi, Gianmarco; Lombardi, Luigi] Azienda Osped Puglieseciaccio, UOC Nefrol & Dialisi, Catanzaro, Italy.
   [Coppolino, Giuseppe; Bolignano, Davide; Riccio, Mara; Buemi, Michele] Univ Messina, Dept Internal Med, Messina, Italy.
   [Giulino, Crispino; Mannella, Ada] Azienda Osped Pugliese Ciaccio, UOC Ematol, Catanzaro, Italy.
   [Coppolino, Giuseppe; Mascaro, Maria Antonietta; Fuiano, Giorgio] Magna Grecia Univ Catanzaro, UOC Nefrol & Dialisi, I 88100 Catanzaro, Italy.
C3 University of Messina; Magna Graecia University of Catanzaro
RP Coppolino, G (通讯作者)，Magna Grecia Univ Catanzaro, UOC Nefrol & Dialisi, Via Michele Torcia, I 88100 Catanzaro, Italy.
EM pepcop77@hotmail.com
RI lombardi, gianmarco/KSL 9228 2024; Bolignano, Davide/AAB 3232 2019;
   Coppolino, Giuseppe/K 7294 2012; Lombardi, Gianmarco/W 3595 2018
OI Bolignano, Davide/0000 0003 3032 245X; Lombardi,
   Gianmarco/0000 0003 2298 1420; Coppolino, Giuseppe/0000 0001 8000 0681
CR Adams GB, 2007, NAT BIOTECHNOL, V25, P238, DOI 10.1038/nbt1281
   Allegra A, 2009, J NEPHROL, V22, P463
   Bahlmann FH, 2003, KIDNEY INT, V64, P1648, DOI 10.1046/j.1523 1755.2003.00279.x
   Ballen KK, 2007, BIOL BLOOD MARROW TR, V13, P838, DOI 10.1016/j.bbmt.2007.03.007
   Blair HC, 1999, BIOCHEM BIOPH RES CO, V255, P778, DOI 10.1006/bbrc.1999.0260
   Brunner S, 2008, EXP HEMATOL, V36, P1157, DOI 10.1016/j.exphem.2008.03.014
   Brunner S, 2007, AM J PHYSIOL ENDOC M, V293, pE1670, DOI 10.1152/ajpendo.00287.2007
   Buemi M, 1999, AM J HYPERTENS, V12, P73, DOI 10.1016/S0895 7061(98)00217 9
   Buemi M, 2000, AM J HYPERTENS, V13, P450, DOI 10.1016/S0895 7061(99)00213 7
   Choi JH, 2004, ARTERIOSCL THROM VAS, V24, P1246, DOI 10.1161/01.ATV.0000133488.56221.4a
   Coppolino G, 2008, HYPERTENS RES, V31, P717, DOI 10.1291/hypres.31.717
   Coppolino G, 2009, J SURG RES, V157, pE129, DOI 10.1016/j.jss.2008.07.017
   de Francisco ALM, 2006, EXPERT OPIN PHARMACO, V7, P2215, DOI 10.1517/14656566.7.16.2215
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131
   Garrett RW, 2008, MOL CELL ENDOCRINOL, V288, P6, DOI 10.1016/j.mce.2008.02.022
   Herbrig K, 2004, AM J KIDNEY DIS, V44, P840, DOI 10.1053/j.ajkd.2004.08.001
   Jansen J, 2005, J CELL MOL MED, V9, P37, DOI 10.1111/j.1582 4934.2005.tb00335.x
   Laufs U, 2004, CIRCULATION, V109, P220, DOI 10.1161/01.CIR.0000109141.48980.37
   Lee SH, 2000, NEW ENGL J MED, V342, P626, DOI 10.1056/NEJM200003023420904
   Leuner S, 1998, BONE MARROW TRANSPL, V22, P699, DOI 10.1038/sj.bmt.1701397
   Majeti R, 2007, CELL STEM CELL, V1, P635, DOI 10.1016/j.stem.2007.10.001
   Maruyama S, 2008, KIDNEY INT, V74, P1603, DOI 10.1038/ki.2008.495
   Mazzaferro S, 2008, NEPHROL DIAL TRANSPL, V23, P2319, DOI 10.1093/ndt/gfm931
   Napoli C, 2008, NAT CLIN PRACT CARD, V5, P571, DOI 10.1038/ncpcardio1214
   Silver J, 2002, AM J PHYSIOL RENAL, V283, pF367, DOI 10.1152/ajprenal.00061.2002
   Sturiale A, 2007, BLOOD PURIFICAT, V25, P242, DOI 10.1159/000101697
   Urbich C, 2004, CIRC RES, V95, P343, DOI 10.1161/01.RES.0000137877.89448.78
   Vasa M, 2001, CIRC RES, V89, pE1, DOI 10.1161/hh1301.093953
   Wood C, 2005, THER APHER DIAL, V9, P4, DOI 10.1111/j.1774 9987.2005.00208.x
   Zaruba MM, 2008, CARDIOVASC RES, V77, P722, DOI 10.1093/cvr/cvm080
NR 31
TC 13
Z9 13
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1081 5589
EI 1708 8267
J9 J INVEST MED
JI J. Invest. Med.
PD JUN
PY 2011
VL 59
IS 5
BP 823
EP 828
PG 6
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA 749IY
UT WOS:000289459700021
PM 21383630
DA 2025 08 17
ER

PT J
AU Koulouvaris, P
   Ly, K
   Ivashkiv, LB
   Bostrom, MP
   Nestor, BJ
   Sculco, TP
   Purdue, PE
AF Koulouvaris, Panagiotis
   Ly, Khanh
   Ivashkiv, Lionel B.
   Bostrom, Mathias P.
   Nestor, Bryan J.
   Sculco, Thomas P.
   Purdue, P. Edward
TI Expression profiling reveals alternative macrophage activation and
   impaired osteogenesis in periprosthetic osteolysis
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE periprosthetic osteolysis; alternative macrophage activation;
   chitotriosidase; CCL18
ID TOTAL HIP ARTHROPLASTY; NECROSIS FACTOR ALPHA; DEBRIS INDUCED
   OSTEOLYSIS; PARTICULATE WEAR DEBRIS; BONE IMPLANT INTERFACE; EVALUATE
   DRUG EFFICACY; GENE EXPRESSION; KAPPA B; MATRIX METALLOPROTEINASES;
   SIGNALING PATHWAYS
AB Interactions between periprosthetic cells and prosthetic wear debris have been recognized as an important event in the development of osteolysis and aseptic loosening. Although the ability of wear debris to activate pro inflammatory macrophage signaling has been documented, the full repertoire of macrophage responses to wear particles has not been established. Here we examined the involvement of alternative macrophage activation and defective osteogenic signaling in osteolysis. Using real time RT PCR analysis of periprosthetic soft tissue from osteolysis patients, we detected elevated levels of expression of alternative macrophage activation markers (CHIT1, CCL18), chemokines (IL8, MIP1 alpha) and markers of osteoclast precursor cell differentiation and multinucleation (Cathepsin K, TRAP, DC STAMP) relative to osteoarthritis controls. The presence of cathepsin K positive multinuclear cells was confirmed by immunohistochemistry. Reduced expression levels of the osteogenic signaling components BMP4 and FGF18 were detected. Expression levels of TNF alpha, IL 6, and RANKL were unchanged, while the anti osteoclastogenic cytokine OPG was reduced in osteolysis patients, resulting in elevated RANKL:OPG ratios. In vitro studies confirmed the role of particulate debris in alternative macrophage activation and inhibition of osteogenic signaling. Taken together, these results suggest involvement in osteolysis of alternative macrophage activation, accompanied by elevated levels of various chemokines. Increased recruitment and maturation of osteoclast precursors is also observed, as is reduced osteogenesis. These findings provide new insights into the molecular pathogenesis of osteolysis, and identify new potential candidate markers for disease progression and therapeutic targeting. (c) 2007 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.
C1 [Koulouvaris, Panagiotis; Ly, Khanh; Ivashkiv, Lionel B.; Bostrom, Mathias P.; Nestor, Bryan J.; Sculco, Thomas P.; Purdue, P. Edward] Hosp Special Surg, Osteolysis Res Lab, New York, NY 10021 USA.
RP Purdue, PE (通讯作者)，Hosp Special Surg, Osteolysis Res Lab, 535 E 70th St, New York, NY 10021 USA.
EM purduee@ahss.edu
RI Koulouvaris, Panagiotis/AAZ 9379 2021
CR Blaine TA, 1996, J BONE JOINT SURG AM, V78A, P1181, DOI 10.2106/00004623 199608000 00008
   Boot RG, 2004, BLOOD, V103, P33, DOI 10.1182/blood 2003 05 1612
   Boven LA, 2004, AM J CLIN PATHOL, V122, P359, DOI 10.1309/BG5VA8JRDQH1M7HN
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   CHIBA J, 1994, CLIN ORTHOP RELAT R, P304
   Childs LM, 2001, J BONE MINER RES, V16, P338, DOI 10.1359/jbmr.2001.16.2.338
   Dumbleton JH, 2002, J ARTHROPLASTY, V17, P649, DOI 10.1054/arth.2002.33664
   Fiorito S, 2003, J BONE JOINT SURG BR, V85B, P1202, DOI 10.1302/0301 620X.85B8.12799
   Fritz EA, 2005, J ORTHOP RES, V23, P1249, DOI 10.1016/j.orthres.2005.03.013
   Gehrke T, 2003, SCAND J RHEUMATOL, V32, P287, DOI 10.1080/03009740310003929
   Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978
   Granchi D, 2005, BIOMATERIALS, V26, P2371, DOI 10.1016/j.biomaterials.2004.07.045
   Granchi D, 1998, J BONE JOINT SURG BR, V80B, P912, DOI 10.1302/0301 620X.80B5.8513
   Hamilton JA, 2003, J LEUKOCYTE BIOL, V73, P702, DOI 10.1189/jlb.0103037
   Haynes DR, 2004, BIOMATERIALS, V25, P4877, DOI 10.1016/j.biomaterials.2004.01.003
   Haynes DR, 2001, J BONE JOINT SURG BR, V83B, P902, DOI 10.1302/0301 620X.83B6.10905
   Hernigou P, 1999, CLIN ORTHOP RELAT R, P147
   Hirakawa K, 1996, J BIOMED MATER RES, V31, P257, DOI 10.1002/(SICI)1097 4636(199606)31:2<257::AID JBM13>3.0.CO;2 I
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Horiki M, 2004, J BONE MINER METAB, V22, P346, DOI 10.1007/s00774 003 0493 8
   Hundric Haspl Z, 2006, CLIN ORTHOP RELAT R, P299, DOI 10.1097/01.blo.0000229365.57985.96
   Ingham E, 2005, BIOMATERIALS, V26, P1271, DOI 10.1016/j.biomaterials.2004.04.035
   Ishiguro N, 1997, J BIOMED MATER RES, V35, P399, DOI 10.1002/(SICI)1097 4636(19970605)35:3<399::AID JBM14>3.3.CO;2 I
   Jacobs JJ, 2001, CLIN ORTHOP RELAT R, P71
   Lassus J, 2000, ARCH ORTHOP TRAUM SU, V120, P328, DOI 10.1007/s004020050475
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Looney RJ, 2006, CURR OPIN RHEUMATOL, V18, P80, DOI 10.1097/01.bor.0000198004.88568.96
   Mandelin J, 2003, J BONE JOINT SURG BR, V85B, P1196, DOI 10.1302/0301 620X.85B8.13311
   Mantovani A, 2005, IMMUNITY, V23, P344, DOI 10.1016/j.immuni.2005.10.001
   MARGEVICIUS KJ, 1994, J BONE JOINT SURG AM, V76A, P1664, DOI 10.2106/00004623 199411000 00010
   Merkel KD, 1999, AM J PATHOL, V154, P203, DOI 10.1016/S0002 9440(10)65266 2
   Millett PJ, 2002, J BONE JOINT SURG AM, V84A, P236, DOI 10.2106/00004623 200202000 00011
   Morawietz L, 2003, VIRCHOWS ARCH, V443, P57, DOI 10.1007/s00428 003 0818 y
   Nakashima Y, 1999, J BONE JOINT SURG AM, V81A, P603, DOI 10.2106/00004623 199905000 00002
   Nivbrant B, 1999, J BONE JOINT SURG BR, V81B, P163, DOI 10.1302/0301 620X.81B1.8664
   Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702
   Pioletti DP, 2002, J BIOMED MATER RES, V61, P408, DOI 10.1002/jbm.10218
   Rader CP, 1999, J ARTHROPLASTY, V14, P840, DOI 10.1016/S0883 5403(99)90035 9
   Rakshit DS, 2006, J BONE JOINT SURG AM, V88A, P788, DOI 10.2106/JBJS.E.00711
   Sabokbar A, 1995, J ARTHROPLASTY, V10, P810, DOI 10.1016/S0883 5403(05)80080 4
   SCHMALZRIED TP, 1992, J BONE JOINT SURG AM, V74A, P849, DOI 10.2106/00004623 199274060 00006
   Schwarz EM, 2003, J ORTHOPAED RES, V21, P1049, DOI 10.1016/S0736 0266(03)00093 7
   Schwarz EM, 2000, J ORTHOPAED RES, V18, P849, DOI 10.1002/jor.1100180602
   Schwarz EM, 2000, J ORTHOPAED RES, V18, P472, DOI 10.1002/jor.1100180321
   SHANBHAG AS, 1995, J ARTHROPLASTY, V10, P498, DOI 10.1016/S0883 5403(05)80152 4
   Shanbhag AS, 1997, CLIN ORTHOP RELAT R, P33
   SHANBHAG AS, 2005, TRANS 51 ANN M ORTH
   Shen ZX, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1938
   Stea S, 2000, CYTOKINE, V12, P1575, DOI 10.1006/cyto.2000.0753
   Suh KT, 2002, J BONE JOINT SURG BR, V84B, P753, DOI 10.1302/0301 620X.84B5.12314
   Takei I, 2000, J BIOMED MATER RES, V52, P613, DOI 10.1002/1097 4636(20001215)52:4<613::AID JBM5>3.0.CO;2 8
   Tanaka R, 2005, J ARTHROPLASTY, V20, P1049, DOI 10.1016/j.arth.2005.03.034
   Vermes C, 2001, J BONE JOINT SURG AM, V83A, P201, DOI 10.2106/00004623 200102000 00007
   Warme BA, 2004, J BIOMED MATER RES B, V71B, P360, DOI 10.1002/jbm.b.30120
   Wilkinson JM, 2005, J ORTHOP RES, V23, P520, DOI 10.1016/j.orthres.2004.11.005
   Wooley PH, 2004, GENE THER, V11, P402, DOI 10.1038/sj.gt.3302202
   Wooley PH, 2002, BIOMATERIALS, V23, P517, DOI 10.1016/S0142 9612(01)00134 X
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yokohama Y, 1995, LAB INVEST, V73, P899
   Zambonin G, 1998, CALCIFIED TISSUE INT, V62, P362, DOI 10.1007/s002239900445
NR 60
TC 62
Z9 68
U1 1
U2 10
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0736 0266
J9 J ORTHOP RES
JI J. Orthop. Res.
PD JAN
PY 2008
VL 26
IS 1
BP 106
EP 116
DI 10.1002/jor.20486
PG 11
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 245FI
UT WOS:000251920100014
PM 17729302
OA Bronze
DA 2025 08 17
ER

PT J
AU Sauer, T
   Facchinetti, G
   Kohl, M
   Kowal, JM
   Rozanova, S
   Horn, J
   Schmal, H
   Kwee, I
   Schulz, AP
   Hartwig, S
   Kassem, M
   Habermann, JK
   Gemoll, T
AF Sauer, Thorben
   Facchinetti, Giulia
   Kohl, Michael
   Kowal, Justyna M.
   Rozanova, Svitlana
   Horn, Julia
   Schmal, Hagen
   Kwee, Ivo
   Schulz, Arndt Peter
   Hartwig, Sonja
   Kassem, Moustapha
   Habermann, Jens K.
   Gemoll, Timo
TI Protein Expression of AEBP1, MCM4, and FABP4 Differentiate Osteogenic,
   Adipogenic, and Mesenchymal Stromal Stem Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE protein profiling; data independent acquisition mass spectrometry;
   SWATH; human stromal; mesenchymal stem cells; differentiation markers;
   machine learning
ID OSTEOBLAST DIFFERENTIATION; QUANTITATIVE PROTEOMICS; ADIPOSE TISSUE;
   BONE; IDENTIFICATION; THERAPY; FAMILY; REGULARIZATION; MECHANISMS;
   PHENOTYPE
AB Mesenchymal stem cells (MSCs) gain an increasing focus in the field of regenerative medicine due to their differentiation abilities into chondrocytes, adipocytes, and osteoblastic cells. However, it is apparent that the transformation processes are extremely complex and cause cellular heterogeneity. The study aimed to characterize differences between MSCs and cells after adipogenic (AD) or osteoblastic (OB) differentiation at the proteome level. Comparative proteomic profiling was performed using tandem mass spectrometry in data independent acquisition mode. Proteins were quantified by deep neural networks in library free mode and correlated to the Molecular Signature Database (MSigDB) hallmark gene set collections for functional annotation. We analyzed 4108 proteins across all samples, which revealed a distinct clustering between MSCs and cell differentiation states. Protein expression profiling identified activation of the Peroxisome proliferator activated receptors (PPARs) signaling pathway after AD. In addition, two distinct protein marker panels could be defined for osteoblastic and adipocytic cell lineages. Hereby, overexpression of AEBP1 and MCM4 for OB as well as of FABP4 for AD was detected as the most promising molecular markers. Combination of deep neural network and machine learning algorithms with data independent mass spectrometry distinguish MSCs and cell lineages after adipogenic or osteoblastic differentiation. We identified specific proteins as the molecular basis for bone formation, which could be used for regenerative medicine in the future.
C1 [Sauer, Thorben; Facchinetti, Giulia; Kohl, Michael; Rozanova, Svitlana; Horn, Julia; Habermann, Jens K.; Gemoll, Timo] Univ Lubeck, Univ Hosp Schleswig Holstein, Dept Surg, Sect Translat Surg Oncol & Biobanking, Campus Luebeck,Ratzeburger Allee 160, D 23562 Lubeck, Germany.
   [Kowal, Justyna M.; Kassem, Moustapha] Univ Hosp Odense, Dept Endocrinol & Metab, JB Winslows Vej 25, DK 5230 Odense, Denmark.
   [Schmal, Hagen] Odense Univ Hosp, Dept Orthoped & Traumatol, JB Winslows Vej 4, DK 5000 Odense, Denmark.
   [Schmal, Hagen] Albert Ludwigs Univ Freiburg, Fac Med, Med Ctr, Dept Orthoped & Trauma Surg, Hugstetter Str 55, D 79106 Freiburg, Germany.
   [Kwee, Ivo] BigOmics Analyt SA, CH 6500 Bellinzona, Switzerland.
   [Schulz, Arndt Peter] Fraunhofer Res Inst Individualized & Cell Based M, Moenkhofer Weg 239a, D 23562 Lubeck, Germany.
   [Schulz, Arndt Peter] BG Klinikum Hamburg, Dept Ctr Klin Forsch, Bergedorfer Str 10, D 21033 Hamburg, Germany.
   [Hartwig, Sonja] German Ctr Diabet Res DZD, D 85764 Munich, Germany.
   [Hartwig, Sonja] Heinrich Heine Univ Duesseldorf, Inst Clin Biochem & Pathobiochem, German Diabet Ctr, Leibniz Ctr Diabet Res, D 40225 Dusseldorf, Germany.
   [Habermann, Jens K.] Univ Lubeck, Interdisciplinary Ctr Biobanking Luebeck, Ratzeburger Allee 160, D 23562 Lubeck, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital; University
   of Lubeck; University of Southern Denmark; Odense University Hospital;
   University of Southern Denmark; Odense University Hospital; University
   of Freiburg; German Center for Diabetes Research (DZD); Leibniz
   Association; Deutsches Diabetes Zentrum (DDZ); Heinrich Heine University
   Dusseldorf; University of Lubeck
RP Gemoll, T (通讯作者)，Univ Lubeck, Univ Hosp Schleswig Holstein, Dept Surg, Sect Translat Surg Oncol & Biobanking, Campus Luebeck,Ratzeburger Allee 160, D 23562 Lubeck, Germany.
EM thorben.sauer@student.uni luebeck.de; facchinetti.giuli@gmail.com;
   michael.kohl@uni luebeck.de; jkowal@health.sdu.dk;
   svitlana.rozanova@ruhr uni bochum.de; julia.horn@uni luebeck.de;
   hagen.schmal@uniklinik freiburg.de; kwee@bigomics.ch;
   schulz@biomechatronics.de; sonja.hartwig@ddz.de; mkassem@health.sdu.dk;
   jens.habermann@uni luebeck.de; timo.gemoll@uni luebeck.de
RI ; Schulz, Arndt/AAV 7099 2020; Schulz, Arndt P./E 2907 2010; Habermann,
   Jens/E 2968 2010; Kassem, Moustapha/J 7688 2013
OI Habermann, Jens K./0000 0002 3127 4755; Gemoll,
   Timo/0000 0001 7400 5240; Sauer, Thorben/0000 0002 4511 6037; Rozanova,
   Svitlana/0000 0001 6861 5587; Schulz, Arndt P./0000 0002 4927 549X;
   Kowal, Justyna Magdalena/0000 0002 8489 4464; Hartwig,
   Sonja/0000 0002 5225 6804; 
FU Interreg 5a Germany Denmark [16 1.0 15]; European Regional Development
FX The study was performed as a part of the BONEBANK project (project
   number: 16 1.0 15) supported by Interreg 5a Germany Denmark with funds
   from the European Regional Development.
CR Aasebo E, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115665
   Akhmedov M, 2020, NAR GENOM BIOINFORM, V2, DOI 10.1093/nargab/lqz019
   [Anonymous], MACH LEARN
   Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002
   Bronckaers A, 2014, PHARMACOL THERAPEUT, V143, P181, DOI 10.1016/j.pharmthera.2014.02.013
   Centeno CJ, 2016, INT ORTHOP, V40, P1755, DOI 10.1007/s00264 016 3162 y
   Charrad M, 2014, J STAT SOFTW, V61, P1
   Chen L, 2015, STEM CELL RES, V15, P281, DOI 10.1016/j.scr.2015.06.009
   Chen TQ, 2016, KDD'16: PROCEEDINGS OF THE 22ND ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING, P785, DOI 10.1145/2939672.2939785
   Chen XD, 2004, FASEB J, V18, P948, DOI 10.1096/fj.03 0899com
   Christiaens V, 2012, BBA GEN SUBJECTS, V1820, P949, DOI 10.1016/j.bbagen.2012.04.001
   Chung MJ, 2021, INT J STEM CELLS, V14, P150, DOI 10.15283/ijsc20167
   Ciuffreda MC, 2016, METHODS MOL BIOL, V1416, P149, DOI 10.1007/978 1 4939 3584 0_8
   Cox J, 2014, MOL CELL PROTEOMICS, V13, P2513, DOI 10.1074/mcp.M113.031591
   Decker M, 2012, J LIPID RES, V53, P2038, DOI 10.1194/jlr.M024448
   Demichev V, 2020, NAT METHODS, V17, P41, DOI 10.1038/s41592 019 0638 x
   Deutsch EW, 2017, NUCLEIC ACIDS RES, V45, pD1100, DOI 10.1093/nar/gkw936
   do Nascimento FV, 2015, DIABETOL METAB SYNDR, V7, DOI 10.1186/s13098 015 0036 1
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Ellis JM, 2010, CELL METAB, V12, P53, DOI 10.1016/j.cmet.2010.05.012
   Elsafadi M, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/9378081
   Eriksson J, 2020, MOL ONCOL, V14, P742, DOI 10.1002/1878 0261.12649
   Fakhry Maya, 2013, World J Stem Cells, V5, P136, DOI 10.4252/wjsc.v5.i4.136
   Fisher RA, 1922, J R STAT SOC, V85, P87, DOI 10.2307/2340521
   Foster LJ, 2005, STEM CELLS, V23, P1367, DOI 10.1634/stemcells.2004 0372
   FRIEDENSTEIN AY, 1968, CLIN ORTHOP RELAT R, P21
   Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01
   Gamucci O, 2012, ADIPOCYTE, V1, P142, DOI 10.4161/adip.20041
   Gautheron J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010013
   Gemoll T, 2015, ONCOTARGET, V6, P16517, DOI 10.18632/oncotarget.4140
   Giannotti S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073893
   Gómez Barrena E, 2011, J CELL MOL MED, V15, P1266, DOI 10.1111/j.1582 4934.2011.01265.x
   Granéli C, 2014, STEM CELL RES, V12, P153, DOI 10.1016/j.scr.2013.09.009
   Hänzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471 2105 14 7
   Heberle H, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859 015 0611 3
   Himmelfarb M, 2004, CANCER LETT, V204, P69, DOI 10.1016/j.canlet.2003.09.011
   Hng CH, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 68261 2
   Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96
   Hunt CJ, 2011, TRANSFUS MED HEMOTH, V38, P107, DOI 10.1159/000326623
   Kadota Y, 2012, J PHYSIOL SCI, V62, P403, DOI 10.1007/s12576 012 0217 8
   Keating A, 2006, CURR OPIN HEMATOL, V13, P419, DOI 10.1097/01.moh.0000245697.54887.6f
   Kim J, 2015, PHARMACOL THERAPEUT, V151, P8, DOI 10.1016/j.pharmthera.2015.02.003
   Kim M, 2018, J TISSUE ENG REGEN M, V12, pE1034, DOI 10.1002/term.2425
   Knight MN, 2013, ADV WOUND CARE, V2, P306, DOI 10.1089/wound.2012.0420
   Korotkevich G, 2019, bioRxiv, DOI [10.1101/060012, 10.1101/060012, DOI 10.1101/060012]
   Kowal JM, 2020, STEM CELL TRANSL MED, V9, P189, DOI 10.1002/sctm.19 0171
   Kowal JM, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02338 1
   Kristensen LP, 2012, MOL CELL PROTEOMICS, V11, P989, DOI 10.1074/mcp.M111.012138
   Kuijjer ML, 2012, GENE CHROMOSOME CANC, V51, P696, DOI 10.1002/gcc.21956
   KUMAR R, 1994, BIOCHEM BIOPH RES CO, V201, P861, DOI 10.1006/bbrc.1994.1780
   Larsen KH, 2010, J BONE MINER RES, V25, P796, DOI 10.1359/jbmr.091018
   Lazar C, 2016, J PROTEOME RES, V15, P1116, DOI 10.1021/acs.jproteome.5b00981
   Le Blanc K, 2012, NAT REV IMMUNOL, V12, P383, DOI 10.1038/nri3209
   Lee HY, 2017, CANCER SCI, V108, P1939, DOI 10.1111/cas.13334
   Li CJ, 2015, J CLIN INVEST, V125, P1509, DOI 10.1172/JCI77716
   Li Q, 2020, J CLIN LAB ANAL, V34, DOI 10.1002/jcla.23107
   Li X, 2008, BLOOD, V112, P159, DOI 10.1182/blood 2007 11 124164
   Liao L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.130
   Liao YJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202155
   Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004
   Liebergall M, 2013, MOL THER, V21, P1631, DOI 10.1038/mt.2013.109
   Liu HB, 2011, J BONE MINER RES, V26, P2052, DOI 10.1002/jbmr.419
   Liu LY, 2017, BIOL CHEM, V398, P1327, DOI 10.1515/hsz 2017 0205
   Manza LL, 2005, PROTEOMICS, V5, P1742, DOI 10.1002/pmic.200401063
   Marcacci M, 2007, TISSUE ENG, V13, P947, DOI 10.1089/ten.2006.0271
   McLeod CM, 2017, EUR CELLS MATER, V34, P217, DOI 10.22203/eCM.v034a14
   Mi HY, 2021, NUCLEIC ACIDS RES, V49, pD394, DOI 10.1093/nar/gkaa1106
   Moena D, 2020, J CELL PHYSIOL, V235, P5328, DOI 10.1002/jcp.29420
   Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004
   O'Keefe RJ, 2020, J BONE MINER RES, V35, P3, DOI 10.1002/jbmr.3839
   Oryan A, 2017, CELLS TISSUES ORGANS, V204, P59, DOI 10.1159/000469704
   Parisuthiman D, 2005, J BONE MINER RES, V20, P1878, DOI 10.1359/JBMR.050612
   Perez Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106
   Pittenger MF, 2019, NPJ REGEN MED, V4, DOI 10.1038/s41536 019 0083 6
   Pizzinat N, 1999, BIOCHEM PHARMACOL, V58, P1735, DOI 10.1016/S0006 2952(99)00270 1
   Post S, 2008, BONE, V43, P32, DOI 10.1016/j.bone.2008.03.011
   Prudovsky I, 2018, J CELL BIOCHEM, V119, P2636, DOI 10.1002/jcb.26429
   Quarto R, 2001, NEW ENGL J MED, V344, P385, DOI 10.1056/NEJM200102013440516
   R Development Core Team, 2021, Computer programme
   Rappaport N, 2013, DATABASE OXFORD, DOI 10.1093/database/bat018
   Rodriguez Cuenca S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162047
   Rossi V, 2019, CURR OPIN PEDIATR, V31, P708, DOI 10.1097/MOP.0000000000000813
   Segal E, 2004, NAT GENET, V36, P1090, DOI 10.1038/ng1434
   Shan TZ, 2013, FASEB J, V27, P277, DOI 10.1096/fj.12 211516
   Shen W, 2012, EUR J CLIN NUTR, V66, P983, DOI 10.1038/ejcn.2012.35
   Shi L, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392 021 00488 5
   Singer NG, 2011, ANNU REV PATHOL MECH, V6, P457, DOI 10.1146/annurev pathol 011110 130230
   Smyth SS, 2003, J BIOL CHEM, V278, P43214, DOI 10.1074/jbc.M306709200
   Stenderup K, 2003, BONE, V33, P919, DOI 10.1016/j.bone.2003.07.005
   Taira K, 2004, J BIOL CHEM, V279, P49488, DOI 10.1074/jbc.M406370200
   Ullah M, 2019, ISCIENCE, V15, P421, DOI 10.1016/j.isci.2019.05.004
   van Driel M, 2006, FASEB J, V20, P2417, DOI 10.1096/fj.06 6374fje
   Volk SW, 2014, CALCIFIED TISSUE INT, V94, P621, DOI 10.1007/s00223 014 9843 x
   Wei X, 2013, ACTA PHARMACOL SIN, V34, P747, DOI 10.1038/aps.2013.50
   Wickham H., 2016, ggplot2: Elegant Graphics for Data Analysis
   Yamada M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205199
   Yang CS, 2005, DEV CELL, V9, P209, DOI 10.1016/j.devcel.2005.06.008
   Ye YP, 2012, INT J MOL MED, V30, P1075, DOI 10.3892/ijmm.2012.1091
   Yong KW, 2016, ADV EXP MED BIOL, V951, P99, DOI 10.1007/978 3 319 45457 3_8
   Yuan ZY, 2016, CURR STEM CELL RES T, V11, P216, DOI 10.2174/1574888X10666150519093429
   Yun CW, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040982
   Zaher W, 2014, ARCH TOXICOL, V88, P1069, DOI 10.1007/s00204 014 1232 8
   Zhang XF, 2018, NAT PROTOC, V13, P530, DOI 10.1038/nprot.2017.147
   Zhao YT, 2005, BIOCHEM J, V385, P493, DOI 10.1042/BJ20041160
   Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467 9868.2005.00503.x
NR 107
TC 8
Z9 9
U1 0
U2 10
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR
PY 2022
VL 23
IS 5
AR 2568
DI 10.3390/ijms23052568
PG 21
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 0A0WV
UT WOS:000773684200001
PM 35269711
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Hu, N
   Jiang, DM
   Huang, EY
   Liu, X
   Li, RD
   Liang, X
   Kim, SH
   Chen, X
   Gao, JL
   Zhang, HY
   Zhang, WW
   Kong, YH
   Zhang, JY
   Wang, JH
   Shui, W
   Luo, XJ
   Liu, B
   Cui, J
   Rogers, MR
   Shen, JK
   Zhao, C
   Wang, N
   Wu, NN
   Luu, HH
   Haydon, RC
   He, TC
   Huang, W
AF Hu, Ning
   Jiang, Dianming
   Huang, Enyi
   Liu, Xing
   Li, Ruidong
   Liang, Xi
   Kim, Stephanie H.
   Chen, Xiang
   Gao, Jian Li
   Zhang, Hongyu
   Zhang, Wenwen
   Kong, Yu Han
   Zhang, Jiye
   Wang, Jinhua
   Shui, Wei
   Luo, Xiaoji
   Liu, Bo
   Cui, Jing
   Rogers, Mary Rose
   Shen, Jikun
   Zhao, Chen
   Wang, Ning
   Wu, Ningning
   Luu, Hue H.
   Haydon, Rex C.
   He, Tong Chuan
   Huang, Wei
TI BMP9 regulated angiogenic signaling plays an important role in the
   osteogenic differentiation of mesenchymal progenitor cells
SO JOURNAL OF CELL SCIENCE
LA English
DT Article
DE Angiogenic signaling; BMP signaling; HIF1 alpha signaling; Hypoxia;
   Mesenchymal stromal progenitor cells; Osteogenic differentiation
ID BONE MORPHOGENETIC PROTEINS; OSTEOBLAST DIFFERENTIATION; TUMOR GROWTH;
   PATHWAY; BMP 9; SYSTEM; BINDS; ALK1; WNT
AB Mesenchymal stromal progenitor cells (MSCs) are multipotent progenitors that can be isolated from numerous tissues. MSCs can undergo osteogenic differentiation under proper stimuli. We have recently demonstrated that bone morphogenetic protein 9 (BMP9) is one of the most osteogenic BMPs. As one of the least studied BMPs, BMP9 has been shown to regulate angiogenesis in endothelial cells. However, it is unclear whether BMP9 regulated angiogenic signaling plays any important role in the BMP9 initiated osteogenic pathway in MSCs. Here, we investigate the functional role of hypoxia inducible factor 1 alpha (HIF1 alpha) mediated angiogenic signaling in BMP9 regulated osteogenic differentiation of MSCs. We find that BMP9 induces HIF1 alpha expression in MSCs through Smad1/5/8 signaling. Exogenous expression of HIF1 alpha potentiates BMP9 induced osteogenic differentiation of MSCs both in vitro and in vivo. siRNA mediated silencing of HIF1 alpha or HIF1 alpha inhibitor CAY10585 profoundly blunts BMP9 induced osteogenic signaling in MSCs. HIF1 alpha expression regulated by cobalt induced hypoxia also recapitulates the synergistic effect between HIF1 alpha and BMP9 in osteogenic differentiation. Mechanistically, HIF1 alpha is shown to exert its synergistic effect with BMP9 by inducing both angiogenic signaling and osteogenic signaling in MSCs. Thus, our findings should not only expand our understanding of the molecular basis behind BMP9 regulated osteoblastic lineage specific differentiation, but also provide an opportunity to harness the BMP9 induced synergy between osteogenic and angiogenic signaling pathways in regenerative medicine.
C1 [Hu, Ning; Jiang, Dianming; Huang, Enyi; Li, Ruidong; Liang, Xi; Zhang, Hongyu; Zhang, Wenwen; Kong, Yu Han; Zhang, Jiye; Wang, Jinhua; Shui, Wei; Luo, Xiaoji; Liu, Bo; Cui, Jing; Wu, Ningning; He, Tong Chuan; Huang, Wei] Chongqing Med Univ, Affiliated Hosp 1, Chinese Minist Educ, Chongqing 400016, Peoples R China.
   [Hu, Ning; Jiang, Dianming; Huang, Enyi; Li, Ruidong; Liang, Xi; Zhang, Hongyu; Zhang, Wenwen; Kong, Yu Han; Zhang, Jiye; Wang, Jinhua; Shui, Wei; Luo, Xiaoji; Liu, Bo; Cui, Jing; Wu, Ningning; He, Tong Chuan; Huang, Wei] Chongqing Med Univ, Key Lab Diagnost Med, Chinese Minist Educ, Chongqing 400016, Peoples R China.
   [Hu, Ning; Huang, Enyi; Liu, Xing; Li, Ruidong; Liang, Xi; Kim, Stephanie H.; Chen, Xiang; Gao, Jian Li; Zhang, Hongyu; Zhang, Wenwen; Kong, Yu Han; Zhang, Jiye; Wang, Jinhua; Shui, Wei; Luo, Xiaoji; Liu, Bo; Cui, Jing; Rogers, Mary Rose; Shen, Jikun; Zhao, Chen; Wang, Ning; Wu, Ningning; Luu, Hue H.; Haydon, Rex C.] Univ Chicago, Med Ctr, Dept Orthopaed Surg, Mol Oncol Lab, Chicago, IL 60637 USA.
   [Liu, Xing; He, Tong Chuan] Chongqing Med Univ, Childrens Hosp, Stem Cell Biol & Therapy Lab, Key Lab Pediat,Chinese Minist Educ, Chongqing 400014, Peoples R China.
   [Liu, Xing; He, Tong Chuan] Chongqing Med Univ, Childrens Hosp, Chongqing Bur Educ, Chongqing 400014, Peoples R China.
   [Chen, Xiang] Fourth Mil Med Univ, Affiliated Tangdu Hosp, Dept Orthopaed Surg, Xian 710032, Peoples R China.
   [Gao, Jian Li] Zhejiang Chinese Med Univ, Inst Mat Med, Hangzhou 310053, Zhejiang, Peoples R China.
   [Zhao, Chen; Wang, Ning] Third Mil Med Univ, Affiliated Southwest Hosp, Sch Lab Med, Chongqing 400038, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University; University
   of Chicago; University of Chicago Medical Center; Chongqing Medical
   University; Chongqing Medical University; Air Force Medical University;
   Zhejiang Chinese Medical University; Army Medical University
RP He, TC (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Chinese Minist Educ, Chongqing 400016, Peoples R China.
EM tche@uchicago.edu; huangwei68@263.net
RI Zhang, Jiye/LSJ 2675 2024; GAO, JianLi/J 4997 2017; Chen,
   Xiangdong/KCX 7707 2024; GAO, Jian Li/J 4997 2017
OI GAO, JianLi/0000 0002 5977 0021; hu, ning/0000 0001 9933 5924; Chen,
   Xiang/0000 0001 7628 516X; 
FU National Institutes of Health [AR50142, AR054381, AT004418 01A1]; 973
   Program of the Ministry of Science and Technology of China
   [2011CB707906]; Natural Science Foundation of China [31070875, 30901530,
   81171685]
FX This work was supported in part by research grants from the National
   Institutes of Health [grant numbers AR50142, AR054381, and AT004418 01A1
   to R. C. H., T. C. H. and H. H. L.]; the 973 Program of the Ministry of
   Science and Technology of China [grant number 2011CB707906 to T. C. H.];
   and the Natural Science Foundation of China [grant numbers 31070875 to
   W. H., 30901530 to X. Luo and 81171685 to D.J.]. Deposited in PMC for
   release after 12 months.
CR Castonguay R, 2011, J BIOL CHEM, V286, P30034, DOI 10.1074/jbc.M111.260133
   Chen C, 2003, NAT BIOTECHNOL, V21, P294, DOI 10.1038/nbt795
   Chen LA, 2010, J BONE MINER RES, V25, P2447, DOI 10.1002/jbmr.133
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Cunha SI, 2010, J EXP MED, V207, P85, DOI 10.1084/jem.20091309
   David L, 2008, CIRC RES, V102, P914, DOI 10.1161/CIRCRESAHA.107.165530
   Deng ZL, 2008, FRONT BIOSCI LANDMRK, V13, P2001, DOI 10.2741/2819
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580
   Huang EY, 2012, J BONE MINER RES, V27, P1566, DOI 10.1002/jbmr.1622
   Huang EY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032428
   Huang JY, 2009, LIVER INT, V29, P1569, DOI 10.1111/j.1478 3231.2009.02111.x
   Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   Kang Q, 2009, STEM CELLS DEV, V18, P545, DOI 10.1089/scd.2008.0130
   López Coviella I, 2000, SCIENCE, V289, P313, DOI 10.1126/science.289.5477.313
   Luo J, 2007, NAT PROTOC, V2, P1236, DOI 10.1038/nprot.2007.135
   Luo JY, 2010, J BIOL CHEM, V285, P29588, DOI 10.1074/jbc.M110.130518
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Luo Q, 2007, GENE, V395, P160, DOI 10.1016/j.gene.2007.02.030
   Luo XJ, 2008, LAB INVEST, V88, P1264, DOI 10.1038/labinvest.2008.98
   Luther G, 2011, CURR GENE THER, V11, P229
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022
   Mitchell D, 2010, MOL CANCER THER, V9, P379, DOI 10.1158/1535 7163.MCT 09 0650
   Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191
   Park JES, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030075
   Peng Y, 2004, J BIOL CHEM, V279, P32941, DOI 10.1074/jbc.M403344200
   Peng Y, 2003, J CELL BIOCHEM, V90, P1149, DOI 10.1002/jcb.10744
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Rastegar F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014182
   Scharpfenecker M, 2007, J CELL SCI, V120, P964, DOI 10.1242/jcs.002949
   Sharff KA, 2009, J BIOL CHEM, V284, P649, DOI 10.1074/jbc.M806389200
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092 8674(03)00432 X
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   SONG JJ, 1995, ENDOCRINOLOGY, V136, P4293, DOI 10.1210/en.136.10.4293
   Su Y, 2011, ONCOGENE, V30, P3907, DOI 10.1038/onc.2011.97
   Suzuki Y, 2010, J CELL SCI, V123, P1684, DOI 10.1242/jcs.061556
   Tang N, 2009, J CELL MOL MED, V13, P2448, DOI 10.1111/j.1582 4934.2008.00569.x
   Truksa J, 2006, P NATL ACAD SCI USA, V103, P10289, DOI 10.1073/pnas.0603124103
   Varga AC, 2005, ONCOGENE, V24, P5713, DOI 10.1038/sj.onc.1208919
   Wan C, 2008, P NATL ACAD SCI USA, V105, P686, DOI 10.1073/pnas.0708474105
   Wan C, 2010, ANN NY ACAD SCI, V1192, P322, DOI 10.1111/j.1749 6632.2009.05238.x
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581
   Yao YC, 2012, BLOOD, V119, P5037, DOI 10.1182/blood 2011 10 385906
   Zhang JW, 2005, DEV BIOL, V284, P1, DOI 10.1016/j.ydbio.2005.05.009
   Zhang WL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011917
   Zhu GH, 2009, DIFFERENTIATION, V78, P195, DOI 10.1016/j.diff.2009.06.001
NR 48
TC 104
Z9 114
U1 2
U2 25
PU COMPANY BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
SN 0021 9533
EI 1477 9137
J9 J CELL SCI
JI J. Cell Sci.
PD JAN 15
PY 2013
VL 126
IS 2
BP 532
EP 541
DI 10.1242/jcs.114231
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 117IA
UT WOS:000316945600016
PM 23203800
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Han, N
   Yan, ZQ
   Guo, CA
   Shen, F
   Liu, J
   Shi, YX
   Zhang, ZY
AF Han, Ning
   Yan, Zuoqin
   Guo, Chang an
   Shen, Feng
   Liu, Jun
   Shi, Yuxing
   Zhang, Zhiyong
TI Effects of P Glycoprotein on Steroid Induced Osteonecrosis of the
   Femoral Head
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE P glycoprotein; Steroid; Osteonecrosis; Bone marrow stromal cell;
   Adipogenesis
ID MULTIDRUG RESISTANT CELLS; BONE MARROW; INDUCED ADIPOGENESIS;
   CYCLOSPORINE A; STEM CELLS; GLUCOCORTICOIDS; APOPTOSIS; DIFFERENTIATION;
   ACCUMULATION; OSTEOBLASTS
AB P glycoprotein (P gp) activity may play an important role in steroid induced osteonecrosis of the femoral head (ONF); however, the precise mechanism of its pathogenesis remains unknown. Therefore, we investigated the effects of increased P gp activity on steroid induced ONF using a rat model. Rats (n = 60) were treated with either a pharmacological stimulant of P gp, rifampicin (group A); a suppressant, verapamil (group B); or normal saline (group C) administered in conjunction with methylprednisolone, an inducer of ONF. P gp activity in bone marrow cells and expression in the femoral head significantly increased in group A (P < 0.05) but decreased in group B (P < 0.05). Likewise, the serum osteocalcin level, trabecular thickness and number, osteoclast and osteoblast numbers, and mean percentage of the epiphyseal ossification center were significantly increased in group A (P < 0.01) but decreased in group B (P < 0.01). In contrast, however, adipocytic variables, trabecular separation, and apoptotic cells decreased in group A (P < 0.01) but increased in group B (P < 0.01). The ONF incidence in group A (50%) and group B (100%) was significantly different from that in the control group C (80%, P < 0.05). Taken together, our findings suggested that enhanced P gp activity was able to decrease the risk of steroid induced ONF, possibly by inhibiting adipogenesis and apoptosis in the femoral head.
C1 [Han, Ning; Yan, Zuoqin; Guo, Chang an; Shen, Feng; Liu, Jun] Fudan Univ, Zhongshan Hosp, Shanghai 200032, Peoples R China.
   [Yan, Zuoqin] Fudan Univ, Shanghai Med Coll, Shanghai 200032, Peoples R China.
   [Shi, Yuxing; Zhang, Zhiyong] Fudan Univ, Publ Hlth Clin Ctr, Shanghai 200032, Peoples R China.
C3 Fudan University; Fudan University; Fudan University
RP Yan, ZQ (通讯作者)，Fudan Univ, Zhongshan Hosp, 180 Fenglin Rd, Shanghai 200032, Peoples R China.
EM yan.zuoqin@zs hospital.sh.cn
RI Zhang, Zhiyong/HJI 4999 2023; han, ning/LBH 4161 2024
FU Shanghai Natural Science Foundation [07ZR14023, 10411962500]
FX This work was supported by the Shanghai Natural Science Foundation
   (grants 07ZR14023 and 10411962500).
CR Arellano C, 2007, J PHARM PHARM SCI, V10, P26
   Asano Takeshi, 2003, Pharmacogenetics, V13, P675, DOI 10.1097/00008571 200311000 00003
   Barnes KM, 1996, BIOCHEMISTRY US, V35, P4820, DOI 10.1021/bi952380k
   Clemens TL, 1997, J BONE MINER RES, V12, P1570, DOI 10.1359/jbmr.1997.12.10.1570
   Cui Q, 1997, J BONE JOINT SURG AM, V79A, P1054, DOI 10.2106/00004623 199707000 00012
   Cui QJ, 2000, CONNECT TISSUE RES, V41, P45
   Dempster DW, 1997, J ENDOCRINOL, V154, P397, DOI 10.1677/joe.0.1540397
   Drescher W, 2001, J BONE JOINT SURG BR, V83B, P274, DOI 10.1302/0301 620X.83B2.10323
   Erben RG, 1998, J BONE MINER RES, V13, P79, DOI 10.1359/jbmr.1998.13.1.79
   FARDEL O, 1995, BIOCHEM PHARMACOL, V49, P1255, DOI 10.1016/0006 2952(95)00045 2
   FELLER N, 1995, BRIT J CANCER, V72, P543, DOI 10.1038/bjc.1995.371
   FICAT RP, 1985, J BONE JOINT SURG BR, V67, P3, DOI 10.1302/0301 620X.67B1.3155745
   Hernigou P, 1999, J BONE JOINT SURG BR, V81B, P349, DOI 10.1302/0301 620X.81B2.8818
   Karssen AM, 2002, J ENDOCRINOL, V175, P251, DOI 10.1677/joe.0.1750251
   Kerachian MA, 2009, J STEROID BIOCHEM, V114, P121, DOI 10.1016/j.jsbmb.2009.02.007
   Kim HJ, 2006, J CLIN INVEST, V116, P2152, DOI 10.1172/JCI28084
   Kuribayashi M, 2008, J ORTHOP SCI, V13, P297, DOI 10.1007/s00776 008 1244 4
   Lee JS, 2006, J ORTHOP RES, V24, P604, DOI 10.1002/jor.20078
   Li XD, 2003, BONE, V33, P652, DOI 10.1016/S8756 3282(03)00239 4
   Miyanishi K, 2002, BONE, V30, P185, DOI 10.1016/S8756 3282(01)00663 9
   Miyanishi K, 2008, IMMUNOPHARM IMMUNOT, V30, P79, DOI [10.1080/08923970701812647, 10.1080/08923970701812647 ]
   Miyanishi K, 2006, ACTA ORTHOP, V77, P813, DOI 10.1080/17453670610013042
   Motomura G, 2005, PATHOL RES PRACT, V200, P807, DOI 10.1016/j.prp.2004.10.003
   Murata M, 2007, J ORTHOP SCI, V12, P289, DOI 10.1007/s00776 007 1129 y
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Odening KE, 2009, CLIN EXP IMMUNOL, V155, P239, DOI 10.1111/j.1365 2249.2008.03817.x
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Parkinson IH, 2003, J BONE MINER RES, V18, P2200, DOI 10.1359/jbmr.2003.18.12.2200
   Seki M, 1998, ARTHRITIS RHEUM, V41, P823, DOI 10.1002/1529 0131(199805)41:5<823::AID ART8>3.0.CO;2 #
   Sekiya I, 2004, J BONE MINER RES, V19, P256, DOI 10.1359/JBMR.0301220
   SHEAGREN JN, 1977, J LAB CLIN MED, V89, P120
   Sivagurunathan S, 2005, J BONE MINER RES, V20, P390, DOI 10.1359/JBMR.041233
   Vautier S, 2006, EUR J PHARM SCI, V27, P167, DOI 10.1016/j.ejps.2005.09.009
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Yin L, 2006, CHINESE MED J PEKING, V119, P581, DOI 10.1097/00029330 200604010 00012
NR 35
TC 32
Z9 39
U1 0
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 967X
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD SEP
PY 2010
VL 87
IS 3
BP 246
EP 253
DI 10.1007/s00223 010 9385 9
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 640WS
UT WOS:000281085300007
PM 20593167
DA 2025 08 17
ER

PT J
AU Zhan, JD
   Yan, ZJ
   Zhao, MY
   Qi, WH
   Lin, J
   Lin, Z
   Huang, YJ
   Pan, XY
   Xue, XH
AF Zhan, Jingdi
   Yan, Zijian
   Zhao, Mengyao
   Qi, Weihui
   Lin, Jian
   Lin, Zeng
   Huang, Yijiang
   Pan, Xiaoyun
   Xue, Xinghe
TI Allicin inhibits osteoblast apoptosis and steroid induced necrosis of
   femoral head progression by activating the PI3K/AKT pathway
SO FOOD & FUNCTION
LA English
DT Article
ID INDUCED OSTEONECROSIS; AVASCULAR NECROSIS; BONE; CELLS; MITOCHONDRIA;
   MECHANISMS; EXPRESSION; STABILITY; CHEMISTRY; INSIGHTS
AB Steroid induced avascular necrosis of the femoral head (SANFH) is a major complication of long term or excessive clinical use of glucocorticoids. Allicin is a classical ingredient extracted from garlic and has many functions such as anti apoptosis and antibacterial effects. The purpose of this study was to investigate the effect and the mechanism of allicin on apoptosis of osteoblasts induced by dexamethasone (Dex) and SANFH in rats.In vitro, we performed CCK 8, western blotting, TUNEL and other experiments, and the results of these experiments showed that allicin could inhibit the Dex induced abnormal expression of C caspase3, C caspase9, Bax, cytochrome C and Bcl 2 by activating the PI3K/AKT pathway.In vivo, the results of micro CT, hematoxylin eosin staining and immunohistochemical analysis suggested that allicin could effectively inhibit the progress of SANFH in rats. In summary, our experiments indicate that allicin is a potential drug for the treatment of SANFH.
C1 [Zhan, Jingdi; Yan, Zijian; Zhao, Mengyao; Qi, Weihui; Lin, Jian; Lin, Zeng; Huang, Yijiang; Pan, Xiaoyun; Xue, Xinghe] Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed, Wenzhou 325000, Zhejiang, Peoples R China.
   [Zhan, Jingdi; Yan, Zijian; Zhao, Mengyao; Qi, Weihui; Lin, Jian; Lin, Zeng; Huang, Yijiang; Pan, Xiaoyun; Xue, Xinghe] Wenzhou Med Univ, Yuying Childrens Hosp, Dept Orthopaed, Wenzhou 325000, Zhejiang, Peoples R China.
   [Zhan, Jingdi; Yan, Zijian; Zhao, Mengyao; Qi, Weihui; Lin, Zeng] Zhejiang Prov Key Lab Orthopaed, Wenzhou 325000, Zhejiang, Peoples R China.
   [Zhan, Jingdi; Yan, Zijian; Zhao, Mengyao; Qi, Weihui; Lin, Zeng] Wenzhou Med Univ, Sch Med 2, Wenzhou 325000, Zhejiang, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical
   University
RP Huang, YJ; Pan, XY; Xue, XH (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed, Wenzhou 325000, Zhejiang, Peoples R China.; Huang, YJ; Pan, XY; Xue, XH (通讯作者)，Wenzhou Med Univ, Yuying Childrens Hosp, Dept Orthopaed, Wenzhou 325000, Zhejiang, Peoples R China.
EM yijiang0116@yahoo.com; xiaoyunpan@126.com; xinghe901130@163.com
RI Qi, Weihui/IQS 9384 2023; Zhan, Jingdi/NOF 7238 2025; Zhao,
   Mengyao/KQU 7993 2024; qi, weihui/IQS 9384 2023
OI Qi, Weihui/0000 0003 2893 8589; Xue, Xinghe/0000 0003 3300 7287; 
FU Wenzhou Municipal Science and Technology Bureau [Y20180027]
FX This work was funded by Wenzhou Municipal Science and Technology Bureau
   (Y20180027).
CR Aziz SA, 2009, CLIN CANCER RES, V15, P3029, DOI 10.1158/1078 0432.CCR 08 2768
   Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001
   Beckmann R, 2014, SCI WORLD J, DOI 10.1155/2014/347813
   Borlinghaus J, 2014, MOLECULES, V19, P12591, DOI 10.3390/molecules190812591
   Borutaite V, 2003, FEBS LETT, V541, P1, DOI 10.1016/S0014 5793(03)00278 3
   Chan SL, 2004, CLIN EXP PHARMACOL P, V31, P119, DOI 10.1111/j.1440 1681.2004.03975.x
   Choi EM, 2012, INFLAMMATION, V35, P1204, DOI 10.1007/s10753 012 9430 0
   Chua CC, 2003, BBA MOL CELL RES, V1642, P79, DOI 10.1016/S0167 4889(03)00100 9
   Deng S, 2019, BIOMED PHARMACOTHER, V110, P602, DOI 10.1016/j.biopha.2018.11.103
   Ding GL, 2016, EXP THER MED, V11, P2553, DOI 10.3892/etm.2016.3179
   Dong YL, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891 015 0589 z
   Fan JB, 2015, MOL CELL BIOCHEM, V398, P105, DOI 10.1007/s11010 014 2210 4
   FELDBERG RS, 1988, ANTIMICROB AGENTS CH, V32, P1763, DOI 10.1128/AAC.32.12.1763
   Feng ZH, 2017, APOPTOSIS, V22, P1001, DOI 10.1007/s10495 017 1383 1
   FREEMAN F, 1995, J AGR FOOD CHEM, V43, P2332, DOI 10.1021/jf00057a004
   Fujisawa H, 2008, J AGR FOOD CHEM, V56, P4229, DOI 10.1021/jf8000907
   Gohel A, 1999, ENDOCRINOLOGY, V140, P5339, DOI 10.1210/en.140.11.5339
   Gu YX, 2013, J BIOMED MATER RES A, V101, P748, DOI 10.1002/jbm.a.34377
   Guntur AR, 2011, J ENDOCRINOL, V211, P123, DOI 10.1530/JOE 11 0175
   Hirsch K, 2000, NUTR CANCER, V38, P245, DOI 10.1207/S15327914NC382_14
   Hu WP, 2007, CHEM RES TOXICOL, V20, P905, DOI 10.1021/tx6003387
   La Corte R, 2010, CURR PHARM DESIGN, V16, P3586, DOI 10.2174/138161210793797924
   Li DW, 2014, MOL MED REP, V9, P2043, DOI 10.3892/mmr.2014.2080
   Li LR, 2011, CELL BIOL INT, V35, P961, DOI 10.1042/CBI20100544
   Li XH, 2012, CARDIOVASC DRUG THER, V26, P457, DOI 10.1007/s10557 012 6415 z
   Lin J, 2019, J BIOCHEM MOL TOXIC, V33, DOI 10.1002/jbt.22265
   Low SC, 2014, J ORTHOP RES, V32, P826, DOI 10.1002/jor.22611
   Lu ZY, 2017, CHEM BIOL INTERACT, V271, P67, DOI 10.1016/j.cbi.2017.04.027
   Magaki S, 2019, METHODS MOL BIOL, V1897, P289, DOI 10.1007/978 1 4939 8935 5_25
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Murata M, 2007, J ORTHOP SCI, V12, P289, DOI 10.1007/s00776 007 1129 y
   Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929
   Qin Ling, 2008, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V22, P258
   ROBERTSON NM, 1993, MOL ENDOCRINOL, V7, P1226, DOI 10.1210/me.7.9.1226
   Samra YA, 2020, J BIOCHEM MOL TOXIC, V34, DOI 10.1002/jbt.22470
   Schäcke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163 7258(02)00297 8
   Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097 0142(20001215)89:12<2637::AID CNCR17>3.0.CO;2 B
   Spreafico A, 2006, J CELL BIOCHEM, V98, P1007, DOI 10.1002/jcb.20836
   Steffen RT, 2010, J BONE JOINT SURG BR, V92B, P787, DOI 10.1302/0301 620X.92B6.23377
   Tanaka Y, 2010, PEDIATR NEPHROL, V25, P877, DOI 10.1007/s00467 009 1341 4
   Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312
   Tong PJ, 2011, CALCIFIED TISSUE INT, V89, P271, DOI 10.1007/s00223 011 9516 y
   Wang J, 2017, BIOL TRACE ELEM RES, V179, P284, DOI 10.1007/s12011 017 0948 8
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049
   Xu XX, 2014, J MOL HISTOL, V45, P473, DOI 10.1007/s10735 014 9571 6
   Yamamoto T, 1997, ARTHRITIS RHEUM, V40, P2055, DOI 10.1002/art.1780401119
   Yun SI, 2009, J BONE MINER METAB, V27, P140, DOI 10.1007/s00774 008 0019 5
   Zalavras C, 2003, CRIT REV EUKAR GENE, V13, P221, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i24.140
   Zhang J, 2000, J IMMUNOL, V165, P2970, DOI 10.4049/jimmunol.165.6.2970
   Zhang LL, 2012, FOOD CHEM TOXICOL, V50, P2591, DOI 10.1016/j.fct.2012.05.045
   Zhang Y, 2020, J CELL PHYSIOL, V235, P5511, DOI 10.1002/jcp.29261
   Zhu YF, 2011, J REINF PLAST COMP, V30, P809, DOI 10.1177/0731684411411336
NR 53
TC 29
Z9 37
U1 1
U2 22
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2042 6496
EI 2042 650X
J9 FOOD FUNCT
JI Food Funct.
PD SEP 1
PY 2020
VL 11
IS 9
BP 7830
EP 7841
DI 10.1039/d0fo00837k
PG 12
WC Biochemistry & Molecular Biology; Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Food Science & Technology
GA NS8ZN
UT WOS:000572544200038
PM 32808945
DA 2025 08 17
ER

PT J
AU Ralston, SH
AF Ralston, Stuart H.
TI Bisphosphonates in the management of Paget's disease
SO BONE
LA English
DT Article
DE Paget's disease; Bisphosphonates; Clinical trials
ID DISTEMPER VIRUS TRANSCRIPTS; GENOME WIDE ASSOCIATION; ACUTE PHASE
   RESPONSE; MEASLES VIRUS; DOUBLE BLIND; ZOLEDRONIC ACID; SINGLE INFUSION;
   DICHLOROMETHYLENE DIPHOSPHONATE; SYMPTOMATIC MANAGEMENT; DISODIUM
   ETIDRONATE
AB The first clinical use of bisphosphonates was in Paget's disease of bone (PDB) when disodium etidronate was found to be effective at suppressing metabolic activity of the disease. Subsequently, PDB became a testing ground for many bisphosphonates using changes in alkaline phosphatase (ALP) as the primary outcome measure in clinical trials. Bisphosphonates are now considered to be the treatment of choice for PDB since they are highly effective at suppressing the elevations in bone turnover that are characteristic of the disease. Short term studies have shown that treatment with alendronate and risedronate can promote formation of lamellar bone in affected sites and improve x ray appearances in some patients. Bisphosphonates have also been shown to improve bone pain in PDB and within the bisphosphonates, zoledronic acid (ZA) is most likely to give a favourable pain response. Many patients with PDB do not have pain however, even when there is increased metabolic activity and more research is needed to find out why this is the case. The effects of bisphosphonates on complications of PDB such as deformity, pathological fractures and deafness have not been adequately studied since most clinical trials have been short term and have not collected information on these important outcomes. The PRISM and PRISM EZ studies investigated the long term effects of bisphosphonates in patients with established PDB using a treat to target approach and showed that intensive bisphosphonate therapy aimed at normalising ALP was no more effective than symptom directed treatment with bisphosphonates at preventing complications of PDB. The Zoledronate in the Prevention of Paget's Disease (ZiPP) trial, which is currently in progress, seeks to determine whether early intervention with this potent bisphosphonate might be effective in preventing disease progression. Should the ZiPP study yield positive results, genetic testing coupled to prophylactic bisphosphonate therapy might represent a new indication for these highly effective inhibitors of bone resorption in future years.
C1 [Ralston, Stuart H.] Univ Edinburgh, Ctr Genom & Expt Med, MRC Inst Genet & Mol Med, Edinburgh EH4 2XU, Midlothian, Scotland.
C3 University of Edinburgh
RP Ralston, SH (通讯作者)，Univ Edinburgh, Ctr Genom & Expt Med, MRC Inst Genet & Mol Med, Edinburgh EH4 2XU, Midlothian, Scotland.
EM stuart.ralston@ed.ac.uk
OI Ralston, Stuart/0000 0002 2804 7586
FU European Research Council (Paget Advance) [787270]; European Research
   Council (ERC) [787270] Funding Source: European Research Council (ERC)
FX Professor Ralston's research on Paget's disease of Bone is supported by
   an advanced investigator award from the European Research Council (Paget
   Advance, 787270).
CR Albagha OME, 2013, J BONE MINER RES, V28, P2338, DOI 10.1002/jbmr.1975
   Albagha OME, 2011, NAT GENET, V43, P685, DOI 10.1038/ng.845
   Albagha OME, 2010, NAT GENET, V42, P520, DOI 10.1038/ng.562
   ALEXANDRE C, 1981, METAB BONE DIS RELAT, V3, P309, DOI 10.1016/0221 8747(81)90047 3
   ALEXANDRE CM, 1983, CLIN ORTHOP RELAT R, P193
   ALTMAN RD, 1973, NEW ENGL J MED, V289, P1379, DOI 10.1056/NEJM197312272892601
   ArdenCordone M, 1997, CALCIFIED TISSUE INT, V60, P415, DOI 10.1007/s002239900255
   BARKER DJP, 1974, BRIT J PREV SOC MED, V28, P226
   BIRCH MA, 1994, J BONE MINER RES, V9, P11
   BOYCE BF, 1984, LANCET, V1, P821
   Brown JP, 2000, BONE, V26, P263, DOI 10.1016/S8756 3282(99)00271 9
   Brown JP, 1999, CALCIFIED TISSUE INT, V64, P93, DOI 10.1007/s002239900584
   Buckler H, 1999, BONE, V24, p81S, DOI 10.1016/S8756 3282(99)00071 X
   CANTRILL JA, 1986, ANN RHEUM DIS, V45, P1012, DOI 10.1136/ard.45.12.1012
   Corral Gudino L, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004956.pub3
   Corral Gudino L, 2013, BONE, V55, P347, DOI 10.1016/j.bone.2013.04.024
   Cronin O, 2020, J BONE MINER RES, V35, P1246, DOI 10.1002/jbmr.4007
   Cronin O, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen 2019 030689
   Cundy T, 2017, J BONE MINER RES, V32, P753, DOI 10.1002/jbmr.3029
   Daroszewska A, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.035576
   Daroszewska A, 2011, HUM MOL GENET, V20, P2734, DOI 10.1093/hmg/ddr172
   DELMAS PD, 1982, J CLIN ENDOCR METAB, V54, P837, DOI 10.1210/jcem 54 4 837
   Fraser WD, 1997, POSTGRAD MED J, V73, P496, DOI 10.1136/pgmj.73.862.496
   Friedrichs WE, 2002, J BONE MINER RES, V17, P2293, DOI 10.1359/jbmr.2002.17.12.2293
   FRIJLINK WB, 1979, LANCET, V1, P799
   GALLACHER SJ, 1991, ANN RHEUM DIS, V50, P930, DOI 10.1136/ard.50.12.930
   GALLACHER SJ, 1989, LANCET, V2, P42
   Gennari L, 2019, CALCIFIED TISSUE INT, V104, P483, DOI 10.1007/s00223 019 00522 3
   GORDON MT, 1992, BONE MINER, V19, P159, DOI 10.1016/0169 6009(92)90923 2
   Grauer A, 1999, BONE, V24, p87S, DOI 10.1016/S8756 3282(99)00072 1
   HARINCK HIJ, 1987, BMJ BRIT MED J, V295, P1301, DOI 10.1136/bmj.295.6609.1301
   Helfrich MH, 2000, J BONE MINER RES, V15, P2315, DOI 10.1359/jbmr.2000.15.12.2315
   Hewitt RE, 2005, CLIN EXP IMMUNOL, V139, P101, DOI 10.1111/j.1365 2249.2005.02665.x
   Hosking D, 2007, J BONE MINER RES, V22, P142, DOI 10.1359/JBMR.061001
   Hosking DJ, 1998, BONE, V22, P51, DOI 10.1016/S8756 3282(97)00222 6
   Idris AI, 2008, CALCIFIED TISSUE INT, V82, P191, DOI 10.1007/s00223 008 9104 y
   JOHNSTON CC, 1980, ARTHRITIS RHEUM, V23, P1172, DOI 10.1002/art.1780231015
   KHAIRI MRA, 1974, JAMA J AM MED ASSOC, V230, P562, DOI 10.1001/jama.230.4.562
   KHAIRI MRA, 1977, ANN INTERN MED, V87, P656, DOI 10.7326/0003 4819 87 6 656
   Kurihara N, 2006, J BONE MINER RES, V21, P446, DOI 10.1359/JBMR.051108
   Kurihara N, 2011, CELL METAB, V13, P23, DOI 10.1016/j.cmet.2010.12.002
   Langston AL, 2010, J BONE MINER RES, V25, P20, DOI 10.1359/jbmr.090709
   Lever JH, 2002, BONE, V31, P434, DOI 10.1016/S8756 3282(02)00833 5
   Matthews BG, 2008, J CLIN ENDOCR METAB, V93, P1398, DOI 10.1210/jc.2007 1978
   Merlotti D., J CLIN ENDOCRINOL ME, V105
   Merlotti D, 2007, J BONE MINER RES, V22, P1510, DOI 10.1359/JBMR.070704
   Merlotti D, 2011, J BONE MINER RES, V26, P512, DOI 10.1002/jbmr.237
   MEUNIER PJ, 1980, ARTHRITIS RHEUM US, V23, P1095, DOI 10.1002/art.1780231005
   MEUNIER PJ, 1979, LANCET, V2, P489
   Miller PD, 1999, AM J MED, V106, P513, DOI 10.1016/S0002 9343(99)00062 5
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   MONSELL EM, 1995, HEARING RES, V83, P114, DOI 10.1016/0378 5955(94)00196 W
   MONTAGU MFA, 1949, AM J HUM GENET, V1, P94
   ODOHERTY DP, 1992, J BONE MINER RES, V7, P81
   ODOHERTY DP, 1995, J BONE MINER RES, V10, P1094
   ODRISCOLL JB, 1985, LANCET, V2, P919
   Ooi CG, 2000, BONE, V27, P417, DOI 10.1016/S8756 3282(00)00343 4
   RALSTON SH, 1987, J BONE MINER RES, V2, P5
   RALSTON SH, 1991, J BONE MINER RES, V6, P1243
   Ralston SH, 2007, J BONE MINER RES, V22, P569, DOI 10.1359/JBMR.070103
   Ralston SH, 2020, J BONE MINER RES, V35, P1385, DOI 10.1002/jbmr.4090
   Ralston SH, 2019, CALCIFIED TISSUE INT, V104, P501, DOI 10.1007/s00223 019 00520 5
   Ralston SH, 2019, J BONE MINER RES, V34, P579, DOI 10.1002/jbmr.3657
   REBEL A, 1974, REV RHUM, V41, P767
   Reddy SV, 1996, J BONE MINER RES, V11, P1602
   REGINSTER JY, 1992, ARTHRITIS RHEUM, V35, P967, DOI 10.1002/art.1780350819
   Reid IR, 2010, J CLIN ENDOCR METAB, V95, P4380, DOI 10.1210/jc.2010 0597
   Reid IR, 2017, CALCIFIED TISSUE INT, V100, P250, DOI 10.1007/s00223 016 0214 7
   Reid IR, 2011, J BONE MINER RES, V26, P2261, DOI 10.1002/jbmr.438
   Reid IR, 1996, AM J MED, V101, P341, DOI 10.1016/S0002 9343(96)00227 6
   Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807
   Reid IR, 2005, NEW ENGL J MED, V353, P898, DOI 10.1056/NEJMoa044241
   Reid IR, 2004, BONE, V35, P224, DOI 10.1016/j.bone.2004.03.023
   Rendina D, 2019, CALCIFIED TISSUE INT, V105, P412, DOI 10.1007/s00223 019 00578 1
   Reyes C, 2016, J CELL BIOCHEM, V117, P20, DOI 10.1002/jcb.25266
   Rima BK, 2002, J BONE MINER RES, V17, P2290, DOI 10.1359/jbmr.2002.17.12.2290
   Roelofs AJ, 2010, J BONE MINER RES, V25, P606, DOI 10.1359/jbmr.091009
   ROUX C, 1995, ARTHRITIS RHEUM, V38, P851, DOI 10.1002/art.1780380620
   RUDDLE NH, 1993, VIROLOGY, V197, P196, DOI 10.1006/viro.1993.1580
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Scotto di Carlo F, 2020, J BONE MINER RES, V35, P1387, DOI 10.1002/jbmr.3964
   Siris E, 1996, J CLIN ENDOCR METAB, V81, P961, DOI 10.1210/jc.81.3.961
   SIRIS ES, 1994, SEMIN ARTHRITIS RHEU, V23, P222, DOI 10.1016/0049 0172(94)90037 X
   SIRIS ES, 1991, J BONE MINER RES, V6, P495
   Siris ES, 1998, J BONE MINER RES, V13, P1032, DOI 10.1359/jbmr.1998.13.6.1032
   SMITH R, 1971, LANCET, V1, P945
   SOFAER JA, 1983, J EPIDEMIOL COMMUN H, V37, P226, DOI 10.1136/jech.37.3.226
   SOLOMON LR, 1979, BRIT MED J, V1, P931, DOI 10.1136/bmj.1.6168.931
   STONE MD, 1990, J BONE MINER RES, V5, P1231
   Tan A, 2017, J BONE MINER RES, V32, P1165, DOI 10.1002/jbmr.3066
   Tan A, 2014, CALCIFIED TISSUE INT, V95, P385, DOI 10.1007/s00223 014 9904 1
   Taylor JP, 2015, NEUROLOGY, V85, P658, DOI 10.1212/WNL.0000000000001862
   Van Staa TP, 2002, J BONE MINER RES, V17, P465, DOI 10.1359/jbmr.2002.17.3.465
   Visconti MR, 2017, CALCIFIED TISSUE INT, V101, P141, DOI 10.1007/s00223 017 0265 4
   Walsh JP, 2004, BONE, V34, P747, DOI 10.1016/j.bone.2003.12.011
   YATES AJP, 1985, LANCET, V1, P1474
NR 97
TC 22
Z9 23
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD SEP
PY 2020
VL 138
AR 115465
DI 10.1016/j.bone.2020.115465
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA MX7BQ
UT WOS:000557876000011
PM 32512166
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Ohbayashi, Y
   Nakai, F
   Iwasaki, A
   Ogawa, T
   Yamamoto, Y
   Nishiyama, Y
   Miyake, M
AF Ohbayashi, Yumiko
   Nakai, Fumi
   Iwasaki, Akinori
   Ogawa, Takaaki
   Yamamoto, Yuka
   Nishiyama, Yoshihiro
   Miyake, Minoru
TI The utility of bone scintigraphy in the assessment of mandibular
   metabolism during long term bisphosphonate administration
SO ODONTOLOGY
LA English
DT Article
DE Osteonecrosis of the jaw; Bisphosphonate; Bone scintigraphy; Metabolism
ID NITROGEN CONTAINING BISPHOSPHONATES; POSTMENOPAUSAL OSTEOPOROTIC WOMEN;
   IN VITRO; METHYLENE DIPHOSPHONATE; OSTEOCLAST FORMATION; MEVALONATE
   PATHWAY; CORTICAL BONE; RISK FACTORS; JAW; ALENDRONATE
AB The duration of antiresorptive therapy is an important risk factor for medication related osteonecrosis of the jaw. We performed a pilot study using quantitative analysis by bone scintigraphy to test the hypothesis that mandibular metabolism is affected by long term bisphosphonate (BP) therapy. Our primary objectives were to assess changes in bone metabolism of the mandible in response to long term BP therapy and compare the bone metabolism changes of the mandible with other bone sites. We compared the metabolic difference at the site in the mandible unaffected by disease, the humerus and the femur between 14 osteoporosis patients who were being treated with BP (BP group) and 14 patients who were not being treated with BP (control group) using a quantitative analysis and bone scintigraphy. Study endpoints were the mean and maximum bone uptake values (BUVs) quantified using bone scintigraphy images of the mandible, humerus and femur. Quantified images of the site in the mandible unaffected by disease had significantly higher mean and maximum BUVs compared to the controls (mean, 0.74 vs. 0.49, p = 0.019; max., 1.29 vs. 0.85, p = 0.009, respectively). The mean and maximum BUV of femur ROIs in the BP group were significantly lower than those in control patients (mean BUV, 0.23 vs. 0.30, p = 0.039; max. BUV, 0.43 vs. 0.53, p = 0.024, respectively). This is the first report of mandible changes in response to long term BP treatment, using bone scintigraphy. The results using bone scintigraphy demonstrated that the bone metabolism of the intact mandible is affected by a long term administration of BP.
C1 [Ohbayashi, Yumiko; Nakai, Fumi; Iwasaki, Akinori; Ogawa, Takaaki; Miyake, Minoru] Kagawa Univ, Dept Oral & Maxillofacial Surg, Fac Med, 1750 1 Ikenobe, Miki, Kagawa 7610793, Japan.
   [Yamamoto, Yuka; Nishiyama, Yoshihiro] Kagawa Univ, Dept Radiol, Fac Med, 1750 1 Ikenobe, Miki, Kagawa 7610793, Japan.
C3 Kagawa University; Kagawa University
RP Ohbayashi, Y (通讯作者)，Kagawa Univ, Dept Oral & Maxillofacial Surg, Fac Med, 1750 1 Ikenobe, Miki, Kagawa 7610793, Japan.
EM yumiko@med.kagawa u.ac.jp
FU JSPS KAKENHI [26463011]; Grants in Aid for Scientific Research
   [26463011, 26462841] Funding Source: KAKEN
FX This study was supported by the JSPS KAKENHI, Grant No. 26463011.
CR AAOMS, 2007, J ORAL MAXIL SURG, V65, P369, DOI 10.1016/j.joms.2006.11.003
   Allen MR, 2010, J BONE MINER RES, V25, P98, DOI 10.1359/jbmr.090713
   Allen MR, 2009, J ORAL MAXIL SURG, V67, P61, DOI 10.1016/j.joms.2009.01.007
   Arlot M, 2005, J BONE MINER RES, V20, P1244, DOI 10.1359/JBMR.050309
   Bala Y, 2011, EUR J ENDOCRINOL, V165, P647, DOI 10.1530/EJE 11 0333
   Bauer DC, 2004, J BONE MINER RES, V19, P1250, DOI 10.1359/JBMR.040512
   Boivin GY, 2000, BONE, V27, P687, DOI 10.1016/S8756 3282(00)00376 8
   Borah B, 2005, BONE, V37, P1, DOI 10.1016/j.bone.2005.03.017
   Breuil V, 1998, J BONE MINER RES, V13, P1721, DOI 10.1359/jbmr.1998.13.11.1721
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Burr DB, 2009, ORTHOD CRANIOFAC RES, V12, P221, DOI 10.1111/j.1601 6343.2009.01456.x
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Carnevale V, 2000, J NUCL MED, V41, P1478
   Chapurlat RD, 2009, OSTEOPOROSIS INT, V20, P1299, DOI 10.1007/s00198 009 0899 9
   Chapurlat RD, 2007, J BONE MINER RES, V22, P1502, DOI 10.1359/JBMR.070609
   Chavassieux P, 2014, J BONE MINER RES, V29, P618, DOI 10.1002/jbmr.2074
   Coxon FP, 2008, BONE, V42, P848, DOI 10.1016/j.bone.2007.12.225
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   FLANAGAN AM, 1989, BONE MINER, V6, P33, DOI 10.1016/0169 6009(89)90021 4
   Gabbert TI, 2015, J CANCER RES CLIN, V141, P749, DOI 10.1007/s00432 014 1853 6
   Gatti D, 2015, EXPERT OPIN PHARMACO, P1
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hoefert S, 2010, CLIN ORAL INVEST, V14, P271, DOI 10.1007/s00784 009 0300 6
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Ito M, 1998, CALCIFIED TISSUE INT, V63, P143, DOI 10.1007/s002239900505
   Iwata K, 2014, BONE, V64, P183, DOI 10.1016/j.bone.2014.04.012
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kimmel DB, 2007, J DENT RES, V86, P1022, DOI 10.1177/154405910708601102
   Kwon JW, 2015, J DENT RES, V94, p212S, DOI 10.1177/0022034515587862
   Lo JC, 2010, J ORAL MAXIL SURG, V68, P243, DOI 10.1016/j.joms.2009.03.050
   Lovy AJ, 2015, OSTEOPOROSIS INT, V26, P1755, DOI 10.1007/s00198 015 3063 8
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   Morris PG, 2011, J ORAL MAXIL SURG, V69, P114, DOI 10.1016/j.joms.2010.06.210
   O'Ryan FS, 2009, J ORAL MAXIL SURG, V67, P1363, DOI 10.1016/j.joms.2009.03.005
   OKAMOTO Y, 1995, ORAL SURG ORAL MED O, V80, P115, DOI 10.1016/S1079 2104(95)80027 1
   Orriss IR, 2009, J CELL BIOCHEM, V106, P109, DOI 10.1002/jcb.21983
   Patel Vishal C, 2010, Orthopedics, V33, P775, DOI 10.3928/01477447 20100826 31
   Reszka Alfred A, 2003, Curr Rheumatol Rep, V5, P65, DOI 10.1007/s11926 003 0085 6
   Ristow O, 2014, J ORAL MAXIL SURG, V72, P903, DOI 10.1016/j.joms.2013.11.005
   Ristow O, 2014, BRIT J ORAL MAX SURG, V52, P308, DOI 10.1016/j.bjoms.2014.01.021
   Ristow O, 2014, J CANCER RES CLIN, V140, P487, DOI 10.1007/s00432 014 1588 4
   Roschger P, 2001, BONE, V29, P185, DOI 10.1016/S8756 3282(01)00485 9
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Selander KS, 1996, MOL PHARMACOL, V50, P1127
   Termaat MF, 2005, J BONE JOINT SURG AM, V87A, P2464, DOI 10.2106/JBJS.D.02691
   Tryniszewsk W, 2011, MED SCI MONITOR, V17, pCR563, DOI 10.12659/MSM.881982
   Uchida K, 2009, J NUCL MED, V50, P1808, DOI 10.2967/jnumed.109.062570
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V255, P491, DOI 10.1006/bbrc.1999.0224
   Yamagami Y, 2013, BONE, V54, P1, DOI 10.1016/j.bone.2013.01.016
   Zanglis A, 2007, HELL J NUCL MED, V10, P177
NR 52
TC 15
Z9 16
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1618 1247
EI 1618 1255
J9 ODONTOLOGY
JI Odontology
PD JUL
PY 2017
VL 105
IS 3
BP 382
EP 390
DI 10.1007/s10266 016 0279 9
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA EZ5DM
UT WOS:000404732000014
PM 27770302
DA 2025 08 17
ER

PT J
AU Huang, XR
   Zhu, YF
   Sun, SY
   Gao, X
   Yang, YL
   Xu, HY
   Jin, AT
   Liu, YQ
   Jia, HB
   Dai, QG
   Jiang, LY
AF Huang, Xiangru
   Zhu, Yanfei
   Sun, Siyuan
   Gao, Xin
   Yang, Yiling
   Xu, Hongyuan
   Jin, Anting
   Liu, Yuanqi
   Jia, Hanbing
   Dai, Qinggang
   Jiang, Lingyong
TI Exercise maintains bone homeostasis by promoting osteogenesis through
   STAT3
SO INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Article
DE exercise; mechanical force; STAT3; running wheel; tail suspension; bone
   homeostasis
ID INHIBITS CELL PROLIFERATION; CANCER; DIFFERENTIATION
AB Bone exhibits changes in density, strength, and microarchitecture in relation to mechanical loading mediated by exercise. Appropriate exercise maintains bone homeostasis, while the absence of exercise leads to disuse bone loss. However, the acting mechanism of mechanotransduction in bone remains unclear. We performed the running wheel exercise and tail suspension model to study the effects of exercise on bone metabolism, and found that osteoblastic Signal transducer and activator of transcription 3 (STAT3) activity was closely related to exercise induced bone mass and metabolism changes. With the Flexcell tension loading system in vitro, mechanical force promoted STAT3 activity, which was accompanied by increased osteoblastic differentiation of the bone marrow mesenchymal stem cells (BMSCs). In contrast, the inhibition of STAT3 phosphorylation blocked force induced osteoblastic differentiation. Furthermore, pharmacological inactivation of STAT3 impaired the increase in exercise induced bone mass and osteogenesis. With an inducible conditional deletion mouse model, we found that the osteoblast lineage specific Stat3 deletion could also block force induced osteoblastic differentiation in vitro and impair exercise promoted bone mass and osteogenesis in vivo. This confirmed the crucial role of osteoblastic STAT3 in exercise mediated bone metabolism. Finally, colivelin, a STAT3 agonist, promoted osteoblastic differentiation in vitro and partly rescued exercise loss induced disuse bone loss by improving osteogenesis in the tail suspension model. Taken together, our study revealed the essential role of STAT3 in maintaining exercise mediated bone homeostasis. In addition, STAT3 might act as a potential target for osteoporosis caused by exercise loss.
C1 [Huang, Xiangru; Zhu, Yanfei; Sun, Siyuan; Gao, Xin; Yang, Yiling; Xu, Hongyuan; Jin, Anting; Liu, Yuanqi; Jia, Hanbing; Jiang, Lingyong] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Ctr Craniofacial Orthodont,Dept Oral & Craniomaxi, Shanghai, Peoples R China.
   [Huang, Xiangru; Zhu, Yanfei; Sun, Siyuan; Gao, Xin; Yang, Yiling; Xu, Hongyuan; Jin, Anting; Liu, Yuanqi; Jia, Hanbing; Dai, Qinggang; Jiang, Lingyong] Shanghai Jiao Tong Univ, Coll Stomatol, Shanghai, Peoples R China.
   [Huang, Xiangru; Zhu, Yanfei; Sun, Siyuan; Gao, Xin; Yang, Yiling; Xu, Hongyuan; Jin, Anting; Liu, Yuanqi; Jia, Hanbing; Dai, Qinggang; Jiang, Lingyong] Natl Ctr Stomatol, Shanghai, Peoples R China.
   [Huang, Xiangru; Zhu, Yanfei; Sun, Siyuan; Gao, Xin; Yang, Yiling; Xu, Hongyuan; Jin, Anting; Liu, Yuanqi; Jia, Hanbing; Dai, Qinggang; Jiang, Lingyong] Natl Clin Res Ctr Oral Dis, Shanghai, Peoples R China.
   [Huang, Xiangru; Zhu, Yanfei; Sun, Siyuan; Gao, Xin; Yang, Yiling; Xu, Hongyuan; Jin, Anting; Liu, Yuanqi; Jia, Hanbing; Dai, Qinggang; Jiang, Lingyong] Shanghai Key Lab Stomatol, Shanghai, Peoples R China.
   [Huang, Xiangru; Zhu, Yanfei; Sun, Siyuan; Gao, Xin; Yang, Yiling; Xu, Hongyuan; Jin, Anting; Liu, Yuanqi; Jia, Hanbing; Dai, Qinggang; Jiang, Lingyong] Shanghai Res Inst Stomatol, Shanghai, Peoples R China.
   [Dai, Qinggang] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Peoples Hosp 9,Dent Ctr 2, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University
RP Jiang, LY (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Ctr Craniofacial Orthodont,Dept Oral & Craniomaxi, Shanghai, Peoples R China.; Dai, QG; Jiang, LY (通讯作者)，Shanghai Jiao Tong Univ, Coll Stomatol, Shanghai, Peoples R China.; Dai, QG; Jiang, LY (通讯作者)，Natl Ctr Stomatol, Shanghai, Peoples R China.; Dai, QG; Jiang, LY (通讯作者)，Natl Clin Res Ctr Oral Dis, Shanghai, Peoples R China.; Dai, QG; Jiang, LY (通讯作者)，Shanghai Key Lab Stomatol, Shanghai, Peoples R China.; Dai, QG; Jiang, LY (通讯作者)，Shanghai Res Inst Stomatol, Shanghai, Peoples R China.; Dai, QG (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Peoples Hosp 9,Dent Ctr 2, Shanghai, Peoples R China.
EM daiqinggang@126.com; jianglingyong@sjtu.edu.cn
RI ; Qinggang, Dai/HLV 8212 2023; Huang, Xiangru/ABG 5316 2021
OI Dai, Qinggang/0000 0002 8177 2496; 
FU National Natural Science Foundation of China [81870740, 82071083,
   82271006, 82101048, 81800949]; National Science Foundation of Shanghai
   [21ZR1436900, 22ZR1436700]; Program of Shanghai Academic/Technology
   Research Leader [20XD1422300]; Cross Disciplinary Research Fund of
   Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School
   of Medicine [JYJC202116, JYJC201902]; Clinical Research Plan of SHDC
   [SHDC2020CR4084]; Biomaterials and Regenerative Medicine Institute
   Cooperative Research Project Shanghai Jiao Tong University School of
   Medicine [2022LHB02, YBKB201909, YBKB202216]; Research Discipline Fund
   [KQYJXK2020]; Ninth People's Hospital, Shanghai Jiao Tong University
   School of Medicine, and College of Stomatology, Shanghai Jiao Tong
   University [JYYC003]; Two Hundred Talent Project of Shanghai Jiao Tong
   University School
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This work was
   supported in part by grants from the National Natural Science Foundation
   of China (81870740, 82071083, 82271006, 82101048, 81800949); the
   National Science Foundation of Shanghai (21ZR1436900, 22ZR1436700); the
   Program of Shanghai Academic/Technology Research Leader (20XD1422300);
   the Cross Disciplinary Research Fund of Shanghai Ninth People's
   Hospital, Shanghai Jiao Tong University School of Medicine (JYJC202116,
   JYJC201902); the Clinical Research Plan of SHDC(SHDC2020CR4084); the
   Biomaterials and Regenerative Medicine Institute Cooperative Research
   Project Shanghai Jiao Tong University School of Medicine (2022LHB02);
   the Project of Biobank of Shanghai Ninth People's Hospital, Shanghai
   Jiao Tong University School of Medicine (YBKB201909, YBKB202216); the
   Research Discipline Fund no. KQYJXK2020 from Ninth People's Hospital,
   Shanghai Jiao Tong University School of Medicine, and College of
   Stomatology, Shanghai Jiao Tong University; the Original Exploration
   Project of Shanghai Ninth People's Hospital, Shanghai Jiao Tong
   University School of Medicine (JYYC003); and Two Hundred Talent Project
   of Shanghai Jiao Tong University School.
CR Aigner P, 2019, CYTOKINE, V118, P27, DOI 10.1016/j.cyto.2018.07.014
   Aragona M, 2013, CELL, V154, P1047, DOI 10.1016/j.cell.2013.07.042
   Chen HJ, 2013, EUR J MED CHEM, V62, P498, DOI 10.1016/j.ejmech.2013.01.023
   Chiu YS, 2021, BONE, V151, DOI 10.1016/j.bone.2021.116024
   Corry KA, 2019, BONE REP, V11, DOI 10.1016/j.bonr.2019.100218
   Ding L, 2010, CELL RES, V20, P784, DOI 10.1038/cr.2010.79
   DUNCAN RL, 1995, CALCIFIED TISSUE INT, V57, P344, DOI 10.1007/BF00302070
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Frost HM, 2000, J BONE MINER METAB, V18, P305, DOI 10.1007/s007740070001
   Gong XY, 2023, J BONE MINER RES, V38, P214, DOI 10.1002/jbmr.4744
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hubbard JM, 2017, DRUGS, V77, P1091, DOI 10.1007/s40265 017 0759 4
   Ishihara A, 1998, J APPL PHYSIOL, V84, P2183, DOI 10.1152/jappl.1998.84.6.2183
   Itoh S, 2006, BONE, V39, P505, DOI 10.1016/j.bone.2006.02.074
   Jin A, 2022, J DENT RES, V101, P196, DOI 10.1177/00220345211021534
   Jin YQ, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 68068 1
   Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8
   Kanai M, 2003, ONCOGENE, V22, P548, DOI 10.1038/sj.onc.1206109
   Kusaba M, 2007, J HEPATOL, V47, P546, DOI 10.1016/j.jhep.2007.04.017
   Lin WX, 2013, BMC MICROBIOL, V13, DOI [10.1186/1472 6882 13 144, 10.1186/1471 2180 13 135]
   Liu Y, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12974
   McGregor NE, 2022, J BONE MINER RES, V37, P547, DOI 10.1002/jbmr.4484
   Nam J, 2015, BONE, V78, P62, DOI 10.1016/j.bone.2015.04.038
   Nicolaidou V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039871
   O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092 8674(02)00701 8
   Pagnotti GM, 2019, NAT REV ENDOCRINOL, V15, P339, DOI 10.1038/s41574 019 0170 1
   Pancotti F, 2012, CELL SIGNAL, V24, P1390, DOI 10.1016/j.cellsig.2012.02.015
   Rodan GA, 1998, P NATL ACAD SCI USA, V95, P13361, DOI 10.1073/pnas.95.23.13361
   RODRIGUEZ JI, 1988, CALCIFIED TISSUE INT, V43, P335, DOI 10.1007/BF02553275
   Roosa SMM, 2011, J BONE MINER RES, V26, P100, DOI 10.1002/jbmr.193
   TILTON FE, 1980, AVIAT SPACE ENVIR MD, V51, P1209
   Vico L, 2000, LANCET, V355, P1607, DOI 10.1016/S0140 6736(00)02217 0
   Wang CD, 2017, EXP CELL RES, V352, P346, DOI 10.1016/j.yexcr.2017.02.021
   Wang LJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14146 6
   Weber Nordt RM, 1998, LEUKEMIA LYMPHOMA, V28, P459, DOI 10.3109/10428199809058353
   WHEDON GD, 1984, CALCIFIED TISSUE INT, V36, pS146
   Wolff J., 1892, Das Gesetz der Transformation der Knochen, V1
   Yadav PS, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2020100118
   Yang YL, 2019, J BIOL CHEM, V294, P15395, DOI 10.1074/jbc.RA119.010139
   Zhou HK, 2011, BONE, V49, P404, DOI 10.1016/j.bone.2011.04.020
   Zhou SR, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 27273 w
NR 42
TC 9
Z9 10
U1 5
U2 20
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449 2288
J9 INT J BIOL SCI
JI Int. J. Biol. Sci.
PY 2023
VL 19
IS 7
BP 2021
EP 2033
DI 10.7150/ijbs.82744
PG 13
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics
GA YH5O6
UT WOS:001267612500002
PM 37151888
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Langlais, AL
   Mountain, RV
   Kunst, RF
   Barlow, D
   Houseknecht, KL
   Motyl, KJ
AF Langlais, Audrie L.
   Mountain, Rebecca V.
   Kunst, Roni F.
   Barlow, Deborah
   Houseknecht, Karen L.
   Motyl, Katherine J.
TI Thermoneutral housing does not rescue olanzapine induced trabecular bone
   loss in C57BL/6J female mice
SO BIOCHIMIE
LA English
DT Article
DE Antipsychotic drugs; Bone; Thermoneutrality; Sympathetic nervous system
ID ATYPICAL ANTIPSYCHOTIC DRUGS; MINERAL DENSITY; LOCOMOTOR ACTIVITY;
   WEIGHT GAIN; RISPERIDONE; RISK; FRACTURE; THERMOGENESIS; CONSEQUENCES;
   OSTEOPOROSIS
AB Antipsychotic drugs are prescribed to a wide range of individuals to treat mental health conditions including schizophrenia. However, antipsychotic drugs cause bone loss and increase fracture risk. We previously found that the atypical antipsychotic (AA) drug risperidone causes bone loss through multiple pharmacological mechanisms, including activation of the sympathetic nervous system in mice treated with clinically relevant doses. However, bone loss was dependent upon housing temperature, which modulates sympathetic activity. Another AA drug, olanzapine, has substantial metabolic side effects, including weight gain and insulin resistance, but it is unknown whether bone and metabolic outcomes of olanzapine are also dependent upon housing temperature in mice. We therefore treated eight week old female mice with vehicle or olanzapine for four weeks, housed at either room temperature (23 & DEG;C) or thermoneutrality (28 30 & DEG;C), which has previously been shown to be positive for bone. Olanzapine caused significant trabecular bone loss ( 13% BV/TV), likely through increased RANKL dependent osteoclast resorption, which was not suppressed by thermoneutral housing. Additionally, olanzapine inhibited cortical bone expansion at thermoneutrality, but did not alter cortical bone expansion at room temperature. Olanzapine also increased markers of thermogenesis within brown and inguinal adipose depots independent of housing temperature. Overall, olanzapine causes trabecular bone loss and inhibits the positive effect of thermoneutral housing on bone. Understanding how housing temperature modulates the impact of AA drugs on bone is important for future pre clinical studies, as well as for the prescription of AA drugs, particularly to older adults and adolescents who are most vulnerable to the effects on bone.& COPY; 2023 Elsevier B.V. and Societe Francaise de Biochimie et Biologie Moleculaire (SFBBM). All rights reserved.
C1 [Langlais, Audrie L.; Mountain, Rebecca V.; Kunst, Roni F.; Motyl, Katherine J.] MaineHealth, MaineHlth Inst Res, Ctr Mol Med, Scarborough, ME USA.
   [Langlais, Audrie L.; Houseknecht, Karen L.; Motyl, Katherine J.] Univ Maine, Grad Sch Biomed Sci & Engn, Orono, ME USA.
   [Barlow, Deborah; Houseknecht, Karen L.] Univ New England, Coll Osteopath Med, Dept Biomed Sci, Biddeford, ME USA.
   [Motyl, Katherine J.] Tufts Univ, Sch Med, Boston, MA USA.
   [Motyl, Katherine J.] 81 Res Dr, Scarborough, ME 04074 USA.
C3 University of Maine System; University of Maine Orono; University of New
   England   Maine; Tufts University
RP Motyl, KJ (通讯作者)，81 Res Dr, Scarborough, ME 04074 USA.
EM Motyl@mainehealth.org
FU NIH National Institute of General Medical Sciences [R01AR076349];
   National Institute of Arthritis and Musculoskeletal and Skin Diseases
   [U54GM115516]; National Institute of General Medical Sciences through
   the Northern New England Clinical and Translational Research (NNE CTR)
   Network; COBRE in Mesenchymal and Neural Regulation of Metabolic
   Networks
FX & nbsp;This work was supported by the NIH National Institute of General
   Medical Sciences (P20GM121301 to KJM) and National Institute of
   Arthritis and Musculoskeletal and Skin Diseases (R01AR076349 to KJM) .
   This work was also supported by the National Institute of General
   Medical Sciences through the Northern New England Clinical and
   Translational Research (NNE CTR) Network (U54GM115516 to Clifford Rosen
   and Gary Stein) , and the COBRE in Mesenchymal and Neural Regulation of
   Metabolic Networks (P20GM121301 to Lucy Liaw) .
CR Barton BB, 2020, EXPERT OPIN DRUG SAF, V19, P295, DOI 10.1080/14740338.2020.1713091
   Beauchemin M, 2020, PHARMACOL RES, V152, DOI 10.1016/j.phrs.2019.104589
   Becker D, 2003, J CLIN PSYCHIAT, V64, P761, DOI 10.4088/JCP.v64n0704
   Bolton JM, 2011, J CLIN PSYCHOPHARM, V31, P56, DOI 10.1097/JCP.0b013e3182075587
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brzek P, 2022, J COMP PHYSIOL B, V192, P161, DOI 10.1007/s00360 021 01410 9
   Calarge CA, 2010, J CLIN PSYCHIAT, V71, P338, DOI 10.4088/JCP.08m04595gre
   Collins S, 2022, ANNU REV PHYSIOL, V84, P1, DOI 10.1146/annurev physiol 060721 092939
   Cope MB, 2009, PHYSIOL BEHAV, V96, P457, DOI 10.1016/j.physbeh.2008.11.011
   Costa S, 2019, BONE, V123, P211, DOI 10.1016/j.bone.2019.03.038
   Crews MPK, 2012, HUM PSYCHOPHARM CLIN, V27, P15, DOI 10.1002/hup.1265
   Davey KJ, 2012, PSYCHOPHARMACOLOGY, V221, P155, DOI 10.1007/s00213 011 2555 2
   Disha Ibrahimi S, 2023, BIOMOL BIOMED, V23, P114, DOI 10.17305/bjbms.2022.7523
   Du JK, 2022, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.778019
   Ersland KM, 2019, INT J NEUROPSYCHOPH, V22, P358, DOI 10.1093/ijnp/pyz012
   Ferno J, 2015, EUR NEUROPSYCHOPHARM, V25, P923, DOI 10.1016/j.euroneuro.2015.03.002
   Ferreira V, 2022, METABOLISM, V137, DOI 10.1016/j.metabol.2022.155335
   Glatt V, 2007, J BONE MINER RES, V22, P1197, DOI 10.1359/JBMR.070507
   Gordon CJ, 2012, J THERM BIOL, V37, P654, DOI 10.1016/j.jtherbio.2012.08.004
   Iwaniec UT, 2016, OSTEOPOROSIS INT, V27, P3091, DOI 10.1007/s00198 016 3634 3
   Kajimura D, 2011, J EXP MED, V208, P841, DOI 10.1084/jem.20102608
   Kim KS, 2002, J CLIN PSYCHIAT, V63, P408, DOI 10.4088/JCP.v63n0506
   Kunst RF, 2021, JBMR PLUS, V5, DOI 10.1002/jbm4.10541
   Lee SH, 2017, OSTEOPOROSIS INT, V28, P1167, DOI 10.1007/s00198 016 3881 3
   Carvalho AL, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0231060
   Li HQ, 2019, SCI REP UK, V9, DOI 10.1038/s41598 018 36930 y
   Li Xingsheng, 2013, Int J Body Compos Res, V11, P21
   Li ZR, 2022, ELIFE, V11, DOI 10.7554/eLife.78496
   Liperoti R, 2007, J CLIN PSYCHIAT, V68, P929, DOI 10.4088/JCP.v68n0616
   Liu XM, 2023, PROG NEURO PSYCHOPH, V122, DOI 10.1016/j.pnpbp.2022.110692
   Lodhi IJ, 2009, CELL METAB, V9, P111, DOI 10.1016/j.cmet.2009.01.004
   Lord CC, 2017, J CLIN INVEST, V127, P3408, DOI 10.1172/JCI93362
   Martin SA, 2019, ENDOCR CONNECT, V8, P1455, DOI 10.1530/EC 19 0359
   Meaney AM, 2004, BRIT J PSYCHIAT, V184, P503, DOI 10.1192/bjp.184.6.503
   Meyer JM, 2002, J CLIN PSYCHIAT, V63, P425, DOI 10.4088/JCP.v63n0509
   Motyl KJ, 2017, BONE, V103, P168, DOI 10.1016/j.bone.2017.07.008
   Motyl KJ, 2015, ENDOCRINOLOGY, V156, P2374, DOI 10.1210/en.2015 1099
   Motyl KJ, 2013, J BONE MINER RES, V28, P1885, DOI 10.1002/jbmr.1943
   Motyl KJ, 2012, BONE, V50, P490, DOI 10.1016/j.bone.2011.08.005
   Nguyen AD, 2018, BONE, V106, P167, DOI 10.1016/j.bone.2015.05.037
   O'Keane V, 2005, J CLIN PSYCHOPHARM, V25, P26, DOI 10.1097/01.jcp.0000150223.31007.e0
   Pallubinsky H, 2019, J THERM BIOL, V79, P199, DOI 10.1016/j.jtherbio.2018.12.014
   Park SY, 2016, J AM ACAD CHILD PSY, V55, P456, DOI 10.1016/j.jaac.2016.03.012
   Ray WA, 2009, NEW ENGL J MED, V360, P225, DOI 10.1056/NEJMoa0806994
   Rigler SK, 2013, J AM GERIATR SOC, V61, P715, DOI 10.1111/jgs.12216
   Sattgast L.H., 2023, BONEKEY REP, V18
   Scahill L, 2016, J AM ACAD CHILD PSY, V55, P415, DOI 10.1016/j.jaac.2016.02.016
   Scheller EL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8808
   Schneider LS, 2006, NEW ENGL J MED, V355, P1525, DOI 10.1056/NEJMoa061240
   Schoretsanitis G, 2022, BASIC CLIN PHARMACOL, V130, P531, DOI 10.1111/bcpt.13715
   Shen SP, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221948
   Skop V, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.03.065
   Smith S, 2002, J CLIN PSYCHOPHARM, V22, P109, DOI 10.1097/00004714 200204000 00002
   Thomas K., 2021, NEW YORK TIMES, P11
   Turner RT, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00117
   Wang XD, 2015, ENDOCRINOLOGY, V156, P1408, DOI 10.1210/en.2014 1872
   Wee NKY, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00668
   Yan D, 2023, AM J GERIAT PSYCHIAT, V31, P124, DOI 10.1016/j.jagp.2022.09.009
   Zhang QS, 2014, PROG NEURO PSYCHOPH, V51, P172, DOI 10.1016/j.pnpbp.2014.02.003
NR 59
TC 2
Z9 2
U1 1
U2 6
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0300 9084
EI 1638 6183
J9 BIOCHIMIE
JI Biochimie
PD JUL
PY 2023
VL 210
BP 50
EP 60
DI 10.1016/j.biochi.2023.05.002
EA JUN 2023
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA L9OO1
UT WOS:001026490600001
PM 37236340
OA Bronze
DA 2025 08 17
ER

PT J
AU Pitcher, T
   Sousa Valente, J
   Malcangio, M
AF Pitcher, Thomas
   Sousa Valente, Joao
   Malcangio, Marzia
TI The Monoiodoacetate Model of Osteoarthritis Pain in the Mouse
SO JOVE JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Medicine; Issue 111; chemical model; allodynia; weight bearing;
   behavior; in vivo; OA
ID IODOACETATE INDUCED OSTEOARTHRITIS; RAT; KNEE; BEHAVIOR; MICE
AB A major symptom of patients with osteoarthritis (OA) is pain that is triggered by peripheral as well as central changes within the pain pathways. The current treatments for OA pain such as NSAIDS or opiates are neither sufficiently effective nor devoid of detrimental side effects. Animal models of OA are being developed to improve our understanding of OA related pain mechanisms and define novel pharmacological targets for therapy. Currently available models of OA in rodents include surgical and chemical interventions into one knee joint. The monoiodoacetate (MIA) model has become a standard for modelling joint disruption in OA in both rats and mice. The model, which is easier to perform in the rat, involves injection of MIA into a knee joint that induces rapid pain like responses in the ipsilateral limb, the level of which can be controlled by injection of different doses. Intra articular injection of MIA disrupts chondrocyte glycolysis by inhibiting glyceraldehyde 3 phosphatase dehydrogenase and results in chondrocyte death, neovascularization, subchondral bone necrosis and collapse, as well as inflammation. The morphological changes of the articular cartilage and bone disruption are reflective of some aspects of patient pathology. Along with joint damage, MIA injection induces referred mechanical sensitivity in the ipsilateral hind paw and weight bearing deficits that are measurable and quantifiable. These behavioral changes resemble some of the symptoms reported by the patient population, thereby validating the MIA injection in the knee as a useful and relevant pre clinical model of OA pain.
   The aim of this article is to describe the methodology of intra articular injections of MIA and the behavioral recordings of the associated development of hypersensitivity with a mind to highlight the necessary steps to give consistent and reliable recordings.
C1 [Pitcher, Thomas; Sousa Valente, Joao; Malcangio, Marzia] Kings Coll London, Wolfson Ctr Age Related Dis, London WC2R 2LS, England.
C3 University of London; King's College London
RP Malcangio, M (通讯作者)，Kings Coll London, Wolfson Ctr Age Related Dis, London WC2R 2LS, England.
EM marzia.malcangio@kcl.ac.uk
RI de Sousa Valente, Joao/AAY 2520 2020
OI Malcangio, Marzia/0000 0003 4296 5727; Sousa Valente,
   Joao/0000 0003 1888 6324
FU European Commission [GAN 603191 PAINCAGE]
FX JSV is supported by a collaborative grant to MM by the European
   Commission (GAN 603191 PAINCAGE).
CR Bove SE, 2003, OSTEOARTHR CARTILAGE, V11, P821, DOI 10.1016/S1063 4584(03)00163 8
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165 0270(94)90144 9
   DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301
   Farrell M, 2000, J RHEUMATOL, V27, P441
   Fernihough J, 2004, PAIN, V112, P83, DOI 10.1016/j.pain.2004.08.004
   Guingamp C, 1997, ARTHRITIS RHEUM, V40, P1670, DOI 10.1002/art.1780400917
   Huebner JL, 2002, OSTEOARTHR CARTILAGE, V10, P758, DOI 10.1053/joca.2002.0821
   Hunter DJ, 2011, NAT REV RHEUMATOL, V7, P13, DOI 10.1038/nrrheum.2010.178
   Im HJ, 2010, ARTHRITIS RHEUM US, V62, P2995, DOI 10.1002/art.27608
   Janusz MJ, 2001, OSTEOARTHR CARTILAGE, V9, P751, DOI 10.1053/joca.2001.0472
   Kuni B, 2015, ACTA ORTHOP, V86, P215, DOI 10.3109/17453674.2014.973343
   Lampropoulou Adamidou Kalliopi, 2014, Eur J Orthop Surg Traumatol, V24, P263, DOI 10.1007/s00590 013 1205 2
   Longo Umile Giuseppe, 2012, Open Orthop J, V6, P558, DOI 10.2174/1874325001206010558
   Marker CL, 2012, METHODS MOL BIOL, V851, P239, DOI 10.1007/978 1 61779 561 9_18
   Ogbonna AC, 2013, EUR J PAIN, V17, P514, DOI 10.1002/j.1532 2149.2012.00223.x
   Pomonis JD, 2005, PAIN, V114, P339, DOI 10.1016/j.pain.2004.11.008
   SABRI MI, 1971, J NEUROCHEM, V18, P1509, DOI 10.1111/j.1471 4159.1971.tb00013.x
   Schuelert N, 2009, NEUROSCI LETT, V465, P184, DOI 10.1016/j.neulet.2009.08.063
   Thysen S, 2015, DIS MODEL MECH, V8, P17, DOI 10.1242/dmm.016881
   VANDERKRAAN PM, 1989, AM J PATHOL, V135, P1001
   Vonsy JL, 2009, EUR J PAIN, V13, P786, DOI 10.1016/j.ejpain.2008.09.008
   Wylde V, 2011, OSTEOARTHR CARTILAGE, V19, P655, DOI 10.1016/j.joca.2011.02.009
   Wylde V, 2011, PAIN, V152, P566, DOI 10.1016/j.pain.2010.11.023
   Yamamoto K, 2005, J Orthop Surg (Hong Kong), V13, P8
NR 24
TC 149
Z9 161
U1 8
U2 25
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940 087X
J9 JOVE J VIS EXP
JI J. Vis. Exp.
PD MAY
PY 2016
IS 111
AR e53746
DI 10.3791/53746
PG 5
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA DS0BJ
UT WOS:000380259900021
PM 27214709
OA Green Published, Green Submitted, Bronze
DA 2025 08 17
ER

PT J
AU Takeda, K
   Adhikari, R
   Yamada, KM
   Dhawan, S
AF Takeda, Kazuyo
   Adhikari, Rewati
   Yamada, Kenneth M.
   Dhawan, Subhash
TI Hemin activation of innate cellular response blocks human
   immunodeficiency virus type 1 induced osteoclastogenesis
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE HIV 1; Hemin; Heme oxygenase 1; Osteoclasts
ID BONE MINERAL DENSITY; MULTINUCLEATED GIANT CELLS; PROTEASE INHIBITORS;
   HIV 1 INFECTION; RISK FACTORS; OXYGENASE 1; RANKL; OSTEOPOROSIS;
   PATHOGENESIS; PREVALENCE
AB The normal skeletal developmental and homeostatic process termed osteoclastogenesis is exacerbated in numerous pathological conditions and causes excess bone loss. In cancer and HIV 1 infected patients, this disruption of homeostasis results in osteopenia and eventual osteoporesis. Counteracting the factors responsible for these metabolic disorders remains a challenge for preventing or minimizing this comorbidity associated with these diseases. In this report, we demonstrate that a hemin induced host protection mechanism not only suppresses HIV 1 associated osteoclastogenesis, but it also exhibits anti osteoclastogenic activity for non infected cells. Since the mode of action of hemin is both physiological and pharmacological through induction of heme oxygenase 1 (HO 1), an endogenous host protective response to an FDA licensed therapeutic used to treat another disease, our study suggests an approach to developing novel, safe and effective therapeutic strategies for treating bone disorders, because hemin administration in humans has previously met required FDA safety standards. Published by Elsevier Inc.
C1 [Adhikari, Rewati; Dhawan, Subhash] US FDA, Ctr Biol Evaluat & Res, Div Transfus Transmitted Dis, Bethesda, MD 20993 USA.
   [Takeda, Kazuyo] US FDA, Ctr Biol Evaluat & Res, Microscopy & Imaging Core Facil, Silver Spring, MD USA.
   [Yamada, Kenneth M.] Natl Inst Dent & Craniofacial Res, NIH, Bethesda, MD USA.
C3 US Food & Drug Administration (FDA); Center for Biologics Evaluation &
   Research (CBER); US Food & Drug Administration (FDA); Center for
   Biologics Evaluation & Research (CBER); National Institutes of Health
   (NIH)   USA; NIH National Institute of Dental & Craniofacial Research
   (NIDCR)
RP Dhawan, S (通讯作者)，US FDA, Ctr Biol Evaluat & Res, Div Transfus Transmitted Dis, Bethesda, MD 20993 USA.
EM subhash.dhawan@fda.hhs.gov
FU FDA; NIDCR Intramural Research Programs
FX S.D.: conceptualized, designed, performed, analyzed experiments, and
   wrote the paper; K.T. performed confocal microscopy and analyzed
   experiments; R.A. performed TRAP activity experiments; K.M.Y. analyzed
   experiments. We thank Dr. Zu Xi Yu, National Heart, Lung and Blood
   Institute, NIH, for his expertise in microscopy. The findings and
   conclusions in this paper have not been formally disseminated by the
   Food and Drug Administration and should not be construed to represent
   any Agency determination or policy. This work was supported by FDA and
   NIDCR Intramural Research Programs.
CR Ballanti P, 1997, OSTEOPOROSIS INT, V7, P39, DOI 10.1007/BF01623458
   Bharucha AE, 2010, CLIN PHARMACOL THER, V87, P187, DOI 10.1038/clpt.2009.221
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Boyce BF, 2012, EUR J CLIN INVEST, V42, P1332, DOI 10.1111/j.1365 2362.2012.02717.x
   Briot K, 2011, BONE, V48, P1133, DOI 10.1016/j.bone.2011.01.015
   Casimiro S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063153
   Chew NS, 2007, CURR OPIN HIV AIDS, V2, P318, DOI 10.1097/COH.0b013e3281a3c092
   Coaccioli S, 2009, CLIN TER, V160, P451
   Dargent JL, 2000, MODERN PATHOL, V13, P1293, DOI 10.1038/modpathol.3880237
   De Crignis E, 2008, NEW MICROBIOL, V31, P155
   Devadas K, 2006, J IMMUNOL, V176, P4252, DOI 10.4049/jimmunol.176.7.4252
   Dhawan S., 2013, CURR TRENDS IMMUNOL, V14, P65
   Edwards JR, 2011, NAT REV RHEUMATOL, V7, P235, DOI 10.1038/nrrheum.2011.23
   El Maouche D, 2011, J HEPATOL, V55, P770, DOI 10.1016/j.jhep.2011.01.035
   Fakruddin JM, 2003, J BIOL CHEM, V278, P48251, DOI 10.1074/jbc.M304676200
   Fessel WJ, 2011, AIDS, V25, P1877, DOI 10.1097/QAD.0b013e32834af637
   Gerstner G, 2009, HAEMOPHILIA, V15, P559, DOI 10.1111/j.1365 2516.2008.01963.x
   Gibellini D, 2010, BIOCHEM BIOPH RES CO, V401, P429, DOI 10.1016/j.bbrc.2010.09.071
   Grigsby IF, 2010, BIOCHEM BIOPH RES CO, V394, P48, DOI 10.1016/j.bbrc.2010.02.080
   Grijsen ML, 2010, AIDS, V24, P2233, DOI 10.1097/QAD.0b013e32833c93fe
   Gutiérrez F, 2011, AIDS REV, V13, P109
   Hill Batorski L, 2013, J VIROL, V87, P13795, DOI 10.1128/JVI.02422 13
   Horizon AA, 2011, HIV AIDS RES PALLIAT, V3, P53, DOI 10.2147/HIV.S15588
   Konishi M, 2005, AIDS, V19, P1240, DOI 10.1097/01.aids.0000176231.24652.02
   Malizia AP, 2007, ANTIVIR RES, V74, P72, DOI 10.1016/j.antiviral.2006.12.003
   McComsey GA, 2011, J INFECT DIS, V203, P1791, DOI 10.1093/infdis/jir188
   Ofotokun I, 2011, DISCOV MED, V11, P385
   Ofotokun I, 2010, CURR OPIN ENDOCRINOL, V17, P523, DOI 10.1097/MED.0b013e32833f48d6
   Orenstein JM, 1999, ULTRASTRUCT PATHOL, V23, P79, DOI 10.1080/019131299281734
   Paccou J, 2009, JOINT BONE SPINE, V76, P637, DOI 10.1016/j.jbspin.2009.10.003
   Neto LFSP, 2011, J CLIN DENSITOM, V14, P74, DOI 10.1016/j.jocd.2010.11.002
   Pollock E, 2009, BRIT MED BULL, V92, P123, DOI 10.1093/bmb/ldp037
   Rafiei S, 2013, BMC CANCER, V13, DOI 10.1186/1471 2407 13 605
   Schmidt WN, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00129
   Sharma A, 2010, AIDS, V24, P2337, DOI 10.1097/QAD.0b013e32833d7da7
   Siegert SWK, 2008, ADV THER, V25, P842, DOI 10.1007/s12325 008 0094 y
   Smith MR, 2015, ANN ONCOL, V26, P368, DOI 10.1093/annonc/mdu519
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Stone B, 2010, ARCH BIOCHEM BIOPHYS, V503, P66, DOI 10.1016/j.abb.2010.07.029
   Takahashi N, 2011, FRONT BIOSCI LANDMRK, V16, P21, DOI 10.2741/3673
   Takhar SS, 2010, EMERG MED CLIN N AM, V28, P335, DOI 10.1016/j.emc.2010.01.009
   Tella SH, 2014, EUR J CLIN PHARMACOL, V70, P1291, DOI 10.1007/s00228 014 1735 5
   WAHL LM, 1984, CELL IMMUNOL, V85, P373, DOI 10.1016/0008 8749(84)90251 X
   Walker RE, 2014, BRIT MED BULL, V111, P117, DOI 10.1093/bmb/ldu016
   Warriner Amy H, 2010, Curr Rheumatol Rep, V12, P163, DOI 10.1007/s11926 010 0099 9
   Yin MT, 2011, J INFECT DIS, V203, P1705, DOI 10.1093/infdis/jir184
   Zhou Zhao Hua, 2013, Curr Trends Immunol, V14, P53
   Zhou ZH, 2013, BIOCHEM BIOPH RES CO, V435, P373, DOI 10.1016/j.bbrc.2013.04.095
   Zwerina J, 2005, FASEB J, V19, P2011, DOI 10.1096/fj.05 4278fje
NR 49
TC 2
Z9 2
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD AUG 14
PY 2015
VL 464
IS 1
BP 7
EP 12
DI 10.1016/j.bbrc.2015.05.037
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA CO5AY
UT WOS:000359173200002
PM 25998388
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Fan, XL
   Duan, XB
   Chen, ZH
   Li, M
   Xu, JS
   Ding, GM
AF Fan, X L.
   Duan, X B.
   Chen, Z H.
   Li, M.
   Xu, J S.
   Ding, G M.
TI Lack of estrogen down regulates CXCR4 expression on Treg cells and
   reduces Treg cell population in bone marrow in OVX mice
SO CELLULAR AND MOLECULAR BIOLOGY
LA English
DT Article
DE Postmenopausal osteoporosis; osteoclasts; Treg cells
ID T CELLS; POSTMENOPAUSAL OSTEOPOROSIS; OSTEOCLAST FORMATION;
   DIFFERENTIATION; ACTIVATION; ALPHA; CYTOKINES; THERAPY; CANCER; BETA
AB Postmenopausal osteoporosis (PMO) is the most common metabolic bone disease in women after menopausal. Recent works focused on cross talk between immune regulation and bone metabolism pathways and suggested Treg cells suppressed bone resorption and osteoclasts (OC) differentiation in bone marrow via cell cell contact interaction and/or secreting of IL 10 and TGF beta. In this study, we investigated the impact of estrogen on regulatory T cells (Treg cells) trafficking and staying in bone marrow and we found that a significant reduction of Treg cell population in bone marrow in estrogen deficiency ovariectomied (OVX) mice. We then studied the expressions of chemokines CXCL12/CXCR4 axes, which were critical to Treg cells migration and our data show the expression of CXCR4 on Treg cells was relative with oestrogen in vivo, however, the expression of CXCL12 was not. Furthermore, the loss of trafficking ability of Treg cells in OVX mice was recoverable in our system. These findings may mechanistically explain why Treg cells lose their suppressive functions on the regulation of OC cells and demonstrate a previously unappreciated role for estrogen, which may be critical to the novel therapy in clinical practice of PMO patients.
C1 [Fan, X L.; Li, M.; Xu, J S.; Ding, G M.] Nanjing Med Univ, Hangzhou Peoples Hosp 1, Dept Orthopaed, Hangzhou 310006, Zhejiang, Peoples R China.
   [Duan, X B.] Shenzhen Peoples Hosp, Dept Orthopaed, Shenzhen 518000, Peoples R China.
   [Chen, Z H.] ChunAnXian Second Peoples Hosp, Dept Orthopaed, Chunanxian 311719, Peoples R China.
C3 Nanjing Medical University; Jinan University
RP Fan, XL (通讯作者)，Nanjing Med Univ, Hangzhou Peoples Hosp 1, Dept Orthopaed, Huansha Rd 261, Hangzhou 310006, Zhejiang, Peoples R China.
EM fanxliang@126.com
CR Almeida M, 2013, J CLIN INVEST, V123, P394, DOI 10.1172/JCI65910
   Capettini SB, 2011, BRAIN RES BULL, V85, P54, DOI 10.1016/j.brainresbull.2011.02.005
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   Elliot SJ, 2007, KIDNEY INT, V72, P464, DOI 10.1038/sj.ki.5002328
   Fonseca CS, 2013, NEUROBIOL LEARN MEM, V101, P19, DOI 10.1016/j.nlm.2012.12.016
   Gao YH, 2004, P NATL ACAD SCI USA, V101, P16618, DOI 10.1073/pnas.0404888101
   Gao YH, 2007, J CLIN INVEST, V117, P122, DOI 10.1172/JCI30074
   Goldstein JD, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00155
   Hammes SR, 2011, ENDOCRINOLOGY, V152, P4489, DOI 10.1210/en.2011 1470
   JILKA RL, 1995, EXP HEMATOL, V23, P500
   JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100
   Kim YG, 2007, BIOCHEM BIOPH RES CO, V357, P1046, DOI 10.1016/j.bbrc.2007.04.042
   Kotsianidis I, 2009, LEUKEMIA, V23, P510, DOI 10.1038/leu.2008.333
   Kramer PR, 2013, EUR J PAIN, V17, P174, DOI 10.1002/j.1532 2149.2012.00183.x
   Luo CY, 2011, CELL MOL IMMUNOL, V8, P50, DOI 10.1038/cmi.2010.54
   Martin TJ, 1998, TRENDS ENDOCRIN MET, V9, P6, DOI 10.1016/S1043 2760(98)00005 8
   Pacifici R, 1996, J BONE MINER RES, V11, P1043
   RALSTON SH, 1994, J BONE MINER RES, V9, P883
   Razis E, 2012, CLIN BREAST CANCER, V12, P183, DOI 10.1016/j.clbc.2012.03.006
   Reid IR, 1996, AM J MED SCI, V312, P278, DOI 10.1097/00000441 199612000 00006
   Rodriguez Lara V, 2014, ARCH MED RES, V45, P158, DOI 10.1016/j.arcmed.2014.01.001
   Sauvé K, 2009, CANCER RES, V69, P5793, DOI 10.1158/0008 5472.CAN 08 4924
   Wang H, 2014, ONCOL LETT, V7, P1581, DOI 10.3892/ol.2014.1926
   Wei S, 2005, J CLIN INVEST, V115, P282, DOI 10.1172/JCI200523394
   Yamaguchi T, 2006, SEMIN CANCER BIOL, V16, P115, DOI 10.1016/j.semcancer.2005.11.005
   Zaiss MM, 2007, ARTHRITIS RHEUM, V56, P4104, DOI 10.1002/art.23138
   Zaiss MM, 2010, ARTHRITIS RHEUM US, V62, P2328, DOI 10.1002/art.27535
   Zeitlin L, 2003, J CELL BIOCHEM, V90, P347, DOI 10.1002/jcb.10620
   Zou LH, 2004, CANCER RES, V64, P8451, DOI 10.1158/0008 5472.CAN 04 1987
NR 29
TC 9
Z9 13
U1 0
U2 7
PU C M B  ASSOC
PI POITIERS
PA 40 AVENUE  RECTEUR PINEAU,  BAT MECANIQUE, 86022 POITIERS, FRANCE
SN 0145 5680
EI 1165 158X
J9 CELL MOL BIOL
JI Cell. Mol. Biol.
PY 2015
VL 61
IS 2
BP 13
EP 17
PG 5
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA CJ7SX
UT WOS:000355701100003
PM 26025396
DA 2025 08 17
ER

PT J
AU Patatsos, K
   Shekhar, TM
   Hawkins, CJ
AF Patatsos, K.
   Shekhar, T. M.
   Hawkins, C. J.
TI Pre clinical evaluation of proteasome inhibitors for canine and human
   osteosarcoma
SO VETERINARY AND COMPARATIVE ONCOLOGY
LA English
DT Article
DE bone cancer; bortezomib; canine cancer; osteosarcoma; proteasome;
   PS 341; Velcade
ID CELL LUNG CANCER; MULTIPLE MYELOMA PATIENTS; PEGYLATED LIPOSOMAL
   DOXORUBICIN; ADVANCED SOLID TUMORS; MULTICENTER PHASE II; APPENDICULAR
   OSTEOSARCOMA; ONCOLOGY GROUP; GROWTH ARREST; VENTRICULAR
   TACHYARRHYTHMIAS; MYOCARDIAL INFARCTION
AB Osteosarcoma, a common malignancy in large dog breeds, typically metastasises from long bones to lungs and is usually fatal within 1 to 2 years of diagnosis. Better therapies are needed for canine patients and their human counterparts, a third of whom die within 5 years of diagnosis. We compared the in vitro sensitivity of canine osteosarcoma cells derived from 4 tumours to the currently used chemotherapy drugs doxorubicin and carboplatin, and 4 new anti cancer drugs. Agents targeting histone deacetylases or PARP were ineffective. Two of the 4 cell lines were somewhat sensitive to the BH3 mimetic navitoclax. The proteasome inhibitor bortezomib potently induced caspase dependent apoptosis, at concentrations substantially lower than levels detected in the bones and lungs of treated rodents. Co treatment with bortezomib and either doxorubicin or carboplatin was more toxic to canine osteosarcoma cells than each agent alone. Newer proteasome inhibitors carfilzomib, ixazomib, oprozomib and delanzomib manifested similar activities to bortezomib. Human osteosarcoma cells were as sensitive to bortezomib as the canine cells, but slightly less sensitive to the newer drugs. Human osteoblasts were less sensitive to proteasome inhibition than osteosarcoma cells, but physiologically relevant concentrations were toxic. Such toxicity, if replicated in vivo, may impair bone growth and strength in adolescent human osteosarcoma patients, but may be tolerated by canine patients, which are usually diagnosed later in life. Proteasome inhibitors such as bortezomib may be useful for treating canine osteosarcoma, and ultimately may improve outcomes for human patients if their osteoblasts survive exposure in vivo, or if osteoblast toxicity can be managed.
C1 [Patatsos, K.; Shekhar, T. M.; Hawkins, C. J.] La Trobe Univ, La Trobe Inst Mol Sci, Dept Biochem & Genet, Melbourne, Vic, Australia.
C3 La Trobe University
RP Hawkins, CJ (通讯作者)，La Trobe Univ, La Trobe Inst Mol Sci, Dept Biochem & Genet, Bundoora, Vic, Australia.
EM c.hawkins@latrobe.edu.au
RI Hawkins, Christine/B 8769 2011
OI Hawkins, Christine/0000 0001 8120 1071
FU Kids' Cancer Project
FX The Kids' Cancer Project
CR Adams J, 1999, CANCER RES, V59, P2615
   Adams JM, 2018, CELL DEATH DIFFER, V25, P27, DOI 10.1038/cdd.2017.161
   Allison Daniel C., 2012, Sarcoma, V2012, P704872, DOI 10.1155/2012/704872
   Araujo KPC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061367
   Bitler BG, 2017, GYNECOL ONCOL, V147, P695, DOI 10.1016/j.ygyno.2017.10.003
   Blaney SM, 2004, J CLIN ONCOL, V22, P4804, DOI 10.1200/JCO.2004.12.185
   Center for Drug Evaluation and Research, MED REV OL LYNP NDA
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008 5472.CAN 09 1947
   Cloos J, 2017, CANCER METAST REV, V36, P599, DOI 10.1007/s10555 017 9699 4
   Davies AM, 2009, J THORAC ONCOL, V4, P87, DOI 10.1097/JTO.0b013e3181915052
   DiNofia AM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151362
   Dobson J.M., 2013, ISRN VET SCI, V2013, DOI DOI 10.1155/2013/941275)
   Dunleavy K, 2009, BLOOD, V113, P6069, DOI 10.1182/blood 2009 01 199679
   Edelman MJ, 2010, LUNG CANCER, V68, P84, DOI 10.1016/j.lungcan.2009.05.003
   Ek ETH, 2006, ONCOL REP, V16, P17
   Erickson RI, 2013, TOXICOL SCI, V131, P247, DOI 10.1093/toxsci/kfs265
   Eriksson E, 2014, JNCI J NATL CANCER I, V106, DOI 10.1093/jnci/djt459
   European Medicines Agency, 2004, IN SCI DISC APPR VEL
   Fenger JM, 2014, ILAR J, V55, P69, DOI 10.1093/ilar/ilu009
   Fulda S, 2017, INT REV CEL MOL BIO, V330, P157, DOI 10.1016/bs.ircmb.2016.09.004
   Gallerani E, 2013, EUR J CANCER, V49, P290, DOI 10.1016/j.ejca.2012.09.009
   Galluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44
   GAVER RC, 1988, CANCER CHEMOTH PHARM, V21, P197
   Giuliani N, 2007, BLOOD, V110, P334, DOI 10.1182/blood 2006 11 059188
   Gu JJ, 2017, ONCOTARGET, V8, P12741, DOI 10.18632/oncotarget.14405
   Gustafson DL, 2010, J VET INTERN MED, V24, P579, DOI 10.1111/j.1939 1676.2010.0496.x
   Han G, 2016, CLIN EXP MED, V16, P577, DOI 10.1007/s10238 015 0382 1
   Hemeryck A, 2007, CANCER CHEMOTH PHARM, V60, P777, DOI 10.1007/s00280 007 0424 9
   Hideshima T, 2001, CANCER RES, V61, P3071
   Houghton PJ, 2007, PEDIATR BLOOD CANCER, V49, P928, DOI 10.1002/pbc.21078
   Huang SJ, 2008, AM J PHYSIOL HEART C, V294, pH1298, DOI 10.1152/ajpheart.00765.2007
   Huang ZB, 2014, FUTURE ONCOL, V10, P1795, DOI [10.2217/fon.14.30, 10.2217/FON.14.30]
   Hutter G, 2012, ANN HEMATOL, V91, P847, DOI 10.1007/s00277 011 1377 y
   Ikezoe T, 2004, CANCER SCI, V95, P271, DOI 10.1111/j.1349 7006.2004.tb02215.x
   Infante JR, 2016, INVEST NEW DRUG, V34, P216, DOI 10.1007/s10637 016 0327 x
   Jandial DA, 2017, GYNECOL ONCOL, V145, P236, DOI 10.1016/j.ygyno.2017.03.013
   Kerr JS, 2010, INT J TOXICOL, V29, P3, DOI 10.1177/1091581809352111
   Kisselev AF, 2012, CHEM BIOL, V19, P99, DOI 10.1016/j.chembiol.2012.01.003
   Kunz P, 2015, ANN SURG ONCOL, V22, P489, DOI 10.1245/s10434 014 4001 2
   Landgren O, 2017, J INTERN MED, V281, P365, DOI 10.1111/joim.12590
   Lee JH, 2012, ADV CANCER RES, V116, P39, DOI 10.1016/B978 0 12 394387 3.00002 1
   Leonard JP, 2017, J CLIN ONCOL, V35, P3538, DOI 10.1200/JCO.2017.73.2784
   Ling YH, 2003, CLIN CANCER RES, V9, P1145
   Ling YH, 2002, MOL CANCER THER, V1, P841
   Lord LK, 2007, J VET INTERN MED, V21, P1243, DOI 10.1892/07 063.1
   Lou ZY, 2013, J INT MED RES, V41, P1505, DOI 10.1177/0300060513490618
   Ma C, 2007, CANCER CHEMOTH PHARM, V59, P207, DOI 10.1007/s00280 006 0259 9
   Maki RG, 2005, CANCER AM CANCER SOC, V103, P1431, DOI 10.1002/cncr.20968
   Manasanch EE, 2017, NAT REV CLIN ONCOL, V24, P206
   Martin P, 2017, CANCER TREAT REV, V58, P51, DOI 10.1016/j.ctrv.2017.05.008
   McStay GP, 2016, METHODS MOL BIOL, V1491, P57, DOI 10.1007/978 1 4939 3581 9_5
   Mohty M, 2014, CANCER AM CANCER SOC, V120, P618, DOI 10.1002/cncr.28481
   Monahan PE, 2010, MOL THER, V18, P1907, DOI 10.1038/mt.2010.170
   Moreau P, 2012, CLIN PHARMACOKINET, V51, P823, DOI 10.1007/s40262 012 0010 0
   Morrow WR, 2012, TRANSPLANTATION, V93, P319, DOI 10.1097/TP.0b013e31823f7eea
   Mpakou V, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170186
   Obrist F, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.974463
   Orlowski RZ, 2016, CANCER AM CANCER SOC, V122, P2050, DOI 10.1002/cncr.30026
   Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978 1 4419 0284 9_1
   Piperdi B, 2012, J THORAC ONCOL, V7, P1032, DOI 10.1097/JTO.0b013e31824de2fa
   Quach H, 2017, CANCER CHEMOTH PHARM, V79, P1067, DOI 10.1007/s00280 017 3287 8
   Richardson PG, 2014, BLOOD, V124, P1038, DOI 10.1182/blood 2014 01 548826
   RIGGS JL, 1974, J GEN VIROL, V25, P21, DOI 10.1099/0022 1317 25 1 21
   Scott MC, 2011, BONE, V49, P356, DOI 10.1016/j.bone.2011.05.008
   Selmic LE, 2014, J VET INTERN MED, V28, P554, DOI 10.1111/jvim.12313
   Shapovalov Y, 2010, INT J CANCER, V127, P67, DOI 10.1002/ijc.25024
   Shekhar TM, 2016, ONCOTARGET, V7, P33866, DOI 10.18632/oncotarget.8980
   Simpson S, 2017, ACTA VET SCAND, V59, DOI 10.1186/s13028 017 0341 9
   Skorupski KA, 2016, VET COMP ONCOL, V14, P81, DOI 10.1111/vco.12069
   SPODNICK GJ, 1992, J AM VET MED ASSOC, V200, P995
   Szewczyk M, 2015, VET RES COMMUN, V39, P61, DOI 10.1007/s11259 014 9623 0
   Thomas R, 2009, CHROMOSOME RES, V17, P365, DOI 10.1007/s10577 009 9028 z
   THOMPSON JP, 1992, J AM VET MED ASSOC, V200, P531
   Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008 5472.CAN 07 5836
   Voorhees P, 2015, BRIT J HAEMATOL, V171, P373, DOI 10.1111/bjh.13592
   Wang ZP, 2013, DRUG METAB DISPOS, V41, P230, DOI 10.1124/dmd.112.047662
   Wiita AP, 2013, ELIFE, V2, DOI 10.7554/eLife.01236
   Williamson MJ, 2009, MOL CANCER THER, V8, P3234, DOI 10.1158/1535 7163.MCT 09 0239
   Wong H, 2012, TOXICOL SCI, V130, P205, DOI 10.1093/toxsci/kfs235
   Wu SF, 2006, ENDOCRINOLOGY, V147, P3761, DOI 10.1210/en.2005 1672
   Xian M, 2017, INT J CANCER, V19, P30792
   Yang Y, 2004, CANCER SCI, V95, P176, DOI 10.1111/j.1349 7006.2004.tb03200.x
   Yin D, 2005, ONCOGENE, V24, P344, DOI 10.1038/sj.onc.1208225
   Yu D, 2015, SCI REP UK, V5, DOI 10.1038/srep16991
   Yu XC, 2005, AM J PHYSIOL HEART C, V289, pH1960, DOI 10.1152/ajpheart.00328.2005
   Zaman F, 2008, LEUKEMIA, V22, P883, DOI 10.1038/sj.leu.2404997
   Zaman F, 2007, CANCER RES, V67, P10078, DOI 10.1158/0008 5472.CAN 06 3982
   Zangari M, 2016, BONE, V86, P131, DOI 10.1016/j.bone.2016.02.019
   Zhang L, 2015, J PHARMACOKINET PHAR, V42, P541, DOI 10.1007/s10928 015 9445 x
   Zhao YJ, 2015, J THORAC ONCOL, V10, P172, DOI 10.1097/JTO.0000000000000383
NR 90
TC 18
Z9 19
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1476 5810
EI 1476 5829
J9 VET COMP ONCOL
JI Vet. Comp. Oncol.
PD DEC
PY 2018
VL 16
IS 4
BP 544
EP 553
DI 10.1111/vco.12413
PG 10
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA HA1WM
UT WOS:000450018900016
PM 29998615
DA 2025 08 17
ER

PT J
AU Chen, YQ
   Yang, C
   Dai, QJ
   Tan, JL
   Dou, C
   Luo, F
AF Chen, Yueqi
   Yang, Chuan
   Dai, Qijie
   Tan, Jiulin
   Dou, Ce
   Luo, Fei
TI Gold nanosphere mitigates osteoporosis through regulating TMAO
   metabolism in a gut microbiota dependent manner
SO JOURNAL OF NANOBIOTECHNOLOGY
LA English
DT Article
DE Gold nanospheres (GNS); Osteoporosis (OP); Gut microbiota; TMAO
   (trimethylamine N oxide) metabolism; Anti inflammation
ID TRIMETHYLAMINE N OXIDE; NANOPARTICLES; INFLAMMATION; DIVERSITY
AB Osteoporosis (OP) is a metabolic bone disease characterized by decreased bone mass and increased bone fragility. The imbalance of bone homeostasis modulated by osteoclasts and osteoblasts is the most crucial pathological change in osteoporosis. As a novel treatment strategy, nanomedicine has been applied in drug delivery and targeted therapy due to its high efficiency, precision, and fewer side effects. Gold nanospheres (GNS), as a common kind of gold nanoparticles (GNPs), possess significant antimicrobial and anti inflammatory activity, which have been applied for the treatment of eye diseases and rheumatoid arthritis. However, the effect of GNS on osteoporosis remains elusive. In this study, we found that GNS significantly prevented ovariectomy (OVX) induced osteoporosis in a gut microbiota dependent manner. 16S rDNA gene sequencing demonstrated GNS markedly altered the gut microbial diversity and flora composition. In addition, GNS reduced the abundance of TMAO related metabolites in OVX mice. Low TMAO levels might alleviate the bone loss phenomenon by reducing the inflammation response. Therefore, we investigated the alteration of cytokine profiles in OVX mice. GNS inhibited the release of pro osteoclastogenic or proinflammatory cytokines including tumor necrosis factor alpha (TNF alpha), interleukin (IL) 6, and granulocyte colony stimulating factor (G CSF) in the serum. In conclusion, GNS suppressed estrogen deficiency induced bone loss by regulating the destroyed homeostasis of gut microbiota so as to reduce its relevant TMAO metabolism and restrain the release of proinflammatory cytokines. These results demonstrated the protective effects of GNS on osteoporosis as a gut microbiota modulator and offered novel insights into the regulation of the "gut bone" axis.
C1 [Chen, Yueqi; Dai, Qijie; Tan, Jiulin; Dou, Ce; Luo, Fei] Third Mil Med Univ, Army Med Univ, Southwest Hosp, Dept Orthoped, Chongqing, Peoples R China.
   [Yang, Chuan] Third Mil Med Univ, Army Med Univ, Dept Biomed Mat Sci, Chongqing, Peoples R China.
C3 Army Medical University; Army Medical University
RP Chen, YQ; Dou, C; Luo, F (通讯作者)，Third Mil Med Univ, Army Med Univ, Southwest Hosp, Dept Orthoped, Chongqing, Peoples R China.
EM chenyueqi1012@sina.com; lance.douce@gmail.com; luofly1009@hotmail.com
RI Chen, Yueqi/AAU 1724 2020; Dou, Ce/B 8841 2012
OI Chen, Yueqi/0000 0001 6975 2874; 
FU National Natural Science Foundation of China [82172489]; Innovative
   Leading Talents Project from the Chongqing [425Z2P12I]; Outstanding
   Talent project from the Third Military Medical University
   [XZ 2019 505 021]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 82172489 for CD), Innovative Leading Talents Project
   from the Chongqing (No. 425Z2P12I for FL) and Outstanding Talent project
   from the Third Military Medical University (Grant No. XZ 2019 505 021
   for FL).
CR Blaser MJ, 2014, J CLIN INVEST, V124, P4162, DOI 10.1172/JCI78366
   Calderón Pérez L, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 63475 w
   Castaneda M, 2021, BONE REP, V14, DOI 10.1016/j.bonr.2021.101065
   Chen ML, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.006347
   Chen YQ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2612 z
   Cheng WW, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01750
   Chou RH, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 40638 y
   Cotts KG, 2018, JAMA J AM MED ASSOC, V319, P1040, DOI 10.1001/jama.2017.21995
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Glaser DL, 1997, SPINE, V22, p12S, DOI 10.1097/00007632 199712151 00003
   Gregory JC, 2015, J BIOL CHEM, V290, P5647, DOI 10.1074/jbc.M114.618249
   Hameed S, 2020, MAT SCI ENG C MATER, V108, DOI 10.1016/j.msec.2019.110338
   He JQ, 2020, AGING US, V12, P8583, DOI 10.18632/aging.103168
   Hu WH, 2021, ANN RHEUM DIS, V80, P413, DOI 10.1136/annrheumdis 2020 218089
   Kim HJ, 2019, INT J MOL SCI
   Komori T, 2015, EUR J PHARMACOL, V759, P287, DOI 10.1016/j.ejphar.2015.03.028
   Laird C, 2023, OSTEOPOROSIS INT, V34, P239, DOI 10.1007/s00198 022 06561 1
   Lee HL, 2013, J CELL PHYSIOL, V228, P1076, DOI 10.1002/jcp.24256
   Li JY, 2020, J CLIN INVEST, V130, P1767, DOI 10.1172/JCI133473
   Li JY, 2016, J CLIN INVEST, V126, P2049, DOI 10.1172/JCI86062
   Li L, 2019, AGING US, V11, P9348, DOI 10.18632/aging.102376
   Li Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.691013
   Lin H, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm 20 5307
   Ling ZG, 2021, CELL MOL LIFE SCI, V78, P7161, DOI 10.1007/s00018 021 03966 9
   Liu JH, 2021, ADV SCI, V8, DOI 10.1002/advs.202004831
   Liu YK, 2020, AGING US, V12, P10633, DOI 10.18632/aging.103283
   Liu YJ, 2020, THERANOSTICS, V10, P5225, DOI 10.7150/thno.43716
   Metch JW, 2018, NAT NANOTECHNOL, V13, P253, DOI 10.1038/s41565 017 0029 3
   Randrianarisoa E, 2016, SCI REP UK, V6, DOI 10.1038/srep26745
   Rohrmann S, 2016, J NUTR, V146, P283, DOI 10.3945/jn.115.220103
   Lacativa PGS, 2010, ARQ BRAS ENDOCRINOL, V54, P123, DOI 10.1590/S0004 27302010000200007
   Seely KD, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179452
   Shahen SM, 2021, CLIN EXP PHARMACOL P, V48, P1346, DOI 10.1111/1440 1681.13531
   Sjögren K, 2012, J BONE MINER RES, V27, P1357, DOI 10.1002/jbmr.1588
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Subramaniam S, 2018, BRIT J PHARMACOL, V175, P1344, DOI 10.1111/bph.13959
   Tu Y, 2021, J LEUKOCYTE BIOL, V110, P525, DOI 10.1002/JLB.3MR0321 755R
   van den Brule S, 2016, PART FIBRE TOXICOL, V13, DOI 10.1186/s12989 016 0149 1
   Velasquez MT, 2016, TOXINS, V8, DOI 10.3390/toxins8110326
   Wang Y, 2022, ISCIENCE, V25, DOI 10.1016/j.isci.2021.103654
   Wang ZN, 2011, NATURE, V472, P57, DOI 10.1038/nature09922
   Wilding LA, 2016, NANOTOXICOLOGY, V10, P513, DOI 10.3109/17435390.2015.1078854
   Xie ZL, 2021, EUR J PHARMACOL, V911, DOI 10.1016/j.ejphar.2021.174526
   Xu X, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.46
   Xu ZM, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00160
   Yang C, 2022, AGEING RES REV, V79, DOI 10.1016/j.arr.2022.101641
   Yausheva E, 2016, ENVIRON SCI POLLUT R, V23, P13245, DOI 10.1007/s11356 016 6474 y
   Yousefzadeh N, 2020, EXCLI J, V19, P89, DOI 10.17179/excli2019 1990
   Yu M, 2021, J CLIN INVEST
   Zeisel SH, 2017, ANNU REV NUTR, V37, P157, DOI 10.1146/annurev nutr 071816 064732
NR 50
TC 20
Z9 24
U1 7
U2 42
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477 3155
J9 J NANOBIOTECHNOL
JI J. Nanobiotechnol.
PD APR 11
PY 2023
VL 21
IS 1
AR 125
DI 10.1186/s12951 023 01872 9
PG 19
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Science & Technology   Other
   Topics
GA D6AP7
UT WOS:000969542200003
PM 37041523
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Li, X
   Zhu, YR
   Lin, XQ
   Chen, CY
   Liu, H
   Shi, Y
AF Li, Xi
   Zhu, Yunrong
   Lin, Xiangquan
   Chen, Chuanyuan
   Liu, Hui
   Shi, Yi
TI Beclin1 and Atg13 dependent autophagy activation and morroniside have
   synergistic effect on osteoblastogenesis
SO EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Morroniside; Osteoblast; mTOR; Atg13; Beclin1
ID STRESS
AB Morroniside is known to improve osteoporosis by promoting osteoblastogenesis. The activation of PI3K/Akt/mTOR signaling is a significant mechanism in morroniside promoted osteoblastogenesis. It is well known that protective autophagy is an important factor in osteoblastogenesis. However, the activation of mTOR signaling can inhibit autophagy. This study aimed to investigate the relationship between mTOR signaling and autophagy in morroniside regulated osteoblastogenesis. In this study, we investigated the effect of morroniside on the autophagic activity (LC3 conversion rate, LC3 puncta formation, and autophagosome number) of differentiated osteoblast precursors (MC3T3 E1 cells). Then, we identified the roles of mTOR knockdown in morroniside regulated alterations of autophagy and osteogenic parameters in MC3T3 E1 cells. Next, mTOR knockdown and overexpression were used to observe the roles of mTOR in morroniside regulated alterations of autophagic molecules (Atg7, Atg13, and Beclin1). Subsequently, the additional value of the above autophagic molecules on morroniside regulated osteogenic parameters in MC3T3 E1 cells was analyzed based on lentiviral transduction. Finally, combined with morroniside and TAT Beclin1, the roles of Beclin1 upregulation in the in vivo effects of morroniside was investigated. Our experimental data showed that morroniside promoted both the mTOR activity and autophagy in MC3T3 E1 cells. Morroniside upregulated autophagic activity and Atg13 or Beclin1 protein level in MC3T3 E1 cells were enhanced by mTOR knockdown. Furthermore, Morroniside upregulated Atg13 and Beclin1 expression was reversed by mTOR overexpression. Importantly, autophagy upregulation with overexpression of the autophagic gene, Atg13 or BECN1 (gene form of Beclin1), significantly promoted osteoblastogenesis regulated by morroniside. The promotional effect of morroniside on bone microarchitecture, bone mass, and bone parameters (including trabecular bone area and OCN expression in trabecular bone) in ovariectomized (OVX) mice was enhanced by TAT Beclin1 administration. In conclusion, the autophagy enhancing drugs related to Beclin1 or Atg13 may be an effective adjuvant therapy in the treatment of osteoporosis with morroniside.
C1 [Li, Xi; Lin, Xiangquan; Chen, Chuanyuan; Liu, Hui; Shi, Yi] Fuzhou Second Hosp, Dept Orthoped, Fuzhou 350007, Peoples R China.
   [Zhu, Yunrong] Affiliated Jiangyin Hosp Nantong Univ, Dept Orthoped, Jiangyin 214400, Peoples R China.
RP Liu, H; Shi, Y (通讯作者)，Fuzhou Second Hosp, Dept Orthoped, Fuzhou 350007, Peoples R China.
EM 14730272@qq.com; Shiyixmdx@163.com
FU Fujian Provincial Natural Science Foundation Projects [2019J01548];
   Fujian Provincial Clinical Medical Research Center for First Aid and
   Rehabilitation in Orthopedic Trauma [2020Y2014]; Talent Training Project
   of Wuxi Taihu Lake [BJ2020103]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This work
   was supported by the Fujian Provincial Natural Science Foundation
   Projects (grant no. 2019J01548), Fujian Provincial Clinical Medical
   Research Center for First Aid and Rehabilitation in Orthopedic Trauma
   (grant no. 2020Y2014), and the Talent Training Project of Wuxi Taihu
   Lake (grant no. BJ2020103).
CR Atwood DJ, 2020, CELL SIGNAL, V74, DOI 10.1016/j.cellsig.2020.109730
   Chen, 2022, AM J TRANSL RES, V14
   Gao X, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.633447
   Gao X, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.533809
   Han H, 2018, MOLECULES, V23, DOI 10.3390/molecules23061412
   Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704
   Huang JG., 2011, CELL MOL BIOL LETT, V16
   Kang CR, 2017, INT J NANOMED, V12, P4323, DOI 10.2147/IJN.S136281
   Kuang, 2018, AGING US, V10
   Lee CG, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910642
   Li MY, 2010, MOLECULES, V15, P7403, DOI 10.3390/molecules15107403
   Linder M, 2018, CELL DEATH DIFFER, V25, P1094, DOI 10.1038/s41418 017 0054 7
   Liu H, 2021, BIOSCI BIOTECH BIOCH, V85, P332, DOI 10.1093/bbb/zbaa010
   Liu WJ, 2014, AUTOPHAGY, V10, P243, DOI 10.4161/auto.27004
   Luo HR, 2003, P NATL ACAD SCI USA, V100, P11712, DOI 10.1073/pnas.1634990100
   Luo ZL, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3018190
   Maiello D, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10051092
   Martínez Cisuelo V, 2016, EXP GERONTOL, V83, P130, DOI 10.1016/j.exger.2016.08.002
   Rezabakhsh A, 2017, BIOMED PHARMACOTHER, V93, P885, DOI 10.1016/j.biopha.2017.07.044
   Shoji Kawata S, 2013, NATURE, V494, P201, DOI 10.1038/nature11866
   Singha UK, 2008, J CELL BIOCHEM, V103, P434, DOI 10.1002/jcb.21411
   Su Y, 2018, INFLAMMATION, V41, P1384, DOI 10.1007/s10753 018 0786 7
   Sun, 2020, CELL PROLIFERAT, V53
   Sun YX, 2018, CIRCULATION, V138, P2247, DOI 10.1161/CIRCULATIONAHA.117.032821
   Tan P, 2019, INT J MOL MED, V43, P1311, DOI 10.3892/ijmm.2019.4074
   Tong XS, 2021, DIFFERENTIATION, V121, P35, DOI 10.1016/j.diff.2021.08.003
   Vidoni C, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964 019 0414 7
   Weng YM, 2018, EUR REV MED PHARMACO, V22, P1224, DOI 10.26355/eurrev_201803_14462
   Yang LM, 2022, FOOD CHEM TOXICOL, V165, DOI 10.1016/j.fct.2022.113128
   Yang YH, 2014, FREE RADICAL BIO MED, V77, P10, DOI 10.1016/j.freeradbiomed.2014.08.028
   Zhang ZD, 2019, MOL MED REP, V19, P3505, DOI 10.3892/mmr.2019.10051
   Zhao E, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046 020 01696 7
NR 32
TC 10
Z9 10
U1 3
U2 15
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1535 3702
EI 1535 3699
J9 EXP BIOL MED
JI Exp. Biol. Med.
PD OCT
PY 2022
VL 247
IS 19
BP 1764
EP 1775
DI 10.1177/15353702221116879
EA AUG 2022
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 5Y1NG
UT WOS:000839876500001
PM 35957534
OA Green Published
DA 2025 08 17
ER

PT J
AU Calzado Martín, A
   Méndez Vilas, A
   Multigner, M
   Saldaña, L
   González Carrasco, JL
   González Martín, ML
   Vilaboa, N
AF Calzado Martin, A.
   Mendez Vilas, A.
   Multigner, M.
   Saldana, L.
   Gonzalez Carrasco, J. L.
   Gonzalez Martin, M. L.
   Vilaboa, N.
TI On the role of RhoA/ROCK signaling in contact guidance of bone forming
   cells on anisotropic Ti6Al4V surfaces
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Contact guidance; Mesenchymal stem cells; Osteoblasts; Rho GTPase;
   Ti6Al4V
ID OSTEOBLAST LIKE CELLS; DEFINED BIOMATERIAL SURFACES; CONNECTIVE TISSUE
   RESPONSES; RHO GTPASES; ACTIN CYTOSKELETON; EPITHELIAL CELLS;
   STEM CELLS; ADHESION; TITANIUM; ALIGNMENT
AB Patterned surfaces direct cell spatial dynamics, yielding cells oriented along the surface geometry, in a process known as contact guidance. The Rho family of GTPases controls the assembly of focal adhesions and cytoskeleton dynamics, but its role in modulating bone cell alignment on patterned surfaces remains unknown. This article describes the interactions of two human cell types involved in osseointegration, specifically mesenchymal stem cells and osteoblasts, with submicron or nano scale Ti6Al4V grooved surfaces generated by mechanical abrasion. The surface chemistry of the alloy was not affected by grinding, ensuring that the differences found in cellular responses were exclusively due to changes in topography. Patterned surfaces supported cell growth and stimulated mesenchymal stem cell viability. Anisotropic surfaces promoted cell orientation and elongation along the grates. Both cell types oriented on nanometric surfaces with grooves of 150 nm depth and 2 mu m width. The number of aligned cells increased by approximately 30% on submicrometric grooves with sizes of about 1 mu m depth and 10 gm width. Cells were treated with drugs that attenuate the activities of the GTPase RhoA and one of its downstream effectors, Rho associated kinase (ROCK), and contact guidance of treated cells on the grooved surfaces was investigated. The data indicate that the RhoA/ROCK pathway is a key modulator of both mesenchymal stem cell and osteoblast orientation on nanometric surface features. RhoA and its effector participate in the alignment of mesenchymal stem cells on submicrometric grooves, but not of osteoblasts. These findings show that RhoA/ROCK signaling is involved in contact guidance of bone related cells on metallic substrates, although to a varying extent depending on the specific cell type and the dimensions of the pattern. (C) 2010 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Calzado Martin, A.; Saldana, L.; Vilaboa, N.] Hosp Univ La Paz IdiPAZ, Madrid 28046, Spain.
   [Calzado Martin, A.; Mendez Vilas, A.; Multigner, M.; Saldana, L.; Gonzalez Carrasco, J. L.; Gonzalez Martin, M. L.; Vilaboa, N.] CIBER BBN, Barcelona, Spain.
   [Mendez Vilas, A.; Gonzalez Martin, M. L.] Univ Extremadura, Dept Fis Aplicada, Badajoz 06006, Spain.
   [Multigner, M.; Gonzalez Carrasco, J. L.] CENIM CSIC, Ctr Nacl Invest Met, Madrid 28040, Spain.
C3 Hospital Universitario La Paz; CIBER   Centro de Investigacion Biomedica
   en Red; CIBERBBN; Universidad de Extremadura; Consejo Superior de
   Investigaciones Cientificas (CSIC); Centro Nacional de Investigaciones
   Metalurgicas (CENIM)
RP Vilaboa, N (通讯作者)，Hosp Univ La Paz IdiPAZ, Paseo Castellana 261, Madrid 28046, Spain.
EM nvilaboa.hulp@salud.madrid.org
RI Gonzalez Martin, Maria Luisa/L 3476 2014; Vilaboa, Nuria/L 1727 2014;
   Saldaña, Laura/N 2412 2014; González Martín, María Luisa/L 3476 2014;
   Carrasco, Jose/A 7971 2008; Multigner, Marta/H 5210 2015;
   Calzado Martín, Alicia/M 1878 2014; Saldana, Laura/N 2412 2014
OI Gonzalez Martin, Maria Luisa/0000 0002 9207 444X; Mendez Vilas,
   Antonio/0000 0002 1839 9326; Gonzalez Carrasco, Jose
   Luis/0000 0003 2004 4505; Multigner, Marta/0000 0002 1584 0163; Vilaboa,
   Nuria/0000 0003 4473 4498; Saldana, Laura/0000 0003 3057 4649
FU Ministerio de Ciencia e Innovacion (Spain) [MAT2009 14695 004 01 02 04];
   Fundacion Mutua Madrilena (Spain) [PRI08A124]; Consejeria de Economia,
   Comercio e Innovacion de la Junta de Extremadura (Spain); Fundacion para
   la Investigacion Biomedica del Hospital Universitario La Paz (Madrid,
   Spain); Fondo de Investigaciones Sanitarias (Spain)
FX This work was supported by grants MAT2009 14695 004 01 02 04 from the
   Ministerio de Ciencia e Innovacion (Spain), grants from Fundacion Mutua
   Madrilena (Spain) and grant PRI08A124 from Consejeria de Economia,
   Comercio e Innovacion de la Junta de Extremadura (Spain). A.
   Calzado Martin is supported by Fundacion para la Investigacion Biomedica
   del Hospital Universitario La Paz (Madrid, Spain). N. Vilaboa is
   supported by Program I3SNS from Fondo de Investigaciones Sanitarias
   (Spain). The authors are greatly indebted to Alba Bore (Unidad de
   Investigacion, Hospital Universitario La Paz and CIBER BBN), to the SEM
   laboratory (National Museum of Science and Technology, MNCT, Madrid) for
   excellent technical support, to the clinical staff of the Orthopaedic
   Department for providing us with bone samples, and to the Section of
   Biostatistics (Hospital Universitario La Paz) for help with statistical
   analysis.
CR Allen WE, 1997, J CELL SCI, V110, P707
   Anselme K, 2002, J BIOMED MATER RES, V60, P529, DOI 10.1002/jbm.10101
   Ball M, 2008, J BIOMED MATER RES A, V86A, P637, DOI 10.1002/jbm.a.31652
   Bettinger CJ, 2006, BIOMATERIALS, V27, P2558, DOI 10.1016/j.biomaterials.2005.11.029
   Biggs MJP, 2008, J R SOC INTERFACE, V5, P1231, DOI 10.1098/rsif.2008.0035
   CHAPLET M, 2004, BIOCHEM J, V15, P591
   Crouch AS, 2009, BIOMATERIALS, V30, P1560, DOI 10.1016/j.biomaterials.2008.11.041
   Dalby MJ, 2008, BIOMATERIALS, V29, P282, DOI 10.1016/j.biomaterials.2007.09.030
   Deligianni DD, 2001, BIOMATERIALS, V22, P1241, DOI 10.1016/S0142 9612(00)00274 X
   Ehrenfest DMD, 2010, TRENDS BIOTECHNOL, V28, P198, DOI 10.1016/j.tibtech.2009.12.003
   Etienne Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148
   Fujita S, 2009, J R SOC INTERFACE, V6, pS269, DOI 10.1098/rsif.2008.0428.focus
   Geetha M, 2009, PROG MATER SCI, V54, P397, DOI 10.1016/j.pmatsci.2008.06.004
   Gerecht S, 2007, BIOMATERIALS, V28, P4068, DOI 10.1016/j.biomaterials.2007.05.027
   Grew JC, 2008, J BIOMED MATER RES A, V85A, P326, DOI 10.1002/jbm.a.31378
   Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632
   Ishizaki T, 2001, NAT CELL BIOL, V3, P8
   Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721
   Jaganathan BG, 2007, STEM CELLS, V25, P1966, DOI 10.1634/stemcells.2007 0167
   Karuri NW, 2004, J CELL SCI, V117, P3153, DOI 10.1242/jcs.01146
   KONONEN M, 1992, J BIOMED MATER RES, V26, P1325
   Lamers E, 2010, BIOMATERIALS, V31, P3307, DOI 10.1016/j.biomaterials.2010.01.034
   Lenhert S, 2005, BIOMATERIALS, V26, P563, DOI 10.1016/j.biomaterials.2004.02.068
   Liao DK, 2007, J CARDIOVASC PHARM, V50, P17, DOI 10.1097/FJC.0b013e318070d1bd
   Loesberg WA, 2007, BIOMATERIALS, V28, P3944, DOI 10.1016/j.biomaterials.2007.05.030
   Lu J, 2008, ACTA BIOMATER, V4, P192, DOI 10.1016/j.actbio.2007.07.008
   Méndez Vilas A, 2006, COLLOID SURFACE B, V52, P157, DOI 10.1016/j.colsurfb.2006.05.002
   Monsees TK, 2005, CELLS TISSUES ORGANS, V180, P81, DOI 10.1159/000086749
   Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235
   Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035
   Rajnicek AM, 2008, BIOMATERIALS, V29, P2082, DOI 10.1016/j.biomaterials.2008.01.015
   Rajnicek AM, 2007, DEV BIOL, V312, P448, DOI 10.1016/j.ydbio.2007.09.051
   Ren XD, 2000, J CELL SCI, V113, P3673
   Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578
   Ricci JL, 2008, J BIOMED MATER RES A, V85A, P313, DOI 10.1002/jbm.a.31379
   Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053
   Saldaña L, 2005, J BIOMED MATER RES A, V73A, P97, DOI 10.1002/jbm.a.30264
   Saldaña L, 2010, ACTA BIOMATER, V6, P1649, DOI 10.1016/j.actbio.2009.10.033
   Teixeira AI, 2003, J CELL SCI, V116, P1881, DOI 10.1242/jcs.00383
   TIPLER PA, 1978, FISICA
   Vogelsgesang M, 2007, N S ARCH PHARMACOL, V374, P347, DOI 10.1007/s00210 006 0113 y
   Weiner S, 1999, J STRUCT BIOL, V126, P241, DOI 10.1006/jsbi.1999.4107
   WEISS P, 1952, P NATL ACAD SCI USA, V38, P264, DOI 10.1073/pnas.38.3.264
   Zhao JM, 2008, J BIOMED MATER RES A, V84A, P988, DOI 10.1002/jbm.a.31426
   Zhou F, 2009, CHINESE SCI BULL, V54, P3200, DOI [10.1007/s11434 009 0366 1, 10.1007/S11434 009 0366 1]
   Zhu BS, 2005, TISSUE ENG, V11, P825, DOI 10.1089/ten.2005.11.825
NR 46
TC 39
Z9 43
U1 0
U2 60
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD APR
PY 2011
VL 7
IS 4
BP 1890
EP 1901
DI 10.1016/j.actbio.2010.11.035
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 742US
UT WOS:000288971300051
PM 21115140
DA 2025 08 17
ER

PT J
AU Jian, CX
   Fan, QS
   Hu, YH
   He, Y
   Li, MZ
   Zheng, WY
   Ren, Y
   Li, CJ
AF Jian, Cong Xiang
   Fan, Quan Shui
   Hu, Yong He
   He, Yong
   Li, Ming Zhe
   Zheng, Wei Yin
   Ren, Yu
   Li, Chen Jun
TI IL 7 suppresses osteogenic differentiation of periodontal ligament stem
   cells through inactivation of mitogen activated protein kinase pathway
SO ORGANOGENESIS
LA English
DT Article
DE IL 7; MAPK; osteoblast; osteogenic differentiation; periodontal ligament
   stem cells
ID VIVO TISSUE REGENERATION; MYELOMA BONE DISEASE; MARROW STROMAL CELLS;
   TRANSCRIPTION FACTOR; IN VITRO; OSTEOBLAST DIFFERENTIATION; MAPK
   PATHWAYS; PATHOPHYSIOLOGY; PROGENITORS; INCREASES
AB Periodontal ligament stem cells (PDLSCs) are tissue specific mesenchymal stem cells (MSCs), having an important role in regenerative therapy for teeth loss. Interleukin 7 (IL 7) is a key cytokine produced by stromal cells including MSCs, and exhibits specific roles for B and T cell development and osteoblasts differentiation of multiple myeloma. However, the effect of IL 7 on osteogenic differentiation of PDLSCs remains unclear. Therefore, in the present study we determined whether IL 7 affects the proliferation and osteogenic differentiation of PDLSCs in vitro and explored the associated signaling pathways for IL 7 mediated cell differentiation. The results demonstrated that the isolated human PDLSCs possessed MSCs features, highly expressing CD90, CD44, CD105, CD29 and CD73, and almost did not expressed CD34, CD45, CD11b, CD14 and CD117. IL 7 could not significantly affect the proliferation of PDLSCs, but it decreased their osteogenic differentiation and inhibited alkaline phosphatase (ALP) activity. The results of quantitative reverse transcriptionpolymerase chain reaction (qRT PCR) and Western blotting exhibited that the expression levels of Runx 2, SP7 and osteocalcin (OCN) were significantly reduced by IL 7. Further studies indicated that IL 7 did not significantly change JNK, ERK1/2 and p38 protein production, but markedly suppressed their phosphorylation levels. These data suggest that IL 7 inhibits the osteogenic differentiation of PDLSCs probably via inactivation of mitogen activated protein kinase (MAPK) signaling pathway.
C1 [Jian, Cong Xiang; He, Yong; Li, Ming Zhe; Zheng, Wei Yin; Ren, Yu; Li, Chen Jun] Chengdu Mil Reg, PLA Gen Hosp, Dept Stomatolog, Chengdu 610083, Sichuan Provinc, Peoples R China.
   [Fan, Quan Shui; Hu, Yong He] Chengdu Mil Garrison Ctr Dis Control & Prevent, Chengdu, Sichuan, Peoples R China.
RP Li, CJ (通讯作者)，Chengdu Mil Reg, PLA Gen Hosp, Dept Stomatolog, Chengdu 610083, Sichuan Provinc, Peoples R China.
EM lichenjun65@sina.com
RI LU, xiong/B 3092 2010; Li, Mingzhe/JLK 8164 2023
FU China Postdoctoral Science Foundation [2015M582908]
FX This work was supported by China Postdoctoral Science Foundation
   (2015M582908).
CR Artigas N, 2014, J BIOL CHEM, V289, P27105, DOI 10.1074/jbc.M114.576793
   Bright R, 2015, J PERIODONTAL RES, V50, P160, DOI 10.1111/jre.12205
   Catón J, 2011, J CELL MOL MED, V15, P1054, DOI 10.1111/j.1582 4934.2010.01251.x
   Cha Y, 2015, J ENDODONT, V41, P1462, DOI 10.1016/j.joen.2015.04.010
   Chen FM, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0288 1
   Chen FM, 2012, BIOMATERIALS, V33, P6320, DOI 10.1016/j.biomaterials.2012.05.048
   Chen X, 2009, J IMMUNOL, V183, P6135, DOI 10.4049/jimmunol.0901576
   Feng F, 2010, ORAL DIS, V16, P20, DOI 10.1111/j.1601 0825.2009.01593.x
   Franceschi RT, 2003, CONNECT TISSUE RES, V44, P109, DOI 10.1080/03008200390152188
   Fujita T, 2007, J PERIODONTAL RES, V42, P283, DOI 10.1111/j.1600 0765.2006.00944.x
   Giuliani N, 2005, BLOOD, V106, P2472, DOI 10.1182/blood 2004 12 4986
   Giuliani N, 2006, BLOOD, V108, P3992, DOI 10.1182/blood 2006 05 026112
   Hwang JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135519
   Iwata M, 2002, BLOOD, V100, P1318, DOI 10.1182/blood 2002 01 0062
   Komori T, 2002, J CELL BIOCHEM, V87, P1, DOI 10.1002/jcb.10276
   Li B, 2016, SCI REP UK, V6, DOI 10.1038/srep26542
   Li BH, 2013, NEURAL REGEN RES, V8, P2827, DOI 10.3969/j.issn.1673 5374.2013.30.005
   Lu H, 2013, CELL TRANSPLANT, V22, P205, DOI 10.3727/096368912X656171
   Maeda H, 2011, INT ENDOD J, V44, P425, DOI 10.1111/j.1365 2591.2010.01845.x
   Manescu A, 2016, J PERIODONTAL RES, V51, P112, DOI 10.1111/jre.12289
   Nierste BA, 2014, AM J BLOOD RES, V4, P73
   Nuñez J, 2012, J PERIODONTAL RES, V47, P33, DOI 10.1111/j.1600 0765.2011.01402.x
   Park JC, 2011, J CLIN PERIODONTOL, V38, P721, DOI 10.1111/j.1600 051X.2011.01716.x
   Parrish YK, 2009, J IMMUNOL, V182, P4255, DOI 10.4049/jimmunol.0800489
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Shui CX, 2003, J BONE MINER RES, V18, P213, DOI 10.1359/jbmr.2003.18.2.213
   Silbermann R, 2013, J BONE ONCOL, V2, P59, DOI 10.1016/j.jbo.2013.04.001
   Sinha KM, 2014, J BONE MINER RES, V29, P855, DOI 10.1002/jbmr.2103
   Trubiani O, 2008, J BIOMED MATER RES A, V87A, P986, DOI 10.1002/jbm.a.31837
   Wei FL, 2015, STEM CELLS DEV, V24, P312, DOI 10.1089/scd.2014.0191
   Weitzmann MN, 2002, J CLIN INVEST, V110, P1643, DOI 10.1172/JCI200215687
   Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453
   Yan XZ, 2015, TISSUE ENG PART B RE, V21, P411, DOI [10.1089/ten.teb.2015.0049, 10.1089/ten.TEB.2015.0049]
   Zhang CX, 2015, ARCH MED SCI, V11, P638, DOI 10.5114/aoms.2015.52370
   Zhang X, 2015, MOL CELL BIOCHEM, V407, P41, DOI 10.1007/s11010 015 2452 9
   Zhu B, 2013, INT J ORAL MAX IMPL, V28, pE494, DOI 10.11607/jomi.te30
NR 36
TC 10
Z9 12
U1 0
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1547 6278
EI 1555 8592
J9 ORGANOGENESIS
JI Organogenesis
PY 2016
VL 12
IS 4
BP 183
EP 193
DI 10.1080/15476278.2016.1229726
PG 11
WC Biochemistry & Molecular Biology; Developmental Biology; Engineering,
   Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Developmental Biology; Engineering
GA EJ3NH
UT WOS:000393118400002
PM 27579861
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Simonaro, CM
   D'Angelo, M
   He, XX
   Eliyahu, E
   Shtraizent, N
   Haskins, ME
   Schuchman, EH
AF Simonaro, Calogera M.
   D'Angelo, Marina
   He, Xingxuan
   Eliyahu, Efrat
   Shtraizent, Nataly
   Haskins, Mark E.
   Schuchman, Edward H.
TI Mechanism of glycosaminoglycan mediated bone and joint disease  
   Implications for the mucopolysaccharidoses and other connective tissue
   diseases
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID ARYLSULFATASE B DEFICIENCY; ENZYME REPLACEMENT THERAPY; MAROTEAUX LAMY
   SYNDROME; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; INFLAMMATORY
   CYTOKINES; SYNOVIAL FIBROBLASTS; NITRIC OXIDE; VI; EXPRESSION
AB We have previously shown that glycosaminoglycan (GAG) storage in animal models of the mucopolysaccharidoses (NIPS) leads to inflammation and apoptosis within cartilage. We have now extended these findings to synovial tissue and further explored the mechanism underlying GAG mediated disease. Analysis of NIPS rats, cats, and/or dogs revealed that NIPS synovial fibroblasts and fluid displayed elevated expression of numerous inflammatory molecules, including several proteins important for lipopolysaccharide signaling (eg, Toll like receptor 4 and lipoprotein binding protein). The expression of tumor necrosis factor, in particular, was elevated up to 50 fold, leading to up regulation of the osteoclast survival factor, receptor activator of nuclear factor kappa B ligand, and the appearance of multinucleated osteoclast like cells in the NIPS bone marrow. Treatment of normal synovial fibroblasts with GAGS also led to production of the prosurvival lipid sphingosine l phosphate, resulting in enhanced cell proliferation, consistent with the hyperplastic synovial tissue observed in MPS patients. In contrast, GAG treatment of normal chondrocytes led to production of the proapoptotic lipid ceramide, confirming the enhanced cell death we had previously observed in MPS cartilage. These findings have important implications for the pathogenesis and treatment of MPS and have further defined the mechanism of GAG stimulated disease.
C1 [Simonaro, Calogera M.; He, Xingxuan; Eliyahu, Efrat; Shtraizent, Nataly; Schuchman, Edward H.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA.
   [Schuchman, Edward H.] Mt Sinai Sch Med, Dept Gene & Cell Med, New York, NY 10029 USA.
   [D'Angelo, Marina] Philadelphia Coll Osteopath Med, Ctr Chron Disorders Aging, Philadelphia, PA USA.
   [Haskins, Mark E.] Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA.
C3 Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at
   Mount Sinai; Philadelphia College of Osteopathic Medicine; University of
   Pennsylvania
RP Simonaro, CM (通讯作者)，Mt Sinai Sch Med, Dept Genet & Genom Sci, 1425 Madison Ave, New York, NY 10029 USA.
EM calogera.simonaro@mssm.edu
FU NCRR NIH HHS [P40 RR002512] Funding Source: Medline; NIDDK NIH HHS [R01
   DK025759, DK 25759] Funding Source: Medline
CR Ainola MM, 2005, CLIN EXP RHEUMATOL, V23, P644
   Auclair D, 2006, PEDIATR RES, V59, P538, DOI 10.1203/01.pdr.0000203090.41012.a6
   BERATIS NG, 1975, PEDIATR RES, V9, P475, DOI 10.1203/00006450 197505000 00003
   Burrage PS, 2006, FRONT BIOSCI LANDMRK, V11, P529, DOI 10.2741/1817
   Chen QQ, 2006, J RHEUMATOL, V33, P1061
   Cheon H, 2002, CLIN EXP IMMUNOL, V127, P547, DOI 10.1046/j.1365 2249.2002.01785.x
   Cox Brinkman J, 2007, J INHERIT METAB DIS, V30, P47, DOI 10.1007/s10545 006 0490 x
   Cuschieri Joseph, 2007, Surg Infect (Larchmt), V8, P91, DOI 10.1089/sur.2006.050
   Cuschieri J, 2006, J LEUKOCYTE BIOL, V80, P407, DOI 10.1189/jlb.1105622
   DEVRIESBOUWSTRA JK, 2007, ANN RHEUM DIS   0112
   Diks SH, 2004, CURR TOP MED CHEM, V4, P1115, DOI 10.2174/1568026043388141
   Doyle SL, 2006, BIOCHEM PHARMACOL, V72, P1102, DOI 10.1016/j.bcp.2006.07.010
   Edward M, 2007, BRIT J DERMATOL, V156, P473, DOI 10.1111/j.1365 2133.2006.07652.x
   Goldring SR, 2002, CURR OPIN RHEUMATOL, V14, P406, DOI 10.1097/00002281 200207000 00013
   GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003 2697(82)90118 X
   HASKINS M, 2002, ACTA PAEDIATR, V9, pS88
   HASKINS ME, 1984, PEDIATR RES, V18, P980, DOI 10.1203/00006450 198418100 00014
   He XX, 2001, ANAL BIOCHEM, V293, P204, DOI 10.1006/abio.2001.5108
   Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628
   Huwiler A, 2007, CRIT REV ONCOL HEMAT, V63, P150, DOI 10.1016/j.critrevonc.2007.04.010
   JEZYK PF, 1977, SCIENCE, V198, P834, DOI 10.1126/science.144321
   Kim MK, 2006, BIOCHEM BIOPH RES CO, V345, P67, DOI 10.1016/j.bbrc.2006.04.042
   KUNIEDA T, 1995, GENOMICS, V29, P582, DOI 10.1006/geno.1995.9962
   Migita K, 2000, BIOCHEM BIOPH RES CO, V269, P70, DOI 10.1006/bbrc.2000.2239
   Migita K, 1996, IMMUNOLOGY, V89, P553, DOI 10.1046/j.1365 2567.1996.d01 789.x
   NEUFELD EF, 2001, METABOLIC MOL BASES, P3421, DOI DOI 10.1036/OMMBID.165
   Nuttall JD, 1999, CALCIFIED TISSUE INT, V65, P47, DOI 10.1007/s002239900656
   Ortutay Z, 2003, ARTHRITIS RHEUM US, V48, P2163, DOI 10.1002/art.11093
   Pålsson McDermott EM, 2004, IMMUNOLOGY, V113, P153, DOI 10.1111/j.1365 2567.2004.01976.x
   Parildar Z, 2002, CLIN RHEUMATOL, V21, P284, DOI 10.1007/s100670200075
   Pastores GM, 2005, CURR OPIN RHEUMATOL, V17, P70, DOI 10.1097/01.bor.0000147283.40529.13
   Rigante D, 2004, QJM INT J MED, V97, P205, DOI 10.1093/qjmed/hch041
   Sakata A, 2007, CELL IMMUNOL, V245, P24, DOI 10.1016/j.cellimm.2007.03.005
   SCHETT G, 2005, RHEUMATOLOGY, V1, P47
   Shigeyama Y, 2000, ARTHRITIS RHEUM, V43, P2523, DOI 10.1002/1529 0131(200011)43:11<2523::AID ANR20>3.0.CO;2 Z
   Simonardo CM, 1997, TRANSPLANTATION, V63, P1386, DOI 10.1097/00007890 199705270 00003
   Simonaro CM, 2005, PEDIATR RES, V57, P701, DOI 10.1203/01.PDR.0000156510.96253.5A
   Simonaro CM, 2001, LAB INVEST, V81, P1319, DOI 10.1038/labinvest.3780345
   Thomas JA, 2006, J INHERIT METAB DIS, V29, P762, DOI 10.1007/s10545 006 0457 y
   TRADIF G, 2004, MOD RHEUMATOL, V14, P197
   Triantafilou M, 2003, J ENDOTOXIN RES, V9, P331, DOI 10.1179/096805103225002557
   Wang JY, 2002, P NATL ACAD SCI USA, V99, P14362, DOI 10.1073/pnas.222536599
   Wang XB, 2004, OSTEOARTHR CARTILAGE, V12, P963, DOI 10.1016/j.joca.2004.08.008
   YOSHIDA M, 1993, J CLIN INVEST, V91, P1099, DOI 10.1172/JCI116268
NR 44
TC 180
Z9 191
U1 0
U2 26
PU AMER SOC INVESTIGATIVE PATHOLOGY, INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3993 USA
SN 0002 9440
J9 AM J PATHOL
JI Am. J. Pathol.
PD JAN
PY 2008
VL 172
IS 1
BP 112
EP 122
DI 10.2353/ajpath.2008.070564
PG 11
WC Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology
GA 251MC
UT WOS:000252376600013
PM 18079441
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Patrick, MT
   Stuart, PE
   Raja, K
   Chi, SY
   He, Z
   Voorhees, JJ
   Tejasvi, T
   Gudjonsson, JE
   Kahlenberg, JM
   Chandran, V
   Rahman, P
   Gladman, DD
   Nair, RP
   Elder, JT
   Tsoi, LC
AF Patrick, Matthew T.
   Stuart, Philip E.
   Raja, Kalpana
   Chi, Sunyi
   He, Zhi
   Voorhees, John J.
   Tejasvi, Trilokraj
   Gudjonsson, Johann E.
   Kahlenberg, J. Michelle
   Chandran, Vinod
   Rahman, Proton
   Gladman, Dafna D.
   Nair, Rajan P.
   Elder, James T.
   Tsoi, Lam C.
TI Integrative Approach to Reveal Cell Type Specificity and Gene Candidates
   for Psoriatic Arthritis Outside the MHC
SO FRONTIERS IN GENETICS
LA English
DT Article
DE psoriatic arthritis; gene candidates; systems biology; epigenomics; GWAS
ID GENOME WIDE ASSOCIATION; IDENTIFICATION
AB We recently conducted a large association analysis to compare the genetic profiles between patients with psoriatic arthritis (PsA) and cutaneous only psoriasis (PsC). Despite including over 7,000 genotyped patients, only the MHC achieved genome wide significance. In this study, we hypothesized that appropriate epigenomic elements (H3K27ac marks for active enhancers) can guide us to reveal valuable information about the loci with suggestive evidence of association. Our aim is to investigate these loci and explore how they may lead to the development of PsA. We evaluated this potential by investigating the genes connected with these loci from the perspective of pharmacogenomics and gene expression. We illustrated that markers with suggestive evidence of association outside the MHC region are enriched in H3K27ac marks for osteoblast and chondrogenic differentiated cells; using pharmacogenomics resources, we showed that genes near these markers are targeted by existing drugs used to treat psoriatic arthritis. Significantly, six of the ten suggestive significant loci overlapping the regulatory elements encompass genes differentially expressed (FDR < 5%) in differentiated osteoblasts, including genes participating in the Wnt signaling such as RUNX1, FUT8, and CTNNAL1. Our approach shows that epigenomic information can be used as cost effective approach to enhance the inferences for GWAS results, especially in situations when few genome wide significant loci are available. Our results also point the way to more directed investigations comparing the genetics of PsA and PsC.
C1 [Patrick, Matthew T.; Stuart, Philip E.; Raja, Kalpana; Chi, Sunyi; Voorhees, John J.; Tejasvi, Trilokraj; Gudjonsson, Johann E.; Nair, Rajan P.; Elder, James T.; Tsoi, Lam C.] Univ Michigan, Sch Med, Dept Dermatol, Ann Arbor, MI 48109 USA.
   [Raja, Kalpana] Morgridge Inst Res, Madison, WI USA.
   [Chi, Sunyi; He, Zhi; Tsoi, Lam C.] Univ Michigan, Ctr Stat Genet, Dept Biostat, Ann Arbor, MI 48109 USA.
   [Tejasvi, Trilokraj; Elder, James T.] Ann Arbor Vet Affairs Hosp, Ann Arbor, MI USA.
   [Kahlenberg, J. Michelle] Univ Michigan, Dept Internal Med, Div Rheumatol, Ann Arbor, MI 48109 USA.
   [Chandran, Vinod; Gladman, Dafna D.] Univ Toronto, Dept Med, Div Rheumatol, Toronto, ON, Canada.
   [Chandran, Vinod; Gladman, Dafna D.] Univ Toronto, Ctr Prognosis Studies Rheumat Dis, Krembil Res Inst, Toronto, ON, Canada.
   [Chandran, Vinod; Gladman, Dafna D.] Univ Toronto, Inst Med Sci, Toronto, ON, Canada.
   [Chandran, Vinod] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.
   [Chandran, Vinod; Rahman, Proton] Mem Univ Newfoundland, Fac Med, St John, NF, Canada.
   [Tsoi, Lam C.] Univ Michigan, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of
   Wisconsin System; University of Wisconsin Madison; The Morgridge
   Institute for Research, Inc.; University of Michigan System; University
   of Michigan; University of Michigan System; University of Michigan;
   University of Toronto; University of Toronto; Krembil Research
   Institute; University of Toronto; University of Toronto; Memorial
   University Newfoundland; University of Michigan System; University of
   Michigan
RP Tsoi, LC (通讯作者)，Univ Michigan, Sch Med, Dept Dermatol, Ann Arbor, MI 48109 USA.; Tsoi, LC (通讯作者)，Univ Michigan, Ctr Stat Genet, Dept Biostat, Ann Arbor, MI 48109 USA.; Tsoi, LC (通讯作者)，Univ Michigan, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA.
EM alextsoi@umich.edu
RI Chi, Sunyi/GXV 3605 2022; Gladman, Dafna/AFM 6487 2022; Voorhees,
   John/AAM 9966 2020
OI Tsoi, Alex L/0000 0003 1627 5722; Chi, Sunyi/0000 0003 4112 2074; 
FU Arthritis National Research Foundation; National Psoriasis Foundation;
   National Institutes of Health [R01AR071384, R01AR042742, R01AR050511,
   R01AR054966, R01AR063611, R01AR065183, K01AR072129]; Dermatology
   Foundation; Dawn and Dudley Holmes Foundation; Babcock Memorial Trust;
   Krembil Foundation; National Institute of Health [AR069071, AR060802];
   Taubman Medical Research Institute; Ann Arbor Veterans Affairs Hospital;
   Doris Duke Charitable Foundation Clinician Scientist Development Award;
   Rheumatology Research Foundation; Taubman Medical Research Institute
   Parfet Emerging Scholar Award; National Institute of Arthritis and
   Musculoskeletal and Skin Diseases [K01AR072129] Funding Source: NIH
   RePORTER
FX This work was supported by the Arthritis National Research Foundation
   and the National Psoriasis Foundation (LT), and awards from the National
   Institutes of Health (R01AR042742, R01AR050511, R01AR054966,
   R01AR063611, R01AR065183 to JE; K01AR072129 to LT). LT was also
   supported by the Dermatology Foundation. LT, PS, TT, JG, JV, RN, and JE
   were supported by the Dawn and Dudley Holmes Foundation and the Babcock
   Memorial Trust. DG and VC were supported by the Krembil Foundation. JG
   was supported by the National Institute of Health (AR069071 and
   AR060802) and the Taubman Medical Research Institute. JE was supported
   by the Ann Arbor Veterans Affairs Hospital. JK was supported by the
   National Institutes of Health R01AR071384, the Doris Duke Charitable
   Foundation Clinician Scientist Development Award, the Rheumatology
   Research Foundation and the Taubman Medical Research Institute Parfet
   Emerging Scholar Award.
CR Alamanos Y, 2008, J RHEUMATOL, V35, P1354
   Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   Boyle EA, 2017, CELL, V169, P1177, DOI 10.1016/j.cell.2017.05.038
   Chandran V, 2010, RHEUMATOLOGY, V49, P1399, DOI 10.1093/rheumatology/keq105
   Chang CC, 2015, GIGASCIENCE, V4, DOI 10.1186/s13742 015 0047 8
   Chimge NO, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10751
   Choi S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01339
   Davis AP, 2015, NUCLEIC ACIDS RES, V43, pD914, DOI 10.1093/nar/gku935
   Dimas AS, 2009, SCIENCE, V325, P1246, DOI 10.1126/science.1174148
   Ellinghaus E, 2010, NAT GENET, V42, P991, DOI 10.1038/ng.689
   Farh KKH, 2015, NATURE, V518, P337, DOI 10.1038/nature13835
   Gasperini M., 2018, BIORXIV, DOI [10.1101/314344, DOI 10.1101/314344]
   Goldring SR, 2007, NAT MED, V13, P133, DOI 10.1038/nm0207 133
   Gudjonsson JE, 2010, J INVEST DERMATOL, V130, P1849, DOI 10.1038/jid.2010.67
   Han Y, 2015, HUM MOL GENET, V24, P5603, DOI 10.1093/hmg/ddv269
   Jansen PR., 2018, bioRxiv, P214973, DOI DOI 10.1101/214973
   Kurimoto A, 2014, J BIOL CHEM, V289, P11704, DOI 10.1074/jbc.M113.502542
   Mahajan A, 2018, NAT GENET, V50, P1505, DOI 10.1038/s41588 018 0241 6
   Manduchi E, 2018, HUM GENET, V137, P413, DOI 10.1007/s00439 018 1893 0
   Merdek KD, 2004, MOL CELL BIOL, V24, P2410, DOI 10.1128/MCB.24.6.2410 2422.2004
   Murtagh F, 2014, J CLASSIF, V31, P274, DOI 10.1007/s00357 014 9161 z
   Nair RP, 2009, NAT GENET, V41, P199, DOI 10.1038/ng.311
   Okada Y, 2014, NATURE, V506, P376, DOI 10.1038/nature12873
   Patrick MT, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06672 6
   Raja K, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03914 3
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Stern RS, 1997, LANCET, V350, P349, DOI 10.1038/nrdp.2016.82
   Stuart PE, 2015, AM J HUM GENET, V97, P816, DOI 10.1016/j.ajhg.2015.10.019
   Thorn Caroline F, 2013, Methods Mol Biol, V1015, P311, DOI 10.1007/978 1 62703 435 7_20
   Tsoi LC, 2018, J INVEST DERMATOL, V138, pE23, DOI 10.1016/j.jid.2018.01.004
   Tsoi LC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15382
   Tsoi LC, 2012, NAT GENET, V44, P1341, DOI 10.1038/ng.2467
   van de Peppel J, 2017, STEM CELL REP, V8, P947, DOI 10.1016/j.stemcr.2017.02.018
   Vosa U, 2018, bioRxiv, DOI DOI 10.1101/447367
   Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
NR 37
TC 6
Z9 6
U1 0
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1664 8021
J9 FRONT GENET
JI Front. Genet.
PD APR 11
PY 2019
VL 10
AR 304
DI 10.3389/fgene.2019.00304
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA HT3LA
UT WOS:000464464100001
PM 31031798
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Suvannasankha, A
   Tompkins, DR
   Edwards, DF
   Petyaykina, KV
   Crean, CD
   Fournier, PG
   Parker, JM
   Sandusky, GE
   Ichikawa, S
   Imel, EA
   Chirgwin, JM
AF Suvannasankha, Attaya
   Tompkins, Douglas R.
   Edwards, Daniel F.
   Petyaykina, Katarina V.
   Crean, Colin D.
   Fournier, Pierrick G.
   Parker, Jamie M.
   Sandusky, George E.
   Ichikawa, Shoji
   Imel, Erik A.
   Chirgwin, John M.
TI FGF23 is elevated in multiple myeloma and increases heparanase
   expression by tumor cells
SO ONCOTARGET
LA English
DT Article
DE multiple myeloma; osteocytes; FGF23; FGF receptor; klotho
ID BONE DISEASE; HYPOPHOSPHATEMIC RICKETS; GROWTH FACTORS; IN VIVO; KLOTHO;
   CANCER; PROGRESSION; RECEPTOR; IRON; TRANSCRIPTION
AB Multiply myeloma (MM) grows in and destroys bone, where osteocytes secrete FGF23, a hormone which affects phosphate homeostasis and aging. We report that multiple myeloma (MM) cells express receptors for and respond to FGF23. FGF23 increased mRNA for EGR1 and its target heparanase, a pro osteolytic factor in MM. FGF23 signals through a complex of klotho and a classical FGF receptor (FGFR); both were expressed by MM cell lines and patient samples. Bone marrow plasma cells from 42 MM patients stained positively for klotho, while plasma cells from 8 patients with monoclonal gammopathy of undetermined significance (MGUS) and 6 controls were negative. Intact, active FGF23 was increased 2.9X in sera of MM patients compared to controls. FGF23 was not expressed by human MM cells, but co culture with mouse bone increased its mRNA. The FGFR inhibitor NVP BGJ398 blocked the heparanase response to FGF23. NVP BGJ398 did not inhibit 8226 growth in vitro but significantly suppressed growth in bone and induction of the osteoclast regulator RANK ligand, while decreasing heparanase mRNA. The bone microenvironment provides resistance to some anti tumor drugs but increased the activity of NVP BGJ398 against 8226 cells. The FGF23/klotho/heparanase signaling axis may offer targets for treatment of MM in bone.
C1 [Suvannasankha, Attaya; Tompkins, Douglas R.; Edwards, Daniel F.; Petyaykina, Katarina V.; Crean, Colin D.; Fournier, Pierrick G.; Ichikawa, Shoji; Imel, Erik A.; Chirgwin, John M.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA.
   [Suvannasankha, Attaya; Chirgwin, John M.] Richard L Roudebush VA Med Ctr, Indianapolis, IN USA.
   [Parker, Jamie M.; Sandusky, George E.] Indiana Univ Sch Med, Dept Pathol, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Bloomington; US Department
   of Veterans Affairs; Veterans Health Administration (VHA); Richard L.
   Roudebush VA Medical Center; Indiana University System; Indiana
   University Bloomington
RP Chirgwin, JM (通讯作者)，Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA.
EM jmchirgw@iu.edu
RI Edwards, Dorothy/L 6720 2016; Imel, Erik/J 3837 2013; Fournier,
   Pierrick/B 6560 2015
OI Chirgwin, John/0009 0001 7638 0842; Imel, Erik/0000 0002 7284 3467; ,
   Daniel F. Edwards III, Daniel F. Edwards, Daniel
   Edwards/0009 0003 4781 0270; Fournier, Pierrick/0000 0001 7633 8129
FU VA Merit award [11346201]; Department of Medicine; Indiana University
   Mel and Bren Simon Cancer Center; NIAMS/NIH [K23AR057096]; Cancer Center
   medical student summer research fellowship
FX The authors thank Drs. G. David Roodman and Michael J. Econs for helpful
   discussions and Kyowa Hakko Kirin Co., Ltd., for the gift of the
   antibody used for klotho IHC. Work was supported by a VA Merit award
   11346201, funds from the Department of Medicine and a pilot project
   award from the Indiana University Mel and Bren Simon Cancer Center to AS
   and JMC and by grant K23AR057096 from NIAMS/NIH to EAI. KVP was
   supported by a Cancer Center medical student summer research fellowship.
CR Balasubramanian P, 2010, AGING US, V2, P632, DOI 10.18632/aging.100219
   Barash U, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051494
   Cafforio P, 2014, J BONE MINER RES, V29, P55, DOI 10.1002/jbmr.2022
   Carpenter TO, 2014, J CLIN INVEST, V124, P1587, DOI 10.1172/JCI72829
   Casimiro S, 2009, MOL CELL ENDOCRINOL, V310, P71, DOI 10.1016/j.mce.2009.07.004
   Château MT, 2010, AGING US, V2, P567, DOI 10.18632/aging.100195
   Chong WH, 2011, ENDOCR RELAT CANCER, V18, pR53, DOI 10.1530/ERC 11 0006
   Chung E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008316
   Curtin P, 2012, BIOMATERIALS, V33, P1065, DOI 10.1016/j.biomaterials.2011.10.046
   de Mestre AM, 2005, J BIOL CHEM, V280, P35136, DOI 10.1074/jbc.M503414200
   Diamond P, 2009, J BONE MINER RES, V24, P1150, DOI [10.1359/JBMR.090210, 10.1359/jbmr.090210]
   Drew AF, 2004, GYNECOL ONCOL, V95, P437, DOI 10.1016/j.ygyno.2004.08.032
   Goetz R, 2013, NAT REV MOL CELL BIO, V14, P166, DOI 10.1038/nrm3528
   Goetz R, 2010, P NATL ACAD SCI USA, V107, P407, DOI 10.1073/pnas.0902006107
   Gonnelli S, 2014, BONE, V61, P27, DOI 10.1016/j.bone.2013.12.017
   Hsieh CC, 2010, AGING US, V2, P582, DOI 10.18632/aging.100194
   Hu MC, 2012, NAT REV NEPHROL, V8, P423, DOI 10.1038/nrneph.2012.92
   Imel EA, 2011, J CLIN ENDOCR METAB, V96, P3541, DOI 10.1210/jc.2011 1239
   Jonsson KB, 2005, NEPHROL DIAL TRANSPL, V20, P479, DOI 10.1093/ndt/gfh701
   Kato Y, 2000, BIOCHEM BIOPH RES CO, V267, P597, DOI 10.1006/bbrc.1999.2009
   Katoh M, 2014, MED RES REV, V34, P280, DOI 10.1002/med.21288
   Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200
   Liang G, 2013, CYTOKINE GROWTH F R, V24, P467, DOI 10.1016/j.cytogfr.2013.05.002
   Lu L, 2008, CANCER INVEST, V26, P185, DOI 10.1080/07357900701638343
   Mahtouk K, 2007, BLOOD, V109, P4914, DOI 10.1182/blood 2006 08 043232
   Martin A, 2012, PHYSIOL REV, V92, P131, DOI 10.1152/physrev.00002.2011
   Masola V, 2014, CURR CANCER DRUG TAR, V14, P286, DOI 10.2174/1568009614666140224155124
   Mohammad Khalid S., 2008, V455, P37, DOI 10.1007/978 1 59745 104 8_3
   Pagel JI, 2011, INDIAN J BIOCHEM BIO, V48, P226
   Purushothaman A, 2008, J BIOL CHEM, V283, P32628, DOI 10.1074/jbc.M806266200
   Raje N, 2011, CLIN CANCER RES, V17, P1278, DOI 10.1158/1078 0432.CCR 10 1804
   Rhee Y, 2011, BONE, V49, P636, DOI 10.1016/j.bone.2011.06.025
   Ritchie JP, 2011, CLIN CANCER RES, V17, P1382, DOI 10.1158/1078 0432.CCR 10 2476
   Ruan J, 2013, BONE, V57, P10, DOI 10.1016/j.bone.2013.07.024
   Sanderson RD, 2004, MATRIX BIOL, V23, P341, DOI 10.1016/j.matbio.2004.08.004
   Schaffler MB, 2014, CALCIFIED TISSUE INT, V94, P5, DOI 10.1007/s00223 013 9790 y
   Scheid C, 2014, EUR J HAEMATOL
   Stewart I, 2006, BONE, V39, P369, DOI 10.1016/j.bone.2006.01.163
   Storti P, 2013, LEUKEMIA, V27, P1697, DOI 10.1038/leu.2013.24
   Tannous BA, 2011, BIOTECHNOL ADV, V29, P997, DOI 10.1016/j.biotechadv.2011.08.021
   Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780
   Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315
   Usuda J, 2011, LUNG CANCER, V74, P332, DOI 10.1016/j.lungcan.2011.03.004
   VanderWall Kristina, 2013, Critical Reviews in Oncogenesis, V18, P449
   Vlodavsky I, 2011, RAMBAM MAIMONIDES ME, V2, DOI 10.5041/RMMJ.10019
   Wesche J, 2011, BIOCHEM J, V437, P199, DOI 10.1042/BJ20101603
   Wöhrle S, 2013, J BONE MINER RES, V28, P899, DOI 10.1002/jbmr.1810
   Wolf I, 2008, ONCOGENE, V27, P7094, DOI 10.1038/onc.2008.292
   Wolf M, 2014, CURR OPIN NEPHROL HY, V23, P411, DOI 10.1097/01.mnh.0000447020.74593.6f
   Wu XL, 2009, AGING US, V1, P1023, DOI 10.18632/aging.100108
   Xu Y, 2015, ENDOCR REV
   Yamazaki Y, 2002, J CLIN ENDOCR METAB, V87, P4957, DOI 10.1210/jc.2002 021105
   Yamazaki Y, 2010, BIOCHEM BIOPH RES CO, V398, P513, DOI 10.1016/j.bbrc.2010.06.110
   Yang Y, 2010, CANCER RES, V70, P8329, DOI 10.1158/0008 5472.CAN 10 2179
   Yuan Joshua S., 2008, Biotechnology Journal, V3, P112, DOI 10.1002/biot.200700169
NR 55
TC 36
Z9 41
U1 1
U2 6
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 14
PY 2015
VL 6
IS 23
BP 19647
EP 19660
DI 10.18632/oncotarget.3794
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA CP8HY
UT WOS:000360135300036
PM 25944690
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Åkesson, A
   Bjellerup, P
   Lundh, T
   Lidfeldt, J
   Nerbrand, C
   Samsioe, G
   Skerfving, S
   Vahter, M
AF Akesson, Agneta
   Bjellerup, Per
   Lundh, Thomas
   Lidfeldt, Jonas
   Nerbrand, Christina
   Samsioe, Goran
   Skerfving, Staffan
   Vahter, Marie
TI Cadmium induced effects on bone in a population based study of women
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article
DE biochemical bone markers; bone mineral density; cadmium; lead;
   osteoporosis; women
ID RENAL TUBULAR DYSFUNCTION; URINARY CADMIUM; ENVIRONMENTAL EXPOSURE;
   PARATHYROID HORMONE; DENSITY; BLOOD; LEAD; METABOLISM; HEALTH; LEVEL
AB High cadmium exposure is known to cause bone damage, but the association between low level cadmium exposure and osteoporosis remains to be clarified. Using a population based women's health survey in southern Sweden [Women's Health in the Lund Area (WHILA)] with no known historical cadmium contamination, we investigated cadmium related effects on bone in 820 women (53 64 years of age). We measured cadmium in blood and urine and lead in blood, an array of markers of bone metabolism, and forearm bone mineral density (BMD). Associations were evaluated in multiple linear regression analysis including information on the possible confounders or effect modifiers: weight, menopausal status, use of hormone replacement therapy, age at menarche, alcohol consumption, smoking history, and physical activity. Median urinary cadmium was 0.52 mu g/L adjusted to density (0.67 mu g/g creatinine). After multivariate adjustment, BMD, parathyroid hormone, and urinary deoxypyridinoline (U DPD) were adversely associated with concentrations of urinary cadmium (p < 0.05) in all subjects. These associations persisted in the group of never smokers, which had the lowest cadmium exposure (mainly dietary). For U DPD, there was a significant interaction between cadmium and menopause (p = 0.022). Our results suggest negative effects of low level cadmium exposure on bone, possibly exerted via increased bone resorption, which seemed to be intensified after menopause. Based on the prevalence of osteoporosis and the low level of exposure, the observed effects, although slight, should be considered as early signals of potentially more adverse health effects.
C1 Karolinska Inst, Inst Environm Med, Div Met & Hlth, S 17177 Stockholm, Sweden.
   Karolinska Univ Hosp, Dept Clin Chem, Huddinge, Sweden.
   Univ Lund Hosp, Dept Occupat & Environm Med, S 22185 Lund, Sweden.
   Malmo Univ Hosp, Dept Community Hlth, Malmo, Sweden.
   Univ Lund Hosp, Dept Med, S 22185 Lund, Sweden.
   Univ Lund Hosp, Dept Gynecol & Obstet, S 22185 Lund, Sweden.
C3 Karolinska Institutet; Karolinska Institutet; Karolinska University
   Hospital; Lund University; Skane University Hospital; Lund University;
   Skane University Hospital; Lund University; Skane University Hospital;
   Lund University; Skane University Hospital
RP Åkesson, A (通讯作者)，Karolinska Inst, Inst Environm Med, Div Met & Hlth, Box 210, S 17177 Stockholm, Sweden.
EM agneta.akesson@imm.ki.se
RI Vahter, Marie/HGB 1674 2022; Akesson, Agneta/GVT 6758 2022
OI Akesson, Agneta/0000 0001 9594 4140
CR Åkesson AA, 2005, ENVIRON HEALTH PERSP, V113, P1627, DOI 10.1289/ehp.8033
   Alfvén T, 2004, J BONE MINER RES, V19, P900, DOI 10.1359/JBMR.040202
   Alfvén T, 2000, J BONE MINER RES, V15, P1579, DOI 10.1359/jbmr.2000.15.8.1579
   Aoshima K, 2003, TOXICOL LETT, V136, P183, DOI 10.1016/S0378 4274(02)00356 9
   Barany E, 1997, J ANAL ATOM SPECTROM, V12, P1005, DOI 10.1039/a700904f
   Berglund M, 2000, TOXICOL LETT, V112, P219, DOI 10.1016/S0378 4274(99)00272 6
   BHATTACHARYYA MH, 1988, P NATL ACAD SCI USA, V85, P8761, DOI 10.1073/pnas.85.22.8761
   Brzóska MM, 2005, TOXICOL APPL PHARM, V202, P68, DOI 10.1016/j.taap.2004.06.007
   Brzóska MM, 2004, BONE, V35, P1180, DOI 10.1016/j.bone.2004.07.010
   Carlsson L, 1996, COMP BIOCHEM PHYS C, V115, P251, DOI 10.1016/S0742 8413(96)00125 9
   Genant HK, 1999, OSTEOPOROSIS INT, V10, P259, DOI 10.1007/s001980050224
   Honda R, 2003, ENVIRON RES, V91, P63, DOI 10.1016/S0013 9351(02)00035 X
   Horiguchi H, 2005, ENVIRON RES, V97, P83, DOI 10.1016/j.envres.2004.03.004
   Ismail AA, 2002, OSTEOPOROSIS INT, V13, P565, DOI 10.1007/s001980200074
   Jarup Lars, 1998, Scandinavian Journal of Work Environment and Health, V24, P1
   Kanis JA, 2002, J BONE MINER RES, V17, P1237, DOI 10.1359/jbmr.2002.17.7.1237
   KIDO T, 1991, J APPL TOXICOL, V11, P161, DOI 10.1002/jat.2550110303
   Kjellstrom T, 1992, IARC Sci Publ, P301
   KJELLSTROM T, 1986, EFFECTS RESPONSE, V2, P257
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Korrick SA, 2002, AM J EPIDEMIOL, V156, P335, DOI 10.1093/aje/kwf042
   Latorre FG, 2003, ENVIRON HEALTH PERSP, V111, P631, DOI 10.1289/ehp.5149
   Lidfeldt J, 2001, EUR J EPIDEMIOL, V17, P943, DOI 10.1023/A:1016291426124
   Nash D, 2004, AM J EPIDEMIOL, V160, P901, DOI 10.1093/aje/kwh296
   NILSSON U, 1991, PHARMACOL TOXICOL, V68, P477, DOI 10.1111/j.1600 0773.1991.tb01273.x
   Nishijo M, 2004, MOL CELL BIOCHEM, V255, P87, DOI 10.1023/B:MCBI.0000007264.37170.39
   NOGAWA K, 1987, International Archives of Occupational and Environmental Health, V59, P21, DOI 10.1007/BF00377675
   NOGAWA K, 1984, INT ARCH OCC ENV HEA, V54, P187, DOI 10.1007/BF00379048
   Nordberg G, 2002, AMBIO, V31, P478, DOI 10.1639/0044 7447(2002)031[0478:LBDARD]2.0.CO;2
   Orlowski C, 1998, HUM EXP TOXICOL, V17, P302, DOI 10.1191/096032798678908792
   PECK WA, 1993, AM J MED, V94, P646
   PETERSSON GK, 2000, ARCH TOXICOL, V73, P519
   Regunathan A, 2003, TOXICOL APPL PHARM, V191, P272, DOI 10.1016/S0041 008X(03)00163 7
   RINGERTZ H, 1995, MEASUREMENT BONE DEN
   SACCOGIBSON N, 1992, TOXICOL APPL PHARM, V113, P274, DOI 10.1016/0041 008X(92)90125 C
   Staessen JA, 1999, LANCET, V353, P1140, DOI 10.1016/S0140 6736(98)09356 8
   Suwazono Y, 2005, BIOMARKERS, V10, P117, DOI 10.1080/13547500500159001
   TSURITANI I, 1992, J TOXICOL ENV HEALTH, V37, P519, DOI 10.1080/15287399209531690
   TSURITANI I, 1994, TOXICOL LETT, V71, P209
   Uriu K, 2000, TOXICOL APPL PHARM, V164, P264, DOI 10.1006/taap.2000.8908
   Vahter Marie, 2004, J Br Menopause Soc, V10, P60, DOI 10.1258/136218004774202364
   Wang DY, 2001, CHINESE PHYS LETT, V18, P553, DOI 10.1088/0256 307X/18/4/329
   Webber CE, 1995, ENVIRON HEALTH PERSP, V103, P1150, DOI 10.2307/3432612
   *WHO, 1994, ASS FRACT RISK ITS A
   Wilson AK, 1996, TOXICOL APPL PHARM, V140, P451, DOI 10.1006/taap.1996.0242
NR 45
TC 262
Z9 295
U1 0
U2 43
PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE
PI RES TRIANGLE PK
PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
   RES TRIANGLE PK, NC 27709 2233 USA
SN 0091 6765
EI 1552 9924
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD JUN
PY 2006
VL 114
IS 6
BP 830
EP 834
DI 10.1289/ehp.8763
PG 5
WC Environmental Sciences; Public, Environmental & Occupational Health;
   Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health; Toxicology
GA 049GS
UT WOS:000238004800029
PM 16759980
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wei, JS
   Chen, SY
   Huang, CS
   Guo, WX
   Yang, SK
   Feng, BL
   Chu, JQ
AF Wei, Jinsong
   Chen, Siyuan
   Huang, Chengshuo
   Guo, Weixiong
   Yang, Shukai
   Feng, Bailin
   Chu, Jiaqi
TI Antagonism of cysteinyl leukot riene receptor 1 (cysLT1R) by montelukast
   regulates differentiation of MC3T3 E1 cells under overloaded mechanical
   environment
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Cysteinyl leukot riene receptor 1; Montelukast; MC3T3 E1; Overload
ID IN VITRO; SIGNALING PATHWAY; MODEL; PROLIFERATION; EXPRESSION; MAPKS
AB Long term exposure to overloaded mechanical environment induces bone fatigue damage symptoms and osteoblast damages. Montelukast is a selective cysteinyl leukot riene receptor 1 (cysLT1R) antagonist, which has been used for the treatment of bronchial asthma in clinics. In the current study, we have identified a novel pharmacological role of montelukast by finding that it has protective properties against overload damage in osteoblastic MC3T3 E1 cells. Firstly, our results show that CysLT1R is expressed in MC3T3 E1 cells. Mechanical tensile strain of 5000 7000 mu epsilon resulted in a significant upregulation of CysLT1R in osteoblastic MC3T3 E1 cells in an intensity dependent manner. Secondly, MTT assay indicates that loading with 5000 mu epsilon mechanical strain inhibited cell proliferation, which was suppressed by montelukast treatment. Furthermore, montelukast promotes cell differentiation by increasing the expression of ALP and RUNX2. Alizarin Red S staining assay showed that montelukast abolished the inhibitory effects of overload mechanics on osteoblast mineralization. Mechanistically, the effect of montelukast on osteoblastic differentiation acted by activating the extracellular regulated protein kinases (ERIC) pathway. The obtained results suggested that montelukast promotes proliferation and differentiation in osteoblasts exposed to overload mechanics. (C) 2017 Published by Elsevier Inc.
C1 [Wei, Jinsong; Chen, Siyuan; Huang, Chengshuo; Guo, Weixiong; Yang, Shukai; Feng, Bailin] Affiliated Hosp Guangdong Med Univ, Dept Orthopaed, 57 South Renmin Ave, Zhanjiang 524001, Guangdong, Peoples R China.
   [Chu, Jiaqi] Affiliated Hosp Guangdong Med Univ, Dept Stem Cell Res, Zhanjiang 524001, Guangdong, Peoples R China.
   [Chu, Jiaqi] Affiliated Hosp Guangdong Med Univ, Cellular Therapy Ctr, Zhanjiang 524001, Guangdong, Peoples R China.
C3 Guangdong Medical University; Guangdong Medical University; Guangdong
   Medical University
RP Wei, JS (通讯作者)，Affiliated Hosp Guangdong Med Univ, Dept Orthopaed, 57 South Renmin Ave, Zhanjiang 524001, Guangdong, Peoples R China.
EM jlgdwei@163.com
RI feng, bailin/NLN 7813 2025; Cheng Shuo, Huang/NCV 4087 2025
CR Akino K, 2006, WOUND REPAIR REGEN, V14, P343, DOI 10.1111/j.1743 6109.2006.00130.x
   Anderson R, 2009, BRIT J PHARMACOL, V156, P105, DOI 10.1111/j.1476 5381.2008.00012.x
   [Anonymous], 2013, JAK STAT
   Barbierato E, 2014, FUTURE GENER COMP SY, V37, P345, DOI 10.1016/j.future.2013.12.036
   Bianchi EN, 2009, BONE, V45, P716, DOI 10.1016/j.bone.2009.06.020
   Bush A, 2015, PAEDIATR RESPIR REV, V16, P97, DOI 10.1016/j.prrv.2014.10.007
   Cakici H, 2011, EKLEM HAST CERRAHISI, V22, P43
   Cottrell JA, 2009, J BONE JOINT SURG AM, V91A, P2653, DOI 10.2106/JBJS.H.01844
   Daglar G, 2009, J SURG RES, V153, P31, DOI 10.1016/j.jss.2008.02.052
   Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306
   Edwards WB, 2010, CLIN BIOMECH, V25, P372, DOI 10.1016/j.clinbiomech.2010.01.001
   Fatokun AA, 2008, EUR J PHARMACOL, V587, P35, DOI 10.1016/j.ejphar.2008.03.024
   FROST HM, 1987, ANAT RECORD, V219, P1, DOI 10.1002/ar.1092190104
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Haddad JJ, 2014, PROTEIN PEPTIDE LETT, V21, P444, DOI 10.2174/092986652105140218112521
   Henderson WR, 2006, AM J RESP CRIT CARE, V173, P718, DOI 10.1164/rccm.200501 088OC
   Hu Y, 2015, BIO MED MATER ENG, V25, pS103, DOI 10.3233/BME 141230
   Kikuta J, 2013, P NATL ACAD SCI USA, V110, P7009, DOI 10.1073/pnas.1218799110
   Komori T, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122045
   Liu YJ, 2017, CELL PHYSIOL BIOCHEM, V41, P1605, DOI 10.1159/000470896
   Miao DS, 2005, J CLIN INVEST, V115, P2402, DOI 10.1172/JCI24918
   Nouri M, 2008, J BRACHIAL PLEX PERI, V3, DOI 10.1186/1749 7221 3 27
   Osaki LH, 2013, INT J MOL SCI, V14, P10143, DOI 10.3390/ijms140510143
   Peters Golden M, 2007, NEW ENGL J MED, V357, P1841, DOI 10.1056/NEJMra071371
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Schlessinger J, 2004, SCIENCE, V306, P1506, DOI 10.1126/science.1105396
   Sila Asna Monnipha, 2007, Kobe J Med Sci, V53, P25
   Singh RK, 2010, PHARMACOLOGY, V85, P336, DOI 10.1159/000312669
   Tang LL, 2006, ARCH ORAL BIOL, V51, P1080, DOI 10.1016/j.archoralbio.2006.06.009
   Theron AJ, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/608930
   Tintinger GR, 2010, THESCIENTIFICWORLDJO, V10, P2403, DOI 10.1100/tsw.2010.229
   Wan Zong ming, 2013, Chinese Medical Sciences Journal, V28, P218
   Wixted JJ, 2009, J CELL PHYSIOL, V221, P31, DOI 10.1002/jcp.21809
   Yan YX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035709
   Yu SY, 2014, ACTA PHARMACOL SIN, V35, P33, DOI 10.1038/aps.2013.130
   Zhang X. Z., 1999, MED EQUIPMENT J, V83, P6
   Zhu C, 2016, CELL SIGNAL, V28, P989, DOI 10.1016/j.cellsig.2016.04.010
NR 38
TC 4
Z9 4
U1 0
U2 11
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 1
PY 2018
VL 495
IS 1
BP 995
EP 1001
DI 10.1016/j.bbrc.2017.10.051
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA FU5MM
UT WOS:000423897600150
PM 29032198
DA 2025 08 17
ER

PT J
AU Khan, A
   Ali, A
   Junaid, M
   Liu, C
   Kaushik, AC
   Cho, WCS
   Wei, DQ
AF Khan, Abbas
   Ali, Arif
   Junaid, Muhammad
   Liu, Chang
   Kaushik, Aman Chandra
   Cho, William C. S.
   Wei, Dong Qing
TI Identification of novel drug targets for diamond blackfan anemia based
   on RPS19 gene mutation using protein protein interaction network
SO BMC SYSTEMS BIOLOGY
LA English
DT Article; Proceedings Paper
CT International Conference on Systems Biology (ISB)
CY AUG 18 21, 2017
CL Shenzhen, PEOPLES R CHINA
DE Diamond Blackfan anemia (DBA); Microarray; Differentially expressed
   gene; KEGG pathways; Gene expression omnibus
ID EXPRESSION; S19; DEFICIENCY; DISCOVERY; IMPROVES; DATABASE; ONTOLOGY;
   DEFECTS; LEUCINE; BIOLOGY
AB Background: Diamond Blackfan anemia (DBA) is a congenital erythroid aplasia that usually presents in infancy. In order to explore the molecular mechanisms of wild and mutated samples from DBA patients were exposed to bioinformatics investigation. Biological network of differentially expressed genes was constructed. This study aimed to identify novel therapeutic signatures in DBA and uncovered their mechanisms. The gene expression dataset of GSE14335 was used, which consists of 6 normal and 4 diseased cases. The gene ontology (GO), as well as Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed, and then proteinprotein interaction (PPI) network of the identified differentially expressed genes (DEGs) was constructed by Cytoscape software.
   Results: A total of 607 DEGs were identified in DBA, including 433 upregulated genes and 174 downregulated genes. GO analysis results showed that upregulated DEGs were significantly enriched in biological processes, negative regulation of transcription from RNA polymerase II promoter, chemotaxis, inflammatory response, immune response, positive regulation of cell proliferation, negative regulation of cell proliferation, response to mechanical stimulus, positive regulation of cell migration, response to lipopolysaccharide, and defence response. KEGG pathway analysis revealed the TNF signalling pathway, Osteoclast differentiation, Chemokine signalling pathway, Cytokine cytokine receptor interaction, Rheumatoid arthritis, Biosynthesis of amino acids, Biosynthesis of antibiotics and Glycine, serine and threonine metabolism. The top 10 hub genes, AKT1, IL6, NFKB1, STAT3, STAT1, RAC1, EGR1, IL8, RELA, RAC3, mTOR and CCR2 were identified from the PPI network and sub networks.
   Conclusion: The present study flagged that the identified DEGs and hub genes enrich our understanding of the molecular mechanisms underlying the development of DBA, and might shine some lights on identifying molecular targets and diagnostic biomarkers for DBA.
C1 [Khan, Abbas; Ali, Arif; Junaid, Muhammad; Liu, Chang; Kaushik, Aman Chandra; Wei, Dong Qing] Shanghai Jiao Tong Univ, Coll Life Sci & Biotechnol, Dept Bioinformat & Biostat, Shanghai 200240, Peoples R China.
   [Cho, William C. S.] Queen Elizabeth Hosp, Dept Clin Oncol, Kowloon, Hong Kong, Peoples R China.
C3 Shanghai Jiao Tong University
RP Wei, DQ (通讯作者)，Shanghai Jiao Tong Univ, Coll Life Sci & Biotechnol, Dept Bioinformat & Biostat, Shanghai 200240, Peoples R China.
EM dqwei@sjtu.edu.cn
RI Khan, Abbas/AAF 2409 2020; Wei, Dongqing/E 6398 2010; Junaid, Dr.
   Muhammad/ABF 9669 2021; Cho, William/H 7429 2019
OI Khan, Abbas/0000 0002 4288 7602; 
FU Ministry of Science and Technology of China [2016YFA0501703]
FX Publication costs were funded by the Key Research Area Grant
   2016YFA0501703 from the Ministry of Science and Technology of China.
CR Arrell DK, 2010, CLIN PHARMACOL THER, V88, P120, DOI 10.1038/clpt.2010.91
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Assenov Y, 2008, BIOINFORMATICS, V24, P282, DOI 10.1093/bioinformatics/btm554
   Avondo F, 2009, BMC GENOMICS, V10, DOI 10.1186/1471 2164 10 442
   Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471 2105 4 2
   Ball SE, 1996, BRIT J HAEMATOL, V94, P645, DOI 10.1046/j.1365 2141.1996.d01 1839.x
   Barabási AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Boria I, 2010, HUM MUTAT, V31, P1269, DOI 10.1002/humu.21383
   Bremer M, 2010, METHODS MOL BIOL, V620, P287, DOI 10.1007/978 1 60761 580 4_9
   Campagnoli MF, 2004, HAEMATOLOGICA, V89, P480
   Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752 0509 8 S4 S11
   Chiocchetti A, 2005, HAEMATOLOGICA, V90, P1453
   Chuang HY, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100180
   Da Costa L, 2001, CURR OPIN PEDIATR, V13, P10
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb 2003 4 9 r60
   Draptchinskaia N, 1999, NAT GENET, V21, P169, DOI 10.1038/5951
   Dudoit S, 2002, STAT SINICA, V12, P111
   DUNBAR CE, 1991, BRIT J HAEMATOL, V79, P316, DOI 10.1111/j.1365 2141.1991.tb04540.x
   Ebert BL, 2005, BLOOD, V105, P4620, DOI 10.1182/blood 2004 08 3313
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   El Beshlawy A, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.4.e44
   Flygare J, 2005, BLOOD, V105, P4627, DOI 10.1182/blood 2004 08 3115
   Gazda HT, 2006, STEM CELLS, V24, P2034, DOI 10.1634/stemcells.2005 0554
   Gazda HT, 2006, BRIT J HAEMATOL, V135, P149, DOI 10.1111/j.1365 2141.2006.06268.x
   Gripp KW, 2001, AM J MED GENET, V101, P268, DOI 10.1002/ajmg.1329
   Gustavsson P, 1998, AM J HUM GENET, V63, P1388, DOI 10.1086/302100
   Hamaguchi I, 2003, MOL THER, V7, P613, DOI 10.1016/S1525 0016(03)00091 1
   Harris MA, 2006, NUCLEIC ACIDS RES, V34, pD322, DOI 10.1093/nar/gkj021
   HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710
   HOLM S, 1979, SCAND J STAT, V6, P65
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Koga Y, 2006, J PEDIAT HEMATOL ONC, V28, P355, DOI 10.1097/00043426 200606000 00007
   Lee M LT, 2007, SPRINGER SCI BUS MED, P143
   Lipton JM, 2001, J PEDIAT HEMATOL ONC, V23, P39, DOI 10.1097/00043426 200101000 00009
   Liu JM, 2006, BLOOD, V107, P4583, DOI 10.1182/blood 2005 12 4831
   Maeda N, 2006, BIOCHEM BIOPH RES CO, V339, P41, DOI 10.1016/j.bbrc.2005.10.184
   Miyake K, 2005, MOL THER, V11, P627, DOI 10.1016/j.ymthe.2004.12.001
   Payne EM, 2012, BLOOD, V120, P2214, DOI 10.1182/blood 2011 10 382986
   Pujana MA, 2007, NAT GENET, V39, P1338, DOI 10.1038/ng.2007.2
   Qin GM, 2014, J THEOR BIOL, V362, P9, DOI 10.1016/j.jtbi.2014.06.007
   Revollo I, 2005, INFLAMM RES, V54, P82, DOI 10.1007/s00011 004 1327 4
   Sadhu A, 2017, INTERDISCIP SCI, V9, P1
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   SIDAK Z, 1967, J AM STAT ASSOC, V62, P626, DOI 10.2307/2283989
   SIMES RJ, 1986, BIOMETRIKA, V73, P751, DOI 10.2307/2336545
   Soulet F, 2001, BIOCHEM BIOPH RES CO, V289, P591, DOI 10.1006/bbrc.2001.5960
   Stipanuk MH, 2007, NUTR REV, V65, P122, DOI 10.1111/j.1753 4887.2007.tb00289.x
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   Team R, 2015, RSTUDIO INT DEV R
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Warde Farley D, 2010, NUCLEIC ACIDS RES, V38, pW214, DOI 10.1093/nar/gkq537
   Wheelock CE, 2009, MOL BIOSYST, V5, P588, DOI 10.1039/b902356a
   Wu J, 2012, GCRMA BACKGROUND ADJ, P2200
   Young NS, 2008, CURR OPIN HEMATOL, V15, P162, DOI 10.1097/MOH.0b013e3282fa7470
   Zhao M, 2017, INTERDISCIP SCI, V9, P1
   Zhao XM, 2015, BIOINFORMATICS, V31, P1226, DOI 10.1093/bioinformatics/btu811
NR 58
TC 20
Z9 21
U1 0
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1752 0509
J9 BMC SYST BIOL
JI BMC Syst. Biol.
PD APR 24
PY 2018
VL 12
SU 4
AR 39
DI 10.1186/s12918 018 0563 0
PG 12
WC Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Mathematical & Computational Biology
GA GE1NN
UT WOS:000430984100002
PM 29745857
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Huang, CH
   Gabelli, SB
   Oldfield, E
   Amzel, LM
AF Huang, Chuan Hsiang
   Gabelli, Sandra B.
   Oldfield, Eric
   Amzel, L. Mario
TI Binding of nitrogen containing bisphosphonates (N BPs) to the
   Trypanosoma cruzi farnesyl diphosphate synthase homodimer
SO PROTEINS STRUCTURE FUNCTION AND BIOINFORMATICS
LA English
DT Article
DE FPPS; crystallography; calorimetry; bisphosphonate; Chagas disease; drug
   development; parasite
ID PYROPHOSPHATE SYNTHASE; POTENT INHIBITORS; STRUCTURAL BASIS;
   RISEDRONATE; MECHANISM; LOCATION; BRUCEI
AB Bisphosphonates (BPs) are a class of compounds that have been used extensively in the treatment of osteoporosis and malignancy related hypercalcemia. Some of these compounds act through inhibition of farnesyl diphosphate synthase (FPPS), a key enzyme in the synthesis of isoprenoids. Recently, nitrogen containing bisphosphonates (N BPs) used in bone resorption therapy have been shown to be active against Trypanosoma cruzi, the parasite that causes American trypanosomiasis (Chagas disease), suggesting that they may be used as anti trypanosomal agents. The crystal structures of TcFPPS in complex with substrate (isopentenyl diphosphate, IPP) and five N BP inhibitors show that the C 1 hydroxyl and the nitrogen containing groups of the inhibitors alter the binding of IPP and the conformation of two TcFPPS residues, Tyr94 and Gln167. Isothermal titration calorimetry experiments suggest that binding of the first N BPs to the homodimeric TcFPPS changes the binding properties of the second site. This mechanism of binding of N BPs to TcFPPS is different to that reported for the binding of the same compounds to human FPPS.
C1 [Huang, Chuan Hsiang; Gabelli, Sandra B.; Amzel, L. Mario] Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA.
   [Oldfield, Eric] Univ Illinois, Dept Chem, Urbana, IL 61801 USA.
C3 Johns Hopkins University; University of Illinois System; University of
   Illinois Urbana Champaign
RP Amzel, LM (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA.
EM gabelli@jhmi.edu; mamzel@jhmi.edu
RI ; Gabelli, Sandra/A 3705 2008
OI Amzel, L. Mario/0000 0002 0129 9572; Gabelli,
   Sandra/0000 0003 1205 5204; Huang, Chuan Hsiang/0000 0001 9993 8004
FU NIH [GM066895, GM65307]
FX Grant sponsor: NIH; Grant numbers: GM066895, GM65307.
CR BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112
   Gabelli SB, 2006, PROTEINS, V62, P80, DOI 10.1002/prot.20754
   Garzoni LR, 2004, INT J ANTIMICROB AG, V23, P273, DOI 10.1016/j.ijantimicag.2003.07.020
   Garzoni LR, 2004, INT J ANTIMICROB AG, V23, P286, DOI 10.1016/j.ijantimicag.2003.07.019
   Hosfield DJ, 2004, J BIOL CHEM, V279, P8526, DOI 10.1074/jbc.C300511200
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Koyama T, 2000, BIOCHEMISTRY US, V39, P463, DOI 10.1021/bi991621b
   Martin MB, 2001, J MED CHEM, V44, P909, DOI 10.1021/jm0002578
   Montalvetti A, 2001, J BIOL CHEM, V276, P33930, DOI 10.1074/jbc.M103950200
   Montalvetti A, 2003, J BIOL CHEM, V278, P17075, DOI 10.1074/jbc.M210467200
   NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Russell RGG, 1999, OSTEOPOROSIS INT, V9, P66, DOI 10.1007/PL00004164
   Szajnman SH, 2003, BIOORG MED CHEM LETT, V13, P3231, DOI 10.1016/S0960 894X(03)00663 2
   Szkopinska A, 2005, ACTA BIOCHIM POL, V52, P45
   TARSHIS LC, 1994, BIOCHEMISTRY US, V33, P10871, DOI 10.1021/bi00202a004
   Urbina JA, 2003, TRENDS PARASITOL, V19, P495, DOI 10.1016/j.pt.2003.09.001
   Yin FL, 2006, J AM CHEM SOC, V128, P3524, DOI 10.1021/ja0601639
NR 20
TC 35
Z9 37
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0887 3585
EI 1097 0134
J9 PROTEINS
JI Proteins
PD MAR
PY 2010
VL 78
IS 4
BP 888
EP 899
DI 10.1002/prot.22614
PG 12
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 559LG
UT WOS:000274825700007
PM 19876942
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Bakeine, GJ
   Benedetti, L
   Galli, D
   Grenci, G
   Pozzato, A
   Prasciolu, M
   Tormen, M
   Cusella, G
AF Bakeine, G. J.
   Benedetti, L.
   Galli, D.
   Grenci, G.
   Pozzato, A.
   Prasciolu, M.
   Tormen, M.
   Cusella, G.
TI Effects of substrate nanopatterning on human osteosarcoma cells (SaOs 2)
   behavior
SO MICROELECTRONIC ENGINEERING
LA English
DT Article; Proceedings Paper
CT 35th International Conference on Micro and Nano Engineering
CY SEP 28 OCT 01, 2009
CL Ghent, BELGIUM
DE Osteoblasts; Bone cell differentiation; Matrix mineralization;
   Osseointegration; Nanostructured matrices; Orthopedic and dental
   implants
AB Engineering of the cellular microenvironment has become an attractive strategy to guide cellular activities such as spreading, motility, proliferation and differentiation. From a technological perspective, the physical crosstalk between a cell and its surrounding represents a design parameter that may be modulated to achieve desired osseointegration in orthopedic and dental implants. In this study we use a surface engineering approach to tap into the interaction between the cell and its surroundings in order to modulate osteogenic adhesion dependent differentiation and bone tissue formation.
   The effectiveness of this approach was studied by observing the in vitro cellular behavior of human osteoblastic cells (SaOs 2) seeded on silicon substrates with different nano scale surface patterns.
   Our findings suggest that substrate nanopattern geometry can differentially control early cell differentiation decisions. Interestingly, rescue of the differentiation process by supplementation of growth medium with soluble differentiation factors did riot appear to compensate for the differences in the early cellular fate decisions observed on the different patterns. Critically, combining surface topography and soluble differentiation factors appeared to modulate the speed of the differentiation process and its shut down at the end of terminal differentiation. Taken together, our findings suggest that cells recognize physical nano scale topography as an instructive signal that is integrated to fine tune the multimodal control and guidance of cell behavior and cell fate. This information may find utility in the design of orthopedic and dental implants or innovative bio materials for regenerative medicine. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Bakeine, G. J.; Benedetti, L.; Galli, D.; Cusella, G.] Univ Pavia, CIT, I 27100 Pavia, Italy.
   [Benedetti, L.; Cusella, G.] Univ Pavia, Dept Expt Med, I 27100 Pavia, Italy.
   [Grenci, G.; Pozzato, A.; Prasciolu, M.; Tormen, M.] Natl Lab Adv Technol & NanoSci TASC, I 34012 Trieste, Italy.
C3 University of Pavia; University of Pavia
RP Bakeine, GJ (通讯作者)，Univ Pavia, Interfac Ctr Tissue Engn CIT, Dipartimento Med Sperimentale, Sez Anat Umana Normale, Via Forlanini N 8, I 27100 Pavia, Italy.
EM jamesbakeine1@yahoo.com
RI Grenci, Gianluca/L 4416 2019; Tormen, Massimo/E 1372 2014; Galli,
   Daniela/L 3179 2015
OI Cusella De Angelis, Maria Gabriella/0000 0003 2642 3346; Prasciolu,
   Mauro/0000 0003 0094 9825; Grenci, Gianluca/0000 0001 9313 6748; Tormen,
   Massimo/0000 0001 7919 0692; Galli, Daniela/0000 0003 0200 5852
CR Bakeine GJ, 2009, MICROELECTRON ENG, V86, P1468, DOI 10.1016/j.mee.2008.12.059
   Brunette DM, 1999, J BIOMECH ENG T ASME, V121, P49, DOI 10.1115/1.2798042
   Goto T, 2004, BIO MED MATER ENG, V14, P537
   Lehnert D, 2004, J CELL SCI, V117, P41, DOI 10.1242/jcs.00836
   Lim JY, 2007, BIOMATERIALS, V28, P1787, DOI 10.1016/j.biomaterials.2006.12.020
NR 5
TC 6
Z9 6
U1 0
U2 18
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0167 9317
EI 1873 5568
J9 MICROELECTRON ENG
JI Microelectron. Eng.
PD MAY AUG
PY 2010
VL 87
IS 5 8
BP 830
EP 833
DI 10.1016/j.mee.2009.10.024
PG 4
WC Engineering, Electrical & Electronic; Nanoscience & Nanotechnology;
   Optics; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Engineering; Science & Technology   Other Topics; Optics; Physics
GA 578NO
UT WOS:000276300700038
DA 2025 08 17
ER

PT J
AU Li, CH
   Wang, FL
   Han, YJ
   Zhai, JY
   Jin, YJ
   Liu, R
   Niu, Y
   Yao, ZQ
   Zhao, JX
AF Li, Changhong
   Wang, Fengliang
   Han, Yijun
   Zhai, Jiayu
   Jin, Yinji
   Liu, Rui
   Niu, Yan
   Yao, Zhongqiang
   Zhao, Jinxia
TI Nitazoxanide reduces inflammation and bone erosion in mice with
   collagen induced arthritis via inhibiting the JAK2/STAT3 and NF dB
   pathways in fibroblast like synoviocytes
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Nitazoxanide; Rheumatoid arthritis; JAK2/STAT3; Inflammation; Bone
   erosion
ID RHEUMATOID ARTHRITIS; GROWTH
AB Our recent study showed that Nitazoxanide (NTZ), an FDA approved anti parasitic drug, prevents ovariectomyinduced bone loss by inhibiting osteoclast activity. However, there have been no investigations to determine whether NTZ has preventive potential in other bone resorbing diseases, especially rheumatoid arthritis (RA). In this study, the primary RA fibroblast like synoviocytes (RA FLS) and collagen induced arthritis (CIA) murine model were used to evaluate the effect of NTZ. The results showed that NTZ potently inhibited proliferation, migration and invasion capacity of RA FLS in a dose dependent manner by restraining cell entry into S phases, without induction of cell apoptosis. NTZ obviously reduced spontaneous mRNA expression of IL 1 beta, IL 6 and RANKL, as well as TNF alpha induced transcription of the IL 1 beta, IL 6, and MMP9 genes. In terms of molecular mechanism, NTZ significantly inhibited the basal or TNF alpha induced activation of JAK2/STAT3 (T705) and NF dB pathway, but not MAPK and STAT3 (S727) phosphorylation. Moreover, NTZ ameliorated synovial inflammation and bone erosion in CIA mice through reducing the production of inflammatory mediators and osteoclast formation, respectively. Collectively, our findings indicate that NTZ exhibits anti inflammatory and anti erosive effects both ex vivo and in vivo, which provides promising evidence for the therapeutic application of NTZ as a novel therapeutic agent for RA.
C1 [Li, Changhong; Han, Yijun; Zhai, Jiayu; Jin, Yinji; Liu, Rui; Yao, Zhongqiang; Zhao, Jinxia] Peking Univ Third Hosp, Dept Rheumatol & Immunol, Beijing 100191, Peoples R China.
   [Li, Changhong; Zhao, Jinxia] Peking Univ Third Hosp, Osteoporosis & Bone Metab Dis Ctr, Beijing 100191, Peoples R China.
   [Wang, Fengliang] Qingdao Fuwai Cardiovasc Hosp, Dept Internal Med, Qingdao 266000, Peoples R China.
   [Niu, Yan] Peking Univ, Hlth Sci Ctr, Sch Pharmaceut Sci, Dept Med Chem, Beijing 100191, Peoples R China.
C3 Peking University; Chinese Academy of Medical Sciences   Peking Union
   Medical College; Fu Wai Hospital   CAMS; Peking University
RP Li, CH; Yao, ZQ; Zhao, JX (通讯作者)，Peking Univ Third Hosp, Dept Rheumatol & Immunol, Beijing 100191, Peoples R China.; Li, CH; Zhao, JX (通讯作者)，Peking Univ Third Hosp, Osteoporosis & Bone Metab Dis Ctr, Beijing 100191, Peoples R China.
EM changhongli@bjmu.edu.cn; yaozhongqiang0210@163.com; zhao jinxia@163.com
RI Wang, Feng Liang/HGD 0888 2022; Wu, Zhangxiong/AAS 9396 2021
FU National Nature Science Foundation of China [81501387, 82270066,
   82271825]; Beijing Municipal Natural Science Foundation [7222264]; Youth
   Backbone Incubation Fund of Peking University Third Hospital
   [BYSYFY2021027]; Key Clinical Projects of Peking University Third
   Hospital [BYSYZD2019042]
FX This work was supported by the National Nature Science Foundation of
   China (No.81501387, 82270066 and 82271825) , Beijing Municipal Natural
   Science Foundation (No.7222264) , Youth Backbone Incubation Fund of
   Peking University Third Hospital (BYSYFY2021027) and Key Clinical
   Projects of Peking University Third Hospital (BYSYZD2019042) .
CR Al kuraishy HM, 2022, MOL BIOL REP, V49, P11169, DOI 10.1007/s11033 022 07822 2
   Aletaha D, 2018, JAMA J AM MED ASSOC, V320, P1360, DOI 10.1001/jama.2018.13103
   Angeles Arvizu A, 2021, ACTA PARASITOL, V66, P1158, DOI 10.1007/s11686 021 00385 5
   Buch MH, 2018, ANN RHEUM DIS, V77, P966, DOI 10.1136/annrheumdis 2017 212862
   Chen Z, 2019, NAT REV RHEUMATOL, V15, P9, DOI 10.1038/s41584 018 0109 2
   Du HY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01620
   El Ashkar Ayman M, 2022, J Parasit Dis, V46, P1070, DOI 10.1007/s12639 022 01527 w
   Gough DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083395
   Hemmati Dinarvand M, 2022, ARCH MED RES, V53, P263, DOI 10.1016/j.arcmed.2021.12.001
   Huang S, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.895573
   Imbaby S, 2023, LIFE SCI, V319, DOI 10.1016/j.lfs.2023.121496
   Leone GM, 2023, J CLIN MED, V12, DOI 10.3390/jcm12041630
   Li CH, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.781640
   Li CH, 2021, INT IMMUNOPHARMACOL, V90, DOI 10.1016/j.intimp.2020.107219
   Lu ZR, 2022, BIOCHEM PHARMACOL, V197, DOI 10.1016/j.bcp.2022.114913
   Lü ZR, 2021, ACS MED CHEM LETT, V12, P696, DOI 10.1021/acsmedchemlett.0c00544
   McLornan DP, 2021, LANCET, V398, P803, DOI 10.1016/S0140 6736(21)00438 4
   Najm A, 2020, ARTHRITIS RHEUMATOL, V72, P2030, DOI 10.1002/art.41441
   Nikolova K, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009182.pub2
   Ohguchi H, 2017, LEUKEMIA, V31, P2661, DOI 10.1038/leu.2017.141
   Orr C, 2017, NAT REV RHEUMATOL, V13, P463, DOI 10.1038/nrrheum.2017.115
   Park JS, 2022, ARTHRITIS RES THER, V24, DOI 10.1186/s13075 022 02941 4
   Peron M, 2021, DEVELOPMENT, V148, DOI 10.1242/dev.199477
   Philips RL, 2022, CELL, V185, P3857, DOI 10.1016/j.cell.2022.09.023
   Rocco PRM, 2021, EUR RESPIR J, V58, DOI 10.1183/13993003.03725 2020
   Saki A, 2021, REUMATOLOGIA, V59, P169, DOI 10.5114/reum.2021.107026
   Smolen J.S., 2023, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease modifying antirheumatic drugs: 2022 update, V82, P3
   Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140 6736(16)30173 8
   Tang W, 2011, SCIENCE, V332, P478, DOI 10.1126/science.1199214
   Wang HY, 2020, INT IMMUNOPHARMACOL, V88, DOI 10.1016/j.intimp.2020.106985
   Wu J, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 021 27948 4
   Xing R, 2016, CLIN EXP IMMUNOL, V184, P147, DOI 10.1111/cei.12751
   Ye CH, 2022, BIOL CHEM, V403, P929, DOI 10.1515/hsz 2022 0148
NR 33
TC 9
Z9 9
U1 1
U2 9
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD FEB
PY 2024
VL 171
AR 116195
DI 10.1016/j.biopha.2024.116195
EA JAN 2024
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA JO0C5
UT WOS:001173980900001
PM 38262149
OA gold
DA 2025 08 17
ER

PT J
AU Guo, W
   Yang, XG
   Shi, YL
   Wang, H
AF Guo, Wei
   Yang, Xiao guang
   Shi, Yu lin
   Wang, Hong
TI The effects and mechanism of paeoniflorin in promoting osteogenic
   differentiation of MC3T3 E1
SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
LA English
DT Article
DE Paeoniflorin; Wnt/beta catenin pathways; Osteogenic differentiation;
   Osteoclastogenesis
ID OSTEOPOROSIS; PREVENTION; ACTIVATION; CELLS; BONE
AB Background: The incidence of osteoporosis and osteoporotic fractures is increasing every year. Traditional Chinese Medicine (TCM) can shed new light on the treatment of osteoporosis. This study aimed to explore the role and mechanism of paeoniflorin in promoting osteogenic differentiation of an osteoblast precursor cell line (MC3T3 E1).
   Methods: MC3T3 E1 cells were cultured in osteogenic induction medium (OIM) and OIM combined with different concentrations of paeoniflorin. The optimal dose of paeoniflorin was assessed by a cell counting kit 8 (CCK 8) assay. Then, alkaline phosphatase (ALP) and Alizarin Red S (ARS) staining were performed to assess the osteogenic capacity of paeoniflorin. The transcription of osteogenic genes and the expression of osteogenic proteins were assessed by RT PCR and Western blotting, respectively. The transcription of Wnt/beta catenin signaling pathway genes and proteins was assessed by RT PCR and Western blotting, respectively. Finally, Dickkopf 1 (DKK 1), a Wnt/beta catenin signaling pathway inhibitor, was used to identify whether the Wnt/beta catenin signaling pathway was involved in the osteogenic differentiation of paeoniflorin. Osteoclastogenesis in RAW264.7 cells was identified by tartrate resistant acid phosphatase (TRAP) staining.
   Results: At concentrations ranging from 0.1 to 100 mu M, paeoniflorin was not cytotoxic to MC3T3 E1 cells. Paeoniflorin significantly increased the osteogenic differentiation of MC3T3 E1 cells in a dose dependent manner. Moreover, paeoniflorin significantly increased osteogenic differentiation gene and protein expression. Through bioinformatic analysis, paeoniflorin affected genes were found to be involved in different signaling pathways, such as the Wnt/beta catenin signaling pathway. Paeoniflorin enhanced beta catenin and CyclinD1 expression compared with that of the control groups. DKK 1 partially reversed the promoting effects of paeoniflorin in promoting osteogenic differentiation of MC3T3 E1 cells. Moreover, paeoniflorin inhibited the osteoclastogenesis of RAW264.7 cells.
   Conclusion: Paeoniflorin promotes osteogenic differentiation in MC3T3 E1 cells by regulating the Wnt/beta catenin pathway. Paeoniflorin is a potential therapeutic agent for the treatment of osteoporosis.
C1 [Guo, Wei; Yang, Xiao guang; Shi, Yu lin; Wang, Hong] Hubei Univ Arts & Sci, Xiangyang Cent Hosp, Dept Rehabil Med, Affiliated Hosp, 136 Jingzhou Rd, Xiangyang 441021, Hubei, Peoples R China.
C3 Hubei University of Arts & Science
RP Shi, YL; Wang, H (通讯作者)，Hubei Univ Arts & Sci, Xiangyang Cent Hosp, Dept Rehabil Med, Affiliated Hosp, 136 Jingzhou Rd, Xiangyang 441021, Hubei, Peoples R China.
EM shitu19830814@163.com; wanjing19730214@163.com
CR Abuna RPF, 2019, COLLOID SURFACE B, V184, DOI 10.1016/j.colsurfb.2019.110513
   Armas LAG, 2012, ENDOCRIN METAB CLIN, V41, P475, DOI 10.1016/j.ecl.2012.04.006
   Baccaro LF, 2015, CLIN INTERV AGING, V10, DOI 10.2147/CIA.S54614
   Baron R, 2018, CURR OPIN PHARMACOL, V40, P134, DOI 10.1016/j.coph.2018.04.011
   Briot K, 2018, JOINT BONE SPINE, V85, P519, DOI 10.1016/j.jbspin.2018.02.009
   Chen X, 2017, MOL MED REP, V15, P2890, DOI 10.3892/mmr.2017.6327
   Duan PP, 2016, INT J BIOCHEM CELL B, V77, P23, DOI 10.1016/j.biocel.2016.05.015
   Ge CX, 2021, J BONE MINER RES, V36, P2096, DOI 10.1002/jbmr.4300
   Hu MZ, 2019, NEUROL RES, V41, P446, DOI 10.1080/01616412.2019.1576361
   Karner CM, 2017, CELL MOL LIFE SCI, V74, P1649, DOI 10.1007/s00018 016 2425 5
   Kerschan Schindl K, 2016, WIEN MED WOCHENSCHR, V166, P22, DOI 10.1007/s10354 015 0417 y
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Komori T, 2018, HISTOCHEM CELL BIOL, V149, P313, DOI 10.1007/s00418 018 1640 6
   Lane JM, 2000, CLIN ORTHOP RELAT R, P139
   Li YC, 2018, NUTRIENTS, V10, DOI 10.3390/nu10081024
   Liu Y, 2018, MUTAGENESIS, V33, P203, DOI 10.1093/mutage/gey010
   Luo X, 2021, INT IMMUNOPHARMACOL, V90, DOI 10.1016/j.intimp.2020.107224
   Maeda K, 2012, NAT MED, V18, P405, DOI 10.1038/nm.2653
   Miller PD, 2016, EXPERT OPIN PHARMACO, V17, P473, DOI 10.1517/14656566.2016.1124856
   Morris HA, 2010, NUTRIENTS, V2, P1073, DOI 10.3390/nu2101073
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Srivastava M, 2002, CLIN GERIATR MED, V18, P529, DOI 10.1016/S0749 0690(02)00022 8
   Sun HJ, 2019, PHARM BIOL, V57, P550, DOI 10.1080/13880209.2019.1651876
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Teufel S, 2019, CURR TOP DEV BIOL, V133, P235, DOI 10.1016/bs.ctdb.2018.11.010
   Vandenbroucke A, 2017, CLIN INTERV AGING, V12, P1065, DOI 10.2147/CIA.S131023
   Wang XY, 2006, J CELL BIOL, V172, P115, DOI 10.1083/jcb.200507106
   Wen J, 2019, PHARMACOL RES, V146, DOI 10.1016/j.phrs.2019.104308
   Xin QQ, 2019, LIFE SCI, V237, DOI 10.1016/j.lfs.2019.116925
   Yang JX, 2020, CELL SIGNAL, V70, DOI 10.1016/j.cellsig.2019.109504
   Yang LY, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/6623464
   Zeng XZ, 2016, ACTA PHARMACOL SIN, V37, P255, DOI 10.1038/aps.2015.85
   Zhang LL, 2020, PHARMACOL THERAPEUT, V207, DOI 10.1016/j.pharmthera.2019.107452
   Zhao ZH, 2018, CHEM BIOL INTERACT, V286, P45, DOI 10.1016/j.cbi.2018.03.002
   Zhou YX, 2020, BIOMED PHARMACOTHER, V130, DOI 10.1016/j.biopha.2020.110505
NR 35
TC 7
Z9 7
U1 2
U2 27
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 799X
J9 J ORTHOP SURG RES
JI J. Orthop. Surg. Res.
PD FEB 14
PY 2022
VL 17
IS 1
AR 90
DI 10.1186/s13018 022 02965 1
PG 10
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA YY9RS
UT WOS:000755122900002
PM 35164817
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhang, YF
   Liu, X
   Li, YY
   Song, MK
   Li, YT
   Yang, AH
   Zhang, YQ
   Wang, D
   Hu, M
AF Zhang, Yongfeng
   Liu, Xin
   Li, Yangyang
   Song, Minkai
   Li, Yutong
   Yang, Anhui
   Zhang, Yaqin
   Wang, Di
   Hu, Min
TI Aucubin slows the development of osteoporosis by inhibiting osteoclast
   differentiation via the nuclear factor erythroid 2 related factor
   2 mediated antioxidation pathway
SO PHARMACEUTICAL BIOLOGY
LA English
DT Article
DE Natural active monomer; metabolic bone disease; reactive oxygen species
ID OVX INDUCED OSTEOPOROSIS; BONE LOSS; POSTMENOPAUSAL OSTEOPOROSIS;
   OXIDATIVE STRESS; RESORPTION
AB Context Osteoporosis (OP) is a metabolic disease. We have previously demonstrated that aucubin (AU) has anti OP effects that are due to its promotion of the formation of osteoblasts. Objectives To investigate the mechanisms of anti OP effects of AU. Materials and methods C57BL/6 mice were randomly divided into control group, 30 mg/kg Dex induced OP group (OP model group, 15 mu g/kg oestradiol treated positive control group, 5 or 45 mg/kg AU treated group), and 45 mg/kg AU alone treated group. The administration lasted for 7 weeks. Subsequently, 1, 2.5 and 5 mu M AU were incubated with 50 ng/mL RANKL induced RAW264.7 cells for 7 days to observe osteoclast differentiation. The effect of AU was evaluated by analysing tissue lesions, biochemical factor and protein expression. Results The LD50 of AU was greater than 45 mg/kg. AU increased the number of trabeculae and reduced the loss of chondrocytes in OP mice. Compared to OP mice, AU treated mice exhibited decreased serum concentrations of TRAP5b (19.6% to 28.4%), IL 1 (12.2% to 12.6%), IL 6 (12.1%) and ROS (5.9% to 10.7%) and increased serum concentrations of SOD (14.6% to 19.4%) and CAT (17.2% to 27.4%). AU treatment of RANKL exposed RAW264.7 cells decreased the numbers of multi nuclear TRAP positive cells, reversed the over expression of TRAP5, NFATc1 and CTSK. Furthermore, AU increased the expression of nuclear factor erythroid 2 related factor 2 (Nrf2) and its downstream proteins in RANKL exposed RAW264.7 cells. Conclusions AU slows the development of OP via Nrf2 mediated antioxidant pathways, indicating the potential use of AU in OP therapy and other types of OP research.
C1 [Zhang, Yongfeng; Li, Yangyang; Li, Yutong; Hu, Min] Jilin Univ, Sch & Hosp Stomatol, Dept Orthodont, Changchun, Peoples R China.
   [Zhang, Yongfeng; Liu, Xin; Song, Minkai; Yang, Anhui; Zhang, Yaqin; Wang, Di] Jilin Univ, Sch Life Sci, Qianjin St 2699, Changchun, Jilin, Peoples R China.
C3 Jilin University; Jilin University
RP Wang, D (通讯作者)，Jilin Univ, Sch Life Sci, Qianjin St 2699, Changchun, Jilin, Peoples R China.; Hu, M (通讯作者)，Jilin Univ, Coll Stomatol, Dept Orthodont, 1500 Qinghua Rd, Changchun, Jilin, Peoples R China.
EM jluwangdi@outlook.com; humin@jlu.edu.cn
RI wang, di/HKD 8820 2023
OI Liu, Xin/0009 0004 7970 2327
FU Science and Technology Research Project, Education Department of Jilin
   Province of China [JJKH20200322KJ]; Natural Science Foundation of China
   [81870795]; Department of Health of Jilin Province [2020Q022]; Special
   Projects of Cooperation between Jilin University and Jilin Province
   [SXGJSFKT2020 1]
FX This work was supported by the Science and Technology Research Project,
   Education Department of Jilin Province of China [No. JJKH20200322KJ],
   the Natural Science Foundation of China [No. 81870795], the Project from
   the Department of Health of Jilin Province [No. 2020Q022] and the
   Special Projects of Cooperation between Jilin University and Jilin
   Province [No. SXGJSFKT2020 1].
CR Al Daghri NM, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005780
   Almeida M, 2017, PHYSIOL REV, V97, P135, DOI 10.1152/physrev.00033.2015
   Bonaccorsi G, 2018, INDIAN J MED RES, V147, P341, DOI 10.4103/ijmr.IJMR_524_18
   Cai WJ, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/4101738
   Chen C, 2015, ACTA PHARMACOL SIN, V36, P1053, DOI 10.1038/aps.2015.65
   Chen SD, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/5416728
   Chen X, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.394
   Compston J, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 017 0324 5
   Compston J, 2018, ENDOCRINE, V61, P7, DOI 10.1007/s12020 018 1588 2
   Czerny B, 2010, EUR J OBSTET GYN R B, V149, P82, DOI 10.1016/j.ejogrb.2009.12.010
   Drake MT, 2017, ENDOCR REV, V38, P325, DOI 10.1210/er.2015 1114
   Fraser JHE, 1996, BONE, V19, P223, DOI 10.1016/8756 3282(96)00177 9
   Georgiou L, 2018, PEERJ, V6, DOI 10.7717/peerj.5156
   Hu LF, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020360
   Ibáñez L, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/726590
   Kanis JA, 2008, OSTEOPOROSIS INT, V19, P399, DOI 10.1007/s00198 008 0560 z
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Levy R, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864 015 2213 x
   Li XH, 2019, INT J CLIN EXP PATHO, V12, P4077
   Li YT, 2020, AGING US, V12, P2226, DOI 10.18632/aging.102742
   Li YT, 2018, CHEM BIOL INTERACT, V283, P51, DOI 10.1016/j.cbi.2018.02.005
   Liu SB, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12613
   Luo K, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/316134
   Ma B, 2012, ACTA PHARMACOL SIN, V33, P479, DOI 10.1038/aps.2011.177
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Mo H, 2019, BRAZ J MED BIOL RES, V52, DOI [10.1590/1414 431X20198754, 10.1590/1414 431x20198754]
   Motyl KJ, 2009, J CELL PHYSIOL, V218, P376, DOI 10.1002/jcp.21608
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Nishikawa A, 2016, CLIN INTERV AGING, V11, P913, DOI 10.2147/CIA.S107285
   Ohishi T, 2017, ENDOCR RES, V42, P232, DOI 10.1080/07435800.2017.1292527
   Ohlsson C, 2018, J ENDOCRINOL, V237, P113, DOI 10.1530/JOE 18 0020
   Qiu XM, 2015, INT J CLIN EXP PATHO, V8, P4408
   Scheffler JM, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 62562 2
   Shen BY, 2019, J CELL MOL MED, V23, P4063, DOI 10.1111/jcmm.14293
   Swanson C, 2006, ENDOCRINOLOGY, V147, P3613, DOI 10.1210/en.2005 0717
   Takahashi T, 2016, J HARD TISSUE BIOL, V25, P257, DOI 10.2485/jhtb.25.257
   Tu WJ, 2019, AGING DIS, V10, P637, DOI 10.14336/AD.2018.0513
   Vasikaran S, 2018, CLIN CHEM LAB MED, V56, P1603, DOI 10.1515/cclm 2017 1109
   Vijayan V, 2014, BRIT J PHARMACOL, V171, P107, DOI 10.1111/bph.12434
   Wang CY, 2020, FRONT PLANT SCI, V11, DOI 10.3389/fpls.2020.00079
   Wang L, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12328
   Wu X, 2018, FOOD NUTR RES, V62, DOI 10.29219/fnr.v62.1478
   Xu ZS, 2018, CELL MOL BIOL LETT, V23, DOI 10.1186/s11658 018 0114 0
   Yan Y, 2018, MOLECULES, V23, DOI 10.3390/molecules23030643
   Zamani M, 2018, ARCH OSTEOPOROS, V13, DOI 10.1007/s11657 018 0540 7
   Zhang HQ, 2015, FREE RADICAL BIO MED, V88, P314, DOI 10.1016/j.freeradbiomed.2015.05.036
   Zhang R, 2009, BONE, V45, P553, DOI 10.1016/j.bone.2008.08.127
   Zhang WP, 2012, AM J CHINESE MED, V40, P735, DOI 10.1142/S0192415X12500553
   Zhong ZY, 2020, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01530
   Zhou QZ, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/7067984
   Zhou YM, 2019, MOL MED REP, V19, P4603, DOI 10.3892/mmr.2019.10131
   Zhu SW, 2018, MOL MED REP, V17, P6969, DOI 10.3892/mmr.2018.8741
   Zhuang YL, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040883
NR 53
TC 14
Z9 17
U1 5
U2 44
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1388 0209
EI 1744 5116
J9 PHARM BIOL
JI Pharm. Biol.
PD JAN 1
PY 2021
VL 59
IS 1
BP 1556
EP 1565
DI 10.1080/13880209.2021.1996614
PG 10
WC Plant Sciences; Medical Laboratory Technology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Medical Laboratory Technology; Pharmacology & Pharmacy
GA WU7SH
UT WOS:000716740700001
PM 34757891
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Irwin Huston, JM
   Bourebaba, L
   Bourebaba, N
   Tomal, A
   Marycz, K
AF Irwin Huston, Jennifer M.
   Bourebaba, Lynda
   Bourebaba, Nabila
   Tomal, Artur
   Marycz, Krzysztof
TI Sex hormone binding globulin promotes the osteogenic differentiation
   potential of equine adipose derived stromal cells by activating the BMP
   signaling pathway
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE osteogenesis; ASCs; SHBG; BMP; mitochondrial dynamics; autophagy
ID MINERALIZATION; FRAGMENTATION; MITOCHONDRIA; MODULATION; EXPRESSION;
   APOPTOSIS; AUTOPHAGY; ROLES; DEATH; SHBG
AB Background Musculoskeletal injuries and chronic degenerative diseases pose significant challenges in equine health, impacting performance and overall well being. Sex Hormone Binding Globulin (SHBG) is a glycoprotein determining the bioavailability of sex hormones in the bloodstream, and exerting critical metabolic functions, thus impacting the homeostasis of many tissues including the bone.Methods In this study, we investigated the potential role of SHBG in promoting osteogenesis and its underlying mechanisms in a model of equine adipose derived stromal cells (ASCs). An SHBG knocked down model has been established using predesigned siRNA, and cells subjected to osteogenic induction medium in the presence of exogenous SHBG protein. Changes in differentiation events where then screened using various analytical methods.Results We demonstrated that SHBG treatment enhances the expression of key osteoconductive regulators in equine ASCs CD34+ cells, suggesting its therapeutic potential for bone regeneration. Specifically, SHBG increased the cellular expression of BMP2/4, osteocalcin (OCL), alkaline phosphatase (ALP), and osteopontin (OPN), crucial factors in early osteogenesis. Furthermore, SHBG treatment maintained adequate apoptosis and enhanced autophagy during osteogenic differentiation, contributing to bone formation and remodeling. SHBG further targeted mitochondrial dynamics, and promoted the reorganization of the mitochondrial network, as well as the expression of dynamics mediators including PINK, PARKIN and MFN1, suggesting its role in adapting cells to the osteogenic milieu, with implications for osteoblast maturation and differentiation.Conclusion Overall, our findings provide novel insights into SHBG's role in bone formation and suggest its potential therapeutic utility for bone regeneration in equine medicine.
C1 [Irwin Huston, Jennifer M.; Bourebaba, Lynda; Bourebaba, Nabila; Marycz, Krzysztof] Univ Environm & Life Sci, Fac Biol & Anim Sci, Dept Expt Biol, Wroclaw, Poland.
   [Tomal, Artur; Marycz, Krzysztof] Int Inst Translat Med, Wiszn Mala, Poland.
   [Marycz, Krzysztof] Univ Calif Davis, Sch Vet Med, Dept Med & Epidemiol, Davis, CA USA.
C3 Wroclaw University of Environmental & Life Sciences; University of
   California System; University of California Davis
RP Bourebaba, L (通讯作者)，Univ Environm & Life Sci, Fac Biol & Anim Sci, Dept Expt Biol, Wroclaw, Poland.
EM lynda.bourebaba@upwr.edu.pl
RI Marycz, Krzysztof/A 2249 2017; Bourebaba, Lynda/AAX 7613 2020;
   Bourebaba, Nabila/JRY 9553 2023
FU National Science Centre in Poland over the course of the realization of
   the project:"Exploring the role and therapeutic potential of sex hormone
   binding globulin (SHBG) in the course of insulin
   resistance,inflammation, lipotoxi city in adipose stem progeni
   [2019/35/B/NZ7/03651]
FX The author(s) declare financial support was received for the research,
   authorship, and/or publication of this article. The work was supported
   by a research grant financed by the National Science Centre in Poland
   over the course of the realization of the project:"Exploring the role
   and therapeutic potential of sex hormone binding globulin (SHBG) in the
   course of insulin resistance,inflammation, lipotoxi city in adipose stem
   progenitor cells and adipocytes in equine metabolic syndrome (EMS)
   mares"(No 2019/35/B/NZ7/03651)
CR Almeida M, 2017, PHYSIOL REV, V97, P135, DOI 10.1152/physrev.00033.2015
   Beederman Maureen, 2013, J Biomed Sci Eng, V6, P32
   Bourebaba L, 2023, STEM CELL REV REP, V19, P2251, DOI 10.1007/s12015 023 10580 8
   Bourebaba N, 2023, CELL COMMUN SIGNAL, V21, DOI 10.1186/s12964 023 01254 6
   Bourebaba N, 2022, BIOMED PHARMACOTHER, V153, DOI 10.1016/j.biopha.2022.113261
   Cruz ACC, 2019, J APPL ORAL SCI, V27, DOI 10.1590/1678 7757 2018 0317
   Catalano MG, 2007, HORM METAB RES, V39, P288, DOI 10.1055/s 2007 973814
   Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046
   Chen MW, 2020, J MATER CHEM B, V8, P9314, DOI 10.1039/d0tb01412e
   Cheng HZ, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 03047 z
   De Toni L, 2016, ENDOCRINOLOGY, V157, P4473, DOI 10.1210/en.2016 1312
   FISSORE F, 1994, STEROIDS, V59, P661, DOI 10.1016/0039 128X(94)90023 X
   Fonseca LN, 2023, HELIYON, V9, DOI 10.1016/j.heliyon.2023.e13464
   Fortunati N, 2010, MOL CELL ENDOCRINOL, V316, P86, DOI 10.1016/j.mce.2009.09.012
   Frazier TP, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471 2121 14 34
   Giner M, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471 2474 14 41
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Grottkau BE, 2013, BONE RES, V1, DOI 10.4248/BR201302003
   Halloran D, 2020, J DEV BIOL, V8, DOI 10.3390/jdb8030019
   Hammond GL, 2011, BIOL REPROD, V85, P431, DOI 10.1095/biolreprod.111.092593
   Hock JM, 2001, J BONE MINER RES, V16, P975, DOI 10.1359/jbmr.2001.16.6.975
   Hoppé E, 2010, JOINT BONE SPINE, V77, P306, DOI 10.1016/j.jbspin.2010.03.011
   Huang CY, 2018, J MOL CELL CARDIOL, V122, P58, DOI 10.1016/j.yjmcc.2018.08.006
   Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793
   Poderoso JJ, 2019, NITRIC OXIDE BIOL CH, V88, P61, DOI 10.1016/j.niox.2019.04.005
   Kamiya N, 2011, BIOFACTORS, V37, P75, DOI 10.1002/biof.139
   Kim HK, 2012, BIOMATERIALS, V33, P7057, DOI 10.1016/j.biomaterials.2012.06.036
   Kim JM, 2022, ELIFE, V11, DOI 10.7554/eLife.78069
   Laurent MR, 2016, SCI REP UK, V6, DOI 10.1038/srep35539
   Lee SY, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02656 4
   Lee SM, 2023, CELLS BASEL, V12, DOI 10.3390/cells12232742
   Li QQ, 2017, PROTEIN CELL, V8, P439, DOI 10.1007/s13238 017 0385 7
   Martinez Calle M, 2023, J CLIN INVEST, V133, DOI 10.1172/JCI159928
   May RD, 2019, CURR STEM CELL RES T, V14, P618, DOI 10.2174/1574888X14666190628103528
   Mende W, 2021, CELLS BASEL, V10, DOI 10.3390/cells10050975
   Newman H, 2021, BIOMATERIALS, V277, DOI 10.1016/j.biomaterials.2021.121114
   Noble BS, 2000, MOL CELL ENDOCRINOL, V159, P7, DOI 10.1016/S0303 7207(99)00174 4
   Noël D, 2004, STEM CELLS, V22, P74, DOI 10.1634/stemcells.22 1 74
   Nojima J, 2010, J BIOL CHEM, V285, P15577, DOI 10.1074/jbc.M109.028019
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Ohta Y, 2008, J BONE MINER METAB, V26, P478, DOI 10.1007/s00774 008 0850 8
   P Mafi, 2011, Open Orthop J, V5, P253, DOI 10.2174/1874325001105010253
   Pantovic A, 2013, BONE, V52, P524, DOI 10.1016/j.bone.2012.10.024
   Ribitsch I, 2021, ANIMALS BASEL, V11, DOI 10.3390/ani11010234
   Shen BJ, 2010, J CELL BIOCHEM, V109, P406, DOI 10.1002/jcb.22412
   Sheridan C, 2008, MOL CELL, V31, P570, DOI 10.1016/j.molcel.2008.08.002
   Shum LC, 2016, STEM CELLS DEV, V25, P114, DOI 10.1089/scd.2015.0193
   Suh J, 2023, CELL METAB, V35, P345, DOI 10.1016/j.cmet.2023.01.003
   Tateiwa D, 2023, N AM SPINE SOC J, V13, DOI 10.1016/j.xnsj.2022.100193
   Traktuev DO, 2008, CIRC RES, V102, P77, DOI 10.1161/CIRCRESAHA.107.159475
   Tsuji Wakako, 2014, World J Stem Cells, V6, P312, DOI 10.4252/wjsc.v6.i3.312
   Wang XY, 2020, BIOCHEM BIOPH RES CO, V532, P613, DOI 10.1016/j.bbrc.2020.08.100
   Winters SJ, 2020, ENDOCR CONNECT, V9, P1009, DOI 10.1530/EC 20 0401
   Xiao L, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00490
   Xin LJ, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1151691
   Xing YF, 2023, J ORTHOP SURG RES, V18, DOI 10.1186/s13018 023 03616 9
   Yamazaki H, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/3062319
   Yan CL, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1077058
   Yang F, 2021, INT J GEN MED, V14, P7707, DOI 10.2147/IJGM.S329992
   Yin X, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0058 7
   Zhang W, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.576104
   Zhang ZY, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.942128
NR 62
TC 0
Z9 0
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD OCT 17
PY 2024
VL 15
AR 1424873
DI 10.3389/fendo.2024.1424873
PG 16
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA K6L4V
UT WOS:001344968900001
PM 39483986
OA gold
DA 2025 08 17
ER

PT J
AU Medalha, CC
   Santos, ALYS
   Veronez, SD
   Fernandes, KR
   Magri, AMP
   Renno, ACM
AF Medalha, Carla Christina
   Yaeko Silva Santos, Ana Lucia
   Veronez, Suellen de Oliveira
   Fernandes, Kelly Rossetti
   Paiva Magri, Angela Maria
   Muniz Renno, Ana Claudia
TI Low level laser therapy accelerates bone healing in spinal cord injured
   rats
SO JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B BIOLOGY
LA English
DT Article
DE Low level laser therapy; Spinal cord injury; Bone; Rats
ID GENE EXPRESSION; IRRADIATION; OSTEOARTHRITIS; STIMULATION; OSTEOCLAST;
   MECHANISMS; ULTRASOUND; OSTEOBLAST; RESPONSES; REPAIR
AB Bone loss occurs rapidly and consistently after the occurrence of a spinal cord injury (SCI), leading to a decrease in bone mineral density (BMD) and a higher risk of fractures. In this context, the stimulatory effects of low level laser therapy (LLLT) also known as photobiomodulation (PBM) have been highlighted, mainly due to its osteogenic potential. The aim of the present study was to evaluate the effects of LLLT on bone healing using an experimental model of tibial bone defect in SCI rats. Twenty four female Wistar rats were randomly divided into 3 groups: Sham group (SG), SCI control group (SC) and SCI laser treated group (SE). Two weeks after the induction of the SCI, animals were submitted to surgery to induce a tibial bone defect. Treatment was performed 3 days a week, for 2 weeks, at a single point over the area of the injury, using an 808 nm laser (30 mW, 100 J/cm(2); 0.028 cm(2), 1.7 W/cm(2), 2.8 J). The results of the histological and morphometric evaluation demonstrated that the SL group showed a larger amount of newly formed bone compared to the SC group. Moreover, a significant immunoexpression of runt related transcription factor 2 (RUNX2) was observed in the SL group. There was no statistical difference in the biomechanical evaluation. In conclusion, the results suggest that LLLT accelerated the process of bone repair in rats with complete SCI. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Medalha, Carla Christina; Yaeko Silva Santos, Ana Lucia; Veronez, Suellen de Oliveira; Fernandes, Kelly Rossetti; Paiva Magri, Angela Maria; Muniz Renno, Ana Claudia] Univ Fed Sao Paulo, Dept Biosci, Ave Ana Costa 95, BR 11050240 Sao Paulo, Brazil.
C3 Universidade Federal de Sao Paulo (UNIFESP)
RP Renno, ACM (通讯作者)，Univ Fed Sao Paulo, Dept Biosci, Ave Ana Costa 95, BR 11050240 Sao Paulo, Brazil.
RI Medalha, Carla/I 2511 2012; Magri, Angela/J 9323 2016; Renno,
   Ana/C 1266 2015; Paiva Magri, Angela Maria/J 9323 2016
OI Santos, Ana Lucia Yaeko da Silva/0000 0001 7169 3797; Renno,
   Ana/0000 0003 2358 0514; Paiva Magri, Angela Maria/0000 0001 5901 7227
CR Afzal F, 2004, J PATHOL, V202, P503, DOI 10.1002/path.1536
   Anandarajah AP, 2009, ADV EXP MED BIOL, V649, P85
   Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098
   Bossini PS, 2011, J TISSUE ENG REGEN M, V5, P229, DOI 10.1002/term.309
   Braga Silva Jefferson, 2007, Acta ortop. bras., V15, P155
   Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143
   Chung H, 2012, ANN BIOMED ENG, V40, P516, DOI 10.1007/s10439 011 0454 7
   Demidova Rice TN, 2007, LASER SURG MED, V39, P706, DOI 10.1002/lsm.20549
   Ding Y, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471 2202 10 35
   Edwards WB, 2014, J BONE MINER RES, V29, P2074, DOI 10.1002/jbmr.2227
   Fávaro Pípi E, 2011, PHOTOMED LASER SURG, V29, P311, DOI 10.1089/pho.2010.2841
   Fernandes KR, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.3.038002
   Freire MAM, 2012, W INDIAN MED J, V61, P751
   Hamajima S, 2003, LASER MED SCI, V18, P78, DOI 10.1007/s10103 003 0255 9
   Hamblin MR, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4354
   HILL EL, 1993, J ORTHOPAED RES, V11, P537, DOI 10.1002/jor.1100110408
   Jamtvedt G, 2008, PHYS THER, V88, P123, DOI 10.2522/ptj.20070043
   Jiang SD, 2007, CALCIFIED TISSUE INT, V80, P167, DOI 10.1007/s00223 006 0085 4
   Jiang SD, 2006, CLIN ENDOCRINOL, V65, P555, DOI 10.1111/j.1365 2265.2006.02683.x
   Karu TI, 2005, PHOTOMED LASER SURG, V23, P355, DOI 10.1089/pho.2005.23.355
   Karu TI, 2001, LASER SURG MED, V29, P274, DOI 10.1002/lsm.1119
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Liu D, 2008, BONE, V43, P119, DOI 10.1016/j.bone.2008.03.015
   Matsumoto MA, 2012, J MATER SCI MATER M, V23, P1447, DOI 10.1007/s10856 012 4612 8
   McGee Lawrence ME, 2013, J BIOL CHEM, V288, P5291, DOI 10.1074/jbc.M112.414995
   Medalha CC, 2012, ARCH MED SCI, V8, P1102, DOI 10.5114/aoms.2012.32424
   Medalha CC, 2010, PHOTOMED LASER SURG, V28, P669, DOI 10.1089/pho.2009.2691
   Oliveira P, 2011, BRAZ J PHYS THER, V15, P200
   Magri AMP, 2015, LASER MED SCI, V30, P1949, DOI 10.1007/s10103 015 1789 3
   Patrocínio Silva TL, 2014, LASER MED SCI, V29, P1357, DOI 10.1007/s10103 013 1418 y
   Picard S, 2008, ANAT REC, V291, P303, DOI 10.1002/ar.20645
   Prindeze NJ, 2012, EXP BIOL MED, V237, P1241, DOI 10.1258/ebm.2012.012180
   Stadler I, 2000, LASER SURG MED, V27, P255, DOI 10.1002/1096 9101(2000)27:3<255::AID LSM7>3.0.CO;2 L
   Tim CR, 2014, LASER MED SCI, V29, P147, DOI 10.1007/s10103 013 1302 9
   Warden SJ, 2002, OSTEOPOROSIS INT, V13, P586, DOI 10.1007/s001980200077
   Yamamoto M, 2001, LASER MED SCI, V16, P213, DOI 10.1007/PL00011357
   Yokobori S, 2015, WORLD NEUROSURG, V83, P867, DOI 10.1016/j.wneu.2013.03.012
   Pinto KNZ, 2013, PHOTOMED LASER SURG, V31, P252, DOI 10.1089/pho.2012.3435
   Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460
NR 39
TC 20
Z9 21
U1 0
U2 14
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1011 1344
J9 J PHOTOCH PHOTOBIO B
JI J. Photochem. Photobiol. B Biol.
PD JUN
PY 2016
VL 159
BP 179
EP 185
DI 10.1016/j.jphotobiol.2016.03.041
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA DM9RC
UT WOS:000376702400026
PM 27077555
DA 2025 08 17
ER

PT J
AU Sun, H
   Zhao, Y
   Wang, K
   Zhu, L
   Dong, J
   Zhao, J
   Wang, YM
   Li, H
   Sun, XL
   Lu, YJ
AF Sun, Han
   Zhao, Yong
   Wang, Kun
   Zhu, Li
   Dong, Jian
   Zhao, Jie
   Wang, Yimin
   Li, Huan
   Sun, Xiaoliang
   Lu, Yunjie
TI Low dose IL 2 suppress osteoclastogenesis in collagen induced arthritis
   via JNK dependent pathway
SO IMMUNITY INFLAMMATION AND DISEASE
LA English
DT Article
DE c Jun N terminal kinase; collagen induced arthritis; interleukin 2;
   NF kappa B; rheumatoid arthritis
ID RHEUMATOID ARTHRITIS; CELLS; AUTOIMMUNE; PHOSPHORYLATION; MICE
AB Background: Rheumatoid arthritis (RA) is one of the most common chronic immune joint diseases, mainly involving blood vessels and small joints. The complex pathogenesis of RA greatly increases the difficulty of treatment. At present, the common hormone and immunosuppressive therapy are not effective, while low dose interleukin 2 (IL 2) recently has been found to possess some advantages for immunotherapy. However, its related signal pathway remains to be elucidated.
   Methods: We fabricated the model of arthritis in mice, and then low dose IL 2 was injected at a fixed time point to observe the changes of related vascular and organ pathology, inflammatory factors, and signal pathway proteins, which were verified by statistical analysis.
   Results: Low dose IL 2 can reduce the severity of vascular and bone lesions in collagen induced arthritis immune model, and inhibit osteoclast formation in vitro by phosphorylation of nuclear factor kappa B (NF kappa B), which inhibits the receptor activator of NF kappa B ligand effect through c Jun N terminal kinase (JNK) pathway, and its immunotherapeutic effect depends on the activation of JNK.
   Conclusion: It is the first time for us to prove that low dose IL 2 can inhibit osteoclast formation in collagen induced arthritis through the JNK dependent pathway, which will provide the angle and theoretical basis for future immunotherapy of IL 2.
C1 [Sun, Han; Wang, Kun; Zhu, Li; Zhao, Jie; Wang, Yimin; Li, Huan; Sun, Xiaoliang; Lu, Yunjie] Soochow Univ, Affiliated Hosp 3, Changzhou 213003, Jiangsu, Peoples R China.
   [Sun, Han; Dong, Jian] Nanjing Univ, Affiliated Hosp, Nanjing Drum Tower Hosp, Med Sch,Dept Sports Med & Adult Reconstruct Surg, Nanjing, Peoples R China.
   [Zhao, Yong] Peoples Hosp Jinsha Cty, Dept Hepatobiliary Surg, Gejiu, Peoples R China.
C3 Soochow University   China; Nanjing University
RP Sun, XL; Lu, YJ (通讯作者)，Soochow Univ, Affiliated Hosp 3, Changzhou 213003, Jiangsu, Peoples R China.
EM xiaoliangsuncz@163.com; yjresearch@qq.com
RI Lu, Yunjie/AAF 2600 2019; Zhao, Yong/AGI 8334 2022; dong,
   jian/AFZ 7183 2022
OI Dong, Jian/0000 0001 6333 3724; 
FU National Natural Science Foundation of China [81971504, 31800806];
   Post Doctoral Special Foundation of China [2020M670065ZX]; Post Doctoral
   Foundation of Jiangsu Province [2020Z021]; Applied Basic Research
   Project of Changzhou [CJ20180063]; Young Talent Development Plan of
   Changzhou Health Commission [2020 233, CZQM2020003]
FX National Natural Science Foundation of China, Grant/Award Numbers:
   81971504, 31800806; Post Doctoral Special Foundation of China,
   Grant/Award Number: 2020M670065ZX; Post Doctoral Foundation of Jiangsu
   Province, Grant/Award Number: 2020Z021; Applied Basic Research Project
   of Changzhou, Grant/Award Number: CJ20180063; Funding from Young Talent
   Development Plan of Changzhou Health Commission (2020 233), Grant/Award
   Number: CZQM2020003
CR Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   Chang EJ, 2008, J CELL SCI, V121, P2555, DOI 10.1242/jcs.028217
   Chen MG, 2013, ARTHRITIS RHEUM US, V65, P1181, DOI 10.1002/art.37894
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Firestein GS, 2017, IMMUNITY, V46, P183, DOI 10.1016/j.immuni.2017.02.006
   FITZGERALD O, 1991, ANN RHEUM DIS, V50, P792, DOI 10.1136/ard.50.11.792
   Gashi Afrim A, 2014, Med Arch, V68, P51
   He J, 2020, ANN RHEUM DIS, V79, P141, DOI 10.1136/annrheumdis 2019 215396
   He J, 2016, NAT MED, V22, P991, DOI 10.1038/nm.4148
   Ikeda F, 2008, J BONE MINER RES, V23, P907, DOI 10.1359/JBMR.080211
   Jeffery HC, 2017, CLIN EXP IMMUNOL, V188, P394, DOI 10.1111/cei.12940
   Jiao ZX, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 16853 w
   Klatzmann D, 2015, NAT REV IMMUNOL, V15, P283, DOI 10.1038/nri3823
   Koga Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061346
   Kong N, 2012, ANN RHEUM DIS, V71, P1567, DOI 10.1136/annrheumdis 2011 201052
   Kong N, 2012, ARTHRITIS RHEUM US, V64, P2548, DOI 10.1002/art.34513
   Kosmaczewska A, 2015, INFLAMMATION, V38, P765, DOI 10.1007/s10753 014 9987 x
   Lee SY, 2012, IMMUNOLOGY, V137, P305, DOI 10.1111/imm.12008
   Otero JE, 2008, J BIOL CHEM, V283, P24546, DOI 10.1074/jbc.M800434200
   Phull AR, 2018, CHEM BIOL INTERACT, V281, P121, DOI 10.1016/j.cbi.2017.12.024
   ROONEY M, 1988, ARTHRITIS RHEUM US, V31, P956, DOI 10.1002/art.1780310803
   Rosenzwajg M, 2019, ANN RHEUM DIS, V78, P209, DOI 10.1136/annrheumdis 2018 214229
   Ruoff G, 2014, J FAM PRACTICE, V63, pS27
   Sakamoto N, 2019, TOHOKU J EXP MED, V248, P209, DOI 10.1620/tjem.248.209
   Senolt L., 2019, F1000Res, P8
   Sucur A, 2014, INT ORTHOP, V38, P1893, DOI 10.1007/s00264 014 2386 y
   Williams MA, 2006, NATURE, V441, P890, DOI 10.1038/nature04790
   Yokoyama Y, 2018, J IMMUNOL, V201, P1899, DOI 10.4049/jimmunol.1701502
NR 28
TC 7
Z9 9
U1 2
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 2050 4527
J9 IMMUN INFLAMM DIS
JI IMMUN. INFLAMM. DIS.
PD DEC
PY 2020
VL 8
IS 4
BP 727
EP 735
DI 10.1002/iid3.364
EA OCT 2020
PG 9
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA OP1AQ
UT WOS:000581916400001
PM 33098626
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Shi, Y
   Long, FX
AF Shi, Yu
   Long, Fanxin
TI Hedgehog signaling via Gli2 prevents obesity induced by high fat diet in
   adult mice
SO ELIFE
LA English
DT Article
ID ADIPOSE TISSUE DEVELOPMENT; OSTEOBLAST DIFFERENTIATION; STEM CELLS;
   ACTIVATION; WHITE; BROWN; ADIPOGENESIS; REGENERATION; MECHANISM; REVEALS
AB Obesity poses a significant risk of developing type II diabetes and other diseases. Hedgehog (Hh) signaling has been shown to inhibit adipose tissue development, but its effect on diet induced obesity during postnatal life is not known. Here by inducing expression of constitutively active Smoothened (SmoM2) or Gli2 (ANGIi2) in the adipocyte lineage of postnatal mice, we show that targeted activation of Hh signaling suppresses high fat diet induced obesity and improves whole body glucose tolerance and insulin sensitivity. Both SmoM2 and ANGIi2 induce the expression of Wnt6, a known anti adipogenic factor, in fat depots of the mouse. Hh Gli2 signaling inhibits not only adipocyte differentiation but also lipogenesis in adipocytes in vitro. Finally, pharmacological inhibition of Porcupine, an acyltransferase essential for Wnt secretion, alleviates both anti adipogenic and anti lipogenic effects of Hh in cell culture models. Overall, targeted activation of Hh signaling ameliorates diet induced obesity and may be explored for pharmaceutical development.
C1 [Shi, Yu; Long, Fanxin] Washington Univ, Sch Med, Dept Orthopaed Surg, St Louis, MO 63130 USA.
   [Long, Fanxin] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
   [Long, Fanxin] Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO 63130 USA.
C3 Washington University (WUSTL); Washington University (WUSTL); Washington
   University (WUSTL)
RP Long, FX (通讯作者)，Washington Univ, Sch Med, Dept Orthopaed Surg, St Louis, MO 63130 USA.; Long, FX (通讯作者)，Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.; Long, FX (通讯作者)，Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO 63130 USA.
EM flong@wustl.edu
RI Shi, Yu/J 5370 2018
FU National Institute of Diabetes and Digestive and Kidney Diseases
   [DK111212]; National Institute of Arthritis and Musculoskeletal and Skin
   Diseases [AR060456]
FX National Institute of Diabetes and Digestive and Kidney Diseases
   DK111212 Fanxin LongNational Institute of Arthritis and Musculoskeletal
   and Skin Diseases AR060456 Fanxin LongThe funders had no role in study
   design, data collection and interpretation, or the decision to submit
   the work for publication.
CR Bai CB, 2002, DEVELOPMENT, V129, P4753
   Bai CYB, 2001, DEVELOPMENT, V128, P5161
   Cawthorn WP, 2012, BONE, V50, P477, DOI 10.1016/j.bone.2011.08.010
   Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137
   Cho I, 2012, NATURE, V488, P621, DOI 10.1038/nature11400
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017
   Flegal KM, 2013, JAMA J AM MED ASSOC, V309, P71, DOI 10.1001/jama.2012.113905
   Flegal KM, 2002, JAMA J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723
   Goetz SC, 2009, METHOD CELL BIOL, V94, P199, DOI 10.1016/S0091 679X(08)94010 3
   Hausman Dorothy B., 2008, V456, P201, DOI 10.1007/978 1 59745 245 8_15
   Hilton MJ, 2005, DEVELOPMENT, V132, P4339, DOI 10.1242/dev.02025
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601
   Jeong JH, 2004, GENE DEV, V18, P937, DOI 10.1101/gad.1190304
   Joeng KS, 2009, DEVELOPMENT, V136, P4177, DOI 10.1242/dev.041624
   Kim S, 2007, P NATL ACAD SCI USA, V104, P16627, DOI 10.1073/pnas.0707797104
   Li B, 2000, NAT MED, V6, P1115, DOI 10.1038/80450
   Long FX, 2001, DEVELOPMENT, V128, P5099
   Longo KA, 2004, J BIOL CHEM, V279, P35503, DOI 10.1074/jbc.M402937200
   Mill P, 2003, GENE DEV, V17, P282, DOI 10.1101/gad.1038103
   Mori H, 2012, J CLIN INVEST, V122, P2405, DOI 10.1172/JCI63604
   Nosavanh L, 2015, P NATL ACAD SCI USA, V112, P5069, DOI 10.1073/pnas.1420978112
   Pan Y, 2006, MOL CELL BIOL, V26, P3365, DOI 10.1128/MCB.26.9.3365 3377.2006
   Park HL, 2000, DEVELOPMENT, V127, P1593
   Perl AKT, 2002, P NATL ACAD SCI USA, V99, P10482, DOI 10.1073/pnas.152238499
   Pospisilik JA, 2010, CELL, V140, P148, DOI 10.1016/j.cell.2009.12.027
   Sasaki H, 1999, DEVELOPMENT, V126, P3915
   Shi Y, 2015, P NATL ACAD SCI USA, V112, P4678, DOI 10.1073/pnas.1502301112
   Shi Y, 2012, J CELL BIOCHEM, V113, P3133, DOI 10.1002/jcb.24190
   Suh JM, 2006, CELL METAB, V3, P25, DOI 10.1016/j.cmet.2005.11.012
   Takahashi K, 2007, NAT PROTOC, V2, P3081, DOI 10.1038/nprot.2007.418
   Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092 8674(00)80678 9
   Wang QA, 2013, NAT MED, V19, P1338, DOI 10.1038/nm.3324
   Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201
   Xu Jianming, 2005, Curr Protoc Mol Biol, VChapter 28, DOI 10.1002/0471142727.mb2801s70
NR 35
TC 53
Z9 58
U1 0
U2 10
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050 084X
J9 ELIFE
JI eLife
PD DEC 5
PY 2017
VL 6
AR e31649
DI 10.7554/eLife.31649
PG 16
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA FO8GX
UT WOS:000417124600001
PM 29205155
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Dalby, MJ
   Andar, A
   Nag, A
   Affrossman, S
   Tare, R
   McFarlane, S
   Oreffo, ROC
AF Dalby, Matthew J.
   Andar, Abhay
   Nag, Abhijit
   Affrossman, Stanley
   Tare, Rahul
   McFarlane, Sara
   Oreffo, Richard O. C.
TI Genomic expression of mesenchymal stem cells to altered nanoscale
   topographies
SO JOURNAL OF THE ROYAL SOCIETY INTERFACE
LA English
DT Article
DE nanobioscience; mesenchymal stem cells; osteogenesis; differentiation;
   nanotopography; microarray
ID OSTEOPROGENITOR RESPONSE; GENE EXPRESSION; BONE FORMATION; GUIDANCE;
   DIFFERENTIATION; PROLIFERATION; MORPHOLOGY; BEHAVIOR; LINEAGE; SHAPE
AB The understanding of cellular response to the shape of their environment would be of benefit in the development of artificial extracellular environments for potential use in the production of biomimetic surfaces. Specifically, the understanding of how cues from the extracellular environment can be used to understand stem cell differentiation would be of special interest in regenerative medicine.
   In this paper, the genetic pro. le of mesenchymal stem cells cultured on two osteogenic nanoscale topographies ( pitted surface versus raised islands) are compared with cells treated with dexamethasone, a corticosteroid routinely used to stimulate bone formation in culture from mesenchymal stem cells, using 19k gene microarrays as well as 101 gene arrays specific for osteoblast and endothelial biology.
   The current studies show that by altering the shape of the matrix a cell response ( genomic pro. le) similar to that achieved with chemical stimulation can be elicited. Here, we show that bone formation can be achieved with efficiency similar to that of dexamethasone with the added benefit that endothelial cell development is not inhibited. We further show that the mechanism of action of the topographies and dexamethasone differs. This could have an implication for tissue engineering in which a simultaneous, targeted, development of a tissue, such as bone, without the suppression of angiogenesis to supply nutrients to the new tissue is required. The results further demonstrate that perhaps the shape of the extracellular matrix is critical to tissue development.
C1 [Dalby, Matthew J.; Andar, Abhay; Nag, Abhijit] Univ Glasgow, Inst Biomed & Life Sci, Ctr Cell Engn, Glasgow G12 8QQ, Lanark, Scotland.
   [Affrossman, Stanley] Univ Strathclyde, Dept Pure & Appl Chem, Glasgow G1 1XL, Lanark, Scotland.
   [Tare, Rahul; Oreffo, Richard O. C.] Univ Southampton, Inst Dev Sci, Ctr Human Dev Stem Cells & Regenerat, Bone & Joint Res Grp, Southampton SO16 6YD, Hants, England.
   [McFarlane, Sara] Univ Glasgow, Dept Elect & Elect Engn, Ctr Cell Engn, Glasgow G12 8QQ, Lanark, Scotland.
C3 University of Glasgow; University of Strathclyde; University of
   Southampton; University of Glasgow
RP Dalby, MJ (通讯作者)，Univ Glasgow, Inst Biomed & Life Sci, Ctr Cell Engn, Joseph Black Bldg, Glasgow G12 8QQ, Lanark, Scotland.
EM m.dalby@bio.gla.ac.uk
RI ; Oreffo, Richard/A 4615 2011; Dalby, Matthew/G 2426 2012
OI Andar, Abhay/0000 0001 6647 7870; Oreffo, Richard/0000 0001 5995 6726;
   Tare, Rahul/0000 0001 8274 8837; Dalby, Matthew/0000 0002 0528 3359; 
FU Biotechnology and Biological Sciences Research Council [JF20604] Funding
   Source: researchfish; Biotechnology and Biological Sciences Research
   Council [JF20604] Funding Source: Medline; Wellcome Trust Funding
   Source: Medline
CR Andersson AS, 2003, IEEE T NANOBIOSCI, V2, P49, DOI 10.1109/TNB.2003.813934
   Andersson AS, 2003, EXP CELL RES, V288, P177, DOI 10.1016/S0014 4827(03)00159 9
   Andersson AS, 2003, BIOMATERIALS, V24, P3427, DOI 10.1016/S0142 9612(03)00208 4
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19 3 180
   Bianco P, 2001, NATURE, V414, P118, DOI 10.1038/35102181
   Breitling R, 2004, FEBS LETT, V573, P83, DOI 10.1016/j.febslet.2004.07.055
   Brown RA, 1998, J CELL PHYSIOL, V175, P323, DOI 10.1002/(SICI)1097 4652(199806)175:3<323::AID JCP10>3.0.CO;2 6
   Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463
   CLARK P, 1990, DEVELOPMENT, V108, P635
   CLARK P, 1991, J CELL SCI, V99, P73
   CLARK P, 1987, DEVELOPMENT, V99, P439
   Cook R, 2007, CELL MOL IMMUNOL, V4, P253
   Curtis A, 2001, TRENDS BIOTECHNOL, V19, P97, DOI 10.1016/S0167 7799(00)01536 5
   CURTIS ASG, 1964, JNCI J NATL CANCER I, V33, P15
   Dai Z, 2007, PHYTOMEDICINE, V14, P806, DOI 10.1016/j.phymed.2007.04.003
   Dalby MJ, 2007, J CELL BIOCHEM, V102, P1234, DOI 10.1002/jcb.21354
   Dalby MJ, 2007, J CELL BIOCHEM, V100, P326, DOI 10.1002/jcb.21058
   Dalby MJ, 2002, TISSUE ENG, V8, P1099, DOI 10.1089/107632702320934191
   Dalby MJ, 2006, BIOMATERIALS, V27, P2980, DOI 10.1016/j.biomaterials.2006.01.010
   Dalby MJ, 2006, BIOMATERIALS, V27, P1306, DOI 10.1016/j.biomaterials.2005.08.028
   Dalby MJ, 2004, INT J BIOCHEM CELL B, V36, P2005, DOI 10.1016/j.biocel.2004.03.001
   Dalby MJ, 2004, BIOMATERIALS, V25, P5415, DOI 10.1016/j.biomaterials.2003.12.049
   Dalby MJ, 2004, J BIOMED MATER RES A, V69A, P314, DOI 10.1002/jbm.a.20138
   Dalby MJ, 2004, CELL BIOL INT, V28, P229, DOI 10.1016/j.cellbi.2003.12.004
   Dalby MJ, 2003, EXP CELL RES, V284, P274, DOI 10.1016/S0014 4827(02)00053 8
   Dalby MJ, 2002, BIOMATERIALS, V23, P2945, DOI 10.1016/S0142 9612(01)00424 0
   Diehn M, 2003, NUCLEIC ACIDS RES, V31, P219, DOI 10.1093/nar/gkg014
   Eastwood M, 1998, P I MECH ENG H, V212, P85, DOI 10.1243/0954411981533854
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Engler AJ, 2004, J CELL BIOL, V166, P877, DOI 10.1083/jcb.200405004
   FRIEDENSTEIN AJ, 1976, INT REV CYTOL, V47, P327, DOI 10.1016/S0074 7696(08)60092 3
   Gadegaard N, 2003, MACROMOL MATER ENG, V288, P76, DOI 10.1002/mame.200290037
   GETZENBERG RH, 1994, J CELL BIOCHEM, V55, P22, DOI 10.1002/jcb.240550105
   Guilak F, 1995, J BIOMECH, V28, P1529, DOI 10.1016/0021 9290(95)00100 X
   HARRIS AK, 1981, NATURE, V290, P249, DOI 10.1038/290249a0
   Hart A, 2007, J MATER SCI MATER M, V18, P1211, DOI 10.1007/s10856 007 0157 7
   Howard D, 2002, BIOCHEM BIOPH RES CO, V299, P208, DOI 10.1016/S0006 291X(02)02561 5
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   Mirmalek Sani SH, 2006, STEM CELLS, V24, P1042, DOI 10.1634/stemcells.2005 0368
   Oreffo ROC, 2005, STEM CELL REV, V1, P169, DOI 10.1385/SCR:1:2:169
   Oreffo ROC, 1998, CLIN SCI, V94, P549, DOI 10.1042/cs0940549
   Rajnicek AM, 1997, J CELL SCI, V110, P2905
   Rajnicek AM, 1997, J CELL SCI, V110, P2915
   Ruiz C, 2007, J BONE MINER METAB, V25, P286, DOI 10.1007/s00774 007 0767 7
   STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424
   TRIFFITT JT, 1998, ADV ORGAN BIOL MOL C, P475
   WEISS P, 1952, P NATL ACAD SCI USA, V38, P264, DOI 10.1073/pnas.38.3.264
   Wilkie AOM, 2005, CYTOKINE GROWTH F R, V16, P187, DOI 10.1016/j.cytogfr.2005.03.001
   WOJCIAKSTOTHARD B, 1995, CELL BIOL INT, V19, P485, DOI 10.1006/cbir.1995.1092
   WojciakStothard B, 1996, EXP CELL RES, V223, P426, DOI 10.1006/excr.1996.0098
   Yang XB, 2003, J BONE MINER RES, V18, P47, DOI 10.1359/jbmr.2003.18.1.47
NR 52
TC 83
Z9 94
U1 0
U2 32
PU ROYAL SOC
PI LONDON
PA 6 9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 1742 5689
EI 1742 5662
J9 J R SOC INTERFACE
JI J. R. Soc. Interface
PD SEP 6
PY 2008
VL 5
IS 26
BP 1055
EP 1065
DI 10.1098/rsif.2008.0016
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 327WU
UT WOS:000257760000008
PM 18270147
OA Green Published
DA 2025 08 17
ER

PT J
AU Di Bartolo, BA
   Kavurma, MM
AF Di Bartolo, Belinda A.
   Kavurma, Mary M.
TI Regulation and Function of Rankl in Arterial Calcification
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Receptor activator of nuclear factor kappa B ligand (RANKL);
   osteoprotegerin (OPG); tumour necrosis factor related apoptosis inducing
   ligand (TRAIL); arterial calcification
ID KAPPA B LIGAND; APOPTOSIS INDUCING LIGAND; INHIBITS VASCULAR
   CALCIFICATION; SERUM OSTEOPROTEGERIN LEVELS; ACTIVATED T LYMPHOCYTES;
   CHRONIC KIDNEY DISEASE; BONE MARROW CULTURES; MATRIX GLA PROTEIN;
   RECEPTOR ACTIVATOR; OSTEOCLAST DIFFERENTIATION
AB Receptor activator of nuclear factor kappa B ligand (RANKL) is a member of the tumour necrosis factor family important in bone remodelling. Recent evidence suggest that calcification in the vessel wall is equivalent to mechanisms mediating bone formation. This review highlights the role of RANKL in vascular arterial calcification. Here, the relationship between RANKL, osteoprotegerin (OPG) and tumour necrosis factor related apoptosis inducing ligand (TRAIL) is discussed. Furthermore, we focus on the regulatory mechanisms mediating RANKL gene expression and transcription in cells of the vessel wall. A better understanding of RANKL mediated signalling may help develop more sophisticated cell based therapies to inhibit calcification of the vessel wall.
C1 [Di Bartolo, Belinda A.] Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2052, Australia.
   [Kavurma, Mary M.] Heart Res Inst, Sydney, NSW 2042, Australia.
   [Kavurma, Mary M.] Univ Sydney, Sydney, NSW 2006, Australia.
C3 University of New South Wales Sydney; University of Sydney; Heart
   Research Institute; University of Sydney
RP Kavurma, MM (通讯作者)，Heart Res Inst, Sydney, NSW 2042, Australia.
EM mary.kavurma@hri.org.au
RI Di Bartolo, Belinda/AAF 5153 2021
OI Kavurma, Mary/0000 0001 7353 0932; Di Bartolo,
   Belinda/0000 0001 8420 0461
FU National Health and Medical Research Council; National Heart Foundation
   of Australia
FX BAD is supported by a National Health and Medical Research Council Early
   Career Training Fellowship MMK is supported by a National Heart
   Foundation of Australia Career Development Fellowship.
CR Allison MA, 2012, ARTERIOSCL THROM VAS, V32, P140, DOI 10.1161/ATVBAHA.111.235234
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Arad Y, 2005, J AM COLL CARDIOL, V46, P158, DOI 10.1016/j.jacc.2005.02.088
   Azahri NSM, 2013, CELL MOL LIFE SCI, V70, P3617, DOI 10.1007/s00018 013 1264 x
   Bishop KA, 2011, J BIOL CHEM, V286, P20880, DOI 10.1074/jbc.M111.231548
   Blaschke F, 2004, REV ENDOCR METAB DIS, V5, P249, DOI 10.1023/B:REMD.0000032413.88756.ee
   Braam LAJLM, 2000, ARTERIOSCL THROM VAS, V20, P1257, DOI 10.1161/01.ATV.20.5.1257
   Browner WS, 2001, J CLIN ENDOCR METAB, V86, P631, DOI 10.1210/jc.86.2.631
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Byon CH, 2008, J BIOL CHEM, V283, P15319, DOI 10.1074/jbc.M800021200
   Byon CH, 2011, ARTERIOSCL THROM VAS, V31, P1387, DOI 10.1161/ATVBAHA.110.222547
   Callegari A, 2013, ARTERIOSCL THROM VAS, V33, P2491, DOI 10.1161/ATVBAHA.113.301755
   Chasseraud M, 2011, THER APHER DIAL, V15, P140, DOI 10.1111/j.1744 9987.2010.00886.x
   Chen NX, 2012, CURR HYPERTENS REP, V14, P228, DOI 10.1007/s11906 012 0265 8
   Collin Osdoby P, 2004, CIRC RES, V95, P1046, DOI 10.1161/01.RES.0000149165.99974.12
   Collin Osdoby P, 2001, J BIOL CHEM, V276, P20659, DOI 10.1074/jbc.M010153200
   Cosson E, 2009, DIABETES METAB, V35, P364, DOI 10.1016/j.diabet.2009.02.007
   Demer LL, 2008, CIRCULATION, V117, P2938, DOI 10.1161/CIRCULATIONAHA.107.743161
   Deuell KA, 2012, J VASC RES, V49, P510, DOI 10.1159/000341216
   Dhore CR, 2001, ARTERIOSCL THROM VAS, V21, P1998, DOI 10.1161/hq1201.100229
   Di Bartolo BA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074211
   Doherty TM, 2003, P NATL ACAD SCI USA, V100, P11201, DOI 10.1073/pnas.1932554100
   Fionda C, 2007, J IMMUNOL, V178, P4039, DOI 10.4049/jimmunol.178.7.4039
   FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092 8674(95)90193 0
   Fu Q, 2002, J BIOL CHEM, V277, P48868, DOI 10.1074/jbc.M208494200
   Grainger DJ, 2007, CARDIOVASC RES, V74, P213, DOI 10.1016/j.cardiores.2007.02.022
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Guerrini MM, 2008, AM J HUM GENET, V83, P64, DOI 10.1016/j.ajhg.2008.06.015
   Guzman RJ, 2007, J VASC SURG, V45, p57A, DOI 10.1016/j.jvs.2007.02.049
   Harith HH, 2013, TRENDS ENDOCRIN MET, V24, P578, DOI 10.1016/j.tem.2013.07.001
   Helas S, 2009, AM J PATHOL, V175, P473, DOI 10.2353/ajpath.2009.080957
   Hikita A, 2006, J BIOL CHEM, V281, P36846, DOI 10.1074/jbc.M606656200
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Horwood NJ, 1999, BIOCHEM BIOPH RES CO, V265, P144, DOI 10.1006/bbrc.1999.1623
   Hruska KA, 2005, CIRC RES, V97, P105, DOI 10.1161/01.RES.00000175571.53833.6c
   Iribarren C, 2000, JAMA J AM MED ASSOC, V283, P2810, DOI 10.1001/jama.283.21.2810
   Ishida A, 2002, J BIOL CHEM, V277, P26217, DOI 10.1074/jbc.M111093200
   Itoh K, 2000, J BONE MINER RES, V15, P1766, DOI 10.1359/jbmr.2000.15.9.1766
   Jono S, 2002, CIRCULATION, V106, P1192, DOI 10.1161/01.CIR.0000031524.49139.29
   Ju JH, 2008, J IMMUNOL, V181, P1507, DOI 10.4049/jimmunol.181.2.1507
   Kanematsu M, 2000, J BONE MINER RES, V15, P1321, DOI 10.1359/jbmr.2000.15.7.1321
   Kavurma MM, 2008, BIOCHEM PHARMACOL, V75, P1441, DOI 10.1016/j.bcp.2007.10.020
   Kiel DP, 2001, CALCIFIED TISSUE INT, V68, P271, DOI 10.1007/BF02390833
   Kim HH, 2003, FASEB J, V17, P2163, DOI 10.1096/fj.03 0215fje
   Kim S, 2007, MOL ENDOCRINOL, V21, P197, DOI 10.1210/me.2006 0315
   Kim YM, 2002, J BIOL CHEM, V277, P6799, DOI 10.1074/jbc.M109434200
   Kitazawa R, 1999, BBA GENE STRUCT EXPR, V1445, P134, DOI 10.1016/S0167 4781(99)00032 9
   Kitazawa R, 2008, J CELL BIOCHEM, V105, P1289, DOI 10.1002/jcb.21929
   Kitazawa S, 2003, J CELL BIOCHEM, V89, P771, DOI 10.1002/jcb.10567
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kovacic JC, 2012, JACC CARDIOVASC IMAG, V5, P367, DOI 10.1016/j.jcmg.2012.02.006
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee SK, 1999, ENDOCRINOLOGY, V140, P3552, DOI 10.1210/en.140.8.3552
   Liu CZ, 2010, J IMMUNOL, V184, P6910, DOI 10.4049/jimmunol.0904033
   Liu X, 2007, BIOCHEM BIOPH RES CO, V358, P18, DOI 10.1016/j.bbrc.2007.03.209
   Luan XD, 2012, J IMMUNOL, V189, P245, DOI 10.4049/jimmunol.1103387
   Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613
   Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0
   Ma RF, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471 2474 13 154
   Min H, 2000, J EXP MED, V192, P463, DOI 10.1084/jem.192.4.463
   Min JK, 2007, BLOOD, V109, P1495, DOI 10.1182/blood 2006 06 029298
   Min JK, 2005, J IMMUNOL, V175, P531, DOI 10.4049/jimmunol.175.1.531
   Mizobuchi M, 2009, J AM SOC NEPHROL, V20, P1453, DOI 10.1681/ASN.2008070692
   Mochizuki A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048795
   Mody N, 2003, J NUCL CARDIOL, V10, P177, DOI 10.1067/mnc.2003.0012
   Moe SM, 2008, J AM SOC NEPHROL, V19, P213, DOI 10.1681/ASN.2007080854
   Moe SM, 2003, PEDIATR NEPHROL, V18, P969, DOI 10.1007/s00467 003 1276 0
   Montagnana M, 2013, ANN MED, V45, P254, DOI 10.3109/07853890.2012.727019
   Morony S, 2012, CALCIFIED TISSUE INT, V91, P379, DOI 10.1007/s00223 012 9655 9
   Morony S, 2008, CIRCULATION, V117, P411, DOI 10.1161/CIRCULATIONAHA.107.707380
   Mosheimer BA, 2004, ARTHRITIS RHEUM US, V50, P2309, DOI 10.1002/art.20352
   Nagai M, 2000, BIOCHEM BIOPH RES CO, V269, P532, DOI 10.1006/bbrc.2000.2314
   Ndip A, 2011, DIABETES, V60, P2187, DOI 10.2337/db10 1220
   Nukaga J, 2004, J PERIODONTOL, V75, P249, DOI 10.1902/jop.2004.75.2.249
   O'Brien CA, 1999, J BIOL CHEM, V274, P19301, DOI 10.1074/jbc.274.27.19301
   O'Brien CA, 2010, BONE, V46, P911, DOI 10.1016/j.bone.2009.08.050
   Okada T, 2003, CLIN EXP METASTAS, V20, P639, DOI 10.1023/A:1027362507683
   Osako MK, 2010, CIRC RES, V107, P466, DOI 10.1161/CIRCRESAHA.110.216846
   Page G, 2005, ARTHRITIS RHEUM US, V52, P2307, DOI 10.1002/art.21211
   Panizo S, 2009, CIRC RES, V104, P1041, DOI 10.1161/CIRCRESAHA.108.189001
   Park H, 2005, EXP MOL MED, V37, P524, DOI 10.1038/emm.2005.65
   Roccisana JL, 2004, J BIOL CHEM, V279, P10500, DOI 10.1074/jbc.M303727200
   Rucci N, 2008, CLIN CASES MINER BON, V5, P49
   Sandberg WJ, 2006, ARTERIOSCL THROM VAS, V26, P857, DOI 10.1161/01.ATV.0000204334.48195.6a
   Sattler AM, 2004, CALCIFIED TISSUE INT, V74, P103, DOI 10.1007/s00223 003 0011 y
   Schoppet M, 2004, J CLIN ENDOCR METAB, V89, P4104, DOI 10.1210/jc.2003 031432
   Schoppet M, 2003, CIRCULATION, V107, pE76, DOI 10.1161/01.CIR.0000060815.25798.02
   Schoppet M, 2003, J CLIN ENDOCR METAB, V88, P1024, DOI 10.1210/jc.2002 020775
   Schoppet M, 2002, ARTERIOSCL THROM VAS, V22, P549, DOI 10.1161/01.ATV.0000012303.37971.DA
   Seno T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025541
   Shao JS, 2005, J CLIN INVEST, V115, P1210, DOI 10.1172/JCI200524140
   Siddappa R, 2009, TISSUE ENG PT A, V15, P2135, DOI 10.1089/ten.tea.2008.0512
   Snell Bergeon JK, 2013, CURR DIABETES REP, V13, P391, DOI 10.1007/s11892 013 0379 7
   Sobacchi C, 2007, NAT GENET, V39, P960, DOI 10.1038/ng2076
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   SUDA T, 1995, BONE, V17, pS87, DOI 10.1016/8756 3282(95)00185 G
   Swanson C, 2006, ENDOCRINOLOGY, V147, P3613, DOI 10.1210/en.2005 0717
   TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo 122 4 1373
   Takayanagi H, 2012, NAT REV RHEUMATOL, V8, P684, DOI 10.1038/nrrheum.2012.167
   Thomas SR, 2008, ANTIOXID REDOX SIGN, V10, P1713, DOI 10.1089/ars.2008.2027
   Tseng W, 2010, J BIOL CHEM, V285, P29925, DOI 10.1074/jbc.M110.117366
   Tsuda E, 1997, BIOCHEM BIOPH RES CO, V234, P137, DOI 10.1006/bbrc.1997.6603
   Tyson KL, 2003, ARTERIOSCL THROM VAS, V23, P489, DOI 10.1161/01.ATV.0000059406.92165.31
   Udagawa N, 1999, BONE, V25, P517, DOI 10.1016/S8756 3282(99)00210 0
   Van Campenhout A, 2009, ATHEROSCLEROSIS, V204, P321, DOI 10.1016/j.atherosclerosis.2008.09.033
   Walsh NC, 2013, GENES IMMUN, V14, P336, DOI 10.1038/gene.2013.29
   Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074 7613(95)90057 8
   Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yen ML, 2008, MOL IMMUNOL, V45, P2205, DOI 10.1016/j.molimm.2007.12.003
   Yen ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038048
   Yuan LQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029037
NR 113
TC 5
Z9 5
U1 0
U2 1
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381 6128
EI 1873 4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2014
VL 20
IS 37
BP 5853
EP 5861
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA AP3YZ
UT WOS:000342015200008
PM 24533935
DA 2025 08 17
ER

PT J
AU Bao, CM
   Liu, YQ
   Sun, X
   Xing, CC
   Zeng, LT
   Sun, GC
AF Bao, Chunmei
   Liu, Yingqin
   Sun, Xin
   Xing, Congcong
   Zeng, Luting
   Sun, Guangchen
TI Periploca forrestii saponin ameliorates CIA via suppressing
   proinflammatory cytokines and nuclear factor kappa B pathways
SO PLOS ONE
LA English
DT Article
ID COLLAGEN INDUCED ARTHRITIS; CANCER IN VITRO; CHEMICAL CONSTITUENTS;
   TISSUE HOMEOSTASIS; ANTITUMOR FRACTION; BONE DESTRUCTION; CATHEPSIN K;
   INFLAMMATION; EXPRESSION; OSTEOCLASTOGENESIS
AB Objective
   Periploca forrestii Schltr has been used as a Chinese folk medicine for the treatment of rheumatism, arthralgia and fractures. However, the anti arthritic activity of Periploca forrestii saponin (PFS) and the active compound has still not been revealed. This study aimed to investigate the protective effects and mechanisms of PFS on collagen type II (CII) collageninduced arthritis (CIA) mice. We sought to investigate whether PFS and Periplocin could regulate osteoclastogenesis, and if so, further investigation on its mechanism of action.
   Methods
   Arthritis was induced in female BALB/c mice by CIA method. PFS was administered at a dose of 50 mg/kg body weight once daily for five weeks. The effects of treatment in mice were assessed by histological and biochemical evaluation in sera and paws. Anti osteoclastogenic action of PFS and Periplocin was identified using an osteoclast formation model induced by RANKL.
   Results
   PFS ameliorated paw erythema and swelling, inhibited bone erosion in ankle joint histopathological examination. PFS treatment resulted in decreased IgG2a, and increased IgG1 levels in the serum of CIA mice. Decreased TNF alpha, and increased interleukin (IL) 4 and IL 22 levels were also found in PFS treated mice. PFS inhibited the I kappa B alpha phosphorylation, blocked nuclear factor (NF) kappa B/p65 phosphorylation and abrogated AP 1/c Fos activity. PFS downregulated toll like receptor (TLR) 4, STAT3 and MMP 9 expression in CIA mice and RANKL induced osteoclastogenesis. PFS and Periplocin inhibited RANKL induced osteoclast formation in a dose dependent manner within nongrowth inhibitory concentration, and PFS decreased osteoclastogenesis related marker expression, including cathepsin K and MMP 9.
   Conclusion
   This study revealed that the protective mechanism of PFS on CIA was associated with regulatory effects on proinflammatory factors and further on the crosstalk between NF kappa B and cFos/AP 1 in vivo and in vitro. Therefore, PFS is a promising therapeutic alternative for the treatment of RA, evidencing the need to conduct further studies that can identify their active components in treating and preventing RA.
C1 [Bao, Chunmei] Guilin Med Univ, Dept Nephrol, Guilin, Guangxi, Peoples R China.
   [Liu, Yingqin] Guilin Med Univ, Biotechnol Coll, Guilin, Guangxi, Peoples R China.
   [Sun, Xin] Xiamen Univ, Coll Med, Xiamen, Fujian, Peoples R China.
   [Xing, Congcong; Zeng, Luting; Sun, Guangchen] Guilin Med Univ, Coll Pharm, Guilin, Guangxi, Peoples R China.
C3 Guilin Medical University; Guilin Medical University; Xiamen University;
   Guilin Medical University
RP Sun, GC (通讯作者)，Guilin Med Univ, Coll Pharm, Guilin, Guangxi, Peoples R China.
EM sungc@gimaedu.cn
RI Sun, Guangchen/ABI 7533 2020
OI SUN, XIN/0000 0002 0234 3571; Sun, Guangchen/0000 0001 8266 6014
FU National Natural Science Foundation of China [81260462, 81460474];
   Nature Science Foundation of Guangxi Province [2015GXNFAA139104]
FX The study was supported by the grants of National Natural Science
   Foundation of China (81260462 and 81460474;
   https://isisn.nsfc.gov.cn/egrantweb/) and Nature Science Foundation of
   Guangxi Province (2015GXNFAA139104;
   http://gxnsf.gxsti.net/stms/login.jsp). The funding bodies were not
   involved in any aspects of the study. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aikawa Y, 2008, NAT BIOTECHNOL, V26, P817, DOI 10.1038/nbt1412
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Bevaart L, 2010, METHODS MOL BIOL, V602, P181, DOI 10.1007/978 1 60761 058 8_11
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   Brennan FM, 2008, J CLIN INVEST, V118, P3537, DOI 10.1172/JCI36389
   Camps M, 2005, NAT MED, V11, P936, DOI 10.1038/nm1284
   Cheng CF, 2013, EVID BASED COMPL ALT, V2013, DOI [10.1155/2013/613950, 10.1155/2013/958025]
   Dudler J, 2000, ANN RHEUM DIS, V59, P529, DOI 10.1136/ard.59.7.529
   Feldmann M, 2003, NAT MED, V9, P1245, DOI 10.1038/nm939
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020
   Heilpern AJ, 2009, INFECT IMMUN, V77, P2643, DOI 10.1128/IAI.00214 09
   Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914
   Hou WS, 2001, AM J PATHOL, V159, P2167, DOI 10.1016/S0002 9440(10)63068 4
   Imboden JB, 2009, ANNU REV PATHOL MECH, V4, P417, DOI 10.1146/annurev.pathol.4.110807.092254
   ITOKAWA H, 1988, CHEM PHARM BULL, V36, P4441
   ITOKAWA H, 1987, CHEM PHARM BULL, V35, P4524
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Joosten LAB, 1999, ARTHRITIS RES, V1, P81, DOI 10.1186/ar14
   Joung YH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159891
   Justa S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093279
   Kiyeko GW, 2016, EUR J IMMUNOL, V46, P2629, DOI 10.1002/eji.201646453
   KNIGHT B, 1992, CLIN EXP IMMUNOL, V90, P459
   Kumar A, 2004, J MOL MED, V82, P434, DOI 10.1007/s00109 004 0555 y
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Leibbrandt A, 2008, ANN NY ACAD SCI, V1143, P123, DOI 10.1196/annals.1443.016
   Liu YQ, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/7941684
   Lu ZJ, 2010, CELL PHYSIOL BIOCHEM, V26, P609, DOI 10.1159/000322328
   Morko J, 2005, ARTHRITIS RHEUM US, V52, P3713, DOI 10.1002/art.21423
   Mukherjee P, 2003, ANN RHEUM DIS, V62, P707, DOI 10.1136/ard.62.8.707
   Murphy G, 2002, ARTHRITIS RES THER, V4, DOI 10.1186/ar572
   Pasparakis M, 2009, NAT REV IMMUNOL, V9, P778, DOI 10.1038/nri2655
   Salminen Mankonen HJ, 2007, CURR DRUG TARGETS, V8, P315, DOI 10.2174/138945007779940188
   Sarkar S, 2013, ARTHRITIS RHEUM US, V65, P960, DOI 10.1002/art.37849
   Son DJ, 2016, SCI REP UK, V6, DOI 10.1038/srep36852
   Sonnenberg GF, 2011, NAT IMMUNOL, V12, P383, DOI 10.1038/ni.2025
   Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003
   van den Berg Wim B., 2007, V136, P243
   VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang Jin, 2009, Zhongguo Zhong Yao Za Zhi, V34, P3214
   WILLIAMS RO, 1992, P NATL ACAD SCI USA, V89, P9784, DOI 10.1073/pnas.89.20.9784
   Xu Ran, 2012, Zhongguo Zhong Yao Za Zhi, V37, P2286
   Zhao LM, 2010, ONCOL REP, V24, P375, DOI 10.3892/or_00000870
NR 46
TC 8
Z9 10
U1 2
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAY 2
PY 2017
VL 12
IS 5
AR e0176672
DI 10.1371/journal.pone.0176672
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA ET9RV
UT WOS:000400646300041
PM 28463993
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Yin, ZY
   Cheng, QH
   Wang, C
   Hu, Q
   Yin, J
   Wang, B
AF Yin, Zhaoyang
   Cheng, Qinghua
   Wang, Chao
   Hu, Qin
   Yin, Jian
   Wang, Bin
TI Apelin 13 alleviates osteoclast formation and osteolysis through
   Nrf2 pyroptosis pathway
SO MICROSCOPY RESEARCH AND TECHNIQUE
LA English
DT Article
DE apelin 13; NLRP3; Nrf2; periprosthetic osteolysis; pyroptosis
ID TOTAL HIP
AB Wear particle induced periprosthetic osteolysis is the key to aseptic loosening after artificial joint replacement. Osteoclastogenesis plays a central role in this process. Apelin 13 is a member of the adipokine family with anti inflammatory effects. Here, we report that apelin 13 alleviates RANKL mediated osteoclast differentiation and titanium particle induced osteolysis in mouse calvaria. Mechanistically, apelin 13 inhibits NLRP3 inflammasome mediated pyroptosis by activating the nuclear factor erythroid 2 related factor 2 (Nrf2) pathway. In summary, apelin 13 is expected to be a potential drug for relieving aseptic osteolysis.Research Highlights This study reveals the molecular mechanism by which apelin 13 inhibits NLRP3 inflammasome activation and pyroptosis by promoting Nrf2. This study confirms that apelin 13 alleviates osteoclast activation by inhibiting pyroptosis. In vivo studies further confirmed that apelin 13 alleviated mouse skull osteolysis by inhibiting the activation of NLRP3 inflammasome.
   Apelin 13 alleviates Ti particle induced osteoclast activation and osteolysis by inhibiting the Nrf2 pyroptosis pathway. image
C1 [Yin, Zhaoyang] Xuzhou Med Univ, Affiliated Lianyungang Hosp, Peoples Hosp Lianyungang 1, Dept Orthoped, Lianyungang, Peoples R China.
   [Cheng, Qinghua] Southeast Univ, Nanjing Lishui Peoples Hosp, Zhongda Hosp, Dept Orthoped,Lishui Branch, Nanjing, Peoples R China.
   [Wang, Chao; Hu, Qin; Yin, Jian; Wang, Bin] Nanjing Med Univ, Affiliated Jiangning Hosp, Dept Orthoped, Nanjing, Peoples R China.
   [Yin, Jian; Wang, Bin] Nanjing Med Univ, Affiliated Jiangning Hosp, Dept Orthoped, Nanjing 211100, Peoples R China.
C3 Xuzhou Medical University; Southeast University   China; Nanjing Medical
   University; Nanjing Medical University
RP Yin, J; Wang, B (通讯作者)，Nanjing Med Univ, Affiliated Jiangning Hosp, Dept Orthoped, Nanjing 211100, Peoples R China.
EM yinjiandoc@njmu.edu.cn; wangbin2495@163.com
RI Yin, Zhaoyang/LBH 6965 2024; Yin, Jian/JBN 1938 2023
FU Jiangsu Provincial Health Commission Scientific Research Project;
   Nanjing Health Science and Technology Development Special Fund Project
   [ZKX22061, YKK22222]; Jiangsu Medical Vocational College Clinical
   Teaching Base Special Scientific Research Development Fund [20229103];
   Jiangsu College of Health Vocational College level Scientific Research
   Project [JKC2022052]; Nanjing Medical University Kangda College
   Scientific Research Development Fund [KD2023KYJJ242]; Key Projects of
   Youth Innovation and Scientific Research Fund of the Affiliated
   Jiangning Hospital with Nanjing Medical University [JNYYZXKY202201];
   Science Foundation of Nanjing Lishui People's Hospital, Zhongda Hospital
   Lishui Branch, Southeast of University [LY202104]; Lianyungang "521
   Scientific Research" Project [LYG06521202380];  [Z2022086]
FX This work was supported by Jiangsu Provincial Health Commission
   Scientific Research Project (No. LGY2020052, 2022 208) and Jiangsu
   Provincial Health Commission Scientific Research Project (No. Z2022086),
   Nanjing Health Science and Technology Development Special Fund Project
   (No. ZKX22061 and YKK22222), Jiangsu Medical Vocational College Clinical
   Teaching Base Special Scientific Research Development Fund (Key Project,
   No. 20229103), Jiangsu College of Health Vocational College level
   Scientific Research Project (No. JKC2022052), Nanjing Medical University
   Kangda College Scientific Research Development Fund (No. KD2023KYJJ242).
   The Key Projects of Youth Innovation and Scientific Research Fund of the
   Affiliated Jiangning Hospital with Nanjing Medical University (No.
   JNYYZXKY202201), Science Foundation of Nanjing Lishui People's Hospital,
   Zhongda Hospital Lishui Branch, Southeast of University (No. LY202104)
   and Lianyungang "521 Scientific Research" Project (No. LYG06521202380).
CR Buendia I, 2016, PHARMACOL THERAPEUT, V157, P84, DOI 10.1016/j.pharmthera.2015.11.003
   Chen B, 2023, NEUROCHEM RES, V48, P1504, DOI 10.1007/s11064 022 03844 1
   Chen DL, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.664836
   Cheng YJ, 2020, INT IMMUNOPHARMACOL, V79, DOI 10.1016/j.intimp.2019.106180
   Duan JL, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974 019 1406 7
   Dupaix John P, 2019, Hawaii J Health Soc Welf, V78, P47
   Gong G, 2023, INT IMMUNOPHARMACOL, V117, DOI 10.1016/j.intimp.2023.109991
   He MY, 2023, J CONTROL RELEASE, V356, P623, DOI 10.1016/j.jconrel.2023.02.040
   Hsu TW, 2019, J CLIN MED, V8, DOI 10.3390/jcm8070932
   Kandahari AM, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.14
   Kremers HM, 2015, J BONE JOINT SURG AM, V97A, P1386, DOI 10.2106/JBJS.N.01141
   Liu ZY, 2023, INT IMMUNOPHARMACOL, V118, DOI 10.1016/j.intimp.2023.110103
   Nyström A, 2020, J BONE MINER RES, V35, P239, DOI 10.1002/jbmr.3883
   Pagliaro P, 2023, ANTIOXIDANTS BASEL, V12, DOI 10.3390/antiox12071396
   Pan BQ, 2023, BIOACT MATER, V26, P181, DOI 10.1016/j.bioactmat.2023.02.028
   Qin A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034132
   Tu WJ, 2019, AGING DIS, V10, P637, DOI 10.14336/AD.2018.0513
   Xian YS, 2021, BIOCHEM PHARMACOL, V193, DOI 10.1016/j.bcp.2021.114761
   Xing FZ, 2022, INT IMMUNOPHARMACOL, V112, DOI 10.1016/j.intimp.2022.109278
   Xu WL, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974 019 1620 3
   Xu Y, 2023, BIOMED PHARMACOTHER, V159, DOI 10.1016/j.biopha.2022.114101
   Yang JL, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00724
   Yin J, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12121733
   Yin J, 2022, FRONT CELL NEUROSCI, V16, DOI 10.3389/fncel.2022.949939
   Yuan YF, 2022, J INFLAMM RES, V15, P2121, DOI 10.2147/JIR.S348850
   Zhang HL, 2018, CELL PHYSIOL BIOCHEM, V49, P1918, DOI 10.1159/000493653
   Zhang P, 2020, BIOMED PHARMACOTHER, V128, DOI 10.1016/j.biopha.2020.110271
   Zhang Y, 2022, INT IMMUNOPHARMACOL, V107, DOI 10.1016/j.intimp.2022.108699
   Zhu C, 2017, BIOMED PHARMACOTHER, V88, P124, DOI 10.1016/j.biopha.2016.11.089
NR 29
TC 1
Z9 1
U1 4
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1059 910X
EI 1097 0029
J9 MICROSC RES TECHNIQ
JI Microsc. Res. Tech.
PD JUN
PY 2024
VL 87
IS 6
BP 1348
EP 1358
DI 10.1002/jemt.24519
EA FEB 2024
PG 11
WC Anatomy & Morphology; Biology; Microscopy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Anatomy & Morphology; Life Sciences & Biomedicine   Other Topics;
   Microscopy
GA OD2U5
UT WOS:001169234800001
PM 38380581
DA 2025 08 17
ER

PT J
AU Kikuta, J
   Iwai, K
   Saeki, Y
   Ishii, M
AF Kikuta, Junichi
   Iwai, Kaori
   Saeki, Yukihiko
   Ishii, Masaru
TI S1P targeted therapy for elderly rheumatoid arthritis patients with
   osteoporosis
SO RHEUMATOLOGY INTERNATIONAL
LA English
DT Article
DE Rheumatoid arthritis; Osteoporosis; Sphingosine 1 phosphate
ID COLLAGEN
AB Therapeutics targeting sphingosine 1 phosphate (S1P), a kind of lipid mediator regulating immune cell trafficking, has been emerging rapidly as a novel line of regimen for autoimmune diseases, including rheumatoid arthritis (RA). Here, we propose that S1P targeted therapy is beneficial not only for limiting inflammation but for preventing bone resorptive disorders, such as osteoporosis, by controlling the migratory behavior of osteoclast precursors and therefore would be good for treating elderly female RA patients who suffer from postmenopausal osteoporosis and arthritis simultaneously.
C1 [Kikuta, Junichi; Ishii, Masaru] Osaka Univ, WPI Immunol Frontier Res Ctr, Lab Biol Imaging, Suita, Osaka 5650871, Japan.
   [Kikuta, Junichi; Iwai, Kaori; Saeki, Yukihiko; Ishii, Masaru] Natl Osaka Minami Med Ctr, Dept Rheumatol & Clin Res, Osaka, Japan.
C3 University of Osaka
RP Ishii, M (通讯作者)，Osaka Univ, WPI Immunol Frontier Res Ctr, Lab Biol Imaging, 3 1 Yamada Oka, Suita, Osaka 5650871, Japan.
EM mishii@ifrec.osaka u.ac.jp
RI Kikuta, Junichi/HHS 8875 2022; Ishii, Masaru/D 2361 2009
FU Grants in Aid for Scientific Research [22689030, 22113007] Funding
   Source: KAKEN
CR Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713
   Japtok L, 2009, CURR OPIN INVEST DR, V10, P1183
   Kappos L, 2006, NEW ENGL J MED, V355, P1124, DOI 10.1056/NEJMoa052643
   Klauschen F, 2009, NAT PROTOC, V4, P1305, DOI 10.1038/nprot.2009.129
   Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238
   Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284
   Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650
   Sasai M, 1999, ARTHRITIS RHEUM, V42, P1635, DOI 10.1002/1529 0131(199908)42:8<1635::AID ANR11>3.0.CO;2 Q
   TERATO K, 1992, J IMMUNOL, V148, P2103
   van Vollenhoven RF, 2009, NAT REV RHEUMATOL, V5, P531, DOI 10.1038/nrrheum.2009.182
NR 10
TC 27
Z9 30
U1 0
U2 7
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 0172 8172
J9 RHEUMATOL INT
JI Rheumatol. Int.
PD JUL
PY 2011
VL 31
IS 7
BP 967
EP 969
DI 10.1007/s00296 010 1634 8
PG 3
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 782DD
UT WOS:000291986900022
PM 21113810
DA 2025 08 17
ER

PT J
AU Teng, MH
   Yuan, X
   Wang, DS
   Gao, H
   Zhang, KY
   Wang, WX
   Zhao, BD
AF Teng, Minhua
   Yuan, Xiao
   Wang, Dashan
   Gao, Hui
   Zhang, Kaiyue
   Wang, Wenxue
   Zhao, Baodong
TI 被撤回的出版物: Scutellarin Loaded on Ultradeformable Nanoliposome Scutellarin
   EDTMP (S UNL E) Promotes Osteogenesis in Osteoporotic Rats (Retracted
   Article)
SO STEM CELLS INTERNATIONAL
LA English
DT Article; Retracted Publication
ID APOPTOSIS; INJURY
AB Scutellarin is known as a safe, effective, and low cost traditional Chinese medicine and has a variety of biological activities. Studies reported that the scutellarin loaded on ultradeformable nanoliposome scutellarin EDTMP (S UNL E) could promote osteoblast differentiation and bone formation in vitro. However, its effect on promoting osteogenesis in vivo is still unclear. In this study, pharmacology network and transcriptome sequencing were used to screen the potential targets and pathways of scutellarin in treating osteoporosis. The female Sprague Dawley (SD) rats were operated on with bilateral oophorectomy and femoral defect to establish an osteoporosis model and then treated separately with bone dust, single scutellarin, 40 mg/kg ultradeformable nanoliposome scutellarin (S UNL), and the optimal concentration of 40 mg/kg S UNL E for a total of 56 d to detect the parameters of trabecular bones. And qRT PCR and western blot were performed to determine the expression of prostaglandin endoperoxide synthase 2 (PTGS2), alkaline phosphatase (ALP), transcription factor 4 (TCF4), and beta catenin. Results of microscopic computed tomography (Micro CT) of trabecular bones showed that single scutellarin, S UNL, and S UNL E all promoted the bone formation of osteoporotic rats, in which S UNL E manifested the most remarkable therapeutic effect. And it is found that 40 mg/kg of S UNL E increased the expression of PTGS2, ALP, TCF4, and beta catenin, which indicated that S UNL E stimulated the secretion of ALP in bone defect areas to promote bone healing, and increased PTGS2 expression thereby enhancing the transcription and translation of key gene beta catenin and TCF4 in the Wnt/beta catenin signaling pathway to treat osteoporotic rats.
C1 [Teng, Minhua; Wang, Dashan; Gao, Hui; Zhang, Kaiyue; Wang, Wenxue; Zhao, Baodong] Qingdao Univ, Affiliated Hosp, Dept Oral Implantol, Qingdao 266000, Peoples R China.
   [Teng, Minhua; Yuan, Xiao; Wang, Dashan; Gao, Hui; Zhang, Kaiyue; Wang, Wenxue; Zhao, Baodong] Qingdao Univ, Sch Stomatol, Qingdao 266003, Peoples R China.
   [Yuan, Xiao] Qingdao Univ, Affiliated Hosp, Dept Orthodont, Qingdao 266000, Peoples R China.
C3 Qingdao University; Qingdao University; Qingdao University
RP Teng, MH; Zhao, BD (通讯作者)，Qingdao Univ, Affiliated Hosp, Dept Oral Implantol, Qingdao 266000, Peoples R China.; Teng, MH; Zhao, BD (通讯作者)，Qingdao Univ, Sch Stomatol, Qingdao 266003, Peoples R China.
EM dentisteng@qdu.edu.cn; yuanxiaoqd@163.com; wdsapple@163.com;
   ghuiqdfy@qdu.edu.cn; 1045998697@qq.com; 1533819417@qq.com;
   zbd315@sina.com
RI Zhang, kaiyue/KGK 4161 2024
FU National Natural Science Foundation of China Youth Science Fund Project;
   Science and Technology Program of Traditional Chinese Medicine of
   Shandong Province; Qingdao Postdoctoral Researcher Applied Research
   Project;  [81800940];  [Q 2022118]
FX AcknowledgmentsThis study was supported by the National Natural Science
   Foundation of China Youth Science Fund Project (No. 81800940), Science
   and Technology Program of Traditional Chinese Medicine of Shandong
   Province (No. Q 2022118), and Qingdao Postdoctoral Researcher Applied
   Research Project.
CR Beheshtizadeh N, 2021, TISSUE CELL, V72, DOI 10.1016/j.tice.2021.101553
   Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166 4328(01)00297 2
   Feng YZ, 2012, LEUKEMIA LYMPHOMA, V53, P2456, DOI 10.3109/10428194.2012.693177
   Guañabens N, 2014, CURR OSTEOPOROS REP, V12, P90, DOI 10.1007/s11914 014 0197 0
   Guo H, 2011, CHINESE J PHYSIOL, V54, P399, DOI 10.4077/CJP.2011.AMM059
   Guo LL, 2013, EXP TOXICOL PATHOL, V65, P579, DOI 10.1016/j.etp.2012.05.003
   Kinoshita Y, 2016, ENDOCR J, V63, P479, DOI 10.1507/endocrj.EJ16 0003
   Lu LY, 2017, J ORTHOP RES, V35, P2378, DOI 10.1002/jor.23553
   Mishra D, 2013, J BIOMED MATER RES A, V101, P3646, DOI 10.1002/jbm.a.34642
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Mu YP, 2019, EUR J PHARMACOL, V842, P314, DOI 10.1016/j.ejphar.2018.10.051
   Qaseem A, 2017, ANN INTERN MED, V166, P818, DOI 10.7326/M15 1361
   Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb 2010 11 3 r25
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Salamanna F, 2016, HISTOL HISTOPATHOL, V31, P83, DOI 10.14670/HH 11 651
   Shen GY, 2020, EBIOMEDICINE, V52, DOI 10.1016/j.ebiom.2020.102626
   Simona AD, 2017, CURR PHARM DESIGN, V23, P2414, DOI 10.2174/1381612823666170220155540
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Teng MH, 2022, BIOENGINEERED, V13, P1013, DOI 10.1080/21655979.2021.2016095
   Wang F, 2016, J AGR FOOD CHEM, V64, P2875, DOI 10.1021/acs.jafc.5b06132
   Wang JT, 2018, GENE, V676, P29, DOI 10.1016/j.gene.2018.06.068
   Xu ZL, 2015, J MOL NEUROSCI, V56, P397, DOI 10.1007/s12031 015 0565 y
   Zhang QY, 2018, CHINESE MED J PEKING, V131, P2589, DOI 10.4103/0366 6999.244111
   Zhao S, 2016, INT IMMUNOPHARMACOL, V40, P458, DOI 10.1016/j.intimp.2016.09.031
   Zheng C, 2019, EUR REV MED PHARMACO, V23, P9721, DOI 10.26355/eurrev_201911_19534
   Zhu W, 2011, J BIOL CHEM, V286, P26794, DOI 10.1074/jbc.M111.250985
NR 26
TC 5
Z9 5
U1 1
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1687 966X
EI 1687 9678
J9 STEM CELLS INT
JI Stem Cells Int.
PD AUG 16
PY 2022
VL 2022
AR 1395299
DI 10.1155/2022/1395299
PG 10
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 4F3LV
UT WOS:000848416600002
PM 36017130
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Borke, JL
   McAllister, B
   Harris, T
   Neiberg, M
   Guevarra Toth, C
   Fulzele, S
   Stoianovici, C
   Guerra, C
AF Borke, James L.
   McAllister, Bennett
   Harris, Tiffenie
   Neiberg, Maryke
   Guevarra Toth, Chestine
   Fulzele, Sadanand
   Stoianovici, Charles
   Guerra, Carlos
TI Correlation of changes in the mandible and retina/choroid vasculature of
   a rat model of BRONJ
SO JOURNAL OF CRANIO MAXILLOFACIAL SURGERY
LA English
DT Article
DE Bisphosphonate; MRONJ; BRONJ; Choroid/retina
ID NITROGEN CONTAINING BISPHOSPHONATES; ANGIOGENESIS IN VITRO; ZOLEDRONIC
   ACID; ENDOTHELIAL CELLS; SIGNALING PATHWAYS; OSTEONECROSIS; BONE; JAWS;
   THERAPY; VIVO
AB Bisphosphonate related osteonecrosis of the jaw (BRONJ) causes bones of the mandible and maxilla to become necrotic and protrude into the oral cavity. Compromised blood supply to bone is also a feature of BRONJ. The design of this study was first to use our established technique of molar extraction and IV bisphosphonate injection to produce features of BRONJ in rats that mimic the human disease; second to confirm vascular changes in the mandible and eye using micro CT of vascular casts, and image analysis of retina/choroid images; and third to show parallel bisphosphonate induced changes in the structure and markers of the vasculature of the bone and eye. The results of this study show structural changes in the eye and mandible as well as biochemical changes including the up regulation of VEGF in response to the bisphosphonate associated ischemia. These changes are not associated with angiogenesis in either the eye or mandible as determined by reduced vascular complexity. These results suggest that observations of direct changes to the vasculature in the retina/choroid structures of the eye in patients taking bisphosphonates could serve as a window to the progression of debilitating changes occurring as a result of bisphosphonate therapy. (C) 2015 European Association for Cranio Maxillo Facial Surgery. Published by Elsevier Ltd. All rights reserved.
C1 [Borke, James L.; Stoianovici, Charles; Guerra, Carlos] Western Univ Hlth Sci, Coll Dent Med, Pomona, CA 91766 USA.
   [McAllister, Bennett; Harris, Tiffenie; Neiberg, Maryke] Western Univ Hlth Sci, Coll Optometry, Pomona, CA 91766 USA.
   [Guevarra Toth, Chestine] US Army, Adv Educ Program Periodont, Ft Gordon, GA 30905 USA.
   [Fulzele, Sadanand] Georgia Regents Univ, Dept Orthoped Surg, Augusta, GA 30912 USA.
C3 Western University of Health Sciences; Western University of Health
   Sciences; United States Department of Defense; United States Army;
   University System of Georgia; Augusta University
RP Borke, JL (通讯作者)，Western Univ Hlth Sci, Coll Dent Med, 309 E Second St, Pomona, CA 91766 USA.
EM jborke@westernu.edu
FU AO Foundation, Davos, Switzerland; The United States Army Advanced
   Education Program in Periodontics, Fort Gordon, GA; Western University
   of Health Sciences College of Dental Medicine, Pomona, CA
FX This work was supported by the AO Foundation, Davos, Switzerland (JLB);
   The United States Army Advanced Education Program in Periodontics, Fort
   Gordon, GA (CSG & JLB); and the Western University of Health Sciences
   College of Dental Medicine, Pomona, CA (JLB, CS, CG).
CR Bagan J, 2014, J ORAL PATHOL MED, V43, P371, DOI 10.1111/jop.12151
   Bellahcène A, 2007, ENDOTHELIUM J ENDOTH, V14, P123, DOI 10.1080/10623320701347187
   Benlidayi IC, 2013, ISRN RHEUMATOL, V6
   Bezzi M, 2003, J BIOL CHEM, V278, P43603, DOI 10.1074/jbc.M308114200
   Corrado A, 2007, JOINT BONE SPINE, V74, P32, DOI 10.1016/j.jbspin.2006.06.005
   Deckers MML, 2002, J BONE MINER RES, V17, P998, DOI 10.1359/jbmr.2002.17.6.998
   Fournier P, 2002, CANCER RES, V62, P6538
   Guevarra CS, 2015, J ORAL IMPLANTOL, V41, pE24, DOI 10.1563/AAID JOI D 13 00074
   Hashimoto K, 2007, BIOCHEM BIOPH RES CO, V354, P478, DOI 10.1016/j.bbrc.2007.01.014
   Hasmim M, 2007, J THROMB HAEMOST, V5, P166, DOI 10.1111/j.1538 7836.2006.02259.x
   Marino KL, 2012, J ORAL IMPLANTOL, V38, P511, DOI 10.1563/AAID JOI D 11 00057
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Melani C, 2007, CANCER RES, V67, P11438, DOI 10.1158/0008 5472.CAN 07 1882
   Misso G, 2012, CANCER BIOL THER, V13, P1491, DOI 10.4161/cbt.22274
   Mozzati M, 2013, CLIN ORAL INVEST, V17, P1259, DOI 10.1007/s00784 012 0800 7
   Ribatti D, 2007, CLIN RHEUMATOL, V26, P1094, DOI 10.1007/s10067 006 0455 3
   Ruggiero SL, 2007, J DENT RES, V86, P1013, DOI 10.1177/154405910708601101
   Santini D, 2002, CLIN CANCER RES, V8, P1080
   Soki FN, 2013, J CELL BIOCHEM, V114, P67, DOI 10.1002/jcb.24301
   Stresing V, 2007, CANCER LETT, V257, P16, DOI 10.1016/j.canlet.2007.07.007
   Stresing V, 2011, BONE, V48, P259, DOI 10.1016/j.bone.2010.09.035
   Tang XD, 2010, INT J CANCER, V126, P90, DOI 10.1002/ijc.24710
   Tsai S H, 2012, PLOS ONE, V7
   van Beek ER, 2003, BONE, V33, P805, DOI 10.1016/j.bone.2003.07.007
   Vieillard MH, 2010, OSTEOPOROSIS INT, V21, P1919, DOI 10.1007/s00198 009 1146 0
   Wehrhan F, 2011, ORAL SURG ORAL MED O, V112, P216, DOI 10.1016/j.tripleo.2011.02.028
   Wiemer AJ, 2011, CLIN PHARMACOL THER, V90, P804, DOI 10.1038/clpt.2011.215
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
NR 29
TC 14
Z9 15
U1 0
U2 6
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1010 5182
EI 1878 4119
J9 J CRANIO MAXILL SURG
JI J. Cranio MaxilloFac. Surg.
PD SEP
PY 2015
VL 43
IS 7
BP 1144
EP 1150
DI 10.1016/j.jcms.2015.05.021
PG 7
WC Dentistry, Oral Surgery & Medicine; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine; Surgery
GA CR1IP
UT WOS:000361078700028
PM 26154398
DA 2025 08 17
ER

PT J
AU Gluz, E
   Grinberg, I
   Corem Salkmon, E
   Mizrahi, D
   Margel, S
AF Gluz, Eran
   Grinberg, Igor
   Corem Salkmon, Enav
   Mizrahi, Dana
   Margel, Shlomo
TI Engineering of New Crosslinked Near Infrared Fluorescent Polyethylene
   Glycol Bisphosphonate Nanoparticles for Bone Targeting
SO JOURNAL OF POLYMER SCIENCE PART A POLYMER CHEMISTRY
LA English
DT Article
DE nanoparticles; biopolymers; biological applications of polymers;
   bisphosphonates nanoparticles; near IR fluorescent nanoparticles
ID MICROMETER SIZED PARTICLES; N BUTYL ACRYLATE; DISPERSION POLYMERIZATION;
   REACTION PARAMETERS; METHYL METHACRYLATE; CYANINE DYES; HYDROGEL
   NANOPARTICLES; CLINICAL EFFICACY; OPTICAL DETECTION; MOLECULAR WEIGHT
AB Bisphosphonates (BPs) are nonhydrolysable pyrophosphate analogs with high affinity to hydroxyapatite (HAP, bone mineral) and are mainly used for treatment of various bone diseases. In this study, we designed and prepared crosslinked BP nanoparticles by dispersion copolymerization of three monomers: methacrylate PEG bisphosphonate, N (3 aminopropyl) methacrylamide, and tetra(ethylene glycol) diacrylate. The size and size distribution of these PEG BP nanoparticles were controlled by changing various polymerization parameters. These BP particles possess dual functionality: covalent attachment of a dye (e.g., near IR fluorescent dye) or drug to the nanoparticles through the primary amine groups belonging to the aminopropyl methacrylamide monomeric units and chelation to the bone mineral HAP through the BP groups belonging to the methacrylate PEG bisphosphonate monomeric units, for enhanced long term bone targeted imaging and therapy applications. Body distribution of the optimal crosslinked BP nanoparticles was tested on a chicken embryo model via intravenous administration. This study indicated that the fluorescence intensity of the all organs (e.g., blood, spleen, liver, kidney, and heart) except the bones decreased significantly within 48 h (p<0.05) while that of the bones hardly changed over that time (p>0.05). (c) 2013 Wiley Periodicals, Inc. J. Polym. Sci., Part A: Polym. Chem. 2013, 51, 4282 4291
C1 [Gluz, Eran; Grinberg, Igor; Corem Salkmon, Enav; Mizrahi, Dana; Margel, Shlomo] Bar Ilan Univ, Inst Nanotechnol & Adv Mat, Dept Chem, IL 52900 Ramat Gan, Israel.
C3 Bar Ilan University
RP Margel, S (通讯作者)，Bar Ilan Univ, Inst Nanotechnol & Adv Mat, Dept Chem, IL 52900 Ramat Gan, Israel.
EM shlomo.margel@mail.biu.ac.il
FU Israeli Ministry of Commerce and Indusrty
FX This study was supported by the Israeli Ministry of Commerce and
   Indusrty (Kamin Grant). The authors thank Dr. Ronen Yehuda for his
   assistance with the fluorescent images.
CR An SY, 2009, J COLLOID INTERF SCI, V331, P98, DOI 10.1016/j.jcis.2008.11.022
   Bamnolker H, 1996, J POLYM SCI POL CHEM, V34, P1857
   Boguslavsky L, 2005, J COLLOID INTERF SCI, V289, P71, DOI 10.1016/j.jcis.2005.03.063
   BRISMAR H, 1995, J HISTOCHEM CYTOCHEM, V43, P699, DOI 10.1177/43.7.7608524
   Budini M, 2012, J BIOL CHEM, V287, P7512, DOI 10.1074/jbc.M111.288720
   Bulmus V, 1996, J APPL POLYM SCI, V60, P697, DOI 10.1002/(SICI)1097 4628(19960502)60:5<697::AID APP6>3.3.CO;2 F
   Chen R, 2013, J POLYM SCI POL CHEM, V51, P2199, DOI 10.1002/pola.26601
   Clézardin P, 2011, BONE, V49, P66, DOI 10.1016/j.bone.2010.11.017
   Cohen S, 2013, MAT SCI ENG C MATER, V33, P923, DOI 10.1016/j.msec.2012.11.022
   Corem Salkmon E, 2012, INT J NANOMED, V7, P5517, DOI 10.2147/IJN.S33710
   COXON FP, 2008, CALCIFIED TISSUE S1, V82, pS127
   DECKER T, 1988, J IMMUNOL METHODS, V115, P61, DOI 10.1016/0022 1759(88)90310 9
   Deligeorgiev T, 2006, DYES PIGMENTS, V70, P185, DOI 10.1016/j.dyepig.2005.05.010
   Du YZ, 2005, J POLYM SCI POL CHEM, V43, P562, DOI 10.1002/pola.20556
   Dufrane D, 2003, J MATER SCI MATER M, V14, P33, DOI 10.1023/A:1021545302732
   Eastell R, 2011, BONE, V49, P82, DOI 10.1016/j.bone.2011.02.011
   Epsztejn S, 1999, BLOOD, V94, P3593, DOI 10.1182/blood.V94.10.3593.422k26_3593_3603
   Galperin A, 2006, J POLYM SCI POL CHEM, V44, P3859, DOI 10.1002/pola.21487
   Gluz E, 2013, POLYMER, V54, P565, DOI 10.1016/j.polymer.2012.11.071
   Goldshtein J, 2009, EUR POLYM J, V45, P2987, DOI 10.1016/j.eurpolymj.2009.08.020
   Goldshtein J, 2009, POLYMER, V50, P3422, DOI 10.1016/j.polymer.2009.05.056
   Grinberg I, 2012, LEUKEMIA LYMPHOMA, V53, P472, DOI 10.3109/10428194.2011.621563
   Grinberg I, 2009, LEUKEMIA RES, V33, P1417, DOI 10.1016/j.leukres.2009.02.009
   Hamidi M, 2008, ADV DRUG DELIVER REV, V60, P1638, DOI 10.1016/j.addr.2008.08.002
   Han H, 2009, MACROMOL RES, V17, P469, DOI 10.1007/BF03218894
   He XX, 2010, WIRES NANOMED NANOBI, V2, P349, DOI 10.1002/wnan.85
   Horák D, 1999, J POLYM SCI POL CHEM, V37, P3785, DOI 10.1002/(SICI)1099 0518(19991015)37:20<3785::AID POLA7>3.0.CO;2 U
   Horák D, 2002, J POLYM SCI POL CHEM, V40, P1625, DOI 10.1002/pola.10238
   Horák D, 2000, J POLYM SCI POL CHEM, V38, P653, DOI 10.1002/(SICI)1099 0518(20000201)38:3<653::AID POLA29>3.0.CO;2 P
   Jiang S, 2010, J R SOC INTERFACE, V7, P3, DOI 10.1098/rsif.2009.0243
   Jiang S, 2007, MACROMOLECULES, V40, P4910, DOI 10.1021/ma062679i
   Jiang S, 2007, J POLYM SCI POL CHEM, V45, P2105, DOI 10.1002/pola.21975
   Kim K, 2006, J AM CHEM SOC, V128, P3490, DOI 10.1021/ja057712f
   Lee KC, 2008, MACROMOL RES, V16, P293, DOI 10.1007/BF03218520
   Macková H, 2006, J POLYM SCI POL CHEM, V44, P968, DOI 10.1002/pola.21223
   Masarachia P, 1996, BONE, V19, P281, DOI 10.1016/8756 3282(96)00182 2
   Miller PD, 2011, BONE, V49, P77, DOI 10.1016/j.bone.2010.12.024
   Momekova D, 2010, SOFT MATTER, V6, P591, DOI 10.1039/b917275k
   Noiman T, 2011, ORGANOGENESIS, V7, P140, DOI 10.4161/org.7.2.16457
   Owens G, 2007, AM J MANAG CARE, V13, pS290
   PAINE AJ, 1990, MACROMOLECULES, V23, P3104, DOI 10.1021/ma00214a012
   Park JW, 2012, BIOCONJUGATE CHEM, V23, P350, DOI 10.1021/bc200232d
   Park K, 2010, J CONTROL RELEASE, V142, P147, DOI 10.1016/j.jconrel.2010.01.025
   Reid IR, 2011, BONE, V49, P89, DOI 10.1016/j.bone.2010.09.002
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   Santra S, 2005, TECHNOL CANCER RES T, V4, P593, DOI 10.1177/153303460500400603
   Sharma P, 2006, ADV COLLOID INTERFAC, V123, P471, DOI 10.1016/j.cis.2006.05.026
   SHEN S, 1994, J POLYM SCI POL CHEM, V32, P1087, DOI 10.1002/pola.1994.080320611
   Shibata K, 2007, IND HEALTH, V45, P426, DOI 10.2486/indhealth.45.426
   Sponarová D, 2008, J POLYM SCI POL CHEM, V46, P6263, DOI 10.1002/pola.22936
   Stresing V, 2007, CANCER LETT, V257, P16, DOI 10.1016/j.canlet.2007.07.007
   Veronese FM, 2008, BIODRUGS, V22, P315, DOI 10.2165/00063030 200822050 00004
   Yang SR, 2006, J CONTROL RELEASE, V114, P60, DOI 10.1016/j.jconrel.2006.05.016
   Yarmoluk SM, 2001, DYES PIGMENTS, V50, P21, DOI 10.1016/S0143 7208(01)00023 7
   Zhang HT, 2002, J APPL POLYM SCI, V85, P2230, DOI 10.1002/app.10840
NR 57
TC 12
Z9 12
U1 3
U2 51
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0887 624X
EI 1099 0518
J9 J POLYM SCI POL CHEM
JI J. Polym. Sci. Pol. Chem.
PD OCT
PY 2013
VL 51
IS 20
BP 4282
EP 4291
DI 10.1002/pola.26858
PG 10
WC Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Polymer Science
GA 217VE
UT WOS:000324389400004
OA Bronze
DA 2025 08 17
ER

PT J
AU Li, HW
   Wu, YY
   Huang, N
   Zhao, Q
   Yuan, Q
   Shao, B
AF Li, Hanwen
   Wu, Yongyao
   Huang, Ning
   Zhao, Qi
   Yuan, Quan
   Shao, Bin
TI γ Aminobutyric Acid Promotes Osteogenic Differentiation of Mesenchymal
   Stem Cells by Inducing TNFAIP3
SO CURRENT GENE THERAPY
LA English
DT Article
DE GABA; osteoporosis; osteoblasts; osteoclasts; MSCs; TNFAIP3
ID NF KAPPA B; CEREBROSPINAL FLUID; BONE; A20; INFLAMMATION; GABA
AB Background: Osteoporosis is the most common metabolic bone disease. There is still an unmet need for novel therapeutic agents that could be beneficial as osteoporosis treatments. It has been reported that the neurotransmitter gamma aminobutyric acid (GABA) might be associated with human bone formation. However, the precise mechanism remains unclear.
   Objective: To investigate the effect of GABA on bone metabolism and explore the possible role of TNFAIP3 in this process.
   Methods: GABA had little effect on the proliferation of human mesenchymal stem cells (hMSCs) and RAW 264.7 cells, as indicated by the cell counting kit 8 (CCK 8) assay. The results showed that GABA enhanced the intensity of ALP staining, ALP activity, and accumulation of Ca2+ mineralized nodules in hMSCs during osteogenic induction.
   Results: The qRT PCR results indicated that GABA treatment significantly increased the mRNA expression of osteogenic genes in hMSCs. In RAW 264.7 cells, TRAP staining showed that GABA did not alter the number or size of osteoclasts or the expression of osteoclastic genes, which suggests that GABA does not affect osteoclastic differentiation. Mechanistically, GABA treatment significantly induced the sustained expression of TNFAIP3. Furthermore, by knocking down TNFAIP3, the osteogenic effect of GABA was antagonized, which suggests that TNFAIP3 mediates the effects of GABA in hMSCs.
   Conclusion: Our results suggested that GABA treatment positively regulated osteogenic differentiation by upregulating TNFAIP3, while no obvious effect on osteoclastic differentiation was detected. Therefore, our results provide a potential gene therapy for the treatment of osteoporosis and low bone mineral density.
C1 [Li, Hanwen; Wu, Yongyao; Huang, Ning; Yuan, Quan; Shao, Bin] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu 610041, Peoples R China.
   [Li, Hanwen; Wu, Yongyao; Huang, Ning; Yuan, Quan; Shao, Bin] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Chengdu 610041, Peoples R China.
   [Zhao, Qi] Univ Tennessee, Coll Med, Dept Prevent Med, Hlth Sci Ctr, Memphis, TN USA.
C3 Sichuan University; Sichuan University; University of Tennessee System;
   University of Tennessee Health Science Center
RP Yuan, Q; Shao, B (通讯作者)，Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu 610041, Peoples R China.; Yuan, Q; Shao, B (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Chengdu 610041, Peoples R China.
EM yuanquan@scu.edu.cn; sklbshaobin@scu.edu.cn
RI yuan, quan/GZM 5597 2022; Li, Hanwen/ABF 7174 2020; Shao,
   Bin/AAE 5957 2019
OI Yuan, Quan/0000 0002 2836 1081; WU, Yongyao/0000 0001 5713 3937
FU National Natural Science Foundation of China [NSFC 81702271, 81722014];
   Department of Science and Technology of Sichuan Province [2019YJ0041];
   Scientific Research Foundation for Recruited Talents, West China
   Hospital of Stomatology Sichuan University [QDIF 2019 1]
FX This work was supported by grants from the National Natural Science
   Foundation of China (NSFC 81702271 and 81722014), the Department of
   Science and Technology of Sichuan Province (2019YJ0041) and the
   Scientific Research Foundation for Recruited Talents, West China
   Hospital of Stomatology Sichuan University (QDIF 2019 1).
CR Afonina IS, 2017, NAT IMMUNOL, V18, P861, DOI 10.1038/ni.3772
   Auger ML, 2020, NEUROPHARMACOLOGY, V162, DOI [10.1016/j.neurophann.2019.107844, 10.1016/j.neuropharm.2019.107844]
   Bhat R, 2010, P NATL ACAD SCI USA, V107, P2580, DOI 10.1073/pnas.0915139107
   Borumandi F, 2015, ANTI CANCER AGENT ME, V15, P736, DOI 10.2174/1871520615666150325232857
   BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201
   Catrysse L, 2014, TRENDS IMMUNOL, V35, P22, DOI 10.1016/j.it.2013.10.005
   Chang J, 2013, P NATL ACAD SCI USA, V110, P9469, DOI 10.1073/pnas.1300532110
   Dhossche Dirk, 2002, Med Sci Monit, V8, pPR1
   DIXIT VM, 1990, J BIOL CHEM, V265, P2973
   Djigoue G B, 2013, ACTA CRYSTALLOGR C, VC68, P231
   Esbrit P, 2013, BIOCHEM PHARMACOL, V85, P1417, DOI 10.1016/j.bcp.2013.03.002
   Fujimori S, 2002, BIOORGAN MED CHEM, V19, P4652, DOI [10.1016/S0006 291X(02)00405 9, DOI 10.1016/S0006 291X(02)00405 9]
   Garg AV, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003699
   Hammer GE, 2011, NAT IMMUNOL, V12, P1184, DOI 10.1038/ni.2135
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hwang I, 2019, P NATL ACAD SCI USA, V116, P11936, DOI 10.1073/pnas.1822067116
   Jembrek MJ, 2015, CURR PHARM DESIGN, V21, P4943, DOI 10.2174/1381612821666150914121624
   Jiménez Jiménez FJ, 1998, J NEURAL TRANSM, V105, P269, DOI 10.1007/s007020050056
   Kenmogne LC, 2016, BIOORG MED CHEM LETT, V26, P2179, DOI 10.1016/j.bmcl.2016.03.069
   Khuhawar MY, 2003, J CHROMATOGR B, V788, P413, DOI 10.1016/S1570 0232(03)00062 X
   Kiessling CY, 2020, NEUROPHARMACOLOGY, V174, DOI 10.1016/j.neuropharm.2020.108138
   Kraenzlin ME, 2011, NAT REV ENDOCRINOL, V7, P647, DOI 10.1038/nrendo.2011.108
   Martens A, 2020, CSH PERSPECT BIOL, V12, DOI 10.1101/cshperspect.a036418
   Matmati M, 2011, NAT GENET, V43, P908, DOI 10.1038/ng.874
   Meldrum B., 1975, INT REV NEUROBIOL, V17
   Nutt D, 2006, J CLIN SLEEP MED, V2, pS7
   Polykratis A, 2019, NAT CELL BIOL, V21, P731, DOI 10.1038/s41556 019 0324 3
   Razani B, 2020, NAT IMMUNOL, V21, P422, DOI 10.1038/s41590 020 0634 4
   Savino S, 2016, PROTEINS, V84, P859, DOI 10.1002/prot.25036
   Seeman E, 2019, NAT REV RHEUMATOL, V15, P225, DOI 10.1038/s41584 019 0172 3
   Song Y, 2005, J CHROMATOGR B, V814, P295, DOI 10.1016/j.jchromb.2004.10.046
   Takahata Y, 2011, J BIOL CHEM, V286, P32906, DOI 10.1074/jbc.M111.253526
   Voet S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 04376 5
   Walsh JS, 2013, NAT REV ENDOCRINOL, V9, P637, DOI 10.1038/nrendo.2013.171
   Wang ZY, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003 020 0766 y
   Yang YS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10809 6
NR 36
TC 11
Z9 12
U1 0
U2 25
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1566 5232
EI 1875 5631
J9 CURR GENE THER
JI Curr. Gene Ther.
PY 2020
VL 20
IS 2
BP 152
EP 161
DI 10.2174/1566523220999200727122502
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA NT8WW
UT WOS:000573219300007
PM 32951573
DA 2025 08 17
ER

PT J
AU Yirmiya, R
   Goshen, I
   Bajayo, A
   Kreisel, T
   Feldman, S
   Tam, J
   Trembovier, V
   Csernus, V
   Shohami, E
   Bab, I
AF Yirmiya, Raz
   Goshen, Inbal
   Bajayo, Alon
   Kreisel, Tirzah
   Feldman, Sharon
   Tam, Joseph
   Trembovier, Victoria
   Csernus, Valer
   Shohami, Esther
   Bab, Itai
TI Depression induces bone loss through stimulation of the sympathetic
   nervous system
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE antidepressant; chronic depression; osteoporosis; bone formation;
   adrenergic signaling
ID CHRONIC MILD STRESS; MINERAL DENSITY; MAJOR DEPRESSION; IMMOBILIZATION
   STRESS; MALE RATS; WOMEN; CORTICOSTERONE; OSTEOCALCIN; MASS;
   TESTOSTERONE
AB Major depression is associated with low bone mass and increased incidence of osteoporotic fractures. However, causality between depression and bone loss has not been established. Here, we show that mice subjected to chronic mild stress (CMS), an established model of depression in rodents, display behavioral depression accompanied by impaired bone mass and structure, as portrayed by decreases in trabecular bone volume density, trabecular number, and trabecular connectivity density assessed in the distal femoral metaphysis and L3 vertebral body. Bone remodeling analysis revealed that the CMS induced skeletal deficiency is accompanied by restrained bone formation resulting from reduced osteoblast number. Antidepressant therapy, which prevents the behavioral responses to CMS, completely inhibits the decrease in bone formation and markedly attenuates the CMS induced bone loss. The depression triggered bone loss is associated with a substantial increase in bone norepinephrine levels and can be blocked by the beta adrenergic antagonist propranolol, suggesting that the sympathetic nervous system mediates the skeletal effects of stress induced depression. These results define a linkage among depression, excessive adrenergic activity, and reduced bone formation, thus demonstrating an interaction among behavioral responses, the brain, and the skeleton, which leads to impaired bone structure. Together with the common occurrence of depression and bone loss in the aging population, the present data implicate depression as a potential major risk factor for osteoporosis and the associated increase in fracture incidence.
C1 Hebrew Univ Jerusalem, Fac Social Sci, Dept Psychol, IL 90105 Jerusalem, Israel.
   Hebrew Univ Jerusalem, Dept Bone Lab, IL 90105 Jerusalem, Israel.
   Hebrew Univ Jerusalem, Dept Pharmacol, IL 90105 Jerusalem, Israel.
   Univ Pecs, Sch Med, Dept Anat, H 7624 Pecs, Hungary.
C3 Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew
   University of Jerusalem; University of Pecs
RP Yirmiya, R (通讯作者)，Hebrew Univ Jerusalem, Fac Social Sci, Dept Psychol, Mt Scopus, IL 90105 Jerusalem, Israel.
EM razyirmiya@huji.ac.il
RI Yirmiya, Raz/D 1090 2014; Goshen, Inbal/GQI 2230 2022; Bab,
   Itai/C 2613 2009
OI Yirmiya, Raz/0000 0002 4009 7316; Kreisel, Tirzah/0000 0001 6757 156X;
   Goshen, Inbal/0000 0001 7578 2615; 
CR Alesci S, 2005, J CLIN ENDOCR METAB, V90, P2522, DOI 10.1210/jc.2004 1667
   Bajayo A, 2005, P NATL ACAD SCI USA, V102, P12956, DOI 10.1073/pnas.0502562102
   Baldock PA, 2002, J CLIN INVEST, V109, P915, DOI 10.1172/JCI200214588
   Bielajew C, 2002, BEHAV BRAIN RES, V136, P583, DOI 10.1016/S0166 4328(02)00222 X
   Black PH, 2003, BRAIN BEHAV IMMUN, V17, P350, DOI 10.1016/S0889 1591(03)00048 5
   Blazer DG II, 2005, PSYCHOL MED, V35, P1241, DOI 10.1017/S0033291705004411
   CHARNEY DS, 2004, SCI STKE
   Cherruau M, 1999, BONE, V25, P545, DOI 10.1016/S8756 3282(99)00211 2
   Chrousos George P., 1998, Annals of Internal Medicine, V129, P229
   Cizza G, 2001, TRENDS ENDOCRIN MET, V12, P198, DOI 10.1016/S1043 2760(01)00407 6
   COLLU R, 1984, BIOL REPROD, V30, P416, DOI 10.1095/biolreprod30.2.416
   CSERNUS V, 1985, ADV STEROID ANAL, P171
   Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092 8674(00)81558 5
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   Franchimont N, 2005, BONE, V37, P601, DOI 10.1016/j.bone.2005.06.002
   FUKAO S, 1988, GEOPHYS RES LETT, V15, P768, DOI 10.1029/GL015i008p00768
   Gold PW, 2005, P NATL ACAD SCI USA, V102, P8303, DOI 10.1073/pnas.0503069102
   HALBREICH U, 1995, PSYCHOSOM MED, V57, P485, DOI 10.1097/00006842 199509000 00011
   Ilias Ioannis, 2006, Hormones (Athens), V5, P9
   Kahl KG, 2005, AM J PSYCHIAT, V162, P168, DOI 10.1176/appi.ajp.162.1.168
   Kendler KS, 1999, AM J PSYCHIAT, V156, P837, DOI 10.1176/ajp.156.6.837
   Konkle ATM, 2003, BRAIN RES, V992, P227, DOI 10.1016/j.brainres.2003.08.047
   Korpelainen R, 2006, BONE, V39, P385, DOI 10.1016/j.bone.2006.01.143
   Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385
   Michelson D, 1996, NEW ENGL J MED, V335, P1176, DOI 10.1056/NEJM199610173351602
   MONDER C, 1994, ENDOCRINOLOGY, V134, P1193, DOI 10.1210/en.134.3.1193
   Muller R, 1997, ST HEAL T, V40, P61
   NAPAL J, 1993, BONE MINER, V21, P113, DOI 10.1016/S0169 6009(08)80013 X
   Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Patterson Buckendahl P, 2001, AM J PHYSIOL REG I, V280, pR79, DOI 10.1152/ajpregu.2001.280.1.R79
   PATTERSONBUCKENDAHL P, 1995, BONE, V17, P467, DOI 10.1016/8756 3282(95)00281 X
   PATTERSONBUCKENDAHL PE, 1988, AM J PHYSIOL, V254, pR828, DOI 10.1152/ajpregu.1988.254.5.R828
   Retana Márquez S, 2003, HORM BEHAV, V44, P327, DOI 10.1016/j.yhbeh.2003.04.001
   SCHUIJERS JA, 1987, AM J PHYSIOL, V252, pR7, DOI 10.1152/ajpregu.1987.252.1.R7
   Schuit SCE, 2004, BONE, V34, P195, DOI 10.1016/j.bone.2003.10.001
   SCHWEIGER U, 1994, AM J PSYCHIAT, V151, P1691
   Seals DR, 2000, J PHYSIOL LONDON, V528, P407, DOI 10.1111/j.1469 7793.2000.00407.x
   Seeman E, 2002, LANCET, V359, P1841, DOI 10.1016/S0140 6736(02)08706 8
   Serre CM, 1999, BONE, V25, P623, DOI 10.1016/S8756 3282(99)00215 X
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Togari A, 2002, MICROSC RES TECHNIQ, V58, P77, DOI 10.1002/jemt.10121
   Weidenfeld J, 1996, NEUROIMMUNOMODULAT, V3, P352, DOI 10.1159/000097295
   Weinstein RS, 2004, ENDOCRINOLOGY, V145, P1980, DOI 10.1210/en.2003 1133
   Whooley MA, 1999, ARCH INTERN MED, V159, P484, DOI 10.1001/archinte.159.5.484
   Willner P, 2005, NEUROPSYCHOBIOLOGY, V52, P90, DOI 10.1159/000087097
   Yazici KM, 2003, PSYCHIAT RES, V117, P271, DOI 10.1016/S0165 1781(03)00017 9
   Yirmiya R, 1996, BRAIN RES, V711, P163, DOI 10.1016/0006 8993(95)01415 2
   Yirmiya R, 1997, BRAIN RES, V749, P71, DOI 10.1016/S0006 8993(96)01295 4
   1994, DIAGNOSTIC STAT MAN
NR 50
TC 179
Z9 203
U1 2
U2 24
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 7
PY 2006
VL 103
IS 45
BP 16876
EP 16881
DI 10.1073/pnas.0604234103
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 104PB
UT WOS:000241969500046
PM 17075068
OA Green Published
DA 2025 08 17
ER

PT J
AU Clark, RP
   Wong, G
   Johnson, LM
   Hagge, RJ
   Ciminello, F
   Lee, J
   Stone, KI
   Clark, IA
AF Clark, Richard P.
   Wong, Granger
   Johnson, Loche M.
   Hagge, Rosalie J.
   Ciminello, Frank
   Lee, John
   Stone, Kiki I.
   Clark, Isabel A.
TI Nasal Dorsal Augmentation with Freeze Dried Allograft Bone
SO PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Article
ID F 18 FLUORIDE; EMISSION TOMOGRAPHY; ALLOGENEIC BONE; GRAFT;
   SCINTIGRAPHY; CANCER; RECONSTRUCTION; F 18 FLUORIDE; METASTASES;
   PROSTATE
AB Background: Properly prepared freeze dried bone has been used with impunity by orthopedic surgeons since 1992 without a single report of disease transmission. The aim of this study was to evaluate freeze dried cortical allograft bone for nasal dorsal augmentation.
   Methods: Freeze dried human cortical bone was obtained from DCI Donor Services, Nashville, Tennessee. Standards recommended by the American Association of Tissue Banks, the U. S. Food and Drug Administration, and the Centers for Disease Control and Prevention were followed. Objective evaluation of the persistence of graft volume was obtained by cephalometric radiography. Vascularization and incorporation of new bone elements within the grafts were demonstrated by using fluorine 18 sodium fluoride positron emission tomographic/computed tomographic scanning.
   Results: The average persistence of projection in 18 patients was 87 percent at 6 months. Thereafter, 10 patients showed 100 percent maintenance of projection at 12 to 36 months. Vascularization and incorporation of new bone elements within the grafts were demonstrated by using fluorine 18 sodium fluoride positron emission tomographic/computed tomographic scanning in four patients.
   Conclusions: The initial loss of 13 percent of projection is most likely attributable to resolution of early surgical edema. The authors postulate that there are two pathways based on whether the recipient bed allows vascular access to the graft. The revascularization or inductive pathway involves stem cell conversion to eventual osteoblasts. The scar bed barrier or noninductive pathway involves the preservation of the graft as an unchanged alloimplant. This report is the first of a series that will include a 5 year and a 10 year follow up. (Plast. Reconstr. Surg. 124: 1312, 2009.)
C1 [Clark, Richard P.; Wong, Granger; Johnson, Loche M.; Hagge, Rosalie J.; Ciminello, Frank; Lee, John; Stone, Kiki I.; Clark, Isabel A.] Univ Calif Davis, Davis, CA 95616 USA.
C3 University of California System; University of California Davis
RP Clark, RP (通讯作者)，83 Scripps Dr,Suite 130, Sacramento, CA 95825 USA.
EM rclark@cwo.com
CR Aspenberg P, 2002, ACTA ORTHOP SCAND, V73, P20, DOI 10.1080/000164702317281350
   Bares R, 1998, Q J NUCL MED, V42, P43
   Bauer TW, 2000, CLIN ORTHOP RELAT R, P10
   BERDING G, 1995, EUR J NUCL MED, V22, P1133, DOI 10.1007/BF00800595
   Berding G, 2001, NUKLEARMED NUCL MED, V40, P51
   BILEZIKIAN JP, 2002, PRINCIPLES BONE BIOL, P231
   Boyce T, 1999, ORTHOP CLIN N AM, V30, P571, DOI 10.1016/S0030 5898(05)70110 3
   BUCK BE, 1994, CLIN ORTHOP RELAT R, P8
   BURCHARDT H, 1983, CLIN ORTHOP RELAT R, P28
   Canale S.TerryMD:., 2007, Campbell's Operative Orthopaedics, V11th
   Chapman MW., 2001, CHAPMANS ORTHOPAEDIC, V3rd
   CONRAD EU, 1993, CLIN ORTHOP RELAT R, P279
   Czitrom AA, 1998, ORTHOPEDICS, V21, P242
   Dasa V, 2008, CLIN ORTHOP RELAT R, V466, P1081, DOI 10.1007/s11999 008 0219 2
   DROSOS GI, 2007, INJURY S4, pS13
   Even Sapir E, 2006, J NUCL MED, V47, P287
   Fallon M., 1984, Endocrine control of bone and calcium metabolism, P144
   FIG LM, 1990, ARCH OTOLARYNGOL, V116, P191
   Fleming JE Jr, 2000, ORTHOP CLIN N AM, V31, P357, DOI 10.1016/S0030 5898(05)70156 5
   FUKUTA K, 1992, ANN PLAS SURG, V29, P136, DOI 10.1097/00000637 199208000 00007
   Garbuz DS, 1998, ORTHOP CLIN N AM, V29, P199, DOI 10.1016/S0030 5898(05)70318 7
   HAGGE RJ, 2008, J NUCL MED S1, V49
   Head WC, 1998, ORTHOP CLIN N AM, V29, P307, DOI 10.1016/S0030 5898(05)70328 X
   Hetzel M, 2003, J BONE MINER RES, V18, P2206, DOI 10.1359/jbmr.2003.18.12.2206
   Hollinger J.O., 2005, BONE TISSUE ENG
   Hubli EH, 1998, ANN PLAS SURG, V41, P81, DOI 10.1097/00000637 199807000 00015
   Jadlowiec JA, 2003, EXPERT OPIN BIOL TH, V3, P409, DOI 10.1517/eobt.3.3.409.21183
   Joyce MJ, 2005, CLIN ORTHOP RELAT R, P22, DOI 10.1097/01.blo.0000165849.32661.5e
   KELLY JF, 1977, J ORAL SURG, V35, P268
   KRISHNAMURTHY GT, 1976, AM J ROENTGENOL, V126, P293, DOI 10.2214/ajr.126.2.293
   Langsteger W, 2006, SEMIN NUCL MED, V36, P73, DOI 10.1053/j.semnuclmed.2005.09.002
   MARX RE, 1981, J ORAL SURG, V39, P264
   McAllister DR, 2007, AM J SPORT MED, V35, P2148, DOI 10.1177/0363546507308936
   Mischen BT, 2008, PLAST RECONSTR SURG, V122, P725, DOI 10.1097/PRS.0b013e318180ec9f
   MOON NF, 1968, J AMER MED ASSOC, V204, P974, DOI 10.1001/jama.204.11.974
   MOSKOWITZ GW, 1988, SEMIN NUCL MED, V18, P246, DOI 10.1016/S0001 2998(88)80032 1
   Palmedo H., 2008, V170, P213
   RAMSAY SC, 1991, J NUCL MED, V32, P33
   Reddi AH, 1998, NAT BIOTECHNOL, V16, P247, DOI 10.1038/nbt0398 247
   REDDY H, 2005, COMMUNICATION
   Redondo LM, 1997, BRIT J ORAL MAX SURG, V35, P166, DOI 10.1016/S0266 4356(97)90556 8
   SALYER KE, 2006, COMMUNICATION
   Sarukawa S, 2004, J CRANIO MAXILL SURG, V32, P233, DOI 10.1016/j.jcms.2004.02.006
   Schirrmeister H, 1999, J NUCL MED, V40, P1623
   Schuepbach Jonas, 2007, Head Face Med, V3, P20, DOI 10.1186/1746 160X 3 20
   Soost F, 1999, Handchir Mikrochir Plast Chir, V31, P42, DOI 10.1055/s 1999 13490
   TOMFORD WW, 1995, J BONE JOINT SURG AM, V77A, P1742, DOI 10.2106/00004623 199511000 00017
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   Urist MR, 2002, CLIN ORTHOP RELAT R, P5
   URIST MR, 1983, P SOC EXP BIOL MED, V173, P194
   Vargel I, 2004, PLAST RECONSTR SURG, V114, P298, DOI 10.1097/01.PRS.0000131983.48201.E2
   WATKINSON JC, 1990, CLIN OTOLARYNGOL, V15, P457, DOI 10.1111/j.1365 2273.1990.tb00501.x
   WOLFE A, 2007, COMMUNICATION
   Yavuzer R, 2004, PLAST RECONSTR SURG, V113, P34, DOI 10.1097/01.PRS.0000096704.34065.03
NR 54
TC 8
Z9 8
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0032 1052
EI 1529 4242
J9 PLAST RECONSTR SURG
JI Plast. Reconstr. Surg.
PD OCT
PY 2009
VL 124
IS 4
BP 1312
EP 1325
DI 10.1097/PRS.0b013e3181b5a55b
PG 14
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery
GA 500UZ
UT WOS:000270332300037
PM 19935318
DA 2025 08 17
ER

PT J
AU Kokubu, N
   Tsujii, M
   Akeda, K
   Iino, T
   Sudo, A
AF Kokubu, Naoki
   Tsujii, Masaya
   Akeda, Koji
   Iino, Takahiro
   Sudo, Akihiro
TI BMP 7/Smad expression in dedifferentiated Schwann cells during axonal
   regeneration and upregulation of endogenous BMP 7 following
   administration of PTH (1 34)
SO JOURNAL OF ORTHOPAEDIC SURGERY
LA English
DT Article
DE bone morphogenetic protein 7; Noggin; parathyroid hormone (PTH) (1 34);
   peripheral nerve regeneration; Schwann cells
ID BONE MORPHOGENETIC PROTEINS; PARATHYROID HORMONE; PERIPHERAL NERVE;
   OSTEOGENIC PROTEIN 1; GROWTH FACTOR; NEUROTROPHIC FACTOR; RECEPTORS;
   DIFFERENTIATION; PROLIFERATION; SUPPRESSION
AB Purpose: To determine the expression and distribution of bone morphogenetic protein (BMP) 7 and related molecules during peripheral nerve regeneration and to assess whether administration of parathyroid hormone (PTH) drug (1 34) potentiates the intrinsic upregulation of BMP 7/Smad signaling. Methods: The rat sciatic nerves were crushed with an aneurysm clip resulting in axonal degeneration. In the normal nerve, and at 1, 2, 4, and 8 weeks after injury, BMP 7, BMP receptors, p Smad 1/5/8, and Noggin, the endogenous BMP antagonist, were evaluated. Additionally, the distribution of BMP 7 was assessed by fluorescent double immunostaining. In vitro studies were also performed to examine the effect of BMP 7 and PTH (1 34) administration on rat Schwann cells (SCs). Results: Aneurysm clip made reliable animal model of the nerve injury with recovery at 8 weeks after the injury. BMP 7/Smad protein and mRNA were significantly upregulated on axon SCs units at 1 week after injury, and this upregulated expression was maintained for 4 weeks. Besides, significant upregulation of Noggin's expression was observed on axon SCs units at 2 weeks after injury. Moreover, fluorescent double immunostaining showed co localization between expression of BMP 7 and p75NTR during axonal regeneration. In the in vitro study, administration of BMP 7 induced significant proliferation of SCs. Application of PTH (1 34) upregulated BMP 7 on SCs. Discussion/conclusion: BMPs were reported to be involved in protection and recovery after injury as well as in neurogenesis. Our current study showed that BMP/Smad signaling molecules were upregulated on dedifferentiated SCs after peripheral nerve injury and that administration of BMP 7 increased SC viability in vitro. These results suggested that axonal regeneration could be induced via upregulation of endogenous BMP 7 on SCs by PTH (1 34) administration.
C1 [Kokubu, Naoki; Tsujii, Masaya; Akeda, Koji; Iino, Takahiro; Sudo, Akihiro] Mie Univ, Dept Orthopaed Surg, Grad Sch Med, 2 174 Edobashi, Tsu, Mie 5148507, Japan.
C3 Mie University
RP Tsujii, M (通讯作者)，Mie Univ, Dept Orthopaed Surg, Grad Sch Med, 2 174 Edobashi, Tsu, Mie 5148507, Japan.
EM m t727@clin.medic.mie u.ac.jp
OI Tsujii, Masaya/0000 0002 0167 2824
CR Baird Evan O, 2009, J Orthop Surg Res, V4, P12, DOI 10.1186/1749 799X 4 12
   BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896 6273(89)90040 8
   Bengtsson H, 1998, J NEUROSCI RES, V53, P559, DOI 10.1002/(SICI)1097 4547(19980901)53:5<559::AID JNR6>3.0.CO;2 8
   Chang CF, 2003, STROKE, V34, P558, DOI 10.1161/01.STR.0000051507.64423.00
   Chen ZL, 2007, ANNU REV NEUROSCI, V30, P209, DOI 10.1146/annurev.neuro.30.051606.094337
   Chorev M, 2002, RECEPTOR CHANNEL, V8, P219, DOI 10.1080/10606820213685
   DEWULF N, 1995, ENDOCRINOLOGY, V136, P2652, DOI 10.1210/en.136.6.2652
   Ebendal T, 1998, J NEUROSCI RES, V51, P139, DOI 10.1002/(SICI)1097 4547(19980115)51:2<139::AID JNR2>3.0.CO;2 E
   Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284
   Helm GA, 2000, NEUROSURGERY, V46, P1213, DOI 10.1097/00006123 200005000 00038
   HEUMANN R, 1987, J CELL BIOL, V104, P1623, DOI 10.1083/jcb.104.6.1623
   Hisa I, 2011, J BIOL CHEM, V286, P9787, DOI 10.1074/jbc.M110.179127
   Khan MP, 2016, BONE, V92, P132, DOI 10.1016/j.bone.2016.08.018
   Koeppen AH, 2004, J NEUROL SCI, V220, P115, DOI 10.1016/j.jns.2004.03.008
   Küry P, 2001, CURR OPIN NEUROL, V14, P635, DOI 10.1097/00019052 200110000 00013
   Lin SZ, 1999, STROKE, V30, P126, DOI 10.1161/01.STR.30.1.126
   MEYER M, 1992, J CELL BIOL, V119, P45, DOI 10.1083/jcb.119.1.45
   Mirsky R, 1996, CURR OPIN NEUROBIOL, V6, P89, DOI 10.1016/S0959 4388(96)80013 4
   Monte Raso VV, 2008, J NEUROSCI METH, V170, P255, DOI 10.1016/j.jneumeth.2008.01.022
   PERIDES G, 1995, NEUROSCI LETT, V187, P21, DOI 10.1016/0304 3940(95)11327 S
   Pountos I, 2010, J ORTHOP TRAUMA, V24, P552, DOI 10.1097/BOT.0b013e3181efa8fe
   Salisbury E, 2011, J CELL BIOCHEM, V112, P2748, DOI 10.1002/jcb.23225
   Sarikcioglu L, 2003, INT J NEUROSCI, V113, P455, DOI 10.1080/00207450390162218
   Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028 3908(00)00005 8
   Scherer SS, 1997, CURR OPIN NEUROL, V10, P386, DOI 10.1097/00019052 199710000 00006
   Segklia A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034088
   Shakhbazau A, 2014, J NEUROSURG, V121, P423, DOI 10.3171/2014.5.JNS132132
   Sun YM, 2010, J BIOL CHEM, V285, P39039, DOI 10.1074/jbc.M110.168351
   TANIUCHI M, 1988, J NEUROSCI, V8, P664
   TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137
   Tsujii M, 2009, CLIN ORTHOP RELAT R, V467, P3183, DOI 10.1007/s11999 009 1009 1
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Wu MY, 2009, DEV CELL, V16, P329, DOI 10.1016/j.devcel.2009.02.012
   Wu SQ, 2017, J BIOL REG HOMEOS AG, V31, P111
   Yamada M, 2008, J ORTHOP RES, V26, P42, DOI 10.1002/jor.20474
   Yu B, 2012, J BONE MINER RES, V27, P2001, DOI 10.1002/jbmr.1663
   Zhang DM, 1998, J NEUROSCI, V18, P3314
   Zhang PX, 2008, ARTIF CELL BLOOD SUB, V36, P150, DOI 10.1080/10731190801932132
   Zhou W, 2017, CELL PHYSIOL BIOCHEM, V42, P551, DOI 10.1159/000477605
   Zou HY, 2009, J NEUROSCI, V29, P7116, DOI 10.1523/JNEUROSCI.5397 08.2009
NR 40
TC 9
Z9 9
U1 0
U2 6
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2309 4990
J9 J ORTHOP SURG HONG K
JI J. Orthop. Surg.
PD NOV 15
PY 2018
VL 26
IS 3
DI 10.1177/2309499018812953
PG 10
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Surgery
GA HB8EY
UT WOS:000451320300001
PM 30442072
OA gold
DA 2025 08 17
ER

PT J
AU Marren, K
AF Marren, Karrie
TI Dimethyl Sulfoxide: An Effective Penetration Enhancer for Topical
   Administration of NSAIDs
SO PHYSICIAN AND SPORTSMEDICINE
LA English
DT Article
DE NSAIDs; dimethyl sulfoxide; DMSO; topical diclofenac; osteoarthritis
ID RANDOMIZED CONTROLLED TRIAL; DICLOFENAC SOLUTION; DIMETHYLSULFOXIDE
   DMSO; PHOSPHOLIPID BILAYERS; PRIMARY OSTEOARTHRITIS; CELL MEMBRANES;
   HUMAN SKIN; KNEE; TOXICOLOGY; PERMEABILITY
AB Dimethyl sulfoxide (DMSO) is a molecule with a long history in pharmaceutics and is now well established as a penetration enhancer in topical pharmaceutical formulations. It is currently used for this purpose in diclofenac sodium topical solution (approved in the United States to treat signs and symptoms of osteoarthritis) and idoxuridine topical solution (approved in Europe for the treatment of herpes zoster). This article reviews the mechanism of action of DMSO as a pharmaceutical penetration enhancer, the characteristics of the molecule that facilitate transdermal drug delivery, and studies of efficacy and safety. The clinical use of pharmaceutical grade DMSO as a penetration enhancer is supported by the robust data that have accumulated over the past 3 decades demonstrating the favorable safety and tolerability profile. Dimethyl sulfoxide is a safe and effective mechanism for facilitating the transdermal delivery of both hydrophilic and lipophilic medications to provide localized drug delivery.
C1 Covidien, Hazelwood, MO 63042 USA.
C3 Covidien
RP Marren, K (通讯作者)，Covidien, 675 McDonnell Blvd, Hazelwood, MO 63042 USA.
EM karrie.liuchan@covidien.com
FU Mallinckrodt, Inc. (Hazelwood, MO), a Covidien company
FX Editorial and medical writing assistance was provided by Michael Shaw,
   PhD, and Synchrony Medical, LLC (West Chester, PA). This support was
   provided by Mallinckrodt, Inc. (Hazelwood, MO), a Covidien company.
CR ANCHORDOGUY TJ, 1992, BIOCHIM BIOPHYS ACTA, V1104, P117, DOI 10.1016/0005 2736(92)90139 D
   [Anonymous], 2010, PENNS PACK INS
   Asbill Charles S., 2000, Pharmaceutical Science and Technology Today, V3, P36, DOI 10.1016/S1461 5347(99)00225 4
   Baer PA, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471 2474 6 44
   BERTELLI G, 1995, J CLIN ONCOL, V13, P2851, DOI 10.1200/JCO.1995.13.11.2851
   Bookman AAM, 2004, CAN MED ASSOC J, V171, P333, DOI 10.1503/cmaj.1031793
   BRAYTON CF, 1986, CORNELL VET, V76, P61
   BROBYN RD, 1975, ANN NY ACAD SCI, V243, P497, DOI 10.1111/j.1749 6632.1975.tb25394.x
   Davis PW, 1984, SOC PROBL, V32, P197
   Fischer JM, 1981, US PHARM, P25
   GARCIA CA, 1983, ANN NY ACAD SCI, V411, P48, DOI 10.1111/j.1749 6632.1983.tb47285.x
   Gaylord Chemical Company LLC, 2007, GAYL CHEM CO LLC B B
   Gordeliy VI, 1998, BIOPHYS J, V75, P2343, DOI 10.1016/S0006 3495(98)77678 7
   Gurtovenko AA, 2007, J PHYS CHEM B, V111, P10453, DOI 10.1021/jp073113e
   Gurtovenko AA, 2010, CHEM REV, V110, P6077, DOI 10.1021/cr1000783
   Hewitt PG, 1998, PHARMACEUT RES, V15, P988, DOI 10.1023/A:1011961607089
   HUCKER HB, 1967, J PHARMACOL EXP THER, V155, P309
   Hui XY, 1998, PHARM RES DORDR, V15, P1589, DOI 10.1023/A:1011911302005
   IKEDA Y, 1990, ACT NEUR S, V51, P74
   JACOB SW, 1983, ANN NY ACAD SCI, V411, pR13, DOI 10.1111/j.1749 6632.1983.tb47276.x
   Kaushik D, 2008, EXPERT OPIN DRUG DEL, V5, P517, DOI [10.1517/17425247.5.5.517, 10.1517/17425247.5.5.517 ]
   Kingery WS, 1997, PAIN, V73, P123, DOI 10.1016/S0304 3959(97)00049 3
   KLIGMAN AM, 1965, J AMER MED ASSOC, V193, P796, DOI 10.1001/jama.1965.03090100042010
   McKinley A., 2008, PHARM TECH, P1
   Notman R, 2007, BIOPHYS J, V93, P2056, DOI 10.1529/biophysj.107.104703
   Notman R, 2006, J AM CHEM SOC, V128, P13982, DOI 10.1021/ja063363t
   Pathan IB, 2009, TROP J PHARM RES, V8, P173
   Rosenstein E.D., 1999, RHEUMATOLOGY DIS CLI, V25, pviii
   Rosenstein ED, 1999, RHEUM DIS CLIN N AM, V25, P899, DOI 10.1016/S0889 857X(05)70109 5
   Roth SH, 2004, ARCH INTERN MED, V164, P2017, DOI 10.1001/archinte.164.18.2017
   RUBIN LF, 1983, ANN NY ACAD SCI, V411, P6, DOI 10.1111/j.1749 6632.1983.tb47278.x
   Santos NC, 2003, BIOCHEM PHARMACOL, V65, P1035, DOI 10.1016/S0006 2952(03)00002 9
   SHIRLEY HH, 1989, PHARMACOTHERAPY, V9, P165
   SHIRLEY S W, 1978, Urology, V11, P215, DOI 10.1016/0090 4295(78)90118 8
   Simon LS, 2009, PAIN, V143, P238, DOI 10.1016/j.pain.2009.03.008
   SMITH EMIL R., 1967, ANN NYACADSCI, V141, P96, DOI 10.1111/j.1749 6632.1967.tb34870.x
   Sum AK, 2003, BIOPHYS J, V85, P3636, DOI 10.1016/S0006 3495(03)74781 X
   Tugwell PS, 2004, J RHEUMATOL, V31, P2002
   URSIN C, 1995, AM IND HYG ASSOC J, V56, P651, DOI 10.1202/0002 8894(1995)056<0651:POCSTL>2.0.CO;2
   US Environmental Protection Agency, 2003, ROB SUMM TEST PLANS
   VOGIN EE, 1970, TOXICOL APPL PHARM, V16, P606, DOI 10.1016/0041 008X(70)90065 7
   WIECHERS JW, 1989, PHARM WEEKBLAD, V11, P185, DOI 10.1007/BF01959410
   Williams AC, 2004, ADV DRUG DELIVER REV, V56, P603, DOI 10.1016/j.addr.2003.10.025
   Yu ZW, 1998, BIOPHYS CHEM, V70, P35, DOI 10.1016/S0301 4622(97)00100 2
NR 44
TC 126
Z9 146
U1 3
U2 42
PU JTE MULTIMEDIA
PI BERWYN
PA 1235 WESTLAKES DR, STE 220, BERWYN, PA 19312 USA
SN 0091 3847
J9 PHYSICIAN SPORTSMED
JI Physician Sportsmed.
PD SEP
PY 2011
VL 39
IS 3
BP 75
EP 82
DI 10.3810/psm.2011.09.1923
PG 8
WC Primary Health Care; Orthopedics; Sport Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Orthopedics; Sport Sciences
GA 893VC
UT WOS:000300384000015
PM 22030943
DA 2025 08 17
ER

PT J
AU Fujisaki, S
   Kajiya, H
   Yanagi, T
   Maeshiba, M
   Kakura, K
   Kido, H
   Ohno, J
AF Fujisaki, Seiichi
   Kajiya, Hiroshi
   Yanagi, Tsukasa
   Maeshiba, Munehisa
   Kakura, Kae
   Kido, Hirofumi
   Ohno, Jun
TI Enhancement of jaw bone regeneration via ERK1/2 activation using
   dedifferentiated fat cells
SO CYTOTHERAPY
LA English
DT Article
DE adipose tissue derived mesenchymal stem; stromal cells; bone
   regeneration; cell transplantation; dedifferentiated fat cells;
   mandibular defect
ID MESENCHYMAL STEM CELLS; TISSUE; TRANSPLANTATION; ADIPOCYTES; KINASE
AB Background aims: Mesenchymal stem/stromal cells (MSCs) are multipotent and self renewing cells that are exten sively used in tissue engineering. Adipose tissues are known to be the source of two types of MSCs; namely, adipose tissue derived MSCs (ASCs) and dedifferentiated fat (DFAT) cells. Although ASCs are sometimes transplanted for clinical cytotherapy, the effects of DFAT cell transplantation on mandibular bone healing remain unclear. Methods: The authors assessed whether DFAT cells have osteogenerative potential compared with ASCs in rats in vitro. In addition, to elucidate the ability of DFAT cells to regenerate the jaw bone, the authors exam ined the effects of DFAT cells on new bone formation in a mandibular defect model in (i) 30 week old rats and (ii) ovariectomy induced osteoporotic rats in vivo. Results: Osteoblast differentiation with bone morphogenetic protein 2 (BMP 2) or osteogenesis induced medium upregulated the osteogenesis related molecules in DFAT cells compared with those in ASCs. BMP 2 activated the phosphorylation signaling pathways of ERK1/2 and Smad2 in DFAT cells, but minor Smad1/5/9 activation was noted in ASCs. The transplantation of DFAT cells into normal or ovariectomy induced osteopo rotic rats with mandibular defects promoted new bone formation compared with that seen with ASCs. Conclusions: DFAT cells promoted osteoblast differentiation and new bone formation through ERK1/2 and Smad2 signaling pathways in vitro. The transplantation of DFAT cells promoted new mandibular bone forma tion in vivo compared with that seen with ASCs. These results suggest that transplantation of ERK1/2 acti vated DFAT cells shorten the mandibular bone healing process in cytotherapy. (c) 2021 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.
C1 [Fujisaki, Seiichi; Kajiya, Hiroshi; Maeshiba, Munehisa; Ohno, Jun] Fukuoka Dent Coll, Oral Med Res Ctr, Fukuoka, Japan.
   [Fujisaki, Seiichi; Yanagi, Tsukasa; Maeshiba, Munehisa; Kakura, Kae; Kido, Hirofumi] Fukuoka Dent Coll, Dept Oral Rehabil, Fukuoka, Japan.
   [Kajiya, Hiroshi] Fukuoka Dent Coll, Dept Physiol Sci & Mol Biol, 2 15 1 Tamura, Fukuoka 8140193, Japan.
C3 Fukuoka Dental College (FDC); Fukuoka Dental College (FDC); Fukuoka
   Dental College (FDC)
RP Kajiya, H (通讯作者)，Fukuoka Dent Coll, Dept Physiol Sci & Mol Biol, 2 15 1 Tamura, Fukuoka 8140193, Japan.
EM kajiya@college.fdcnet.ac.jp
RI Ohno, Jun/K 3466 2019
OI Kajiya, Hiroshi/0000 0003 3275 3632
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [15K11062]; Private University Research Branding Project of Fukuoka
   Dental College; Grants in Aid for Scientific Research [21K09948,
   15K11062] Funding Source: KAKEN
FX This work was supported by Grants in Aid for Scientific Research from
   the Ministry of Education, Culture, Sports, Science and Technology of
   Japan (HK; 15K11062) and the Private University Research Branding
   Project of Fukuoka Dental College.
CR Akita D, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00050
   Aldahmash A, 2012, ANN SAUDI MED, V32, P68, DOI 10.5144/0256 4947.2012.68
   Barry F, 2019, J ORTHOP RES, V37, P1229, DOI 10.1002/jor.24343
   Bougioukli S, 2018, HUM GENE THER, V29, P507, DOI 10.1089/hum.2017.097
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   D'Ippolito G, 1999, J BONE MINER RES, V14, P1115, DOI 10.1359/jbmr.1999.14.7.1115
   Ge CX, 2012, J BONE MINER RES, V27, P538, DOI 10.1002/jbmr.561
   Jeong JA, 2007, STEM CELLS, V25, P994, DOI 10.1634/stemcells.2006 0604
   Jevotovsky DS, 2018, OSTEOARTHR CARTILAGE, V26, P711, DOI 10.1016/j.joca.2018.02.906
   Jumabay M, 2009, J MOL CELL CARDIOL, V47, P565, DOI 10.1016/j.yjmcc.2009.08.004
   Katsumata Y, 2015, BIOCHEM BIOPH RES CO, V468, P622, DOI 10.1016/j.bbrc.2015.10.172
   Kazama T, 2008, BIOCHEM BIOPH RES CO, V377, P780, DOI 10.1016/j.bbrc.2008.10.046
   Kikuta S, 2013, TISSUE ENG PT A, V19, P1792, DOI [10.1089/ten.tea.2012.0380, 10.1089/ten.TEA.2012.0380]
   Kishimoto N, 2018, ORAL DIS, V24, P1161, DOI 10.1111/odi.12832
   Kishimoto N, 2013, CYTOTECHNOLOGY, V65, P15, DOI 10.1007/s10616 012 9456 z
   Levi B, 2011, STEM CELLS, V29, P576, DOI 10.1002/stem.612
   Li Y, 2017, J CELL PHYSIOL, V232, P2427, DOI 10.1002/jcp.25517
   Matsumoto T, 2008, J CELL PHYSIOL, V215, P234, DOI 10.1002/jcp.21309
   Nickel J, 2019, CELLS BASEL, V8, DOI 10.3390/cells8121579
   Nobusue H, 2008, CELL TISSUE RES, V332, P435, DOI 10.1007/s00441 008 0593 9
   Obinata D, 2011, INT J UROL, V18, P827, DOI 10.1111/j.1442 2042.2011.02865.x
   Poloni A, 2012, STEM CELLS, V30, P965, DOI 10.1002/stem.1067
   Sakuma T, 2009, J UROLOGY, V182, P355, DOI 10.1016/j.juro.2009.02.103
   Sugawara A, 2014, HUM CELL, V27, P12, DOI 10.1007/s13577 013 0075 6
   Suzuki D, 2017, J ORAL SCI, V59, P611, DOI 10.2334/josnusd.16 0878
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Trappanese DM, 2016, AM J PHYSIOL CELL PH, V310, pC921, DOI 10.1152/ajpcell.00311.2015
   Wei X, 2013, ACTA PHARMACOL SIN, V34, P747, DOI 10.1038/aps.2013.50
   Wu YK, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/4960831
   Yagi K, 2004, BIOCHEM BIOPH RES CO, V321, P967, DOI 10.1016/j.bbrc.2004.07.055
   Zhang C, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749 799X 5 37
   Zhang ZY, 2012, BIOMATERIALS, V33, P2656, DOI 10.1016/j.biomaterials.2011.12.025
   Zhou Z, 2010, DEV CELL, V19, P90, DOI 10.1016/j.devcel.2010.06.016
NR 33
TC 5
Z9 5
U1 1
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1465 3249
EI 1477 2566
J9 CYTOTHERAPY
JI Cytotherapy
PD JUL
PY 2021
VL 23
IS 7
BP 608
EP 616
DI 10.1016/j.jcyt.2021.02.115
EA JUN 2021
PG 9
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Hematology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research
   & Experimental Medicine
GA SV4RD
UT WOS:000663808100006
PM 33863640
DA 2025 08 17
ER

PT J
AU Wang, WY
   Chu, YR
   Zhang, PY
   Liang, Z
   Fan, ZL
   Guo, XQ
   Zhou, GD
   Ren, WJ
AF Wang, Weiyun
   Chu, Yaru
   Zhang, Pengyuan
   Liang, Zhuo
   Fan, Zhenlin
   Guo, Xueqiang
   Zhou, Guangdong
   Ren, Wenjie
TI Targeting macrophage polarization as a promising therapeutic strategy
   for the treatment of osteoarthritis
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Osteoarthritis; Synovitis; Macrophage polarization; Disease  modifying
   OA drugs (DMOADs)
ID PLATELET RICH PLASMA; MESENCHYMAL STEM CELLS; KNEE OSTEOARTHRITIS;
   CHONDROITIN SULFATE; DEGENERATIVE OSTEOARTHRITIS; SYNOVIAL MACROPHAGES;
   CARTILAGE REPAIR; II COLLAGEN; PAIN; INFLAMMATION
AB Osteoarthritis (OA) is a chronic osteoarthropathy characterized by the progressive degeneration of articular cartilage and synovial inflammation. Early OA clinical treatments involve intra articular injection of glucocorticoids, oral acetaminophen and non steroidal anti inflammatory drugs (NSAIDs), which are used for antiinflammation and pain relief. However, long term use of these agents will lead to inevitable side effects, even aggravate cartilage loss. At present, there are no disease modifying OA drugs (DMOADs) yet approved by regulatory agencies. Polarization regulation of synovial macrophages is a new target for OA treatment. Inhibiting M1 polarization and promoting M2 polarization of synovial macrophages can alleviate synovial inflammation, relieve joint pain and inhibit articular cartilage degradation, which is a promising strategy for OA treatment. In this study, we describe the molecular mechanisms of macrophage polarization and its key role in the development of OA. Subsequently, we summarize the latest progress of strategies for OA treatment through macrophage reprogramming, including small molecule compounds (conventional western medicine and synthetic compounds, monomer compounds of traditional Chinese medicine), biomacromolecules, metal/metal oxides, cells, and cell derivatives, and interprets the molecular mechanisms, hoping to provide some information for DMOADs development.
C1 [Wang, Weiyun; Chu, Yaru; Liang, Zhuo; Fan, Zhenlin; Guo, Xueqiang; Zhou, Guangdong; Ren, Wenjie] Xinxiang Med Univ, Third Affiliated Hosp Xinxiang Med Univ, Inst Hlth Cent Plain, Clin Med Ctr Tissue Engn & Regenerat, Xinxiang, Peoples R China.
   [Zhang, Pengyuan] Xinxiang Med Univ, Affiliated Hosp 3, Dept Trauma Med, Xinxiang, Peoples R China.
   [Zhou, Guangdong] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Plast & Reconstruct Surg, Shanghai Key Lab Tissue Engn,Sch Med, Shanghai, Peoples R China.
C3 Henan Medical University; Henan Medical University; Shanghai Jiao Tong
   University
RP Zhou, GD; Ren, WJ (通讯作者)，Xinxiang Med Univ, Third Affiliated Hosp Xinxiang Med Univ, Inst Hlth Cent Plain, Clin Med Ctr Tissue Engn & Regenerat, Xinxiang, Peoples R China.; Zhou, GD (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Plast & Reconstruct Surg, Shanghai Key Lab Tissue Engn,Sch Med, Shanghai, Peoples R China.
EM weiyun@xxmu.edu.cn; chuyaru5625@163.com; zhangpengyuan0303@163.com;
   liangzhuo@xxmu.edu.cn; fanzl0214@163.com; gxqxll@163.com;
   guangdongzhou@126.com; wjren1966@163.com
RI ; Ren, Wenjie/JFK 8231 2023; Guo, Xueqiang/GYR 2551 2022
OI Ren, Wenjie/0000 0003 4711 2352; Guo, Xueqiang/0000 0003 2318 8678;
   Wang, Weiyun/0000 0001 7152 1565
FU National Natural Science Foundation of China [32200754]; Key Research
   and Development Program of Henan province [221111310100]; Major Science
   and Technology Projects of Xinxiang City [21ZD006]; Open Project Program
   of the Third Affiliated Hospital of Xinxiang Medical University
   [KFKTZD202105, KFKTYB202107, KFKTYB202119]
FX This study was supported by the grants from National Natural Science
   Foundation of China (No. 32200754) for Weiyun Wang; the Key Research and
   Development Program of Henan province (No. 221111310100) for Wenjie Ren;
   the Major Science and Technology Projects of Xinxiang City (No. 21ZD006)
   for Wenjie Ren; and the Open Project Program of the Third Affiliated
   Hospital of Xinxiang Medical University (No. KFKTZD202105 for Wenjie
   Ren; No. KFKTYB202107 for Zhenlin Fan; No. KFKTYB202119 for Xueqiang
   Guo) .
CR ALBINA JE, 1988, AM J PHYSIOL, V254, pE459, DOI 10.1152/ajpendo.1988.254.4.E459
   Alsaleh G, 2022, NAT REV RHEUMATOL, V18, P694, DOI 10.1038/s41584 022 00863 8
   Bai Y, 2019, FREE RADICAL BIO MED, V132, P83, DOI 10.1016/j.freeradbiomed.2018.10.443
   Bannuru RR, 2019, OSTEOARTHR CARTILAGE, V27, P1578, DOI 10.1016/j.joca.2019.06.011
   Barzilai N, 2016, CELL METAB, V23, P1060, DOI 10.1016/j.cmet.2016.05.011
   Bauer C, 2016, J INFLAMM LOND, V13, DOI 10.1186/s12950 016 0139 y
   Benito MJ, 2005, ANN RHEUM DIS, V64, P1263, DOI 10.1136/ard.2004.025270
   Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937
   Black R, 2019, EUR CELLS MATER, V38, P246, DOI 10.22203/eCM.v038a17
   Bondeson J, 2010, ARTHRITIS RHEUM US, V62, P647, DOI 10.1002/art.27290
   Boswell SG, 2012, ARTHROSCOPY, V28, P429, DOI 10.1016/j.arthro.2011.10.018
   Burrello J, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00083
   Cameron AR, 2016, CIRC RES, V119, P652, DOI 10.1161/CIRCRESAHA.116.308445
   Cao Y, 2021, PHARMACEUTICS, V13
   Caplan AI, 2011, CELL STEM CELL, V9, P11, DOI 10.1016/j.stem.2011.06.008
   Caron JP, 1996, ARTHRITIS RHEUM, V39, P1535, DOI 10.1002/art.1780390914
   Chang KV, 2014, ARCH PHYS MED REHAB, V95, P562, DOI 10.1016/j.apmr.2013.11.006
   Chen D, 2017, BONE RES, V5, DOI 10.1038/boneres.2016.44
   Chen YL, 2020, AM J TRANSL RES, V12, P261
   Cho DI, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2013.135
   Corradetti B, 2016, STEM CELL TRANSL MED, V5, P670, DOI 10.5966/sctm.2015 0233
   Cosenza S, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 15376 8
   Crofford LJ, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4174
   Culemann S, 2019, NATURE, V572, P670, DOI 10.1038/s41586 019 1471 1
   da Costa BR, 2021, BMJ BRIT MED J, V375, DOI 10.1136/bmj.n2321
   Dai ML, 2018, BIOMATERIALS, V180, P91, DOI 10.1016/j.biomaterials.2018.07.011
   Dai ML, 2018, MAT SCI ENG C MATER, V89, P283, DOI 10.1016/j.msec.2018.04.021
   Dieppe PA, 2005, LANCET, V365, P965, DOI 10.1016/S0140 6736(05)71086 2
   Ding L., STEM CELL RES THER
   Diskin C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00270
   Domoto R, 2021, CELLS BASEL, V10, DOI 10.3390/cells10081881
   Dvir Ginzberg M, 2016, CURR RHEUMATOL REP, V18, DOI 10.1007/s11926 016 0591 y
   Fang WJ, 2022, INT J PHARMACEUT, V622, DOI 10.1016/j.ijpharm.2022.121802
   Feng XF, 2020, AGING US, V12, P1087, DOI 10.18632/aging.102635
   Gao YY, 2021, EXP NEUROL, V336, DOI 10.1016/j.expneurol.2020.113532
   Gerlach BD, 2021, CELL METAB, V33, P2445, DOI 10.1016/j.cmet.2021.10.015
   Goldring MB, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2592
   Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007
   Grevers L.C., ARTHRITIS RHEUM
   Gupta PK, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt116
   Hannan MT, 2000, J RHEUMATOL, V27, P1513
   Haschemi A, 2012, CELL METAB, V15, P813, DOI 10.1016/j.cmet.2012.04.023
   Haubruck P, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.763702
   He YZ, 2022, ACTA BIOMATER, V151, P512, DOI 10.1016/j.actbio.2022.07.052
   Hsu YY, 2010, TOXICOLOGY, V268, P46, DOI 10.1016/j.tox.2009.11.021
   Hu Y, 2019, FREE RADICAL BIO MED, V145, P146, DOI 10.1016/j.freeradbiomed.2019.09.024
   Huang PH, 2017, INT J SURG, V42, P117, DOI 10.1016/j.ijsu.2017.04.067
   Huang SE, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9060615
   Huang YY, 2019, CHEM REV, V119, P4357, DOI 10.1021/acs.chemrev.8b00672
   Hunter DJ, 2020, LANCET, V396, P1711, DOI 10.1016/S0140 6736(20)32230 3
   Hyunchul C, 2017, AM J SPORT MED, V45, P2774, DOI 10.1177/0363546517716641
   Jia H, 2022, INT IMMUNOPHARMACOL, V111, DOI 10.1016/j.intimp.2022.109135
   Jia ZX, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 02813 3
   Jiang T., 2019, CELL DEATH DIS, V8, P10
   Ke feng Z., RES ASTRON ASTROPHYS
   Klein Wieringa IR, 2016, J RHEUMATOL, V43, P771, DOI 10.3899/jrheum.151068
   Krasnokutsky S, 2011, ARTHRITIS RHEUM US, V63, P2983, DOI 10.1002/art.30471
   Kraus VB, 2016, OSTEOARTHR CARTILAGE, V24, P1613, DOI 10.1016/j.joca.2016.04.010
   Kraynak CA, 2020, ACTA BIOMATER, V108, P250, DOI 10.1016/j.actbio.2020.03.041
   Lai RC, 2015, SEMIN CELL DEV BIOL, V40, P82, DOI 10.1016/j.semcdb.2015.03.001
   Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088
   Lee CT, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222010948
   Lee J, 2015, INT IMMUNOPHARMACOL, V26, P103, DOI 10.1016/j.intimp.2015.03.017
   Lee JY, 2004, ARCH PHARM RES, V27, P340, DOI 10.1007/BF02980070
   Lee WYW, 2017, J ORTHOP TRANSL, V9, P76, DOI 10.1016/j.jot.2017.03.005
   Lepetsos P, 2016, BBA MOL BASIS DIS, V1862, P576, DOI 10.1016/j.bbadis.2016.01.003
   Li DL, 2023, RHEUMATOLOGY, V62, P1652, DOI 10.1093/rheumatology/keac467
   Li J, 2020, ANN RHEUM DIS, V79, P635, DOI 10.1136/annrheumdis 2019 216713
   Li KL, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 021 01236 1
   Li XZ, 2018, COLLOID SURFACE B, V171, P276, DOI 10.1016/j.colsurfb.2018.07.032
   Li YL, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 022 01367 z
   Lin X, 2021, OSTEOARTHR CARTILAGE, V29, P1225, DOI 10.1016/j.joca.2021.04.009
   Loeser RF, 2016, NAT REV RHEUMATOL, V12, P412, DOI 10.1038/nrrheum.2016.65
   Lu JS, 2021, J CELL MOL MED, V25, P6664, DOI 10.1111/jcmm.16670
   Lu JS, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075 021 02512 z
   Lu Y., CELL DEATH DIS, V12
   Ma YD, 2021, BIOMATERIALS, V274, DOI 10.1016/j.biomaterials.2021.120865
   Mahon OR, 2020, OSTEOARTHR CARTILAGE, V28, P603, DOI 10.1016/j.joca.2019.10.010
   Malfait AM, 2013, NAT REV RHEUMATOL, V9, P654, DOI 10.1038/nrrheum.2013.138
   Martel Pelletier J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.72
   Mathiessen A, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1229 9
   McAlindon TE, 2017, JAMA J AM MED ASSOC, V317, P1967, DOI 10.1001/jama.2017.5283
   Meghdadi M, 2019, INT J BIOL MACROMOL, V136, P616, DOI 10.1016/j.ijbiomac.2019.06.061
   Mehranfar S, 2019, ARTIF CELL NANOMED B, V47, P882, DOI 10.1080/21691401.2019.1576710
   Menarim BC, 2019, FASEB J, V33, P14337, DOI 10.1096/fj.201901684RR
   Meurot C, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 05323 7
   Miller RE, 2012, P NATL ACAD SCI USA, V109, P20602, DOI 10.1073/pnas.1209294110
   Miyaji N, 2021, CARTILAGE, V13, p1356S, DOI 10.1177/1947603519900795
   Nakatani Y, 2017, EUR J PHARMACOL, V815, P381, DOI 10.1016/j.ejphar.2017.09.040
   Neogi T, 2015, ANN RHEUM DIS, V74, P682, DOI 10.1136/annrheumdis 2013 204191
   O'Neill LAJ, 2016, NAT REV IMMUNOL, V16, P553, DOI 10.1038/nri.2016.70
   Ouyang XS, 2018, CELL METAB, V27, P339, DOI 10.1016/j.cmet.2018.01.007
   Palmer RH, 2015, CLIN GASTROENTEROL H, V13, P2023, DOI 10.1016/j.cgh.2015.05.025
   Park JY, 2020, ACS APPL MATER INTER, V12, P38936, DOI 10.1021/acsami.0c09842
   Patel S, 2013, AM J SPORT MED, V41, P356, DOI 10.1177/0363546512471299
   Pelletier JP, 2001, ARTHRITIS RHEUM US, V44, P1237, DOI 10.1002/1529 0131(200106)44:6<1237::AID ART214>3.0.CO;2 F
   Phinney DG, 2017, STEM CELLS, V35, P851, DOI 10.1002/stem.2575
   Portal Núñez S, 2016, BIOCHEM PHARMACOL, V108, P1, DOI 10.1016/j.bcp.2015.12.012
   Qiao H, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.255
   Qiao W., NAT COMMUN
   Quero L, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03087
   Ragni E, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01677 9
   Runhaar J., ANN RHEUM DIS
   Sanchez Lopez E, 2022, NAT REV RHEUMATOL, V18, P258, DOI 10.1038/s41584 022 00749 9
   Sandy JD, 2006, OSTEOARTHR CARTILAGE, V14, P95, DOI 10.1016/j.joca.2005.09.004
   Schäfer N, 2022, NAT MED, V28, P2473, DOI 10.1038/s41591 022 02057 x
   Shembade N, 2008, NAT IMMUNOL, V9, P254, DOI 10.1038/ni1563
   Shi HR, 2016, BRIT J PHARMACOL, V173, P1517, DOI 10.1111/bph.13453
   Siebelt M, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0865 1
   Sivitz WI, 2020, DIABETES CARE, V43, P940, DOI 10.2337/dc19 1769
   Stranks AJ, 2015, J INNATE IMMUN, V7, P375, DOI 10.1159/000370112
   Sun Y, 2010, INT ORTHOP, V34, P589, DOI 10.1007/s00264 009 0793 2
   Sun YL, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228513
   Sun Z., 2021, CELL DEATH DIS, V12
   Tan CY, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt465
   Tan SSH, 2021, TISSUE ENG PART B RE, V27, P1, DOI [10.1089/ten.teb.2019.0326, 10.1089/ten.TEB.2019.0326]
   Tang SJ, 2021, INT J NANOMED, V16, P8185, DOI 10.2147/IJN.S336062
   Teng P, 2019, J IMMUNOL, V203, P485, DOI 10.4049/jimmunol.1801513
   Pham TH, 2017, PHYTOMEDICINE, V24, P96, DOI 10.1016/j.phymed.2016.11.014
   Tian ZS, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.669213
   Toh WS, 2017, SEMIN CELL DEV BIOL, V67, P56, DOI 10.1016/j.semcdb.2016.11.008
   Uchiyama R, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052336
   Uebelhart D., ARTHRIT CARE RES
   Utomo L, 2016, OSTEOARTHR CARTILAGE, V24, P1629, DOI 10.1016/j.joca.2016.04.013
   van Buul GM, 2011, AM J SPORT MED, V39, P2362, DOI 10.1177/0363546511419278
   Van den Bossche J, 2017, TRENDS IMMUNOL, V38, P395, DOI 10.1016/j.it.2017.03.001
   von Kaeppler EP, 2021, CLIN IMMUNOL, V229, DOI 10.1016/j.clim.2021.108784
   Wang D, 2022, OSTEOARTHR CARTILAGE, V30, P406, DOI 10.1016/j.joca.2021.11.014
   Wang Hao, 2021, Rheumatology (Oxford), V60, P4899, DOI 10.1093/rheumatology/keab018
   Wang JR, 2020, N S ARCH PHARMACOL, V393, P1987, DOI 10.1007/s00210 019 01763 7
   Wang LLW, 2021, BIOENG TRANSL MED, V6, DOI 10.1002/btm2.10214
   Wang L, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.967193
   Wang R, 2021, CELL TISSUE RES, V384, P113, DOI 10.1007/s00441 020 03319 1
   Woo CH, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1735249
   Wu BN, 2006, MOL PHARMACOL, V70, P977, DOI 10.1124/mol.106.024919
   Wu CL, 2020, OSTEOARTHR CARTILAGE, V28, P544, DOI 10.1016/j.joca.2019.12.007
   Wu L, 2011, OSTEOARTHR CARTILAGE, V19, pS105, DOI 10.1016/S1063 4584(11)60240 9
   Xia QQ, 2015, STEM CELL TRANSL MED, V4, P523, DOI 10.5966/sctm.2014 0200
   Xie JW, 2021, OSTEOARTHR CARTILAGE, V29, P1048, DOI 10.1016/j.joca.2021.04.006
   Xie JW, 2019, CYTOKINE GROWTH F R, V46, P36, DOI 10.1016/j.cytogfr.2019.03.004
   Xiong H, 2022, SMALL, V18, DOI 10.1002/smll.202203240
   Yang H., 2022, Adv Funct Mater, V32
   Yeh JL, 2010, BRIT J PHARMACOL, V159, P1151, DOI 10.1111/j.1476 5381.2009.00587.x
   Yu ZY, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 1014 y
   Zavatti M, 2020, BIOFACTORS, V46, P106, DOI 10.1002/biof.1576
   Zhang F, 2019, NAT IMMUNOL, V20, P928, DOI 10.1038/s41590 019 0378 1
   Zhang H., 2020, MACROPHAGES REGULATE, V28
   Zhang HY, 2018, ANN RHEUM DIS, V77, P1524, DOI 10.1136/annrheumdis 2018 213450
   Zhang JY, 2020, AGING US, V12, P25138, DOI 10.18632/aging.104110
   Zhang LL, 2022, ADV MATER, V34, DOI 10.1002/adma.202106316
   Zhao JH, 2022, BIOMATER ADV, V134, DOI 10.1016/j.msec.2022.112719
   Zhao P., AM J PHYSIOL GASTR L
   Zhou F, 2020, ACS APPL MATER INTER, V12, P2009, DOI 10.1021/acsami.9b16327
   Zhou F, 2019, ACTA PHARM SIN B, V9, P973, DOI 10.1016/j.apsb.2019.01.015
   Zhou H, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 03005 9
   Zhou T, 2022, MATER TODAY NANO, V17, DOI 10.1016/j.mtnano.2021.100164
NR 156
TC 38
Z9 38
U1 12
U2 75
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD MAR
PY 2023
VL 116
AR 109790
DI 10.1016/j.intimp.2023.109790
EA FEB 2023
PG 15
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA E2GF9
UT WOS:000973776800001
PM 36736223
DA 2025 08 17
ER

PT J
AU Kou, JQ
   Zheng, XJ
   Guo, JW
   Liu, Y
   Liu, XY
AF Kou, Jianqiang
   Zheng, Xiujun
   Guo, Jianwei
   Liu, Yang
   Liu, Xiangyun
TI MicroRNA 218 5p relieves postmenopausal osteoporosis through promoting
   the osteoblast differentiation of bone marrow mesenchymal stem cells
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE bone marrow mesenchymal stem cells; microRNA 218 5p; osteoblast
   differentiation; postmenopausal osteoporosis
ID OSTEOGENIC DIFFERENTIATION; FRACTURE PREVENTION; MIR 218; PROLIFERATION;
   EXPRESSION; DRUGS
AB MicroRNAs (miRs) are short noncoding RNAs that play key regulatory roles in osteoblast differentiation. In this study, the specific regulatory roles of miR 218 5p on postmenopausal osteoporosis (PMOP) were investigated. The mouse model of PMOP was established by bilateral ovariectomy, and the injection of miR 218 5p mimics significantly relieved PMOP degree. Then, bone marrow mesenchymal stem cells (BMMSCs) isolated from PMOP mice were induced into osteoblasts. When compared with normal BMMSCs, PMOP BMMSCs exhibited significantly lower alkaline phosphatase (ALP) activity and less mineralized nodules, as well as downregulated miR 218 5p, Runx2, Osterix, COL1A1, and OCN after induction (P < .05). The transfection of miR 218 5p mimics, and inhibitor significantly promoted, inhibited the osteoblast differentiation of PMOP BMMSCs, respectively. In addition, COL1A1 was a target of miR 218 5p. The transfection of miR 218 5p mimics into PMOP BMMSCs significantly upregulated COL1A1 at 14th and 21st day post induction, but not at 7th day. Our findings suggest miR 218 5p may relieve PMOP through promoting the osteoblast differentiation of BMMSCs.
C1 [Kou, Jianqiang; Zheng, Xiujun; Guo, Jianwei; Liu, Yang; Liu, Xiangyun] Qingdao Univ, Affiliated Hosp, Dept Spinal Surg, 16 Jiangsu Rd, Qingdao 266003, Shandong, Peoples R China.
C3 Qingdao University
RP Liu, XY (通讯作者)，Qingdao Univ, Affiliated Hosp, Dept Spinal Surg, 16 Jiangsu Rd, Qingdao 266003, Shandong, Peoples R China.
EM liuxiangyun25@163.com
OI kou, jianqiang/0000 0003 4901 414X; Liu, Xiangyun/0000 0003 4377 8253
CR Alajez NM, 2011, CANCER RES, V71, P2381, DOI 10.1158/0008 5472.CAN 10 2754
   An JH, 2013, TISSUE ENG PT A, V19, P685, DOI [10.1089/ten.tea.2012.0047, 10.1089/ten.TEA.2012.0047]
   Boyanov M, 2017, DRUGS R&D, V17, P125, DOI 10.1007/s40268 016 0159 3
   Cao Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097098
   Chen X., 2017, DIER JUN YI XUE XUE, V38, P397
   De La Cruz Montoya AH, 2018, EXP BIOL MED, V243, P1027, DOI 10.1177/1535370218806828
   Delmas PD, 2003, NEW ENGL J MED, V359, P2018
   Gennari L, 2016, EXPERT OPIN PHARMACO, V17, P1141, DOI 10.1080/14656566.2016.1176147
   Guo Y, 2015, MOL MED REP, V12, P3033, DOI 10.3892/mmr.2015.3705
   Hassan MQ, 2012, J BIOL CHEM, V287, P42084, DOI 10.1074/jbc.M112.377515
   Hiligsmann M, 2015, PHARMACOECONOMICS, V33, P205, DOI 10.1007/s40273 014 0231 1
   Hong D, 2010, EXP CELL RES, V316, P2291, DOI 10.1016/j.yexcr.2010.05.011
   Kokabu S, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/3753581
   Kureel J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.4
   Lewiecki EM, 2009, EXPERT OPIN EMERG DR, V14, P129, DOI [10.1517/14728210902766813 , 10.1517/14728210902766813]
   Li JR, 2012, INT J MOL SCI, V13, P16053, DOI 10.3390/ijms131216053
   Li M, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/132642
   Li ZY, 2009, J BIOL CHEM, V284, P15676, DOI 10.1074/jbc.M809787200
   Lin H, 2019, BIOMATERIALS, V203, P96, DOI 10.1016/j.biomaterials.2018.06.026
   Liu B, 2016, ONCOL REP, V35, P3178, DOI 10.3892/or.2016.4749
   Liu XD, 2015, BIOL CHEM, V396, P339, DOI 10.1515/hsz 2014 0268
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Maeda SS, 2014, ARQ BRAS ENDOCRINOL, V58, P162, DOI 10.1590/0004 2730000003039
   McCarus DC, 2006, OBSTET GYNECOL SURV, V61, P39, DOI 10.1097/01.ogx.0000197807.08697.06
   Meng J, 2015, PEERJ, V3, DOI 10.7717/peerj.971
   Pfeifer M, 2011, AM J PHYS MED REHAB, V90, P805, DOI 10.1097/PHM.0b013e31821f6df3
   Qiu J, 2018, MOL MED REP, V17, P6301, DOI 10.3892/mmr.2018.8713
   Ramírez Salazar EG, 2018, GENE, V679, P19, DOI 10.1016/j.gene.2018.08.074
   Sherstyuk VV, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 02632 0
   Shi L, 2018, CALCIFIED TISSUE INT, V103, P227, DOI 10.1007/s00223 018 0410 8
   Tanaka K, 2014, CALCIFIED TISSUE INT, V94, P454, DOI 10.1007/s00223 013 9828 1
   Tantikanlayaporn D, 2013, PHYTOMEDICINE, V20, P676, DOI 10.1016/j.phymed.2013.02.008
   Tie J, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000879
   Wang C, 2016, MED SCI MONITOR, V22, P226, DOI 10.12659/MSM.897044
   Wang G, 2017, BONE JOINT RES, V6, P452, DOI 10.1302/2046 3758.67.BJR 2016 0292.R1
   Wang WW, 2017, EUR REV MED PHARMACO, V21, P5534, DOI 10.26355/eurrev_201712_13989
   Wang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034641
   Yang L, 2016, CELL PHYSIOL BIOCHEM, V38, P809, DOI 10.1159/000443036
   You L, 2016, CELL PHYSIOL BIOCHEM, V39, P253, DOI 10.1159/000445621
   Zhong YX, 2019, EUR REV MED PHARMACO, V23, P3575, DOI 10.26355/eurrev_201905_17779
NR 40
TC 25
Z9 32
U1 0
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD FEB
PY 2020
VL 121
IS 2
BP 1216
EP 1226
DI 10.1002/jcb.29355
EA SEP 2019
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA LK1NC
UT WOS:000484859600001
PM 31478244
DA 2025 08 17
ER

PT J
AU Ray, A
   Das, DS
   Song, Y
   Macri, V
   Richardson, P
   Brooks, CL
   Chauhan, D
   Anderson, KC
AF Ray, A.
   Das, D. S.
   Song, Y.
   Macri, V.
   Richardson, P.
   Brooks, C. L.
   Chauhan, D.
   Anderson, K. C.
TI A novel agent SL 401 induces anti myeloma activity by targeting
   plasmacytoid dendritic cells, osteoclastogenesis and cancer stem like
   cells
SO LEUKEMIA
LA English
DT Article
ID MULTIPLE MYELOMA; INTERLEUKIN 3 RECEPTOR; T CELLS; IN VIVO; GROWTH;
   IL 3; MICROENVIRONMENT; INHIBITION; EXPRESSION; EFFICACY
AB Novel therapies for multiple myeloma (MM) can target mechanism(s) in the host MM bone marrow (BM) microenvironment mediating MM progression and chemoresistance. Our studies showed increased numbers of tumor promoting, immunosuppressive and drug resistant plasmacytoid dendritic cells (pDCs) in the MM BM microenvironment. pDC MM cell interactions upregulate interleukin 3 (IL 3), which stimulates both pDC survival and MM cell growth. Since IL 3 R is highly expressed on pDCs in the MM BM milieu, we here targeted pDCs using a novel IL 3 R targeted therapeutic SL 401. In both in vitro and in vivo models of MM in its BM milieu, SL 401 decreases viability of pDCs, blocks pDC induced MM cell growth, and synergistically enhances anti MM activity of bortezomib and pomalidomide. Besides promoting pDC survival and MM cell growth, IL 3 also mediates progression of osteolytic bone disease in MM. Osteoclast (OCL) progenitor cells express IL 3 R, and we show that SL 401 abrogates monocyte derived OCL formation and bone resorption. Finally, we show that SL 401 also decreases the viability of IL 3 R expressing cancer stem like cells in MM. Overall, our study provides the preclinical basis for clinical trials of SL 401 to block pDC induced MM cell growth, inhibit osteoclastogenesis and target MM stem like cell subpopulations to improve patient outcome in MM.
C1 [Ray, A.; Das, D. S.; Song, Y.; Richardson, P.; Chauhan, D.; Anderson, K. C.] Harvard Med Sch, Dept Med Oncol, LeBow Inst Myeloma Therapeut, M561,450 Brookline Ave, Boston, MA 02215 USA.
   [Ray, A.; Das, D. S.; Song, Y.; Richardson, P.; Chauhan, D.; Anderson, K. C.] Harvard Med Sch, Jerome Lipper Myeloma Ctr, Dana Farber Canc Inst, M561,450 Brookline Ave, Boston, MA 02215 USA.
   [Macri, V.; Brooks, C. L.] Stemline Therapeut, New York, NY USA.
C3 Harvard University; Harvard Medical School; Harvard University; Harvard
   University Medical Affiliates; Dana Farber Cancer Institute; Harvard
   Medical School
RP Chauhan, D; Anderson, KC (通讯作者)，Harvard Med Sch, Dept Med Oncol, LeBow Inst Myeloma Therapeut, M561,450 Brookline Ave, Boston, MA 02215 USA.; Chauhan, D; Anderson, KC (通讯作者)，Harvard Med Sch, Jerome Lipper Myeloma Ctr, Dana Farber Canc Inst, M561,450 Brookline Ave, Boston, MA 02215 USA.
EM Dharminder_Chauhan@dfci.harvard.edu; Kenneth_Anderson@dfci.harvard.edu
RI Anderson, Kenneth/ACP 5073 2022
OI Brooks, Christopher/0000 0003 3487 6644
FU National Institutes of Health Specialized Programs of Research
   Excellence (SPORE) [P50100707, R01CA207237, RO1 CA050947]
FX The grant support for this investigation was provided by National
   Institutes of Health Specialized Programs of Research Excellence (SPORE)
   grant P50100707, R01CA207237, and RO1 CA050947. KCA is an American
   Cancer Society Clinical Research Professor.
CR An G, 2016, BLOOD, V128, P1590, DOI 10.1182/blood 2016 03 707547
   Anderson KC, 2014, HEMATOL ONCOL CLIN N, V28, pXI, DOI 10.1016/j.hoc.2014.08.001
   Anderson KC, 2012, J CLIN ONCOL, V30, P445, DOI 10.1200/JCO.2011.37.8919
   Angelot Delettre F, 2015, HAEMATOLOGICA, V100, P223, DOI 10.3324/haematol.2014.111740
   [Anonymous], 2016, BLOOD
   [Anonymous], 2016, BLOOD
   [Anonymous], BLOOD
   [Anonymous], BLOOD
   [Anonymous], BLOOD
   Brooks CR, 2013, CYTOM PART B CLIN CY, V84B, P104, DOI 10.1002/cyto.b.21069
   Brown RD, 2001, BLOOD, V98, P2992, DOI 10.1182/blood.V98.10.2992
   Chauhan D, 2012, CANCER CELL, V22, P345, DOI 10.1016/j.ccr.2012.08.007
   Chauhan D, 2009, CANCER CELL, V16, P309, DOI 10.1016/j.ccr.2009.08.019
   Ehrlich LA, 2005, BLOOD, V106, P1407, DOI 10.1182/blood 2005 03 1080
   Frankel AE, 2014, BLOOD, V124, P385, DOI 10.1182/blood 2014 04 566737
   Frolova O, 2014, BRIT J HAEMATOL, V166, P862, DOI 10.1111/bjh.12978
   Gerrard L, 2005, STEM CELLS, V23, P124, DOI 10.1634/stemcells.2004 0102
   Gionco J, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.4724.4724
   Goswami S, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.2748.2748
   Grouard G, 1997, J EXP MED, V185, P1101, DOI 10.1084/jem.185.6.1101
   Hogge DE, 2004, LEUKEMIA RES, V28, P1221, DOI 10.1016/j.leukres.2004.03.015
   Jakubikova J, 2011, BLOOD, V117, P4409, DOI 10.1182/blood 2010 02 267344
   Lee JW, 2004, BLOOD, V103, P2308, DOI 10.1182/blood 2003 06 1992
   Liu YQ, 2005, CANCER GENE THER, V12, P122, DOI 10.1038/sj.cgt.7700757
   Luu TH, 2013, J CLIN ONCOL, V31
   Maeda T, 2005, INT J HEMATOL, V81, P148, DOI 10.1532/IJH97.04116
   Masarova L, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.e18558
   Matsui W, 2004, BLOOD, V103, P2332, DOI 10.1182/blood 2003 09 3064
   Patnaik MM, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.110.110
   Pinnamaneni P, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.1015.1015
   Ratta M, 2002, BLOOD, V100, P230, DOI 10.1182/blood.V100.1.230
   Ray A, 2015, LEUKEMIA, V29, P1441, DOI 10.1038/leu.2015.11
   Ray A, 2014, LEUKEMIA, V28, P1716, DOI 10.1038/leu.2014.46
   Reizis B, 2011, ANNU REV IMMUNOL, V29, P163, DOI 10.1146/annurev immunol 031210 101345
   Richardson PG, 2013, BLOOD, V121, P1961, DOI 10.1182/blood 2012 08 450742
   Silbermann R, 2014, LEUKEMIA, V28, P951, DOI 10.1038/leu.2013.385
   Tai YT, 2016, BLOOD, V127, P3225, DOI 10.1182/blood 2016 01 691162
   Tai YT, 2012, BLOOD, V120, P1877, DOI 10.1182/blood 2011 12 396853
   Tassone P, 2005, BLOOD, V106, P713, DOI 10.1182/blood 2005 01 0373
   Tefferi A, 2014, BLOOD, V124
NR 40
TC 34
Z9 34
U1 0
U2 7
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0887 6924
EI 1476 5551
J9 LEUKEMIA
JI Leukemia
PD DEC
PY 2017
VL 31
IS 12
BP 2652
EP 2660
DI 10.1038/leu.2017.135
PG 9
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Hematology
GA FO8ZJ
UT WOS:000417177100014
PM 28479592
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Lu, YT
   He, JT
   Zhu, HX
   Wang, YX
AF Lu, Yongtao
   He, Jintao
   Zhu, Hanxing
   Wang, Yongxuan
TI Effect of parathyroid hormone on the structural, densitometric and
   failure behaviors of mouse tibia in the spatiotemporal space
SO PLOS ONE
LA English
DT Article
ID MICRO COMPUTED TOMOGRAPHY; FINITE ELEMENT ANALYSIS; BONE ARCHITECTURE;
   ALENDRONATE; REPRODUCIBILITY; COMBINATION; STRENGTH; FEMUR; PTH;
   ADAPTATION
AB Parathyroid hormone (PTH) is an anabolic bone drug approved by the US Food and Drug Administration (FDA) to treat osteoporosis. However, previous studies using cross sectional designs have reported variable and sometimes contradictory results. The aim of the present study was to quantify the localized effect of PTH on the structural and densitometric behaviors of mouse tibia and their links with the global mechanical behavior of bone using a novel spatiotemporal image analysis approach and a finite element analysis technique. Twelve female C57BL/6J mice were divided into two groups: the control and PTH treated groups. The entire right tibiae were imaged using an in vivo micro computed tomography (mu CT) system eight consecutive times. Next, the in vivo longitudinal tibial mu CT images were rigidly registered and divided into 10 compartments across the entire tibial space. The bone volume (BV), bone mineral content (BMC), bone tissue mineral density (TMD), and tibial endosteal and periosteal areas (TEA and TPA) were quantified in each compartment. Additionally, finite element models of all the tibiae were generated to analyze the failure behavior of the tibia. It was found that both the BMC and BV started to increase in the proximal tibial region, and then the increases extended to the entire tibial region after two weeks of treatment (p < 0.05). PTH intervention significantly reduced the TEA in most tibial compartments after two weeks of treatment, and the TPA increased in most tibial regions after four weeks of treatment (p < 0.05). Tibial failure loads significantly increased after three weeks of PTH treatment (p < 0.01). The present study provided the first evidence of the localized effect of PTH on bone structural and densitometric properties, as well as their links with the global mechanical behaviors of bone, which are important pieces of information for unveiling the mechanism of PTH intervention.
C1 [Lu, Yongtao; He, Jintao] Dalian Univ Technol, Dept Engn Mech, Dalian, Peoples R China.
   [Lu, Yongtao] Dalian Univ Technol, State Key Lab Struct Anal Ind Equipment, Dalian, Peoples R China.
   [Zhu, Hanxing] Cardiff Univ, Sch Engn, Cardiff, S Glam, Wales.
   [Wang, Yongxuan] Dalian Univ, Affiliated Zhongshan Hosp, Dalian, Liaoning, Peoples R China.
C3 Dalian University of Technology; Dalian University of Technology;
   Cardiff University; Dalian University
RP Wang, YX (通讯作者)，Dalian Univ, Affiliated Zhongshan Hosp, Dalian, Liaoning, Peoples R China.
EM wangyongxuan@dlu.edu.cn
RI Zhu, Hanxing/ABC 4807 2020; Lu, Yongtao/AAC 2394 2021
OI Lu, Yongtao/0000 0002 8511 6111; 
FU National Natural Science Foundation of China [11702057]; Chinese
   Fundamental Research Funds for the Central Universities [DUT18LK19];
   State Key Laboratory of Structural Analysis for Industrial Equipment
   [GZ18104]
FX Dr. Yongtao Lu received the funding from the National Natural Science
   Foundation of China (grant number: 11702057 to Dr. Yongtao Lu) and from
   the Chinese Fundamental Research Funds for the Central Universities
   (grant number: DUT18LK19). These fundings sponsored Dr. Yongtao Lu's
   research activities including study design, data analysis and
   preparation of the manuscript. Dr. Yongtao Lu and Dr. Hanxing Zhu
   jointly received the funding from the State Key Laboratory of Structural
   Analysis for Industrial Equipment (grant number: GZ18104). This funding
   sponsored Dr. Hanxing Zhu's research activities including the revision
   of the manuscript.
CR Altman AR, 2015, BONE, V81, P370, DOI 10.1016/j.bone.2015.07.037
   Altman AR, 2014, BONE, V61, P149, DOI 10.1016/j.bone.2014.01.008
   Ausk BJ, 2013, BONE, V57, P413, DOI 10.1016/j.bone.2013.09.009
   Birkhold AI, 2015, BONE, V75, P210, DOI 10.1016/j.bone.2015.02.027
   Birkhold AI, 2014, BIOMATERIALS, V35, P9290, DOI 10.1016/j.biomaterials.2014.07.051
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Boyd SK, 2006, BONE, V39, P854, DOI 10.1016/j.bone.2006.04.017
   Brouwers JEM, 2009, OSTEOPOROSIS INT, V20, P1823, DOI 10.1007/s00198 009 0882 5
   Buie HR, 2007, BONE, V41, P505, DOI 10.1016/j.bone.2007.07.007
   Buie HR, 2008, J BONE MINER RES, V23, P2048, DOI 10.1359/JBMR.080808
   Campbell GM, 2011, BONE, V49, P225, DOI 10.1016/j.bone.2011.04.008
   Dall'Ara E, 2014, J BIOMECH, V47, P2956, DOI 10.1016/j.jbiomech.2014.07.019
   de Bakker CMJ, 2015, BONE, V73, P198, DOI 10.1016/j.bone.2014.12.061
   Ferrari SL, 2005, ENDOCRINOLOGY, V146, P1854, DOI 10.1210/en.2004 1282
   Glatt V, 2007, J BONE MINER RES, V22, P1197, DOI 10.1359/JBMR.070507
   GLUER CC, 1995, OSTEOPOROSIS INT, V5, P262, DOI 10.1007/BF01774016
   Johnell O, 2005, OSTEOPOROSIS INT, V16, pS3, DOI 10.1007/s00198 004 1702 6
   Johnston S, 2007, ENDOCRINOLOGY, V148, P4466, DOI 10.1210/en.2007 0229
   Kanis JA, 2005, OSTEOPOROSIS INT, V16, P229, DOI 10.1007/s00198 004 1811 2
   Keaveny TM, 2008, J BONE MINER RES, V23, P1974, DOI [10.1359/jbmr.080805, 10.1359/JBMR.080805]
   Klinck RJ, 2008, MED ENG PHYS, V30, P888, DOI 10.1016/j.medengphy.2007.11.004
   Kohler T, 2005, CALCIFIED TISSUE INT, V77, P281, DOI 10.1007/s00223 005 0039 2
   Lambers FM, 2012, CALCIFIED TISSUE INT, V90, P108, DOI 10.1007/s00223 011 9553 6
   Lu YT, 2018, ANN BIOMED ENG, V46, P749, DOI 10.1007/s10439 018 1994 x
   Lu YT, 2018, J MECH MED BIOL, V18, DOI 10.1142/S0219519418500112
   Lu YT, 2017, J MECH BEHAV BIOMED, V75, P244, DOI 10.1016/j.jmbbm.2017.07.034
   Lu YT, 2016, J BIOMECH, V49, P2095, DOI 10.1016/j.jbiomech.2016.05.022
   Lu YT, 2015, MED ENG PHYS, V37, P1091, DOI 10.1016/j.medengphy.2015.08.017
   Lu YT, 2014, J BIOMECH, V47, P2512, DOI 10.1016/j.jbiomech.2014.04.015
   Nishiyama KK, 2010, BONE, V46, P155, DOI 10.1016/j.bone.2009.09.023
   Pierroz DD, 2010, J BIOL CHEM, V285, P28164, DOI 10.1074/jbc.M110.101964
   Pistoia W, 2002, BONE, V30, P842, DOI 10.1016/S8756 3282(02)00736 6
   Qasim M, 2016, OSTEOPOROSIS INT, V27, P2815, DOI 10.1007/s00198 016 3597 4
   Schulte FA, 2013, BONE, V52, P485, DOI 10.1016/j.bone.2012.09.008
   Schulte FA, 2011, BONE, V48, P433, DOI 10.1016/j.bone.2010.10.007
   Stadelmann VA, 2011, CLIN BIOMECH, V26, P101, DOI 10.1016/j.clinbiomech.2010.08.014
   Sugiyama T, 2008, BONE, V43, P238, DOI 10.1016/j.bone.2008.04.012
   Wu XW, 2010, CELL STEM CELL, V7, P571, DOI 10.1016/j.stem.2010.09.012
NR 38
TC 2
Z9 3
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUL 10
PY 2019
VL 14
IS 7
AR e0219575
DI 10.1371/journal.pone.0219575
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA IW4JZ
UT WOS:000484947800119
PM 31291372
OA Green Accepted, Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Aleksic, V
   Aoki, A
   Iwasaki, K
   Takasaki, AA
   Wang, CY
   Abiko, Y
   Ishikawa, I
   Izumi, Y
AF Aleksic, Verica
   Aoki, Akira
   Iwasaki, Kengo
   Takasaki, Aristeo Atsushi
   Wang, Chen Ying
   Abiko, Yoshimitsu
   Ishikawa, Isao
   Izumi, Yuichi
TI Low level Er:YAG laser irradiation enhances osteoblast proliferation
   through activation of MAPK/ERK
SO LASERS IN MEDICAL SCIENCE
LA English
DT Article
DE Er:YAG laser; LLLT/LPLI; Photobiomodulation; Osteoblast cell
   proliferation; MAPK/ERK; Western blotting
ID ER YAG LASER; BONE NODULE FORMATION; THERAPY; LESIONS
AB Although the use of high level Er:YAG laser irradiation has been increasing in periodontal and peri implant therapy, the effects of low level Er:YAG laser on surrounding tissues and cells remain unclear. In the present study, the effects of low level Er:YAG laser irradiation on osteoblast proliferation were investigated. Cells of the osteoblastic cell line MC3T3 E1 were treated with low level Er:YAG laser irradiation with various combinations of laser settings (fluence 0.7 17.2 J/cm(2)) and in the absence or presence of culture medium during irradiation. On day 1 and/or day 3, cell proliferation and death were determined by cell counting and by measurement of lactate dehydrogenase (LDH) levels. Further, the role of mitogen activated protein kinase (MAPK) pathways in laser enhanced cell proliferation was investigated by inhibiting the MAPK pathways and then measuring MAPK phosphorylation by Western blotting. Higher proliferation rates were found with various combinations of irradiation parameters on days 1 and 3. Significantly higher proliferation was also observed in laser irradiated MC3T3 E1 cells at a fluence of approximately 1.0 15.1 J/cm(2), whereas no increase in LDH activity was observed. Further, low level Er:YAG irradiation induced the phosphorylation of extracellular signal regulated protein kinase (MAPK/ERK) 5 to 30 min after irradiation. Although MAPK/ERK 1/2 inhibitor U0126 significantly inhibited laser enhanced cell proliferation, activation of stress activated protein kinases/Jun N terminal kinase (SAPK/JNK) and p38 MAPK was not clearly detected. These results suggest that low level Er:YAG laser irradiation increases osteoblast proliferation mainly by activation of MAPK/ERK, suggesting that the Er:YAG laser may be able to promote bone healing following periodontal and peri implant therapy.
C1 [Aleksic, Verica; Aoki, Akira; Takasaki, Aristeo Atsushi; Izumi, Yuichi] Tokyo Med & Dent Univ, Grad Sch, Dept Hard Tissue Engn, Sect Periodontol,Bunkyo Ku, Tokyo 1138549, Japan.
   [Aleksic, Verica; Izumi, Yuichi] Tokyo Med & Dent Univ, Int Res Ctr Mol Sci Tooth & Bone Dis, Global Ctr Excellence GCOE Program, Tokyo 1138549, Japan.
   [Iwasaki, Kengo] Tokyo Womens Med Univ, Dept Oral & Maxillofacial Surg, Shinjuku Ku, Tokyo 1628666, Japan.
   [Wang, Chen Ying] Natl Taiwan Univ, Dept Dent, Div Periodontol, Taipei 10764, Taiwan.
   [Abiko, Yoshimitsu] Nihon Univ, Sch Dent, Dept Biochem, Matsudo, Chiba 271, Japan.
   [Ishikawa, Isao] Tokyo Womens Med Univ, Inst Adv Biomed Engn & Sci, Tokyo 1628666, Japan.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Tokyo Women's Medical University; National Taiwan University; Nihon
   University; Tokyo Women's Medical University
RP Aoki, A (通讯作者)，Tokyo Med & Dent Univ, Grad Sch, Dept Hard Tissue Engn, Sect Periodontol,Bunkyo Ku, 1 5 45 Yushima, Tokyo 1138549, Japan.
EM aoperi@tmd.ac.jp; k iwasaki.peri@tmd.ac.jp
RI wang, chen/AAM 9871 2020; Iwasaki, Kengo/AAG 7902 2021
OI Pavlic, Verica/0000 0001 6737 6449; WANG, CHEN YING/0000 0001 8129 6701;
   
FU Global Center of Excellence Program for Frontier Research in Tooth and
   Bone Diseases at Tokyo Medical and Dental University; Ministry of
   Education, Culture, Sports, Science and Technology of Japan [16592064,
   19592382]; Grants in Aid for Scientific Research [22592308, 16592064,
   19592382] Funding Source: KAKEN
FX This study was supported in part by a grant from the Global Center of
   Excellence Program for Frontier Research in Tooth and Bone Diseases at
   Tokyo Medical and Dental University, and by a Grand in Aid for
   Scientific Research (c)(2) (no. 16592064 and no. 19592382) to A. A.,
   from the Ministry of Education, Culture, Sports, Science and Technology
   of Japan. Authors wish to thank Drs. Motohiro Komaki and Keiko Tanaka
   for their kind assistance and support.
CR Aoki A, 2004, PERIODONTOL 2000, V36, P59, DOI 10.1111/j.1600 0757.2004.03679.x
   Aoki Akira, 2008, General Dentistry, V56, P674
   Arisu HD, 2006, LASER MED SCI, V21, P175, DOI 10.1007/s10103 006 0398 6
   de Mello EDA, 2008, LASER MED SCI, V23, P253, DOI 10.1007/s10103 007 0475 5
   Bogoyevitch MA, 2004, BBA PROTEINS PROTEOM, V1697, P89, DOI 10.1016/j.bbapap.2003.11.016
   Crespi R, 2007, J PERIODONTOL, V78, P1195, DOI 10.1902/jop.2007.060460
   HALE GM, 1973, APPL OPTICS, V12, P555, DOI 10.1364/AO.12.000555
   Ishikawa I, 2004, J PERIODONTAL RES, V39, P275, DOI 10.1111/j.1600 0765.2004.00738.x
   ISHIKAWA I, 2009, PERIODONTOL, V90, P126
   Miyata H, 2006, INT ENDOD J, V39, P238, DOI 10.1111/j.1365 2591.2006.01080.x
   Ohshiro T, 1991, J Clin Laser Med Surg, V9, P267
   Ozawa Y, 1998, BONE, V22, P347, DOI 10.1016/S8756 3282(97)00294 9
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   Pinheiro ALB, 2006, PHOTOMED LASER SURG, V24, P169, DOI 10.1089/pho.2006.24.169
   Pourzarandian A, 2005, J PERIODONTAL RES, V40, P182, DOI 10.1111/j.1600 0765.2005.00789.x
   Pourzarandian A, 2005, J PERIODONTOL, V76, P187, DOI 10.1902/jop.2005.76.2.187
   Pourzarandian A, 2004, PHOTOMED LASER SURG, V22, P342, DOI 10.1089/1549541041797913
   Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955 0674(97)80061 0
   Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320 344.2004
   Schwarz F, 2008, J CLIN PERIODONTOL, V35, P29, DOI 10.1111/j.1600 051X.2008.01259.x
   Schwarz F, 2006, CLIN ORAL INVEST, V10, P279, DOI 10.1007/s00784 006 0070 3
   Schwarz F, 2006, J CLIN PERIODONTOL, V33, P584, DOI 10.1111/j.1600 051X.2006.00956.x
   Schwarz F, 2009, PERIODONTOL 2000, V51, P79, DOI 10.1111/j.1600 0757.2009.00301.x
   Sculean A, 2004, J CLIN PERIODONTOL, V31, P604, DOI 10.1111/j.1600 051X.2004.00525.x
   Shefer G, 2001, J CELL PHYSIOL, V187, P73, DOI 10.1002/1097 4652(2001)9999:9999<::AID JCP1053>3.0.CO;2 9
   Shimizu N, 2007, LASER SURG MED, V39, P551, DOI 10.1002/lsm.20521
   Stein A, 2005, PHOTOMED LASER SURG, V23, P161, DOI 10.1089/pho.2005.23.161
   Takasaki AA, 2007, LASER MED SCI, V22, P143, DOI 10.1007/s10103 006 0430 x
   Theodoro LH, 2006, J PERIODONTAL RES, V41, P381, DOI 10.1111/j.1600 0765.2005.00846.x
   Yoshino T, 2009, J PERIODONTOL, V80, P82, DOI [10.1902/jop.2009.080097, 10.1902/jop.2009.080097 ]
NR 30
TC 100
Z9 107
U1 0
U2 21
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268 8921
EI 1435 604X
J9 LASER MED SCI
JI Lasers Med. Sci.
PD JUL
PY 2010
VL 25
IS 4
BP 559
EP 569
DI 10.1007/s10103 010 0761 5
PG 11
WC Engineering, Biomedical; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Surgery
GA 591ZE
UT WOS:000277343300014
PM 20186556
DA 2025 08 17
ER

PT J
AU Samadfam, R
   Gallant, MA
   Miousse, MC
   Parent, JL
   de Brum Fernandes, AJ
AF Samadfam, Rana
   Gallant, Maxime A.
   Miousse, Marie Claude
   Parent, Jean Luc
   de Brum Fernandes, Artur J.
TI Implication of prostaglandin receptors in the accumulation of
   osteoprotegerin in human osteoblast cultures
SO JOURNAL OF RHEUMATOLOGY
LA English
DT Article
DE osteoprotegerin; prostaglandin; osteoblast; cyclooxygenase
ID OSTEOCLASTOGENESIS INHIBITORY FACTOR; MESSENGER RNA LEVELS; C TERMINAL
   TAIL; RHEUMATOID ARTHRITIS; BONE RESORPTION; DIFFERENTIATION FACTOR;
   PROSTANOID RECEPTORS; EP3 SUBTYPE; ACUTE PAIN; IN VITRO
AB Objective. Prostaglandins are important mediators in bone metabolism and in pathologies such as rheumatoid arthritis and osteoarthritis. We investigated the roles of cyclooxygenases (COX) and prostaglandin receptors in the accumulation of osteoprotegerin (OPG) in the supernatants of human osteoblasts in culture.
   Methods. Three different cellular models were used, the human osteosarcoma cell lines MG 63 and Saos 2, and primary cultures of human osteoblasts. OPG concentrations were determined by ELISA.
   Results. RTLPCR analysis showed that, like primary human osteoblasts, MG 63 cells express DP, EP4, FP, IP, and TP receptors, whereas the Saos 2 cells lack IP. Concentration of OPG was highest in MG 63 cell supernatants (36 +/  12.5 ng/ml), followed by human osteoblasts (12.77 +/  2.2 ng/ml) and Saos 2 (3.6 +/  0.76 ng/ml). COX inhibitors did not alter these values. Prostaglandin E 2 and BW 245C (a synthetic DP receptor agonist) decreased OPG in the supernatants of human osteoblasts but not in immortalized cell lines. These effects were concentration dependent and were inhibited by EP4 and DP receptor antagonists. Fluprostenol, an FP receptor agonist, increased the accumulation of OPG in MG 63 but not in primary human osteoblasts or Saos 2.
   Conclusion. Our results show that activation of EP4 or DP receptors decreased the accumulation of OPG in supernatants of osteoblasts in culture, and suggest that these receptors could be interesting pharmacological targets in bone diseases. They also demonstrate important differences between primary osteoblasts and immortalized cell lines, both in the distribution and in the effects mediated by prostaglandin receptors.
C1 Univ Sherbrooke, Fac Med, Div Rheumatol, Fleurimont, PQ J1H 5N4, Canada.
C3 University of Sherbrooke
RP de Brum Fernandes, AJ (通讯作者)，Univ Sherbrooke, Fac Med, Div Rheumatol, 3001 12th Ave N, Fleurimont, PQ J1H 5N4, Canada.
EM Artur.Fernandes@USherbrooke.ca
CR AN SZ, 1994, BIOCHEMISTRY US, V33, P14496, DOI 10.1021/bi00252a016
   Bensen W, 2002, RHEUMATOLOGY, V41, P1008, DOI 10.1093/rheumatology/41.9.1008
   Brändström H, 1998, BIOCHEM BIOPH RES CO, V247, P338, DOI 10.1006/bbrc.1998.8783
   Brändström H, 2001, BIOCHEM BIOPH RES CO, V280, P831, DOI 10.1006/bbrc.2000.4223
   Chrétien L, 1998, J ENDOCRINOL, V156, P449, DOI 10.1677/joe.0.1560449
   Clemett D, 2000, DRUGS, V59, P957, DOI 10.2165/00003495 200059040 00017
   DEBRUMFERNANDES AJ, 1994, BIOCHEM BIOPH RES CO, V198, P955, DOI 10.1006/bbrc.1994.1136
   Fujieda M, 1999, J CELL BIOCHEM, V75, P215, DOI 10.1002/(SICI)1097 4644(19991101)75:2<215::AID JCB4>3.0.CO;2 S
   Gallant MA, 2005, J BONE MINER RES, V20, P672, DOI 10.1359/JBMR.041211
   Halladay DL, 2002, J CELL BIOCHEM, V84, P1, DOI 10.1002/jcb.1273
   IRIE A, 1993, EUR J BIOCHEM, V217, P313, DOI 10.1111/j.1432 1033.1993.tb18248.x
   KLEIN DC, 1970, ENDOCRINOLOGY, V86, P1436, DOI 10.1210/endo 86 6 1436
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Li X, 2002, BONE, V30, P567, DOI 10.1016/S8756 3282(02)00683 X
   Maciel FMB, 1997, J RHEUMATOL, V24, P2429
   Matheson AJ, 2001, DRUGS, V61, P833, DOI 10.2165/00003495 200161060 00019
   Matsumoto AK, 2002, J RHEUMATOL, V29, P1623
   Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697
   Murakami T, 1998, BIOCHEM BIOPH RES CO, V252, P747, DOI 10.1006/bbrc.1998.9723
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0
   Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193
   O'Brien EA, 2001, BONE, V28, P208, DOI 10.1016/S8756 3282(00)00431 2
   Ohshiba T, 2003, BIOCHEM BIOPH RES CO, V300, P957, DOI 10.1016/S0006 291X(02)02937 6
   Ono K, 1998, J ENDOCRINOL, V158, pR1, DOI 10.1677/joe.0.158R001
   RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256
   SANTORO MG, 1977, P SOC EXP BIOL MED, V156, P373
   Sarrazin P, 2001, PROSTAG LEUKOTR ESS, V64, P203, DOI 10.1054/plef.1999.0127
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Suda M, 2000, CALCIFIED TISSUE INT, V66, P217, DOI 10.1007/s002230010043
   Suda M, 1996, ENDOCRINOLOGY, V137, P1698, DOI 10.1210/en.137.5.1698
   Tomita M, 2002, BONE, V30, P159, DOI 10.1016/S8756 3282(01)00688 3
   Tsuda E, 1997, BIOCHEM BIOPH RES CO, V234, P137, DOI 10.1006/bbrc.1997.6603
   Wang XX, 2002, J BONE MINER RES, V17, P91, DOI 10.1359/jbmr.2002.17.1.91
   Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190
   Wright DH, 2001, AM J PHYSIOL REG I, V281, pR1343, DOI 10.1152/ajpregu.2001.281.5.R1343
   Yamaguchi K, 1998, J BIOL CHEM, V273, P5117, DOI 10.1074/jbc.273.9.5117
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
   Yasuda H, 1999, BONE, V25, P109, DOI 10.1016/S8756 3282(99)00121 0
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 40
TC 6
Z9 11
U1 0
U2 0
PU J RHEUMATOL PUBL CO
PI TORONTO
PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA
SN 0315 162X
EI 1499 2752
J9 J RHEUMATOL
JI J. Rheumatol.
PD JUN
PY 2006
VL 33
IS 6
BP 1167
EP 1175
PG 9
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 048OB
UT WOS:000237955300026
PM 16755666
DA 2025 08 17
ER

PT J
AU Sun, S
   Wang, YF
   Li, JH
   Wu, AL
   Xie, Y
   Wang, Z
   Zhao, XJ
   Wang, DD
   Wu, XL
   Liu, XG
AF Sun, Shi
   Wang, Yifang
   Li, Jinhu
   Wu, Ailing
   Xie, Yan
   Wang, Zhao
   Zhao, Xinjie
   Wang, Dandan
   Wu, Xiaolong
   Liu, Xinguang
TI Network Pharmacology Based Approach to Investigate the Active
   Ingredients and Therapeutic Mechanisms of Jingu Tongxiao Pill against
   Osteoarthritis
SO ACS OMEGA
LA English
DT Article; Early Access
ID LIQUID CHROMATOGRAPHY; RAPID CHARACTERIZATION; FILTERING STRATEGY;
   IDENTIFICATION; CONSTITUENTS; INFLAMMATION; DECOCTION; PATHWAY
AB This study aimed to investigate the active ingredientsand therapeuticmechanisms of Jingu Tongxiao Pill (JGTXP), a commonly used Chinesepatent medicine, in treating osteoarthritis (OA) via network pharmacologyanalysis combined with experimental validation. First, we administeredJGTXP to rat plasma and identified the candidate active compounds.Next, target prediction, protein protein interaction, compound targetnetwork construction, gene ontology (GO), and Kyoto Encyclopedia ofGenes and Genomes pathway enrichment analyses were conducted for JGTXP.Lastly, the network derived key targets and pathways were validatedin vitro and in vivo. Finally, we identified 106 compounds in JGTXPand 24 absorbed compounds in the rat plasma. Network analysis revealedthat JGTXP interferes with OA mainly via regulating the inflammatoryresponse, collagen catabolic process, and osteoclast differentiation,and the nuclear factor kappa B (NF & kappa;B) signaling pathway playsa pivotal role in these processes. Experimentally, JGTXP exerted potentialprotective effects on articular cartilage and inhibited expressionof inflammatory mediators and collagen catabolism related proteins,including interleukin 1 beta (IL 1 & beta;), interleukin 6, tumor necrosisfactor alpha (TNF & alpha;), and matrix metalloproteinase (MMP) 3 andMMP13, in a papain induced OA rat model. Consistently, mRNA expressionlevels of these factors and nitric oxide release were suppressed byJGTXP in an LPS induced RAW 264.7 inflammation model. The reportergene assay showed that JGTXP could reduce the transcriptional activityof NF & kappa;B. Consecutive western blot analysis demonstrated thatnuclear NF & kappa;B p65, inducible nitric oxide synthase (iNOS), andcyclooxygenase 2 (COX 2) expression were inhibited while cytoplasmicNF & kappa;B p65 was upregulated by JGTXP. Using a combination of chemicalprofiling, network pharmacology analysis, and experimental validation,we preliminarily clarified the active ingredients of JGTXP interventionfor OA and demonstrated that JGTXP ameliorates OA, at least partially,by regulating the NF & kappa;B signaling pathway.
C1 [Sun, Shi; Wang, Yifang; Li, Jinhu; Wu, Ailing; Xie, Yan; Wang, Zhao; Zhao, Xinjie; Wang, Dandan; Wu, Xiaolong] Orthoped Hosp Henan Prov, Luoyang Orthoped Traumatol Hosp Henan Prov, Dept Pharm, Luoyang 471000, Peoples R China.
   [Li, Jinhu; Liu, Xinguang] Henan Univ Chinese Med, Acad Chinese Med Sci, Zhengzhou 450046, Peoples R China.
C3 Henan University of Traditional Chinese Medicine
RP Wu, XL (通讯作者)，Orthoped Hosp Henan Prov, Luoyang Orthoped Traumatol Hosp Henan Prov, Dept Pharm, Luoyang 471000, Peoples R China.; Liu, XG (通讯作者)，Henan Univ Chinese Med, Acad Chinese Med Sci, Zhengzhou 450046, Peoples R China.
EM HLOH_WXL@163.com; xgliu2016@126.com
RI Wang, Dandan/AEC 1897 2022; Li, Jinhu/N 8954 2014; Xie,
   Yan/ISA 9411 2023
OI Liu, Xinguang/0000 0001 6172 1328; 
FU Science and Technology Project of Henan Province [202102310193];
   Scientific Research Project for Traditional Chinese Medicine of Henan
   Province [2017ZY1001, 20 21ZY2241, 2023ZY3014]
FX This work was financially supported by the Science and Technology
   Project of Henan Province (no. 202102310193) and Scientific Research
   Project for Traditional Chinese Medicine of Henan Province (nos.
   2017ZY1001, 20 21ZY2241, and 2023ZY3014).
CR Bay Jensen AC, 2018, CURR OPIN RHEUMATOL, V30, P121, DOI 10.1097/BOR.0000000000000467
   Berenbaum F, 2013, CURR OPIN RHEUMATOL, V25, P114, DOI 10.1097/BOR.0b013e32835a9414
   Cao JL, 2016, J CHROMATOGR A, V1427, P79, DOI 10.1016/j.chroma.2015.11.078
   Chen MP, 2010, INFLAMM RES, V59, P587, DOI 10.1007/s00011 010 0165 9
   Cheng F, 2019, PHARM BIOL, V57, P649, DOI 10.1080/13880209.2019.1651874
   Cheng XL, 2011, J CHROMATOGR A, V1218, P5774, DOI 10.1016/j.chroma.2011.06.091
   Choi MC, 2019, CELLS BASEL, V8, DOI 10.3390/cells8070734
   Daina A, 2019, NUCLEIC ACIDS RES, V47, pW357, DOI 10.1093/nar/gkz382
   [邓桂明 Deng Guiming], 2016, [中药材, Journal of Chinese Medicinal Materials], V39, P2229
   Dong L, 2017, MOL IMMUNOL, V83, P46, DOI 10.1016/j.molimm.2017.01.007
   Du KW, 2021, IMMUN INFLAMM DIS, V9, P710, DOI 10.1002/iid3.424
   Felson DT, 2000, ANN INTERN MED, V133, P635, DOI 10.7326/0003 4819 133 8 200010170 00016
   Fernandes TL, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00111
   Francisco V, 2018, J ORTHOP RES, V36, P594, DOI 10.1002/jor.23788
   Gao D, 2017, J PHARMACEUT BIOMED, V140, P301, DOI 10.1016/j.jpba.2017.03.033
   Hu PF, 2018, EXP THER MED, V16, P1513, DOI 10.3892/etm.2018.6325
   Hu PF, 2018, MOL MED REP, V17, P6194, DOI 10.3892/mmr.2018.8631
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Huang JH, 2017, MOL MED REP, V16, P4583, DOI 10.3892/mmr.2017.7149
   Hunter DJ, 2019, LANCET, V393, P1745, DOI 10.1016/S0140 6736(19)30417 9
   Jimi E, 2019, CELLS BASEL, V8, DOI 10.3390/cells8121636
   Keiser MJ, 2007, NAT BIOTECHNOL, V25, P197, DOI 10.1038/nbt1284
   Kim MH, 2020, J ETHNOPHARMACOL, V261, DOI 10.1016/j.jep.2020.113074
   Kuroda M, 2010, BIOORGAN MED CHEM, V18, P962, DOI 10.1016/j.bmc.2009.11.027
   Lepetsos P, 2016, BBA MOL BASIS DIS, V1862, P576, DOI 10.1016/j.bbadis.2016.01.003
   Li J., 2018, JINGU XIAOTONG PILLS, V33, P803
   Li SL, 2019, J ETHNOPHARMACOL, V242, DOI 10.1016/j.jep.2019.112029
   Li SL, 2009, J PHARMACEUT BIOMED, V49, P253, DOI 10.1016/j.jpba.2008.11.007
   Li Y, 2017, TOXINS, V9, DOI 10.3390/toxins9110359
   Liang F., 2018, ACTA CHIN MED, V33, P503, DOI [10.16368/j.issn.1674 8999.2018.03.121, DOI 10.16368/J.ISSN.1674 8999.2018.03.121]
   Peng JQ, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.794405
   Pereira D, 2015, ACTA MEDICA PORT, V28, P99
   Piñero J, 2020, NUCLEIC ACIDS RES, V48, pD845, DOI 10.1093/nar/gkz1021
   Ren JL, 2020, PHYTOMEDICINE, V77, DOI 10.1016/j.phymed.2020.153266
   Rigoglou S, 2013, INT J BIOCHEM CELL B, V45, P2580, DOI 10.1016/j.biocel.2013.08.018
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Sun S., 2021, CHINA PHARMACY, V32, P1235, DOI DOI 10.6039/j.issn.1001 0408.2021.10.13
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Tan X., 2014, CHIN J TRADIT FEB TR, V22, P18
   Tan X., 2013, GUID J TRADIT CHIN M, V19, P35, DOI [10.16448/j.cjtcm.2016.0580, DOI 10.16448/J.CJTCM.2016.0580]
   Taylor N, 2017, CLIN GERIATR MED, V33, P41, DOI 10.1016/j.cger.2016.08.004
   Van Quickelberghe E, 2018, SCI DATA, V5, DOI 10.1038/sdata.2018.289
   [王长生 Wang Changsheng], 2016, [中草药, Chinese Traditional and Herbal Drugs], V47, P3175
   Wang L, 2020, PAIN RES MANAG, V2020, DOI 10.1155/2020/5712187
   Wang X, 2017, NUCLEIC ACIDS RES, V45, pW356, DOI 10.1093/nar/gkx374
   Wang YX, 2020, NUCLEIC ACIDS RES, V48, pD1031, DOI 10.1093/nar/gkz981
   Wu JR, 2016, BIOMED CHROMATOGR, V30, P2061, DOI 10.1002/bmc.3763
   Xie JW, 2019, CYTOKINE GROWTH F R, V46, P36, DOI 10.1016/j.cytogfr.2019.03.004
   Xie XQ, 2019, INT IMMUNOPHARMACOL, V76, DOI 10.1016/j.intimp.2019.105840
   Xu TT, 2013, RAPID COMMUN MASS SP, V27, P2297, DOI 10.1002/rcm.6696
   Zhang H, 2012, J PHARMACEUT BIOMED, V70, P169, DOI 10.1016/j.jpba.2012.06.025
   Zhao L, 2015, J ETHNOPHARMACOL, V172, P100, DOI 10.1016/j.jep.2015.06.031
   Zhao L, 2018, MOL MED REP, V17, P3306, DOI 10.3892/mmr.2017.8222
   Zhou Y, 2009, J CHROMATOGR A, V1216, P4847, DOI 10.1016/j.chroma.2009.04.017
   Zhu NQ, 2019, MED SCI MONITOR, V25, P6051, DOI 10.12659/MSM.915821
NR 56
TC 1
Z9 2
U1 3
U2 12
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2470 1343
J9 ACS OMEGA
JI ACS Omega
PD 2023 AUG 16
PY 2023
DI 10.1021/acsomega.3c04724
EA AUG 2023
PG 12
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA P2EJ9
UT WOS:001048821100001
PM 37663478
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU McGuire, JJ
   Frieling, JS
   Lo, CH
   Li, T
   Muhammad, A
   Lawrence, HR
   Lawrence, NJ
   Cook, LM
   Lynch, CC
AF McGuire, Jeremy J.
   Frieling, Jeremy S.
   Lo, Chen Hao
   Li, Tao
   Muhammad, Ayaz
   Lawrence, Harshani R.
   Lawrence, Nicholas J.
   Cook, Leah M.
   Lynch, Conor C.
TI Mesenchymal stem cell derived interleukin 28 drives the selection of
   apoptosis resistant bone metastatic prostate cancer
SO NATURE COMMUNICATIONS
LA English
DT Article
AB Bone metastatic prostate cancer (PCa) promotes mesenchymal stem cell (MSC) recruitment and their differentiation into osteoblasts. However, the effects of bone marrow derived MSCs on PCa cells are less explored. Here, we report MSC derived interleukin 28 (IL 28) triggers prostate cancer cell apoptosis via IL 28 receptor alpha (IL 28R alpha) STAT1 signaling. However, chronic exposure to MSCs drives the selection of prostate cancer cells that are resistant to IL 28 induced apoptosis and therapeutics such as docetaxel. Further, MSC selected/IL 28 resistant prostate cancer cells grow at accelerated rates in bone. Acquired resistance to apoptosis is PCa cell intrinsic, and is associated with a shift in IL 28R alpha signaling via STAT1 to STAT3. Notably, STAT3 ablation or inhibition impairs MSC selected prostate cancer cell growth and survival. Thus, bone marrow MSCs drive the emergence of therapy resistant bone metastatic prostate cancer yet this can be disabled by targeting STAT3. The effects of bone marrow derived MSCs on prostate cancer cells remain unknown. Here the authors show that MSC derived IL 28 induces prostate cancer cell apoptosis via IL 28R alpha  STAT1 signalling, while acquired resistance to apoptosis is associated with a shift in IL 28R alpha signalling via STAT1 to STAT3.
C1 [McGuire, Jeremy J.; Lo, Chen Hao] Univ S Florida, Canc Biol PhD Program, Tampa, FL 33620 USA.
   [McGuire, Jeremy J.; Frieling, Jeremy S.; Lo, Chen Hao; Li, Tao; Lynch, Conor C.] H Lee Moffitt Canc Ctr & Res Inst, Tumor Biol Dept, Tampa, FL 33612 USA.
   [Muhammad, Ayaz; Lawrence, Harshani R.; Lawrence, Nicholas J.] H Lee Moffitt Canc Ctr & Res Inst, Dept Drug Discovery, Tampa, FL USA.
   [Cook, Leah M.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA.
C3 State University System of Florida; University of South Florida; H Lee
   Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center
   & Research Institute; University of Nebraska System; University of
   Nebraska Medical Center
RP Lynch, CC (通讯作者)，H Lee Moffitt Canc Ctr & Res Inst, Tumor Biol Dept, Tampa, FL 33612 USA.
EM conor.lynch@moffitt.org
RI ; Cook, Leah/AAV 9640 2021
OI Lo, Chen Hao/0000 0001 8848 2507; Lawrence,
   Nicholas/0000 0003 1129 2558; McGuire, Jeremy/0000 0002 3439 8227
FU Department of Defense Prostate Cancer Research Program (DOD PCRP) award
   [CCL: W81XWH1810523]; Miles for Moffitt Foundation Award; Core
   Facilities of the Moffitt Cancer Center Grant [P30 CA076292]; Pacific
   Northwest Prostate Cancer SPORE [P50CA97186];  [R50CA211447]; U.S.
   Department of Defense (DOD) [W81XWH1810523] Funding Source: U.S.
   Department of Defense (DOD); National Cancer Institute [R50CA211447]
   Funding Source: NIH RePORTER
FX This work was supported by a Department of Defense Prostate Cancer
   Research Program (DOD PCRP) award (CCL: W81XWH1810523) and a Miles for
   Moffitt Foundation Award. This work was also supported in part by the
   Core Facilities of the Moffitt Cancer Center Grant P30 CA076292 and by
   R50CA211447 (HRL). We thank the patients, families, and dedicated
   researchers; Celestia Higano, Pete Nelson, Evan Yu, Elahe Mostaghel,
   Bruce Montgomery, Paul Lange, Xiaotun Zhang, Martine Roudier, Lawrence
   True, Robert Vessella, Eva Corey, Colm Morrissey and the rapid autopsy
   teams for their contributions to the University of Washington Medical
   Center Prostate Cancer Donor Rapid Autopsy Program; supported by the
   Pacific Northwest Prostate Cancer SPORE (P50CA97186). The authors would
   also like to thank Drs. John Cleveland and Srikumar Chellappan for
   critical review of this study.
CR Abdulghani J, 2008, AM J PATHOL, V172, P1717, DOI 10.2353/ajpath.2008.071054
   Araujo A, 2014, CANCER RES, V74, P2391, DOI 10.1158/0008 5472.CAN 13 2652
   Atsuta I, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt322
   Boeru V, 1989, Endocrinologie, V27, P65
   Brennen WN, 2013, ONCOTARGET, V4, P106, DOI 10.18632/oncotarget.805
   Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Chang Q, 2013, NEOPLASIA, V15, P848, DOI 10.1593/neo.13706
   Chen WG, 2004, J ALLERGY CLIN IMMUN, V114, P476, DOI 10.1016/j.jaci.2004.06.042
   Cheng XL, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 15342 4
   Cimica V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020188
   Cook LM, 2016, SCI REP UK, V6, DOI 10.1038/srep29384
   De Boeck A, 2013, GUT, V62, P550, DOI 10.1136/gutjnl 2011 301393
   Dias S, 2002, BLOOD, V99, P2532, DOI 10.1182/blood.V99.7.2532
   Don Doncow N, 2017, EUR UROL, V71, P313, DOI 10.1016/j.eururo.2016.06.018
   Drake JM, 2013, P NATL ACAD SCI USA, V110, pE4762, DOI 10.1073/pnas.1319948110
   Fingleton B, 2001, NEOPLASIA, V3, P459, DOI 10.1038/sj.neo.7900190
   Frank DA, 2007, CANCER LETT, V251, P199, DOI 10.1016/j.canlet.2006.10.017
   Friedrich K, 2017, BIOSCI TRENDS, V11, P1, DOI 10.5582/bst.2016.01250
   Frieling JS, 2015, CANCER CONTROL, V22, P109, DOI 10.1177/107327481502200114
   Fritz V, 2011, J CELL BIOCHEM, V112, P3234, DOI 10.1002/jcb.23258
   Girkin JL, 2017, AM J PHYSIOL LUNG C, V312, pL89, DOI 10.1152/ajplung.00200.2016
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Ho HH, 2006, J BIOL CHEM, V281, P14111, DOI 10.1074/jbc.M511797200
   Hodde JP, 2004, J SURG RES, V120, P189, DOI 10.1016/j.jss.2003.10.022
   Hubbard SR, 2018, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00361
   JANDHYALA BS, 1976, EUR J PHARMACOL, V36, P21, DOI 10.1016/0014 2999(76)90252 1
   Jin FC, 2013, MOL MED REP, V8, P1486, DOI 10.3892/mmr.2013.1698
   Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Klopp AH, 2011, STEM CELLS, V29, P11, DOI 10.1002/stem.559
   Kobolak J, 2016, METHODS, V99, P62, DOI 10.1016/j.ymeth.2015.09.016
   Konig A, 1997, LEUKEMIA, V11, P258, DOI 10.1038/sj.leu.2400556
   Kotenko SV, 2011, CURR OPIN IMMUNOL, V23, P583, DOI 10.1016/j.coi.2011.07.007
   Lasfar A, 2006, CANCER RES, V66, P4468, DOI 10.1158/0008 5472.CAN 05 3653
   Lee YC, 2015, CANCER RES, V75, P4949, DOI 10.1158/0008 5472.CAN 15 1215
   Li Q, 2013, FRONT BIOSCI LANDMRK, V18, P909, DOI 10.2741/4152
   Logothetis C, 2018, CANCER METAST REV, V37, P189, DOI 10.1007/s10555 017 9719 4
   Luhach I, 2014, MAGN RESON MED, V72, P858, DOI 10.1002/mrm.24979
   Luo J, 2014, ONCOGENE, V33, P2768, DOI 10.1038/onc.2013.233
   Mi F, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20170181
   Mohanty SK, 2017, ONCOTARGET, V8, P85997, DOI 10.18632/oncotarget.20844
   Pencik J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8736
   Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318
   Poli V, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00121
   Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960 9822(00)80113 X
   Ramasamy R, 2007, LEUKEMIA, V21, P304, DOI 10.1038/sj.leu.2404489
   Ren GW, 2015, J MOL MED, V93, P1203, DOI 10.1007/s00109 015 1329 4
   Rhee KJ, 2015, INT J MOL SCI, V16, P30015, DOI 10.3390/ijms161226215
   Ridge SM, 2017, MOL CANCER, V16, DOI 10.1186/s12943 017 0597 8
   Roudier MP, 2008, J UROLOGY, V180, P1154, DOI 10.1016/j.juro.2008.04.140
   Ryu H, 2014, CANCER LETT, V352, P220, DOI 10.1016/j.canlet.2014.06.018
   Santoni M, 2015, FUTUR SCI OA, V1, DOI [10.4155/FSO.15.13, 10.4155/fso.15.13]
   Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104
   Song B, 2015, INT J CLIN EXP MED, V8, P12509
   Spaeth EL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004992
   Tanaka T, 2005, IMMUNITY, V22, P729, DOI 10.1016/j.immuni.2005.04.008
   Tezuka Y, 2012, LUNG CANCER, V78, P185, DOI 10.1016/j.lungcan.2012.09.005
   Vargo Gogola T, 2002, CANCER RES, V62, P5559
   Wake MS, 2015, FEBS J, V282, P2600, DOI 10.1111/febs.13285
   Wang H, 2015, CANCER CELL, V27, P193, DOI 10.1016/j.ccell.2014.11.017
   Wegrzyn J, 2009, SCIENCE, V323, P793, DOI 10.1126/science.1164551
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Wexler SA, 2003, BRIT J HAEMATOL, V121, P368, DOI 10.1046/j.1365 2141.2003.04284.x
   Xie L, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/762098
   Xu WT, 2009, CANCER LETT, V281, P32, DOI 10.1016/j.canlet.2009.02.022
   Zhu W, 2006, EXP MOL PATHOL, V80, P267, DOI 10.1016/j.yexmp.2005.07.004
   Zong C, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0366 7
NR 68
TC 38
Z9 40
U1 2
U2 17
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD FEB 1
PY 2021
VL 12
IS 1
AR 723
DI 10.1038/s41467 021 20962 6
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA QF5NQ
UT WOS:000616941000004
PM 33526787
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Urdaneta, RA
   Daher, S
   Leary, J
   Emanuel, K
   Chuang, SK
AF Urdaneta, Rainier A.
   Daher, Shadi
   Leary, Joseph
   Emanuel, Kimberly
   Chuang, Sung Kiang
TI Factors Associated with Crestal Bone Gain on Single Tooth Locking Taper
   Implants: The Effect of Nonsteroidal Anti Inflammatory Drugs
SO INTERNATIONAL JOURNAL OF ORAL & MAXILLOFACIAL IMPLANTS
LA English
DT Article
DE dental implants; nonsteroidal anti inflammatory drugs; peri implant bone
   gain; prospective cohort study; risk factors
ID DENTAL IMPLANTS; RADIOGRAPHIC EVALUATION; BRANEMARK IMPLANTS; TITANIUM
   IMPLANTS; WIDE DIAMETER; REPLACEMENT; RATS; INHIBITION; DICLOFENAC;
   MECHANISM
AB Purpose: To identify factors associated with crestal bone gain around single tooth implants. Materials and Methods: A retrospective cohort study was conducted. More than 90 different local and systemic factors were documented. Descriptive statistics and univariate and multivariate mixed effects regression models, adjusted for multiple implants in the same patient, were used to identify predictors of crestal bone gain after insertion of definitive restorations. Results: Eighty one subjects who received 326 Bicon implants were followed for an average of 70.7 months. Eighty one implants in 46 patients showed varying degrees of apparent bone gain over time. Variables associated with peri implant bone gain in the first multivariate model were: type of opposing structure, tooth (P = .02); type of restoration, crown cemented on a prefabricated titanium abutment with a spherical base (P = .006); hydroxyapatite coating (P = .0005); implant size 5 x 8 mm (P = .02); and daily intake of nonsteroidal anti inflammatory drugs (NSAIDs) (P =. 04). NSAIDs remained significantly correlated to crestal bone gain in the second multivariate analysis; an implant was significantly more likely to gain bone if the patient was taking NSAIDs daily (P = .02), but this effect was specific to hydroxyapatite coated implants (P = .01). Conclusion: Daily doses of NSAIDs were correlated with a significant increase in crestal bone levels around single tooth hydroxyapatite coated implants following crown insertion. INT J ORAL MAXILLOFAC IMPLANTS 2011;26:1063 1078
C1 [Urdaneta, Rainier A.; Daher, Shadi; Emanuel, Kimberly] Implant Dent Ctr, Boston, MA USA.
   [Daher, Shadi] Boston Univ, Dept Oral & Maxillofacial Surg, Henry M Goldman Sch Dent Med, Boston, MA 02215 USA.
   [Chuang, Sung Kiang] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA.
   [Chuang, Sung Kiang] Harvard Univ, Sch Dent Med, Boston, MA 02115 USA.
   [Leary, Joseph] Private Practice Ltd Periodont, Norwood, MA USA.
C3 Boston University; Harvard University; Harvard University Medical
   Affiliates; Massachusetts General Hospital; Harvard University; Harvard
   School of Dental Medicine
RP Urdaneta, RA (通讯作者)，25 Prairie Ave, Auburndale, MA 02466 USA.
EM rainieru@yahoo.com
CR ADELL R, 1981, INT J ORAL MAXILLOF, V10, P387, DOI 10.1016/S0300 9785(81)80077 4
   Alissa R, 2009, EUR J ORAL IMPLANTOL, V2, P185
   Arvidson K, 1992, Int J Oral Maxillofac Implants, V7, P321
   BECKER W, 1995, J PROSTHET DENT, V74, P51, DOI 10.1016/S0022 3913(05)80229 X
   Bianco G, 2000, Clin Implant Dent Relat Res, V2, P152, DOI 10.1111/j.1708 8208.2000.tb00006.x
   Blanes RJ, 2007, CLIN ORAL IMPLAN RES, V18, P699, DOI 10.1111/j.1600 0501.2006.01306.x
   Brunski J B, 1999, Adv Dent Res, V13, P99
   Buser D, 1990, CLIN ORAL IMPLAN RES, V1, P33, DOI 10.1034/j.1600 0501.1990.010105.x
   Chikazu D, 2007, INT J ORAL MAX SURG, V36, P441, DOI 10.1016/j.ijom.2006.11.011
   Chou HY, 2010, J PROSTHET DENT, V104, P293, DOI 10.1016/S0022 3913(10)60142 4
   Chuang SK, 2002, J DENT RES, V81, P572, DOI 10.1177/154405910208100814
   Coelho PG, 2009, J BIOMED MATER RES B, V91B, P975, DOI 10.1002/jbm.b.31455
   Dean David D, 2008, J Oral Implantol, V34, P303, DOI 10.1563/1548 1336 34.6.303
   Degidi M, 2007, J PERIODONTOL, V78, P52, DOI 10.1902/jop.2007.060139
   Dibart S, 2005, INT J ORAL MAX IMPL, V20, P732
   ENGQUIST B, 1995, CLIN ORAL IMPLAN RES, V6, P238, DOI 10.1034/j.1600 0501.1995.060407.x
   Fracon Ricardo N, 2008, J Oral Sci, V50, P247, DOI 10.2334/josnusd.50.247
   Ganeles J, 2008, CLIN ORAL IMPLAN RES, V19, P1119, DOI 10.1111/j.1600 0501.2008.01626.x
   Giannoudis PV, 2000, J BONE JOINT SURG BR, V82B, P655, DOI 10.1302/0301 620X.82B5.9899
   Gibbard Leslie Laing, 2002, J Can Dent Assoc, V68, P110
   Glassman SD, 1998, SPINE, V23, P834, DOI 10.1097/00007632 199804010 00020
   Herlitz J, 2010, AM J CARDIOVASC DRUG, V10, P125, DOI 10.2165/11318440 000000000 00000
   JACOBSSON SA, 1994, J BONE JOINT SURG BR, V76B, P831, DOI 10.1302/0301 620X.76B5.8083279
   JEFFCOAT MK, 1995, J AM DENT ASSOC, V126, P305, DOI 10.14219/jada.archive.1995.0173
   Jemt T, 1997, INT J PERIODONT REST, V17, P327
   Joly JC, 2003, J PERIODONTOL, V74, P1097, DOI 10.1902/jop.2003.74.8.1097
   Karlsson U, 1997, INT J PROSTHODONT, V10, P318
   Mayer TM, 2002, J PERIODONTOL, V73, P687, DOI 10.1902/jop.2002.73.7.687
   Oliveira TM, 2008, J PERIODONTOL, V79, P1062, DOI [10.1902/jop.2008.070411, 10.1902/jop.2008.070411 ]
   Pablos AB, 2008, J PERIODONTOL, V79, P300, DOI [10.1902/jop.2008.070301, 10.1902/jop.2008.070301 ]
   QUIRYNEN M, 1992, J CLIN PERIODONTOL, V19, P118, DOI 10.1111/j.1600 051X.1992.tb00450.x
   Quirynen M, 1992, Clin Oral Implants Res, V3, P104, DOI 10.1034/j.1600 0501.1992.030302.x
   REDDY M S, 1990, Journal of Oral Implantology, V16, P272
   Ribeiro FV, 2009, INT J ORAL MAX IMPL, V24, P226
   ROBINSON DR, 1983, AM J MED, V75, P26, DOI 10.1016/0002 9343(83)90325 X
   Salvi GE, 2005, CURR PHARM DESIGN, V11, P1757, DOI 10.2174/1381612053764878
   Scholander S, 1999, INT J PROSTHODONT, V12, P483
   Schwartz Arad D, 1999, J PERIODONTOL, V70, P449, DOI 10.1902/jop.1999.70.4.449
   Schwarz F, 2007, J CLIN PERIODONTOL, V34, P78, DOI 10.1111/j.1600 051X.2006.01008.x
   SMITH DE, 1989, J PROSTHET DENT, V62, P567, DOI 10.1016/0022 3913(89)90081 4
   Urdaneta Rainier A, 2008, J Prosthodont, V17, P562, DOI 10.1111/j.1532 849X.2008.00343.x
   Urdaneta RA, 2010, INT J ORAL MAX IMPL, V25, P729
   Urdaneta Rainier A, 2007, J Prosthodont, V16, P311, DOI 10.1111/j.1532 849X.2007.00194.x
   VANE JR, 1971, NATURE NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0
   Weber H P, 1992, Clin Oral Implants Res, V3, P181, DOI 10.1034/j.1600 0501.1992.030405.x
   Yoo RH, 2006, INT J ORAL MAX IMPL, V21, P253
NR 46
TC 35
Z9 40
U1 0
U2 5
PU QUINTESSENCE PUBLISHING CO INC
PI HANOVER PARK
PA 4350 CHANDLER DRIVE, HANOVER PARK, IL 60133 USA
SN 0882 2786
EI 1942 4434
J9 INT J ORAL MAX IMPL
JI Int. J. Oral Maxillofac. Implants
PD SEP OCT
PY 2011
VL 26
IS 5
BP 1063
EP 1078
PG 16
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 837WB
UT WOS:000296237700021
PM 22010091
DA 2025 08 17
ER

PT J
AU Koide, M
   Kobayashi, Y
   Ninomiya, T
   Nakamura, M
   Yasuda, H
   Arai, Y
   Okahashi, N
   Yoshinari, N
   Takahashi, N
   Udagawa, N
AF Koide, Masanori
   Kobayashi, Yasuhiro
   Ninomiya, Tadashi
   Nakamura, Midori
   Yasuda, Hisataka
   Arai, Yoshinori
   Okahashi, Nobuo
   Yoshinari, Nobuo
   Takahashi, Naoyuki
   Udagawa, Nobuyuki
TI Osteoprotegerin Deficient Male Mice as a Model for Severe Alveolar Bone
   Loss: Comparison With RANKL Overexpressing Transgenic Male Mice
SO ENDOCRINOLOGY
LA English
DT Article
ID OSTEOCLASTOGENESIS INHIBITORY FACTOR; GINGIVAL CREVICULAR FLUID;
   BISPHOSPHONATE TREATMENT; DIFFERENTIATION FACTOR; POSTMENOPAUSAL WOMEN;
   PERIODONTAL DISEASE; SEVERE OSTEOPOROSIS; LIGAND; EXPRESSION;
   IDENTIFICATION
AB Periodontitis, an inflammatory disease of periodontal tissues, is characterized by excessive alveolar bone resorption. An increase in the receptor activator of nuclear factor kappa B ligand (RANKL) to osteoprotegerin (OPG) ratio is thought to reflect the severity of periodontitis. Here, we examined alveolar bone loss in OPG deficient (OPG( / )) mice and RANKL overexpressing transgenic (RANKL Tg) mice. Alveolar bone loss in OPG( / ) mice at 12 weeks was significantly higher than that in RANKL Tg mice. OPG( / ) but not RANKL Tg mice exhibited severe bone resorption especially in cortical areas of the alveolar bone. An increased number of osteoclasts was observed in the cortical areas in OPG( / ) but not in RANKL Tg mice. Immunohistochemical analyses showed many OPG positive signals in osteocytes but not osteoblasts. OPG positive osteocytes in the cortical area of alveolar bones and long bones were abundant in both wild type and RANKL Tg mice. This suggests the resorption in cortical bone areas to be prevented by OPG produced locally. To test the usefulness of OPG( / ) mice as an animal model for screening drugs to prevent alveolar bone loss, we administered an antimouse RANKL antibody or risedronate, a bisphosphonate, to OPG( / ) mice. They suppressed alveolar bone resorption effectively. OPG( / ) mice are useful for screening therapeutic agents against alveolar bone loss. (Endocrinology 154: 773 782, 2013)
C1 [Koide, Masanori; Kobayashi, Yasuhiro; Ninomiya, Tadashi; Takahashi, Naoyuki; Udagawa, Nobuyuki] Matsumoto Dent Univ, Inst Oral Sci, Nagano 3990781, Japan.
   [Nakamura, Midori; Udagawa, Nobuyuki] Matsumoto Dent Univ, Dept Biochem, Nagano 3990781, Japan.
   [Yoshinari, Nobuo] Matsumoto Dent Univ, Dept Periodontol, Nagano 3990781, Japan.
   [Yasuda, Hisataka] Oriental Yeast Co Ltd, Bioind Div, Planning & Dev, Tokyo 1748505, Japan.
   [Arai, Yoshinori] Nihon Univ, Sch Dent, Tokyo 1018310, Japan.
   [Okahashi, Nobuo] Osaka Univ, Grad Sch Dent, Ctr Frontier Oral Sci, Dept Oral Frontier Biol, Suita, Osaka 5650871, Japan.
C3 Matsumoto Dental University; Matsumoto Dental University; Matsumoto
   Dental University; Oriental Yeast Co., Ltd.; Nihon University;
   University of Osaka
RP Udagawa, N (通讯作者)，Matsumoto Dent Univ, Dept Biochem, 1780 Hiro Oka Gobara, Nagano 3990781, Japan.
EM udagawa@po.mdu.ac.jp
RI ; okahashi, nobuo/A 4032 2010; Koide, Masanori/ABE 9670 2020; KOBAYASHI,
   YASUHIRO/AAU 4931 2021; Yoshinari, Nobuo/AAI 4494 2020
OI Yasuda, Hisataka/0000 0003 3511 609X; okahashi,
   nobuo/0000 0002 8045 7021; Kobayashi, Yasuhiro/0000 0002 0903 3226;
   Yoshinari, Nobuo/0000 0003 4248 1415; Koide,
   Masanori/0000 0002 6511 9999; 
FU Ministry of Education, Culture, Sports, Science, and Technology of Japan
   [24593132, 22792102, 20791623, 24390417]; Grants in Aid for Scientific
   Research [23593054, 23593027, 24592786, 24592849, 24659833, 22792102,
   20791623, 23659883, 24390417, 21390505, 24593132] Funding Source: KAKEN
FX This work was supported in part by Grants in Aid 24593132, 22792102,
   20791623, and 24390417 from the Ministry of Education, Culture, Sports,
   Science, and Technology of Japan.
CR Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Cetinkaya BO, 2008, J PERIODONTOL, V79, P1950, DOI [10.1902/jop.2008.080041, 10.1902/jop.2008.080041 ]
   Cochran DL, 2008, J PERIODONTOL, V79, P1569, DOI 10.1902/jop.2008.080233
   Darveau RP, 2010, NAT REV MICROBIOL, V8, P481, DOI 10.1038/nrmicro2337
   Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363
   EVANS RT, 1992, INFECT IMMUN, V60, P2926, DOI 10.1128/IAI.60.7.2926 2935.1992
   Favus MJ, 2010, NEW ENGL J MED, V363, P2027, DOI 10.1056/NEJMct1004903
   Furuya Y, 2011, J BIOL CHEM, V286, P37023, DOI 10.1074/jbc.M111.246280
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Jeffcoat MK, 2006, INT J ORAL MAX IMPL, V21, P349
   Kawai T, 2011, IMMUNITY, V34, P637, DOI 10.1016/j.immuni.2011.05.006
   Kim HKW, 2006, J BONE MINER RES, V21, P1946, DOI 10.1359/JBMR.060905
   Kimura M, 2008, CALCIFIED TISSUE INT, V82, P137, DOI 10.1007/s00223 007 9097 y
   Kinugawa S, 2012, J IMMUNOL, V188, P1772, DOI 10.4049/jimmunol.1101174
   Koide M, 2010, PERIODONTOL 2000, V54, P235, DOI 10.1111/j.1600 0757.2010.00355.x
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   Lu HK, 2006, J PERIODONTAL RES, V41, P354, DOI 10.1111/j.1600 0765.2006.00883.x
   Lucas H, 2010, J DENT RES, V89, P29, DOI 10.1177/0022034509350708
   Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697
   Mizuno A, 2002, J BONE MINER METAB, V20, P337, DOI 10.1007/s007740200049
   Mogi M, 2004, J DENT RES, V83, P166, DOI 10.1177/154405910408300216
   Nakamura M, 2003, ENDOCRINOLOGY, V144, P5441, DOI 10.1210/en.2003 0717
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Nibali L, 2009, J MED MICROBIOL, V58, P1269, DOI 10.1099/jmm.0.012021 0
   Ninomiya T, 2007, BONE, V40, P140, DOI 10.1016/j.bone.2006.07.026
   Onyia JE, 2000, J BONE MINER RES, V15, P863, DOI 10.1359/jbmr.2000.15.5.863
   Rocha ML, 2004, J PERIODONTOL, V75, P1579, DOI 10.1902/jop.2004.75.12.1579
   Roodman GD, 2006, ANN NY ACAD SCI, V1068, P100, DOI 10.1196/annals.1346.013
   Sheng ZF, 2009, OSTEOPOROSIS INT, V20, P151, DOI 10.1007/s00198 008 0640 0
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Suda K, 2004, J IMMUNOL, V172, P2504, DOI 10.4049/jimmunol.172.4.2504
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tanaka M, 2003, ORAL SURG ORAL MED O, V95, P495, DOI 10.1067/moe.2003.135
   Teng YTA, 2000, J CLIN INVEST, V106, pR59, DOI 10.1172/JCI10763
   Torres J, 2009, ORAL SURG ORAL MED O, V107, P387, DOI 10.1016/j.tripleo.2008.11.024
   Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074 7613(95)90057 8
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yasuhara R, 2009, BIOCHEM J, V419, P159, DOI 10.1042/BJ20081469
   Yen ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038048
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
NR 46
TC 50
Z9 54
U1 0
U2 13
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815 5817 USA
SN 0013 7227
J9 ENDOCRINOLOGY
JI Endocrinology
PD FEB
PY 2013
VL 154
IS 2
BP 773
EP 782
DI 10.1210/en.2012 1928
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 076ME
UT WOS:000313959800022
PM 23291450
OA Bronze
DA 2025 08 17
ER

PT J
AU Busse, B
   Jobke, B
   Hahn, M
   Priemel, M
   Niecke, M
   Seitz, S
   Zustin, J
   Semler, J
   Amling, M
AF Busse, B.
   Jobke, B.
   Hahn, M.
   Priemel, M.
   Niecke, M.
   Seitz, S.
   Zustin, J.
   Semler, J.
   Amling, M.
TI Effects of strontium ranelate administration on bisphosphonate altered
   hydroxyapatite: Matrix incorporation of strontium is accompanied by
   changes in mineralization and microstructure
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Hydroxyapatite; Bone microstructure; Histomorphometry; Strontium;
   Electron microscopy
ID POSTMENOPAUSAL WOMEN; BONE FORMATION; NONVERTEBRAL FRACTURES; DENSITY
   DISTRIBUTION; RISK; ALENDRONATE; THERAPY; QUALITY; OSTEOPOROSIS;
   STRENGTH
AB Strontium ranelate (SR) is one therapeutic option for reducing risk of fracture in osteoporosis. The effects of SR treatment on hydroxyapatite (HA) previously altered by bisphosphonate (BP) administration remain to be established. Patients who have received long term BP treatment and present with persistent high fracture risk are of particular interest. Paired iliac crest biopsies from 15 patients post BP therapy were subjected to a baseline biopsy and a follow up biopsy after treatment with 2 g SR day( 1) after either 6 months (n = 5) or 12 months (n = 10). Dual energy X ray absorptiometry scans, serum parameters and biochemical markers were obtained. Quantitative backscattered electron imaging and energy dispersive X ray analyses combined with micro X ray fluorescence determinations were performed to observe any mineralization changes. Static 2 D histomorphometry was carried out to evaluate cellular and structural indices. After 6 months of SR treatment, increases in osteoid surface and strontium content were observed, but no other indices showed significant change. After 12 months of SR treatment, there was a significant increase in bone volume and trabecular thickness, and further increases in strontium content and backscattered signal intensity. These structural changes were accompanied by increased numbers of osteoblasts and increased osteoid surface and volume. Additionally, low bone resorption, as measured by beta cross laps, and a low number of osteoclasts were observed. SR treatment led to increased strontium content within the BP HA nanocomposites and to increased osteoid indices and bone volume, which is indicative of newly formed bone, while osteoclasts were still suppressed. These data points suggest that SR might be considered as a therapeutic option for patients following long term BP treatment. (C) 2010 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Busse, B.; Hahn, M.; Priemel, M.; Seitz, S.; Amling, M.] Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, D 22529 Hamburg, Germany.
   [Jobke, B.] Helios Klinikum Berlin Buch, Inst Radiol, D 13125 Berlin, Germany.
   [Priemel, M.; Seitz, S.] Univ Med Ctr Hamburg Eppendorf, Dept Trauma Hand & Reconstruct Surg, D 20246 Hamburg, Germany.
   [Niecke, M.] Univ Hamburg, Inst Expt Phys, D 22761 Hamburg, Germany.
   [Zustin, J.] Univ Med Ctr Hamburg Eppendorf, Inst Pathol, D 20246 Hamburg, Germany.
   [Semler, J.] Immanuel Hosp Berlin Wannsee, Dept Bone Metab & Osteol, D 14109 Berlin, Germany.
C3 University of Hamburg; University Medical Center Hamburg Eppendorf;
   Helios Kliniken; University of Hamburg; University Medical Center
   Hamburg Eppendorf; University of Hamburg; University of Hamburg;
   University Medical Center Hamburg Eppendorf
RP Busse, B (通讯作者)，Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, 1 Cyclotron Rd, Berkeley, CA 94720 USA.
EM b.busse@uke.uni hamburg.de; amling@uke.uni hamburg.de
RI ; Bloch, Michael/O 7845 2017; Busse, Björn/AAC 4033 2020
OI Busse, Bjorn/0000 0002 3099 8073; 
FU University Medical Center Hamburg Eppendorf; ENDO   Stiftung: Stiftung
   des Gemeinnutzigen Vereins ENDO Klinik e.V.
FX The authors wish to thank Dr. Michael Haschke and Dipl. Phys. Natalia
   Kemf for microanalysis expert support. The study was funded by the
   University Medical Center Hamburg Eppendorf and in part by the "ENDO  
   Stiftung: Stiftung des Gemeinnutzigen Vereins ENDO Klinik e.V." Dr.
   Bjorn Busse is a fellow of the "DFG   Deutsche Forschungsgemeinschaft".
CR Ammann P, 2004, J BONE MINER RES, V19, P2012, DOI 10.1359/JBMR.040906
   Ammann P, 2007, J BONE MINER RES, V22, P1419, DOI 10.1359/jbmr.070607
   Arlot ME, 2008, J BONE MINER RES, V23, P215, DOI 10.1359/JBMR.071012
   Bain SD, 2009, OSTEOPOROSIS INT, V20, P1417, DOI 10.1007/s00198 008 0815 8
   Baron R, 2002, EUR J PHARMACOL, V450, P11, DOI 10.1016/S0014 2999(02)02040 X
   Bilezikian JP, 2009, AM J MED, V122, P14, DOI 10.1016/j.amjmed.2008.12.003
   Bjeoumikhov A, 2005, X RAY SPECTROM, V34, P493, DOI 10.1002/xrs.872
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Blake GM, 2007, J CLIN DENSITOM, V10, P113, DOI 10.1016/j.jocd.2007.01.002
   Blake GM, 2007, J CLIN DENSITOM, V10, P34, DOI 10.1016/j.jocd.2006.10.004
   Blake GM, 2005, J BONE MINER RES, V20, P1901, DOI 10.1359/JBMR.050810
   Boivin G., 2006, Calcified Tissue International, V78, pS36
   Boivin G, 2010, OSTEOPOROSIS INT, V21, P667, DOI 10.1007/s00198 009 1005 z
   Bruyere O, 2007, J CLIN ENDOCR METAB, V92, P3076, DOI 10.1210/jc.2006 2758
   Busse B, 2008, J BIOMED MATER RES A, V87A, P536, DOI 10.1002/jbm.a.31794
   Busse B, 2006, PATHOLOGE, V27, P73, DOI 10.1007/s00292 005 0799 5
   Busse B, 2009, BONE, V45, P1034, DOI 10.1016/j.bone.2009.08.002
   Canalis E, 1996, BONE, V18, P517, DOI 10.1016/8756 3282(96)00080 4
   Chavassieux PM, 1997, J CLIN INVEST, V100, P1475, DOI 10.1172/JCI119668
   Djuric M, 2010, CALCIFIED TISSUE INT, V86, P192, DOI 10.1007/s00223 009 9325 8
   DONATH K, 1982, J ORAL PATHOL MED, V11, P318, DOI 10.1111/j.1600 0714.1982.tb00172.x
   Ensrud KE, 2008, J BONE MINER RES, V23, P112, DOI 10.1359/JBMR.070904
   Farlay D, 2005, J BONE MINER RES, V20, P1569, DOI 10.1359/JBMR.050405
   Felsenberg D, 2005, CLIN THER, V27, P1, DOI 10.1016/j.clinthera.2004.12.020
   Fratzl P, 1996, J BONE MINER RES, V11, P248
   Fuchs RK, 2008, OSTEOPOROSIS INT, V19, P1331, DOI 10.1007/s00198 008 0602 6
   Fuchs RK, 2008, J BONE MINER RES, V23, P1689, DOI [10.1359/jbmr.080501, 10.1359/JBMR.080501]
   HAHN M, 1991, VIRCHOWS ARCH A, V418, P1, DOI 10.1007/BF01600238
   Haschke M, 2007, X RAY SPECTROM, V36, P254, DOI 10.1002/xrs.974
   Hernandez CJ, 2006, BONE, V39, P1173, DOI 10.1016/j.bone.2006.06.001
   Hwang JS, 2008, CALCIFIED TISSUE INT, V83, P308, DOI 10.1007/s00223 008 9180 z
   JAMSHIDI K, 1971, J LAB CLIN MED, V77, P335
   Kendler DL, 2009, OSTEOPOROSIS INT, V20, P1101, DOI 10.1007/s00198 009 0886 1
   LI C, 2009, J BONE MINER RES, V29
   Lips P, 2001, ENDOCR REV, V22, P477, DOI 10.1210/er.22.4.477
   MARIE PJ, 1993, J BONE MINER RES, V8, P607
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Middleton ET, 2010, J BONE MINER RES, V25, P455, DOI 10.1359/jbmr.090821
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nielsen SP, 1999, J CLIN DENSITOM, V2, P371, DOI 10.1016/S1094 6950(06)60402 2
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Recker R R, 2004, Osteoporos Int, V15, P231, DOI 10.1007/s00198 003 1530 0
   Reginster JY, 2008, ARTHRITIS RHEUM US, V58, P1687, DOI 10.1002/art.23461
   Reginster JY, 2005, J CLIN ENDOCR METAB, V90, P2816, DOI 10.1210/jc.2004 1774
   Roschger P, 1998, BONE, V23, P319, DOI 10.1016/S8756 3282(98)00112 4
   Roschger P, 2008, BONE, V42, P456, DOI 10.1016/j.bone.2007.10.021
   ROSCHGER P, 1995, SCANNING MICROSCOPY, V9, P75
   ROSCHGER P, 2009, J BONE MINER RE 1019
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Seitz S, 2010, OSTEOPOROSIS INT, V21, P119, DOI 10.1007/s00198 009 0933 y
   SKEDROS JG, 1993, J BIOMED MATER RES, V27, P57, DOI 10.1002/jbm.820270108
   Takahashi N, 2003, J BONE MINER RES, V18, P1082, DOI 10.1359/jbmr.2003.18.6.1082
   Torgerson DJ, 2001, JAMA J AM MED ASSOC, V285, P2891, DOI 10.1001/jama.285.22.2891
   Zhu LL, 2007, BIOCHEM BIOPH RES CO, V355, P307, DOI 10.1016/j.bbrc.2007.01.120
NR 54
TC 64
Z9 68
U1 1
U2 17
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD DEC
PY 2010
VL 6
IS 12
BP 4513
EP 4521
DI 10.1016/j.actbio.2010.07.019
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 682EX
UT WOS:000284385300006
PM 20654744
DA 2025 08 17
ER

PT J
AU von Kaeppler, EP
   Wang, Q
   Raghu, H
   Bloom, MS
   Wong, HD
   Robinson, WH
AF von Kaeppler, Ericka P.
   Wang, Qian
   Raghu, Harini
   Bloom, Michelle S.
   Wong, Heidi
   Robinson, William H.
TI Interleukin 4 promotes anti inflammatory macrophages that clear
   cartilage debris and inhibits osteoclast development to protect against
   osteoarthritis
SO CLINICAL IMMUNOLOGY
LA English
DT Article
DE Osteoarthritis; Inflammation; Inerleukin 4; Myeloid; Macrophage;
   Osteoclast
ID SUBCHONDRAL BONE RESORPTION; LOW GRADE INFLAMMATION; ALENDRONATE
   TREATMENT; KNEE; DIFFERENTIATION; RECEPTOR; MODEL; SUSCEPTIBILITY;
   DESTRUCTION; ACTIVATION
AB Objective: Osteoarthritis (OA), the leading cause of joint failure, is characterized by breakdown of articular cartilage and remodeling of subchondral bone in synovial joints. Despite the high prevalence and debilitating effects of OA, no disease modifying drugs exist. Increasing evidence, including genetic variants of the interleukin 4 (IL 4) and IL 4 receptor genes, implicates a role for IL 4 in OA, however, the mechanism underlying IL 4 function in OA remains unknown. Here, we investigated the role of IL 4 in OA pathogenesis. Methods: Il4 , myeloid specific Il4ra , and Stat6 deficient and control mice were subjected to destabilization of the medial meniscus to induce OA. Macrophages, osteoclasts, and synovial explants were stimulated with IL 4 in vitro, and their function and expression profiles characterized. Results: Mice lacking IL 4, IL 4Ra in myeloid cells, or STAT6 developed exacerbated cartilage damage and osteophyte formation relative to WT controls. In vitro analyses revealed that IL 4 downregulates osteoarthritisassociated genes, enhances macrophage phagocytosis of cartilage debris, and inhibits osteoclast differentiation and activation via the type I receptor. Conclusion: Our findings demonstrate that IL 4 protects against osteoarthritis in a myeloid and STAT6 dependent manner. Further, IL 4 can promote an immunomodulatory microenvironment in which joint resident macrophages polarize towards an M2 phenotype and efficiently clear pro inflammatory debris, and osteoclasts maintain a homeostatic level of activity in subchondral bone. These findings support a role for IL 4 modulation of myeloid cell types in maintenance of joint health and identify a pathway that could provide therapeutic benefit for osteoarthritis.
C1 [von Kaeppler, Ericka P.] Stanford Univ, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA.
   [von Kaeppler, Ericka P.; Wang, Qian; Raghu, Harini; Bloom, Michelle S.; Wong, Heidi; Robinson, William H.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA.
   [Wang, Qian; Raghu, Harini; Bloom, Michelle S.; Wong, Heidi; Robinson, William H.] Stanford Univ, Div Immunol & Rheumatol, Stanford, CA 94305 USA.
C3 Stanford University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); VA Palo Alto Health Care System; Stanford
   University
RP Robinson, WH (通讯作者)，Stanford Univ, Div Immunol & Rheumatol, Stanford, CA 94305 USA.
EM w.robinson@stanford.edu
OI Robinson, William/0000 0003 4385 704X
FU VA Merit Awards [I01RX002689, BX004713 01A1]
FX The research was supported by VA Merit Awards I01RX002689 and
   BX004713 01A1 to W.H.R.
CR Barkal A.A., 2019, NATURE, V1
   Berenbaum F, 2013, OSTEOARTHR CARTILAGE, V21, P16, DOI 10.1016/j.joca.2012.11.012
   Bertuglia A, 2016, OSTEOARTHR CARTILAGE, V24, P555, DOI 10.1016/j.joca.2015.10.008
   Boonen S, 2012, CURR OSTEOPOROS REP, V10, P73, DOI 10.1007/s11914 011 0085 9
   Botter SM, 2011, ARTHRITIS RHEUM US, V63, P2690, DOI 10.1002/art.30307
   Durand M, 2013, ARTHRITIS RHEUM US, V65, P148, DOI 10.1002/art.37722
   Fang H, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 21184 5
   Felson DT, 2010, BEST PRACT RES CL RH, V24, P47, DOI 10.1016/j.berh.2009.08.002
   Forster T, 2004, HUM GENET, V114, P391, DOI 10.1007/s00439 004 1083 0
   Gieseck R.L., 2017, NAT PUBL GROUP, V18
   Glasson SS, 2007, OSTEOARTHR CARTILAGE, V15, P1061, DOI 10.1016/j.joca.2007.03.006
   Hm BerkelaarM., 2018, J Rheum Dis Treat, V4, P59
   Huang ZP, 2018, RHEUMATOLOGY, V57, P108, DOI 10.1093/rheumatology/kex496
   Hunter DJ, 2019, LANCET, V393, P1745, DOI 10.1016/S0140 6736(19)30417 9
   Hwang SY, 2012, FASEB J, V26, P1484, DOI 10.1096/fj.11 194399
   Joosten LAB, 1997, ARTHRITIS RHEUM, V40, P249, DOI 10.1002/art.1780400209
   Junttila IS, 2012, NAT CHEM BIOL, V8, P990, DOI [10.1038/NCHEMBIO.1096, 10.1038/nchembio.1096]
   Kamekura S, 2005, OSTEOARTHR CARTILAGE, V13, P632, DOI 10.1016/j.joca.2005.03.004
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   Karsdal MA, 2014, ANN RHEUM DIS, V73, P336, DOI 10.1136/annrheumdis 2013 204111
   Kraus V.B., 2015, OSTEOARTHR CARTIL, P1
   Liu HR, 2014, J HISTOCHEM CYTOCHEM, V62, P556, DOI 10.1369/0022155414537830
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   May RD, 2015, CYTOKINE, V75, P89, DOI 10.1016/j.cyto.2015.05.018
   McCormick SM, 2015, CYTOKINE, V75, P38, DOI 10.1016/j.cyto.2015.05.023
   MIOSSEC P, 1994, ARTHRITIS RHEUM, V37, P1715, DOI 10.1002/art.1780371202
   Mohan G, 2013, OSTEOARTHR CARTILAGE, V21, P1595, DOI 10.1016/j.joca.2013.06.020
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Neogi T, 2018, ANN RHEUM DIS, V77, P92, DOI 10.1136/annrheumdis 2017 211811
   Pelletier JP, 2004, BONE, V34, P527, DOI 10.1016/j.bone.2003.11.021
   Raghu H, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis 2016 210426
   Rahmati M, 2016, BONE, V85, P81, DOI 10.1016/j.bone.2016.01.019
   Ramaswamy G, 2017, SCI REP UK, V7, DOI 10.1038/srep45140
   REIMANN I, 1977, ACTA ORTHOP SCAND, V48, P63, DOI 10.3109/17453677708985113
   RIANCHO JA, 1993, BIOCHEM BIOPH RES CO, V196, P678, DOI 10.1006/bbrc.1993.2303
   Robinson WH, 2016, NAT REV RHEUMATOL, V12, P580, DOI 10.1038/nrrheum.2016.136
   Rogoveanu OC, 2018, EXP THER MED, V16, P2659, DOI 10.3892/etm.2018.6477
   Saradna A, 2018, TRANSL RES, V191, P1, DOI 10.1016/j.trsl.2017.09.002
   Scanzello CR, 2017, CURR OPIN RHEUMATOL, V29, P79, DOI 10.1097/BOR.0000000000000353
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Shapouri Moghaddam A, 2018, J CELL PHYSIOL, V233, P6425, DOI 10.1002/jcp.26429
   Shi JY, 2018, METHODS MOL BIOL, V1784, P263, DOI 10.1007/978 1 4939 7837 3_24
   Shibakawa A, 2005, OSTEOARTHR CARTILAGE, V13, P679, DOI 10.1016/j.joca.2005.04.010
   Siebelt M, 2014, BONE, V66, P163, DOI 10.1016/j.bone.2014.06.009
   Silvestri T, 2006, OSTEOARTHR CARTILAGE, V14, P717, DOI 10.1016/j.joca.2006.02.015
   Torabinia N, 2011, J ORAL PATHOL MED, V40, P334, DOI 10.1111/j.1600 0714.2010.00944.x
   van Helvoort EM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219587
   Vargiolu M, 2010, OSTEOARTHR CARTILAGE, V18, P810, DOI 10.1016/j.joca.2010.02.005
   Wang Q, 2011, NAT MED, V17, P1674, DOI 10.1038/nm.2543
   Wang Y, 2013, J SURG RES, V180, pE73, DOI 10.1016/j.jss.2012.04.016
   WATANABE K, 1990, BIOCHEM BIOPH RES CO, V172, P1035, DOI 10.1016/0006 291X(90)91550 C
   Xue J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8158
   Yigit S, 2014, GENE, V537, P6, DOI 10.1016/j.gene.2013.12.060
   Yorimitsu M, 2008, OSTEOARTHR CARTILAGE, V16, P764, DOI 10.1016/j.joca.2007.11.006
   Zhou C, 2016, OSTEOARTHR CARTILAGE, V24, P1648, DOI 10.1016/j.joca.2016.04.016
NR 55
TC 31
Z9 31
U1 1
U2 21
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 1521 6616
EI 1521 7035
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD AUG
PY 2021
VL 229
AR 108784
DI 10.1016/j.clim.2021.108784
EA JUN 2021
PG 10
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA TU7NG
UT WOS:000681218600001
PM 34126239
DA 2025 08 17
ER

PT J
AU Fionda, C
   Nappi, F
   Piccoli, M
   Frati, L
   Santoni, A
   Cippitelli, M
AF Fionda, Cinzia
   Nappi, Filomena
   Piccoli, Mario
   Frati, Luigi
   Santoni, Angela
   Cippitelli, Marco
TI 15 Deoxy Δ<SUP>12,14</SUP> prostaglandin J2 negatively
   regulates rankl gene expression in activated T lymphocytes:: Role
   of NF κB and early growth response transcription factors
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID TUMOR NECROSIS FACTOR; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS;
   MYELOMA BONE DISEASE; GAMMA PPAR GAMMA; LOSS IN VIVO; RECEPTOR GAMMA;
   NUCLEAR FACTOR; MULTIPLE MYELOMA; LIGAND GENE; CYCLOPENTENONE
   PROSTAGLANDINS
AB Receptor activator of NF KB ligand (RANKL) and its receptor RANK are cell surface proteins abundantly expressed in bone and lymphoid tissues, whose interaction triggers different signaling pathways leading to activation and' differentiation of osteoclasts, pivotal actors of the normal bone remodeling cycle. Moreover, RANKL may act as an immunomodulator, representing an important dendritic cell survival factor produced by activated T cells. A large body of research has shown that not only does the RANKL/RANK system regulate the physiology of bone development but also plays an important pathological role in bone destruction mediated by inflammatory disorders or bone metastatic tumors. 15 Deoxy Delta(12,14) PGJ(2) (15d PGJ(2)) is a cyclopentenone type PG endowed with anti inflammatory properties and produced by different cells, including those of the immune system. Although 15d PGJ(2) has been studied as a natural ligand of the peroxisome proliferator activated receptor gamma nuclear receptor, relevant peroxisome proliferator activated receptor gamma independent actions mediated by this prostanoid have been described. In this study, we describe the effect of 15d PGJ(2) on the expression of the rankl gene in T lymphocytes. We show that 15d PGJ2 inhibits rankl mRNA expression, protein, and rankl promoter activity by mechanisms mediated by its chemically reactive cyclopentenone moiety. Our data also indicate that 15d PGJ(2) represses rankl activation by interfering with the expression and/or activity of the transcription factors NF kappa B, early growth response 2, and early growth response 3, whose altered balancing and transactivation may contribute for the repression of this gene. These results place rankl as a novel molecular target for the different immunoregulatory activities mediated by 15d PGJ(2). The physiological and pharmacological implications of these observations are discussed.
C1 Univ Roma La Sapienza, Dept Expt Med & Pathol, Ist Pasteur, Fdn Cenci Bolognetti, Rome, Italy.
   Ctr Ric Sperimentale, Regina Elena Canc Inst, Rome, Italy.
   Ist Mediterraneo Neurosci Neuromed, Pozzilli, Italy.
   Ist Super Sanita, Natl AIDS Ctr, I 00161 Rome, Italy.
C3 Sapienza University Rome; Fondazione Cenci Bolognetti; IRCCS Neuromed;
   Istituto Superiore di Sanita (ISS)
RP Cippitelli, M (通讯作者)，Univ Roma La Sapienza, Dept Expt Med & Pathol, Ist Pasteur, Fdn Cenci Bolognetti, Viale Regina Elena 324, Rome, Italy.
EM cippitelli@ifo.it
RI Cippitelli, Marco/AAF 4857 2021; santoni, angela/K 8997 2016; Frati,
   Luigi/ABI 7437 2020
OI CIPPITELLI, Marco/0000 0002 9620 538X; Nappi,
   Filomena/0000 0003 2313 7694; 
CR Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Blair JM, 2006, NAT CLIN PRACT ONCOL, V3, P41, DOI 10.1038/ncponc0381
   Carayol N, 2006, J BIOL CHEM, V281, P31142, DOI 10.1074/jbc.M603417200
   Cernuda Morollón E, 2001, J BIOL CHEM, V276, P35530, DOI 10.1074/jbc.M104518200
   Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336
   Cippitelli M, 2003, J IMMUNOL, V170, P4578, DOI 10.4049/jimmunol.170.9.4578
   Cippitelli M, 2002, J IMMUNOL, V168, P1154, DOI 10.4049/jimmunol.168.3.1154
   Clowes JA, 2005, IMMUNOL REV, V208, P207, DOI 10.1111/j.0105 2896.2005.00334.x
   Colucci S, 2004, BLOOD, V104, P3722, DOI 10.1182/blood 2004 02 0474
   Cuzzocrea S, 2003, BRIT J PHARMACOL, V140, P366, DOI 10.1038/sj.bjp.0705419
   Cuzzocrea S, 2003, BRIT J PHARMACOL, V138, P678, DOI 10.1038/sj.bjp.0705077
   Decker EL, 1998, J BIOL CHEM, V273, P26923, DOI 10.1074/jbc.273.41.26923
   Diab A, 2004, J NEUROIMMUNOL, V148, P116, DOI 10.1016/j.jneuroim.2003.11.010
   Diab A, 2002, J IMMUNOL, V168, P2508, DOI 10.4049/jimmunol.168.5.2508
   Drew PD, 2001, J NEUROIMMUNOL, V115, P28, DOI 10.1016/S0165 5728(01)00267 3
   Droin NM, 2003, MOL CELL BIOL, V23, P7638, DOI 10.1128/MCB.23.21.7638 7647.2003
   Ehrlich LA, 2005, IMMUNOL REV, V208, P252, DOI 10.1111/j.0105 2896.2005.00323.x
   Fan X, 2004, J CELL BIOCHEM, V93, P807, DOI 10.1002/jcb.20217
   Faveeuw C, 2000, FEBS LETT, V486, P261, DOI 10.1016/S0014 5793(00)02319 X
   FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092 8674(95)90193 0
   Fu Q, 2002, J BIOL CHEM, V277, P48868, DOI 10.1074/jbc.M208494200
   Giuliani N, 2004, EXP HEMATOL, V32, P685, DOI 10.1016/j.exphem.2004.03.015
   Giuliani N, 2002, BLOOD, V100, P4615, DOI 10.1182/blood 2002 04 1121
   Harris SG, 2002, TRENDS IMMUNOL, V23, P144, DOI 10.1016/S1471 4906(01)02154 8
   Hortelano S, 2000, J IMMUNOL, V165, P6525, DOI 10.4049/jimmunol.165.11.6525
   Ishihara Shunji, 2004, Current Medicinal Chemistry   Anti Cancer Agents, V4, P379, DOI 10.2174/1568011043352902
   Jimi E, 2005, IMMUNOL REV, V208, P80, DOI 10.1111/j.0105 2896.2005.00329.x
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Knobel H, 2001, AIDS, V15, P807, DOI 10.1097/00002030 200104130 00022
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kotake S, 2001, ARTHRITIS RHEUM, V44, P1003, DOI 10.1002/1529 0131(200105)44:5<1003::AID ANR179>3.3.CO;2 R
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lin JX, 1997, MOL CELL BIOL, V17, P3714, DOI 10.1128/MCB.17.7.3714
   Liu JZ, 2005, J CELL BIOCHEM, V96, P716, DOI 10.1002/jcb.20569
   Mbalaviele G, 2000, J BIOL CHEM, V275, P14388, DOI 10.1074/jbc.275.19.14388
   Mittelstadt PR, 1998, MOL CELL BIOL, V18, P3744, DOI 10.1128/MCB.18.7.3744
   Mittelstadt PR, 1999, J BIOL CHEM, V274, P3222, DOI 10.1074/jbc.274.5.3222
   Mori K, 2006, J CELL BIOCHEM, V98, P1629, DOI 10.1002/jcb.20891
   O'Donovan KJ, 1999, TRENDS NEUROSCI, V22, P167, DOI 10.1016/S0166 2236(98)01343 5
   PARFITT AM, 1984, CALCIFIED TISSUE INT, V36, pS37, DOI 10.1007/BF02406132
   Piepkorn B, 1997, HORM METAB RES, V29, P584, DOI 10.1055/s 2007 979106
   Piva R, 2005, BLOOD, V105, P1750, DOI 10.1182/blood 2004 04 1360
   Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178
   Roato I, 2004, FASEB J, V18, P228, DOI 10.1096/fj.04 1823fje
   Roccisana JL, 2004, J BIOL CHEM, V279, P10500, DOI 10.1074/jbc.M303727200
   Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698
   Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301 472X(99)00061 2
   Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520
   Rossi A, 1996, J BIOL CHEM, V271, P32192, DOI 10.1074/jbc.271.50.32192
   Scher JU, 2005, CLIN IMMUNOL, V114, P100, DOI 10.1016/j.clim.2004.09.008
   STELLON AJ, 1985, GASTROENTEROLOGY, V89, P1078, DOI 10.1016/0016 5085(85)90212 4
   Strandell A, 2000, HUM REPROD, V15, P14
   Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006.abs
   Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Teng YTA, 2000, J CLIN INVEST, V106, pR59, DOI 10.1172/JCI10763
   Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753
   Toraldo G, 2003, P NATL ACAD SCI USA, V100, P125, DOI 10.1073/pnas.0136772100
   Walsh NC, 2005, IMMUNOL REV, V208, P228, DOI 10.1111/j.0105 2896.2005.00338.x
   Weitzmann MN, 2001, J BONE MINER RES, V16, P328, DOI 10.1359/jbmr.2001.16.2.328
   Willoughby DA, 2000, NAT MED, V6, P137, DOI 10.1038/72224
   Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075
   Yang XY, 2000, J BIOL CHEM, V275, P4541, DOI 10.1074/jbc.275.7.4541
   Zhang X, 2004, BLOOD, V104, P3276, DOI 10.1182/blood 2004 02 0664
NR 65
TC 14
Z9 19
U1 0
U2 4
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022 1767
EI 1550 6606
J9 J IMMUNOL
JI J. Immunol.
PD APR 1
PY 2007
VL 178
IS 7
BP 4039
EP 4050
DI 10.4049/jimmunol.178.7.4039
PG 12
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA 150EB
UT WOS:000245197300008
PM 17371958
OA Bronze
DA 2025 08 17
ER

PT J
AU Sartoretto, S
   Gemini Piperni, S
   da Silva, RA
   Calasans, MD
   Rucci, N
   dos Santos, TMD
   Lima, IBC
   Rossi, AM
   Alves, G
   Granjeiro, JM
   Teti, A
   Zambuzzi, WF
AF Sartoretto, Suelen
   Gemini Piperni, Sara
   da Silva, Rodrigo A.
   Calasans, Monica D.
   Rucci, Nadia
   Pires dos Santos, Thais M.
   Lima, Inaya B. C.
   Rossi, Alexandre M.
   Alves, Gutemberg
   Granjeiro, Jose M.
   Teti, Anna
   Zambuzzi, Willian F.
TI Apoptosis associated speck like protein containing a caspase 1
   recruitment domain (ASC) contributes to osteoblast differentiation and
   osteogenesis
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE ASC; bone formation; inflammasome; osteoblast; osteogenesis;
   regenerative medicine
ID BONE REPAIR; INFLAMMASOME; INTERLEUKIN 18; INHIBITION; ACTIVATION;
   IL 18; GAMMA
AB The role of apoptosis associated speck like protein containing a caspase 1 recruitment domain (ASC) in bone healing remains to be understood. To address this issue, we investigated the requirement of inflammasome related genes in response to bone morphogenetic protein 7 (BMP7) induced osteoblast differentiation in vitro. To validate the importance of ASC on osteogenesis, we subjected wild type (WT) and ASC knockout C57BL/6 mice (ASC KO) to tibia defect to evaluate the bone healing process (up to 28 days). Our in vitro data showed that there is an involvement of ASC during BMP7 induced osteoblast differentiation, concomitant to osteogenic biomarker expression. Indeed, primary osteogenic cells from ASC KO presented a lower osteogenic profile than those obtained from WT mice. To validate this hypothesis, we evaluated the bone healing process of tibia defects on both WT and ASC KO mice genotypes and the ASC KO mice were not able to fully heal tibia defects up to 28 days, whereas WT tibia defects presented a higher bone de novo volume at this stage, evidencing ASC as an important molecule during osteogenic phenotype. In addition, we have shown a higher involvement of runt related transcription factor 2 in WT sections during bone repair, as well as circulating bone alkaline phosphatase isoform when both were compared with ASC KO mice behavior. Altogether, our results showed for the first time the involvement of inflammasome during osteoblast differentiation and osteogenesis, which opens new avenues to understand the pathways involved in bone healing.
C1 [Sartoretto, Suelen; Calasans, Monica D.] Fluminense Fed Univ, Oral Surg Dept, Niteroi, RJ, Brazil.
   [Gemini Piperni, Sara; Granjeiro, Jose M.] Inst Nacl Metrol Normalizacao & Qual Ind INMETRO, Div Life Sci Appl Metrol Dimav, Xerem, RJ, Brazil.
   [da Silva, Rodrigo A.; Zambuzzi, Willian F.] Univ Estadual Paulista, UNESP, Biosci Inst, Dept Chem & Biochem,Lab Bioensaios & Dinam Celula, Campus Botucatu, BR 18618970 Botucatu 510, SP, Brazil.
   [Rucci, Nadia; Teti, Anna] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Via Vetoio Coppito, Laquila, Italy.
   [Pires dos Santos, Thais M.; Lima, Inaya B. C.] Univ Fed Rio de Janeiro, Nucl Engn Program, Nucl Instrumentat Dept, COPPE, Rio De Janeiro, Brazil.
   [Rossi, Alexandre M.] Brazilian Ctr Phys Res, Dept Appl Phys, Rua Dr Xavier Sigaud, Urca, RJ, Brazil.
   [Alves, Gutemberg; Granjeiro, Jose M.] Fluminense Fed Univ, Antonio Pedro Hosp, Div Clin Res, Av Marques do Parana,303 Ctr, Niteroi, RJ, Brazil.
C3 Universidade Federal Fluminense; Instituto Nacional de Metrologia,
   Qualidade e Tecnologia (INMETRO); Universidade Estadual Paulista;
   University of L'Aquila; Universidade Federal do Rio de Janeiro; Centro
   Brasileiro de Pesquisas Fisicas; Universidade Federal Fluminense
RP Zambuzzi, WF (通讯作者)，Univ Estadual Paulista, UNESP, Biosci Inst, Dept Chem & Biochem,Lab Bioensaios & Dinam Celula, Campus Botucatu, BR 18618970 Botucatu 510, SP, Brazil.
EM w.zambuzzi@unesp.br
RI Alves, Gutemberg/E 2742 2013; Zambuzzi, Willian/ABD 8339 2020; da Silva,
   Rodrigo/G 1222 2012; Granjeiro, Jose/D 8289 2012; Malta Rossi,
   Alexandre/H 1684 2012; Calasans Maia, Monica/G 6203 2013; Sartoretto,
   Suelen/AAR 4428 2020; da Silva, Rodrigo Augusto/G 1222 2012; Rossi,
   Alexandre/H 1684 2012; Gemini Piperni, Sara/A 9858 2015; Zambuzzi,
   Willian/F 9519 2012
OI Calasans Maia, Monica/0000 0001 5759 7926; Rucci,
   Nadia/0000 0002 1371 8252; Teti, Anna Maria/0000 0002 5887 4419;
   Granjeiro, Jose/0000 0002 8027 8293; Malta Rossi,
   Alexandre/0000 0003 4244 8455; da Silva, Rodrigo
   Augusto/0000 0002 7754 1855; Gemini Piperni, Sara/0000 0002 7724 9491;
   Zambuzzi, Willian/0000 0002 4149 5965
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2014/22689 3]; Marie Curie International Research Staff Exchange Scheme
   Fellowship European Commission FP7 Program INTERBONE Grant
   [PIRSES GA 2011  295181]; Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq); Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) [14/22689 3] Funding Source: FAPESP
FX Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP),
   Grant/Award Number: 2014/22689 3; Marie Curie International Research
   Staff Exchange Scheme Fellowship European Commission FP7 Program
   INTERBONE Grant PIRSES GA 2011  295181; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)
CR Bastian O, 2011, J LEUKOCYTE BIOL, V89, P669, DOI 10.1189/jlb.0810446
   Bonar SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035979
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brodbeck WG, 2002, CYTOKINE, V18, P311, DOI 10.1006/cyto.2002.1048
   Carreira AC, 2014, ARCH BIOCHEM BIOPHYS, V561, P64, DOI 10.1016/j.abb.2014.07.011
   Cornish J, 2003, ENDOCRINOLOGY, V144, P1194, DOI 10.1210/en.2002 220936
   Fernandes CJD, 2017, MOL CELL BIOCHEM, V436, P111, DOI 10.1007/s11010 017 3083 0
   Dasmah A, 2012, J CRANIO MAXILL SURG, V40, P654, DOI 10.1016/j.jcms.2011.10.032
   de Veerdonk FLV, 2011, TRENDS IMMUNOL, V32, P110, DOI 10.1016/j.it.2011.01.003
   Dinarello CA, 2013, SEMIN IMMUNOL, V25, P389, DOI 10.1016/j.smim.2013.10.001
   FELDKAMP LA, 1984, J OPT SOC AM A, V1, P612, DOI 10.1364/JOSAA.1.000612
   Filbin MT, 2006, NAT NEUROSCI, V9, P715, DOI 10.1038/nn0606 715
   Fisher DM, 2013, CURR STEM CELL RES T, V8, P260
   Gaston MS, 2007, J BONE JOINT SURG BR, V89B, P1553, DOI 10.1302/0301 620X.89B12
   Gemini Piperni S, 2014, ARCH BIOCHEM BIOPHYS, V561, P88, DOI 10.1016/j.abb.2014.06.019
   Gemini Piperni S, 2014, BIOTECHNOL BIOENG, V111, P1900, DOI 10.1002/bit.25246
   Giannoudis PV, 2005, INJURY, V36, P20, DOI 10.1016/j.injury.2005.07.029
   GOLUB EE, 1992, BONE MINER, V17, P273, DOI 10.1016/0169 6009(92)90750 8
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   Klijn RJ, 2010, TISSUE ENG PART B RE, V16, P493, DOI [10.1089/ten.teb.2010.0035, 10.1089/ten.TEB.2010.0035]
   Könnecke I, 2014, BONE, V64, P155, DOI 10.1016/j.bone.2014.03.052
   Landgraeber S, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/185150
   Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651
   Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664
   Modrowski D, 1997, J CELL PHYSIOL, V170, P35
   Mountziaris PM, 2008, TISSUE ENG PART B RE, V14, P179, DOI 10.1089/ten.teb.2008.0038
   NAKAMURA K, 1989, INFECT IMMUN, V57, P590, DOI 10.1128/IAI.57.2.590 595.1989
   Netea MG, 2015, CELL METAB, V21, P513, DOI 10.1016/j.cmet.2015.03.012
   NGUYEN L, 1991, LYMPHOKINE CYTOK RES, V10, P15
   Carreira ACO, 2015, VITAM HORM, V99, P293, DOI 10.1016/bs.vh.2015.06.002
   Papakostidis C, 2013, BONE JOINT J, V95B, P1673, DOI 10.1302/0301 620X.95B12.32385
   Park CC, 2001, J IMMUNOL, V167, P1644, DOI 10.4049/jimmunol.167.3.1644
   Patel MN, 2017, TRENDS MOL MED, V23, P165, DOI 10.1016/j.molmed.2016.12.007
   Rennert RC, 2012, REGEN MED, V7, P833, DOI [10.2217/RME.12.82, 10.2217/rme.12.82]
   Rossi MC, 2017, J BIOMED MATER RES A, V105, P2968, DOI 10.1002/jbm.a.36150
   Saran U, 2014, ARCH BIOCHEM BIOPHYS, V561, P109, DOI 10.1016/j.abb.2014.07.006
   Udagawa N, 1997, J EXP MED, V185, P1005, DOI 10.1084/jem.185.6.1005
   Vanaja SK, 2015, TRENDS CELL BIOL, V25, P308, DOI 10.1016/j.tcb.2014.12.009
   Vimalraj S, 2015, INT J BIOL MACROMOL, V78, P202, DOI 10.1016/j.ijbiomac.2015.04.008
   Werts C, 2006, CELL DEATH DIFFER, V13, P798, DOI 10.1038/sj.cdd.4401890
NR 40
TC 28
Z9 33
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD APR
PY 2019
VL 234
IS 4
BP 4140
EP 4153
DI 10.1002/jcp.27226
PG 14
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA HK0TE
UT WOS:000457613700082
PM 30171612
DA 2025 08 17
ER

PT J
AU Haseltine, KN
   Chukir, T
   Smith, PJ
   Jacob, JT
   Bilezikian, JP
   Farooki, A
AF Haseltine, Katherine N.
   Chukir, Tariq
   Smith, Pinar J.
   Jacob, Justin T.
   Bilezikian, John P.
   Farooki, Azeez
TI Bone Mineral Density: Clinical Relevance and Quantitative Assessment
SO JOURNAL OF NUCLEAR MEDICINE
LA English
DT Article
DE bone mineral density; DXA; fracture risk; osteoporosis; FRAX
ID POSTMENOPAUSAL WOMEN; FRACTURE RISK; VERTEBRAL FRACTURES;
   AMERICAN COLLEGE; HIP FRACTURE; OLDER WOMEN; OSTEOPOROSIS; DIAGNOSIS;
   DXA; PREVENTION
AB Bone mineral density (BMD) measurement by dual energy x ray absorptiometry (DXA) is an internationally accepted standard of care screening tool used to assess fragility fracture risk. Society guidelines have recommended which populations may benefit from DXA screening and the use of the fracture risk assessment tool (FRAX) to guide decisions regarding pharmacologic treatment for osteoporosis. According to the U.S. National Osteoporosis Foundation guidelines, postmenopausal women and men at least 50 y old with osteopenic BMD warrant pharmacologic treatment if they have a FRAX calculated 10 y probability of at least 3% for hip fracture or at least 20% for major osteoporotic fracture. Patients with osteoporosis defined by a clinical event, namely a fragility fracture, or with an osteoporotic BMD should also be treated. Patients who are treated for osteoporosis should be monitored regularly to track expected gains in BMD by serial DXA scans. With some drug therapies, BMD targets can be reached whereby further improvements in BMD are not associated with further reductions in fracture risk. Although reaching this target might suggest a stopping point for therapy, the reversibility of most treatments for osteoporosis, except for the bisphosphonates, has dampened enthusiasm for this approach. In the case of denosumab, it is now apparent that stopping therapy at any point can lead to an increase in multiple fracture risk. For patients who do not respond to antiosteoporosis pharmacologic therapy with an improvement in BMD, or who have an incident fragility fracture on therapy, secondary causes of osteoporosis or non compliance with medical therapy should be considered.
   Bone mineral density (BMD) measurement by dual energy x ray absorptiometry (DXA) is an internationally accepted standard of care screening tool used to assess fragility fracture risk. Society guidelines have recommended which populations may benefit from DXA screening and the use of the fracture risk assessment tool (FRAX) to guide decisions regarding pharmacologic treatment for osteoporosis. According to the U.S. National Osteoporosis Foundation guidelines, postmenopausal women and men at least 50 y old with osteopenic BMD warrant pharmacologic treatment if they have a FRAX calculated 10 y probability of at least 3% for hip fracture or at least 20% for major osteoporotic fracture. Patients with osteoporosis defined by a clinical event, namely a fragility fracture, or with an osteoporotic BMD should also be treated. Patients who are treated for osteoporosis should be
C1 [Haseltine, Katherine N.; Chukir, Tariq; Farooki, Azeez] Mem Sloan Kettering Canc Ctr, Dept Med, Endocrinol Serv, New York, NY 10065 USA.
   [Smith, Pinar J.] Icahn Sch Med Mt Sinai, Div Endocrinol Diabet & Bone Dis, New York, NY 10029 USA.
   [Jacob, Justin T.] Mem Sloan Kettering Canc Ctr, Dept Radiol, Mol Imaging & Therapy Serv, New York, NY 10065 USA.
   [Bilezikian, John P.] Columbia Univ, Vagelos Coll Phys & Surg, Div Endocrinol, New York, NY USA.
C3 Memorial Sloan Kettering Cancer Center; Icahn School of Medicine at
   Mount Sinai; Memorial Sloan Kettering Cancer Center; Columbia University
RP Farooki, A (通讯作者)，Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA.
EM farookia@mskcc.org
FU NIH/NCI Memorial Sloan Kettering Cancer Center support grant [P30
   CA008748]
FX Dr. Farooki has received consulting fees from Amgen and has been an
   Amgen advisory board member. Dr. Bilezikian has received consulting fees
   from Radius and Amgen. This work was supported in part by NIH/NCI
   Memorial Sloan Kettering Cancer Center support grant P30 CA008748. The
   authors of this article have indicated no other relevant relationships
   that could be perceived as a real or apparent conflict of interest.
CR Adler RA, 2016, J BONE MINER RES, V31, P16, DOI 10.1002/jbmr.2708
   [Anonymous], 1994, World Health Organ Tech Rep Ser, V843, P1
   [Anonymous], Bone mass measurement: what the numbers mean.
   [Anonymous], ADULT POSITIONS
   Bhambri R, 2006, J CLIN DENSITOM, V9, P120, DOI 10.1016/j.jocd.2005.11.001
   Blake GM, 2013, J CLIN DENSITOM, V16, P257, DOI 10.1016/j.jocd.2013.03.011
   Bonnick SL, 2010, CURR CLIN PRACT, P1, DOI 10.1007/978 1 60327 499 9
   Bonnick SL, 2010, MENOPAUSE, V17, P25, DOI [10.1097/gme.0b013e3181c617e6, 10.1097/gme.0b013e3181e617e6]
   Borah B, 2001, ANAT RECORD, V265, P101, DOI 10.1002/ar.1060
   Boyd S, 2020, Principles of Bone Biology, VFourth, P1833
   Briot K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083436
   Buckley L, 2017, ARTHRITIS RHEUMATOL, V69, P1521, DOI [10.1002/art.40137, 10.1002/acr.23279]
   Camacho PM, 2016, ENDOCR PRACT, V22, P1, DOI 10.4158/EP161435.GL
   Camacho PM, 2016, ENDOCR PRACT, V22, P1111, DOI 10.4158/EP161435.ESGL
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Cheung AM, 2019, J CLIN DENSITOM, V22, P506, DOI 10.1016/j.jocd.2019.07.003
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Cosman F, 2015, OSTEOPOROSIS INT, V26, P2045, DOI 10.1007/s00198 015 3037 x
   Cranney A, 2002, ENDOCR REV, V23, P508, DOI 10.1210/er.2001 2002
   Damilakis J, 2010, EUR RADIOL, V20, P2707, DOI 10.1007/s00330 010 1845 0
   El Maghraoui A, 2008, QJM INT J MED, V101, P605, DOI 10.1093/qjmed/hcn022
   Ensrud KE, 2000, J AM GERIATR SOC, V48, P241, DOI 10.1111/j.1532 5415.2000.tb02641.x
   GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915
   Giangregorio LM, 2012, J BONE MINER RES, V27, P301, DOI 10.1002/jbmr.556
   Greenblatt MB, 2017, CLIN CHEM, V63, P464, DOI 10.1373/clinchem.2016.259085
   Harvey NC, 2015, BONE, V78, P216, DOI 10.1016/j.bone.2015.05.016
   Headley JA, 1998, CANCER INVEST, V16, P6, DOI 10.3109/07357909809039747
   Huang KM, 2020, ANN NUCL MED, V34, P136, DOI 10.1007/s12149 019 01425 x
   Kanis JA, 2000, OSTEOPOROSIS INT, V11, P669, DOI 10.1007/s001980070064
   Kanis JA, 2018, ARCH OSTEOPOROS, V13, DOI 10.1007/s11657 018 0510 0
   Kanis JA, 2015, J BONE MINER RES, V30, P1747, DOI 10.1002/jbmr.2531
   Kim JH, 2016, OSTEOPOROSIS INT, V27, P1161, DOI 10.1007/s00198 015 3329 1
   Kleerekoper M, 2001, CLIN CHEM, V47, P1347
   Kolta S, 2014, OSTEOPOROSIS INT, V25, P1759, DOI 10.1007/s00198 014 2685 6
   Langdahl BL, 2017, LANCET, V390, P1585, DOI 10.1016/S0140 6736(17)31613 6
   Leidig Bruckner G, 2001, LANCET, V357, P342, DOI 10.1016/S0140 6736(00)03641 2
   Leslie WD, 2019, J BONE MINER RES, V34, P1808, DOI 10.1002/jbmr.3813
   Liu JJ, 2020, J NUCL MED, V61, P177, DOI 10.2967/jnumed.119.227652
   Looker AC, 2016, OSTEOPOROSIS INT, V27, P2467, DOI 10.1007/s00198 016 3550 6
   Melton LJ, 1999, OSTEOPOROSIS INT, V10, P214, DOI 10.1007/s001980050218
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   Morrison RS, 1998, ANN INTERN MED, V128, P1010, DOI 10.7326/0003 4819 128 12_Part_1 199806150 00010
   Njeh CF, 1999, APPL RADIAT ISOTOPES, V50, P215, DOI 10.1016/S0969 8043(98)00026 8
   Panula J, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 105
   Prevrhal S, 2009, CURR MED RES OPIN, V25, P921, DOI 10.1185/03007990902790993 
   Reid IR, 2018, NEW ENGL J MED, V379, P2407, DOI 10.1056/NEJMoa1808082
   Ross Philip D., 1997, American Journal of Medicine, V103, p30S, DOI 10.1016/S0002 9343(97)90025 5
   Ross RW, 2002, J UROLOGY, V167, P1952, DOI 10.1016/S0022 5347(05)65060 4
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Seeman E, 2013, J GERONTOL A BIOL, V68, P1218, DOI 10.1093/gerona/glt071
   Shane E, 1996, J CLIN ENDOCR METAB, V81, P1740, DOI 10.1210/jc.81.5.1740
   Shepherd JA, 2015, J CLIN DENSITOM, V18, P274, DOI 10.1016/j.jocd.2015.06.013
   Shoback D, 2020, J CLIN ENDOCR METAB, V105, P587, DOI 10.1210/clinem/dgaa048
   Shuhart CR, 2019, J CLIN DENSITOM, V22, P453, DOI 10.1016/j.jocd.2019.07.001
   Silva BC, 2015, J CLIN DENSITOM, V18, P309, DOI 10.1016/j.jocd.2015.06.008
   Silva BC, 2014, J BONE MINER RES, V29, P518, DOI 10.1002/jbmr.2176
   Silva BC, 2013, J CLIN DENSITOM, V16, P554, DOI 10.1016/j.jocd.2013.07.001
   Siris E, 2014, OSTEOPOROSIS INT, V25, P1439, DOI 10.1007/s00198 014 2655 z
   Solomon DH, 2014, J BONE MINER RES, V29, P1929, DOI 10.1002/jbmr.2202
   Stein E, 2007, ENDOCRIN METAB CLIN, V36, P937, DOI 10.1016/j.ecl.2007.07.008
   Stepan J J, 2003, Endocr Regul, V37, P225
   Watts Nelson B, 2010, Endocr Pract, V16 Suppl 3, P1
   Whitaker M, 2012, NEW ENGL J MED, V366, P2048, DOI 10.1056/NEJMp1202619
   Wildberger L, 2017, JOINT BONE SPINE, V84, P463, DOI 10.1016/j.jbspin.2016.05.015
NR 64
TC 61
Z9 69
U1 0
U2 8
PU SOC NUCLEAR MEDICINE INC
PI RESTON
PA 1850 SAMUEL MORSE DR, RESTON, VA 20190 5316 USA
SN 0161 5505
EI 1535 5667
J9 J NUCL MED
JI J. Nucl. Med.
PD APR 1
PY 2021
VL 62
IS 4
BP 446
EP 454
DI 10.2967/jnumed.120.256180
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA SN6SD
UT WOS:000658416500004
PM 33310738
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Ouanounou, A
   Hassanpour, S
   Glogauer, M
AF Ouanounou, Aviv
   Hassanpour, Siavash
   Glogauer, Michael
TI The Influence of Systemic Medications on Osseointegration of Dental
   Implants
SO JOURNAL OF THE CANADIAN DENTAL ASSOCIATION
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SEROTONIN REUPTAKE INHIBITORS; ORAL
   BISPHOSPHONATES; CYCLOSPORINE A; TITANIUM IMPLANTS; MINERAL DENSITY;
   RISK FACTORS; BONE; OSTEONECROSIS; CHEMOTHERAPY
AB Dental implants are routinely used to treat edentulism. Their success depends on osseointegration, the direct functional and structural interlocking of implant and bone. The osseointegration mechanism is similar to bone remodeling and healing. Thus, chronic use of systemic medications that can interfere with bone turnover and healing may affect osseointegration, resulting in premature implant loss. The aim of this narrative review is to analyze the reported effects of systemic medications on osseointegration.
C1 [Ouanounou, Aviv] Univ Toronto, Fac Dent, Dept Clin Sci Pharmacol, 124 Edward St, Toronto, ON M5G 1G6, Canada.
   [Hassanpour, Siavash] Univ Toronto, Fac Dent, Dept Periodontol, 124 Edward St, Toronto, ON M5G 1G6, Canada.
   [Glogauer, Michael] Univ Toronto, Fac Dent, 124 Edward St, Toronto, ON M5G 1G6, Canada.
C3 University of Toronto; University of Toronto; University of Toronto
RP Ouanounou, A (通讯作者)，Univ Toronto, Fac Dent, Dept Clin Sci, Pharmacol, 124 Edward St,Room 513, Toronto, ON M5G 1G6, Canada.
EM aviv.ouanounou@dentistry.utoronto.ca
RI Glogauer, Michael/D 2504 2011
CR Abu Ta'a M, 2008, J CLIN PERIODONTOL, V35, P58, DOI 10.1111/j.1600 051X.2007.01162.x
   Alissa R, 2012, J ORAL IMPLANTOL, V38, P51, DOI 10.1563/AAID JOI D 10 00086
   Alissa R, 2009, EUR J ORAL IMPLANTOL, V2, P185
   [Anonymous], 2005, Key Findings and Results from Campaign Evaluation 2004
   [Anonymous], PRACT GUID TREATM PA
   Avedian RS, 2007, CLIN ORTHOP RELAT R, P48, DOI 10.1097/BLO.0b013e3180514c66
   Bain C A, 1993, Int J Oral Maxillofac Implants, V8, P609
   Beck A, 2003, ARCH ORTHOP TRAUM SU, V123, P327, DOI 10.1007/s00402 003 0537 5
   Bencharit S, 2010, INT J ORAL MAX IMPL, V25, P1241
   Beumer J., 1986, RECONSTRUCTIVE PREPR, V2nd, P41
   Brägger U, 2001, CLIN ORAL IMPLAN RES, V12, P26, DOI 10.1034/j.1600 0501.2001.012001026.x
   BRANEMARK PI, 1983, J PROSTHET DENT, V50, P399, DOI 10.1016/S0022 3913(83)80101 2
   Branemark PI., 1985, TISSUE INTEGRATED PR, P11
   Brooks JK, 2007, ORAL SURG ORAL MED O, V103, P780, DOI 10.1016/j.tripleo.2006.10.010
   Cayco AV, 2000, TRANSPLANTATION, V70, P1722, DOI 10.1097/00007890 200012270 00011
   Chikazu D, 2007, INT J ORAL MAX SURG, V36, P441, DOI 10.1016/j.ijom.2006.11.011
   Coutinho AE, 2011, MOL CELL ENDOCRINOL, V335, P2, DOI 10.1016/j.mce.2010.04.005
   COWIN SC, 1976, J ELASTICITY, V6, P313, DOI 10.1007/BF00041724
   CRANIN A N, 1991, Journal of Oral Implantology, V17, P414
   Da Silva JD, 2014, J AM DENT ASSOC, V145, P704, DOI 10.14219/jada.2014.27
   Dai JL, 2000, J CLIN INVEST, V106, P887, DOI 10.1172/JCI10483
   de Deco CP, 2015, J ORAL IMPLANTOL, V41, pE44, DOI 10.1563/AAID JOI D 13 00111
   Duarte PM, 2001, J PERIODONTOL, V72, P1391, DOI 10.1902/jop.2001.72.10.1391
   Ekfeldt A, 2001, CLIN ORAL IMPLAN RES, V12, P462, DOI 10.1034/j.1600 0501.2001.120505.x
   El Hadary AA, 2011, J ORAL IMPLANTOL, V37, P247, DOI 10.1563/AAID JOI D 09 00098
   FRIEDLAENDER GE, 1984, J BONE JOINT SURG AM, V66A, P602, DOI 10.2106/00004623 198466040 00016
   Friedlander AH, 2003, J AM DENT ASSOC, V134, P731, DOI 10.14219/jada.archive.2003.0260
   Fu JH, 2012, IMPLANT DENT, V21, P362, DOI 10.1097/ID.0b013e3182611ff6
   Fugazzotto PA, 2007, J PERIODONTOL, V78, P1664, DOI 10.1902/jop.2007.060514
   Fujimoto T, 1998, INT J ORAL MAX IMPL, V13, P183
   Gebara MA, 2014, J AM GERIATR SOC, V62, P1434, DOI 10.1111/jgs.12945
   Grant BT, 2008, J ORAL MAXIL SURG, V66, P223, DOI 10.1016/j.joms.2007.09.019
   Haney EM, 2007, ARCH INTERN MED, V167, P1246, DOI 10.1001/archinte.167.12.1246
   Hasler G, 2010, WORLD PSYCHIATRY, V9, P155
   Hwang Debby, 2006, Implant Dent, V15, P353, DOI 10.1097/01.id.0000247855.75691.03
   Jeffcoat MK, 2006, INT J ORAL MAX IMPL, V21, P349
   Jones MK, 1999, NAT MED, V5, P1418
   JULIAN BA, 1991, NEW ENGL J MED, V325, P544, DOI 10.1056/NEJM199108223250804
   KANIS JA, 1995, OSTEOPOROSIS INT, V5, P1, DOI 10.1007/BF01623652
   Kessler RC, 2009, EPIDEMIOL PSICHIAT S, V18, P23, DOI 10.1017/S1121189X00001421
   Klein RF, 1996, ALCOHOL CLIN EXP RES, V20, P572, DOI 10.1111/j.1530 0277.1996.tb01095.x
   Koenig AM, 2009, POL ARCH MED WEWN, V119, P478, DOI 10.20452/pamw.743
   Koo Samuel, 2004, Implant Dent, V13, P232, DOI 10.1097/01.id.0000140462.33075.34
   Kovács AF, 2001, INT J ORAL MAX SURG, V30, P144, DOI 10.1054/ijom.2000.0023
   Kovács AF, 2000, HEAD NECK J SCI SPEC, V22, P111, DOI 10.1002/(SICI)1097 0347(200003)22:2<111::AID HED2>3.0.CO;2 V
   Lane NE, 1998, ENDOCRIN METAB CLIN, V27, P465, DOI 10.1016/S0889 8529(05)70017 7
   Lazarovici TS, 2010, J ORAL MAXIL SURG, V68, P790, DOI 10.1016/j.joms.2009.09.017
   Lopez BC., 2011, Journal of Clinical and Experimental Dentistry, V3, P31, DOI [DOI 10.4317/JCED.3.E31, 10.4317/jced.3.e31]
   Madrid C, 2009, CLIN ORAL IMPLAN RES, V20, P87, DOI 10.1111/j.1600 0501.2009.01772.x
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Marx RE, 2007, J ORAL MAXIL SURG, V65, P2397, DOI 10.1016/j.joms.2007.08.003
   McDonald A R, 1998, J Oral Implantol, V24, P11, DOI 10.1563/1548 1336(1998)024<0011:EOCOOO>2.3.CO;2
   Moraschini V, 2016, INT J ORAL MAX SURG, V45, P205, DOI 10.1016/j.ijom.2015.08.996
   MOVSOWITZ C, 1988, ENDOCRINOLOGY, V123, P2571, DOI 10.1210/endo 123 5 2571
   Moy PK, 2005, INT J ORAL MAX IMPL, V20, P569
   Mukherjee S, 2013, CURR NEUROVASC RES, V10, P256, DOI 10.2174/15672026113109990004
   Pablos AB, 2008, J PERIODONTOL, V79, P300, DOI [10.1902/jop.2008.070301, 10.1902/jop.2008.070301 ]
   Purgato M, COCHRANE DATABASE SY, V3
   Rabenda V, 2013, OSTEOPOROSIS INT, V24, P121, DOI 10.1007/s00198 012 2015 9
   Ribeiro FV, 2006, J PERIODONTOL, V77, P1731, DOI 10.1902/jop.2006.060119
   Ribeiro FV, 2009, INT J ORAL MAX IMPL, V24, P226
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Sakakura CE, 2003, J PERIODONTOL, V74, P976, DOI 10.1902/jop.2003.74.7.976
   Sakakura CE, 2007, CLIN ORAL IMPLAN RES, V18, P34, DOI 10.1111/j.1600 0501.2006.01253.x
   Sakakura CE, 2011, J OSSEOINTEGRATION, V3, P25
   Sampson HW, 1996, ALCOHOL CLIN EXP RES, V20, P1375, DOI 10.1111/j.1530 0277.1996.tb01137.x
   Sampson HW, 1998, ALCOHOL HEALTH RES W, V22, P190
   SCHLOSBERG M, 1989, ENDOCRINOLOGY, V124, P2179, DOI 10.1210/endo 124 5 2179
   Scully Crispian, 2006, Implant Dent, V15, P212, DOI 10.1097/01.id.0000236120.22719.02
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Smith R A, 1992, Int J Oral Maxillofac Implants, V7, P367
   Starck W J, 1995, Int J Oral Maxillofac Implants, V10, P74
   Steiner M, 1995, J Oral Implantol, V21, P142
   Tsapakis EM, 2012, EUR PSYCHIAT, V27, P156, DOI 10.1016/j.eurpsy.2010.10.006
   Walker FR, 2013, NEUROPHARMACOLOGY, V67, P304, DOI 10.1016/j.neuropharm.2012.10.002
   Wang HL, 2007, J PERIODONTOL, V78, P584, DOI 10.1902/jop.2007.060239
   Werner S B, 1996, J Oral Implantol, V22, P216
   Winnett B, 2016, CLIN ORAL IMPLAN RES, V27, pE1, DOI 10.1111/clr.12493
   Wood B, 2010, J CAN DENT ASSOC, V76
   Wu Q, 2012, OSTEOPOROSIS INT, V23, P365, DOI 10.1007/s00198 011 1778 8
   Wu X, 2014, J DENT RES, V93, P1054, DOI 10.1177/0022034514549378
   Yarom N, 2007, OSTEOPOROSIS INT, V18, P1363, DOI 10.1007/s00198 007 0384 2
   Young DR, 1997, J ORTHOP RES, V15, P773, DOI 10.1002/jor.1100150521
   Zhang Y, 2013, ASIA PAC PSYCHIAT, V5, P231, DOI 10.1111/appy.12022
NR 84
TC 17
Z9 23
U1 0
U2 21
PU CANADIAN DENTAL ASSOC
PI OTTAWA
PA 1815 ALTA VISTA DRIVE, OTTAWA, ON K1G 3Y6, CANADA
SN 1488 2159
J9 J CAN DENT ASSOC
JI J. Can. Dent. Assoc.
PD APR 15
PY 2016
VL 82
AR g7
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA DJ4DF
UT WOS:000374154900001
PM 27548672
DA 2025 08 17
ER

PT J
AU Bergmann, R
   Meckel, M
   Kubícek, V
   Pietzsch, J
   Steinbach, J
   Hermann, P
   Rösh, F
AF Bergmann, Ralf
   Meckel, Marian
   Kubicek, Vojtech
   Pietzsch, Jens
   Steinbach, Joerg
   Hermann, Petr
   Roesh, Frank
TI <SUP>177</SUP>Lu labelled macrocyclic bisphosphonates for targeting bone
   metastasis in cancer treatment
SO EJNMMI RESEARCH
LA English
DT Article
DE Bisphosphonate; Bone metastases; Lu 177; DO2A; DOTA; Biodistribution;
   Theranostics
ID PALLIATIVE RADIOTHERAPY; POTENTIAL AGENTS; DOTA; COMPLEXES; LU 177 EDTMP
AB Background: Metastatic bone lesion is a common syndrome of many cancer diseases in an advanced state. The major symptom is severe pain, spinal cord compression, and pathological fracture, associated with an obvious morbidity. Common treatments including systemic application of bisphosphonate drugs aim on pain reduction and on improving the quality of life of the patient. Particularly, patients with multiple metastatic lesions benefit from bone targeting therapeutic radiopharmaceuticals. Agents utilizing beta emitting radionuclides in routine clinical praxis are, for example, [Sr 89]SrCl2 and [Sm 153]Sm EDTMP. No carrier added (n.c.a.) Lu 177 is remarkably suitable for an application in this scope.
   Methods: Five 1,4,7,10 tetraazacyclododecane N,N',N '',N '' tetra acetic acid (DOTA) and DO2A based bisphosphonates, including monomeric and dimeric structures and one 1,4,7 triazacyclononane 1,4 diacetic acid (NO2A) derivative, were synthesized and labelled with n.c.a. Lu 177. Radio TLC and high performance liquid chromatography (HPLC) methods were successfully established for determining radiochemical yields and for quality control. Their binding to hydroxyapatite was measured in vitro. Ex vivo biodistribution experiments and dynamic in vivo single photon computed tomography (SPECT)/CT measurements were performed in healthy rats for 5 min and 1 h periods. Data on %ID/g or standard uptake value (SUV) for femur, blood, and soft tissue organs were analyzed and compared with [Lu 177] citrate.
   Results: Radiolabelling yields for [Lu 177]Lu DOTA and [Lu 177]Lu NO2A monomeric bisphosphonate complexes were >98 % within 15 min. The dimeric macrocyclic bisphosphonates showed a decelerated labelling kinetics, reaching a plateau after 30 min of 60 to 90 % radiolabelling yields. All Lu 177 bisphosphonate complexes showed exclusive accumulation in the skeleton. Blood clearance and renal elimination were fast. SUV data (all for 1 h p.i.) in the femur ranged from 3.34 to 5.67. The bone/blood ratios were between 3.6 and 135.6, correspondingly. Lu 177 bisphosphonate dimers showed a slightly higher bone accumulation (SUVfemur = 4.48 +/  0.38 for [Lu 177] Lu DO2A(P BP)(2); SUVfemur = 5.41 +/  0.46 for [Lu 177]Lu DOTA(M BP)(2)) but a slower blood clearance (SUVblood = 1.25 +/  0.09 for [Lu 177]Lu DO2A(P BP)(2); SUVblood = 1.43 +/  0.32 for [Lu 177]Lu DOTA(M BP)(2)).
   Conclusions: Lu complexes of macrocyclic bisphosphonates might become options for the therapy of skeletal metastases in the near future, since they show high uptake in bone together with a very low soft tissue accumulation.
C1 [Meckel, Marian; Roesh, Frank] Johannes Gutenberg Univ Mainz, Inst Nucl Chem, Fritz Strassmann Weg 2, D 55128 Mainz, Germany.
   [Bergmann, Ralf; Pietzsch, Jens; Steinbach, Joerg] Helmholtz Zentrum Dresden Rossendorf, Inst Radiopharmaceut Canc Res, D 01314 Dresden, Germany.
   [Kubicek, Vojtech; Hermann, Petr] Charles Univ Prague, Dept Inorgan Chem, Fac Sci, Prague, Czech Republic.
C3 Johannes Gutenberg University of Mainz; Helmholtz Association;
   Helmholtz Zentrum Dresden Rossendorf (HZDR); Charles University Prague
RP Rösh, F (通讯作者)，Johannes Gutenberg Univ Mainz, Inst Nucl Chem, Fritz Strassmann Weg 2, D 55128 Mainz, Germany.
EM frank.roesch@uni mainz.de
RI Roesch, Frank/AAU 9403 2020; Kubíček, Vojtěch/I 6607 2016; Pietzsch,
   Jens/O 5070 2017; Steinbach, Jorg/B 5940 2015; Bergmann,
   Ralf/HKE 5385 2023; Steinbach, Joerg/B 5940 2015; Hermann,
   Petr/A 1880 2008; Kubicek, Vojtech/I 6607 2016
OI Pietzsch, Jens/0000 0002 1610 1493; Steinbach, Jorg/0000 0002 1708 6440;
   Hermann, Petr/0000 0001 6250 5125; Kubicek, Vojtech/0000 0003 0171 5713
FU THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging
   ENETS, Bad Berka (Germany); Max Planck Graduate Center Mainz
FX The authors are grateful to the working group of Prof. Petr Hermann for
   providing the bisphosphonate compounds BPAMD, BPAPD, DO3AP<SUP>BP</SUP>,
   and NO2AP<SUP>BP</SUP>. The n.c.a. <SUP>177</SUP>Lu was provided from
   ITG, Germany. We are grateful to Regina Herrlich and Andrea Suhr for
   technical assistance. Financial support from the THERANOSTICS Center for
   Molecular Radiotherapy and Molecular Imaging ENETS, Bad Berka (Germany)
   is particularly acknowledged. This study was supported by the grant of
   the Max Planck Graduate Center Mainz.
CR [Anonymous], 2010, LUT 177 HANDL PREC
   Beyer GJ, 1997, NUCL MED BIOL, V24, P367, DOI 10.1016/S0969 8051(97)00011 5
   Byegård J, 1999, J RADIOANAL NUCL CH, V241, P281, DOI 10.1007/BF02347463
   Chakraborty S, 2002, NUCL MED COMMUN, V23, P67, DOI 10.1097/00006231 200201000 00011
   Chakraborty S, 2008, APPL RADIAT ISOTOPES, V66, P1196, DOI 10.1016/j.apradiso.2008.02.061
   Fellner M, 2012, NUCL MED BIOL, V39, P993, DOI 10.1016/j.nucmedbio.2012.04.007
   Fellner M, 2011, RADIOCHIM ACTA, V99, P43, DOI 10.1524/ract.2011.1791
   Fellner M, 2010, EUR J NUCL MED MOL I, V37, P834, DOI 10.1007/s00259 009 1355 y
   Holub J, 2015, CONTRAST MEDIA MOL I, V10, P122, DOI 10.1002/cmmi.1606
   Kálmán FK, 2008, EUR J INORG CHEM, P4719, DOI 10.1002/ejic.200800582
   Kubícek V, 2005, J AM CHEM SOC, V127, P16477, DOI 10.1021/ja054905u
   KUTZNER J, 1978, STRAHLENTHER ONKOL, V154, P317
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Meckel M, 2013, NUCL MED BIOL, V40, P823, DOI 10.1016/j.nucmedbio.2013.04.012
   Mitterhauser M, 2007, NUCL MED BIOL, V34, P391, DOI 10.1016/j.nucmedbio.2007.03.002
   Ogawa K, 2011, NUCL MED BIOL, V38, P631, DOI 10.1016/j.nucmedbio.2010.12.004
   OMARA RE, 1969, J NUCL MED, V10, P49
   Riss PJ, 2011, CONTRAST MEDIA MOL I, V6, P492, DOI 10.1002/cmmi.451
   Rosch F, 2000, APPL RADIAT ISOTOPES, V53, P421
   Sartor O, 2013, CANCER TREAT REV, V39, P18, DOI 10.1016/j.ctrv.2012.03.006
   Smentek L, 2011, J PHYS CONDENS MAT, V23, DOI 10.1088/0953 8984/23/14/143202
   SONTAG W, 1984, HUM TOXICOL, V3, P469, DOI 10.1177/096032718400300602
   Tomassetti P, 2013, EJMMI, V40, P1197
   Vitha T, 2008, LANGMUIR, V24, P1952, DOI 10.1021/la702753j
   Vitha T, 2009, DALTON T, P3204, DOI 10.1039/b820705d
   Vitha T, 2008, J MED CHEM, V51, P677, DOI 10.1021/jm7012776
   Williams MH, 1956, USAEC REPORT, V12, P171
   Yuan J, 2013, CLIN NUCL MED, V38, P88, DOI 10.1097/RLU.0b013e318279bf4d
   Zenda S, 2014, INT J CLIN ONCOL, V19, P739, DOI 10.1007/s10147 013 0597 7
NR 29
TC 35
Z9 35
U1 0
U2 91
PU SPRINGEROPEN
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2191 219X
J9 EJNMMI RES
JI EJNMMI Res.
PD JAN 16
PY 2016
VL 6
AR 5
DI 10.1186/s13550 016 0161 3
PG 12
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA DC8RF
UT WOS:000369486700002
PM 26780082
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Allen, MR
   Erickson, AM
   Wang, X
   Burr, DB
   Martin, RB
   Hazelwood, SJ
AF Allen, Matthew R.
   Erickson, Antonia M.
   Wang, Xiang
   Burr, David B.
   Martin, R. Bruce
   Hazelwood, Scott J.
TI Morphological Assessment of Basic Multicellular Unit Resorption
   Parameters in Dogs Shows Additional Mechanisms of Bisphosphonate Effects
   on Bone
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Basic multicellular unit (BMU); Alendronate; Risedronate;
   Histomorphometry; Trabecular bone; Antiresorptive
ID POSTMENOPAUSAL OSTEOPOROSIS; CANCELLOUS BONE; TRABECULAR BONE;
   RISEDRONATE; RECONSTRUCTION; ALENDRONATE; TURNOVER; CAVITIES; QUALITY
AB Bisphosphonates (BPs) slow bone loss by reducing initiation of new basic multicellular units (BMUs). Whether or not BPs simply prevent osteoclasts from initiating new BMUs that resorb bone or also reduce the amount of bone they resorb at the BMU level is not clear. The goal of this study was to determine the effects of BPs on three morphological parameters of individual BMUs, resorption depth (Rs.De), area (Rs.Ar), and width (Rs.Wi). After 1 year of treatment with vehicle (VEH), alendronate (ALN; 0.10, 0.20, or 1.00 mg/kg/day), or risedronate (RIS; 0.05, 0.10, or 0.50 mg/kg/day), resorption cavity morphology was assessed in vertebral trabecular bone of beagle dogs by histology. Animals treated with ALN or RIS at the doses representing those used to treat postmenopausal osteoporosis (0.20 and 0.10 mg/kg/day, respectively) had significantly lower Rs.Ar ( 27%) and Rs.Wi ( 17%), with no difference in Rs.De, compared to VEH treated controls. Low doses of ALN and RIS did not affect any parameters, whereas higher doses resulted in similar changes to those of the clinical dose. There were no significant differences in the resorption cavity measures between RIS and ALN at any of the dose equivalents. These results highlight the importance of examining parameters beyond erosion depth for assessment of resorption parameters. Furthermore, these results suggest that in addition to the well known effects of BPs on reducing the number of active BMUs, these drugs also reduce the activity of osteoclasts at the individual BMU level at doses at and above those used clinically for the treatment of postmenopausal osteoporosis.
C1 [Allen, Matthew R.; Burr, David B.] Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
   [Burr, David B.] Indiana Univ, Sch Med, Dept Orthopaed Surg, Indianapolis, IN 46202 USA.
   [Burr, David B.] Indiana Univ Purdue Univ Indianapolis, Dept Biomed Engn Program, Indianapolis, IN 46202 USA.
   [Erickson, Antonia M.; Wang, Xiang; Martin, R. Bruce] Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA.
   [Wang, Xiang] Univ Calif Berkeley, Berkeley, CA 94720 USA.
   [Hazelwood, Scott J.] Calif Polytech State Univ San Luis Obispo, San Luis Obispo, CA 93407 USA.
C3 Indiana University System; Indiana University Indianapolis; Indiana
   University System; Indiana University Indianapolis; Purdue University
   System; Purdue University; Purdue University in Indianapolis; University
   of California System; University of California Davis; University of
   California System; University of California Berkeley; California State
   University System; California Polytechnic State University San Luis
   Obispo
RP Allen, MR (通讯作者)，Indiana Univ, Sch Med, Dept Anat & Cell Biol, 635 Barnhill Dr,MS 5035, Indianapolis, IN 46202 USA.
EM matallen@iupui.edu
RI Allen, Matthew/A 8799 2015
OI Allen, Matthew/0000 0002 1174 9004
FU NIH [R01 AR51555, R01 AR047838, T32 AR007581]; Alliance for Better Bone
   Health (Procter and Gamble Pharmaceuticals and Sanofi Aventis); Eli
   Lilly; NIH National Center for Research Resources [C06RR10601]
FX This work was supported by NIH grants R01 AR51555, R01 AR047838, and T32
   AR007581, and a research grant from the Alliance for Better Bone Health
   (Procter and Gamble Pharmaceuticals and Sanofi Aventis) and Eli Lilly.
   Merck and Co. kindly provided the ALN. This investigation utilized an
   animal facility constructed with support from Research Facilities
   Improvement Program (grant C06RR10601) from the NIH National Center for
   Research Resources.
CR Allen MR, 2006, BONE, V39, P872, DOI 10.1016/j.bone.2006.04.028
   BOYCE RW, 1995, J BONE MINER RES, V10, P211
   Chavassieux PM, 1997, J CLIN INVEST, V100, P1475, DOI 10.1172/JCI119668
   COHENSOLAL ME, 1991, J BONE MINER RES, V6, P1331
   Eriksen EF, 2002, BONE, V31, P620, DOI 10.1016/S8756 3282(02)00869 4
   ERIKSEN EF, 1990, J BONE MINER RES, V5, P311, DOI 10.1002/jbmr.5650050402
   ERIKSEN EF, 1986, ENDOCR REV, V7, P379, DOI 10.1210/edrv 7 4 379
   ERIKSEN EF, 1985, BONE, V6, P381, DOI 10.1016/8756 3282(85)90337 0
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   ROUX C, 1994, BONE, V15, P41, DOI 10.1016/8756 3282(94)90890 7
   ROUX JP, 1995, BONE, V17, P153, DOI 10.1016/S8756 3282(95)00174 3
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   STORM T, 1993, J BONE MINER RES, V8, P199
   Tkachenko EV, 2009, BONE, V45, P487, DOI 10.1016/j.bone.2009.05.019
NR 14
TC 26
Z9 31
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 967X
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD JAN
PY 2010
VL 86
IS 1
BP 67
EP 71
DI 10.1007/s00223 009 9315 x
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 537HA
UT WOS:000273102700009
PM 19953232
OA Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Wang, ZZ
   Shi, YW
   Gao, BT
   Dang, ZH
   Yang, S
   Chung, CH
   Yu, XL
   Zhou, XT
   Lin, ZF
   Cheang, LH
   Tam, MS
   Wang, HJ
   Zheng, XF
   Wu, TT
AF Wang, Zhaozhen
   Shi, Yiwan
   Gao, Botao
   Dang, Zhaohui
   Yang, Shan
   Chung, Chia Hsuan
   Yu, Xiaolu
   Zhou, Xinting
   Lin, Zefeng
   Cheang, Lek Hang
   Tam, Man Seng
   Wang, Huajun
   Zheng, Xiaofei
   Wu, Tingting
TI Development of a multi functional naringin loaded bioglass/
   carboxymethyl chitosan/silk fibroin porous scaffold for hemostasis and
   critical size bone regeneration
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Bioglass/silk fibroin/ carboxymethyl chitosan; Naringin; Bone repair;
   Hemostasis; Neurovascularization; Immunomodulation
ID MESENCHYMAL STEM CELLS; SILICATE BIOCERAMICS; GROWTH FACTOR;
   OSTEOGENESIS; ACTIVATION; DELIVERY; SULFATE; GENIPIN; INJURY
AB Persistent bleeding and limited repair capacity greatly threaten patients with bone destruction. Designing inorganic organic biomimetic scaffolds with quick hemostasis and osteogenesis functions will solve this problem. A novel degradable and naringin (NG) loaded porous scaffold (SCB N) based on APTES modified bioactive glass (ABG), carboxymethyl chitosan and silk fibroin is developed. ABG and NG enhance the strength of the scaffolds. The scaffolds can release NG and bioactive ions (Ca2+ and Si4+), promoting the expression of osteogenesis (OCN, BMP 2), angiogenesis (VEGF), and neurogenesis (TB3, GFAP) genes in bone mesenchymal stem cells (BMSCs) and the related proteins (OCN, BMP 2, VEGF, GFAP). When implanting the scaffolds in rat cranial critical size defects, all scaffolds exhibit good compatibility, and SCB N2 (with ABG and 1 mg/mL NG) group significantly promotes new bone regeneration and the formation of M2 type macrophages. Transcriptome sequencing results confirmed the osteogenic differentiation of BMSCs stimulated by SCB N2 scaffolds is mainly regulated through MAPK and Wnt signaling pathways. Moreover, SCB N2 group demonstrates quick hemostasis in vitro and in vivo due to the high adsorption ability and Ca ions release. The novel bionic scaffolds loaded with ion/traditional Chinese medicine monomer, possess the capabilities of hemostasis, neurovascularization, osteogenesis and immunomodulation, therefore exhibiting potential in bone repair.
C1 [Wang, Zhaozhen; Shi, Yiwan; Gao, Botao; Dang, Zhaohui; Chung, Chia Hsuan; Yu, Xiaolu; Zhou, Xinting; Wu, Tingting] Guangdong Acad Sci, Inst Biol & Med Engn, Natl Engn Res Ctr Healthcare Devices, Guangdong Prov Key Lab Med Elect Instruments & Mat, Guangzhou 510316, Peoples R China.
   [Wang, Zhaozhen; Shi, Yiwan; Chung, Chia Hsuan; Yu, Xiaolu; Wang, Huajun; Zheng, Xiaofei] Jinan Univ, Affiliated Hosp 1, Guangdong Prov Key Lab Speed Capabil, Dept Sports Med,Guangzhou Key Lab Precis Orthoped, Guangzhou 510630, Peoples R China.
   [Yang, Shan; Lin, Zefeng] Gen Hosp Southern Theater Command PLA, Guangzhou 510010, Peoples R China.
   [Lin, Zefeng] South China Univ Technol, Sch Mat Sci & Engn, Guangzhou 510641, Peoples R China.
   [Wang, Huajun; Zheng, Xiaofei; Wu, Tingting] Jinan Univ, Engn Res Ctr Artificial Organs & Mat, Minist Educ, Guangzhou 510632, Peoples R China.
   [Cheang, Lek Hang] Ctr Hosp Conde Sao Januario, Dept Orthoped Surg, Macau, Peoples R China.
   [Tam, Man Seng] IAN WO Med Ctr, Macau, Peoples R China.
   [Wang, Zhaozhen] Southern Med Univ, Zhujiang Hosp, Orthoped & Traumatol Dept, Guangzhou 510282, Peoples R China.
C3 Guangdong Academy of Sciences; Institute of Biological & Medical
   Engineering, Guangdong Academy of Sciences; Jinan University; Southern
   Theater Command General Hospital; South China University of Technology;
   Jinan University; Southern Medical University   China
RP Wu, TT (通讯作者)，Guangdong Acad Sci, Inst Biol & Med Engn, Natl Engn Res Ctr Healthcare Devices, Guangdong Prov Key Lab Med Elect Instruments & Mat, Guangzhou 510316, Peoples R China.; Wang, HJ; Zheng, XF (通讯作者)，Jinan Univ, Affiliated Hosp 1, Guangdong Prov Key Lab Speed Capabil, Dept Sports Med,Guangzhou Key Lab Precis Orthoped, Guangzhou 510630, Peoples R China.
EM whj323@126.com; xfzheng@jnu.edu.cn; wtt_08@126.com
RI Gao, Botao/U 1898 2018
FU Research and Development Plans in Key Areas of Guangdong Province
   [2020B1111560001]; National Natural Science Foundation of China
   [52102343, 82172440]; Special Fund Project for GDAS to Build First Class
   Research Institutions in China [2019GDASYL 0102004/0103018]; National
   Key Research and Development Program of China [2022YFE0206200]; Science
   and technology development fund (FDCT) of Macao (FDCT) [0009/2021/AMMJ,
   FDCT 0032/2022/AGJ]; Science and Technology Planning Project of
   Guangdong Province [2024A1515010571]; Guangdong Macao Joint Innovation
   Project [2023A0505020008, 2023A1515011860]; Open Fund of Engineering
   Research Center of Artificial Organs and Materials, Ministry of
   Education [ERCAOM202202]; Science and Technology Projects in Guangzhou
   [2024A03J0971, 2023A03J1015, 2023A03J0566, 202206010158, 202201020566,
   2024A04J3423]; GDAS' Project of Science and Technology Development
   [JNU1AF CFTP 2022 a01204]; Clinical Frontier Technology Program of the
   First Affiliated Hospital of Jinan University; Guangdong Provincial Key
   Laboratory of Speed Capability Research [2023B1212010009]; 
   [2023GDASZH 2023010102]
FX This study was supported by Research and Development Plans in Key Areas
   of Guangdong Province (2020B1111560001) , the National Natural Science
   Foundation of China (52102343, 82172440) , the Special Fund Project for
   GDAS to Build First Class Research Institutions in China
   (2019GDASYL 0102004/0103018) , the National Key Research and Development
   Program of China (2022YFE0206200) , Science and technology development
   fund (FDCT) of Macao (FDCT 0009/2021/AMMJ, FDCT 0032/2022/AGJ) , the
   Science and Technology Planning Project of Guangdong Province
   (2024A1515010571; Guangdong Macao Joint Innovation Project,
   2023A0505020008, 2023A1515011860) of China, GDAS' Project of Science and
   Technology Development (2023GDASZH 2023010102) , the Open Fund of
   Engineering Research Center of Artificial Organs and Materials, Ministry
   of Education (No. ERCAOM202202) , Science and Technology Projects in
   Guangzhou (2024A03J0971, 2023A03J1015, 2023A03J0566, 202206010158,
   202201020566, 2024A04J3423) , the Clinical Frontier Technology Program
   of the First Affiliated Hospital of Jinan University (No.
   JNU1AF CFTP 2022 a01204) , Guangdong Provincial Key Laboratory of Speed
   Capability Research (2023B1212010009) .
CR Acharya S, 2019, CANCER RES, V79, P4211, DOI 10.1158/0008 5472.CAN 18 3803
   Baasch S, 2021, CELL, V184, P3774, DOI 10.1016/j.cell.2021.05.009
   Chan NJA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 15312 x
   Chen YF, 2013, CURR MED CHEM, V20, P3022, DOI 10.2174/0929867311320240007
   Chen YF, 2019, ACS APPL MATER INTER, V11, P14608, DOI 10.1021/acsami.9b01532
   Cheng PZ, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0925 y
   Choi J, 2014, INT J NANOMED, V9, P5189, DOI 10.2147/IJN.S71304
   El Fiqi A, 2021, BIOACT MATER, V6, P123, DOI 10.1016/j.bioactmat.2020.07.010
   Fan LL, 2020, THERANOSTICS, V10, P5895, DOI 10.7150/thno.43198
   Fievet L, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.913539
   Fu YC, 2015, INT J NANOMED, V10, P7231, DOI 10.2147/IJN.S88134
   Gao YJ, 2019, MAR DRUGS, V17, DOI 10.3390/md17100575
   Giannarelli C, 2014, CIRCULATION, V130, P1274, DOI 10.1161/CIRCULATIONAHA.114.006614
   Guan JJ, 2015, BIOMATERIALS, V55, P1, DOI 10.1016/j.biomaterials.2015.03.029
   [郭海雷 Guo Hailei], 2021, [中华急诊医学杂志, Chinese Journal of Emergency Medicine], V30, P197
   Guo WH, 2017, J MECH BEHAV BIOMED, V68, P8, DOI 10.1016/j.jmbbm.2017.01.032
   Guo Y, 2023, THERANOSTICS, V13, P161, DOI 10.7150/thno.79639
   Hayashi K, 2022, J ADV RES, V41, P101, DOI 10.1016/j.jare.2021.12.010
   Hickman DA, 2018, ADV MATER, V30, DOI 10.1002/adma.201700859
   Hsieh LTH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030595
   Hsieh TE, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00511
   Huang YZ, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/4242178
   Lei QJ, 2023, MATER DESIGN, V227, DOI 10.1016/j.matdes.2023.111754
   Leonhardt EE, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10290 1
   Li HL, 2021, STEM CELLS INT, V2021, DOI 10.1155/2021/8359582
   Li HY, 2014, BIOMATERIALS, V35, P3803, DOI 10.1016/j.biomaterials.2014.01.039
   Li ZL, 2021, MOL THER NUCL ACIDS, V25, P502, DOI 10.1016/j.omtn.2021.07.005
   Lin XW, 2021, NANOMATERIALS BASEL, V11, DOI 10.3390/nano11112879
   Ling Y, 2020, REGEN BIOMATER, V7, P443, DOI 10.1093/rb/rbaa024
   Liu JX, 2022, J BIOMED MATER RES B, V110, P1255, DOI 10.1002/jbm.b.34996
   Liu X, 2013, ACTA BIOMATER, V9, P7506, DOI 10.1016/j.actbio.2013.03.039
   Luo Y, 2022, STEM CELLS INT, V2022, DOI 10.1155/2022/2190447
   Montalbán MG, 2018, NANOMATERIALS BASEL, V8, DOI 10.3390/nano8020126
   Tirpe AA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246140
   Tsai CC, 2000, J BIOMED MATER RES, V52, P58, DOI 10.1002/1097 4636(200010)52:1<58::AID JBM8>3.0.CO;2 0
   Wang HY, 2022, FOODS, V11, DOI 10.3390/foods11142147
   Wang H, 2021, INT J BIOL SCI, V17, P913, DOI 10.7150/ijbs.59031
   Wang L, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.862532
   Wang L, 2015, CHEM BIOL INTERACT, V242, P255, DOI 10.1016/j.cbi.2015.10.010
   Wang LT, 2022, BIOACT MATER, V15, P330, DOI 10.1016/j.bioactmat.2021.12.012
   Wang YY, 2018, J CELL MOL MED, V22, P2791, DOI 10.1111/jcmm.13572
   Wu JJ, 2021, REGEN BIOMATER, V8, DOI 10.1093/rb/rbab065
   Xiang G, 2021, ADV SCI, V8, DOI 10.1002/advs.202002328
   Xiao LF, 2024, J NANOBIOTECHNOL, V22, DOI 10.1186/s12951 024 02578 2
   Xiao LF, 2021, INT J BIOL MACROMOL, V172, P19, DOI 10.1016/j.ijbiomac.2021.01.036
   Xing F, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14071437
   Yan XT, 2017, MAR DRUGS, V15, DOI 10.3390/md15050127
   Yang C, 2020, J ORTHOP SURG RES, V15, DOI 10.1186/s13018 020 02145 z
   Yang ZY, 2022, BIOMATERIALS, V283, DOI 10.1016/j.biomaterials.2022.121438
   Yu GY, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/7130653
   Yu YB, 2019, ASIAN J PHARM SCI, V14, P423, DOI 10.1016/j.ajps.2018.08.002
   Yuan ZG, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13101550
   Zeng X, 2022, NUTRIENTS, V14, DOI 10.3390/nu14183765
   Zhai XY, 2018, ADV SCI, V5, DOI 10.1002/advs.201700550
   Zhang HJ, 2024, NATL SCI REV, V11, DOI 10.1093/nsr/nwae035
   Zhang M, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz6725
   Zhang XR, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01662 2
   Zhang YF, 2022, BIOACT MATER, V11, P130, DOI 10.1016/j.bioactmat.2021.09.033
   Zhao FJ, 2023, BIOACT MATER, V22, P201, DOI 10.1016/j.bioactmat.2022.09.007
   Zhao HJ, 2022, BIOACT MATER, V18, P507, DOI 10.1016/j.bioactmat.2022.03.001
   Zhao ZH, 2022, MATER TODAY BIO, V13, DOI 10.1016/j.mtbio.2022.100206
   Zhao ZH, 2018, CHEM BIOL INTERACT, V286, P45, DOI 10.1016/j.cbi.2018.03.002
   Zhou L, 2021, BIOACT MATER, V6, P890, DOI 10.1016/j.bioactmat.2020.09.012
   Zhou ZB, 2023, INT J BIOL MACROMOL, V230, DOI 10.1016/j.ijbiomac.2023.123158
   Zhu SJ, 2022, BIOACT MATER, V13, P119, DOI 10.1016/j.bioactmat.2021.11.011
NR 65
TC 2
Z9 2
U1 24
U2 28
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141 8130
EI 1879 0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD FEB
PY 2025
VL 290
AR 138888
DI 10.1016/j.ijbiomac.2024.138888
EA DEC 2024
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA R7K1R
UT WOS:001393183900001
PM 39701255
DA 2025 08 17
ER

PT J
AU Zhao, Y
   Huai, Y
   Jin, J
   Geng, M
   Li, JX
AF Zhao, Yu
   Huai, Yue
   Jin, Jie
   Geng, Mei
   Li, Jian Xin
TI Quinoxaline derivative of oleanolic acid inhibits osteoclastic bone
   resorption and prevents ovariectomy induced bone loss
SO MENOPAUSE THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
LA English
DT Article
DE Quinoxaline derivative of oleanolic acid; Osteoclast; Apoptosis;
   Ovariectomized mice; Osteoporosis
ID HORMONE REPLACEMENT THERAPY; KAPPA B; DIFFERENTIATION; EXPRESSION;
   APOPTOSIS; LIGAND; GROWTH
AB Objective: Through bioassay guided natural product research, it has been discovered that oleanolic acid and its glycosides possess an antibone resorption activity. Quinoxaline derivative of oleanolic acid (QOA 8a), a novel compound, is sourced from a structural modification of oleanolic acid. The aim of the present study was to evaluate the activities of QOA 8a on bone resorption in vitro and its osteoprotective effect in vivo.
   Methods: Osteoclast precursors and mature osteoclasts were used to assay antibone resorption activities in vitro. RAW264.7 cells cultured for 2 days in the presence of the receptor activator for nuclear factor kappa B ligand were used as osteoclast precursors. Mature osteoclasts were generated from either primary cultures of mouse bone marrow derived macrophages or RAW264.7 cells. Eight week old female mice that underwent either ovariectomy or sham surgical operation were used for the evaluation of the osteoprotective effect of QOA 8a at doses of 0.1, 1, and 10 mg kg( 1) day( 1).
   Results: QOA 8a significantly inhibited the differentiation, formation, and bone resorptive activity of mature osteoclasts without cytotoxicity. QOA 8a selectively induced apoptosis at an early stage of mature osteoclasts at least via increasing the caspase 3 activity, but not osteoclast precursors. Furthermore, QOA 8a significantly prevented bone loss in ovariectomized mice without any hormone like adverse effects, whereas the mice treated with 1 mg kg( 1) day( 1) kept the same bone mineral density level as that of the sham mice.
   Conclusions: QOA 8a inhibits bone resorption without cytotoxicity and prevents bone loss without any hormone like adverse effects. Although further investigations are necessary to elucidate the detailed molecular mechanisms, QOA 8a demonstrates great potential as a novel agent for the treatment of osteoporosis.
C1 [Zhao, Yu; Huai, Yue; Jin, Jie; Geng, Mei; Li, Jian Xin] Nanjing Univ, Key Lab Analyt Chem Life Sci, Sch Chem & Chem Engn, Nanjing 210093, Peoples R China.
C3 Nanjing University
RP Li, JX (通讯作者)，Nanjing Univ, Key Lab Analyt Chem Life Sci, Sch Chem & Chem Engn, Nanjing 210093, Peoples R China.
EM lijxnju@nju.edu.cn
RI Jin, Jie/E 8863 2019; Li, Jianxin/IWE 1439 2023
OI Jin, Jie/0000 0001 7842 3116; 
FU 973 Program [2007CB714504]; National Natural Science Fund [20821063]
FX This study was supported by the 973 Program (2007CB714504) and the
   National Natural Science Fund for Creative Research Groups of China
   (20821063).
CR Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Canderelli R, 2007, J AM ACAD NURSE PRAC, V19, P635, DOI 10.1111/j.1745 7599.2007.00269.x
   Emerton KB, 2010, BONE, V46, P577, DOI 10.1016/j.bone.2009.11.006
   Giner Larza EM, 2001, EUR J PHARMACOL, V428, P137, DOI 10.1016/S0014 2999(01)01290 0
   He CC, 2010, J ETHNOPHARMACOL, V127, P229, DOI 10.1016/j.jep.2009.11.016
   Hsu HY, 1997, CANCER LETT, V111, P7, DOI 10.1016/S0304 3835(96)04481 3
   Jayaprakasam B, 2003, LIFE SCI, V74, P125, DOI 10.1016/j.lfs.2003.07.007
   Jeong HG, 1999, TOXICOL LETT, V105, P215, DOI 10.1016/S0378 4274(99)00004 1
   JIMI E, 1995, ENDOCRINOLOGY, V136, P808, DOI 10.1210/en.136.2.808
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kim MH, 2009, J CELL PHYSIOL, V221, P618, DOI 10.1002/jcp.21892
   Komarova SV, 2003, J BIOL CHEM, V278, P8286, DOI 10.1074/jbc.M206421200
   Kuo JHS, 2005, COLLOID SURFACE B, V41, P189, DOI 10.1016/j.colsurfb.2004.12.008
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Li JF, 2009, EUR J MED CHEM, V44, P2796, DOI 10.1016/j.ejmech.2008.12.024
   Li JF, 2009, CARBOHYD RES, V344, P599, DOI 10.1016/j.carres.2009.01.019
   Li JX, 2005, PLANTA MED, V71, P673, DOI 10.1055/s 2005 871275
   McLeod KM, 2009, GERIATR NURS, V30, P164, DOI 10.1016/j.gerinurse.2008.07.003
   Miller K, 2009, EUR UROL SUPPL, V8, P747, DOI 10.1016/j.eursup.2009.07.001
   Nelson HD, 2002, JAMA J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872
   Newbold RR, 2001, REPROD TOXICOL, V15, P245, DOI 10.1016/S0890 6238(01)00130 7
   O'Brien CA, 2010, BONE, V46, P911, DOI 10.1016/j.bone.2009.08.050
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Rodriguez C, 2001, JAMA J AM MED ASSOC, V285, P1460, DOI 10.1001/jama.285.11.1460
   Simon LS, 2005, CLIN GERIATR MED, V21, P603, DOI 10.1016/j.cger.2005.02.002
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   Tanaka S, 2010, ADV EXP MED BIOL, V658, P111, DOI 10.1007/978 1 4419 1050 9_12
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Väänänen HK, 2000, J CELL SCI, V113, P377
   Vainio Harri, 2003, Asian Pac J Cancer Prev, V4, P275
   Zhang Y, 2005, BIOORG MED CHEM LETT, V15, P1629, DOI 10.1016/j.bmcl.2005.01.061
NR 31
TC 23
Z9 25
U1 0
U2 18
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1072 3714
EI 1530 0374
J9 MENOPAUSE
JI Menopause J. N. Am. Menopause Soc.
PD JUN
PY 2011
VL 18
IS 6
BP 690
EP 697
DI 10.1097/gme.0b013e3181fd7f4b
PG 8
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Obstetrics & Gynecology
GA 769HV
UT WOS:000291004400017
PM 21228726
DA 2025 08 17
ER

PT J
AU de Boissieu, P
   Kanagaratnam, L
   Abou Taam, M
   Roux, MP
   Dramé, M
   Trenque, T
AF de Boissieu, Paul
   Kanagaratnam, Lukshe
   Abou Taam, Malak
   Roux, Marie Paule
   Drame, Moustapha
   Trenque, Thierry
TI Notoriety bias in a database of spontaneous reports: the example of
   osteonecrosis of the jaw under bisphosphonate therapy in the French
   national pharmacovigilance database
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Article
DE pharmacovigilance; adverse reaction; notoriety bias; spontaneous report;
   osteonecrosis of the jaw; pharmacoepidemiology
ID COMPETITION BIAS; SIGNAL DETECTION; DISPROPORTIONALITY
AB Purpose The purpose of this study was to identify a notoriety bias in a database of spontaneous reports and its consequences on the calculation of the reporting odds ratio (ROR). Methods We used the case/noncase methodology to calculate the ROR for bisphosphonates and osteonecrosis of the jaw (ONJ) in the French national pharmacovigilance database (from 1985 to 2013). To evaluate notoriety bias, drug related risk factors for ONJ [as specified in the summary of product characteristics (SPC) of bisphosphonates] were systematically scanned for notifications of reports of ONJ occurring under bisphosphonate therapy. When a risk factor was present, the ONJ was considered as not due to bisphosphonates, and a second ROR was calculated under the hypothesis of maximum bias. Results In total, 148 cases of ONJ were reported (143 with bisphosphonates and five without). The raw ROR was 3448 (95% confidence interval 1413 8417). After analysis of the reports, only 86 had no mention of a risk factor for ONJ. The ROR under the maximum bias hypothesis was 87 (95% confidence interval 63 121). Among ONJ where chemotherapy was being administered simultaneously to bisphosphonates, 27 reports did not consider the chemotherapy to be implicated, despite seven of these occurring in cases where ONJ was mentioned in the summary of product characteristics. Conclusions The existence of a notoriety bias has an impact on measures of disproportionality. The detection of pharmacovigilance signals might be delayed. It is advisable to list all drugs being taken when an adverse drug reaction occurs, and not only those known to be associated with the observed reaction. Copyright (c) 2014 John Wiley & Sons, Ltd.
C1 [de Boissieu, Paul; Kanagaratnam, Lukshe; Abou Taam, Malak; Roux, Marie Paule; Trenque, Thierry] Reims Univ Hosp, Reg Ctr Pharmacovigilance & Pharmacoepidemiol, Reims, France.
   [de Boissieu, Paul; Kanagaratnam, Lukshe; Drame, Moustapha; Trenque, Thierry] Univ Reims, Fac Med, EA 3797, Reims, France.
   [Drame, Moustapha] Reims Univ Hosp, Dept Res & Innovat, Reims, France.
C3 Universite de Reims Champagne Ardenne; CHU de Reims; Universite de Reims
   Champagne Ardenne; CHU de Reims; Universite de Reims Champagne Ardenne
RP Trenque, T (通讯作者)，Reims Univ Teaching Hosp, Reg Ctr Pharmacovigilance & Pharmacoepidemiol, Ave Gen Koenig, F 51100 Reims, France.
EM ttrenque@chu reims.fr
RI ; Dramé, Moustapha/E 6888 2017; Thierry, TRENQUE/AAN 9125 2020;
   Kanagaratnam, Lukshe/AAG 4193 2020
OI Drame, Moustapha/0000 0002 6662 8832; 
CR [Anonymous], CHMP ASS REP BISPH O
   Badros A, 2006, J CLIN ONCOL, V24, P945, DOI 10.1200/JCO.2005.04.2465
   Brown EG, 1999, DRUG SAFETY, V20, P109, DOI 10.2165/00002018 199920020 00002
   Edwards IR, 2010, DRUG SAFETY, V33, P257, DOI 10.2165/11532310 000000000 00000
   Estilo CL, 2008, J CLIN ONCOL, V26, P4037, DOI 10.1200/JCO.2007.15.5424
   Moore N, 1997, BRIT J CLIN PHARMACO, V44, P513, DOI 10.1046/j.1365 2125.1997.00615.x
   MOORE N, 1985, LANCET, V2, P1056
   Pariente A, 2007, DRUG SAFETY, V30, P891, DOI 10.2165/00002018 200730100 00007
   Pariente A, 2010, PHARMACOEPIDEM DR S, V19, P1166, DOI 10.1002/pds.2022
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Salvo F, 2013, DRUG SAFETY, V36, P565, DOI 10.1007/s40264 013 0063 5
   van Puijenbroek EP, 2002, PHARMACOEPIDEM DR S, V11, P3, DOI 10.1002/pds.668
   WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469 1809.1955.tb01348.x
NR 13
TC 35
Z9 36
U1 0
U2 0
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1053 8569
EI 1099 1557
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD SEP
PY 2014
VL 23
IS 9
BP 989
EP 992
DI 10.1002/pds.3622
PG 4
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA AO8DS
UT WOS:000341584200013
PM 24737486
OA Bronze
DA 2025 08 17
ER

PT J
AU Liu, MM
   Li, Y
   Yang, ST
AF Liu, Meimei
   Li, Yan
   Yang, Shang Tian
TI Effects of naringin on the proliferation and osteogenic differentiation
   of human amniotic fluid derived stem cells
SO JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Article
DE amniotic fluid derived stem cell; naringin; osteogenic differentiation;
   proliferation; mesenchymal stem cells; signalling pathways
ID HORMONE REPLACEMENT THERAPY; OSTEOBLAST DIFFERENTIATION; IMPROVES
   OSTEOGENESIS; IN VITRO; BONE; OSTEOPOROSIS; EXPRESSION; HEALTH; GENE;
   MICE
AB Human amniotic fluid derived stem cells (hAFSCs) are a novel cell source for generating osteogenic cells to treat bone diseases. Effective induction of osteogenic differentiation from hAFSCs is critical to fulfil their therapeutic potential. In this study, naringin, the main active compound of Rhizoma drynariae (a Chinese herbal medicine), was used to stimulate the proliferation and osteogenic differentiation of hAFSCs. The results showed that naringin enhanced the proliferation and alkaline phosphatase activity (ALP) of hAFSCs in a dose dependent manner in the range 1 100 mu g/ml, while an inhibition effect was observed at 200 mu g/ml. Consistently, the calcium content also increased with naringin concentration up to 100 mu g/ml. The enhanced osteogenic differentiation of hAFSCs by naringin was further confirmed by the dose dependent upregulation of marker genes, including osteopontin (OPN) and Collagen I from RT PCR analysis. The increased osteoprotegerin (OPG) expression and minimal expression of receptor activator of nuclear factor B ligand (RANKL) suggested that naringin also inhibited osteoclastogenesis of hAFSCs. In addition, the gene expressions of bone morphogenetic protein 4 (BMP4), runt related transcription factor 2 (RUNX2),  catenin and Cyclin D1 also increased significantly, indicating that naringin promotes the osteogenesis of hAFSCs via the BMP and Wnt  catenin signalling pathways. These results suggested that naringin can be used to upregulate the osteogenic differentiation of hAFSCs, which could provide an attractive and promising treatment for bone disorders. Copyright (c) 2014 John Wiley & Sons, Ltd.
C1 [Liu, Meimei; Yang, Shang Tian] Ohio State Univ, William G Lowrie Dept Chem & Biomol Engn, 140 West 19th Ave, Columbus, OH 43210 USA.
   [Li, Yan] Florida State Univ, FAMU FSU Coll Engn, Dept Chem & Biomed Engn, 2525 Pottsdamer St, Tallahassee, FL 32310 USA.
C3 University System of Ohio; Ohio State University; State University
   System of Florida; Florida State University; Florida A&M University
RP Yang, ST (通讯作者)，Ohio State Univ, William G Lowrie Dept Chem & Biomol Engn, 140 West 19th Ave, Columbus, OH 43210 USA.; Li, Y (通讯作者)，Florida State Univ, FAMU FSU Coll Engn, Dept Chem & Biomed Engn, 2525 Pottsdamer St, Tallahassee, FL 32310 USA.
EM yli@eng.fsu.edu; yang.15@osu.edu
RI Yang, Shang Tian/A 7892 2009; Liu, Meimei/I 5650 2017
OI Yang, Shang Tian/0000 0002 5990 8529; 
FU Alumni Grants for Graduate Research and Scholarship (AGGRS) of Ohio
   State University
FX This study was supported in part by Alumni Grants for Graduate Research
   and Scholarship (AGGRS) of Ohio State University. We would like to
   acknowledge Dr Anthony Atala and Dr James Yoo of the Wake Forest
   Institute for Regenerative Medicine (Winston Salem, NC) for kindly
   providing hAFSCs used in this study. We also would like to acknowledge
   Dr Sebastien Sart for assistance in ImageJ analysis.
CR [Anonymous], 2008, FOR AN DIS FOR EM DI
   Arum SM, 2008, CURR OPIN ENDOCRINOL, V15, P508, DOI 10.1097/MED.0b013e3283184017
   Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960
   Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006 291X(02)02951 0
   Bandyopadhyay A, 2013, BIOCHEM PHARMACOL, V85, P857, DOI 10.1016/j.bcp.2013.01.004
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Chen KY, 2013, EVID BASED COMPL ALT, P1
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   De Coppi P, 2007, NAT BIOTECHNOL, V25, P100, DOI 10.1038/nbt1274
   Egermann M, 2005, OSTEOPOROSIS INT, V16, pS129, DOI 10.1007/s00198 005 1859 7
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Guan XA, 2011, J TISSUE ENG REGEN M, V5, P220, DOI 10.1002/term.308
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hamidouche Z, 2008, FASEB J, V22, P3813, DOI 10.1096/fj.08 106302
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   Jeong JC, 2005, J ETHNOPHARMACOL, V96, P489, DOI 10.1016/j.jep.2004.09.038
   Jiao L, 2009, PHYTOMEDICINE, V16, P874, DOI 10.1016/j.phymed.2009.01.005
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Komori T, 2011, J CELL BIOCHEM, V112, P750, DOI 10.1002/jcb.22994
   Krieger N, 2005, J EPIDEMIOL COMMUN H, V59, P740, DOI 10.1136/jech.2005.033316
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Li D, 2013, BIOTECHNOL PROGR, V29, P738, DOI 10.1002/btpr.1731
   Li D, 2013, PROCESS BIOCHEM, V48, P517, DOI 10.1016/j.procbio.2013.02.005
   Li NH, 2013, J ORTHOP SCI, V18, P478, DOI 10.1007/s00776 013 0362 9
   Lian JB, 2006, REV ENDOCR METAB DIS, V7, P1, DOI 10.1007/s11154 006 9001 5
   Licata AA, 2005, ANN PHARMACOTHER, V39, P668, DOI 10.1345/aph.1E357
   Liu MM, 2017, J TISSUE ENG REGEN M, V11, P276, DOI 10.1002/term.1911
   Liu MM, 2014, BIOCHEM ENG J, V82, P71, DOI 10.1016/j.bej.2013.11.001
   Liu MM, 2014, STEM CELLS DEV, V23, P146, DOI 10.1089/scd.2013.0261
   Liu Y, 2014, CLIN EXP MED, V14, P13, DOI 10.1007/s10238 012 0218 1
   Ma XR, 2012, J TISSUE ENG REGEN M, V6, P598, DOI 10.1002/term.462
   Marshall John K, 2002, Expert Opin Drug Saf, V1, P71, DOI 10.1517/14740338.1.1.71
   Mathews S, 2012, DIFFERENTIATION, V84, P185, DOI 10.1016/j.diff.2012.05.001
   Nishio Y, 2006, GENE, V372, P62, DOI 10.1016/j.gene.2005.12.022
   Orsini LS, 2005, OSTEOPOROSIS INT, V16, P359, DOI 10.1007/s00198 004 1694 2
   Pang WY, 2010, BRIT J PHARMACOL, V159, P1693, DOI 10.1111/j.1476 5381.2010.00664.x
   Peng Y, 2003, J CELL BIOCHEM, V90, P1149, DOI 10.1002/jcb.10744
   Peng Zhang, 2009, EUR J PHARMACOL, V607, P1, DOI 10.1016/j.ejphar.2009.01.035
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Rodrigues MT, 2012, TISSUE ENG PT A, V18, P2518, DOI 10.1089/ten.tea.2011.0672
   Rossini M, 2013, CALCIFIED TISSUE INT, V93, P121, DOI 10.1007/s00223 013 9749 z
   Rotella DP, 2002, CURR OPIN DRUG DISC, V5, P477
   Roubelakis MG, 2007, STEM CELLS DEV, V16, P931, DOI 10.1089/scd.2007.0036
   Ryoo HM, 2006, GENE, V366, P51, DOI 10.1016/j.gene.2005.10.011
   Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522
   Teede HJ, 2003, BEST PRACT RES CL EN, V17, P73, DOI 10.1016/S1521 690X(02)00083 0
   Trohatou O, 2013, CURR STEM CELL RES T, V8, P125, DOI 10.2174/1574888X11308020003
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Wong R., 2007, CHIN MED UK, V2, P13, DOI [10.1186/1749 8546 2 13, DOI 10.1186/1749 8546 2 13]
   Yeh YC, 2010, TISSUE ENG PT A, V16, P1925, DOI [10.1089/ten.tea.2009.0728, 10.1089/ten.TEA.2009.0728]
   Zhai Yuan Kun, 2013, Zhongguo Zhong Yao Za Zhi, V38, P105
   Zhang JF, 2010, MOL CELL ENDOCRINOL, V314, P70, DOI 10.1016/j.mce.2009.08.012
   Zhang JF, 2009, PHYTOMEDICINE, V16, P521, DOI 10.1016/j.phymed.2009.01.003
NR 56
TC 50
Z9 59
U1 0
U2 30
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1932 6254
EI 1932 7005
J9 J TISSUE ENG REGEN M
JI J. Tissue Eng. Regen. Med.
PD JAN
PY 2017
VL 11
IS 1
BP 276
EP 284
DI 10.1002/term.1911
PG 9
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering
GA EK8KW
UT WOS:000394173600025
PM 24915843
DA 2025 08 17
ER

PT J
AU Wang, F
   Qian, J
   Yang, MY
   He, Y
   Tao, X
   Shi, YX
   Bian, XT
   Chen, W
   Wang, YJ
   Wang, H
   Yang, AN
   Li, Y
   Tang, H
   Huang, P
   Mu, MD
   He, G
   Zhou, M
   Kang, X
   Tang, KL
AF Wang Feng
   Qian Jin
   Yang Ming yu
   He Yang
   Tao Xu
   Shi You xing
   Bian Xu ting
   Chen Wan
   Wang Yun jiao
   Wang Huan
   Yang Ai ning
   Li Yan
   Tang Hong
   Huang Pan
   Mu Mi duo
   He Gang
   Zhou Mei
   Kang Xia
   Tang Kang lai
TI MiR 6924 5p rich exosomes derived from genetically modified
   Scleraxis overexpressing PDGFRα(+) BMMSCs as novel nanotherapeutics for
   treating osteolysis during tendon bone healing and improving healing
   strength
SO BIOMATERIALS
LA English
DT Article
DE miR 6924 5p; Scx; Tendon bone healing; PDGFR alpha(+) BMMSCs;
   Osteoclastogenesis; Exosomes
ID MESENCHYMAL STEM CELLS; OSTEOCLAST DIFFERENTIATION; PROMOTES;
   RECONSTRUCTION; EXPRESSION; CONTRIBUTE
AB Osteolysis at the tendon bone interface can impair pullout strength during tendon bone healing and lead to surgery failure, but the effects of clinical treatments are not satisfactory. Mesenchymal stem cell (MSC) derived exosomes have been used as potent and feasible natural nanocarriers for drug delivery and have been proven to enhance tendon bone healing strength, indicating that MSC derived exosomes could be a promising therapeutic strategy. In this study, we explored Scleraxis (Scx) dynamically expressed in PDGFR alpha(+) bone marrow derived mesenchymal stem cells (BMMSCs) during natural tendon bone healing. Then, we investigated the role of PDGFR alpha(+) BMMSCs in tendon bone healing after Scx overexpression as well as the underlying mechanisms. Our data demonstrated that Scx overexpressing PDGFR alpha(+) BMMSCs (BMMSCScx) could efficiently inhibit peritunnel osteolysis and enhance tendon bone healing strength by preventing osteoclastogenesis in an exosomes dependent manner. Exosomal RNA seq revealed that the abundance of a novel miRNA, miR 6924 5p, was highest among miRNAs. miR 6924 5p could directly inhibit osteoclast formation by binding to the 3' untranslated regions (3'UTRs) of OCSTAMP and CXCL12. Inhibition of miR 6924 5p expression reversed the prevention of osteo clastogenic differentiation by BMMSCScx derived exosomes (BMMSCScx exos). Local injection of BMMSCScx exos or miR 6924 5p dramatically reduced osteoclast formation and improved tendon bone healing strength. Furthermore, delivery of miR 6924 5p efficiently inhibited the osteoclastogenesis of human monocytes. In brief, our study demonstrates that BMMSCScx exos or miR 6924 5p could serve as a potential therapy for the treatment of osteolysis during tendon bone healing and improve the outcome.
C1 [Wang Feng; Qian Jin; Yang Ming yu; He Yang; Tao Xu; Shi You xing; Bian Xu ting; Chen Wan; Wang Yun jiao; Wang Huan; Yang Ai ning; Li Yan; Tang Hong; Huang Pan; Mu Mi duo; He Gang; Zhou Mei; Kang Xia; Tang Kang lai] Third Mil Med Univ, Army Med Univ, State Key Lab Trauma Burn & Combined Injury, Dept Orthoped,Sports Med Ctr, Chongqing 400000, Peoples R China.
   [Qian Jin; Kang Xia; Tang Kang lai] Third Mil Med Univ, Dept Biochem & Mol Biol, Army Med Univ, Chongqing 400038, Peoples R China.
C3 Army Medical University; Army Medical University
RP Kang, X; Tang, KL (通讯作者)，Third Mil Med Univ, Army Med Univ, State Key Lab Trauma Burn & Combined Injury, Dept Orthoped,Sports Med Ctr, Chongqing 400000, Peoples R China.
EM kxpaper@sina.com; tangkanglai@hotmail.com
RI wang, yunjiao/HLP 8098 2023; Pan, Huang/LFG 0248 2024; tang,
   kang/HNQ 2884 2023; Yang, Mingyu/IWM 2177 2023
FU National Natural Science Foundation of China [82072516]
FX This work was supported by the National Natural Science Foundation of
   China (82072516 to T. K.L.) .
CR Agarwal S, 2017, STEM CELLS, V35, P705, DOI 10.1002/stem.2515
   Araki Y, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.667109
   Bhullar R, 2019, KNEE SURG SPORT TR A, V27, P524, DOI 10.1007/s00167 018 5142 9
   Blitz E, 2013, DEVELOPMENT, V140, P2680, DOI 10.1242/dev.093906
   Chen CY, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0056 9
   Chen P, 2020, CELL TRANSPLANT, V29, DOI 10.1177/0963689720973647
   Chen X, 2019, RNA BIOL, V16, P1249, DOI 10.1080/15476286.2019.1624470
   Christensen JE, 2018, CLIN SPORT MED, V37, P265, DOI 10.1016/j.csm.2017.12.006
   Corley M, 2020, MOL CELL, V78, P9, DOI 10.1016/j.molcel.2020.03.011
   Crane JL, 2014, J CLIN INVEST, V124, P466, DOI 10.1172/JCI70050
   Familtseva A, 2019, MOL CELL BIOCHEM, V459, P1, DOI 10.1007/s11010 019 03545 4
   Gong NY, 2020, BIOCHEM BIOPH RES CO, V525, P341, DOI 10.1016/j.bbrc.2020.02.058
   Gronthos S, 2007, TRENDS ENDOCRIN MET, V18, P108, DOI 10.1016/j.tem.2007.02.002
   Gulotta LV, 2011, AM J SPORT MED, V39, P1282, DOI 10.1177/0363546510395485
   Guo J, 2019, CELL MICROBIOL, V21, DOI 10.1111/cmi.12979
   Han L, 2019, EUR REV MED PHARMACO, V23, P9075, DOI 10.26355/eurrev_201910_19310
   Hjorthaug GA, 2018, ACTA ORTHOP, V89, P360, DOI 10.1080/17453674.2018.1440189
   Houlihan DD, 2012, NAT PROTOC, V7, P2103, DOI 10.1038/nprot.2012.125
   Huang Y, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 02005 x
   Ideo K, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0242286
   Killian ML, 2016, FASEB J, V30, P301, DOI 10.1096/fj.14 258236
   Ko NY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21144886
   Léjard V, 2007, J BIOL CHEM, V282, P17665, DOI 10.1074/jbc.M610113200
   Liao W, 2019, ACTA BIOMATER, V86, P1, DOI 10.1016/j.actbio.2018.12.045
   Liu H, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.654397
   Liu Q, 2019, BIOMATERIALS, V192, P189, DOI 10.1016/j.biomaterials.2018.10.037
   Lu J, 2019, AM J SPORT MED, V47, P2729, DOI 10.1177/0363546519862284
   Ma C, 2021, BONE, V142, DOI 10.1016/j.bone.2020.115687
   Mashimo T, 2019, J ORAL SCI, V61, P284, DOI 10.2334/josnusd.18 0143
   Muruganandan S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072277
   Mutsuzaki H, 2012, KNEE, V19, P455, DOI 10.1016/j.knee.2011.03.008
   Negri S, 2020, STEM CELL TRANSL MED, V9, P1617, DOI 10.1002/sctm.20 0152
   Peyrache M D, 1996, Knee Surg Sports Traumatol Arthrosc, V4, P2, DOI 10.1007/BF01565989
   Rodeo SA, 2007, J BONE JOINT SURG AM, V89A, P2250, DOI 10.2106/JBJS.F.00409
   Schweitzer R, 2001, DEVELOPMENT, V128, P3855
   Shi YX, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.923328
   Sugimoto Y, 2013, DEVELOPMENT, V140, P2280, DOI 10.1242/dev.096354
   Sun L, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658 019 0146 0
   Tan CL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097453
   Tang TT, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz0748
   Tian F, 2015, INT J MOL SCI, V16, P3178, DOI 10.3390/ijms16023178
   Tian XG, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/3849760
   Wang CY, 2020, AM J SPORT MED, V48, P1456, DOI 10.1177/0363546520908847
   Wang LL, 2018, J CELL BIOCHEM, V119, P8897, DOI 10.1002/jcb.27143
   Wang R, 2017, CELL PHYSIOL BIOCHEM, V41, P213, DOI 10.1159/000456046
   Witwicka H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128275
   Yi S, 2020, BMB REP, V53, P646, DOI 10.5483/BMBRep.2020.53.12.199
   Yumashev AV, 2021, ACTA ORTHOP, V92, P443, DOI 10.1080/17453674.2021.1897744
   Zhang HK, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01808 2
   Zhao HY, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20170302
   Zhou Y, 2020, BRIT J PHARMACOL, V177, P2106, DOI 10.1111/bph.14972
NR 51
TC 48
Z9 50
U1 2
U2 75
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD DEC
PY 2021
VL 279
AR 121242
DI 10.1016/j.biomaterials.2021.121242
EA NOV 2021
PG 14
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA WY6EZ
UT WOS:000719373100004
PM 34768151
OA hybrid
DA 2025 08 17
ER

PT J
AU Oh, Y
   Ahn, CB
   Hyung, JH
   Je, JY
AF Oh, Yunok
   Ahn, Chang Bum
   Hyung, Jun Ho
   Je, Jae Young
TI Two novel peptides from ark shell protein stimulate osteoblast
   differentiation and rescue ovariectomy induced bone loss
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE Osteogenic peptides; BMP; OVX; Bone formation; Osteoporosis
ID BMP 2 INDUCED OSTEOGENESIS; KINASE; ACTIVATION; PATHWAY; HEALTH; CELLS
AB Osteoporosis is a common bone disease resulting from imbalance between bone formation and bone resorption. Currently, anti resorptive agents that inhibit bone resorption are the most available drugs on the market. Biosphosphonates, anti resorptive drugs most commonly used to treat osteoporosis, are limited by their side effects for long term continuous treatment. It is important to develop appropriate therapeutic stragegies capable of promoting bone formation to counteract osteoporotic bone loss. Thus, anabolic agents that stimulate bone formation are undoubtedly of interest. Here, we purified and identified two novel osteogenic peptides AWLNH and PHDL from ark shell protein hydrolysates. AWLNH and PHDL stimulated osteoblast differentiation via mitogen activated protein kinase (MAPK) and bone morphogenetic protein 2 (BMP 2) pathways. The activation of BMP 2 pathway stimulated by AWLNH and PHDL was abolished by treating noggin, BMP antagonist, in bone marrow derived mesenchymal stem cells (BMMSCs), but not the phosphorylation of JNK1/2, ERK1/2, and p38 MAPK. However, treatment with MAPK inhibitors in BMMSCs downregulated the expression of BMP 2 and p Smad1/5 and inhibited alkaline phosphatase activity. The dominant inhibitory effects by JNK inhibitor and ERK inhibitor are observed. In ovariectomized (OVX) mice, a reduction of femoral bone mineral density (BMD) was significantly observed, however, AWLNH and PHDL (0.2 mg/kg/per day) injection restored BMD as well as the osteoporotic conditions in OVX mice. Moreover, the increased serum osteocalcin and alkaline phosphatase activity in OVX mice were significantly reduced in AWLNH and PHDL injected OVX mice. These results suggest that two novel osteogenic peptides AWLNH and PHDL could be attractive therapeutic agents for osteoporosis treatment.
C1 [Oh, Yunok; Hyung, Jun Ho; Je, Jae Young] Pukyong Natl Univ, Dept Marine Bio Convergence Sci, Busan 48547, South Korea.
   [Ahn, Chang Bum] Chonnam Natl Univ, Div Food & Nutr, Gwangju 61186, South Korea.
C3 Pukyong National University; Chonnam National University
RP Je, JY (通讯作者)，Pukyong Natl Univ, Dept Marine Bio Convergence Sci, Busan 48547, South Korea.
EM jjy1915@pknu.ac.kr
OI Je, Jae Young/0000 0002 4800 0566
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Education [NRF 2016R1A2B4016004]
FX This study was supported by the Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education (NRF 2016R1A2B4016004).
CR [Anonymous], 2012, OA BIOTECHNOLOGY, DOI DOI 10.13172/2052 0069 1 2 294
   Aoki K, 2012, ADV DRUG DELIVER REV, V64, P1220, DOI 10.1016/j.addr.2012.05.017
   Boergermann JH, 2010, INT J BIOCHEM CELL B, V42, P1802, DOI 10.1016/j.biocel.2010.07.018
   Canpolat S, 2010, J PHYSIOL BIOCHEM, V66, P23, DOI 10.1007/s13105 010 0008 8
   Chen C, 2012, J CELL BIOCHEM, V113, P3672, DOI 10.1002/jcb.24240
   Cummings SR, 2002, JAMA J AM MED ASSOC, V288, P1889, DOI 10.1001/jama.288.15.1889
   Daroszewska A., 2012, Obs., Gynaecol. Reprod. Med., V22, P162, DOI 10.1016/j.ogrm.2012.02.007
   Feeley BT, 2006, BONE, V38, P154, DOI 10.1016/j.bone.2005.07.015
   Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756 3282(01)00415 X
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060
   Guillerminet F, 2012, OSTEOPOROSIS INT, V23, P1909, DOI 10.1007/s00198 011 1788 6
   Han JF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181175
   Hyung JH, 2018, FOOD CHEM, V242, P156, DOI 10.1016/j.foodchem.2017.09.043
   Hyung JH, 2016, RSC ADV, V6, P29365, DOI 10.1039/c6ra00898d
   Iñiguez Ariza NM, 2015, MATURITAS, V82, P245, DOI 10.1016/j.maturitas.2015.07.003
   Kim HK, 2012, BIOMATERIALS, V33, P7057, DOI 10.1016/j.biomaterials.2012.06.036
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Lee JS, 2018, STEM CELL RES, V26, P28, DOI 10.1016/j.scr.2017.11.016
   Makras P, 2015, METABOLISM, V64, P1199, DOI 10.1016/j.metabol.2015.07.011
   Marie PJ, 2008, ARCH BIOCHEM BIOPHYS, V473, P98, DOI 10.1016/j.abb.2008.02.030
   Mckay WF, 2007, INT ORTHOP, V31, P729, DOI 10.1007/s00264 007 0418 6
   Min SK, 2018, CELL DEATH DIFFER, V25, P268, DOI 10.1038/cdd.2017.153
   Porch JV, 2002, CANCER CAUSE CONTROL, V13, P847, DOI 10.1023/A:1020617415381
   Reddi S, 2016, J NUTR BIOCHEM, V38, P134, DOI 10.1016/j.jnutbio.2016.08.003
   Roux S, 2010, JOINT BONE SPINE, V77, P222, DOI 10.1016/j.jbspin.2010.02.004
   Saidak Z., 2015, J BIOL CHEM M, V114
   Shapses SA, 2017, NUTR RES, V39, P1, DOI 10.1016/j.nutres.2016.12.010
   Subbiah V, 2010, OSTEOPOROSIS INT, V21, P1041, DOI 10.1007/s00198 009 1004 0
   Thouverey C., 2015, BONEKEY REP, V4
   Wu CJ, 2008, J DENT SCI, V3, P13
   Yoon KH, 2012, J KOREAN NEUROSURG S, V51, P323, DOI 10.3340/jkns.2012.51.6.323
   Zhao X, 2011, J ETHNOPHARMACOL, V137, P1083, DOI 10.1016/j.jep.2011.07.017
NR 33
TC 18
Z9 19
U1 4
U2 26
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0041 008X
EI 1096 0333
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD DEC 15
PY 2019
VL 385
AR 114779
DI 10.1016/j.taap.2019.114779
PG 11
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA JU8SN
UT WOS:000501939900003
PM 31697996
DA 2025 08 17
ER

PT J
AU Shi, YP
   Su, ZG
   Li, S
   Chen, YN
   Chen, X
   Xiao, YY
   Sun, MJ
   Ping, QN
   Zong, L
AF Shi, Yongping
   Su, Zhigui
   Li, Sai
   Chen, Yinan
   Chen, Xi
   Xiao, Yanyu
   Sun, Minjie
   Ping, Qineng
   Zong, Li
TI Multistep Targeted Nano Drug Delivery System Aiming at Leukemic Stem
   Cells and Minimal Residual Disease
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE refractory leukemia; minimal residual disease; leukemic stem cell;
   multistep targeting delivery
ID SOLID LIPID NANOPARTICLES; RECEPTOR TYPE BETA; FOLATE RECEPTOR;
   LIPOSOMAL DOXORUBICIN; BIODISTRIBUTION; INDUCTION; STABILITY; PROGRESS;
   DESIGN; NICHE
AB Refractory leukemia remains the most common therapeutic problem in clinical treatment of leukemia. The key therapy of refractory leukemia is to kill, thoroughly, the minimal residual disease and leukemia stem cells in the highly vascularized red marrow areas. In this study, two new conjugates, alendronate polyethylene glycol (100) monostearate and folate polyethylene glycol (100) monostearate, were synthesized to develop a multistep targeting nanostructured lipid carriers by enhancing drug transport to the high bone turnover areas adjacent to the red marrow and targeting the minimal residual disease and leukemia stem cells. This dual targeting system demonstrated a great binding affinity to hydroxyapatite, a model component of bone minerals, and higher cell uptake (in the form of carriers but not drug) and cytotoxicity in the K562 cell line, a leukemia cell line with overexpressed folate receptors, were observed in vitro compared to unmodified carriers, especially when the cells were pretreated and the receptors were up regulated by all trans retinoic acid. The comodel test of K562 cells and HA showed that this dual targeting system could desorb from bone surface and be taken up by leukemia cells. For the in vivo study, this dual targeting system exhibited a significant increase in plasma half life and could specifically accumulate in the bone tissue of rats or mice after intravenous injection. Ex vivo imaging of mice femurs and confocal laser scanning microscope imaging of mice femur slices further confirmed that this dual targeting system could favorably deposit to the osteoblast enriched areas of high bone turnover in regions of trabecular bone surrounded by red marrow. In vivo antitumor activity in K562/BALB/c nu leukemia mice showed that the treatment of this dual targeting system significantly reduced the white blood cell (WBC) number in peripheral blood and bone marrow to the normal level. In conclusion, this dual targeting system could precisely target to the regions where the minimal residual disease and leukemia stem cells are located and then be specifically uptaken in large amounts, which is a valuable target for refractory leukemia therapy.
C1 [Shi, Yongping; Su, Zhigui; Li, Sai; Chen, Yinan; Chen, Xi; Xiao, Yanyu; Sun, Minjie; Ping, Qineng; Zong, Li] China Pharmaceut Univ, Key Lab State Nat Med, Dept Pharmaceut, Nanjing 210009, Jiangsu, Peoples R China.
C3 China Pharmaceutical University
RP Ping, QN (通讯作者)，China Pharmaceut Univ, Key Lab State Nat Med, Dept Pharmaceut, Nanjing 210009, Jiangsu, Peoples R China.
EM pingqn2004@yahoo.cn; zong216@yahoo.com.cn
FU National Natural Science Foundation of China [81273467]
FX We thank Dr. Sulieman Eltayeb for writing improvement. This work was
   financially supported by National Natural Science Foundation of China
   (No. 81273467).
CR Bukowski JF, 2005, BIOCHEM BIOPH RES CO, V328, P746, DOI 10.1016/j.bbrc.2004.11.075
   Campana D, 2010, CURR HEMATOL MALIG R, V5, P169, DOI 10.1007/s11899 010 0056 8
   Chang CW, 1997, BRIT J CANCER, V75, P169, DOI 10.1038/bjc.1997.28
   Choi SW, 2007, J CONTROL RELEASE, V122, P24, DOI 10.1016/j.jconrel.2007.06.003
   Dolman MEM, 2010, ADV DRUG DELIVER REV, V62, P1344, DOI 10.1016/j.addr.2010.07.011
   FROST H. M., 1960, HENRY FORD HOSP MED BULL, V8, P239
   Gabizon A, 1999, BIOCONJUGATE CHEM, V10, P289, DOI 10.1021/bc9801124
   Gao HL, 2012, BIOMATERIALS, V33, P5115, DOI 10.1016/j.biomaterials.2012.03.058
   Gualbert J, 2003, INT J PHARMACEUT, V257, P69, DOI 10.1016/S0378 5173(03)00138 8
   Ishikawa F, 2007, NAT BIOTECHNOL, V25, P1315, DOI 10.1038/nbt1350
   Kuljanin J, 2002, J PHARMACEUT BIOMED, V28, P1215, DOI 10.1016/S0731 7085(02)00021 3
   Laczika K, 2001, LEUKEMIA LYMPHOMA, V42, P923, DOI 10.3109/10428190109097711
   LEE RJ, 1994, J BIOL CHEM, V269, P3198
   Li M, 1999, BONE, V24, P95, DOI 10.1016/S8756 3282(98)00167 7
   Li SD, 2008, MOL PHARMACEUT, V5, P496, DOI 10.1021/mp800049w
   Liang XM, 2005, J COLLOID INTERF SCI, V285, P360, DOI 10.1016/j.jcis.2004.11.042
   Lim SJ, 2002, INT J PHARM, V243, P135, DOI 10.1016/S0378 5173(02)00269 7
   Moore NW, 2006, BIOPHYS J, V91, P1675, DOI [10.1529/biophysj.105.079871, 10.1529/biophysj.105.07987J]
   Pan XQ, 2002, BLOOD, V100, P594, DOI 10.1182/blood.V100.2.594
   Pignatello R, 2009, NANOMEDICINE UK, V4, P161, DOI 10.2217/17435889.4.2.161
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   RICCI C, 1990, RADIOLOGY, V177, P83, DOI 10.1148/radiology.177.1.2399343
   Riviere K, 2011, J DRUG TARGET, V19, P14, DOI 10.3109/10611861003733953
   Ross JF, 1999, CANCER AM CANCER SOC, V85, P348, DOI 10.1002/(SICI)1097 0142(19990115)85:2<348::AID CNCR12>3.0.CO;2 4
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Shahgaldian P, 2003, INT J PHARMACEUT, V253, P23, DOI 10.1016/S0378 5173(02)00639 7
   Shea JE, 2005, ADV DRUG DELIVER REV, V57, P945, DOI 10.1016/j.addr.2004.12.017
   Sun MJ, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957 4484/21/47/475101
   Suzuki N, 2006, P NATL ACAD SCI USA, V103, P2202, DOI 10.1073/pnas.0508928103
   Valencia PM, 2011, BIOMATERIALS, V32, P6226, DOI 10.1016/j.biomaterials.2011.04.078
   Wang D, 2003, BIOCONJUGATE CHEM, V14, P853, DOI 10.1021/bc034090j
   Wang H, 2000, BLOOD, V96, P3529
   Williams DA, 2006, NATURE, V444, P827, DOI 10.1038/444827a
   Yang DB, 2008, COLLOID SURFACE B, V63, P192, DOI 10.1016/j.colsurfb.2007.11.019
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
   Zhuang J, 2010, INT J NANOMED, V5, P407
NR 37
TC 25
Z9 34
U1 0
U2 76
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543 8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD JUN
PY 2013
VL 10
IS 6
BP 2479
EP 2489
DI 10.1021/mp4001266
PG 11
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 159AE
UT WOS:000320015600038
PM 23646913
DA 2025 08 17
ER

PT J
AU Kocijan, R
   Weigl, M
   Skalicky, S
   Geiger, E
   Ferguson, J
   Leinfellner, G
   Heimel, P
   Pietschmann, P
   Grillari, J
   Redl, H
   Hackl, M
AF Kocijan, Roland
   Weigl, Moritz
   Skalicky, Susanna
   Geiger, Elisabeth
   Ferguson, James
   Leinfellner, Gabriele
   Heimel, Patrick
   Pietschmann, Peter
   Grillari, Johannes
   Redl, Heinz
   Hackl, Matthias
TI MicroRNA levels in bone and blood change during bisphosphonate and
   teriparatide therapy in an animal model of postmenopausal osteoporosis
SO BONE
LA English
DT Article
DE Bone microstructure; Circulating microRNA; Osteoporosis; Bisphosphonate;
   Parathyroid hormone (PTH); mu CT; RUNX2
ID MESENCHYMAL STEM CELLS; EXPRESSION; DIFFERENTIATION; TURNOVER; PROFILE;
   TISSUE; WOMEN; SERUM
AB MicroRNAs control the activity of a variety of genes that are pivotal to bone metabolism. Therefore, the clinical utility of miRNAs as biomarkers and drug targets for bone diseases certainly merits further investigation. This study describes the use of an animal model of postmenopausal osteoporosis to generate a comprehensive dataset on miRNA regulation in bone tissue and peripheral blood during bone loss and specifically anti resorptive and osteo anabolic treatment.
   Forty two Sprague Dawley rats were randomized to SHAM surgery (n = 10) or ovariectomy (OVX, n = 32). Eight weeks after surgery, OVX animals were further randomized to anti resorptive treatment with zoledronate (n = 11), osteo anabolic treatment with teriparatide (n = 11), or vehicle treatment (n = 10). After 12 weeks of treatment, bone and serum samples were used for microRNA analysis using next generation sequencing (NGS), mRNA levels using RT qPCR, and bone microarchitecture analysis using nanoCT.
   Ovariectomy resulted in loss of trabecular bone, which was fully rescued using osteo anabolic treatment, and partially rescued using anti resorptive treatment. NGS revealed that both, anti resorptive and anabolic treatment had a significant impact on miRNA levels in bone tissue and serum: out of 426 detected miRNAs, 46 miRNAs were regulated by teriparatide treatment an d 10 by zoledronate treatment (p adj. < 0.1). Interestingly, teriparatide and zoledronate treatment were able to revert miRNA changes in tissue and serum of untreated OVX animals, such as the up regulation of miR 203a 3p, a known osteo inhibitory miRNA. We confirmed previously established mechanisms of miR 203a by analyzing its direct target Dlx5 in femoral head.
   Our data reveal a significant effect of ovariectomy induced bone loss, as well as the two major types of anti osteoporotic treatment on miRNA transcription in femoral head tissue. These changes are associated with altered activity of target genes relevant to bone formation, such as DLx5. The observed effects of bone loss and treatment response on miRNA levels in bone are also reflected in the peripheral blood, suggesting the possibility of minimally invasive monitoring of bone derived miRNAs using liquid biopsies.
C1 [Kocijan, Roland; Ferguson, James; Leinfellner, Gabriele; Heimel, Patrick; Grillari, Johannes; Redl, Heinz] Ludwig Boltzmann Inst Expt & Clin Traumatol, AUVA Res Ctr, Donaueschingenstr 13, A 1200 Vienna, Austria.
   [Kocijan, Roland] Hanusch Hosp, Med Dept 1, Heinrich Collin Str 30, A 1140 Vienna, Austria.
   [Weigl, Moritz; Skalicky, Susanna; Geiger, Elisabeth; Hackl, Matthias] TAmiRNA GmbH, Leberstr 20, A 1110 Vienna, Austria.
   [Ferguson, James; Leinfellner, Gabriele; Heimel, Patrick; Grillari, Johannes; Redl, Heinz; Hackl, Matthias] Austrian Cluster Tissue Regenerat, Vienna, Austria.
   [Heimel, Patrick] Univ Clin Dent, Dept Oral Surg, Karl Donath Lab Hard Tissue & Biomat Res, Vienna, Austria.
   [Pietschmann, Peter] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Vienna, Austria.
   [Grillari, Johannes] BOKU Univ Nat Resources & Life Sci Vienna, Dept Biotechnol, Christian Doppler Lab Biotechnol Skin Aging, Vienna, Austria.
C3 Ludwig Boltzmann Institute; Ludwig Boltzmann Institute for Experimental
   & Clinical Traumatology; WGKK   Hanusch Hospital; Medical University of
   Vienna; BOKU University
RP Hackl, M (通讯作者)，TAmiRNA GmbH, Muthgasse 18, A 1190 Vienna, Austria.
EM matthias.hackl@tamirna.com
RI Grillari, Johannes/B 2967 2011; Hackl, Matthias/LSK 0315 2024
OI Grillari, Johannes/0000 0001 5474 6332; Ferguson, James
   C./0000 0002 5646 3851; Weigl, Moritz/0000 0002 3941 5671
FU FFG Feasibility Project [852770]; Christian Doppler Gesellschaft; EU FP7
   Health Project [FRAILOMIC305483, SYBIL602300]
FX This study was supported by the FFG Feasibility Project Grant 852770,
   the Christian Doppler Gesellschaft, EU FP7 Health Project
   FRAILOMIC305483and EU FP7 Health Project SYBIL602300.
CR An JH, 2014, J BONE MINER RES, V29, P644, DOI 10.1002/jbmr.2060
   Anastasilakis AD, 2018, J CLIN ENDOCR METAB, V103, P1206, DOI 10.1210/jc.2017 02406
   [Anonymous], GENES
   [Anonymous], 2018, SCI REP UK
   [Anonymous], JCEM
   [Anonymous], SCI REP
   Blondal T, 2013, METHODS, V59, pS1, DOI 10.1016/j.ymeth.2012.09.015
   Brouwers JEM, 2008, CALCIFIED TISSUE INT, V82, P202, DOI 10.1007/s00223 007 9084 3
   Carter LE, 2012, BMC BIOTECHNOL, V12, DOI 10.1186/1472 6750 12 5
   Cheng VKF, 2019, JBMR PLUS, V3, P2, DOI 10.1002/jbm4.10115
   De Ugarte L, 2018, HUM CELL, V31, P33, DOI 10.1007/s13577 017 0181 y
   Deng Y, 2014, EUR CELLS MATER, V27, P13, DOI 10.22203/eCM.v027a02
   Deng Y, 2013, STEM CELLS DEV, V22, P2278, DOI 10.1089/scd.2012.0686
   Eastell R, 2017, LANCET DIABETES ENDO, V5, P908, DOI 10.1016/S2213 8587(17)30184 5
   Garnero P, 2017, MOL DIAGN THER, V21, P401, DOI 10.1007/s40291 017 0272 1
   Gasser JA, 2008, J BONE MINER RES, V23, P544, DOI 10.1359/JBMR.071207
   Hackl M, 2016, MOL CELL ENDOCRINOL, V432, P93, DOI 10.1016/j.mce.2015.10.015
   Heilmeier U., 2016, J BONE MINER RES MON, Vxx, P1
   Kelch S, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 16113 x
   Kendler DL, 2018, LANCET, V391, P230, DOI 10.1016/S0140 6736(17)32137 2
   Kocijan R, 2016, J CLIN ENDOCR METAB, V101, P4125, DOI 10.1210/jc.2016 2365
   Laxman N, 2016, BONE, V84, P181, DOI 10.1016/j.bone.2015.12.053
   Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058
   Maeda SS, 2014, ARQ BRAS ENDOCRINOL, V58, P162, DOI 10.1590/0004 2730000003039
   Metsalu T, 2015, NUCLEIC ACIDS RES, V43, pW566, DOI 10.1093/nar/gkv468
   Nanes MS, 2014, SEMIN NUCL MED, V44, P439, DOI 10.1053/j.semnuclmed.2014.06.006
   Odén A, 2015, OSTEOPOROSIS INT, V26, P2243, DOI 10.1007/s00198 015 3154 6
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Seeliger C, 2014, J BONE MINER RES, V29, P1718, DOI 10.1002/jbmr.2175
   Sera SR, 2017, CURR OSTEOPOROS REP, V15, P353, DOI 10.1007/s11914 017 0379 7
   Shenoy A, 2014, NAT REV MOL CELL BIO, V15, P565, DOI 10.1038/nrm3854
   Smith Vikos T, 2012, J CELL SCI, V125, P7, DOI 10.1242/jcs.099200
   Sun SJ, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 10620 7
   Taipaleenmäki H, 2018, CURR OSTEOPOROS REP, V16, P1, DOI 10.1007/s11914 018 0417 0
   Taipaleenmäki H, 2015, CANCER RES, V75, P1433, DOI 10.1158/0008 5472.CAN 14 1026
   Tian Y, 2011, MOL CELL BIOCHEM, V355, P211, DOI 10.1007/s11010 011 0856 8
   Xu XY, 2017, MOL MED REP, V15, P1571, DOI 10.3892/mmr.2017.6178
   Yavropoulou MP, 2017, EUR J ENDOCRINOL, V176, P169, DOI 10.1530/EJE 16 0583
   Zhang JF, 2011, RNA BIOL, V8, P829, DOI 10.4161/rna.8.5.16043
   Zhao X, 2014, J BONE MINER METAB, V32, P221, DOI 10.1007/s00774 013 0537 7
NR 40
TC 43
Z9 44
U1 1
U2 25
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD FEB
PY 2020
VL 131
AR 115104
DI 10.1016/j.bone.2019.115104
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA KD2JO
UT WOS:000507697800003
PM 31683019
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Middleton, K
   Al Dujaili, S
   Mei, X
   Günther, A
   You, L
AF Middleton, K.
   Al Dujaili, S.
   Mei, X.
   Guenther, A.
   You, L.
TI Microfluidic co culture platform for investigating osteocyte osteoclast
   signalling during fluid shear stress mechanostimulation
SO JOURNAL OF BIOMECHANICS
LA English
DT Article
DE Mechanobiology; Fluid flow shear stress; Microfluidic; Osteocytes;
   Osteoclasts; Co culture
ID IN VITRO; BONE FORMATION; GAP JUNCTIONS; LOADED BONE; CELL; APOPTOSIS;
   STIMULATION; ACTIVATION; FLOW; RANKL
AB Bone cells exist in a complex environment where they are constantly exposed to numerous dynamic biochemical and mechanical stimuli. These stimuli regulate bone cells that are involved in various bone disorders, such as osteoporosis. Knowledge of how these stimuli affect bone cells have been utilised to develop various treatments, such as pharmaceuticals, hormone therapy, and exercise. To investigate the role that bone loading has on these disorders in vitro, bone cell mechanotransduction studies are typically performed using parallel plate flow chambers (PPFC). However, these chambers do not allow for dynamic cellular interactions among different cell populations to be investigated. We present a microfluidic approach that exposes different cell populations, which are located at physiologically relevant distances within adjacent channels, to different levels of fluid shear stress, and promotes cell cell communication between the different channels. We employed this microfluidic system to assess mechanically regulated osteocyte osteoclast communication. Osteoclast precursors (RAW264.7 cells) responded to cytokine gradients (e.g., RANKL, OPG, PGE 2) developed by both mechanically stimulated (fOCY) and unstimulated (nOCY) osteocyte like MLO Y4 cells simultaneously. Specifically, we observed increased osteoclast precursor cell densities and osteoclast differentiation towards nOCY. We also used this system to show an increased mechanoresponse of osteocytes when in co culture with osteoclasts. We envision broad applicability of the presented approach for microfluidic perfusion co culture of multiple cell types in the presence of fluid flow stimulation, and as a tool to investigate osteocyte mechanotransduction, as well as bone metastasis extravasation. This system could also be applied to any multi cell population cross talk studies that are typically performed using PPFCs (e.g. endothelial cells, smooth muscle cells, and fibroblasts). (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Middleton, K.; Al Dujaili, S.; Guenther, A.; You, L.] Univ Toronto, Inst Biomat & Biomed Engn, 164 Coll St, Toronto, ON M5S 3G9, Canada.
   [Mei, X.; Guenther, A.; You, L.] Univ Toronto, Dept Mech & Ind Engn, 5 Kings Coll Rd, Toronto, ON M5S 3G8, Canada.
C3 University of Toronto; University of Toronto
RP You, L (通讯作者)，Univ Toronto, Dept Mech & Ind Engn, 5 Kings Coll Rd, Toronto, ON M5S 3G8, Canada.
EM youlidan@mie.utoronto.ca
RI You, Lidan/HOC 7310 2023; Guenther, Axel/B 9013 2008
OI Guenther, Axel/0000 0002 0592 2261
FU Natural Sciences and Engineering Research Council (NSERC); NSERC CREATE
   Microfluidic Applications and Training in Cardiovascular Health; Toronto
   Musculoskeletal Centre; Barbara and Frank Milligan; Canadian Institutes
   of Health Research [282723]; Canada Foundation for Innovation; Ontario
   Research Fund
FX We would like to thank Junyi (Danny) Cen for performing the ELISA
   experiments presented in the supplement. We also acknowledge
   postgraduate scholarships provided by the Natural Sciences and
   Engineering Research Council (NSERC), the NSERC CREATE Microfluidic
   Applications and Training in Cardiovascular Health program, the Toronto
   Musculoskeletal Centre, and Barbara and Frank Milligan. Funding for this
   research was provided by the Canadian Institutes of Health Research
   (fund #282723). Microfluidic fabrication facilities were provided by the
   Centre for Microfluidic Systems in Chemistry and Biology at the
   University of Toronto that is funded by the Canada Foundation for
   Innovation and the Ontario Research Fund.
CR Al Dujaili SA, 2011, J CELL BIOCHEM, V112, P2412, DOI 10.1002/jcb.23164
   Amsden B, 1998, MACROMOLECULES, V31, P8382, DOI 10.1021/ma980765f
   Atkins GJ, 2011, J BONE MINER RES, V26, P1425, DOI 10.1002/jbmr.345
   Bacabac RG, 2005, J BIOMECH, V38, P159, DOI 10.1016/j.jbiomech.2004.03.020
   Bakker A, 2004, BIOCHEM BIOPH RES CO, V320, P1163, DOI 10.1016/j.bbrc.2004.06.056
   Beaton R, 2009, PHYSIOTHER CAN, V61, P141, DOI 10.3138/physio.61.3.141
   BISKOBING DM, 1995, J BONE MINER RES, V10, P1025
   Bonewald L. F., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P101
   Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224
   Booth R, 2012, LAB CHIP, V12, P1784, DOI 10.1039/c2lc40094d
   Chen MB, 2013, LAB CHIP, V13, P2591, DOI [10.1039/c3lc00051f, 10.1039/c31c00051f]
   Cheung WY, 2011, J ORTHOP RES, V29, P523, DOI 10.1002/jor.21283
   CLANCY RM, 1990, ANAL BIOCHEM, V191, P138, DOI 10.1016/0003 2697(90)90400 4
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Jeon JS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056910
   Jiang JX, 2007, FRONT BIOSCI LANDMRK, V12, P1450, DOI 10.2741/2159
   Kaji H, 1996, J BONE MINER RES, V11, P62
   Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014
   Kennedy OD, 2012, BONE, V50, P1115, DOI 10.1016/j.bone.2012.01.025
   Kitase Y, 2010, J BONE MINER RES, V25, P2381, DOI 10.1002/jbmr.168
   KONG SK, 1995, BIOCHEM EDUC, V23, P97, DOI 10.1016/0307 4412(95)00003 L
   Kou SZ, 2011, BIOCHEM BIOPH RES CO, V408, P350, DOI 10.1016/j.bbrc.2011.04.044
   Li J, 2012, J BIOMECH, V45, P247, DOI 10.1016/j.jbiomech.2011.10.037
   Lu XL, 2012, J BONE MINER RES, V27, P563, DOI 10.1002/jbmr.1474
   Miki Y, 2012, J STEROID BIOCHEM, V131, P68, DOI 10.1016/j.jsbmb.2011.12.004
   Nguyen J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053813
   Nikander R, 2010, BMC MED, V8, DOI 10.1186/1741 7015 8 47
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Pfeiffer S, 1998, AM J PHYS ANTHROPOL, V106, P219
   Price C, 2011, J BONE MINER RES, V26, P277, DOI 10.1002/jbmr.211
   Rochefort GY, 2014, THER ADV MUSCULOSKEL, V6, P79, DOI 10.1177/1759720X14523500
   Schaffler MB, 2012, CURR OSTEOPOROS REP, V10, P118, DOI 10.1007/s11914 012 0105 4
   Schneider P, 2010, BONE, V47, P848, DOI 10.1016/j.bone.2010.07.026
   Sellgren KL, 2015, BIOMICROFLUIDICS, V9, DOI 10.1063/1.4935594
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Song SH, 2010, ELECTROPHORESIS, V31, P2762, DOI 10.1002/elps.201000201
   Takeshita Y, 2014, J NEUROSCI METH, V232, P165, DOI 10.1016/j.jneumeth.2014.05.013
   Tan SD, 2006, J DENT RES, V85, P905, DOI 10.1177/154405910608501006
   Taylor AF, 2007, AM J PHYSIOL CELL PH, V292, pC545, DOI 10.1152/ajpcell.00611.2005
   van Oers RFM, 2008, BONE, V42, P250, DOI 10.1016/j.bone.2007.10.009
   Vatsa A, 2007, J BIOMECH, V40, pS89, DOI 10.1016/j.jbiomech.2007.02.015
   Wallace CS, 2010, AM J PHYSIOL HEART C, V299, pH338, DOI 10.1152/ajpheart.01029.2009
   Woo KM, 2002, EXP MOL MED, V34, P340, DOI 10.1038/emm.2002.48
   Wright HL, 2009, CURR REV MUSCULOSKE, V2, P56, DOI 10.1007/s12178 009 9046 7
   Xiong JH, 2012, J BONE MINER RES, V27, P499, DOI 10.1002/jbmr.1547
   Yoshida K, 2002, P NATL ACAD SCI USA, V99, P4580, DOI 10.1073/pnas.062053399
   You LD, 2004, ANAT REC PART A, V278A, P505, DOI 10.1002/ar.a.20050
   You LD, 2008, BONE, V42, P172, DOI 10.1016/j.bone.2007.09.047
   You LD, 2008, CELL MOL BIOENG, V1, P103, DOI 10.1007/s12195 008 0010 1
   Zhang JN, 2015, BONE, V79, P71, DOI 10.1016/j.bone.2015.05.017
   Zhang SQ, 2009, ARCH BIOCHEM BIOPHYS, V487, P49, DOI 10.1016/j.abb.2009.04.008
   Zhao S, 2002, J BONE MINER RES, V17, P2068, DOI 10.1359/jbmr.2002.17.11.2068
   Zheng Y, 2013, J BONE ONCOL, V2, P47, DOI 10.1016/j.jbo.2012.11.002
   Zhou JZ, 2016, ONCOGENE, V35, P5597, DOI 10.1038/onc.2016.101
NR 54
TC 59
Z9 70
U1 4
U2 75
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0021 9290
EI 1873 2380
J9 J BIOMECH
JI J. Biomech.
PD JUL 5
PY 2017
VL 59
BP 35
EP 42
DI 10.1016/j.jbiomech.2017.05.012
PG 8
WC Biophysics; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Engineering
GA FA9KB
UT WOS:000405763400005
PM 28552413
DA 2025 08 17
ER

PT J
AU Chen, RJ
   Feng, TJ
   Cheng, S
   Chen, M
   Li, Y
   Yu, ZH
   Xu, ZY
   Yin, PB
   Zhang, LC
   Tang, PF
AF Chen, Ruijing
   Feng, Taojin
   Cheng, Shi
   Chen, Ming
   Li, Yi
   Yu, Zihui
   Xu, Ziying
   Yin, Pengbin
   Zhang, Licheng
   Tang, Peifu
TI Evaluating the defect targeting effects and osteogenesis promoting
   capacity of exosomes from 2D and 3D cultured human adipose derived stem
   cells
SO NANO TODAY
LA English
DT Article
DE Exosomes; 3D culture; Bone targeting; Osteogenesis; Bone defect;
   Regeneration
ID OSTEOBLAST DIFFERENTIATION; EXTRACELLULAR VESICLES; BONE; EXPRESSION;
   PROLIFERATION; THERAPEUTICS; SPHEROIDS; THERAPIES; PROGRESS; HYDROGEL
AB Exosomes derived from stem cells show great therapeutic potential in bone defect repair. Systemic ad ministration of exosomes represents as a minimally invasive delivery approach; however, evaluation for the lesion targeting capacity and repair promotion efficacy lacks. In this study, exosomes produced by human adipose derived stem cells (hADSCs) are intravenously injected to calvarial defect mice. It is found that exosomes preferentially accumulate at bone and especially at the calvarial defect site. In addition, exosomes treatment promotes osteogenesis as indicated by more newly formed bone at the lesion site. Furthermore, the impact of three dimensional (3D) culture on hADSCs is evaluated by transcriptome sequencing and several pathways such as bone development, cartilage development are up regulated in 3D cultured hADSCs, suggesting an improved tissue repair capacity. Moreover, exosomes from 3D cultured hADSCs show distinctly superior bone targeting effects and bone repair capacity, as compared to those derived from 2D cultured hADSCs. Collectively, this study highlights the bone targeting and pro osteogenic effects of hADSCs derived exosomes, which could be further enhanced by 3D culture of the parental cells. Systemic injection of stem cell derived exosomes could serve as a simple and minimally invasive approach to fa cilitate bone defect repair. (c) 2023 Elsevier Ltd. All rights reserved.
C1 [Chen, Ruijing; Feng, Taojin; Chen, Ming; Li, Yi; Yin, Pengbin; Zhang, Licheng; Tang, Peifu] Chinese Peoples Liberat Army Gen Hosp, Dept Orthoped, Beijing 100853, Peoples R China.
   [Chen, Ruijing; Feng, Taojin; Chen, Ming; Li, Yi; Yin, Pengbin; Zhang, Licheng; Tang, Peifu] Natl Clin Res Ctr Orthoped Sports Med & Rehabil, Beijing 100853, Peoples R China.
   [Cheng, Shi] Harbin Med Univ, Affiliated Hosp 2, Dept Orthoped Surg, Harbin 150010, Peoples R China.
   [Yu, Zihui; Xu, Ziying] Capital Inst Pediat, Beijing 100020, Peoples R China.
C3 Chinese People's Liberation Army General Hospital; Harbin Medical
   University; Capital Institute of Pediatrics (CIP)
RP Yin, PB; Zhang, LC; Tang, PF (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Dept Orthoped, Beijing 100853, Peoples R China.
EM yinpengbin@gmail.com; zhanglcheng218@126.com; pftang301@126.com
RI Chen, Ming/B 4918 2008
FU National Natural Science Foundation of China [81972102, 81972115,
   82002330]; National Science Fund for Distinguished Young Scholars
   [2020 JQPY 003]; Young Elite Scientist Sponsorship Program by the China
   Association for Science and Technology [2020 JCJQ QT 033]
FX This work was supported by National Natural Science Foundation of China
   [Grant No. 81972102, 81972115 and 82002330]; The National Science Fund
   for Distinguished Young Scholars [Grant No. 2020 JQPY 003]; and Young
   Elite Scientist Sponsorship Program by the China Association for Science
   and Technology [Grant No. 2020 JCJQ QT 033]. The original elements used
   in the graphic abstract are from Servier Medical Art
   (http://smart.servier.com /) .
CR Amer MH, 2017, NPJ REGEN MED, V2, DOI 10.1038/s41536 017 0028 x
   Bajada S, 2007, J BONE JOINT SURG BR, V89B, P1382, DOI 10.1302/0301 620X.89B10.19103
   Baroli B, 2009, J PHARM SCI US, V98, P1317, DOI 10.1002/jps.21528
   Bartosh TJ, 2010, P NATL ACAD SCI USA, V107, P13724, DOI 10.1073/pnas.1008117107
   Bosse MJ, 2002, NEW ENGL J MED, V347, P1924, DOI 10.1056/NEJMoa012604
   Bou Ghannam S, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 87571 7
   Cao JY, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01719 2
   Chan YH, 2021, STEM CELL REV REP, V17, P1810, DOI 10.1007/s12015 021 10172 4
   CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798
   De Pieri A, 2021, NPJ REGEN MED, V6, DOI 10.1038/s41536 021 00133 3
   Di Pietro L, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 00511 3
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Dong YQ, 2022, HISTOL HISTOPATHOL, V37, P355, DOI 10.14670/HH 18 411
   EL Andaloussi S, 2013, NAT REV DRUG DISCOV, V12, P348, DOI 10.1038/nrd3978
   El Rashidy AA, 2017, ACTA BIOMATER, V62, P1, DOI 10.1016/j.actbio.2017.08.030
   EYRE DR, 1991, SEMIN ARTHRITIS RHEU, V21, P2, DOI 10.1016/0049 0172(91)90035 X
   Gangji V, 2011, BONE, V49, P1005, DOI 10.1016/j.bone.2011.07.032
   Gimble JM, 2003, CYTOTHERAPY, V5, P362, DOI 10.1080/14653240310003026
   Haraszti RA, 2018, MOL THER, V26, P2838, DOI 10.1016/j.ymthe.2018.09.015
   Hu SQ, 2019, ACS NANO, V13, P11273, DOI 10.1021/acsnano.9b04384
   Huang CC, 2019, J PINEAL RES, V66, DOI 10.1111/jpi.12560
   Jensen C, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00033
   Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977
   Ke YB, 2022, BIOSCIENCE REP, V42, DOI 10.1042/BSR20211895
   Li Y, 2015, CELL TISSUE RES, V360, P297, DOI 10.1007/s00441 014 2055 x
   Li YM, 2021, TRANSL LUNG CANCER R, V10, P1841, DOI 10.21037/tlcr 21 299
   Liu CY, 2019, THERANOSTICS, V9, P1015, DOI 10.7150/thno.30853
   Liu K, 2019, J CELL PHYSIOL, V234, P11380, DOI 10.1002/jcp.27795
   Liu X., 2014, TISSUE ENG PT A
   Liu Z, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420 019 0159 5
   Luo JH, 2018, EXP THER MED, V16, P4824, DOI 10.3892/etm.2018.6806
   MacKenzie EJ, 2005, J BONE JOINT SURG AM, V87A, P1801, DOI 10.2106/JBJS.E.00032
   Man K, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12118
   Mao AS, 2015, P NATL ACAD SCI USA, V112, P14452, DOI 10.1073/pnas.1508520112
   Mauffrey C, 2015, J AM ACAD ORTHOP SUR, V23, P143, DOI 10.5435/JAAOS D 14 00018
   Mazini L., 2020, INT J MOL SCI, V21
   Mi YY, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.737812
   Murphy DE, 2019, EXP MOL MED, V51, DOI 10.1038/s12276 019 0223 5
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Ni JS, 2018, CELL PHYSIOL BIOCHEM, V48, P1710, DOI 10.1159/000492298
   Nojima H, 2016, J HEPATOL, V64, P60, DOI 10.1016/j.jhep.2015.07.030
   Perez JR, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00105
   Qiao L, 2020, THERANOSTICS, V10, P3474, DOI 10.7150/thno.39434
   Rashid F, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071375
   Rutkowska K, 2018, PLACENTA, V70, P50, DOI 10.1016/j.placenta.2018.09.004
   Salhotra A, 2020, NAT REV MOL CELL BIO, V21, P696, DOI 10.1038/s41580 020 00279 w
   Shi ZY, 2021, THERANOSTICS, V11, P3376, DOI 10.7150/thno.52190
   Song LQ, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 47444 6
   Song YY, 2019, THERANOSTICS, V9, P2910, DOI 10.7150/thno.30879
   Sun WR, 2019, MOL THER NUCL ACIDS, V16, P519, DOI 10.1016/j.omtn.2019.04.006
   Tang WM, 2022, ONCOGENE, V41, P4823, DOI 10.1038/s41388 022 02451 2
   Tao SC, 2021, BIOACT MATER, V6, P4455, DOI 10.1016/j.bioactmat.2021.04.031
   Tran PHL, 2020, ADV MATER, V32, DOI 10.1002/adma.201904040
   Tu YH, 2022, BIOENGINEERED, V13, P3044, DOI 10.1080/21655979.2021.2017577
   Uy HL, 1997, CANCER RES, V57, P3194
   Wang WT, 2022, MATER TODAY BIO, V16, DOI 10.1016/j.mtbio.2022.100355
   Watanabe Y, 2021, CLIN MOL HEPATOL, V27, P70, DOI 10.3350/cmh.2020.0194
   Webb RL, 2018, TRANSL STROKE RES, V9, P530, DOI 10.1007/s12975 017 0599 2
   Wei DX, 2018, ADV MATER, V30, DOI 10.1002/adma.201802273
   Xing RW, 2019, J NANOSCI NANOTECHNO, V19, P7526, DOI 10.1166/jnn.2019.16413
   Xu CJ, 2022, ECOTOX ENVIRON SAFE, V233, DOI 10.1016/j.ecoenv.2022.113302
   Xu MQ, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.586130
   Xu QX, 2020, AGING US, V12, P24957, DOI 10.18632/aging.103464
   Yang HD, 2019, HEPATOLOGY, V70, P1262, DOI 10.1002/hep.30657
   You B, 2022, CANCER LETT, V531, P14, DOI 10.1016/j.canlet.2022.01.019
   Yuan X., 2022, MATER CORROS, V11
   Zaborowski MP, 2015, BIOSCIENCE, V65, P783, DOI 10.1093/biosci/biv084
   Zeng QC, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658 019 0136 2
   Zhang B, 2018, CELL PHYSIOL BIOCHEM, V45, P2506, DOI 10.1159/000488269
   Zhang JX, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/8810813
   Zhang M, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1815 7
   Zhang MM, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.920378
   Zhang Y, 2020, INT J NANOMED, V15, P6917, DOI 10.2147/IJN.S264498
   Zhang ZL, 2021, J BIOENERG BIOMEMBR, V53, P561, DOI 10.1007/s10863 021 09917 0
   Zhao LM, 2020, ONCOTARGETS THER, V13, P6063, DOI 10.2147/OTT.S247900
   Zheng R, 2022, ADV SCI, V9, DOI 10.1002/advs.202102460
   Zheng Y, 2020, J CELL COMMUN SIGNAL, V14, P389, DOI 10.1007/s12079 020 00546 7
   Zhou PP, 2017, BIOCHEM BIOPH RES CO, V491, P323, DOI 10.1016/j.bbrc.2017.07.102
   Zhou Y, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 02980 3
NR 79
TC 9
Z9 10
U1 7
U2 49
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1748 0132
EI 1878 044X
J9 NANO TODAY
JI Nano Today
PD APR
PY 2023
VL 49
AR 101789
DI 10.1016/j.nantod.2023.101789
EA FEB 2023
PG 13
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA D0LN6
UT WOS:000965729300001
DA 2025 08 17
ER

PT J
AU Adachi, M
   Miyoshi, T
   Shiraishi, N
   Shimada, H
   Sakaguchi, S
   Tomita, K
   Kitamura, K
AF Adachi, M.
   Miyoshi, T.
   Shiraishi, N.
   Shimada, H.
   Sakaguchi, S.
   Tomita, K.
   Kitamura, K.
TI A study of maintenance therapy after intravenous maxacalcitol for
   secondary hyperparathyroidism
SO CLINICAL NEPHROLOGY
LA English
DT Article
DE secondary hyperparathyroidism; maxacalcitol; maintenance therapy;
   alfacalcidol
ID CHRONIC HEMODIALYSIS PATIENTS; PARATHYROID HORMONE; DIALYSIS PATIENTS;
   UREMIC PATIENTS; KIDNEY DISEASE; RENAL FAILURE; BONE DISEASE;
   CALCITRIOL; CALCIUM; TRIAL
AB Aim: Intravenous vitamin D therapy is an established treatment for secondary hyperparathyroidism (SHPT). However, no protocols have been established for maintenance therapy with intravenous or oral vitamin D after control of intact parathyroid hormone (iPTH) within the target range. Methods: Step I. For patients with SHPT (200 <= iPTH 500 <= pg/ml), a dose of 2.5 mu g maxacalcitol (OCT) was administered intravenously three times a week with oral sevelamer hydrochloride; the dose was increased to a 10 mu g maximum three times a week to control iPTH to < 150 pg/ml. Step II. When iPTH reached the target level, patients were assigned to Group A (oral alfacalcidol 1.0 mu g/d) or B (oral alfacalcidol 0.25 mu g/d). Serum iPTH, calcium, and inorganic phosphorus were measured each month for 6 months. Maintenance rates for the target iPTH levels were evaluated, < 150 pg/ml at Step I and < 200 pg/ml at Step II. Results: iPTH decreased to < 150 pg/ml by OCT in 24 of 35 patients (68.6%). During the 24 week observation period, iPTH was controlled for 83.3% patients in Group A vs. 36.4% for Group B (p < 0.05). No dropouts due to hypercalcemia or hyperphosphatemia occurred. Conclusion: OCT dose titration was effective for SHPT. A higher daily dose of oral alfacalcidol (1.0 mu g) appears to be more effective than a lower dose (0.25 mu g) as maintenance therapy after iPTH control.
C1 [Adachi, M.; Miyoshi, T.; Shiraishi, N.; Tomita, K.; Kitamura, K.] Kumamoto Univ, Grad Sch Med Sci, Dept Nephrol, Kumamoto 8608556, Japan.
   [Shimada, H.] Josuikai Shimada Hosp, Kumamoto, Japan.
   [Sakaguchi, S.] Gyokuwakai Midorigaoka Clin, Arao, Japan.
C3 Kumamoto University
RP Adachi, M (通讯作者)，Kumamoto Univ, Grad Sch Med Sci, Dept Nephrol, 1 1 1 Honjo, Kumamoto 8608556, Japan.
EM m adachi@gpo.kumamoto u.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology in Japan
   [20590977, 19590956, 19590958, 2039023]; Grants in Aid for Scientific
   Research [21591056, 20590977, 21591035, 19590958, 19590956] Funding
   Source: KAKEN
FX This work was supported by Grants in Aid for Scientific Research from
   the Ministry of Education, Culture, Sports, Science and Technology in
   Japan (20590977 to M. A., 19590956 to K. K., 19590958 to T. M., and
   2039023 to K. T.).
CR Akiba T, 1998, AM J KIDNEY DIS, V32, P238, DOI 10.1053/ajkd.1998.v32.pm9708607
   Akizawa T, 2004, THER APHER DIAL, V8, P480, DOI 10.1111/j.1774 9987.2004.00191.x
   Andress DL, 2001, AM J KIDNEY DIS, V38, pS41, DOI 10.1053/ajkd.2001.28108
   Block GA, 2000, AM J KIDNEY DIS, V35, P1226, DOI 10.1016/S0272 6386(00)70064 3
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   FUKUDA N, 1993, J CLIN INVEST, V92, P1436, DOI 10.1172/JCI116720
   Gogusev J, 1997, KIDNEY INT, V51, P328, DOI 10.1038/ki.1997.41
   Gu Y, 2005, RENAL FAILURE, V27, P205, DOI 10.1081/JDI 200049538
   Hayashi M, 2004, NEPHROL DIAL TRANSPL, V19, P2067, DOI 10.1093/ndt/gfh329
   HENDERSON RG, 1974, LANCET, V1, P379
   HERRMANN P, 1994, NEPHRON, V67, P48, DOI 10.1159/000187887
   Indridason OS, 2000, KIDNEY INT, V57, P282, DOI 10.1046/j.1523 1755.2000.00819.x
   Kazama JJ, 2007, THER APHER DIAL, V11, pS44, DOI 10.1111/j.1744 9987.2007.00516.x
   Koshikawa S, 2002, NEPHRON, V90, P413, DOI 10.1159/000054729
   Levine BS, 1996, J AM SOC NEPHROL, V7, P488
   Mochizuki T, 2007, CLIN NEPHROL, V67, P12
   Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
   MURAMOTO H, 1991, NEPHRON, V58, P288, DOI 10.1159/000186438
   Nakai S, 2008, THER APHER DIAL, V12, P49, DOI 10.1111/j.1744 9987.2007.00540.x
   *NAT KIDN FDN, 2007, AM J KIDNEY DIS    S, V42, pS1
   Noordzij M, 2005, AM J KIDNEY DIS, V46, P925, DOI 10.1053/j.ajkd.2005.08.013
   Oyama Yuko, 2005, Clin Exp Nephrol, V9, P142, DOI 10.1007/s10157 005 0342 2
   Rodriguez Benot A, 2005, AM J KIDNEY DIS, V46, P68, DOI 10.1053/j.ajkd.2005.04.006
   SHERRARD DJ, 1993, KIDNEY INT, V43, P436, DOI 10.1038/ki.1993.64
   SHINZATO T, 1994, NEPHRON, V67, P280, DOI 10.1159/000187980
   SLATOPOLSKY E, 1984, J CLIN INVEST, V74, P2136, DOI 10.1172/JCI111639
   Slinin Y, 2005, J AM SOC NEPHROL, V16, P1788, DOI 10.1681/ASN.2004040275
   Tan AU, 1997, KIDNEY INT, V51, P317, DOI 10.1038/ki.1997.39
   Tarrass F, 2006, CLIN NEPHROL, V65, P415
   Tominaga Y, 2007, THER APHER DIAL, V11, P266, DOI 10.1111/j.1744 9987.2007.00489.x
   VANDERMERWE WM, 1990, NEPHROL DIAL TRANSPL, V5, P874, DOI 10.1093/ndt/5.10.874
   WARD MK, 1978, LANCET, V1, P841
NR 32
TC 3
Z9 3
U1 0
U2 3
PU DUSTRI VERLAG DR KARL FEISTLE
PI DEISENHOFEN MUENCHEN
PA BAHNHOFSTRASSE 9 POSTFACH 49, D 82032 DEISENHOFEN MUENCHEN, GERMANY
SN 0301 0430
J9 CLIN NEPHROL
JI Clin. Nephrol.
PD OCT
PY 2011
VL 76
IS 4
BP 266
EP 272
DI 10.5414/CN106595
PG 7
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 840YB
UT WOS:000296476900002
PM 21955861
DA 2025 08 17
ER

PT J
AU Kaplan, M
   Kalajzic, Z
   Choi, T
   Maleeh, I
   Ricupero, CL
   Skelton, MN
   Daily, ML
   Chen, J
   Wadhwa, S
AF Kaplan, Michele
   Kalajzic, Zana
   Choi, Thomas
   Maleeh, Imad
   Ricupero, Christopher L.
   Skelton, Michelle N.
   Daily, Madeleine L.
   Chen, Jing
   Wadhwa, Sunil
TI The role of inhibition of osteocyte apoptosis in mediating orthodontic
   tooth movement and periodontal remodeling: a pilot study
SO PROGRESS IN ORTHODONTICS
LA English
DT Article
DE Orthodontic tooth movement; Osteocyte apoptosis; Bisphosphonate
ID DIFFERENT FORCE MAGNITUDES; MOLECULAR MECHANISMS; BONE RESORPTION;
   EXPRESSION; LIGAMENT; PREVENTS; TEETH
AB Background Orthodontic tooth movement (OTM) has been shown to induce osteocyte apoptosis in alveolar bone shortly after force application. However, how osteocyte apoptosis affects orthodontic tooth movement is unknown. The goal of this study was to assess the effect of inhibition of osteocyte apoptosis on osteoclastogenesis, changes in the alveolar bone density, and the magnitude of OTM using a bisphosphonate analog (IG9402), a drug that affects osteocyte and osteoblast apoptosis but does not affect osteoclasts. Material and methods Two sets of experiments were performed. Experiment 1 was used to specifically evaluate the effect of IG9402 on osteocyte apoptosis in the alveolar bone during 24 h of OTM. For this experiment, twelve mice were divided into two groups: group 1, saline administration + OTM24 h (n=6), and group 2, IG9402 administration + OTM24 h (n=6). The contralateral unloaded sides served as the control. The goal of experiment 2 was to evaluate the role of osteocyte apoptosis on OTM magnitude and osteoclastogenesis 10 days after OTM. Twenty mice were divided into 4 groups: group 1, saline administration without OTM (n=5); group 2, IG9402 administration without OTM (n=5); group 3, saline + OTM10 day (n=6); and group 4, IG9402 + OTM10 day (n=4). For both experiments, tooth movement was achieved using Ultra Light (25g) Sentalloy Closed Coil Springs attached between the first maxillary molar and the central incisor. Linear measurements of tooth movement and alveolar bone density (BVF) were assessed by MicroCT analysis. Cell death (or apoptosis) was assessed by terminal dUTP nick end labeling (TUNEL) assay, while osteoclast and macrophage formation were assessed by tartrate resistant acid phosphatase (TRAP) staining and F4/80+ immunostaining. Results We found that IG9402 significantly blocked osteocyte apoptosis in alveolar bone (AB) at 24 h of OTM. At 10 days, IG9402 prevented OTM induced loss of alveolar bone density and changed the morphology and quality of osteoclasts and macrophages, but did not significantly affect the amount of tooth movement. Conclusion Our study demonstrates that osteocyte apoptosis may play a significant role in osteoclast and macrophage formation during OTM, but does not seem to play a role in the magnitude of orthodontic tooth movement.
C1 [Kaplan, Michele; Choi, Thomas; Maleeh, Imad; Ricupero, Christopher L.; Skelton, Michelle N.; Daily, Madeleine L.; Chen, Jing; Wadhwa, Sunil] Columbia Univ, Coll Dent Med, Div Orthodont, New York, NY 10027 USA.
   [Kalajzic, Zana] UConn Hlth, Div Oral Med, Dept Oral Hlth & Diagnost Sci, Farmington, CT USA.
C3 Columbia University
RP Kaplan, M (通讯作者)，Columbia Univ, Coll Dent Med, Div Orthodont, New York, NY 10027 USA.
EM michelekaplan22@gmail.com
CR Basso N, 2006, BONE, V39, P807, DOI 10.1016/j.bone.2006.04.014
   Bister D, 2013, EUR J ORTHODONT, V35, P160, DOI 10.1093/ejo/cjs007
   Bumann EE, 2017, ORTHOD CRANIOFAC RES, V20, P125, DOI 10.1111/ocr.12176
   Celebi AA, 2013, ANGLE ORTHOD, V83, P70, DOI 10.2319/012912 78.1
   Chang JH, 2020, EUR J ORTHODONT, V42, P317, DOI 10.1093/ejo/cjz027
   Chen H, 2015, MED MOL MORPHOL, V48, P61, DOI 10.1007/s00795 015 0099 y
   Dutra EH, 2016, CURR OSTEOPOROS REP, V14, P280, DOI 10.1007/s11914 016 0328 x
   Fan LX, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.32
   Garlet TP, 2007, EUR J ORAL SCI, V115, P355, DOI 10.1111/j.1600 0722.2007.00469.x
   Hemmatian H, 2017, CURR OSTEOPOROS REP, V15, P401, DOI 10.1007/s11914 017 0402 z
   Henneman S, 2008, EUR J ORTHODONT, V30, P299, DOI 10.1093/ejo/cjn020
   Kalajzic Z, 2014, ANGLE ORTHOD, V84, P297, DOI 10.2319/032213 234.1
   Kassem HE, 2017, EUR J ORAL SCI, V125, P361, DOI 10.1111/eos.12366
   Kennedy OD, 2014, BONE, V64, P132, DOI 10.1016/j.bone.2014.03.049
   Komori T, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122045
   Komori Toshihisa, 2014, J Bone Metab, V21, P55, DOI 10.11005/jbm.2014.21.1.55
   Krishnan V., 2006, AM J ORTHOD DENTOFAC, V129, p469., DOI [10.1016/j.ajodo.2005.10.007, DOI 10.1016/J.AJODO.2005.10.007]
   LANYON LE, 1987, J BIOMECH, V20, P1083, DOI 10.1016/0021 9290(87)90026 1
   Matsumoto T, 2013, J DENT RES, V92, P340, DOI 10.1177/0022034513476037
   Maycas M, 2017, HISTOL HISTOPATHOL, V32, P751, DOI 10.14670/HH 11 858
   McManus A, 2014, ORTHOD CRANIOFAC RES, V17, P239, DOI 10.1111/ocr.12049
   Milne TJ, 2009, EUR J ORTHODONT, V31, P221, DOI 10.1093/ejo/cjp032
   Moin S, 2014, ANGLE ORTHOD, V84, P1086, DOI 10.2319/110713 813.1
   Murphy CA, 2014, AM J ORTHOD DENTOFAC, V146, P55, DOI 10.1016/j.ajodo.2014.03.024
   Murshid SA, 2017, ARCH ORAL BIOL, V73, P25, DOI 10.1016/j.archoralbio.2016.09.001
   Nelson PA, 1997, AM J ORTHOD DENTOFAC, V111, P328, DOI 10.1016/S0889 5406(97)70192 6
   Olson C, 2012, ORTHOD CRANIOFAC RES, V15, P52, DOI 10.1111/j.1601 6343.2011.01536.x
   Plotkin LI, 2011, BONE, V49, P122, DOI 10.1016/j.bone.2010.08.011
   Plotkin LI, 2015, J BIOL CHEM, V290, P18934, DOI 10.1074/jbc.M115.642090
   Plotkin LI, 2014, CURR OSTEOPOROS REP, V12, P121, DOI 10.1007/s11914 014 0194 3
   Roelofs AJ, 2010, CURR PHARM DESIGN, V16, P2950
   Shoji Matsunaga A, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 09326 7
   Uda Y, 2017, CURR OSTEOPOROS REP, V15, P318, DOI 10.1007/s11914 017 0373 0
   Verna C, 2004, EUR J ORTHODONT, V26, P459, DOI 10.1093/ejo/26.5.459
   Will LA, 2016, FRONT ORAL BIOL, V18, P46, DOI 10.1159/000351899
   Zhong W, 2008, ORAL DIS, V14, P270, DOI 10.1111/j.1601 0825.2007.01375.x
NR 36
TC 3
Z9 3
U1 1
U2 8
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2196 1042
J9 PROG ORTHOD
JI Prog. Orthod.
PD JUL 26
PY 2021
VL 22
IS 1
AR 21
DI 10.1186/s40510 021 00366 4
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA TP6IT
UT WOS:000677701900001
PM 34308514
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Bauer, K
   Hauswirth, A
   Gleixner, KV
   Greiner, G
   Thaler, J
   Bettelheim, P
   Filik, Y
   Koller, E
   Hoermann, G
   Staber, PB
   Sperr, WR
   Keil, F
   Valent, P
AF Bauer, Karin
   Hauswirth, Alexander
   Gleixner, Karoline V.
   Greiner, Georg
   Thaler, Johannes
   Bettelheim, Peter
   Filik, Yueksel
   Koller, Elisabeth
   Hoermann, Gregor
   Staber, Philipp B.
   Sperr, Wolfgang R.
   Keil, Felix
   Valent, Peter
TI BRD4 degraders may effectively counteract therapeutic resistance of
   leukemic stem cells in AML and ALL
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Article
ID ACUTE MYELOID LEUKEMIA; BONE MARROW MICROENVIRONMENT; C MYC; INITIATING
   CELLS; PROGENITOR CELLS; INHIBITION; TARGET; HIERARCHY
AB Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are life threatening hematopoietic malignancies characterized by clonal expansion of leukemic blasts in the bone marrow and peripheral blood. The epigenetic reader BRD4 and its downstream effector MYC have recently been identified as potential drug targets in human AML and ALL. We compared anti leukemic efficacies of the small molecule BET inhibitor JQ1 and the recently developed BRD4 degraders dBET1 and dBET6 in AML and ALL cells. JQ1, dBET1, and dBET6 were found to suppress growth and viability in all AML and ALL cell lines examined as well as in primary patient derived AML and ALL cells, including CD34(+)/CD38( ) and CD34(+)/CD38(+) leukemic stem and progenitor cells, independent of the type (variant) of leukemia or molecular driver expressed in leukemic cells. Moreover, we found that dBET6 overcomes osteoblast induced drug resistance in AML and ALL cells, regardless of the type of leukemia or the drug applied. Most promising cooperative or even synergistic drug combination effects were seen with dBET6 and the FLT3 ITD blocker gilteritinib in FLT3 ITD mutated AML cells, and with dBET6 and the multi kinase blocker ponatinib in BCR::ABL1+ ALL cells. Finally, all BRD4 targeting drugs suppressed interferon gamma  and tumor necrosis factor alpha induced expression of the resistance related checkpoint antigen PD L1 in AML and ALL cells, including LSC. In all assays examined, the BRD4 degrader dBET6 was a superior anti leukemic drug compared with dBET1 and JQ1. Together, BRD4 degraders may provide enhanced inhibition of multiple mechanisms of therapy resistance in AML and ALL.
C1 [Bauer, Karin; Hauswirth, Alexander; Gleixner, Karoline V.; Greiner, Georg; Filik, Yueksel; Hoermann, Gregor; Staber, Philipp B.; Sperr, Wolfgang R.; Keil, Felix; Valent, Peter] Med Univ Vienna, Ludwig Boltzmann Inst Hematol & Oncol, Waehringer Guertel 18 20, A 1090 Vienna, Austria.
   [Bauer, Karin; Hauswirth, Alexander; Gleixner, Karoline V.; Thaler, Johannes; Filik, Yueksel; Staber, Philipp B.; Sperr, Wolfgang R.; Valent, Peter] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Waehringer Guertel 18 20, A 1090 Vienna, Austria.
   [Greiner, Georg] Med Diagnost Labs, Ihr Lab, Vienna, Austria.
   [Bettelheim, Peter] Lab Europaplatz, Linz, Austria.
   [Koller, Elisabeth; Keil, Felix] Hanusch Hosp Vienna, Med Dept Hematol & Oncol 3, Vienna, Austria.
   [Hoermann, Gregor] MLL Munich Leukemia Lab, Munich, Germany.
C3 Ludwig Boltzmann Institute; Medical University of Vienna; Medical
   University of Vienna; WGKK   Hanusch Hospital; MLL Munich Leukemia
   Laboratory
RP Valent, P (通讯作者)，Med Univ Vienna, Ludwig Boltzmann Inst Hematol & Oncol, Waehringer Guertel 18 20, A 1090 Vienna, Austria.; Valent, P (通讯作者)，Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Waehringer Guertel 18 20, A 1090 Vienna, Austria.
EM peter.valent@meduniwien.ac.at
RI Hoermann, Gregor/B 8832 2016; Staber, Philipp/ADK 1536 2022
FU Austrian Science Fund (FWF); Medical University of Vienna; 
   [TRANSCAN 2];  [ERANET PLL I 4156B];  [EuroTCLym I 4154B]
FX We are grateful to our patients for donating samples and clinical data
   for this study. P.B.S. was supported by the Austrian Science Fund (FWF),
   TRANSCAN 2 grant ERANET PLL I 4156B, and TRANSCAN 2 grant EuroTCLym I
   4154B. This study was supported by a stem cell grant of the Medical
   University of Vienna.
CR Agarwal P, 2015, ADV CANCER RES, V127, P227, DOI 10.1016/bs.acr.2015.04.007
   Bair SM, 2020, CANCER AM CANCER SOC, V126, P1837, DOI 10.1002/cncr.32659
   Barrett AJ, 2020, BRIT J HAEMATOL, V188, P147, DOI 10.1111/bjh.16310
   Blatt K, 2018, NEOPLASIA, V20, P632, DOI 10.1016/j.neo.2018.04.004
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797 730
   Davis K, 2023, SEMIN DIAGN PATHOL, V40, P202, DOI 10.1053/j.semdp.2023.04.003
   Döhner H, 2022, BLOOD, V140, P1345, DOI 10.1182/blood.2022016867
   Fedorov K, 2023, CANCERS, V15, DOI 10.3390/cancers15082312
   Follini E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20123021
   Fong CY, 2015, NATURE, V525, P538, DOI 10.1038/nature14888
   Herrmann H, 2020, BLOOD ADV, V4, P5118, DOI 10.1182/bloodadvances.2020001742
   Herrmann H, 2012, ONCOTARGET, V3, P1588, DOI 10.18632/oncotarget.733
   Hope KJ, 2004, NAT IMMUNOL, V5, P738, DOI 10.1038/ni1080
   Kayser S, 2023, HAEMATOLOGICA, V108, P308, DOI 10.3324/haematol.2022.280801
   Khaldoyanidi SK, 2022, CRIT REV ONCOL HEMAT, V175, DOI 10.1016/j.critrevonc.2022.103710
   Khoury JD, 2022, LEUKEMIA, V36, P1703, DOI 10.1038/s41375 022 01613 1
   Kong Y, 2008, LEUKEMIA, V22, P1207, DOI 10.1038/leu.2008.83
   Ladikou EE, 2020, CURR ONCOL REP, V22, DOI 10.1007/s11912 020 0885 0
   LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0
   Löwenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407
   Malard F, 2020, LANCET, V395, P1146, DOI 10.1016/S0140 6736(19)33018 1
   Ott CJ, 2012, BLOOD, V120, P2843, DOI 10.1182/blood 2012 02 413021
   Pabon CM, 2022, EXPERT OPIN THER TAR, V26, P547, DOI 10.1080/14728222.2022.2083957
   Peter B, 2022, AM J HEMATOL, V97, P1215, DOI 10.1002/ajh.26650
   Phelan KW, 2018, CURR HEMATOL MALIG R, V13, P289, DOI 10.1007/s11899 018 0457 7
   Piya S, 2019, J CLIN INVEST, V129, P1878, DOI 10.1172/JCI120654
   Rathert P, 2015, NATURE, V525, P543, DOI 10.1038/nature14898
   Roderick JE, 2014, BLOOD, V123, P1040, DOI 10.1182/blood 2013 08 522698
   Roskoski R Jr, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104725
   Shafat MS, 2017, BLOOD REV, V31, P277, DOI 10.1016/j.blre.2017.03.004
   Shimony S, 2023, AM J HEMATOL, V98, P502, DOI 10.1002/ajh.26822
   Short NJ, 2020, CANCER DISCOV, V10, P506, DOI 10.1158/2159 8290.CD 19 1011
   Stelmach P, 2023, HAEMATOLOGICA, V108, P353, DOI 10.3324/haematol.2022.280800
   Sun YL, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.621093
   Tabe Y, 2015, CURR HEMATOL MALIG R, V10, P96, DOI 10.1007/s11899 015 0253 6
   Taussig DC, 2008, BLOOD, V112, P568, DOI 10.1182/blood 2007 10 118331
   Tsumura A, 2023, FRONT ONCOL, V13, DOI 10.3389/fonc.2023.1288172
   Vago L, 2020, J CLIN INVEST, V130, P1552, DOI 10.1172/JCI129204
   Valent P, 2011, CURR CANCER DRUG TAR, V11, P56, DOI 10.2174/156800911793743655
   Valent P, 2020, STEM CELL TRANSL MED, V9, P1331, DOI 10.1002/sctm.20 0147
   Valent P, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174233
   van Gils N, 2021, HEMASPHERE, V5, DOI 10.1097/HS9.0000000000000610
   Vetrie D, 2020, NAT REV CANCER, V20, P158, DOI 10.1038/s41568 019 0230 9
   Walter RB, 2020, BLOOD REV, V44, DOI 10.1016/j.blre.2020.100679
   Wang AD, 2018, HEMATOLOGY, V23, P729, DOI 10.1080/10245332.2018.1486064
   Winter GE, 2017, MOL CELL, V67, P5, DOI 10.1016/j.molcel.2017.06.004
   Winter GE, 2015, SCIENCE, V348, P1376, DOI 10.1126/science.aab1433
   Xia B, 2015, LEUKEMIA RES, V39, P92, DOI 10.1016/j.leukres.2014.11.004
   Zhang KL, 2022, PATHOL ONCOL RES, V28, DOI 10.3389/pore.2022.1610447
   Zhou Jianbiao, 2014, World J Stem Cells, V6, P473, DOI 10.4252/wjsc.v6.i4.473
   Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334
NR 51
TC 10
Z9 11
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0361 8609
EI 1096 8652
J9 AM J HEMATOL
JI Am. J. Hematol.
PD SEP
PY 2024
VL 99
IS 9
BP 1721
EP 1731
DI 10.1002/ajh.27385
EA JUN 2024
PG 11
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA A6X8S
UT WOS:001236554500001
PM 38822666
OA hybrid
DA 2025 08 17
ER

PT J
AU Cui, Q
   Shibata, H
   Oda, A
   Amou, H
   Nakano, A
   Yata, K
   Hiasa, M
   Watanabe, K
   Nakamura, S
   Miki, H
   Harada, T
   Fujii, S
   Kagawa, K
   Takeuchi, K
   Ozaki, S
   Matsumoto, T
   Abe, M
AF Cui, Qu
   Shibata, Hironobu
   Oda, Asuka
   Amou, Hiroe
   Nakano, Ayako
   Yata, Kenichiro
   Hiasa, Masahiro
   Watanabe, Keiichiro
   Nakamura, Shingen
   Miki, Hirokazu
   Harada, Takeshi
   Fujii, Shiro
   Kagawa, Kumiko
   Takeuchi, Kyoko
   Ozaki, Shuji
   Matsumoto, Toshio
   Abe, Masahiro
TI Targeting myeloma osteoclast interaction with Vγ9Vδ2 T cells
SO INTERNATIONAL JOURNAL OF HEMATOLOGY
LA English
DT Article
DE Multiple myeloma; Osteoclast; V gamma 9V delta 2 T cell; Zoledronic
   acid; Immunotherapy
ID MACROPHAGE INFLAMMATORY PROTEIN 1 ALPHA; PROTEIN (MIP) 1 ALPHA;
   NONPEPTIDE ANTIGENS; VICIOUS CYCLE; BONE; IMMUNOTHERAPY; RECOGNITION;
   MIP 1 BETA; CYTOTOXICITY; ACTIVATION
AB Multiple myeloma (MM) cells stimulate osteoclastogenesis, and osteoclasts (OCs) in turn enhance MM growth and drug resistance, resulting in a vicious cycle. V gamma 9V delta 2 T cells exert potent anti tumor effects, making T cell based immunotherapies using these cells attractive candidates for currently incurable malignancies, such as MM. However, the impact of such treatments on the MM OC interaction is largely unknown. We demonstrate here that V gamma 9V delta 2 T cells expanded by zoledronic acid and IL 2 exerted potent cytotoxic effects on both MM cells and OCs, even in coculture settings, but showed no such effect on bone marrow stromal cells. V gamma 9V delta 2 T cells marginally affected colony formation from normal hematopoietic progenitors, and furthermore migrated toward osteopontin and MIP 1 alpha, factors produced by the MM OC interaction. These results suggest that V gamma 9V delta 2 T cells expanded by zoledronic acid and IL 2 are able to migrate to MM bone lesions and preferentially target OCs as well as MM cells, thereby inhibiting both tumor expansion and bone destruction.
C1 [Cui, Qu; Shibata, Hironobu; Oda, Asuka; Amou, Hiroe; Nakano, Ayako; Yata, Kenichiro; Hiasa, Masahiro; Watanabe, Keiichiro; Nakamura, Shingen; Miki, Hirokazu; Harada, Takeshi; Fujii, Shiro; Kagawa, Kumiko; Takeuchi, Kyoko; Ozaki, Shuji; Matsumoto, Toshio; Abe, Masahiro] Univ Tokushima, Grad Sch Med, Dept Med & Bioregulatory Sci, Tokushima 7708503, Japan.
   [Shibata, Hironobu; Ozaki, Shuji] Tokushima Prefectural Cent Hosp, Div Internal Med, Tokushima, Japan.
   [Hiasa, Masahiro] Univ Tokushima, Grad Sch Oral Sci, Dept Biomat & Bioengn, Tokushima 7708503, Japan.
   [Watanabe, Keiichiro] Univ Tokushima, Grad Sch Oral Sci, Dept Orthodont & Dentofacial Orthoped, Tokushima 7708503, Japan.
C3 Tokushima University; Tokushima University; Tokushima University
RP Abe, M (通讯作者)，Univ Tokushima, Grad Sch Med, Dept Med & Bioregulatory Sci, 3 18 15 Kuramoto, Tokushima 7708503, Japan.
EM masabe@clin.med.tokushima u.ac.jp
RI Nakamura, Shingen/GPX 5438 2022; Abe, Masahiro/AAJ 3032 2021; 日浅,
   雅博/S 1537 2019
OI HIASA, MASAHIRO/0000 0002 4830 6274
FU Ministry of Health, Labor and Welfare of Japan; Grants in Aid for
   Scientific Research [23659946, 23591390] Funding Source: KAKEN
FX This work was supported in part by Grants in aid for Scientific Research
   (A) to Toshio Matsumoto, and a Grant in aid for Cancer Research (21 8)
   to Masahiro Abe from the Ministry of Health, Labor and Welfare of Japan.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Abe M, 2006, LEUKEMIA, V20, P1313, DOI 10.1038/sj.leu.2404228
   Abe M, 2004, BLOOD, V104, P2484, DOI 10.1182/blood 2003 11 3839
   Abe M, 2002, BLOOD, V100, P2195, DOI 10.1182/blood.V100.6.2195.h81802002195_2195_2202
   Abe M, 2009, J BONE MINER METAB, V27, P16, DOI 10.1007/s00774 008 0012 z
   Abe Y, 2009, EXP HEMATOL, V37, P956, DOI 10.1016/j.exphem.2009.04.008
   Bonneville M, 2005, MICROBES INFECT, V7, P503, DOI 10.1016/j.micinf.2005.03.004
   Bonneville M, 2006, CURR OPIN IMMUNOL, V18, P539, DOI 10.1016/j.coi.2006.07.002
   Bonneville M, 2010, NAT REV IMMUNOL, V10, P467, DOI 10.1038/nri2781
   Brandes M, 2005, SCIENCE, V309, P264, DOI 10.1126/science.1110267
   Choi SJ, 2000, BLOOD, V96, P671
   Corvaisier M, 2005, J IMMUNOL, V175, P5481, DOI 10.4049/jimmunol.175.8.5481
   Espinosa E, 2001, J BIOL CHEM, V276, P18337, DOI 10.1074/jbc.M100495200
   Ge Y, 2006, BRIT J HAEMATOL, V133, P83, DOI 10.1111/j.1365 2141.2006.05976.x
   Gober HJ, 2003, J EXP MED, V197, P163, DOI 10.1084/jem.20021500
   Han JH, 2001, BLOOD, V97, P3349, DOI 10.1182/blood.V97.11.3349
   Hashimoto T, 2004, BRIT J HAEMATOL, V125, P38, DOI 10.1111/j.1365 2141.2004.04864.x
   Hayday AC, 2009, IMMUNITY, V31, P184, DOI 10.1016/j.immuni.2009.08.006
   Kobayashi H, 2007, CANCER IMMUNOL IMMUN, V56, P469, DOI 10.1007/s00262 006 0199 6
   Kunzmann V, 2000, BLOOD, V96, P384
   Mahtani R, 2011, CLIN LUNG CANCER, V12, P26, DOI 10.3816/CLC.2011.n.003
   Miyagawa F, 2001, J IMMUNOL, V167, P6773, DOI 10.4049/jimmunol.167.12.6773
   Pennisi A, 2009, BRIT J HAEMATOL, V145, P775, DOI 10.1111/j.1365 2141.2009.07696.x
   Sabokbar A, 2003, METH MOLEC MED, V80, P101
   Saitoh A, 2008, MED ONCOL, V25, P137, DOI 10.1007/s12032 007 9004 4
   TANAKA Y, 1995, NATURE, V375, P155, DOI 10.1038/375155a0
   Thedrez A, 2007, IMMUNOL REV, V215, P123, DOI 10.1111/j.1600 065X.2006.00468.x
   Thompson K, 2006, BLOOD, V107, P651, DOI 10.1182/blood 2005 03 1025
   von Lilienfeld Toal M, 2006, CLIN EXP IMMUNOL, V144, P528, DOI 10.1111/j.1365 2249.2006.03078.x
   Wilhelm M, 2003, BLOOD, V102, P200, DOI 10.1182/blood 2002 12 3665
   Yaccoby S, 2004, CANCER RES, V64, P2016, DOI 10.1158/0008 5472.CAN 03 1131
   Yaccoby S, 2010, BRIT J HAEMATOL, V149, P311, DOI 10.1111/j.1365 2141.2010.08141.x
   Yamashita S, 2005, BIOCHEM BIOPH RES CO, V334, P349, DOI 10.1016/j.bbrc.2005.06.100
NR 32
TC 14
Z9 15
U1 0
U2 3
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0925 5710
EI 1865 3774
J9 INT J HEMATOL
JI Int. J. Hematol.
PD JUL
PY 2011
VL 94
IS 1
BP 63
EP 70
DI 10.1007/s12185 011 0885 9
PG 8
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 789JX
UT WOS:000292512900008
PM 21698356
DA 2025 08 17
ER

PT J
AU Jiang, T
   Zhang, JH
   Ruan, BT
   Xi, XB
   Yang, Z
   Liu, JM
   Zhao, HY
   Xu, X
   Jiang, M
AF Jiang, Tao
   Zhang, Jiahui
   Ruan, Beite
   Xi, Xiaobing
   Yang, Zhuo
   Liu, Jianmin
   Zhao, Hongyan
   Xu, Xing
   Jiang, Min
TI Trachelogenin alleviates osteoarthritis by inhibiting osteoclastogenesis
   and enhancing chondrocyte survival
SO CHINESE MEDICINE
LA English
DT Article
DE Osteoarthritis; Trachelogenin; Subchondral bone; Chondrocyte; Rap1;
   Glycolysis
ID CARTILAGE DEGENERATION; SUBCHONDRAL BONE; C SRC; INTEGRIN; TARGET
AB BackgroundOsteoarthritis (OA) is a prevalent global health concern associated with the loss of articular cartilage and subchondral bone. The lack of disease modifying drugs for OA necessitates the exploration of novel therapeutic options. Our previous study has demonstrated that traditional Chinese medical herb Trachelospermum jasminoides (Lindl.) Lem. extract suppressed osteoclastogenesis and identified trachelogenin (TCG) as a representative compound. Here, we delved into TCG's potential to alleviate OA.MethodsWe initially validated the in vivo efficacy of TCG in alleviating OA using a rat OA model. Subsequently, we isolated primary bone marrow derived macrophages in vitro to investigate TCG's impact on osteoclastogenesis. We further employed a small molecule pull down assay to verify TCG's binding target within osteoclasts. Finally, we isolated primary mouse chondrocytes in vitro to study TCG's regulatory effects and mechanisms on chondrocyte survival.ResultsTCG preserved subchondral bone integrity and protected articular cartilage in a rat OA model. Subsequently, in vitro experiments unveiled TCG's capability to inhibit osteoclastogenesis and function through binding to Ras association proximate 1 (Rap1) and inhibiting its activation. Further study demonstrated that TCG inhibited Rap1/integrin alpha v beta 3/c Src/Pyk2 signaling cascade, and consequently led to failed F actin ring formation. Besides, TCG promoted the proliferation of mouse primary chondrocytes while suppressing apoptosis in vitro. This is attributed to TCG's ability to upregulate HIF1 alpha, thereby promoting glycolysis.ConclusionTCG exerted inhibitory effects on osteoclastogenesis through binding to Rap1 and inhibiting Rap1 activation, consequently preventing subchondral bone loss. Moreover, TCG enhanced chondrocyte survival by upregulating HIF1 alpha and promoting glycolysis. These dual mechanisms collectively provide a novel approach to prevented against cartilage degradation.
C1 [Jiang, Tao; Liu, Jianmin; Zhao, Hongyan] Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Inst Endocrine & Metab Dis, Dept Endocrine & Metab Dis,Sch Med, Shanghai, Peoples R China.
   [Jiang, Tao; Liu, Jianmin; Zhao, Hongyan] Shanghai Jiao Tong Univ, Ruijin Hosp, State Key Lab Med Genom, Shanghai Natl Clin Res Ctr Metab Dis,Key Lab Endoc, Shanghai, Peoples R China.
   [Zhang, Jiahui; Xi, Xiaobing; Xu, Xing; Jiang, Min] Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Inst Traumatol & Orthopaed, Dept Orthopaed,Shanghai Key Lab Prevent & Treatmen, Shanghai, Peoples R China.
   [Ruan, Beite] Shanghai Univ Tradit Chinese Med, Peoples Hosp 7, Shanghai, Peoples R China.
   [Yang, Zhuo] Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, Ctr Excellence Mol Cell Sci, Chem Biol Core Facil, Shanghai, Peoples R China.
   [Yang, Zhuo] Univ Chinese Acad Sci, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chinese
   Academy of Sciences; Shanghai Jiao Tong University; Shanghai University
   of Traditional Chinese Medicine; Chinese Academy of Sciences; Center for
   Excellence in Molecular Cell Science, CAS; Chinese Academy of Sciences;
   University of Chinese Academy of Sciences, CAS
RP Zhao, HY (通讯作者)，Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Inst Endocrine & Metab Dis, Dept Endocrine & Metab Dis,Sch Med, Shanghai, Peoples R China.; Zhao, HY (通讯作者)，Shanghai Jiao Tong Univ, Ruijin Hosp, State Key Lab Med Genom, Shanghai Natl Clin Res Ctr Metab Dis,Key Lab Endoc, Shanghai, Peoples R China.; Xu, X; Jiang, M (通讯作者)，Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Inst Traumatol & Orthopaed, Dept Orthopaed,Shanghai Key Lab Prevent & Treatmen, Shanghai, Peoples R China.
EM hyanzhao@163.com; xuxing0510315@126.com; jiangm263@163.com
RI Liu, Jianmin/KEI 9744 2024
FU National Natural Science Foundation of China
FX Not applicable.
CR Bapat S, 2018, CLIN TRANSL MED, V7, DOI 10.1186/s40169 018 0215 4
   Bos JL, 2005, CURR OPIN CELL BIOL, V17, P123, DOI 10.1016/j.ceb.2005.02.009
   Castañeda S, 2012, BIOCHEM PHARMACOL, V83, P315, DOI 10.1016/j.bcp.2011.09.018
   Chen WJ, 2023, CHIN MED UK, V18, DOI 10.1186/s13020 023 00802 z
   Cho Y, 2021, EXP MOL MED, V53, P1689, DOI 10.1038/s12276 021 00710 y
   Conaghan PG, 2020, ANN INTERN MED, V172, P86, DOI 10.7326/M19 0675
   Duong L, 2000, MATRIX BIOL, V19, P97, DOI 10.1016/S0945 053X(00)00051 2
   Fang C, 2022, ACTA PHARMACOL SIN, V43, P1299, DOI 10.1038/s41401 021 00747 9
   Hu Y, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00147 z
   Hunter DJ, 2020, LANCET, V396, P1711, DOI 10.1016/S0140 6736(20)32230 3
   Iijima H, 2014, OSTEOARTHR CARTILAGE, V22, P1036, DOI 10.1016/j.joca.2014.05.009
   Itzstein Cecile, 2011, Small GTPases, V2, P117
   Izawa T, 2012, MOL CELL BIOL, V32, P2943, DOI 10.1128/MCB.00077 12
   Jiang T, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110341
   Kierans SJ, 2021, J PHYSIOL LONDON, V599, P23, DOI 10.1113/JP280572
   Lagarrigue F, 2020, BLOOD, V136, P1180, DOI 10.1182/blood.2020005348
   Leifer VP, 2022, OSTEOARTHR CARTILAGE, V30, P10, DOI 10.1016/j.joca.2021.05.007
   Lin SY, 2022, CELL COMMUN SIGNAL, V20, DOI 10.1186/s12964 022 00881 9
   Liu ZC, 2019, FASEB J, V33, P9828, DOI 10.1096/fj.201802242RR
   Lo TY, 2023, CHIN MED UK, V18, DOI 10.1186/s13020 023 00813 w
   Löfvall H, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1564 5
   Neogi T, 2018, ANN RHEUM DIS, V77, P92, DOI 10.1136/annrheumdis 2017 211811
   NOSE M, 1992, PLANTA MED, V58, P520, DOI 10.1055/s 2006 961540
   Nowaczyk A, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031566
   Pritzker KPH, 2006, OSTEOARTHR CARTILAGE, V14, P13, DOI 10.1016/j.joca.2005.07.014
   Semenza GL, 2014, ANNU REV PHYSIOL, V76, P39, DOI 10.1146/annurev physiol 021113 170322
   Stegen S, 2019, NATURE, V565, P511, DOI 10.1038/s41586 019 0874 3
   Tan XQ, 2005, PLANTA MED, V71, P93, DOI 10.1055/s 2005 837761
   Tian H, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.780590
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   van den Bosch MHJ, 2021, OSTEOARTHR CARTILAGE, V29, P143, DOI 10.1016/j.joca.2020.10.006
   Vonkeman HE, 2010, SEMIN ARTHRITIS RHEU, V39, P294, DOI 10.1016/j.semarthrit.2008.08.001
   Weivoda M.M., 2014, Orthopedic Muscular System: Current Research, V3, P161, DOI [DOI 10.4172/2161 0533.1000161, 10.4172/2161 0533.1000161]
   Xu YM, 2022, CHIN MED UK, V17, DOI 10.1186/s13020 022 00576 w
   Zhao ZF, 2017, MOLECULES, V22, DOI 10.3390/molecules22091406
   Zhu SA, 2019, J CLIN INVEST, V129, P1076, DOI 10.1172/JCI121561
   Zou W, 2007, J CELL BIOL, V176, P877, DOI 10.1083/jcb.200611083
   Zou W, 2013, MOL CELL BIOL, V33, P830, DOI 10.1128/MCB.00790 12
NR 38
TC 4
Z9 4
U1 2
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 8546
J9 CHIN MED UK
JI Chin. Med.
PD MAR 1
PY 2024
VL 19
IS 1
AR 37
DI 10.1186/s13020 024 00909 x
PG 17
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA JX8H5
UT WOS:001176545700002
PM 38429848
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Su, W
   Lv, C
   Huang, LT
   Zheng, XH
   Yang, SW
AF Su, Wei
   Lv, Chen
   Huang, Lingtuo
   Zheng, XiaoHang
   Yang, Shengwu
TI Glucosamine delays the progression of osteoporosis in senile mice by
   promoting osteoblast autophagy
SO NUTRITION & METABOLISM
LA English
DT Article
DE Glucosamine; d Galactose; Senile osteoporosis; Osteogenesis; Autophagy
ID OXIDATIVE STRESS; OSTEOARTHRITIS; SULFATE; CELL
AB Background Senile osteoporosis (SOP) is one of the most prevalent diseases that afflict the elderly population, which characterized by decreased osteogenic ability. Glucosamine (GlcN) is an over the counter dietary supplement. Our previous study reported that GlcN promotes osteoblast proliferation by activating autophagy in vitro. The purpose of this study is to determine the effects and mechanisms of GlcN on senile osteoporosis and osteogenic differentiation in vivo. Methods Aging was induced by subcutaneous injection of d Galactose (d Gal), and treated with GlcN or vehicle. The anti senile osteoporosis effect of GlcN was explored by examining changes in micro CT, serum indicators, body weight, protein and gene expression of aging and apoptosis. Additionally, the effects of GlcN on protein and gene expression of osteogenesis and autophagy were observed by inhibiting autophagy with 3 methyladenine (3 MA). Results GlcN significantly improved bone mineral density (BMD) and bone micro architecture, decreased skeletal senescence and apoptosis and increased osteogenesis in d Gal induced osteoporotic mice. While all effect was reversed with 3 MA. Conclusion GlcN effectively delayed the progression of osteoporosis in senile osteoporotic mice by promoting osteoblast autophagy. This study suggested that GlcN may be a prospective candidate drug for the treatment of SOP.
C1 [Su, Wei; Lv, Chen; Huang, Lingtuo; Zheng, XiaoHang; Yang, Shengwu] Wenzhou Med Univ, Dept Orthoped, Affiliated Hosp 1, Wenzhou 325000, Zhejiang, Peoples R China.
C3 Wenzhou Medical University
RP Yang, SW (通讯作者)，Wenzhou Med Univ, Dept Orthoped, Affiliated Hosp 1, Wenzhou 325000, Zhejiang, Peoples R China.
EM yangshengwu188@sina.com
RI Zhang, Hailiang/AAF 4937 2020
FU National Natural Science Foundation of China [82102534]; Natural Science
   Foundation of Zhejiang Province [LQ20H060003]; Medical and Health
   Science and Technology Project of Zhejiang Province [2020KY633];
   Technology Bureau Projects of Wenzhou City [Y20190393, Y2020397]
FX This study was supported by the National Natural Science Foundation of
   China (82102534), the Natural Science Foundation of Zhejiang Province
   (LQ20H060003), the Medical and Health Science and Technology Project of
   Zhejiang Province (2020KY633) and the Technology Bureau Projects of
   Wenzhou City (Y20190393 and Y2020397).
CR Ali T, 2015, J PINEAL RES, V58, P71, DOI 10.1111/jpi.12194
   [Anonymous], 2021, LANCET DIABETES ENDO, V9, P1, DOI 10.1016/S2213 8587(20)30408 3
   Berent TE, 2019, BIOCHEM BIOPH RES CO, V519, P566, DOI 10.1016/j.bbrc.2019.09.045
   Boquete Castro A, 2016, CLIN ORAL IMPLAN RES, V27, P367, DOI 10.1111/clr.12556
   Chawalitpong S, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 23912 3
   Chen YJ, 2015, INVEST OPHTH VIS SCI, V56, P1506, DOI 10.1167/iovs.14 15726
   Chen Y, 2020, J CELL MOL MED, V24, P12411, DOI 10.1111/jcmm.15753
   Doherty J, 2018, NAT CELL BIOL, V20, P1110, DOI 10.1038/s41556 018 0201 5
   Duque G, 2008, J AM GERIATR SOC, V56, P935, DOI 10.1111/j.1532 5415.2008.01764.x
   El Baz FK, 2019, BIOMED PHARMACOTHER, V116, DOI 10.1016/j.biopha.2019.109017
   Farr JN, 2017, NAT MED, V23, P1072, DOI 10.1038/nm.4385
   Fischer V, 2022, SEMIN CELL DEV BIOL, V123, P14, DOI 10.1016/j.semcdb.2021.05.014
   Florencio Silva R, 2018, BIOMED PHARMACOTHER, V98, P406, DOI 10.1016/j.biopha.2017.12.089
   Xiaoling GL, 2020, BMC MED GENET, V21, DOI 10.1186/s12881 020 0948 y
   Habieb ME, 2021, ARCH GERONTOL GERIAT, V92, DOI 10.1016/j.archger.2020.104288
   Hardy RS, 2018, ENDOCR REV, V39, P519, DOI 10.1210/er.2018 00097
   Hsu WH, 2020, AGING US, V12, P10556, DOI 10.18632/aging.103279
   Hu JC, 2017, FREE RADICAL BIO MED, V103, P121, DOI 10.1016/j.freeradbiomed.2016.12.032
   Igarashi M, 2011, INT J MOL MED, V28, P373, DOI 10.3892/ijmm.2011.686
   Jiang ZW, 2018, MOLECULES, V23, DOI 10.3390/molecules23092302
   Kumar Anil, 2011, Int J Alzheimers Dis, V2011, P347569, DOI 10.4061/2011/347569
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451
   Lenoir O, 2015, AUTOPHAGY, V11, P1130, DOI 10.1080/15548627.2015.1049799
   Li HX, 2018, AUTOPHAGY, V14, P1726, DOI 10.1080/15548627.2018.1483807
   Li X, 2020, AGEING RES REV, V62, DOI 10.1016/j.arr.2020.101098
   Liu F, 2021, REDOX BIOL, V43, DOI 10.1016/j.redox.2021.101963
   Lu JM, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1345 3
   Luo D, 2016, OSTEOPOROSIS INT, V27, P1093, DOI 10.1007/s00198 015 3325 5
   Lv C, 2018, BIOMED PHARMACOTHER, V99, P271, DOI 10.1016/j.biopha.2018.01.066
   McCormick JJ, 2021, J APPL PHYSIOL, V130, P1, DOI 10.1152/japplphysiol.00542.2020
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Montalcini T, 2013, ENDOCRINE, V43, P59, DOI 10.1007/s12020 012 9813 x
   Neugebauer J, 2018, HUM MOL GENET, V27, P4249, DOI 10.1093/hmg/ddy318
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Onal M, 2013, J BIOL CHEM, V288, P17432, DOI 10.1074/jbc.M112.444190
   Parzych KR, 2014, ANTIOXID REDOX SIGN, V20, P460, DOI 10.1089/ars.2013.5371
   Pereira DD, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.554565
   Qadir A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010349
   Reginster JY, 2012, RHEUMATOL INT, V32, P2959, DOI 10.1007/s00296 012 2416 2
   Reginster JY, 2001, LANCET, V357, P251, DOI 10.1016/S0140 6736(00)03610 2
   Sai XY, 2020, J INT MED RES, V48, DOI 10.1177/0300060520923522
   Shanbhag S, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00968
   Stoppoloni D, 2015, OSTEOARTHR CARTILAGE, V23, P103, DOI 10.1016/j.joca.2014.09.005
   Subbiah V, 2010, OSTEOPOROSIS INT, V21, P1041, DOI 10.1007/s00198 009 1004 0
   Tang N, 2019, J CELL PHYSIOL, V234, P5023, DOI 10.1002/jcp.27304
   Valvason C, 2008, RHEUMATOLOGY, V47, P31, DOI 10.1093/rheumatology/kem289
   Vrahnas C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 11373 9
   Wang W, 2020, NUTR METAB, V17, DOI 10.1186/s12986 020 00449 9
   Wang Y, 2009, OSTEOPOROSIS INT, V20, P1651, DOI 10.1007/s00198 009 0925 y
   Wong SQ, 2020, HUM GENET, V139, P277, DOI 10.1007/s00439 019 02031 7
   Wu JH, 2022, MOL CELL ENDOCRINOL, V539, DOI 10.1016/j.mce.2021.111490
   Wu XH, 2020, ACTA HISTOCHEM, V122, DOI 10.1016/j.acthis.2020.151549
   Xiao L, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00490
   Sun XL, 2015, SCI REP UK, V5, DOI 10.1038/srep13009
   Yang YH, 2020, FASEB J, V34, P8876, DOI 10.1096/fj.201903216RR
   Yu YJ, 2020, BIOMED PHARMACOTHER, V128, DOI 10.1016/j.biopha.2020.110304
   Zhang HY, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00187
   Zhao FL, 2021, ARCH OSTEOPOROS, V16, DOI 10.1007/s11657 020 00854 w
NR 60
TC 4
Z9 5
U1 0
U2 25
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1743 7075
J9 NUTR METAB
JI Nutr. Metab.
PD NOV 8
PY 2022
VL 19
IS 1
AR 75
DI 10.1186/s12986 022 00688 y
PG 16
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA 6A0DK
UT WOS:000880333500002
PM 36348458
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Idris, AI
AF Idris, Aymen I.
TI Cannabinoid Receptors as Target for Treatment of Osteoporosis: A Tale of
   Two Therapies
SO CURRENT NEUROPHARMACOLOGY
LA English
DT Article
DE Cannabinoid; osteoporosis; bone; anti resorptive; anabolic; Rimonabant
   (c); CB1; CB2; GPR55
ID SYMPATHETIC NERVOUS SYSTEM; AGE RELATED OSTEOPOROSIS; REGULATES
   BONE FORMATION; INVERSE AGONIST; OSTEOCLAST DIFFERENTIATION; VANILLOID
   RECEPTOR; MINERAL DENSITY; NITRIC OXIDE; PPAR GAMMA; ANANDAMIDE
AB The central nervous system plays an important role in regulating bone metabolism in health and in disease with a number of neurotransmitters been reported to influence bone cell activity through a central relay. In keeping with this, recent studies demonstrated that endocannabinoids and their receptors are involved in the pathogenesis of osteoporosis. The endocannabinoids anandamide and 2 arachidonylglycerol are found in the skeleton and numerous studies also showed that bone cells express the cannabinoid receptors CB1 and CB2 and the orphan receptor GPR55. Pharmacological and genetic inactivation of CB1, CB2 and GPR55 in adult mice suppress bone resorption, increase bone mass and protect against bone loss, suggesting that inverse agonists/antagonists of these receptors may serve as anti resorptive agents. In the ageing skeleton however CB1 and CB2 receptors have a protective effect against age dependent bone loss in both male and female mice. CB1 receptor deficiency in aged mice results in accelerated age dependent osteoporosis due to marked increase in bone resorption and significant reduction in bone formation coupled to enhanced adipocyte accumulation in the bone marrow compartment. Similar acceleration of bone loss was also reported in CB2 deficient mice of similar age but found to be associated with enhanced bone turnover. This review summarises in vitro and in vivo findings relating to the influence of cannabinoid ligands on bone metabolism and argues in favour of the exploitation of cannabinoid receptors as targets for both anabolic and anti resorptive therapy for treatment of complex multifaceted bone diseases such as osteoporosis.
C1 Univ Edinburgh, Western Gen Hosp, Mol Med Ctr, Bone Res Grp, Edinburgh EH4 2XU, Midlothian, Scotland.
C3 University of Edinburgh
RP Idris, AI (通讯作者)，Univ Edinburgh, Western Gen Hosp, Mol Med Ctr, Bone Res Grp, Edinburgh EH4 2XU, Midlothian, Scotland.
EM aymen.idris@ed.ac.uk
RI ; Idris, Aymen/AAX 1138 2020
OI Idris, Aymen/0000 0003 4327 5306; 
FU European Calcified Tissue International Society (ECTS); Amgen; Arthritis
   Research Campaign
FX Aymen I. Idris is a recipient of a fellowship from the European
   Calcified Tissue International Society (ECTS) and Amgen and his research
   is also supported by grants from the Arthritis Research Campaign. The
   author would like to thank Professor Stuart H. Ralston, Dr Antonia
   Sophocleous and Mrs Euphemie Landao Bassonga for their contribution to
   this project.
CR Abe E, 2003, CELL, V115, P151, DOI 10.1016/S0092 8674(03)00771 2
   Abed E, 2009, MOL MEMBR BIOL, V26, P146, DOI 10.1080/09687680802612721
   Ahluwalia J, 2003, EUR J NEUROSCI, V17, P2611, DOI 10.1046/j.1460 9568.2003.02703.x
   Amin Shreyasee, 2003, Curr Osteoporos Rep, V1, P71, DOI 10.1007/s11914 003 0012 9
   Amling M, 2001, ADV EXP MED BIOL, V496, P85
   Bab I, 2008, J NEUROENDOCRINOL, V20, P69, DOI 10.1111/j.1365 2826.2008.01675.x
   Bab I, 2008, BRIT J PHARMACOL, V153, P182, DOI 10.1038/sj.bjp.0707593
   Begg M, 2005, PHARMACOL THERAPEUT, V106, P133, DOI 10.1016/j.pharmthera.2004.11.005
   Benarroch EE, 2009, NEUROLOGY, V72, P1016, DOI 10.1212/01.wnl.0000345258.18071.54
   BONEWALD LF, 1994, J CELL BIOCHEM, V55, P350, DOI 10.1002/jcb.240550312
   Bord S, 2003, BONE, V32, P136, DOI 10.1016/S8756 3282(02)00953 5
   BOUABOULA M, 1993, EUR J BIOCHEM, V214, P173, DOI 10.1111/j.1432 1033.1993.tb17910.x
   Bouaboula M, 2005, EUR J PHARMACOL, V517, P174, DOI 10.1016/j.ejphar.2005.05.032
   Bouaboula M, 1997, J BIOL CHEM, V272, P22330, DOI 10.1074/jbc.272.35.22330
   Brown AJ, 2007, BRIT J PHARMACOL, V152, P567, DOI 10.1038/sj.bjp.0707481
   Burstein S, 2005, LIFE SCI, V77, P1674, DOI 10.1016/j.lfs.2005.05.039
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Center JR, 1999, LANCET, V353, P878, DOI 10.1016/S0140 6736(98)09075 8
   Chenu C, 2005, JOINT BONE SPINE, V72, P481, DOI 10.1016/j.jbspin.2005.10.007
   Cherruau M, 1999, BONE, V25, P545, DOI 10.1016/S8756 3282(99)00211 2
   CHESTNUT CH, 1993, OSTEOPOROSIS INT, V3, pS206, DOI 10.1007/BF01621908
   CHOW JWM, 2004, BONE RES PROTOCOLS, P361
   Coleman RE, 2008, BRIT J CANCER, V98, P1736, DOI 10.1038/sj.bjc.6604382
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   De Petrocellis L, 2000, FEBS LETT, V483, P52, DOI 10.1016/S0014 5793(00)02082 2
   DELANY AM, 1995, J CELL BIOCHEM, V57, P488, DOI 10.1002/jcb.240570314
   Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495
   Di Marzo V, 2002, PROSTAG LEUKOTR ESS, V66, P377, DOI 10.1054/plef.2001.0349
   Di Marzo V, 2008, NAT REV DRUG DISCOV, V7, P438, DOI 10.1038/nrd2553
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092 8674(00)81558 5
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   ERIKSEN EF, 1985, BONE, V6, P141, DOI 10.1016/8756 3282(85)90046 8
   Felder CC, 1996, FEBS LETT, V393, P231, DOI 10.1016/0014 5793(96)00891 5
   FELDER CC, 1993, P NATL ACAD SCI USA, V90, P7656, DOI 10.1073/pnas.90.16.7656
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432 1033.1995.tb20780.x
   Gary Bobo M, 2006, MOL PHARMACOL, V69, P471, DOI 10.1124/mol.105.015040
   Gatley SJ, 1996, EUR J PHARMACOL, V307, P331, DOI 10.1016/0014 2999(96)00279 8
   Gatley SJ, 1997, LIFE SCI, V61, pPL191, DOI 10.1016/S0024 3205(97)00690 5
   George KL, 2008, J CELL PHYSIOL, V214, P714, DOI 10.1002/jcp.21263
   Gimble JM, 2006, J CELL BIOCHEM, V98, P251, DOI 10.1002/jcb.20777
   Grant I, 2005, CLIN NEUROSCI RES, V5, P185, DOI 10.1016/j.cnr.2005.08.015
   Green MJ, 2001, BEST PRACT RES CL RH, V15, P105, DOI 10.1053/berh.2000.0129
   Guzmán M, 2001, TRENDS PHARMACOL SCI, V22, P19, DOI 10.1016/S0165 6147(00)01586 8
   Hermann H, 2003, CELL MOL LIFE SCI, V60, P607, DOI 10.1007/s000180300052
   Hosohata K, 1997, LIFE SCI, V61, pPL115, DOI 10.1016/S0024 3205(97)00596 1
   Hosohata Y, 1997, EUR J PHARMACOL, V321, pR1, DOI 10.1016/S0014 2999(97)00047 2
   Howlett AC, 2005, HANDB EXP PHARMACOL, V168, P53
   Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255
   Idris AI, 2008, ENDOCRINOLOGY, V149, P5619, DOI 10.1210/en.2008 0150
   Idris AI, 2010, BONE, V46, P1089, DOI 10.1016/j.bone.2010.01.368
   Idris AI, 2009, CELL METAB, V10, P139, DOI 10.1016/j.cmet.2009.07.006
   Ismail AA, 1998, OSTEOPOROSIS INT, V8, P291, DOI 10.1007/s001980050067
   Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793
   Kameda T, 1997, J EXP MED, V186, P489, DOI 10.1084/jem.186.4.489
   Kanis J, 1999, OSTEOPOROSIS INT, V9, P45, DOI 10.1007/s001980050115
   Kannus P, 1996, BONE, V18, pS57, DOI 10.1016/8756 3282(95)00381 9
   Karsak M, 2005, HUM MOL GENET, V14, P3389, DOI 10.1093/hmg/ddi370
   Kaufman JM, 2000, ANN RHEUM DIS, V59, P765, DOI 10.1136/ard.59.10.765
   Klein TW, 2000, P SOC EXP BIOL MED, V225, P1, DOI 10.1046/j.1525 1373.2000.22501.x
   Klein TW, 2003, J LEUKOCYTE BIOL, V74, P486, DOI 10.1189/jlb.0303101
   Kondo H, 2005, J BIOL CHEM, V280, P30192, DOI 10.1074/jbc.M504179200
   Kondo S, 1998, FEBS LETT, V429, P152, DOI 10.1016/S0014 5793(98)00581 X
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lan RX, 1999, J MED CHEM, V42, P769, DOI 10.1021/jm980363y
   Landsman RS, 1998, LIFE SCI, V62, pPL109, DOI 10.1016/S0024 3205(97)01187 9
   Lee SK, 1999, ENDOCRINOLOGY, V140, P3552, DOI 10.1210/en.140.8.3552
   LIPS P, 1978, CALC TISS RES, V26, P13, DOI 10.1007/BF02013227
   Lunn CA, 2007, IMMUNOPHARM IMMUNOT, V29, P387, DOI 10.1080/08923970701674997
   Maccarrone M, 2002, VITAM HORM, V65, P225, DOI 10.1016/S0083 6729(02)65066 6
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Melton LJ, 2003, J BONE MINER RES, V18, P1139, DOI 10.1359/jbmr.2003.18.6.1139
   Melton LJ, 2003, OSTEOPOROSIS INT, V14, P383, DOI 10.1007/s00198 003 1385 4
   Meschler JP, 2000, BIOCHEM PHARMACOL, V60, P1315, DOI 10.1016/S0006 2952(00)00447 0
   Nefussi J R, 1991, J Biol Buccale, V19, P75
   Nong L, 2001, ADV EXP MED BIOL, V493, P229
   Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103
   Palazuelos J, 2008, J BIOL CHEM, V283, P13320, DOI 10.1074/jbc.M707960200
   Partridge NC, 1996, CRIT REV EUKAR GENE, V6, P15, DOI 10.1615/CritRevEukarGeneExpr.v6.i1.20
   Patel MS, 2007, CALCIFIED TISSUE INT, V80, P337, DOI 10.1007/s00223 007 9015 3
   Patschan D, 2001, BONE, V29, P498, DOI 10.1016/S8756 3282(01)00610 X
   Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163 7258(97)82001 3
   Pertwee RG, 2005, HANDB EXP PHARMACOL, V168, P1
   Pertwee RG, 2002, PROSTAG LEUKOTR ESS, V66, P101, DOI 10.1054/plef.2001.0341
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   RIDGE SA, 2007, CALCIFIED TISSUE INT, pS120
   RIGGS BL, 1995, BONE, V17, pS505, DOI 10.1016/8756 3282(95)00258 4
   RIGGS BL, 1982, J CLIN INVEST, V70, P716, DOI 10.1172/JCI110667
   Ross RA, 1999, BRIT J PHARMACOL, V126, P665, DOI 10.1038/sj.bjp.0702351
   Ross RA, 2003, BRIT J PHARMACOL, V140, P790, DOI 10.1038/sj.bjp.0705467
   Rossi F, 2009, BONE, V44, P476, DOI 10.1016/j.bone.2008.10.056
   Ryberg E, 2007, BRIT J PHARMACOL, V152, P1092, DOI 10.1038/sj.bjp.0707460
   Sánchez MG, 2003, CELL SIGNAL, V15, P851, DOI 10.1016/S0898 6568(03)00036 6
   Sarma U, 1996, BLOOD, V88, P2531, DOI 10.1182/blood.V88.7.2531.bloodjournal8872531
   Saunders CIM, 2007, MOL IMMUNOL, V44, P1429, DOI 10.1016/j.molimm.2006.04.027
   Sawzdargo M, 1999, MOL BRAIN RES, V64, P193, DOI 10.1016/S0169 328X(98)00277 0
   Scutt A, 2007, CALCIFIED TISSUE INT, V80, P50, DOI 10.1007/s00223 006 0171 7
   Serre CM, 1999, BONE, V25, P623, DOI 10.1016/S8756 3282(99)00215 X
   Sisask G, 1996, J AUTONOM NERV SYST, V59, P27, DOI 10.1016/0165 1838(95)00139 5
   Skerry TM, 2001, TRENDS PHARMACOL SCI, V22, P174, DOI 10.1016/S0165 6147(00)01642 4
   Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050
   Sophocleous A, 2009, BONE, V44, pS219, DOI 10.1016/j.bone.2009.03.059
   Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015
   Suda T, 2003, J CELL BIOCHEM, V88, P259, DOI 10.1002/jcb.10331
   Suda T, 1997, J BONE MINER RES, V12, P869, DOI 10.1359/jbmr.1997.12.6.869
   Sun L, 2006, CELL, V125, P247, DOI 10.1016/j.cell.2006.01.051
   Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378 1119(01)00798 3
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Tam J, 2008, FASEB J, V22, P285, DOI 10.1096/fj.06 7957com
   Tam J, 2006, MOL PHARMACOL, V70, P786, DOI 10.1124/mol.106.026435
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Trillou CR, 2004, INT J OBESITY, V28, P640, DOI 10.1038/sj.ijo.0802583
   van der Stelt M, 2005, PROSTAG OTH LIPID M, V77, P111, DOI 10.1016/j.prostaglandins.2004.09.007
   van't Hof RJ, 2004, ENDOCRINOLOGY, V145, P5068, DOI 10.1210/en.2004 0205
   van't Hof RJ, 2001, IMMUNOLOGY, V103, P255, DOI 10.1046/j.1365 2567.2001.01261.x
   Weinstein RS, 2000, AM J MED, V108, P153, DOI 10.1016/S0002 9343(99)00420 9
   Whyte LS, 2009, P NATL ACAD SCI USA, V106, P16511, DOI 10.1073/pnas.0902743106
   Yamada Y, 2007, INT J MOL MED, V19, P791
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 120
TC 25
Z9 29
U1 0
U2 4
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570 159X
EI 1875 6190
J9 CURR NEUROPHARMACOL
JI Curr. Neuropharmacol.
PD SEP
PY 2010
VL 8
IS 3
BP 243
EP 253
PG 11
WC Neurosciences; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 645FK
UT WOS:000281436200009
PM 21358974
OA Green Published
DA 2025 08 17
ER

PT J
AU Constanze, B
   Popper, B
   Aggarwal, BB
   Shakibaei, M
AF Constanze, Buhrmann
   Popper, Bastian
   Aggarwal, Bharat B.
   Shakibaei, Mehdi
TI Evidence that TNF β suppresses osteoblast differentiation of mesenchymal
   stem cells and resveratrol reverses it through modulation of NF κB,
   Sirt1 and Runx2
SO CELL AND TISSUE RESEARCH
LA English
DT Article
DE Resveratrol; MSC; Osteogenesis; TNF beta (lymphotoxin alpha); NF kappa B
ID TUMOR NECROSIS FACTOR; HUMAN ADIPOSE TISSUE; RHEUMATOID ARTHRITIS;
   SERIOUS INFECTION; GENE EXPRESSION; BONE RESORPTION; RISK; APOPTOSIS;
   THERAPY; OSTEOGENESIS
AB It has been established that inflammation plays an important role in bone formation and bone loss. Although a lot is known about the role of TNF alpha in bone health, very little is understood about TNF beta, also called lymphotoxin. In this report, we examine the effect of TNF beta on osteogenic differentiation of mesenchymal stem cells (MSCs) and its modulation by resveratrol. Monolayer and high density cultures of MSCs were treated with osteogenic induction medium with/without TNF beta, Sirt1 inhibitor nicotinamide (NAM), antisense oligonucleotides against Sirt1 (ASO) and/or Sirt1 stimulator resveratrol. We found that TNF beta inhibits, in a similar way to NAM or Sirt1 ASO, the early stage of osteogenic differentiation of MSCs and this was accompanied with downregulation of bone specific matrix, beta 1 integrin, Runx2 and with upregulation of NF kappa B phosphorylation and NF kappa B regulated gene products involved in the inflammatory, degradative processes and apoptosis. However, resveratrol reversed TNF beta  and NAM suppressed MSCs osteogenesis by activation of Sirt1 and Runx2 that led to osteoblast differentiation. Furthermore, downregulation of Sirt1 by mRNA inhibited the effect of resveratrol, highlighting the important impact of this enzyme in the TNF beta signaling pathway. Finally, resveratrol was able to manifest its effect both by suppression of TNF beta induced NF kappa B and through direct activation of the Sirt1 and Runx2 pathway. Thus, through these studies, we present a mechanism by which a T cell derived cytokine, TNF beta can affect bone formation through modulation of MSCs differentiation that involves NF kappa B, Sirt1, Runx2 and resveratrol reversed TNF beta promoted impairments in MSCs osteogenesis.
C1 [Constanze, Buhrmann; Shakibaei, Mehdi] Ludwig Maximilian Univ Munich, Inst Anat, Fac Med, Musculoskeletal Res Grp, Pettenkoferstr 11, D 80336 Munich, Germany.
   [Constanze, Buhrmann; Shakibaei, Mehdi] Ludwig Maximilian Univ Munich, Inst Anat, Fac Med, Tumour Biol,Chair Vegetat Anat, Pettenkoferstr 11, D 80336 Munich, Germany.
   [Popper, Bastian] Ludwig Maximilian Univ Munich, Biomed Ctr, Core Facil Anim Models, D 82152 Martinsried, Germany.
   [Popper, Bastian] Tech Univ Munich, Inst Pathol, Sch Med, D 81675 Munich, Germany.
   [Aggarwal, Bharat B.] Inflammat Res Ctr, San Diego, CA 92126 USA.
C3 University of Munich; University of Munich; University of Munich;
   Technical University of Munich
RP Shakibaei, M (通讯作者)，Ludwig Maximilian Univ Munich, Inst Anat, Fac Med, Musculoskeletal Res Grp, Pettenkoferstr 11, D 80336 Munich, Germany.; Shakibaei, M (通讯作者)，Ludwig Maximilian Univ Munich, Inst Anat, Fac Med, Tumour Biol,Chair Vegetat Anat, Pettenkoferstr 11, D 80336 Munich, Germany.
EM Bastian.Popper@bmc.med.lmu.de; bbaggarwal@gmail.com;
   mehdi.shakibaei@med.uni muenchen.de
RI ; Shakibaei, Prof. Dr. Mehdi/AAA 7004 2020; Aggarwal, Bharat/G 3388 2013
OI Buhrmann, Constanze/0000 0002 0786 0463; Shakibaei, Prof. Dr.
   Mehdi/0000 0002 6304 7506
CR AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345
   AGGARWAL BB, 1984, J BIOL CHEM, V259, P686
   Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184
   AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0
   Aggarwal BB, 2012, BLOOD, V119, P651, DOI 10.1182/blood 2011 04 325225
   [Anonymous], 2017, PLOS ONE
   Armiento AR, 2018, ADV DRUG DELIV REV
   Bäckesjö CM, 2006, J BONE MINER RES, V21, P993, DOI 10.1359/JBMR.060415
   Bongartz T, 2006, JAMA J AM MED ASSOC, V295, P2275, DOI 10.1001/jama.295.19.2275
   Buhrmann C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186993
   Buhrmann C, 2014, J BIOL CHEM, V289, P22048, DOI 10.1074/jbc.M114.568790
   Buhrmann C, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4393
   Buhrmann C, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3065
   Busch F, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.377028
   Busch F, 2012, J BIOL CHEM, V287, P25770, DOI 10.1074/jbc.M112.355420
   Calmon Hamaty F, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3376
   Calmon Hamaty F, 2011, CYTOKINE, V53, P207, DOI 10.1016/j.cyto.2010.10.010
   Cao L, 1999, MATRIX BIOL, V18, P343, DOI 10.1016/S0945 053X(99)00027 X
   Corrado A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061272
   Csaki C, 2007, HISTOCHEM CELL BIOL, V128, P507, DOI 10.1007/s00418 007 0337 z
   Csaki C, 2009, HISTOCHEM CELL BIOL, V131, P251, DOI 10.1007/s00418 008 0524 6
   De Bari C, 2018, CURR OPIN PHARMACOL, V40, P74, DOI 10.1016/j.coph.2018.03.009
   Dinarello CA, 2006, ANN RHEUM DIS, V65, P61, DOI 10.1136/ard.2006.058511
   Dixon WG, 2007, ARTHRITIS RHEUM, V56, P2896, DOI 10.1002/art.22808
   Dosier CR, 2012, J MECH BEHAV BIOMED, V11, P112, DOI 10.1016/j.jmbbm.2011.08.014
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Edwards JR, 2013, J BONE MINER RES, V28, P960, DOI 10.1002/jbmr.1824
   Erdman CP, 2012, J TISSUE ENG REGEN M, V6, ps34, DOI 10.1002/term.513
   Estrov Z, 2003, BLOOD, V102, P987, DOI 10.1182/blood 2002 11 3550
   Ferreira SA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06183 4
   Frith JE, 2012, STEM CELLS DEV, V21, P2442, DOI 10.1089/scd.2011.0615
   Gartlehner G, 2006, J RHEUMATOL, V33, P2398
   Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200
   Gimble JM, 2003, CYTOTHERAPY, V5, P362, DOI 10.1080/14653240310003026
   Gramaglia I, 1999, J IMMUNOL, V162, P1333
   Gronthos S, 2001, BONE, V28, P174, DOI 10.1016/S8756 3282(00)00424 5
   Gupta SC, 2010, BBA GENE REGUL MECH, V1799, P775, DOI 10.1016/j.bbagrm.2010.05.004
   Harth M., 2019, EXPERT REV CLIN IMMU
   Hirose T, 2018, INFLAMM RES, V67, P495, DOI 10.1007/s00011 018 1139 6
   Hochberg MC, 2005, SEMIN ARTHRITIS RHEU, V34, P819, DOI 10.1016/j.semarthrit.2004.11.006
   Jue DM, 1999, J KOREAN MED SCI, V14, P231, DOI 10.3346/jkms.1999.14.3.231
   Kamath MS, 2014, INT J NANOMED, V9, P183, DOI 10.2147/IJN.S49460
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   Kauppinen A, 2013, CELL SIGNAL, V25, P1939, DOI 10.1016/j.cellsig.2013.06.007
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Komori T, 2008, FRONT BIOSCI LANDMRK, V13, P898, DOI 10.2741/2730
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Kotake S, 2014, BBA GEN SUBJECTS, V1840, P1209, DOI 10.1016/j.bbagen.2013.12.013
   Lei M, 2008, ACTA PHARMACOL SIN, V29, P1350, DOI 10.1111/j.1745 7254.2008.00880.x
   Leombruno JP, 2009, ANN RHEUM DIS, V68, P1136, DOI 10.1136/ard.2008.091025
   Lepage S, 2019, TISSUE ENG B
   Liu C, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/4069032
   Liu Y, 2011, NAT MED, V17, P1594, DOI 10.1038/nm.2542
   Luo KY, 2019, ACTA BIOMATER, V85, P106, DOI 10.1016/j.actbio.2018.12.018
   Manna SK, 2000, J IMMUNOL, V164, P6509, DOI 10.4049/jimmunol.164.12.6509
   Matsuda Y, 2018, ORAL DIS, V24, P412, DOI 10.1111/odi.12785
   Mendes KL, 2017, CYTOKINE GROWTH F R, V38, P98, DOI 10.1016/j.cytogfr.2017.11.001
   O'Rourke KP, 2008, RHEUMATOL INT, V28, P979, DOI 10.1007/s00296 008 0574 z
   Okay E, 2015, STEM CELL REV REP, V11, P322, DOI 10.1007/s12015 014 9572 6
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Pfeilschifter J, 2002, ENDOCR REV, V23, P90, DOI 10.1210/er.23.1.90
   Pillarisetti Sivaram, 2008, Recent Pat Cardiovasc Drug Discov, V3, P156, DOI 10.2174/157489008786263989
   Pinarli FA, 2013, PEDIATR HEMAT ONCOL, V30, P226, DOI 10.3109/08880018.2012.762962
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rajshankar D, 2017, FASEB J, V31, P937, DOI 10.1096/fj.201600645R
   Ramiro S, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008886.pub2
   Ren Z, 2013, PHARM, V68, p[689, 689]
   Rutledge K, 2016, J NANOMEDICINE NANOT, V7
   Safaeinejad Z, 2018, EUR J MED CHEM, V155, P651, DOI 10.1016/j.ejmech.2018.06.037
   Salliot C, 2009, ANN RHEUM DIS, V68, P25, DOI 10.1136/ard.2007.083188
   Schneeweiss S, 2007, ARTHRITIS RHEUM US, V56, P1754, DOI 10.1002/art.22600
   Shakibaei M, 2009, MOL NUTR FOOD RES, V53, P115, DOI 10.1002/mnfr.200800148
   Shakibaei M, 2008, BIOCHEM PHARMACOL, V76, P1426, DOI 10.1016/j.bcp.2008.05.029
   Shakibaei M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035712
   Shakibaei M, 2011, J BIOL CHEM, V286, P11492, DOI 10.1074/jbc.M110.198713
   Shui CX, 2003, J BONE MINER RES, V18, P213, DOI 10.1359/jbmr.2003.18.2.213
   Siebers MC, 2005, BIOMATERIALS, V26, P137, DOI 10.1016/j.biomaterials.2004.02.021
   Thompson AE, 2011, ARTHRITIS RHEUM US, V63, P1479, DOI 10.1002/art.30310
   Tseng PC, 2011, J BONE MINER RES, V26, P2552, DOI 10.1002/jbmr.460
   Weitzmann MN, 2017, TOXICOL PATHOL, V45, P911, DOI 10.1177/0192623317735316
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Wellman AS, 2017, GASTROENTEROLOGY, V153, P772, DOI 10.1053/j.gastro.2017.05.022
   Westlake SL, 2011, RHEUMATOLOGY, V50, P518, DOI 10.1093/rheumatology/keq316
   Wolfe F, 2006, ARTHRITIS RHEUM US, V54, P628, DOI 10.1002/art.21568
   Zhao BH, 2012, J EXP MED, V209, P319, DOI 10.1084/jem.20111566
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 87
TC 46
Z9 48
U1 0
U2 24
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0302 766X
EI 1432 0878
J9 CELL TISSUE RES
JI Cell Tissue Res.
PD JUL
PY 2020
VL 381
IS 1
BP 83
EP 98
DI 10.1007/s00441 020 03188 8
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA LZ6QA
UT WOS:000541344800008
PM 32140928
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Yu, GT
   Zhu, WX
   Zhao, YY
   Cui, H
   Chen, H
   Chen, Y
   Ning, TT
   Rong, MD
   Rao, L
   Ma, DD
AF Yu, Guang Tao
   Zhu, Wen Xiang
   Zhao, Yu Yue
   Cui, Hao
   Chen, Hao
   Chen, Yan
   Ning, Ting Ting
   Rong, Ming Deng
   Rao, Lang
   Ma, Dan Dan
TI 3D printed bioink loading with stem cells and cellular vesicles for
   periodontitis derived bone defect repair
SO BIOFABRICATION
LA English
DT Article
DE 3D printing; bone regeneration; membrane vesicle; EPL; PDLSCs
ID SUPPRESSOR CELLS; TISSUE; LIGAMENT; THERAPY
AB The suitable microenvironment of bone regeneration is critically important for periodontitis derived bone defect repair. Three major challenges in achieving a robust osteogenic reaction are the exist of oral inflammation, pathogenic bacteria invasion and unaffluent seed cells. Herein, a customizable and multifunctional 3D printing module was designed with glycidyl methacrylate (GMA) modified epsilon poly L lysine (EPLGMA) loading periodontal ligament stem cells (PDLSCs) and myeloid derived suppressive cells membrane vesicles (MDSCs MV) bioink (EPLGMA/PDLSCs/MDSCs MVs, abbreviated as EPM) for periodontitis derived bone defect repair. The EPM showed excellent mechanical properties and physicochemical characteristics, providing a suitable microenvironment for bone regeneration. In vitro, EPMs presented effectively kill the periodontopathic bacteria depend on the natural antibacterial properties of the EPL. Meanwhile, MDSCs MV was confirmed to inhibit T cells through CD73/CD39/adenosine signal pathway, exerting an anti inflammatory role. Additionally, seed cells of PDLSCs provide an adequate supply for osteoblasts. Moreover, MDSCs MV could significantly enhance the mineralizing capacity of PDLSCs derived osteoblast. In the periodontal bone defect rat model, the results of micro CT and histological staining demonstrated that the EPM scaffold similarly had an excellent anti inflammatory and bone regeneration efficacy in vivo. This biomimetic and multifunctional 3D printing bioink opens new avenues for periodontitis derived bone defect repair and future clinical application.
C1 [Yu, Guang Tao; Zhao, Yu Yue; Cui, Hao; Chen, Hao; Chen, Yan; Ning, Ting Ting; Rong, Ming Deng; Ma, Dan Dan] Southern Med Univ, Stomatol Hosp, Sch Stomatol, Guangzhou 510280, Peoples R China.
   [Zhu, Wen Xiang; Rao, Lang] Shenzhen Bay Lab, Inst Biomed Hlth Technol & Engn, Shenzhen, Peoples R China.
   [Zhu, Wen Xiang] Hunan Univ, Coll Mat Sci & Engn, Changsha 410082, Peoples R China.
C3 Southern Medical University   China; Shenzhen Bay Laboratory; Hunan
   University
RP Rong, MD; Ma, DD (通讯作者)，Southern Med Univ, Stomatol Hosp, Sch Stomatol, Guangzhou 510280, Peoples R China.; Rao, L (通讯作者)，Shenzhen Bay Lab, Inst Biomed Hlth Technol & Engn, Shenzhen, Peoples R China.
EM guangtao1986@smu.edu.cn; rmdeng@smu.edu.cn; lrao@szbl.ac.cn;
   mdd@smu.edu.cn
RI ; Rao, Lang/ABD 4926 2021; zhu, wenxiang/IWU 7464 2023; 小,
   蜜蜂/GZM 9721 2022; rong, mingdeng/GRJ 8507 2022; Yu,
   Guang Tao/GLV 5025 2022
OI Zhu, Wenxiang/0009 0001 2392 6661; Yu, Guang Tao/0000 0003 1642 3924; 
FU Guangzhou Basic and Applied Basic Research Foundation; National Natural
   Science Foundation of China [82103404, 82222035]; Guangdong Basic and
   Applied Basic Research Foundation [2021A1515111036]; Stomatological
   Hospital of Southern Medical University Startup Funds [PY2020001]; 
   [2024A04J9988]
FX We thank financial support from National Natural Science Foundation of
   China (Nos. 82103404 and 82222035), Guangdong Basic and Applied Basic
   Research Foundation (No. 2021A1515111036), Guangzhou Basic and Applied
   Basic Research Foundation (2024A04J9988), and Stomatological Hospital of
   Southern Medical University Startup Funds (No. PY2020001).
CR Chen W, 2020, ACS APPL MATER INTER, V12, P21470, DOI 10.1021/acsami.0c03822
   Cui H, 2023, CANCER IMMUNOL IMMUN, V72, P1315, DOI 10.1007/s00262 022 03336 9
   Diepenhorst N, 2018, PHARMACOL THERAPEUT, V184, P1, DOI 10.1016/j.pharmthera.2017.10.015
   Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506
   Graziani F, 2023, PERIODONTOL 2000, V92, P21, DOI 10.1111/prd.12478
   Hegde S, 2021, IMMUNITY, V54, P875, DOI 10.1016/j.immuni.2021.04.004
   Hu L, 2018, ORAL DIS, V24, P696, DOI 10.1111/odi.12703
   Kinane DF, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.38
   Li JH, 2021, CHEM SOC REV, V50, P2794, DOI 10.1039/d0cs01062f
   Li S, 2022, ADV FUNCT MATER, V32, DOI 10.1002/adfm.202110848
   Li XD, 2020, CHEM REV, V120, P10596, DOI 10.1021/acs.chemrev.0c00008
   Liang YX, 2022, ACS APPL MATER INTER, V14, P36451, DOI 10.1021/acsami.2c09420
   Liu YZ, 2021, BIOMATERIALS, V279, DOI 10.1016/j.biomaterials.2021.121216
   Luan JY, 2023, ACTA PHARM SIN B, V13, P2310, DOI 10.1016/j.apsb.2022.10.026
   Ma YF, 2015, BIOFABRICATION, V7, DOI 10.1088/1758 5090/7/4/044105
   Mandrycky C, 2016, BIOTECHNOL ADV, V34, P422, DOI 10.1016/j.biotechadv.2015.12.011
   Matai I, 2020, BIOMATERIALS, V226, DOI 10.1016/j.biomaterials.2019.119536
   Men Y, 2020, DEV CELL, V54, P639, DOI 10.1016/j.devcel.2020.06.006
   Meng LX, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.1017613
   Nuñez J, 2019, PERIODONTOL 2000, V79, P107, DOI 10.1111/prd.12250
   Ostrovidov S, 2019, SMALL, V15, DOI 10.1002/smll.201805530
   Peres MA, 2019, LANCET, V394, P249, DOI 10.1016/S0140 6736(19)31146 8
   Preshaw PM, 2018, PERIODONTOL 2000, V76, P131, DOI 10.1111/prd.12148
   Ravanbakhsh H, 2021, ADV MATER, V33, DOI 10.1002/adma.202104730
   Salhotra A, 2020, NAT REV MOL CELL BIO, V21, P696, DOI 10.1038/s41580 020 00279 w
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Shang LL, 2021, BIOACT MATER, V6, P1175, DOI 10.1016/j.bioactmat.2020.10.010
   Shi NY, 2024, SMALL, V20, DOI 10.1002/smll.202305218
   Shi NY, 2021, SMALL METHODS, V5, DOI 10.1002/smtd.202100276
   Slots J, 2017, PERIODONTOL 2000, V75, P7, DOI 10.1111/prd.12221
   Song HHG, 2018, CELL STEM CELL, V22, P340, DOI 10.1016/j.stem.2018.02.009
   Thomas MV, 2011, J DENT RES, V90, P1052, DOI 10.1177/0022034510393967
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Tuganbaev T, 2022, SCIENCE, V376, P934, DOI 10.1126/science.abn1890
   Veglia F, 2021, NAT REV IMMUNOL, V21, P485, DOI 10.1038/s41577 020 00490 y
   Veglia F, 2018, NAT IMMUNOL, V19, P108, DOI 10.1038/s41590 017 0022 x
   Yang H, 2013, BIOMATERIALS, V34, P7033, DOI 10.1016/j.biomaterials.2013.05.025
   Yeo AT, 2022, NAT IMMUNOL, V23, P971, DOI 10.1038/s41590 022 01215 0
   Yu QT, 2023, ADV DRUG DELIVER REV, V197, DOI 10.1016/j.addr.2023.114823
   Zhang WB, 2021, TRENDS MOL MED, V27, P501, DOI 10.1016/j.molmed.2021.02.005
   Zhao YY, 2023, BIOACT MATER, V19, P237, DOI 10.1016/j.bioactmat.2022.04.011
   Zhou CC, 2011, BIOMATERIALS, V32, P2704, DOI 10.1016/j.biomaterials.2010.12.040
   Zhou L, 2018, CIRCULATION, V138, P181, DOI 10.1161/CIRCULATIONAHA.117.030811
   Zub K, 2022, ADV MATER, V34, DOI 10.1002/adma.202105015
NR 44
TC 9
Z9 10
U1 9
U2 60
PU IOP Publishing Ltd
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 1758 5082
EI 1758 5090
J9 BIOFABRICATION
JI Biofabrication
PD APR 1
PY 2024
VL 16
IS 2
AR 025007
DI 10.1088/1758 5090/ad2081
PG 14
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA GM0V4
UT WOS:001152975900001
PM 38241709
DA 2025 08 17
ER

PT J
AU Wu, TL
   Li, F
   Sha, X
   Li, FY
   Zhang, BB
   Ma, WR
   Liu, M
   Yang, WZ
   Li, H
   Tao, HR
AF Wu, Tailin
   Li, Feng
   Sha, Xin
   Li, Fuyang
   Zhang, Bobo
   Ma, Wenrui
   Liu, Ming
   Yang, Weizhou
   Li, Huan
   Tao, Huiren
TI A novel recombinant RANKL vaccine prepared by incorporation of an
   unnatural amino acid into RANKL and its preventive effect in a murine
   model of collagen induced arthritis
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Rheumatoid arthritis; RANKL; Vaccine; Unnatural amino acid; Immunization
ID RHEUMATOID ARTHRITIS; BONE EROSION; IMMUNOCHEMICAL TERMINATION;
   OSTEOCLAST DIFFERENTIATION; SELF TOLERANCE; DENOSUMAB; OSTEOPOROSIS;
   PATHOGENESIS; OSTEOPROTEGERIN; THERAPY
AB Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammatory synovitis, bone atrophy, and subsequent progressive destruction of articular tissue. Targeted inhibition of receptor activator of NF kappa B ligand (RANKL) has been highly successful in preventing RA mediated bone erosion in animal models and patients, suggesting that development of a RANKL vaccine might be of therapeutic value. Our previous study has shown that the recombinant RANKL vaccine Y(234)pNO(2)Phe, generated by replacement of a single tyrosine residue (Tyr(234)) in murine RANKL (mRANKL) with p nitrophenylalanine (pNO(2)Phe), induces a high titer antibody response and prevents ovariectomy (OVX) induced bone loss in mice. This aim of this study was to further evaluate the vaccine's preventive effects in a murine model of collagen induced arthritis. The results of this study showed that Y(234)pNO(2) Phe not only induced a high titer antibody response and inhibited osteoclastogenesis but also significantly prevented bone erosion and ameliorated the severity of a collagen induced arthritis (CIA) model in mice. Moreover, use of the vaccine improved the clinical situations of the CIA mice. These results suggest a potential application of an anti RANKL vaccine in the treatment of RA induced bone erosion.
C1 [Wu, Tailin] 208th Hosp Peoples Liberat Army, Dept Emergency Med, Changchun 130000, Jilin, Peoples R China.
   [Li, Feng; Ma, Wenrui; Liu, Ming] Fourth Mil Med Univ, Xijing Hosp, Dept Orthopaed, Xian 710032, Shaanxi, Peoples R China.
   [Li, Feng] Gen Hosp PLA Rocket Force, Dept Orthopaed, Beijing 100088, Peoples R China.
   [Sha, Xin] 306th Hosp Peoples Liberat Army, Dept Orthopaed, Beijing 100000, Peoples R China.
   [Li, Fuyang] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA.
   [Zhang, Bobo; Yang, Weizhou] Xi An Jiao Tong Univ, Dept Orthopaed, Affiliated Hosp 1, Xian 710032, Shaanxi, Peoples R China.
   [Li, Huan] Fourth Mil Med Univ, Xijing Hosp, Dept Cardiol, Xian 710032, Shaanxi, Peoples R China.
   [Tao, Huiren] Shenzhen Univ, Dept Orthopaed, Gen Hosp, Shenzhen 518000, Peoples R China.
C3 Air Force Medical University; University of Texas System; University of
   Texas Health Science Center at San Antonio; Xi'an Jiaotong University;
   Air Force Medical University; Shenzhen University
RP Li, H (通讯作者)，Fourth Mil Med Univ, Xijing Hosp, Dept Cardiol, Xian 710032, Shaanxi, Peoples R China.; Tao, HR (通讯作者)，Shenzhen Univ, Dept Orthopaed, Gen Hosp, Shenzhen 518000, Peoples R China.
EM Lihuan816@yahoo.com; Huiren_tao@163.com
RI Wu, Tailin/GRF 3911 2022; Zhang, Bob/HIR 3656 2022; LIU,
   Fangyuan/GRX 8688 2022
FU Science and Technology Innovation Project in Shaanxi Province of China
   [2015KTCL03 09]; National Natural Science Foundation of China [81070698]
FX This work was supported by Science and Technology Innovation Project in
   Shaanxi Province of China (2015KTCL03 09), National Natural Science
   Foundation of China (81070698). Thank Professor Peter G. Schultz for
   providing plasmid pEVOL aaRS free of charge.
CR Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Bachmann MF, 2004, NAT REV DRUG DISCOV, V3, P81, DOI 10.1038/nrd1284
   Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   Danks L, 2016, ANN RHEUM DIS, V75, P1187, DOI 10.1136/annrheumdis 2014 207137
   Deodhar A, 2010, ARTHRIT CARE RES, V62, P569, DOI 10.1002/acr.20004
   Gan K, 2015, INT IMMUNOPHARMACOL, V24, P239, DOI 10.1016/j.intimp.2014.12.012
   Gruenewald J, 2008, P NATL ACAD SCI USA, V105, P11276, DOI 10.1073/pnas.0804157105
   Grünewald J, 2009, P NATL ACAD SCI USA, V106, P4337, DOI 10.1073/pnas.0900507106
   Inoue A, 2009, MOD RHEUMATOL, V19, P125, DOI 10.1007/s10165 008 0131 3
   Kamijo S, 2006, BIOCHEM BIOPH RES CO, V347, P124, DOI 10.1016/j.bbrc.2006.06.098
   Kessel C, 2014, ARTHRITIS RHEUMATOL, V66, P610, DOI 10.1002/art.38237
   Kotake S, 2001, ARTHRITIS RHEUM, V44, P1003, DOI 10.1002/1529 0131(200105)44:5<1003::AID ANR179>3.3.CO;2 R
   Li AF, 2010, EXPERT OPIN BIOL TH, V10, P903, DOI 10.1517/14712591003796546
   Li F, 2018, BIOCHEM BIOPH RES CO, V499, P648, DOI 10.1016/j.bbrc.2018.03.205
   McLachlan JM, 2013, MED J AUSTRALIA, V199, P242, DOI 10.5694/mja13.10038
   Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006
   Papapoulos S, 2012, J BONE MINER RES, V27, P694, DOI 10.1002/jbmr.1479
   Pesek R, 2011, ALLERGY, V66, P25, DOI 10.1111/j.1398 9995.2010.02462.x
   Romas E, 2002, AM J PATHOL, V161, P1419, DOI 10.1016/S0002 9440(10)64417 3
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Semerano L, 2012, AUTOIMMUN REV, V11, P785, DOI 10.1016/j.autrev.2012.02.003
   Shigeyama Y, 2000, ARTHRITIS RHEUM, V43, P2523, DOI 10.1002/1529 0131(200011)43:11<2523::AID ANR20>3.0.CO;2 Z
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Smolen JS, 2012, NAT REV RHEUMATOL, V8, P235, DOI 10.1038/nrrheum.2012.23
   Spohn G, 2005, J IMMUNOL, V175, P6211, DOI 10.4049/jimmunol.175.9.6211
   Tanaka Yoshiya, 2011, Clin Calcium, V21, P1223, DOI CliCa110812231229
   Turner JD, 2015, CURR OPIN RHEUMATOL, V27, P175, DOI 10.1097/BOR.0000000000000148
   Xu SQ, 2012, RHEUMATOL INT, V32, P3397, DOI 10.1007/s00296 011 2175 5
   Young TS, 2010, J MOL BIOL, V395, P361, DOI 10.1016/j.jmb.2009.10.030
   Yuan HH, 2012, BIOMATERIALS, V33, P8177, DOI 10.1016/j.biomaterials.2012.07.047
NR 30
TC 11
Z9 13
U1 1
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD NOV
PY 2018
VL 64
BP 326
EP 332
DI 10.1016/j.intimp.2018.09.022
PG 7
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA GX9EL
UT WOS:000448101200040
PM 30243068
DA 2025 08 17
ER

PT J
AU Gugliandolo, E
   Fusco, R
   D'Amico, R
   Militi, A
   Oteri, G
   Wallace, JL
   Di Paola, R
   Cuzzocrea, S
AF Gugliandolo, Enrico
   Fusco, Roberta
   D'Amico, Ramona
   Militi, Angela
   Oteri, Giacomo
   Wallace, John L.
   Di Paola, Rosanna
   Cuzzocrea, Salvatore
TI Anti inflammatory effect of ATB 352, a H2S releasing ketoprofen
   derivative, on lipopolysaccharide induced periodontitis in rats
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article
DE Periodontitis; Inflammation; LPS; Ketoprophen
ID HYDROGEN SULFIDE; BONE RESORPTION; KAPPA B; INFLAMMATION; MODEL;
   EXPRESSION; CYCLOOXYGENASE 2; MODULATION; MANAGEMENT; MEDIATOR
AB Periodontal disease is the most common cause of tooth loss in humans, is an inflammatory disease initiated by oral microbial biofilm. Given the involvement of the inflammatory pathway in this type of pathology, the main pharmacological strategy for the treatment of periodontitis, is the inhibition of the inflammatory process in order to prevent tissue destruction and bone resorption, a condition associated with a painful state. To do this, the best class of drugs are Non steroidal anti inflammatory drugs (NSAIDs), however, the presence of side effects, especially at the gastrointestinal tract, limits their use for long term therapy. Recently, some evidence shows that derivatives of NSAIDs capable of releasing hydrogen sulphide exhibit lower collateral effects, particularly at the gastric level. In fact, H2S is an endogenous gaseous mediator with a cytoprotective role at the gastric level. In this study, we have compared the protective effects of ketoprofen with ATB 352, a hydrogen sulfide releasing derivative of ketoprofen, in an experimental model of periodontitis in rat. Periodontitis was induced by a single intragingival injection of 1 mu l LPS (10 mu g/mu l), Our results show that 14 h after intragingival injection of LPS, there was a high tissue damage associated with bone resorption, and in gingivomucosal tissues there was a significant expression of NF kb p65 and pro inflammatory cytokine as well as a higher expression of COX 2 and iNOS, activation of the apoptotic process, and also increased levels of NGF expression, often associated with a higher nociceptive perception. Treatment with ATB 352 at the dose of 20mg\kg, was able to reduce the inflammatory process associated with intragingival LPS injection and also had a positive effect on bone resorption and tissue damage. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Gugliandolo, Enrico; Fusco, Roberta; D'Amico, Ramona; Di Paola, Rosanna; Cuzzocrea, Salvatore] Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, Viale Ferdinando Stagno DAlcontres 31, I 98166 Messina, Italy.
   [Militi, Angela] Univ Messina, Dept Biomed Dent & Morphol & Funct Images, Messina, Italy.
   [Oteri, Giacomo] Univ Messina, Dept Dent & Med & Surg Expt Sci, Messina, Italy.
   [Wallace, John L.] Univ Calgary, Inflammat Res Network, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.
   [Cuzzocrea, Salvatore] St Louis Univ, Dept Pharmacol & Physiol Sci, St Louis, MO 63103 USA.
C3 University of Messina; University of Messina; University of Messina;
   University of Calgary; Saint Louis University
RP Di Paola, R (通讯作者)，Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, Viale Ferdinando Stagno DAlcontres 31, I 98166 Messina, Italy.; Cuzzocrea, S (通讯作者)，St Louis Univ, Dept Pharmacol & Physiol Sci, St Louis, MO 63103 USA.
EM wallacej@ucalgary.ca; dipaolar@unime.it; salvator@unime.it
RI Cuzzocrea, Salvatore/K 4734 2016; FUSCO, Roberta/AAC 1745 2019; di
   paola, rosanna/U 4356 2019; Gugliandolo, Enrico/AAB 9972 2019; D'Amico,
   Ramona/AAC 9061 2019; Wallace, John/AAL 3763 2021
OI FUSCO, Roberta/0000 0003 0223 1403; di paola,
   rosanna/0000 0001 6725 8581; Gugliandolo, Enrico/0000 0001 6840 3154;
   Oteri, Giacomo/0000 0002 0941 1645; Cuzzocrea,
   Salvatore/0000 0001 6131 3690; D'Amico, Ramona/0000 0003 0389 3871; 
CR Anisimova I. E., 2004, Sudebno Meditsinskaya Ekspertiza, V47, P37
   Barksby HE, 2009, CLIN EXP IMMUNOL, V156, P479, DOI 10.1111/j.1365 2249.2009.03920.x
   Beklen A, 2007, J DENT RES, V86, P347, DOI 10.1177/154405910708600409
   Bezerra MM, 2000, J PERIODONTOL, V71, P1009, DOI 10.1902/jop.2000.71.6.1009
   Campolo M., 2013, FASEB J, V27
   Chen YH, 2009, CYTOKINE, V45, P117, DOI 10.1016/j.cyto.2008.11.009
   Di Paola R, 2004, J DENT RES, V83, P343, DOI 10.1177/154405910408300414
   Di Paola R., 2011, MEDIAT INFLAMM, V2011, P1876
   Dumitrescu AL, 2004, J CLIN PERIODONTOL, V31, P596, DOI 10.1111/j.1600 051X.2004.00528.x
   Fiorucci S, 2005, GASTROENTEROLOGY, V129, P1210, DOI 10.1053/j.gastro.2005.07.060
   Frencken JE, 2017, J CLIN PERIODONTOL, V44, pS94, DOI 10.1111/jcpe.12677
   Gaje P. N., 2016, BIOMED RES INT, V2016, P5197
   Gaspersic R, 2010, J DENT RES, V89, P515, DOI 10.1177/0022034510363108
   Gemici B, 2015, NITRIC OXIDE BIOL CH, V46, P25, DOI 10.1016/j.niox.2014.11.010
   Herrera BS, 2015, MED GAS RES, V5, DOI 10.1186/s13618 015 0025 3
   Hienz SA, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/615486
   Holzhausen M., 2016, J PERIODONTOL, V73, P313
   Huang SG, 2014, ARCH ORAL BIOL, V59, P654, DOI 10.1016/j.archoralbio.2014.03.016
   Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279
   Lappin DF, 2000, J PERIODONTAL RES, V35, P369, DOI 10.1034/j.1600 0765.2000.035006369.x
   Li L, 2013, J CELL MOL MED, V17, P365, DOI 10.1111/jcmm.12016
   Li L, 2009, FREE RADICAL BIO MED, V47, P103, DOI 10.1016/j.freeradbiomed.2009.04.014
   Li XY, 2017, J OCEAN U CHINA, V16, P547, DOI 10.1007/s11802 017 3297 5
   McMahon SB, 1996, PHILOS T R SOC B, V351, P431, DOI 10.1098/rstb.1996.0039
   Morton RS, 2001, J PERIODONTOL, V72, P461, DOI 10.1902/jop.2001.72.4.461
   MULLANE KM, 1985, J PHARMACOL METHOD, V14, P157, DOI 10.1016/0160 5402(85)90029 4
   OFFENBACHER S, 1993, J PERIODONTOL, V64, P432, DOI 10.1902/jop.1993.64.5s.432
   PAGE RC, 2000, PERIODONTOL, V14, P9
   Petrosino S, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00308
   Salvi GE, 2005, J CLIN PERIODONTOL, V32, P108, DOI 10.1111/j.1600 051X.2005.00785.x
   Siracusa R, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00233
   Sivarajah A, 2009, SHOCK, V31, P267, DOI 10.1097/SHK.0b013e318180ff89
   Sparatore Anna, 2011, Expert Rev Clin Pharmacol, V4, P109, DOI 10.1586/ecp.10.122
   Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830
   Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01 0390rev
   Van Dyke TE, 2008, J PERIODONTOL, V79, P1601, DOI 10.1902/jop.2008.080173
   Wallace JL, 2008, PHYSIOL REV, V88, P1547, DOI 10.1152/physrev.00004.2008
   Wallace JL, 2007, TRENDS PHARMACOL SCI, V28, P501, DOI 10.1016/j.tips.2007.09.003
   Wallace JL, 2012, ANTIOXID REDOX SIGN, V17, P58, DOI 10.1089/ars.2011.4351
   Zanardo RCO, 2006, FASEB J, V20, P2118, DOI 10.1096/fj.06 6270fje
NR 40
TC 54
Z9 58
U1 3
U2 28
PU ACADEMIC PRESS LTD  ELSEVIER SCIENCE LTD
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043 6618
J9 PHARMACOL RES
JI Pharmacol. Res.
PD JUN
PY 2018
VL 132
BP 220
EP 231
DI 10.1016/j.phrs.2017.12.022
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GL1ZY
UT WOS:000436914000023
PM 29287688
DA 2025 08 17
ER

PT J
AU Dittmar, MC
   Tohidnezhad, M
   Fragoulis, A
   Bücker, A
   Stein, M
   Pufe, T
   Kubo, Y
AF Dittmar, Maja Charlotte
   Tohidnezhad, Mersedeh
   Fragoulis, Athanassios
   Buecker, Annette
   Stein, Matthias
   Pufe, Thomas
   Kubo, Yusuke
TI Pharmacological effects of methysticin and L sulforaphane through the
   Nrf2/ARE signaling pathway in MLO Y4 osteocytes: in vitro study
SO ANNALS OF ANATOMY ANATOMISCHER ANZEIGER
LA English
DT Article
DE Osteocytes; MLO Y4; Oxidative stress; L sulforaphane; Methysticin
ID OSTEOCLASTIC BONE RESORPTION; OXIDATIVE STRESS; APOPTOSIS; OSTEOPOROSIS;
   OSTEOPONTIN; HOMEOSTASIS; MODULATION; OSTEOBLAST; RESPONSES; CELLS
AB Background: Oxidative stress plays a crucial role in the pathogenesis of many skeletal diseases by inducing osteocyte death. The transcription factor nuclear factor erythroid 2 related factor 2 (Nrf2) is a master regulator of various antioxidant gene expressions through antioxidant response element (ARE) against cellular oxidative stress and can be induced by various stimulants, including the phytochemicals methysticin (MET) and L sulforaphane (SFN). This study aimed to establish an osteocyte in vitro model to investigate the pharmacological effects of MET and SFN on the Nrf2/ARE pathway. Methods: MLO Y4 murine osteocytes and the stably transduced MLO Y4 SIN lenti ARE reporter gene cell line were used. MET and SFN were used as Nrf2 inducers. The cytotoxicity of MET, SFN, and hydrogen peroxide (H 2 O 2 ) was evaluated using the CytoTox Glo TM Assay. Time  and dose  dependent ARE induction was examined by Monoluciferase Assay. The mRNA and protein expressions of Nrf2 target markers, such as heme oxygenase 1 (Ho  1), NADPH quinone dehydrogenase 1 (Nqo1), and thioredoxin reductase 1 (Txnrd1), were detected by RTqPCR, Western Blot, and immunofluorescence staining, respectively. Osteogenesis markers, osteopontin, and osteocalcin were compared with and without treatment by immunofluorescence staining. Results: The experimental data showed that MET and SFN induced ARE activity in a time  and dose  dependent manner and increased the mRNA and protein expression of antioxidant markers compared to vehicle treated controls. The protein expression of osteopontin and osteocalcin in the samples treated with SFN were significantly higher than without treatment, and the number of cell death treated with SFN was significantly lower than without treatment under H 2 O 2  induced stress conditions. Conclusions: Nrf2 inducers MET and SFN increased the mRNA expression of antioxidant genes through the Nrf2/ ARE pathway in osteocytes. Notably, SFN increased the protein expression of osteocyte associated osteogenic markers and suppressed cell death under H 2 O 2  induced stress condition. Thus, Nrf2 stimulators can exert stressrelieving and osteogenic effects on osteocytes.
C1 [Dittmar, Maja Charlotte; Tohidnezhad, Mersedeh; Fragoulis, Athanassios; Buecker, Annette; Stein, Matthias; Pufe, Thomas; Kubo, Yusuke] Uniklin RWTH Aachen, Dept Anat & Cell Biol, Wendlingweg 2, D 52074 Aachen, Germany.
   [Kubo, Yusuke] Kyushu Univ, Grad Sch Med Sci, Dept Orthopaed Surg, 3 1 1 Maidashi,Higashi Ku, Fukuoka 8128582, Japan.
C3 RWTH Aachen University; RWTH Aachen University Hospital; Kyushu
   University
RP Kubo, Y (通讯作者)，Uniklin RWTH Aachen, Dept Anat & Cell Biol, Wendlingweg 2, D 52074 Aachen, Germany.
EM y.kubokku@gmail.com
RI ; Fragoulis, Athanassios/O 1191 2019; Stein, Matthias/A 2865 2011
OI Stein, Matthias/0009 0004 0454 1207; 
FU ON Kick Starter Grant from Orthoregeneration Network [21 276];
   Excellence Initiative of the German Federal and State Governments;
   Interdisciplinary Centre for Clinical Research of the Faculty of
   Medicine of the RWTH Aachen University [T9 3, T9 5, OC1 1]; Deutscher
   Akademischer Austauschdienst (DAAD) [57440921]
FX We thank Felix Waldmann, Angela Ruben, Susanne Echterhagen, Nina Koch,
   and Michaela Nicolau for technical support. This research project was
   supported by the ON Kick Starter Grant from Orthoregeneration Network
   (grant No. 21 276), the Excellence Initiative of the German Federal and
   State Governments and the Interdisciplinary Centre for Clinical Research
   of the Faculty of Medicine of the RWTH Aachen University (T9 3; T9 5;
   OC1 1) and the Deutscher Akademischer Austauschdienst (DAAD) (57440921).
   We thank Prof. Dr. Lynda Bonewald for the distribution of the MLO Y4
   cells.
CR Abcam, 2023, General western blot protocol
   Baek KH, 2010, CALCIFIED TISSUE INT, V87, P226, DOI 10.1007/s00223 010 9393 9
   BAX BE, 1992, BIOCHEM BIOPH RES CO, V183, P1153, DOI 10.1016/S0006 291X(05)80311 0
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Capulli M, 2014, ARCH BIOCHEM BIOPHYS, V561, P3, DOI 10.1016/j.abb.2014.05.003
   Carter M, 2015, GAMES CULT, V10, P311, DOI 10.1177/1555412014558089
   Casati L, 2020, EUR J NUTR, V59, P1975, DOI 10.1007/s00394 019 02047 9
   Chen K, 2020, INT J BIOL SCI, V16, P1888, DOI 10.7150/ijbs.40917
   Chen XR, 2021, BONE RES, V9, DOI 10.1038/s41413 020 00128 8
   Covas G, 2013, METHOD ENZYMOL, V528, P157, DOI 10.1016/B978 0 12 405881 1.00009 4
   Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477 8486.2004
   Dai JQ, 2015, INT J CLIN EXP PATHO, V8, P4356
   Derkx P, 1998, BONE, V22, P367, DOI 10.1016/S8756 3282(97)00299 8
   Fragoulis A, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24097722
   Fragoulis A, 2017, REDOX BIOL, V12, P843, DOI 10.1016/j.redox.2017.04.024
   Frias DP, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 59930 3
   GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485
   Gerstenfeld LC, 1999, J BONE MINER RES, V14, P850, DOI 10.1359/jbmr.1999.14.6.850
   Harbottle JA, 2020, ANAL BIOCHEM, V592, DOI 10.1016/j.ab.2020.113583
   Ibáñez L, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/726590
   Ishii T, 2022, FREE RADICAL BIO MED, V191, P191, DOI 10.1016/j.freeradbiomed.2022.08.036
   Jansen S, 2017, J NEUROCHEM, V141, P86, DOI 10.1111/jnc.13959
   Jilka RL, 2007, J BONE MINER RES, V22, P1492, DOI 10.1359/JBMR.070518
   Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014
   Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046
   Kim JH, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.33
   Kubo Y, 2022, BMC MUSCULOSKEL DIS, V23, DOI 10.1186/s12891 022 05942 1
   Kubo Y, 2022, ANTIOXIDANTS BASEL, V11, DOI 10.3390/antiox11020263
   Kubo Y, 2019, CALCIFIED TISSUE INT, V105, P341, DOI 10.1007/s00223 019 00576 3
   Licznerska B, 2021, MOL CELL BIOCHEM, V476, P525, DOI 10.1007/s11010 020 03913 5
   Liessem Schmitz A, 2018, J MOL NEUROSCI, V66, P229, DOI 10.1007/s12031 018 1159 2
   Lippross S, 2014, CALCIFIED TISSUE INT, V95, P349, DOI 10.1007/s00223 014 9900 5
   Murray JR, 2019, CHEM RES TOXICOL, V32, P2538, DOI 10.1021/acs.chemrestox.9b00399
   Panich U, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/7370642
   Park C, 2020, EXCLI J, V19, P1102, DOI 10.17179/excli2020 2376
   Park CK, 2014, BONE, V63, P36, DOI 10.1016/j.bone.2014.01.025
   Pellegrini GG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171161
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Prasad Ganesh, 2003, Acta Orthop Belg, V69, P546
   Rada P, 2011, MOL CELL BIOL, V31, P1121, DOI 10.1128/MCB.01204 10
   Robledinos Antón N, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9372182
   Robling AG, 2020, ANNU REV PHYSIOL, V82, P485, DOI 10.1146/annurev physiol 021119 034332
   Ruijter JM, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp045
   Sánchez de Diego C, 2021, REDOX BIOL, V40, DOI 10.1016/j.redox.2020.101845
   Sies H, 2020, NAT REV MOL CELL BIO, V21, P363, DOI 10.1038/s41580 020 0230 3
   Sun YX, 2015, BONE, V74, P1, DOI 10.1016/j.bone.2014.12.066
   Tang J, 2011, PHYTOTHER RES, V25, P417, DOI 10.1002/ptr.3283
   Terai K, 1999, J BONE MINER RES, V14, P839, DOI 10.1359/jbmr.1999.14.6.839
   Thaler R, 2016, J BIOL CHEM, V291, P6754, DOI 10.1074/jbc.M115.678235
   Thimmulappa RK, 2002, CANCER RES, V62, P5196
   Wakabayashi N, 2015, FREE RADICAL BIO MED, V88, P158, DOI 10.1016/j.freeradbiomed.2015.05.017
   Wang Y, 2017, BIOMED PHARMACOTHER, V96, P993, DOI 10.1016/j.biopha.2017.11.136
   Weinstein RS, 2010, BONE, V46, P564, DOI 10.1016/j.bone.2009.06.030
   Wruck CJ, 2008, MOL PHARMACOL, V73, P1785, DOI 10.1124/mol.107.042499
   Yamamoto M, 2018, PHYSIOL REV, V98, P1169, DOI 10.1152/physrev.00023.2017
   Yin YK, 2020, SCI REP UK, V10, DOI 10.1038/s41598 019 57185 1
   Yoshida E, 2018, GENES CELLS, V23, P386, DOI 10.1111/gtc.12579
   Zanichelli F, 2012, AGE, V34, P281, DOI 10.1007/s11357 011 9231 7
   Zanotto A, 2016, MOL CANCER THER, V15, P3000, DOI 10.1158/1535 7163.MCT 16 0271
   Zou L, 2004, PHYTOMEDICINE, V11, P285, DOI 10.1078/0944711041495263
NR 60
TC 2
Z9 2
U1 0
U2 3
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0940 9602
EI 1618 0402
J9 ANN ANAT
JI Ann. Anat. Anat. Anz.
PD JUN
PY 2024
VL 254
AR 152260
DI 10.1016/j.aanat.2024.152260
EA APR 2024
PG 13
WC Anatomy & Morphology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Anatomy & Morphology
GA QY3T9
UT WOS:001224398000001
PM 38521364
OA hybrid
DA 2025 08 17
ER

PT J
AU Nile, AH
   Mukund, S
   Stanger, K
   Wang, WR
   Hannoush, RN
AF Nile, Aaron H.
   Mukund, Susmith
   Stanger, Karen
   Wang, Weiru
   Hannoush, Rami N.
TI Unsaturated fatty acyl recognition by Frizzled receptors mediates
   dimerization upon Wnt ligand binding
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE Frizzled; fatty acid; cysteine rich domain; Wnt; dimerization
ID MUTATIONAL LANDSCAPE; STRUCTURAL BASIS; PROTEIN; DESATURASE; COMPLEX;
   STATE; ACIDS
AB Frizzled (FZD) receptors mediate Wnt signaling in diverse processes ranging from bone growth to stem cell activity. Moreover, high FZD receptor expression at the cell surface contributes to overactive Wnt signaling in subsets of pancreatic, ovarian, gastric, and colorectal tumors. Despite the progress in biochemical understanding of Wnt FZD receptor interactions, the molecular basis for recognition of Wnt cis unsaturated fatty acyl groups by the cysteine rich domain (CRD) of FZD receptors remains elusive. Here, we determined a crystal structure of human FZD7 CRD unexpectedly bound to a 24 carbon fatty acid. We also report a crystal structure of human FZD5 CRD bound to C16:1 cis Delta 9 unsaturated fatty acid. Both structures reveal a dimeric arrangement of the CRD. The lipid binding groove exhibits flexibility and spans both monomers, adopting a U shaped geometry that accommodates the fatty acid. Re evaluation of the published mouse FZD8 CRD structure reveals that it also shares the same architecture as FZD5 and FZD7 CRDs. Our results define a common molecular mechanism for recognition of the cis unsaturated fatty acyl group, a necessary posttranslational modification of Wnts, by multiple FZD receptors. The fatty acid bridges two CRD monomers, implying that Wnt binding mediates FZD receptor dimerization. Our data uncover possibilities for the arrangement of Wnt FZD CRD complexes and shed structural insights that could aide in the identification of pharmacological strategies to modulate FZD receptor function.
C1 [Nile, Aaron H.; Stanger, Karen; Hannoush, Rami N.] Genentech Inc, Dept Early Discovery Biochem, San Francisco, CA 94080 USA.
   [Mukund, Susmith; Wang, Weiru] Genentech Inc, Dept Struct Biol, San Francisco, CA 94080 USA.
C3 Roche Holding; Roche Holding USA; Genentech; Roche Holding; Roche
   Holding USA; Genentech
RP Hannoush, RN (通讯作者)，Genentech Inc, Dept Early Discovery Biochem, San Francisco, CA 94080 USA.
EM hannoush.rami@gene.com
OI Mukund, Susmith/0009 0008 0605 5658; Nile, Aaron/0000 0002 7370 8769;
   Wang, Weiru/0000 0001 8845 301X
CR Backmark AE, 2013, PROTEIN SCI, V22, P1124, DOI 10.1002/pro.2297
   Bai YH, 2015, NATURE, V524, P252, DOI 10.1038/nature14549
   Bienz M, 2014, TRENDS BIOCHEM SCI, V39, P487, DOI 10.1016/j.tibs.2014.08.006
   Bourhis E, 2010, J BIOL CHEM, V285, P9172, DOI 10.1074/jbc.M109.092130
   Carron C, 2003, J CELL SCI, V116, P2541, DOI 10.1242/jcs.00451
   Chang TH, 2015, ELIFE, V4, DOI 10.7554/eLife.06554
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Cui M, 2014, P NATL ACAD SCI USA, V111, pE5029, DOI 10.1073/pnas.1419141111
   Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601
   Dijksterhuis JP, 2015, J BIOL CHEM, V290, P6789, DOI 10.1074/jbc.M114.612648
   Fernandez A, 2014, P NATL ACAD SCI USA, V111, P1409, DOI 10.1073/pnas.1323697111
   Flanagan DJ, 2015, STEM CELL REP, V4, P759, DOI 10.1016/j.stemcr.2015.03.003
   Gammons MV, 2016, MOL CELL, V64, P92, DOI 10.1016/j.molcel.2016.08.026
   Gao XX, 2014, NAT CHEM BIOL, V10, P61, DOI [10.1038/NCHEMBIO.1392, 10.1038/nchembio.1392]
   Giannakis M, 2014, NAT GENET, V46, P1264, DOI 10.1038/ng.3127
   Gregorieff A, 2005, GASTROENTEROLOGY, V129, P626, DOI 10.1053/j.gastro.2005.06.007
   Hannoush RN, 2009, ACS CHEM BIOL, V4, P581, DOI 10.1021/cb900085z
   Holstein TW, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007922
   Huang PX, 2016, CELL, V166, P1176, DOI 10.1016/j.cell.2016.08.003
   Janda CY, 2012, SCIENCE, V337, P59, DOI 10.1126/science.1222879
   Kakugawa S, 2015, NATURE, V519, P187, DOI 10.1038/nature14259
   Kaykas A, 2004, NAT CELL BIOL, V6, P52, DOI 10.1038/ncb1081
   LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648
   Mariadason JM, 2005, GASTROENTEROLOGY, V128, P1081, DOI 10.1053/j.gastro.2005.01.054
   Mei H, 2014, STEM CELLS, V32, P938, DOI 10.1002/stem.1582
   Milligan G, 2008, BRIT J PHARMACOL, V153, pS216, DOI 10.1038/sj.bjp.0707490
   Nile AH, 2016, NAT CHEM BIOL, V12, P60, DOI [10.1038/NCHEMBIO.2005, 10.1038/nchembio.2005]
   Phesse T, 2016, CANCERS, V8, pE50
   Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052
   Rios Esteves J, 2013, CELL REP, V4, P1072, DOI 10.1016/j.celrep.2013.08.027
   Ryland GL, 2015, GENOME MED, V7, DOI 10.1186/s13073 015 0210 y
   Sharpe HJ, 2015, NAT CHEM BIOL, V11, P246, DOI [10.1038/NCHEMBIO.1776, 10.1038/nchembio.1776]
   Shen GB, 2015, CELL RES, V25, P1078, DOI 10.1038/cr.2015.92
   Steinhart Z, 2017, NAT MED, V23, P60, DOI 10.1038/nm.4219
   Takada R, 2006, DEV CELL, V11, P791, DOI 10.1016/j.devcel.2006.10.003
   Van Camp J, 2014, STEM CELL REV REP, V10, P207, DOI 10.1007/s12015 013 9486 8
   VORUM H, 1992, BIOCHIM BIOPHYS ACTA, V1126, P135, DOI 10.1016/0005 2760(92)90283 2
   Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169
   Wang H, 2015, NAT STRUCT MOL BIOL, V22, P581, DOI 10.1038/nsmb.3049
   Wang JB, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007963
   Willert K, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007864
   Zhang XJ, 2015, DEV CELL, V32, P719, DOI 10.1016/j.devcel.2015.02.014
NR 42
TC 88
Z9 99
U1 2
U2 16
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
EI 1091 6490
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 18
PY 2017
VL 114
IS 16
BP 4147
EP 4152
DI 10.1073/pnas.1618293114
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA ES2WA
UT WOS:000399387400053
PM 28377511
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Maru, BS
   Tobias, JH
   Rivers, C
   Caunt, CJ
   Norman, MR
   McArdle, CA
AF Maru, Benit S.
   Tobias, Jonathan H.
   Rivers, Caroline
   Caunt, Christopher J.
   Norman, Michael R.
   McArdle, Craig A.
TI Potential use of an estrogen glucocorticoid receptor chimera as a drug
   screen for tissue selective estrogenic activity
SO BONE
LA English
DT Article
DE SERMs; Estrogen receptor alpha; Osteoblasts; Estradiol; Reporter assay
ID CANCELLOUS BONE FORMATION; FEMALE MICE; ER ALPHA; BETA; DIFFERENTIATION;
   MODULATORS; MOBILITY; LIGAND; PHOSPHORYLATION; ANTIESTROGENS
AB SERMs act as ER agonists in bone despite their antagonistic properties in other tissues. As well as inhibiting bone remodelling, this effect may involve stimulation of osteoblast activity, in light of evidence from recent in vivo studies. However, progress in exploring this action has been hampered by a lack of accurate in vitro models. For example, ER antagonists are reported to stimulate reporter assays based on estrogen target genes in osteoblasts, contrary to their inhibitory effects in vivo. We examined whether evaluating global aspects of ER function Provides a more accurate reflection of ER activation in osteoblasts, based on the use of morphological and/or transcriptional read outs with green fluorescent protein (GFP) receptor chimeras. Osteoblast like (ROS and U2OS) and breast cancer (MCF7) cells were transfected with a human ER alpha GFP fusion protein, and treated with ER agonists (17 beta estradiol, and dienestrol), antagonists (ICI 182,780 and ZK 164015) and SERMs (tamoxifen, raloxifene, 4 hydroxytamoxifen (4 HT) and hexestrol). We investigated cellular compartmentalisation of these constructs by fluorescence microscopy, nuclear mobility by fluorescence recovery after photobleaching (FRAP), and global activation of estrogenic transcription using a ERE luc reporter. SERMs caused a modest increase in ERE luc activity in osteoblast like cells (but not in breast cells), and a reduction in nuclear mobility in breast (but not osteoblast like) cells. These studies were then repeated using a GFP chimera where the human GR ligand binding domain (LBD) was replaced by the human ER alpha LBD (ERGR GFP), combined with a GRE luc reporter. Interestingly, SERMs increased both cytoplasmic to nuclear translocation of ERGR GFP, and GRE luc reporter activity, in osteoblast like (but not breast) cells. Indeed, transcriptional responses to SERMs in osteoblast like cells were considerably greater with the ERGR/GRE luc than the ER alpha/ERE luc system, 4 HT inducing 300 and 25% increases in reporter activity respectively. ER antagonists were entirely without effect. We conclude that evaluation of global estrogenic activity, as opposed to activation of a specific target gene, provides a more accurate read out for osteoblast stimulation. In Particular, ERGR mediated GRE luc activity provides a high signal response to estrogen agonists and SERMs, in a cell context dependent manner closely resembling that observed in vivo. Further studies utilising this system are justified to explore the mechanistic basis for estrogenic stimulation of osteoblast activity, and to identify newer SERMs capable of targeting this activity. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Tobias, Jonathan H.] Univ Bristol, Southmead Hosp, Avon Orthopaed Ctr, Acad Rheumatol, Bristol BS10 5NB, Avon, England.
   [Maru, Benit S.; Rivers, Caroline; Caunt, Christopher J.; Norman, Michael R.; McArdle, Craig A.] Univ Bristol, Lab Integrated Neurosci & Endocrinol, Bristol BS10 5NB, Avon, England.
C3 University of Bristol; Southmead Hospital; University of Bristol
RP Tobias, JH (通讯作者)，Univ Bristol, Southmead Hosp, Avon Orthopaed Ctr, Acad Rheumatol, Bristol BS10 5NB, Avon, England.
EM Jon.Tobias@bristol.ac.uk
RI Tobias, Jon/E 2832 2014; McArdle, Craig/AAQ 5660 2021
OI Tobias, Jon/0000 0002 7475 3932; McArdle, Craig/0000 0003 4836 5351
FU Procter and Gamble; Research Foundation of the Charitable Trust [285];
   Wellcome Trust [078407]
FX This work was supported by project grants from Procter and Gamble, the
   Research Foundation of the Charitable Trust for the United Bristol
   Hospitals (Project 285) and by an Equipment Grant from the Wellcome
   Trust (078407).
CR Arts J, 1997, ENDOCRINOLOGY, V138, P5067, DOI 10.1210/en.138.11.5067
   Bord S, 2001, J CLIN ENDOCR METAB, V86, P2309, DOI 10.1210/jc.86.5.2309
   Driggers PH, 2002, TRENDS ENDOCRIN MET, V13, P422, DOI 10.1016/S1043 2760(02)00634 3
   Elbi C, 2004, P NATL ACAD SCI USA, V101, P2876, DOI 10.1073/pnas.0400116101
   GALLAGHER A, 1993, ENDOCRINOLOGY, V133, P2787, DOI 10.1210/en.133.6.2787
   Katzenellenbogen BS, 2000, J STEROID BIOCHEM, V74, P279, DOI 10.1016/S0960 0760(00)00104 7
   Kousteni S, 2007, MOL CELL BIOL, V27, P1516, DOI 10.1128/MCB.01550 06
   Likhite VS, 2006, MOL ENDOCRINOL, V20, P3120, DOI 10.1210/me.2006 0068
   Martinez ED, 2005, J STEROID BIOCHEM, V97, P307, DOI 10.1016/j.jsbmb.2005.06.033
   Maruvada P, 2003, J BIOL CHEM, V278, P12425, DOI 10.1074/jbc.M202752200
   McDougall KE, 2003, ENDOCRINOLOGY, V144, P1994, DOI 10.1210/en.2002 0074
   McDougall KE, 2002, AM J PHYSIOL ENDOC M, V283, pE817, DOI 10.1152/ajpendo.00071.2002
   Michalides R, 2004, CANCER CELL, V5, P597, DOI 10.1016/j.ccr.2004.05.016
   MONROE DG, 2005, ESTROGEN RECEPTOR AL
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Ogawa S, 2005, GENES CELLS, V10, P1095, DOI 10.1111/j.1365 2443.2005.00904.x
   Ong DB, 2004, J BONE MINER RES, V19, P447, DOI 10.1359/JBMR.0301249
   Onoe Y, 1997, ENDOCRINOLOGY, V138, P4509, DOI 10.1210/en.138.10.4509
   Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999
   Perry MJ, 2005, ENDOCRINOLOGY, V146, P1060, DOI 10.1210/en.2004 1114
   Pratt WB, 2006, HANDB EXP PHARM, V172, P111
   Prossnitz ER, 2007, MOL CELL ENDOCRINOL, V265, P138, DOI 10.1016/j.mce.2006.12.010
   Qu Q, 1999, J CELL BIOCHEM, V73, P500, DOI 10.1002/(SICI)1097 4644(19990615)73:4<500::AID JCB8>3.3.CO;2 5
   Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097 2765(03)00090 X
   Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003 0023
   SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604
   Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515
   Taranta A, 2002, BONE, V30, P368, DOI 10.1016/S8756 3282(01)00685 8
   Tobias JH, 1999, BONE, V24, P121, DOI 10.1016/S8756 3282(98)00156 2
   Tou LQ, 2001, MOL CELL ENDOCRINOL, V183, P71, DOI 10.1016/S0303 7207(01)00594 9
   van den Wijngaard A, 2000, MOL ENDOCRINOL, V14, P623, DOI 10.1210/me.14.5.623
   Yang NN, 1996, SCIENCE, V273, P1222, DOI 10.1126/science.273.5279.1222
NR 32
TC 8
Z9 10
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JAN
PY 2009
VL 44
IS 1
BP 102
EP 112
DI 10.1016/j.bone.2008.09.016
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 395TV
UT WOS:000262547300012
PM 18976723
DA 2025 08 17
ER

PT J
AU Bellinger, DL
   Wood, C
   Wergedal, JE
   Lorton, D
AF Bellinger, Denise L.
   Wood, Carlo
   Wergedal, Jon E.
   Lorton, Dianne
TI Driving β2  While Suppressing α Adrenergic Receptor Activity
   Suppresses Joint Pathology in Inflammatory Arthritis
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE terbutaline; sympathetic nerves; bone and cartilage sparing; disease
   severity; adrenergic signaling; rheumatoid arthritis; bone marrow
   adiposity; phentolamine
ID SYMPATHETIC NERVOUS SYSTEM; RESISTANT ACID PHOSPHATASE;
   RHEUMATOID ARTHRITIS; BONE MASS; RAT MODEL; MOLECULAR MECHANISMS; HUMAN
   SYNOVIUM; LYMPH NODES; MOUSE MODEL; IN VITRO
AB Objective Hypersympathetic activity is prominent in rheumatoid arthritis, and major life stressors precede onset in similar to 80% of patients. These findings and others support a link between stress, the sympathetic nervous system and disease onset and progression. Here, we extend previous research by evaluating how selective peripherally acting alpha/beta(2) adrenergic drugs affect joint destruction in adjuvant induced arthritis.
   Methods Complete Freund's adjuvant induced inflammatory arthritis in male Lewis rats. Controls received no treatment. Arthritic rats then received vehicle or twice daily treatment with the alpha adrenergic antagonist, phentolamine (0.5 mg/day) and the beta(2) adrenergic agonist, terbutaline (1200 mu g/day, collectively named SH1293) from day (D) of disease onset (D12) through acute (D21) and severe disease (D28). Disease progression was assessed in the hind limbs using dorsoplantar widths, X ray analysis, micro computed tomography, and routine histology on D14, D21, and D28 post immunization.
   Results On D21, SH1293 significantly attenuated arthritis in the hind limbs, based on reduced lymphocytic infiltration, preservation of cartilage, and bone volume. Pannus formation and sympathetic nerve loss were not affected by SH1293. Bone area and osteoclast number revealed high  and low treatment responding groups. In high responding rats, treatment with SH1293 significantly preserved bone area and decreased osteoclast number, data that correlated with drug mediated joint preservation. SH1293 suppressed abnormal bone formation based on reduced production of osteophytes. On D28, the arthritic sparing effects of SH1293 on lymphocytic infiltration, cartilage and bone sparing were maintained at the expense of bone marrow adipocity. However, sympathetic nerves were retracted from the talocrural joint.
   Conclusion and Significance Our findings support a significant delay in early arthritis progression by treatment with SH1293. Targeting sympathetic neurotransmission may provide a strategy to slow disease progression.
C1 [Bellinger, Denise L.; Wood, Carlo] Loma Linda Univ, Sch Med, Dept Human Anat & Pathol, Loma Linda, CA 92350 USA.
   [Wergedal, Jon E.] VA Loma Linda Healthcare Syst, Musculoskeletal Dis Ctr, Loma Linda, CA USA.
   [Wergedal, Jon E.] Loma Linda Univ, Dept Med, Loma Linda, CA 92350 USA.
   [Wergedal, Jon E.] Loma Linda Univ, Dept Biochem, Loma Linda, CA 92350 USA.
   [Lorton, Dianne] Banner Hlth Res Inst, Hoover Arthrit Res Ctr, Sun City, AZ USA.
C3 Loma Linda University; Loma Linda University; Loma Linda University;
   Banner Research; Banner Health; Banner Sun Health Research Institute
RP Bellinger, DL (通讯作者)，Loma Linda Univ, Sch Med, Dept Human Anat & Pathol, Loma Linda, CA 92350 USA.
EM dbellinger@llu.edu
RI Wood, Carlo/NKQ 5434 2025
FU Department of Pathology and Human Anatomy;  [R01 NS055673]
FX This study was supported by R01 NS055673 and an intramural grant from
   the Department of Pathology and Human Anatomy.
CR ALOE L, 1992, RHEUMATOL INT, V12, P213, DOI 10.1007/BF00302155
   Angel NZ, 2000, J BONE MINER RES, V15, P103, DOI 10.1359/jbmr.2000.15.1.103
   Arai M, 2003, BBA MOL CELL RES, V1640, P137, DOI 10.1016/S0167 4889(03)00042 9
   Arai M, 2013, EUR J PHARMACOL, V701, P7, DOI 10.1016/j.ejphar.2012.12.016
   Arcaroli J, 2002, J LEUKOCYTE BIOL, V72, P571
   Baek K, 2014, BMB REP, V47, P506, DOI 10.5483/BMBRep.2014.47.9.265
   Baek K, 2012, J APPL PHYSIOL, V113, P1792, DOI 10.1152/japplphysiol.00187.2012
   Bartok B, 2010, IMMUNOL REV, V233, P233, DOI 10.1111/j.0105 2896.2009.00859.x
   Bassi GS, 2017, BRAIN BEHAV IMMUN, V64, P330, DOI 10.1016/j.bbi.2017.04.003
   Bellinger DL, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041188
   Bhattaram P, 2019, BIOCHEM PHARMACOL, V165, P145, DOI 10.1016/j.bcp.2019.03.018
   BOEHM S, 1995, NEUROSCIENCE, V69, P221, DOI 10.1016/0306 4522(95)00235 B
   Boyette LB, 2014, STEM CELL TRANSL MED, V3, P241, DOI 10.5966/sctm.2013 0079
   Capellino S, 2008, J RHEUMATOL, V35, P91
   Cappellen D, 2002, J BIOL CHEM, V277, P21971, DOI 10.1074/jbc.M200434200
   Chaweewannakorn W, 2019, J CELL PHYSIOL, V234, P1745, DOI 10.1002/jcp.27045
   Chen JY, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00563
   DASILVA JAP, 1990, J RHEUMATOL, V17, P1592
   Deane KD, 2021, ARTHRITIS RHEUMATOL, V73, P181, DOI 10.1002/art.41417
   Denu RA, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2989076
   El Bagdadi K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133127
   Elefteriou F, 2008, ARCH BIOCHEM BIOPHYS, V473, P231, DOI 10.1016/j.abb.2008.03.016
   Elefteriou F, 2018, PHYSIOL REV, V98, P1083, DOI 10.1152/physrev.00014.2017
   Elefteriou F, 2014, CALCIFIED TISSUE INT, V94, P140, DOI 10.1007/s00223 013 9752 4
   Fassold A, 2009, ARTHRITIS RHEUM US, V60, P2892, DOI 10.1002/art.24860
   Fonseca TL, 2011, J BONE MINER RES, V26, P591, DOI 10.1002/jbmr.243
   Garimella MG, 2015, J IMMUNOL, V195, P5136, DOI 10.4049/jimmunol.1500332
   Ghilardi JR, 2012, ARTHRITIS RHEUM US, V64, P2223, DOI 10.1002/art.34385
   Gil DW, 2016, NEUROGASTROENT MOTIL, V28, P423, DOI 10.1111/nmo.12742
   Grässel S, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075 014 0485 1
   Grahnemo L, 2018, AM J PHYSIOL ENDOC M, V315, pE1274, DOI 10.1152/ajpendo.00257.2018
   Guo W, 2007, AM J PHYSIOL ENDOC M, V293, pE576, DOI 10.1152/ajpendo.00523.2006
   GUYENET PG, 1981, J NEUROSCI, V1, P908
   Härle P, 2008, ARTHRITIS RHEUM US, V58, P2347, DOI 10.1002/art.23628
   Hamajima K, 2018, BIOMED REP, V8, P407, DOI 10.3892/br.2018.1075
   Han J, 2009, ARCH BIOCHEM BIOPHYS, V490, P96, DOI 10.1016/j.abb.2009.08.009
   Härle P, 2005, ARTHRITIS RHEUM US, V52, P1305, DOI 10.1002/art.20987
   Hedderich J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113924
   Hoover DB, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01712
   Huang HH, 2009, J CELL PHYSIOL, V220, P267, DOI 10.1002/jcp.21761
   Huang JL, 2012, INFLAMMATION, V35, P527, DOI 10.1007/s10753 011 9342 4
   Jenei Lanzl Z, 2015, BRAIN BEHAV IMMUN, V50, P266, DOI 10.1016/j.bbi.2015.07.020
   Jenei Lanzl Z, 2014, ARTHRITIS RHEUMATOL, V66, P2472, DOI 10.1002/art.38695
   Jiao K, 2016, SCI REP UK, V6, DOI [10.1038/srep30085, 10.1038/srep36454]
   Jiao K, 2015, SCI REP UK, V5, DOI 10.1038/srep12593
   Jimenez Andrade JM, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3826
   Kanashiro A, 2018, FUND CLIN PHARMACOL, V32, P155, DOI 10.1111/fcp.12338
   Khajuria DK, 2013, J ORTHOP SCI, V18, P832, DOI 10.1007/s00776 013 0433 y
   Kim BJ, 2010, BRAIN BEHAV IMMUN, V24, P1126, DOI 10.1016/j.bbi.2010.05.003
   Kodama D, 2013, BRIT J PHARMACOL, V168, P1230, DOI 10.1111/bph.12000
   Koopman FA, 2017, J INTERN MED, V282, P64, DOI 10.1111/joim.12626
   Kunath J, 2017, LIFE SCI, V168, P47, DOI 10.1016/j.lfs.2016.11.009
   Lago R, 2008, CELL IMMUNOL, V252, P139, DOI 10.1016/j.cellimm.2007.09.004
   LANGER SZ, 1980, PHARMACOL REV, V32, P337
   LEVINE JD, 1988, P NATL ACAD SCI USA, V85, P4553, DOI 10.1073/pnas.85.12.4553
   LEVINE JD, 1987, RHEUM DIS CLIN N AM, V13, P369
   Li DP, 2005, J NEUROPHYSIOL, V93, P393, DOI 10.1152/jn.00564.2004
   Li HF, 2012, J GENET GENOMICS, V39, P173, DOI 10.1016/j.jgg.2012.03.003
   Li ZG, 2017, CELL STRESS CHAPERON, V22, P767, DOI 10.1007/s12192 017 0805 x
   Liu Y, 2018, MED SCI MONITOR, V24, P1196, DOI 10.12659/MSM.906184
   Longo G, 2013, J NEUROSCI, V33, P10066, DOI 10.1523/JNEUROSCI.5784 12.2013
   Lorton D., 2015, Brain, Behavior, and Immunity, V49, pe32, DOI [10.1016/j.bbi.2015.06.126, DOI 10.1016/J.BBI.2015.06.126]
   Lorton D, 2015, INT J MOL SCI, V16, P5635, DOI 10.3390/ijms16035635
   Lorton D, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/764395
   Lorton D, 2009, BRAIN BEHAV IMMUN, V23, P276, DOI 10.1016/j.bbi.2008.10.004
   Lubahn CL, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00346
   Lubahn CL, 2004, BRAIN BEHAV IMMUN, V18, P563, DOI 10.1016/j.bbi.2004.02.004
   Ma Y, 2013, J BIOL CHEM, V288, P30105, DOI 10.1074/jbc.M113.481309
   Ma Y, 2011, ENDOCRINOLOGY, V152, P1412, DOI 10.1210/en.2010 0881
   Madden CJ, 2013, J NEUROSCI, V33, P2017, DOI 10.1523/JNEUROSCI.4701 12.2013
   MAPP PI, 1994, ANN RHEUM DIS, V53, P240, DOI 10.1136/ard.53.4.240
   Martinez Lavin M, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2146
   Miller LE, 2000, FASEB J, V14, P2097, DOI 10.1096/fj.99 1082com
   MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252
   Mishima K, 2001, JPN J PHARMACOL, V85, P214, DOI 10.1254/jjp.85.214
   Mititelu RR, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8050125
   Mlakar V, 2015, J CELL MOL MED, V19, P1520, DOI 10.1111/jcmm.12505
   Mohammed M, 2016, AM J PHYSIOL REG I, V310, pR1109, DOI 10.1152/ajpregu.00058.2016
   Nelson Dooley C, 2005, CURR MED CHEM, V12, P2215, DOI 10.2174/0929867054864886
   Obata K, 2007, FEBS LETT, V581, P5917, DOI 10.1016/j.febslet.2007.11.065
   Opolka A, 2012, ARTHRITIS RHEUM US, V64, P729, DOI 10.1002/art.33449
   Otero M, 2006, RHEUMATOLOGY, V45, P944, DOI 10.1093/rheumatology/kel157
   Page KA, 2004, DOMEST ANIM ENDOCRIN, V26, P23, DOI 10.1016/j.domaniend.2003.08.004
   Patki G, 2013, BRAIN RES, V1539, P73, DOI 10.1016/j.brainres.2013.09.033
   Pongratz G, 2012, ANN RHEUM DIS, V71, P432, DOI 10.1136/ard.2011.153056
   Popa NL, 2014, J BONE MINER METAB, V32, P124, DOI 10.1007/s00774 013 0475 4
   Ra JC, 2011, J TRANSL MED, V9, DOI 10.1186/1479 5876 9 181
   Reardon C, 2018, PHYSIOL REV, V98, P2287, DOI 10.1152/physrev.00035.2017
   Stangl H, 2015, BRAIN BEHAV IMMUN, V46, P180, DOI 10.1016/j.bbi.2015.02.022
   Stofkova A, 2016, AUTOIMMUNITY, V49, P268, DOI 10.3109/08916934.2016.1164145
   Straub RH, 2007, BRAIN BEHAV IMMUN, V21, P528, DOI 10.1016/j.bbi.2007.04.005
   Straub RH, 2020, NEUROIMMUNOMODULAT, V27, P58, DOI 10.1159/000508109
   Straub RH, 2011, ARTHRITIS RHEUM US, V63, P3234, DOI 10.1002/art.30516
   Straub RH, 2005, RHEUM DIS CLIN N AM, V31, P43, DOI 10.1016/j.rdc.2004.09.003
   Tague SE, 2014, NEUROSCIENCE, V279, P77, DOI 10.1016/j.neuroscience.2014.08.035
   Takeuchi Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01989
   Tanaka K, 2016, BRIT J PHARMACOL, V173, P1058, DOI 10.1111/bph.13418
   Togari A, 1997, NEUROSCI LETT, V233, P125, DOI 10.1016/S0304 3940(97)00649 6
   Togari A, 2012, JPN DENT SCI REV, V48, P61, DOI 10.1016/j.jdsr.2011.12.002
   Turner RT, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00117
   Vlcek M, 2012, CELL MOL NEUROBIOL, V32, P897, DOI 10.1007/s10571 012 9805 7
   Wahle M, 1999, ANN NY ACAD SCI, V876, P287, DOI 10.1111/j.1749 6632.1999.tb07651.x
   Wahle M, 2002, ANN NY ACAD SCI, V966, P425, DOI 10.1111/j.1749 6632.2002.tb04243.x
   Wang F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00884
   Wang WH, 2019, PHYSIOL GENOMICS, V51, P241, DOI 10.1152/physiolgenomics.00009.2019
   Wu HX, 2019, INFLAMMOPHARMACOLOGY, V27, P271, DOI 10.1007/s10787 018 0477 x
   Zhu Yuantee, 2018, Bone Rep, V9, P188, DOI 10.1016/j.bonr.2018.11.002
NR 107
TC 11
Z9 11
U1 0
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUN 17
PY 2021
VL 12
AR 628065
DI 10.3389/fimmu.2021.628065
PG 24
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA TC5FM
UT WOS:000668664700001
PM 34220796
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Feigenson, M
   Eliseev, RA
   Jonason, JH
   Mills, BN
   O'Keefe, RJ
AF Feigenson, Marina
   Eliseev, Roman A.
   Jonason, Jennifer H.
   Mills, Bradley N.
   O'Keefe, Regis J.
TI PGE2 Receptor Subtype 1 (EP1) Regulates Mesenchymal Stromal Cell
   Osteogenic Differentiation by Modulating Cellular Energy Metabolism
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE MESENCHYMAL STROMAL CELL; PGE2; EP1; OXIDATIVE PHOSPHORYLATION
ID HEMATOPOIETIC STEM CELLS; PROSTAGLANDIN E 2; BONE MARROW; OSTEOBLAST
   DIFFERENTIATION; MITOCHONDRIAL BIOGENESIS; IN VIVO; INCREASES; PGE(2);
   NICHE; MICE
AB Mesenchymal stromal cells (MSCs) are multipotent progenitors capable of differentiation into osteoblasts and can potentially serve as a source for cell based therapies for bone repair. Many factors have been shown to regulate MSC differentiation into the osteogenic lineage such as the Cyclooxygenase 2 (COX2)/Prostaglandin E2 (PGE2) signaling pathway that is critical for bone repair. PGE2 binds four different receptors EP1 4. While most studies focus on the role PGE2 receptors EP2 and EP4 in MSC differentiation, our study focuses on the less studied, receptor subtype 1 (EP1) in MSC function. Recent work from our laboratory showed that EP1( / ) mice have enhanced fracture healing, stronger cortical bones, higher trabecular bone volume and increased in vivo bone formation, suggesting that EP1 is a negative regulator of bone formation. In this study, the regulation of MSC osteogenic differentiation by EP1 receptor was investigated using EP1 genetic deletion in EP1( / ) mice. The data suggest that EP1 receptor functions to maintain MSCs in an undifferentiated state. Loss of the EP1 receptor changes MSC characteristics and permits stem cells to undergo more rapid osteogenic differentiation. Notably, our studies suggest that EP1 receptor regulates MSC differentiation by modulating MSC bioenergetics, preventing the shift to mitochondrial oxidative phosphorylation by maintaining high Hif1 activity. Loss of EP1 results in inactivation of Hif1, increased oxygen consumption rate and thus increased osteoblast differentiation. J. Cell. Biochem. 118: 4383 4393, 2017. (c) 2017 Wiley Periodicals, Inc.
C1 [Feigenson, Marina] Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14620 USA.
   [Feigenson, Marina; Eliseev, Roman A.; Jonason, Jennifer H.] Univ Rochester, Ctr Musculoskeletal Res, Sch Med & Dent, Rochester, NY 14620 USA.
   [Mills, Bradley N.] Univ Rochester, Dept Neurol, Sch Med & Dent, Rochester, NY 14620 USA.
   [O'Keefe, Regis J.] Washington Univ, Sch Med, Dept Orthopaed Surg, 660 S Euclid,CB 8233, St Louis, MO 63110 USA.
C3 University of Rochester; University of Rochester; University of
   Rochester; Washington University (WUSTL)
RP O'Keefe, RJ (通讯作者)，Washington Univ, Sch Med, Dept Orthopaed Surg, 660 S Euclid,CB 8233, St Louis, MO 63110 USA.
EM okeefer@wudosis.wustl.edu
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
   [P50AR054041, RO1AR048681]
FX Grant sponsor: National Institute of Arthritis and Musculoskeletal and
   Skin Diseases; Grant numbers: P50AR054041, RO1AR048681.
CR Asai S, 2014, STEM CELLS, V32, P3266, DOI 10.1002/stem.1847
   Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Chen CT, 2008, STEM CELLS, V26, P960, DOI 10.1634/stemcells.2007 0509
   Chen C, 2008, J EXP MED, V205, P2397, DOI 10.1084/jem.20081297
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017
   Folmes CDL, 2012, CELL STEM CELL, V11, P596, DOI 10.1016/j.stem.2012.10.002
   Goessling W, 2011, CELL STEM CELL, V8, P445, DOI 10.1016/j.stem.2011.02.003
   Goessling W, 2009, CELL, V136, P1136, DOI 10.1016/j.cell.2009.01.015
   Guan Y, 2007, J CLIN INVEST, V117, P2496, DOI 10.1172/JCI29838
   Ishibashi O, 2010, J CELL PHYSIOL, V222, P465, DOI 10.1002/jcp.21968
   Ji RY, 2010, MOL PHARMACOL, V77, P1025, DOI 10.1124/mol.110.063933
   Kohler EE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085549
   Lee CM, 2010, J BONE MINER METAB, V28, P8, DOI 10.1007/s00774 009 0096 0
   Levi B, 2011, J BIOL CHEM, V286, P39497, DOI 10.1074/jbc.M111.256529
   Li X, 2002, BONE, V30, P567, DOI 10.1016/S8756 3282(02)00683 X
   Liu ML, 2012, NEUROSCI LETT, V508, P31, DOI 10.1016/j.neulet.2011.12.010
   Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev cellbio 092910 154237
   Marelli B, 2015, BIOMATERIALS, V54, P126, DOI 10.1016/j.biomaterials.2015.03.018
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Miyaura C, 2000, J BIOL CHEM, V275, P19819, DOI 10.1074/jbc.M002079200
   Morikawa S, 2009, J EXP MED, V206, P2483, DOI 10.1084/jem.20091046
   Nakada D, 2010, NATURE, V468, P653, DOI 10.1038/nature09571
   Nissim S, 2014, DEV CELL, V28, P423, DOI 10.1016/j.devcel.2014.01.006
   NORRDIN RW, 1990, PROSTAG LEUKOTR ESS, V41, P139, DOI 10.1016/0952 3278(90)90081 U
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Porter RL, 2013, STEM CELLS, V31, P372, DOI 10.1002/stem.1286
   Rehman J, 2010, J MOL MED, V88, P981, DOI 10.1007/s00109 010 0678 2
   SCUTT A, 1995, PROSTAGLANDINS, V49, P383, DOI 10.1016/0090 6980(95)00070 Q
   Shamir D, 2004, BONE, V34, P157, DOI 10.1016/j.bone.2003.09.008
   Shum LC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155709
   Simsek T, 2010, CELL STEM CELL, V7, P380, DOI 10.1016/j.stem.2010.07.011
   Suponitzky I, 1998, J ENDOCRINOL, V156, P51, DOI 10.1677/joe.0.1560051
   Suzawa T, 2000, ENDOCRINOLOGY, V141, P1554, DOI 10.1210/en.141.4.1554
   Varum S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020914
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581
   Weinreb M, 2006, PROSTAG LEUKOTR ESS, V75, P81, DOI 10.1016/j.plefa.2006.06.004
   Weinreb M, 1997, J DENT RES, V76, P1660, DOI 10.1177/00220345970760100701
   Weinreb M, 1997, BONE, V20, P521, DOI 10.1016/S8756 3282(97)00033 1
   Weinreb M, 1997, BONE, V20, P347, DOI 10.1016/S8756 3282(97)00011 2
   Xu XL, 2013, CELL METAB, V18, P325, DOI 10.1016/j.cmet.2013.06.005
   Yilmaz ÖH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703
   Yoshida Y, 2009, CELL STEM CELL, V5, P237, DOI 10.1016/j.stem.2009.08.001
   Zhang M, 2014, BONE C, V72C, P92
   Zhang MJ, 2015, BONE, V72, P92, DOI 10.1016/j.bone.2014.11.018
   Zhang MJ, 2011, J BONE MINER RES, V26, P792, DOI 10.1002/jbmr.272
   Zhou WY, 2012, EMBO J, V31, P2103, DOI 10.1038/emboj.2012.71
NR 47
TC 25
Z9 28
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD DEC
PY 2017
VL 118
IS 12
BP 4383
EP 4393
DI 10.1002/jcb.26092
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA FK4QP
UT WOS:000413481300028
PM 28444901
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Zhao, R
   Chen, NN
   Zhou, XW
   Miao, P
   Hu, CY
   Qian, L
   Yu, QW
   Zhang, JY
   Nie, H
   Chen, XH
   Li, P
   Xu, R
   Xiao, LB
   Zhang, X
   Liu, JR
   Zhang, DQ
AF Zhao, Rong
   Chen, Ni Nan
   Zhou, Xiao Wei
   Miao, Ping
   Hu, Chao Ying
   Qian, Liu
   Yu, Qi Wen
   Zhang, Ji Ying
   Nie, Hong
   Chen, Xue hua
   Li, Pu
   Xu, Rong
   Xiao, Lian Bo
   Zhang, Xin
   Liu, Jian Ren
   Zhang, Dong Qing
TI Exogenous IFN beta regulates the RANKL c Fos IFN beta signaling pathway
   in the collagen antibody induced arthritis model
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Rheumatoid arthritis; Interferon beta; Collagen II antibody induced
   arthritis; Receptor activator of nuclear factor kappa B ligand; c Fos
ID RHEUMATOID ARTHRITIS; INTERFERON BETA; OSTEOCLAST; EXPRESSION; MICE;
   INFLAMMATION; PHASE
AB Background: Although a variety of drugs have been used to treat the symptoms of rheumatoid arthritis (RA), none of them are able to cure the disease. Interferon beta (IFN beta) has pleiotropic effects on RA, but whether it can be used to treat RA remains globally controversial. Thus, in this study we tested the effects of IFN beta on RA patients and on collagen antibody induced arthritis (CAIA) model mice.
   Methods: The cytokine and auto antibody expression profiles in the serum and synovial fluid (SF) from RA patients were assessed using enzyme linked immunosorbent assay (ELISA) and compared with the results from osteoarthritis (OA) patients. Exogenous IFN beta was administered to RA patients and CAIA model mice, and the therapeutic effects were evaluated. Endogenous IFN beta expression in the joint bones of CAIA model mice was evaluated by quantitative real time PCR (qRT PCR). The effects of exogenous IFN beta on CAIA model mice were assessed using a clinical scoring system, hematoxylin eosin and safranin O with fast green counterstain histology, molybdenum target X ray, and tartrate resistant acid phosphatase (TRAP) staining. The RANKL RANK signaling pathway was analyzed using qRT PCR. The RAW 264.7 cell line was differentiated into osteoclasts with RANKL stimulation and then treated with exogenous IFN beta.
   Results: The expression of inflammatory cytokines (IFN gamma, IL 17, MMP 3, and RANKL) and auto antibodies (CII antibodies, RF IgM, and anti CCP/ GPI) were significantly higher in RA compared with OA patients. After IFN beta intervention, some clinical symptoms in RA patients were partially alleviated, and the expression of IFN gamma, IL 17, MMP 3, and OPG) returned to normal levels. In the CAIA model, the expression of endogenous IFN beta in the joint bones was decreased. After IFN beta administration, the arthritis scores were decreased; synovial inflammation, cartilage, and bone destruction were clearly attenuated; and the expression of c Fos and NFATc1 were reduced, while RANKL and TRAF6 expression was unchanged. In addition, exogenous IFN beta directly inhibited RANKL induced osteoclastogenesis.
   Conclusions: Exogenous IFN beta administration immunomodulates CAIA, may reduce joint inflammation and, perhaps more importantly, bone destruction by inhibiting the RANKL c Fos signaling pathway. Exogenous IFN beta intervention should be selectively used on RA patients because it may only be useful for RA patients with low endogenous IFN beta expression.
C1 [Zhao, Rong; Zhang, Xin; Liu, Jian Ren] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Sch Med, Dept Neurol, Shanghai 200025, Peoples R China.
   [Zhao, Rong; Chen, Ni Nan; Zhou, Xiao Wei; Miao, Ping; Qian, Liu; Yu, Qi Wen; Zhang, Ji Ying; Nie, Hong; Zhang, Dong Qing] Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Immunol, Shanghai 200025, Peoples R China.
   [Hu, Chao Ying] Shanghai Xuhui Cent Hosp, Cent Lab, Shanghai 200031, Peoples R China.
   [Chen, Xue hua; Li, Pu] Shanghai Jiao Tong Univ, Shanghai Ruijin Hosp, Sch Med, Shanghai 200025, Peoples R China.
   [Xu, Rong; Xiao, Lian Bo] Shanghai Guanghua Hosp Integrated Tradit Chinese, Dept Cent Lab, Shanghai 200052, Peoples R China.
C3 Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai
   Jiao Tong University; Shanghai Jiao Tong University
RP Zhang, DQ (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Immunol, Shanghai 200025, Peoples R China.
EM dqzhang1333@163.com
RI Xiao, Lianbo/HKF 8530 2023; LIU, Qi/I 4900 2017; Xu, Rong/W 1112 2018
FU National Natural Science Foundation of China [31270963, 81300935,
   81273307, 81072470, 30872304, 81372187, 8130029]; Shanghai Municipal
   Science and Technology Commission of key projects [10JC1408500,
   14431903700, 09DZ2260200]; Shanghai Municipal Education Commission
   [14ZZ106]
FX We thank Professor Jian Luo of East China Normal University for
   providing the RAW 264.7 cells. This work was supported in part by grants
   from the National Natural Science Foundation of China (No. 31270963, No.
   81300935, No. 81273307, No. 81072470, No. 30872304, No. 81372187, No.
   8130029), the Shanghai Municipal Science and Technology Commission of
   key projects [Nos. 10JC1408500, 14431903700, 09DZ2260200], and the
   Shanghai Municipal Education Commission (14ZZ106).
CR Adriaansen J, 2006, HUM GENE THER, V17, P985, DOI 10.1089/hum.2006.17.985
   Al Dujaili SA, 2011, J CELL BIOCHEM, V112, P2412, DOI 10.1002/jcb.23164
   ARNETT FC, 1988, ARTHRITIS RHEUM US, V31, P315, DOI 10.1002/art.1780310302
   Bender AT, 2013, AM J TRANSL RES, V5, P92
   Croxford AM, 2013, ARTHRITIS RHEUM US, V65, P650, DOI 10.1002/art.37805
   Dimitrova P, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3926
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Formica MK, 2010, ARTHRIT CARE RES, V62, P235, DOI 10.1002/acr.20073
   Hutamekalin P, 2009, J IMMUNOL METHODS, V343, P49, DOI 10.1016/j.jim.2009.01.009
   Karlson EW, 2009, ARTHRITIS RHEUM US, V60, P641, DOI 10.1002/art.24350
   KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494
   Khachigian LM, 2006, NAT PROTOC, V1, P2512, DOI 10.1038/nprot.2006.393
   Kremenchutzky M, 2007, EXPERT OPIN DRUG SAF, V6, P279, DOI 10.1517/14740338.6.3.279
   Lapadula G, 2014, INT J IMMUNOPATH PH, V27, P33, DOI 10.1177/03946320140270S103
   Loma I, 2011, CURR NEUROPHARMACOL, V9, P409, DOI 10.2174/157015911796557911
   Martin TJ, 2013, WORLD J ORTHOP, V4, P186, DOI 10.5312/wjo.v4.i4.186
   Mohamed SGK, 2007, BONE, V41, P592, DOI 10.1016/j.bone.2007.05.016
   Nandakumar KS, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2089
   Seeuws S, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3119
   Smeets TJM, 2000, ARTHRITIS RHEUM US, V43, P270, DOI 10.1002/1529 0131(200002)43:2<270::AID ANR5>3.0.CO;2 H
   Smolen JS, 2007, LANCET, V370, P1861, DOI 10.1016/S0140 6736(07)60784 3
   Soe K, 2013, BONE, V56, P191, DOI 10.1016/j.bone.2013.06.007
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Thurlings RM, 2009, ARTHRITIS RHEUM, V60, pS626
   van Holten J, 2005, ANN RHEUM DIS, V64, P64, DOI 10.1136/ard.2003.020347
   van Holten J, 2004, ARTHRITIS RES THER, V6, pR239, DOI 10.1186/ar1165
   van Holten J, 2002, ARTHRITIS RES, V4, P346, DOI 10.1186/ar598
   Vis M, 2013, OSTEOPOROSIS INT, V24, P2541, DOI 10.1007/s00198 013 2334 5
   Xing LP, 2005, IMMUNOL REV, V208, P19, DOI 10.1111/j.0105 2896.2005.00336.x
NR 29
TC 16
Z9 21
U1 0
U2 27
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1479 5876
J9 J TRANSL MED
JI J. Transl. Med.
PD DEC 10
PY 2014
VL 12
AR 330
DI 10.1186/s12967 014 0330 y
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA AX9FT
UT WOS:000347209800001
PM 25491303
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Montanaro, R
   D'Addona, A
   Izzo, A
   Ruosi, C
   Brancaleone, V
AF Montanaro, Rosangela
   D'Addona, Alessio
   Izzo, Andrea
   Ruosi, Carlo
   Brancaleone, Vincenzo
TI In vitro evidence for the involvement of H2S pathway in the
   effect of clodronate during inflammatory response
SO SCIENTIFIC REPORTS
LA English
DT Article
ID HYDROGEN SULFIDE; DOUBLE BLIND; KNEE OSTEOARTHRITIS; NITRIC OXIDE;
   GM CSF; BISPHOSPHONATES; FIBROBLASTS; MECHANISM; ALPHA; EGR 1
AB Clodronate is a bisphosphonate agent commonly used as anti osteoporotic drug. Throughout its use, additional anti inflammatory and analgesic properties have been reported, although the benefits described in the literature could not solely relate to their inhibition of bone resorption. Thus, the purpose of our in vitro study is to investigate whether there are underlying mechanisms explaining the anti inflammatory effect of clodronate and possibly involving hydrogen sulphide (H2S). Immortalised fibroblast like synoviocyte cells (K4IM) were cultured and treated with clodronate in presence of TNF alpha. Clodronate significantly modulated iNOS expression elicited by TNF alpha. Inflammatory markers induced by TNF alpha, including IL 1, IL 6, MCP 1 and RANTES, were also suppressed following administration of clodronate. Furthermore, the reduction in enzymatic biosynthesis of CSE derived H2S, together with the reduction in CSE expression associated with TNF alpha treatment, was reverted by clodronate, thus rescuing endogenous H2S pathway activity. Clodronate displays antinflammatory properties through the modulation of H2S pathway and cytokines levels, thus assuring the control of the inflammatory state. Although further investigation is needed to stress out how clodronate exerts its control on H2S pathway, here we showed for the first the involvement of H2S in the additive beneficial effects observed following clodronate therapy.
C1 [Montanaro, Rosangela; Brancaleone, Vincenzo] Univ Basilicata, Dept Sci, Via Ateneo Lucano, I 85100 Potenza, Italy.
   [D'Addona, Alessio] IRCCS, Humanitas Clin & Res Ctr, Via Alessandro Manzoni 56, I 20089 Rozzano, Italy.
   [Izzo, Andrea; Ruosi, Carlo] Federico II Naples, Dept Publ Hlth, Sect Orthopaed & Trauma Surg, Sch Med & Surg,AOU Federico II, Naples, Italy.
C3 University of Basilicata; Italfarmaco; IRCCS Humanitas Research Hospital
RP Brancaleone, V (通讯作者)，Univ Basilicata, Dept Sci, Via Ateneo Lucano, I 85100 Potenza, Italy.; D'Addona, A (通讯作者)，IRCCS, Humanitas Clin & Res Ctr, Via Alessandro Manzoni 56, I 20089 Rozzano, Italy.
EM alessio.daddona@gmail.com; vincenzo.brancaleone@unibas.it
RI Montanaro, Rosangela/JVZ 5887 2024
FU Regione Basilicata [R.I.L.2015]; Ministry of Education, Universities and
   Research (MIUR) [2017NKB2N4_004]
FX This work has been supported by the Regione Basilicata (Grant Number:
   R.I.L.2015) and the Ministry of Education, Universities and Research
   (MIUR) (PRIN project, Grant Number 2017NKB2N4_004).
CR Batallé G, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9010031
   Bhattacharya P, 2015, J INTERF CYTOK RES, V35, P585, DOI 10.1089/jir.2014.0149
   Bonabello A, 2003, BONE, V33, P567, DOI 10.1016/S8756 3282(03)00229 1
   Bonabello A, 2001, PAIN, V91, P269, DOI 10.1016/S0304 3959(00)00447 4
   Brancaleone V, 2014, J PHARMACOL EXP THER, V351, P96, DOI 10.1124/jpet.114.217034
   Cirino G, 2017, BRIT J PHARMACOL, V174, P4021, DOI 10.1111/bph.13815
   Corrado A, 2005, REUMATISMO, V57, P142, DOI 10.4081/reumatismo.2005.142
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   Cremers S, 2011, BONE, V49, P42, DOI 10.1016/j.bone.2011.01.014
   CUNHA FQ, 1992, BRIT J PHARMACOL, V107, P660, DOI 10.1111/j.1476 5381.1992.tb14503.x
   Distrutti E, 2006, J PHARMACOL EXP THER, V316, P325, DOI 10.1124/jpet.105.091595
   Fox B, 2012, J CELL MOL MED, V16, P896, DOI 10.1111/j.1582 4934.2011.01357.x
   Frediani B, 2020, DRUGS R&D, V20, P39, DOI 10.1007/s40268 020 00294 4
   Frediani B, 2018, MINERVA MED, V109, P300, DOI 10.23736/S0026 4806.18.05688 4
   Frediani B, 2015, CLIN CASES MINER BON, V12, P97, DOI 10.11138/ccmbm/2015.12.2.097
   Frith JC, 2001, ARTHRITIS RHEUM, V44, P2201, DOI 10.1002/1529 0131(200109)44:9<2201::AID ART374>3.0.CO;2 E
   Gilmore TD, 2006, ONCOGENE, V25, P6887, DOI 10.1038/sj.onc.1209982
   Grimbacher B, 1998, RHEUMATOL INT, V17, P185, DOI 10.1007/s002960050032
   Haas C, 1997, RHEUMATOL INT, V16, P241, DOI 10.1007/BF01375656
   Kellinsalmi M, 2005, BASIC CLIN PHARMACOL, V97, P382, DOI 10.1111/j.1742 7843.2005.pto_176.x
   Kim S, 2013, EUR J PHARMACOL, V699, P14, DOI 10.1016/j.ejphar.2012.11.031
   Laan M, 2003, EUR RESPIR J, V21, P387, DOI 10.1183/09031936.03.00303503
   Lin VS, 2013, P NATL ACAD SCI USA, V110, P7131, DOI 10.1073/pnas.1302193110
   Liu L, 2006, J DENT RES, V85, P757, DOI 10.1177/154405910608500813
   Lohmann AB, 1999, EUR J PHARMACOL, V385, P119, DOI 10.1016/S0014 2999(99)00618 4
   Makkonen N, 1999, EUR J PHARM SCI, V8, P109, DOI 10.1016/S0928 0987(98)00065 7
   McCloskey E, 2004, J BONE MINER RES, V19, P728, DOI 10.1359/JBMR.040116
   Miller G, 2002, J IMMUNOL, V169, P2875, DOI 10.4049/jimmunol.169.6.2875
   Mitidieri E, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9100917
   Mitidieri E, 2016, PHARMACOL RES, V111, P283, DOI 10.1016/j.phrs.2016.06.017
   Olas B, 2015, CLIN CHIM ACTA, V439, P212, DOI 10.1016/j.cca.2014.10.037
   Pazianas M, 2011, BONE, V49, P103, DOI 10.1016/j.bone.2011.01.003
   Ribatti D, 2008, ONCOL REP, V19, P1109
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Rossini M, 2015, RHEUMATOL INT, V35, P255, DOI 10.1007/s00296 014 3100 5
   Simmons DL, 2004, PHARMACOL REV, V56, P387, DOI 10.1124/pr.56.3.3
   Spiller F, 2019, NITRIC OXIDE BIOL CH, V89, P32, DOI 10.1016/j.niox.2019.04.011
   Suzuki H, 2019, BIOL PHARM BULL, V42, P164, DOI 10.1248/bpb.b18 00408
   Syhr KMJ, 2015, BRAIN RES, V1624, P380, DOI 10.1016/j.brainres.2015.07.058
   Teronen O, 1997, CALCIFIED TISSUE INT, V61, P59, DOI 10.1007/s002239900295
   Valenti MT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010041
   Varenna M, 2000, J RHEUMATOL, V27, P1477
   Varenna M, 2017, PAIN MED, V18, P1131, DOI 10.1093/pm/pnw207
   Varenna M, 2014, RHEUMATOLOGY, V53, P965, DOI 10.1093/rheumatology/ket370
   Vaysbrot EE, 2018, OSTEOARTHR CARTILAGE, V26, P154, DOI 10.1016/j.joca.2017.11.013
   Vergnolle N, 2014, BIOCHEM PHARMACOL, V89, P157, DOI 10.1016/j.bcp.2014.01.005
   Whiteman Matthew, 2011, Expert Rev Clin Pharmacol, V4, P13, DOI 10.1586/ecp.10.134
   Whiteman M, 2009, J CELL MOL MED, V13, P488, DOI 10.1111/j.1582 4934.2009.00645.x
   Zanardo RCO, 2006, FASEB J, V20, P2118, DOI 10.1096/fj.06 6270fje
   Zanetti M, 2000, RADIOLOGY, V215, P835, DOI 10.1148/radiology.215.3.r00jn05835
NR 50
TC 6
Z9 6
U1 0
U2 4
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD JUL 20
PY 2021
VL 11
IS 1
AR 14811
DI 10.1038/s41598 021 94228 y
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA UK8FY
UT WOS:000692201400028
PM 34285296
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhao, CJ
   Liu, QB
   Wang, KZ
AF Zhao, Chengjin
   Liu, Qingbai
   Wang, Kunzheng
TI Artesunate attenuates ACLT induced osteoarthritis by suppressing
   osteoclastogenesis and aberrant angiogenesis
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Artesunate; Osteoarthritis; Osteoclast; Angiogenesis; JAK/STAT
ID KNEE OSTEOARTHRITIS; SIGNALING PATHWAY; BONE RESORPTION; GROWTH FACTOR;
   ARTEMISININ; EXPRESSION; INHIBITION; CARTILAGE; OUTCOMES; CELLS
AB Artesunate (ART) is a semi synthetic derivative of artemisinin and used preferentially in treatment of malaria in China. ART has strong anti inflammatory, anti tumor, and anti angiogenic properties. Although the pharmacological effect of ART in osteoarthritis (OA) is unknown, evidence suggests that ART might regulate osteoclastogenesis through NF kappa B signaling. In this study we explored the therapeutic effect of ART in an anterior cruciate ligament transection (ACLT) induced OA model. We found that ART effectively relieved ACLT induced osteoarthritis, as demonstrated by the improvement expression of pathological genes. We further demonstrated that ART markedly reduced OA associated osteoclastogenesis and angiogenesis. In addition, ART also regulated inflammatory response and inhibited the activation of Janus Kinase/Signal Transducers and Activators of Transcription (JAK/STAT) signaling in ACLT rats. Taken together our study has identified a novel function of ART and provided a molecular basis for ART potential applications in the treatment of OA and other joint disorders.
C1 [Zhao, Chengjin] Xi An Jiao Tong Univ, Hlth Sci Ctr, Xian 710049, Shaanxi, Peoples R China.
   [Zhao, Chengjin] Yanan Univ, Dept Orthoped, Affiliated Hosp, Yanan 716000, Peoples R China.
   [Liu, Qingbai] Lianshui Cty Peoples Hosp, Dept Orthoped, Huaian 223400, Peoples R China.
   [Wang, Kunzheng] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Orthoped, Xian 710004, Shaanxi, Peoples R China.
C3 Xi'an Jiaotong University; Yanan University; Xi'an Jiaotong University
RP Wang, KZ (通讯作者)，157 Xiwu Rd, Xian 710000, Shaanxi, Peoples R China.
EM docwangzk@163.com
CR Aittomäki S, 2014, BASIC CLIN PHARMACOL, V114, P18, DOI 10.1111/bcpt.12164
   Ashraf S, 2008, CURR OPIN RHEUMATOL, V20, P573, DOI 10.1097/BOR.0b013e3283103d12
   Baker LePain JC, 2012, BONE, V51, P197, DOI 10.1016/j.bone.2012.01.008
   Bettica P, 2002, ARTHRITIS RHEUM, V46, P3178, DOI 10.1002/art.10630
   Blazquez AG, 2013, BIOORGAN MED CHEM, V21, P4432, DOI 10.1016/j.bmc.2013.04.059
   Bonnet CS, 2005, RHEUMATOLOGY, V44, P7, DOI 10.1093/rheumatology/keh344
   Coluet J, 2009, DRUG DISCOV TODAY, V14, P913, DOI 10.1016/j.drudis.2009.07.012
   Efferth T, 2003, MOL PHARMACOL, V64, P382, DOI 10.1124/mol.64.2.382
   Farkouh ME, 2007, ANN RHEUM DIS, V66, P764, DOI 10.1136/ard.2006.066001
   Galois L, 2004, OSTEOARTHR CARTILAGE, V12, P779, DOI 10.1016/j.joca.2004.06.008
   Gao YH, 2007, J CLIN INVEST, V117, P122, DOI 10.1172/JCI30074
   Geurts J, 2016, J ORTHOP RES, V34, P262, DOI 10.1002/jor.23009
   Glyn Jones S, 2015, LANCET, V386, P376, DOI 10.1016/S0140 6736(14)60802 3
   Gore Mugdha, 2011, J Med Econ, V14, P497, DOI 10.3111/13696998.2011.594347
   Hashimoto S, 2002, OSTEOARTHR CARTILAGE, V10, P180, DOI 10.1053/joca.2001.0505
   Horner A, 2001, BONE, V28, P65, DOI 10.1016/S8756 3282(00)00422 1
   Hu PF, 2011, PHYTOTHER RES, V25, P878, DOI 10.1002/ptr.3359
   Jay G. D., 2012, ARTHRITIS RHEUMATOL, V64, P2382
   Jeong DE, 2015, ONCOTARGET, V6, P33046, DOI 10.18632/oncotarget.5422
   KLAYMAN DL, 1985, SCIENCE, V228, P1049, DOI 10.1126/science.3887571
   Lai LN, 2015, EUR J PHARMACOL, V765, P234, DOI 10.1016/j.ejphar.2015.08.040
   Legendre F, 2009, SCAND J RHEUMATOL, V38, P104, DOI 10.1080/03009740802421996
   Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293
   Liu SH, 2016, AM J MED, V129, P497, DOI 10.1016/j.amjmed.2015.12.029
   Malemud CJ, 2009, CURR SIGNAL TRANSD T, V4, P201, DOI 10.2174/157436209789057467
   Maragoudakis M.E., 1992, ANGIOGENESIS HLTH DI
   Murata M, 2008, OSTEOARTHR CARTILAGE, V16, P279, DOI 10.1016/j.joca.2007.09.003
   Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379
   Neuss S, 2004, STEM CELLS, V22, P405, DOI 10.1634/stemcells.22 3 405
   Okorji UP, 2014, BIOORGAN MED CHEM, V22, P4726, DOI 10.1016/j.bmc.2014.07.007
   Pickarski M, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 197
   Polverini Peter J, 2002, J Dent Educ, V66, P962
   Richards MM, 2016, PHYSICIAN SPORTSMED, V44, P101, DOI 10.1080/00913847.2016.1168272
   Siebelt M, 2014, BONE, V66, P163, DOI 10.1016/j.bone.2014.06.009
   Strassle BW, 2010, OSTEOARTHR CARTILAGE, V18, P1319, DOI 10.1016/j.joca.2010.06.007
   Tubach F, 2005, ANN RHEUM DIS, V64, P29, DOI 10.1136/ard.2004.022905
   Wang DJ, 2015, INFLAMMATION, V38, P1925, DOI 10.1007/s10753 015 0172 7
   Wang XQ, 2011, INVEST OPHTH VIS SCI, V52, P916, DOI 10.1167/iovs.10 5892
   Wei C. M., 2017, J CELL PHYSL
   Yang Hui qin, 2008, Zhong Xi Yi Jie He Xue Bao, V6, P1275, DOI 10.3736/jcim20081213
   Yang Z, 2012, CURR MED CHEM, V19, P4541, DOI 10.2174/092986712803251575
   Zamli Z, 2011, INT J RHEUM DIS, V14, P159, DOI 10.1111/j.1756 185X.2011.01618.x
   Zhao D, 2017, INT J ROBUST NONLIN, V27, P3296, DOI 10.1002/rnc.3742
NR 43
TC 31
Z9 38
U1 1
U2 24
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD DEC
PY 2017
VL 96
BP 410
EP 416
DI 10.1016/j.biopha.2017.10.018
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA FQ6VL
UT WOS:000418502100050
PM 29031199
DA 2025 08 17
ER

PT J
AU Takeuchi, A
   Tsuchiya, H
   Ishii, T
   Nishida, Y
   Abe, S
   Matsumine, A
   Kawai, A
   Yoshimura, K
   Ueda, T
AF Takeuchi, Akihiko
   Tsuchiya, Hiroyuki
   Ishii, Takeshi
   Nishida, Yoshihiro
   Abe, Satoshi
   Matsumine, Akihiko
   Kawai, Akira
   Yoshimura, Kenichi
   Ueda, Takafumi
TI Clinical outcome of recurrent giant cell tumor of the extremity in the
   era before molecular target therapy: the Japanese Musculoskeletal
   Oncology Group study
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE Giant cell tumor of bone; Local recurrence; Extremity; Surgical
   treatment; Multicenter study
ID PHASE II TRIAL; LONG BONES; CURETTAGE; DENOSUMAB
AB Background: Giant cell tumor of the bone (GCTB) is classified as an intermediate, locally aggressive but rarely metastasizing tumor. The mainstay of treatment for the treatment of GCTB had been the surgical removal until an anti receptor activator of nuclear factor  kappa B ligands (RANKL) antibody denosumab was developed. And favorable responses and the possibility of surgical downstaging have been reported. However, the long term outcome of denosumab has not yet been confirmed and moreover the long term clinical outcome after the recurrence of GCTB in the era before molecular target therapy is still uncertain. The aim of this study was to evaluate the long term clinical outcome of recurrent GCTB of the extremity in the era before molecular target therapy and to determine the factors that affect the repetitive recurrence and sacrifice of adjacent joints.
   Methods: This multicenter study focused only recurrent GCTB of the extremity with no medical treatment and included 103 patients treated from 1980 to 2008.
   Results: Thirty two (31.1 %) patients developed repetitive recurrences after salvage surgery. Second curettage and venue of initial surgery (non  cancer hospital) were both significantly correlated with repetitive recurrence in univariate (P = 0.034 and P = 0.002) and multivariate (P = 0.004 and P = 0.001) analyses. Seventy  two (76.6 %) of 94 patients achieved successful preservation of adjacent joints. Campanacci Grade III was significantly correlated with sacrifice of the adjacent joint by univariate statistical analysis (P = 0.019), although its impact was only marginally significant by multivariate analysis (P = 0.059). Seventeen patients (16.5 %) developed distant metastasis, and one patient (0.97 %) developed malignant transformation. Finally, 94/ 103 patients (91.3 %) with recurrent GCTB were successfully rendered NED by further surgical treatment.
   Conclusions: We concluded that repetitive, thorough curettage with surgical adjuvant treatment resulted in a favorable rate of adjacent joint preservation (76.6 %), but recurettage inferred a risk of repetitive recurrences. Although the treatment strategy against the recurrent GCTB is being updated with denosumab, we believe that our data will be useful for future comparisons with the long term clinical benefit of denosumab.
C1 [Takeuchi, Akihiko; Tsuchiya, Hiroyuki] Kanazawa Univ, Dept Orthopaed Surg, Grad Sch Med Sci, 13 1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan.
   [Ishii, Takeshi] Chiba Canc Ctr Hosp, Dept Orthoped Surg, Chuo Ku, 666 2 Nitona, Chiba 2608717, Japan.
   [Nishida, Yoshihiro] Nagoya Univ, Dept Orthopaed Surg, Sch Med, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4668550, Japan.
   [Abe, Satoshi] Teikyo Univ, Dept Orthopaed, Sch Med, Itabashi Ku, 11 1 Kago 2 Chome, Tokyo 1738605, Japan.
   [Matsumine, Akihiko] Mie Univ, Dept Orthopaed Surg, Fac Med, 2 174 Edobashi, Tsu, Mie 5148507, Japan.
   [Kawai, Akira] Natl Canc Ctr, Dept Musculoskeletal Oncol, Chuo Ku, 5 1 1 Tsukiji, Tokyo 1040045, Japan.
   [Yoshimura, Kenichi] Kanazawa Univ Hosp, Innovat Clin Res Ctr iCREK, 13 1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan.
   [Ueda, Takafumi] Osaka Natl Hosp, Dept Orthopaed Surg, Chuo Ku, 2 1 14 Hoenzaka, Osaka 5400006, Japan.
C3 Kanazawa University; Chiba Cancer Center; Nagoya University; Teikyo
   University; Mie University; National Cancer Center   Japan; Kanazawa
   University; Osaka National Hospital
RP Takeuchi, A (通讯作者)，Kanazawa Univ, Dept Orthopaed Surg, Grad Sch Med Sci, 13 1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan.
EM a_take@med.kanazawa u.ac.jp
RI TSUCHIYA, HIROYUKI/C 5142 2015; Takeuchi, Akihiko/AAJ 1563 2020
OI Takeuchi, Akihiko/0000 0002 4071 5620
FU Grants in Aid for Scientific Research [16K15658, 26293333] Funding
   Source: KAKEN
CR Athanasou NA, 2013, TUMOURS SOFT TISSUE, P321
   Bertoni F, 2003, CANCER, V97, P2520, DOI 10.1002/cncr.11359
   Blackley HR, 1999, J BONE JOINT SURG AM, V81A, P811, DOI 10.2106/00004623 199906000 00008
   Brien EW, 1997, SKELETAL RADIOL, V26, P246, DOI 10.1007/s002560050230
   CAMPANACCI M, 1987, J BONE JOINT SURG AM, V69A, P106, DOI 10.2106/00004623 198769010 00018
   DORWART RH, 1984, AM J ROENTGENOL, V143, P877, DOI 10.2214/ajr.143.4.877
   Errani C, 2010, CANCER TREAT REV, V36, P1, DOI 10.1016/j.ctrv.2009.09.002
   KAY RM, 1994, CLIN ORTHOP RELAT R, V302, P219
   LARSSON SE, 1975, J BONE JOINT SURG AM, VA 57, P167, DOI 10.2106/00004623 197557020 00007
   MARCOVE RC, 1982, CLIN ORTHOP RELAT R, P231
   MCDONALD DJ, 1986, J BONE JOINT SURG AM, V68A, P235, DOI 10.2106/00004623 198668020 00009
   McGough RL, 2005, CLIN ORTHOP RELAT R, P116, DOI 10.1097/01.blo.0000180055.769669.08
   ODONNELL RJ, 1994, J BONE JOINT SURG AM, V76A, P1827, DOI 10.2106/00004623 199412000 00009
   Prosser GH, 2005, CLIN ORTHOP RELAT R, P211, DOI 10.1097/01.blo.0000160024.06739.ff
   Roux S, 2002, AM J CLIN PATHOL, V117, P210
   Rutkowski P, 2015, ANN SURG ONCOL, V22, P2860, DOI 10.1245/s10434 015 4634 9
   Takeuchi A, 2011, J ORTHOP SCI, V16, P196, DOI 10.1007/s00776 011 0030 x
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   TUBBS WS, 1992, AM J ROENTGENOL, V158, P331, DOI 10.2214/ajr.158.2.1729794
   Ueda T, 2015, ANN ONCOL, V26, P2149, DOI 10.1093/annonc/mdv307
   Vidal J, 1969, MONTPELLIER CHIRURGI, V15, P389
NR 21
TC 9
Z9 9
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD JUL 22
PY 2016
VL 17
AR 306
DI 10.1186/s12891 016 1163 z
PG 7
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA EM0MX
UT WOS:000395013500004
PM 27448567
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Pirapaharan, DC
   Soe, K
   Panwar, P
   Madsen, JS
   Bergmann, ML
   Overgaard, M
   Brömme, D
   Delaisse, JM
AF Pirapaharan, Dinisha Cyril
   Soe, Kent
   Panwar, Preety
   Madsen, Jonna Skov
   Bergmann, Marianne Lerbaek
   Overgaard, Martin
   Bromme, Dieter
   Delaisse, Jean Marie
TI A Mild Inhibition of Cathepsin K Paradoxically Stimulates the Resorptive
   Activity of Osteoclasts in Culture
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Bone resorption; Cathepsin K; Osteoporosis; Odanacatib; Osteoclast
ID BONE RESORPTION; CYSTEINE PROTEINASES; MATRIX METALLOPROTEINASES;
   DEFICIENT MICE; DEGRADATION; COLLAGEN; OSTEOPOROSIS; ODANACATIB; CELL;
   PYCNODYSOSTOSIS
AB Cathepsin K (CatK) inhibition allows reducing bone resorption with specific advantages compared to the existing anti osteoporosis drugs. Its clinical use appears even more promising with the recent development of ectosteric inhibitors. A confusing observation, however, is that a low dose of the active site CatK inhibitor odanacatib (ODN) was reported to decrease bone mineral density and increase serum levels of the bone resorption marker carboxy terminal collagen crosslinks (CTX). The present study provides a possible explanation for this paradox. The resorptive activity of human osteoclasts seeded on bone slices was inhibited when subjected to ODN at doses of 20nM, but about 100 fold lower doses induced a significant increase in CTX levels and in eroded surface (12 repeats). This low dose induced stimulation was prevented by inhibition of non CatK cysteine proteinases, thereby indicating that the stimulation results from an interplay between CatK and other cysteine proteinases. Effective interplay between these proteinases was also shown in enzymatic assays where the CatK mediated degradation of collagen was enhanced upon addition of cathepsins B or L. Furthermore, extracts of osteoclasts subjected to a low dose of ODN showed higher levels of cathepsin B compared with extracts of control osteoclasts. In conclusion, the low dose induced stimulation of resorption observed in the clinical study can be reproduced in osteoclasts cultured in the absence of any other cell. Our data support an osteoclast intrinsic mechanism where a mild inhibition of CatK results in increased levels of other proteinases contributing to the collagen degradation process.
C1 [Pirapaharan, Dinisha Cyril; Soe, Kent; Delaisse, Jean Marie] Univ Southern Denmark, Vejle Hosp, Lillebaelt Hosp, Dept Clin Cell Biol,Inst Reg Hlth Res, DK 7100 Vejle, Denmark.
   [Panwar, Preety; Bromme, Dieter] Univ British Columbia, Fac Med, Dept Biochem & Mol Biol, Vancouver, WA USA.
   [Madsen, Jonna Skov; Bergmann, Marianne Lerbaek] Univ Southern Denmark, Dept Biochem & Immunol, Inst Reg Hlth Res, Vejle Hosp,Lillebaelt Hosp, DK 7100 Vejle, Denmark.
   [Overgaard, Martin] Odense Univ Hosp, Dept Clin Biochem & Pharmacol, Odense, Denmark.
C3 University of Southern Denmark; Lillebaelt Hospital; University of
   Southern Denmark; Lillebaelt Hospital; University of Southern Denmark;
   Odense University Hospital
RP Soe, K; Delaisse, JM (通讯作者)，Univ Southern Denmark, Vejle Hosp, Lillebaelt Hosp, Dept Clin Cell Biol,Inst Reg Hlth Res, DK 7100 Vejle, Denmark.
EM kent.soee@rsyd.dk; Jean Marie.Delaisse@rsyd.dk
RI Madsen, Jonna/AAF 7054 2019; Soe, Kent/N 3618 2017; Madsen, Jonna
   Skov/AAF 7054 2019
OI Delaisse, Jean Marie/0000 0001 7370 1500; Soe, Kent/0000 0001 7402 314X;
   Bergmann, Marianne Lerbaek/0000 0001 9213 3676; Madsen, Jonna
   Skov/0000 0001 6668 4714; Overgaard, Martin/0000 0003 2277 590X
FU Region of Southern Denmark [13/27663]; Vejle Hospital/Lillebaelt
   Hospital; University of Southern Denmark
FX We thank Jacob Bastholm Olesen for excellent technical assistance and
   Anne V Schmedes and Merete Villiumsen for her kind assistance on
   biochemical procedures. This study has received financial support from
   The Region of Southern Denmark (Grant No. 13/27663), Vejle
   Hospital/Lillebaelt Hospital and the University of Southern Denmark.
CR Aguda AH, 2014, P NATL ACAD SCI USA, V111, P17474, DOI 10.1073/pnas.1414126111
   Andersen TL, 2004, BONE, V35, P1107, DOI 10.1016/j.bone.2004.06.019
   Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   Brömme D, 2016, EXPERT OPIN DRUG DIS, V11, P457, DOI 10.1517/17460441.2016.1160884
   Brömme D, 2004, METHODS, V32, P199, DOI 10.1016/S1046 2023(03)00212 3
   Creemers LB, 1998, MATRIX BIOL, V16, P575, DOI 10.1016/S0945 053X(98)90068 3
   DELAISSE JM, 1987, BONE, V8, P305, DOI 10.1016/8756 3282(87)90007 X
   Delaissé JM, 2003, MICROSC RES TECHNIQ, V61, P504, DOI 10.1002/jemt.10374
   Desmarais S, 2009, BIOL CHEM, V390, P941, DOI 10.1515/BC.2009.092
   Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511
   Drake MT, 2017, ENDOCR REV, V38, P325, DOI 10.1210/er.2015 1114
   Duong Le T, 2012, Bonekey Rep, V1, P67, DOI 10.1038/bonekey.2012.67
   Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879
   EVERTS V, 1992, J CELL PHYSIOL, V150, P221, DOI 10.1002/jcp.1041500202
   Everts V, 2002, J BONE MINER RES, V17, P77, DOI 10.1359/jbmr.2002.17.1.77
   Everts V, 2006, J BONE MINER RES, V21, P1399, DOI 10.1359/JBMR.060614
   Garnero P, 2003, J BONE MINER RES, V18, P859, DOI 10.1359/jbmr.2003.18.5.859
   Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347
   Gelb BD, 1996, BIOCHEM MOL MED, V59, P200, DOI 10.1006/bmme.1996.0088
   HILL PA, 1994, J CELL BIOCHEM, V56, P118, DOI 10.1002/jcb.240560116
   Ishibashi O, 2001, CALCIFIED TISSUE INT, V68, P109, DOI 10.1007/BF02678149
   James IE, 2001, J BIOL CHEM, V276, P11507, DOI 10.1074/jbc.M010684200
   Kiviranta R, 2005, BONE, V36, P159, DOI 10.1016/j.bone.2004.09.020
   KOMINAMI E, 1987, BIOCHEM BIOPH RES CO, V144, P749, DOI 10.1016/S0006 291X(87)80028 1
   LEE ER, 1995, J HISTOCHEM CYTOCHEM, V43, P525, DOI 10.1177/43.5.7730591
   Leung P, 2011, BONE, V49, P623, DOI 10.1016/j.bone.2011.06.014
   Li CS, 2006, BIOORG MED CHEM LETT, V16, P1985, DOI 10.1016/j.bmcl.2005.12.071
   MACIEWICZ RA, 1990, FEBS LETT, V269, P189, DOI 10.1016/0014 5793(90)81151 D
   Merrild DMH, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.32
   MOIN K, 1992, BIOCHEM J, V285, P427, DOI 10.1042/bj2850427
   Moller AMJ, 2017, J CELL PHYSIOL, V232, P1396, DOI 10.1002/jcp.25633
   MONTENEZ JP, 1994, LIFE SCI, V55, P1199, DOI 10.1016/0024 3205(94)00659 8
   Mukherjee K, 2016, BIOCHEM PHARMACOL, V117, P10, DOI 10.1016/j.bcp.2016.04.010
   Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446
   Panwar P, 2018, MATRIX BIOL, V65, P30, DOI 10.1016/j.matbio.2017.06.004
   Panwar P, 2017, J BONE MINER RES, V32, P2415, DOI 10.1002/jbmr.3227
   Panwar P, 2016, BRIT J PHARMACOL, V173, P396, DOI 10.1111/bph.13383
   Panwar P, 2013, J BIOL CHEM, V288, P5940, DOI 10.1074/jbc.M112.419689
   Potts W, 2004, INT J EXP PATHOL, V85, P85, DOI 10.1111/j.0959 9673.2004.00373.x
   REILLY JJ, 1989, BIOCHEM J, V257, P493, DOI 10.1042/bj2570493
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Soe K, 2013, BONE, V56, P191, DOI 10.1016/j.bone.2013.06.007
   Soe K, 2010, J BONE MINER RES, V25, P2184, DOI 10.1002/jbmr.113
   SUTHERLAND JHR, 1983, BIOCHEM BIOPH RES CO, V110, P332, DOI 10.1016/0006 291X(83)91300 1
   TANAKA K, 1981, ARCH BIOCHEM BIOPHYS, V208, P296, DOI 10.1016/0003 9861(81)90152 1
   Xia LH, 1999, BIOL CHEM, V380, P679, DOI 10.1515/BC.1999.084
   Zhuo Y, 2014, BONE, V67, P269, DOI 10.1016/j.bone.2014.07.013
NR 47
TC 6
Z9 6
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD JAN
PY 2019
VL 104
IS 1
BP 92
EP 101
DI 10.1007/s00223 018 0472 7
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA HH2CL
UT WOS:000455526100010
PM 30194476
DA 2025 08 17
ER

PT J
AU Limraksasin, P
   Kosaka, Y
   Zhang, ML
   Horie, N
   Kondo, T
   Okawa, H
   Yamada, M
   Egusa, H
AF Limraksasin, Phoonsuk
   Kosaka, Yukihiro
   Zhang, Maolin
   Horie, Naohiro
   Kondo, Takeru
   Okawa, Hiroko
   Yamada, Masahiro
   Egusa, Hiroshi
TI Shaking culture enhances chondrogenic differentiation of mouse induced
   pluripotent stem cell constructs
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ARTICULAR CARTILAGE; BONE MARROW; CHONDROCYTE DIFFERENTIATION;
   MECHANICAL STIMULATION; EXTRACELLULAR MATRIX; TISSUE; EXPRESSION; SHEAR;
   MODULATION; MECHANOTRANSDUCTION
AB Mechanical loading on articular cartilage induces various mechanical stresses and strains. In vitro hydrodynamic forces such as compression, shear and tension impact various cellular properties including chondrogenic differentiation, leading us to hypothesize that shaking culture might affect the chondrogenic induction of induced pluripotent stem cell (iPSC) constructs. Three dimensional mouse iPSC constructs were fabricated in a day using U bottom 96 well plates, and were subjected to preliminary chondrogenic induction for 3 days in static condition, followed by chondrogenic induction culture using a see saw shaker for 17 days. After 21 days, chondrogenically induced iPSC (CI iPSC) constructs contained chondrocyte like cells with abundant ECM components. Shaking culture significantly promoted cell aggregation, and induced significantly higher expression of chondrogenic related marker genes than static culture at day 21. Immunohistochemical analysis also revealed higher chondrogenic protein expression. Furthemore, in the shaking groups, CI iPSCs showed upregulation of TGF beta and Wnt signaling related genes, which are known to play an important role in regulating cartilage development. These results suggest that shaking culture activates TGF beta expression and Wnt signaling to promote chondrogenic differentiation in mouse iPSCs in vitro. Shaking culture, a simple and convenient approach, could provide a promising strategy for iPSC based cartilage bioengineering for study of disease mechanisms and new therapies.
C1 [Limraksasin, Phoonsuk; Kosaka, Yukihiro; Zhang, Maolin; Horie, Naohiro; Kondo, Takeru; Okawa, Hiroko; Yamada, Masahiro; Egusa, Hiroshi] Tohoku Univ, Grad Sch Dent, Div Mol & Regenerat Prosthodont, Aoba Ku, 4 1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.
   [Kondo, Takeru] Univ Calif Los Angeles, Sch Dent, Weintraub Ctr Reconstruct Biotechnol, Los Angeles, CA 90095 USA.
   [Egusa, Hiroshi] Tohoku Univ, Grad Sch Dent, Ctr Adv Stem Cell & Regenerat Res, Sendai, Miyagi 9808575, Japan.
C3 Tohoku University; University of California System; University of
   California Los Angeles; Tohoku University
RP Egusa, H (通讯作者)，Tohoku Univ, Grad Sch Dent, Div Mol & Regenerat Prosthodont, Aoba Ku, 4 1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.; Egusa, H (通讯作者)，Tohoku Univ, Grad Sch Dent, Ctr Adv Stem Cell & Regenerat Res, Sendai, Miyagi 9808575, Japan.
EM egu@dent.tohoku.ac.jp
RI Egusa, Hiroshi/AFT 9694 2022; Yamada, Masahiro/AAC 7864 2019
OI Egusa, Hiroshi/0000 0002 0200 8132; Limraksasin,
   Phoonsuk/0000 0002 6189 8657; Kondo, Takeru/0009 0002 1560 1741
FU Japan Society for the Promotion of Science [19H03840, 16K15797];
   Grants in Aid for Scientific Research [19H03840, 16K15797] Funding
   Source: KAKEN
FX This work was supported by Grant in Aids for Scientific Research (B:
   19H03840, M.Y. and H.E.) and Challenging Exploratory Research (16K15797,
   H.E.) from the Japan Society for the Promotion of Science.
CR Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802
   Anderson DE, 2017, FRONT BIOENG BIOTECH, V5, DOI 10.3389/fbioe.2017.00076
   Arokoski JPA, 2000, SCAND J MED SCI SPOR, V10, P186, DOI 10.1034/j.1600 0838.2000.010004186.x
   Barry F, 2001, EXP CELL RES, V268, P189, DOI 10.1006/excr.2001.5278
   Browning JA, 1999, ACTA PHYSIOL SCAND, V166, P39
   Castro Viñuelas R, 2018, EUR CELLS MATER, V36, P96, DOI 10.22203/eCM.v036a08
   Cortes P, 1996, CONTRIB NEPHROL, V118, P229
   Coyle CH, 2009, J ORTHOP RES, V27, P793, DOI 10.1002/jor.20816
   Davidson ENB, 2009, J IMMUNOL, V182, P7937, DOI 10.4049/jimmunol.0803991
   Diekman BO, 2012, P NATL ACAD SCI USA, V109, P19172, DOI 10.1073/pnas.1210422109
   Egorova AD, 2011, DEV DYNAM, V240, P1670, DOI 10.1002/dvdy.22660
   Egusa H, 2014, STEM CELLS DEV, V23, P2156, DOI 10.1089/scd.2013.0344
   Egusa H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012743
   Eslaminejad MB, 2013, HISTOCHEM CELL BIOL, V140, P623, DOI 10.1007/s00418 013 1121 x
   Fahy N, 2018, J ORTHOP RES, V36, P52, DOI 10.1002/jor.23670
   Franco CA, 2016, ELIFE, V5, DOI 10.7554/eLife.07727
   Frank EH, 2000, J BIOMECH, V33, P1523, DOI 10.1016/S0021 9290(00)00100 7
   Goddard LM, 2017, DEV CELL, V43, P274, DOI 10.1016/j.devcel.2017.09.023
   Grabias BM, 2013, AM J PHYSIOL RENAL, V305, pF123, DOI 10.1152/ajprenal.00594.2012
   Green JD, 2015, GENES DIS, V2, P307, DOI 10.1016/j.gendis.2015.09.003
   Griffin TM, 2005, EXERC SPORT SCI REV, V33, P195, DOI 10.1097/00003677 200510000 00008
   Grodzinsky AJ, 2000, ANNU REV BIOMED ENG, V2, P691, DOI 10.1146/annurev.bioeng.2.1.691
   Guilak F, 2000, J BIOMECH, V33, P1663, DOI 10.1016/S0021 9290(00)00105 6
   Hellingman CA, 2011, TISSUE ENG PT A, V17, P1157, DOI [10.1089/ten.tea.2010.0043, 10.1089/ten.TEA.2010.0043]
   Hontani K, 2019, J BIOMED MATER RES A, V107, P1086, DOI 10.1002/jbm.a.36615
   Hu MY, 2015, ARCH BIOCHEM BIOPHYS, V579, P55, DOI 10.1016/j.abb.2015.05.012
   Huber D, 2018, CHEM REV, V118, P2042, DOI 10.1021/acs.chemrev.7b00317
   Kirton JP, 2007, CIRC RES, V101, P581, DOI 10.1161/CIRCRESAHA.107.156372
   Kunnen SJ, 2017, CELL MOL LIFE SCI, V74, P2283, DOI 10.1007/s00018 017 2460 x
   Kuo YC, 2015, STEM CELLS, V33, P429, DOI 10.1002/stem.1860
   Kwon H, 2016, CELL MOL LIFE SCI, V73, P1173, DOI 10.1007/s00018 015 2115 8
   Lach MS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112711
   Limraksasin P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020581
   Matta Csaba, 2013, Front Biosci (Schol Ed), V5, P305
   Miyamoto D, 2016, J BIOSCI BIOENG, V122, P507, DOI 10.1016/j.jbiosc.2016.03.018
   Miyamoto D, 2016, J BIOSCI BIOENG, V121, P105, DOI 10.1016/j.jbiosc.2015.04.018
   Nii T, 2019, J BIOSCI BIOENG, V128, P606, DOI 10.1016/j.jbiosc.2019.04.013
   O'Conor Christopher J, 2013, Stem Cell Res Ther, V4, P61, DOI 10.1186/scrt211
   Okawa H, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/6240794
   Park J, 2007, LAB CHIP, V7, P1018, DOI 10.1039/b704739h
   Platas OB, 2013, BMC P, V7, P17, DOI [10.1186/1753 6561 7 S6 P17, DOI 10.1186/1753 6561 7 S6 P17]
   Roelen Bernard A J, 2003, J Orthop Sci, V8, P740, DOI 10.1007/s00776 003 0702 2
   Ryan JA, 2009, J TISSUE ENG REGEN M, V3, P107, DOI 10.1002/term.146
   SANDELL LJ, 1991, J CELL BIOL, V114, P1307, DOI 10.1083/jcb.114.6.1307
   Shi Y, 2017, NAT REV DRUG DISCOV, V16, P115, DOI 10.1038/nrd.2016.245
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tanthaisong P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168059
   Tarbell JM, 2013, BIOMECH MODEL MECHAN, V12, P111, DOI 10.1007/s10237 012 0385 8
   Teixeira FG, 2016, SCI REP UK, V6, DOI 10.1038/srep27791
   Thielen NGM, 2019, CELLS BASEL, V8, DOI 10.3390/cells8090969
   Tsumaki N, 2015, BONE, V70, P48, DOI 10.1016/j.bone.2014.07.011
   Tuli R, 2003, J BIOL CHEM, V278, P41227, DOI 10.1074/jbc.M305312200
   Usami Y, 2016, LAB INVEST, V96, P186, DOI 10.1038/labinvest.2015.142
   Van Winkle AP, 2012, CELLS TISSUES ORGANS, V196, P34, DOI 10.1159/000330691
   Wang N, 2009, NAT REV MOL CELL BIO, V10, P75, DOI 10.1038/nrm2594
   Wang WG, 2014, BIRTH DEFECTS RES C, V102, P37, DOI 10.1002/bdrc.21058
   Wang X, 2019, OSTEOARTHR CARTILAGE, V27, P1702, DOI 10.1016/j.joca.2019.07.007
   WIDELITZ RB, 1993, J CELL PHYSIOL, V156, P399, DOI 10.1002/jcp.1041560224
   Wright MO, 1997, J ORTHOPAED RES, V15, P742, DOI 10.1002/jor.1100150517
   Wu QQ, 2001, J BIOL CHEM, V276, P35290, DOI 10.1074/jbc.M101055200
   Yamashita A, 2015, STEM CELL REP, V4, P404, DOI 10.1016/j.stemcr.2015.01.016
   Yeatts AB, 2011, BONE, V48, P171, DOI 10.1016/j.bone.2010.09.138
   Zhao ZX, 2020, J CELL MOL MED, V24, P5408, DOI 10.1111/jcmm.15204
   Zhu M, 2009, J BONE MINER RES, V24, P12, DOI [10.1359/jbmr.080901, 10.1359/JBMR.080901]
   Zuscik MJ, 2008, J CLIN INVEST, V118, P429, DOI 10.1172/JCI34174
NR 65
TC 22
Z9 22
U1 0
U2 10
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD SEP 14
PY 2020
VL 10
IS 1
AR 14996
DI 10.1038/s41598 020 72038 y
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA NT9QB
UT WOS:000573274900008
PM 32929163
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Louvet, L
   Leterme, D
   Delplace, S
   Miellot, F
   Marchandise, P
   Gauthier, V
   Hardouin, P
   Chauveau, C
   Mhenni, OG
AF Louvet, Loic
   Leterme, Damien
   Delplace, Severine
   Miellot, Flore
   Marchandise, Pierre
   Gauthier, Veronique
   Hardouin, Pierre
   Chauveau, Christophe
   Mhenni, Olfa Ghali
TI Sirtuin 1 deficiency decreases bone mass and increases bone marrow
   adiposity in a mouse model of chronic energy deficiency
SO BONE
LA English
DT Article
DE Sirtuin of type 1; Bone marrow adiposity; Anorexia nervosa; Osteoblast;
   Bone marrow stromal cells; Separation based anorexia
ID MESENCHYMAL STEM CELLS; ADIPOCYTE DIFFERENTIATION; CALORIC RESTRICTION;
   OSTEOBLASTIC DIFFERENTIATION; TRANSCRIPTION FACTORS; FAT; TISSUE;
   PROLIFERATION; INHIBITION; PREVENTS
AB Sirtuin of type 1 (Sirt1), a class III HDAC, is known to be involved in the regulation of differentiation of skeletal stem cells (SSCs) into osteoblasts and adipocytes. In caloric restriction, it has been shown that the expression and activity of Sirt1 is a tissue dependent regulation. However, at present, no study has focused on the link between Sirt1, bone marrow adiposity (BMA) and osteoporosis related to anorexia nervosa (AN). Thus, the aims of this work were to (i) determine BMA and bone changes in a mouse model replicating the phenotypes of AN (separation based anorexia model (SBA)); (ii) determine the expression of Sirt1 in bone marrow stromal cells (BMSCs) extracted from these mice and identify their differentiation capacities; (iii) study the effects of pharmacological activation and inhibition of Sirt1 on the osteoblastogenesis and adipogenesis of these cells and (iiii) delineate the molecular mechanism by which Sirt1 could regulate osteogenesis in an SBA model. Our results demonstrated that SBA protocol induces an increase in BMA and alteration of bone architecture. In addition, BMSCs from restricted mice present a down regulation of Sirt1 which is accompanied by an increase in adipogenesis at expense of osteogenesis. After a 10 day organotypic culture, tibias from SBA mice displayed low levels of Sirt1 mRNA which are restored by resveratrol treatment. Interestingly, this recovery of Sirt1 levels also returned the BMA, BV/TV and Tb.Th in cultured tibias from SBA mice to normal levels. In contrast of down regulation of Sirt1 expression induced by sirtinol treatment, stimulation of Sirt1 expression by resveratrol lead to a decrease in adipogenesis and increase in osteogenesis. Finally, to investigate the molecular mechanisms by which Sirt1 could regulate osteogenesis in the SBA model, the acetylation levels of Runx2 and Foxo1 transcription factors were determined. Our data show that this chronic energy deficiency in female mice causes a decrease in BMSC activity, resulting in critical changes to Runx2 and Foxo1 acetylation levels and thus to their activity. Altogether, these data suggest that Sirt1 could be considered as a potential therapeutic target in osteoporosis related to AN.
C1 [Louvet, Loic; Leterme, Damien; Delplace, Severine; Miellot, Flore; Marchandise, Pierre; Gauthier, Veronique; Hardouin, Pierre; Chauveau, Christophe; Mhenni, Olfa Ghali] Univ Littoral Cate dOpale, Marrow Adipos & Bone Lab MABLab, Ex PMOI, ULR4490, F 62200 Boulogne Sur Mer, France.
   [Louvet, Loic; Leterme, Damien; Delplace, Severine; Miellot, Flore; Marchandise, Pierre; Gauthier, Veronique; Hardouin, Pierre; Chauveau, Christophe; Mhenni, Olfa Ghali] Univ Lille, F 59000 Lille, France.
   [Louvet, Loic; Leterme, Damien; Delplace, Severine; Miellot, Flore; Marchandise, Pierre; Gauthier, Veronique; Hardouin, Pierre; Chauveau, Christophe; Mhenni, Olfa Ghali] CHU Lille, F 59000 Lille, France.
C3 Universite de Lille; Universite de Lille; CHU Lille
RP Mhenni, OG (通讯作者)，Univ Littoral Cate dOpale, Marrow Adipos & Bone Lab MABLab, Ex PMOI, ULR4490, F 62200 Boulogne Sur Mer, France.
EM olfa.ghali@univ littoral.fr
RI ; Delplace, Séverine/HRD 6908 2023
OI Chauveau, Christophe/0000 0003 4668 9272; 
FU Societe Francaise de Rhumatologie (SFR), Region Hauts de France
   (France); Universite du Littoral Cote d'Opale, Dunkerque, France
FX This work is supported by grants from Societe Francaise de Rhumatologie
   (SFR), Region Hauts de France (France) and Universite du Littoral Cote
   d'Opale, Dunkerque, France.
CR Abella E, 2002, AM J CLIN PATHOL, V118, P582, DOI 10.1309/2Y7X YDXK 006B XLT2
   Ahdjoudj S, 2002, J BONE MINER RES, V17, P668, DOI 10.1359/jbmr.2002.17.4.668
   Akbari M, 2019, HIGH BLOOD PRESS CAR, V26, P305, DOI 10.1007/s40292 019 00324 6
   Artsi H, 2014, ENDOCRINOLOGY, V155, P3508, DOI 10.1210/en.2014 1334
   Bäckesjö CM, 2009, CELLS TISSUES ORGANS, V189, P93, DOI 10.1159/000151744
   Badr S, 2019, BONE, V127, P135, DOI 10.1016/j.bone.2019.05.033
   Baek K, 2012, J APPL PHYSIOL, V113, P1792, DOI 10.1152/japplphysiol.00187.2012
   BERESFORD JN, 1992, J CELL SCI, V102, P341
   Bianco P, 2010, HUM GENE THER, V21, P1057, DOI 10.1089/hum.2010.136
   Bordone L, 2006, PLOS BIOL, V4, P210, DOI 10.1371/journal.pbio.0040031
   Bordone L, 2007, AGING CELL, V6, P759, DOI 10.1111/j.1474 9726.2007.00335.x
   Botolin S, 2007, ENDOCRINOLOGY, V148, P198, DOI 10.1210/en.2006 1006
   Bradley EW, 2011, CRIT REV EUKAR GENE, V21, P101, DOI 10.1615/CritRevEukarGeneExpr.v21.i2.10
   Bredella MA, 2014, BONE, V66, P199, DOI 10.1016/j.bone.2014.06.014
   Bredella MA, 2011, OBESITY, V19, P49, DOI 10.1038/oby.2010.106
   Bredella MA, 2009, J CLIN ENDOCR METAB, V94, P2129, DOI 10.1210/jc.2008 2532
   Cawthorn WP, 2016, ENDOCRINOLOGY, V157, P508, DOI 10.1210/en.2015 1477
   Chen D, 2008, EXP GERONTOL, V43, P1086, DOI 10.1016/j.exger.2008.08.050
   Chiara B, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/783459
   Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196
   Cohen Kfir E, 2011, ENDOCRINOLOGY, V152, P4514, DOI 10.1210/en.2011 1128
   Coutel X, 2018, CALCIFIED TISSUE INT, V103, P189, DOI 10.1007/s00223 018 0397 1
   Devlin MJ, 2010, J BONE MINER RES, V25, P2078, DOI 10.1002/jbmr.82
   Donmez G, 2010, CELL, V142, P320, DOI 10.1016/j.cell.2010.06.020
   Ecklund K, 2010, J BONE MINER RES, V25, P298, DOI 10.1359/jbmr.090805
   Elbaz A, 2010, J CELL MOL MED, V14, P982, DOI 10.1111/j.1582 4934.2009.00751.x
   Fazeli PK, 2013, J CLIN ENDOCR METAB, V98, P935, DOI 10.1210/jc.2012 3634
   Fazeli PK, 2012, J BONE MINER RES, V27, P1864, DOI 10.1002/jbmr.1640
   Finkel T, 2009, NATURE, V460, P587, DOI 10.1038/nature08197
   Fretz JA, 2010, ENDOCRINOLOGY, V151, P1611, DOI 10.1210/en.2009 0987
   Gerin I, 2009, J BIOL CHEM, V284, P10755, DOI 10.1074/jbc.M809115200
   Ghali O, 2015, BMC CELL BIOL, V16, DOI 10.1186/s12860 015 0056 6
   Ghali O, 2010, J BONE MINER RES, V25, P1616, DOI 10.1002/jbmr.52
   Griffith JF, 2012, J MAGN RESON IMAGING, V36, P225, DOI 10.1002/jmri.23619
   Haberland M, 2010, J BIOL CHEM, V285, P14663, DOI 10.1074/jbc.M109.081679
   Hamrick MW, 2008, J BONE MINER RES, V23, P870, DOI 10.1359/JBMR.080213
   Herranz D, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1001
   Hoseini A, 2019, FOOD FUNCT, V10, P6042, DOI [10.1039/C9FO01075K, 10.1039/c9fo01075k]
   Huhn S, 2018, NEUROIMAGE, V174, P177, DOI 10.1016/j.neuroimage.2018.03.023
   Iyer S, 2014, J BIOL CHEM, V289, P24069, DOI 10.1074/jbc.M114.561803
   Justesen J, 2001, BIOGERONTOLOGY, V2, P165, DOI 10.1023/A:1011513223894
   Kim HN, 2015, MOL ENDOCRINOL, V29, P1498, DOI 10.1210/me.2015 1133
   Kim SY, 2016, ARCH BIOCHEM BIOPHYS, V598, P1, DOI 10.1016/j.abb.2016.03.025
   Lee YM, 2011, J PERIODONTAL RES, V46, P712, DOI 10.1111/j.1600 0765.2011.01394.x
   Li J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.348
   Lynch CJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013502
   McGee Lawrence ME, 2016, J BONE MINER RES, V31, P116, DOI 10.1002/jbmr.2602
   McGee Lawrence ME, 2013, BONE, V52, P296, DOI 10.1016/j.bone.2012.10.015
   Milne JC, 2007, NATURE, V450, P712, DOI 10.1038/nature06261
   Mizutani K, 1998, BIOCHEM BIOPH RES CO, V253, P859, DOI 10.1006/bbrc.1998.9870
   Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474 9728.2004.00127.x
   MOORE SG, 1990, RADIOLOGY, V175, P219, DOI 10.1148/radiology.175.1.2315484
   Muruganandan S, 2009, CELL MOL LIFE SCI, V66, P236, DOI 10.1007/s00018 008 8429 z
   Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534 5807(02)00401 X
   Nishimura R, 2008, J BONE MINER METAB, V26, P203, DOI 10.1007/s00774 007 0824 2
   Nuttall ME, 2014, CALCIFIED TISSUE INT, V94, P78, DOI 10.1007/s00223 013 9807 6
   Orecchia A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024307
   OWEN M, 1988, J CELL SCI, P63
   Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583
   Piccinin MA, 2014, ADIPOCYTE, V3, P263, DOI 10.4161/adip.32215
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Qiang L, 2012, CELL, V150, P620, DOI 10.1016/j.cell.2012.06.027
   Rached MT, 2010, CELL METAB, V11, P147, DOI 10.1016/j.cmet.2010.01.001
   Rauch A, 2019, NAT GENET, V51, P716, DOI 10.1038/s41588 019 0359 1
   Razidlo DF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011492
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Schafer AL, 2015, BONE, V74, P140, DOI 10.1016/j.bone.2015.01.010
   Shakibaei M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035712
   Shen W, 2012, EUR J CLIN NUTR, V66, P983, DOI 10.1038/ejcn.2012.35
   Simic P, 2013, EMBO MOL MED, V5, P430, DOI 10.1002/emmm.201201606
   Siqueira MF, 2011, BONE, V48, P1043, DOI 10.1016/j.bone.2011.01.019
   Skillington J, 2002, J CELL BIOL, V159, P135, DOI 10.1083/jcb.200204060
   Song LH, 2006, TOXICOL IN VITRO, V20, P915, DOI 10.1016/j.tiv.2006.01.016
   Song LG, 2012, J BONE MINER RES, V27, P2344, DOI 10.1002/jbmr.1694
   Sugatani T, 2015, BONE, V81, P168, DOI 10.1016/j.bone.2015.07.018
   Tseng PC, 2011, J BONE MINER RES, V26, P2552, DOI 10.1002/jbmr.460
   Verma S, 2002, J CLIN PATHOL, V55, P693, DOI 10.1136/jcp.55.9.693
   Wren TAL, 2011, J CLIN ENDOCR METAB, V96, P782, DOI 10.1210/jc.2010 1922
   Wu XY, 2016, DNA CELL BIOL, V35, P542, DOI 10.1089/dna.2016.3280
   Xu C, 2013, AM J TRANSL RES, V5, P412
   Zainabadi K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178520
   Zgheib S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103775
NR 82
TC 36
Z9 39
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUL
PY 2020
VL 136
AR 115361
DI 10.1016/j.bone.2020.115361
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA LQ6SP
UT WOS:000535131500020
PM 32289519
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Jo, S
   Wang, SE
   Lee, YL
   Kang, S
   Lee, B
   Han, J
   Sung, IH
   Park, YS
   Bae, SC
   Kim, TH
AF Jo, Sungsin
   Wang, Sung Eun
   Lee, Young Lim
   Kang, Suman
   Lee, Bitnara
   Han, Jinil
   Sung, Il Hoon
   Park, Ye Soo
   Bae, Sang Cheol
   Kim, Tae Hwan
TI IL 17A induces osteoblast differentiation by activating JAK2/STAT3 in
   ankylosing spondylitis
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
DE Ankylosing spondylitis; Osteoblastic activity and differentiation;
   IL 17A; JAK2/STAT3 signaling
ID MESENCHYMAL STEM CELLS; RADIOGRAPHIC PROGRESSION; RHEUMATOID ARTHRITIS;
   DISEASE ACTIVITY; BONE FORMATION; CRITERIA; SPONDYLOARTHRITIS;
   INTERLEUKIN 17A; CLASSIFICATION; SECUKINUMAB
AB Background: IL 17A has recently emerged as a potential target that regulates the extensive inflammation and abnormal bone formation observed in ankylosing spondylitis (AS). Blocking IL 17A is expected to inhibit bony ankylosis. Here, we investigated the effects of anti IL 17A agents in AS.
   Methods: TNF alpha, IL 17A, and IL 12/23 p40 levels in serum and synovial fluid from patients with ankylosing spondylitis (AS), rheumatoid arthritis (RA), osteoarthritis (OA), or healthy controls (HC) were measured by ELISA. Bone tissue samples were obtained at surgery from the facet joints of ten patients with AS and ten control (Ct) patients with noninflammatory spinal disease. The functional relevance of IL 17A, biological blockades, Janus kinase 2 (JAK2), and non receptor tyrosine kinase was assessed in vitro with primary bone derived cells (BdCs) and serum from patients with AS.
   Results: Basal levels of IL 17A and IL 12/ 23 p40 in body fluids were elevated in patients with AS. JAK2 was also highly expressed in bone tissue and primary BdCs from patients with AS. Furthermore, addition of exogenous IL 17A to primary Ct BdCs promoted the osteogenic stimulus induced increase in ALP activity and mineralization. Intriguingly, blocking IL 17A with serum from patients with AS attenuated ALP activity and mineralization in both Ct and AS BdCs by inhibiting JAK2 phosphorylation and downregulating osteoblast involved genes. Moreover, JAK2 inhibitors effectively reduced JAK2 driven ALP activity and JAK2 mediated events.
   Conclusions: Our findings indicate that IL 17A regulates osteoblast activity and differentiation via JAK2/STAT3 signaling. They shed light on AS pathogenesis and suggest new rational therapies for clinical AS ankylosis.
C1 [Jo, Sungsin; Lee, Young Lim; Kang, Suman; Lee, Bitnara; Bae, Sang Cheol; Kim, Tae Hwan] Hanyang Univ, Hosp Rheumat Dis, Dept Rheumatol, 222 1 Wangsimni Ro, Seoul 04763, South Korea.
   [Wang, Sung Eun] Hanyang Univ, Hanyang Biomed Res Inst, Seoul, South Korea.
   [Han, Jinil] Gencurix Inc, Hanhwan Bizmetro 1,Guro 3 Dong, Seoul, South Korea.
   [Sung, Il Hoon] Hanyang Univ Hosp, Dept Orthoped Surg, Seoul, South Korea.
   [Park, Ye Soo] Hanyang Univ Hosp, Dept Orthoped Surg, Guri, South Korea.
   [Bae, Sang Cheol] CRCRA, Seoul, South Korea.
C3 Hanyang University; Hanyang University; Hanyang University; Hanyang
   University Hospital; Hanyang University; Hanyang University Hospital
RP Kim, TH (通讯作者)，Hanyang Univ, Hosp Rheumat Dis, Dept Rheumatol, 222 1 Wangsimni Ro, Seoul 04763, South Korea.
EM thkim@hanyang.ac.kr
RI Wang, Sungeun/KRQ 9914 2024; Jo, Sungsin/AAL 3659 2021; Kim,
   Tae Hwan/M 3962 2017; Bae, Sang Cheol/P 2051 2015
OI Kim, Tae Hwan/0000 0002 3542 2276; Wang, Sung Eun/0000 0002 0526 588X;
   Jo, Sungsin/0000 0003 3034 5029
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Science, ICT and Future
   [NRF 2016R1A2B4008606]; Ministry of Education [2017R1A6A3A11034394];
   Korea Health Technology R&D grant through the Korea Health Industry
   Development Institute (KHIDI)   Ministry of Health and Welfare, Republic
   of Korea [HI17C0888]
FX This work was supported by the Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Science, ICT and Future (NRF 2016R1A2B4008606) and the Ministry of
   Education (2017R1A6A3A11034394). It was also supported by a Korea Health
   Technology R&D grant through the Korea Health Industry Development
   Institute (KHIDI), which is funded by the Ministry of Health and
   Welfare, Republic of Korea (HI17C0888).
CR Aletaha D, 2010, ARTHRITIS RHEUM US, V62, P2569, DOI 10.1002/art.27584
   ALTMAN R, 1986, ARTHRITIS RHEUM US, V29, P1039, DOI 10.1002/art.1780290816
   Baeten D, 2013, LANCET, V382, P1705, DOI 10.1016/S0140 6736(13)61134 4
   Baraliakos X, 2014, ANN RHEUM DIS, V73, P710, DOI 10.1136/annrheumdis 2012 202698
   Barkham N, 2009, ARTHRITIS RHEUM US, V60, P946, DOI 10.1002/art.24408
   Beck GR Jr, 2000, P NATL ACAD SCI USA, V97, P8352, DOI 10.1073/pnas.140021997
   Boonrungsiman S, 2012, P NATL ACAD SCI USA, V109, P14170, DOI 10.1073/pnas.1208916109
   Braun J, 2017, ANN RHEUM DIS, V76, P1070, DOI 10.1136/annrheumdis 2016 209730
   Choi YH, 2014, FEBS J, V281, P3656, DOI 10.1111/febs.12887
   Dimai HP, 1998, BONE, V22, P211, DOI 10.1016/S8756 3282(97)00268 8
   FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235
   Haroon N, 2013, ARTHRITIS RHEUM US, V65, P2645, DOI 10.1002/art.38070
   Huang H, 2009, CELL DEATH DIFFER, V16, P1332, DOI 10.1038/cdd.2009.74
   Jo S, 2018, J BONE MINER METAB, V36, P307, DOI 10.1007/s00774 017 0846 3
   Jo S, 2018, BIOCHEM BIOPH RES CO, V495, P1257, DOI 10.1016/j.bbrc.2017.11.155
   Jo S, 2017, BIOCHEM BIOPH RES CO, V491, P787, DOI 10.1016/j.bbrc.2017.07.079
   Kenna TJ, 2012, ARTHRITIS RHEUM US, V64, P1420, DOI 10.1002/art.33507
   Lee EJ, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0870 4
   Li Jiliang, 2013, JAKSTAT, V2, pe23930, DOI 10.4161/jkst.23930
   Lubberts E, 2015, NAT REV RHEUMATOL, V11, P415, DOI 10.1038/nrrheum.2015.53
   Maas F, 2017, ARTHRIT CARE RES, V69, P1011, DOI 10.1002/acr.23097
   Mei Y, 2011, CLIN RHEUMATOL, V30, P269, DOI 10.1007/s10067 010 1647 4
   Molnar C, 2018, ANN RHEUM DIS, V77, P63, DOI 10.1136/annrheumdis 2017 211544
   Noh M, 2012, BIOCHEM PHARMACOL, V83, P661, DOI 10.1016/j.bcp.2011.12.010
   Osta B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00425
   Raychaudhuri SP, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1249 5
   Sieper J, 2016, NAT REV RHEUMATOL, V12, P282, DOI 10.1038/nrrheum.2016.42
   Sung YK, 2012, SEMIN ARTHRITIS RHEU, V41, P745, DOI 10.1016/j.semarthrit.2011.09.007
   van der Heijde D, 2008, ARTHRITIS RHEUM US, V58, P1324, DOI 10.1002/art.23471
   van der Heijde D, 2008, ARTHRITIS RHEUM US, V58, P3063, DOI 10.1002/art.23901
   van der Heijde D, 2017, ANN RHEUM DIS, V76, P1340, DOI 10.1136/annrheumdis 2016 210322
   van der Heijde DM, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2790
   VANDERLINDEN S, 1984, ARTHRITIS RHEUM, V27, P361
   Wendling D, 2009, CLIN RHEUMATOL, V28, P187, DOI 10.1007/s10067 008 1011 0
   Xie ZY, 2016, ARTHRITIS RHEUMATOL, V68, P430, DOI 10.1002/art.39433
NR 35
TC 125
Z9 132
U1 3
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1478 6354
EI 1478 6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PD JUN 7
PY 2018
VL 20
AR 115
DI 10.1186/s13075 018 1582 3
PG 10
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA GI6CO
UT WOS:000434457300003
PM 29880011
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhan, WQ
   Deng, MZ
   Huang, XQ
   Xie, D
   Gao, X
   Chen, JX
   Shi, Z
   Lu, JX
   Lin, H
   Li, P
AF Zhan, Weiqiang
   Deng, Mingzhu
   Huang, Xinqia
   Xie, Dong
   Gao, Xiang
   Chen, Jiaxian
   Shi, Zhen
   Lu, Jiaxu
   Lin, Hao
   Li, Peng
TI Pueraria lobata derived exosome like nanovesicles alleviate osteoporosis
   by enhacning autophagy
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Osteoporosis; Pueraria lobata  derived exosome like nano; vesicles; Gut
   microbiota; Autophagy; TMAO
ID GUT MICROBIOTA; TMAO
AB Osteoporosis (OP) is the most common bone disorder worldwide, especially in postmenopausal women. However, many OP drugs are not suitable for long term use due to major adverse effects. Therefore, there is an urgent need to identify more effective and safe therapeutic drugs. Pueraria lobata has been reported to promote osteoblast growth in bone regeneration, but the exact mechanisms still need further exploration. The current study found that Pueraria lobata derived exosome like nanovesicles (PELNs) promoting primary human bone mesenchymal stem cells (hBMSCs) differentiation and mineralization both in vitro and in ovariectomized (OVX)induced osteoporotic rats. Interestingly, the relative abundance of harmful strains significantly decreased in the intestine of the osteoporosis SD rat model administrated PELNs via the regulation of trimethylamine N oxide (TMAO), a metabolite of gut microbiota. Moreover, RNA sequencing revealed that the osteogenic activity of PELNs is revealed to autophagy signaling. In vitro and in vivo experiments also showed that the treatment with PELNs promoted the differentiation and function of hBMSCs by elevating autophagy via the degradation of TMAO. Collectively, PELNs demonstrate promise as a therapeutic approach for OP, with TMAO emerging as a potential target of OP treatment.
C1 [Zhan, Weiqiang; Deng, Mingzhu; Huang, Xinqia; Gao, Xiang; Lu, Jiaxu; Li, Peng] Guangdong Med Univ, Stem Cell Res & Cellular Therapy Ctr, Affiliated Hosp, Zhanjiang 524001, Peoples R China.
   [Zhan, Weiqiang; Deng, Mingzhu; Huang, Xinqia; Xie, Dong; Chen, Jiaxian; Shi, Zhen; Lu, Jiaxu; Lin, Hao] Guangdong Med Univ, Affiliated Hosp, Orthoped Ctr, Zhanjiang 524001, Peoples R China.
C3 Guangdong Medical University; Guangdong Medical University
RP Li, P (通讯作者)，Guangdong Med Univ, Stem Cell Res & Cellular Therapy Ctr, Affiliated Hosp, Zhanjiang 524001, Peoples R China.; Lin, H (通讯作者)，Guangdong Med Univ, Affiliated Hosp, Orthoped Ctr, Zhanjiang 524001, Peoples R China.
EM linhao@gdmu.edu.cn; 13763086273@163.com
RI Zhan, Weiqiang/A 2077 2010; shi, zhen/KHC 6112 2024
FU National Natural Science Foundation of China [81570260]; Guangdong and
   Enterprises Joint Fund of Public Health and Medicine Area, China
   [2022A1515220054]; Science and Technology Program of Zhanjiang, China
   [2021A05069]; Doctor Foundation of the Affiliated Hospital of Guangdong
   Medical University [BJ201802]; Special fund for Affiliated Hospital of
   Guangdong Medical University "Clinical Medicine +" CnTech Co
    construction Platform [CLP2021A001]; Open funding of Affiliated
   Hospital of Guangdong Medical University  research of autophagy and
   diseases
FX This research was funded by the National Natural Science Foundation of
   China (81570260) ; Guangdong and Enterprises Joint Fund of Public Health
   and Medicine Area, China (2022A1515220054) , Science and Technology
   Program of Zhanjiang, China (2021A05069) , Doctor Foundation of the
   Affiliated Hospital of Guangdong Medical University (BJ201802) , Special
   fund for Affiliated Hospital of Guangdong Medical University "Clinical
   Medicine +" CnTech Co  construction Platform (CLP2021A001) , Open
   funding of Affiliated Hospital of Guangdong Medical University  research
   of autophagy and diseases.
CR Adami G, 2019, CURR RHEUMATOL REP, V21, DOI 10.1007/s11926 019 0836 7
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Brown JP, 2021, ENDOCRINOL METAB, V36, P544, DOI 10.3803/EnM.2021.301
   Chen YQ, 2023, J NANOBIOTECHNOL, V21, DOI 10.1186/s12951 023 01872 9
   D'Amelio P, 2018, CALCIFIED TISSUE INT, V102, P415, DOI 10.1007/s00223 017 0331 y
   El Miedany Y, 2023, CURR OSTEOPOROS REP, V21, P472, DOI 10.1007/s11914 023 00791 w
   Elam RE, 2022, BONE, V161, DOI 10.1016/j.bone.2022.116431
   Gioia C, 2020, NUTRIENTS, V12, DOI 10.3390/nu12051456
   Hu YK, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6324912
   Huang W, 2020, ACS OMEGA, V5, P12251, DOI 10.1021/acsomega.0c00950
   Hwang JH, 2023, J CONTROL RELEASE, V355, P184, DOI 10.1016/j.jconrel.2023.01.071
   Jia Y, 2022, BIOENGINEERED, V13, P5581, DOI 10.1080/21655979.2022.2038941
   Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Li L, 2019, AGING US, V11, P9348, DOI 10.18632/aging.102376
   Lin H, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm 20 5307
   Liu YK, 2020, AGING US, V12, P10633, DOI 10.18632/aging.103283
   Lu LY, 2021, FASEB J, V35, DOI 10.1096/fj.202100451R
   Prestwood KM, 2000, J CLIN ENDOCR METAB, V85, P4462, DOI 10.1210/jc.85.12.4462
   Song SS, 2022, PHARMACOL THERAPEUT, V237, DOI 10.1016/j.pharmthera.2022.108168
   Song XY, 2023, J CONTROL RELEASE, V355, P18, DOI 10.1016/j.jconrel.2023.01.057
   Suthon S, 2016, J NAT MED TOKYO, V70, P225, DOI 10.1007/s11418 016 0965 5
   Teng Y, 2018, CELL HOST MICROBE, V24, P637, DOI 10.1016/j.chom.2018.10.001
   Thomas MS, 2021, CURR ATHEROSCLER REP, V23, DOI 10.1007/s11883 021 00910 x
   Wang N, 2022, NUTRIENTS, V14, DOI 10.3390/nu14193955
   Wang SG, 2020, BIOMED PHARMACOTHER, V131, DOI 10.1016/j.biopha.2020.110734
   Xiao L, 2020, AGING US, V12, P21706, DOI 10.18632/aging.103976
   Xu XH, 2021, NANO LETT, V21, P8151, DOI 10.1021/acs.nanolett.1c02530
   Yan J, 2016, P NATL ACAD SCI USA, V113, pE7554, DOI 10.1073/pnas.1607235113
   Zhang L, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.1005665
   Zhang MZ, 2016, BIOMATERIALS, V101, P321, DOI 10.1016/j.biomaterials.2016.06.018
   Zhang ZY, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.896745
NR 32
TC 34
Z9 35
U1 15
U2 110
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168 3659
EI 1873 4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD DEC
PY 2023
VL 364
BP 644
EP 653
DI 10.1016/j.jconrel.2023.11.020
EA NOV 2023
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA Z9BX4
UT WOS:001114964600001
PM 37967723
OA hybrid
DA 2025 08 17
ER

PT J
AU Wang, C
   Kaur, K
   Xu, CX
   Abu Amer, Y
   Mbalaviele, G
AF Wang, Chun
   Kaur, Khushpreet
   Xu, Canxin
   Abu Amer, Yousef
   Mbalaviele, Gabriel
TI Chemotherapy activates inflammasomes to cause inflammation associated
   bone loss
SO ELIFE
LA English
DT Article
DE chemotherapy; doxorubicin; bone; inflammation; inflammasome; pyroptosis;
   Mouse
ID NLRP3 INFLAMMASOME; DOXORUBICIN; CANCER; MUTATIONS; TOXICITY; DENSITY;
   DISEASE; CIAS1
AB Chemotherapy is a widely used treatment for a variety of solid and hematological malignancies. Despite its success in improving the survival rate of cancer patients, chemotherapy causes significant toxicity to multiple organs, including the skeleton, but the underlying mechanisms have yet to be elucidated. Using tumor free mouse models, which are commonly used to assess direct off target effects of anti neoplastic therapies, we found that doxorubicin caused massive bone loss in wild type mice, a phenotype associated with increased number of osteoclasts, leukopenia, elevated serum levels of danger associated molecular patterns (DAMPs; e.g. cell free DNA and ATP) and cytokines (e.g. IL 1 beta and IL 18). Accordingly, doxorubicin activated the absent in melanoma (AIM2) and NLR family pyrin domain containing 3 (NLRP3) inflammasomes in macrophages and neutrophils, causing inflammatory cell death pyroptosis and NETosis, which correlated with its leukopenic effects. Moreover, the effects of this chemotherapeutic agent on cytokine secretion, cell demise, and bone loss were attenuated to various extent in conditions of AIM2 and/or NLRP3 insufficiency. Thus, we found that inflammasomes are key players in bone loss caused by doxorubicin, a finding that may inspire the development of a tailored adjuvant therapy that preserves the quality of this tissue in patients treated with this class of drugs.
C1 [Wang, Chun; Kaur, Khushpreet; Mbalaviele, Gabriel] Washington Univ, Sch Med, Div Bone & Mineral Dis, St Louis, MO 63130 USA.
   [Xu, Canxin] Aclaris Therapeut Inc, St Louis, MO USA.
   [Abu Amer, Yousef] Washington Univ, Sch Med, Dept Orthopaed Surg, St Louis, MO USA.
   [Abu Amer, Yousef] Shriners Hosp Children, St Louis, MO USA.
C3 Washington University (WUSTL); Washington University (WUSTL)
RP Mbalaviele, G (通讯作者)，Washington Univ, Sch Med, Div Bone & Mineral Dis, St Louis, MO 63130 USA.
EM gmbalaviele@wustl.edu
RI Kaur, Khushpreet/MCY 2960 2025
OI Kaur, Khushpreet/0000 0002 8277 6114; Abu Amer,
   Yousef/0000 0002 5890 5086
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
   [R01 AR072623, R01 AR082192, P30 AR074992, R01 AR076758]; Shriners
   Hospitals for Children [85109]; National Institute of Allergy and
   Infectious Diseases [R01 AI161022]; National Institute on Aging [R01
   AG077732]
FX National Institute of Arthritis and Musculoskeletal and Skin Diseases
   R01 AR072623 Yousef Abu Amer National Institute of Arthritis and
   Musculoskeletal and Skin Diseases R01 AR082192 Yousef Abu Amer Shriners
   Hospitals for Children 85109 Yousef Abu Amer National Institute of
   Arthritis and Musculoskeletal and Skin Diseases P30 AR074992 Yousef
   Abu Amer National Institute of Arthritis and Musculoskeletal and Skin
   Diseases R01 AR076758 Gabriel Mbalaviele National Institute of Allergy
   and Infectious Diseases R01 AI161022 Gabriel Mbalaviele National
   Institute on Aging R01 AG077732 Gabriel Mbalaviele The funders had no
   role in study design, data collection and interpretation, or the
   decision to submit the work for publication
CR Abe K, 2022, SCI SIGNAL, V15, DOI 10.1126/scisignal.abn8017
   Aksentijevich I, 2002, ARTHRITIS RHEUM US, V46, P3340, DOI 10.1002/art.10688
   Alippe Y, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 07014 0
   Apel F, 2021, SCI SIGNAL, V14, DOI 10.1126/scisignal.aax7942
   Blayney DW, 2022, CANCER TREAT REV, V109, DOI 10.1016/j.ctrv.2022.102427
   Boccia R, 2022, ONCOLOGIST, V27, P625, DOI 10.1093/oncolo/oyac074
   Bonar SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035979
   BONNER JA, 1990, INT J RADIAT BIOL, V57, P55, DOI 10.1080/09553009014550341
   Borniger JC, 2015, BRAIN BEHAV IMMUN, V47, P218, DOI 10.1016/j.bbi.2014.11.001
   Brydges SD, 2009, IMMUNITY, V30, P875, DOI 10.1016/j.immuni.2009.05.005
   Buttiglieri S, 2011, EXP HEMATOL, V39, P1171, DOI 10.1016/j.exphem.2011.08.009
   Cardinale D, 2015, CIRCULATION, V131, P1981, DOI 10.1161/CIRCULATIONAHA.114.013777
   Carta S, 2015, P NATL ACAD SCI USA, V112, P2835, DOI 10.1073/pnas.1424741112
   Cauley JA, 2009, J BONE MINER RES, V24, P134, DOI 10.1359/JBMR.080813
   Cawthon PM, 2012, J BONE MINER RES, V27, P2179, DOI 10.1002/jbmr.1671
   Cawthon PM, 2009, J BONE MINER RES, V24, P1728, DOI [10.1359/JBMR.090419, 10.1359/jbmr.090419]
   Chai RC, 2014, J BIOL CHEM, V289, P13602, DOI 10.1074/jbc.M113.530626
   Chen S, 2020, JACC BASIC TRANSL SC, V5, P582, DOI 10.1016/j.jacbts.2020.03.016
   Chen SD, 2023, PLOS ONE, V18, DOI 10.1371/journal.pone.0288422
   Coleman RE, 2013, NAT REV RHEUMATOL, V9, P365, DOI 10.1038/nrrheum.2013.36
   Eljack S, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14112537
   Fan CM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020484
   Fan CM, 2017, BREAST CANCER RES TR, V165, P41, DOI 10.1007/s10549 017 4308 3
   Feldmann J, 2002, AM J HUM GENET, V71, P198, DOI 10.1086/341357
   Gatti DM, 2018, PHARMACOGENOMICS J, V18, P319, DOI 10.1038/tpj.2017.23
   Geffen DB, 2002, ISR MED ASSOC J, V4, P1124
   Goldshtein H, 2009, ANN CLIN BIOCHEM, V46, P488, DOI 10.1258/acb.2009.009002
   Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893
   HARRISON SD, 1980, CANCER CHEMOTH PHARM, V4, P199
   Jang JY, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24098457
   Jeong JH, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075 021 02472 4
   Karmakar M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10555
   Khan MA, 2019, CANCERS, V11, DOI 10.3390/cancers11091328
   Komada T, 2018, J AM SOC NEPHROL, V29, P1165, DOI 10.1681/ASN.2017080863
   LAWRENCE TS, 1988, CANCER RES, V48, P725
   Lu B, 2014, MOL MED, V20, P350, DOI 10.2119/molmed.2013.00117
   Lu ZZ, 2021, J CONTROL RELEASE, V338, P662, DOI 10.1016/j.jconrel.2021.08.047
   Meng GX, 2009, IMMUNITY, V30, P860, DOI 10.1016/j.immuni.2009.04.012
   Müller A, 2020, J BONE ONCOL, V25, DOI 10.1016/j.jbo.2020.100326
   Nakazawa D, 2016, J AUTOIMMUN, V67, P19, DOI 10.1016/j.jaut.2015.08.018
   Park HJ, 2022, ANTIOXIDANTS BASEL, V11, DOI 10.3390/antiox11081476
   Qu C, 2015, FASEB J, V29, P1269, DOI 10.1096/fj.14 264804
   Rana T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078043
   Rathinam VAK, 2010, NAT IMMUNOL, V11, P395, DOI 10.1038/ni.1864
   ROBSON CN, 1987, CANCER RES, V47, P1560
   Saleh HA, 2021, SCI REP UK, V11, DOI 10.1038/s41598 020 80804 1
   Sharma BR, 2021, NAT IMMUNOL, V22, P550, DOI 10.1038/s41590 021 00886 5
   Shimada K, 2012, IMMUNITY, V36, P401, DOI 10.1016/j.immuni.2012.01.009
   Smith LA, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 337
   Snouwaert JN, 2016, CELL REP, V17, P3077, DOI 10.1016/j.celrep.2016.11.052
   Stutz Andrea, 2013, Methods Mol Biol, V1040, P91, DOI 10.1007/978 1 62703 523 1_8
   Sun K, 2022, ELIFE, V11, DOI 10.7554/eLife.75753
   Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458
   Svendsen P, 2017, LEUKEMIA LYMPHOMA, V58, P1105, DOI 10.1080/10428194.2016.1233543
   Tacar O, 2013, J PHARM PHARMACOL, V65, P157, DOI 10.1111/j.2042 7158.2012.01567.x
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249
   Villalba Campos M, 2016, J OCCUP MED TOXICOL, V11, DOI 10.1186/s12995 016 0123 8
   Wang C, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abj3859
   Wang C, 2020, J BONE MINER RES, V35, P776, DOI 10.1002/jbmr.3927
   Wang C, 2018, J EXP MED, V215, P1315, DOI 10.1084/jem.20172063
   Wang C, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 05033 5
   Wang WL, 2012, CLIN SARCOMA RES, V2, DOI 10.1186/2045 3329 2 25
   Wittenburg LA, 2019, VET COMP ONCOL, V17, P147, DOI 10.1111/vco.12455
   Xian HX, 2022, IMMUNITY, V55, P1370, DOI 10.1016/j.immuni.2022.06.007
   Xiao JQ, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000807
   Yang CA, 2015, RHEUMATOLOGY, V54, P324, DOI 10.1093/rheumatology/keu318
   Yao ZT, 2020, CANCER RES, V80, P1171, DOI 10.1158/0008 5472.CAN 19 2348
   Youm YH, 2013, CELL METAB, V18, P519, DOI 10.1016/j.cmet.2013.09.010
   Zhang X, 2014, CELL REP, V6, P421, DOI 10.1016/j.celrep.2014.01.003
   Zhou L, 2020, AM J TRANSL RES, V12, P5640
   ZIMNY ML, 1988, AM J ANAT, V182, P16, DOI 10.1002/aja.1001820103
NR 72
TC 7
Z9 7
U1 1
U2 3
PU eLIFE SCIENCES PUBL LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050 084X
J9 ELIFE
JI eLife
PD APR 11
PY 2024
VL 13
AR RP92885
DI 10.7554/eLife.92885
PG 22
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA NO6U4
UT WOS:001201439100001
PM 38602733
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Labelle, D
   Jumarie, C
   Moreau, R
AF Labelle, D.
   Jumarie, C.
   Moreau, R.
TI Capacitative calcium entry and proliferation of human osteoblast like
   MG 63 cells
SO CELL PROLIFERATION
LA English
DT Article
ID FIBROBLAST GROWTH FACTOR; OPERATED CA2+ CHANNELS; BONE CELLS; CATION
   CHANNELS; STEM CELLS; 2 AMINOETHOXYDIPHENYL BORATE; MC3T3 E1
   OSTEOBLASTS; SIGNAL TRANSDUCTION; MECHANICAL STRAIN; CYCLE PROGRESSION
AB Adult bone tissue is continuously being remodelled and bone mass is maintained by a balance between osteoclastic bone resorption and osteoblastic bone formation. Alteration of osteoblastic cell proliferation may account in part for lack of balance between these two processes in bone loss of osteoporosis. There is calcium (Ca2+) control in numerous cellular functions; however, involvement of capacitative Ca2+ entry (CCE) in proliferation of bone cells is less well investigated. Objectives : The study described here was aimed to investigate roles of CCE in the proliferation of osteoblast like MG 63 cells. Meterials and Methods : Pharmacological characterizations of CCE were undertaken in parallel, with evaluation of the expression of transient receptor potential canonical (TRPC) channels and of cell proliferation. Results : Intracellular Ca2+ store depletion by thapsigargin induced CCE in MG 63 cells; this was characterized by a rapid transient increase of intracellular Ca2+ followed by significant CCE, induced by conditions that stimulated cell proliferation, namely serum and platelet derived growth factor. Inhibitors of store operated Ca2+ channels (2 APB and SKF 96365) prevented CCE, while voltage dependent Ca2+ channel blockers had no effect. Expression of various TRPC channels was shown in the cells, some having been shown to be responsible for CCE. Voltage dependent Ca2+ channel blockers had no effect on osteoblast proliferation while thapsigargin, 2 APB and SKF 96395, inhibited it. Cell cycle analysis showed that 2 APB and SKF 96395 lengthen the S and G(2)/M phases, which would account for the reduction in cell proliferation. Conclusions : Our results indicate that CCE, likely attributed to the activation of TRPCs, might be the main route for Ca2+ influx involved in osteoblast proliferation.
C1 Univ Quebec, Dept Sci Biol, Lab Metab Osseux, Ctr BioMed, Montreal, PQ H3C 3P8, Canada.
   Univ Quebec, Dept Sci Biol, Lab Transport Membranaire, Ctr Rech Toxicol Environm, Montreal, PQ H3C 3P8, Canada.
C3 University of Quebec; University of Quebec Montreal; University of
   Quebec; University of Quebec Montreal
RP Moreau, R (通讯作者)，Univ Quebec, Dept Sci Biol, Lab Metab Osseux, Ctr BioMed, CP 8888,Succ Ctr Ville, Montreal, PQ H3C 3P8, Canada.
EM moreau.robert@uqam.ca
RI Moreau, Richard/S 1300 2019
CR ALVAREZ J, 1992, FASEB J, V6, P786, DOI 10.1096/fasebj.6.2.1537469
   [Anonymous], BONE OSTEOBLAST OSTE
   Baldi C, 2003, J CELL BIOCHEM, V90, P197, DOI 10.1002/jcb.10612
   Baldi C, 2002, J CELL BIOCHEM, V86, P678, DOI 10.1002/jcb.10255
   Barry ELR, 2000, CALCIFIED TISSUE INT, V66, P145, DOI 10.1007/s002230010029
   Bergh JJ, 2004, ENDOCRINOLOGY, V145, P426, DOI 10.1210/en.2003 0319
   Bergman RJ, 1996, J BONE MINER RES, V11, P568
   Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035
   Berridge MJ, 2000, SCIENCE, V287, P1604, DOI 10.1126/science.287.5458.1604
   Bilmen JG, 2002, EUR J BIOCHEM, V269, P3678, DOI 10.1046/j.1432 1033.2002.03060.x
   Bilmen JG, 2002, CELL SIGNAL, V14, P955, DOI 10.1016/S0898 6568(02)00042 6
   Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195
   Bornfeldt KE, 1995, ANN NY ACAD SCI, V766, P416, DOI 10.1111/j.1749 6632.1995.tb26691.x
   Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672
   BROCKSTEDT H, 1993, BONE, V14, P681, DOI 10.1016/8756 3282(93)90092 O
   Burns DM, 2004, AM J PHYSIOL CELL PH, V287, pC457, DOI 10.1152/ajpcell.00274.2003
   Chan GK, 2002, GERONTOLOGY, V48, P62, DOI 10.1159/000048929
   Chen TL, 2004, BONE, V35, P83, DOI 10.1016/j.bone.2004.03.019
   Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544
   Conconi MT, 2002, INT J MOL MED, V10, P451
   D'Ippolito G, 1999, J BONE MINER RES, V14, P1115, DOI 10.1359/jbmr.1999.14.7.1115
   Danciu TE, 2003, FEBS LETT, V536, P193, DOI 10.1016/S0014 5793(03)00055 3
   DIOCHOT S, 1995, PFLUG ARCH EUR J PHY, V431, P10, DOI 10.1007/BF00374372
   DUNCAN RL, 1995, CALCIFIED TISSUE INT, V57, P344, DOI 10.1007/BF00302070
   Duncan RL, 1998, SEMIN NEPHROL, V18, P178
   Enfissi A, 2004, CELL CALCIUM, V36, P459, DOI 10.1016/j.ceca.2004.04.004
   Genetos DC, 2005, J BONE MINER RES, V20, P41, DOI 10.1359/jbmr.041009
   Ghayor C, 2005, BONE, V36, P93, DOI 10.1016/j.bone.2004.10.007
   Golovina VA, 2001, AM J PHYSIOL HEART C, V280, pH746, DOI 10.1152/ajpheart.2001.280.2.H746
   GUGGINO SE, 1989, P NATL ACAD SCI USA, V86, P2957, DOI 10.1073/pnas.86.8.2957
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711
   Hu HZ, 2004, J BIOL CHEM, V279, P35741, DOI 10.1074/jbc.M404164200
   Huang MS, 2000, AM J PHYSIOL RENAL, V278, pF576, DOI 10.1152/ajprenal.2000.278.4.F576
   Iqbal J, 2005, BIOCHEM BIOPH RES CO, V328, P751, DOI 10.1016/j.bbrc.2004.12.087
   Kahl CR, 2003, ENDOCR REV, V24, P719, DOI 10.1210/er.2003 0008
   Kassem M, 1997, OSTEOPOROSIS INT, V7, P514, DOI 10.1007/BF02652556
   KATO H, 1995, GERONTOLOGY, V41, P20
   Khachaturian Z S, 1989, Aging (Milano), V1, P17
   KIM YS, 1991, CONTRIB NEPHROL, V91, P43
   Kotev Emeth S, 2000, BONE, V27, P777, DOI 10.1016/S8756 3282(00)00389 6
   KRAGSTRUP J, 1984, METAB BONE DIS RELAT, V5, P17, DOI 10.1016/0221 8747(83)90046 2
   LEIS HJ, 1995, BRIT J PHARMACOL, V114, P598, DOI 10.1111/j.1476 5381.1995.tb17181.x
   LIANG CT, 1992, BONE, V13, P435, DOI 10.1016/8756 3282(92)90087 D
   Liu XB, 2003, J BIOL CHEM, V278, P11337, DOI 10.1074/jbc.M213271200
   Lorich DG, 1998, CLIN ORTHOP RELAT R, P246
   Mackie EJ, 2003, INT J BIOCHEM CELL B, V35, P1301, DOI 10.1016/S1357 2725(03)00107 9
   MagnierGaubil C, 1996, J BIOL CHEM, V271, P27788, DOI 10.1074/jbc.271.44.27788
   Maroto R, 2005, NAT CELL BIOL, V7, P179, DOI 10.1038/ncb1218
   Martínez ME, 1999, CALCIFIED TISSUE INT, V64, P280, DOI 10.1007/s002239900619
   Mitsui Saito M, 2000, JPN J PHARMACOL, V82, P269, DOI 10.1254/jjp.82.269
   Mohiti J, 1997, EXP CELL RES, V234, P98, DOI 10.1006/excr.1997.3584
   MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896 6273(89)90069 X
   Moreau R, 1996, J MEMBRANE BIOL, V150, P175, DOI 10.1007/s002329900042
   Moreau R, 1997, J BONE MINER RES, V12, P1984, DOI 10.1359/jbmr.1997.12.12.1984
   NeidlingerWilke C, 1995, J BIOMECH, V28, P1411, DOI 10.1016/0021 9290(95)00089 5
   Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003
   Peterson WJ, 2004, CELL PROLIFERAT, V37, P325, DOI 10.1111/j.1365 2184.2004.00316.x
   PFEILSCHIFTER J, 1993, J BONE MINER RES, V8, P707
   QUARTO R, 1995, CALCIFIED TISSUE INT, V56, P123, DOI 10.1007/BF00296343
   ROHOLL PJM, 1994, J BONE MINER RES, V9, P355
   Sandy J, 1998, BONE, V23, P17, DOI 10.1016/S8756 3282(98)00067 2
   Stenderup K, 2003, BONE, V33, P919, DOI 10.1016/j.bone.2003.07.005
   SUGIMOTO T, 1994, AM J PHYSIOL, V266, pE709, DOI 10.1152/ajpendo.1994.266.5.E709
   Sugioka M, 1999, INT J DEV NEUROSCI, V17, P163, DOI 10.1016/S0736 5748(99)00027 1
   Sweeney M, 2002, AM J PHYSIOL LUNG C, V283, pL144, DOI 10.1152/ajplung.00412.2001
   TAKUWA N, 1995, CELL SIGNAL, V7, P93, DOI 10.1016/0898 6568(94)00074 L
   Trebak M, 2003, CELL CALCIUM, V33, P451, DOI 10.1016/S0143 4160(03)00056 3
   Tsai KS, 2004, CHEM RES TOXICOL, V17, P679, DOI 10.1021/tx0499517
   Vazquez G, 2004, BBA MOL CELL RES, V1742, P21, DOI 10.1016/j.bbamcr.2004.08.015
   Walker LM, 2000, J CELL BIOCHEM, V79, P648, DOI 10.1002/1097 4644(20001215)79:4<648::AID JCB130>3.0.CO;2 Q
   Wang XX, 2004, AM J PHYSIOL CELL PH, V287, pC357, DOI 10.1152/ajpcell.00068.2004
   WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652
   Wiemann M, 1998, CALCIFIED TISSUE INT, V63, P154, DOI 10.1007/s002239900507
   You J, 2001, J BIOL CHEM, V276, P13365, DOI 10.1074/jbc.M009846200
   Zahanich I, 2005, J BONE MINER RES, V20, P1637, DOI 10.1359/JBMR.050521
   Ziros PG, 2002, J BIOL CHEM, V277, P23934, DOI 10.1074/jbc.M109881200
   Zitt C, 2002, PROG NEUROBIOL, V66, P243, DOI 10.1016/S0301 0082(02)00002 3
NR 78
TC 32
Z9 37
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0960 7722
EI 1365 2184
J9 CELL PROLIFERAT
JI Cell Prolif.
PD DEC
PY 2007
VL 40
IS 6
BP 866
EP 884
DI 10.1111/j.1365 2184.2007.00477.x
PG 19
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 232NG
UT WOS:000251025800006
PM 18021176
OA Green Published
DA 2025 08 17
ER

PT J
AU Terpos, E
   Politou, M
   Viniou, N
   Rahemtulla, A
AF Terpos, E
   Politou, M
   Viniou, N
   Rahemtulla, A
TI Significance of macrophage inflammatory protein 1 alpha (MIP 1α) in
   multiple myeloma
SO LEUKEMIA & LYMPHOMA
LA English
DT Article
DE macrophage inflammatory protein 1 alpha (MIP 1 alpha); multiple myeloma;
   bone disease; osteoclasts
ID RECEPTOR ACTIVATOR; BONE DISEASE; T CELLS; MARROW; (MIP) 1 ALPHA;
   MIP 1 BETA; EXPRESSION; SURVIVAL; LESIONS; DIFFERENTIATION
AB Macrophage inflammatory protein 1 alpha (MIP 1 alpha) is a member of the CC chemokine family and is primarily associated with cell adhesion and migration. It is produced by myeloma (MM) cells and directly stimulates osteoclast formation and differentiation in a dose dependent way. MIP 1 alpha protein levels were elevated in the bone marrow plasma of MM patients and correlated with disease stage and activity. MIP 1 alpha was also elevated in the serum of myeloma patients with severe bone disease and correlated positively with bone resorption markers providing evidence for a causal role of MIP 1 alpha in the development of lytic bone lesions in MM. MIP 1 alpha has also been found to stimulate proliferation, migration and survival of plasma cells. Mice, which were inoculated with myeloma cells and treated with a monoclonal rat anti mouse MIP 1 alpha antibody, showed a reduction of both paraprotein and lytic lesions. In addition, MIP 1 alpha enhanced adhesive interactions between myeloma and marrow stromal cells, increasing the expression of RANKL and IL 6, which further increased bone destruction and tumor burden. Myeloma patients with high MIP 1 alpha serum levels have poor prognosis. The positive correlation between MIP 1 alpha and beta(2) microglobulin that has been observed in MM patients at diagnosis further supports the notion that MIP 1 alpha is not only a chemokine with osteoclast activity function but is also implicated in myeloma growth and survival. Therefore, MIP 1 alpha pathway may serve as a target for the development of novel anti myeloma therapies.
C1 215 Gen Ariforce Hosp, Dept Hematol, GR 11525 Athens, Greece.
   Hammersmith Hosp, Imperial Coll London, Fac Med, Dept Hematol, London, England.
   Univ Athens, Sch Med, Dept Internal Med 1, Athens, Greece.
C3 Imperial College London; National & Kapodistrian University of Athens
RP Terpos, E (通讯作者)，215 Gen Ariforce Hosp, Dept Hematol, 3 Kanellopulou St, GR 11525 Athens, Greece.
EM e.terpos@imperial.ac.uk
RI Terpos, Evangelos/AAD 3667 2019
OI Terpos, Evangelos/0000 0001 5133 1422
CR Abe M, 2002, BLOOD, V100, P2195, DOI 10.1182/blood.V100.6.2195.h81802002195_2195_2202
   BLUM S, 1990, DNA CELL BIOL, V9, P589, DOI 10.1089/dna.1990.9.589
   Broxmeyer HE, 1999, EXP HEMATOL, V27, P1113, DOI 10.1016/S0301 472X(99)00045 4
   Choi SJ, 2001, J CLIN INVEST, V108, P1833, DOI 10.1172/JCI13116
   Choi SJ, 2000, BLOOD, V96, P671
   Cocchi F, 2000, P NATL ACAD SCI USA, V97, P13812, DOI 10.1073/pnas.240469997
   COOK DN, 1995, SCIENCE, V269, P1583, DOI 10.1126/science.7667639
   DiPietro LA, 1998, J CLIN INVEST, V101, P1693, DOI 10.1172/JCI1020
   Fuke S, 2004, AM J RESP CELL MOL, V31, P405, DOI 10.1165/rcmb.2004 0131OC
   Han JH, 2001, BLOOD, V97, P3349, DOI 10.1182/blood.V97.11.3349
   Hanyuda M, 2003, RHEUMATOLOGY, V42, P1390, DOI 10.1093/rheumatology/keg391
   Hashimoto T, 2004, BRIT J HAEMATOL, V125, P38, DOI 10.1111/j.1365 2141.2004.04864.x
   HASHIMOTO T, 2005, HAEMATOLOGICA J, V90, P46
   Hirashima M, 1992, DNA Seq, V3, P203, DOI 10.3109/10425179209034019
   KRAJ M, 2005, HAEMATOLOGICA S1, V90, P193
   Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746
   Kukita T, 1997, LAB INVEST, V76, P399
   KUKITA T, 1992, BONE MINER, V19, P215, DOI 10.1016/0169 6009(92)90871 A
   Kusugami K, 1999, J GASTROEN HEPATOL, V14, P20, DOI 10.1046/j.1440 1746.1999.01810.x
   Lean JM, 2002, J CELL BIOCHEM, V87, P386, DOI 10.1002/jcb.10319
   Lee SC, 2000, J IMMUNOL, V164, P3392, DOI 10.4049/jimmunol.164.6.3392
   Lentzsch S, 2003, BLOOD, V101, P3568, DOI 10.1182/blood 2002 08 2383
   Magrangeas F, 2003, BLOOD, V101, P4998, DOI 10.1182/blood 2002 11 3385
   Menten P, 1999, J CLIN INVEST, V104, pR1, DOI 10.1172/JCI7318
   Menten P, 2002, CYTOKINE GROWTH F R, V13, P455, DOI 10.1016/S1359 6101(02)00045 X
   Michigami T, 2000, BLOOD, V96, P1953, DOI 10.1182/blood.V96.5.1953.h8001953_1953_1960
   Min DJ, 2004, ARTHRITIS RHEUM US, V50, P1146, DOI 10.1002/art.20133
   Möller C, 2003, LEUKEMIA, V17, P203, DOI 10.1038/sj.leu.2402717
   Oba Y, 2005, EXP HEMATOL, V33, P272, DOI 10.1016/j.exphem.2004.11.015
   Owen Lynch PJ, 1998, LEUKEMIA LYMPHOMA, V30, P41, DOI 10.3109/10428199809050928
   Oyajobi BO, 2003, BLOOD, V102, P311, DOI 10.1182/blood 2002 12 3905
   OYAJOBI BO, 2005, HAEMATOLOGICA S1, V90, P42
   Politou M, 2004, BRIT J HAEMATOL, V126, P686, DOI 10.1111/j.1365 2141.2004.05092.x
   Roodman G David, 2004, Cancer Treat Res, V118, P83
   Scheven BAA, 1999, BIOCHEM BIOPH RES CO, V254, P773, DOI 10.1006/bbrc.1998.9909
   Schuyler M, 2004, LUNG, V182, P135, DOI 10.1007/s00408 004 0311 7
   Su SB, 1997, BLOOD, V90, P605, DOI 10.1182/blood.V90.2.605.605_605_611
   Terpos E, 2003, BRIT J HAEMATOL, V123, P758, DOI 10.1046/j.1365 2141.2003.04712.x
   Terpos E, 2003, BRIT J HAEMATOL, V123, P106, DOI 10.1046/j.1365 2141.2003.04561.x
   Terpos E, 2003, BLOOD, V102, P1064, DOI 10.1182/blood 2003 02 0380
   Tow K, 2004, LAB INVEST, V84, P1092, DOI 10.1038/labinvest.3700132
   Uneda S, 2003, BRIT J HAEMATOL, V120, P53, DOI 10.1046/j.1365 2141.2003.04040.x
   Watanabe T, 2004, J ENDOCRINOL, V180, P193, DOI 10.1677/joe.0.1800193
   Zhao L, 2004, NAT MED, V10, P966, DOI 10.1038/nm1099
NR 44
TC 62
Z9 74
U1 0
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1042 8194
EI 1029 2403
J9 LEUKEMIA LYMPHOMA
JI Leuk. Lymphoma
PD DEC
PY 2005
VL 46
IS 12
BP 1699
EP 1707
DI 10.1080/10428190500175049
PG 9
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Hematology
GA 979JE
UT WOS:000232937400003
PM 16263571
DA 2025 08 17
ER

PT J
AU Zheng, ZY
   Zhang, XY
   Huang, B
   Liu, JH
   Wei, XA
   Shan, Z
   Wu, H
   Feng, ZH
   Chen, YL
   Fan, SW
   Zhao, FD
   Chen, J
AF Zheng, Zeyu
   Zhang, Xuyang
   Huang, Bao
   Liu, Junhui
   Wei, Xiaoan
   Shan, Zhi
   Wu, Hao
   Feng, Zhenhua
   Chen, Yilei
   Fan, Shunwu
   Zhao, Fengdong
   Chen, Jian
TI Site 1 protease controls osteoclastogenesis by mediating LC3
   transcription
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Article
ID INDUCED BONE LOSS; SWISS MODEL; AUTOPHAGY; STRESS; MIR 9; ATF6
AB Site 1 protease (S1P) is a Golgi located protein that activates unique membrane bound latent transcription factors, and it plays an indispensable role in endoplasmic reticulum stress, lipid metabolism, inflammatory response and lysosome function. A patient with S1P mutation exhibits severe skeletal dysplasia with kyphoscoliosis, dysmorphic facial features and pectus carinatum. However, whether S1P regulates bone remodeling by affecting osteoclastogenesis remains elusive. Here, we show that S1P is indeed a positive regulator of osteoclastogenesis. S1P ablation in mice led to significant osteosclerosis compared with wild type littermates. Mechanistically, S1P showed upregulated during osteoclastogenesis and was identified as a direct target of miR 9 5p. S1P deletion in bone marrow monocytes (BMMs) inhibited ATF6 and SREBP2 maturation, which subsequently impeded CHOP/SREBP2 complex induced LC3 expression and autophagy flux. Consistently, transfection of LC3 adenovirus evidently rescued osteoclastogenesis in S1P deficient BMMs. We then identified the interaction regions between CHOP and SREBP2 by Co immunoprecipitation (Co IP) and molecular docking. Furthermore, S1P deletion or inhibitor efficaciously rescued ovariectomized (OVX)  and LPS induced bone loss in vivo. Collectively, we showed that S1P regulates osteoclast differentiation in a LC3 dependent manner and so is a potential therapy target for osteoporosis.
C1 [Zheng, Zeyu; Zhang, Xuyang; Huang, Bao; Liu, Junhui; Wei, Xiaoan; Shan, Zhi; Feng, Zhenhua; Chen, Yilei; Fan, Shunwu; Zhao, Fengdong; Chen, Jian] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Orthopaed Surg, Sch Med, Hangzhou, Peoples R China.
   [Zheng, Zeyu; Zhang, Xuyang; Huang, Bao; Liu, Junhui; Wei, Xiaoan; Shan, Zhi; Feng, Zhenhua; Chen, Yilei; Fan, Shunwu; Zhao, Fengdong; Chen, Jian] Key Lab Musculoskeletal Syst Degenerat & Regenera, Hangzhou, Peoples R China.
   [Wu, Hao] Univ Hong Kong, Dept Orthopaed & Traumatol, Pokfulam, Hong Kong, Peoples R China.
C3 Zhejiang University; University of Hong Kong
RP Zhao, FD; Chen, J (通讯作者)，Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Orthopaed Surg, Sch Med, Hangzhou, Peoples R China.; Zhao, FD; Chen, J (通讯作者)，Key Lab Musculoskeletal Syst Degenerat & Regenera, Hangzhou, Peoples R China.
EM zhaofengdong@zju.edu.cn; chenjian bio@zju.edu.cn
RI zhang, xuyang/GQH 3712 2022; Wu, Hao/HHC 1323 2022; zheng,
   zeyu/A 3867 2013
OI Chen, Jian/0000 0001 8568 9991; Zhang, Xuyang/0000 0002 4665 3934; Wei,
   Xiaoan/0000 0002 1132 8760; 
FU National Natural Science Foundation of China [81902231, 81871796,
   81802192, 81802188]; Zhejiang Provincial Natural Science Foundation of
   China [LQ19H060005]
FX This work was supported by the National Natural Science Foundation of
   China (81902231, 81871796, 81802192, 81802188), Zhejiang Provincial
   Natural Science Foundation of China (LQ19H060005).
CR Achilleos A, 2015, HUM MOL GENET, V24, P2884, DOI 10.1093/hmg/ddv050
   Bazzoni F, 2009, P NATL ACAD SCI USA, V106, P5282, DOI 10.1073/pnas.0810909106
   Bertoni M, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 09654 8
   Bienert S, 2017, NUCLEIC ACIDS RES, V45, pD313, DOI 10.1093/nar/gkw1132
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Chung YH, 2012, INT J BIOCHEM CELL B, V44, P989, DOI 10.1016/j.biocel.2012.03.007
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   DeSelm CJ, 2011, DEV CELL, V21, P966, DOI 10.1016/j.devcel.2011.08.016
   Guex N, 2009, ELECTROPHORESIS, V30, pS162, DOI 10.1002/elps.200900140
   Guo CS, 2018, IMMUNITY, V49, P842, DOI 10.1016/j.immuni.2018.08.021
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Inoue K, 2015, BBA MOL BASIS DIS, V1852, P2432, DOI 10.1016/j.bbadis.2015.08.018
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Kondo Y, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121596
   Lee WS, 2020, CLIN IMMUNOL, V212, P48, DOI 10.1016/j.clim.2020.108348
   Levine B, 2019, CELL, V176, P11, DOI 10.1016/j.cell.2018.09.048
   Lin NY, 2016, ANN RHEUM DIS, V75, P1203, DOI 10.1136/annrheumdis 2015 207240
   Lin NY, 2013, ANN RHEUM DIS, V72, P761, DOI 10.1136/annrheumdis 2012 201671
   McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Patra D, 2007, J CELL BIOL, V179, P687, DOI 10.1083/jcb.200708092
   Pierce BG, 2014, BIOINFORMATICS, V30, P1771, DOI 10.1093/bioinformatics/btu097
   Qu C, 2015, FASEB J, V29, P1269, DOI 10.1096/fj.14 264804
   Seo YK, 2011, CELL METAB, V13, P367, DOI 10.1016/j.cmet.2011.03.005
   Studer G, 2020, BIOINFORMATICS, V36, P2647, DOI 10.1093/bioinformatics/btaa058
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Veletic I, 2019, BLOOD, V133, P2320, DOI 10.1182/blood 2018 10 878926
   Wang J, 2014, AUTOPHAGY, V10, P766, DOI 10.4161/auto.27954
   Wang KK, 2011, J MOL CELL BIOL, V3, P360, DOI 10.1093/jmcb/mjr021
   Wang SL, 2014, INT J CLIN EXP PATHO, V7, P2209
   WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092 8674(94)90234 8
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Wu MR, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13700
   Xie Z, 2018, J BONE MINER RES, V33, P667, DOI 10.1002/jbmr.3334
   Yang J, 2001, P NATL ACAD SCI USA, V98, P13607, DOI 10.1073/pnas.201524598
   Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097 2765(00)00133 7
   Yue PJ, 2019, LIFE SCI, V233, DOI 10.1016/j.lfs.2019.116731
   Zang Y, 2020, J DENT RES, V99, P1287, DOI 10.1177/0022034520933533
   Zhao Y, 2012, J CELL PHYSIOL, V227, P639, DOI 10.1002/jcp.22768
   Zheng ZG, 2020, CELL DEATH DIFFER, V27, P2048, DOI 10.1038/s41418 019 0484 5
   Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982
NR 41
TC 28
Z9 32
U1 2
U2 39
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1350 9047
EI 1476 5403
J9 CELL DEATH DIFFER
JI Cell Death Differ.
PD JUN
PY 2021
VL 28
IS 6
BP 2001
EP 2018
DI 10.1038/s41418 020 00731 6
EA JAN 2021
PG 18
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA SO2VA
UT WOS:000608964800002
PM 33469231
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Wei, XQ
   Zhang, YM
   Wang, ZY
   He, YN
   Ju, SG
   Fu, JX
AF Wei, Xiaoqian
   Zhang, Yangmin
   Wang, Ziyan
   He, Yuanning
   Ju, Songguang
   Fu, Jinxiang
TI Bone marrow adipocytes is a new player in supporting myeloma cells
   proliferation and survival in myeloma microenvironment
SO TRANSLATIONAL ONCOLOGY
LA English
DT Article
DE Multiple myeloma; Myeloma associated adipocytes; Mesenchymal stem cells;
   Survival; Drug resistance
ID MULTIPLE MYELOMA; GROWTH; PROGRESSION; EXPRESSION; MIGRATION;
   DIFFERENTIATION; ADIPOGENESIS; METASTASIS; OBESITY; GAMMA
AB Multiple myeloma (MM) is a lethal B cell neoplasm characterized by clonal expansion of malignant plasma cells in the bone marrow and remains incurable due to disease relapse and drug resistance. Bone marrow adipocytes (BMAs) are emerging as playing active functions that can support myeloma cell growth and survival. The aim of this study is to investigate myeloma mesenchymal stem cells (MSCs) interaction and the impact of such interactions on the pathogenesis of MM using in vitro co culture assay. Here we provide evidence that MM cell upregulated MSCs to express PPAR gamma and pushes MSCs differentiation toward adipocytes at the expense of osteoblasts in co culture manner. The increased BMAs can effectively enhance MM cell to proliferation, migration, and chemoresistance via cell cell contact and/or cytokines release regulated by PPAR gamma signal pathway. This effect was partially reversed in medium containing PPAR gamma antagonist G3335 and indicated that G3335 distorts the maturation of MSC derived adipocytes and cytokines release by adipocytes through inhibition of PPAR gamma, a key transcriptional factor for the activation of adipogenesis, or cell to cell contact, or both. In meantime, we observed higher expression of adipocyte differentiation associated genes DLK1, DGAT1, FABP4, and FASN both in MSCs and MSC derived adipocytes, but the osteoblast differentiation associated gene ALP was down regulated in MSCs. These finding mean that direct consequence of MM/MSC interaction that play a role in MM pathogenesis. Consistent with those in vitro results, our primary clinical observation also showed that bone marrow samples from MM patients had significantly higher bone adiposity in comparison with controls and the number of adipocytes decreased in those who were response to anti MM therapy. Our finding suggested that BMAs may have an important contribution to MM progression, particularly in drugs resistant of MM cells, and plays an important contribution in MM bone disease and treatment failure, but more clinical studies are needed to confirm its role.
C1 [Wei, Xiaoqian; Zhang, Yangmin; Wang, Ziyan; He, Yuanning; Fu, Jinxiang] Soochow Univ, Affiliated Hosp 2, Dept Oncol, Suzhou, Jiangsu 215004, Peoples R China.
   [Ju, Songguang] Soochow Univ, Inst Biotechnol, Suzhou 215007, Peoples R China.
C3 Soochow University   China; Soochow University   China
RP Fu, JX (通讯作者)，Soochow Univ, Affiliated Hosp 2, Dept Oncol, Suzhou, Jiangsu 215004, Peoples R China.
EM fujinxiang@suda.edu.cn
RI Ju, Songguang/G 9204 2015
FU National Natural Science Foundation of China [81272631]
FX This study was funded by the National Natural Science Foundation of
   China (Grant No. 81272631).
CR Abdelkarim M, 2010, J BIOL CHEM, V285, P36759, DOI 10.1074/jbc.M110.166231
   Alsayed Y, 2007, BLOOD, V109, P2708, DOI 10.1182/blood 2006 07 035857
   Baghaban Eslaminejad Mohamadreza, 2014, World J Stem Cells, V6, P344, DOI 10.4252/wjsc.v6.i3.344
   Birbrair A, 2016, ANN NY ACAD SCI, V1370, P82, DOI 10.1111/nyas.13016
   Branagan A, 2020, JCO ONCOL PRACT, V16, P5, DOI 10.1200/JOP.19.00244
   Bullwinkle EM, 2016, CANCER LETT, V380, P114, DOI 10.1016/j.canlet.2016.06.010
   Cao YH, 2019, J CLIN INVEST, V129, P3006, DOI 10.1172/JCI127201
   Chan CKF, 2015, CELL, V160, P285, DOI 10.1016/j.cell.2014.12.002
   Colombo M, 2013, LEUKEMIA, V27, P1009, DOI 10.1038/leu.2013.6
   Cristancho AG, 2011, NAT REV MOL CELL BIO, V12, P722, DOI 10.1038/nrm3198
   Das R, 2016, NAT MED, V22, P1351, DOI 10.1038/nm.4202
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Fairfield H, 2021, CANCER RES, V81, P634, DOI 10.1158/0008 5472.CAN 20 1088
   Freese KE, 2015, CANCER RES, V75, P1161, DOI 10.1158/0008 5472.CAN 14 2744
   Fu JX, 2017, ARCH MED SCI, V13, P236, DOI 10.5114/aoms.2017.64722
   Grottkau BE, 2013, BONE RES, V1, P282, DOI 10.4248/BR201303006
   Hofmann JN, 2016, CANCER RES, V76, P1935, DOI 10.1158/0008 5472.CAN 15 2406
   Imai Y, 2020, CANCERS, V12, DOI 10.3390/cancers12092544
   Kawai M, 2010, NAT REV ENDOCRINOL, V6, P629, DOI 10.1038/nrendo.2010.155
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Liu ZQ, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aay8203
   Liu ZQ, 2015, ONCOTARGET, V6, P34329, DOI 10.18632/oncotarget.6020
   Mori K, 2006, J CELL BIOCHEM, V98, P1629, DOI 10.1002/jcb.20891
   Morris A, 2019, NAT REV ENDOCRINOL, V15, P439, DOI 10.1038/s41574 019 0231 5
   Morris EV, 2020, J BONE MINER RES, V35, P942, DOI 10.1002/jbmr.3951
   Morris EV, 2019, BONE, V118, P42, DOI 10.1016/j.bone.2018.03.011
   Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492
   Palomares B, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 34259 0
   Panaroni C, 2022, BLOOD, V139, P876, DOI 10.1182/blood.2021013832
   Pinto V, 2020, CANCERS, V12, DOI 10.3390/cancers12020407
   Pope BD, 2016, TRENDS CELL BIOL, V26, P745, DOI 10.1016/j.tcb.2016.05.005
   Scheller EL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8808
   Strong AL, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058 015 0622 z
   Sulston RJ, 2016, HORM MOL BIOL CLIN I, V28, P21, DOI 10.1515/hmbci 2016 0012
   Takeshita S, 2014, J BIOL CHEM, V289, P16699, DOI 10.1074/jbc.M114.547919
   Trotter TN, 2016, AM J PATHOL, V186, P3054, DOI 10.1016/j.ajpath.2016.07.012
   Trotter TN, 2015, BLOOD, V125, P3598, DOI 10.1182/blood 2014 12 613968
   Tsukamoto S, 2018, LEUKEMIA, V32, P1739, DOI 10.1038/s41375 018 0161 6
   Vogl DT, 2011, BIOL BLOOD MARROW TR, V17, P1765, DOI 10.1016/j.bbmt.2011.05.005
   Wang J, 2017, LAB INVEST, V97, P737, DOI 10.1038/labinvest.2017.14
   Xiao JG, 2013, MOL CELL BIOCHEM, V377, P107, DOI 10.1007/s11010 013 1575 0
   Zhang XH, 2015, LEUKEMIA LYMPHOMA, V56, P211, DOI 10.3109/10428194.2014.913289
   Zhang YM, 2017, ARCH MED SCI, V13, P1335, DOI 10.5114/aoms.2017.71065
NR 43
TC 7
Z9 7
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1936 5233
J9 TRANSL ONCOL
JI Transl. Oncol.
PD FEB
PY 2024
VL 40
AR 101856
DI 10.1016/j.tranon.2023.101856
EA DEC 2023
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA FF5R8
UT WOS:001144366200001
PM 38134840
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Stillman, MJ
   Stillman, MT
AF Stillman, Martin J.
   Stillman, M. Thomas
TI Choosing nonselective NSAIDs and selective COX 2 inhibitors in the
   elderly   A clinical use pathway
SO GERIATRICS US
LA English
DT Article
DE nonsteroidal anti inflammatory drugs (NSAIDs); selective COX 2
   inhibitors (coxibs); gastrointestinal adverse events; proton pump
   inhibitors (PPIs); aspirin; clinical use pathway
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GASTROINTESTINAL TOXICITY; RISK;
   CELECOXIB; ARTHRITIS; OSTEOARTHRITIS; OMEPRAZOLE; NAPROXEN; ASPIRIN;
   EVENTS
AB The literature has well established that nonsteroidal anti inflammatory drugs (NSAIDs) are very effective in treating pain and inflammation, but these drugs are associated with significant gastrointestinal (GI) toxicity. This is especially true in the elderly patient population. Selective cyclooxygenase 2 (COX 2) inhibitors (coxibs) were developed to decrease the incidence of GI adverse events. Nevertheless, recent concerns regarding coxibs and their association with adverse cardiovascular events have led physicians to re examine the appropriate use of all NSAIDs. Part 1 of this two part article reviews essential data related to adverse GI events to help physicians select appropriate patients to receive nonselective NSAIDs or coxibs. Other considerations, such as the benefits of proton pump inhibitors (PPIs) and the mitigating effects of concurrent aspirin use, are also discussed. Our clinical use pathway or algorithm will frame the discussion and guide clinicians through what has become a difficult decision in daily practice.
C1 Hennepin Cty Med Ctr, Dept Med, Div Rheumatol, Minneapolis, MN 55415 USA.
   Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA.
   Pfizer Inc, Groton, CT 06340 USA.
   Novartis Pharmaceut, E Hanover, NJ 07936 USA.
   Merck & Co Inc, Whitehouse Stn, NJ 08889 USA.
C3 Hennepin County Medical Center; University of Minnesota System;
   University of Minnesota Twin Cities; Pfizer; Pfizer USA; Novartis;
   Novartis USA; Merck & Company; Merck & Company USA
RP Stillman, MJ (通讯作者)，Hennepin Cty Med Ctr, Dept Med, Div Rheumatol, Minneapolis, MN 55415 USA.
RI Stillman, Martin/O 3191 2016
CR Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103
   Chan FKL, 2004, GASTROENTEROLOGY, V127, P1038, DOI 10.1053/j.gastro.2004.07.010
   Chan FKL, 2002, NEW ENGL J MED, V347, P2104, DOI 10.1056/NEJMoa021907
   Gibofsky A, 2006, POSTGRAD MED, P16
   Goldstein JL, 2003, AM J GASTROENTEROL, V98, P2627, DOI 10.1016/j.amjgastroenterol.2003.08.024
   Goldstein JL, 2001, ARTHRITIS RHEUM, V44, pS136
   Komhoff M, 1997, AM J PHYSIOL RENAL, V272, pF460, DOI 10.1152/ajprenal.1997.272.4.F460
   Laine L, 2004, GASTROENTEROLOGY, V127, P395, DOI 10.1053/j.gastro.2004.05.001
   Laine L, 2003, GASTROENTEROLOGY, V124, P288, DOI 10.1053/gast.2003.50054
   Laine L, 2002, GASTROENTEROLOGY, V123, P1006, DOI 10.1053/gast.2002.36013
   Laine L, 2001, GASTROENTEROLOGY, V120, P594, DOI 10.1053/gast.2001.21907
   LOCKREY GJ, 1999, AUST J HOSP PHARM, V29, P45
   MacDonald TM, 2003, GUT, V52, P1265, DOI 10.1136/gut.52.9.1265
   Nikanne E, 2005, OTOLARYNG HEAD NECK, V132, P287, DOI 10.1016/j.otohns.2004.09.005
   Peterson WL, 1999, JAMA J AM MED ASSOC, V282, P1961, DOI 10.1001/jama.282.20.1961
   Rahme E, 2005, GASTROENTEROLOGY, V128, pA139
   RAHME E, 2004, EULAR
   Scheiman JM, 2001, AM J MANAG CARE, V7, pS10
   Schnitzer TJ, 2004, LANCET, V364, P665, DOI 10.1016/S0140 6736(04)16893 1
   Schoenfeld P., 1999, The American journal of medicine, V107, P48
   Silverstein FE, 2000, JAMA J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247
   Singh G., 1998, Am J Med, V105, p31S, DOI DOI 10.1016/S0002 9343(98)00072 2
   Sorensen HT, 2000, AM J GASTROENTEROL, V95, P2218
   STILLMAN MT, 1990, ARCH INTERN MED, V150, P268
   WEIL J, 1995, BMJ BRIT MED J, V310, P827, DOI 10.1136/bmj.310.6983.827
   Wilcox CM, 1997, DIGEST DIS SCI, V42, P990, DOI 10.1023/A:1018832902287
NR 26
TC 25
Z9 26
U1 1
U2 5
PU ADVANSTAR COMMUNICATIONS INC
PI DULUTH
PA 131 W 1ST STREET, DULUTH, MN 55802 USA
SN 0016 867X
EI 1936 5764
J9 GERIATRICS US
JI Geriatrics
PD FEB
PY 2007
VL 62
IS 2
BP 26
EP +
PG 6
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Geriatrics & Gerontology
GA 139JB
UT WOS:000244427000011
PM 17291140
DA 2025 08 17
ER

PT J
AU Wang, XF
   Wang, DR
   Deng, BY
   Yan, LT
AF Wang, Xianfeng
   Wang, Dangrang
   Deng, Biyong
   Yan, Litao
TI Syringaresinol attenuates osteoarthritis via regulating the NF ?B
   pathway
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Osteoarthritis; Syringaresinol; Anti inflammation; NF kB signaling
   pathway; Therapuetic agent
ID KAPPA B; PHYTIC ACID; IL 1 BETA INDUCED INFLAMMATION; CARTILAGE
   HISTOPATHOLOGY; SUBCHONDRAL BONE; EXPRESSION; MODEL; PATHOGENESIS;
   CHONDROCYTES; PROGRESSION
AB Osteoarthritis (OA) is a now regarded as a worldwide whole joint disease with synovial inflammation, cartilage degeneration, and subchondral sclerosis. Non steroidal anti inflammatory drugs (NSAIDs) are commonly used drugs for OA treatment which only relieve the symptoms and restrain the progression of OA. However, various severe adverse effects often occur in patients with long term NSAIDs use, which heavily burdens the healthcare system and impacts the quality of life. Therefore, it is much imperative to identify alternative drugs with increased efficacy. Syringaresinol (Syr), a naturally occurring phytochemical which belonging to the lignan group of polyphenols, shows anti tumor and anti oxidant activities, which to benefit human health. Studies has shown Syr can regulate the inflammatory response by modulating the secretion and expression level of cytokines IL 6, IL 8, and tumor necrosis factor (TNF) alpha. it also shows the inhibitory effect on NF kappa B pathway in mouse cells. In the present study, we aimed to demonstrate the anti inflammatory effects of Syr in OA. In vitro Syr treatment in IL 1 beta activated mouse chondrocytes significantly restrained the expression of NO, PGE2, IL 6, TNF alpha, INOS, COX2 and MMP 13. Moreover, it considerably ameliorated the degradation of aggrecan and collagen II. Furthermore, the phosphorylation of the NF kB signaling pathway was significantly suppressed by Syr. Moreover, in vivo, the cartilage degeneration was attenuated and the increased Osteoarthritis Research Society International (OARSI) scores were reversed in the DMM + Syr group, comprared to those in the DMM group. In sum, our study demonstrated that Syr can attenuate the inflammation in vitro and further verified its effect on OA in vivo. Thus, Syr might be a potent therapeautic alternative for OA treatment.
C1 [Wang, Xianfeng; Deng, Biyong] Guizhou Prov Orthoped Hosp, Dept Orthoped Surg, Guiyang, Peoples R China.
   [Wang, Dangrang] Dalian Med Univ, Dept Gastroenterol, Hosp 2, Dalian, Peoples R China.
   [Yan, Litao] Soochow Univ, Dept Articular Orthopaed, Affiliated Hosp 3, Changzhou, Peoples R China.
C3 Dalian Medical University; Soochow University   China
RP Deng, BY (通讯作者)，Guizhou Prov Orthoped Hosp, Dept Orthoped Surg, Guiyang, Peoples R China.; Yan, LT (通讯作者)，Soochow Univ, Dept Articular Orthopaed, Affiliated Hosp 3, Changzhou, Peoples R China.
EM biyong61@163.com; yanlitaodtc@163.com
OI yan, litao/0000 0002 6653 2865
FU National Natural Science Founda  tion of China [82202679]; Natural
   Science Foundation of Jiangsu Higher Education Institutions of China
   [22KJB320008]; Applied Basic Research Project of Changzhou
FX This research was funded by the National Natural Science Founda  tion of
   China (Grant No.82202679) ; The Natural Science Foundation of Jiangsu
   Higher Education Institutions of China (Grant No.22KJB320008) ; Applied
   Basic Research Project of Changzhou (Grant No.CJ20220109) .
CR Agarwal C, 2003, ANTICANCER RES, V23, P3855
   Au R.Y., 2007, OSTEOARTHR CARTILAGE, V15
   Bertrand J, 2010, INT J BIOCHEM CELL B, V42, P1594, DOI 10.1016/j.biocel.2010.06.022
   Bondeson J, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2099
   Brebion F, 2021, J MED CHEM, V64, P2937, DOI 10.1021/acs.jmedchem.0c02008
   Cabral Pacheco GA, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249739
   Chen JZ, 2013, J CELL BIOCHEM, V114, P245, DOI 10.1002/jcb.24362
   Choi MC, 2019, CELLS BASEL, V8, DOI 10.3390/cells8070734
   Cholewa K, 2008, ACTA POL PHARM, V65, P75
   Chu XY, 2013, INT J MOL MED, V31, P1222, DOI 10.3892/ijmm.2013.1318
   Daheshia M, 2008, J RHEUMATOL, V35, P2306, DOI 10.3899/jrheum.080346
   de Lange Brokaar BJE, 2012, OSTEOARTHR CARTILAGE, V20, P1484, DOI 10.1016/j.joca.2012.08.027
   Fei JL, 2019, BIOMED PHARMACOTHER, V109, P1586, DOI 10.1016/j.biopha.2018.09.161
   Feng K, 2020, INFLAMM RES, V69, P385, DOI 10.1007/s00011 020 01327 z
   Ferry S, 2002, CARCINOGENESIS, V23, P2031, DOI 10.1093/carcin/23.12.2031
   Glasson SS, 2007, OSTEOARTHR CARTILAGE, V15, P1061, DOI 10.1016/j.joca.2007.03.006
   Glyn Jones S, 2015, LANCET, V386, P376, DOI 10.1016/S0140 6736(14)60802 3
   Goldring MB, 2010, ANN NY ACAD SCI, V1192, P230, DOI 10.1111/j.1749 6632.2009.05240.x
   GOLDRING MB, 1994, J CELL BIOCHEM, V54, P85, DOI 10.1002/jcb.240540110
   Goldring SR, 2016, NAT REV RHEUMATOL, V12, P632, DOI 10.1038/nrrheum.2016.148
   Guan FX, 2019, PROG NEURO PSYCHOPH, V95, DOI 10.1016/j.pnpbp.2019.109684
   HAN YW, 1988, J AGR FOOD CHEM, V36, P1181, DOI 10.1021/jf00084a014
   He LJ, 2021, INT IMMUNOPHARMACOL, V97, DOI 10.1016/j.intimp.2021.107657
   Hinton R, 2002, AM FAM PHYSICIAN, V65, P841
   Hoshi H, 2017, CELL TISSUE RES, V368, P379, DOI 10.1007/s00441 016 2563 y
   Jenei Lanzl Z, 2019, CELL SIGNAL, V53, P212, DOI 10.1016/j.cellsig.2018.10.005
   Jiang LJ, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.703110
   Jimi E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246275
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   Lepetsos P, 2019, FREE RADICAL BIO MED, V132, P90, DOI 10.1016/j.freeradbiomed.2018.09.025
   Liang S, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01378
   Liao CR, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101306
   Lv YQ, 2015, NEUROSCI LETT, V597, P132, DOI 10.1016/j.neulet.2015.04.040
   Marcu KB, 2010, CURR DRUG TARGETS, V11, P599, DOI 10.2174/138945010791011938
   Martel Pelletier J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.72
   Moskowitz RW, 2006, OSTEOARTHR CARTILAGE, V14, P1, DOI 10.1016/j.joca.2005.08.015
   NELSON TS, 1968, POULTRY SCI, V47, P1372, DOI 10.3382/ps.0471372
   Neuhold LA, 2001, J CLIN INVEST, V107, P35, DOI 10.1172/JCI10564
   Pacheco Fernandez N, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201907058
   Palazzo C, 2016, ANN PHYS REHABIL MED, V59, P134, DOI 10.1016/j.rehab.2016.01.006
   Pan TL, 2017, INT IMMUNOPHARMACOL, V52, P34, DOI 10.1016/j.intimp.2017.08.010
   Pasternak B, 2009, ACTA ORTHOP, V80, P693, DOI 10.3109/17453670903448257
   Pritzker KPH, 2006, OSTEOARTHR CARTILAGE, V14, P13, DOI 10.1016/j.joca.2005.07.014
   Rigoglou S, 2013, INT J BIOCHEM CELL B, V45, P2580, DOI 10.1016/j.biocel.2013.08.018
   Sharma AR, 2013, INT J MOL SCI, V14, P19805, DOI 10.3390/ijms141019805
   Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641
   Verma P, 2011, J CELL BIOCHEM, V112, P3507, DOI 10.1002/jcb.23298
   Wallace IJ, 2017, P NATL ACAD SCI USA, V114, P9332, DOI 10.1073/pnas.1703856114
   Wang YS, 2018, BIOMED PHARMACOTHER, V107, P1128, DOI 10.1016/j.biopha.2018.08.103
   Wawszczyk J, 2012, ACTA POL PHARM, V69, P1313
   Weglarz L, 2007, DIGEST DIS SCI, V52, P93, DOI 10.1007/s10620 006 9320 0
   Wu YF, 2020, INT IMMUNOPHARMACOL, V86, DOI 10.1016/j.intimp.2020.106713
   Xi LQ, 2017, ACTA HISTOCHEM, V119, P64, DOI 10.1016/j.acthis.2016.11.008
NR 53
TC 14
Z9 15
U1 2
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD MAY
PY 2023
VL 118
AR 109982
DI 10.1016/j.intimp.2023.109982
EA MAR 2023
PG 13
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA D0MQ1
UT WOS:000965758000001
PM 36989902
OA hybrid
DA 2025 08 17
ER

PT J
AU Elsayed, M
   Kobayashi, D
   Kubota, T
   Matsunaga, N
   Murata, R
   Yoshizawa, Y
   Watanabe, N
   Matsuura, T
   Tsurudome, Y
   Ogino, T
   Ohdo, S
   Shimazoe, T
AF Elsayed, Mahitab
   Kobayashi, Daisuke
   Kubota, Toshio
   Matsunaga, Naoya
   Murata, Ryusei
   Yoshizawa, Yuko
   Watanabe, Natsuki
   Matsuura, Tohru
   Tsurudome, Yuya
   Ogino, Takashi
   Ohdo, Shigehiro
   Shimazoe, Takao
TI Synergistic Antiproliferative Effects of Zoledronic Acid and Fluvastatin
   on Human Pancreatic Cancer Cell Lines: An in Vitro Study
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article
DE pancreatic cancer; zoledronic acid; fluvastatin; combination treatment;
   synergistic
ID NITROGEN CONTAINING BISPHOSPHONATES; MEVALONATE PATHWAY; INDUCE
   APOPTOSIS; PROSTATE CANCER; MULTIPLE MYELOMA; BREAST CARCINOMA;
   CYTOTOXIC AGENTS; BONE METASTASES; PAMIDRONATE; INHIBITION
AB Bisphosphonates and statins are known to have antitumor activities against different types of cancer cell lines. In the present study, we investigated the antiproliferative effects of the combination of zoledronic acid (ZOL), a bisphophosphonate, and fluvastatin (FLU), a statin, in vitro on two types of human pancreatic cancer cell lines, Mia PaCa 2 and Suit 2. The pancreatic cancer cell lines were treated with ZOL and FLU both individually and in combination to evaluate their antiproliferative effects using WST 8 cell proliferation assay. In this study, we demonstrated a potent synergistic antiproliferative effect of both drugs when used in combination in both cell lines. Moreover, we studied the molecular mechanism behind this synergistic effect, which was inhibited by the addition of the mevalonate pathway products, farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP). Furthermore, we aimed to determine the effect of ZOL and FLU combination on RhoA and Ras guanosine 5' triphosphate (GTP) proteins. The combination induced a marked accumulation in RhoA and unprenylated Ras. GGPP and FPP reversed the increase in the amount of both proteins. These results indicated that the combination treatment impaired RhoA and Ras signaling pathway by the inhibition of geranylgeranylation and/or farnesylation. This study provides a potentially effective approach for the treatment of pancreatic cancer using a combination treatment of ZOL and FLU.
C1 [Elsayed, Mahitab; Kobayashi, Daisuke; Kubota, Toshio; Murata, Ryusei; Yoshizawa, Yuko; Watanabe, Natsuki; Matsuura, Tohru; Shimazoe, Takao] Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Clin Pharm & Pharmaceut Care, Higashi Ku, 3 1 1 Maidashi, Fukuoka 8128582, Japan.
   [Matsunaga, Naoya] Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Glocal Hlth Care Sci, Higashi Ku, 3 1 1 Maidashi, Fukuoka 8128582, Japan.
   [Tsurudome, Yuya; Ogino, Takashi; Ohdo, Shigehiro] Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Pharmaceut, Higashi Ku, 3 1 1 Maidashi, Fukuoka 8128582, Japan.
C3 Kyushu University; Kyushu University; Kyushu University
RP Kubota, T (通讯作者)，Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Clin Pharm & Pharmaceut Care, Higashi Ku, 3 1 1 Maidashi, Fukuoka 8128582, Japan.
EM t kubota@med.kyushu u.ac.jp
OI Tsurudome, Yuya/0000 0002 6454 9778; Kobayashi,
   Daisuke/0000 0002 7312 9919; matsunaga2, naoya2/0000 0001 6226 8473
CR Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949
   Billadeau DD, 2002, J GASTROINTEST CANC, V31, P5, DOI 10.1385/IJGC:31:1 3:5
   Bocci G, 2005, BRIT J CANCER, V93, P319, DOI 10.1038/sj.bjc.6602720
   Boissier S, 2000, CANCER RES, V60, P2949
   Bruzzese F, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.406
   Budman DR, 2007, BREAST CANCER RES TR, V104, P93, DOI 10.1007/s10549 006 9395 5
   Budman DR, 2006, ONCOLOGY BASEL, V70, P147, DOI 10.1159/000093006
   Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403
   Caraglia M, 2004, ONCOGENE, V23, P6900, DOI 10.1038/sj.onc.1207814
   Chaplet ML, 2004, BIOCHEM J, V384, P591, DOI 10.1042/BJ20040380
   Chen L, 2013, INT J NANOMED, V8, P137, DOI 10.2147/IJN.S38928
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065 2571(84)90007 4
   Clézardin P, 2005, CANCER RES, V65, P4971, DOI 10.1158/0008 5472.CAN 05 0264
   Corsini A, 2004, DRUGS, V64, P1305, DOI 10.2165/00003495 200464120 00004
   Dulak J, 2005, CURR CANCER DRUG TAR, V5, P579, DOI 10.2174/156800905774932824
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Gbelcová H, 2008, INT J CANCER, V122, P1214, DOI 10.1002/ijc.23242
   Goffinet M, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 60
   GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0
   Ikeuchi H, 2004, NEPHRON EXP NEPHROL, V97, P115, DOI 10.1159/000079176
   Issat T, 2007, INT J ONCOL, V30, P1413
   Iwamura T, 1997, CANCER RES, V57, P1206
   Jiang P, 2014, BRIT J CANCER, V111, P1562, DOI 10.1038/bjc.2014.431
   Khvalevsky EZ, 2013, P NATL ACAD SCI USA, V110, P20723, DOI 10.1073/pnas.1314307110
   Kivistö KT, 1998, BRIT J CLIN PHARMACO, V46, P49, DOI 10.1046/j.1365 2125.1998.00034.x
   Knight LA, 2009, BMC CANCER, V9, DOI 10.1186/1471 2407 9 38
   Koto K, 2010, ONCOL REP, V24, P233, DOI 10.3892/or_00000851
   Kusama T, 2002, GASTROENTEROLOGY, V122, P308, DOI 10.1053/gast.2002.31093
   Lee MV, 2001, CANCER RES, V61, P2602
   Li Shaojuan, 2011, Cancers (Basel), V3, P662, DOI 10.3390/cancers3010662
   Liao JK, 2002, J CLIN INVEST, V110, P285, DOI 10.1172/JCI200216421
   Liu SS, 2014, BIOMED PHARMACOTHER, V68, P1031, DOI 10.1016/j.biopha.2014.09.004
   Low SK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011824
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Massaia M, 2009, HEMATOL MEET REP, V1, P77
   Mistafa O, 2009, BIOCHEM PHARMACOL, V78, P1115, DOI 10.1016/j.bcp.2009.06.016
   Mitrofan LM, 2009, BONE, V45, P1153, DOI 10.1016/j.bone.2009.08.010
   Neuvonen PJ, 2008, CLIN PHARMACOKINET, V47, P463, DOI 10.2165/00003088 200847070 00003
   Ottewell PD, 2009, MOL CANCER THER, V8, P2821, DOI 10.1158/1535 7163.MCT 09 0462
   Parikh A, 2010, PROSTATE, V70, P971, DOI 10.1002/pros.21131
   Qi XF, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.44
   Räikkönen J, 2010, BIOCHEM PHARMACOL, V79, P777, DOI 10.1016/j.bcp.2009.10.003
   Riebeling C, 2002, BRIT J CANCER, V87, P366, DOI 10.1038/sj.bjc.6600476
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Rosen LS, 2004, CANCER, V100, P36, DOI 10.1002/cncr.11892
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Rozenblum E, 1997, CANCER RES, V57, P1731
   Sanfilippo KM, 2015, LEUKEMIA LYMPHOMA, V56, P615, DOI 10.3109/10428194.2014.924117
   Senaratne SG, 2002, BRIT J CANCER, V86, P1479, DOI 10.1038/sj.bjc.6600297
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   Stubbs EB, 2012, MOL NEUROBIOL, V46, P28, DOI 10.1007/s12035 012 8249 x
   Takeda N, 2012, J ORTHOP SCI, V17, P770, DOI 10.1007/s00776 012 0294 9
   Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986
   Taylor Harding B, 2010, GYNECOL ONCOL, V119, P549, DOI 10.1016/j.ygyno.2010.08.017
   Thompson K, 2011, BONE, V49, P140, DOI 10.1016/j.bone.2010.10.177
   Torres MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080580
   Tsubaki M, 2015, AM J CANCER RES, V5, P168
   Tsubaki M, 2013, BIOCHEM PHARMACOL, V85, P163, DOI 10.1016/j.bcp.2012.10.009
   Ullén A, 2005, ACTA ONCOL, V44, P644, DOI 10.1080/02841860510029617
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   Walker K, 2005, CURR OPIN GENET DEV, V15, P62, DOI 10.1016/j.gde.2004.11.001
   Zhao M, 2012, CANCER SCI, V103, P58, DOI 10.1111/j.1349 7006.2011.02113.x
NR 64
TC 24
Z9 25
U1 0
U2 10
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2 12 15 SHIBUYA, SHIBUYA KU, TOKYO, 150 0002, JAPAN
SN 0918 6158
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD AUG
PY 2016
VL 39
IS 8
BP 1238
EP 1246
DI 10.1248/bpb.b15 00746
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA DT1HN
UT WOS:000381232400002
PM 27181081
OA gold
DA 2025 08 17
ER

PT J
AU Noordzij, M
   Korevaar, JC
   Boeschoten, EW
   Dekker, FW
   Bos, WJ
   Krediet, RT
AF Noordzij, M
   Korevaar, JC
   Boeschoten, EW
   Dekker, FW
   Bos, WJ
   Krediet, RT
CA Netherlands Cooperative Study Ade
TI The kidney disease outcomes quality initiative (K/DOQI) guideline for
   bone metabolism and disease in CKD: Association with mortality in
   dialysis patients
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE calcium; phosphorus; intact parathyroid hormone; hemodialysis (HD);
   peritoneal dialysis (PD); guidelines; mortality
ID PARATHYROID HORMONE; MINERAL METABOLISM; PHOSPHATE; CALCIUM;
   SUPPRESSION; PRODUCT; RISK
AB Background In 2003, the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) published a guideline recommending tight control of serum calcium, phosphorus, calcium phosphorus product (Ca x P), and intact parathyroid hormone levels in patients with chronic kidney disease. Within the context of this guideline, we explored associations of these plasma concentrations with all cause mortality risk in incident dialysis patients in The Netherlands. Methods: In a large, prospective, multicenter, cohort study (Netherlands Cooperative Study on the Adequacy of Dialysis), we included 1,629 patients new on hemodialysis or peritoneal dialysis therapy between 1997 and 2004. Multivariate Cox regression models containing calcium level, phosphorus level, intact parathyroid hormone level, age, comorbidity, primary kidney disease, nutritional status, albumin level, dialysis dose, and hemoglobin level were used to examine mortality risks. Results: Mean age was 60 +/  15 (SD) years, 61% were men, and 64% were treated with hemodialysis. In adjusted time dependent survival analysis, all cause mortality risk increased in hemodialysis patients by 40% (hazard ratio [HR], 1.4; 95% confidence interval [CI], 1.1 to 1.7) and in peritoneal dialysis patients by 60% (HR, 1.6; 95% Cl, 1.1 to 2.4) for plasma phosphorus levels greater than the target. In addition, having elevated plasma Ca x P product levels increased mortality risk by 40% (HR, 1.4; 95% CI, 1.1 to 1.8) in hemodialysis patients and 50% in peritoneal dialysis patients (HR, 1.5; 95% CI, 1.0 to 2.2). In both patient groups, no significant effects were observed for plasma levels less than the targets. Conclusion: In time dependent survival analysis, the presence of plasma phosphorus and Ca x P product concentrations greater than K/DOQI targets increased all cause mortality risk in hemodialysis and peritoneal dialysis patients.
C1 Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL 1100 DD Amsterdam, Netherlands.
   Univ Amsterdam, Acad Med Ctr, Dept Nephrol, NL 1100 DD Amsterdam, Netherlands.
   Hans Mak Inst, Naarden, Netherlands.
   Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands.
   St Antonius Hosp, Dept Internal Med, Nieuwegein, Netherlands.
C3 University of Amsterdam; Academic Medical Center Amsterdam; University
   of Amsterdam; Academic Medical Center Amsterdam; Leiden University;
   Leiden University Medical Center (LUMC); Leiden University   Excl LUMC;
   St. Antonius Hospital Utrecht
RP Noordzij, M (通讯作者)，Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, POB 22660, NL 1100 DD Amsterdam, Netherlands.
EM m.noordzij@amc.uva.nl
RI Noordzij, Marlies/G 3166 2013; Krediet, Raymond/AAP 3291 2021; Dekker,
   Friedo/B 6452 2011
OI Bos, Willem Jan W/0000 0002 5062 2567; Dekker,
   Friedo/0000 0002 2433 2494
CR Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176
   DAUGIRDAS JT, 1993, J AM SOC NEPHROL, V4, P1205
   DAVIES SJ, 1995, AM J KIDNEY DIS, V26, P353, DOI 10.1016/0272 6386(95)90657 6
   Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470
   Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131
   Kant KS, 2002, AM J MED SCI, V323, P210, DOI 10.1097/00000441 200204000 00008
   Marco MP, 2003, KIDNEY INT, V63, pS111, DOI 10.1046/j.1523 1755.63.s85.26.x
   *NAT KIDN FDN, 2000, AM J KIDNEY DIS, V42, pS1
   Portale AA, 1999, PRIMER METABOLIC BON, P115
   SLATOPOLSKY E, 1984, J CLIN INVEST, V74, P2136, DOI 10.1172/JCI111639
   Stevens LA, 2004, J AM SOC NEPHROL, V15, P770, DOI 10.1097/01.ASN.0000113243.24155.2F
   *US REN DAT SYST, 2003, USRDS 2003 ANN DAT R
   Visser R, 1999, ADV PERIT D, V15, P222
   WATSON PE, 1980, AM J CLIN NUTR, V33, P27, DOI 10.1093/ajcn/33.1.27
   Young EW, 2005, KIDNEY INT, V67, P1179, DOI 10.1111/j.1523 1755.2005.00185.x
NR 16
TC 187
Z9 211
U1 0
U2 9
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0272 6386
EI 1523 6838
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD NOV
PY 2005
VL 46
IS 5
BP 925
EP 932
DI 10.1053/j.ajkd.2005.08.013
PG 8
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 993DR
UT WOS:000233933400017
PM 16253734
DA 2025 08 17
ER

PT J
AU Ke, LQ
   He, QF
   Qu, J
   Wang, XY
   Li, KB
   Gong, X
   Li, L
   Xu, JK
   Yu, QLY
   Yu, H
   Lin, XF
   Li, J
   Tan, NS
   Sun, W
   Li, L
   Zhang, P
   Cheng, WX
AF Ke, Liqing
   He, Qifei
   Qu, Jing
   Wang, Xiyue
   Li, Kaibo
   Gong, Xun
   Li, Lan
   Xu, Jiake
   Yu, Qiuliyang
   Yu, Hao
   Lin, Xuefei
   Li, Jian
   Tan, Nguan Soon
   Sun, Wei
   Li, Liang
   Zhang, Peng
   Cheng, Wenxiang
TI Bone protective effects of neutralizing angiopoietin like protein 4
   monoclonal antibody in rheumatoid arthritis
SO MOLECULAR THERAPY
LA English
DT Article
ID IN VIVO; INFLAMMATION; CLASSIFICATION; OSTEOARTHRITIS; MECHANISMS;
   EXPRESSION; ADIPOKINE; CRITERIA; RISK
AB Despite recent advances, rheumatoid arthritis (RA) patients remain refractory to therapy. Dysregulated overproduction of angiopoietin like protein 4 (ANGPTL4) is thought to contribute to the disease development. ANGPTL4 was initially identified as a regulator of lipid metabolism, which is hydrolyzed to N terminal and C terminal (cANGPTL4) fragments in vivo. cANGPTL4 is involved in several non lipid related processes, including angiogenesis and inflammation. This study revealed that the level of ANGPTL4 was markedly elevated in the sera and synovial tissues from patients with RA versus controls. The administration of a neutralizing antibody against cANGPTL4 (anti cANGPTL4 Ab) resulted in the inhibition of inflammatory processes and bone loss in animal models of collagen induced arthritis and adjuvant induced arthritis (AIA). Transcriptomic and proteomic profiling of synovial tissues from an AIA model indicated that the anti cANGPTL4 Ab inhibited fibroblast like synoviocyte (FLS) immigration and inflammatory induced osteoclastogenesis. Mechanistically, the anti cANGPTL4 Ab has been shown to inhibit TNF a induced inflammatory cascades in RA FLS through the sirtuin 1/nuclear factor kB signaling pathway. Moreover, the anti cANGPTL4 Ab was found to block FLS invasion  and immigration induced osteoclast activation. Collectively, these findings identify ANGPTL4 as a prospective biomarker for the diagnosis of RA, and targeting cANGPTL4 should represent a potential therapeutic strategy.
C1 [Ke, Liqing; Wang, Xiyue; Li, Kaibo; Xu, Jiake; Yu, Qiuliyang; Yu, Hao; Lin, Xuefei; Li, Jian; Zhang, Peng; Cheng, Wenxiang] Chinese Acad Sci, Shenzhen Inst Adv Technol, Shenzhen 518055, Guangdong, Peoples R China.
   [He, Qifei; Sun, Wei] Shenzhen Univ, Affiliated Hosp 1, Shenzhen Peoples Hosp 2, Dept Spine Surg, Shenzhen 518035, Guangdong, Peoples R China.
   [Qu, Jing] Shenzhen Ctr Dis Control & Prevent, Shenzhen 518055, Guangdong, Peoples R China.
   [Gong, Xun] China Acad Chinese Med Sci, Guanganmen Hosp, Beijing 100053, Peoples R China.
   [Li, Lan] Capital Med Univ, Beijing Jishuitan Hosp, Dept Pathol, Beijing 100035, Peoples R China.
   [Xu, Jiake; Yu, Qiuliyang; Zhang, Peng] Shenzhen Univ, Shenzhen 518060, Guangdong, Peoples R China.
   [Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA 6009, Australia.
   [Tan, Nguan Soon] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore 308232, Singapore.
   [Tan, Nguan Soon] Nanyang Technol Univ, Sch Biol Sci, Singapore 138673, Singapore.
   [Li, Liang] Southern Univ Sci & Technol, Sch Med, Dept Pharmacol, Shenzhen 518055, Guangdong, Peoples R China.
   [Zhang, Peng] Chinese Acad Sci, Key Lab Biomed Imaging Sci & Syst, Shenzhen 518000, Peoples R China.
   [Zhang, Peng] Shandong Zhongke Adv Technol Co Ltd, Jinan 250300, Shandong, Peoples R China.
C3 Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology,
   CAS; Shenzhen University; Shenzhen Center for Disease Control &
   Prevention (SZCDC); China Academy of Chinese Medical Sciences;
   Guang'anmen Hospital, CACMS; Capital Medical University; Shenzhen
   University; University of Western Australia; Nanyang Technological
   University; Nanyang Technological University; Southern University of
   Science & Technology; Chinese Academy of Sciences
RP Zhang, P; Cheng, WX (通讯作者)，Chinese Acad Sci, Shenzhen Inst Adv Technol, Shenzhen 518055, Guangdong, Peoples R China.; Li, L (通讯作者)，Southern Univ Sci & Technol, Sch Med, Dept Pharmacol, Shenzhen 518055, Guangdong, Peoples R China.
EM lil@sustech.edu.cn; peng.zhang@siat.ac.cn; wx.cheng@siat.ac.cn
RI ; Tan, Nguan/A 2220 2011; LI, Kaibo/ABG 8144 2021; LI,
   Junfeng/GSE 0020 2022; Lin, Xuefei/MGU 9931 2025; Tan, Nguan
   Soon/A 2220 2011
OI Xu, Jiake/0000 0003 2021 8309; Tan, Nguan Soon/0000 0003 0136 7341
FU National Natural Science Foundation of China; Key Area Research and
   Development Program of Guangdong Province; National Key R&D Program of
   China; Shenzhen Medical Research Fund; SIAT Innovation Program for
   Excellent Young Researchers (2022); High Level Chinese Medical Hospital
   Promotion Project [HLCMHPP2023087]; Shenzhen Second People's Hospital
   Clinical Research Fund of Shenzhen High level Hospital Construction
   Project [20223357010];  [82230119];  [82104497];  [2023B1111030002]; 
   [2021YFF1200300];  [B2302005]
FX We thank Prof. Jianping Guo for her insightful advice on the manuscript.
   We thank Shanghai Luming Biological Technology Co., Ltd (Shanghai,
   China) for providing proteomics services. This work was supported by
   grants from the National Natural Science Foundation of China (82230119,
   82104497) , the Key Area Research and Development Program of Guangdong
   Province (2023B1111030002) , the National Key R&D Program of China
   (2021YFF1200300) , the Shenzhen Medical Research Fund (B2302005) , the
   SIAT Innovation Program for Excellent Young Researchers (2022) , the
   High Level Chinese Medical Hospital Promotion Project (HLCMHPP2023087) ,
   and the Shenzhen Second People's Hospital Clinical Research Fund of
   Shenzhen High level Hospital Construction Project (20223357010) . The
   graphic abstract was created with Figdraw (www.figdraw.com) .
CR Aletaha D, 2010, ARTHRITIS RHEUM US, V62, P2569, DOI 10.1002/art.27584
   Alivernini S, 2022, IMMUNITY, V55, P2255, DOI 10.1016/j.immuni.2022.11.009
   Alivernini S, 2020, NAT MED, V26, P1295, DOI 10.1038/s41591 020 0939 8
   ALTMAN R, 1986, ARTHRITIS RHEUM US, V29, P1039, DOI 10.1002/art.1780290816
   Bae S, 2023, CELL MOL IMMUNOL, V20, P94, DOI 10.1038/s41423 022 00959 x
   Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   Bergholt NL, 2019, CARTILAGE, V10, P370, DOI 10.1177/1947603518764262
   Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   Brown R, 2009, J NEUROIMMUNOL, V209, P96, DOI 10.1016/j.jneuroim.2009.02.001
   Chaube B, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 43900 0
   Chen T, 2022, NUCLEIC ACIDS RES, V50, pD1522, DOI 10.1093/nar/gkab1081
   Chen Y, 2021, LIFE SCI, V269, DOI 10.1016/j.lfs.2021.119041
   Cilenti F, 2021, IMMUNITY, V54, P1665, DOI 10.1016/j.immuni.2021.05.016
   De Armas Rillo L, 2022, ARTHRITIS RES THER, V24, DOI 10.1186/s13075 022 02784 z
   Elhai M, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 44053 w
   Gao YS, 2024, MOL THER, V32, DOI 10.1016/j.ymthe.2024.02.034
   García Manrique M, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 84582 2
   Gremese E, 2023, FRONT MED LAUSANNE, V10, DOI 10.3389/fmed.2023.956127
   Gu R, 2015, CYTOKINE, V72, P135, DOI 10.1016/j.cyto.2014.11.015
   Guo L, 2015, J CELL PHYSIOL, V230, P2390, DOI 10.1002/jcp.24969
   Hartley JW, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742 4690 5 1
   Hayer S, 2021, ANN RHEUM DIS, V80, P714, DOI 10.1136/annrheumdis 2020 219247
   Hermann LM, 2005, CLIN IMMUNOL, V115, P93, DOI 10.1016/j.clim.2004.12.002
   Hong JL, 2024, INT IMMUNOPHARMACOL, V133, DOI 10.1016/j.intimp.2024.112151
   Huang RL, 2011, BLOOD, V118, P3990, DOI 10.1182/blood 2011 01 328716
   Jung KH, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.201911222
   Kalden JR, 2017, NAT REV RHEUMATOL, V13, P707, DOI 10.1038/nrrheum.2017.187
   Kerschbaumer A, 2020, ANN RHEUM DIS, V79, P744, DOI 10.1136/annrheumdis 2019 216656
   Kitaura H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145169
   Kolb R, 2019, ONCOGENE, V38, P2351, DOI 10.1038/s41388 018 0592 6
   Komatsu N, 2022, NAT REV RHEUMATOL, V18, P415, DOI 10.1038/s41584 022 00793 5
   Kracht M, 2020, J ALLERGY CLIN IMMUN, V146, P694, DOI 10.1016/j.jaci.2020.07.027
   Li L, 2019, MBIO, V10, DOI 10.1128/mBio.02469 18
   Li L, 2015, CELL REP, V10, P654, DOI 10.1016/j.celrep.2015.01.011
   Li XH, 2021, MOL THER, V29, P347, DOI 10.1016/j.ymthe.2020.09.031
   Li X, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abc5539
   Liao ZH, 2024, ADV HEALTHC MATER, V13, DOI 10.1002/adhm.202303481
   Ma J, 2019, NUCLEIC ACIDS RES, V47, pD1211, DOI 10.1093/nar/gky869
   McWilliams DF, 2018, BMC RHEUMATOL, V2, DOI 10.1186/s41927 018 0016 9
   Meng XB, 2023, J MATER SCI TECHNOL, V156, P20, DOI 10.1016/j.jmst.2023.01.035
   Miyazawa K, 1998, J BIOCHEM TOKYO, V124, P1153, DOI 10.1093/oxfordjournals.jbchem.a022233
   Ng CT, 2010, ANN RHEUM DIS, V69, P1389, DOI 10.1136/ard.2009.119776
   Nygaard G, 2020, NAT REV RHEUMATOL, V16, P316, DOI 10.1038/s41584 020 0413 5
   Oeckinghaus A, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000034
   Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046
   Pertsinidou E, 2024, ANN RHEUM DIS, V83, P277, DOI 10.1136/ard 2023 224728
   Romao VC, 2021, FRONT MED LAUSANNE, V8, DOI 10.3389/fmed.2021.689698
   Sarmanova A, 2020, RHEUMATOLOGY, V59, P2898, DOI 10.1093/rheumatology/keaa044
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Schoels M, 2012, ANN RHEUM DIS, V71, P1303, DOI 10.1136/annrheumdis 2011 200490
   Smolen JS, 2020, ANN RHEUM DIS, V79, P685, DOI 10.1136/annrheumdis 2019 216655
   Su Gang, 2014, Curr Protoc Bioinformatics, V47, DOI 10.1002/0471250953.bi0813s47
   Swales C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109524
   Szekanecz Z, 2000, ARTHRITIS RHEUM, V43, P1266, DOI 10.1002/1529 0131(200006)43:6<1266::AID ANR9>3.0.CO;2 P
   Tascilar K, 2016, ARTHRITIS RHEUMATOL, V68, P2603, DOI 10.1002/art.39774
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Xie GY, 2024, J ORTHOP TRANSL, V46, P33, DOI 10.1016/j.jot.2024.04.003
   Yang HY, 2011, FASEB J, V25
   Yao H, 2023, PHYTOMEDICINE, V118, DOI 10.1016/j.phymed.2023.154967
   Yu HM, 2023, CELL MOL GASTROENTER, V15, P1000, DOI 10.1016/j.jcmgh.2022.12.013
   Zhang WF, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI151803
   Zhu PC, 2011, CANCER CELL, V19, P401, DOI 10.1016/j.ccr.2011.01.018
NR 62
TC 4
Z9 4
U1 10
U2 14
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1525 0016
EI 1525 0024
J9 MOL THER
JI Mol. Ther.
PD DEC 4
PY 2024
VL 32
IS 12
BP 4497
EP 4513
DI 10.1016/j.ymthe.2024.09.031
EA DEC 2024
PG 17
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA P0F3B
UT WOS:001374772300001
PM 39367607
DA 2025 08 17
ER

PT J
AU Durand, EM
   Zon, LI
AF Durand, Ellen M.
   Zon, Leonard I.
TI Newly emerging roles for prostaglandin E2 regulation of
   hematopoiesis and hematopoietic stem cell engraftment
SO CURRENT OPINION IN HEMATOLOGY
LA English
DT Article
DE engraftment; homing; hematopoietic stem cells; prostaglandin E 2
ID PROSTANOID RECEPTORS; EP4; SUBTYPES
AB Purpose of review
   Hematopoietic stem cell (HSC) transplantation is an effective treatment for leukemia, lymphoma, blood disorders, and autoimmune diseases. Successful transplantation is dependent upon efficient homing and engraftment of HSCs. Recently, prostaglandin E 2 (PGE(2)) exposure, either in vivo or ex vivo, has been shown to increase engraftment. These results establish PGE(2) as a regulator of hematopoietic development.
   Recent findings
   The underlying mechanisms of PGE(2) regulation of HSC development were poorly understood until recently. Ex vivo exposure of LSK cells to PGE(2) results in increased homing efficiency of HSCs to the murine bone marrow compartment. In addition, in vivo treatment with PGE(2) preferentially expands short term HSCs without affecting long term HSC number and engraftment in murine bone marrow. PGE(2) acts through EP4 receptors to mediate lymphoid precursor development in the zebrafish. An in vivo interaction between PGE(2) and the Wnt signaling pathways controls HSC engraftment.
   Summary
   PGE(2) has a new role in HSC homing and survival, as well as short term HSC engraftment. PGE(2) is currently being tested in clinical trials as a potential therapy to enhance HSC engraftment following a transplantation procedure.
C1 [Durand, Ellen M.; Zon, Leonard I.] Childrens Hosp, Boston, MA 02115 USA.
C3 Harvard University; Harvard University Medical Affiliates; Boston
   Children's Hospital
RP Zon, LI (通讯作者)，Harvard Univ, Sch Med, Stem Cell Program, Boston, MA 02115 USA.
EM zon@enders.tch.harvard.edu
CR Boniface K, 2009, J EXP MED, V206, P535, DOI 10.1084/jem.20082293
   Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661
   Chen JC, 2008, EXP HEMATOL, V36, P1236, DOI 10.1016/j.exphem.2008.04.012
   Chizzolini C, 2008, BLOOD, V112, P3696, DOI 10.1182/blood 2008 05 155408
   Desai S, 2000, MOL PHARMACOL, V58, P1279, DOI 10.1124/mol.58.6.1279
   Frisch BJ, 2009, BLOOD, V114, P4054, DOI 10.1182/blood 2009 03 205823
   Fujino H, 2002, J BIOL CHEM, V277, P2614, DOI 10.1074/jbc.M109440200
   Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871
   Goessling W, 2009, CELL, V136, P1136, DOI 10.1016/j.cell.2009.01.015
   Golan D.E., 2008, Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy, V2nd
   Gross S, 2007, J EXP MED, V204, P311, DOI 10.1084/jem.20061617
   Hata AN, 2004, PHARMACOL THERAPEUT, V103, P147, DOI 10.1016/j.pharmthera.2004.06.003
   Hoggatt J, 2009, BLOOD, V113, P5444, DOI 10.1182/blood 2009 01 201335
   Jetmore A, 2002, BLOOD, V99, P1585, DOI 10.1182/blood.V99.5.1585
   Jones RL, 2009, BRIT J PHARMACOL, V158, P104, DOI 10.1111/j.1476 5381.2009.00317.x
   Kondo M, 2003, ANNU REV IMMUNOL, V21, P759, DOI 10.1146/annurev.immunol.21.120601.141007
   Lapidot T, 2005, BLOOD, V106, P1901, DOI 10.1182/blood 2005 04 1417
   Lord AM, 2007, CELL CYCLE, V6, P3054, DOI 10.4161/cc.6.24.5129
   Miller SB, 2006, SEMIN ARTHRITIS RHEU, V36, P37, DOI 10.1016/j.semarthrit.2006.03.005
   MORI S, 1990, BONE, V11, P103, DOI 10.1016/8756 3282(90)90057 6
   Mukouyama YS, 1999, CURR BIOL, V9, P833, DOI 10.1016/S0960 9822(99)80368 6
   Nishigaki N, 1996, MOL PHARMACOL, V50, P1031
   North TE, 2002, IMMUNITY, V16, P661, DOI 10.1016/S1074 7613(02)00296 0
   North TE, 2007, NATURE, V447, P1007, DOI 10.1038/nature05883
   Orkin SH, 2008, CELL, V132, P631, DOI 10.1016/j.cell.2008.01.025
   Regan JW, 2003, LIFE SCI, V74, P143, DOI 10.1016/j.lfs.2003.09.031
   Reya T, 2003, RECENT PROG HORM RES, V58, P283, DOI 10.1210/rp.58.1.283
   Shizuru JA, 2005, ANNU REV MED, V56, P509, DOI 10.1146/annurev.med.54.101601.152334
   Zon LI, 2008, NATURE, V453, P306, DOI 10.1038/nature07038
NR 29
TC 46
Z9 66
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1065 6251
EI 1531 7048
J9 CURR OPIN HEMATOL
JI Curr. Opin. Hematol.
PD JUL
PY 2010
VL 17
IS 4
BP 308
EP 312
DI 10.1097/MOH.0b013e32833a888c
PG 5
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 613ZJ
UT WOS:000279023700007
PM 20473159
DA 2025 08 17
ER

PT J
AU Zhou, J
   Liu, H
   Zhang, L
   Liu, X
   Zhang, CD
   Wang, YT
   He, Q
   Zhang, Y
   Li, Y
   Chen, QM
   Zhang, L
   Wang, K
   Bu, YQ
   Lei, YL
AF Zhou, Jing
   Liu, Hao
   Zhang, Lian
   Liu, Xin
   Zhang, Chundong
   Wang, Yitao
   He, Qing
   Zhang, Ying
   Li, Yi
   Chen, Quanmei
   Zhang, Lu
   Wang, Kui
   Bu, Youquan
   Lei, Yunlong
TI DJ 1 promotes colorectal cancer progression through activating
   PLAGL2/Wnt/BMP4 axis
SO CELL DEATH & DISEASE
LA English
DT Article
ID EPITHELIAL MESENCHYMAL TRANSITION; BONE MORPHOGENETIC PROTEIN 4;
   GENE LIKE 2; WNT/BETA CATENIN; COLON CANCER; SIGNALING PATHWAY;
   STEM CELLS; EXPRESSION; REGULATOR; INVASION
AB Metastasis remains a big barrier for the clinical treatment of colorectal cancer (CRC). Our previous proteomics analysis identified DJ 1 as a potential metastasis biomarker of CRC. In this study, we found that DJ 1 was upregulated in CRC. The levels of DJ 1 were closely correlated with the depths of invasion and predicted patient outcome. Enforced expression of DJ 1 could enhance CRC proliferation and metastasis in vitro and in vivo by stimulating Wnt beta catenin signaling. Specifically, DJ 1 induced beta catenin nuclear translocation stimulated TCF transcription activity, which promoted BMP4 expression for CRC cell migration and invasion, and elevated CCND1 expression for CRC cell proliferation, respectively. Furthermore, DJ 1 induced Wnt signaling activation was dependent on PLAGL2 expression. In conclusion, our study demonstrates that DJ 1 can promote CRC metastasis by activating PLAGL2 Wnt BMP4 axis, suggesting novel therapeutic opportunities for postoperative adjuvant therapy in CRC patients.
C1 [Zhou, Jing; Liu, Hao; Zhang, Lian; Liu, Xin; Zhang, Chundong; Wang, Yitao; He, Qing; Zhang, Ying; Li, Yi; Chen, Quanmei; Bu, Youquan; Lei, Yunlong] Chongqing Med Univ, Dept Biochem & Mol Biol, Chongqing 400016, Peoples R China.
   [Zhou, Jing; Liu, Hao; Zhang, Lian; Liu, Xin; Zhang, Chundong; Wang, Yitao; He, Qing; Zhang, Ying; Li, Yi; Chen, Quanmei; Bu, Youquan; Lei, Yunlong] Chongqing Med Univ, Mol Med & Canc Res Ctr, Chongqing 400016, Peoples R China.
   [Zhou, Jing; Zhang, Lu; Wang, Kui] Sichuan Univ, West China Sch Basic Med Sci & Forens Med, West China Hosp, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China.
   [Zhou, Jing; Zhang, Lu; Wang, Kui] Sichuan Univ, West China Sch Basic Med Sci & Forens Med, West China Hosp, Canc Ctr, Chengdu 610041, Sichuan, Peoples R China.
   [Zhou, Jing; Zhang, Lu; Wang, Kui] Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Sichuan, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University; Sichuan
   University; Sichuan University
RP Lei, YL (通讯作者)，Chongqing Med Univ, Dept Biochem & Mol Biol, Chongqing 400016, Peoples R China.; Lei, YL (通讯作者)，Chongqing Med Univ, Mol Med & Canc Res Ctr, Chongqing 400016, Peoples R China.
EM leiyunlong@126.com
RI ; Zhang, Chundong/F 3621 2016
OI , Kui/0000 0003 3503 1563; Lei, Yunlong/0000 0002 7918 0221
FU National Natural Science Foundation of China [81401951, 81502131,
   81602159, 81501979]; Chongqing Natural Science Foundation
   [cstc2016jcyjA0227, cstc2016jcyjA0054]; Chongqing Municipal Education
   Commission [KJ1400207]
FX This work was supported by the National Natural Science Foundation of
   China (81401951, 81502131 to L.Y.L., 81602159 to Y.L., and 81501979 to
   C.D.Z.), Chongqing Natural Science Foundation (cstc2016jcyjA0227 to
   L.Y.L., cstc2016jcyjA0054 to Y.L.), and Scientific and Technological
   Research Program of Chongqing Municipal Education Commission (KJ1400207
   to L.Y.L.).
CR Ahmad R, 2017, ONCOGENE, V36, P6592, DOI 10.1038/onc.2017.259
   Akiyoshi T, 2006, GUT, V55, P991, DOI 10.1136/gut.2005.080333
   Boon EMJ, 2004, BRIT J CANCER, V90, P224, DOI 10.1038/sj.bjc.6601505
   Bowen KA, 2009, ANTICANCER RES, V29, P4439
   Cao J, 2015, BIOCHEM PHARMACOL, V93, P241, DOI 10.1016/j.bcp.2014.11.012
   Chatel G, 2007, INT J CANCER, V121, P2622, DOI 10.1002/ijc.22998
   Chen HN, 2016, CANCER RES, V76, P1122, DOI 10.1158/0008 5472.CAN 15 1962
   Davidson B, 2008, HUM PATHOL, V39, P87, DOI 10.1016/j.humpath.2007.05.014
   Deng HY, 2007, EXP CELL RES, V313, P1033, DOI 10.1016/j.yexcr.2006.12.020
   Deng HY, 2009, CANCER LETT, V281, P220, DOI 10.1016/j.canlet.2009.02.046
   Feng Y, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005638
   Guo J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158667
   Hanks TS, 2012, APOPTOSIS, V17, P236, DOI 10.1007/s10495 011 0672 3
   He XY, 2012, CARCINOGENESIS, V33, P555, DOI 10.1093/carcin/bgs002
   Herbst A, 2014, BMC GENOMICS, V15, DOI 10.1186/1471 2164 15 74
   Huang S, 2017, CANCER RES, V77, P6562, DOI 10.1158/0008 5472.CAN 17 1570
   Ismail IA, 2014, BRIT J CANCER, V110, P1298, DOI 10.1038/bjc.2014.40
   Kim RH, 2005, CANCER CELL, V7, P263, DOI 10.1016/j.ccr.2005.02.010
   Kramer N, 2017, ONCOGENE, V36, P5460, DOI 10.1038/onc.2017.144
   Lee K, 2017, J BIOMED RES, V31, P189, DOI 10.7555/JBR.31.20160133
   Lei YL, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.005397
   Lin XM, 2012, SCI REP UK, V2, DOI 10.1038/srep00954
   Liu B, 2014, INT J CLIN EXP PATHO, V7, P3089
   Liu R, 2013, CANCER RES, V73, P5926, DOI 10.1158/0008 5472.CAN 12 4718
   Lombardo Y, 2011, GASTROENTEROLOGY, V140, P297, DOI 10.1053/j.gastro.2010.10.005
   Lorente Trigos A, 2010, J MOL CELL BIOL, V2, P318, DOI 10.1093/jmcb/mjq035
   Mizutani A, 2002, J BIOL CHEM, V277, P15851, DOI 10.1074/jbc.M111431200
   Nishanian TG, 2004, CANCER BIOL THER, V3, P667
   Pardo M, 2006, INT J CANCER, V119, P1014, DOI 10.1002/ijc.21942
   Sekiya R, 2014, CARCINOGENESIS, V35, P1993, DOI 10.1093/carcin/bgu081
   Siegel RL, 2020, CA CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Sitaram RT, 2009, INT J CANCER, V125, P783, DOI 10.1002/ijc.24335
   Song L, 2015, CANCER BIOL THER, V16, P1, DOI 10.4161/15384047.2014.972215
   Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247
   Tsuchida R, 2014, ONCOGENE, V33, P3803, DOI 10.1038/onc.2013.358
   Vasseur S, 2012, ONCOGENE, V31, P664, DOI 10.1038/onc.2011.268
   Wang YP, 2017, ONCOL REP, V37, P1961, DOI 10.3892/or.2017.5485
   Whissell G, 2014, NAT CELL BIOL, V16, P695, DOI 10.1038/ncb2992
   Wu JH, 2013, CARCINOGENESIS, V34, P2861, DOI 10.1093/carcin/bgt229
   Yokoyama Y, 2017, CANCER RES, V77, P4026, DOI 10.1158/0008 5472.CAN 17 0112
   Zheng G, 2007, BIOCHEM BIOPH RES CO, V364, P344, DOI 10.1016/j.bbrc.2007.10.003
   Zheng HW, 2010, CANCER CELL, V17, P497, DOI 10.1016/j.ccr.2010.03.020
NR 42
TC 60
Z9 66
U1 0
U2 21
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD AUG 29
PY 2018
VL 9
AR 865
DI 10.1038/s41419 018 0883 4
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA GR9MN
UT WOS:000443088000001
PM 30158634
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ren, XB
   Zhang, MZ
   Zhang, WL
   Xie, J
   Luo, HC
   Zhang, HM
   He, HB
AF Ren, Xiaobin
   Zhang, Mingzhu
   Zhang, Wanli
   Xie, Jing
   Luo, Hongcan
   Zhang, Hongming
   He, Hongbing
TI Yunnan Baiyao Ameliorates Rheumatoid Arthritis in Rats by Shifting the
   Th17/Treg Cell Balance and Preventing Osteoclast Differentiation
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID KAPPA B; MEDICINE; THERAPY
AB Yunnan Baiyao (YNB) is a traditional Chinese medicine that possesses anti inflammatory effects. Previously, we have demonstrated the effects of YNB in rheumatoid arthritis (RA) animal models; however, the underlying mechanisms are unclear. In the present study, we aimed to investigate the effects of YNB on the T helper (Th)17/T regulatory (Treg) cell balance in a collagen induced arthritis rat model orally administrated YNB or methotrexate, a widely used therapeutic agent for treating RA. Our results showed that YNB treatment significantly decreased the voix pedis thickness and joint functionality scores and alleviated joint histopathology in these rats. These YNB induced effects were achieved by decreasing the number of Th17 cells and increasing that of Treg cells in the spleen. Moreover, the interleukin  (IL ) 17 level considerably decreased in the serum of YNB treated rats, whereas the IL 10 level significantly increased. Furthermore, YNB could inhibit RANKL induced osteoclast formation by regulating the tumor necrosis factor receptor associated factor 6/NF kappa B/nuclear factor of the activated T cell pathway. In summary, our study shows that YNB exhibits antiarthritic activity by decreasing the ratio of Th17/Treg cells, regulating the cytokine balance, and inhibiting osteoclast activation, providing an experimental basis that supports the use of this traditional Chinese medicine for the clinical treatment of RA.
C1 [Ren, Xiaobin; Zhang, Mingzhu; Zhang, Wanli; Xie, Jing; Luo, Hongcan; Zhang, Hongming; He, Hongbing] Kunming Med Univ, Affiliated Stomatol Hosp, Dept Periodontol, Kunming 650031, Yunnan, Peoples R China.
C3 Kunming Medical University
RP He, HB (通讯作者)，Kunming Med Univ, Affiliated Stomatol Hosp, Dept Periodontol, Kunming 650031, Yunnan, Peoples R China.
EM renxiaobin6688@163.com; 543377192@qq.com; zwlkqyz@126.com;
   1812059414@qq.com; lhckqyz@163.com; zhmkqyz@yeah.net; hhbkqyz@163.com
RI ; Wanli, Zhang/AAO 4066 2020
OI Zhang, Mingzhu/0000 0003 2657 3838; 
FU National Natural Science Foundation of China [8166040056]; Yunnan
   Provincial Department of Science and Technology [2019FE001( 168),
   202001AY070001 085]
FX AcknowledgmentsThe present study was supported by the National Natural
   Science Foundation of China (grant no. 8166040056) and the Yunnan
   Provincial Department of Science and Technology (grant nos.
   2019FE001( 168) and 202001AY070001 085).
CR Alunno A, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/751793
   Bai L, 2020, INT IMMUNOPHARMACOL, V81, DOI 10.1016/j.intimp.2020.106255
   Chen SJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061332
   Chen Y, 2021, CLIN EXP PHARMACOL P, V48, P626, DOI 10.1111/1440 1681.13461
   Fujikawa Y, 1996, ENDOCRINOLOGY, V137, P4058, DOI 10.1210/en.137.9.4058
   Han SY, 2019, AM J CHINESE MED, V47, P439, DOI [10.1142/S0192415X19500228, 10.1142/s0192415x19500228]
   Harnanik Titut, 2020, Oman Med J, V35, pe90, DOI 10.5001/omj.2020.08
   He HB, 2012, J PHARMACEUT BIOMED, V59, P130, DOI 10.1016/j.jpba.2011.10.019
   Hu XX, 2019, INT IMMUNOPHARMACOL, V70, P428, DOI 10.1016/j.intimp.2019.03.008
   Hui WP, 2019, INT IMMUNOPHARMACOL, V68, P226, DOI 10.1016/j.intimp.2019.01.018
   Ikeda T, 2001, ENDOCRINOLOGY, V142, P1419, DOI 10.1210/en.142.4.1419
   Jiang C, 2016, J CELL PHYSIOL, V231, P142, DOI 10.1002/jcp.25065
   Jung SM, 2019, YONSEI MED J, V60, P88, DOI 10.3349/ymj.2019.60.1.88
   Kesharwani D, 2019, J PHARMACOPUNCT, V22, P210
   Ladas EJ, 2012, SUPPORT CARE CANCER, V20, P3379, DOI 10.1007/s00520 012 1598 1
   Li R, 2011, INT J CLIN EXP MED, V4, P309
   Ma YH, 2016, WORLD J GASTROENTERO, V22, P9356, DOI 10.3748/wjg.v22.i42.9356
   Rådmark O, 2015, BBA MOL CELL BIOL L, V1851, P331, DOI 10.1016/j.bbalip.2014.08.012
   Ren XB, 2017, MOL MED REP, V16, P4045, DOI 10.3892/mmr.2017.7104
   Strand V, 2005, J RHEUMATOL, V32, P590
   Takayanagi H, 2012, NAT REV RHEUMATOL, V8, P684, DOI 10.1038/nrrheum.2012.167
   Terashima A, 2018, CALCIFIED TISSUE INT, V102, P503, DOI 10.1007/s00223 018 0417 1
   van Hamburg JP, 2018, J AUTOIMMUN, V87, P69, DOI 10.1016/j.jaut.2017.12.006
   Wang Hui Min, 2019, Zhongguo Zhong Yao Za Zhi, V44, P3908, DOI 10.19540/j.cnki.cjcmm.20190630.309
   Wirth KA, 2016, VET COMP ONCOL, V14, P281, DOI 10.1111/vco.12100
   Yang B, 2014, INT J CLIN EXP MED, V7, P461
   Yin XW, 2019, INFLAMM RES, V68, P761, DOI 10.1007/s00011 019 01260 w
   Zhang P, 2010, RHEUMATOL INT, V30, P713, DOI 10.1007/s00296 010 1370 0
NR 28
TC 6
Z9 7
U1 1
U2 16
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PD FEB 7
PY 2022
VL 2022
AR 3764444
DI 10.1155/2022/3764444
PG 10
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA ZU3WT
UT WOS:000769774400001
PM 35178101
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Garibaldi, N
   Besio, R
   Pirota, V
   Albini, B
   Colombo, G
   Galinetto, P
   Doria, F
   Carriero, A
   Forlino, A
AF Garibaldi, Nadia
   Besio, Roberta
   Pirota, Valentina
   Albini, Benedetta
   Colombo, Giorgio
   Galinetto, Pietro
   Doria, Filippo
   Carriero, Alessandra
   Forlino, Antonella
TI A novel chemical chaperone ameliorates osteoblast homeostasis and
   extracellular matrix in osteogenesis imperfecta
SO LIFE SCIENCES
LA English
DT Article
DE Osteogenesis imperfecta; Collagen; Molecular modelling; Chemical
   chaperone; Osteoblast; Transcriptomic
ID ENDOPLASMIC RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE;
   DNA POLYMERASE BETA; INDUCED APOPTOSIS; 4 PHENYLBUTYRIC ACID;
   CROSS LINKS; I COLLAGEN; UBIQUITINATION; CELLS; DEGRADATION
AB Aims: Osteogenesis imperfecta (OI) is a collagen I related heritable family of skeletal diseases associated to extreme bone fragility and deformity. Its classical forms are caused by dominant mutations in COL1A1 and COL1A2, which encode for the protein alpha chains, and are characterized by impairment in collagen I structure, folding, and secretion. Mutant collagen I assembles in an altered extracellular matrix affecting mineralization and bone properties and partially accumulating inside the cells, leading to impaired trafficking and cellular stress. Recently, the chemical chaperone 4 phenylbutyrate (4 PBA) has been proposed as an innovative drug for OI based on its ability to restore intracellular homeostasis, stimulate secretion, and ameliorate collagenproducing cell functions, positively affecting bone properties. However, the limited half life of the molecule represents a serious hurdle for its use. Materials and methods: To efficiently target cellular stress as OI treatment, two new compounds were designed by molecular modelling based on the 4 PBA structure to increase its stability and its ability to implement protein secretion. The short butyryl fatty acid chain of 4 PBA was substituted with a nitro functional group or with a glycine, respectively. The latter, N benzyl glycine (N BG), showed the best docking score, less toxicity, and higher stability than 4 PBA. Key findings: N BG improved extracellular matrix quality and mineral content together with ameliorating OI cells' homeostasis by increasing ER associated degradation pathway, reducing apoptosis, and stimulating protein secretion, thus facilitating intracellular clearance from accumulated misfolded proteins. Significance: In conclusion, N BG represents a novel potential available compound to target altered homeostasis in OI with the aim to ameliorate the disease phenotype.
C1 [Garibaldi, Nadia; Carriero, Alessandra] CUNY City Coll, Dept Biomed Engn, New York, NY 10031 USA.
   [Garibaldi, Nadia; Besio, Roberta; Forlino, Antonella] Univ Pavia, Dept Mol Med, Biochem Unit, Via Taramelli 3B, I 27100 Pavia, Italy.
   [Pirota, Valentina; Colombo, Giorgio; Doria, Filippo] Univ Pavia, Dept Chem, Pavia, Italy.
   [Albini, Benedetta; Galinetto, Pietro] Univ Pavia, Dept Phys, Pavia, Italy.
C3 City University of New York (CUNY) System; City College of New York
   (CUNY); University of Pavia; University of Pavia; University of Pavia
RP Carriero, A (通讯作者)，CUNY City Coll, Dept Biomed Engn, New York, NY 10031 USA.; Forlino, A (通讯作者)，Univ Pavia, Dept Mol Med, Biochem Unit, Via Taramelli 3B, I 27100 Pavia, Italy.
EM nadia.garibaldi@unipv.it; roberta.besio@unipv.it;
   valentina.pirota@unipv.it; benedetta.albini@unipv.it;
   g.colombo@unipv.it; pietro.galinetto@unipv.it; filippo.doria@unipv.it;
   acarriero@ccny.cuny.edu; antonella.forlino@unipv.it
RI Besio, Roberta/AAQ 7151 2020; Pirota, Valentina/H 2169 2013; Carriero,
   Alessandra/D 7893 2013; Forlino, Antonella/H 5385 2015; Albini,
   Benedetta/JPX 8490 2023; Colombo, Giorgio/A 2730 2012; Pirota,
   Valentina/AAA 5553 2020; Garibaldi, Nadia/KVB 3423 2024
OI Pirota, Valentina/0000 0002 6683 1726; Carriero,
   Alessandra/0000 0001 8103 4795; Albini, Benedetta/0000 0002 9745 5882;
   Forlino, Antonella/0000 0002 6385 1182; Besio,
   Roberta/0000 0003 1430 2934; Colombo, Giorgio/0000 0002 1318 668X;
   Garibaldi, Nadia/0000 0003 0353 537X; Doria, Filippo/0000 0002 1308 1060
FU National Institutes of Health (NIH, USA); Italian Ministry of University
   and Research (MUR) [Dipartimenti di Eccellenza]; Italian Ministry of
   University and Research (MUR) [PRIN 20223C8C5B];  [R21HD106607]
FX This work was supported by the National Institutes of Health (NIH, USA)
   grant R21HD106607 to AC and AF, by the Italian Ministry of University
   and Research (MUR) [Dipartimenti di Eccellenza (2023 2027) ] to AF and
   by the Italian Ministry of University and Research (MUR) PRIN 20223C8C5B
   to AF
CR Alcock F, 2009, J MOL BIOL, V385, P1032, DOI 10.1016/j.jmb.2008.11.045
   Américo Da Silva L, 2018, FASEB J, V32, P4681, DOI 10.1096/fj.201701229RR
   Andersen E, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578 019 0333 8
   Bank RA, 2000, J BONE MINER RES, V15, P1330, DOI 10.1359/jbmr.2000.15.7.1330
   Barutcu SA, 2018, AUTOPHAGY, V14, P1586, DOI 10.1080/15548627.2018.1466013
   Behrendt P, 2016, OSTEOARTHR CARTILAGE, V24, P1981, DOI 10.1016/j.joca.2016.06.016
   Besio R, 2019, FEBS J, V286, P3033, DOI 10.1111/febs.14963
   Duy BH, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246 016 0083 1
   Chan SL, 2004, J BIOL CHEM, V279, P28733, DOI 10.1074/jbc.M404272200
   Chen X, 2016, CELL PHYSIOL BIOCHEM, V39, P2501, DOI 10.1159/000452517
   Dasgupta Y, 2016, BLOOD, V127, P2131, DOI 10.1182/blood 2015 11 681171
   Dong XH, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108144
   Eyre D., 2005, Collagen Cross links
   Fratzl Zelman N, 2011, CALCIFIED TISSUE INT, V88, P378, DOI 10.1007/s00223 011 9466 4
   Fréchet M, 2001, FEBS LETT, V505, P229, DOI 10.1016/S0014 5793(01)02834 4
   Gebert M, 2023, CELL COMMUN SIGNAL, V21, DOI 10.1186/s12964 023 01349 0
   Gistelinck C, 2021, JBMR PLUS, V5, DOI 10.1002/jbm4.10454
   Gupta M, 2006, J BIOL CHEM, V281, P17552, DOI 10.1074/jbc.M600950200
   Hayashida N, 2006, EMBO J, V25, P4773, DOI 10.1038/sj.emboj.7601370
   Hemwong N, 2020, J ADV RES, V21, P121, DOI 10.1016/j.jare.2019.10.006
   Hess S, 1998, EUR J IMMUNOL, V28, P3594, DOI 10.1002/(SICI)1521 4141(199811)28:11<3594::AID IMMU3594>3.0.CO;2 D
   Hu Q, 2020, FEBS J, V287, P2348, DOI 10.1111/febs.15144
   Huang ZL, 2013, ONCOTARGET, V4, P2249, DOI 10.18632/oncotarget.1339
   Iannitti T, 2011, DRUGS R&D, V11, P227, DOI 10.2165/11591280 000000000 00000
   Jo Y, 2013, MOL BIOL CELL, V24, P169, DOI 10.1091/mbc.E12 07 0564
   John T, 2007, CYTOKINE, V40, P226, DOI 10.1016/j.cyto.2007.10.002
   Joshi V, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00259
   Kaiser C, 2000, P NATL ACAD SCI USA, V97, P3783, DOI 10.1073/pnas.97.8.3783
   Kolb PS, 2015, INT J BIOCHEM CELL B, V61, P45, DOI 10.1016/j.biocel.2015.01.015
   Kreckel J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02024
   Kuznetsova NV, 2004, MATRIX BIOL, V23, P101, DOI 10.1016/j.matbio.2004.03.002
   Lehman JA, 2011, J BIOL CHEM, V286, P36631, DOI 10.1074/jbc.M110.217620
   Lilley BN, 2005, P NATL ACAD SCI USA, V102, P14296, DOI 10.1073/pnas.0505014102
   Lin Y, 2003, MOL CELL BIOL, V23, P5849, DOI 10.1128/MCB.23.16.5849 5856.2003
   Lindholm D, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00048
   Marciniak SJ, 2022, NAT REV DRUG DISCOV, V21, P115, DOI 10.1038/s41573 021 00320 3
   Mimori S, 2013, CHEM LETT, V42, P1051, DOI 10.1246/cl.130419
   Mimori S, 2012, BIOL PHARM BULL, V35, P84, DOI 10.1248/bpb.35.84
   Nguyen CC, 2018, J VIROL, V92, DOI 10.1128/JVI.00688 18
   Ochs K, 1999, CANCER RES, V59, P1544
   Ogen Shtern N, 2023, ISCIENCE, V26, DOI 10.1016/j.isci.2023.106232
   Paredes F, 2016, FREE RADICAL BIO MED, V90, P206, DOI 10.1016/j.freeradbiomed.2015.11.024
   Paschalis EP, 2016, J BONE MINER RES, V31, P1050, DOI 10.1002/jbmr.2780
   Pasquali M, 1997, P ASSOC AM PHYSICIAN, V109, P33
   Sato T, 2012, MOL CELL, V47, P99, DOI 10.1016/j.molcel.2012.04.015
   Seo B, 2022, PATHOLOGY, V54, P874, DOI 10.1016/j.pathol.2022.04.003
   TENNI R, 1993, AM J MED GENET, V45, P252, DOI 10.1002/ajmg.1320450219
   Tsukumo Y, 2007, J BIOL CHEM, V282, P29264, DOI 10.1074/jbc.M705038200
   Wang Y, 2007, J BIOL CHEM, V282, P36561, DOI 10.1074/jbc.M703903200
   Westhoff B, 2005, CURR BIOL, V15, P1058, DOI 10.1016/j.cub.2005.04.058
   Yamaguchi Y, 2008, J BIOL CHEM, V283, P17020, DOI 10.1074/jbc.M802466200
   Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903
   Yuan W, 2013, INFLAMMATION, V36, P567, DOI 10.1007/s10753 012 9578 7
   Zhytnik L, 2017, HUM GENOMICS, V11, DOI 10.1186/s40246 017 0115 5
NR 54
TC 0
Z9 0
U1 2
U2 3
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024 3205
EI 1879 0631
J9 LIFE SCI
JI Life Sci.
PD JAN 15
PY 2025
VL 361
AR 123320
DI 10.1016/j.lfs.2024.123320
EA DEC 2024
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA R7Q1V
UT WOS:001393340300001
PM 39706289
DA 2025 08 17
ER

PT J
AU Wang, N
   Rumney, RMH
   Yang, L
   Robaye, B
   Boeynaems, JM
   Skerry, TM
   Gartland, A
AF Wang, Ning
   Rumney, Robin M. H.
   Yang, Lang
   Robaye, Bernard
   Boeynaems, Jean Marie
   Skerry, Timothy M.
   Gartland, Alison
TI The P2Y13 receptor regulates extracellular ATP metabolism and the
   osteogenic response to mechanical loading
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE P2Y13 RECEPTOR; OSTEOGENIC; MECHANICAL LOADING; ATP RELEASE; ATP
   HYDROLYSIS
ID CORTICAL BONE; FLUID SHEAR; FUNCTIONAL ADAPTATION; PURINERGIC RECEPTORS;
   RELEASE; ACTIVATION; MICE; OSTEOBLASTS; STRAIN; PROLIFERATION
AB ATP release and subsequent activation of purinergic receptors has been suggested to be one of the key transduction pathways activated by mechanical stimulation of bone. The P2Y13 receptor, recently found to be expressed by osteoblasts, has been suggested to provide a negative feedback pathway for ATP release in different cell types. Therefore, we hypothesized that the P2Y13 receptor may contribute to the mediation of osteogenic responses to mechanical stimulation by regulating ATP metabolism by osteoblasts. To test this hypothesis, wild type (WT) and P2Y13 receptor knockout (P2Y13R/) mice were subject to non invasive axial mechanical loading of the left tibiae to induce an osteogenic response. Micro computed tomography analysis showed mechanical loading induced an osteogenic response in both strains of mice in terms of increased total bone volume and cortical bone volume, with the P2Y13R/ mice having a significantly greater response. The extent of the increased osteogenic response was defined by dynamic histomorphometry data showing dramatically increased bone formation and mineral apposition rates in P2Y13R/ mice compared with controls. In vitro, primary P2Y13R/ osteoblasts had an accumulation of mechanically induced extracellular ATP and reduced levels of hydrolysis. In addition, P2Y13R/ osteoblasts also had a reduction in their maximal alkaline phosphatase (ALP) activity, one of the main ecto enzymes expressed by osteoblasts, which hydrolyzes extracellular ATP. In conclusion, deletion of the P2Y13 receptor leads to an enhanced osteogenic response to mechanical loading in vivo, possibly because of the reduced extracellular ATP degradation by ALP. The augmented osteogenic response to mechanical stimulation, combined with suppressed bone remodeling activities and protection from OVX induced bone loss after P2Y13 receptor depletion as previously described, suggests a potential role for P2Y13 receptor antagonist based therapy, possibly in combination with mechanical loading, for the treatment of osteoporosis.
C1 [Wang, Ning; Rumney, Robin M. H.; Yang, Lang; Skerry, Timothy M.; Gartland, Alison] Univ Sheffield, Mellanby Ctr Bone Res, Dept Human Metab, Sheffield S10 2RX, S Yorkshire, England.
   [Robaye, Bernard; Boeynaems, Jean Marie] Univ Libre Bruxelles, IRIBHM, Inst Interdisciplinary Res, Gosselies, Belgium.
   [Boeynaems, Jean Marie] Free Univ Brussels, Erasme Hosp, Dept Lab Med, B 1050 Brussels, Belgium.
C3 University of Sheffield; Universite Libre de Bruxelles; Universite Libre
   de Bruxelles
RP Gartland, A (通讯作者)，Univ Sheffield, Mellanby Ctr Bone Res, Dept Human Metab, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.
EM a.gartland@sheffield.ac.uk
RI Gartland, Alison/A 2152 2012; Rumney, Robin/H 6805 2019; Wang,
   Ning/HKO 8446 2023
OI WANG, NING/0000 0002 2663 7515; Skerry, Timothy/0000 0003 1319 5575;
   Gartland, Alison/0000 0002 3712 2437; Rumney, Robin Mark
   Howard/0000 0002 4266 5962; 
FU European Commission [202231]
FX The authors thank the staff of the Bone Analysis Laboratory, The
   University of Sheffield, for tissue processing. This study was supported
   by the European Commission under the 7th Framework Programme (proposal
   #202231) performed as a collaborative project among the members of the
   ATPBone Consortium (Copenhagen University, University College London,
   University of Maastricht, University of Ferrara, University of
   Liverpool, University of Sheffield, and Universite Libre de Bruxelles),
   and is a substudy under the main study "Fighting osteoporosis by
   blocking nucleotides: purinergic signaling in bone formation and
   homeostasis."
CR Akhter MP, 1998, CALCIFIED TISSUE INT, V63, P442, DOI 10.1007/s002239900554
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Bowler WB, 2001, BONE, V28, P507, DOI 10.1016/S8756 3282(01)00430 6
   Braith RW, 2007, J HEART LUNG TRANSPL, V26, P132, DOI 10.1016/j.healun.2006.11.004
   Braith RW, 2003, J HEART LUNG TRANSPL, V22, P1082, DOI 10.1016/S1053 2498(02)01184 1
   Burger E H, 1999, Adv Dent Res, V13, P93
   Carrasquero LMG, 2009, J NEUROCHEM, V110, P879, DOI 10.1111/j.1471 4159.2009.06179.x
   Cooper C., 2003, Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, V5th, P307
   De Souza RL, 2005, BONE, V37, P810, DOI 10.1016/j.bone.2005.07.022
   de Souza RL, 2005, J BONE MINER RES, V20, P2159, DOI 10.1359/JBMR.050812
   Fabre AC, 2010, HEPATOLOGY, V52, P1477, DOI 10.1002/hep.23897
   Fritton JC, 2005, BONE, V36, P1030, DOI 10.1016/j.bone.2005.02.013
   Galloway M T, 2000, J Am Acad Orthop Surg, V8, P37
   Genetos DC, 2005, J BONE MINER RES, V20, P41, DOI 10.1359/jbmr.041009
   HAHN M, 1992, BONE, V13, P327, DOI 10.1016/8756 3282(92)90078 B
   Heath DJ, 2009, J BONE MINER RES, V24, P425, DOI 10.1359/JBMR.081104
   Hildebrand TOR, 1997, Comput Methods Biomech Biomed Engin, V1, P15, DOI 10.1080/01495739708936692
   Jessop HL, 2002, BONE, V31, P186, DOI 10.1016/S8756 3282(02)00797 4
   Jiang GL, 2002, AM J PHYSIOL ENDOC M, V283, pE383, DOI 10.1152/ajpendo.00547.2001
   Kapur S, 2005, J BIOL CHEM, V280, P20163, DOI 10.1074/jbc.M501460200
   Khatiwala CB, 2009, J BONE MINER RES, V24, P886, DOI [10.1359/jbmr.081240, 10.1359/JBMR.081240]
   Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200
   Li JL, 2005, J BIOL CHEM, V280, P42952, DOI 10.1074/jbc.M506415200
   Liu DW, 2008, BONE, V42, P644, DOI 10.1016/j.bone.2007.09.058
   McClung MR, 2012, J BONE MINER RES, V27, P211, DOI 10.1002/jbmr.536
   McKenzie JA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029328
   Moustafa A, 2009, BONE, V44, P930, DOI 10.1016/j.bone.2008.12.026
   Noble BS, 2003, AM J PHYSIOL CELL PH, V284, pC934, DOI 10.1152/ajpcell.00234.2002
   Okada SF, 2004, J GEN PHYSIOL, V124, P513, DOI 10.1085/jgp.200409154
   Okumura H, 2008, BIOCHEM BIOPH RES CO, V372, P486, DOI 10.1016/j.bbrc.2008.05.066
   Orriss IR, 2009, J CELL PHYSIOL, V220, P155, DOI 10.1002/jcp.21745
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Romanello M, 2005, BIOCHEM BIOPH RES CO, V331, P1429, DOI 10.1016/j.bbrc.2005.03.246
   Romanello M, 2001, BIOCHEM BIOPH RES CO, V289, P1275, DOI 10.1006/bbrc.2001.6124
   Rubin C, 2001, NATURE, V412, P603, DOI 10.1038/35088122
   Rumney RMH, 2012, J BIOMECH, V45, P549, DOI 10.1016/j.jbiomech.2011.11.036
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   Saxon LK, 2007, AM J PHYSIOL ENDOC M, V293, pE484, DOI 10.1152/ajpendo.00189.2007
   Silva MJ, 2005, ANAT REC PART A, V283A, P380, DOI 10.1002/ar.a.20171
   SKERRY TM, 1989, J BONE MINER RES, V4, P783, DOI 10.1002/jbmr.5650040519
   Somerville JN, 2004, CALCIFIED TISSUE INT, V74, P469, DOI 10.1007/s00223 003 0101 x
   Sugiyama T, 2008, BONE, V43, P238, DOI 10.1016/j.bone.2008.04.012
   Sugiyama T, 2012, J BONE MINER RES, V27, P1784, DOI 10.1002/jbmr.1599
   Sugiyama T, 2010, BONE, V46, P314, DOI 10.1016/j.bone.2009.08.054
   Tan CY, 2010, CELL MOL LIFE SCI, V67, P445, DOI 10.1007/s00018 009 0191 3
   Turner CH, 1998, BONE, V22, P463, DOI 10.1016/S8756 3282(98)00041 6
   Wallace JM, 2007, BONE, V40, P1120, DOI 10.1016/j.bone.2006.12.002
   Wang LW, 2005, CIRC RES, V96, P189, DOI 10.1161/01.RES.0000153670.07559.E4
   Wang N, 2012, MOL ENDOCRINOL, V26, P142, DOI 10.1210/me.2011 1083
   Windahl SH, 2013, J BONE MINER RES, V28, P291, DOI 10.1002/jbmr.1754
   Yegutkin GG, 2008, BBA MOL CELL RES, V1783, P673, DOI 10.1016/j.bbamcr.2008.01.024
NR 51
TC 32
Z9 33
U1 1
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUN
PY 2013
VL 28
IS 6
BP 1446
EP 1456
DI 10.1002/jbmr.1877
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 149VS
UT WOS:000319350100022
PM 23362109
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Wang, Y
   Qin, D
   Gao, YY
   Zhang, YX
   Liu, Y
   Huang, LH
AF Wang, Yan
   Qin, Di
   Gao, Yiyao
   Zhang, Yunxin
   Liu, Yao
   Huang, Lihong
TI Identification of therapeutic targets for osteosarcoma by integrating
   single cell RNA sequencing and network pharmacology
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE osteosarcoma; single cell RNA sequencing; network pharmacology;
   molecular docking; therapeutic target
ID METASTASIS; EXPRESSION; PATHWAY; CATENIN
AB Background: Osteosarcoma (OS) is a common primary tumor with extensive heterogeneity. In this study, we used single cell RNA sequencing (scRNA seq) and network pharmacology to analyze effective targets for Osteosarcoma treatment.Methods: The cell heterogeneity of the Osteosarcoma single cell dataset GSE162454 was analyzed using the Seurat package. The bulk RNA transcriptome dataset GSE36001 was downloaded and analyzed using the CIBERSORT algorithm. The key targets for OS therapy were determined using Pearson's correlation analysis. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed on key targets. The DeepDR algorithm was used to predict potential drugs for Osteosarcoma treatment. Molecular docking analysis was performed to verify the binding abilities of the predicted drugs and key targets. qRT PCR assay was used to detect the expression of key targets in osteoblasts and OS cells.Results: A total of 21 cell clusters were obtained based on the GSE162454 dataset, which were labeled as eight cell types by marker gene tagging. Four cell types (B cells, cancer associated fibroblasts (CAFs), endothelial cells, and plasmocytes) were identified in Osteosarcoma and normal tissues, based on differences in cell abundance. In total, 17 key targets were identified by Pearson's correlation analysis. GO and KEGG analysis showed that these 17 genes were associated with immune regulation pathways. Molecular docking analysis showed that RUNX2, OMD, and CD4 all bound well to vincristine, dexamethasone, and vinblastine. The expression of CD4, OMD, and JUN was decreased in Osteosarcoma cells compared with osteoblasts, whereas RUNX2 and COL9A3 expression was increased.Conclusion: We identified five key targets (CD4, RUNX2, OMD, COL9A3, and JUN) that are associated with Osteosarcoma progression. Vincristine, dexamethasone, and vinblastine may form a promising drug target pair with RUNX2, OMD, and CD4 for Osteosarcoma treatment.
C1 [Wang, Yan; Gao, Yiyao] Jilin Univ, Sci Res Ctr, China Japan Union Hosp, Changchun, Peoples R China.
   [Qin, Di; Liu, Yao; Huang, Lihong] Jilin Univ, Dept Geriatr, China Japan Union Hosp, Changchun, Peoples R China.
   [Zhang, Yunxin] Jilin Univ, Dept Gastrointestinal Colorectal & Anal Surg, China Japan Union Hosp, Changchun, Peoples R China.
C3 Jilin University; Jilin University; Jilin University
RP Huang, LH (通讯作者)，Jilin Univ, Dept Geriatr, China Japan Union Hosp, Changchun, Peoples R China.
EM lhhuang@jlu.edu.cn
RI huang, lihong/AGW 6502 2022; yan, wang/JRW 9981 2023
FU Natural Science Foundation of Science and Technology Department of Jilin
   Province [20210101266JC]; Development and Reform Commission of Jilin
   Province [2020C034 3]
FX Funding This work was supported by Natural Science Foundation of Science
   and Technology Department of Jilin Province (grant number 20210101266JC)
   and Development and Reform Commission of Jilin Province (grant number
   2020C034 3).
CR Ahlström M, 2005, BIOCHEM PHARMACOL, V69, P267, DOI 10.1016/j.bcp.2004.09.012
   Aran D, 2019, NAT IMMUNOL, V20, P163, DOI 10.1038/s41590 018 0276 y
   Aynaud MM, 2020, CELL REP, V30, P1767, DOI 10.1016/j.celrep.2020.01.049
   Bonjardim CA, 2017, VIROLOGY, V507, P267, DOI 10.1016/j.virol.2016.12.011
   BOSCOBOINIK D, 1994, BIOCHEM BIOPH RES CO, V199, P374, DOI 10.1006/bbrc.1994.1239
   Burley SK, 2017, METHODS MOL BIOL, V1606, P627, DOI 10.1007/978 1 4939 7000 1_26
   Chen JC, 2016, ONCOTARGET, V7, P70276, DOI 10.18632/oncotarget.11839
   Chen R, 2019, MOL MED REP, V19, P1571, DOI 10.3892/mmr.2018.9774
   Cohen Solal KA, 2015, MOL CANCER, V14, DOI 10.1186/s12943 015 0404 3
   Cui J, 2022, DIS MARKERS, V2022, DOI 10.1155/2022/5447017
   Fan Y, 2020, COMPUT MATH METHOD M, V2020, DOI 10.1155/2020/6138039
   Feng CQ, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/6680637
   Fisher LD, 1999, ANNU REV PUBL HEALTH, V20, P145, DOI 10.1146/annurev.publhealth.20.1.145
   Han JC, 2021, NAT REV GASTRO HEPAT, V18, P451, DOI 10.1038/s41575 021 00471 z
   Hao YH, 2021, CELL, V184, P3573, DOI 10.1016/j.cell.2021.04.048
   Huang KX, 2020, BIOINFORMATICS, V36, P5545, DOI 10.1093/bioinformatics/btaa1005
   Jiang BE, 2021, COMPUT MATH METHOD M, V2021, DOI 10.1155/2021/2895893
   Jiang HP, 2022, CLIN TRANSL MED, V12, DOI 10.1002/ctm2.730
   Kim JY, 2021, BIOCHEM BIOPH RES CO, V581, P74, DOI 10.1016/j.bbrc.2021.10.025
   Kuijjer ML, 2013, INT J CANCER, V133, P2512, DOI 10.1002/ijc.28124
   Li B, 2020, INT J BIOL SCI, V16, P74, DOI 10.7150/ijbs.33787
   Li GQ, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.630355
   Liu ZC, 2020, AGING US, V12, P1213, DOI 10.18632/aging.102679
   Lv HH, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/5021983
   Miao YD, 2020, INT IMMUNOPHARMACOL, V89, DOI 10.1016/j.intimp.2020.107080
   Morad G, 2021, CELL, V184, P5309, DOI 10.1016/j.cell.2021.09.020
   Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]
   Ochando J, 2017, ONCOTARGET, V8, P112116, DOI 10.18632/oncotarget.22788
   Piñero J, 2020, NUCLEIC ACIDS RES, V48, pD845, DOI 10.1093/nar/gkz1021
   Prasetyanti PR, 2017, MOL CANCER, V16, DOI 10.1186/s12943 017 0600 4
   Rothzerg E, 2022, EXP BIOL MED, V247, P310, DOI 10.1177/15353702211067718
   Rothzerg E, 2021, J CELL PHYSIOL, V236, P1606, DOI 10.1002/jcp.29967
   Safran M, 2010, DATABASE OXFORD, DOI 10.1093/database/baq020
   Seeliger Daniel, 2010, J Comput Aided Mol Des, V24, P417, DOI 10.1007/s10822 010 9352 6
   Stamm H, 2018, MAMM GENOME, V29, P694, DOI 10.1007/s00335 018 9770 7
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Szklarczyk D, 2021, NUCLEIC ACIDS RES, V49, pD605, DOI 10.1093/nar/gkaa1074
   Tang F, 2019, J ORTHOP RES, V37, P789, DOI 10.1002/jor.24227
   Tang XF, 2019, CANCER MANAG RES, V11, P547, DOI 10.2147/CMAR.S185495
   Vega OA, 2017, J CELL BIOCHEM, V118, P3662, DOI 10.1002/jcb.26011
   Yang JZ, 2018, ONCOL LETT, V15, P250, DOI 10.3892/ol.2017.7317
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Yuan XH, 2020, AM J TRANSL RES, V12, P5381
   Zeng XX, 2019, BIOINFORMATICS, V35, P5191, DOI 10.1093/bioinformatics/btz418
   Zhang YJ, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046 021 01874 1
   Zhang Y, 2021, THERANOSTICS, V11, P1473, DOI 10.7150/thno.51245
   Zhao X, 2021, BIOMED ENG ONLINE, V20, DOI 10.1186/s12938 021 00860 0
   Zhou JG, 2020, ACTA HISTOCHEM, V122, DOI 10.1016/j.acthis.2019.151455
   Zhu KP, 2019, MOL THER, V27, P518, DOI 10.1016/j.ymthe.2019.01.001
NR 49
TC 6
Z9 6
U1 0
U2 27
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JAN 6
PY 2023
VL 13
AR 1098800
DI 10.3389/fphar.2022.1098800
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 8A5SH
UT WOS:000916298300001
PM 36686663
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Song, RP
   Tian, K
   Wang, WD
   Wang, LM
AF Song, Ruipeng
   Tian, Ke
   Wang, Weidong
   Wang, Limin
TI P53 suppresses cell proliferation, metastasis, and angiogenesis of
   osteosarcoma through inhibition of the PI3K/AKT/mTOR pathway
SO INTERNATIONAL JOURNAL OF SURGERY
LA English
DT Article
DE Osteosarcoma; MG63; P53; Mammalian target of rapamycin (mTOR);
   PI3K/AKT/mTOR pathway; Invasion; Migration; Target therapy
ID SIGNALING PATHWAY; PROGRESSION; MIGRATION; INVASION; EXPRESSION;
   APOPTOSIS
AB Objective: To investigate the role of P53 in the pathogenesis of osteosarcoma and the possible mechanism involved in it.
   Methods: The anti proliferative effect of P53 was assessed using the cell counting Kit 8 assay. The migration and invasion potential were analyzed using wound healing and transwell assays, respectively. The Matrigel capillary tube formation assay was performed to mimic in vivo angiogenesis. Immunoblotting and immunofluorescence were used to observe protein levels and distribution of actin fibers. Finally, S2448p mammalian target of rapamycin (mTOR) expression was detected on osteosarcoma tissues using immunohistochemistry.
   Results: Firstly, P53 potently inhibited cell proliferation in osteosarcoma cell line (MG63) and in human normal osteoblasts (hFOB1.19) in vitro at the IC50 ranged from 50 to 500 nmol/l. Then, an inhibitory effect of P53 on metastasis was observed in osteosarcoma cell line MG63, along with the cytoskeletal rearrangements and suppression of the phosphorylation of PI3K downstream factors including AKT and mTOR.
   Conclusion: These results show that P53 suppresses cell proliferation and angiogenesis of osteosarcoma through inhibition of the PI3K/AKT/mTOR pathway, which might be an effective novel therapeutic candidate against osteosarcoma in the future. (C) 2015 Published by Elsevier Ltd on behalf of IJS Publishing Group Limited.
C1 [Song, Ruipeng; Tian, Ke; Wang, Weidong; Wang, Limin] Zhengzhou Univ, Affiliated Hosp 1, Bone Dept, Zhengzhou, Peoples R China.
C3 Zhengzhou University
RP Wang, LM (通讯作者)，Zhengzhou Univ, Affiliated Hosp 1, Bone Dept, Zhengzhou, Peoples R China.
EM 13810749892@163.com; 297634506@qq.com; sunmeizhongvip@163.com;
   wangliminvip12@163.com
CR Cai H., 2014, SURG RES
   Chong Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114585
   Dai N, 2013, NEOPLASMA, V60, P384, DOI 10.4149/neo_2013_050
   Dylla L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063032
   He Y., 2014, STEM CELLS
   Ji F, 2013, BONE, V56, P220, DOI 10.1016/j.bone.2013.05.020
   Jin Y, 2013, DNA CELL BIOL, V32, P302, DOI 10.1089/dna.2013.1977
   Li GD, 2012, CELL PHYSIOL BIOCHEM, V30, P1481, DOI 10.1159/000343336
   Li HZ, 2015, MOL MED REP, V11, P851, DOI 10.3892/mmr.2014.2777
   Li J, 2014, CELL PROLIFERAT, V47, P152, DOI 10.1111/cpr.12093
   Lin S, 2014, J HUAZHONG U SCI MED, V34, P889, DOI 10.1007/s11596 014 1369 y
   Long XH, 2013, EXP THER MED, V5, P1048, DOI 10.3892/etm.2013.959
   Luo XJ, 2014, CELL PHYSIOL BIOCHEM, V34, P2180, DOI 10.1159/000369661
   Miao JL, 2013, TUMOR BIOL, V34, P2093, DOI 10.1007/s13277 013 0940 7
   Mishra PJ, 2014, BIOMARK RES, V2, DOI 10.1186/2050 7771 2 19
   Novello C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114757
   Sanchez Diaz Patricia C, 2014, Oncoscience, V1, P599
   Song L, 2013, ARCH BIOCHEM BIOPHYS, V535, P128, DOI 10.1016/j.abb.2013.04.001
   Tao T, 2013, EUR J CANCER, V49, P3055, DOI 10.1016/j.ejca.2013.05.010
   van der Deen M, 2013, J BIOL CHEM, V288, P21307, DOI 10.1074/jbc.M112.445890
   Won KY, 2013, HUM PATHOL, V44, P1648, DOI 10.1016/j.humpath.2013.01.016
   Xu JL, 2013, BIOMED PHARMACOTHER, V67, P381, DOI 10.1016/j.biopha.2013.03.013
   Xu N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115300
   Yang J, 2013, MOL CELL BIOCHEM, V381, P9, DOI 10.1007/s11010 013 1677 8
   Yuan JD, 2015, MED ONCOL, V32, DOI 10.1007/s12032 014 0324 x
   Zhang KX, 2014, INT J CLIN EXP PATHO, V7, P5701
   Zhou J., 2015, EXP BIOL MED MAYWOOD
   Zhu JW, 2013, TUMOR BIOL, V34, P3331, DOI 10.1007/s13277 013 0902 0
   Ziyan W., 2014, IR J MED SCI
NR 29
TC 50
Z9 53
U1 2
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1743 9191
EI 1743 9159
J9 INT J SURG
JI Int. J. Surg.
PD AUG
PY 2015
VL 20
BP 80
EP 87
DI 10.1016/j.ijsu.2015.04.050
PG 8
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery
GA CO6YX
UT WOS:000359305200014
PM 25936826
OA Bronze
DA 2025 08 17
ER

PT J
AU Tian, WK
   Zhang, W
   Chen, L
   Liao, JL
   Yang, XS
AF Tian, Weike
   Zhang, Wei
   Chen, Li
   Liao, Junlei
   Yang, Xuesong
TI Bioflavonoid Tangeretin regulates RANK/RANKL/OPG Signaling Proteins via
   Stimulating Estrogenic Activity in Ovariectomized Rats
SO PHARMACOGNOSY MAGAZINE
LA English
DT Article
DE Post menopause; estrogen deficiency; osteoporosis; bioflavonoid;
   tangeretin; antiresorptive drug
ID BONE; OSTEOPOROSIS; MANAGEMENT; FRACTURE; RECEPTOR; RISK; PREVALENCE;
   METABOLISM; DENOSUMAB; HEALTH
AB Background: Globally, osteoporosis has arisen as a significant health hazard, impacting over 200 million individuals. It is often reported in women, especially those who are in the postmenopausal stage. Even though numerous reasons are linked with osteoporosis etiology, estrogen deprivation is the prime inducer of osteoporosis.Purpose: The present research was intended to detect the bioflavonoid tangeretin potency against ameliorating osteoporosis in ovariectomized rats.Methods: Ovariectomy was performed in healthy female Sprague rats and treated with two different doses of the drug tangeretin. The body weight gain obtained by the experimental animals was noted throughout the experimental period. The uterus and vagina, the organ responsible for estrogen production and activity, were measured. Bone mineral density (BMD) and biomechanical properties of the femur were evaluated to study the impact of tangeretin. Bone biomarkers estradiol, bone GLA protein, and acid phosphatase were quantified to assess the impact of tangeretin on bone turnover. Serum phosphorous, calcium, creatinine, and tartrate resistant acid phosphatase (TRAP), which are the osteoporosis risk factors, were analyzed in tangeretin treated ovariectomized rats. Signaling proteins involved in the receptor activator of nuclear factor kappa B (RANK)/receptor activator of nuclear factor kappa B ligand (RANKL)/osteoprotegerin (OPG) pathway, which is responsible for bone turnover, were quantified.Results: Tangeretin treatment significantly inhibited excess weight gain and increased the uterus and vaginal weight. BMD and biomechanical analysis of the femur prove tangeretin treatment increased the BMD and upgraded the biomechanical properties in ovariectomized animals. Tangeretin increased the estradiol and decreased the bone GLA protein and acid phosphatase. It also increased serum phosphorous, calcium, and creatinine and decreased the TRAP levels, confirming its ameliorative potency against bone turnover. It inhibited RANKL protein and increased the levels of OPG and its signaling molecules in ovariectomized rats. The anti inflammatory bioflavonoid tangeretin attenuated the inflammatory stimulating cytokines in ovariectomized rats.Conclusion: Overall, our analysis confirms tangeretin possesses antiosteoporotic potency which effectively elevates estradiol and attenuates the bone turnover signaling pathway RANK/RANKL/OPG proteins in ovariectomized rats. The results of our research prove the establishment of a treatment strategy using tangeretin can improve bone health and prevent osteoporosis in menopausal women.
C1 [Tian, Weike; Liao, Junlei; Yang, Xuesong] North Sichuan Med Coll, Hlth Management Ctr, Affiliated Hosp, Nanchong 637000, Sichuan, Peoples R China.
   [Zhang, Wei] North Sichuan Med Coll, Dept Orthoped, Affiliated Hosp, Nanchong, Sichuan, Peoples R China.
   [Chen, Li] North Sichuan Med Coll, Dept Hosp Infect Management, Affiliated Hosp, Nanchong, Sichuan, Peoples R China.
C3 North Sichuan Medical University; North Sichuan Medical University;
   North Sichuan Medical University
RP Yang, XS (通讯作者)，North Sichuan Med Coll, Hlth Management Ctr, Affiliated Hosp, Nanchong 637000, Sichuan, Peoples R China.
EM q63963462@outlook.com
RI ; Zhang, wei/LLM 6439 2024; Tian, Weike/LKM 7195 2024
OI Tian, Weike/0009 0006 4388 5605; 
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Alex B., 2021, ADV CANC BIOLOGYMETA, V3
   Almeida M, 2013, J CLIN INVEST, V123, P394, DOI 10.1172/JCI65910
   Arafa EA, 2021, ADV PHARM PHARM SCI, V2021, DOI 10.1155/2021/4709818
   Ashrafizadeh Milad, 2020, J Basic Clin Physiol Pharmacol, V31, DOI 10.1515/jbcpp 2019 0191
   Askari M., 2019, Journal of Sabzevar University of Medical Science, V25, P854
   Bado I, 2017, ONCOGENE, V36, P4527, DOI 10.1038/onc.2017.94
   Barnsley J, 2021, AGING CLIN EXP RES, V33, P759, DOI 10.1007/s40520 021 01817 y
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Braidy N, 2017, CNS NEUROL DISORD DR, V16, P387, DOI 10.2174/1871527316666170328113309
   Charde SH, 2023, CUREUS J MED SCIENCE, V15, DOI 10.7759/cureus.48582
   Chen SH, 2024, CLIN EXP OBSTET GYN, V51, DOI 10.31083/j.ceog5102046
   Cheng CH, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031376
   Cremers S, 2019, BRIT J CLIN PHARMACO, V85, P1052, DOI 10.1111/bcp.13867
   Deeks ED, 2018, DRUG AGING, V35, P163, DOI 10.1007/s40266 018 0525 7
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   El Khoudary SR, 2019, MENOPAUSE, V26, P1213, DOI 10.1097/GME.0000000000001424
   Everts Graber J, 2022, J BONE MINER RES, V37, P340, DOI 10.1002/jbmr.4472
   Fang Y, 2021, OSTEOPOROSIS INT, V32, P633, DOI 10.1007/s00198 020 05578 8
   He CC, 2010, J ETHNOPHARMACOL, V127, P229, DOI 10.1016/j.jep.2009.11.016
   Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226
   Ilyas Z, 2019, CURR OPIN ENDOCRINOL, V26, P335, DOI 10.1097/MED.0000000000000501
   Karimi SM, 2024, J TRADIT COMPL MED, V14, P1, DOI 10.1016/j.jtcme.2023.08.001
   Karvonen Gutierrez C, 2016, HEALTHCARE BASEL, V4, DOI 10.3390/healthcare4030042
   Kulkarni SL, 2024, J CLIN DIAGN RES, V18, pRE1, DOI 10.7860/JCDR/2024/69058.19248
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Liang B, 2022, CELL MOL BIOL LETT, V27, DOI 10.1186/s11658 022 00371 3
   Lin JJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051017
   Lin YG, 2011, J AGR FOOD CHEM, V59, P4496, DOI 10.1021/jf1044475
   Magne D, 2003, J BONE MINER RES, V18, P1430, DOI 10.1359/jbmr.2003.18.8.1430
   Marlatt KL, 2022, OBESITY, V30, P14, DOI 10.1002/oby.23289
   McLean Robert R, 2009, Curr Osteoporos Rep, V7, P134
   Mohammed ZA, 2019, INDO AM J PHARM SCI, V6, P357, DOI 10.5281/zenodo.2530873
   Nardone V, 2014, CLINICS, V69, P438, DOI 10.6061/clinics/2014(06)12
   Noirrit Esclassan E, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041568
   Pang KL, 2020, DRUG DES DEV THER, V14, P4029, DOI 10.2147/DDDT.S270829
   Pinar G, 2017, WOMEN HEALTH, V57, P1080, DOI 10.1080/03630242.2016.1243604
   Pisani P, 2016, WORLD J ORTHOP, V7, P171, DOI 10.5312/wjo.v7.i3.171
   Rajeshwari, 2014, INT J PHARM BIOSCIEN, V5, pB456
   Rashki Kemmak Asma, 2020, Med J Islam Repub Iran, V34, P154, DOI 10.34171/mjiri.34.154
   Sadeghi O, 2019, CRIT REV FOOD SCI, V59, P1320, DOI 10.1080/10408398.2017.1405908
   Salari N, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02772 0
   Seibel Markus J, 2005, Clin Biochem Rev, V26, P97
   Seibel MJ, 2013, LANCET DIABETES ENDO, V1, P59, DOI 10.1016/S2213 8587(13)70045 7
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Stamenkovic BN, 2022, MEDICINA LITHUANIA, V58, DOI 10.3390/medicina58091207
   Sundaram R, 2014, PHYTOMEDICINE, V21, P793, DOI 10.1016/j.phymed.2014.01.007
   Tobeiha M, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/6910312
   Tu Kristie N, 2018, P T, V43, P92
   Vaiyapuri S, 2013, ARTERIOSCL THROM VAS, V33, P2740, DOI 10.1161/ATVBAHA.113.301988
   Wani I, 2024, LIFE BASEL, V14, DOI 10.3390/life14040504
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Wu J, 2018, INFLAMMOPHARMACOLOGY, V26, P119, DOI 10.1007/s10787 017 0394 4
   Xu H, 2003, AM J PHYSIOL GASTR L, V285, pG1317, DOI 10.1152/ajpgi.00172.2003
NR 54
TC 1
Z9 1
U1 5
U2 7
PU SAGE PUBLICATIONS INDIA  PVT LTD
PI NEW DELHI
PA B 1 I 1 MOHAN CO OPERATIVE INDUSTRIAL AREA, MATHURA RD, POST BAG NO 7,
   NEW DELHI 110 044, INDIA
SN 0973 1296
EI 0976 4062
J9 PHARMACOGN MAG
JI Pharmacogn. Mag.
PD SEP
PY 2025
VL 21
IS 3
BP 1001
EP 1012
DI 10.1177/09731296241296201
EA NOV 2024
PG 12
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 4VK8H
UT WOS:001356721700001
OA hybrid
DA 2025 08 17
ER

PT J
AU Fatima, S
   Alfrayh, R
   Alrashed, M
   Alsobaie, S
   Ahmad, R
   Mahmood, A
AF Fatima, Sabiha
   Alfrayh, Rawan
   Alrashed, May
   Alsobaie, Sarah
   Ahmad, Rehan
   Mahmood, Amer
TI Selenium Nanoparticles by Moderating Oxidative Stress Promote
   Differentiation of Mesenchymal Stem Cells to Osteoblasts
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE selenium nanoparticles stem cells; antioxidant; osteogenic
   differentiation
ID OSTEOGENIC DIFFERENTIATION; ADIPOGENIC DIFFERENTIATION; KINASE
AB Purpose: Redox homeostasis plays an important role in the osteogenic differentiation of human mesenchymal stem cells (hMSCs) for bone engineering. Oxidative stress (OS) is believed to induce osteoporosis by changing bone homeostasis. Selenium nanoparticles (SeNPs), an antioxidant with pleiotropic pharmacological activity, prevent bone loss. However, the molecular mechanism underlying the osteogenic activity during hMSCSeNP interaction is unclear.
   Methods: This study assessed the effects of different concentrations (25, 50, 100, and 300 ng/mL) of SeNPs on the cell viability and differentiation ability of human embryonic stem cell derived hMSCs. In addition, we analyzed OS markers and their effect on mitogen activated protein kinase (MAPK) and Forkhead box O 3 (FOXO3) during osteogenesis.
   Results: SeNPs increased the cell viability of hMSCs and induced their differentiation toward an osteogenic over an adipogenic lineage by enhancing osteogenic transcription and mineralization, while inhibiting Nile red staining and adipogenic gene expression. By preventing excessive reactive oxygen species accumulation, SeNPs increased antioxidant levels in hMSCs undergoing osteogenesis compared to untreated cells. In addition, SeNPs significantly upregulated the gene and protein expression of phosphorylated c Jun N terminal kinase (JNK) and FOXO3a, with no significant change in the expression levels of extracellular signal related kinase (ERK) and p38 MAPK.
   Conclusion: The results approved that low concentrations of SeNPs might enhance the cell viability and osteogenic potential of hMSCs by moderating OS. Increased JNK and FOXO3a expression shows that SeNPs might enhance osteogenesis via activation of the JNK/FOXO3 pathway. In addition, SeNP co supplementation might prevent bone loss by enhancing osteogenesis and, thus, can be an effective candidate for treating osteoporosis through cellbased therapy.
C1 [Fatima, Sabiha; Alfrayh, Rawan; Alsobaie, Sarah] King Saud Univ, Coll Appl Med Sci, Dept Clin Lab Sci, Riyadh 11433, Saudi Arabia.
   [Alrashed, May] King Saud Univ, Coll Appl Med Sci, Dept Clin Lab Sci, Chair Med & Mol Genet Res, Riyadh 11433, Saudi Arabia.
   [Ahmad, Rehan] King Saud Univ, Coll Med, Dept Surg, Colorectal Res Chair, Riyadh 11472, Saudi Arabia.
   [Mahmood, Amer] King Saud Univ, King Khalid Univ Hosp, Coll Med, Stem Cell Unit,Dept Anat, Riyadh 11461, Saudi Arabia.
C3 King Saud University; King Saud University; King Saud University; King
   Saud University
RP Fatima, S (通讯作者)，King Saud Univ, Coll Appl Med Sci, Dept Clin Lab Sci, Riyadh 11433, Saudi Arabia.; Mahmood, A (通讯作者)，King Saud Univ, Dept Anat, Coll Med, Stem Cell Unit, Riyadh 11461, Saudi Arabia.
EM sabmehdi@ksu.edu.sa; ammahmood@ksu.edu.sa
RI Fatima, Sabiha/ABD 3842 2020; alrashed, may/AAY 5134 2021; Alsobaie,
   Sarah/GZH 0863 2022; alfrayh, rawan/HSE 5834 2023; Mahmood,
   Amer/A 9514 2011
OI Ahmad, Rehan/0000 0003 2612 2818; Mahmood, Amer/0000 0002 9199 0120;
   Alsobaie, Sarah/0000 0002 1707 6461; Alrashed, May/0000 0002 3056 6393;
   Fatima, Sabiha/0000 0001 8641 1369; Alfrayh, Rawan/0000 0002 9226 8332; 
FU "Research Center of the Female Scientific and Medical Colleges",
   Deanship of Scientific Research, King Saud University
FX This research project was supported by a grant from the "Research Center
   of the Female Scientific and Medical Colleges", Deanship of Scientific
   Research, King Saud University.
CR Alkhudhayri A, 2020, AN ACAD BRAS CIENC, V92, DOI 10.1590/0001 3765202020191107
   Almeida M, 2011, BONE, V49, P319, DOI 10.1016/j.bone.2011.05.023
   Alves H, 2013, TISSUE ENG PT A, V19, P928, DOI [10.1089/ten.tea.2011.0700, 10.1089/ten.TEA.2011.0700]
   Atashi F, 2015, STEM CELLS DEV, V24, P1150, DOI 10.1089/scd.2014.0484
   Behzadi S, 2017, CHEM SOC REV, V46, P4218, DOI 10.1039/c6cs00636a
   Chen D, CELL PROLIF
   Chen GC, 2014, CELL TISSUE BANK, V15, P513, DOI 10.1007/s10561 014 9420 6
   Courtial L, 2017, SCI REP UK, V7, DOI 10.1038/srep45713
   Dai XZ, 2020, TRENDS MOL MED, V26, P185, DOI 10.1016/j.molmed.2019.09.007
   Denu RA, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2989076
   Dhoke NR, 2018, ANTIOXID REDOX SIGN, V28, P1047, DOI 10.1089/ars.2016.6974
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Drela K, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/7012692
   Ge CX, 2016, J CELL PHYSIOL, V231, P587, DOI 10.1002/jcp.25102
   Geng QH, 2019, INT J BIOL SCI, V15, P58, DOI 10.7150/ijbs.25783
   Gu HJ, 2015, EXP CELL RES, V339, P112, DOI 10.1016/j.yexcr.2015.08.005
   Hass R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478 811X 9 12
   Hosnedlova B, 2018, INT J NANOMED, V13, P2107, DOI 10.2147/IJN.S157541
   Hu CX, 2018, J CELL MOL MED, V22, P5196, DOI 10.1111/jcmm.13835
   Khurana A, 2019, BIOMED PHARMACOTHER, V111, P802, DOI 10.1016/j.biopha.2018.12.146
   Kursvietiene L, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9010080
   Lee J, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4081890
   Li J., 2018, Case Reports in Orthopedic Research, V1, P2, DOI DOI 10.1159/000489053
   Li QQ, 2017, PROTEIN CELL, V8, P439, DOI 10.1007/s13238 017 0385 7
   Lin CH, 2018, J CELL MOL MED, V22, P786, DOI 10.1111/jcmm.13356
   Lin S, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0672 5
   Liu BY, 2019, CELL TISSUE BANK, V20, P173, DOI 10.1007/s10561 019 09751 0
   Liu SP, 2010, CELL TRANSPLANT, V19, P1261, DOI 10.3727/096368910X507204
   Maggio D, 2003, J CLIN ENDOCR METAB, V88, P1523, DOI 10.1210/jc.2002 021496
   Muthusami S, 2005, CLIN CHIM ACTA, V360, P81, DOI 10.1016/j.cccn.2005.04.014
   Sart S, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/105135
   Shaban S, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5032102
   Shao J, 2015, BIOL RES, V48, DOI [10.1186/s40659 015 0053 4, 10.1186/S40659 015 0053 4]
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Wei M, 2017, J NANOBIOTECHNOL, V15, DOI 10.1186/s12951 017 0310 5
   Wei X, 2013, ACTA PHARMACOL SIN, V34, P747, DOI 10.1038/aps.2013.50
   Yang SR, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/486263
   Yi CQ, 2010, ACS NANO, V4, P6439, DOI 10.1021/nn101373r
   Yoon SW, 2014, STEM CELLS DEV, V23, P2700, DOI 10.1089/scd.2014.0129
NR 39
TC 44
Z9 47
U1 1
U2 51
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2021
VL 16
BP 331
EP 343
DI 10.2147/IJN.S285233
PG 13
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Pharmacology & Pharmacy
GA PR9SS
UT WOS:000607571100001
PM 33488075
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Li, D
   Dong, JD
   Xiong, T
   Zhou, XY
   Li, YH
   Chen, CC
   Li, SJ
   Song, ZY
   Xu, NG
   Yang, MJ
   Yan, XX
   Liu, T
   Liu, SH
AF Li, Du
   Dong, Jindian
   Xiong, Tong
   Zhou, Xingyu
   Li, Yanhui
   Chen, Chuncheng
   Li, Shijie
   Song, Zhuoyue
   Xu, Nenggui
   Yang, Mingjing
   Yan, Xiaoxia
   Liu, Tao
   Liu, Shihui
TI Transdermal delivery of iguratimod and colchicine ethosome by dissolving
   microneedle patch for the treatment of recurrent gout
SO COLLOIDS AND SURFACES B BIOINTERFACES
LA English
DT Article
DE Microneedle; Iguratimod; Colchicine; Gout; Bone protection
ID JOINT DAMAGE; INFLAMMATION; MECHANISMS; PATHOGENESIS; MANAGEMENT
AB This study introduces a novel approach of repetitive modeling to simulate the pathological process of recurrent gout attacks in humans. This methodology addresses the instability issues present in rat models of gout, providing a more accurate representation of the damage recurrent gout episodes inflict on human skeletal systems. A soluble nanoneedle system encapsulating colchicine and iguratimod ethosomal formulations was developed. This system aims to modulate inflammatory cytokines and inhibit osteoclast activity, thereby treating inflammatory pain and bone damage associated with recurrent gout. Additionally, a comprehensive evaluation of the microneedles' appearance, morphology, mechanical properties, and penetration capability confirmed their effectiveness in penetrating the stratum corneum. Dissolution tests and skin irritation assessments demonstrated that these microneedles dissolve rapidly without irritating the skin. In vitro permeation studies indicated that transdermal drug delivery via these microneedles is more efficient and incurs lower drug loss compared to traditional topical applications. In vivo pharmacodynamic assessments conducted in animal models revealed significant analgesic and anti inflammatory effects when both types of microneedles were used together. Further analyses, including X ray imaging, hematoxylin and eosin (H&E) staining, Safranin O/fast green staining, tartrate resistant acid phosphatase staining, and quantification of osteoclasts, confirmed the bone protective effects of the microneedle combination. In conclusion, the findings of this research underscore the potential of this novel therapeutic approach for clinical application in the treatment of recurrent gout.
C1 [Li, Du; Dong, Jindian; Xiong, Tong; Zhou, Xingyu; Li, Yanhui; Chen, Chuncheng; Li, Shijie; Xu, Nenggui; Yang, Mingjing; Yan, Xiaoxia; Liu, Tao; Liu, Shihui] Guangzhou Univ Chinese Med, Med Coll Acu Moxi & Rehabil, Guangzhou 510006, Peoples R China.
   [Song, Zhuoyue] Guangdong Acad Sci, Inst Biol & Med Engn, Bioengn Lab, Guangzhou 510070, Guangdong, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangdong Academy of Sciences
RP Li, SJ; Liu, T; Liu, SH (通讯作者)，Guangzhou Univ Chinese Med, Med Coll Acu Moxi & Rehabil, Guangzhou 510006, Peoples R China.
EM lsj123@gzucm.edu.cn; lt045021@gzucm.edu.cn; liushihui@gzucm.edu.cn
RI zhou, xingyu/JAN 7591 2023; yan, xiaoxia/B 6998 2013; Liu,
   Tao/P 6401 2015; song, zhuoyue/JOK 9301 2023; Liu, Shihui/AAO 5153 2021
OI yang, ming jing/0009 0008 8783 4150; 
FU National Natural Science Foundation of China [32071329, 82305397,
   82004025]; Basic and Applied Basic Research Foundation of Guangdong
   Province [2021A1515011274, 2022A1515011349, 2023A1515030172,
   2022A1515010377]; Basic Research Program Basic and Applied Basic
   Research Project of Guangzhou [202201011283]; Guangzhou University of
   Chinese Medicine Young Talents (Team) Cultivation "Jie  BangGuaShuai"
   Programme; Discipline Collaborative Innovation Team Program of Double
   First class and High level Universities for Guangzhou University of
   Chinese Medicine [2021XK01]
FX This work was financially supported by the National Natural Science
   Foundation of China (32071329, 82305397 and 82004025) , Basic and
   Applied Basic Research Foundation of Guangdong Province
   (2021A1515011274, 2022A1515011349, 2023A1515030172, and 2022A1515010377)
   , Basic Research Program Basic and Applied Basic Research Project of
   Guangzhou (202201011283) , Guangzhou University of Chinese Medicine
   Young Talents (Team) Cultivation "Jie  BangGuaShuai" Programme (2023) ,
   and Discipline Collaborative Innovation Team Program of Double
   First class and High level Universities for Guangzhou University of
   Chinese Medicine (2021XK01).
CR Akhtar N, 2022, J COSMET DERMATOL US, V21, P4942, DOI 10.1111/jocd.14907
   Alekos NS, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.578194
   Alsalem M, 2020, EXP THER MED, V20, DOI 10.3892/etm.2020.9294
   Apolinário AC, 2022, AAPS PHARMSCITECH, V23, DOI 10.1208/s12249 022 02257 1
   Ben Chetrit E, 2006, RHEUMATOLOGY, V45, P274, DOI 10.1093/rheumatology/kei140
   Cavalcanti NG, 2016, IMMUNOL INVEST, V45, P383, DOI 10.3109/08820139.2016.1153651
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Chhana A, 2014, RHEUM DIS CLIN N AM, V40, P291, DOI 10.1016/j.rdc.2014.01.006
   Chhana A, 2011, ANN RHEUM DIS, V70, P1684, DOI 10.1136/ard.2010.144774
   Clebak KT, 2020, AM FAM PHYSICIAN, V102, P533
   Corrado A, 2006, Minerva Med, V97, P495
   Dalbeth N, 2005, RHEUMATOLOGY, V44, P1090, DOI [10.1093/rheumatology/keh640, 10.1186/ar2952]
   Dalbeth N, 2008, ARTHRITIS RHEUM US, V58, P1854, DOI 10.1002/art.23488
   Dalbeth N, 2021, LANCET, V397, P1843, DOI 10.1016/S0140 6736(21)00569 9
   Danve A, 2021, BEST PRACT RES CL RH, V35, DOI 10.1016/j.berh.2021.101723
   Das SK, 2018, CURR DRUG DELIV, V15, P795, DOI 10.2174/1567201815666180116091604
   Ferron GM, 1996, J CLIN PHARMACOL, V36, P874, DOI 10.1002/j.1552 4604.1996.tb04753.x
   Finkelstein Y, 2010, CLIN TOXICOL, V48, P407, DOI 10.3109/15563650.2010.495348
   Fissel B.M.., 2015, Tumor necrosis factor alpha and interleukin 6 drive a rankindependent pathway of osteoclast activation
   Grebenciucova E, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1255533
   Guo JC, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 03046 z
   Hainer BL, 2014, AM FAM PHYSICIAN, V90, P831
   Hammell DC, 2016, EUR J PAIN, V20, P936, DOI 10.1002/ejp.818
   Hu LL, 2018, INT J BIOL MACROMOL, V117, P928, DOI 10.1016/j.ijbiomac.2018.05.097
   J XW, 2023, PHARMAZIE, V78, P31, DOI 10.1691/ph.2023.2572
   Jiang HH, 2020, BIOMED PHARMACOTHER, V122, DOI 10.1016/j.biopha.2019.109704
   Jin P, 2019, J AGR FOOD CHEM, V67, P1371, DOI 10.1021/acs.jafc.8b06278
   Jung YK, 2019, IMMUNE NETW, V19, DOI 10.4110/in.2019.19.e2
   Kany S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236008
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Leone M, 2017, PHARM RES DORDR, V34, P2223, DOI 10.1007/s11095 017 2223 2
   Li CH, 2021, INT IMMUNOPHARMACOL, V90, DOI 10.1016/j.intimp.2020.107219
   Li HW, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2609 7
   Li HQ, 2024, BMC CARDIOVASC DISOR, V24, DOI 10.1186/s12872 023 03697 8
   Li JW, 2017, CURR MED CHEM, V24, P2413, DOI 10.2174/0929867324666170526124053
   Li XL, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.979939
   Lin YY, 2020, J ADV RES, V24, P109, DOI 10.1016/j.jare.2020.02.014
   Long ZY, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1150661
   Long ZY, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.993860
   Mbah CC, 2014, EXPERT OPIN DRUG DEL, V11, P45, DOI 10.1517/17425247.2013.860130
   McQueen FM, 2012, NAT REV RHEUMATOL, V8, P173, DOI 10.1038/nrrheum.2011.207
   Nainwal N, 2019, J LIPOSOME RES, V29, P103, DOI 10.1080/08982104.2018.1517160
   Narang RK, 2020, SEMIN NEPHROL, V40, P550, DOI 10.1016/j.semnephrol.2020.12.001
   Paiva Santos AC, 2021, PHARM RES DORDR, V38, P947, DOI 10.1007/s11095 021 03053 5
   Raghuvanshi A, 2022, J MICROENCAPSUL, V39, P352, DOI 10.1080/02652048.2022.2084169
   Rao YF, 2015, DRUG DELIV, V22, P1003, DOI 10.3109/10717544.2013.839128
   Sartawi Z, 2022, J CONTROL RELEASE, V348, P186, DOI 10.1016/j.jconrel.2022.05.045
   Schlesinger N, 2010, ANN RHEUM DIS, V69, P1907, DOI 10.1136/ard.2010.128454
   Scuiller A, 2020, REV MED INTERNE, V41, P396, DOI 10.1016/j.revmed.2020.02.014
   Shen S, 2015, INT J NANOMED, V10, P4239, DOI 10.2147/IJN.S83402
   Sherman MR, 2008, ADV DRUG DELIVER REV, V60, P59, DOI 10.1016/j.addr.2007.06.011
   Slobodnick Anastasia, 2018, Rheumatology (Oxford), V57, pi4, DOI 10.1093/rheumatology/kex453
   So AK, 2017, NAT REV RHEUMATOL, V13, P639, DOI 10.1038/nrrheum.2017.155
   Soba SV, 2021, ADV PHARM BULL, V11, P137, DOI 10.34172/apb.2021.015
   Song JL, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4901591
   Sudhakar K, 2021, INT J PHARMACEUT, V610, DOI 10.1016/j.ijpharm.2021.121226
   Sudol Szopinska, 2020, ACTA REUMATOL PORT, V45, P20
   Sugumar V, 2023, BIOMEDICINES, V11, DOI 10.3390/biomedicines11030664
   Temmoku J, 2021, MOD RHEUMATOL, V31, P270, DOI 10.1080/14397595.2020.1740410
   Towiwat P, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 1105 z
   Xiao L, 2023, CELL DEATH DISCOV, V9, DOI 10.1038/s41420 023 01388 z
   Xie SS, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00073
   Xu J, 2021, MOLECULES, V26, DOI 10.3390/molecules26195912
   Yan QY, 2021, POLYMERS BASEL, V13, DOI 10.3390/polym13183043
   Yang H, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12111067
   Yang LPH, 2010, DRUGS, V70, P1603, DOI 10.2165/11205470 000000000 00000
   Yang Y, 2023, ACTA PHARM SIN B, V13, P3454, DOI 10.1016/j.apsb.2023.02.011
   Yip Kevin, 2021, JAMA, V326, P2541, DOI 10.1001/jama.2021.19770
   Yu YQ, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.646554
   Zelová H, 2013, INFLAMM RES, V62, P641, DOI 10.1007/s00011 013 0633 0
   Zhang BH, 2021, THERANOSTICS, V11, P3074, DOI 10.7150/thno.53755
   Zhang Y, 2020, ANN PALLIAT MED, V9, P4332, DOI 10.21037/apm 20 2072
   Zhang YJ, 2019, DRUG DELIV, V26, P70, DOI 10.1080/10717544.2018.1559258
   Zhou CP, 2010, INT J PHARMACEUT, V392, P127, DOI 10.1016/j.ijpharm.2010.03.041
NR 74
TC 6
Z9 6
U1 15
U2 38
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0927 7765
EI 1873 4367
J9 COLLOID SURFACE B
JI Colloid Surf. B Biointerfaces
PD OCT
PY 2024
VL 242
AR 114087
DI 10.1016/j.colsurfb.2024.114087
EA JUL 2024
PG 14
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Chemistry; Materials Science
GA YW3N3
UT WOS:001271483800001
PM 39003846
DA 2025 08 17
ER

PT J
AU Ghosh, LD
   Ravi, V
   Jain, A
   Panicker, AG
   Sundaresan, NR
   Chatterjee, K
AF Ghosh, Lopamudra Das
   Ravi, Venkatraman
   Jain, Aditi
   Panicker, Arpana G.
   Sundaresan, Nagalingam R.
   Chatterjee, Kaushik
TI Sirtuin 6 mediated stem cell cardiomyogenesis on protein coated
   nanofibrous scaffolds
SO NANOMEDICINE NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Extracellular matrix; Stem cells; Cardiomyogenesis; Tissue scaffolds;
   Sirtuin6; Nanofibers
ID OSTEOGENIC DIFFERENTIATION; EXTRACELLULAR MATRIX; REGENERATION;
   INHIBITION; MECHANISMS; THERAPY; DISEASE; REPAIR; ROLES; FACES
AB The cellular niche provides combination of biomolecular and biophysical cues to control stem cell fate. Three dimensional (3D) aligned nanofibrous scaffolds can effectively augment stem cell cardiomyogenesis. This work aims to understand the role of biomolecular signals from extracellular matrix (ECM) proteins and leverage them to further promote cardiomyogenesis on nanofibrous scaffolds. Human mesenchymal stem cells (hMSCs) were cultured on 3D aligned polycaprolactone scaffolds coated with different ECM proteins. Among multiple coatings tested, collagen coated fibers were most effective in promoting cardiomyogenesis as determined from increased expression of cardiac biomarkers and intracellular calcium flux. At molecular level, enhanced differentiation on collagen coated fibers was associated with an increased level of sirtuin 6 (SIRT6). Depletion of SIRT6 using siRNA attenuated the differentiation process through activation of Wnt signaling pathway. This study, thus, demonstrates that protein coated scaffolds can augment cardiomyogenic differentiation of stem cells through a combination of topographical and biomolecular signals. (C) 2019 Elsevier Inc. All rights reserved.
C1 [Ghosh, Lopamudra Das; Panicker, Arpana G.; Chatterjee, Kaushik] Indian Inst Sci, Dept Mat Engn, Bangalore 560012, Karnataka, India.
   [Ravi, Venkatraman; Sundaresan, Nagalingam R.] Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore, Karnataka, India.
   [Jain, Aditi; Sundaresan, Nagalingam R.; Chatterjee, Kaushik] Indian Inst Sci, Ctr Biosyst Sci & Engn, Bangalore, Karnataka, India.
C3 Indian Institute of Science (IISC)   Bangalore; Indian Institute of
   Science (IISC)   Bangalore; Indian Institute of Science (IISC)  
   Bangalore
RP Chatterjee, K (通讯作者)，Indian Inst Sci, Dept Mat Engn, Bangalore 560012, Karnataka, India.; Sundaresan, NR (通讯作者)，Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore, Karnataka, India.; Sundaresan, NR; Chatterjee, K (通讯作者)，Indian Inst Sci, Ctr Biosyst Sci & Engn, Bangalore, Karnataka, India.
EM rsundaresan@iisc.ac.in; kchatterjee@iisc.ac.in
RI ; Chatterjee, Kaushik/AGN 9820 2022; Jain, Aditi/AAD 8922 2019; Ravi,
   Venkatraman/C 7967 2014
OI Ravi, Venkatraman/0000 0002 1409 682X; Das Ghosh,
   Lopamudra/0000 0003 3867 6711; 
FU Department of Biotechnology, India (DBT) [BT/PR8274/MED/31/221/2013];
   Department of Science and Technology, India (DST) Young Scientist
   fellowship [YSS/2015/001448]; Ramalingswamy fellowship from DBT;
   Innovative Young Biotechnology Award from DBT [BT/07/IYBA/2013 10];
   DBT IISc Partnership Program
FX This work was funded by the Department of Biotechnology, India (DBT)
   (BT/PR8274/MED/31/221/2013). L.D.G. acknowledges support from Department
   of Science and Technology, India (DST) Young Scientist fellowship
   (YSS/2015/001448). N.R.S. acknowledges support from Ramalingswamy
   fellowship and the Innovative Young Biotechnology Award
   (BT/07/IYBA/2013 10) from DBT and the DBT IISc Partnership Program.
   Access to equipment at the Center for Nanoscience and Engineering, the
   Central Confocal Imaging Facility, Confocal Facility of Department of
   Microbiology and Cell Biology all at IISc is acknowledged.
CR Ahuja P, 2007, PHYSIOL REV, V87, P521, DOI 10.1152/physrev.00032.2006
   Amado LC, 2005, P NATL ACAD SCI USA, V102, P11474, DOI 10.1073/pnas.0504388102
   Bartunek J, 2007, AM J PHYSIOL HEART C, V292, pH1095, DOI 10.1152/ajpheart.01009.2005
   Berrier AL, 2007, J CELL PHYSIOL, V213, P565, DOI 10.1002/jcp.21237
   Bisping E, 2006, P NATL ACAD SCI USA, V103, P14471, DOI 10.1073/pnas.0602543103
   Boengler K, 2018, CURR OPIN PHYSIOL, V2, P123, DOI 10.1016/j.cophys.2018.02.003
   Cambria E, 2017, NPJ REGEN MED, V2, DOI 10.1038/s41536 017 0024 1
   Carvalho E, 2015, REGEN MED, V10, P1025, DOI 10.2217/rme.15.63
   Chen Q, 2017, CELL REP, V18, P3155, DOI 10.1016/j.celrep.2017.03.006
   Chen W, 2013, BBA MOL CELL RES, V1833, P945, DOI 10.1016/j.bbamcr.2012.08.023
   Chiong M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.130
   Chiu LH, 2014, BIOMATERIALS, V35, P2680, DOI 10.1016/j.biomaterials.2013.12.005
   Cohen ED, 2008, DEVELOPMENT, V135, P789, DOI 10.1242/dev.016865
   Crowder SW, 2016, CELL STEM CELL, V18, P39, DOI 10.1016/j.stem.2015.12.012
   Das Ghosh L, 2017, COLLOID SURFACE B, V151, P178, DOI 10.1016/j.colsurfb.2016.12.023
   Etchegaray JP, 2015, NAT CELL BIOL, V17, P545, DOI 10.1038/ncb3147
   Fearnley CJ, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004242
   Garbern JC, 2013, CELL STEM CELL, V12, P689, DOI 10.1016/j.stem.2013.05.008
   Gessert S, 2010, CIRC RES, V107, P186, DOI 10.1161/CIRCRESAHA.110.221531
   Ghosh L. D., 2016, COLLOID SURFACE B, V151, P178
   Ghosh LD, 2018, MAT SCI ENG C MATER, V88, P104, DOI 10.1016/j.msec.2018.03.012
   Haigis MC, 2010, ANNU REV PATHOL MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250
   Hansson EM, 2009, CELL STEM CELL, V5, P364, DOI 10.1016/j.stem.2009.09.004
   Hynes RO, 2009, SCIENCE, V326, P1216, DOI 10.1126/science.1176009
   Jain S, 2016, ACS BIOMATER SCI ENG, V2, P1376, DOI 10.1021/acsbiomaterials.6b00297
   Khan D, 2018, J CELL PHYSIOL, V233, P5478, DOI 10.1002/jcp.26434
   Kugel S, 2014, TRENDS BIOCHEM SCI, V39, P72, DOI 10.1016/j.tibs.2013.12.002
   Kumar G, 2011, BIOMATERIALS, V32, P9188, DOI 10.1016/j.biomaterials.2011.08.054
   Kuo YC, 2017, J TAIWAN INST CHEM E, V77, P41, DOI 10.1016/j.jtice.2017.04.043
   Laflamme MA, 2005, NAT BIOTECHNOL, V23, P845, DOI 10.1038/nbt1117
   Legate KR, 2009, GENE DEV, V23, P397, DOI 10.1101/gad.1758709
   Lian XJ, 2012, P NATL ACAD SCI USA, V109, pE1848, DOI 10.1073/pnas.1200250109
   Majka M, 2017, STEM CELL TRANSL MED, V6, P1859, DOI 10.1002/sctm.16 0484
   Marvin MJ, 2001, GENE DEV, V15, P316, DOI 10.1101/gad.855501
   Meka SRK, 2017, ACS BIOMATER SCI ENG, V3, P551, DOI 10.1021/acsbiomaterials.6b00725
   Naito AT, 2006, P NATL ACAD SCI USA, V103, P19812, DOI 10.1073/pnas.0605768103
   Park SJ, 2016, SCI REP UK, V6, DOI 10.1038/srep26186
   Piao J, 2013, SCI REP UK, V3, DOI 10.1038/srep03022
   Prager Khoutorsky M, 2011, NAT CELL BIOL, V13, P1457, DOI 10.1038/ncb2370
   Rasmussen CH, 2016, PLOS ONE, V10
   Reddy K, 2015, WORLD J CARDIOL, V7, P243, DOI 10.4330/wjc.v7.i5.243
   Roth GA, 2015, CIRCULATION, V132, P1667, DOI 10.1161/CIRCULATIONAHA.114.008720
   Singh A, 2017, EXP CELL RES, V360, P365, DOI 10.1016/j.yexcr.2017.09.028
   Song HY, 2018, ANTICANCER RES, V38, P647, DOI 10.21873/anticanres.12268
   Sun HL, 2014, STEM CELLS, V32, P1943, DOI 10.1002/stem.1671
   Sundaresan NR, 2012, NAT MED, V18, P1643, DOI 10.1038/nm.2961
   Tasselli L, 2017, TRENDS ENDOCRIN MET, V28, P168, DOI 10.1016/j.tem.2016.10.002
   Trappmann B, 2012, NAT MATER, V11, P642, DOI [10.1038/NMAT3339, 10.1038/nmat3339]
   Ueno S, 2007, P NATL ACAD SCI USA, V104, P9685, DOI 10.1073/pnas.0702859104
   Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150
   Van Camp J, 2014, STEM CELL REV REP, V10, P207, DOI 10.1007/s12015 013 9486 8
   Wakasa S, 2013, INTERACT CARDIOV TH, V16, P785, DOI 10.1093/icvts/ivt096
   Wang H, 2016, CELL STEM CELL, V18, P495, DOI 10.1016/j.stem.2016.03.005
   Wang XX, 2016, BASIC RES CARDIOL, V111, DOI 10.1007/s00395 016 0531 z
   Weston CR, 2001, SCIENCE, V292, P2439, DOI 10.1126/science.1063279
   Yi BA, 2010, J CLIN INVEST, V120, P20, DOI 10.1172/JCI40820
   Yin ZY, 2015, BBA MOL BASIS DIS, V1852, P47, DOI 10.1016/j.bbadis.2014.11.003
   ZHANG P, 2017, SCI REP, V7
   Zhang ZP, 2013, EXPERT OPIN BIOL TH, V13, P527, DOI 10.1517/14712598.2013.756468
NR 59
TC 7
Z9 7
U1 1
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549 9634
EI 1549 9642
J9 NANOMED NANOTECHNOL
JI Nanomed. Nanotechnol. Biol. Med.
PD JUL
PY 2019
VL 19
BP 145
EP 155
DI 10.1016/j.nano.2019.03.005
PG 11
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Research & Experimental Medicine
GA IE8MD
UT WOS:000472626700014
PM 30926577
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Fu, GT
   Wen, ZK
   Deng, ZT
   Li, MY
   Li, QT
   Ma, YC
   Chen, YF
   Zheng, QJ
AF Fu Guangtao
   Wen Zhenkang
   Deng Zhantao
   Li Mengyuan
   Li Qingtian
   Ma Yuanchen
   Chen Yuanfeng
   Zheng Qiujian
TI Icariin Alleviates Wear Particle Induced Periprosthetic Osteolysis
   via Down Regulation of the Estrogen Receptor α mediated NF κB
   Signaling Pathway in Macrophages
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE icariin; wear particle; osteolysis; estrogen receptor alpha; macrophage
ID TOTAL HIP ARTHROPLASTY; BONE LOSS; INFLAMMATORY RESPONSE; OSTEOCLAST
   FORMATION; DIFFERENTIATION; EXPRESSION; OSTEOBLAST; CELLS; ACID
AB Periprosthetic osteolysis is one of the major long term complications following total joint replacement. Its cause is widely accepted to be wear particle induced activation of inflammatory macrophages. No effective strategy for the prevention and treatment of periprosthetic osteolysis is yet available. Recently, considerable evidence has shown that icariin effectively protects against estrogen deficiency related bone loss and bone deterioration. However, the molecular mechanism underlying the inhibitory effect of icariin on wear particle induced periprosthetic osteolysis is not yet clear. In this study, nanoscale CoCrMo wear particles were obtained by high vacuum three electrode direct current from the femoral head implant of a patient diagnosed with aseptic loosening. The effects of icariin on wear particle induced expression of proinflammatory factors, NF kappa B signaling modulation, osteolysis, and estrogen receptor alpha (ER alpha) activation were evaluated in vitro and in vivo using bone marrow derived macrophages and C57/BL6J mice, respectively. A possible link between ER alpha and the protective effect of icariin was further studied using an ER alpha antagonist and the ER alpha siRNA interference. Chemical composition analysis showed that Cr and Co were the major metallic elements of the nanoscale particles, with a mean size of 150.2 +/  37.4 nm for the CoCrMo particles. Following icariin treatment, significant decreases were observed in CoCrMo wear particle induced TNF alpha and IL 6 mRNA expression in BMDMs, and osteolysis in mice calvaria. Marked decreases in the protein expression level of p IKK beta, p p65 and p I kappa B alpha were also observed, together with significant decreases in the nuclear import of P65 and macrophage M1 polarization. RNA sequencing revealed that ER alpha was closely associated with TNF alpha and IL 6 in wear particle stimulated macrophages. Furthermore, marked increases in phospho ER alpha Ser118 and phospho ER alpha Ser167 protein expression and the nuclear import of ER alpha were also found in the icariin group. The protective effects of icariin on CoCrMo particle induced mouse calvarial osteolysis and on the inflammation response in BMDMs were reversed by ER alpha antagonist and by ER alpha siRNA interference. In conclusion, icariin attenuates wear particle induced inflammation and osteolysis via down regulation of the ER alpha mediated NF kappa B signaling pathway in macrophages. The potential application of icariin as a non hormonal therapy for wear particle induced periprosthetic osteolysis is worthy of further investigation.
C1 [Fu Guangtao; Deng Zhantao; Li Mengyuan; Li Qingtian; Ma Yuanchen; Chen Yuanfeng; Zheng Qiujian] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Orthoped, Guangzhou, Peoples R China.
   [Wen Zhenkang] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Orthoped, Guangzhou, Peoples R China.
   [Chen Yuanfeng] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Res Dept Med Sci, Guangzhou, Peoples R China.
C3 Guangdong Academy of Medical Sciences & Guangdong General Hospital;
   Southern Medical University   China; Sun Yat Sen University; Southern
   Medical University   China; Guangdong Academy of Medical Sciences &
   Guangdong General Hospital
RP Ma, YC; Chen, YF; Zheng, QJ (通讯作者)，Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Orthoped, Guangzhou, Peoples R China.; Chen, YF (通讯作者)，Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Res Dept Med Sci, Guangzhou, Peoples R China.
EM myc998@qq.com; chenyuanfeng@gdph.org.cn; zhengqiujian@gdph.org.cn
RI Fu, Guangtao/AAJ 7483 2020
OI Fu, Guangtao/0000 0003 1071 3680
FU Program of Science and Technology of Guangzhou [202102020050,
   201904010424]; NSFC Incubation Program of GDPH [KY012021163]; Natural
   Science Foundation of China [32000958]; Talent introduction project of
   Guangdong Provincial People's Hospital [KJ012020636]; Natural Science
   Foundation of Guangdong Province [2021A1515011008]
FX This work was supported by the Program of Science and Technology of
   Guangzhou (202102020050), NSFC Incubation Program of GDPH (KY012021163),
   Program of Science and Technology of Guangzhou (201904010424), Natural
   Science Foundation of China (32000958), Talent introduction project of
   Guangdong Provincial People's Hospital (KJ012020636), and the Natural
   Science Foundation of Guangdong Province (2021A1515011008).
CR Arnal JF, 2017, PHYSIOL REV, V97, P1045, DOI 10.1152/physrev.00024.2016
   Bresalier RS, 1997, CANCER, V80, P776
   Cui JF, 2014, J SURG RES, V192, P447, DOI 10.1016/j.jss.2014.05.038
   Davis AM, 2008, J MOL ENDOCRINOL, V41, P205, DOI 10.1677/JME 08 0029
   Deng ZT, 2021, BIOMATER SCI UK, V9, P1291, DOI 10.1039/d0bm01256d
   Ding Y, 2012, BIOMED MATER, V7, DOI 10.1088/1748 6041/7/4/045019
   Eger M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02963
   Fu GT, 2019, ORTHOP SURG, V11, P653, DOI 10.1111/os.12513
   Fu GT, 2018, ARTIF ORGANS, V42, pE259, DOI 10.1111/aor.13271
   Gao XR, 2018, CELL CYCLE, V17, P2134, DOI 10.1080/15384101.2018.1515549
   Goodman SB, 2020, EXPERT REV MED DEVIC, V17, P41, DOI 10.1080/17434440.2020.1702024
   Goodman SB, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122091
   HARRIS WH, 1994, ACTA ORTHOP SCAND, V65, P113, DOI 10.3109/17453679408993734
   Ho MX, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00474
   Hu SH, 2021, BIOMATER SCI UK, V9, P5791, DOI 10.1039/d1bm00563d
   Hu XT, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00385
   James SJ, 2014, BONE JOINT RES, V3, P14, DOI 10.1302/2046 3758.31.2000218
   Kim B, 2018, PHYTOMEDICINE, V51, P181, DOI 10.1016/j.phymed.2018.06.020
   Koenig A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01585
   Li XY, 2018, MOL MED REP, V18, P3483, DOI 10.3892/mmr.2018.9325
   Lin TH, 2017, J BIOMED MATER RES A, V105, P3169, DOI 10.1002/jbm.a.36169
   Nich C, 2013, BIOMATERIALS, V34, P641, DOI 10.1016/j.biomaterials.2012.10.030
   Pincus D, 2020, JAMA J AM MED ASSOC, V323, P1070, DOI 10.1001/jama.2020.0785
   Qiu JX, 2020, BIOMATER SCI UK, V8, P3147, DOI 10.1039/d0bm00147c
   Sawyer A, 2003, BIOTECH HISTOCHEM, V78, P271, DOI 10.1080/10520290310001646668
   Shao HG, 2015, BIOMATERIALS, V60, P92, DOI 10.1016/j.biomaterials.2015.04.048
   Taylor JW, 2018, J ARTHROPLASTY, V33, P491, DOI 10.1016/j.arth.2017.09.047
   von Knoch M, 2004, BIOMATERIALS, V25, P4675, DOI 10.1016/j.biomaterials.2004.02.069
   Wei QS, 2016, BIOMED PHARMACOTHER, V84, P931, DOI 10.1016/j.biopha.2016.09.107
   Xu HY, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12743
   Xu Q, 2019, BIOCHEM BIOPH RES CO, V508, P902, DOI 10.1016/j.bbrc.2018.11.201
   Yu T, 2020, AGING US, V12, P8191, DOI 10.18632/aging.103133
   Zhang C, 2018, J BIOMED NANOTECHNOL, V14, P609, DOI 10.1166/jbn.2018.2533
   Zhang DW, 2016, CALCIFIED TISSUE INT, V99, P187, DOI 10.1007/s00223 016 0138 2
   Zhang G, 2007, J BONE MINER RES, V22, P1072, DOI 10.1359/JBMR.070405
   Zhang SC, 2017, BIOMED PHARMACOTHER, V88, P436, DOI 10.1016/j.biopha.2017.01.050
   Zhou LP, 2021, PHYTOMEDICINE, V82, DOI 10.1016/j.phymed.2020.153413
   Zhou LP, 2020, J ENDOCR SOC, V4, DOI 10.1210/jendso/bvz025
   Zhu KC, 2019, INT IMMUNOPHARMACOL, V76, DOI 10.1016/j.intimp.2019.105865
NR 39
TC 13
Z9 13
U1 0
U2 14
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 3
PY 2021
VL 12
AR 746391
DI 10.3389/fphar.2021.746391
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA WZ5JQ
UT WOS:000720003700001
PM 34803690
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lim, YG
   Kim, HJ
   Kim, JW
   Park, K
AF Lim, Yong Geun
   Kim, Hyun Jung
   Kim, Jin Won
   Park, Kyeongsoon
TI Calcium binding near infrared fluorescent nanoprobe for bone tissue
   imaging
SO JOURNAL OF INDUSTRIAL AND ENGINEERING CHEMISTRY
LA English
DT Article
DE Calcium binding nanoprobe; Alendronate; Copper free click chemistry;
   Intracellular calcium detection; Bone tissue imaging
ID DRUG DELIVERY; BISPHOSPHONATES; FLUOROPHORES; BIOLOGY
AB We report a self assembled calcium binding nanoprobe which emits a near infrared fluorescence (NIRF) signal. We have designed a calcium binding NIRF nanoprobe by chemically coupling alendronate (ALN), a specific targeting ligand, and NIRF emitting Cy5.5 labeled dibenzocyclooctyne, to the two respective ends of azide polyethylene glycol NHS ester. Prepared ALN PEG Cy5.5 forms the self assembled nanostructures and has high affinity for calcium phosphates containing bone minerals. In addition, ALN PEG Cy5.5 can be employed to visualize intracellular calcium ion levels in vitro as well as normal bone tissues in vivo. These results suggest that our calcium binding NIRF nanoprobe has a promising potential for calcium imaging in vitro and in vivo. (C) 2020 The Korean Society of Industrial and Engineering Chemistry. Published by Elsevier B.V. All rights reserved.
C1 [Lim, Yong Geun; Park, Kyeongsoon] Chung Ang Univ, Dept Syst Biotechnol, Gyeonggi Do 17546, South Korea.
   [Kim, Hyun Jung; Kim, Jin Won] Korea Univ, Cardiovasc Ctr, Multimodal Imaging & Theranost Lab, Guro Hosp, Seoul 08308, South Korea.
C3 Chung Ang University; Korea University; Korea University Medicine (KU
   Medicine)
RP Park, K (通讯作者)，Chung Ang Univ, Dept Syst Biotechnol, Gyeonggi Do 17546, South Korea.
EM kspark1223@cau.ac.kr
RI Park, Kyeongsoon/AGQ 9584 2022; Kim, Jin Won/KRP 6036 2024
OI Park, Kyeongsoon/0000 0002 8558 3983; 
FU National Research Foundation of Korea [NRF 2018R1A2B3002001,
   2019M3A9E2066883]
FX This work was supported by grants from the National Research Foundation
   of Korea (NRF 2018R1A2B3002001 and 2019M3A9E2066883).
CR Alexopoulos N, 2009, NAT REV CARDIOL, V6, P681, DOI 10.1038/nrcardio.2009.165
   Alves RDAM, 2014, BMC GENOMICS, V15, DOI 10.1186/1471 2164 15 965
   BACHMAN CH, 1965, NATURE, V206, P1328, DOI 10.1038/2061328a0
   Bao K, 2015, THERANOSTICS, V5, P609, DOI 10.7150/thno.11222
   Bhushan KR, 2007, ANGEW CHEM INT EDIT, V46, P7969, DOI 10.1002/anie.200701216
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cheng ZL, 2012, SCIENCE, V338, P903, DOI 10.1126/science.1226338
   Deiters A, 2003, J AM CHEM SOC, V125, P11782, DOI 10.1021/ja0370037
   Frangioni JV, 2003, CURR OPIN CHEM BIOL, V7, P626, DOI 10.1016/j.cbpa.2003.08.007
   Gartner ZJ, 2009, P NATL ACAD SCI USA, V106, P4606, DOI 10.1073/pnas.0900717106
   Hyun H, 2014, ANGEW CHEM INT EDIT, V53, P10668, DOI 10.1002/anie.201404930
   Jakoby MG, 2000, CURR OPIN NEPHROL HY, V9, P11, DOI 10.1097/00041552 200001000 00003
   JUNG A, 1973, CALC TISS RES, V11, P269, DOI 10.1007/BF02547227
   KAO JPY, 1989, J BIOL CHEM, V264, P8179
   Langdahl B, 2016, THER ADV MUSCULOSKEL, V8, P225, DOI 10.1177/1759720X16670154
   Lee KK, 2019, RSC ADV, V9, P2708, DOI 10.1039/c8ra09729a
   Lee S, 2014, ACS NANO, V8, P2048, DOI 10.1021/nn406584y
   Lu SH, 2019, MAR DRUGS, V17, DOI 10.3390/md17060345
   MARKS SC, 1988, AM J ANAT, V183, P1, DOI 10.1002/aja.1001830102
   Ngo JT, 2009, NAT CHEM BIOL, V5, P715, DOI 10.1038/nchembio.200
   PRENTICE AI, 1967, J CLIN PATHOL, V20, P717, DOI 10.1136/jcp.20.5.717
   Ryu TK, 2016, J CONTROL RELEASE, V232, P152, DOI 10.1016/j.jconrel.2016.04.025
   Sun ST, 2016, BIOCONJUGATE CHEM, V27, P329, DOI 10.1021/acs.bioconjchem.5b00369
   Tang ZR, 2018, REGEN BIOMATER, V5, P43, DOI 10.1093/rb/rbx024
   Uludag H, 2002, CURR PHARM DESIGN, V8, P1929, DOI 10.2174/1381612023393585
   Vaz S, 2019, Q J NUCL MED MOL IM, V63, P112, DOI 10.23736/S1824 4785.19.03198 4
   Wang D, 2003, BIOCONJUGATE CHEM, V14, P853, DOI 10.1021/bc034090j
   Weissleder R, 2003, NAT MED, V9, P123, DOI 10.1038/nm0103 123
   Zaheer A, 2001, NAT BIOTECHNOL, V19, P1148, DOI 10.1038/nbt1201 1148
   Zhao N, 2015, LIFE SCI, V143, P1, DOI 10.1016/j.lfs.2015.10.027
NR 30
TC 8
Z9 8
U1 2
U2 35
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1226 086X
EI 1876 794X
J9 J IND ENG CHEM
JI J. Ind. Eng. Chem.
PD SEP 25
PY 2020
VL 89
BP 442
EP 447
DI 10.1016/j.jiec.2020.06.018
PG 6
WC Chemistry, Multidisciplinary; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Engineering
GA MQ2DD
UT WOS:000552706400044
DA 2025 08 17
ER

PT J
AU Kumar, A
   Anand, T
   Bhattacharyya, J
   Sharma, A
   Jaganathan, BG
AF Kumar, Atul
   Anand, Trishna
   Bhattacharyya, Jina
   Sharma, Amit
   Jaganathan, Bithiah Grace
TI K562 chronic myeloid leukemia cells modify osteogenic differentiation
   and gene expression of bone marrow stromal cells
SO JOURNAL OF CELL COMMUNICATION AND SIGNALING
LA English
DT Article
DE Bone marrow stroma; Osteoblasts; Therapy resistance; IL6, NF kappa B
   signaling; Paracrine factors; Cell cell communication
ID MESENCHYMAL STEM CELLS; NICHE; INHIBITION; ABNORMALITIES; SURVIVAL;
   CD90; MICE
AB Bone marrow (BM) microenvironment plays an important role in normal and malignant hematopoiesis. As a consequence of interaction with the leukemic cells, the stromal cells of the bone marrow become deregulated in their normal function and gene expression. In our study, we found that mesenchymal stem cells (MSC) from BM of chronic myeloid leukemia (CML) patients have defective osteogenic differentiation and on interaction with K562 CML cells, the normal MSC showed reduced osteogenic differentiation. On interaction with K562 cells or its secreted factors, MSC acquired phenotypic abnormalities and secreted high levels of IL6 through NF kappa B activation. The MSC derived secreted factors provided a survival advantage to CML cells from imatinib induced apoptosis. Thus, a therapy targeting stromal cells in addition to leukemia cells might be more effective in eliminating CML cells.
C1 [Kumar, Atul; Anand, Trishna; Sharma, Amit; Jaganathan, Bithiah Grace] Indian Inst Technol Guwahati, Dept Biosci & Bioengn, Stem Cell & Canc Biol Grp, Gauhati, Assam, India.
   [Bhattacharyya, Jina] Gauhati Med Coll, Dept Hematol, Gauhati, Assam, India.
C3 Indian Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT)   Guwahati; Gauhati Medical College & Hospital
RP Jaganathan, BG (通讯作者)，Indian Inst Technol Guwahati, Dept Biosci & Bioengn, Stem Cell & Canc Biol Grp, Gauhati, Assam, India.
EM bithiahgj@iitg.ernet.in
OI Kumar, Atul/0000 0001 9682 5725
FU Indian Council of Medical Research (ICMR); Department of Biotechnology
   (DBT)
FX This work was supported by grants from Indian Council of Medical
   Research (ICMR) to BGJ, JB and Department of Biotechnology (DBT) to BGJ.
   ICMR, DBT did not have any role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Arnulf B, 2007, LEUKEMIA, V21, P158, DOI 10.1038/sj.leu.2404466
   Blau O, 2011, BLOOD, V118, P5583, DOI 10.1182/blood 2011 03 343467
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Campioni D, 2009, CYTOM PART B CLIN CY, V76B, P225, DOI 10.1002/cyto.b.20461
   Chang J, 2013, P NATL ACAD SCI USA, V110, P9469, DOI 10.1073/pnas.1300532110
   Civini S, 2013, J TRANSL MED, V11, DOI 10.1186/1479 5876 11 298
   Geyh S, 2016, LEUKEMIA, V30, P683, DOI 10.1038/leu.2015.325
   Giallongo C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158392
   Huang JC, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.17
   Jaganathan BG, 2010, LEUKEMIA, V24, P1791, DOI 10.1038/leu.2010.164
   Kang K, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/659890
   Kode A, 2016, LEUKEMIA, V30, P1, DOI 10.1038/leu.2015.161
   Kode A, 2014, NATURE, V506, P240, DOI 10.1038/nature12883
   Krause DS, 2015, HAEMATOLOGICA, V100, P1376, DOI 10.3324/haematol.2014.113852
   Krevvata M, 2014, BLOOD, V124, P2834, DOI 10.1182/blood 2013 07 517219
   Kumar A, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 10373 3
   Kumar A, 2016, TUMOR BIOL, V37, P11611, DOI 10.1007/s13277 016 5112 0
   Lévesque JP, 2010, LEUKEMIA, V24, P1979, DOI 10.1038/leu.2010.214
   Lo Celso C, 2011, J CELL SCI, V124, P3529, DOI 10.1242/jcs.074112
   Martinaud C, 2015, CANCER RES, V75, P4753, DOI 10.1158/0008 5472.CAN 14 3696
   Mawrie D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156697
   Morrison SJ, 2014, NATURE, V505, P327, DOI 10.1038/nature12984
   Nievergall E, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.1788.1788
   Pricola KL, 2009, J CELL BIOCHEM, V108, P577, DOI 10.1002/jcb.22289
   Raaijmakers MHGP, 2010, NATURE, V464, P852, DOI 10.1038/nature08851
   Saini AS, 2014, NAT IMMUNOL, V15, P275, DOI 10.1038/ni.2806
   Schmidt T, 2011, CANCER CELL, V19, P740, DOI 10.1016/j.ccr.2011.05.007
   Schroeder T, 2016, BLOOD RES, V51, P225, DOI 10.5045/br.2016.51.4.225
   Semesiuk N., 2013, Experimental Oncology, V35, P295
   Somaiah C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145068
   Sonowal H, 2013, J BIOMED SCI, V20, DOI 10.1186/1423 0127 20 71
   Traer E, 2014, BLOOD, V123, P1516, DOI 10.1182/blood 2013 07 518381
   López AV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084496
   Wallace SR, 2001, CANCER AM CANCER SOC, V91, P1219, DOI 10.1002/1097 0142(20010401)91:7<1219::AID CNCR1122>3.0.CO;2 1
   Wöhrer S, 2007, ANTICANCER RES, V27, P3837
   Xu S, 2012, LEUKEMIA, V26, P2546, DOI 10.1038/leu.2012.126
   Zhang B, 2012, CANCER CELL, V21, P577, DOI 10.1016/j.ccr.2012.02.018
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
NR 38
TC 25
Z9 25
U1 0
U2 6
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1873 9601
EI 1873 961X
J9 J CELL COMMUN SIGNAL
JI J. Cell Commun. Signal
PD JUN
PY 2018
VL 12
IS 2
BP 441
EP 450
DI 10.1007/s12079 017 0412 8
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA HC7FQ
UT WOS:000451966600003
PM 28963654
OA Green Published
DA 2025 08 17
ER

PT J
AU Yang, YF
   Yuan, LY
   Xiong, H
   Guo, KM
   Zhang, MY
   Yan, TT
   Wang, WJ
   Zhou, SP
   Sun, H
   Zhang, S
   Duan, YJ
   Hu, YH
AF Yang, Yanfang
   Yuan, Liying
   Xiong, Hui
   Guo, Kaimin
   Zhang, Mengying
   Yan, Tengteng
   Wang, Wenjia
   Zhou, Shuiping
   Sun, He
   Zhang, Shuang
   Duan, Yajun
   Hu, Yunhui
TI Inhibition of vascular calcification by Compound Danshen Dripping Pill
   through multiple mechanisms
SO PHYTOMEDICINE
LA English
DT Article
DE Vascular calcification; Compound Danshen Dripping Pill; Wnt signaling
   pathway; Sirt1
ID SMOOTH MUSCLE CELLS; ENDOTHELIAL DYSFUNCTION; CELLULAR SENESCENCE;
   SECRETORY PHENOTYPE; PROMOTES; DKK1; MICE
AB Background: Vascular calcification refers to the abnormal accumulation of calcium in the walls of blood vessels and is a risk factor often overlooked in cardiovascular disease. However, there is currently no specific drug for treating vascular calcification. Compound Danshen Dripping Pill (CDDP) is widely used to treat cardiovascular diseases, but its effect on vascular calcification has not been reported. Purpose: We investigated the effects of CDDP on vascular calcification in ApoE /  mice and in vitro and elucidated its mechanism of action. Study design: Firstly, we found that CDDP has the potential to improve calcification based on network pharmacology analysis. Then, we performed the following experiments: in vivo, ApoE /  mice were fed a high fat diet randomly supplemented with CDDP for 16 weeks. Atherosclerosis and vascular calcification were determined. In vitro, human aortic smooth muscle cells (HASMCs), human umbilical vein endothelial cells (HUVECs), and human aortic endothelial cells (HAECs) were used to determine the mechanisms for CDDP inhibited vascular calcification. Results: In this study, we observed that CDDP reduced intimal calcification in atherosclerotic lesions of ApoEdeficient mice fed a high fat diet, as well as the calcification in cultured SMCs and ECs. Mechanistically, CDDP inhibited the Wnt/beta catenin pathway by up regulating the expression of DKK1 and LRP6, which are upstream inhibitors of Wnt, leading to a reduction in the expression of osteoblastic transition markers (ALP, OPN, BMP2, and RUNX2). Furthermore, CDDP enhanced the secretion of DKK1, which plays a role in mediating ECSMC crosstalk in calcification. Additionally, VC contributes to vascular aging by inhibiting Sirt1 and increasing senescence parameters (SA beta gal, p21, and p16). However, CDDP reversed these changes by activating Sirt1. CDDP also reduced the levels of pro inflammatory cytokines and the senescence associated secretory phenotype in vivo and in vitro. Conclusions: Our study suggests that CDDP reduces vascular calcification by regulating the DKK1/LRP6/beta catenin signaling pathway in ECs/SMCs and interactions with the crosstalk of ECs and SMCs. It also reduces the senescence of ECs/SMCs, contributing to the Sirt1 activation, indicating CDDP's novel role in ameliorating vascular calcification.
C1 [Yang, Yanfang; Yuan, Liying] Nankai Univ, Coll Life Sci, State Key Lab Med Chem Biol, Key Lab Bioact Mat,Minist Educ, Tianjin 300071, Peoples R China.
   [Xiong, Hui; Guo, Kaimin; Zhang, Mengying; Wang, Wenjia; Zhou, Shuiping; Sun, He; Hu, Yunhui] Tasly Pharmaceut Grp Co Ltd, Tianjin 300410, Peoples R China.
   [Xiong, Hui; Guo, Kaimin; Zhang, Mengying; Wang, Wenjia; Zhou, Shuiping; Sun, He; Hu, Yunhui] Natl Key Lab Chinese Med Modernizat, Tianjin 301617, Peoples R China.
   [Yan, Tengteng; Zhang, Shuang] Hefei Univ Technol, Key Lab Metab & Regulat Major Dis Anhui Higher Edu, Key Lab Metab & Regulat Major Dis, Hefei 230009, Peoples R China.
   [Duan, Yajun] Univ Sci & Technol China, Affiliated Hosp USTC 1, Dept Cardiol, Div Life Sci & Med, Hefei 230001, Anhui, Peoples R China.
C3 Nankai University; Tasly Holding Group Co Ltd; Hefei University of
   Technology; Chinese Academy of Sciences; University of Science &
   Technology of China, CAS
RP Hu, YH (通讯作者)，Tasly Pharmaceut Grp Co Ltd, Tianjin 300410, Peoples R China.; Hu, YH (通讯作者)，Natl Key Lab Chinese Med Modernizat, Tianjin 301617, Peoples R China.; Duan, YJ (通讯作者)，Univ Sci & Technol China, Affiliated Hosp USTC 1, Dept Cardiol, Div Life Sci & Med, Hefei 230001, Anhui, Peoples R China.
EM yajunduan@ustc.edu.cn; yunhuihu200408@163.com
RI Duan, Yajun/LJK 9029 2024
FU National Natural Science Foundation of China (NSFC) [U22A20272,
   82173807]
FX <BOLD>Funding</BOLD> This work was supported by the National Natural
   Science Foundation of China (NSFC) Grants U22A20272 and 82173807 to
   Yajun Duan.
CR Badi I, 2015, J GERONTOL A BIOL, V70, P1304, DOI 10.1093/gerona/glu180
   Bundy K, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.708470
   Cai T, 2016, EXP CELL RES, V345, P206, DOI 10.1016/j.yexcr.2016.06.007
   Cheng SL, 2015, CIRC RES, V117, P142, DOI 10.1161/CIRCRESAHA.117.306712
   Chi C, 2019, BBA MOL BASIS DIS, V1865, P1810, DOI 10.1016/j.bbadis.2018.08.015
   Davenport C, 2016, INT J BIOCHEM CELL B, V77, P171, DOI 10.1016/j.biocel.2016.06.009
   Durik M, 2012, CIRCULATION, V126, P468, DOI 10.1161/CIRCULATIONAHA.112.104380
   Gong K., 2023, HepatolCommun, V7
   Li X, 2022, J CARDIOVASC TRANSL, V15, P1327, DOI 10.1007/s12265 022 10251 y
   Liu YW, 2013, CIRC RES, V112, pE99, DOI 10.1161/CIRCRESAHA.111.300543
   Loaiza S, 2018, BIOMATERIALS, V183, P102, DOI 10.1016/j.biomaterials.2018.08.041
   Lu CL, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051593
   Nie B, 2019, CURR MED SCI, V39, P28, DOI 10.1007/s11596 019 1996 4
   Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892
   Park B, 2020, J HYPERTENS, V38, P95, DOI 10.1097/HJH.0000000000002217
   Pescatore LA, 2019, ARTERIOSCL THROM VAS, V39, P1307, DOI 10.1161/ATVBAHA.118.311576
   Salama R, 2014, GENE DEV, V28, P99, DOI 10.1101/gad.235184.113
   Sanchis P, 2019, KIDNEY INT, V95, P958, DOI 10.1016/j.kint.2018.12.014
   Schlotter F, 2018, CIRCULATION, V138, P377, DOI 10.1161/CIRCULATIONAHA.117.032291
   Sutton NR, 2023, ARTERIOSCL THROM VAS, V43, P15, DOI 10.1161/ATVBAHA.122.317332
   Szulc P, 2014, J CLIN ENDOCR METAB, V99, P617, DOI 10.1210/jc.2013 3201
   Takemura A, 2011, ARTERIOSCL THROM VAS, V31, P2054, DOI 10.1161/ATVBAHA.110.216739
   Tchkonia T, 2013, J CLIN INVEST, V123, P966, DOI 10.1172/JCI64098
   Tesauro M, 2017, J INTERN MED, V281, P471, DOI 10.1111/joim.12605
   Thambiah S, 2012, CALCIFIED TISSUE INT, V90, P473, DOI 10.1007/s00223 012 9595 4
   van Essen BJ, 2023, EUR J HEART FAIL, V25, P35, DOI 10.1002/ejhf.2695
   Xian JZ, 2021, ARTERIOSCL THROM VAS, V41, pe185, DOI 10.1161/ATVBAHA.120.315737
   Xu SW, 2021, PHARMACOL REV, V73, P924, DOI 10.1124/pharmrev.120.000096
   Xue YJ, 2022, PHYTOMEDICINE, V104, DOI 10.1016/j.phymed.2022.154271
   Yang XY, 2015, SCI REP UK, V5, DOI 10.1038/srep10739
   Yang YF, 2023, ACTA PHARM SIN B, V13, P1036, DOI 10.1016/j.apsb.2022.11.012
   Zeng P, 2021, THERANOSTICS, V11, P1129, DOI 10.7150/thno.49771
   Zhai JH, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/9846325
   Zhao D, 2020, J BIOL CHEM, V295, P16314, DOI 10.1074/jbc.RA120.015486
   Zhao XK, 2023, ACTA PHARMACOL SIN, V44, P1625, DOI 10.1038/s41401 023 01077 8
   Zheng ZD, 2020, MOL MED REP, V22, P247, DOI 10.3892/mmr.2020.11096
NR 36
TC 3
Z9 4
U1 2
U2 8
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944 7113
EI 1618 095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD JUL
PY 2024
VL 129
AR 155618
DI 10.1016/j.phymed.2024.155618
EA APR 2024
PG 12
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA SO5O9
UT WOS:001235408900001
PM 38678949
OA hybrid
DA 2025 08 17
ER

PT J
AU Zhou, JZ
   Riquelme, MA
   Gu, S
   Kar, R
   Gao, X
   Sun, L
   Jiang, JX
AF Zhou, J. Z.
   Riquelme, M. A.
   Gu, S.
   Kar, R.
   Gao, X.
   Sun, L.
   Jiang, J. X.
TI Osteocytic connexin hemichannels suppress breast cancer growth and bone
   metastasis
SO ONCOGENE
LA English
DT Article
ID GAP JUNCTION HEMICHANNELS; HUMAN TUMOR CELLS; PARATHYROID HORMONE;
   IN VIVO; INTERCELLULAR COMMUNICATION; PHYSICAL ACTIVITY; ATP RELEASE;
   FLUID FLOW; SURVIVAL; MICE
AB Although the skeleton is one of the predominant sites for breast cancer metastasis, why breast cancer cells often become dormant after homing to bone is not well understood. Here, we reported an intrinsic self defense mechanism of bone cells against breast cancer cells: a critical role of connexin (Cx) 43 hemichannels in osteocytes in the suppression of breast cancer bone metastasis. Cx43 hemichannels allow passage of small molecules between the intracellular and extracellular environments. The treatment of bisphosphonate drugs, either alendronate (ALN) or zoledronic acid (ZOL), opened Cx43 hemichannels in osteocytes. Conditioned media (CM) collected from MLO Y4 osteocyte cells treated with bisphosphonates inhibited the anchorage independent growth, migration and invasion of MDA MB 231 human breast cancer cells and Py8119 mouse mammary carcinoma cells, and this inhibitory effect was attenuated with Cx43(E2), a specific hemichannel blocking antibody. The opening of osteocytic Cx43 hemichannels by mechanical stimulation had similar inhibitory effects on breast cancer cells and this inhibition was attenuated by Cx43(E2) antibody as well. These inhibitory effects on cancer cells were mediated by ATP released from osteocyte Cx43 hemichannels. Furthermore, both Cx43 osteocyte specific knockout mice and osteocyte specific.130 136 transgenic mice with impaired Cx43 gap junctions and hemichannels showed significantly increased tumor growth and attenuated the inhibitory effect of ZOL. However, R76W transgenic mice with functional hemichannels but not gap junctions in osteocytes did not display a significant difference. Together, our studies establish the specific inhibitory role of osteocytic Cx43 hemichannels, and exploiting the activity of this channel could serve as a de novo therapeutic strategy.
C1 [Zhou, J. Z.; Riquelme, M. A.; Gu, S.; Kar, R.; Gao, X.; Jiang, J. X.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
   [Sun, L.] Dept Cellular & Struct Biol, San Antonio, TX USA.
   [Sun, L.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
C3 University of Texas System; University of Texas Health Science Center at
   San Antonio; University of Texas System; University of Texas Health
   Science Center at San Antonio; Cancer Therapy & Research Center
RP Jiang, JX (通讯作者)，Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM jiangj@uthscsa.edu
RI Jiang, Jia Xing/F 4036 2012; Riquelme, Manuel/B 1082 2015
OI Jiang, Jean/0000 0002 2185 5716; 
FU Welch Foundation [AQ 1507]; NIH [EY012085, ES022057]; NCI Cancer Center
   grant [2 P30 CA054174 17]
FX We thank Hongyun Cheng for technical assistance, Dr Lesley Ellies at the
   University of California at San Diego for providing Py8119 cells, Dr
   Lynda Bonewald at the University of Missouri at Kansas City for MLO Y4
   osteocytic cells, Dr Stephen Harris at UTHSCSA for 10 kb dentin matrix
   protein 1 (DMP1) Cre mice and Dr Klaus Willecke at the University of
   Bonn and Dr Roberto Civitelli for mice with floxed Cx43 gene. The work
   was supported by Welch Foundation grant AQ 1507 and NIH grant EY012085
   to JXJ, ES022057 to LZS and the NCI Cancer Center grant 2 P30
   CA054174 17 to Cancer Therapy and Research Center.
CR AARDEN EM, 1994, J CELL BIOCHEM, V55, P287, DOI 10.1002/jcb.240550304
   Avanzo JL, 2004, CARCINOGENESIS, V25, P1973, DOI 10.1093/carcin/bgh193
   Bennett MVL, 2012, BRAIN RES, V1487, P3, DOI 10.1016/j.brainres.2012.08.042
   Bivi N, 2013, J ORTHOP RES, V31, P1075, DOI 10.1002/jor.22341
   Bivi N, 2012, J BONE MINER RES, V27, P374, DOI 10.1002/jbmr.548
   Bonewald LF, 2007, ANN NY ACAD SCI, V1116, P281, DOI 10.1196/annals.1402.018
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Brown Sue A, 2007, Curr Osteoporos Rep, V5, P120
   Calder BW, 2015, TISSUE ENG PT A, V21, P1752, DOI [10.1089/ten.tea.2014.0651, 10.1089/ten.TEA.2014.0651]
   Cheng BX, 2001, J BONE MINER RES, V16, P249, DOI 10.1359/jbmr.2001.16.2.249
   Cherian PP, 2005, MOL BIOL CELL, V16, P3100, DOI 10.1091/mbc.E04 10 0912
   Cherian PP, 2008, CELL COMMUN ADHES, V15, P43, DOI 10.1080/15419060802310208
   Chung DJ, 2006, J CELL SCI, V119, P4187, DOI 10.1242/jcs.03162
   Cronier L, 2009, ANTIOXID REDOX SIGN, V11, P323, DOI 10.1089/ars.2008.2153
   D'hondt C, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00348
   Dbouk HA, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478 811X 7 4
   Elzarrad MK, 2008, BMC MED, V6, DOI 10.1186/1741 7015 6 20
   Evans WH, 2006, BIOCHEM J, V397, P1, DOI 10.1042/BJ20060175
   Genetos DC, 2007, J CELL PHYSIOL, V212, P207, DOI 10.1002/jcp.21021
   Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355
   Goodenough DA, 2003, NAT REV MOL CELL BIO, V4, P285, DOI 10.1038/nrm1072
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Holick CN, 2008, CANCER EPIDEM BIOMAR, V17, P379, DOI 10.1158/1055 9965.EPI 07 0771
   Irwin ML, 2011, CANCER PREV RES, V4, P522, DOI 10.1158/1940 6207.CAPR 10 0295
   Jiang JX, 2007, FRONT BIOSCI LANDMRK, V12, P1450, DOI 10.2741/2159
   Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618
   Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014
   Kato Y, 2001, J BONE MINER RES, V16, P1622, DOI 10.1359/jbmr.2001.16.9.1622
   Klein Nulend J, 2013, BONE, V54, P182, DOI 10.1016/j.bone.2012.10.013
   Kohno N, 2008, INT J CLIN ONCOL, V13, P18, DOI 10.1007/s10147 007 0726 2
   Kretschmann KL, 2012, CANCER METAST REV, V31, P579, DOI 10.1007/s10555 012 9378 4
   Laird DW, 1999, CANCER RES, V59, P4104
   Laird DW, 2006, BIOCHEM J, V394, P527, DOI 10.1042/BJ20051922
   Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241
   Loiselle AE, 2013, J ORTHOP RES, V31, P147, DOI 10.1002/jor.22178
   Lynch ME, 2013, J BONE MINER RES, V28, P2357, DOI 10.1002/jbmr.1966
   Matsuo K, 2009, CURR OPIN NEPHROL HY, V18, P292, DOI 10.1097/MNH.0b013e32832b75f1
   Mesnil M, 2005, BBA BIOMEMBRANES, V1719, P125, DOI 10.1016/j.bbamem.2005.11.004
   Mesnil M, 2002, BIOL CELL, V94, P493, DOI 10.1016/S0248 4900(02)00025 4
   Milne HM, 2008, BREAST CANCER RES TR, V108, P279, DOI 10.1007/s10549 007 9602 z
   Orellana JA, 2012, GLIA, V60, P53, DOI 10.1002/glia.21246
   Orellana JA, 2011, J NEUROSCI, V31, P4962, DOI 10.1523/JNEUROSCI.6417 10.2011
   Orellana JA, 2011, J NEUROCHEM, V118, P826, DOI 10.1111/j.1471 4159.2011.07210.x
   Paget S., LANCET, V1, P571, DOI DOI 10.1016/S0140 6736(00)49915 0
   Place AE, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2912
   Plante I, 2011, ONCOGENE, V30, P1681, DOI 10.1038/onc.2010.551
   Plotkin LI, 2001, CELL COMMUN ADHES, V8, P377, DOI 10.3109/15419060109080757
   Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200
   Plotkin LI, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00131
   RAPAPORT E, 1983, CANCER RES, V43, P4402
   Riquelme MA, 2013, NEUROPHARMACOLOGY, V75, P525, DOI 10.1016/j.neuropharm.2013.02.021
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sáez JC, 2003, ACTA PHYSIOL SCAND, V179, P9, DOI 10.1046/j.1365 201X.2003.01196.x
   Sáez JC, 2003, PHYSIOL REV, V83, P1359, DOI 10.1152/physrev.00007.2003
   Savariar EN, 2013, CANCER RES, V73, P855, DOI 10.1158/0008 5472.CAN 12 2969
   Schwartz AL, 2007, ONCOL NURS FORUM, V34, P627, DOI 10.1188/07.ONF.627 633
   Shabbir M, 2009, INT J UROL, V16, P143, DOI 10.1111/j.1442 2042.2008.02207.x
   Siller Jackson AJ, 2008, J BIOL CHEM, V283, P26374, DOI 10.1074/jbc.M803136200
   Stains JP, 2005, BBA BIOMEMBRANES, V1719, P69, DOI 10.1016/j.bbamem.2005.10.012
   Sterling Julie A, 2011, Curr Osteoporos Rep, V9, P89, DOI 10.1007/s11914 011 0052 5
   Stoletov K, 2013, J CELL SCI, V126, P904, DOI 10.1242/jcs.112748
   Theis M, 2001, GENESIS, V29, P1, DOI 10.1002/1526 968X(200101)29:1<1::AID GENE1000>3.0.CO;2 0
   Theriault RL, 2012, CANCER CONTROL, V19, P92, DOI 10.1177/107327481201900203
   Van der Pluijm G, 2001, J BONE MINER RES, V16, P1077, DOI 10.1359/jbmr.2001.16.6.1077
   Welch D. R., 2003, Journal of Musculoskeletal & Neuronal Interactions, V3, P30
   White N, 2006, TRENDS PHARMACOL SCI, V27, P211, DOI 10.1016/j.tips.2006.02.004
   Xu HY, 2014, J BONE MINER RES, V29, pS430
   Xu HY, 2015, J BONE MINER RES, V30, P550, DOI 10.1002/jbmr.2374
   Yang WC, 2005, J BIOL CHEM, V280, P20680, DOI 10.1074/jbc.M500104200
   Zhang W, 2011, BIOCHEM PHARMACOL, V82, P411, DOI 10.1016/j.bcp.2011.05.009
   Zhang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023516
   Zhou JZ, 2015, ONCOGENE, V34, P1831, DOI 10.1038/onc.2014.113
   Zhou JZ, 2014, FEBS LETT, V588, P1186, DOI 10.1016/j.febslet.2014.01.001
NR 74
TC 76
Z9 86
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950 9232
EI 1476 5594
J9 ONCOGENE
JI Oncogene
PD OCT 27
PY 2016
VL 35
IS 43
BP 5597
EP 5607
DI 10.1038/onc.2016.101
PG 11
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA EA9XP
UT WOS:000386998300003
PM 27041582
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Jin, FJ
   Li, JH
   Zhang, YB
   Liu, XN
   Cai, MX
   Liu, MJ
   Li, MY
   Ma, C
   Yue, R
   Zhu, YX
   Lai, RF
   Wang, ZL
   Ji, XM
   Wei, HW
   Dong, J
   Liu, ZD
   Wang, YF
   Sun, Y
   Wang, XG
AF Jin, Fujun
   Li, Junhui
   Zhang, Yong Biao
   Liu, Xiangning
   Cai, Mingxiang
   Liu, Meijing
   Li, Mengyao
   Ma, Cui
   Yue, Rui
   Zhu, Yexuan
   Lai, Renfa
   Wang, Zuolin
   Ji, Xunming
   Wei, Huawei
   Dong, Jun
   Liu, Zhiduo
   Wang, Yifei
   Sun, Yao
   Wang, Xiaogang
TI A functional motif of long noncoding RNA Nron against osteoporosis
SO NATURE COMMUNICATIONS
LA English
DT Article
ID ESTROGEN RECEPTOR; OSTEOCLASTS; CANCER; DIFFERENTIATION; MECHANISMS;
   MODELS; LIGAND
AB Long noncoding RNAs are widely implicated in diverse disease processes. Nonetheless, their regulatory roles in bone resorption are undefined. Here, we identify lncRNA Nron as a critical suppressor of bone resorption. We demonstrate that osteoclastic Nron knockout mice exhibit an osteopenia phenotype with elevated bone resorption activity. Conversely, osteoclastic Nron transgenic mice exhibit lower bone resorption and higher bone mass. Furthermore, the pharmacological overexpression of Nron inhibits bone resorption, while caused apparent side effects in mice. To minimize the side effects, we further identify a functional motif of Nron. The delivery of Nron functional motif to osteoclasts effectively reverses bone loss without obvious side effects. Mechanistically, the functional motif of Nron interacts with E3 ubiquitin ligase CUL4B to regulate ER alpha stability. These results indicate that Nron is a key bone resorption suppressor, and the lncRNA functional motif could potentially be utilized to treat diseases with less risk of side effects. LncRNAs are implicated in the pathogenesis of a number of diseases. Here, the authors show that the lncRNA Nron suppresses bone resorption, and show that delivery of a functional motif of Nron increases bone mass in mouse models of osteoporosis.
C1 [Jin, Fujun; Liu, Xiangning; Cai, Mingxiang; Lai, Renfa; Wang, Xiaogang] Jinan Univ, Affiliated Hosp 1, Clin Res Platform Interdiscipline Stomatol, Guangzhou, Peoples R China.
   [Jin, Fujun; Liu, Xiangning; Cai, Mingxiang; Lai, Renfa; Wang, Xiaogang] Jinan Univ, Coll Stomatol, Dept Stomatol, Guangzhou, Peoples R China.
   [Jin, Fujun; Zhang, Yong Biao; Liu, Meijing; Ma, Cui; Wang, Xiaogang] Beihang Univ, Sch Engn Med, Beijing Adv Innovat Ctr Big Data Based Precis Med, Beijing, Peoples R China.
   [Li, Junhui; Cai, Mingxiang; Wang, Zuolin; Sun, Yao] Tongji Univ, Shanghai Engn Res Ctr Tooth Restorat & Regenerat, Sch Stomatol, Dept Oral Implantol, Shanghai, Peoples R China.
   [Liu, Xiangning; Zhu, Yexuan; Dong, Jun; Wang, Yifei] Jinan Univ, Guangzhou Jinan Biomed Res & Dev Ctr, Natl Engn Res Ctr Genet Med, Coll Life Sci & Technol,Inst Biomed, Guangzhou, Peoples R China.
   [Li, Mengyao; Liu, Zhiduo] Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Immunol, Dept Immunol & Microbiol, Shanghai, Peoples R China.
   [Yue, Rui] Tongji Univ, Shanghai East Hosp, Sch Life Sci & Technol,Frontier Sci Ctr Stem Cell, Inst Regenerat Med,Shanghai Key Lab Signaling & D, Shanghai, Peoples R China.
   [Ji, Xunming] Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Wei, Huawei] Capital Med Univ, Xuanwu Hosp, China Amer Inst Neurosci, Beijing, Peoples R China.
   [Wei, Huawei] Zeki Biotechnol & Pharmaceut Co Ltd, Beijing, Peoples R China.
C3 Jinan University; Jinan University; Beihang University; Tongji
   University; Jinan University; Shanghai Jiao Tong University; Chinese
   Academy of Sciences; Tongji University; Capital Medical University;
   Capital Medical University
RP Wang, XG (通讯作者)，Jinan Univ, Affiliated Hosp 1, Clin Res Platform Interdiscipline Stomatol, Guangzhou, Peoples R China.; Wang, XG (通讯作者)，Jinan Univ, Coll Stomatol, Dept Stomatol, Guangzhou, Peoples R China.; Wang, XG (通讯作者)，Beihang Univ, Sch Engn Med, Beijing Adv Innovat Ctr Big Data Based Precis Med, Beijing, Peoples R China.; Sun, Y (通讯作者)，Tongji Univ, Shanghai Engn Res Ctr Tooth Restorat & Regenerat, Sch Stomatol, Dept Oral Implantol, Shanghai, Peoples R China.; Wang, YF (通讯作者)，Jinan Univ, Guangzhou Jinan Biomed Res & Dev Ctr, Natl Engn Res Ctr Genet Med, Coll Life Sci & Technol,Inst Biomed, Guangzhou, Peoples R China.
EM twangyf@jnu.edu.cn; yaosun@tongji.edu.cn; xiaogangwang@buaa.edu.cn
RI wang, Xiaogang/J 5003 2017; Ji, Xunming/AAN 3370 2021; Zhang,
   Yongbiao/KLB 9206 2024; Li, Junhui/ITV 9904 2023; cai,
   mingxiang/IYT 1913 2023; sun, yao/MEP 9275 2025; LI,
   MENGYAO/AAY 8923 2021
OI Jin, Fujun/0000 0002 7314 0085; sun, yao/0000 0002 4323 0506; Yue,
   Rui/0000 0002 3401 369X; 
FU National Natural Science Foundation Projects of China [92049201,
   81770873, 81802193, 81822012, 81771043, 31870871, 82061130222, 32070901,
   31671313]; National Key Research and Development Program of China
   [2016YFC1102705, 2018YFE0202200]; Shanghai Health System [2017BR009];
   Shanghai Science and Technology Commission [17ZR1425000, 201409006400,
   20XD1424000]; Guangdong Natural Science Funds [2018A030313604]; General
   Financial Grant from the China Postdoctoral Science Foundation
   [2017M622900, 2020M680303]
FX This research was supported by the National Natural Science Foundation
   Projects of China (No. 92049201, 81770873, 81802193, 81822012, 81771043,
   31870871, 82061130222, 32070901 and 31671313); The National Key Research
   and Development Program of China (No. 2016YFC1102705 and
   2018YFE0202200); Shanghai Health System (No. 2017BR009); Shanghai
   Science and Technology Commission (No. 17ZR1425000, 201409006400 and
   20XD1424000); Guangdong Natural Science Funds (No. 2018A030313604);
   General Financial Grant from the China Postdoctoral Science Foundation
   (No. 2017M622900 and 2020M680303).
CR Almeida M, 2017, PHYSIOL REV, V97, P135, DOI 10.1152/physrev.00033.2015
   Arun G, 2018, TRENDS MOL MED, V24, P257, DOI 10.1016/j.molmed.2018.01.001
   Awasthi H, 2018, MED RES REV, V38, P2024, DOI 10.1002/med.21504
   Basak P, 2018, CELL PHYSIOL BIOCHEM, V51, P1518, DOI 10.1159/000495643
   Beermann J, 2016, PHYSIOL REV, V96, P1297, DOI 10.1152/physrev.00041.2015
   Boon RA, 2016, J AM COLL CARDIOL, V67, P1214, DOI 10.1016/j.jacc.2015.12.051
   Brown C, 2017, NATURE, V550, pS15, DOI 10.1038/550S15a
   Cai MX, 2017, INT J NANOMED, V12, P7469, DOI 10.2147/IJN.S139775
   Chang YY, 2020, BONE, V130, DOI 10.1016/j.bone.2019.115072
   Cherng JY, 2013, INT J PHARMACEUT, V450, P145, DOI 10.1016/j.ijpharm.2013.04.063
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Fiorenzano A, 2018, STEM CELL REP, V10, P1102, DOI 10.1016/j.stemcr.2018.01.014
   Guañabens N, 2015, CLIN REV BONE MINER, V13, P83, DOI 10.1007/s12018 015 9185 x
   Hosono Y, 2017, CELL, V171, P1559, DOI 10.1016/j.cell.2017.11.040
   Hu HB, 2018, EUR REV MED PHARMACO, V22, P1987, DOI 10.26355/eurrev_201804_14726
   Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040
   Hudson WH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6395
   Kim J, 2019, CELL METAB, V30, P434, DOI 10.1016/j.cmet.2019.08.013
   Komori T, 2015, EUR J PHARMACOL, V759, P287, DOI 10.1016/j.ejphar.2015.03.028
   Kung JTY, 2013, GENETICS, V193, P651, DOI 10.1534/genetics.112.146704
   Lee CP, 2019, ENVIRON TOXICOL, V34, P179, DOI 10.1002/tox.22672
   Li AP, 2004, CHEM BIOL INTERACT, V150, P3, DOI 10.1016/j.cbi.2004.09.008
   Li CJ, 2018, J CLIN INVEST, V128, P5251, DOI 10.1172/JCI99044
   Li ZH, 2017, MOL MED REP, V16, P8380, DOI 10.3892/mmr.2017.7625
   Lin NW, 2014, MOL CELL, V53, P1005, DOI 10.1016/j.molcel.2014.01.021
   Liu C, 2019, J CELL PHYSIOL, V234, P1606, DOI 10.1002/jcp.27031
   Liu J, 2015, BIOMATERIALS, V52, P148, DOI 10.1016/j.biomaterials.2015.02.007
   Manolagas SC, 2013, NAT REV ENDOCRINOL, V9, P699, DOI 10.1038/nrendo.2013.179
   Marín Béjar O, 2017, GENOME BIOL, V18, DOI 10.1186/s13059 017 1331 y
   Moon YJ, 2019, CELL DEATH DIFFER, V26, P2358, DOI 10.1038/s41418 019 0306 9
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Ohtake F, 2007, NATURE, V446, P562, DOI 10.1038/nature05683
   Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159 8290.CD 11 0209
   Quan HY, 2018, CELL PHYSIOL BIOCHEM, V46, P401, DOI 10.1159/000488474
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rooney AM, 2017, ANN NY ACAD SCI, V1410, P85, DOI 10.1111/nyas.13523
   Silva AM, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0048 9
   Snaebjornsson MT, 2020, CELL METAB, V31, P62, DOI 10.1016/j.cmet.2019.11.010
   Sun Y, 2019, NAT METAB, V1, P485, DOI 10.1038/s42255 019 0053 8
   Tabatabaei Malazy O, 2017, DARU, V25, DOI 10.1186/s40199 017 0167 z
   Teitelbaum SL, 2010, CELL STEM CELL, V7, P553, DOI 10.1016/j.stem.2010.10.004
   Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002
   Unzu C, 2012, J TRANSL MED, V10, DOI 10.1186/1479 5876 10 122
   Wang D, 2007, BIOCONJUGATE CHEM, V18, P1375, DOI 10.1021/bc7002132
   Wang Y, 2018, CELL PHYSIOL BIOCHEM, V47, P2291, DOI 10.1159/000491539
   Wang ZH, 2016, NAT MED, V22, P1131, DOI 10.1038/nm.4179
   Wapinski O, 2011, TRENDS CELL BIOL, V21, P354, DOI 10.1016/j.tcb.2011.04.001
   Weske S, 2018, NAT MED, V24, P667, DOI 10.1038/s41591 018 0005 y
   Willingham AT, 2005, SCIENCE, V309, P1570, DOI 10.1126/science.1115901
   Wu QY, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00587
   Yang L, 2019, MOL THER, V27, P394, DOI 10.1016/j.ymthe.2018.11.019
   Yang SH, 2018, J BONE MINER RES, V33, P1799, DOI 10.1002/jbmr.3479
   Yao RW, 2019, NAT CELL BIOL, V21, P542, DOI 10.1038/s41556 019 0311 8
   Yu F, 2019, ARCH OSTEOPOROS, V14, DOI 10.1007/s11657 018 0549 y
   Zhou W, 2014, NAT REV CANCER, V14, P26, DOI 10.1038/nrc3622
   Zhu QQ, 2011, AM J HUM GENET, V88, P458, DOI 10.1016/j.ajhg.2011.03.008
NR 58
TC 44
Z9 45
U1 6
U2 96
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUN 3
PY 2021
VL 12
IS 1
AR 3319
DI 10.1038/s41467 021 23642 7
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA SS2LF
UT WOS:000661572200004
PM 34083547
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Jung, JY
   Yoo, CI
   Kim, HT
   Kwon, CH
   Park, JY
   Kim, YK
AF Jung, Ju Young
   Yoo, Chong Il
   Kim, Hui Taek
   Kwon, Chae Hwa
   Park, Ji Yeon
   Kim, Yong Keun
TI Role of mitogen activated protein kinase (MAPK) in troglitazone induced
   osteoblastic cell death
SO TOXICOLOGY
LA English
DT Article
DE troglitazone; apoptosis; MAPK; mitochondrial membrane potential;
   caspase; osteoblasts
ID PPAR GAMMA AGONISTS; RECEPTOR GAMMA; OXIDATIVE STRESS; DOWN REGULATION;
   APOPTOSIS; GROWTH; INDUCTION; LIGAND; INHIBITION; SURVIVAL
AB Troglitazone, a PPAR gamma agonist, has been reported to induce cell death on different cell types. However, its mechanism of action remains unclear. The present study was undertaken to investigate the effect of troglitazone on cell death and to determine its underlying mechanism in MC3T3 E1 cells, an established osteoblast cell line. Troglitazone induced loss of cell viability in a dose  and time dependent manner, which was accompanied by apoptosis. Troglitazone increased reactive oxygen species (ROS), but troglitazone induced cell death was not affected by the antioxidant N acetylcysteine, suggesting that the ROS generation is not involved in the cytotoxicity of troglitazone. Troglitazone induced cell death was prevented by the PPAR gamma antagonist GW9662. Troglitazone treatment inhibited activation of extracellular signal regulated protein kinase (ERK) and stimulated p38 activation. Troglitazone induced cell death was increased by the ERK inhibitor U0126 and prevented by transfection with constitutively active MEK1 and the p38 inhibitor SB203580. Troglitazone induced depolarization of mitochondrial membrane potential and its effect was blocked by SB203580 and GW9662. Caspase 3 was activated by troglitazone treatment and pharmacological inhibition of caspase blocked troglitazone induced cell death. Taken together, these data suggest that troglitazone induces apoptosis via a caspase dependent mechanism associated with down regulation of ERK and up regulation of p38. (C) 2007 Elsevier Ireland Ltd. All rights reserved.
C1 Pusan Natl Univ, Coll Med, Dept Physiol, Pusan 602739, South Korea.
   Pusan Natl Univ, Coll Med, Dept Orthoped Surg, Pusan 602739, South Korea.
   Pusan Natl Univ, Coll Med, MRC Ischem Tissue Regenerat, Pusan 602739, South Korea.
C3 Pusan National University; Pusan National University; Pusan National
   University Hospital; Pusan National University
RP Kim, YK (通讯作者)，Pusan Natl Univ, Coll Med, Dept Physiol, Pusan 602739, South Korea.
EM kim430@pusan.ac.kr
CR Akasaki Y, 2006, J BIOL CHEM, V281, P6165, DOI 10.1074/jbc.M505266200
   Aoun P, 2003, EUR J PHARMACOL, V472, P65, DOI 10.1016/S0014 2999(03)01867 3
   Atarod EB, 2004, FREE RADICAL BIO MED, V37, P36, DOI 10.1016/j.freeradbiomed.2004.04.015
   Bruemmer D, 2003, CIRC RES, V93, pE38, DOI 10.1161/01.RES.0000088344.15288.E6
   Chen F, 2003, J CELL BIOCHEM, V90, P732, DOI 10.1002/jcb.10668
   Clay CE, 2000, PROSTAG OTH LIPID M, V62, P23, DOI 10.1016/S0090 6980(00)00073 3
   Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079 6107(98)00056 X
   Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001
   DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022 1759(86)90368 6
   Fujiwara T, 2000, LIFE SCI, V67, P2405, DOI 10.1016/S0024 3205(00)00829 8
   Gardner OS, 2003, J BIOL CHEM, V278, P46261, DOI 10.1074/jbc.M307827200
   Grommes C, 2004, LANCET ONCOL, V5, P419, DOI 10.1016/S1470 2045(04)01509 8
   Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709
   Kim EJ, 2003, J PHARMACOL EXP THER, V307, P505, DOI 10.1124/jpet.103.053876
   Kim SH, 2006, TOXICOL APPL PHARM, V215, P198, DOI 10.1016/j.taap.2006.03.001
   Kondo M, 2001, J BIOL CHEM, V276, P12076, DOI 10.1074/jbc.M009630200
   Krämer DK, 2005, DIABETES, V54, P1157, DOI 10.2337/diabetes.54.4.1157
   Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619
   Leesnitzer LM, 2002, BIOCHEMISTRY US, V41, P6640, DOI 10.1021/bi0159581
   LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953
   Lennon AM, 2002, J BIOL CHEM, V277, P29681, DOI 10.1074/jbc.M201517200
   Li LY, 2001, J BIOL CHEM, V276, P38152
   Li MY, 2005, J CELL BIOCHEM, V96, P760, DOI 10.1002/jcb.20474
   LIM M, 2006, J CELL PHYSL, V209, P428
   Lovekamp Swan T, 2005, MOL CELL ENDOCRINOL, V233, P15, DOI 10.1016/j.mce.2005.01.011
   Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119
   Motomura W, 2005, BIOCHEM BIOPH RES CO, V332, P89, DOI 10.1016/j.bbrc.2005.04.095
   Murphy GJ, 2000, TRENDS PHARMACOL SCI, V21, P469, DOI 10.1016/S0165 6147(00)01559 5
   Narayanan PK, 2003, CYTOM PART A, V52A, P28, DOI 10.1002/cyto.a.10011
   Nikitakis NG, 2002, BRIT J CANCER, V87, P1396, DOI 10.1038/sj.bjc.6600618
   Nishijima C, 2001, J NEUROCHEM, V76, P383, DOI 10.1046/j.1471 4159.2001.00039.x
   Pandhare J, 2006, J BIOL CHEM, V281, P2044, DOI 10.1074/jbc.M507867200
   Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770
   PASTORINO JG, 1993, J BIOL CHEM, V268, P13791
   Pérez Ortiz JM, 2004, J BIOL CHEM, V279, P8976, DOI 10.1074/jbc.M308518200
   Piva R, 2005, BLOOD, V105, P1750, DOI 10.1182/blood 2004 04 1360
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200
   Shan ZZ, 2004, J BIOL CHEM, V279, P37939, DOI 10.1074/jbc.M402424200
   Strakova N, 2005, NEOPLASMA, V52, P126
   Teruel T, 2003, J BIOL CHEM, V278, P263, DOI 10.1074/jbc.M207200200
   Tsuchiya T, 2003, AM J NEPHROL, V23, P222, DOI 10.1159/000072053
   Ward C, 2002, J IMMUNOL, V168, P6232, DOI 10.4049/jimmunol.168.12.6232
   Willson TM, 2001, ANNU REV BIOCHEM, V70, P341, DOI 10.1146/annurev.biochem.70.1.341
   XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326
   Yamakawa Karakida N, 2002, CELL DEATH DIFFER, V9, P513, DOI 10.1038/sj.cdd.4401000
   Yoshida K, 2003, ANTICANCER RES, V23, P267
   Zander T, 2002, J NEUROCHEM, V81, P1052, DOI 10.1046/j.1471 4159.2002.00899.x
NR 48
TC 27
Z9 43
U1 1
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0300 483X
EI 1879 3185
J9 TOXICOLOGY
JI Toxicology
PD MAY 5
PY 2007
VL 234
IS 1 2
BP 73
EP 82
DI 10.1016/j.tox.2007.02.005
PG 10
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA 165AI
UT WOS:000246275800008
PM 17363128
DA 2025 08 17
ER

PT J
AU Warren, JT
   Zou, W
   Decker, CE
   Rohatgi, N
   Nelson, CA
   Fremont, DH
   Teitelbaum, SL
AF Warren, Julia T.
   Zou, Wei
   Decker, Corinne E.
   Rohatgi, Nidhi
   Nelson, Christopher A.
   Fremont, Daved H.
   Teitelbaum, Steven L.
TI Correlating RANK Ligand/RANK Binding Kinetics With Osteoclast Formation
   and Function
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE OSTEOCLAST; SIGNAL TRANSDUCTION; KINETICS; RANK; RANKL; TNF SUPERFAMILY;
   BONE; RECEPTOR
ID TUMOR NECROSIS FACTOR; TNF SUPERFAMILY MEMBERS; T CELL RESPONSIVENESS;
   SIGNAL TRANSDUCTION; RECEPTOR SUPERFAMILY; BIOLOGY; SYSTEM; DEATH;
   DIFFERENTIATION; OSTEOPROTEGERIN
AB The interaction between Receptor Activator of NF B Ligand (RANKL) and its receptor RANK is essential for the differentiation and bone resorbing capacity of the osteoclast. Osteoprotegerin (OPG), a soluble homodimer, acts as a decoy receptor for RANKL and thus inhibits osteoclastogenesis. An imbalance in the RANKL/RANK/OPG axis, with decreased OPG and/or increased RANKL, is associated with diseases that favor bone loss, including osteoporosis. Recently, we established a yeast surface display system and screened libraries of randomly mutated RANKL proteins to identify mutations that abolish binding to OPG while preserving recognition of RANK. These efforts yielded several RANKL variants possessing substantially higher affinity for RANK compared to their wild type (WT) counterpart. Using recombinant RANKL mutant proteins, we find those with increased affinity for RANK produce more robust signaling in osteoclast lineage cells and have greater osteoclastogenic potential. Our results are the first to document gain of function RANKL mutations. They indicate that the physiological RANKL/RANK interaction is not optimized for maximal signaling and function, perhaps reflecting the need to maintain receptor specificity within the tumor necrosis factor superfamily (TNFSF). Instead, we find, a biphasic relationship exists between RANKL/RANK affinity and osteoclastogenic capacity. In our panel of RANKL variants, this relationship is driven entirely by manipulation of the kinetic off rate. Our structure based and yeast surface display derived insights into manipulating this critical signaling axis may aid in the design of novel anti resorptive therapies as well as provide a paradigm for design of other receptor specific TNF superfamily ligand variants. J. Cell. Biochem. 116: 2476 2483, 2015. (c) 2015 Wiley Periodicals, Inc.
C1 [Warren, Julia T.; Zou, Wei; Rohatgi, Nidhi; Nelson, Christopher A.; Fremont, Daved H.; Teitelbaum, Steven L.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA.
   [Decker, Corinne E.] Washington Univ, Sch Med, Dept Orthopaed Surg, St Louis, MO USA.
   [Teitelbaum, Steven L.] Washington Univ, Sch Med, Dept Med, Div Bone & Mineral Dis, St Louis, MO 63110 USA.
C3 Washington University (WUSTL); Washington University (WUSTL); Washington
   University (WUSTL)
RP Teitelbaum, SL (通讯作者)，Dept Pathol & Immunol, Campus Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.
EM teitelbs@wustl.edu
RI Rohatgi, Nidhi/GWR 1096 2022
OI Fremont, Daved/0000 0002 8544 2689; Warren, Julia/0000 0003 2017 6444;
   Teitelbaum, Steven/0000 0002 4054 6679
FU National Institutes of Health [R01 AR032788, R01 AR057037, R01 AR046523,
   P30 AR057235, F30 AG039896]; Shriner's Hospital for Children [85400 STL]
FX Grant sponsor: National Institutes of Health; Grant numbers: R01
   AR032788, R01 AR057037, R01 AR046523, P30 AR057235, F30 AG039896; Grant
   sponsor: Shriner's Hospital for Children; Grant number: 85400 STL.
CR Abu Amer Y, 2000, J BIOL CHEM, V275, P27307
   AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679
   Aggarwal BB, 2012, BLOOD, V119, P651, DOI 10.1182/blood 2011 04 325225
   Aricescu AR, 2006, ACTA CRYSTALLOGR D, V62, P1243, DOI 10.1107/S0907444906029799
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Ban LQ, 2008, P NATL ACAD SCI USA, V105, P13644, DOI 10.1073/pnas.0803429105
   Blair HC, 2005, BIOCHEM BIOPH RES CO, V328, P728, DOI 10.1016/j.bbrc.2004.11.077
   Bodmer JL, 2002, TRENDS BIOCHEM SCI, V27, P19, DOI 10.1016/S0968 0004(01)01995 8
   Boschert V, 2010, CELL SIGNAL, V22, P1088, DOI 10.1016/j.cellsig.2010.02.011
   Cabal Hierro L, 2012, CELL SIGNAL, V24, P1297, DOI 10.1016/j.cellsig.2012.02.006
   Chervin AS, 2009, J IMMUNOL, V183, P1166, DOI 10.4049/jimmunol.0900054
   Cheung TC, 2010, J IMMUNOL, V185, P1949, DOI 10.4049/jimmunol.1001159
   Croft M, 2013, NAT REV DRUG DISCOV, V12, P147, DOI 10.1038/nrd3930
   Croft M, 2009, NAT REV IMMUNOL, V9, P271, DOI 10.1038/nri2526
   deLuca LS, 2012, NAT REV IMMUNOL, V12, P339, DOI 10.1038/nri3193
   Ebach DR, 2005, SHOCK, V23, P311, DOI 10.1097/01.shk.0000157301.87051.77
   Faustman D, 2010, NAT REV DRUG DISCOV, V9, P482, DOI 10.1038/nrd3030
   Hanada R, 2010, BIOL CHEM, V391, P1365, DOI 10.1515/BC.2010.149
   Hehlgans T, 2005, IMMUNOLOGY, V115, P1, DOI 10.1111/j.1365 2567.2005.02143.x
   Henkler F, 2005, J CELL BIOL, V168, P1087, DOI 10.1083/jcb.200501048
   Holler N, 2003, MOL CELL BIOL, V23, P1428, DOI 10.1128/MCB.23.4.1428 1440.2003
   Irving M, 2012, J BIOL CHEM, V287, P23068, DOI 10.1074/jbc.M112.357673
   Jiang DS, 2008, J IMMUNOL, V181, P3923, DOI 10.4049/jimmunol.181.6.3923
   Kontermann RE, 2008, J IMMUNOTHER, V31, P225, DOI 10.1097/CJI.0b013e31816a88f9
   Levin AM, 2012, NATURE, V484, P529, DOI 10.1038/nature10975
   Li JX, 2013, ADV IMMUNOL, V119, P135, DOI 10.1016/B978 0 12 407707 2.00005 9
   Mackay F, 2009, NAT REV IMMUNOL, V9, P491, DOI 10.1038/nri2572
   Mukai Y, 2009, J MOL BIOL, V385, P1221, DOI 10.1016/j.jmb.2008.11.053
   Nagano K, 2011, J BONE MINER METAB, V29, P671, DOI 10.1007/s00774 011 0270 z
   Nelson CA, 2012, STRUCTURE, V20, P1971, DOI 10.1016/j.str.2012.08.030
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   Peschon JJ, 1998, J IMMUNOL, V160, P943
   Schmid DA, 2010, J IMMUNOL, V184, P4936, DOI 10.4049/jimmunol.1000173
   SELMAJ K, 1991, ANN NEUROL, V30, P694, DOI 10.1002/ana.410300510
   Siegel RM, 2004, J CELL BIOL, V167, P735, DOI 10.1083/jcb.200406101
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sudhamsu J, 2013, P NATL ACAD SCI USA, V110, P19896, DOI 10.1073/pnas.1310838110
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Upadhyay V, 2013, NAT REV IMMUNOL, V13, P270, DOI 10.1038/nri3406
   VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0
   Vujanovic NL, 2011, IMMUNOL RES, V50, P159, DOI 10.1007/s12026 011 8228 8
   Warren JT, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004948
   Wu H., 2010, Handb. Cell Signaling, P265, DOI [10.1016/B978 0 12 374145 5.00040 1, DOI 10.1016/B978 0 12 374145 5.00040 1]
   Wu H, 2013, CELL, V153, P287, DOI 10.1016/j.cell.2013.03.013
   Yamaguchi K, 1998, J BIOL CHEM, V273, P5117, DOI 10.1074/jbc.273.9.5117
   Zauli G, 2006, CYTOKINE GROWTH F R, V17, P245, DOI 10.1016/j.cytogfr.2006.04.002
   Zhu MZ, 2011, IMMUNOL REV, V244, P75, DOI 10.1111/j.1600 065X.2011.01061.x
NR 47
TC 35
Z9 40
U1 0
U2 18
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD NOV
PY 2015
VL 116
IS 11
BP 2476
EP 2483
DI 10.1002/jcb.25191
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA CR3MJ
UT WOS:000361236800007
PM 25864714
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Barcelos, RP
   Bresciani, G
   Cuevas, MJ
   Martínez Flórez, S
   Soares, FAA
   González Gallego, J
AF Barcelos, Romulo Pillon
   Bresciani, Guilherme
   Cuevas, Maria Jose
   Martinez Florez, Susana
   Antunes Soares, Felix Alexandre
   Gonzalez Gallego, Javier
TI Diclofenac pretreatment modulates exercise induced inflammation in
   skeletal muscle of rats through the TLR4/NF κB pathway
SO APPLIED PHYSIOLOGY NUTRITION AND METABOLISM
LA English
DT Article
DE eccentric exercise; skeletal muscle; inflammation; NSAIDs; COX; NF kappa
   B
ID NF KAPPA B; COX INHIBITING DRUGS; TOLL LIKE RECEPTORS; ECCENTRIC
   EXERCISE; RESISTANCE EXERCISE; PROTEIN SYNTHESIS; OVER EXPRESSION;
   IBUPROFEN; SORENESS; RESPONSES
AB Nonsteroidal anti inflammatory drugs, such as diclofenac, are widely used to treat inflammation and pain in several conditions, including sports injuries. This study analyzes the influence of diclofenac on the toll like receptor nuclear factor kappa B (TLR NF kappa B) pathway in skeletal muscle of rats submitted to acute eccentric exercise. Twenty male Wistar rats were divided into 4 groups: control saline, control diclofenac, exercise saline, and exercise diclofenac. Diclofenac or saline were administered for 7 days prior to an acute eccentric exercise bout. The inflammatory status was evaluated through mRNA levels of cyclooxygenase 2 (COX 2), inducible nitric oxide synthase (iNOS), interleukin 6 (IL 6), IL 1 beta, and tumor necrosis factor alpha (TNF alpha), and protein content of COX 2, IL 6, and TNF alpha in vastus lateralis muscle. Data obtained showed that a single bout of eccentric exercise significantly increased COX 2 gene expression. Similarly, mRNA expression and protein content of other inflammation related genes also increased after the acute exercise. However, these effects were attenuated in the exercise + diclofenac group. TLR4, myeloid differentiation primary response gene 88 (MyD88), and p65 were also upregulated after the acute eccentric bout and the effect was blunted by the anti inflammatory drug. These findings suggest that pretreatment with diclofenac may represent an effective tool to ameliorate the pro inflammatory status induced by acute exercise in rat skeletal muscle possibly through an attenuation of the TLR4 NF kappa B signaling pathway.
C1 [Barcelos, Romulo Pillon] Univ Passo Fundo, Programa Posgrad Bioexperimentacao, BR 99052900 Passo Fundo, RS, Brazil.
   [Barcelos, Romulo Pillon; Cuevas, Maria Jose; Martinez Florez, Susana; Gonzalez Gallego, Javier] Univ Leon, Inst Biomed, Campus Univ, E 24071 Leon, Spain.
   [Barcelos, Romulo Pillon; Antunes Soares, Felix Alexandre] Univ Fed Santa Maria, Programa Posgrad Bioquim Toxicol, Ctr Ciencias Nat & Exatas, BR 97105900 Santa Maria, RS, Brazil.
   [Bresciani, Guilherme] Pontificia Univ Catolica Valparaiso, Escuela Educ Fis, Grp Invest Rendimiento Fis & Salud, Valparaiso 2530388, Chile.
C3 Universidade de Passo Fundo; Universidad de Leon; Universidade Federal
   de Santa Maria (UFSM); Pontificia Universidad Catolica de Valparaiso
RP Barcelos, RP (通讯作者)，Univ Passo Fundo, Programa Posgrad Bioexperimentacao, BR 99052900 Passo Fundo, RS, Brazil.; Barcelos, RP (通讯作者)，Univ Leon, Inst Biomed, Campus Univ, E 24071 Leon, Spain.; Barcelos, RP (通讯作者)，Univ Fed Santa Maria, Programa Posgrad Bioquim Toxicol, Ctr Ciencias Nat & Exatas, BR 97105900 Santa Maria, RS, Brazil.
EM romulo1604@hotmail.com
RI ; Martínez Flórez, Susana/LKM 2602 2024; Soares, Félix/K 7611 2012;
   Barcelos, Rômulo/J 8231 2015; Soares, Felix/K 7611 2012; Barcelos,
   Romulo/J 8231 2015; Gonzalez Gallego, Javier/D 8219 2012; GONZÁLEZ,
   MARÍA/M 4927 2015; Bresciani, Guilherme/M 6805 2014
OI Gonzalez Gallego, Javier/0000 0002 4386 9342; Soares,
   Felix/0000 0002 6453 7902; Barcelos, Romulo/0000 0002 6366 6366;
   Bresciani, Guilherme/0000 0003 1526 5573; Martinez,
   Susana/0000 0002 7200 8744; 
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico/Fundacao
   de Amparo a Pesquisa do Estado do Rio Grande do Sul [11/2029 1]; CNPQ;
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
FX The work was supported by the PRONEM # 11/2029 1 research grant of
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico/Fundacao
   de Amparo a Pesquisa do Estado do Rio Grande do Sul. FAAS received a
   fellowship from CNPQ. RPB received a fellowship from Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior.
CR Akira S, 2006, CURR TOP MICROBIOL, V311, P1
   Akira S, 2003, SCAND J INFECT DIS, V35, P555, DOI 10.1080/00365540310015683
   Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   Alonso M, 2006, J PINEAL RES, V41, P8, DOI 10.1111/j.1600 079X.2006.00323.x
   ARMSTRONG RB, 1983, J APPL PHYSIOL, V54, P80, DOI 10.1152/jappl.1983.54.1.80
   Bondesen BA, 2006, AM J PHYSIOL CELL PH, V290, pC1651, DOI 10.1152/ajpcell.00518.2005
   Bondesen BA, 2004, AM J PHYSIOL CELL PH, V287, pC475, DOI 10.1152/ajpcell.00088.2004
   Burd NA, 2010, AM J PHYSIOL ENDOC M, V298, pE354, DOI 10.1152/ajpendo.00423.2009
   Cheung K, 2003, SPORTS MED, V33, P145, DOI 10.2165/00007256 200333020 00005
   Ciocca M, 2005, CLIN SPORT MED, V24, P719, DOI 10.1016/j.csm.2005.03.005
   Connolly DJ, 2012, CURR OPIN PHARMACOL, V12, P510, DOI 10.1016/j.coph.2012.06.002
   Corrigan B, 2003, CLIN J SPORT MED, V13, P33, DOI 10.1097/00042752 200301000 00007
   Fernandez Gonzalo R, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/479395
   Fernandez Gonzalo R, 2012, J APPL PHYSIOL, V112, P2011, DOI 10.1152/japplphysiol.01499.2011
   García Mediavilla MV, 2005, J HEPATOL, V43, P606, DOI 10.1016/j.jhep.2005.04.019
   Gleeson M, 2006, EXERC IMMUNOL REV, V12, P34
   Gómez Lechón MJ, 2003, BIOCHEM PHARMACOL, V66, P2155, DOI 10.1016/j.bcp.2003.08.003
   Gorski T, 2011, BRIT J SPORT MED, V45, P85, DOI 10.1136/bjsm.2009.062166
   Green G A, 2001, Clin Cornerstone, V3, P50, DOI 10.1016/S1098 3597(01)90069 9
   HASSON SM, 1993, MED SCI SPORT EXER, V25, P9, DOI 10.1249/00005768 199301000 00003
   Huang SH, 2006, CLIN J SPORT MED, V16, P27, DOI 10.1097/01.jsm.0000194766.35443.9c
   Inotai A, 2010, PHARMACOEPIDEM DR S, V19, P183, DOI 10.1002/pds.1893
   Jiang WW, 2010, HEPATOL RES, V40, P318, DOI 10.1111/j.1872 034X.2009.00603.x
   Jiménez Jiménez R, 2008, MECH AGEING DEV, V129, P313, DOI 10.1016/j.mad.2008.02.007
   Karamouzis M, 2001, PROSTAG LEUKOTR ESS, V64, P259, DOI 10.1054/plef.2001.0269
   Kawai T, 2006, CELL DEATH DIFFER, V13, P816, DOI 10.1038/sj.cdd.4401850
   Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002
   Kraemer WJ, 2010, PEPTIDES, V31, P88, DOI 10.1016/j.peptides.2009.09.031
   Kramer HF, 2007, J APPL PHYSIOL, V103, P388, DOI 10.1152/japplphysiol.00085.2007
   Krentz JR, 2008, APPL PHYSIOL NUTR ME, V33, P470, DOI 10.1139/H08 019
   Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651
   Leone S, 2007, CURR TOP MED CHEM, V7, P265, DOI 10.2174/156802607779941341
   Liao P, 2010, AM J PHYSIOL REG I, V298, pR599, DOI 10.1152/ajpregu.00480.2009
   Lima FD, 2016, SCAND J MED SCI SPOR, V26, P1160, DOI 10.1111/sms.12549
   Markworth JF, 2014, J APPL PHYSIOL, V117, P20, DOI 10.1152/japplphysiol.01299.2013
   McFarlin BK, 2006, J GERONTOL A BIOL, V61, P388, DOI 10.1093/gerona/61.4.388
   Mikkelsen UR, 2011, SCAND J MED SCI SPOR, V21, P630, DOI 10.1111/j.1600 0838.2010.01170.x
   Novak ML, 2009, AM J PHYSIOL REG I, V296, pR1132, DOI 10.1152/ajpregu.90874.2008
   Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886
   Paulsen G, 2010, SCAND J MED SCI SPOR, V20, pE195, DOI 10.1111/j.1600 0838.2009.00947.x
   Paulsen G, 2012, EXERC IMMUNOL REV, V18, P42
   Peake J, 2005, EXERC IMMUNOL REV, V11, P64
   Peterson JM, 2003, MED SCI SPORT EXER, V35, P892, DOI 10.1249/01.MSS.0000069917.51742.98
   Barcelos RP, 2016, LIFE SCI, V148, P247, DOI 10.1016/j.lfs.2016.02.006
   Pradeu T, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00287
   Ramm S, 2013, TOXICOLOGY, V312, P83, DOI 10.1016/j.tox.2013.08.002
   Shen W, 2005, AM J PATHOL, V167, P1105, DOI 10.1016/S0002 9440(10)61199 6
   Silveira EMS, 2007, CELL BIOCHEM FUNCT, V25, P63, DOI 10.1002/cbf.1365
   Soltow QA, 2006, MED SCI SPORT EXER, V38, P840, DOI 10.1249/01.mss.0000218142.98704.66
   Stone MB, 2002, CLIN J SPORT MED, V12, P373, DOI 10.1097/00042752 200211000 00009
   Trappe RA, 2002, AM J PHYSIOL ENDOC M, V282, pE551, DOI 10.1152/ajpendo.00352.2001
   Trappe TA, 2013, J APPL PHYSIOL, V115, P909, DOI 10.1152/japplphysiol.00061.2013
   Trappe TA, 2011, AM J PHYSIOL REG I, V300, pR655, DOI 10.1152/ajpregu.00611.2010
   Tscholl P, 2010, AM J SPORT MED, V38, P133, DOI 10.1177/0363546509344071
   Urso ML, 2013, J APPL PHYSIOL, V115, P920, DOI 10.1152/japplphysiol.00036.2013
   Weinheimer EM, 2007, AM J PHYSIOL REG I, V292, pR2241, DOI 10.1152/ajpregu.00718.2006
   Zbinden Foncea H, 2012, MED SCI SPORT EXER, V44, P1463, DOI 10.1249/MSS.0b013e31824e0d5d
   Ziltener J.  L., 2010, Annals of Physical and Rehabilitation Medicine, V53, P278, DOI 10.1016/j.rehab.2010.03.001
NR 58
TC 23
Z9 23
U1 0
U2 11
PU CANADIAN SCIENCE PUBLISHING
PI OTTAWA
PA 65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA
SN 1715 5312
EI 1715 5320
J9 APPL PHYSIOL NUTR ME
JI Appl. Physiol. Nutr. Metab.
PD JUL
PY 2017
VL 42
IS 7
BP 757
EP 764
DI 10.1139/apnm 2016 0593
PG 8
WC Nutrition & Dietetics; Physiology; Sport Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics; Physiology; Sport Sciences
GA EZ1GW
UT WOS:000404459400011
PM 28235185
DA 2025 08 17
ER

PT J
AU Lee, K
   Jang, YJ
   Lee, H
   Kim, E
   Kim, Y
   Yoo, TK
   Hyun, TK
   Park, JI
   Yi, SJ
   Kim, K
AF Lee, Kyubin
   Jang, You Jee
   Lee, Hyerim
   Kim, Eunbin
   Kim, Yeojin
   Yoo, Tong Kewn
   Hyun, Tae Kyung
   Park, Jae Il
   Yi, Sun Ju
   Kim, Kyunghwan
TI Transcriptome Analysis Reveals ThatAbeliophyllum distichumNakai
   Extract Inhibits RANKL Mediated Osteoclastogenensis Mainly through
   Suppressing Nfatc1 Expression
SO BIOLOGY BASEL
LA English
DT Article
DE Abeliophyllum distichumNakai; osteoclast; NFATc1; osteoporosis
ID NF KAPPA B; GLUCOCORTICOID INDUCED OSTEOPOROSIS;
   ABELIOPHYLLUM DISTICHUM; DIFFERENTIATION; RECEPTOR; ACTIVATION; ACID
AB Abeliophyllum distichumNakai is known as a monotypic genus endemic to South Korea. Currently, several pharmacological studies have revealed thatA. distichumextract exhibits diverse biological functions, including anti cancer, anti diabetic, anti hypertensive, and anti inflammatory activities. In this study, we present the anti osteoporotic activity ofA. distichumextract by inhibiting osteoclast formation. First, we show that the methanolic extract of the leaves ofA. distichum, but not extracts of the branches or fruits, significantly inhibits receptor activator of the NF kappa B ligand (RANKL) induced osteoclast differentiation. Second, our transcriptome analysis revealed that the leaf extract (LE) blocks sets of RANKL mediated osteoclast related genes. Third, the LE attenuates the phosphorylation of extracellular signal related kinase. Finally, treatment with the LE effectively prevents postmenopausal bone loss in ovariectomized mice and glucocorticoid induced osteoporosis in zebrafish. Our findings show that the extract ofA. distichumefficiently suppressed osteoclastogenesis by regulating osteoclast related genes, thus offering a novel therapeutic strategy for osteoporosis.
C1 [Lee, Kyubin; Lee, Hyerim; Kim, Yeojin; Yi, Sun Ju; Kim, Kyunghwan] Chungbuk Natl Univ, Sch Biol Sci, Coll Nat Sci, Cheongju 28644, South Korea.
   [Jang, You Jee; Kim, Eunbin; Park, Jae Il] Chonnam Natl Univ, Gwangju Ctr, Korea Basic Sci Inst, Gwangju 61886, South Korea.
   [Yoo, Tong Kewn; Hyun, Tae Kyung] Chungbuk Natl Univ, Dept Ind Plant Sci & Technol, Cheongju 28644, South Korea.
C3 Chungbuk National University; Chonnam National University; Korea Basic
   Science Institute (KBSI); Chungbuk National University
RP Yi, SJ; Kim, K (通讯作者)，Chungbuk Natl Univ, Sch Biol Sci, Coll Nat Sci, Cheongju 28644, South Korea.; Park, JI (通讯作者)，Chonnam Natl Univ, Gwangju Ctr, Korea Basic Sci Inst, Gwangju 61886, South Korea.
EM kblee816@hanmail.net; kshowmin80@gmail.com; qjsro1324@gmail.com;
   kbsi.eunbin02@gmail.com; wlsldmsl97@naver.com; tongkewn2003@naver.com;
   taekyung7708@cbnu.ac.kr; jaeil74@kbsi.re.kr; sjyi@chungbuk.ac.kr;
   kyungkim@chungbuk.ac.kr
RI Lee, Kyubin/AFQ 3694 2022
FU National Research Foundation of Korea [2020R1A2C1008179,
   2019R1I1A1A01061125]; Korea Institute of Oriental Medicine, Ministry of
   Education, Science and Technology, Republic of Korea [KSN2012330,
   W20102]; R&D Program for Forest Science Technology by Korea Forest
   Service (Korea Forestry Promotion Institute) [2019139A00 1920 0001,
   2020249A00 2021 0001]
FX This work was carried out with the support of the National Research
   Foundation of Korea (2020R1A2C1008179 to K.K.; 2019R1I1A1A01061125 to
   S. J.Y.), the Korea Institute of Oriental Medicine, Ministry of
   Education, Science and Technology, Republic of Korea (KSN2012330, W20102
   to J. I.P.) and R&D Program for Forest Science Technology (Project No.
   2019139A00 1920 0001 and 2020249A00 2021 0001 to K.L.) provided by Korea
   Forest Service (Korea Forestry Promotion Institute).
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   An D, 2014, J BIOL CHEM, V289, P24366, DOI 10.1074/jbc.M114.563817
   Ang ESM, 2009, J CELL PHYSIOL, V221, P642, DOI 10.1002/jcp.21898
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Barrett Ruth, 2006, Biotechnology Journal, V1, P651, DOI 10.1002/biot.200600043
   Boyce BF, 2005, J BONE MINER METAB, V23, P11, DOI 10.1007/BF03026317
   Cauley JA, 2013, J GERONTOL A BIOL, V68, P1243, DOI 10.1093/gerona/glt093
   Cheon YH, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906 015 0801 6
   Choi JH, 2017, J APPL BOT FOOD QUAL, V90, P266, DOI 10.5073/JABFQ.2017.090.033
   Compston J, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 017 0324 5
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dobbs M B, 1999, Iowa Orthop J, V19, P43
   Doss HM, 2018, LIFE SCI, V207, P284, DOI 10.1016/j.lfs.2018.06.013
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Fraser LA, 2009, THER ADV MUSCULOSKEL, V1, P71, DOI 10.1177/1759720X09343729
   Glaser DL, 1997, SPINE, V22, p12S, DOI 10.1097/00007632 199712151 00003
   He HL, 2018, BIOMED PHARMACOTHER, V101, P981, DOI 10.1016/j.biopha.2018.02.082
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Hwang YH, 2019, NUTRIENTS, V11, DOI 10.3390/nu11081831
   Kim EY, 2020, J ETHNOPHARMACOL, V257, DOI 10.1016/j.jep.2020.112828
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim K, 2007, BLOOD, V109, P3253, DOI 10.1182/blood 2006 09 048249
   Kim Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20164038
   Kwak SC, 2013, BIOL PHARM BULL, V36, P1779
   Kyung TW, 2008, EXP MOL MED, V40, P52, DOI 10.3858/emm.2008.40.1.52
   La VD, 2009, J PERIODONTAL RES, V44, P193, DOI 10.1111/j.1600 0765.2008.01107.x
   Lee H., 2020, INT J MED SCI, V17, P21
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lee SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080873
   Li HM, 2013, ARCH PHARM RES, V36, P1104, DOI 10.1007/s12272 013 0127 1
   Liu CZ, 2010, J IMMUNOL, V184, P6910, DOI 10.4049/jimmunol.0904033
   Masuhara Masaaki, 2016, Biochem Biophys Rep, V8, P389, DOI 10.1016/j.bbrep.2016.10.013
   Mazziotti G, 2006, TRENDS ENDOCRIN MET, V17, P144, DOI 10.1016/j.tem.2006.03.009
   Monje P, 2005, J BIOL CHEM, V280, P35081, DOI 10.1074/jbc.C500353200
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   Oh H, 2003, PHYTOTHER RES, V17, P811, DOI 10.1002/ptr.1199
   Park GH, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472 6882 14 487
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Suvarna V, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00981
   Yi SJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133147
   Yoo TK, 2020, PLANTS BASEL, V9, DOI 10.3390/plants9060757
   Zhao BH, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3379
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09234 6
NR 45
TC 10
Z9 12
U1 2
U2 18
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2079 7737
J9 BIOLOGY BASEL
JI Biology Basel
PY 2020
VL 9
IS 8
AR 212
DI 10.3390/biology9080212
PG 14
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA NM4PQ
UT WOS:000568080500001
PM 32781784
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Balooch, G
   Yao, W
   Ager, JW
   Balooch, M
   Nalla, RK
   Porter, AE
   Ritchie, RO
   Lane, NE
AF Balooch, Guive
   Yao, Wei
   Ager, Joel W.
   Balooch, Mehdi
   Nalla, Ravi K.
   Porter, Alexandra E.
   Ritchie, Robert O.
   Lane, Nancy E.
TI The aminobisphosphonate risedronate preserves localized mineral and
   material properties of bone in the presence of Glucocorticoids
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; RHEUMATOID ARTHRITIS;
   VERTEBRAL FRACTURE; MEVALONATE PATHWAY; BISPHOSPHONATES; OSTEOCLAST;
   PREVENTION; APOPTOSIS; ALENDRONATE
AB Objective. Glucocorticoids (GCs) alter bone strength such that patients receiving these medications have a high rate of fragility related fractures. The purpose of this study was to assess whether concurrent treatment with GCs (prednisolone) and risedronate (an aminobisphosphonate) would prevent the reduction in bone strength induced by GCs, in a mouse model of GC induced bone loss and in patients enrolled in a clinical study.
   Methods. We evaluated mice treated with prednisolone pellets alone, GCs plus risedronate, or placebo alone and iliac crest biopsy specimens obtained from patients who were treated with GCs plus placebo or GCs plus risedronate for 1 year. We measured the mass, architecture, and physical and material properties of bone (subject to therapeutic treatments) at nanoscale to macroscopic dimensions, using synchrotron x ray tomography, elastic modulus mapping, transmission electron microscopy, and small angle x ray scattering techniques.
   Results. GC treatment reduced trabecular bone mass, microarchitecture, and the degree of bone mineralization and elastic modulus within the trabeculae. Concurrent treatment with GCs and risedronate prevented the deterioration of trabecular bone architecture, reduced the degree of mineralization, and preserved elastic modulus within the trabeculae, in both mouse and human bone. In addition, treatment with risedronate plus GCs in mice appeared to preserve bone crystal orientation, compared with treatment with GCs alone.
   Conclusion. Risedronate prevented the localized changes in mineral and material properties of bone induced by GCs, which may ultimately improve bone strength.
C1 Univ Calif Davis, Dept Med, Sacramento, CA 95817 USA.
   Univ Calif San Francisco, Lawrence Berkeley Natl Lab, San Francisco, CA 94143 USA.
   Univ Calif Davis, Ctr Hlth Aging, Sacramento, CA 95817 USA.
   Univ Cambridge, Nanosci Ctr, Cambridge, England.
C3 University of California System; University of California Davis; United
   States Department of Energy (DOE); Lawrence Berkeley National
   Laboratory; University of California System; University of California
   San Francisco; University of California System; University of California
   Davis; University of Cambridge
RP Lane, NE (通讯作者)，Univ Calif Davis, Dept Med, 4800 Sec Ave, Suite 2600, Sacramento, CA 95817 USA.
EM nelane@ucdavis.edu
RI Yao, Wei/O 8187 2019; Ritchie, Robert/A 8066 2008
OI Ager, Joel/0000 0001 9334 9751; 
FU NIAMS NIH HHS [R01 AR043052, K24 AR048841, R01 AR 043052 07,
   K24 AR 48841 03, P50 AR063043] Funding Source: Medline; NIDDK NIH HHS
   [R01 DK 46661 10] Funding Source: Medline
CR Adachi JD, 1997, NEW ENGL J MED, V337, P382, DOI 10.1056/NEJM199708073370603
   Akhter MP, 2001, BONE, V29, P121, DOI 10.1016/S8756 3282(01)00486 0
   Asahi H, 2006, INT J UROL, V13, P593, DOI 10.1111/j.1442 2042.2006.01360.x
   Balooch G, 2004, J BIOMECH, V37, P1223, DOI 10.1016/j.jbiomech.2003.12.012
   Bauer DC, 2004, J BONE MINER RES, V19, P1250, DOI 10.1359/JBMR.040512
   Borah B, 2006, BONE, V39, P345, DOI 10.1016/j.bone.2006.01.161
   Boutsen Y, 2001, J BONE MINER RES, V16, P104, DOI 10.1359/jbmr.2001.16.1.104
   Chavassieux PM, 2000, J BONE MINER RES, V15, P754, DOI 10.1359/jbmr.2000.15.4.754
   Cohen S, 1999, ARTHRITIS RHEUM, V42, P2309, DOI 10.1002/1529 0131(199911)42:11<2309::AID ANR8>3.0.CO;2 K
   COOPER C, 1995, ANN RHEUM DIS, V54, P49, DOI 10.1136/ard.54.1.49
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Delaney MF, 2003, J CLIN DENSITOM, V6, P45, DOI 10.1385/JCD:6:1:45
   Eastell R, 2000, OSTEOPOROSIS INT, V11, P331, DOI 10.1007/s001980070122
   Eastell R, 2003, J BONE MINER RES, V18, P1051, DOI 10.1359/jbmr.2003.18.6.1051
   Engqvist H, 2006, J BIOMED MATER RES A, V78A, P20, DOI 10.1002/jbm.a.30696
   Faibish D, 2006, CLIN ORTHOP RELAT R, P28, DOI 10.1097/01.blo.0000200241.14684.4e
   Fratzl P, 1996, Connect Tissue Res, V34, P247, DOI 10.3109/03008209609005268
   Kim HJ, 2006, J CLIN INVEST, V116, P2152, DOI 10.1172/JCI28084
   Kinney JH, 2000, J BONE MINER RES, V15, P1981, DOI 10.1359/jbmr.2000.15.10.1981
   Lane NE, 2006, J BONE MINER RES, V21, P466, DOI 10.1359/JBMR.051103
   Lane NE, 2001, RHEUM DIS CLIN N AM, V27, P235, DOI 10.1016/S0889 857X(05)70196 4
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Monier Faugere MC, 1999, J BONE MINER RES, V14, P1768, DOI 10.1359/jbmr.1999.14.10.1768
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   PARFITT AM, 1988, BONE, V9, P67, DOI 10.1016/8756 3282(88)90029 4
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Porter AE, 2006, J BIOMED MATER RES A, V78A, P25, DOI 10.1002/jbm.a.30690
   Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967
   Rohanizadeh R, 2000, CALCIFIED TISSUE INT, V67, P330, DOI 10.1007/s002230001141
   Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502
   Saag KG, 2003, ENDOCRIN METAB CLIN, V32, P135, DOI 10.1016/S0889 8529(02)00064 6
   Wallach S, 2000, CALCIFIED TISSUE INT, V67, P277, DOI 10.1007/s002230001146
   Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538
   Yao W, 2005, OSTEOPOROSIS INT, V16, P1939, DOI 10.1007/s00198 005 1969 2
   Yao W, 2006, BONE, V39, P460, DOI 10.1016/j.bone.2006.03.008
NR 36
TC 29
Z9 33
U1 0
U2 5
PU WILEY LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0004 3591
J9 ARTHRITIS RHEUM
JI Arthritis Rheum.
PD NOV
PY 2007
VL 56
IS 11
BP 3726
EP 3737
DI 10.1002/art.22976
PG 12
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 230QM
UT WOS:000250891000026
PM 17968931
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Wang, XM
   Zhu, SS
   Jiang, XW
   Li, YF
   Song, DH
   Hu, J
AF Wang, Xuemei
   Zhu, Songsong
   Jiang, Xiaowen
   Li, Yunfeng
   Song, Donghui
   Hu, Jing
TI Systemic Administration of Lithium Improves Distracted Bone Regeneration
   in Rats
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Lithium; Distraction osteogenesis; Limb lengthening; Bone regeneration
ID OSTEOGENESIS; DIFFERENTIATION; THERAPY; MODEL; INHIBITION; RISK; GENE
AB Lithium, popular in psychology field, has been recognized as an activator component of the canonical Wnt signaling pathway. The effect of lithium on osteogenesis or on the human fracture risk has been widely reported. However, little is known on its role in distraction osteogenesis to date. In this study, the effect of systematic administrated lithium on distraction osteogenesis in a rat model was investigated. The osteotomy was performed on the right tibia in 40 adult male Sprague Dawley rats. Then they were randomly assigned into two equal groups (n = 20/group), which underwent Lithium or saline treatment through gastric gavage until the day they were killed. One week after the osteotomy, the tibias were distracted for 14 days (rate 0.6 mm/day). Following 8 weeks consolidation period, the distracted tibias in both groups were harvested and examined by X ray plain radiography, histology, dual energy X ray absorptiometry, Micro CT, and biomechanical tests. The results showed that lithium group possessed higher bone mineral density, more mature new bone tissue, and better regenerated bone mass continuity in the distraction gaps without any local or systemic adverse effects was encountered. This study suggested lithium could increase bony callus ossification volume and accelerate distracted tissue mineralization to facilitate bone regeneration in distraction gap.
C1 [Wang, Xuemei; Zhu, Songsong; Jiang, Xiaowen; Li, Yunfeng; Song, Donghui; Hu, Jing] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu 610041, Peoples R China.
   [Wang, Xuemei; Zhu, Songsong; Jiang, Xiaowen; Li, Yunfeng; Song, Donghui; Hu, Jing] Sichuan Univ, West China Hosp Stomatol, Dept Oral & Maxillofacial Surg, Chengdu 610041, Peoples R China.
   [Wang, Xuemei] Jinan Stomatol Hosp, Dept Oral & Maxillofacial Surg, Jinan 250001, Peoples R China.
C3 Sichuan University; Sichuan University
RP Hu, J (通讯作者)，Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu 610041, Peoples R China.
EM drhu@vip.sohu.com
RI ; wang, meng/GWZ 9558 2022; Wang, Minjin/GZA 6229 2022
OI Li, Yunfeng/0000 0003 2659 8074; 
FU National Natural Science Foundation of China [81271106]
FX This work was supported by the National Natural Science Foundation of
   China (No.81271106).
CR Ai Aql ZS, 2008, J DENT RES, V87, P107, DOI 10.1177/154405910808700215
   Amir LR, 2009, ODONTOLOGY, V97, P63, DOI 10.1007/s10266 009 0101 z
   Aronson J, 1997, J BONE JOINT SURG AM, V79A, P1243, DOI 10.2106/00004623 199708000 00019
   ARONSON J, 1994, CLIN ORTHOP RELAT R, P124
   Aronson J, 1997, J ORTHOPAED RES, V15, P221, DOI 10.1002/jor.1100150210
   Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006 291X(02)02951 0
   BARAN DT, 1978, J CLIN INVEST, V61, P1691, DOI 10.1172/JCI109090
   BOTON R, 1987, AM J KIDNEY DIS, V10, P329, DOI 10.1016/S0272 6386(87)80098 7
   Carney SM, 2005, ACTA PSYCHIAT SCAND, V111, P7, DOI 10.1111/j.1600 0447.2005.00521.x
   Chappard D, 2011, OSTEOPOROSIS INT, V22, P2225, DOI 10.1007/s00198 011 1573 6
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Choi IH, 2002, J KOREAN MED SCI, V17, P435, DOI 10.3346/jkms.2002.17.4.435
   Choi IH, 2000, J ORTHOP RES, V18, P698, DOI 10.1002/jor.1100180504
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Cohen Y, 1998, MED ONCOL, V15, P32, DOI 10.1007/BF02787342
   Davies J, 1998, BRIT DENT J, V185, P462, DOI 10.1038/sj.bdj.4809838
   Grandjean EM, 2009, CNS DRUGS, V23, P397, DOI 10.2165/00023210 200923050 00004
   GUNDBERG CM, 1992, ENDOCRINOLOGY, V130, P1909, DOI 10.1210/en.130.4.1909
   Guo SZ, 2009, STROKE, V40, P652, DOI 10.1161/STROKEAHA.108.524504
   HAHN M, 1991, VIRCHOWS ARCH A, V418, P1, DOI 10.1007/BF01600238
   Heo JS, 2010, MOL CELLS, V30, P449, DOI 10.1007/s10059 010 0139 3
   Hoang MV, 2010, ANGIOGENESIS, V13, P269, DOI 10.1007/s10456 010 9184 y
   Hu J, 2007, J ORTHOP RES, V25, P241, DOI 10.1002/jor.20288
   Kirton JP, 2007, CIRC RES, V101, P581, DOI 10.1161/CIRCRESAHA.107.156372
   Kugimiya F, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000837
   Li G, 2005, J ORTHOP RES, V23, P196, DOI 10.1016/j.orthres.2004.05.006
   Li G, 2002, J ORTHOP RES, V20, P887, DOI 10.1016/S0736 0266(01)00184 X
   Masckauchán THN, 2006, PHYSIOLOGY, V21, P181, DOI 10.1152/physiol.00058.2005
   Seebach C, 2004, J ORTHOP RES, V22, P472, DOI 10.1016/j.orthers.2003.08.018
   Silva R, 2007, NEUROSCI LETT, V429, P33, DOI 10.1016/j.neulet.2007.09.062
   Tang GH, 2011, J DENT RES, V90, P336, DOI 10.1177/0022034510389180
   Vestergaard P, 2005, CALCIFIED TISSUE INT, V77, P1, DOI 10.1007/s00223 004 0258 y
   Wang H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091730
   Wang JF, 1999, MOL BRAIN RES, V70, P66, DOI 10.1016/S0169 328X(99)00128 X
   Warden SJ, 2010, BONE, V46, P985, DOI 10.1016/j.bone.2009.12.031
   Wilting I, 2007, BONE, V40, P1252, DOI 10.1016/j.bone.2006.12.055
   Young AH, 2006, J PSYCHOPHARMACOL, V20, P17, DOI 10.1177/1359786806063072
   Zamani A, 2009, BONE, V44, P331, DOI 10.1016/j.bone.2008.10.001
   Zerlin M, 2008, ANGIOGENESIS, V11, P63, DOI 10.1007/s10456 008 9095 3
NR 39
TC 36
Z9 41
U1 0
U2 27
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD JUN
PY 2015
VL 96
IS 6
BP 534
EP 540
DI 10.1007/s00223 015 0004 7
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CI4FU
UT WOS:000354704100007
PM 25903228
DA 2025 08 17
ER

PT J
AU Yu, RG
   Zhang, JY
   Liu, ZT
   Zhuo, YG
   Wang, HY
   Ye, J
   Liu, NN
   Zhang, YY
AF Yu, Rong Guo
   Zhang, Jia Yu
   Liu, Zhen Tao
   Zhuo, You Guang
   Wang, Hai Yang
   Ye, Jie
   Liu, Nannan
   Zhang, Yi Yuan
TI Text Mining Based Drug Discovery in Osteoarthritis
SO JOURNAL OF HEALTHCARE ENGINEERING
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; AMERICAN COLLEGE; CARTILAGE; KNEE;
   COLITIS; DISEASE; INFLAMMATION; MANAGEMENT; GUIDELINE; ASPIRIN
AB Background. Osteoarthritis (OA) is a chronic and degenerative joint disease, which causes stiffness, pain, and decreased function. At the early stage of OA, nonsteroidal anti inflammatory drugs (NSAIDs) are considered the first line treatment. However, the efficacy and utility of available drug therapies are limited. We aim to use bioinformatics to identify potential genes and drugs associated with OA. Methods. The genes related to OA and NSAIDs therapy were determined by text mining. Then, the common genes were performed for GO, KEGG pathway analysis, and protein protein interaction (PPI) network analysis. Using the MCODE plugin obtained hub genes, the expression levels of hub genes were verified using quantitative real time polymerase chain reaction (qRT PCR). The confirmed genes were queried in the Drug Gene Interaction Database to determine potential genes and drugs. Results. The qRT PCR result showed that the expression level of 15 genes was significantly increased in OA samples. Finally, eight potential genes were targetable to a total of 53 drugs, twenty one of which have been employed to treat OA and 32 drugs have not yet been used in OA. Conclusions. The 15 genes (including PTGS2, NLRP3, MMP9, IL1RN, CCL2, TNF, IL10, CD40, IL6, NGF, TP53, RELA, BCL2L1, VEGFA, and NOTCH1) and 32 drugs, which have not been used in OA but approved by the FDA for other diseases, could be potential genes and drugs, respectively, to improve OA treatment. Additionally, those methods provided tremendous opportunities to facilitate drug repositioning efforts and study novel target pharmacology in the pharmaceutical industry.
C1 [Yu, Rong Guo; Zhuo, You Guang; Wang, Hai Yang; Ye, Jie; Liu, Nannan; Zhang, Yi Yuan] Xiamen Univ, Fuzhou Hosp 2, Dept Orthoped, Fuzhou 350007, Fujian, Peoples R China.
   [Zhang, Jia Yu] Yunnan Univ Tradit Chinese Med, Sch Clin Med, Kunming 650032, Yunnan, Peoples R China.
   [Liu, Zhen Tao] Fujian Univ Tradit Chinese Med, Coll Integrated Chinese & Western Med, Fuzhou 350122, Fujian, Peoples R China.
C3 Xiamen University; Yunnan University of Chinese Medicine; Fujian
   University of Traditional Chinese Medicine
RP Zhang, YY (通讯作者)，Xiamen Univ, Fuzhou Hosp 2, Dept Orthoped, Fuzhou 350007, Fujian, Peoples R China.
EM 876309664@qq.com; zhangjiayu9099@163.com; 136162730@qq.com;
   871287899@qq.com; 18254118970@163.com; whichye@163.com;
   1300867866@qq.com; rongsteer@163.com
FU Project of Innovation Platform for Fuzhou Health and Family Planning
   Commission [2017 S wp1]
FX This study was supported by the Project of Innovation Platform for
   Fuzhou Health and Family Planning Commission (no. 2017 S wp1).
CR Abramson SB, 2004, J RHEUMATOL, V31, P70, DOI 10.1097/BOR.0b013e328349c2b1
   Adams CP, 2006, HEALTH AFFAIR, V25, P420, DOI 10.1377/hlthaff.25.2.420
   Akkoc N, 2006, BEST PRACT RES CL RH, V20, P539, DOI 10.1016/j.berh.2006.03.003
   Attur M, 2008, J IMMUNOL, V181, P5082, DOI 10.4049/jimmunol.181.7.5082
   Bannuru RR, 2019, OSTEOARTHR CARTILAGE, V27, P1578, DOI 10.1016/j.joca.2019.06.011
   Baran J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024716
   Bedson J, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471 2474 9 116
   Chidlow JH, 2007, AM J PHYSIOL GASTR L, V293, pG5, DOI 10.1152/ajpgi.00107.2007
   da Costa BR, 2017, LANCET, V390, pE21, DOI 10.1016/S0140 6736(17)31744 0
   Dignass A, 2012, J CROHNS COLITIS, V6, P991, DOI 10.1016/j.crohns.2012.09.002
   Duan XC, 2015, DEVELOPMENT, V142, P1984, DOI 10.1242/dev.117952
   Eremina V, 2006, J AM SOC NEPHROL, V17, P724, DOI 10.1681/ASN.2005080810
   Flyvbjerg A, 2002, DIABETES, V51, P3090, DOI 10.2337/diabetes.51.10.3090
   Glyn Jones S, 2015, LANCET, V386, P376, DOI 10.1016/S0140 6736(14)60802 3
   Goldring M B, 2000, Curr Rheumatol Rep, V2, P459, DOI 10.1007/s11926 000 0021 y
   Gore M, 2012, PAIN PRACT, V12, P550, DOI 10.1111/j.1533 2500.2012.00532.x
   Hochberg MC, 2012, ARTHRIT CARE RES, V64, P465, DOI 10.1002/acr.21596
   Jevsevar DS, 2013, J AM ACAD ORTHOP SUR, V21, P571, DOI 10.5435/JAAOS 21 09 571
   Jin GX, 2014, DRUG DISCOV TODAY, V19, P637, DOI 10.1016/j.drudis.2013.11.005
   Kearney PM, 2006, BMJ BRIT MED J, V332, P1302, DOI 10.1136/bmj.332.7553.1302
   Kida T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096481
   Kornbluth A, 2010, AM J GASTROENTEROL, V105, P501, DOI 10.1038/ajg.2009.727
   Lajeunesse D, 2003, Mod Rheumatol, V13, P7, DOI 10.3109/s101650300001
   Lichtenstein GR, 2018, AM J GASTROENTEROL, V113, P481, DOI 10.1038/ajg.2018.27
   Maes C, 2010, EMBO J, V29, P424, DOI 10.1038/emboj.2009.361
   Martel Pelletier J, 2008, BEST PRACT RES CL RH, V22, P351, DOI 10.1016/j.berh.2008.02.001
   Mastbergen SC, 2008, ANN RHEUM DIS, V67, P52, DOI 10.1136/ard.2006.065946
   Moosavinasab S, 2016, DATABASE OXFORD, DOI 10.1093/database/baw083
   Mosca E, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471 2105 10 S12 S8
   Novac N, 2013, TRENDS PHARMACOL SCI, V34, P267, DOI 10.1016/j.tips.2013.03.004
   Pitta M, 2018, J ARTHROPLASTY, V33, P407, DOI 10.1016/j.arth.2017.09.041
   Plosker GL, 2005, DRUGS, V65, P1825, DOI 10.2165/00003495 200565130 00008
   Saito R, 2012, NAT METHODS, V9, P1069, DOI [10.1038/NMETH.2212, 10.1038/nmeth.2212]
   Scott DL, 2000, RHEUMATOLOGY, V39, P1095, DOI 10.1093/rheumatology/39.10.1095
   Sostres C, 2010, BEST PRACT RES CL GA, V24, P121, DOI 10.1016/j.bpg.2009.11.005
   Tchetina EV, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2273
   Trelle S, 2011, BMJ BRIT MED J, V342, DOI 10.1136/bmj.c7086
   van den Berg WB, 2011, OSTEOARTHR CARTILAGE, V19, P338, DOI 10.1016/j.joca.2011.01.022
   VANE JR, 1971, NATURE NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0
   Wagner AH, 2016, NUCLEIC ACIDS RES, V44, pD1036, DOI 10.1093/nar/gkv1165
   Wang QW, 2013, OPHTHALMOLOGICA, V229, P187, DOI 10.1159/000346847
   Wenham CYJ, 2010, THER ADV MUSCULOSKEL, V2, P349, DOI 10.1177/1759720X10378373
   Zweers MC, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3437
NR 43
TC 4
Z9 4
U1 0
U2 10
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2040 2295
EI 2040 2309
J9 J HEALTHC ENG
JI J. Healthc. Eng.
PD APR 14
PY 2021
VL 2021
DI 10.1155/2021/6674744
PG 14
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI EXPANDED)
SC Health Care Sciences & Services
GA SW9PV
UT WOS:000664846500003
PM 33953899
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Li, SH
   Li, SQ
   Li, QJ
   Zhou, QF
   Liao, WL
   Yu, LZ
   Ouyang, CH
   Xia, HL
   Liu, C
   Li, MC
AF Li, Shihuan
   Li, Suqin
   Li, Qingjie
   Zhou, Qiaofeng
   Liao, Wenli
   Yu, Liangzhu
   Ouyang, Changhan
   Xia, Hongli
   Liu, Chao
   Li, Mincai
TI Identification of key genes and pathways in atherosclerosis using
   integrated bioinformatics analysis
SO BMC MEDICAL GENOMICS
LA English
DT Article
DE Atherosclerosis; Differentially expressed genes (DEGs); Network modules;
   Biomarker; Bioinformatics analysis
ID CELLS; CCR5; MACROPHAGES
AB BackgroundAtherosclerosis (AS) is a chronic inflammatory disease that might induce severe cardiovascular events, such as myocardial infarction and cerebral infarction. These risk factors in the pathogenesis of AS remain uncertain and further research is needed. This study aims to explore the potential molecular mechanisms of AS by bioinformatics analyses.MethodsGSE100927 gene expression profiles, including 69 AS samples and 35 healthy controls, were downloaded from Gene Expression Omnibus database and indenfied for key genes and pathways in AS.ResultsA total of 443 differentially expressed genes (DEGs) between control and AS were identified, including 323 down regulated genes and 120 up regulated genes. The Gene ontology terms enriched by the up regulated DEGs were associated with the regulation of leukocyte activation, endocytic vesicle, and cytokine binding, while the down regulated DEGs were associated with negative regulation of cell growth, extracellular matrix, and G protein coupled receptor binding. KEGG pathway analysis showed that the up regulated DEGs were enriched in Osteoclast differentiation and Phagosome, while the down regulated DEGs were enriched in vascular smooth muscle contraction and cGMP PKG signaling pathway. Using the modular analysis of Cytoscape, we identified 3 modules mainly involved in Leishmaniasis and Osteoclast differentiation. The GSEA analysis showed the up regulated gene sets were enriched in the ribosome, ascorbated metabolism, and propanoate metabolism. The LASSO Cox regression analysis showed the top 3 genes were TNF, CX3CR1, and COL1R1. Finally, we found these immune cells were conferred significantly higher infiltrating density in the AS group.ConclusionsOur data showed the pathway of Osteoclast differentiation and Leishmaniasis was involved in the AS process and we developed a three gene model base on the prognosis of AS. These findings clarified the gene regulatory network of AS and may provide a novel target for AS therapy.
C1 [Li, Shihuan; Li, Qingjie; Zhou, Qiaofeng; Liu, Chao; Li, Mincai] Hubei Univ Sci & Technol, Xianning Med Coll, Hubei Key Lab Diabet & Angiopathy, Xianning 437100, Peoples R China.
   [Li, Suqin; Liao, Wenli; Yu, Liangzhu; Li, Mincai] Hubei Univ Sci & Technol, Xianning Med Coll, Sch Basic Med Sci, Xianning 437100, Peoples R China.
   [Li, Shihuan; Li, Qingjie; Zhou, Qiaofeng; Ouyang, Changhan] Hubei Univ Sci & Technol, Xianning Med Coll, Sch Pharm, Xianning 437100, Peoples R China.
   [Xia, Hongli] Hubei Univ Sci & Technol, Cent Hosp Xianning, Xianning Med Coll, Xianning 437100, Peoples R China.
C3 Hubei University of Science & Technology; Hubei University of Science &
   Technology; Hubei University of Science & Technology; Hubei University
   of Science & Technology
RP Liu, C; Li, MC (通讯作者)，Hubei Univ Sci & Technol, Xianning Med Coll, Hubei Key Lab Diabet & Angiopathy, Xianning 437100, Peoples R China.; Li, MC (通讯作者)，Hubei Univ Sci & Technol, Xianning Med Coll, Sch Basic Med Sci, Xianning 437100, Peoples R China.
EM tnbsys_liuchao@126.com; mincaili@163.com
RI Liu, Chao/MEP 0183 2025; Li, Qingjie/HGF 2080 2022; yu,
   liangzhu/AAE 1941 2019
CR Bezsonov EE, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22084080
   Brawn LC, 2007, CELL HOST MICROBE, V1, P63, DOI 10.1016/j.chom.2007.02.001
   Chen J, 2021, ADV DRUG DELIVER REV, V170, P142, DOI 10.1016/j.addr.2021.01.005
   Chistiakov DA, 2013, IMMUNOL LETT, V151, P10, DOI 10.1016/j.imlet.2013.01.014
   Durham AL, 2018, CARDIOVASC RES, V114, P590, DOI 10.1093/cvr/cvy010
   Efendi A, 2018, AIP CONF PROC, V2021, DOI 10.1063/1.5062766
   Garrè JM, 2017, NAT MED, V23, P714, DOI 10.1038/nm.4340
   Gazioglu SB, 2015, INT J CLIN EXP PATHO, V8, P15919
   Han NN, 2021, J CANCER, V12, P3045, DOI 10.7150/jca.55580
   Hrdlicka Henry C, 2019, Curr Mol Biol Rep, V5, P65, DOI 10.1007/s40610 019 0116 3
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kanehisa M, 2022, PROTEIN SCI, V31, P47, DOI 10.1002/pro.4172
   Kanehisa M, 2021, NUCLEIC ACIDS RES, V49, pD545, DOI 10.1093/nar/gkaa970
   Lanzer P, 2021, J AM COLL CARDIOL, V78, P1145, DOI 10.1016/j.jacc.2021.06.049
   Lee D, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0562 5
   Li BL, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.753711
   Li XL, 2021, EUR J HISTOCHEM, V65, DOI 10.4081/ejh.2021.3184
   Li ZM, 2021, BIOENGINEERED, V12, P1026, DOI 10.1080/21655979.2021.1899533
   Libby P, 2021, NATURE, V592, P524, DOI 10.1038/s41586 021 03392 8
   Lin CS, 2018, CELL PHYSIOL BIOCHEM, V47, P707, DOI 10.1159/000490024
   Liu CY, 2021, FRONT GENET, V11, DOI 10.3389/fgene.2020.602908
   Lu JJ, 2021, BMC CANCER, V21, DOI 10.1186/s12885 021 08456 6
   Mezentsev A, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9060600
   Moore KJ, 2018, J AM COLL CARDIOL, V72, P2181, DOI 10.1016/j.jacc.2018.08.2147
   Morimura S, 2016, J DERMATOL SCI, V82, P175, DOI 10.1016/j.jdermsci.2016.03.004
   Newman AM, 2019, NAT BIOTECHNOL, V37, P773, DOI 10.1038/s41587 019 0114 2
   Ni YH, 2022, METABOLISM, V136, DOI 10.1016/j.metabol.2022.155272
   Nie H, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/5491038
   Roy P, 2022, NAT REV IMMUNOL, V22, P251, DOI 10.1038/s41577 021 00584 1
   Salih MAM, 2017, PARASITE IMMUNOL, V39, DOI 10.1111/pim.12431
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Skinkyte Juskiene R, 2018, CURR GENOMICS, V19, P289, DOI 10.2174/1389202918666171005095059
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Szklarczyk D, 2021, NUCLEIC ACIDS RES, V49, pD605, DOI 10.1093/nar/gkaa1074
   Szukiewicz D, 2015, CARDIOVASC DRUG THER, V29, P219, DOI 10.1007/s10557 015 6589 2
   Vallejo A, 2015, EUR J CLIN MICROBIOL, V34, P267, DOI 10.1007/s10096 014 2229 1
   Wang X, 2021, AGING US, V13, P23810, DOI 10.18632/aging.203654
   Wei YY, 2015, ARTERIOSCL THROM VAS, V35, P796, DOI 10.1161/ATVBAHA.114.304723
   Wesseling M, 2018, VASC PHARMACOL, V106, P1, DOI 10.1016/j.vph.2018.02.006
   Xu SW, 2021, PHARMACOL REV, V73, P924, DOI 10.1124/pharmrev.120.000096
   Xu XX, 2021, PHARMACOGEN PERS MED, V14, P431, DOI 10.2147/PGPM.S301098
   Yang J, 2017, INT J CANCER, V141, P2082, DOI 10.1002/ijc.30912
   Yao ZQ, 2022, CELLS BASEL, V11, DOI 10.3390/cells11010132
   Yuan S, 2020, EBIOMEDICINE, V59, DOI 10.1016/j.ebiom.2020.102956
   Zavaczki E, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/3721383
   Zhao B, 2020, CARDIOVASC THER, V2020, DOI 10.1155/2020/1230513
   Zhao TX, 2019, J AM COLL CARDIOL, V73, P1691, DOI 10.1016/j.jacc.2018.12.083
NR 48
TC 4
Z9 4
U1 3
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1755 8794
J9 BMC MED GENOMICS
JI BMC Med. Genomics
PD MAY 13
PY 2023
VL 16
IS 1
AR 102
DI 10.1186/s12920 023 01533 8
PG 14
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA F9XA6
UT WOS:000985791400002
PM 37179331
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Yao, KT
   Zhang, Q
   Weng, L
   Li, SY
   Zheng, XZ
   Hu, LQ
   Luo, YX
   Huang, XY
   Gong, ZF
   Wang, Z
   Liu, C
   Yan, JY
   Ge, JH
   Chen, XT
   Yin, YR
AF Yao, Kaitao
   Zhang, Qian
   Weng, Lian
   Li, Shuyang
   Zheng, Xuzhou
   Hu, Liqun
   Luo, Yuxi
   Huang, Xiaoyu
   Gong, Zhangfan
   Wang, Zi
   Liu, Chang
   Yan, Jiyuan
   Ge, Jianhua
   Chen, Xingtao
   Yin, Yiran
TI Cerium Doped, Alendronate Loaded, Metal Organic Framework Nanodrug for
   Delayed Osteoporosis Progress
SO ACS APPLIED NANO MATERIALS
LA English
DT Article
DE osteoporosis; alendronate sodium; zeolite imidazoleskeleton; cerium;
   reactive oxygen species
ID OSTEOGENIC DIFFERENTIATION; BONE REGENERATION; DRUG RELEASE; THERAPY;
   OSTEOCLASTOGENESIS; NANOPARTICLES; NANOMATERIALS; EXPRESSION; EFFICIENT;
   CELLS
AB Osteoporosis (OP) is a global disease featured by decreased osteogenesis and overactivation of osteoclast generation with chronic inflammation, which has no satisfactory treatment currently. Accordingly, normalizing the inflammatory microenvironments by introducing osteogenic and anti inflammatory agents is emerging as a promising approach for OP treatment. Herein, zinc based zeolite imidazolium skeleton (ZIF 8) nanoparticles (NPs) are doped with cerium ions, loaded with alendronate sodium (Aln), and coated with poly(sodium 4 styrenesulfonate) (PSS) (Aln/PSS@ZIF 8:Ce) for OP treatment. The NPs can be uniformly dispersed and remain stable at pH = 7.4 and gradually release Aln and Ce ions at pH = 6.8, thus potentially providing antioxidative activity in OP microenvironments. The in vitro study indicates that the NPs can not only promote osteogenic differentiation and biomineralization, but also inhibit osteoclast formation and bone resorption by inhibiting reactive oxygen species production, mitogen activated protein kinase, and nuclear factor kappa B signaling pathways. After intravenous injection into OP mice, the Aln/PSS@ZIF 8:Ce NPs due to their nanoscale properties can significantly reduce bone loss and delay OP progression. Additionally, the NPs exhibit good cytocompatibility in vitro and good histocompatibility in vivo with no adverse reaction. This study demonstrates the efficacy of Aln/PSS@ZIF 8:Ce NPs to normalize OP microenvironments and delay OP progression, and the NPs also hold promise for application in other inflammation related diseases.
C1 [Yao, Kaitao; Zhang, Qian; Li, Shuyang; Zheng, Xuzhou; Hu, Liqun; Luo, Yuxi; Huang, Xiaoyu; Gong, Zhangfan; Wang, Zi; Liu, Chang; Yan, Jiyuan; Ge, Jianhua; Chen, Xingtao; Yin, Yiran] Southwest Med Univ, Affiliated Hosp, Dept Orthopaed, Luzhou 646000, Peoples R China.
   [Yao, Kaitao; Zhang, Qian; Li, Shuyang; Zheng, Xuzhou; Hu, Liqun; Luo, Yuxi; Huang, Xiaoyu; Gong, Zhangfan; Wang, Zi; Liu, Chang; Yan, Jiyuan; Ge, Jianhua; Chen, Xingtao; Yin, Yiran] Southwest Med Univ, Sichuan Prov Lab Orthoped Engn, Luzhou 646000, Peoples R China.
   [Weng, Lian; Huang, Xiaoyu] Luzhou Longmatan Dist Peoples Hosp, Luzhou 646000, Peoples R China.
C3 Southwest Medical University; Southwest Medical University
RP Ge, JH; Chen, XT; Yin, YR (通讯作者)，Southwest Med Univ, Affiliated Hosp, Dept Orthopaed, Luzhou 646000, Peoples R China.; Ge, JH; Chen, XT; Yin, YR (通讯作者)，Southwest Med Univ, Sichuan Prov Lab Orthoped Engn, Luzhou 646000, Peoples R China.
EM orthodrgjh@126.com; chenxingtao007@126.com; yiranyin@swmu.edu.cn
RI ; xiaoyu, huang/AGA 4275 2022; Hu, Liqun/KXR 5374 2024
OI yao, kai tao/0009 0006 2657 7184; 
FU Science and Technology Department of Sichuan Province [2020YFS0455,
   2022YFS0628, 24QYCX0447]; Key Research and Development Program of
   Sichuan Province [HYX22006]; Project of Sichuan Key Laboratory of
   Nuclear Medicine and Molecular Imaging [2021LZXNYD J05, 2022 GYF 13];
   Luzhou Science and Technology Program [2021CxYY02]; Southwest Medical
   University
FX This work was supported by the Key Research and Development Program of
   Sichuan Province (No. 2020YFS0455, 2022YFS0628 and 24QYCX0447), Project
   of Sichuan Key Laboratory of Nuclear Medicine and Molecular Imaging (No.
   HYX22006), Luzhou Science and Technology Program (No. 2021LZXNYD J05 and
   2022 GYF 13), and Southwest Medical University (No. 2021CxYY02). We
   gratefully acknowledge the technical support by Figdraw software
   [ID:ROOTU6eeee].
CR Abdelhamid HN, 2021, CURR MED CHEM, V28, P7023, DOI 10.2174/0929867328666210608143703
   Al Baadani MA, 2022, MATER DESIGN, V217, DOI 10.1016/j.matdes.2022.110596
   Amin K, 2006, J PHARM SCI US, V95, P1173, DOI 10.1002/jps.20627
   Anagnostis P, 2019, MATURITAS, V120, P1, DOI 10.1016/j.maturitas.2018.11.010
   Arnett TR, 2008, J NUTR, V138, p415S, DOI 10.1093/jn/138.2.415S
   Ayers C, 2023, ANN INTERN MED, V176, DOI 10.7326/M22 0684
   Bautista Villanueva S, 2022, J INVEST ALLERG CLIN, V32, P69, DOI 10.18176/jiaci.0709
   Bêche E, 2008, SURF INTERFACE ANAL, V40, P264, DOI 10.1002/sia.2686
   Cai W, 2019, ADV SCI, V6, DOI 10.1002/advs.201801526
   Carnovali M, 2023, ANTIOXIDANTS BASEL, V12, DOI 10.3390/antiox12020345
   Chen XT, 2020, THERANOSTICS, V10, P3281, DOI 10.7150/thno.37599
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   D'Amelio P, 2010, OSTEOPOROSIS INT, V21, P1741, DOI 10.1007/s00198 009 1129 1
   Ferraz LRD, 2021, J MATER SCI MATER M, V32, DOI 10.1007/s10856 021 06530 w
   Dou C, 2021, BIOACT MATER, V6, P4697, DOI 10.1016/j.bioactmat.2021.04.038
   Duan L, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 02374 x
   Eskandarynasab M, 2020, NANOMED NANOTECHNOL, V29, DOI 10.1016/j.nano.2020.102273
   Force C, 2007, LANGMUIR, V23, P4569, DOI 10.1021/la0628118
   Gehrke B, 2024, ARCH ENDOCRIN METAB, V68, P1, DOI 10.20945/2359 4292 2022 0334
   Hong GJ, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.392
   Iantomasi T, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24043772
   Inoue Y, 2010, EXP CLIN ENDOCR DIAB, V118, P719, DOI 10.1055/s 0030 1249084
   Jeong D., 2023, RES SQUARE, DOI [10.21203/rs.3.rs 2787673/v1, DOI 10.21203/RS.3.RS 2787673/V1]
   Kim HK, 2009, CLIN ORTHOP RELAT R, V467, P3121, DOI 10.1007/s11999 008 0409 y
   Kim H, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22565 7
   Kim J, 2021, INT J MED SCI, V18, P3261, DOI 10.7150/ijms.61552
   Klara J, 2022, INT J NANOMED, V17, P6065, DOI 10.2147/IJN.S388430
   Komeili M, 2021, LIFE SCI, V265, DOI 10.1016/j.lfs.2020.118780
   Krüger TB, 2022, ACTA ODONTOL SCAND, V80, P619, DOI 10.1080/00016357.2022.2072522
   Kundert DN, 2023, HELIYON, V9, DOI 10.1016/j.heliyon.2023.e19468
   Li JM, 2021, BIOACT MATER, V6, P3839, DOI 10.1016/j.bioactmat.2021.03.039
   Liu Q, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.601224
   Liu XL, 2023, J NANOBIOTECHNOL, V21, DOI 10.1186/s12951 023 01988 y
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lorentzon M, 2022, CLIMACTERIC, V25, P4, DOI 10.1080/13697137.2021.1951206
   Matussin SN, 2023, J RARE EARTH, V41, P167, DOI 10.1016/j.jre.2022.09.003
   Partoazar A, 2022, J FOOD BIOCHEM, V46, DOI 10.1111/jfbc.14120
   Peng X, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202102583
   Prabu C, 2017, J MAGN MAGN MATER, V427, P258, DOI 10.1016/j.jmmm.2016.11.030
   Purikova O, 2022, ADV FUNCT MATER, V32, DOI 10.1002/adfm.202208316
   Qiu MX, 2022, COLLOID SURFACE B, V212, DOI 10.1016/j.colsurfb.2022.112354
   Qu ZC, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1043975
   Ren SS, 2022, BIOACT MATER, V7, P242, DOI 10.1016/j.bioactmat.2021.05.037
   Ren W, 2020, WATER RES, V186, DOI 10.1016/j.watres.2020.116361
   Ren XX, 2022, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.820468
   Shi HX, 2023, THERANOSTICS, V13, P3245, DOI 10.7150/thno.84759
   Sun H, 2023, BIOACT MATER, V24, P477, DOI 10.1016/j.bioactmat.2022.12.021
   Tang DE, 2020, AGING US, V12, P13297, DOI 10.18632/aging.103434
   Tu TY, 2019, COLLOID SURFACE B, V173, P788, DOI 10.1016/j.colsurfb.2018.10.043
   Wang CL, 2024, BMEMAT, V2, DOI 10.1002/bmm2.12068
   Wang KM, 2022, WORLD J CLIN CASES, V10, P7324, DOI 10.12998/wjcc.v10.i21.7324
   Xiao L, 2020, AGING US, V12, P21706, DOI 10.18632/aging.103976
   Xiao ZH, 2022, J ORTHOP SURG RES, V17, DOI 10.1186/s13018 022 03330 y
   Xu MY, 2019, J MATER CHEM B, V7, P5535, DOI 10.1039/c9tb01012b
   Xu YY, 2023, ACS NANO, V17, P18732, DOI 10.1021/acsnano.3c01940
   Yan L, 2013, CHEM ASIAN J, V8, P2342, DOI 10.1002/asia.201300542
   Ye CY, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12752
   Yin Y, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202000973
   Zhang C, 2023, BIOMED PHARMACOTHER, V163, DOI 10.1016/j.biopha.2023.114834
   Zhang DZ, 2022, SENSOR ACTUAT B CHEM, V357, DOI 10.1016/j.snb.2022.131419
   Zhang HY, 2017, ACS APPL MATER INTER, V9, P19687, DOI 10.1021/acsami.7b05142
   Zhang QH, 2013, MOL MED REP, V8, P1195, DOI 10.3892/mmr.2013.1630
   Zhao BK, 2022, CELLS BASEL, V11, DOI 10.3390/cells11111724
   Zhao HQ, 2021, J MATER CHEM B, V9, P6939, DOI 10.1039/d1tb00720c
   Zhao XF, 2020, BONE RES, V8, DOI 10.1038/s41413 020 0085 4
   Zhao YN, 2011, ACS NANO, V5, P1366, DOI 10.1021/nn103077k
   Zhivodernikov IV, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms242115772
   Zhou YN, 2022, FUND RES CHINA, V2, P674, DOI 10.1016/j.fmre.2021.12.001
   Zou DT, 2018, ENERGY ENVIRON MATER, V1, P209, DOI 10.1002/eem2.12018
NR 69
TC 1
Z9 1
U1 8
U2 15
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
EI 2574 0970
J9 ACS APPL NANO MATER
JI ACS Appl. Nano Mater.
PD DEC 9
PY 2024
VL 7
IS 24
BP 28504
EP 28518
DI 10.1021/acsanm.4c05640
EA DEC 2024
PG 15
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA Q6F1Q
UT WOS:001372902300001
DA 2025 08 17
ER

PT J
AU Schilrreff, P
   Cervini, G
   Romero, EL
   Morilla, MJ
AF Schilrreff, Priscila
   Cervini, Gabriela
   Romero, Eder Lilia
   Morilla, Maria Jose
TI Enhanced antimelanoma activity of methotrexate and zoledronic acid
   within polymeric sandwiches
SO COLLOIDS AND SURFACES B BIOINTERFACES
LA English
DT Article
DE Melanoma; Dendrimers; Antifolates; Bisphosphonates
ID MELANOMA CELLS; CAVEOLAR ENDOCYTOSIS; FOLATE RECEPTOR; TUMOR GROWTH;
   IN VIVO; INTERNALIZATION; MACROPINOCYTOSIS; INHIBITION; DELIVERY;
   BISPHOSPHONATES
AB New therapies are urgently needed against melanoma, one of the most aggressive tumors. Melanoma cells are resistant to the antifolate methotrexate (MTX), since MTX is taken up by the folate receptor alpha (FR alpha), sequestered in melanosomes and exported out of the cell. The bisphosphonate zoledronic acid (ZOL) is active in several non skeletal tumors; however, its antitumotal activity is hampered by its long term accumulation in bones and low cellular permeability. Recently, we showed that core shell tecto dendrimers made of amine terminated polyamidoamine generation 5 dendrimer (G5) as core and carboxyl terminated G2.5 dendrimer as shell (G5G2.5) had selective cytotoxicity to melanoma cells. We hypothesized here that the activity of MTX and ZOL on melanoma cells could be enhanced when loaded within G5G2.5.
   MTX and ZOL were loaded within G5 cores, which were coated by a covalently bound shell of G2.5 dendrimers (drug sandwiches). 12 nm mean diameter and  12 mV Z potential drug sandwiches incorporating 6 and 31 molecules of MTX and ZOL, respectively, per G5G2.5, showed higher cytotoxicity (by MTT and apoptosis/necrosis assays) to melanoma (Sk Mel 28) cells than free drugs and G5G2.5. Only MTX sandwich was cytotoxic to Sk Mel 28 cells and harmless to keratinocytes (HaCaT cells). The intracellular pathway of G5G2.5 was followed using chemical inhibitors of endocytosis. The increased cytotoxicity of MTX sandwich could be due to its uptake by macropinocytosis instead of by FRa, avoiding MTX exocytosis. The increased cytotoxicity of ZOL sandwich could be due to an increased intracellular accumulation of ZOL, owed by its endocytic uptake instead of diffusing as free drug. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Schilrreff, Priscila; Cervini, Gabriela; Romero, Eder Lilia; Morilla, Maria Jose] Univ Nacl Quilmes, Dept Ciencia & Tecnol, Nanomed Res Program, Buenos Aires, DF, Argentina.
RP Morilla, MJ (通讯作者)，Univ Nacl Quilmes, Dept Ciencia & Tecnol, Nanomed Res Program, Roque Saenz Pena 352,Bernal B1876 BXD, Buenos Aires, DF, Argentina.
EM jmorilla@unq.edu.ar
RI romero, eder/N 9329 2014; Schilrreff, Priscila/JXY 4918 2024
OI Morilla, Maria Jose/0000 0003 3706 9207; romero, eder
   lilia/0000 0003 3020 1746; Schilrreff, Priscila/0000 0002 8003 2250
FU EULANEST project Nanoskin; Secretaria de Investigaciones, Universidad
   Nacional de Quilmes; National Council for Scientific and Technological
   Research (CONICET); CIN
FX This work was supported by EULANEST project Nanoskin and Secretaria de
   Investigaciones, Universidad Nacional de Quilmes. PS has a fellowship
   from National Council for Scientific and Technological Research
   (CONICET) and GC has a fellowship from CIN. ELR and MJM are members of
   the Research Career Program from CONICET.
CR Albertazzi L, 2010, MOL PHARMACEUT, V7, P680, DOI 10.1021/mp9002464
   Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249
   Bandarchi B, 2010, DERMAT RES PRACT, V2010, DOI 10.1155/2010/583748
   Benzaïd I, 2011, CANCER RES, V71, P4562, DOI 10.1158/0008 5472.CAN 10 3862
   Bleyer WA, 1997, J PEDIAT HEMATOL ONC, V19, P530, DOI 10.1097/00043426 199711000 00008
   BOETTCHER C, 1961, ANAL CHIM ACTA, V24, P203, DOI 10.1016/0003 2670(61)80041 X
   Chen K.G., 2005, MELANOCYTES MALIGNAN
   Cheng ZJ, 2006, MOL MEMBR BIOL, V23, P101, DOI 10.1080/09687860500460041
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   del Campo L. Sanchez, 2013, MELANOMA EARLY DETEC
   FITZPATRICK T B, 1971, Birth Defects Original Article Series, V7, P5
   Forsea AM, 2004, BRIT J CANCER, V91, P803, DOI 10.1038/sj.bjc.6602052
   Gray Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661
   Green JR, 2011, CRIT REV ONCOL HEMAT, V77, pS3, DOI 10.1016/S1040 8428(11)70003 8
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9 90004 3
   Grim J, 2003, CLIN PHARMACOKINET, V42, P139, DOI 10.2165/00003088 200342020 00003
   Guenther A, 2010, INT J CANCER, V126, P239, DOI 10.1002/ijc.24758
   Haaka A., 2001, BIOL SKIN
   Hirbe AC, 2009, BONE, V44, P908, DOI 10.1016/j.bone.2009.01.010
   Kaminskas LM, 2009, MOL PHARMACEUT, V6, P1190, DOI 10.1021/mp900049a
   [孔淑仪 KONG Shuyi], 2008, [中国药学杂志, Chinese Pharmaceutical Journal], V43, P1085
   KUFE DW, 1980, J INVEST DERMATOL, V75, P357, DOI 10.1111/1523 1747.ep12531146
   Majoros IJ, 2009, WIRES NANOMED NANOBI, V1, P502, DOI 10.1002/wnan.37
   Marra M, 2012, BIOTECHNOL ADV, V30, P302, DOI 10.1016/j.biotechadv.2011.06.018
   Mercer J, 2012, CURR OPIN MICROBIOL, V15, P490, DOI 10.1016/j.mib.2012.05.016
   Michihara A, 2005, BIOL PHARM BULL, V28, P947, DOI 10.1248/bpb.28.947
   Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028
   Nordlund J.J., 2001, BIOL SKIN
   Ottewell PD, 2010, INT J CANCER, V126, P522, DOI 10.1002/ijc.24756
   PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199
   Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539
   Pless DD, 1996, J CELL BIOCHEM, V62, P27, DOI 10.1002/(SICI)1097 4644(199607)62:1<27::AID JCB4>3.0.CO;2 3
   Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111
   Quintana A, 2002, PHARM RES DORDR, V19, P1310, DOI 10.1023/A:1020398624602
   Sánchez del Campo L, 2009, PIGM CELL MELANOMA R, V22, P588, DOI 10.1111/j.1755 148X.2009.00586.x
   Saovapakhiran A, 2009, BIOCONJUGATE CHEM, V20, P693, DOI 10.1021/bc8002343
   Schilrreff P, 2012, INT J NANOMED, V7, P4121, DOI 10.2147/IJN.S32785
   Shih CH, 2013, MATRIX BIOL, V32, P152, DOI 10.1016/j.matbio.2013.01.001
   Shmeeda H, 2010, J CONTROL RELEASE, V146, P76, DOI 10.1016/j.jconrel.2010.04.028
   Subtil A, 1997, J CELL SCI, V110, P2441
   Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775
   SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962 8924(00)89101 1
   Velho T.R., 2012, DRUGS CONTEXT
   Vercauteren D, 2012, J CONTROL RELEASE, V161, P566, DOI 10.1016/j.jconrel.2012.05.020
   WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107
   Zinchuk V., 2008, Curr. Protoc. Cell Biol, V39, p4.19.1
   Zong H, 2012, BIOMACROMOLECULES, V13, P982, DOI 10.1021/bm201639c
NR 47
TC 11
Z9 11
U1 0
U2 39
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927 7765
EI 1873 4367
J9 COLLOID SURFACE B
JI Colloid Surf. B Biointerfaces
PD OCT 1
PY 2014
VL 122
BP 19
EP 29
DI 10.1016/j.colsurfb.2014.06.033
PG 11
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Chemistry; Materials Science
GA AR5GK
UT WOS:000343612900004
PM 25016541
OA Green Published
DA 2025 08 17
ER

PT J
AU John, MR
   Harfst, E
   Loeffler, J
   Belleli, R
   Mason, J
   Bruin, GJM
   Seuwen, K
   Klickstein, LB
   Mindeholm, L
   Widler, L
   Kneissel, M
AF John, Markus R.
   Harfst, Evita
   Loeffler, Juergen
   Belleli, Rossella
   Mason, June
   Bruin, Gerard J. M.
   Seuwen, Klaus
   Klickstein, Lloyd B.
   Mindeholm, Linda
   Widler, Leo
   Kneissel, Michaela
TI AXT914 a novel, orally active parathyroid hormone releasing drug in two
   early studies of healthy volunteers and postmenopausal women
SO BONE
LA English
DT Article
DE Calcilytics; Bone formation; Osteoporosis; Parathyroid hormone;
   Teriparatide
ID CALCIUM SENSING RECEPTOR; BONE MINERAL DENSITY; ANTAGONIST; RONACALERET;
   PTH; OSTEOPOROSIS
AB Antagonism of the calcium sensing receptor in the parathyroid gland leads to parathyroid hormone (PTH) release. Calcilytics are a new class of molecules designed to exploit this mechanism. In order to mimic the known bone anabolic pharmacokinetic (PK) profile of s.c. administered PTH, such molecules must trigger sharp, transient and robust release of PTH. The results of two early clinical studies with the orally active calcilytic AXT914, a quinazolin 2ne derivative are reported. These were GCP compliant, single and multiple dose studies of PK/PD and tolerability in healthy volunteers and postmenopausal women.
   The first study, examined single ascending doses (4 to 120 mg) and limited multiple doses (60 or 120 mg q.d. for 12 days) of AXT914. The second study was a randomized, double blind, active  and placebo controlled, 4 week repeat dose parallel group study of healthy postmenopausal women (45 and 60 mg AXT914, placebo, 20 mu g Forteo/teriparatide/PTH(1 34) fragment).
   AXT914 was well tolerated at all doses and reproducibly induced the desired FM release profiles. Yet, 4 weeks of 45 or 60 mg AXT914 did not result in the expected changes in circulating bone biomarkers seen with teriparatide. However total serum calcium levels increased above baseline in the 45 and 60 mg AXT914 treatment groups (8.0% and 10.7%, respectively), compared to that in the teriparatide and placebo groups (1.3% and 1.0%, respectively). Thus the trial was terminated after a planned interim analysis due to lack of effect on bone formation biomarkers and dose limiting effects on serum calcium.
   In conclusion, AXT914 was well tolerated but the observed transient and reproducible PTH release after repeat oral administration of AXT914 which showed an exposure profile close to that of s c. PTH, did not translate into a bone anabolic response and was associated with a persistent dose related increase in serum calcium concentrations. (C) 2014 Elsevier Inc. All rights reserved.
C1 [John, Markus R.; Harfst, Evita; Loeffler, Juergen; Belleli, Rossella; Mason, June; Mindeholm, Linda] Novartis Pharma AG, Basel, Switzerland.
   [John, Markus R.; Harfst, Evita; Loeffler, Juergen; Belleli, Rossella; Mason, June; Mindeholm, Linda] Novartis Corp, E Hanover, NJ USA.
   [Bruin, Gerard J. M.; Seuwen, Klaus; Klickstein, Lloyd B.; Widler, Leo; Kneissel, Michaela] Novartis Inst Biomed Res, CH 4056 Basel, Switzerland.
   [Bruin, Gerard J. M.; Seuwen, Klaus; Klickstein, Lloyd B.; Widler, Leo; Kneissel, Michaela] Novartis Inst Biomed Res, Cambridge, MA USA.
C3 Novartis; Novartis; Novartis USA; Novartis; Novartis; Novartis USA
RP Kneissel, M (通讯作者)，Novartis Inst Biomed Res, WSJ360 4 08, CH 4056 Basel, Switzerland.
EM michaela.kneissel@novartis.com
OI Bruin, Gerard/0000 0002 8773 0705
CR Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Bilezikian JP, 2007, WOMENS HEALTH, V3, P243, DOI 10.2217/17455057.3.2.243
   Caltabiano S, 2013, BONE, V56, P154, DOI 10.1016/j.bone.2013.05.021
   Chakravarti B, 2012, ADV EXP MED BIOL, V740, P103, DOI 10.1007/978 94 007 2888 2_5
   Das S, 2013, DRUG DES DEV THER, V7, P435, DOI 10.2147/DDDT.S31504
   El Sherif N, 2011, CARDIOL J, V18, P233
   Fitzpatrick LA, 2012, J BONE MINER RES, V27, P255, DOI 10.1002/jbmr.554
   Fitzpatrick LA, 2011, BONE, V49, P845, DOI 10.1016/j.bone.2011.06.017
   Fitzpatrick LA, 2011, J CLIN ENDOCR METAB, V96, P2441, DOI 10.1210/jc.2010 2855
   Glover SJ, 2009, BONE, V45, P1053, DOI 10.1016/j.bone.2009.07.091
   John MR, 2011, BONE, V49, P233, DOI 10.1016/j.bone.2011.04.007
   John MR, 1999, J CLIN ENDOCR METAB, V84, P4287, DOI 10.1210/jc.84.11.4287
   John MR, 2010, J BONE MINER RES  S1
   Kumar S, 2010, BONE, V46, P534, DOI 10.1016/j.bone.2009.09.028
   Loupy A, 2012, J CLIN INVEST, V122, P3355, DOI 10.1172/JCI57407
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Park SY, 2013, CLIN ENDOCRINOL, V78, P687, DOI 10.1111/cen.12056
   REEVE J, 1976, LANCET, V1, P1035
   Riccardi Daniela, 2012, Curr Mol Pharmacol, V5, P182
   Schwietert HR, 1997, CLIN PHARMACOL THER, V61, P360, DOI 10.1016/S0009 9236(97)90169 7
   Silverman Stuart L, 2005, Curr Rheumatol Rep, V7, P39, DOI 10.1007/s11926 005 0007 x
   Ward BK, 2012, CLIN BIOCHEM, V45, P943, DOI 10.1016/j.clinbiochem.2012.03.034
   Widler L, 2008, J BONE MINER RES  S1, pS1173
   Widler L, 2011, FUTURE MED CHEM, V3, P535, DOI [10.4155/fmc.11.17, 10.4155/FMC.11.17]
NR 24
TC 31
Z9 35
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUL
PY 2014
VL 64
BP 204
EP 210
DI 10.1016/j.bone.2014.04.015
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AI6UC
UT WOS:000337011500028
PM 24769332
DA 2025 08 17
ER

PT J
AU Makris, G
   Tseligka, ED
   Pirmettis, I
   Papadopoulos, MS
   Vizirianakis, IS
   Papagiannopoulou, D
AF Makris, George
   Tseligka, Eirini D.
   Pirmettis, Ioannis
   Papadopoulos, Minas S.
   Vizirianakis, Ioannis S.
   Papagiannopoulou, Dionysia
TI Development and Pharmacological Evaluation of New Bone Targeted
   <SUP>99m</SUP>Tc Radiolabeled Bisphosphonates
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE bisphosphonates; technetium 99m; rhenium; cell studies; imaging agents
ID STRUCTURAL CHARACTERIZATION; IN VITRO; PAIN; COMPLEXES; DERIVATIVES;
   PALLIATION; THERAPY; RE; DIFFERENTIATION; SUBSTITUTION
AB A novel bisphosphonate, 1 (3aminopropylamino)ethane 1,1 diyldiphosphonic acid (3), was coupled to the tridentate chelators di 2 picolylamine, 2picolylamine N acetic acid, iminodiacetic acid, 34(2aminoethyl)thio) 3 (1H imidazol 4 y propanoic acid, and 2((2 carboxyethyl)thio) 3 (1H imidazol 4 yl)propanoic acid to form ligands 6, 9, 11, 15, and 19, respectively. Organometallic complexes of the general formula [Re/Tc 99m(CO)(3)(kappa(3) L)] were synthesized, where L denotes ligand 6, 9, 11, 15, or 19. The rhenium complexes were prepared at the macroscopic level and characterized by spectroscopic methods. The technetium 99m organometallic complexes were synthesized in high yield and were identified by comparative reversed phase HPLC with their Re analogues. The Tc 99m tracers were stable in vitro and exhibited binding to hydroxyapatite. In biodistribution studies, all of the Tc 99m complexes exhibited high bone uptake superior to that of 25, which is the directly Tc 99m labeled bisphosphonate 3, and comparable to that of Tc 99m methylene diphosphonate ((TcMDP) Tc 99m). The tracers [Tc 99m(C0)3(6)] (26), [Tc 99m(C0)3(9)] (27), [Tc 99m(C0)3(11)] (28), and [Tc 99m(C0)3(15)] (29) exhibited higher bone/blood ratios than (99m) MDP. 26 had the highest bone uptake at 1 h p.i. The new bisphosphonates showed no substantial growth inhibitory capacity in PC 3, Saos 2, and MCF 7 established cancer cell lines at low concentrations. Incubation of 26 with the same cancer cell lines indicated a rapid and saturated uptake. The promising properties of 26 29 indicate their potential for use as bone imaging agents.
C1 [Makris, George; Papagiannopoulou, Dionysia] Aristotle Univ Thessaloniki, Dept Pharmaceut Chem, Sch Pharm, Thessaloniki 54124, Greece.
   [Tseligka, Eirini D.; Vizirianakis, Ioannis S.] Aristotle Univ Thessaloniki, Sch Pharm, Pharmacol Lab, Thessaloniki 54124, Greece.
   [Pirmettis, Ioannis; Papadopoulos, Minas S.] NCSR Demokritos, Inst Nucl & Radiol Sci & Technol, Energy & Safety INRASTES, Agia Paraskevi Athens 15310, Greece.
   [Makris, George] Frederick Univ, Sch Hlth Sci, Dept Pharm, CY 1036 Nicosia, Cyprus.
   [Vizirianakis, Ioannis S.] Univ Nicosia, Dept Life & Hlth Sci, CY 1700 Nicosia, Cyprus.
C3 Aristotle University of Thessaloniki; Aristotle University of
   Thessaloniki; National Centre of Scientific Research "Demokritos";
   University of Nicosia
RP Papagiannopoulou, D (通讯作者)，Aristotle Univ Thessaloniki, Dept Pharmaceut Chem, Sch Pharm, Thessaloniki 54124, Greece.; Papagiannopoulou, D (通讯作者)，Aristotle Univ Thessaloniki, Sch Pharm, Dept Pharmaceut Chem, Univ Campus, Thessaloniki 54124, Greece.
EM papagd@pharm.auth.gr
RI ; Makris, George/AAD 1628 2020; Vizirianakis, Ioannis/AAK 6067 2020
OI Vizirianakis, Ioannis/0000 0003 1459 9774; 
FU Hellenic Ministry of Development; Institute of Nuclear and Radiological
   Sciences and Technology, Energy and Safety, NCSR "Demokritos"; Aristotle
   University of Thessaloniki Research Committee
FX G.M. acknowledges the Hellenic Ministry of Development and Institute of
   Nuclear and Radiological Sciences and Technology, Energy and Safety,
   NCSR "Demokritos" (Doctoral Fellowship) and the Aristotle University of
   Thessaloniki Research Committee (Award of Excellence) for their
   financial support. The authors are thankful to Dr. L. Vardouli and Ms.
   M. Akrivou for their assistance.
CR Alberto R, 2005, TOP CURR CHEM, V252, P1, DOI 10.1007/b101223
   ALBERTO R, 1994, J CHEM SOC DALTON, P2815, DOI 10.1039/dt9940002815
   Allali M, 2006, INORG CHIM ACTA, V359, P2128, DOI 10.1016/j.ica.2006.02.023
   Amorino GP, 2007, ONCOGENE, V26, P745, DOI 10.1038/sj.onc.1209814
   Angelucci A, 2008, ENDOCR RELAT CANCER, V15, P91, DOI 10.1677/ERC 07 0100
   Bartl R, 2007, BISPHOSPHONATES MED, P33
   Chlotellis A, 2008, INORG CHEM, V47, P2601, DOI 10.1021/ic7019268
   Clézardin P, 2005, CANCER RES, V65, P4971, DOI 10.1158/0008 5472.CAN 05 0264
   de Rosales RTM, 2009, CHEM COMMUN, P4847, DOI 10.1039/b908652h
   de Rosales RTM, 2010, BIOCONJUGATE CHEM, V21, P811, DOI 10.1021/bc100071k
   Edlbacher S, 1942, H S Z PHYSIOL CHEM, V276, P126, DOI 10.1515/bchm2.1942.276.3.126
   Falk S, 2014, J CLIN ONCOL, V32, P1647, DOI 10.1200/JCO.2013.51.7219
   Fernandes C, 2014, J ORGANOMET CHEM, V760, P197, DOI 10.1016/j.jorganchem.2013.10.038
   Finlay OG, 2005, LANCET ONCOL, V6, P392, DOI 10.1016/S1470 2045(05)70206 0
   Giglio J, 2008, EUR J MED CHEM, V43, P741, DOI 10.1016/j.ejmech.2007.05.015
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Lam MGEH, 2004, EUR J NUCL MED MOL I, V31, pS162, DOI 10.1007/s00259 004 1539 4
   LIBSON K, 1980, J AM CHEM SOC, V102, P2476, DOI 10.1021/ja00527a066
   Love C, 2003, RADIOGRAPHICS, V23, P341, DOI 10.1148/rg.232025103
   Makris G, 2016, J ORGANOMET CHEM, V805, P100, DOI 10.1016/j.jorganchem.2016.01.005
   Makris G, 2012, EUR J INORG CHEM, P3132, DOI 10.1002/ejic.201200056
   Mallia MB, 2012, NUCL MED BIOL, V39, P1236, DOI 10.1016/j.nucmedbio.2012.07.005
   Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304 3959(96)03267 8
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Ogawa K, 2005, BIOCONJUGATE CHEM, V16, P751, DOI 10.1021/bc040249w
   Ogawa K, 2004, J LABELLED COMPD RAD, V47, P753, DOI 10.1002/jlcr.864
   Ogawa K, 2007, J NUCL MED, V48, P122
   Ogawa K, 2006, NUCL MED BIOL, V33, P513, DOI 10.1016/j.nucmedbio.2006.03.006
   Ogawa K, 2009, EUR J NUCL MED MOL I, V36, P115, DOI 10.1007/s00259 008 0925 8
   Ogawa K, 2006, J NUCL MED, V47, P2042
   Olive G, 2007, PHOSPHORUS SULFUR, V182, P2359, DOI 10.1080/10426500701441499
   Palma E, 2007, J BIOL INORG CHEM, V12, P667, DOI 10.1007/s00775 007 0215 0
   Palma E, 2011, MOL BIOSYST, V7, P2950, DOI 10.1039/c1mb05242j
   Palma E, 2011, DALTON T, V40, P2787, DOI 10.1039/c0dt01396j
   Papagiannopoulou D, 2011, INORG CHIM ACTA, V378, P333, DOI 10.1016/j.ica.2011.08.062
   Papagiannopoulou D, 2010, POLYHEDRON, V29, P876, DOI 10.1016/j.poly.2009.10.009
   Pons JF, 1998, EUR J ORG CHEM, V1998, P853, DOI 10.1002/(SICI)1099 0690(199805)1998:5<853::AID EJOC853>3.0.CO;2 F
   Regueiro Ren A., 2011, C 28 amides of modified C 3 betulinic acid derivatives as HIV maturation inhibitors, Patent No. [WO2011153319 A1, 2011153319]
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sartor O, 2013, CANCER TREAT REV, V39, P18, DOI 10.1016/j.ctrv.2012.03.006
   Scheffler Justyna, 2003, Nucl Med Rev Cent East Eur, V6, P55
   Schibli R, 2000, BIOCONJUGATE CHEM, V11, P345, DOI 10.1021/bc990127h
   STRIJTVEEN B, 1986, J ORG CHEM, V51, P3664, DOI 10.1021/jo00369a020
   Szabo CM, 2002, J MED CHEM, V45, P2185, DOI 10.1021/jm010412y
   Szajnman SH, 2005, BIOORG MED CHEM LETT, V15, P4685, DOI 10.1016/j.bmcl.2005.07.060
   Theodoropoulos D, 2013, BIOORG MED CHEM LETT, V23, P6161, DOI 10.1016/j.bmcl.2013.09.003
   Vainio P, 2011, AM J PATHOL, V178, P525, DOI 10.1016/j.ajpath.2010.10.002
   vanBeek E, 1996, J BONE MINER RES, V11, P1492
   Vizirianakis I. S., 2014, HDB PERSONALIZED MED, P893
   Vizirianakis IS, 2005, BBA MOL CELL RES, V1743, P101, DOI 10.1016/j.bbamcr.2004.09.003
   Xiong Y, 2009, J INT MED RES, V37, P407, DOI 10.1177/147323000903700216
   Yoshitani K, 2011, PATHOL RES PRACT, V207, P417, DOI 10.1016/j.prp.2011.04.007
NR 53
TC 16
Z9 17
U1 0
U2 14
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543 8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD JUL
PY 2016
VL 13
IS 7
BP 2301
EP 2317
DI 10.1021/acs.molpharmaceut.6b00081
PG 17
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA DQ8JB
UT WOS:000379455800019
PM 27170456
DA 2025 08 17
ER

PT J
AU Pyo, SJ
   Song, WW
   Kim, IR
   Park, BS
   Kim, CH
   Shin, SH
   Chung, IK
   Kim, YD
AF Pyo, Se Jeong
   Song, Won Wook
   Kim, In Ryoung
   Park, Bong Soo
   Kim, Cheul Hong
   Shin, Sang Hun
   Chung, In Kyo
   Kim, Yong Deok
TI Low level laser therapy induces the expressions of BMP 2, osteocalcin,
   and TGF β1 in hypoxic cultured human osteoblasts
SO LASERS IN MEDICAL SCIENCE
LA English
DT Article
DE Hypoxia; HIF 1; Oxygen tension; Cell viability; Type 1 collagen
ID GROWTH FACTOR BETA; IN VITRO; OSTEOGENIC DIFFERENTIATION; SIGNALING
   PATHWAY; GENE EXPRESSION; VEGF EXPRESSION; BONE MARROW; CELLS;
   PROLIFERATION; IRRADIATION
AB The aim of this study was to examine the effect of low level laser therapy (LLLT) on the cell viability and the expression of hypoxia inducible factor 1s (HIF 1s), bone morphogenic protein 2 (BMP 2), osteocalcin, type I collagen, transforming growth factor beta 1 (TGF beta 1), and Akt in hypoxic cultured human osteoblasts. Human fetal osteoblast cells (cell line 1.19) were cultured under 1 % oxygen tension for 72 h. Cell cultures were divided into two groups. At the experimental side, low level laser (808 nm, GaAlAs diode) was applied at 0, 24, and 48 h. After irradiation, each cell culture was incubated 24 h more under hypoxia. Total energy was 1.2, 2.4, and 3.6 J/cm(2), respectively. Non irradiated cultures served as controls. Comparisons between the two groups were analyzed by t test; a p value < 0.05 was considered statistically significant. Hypoxia resulted in a decrease in the expression of type I collagen, osteocalcin, and TGF beta 1 (p < 0.001, p < 0.001, and p < 0.01, respectively). Cell viability and BMP 2 expression were not decreased by hypoxic condition. On the other hand, LLLT on hypoxic cultured osteoblast promoted the expression of BMP 2, osteocalcin, and TGF beta 1 (p < 0.05, p < 0.01, and p < 0.001, respectively). Cell proliferation was also increased time dependently. However, hypoxia decreased in type I collagen expression (p < 0.001), and LLLT did not affect type I collagen expression in hypoxic cultured osteoblasts. Furthermore, LLLT inhibited HIF 1 and Akt expression in hypoxic conditioned osteoblasts. We concluded that LLLT induces the expression of BMP 2, osteocalcin, and TGF  beta 1 in 1 % hypoxic cultured human osteoblasts.
C1 [Pyo, Se Jeong; Song, Won Wook; Shin, Sang Hun; Chung, In Kyo; Kim, Yong Deok] Pusan Natl Univ, Sch Dent, Dept Oral & Maxillofacial Surg, Yangsan 626770, South Korea.
   [Kim, In Ryoung; Park, Bong Soo] Pusan Natl Univ, Sch Dent, Dept Oral Anat, Yangsan 626770, South Korea.
   [Kim, Cheul Hong] Pusan Natl Univ, Sch Dent, Dept Dent Anesthesia & Pain Med, Yangsan 626770, South Korea.
C3 Pusan National University; Pusan National University Hospital; Pusan
   National University; Pusan National University Hospital; Pusan National
   University; Pusan National University Hospital
RP Kim, YD (通讯作者)，Pusan Natl Univ, Sch Dent, Dept Oral & Maxillofacial Surg, Yangsan 626770, South Korea.
EM ydkimdds@pusan.ac.kr
RI Kim, YongDeok/JLM 4590 2023; Kim, In Ryoung/AGF 2385 2022
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF); Ministry of Education, Science and Technology
   [2011 0026921]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education, Science and Technology (2011 0026921).
CR CENTRELLA M, 1986, ENDOCRINOLOGY, V119, P2306, DOI 10.1210/endo 119 5 2306
   CENTRELLA M, 1987, J BIOL CHEM, V262, P2869
   Choi YH, 2011, BIOCHEM BIOPH RES CO, V411, P637, DOI 10.1016/j.bbrc.2011.07.009
   D'Angio CT, 2000, MOL GENET METAB, V71, P371, DOI 10.1006/mgme.2000.3074
   D'Ippolito G, 2006, BONE, V39, P513, DOI 10.1016/j.bone.2006.02.061
   Dinenno FA, 2001, J PHYSIOL LONDON, V531, P573, DOI 10.1111/j.1469 7793.2001.0573i.x
   Fujimoto K, 2010, LASER SURG MED, V42, P519
   Harrison JS, 2002, BLOOD, V99, P394, DOI 10.1182/blood.V99.1.394
   Hirata S, 2010, J CELL BIOCHEM, V111, P1445, DOI 10.1002/jcb.22872
   Houreld NN, 2010, LASER SURG MED, V42, P494, DOI 10.1002/lsm.20812
   Hwang JM, 2008, MOL CELL BIOCHEM, V311, P179, DOI 10.1007/s11010 008 9708 6
   Kanichai M, 2008, J CELL PHYSIOL, V216, P708, DOI 10.1002/jcp.21446
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Khadra M, 2005, BIOMATERIALS, V26, P3503, DOI 10.1016/j.biomaterials.2004.09.033
   Kim YD, 2007, LASER SURG MED, V39, P441, DOI 10.1002/lsm.20508
   Kim YD, 2009, LASER MED SCI, V24, P577, DOI 10.1007/s10103 008 0614 7
   Kiyosaki T, 2010, PHOTOMED LASER SURG, V28, pS167, DOI 10.1089/pho.2009.2693
   Lee CM, 2007, J CELL PHYSIOL, V212, P182, DOI 10.1002/jcp.21017
   Lewis JS, 1999, J LEUKOCYTE BIOL, V66, P889, DOI 10.1002/jlb.66.6.889
   Li XL, 2006, ANN NY ACAD SCI, V1068, P26, DOI 10.1196/annals.1346.006
   Lundy MW, 1991, GROWTH FACTORS, V4, P257, DOI 10.3109/08977199109043911
   Mukherjee A, 2009, J CELL SCI, V122, P716, DOI 10.1242/jcs.042770
   Oikawa A, 2010, ARTERIOSCL THROM VAS, V30, P498, DOI 10.1161/ATVBAHA.109.200154
   Park JH, 2002, MOL CELL ENDOCRINOL, V192, P197, DOI 10.1016/S0303 7207(02)00036 9
   Renno ACM, 2007, PHOTOMED LASER SURG, V25, P275, DOI 10.1089/pho.2007.2055
   ROBEY PG, 1987, J CELL BIOL, V105, P457, DOI 10.1083/jcb.105.1.457
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Salim A, 2004, J BIOL CHEM, V279, P40007, DOI 10.1074/jbc.M403715200
   Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959 437X(98)80016 6
   Sharp FR, 2004, NAT REV NEUROSCI, V5, P437, DOI 10.1038/nrn1408
   Spector JA, 2001, AM J PHYSIOL CELL PH, V280, pC72, DOI 10.1152/ajpcell.2001.280.1.C72
   Stein A, 2005, PHOTOMED LASER SURG, V23, P161, DOI 10.1089/pho.2005.23.161
   Steinbrech DS, 1999, PLAST RECONSTR SURG, V104, P738, DOI 10.1097/00006534 199909030 00019
   Steinbrech DS, 2000, AM J PHYSIOL CELL PH, V278, pC853, DOI 10.1152/ajpcell.2000.278.4.C853
   Tseng WP, 2010, J CELL PHYSIOL, V223, P810, DOI 10.1002/jcp.22104
   Utting JC, 2006, EXP CELL RES, V312, P1693, DOI 10.1016/j.yexcr.2006.02.007
   VANDERKOOI JM, 1991, AM J PHYSIOL, V260, pC1131, DOI 10.1152/ajpcell.1991.260.6.C1131
   VAUPEL P, 1991, CANCER RES, V51, P3316
   Warren SM, 2001, J SURG RES, V99, P147, DOI 10.1006/jsre.2001.6128
   WRANA JL, 1988, J CELL BIOL, V106, P915, DOI 10.1083/jcb.106.3.915
   Zhang JT, 2008, J CELL PHYSIOL, V217, P518, DOI 10.1002/jcp.21529
NR 41
TC 65
Z9 66
U1 0
U2 14
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268 8921
J9 LASER MED SCI
JI Lasers Med. Sci.
PD FEB
PY 2013
VL 28
IS 2
BP 543
EP 550
DI 10.1007/s10103 012 1109 0
PG 8
WC Engineering, Biomedical; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Surgery
GA 098WI
UT WOS:000315579400026
PM 22552925
DA 2025 08 17
ER

PT J
AU Sun, HL
   Feng, K
   Hu, J
   Soker, S
   Atala, A
   Ma, PX
AF Sun, Hongli
   Feng, Kai
   Hu, Jiang
   Soker, Shay
   Atala, Anthony
   Ma, Peter X.
TI Osteogenic differentiation of human amniotic fluid derived stem cells
   induced by bone morphogenetic protein 7 and enhanced by nanofibrous
   scaffolds
SO BIOMATERIALS
LA English
DT Article
DE Human amniotic fluid derived stem cell; Bone morphogenetic protein;
   Extracellular matrix; Nanofiber; Tissue engineering scaffold; Bone
ID KINASE SIGNALING PATHWAYS; NANO FIBROUS SCAFFOLDS; EXTRACELLULAR MATRIX;
   OSTEOBLAST DIFFERENTIATION; TISSUE; REGENERATION; BIOMATERIALS;
   VERTEBRATES; FRACTURES; MEDICINE
AB Amniotic fluid derived stem cells (AFSCs) are becoming an important source of cells for regenerative medicine given their apparent advantages of accessibility, renewal capacity and multi potentiality. In the intermediate stage between the embryonic stem cells (ESCs) and adult stem cells, AFSCs may have a distinct mechanism to choose their fate. Unfortunately, until now, little is known about how bone morphogenetic proteins (BMPs) control the osteoblastic differentiation of AFSCs, especially on 3D scaffolds. Our research shows that human AFSCs (hAFSCs) can be induced for osteoblastic differentiation by rhBMP 7, and hAFSCs respond to rhBMP 7 more strongly than human mesenchymal stem cells (hMSCs). As synthetic ECM, scaffolds play a central role in tissue engineering. The hAFSCs, on the nanofibrous scaffolds (NF scaffolds) with morphology similar to that of natural collagen fibers, showed significantly enhanced alkaline phosphatase (ALP) activity, calcium content, von Kossa staining and the expression of osteogenic genes than those on the traditional scaffolds, i.e. solid walled scaffolds. The data on the bone formation in vivo presented further evidence that biomimetic NF scaffolds provided hAFSCs a more favorable synthetic ECM, and thus, facilitated the osteogenic differentiation of hAFSCs. The relative strong responsiveness to rhBMP 7 makes hAFSCs promising in bone regeneration. The synthetic NF scaffolds, which mimic the morphology of natural collagen fibers, enhanced the osteoblastic differentiation of hAFSCs in vitro and bone formation in vivo. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Sun, Hongli; Hu, Jiang; Ma, Peter X.] Univ Michigan, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA.
   [Ma, Peter X.] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA.
   [Feng, Kai; Ma, Peter X.] Univ Michigan, Macromol Sci & Engn Ctr, Ann Arbor, MI 48109 USA.
   [Soker, Shay; Atala, Anthony] Wake Forest Univ, Sch Med, Wake Forest Inst Regenerat Med, Winston Salem, NC 27157 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan; Wake Forest University
RP Ma, PX (通讯作者)，Univ Michigan, Dept Biol & Mat Sci, 1011 N Univ Ave,Room 2211, Ann Arbor, MI 48109 USA.
EM mapx@umich.edu
RI Sun, Hongli/F 9057 2011; FENG, KAI/D 8756 2015; Hu, Jiang/D 7904 2012;
   Atala, Anthony/J 3052 2013; X, Peter/E 4895 2011
OI Atala, Anthony/0000 0001 8186 2160
FU National Institutes of Health [NIDCR DE017689, DE015384]
FX The authors would like to acknowledge the financial support from the
   National Institutes of Health (Research Grants NIDCR DE017689 &
   DE015384: PXM). The authors thank Stryker Biotech for kindly supplying
   the rhBMP 7 and Kevin Downey for reading the manuscript.
CR Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779
   Chen VJ, 2006, BIOMATERIALS, V27, P3973, DOI 10.1016/j.biomaterials.2006.02.043
   Chen VJ, 2004, BIOMATERIALS, V25, P2065, DOI 10.1016/j.biomaterials.2003.08.058
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Damsky CH, 1999, BONE, V25, P95, DOI 10.1016/S8756 3282(99)00106 4
   De Coppi P, 2007, NAT BIOTECHNOL, V25, P100, DOI 10.1038/nbt1274
   Diefenderfer DL, 2003, CONNECT TISSUE RES, V44, P305, DOI 10.1080/03008200390181825
   Einhorn TA, 2003, J BONE JOINT SURG AM, V85A, P82, DOI 10.2106/00004623 200300003 00014
   ELSDALE T, 1972, J CELL BIOL, V54, P626, DOI 10.1083/jcb.54.3.626
   Goldberg M, 2007, J BIOMAT SCI POLYM E, V18, P241, DOI 10.1163/156856207779996931
   Govender S, 2002, J BONE JOINT SURG AM, V84A, P2123, DOI 10.2106/00004623 200212000 00001
   Groeneveld EHJ, 2000, EUR J ENDOCRINOL, V142, P9, DOI 10.1530/eje.0.1420009
   HAHN TJ, 1979, J CLIN INVEST, V64, P655, DOI 10.1172/JCI109506
   Hipp J, 2008, STEM CELL REV, V4, P3, DOI 10.1007/s12015 008 9010 8
   Hu J, 2008, BIOMATERIALS, V29, P3815, DOI 10.1016/j.biomaterials.2008.06.015
   Kaviani A, 2001, J PEDIATR SURG, V36, P1662, DOI 10.1053/jpsu.2001.27945
   Kolambkar YM, 2007, J MOL HISTOL, V38, P405, DOI 10.1007/s10735 007 9118 1
   Kunisaki SM, 2007, J PEDIATR SURG, V42, P974, DOI 10.1016/j.jpedsurg.2007.01.031
   Langer R, 2004, NATURE, V428, P487, DOI 10.1038/nature02388
   LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529
   Li WJ, 2002, J BIOMED MATER RES, V60, P613, DOI 10.1002/jbm.10167
   Lutolf MP, 2005, NAT BIOTECHNOL, V23, P47, DOI 10.1038/nbt1055
   Ma PX, 2008, ADV DRUG DELIVER REV, V60, P184, DOI 10.1016/j.addr.2007.08.041
   Ma PX, 1999, J BIOMED MATER RES, V46, P60, DOI 10.1002/(SICI)1097 4636(199907)46:1<60::AID JBM7>3.0.CO;2 H
   Matthews JA, 2002, BIOMACROMOLECULES, V3, P232, DOI 10.1021/bm015533u
   Meijer GJ, 2007, PLOS MED, V4, P260, DOI 10.1371/journal.pmed.0040009
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Reddi AH, 1998, NAT BIOTECHNOL, V16, P247, DOI 10.1038/nbt0398 247
   Salasznyk RM, 2007, EXP CELL RES, V313, P22, DOI 10.1016/j.yexcr.2006.09.013
   Schneider GB, 2001, J DENT RES, V80, P1540, DOI 10.1177/00220345010800061201
   Smith LA, 2009, BIOMATERIALS, V30, P2516, DOI 10.1016/j.biomaterials.2009.01.009
   Valentin Opran A, 2002, CLIN ORTHOP RELAT R, P110
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
   von Bubnoff A, 2001, DEV BIOL, V239, P1, DOI 10.1006/dbio.2001.0388
   Wei GB, 2007, BIOMATERIALS, V28, P2087, DOI 10.1016/j.biomaterials.2006.12.028
   Wei GB, 2008, ADV FUNCT MATER, V18, P3568, DOI 10.1002/adfm.200800662
   Woo KM, 2003, J BIOMED MATER RES A, V67A, P531, DOI 10.1002/jbm.a.10098
   Woo KM, 2007, BIOMATERIALS, V28, P335, DOI 10.1016/j.biomaterials.2006.06.013
   Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101
   Zhang RY, 2000, J BIOMED MATER RES, V52, P430, DOI 10.1002/1097 4636(200011)52:2<430::AID JBM25>3.0.CO;2 L
NR 40
TC 114
Z9 129
U1 1
U2 38
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD FEB
PY 2010
VL 31
IS 6
BP 1133
EP 1139
DI 10.1016/j.biomaterials.2009.10.030
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 548RY
UT WOS:000273985100013
PM 19857889
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Ji, L
   Lu, B
   Zamponi, R
   Charlat, O
   Aversa, R
   Yang, ZE
   Sigoillot, F
   Zhu, XP
   Hu, TC
   Reece Hoyes, JS
   Russ, C
   Michaud, G
   Tchorz, JS
   Jiang, XM
   Cong, F
AF Ji, Lei
   Lu, Bo
   Zamponi, Raffaella
   Charlat, Olga
   Aversa, Robert
   Yang, Zinger
   Sigoillot, Frederic
   Zhu, Xiaoping
   Hu, Tiancen
   Reece Hoyes, John S.
   Russ, Carsten
   Michaud, Gregory
   Tchorz, Jan S.
   Jiang, Xiaomo
   Cong, Feng
TI USP7 inhibits Wnt/β catenin signaling through promoting stabilization of
   Axin
SO NATURE COMMUNICATIONS
LA English
DT Article
ID SMALL MOLECULE INHIBITOR; BETA CATENIN; DEUBIQUITINATING ENZYME;
   CRYSTAL STRUCTURE; WNT; HAUSP; P53; SUBSTRATE; ADIPOGENESIS; RECOGNITION
AB Axin is a key scaffolding protein responsible for the formation of the beta catenin destruction complex. Stability of Axin protein is regulated by the ubiquitin proteasome system, and modulation of cellular concentration of Axin protein has a profound effect on Wnt/beta catenin signaling. Although E3s promoting Axin ubiquitination have been identified, the deubiquitinase responsible for Axin deubiquitination and stabilization remains unknown. Here, we identify USP7 as a potent negative regulator of Wnt/beta catenin signaling through CRISPR screens. Genetic ablation or pharmacological inhibition of USP7 robustly increases Wnt/beta catenin signaling in multiple cellular systems. USP7 directly interacts with Axin through its TRAF domain, and promotes deubiquitination and stabilization of Axin. Inhibition of USP7 regulates osteoblast differentiation and adipocyte differentiation through increasing Wnt/beta catenin signaling. Our study reveals a critical mechanism that prevents excessive degradation of Axin and identifies USP7 as a target for sensitizing cells to Wnt/beta catenin signaling.
C1 [Ji, Lei; Lu, Bo; Zamponi, Raffaella; Charlat, Olga; Aversa, Robert; Yang, Zinger; Sigoillot, Frederic; Zhu, Xiaoping; Hu, Tiancen; Reece Hoyes, John S.; Russ, Carsten; Michaud, Gregory; Jiang, Xiaomo; Cong, Feng] Novartis Pharma AG, Novartis Inst Biomed Res, Cambridge, MA 02139 USA.
   [Tchorz, Jan S.] Novartis Pharma AG, Novartis Inst Biomed Res, Basel, Switzerland.
   [Zamponi, Raffaella] Azienda USL IRCCS Reggio Emilia, Viale Risorgimento 80, I 42123 Reggio Emila, Italy.
C3 Novartis; Novartis USA; Novartis
RP Cong, F (通讯作者)，Novartis Pharma AG, Novartis Inst Biomed Res, Cambridge, MA 02139 USA.
EM feng.cong@novartis.com
RI ; Reece Hoyes, John/B 2321 2008; zhu, xiaoping/A 3979 2013; Zamponi,
   Raffaella/V 5683 2018
OI Sigoillot, Frederic/0000 0002 8695 4838; Yang Loureiro,
   Zinger/0000 0001 8543 4841; Reece Hoyes, John/0000 0001 5251 5813;
   Tchorz, Jan/0000 0003 1745 6621; Zamponi, Raffaella/0000 0002 3313 1387;
   
CR An T, 2017, BIOCHEM PHARMACOL, V131, P29, DOI 10.1016/j.bcp.2017.02.011
   Bhattacharya S, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392 018 0012 y
   Chauhan D, 2012, CANCER CELL, V22, P345, DOI 10.1016/j.ccr.2012.08.007
   Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137
   Cheng JD, 2015, PROTEIN CELL, V6, P849, DOI 10.1007/s13238 015 0192 y
   Christodoulides C, 2009, TRENDS ENDOCRIN MET, V20, P16, DOI 10.1016/j.tem.2008.09.002
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Colland F, 2009, MOL CANCER THER, V8, P2286, DOI 10.1158/1535 7163.MCT 09 0097
   Cummins JM, 2004, NATURE, V428, DOI 10.1038/nature02501
   Dar A, 2013, MOL CELL BIOL, V33, P3309, DOI 10.1128/MCB.00358 13
   Faesen AC, 2011, MOL CELL, V44, P147, DOI 10.1016/j.molcel.2011.06.034
   Gammons M, 2018, CURR OPIN CELL BIOL, V51, P42, DOI 10.1016/j.ceb.2017.10.008
   Gao CX, 2014, CELL BIOSCI, V4, DOI 10.1186/2045 3701 4 13
   Gavory G, 2018, NAT CHEM BIOL, V14, P118, DOI 10.1038/nchembio.2528
   Georges A, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 34197 x
   Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092 8674(02)01199 6
   Hu M, 2006, PLOS BIOL, V4, P228, DOI 10.1371/journal.pbio.0040027
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Ji L, 2017, GENE DEV, V31, P904, DOI 10.1101/gad.300053.117
   Kategaya L, 2017, NATURE, V550, P534, DOI 10.1038/nature24006
   Kon N, 2010, ONCOGENE, V29, P1270, DOI 10.1038/onc.2009.427
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lebensohn AM, 2016, ELIFE, V5, DOI 10.7554/eLife.21459
   Lee E, 2003, PLOS BIOL, V1, P116, DOI 10.1371/journal.pbio.0000010
   Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737
   Ling L, 2009, GENE, V433, P1, DOI 10.1016/j.gene.2008.12.008
   Liu J, 2013, P NATL ACAD SCI USA, V110, P20224, DOI 10.1073/pnas.1314239110
   Liu XX, 2005, CURR BIOL, V15, P1989, DOI 10.1016/j.cub.2005.10.050
   Lui TTH, 2011, MOL CELL BIOL, V31, P2053, DOI 10.1128/MCB.01094 10
   Ma PC, 2014, MOL CELL BIOL, V34, P4355, DOI 10.1128/MCB.00731 14
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021
   Major MB, 2007, SCIENCE, V316, P1043, DOI 10.1126/science/1141515
   Meulmeester E, 2005, MOL CELL, V18, P565, DOI 10.1016/j.molcel.2005.04.024
   Molchadsky A, 2013, CELL DEATH DIFFER, V20, P774, DOI 10.1038/cdd.2013.9
   Morrone S, 2012, P NATL ACAD SCI USA, V109, P1500, DOI 10.1073/pnas.1116618109
   Novellasdemunt L, 2017, CELL REP, V21, P612, DOI 10.1016/j.celrep.2017.09.072
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   O'Dowd CR, 2018, ACS MED CHEM LETT, V9, P238, DOI 10.1021/acsmedchemlett.7b00512
   Olbrich T, 2017, P NATL ACAD SCI USA, V114, P9367, DOI 10.1073/pnas.1705133114
   Pozhidaeva A, 2017, CELL CHEM BIOL, V24, P1501, DOI 10.1016/j.chembiol.2017.09.004
   Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950
   Sarkari F, 2013, J BIOL CHEM, V288, P16975, DOI 10.1074/jbc.M113.469262
   Sarkari F, 2010, J MOL BIOL, V402, P825, DOI 10.1016/j.jmb.2010.08.017
   Schwertman P, 2012, NAT GENET, V44, P598, DOI 10.1038/ng.2230
   Sheng Y, 2006, NAT STRUCT MOL BIOL, V13, P285, DOI 10.1038/nsmb1067
   Song MS, 2008, NATURE, V455, P813, DOI 10.1038/nature07290
   Sumida T, 2018, NAT IMMUNOL, V19, P1391, DOI 10.1038/s41590 018 0236 6
   Tavana O, 2017, J MOL CELL BIOL, V9, P45, DOI 10.1093/jmcb/mjw049
   Tavana O, 2016, NAT MED, V22, P1180, DOI 10.1038/nm.4180
   Tian XF, 2011, ASSAY DRUG DEV TECHN, V9, P165, DOI 10.1089/adt.2010.0317
   Turnbull AP, 2017, NATURE, V550, P481, DOI 10.1038/nature24451
   van Loosdregt J, 2013, IMMUNITY, V39, P259, DOI 10.1016/j.immuni.2013.05.018
   van Loosdregt J, 2013, IMMUNITY, V39, P298, DOI 10.1016/j.immuni.2013.07.019
   Wang LQ, 2016, EBIOMEDICINE, V13, P99, DOI 10.1016/j.ebiom.2016.10.018
   Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768
   Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681
   Zemp I, 2014, J BIOL CHEM, V289, P28595, DOI 10.1074/jbc.M114.596056
   Zhang Y, 2011, NAT CELL BIOL, V13, P623, DOI 10.1038/ncb2222
   Zhou ZZ, 2015, DEV CELL, V34, P58, DOI 10.1016/j.devcel.2015.05.016
NR 60
TC 101
Z9 118
U1 0
U2 43
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD SEP 13
PY 2019
VL 10
AR 4184
DI 10.1038/s41467 019 12143 3
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA IX4WH
UT WOS:000485685900023
PM 31519875
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Shehabeldin, M
   Gao, J
   Cho, YJ
   Chong, R
   Tabib, T
   Li, L
   Smardz, M
   Gaffen, SL
   Diaz, PI
   Lafyatis, R
   Little, SR
   Sfeir, C
AF Shehabeldin, Mostafa
   Gao, Jin
   Cho, Yejin
   Chong, Rong
   Tabib, Tracy
   Li, Lu
   Smardz, Matthew
   Gaffen, Sarah L.
   Diaz, Patricia I.
   Lafyatis, Robert
   Little, Steven R.
   Sfeir, Charles
TI Therapeutic delivery of CCL2 modulates immune response and restores
   host microbe homeostasis
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE trating macrophages. Finally; 16S ribosomal ribonucleic acid (rRNA)
   sequencing showed; host modulation therapy | chemokines | microbiome |
   periodontal disease | macrophages
ID MYELOID CELLS 1; OSTEOCLAST DIFFERENTIATION; RESOLVIN E1;
   PERIODONTAL DISEASE; BONE LOSS; RECEPTOR; INFLAMMATION; MURINE;
   RECRUITMENT; EXPRESSION
AB Many chronic inflammatory diseases are attributed to disturbances in host microbe interactions, which drive immune  mediated tissue damage. Depending on the anatomic setting, a chronic inflammatory disease can exert unique local and systemic influences, which provide an exceptional opportunity for understanding disease mechanism and testing therapeutic interventions. The oral cavity is an easily accessible environment that allows for protective interventions aiming at modulating the immune response to control disease processes driven by a breakdown of host microbe homeostasis. Periodontal disease (PD) is a prevalent condition in which quantitative and qualitative changes of the oral microbiota (dysbiosis) trigger nonresolving chronic inflammation, progressive bone loss, and ultimately tooth loss. Here, we demonstrate the therapeutic benefit of local sustained delivery of the PD using clinically relevant models as a preventive, interventional, or reparative therapy. Local delivery of CCL2 into the periodontium inhibited bone loss and accelerated bone gain that could be ascribed to reduced osteoclasts numbers. CCL2 treatment up  regulated M2  macrophage and downregulated proinflammatory and pro  osteoclastic markers. Furthermore, single  cell ribonucleic acid (RNA) sequencing indicated that CCL2 therapy reversed disease  associated transcriptomic profiles of murine gingival macrophages via inhibiting the triggering receptor expressed on myeloid cells  1 (TREM  1) signaling in classically activated macrophages and inducing protein kinase A (PKA) signaling in infilmitigation of microbial dysbiosis in the periodontium that correlated with a reduction in microbial load in CCL2  treated mice. This study reveals a novel protective effect of CCL2 local delivery in PD as a model for chronic inflammatory diseases caused by a disturbance in host microbe homeostasis.
C1 [Shehabeldin, Mostafa; Gao, Jin; Chong, Rong; Sfeir, Charles] Univ Pittsburgh, Ctr Craniofacial Regenerat, Sch Dent Med, Pittsburgh, PA 15261 USA.
   [Shehabeldin, Mostafa; Sfeir, Charles] Univ Pittsburgh, Sch Dent Med, Dept Periodont & Prevent Dent, Pittsburgh, PA 15261 USA.
   [Shehabeldin, Mostafa; Cho, Yejin; Sfeir, Charles] Univ Pittsburgh, Sch Dent Med, Dept Oral & Craniofacial Sci, Pittsburgh, PA 15261 USA.
   [Tabib, Tracy; Gaffen, Sarah L.; Lafyatis, Robert] Univ Pittsburgh, Div Rheumatol & Clin Immunol, Pittsburgh, PA 15261 USA.
   [Li, Lu; Smardz, Matthew; Diaz, Patricia I.] Univ Buffalo, State Univ New York, Sch Dent Med, Dept Oral Biol, Buffalo, NY 14214 USA.
   [Li, Lu; Smardz, Matthew; Diaz, Patricia I.] Univ Buffalo, Univ Buffalo Microbiome Ctr, State Univ New York, Sch Dent Med, Buffalo, NY 14214 USA.
   [Little, Steven R.; Sfeir, Charles] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15219 USA.
   [Little, Steven R.] Univ Pittsburgh, Dept Chem & Petr Engn, Pittsburgh, PA 15261 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; State University of New York (SUNY) System; SUNY Delhi;
   University at Buffalo, SUNY; State University of New York (SUNY) System;
   SUNY Delhi; University at Buffalo, SUNY; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); University of Pittsburgh;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Sfeir, C (通讯作者)，Univ Pittsburgh, Ctr Craniofacial Regenerat, Sch Dent Med, Pittsburgh, PA 15261 USA.; Sfeir, C (通讯作者)，Univ Pittsburgh, Sch Dent Med, Dept Periodont & Prevent Dent, Pittsburgh, PA 15261 USA.; Sfeir, C (通讯作者)，Univ Pittsburgh, Sch Dent Med, Dept Oral & Craniofacial Sci, Pittsburgh, PA 15261 USA.; Sfeir, C (通讯作者)，Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15219 USA.
EM csfeir@pitt.edu
RI Shehabeldin, Mostafa/JRY 4368 2023; Li, Lu/AAN 8838 2021; Gaffen,
   Sarah/B 1560 2009
OI Cho, Yejin/0000 0002 1500 9222; Gao, Jin/0000 0002 6200 4141;
   Shehabeldin, Mostafa/0000 0002 2122 4105; Lafyatis,
   Robert/0000 0002 9398 5034; 
CR Abe T, 2013, J IMMUNOL METHODS, V394, P49, DOI 10.1016/j.jim.2013.05.002
   Abusleme L, 2013, ISME J, V7, P1016, DOI 10.1038/ismej.2012.174
   Araujo Pires AC, 2015, J BONE MINER RES, V30, P400, DOI 10.1002/jbmr.2376
   Auffray C, 2007, SCIENCE, V317, P666, DOI 10.1126/science.1142883
   Bisson C, 2012, J CLIN PERIODONTOL, V39, P1141, DOI 10.1111/jcpe.12008
   Bostanci N, 2013, J DENT RES, V92, P161, DOI 10.1177/0022034512470691
   Bostanci N, 2019, J CLIN MED, V8, DOI 10.3390/jcm8101579
   Caldwell RW, 2018, PHYSIOL REV, V98, P641, DOI 10.1152/physrev.00037.2016
   Chiang N, 2017, J IMMUNOL, V198, P842, DOI 10.4049/jimmunol.1601650
   Curtis MA, 2020, PERIODONTOL 2000, V83, P14, DOI 10.1111/prd.12296
   DePaolo RW, 2005, INFECT IMMUN, V73, P6514, DOI 10.1128/IAI.73.10.6514 6522.2005
   Dominy SS, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau3333
   Dutzan N, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat0797
   Dutzan N, 2016, JOVE J VIS EXP, DOI 10.3791/53736
   Eke PI, 2015, J PERIODONTOL, V86, P611, DOI 10.1902/jop.2015.140520
   Eltboli O, 2014, BMC PULM MED, V14, DOI 10.1186/1471 2466 14 112
   Eskan MA, 2012, NAT IMMUNOL, V13, P465, DOI 10.1038/ni.2260
   Gemmell E, 2001, J PERIODONTAL RES, V36, P92, DOI 10.1034/j.1600 0765.2001.360205.x
   Glowacki AJ, 2013, P NATL ACAD SCI USA, V110, P18525, DOI 10.1073/pnas.1302829110
   Gomes RN, 2013, SHOCK, V39, P63, DOI 10.1097/SHK.0b013e31827802b5
   Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785
   Hajishengallis G, 2014, TRENDS IMMUNOL, V35, P3, DOI 10.1016/j.it.2013.09.001
   Hannemann N, 2019, J CLIN INVEST, V129, P2669, DOI 10.1172/JCI96832
   Herová M, 2015, J IMMUNOL, V194, P2330, DOI 10.4049/jimmunol.1402166
   Herrera BS, 2008, BRIT J PHARMACOL, V155, P1214, DOI 10.1038/bjp.2008.367
   Kassebaum NJ, 2014, J DENT RES, V93, P1045, DOI 10.1177/0022034514552491
   Kitamoto S, 2020, CELL, V182, P447, DOI 10.1016/j.cell.2020.05.048
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Kong DP, 2016, J EXP MED, V213, P2209, DOI 10.1084/jem.20160459
   Kosaka T, 2014, J CLIN PERIODONTOL, V41, P497, DOI 10.1111/jcpe.12241
   Kourtzelis I, 2019, NAT IMMUNOL, V20, P40, DOI 10.1038/s41590 018 0249 1
   Lapaquette P, 2010, CELL MICROBIOL, V12, P99, DOI 10.1111/j.1462 5822.2009.01381.x
   Lee CT, 2016, J IMMUNOL, V197, P2796, DOI 10.4049/jimmunol.1600859
   Li L, 2018, CELL PHYSIOL BIOCHEM, V51, P557, DOI 10.1159/000495276
   Liechty WB, 2010, ANNU REV CHEM BIOMOL, V1, P149, DOI 10.1146/annurev chembioeng 073009 100847
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   Marouf N, 2021, J CLIN PERIODONTOL, V48, P483, DOI 10.1111/jcpe.13435
   McBride DA, 2023, ADV SCI, V10, DOI 10.1002/advs.202202720
   Mizraji G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00785
   Murakami Y, 2009, ARTHRITIS RHEUM US, V60, P1615, DOI 10.1002/art.24554
   Mustafa M, 2013, AM J PHYSIOL CELL PH, V305, pC673, DOI 10.1152/ajpcell.00242.2012
   Negreiros Lima GL, 2020, CELLS BASEL, V9, DOI 10.3390/cells9010128
   Oishi Y, 2018, INT IMMUNOL, V30, P511, DOI 10.1093/intimm/dxy054
   Pellionisz PA, 2018, OTOLARYNG HEAD NECK, V158, P110, DOI 10.1177/0194599817730304
   Poon IKH, 2014, NAT REV IMMUNOL, V14, P166, DOI 10.1038/nri3607
   Roca H, 2009, J BIOL CHEM, V284, P34342, DOI 10.1074/jbc.M109.042671
   Schenk M, 2007, J CLIN INVEST, V117, P3097, DOI 10.1172/JCI30602
   Schloss PD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008230
   Shehabeldin M., NCBI Sequence Read Archive
   Shehabeldin M., Gene Expression Omnibus (GEO)
   Sierra Filardi E, 2014, J IMMUNOL, V192, P3858, DOI 10.4049/jimmunol.1302821
   Tacke F, 2007, J CLIN INVEST, V117, P185, DOI 10.1172/JCI28549
   Tammaro A, 2017, PHARMACOL THERAPEUT, V177, P81, DOI 10.1016/j.pharmthera.2017.02.043
   Tanaka T, 2010, BIOCHEM BIOPH RES CO, V399, P677, DOI 10.1016/j.bbrc.2010.07.141
   UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461
   Viniegra A, 2018, J DENT RES, V97, P1160, DOI 10.1177/0022034518777973
   Wang Z, 2018, THORAX, V73, P331, DOI 10.1136/thoraxjnl 2017 210741
   Willi M, 2014, CLIN EXP IMMUNOL, V178, P190, DOI 10.1111/cei.12397
   Wong RL, 2017, J ORAL IMPLANTOL, V43, P437, DOI 10.1563/aaid joi D 17 00157
   Wood S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091574
   XU LX, 1995, J CELL PHYSIOL, V165, P624, DOI 10.1002/jcp.1041650321
   Yamaguchi T, 2016, INFECT IMMUN, V84, P2802, DOI 10.1128/IAI.00461 16
   Yamashiro S, 1998, INT ARCH ALLERGY IMM, V115, P15, DOI 10.1159/000023825
   Yu JJ, 2008, INFECT IMMUN, V76, P4206, DOI 10.1128/IAI.01209 07
   Yu JJ, 2007, BLOOD, V109, P3794, DOI 10.1182/blood 2005 09 010116
   Yu T, 2016, J PERIODONTOL, V87, P1092, DOI 10.1902/jop.2016.160081
   Zhou LN, 2019, ORAL DIS, V25, P265, DOI 10.1111/odi.12983
   Zhuang Z, 2019, J DENT RES, V98, P200, DOI 10.1177/0022034518805984
   Zysset D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13151
NR 69
TC 1
Z9 1
U1 1
U2 9
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
EI 1091 6490
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 3
PY 2024
VL 121
IS 36
AR e2400528121
DI 10.1073/pnas.2400528121
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA L0A0M
UT WOS:001347423700001
PM 39186644
DA 2025 08 17
ER

PT J
AU Sun, W
   Yang, GY
   Zhang, F
   Feng, CG
   Liang, MJ
   Jia, PF
   Zhao, ZL
   Guo, HL
   Zhao, YF
AF Sun, Wen
   Yang, Guangyue
   Zhang, Fang
   Feng, Chenguo
   Liang, Mingjie
   Jia, Pengfei
   Zhao, Zhongliang
   Guo, Hailing
   Zhao, Yongfang
TI Effects of Artemisia annua L. Essential Oil on Osteoclast
   Differentiation and Function Induced by RANKL
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID IN VITRO; FUSION; DRUG
AB Objective. This study aimed to assess the main components of Artemisia annua L. essential oil (AEO) and determine their effect on the proliferation and differentiation of RAW264.7 cells induced by receptor activator for nuclear factor ligand (RANKL) in vitro. Then, we tried to explain part of the function of its possible mechanisms. Materials and Methods. Essential oil was extracted from Artemisia annua L. Osteoclasts were induced in vitro by RANKL in mouse RAW264.7 cells. The experimental group was treated with different concentrations of AEO, while the control group was not treated with AEO. CCK8 was used to detect osteoclast proliferation. The osteoclasts were stained with TRAP. Western blot was used to detect protein in the MAPK pathway and the NF kappa B pathway after treatment with different concentrations of AEO. RT PCR was used to determine the expression of osteoclast related mRNA in cells. Results. The GC MS analysis was used to obtain the main components of AEO, including camphor, borneol, camphor, borneol, terpinen 4 ol, p cymene, eucalyptol, deoxyartemisinin, and artemisia ketone. The CCK8 results showed that the AEO volume ratio of 1 : 4000, 1 : 5000, and 1 : 6000 did not affect the proliferation of RAW264.7 cells. However, TRAP staining showed that AEO decreased osteoclast formation. Western blot results showed that the expression of protein TRAF6, p p38, p ERK, p p65, and NFATc1 decreased in the MAPK pathway and the NF kappa B pathway affected by AEO. Furthermore, RT PCR results showed that the expression of osteoclast resorption related mRNAs (MMP 9, DC STAMP, TRAP, and CTSK) and osteoclast differentiation related mRNAs (OSCAR, NFATc1, c Src, and c Fos) also decreased in the experimental group. Conclusions. AEO inhibits osteoclast differentiation in vitro, probably by reducing TRAF6 activation, acting on the MAPK pathway and NF kappa B pathway, and inhibiting the expression of osteoclast related genes.
C1 [Sun, Wen; Yang, Guangyue; Guo, Hailing; Zhao, Yongfang] Shanghai Univ Tradit Chinese Med, Shis Ctr Orthoped & Traumatol, Shuguang Hosp, Shanghai 201203, Peoples R China.
   [Sun, Wen; Yang, Guangyue; Guo, Hailing; Zhao, Yongfang] Shanghai Acad Tradit Chinese Med, Inst Traumatol & Orthoped, Shanghai 201203, Peoples R China.
   [Zhang, Fang; Feng, Chenguo] Shanghai Univ Tradit Chinese Med, Innovat Res Inst Tradit Chinese Med, Res Ctr Chiral Drugs, Shanghai 201203, Peoples R China.
   [Liang, Mingjie; Jia, Pengfei; Zhao, Zhongliang] Yuzhou Tianyuan Biotechnol Co Ltd, Yuzhou 461000, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai University
   of Traditional Chinese Medicine
RP Guo, HL; Zhao, YF (通讯作者)，Shanghai Univ Tradit Chinese Med, Shis Ctr Orthoped & Traumatol, Shuguang Hosp, Shanghai 201203, Peoples R China.; Guo, HL; Zhao, YF (通讯作者)，Shanghai Acad Tradit Chinese Med, Inst Traumatol & Orthoped, Shanghai 201203, Peoples R China.
EM crazyheart001@icloud.com; y_guangyue@163.com; fzhang@shutcm.edu.cn;
   fengcg@shutcm.edu.cn; liangmingjie0706@163.com; jiapengfei812@126.com;
   junenzzl@163.com; hailing_guo@shutcm.edu.cn; zhao_dingding@126.com
RI Guo, Hailing/HTQ 5112 2023
OI guo, hailing/0000 0002 6344 4181; zhao, yongfang/0000 0001 5097 1209
FU National Natural Science Foundation of China [82174404, 81774342,
   81473703]; Shanghai Clinical Research Center for Musculoskeletal Health
   [20MC1920600]; Shanghai Municipal Science and Technology Commission
   [21Y31920200, 17401901900]; Opening Project of Shanghai Collaborative
   Innovation Center of Traditional Chinese Medicine Health Service
   [ZYJKFW201811005]
FX AcknowledgmentsThe authors greatly appreciate the support of the
   National Natural Science Foundation of China (Grant nos. 82174404,
   81774342, and 81473703), Shanghai Clinical Research Center for
   Musculoskeletal Health (20MC1920600), Shanghai Municipal Science and
   Technology Commission (21Y31920200 and 17401901900), and Opening Project
   of Shanghai Collaborative Innovation Center of Traditional Chinese
   Medicine Health Service (ZYJKFW201811005).
CR Abd Rashed A, 2017, J ESSENT OIL RES, V29, P1, DOI 10.1080/10412905.2016.1213668
   Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   [Anonymous], 2015, STREPTOCOCCUS PNEUMO
   [Anonymous], 2016, PAIN FREEMENTHOL MET
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Bai D., 2018, CHINA PHARM, V21, P88
   Bi XX, 2017, MOLECULES, V22, DOI 10.3390/molecules22050715
   Brand C, 2001, INFLAMM RES, V50, P213, DOI 10.1007/s000110050746
   Brown KD, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2457
   Camphor, NAT LIB MED MED SUBJ
   Cappariello A, 2014, ARCH BIOCHEM BIOPHYS, V558, P70, DOI 10.1016/j.abb.2014.06.017
   Cen Yan Yan, 2018, Zhongguo Zhong Yao Za Zhi, V43, P3970, DOI 10.19540/j.cnki.cjcmm.20180726.010
   Collin Osdoby P., 2012, METHODS MOL MED, V80, P153, DOI [10.1385/1 59259 366 6:153, DOI 10.1385/1 59259 366 6:153]
   Das S, 2020, MOLECULES, V25, DOI 10.3390/molecules25102390
   Durand M, 2011, BONE, V48, P588, DOI 10.1016/j.bone.2010.10.167
   Efferth T, 2017, SEMIN CANCER BIOL, V46, P65, DOI 10.1016/j.semcancer.2017.02.009
   Ferrero GO, 2012, ONCOGENE, V31, P3381, DOI 10.1038/onc.2011.510
   Fischer Juergen, 2013, Cough, V9, P25, DOI 10.1186/1745 9974 9 25
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Jaradat N, 2021, MOLECULES, V26, DOI 10.3390/molecules26092831
   Jeong E, 2018, CELL DEATH DIFFER, V25, P1364, DOI 10.1038/s41418 017 0048 5
   Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601 0825.2002.01829.x
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim N, 2002, J EXP MED, V195, P201, DOI 10.1084/jem.20011681
   Lampiasi N, 2021, BIOLOGY BASEL, V10, DOI 10.3390/biology10020117
   Lee DE, 2015, J PERIODONTAL RES, V50, P256, DOI 10.1111/jre.12203
   [李海波 Li Haibo], 2019, [中草药, Chinese Traditional and Herbal Drugs], V50, P3461
   Li YX, 2021, J CELL PHYSIOL, V236, P1950, DOI 10.1002/jcp.29978
   Miyamoto H, 2012, J BONE MINER RES, V27, P1289, DOI 10.1002/jbmr.1575
   Miyamoto Takeshi, 2006, Mod Rheumatol, V16, P341
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   Santomauro F, 2018, PLANTA MED, V84, P160, DOI 10.1055/s 0043 118912
   Shalitanati W., 2020, CHINESE J TISSUE ENG, V24, P2636, DOI [10.3969/j.issn.2095 4344.2672, DOI 10.3969/J.ISSN.2095 4344.2672]
   Sokolova AS, 2017, CHEM HETEROCYCL COM+, V53, P371, DOI 10.1007/s10593 017 2063 3
   Souza PPC, 2013, IMMUNOL INVEST, V42, P555, DOI 10.3109/08820139.2013.822766
   Soysa NS, 2009, BIOCHEM BIOPH RES CO, V378, P1, DOI 10.1016/j.bbrc.2008.10.146
   Takahashi Naoyuki, 2007, V135, P285
   Takahashi N, 2011, FRONT BIOSCI LANDMRK, V16, P21, DOI 10.2741/3673
   Tschesche H, 1992, Matrix Suppl, V1, P245
   Wang C, 2003, J BONE MINER RES, V18, P2159, DOI 10.1359/jbmr.2003.18.12.2159
   Wei CM, 2018, J CELL PHYSIOL, V233, P476, DOI 10.1002/jcp.25907
   Wu X., 2018, CHINESE J EXPT TRADI, V4, P92, DOI [10.13422/j.cnki.syfjx.2018040084, DOI 10.13422/J.CNKI.SYFJX.2018040084]
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zhang CC, 2014, J CELL PHYSIOL, V229, P1330, DOI 10.1002/jcp.24553
   Zhigzhitzhapova SV, 2020, NAT PROD RES, V34, P2668, DOI 10.1080/14786419.2018.1548461
   Zhou L, 2016, J BONE MINER RES, V31, P964, DOI 10.1002/jbmr.2771
   Zito F, 2016, EUR J CELL BIOL, V95, P552, DOI 10.1016/j.ejcb.2016.09.002
NR 48
TC 3
Z9 3
U1 4
U2 22
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PD APR 7
PY 2022
VL 2022
AR 1322957
DI 10.1155/2022/1322957
PG 13
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA 0Z7KH
UT WOS:000791252200007
PM 35432559
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhao, RQ
   Bu, WQ
   Chen, YF
AF Zhao, Renqing
   Bu, Wenqian
   Chen, Yingfeng
TI Icariin Treatment Enhanced the Skeletal Response to Exercise in
   Estrogen Deficient Rats
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE exercise; icariin; osteoporosis; estrogen; osteoblast
ID HORMONE REPLACEMENT THERAPY; BONE LOSS; POSTMENOPAUSAL WOMEN; RECEPTOR;
   OSTEOPOROSIS; RESISTANCE; DENSITY
AB Estrogen deficiency frequently leads to a fall in estrogen receptor alpha (ER alpha) numbers and then reduces the skeletal response to mechanical strain. It, however, is still unclear whether phytoestrogen administration will enhance the effects of exercise on the estrogen deficient bone loss. This study aimed to determine the effect of Icariin treatment on the response of osteogenic formation to exercise in ovariectomized (OVX) rats. Thirty two 3 month old female Sprague Dawley rats were randomly allocated into four groups: (1) Sham operated (SO); (2) OVX; (3) OVX plus exercise (EX); and (4) OVX plus exercise and Icariin (EI). After 8 week interventions, the rats were killed and samples were collected for bone morphometry, reverse transcription polymerase chain reaction (RT PCR), and Western blot analyses. EI interventions showed a greater improvement for the OVX induced bone loss and the elevated serum tartrate resistant acid phosphatase (TRAP) and alkaline phosphatase (ALP) compared with EX only. Both EX and EI interventions bettered the OVX related reduction of BV/TV and trabecular number and thickness, and decreased the enlargement of trabecular bone separation (Tb. Sp); the improvement for BV/TV and Tb. Sp was greater in EI group. Furthermore, EX and EI treatment significantly increased the number of ALP(+) cells and mineralized nodule areas compared with OVX group; the change was higher in EI group. Additionally, in comparison to OVX rats, the protein and mRNA expression of beta catenin, phosphorylated Akt (p Akt) or Akt, ER alpha, and Runt related transcription factor 2 (Runx2) in osteoblasts were elevated in EX and EI intervention rats, with greater change observed in EI group. The upregulated beta catenin and Akt mRNA levels in EX and EI groups was depressed by ICI182780 treatment, and the difference in beta catenin and Akt mRNA levels between EX and EI groups was no longer significant. Conclusively, the combination of Icariin and exercise significantly prevent OVX induced bone loss and increase osteoblast differentiation and the ability of mineralization compared with exercise alone; the changes might be regulated partly by ER alpha/Akt/beta catenin pathway.
C1 [Zhao, Renqing; Bu, Wenqian; Chen, Yingfeng] Yangzhou Univ, Coll Phys Educ, 88 Daxue South Rd, Yangzhou 225009, Jiangsu, Peoples R China.
   [Zhao, Renqing] Zhejiang Normal Univ, Coll Phys Educ & Hlth Sci, 688 Yingbin Ave, Jinhua 321004, Zhejiang, Peoples R China.
C3 Yangzhou University; Zhejiang Normal University
RP Zhao, RQ (通讯作者)，Yangzhou Univ, Coll Phys Educ, 88 Daxue South Rd, Yangzhou 225009, Jiangsu, Peoples R China.; Zhao, RQ (通讯作者)，Zhejiang Normal Univ, Coll Phys Educ & Hlth Sci, 688 Yingbin Ave, Jinhua 321004, Zhejiang, Peoples R China.
EM renqing.zhao@yzu.edu.cn; bwq1208@163.com; cyf_yzu@163.com
FU Natural Science Foundation of Zhejiang Province [LY14H070001]
FX This work was supported in part by Natural Science Foundation of
   Zhejiang Province (LY14H070001).
CR Ankrom MA, 1998, BIOCHEM J, V333, P787, DOI 10.1042/bj3330787
   Armstrong VJ, 2007, J BIOL CHEM, V282, P20715, DOI 10.1074/jbc.M703224200
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Braithwaite RS, 2003, J AM GERIATR SOC, V51, P364, DOI 10.1046/j.1532 5415.2003.51110.x
   Bu SM, 2012, EUR J APPL PHYSIOL, V112, P3295, DOI 10.1007/s00421 011 2306 4
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cotts KG, 2018, JAMA J AM MED ASSOC, V319, P1040, DOI 10.1001/jama.2017.21995
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Dondorp AM, 2009, NEW ENGL J MED, V361, P455, DOI 10.1056/NEJMoa0808859
   Howe TE, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000333, 10.1002/14651858.CD000333.pub2]
   Indran IR, 2016, PHARMACOL THERAPEUT, V162, P188, DOI 10.1016/j.pharmthera.2016.01.015
   Kelley GA, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471 2474 13 177
   Kemmler W, 2003, ARCH PHYS MED REHAB, V84, P673, DOI 10.1016/S0003 9993(03)04908 0
   Lan DM, 2016, ELECTRON J BIOTECHN, V22, P62, DOI 10.1016/j.ejbt.2016.06.003
   Lau KHW, 2006, J BIOL CHEM, V281, P9576, DOI 10.1074/jbc.M509205200
   Lee K, 2003, NATURE, V424, P389, DOI 10.1038/424389a
   Lennon DP, 2006, EXP HEMATOL, V34, P1606, DOI 10.1016/j.exphem.2006.07.015
   Lobo RA, 2017, NAT REV ENDOCRINOL, V13, P220, DOI 10.1038/nrendo.2016.164
   Martyn St James M, 2006, OSTEOPOROSIS INT, V17, P1225, DOI 10.1007/s00198 006 0083 4
   Martyn St James M, 2009, BRIT J SPORT MED, V43, P898, DOI 10.1136/bjsm.2008.052704
   Mok SK, 2010, BRIT J PHARMACOL, V159, P939, DOI 10.1111/j.1476 5381.2009.00593.x
   Nelson HD, 2002, JAMA J AM MED ASSOC, V288, P882, DOI 10.1001/jama.288.7.882
   Nian H, 2009, PHYTOMEDICINE, V16, P320, DOI 10.1016/j.phymed.2008.12.006
   Shi Xiao Lin, 2017, Zhongguo Gu Shang, V30, P743, DOI 10.3969/j.issn.1003 0034.2017.08.013
   Snow CM, 2000, J GERONTOL A BIOL, V55, pM489, DOI 10.1093/gerona/55.9.M489
   Tobias JH, 2003, TRENDS ENDOCRIN MET, V14, P441, DOI 10.1016/j.tem.2003.09.010
   van den Bergh JP, 2012, NAT REV RHEUMATOL, V8, P163, DOI 10.1038/nrrheum.2011.217
   Wei QS, 2016, BIOMED PHARMACOTHER, V84, P931, DOI 10.1016/j.biopha.2016.09.107
   Wu J, 2004, METABOLISM, V53, P942, DOI 10.1016/j.metabol.2004.01.019
   Wu T., 2011, GUIZHOU MED J, V34, P79
   Zhao R, 2015, OSTEOPOROSIS INT, V26, P1605, DOI 10.1007/s00198 015 3034 0
   Zhao RQ, 2017, INT J EPIDEMIOL, V46, P149, DOI 10.1093/ije/dyw142
NR 32
TC 3
Z9 4
U1 0
U2 7
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1660 4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD OCT
PY 2019
VL 16
IS 19
AR 3779
DI 10.3390/ijerph16193779
PG 10
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA JK3MF
UT WOS:000494748600275
PM 31597358
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ye, J
   Jiang, JK
   Zhou, ZR
   Weng, ZZ
   Xu, YY
   Liu, LB
   Zhang, W
   Yang, YF
   Luo, J
   Wang, XL
AF Ye, Jing
   Jiang, Junkai
   Zhou, Zhirui
   Weng, Zhenzhen
   Xu, Yingying
   Liu, Lubing
   Zhang, Wei
   Yang, Yifei
   Luo, Jun
   Wang, Xiaolei
TI Near Infrared Light and Upconversion Nanoparticle Defined Nitric
   Oxide Based Osteoporosis Targeting Therapy
SO ACS NANO
LA English
DT Article
DE nitric oxide; osteoporosis; upconversion; bone targeting; 808 nm NIR
ID ANTICANCER DRUG DELIVERY; BONE; LUMINESCENT; RELEASE; MYELOMA; WOMEN
AB Osteoporosis is one of the most common diseases affecting bone metabolism. Nitric oxide (NO), an endogenous gas molecule involved in osteogenesis, can effectively promote the proliferation and differentiation of osteoblasts. Although exogenous NO can reverse osteoporosis to a certain extent, the transitory half life and short diffusion radius of NO severely limit its application. In this work, a gas generation nanoplatform of NO with bone targeting property (UCPA) is developed based on the upconversion nanoparticles (UCNPs) that can convert 808 nm near infrared (NIR) light into UV/blue light, and further stimulate the NO donor (BNN) to release NO. With an adjustment of the output power of the 808 nm NIR, the amount of released NO can be precisely controlled. Both in vitro and in vivo experiments demonstrate the favorable affinity of UCPA to bone due to the modification of alendronate; thus, it can directly release NO in bone and reverse osteoporosis. In addition, the cellular uptake of nanocomposites and intracellular NO release can be observed in preosteoblasts, thereby promoting their differentiation efficiently.
C1 [Ye, Jing; Luo, Jun] Nanchang Univ, Affiliated Hosp 2, Dept Rehabil Med, Nanchang 330006, Jiangxi, Peoples R China.
   [Ye, Jing; Jiang, Junkai; Zhou, Zhirui; Weng, Zhenzhen; Xu, Yingying; Liu, Lubing; Zhang, Wei; Wang, Xiaolei] Nanchang Univ, Natl Engn Res Ctr Bioengn Drugs & Technol, Inst Translat Med, Nanchang 330088, Jiangxi, Peoples R China.
   [Ye, Jing; Weng, Zhenzhen; Xu, Yingying; Liu, Lubing; Zhang, Wei; Wang, Xiaolei] Nanchang Univ, Coll Chem, Nanchang 330088, Jiangxi, Peoples R China.
   [Yang, Yifei] Nanchang Univ, Sch Publ Hlth, Jiangxi Prov Key Lab Prevent Med, Nanchang 330088, Jiangxi, Peoples R China.
C3 Nanchang University; Nanchang University; Nanchang University; Nanchang
   University
RP Luo, J (通讯作者)，Nanchang Univ, Affiliated Hosp 2, Dept Rehabil Med, Nanchang 330006, Jiangxi, Peoples R China.; Wang, XL (通讯作者)，Nanchang Univ, Natl Engn Res Ctr Bioengn Drugs & Technol, Inst Translat Med, Nanchang 330088, Jiangxi, Peoples R China.; Wang, XL (通讯作者)，Nanchang Univ, Coll Chem, Nanchang 330088, Jiangxi, Peoples R China.
EM luojun1786@163.com; wangxiaolei@ncu.edu.cn
RI ; Yang, Yifei/HJA 0450 2022
OI Ye, Jing/0000 0001 7289 4611; 
FU National Key Research and Development Program of China [2020YFC2005800];
   National Natural Science Foundation of China [31860263, 81760408]; Key
   Youth Project of Jiangxi Province [20202ACB216002]; Natural Science
   Foundation of Jiangxi Province [20113BCB22005, 20181BCG42001]; Graduate
   Innovation Special Fund of Jiangxi Province [YC2020 B051]
FX This work was funded by the National Key Research and Development
   Program of China (No. 2020YFC2005800 to J.L.), National Natural Science
   Foundation of China (No. 31860263 to X.l. W.; No. 81760408 to J.L.), Key
   Youth Project of Jiangxi Province (20202ACB216002 to X.l. W.), Natural
   Science Foundation of Jiangxi Province (20113BCB22005 and 20181BCG42001
   to J.L.) and Graduate Innovation Special Fund of Jiangxi Province
   (YC2020 B051 to J.Y.).
CR Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001 907
   Carpenter AW, 2012, CHEM SOC REV, V41, P3742, DOI 10.1039/c2cs15273h
   Chen LC, 2019, ACS NANO, V13, P10887, DOI 10.1021/acsnano.9b04954
   Chen WS, 2015, CHEM COMMUN, V51, P9193, DOI 10.1039/c5cc02508g
   Cheng L, 2013, NANOSCALE, V5, P23, DOI 10.1039/c2nr32311g
   Cheng XG, 2007, J CLIN DENSITOM, V10, P276, DOI 10.1016/j.jocd.2007.05.004
   Deng Q., ACS NANO, V15, P6604
   Deng Y, 2020, CHEM MATER, V32, P2180, DOI 10.1021/acs.chemmater.0c00290
   Feng W, 2013, ADV MATER, V25, P5287, DOI 10.1002/adma.201301946
   Gao Q, 2018, SMALL, V14, DOI 10.1002/smll.201802290
   Hu QY, 2016, ADV MATER, V28, P9573, DOI 10.1002/adma.201603463
   Johnson NJJ, 2012, J AM CHEM SOC, V134, P11068, DOI 10.1021/ja302717u
   Kecht J, 2008, CHEM MATER, V20, P7207, DOI 10.1021/cm801484r
   Li CX, 2013, BIOMATER SCI UK, V1, P213, DOI 10.1039/c2bm00087c
   Li Y, 2016, ACS NANO, V10, P2766, DOI 10.1021/acsnano.5b07873
   Lin YJ, 2018, ADV MATER, V30, DOI 10.1002/adma.201705605
   Liu JA, 2013, ANGEW CHEM INT EDIT, V52, P4375, DOI 10.1002/anie.201300183
   MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449
   Mora Raimundo P, 2019, ACS NANO, V13, P5451, DOI 10.1021/acsnano.9b00241
   Nichols SP, 2012, ADV DRUG DELIVER REV, V64, P1177, DOI 10.1016/j.addr.2012.03.002
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Shao JD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12967
   Sortino S, 2010, CHEM SOC REV, V39, P2903, DOI 10.1039/b908663n
   Swami A, 2014, P NATL ACAD SCI USA, V111, P10287, DOI 10.1073/pnas.1401337111
   Wang PG, 2002, CHEM REV, V102, P1091, DOI 10.1021/cr000040l
   Wimalawansa SJ, 2008, EXPERT OPIN PHARMACO, V9, P3025, DOI 10.1517/14656560802197162 
   Zhang X, 2019, ADV SCI, V6, DOI 10.1002/advs.201801122
   Zhang X, 2015, ADV FUNCT MATER, V25, P3049, DOI 10.1002/adfm.201404402
   Zhang YF, 2012, BIOMATERIALS, V33, P6698, DOI 10.1016/j.biomaterials.2012.06.021
   Zhou RP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166751
   Zuin M, 2017, EUR J INTERN MED, V43, pE22, DOI 10.1016/j.ejim.2017.06.006
NR 31
TC 69
Z9 71
U1 16
U2 211
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936 0851
EI 1936 086X
J9 ACS NANO
JI ACS Nano
PD AUG 24
PY 2021
VL 15
IS 8
BP 13692
EP 13702
DI 10.1021/acsnano.1c04974
EA JUL 2021
PG 11
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA UM1NO
UT WOS:000693105500102
PM 34328303
DA 2025 08 17
ER

PT J
AU Li, ZW
   Piao, CD
   Sun, HH
   Ren, XS
   Bai, YS
AF Li, Zheng Wei
   Piao, Cheng dong
   Sun, Hong Hui
   Ren, Xian Sheng
   Bai, Yun Shen
TI Asiatic Acid Inhibits Adipogenic Differentiation of Bone Marrow Stromal
   Cells
SO CELL BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE Asiatic acid; Bone marrow stromal cells; Adipogenesis; PPAR gamma; C/EBP
   beta
ID CENTELLA ASIATICA; PPAR GAMMA; ADIPOCYTE DIFFERENTIATION; IN VITRO;
   TRITERPENE; APOPTOSIS; PATHWAYS; GENE; MICE
AB Bone marrow mesenchymal stromal cells (BMSCs) are the common precursors for both osteoblasts and adipocytes. With aging, BMSC osteoblast differentiation decreases whereas BMSC differentiation into adipocytes increases, resulting in increased adipogenesis and bone loss. In the present study, we investigated the effect of asiatic acid (AA) on adipocytic differentiation of BMSCs. AA inhibited the adipogenic induction of lipid accumulation, activity of glycerol 3 phosphate dehydrogenase, and expression of marker genes in adipogenesis: peroxisome proliferation activated receptor (PPAR)gamma, adipocyte fatty acid binding protein (ap) 2, and adipsin. Further, we found that AA did not alter clonal expansion rate and expression of C/EBP beta, upstream key regulator of PPAR gamma, and binding activity of C/EBP beta to PPAR gamma promoter was not affected by AA as well. These findings suggest that AA may modulate differentiation of BMSCs to cause a lineage shift away from the adipocytes, and inhibition of PPAR gamma by AA is through C/EBP beta independent mechanisms. Thus, AA could be a potential candidate for a novel drug against osteoporosis.
C1 [Li, Zheng Wei; Piao, Cheng dong; Sun, Hong Hui; Ren, Xian Sheng; Bai, Yun Shen] Jilin Univ, Clin Hosp 2, Changchun 130041, Peoples R China.
C3 Jilin University
RP Bai, YS (通讯作者)，Jilin Univ, Clin Hosp 2, Changchun 130041, Peoples R China.
EM zhengweilicc@gmail.com
RI li, zhengwei/ABF 3014 2020
CR Ahdjoudj S, 2004, HISTOL HISTOPATHOL, V19, P151, DOI 10.14670/HH 19.151
   Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   BERESFORD JN, 1992, J CELL SCI, V102, P341
   Cheng CL, 2004, LIFE SCI, V74, P2237, DOI 10.1016/j.lfs.2003.09.055
   Dominici M, 2001, J BIOL REG HOMEOS AG, V15, P28
   GIMBLE J M, 1990, New Biologist, V2, P304
   Hsu YL, 2005, J PHARMACOL EXP THER, V313, P333, DOI 10.1124/jpet.104.078808
   Kimura Y, 2008, EUR J PHARMACOL, V584, P415, DOI 10.1016/j.ejphar.2008.02.036
   Klein RF, 2004, SCIENCE, V303, P229, DOI 10.1126/science.1090985
   Krishnamurthy RG, 2009, J NEUROSCI RES, V87, P2541, DOI 10.1002/jnr.22071
   Lazar MA, 2005, BIOCHIMIE, V87, P9, DOI 10.1016/j.biochi.2004.10.021
   Mundy G. R., 1996, P301
   Nuttall ME, 2000, BONE, V27, P177, DOI 10.1016/S8756 3282(00)00317 3
   Park BC, 2005, CANCER LETT, V218, P81, DOI 10.1016/j.canlet.2004.06.039
   Pittella F, 2009, INT J MOL SCI, V10, P3713, DOI 10.3390/ijms10093713
   Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097 2765(00)80211 7
   Sakaguchi K, 2000, PROSTAG LEUKOTR ESS, V62, P319, DOI 10.1054/plef.2000.0161
   Schaneberg BT, 2003, PHARMAZIE, V58, P381
   Soumyanath A, 2005, J PHARM PHARMACOL, V57, P1221, DOI 10.1211/jpp.57.9.0018
   Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432
   Tang QQ, 2003, P NATL ACAD SCI USA, V100, P44, DOI 10.1073/pnas.0137044100
   Won JH, 2010, PLANTA MED, V76, P251, DOI 10.1055/s 0029 1186142
   YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168
   Yun KJ, 2008, INT IMMUNOPHARMACOL, V8, P431, DOI 10.1016/j.intimp.2007.11.003
NR 24
TC 11
Z9 17
U1 0
U2 17
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1085 9195
EI 1559 0283
J9 CELL BIOCHEM BIOPHYS
JI Cell Biochem. Biophys.
PD MAR
PY 2014
VL 68
IS 2
BP 437
EP 442
DI 10.1007/s12013 013 9725 2
PG 6
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA AB2VW
UT WOS:000331651200022
PM 23934183
DA 2025 08 17
ER

PT J
AU Varkaris, A
   Corn, PG
   Parikh, NU
   Efstathiou, E
   Song, JH
   Lee, YC
   Aparicio, A
   Hoang, AG
   Gaur, S
   Thorpe, L
   Maity, SN
   Bar Eli, M
   Czerniak, BA
   Shao, YP
   Alauddin, M
   Lin, SH
   Logothetis, CJ
   Gallick, GE
AF Varkaris, Andreas
   Corn, Paul G.
   Parikh, Nila U.
   Efstathiou, Eleni
   Song, Jian H.
   Lee, Yu Chen
   Aparicio, Ana
   Hoang, Anh G.
   Gaur, Sanchaika
   Thorpe, Lynnelle
   Maity, Sankar N.
   Bar Eli, Menashe
   Czerniak, Bogdan A.
   Shao, Yiping
   Alauddin, Mian
   Lin, Sue Hwa
   Logothetis, Christopher J.
   Gallick, Gary E.
TI Integrating Murine and Clinical Trials with Cabozantinib to Understand
   Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate
   Cancer
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID VASCULAR ENDOTHELIAL GROWTH; C MET; INTRATUMOR HETEROGENEITY;
   LUNG CANCER; PHASE II; RECEPTOR; METASTASIS; ACTIVATION; RESISTANCE;
   KINASE
AB Purpose: We performed parallel investigations in cabozantinib  treated patients in a phase II trial and simultaneously in patient derived xenograft (PDX) models to better understand the roles of MET and VEGFR2 as targets for prostate cancer therapy.
   Experimental Design: In the clinical trial, radiographic imaging and serum markers were examined, as well as molecular markers in tumors from bone biopsies. In mice harboring PDX intrafemurally or subcutaneously, cabozantinib effects on tumor growth, MET, PDX in which MET was silenced, VEGFR2, bone turnover, angiogenesis, and resistance were examined.
   Results: In responsive patients and PDX, islets of viable pMET positive tumor cells persisted, which rapidly regrew after drug withdrawal. Knockdown of MET in PDX did not affect tumor growth in mice nor did it affect cabozantinib induced growth inhibition but did lead to induction of FGFR1. Inhibition of VEGFR2 and MET in endothelial cells reduced the vasculature, leading to necrosis. However, each islet of viable cells surrounded a VEGFR2 negative vessel. Reduction of bone turnover was observed in both cohorts.
   Conclusions: Our studies demonstrate that MET in tumor cells is not a persistent therapeutic target for metastatic castrate resistant prostate cancer (CRPC), but inhibition of VEGFR2 and MET in endothelial cells and direct effects on osteoblasts are responsible for cabozantinib induced tumor inhibition. However, vascular heterogeneity represents one source of primary therapy resistance, whereas induction of FGFR1 in tumor cells suggests a potential mechanism of acquired resistance. Thus, integrated cross species investigations demonstrate the power of combining preclinical models with clinical trials to understand mechanisms of activity and resistance of investigational agents. (C)2015 AACR.
C1 [Varkaris, Andreas; Corn, Paul G.; Parikh, Nila U.; Efstathiou, Eleni; Song, Jian H.; Lee, Yu Chen; Aparicio, Ana; Hoang, Anh G.; Gaur, Sanchaika; Thorpe, Lynnelle; Maity, Sankar N.; Lin, Sue Hwa; Logothetis, Christopher J.; Gallick, Gary E.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, David H Koch Ctr Appl Res Genitourinary Canc, Houston, TX 77030 USA.
   [Lee, Yu Chen; Lin, Sue Hwa] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA.
   [Gaur, Sanchaika; Thorpe, Lynnelle; Bar Eli, Menashe; Gallick, Gary E.] Univ Texas Houston, Grad Sch Biomed Sci Houston, Programs Canc Biol & Canc Metastasis, Houston, TX USA.
   [Bar Eli, Menashe] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA.
   [Czerniak, Bogdan A.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
   [Shao, Yiping] Univ Texas MD Anderson Canc Ctr, Dept Imaging Phys Res, Houston, TX 77030 USA.
   [Alauddin, Mian] Univ Texas MD Anderson Canc Ctr, Dept Canc Syst Imaging, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; University of Texas System;
   University of Texas Health Science Center Houston; University of Texas
   System; UTMD Anderson Cancer Center; University of Texas System; UTMD
   Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer
   Center; University of Texas System; UTMD Anderson Cancer Center
RP Gallick, GE (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Unit 0018 4, Clinical Res Bldg T7 3891,1515 Holcombe Blvd, Houston, TX 77030 USA.
EM ggallick@mdanderson.org
RI ; varkaris, andreas/AAS 4833 2020
OI Maity, Sankar/0000 0002 2387 6545; Corn, Paul/0000 0002 4106 6335; 
FU National Cancer Institute (NCI) [P50 CA140388]; Prostate Cancer
   Foundation (PCF) Challenge award; PCF; University of Texas MD Anderson;
   UT Health Innovation for Cancer Prevention Research Pre doctoral
   Fellowship; University of Texas School of Public Health Cancer
   Prevention and Research Institute of Texas [RP101503]; Cancer Prevention
   and Research Institute of Texas grant [RPO150282]; Cancer Center Support
   Grant [CA16672]
FX This work is supported by the National Cancer Institute (NCI) Grant No.
   P50 CA140388; a Prostate Cancer Foundation (PCF) Challenge award; a PCF
   Creativity Award; and The University of Texas MD Anderson Prostate
   Cancer Moon Shots Program (C.J. Logothetis and G.E. Gallick); a PCF
   Young Investigator Award (A. Varkaris); a PCF Career Development Award
   (E. Efstathiou), a UT Health Innovation for Cancer Prevention Research
   Pre doctoral Fellowship, The University of Texas School of Public
   Health Cancer Prevention and Research Institute of Texas grant #RP101503
   (S. Gaur), Cancer Prevention and Research Institute of Texas grant
   #RPO150282 (G.E. Gallick) and Cancer Center Support Grant (CA16672), and
   the Solon Scott III donor funds (P.G. Corn).
CR Aftab DT, 2011, CLIN TRANSL ONCOL, V13, P703, DOI 10.1007/s12094 011 0719 5
   Aparicio A, 2011, PROSTATE, V71, P846, DOI 10.1002/pros.21301
   Aparicio AM, 2013, CLIN CANCER RES, V19, P3621, DOI 10.1158/1078 0432.CCR 12 3791
   Bachleitner Hofmann T, 2008, MOL CANCER THER, V7, P3499, DOI 10.1158/1535 7163.MCT 08 0374
   Basch E, 2015, EUR UROL, V67, P310, DOI 10.1016/j.eururo.2014.02.013
   Bocci G, 2004, CANCER RES, V64, P6616, DOI 10.1158/0008 5472.CAN 04 0401
   Breindel JL, 2013, CANCER RES, V73, P5053, DOI 10.1158/0008 5472.CAN 12 3775
   Chang JJ, 2015, ONCOTARGET, V6, P2009, DOI 10.18632/oncotarget.2987
   Chen Z, 2012, NATURE, V483, P613, DOI 10.1038/nature10937
   Chu GCY, 2014, ENDOCR RELAT CANCER, V21, P311, DOI 10.1530/ERC 13 0548
   Dai JL, 2014, CLIN CANCER RES, V20, P617, DOI 10.1158/1078 0432.CCR 13 0839
   Dulak AM, 2011, ONCOGENE, V30, P3625, DOI 10.1038/onc.2011.84
   Ebos JML, 2008, CANCER RES, V68, P521, DOI 10.1158/0008 5472.CAN 07 3217
   Elisei R, 2013, J CLIN ONCOL, V31, P3639, DOI 10.1200/JCO.2012.48.4659
   Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478
   Fisher R, 2013, BRIT J CANCER, V108, P479, DOI 10.1038/bjc.2012.581
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Graham TJ, 2014, JNCI J NATL CANCER I, V106, DOI 10.1093/jnci/dju033
   Jacobsen F, 2013, EXP THER MED, V5, P102, DOI 10.3892/etm.2012.764
   Knudsen BS, 2002, UROLOGY, V60, P1113, DOI 10.1016/S0090 4295(02)01954 4
   Kurzrock R, 2011, J CLIN ONCOL, V29, P2660, DOI 10.1200/JCO.2010.32.4145
   Lee RJ, 2013, CLIN CANCER RES, V19, P3088, DOI 10.1158/1078 0432.CCR 13 0319
   Lee YC, 2011, CANCER RES, V71, P5194, DOI 10.1158/0008 5472.CAN 10 4374
   Li ZG, 2008, J CLIN INVEST, V118, P2697, DOI 10.1172/JCI33093
   Lindner G, 2008, NEPHROL DIAL TRANSPL, V23, P3501, DOI 10.1093/ndt/gfn476
   Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037
   Meyer AS, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004155
   Nardella C, 2011, CANCER DISCOV, V1, P108, DOI 10.1158/2159 8290.CD 11 0061
   Norden Zfoni A, 2007, CLIN CANCER RES, V13, P2643, DOI 10.1158/1078 0432.CCR 06 0919
   Park SI, 2008, CANCER RES, V68, P3323, DOI 10.1158/0008 5472.CAN 07 2997
   Posadas EM, 2013, J CLIN ONCOL, V31, P169, DOI 10.1200/JCO.2012.46.7738
   Postel Vinay S, 2013, ANN ONCOL, V24, P2201, DOI 10.1093/annonc/mdt331
   Ryan CJ, 2013, CLIN CANCER RES, V19, P215, DOI 10.1158/1078 0432.CCR 12 2605
   Sennino B, 2013, CANCER RES, V73, P3692, DOI 10.1158/0008 5472.CAN 12 2160
   Sennino B, 2012, NAT REV CANCER, V12, P699, DOI 10.1038/nrc3366
   Sennino B, 2012, CANCER DISCOV, V2, P270, DOI 10.1158/2159 8290.CD 11 0240
   Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008 5472.CAN 04 2442
   Sitohy B, 2012, CANCER RES, V72, P1909, DOI 10.1158/0008 5472.CAN 11 3406
   Sitohy B, 2011, CANCER RES, V71, P7021, DOI 10.1158/0008 5472.CAN 11 1693
   Smith DC, 2013, J CLIN ONCOL, V31, P412, DOI 10.1200/JCO.2012.45.0494
   Swanton C, 2012, CANCER RES, V72, P4875, DOI 10.1158/0008 5472.CAN 12 2217
   Troiani T, 2013, CLIN CANCER RES, V19, P6751, DOI 10.1158/1078 0432.CCR 13 0423
   Tzelepi V, 2012, CLIN CANCER RES, V18, P666, DOI 10.1158/1078 0432.CCR 11 1867
   Vaishampayan U, 2013, CURR ONCOL REP, V15, P76, DOI 10.1007/s11912 012 0289 x
   Varkaris A, 2013, INT J CANCER, V133, P1536, DOI 10.1002/ijc.28169
   Vazquez Martin A, 2013, SCI REP UK, V3, DOI 10.1038/srep02560
   Verras M, 2007, CANCER RES, V67, P967, DOI 10.1158/0008 5472.CAN 06 3552
   Wagner JP, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003994
   Wan XH, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009332
   Wanjala J, 2015, MOL CANCER THER, V14, P278, DOI 10.1158/1535 7163.MCT 14 0542 T
   Ware KE, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.4
   Yakes FM, 2011, MOL CANCER THER, V10, P2298, DOI 10.1158/1535 7163.MCT 11 0264
   You WK, 2011, CANCER RES, V71, P4758, DOI 10.1158/0008 5472.CAN 10 2527
   Zhou Y, 2014, MOL CANCER THER, V13, P134, DOI 10.1158/1535 7163.MCT 13 0187
NR 54
TC 43
Z9 46
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1078 0432
EI 1557 3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JAN 1
PY 2016
VL 22
IS 1
BP 107
EP 121
DI 10.1158/1078 0432.CCR 15 0235
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA DA1IU
UT WOS:000367550300015
PM 26272062
OA Green Accepted, Green Submitted
DA 2025 08 17
ER

PT J
AU Deng, JY
   Cohen, DJ
   Matias, EB
   Olson, LO
   Mcclure, MJ
   Boyan, BD
   Schwartz, Z
AF Deng, Jingyao
   Cohen, David Joshua
   Matias, Enrique B.
   Olson, Lucas O.
   Mcclure, Michael J.
   Boyan, Barbara D.
   Schwartz, Zvi
TI Reduced osseointegration in disuse and denervation rat models results
   from impaired cellular responses to multiscale microstructured titanium
   surfaces
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE denervation; disuse atrophy; microstructured titanium implants;
   osseointegration; osteoblast differentiation
ID INDUCED BONE; PREDICTORS; NEURECTOMY; OSTEOPENIA; TURNOVER; DENSITY;
   FALLS
AB Immobilization induced skeletal unloading results in muscle atrophy and rapid bone loss, thereby increasing the risk of falling and the need for implant therapy in patients with extended bed rest or neuromuscular injuries. Skeletal unloading causes bone loss by altering bone growth and resorption, suggesting that implant performance might be affected. To test this, we focused on early events in implant osseointegration. We used the rat sciatic neurectomy induced disuse model under two different settings. In Study 1, 16 Sprague Dawley rats (SD) were separated into control, sham operated+cast immobilization, and sciatic neurectomy+casting groups; titanium implants with multiscale microtextured topography and hydrophilic chemistry (modSLA) were inserted in the distal femoral metaphysis. Neurectomy surgeries and casting were performed at the same surgical setting as implant placement; rats were euthanized 4 weeks post implantation. In Study 2, we established the unloaded condition before implantation. A total of 12 SD rats were divided into control and sciatic+femoral neurectomy groups. A total of 24 days after sciatic and femoral neurectomy surgery, rats received implants. Study 2 rats were euthanized at 4 weeks post implantation. MicroCT and histomorphometry showed that trabecular bone and osseointegration were reduced when disuse was established before implantation. Osteoblasts isolated from Study 1 sciatic neurectomy tibial bones exhibited impaired differentiation on modSLA culture disks, revealing a possible mechanism responsible for the decreased osseointegration observed in the Study 2 rats. This study addressed the importance of considering the mechanical unloading and muscle function history before implant insertion and suggests that implant performance was reduced due to poor cellular ability to regenerate.
C1 [Deng, Jingyao; Cohen, David Joshua; Matias, Enrique B.; Olson, Lucas O.; Mcclure, Michael J.; Boyan, Barbara D.; Schwartz, Zvi] Virginia Commonwealth Univ, Coll Engn, Dept Biomed Engn, Richmond, VA USA.
   [Boyan, Barbara D.] Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA USA.
   [Schwartz, Zvi] Univ Texas Hlth Sci Ctr San Antonio, Dept Periodont, San Antonio, TX USA.
   [Boyan, Barbara D.] Virginia Commonwealth Univ, Coll Engn, 601 West Main St, Richmond, VA 23284 USA.
C3 Virginia Commonwealth University; University System of Georgia; Georgia
   Institute of Technology; University of Texas System; University of Texas
   Health Science Center at San Antonio; Virginia Commonwealth University
RP Boyan, BD (通讯作者)，Virginia Commonwealth Univ, Coll Engn, 601 West Main St, Richmond, VA 23284 USA.
EM bboyan@vcu.edu
OI McClure, Michael/0000 0002 5428 5270; Cohen, David/0000 0003 1212 6164;
   Boyan, Barbara D./0000 0002 9642 0311
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases;
   Institut Straumann AG (Basel, Switzerland) [R01AR072500]; National
   Institute of Arthritis and Musculoskeletal and Skin Disease of the
   National Institute of Health
FX Institut Straumann AG (Basel, Switzerland) provided all Ti implants and
   disks for this study. Additional support was provided by the National
   Institute of Arthritis and Musculoskeletal and Skin Disease of the
   National Institute of Health under Award Number R01AR072500. The content
   is solely the authors' responsibility and does not necessarily represent
   the official views of the National Institutes of Health. The authors
   would like to acknowledge the Nanomaterials Characterization Core at
   Virginia Commonwealth University for instrument access. The study is in
   partial fulfillment of the PhD degree for Jingyao Deng.
CR Arteaga Alexandra, 2021, J Bio Tribocorros, V7, DOI 10.1007/s40735 021 00486 8
   Ashe M. C., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P226
   Basudan AM, 2021, APPL SCI BASEL, V11, DOI 10.3390/app11020723
   Bateman TA, 2001, J ORTHOPAED RES, V19, P518, DOI 10.1016/S0736 0266(00)00057 7
   Berger MB, 2022, BIOMIMETICS BASEL, V7, DOI 10.3390/biomimetics7020046
   Berger MB, 2021, J ORTHOP RES, V39, P1908, DOI 10.1002/jor.24869
   Boyan BD, 2022, J AM ACAD ORTHOP SUR, V30, pE894, DOI 10.5435/JAAOS D 21 00523
   Boyan BD, 2017, TISSUE ENG PT A, V23, P1479, DOI [10.1089/ten.tea.2017.0048, 10.1089/ten.TEA.2017.0048]
   Boyan BD, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 26901 8
   Boyan BD., 2023, SURG RES IMPLANT DEN, P211, DOI [10.1007/978 3 031 37234 6_11, DOI 10.1007/978 3 031 37234 6_11]
   Brent MB, 2021, CALCIFIED TISSUE INT, V108, P561, DOI 10.1007/s00223 020 00799 9
   Chakravorty N, 2017, SPRING SER BIOMAT S, V8, P107, DOI 10.1007/978 3 662 53574 5_4
   de Molon RS, 2013, CLIN ORAL IMPLAN RES, V24, P831, DOI 10.1111/j.1600 0501.2012.02467.x
   Deng JY, 2023, ACTA BIOMATER, V157, P236, DOI 10.1016/j.actbio.2022.11.030
   Deng JY, 2021, BONE, V153, DOI 10.1016/j.bone.2021.116145
   Friedman MA, 2019, J BIOMECH, V83, P181, DOI 10.1016/j.jbiomech.2018.11.049
   Gittens RA, 2014, ACTA BIOMATER, V10, P3363, DOI 10.1016/j.actbio.2014.03.037
   Gordon T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228652
   He YD, 2022, BIOACT MATER, V8, P109, DOI 10.1016/j.bioactmat.2021.06.033
   Hotchkiss KM, 2016, ACTA BIOMATER, V31, P425, DOI 10.1016/j.actbio.2015.12.003
   Hu B, 2020, J CLIN INVEST, V130, P3483, DOI 10.1172/JCI131554
   Huang B, 2019, ROY SOC OPEN SCI, V6, DOI 10.1098/rsos.181082
   Ito M, 1999, J BONE MINER METAB, V17, P45, DOI 10.1007/s007740050062
   Li TS, 2016, MED SCI MONITOR, V22, P4651, DOI 10.12659/MSM.898137
   Lotz EM, 2020, CLIN ORAL IMPLAN RES, V31, P374, DOI 10.1111/clr.13575
   Lotz EM, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10184
   Lotz EM, 2016, J BIOMED MATER RES A, V104, P3137, DOI 10.1002/jbm.a.35852
   Ma XL, 2016, SCI REP UK, V6, DOI 10.1038/srep24562
   Maki BE, 1997, J AM GERIATR SOC, V45, P313, DOI 10.1111/j.1532 5415.1997.tb00946.x
   McMillan J, 2007, BONE, V40, P111, DOI 10.1016/j.bone.2006.07.022
   Nakamura H, 2001, ACTA ASTRONAUT, V49, P179, DOI 10.1016/S0094 5765(01)00097 2
   Olivares Navarrete R, 2012, J BONE MINER RES, V27, P1773, DOI 10.1002/jbmr.1628
   Olivares Navarrete R, 2011, ACTA BIOMATER, V7, P2740, DOI 10.1016/j.actbio.2011.02.030
   Olson LC, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168832
   Paiva AG, 2016, BRAZ J MED BIOL RES, V49, DOI 10.1590/1414 431X20155076
   ROBBINS AS, 1989, ARCH INTERN MED, V149, P1628, DOI 10.1001/archinte.149.7.1628
   Sakai A, 2005, J BONE MINER METAB, V23, P8, DOI 10.1007/s00774 004 0534 y
   Schwarz F, 2009, J BIOMED MATER RES B, V88B, P544, DOI 10.1002/jbm.b.31233
   Shen V, 1997, BONE, V21, P71, DOI 10.1016/S8756 3282(97)00070 7
   Skelton AM, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms241612770
   Stavnichuk M, 2020, NPJ MICROGRAVITY, V6, DOI 10.1038/s41526 020 0103 2
   Stich T, 2022, BIOENG TRANSL MED, V7, DOI 10.1002/btm2.10239
   Sun HB, 2013, CHIN J TRAUMATOL, V16, P158, DOI 10.3760/cma.j.issn.1008 1275.2013.03.006
   SWETT JE, 1991, EXP NEUROL, V114, P82, DOI 10.1016/0014 4886(91)90087 S
   Uusltalo H, 2005, BONE, V36, P142, DOI 10.1016/j.bone.2004.09.010
   WAKLEY GK, 1992, AM J PHYSIOL, V263, pE1029
   Wang LJ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00190 4
   Watanabe R, 2016, BIOCHEM BIOPH RES CO, V480, P662, DOI 10.1016/j.bbrc.2016.10.112
   WEINREB M, 1989, BONE, V10, P187, DOI 10.1016/8756 3282(89)90052 5
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zerwekh JE, 1998, J BONE MINER RES, V13, P1594, DOI 10.1359/jbmr.1998.13.10.1594
   Zhu G, 2021, MATER ADV, V2, P6901, DOI 10.1039/d1ma00675d
NR 52
TC 0
Z9 0
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD SEP
PY 2024
VL 42
IS 9
BP 1984
EP 1997
DI 10.1002/jor.25843
EA APR 2024
PG 14
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA A5Z2U
UT WOS:001205653500001
PM 38644051
OA hybrid
DA 2025 08 17
ER

PT J
AU Eddington, H
   Hudson, JE
   Oliver, RL
   Fraser, WD
   Hutchison, AJ
   Kalra, PA
AF Eddington, Helen
   Hudson, Julie E.
   Oliver, Robert L.
   Fraser, William D.
   Hutchison, Alastair J.
   Kalra, Philip A.
TI Variability in parathyroid hormone assays confounds clinical practice in
   chronic kidney disease patients
SO ANNALS OF CLINICAL BIOCHEMISTRY
LA English
DT Article
DE Renal disease; clinical studies; parathyroid hormone; chronic kidney
   disease; PTH assay; haemodialysis
ID HEMODIALYSIS PATIENTS; BONE TURNOVER; PREDICTIVE VALUE; PTH ASSAYS;
   SERUM; DIALYSIS; MANAGEMENT; CALCIUM; MARKERS; PLASMA
AB BackgroundIntact parathyroid hormone (iPTH) measurements are used to guide therapy in renal patients, but variability in results can occur depending on the assay used. This study has investigated iPTH assay variation in North West England and paired data with regional audit data to determine clinical relevance of assay variability.
   MethodsThirty seven haemodialysis patients had blood taken (EDTA plasma, and serum), and samples were processed at 17 laboratories that analyse iPTH for North West dialysis patients. Correction factors were calculated and applied to the iPTH assay results to enable direct comparisons. These correction factors were also applied to Regional Audit data to determine if iPTH assay variability explains the variation in unit performance in achieving PTH targets.
   ResultsThe iPTH results from the 37 patients were significantly different when either analysed by different assays and/or different laboratories (P<0.001). The Abbott Architect method consistently produced the highest iPTH results. Of the 37 patients, between 49% and 65% would achieve the Kidney Disease: Improving Global Outcomes (KDIGO) iPTH target depending on the assay used. When results were adjusted using correction factors, 21% of the patients would require a change of management according to guidelines. Data from all haemodialysis units submitted for the regional audit were adjusted to the Roche assay and this led to a small change in achievement of KDIGO iPTH targets in individual units when compared to each other.
   ConclusionsA combination of iPTH assay variability and diversity in clinical management leads to variation in achieving iPTH targets. Both need to be improved and/or standardized to improve patient care.
C1 [Eddington, Helen; Hudson, Julie E.; Oliver, Robert L.; Kalra, Philip A.] Univ Manchester, Salford Royal Hosp, Manchester Acad Hlth Sci Ctr, Renal Dept, Salford, Lancs, England.
   [Fraser, William D.] Univ E Anglia, Norwich Med Sch, Fac Med & Hlth Sci, Norwich NR4 7TJ, Norfolk, England.
   [Hutchison, Alastair J.] Cent Manchester & Manchester Childrens Hosp Trust, Renal Dept, Manchester, Lancs, England.
   [Hutchison, Alastair J.] Cent Manchester & Manchester Childrens Hosp Trust, Manchester Inst Nephrol & Transplantat, Manchester, Lancs, England.
C3 Salford Royal NHS Foundation Trust; Salford Royal Hospital; University
   of Manchester; University of East Anglia; Manchester University NHS
   Foundation Trust; Royal Manchester Children's Hospital; Manchester
   University NHS Foundation Trust; Royal Manchester Children's Hospital
RP Eddington, H (通讯作者)，Univ Manchester, Salford Royal Hosp, Manchester Acad Hlth Sci Ctr, Renal Dept, Salford, Lancs, England.
EM Helen.eddington@uhb.nhs.uk
RI ; Hutchison, Alastair/AAT 8922 2021
OI Hutchison, Alastair/0000 0003 3268 8324; 
FU Shire; Amgen; Sanofi (Genzyme); Siemens; Roche; Abbott
FX PAK does consultancy for Shire, Amgen and Sanofi (Genzyme) and has
   received research grants and honorariums from the same companies. WDF
   has been paid for developing and delivering educational presentations
   for Siemens and received honorariums from Roche, Siemens and Abbott. HE
   has received honorariums from Shire and Amgen. AJH none declared.
CR Almond A, 2012, ANN CLIN BIOCHEM, V49, P63, DOI 10.1258/acb.2011.011094
   [Anonymous], 2003, Am J Kidney Dis, V42, pS1
   Brossard JH, 2000, CLIN CHEM, V46, P697
   Cantor T, 2006, CLIN CHEM, V52, P1771, DOI 10.1373/clinchem.2006.071589
   Coen G, 2002, AM J KIDNEY DIS, V40, P348, DOI 10.1053/ajkd.2002.34519
   Dawnay A, 2010, NEPHRON CLIN PRACT, V115, pC187, DOI 10.1159/000301233
   Divieti P, 2002, ENDOCRINOLOGY, V143, P171, DOI 10.1210/en.143.1.171
   Floege J, 2011, NEPHROL DIAL TRANSPL, V26, P1948, DOI 10.1093/ndt/gfq219
   Gardham C, 2010, CLIN J AM SOC NEPHRO, V5, P1261, DOI 10.2215/CJN.09471209
   Herberth J, 2010, AM J KIDNEY DIS, V55, P897, DOI 10.1053/j.ajkd.2009.12.041
   Holmes DT, 2005, CLIN CHEM, V51, P915, DOI 10.1373/clinchem.2004.046821
   Joly D, 2008, AM J KIDNEY DIS, V51, P987, DOI 10.1053/j.ajkd.2008.01.017
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Monge M, 2009, CLIN CHEM LAB MED, V47, P362, DOI 10.1515/CCLM.2009.068
   Monier Faugere MC, 2001, KIDNEY INT, V60, P1460, DOI 10.1046/j.1523 1755.2001.00949.x
   Naves Díaz M, 2011, NEPHROL DIAL TRANSPL, V26, P1938, DOI 10.1093/ndt/gfq304
   Picton ML, 2000, KIDNEY INT, V58, P1440, DOI 10.1046/j.1523 1755.2000.00306.x
   QI QL, 1995, AM J KIDNEY DIS, V26, P622, DOI 10.1016/0272 6386(95)90599 5
   Salusky IB, 2003, KIDNEY INT, V63, P1801, DOI 10.1046/j.1523 1755.2003.00915.x
   Slatopolsky E, 2000, KIDNEY INT, V58, P753, DOI 10.1016/S0085 2538(15)47156 X
   Souberbielle JC, 2006, KIDNEY INT, V70, P345, DOI 10.1038/sj.ki.5001606
   Souberbielle JCP, 2010, KIDNEY INT, V77, P93, DOI 10.1038/ki.2009.374
   Stokes FJ, 2011, CLIN CHEM, V57, P138, DOI 10.1373/clinchem.2010.157289
   Sturgeon CM, 2011, NEPHROL DIAL TRANSPL, V26, P3440, DOI 10.1093/ndt/gfr614
   Tomaschitz A, 2012, BMC ENDOCR DISORD, V12, DOI 10.1186/1472 6823 12 19
   Toussaint ND, 2011, NEPHROL DIAL TRANSPL, V26, P1319, DOI 10.1093/ndt/gfq602
   UK Renal Association, 2007, CLIN PRACT GUID MOD
   Vieira JGH, 2012, J OSTEOPOROS, V2012, DOI 10.1155/2012/523246
NR 28
TC 11
Z9 11
U1 0
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0004 5632
EI 1758 1001
J9 ANN CLIN BIOCHEM
JI Ann. Clin. Biochem.
PD MAR
PY 2014
VL 51
IS 2
BP 228
EP 236
DI 10.1177/0004563213491236
PG 9
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Medical Laboratory Technology
GA AA8WH
UT WOS:000331375200009
PM 24000371
DA 2025 08 17
ER

PT J
AU Rawat, P
   Ahmad, I
   Thomas, SC
   Pandey, S
   Vohora, D
   Gupta, S
   Ahmad, FJ
   Talegaonkar, S
AF Rawat, Purnima
   Ahmad, Iqbal
   Thomas, Shindu C.
   Pandey, Shweta
   Vohora, Divya
   Gupta, Sarika
   Ahmad, Farhan Jalees
   Talegaonkar, Sushama
TI Revisiting bone targeting potential of novel hydroxyapatite based
   surface modified PLGA nanoparticles of risedronate: Pharmacokinetic and
   biochemical assessment
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Nanoparticles; Biochemical; Pharmacokinetics; Risedronate; Osteoporosis;
   Bioavailability
ID NITROGEN CONTAINING BISPHOSPHONATES; IN VITRO; OSTEOBLASTIC CELLS;
   MARROW CULTURES; HIGH AFFINITY; OSTEOPOROSIS; ALENDRONATE; DELIVERY;
   RESORPTION; RELEASE
AB Hydroxyapatite based biodegradable mPEG PLGA nanoparticles of risedronate (mPEG PLGA RIS HA) were prepared by water miscible dialysis method for synergistic treatment of osteoporosis. The bone targeting potential of prepared nanoparticles was evaluated by performing the cell viability study and protein estimation in pre osteoblast cell line (MC3T3E1). Biochemical and in vivo pharmacokinetic studies on osteoporotic rat model treated with different formulations were performed. Under the biochemical study ALP, TRAP, HxP and Calcium levels were determined. Osteoporotic model treated with prepared nanoparticles indicated significant effect on bone. Pharmacokinetic studies revealed 6 fold and 4 fold increase in the relative bioavailability after intravenous and oral administration of nanoparticles respectively as compared to marketed formulation confirming better effective drug transport. Biochemical investigations also showed a significant change in biomarker level which ultimately lead to bone formation/resorption. A stability analysis has also been carried out according to ICH guidelines (Q(1)AR(2)) and shelf life was found to be 1year and 4 months for the prepared formulation. Thus the results of present studies indicated that mPEG PLGA RIS HA NPs has a great potential for sustained delivery of RIS for the treatment and prevention of osteoporosis and to minimize the adverse effects of RIS typically induced by its oral administration. (c) 2016 Elsevier B.V. All rights reserved.
C1 [Rawat, Purnima; Ahmad, Iqbal; Thomas, Shindu C.; Pandey, Shweta; Ahmad, Farhan Jalees; Talegaonkar, Sushama] Jamia Hamdard, Fac Pharm, Dept Pharmaceut, Nanomed Res Lab, New Delhi 110062, India.
   [Vohora, Divya] Jamia Hamdard, Fac Pharm, Dept Pharmacol, New Delhi 110062, India.
   [Gupta, Sarika] Natl Inst Immunol, Mol Sci Lab, New Delhi 110067, New Delhi, India.
C3 Jamia Hamdard University; Jamia Hamdard University; Department of
   Biotechnology (DBT) India; National Institute of Immunology (NII)
RP Talegaonkar, S (通讯作者)，Jamia Hamdard, Fac Pharm, Dept Pharmaceut, Nanomed Res Lab, New Delhi 110062, India.
EM stalegaonkar@gmail.com
RI ; Vohora, Divya/H 4245 2019; Thomas, Shindu/AHC 3718 2022; Ahmad,
   Farhan/HMO 6565 2023; Pandey, Shweta/HNQ 9625 2023; Thomas, Shindu
   Chamakkalayil/AHC 3718 2022; Rawat, Purnima/ABC 6345 2020; Talegoankar,
   Sushama/AAW 8374 2020; Ahmad, Iqbal/AAS 3169 2021
OI Talegaonkar, sushama/0000 0003 2211 5119; Vohora,
   Divya/0000 0003 1852 9191; /0000 0003 3323 018X; Ahmad,
   Farhan/0000 0002 0740 8573; Thomas, Shindu
   Chamakkalayil/0000 0003 0371 620X; Ahmad, Iqbal/0000 0002 2425 6217; 
FU Indian Council of Medical Research (ICMR), New Delhi
   [45/10/2011/NAN BMS]
FX The authors are thankful to Indian Council of Medical Research (ICMR)
   (Ref. no. 45/10/2011/NAN BMS), New Delhi for the financial assistance.
   We also acknowledge Evonik Research (Bangalore, India) for providing the
   gift sample of PLGA (50: 50) polymer. The authors are also thankful to
   Mr. Jitender Singh and Mr. Abul Kalam, Faculty of Pharmacy, Jamia
   Hamdard, New Delhi for their help in performing animal studies.
CR Balani K, 2007, BIOMATERIALS, V28, P618, DOI 10.1016/j.biomaterials.2006.09.013
   Banji D, 2014, INDIAN J EXP BIOL, V52, P153
   Bell KJL, 2012, J BONE MINER RES, V27, P195, DOI 10.1002/jbmr.525
   Blanco Prieto MJ, 2004, J CONTROL RELEASE, V96, P437, DOI 10.1016/j.jconrel.2004.02.015
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Cenni E, 2008, BIOMATERIALS, V29, P1400, DOI 10.1016/j.biomaterials.2007.12.022
   Christenson RH, 1997, CLIN BIOCHEM, V30, P573, DOI 10.1016/S0009 9120(97)00113 6
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Ezra A, 2000, ADV DRUG DELIVER REV, V42, P175, DOI 10.1016/S0169 409X(00)00061 2
   Ezra A, 2000, J MED CHEM, V43, P3641, DOI 10.1021/jm980645y
   FLEISCH H, 1987, CLIN ORTHOP RELAT R, P72
   GIULIANI N, 1995, J BONE MINER RES, V10, pS171
   Hirabayashi H, 2001, J CONTROL RELEASE, V70, P183, DOI 10.1016/S0168 3659(00)00355 2
   Hirsjärvi S, 2013, INT J PHARMACEUT, V453, P594, DOI 10.1016/j.ijpharm.2013.05.057
   Hlaing TT, 2014, ANN CLIN BIOCHEM, V51, P189, DOI 10.1177/0004563213515190
   Jia HJ, 2006, ANAL CHIM ACTA, V562, P171, DOI 10.1016/j.aca.2006.01.077
   Khajuria DK, 2011, REV BRAS REUMATOL, V51, P365
   Khanna S, 2011, BONE, V48, P597, DOI 10.1016/j.bone.2010.10.172
   Khosla S, 2012, J CLIN ENDOCR METAB, V97, P2272, DOI 10.1210/jc.2012 1027
   Kitamura N, 2016, INT J RHEUM DIS
   Lambrinoudaki I, 2006, ANN NY ACAD SCI, V1092, P397, DOI 10.1196/annals.1365.036
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Mauck KF, 2006, MAYO CLIN PROC, V81, P662, DOI 10.4065/81.5.662
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Niemi R, 1999, J MED CHEM, V42, P5053, DOI 10.1021/jm991109o
   Nishikawa M, 1996, BONE, V18, P9, DOI 10.1016/8756 3282(95)00426 2
   Ogawa K, 2006, J NUCL MED, V47, P2042
   Ong HT, 2008, J NANOPART RES, V10, P141, DOI 10.1007/s11051 007 9239 1
   Ossipov D.A., 2015, EXP OPIN DRUG DELIV, V12
   Palazzo B, 2007, ADV FUNCT MATER, V17, P2180, DOI 10.1002/adfm.200600361
   Park JB, 2012, EXP THER MED, V4, P303, DOI 10.3892/etm.2012.590
   Planell JA, 2009, WOODHEAD PUBL MATER, P3, DOI 10.1533/9781845696610.1.3
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Rawat P, 2015, PHARM RES DORDR, V32, P3149, DOI 10.1007/s11095 015 1692 4
   Rawat P, 2015, J PHARM INNOV, V10, P130, DOI 10.1007/s12247 015 9213 x
   Sahana H, 2013, J BIOMED NANOTECHNOL, V9, P193, DOI 10.1166/jbn.2013.1482
   Sakai S, 2015, BONE, V81, P449, DOI 10.1016/j.bone.2015.08.004
   SCHENK R, 1986, CALCIFIED TISSUE INT, V38, P342, DOI 10.1007/BF02555748
   Schneider J.P., 2006, SHOULD BISPHOSPHONAT
   Shi XT, 2008, J MATER SCI MATER M, V19, P2933, DOI 10.1007/s10856 008 3424 3
   Shi XT, 2009, PHARM RES DORDR, V26, P422, DOI 10.1007/s11095 008 9759 0
   STEGEMAN.H, 1967, CLIN CHIM ACTA, V18, P267, DOI 10.1016/0009 8981(67)90167 2
   van Beek ER, 2003, BONE, V33, P805, DOI 10.1016/j.bone.2003.07.007
   Viguet Carrin S, 2006, OSTEOPOROSIS INT, V17, P319, DOI 10.1007/s00198 005 2035 9
   Wright JEI, 2006, BIOMATERIALS, V27, P769, DOI 10.1016/j.biomaterials.2005.06.012
NR 46
TC 21
Z9 23
U1 1
U2 43
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378 5173
EI 1873 3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD JUN 15
PY 2016
VL 506
IS 1 2
BP 253
EP 261
DI 10.1016/j.ijpharm.2016.04.049
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA DN4JH
UT WOS:000377031200027
PM 27113864
DA 2025 08 17
ER

PT J
AU Kavanagh, N
   O'Brien, FJ
   Kerrigan, SW
AF Kavanagh, Nicola
   O'Brien, Fergal J.
   Kerrigan, Steve W.
TI Staphylococcus aureus protein A causes osteoblasts to
   hyper mineralise in a 3D extra cellular matrix environment
SO PLOS ONE
LA English
DT Article
ID MODELS; BINDING; OSTEOCLASTOGENESIS; FIBRONECTIN; MANAGEMENT; SCAFFOLDS;
   MIGRATION; BEHAVIOR; TISSUES
AB Osteomyelitis is an inflammatory bone infection that is caused most commonly by the opportunistic pathogen Staphylococcus aureus. Research into staphylococcal induced bone infection is typically conducted using traditional 2D in vitro culture settings, which is not fully representative of the dynamic in vivo environment. In this study we utilised a collagen glycosaminoglycan scaffold, previously developed for bone tissue engineering, as a representative 3D model of infection. The scaffold resisted degradation and retained its pore structure, which is important for cellular function and survival, when seeded with both cells and bacteria. Using this model, we showed that in the presence of S. aureus, osteoblast proliferation was reduced over 21 days. Interestingly however these cells were more metabolically active compared to the uninfected cells and demonstrated increased mineralisation. Protein A (SpA) is a virulence factor found on the surface of S. aureus and has been shown to interact with osteoblasts. When SpA was removed from the surface of S. aureus, the osteoblasts show comparable activity with the uninfected cells demonstrating the importance of SpA in the interaction between bone cells and S. aureus. Our results suggest that infected osteoblasts are capable of over compensating for bone loss and bone destruction by increasing mineralisation in a 3D environment, key elements required for ensuring bone strength. It also reinforces our previously established result that S. aureus SpA is a critical mediator in osteomyelitis and might be a potential novel drug target to treat osteomyelitis by preventing the interaction between S. aureus and osteoblasts.
C1 [Kavanagh, Nicola; Kerrigan, Steve W.] Royal Coll Surgeons Ireland, Irish Ctr Vasc Biol, Cardiovasc Infect Res Grp, Dublin, Ireland.
   [Kavanagh, Nicola; O'Brien, Fergal J.; Kerrigan, Steve W.] Royal Coll Surgeons Ireland, Dept Anat, Tissue Engn Res Grp, Dublin, Ireland.
   [O'Brien, Fergal J.] Trinity Coll Dublin, Trinity Ctr Bioengn, Trinity Biomed Sci Inst, Dublin, Ireland.
   [O'Brien, Fergal J.] Royal Coll Surgeons Ireland, Adv Mat & Bioengn Res AMBER Ctr, Dublin, Ireland.
   [O'Brien, Fergal J.] Trinity Coll Dublin, Dublin, Ireland.
   [Kerrigan, Steve W.] Royal Coll Surgeons Ireland, Sch Pharm & Mol & Cellular Therapeut, Dublin, Ireland.
C3 Royal College of Surgeons   Ireland; Royal College of Surgeons  
   Ireland; Trinity College Dublin; Royal College of Surgeons   Ireland;
   Trinity College Dublin; Royal College of Surgeons   Ireland
RP Kerrigan, SW (通讯作者)，Royal Coll Surgeons Ireland, Irish Ctr Vasc Biol, Cardiovasc Infect Res Grp, Dublin, Ireland.; Kerrigan, SW (通讯作者)，Royal Coll Surgeons Ireland, Dept Anat, Tissue Engn Res Grp, Dublin, Ireland.; Kerrigan, SW (通讯作者)，Royal Coll Surgeons Ireland, Sch Pharm & Mol & Cellular Therapeut, Dublin, Ireland.
EM skerrigan@rcsi.ie
RI Kerrigan, Steven/C 3922 2012; O'Brien, Fergal/F 9485 2011
OI O'Brien, Fergal/0000 0003 2030 8005
FU Science Foundation Ireland Research Frontiers Programme [BMT/2008/1709];
   Irish Research Council [GOIP/2013/1171]
FX This work was supported by a grant from the Science Foundation Ireland
   Research Frontiers Programme awarded to SWK. (no.BMT/2008/1709) and
   Irish Research Council awarded to NK, SWK (GOIP/2013/1171). This work
   was supported by a grant from the Science Foundation Ireland Research
   Frontiers Programme awarded to SWK. (no.BMT/2008/1709) and Irish
   Research Council awarded to NK, SWK (GOIP/2013/1171).
CR Baker BM, 2012, J CELL SCI, V125, P3015, DOI 10.1242/jcs.079509
   Balcerzak M, 2003, ACTA BIOCHIM POL, V50, P1019
   Birt MC, 2017, J ORTHOP, V14, P45, DOI 10.1016/j.jor.2016.10.004
   Bouchoucha Sami, 2012, Tunis Med, V90, P473
   Brown AE, 2014, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00507
   Cassat JE, 2013, CELL HOST MICROBE, V13, P759, DOI 10.1016/j.chom.2013.05.003
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Claro T, 2013, MICROBIOL SGM, V159, P147, DOI 10.1099/mic.0.063016 0
   Claro T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018748
   Fitzgerald KA, 2016, INT J PHARMACEUT, V511, P1058, DOI 10.1016/j.ijpharm.2016.07.079
   Fitzgerald KA, 2015, J CONTROL RELEASE, V215, P39, DOI 10.1016/j.jconrel.2015.07.020
   Foster TJ, 2014, NAT REV MICROBIOL, V12, P49, DOI 10.1038/nrmicro3161
   Gu L, 2016, NAT REV CANCER, V16, P56, DOI 10.1038/nrc.2015.3
   Hardcastle SA, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2014.119
   Harley BAC, 2008, BIOPHYS J, V95, P4013, DOI 10.1529/biophysj.107.122598
   Haugh MG, 2011, TISSUE ENG PT A, V17, P1201, DOI [10.1089/ten.tea.2010.0590, 10.1089/ten.TEA.2010.0590]
   Haugh MG, 2010, TISSUE ENG PART C ME, V16, P887, DOI 10.1089/ten.TEC.2009.0422
   Ignat'eva NY, 2007, J ANAL CHEM+, V62, P51, DOI 10.1134/S106193480701011X
   Imamura Y, 2015, ONCOL REP, V33, P1837, DOI 10.3892/or.2015.3767
   Kafienah W, 2003, METH MOL B, V238, P217
   Keogh MB, 2010, ACTA BIOMATER, V6, P4305, DOI 10.1016/j.actbio.2010.06.001
   Keogh MB, 2010, CELL TISSUE RES, V340, P169, DOI 10.1007/s00441 010 0939 y
   Koh W, 2008, METHOD ENZYMOL, V443, P83, DOI 10.1016/S0076 6879(08)02005 3
   Lavery L A, 1995, J Foot Ankle Surg, V34, P61
   Levine SM, 2003, RADIOGRAPHICS, V23, P157, DOI 10.1148/rg.231015088
   Massey RC, 2001, CELL MICROBIOL, V3, P839, DOI 10.1046/j.1462 5822.2001.00157.x
   Bertelli AM, 2016, BBA MOL BASIS DIS, V1862, P1975, DOI 10.1016/j.bbadis.2016.07.016
   Metallo CM, 2013, MOL CELL, V49, P388, DOI 10.1016/j.molcel.2013.01.018
   Mouzopoulos G, 2011, INJURY, V42, pS18, DOI 10.1016/S0020 1383(11)70128 0
   O'Leary C, 2016, BIOMATERIALS, V85, P111, DOI 10.1016/j.biomaterials.2016.01.065
   Ohbayashi T, 2011, MICROBIOL SGM, V157, P786, DOI 10.1099/mic.0.044503 0
   Otto Michael, 2010, Expert Rev Dermatol, V5, P183, DOI 10.1586/edm.10.6
   Patel Mitul, 2009, Semin Plast Surg, V23, P148, DOI 10.1055/s 0029 1214167
   Penn Barwell JG, 2013, BONE JOINT J, V95B, P101, DOI 10.1302/0301 620X.95B1.30580
   Popov L, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00041
   Reizner W, 2014, EUR CELLS MATER, V27, P196, DOI 10.22203/eCM.v027a15
   Ryan AJ, 2016, DRUG DISCOV TODAY, V21, P1437, DOI 10.1016/j.drudis.2016.04.014
   Waarsing JH, 2006, J ORTHOP RES, V24, P926, DOI 10.1002/jor.20063
   Walter G, 2012, DTSCH ARZTEBL INT, V109, P257, DOI [10.3238/arztebl.012.0257, 10.3238/arztebl.2012.0257]
   Wang Y, 2017, J CELL PHYSIOL, V232, P2396, DOI 10.1002/jcp.25774
   Wann ER, 2000, J BIOL CHEM, V275, P13863, DOI 10.1074/jbc.275.18.13863
   Widaa A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040586
NR 43
TC 11
Z9 13
U1 2
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUN 21
PY 2018
VL 13
IS 6
AR e0198837
DI 10.1371/journal.pone.0198837
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA GK0LV
UT WOS:000435802500031
PM 29927956
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Kanaya, S
   Nemoto, E
   Ebe, Y
   Somerman, MJ
   Shimauchi, H
AF Kanaya, Sousuke
   Nemoto, Eiji
   Ebe, Yukari
   Somerman, Martha J.
   Shimauchi, Hidetoshi
TI Elevated extracellular calcium increases fibroblast growth factor 2 gene
   and protein expression levels via a cAMP/PKA dependent pathway in
   cementoblasts
SO BONE
LA English
DT Article
DE Extracellular calcium; Cementoblast; FGF 2; PKA; cAMP
ID CATION SENSING MECHANISM; IN VITRO; FACTOR BETA; MC3T3 E1 OSTEOBLASTS;
   BONE FORMATION; MESSENGER RNA; LINING CELLS; KINASE C; RECEPTOR;
   CEMENTUM
AB Cementoblasts, tooth root lining cells, are responsible for laying down cementum on the root surface, a process that is indispensable for establishing a functional periodontal ligament. Cementoblasts share phenotypical features with osteoblasts. Elevated levels of extracellular Ca2+ have been implicated in osteogenesis by stimulating the proliferation and differentiation of osteoblasts; however, the role of extracellular Ca2+ signaling in cementogenesis has not been examined. Using RT PCR, we found that elevated levels of extracellular Ca2+ increase fibroblast growth factor (FGF) 2 gene expression with a peak at 6 h. Pretreatment with a protein kinase A (PKA) inhibitor, H89, or an adenylate cyclase inhibitor, MDL 12,330A, inhibited Ca2+ stimulated Fgf 2 expression. In contrast, pretreatment with the protein kinase C (PKC) inhibitor GF 109203X or the phospholipase C (PLC) inhibitor U73122 did not affect the expression of Fgf 2 transcripts, suggesting that the increase in Fgf 2 expression was dependent on the PKA but not the PLC/PKC signaling pathway. Treatment with an activator of adenylate cyclase, forskolin, or a cell permeable analog of cAMP, 8 Br cAMP, enhanced Ca2+ stimulated Fgf 2 expression, but a single treatment with forskolin or 8 Br cAMP did not, suggesting that cAMP generation is indispensable but not sufficient for Ca2+ stimulated FGF2 expression. Next, we examined the cation specificity of the putative receptor and showed that treatment with trivalent/divalent inorganic ions, Ca2+, Gd3+, Sr2+, or Al3+, caused a dose dependent increase in Fgf 2 mRNA levels in a cAMP dependent fashion, whereas Mg2+ and the organic ions neomycin and spermine had no effect on Fgf 2 gene expression levels. These findings suggest that an extracellular Ca2+ sensing mechanism is present in cementoblasts and its activation leads to FGF 2 stimulation in a cAMP/PKA dependent fashion. Understanding the pathway regulating key genes involved in modulating the regeneration of oral tissues will assist in designing regenerative therapies based on reliable biological principles. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Kanaya, Sousuke; Nemoto, Eiji; Ebe, Yukari; Shimauchi, Hidetoshi] Tohoku Univ, Grad Sch Dent, Dept Periodontol & Endodontol, Sendai, Miyagi 9808575, Japan.
   [Somerman, Martha J.] Univ Washington, Sch Dent, Dept Periodont, Seattle, WA 98195 USA.
   [Somerman, Martha J.] Univ Washington, Sch Dent, Dept Oral Biol, Seattle, WA 98195 USA.
C3 Tohoku University; University of Washington; University of Washington
   Seattle; University of Washington; University of Washington Seattle
RP Nemoto, E (通讯作者)，Tohoku Univ, Grad Sch Dent, Dept Periodontol & Endodontol, 4 1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.
EM e nemoto@umin.ac.jp
FU Japan Society for the Promotion of Science [20791605, 20390527,
   21390552]; Tohoku University; Grants in Aid for Scientific Research
   [20791605, 20390527, 21390552] Funding Source: KAKEN
FX We thank Dr. S. Tamura (Tohoku University, Institute of Development,
   Aging and Cancer) for the helpful discussions and comments. This work
   was supported by a Grant in Aid for Scientific Research (20791605 and
   20390527, 21390552) from the Japan Society for the Promotion of Science
   and by the Tohoku University Biomaterial Interface Research Program.
CR Ahlstrom M, 2008, BONE, V42, P483, DOI 10.1016/j.bone.2007.10.025
   Bosshardt DD, 2005, J DENT RES, V84, P390, DOI 10.1177/154405910508400501
   BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0
   CANALIS E, 1988, J CLIN INVEST, V81, P1572, DOI 10.1172/JCI113490
   Chang YH, 1999, ENDOCRINOLOGY, V140, P5883, DOI 10.1210/en.140.12.5883
   Choudhary S, 2004, BIOCHEM BIOPH RES CO, V322, P395, DOI 10.1016/j.bbrc.2004.07.129
   D'Errico JA, 2000, J PERIODONTOL, V71, P63, DOI 10.1902/jop.2000.71.1.63
   de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884
   DErrico JA, 1997, BONE, V20, P117, DOI 10.1016/S8756 3282(96)00348 1
   Dvorak MM, 2004, P NATL ACAD SCI USA, V101, P5140, DOI 10.1073/pnas.0306141101
   Gao J, 1996, J PERIODONTAL RES, V31, P260, DOI 10.1111/j.1600 0765.1996.tb00491.x
   GLOBUS RK, 1988, ENDOCRINOLOGY, V123, P98, DOI 10.1210/endo 123 1 98
   Godwin SL, 2002, BONE, V30, P559, DOI 10.1016/S8756 3282(01)00700 1
   Godwin SL, 1997, J BIOL CHEM, V272, P11307
   GOSPODAROWICZ D, 1986, CELL DIFFER DEV, V19, P1, DOI 10.1016/0045 6039(86)90021 7
   Hakki SS, 2005, J PERIODONTOL, V76, P1550, DOI 10.1902/jop.2005.76.9.1550
   Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154
   Hurley MM, 1999, J BONE MINER RES, V14, P776, DOI 10.1359/jbmr.1999.14.5.776
   Kamp TJ, 2000, CIRC RES, V87, P1095, DOI 10.1161/01.RES.87.12.1095
   Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275
   Kitagawa M, 2006, BONE, V39, P1035, DOI 10.1016/j.bone.2006.05.022
   Kubo Y, 1998, SCIENCE, V279, P1722, DOI 10.1126/science.279.5357.1722
   Li AQ, 2006, FASEB J, V20, DOI 10.1096/fj.05 5510fje
   Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898 6568(98)00012 6
   Marie PJ, 2003, GENE, V316, P23, DOI 10.1016/S0378 1119(03)00748 0
   MAYAHARA H, 1993, GROWTH FACTORS, V9, P73, DOI 10.3109/08977199308991583
   Murakami S, 1999, J PERIODONTAL RES, V34, P425, DOI 10.1111/j.1600 0765.1999.tb02277.x
   Nagano N, 2006, PHARMACOL THERAPEUT, V109, P339, DOI 10.1016/j.pharmthera.2005.06.019
   NAKAE H, 1991, BIOCHEMISTRY US, V30, P7047, DOI 10.1021/bi00243a002
   Pi M, 2005, J BIOL CHEM, V280, P40201, DOI 10.1074/jbc.M505186200
   Pi M, 2005, J CELL BIOCHEM, V95, P1081, DOI 10.1002/jcb.20500
   Pi M, 2000, J BIOL CHEM, V275, P3256, DOI 10.1074/jbc.275.5.3256
   Quarles LD, 1997, J BONE MINER RES, V12, P393, DOI 10.1359/jbmr.1997.12.3.393
   RODAN SB, 1989, J BIOL CHEM, V264, P19934
   Sabbieti MG, 1999, ENDOCRINOLOGY, V140, P434, DOI 10.1210/en.140.1.434
   Sato Y, 2004, J PERIODONTOL, V75, P243, DOI 10.1902/jop.2004.75.2.243
   Saygin NE, 2000, PERIODONTOL 2000, V24, P73, DOI 10.1034/j.1600 0757.2000.2240105.x
   Sobue T, 2002, J BONE MINER RES, V17, P502, DOI 10.1359/jbmr.2002.17.3.502
   STACHOWIAK MK, 1994, J CELL BIOL, V127, P203, DOI 10.1083/jcb.127.1.203
   Story MT, 1996, PROSTATE, V28, P219
   Tada H, 2010, BIOCHEM BIOPH RES CO, V394, P1093, DOI 10.1016/j.bbrc.2010.03.135
   Takayama S, 2001, J DENT RES, V80, P2075, DOI 10.1177/00220345010800121001
   Takayama S, 1997, J PERIODONTAL RES, V32, P667, DOI 10.1111/j.1600 0765.1997.tb00577.x
   Yamaguchi T, 1998, J BONE MINER RES, V13, P1530, DOI 10.1359/jbmr.1998.13.10.1530
   Yamaguchi T, 1998, J BONE MINER RES, V13, P1390, DOI 10.1359/jbmr.1998.13.9.1390
   Yamauchi M, 2005, AM J PHYSIOL ENDOC M, V288, pE608, DOI 10.1152/ajpendo.00229.2004
NR 46
TC 27
Z9 32
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD SEP
PY 2010
VL 47
IS 3
BP 564
EP 572
DI 10.1016/j.bone.2010.05.042
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 645MO
UT WOS:000281464200013
PM 20542497
DA 2025 08 17
ER

PT J
AU Lillis, T
   Dabarakis, N
   Sakellaridis, N
   Fotopoulos, I
   Tsolakis, I
   Dailiana, Z
AF Lillis, Theodoros
   Dabarakis, Nikolaos
   Sakellaridis, Nikolaos
   Fotopoulos, Ioannis
   Tsolakis, Ioannis
   Dailiana, Zoe
TI The Effect of Clopidogrel Treatment on Osseointegration of Titanium
   Implants: A Histomorphometric Study in Rabbits
SO INTERNATIONAL JOURNAL OF ORAL & MAXILLOFACIAL IMPLANTS
LA English
DT Article
DE clopidogrel; titanium implant; purinergic signaling; bone
ID ANTIPLATELET THERAPY; OSTEOCLAST FUNCTION; TRABECULAR BONE;
   INFLAMMATION; ANTAGONIST; OSTEOBLAST; MANAGEMENT; RELEASE; SURFACE;
   DRUGS
AB Purpose: To evaluate the effect of continuous perioperative clopidogrel treatment on the osseointegration of titanium implants. Materials and Methods: A total of 32 New Zealand rabbits were randomly divided between two groups: a clopidogrel group (n = 16) and a control group (n = 16). For 1 week prior to the surgical placement of a titanium implant in their medial femoral condyle, rabbits in the clopidogrel group received 3 mg/kg of clopidogrel daily, and the control group received only the vehicle. This treatment was continued for another 6 weeks postoperatively. At 6 weeks, the rabbits were euthanized and postmortem histologic and histomorphometric evaluation of the implants was performed. Results: The surgical procedures and postoperative period were uneventful and well tolerated by all animals without any surgical wound dehiscence, signs of infection, or other complication. No implant failure was observed in any of the groups. Histomorphometric analysis showed that bone to implant contact (BIC) was 48.77% for the clopidogrel group and 34.65% for the control group, with statistically significant difference between them (P < .001). Moreover, clopidogrel group had significantly greater bone tissue density (40.52% vs 28.74%, respectively; P <.001) and mean trabecular thickness (284.7 mu m vs 180.7 mu m, respectively; P < .001) in proximity to the implant surface than the control group, while the mean trabecular number had no difference between groups (1.56 vs 1.60, respectively; P = .961). Conclusions: The present study showed that continuous clopidogrel treatment does not negatively affect osseointegration, but rather promotes it in terms of BIC and bone density around the titanium implants. Further studies on the effect of the P2Y12 receptor and its antagonists on peri implant bone homeostasis may provide useful information or applications for long term success of dental implant therapy.
C1 [Lillis, Theodoros; Dabarakis, Nikolaos; Fotopoulos, Ioannis] Aristotle Univ Thessaloniki, Fac Dent, Dept Dentoalveolar Surg Implantol & Oral Radiol, Thessaloniki, Greece.
   [Sakellaridis, Nikolaos] Univ Thessaly, Fac Med, Dept Pharmacol, Biopolis, Greece.
   [Tsolakis, Ioannis] Aristotle Univ Thessaloniki, Fac Dent, Dept Orthodont, Thessaloniki, Greece.
   [Dailiana, Zoe] Univ Thessaly, Fac Med, Dept Orthopaed Surg, Biopolis, Larisa, Greece.
C3 Aristotle University of Thessaloniki; University of Thessaly; Aristotle
   University of Thessaloniki; University of Thessaly
RP Lillis, T (通讯作者)，Aristotle Univ Thessaloniki, Fac Dent, Dept Dentoalveolar Surg Implantol & Oral Radiol, Thessaloniki, Greece.
EM theolillisdent@hotmail.com
OI TSOLAKIS, IOANNIS/0000 0002 5435 4889
FX We would like to thank Professor Ioannis Taitzoglou, DVM, PhD and Dr
   Ioannis Margaritis DVM, PhD, MSc for their assistance in animal welfare.
CR Aghaloo T, 2019, INT J ORAL MAX IMPL, V34, pS35, DOI 10.11607/jomi.19suppl.g3
   Albrektsson T., 2017, Journal of Science Medical, V2, P1022, DOI DOI 10.1016/B978 0 12 813384 2.00002 3
   Albrektsson T, 2019, CLIN IMPLANT DENT R, V21, P183, DOI 10.1111/cid.12711
   Apostu D, 2017, DRUG METAB REV, V49, P92, DOI 10.1080/03602532.2016.1277737
   Blanco J, 2011, CLIN ORAL IMPLAN RES, V22, P92, DOI 10.1111/j.1600 0501.2010.02009.x
   Buckley KA, 2003, FASEB J, V17, P1401, DOI 10.1096/fj.02 0940com
   Burnstock G, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.11
   Burnstock G, 2014, EXP PHYSIOL, V99, P16, DOI 10.1113/expphysiol.2013.071951
   Burnstock G, 2013, PURINERG SIGNAL, V9, P541, DOI 10.1007/s11302 013 9381 4
   Chen JZ, 2022, MOL THER, V30, P3017, DOI 10.1016/j.ymthe.2022.06.019
   Coimbra LS, 2015, J DENT RES, V94, P1691, DOI 10.1177/0022034515598273
   Coimbra LS, 2014, J PERIODONTAL RES, V49, P729, DOI 10.1111/jre.12155
   Coimbra LS, 2014, J CLIN PERIODONTOL, V41, P295, DOI 10.1111/jcpe.12203
   Coimbra LS, 2011, J PERIODONTOL, V82, P767, DOI 10.1902/jop.2010.100555
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Fontana F, 2011, CLIN ORAL IMPLAN RES, V22, P760, DOI 10.1111/j.1600 0501.2010.02056.x
   Johansson CB, 1991, CLIN ORAL IMPLAN RES, V2, P24, DOI 10.1034/j.1600 0501.1991.020103.x
   Johansson CB, 2012, CLIN ORAL IMPLAN RES, V23, P943, DOI 10.1111/j.1600 0501.2011.02233.x
   Jorgensen NR, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00821
   Kämmerer PW, 2012, CLIN ORAL IMPLAN RES, V23, P504, DOI 10.1111/j.1600 0501.2011.02153.x
   Kang JH, 2018, MOL MED REP, V18, P2387, DOI 10.3892/mmr.2018.9179
   Kloss L, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2010 6
   Kobat MA, 2022, J Health Sci Med, V5, P144
   Kobat MA, 2023, J CRANIOFAC SURG, V34, P1590, DOI 10.1097/SCS.0000000000009137
   Koskinas KC, 2012, ANGIOLOGY, V63, P245, DOI 10.1177/0003319711425921
   Li L, 2019, CLIN ORAL INVEST, V23, P1615, DOI 10.1007/s00784 018 2591 y
   Lillis T, 2019, WORLD J ORTHOP, V10, P434, DOI 10.5312/wjo.v10.i12.434
   Lillis T, 2011, AM J CARDIOL, V108, P964, DOI 10.1016/j.amjcard.2011.05.029
   Mediero A, 2016, FASEB J, V30, P3887, DOI 10.1096/fj.201600616R
   Muhlestein JB, 2010, THROMB HAEMOSTASIS, V103, P71, DOI 10.1160/TH09 03 0177
   Nurden AT, 2011, THROMB HAEMOSTASIS, V105, pS13, DOI 10.1160/THS10 11 0720
   Orriss IR, 2010, CURR OPIN PHARMACOL, V10, P322, DOI 10.1016/j.coph.2010.01.003
   PARFITT AM, 1983, J CLIN INVEST, V72, P1396, DOI 10.1172/JCI111096
   Plosker GL, 2007, DRUGS, V67, P613, DOI 10.2165/00003495 200767040 00013
   Rossini R, 2018, JACC CARDIOVASC INTE, V11, P417, DOI 10.1016/j.jcin.2017.10.051
   Rumney Robin M H, 2012, Front Endocrinol (Lausanne), V3, P116, DOI 10.3389/fendo.2012.00116
   Schrottmaier WC, 2015, THROMB HAEMOSTASIS, V114, P478, DOI 10.1160/TH14 11 0943
   Siegel PM, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 95710 3
   Steinhubl SR, 2007, VASC MED, V12, P113, DOI 10.1177/1358863X07077462
   Su XM, 2012, J CLIN INVEST, V122, P3579, DOI 10.1172/JCI38576
   Suh DH, 2016, J CELL MOL MED, V20, P333, DOI 10.1111/jcmm.12727
   Syberg S, 2012, J BONE MINER RES, V27, P2373, DOI 10.1002/jbmr.1690
   Tabrizi R, 2018, J ORAL MAXIL SURG, V76, P2092, DOI 10.1016/j.joms.2018.04.036
   Trindade R, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060814
   Trindade R, 2018, J CLIN MED, V7, DOI 10.3390/jcm7120526
   Wang X, 2020, J BIOMED MATER RES A, V108, P2206, DOI 10.1002/jbm.a.36978
   Wong PC, 2007, J CARDIOVASC PHARM, V49, P316, DOI 10.1097/FJC.0b013e31803e8772
   World Health Organization, 20th WHO Model List of Essential Medicines
NR 48
TC 1
Z9 1
U1 0
U2 0
PU QUINTESSENCE PUBLISHING CO INC
PI HANOVER PARK
PA 4350 CHANDLER DRIVE, HANOVER PARK, IL 60133 USA
SN 0882 2786
EI 1942 4434
J9 INT J ORAL MAX IMPL
JI Int. J. Oral Maxillofac. Implants
PD MAR APR
PY 2024
VL 39
IS 2
BP e1
EP e7
DI 10.11607/jomi.10449
PG 7
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA A0K9O
UT WOS:001279526600001
PM 37939235
DA 2025 08 17
ER

PT J
AU Lambrinoudaki, I
   Kaparos, G
   Armeni, E
   Alexandrou, A
   Damaskos, C
   Logothetis, E
   Creatsa, M
   Antoniou, A
   Kouskouni, E
   Triantafyllou, N
AF Lambrinoudaki, I.
   Kaparos, G.
   Armeni, E.
   Alexandrou, A.
   Damaskos, C.
   Logothetis, E.
   Creatsa, M.
   Antoniou, A.
   Kouskouni, E.
   Triantafyllou, N.
TI BsmI vitamin D receptor's polymorphism and bone mineral density in men
   and premenopausal women on long term antiepileptic therapy
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Article
DE bone mineral density; BsmI; epilepsy; VDR
ID GENE POLYMORPHISMS; EPILEPSY; ASSOCIATION; DRUGS; RISK;
   PHARMACOGENETICS; FRACTURES; GENOTYPE; HEALTH; HORMONE
AB Background:
   Utilization of antiepileptic drugs (AEDs) has long been associated with bone deleterious effects. Furthermore, the BsmI restriction fragment polymorphism of the vitamin D receptor (VDR) has been associated with reduced bone mineral density (BMD), mostly in postmenopausal women. This study evaluates the association between bone metabolism of patients with epilepsy and the BsmI VDR's polymorphism in chronic users of AEDs.
   Methods:
   This study evaluated 73 long term users of antiepileptic drug monotherapy, in a cross sectional design. Fasting blood samples were obtained to estimate the circulating serum levels of calcium, magnesium, phosphorus, parathormone, 25hydroxyvitamin D as well as the VDR's genotype. Bone mineral density at the lumbar spine was measured with Dual Energy X Ray Absorptiometry.
   Results:
   Bone mineral density was significantly associated with the genotype of VDR (mean BMD: Bb genotype 1.056 +/  0.126 g/cm2; BB genotype 1.059 +/  0.113 g/cm2; bb genotype 1.179 +/  0.120 g/cm2; P < 0.05). Additionally, the presence of at least one B allele was significantly associated with lower bone mineral density (B allele present: BMD = 1.057 +/  0.12 g/cm2, B allele absent: BMD = 1.179 +/  0.119 g/cm2; P < 0.01). Patients with at least one B allele had lower serum levels of 25hydroxyvitamin D when compared with bb patients (22.61 ng/ml vs. 33.27 ng/ml, P < 0.05), whilst they tended to have higher levels of parathyroid hormone.
   Discussion:
   Vitamin D receptor polymorphism is associated with lower bone mass in patients with epilepsy. This effect might be mediated through the vitamin D parathormone pathway.
C1 [Lambrinoudaki, I.; Armeni, E.; Creatsa, M.] Univ Athens, Areta Hosp, Dept Obstet & Gynecol 2, Athens, Greece.
   [Kaparos, G.; Logothetis, E.; Kouskouni, E.] Univ Athens, Aretaie Hosp, Hormonal Lab, Athens, Greece.
   [Alexandrou, A.; Damaskos, C.] Univ Athens, Laiko Hosp, Dept Surg 1, Athens, Greece.
   [Antoniou, A.] Univ Athens, Aretaie Hosp, Dept Radiol, Athens, Greece.
   [Triantafyllou, N.] Univ Athens, Aiginite Hosp, Dept Neurol, Athens, Greece.
C3 National & Kapodistrian University of Athens; National & Kapodistrian
   University of Athens; National & Kapodistrian University of Athens;
   Laiko General Hospital; National & Kapodistrian University of Athens;
   National & Kapodistrian University of Athens
RP Armeni, E (通讯作者)，8B Nestou St, GR 15235 Athens, Greece.
EM elenaarmeni@hotmail.com
RI Armeni, Eleni/ABW 4946 2022; Triantafyllou, Nikolaos/AAA 1215 2019
OI Armeni, Eleni/0000 0003 3310 1521; Damaskos,
   Christos/0000 0002 5454 2564; 
FU National and Kapodistrian University of Athens [SARG 70/3/8259]
FX Funding for this study was provided by the Special Account for Research
   Grants by the National and Kapodistrian University of Athens, SARG
   70/3/8259.
CR Ali II, 2004, EPILEPSY BEHAV, V5, P296, DOI 10.1016/j.yebeh.2004.02.005
   [Anonymous], 2009, FACT SHEET 999
   Boluk A, 2004, PHARMACOL RES, V50, P93, DOI 10.1016/j.phrs.2003.11.011
   Chatzipapas C, 2009, HORM METAB RES, V41, P635, DOI 10.1055/s 0029 1216375
   Christakos S, 1996, BIOCHEM J, V316, P361, DOI 10.1042/bj3160361
   Eisman JA, 2001, DRUG METAB DISPOS, V29, P505
   Ensrud KE, 2008, NEUROLOGY, V71, P723, DOI 10.1212/01.wnl.0000324919.86696.a9
   Fernandez E, 1997, J AM SOC NEPHROL, V8, P1546
   Ferrara M, 2002, BRIT J HAEMATOL, V117, P436, DOI 10.1046/j.1365 2141.2002.03426.x
   Feskanich D, 1998, EPIDEMIOLOGY, V9, P535, DOI 10.1097/00001648 199809000 00011
   FLEET JC, 1995, J BONE MINER RES, V10, P985
   FULCIHAN GE, 2008, BONE, V43, P149
   Garnero P, 2005, J CLIN ENDOCR METAB, V90, P4829, DOI 10.1210/jc.2005 0364
   Goldstein DB, 2007, AM J MED, V120, P21, DOI 10.1016/j.amjmed.2007.02.004
   Hadjidakis D, 1997, EUR J CLIN INVEST, V27, P219, DOI 10.1046/j.1365 2362.1997.980636.x
   Haussler MR, 1997, J ENDOCRINOL, V154, pS57
   Honkakoski P, 2000, BIOCHEM J, V347, P321, DOI 10.1042/0264 6021:3470321
   HOWARD G, 1995, J CLIN ENDOCR METAB, V80, P2800, DOI 10.1210/jc.80.9.2800
   Jurutka P W, 2001, Rev Endocr Metab Disord, V2, P203, DOI 10.1023/A:1010062929140
   Löscher W, 2009, EPILEPSIA, V50, P1, DOI 10.1111/j.1528 1167.2008.01716.x
   Lorentzon M, 2001, J BONE MINER METAB, V19, P302, DOI 10.1007/s007740170014
   Macdonald HM, 2006, J BONE MINER RES, V21, P151, DOI 10.1359/JBMR.050906
   MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0
   Obermayer Pietsch BM, 2000, J BONE MINER RES, V15, P1950, DOI 10.1359/jbmr.2000.15.10.1950
   Pack A, 2008, SEIZURE EUR J EPILEP, V17, P181, DOI 10.1016/j.seizure.2007.11.020
   Pack AM, 2004, EPILEPSY BEHAV, V5, pS24, DOI 10.1016/j.yebeh.2003.11.029
   Petty SJ, 2007, OSTEOPOROSIS INT, V18, P129, DOI 10.1007/s00198 006 0185 z
   Samaniego Edgar A, 2007, Semin Pediatr Neurol, V14, P196, DOI 10.1016/j.spen.2007.08.006
   Spina E, 2004, EPILEPTIC DISORD, V6, P57
   Stephen LJ, 1999, SEIZURE EUR J EPILEP, V8, P339, DOI 10.1053/seiz.1999.0301
   Szoeke CEI, 2006, LANCET NEUROL, V5, P189, DOI 10.1016/S1474 4422(06)70352 0
   Thakkinstian A, 2004, J BONE MINER RES, V19, P419, DOI 10.1359/JBMR.0301265
   Torres A, 1996, KIDNEY INT, V50, P1726, DOI 10.1038/ki.1996.492
   Tsiropoulos I, 2008, EPILEPSIA, V49, P2092, DOI 10.1111/j.1528 1167.2008.01640.x
   Tsukahara H, 2002, PEDIATR INT, V44, P247, DOI 10.1046/j.1442 200X.2002.01561.x
   Valsamis HA, 2006, NUTR METABOLISM, V3, DOI 10.1186/1743 7075 3 36
   Zmuda JM, 2000, EPIDEMIOL REV, V22, P203, DOI 10.1093/oxfordjournals.epirev.a018033
NR 37
TC 25
Z9 25
U1 0
U2 3
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1351 5101
EI 1468 1331
J9 EUR J NEUROL
JI Eur. J. Neurol.
PD JAN
PY 2011
VL 18
IS 1
BP 93
EP 98
DI 10.1111/j.1468 1331.2010.03103.x
PG 6
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA 695FP
UT WOS:000285356300014
PM 20500803
DA 2025 08 17
ER

PT J
AU McCloskey, E
AF McCloskey, Eugene
TI Effects of third generation aromatase inhibitors on bone
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE anastrozole; letrozole; exemestane; bone; bone mineral density;
   fracture; breast cancer
ID HEALTHY POSTMENOPAUSAL WOMEN; ADVANCED BREAST CANCER; MINERAL DENSITY;
   RANDOMIZED TRIAL; OSTEOCLAST DIFFERENTIATION; ENDOGENOUS HORMONES;
   TAMOXIFEN THERAPY; AMERICAN SOCIETY; ANASTROZOLE; EXEMESTANE
AB Low oestradiol levels in women are associated with decreased bone mineral density (BMD) and increased fracture risk. The third generation aromatase inhibitors (AIs; anastrozole, letrozole, and exemestane) are used in the treatment of early and advanced breast cancer and act by substantially reducing oestrogen synthesis in postmenopausal women. However, due to their mechanism of action, there is concern regarding the long term effects of these agents on bone, particularly when used in the adjuvant setting. In this paper, the currently available data on the effects of the third generation AIs on markers of bone turnover, BMD, and fracture risk are reviewed, with the emphasis on results in the adjuvant treatment of early breast cancer. These data suggest that both the steroidal (exemestane) and non steroidal (anastrozole and letrozole) AIs appear to affect bone turnover. Conclusions regarding any clinically relevant differences between these agents are difficult to make, and further data are awaited from long term adjuvant use of these three agents in ongoing clinical studies. Postmenopausal women are at increased risk of osteoporosis and fracture, and the increasing use of AIs in the adjuvant treatment of postmenopausal breast cancer patients will require appropriate consideration of fracture risk, with the use of anti osteoporotic therapies, if necessary. (c) 2006 Elsevier Ltd. All rights reserved.
C1 No Gen Hosp, Acad Unit Bone Metab, Metab Bone Ctr, Sheffield S5 7AU, S Yorkshire, England.
C3 Northern General Hospital; University of Sheffield
RP McCloskey, E (通讯作者)，No Gen Hosp, Acad Unit Bone Metab, Metab Bone Ctr, Sorby Wing,Herries Rd, Sheffield S5 7AU, S Yorkshire, England.
EM e.v.mccloskey@shef.ac.uk
RI McCloskey, Eugene/T 5197 2019
CR Allolio B, 1999, OSTEOPOROSIS INT, V9, P9
   ANON S, 2002, J BONE MINER RES, V17, P716
   [Anonymous], 1988, NEW ENGL J MED, V319, P1681
   Bajetta E, 2002, ANN ONCOL, V13, P1059, DOI 10.1093/annonc/mdf083
   Baum M, 2002, LANCET, V359, P2131
   Baum M, 2003, Cancer, V98, P1802
   Baum M., 2003, CANCER, V98, P1802, DOI DOI 10.1002/CNCR.11745
   BERNSTEIN L, 1993, EPIDEMIOL REV, V15, P48, DOI 10.1093/oxfordjournals.epirev.a036116
   Bonneterre J, 2001, CANCER, V92, P2247, DOI 10.1002/1097 0142(20011101)92:9<2247::AID CNCR1570>3.0.CO;2 Y
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   BRODIE AMH, 1987, J STEROID BIOCHEM, V27, P899, DOI 10.1016/0022 4731(87)90166 X
   BRODIE AMH, 1994, J STEROID BIOCHEM, V49, P281, DOI 10.1016/0960 0760(94)90269 0
   Chang J, 1996, ANN ONCOL, V7, P671
   Chantraine J., 1982, B BUR RECH GEOL MIN, V1, P3
   Chapurlat RD, 2001, BONE, V29, P381, DOI 10.1016/S8756 3282(01)00584 1
   Coleman R, 2004, EJC SUPPL, V2, P140, DOI 10.1016/S1359 6349(04)90892 0
   Coombes RC, 2004, NEW ENGL J MED, V350, P1081, DOI 10.1056/NEJMoa040331
   Cummings SR, 2002, JAMA J AM MED ASSOC, V287, P216, DOI 10.1001/jama.287.2.216
   Davidge ST, 2001, AM J PHYSIOL REG I, V280, pR904, DOI 10.1152/ajpregu.2001.280.3.R904
   Dukes M, 1997, ONCOLOGY, V54, P6
   Eastell R., 2003, AM SOC BON MIN RES 2
   EASTELL R, 2002, ANN ONCOL, V13, P32
   Ferrari L, 2003, INT J ONCOL, V22, P1081
   Gao YH, 2004, P NATL ACAD SCI USA, V101, P16618, DOI 10.1073/pnas.0404888101
   GEISLER J, 2004, P AN M AM SOC CLIN, V23, P9
   Gnant M, 2002, BREAST CANCER RES TR, V76, pS31
   Goss P, 2002, BREAST CANCER RES TR, V76, pS76
   Goss PE, 2003, BREAST CANCER RES TR, V82, pS101
   Goss PE, 2004, BONE, V34, P384, DOI 10.1016/j.bone.2003.11.006
   Goss PE, 2003, NEW ENGL J MED, V349, P1793, DOI 10.1056/NEJMoa032312
   GOSS PE, 2004, P AN M AM SOC CLIN, V22, pS14
   GOSS PE, 2004, P AN M AM SOC CLIN, V23, P87
   Harper Wynne C, 2002, CANCER EPIDEM BIOMAR, V11, P614
   Heshmati HM, 2002, J BONE MINER RES, V17, P172, DOI 10.1359/jbmr.2002.17.1.172
   Hillner BE, 2003, J CLIN ONCOL, V21, P4042, DOI 10.1200/JCO.2003.08.017
   Hough S, 1998, DRUG AGING, V12, P1, DOI 10.2165/00002512 199812001 00001
   Howell A, 2004, BREAST CANCER RES TR, V88, pS7
   Howell A, 2005, LANCET, V365, P60, DOI 10.1016/s0140 6736(04)17666 6
   Ismail AA, 2002, OSTEOPOROSIS INT, V13, P565, DOI 10.1007/s001980200074
   Jimi E, 1999, J IMMUNOL, V163, P434
   Kenny AM, 2002, J REPROD MED, V47, P63
   Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002 9440(10)64556 7
   Locker GY, 2003, P AN M AM SOC CLIN, V22, P25
   LONNING PE, 2004, P AN M AM SOC CLIN, V23, P6
   Martinetti A, 2003, ANTICANCER RES, V23, P3485
   *NAT OST FDN, 2003, PHYS GUID PREV TREAT
   *NIH, OST REL BON DIS NAT
   NOTELOVITZ M, 1993, FERTIL STERIL, V59, P707
   OSBORNE CK, 1985, CANCER RES, V45, P584
   Powles T, 1996, J CLIN ONCOL, V14, P78, DOI 10.1200/JCO.1996.14.1.78
   Rodan GA, 2003, CANCER, V97, P726, DOI 10.1002/cncr.11147
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Royal College of Physicians, 1999, OST CLIN GUID PREV T
   Sainsbury R, 2002, BREAST CANCER RES TR, V76, pS156
   Seeman E, 2002, LANCET, V359, P1841, DOI 10.1016/S0140 6736(02)08706 8
   SPICER DV, J NATL CANC I MONOGR, P139
   SUBAR M, 2004, P AN M AM SOC CLIN, V23, P734
   Winer EP, 2002, J CLIN ONCOL, V20, P3317, DOI 10.1200/JCO.2002.06.020
   Wojtacki J, 2003, BREAST CANCER RES TR, V82, pS107
   WORLD HEALTH ORGANIZATION, 1994, TECHN REP SER WHO
NR 60
TC 65
Z9 73
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959 8049
EI 1879 0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD MAY
PY 2006
VL 42
IS 8
BP 1044
EP 1051
DI 10.1016/j.ejca.2005.10.028
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 052CP
UT WOS:000238208900014
PM 16554149
DA 2025 08 17
ER

PT J
AU Ozeki, N
   Hase, N
   Higuchi, N
   Hiyama, T
   Yamaguchi, H
   Kawai, R
   Matsumoto, T
   Nakata, K
   Mogi, M
AF Ozeki, Nobuaki
   Hase, Naoko
   Higuchi, Naoya
   Hiyama, Taiki
   Yamaguchi, Hideyuki
   Kawai, Rie
   Matsumoto, Toru
   Nakata, Kazuhiko
   Mogi, Makio
TI 被撤回的出版物: Gelatin scaffold combined with bone morphogenetic protein 4
   induces odontoblast like cell differentiation involving integrin profile
   changes, autophagy related gene 10, and Wnt5 sequentially in human
   induced pluripotent stem cells (Retracted article. See vol. 117, pg. 16,
   2021)
SO DIFFERENTIATION
LA English
DT Article; Retracted Publication
DE Atg10; Wnt5 Matrix metalloproteinase 3; Human induced pluripotent stem
   cell; Odontoblast Cell differentiation
ID MATRIX METALLOPROTEINASE EXPRESSION; ENHANCER BINDING FACTOR 1;
   OSTEOBLAST DIFFERENTIATION; ACTIVATION; INDUCTION; ADHESION; DISEASE
AB While human induced pluripotent stem (hiPS) cells have potential use in regenerative medicine, there are no reports on odontoblastic differentiation of hiPS cells. In the current study, to examine integrin profiles and explore the early signaling cascade of odontoblastic differentiation in hiPS cells, we investigated the regulation of autophagy related gene (Atg) and wingless/intl (Wnt) signaling in gelatin scaffold (GS) combined with bone morphogenetic protein (BMP) 4 (GS/BMP 4) mediated odontoblastic differentiation. Following GS/BMP 4 treatment, there was a dramatic loss of alpha 3 and alpha 6 integrins, and reciprocal strong induction of alpha 1 integrin expression in the differentiated cells. GS/BMP 4 increased the mRNA and protein levels of Atg10, Lrp5/Fzd9 (an Atg10 receptor), and Wnt5 together with the amount of autophagosomes and autophagic fluxes. Treatment with siRNAs against Atg10 and Wnt5a individually suppressed the GS/BMP 4 induced increase in odontoblastic differentiation. The odontoblastic phenotype was inhibited by chloroquine, but increased after treatment with rapamycin (an autophagy enhancer). Taken together with our previous findings, we have replicated our results from the rodent system in a novel human system. We have revealed a unique sequential cascade involving Atg10, Wnt5a, alpha 1 integrin, and matrix metalloproteinase 3 in GS/BMP 4 induced differentiation of hiPS cells into odontoblast like cells at a relatively early stage. (C) 2016 International Society of Differentiation. Published by Elsevier B.V. All rights reserved.
C1 [Ozeki, Nobuaki; Hase, Naoko; Higuchi, Naoya; Hiyama, Taiki; Yamaguchi, Hideyuki; Kawai, Rie; Matsumoto, Toru; Nakata, Kazuhiko] Aichi Gakuin Univ, Sch Dent, Dept Endodont, Nagoya, Aichi 4648651, Japan.
   [Mogi, Makio] Aichi Gakuin Univ, Sch Pharm, Dept Integrat Educ Pharm, Nagoya, Aichi 4648650, Japan.
C3 Aichi Gakuin University; Aichi Gakuin University
RP Mogi, M (通讯作者)，Aichi Gakuin Univ, Sch Pharm, Dept Integrat Educ Pharm, Nagoya, Aichi 4648650, Japan.
EM makio@dpc.agu.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [25253101, 26462903, 25462976, 26462904]; Grants in Aid for Scientific
   Research [26462903, 25462976, 25253101] Funding Source: KAKEN
FX We thank Dr. Randall H. Kramer for the donation of experimental reagents
   and helpful discussions. This work was supported by a Grant in Aid for
   Scientific Research (A) (Grant no. 25253101; to SY), a Grant in Aid for
   Scientific Research (C) (Grant no. 26462903; to TM), a Grant in Aid for
   Scientific Research (C) (Grant no. 25462976; to NH), and a
   Grant in Aid for Scientific Research (C) (Grant no. 26462904; to NO)
   from the Ministry of Education, Culture, Sports, Science and Technology
   of Japan.
CR Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286
   Eskelinen EL, 2005, AUTOPHAGY, V1, P1, DOI 10.4161/auto.1.1.1270
   Fuerer C, 2008, EMBO REP, V9, P134, DOI 10.1038/sj.embor.7401159
   Ge XP, 2009, ARTHRITIS RHEUM US, V60, P2714, DOI 10.1002/art.24779
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Ha SW, 2014, ACS NANO, V8, P5898, DOI 10.1021/nn5009879
   Jullien N, 2012, J CELL BIOCHEM, V113, P2047, DOI 10.1002/jcb.24076
   Kamada Y, 2003, CURR TOP MICROBIOL, V279, P73
   Kawaguchi J, 2005, BONE, V36, P758, DOI 10.1016/j.bone.2004.07.019
   Kawai R, 2014, ORAL DIS, V20, P395, DOI 10.1111/odi.12134
   Koizumi Y, 2013, CONGENIT ANOM, V53, P101, DOI 10.1111/cga.12011
   Lin CX, 2011, DEV BIOL, V356, P40, DOI 10.1016/j.ydbio.2011.05.002
   Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287
   Lucchini M, 2004, J DENT RES, V83, P552, DOI 10.1177/154405910408300708
   Lujan E, 2015, NATURE, V521, P352, DOI 10.1038/nature14274
   Ma B, 2012, ARTHRITIS RHEUM US, V64, P2589, DOI 10.1002/art.34425
   Maeda K, 2012, NAT MED, V18, P405, DOI 10.1038/nm.2653
   Mogi M, 2004, BONE, V35, P507, DOI 10.1016/j.bone.2004.03.003
   Mogi M, 2003, J BIOL CHEM, V278, P47477, DOI 10.1074/jbc.M307055200
   Nakatomi M, 2013, J ENDODONT, V39, P612, DOI 10.1016/j.joen.2012.12.016
   Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260
   Oeste CL, 2013, HISTOCHEM CELL BIOL, V139, P659, DOI 10.1007/s00418 012 1057 6
   Okamoto M, 2014, SCI REP UK, V4, DOI 10.1038/srep04493
   Otsu K, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00036
   Ozeki N, 2006, EXP CELL RES, V312, P4162, DOI 10.1016/j.yexcr.2006.09.017
   Ozeki N, 2016, EXP CELL RES, V341, P92, DOI 10.1016/j.yexcr.2016.01.010
   Ozeki N, 2015, EXP CELL RES, V331, P21, DOI 10.1016/j.yexcr.2014.08.004
   Ozeki N, 2014, EXP CELL RES, V328, P69, DOI 10.1016/j.yexcr.2014.05.006
   Ozeki N, 2014, J BIOL CHEM, V289, P14380, DOI 10.1074/jbc.M113.526772
   Ozeki N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080026
   Peng L, 2010, INT ENDOD J, V43, P404, DOI 10.1111/j.1365 2591.2010.01693.x
   Roberts AI, 1999, IMMUNOLOGY, V97, P679
   Rubinsztein DC, 2011, CELL, V146, P682, DOI 10.1016/j.cell.2011.07.030
   Staquet MJ, 2006, CELL TISSUE RES, V323, P457, DOI 10.1007/s00441 005 0104 1
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Tomizawa M, 2015, J CELL BIOCHEM, V116, P1479, DOI 10.1002/jcb.25139
   Vizirianakis IS, 2001, ARCH BIOCHEM BIOPHYS, V385, P108, DOI 10.1006/abbi.2000.2134
   Wang CL, 2010, J ENDODONT, V36, P238, DOI 10.1016/j.joen.2009.09.007
   Wang RC, 2010, FEBS LETT, V584, P1417, DOI 10.1016/j.febslet.2010.01.009
   Wang S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0026871
   Yamashiro T, 2007, DIFFERENTIATION, V75, P452, DOI 10.1111/j.1432 0436.2006.00150.x
   Yokose S, 2010, J BONE MINER METAB, V28, P650, DOI 10.1007/s00774 010 0185 0
   Zhu LX, 2013, J ENDODONT, V39, P1379, DOI 10.1016/j.joen.2013.07.013
NR 44
TC 10
Z9 12
U1 0
U2 16
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0301 4681
EI 1432 0436
J9 DIFFERENTIATION
JI Differentiation
PD JAN FEB
PY 2017
VL 93
BP 1
EP 14
DI 10.1016/j.diff.2016.09.002
PG 14
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA EL5AG
UT WOS:000394633200001
PM 27639333
DA 2025 08 17
ER

PT J
AU Ruscitto, A
   Morel, MM
   Shawber, CJ
   Reeve, G
   Lecholop, MK
   Bonthius, D
   Yao, H
   Embree, MC
AF Ruscitto, Angela
   Morel, Mallory M.
   Shawber, Carrie J.
   Reeve, Gwendolyn
   Lecholop, Michael K.
   Bonthius, Daniel
   Yao, Hai
   Embree, Mildred C.
TI Evidence of vasculature and chondrocyte to osteoblast
   transdifferentiation in craniofacial synovial joints: Implications for
   osteoarthritis diagnosis and therapy
SO FASEB JOURNAL
LA English
DT Article
DE angiogenesis; cartilage; chondrogenesis; miniature pigs; osteoarthritis;
   osteogenesis; temporomandibular joint; transdifferentiation
ID TEMPOROMANDIBULAR JOINT; CONDYLAR CARTILAGE; ENDOTHELIAL CELL;
   ARTICULAR CARTILAGE; GROWTH FACTOR; MIDDLE EAR; PATHOGENESIS;
   EXPRESSION; MOUSE; DIFFERENTIATION
AB Temporomandibular joint osteoarthritis (TMJ OA) leads to permanent cartilage destruction, jaw dysfunction, and compromises the quality of life. However, the pathological mechanisms governing TMJ OA are poorly understood. Unlike appendicular articular cartilage, the TMJ has two distinct functions as the synovial joint of the craniofacial complex and also as the site for endochondral jaw bone growth. The established dogma of endochondral bone ossification is that hypertrophic chondrocytes undergo apoptosis, while invading vasculature with osteoprogenitors replace cartilage with bone. However, contemporary murine genetic studies support the direct differentiation of chondrocytes into osteoblasts and osteocytes in the TMJ. Here we sought to characterize putative vasculature and cartilage to bone transdifferentiation using healthy and diseased TMJ tissues from miniature pigs and humans. During endochondral ossification, the presence of fully formed vasculature expressing CD31(+) endothelial cells and alpha SMA(+) vascular smooth muscle cells were detected within all cellular zones in growing miniature pigs. Arterial, endothelial, venous, angiogenic, and mural cell markers were significantly upregulated in miniature pig TMJ tissues relative to donor matched knee meniscus fibrocartilage tissue. Upon surgically creating TMJ OA in miniature pigs, we discovered increased vasculature and putative chondrocyte to osteoblast transformation dually marked by COL2 and BSP or RUNX2 within the vascular bundles. Pathological human TMJ tissues also exhibited increased vasculature, while isolated diseased human TMJ cells exhibited marked increased in vasculature markers relative to control 293T cells. Our study provides evidence to suggest that the TMJ in higher order species are in fact vascularized. There have been no reports of cartilage to bone transdifferentiation or vasculature in human relevant TMJ OA large animal models or in human TMJ tissues and cells. Therefore, these findings may potentially alter the clinical management of TMJ OA by defining new drugs that target angiogenesis or block the cartilage to bone transformation.
C1 [Ruscitto, Angela; Morel, Mallory M.; Embree, Mildred C.] Columbia Univ, Coll Dent Med, Cartilage Biol & Regenerat Med Lab, Irving Med Ctr, New York, NY 10027 USA.
   [Shawber, Carrie J.] Columbia Univ, Coll Phys & Surg, Dept OB GYN, Div Reprod Sci,Irving Med Ctr, New York, NY USA.
   [Reeve, Gwendolyn] New York Presbyterian Weill Cornell Med Ctr, Div Oral & Maxillofacial Surg, New York, NY USA.
   [Lecholop, Michael K.] Med Univ South Carolina, Dept Oral & Maxillofacial Surg, Coll Dent Med, Charleston, SC 29425 USA.
   [Bonthius, Daniel; Yao, Hai] Clemson Univ, Clemson MUSC Bioengn Program, Dept Bioengn, Greenville, SC USA.
   [Yao, Hai] Med Univ South Carolina, Dept Oral Hlth Sci, Charleston, SC 29425 USA.
C3 Columbia University; NewYork Presbyterian Hospital; Columbia University;
   NewYork Presbyterian Hospital; Cornell University; Weill Cornell
   Medicine; Weill Cornell Medical Center; Medical University of South
   Carolina; Medical University of South Carolina; Clemson University;
   Medical University of South Carolina
RP Embree, MC (通讯作者)，Columbia Univ, Coll Dent Med, Cartilage Biol & Regenerat Med Lab, Irving Med Ctr, New York, NY 10027 USA.
EM mce2123@cumc.columbia.edu
FU NIH [5R00DE0220660, R01DE021134, P20GM121342]
FX NIH, Grant/Award Number: 5R00DE0220660, R01DE021134 and P20GM121342
CR Aigner T, 2002, CURR OPIN RHEUMATOL, V14, P578, DOI 10.1097/00002281 200209000 00018
   Aigner T, 2007, NAT CLIN PRACT RHEUM, V3, P391, DOI 10.1038/ncprheum0534
   Almarza AJ, 2018, TISSUE ENG PART B RE, V24, P171, DOI [10.1089/ten.teb.2017.0341, 10.1089/ten.TEB.2017.0341]
   Ameye L, 2002, GLYCOBIOLOGY, V12, p107R, DOI 10.1093/glycob/cwf065
   Anthwal N, 2013, J ANAT, V222, P147, DOI 10.1111/j.1469 7580.2012.01526.x
   ARNOCZKY SP, 1982, AM J SPORT MED, V10, P90, DOI 10.1177/036354658201000205
   ARNOCZKY SP, 1983, AM J SPORT MED, V11, P131, DOI 10.1177/036354658301100305
   Aurich M, 2005, ARTHRITIS RHEUM US, V52, P112, DOI 10.1002/art.20740
   BENJAMIN M, 1990, J ANAT, V171, P1
   Berendsen AD, 2015, BONE, V80, P14, DOI 10.1016/j.bone.2015.04.035
   BERMEJO A, 1993, ORAL SURG ORAL MED O, V75, P18, DOI 10.1016/0030 4220(93)90399 O
   Bharathi SC, 2014, J INT SOC PREV COMMU, V4, P67, DOI 10.4103/2231 0762.127853
   BORA FW, 1987, HAND CLIN, V3, P325
   de Moraes LOC, 2015, EUR J HISTOCHEM, V59, P263, DOI 10.4081/ejh.2015.2569
   Colnot C, 2004, DEV BIOL, V269, P55, DOI 10.1016/j.ydbio.2004.01.011
   Decker RS, 2014, MATRIX BIOL, V39, P5, DOI 10.1016/j.matbio.2014.08.006
   Delaire J., 1998, Revue de Stomatologie et de Chirurgie Maxillo Faciale, V99, P3
   Di Giancamillo A, 2017, J CELL MOL MED, V21, P3066, DOI 10.1111/jcmm.13218
   DONES M, 1959, Oral Surg Oral Med Oral Pathol, V12, P1433, DOI 10.1016/0030 4220(59)90262 2
   Duan XC, 2016, MATRIX BIOL, V52 54, P127, DOI 10.1016/j.matbio.2016.02.005
   Durkin J.F., 1973, ORAL SCI REV, V2, P29
   EISENSTEIN R, 1973, AM J PATHOL, V73, P765
   Embree MC, 2015, OSTEOARTHR CARTILAGE, V23, P629, DOI 10.1016/j.joca.2014.12.015
   Embree MC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13073
   Embree MC, 2010, AM J PATHOL, V176, P812, DOI 10.2353/ajpath.2010.090450
   Eyre D, 2002, ARTHRITIS RES, V4, P30, DOI 10.1186/ar380
   Gale NW, 2001, DEV BIOL, V230, P151, DOI 10.1006/dbio.2000.0112
   Gill M, 2001, CIRC RES, V88, P167
   Gray JC, 1999, J ORTHOP SPORT PHYS, V29, P23, DOI 10.2519/jospt.1999.29.1.23
   Gu SP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101000
   Hall AC, 2019, CURR RHEUMATOL REP, V21, DOI 10.1007/s11926 019 0837 6
   Heinemeier KM, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad8335
   Herring SW, 2002, ANAT RECORD, V266, P152, DOI 10.1002/ar.10049
   HERRING SW, 1976, ARCH ORAL BIOL, V21, P473, DOI 10.1016/0003 9969(76)90105 9
   Hinton RJ, 2017, J DENT RES, V96, P23, DOI 10.1177/0022034516668321
   Hirschi KK, 1999, CIRC RES, V84, P298, DOI 10.1161/01.RES.84.3.298
   Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805
   Hu DP, 2017, DEVELOPMENT, V144, P221, DOI 10.1242/dev.130807
   Huang GTJ, 2013, STEM CELLS IN CRANIOFACIAL DEVELOPMENT AND REGENERATION, P1, DOI 10.1002/9781118498026
   Ji Q, 2009, SCIENCE, V326, P278, DOI 10.1126/science.1178501
   Jing Y, 2015, J DENT RES, V94, P1668, DOI 10.1177/0022034515598135
   Jing Y, 2018, INT J BIOL SCI, V14, P1, DOI 10.7150/ijbs.23165
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   KERMACK KA, 1972, P ROY SOC MED, V65, P389, DOI 10.1177/003591577206500439
   KESSEL L J, 1969, British Journal of Oral Surgery, V7, P124
   Kim YH, 2008, DEVELOPMENT, V135, P3755, DOI 10.1242/dev.022475
   Kobayashi T, 2014, METHODS MOL BIOL, V1130, P3, DOI 10.1007/978 1 62703 989 5_1
   Koyama E, 2008, DEV BIOL, V316, P62, DOI 10.1016/j.ydbio.2008.01.012
   Kronenberg HM, 2007, ANN NY ACAD SCI, V1116, P59, DOI 10.1196/annals.1402.059
   Kume T, 2010, HISTOL HISTOPATHOL, V25, P637, DOI 10.14670/HH 25.637
   LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203
   Lamy S, 2010, VASC PHARMACOL, V53, P200, DOI 10.1016/j.vph.2010.08.002
   Lark MW, 1997, J CLIN INVEST, V100, P93, DOI 10.1172/JCI119526
   Lautenschlager S, 2018, NATURE, V561, P533, DOI 10.1038/s41586 018 0521 4
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Lin AW, 2018, J COMP PATHOL, V161, P55, DOI 10.1016/j.jcpa.2018.05.001
   Long FX, 1998, DEVELOPMENT, V125, P1067
   Mair KH, 2014, DEV COMP IMMUNOL, V45, P321, DOI 10.1016/j.dci.2014.03.022
   Mei H, 2014, J BIOL CHEM, V289, P20836, DOI 10.1074/jbc.M114.557454
   Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731
   Miyake T, 1997, J ANAT, V190, P239, DOI 10.1046/j.1469 7580.1997.19020239.x
   MORIMOTO K, 1987, J PROSTHET DENT, V57, P723, DOI 10.1016/0022 3913(87)90372 6
   Nathan J, 2018, J DENT RES, V97, P329, DOI 10.1177/0022034517735094
   Ono N, 2014, NAT CELL BIOL, V16, P1157, DOI 10.1038/ncb3067
   Owtad P, 2013, J DENT RES, V92, P315, DOI 10.1177/0022034513476302
   Pacifici M, 2006, ANN NY ACAD SCI, V1068, P74, DOI 10.1196/annals.1346.010
   Park J, 2015, BIOL OPEN, V4, P608, DOI 10.1242/bio.201411031
   Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958
   Poole A R, 1993, Agents Actions Suppl, V39, P3
   Purcell P, 2012, J DENT RES, V91, P387, DOI 10.1177/0022034512438401
   Purcell P, 2009, P NATL ACAD SCI USA, V106, P18297, DOI 10.1073/pnas.0908836106
   Rotter A, 2017, J DTSCH DERMATOL GES, V15, P1185, DOI 10.1111/ddg.13365
   Schneider RA, 2015, CURR TOP DEV BIOL, V115, P271, DOI 10.1016/bs.ctdb.2015.08.002
   Schomberg DT, 2016, TOXICOL PATHOL, V44, P299, DOI 10.1177/0192623315618292
   Scrivani SJ, 2008, NEW ENGL J MED, V359, P2693, DOI 10.1056/NEJMra0802472
   Shen G, 2005, Orthod Craniofac Res, V8, P114
   Shen G, 2006, ARCH ORAL BIOL, V51, P315, DOI 10.1016/j.archoralbio.2005.08.004
   Shen G, 2005, J DENT RES, V84, P691, DOI 10.1177/154405910508400802
   Sherwood J, 2019, OSTEOARTHR CARTILAGE, V27, P365, DOI 10.1016/j.joca.2018.10.005
   Shibata S, 2008, J ANAT, V213, P274, DOI 10.1111/j.1469 7580.2008.00934.x
   Shibukawa Y, 2007, DEV DYNAM, V236, P426, DOI 10.1002/dvdy.21036
   Sindelar BJ, 2005, CELLS TISSUES ORGANS, V180, P36, DOI 10.1159/000086197
   Singh P, 2019, ANN NY ACAD SCI, V1442, P17, DOI 10.1111/nyas.13930
   Squires GR, 2003, ARTHRITIS RHEUM US, V48, P1261, DOI 10.1002/art.10976
   STROM D, 1986, ARCH ORAL BIOL, V31, P763, DOI 10.1016/0003 9969(86)90009 9
   Sun ZY, 2002, ARCH ORAL BIOL, V47, P293, DOI 10.1016/S0003 9969(02)00004 3
   Swift MR, 2009, CIRC RES, V104, P576, DOI 10.1161/CIRCRESAHA.108.188805
   Ten Cate A.R., 1980, Oral histology: development, structure and function
   Tripathi Tulika, 2019, J Clin Orthod, V53, P29
   Vapniarsky N, 2017, TISSUE ENG PART C ME, V23, P700, DOI [10.1089/ten.tec.2017.0149, 10.1089/ten.TEC.2017.0149]
   Wadhwa S, 2005, OSTEOARTHR CARTILAGE, V13, P817, DOI 10.1016/j.joca.2005.04.016
   Wang XD, 2015, J DENT RES, V94, P666, DOI 10.1177/0022034515574770
   Wang Y, 2011, DEV DYNAM, V240, P2466, DOI 10.1002/dvdy.22748
   Yang L, 2014, P NATL ACAD SCI USA, V111, P12097, DOI 10.1073/pnas.1302703111
   Zhou X, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004820
   Zou HX, 2013, CARDIOVASC PATHOL, V22, P203, DOI 10.1016/j.carpath.2012.10.001
NR 96
TC 27
Z9 32
U1 1
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD MAR
PY 2020
VL 34
IS 3
BP 4445
EP 4461
DI 10.1096/fj.201902287R
EA FEB 2020
PG 17
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA KT7UL
UT WOS:000512333200001
PM 32030828
OA Green Accepted, hybrid
DA 2025 08 17
ER

PT J
AU Liu, P
   Gao, YS
   Luo, PB
   Yu, HP
   Guo, S
   Liu, FY
   Gao, JJ
   Xu, JZ
   Wang, SD
   Zhang, CQ
AF Liu, Pei
   Gao, Youshui
   Luo, Pengbo
   Yu, Hongping
   Guo, Shang
   Liu, Fuyun
   Gao, Junjie
   Xu, Jianzhong
   Wang, Shengdian
   Zhang, Changqing
TI Glucocorticoid induced expansion of classical monocytes contributes to
   bone loss
SO EXPERIMENTAL AND MOLECULAR MEDICINE
LA English
DT Article
ID INFLAMMATORY ARTHRITIS; OSTEOCLAST PRECURSORS; INDUCED OSTEOPOROSIS;
   ANIMAL MODELS; IMMUNE; RECEPTOR; OSTEOIMMUNOLOGY; DIFFERENTIATION;
   SUBPOPULATIONS; ADHESION
AB Osteoporosis: Steroid induced bone loss fueled by immune cell activity Immune cells involved in innate inflammatory responses are key mediators of steroid induced osteoporosis, a finding that could inform development of new therapies for this common bone disease. Pei Liu from Shanghai Jiao Tong University Affiliated Sixth People's Hospital, China, and colleagues studied the role of immune cells known as classical monocytes in rodent models of steroid induced osteoporosis. The researchers showed that the monocytes express receptors for the steroid hormone, which results in promoting their proliferation. The immune cells then accumulate in the bone marrow, where they spur bone degradation. Experimental depletion of the monocytes helped reduce steroid triggered bone loss in mice by preventing bone resorption and eliciting growth of blood vessels that support bone formation. The authors suggest that similar therapeutic strategies could be of promise in humans.
   Classical monocytes are commonly involved in the innate inflammatory response and are the progenitors of osteoclasts. Excess endogenous glucocorticoids (GCs) can increase the levels of classical monocytes in blood and bone marrow. The role of this cell population in high dose exogenous GC induced osteoporosis (GIOP) remains to be elucidated. In this study, GIOP was established in rats and mice by daily methylprednisolone injection, and monocyte subsets were analyzed by flow cytometry. We demonstrated that classical monocytes accumulate in bone marrow during GIOP. Similarly, the monocyte proportion among bone marrow nucleated cells was also increased in patients with steroid treatment history. We sorted classical monocytes and analyzed their transcriptional profile in response to GCs by RNA sequencing. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis showed that classical monocytes isolated from GC treated rats exhibited osteoclast differentiation potential. Deletion of classical monocytes by clodronate liposome treatment prevented GIOP via inhibition of osteoclastogenesis and restoration of CD31(Hi)endomucin(Hi) vessels. Regarding the molecular mechanism, classical monocytes express high levels of glucocorticoid receptors. In vitro treatment with GCs increased both the percentage and absolute number of monocytes and promoted their proliferation. In summary, classical monocytes mediated GC induced bone loss and are a potential target for therapeutic intervention in GIOP treatment.
C1 [Liu, Pei; Gao, Youshui; Luo, Pengbo; Yu, Hongping; Guo, Shang; Gao, Junjie; Zhang, Changqing] Shanghai Jiao Tong Univ, Dept Orthoped Surg, Affiliated Peoples Hosp 6, Shanghai 200233, Peoples R China.
   [Liu, Fuyun] Zhengzhou Univ, Dept Orthoped Surg, Affiliated Hosp 3, Zhengzhou 450052, Henan, Peoples R China.
   [Xu, Jianzhong] Zhengzhou Univ, Dept Orthoped Surg, Affiliated Hosp 1, Zhengzhou 450000, Henan, Peoples R China.
   [Wang, Shengdian] Chinese Acad Sci, Inst Biophys, CAS Key Lab Infect & Immun, Beijing 100101, Peoples R China.
C3 Shanghai Jiao Tong University; Zhengzhou University; Zhengzhou
   University; Chinese Academy of Sciences; Institute of Biophysics, CAS
RP Zhang, CQ (通讯作者)，Shanghai Jiao Tong Univ, Dept Orthoped Surg, Affiliated Peoples Hosp 6, Shanghai 200233, Peoples R China.; Xu, JZ (通讯作者)，Zhengzhou Univ, Dept Orthoped Surg, Affiliated Hosp 1, Zhengzhou 450000, Henan, Peoples R China.; Wang, SD (通讯作者)，Chinese Acad Sci, Inst Biophys, CAS Key Lab Infect & Immun, Beijing 100101, Peoples R China.
EM 13937133786@163.com; sdwang@ibp.ac.cn; zhangcq@sjtu.edu.cn
RI ; GAO, YOUSHUI/U 8349 2019
OI zhang, changqing/0000 0002 7408 4126; 
CR Acharya N, 2020, IMMUNITY, V53, P658, DOI 10.1016/j.immuni.2020.08.005
   Adami G, 2019, OSTEOPOROSIS INT, V30, P1145, DOI 10.1007/s00198 019 04906 x
   Amend Sarah R, 2016, J Vis Exp, DOI 10.3791/53936
   Arron JR, 2000, NATURE, V408, P535, DOI 10.1038/35046196
   Barnett Vanes A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0142520
   Baschant U, 2012, NAT REV RHEUMATOL, V8, P645, DOI 10.1038/nrrheum.2012.166
   Bitto A, 2009, BRIT J PHARMACOL, V156, P1287, DOI 10.1111/j.1476 5381.2008.00100.x
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Busillo JM, 2011, J BIOL CHEM, V286, P38703, DOI 10.1074/jbc.M111.275370
   Charles JF, 2012, J CLIN INVEST, V122, P4592, DOI 10.1172/JCI60920
   Cho SW, 2014, P NATL ACAD SCI USA, V111, P1545, DOI 10.1073/pnas.1315153111
   Chotiyarnwong P, 2020, NAT REV ENDOCRINOL, V16, P437, DOI 10.1038/s41574 020 0341 0
   Compston J, 2018, ENDOCRINE, V61, P7, DOI 10.1007/s12020 018 1588 2
   Dobbs KR, 2020, IMMUNOL REV, V293, P8, DOI 10.1111/imr.12830
   Eastell R, 1998, J INTERN MED, V244, P271, DOI 10.1046/j.1365 2796.1998.00408.x
   Fang P, 2019, ARTERIOSCL THROM VAS, V39, P2097, DOI 10.1161/ATVBAHA.119.313138
   França CN, 2017, CLIN SCI, V131, P1215, DOI 10.1042/CS20170009
   Fujii T, 2021, BONE RES, V9, DOI 10.1038/s41413 020 00120 2
   Gao YS, 2013, J ARTHROPLASTY, V28, P531, DOI 10.1016/j.arth.2012.09.002
   Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733
   Heidt T, 2014, NAT MED, V20, P754, DOI 10.1038/nm.3589
   Henneicke H, 2014, TRENDS ENDOCRIN MET, V25, P197, DOI 10.1016/j.tem.2013.12.006
   Hsiao HM, 2018, J CLIN INVEST, V128, P2833, DOI 10.1172/JCI98436
   Kadmiel M, 2013, TRENDS PHARMACOL SCI, V34, P518, DOI 10.1016/j.tips.2013.07.003
   Kröller Schön S, 2019, BASIC RES CARDIOL, V114, DOI 10.1007/s00395 019 0717 2
   Kumar RA, 2018, INT IMMUNOPHARMACOL, V65, P348, DOI 10.1016/j.intimp.2018.10.016
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Lewis AJM, 2018, CIRC RES, V122, P1084, DOI 10.1161/CIRCRESAHA.117.312535
   Lin NY, 2016, ANN RHEUM DIS, V75, P1203, DOI 10.1136/annrheumdis 2015 207240
   Loke YK, 2011, THORAX, V66, P699, DOI 10.1136/thx.2011.160028
   Macfarlane E, 2020, BONE RES, V8, DOI 10.1038/s41413 020 00112 2
   Murray PJ, 2018, SEMIN IMMUNOL, V35, P12, DOI 10.1016/j.smim.2017.12.005
   Narasimhan PB, 2019, ANNU REV IMMUNOL, V37, P439, DOI 10.1146/annurev immunol 042617 053119
   Niraula A, 2018, J NEUROSCI, V38, P2328, DOI 10.1523/JNEUROSCI.2568 17.2018
   Ogawa T, 2021, INJURY, V52, P3002, DOI 10.1016/j.injury.2021.02.092
   Okamoto K, 2017, PHYSIOL REV, V97, P1295, DOI 10.1152/physrev.00036.2016
   Reinwald S, 2008, J BONE MINER RES, V23, P1353, DOI 10.1359/JBMR.080516
   Seeling M, 2013, P NATL ACAD SCI USA, V110, P10729, DOI 10.1073/pnas.1301001110
   Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070
   Shi CS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165317
   Sprangers S, 2017, EXP CELL RES, V350, P161, DOI 10.1016/j.yexcr.2016.11.018
   Strauss Ayali D, 2007, J LEUKOCYTE BIOL, V82, P244, DOI 10.1189/jlb.0307191
   Suami H, 2011, ANAT REC, V294, P1566, DOI 10.1002/ar.21446
   Sunderkötter C, 2004, J IMMUNOL, V172, P4410, DOI 10.4049/jimmunol.172.7.4410
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   van Gaalen SM, 2010, TISSUE ENG PART B RE, V16, P209, DOI 10.1089/ten.TEB.2009.0503
   Wang L, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.36
   Wolf AA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01642
   Wood CL, 2018, J ENDOCRINOL, V236, pR69, DOI 10.1530/JOE 17 0361
   Xie Y, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0066 7
   Yang P, 2018, BONE, V114, P1, DOI 10.1016/j.bone.2018.05.025
   Yin JM, 2019, J BONE JOINT SURG AM, V101, P1294, DOI 10.2106/JBJS.18.01132
NR 53
TC 18
Z9 19
U1 2
U2 13
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1226 3613
EI 2092 6413
J9 EXP MOL MED
JI Exp. Mol. Med.
PD JUN
PY 2022
VL 54
IS 6
BP 765
EP 776
DI 10.1038/s12276 022 00764 6
EA JUN 2022
PG 12
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA 2R4BH
UT WOS:000807325100002
PM 35672449
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhang, YC
   Yan, JY
   Xu, HR
   Yang, Y
   Li, WK
   Wu, H
   Liu, CX
AF Zhang, Yingchi
   Yan, Jiyuan
   Xu, Haoran
   Yang, Yong
   Li, Wenkai
   Wu, Hua
   Liu, Chaoxu
TI Extremely low frequency electromagnetic fields promote mesenchymal stem
   cell migration by increasing intracellular Ca<SUP>2+</SUP> and
   activating the FAK/Rho GTPases signaling pathways in vitro
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Electromagnetic fields; Cell migration; Intracellular Ca2+; Focal
   adhesion kinase; Rho GTPase protein family
ID FOCAL ADHESION KINASE; OSTEOGENIC DIFFERENTIATION; RHO GTPASES;
   PROLIFERATION; OSTEOBLASTS; EXPRESSION; EXPOSURE
AB Background: The ability of mesenchymal stem cells (MSCs) to migrate to the desired tissues or lesions is crucial for stem cell based regenerative medicine and tissue engineering. Optimal therapeutics for promoting MSC migration are expected to become an effective means for tissue regeneration. Electromagnetic fields (EMF), as a noninvasive therapy, can cause a lot of biological changes in MSCs. However, whether EMF can promote MSC migration has not yet been reported.
   Methods: We evaluated the effects of EMF on cell migration in human bone marrow derived MSCs. With the use of Helmholtz coils and an EMF stimulator, 7.5, 15, 30, 50, and 70 Hz/1 mT EMF was generated. Additionally, we employed the L type calcium channel blocker verapamil and the focal adhesion kinase (FAK) inhibitor PF 573228 to investigate the role of intracellular calcium content, cell adhesion proteins, and the Rho GTPase protein family (RhoA, Rac1, and Cdc42) in EMF mediated MSC migration. Cell adhesion proteins (FAK, talin, and vinculin) were detected by Western blot analysis. The Rho GTPase protein family activities were assessed by G LISA, and F actin levels, which reflect actin cytoskeletal organization, were detected using immunofluorescence.
   Results: All the 7.5, 15, 30, 50, and 70 Hz/1 mT EMF promoted MSC migration. EMF increased MSC migration in an intracellular calcium dependent manner. Notably, EMF enhanced migration was mediated by FAK activation, which was critical for the formation of focal contacts, as evidenced by increased talin and vinculin expression. Moreover, RhoA, Rac1, and Cdc42 were activated by FAK to increase cytoskeletal organization, thus promoting cell contraction.
   Conclusions: EMF promoted MSC migration by increasing intracellular calcium and activating the FAK/Rho GTPase signaling pathways. This study provides insights into the mechanisms of MSC migration and will enable the rational design of targeted therapies to improve MSC engraftment.
C1 [Zhang, Yingchi; Yan, Jiyuan; Xu, Haoran; Yang, Yong; Li, Wenkai; Wu, Hua; Liu, Chaoxu] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Orthoped, Jiefang Ave 1095, Wuhan 430030, Hubei, Peoples R China.
C3 Huazhong University of Science & Technology
RP Wu, H; Liu, CX (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Orthoped, Jiefang Ave 1095, Wuhan 430030, Hubei, Peoples R China.
EM wuhua360@aliyun.com; liu.chaoxu@tjh.tjmu.edu.cn
RI Xu, Hao Ran/JED 9378 2023; Zhang, Yuanyuan/GYE 1266 2022
FU National Natural Science Foundation of China [51537004, 31300799];
   Independent Innovative Research Funds of HUST [2014QN094]
FX This study was supported by the National Natural Science Foundation of
   China (grant nos. 51537004 and 31300799) and the Independent Innovative
   Research Funds of HUST (2014QN094).
CR Amano M, 2010, CYTOSKELETON, V67, P545, DOI 10.1002/cm.20472
   Androjna C, 2014, BIOELECTROMAGNETICS, V35, P396, DOI 10.1002/bem.21855
   Atalay Y, 2015, DRUG DES DEV THER, V9, P5195, DOI 10.2147/DDDT.S89669
   Bagnato GL, 2016, RHEUMATOLOGY, V55, P755, DOI 10.1093/rheumatology/kev426
   Bianco P, 2014, ANNU REV CELL DEV BI, V30, P677, DOI 10.1146/annurev cellbio 100913 013132
   Cheng K, 2006, MED HYPOTHESES, V66, P148, DOI 10.1016/j.mehy.2005.07.007
   Cheng ZK, 2008, MOL THER, V16, P571, DOI 10.1038/sj.mt.6300374
   Chun J, 2009, J LEUKOCYTE BIOL, V86, P1135, DOI 10.1189/jlb.0209072
   Clapham DE, 2007, CELL, V131, P1047, DOI 10.1016/j.cell.2007.11.028
   Ferrari D, 2011, EXP HEMATOL, V39, P360, DOI 10.1016/j.exphem.2010.12.001
   Fogh BS, 2014, J HISTOCHEM CYTOCHEM, V62, P172, DOI 10.1369/0022155413517701
   Geng DY, 2014, BIO MED MATER ENG, V24, P1391, DOI 10.3233/BME 130943
   Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962 8924(01)02179 1
   Griffin XL, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008471.pub2
   HENDEY B, 1992, SCIENCE, V258, P296, DOI 10.1126/science.1384129
   Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481
   Hwang SJ, 2017, J BIOMED MAT RES A
   Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721
   Jasti A C, 2001, Biomed Sci Instrum, V37, P209
   Jiang LH, 2017, CELL MOL LIFE SCI, V74, P3697, DOI 10.1007/s00018 017 2545 6
   Jiang LH, 2017, J CELL PHYSIOL, V232, P287, DOI 10.1002/jcp.25484
   Karantalis V, 2015, CIRC RES, V116, P1413, DOI 10.1161/CIRCRESAHA.116.303614
   Kaszuba Zwoinska J, 2012, J PHYSIOL PHARMACOL, V63, P537
   Kim SK, 2016, J BIOMED MATER RES B, V104, P1535, DOI 10.1002/jbm.b.33498
   Lei T, 2018, BONE, V108, P10, DOI 10.1016/j.bone.2017.12.008
   Li KC, 2014, ARCH ORAL BIOL, V59, P921, DOI 10.1016/j.archoralbio.2014.05.015
   Li KC, 2014, BIOL TRACE ELEM RES, V158, P81, DOI 10.1007/s12011 014 9903 0
   Liu CX, 2017, BIOELECTROMAGNETICS, V38, P137, DOI 10.1002/bem.22022
   Liu CX, 2013, BIOELECTROMAGNETICS, V34, P453, DOI 10.1002/bem.21791
   Luo F, 2012, ORTHOPEDICS, V35, pE526, DOI 10.3928/01477447 20120327 11
   Melchionda M, 2016, J CELL BIOL, V212, P803, DOI 10.1083/jcb.201510019
   Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549
   Nitzsche F, 2017, STEM CELLS, V35, P1446, DOI 10.1002/stem.2614
   Pall ML, 2013, J CELL MOL MED, V17, P958, DOI 10.1111/jcmm.12088
   PAPATHEOFANIS FJ, 1990, RADIAT RES, V122, P24, DOI 10.2307/3577578
   Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003
   Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053
   Sohni A, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/130763
   Song MY, 2014, BIOELECTROMAGNETICS, V35, P479, DOI 10.1002/bem.21867
   Tomakidi P, 2014, CELL TISSUE RES, V357, P515, DOI 10.1007/s00441 014 1945 2
   Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395
   WALLECZEK J, 1992, FASEB J, V6, P3177, DOI 10.1096/fasebj.6.13.1397839
   Wang J, 2014, ACTA BIOMATER, V10, P975, DOI 10.1016/j.actbio.2013.10.008
   Wang R, 2016, ELECTROMAGN BIOL MED, V35, P384, DOI 10.3109/15368378.2015.1107840
   Wei CL, 2012, CURR OPIN CELL BIOL, V24, P254, DOI 10.1016/j.ceb.2011.12.002
   Xu XP, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0617 z
   Yang HJ, 2015, TISSUE ENG PT A, V21, P2629, DOI [10.1089/ten.tea.2015.0032, 10.1089/ten.TEA.2015.0032]
   Yong Y, 2016, J TISSUE ENG REGEN M, V10, pE537, DOI 10.1002/term.1864
   Yu JZ, 2014, J HUAZHONG U SCI MED, V34, P247, DOI 10.1007/s11596 014 1266 4
   Zocchi E, 1998, J BIOL CHEM, V273, P8017, DOI 10.1074/jbc.273.14.8017
NR 50
TC 48
Z9 49
U1 0
U2 19
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD MAY 21
PY 2018
VL 9
AR 143
DI 10.1186/s13287 018 0883 4
PG 10
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA GH0LN
UT WOS:000433093900001
PM 29784011
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Crivaro, AN
   Mucci, JM
   Bonder, CM
   Ormazabal, ME
   Ceci, R
   Simonaro, C
   Rozenfeld, PA
AF Crivaro, Andrea N.
   Mucci, Juan M.
   Bonder, Constanza M.
   Ormazabal, Maximiliano E.
   Ceci, Romina
   Simonaro, Calogera
   Rozenfeld, Paula A.
TI Efficacy of pentosan polysulfate in in vitro models of lysosomal
   storage disorders: Fabry and Gaucher Disease
SO PLOS ONE
LA English
DT Article
ID BONE; IMMUNE; SODIUM; CELLS
AB Gaucher and Fabry diseases are the most prevalent sphingolipidoses. Chronic inflammation is activated in those disorders, which could play a role in pathogenesis. Significant degrees of amelioration occur in patients upon introduction of specific therapies; however, restoration to complete health status is not always achieved. The idea of an adjunctive therapy that targets inflammation may be a suitable option for patients. PPS is a mixture of semisynthetic sulfated polyanions that have been shown to have anti inflammatory effects in mucopoly saccharidosis type I and II patients and animal models of type I, IIIA and VI. We hypothesized PPS could be a useful adjunctive therapy to inflammation for Gaucher and Fabry diseases. The objective of this work is to analyze the in vitro effect of PPS on inflammatory cytokines in cellular models of Gaucher and Fabry diseases, and to study its effect in Gaucher disease associated in vitro bone alterations. Cultures of peripheral blood mononuclear cells from Fabry and Gaucher patients were exposed to PPS. The secretion of proinflammatory cytokines was significantly reduced. Peripheral blood cells exposed to PPS from Gaucher patients revealed a reduced tendency to differentiate to osteoclasts. Osteoblasts and osteocytes cell lines were incubated with an inhibitor of glucocerebrosidase, and conditioned media was harvested in order to analyze if those cells secrete factors that induce osteoclastogenesis. Conditioned media from this cell cultures exposed to PPS produced lower numbers of osteoclasts. We could demonstrate PPS is an effective molecule to reduce the production of proinflammatory cytokines in in vitro models of Fabry and Gaucher diseases. Moreover, it was effective at ameliorating bone alterations of in vitro models of Gaucher disease. These results serve as preclinical supportive data to start clinical trials in human patients to analyze the effect of PPS as a potential adjunctive therapy for Fabry and Gaucher diseases.
C1 [Crivaro, Andrea N.; Mucci, Juan M.; Bonder, Constanza M.; Ormazabal, Maximiliano E.; Ceci, Romina; Rozenfeld, Paula A.] Univ Nacl La Plata, CONICET, IIFP, Fac Ciencias Exactas,Dept Ciencias Biol, La Plata, Buenos Aires, Argentina.
   [Simonaro, Calogera] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
C3 National University of La Plata; Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET); Icahn School of Medicine at Mount
   Sinai
RP Rozenfeld, PA (通讯作者)，Univ Nacl La Plata, CONICET, IIFP, Fac Ciencias Exactas,Dept Ciencias Biol, La Plata, Buenos Aires, Argentina.
EM paularozenfeld@gmail.com
OI , Paula/0000 0002 8138 3087; Ormazabal, Maximiliano
   Emanuel/0000 0003 0455 5532
CR Beck M, 2018, DEV MED CHILD NEUROL, V60, P13, DOI 10.1111/dmcn.13600
   Bondar C, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010112
   Chen KH, 2016, CAN J CARDIOL, V32, DOI 10.1016/j.cjca.2015.10.033
   De Francesco PN, 2013, MOL GENET METAB, V109, P93, DOI 10.1016/j.ymgme.2013.02.003
   Frohbergh M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100882
   Fujitsuka H, 2019, MOL GENET METAB REP, V19, DOI 10.1016/j.ymgmr.2019.100455
   GRABOWSKI GA, 2009, ONLINE METABOLIC MOL
   Grabowski GA, 2017, MOL GENET METAB, V120, P38, DOI 10.1016/j.ymgme.2016.11.388
   Grosjean F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204366
   Hennermann JB, 2016, J INHERIT METAB DIS, V39, P831, DOI 10.1007/s10545 016 9974 5
   Krüger R, 2012, J CHROMATOGR B, V883, P128, DOI 10.1016/j.jchromb.2011.11.020
   Kumar Vinay., 2012, Robbins Basic Pathology (Robbins Pathology), V9
   Liao HC, 2017, CLIN CHEM, V63, P1363, DOI 10.1373/clinchem.2016.264952
   Mathur A, 2018, J LEUKOCYTE BIOL, V103, P233, DOI 10.1189/jlb.3MR0617 250R
   Mori G, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/720504
   Morishita K, 2011, RHEUMATOLOGY, V50, pV19, DOI 10.1093/rheumatology/ker397
   Mucci JM, 2015, BLOOD CELL MOL DIS, V55, P134, DOI 10.1016/j.bcmd.2015.05.009
   Nagata M, 2017, P NATL ACAD SCI USA, V114, pE3285, DOI 10.1073/pnas.1618133114
   Nickel JC, 2005, UROLOGY, V65, P654, DOI 10.1016/j.urology.2004.10.071
   Okamoto K, 2017, PHYSIOL REV, V97, P1295, DOI 10.1152/physrev.00036.2016
   Panicker LM, 2018, HUM MOL GENET, V27, P811, DOI 10.1093/hmg/ddx442
   Rigante D, 2017, IMMUNOL LETT, V188, P79, DOI 10.1016/j.imlet.2017.07.004
   Rozenfeld P, 2017, MOL GENET METAB, V122, P19, DOI 10.1016/j.ymgme.2017.09.004
   Sadhukhan PC, 2002, J UROLOGY, V168, P289, DOI 10.1016/S0022 5347(05)64909 9
   Sampson MJ, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1754 3
   Schuchman EH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054459
   Simonaro CM, 2008, AM J PATHOL, V172, P112, DOI 10.2353/ajpath.2008.070564
   Simonaro CM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153136
   Simonaro CM, 2010, P NATL ACAD SCI USA, V107, P222, DOI 10.1073/pnas.0912937107
   Stirnemann J, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020441
   Vistnes M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089621
   Wijekoon HMS, 2018, BMC VET RES, V14, DOI 10.1186/s12917 018 1466 4
   Wu J, 2011, LAB INVEST, V91, P1459, DOI 10.1038/labinvest.2011.93
   Xiong JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138189
   Zancan I, 2015, HUM MOL GENET, V24, P1280, DOI 10.1093/hmg/ddu538
NR 35
TC 16
Z9 18
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAY 31
PY 2019
VL 14
IS 5
AR e0217780
DI 10.1371/journal.pone.0217780
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA IA7TI
UT WOS:000469759100105
PM 31150494
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Takács, I
   Jókai, E
   Kováts, DE
   Aradi, I
AF Takacs, I.
   Jokai, E.
   Kovats, D. E.
   Aradi, I.
TI The first biosimilar approved for the treatment of osteoporosis: results
   of a comparative pharmacokinetic/pharmacodynamic study
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Bioequivalence; Biosimilar; Clinical trial; Osteoporosis; Teriparatide
ID HUMAN PARATHYROID HORMONE; TERIPARATIDE; PHARMACOKINETICS; SINGLE;
   SAFETY; PHARMACODYNAMICS; TOLERABILITY; FRACTURES; DESIGN
AB The SummaryTo demonstrate the clinical comparability between RGB 10 (a biosimilar teriparatide) and the originator, a comparative pharmacokinetic trial was conducted. The study was successful in establishing bioequivalence. Marketing authorisation for RGB 10 (Terrosa (R)) was granted by the European Medicines Agency in 2017.IntroductionTeriparatide, the first bone anabolic agent, is the biologically active fragment of human parathyroid hormone. The imminent patent expiry of the originator will open the door for biosimilars to enter the osteology market, thereby improving access to a highly effective, yet prohibitively expensive therapy.MethodsSubsequent to establishing comparability on the quality and non clinical levels between RGB 10, a biosimilar teriparatide, and its reference product (Forsteo (R)), a randomised, double blind, 2 way cross over comparative study (duration: four days) was conducted in 54 healthy women (ages: 18 to 55years) to demonstrate the pharmacokinetic/pharmacodynamic (PK/PD) equivalence and comparable safety of these products. Extents of exposure (AUC(0 tlast)) and peak exposure (C max), as measured by means of ELISA, were evaluated as co primary PK endpoints, and serum calcium levels, as measured using standard automated techniques, were assessed for PD effects. Safety was monitored throughout the study.ResultsThe 94.12% CIs for the ratio of the test to the reference treatments, used due to the two stage design (85.20 98.60% and 85.51 99.52% for AUC(0 tlast) and C max, respectively), fell within the 80.00 125.00% acceptance range. The calcium PD parameters were essentially identical with geometric mean ratios (GMRs) of 99.93% and 99.87% for AUC and C max, respectively. Analysis of the safety data did not reveal any differences between RGB 10 and its reference.ConclusionBased on the high level of similarity in the preclinical data and the results of this clinical study, marketing authorisation for RGB 10 (Terrosa (R)) was granted by the European Medicines Agency (EMA) in 2017.
C1 [Takacs, I.] Semmelweis Univ, Budapest, Hungary.
   [Jokai, E.; Kovats, D. E.; Aradi, I.] Gedeon Richter Plc, 19 21 Gyomroi Ut, H 1103 Budapest, Hungary.
C3 Semmelweis University; Gedeon Richter Chemistry Works
RP Jókai, E (通讯作者)，Gedeon Richter Plc, 19 21 Gyomroi Ut, H 1103 Budapest, Hungary.
EM e.jokai@richter.hu
OI Jokai, Eniko/0000 0002 5066 8231
FU Gedeon Richter Plc.
FX The study was funded by Gedeon Richter Plc.
CR Andrews EB, 2012, J BONE MINER RES, V27, P2429, DOI 10.1002/jbmr.1768
   [Anonymous], 2010, CPMPEWPQWP140198
   [Anonymous], 1996, GUIDELINE GOOD CLIN
   [Anonymous], 2014, CHMP43704
   [Anonymous], 2017, BIOS EU INF GUID HEA
   [Anonymous], 2013, WMA DECLARATION HELS
   [Anonymous], 2007, CHMPEWP245902
   Bilezikian John P, 2008, Curr Osteoporos Rep, V6, P24, DOI 10.1007/s11914 008 0005 9
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Chu NN, 2007, PHARMAZIE, V62, P869, DOI 10.1691/ph.2007.11.7576
   Dobnig H, 2004, EXPERT OPIN PHARMACO, V5, P1153, DOI 10.1517/eoph.5.5.1153.31088
   Eriksen EF, 2014, BONE, V67, P246, DOI 10.1016/j.bone.2014.07.014
   Forsteo EPAR European Medicines Agency, 2005, EUR PUBL ASS REP SCI
   Gagnon C, 2008, CLIN INTERV AGING, V3, P635
   Gonzalez MJ, 2010, REV OSTEOPOR METAB M, V2, pS5
   Liu YN, 2014, CLIN THER, V36, P940, DOI 10.1016/j.clinthera.2014.03.015
   Liu Y, 2012, BASIC CLIN PHARMACOL, V110, P154, DOI 10.1111/j.1742 7843.2011.00768.x
   Medicines for Europe, 2016, BIOS MED HDB
   Mitlak BH, 2002, CURR OPIN PHARMACOL, V2, P694, DOI 10.1016/S1471 4892(02)00208 4
   Murad MH, 2012, J CLIN ENDOCR METAB, V97, P1871, DOI 10.1210/jc.2011 3060
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Potvin D, 2008, PHARM STAT, V7, P245, DOI 10.1002/pst.294
   Prince R, 2005, J BONE MINER RES, V20, P1507, DOI 10.1359/JBMR.050501
   Schwietert HR, 1997, CLIN PHARMACOL THER, V61, P360, DOI 10.1016/S0009 9236(97)90169 7
   Shiraki M, 2013, OSTEOPOROSIS INT, V24, P219, DOI 10.1007/s00198 012 2159 7
NR 25
TC 17
Z9 17
U1 1
U2 8
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD MAR
PY 2019
VL 30
IS 3
BP 675
EP 683
DI 10.1007/s00198 018 4741 0
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA HP3KW
UT WOS:000461576600017
PM 30357438
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Huang, B
   Wang, JS
   Zhang, XY
   Xie, ZA
   Wu, H
   Liu, JH
   Jie, ZW
   Zhao, XD
   Qin, A
   Fan, SW
   Chen, J
   Zhao, FD
AF Huang, Bao
   Wang, Jiasheng
   Zhang, Xuyang
   Xie, Ziang
   Wu, Hao
   Liu, Junhui
   Jie, Zhiwei
   Zhao, Xiangde
   Qin, An
   Fan, Shunwu
   Chen, Jian
   Zhao, Fengdong
TI Administration of SB239063 Ameliorates Ovariectomy Induced Bone Loss
   via Suppressing Osteoclastogenesis in Mice
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE SB239063; osteoclastogenesis; c Fos; MEF2C; p38; bone loss
ID MYOCYTE ENHANCER FACTOR 2; NF KAPPA B; MAP KINASE; C FOS;
   TRANSCRIPTIONAL ACTIVITY; GROWTH FACTOR; FACTOR 2C; IN VITRO;
   ACTIVATION; P38
AB Activation of osteoclast formation and function is crucial for the development of osteolytic diseases such as osteoporosis. RANKL (receptor activator of nuclear factor kappa B ligand) activates NF kappa B (nuclear factor kappa B), MAPK (mitogen activated protein kinase), and NFATc1 (nuclear factor of activated T cells, cytoplasmic 1) signaling pathways to induce osteoclastogenesis. In this study, we demonstrated that SB239063, a p38 specific inhibitor, suppressed osteoclastogenesis and bone resorption via inhibiting phosphorylation of MEF2C (myocyte enhancer factor 2C) and subsequently leading to MEF2C degradation by ubiquitination. Knockdown of MEF2C impaired osteoclast formation due to decreased c Fos expression. Furthermore, MEF2C can directly bind to the promoter region of c Fos to initiate its transcription. Interestingly, overexpression of either MEF2C or c Fos can partially rescue the inhibitory effect of SB239063 on osteoclastogenesis. In addition, in vivo data proved that SB239063 also played a preventive role in both LPS (lipopolysaccharide) and OVX (ovariectomy) induced bone loss in mice. In conclusion, our results show that SB239063 can be a potential therapy for osteolytic diseases, and a novel p38/MEF2C/c Fos axis is essential for osteoclastogenesis.
C1 [Huang, Bao; Wang, Jiasheng; Zhang, Xuyang; Xie, Ziang; Wu, Hao; Liu, Junhui; Jie, Zhiwei; Zhao, Xiangde; Fan, Shunwu; Chen, Jian; Zhao, Fengdong] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Orthopaed Surg, Hangzhou, Zhejiang, Peoples R China.
   [Huang, Bao; Wang, Jiasheng; Zhang, Xuyang; Xie, Ziang; Wu, Hao; Liu, Junhui; Jie, Zhiwei; Zhao, Xiangde; Fan, Shunwu; Chen, Jian; Zhao, Fengdong] Key Lab Musculoskeletal Syst Degenerat & Regenera, Hangzhou, Zhejiang, Peoples R China.
   [Qin, An] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Shanghai Key Lab Orthopaed Implant,Dept Orthopaed, Shanghai, Peoples R China.
C3 Zhejiang University; Shanghai Jiao Tong University
RP Chen, J; Zhao, FD (通讯作者)，Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Orthopaed Surg, Hangzhou, Zhejiang, Peoples R China.; Chen, J; Zhao, FD (通讯作者)，Key Lab Musculoskeletal Syst Degenerat & Regenera, Hangzhou, Zhejiang, Peoples R China.
EM chenjian bio@zju.edu.cn; zhaofengdong@zju.edu.cn
RI zhang, xuyang/GQH 3712 2022; Qin, An/J 2518 2019
OI Jie, Zhiwei/0000 0002 9469 4490; Zhang, Xuyang/0000 0002 4665 3934;
   Chen, Jian/0000 0001 8568 9991
FU Natural Science Foundation of China [81672208]
FX This study is sponsored by the Natural Science Foundation of China (no.
   81672208). We thank Xiaozhen Zhang for MEF2C plasmid; Qingxiao Chen for
   providing the part of MCSF and RANKL.
CR Agusti A, 2011, GUT, V60, P1572, DOI 10.1136/gut.2010.236083
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   ASH P, 1980, NATURE, V283, P669, DOI 10.1038/283669a0
   Bai XL, 2015, ONCOGENE, V34, P4089, DOI 10.1038/onc.2014.337
   Borghi S, 2001, J CELL SCI, V114, P4477
   Brown FC, 2018, CANCER DISCOV, V8, P478, DOI 10.1158/2159 8290.CD 17 1271
   Canté Barrett K, 2014, ONCOGENE, V33, P403, DOI 10.1038/onc.2013.56
   Chawalitpong S, 2016, EUR J PHARMACOL, V788, P351, DOI 10.1016/j.ejphar.2016.08.012
   Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724
   de Angelis L, 2005, DEV BIOL, V283, P171, DOI 10.1016/j.ydbio.2005.04.009
   De Angelis L, 1998, P NATL ACAD SCI USA, V95, P12358, DOI 10.1073/pnas.95.21.12358
   Deepak V, 2015, BIOFACTORS, V41, P403, DOI 10.1002/biof.1241
   Feng HT, 2009, J BIOL CHEM, V284, P14667, DOI 10.1074/jbc.M901670200
   Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0
   HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092 8674(95)90403 4
   Hu XY, 2017, ACTA BIOMATER, V48, P479, DOI 10.1016/j.actbio.2016.11.022
   Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955 0674(97)80068 3
   Kramer I, 2012, J BONE MINER RES, V27, P360, DOI 10.1002/jbmr.1492
   Langfermann DS, 2018, MOL CELL ENDOCRINOL, V472, P126, DOI 10.1016/j.mce.2017.12.003
   Li CH, 2011, J BONE MINER RES, V26, P644, DOI 10.1002/jbmr.242
   Li JK, 2016, J TRANSL MED, V14, DOI 10.1186/s12967 016 0833 9
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Maedler K, 2008, FASEB J, V22, P1905, DOI 10.1096/fj.07 101824
   Monje P, 2005, J BIOL CHEM, V280, P35081, DOI 10.1074/jbc.C500353200
   Nakatani T, 2017, ENDOCRINOLOGY, V158, P3778, DOI 10.1210/en.2017 00159
   Naya FJ, 1999, DEVELOPMENT, V126, P2045
   Okamoto S, 2000, P NATL ACAD SCI USA, V97, P7561, DOI 10.1073/pnas.130502697
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   SCHEVEN BAA, 1986, NATURE, V321, P79, DOI 10.1038/321079a0
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955 0674(96)80067 6
   Tu XL, 2015, P NATL ACAD SCI USA, V112, pE478, DOI 10.1073/pnas.1409857112
   Vaira S, 2008, J CLIN INVEST, V118, P2088, DOI 10.1172/JCI33392
   Wang LJ, 2018, FASEB J, V32, P875, DOI 10.1096/fj.201700672RR
   Wei CM, 2018, J CELL PHYSIOL, V233, P476, DOI 10.1002/jcp.25907
   Xie Z, 2018, J BONE MINER RES, V33, P667, DOI 10.1002/jbmr.3334
   Xiong LL, 2016, INT IMMUNOPHARMACOL, V38, P54, DOI 10.1016/j.intimp.2016.03.036
   Yu CH, 2018, J OBSTET GYNAECOL RE, V44, P253, DOI 10.1111/jog.13498
   Zhang JJ, 2014, MOL CANCER, V13, DOI 10.1186/1476 4598 13 130
   Zhao JJ, 2018, J CELL PHYSIOL, V233, P7182, DOI 10.1002/jcp.26548
NR 41
TC 5
Z9 6
U1 0
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD AUG 15
PY 2019
VL 10
AR 900
DI 10.3389/fphar.2019.00900
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA IQ4HH
UT WOS:000480711200001
PM 31474861
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yang, F
   Lu, JW
   Ke, QF
   Peng, XY
   Guo, YP
   Xie, XT
AF Yang, Fan
   Lu, Jiawei
   Ke, Qinfei
   Peng, Xiaoyuan
   Guo, Yaping
   Xie, Xuetao
TI Magnetic Mesoporous Calcium Sillicate/Chitosan Porous Scaffolds for
   Enhanced Bone Regeneration and Photothermal Chemotherapy of Osteosarcoma
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GLUCOCORTICOID INDUCED OSTEONECROSIS; FERRITE NANOPARTICLES; GOLD
   NANORODS; FEMORAL HEAD; IN VITRO; CELLS; OSTEOBLAST; DELIVERY; DRUG
AB The development of multifunctional biomaterials to repair bone defects after neoplasm removal and inhibit tumor recurrence remained huge clinical challenges. Here, we demonstrate a kind of innovative and multifunctional magnetic mesoporous calcium sillicate/chitosan (MCSC) porous scaffolds, made of M type ferrite particles (SrFe12O19), mesoporous calcium silicate (CaSiO3) and chitosan (CS), which exert robust anti tumor and bone regeneration properties. The mesopores in the CaSiO3 microspheres contributed to the drug delivery property, and the SrFe12O19 particles improved photothermal therapy (PTT) conversion efficacy. With the irradiation of NIR laser, doxorubicin (DOX) was rapidly released from the MCSC/DOX scaffolds. In vitro and in vivo tests demonstrated that the MCSC scaffolds possessed the excellent anti tumor efficacy via the synergetic effect of DOX drug release and hyperthermia ablation. Moreover, BMP 2/Smad/Runx2 pathway was involved in the MCSC scaffolds promoted proliferation and osteogenic differentiation of human bone marrow stromal cells (hBMSCs). Taken together, the MCSC scaffolds have the ability to promote osteogenesis and enhance synergetic photothermal chemotherapy against osteosarcoma, indicating MCSC scaffolds may have great application potential for bone tumor related defects.
C1 [Yang, Fan; Peng, Xiaoyuan; Xie, Xuetao] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Orthoped Surg, Shanghai, Peoples R China.
   [Lu, Jiawei; Ke, Qinfei; Guo, Yaping] Shanghai Normal Univ, Educ Minist, Key Lab Resource Chem, Shanghai, Peoples R China.
   [Lu, Jiawei; Ke, Qinfei; Guo, Yaping] Shanghai Normal Univ, Educ Minist, Shanghai Key Lab Rare Earth Funct Mat, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Normal University; Shanghai
   Normal University
RP Xie, XT (通讯作者)，Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Orthoped Surg, Shanghai, Peoples R China.; Guo, YP (通讯作者)，Shanghai Normal Univ, Educ Minist, Key Lab Resource Chem, Shanghai, Peoples R China.; Guo, YP (通讯作者)，Shanghai Normal Univ, Educ Minist, Shanghai Key Lab Rare Earth Funct Mat, Shanghai, Peoples R China.
EM ypguo@shnu.edu.cn; Xuetaoxie@outlook.com
RI ; Yang, Fan/LGY 6359 2024
OI Guo, Ya Ping/0000 0002 5450 2968; peng, xiao yuan/0000 0003 2302 362X; 
FU Natural Science Foundation of China [51372152]; Innovation Foundation of
   Shanghai Education Committee [14ZZ124]; Key Disciplines of Shanghai
   Municipal Education Commission [J50206]; National High Technology
   Research and Development Program of China [2012AA020506]; "Priority
   Among Priorities" Clinical Medical Center Construction Project of the
   Shanghai Municipal; Science and Technology Commission of Shanghai
   Municipality [12JC1405600]
FX This research was supported by Natural Science Foundation of China (no.
   51372152), Innovation Foundation of Shanghai Education Committee (no.
   14ZZ124), Key Disciplines of Shanghai Municipal Education Commission
   (no. J50206), National High Technology Research and Development Program
   of China (2012AA020506), "Priority Among Priorities" Clinical Medical
   Center Construction Project of the Shanghai Municipal, Science and
   Technology Commission of Shanghai Municipality (no. 12JC1405600).
CR Adams CF, 2013, NANOMED NANOTECHNOL, V9, P737, DOI 10.1016/j.nano.2013.05.014
   Alpaslan E, 2015, ACS BIOMATER SCI ENG, V1, P1096, DOI 10.1021/acsbiomaterials.5b00194
   [Anonymous], 2016, Math Probl Eng
   Boda SK, 2017, ACS APPL MATER INTER, V9, P19389, DOI 10.1021/acsami.6b08694
   Oliveira ABB, 2016, J PROTEOME RES, V15, P4337, DOI 10.1021/acs.jproteome.6b00411
   Chen F, 2016, ACS NANO, V10, P11483, DOI 10.1021/acsnano.6b07239
   Cheng L, 2014, CHEM REV, V114, P10869, DOI 10.1021/cr400532z
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   De Santis R, 2015, J BIOMED NANOTECHNOL, V11, P1236, DOI 10.1166/jbn.2015.2065
   Dinarvand R, 2006, DRUG DELIV, V13, P345, DOI 10.1080/10717540500394729
   Guo YP, 2015, J MATER CHEM B, V3, P4679, DOI 10.1039/c5tb00175g
   Han N, 2016, J CELL MOL MED, V20, P2173, DOI 10.1111/jcmm.12917
   Hartung A, 2006, MOL CELL BIOL, V26, P7791, DOI 10.1128/MCB.00022 06
   Huang MH, 2016, MAT SCI ENG C MATER, V65, P1, DOI 10.1016/j.msec.2016.04.016
   Jaque D, 2014, NANOSCALE, V6, P9494, DOI 10.1039/c4nr00708e
   Kaneti YV, 2015, ACS APPL MATER INTER, V7, P25658, DOI 10.1021/acsami.5b07975
   Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601 0825.2002.01829.x
   Kim EC, 2015, BIOELECTROMAGNETICS, V36, P267, DOI 10.1002/bem.21903
   Kolosnjaj Tabi J, 2014, ACS NANO, V8, P4268, DOI 10.1021/nn405356r
   Kotani H, 2002, J BONE MINER RES, V17, P1814, DOI 10.1359/jbmr.2002.17.10.1814
   Lee JH, 2017, ACTA BIOMATER, V60, P93, DOI 10.1016/j.actbio.2017.07.021
   Lei Y, 2015, RSC ADV, V5, P25462, DOI 10.1039/c5ra01628b
   Li KC, 2016, ACS APPL MATER INTER, V8, P12082, DOI 10.1021/acsami.6b04579
   Li ZB, 2016, BIOMATERIALS, V74, P144, DOI 10.1016/j.biomaterials.2015.09.038
   Liu WQ, 2018, CANCER LETT, V414, P88, DOI 10.1016/j.canlet.2017.10.039
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   Ma HC, 2015, ACS APPL MATER INTER, V7, P27040, DOI 10.1021/acsami.5b09112
   Marycz K, 2017, CELL MOL BIOENG, V10, P209, DOI 10.1007/s12195 017 0480 0
   Matsuzaki S, 2018, INT J CANCER, V142, P1056, DOI 10.1002/ijc.31124
   Meijer TWH, 2012, CLIN CANCER RES, V18, P5585, DOI 10.1158/1078 0432.CCR 12 0858
   Qin D, 2016, ONCOTARGET, V7, P77096, DOI 10.18632/oncotarget.12801
   Ravarian R, 2013, ACS NANO, V7, P8469, DOI 10.1021/nn402157n
   Rossella F, 2012, ADV MATER, V24, P2453, DOI 10.1002/adma.201104393
   Tan GL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167084
   Tu MG, 2015, J MATER SCI MATER M, V26, DOI 10.1007/s10856 015 5607 z
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   Verron E, 2014, DRUG DISCOV TODAY, V19, P1419, DOI 10.1016/j.drudis.2014.04.004
   Volsi AL, 2017, ACS APPL MATER INTER, V9, P14453, DOI 10.1021/acsami.7b03711
   Young JK, 2012, ANN BIOMED ENG, V40, P438, DOI 10.1007/s10439 011 0472 5
   Yuan A, 2015, BIOMATERIALS, V51, P184, DOI 10.1016/j.biomaterials.2015.01.069
   Yue CX, 2013, BIOMATERIALS, V34, P6853, DOI 10.1016/j.biomaterials.2013.05.071
   Zhang NL, 2013, BIOMATER SCI UK, V1, P1101, DOI 10.1039/c3bm60034c
   Zhang XM, 2014, J MATER CHEM B, V2, P885, DOI 10.1039/c3tb21441a
   Zhang YL, 2016, INT J BIOL SCI, V12, P347, DOI 10.7150/ijbs.13269
   Zhang YL, 2016, INT J BIOL SCI, V12, P776, DOI 10.7150/ijbs.15248
   Zhao YJ, 2015, ACS APPL MATER INTER, V7, P14231, DOI 10.1021/acsami.5b01873
   Zhou ZG, 2014, BIOMATERIALS, V35, P7470, DOI 10.1016/j.biomaterials.2014.04.063
NR 47
TC 59
Z9 63
U1 1
U2 105
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD MAY 9
PY 2018
VL 8
AR 7345
DI 10.1038/s41598 018 25595 2
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA GF1ZX
UT WOS:000431737300031
PM 29743489
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Cabal, A
   Mehta, K
   Ross, DS
   Shrestha, RP
   Comisar, W
   Denker, A
   Pai, SM
   Ishikawa, T
AF Cabal, Antonio
   Mehta, Khamir
   Ross, David S.
   Shrestha, Rajiv P.
   Comisar, Wendy
   Denker, Andrew
   Pai, Sudhakar M.
   Ishikawa, Tomohiro
TI A semimechanistic model of the time course of release of PTH into plasma
   following administration of the calcilytic JTT 305/MK 5442 in humans
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE CALCILYTIC; MECHANISTIC PK; PD; MODELING; JTT 305; MK 5442; OSTEOPOROSIS
ID CALCIUM SENSING RECEPTOR; BONE MINERAL DENSITY; PARATHYROID HORMONE;
   POSTMENOPAUSAL WOMEN; OSTEOPOROSIS; ANTAGONIST; MECHANISMS; SECRETION;
   JTT 305; RATS
AB JTT 305/MK 5442 is a calcium sensing receptor (CaSR) allosteric antagonist being investigated for the treatment of osteoporosis. JTT 305/MK 5442 binds to CaSRs, thus preventing receptor activation by Ca2+. In the parathyroid gland, this results in the release of parathyroid hormone (PTH). Sharp spikes in PTH secretion followed by rapid returns to baseline are associated with bone formation, whereas sustained elevation in PTH is associated with bone resorption. We have developed a semimechanistic, nonpopulation model of the time course relationship between JTT 305/MK 5442 and whole plasma PTH concentrations to describe both the secretion of PTH and the kinetics of its return to baseline levels. We obtained mean concentration data for JTT 305/MK 5442 and whole PTH from a multiple dose study in U. S. postmenopausal women at doses of 5, 10, 15, and 20 mg. We hypothesized that PTH is released from two separate sources: a reservoir that is released rapidly (within minutes) in response to reduction in Ca2+ binding, and a second source released more slowly following hours of reduced Ca2+ binding. We modeled the release rates of these reservoirs as maximum pharmacologic effect (E max) functions of JTT 305/MK 5442 concentration. Our model describes both the dose dependence of PTH time of occurrence for maximum drug concentration (T max) and maximum concentration of drug (C max), and the extent and duration of the observed nonmonotonic return of PTH to baseline levels following JTT 305/MK 5442 administration. (C) 2013 American Society for Bone and Mineral Research.
C1 [Cabal, Antonio] Merck & Co Inc, Early Stage Dev ESD Modeling & Simulat, Upper Gwynedd, PA USA.
   [Mehta, Khamir] Merck & Co Inc, Appl Comp Sci & Math, West Point, PA USA.
   [Ross, David S.] Rochester Inst Technol, Sch Math Sci, Rochester, NY 14623 USA.
   [Shrestha, Rajiv P.] Univ Massachusetts, Dept Mech & Ind Engn, Amherst, MA 01003 USA.
   [Comisar, Wendy] Merck & Co Inc, Clin Pharmacokinet Pharmacodynam PK PD, West Point, PA USA.
   [Denker, Andrew] Merck & Co Inc, Project Leadership Management PLM Oncol, Kenilworth, NJ USA.
   [Pai, Sudhakar M.] Akros Pharma Inc, Clin Pharmacol, Princeton, NJ USA.
   [Ishikawa, Tomohiro] Japan Tobacco Inc, Clin Dev Dept, Clin Pharmacol, Tokyo, Japan.
   Merck & Co Inc, Boston, MA USA.
C3 Merck & Company; Merck & Company USA; Merck & Company; Merck & Company
   USA; Rochester Institute of Technology; University of Massachusetts
   System; University of Massachusetts Amherst; Merck & Company; Merck &
   Company USA; Merck & Company; Merck & Company USA; Japan Tobacco Inc.;
   Merck & Company; Merck & Company USA
RP Cabal, A (通讯作者)，Merck Sharpe & Dohme Inc, N Wales, PA 19454 USA.
EM antonio.cabal@merck.com
RI Ishikawa, Tomohiro/MCB 0126 2025
FU Merck Sharp Dohme Corp.
FX AC, KM, WC, RPS, and AD are employees of Merck Sharp & Dohme Corp. and
   may own stock options in the company. DSR has received consultancy fees
   from Merck Sharp & Dohme Corp. TI is an employee of Japan Tobacco. SMP
   has no conflicts of interest.
CR Abraham AK, 2009, J PHARMACOL EXP THER, V330, P169, DOI 10.1124/jpet.109.152033
   Brown E M, 2000, Rev Endocr Metab Disord, V1, P307, DOI 10.1023/A:1026570518919
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Cosman F, 2010, J CLIN ENDOCR METAB, V95, P151, DOI 10.1210/jc.2009 0358
   Fitzpatrick LA, 2011, J CLIN ENDOCR METAB, V96, P2441, DOI 10.1210/jc.2010 2855
   Frolik CA, 2003, BONE, V33, P372, DOI 10.1016/S8756 3282(03)00202 3
   Fukumoto S, 2011, BONE, V48, pS76, DOI 10.1016/j.bone.2011.03.091
   Fukumoto S, 2009, J BONE MINER RES  S1, V24, pS40
   Fukumoto Seiji, 2011, Clin Calcium, V21, P89, DOI CliCa11018993
   Goodman WG, 2001, KIDNEY INT, V59, P1187, DOI 10.1046/j.1523 1755.2001.0590031187.x
   HOCK JM, 1992, J BONE MINER RES, V7, P65, DOI 10.1002/jbmr.5650070110
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Joseph F, 2007, J CLIN ENDOCR METAB, V92, P3230, DOI 10.1210/jc.2006 1832
   Kimura S, 2011, J BONE MINER RES  S1, V26, pS149
   Kimura S, 2011, EUR J PHARMACOL, V668, P331, DOI 10.1016/j.ejphar.2011.07.015
   Mager DE, 2003, DRUG METAB DISPOS, V31, P510, DOI 10.1124/dmd.31.5.510
   Moen MD, 2006, DRUGS, V66, P2371, DOI 10.2165/00003495 200666180 00008
   Nemeth EF, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290015
   RITCHIE CK, 1992, ENDOCRINOLOGY, V131, P2638, DOI 10.1210/en.131.6.2638
   Schwietert HR, 1997, CLIN PHARMACOL THER, V61, P360, DOI 10.1016/S0009 9236(97)90169 7
   Sharma A, 1998, J PHARM SCI, V87, P1577, DOI 10.1021/js980171q
   Shinagawa Y, 2011, ACS MED CHEM LETT, V2, P238, DOI 10.1021/ml100268k
   Shrestha RP, 2010, MATH BIOSCI, V226, P46, DOI 10.1016/j.mbs.2010.04.001
   Yano S, 2005, MOL B INT U, P44, DOI 10.1007/0 387 27530 4_4
NR 24
TC 9
Z9 11
U1 0
U2 5
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD AUG
PY 2013
VL 28
IS 8
BP 1830
EP 1836
DI 10.1002/jbmr.1900
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 185EU
UT WOS:000321949200017
PM 23436611
OA Bronze
DA 2025 08 17
ER

PT J
AU Coenegrachts, L
   Maes, C
   Torrekens, S
   Van Looveren, R
   Mazzone, M
   Guise, TA
   Bouillon, R
   Stassen, JM
   Carmeliet, P
   Carmeliet, G
AF Coenegrachts, Lieve
   Maes, Christa
   Torrekens, Sophie
   Van Looveren, Riet
   Mazzone, Massimiliano
   Guise, Theresa A.
   Bouillon, Roger
   Stassen, Jean Marie
   Carmeliet, Peter
   Carmeliet, Geert
TI Anti Placental Growth Factor Reduces Bone Metastasis by Blocking Tumor
   Cell Engraftment and Osteoclast Differentiation
SO CANCER RESEARCH
LA English
DT Article
ID BREAST CANCER CELLS; COLONY STIMULATING FACTOR; ANGIOGENESIS; PLGF;
   SURVIVAL; MICROENVIRONMENT; INHIBITION; EXPRESSION; RECEPTOR; BLOCKADE
AB Treatment of bone metastases is largely symptomatic and is still an unmet medical need. Current therapies mainly target the late phase of tumor induced osteoclast activation and hereby inhibit further metastatic growth. This treatment method is, however, less effective in preventing initial tumor engraftment, a process that is supposed to depend on the bone microenvironment. We explored whether bone derived placental growth factor (PlGF), a homologue of vascular endothelial growth factor A, regulates osteolytic metastasis. Osteogenic cells secrete PlGF, the expression of which is enhanced by bone metastasizing breast tumor cells. Selective neutralization of host derived PlGF by anti mouse PlGF (alpha PlGF) reduced the incidence, number, and size of bone metastases, and preserved bone mass. alpha PlGF did not affect metastatic tumor angiogenesis but inhibited osteoclast formation by preventing the upregulation of the osteoclastogenic cytokine receptor activator of NF kappa B ligand in osteogenic cells, as well as by blocking the autocrine osteoclastogenic activity of PlGF. alpha PlGF also reduced the engraftment of tumor cells in the bone and inhibited their interaction with matrix components in the metastatic niche. alpha PlGF therefore inhibits not only the progression of metastasis but also the settlement of tumor in the bone. These findings identify novel properties of PlGF and suggest that alpha PlGF might offer opportunities for adjuvant therapy of bone metastasis. Cancer Res; 70(16); 6537 47. (C)2010 AACR.
C1 [Coenegrachts, Lieve; Maes, Christa; Torrekens, Sophie; Van Looveren, Riet; Bouillon, Roger; Carmeliet, Geert] Katholieke Univ Leuven, Lab Expt Med & Endocrinol, B 3000 Louvain, Belgium.
   [Mazzone, Massimiliano; Carmeliet, Peter] Katholieke Univ Leuven, Vesalius Res Ctr, VIB, B 3000 Louvain, Belgium.
   [Stassen, Jean Marie] ThromboGen NV, Leuven, Belgium.
   [Guise, Theresa A.] Indiana Univ, Sch Med, Dept Internal Med, Indianapolis, IN USA.
C3 KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven;
   Indiana University System; Indiana University Indianapolis
RP Carmeliet, G (通讯作者)，Katholieke Univ Leuven, Lab Expt Med & Endocrinol, O&N 1,Herestr 49,Bus 902, B 3000 Louvain, Belgium.
EM Geert.Carmeliet@med.kuleuven.be
RI ; Carmeliet, Peter/AAQ 5140 2020; Mazzone, Massimiliano/NIV 0920 2025
OI Carmeliet, Peter/0000 0001 7961 1821; Mazzone,
   Massimiliano/0000 0001 8824 4015; Maes, Christa/0000 0003 4243 5486
FU Fund for Scientific Research Flanders (FWO) [G.0229.04, G.0500.08,
   SCIE2006 31, EF/05/08]; Flemish Government; FWO; Interuniversitaire
   Attractiepolen
FX Fund for Scientific Research Flanders (FWO; G.0229.04, G.0500.08),
   "Stichting tegen Kanker" (SCIE2006 31), and Center of Excellence
   (Mosaic, EF/05/08; G. Carmeliet); and Long Term Structural Methusalem
   Funding by the Flemish Government and projects funded by FWO and
   Interuniversitaire Attractiepolen (P. Carmeliet). C. Maes is a
   postdoctoral fellow of the FWO.
CR Aldridge SE, 2005, BRIT J CANCER, V92, P1531, DOI 10.1038/sj.bjc.6602417
   Aldridge SE, 2005, BIOCHEM BIOPH RES CO, V335, P793, DOI 10.1016/j.bbrc.2005.07.145
   Alix Panabières C, 2008, CLIN CANCER RES, V14, P5013, DOI 10.1158/1078 0432.CCR 07 5125
   ARGUELLO F, 1988, CANCER RES, V48, P6876
   Bäuerle T, 2008, NEOPLASIA, V10, P511, DOI 10.1593/neo.08220
   Bais C, 2010, CELL, V141, P166, DOI 10.1016/j.cell.2010.01.033
   Barkan D, 2008, CANCER RES, V68, P6241, DOI 10.1158/0008 5472.CAN 07 6849
   Blair JM, 2006, NAT CLIN PRACT ONCOL, V3, P41, DOI 10.1038/ncponc0381
   Braun S, 2005, NEW ENGL J MED, V353, P793, DOI 10.1056/NEJMoa050434
   Burger JA, 2009, LEUKEMIA, V23, P43, DOI 10.1038/leu.2008.299
   Bussard KM, 2008, CANCER METAST REV, V27, P41, DOI 10.1007/s10555 007 9109 4
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Chen XD, 2007, J BONE MINER RES, V22, P1943, DOI 10.1359/JBMR.070725
   Chirgwin JM, 2007, J CELL BIOCHEM, V102, P1333, DOI 10.1002/jcb.21556
   Coleman RE, 2008, BRIT J CANCER, V98, P1736, DOI 10.1038/sj.bjc.6604382
   Daci E, 1999, J BONE MINER RES, V14, P946, DOI 10.1359/jbmr.1999.14.6.946
   Dawson MR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006525
   Fischer C, 2007, CELL, V131, P463, DOI 10.1016/j.cell.2007.08.038
   Fischer C, 2008, NAT REV CANCER, V8, P942, DOI 10.1038/nrc2524
   Guise TA, 2002, BONE, V30, P670, DOI 10.1016/S8756 3282(02)00685 3
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Kang SY, 2008, APMIS, V116, P638, DOI 10.1111/j.1600 0463.2008.01138.x
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186
   Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596
   Khurana R, 2005, CIRCULATION, V111, P2828, DOI 10.1161/CIRCULATIONAHA.104.495887
   Lipton A, 2007, ONCOLOGIST, V12, P1035, DOI 10.1634/theoncologist.12 9 1035
   Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731
   Maes C, 2006, J CLIN INVEST, V116, P1230, DOI 10.1172/JCI26772
   Masuyama R, 2008, CELL METAB, V8, P257, DOI 10.1016/j.cmet.2008.08.002
   Masuyama R, 2006, J CLIN INVEST, V116, P3150, DOI 10.1172/JCI29463
   Matsumoto K, 2003, ANTICANCER RES, V23, P4953
   Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320
   Niida S, 1999, J EXP MED, V190, P293, DOI 10.1084/jem.190.2.293
   Niida S, 2005, P NATL ACAD SCI USA, V102, P14016, DOI 10.1073/pnas.0503544102
   NORDAHL J, 1995, CALCIFIED TISSUE INT, V57, P442, DOI 10.1007/BF00301948
   Parr C, 2005, EUR J CANCER, V41, P2819, DOI 10.1016/j.ejca.2005.07.022
   Pipp F, 2003, CIRC RES, V92, P378, DOI 10.1161/01.RES.0000057997.77714.72
   Raemaekers T, 2003, J CELL BIOL, V162, P1017, DOI 10.1083/jcb.200302129
   Rennebeck G, 2005, CANCER RES, V65, P11230, DOI 10.1158/0008 5472.CAN 05 2763
   Sangai T, 2008, CLIN EXP METASTAS, V25, P401, DOI 10.1007/s10585 008 9144 8
   Sawano A, 2001, BLOOD, V97, P785, DOI 10.1182/blood.V97.3.785
   Selvaraj SK, 2003, BLOOD, V102, P1515, DOI 10.1182/blood 2002 11 3423
   Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469
   Taylor AP, 2007, MOL CANCER THER, V6, P524, DOI 10.1158/1535 7163.MCT 06 0461
   Van de Veire S, 2010, CELL, V141, P178, DOI 10.1016/j.cell.2010.02.039
   Wu D, 2007, ONCOGENE, V26, P5070, DOI 10.1038/sj.onc.1210316
   Xu L, 2006, CANCER RES, V66, P3971, DOI 10.1158/0008 5472.CAN 04 3085
   Yasunori K, 2008, CLIN RHEUMATOL, V27, P1093, DOI 10.1007/s10067 008 0870 8
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017
NR 51
TC 43
Z9 46
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 0008 5472
EI 1538 7445
J9 CANCER RES
JI Cancer Res.
PD AUG 15
PY 2010
VL 70
IS 16
BP 6537
EP 6547
DI 10.1158/0008 5472.CAN 09 4092
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 638IK
UT WOS:000280887000016
PM 20682798
OA Bronze, Green Submitted
DA 2025 08 17
ER

PT J
AU Acevedo Olvera, LF
   Diaz Garcia, H
   Rodríguez Cortes, O
   Campos Rodríguez, RR
   Cáceres Cortes, J
   Araujo Alvarez, JM
   Parra Barrera, A
   Gutiérrez Iglesias, G
AF Acevedo Olvera, L. F.
   Diaz Garcia, H.
   Rodriguez Cortes, O.
   Campos Rodriguez, R. R.
   Caceres Cortes, J.
   Araujo Alvarez, J. M.
   Parra Barrera, A.
   Gutierrez Iglesias, G.
TI EFFECT OF DEHYDROEPIANDROSTERONE ON EXPRESSION OF BMP2, SPARC AND RUNX2
   IN HUMAN BONE MARROW MESENCHYMAL STEM CELLS
SO REVISTA MEXICANA DE INGENIERIA QUIMICA
LA English
DT Article
DE mesenchymal stem cells; dehydroepiandrosterone; osteogenic
   differentiation
ID OSTEOBLAST DIFFERENTIATION; DHEA; MEN; TRANSCRIPTION; PATHWAY; SULFATE;
   GROWTH; WOMEN; SUPPLEMENTATION; EXPANSION
AB Osteoporosis, characterized by diminished bone mineral density (BMD) and augmented susceptibility to fractures, is tied to a low level of the suprarenal steroid called dehydroepiandrosterone (DHEA). when administrated in hormonal replacement therapy, DHEA improves BMD. Although there are various physical and drug treatments to prevent bone loss, the results have generally been poor. For this reason, cellular therapy based on the application of mesenchymal stem cells has emerged as an attractive alternative. In this study the effect of DHEA on osteogenic gene expression of human bone marrow mesenchymal stem cells (hBM MSCs). Cell population obtained was characterized as having fibroblastoid morphology and the expression of antigens positive for CD90, CD73, CD13 and CD105. The plasticity of hBM MSCs was evident and corroboratedby adipocytes and osteoblast differentiation. DHEA concentration used in all experiments were 1, 10 and 100 mu M during seven days and after the expression of mRNA BMP2, RUNX2 and SPARC (the main involved genes on osteogenic differentiation) was evaluated. Results showed that all DBEA concentration induced high expression on mRNA of BMP2, RUNX2 and SPARC. However, DHEA at 1 mu M induced a higher. Accumulation of extracellular Ca++ which it's a characteristic for bone formation. This work confirms that DHEA could be considered an alternative in the treatment of bOne diseases.
C1 [Acevedo Olvera, L. F.; Diaz Garcia, H.; Rodriguez Cortes, O.; Campos Rodriguez, R. R.; Caceres Cortes, J.; Araujo Alvarez, J. M.; Parra Barrera, A.; Gutierrez Iglesias, G.] Inst Politecn Nacl, Escuela Super Med, Dept Posgrad, Mexico City 11340, DF, Mexico.
C3 Instituto Politecnico Nacional   Mexico
RP Parra Barrera, A (通讯作者)，Inst Politecn Nacl, Escuela Super Med, Dept Posgrad, Mexico City 11340, DF, Mexico.
EM alberto_parrabl@hotmail.com; iglesiasgg@yahoo.com
FU Consejo Nacional de Ciencia y Tecnologia (CONACyT) [273099, 263830];
   BEIFI; SIP [20131092]; Academy of Finland (AKA) [273099] Funding Source:
   Academy of Finland (AKA)
FX We thank Hospital General de Puebla "Dr. Eduardo Vazquez Navarro" and
   the Centro Nacional de la Transfusion Sanguinea (Mexico City).
   Acevedo Olvera L.F. and Diaz Garcia H., PhD students in the Escuela
   Superior de Medicina, Institute Politecnico Nacional, are grateful for
   grants received from Consejo Nacional de Ciencia y Tecnologia (CONACyT:
   scholarship.# 273099 and 263830, respectively). This work was supported
   by the BEIFI and SIP (project # 20131092).
CR Andrade Zaldívar H, 2014, REV MEX ING QUIM, V13, P379
   Arlt W, 2001, J CLIN ENDOCR METAB, V86, P4686, DOI 10.1210/jc.86.10.4686
   Baeza Jimenez R., 2014, REV MEX ING QUIM, V13, P2947
   BARRETTCONNOR E, 1986, NEW ENGL J MED, V315, P1519, DOI 10.1056/NEJM198612113152405
   Baulieu EE, 2000, P NATL ACAD SCI USA, V97, P4279, DOI 10.1073/pnas.97.8.4279
   Bellino F.L., 1995, DEHYDROEPIANDROSTERO
   CASSON PR, 1993, AM J OBSTET GYNECOL, V169, P1536, DOI 10.1016/0002 9378(93)90431 H
   Chen CH, 2005, OSTEOPOROSIS INT, V16, P2039, DOI 10.1007/s00198 005 1995 0
   Cormier C, 2001, JOINT BONE SPINE, V68, P588, DOI 10.1016/S1297 319X(01)00327 X
   Davis HE, 2011, BIOTECHNOL BIOENG, V108, P2727, DOI 10.1002/bit.23227
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Flores Figueroa E, 2006, REV INVEST CLIN, V58, P498
   Gavi S, 2006, TRENDS ENDOCRIN MET, V17, P46, DOI 10.1016/j.tem.2006.01.006
   Gnecchi Massimiliano, 2009, V482, P281, DOI 10.1007/978 1 59745 060 7_18
   Gutiérrez G, 2007, ATHEROSCLEROSIS, V190, P90, DOI 10.1016/j.atherosclerosis.2006.02.031
   Huang J, 2015, MOL MED REP, V11, P1777, DOI 10.3892/mmr.2014.2892
   Hughes FJ, 2006, PERIODONTOL 2000, V41, P48, DOI 10.1111/j.1600 0757.2006.00161.x
   Ionescu AM, 2004, J CELL PHYSIOL, V198, P428, DOI 10.1002/jcp.10421
   Jang WG, 2012, J BIOL CHEM, V287, P905, DOI 10.1074/jbc.M111.253187
   Kahn AJ, 2002, J CLIN ENDOCR METAB, V87, P1544, DOI 10.1210/jc.87.4.1544
   Kaivosoja E, 2015, J TISSUE ENG REGEN M, V9, P31, DOI 10.1002/term.1612
   Karaoz E, 2009, HISTOCHEM CELL BIOL, V132, P533, DOI 10.1007/s00418 009 0629 6
   Ko CH, 2011, J AGR FOOD CHEM, V59, P9870, DOI 10.1021/jf202015t
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Legrain S, 2003, DRUG AGING, V20, P949, DOI 10.2165/00002512 200320130 00001
   Li Q, 2013, ELECTRON J DIFFER EQ
   MACEWEN EG, 1991, J NUTR, V121, pS51, DOI 10.1093/jn/121.suppl_11.S51
   Mafi R, 2011, Open Orthop J, V5 Suppl 2, P242, DOI 10.2174/1874325001105010242
   Malik AK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013566
   Morales AJ, 1998, CLIN ENDOCRINOL, V49, P421, DOI 10.1046/j.1365 2265.1998.00507.x
   Nakamura S., 2004, CIRCULATION, V110
   Neaugu M., 2005, ROMANIAN J BIOPHYSIC, V15, P29
   NESTLER JE, 1988, J CLIN ENDOCR METAB, V66, P57, DOI 10.1210/jcem 66 1 57
   Niu DF, 2012, LAB INVEST, V92, P1181, DOI 10.1038/labinvest.2012.84
   Phinney DG, 1999, J CELL BIOCHEM, V72, P570
   Qing W., 2012, J BIOMED BIOTECHNOL
   Rodríguez Pardo Viviana Marcela, 2010, Univ. Sci., V15, P224
   Ronchetti Ivonne, 2013, Frontiers in Genetics, V4, P22, DOI 10.3389/fgene.2013.00022
   Sánchez Rangel JC, 2014, REV MEX ING QUIM, V13, P49
   Savineau JP, 2013, BIOCHEM PHARMACOL, V85, P718, DOI 10.1016/j.bcp.2012.12.004
   SCHRIOCK ED, 1988, J CLIN ENDOCR METAB, V66, P1329, DOI 10.1210/jcem 66 6 1329
   SCHWARTZ A G, 1986, Toxicologic Pathology, V14, P357
   Siddappa R, 2008, P NATL ACAD SCI USA, V105, P7281, DOI 10.1073/pnas.0711190105
   WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220
   Wang L, 2007, J MOL ENDOCRINOL, V38, P467, DOI 10.1677/jme.1.02173
   Wang YD, 2012, CHINESE MED J PEKING, V125, P1230, DOI 10.3760/cma.j.issn.0366 6999.2012.07.008
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Zhang J, 2014, OSTEOPOROSIS INT, V25, P317, DOI 10.1007/s00198 013 2444 0
   Zhang Y, 2012, BONE, V50, pS146, DOI 10.1016/j.bone.2012.02.453
NR 49
TC 3
Z9 3
U1 0
U2 5
PU UNIV AUTONOMA METROPOLITANA IZTAPALAPA
PI MEXICO
PA C/O DR JAIME VERNON CARTER, SAN RAFAEL ATLIXCO NO 186, COL VICENTINA,
   DELEGACION IZTAPALAPA, MEXICO, 09340, MEXICO
SN 1665 2738
J9 REV MEX ING QUIM
JI Rev. Mex. Ing. Quim.
PD APR
PY 2016
VL 15
IS 1
BP 39
EP 49
PG 11
WC Chemistry, Applied; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Engineering
GA DJ0BP
UT WOS:000373866700005
DA 2025 08 17
ER

PT J
AU Petruk, N
   Siddiqui, A
   Tadayon, S
   Määttä, J
   Mattila, PK
   Jukkola, A
   Sandholm, J
   Selander, KS
AF Petruk, Nataliia
   Siddiqui, Arafat
   Tadayon, Sina
   Maatta, Jorma
   Mattila, Pieta K.
   Jukkola, Arja
   Sandholm, Jouko
   Selander, Katri S.
TI CD73 regulates zoledronate induced lymphocyte infiltration in
   triple negative breast cancer tumors and lung metastases
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE CD73; TNBC; zoledronate; tumor growth; tumor infiltrating lymphocytes
ID B CELLS; ANTITUMOR IMMUNITY; BISPHOSPHONATES; EXPRESSION; PROGNOSIS;
   CORRELATE; BLOCKADE; THERAPY; INHIBIT; ACID
AB IntroductionBisphosphonates (BPs) are bone protecting osteoclast inhibitors, typically used in the treatment of osteoporosis and skeletal complications of malignancies. When given in the adjuvant setting, these drugs may also prevent relapses and prolong overall survival in early breast cancer (EBC), specifically among postmenopausal patients. Because of these findings, adjuvant nitrogen containing BPs (N BPs), such as zoledronate (ZOL), are now the standard of care for high risk EBC patients, but there are no benefit associated biomarkers, and the efficacy remains low. BPs have been demonstrated to possess anti tumor activities, but the mechanisms by which they provide the beneficial effects in EBC are not known. MethodsWe used stably transfected 4T1 breast cancer cells together with suppression of CD73 (sh CD73) or control cells (sh NT). We compared ZOL effects on tumor growth and infiltrating lymphocytes (TILs) into tumors and lung metastases using two mouse models. B cell depletion was performed using anti CD20 antibody. ResultsSh CD73 4T1 cells were significantly more sensitive to the growth inhibitory effects of n BPs in vitro. However, while ZOL induced growth inhibition was similar between the tumor groups in vivo, ZOL enhanced B and T lymphocyte infiltration into the orthotopic tumors with down regulated CD73. A similar trend was detected in lung metastases. ZOL induced tumor growth inhibition was found to be augmented with B cell depletion in sh NT tumors, but not in sh CD73 tumors. As an internal control, ZOL effects on bone were similar in mice bearing both tumor groups. DiscussionTaken together, these results indicate that ZOL modifies TILs in breast cancer, both in primary tumors and metastases. Our results further demonstrate that B cells may counteract the growth inhibitory effects of ZOL. However, all ZOL induced TIL effects may be influenced by immunomodulatory characteristics of the tumor.
C1 [Petruk, Nataliia; Siddiqui, Arafat; Mattila, Pieta K.] Univ Turku, Inst Biomed, Turku, Finland.
   [Siddiqui, Arafat] Western Canc Ctr FICAN West, Turku, Finland.
   [Tadayon, Sina; Mattila, Pieta K.] Univ Turku, MediCity Res Lab, Turku, Finland.
   [Tadayon, Sina; Mattila, Pieta K.] Univ Turku, InFLAMES Res Flagship Ctr, Turku, Finland.
   Univ Turku, Turku Ctr Dis Modeling, Turku, Finland.
   [Mattila, Pieta K.; Sandholm, Jouko] Univ Turku, Turku Biosci Ctr, Turku, Finland.
   [Mattila, Pieta K.; Sandholm, Jouko] Abo Akad Univ, Turku, Finland.
   [Jukkola, Arja] Tampere Univ Hosp, Tays Canc Ctr, Dept Oncol, Tampere, Finland.
   [Selander, Katri S.] Oulu Univ Hosp, Dept Oncol & Radiat Therapy, Oulu, Finland.
   [Selander, Katri S.] Univ Oulu, Canc Res & Translat Med Res Unit, Oulu, Finland.
C3 University of Turku; University of Turku; University of Turku;
   University of Turku; University of Turku; Abo Akademi University;
   Tampere University; Tampere University Hospital; University of Oulu;
   University of Oulu
RP Selander, KS (通讯作者)，Oulu Univ Hosp, Dept Oncol & Radiat Therapy, Oulu, Finland.; Selander, KS (通讯作者)，Univ Oulu, Canc Res & Translat Med Res Unit, Oulu, Finland.
EM Katri.Selander@ppshp.fi
RI MÃ¤Ã¤ttÃ¤, Jorma/HNS 1621 2023; Selander, Katri/GWM 8685 2022; Mattila,
   Pieta/G 6815 2013
OI Sandholm, Jouko/0000 0003 0638 2444; Petruk,
   Nataliia/0000 0003 3130 6750; Mattila, Pieta/0000 0003 2805 0686;
   Maatta, Jorma/0000 0001 8752 6862; Tadayon, Sina/0000 0002 7609 5486
FU Academy of Finland [308375]; Academy of Finland (AKA) [308375] Funding
   Source: Academy of Finland (AKA)
FX This study was supported by Academy of Finland (308375).
CR Bankhead P, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 17204 5
   Barrière DA, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 56622 5
   Berrueta L, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 26198 7
   Bruno TC, 2020, NATURE, V577, DOI 10.1038/d41586 019 03943 0
   Buisseret L, 2018, ANN ONCOL, V29, P1056, DOI 10.1093/annonc/mdx730
   Burger JA, 2018, NAT REV CANCER, V18, P148, DOI 10.1038/nrc.2017.121
   Cerbelli B, 2020, VIRCHOWS ARCH, V476, P569, DOI 10.1007/s00428 019 02722 6
   Chen QD, 2020, J CELL MOL MED, V24, P8674, DOI 10.1111/jcmm.15500
   Chen YH, 2021, CANCERS, V13, DOI 10.3390/cancers13163982
   De Caluwé A, 2021, BMC CANCER, V21, DOI 10.1186/s12885 021 08601 1
   Dieli F, 2003, BLOOD, V102, P2310, DOI 10.1182/blood 2003 05 1655
   du Sert NP, 2020, BRIT J PHARMACOL, V177, P3617, DOI [10.1111/bph.15193, 10.1136/bmjos 2020 100115]
   Forte G, 2012, J IMMUNOL, V189, P2226, DOI 10.4049/jimmunol.1200744
   Frith JC, 2001, ARTHRITIS RHEUM, V44, P2201, DOI 10.1002/1529 0131(200109)44:9<2201::AID ART374>3.0.CO;2 E
   Gao X, 2015, TUMOR BIOL, V36, P5315, DOI 10.1007/s13277 015 3192 x
   Ge SX, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859 018 2486 6
   Hasmim M, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.982821
   He XD, 2021, EUR J CANCER, V157, P114, DOI 10.1016/j.ejca.2021.08.006
   Hoefert S, 2016, CLIN ORAL INVEST, V20, P1043, DOI 10.1007/s00784 015 1584 3
   Jansson L, 1998, INFLAMM RES, V47, P290, DOI 10.1007/s000110050332
   Jin FY, 2021, J CONTROL RELEASE, V337, P90, DOI 10.1016/j.jconrel.2021.07.021
   Kaneko J, 2018, INFLAMM REGEN, V38, DOI 10.1186/s41232 018 0074 9
   Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]
   Kuroda H, 2021, BMC CANCER, V21, DOI 10.1186/s12885 021 08009 x
   Liu H, 2019, BMC CANCER, V19, DOI 10.1186/s12885 019 5379 9
   Liu YT, 2021, THERANOSTICS, V11, P5365, DOI 10.7150/thno.58390
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Maglioco A, 2017, ONCOL LETT, V13, P3225, DOI 10.3892/ol.2017.5810
   Martin M., 2011, EMBnet.Journal, V17, DOI [10.14806/ej.17.1.200, DOI 10.14806/EJ.17.1.200]
   Pertea M, 2015, NAT BIOTECHNOL, V33, P290, DOI 10.1038/nbt.3122
   Petruk N, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 85379 z
   Rachner TD, 2010, CANCER LETT, V287, P109, DOI 10.1016/j.canlet.2009.06.003
   Ren ZH, 2017, CLIN CANCER RES, V23, P193, DOI 10.1158/1078 0432.CCR 16 0040
   Rennert G, 2017, CLIN CANCER RES, V23, P1684, DOI 10.1158/1078 0432.CCR 16 0547
   Ribeiro JM, 2022, INT IMMUNOPHARMACOL, V110, DOI 10.1016/j.intimp.2022.108952
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Rocha P, 2021, CANCER IMMUNOL IMMUN, V70, P1965, DOI 10.1007/s00262 020 02820 4
   Sandholm J, 2016, ONCOTARGET, V7, P87373, DOI 10.18632/oncotarget.13570
   Sandholm J, 2012, BREAST CANCER RES TR, V132, P411, DOI 10.1007/s10549 011 1590 3
   Schuh E, 2016, J IMMUNOL, V197, P1111, DOI 10.4049/jimmunol.1600089
   Shi JY, 2013, CLIN CANCER RES, V19, P5994, DOI 10.1158/1078 0432.CCR 12 3497
   Stagg J, 2010, P NATL ACAD SCI USA, V107, P1547, DOI 10.1073/pnas.0908801107
   Stanton SE, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425 016 0165 6
   Strobl S, 2018, CURR TREAT OPTION ON, V19, DOI 10.1007/s11864 018 0535 z
   Tokunaga R, 2019, CANCER TREAT REV, V73, P10, DOI 10.1016/j.ctrv.2018.12.001
   Tonti E, 2013, CELL REP, V5, P323, DOI 10.1016/j.celrep.2013.09.004
   Tripathi A, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc 2020 001467
   Tripathi R, 2016, NUTR CANCER, V68, P679, DOI 10.1080/01635581.2016.1158293
   Vasan N, 2019, NATURE, V575, P299, DOI 10.1038/s41586 019 1730 1
   Vigano S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00925
   von Essen MR, 2019, BRAIN, V142, P120, DOI 10.1093/brain/awy301
   Wang L, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 019 1109 z
   Westbrook JA, 2016, JNCI J NATL CANCER I, V108, DOI 10.1093/jnci/djv360
   Wilson C, 2018, EUR J CANCER, V94, P70, DOI 10.1016/j.ejca.2018.02.004
   Winter MC, 2013, CLIN ONCOL UK, V25, P135, DOI 10.1016/j.clon.2012.10.010
   Xing Y, 2022, ACTA PHARMACOL SIN, V43, P2410, DOI 10.1038/s41401 021 00840 z
   Yegutkin GG, 2001, FASEB J, V15, P251, DOI 10.1096/fj.00 0268com
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Yusuf AA, 2018, ARCH OSTEOPOROS, V13, DOI 10.1007/s11657 018 0439 3
   Zhu WW, 2019, FASEB J, V33, P5208, DOI 10.1096/fj.201801791RR
   Zugazagoitia J, 2016, CLIN THER, V38, P1551, DOI 10.1016/j.clinthera.2016.03.026
NR 61
TC 5
Z9 5
U1 1
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUL 18
PY 2023
VL 14
AR 1179022
DI 10.3389/fimmu.2023.1179022
PG 14
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA N9JI2
UT WOS:001040086700001
PM 37533856
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zafar, S
   Coates, DE
   Cullinan, MP
   Drummond, BK
   Milne, T
   Seymour, GJ
AF Zafar, S.
   Coates, D. E.
   Cullinan, M. P.
   Drummond, B. K.
   Milne, T.
   Seymour, G. J.
TI Effects of zoledronic acid and geranylgeraniol on the cellular behaviour
   and gene expression of primary human alveolar osteoblasts
SO CLINICAL ORAL INVESTIGATIONS
LA English
DT Article
DE Zoledronic acid; Geranylgeraniol; Mevalonate pathway; Alveolar
   osteoblasts; BRONJ
ID BISPHOSPHONATE ASSOCIATED OSTEONECROSIS; HUMAN GINGIVAL FIBROBLASTS;
   EARLY TOOTH DEVELOPMENT; OSTEOGENIC CELLS; PROTEIN GERANYLGERANYLATION;
   BONE TURNOVER; JAW; INHIBITION; MODULATE; RECEPTOR
AB Bisphosphonate related osteonecrosis of the jaw (BRONJ) is a serious complication of bisphosphonate therapy. The mechanism underlying BRONJ pathogenesis is poorly understood.
   To determine the effects of zoledronic acid (ZA) and geranylgeraniol (GGOH) on the mevalonate pathway (MVP) in osteoblasts generated from the human mandibular alveolar bone in terms of cell viability/proliferation, migration, apoptosis and gene expression.
   Primary human osteoblasts (HOBs) isolated from the mandibular alveolar bone were phenotyped. HOBs were cultured with or without ZA and GGOH for up to 72 h. Cellular behaviour was examined using a CellTiter BlueA (R) viability assay, an Ibidi culture insert migration assay, an Apo ONEA (R) Homogeneous Caspase 3/7 apoptosis assay and transmission electron microscopy (TEM). Quantitative real time reverse transcriptase polymerase chain reaction (qRT(2) PCR) was used to determine the simultaneous expression of 168 osteogenic and angiogenic genes modulated in the presence of ZA and GGOH.
   ZA decreased cell viability and migration and induced apoptosis in HOBs. TEM revealed signs of apoptosis in ZA treated HOBs. However, the co addition of GGOH ameliorated the effect of ZA and partially restored the cells to the control state. Twenty eight genes in the osteogenic array and 27 genes in the angiogenic array were significantly regulated in the presence of ZA compared with those in the controls at one or more time points.
   The cytotoxic effect of ZA on HOBs and its reversal by the addition of GGOH suggests that the effect of ZA on HOBs is mediated via the MVP.
   The results suggest that GGOH could be used as a possible therapeutic/preventive strategy for BRONJ.
C1 [Zafar, S.; Coates, D. E.; Cullinan, M. P.; Drummond, B. K.; Milne, T.; Seymour, G. J.] Univ Otago, Sir John Walsh Res Inst, Fac Dent, 310 Great King St,POB 647, Dunedin 9054, New Zealand.
C3 University of Otago
RP Zafar, S (通讯作者)，Univ Otago, Sir John Walsh Res Inst, Fac Dent, 310 Great King St,POB 647, Dunedin 9054, New Zealand.
EM sobia.zafar@uwa.edu.au
RI Milne, Trudy/G 2630 2011; Seymour, Gregory/L 4482 2019; Zafar,
   Sobia/AAT 4630 2021; Coates, Dawn/B 5134 2012
OI Zafar, Sobia/0000 0001 5551 8147; Cullinan, Mary/0000 0002 0423 1581;
   Seymour, Gregory/0000 0001 7595 5651; Coates, Dawn/0000 0003 4242 6846
FU Ministry of Oral Health and Lottery Health research grants, New Zealand
FX This research was funded by the Ministry of Oral Health and Lottery
   Health research grants, New Zealand. The foundation is a non profit
   organisation. The funders played no role in the experiment design,
   execution, analysis or preparation of the paper.
CR Açil Y, 2012, J CRANIO MAXILL SURG, V40, pE229, DOI 10.1016/j.jcms.2011.10.024
   Bei M, 1998, DEVELOPMENT, V125, P4325
   Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027
   Chaudhry Ahmad N, 2007, Oral Maxillofac Surg Clin North Am, V19, P199, DOI 10.1016/j.coms.2007.01.005
   Chen YP, 1996, DEVELOPMENT, V122, P3035
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Cozin M, 2011, J ORAL MAXIL SURG, V69, P2564, DOI 10.1016/j.joms.2011.03.005
   Dillon JP, 2012, METHODS MOL BIOL, V816, P3, DOI 10.1007/978 1 61779 415 5_1
   GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0
   Hagelauer N, 2015, CLIN ORAL INVEST, V19, P1079, DOI 10.1007/s00784 014 1320 4
   Häkkinen L, 2000, PERIODONTOL 2000, V24, P127, DOI 10.1034/j.1600 0757.2000.2240107.x
   Ikebe T, 2013, ORAL SCI INT, V10, P1, DOI 10.1016/S1348 8643(12)00045 6
   Kaiser T, 2013, BREAST CANCER RES TR, V140, P35, DOI 10.1007/s10549 013 2613 z
   Khanna S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009539
   KOVACS EJ, 1994, FASEB J, V8, P854, DOI 10.1096/fasebj.8.11.7520879
   Lazarovici TS, 2010, J ORAL MAXIL SURG, V68, P2241, DOI 10.1016/j.joms.2010.05.043
   Lee JT, 2015, CLIN ORAL INVEST, V19, P1223, DOI 10.1007/s00784 014 1353 8
   Lehrer S, 2008, ORAL SURG ORAL MED O, V106, P389, DOI 10.1016/j.tripleo.2008.01.033
   Ma S, 2008, BRIT J HAEMATOL, V144, P667
   MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631
   Mashiba T, 2000, J BONE MINER RES, V15, P613, DOI 10.1359/jbmr.2000.15.4.613
   McTaggart SJ, 2006, CELL MOL LIFE SCI, V63, P255, DOI 10.1007/s00018 005 5298 6
   Nagaoka Y, 2015, J DENT RES, V94, P594, DOI 10.1177/0022034514564187
   Neustadt J, 2012, INTEGR MED, V11, P4
   Ohe JY, 2012, CLIN ORAL INVEST, V16, P1153, DOI 10.1007/s00784 011 0614 z
   Ohlrich EJ, 2010, THESIS
   Pabst AM, 2014, CLIN ORAL INVEST, V18, P1015, DOI 10.1007/s00784 013 1060 x
   Ravosa MJ, 2011, ARCH ORAL BIOL, V56, P491, DOI 10.1016/j.archoralbio.2010.11.003
   Santini D, 2009, CRIT REV ONCOL HEMAT, V69, P83, DOI 10.1016/j.critrevonc.2008.07.008
   SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494 348
   Sawatari Yoh, 2007, Oral Maxillofac Surg Clin North Am, V19, P487, DOI 10.1016/j.coms.2007.07.003
   Siddiqi A, 2009, ORAL SURG ORAL MED O, V108, pE1, DOI 10.1016/j.tripleo.2009.04.027
   Stefanik D, 2008, ORAL DIS, V14, P465, DOI 10.1111/j.1601 0825.2007.01402.x
   Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092 8674(00)81813 9
   Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153
   VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/0092 8674(93)90678 J
   Van Beek ER, 2002, BONE, V30, P64, DOI 10.1016/S8756 3282(01)00655 X
   Walter C, 2010, CLIN ORAL INVEST, V14, P35, DOI 10.1007/s00784 009 0266 4
   Wan C, 2008, P NATL ACAD SCI USA, V105, P686, DOI 10.1073/pnas.0708474105
   Wang EP, 2007, J ORAL MAXIL SURG, V65, P1328, DOI 10.1016/j.joms.2007.03.006
   Wehrhan F, 2011, ORAL DIS, V17, P433, DOI 10.1111/j.1601 0825.2010.01778.x
   Wehrhan F, 2010, J TRANSL MED, V8, DOI 10.1186/1479 5876 8 96
   Wetzler C, 2000, J INVEST DERMATOL, V115, P245, DOI 10.1046/j.1523 1747.2000.00029.x
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Zafar S, 2014, J ORAL PATHOL MED, V43, P711, DOI 10.1111/jop.12181
   Zafar S, 2014, THESIS
   Ziebart T, 2011, ORAL ONCOL, V47, P195, DOI 10.1016/j.oraloncology.2010.12.003
NR 47
TC 35
Z9 36
U1 0
U2 9
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1432 6981
EI 1436 3771
J9 CLIN ORAL INVEST
JI Clin. Oral Investig.
PD NOV
PY 2016
VL 20
IS 8
BP 2023
EP 2035
DI 10.1007/s00784 015 1706 y
PG 13
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA EA3KS
UT WOS:000386501800020
PM 26795621
DA 2025 08 17
ER

PT J
AU Yadav, LR
   Balagangadharan, K
   Lavanya, K
   Selvamurugan, N
AF Yadav, L. Roshini
   Balagangadharan, K.
   Lavanya, K.
   Selvamurugan, N.
TI Orsellinic acid loaded chitosan nanoparticles in gelatin/
   nanohydroxyapatite scaffolds for bone formation in vitro
SO LIFE SCIENCES
LA English
DT Article
DE Orsellinic acid; Chitosan nanoparticles; Gelatin; Nanohydroxyapatite;
   Runx2
ID OSTEOGENIC DIFFERENTIATION; DRUG DELIVERY; OSTEOBLASTIC DIFFERENTIATION;
   KINASE ACTIVITY; TISSUE; ADHESION; PROTEIN; RUNX2; PHOSPHORYLATION;
   MATRIX
AB Aim: Orsellinic acid (2,4 Dimethoxy 6 methylbenzoic acid) (OA) is a hydrophobic polyphenolic compound with therapeutic potential, but its impact on actuating osteogenesis remains unknown. The bioavailability of OA is hampered by its hydrophobic nature. This study aimed to fabricate nano drug delivery system based scaffolds for OA and test its potential for osteogenesis in vitro.
   Materials and methods: OA was loaded into chitosan nanoparticles (nCS + OA) using the ionic gelation technique at different concentrations. nCS + OA were incorporated onto the scaffolds containing gelatin (Gel) and nanohydroxyapatite (nHAp) by the lyophilization method. Biocomposite scaffolds were examined for their physicochemical and material characteristic properties. The effect of OA in the scaffolds for osteoblast differentiation was determined by alizarin red and von Kossa staining at the cellular level and by reverse transcriptase qPCR and western blot analysis at the molecular level.
   Key findings: The scaffolds showed excellent physiochemical and material characteristics and remained cytofriendly to mouse mesenchymal stem cells (mMSCs, C3H10T1/2). The release of OA from Gel/nHAp/nCS scaffolds enhanced the differentiation of mMSCs towards osteoblasts, as observed through cellular and molecular studies. Moreover, the osteogenic potential of OA was mediated by the activation of FAK and ERK signaling pathways through integrins.
   Significance: The inclusion of OA into Gel/nHAp/nCS biocomposite scaffolds at 80 mu M concentration promoted osteoblast differentiation via cell adhesion mediated signaling, compared with that shown by Gel/nHAp/nCS alone. Overall, this study identified the potential therapeutic OA containing Gel/nHAp/nCS scaffolds, accelerating its potential for clinical application towards bone regeneration.
C1 [Yadav, L. Roshini; Balagangadharan, K.; Lavanya, K.; Selvamurugan, N.] SRM Inst Sci & Technol, Coll Engn & Technol, Sch Bioengn, Dept Biotechnol, Kattankulathur 603203, Tamil Nadu, India.
C3 SRM Institute of Science & Technology Chennai
RP Selvamurugan, N (通讯作者)，SRM Inst Sci & Technol, Coll Engn & Technol, Sch Bioengn, Dept Biotechnol, Kattankulathur 603203, Tamil Nadu, India.
EM selvamun@srmist.edu.in
RI Selvamurugan, Nagarajan/P 7894 2016
CR Alhosseini SN, 2012, INT J NANOMED, V7, P25, DOI 10.2147/IJN.S25376
   Artigas N, 2014, J BIOL CHEM, V289, P27105, DOI 10.1074/jbc.M114.576793
   Arumugam B, 2018, J CELL PHYSIOL, V233, P1082, DOI 10.1002/jcp.25964
   Ashwin B, 2020, INT J BIOL MACROMOL, V162, P523, DOI 10.1016/j.ijbiomac.2020.06.157
   Bacáková L, 2004, PHYSIOL RES, V53, pS35, DOI 10.33549/physiolres.930000.53.S35
   Balagangadharan K, 2019, CARBOHYD POLYM, V216, P1, DOI 10.1016/j.carbpol.2019.04.002
   Banerjee A, 2015, MATER RES EXPRESS, V2, DOI 10.1088/2053 1591/2/4/045303
   Baranwal A, 2018, INT J BIOL MACROMOL, V110, P110, DOI 10.1016/j.ijbiomac.2018.01.006
   Bose S, 2013, MATER TODAY, V16, P496, DOI 10.1016/j.mattod.2013.11.017
   Camci Unal G, 2016, SCI REP UK, V6, DOI 10.1038/srep27693
   Chandran SV, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 48429 1
   Chen XB, 2019, BIOMED MATER, V14, DOI 10.1088/1748 605X/ab388d
   Choudhary MI, 2011, SCI CHINA CHEM, V54, P1926, DOI 10.1007/s11426 011 4436 2
   CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514
   Domingos M, 2017, P I MECH ENG H, V231, P555, DOI 10.1177/0954411916680236
   Donnaloja F, 2020, POLYMERS BASEL, V12, DOI 10.3390/polym12040905
   Dounighi NM, 2012, J VENOM ANIM TOXINS, V18, P44
   Ebisuya M, 2005, J CELL SCI, V118, P2997, DOI 10.1242/jcs.02505
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Freyman TM, 2001, PROG MATER SCI, V46, P273, DOI 10.1016/S0079 6425(00)00018 9
   Giri T., 2016, NANOARCHITECTURED PO, V119
   Guo LQ, 2021, J CONTROL RELEASE, V338, P571, DOI 10.1016/j.jconrel.2021.08.055
   Hollister SJ, 2005, NAT MATER, V4, P518, DOI 10.1038/nmat1421
   Hsu YL, 2008, J BONE MINER RES, V23, P949, DOI 10.1359/JBMR.080219
   Hu J, 2016, SCI REP UK, V6, DOI 10.1038/srep20875
   Jaidev LR, 2019, MATER DESIGN, V161, P44, DOI 10.1016/j.matdes.2018.11.018
   Jain D, 2008, J BIOMED MATER RES B, V86B, P105, DOI 10.1002/jbm.b.30994
   Kamath MS, 2014, INT J NANOMED, V9, P183, DOI 10.2147/IJN.S49460
   Khadem S, 2010, MOLECULES, V15, P7985, DOI 10.3390/molecules15117985
   Kim HW, 2005, BIOMATERIALS, V26, P5221, DOI 10.1016/j.biomaterials.2005.01.047
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   Komori T, 2011, J CELL BIOCHEM, V112, P750, DOI 10.1002/jcb.22994
   Langenbach F, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt328
   Leena RS, 2017, COLLOID SURFACE B, V158, P308, DOI 10.1016/j.colsurfb.2017.06.048
   Lu Y, 2016, WIRES NANOMED NANOBI, V8, P654, DOI 10.1002/wnan.1391
   Maietta S, 2018, MATERIALS, V11, DOI 10.3390/ma11020312
   Maji K, 2016, INT J BIOMATER, V2016, DOI 10.1155/2016/9825659
   Miraoui H, 2009, J BIOL CHEM, V284, P4897, DOI 10.1074/jbc.M805432200
   Mohammed MA, 2017, PHARMACEUTICS, V9, DOI 10.3390/pharmaceutics9040053
   Mouriño V, 2010, J R SOC INTERFACE, V7, P209, DOI 10.1098/rsif.2009.0379
   Nga NK, 2020, RSC ADV, V10, P43045, DOI 10.1039/d0ra09432c
   Olivares Navarrete R, 2015, BIOMATERIALS, V51, P69, DOI 10.1016/j.biomaterials.2015.01.035
   Park SN, 2004, BIOMATERIALS, V25, P3689, DOI 10.1016/j.biomaterials.2003.10.072
   Pina S, 2015, ADV MATER, V27, P1143, DOI 10.1002/adma.201403354
   Pooja D, 2014, INT J BIOL MACROMOL, V69, P267, DOI 10.1016/j.ijbiomac.2014.05.035
   Prasadh S, 2018, ORAL SCI INT, V15, P48, DOI 10.1016/S1348 8643(18)30005 3
   Rizvi SAA, 2018, SAUDI PHARM J, V26, P64, DOI 10.1016/j.jsps.2017.10.012
   Rojas A, 2015, J BIOL CHEM, V290, P28329, DOI 10.1074/jbc.M115.657825
   Salasznyk RM, 2007, EXP CELL RES, V313, P22, DOI 10.1016/j.yexcr.2006.09.013
   Salgado AJ, 2004, MACROMOL BIOSCI, V4, P743, DOI 10.1002/mabi.200400026
   Selvamurugan N, 2009, FEBS LETT, V583, P1141, DOI 10.1016/j.febslet.2009.02.040
   Shen JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093514
   Singh R, 2009, EXP MOL PATHOL, V86, P215, DOI 10.1016/j.yexmp.2008.12.004
   Song LG, 2013, EUR J PHARMACOL, V714, P15, DOI 10.1016/j.ejphar.2013.05.039
   Sruthi R, 2020, COLLOID SURFACE B, V193, DOI 10.1016/j.colsurfb.2020.111110
   Swetha S, 2021, BIOTECHNOL J, V16, DOI 10.1002/biot.202100282
   Tamura Y, 2001, J BONE MINER RES, V16, P1772, DOI 10.1359/jbmr.2001.16.10.1772
   Thadhani VM, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/2079697
   Tsao YT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010159
   Valentino A, 2021, APPL SCI BASEL, V11, DOI 10.3390/app11115122
   Veevers Lowe J, 2011, J CELL SCI, V124, P1288, DOI 10.1242/jcs.076935
   Vimalraj S, 2015, INT J BIOL MACROMOL, V78, P202, DOI 10.1016/j.ijbiomac.2015.04.008
   Wang Liang, 2015, Chinese Medical Sciences Journal, V30, P108
   Wang WQ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020487
   Wu T, 2017, MATERIALS, V10, DOI 10.3390/ma10101187
   Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499
   Zhao FL, 2015, NANOMATERIALS BASEL, V5, P2054, DOI 10.3390/nano5042054
NR 67
TC 10
Z9 10
U1 1
U2 17
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024 3205
EI 1879 0631
J9 LIFE SCI
JI Life Sci.
PD JUN 15
PY 2022
VL 299
AR 120559
DI 10.1016/j.lfs.2022.120559
EA APR 2022
PG 15
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 1H4WX
UT WOS:000796545300009
PM 35447131
DA 2025 08 17
ER

PT J
AU Imamura, T
   Tsurumoto, T
   Saiki, K
   Nishi, K
   Okamoto, K
   Manabe, Y
   Oyamada, J
   Ogami Takamura, K
AF Imamura, Takeshi
   Tsurumoto, Toshiyuki
   Saiki, Kazunobu
   Nishi, Keita
   Okamoto, Keishi
   Manabe, Yoshitaka
   Oyamada, Joichi
   Ogami Takamura, Keiko
TI Morphological profile of atypical femoral fractures: age related changes
   to the cross sectional geometry of the diaphysis
SO JOURNAL OF ANATOMY
LA English
DT Article
DE atypical femoral fracture; cortical bone; cross sectional geometry;
   femur
ID CORTICAL BONE; BISPHOSPHONATE USE; FEMUR; WOMEN; PERIOSTEAL; MECHANISM;
   EXPANSION; TIBIA; SEX
AB The use of bisphosphonates for osteoporosis patients has markedly decreased the incidence of femoral neck or trochanteric fractures. However, anti osteoporosis drugs have been reported to increase the incidence of atypical femoral fractures, which involve stress fractures in the subtrochanteric region or the proximal diaphysis. In this study, the morphological characteristics of the cortical bone in human femoral diaphysis samples were analyzed from individuals who lived before bisphosphonate drugs were available in Japan. A total of 90 right femoral bones were arbitrarily selected (46 males and 44 females) from modern Japanese skeletal specimens. Full length images of these femurs were acquired using a computed tomography scanner. An image processing method for binarization was used to calculate the threshold values of individual bones for determining their contours. The range between the lower end of the lesser trochanter and the adductor tubercle of each femur was divided at regular intervals to obtain 10 planes. The mean value of cortical bone thickness, periosteal border length, and the cortical cross sectional area was evaluated for all planes. Moreover, the ratio of the area of the cortical bone to the total area of cross section at the mid diaphysis was calculated. A comparison between males and females demonstrated that most females had lower cortical bone area ratios at the mid diaphysis. The femoral outer shape did not differ markedly according to age or sex; however, substantial individual differences were observed in the shape of the inner surface of the cortical bone. The cortical bone thickness and the cross sectional area decreased with age in the femoral diaphysis; furthermore, in females, the decrease was higher for the former than for the latter. This may be due to a compensatory increase in the circumference of the femoral diaphysis. In addition, in about half of the subjects there was a discrepancy between the region with maximal value of the cortical bone thickness and that of the total cross sectional area. Biological responses to mechanical stresses to the femoral diaphysis are thought not to be uniform. Bisphosphonates inhibit bone resorption and may promote non physiological bone remodeling. Thus, a nonhomogeneous decrease in cortical thickness may be related to the fracture occurrence in the femoral diaphysis in some cases. Thus, long term administration of bisphosphonates in patients with morphological vulnerability in the femoral cortical bones may increase the occurrence of atypical femoral fractures.
C1 [Imamura, Takeshi; Tsurumoto, Toshiyuki; Saiki, Kazunobu; Okamoto, Keishi; Ogami Takamura, Keiko] Nagasaki Univ, Grad Sch Biomed Sci, Dept Macroscop Anat, Nagasaki, Japan.
   [Nishi, Keita; Manabe, Yoshitaka; Oyamada, Joichi] Nagasaki Univ, Grad Sch Biomed Sci, Dept Oral Anat & Dent Anthropol, Nagasaki, Japan.
C3 Nagasaki University; Nagasaki University
RP Tsurumoto, T (通讯作者)，Nagasaki Univ, Grad Sch Biomed Sci, Dept Macroscop Anat, Nagasaki, Japan.
EM tsurumot@nagasaki u.ac.jp
OI Tsurumoto, Toshiyuki/0000 0001 6069 6490
CR Abimanyi Ochom J, 2015, OSTEOPOROSIS INT, V26, P1781, DOI 10.1007/s00198 015 3088 z
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Bousson V, 2004, J BONE MINER RES, V19, P794, DOI 10.1359/JBMR.040124
   Burr DB, 2010, LANCET, V375, P1672, DOI 10.1016/S0140 6736(10)60444 8
   Chen H, 2010, OSTEOPOROSIS INT, V21, P627, DOI 10.1007/s00198 009 0993 z
   CHOW CK, 1972, COMPUT BIOMED RES, V5, P388, DOI 10.1016/0010 4809(72)90070 5
   Coleman MN, 2007, AM J PHYS ANTHROPOL, V133, P723, DOI 10.1002/ajpa.20583
   Donnelly E, 2012, J BONE MINER RES, V27, P672, DOI 10.1002/jbmr.560
   Geissler JR, 2015, J BIOMECH, V48, P883, DOI 10.1016/j.jbiomech.2015.01.032
   Hagen JE, 2014, J BONE JOINT SURG AM, V96A, P1905, DOI 10.2106/JBJS.N.00075
   HAYES WC, 1982, SCIENCE, V217, P945, DOI 10.1126/science.7112107
   Jepsen KJ, 2015, CLIN ORTHOP RELAT R, V473, P2530, DOI 10.1007/s11999 015 4184 2
   Kanemaru A, 2010, ARCH GERONTOL GERIAT, V51, P169, DOI 10.1016/j.archger.2009.10.003
   Kazakia GJ, 2014, BONE, V63, P132, DOI 10.1016/j.bone.2014.02.014
   Koeppen VA, 2012, OSTEOPOROSIS INT, V23, P2893, DOI 10.1007/s00198 012 2173 9
   Leung CK, 1996, PATTERN RECOGN, V29, P1523, DOI 10.1016/0031 3203(96)00009 X
   Macintosh AA, 2013, AM J PHYS ANTHROPOL, V150, P442, DOI 10.1002/ajpa.22218
   Marcano A, 2014, CLIN ORTHOP RELAT R, V472, P1020, DOI 10.1007/s11999 013 3352 5
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   Mizushima S, 2009, ANTHROPOL SCI, V117, P99
   Niimi R, 2015, J BONE MINER RES, V30, P225, DOI 10.1002/jbmr.2345
   Oh Y, 2014, INJURY, V45, P1764, DOI 10.1016/j.injury.2014.08.037
   Ostertag A, 2014, BONE, V63, P7, DOI 10.1016/j.bone.2014.02.009
   Papapoulos SE, 2005, OSTEOPOROSIS INT, V16, P468, DOI 10.1007/s00198 004 1725 z
   Patton DM, 2019, J BIOMECH, V83, P125, DOI 10.1016/j.jbiomech.2018.11.030
   RUFF CB, 1983, AM J PHYS ANTHROPOL, V60, P359, DOI 10.1002/ajpa.1330600308
   Ryan TM, 2002, J HUM EVOL, V43, P241, DOI 10.1006/jhev.2002.0575
   Scherf H, 2009, AM J PHYS ANTHROPOL, V140, P39, DOI 10.1002/ajpa.21033
   Schilcher J, 2015, J BONE MINER RES, V30, P2127, DOI 10.1002/jbmr.2547
   Schilcher J, 2011, NEW ENGL J MED, V364, P1728, DOI 10.1056/NEJMoa1010650
   Schlecht SH, 2015, CLIN ORTHOP RELAT R, V473, P2540, DOI 10.1007/s11999 015 4229 6
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Shibata S, 1992, TOKYO JIKEIKAI MED J, V107, P925
   Shin WC, 2017, J ORTHOP SCI, V22, P99, DOI 10.1016/j.jos.2016.09.009
   SMITH RW, 1964, SCIENCE, V145, P156, DOI 10.1126/science.145.3628.156
   Szolomayer LK, 2017, SKELETAL RADIOL, V46, P241, DOI 10.1007/s00256 016 2526 0
   Taormina DP, 2014, BONE, V63, P1, DOI 10.1016/j.bone.2014.02.006
   Ward KA, 2005, CALCIFIED TISSUE INT, V77, P275, DOI 10.1007/s00223 005 0031 x
NR 39
TC 12
Z9 13
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 8782
EI 1469 7580
J9 J ANAT
JI J. Anat.
PD NOV
PY 2019
VL 235
IS 5
BP 892
EP 902
DI 10.1111/joa.13060
EA JUL 2019
PG 11
WC Anatomy & Morphology
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Anatomy & Morphology
GA JD6UL
UT WOS:000478450800001
PM 31355449
OA Bronze, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Briolay, A
   Lencel, P
   Bessueille, L
   Caverzasio, J
   Buchet, R
   Magne, D
AF Briolay, A.
   Lencel, P.
   Bessueille, L.
   Caverzasio, J.
   Buchet, R.
   Magne, D.
TI Autocrine stimulation of osteoblast activity by Wnt5a in response to
   TNF α in human mesenchymal stem cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Osteoblast; Alkaline phosphatase; Mineralization; Inflammation;
   TNF alpha; Wnt; Ankylosing spondylitis
ID ALKALINE PHOSPHATASE ACTIVITY; OSTEOGENIC DIFFERENTIATION;
   ANKYLOSING SPONDYLITIS; BONE FORMATION; CHONDROCYTE DIFFERENTIATION;
   SYNDESMOPHYTE FORMATION; MULTIPLE MYELOMA; INFLAMMATION; DICKKOPF 1;
   EXPRESSION
AB Although anti tumor necrosis factor (TNF) alpha treatments efficiently block inflammation in ankylosing spondylitis (AS), they are inefficient to prevent excessive bone formation. In AS, ossification seems more prone to develop in sites where inflammation has resolved following anti TNF therapy, suggesting that TNF alpha indirectly stimulates ossification. In this context, our objectives were to determine and compare the involvement of Wnt proteins, which are potent growth factors of bone formation, in the effects of TNF alpha on osteoblast function. In human mesenchymal stem cells (MSCs), TNF alpha significantly increased the levels of Wnt10b and Wnt5a. Associated with this effect, TNF alpha stimulated tissue non specific alkaline phosphatase (TNAP) and mineralization. This effect was mimicked by activation of the canonical beta catenin pathway with either anti Dkk1 antibodies, lithium chloride (LiCl) or SB216763. TNF alpha reduced, and activation of beta catenin had little effect on expression of osteocalcin, a late marker of osteoblast differentiation. Surprisingly, TNF alpha failed to stabilize beta catenin and Dkk1 did not inhibit TNF alpha effects. In fact, Dkk1 expression was also enhanced in response to TNF alpha, perhaps explaining why canonical signaling by Wnt10b was not activated by TNF alpha. However, we found that Wnt5a also stimulated TNAP in MSCs cultured in osteogenic conditions, and increased the levels of inflammatory markers such as COX 2. Interestingly, treatment with anti Wnt5a antibodies reduced endogenous TNAP expression and activity. Collectively, these data suggest that increased levels of Dkk1 may blunt the autocrine effects of Wnt10b, but not that of Wnt5a, acting through non canonical signaling. Thus, Wnt5a may be potentially involved in the effects of inflammation on bone formation. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Briolay, A.; Bessueille, L.; Buchet, R.; Magne, D.] Univ Lyon 1, ICBMS, CNRS, UMR 5246, F 69622 Villeurbanne, France.
   [Lencel, P.] ULCO, EA4490, F 62327 Boulogne, France.
   [Caverzasio, J.] Univ Hosp Geneva, Serv Bone Dis, Dept Internal Med Specialties, CH 1211 Geneva 14, Switzerland.
C3 Centre National de la Recherche Scientifique (CNRS); CNRS   Institute of
   Chemistry (INC); Institut National des Sciences Appliquees de Lyon  
   INSA Lyon; Universite Claude Bernard Lyon 1; Universite du
   Littoral Cote d'Opale; University of Geneva
RP Magne, D (通讯作者)，Univ Lyon 1, ICBMS, CNRS, UMR 5246, Batiment Raulin,43 Bd 11 Novembre 1918, F 69622 Villeurbanne, France.
EM david.magne@univ Iyon1.fr
RI Rene, Buchet/I 9781 2019
OI Magne, David/0000 0002 6511 9390; Buchet, Rene/0000 0002 7966 3856
FU Societe Francaise de Rhumatologie; Association France Spondylarthrites
FX This study was supported by the "Societe Francaise de Rhumatologie" and
   the "Association France Spondylarthrites".
CR Agholme F, 2011, BONE, V48, P988, DOI 10.1016/j.bone.2011.02.008
   Andrade AC, 2007, BONE, V40, P1361, DOI 10.1016/j.bone.2007.01.005
   Baksh D, 2007, J CELL BIOCHEM, V101, P1109, DOI 10.1002/jcb.21097
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bilkovski R, 2010, J BIOL CHEM, V285, P6170, DOI 10.1074/jbc.M109.054338
   Caverzasio J, 2007, ENDOCRINOLOGY, V148, P5323, DOI 10.1210/en.2007 0520
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Ding J, 2009, LIFE SCI, V84, P499, DOI 10.1016/j.lfs.2009.01.013
   Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood 2008 11 191577
   Gaur T, 2009, J CELL PHYSIOL, V220, P174, DOI 10.1002/jcp.21747
   Gerstenfeld LC, 2003, J BONE MINER RES, V18, P1584, DOI 10.1359/jbmr.2003.18.9.1584
   Gerstenfeld LC, 2001, CELLS TISSUES ORGANS, V169, P285, DOI 10.1159/000047893
   Guo J, 2008, BONE, V43, P961, DOI 10.1016/j.bone.2008.06.011
   Gustafson B, 2006, J BIOL CHEM, V281, P9507, DOI 10.1074/jbc.M512077200
   Hadjiargyrou M, 2002, J BIOL CHEM, V277, P30177, DOI 10.1074/jbc.M203171200
   Heath DJ, 2009, J BONE MINER RES, V24, P425, DOI 10.1359/JBMR.081104
   Heiland GR, 2012, ANN RHEUM DIS, V71, P572, DOI 10.1136/annrheumdis 2011 200216
   Heiland GR, 2010, ANN RHEUM DIS, V69, P2152, DOI 10.1136/ard.2010.132852
   Kaneki H, 2006, J BIOL CHEM, V281, P4326, DOI 10.1074/jbc.M509430200
   Kim JB, 2007, J BONE MINER RES, V22, P1913, DOI 10.1359/JBMR.070802
   Kim J, 2010, J IMMUNOL, V185, P1274, DOI 10.4049/jimmunol.1000181
   Komatsu DE, 2010, J ORTHOP RES, V28, P928, DOI 10.1002/jor.21078
   Krause U, 2010, P NATL ACAD SCI USA, V107, P4147, DOI 10.1073/pnas.0914360107
   Lencel P, 2011, BONE, V48, P242, DOI 10.1016/j.bone.2010.09.001
   Lencel P, 2011, LAB INVEST, V91, P1434, DOI 10.1038/labinvest.2011.83
   Lu ZF, 2012, STEM CELLS DEV, V21, P2420, DOI 10.1089/scd.2011.0589
   Maeda K, 2012, NAT MED, V18, P405, DOI 10.1038/nm.2653
   Matzelle MM, 2012, ARTHRITIS RHEUM US, V64, P1540, DOI 10.1002/art.33504
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Olivares Navarrete R, 2011, BIOMATERIALS, V32, P6399, DOI 10.1016/j.biomaterials.2011.05.036
   Pedersen SJ, 2011, ARTHRITIS RHEUM US, V63, P3789, DOI 10.1002/art.30627
   Pereira C, 2008, ARTERIOSCL THROM VAS, V28, P504, DOI 10.1161/ATVBAHA.107.157438
   Pinzone JJ, 2009, BLOOD, V113, P517, DOI 10.1182/blood 2008 03 145169
   Schett G, 2010, BEST PRACT RES CL RH, V24, P363, DOI 10.1016/j.berh.2010.01.005
   Sen M, 2000, P NATL ACAD SCI USA, V97, P2791, DOI 10.1073/pnas.050574297
   Sieper J, 2002, ANN RHEUM DIS, V61, P8
   Sonomoto K, 2012, ARTHRITIS RHEUM US, V64, P3355, DOI 10.1002/art.34555
   Takada I, 2007, NAT CELL BIOL, V9, P1273, DOI 10.1038/ncb1647
   Vincent C, 2009, J BONE MINER RES, V24, P1434, DOI [10.1359/JBMR.090305, 10.1359/jbmr.090305]
   Walsh NC, 2005, IMMUNOL REV, V208, P228, DOI 10.1111/j.0105 2896.2005.00338.x
   Zhong ZD, 2012, P NATL ACAD SCI USA, V109, pE2197, DOI 10.1073/pnas.1120407109
NR 42
TC 75
Z9 92
U1 0
U2 33
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 18
PY 2013
VL 430
IS 3
BP 1072
EP 1077
DI 10.1016/j.bbrc.2012.12.036
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 082EW
UT WOS:000314376100034
PM 23266365
OA Green Published
DA 2025 08 17
ER

PT J
AU Nguyen, AN
   Stebbins, EG
   Henson, M
   O'Young, G
   Choi, SJ
   Quon, D
   Damm, D
   Reddy, M
   Ma, JY
   Haghnazari, E
   Kapoun, AM
   Medicherla, S
   Protter, A
   Schreiner, GF
   Kurihara, N
   Anderson, J
   Roodman, GD
   Navas, TA
   Higgins, LS
AF Nguyen, Aaron N.
   Stebbins, Elizabeth G.
   Henson, Margaret
   O'Young, Gilbert
   Choi, Sun J.
   Quon, Diana
   Damm, Debby
   Reddy, Mamatha
   Ma, Jing Y.
   Haghnazari, Edwin
   Kapoun, Ann M.
   Medicherla, Satyanarayana
   Protter, Andy
   Schreiner, George F.
   Kurihara, Noriyoshi
   Anderson, Judy
   Roodman, G. David
   Navas, Tony A.
   Higgins, Linda S.
TI Normalizing the bone marrow microenvironment with p38 inhibitor reduces
   multiple myeloma cell proliferation and adhesion and suppresses
   osteoclast formation
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE p38 MAPK inhibitor; SCIO 469; bone marrow microenvironment; IL 6; VEGF;
   cell adhesion; chemokines; CXCL10; CCL8; osteoclast formation
ID TUMOR NECROSIS FACTOR; KAPPA B LIGAND; GROWTH FACTOR; DRUG RESISTANCE;
   STROMAL CELLS; THERAPEUTIC APPLICATIONS; OSTEOLYTIC LESIONS; SIGNALING
   CASCADES; RECEPTOR ACTIVATOR; SERUM LEVELS
AB The multiple myeloma (MM) bone marrow (BM) microenvironment plays a critical role in supporting tumor growth and survival as well as in promoting formation of osteolytic lesions. Recent results suggest that the p38 mitogen activated protein kinase (MAPK) is an important factor in maintaining this activated environment. In this report, we demonstrate that the p38 alpha MAPK inhibitor, SCIO 469, suppresses secretion of the tumor supportive factors IL 6 and VEGF from BM stromal cells (BMSCs) as well as cocultures of BMSCs with MM cells, resulting in reduction in MM cell proliferation. Additionally, we show that SCIO 469 prevents TNF alpha induced adhesion of MM cells to BMSCs through an ICAM 1  and VCAM 1 independent mechanism. Microarray analysis revealed a novel set of TNF alpha induced chemokines in BMSCs that is strongly inhibited by SCIO 469. Furthermore, reintroduction of chemokines CXCL10 and CCL8 to BMSCs overcomes the inhibitory effect of SCIO 469 on TNF alpha induced MM adhesion. Lastly, we show that SCIO 469 inhibits secretion and expression of the osteoclast activating factors IL 11, RANKL, and MIP 1 alpha as well as prevents human osteoclast formation in vitro. Collectively, these results suggest that SCIO 469 treatment can suppress factors in the bone marrow micro environment to inhibit MM cell proliferation and adhesion and also to alleviate osteolytic activation in MM. (c) 2006 Elsevier Inc. All rights reserved.
C1 Scios Inc, Fremont, CA 94555 USA.
   Univ Pittsburgh, Dept Med, Div Hematol Oncol, Pittsburgh, PA USA.
   VA Med Ctr, Pittsburgh, PA USA.
C3 Scios; Pennsylvania Commonwealth System of Higher Education (PCSHE);
   University of Pittsburgh
RP Higgins, LS (通讯作者)，Scios Inc, 6500 Paseo Padre Pkwy, Fremont, CA 94555 USA.
EM lhiggin3@scius.jnj.com
CR Abe M, 2002, BLOOD, V100, P2195, DOI 10.1182/blood.V100.6.2195.h81802002195_2195_2202
   Anderson Kenneth C, 2002, Hematology Am Soc Hematol Educ Program, P214
   Attal M, 1996, NEW ENGL J MED, V335, P91, DOI 10.1056/NEJM199607113350204
   Barille Nion Sophie, 2003, Hematology Am Soc Hematol Educ Program, P248
   Barlogie B, 1997, BLOOD, V89, P789, DOI 10.1182/blood.V89.3.789
   BATAILLE R, 1995, BLOOD, V86, P685, DOI 10.1182/blood.V86.2.685.bloodjournal862685
   BATAILLE R, 1989, J CLIN ONCOL, V7, P1909, DOI 10.1200/JCO.1989.7.12.1909
   Bataille R, 1997, HEMATOL ONCOL CLIN N, V11, P349, DOI 10.1016/S0889 8588(05)70435 4
   BATAILLE R, 1989, J CLIN INVEST, V84, P2008, DOI 10.1172/JCI114392
   Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802
   Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460 2075.1996.tb00542.x
   Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002 0023
   Cavo M, 1998, BONE MARROW TRANSPL, V22, P27, DOI 10.1038/sj.bmt.1701280
   Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104
   Dalton WS, 2003, CANCER TREAT REV, V29, P11, DOI 10.1016/S0305 7372(03)00077 X
   Dalton WS, 2002, SEMIN ONCOL, V29, P21, DOI 10.1053/sonc.2002.34073
   Dalton WS, 1999, DRUG RESIST UPDATE, V2, P285, DOI 10.1054/drup.1999.0097
   Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658
   Devlin RD, 1998, J BONE MINER RES, V13, P393, DOI 10.1359/jbmr.1998.13.3.393
   Dhodapkar MV, 1998, BRIT J HAEMATOL, V103, P530, DOI 10.1046/j.1365 2141.1998.00976.x
   Filella X, 1996, CANCER DETECT PREV, V20, P52
   GAHRTON G, 1991, NEW ENGL J MED, V325, P1267, DOI 10.1056/NEJM199110313251802
   Giuliani N, 2005, BLOOD, V106, P2472, DOI 10.1182/blood 2004 12 4986
   Gupta D, 2001, LEUKEMIA, V15, P1950, DOI 10.1038/sj.leu.2402295
   Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21
   Han JH, 2001, BLOOD, V97, P3349, DOI 10.1182/blood.V97.11.3349
   Hazlehurst LA, 2003, ONCOGENE, V22, P7396, DOI 10.1038/sj.onc.1206943
   Hideshima T, 2001, CANCER RES, V61, P3071
   Hideshima T, 2004, ONCOGENE, V23, P8766, DOI 10.1038/sj.onc.1208118
   Hideshima T, 2003, ONCOGENE, V22, P8386, DOI 10.1038/sj.onc.1207170
   Hideshima T, 2003, BLOOD, V101, P703, DOI 10.1182/blood 2002 06 1874
   Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952
   Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood 2004 01 0037
   Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623
   Imhof BA, 2004, NAT REV IMMUNOL, V4, P432, DOI 10.1038/nri1375
   Kapoun AM, 2004, CIRC RES, V94, P453, DOI 10.1161/01.RES.0000117070.86556.9F
   KLEIN B, 1995, SEMIN HEMATOL, V32, P4
   KLEIN B, 1989, BLOOD, V73, P517
   Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746
   KURIHARA N, 1990, J IMMUNOL, V144, P4226
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Landry J, 1995, BIOCHEM CELL BIOL, V73, P703, DOI 10.1139/o95 078
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Merrell M, 2003, BREAST CANCER RES TR, V81, P231, DOI 10.1023/A:1026126430905
   NACHBAUR DM, 1991, ANN HEMATOL, V62, P54, DOI 10.1007/BF01714900
   Oba Y, 2005, EXP HEMATOL, V33, P272, DOI 10.1016/j.exphem.2004.11.015
   Pearse RN, 2001, P NATL ACAD SCI USA, V98, P11581, DOI 10.1073/pnas.201394498
   Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood 2002 12 3647
   Podar K, 2004, BLOOD, V103, P3474, DOI 10.1182/blood 2003 10 3527
   Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428
   Sati HIA, 1999, BRIT J HAEMATOL, V104, P350, DOI 10.1046/j.1365 2141.1999.01193.x
   Secchiero P, 2005, BLOOD, V105, P3413, DOI 10.1182/blood 2004 10 4111
   Suda T, 1997, J BONE MINER RES, V12, P869, DOI 10.1359/jbmr.1997.12.6.869
   Tassone P, 2002, INT J ONCOL, V21, P867
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Tricot G, 2000, LANCET, V355, P248, DOI 10.1016/S0140 6736(00)00019 2
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Yaccoby S, 2002, BRIT J HAEMATOL, V116, P278, DOI 10.1046/j.1365 2141.2002.03257.x
   Yaccoby S, 2004, CANCER RES, V64, P2016, DOI 10.1158/0008 5472.CAN 03 1131
   Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15
   Zauli G, 2004, BLOOD, V104, P2044, DOI 10.1182/blood 2004 03 1196
NR 62
TC 50
Z9 58
U1 0
U2 3
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0014 4827
EI 1090 2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD JUN 10
PY 2006
VL 312
IS 10
BP 1909
EP 1923
DI 10.1016/j.yexcr.2006.02.026
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA 051RT
UT WOS:000238179100020
PM 16600214
DA 2025 08 17
ER

PT J
AU Gerdesmeyer, L
   Tuebel, J
   Obermeier, A
   Harrasser, N
   Glowalla, C
   von Eisenhart Rothe, R
   Burgkart, R
AF Gerdesmeyer, Lennart
   Tuebel, Jutta
   Obermeier, Andreas
   Harrasser, Norbert
   Glowalla, Claudio
   von Eisenhart Rothe, Ruediger
   Burgkart, Rainer
TI Extracorporeal Magnetotransduction Therapy as a New Form of
   Electromagnetic Wave Therapy: From Gene Upregulation to Accelerated
   Matrix Mineralization in Bone Healing
SO BIOMEDICINES
LA English
DT Article
DE electromagnetic wave therapy; bone regeneration; matrix mineralization;
   osteoblastogenesis; fracture healing; non invasive therapy
ID OSTEOBLAST DIFFERENTIATION; CELL PROLIFERATION; FIELDS; PEMF
AB Background: Electromagnetic field therapy is gaining attention for its potential in treating bone disorders, with Extracorporeal Magnetotransduction Therapy (EMTT) emerging as an innovative approach. EMTT offers a higher oscillation frequency and magnetic field strength compared to traditional Pulsed Electromagnetic Field (PEMF) therapy, showing promise in enhancing fracture healing and non union recovery. However, the mechanisms underlying these effects remain unclear. Results: This study demonstrates that EMTT significantly enhances osteoblast bone formation at multiple levels, from gene expression to extracellular matrix mineralization. Key osteoblastogenesis regulators, including SP7 and RUNX2, and bone related genes such as COL1A1, ALPL, and BGLAP, were upregulated, with expression levels surpassing those of the control group by over sevenfold (p < 0.001). Enhanced collagen synthesis and mineralization were confirmed by von Kossa and Alizarin Red staining, indicating increased calcium and phosphate deposition. Additionally, calcium imaging revealed heightened calcium influx, suggesting a cellular mechanism for EMTT's osteogenic effects. Importantly, EMTT did not compromise cell viability, as confirmed by live/dead staining and WST 1 assays. Conclusion: This study is the first to show that EMTT can enhance all phases of osteoblastogenesis and improve the production of critical mineralization components, offering potential clinical applications in accelerating fracture healing, treating osteonecrosis, and enhancing implant osseointegration.
C1 [Gerdesmeyer, Lennart; Tuebel, Jutta; Obermeier, Andreas; Harrasser, Norbert; Glowalla, Claudio; von Eisenhart Rothe, Ruediger; Burgkart, Rainer] Tech Univ Munich, Dept Orthopaed & Sports Orthopaed, Klinikum Rechts Isar, Ismaninger Str 22, D 81675 Munich, Germany.
   [Harrasser, Norbert] ECOM Excellent Ctr Med, Arabellastr 17, D 81925 Munich, Germany.
   [Glowalla, Claudio] BG Unfallklin Murnau, Prof Kuntscher Str 8, D 82418 Murnau, Germany.
C3 Technical University of Munich
RP Gerdesmeyer, L (通讯作者)，Tech Univ Munich, Dept Orthopaed & Sports Orthopaed, Klinikum Rechts Isar, Ismaninger Str 22, D 81675 Munich, Germany.
EM lennart.gerdesmeyer@tum.de
RI ; von Eisenhart Rothe, Ruediger/E 4839 2017; Tuebel,
   Jutta/ADN 6960 2022; Gerdesmeyer, Lennart/LRC 6056 2024; Obermeier,
   Andreas/B 3020 2016
OI von Eisenhart Rothe, Rudiger/0000 0002 2352 1357; Obermeier,
   Andreas/0000 0002 1774 5194; Glowalla, Claudio/0000 0003 3540 6302;
   Gerdesmeyer, Lennart/0009 0008 7963 3965
FU STORZ Medical
FX The study was supported by STORZ Medical, which provided the treatment
   device within the study time. The sponsor did not influence the handling
   of subjects, data collection, data analysis, or manuscript preparation.
CR Blair HC, 2017, TISSUE ENG PART B RE, V23, P268, DOI [10.1089/ten.teb.2016.0454, 10.1089/ten.TEB.2016.0454]
   Bonewald LF, 2007, ANN NY ACAD SCI, V1116, P281, DOI 10.1196/annals.1402.018
   Borza R, 2022, J BIOL CHEM, V298, DOI 10.1016/j.jbc.2021.101526
   Brodsky B, 2005, ADV PROTEIN CHEM, V70, P301, DOI 10.1016/S0065 3233(05)70009 7
   Caliogna L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22147403
   Carpenter LL, 2012, DEPRESS ANXIETY, V29, P587, DOI 10.1002/da.21969
   Collins TJ, 2007, BIOTECHNIQUES, V43, P25, DOI 10.2144/000112517
   FLEISCH H, 1962, NATURE, V195, P911, DOI 10.1038/195911a0
   FUKADA E, 1957, J PHYS SOC JPN, V12, P1158, DOI 10.1143/JPSJ.12.1158
   Gerdesmeyer L, 2024, J MED CASE REP, V18, DOI 10.1186/s13256 024 04482 7
   Gerdesmeyer L, 2022, ELECTROMAGN BIOL MED, V41, P304, DOI 10.1080/15368378.2022.2079672
   Giorgi C, 2018, TRENDS CELL BIOL, V28, P258, DOI 10.1016/j.tcb.2018.01.002
   Huang XB, 2018, REGEN ENG TRANSL MED, V4, P216, DOI 10.1007/s40883 018 0064 0
   JUNQUEIRA LCU, 1979, HISTOCHEM J, V11, P447, DOI 10.1007/BF01002772
   Khan Munna, 2022, Natl J Maxillofac Surg, V13, pS11, DOI 10.4103/njms.njms_400_21
   Klter T., 2018, J. Orthop. Ther. JORT, V10, P2575, DOI [10.29011/2575 8241.001113, DOI 10.29011/2575 8241.001113]
   Klüter T, 2018, ELECTROMAGN BIOL MED, V37, P175, DOI 10.1080/15368378.2018.1499030
   Knobloch K, 2022, UNFALLCHIRURG, V125, P323, DOI 10.1007/s00113 021 01025 3
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   Krath A, 2017, J ORTHOP, V14, P410, DOI 10.1016/j.jor.2017.06.016
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Lei T, 2018, BONE, V108, P10, DOI 10.1016/j.bone.2017.12.008
   Li Y, 2021, BONE JOINT RES, V10, P767, DOI 10.1302/2046 3758.1012.BJR 2021 0274.R1
   Liao JF, 2021, BIOTECHNIQUES, V70, DOI 10.2144/btn 2020 0161
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Malaval L, 2008, J EXP MED, V205, P1145, DOI 10.1084/jem.20071294
   Mansourian M, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/6647497
   Markovic L, 2022, WIEN KLIN WOCHENSCHR, V134, P425, DOI 10.1007/s00508 022 02020 3
   MIKUNITAKAGAKI Y, 1995, J BONE MINER RES, V10, P231, DOI 10.1002/jbmr.5650100209
   Millán JL, 2013, CALCIFIED TISSUE INT, V93, P299, DOI 10.1007/s00223 012 9672 8
   Murshed M, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031229
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Pall ML, 2013, J CELL MOL MED, V17, P958, DOI 10.1111/jcmm.12088
   Petecchia L, 2015, SCI REP UK, V5, DOI 10.1038/srep13856
   Präbst K, 2017, METHODS MOL BIOL, V1601, P1, DOI 10.1007/978 1 4939 6960 9_1
   Ren RY, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.13122
   Robertson GAJ, 2016, BRIT MED BULL, V119, P111, DOI 10.1093/bmb/ldw029
   SABOKBAR A, 1994, BONE MINER, V27, P57, DOI 10.1016/S0169 6009(08)80187 0
   Selvarnurugan N, 2007, J ORTHOP RES, V25, P1213, DOI 10.1002/jor.20409
   Soltanoff CS, 2009, CRIT REV EUKAR GENE, V19, P1, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.10
   Spaepen P, 2011, METHODS MOL BIOL, V740, P209, DOI 10.1007/978 1 61779 108 6_21
   Tuebel J, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 96719 4
   Vadalà M, 2016, CANCER MED US, V5, P3128, DOI 10.1002/cam4.861
   Vimalraj S, 2020, GENE, V754, DOI 10.1016/j.gene.2020.144855
   Wang P, 2017, BIOELECTROMAGNETICS, V38, P602, DOI 10.1002/bem.22070
   Wang YH, 2006, BIOTECHNOL PROGR, V22, P1697, DOI 10.1021/bp060274b
   Yan ZD, 2022, SCI ADV, V8, DOI 10.1126/sciadv.abq0222
   Zhu L, 2001, CURR OPIN GENET DEV, V11, P91, DOI 10.1016/S0959 437X(00)00162 3
   Zoch ML, 2016, BONE, V82, P42, DOI 10.1016/j.bone.2015.05.046
NR 49
TC 1
Z9 1
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2227 9059
J9 BIOMEDICINES
JI Biomedicines
PD OCT
PY 2024
VL 12
IS 10
AR 2269
DI 10.3390/biomedicines12102269
PG 17
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA K4V9H
UT WOS:001343879400001
PM 39457582
OA gold
DA 2025 08 17
ER

PT J
AU Xu, ZY
   Yan, Y
   He, J
   Shan, XF
   Wu, WG
AF Xu, Zhengyuan
   Yan, Yan
   He, Jian
   Shan, Xinfang
   Wu, Weiguo
TI Pathway Cross Talk Analysis in Detecting Significant Pathways in
   Barrett's Esophagus Patients
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE Barrett Esophagus; Critical Pathways; Gene Regulatory Networks
ID KYOTO ENCYCLOPEDIA; GENE; ADENOCARCINOMA; PROGRESSION; POWERFUL; TERMS;
   KEGG; CELL; TOOL
AB Background: The pathological mechanism of Barrett's esophagus (BE) is still unclear. In the present study, pathway crosstalks were analyzed to identify hub pathways for BE, with the purpose of finding an efficient and cost effective detection method to discover BE at its early stage and take steps to prevent its progression.
   Material/Methods: We collected and preprocessed gene expression profile data, original pathway data, and protein protein interaction (PPI) data. Then, we constructed a background pathway cross talk network (BPCN) based on the original pathway data and PPI data, and a disease pathway cross talk network (DPCN) based on the differential pathways between the PPI data and the BE and normal control. Finally, a comprehensive analysis was conducted on these 2 networks to identify hub pathway cross talks for BE, so as to better understand the pathological mechanism of BE from the pathway level.
   Results: A total of 12 411 genes, 300 pathways (6919 genes), and 787 896 PPI interactions (16 730 genes) were separately obtained from their own databases. Then, we constructed a BPCN with 300 nodes (42 293 interactions) and a DPCN with 296 nodes (15 073 interactions). We identified 4 hub pathways: AMP signaling pathway, cGMP PKG signaling pathway, natural killer cell mediated cytotoxicity, and osteoclast differentiation. We found that these pathways might play important roles during the occurrence and development of BE.
   Conclusions: We predicted that these pathways (such as AMP signaling pathway and cAMP signaling pathway) could be used as potential biomarkers for early diagnosis and therapy of BE.
C1 [Xu, Zhengyuan] Shuyang Peoples Hosp, Dept Digest Med, Shuyang, Jiangsu, Peoples R China.
   [Yan, Yan] 1st Peoples Hosp Jinan, Supply Room, Jinan, Shandong, Peoples R China.
   [He, Jian] Ist Peoples Hosp Jinan, Dept Digest Med, Jinan, Shandong, Peoples R China.
   [Shan, Xinfang] Binzhou City Ctr Hosp, Dept Thyroid & Breast Surg, Binzhou, Shandong, Peoples R China.
   [Wu, Weiguo] Nanjing Med Univ, Affiliated Wuxi Hosp 2, Dept Med, Wuxi, Jiangsu, Peoples R China.
C3 Nanjing Medical University
RP Wu, WG (通讯作者)，Nanjing Med Univ, Affiliated Wuxi Hosp 2, Dept Med, Wuxi, Jiangsu, Peoples R China.
EM wuweiguoa@yeah.net
CR Al Shahrour F, 2004, BIOINFORMATICS, V20, P578, DOI 10.1093/bioinformatics/btg455
   [Anonymous], 2004, Approximating clustering coefficient and transitivity
   [Anonymous], 1994, Social network analysis
   Barthélemy M, 2004, EUR PHYS J B, V38, P163, DOI 10.1140/epjb/e2004 00111 4
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Breitling R, 2004, FEBS LETT, V573, P83, DOI 10.1016/j.febslet.2004.07.055
   Choi JK, 2004, FEBS LETT, V565, P93, DOI 10.1016/j.febslet.2004.03.081
   Clément G, 2006, ONCOGENE, V25, P3084, DOI 10.1038/sj.onc.1209338
   Cook MB, 2015, CANCER RES, V75, DOI 10.1158/1538 7445.AM2015 837
   Dumaz N, 2005, FEBS J, V272, P3491, DOI 10.1111/j.1742 4658.2005.04763.x
   Dvorak K, 2007, CLIN CANCER RES, V13, P5305, DOI 10.1158/1078 0432.CCR 07 0483
   Ein Dor L, 2005, BIOINFORMATICS, V21, P171, DOI 10.1093/bioinformatics/bth469
   Feilchenfeldt J, 2015, BRIT J CANCER, V113, P716, DOI 10.1038/bjc.2015.279
   Gilbert D, 2005, BRIEF BIOINFORM, V6, P194, DOI 10.1093/bib/6.2.194
   Glazko GV, 2009, BIOINFORMATICS, V25, P2348, DOI 10.1093/bioinformatics/btp406
   Goeman JJ, 2007, BIOINFORMATICS, V23, P980, DOI 10.1093/bioinformatics/btm051
   Haythornthwaite C., 1996, LIB INFORM SCI RES, V18, P323, DOI DOI 10.1016/S0740 8188(96)90003 1
   Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb 2007 8 9 r183
   Hyland PL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093219
   Jensen LJ, 2009, NUCLEIC ACIDS RES, V37, pD412, DOI 10.1093/nar/gkn760
   Joshi Tope G, 2005, NUCLEIC ACIDS RES, V33, pD428, DOI 10.1093/nar/gki072
   Kaakoush NO, 2015, TRENDS MICROBIOL, V23, P455, DOI 10.1016/j.tim.2015.03.009
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kapoor H, 2015, TRANSL RES, V166, P28, DOI 10.1016/j.trsl.2015.01.009
   Li X, 2015, CANCER PREV RES, V8, P845, DOI 10.1158/1940 6207.CAPR 15 0130
   Li Y, 2008, BIOINFORMATICS, V24, P1442, DOI 10.1093/bioinformatics/btn200
   Mar JC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025445
   Myers L., 2004, Encyclopedia of Statistical Sciences
   Pera M, 2005, J SURG ONCOL, V92, P151, DOI 10.1002/jso.20357
   Souza RF, 2002, GASTROENTEROLOGY, V122, P299, DOI 10.1053/gast.2002.30993
   Stairs DB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003534
   Stark C, 2006, NUCLEIC ACIDS RES, V34, pD535, DOI 10.1093/nar/gkj109
   Streppel MM, 2014, ONCOGENE, V33, P347, DOI 10.1038/onc.2012.586
   Sun SY, 2013, SCI REP UK, V3, DOI 10.1038/srep02268
   Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317
   Wellmann A, 2000, BLOOD, V96, P398
   Wu YM, 2014, AMINO ACIDS, V46, P2025, DOI 10.1007/s00726 014 1760 9
   Zeng HT, 2014, BIOL REPROD, V91, DOI 10.1095/biolreprod.114.118471
NR 38
TC 2
Z9 2
U1 0
U2 2
PU INT SCIENTIFIC INFORMATION, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
SN 1643 3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD MAR 6
PY 2017
VL 23
DI 10.12659/MSM.899623
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA EM8HH
UT WOS:000395551600002
PM 28263955
OA Green Published
DA 2025 08 17
ER

PT J
AU Bolognese, MA
AF Bolognese, Michael A.
TI SERMs and SERMs with estrogen for postmenopausal osteoporosis
SO REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
LA English
DT Article
DE Osteoporosis; SERMs; FRAX; Tissue selective estrogen complex (TSEC)
ID CONTINUING OUTCOMES RELEVANT; BONE MINERAL DENSITY; BREAST CANCER;
   BAZEDOXIFENE/CONJUGATED ESTROGENS; RECEPTOR MODULATOR; MULTIPLE
   OUTCOMES; URINARY INCONTINENCE; MENOPAUSAL SYMPTOMS; ADVERSE EVENTS;
   RALOXIFENE
AB Bone loss with aging places postmenopausal women at a higher risk for osteoporosis and its consequences such as fractures, pain, disability, and increased morbidity and mortality. Approximately 200 million patients worldwide are affected. The Third National Health and Nutrition Examination Survey (NHANES III) estimated that up to 18% of US women aged 50 and older have osteoporosis and up to 50% have osteopenia. Greater than 2 million osteoporotic related fractures occurred in the United States with direct healthcare costs exceeding $17 billion. Hormone Replacement Therapy (HRT) was a popular option for postmenopausal women before the Women's Health Initiative (WHI). Several agents are available in the U.S., including bisphosphonates, hormone therapy, calcitonin, parathyroid hormone and the selective estrogen receptor modulator (SERM) raloxifene. There are concerns about long term safety and compliance. Therefore, other agents are under investigation. SERMs are a diverse group of agents that bind to the estrogen receptor and each SERM appears to have a unique set of clinical responses, which are not always consistent with the typical responses seen with other SERMs. This article will discuss the SERMs approved in the United States, tamoxifene and raloxifene, and investigational SERMs. The ideal SERM would include the beneficial effects of estrogen in bone, heart and the central nervous system, with neutral or antagonistic effects in tissues where estrogen effects are undesirable(breast and endometrium). A new target in treating postmenopausal osteoporosis is the tissue estrogen complex or the pairing of a SERM with a conjugated estrogen known as a tissue selective estrogen complex (TSEC). This novel approach is currently being evaluated with bazodoxifene which could yield the beneficial effects of estrogens and SERMS, while potentially being more tolerable and safer than either therapy alone.
C1 [Bolognese, Michael A.] Bethesda Hlth Res, Bethesda, MD USA.
   [Bolognese, Michael A.] Johns Hopkins Suburban Hosp, Bethesda, MD 20817 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Bolognese, MA (通讯作者)，Bethesda Hlth Res, Bethesda, MD USA.
EM mbolognese@erols.com
CR ALERTAZZI P, 2005, CLIMACTERIC, V8, P214
   Archer DE, 2009, FERTIL STERIL, V92, P1039, DOI 10.1016/j.fertnstert.2009.05.093
   Ariazi EA, 2006, CURR TOP MED CHEM, V6, P181, DOI 10.2174/156802606776173483
   Barrett Connor E, 2006, NEW ENGL J MED, V355, P125, DOI 10.1056/NEJMoa062462
   Bolognese M, 2009, BONE, V44, pS230, DOI 10.1016/j.bone.2009.03.084
   Boss SM, 1997, AM J OBSTET GYNECOL, V177, P1458, DOI 10.1016/S0002 9378(97)70091 7
   BUDZAR A, 2002, BREAST CANC RES TREA, V73, P161
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Cauley JA, 2001, BREAST CANCER RES TR, V65, P125, DOI 10.1023/A:1006478317173
   Cummings SR, 1999, JAMA J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189
   Cummings SR, 2010, NEW ENGL J MED, V362, P686, DOI 10.1056/NEJMoa0808692
   Davies GC, 1999, MENOPAUSE, V6, P188
   Davies GC, 1999, OBSTET GYNECOL, V93, P558, DOI 10.1016/S0029 7844(98)00476 1
   Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301
   Dignam JJ, 2000, LANCET, V355, P848, DOI 10.1016/S0140 6736(05)72466 1
   Draper MW, 1996, J BONE MINER RES, V11, P835
   Duvernoy CS, 2005, MENOPAUSE, V12, P444, DOI 10.1097/01.GME.0000151653.02620.89
   *E LILL CO, 2007, EV RAL HCL PACK INS
   Ensrud K, 2006, AM J CARDIOL, V97, P520, DOI 10.1016/j.amjcard.2005.09.083
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371
   Fleischer AC, 1999, J ULTRAS MED, V18, P503
   Gardner M, 2006, J CLIN PHARMACOL, V46, P52, DOI 10.1177/0091270005283280
   Goldstein SR, 2005, MENOPAUSE, V12, P160, DOI 10.1097/00042192 200512020 00010
   Goldstein SR, 2001, OBSTET GYNECOL, V98, P91, DOI 10.1016/S0029 7844(01)01390 4
   Grady D, 2004, OBSTET GYNECOL, V104, P837, DOI 10.1097/01.AOG.0000137349.79204.b8
   Johnston CC, 2000, ARCH INTERN MED, V160, P3444, DOI 10.1001/archinte.160.22.3444
   Jolly EE, 2003, MENOPAUSE, V10, P337, DOI 10.1097/01.GME.0000058772.59606.2A
   Kanis JA, 2009, BONE, V44, P734, DOI 10.1016/j.bone.2009.01.373
   Kharode Y, 2008, ENDOCRINOLOGY, V149, P6084, DOI 10.1210/en.2008 0817
   Komm BS, 2008, REPROD SCI, V15, P984, DOI 10.1177/1933719108325759
   Komm BS, 2005, ENDOCRINOLOGY, V146, P3999, DOI 10.1210/en.2005 0030
   Lindsay R, 2009, FERTIL STERIL, V92, P1045, DOI 10.1016/j.fertnstert.2009.02.093
   Lobo RA, 2009, FERTIL STERIL, V92, P1025, DOI 10.1016/j.fertnstert.2009.03.113
   Looker AC, 1997, J BONE MINER RES, V12, P1761, DOI 10.1359/jbmr.1997.12.11.1761
   LOVE RR, 1991, ARCH INTERN MED, V151, P1842, DOI 10.1001/archinte.151.9.1842
   Martino S, 2005, CURR MED RES OPIN, V21, P1441, DOI 10.1185/030079905X61839
   Martino S, 2004, J NATL CANCER I, V96, P1751, DOI 10.1093/jnci/djh319
   McClung MR, 2006, MENOPAUSE, V13, P377, DOI 10.1097/01.gme.0000188736.69617.4f
   Miller PD, 2008, J BONE MINER RES, V23, P525, DOI 10.1359/JBMR.071206
   Neven P, 2005, MATURITAS, V52, P87, DOI 10.1016/j.maturitas.2005.03.010
   Neven P, 2002, GYNECOL ONCOL, V85, P388, DOI 10.1006/gyno.2001.6578
   Pickar JH, 2009, FERTIL STERIL, V92, P1018, DOI 10.1016/j.fertnstert.2009.05.094
   Ravn P, 2006, ACTA OBSTET GYN SCAN, V85, P135, DOI 10.1080/00016340500345691
   Reid IR, 2004, ARCH INTERN MED, V164, P871, DOI 10.1001/archinte.164.8.871
   Ronkin S, 2005, OBSTET GYNECOL, V105, P1397, DOI 10.1097/01.AOG.0000163253.27610.b9
   Shelly W, 2008, OBSTET GYNECOL SURV, V63, P163, DOI 10.1097/OGX.0b013e31816400d7
   Siris ES, 2004, J BONE MINER RES, V19, pS96
   Siris ES, 2005, J BONE MINER RES, V20, P1514, DOI 10.1359/JBMR.050509
   Siris ES, 2004, ARCH INTERN MED, V164, P1108, DOI 10.1001/archinte.164.10.1108
   Taylor HS, 2010, FORMULARY, V45, P52
   van Rietbergen B, 2002, CLIN BIOMECH, V17, P81, DOI 10.1016/S0268 0033(01)00110 3
   Veronesi U, 2005, LANCET, V365, P1727, DOI 10.1016/S0140 6736(05)66546 4
   Vogel VG, 2006, JAMA J AM MED ASSOC, V295, P2727, DOI 10.1001/jama.295.23.joc60074
   Vogelvang TE, 2006, DRUGS, V66, P191, DOI 10.2165/00003495 200666020 00005
   Waetjen LE, 2004, OBSTET GYNECOL, V103, P261, DOI 10.1097/01.AOG.0000109429.67671.d1
   Yaffe K, 2005, AM J PSYCHIAT, V162, P683, DOI 10.1176/appi.ajp.162.4.683
   Yaffe K, 2001, NEW ENGL J MED, V344, P1207, DOI 10.1056/NEJM200104193441604
NR 58
TC 19
Z9 22
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1389 9155
EI 1573 2606
J9 REV ENDOCR METAB DIS
JI Rev. Endocr. Metab. Disord.
PD DEC
PY 2010
VL 11
IS 4
BP 253
EP 259
DI 10.1007/s11154 010 9137 1
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 711YJ
UT WOS:000286627900005
PM 20446043
DA 2025 08 17
ER

PT J
AU Furugen, M
   Watanabe, N
   Nishino, S
   Kimura, T
   Ashikaga, K
   Kuriyama, N
   Shibata, Y
AF Furugen, Makoto
   Watanabe, Nozomi
   Nishino, Shun
   Kimura, Toshiyuki
   Ashikaga, Keiichi
   Kuriyama, Nehiro
   Shibata, Yoshisato
TI Impact of osteogenic activity on degenerative aortic valve disease in
   patients with osteoporotic hip fracture
SO JOURNAL OF CARDIOLOGY
LA English
DT Article
DE Osteoporosis; Degenerative aortic valve disease; Osteoblast
ID MITRAL ANNULAR CALCIFICATION; CARDIOVASCULAR RISK FACTORS; BONE TURNOVER
   MARKERS; MINERAL DENSITY; SEX DIFFERENCES; STENOSIS; INFLAMMATION; MEN
AB Background: Previous studies have proposed that osteogenic and apoptotic processes of valve intersti tial cells contribute to the mineralization and then calcification of the aortic valve. Osteoblast like cells subsequently mediate calcification of the aortic valve as part of a highly regulated process analogous to skeletal bone formation. The objective of this study was to evaluate the pathogenesis of the scle rotic/calcific changes in the aortic valve from histological and biological findings, and investigate the role of osteoblasts in the calcified pathway of aortic stenosis. Methods: Preoperative echocardiography in 550 consecutive patients with osteoporotic hip fracture were retrospectively examined (475 females, mean 25th 75th, 89 [85 93] years). One hundred sixteen patients were under medical treatment with anti osteoporosis drugs. We evaluated the prevalence and degree of degenerative changes in the aortic valve and examined the associations of bone turnover biomarkers N terminal pro peptide of type 1 collagen (P1NP) and serum tartrate resistant acid phosphatase (TRACP 5b) with degenerative calcific changes in the aortic valve. Results: Of 550 patients, 112 patients (20.9%) showed no leaflet calcification; 296 (53.8%), 1 leaflet calcifi cation; and 142 (25.8%), 2 > leaflets calcification. Significant (peak velocity > 3.0m/s) Aortic stenosis was found in 43 patients (7.8%). In patients who were not taking anti osteoporotic drugs, P1NP was higher in the 2 > leaflets calcification group than in the other groups (p < 0.01). TRACP 5b was not significantly different among the three groups (p = 0.15). Conclusions: Degenerative changes in the aortic valve were related to bone biomarker activation in os teoporotic hip fracture patients. (c) 2021 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
C1 [Furugen, Makoto; Watanabe, Nozomi; Nishino, Shun; Kimura, Toshiyuki; Ashikaga, Keiichi; Kuriyama, Nehiro; Shibata, Yoshisato] Miyazaki Med Assoc Hosp, Cardiovasc Ctr, Miyazaki, Japan.
   [Furugen, Makoto] Hokkaido Cardiovasc Hosp, Dept Cardiol, Sapporo, Hokkaido, Japan.
   [Watanabe, Nozomi] Univ Miyazaki, Fac Med, Div Cardiovasc Physiol, Miyazaki, Japan.
C3 University of Miyazaki
RP Furugen, M (通讯作者)，Miyazaki Med Assoc Hosp, Cardiovasc Ctr, Miyazaki, Japan.; Furugen, M (通讯作者)，Hokkaido Cardiovasc Hosp, Dept Cardiol, Sapporo, Hokkaido, Japan.
EM m_furugen@hotmail.com
RI Nishino, Shun/AGL 6979 2022
OI Nishino, Shun/0000 0001 5879 4382
CR Aggarwal SR, 2013, CIRC CARDIOVASC IMAG, V6, P40, DOI 10.1161/CIRCIMAGING.112.980052
   Aksoy Y, 2005, CORONARY ARTERY DIS, V16, P379, DOI 10.1097/00019501 200509000 00007
   Appelman Y, 2015, ATHEROSCLEROSIS, V241, P211, DOI 10.1016/j.atherosclerosis.2015.01.027
   Arounlangsy Phetsamone, 2004, Journal of Medical and Dental Sciences, V51, P35
   Choi SH, 2009, CLIN ENDOCRINOL, V71, P644, DOI 10.1111/j.1365 2265.2009.03535.x
   Côté N, 2012, J MOL CELL CARDIOL, V52, P1191, DOI 10.1016/j.yjmcc.2012.02.003
   Davutoglu V, 2004, AM HEART J, V147, P1113, DOI 10.1016/j.ahj.2003.12.002
   Di Pasquale G, 2019, EUR HEART J SUPPL, V21, pB52, DOI 10.1093/eurheartj/suz017
   Freeman RV, 2005, CIRCULATION, V111, P3316, DOI 10.1161/CIRCULATIONAHA.104.486738
   Fujita Y, 2013, BONE, V56, P61, DOI 10.1016/j.bone.2013.05.004
   Halleen JM, 2006, CLIN LAB, V52, P499
   Ivaska KK, 2007, J BONE MINER RES, V22, P1155, DOI 10.1359/JBMR.070505
   Iwata S, 2012, J CLIN ENDOCR METAB, V97, P132, DOI 10.1210/jc.2011 2107
   Jousilahti P, 1999, CIRCULATION, V99, P1165, DOI 10.1161/01.cir.99.9.1165
   Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244
   Lerman D. A., 2016, INT J CARDIOVASC RES, V5
   Lindman BR, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.6
   Marquis Gravel G, 2016, CIRCULATION, V134, P1766, DOI 10.1161/CIRCULATIONAHA.116.023997
   Meng XZ, 2008, AM J PHYSIOL CELL PH, V294, pC29, DOI 10.1152/ajpcell.00137.2007
   Mohler ER, 2001, CIRCULATION, V103, P1522, DOI 10.1161/01.cir.103.11.1522
   OTTO CM, 1994, CIRCULATION, V90, P844, DOI 10.1161/01.CIR.90.2.844
   Persy V, 2009, TRENDS MOL MED, V15, P405, DOI 10.1016/j.molmed.2009.07.001
   Rajamannan NM, 2003, CIRCULATION, V107, P2181, DOI 10.1161/01.CIR.0000070591.21548.69
   Simard L, 2017, CIRC RES, V120, P681, DOI 10.1161/CIRCRESAHA.116.309306
   Skolnick AH, 2009, AM J CARDIOL, V104, P122, DOI 10.1016/j.amjcard.2009.02.051
   Spampinato RA, 2020, J CARDIOL, V76, P154, DOI 10.1016/j.jjcc.2020.02.019
   Sritharen Y, 2017, PHYSIOLOGY, V32, P182, DOI 10.1152/physiol.00025.2016
   SUGIHARA N, 1993, JPN CIRC J, V57, P14, DOI 10.1253/jcj.57.14
   Synetos A, 2018, J CARDIOVASC TRANSL, V11, P192, DOI 10.1007/s12265 018 9802 4
   Szulc P, 2017, OSTEOPOROSIS INT, V28, P2541, DOI 10.1007/s00198 017 4082 4
   Tokuda Y, 2020, CIRC J, V84, P277, DOI 10.1253/circj.CJ 19 0674
   Yamamoto K, 2010, HYPERTENS RES, V33, P269, DOI 10.1038/hr.2009.225
   Yamaura Y, 2019, CIRC CARDIOVASC IMAG, V12, DOI 10.1161/CIRCIMAGING.119.008901
NR 33
TC 3
Z9 3
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0914 5087
EI 1876 4738
J9 J CARDIOL
JI J. Cardiol.
PD NOV
PY 2021
VL 78
IS 5
BP 423
EP 430
DI 10.1016/j.jjcc.2021.05.014
EA SEP 2021
PG 8
WC Cardiac & Cardiovascular Systems
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cardiovascular System & Cardiology
GA WB2YW
UT WOS:000703444100011
PM 34130877
OA Bronze
DA 2025 08 17
ER

PT J
AU Hutton, B
   Morretto, P
   Emmenegger, U
   Mazzarello, S
   Kuchuk, I
   Addison, CL
   Crawley, F
   Canil, C
   Malone, S
   Berry, S
   Fergusson, D
   Clemons, M
AF Hutton, Brian
   Morretto, Patricia
   Emmenegger, Urban
   Mazzarello, Sasha
   Kuchuk, Iryna
   Addison, Christina L.
   Crawley, Freya
   Canil, Christine
   Malone, Shawn
   Berry, Scott
   Fergusson, Dean
   Clemons, Mark
TI Bone targeted agent use for bone metastases from breast cancer and
   prostate cancer: A patient survey
SO JOURNAL OF BONE ONCOLOGY
LA English
DT Article
DE Bone metastases; Breast cancer; Prostate cancer; Patients; Survey
ID ZOLEDRONIC ACID; SKELETAL COMPLICATIONS; IBANDRONATE; PLACEBO; TRIAL
AB Background: In order to design studies assessing the optimal use of bone targeted agents (BTAs) patient input is clearly desirable.
   Methods: Patients who were receiving a BTA for metastatic prostate or breast cancer were surveyed at two Canadian cancer centres. Statistical analysis of respondent data was performed to establish relevant proportions of patient responses.
   Results: Responses were received from 141 patients, 76 (53.9%) with prostate cancer and 65 (46.1%) with breast cancer. Duration of BTA use was < 3 months (15.9%) to > 24 months (35.2%). Patients were uncertain how long they would remain on a BTA. While most felt their BTA was given to reduce the chance of bone fractures (77%), 52% thought it would slow tumour growth. Prostate patients were more likely to receive denosumab and breast cancer patients, pamidronate. There was more variability in the dosing interval for breast cancer patients. Given a choice, most patients (49 57%) would prefer injection therapy to oral therapy (21 23%). Most patients (58 64%) were interested in enrolling in clinical trials of de escalated therapy.
   Conclusion: While there were clear differences in the types of BTAs patients received, our survey showed similarity for both prostate and breast cancer patients with respect to their perceptions of the goals of therapy. Patients were interested in participating in trials of de escalated therapy. However, given that patients receive a range of agents for varying periods of time and in different locations (e.g. hospital vs. home), the design of future trials will need to be pragmatic to reflect this. (C) 2013 Elsevier GmbH. All rights reserved.
C1 [Hutton, Brian; Addison, Christina L.; Fergusson, Dean; Clemons, Mark] Ottawa Hosp, Res Inst, Ottawa, ON K1H 8L6, Canada.
   [Hutton, Brian; Fergusson, Dean] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada.
   [Morretto, Patricia; Mazzarello, Sasha; Kuchuk, Iryna; Crawley, Freya; Canil, Christine; Clemons, Mark] Ottawa Hosp, Ctr Canc, Ottawa, ON K1H 8L6, Canada.
   [Morretto, Patricia; Mazzarello, Sasha; Kuchuk, Iryna; Crawley, Freya; Canil, Christine; Clemons, Mark] Univ Ottawa, Dept Med, Ottawa, ON K1H 8L6, Canada.
   [Emmenegger, Urban; Berry, Scott] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.
   [Malone, Shawn] Ottawa Gen Hosp, Dept Radiol, Ottawa, ON K1H 8L6, Canada.
C3 University of Ottawa; Ottawa Hospital Research Institute; University of
   Ottawa; University of Ottawa; Ottawa Hospital Research Institute;
   University of Ottawa; University of Toronto; Sunnybrook Health Science
   Center; Sunnybrook Research Institute; University of Ottawa; Ottawa
   Hospital Research Institute
RP Clemons, M (通讯作者)，Ottawa Hosp, Div Med Oncol, Ctr Canc, Box 912,501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.
EM mclemons@toh.on.ca
RI Fergusson, Dean/A 5729 2013
OI Fergusson, Dean/0000 0002 3389 2485; Mazzarello,
   Sasha/0000 0003 1299 5132; Hutton, Brian/0000 0001 5662 8647
CR Amadori D, 2012, J CLIN ONCOLOGY, V30
   Amir E, 2012, AM J CLIN ONCOLOGY
   Espinosa JC, 2012, CLIN TRANSL ONCOL, V14, P505, DOI 10.1007/s12094 012 0832 0
   Clemons M, 2008, BREAST CANCER RES TR, V108, P79, DOI 10.1007/s10549 007 9583 y
   Coleman RE, 2012, NAT REV CLIN ONCOL, V9, P76, DOI 10.1038/nrclinonc.2011.198
   Coleman RE, 2012, J CLIN ONCOL, V30
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401
   Kohno N, 2005, J CLIN ONCOL, V23, P3314, DOI 10.1200/JCO.2005.05.116
   Kuchuk I, 2012, CURR ONCOL, V19, pE303, DOI 10.3747/co.19.1009
   Kuchuk I, 2012, J BONE ONCOLOGY 2012
   Low E, 2012, 54 ASH M
   Ryzner Kristi L, 2010, Consult Pharm, V25, P671, DOI 10.4140/TCP.n.2010.671
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Tripathy D, 2004, CLIN THER, V26, P1947, DOI 10.1016/j.clinthera.2004.12.010
   Van Poznak CH, 2011, J ONCOL PRACT, V7, P117, DOI 10.1200/JOP.2011.000212
   Van Poznak CH, 2011, J CLIN ONCOL, V29, P1221, DOI 10.1200/JCO.2010.32.5209
NR 18
TC 17
Z9 17
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2212 1374
J9 J BONE ONCOL
JI J. Bone Oncol.
PD SEP
PY 2013
VL 2
IS 3
BP 105
EP 109
DI 10.1016/j.jbo.2013.05.002
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA V37LO
UT WOS:000209277500002
PM 26909279
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Rossi, F
   Perrotta, S
   Bellini, G
   Luongo, L
   Tortora, C
   Siniscalco, D
   Francese, M
   Torella, M
   Nobili, B
   Di Marzo, V
   Maione, S
AF Rossi, Francesca
   Perrotta, Silverio
   Bellini, Giulia
   Luongo, Livio
   Tortora, Chiara
   Siniscalco, Dario
   Francese, Matteo
   Torella, Marco
   Nobili, Bruno
   Di Marzo, Vincenzo
   Maione, Sabatino
TI Iron overload causes osteoporosis in thalassemia major patients through
   interaction with transient receptor potential vanilloid type 1
   (TRPV1) channels
SO HAEMATOLOGICA
LA English
DT Article
ID CANNABINOID RECEPTOR; OSTEOCLAST ACTIVITY; MAGNETIC RESONANCE; BONE
   METABOLISM; DISEASE; HISTOMORPHOMETRY; DIFFERENTIATION; OSTEOPROTEGERIN;
   PAMIDRONATE; EXPRESSION
AB The pathogenesis of bone resorption in beta thalassemia major is multifactorial and our understanding of the under lying molecular and cellular mechanisms remains incomplete. Considering the emerging importance of the endocannabinoid/endovanilloid system in bone metabolism, it may be instructive to examine a potential role for this system in the development of osteoporosis in patients with beta thalassemia major and its relationship with iron overload and iron chelation therapy. This study demonstrates that, in thalassemic derived osteoclasts, tartrate resistant acid phosphatase expression inversely correlates with femoral and lumbar bone mineral density, and directly correlates with ferritin levels and liver iron concentration. The vanilloid agonist resiniferatoxin dramatical ly reduces cathepsin K levels and osteoclast numbers in vitro, without affecting tartrate resistant acid phosphatase expression. The iron chelators deferoxamine, deferiprone and deferasirox decrease both tartrate resistant acid phosphatase and cathepsin K expression, as well as osteoclast activity. Taken together, these data show that transient receptor potential vanilloid type 1 activation/desensitization influences tartrate resistant acid phosphatase expression and activity, and this effect is dependent on iron, suggesting a pivotal role for iron overload in the dysregulation of bone metabolism in patients with thalassemia major. Our applied pharmacology provides evidence for the potential of iron chelators to abrogate these effects by reducing osteoclast activity. Whether iron chelation therapy is capable of restoring bone health in humans requires further study, but the potential to provide dual benefits for patients with beta thalassemia major  preventing iron overload and alleviating associated osteoporotic changes   is exciting.
C1 [Rossi, Francesca; Perrotta, Silverio; Tortora, Chiara; Francese, Matteo; Torella, Marco; Nobili, Bruno] Univ Naples 2, Dept Woman Child & Gen & Specialist Surg, Pozzuoli, Italy.
   [Bellini, Giulia; Luongo, Livio; Tortora, Chiara; Siniscalco, Dario; Maione, Sabatino] Univ Naples 2, Dept Expt Med, Pozzuoli, Italy.
   [Di Marzo, Vincenzo] CNR, Inst Biomol Chem, Pozzuoli, Italy.
   [Di Marzo, Vincenzo; Maione, Sabatino] Endocannabinoid Res Grp, Pozzuoli, Italy.
C3 Universita della Campania Vanvitelli; Universita della Campania
   Vanvitelli; Consiglio Nazionale delle Ricerche (CNR)
RP Perrotta, S (通讯作者)，Univ Naples 2, Dept Woman Child & Gen & Specialist Surg, Pozzuoli, Italy.
EM silverio.perrotta@unina2.it
RI ; Siniscalco, Dario/H 4657 2019; Di Marzo, Vincenzo/AAD 7742 2019;
   maione, sabatino/HTM 5113 2023; Luongo, Livio/GXV 1993 2022; torella,
   marco/I 7608 2012; Rossi, Francesca/HTP 5870 2023
OI Luongo, Livio/0000 0002 1949 2039; Di Marzo,
   Vincenzo/0000 0002 1490 3070; Maione, Sabatino/0000 0003 3850 6704;
   Torella, Marco/0000 0001 8853 5760; Rossi,
   Francesca/0000 0003 2879 6277; Perrotta, Silverio/0000 0001 6149 6845
FU Italian Medicines Agency (AIFA); national authority responsible for drug
   regulation in Italy [FARM5JJASJ]; Department of Women, Children and of
   General and Specialist Surgery at the Second University of Naples (Grant
   on Normal and Pathological Hematopoiesis)
FX The authors would like to thank all patients and their families for
   their participation in this study. This work was partially supported by
   the Italian Medicines Agency (AIFA) Project 2005, the national authority
   responsible for drug regulation in Italy (FARM5JJASJ) and by the
   Department of Women, Children and of General and Specialist Surgery at
   the Second University of Naples (Grant on Normal and Pathological
   Hematopoiesis). We thank Novartis for providing the DFX. The authors
   thank Kaivan Khavandi MD for medical editorial assistance with this
   manuscript. Financial support for editorial assistance was provided by
   Novartis Pharmaceuticals.
CR Anderson LJ, 2001, EUR HEART J, V22, P2171, DOI 10.1053/euhj.2001.2822
   Angelopoulos NG, 2007, PEDIATR HEMAT ONCOL, V24, P481, DOI 10.1080/08880010701533611
   [Anonymous], 1994, World Health Organ Tech Rep Ser, V843, P1
   Bab I, 2008, J NEUROENDOCRINOL, V20, P69, DOI 10.1111/j.1365 2826.2008.01675.x
   Bab I, 2009, ANN MED, V41, P560, DOI 10.1080/07853890903121025
   Bisogno T, 1997, BIOCHEM J, V322, P671, DOI 10.1042/bj3220671
   Chatterjee R, 2012, BRIT J HAEMATOL, V159, P462, DOI 10.1111/bjh.12048
   Chatterjee R, 2011, HEMOGLOBIN, V35, P653, DOI 10.3109/03630269.2011.630120
   Chatterjee Ratna, 2009, Hemoglobin, V33 Suppl 1, pS136, DOI 10.3109/03630260903347898
   DeSanctis V, 1996, EUR J PEDIATR, V155, P368, DOI 10.1007/BF01955263
   El Rawas R, 2011, BRAIN RES, V1390, P80, DOI 10.1016/j.brainres.2011.03.025
   Furukawa Y, 1997, Hum Cell, V10, P159
   Haidar R, 2011, BONE, V48, P425, DOI 10.1016/j.bone.2010.10.173
   Hankins JS, 2009, BLOOD, V113, P4853, DOI 10.1182/blood 2008 12 191643
   Hong SS, 2011, GASTROENTEROLOGY, V140, P627, DOI 10.1053/j.gastro.2010.11.003
   Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255
   Idris AI, 2008, ENDOCRINOLOGY, V149, P5619, DOI 10.1210/en.2008 0150
   Idris AI, 2010, BONE, V46, P1089, DOI 10.1016/j.bone.2010.01.368
   Idris AI, 2009, CELL METAB, V10, P139, DOI 10.1016/j.cmet.2009.07.006
   Isomura H, 2004, TOXICOLOGY, V197, P93, DOI 10.1016/j.tox.2003.12.006
   Izzo AA, 2010, OBESITY, V18, P55, DOI 10.1038/oby.2009.186
   Kramer JL, 2002, BRIT J HAEMATOL, V117, P727, DOI 10.1046/j.1365 2141.2002.03498.x
   Laprairie RB, 2012, BRIT J PHARMACOL, V167, P1583, DOI 10.1111/j.1476 5381.2012.02175.x
   Ljusberg J, 2005, J BIOL CHEM, V280, P28370, DOI 10.1074/jbc.M502469200
   Maggio A, 2011, BLOOD CELL MOL DIS, V47, P166, DOI 10.1016/j.bcmd.2011.07.002
   Mahachoklertwattana P, 2003, J CLIN ENDOCR METAB, V88, P3966, DOI 10.1210/jc.2002 021548
   Marsicano G, 2002, NATURE, V418, P530, DOI 10.1038/nature00839
   Morabito N, 2004, J BONE MINER RES, V19, P722, DOI 10.1359/JBMR.040113
   Morabito N, 2007, BONE, V40, P1588, DOI 10.1016/j.bone.2007.02.020
   Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103
   Perrotta S, 2000, BRIT J HAEMATOL, V111, P461, DOI 10.1046/j.1365 2141.2000.02382.x
   Pollak RD, 2000, BRIT J HAEMATOL, V111, P902
   Rossi F, 2009, BONE, V44, P476, DOI 10.1016/j.bone.2008.10.056
   Rossi F, 2012, PLOS ONE, P7
   Rossi F, 2013, PHARMACOL RES, V68, P7, DOI 10.1016/j.phrs.2012.10.017
   Rossi F, 2012, PHARMACOL RES, V66, P88, DOI 10.1016/j.phrs.2012.03.011
   Rossi F, 2011, BONE, V48, P997, DOI 10.1016/j.bone.2011.01.001
   Skordis Nicos, 2011, Pediatr Endocrinol Rev, V8 Suppl 2, P300
   Sooampon S, 2013, J PERIODONTAL RES, V48, P22, DOI 10.1111/j.1600 0765.2012.01493.x
   Straiker A, 2012, BRIT J PHARMACOL, V165, P2660, DOI 10.1111/j.1476 5381.2011.01744.x
   Terpos E, 2010, ANN NY ACAD SCI, V1202, P237, DOI 10.1111/j.1749 6632.2010.05542.x
   Toumba M, 2010, J OSTEOPOROS, V2010, DOI 10.4061/2010/537673
   Valenti L, 2009, OSTEOPOROSIS INT, V20, P549, DOI 10.1007/s00198 008 0701 4
   Vogiatzi MG, 2009, J BONE MINER RES, V24, P543, DOI 10.1359/JBMR.080505
   Voskaridou E, 2005, EUR J HAEMATOL, V74, P359, DOI 10.1111/j.1600 0609.2004.00395.x
   Voskaridou E, 2004, BRIT J HAEMATOL, V127, P127, DOI 10.1111/j.1365 2141.2004.05143.x
   Voskaridou E, 2003, BRIT J HAEMATOL, V123, P730, DOI 10.1046/j.1365 2141.2003.04657.x
   Voskaridou E, 2001, BRIT J HAEMATOL, V112, P36, DOI 10.1046/j.1365 2141.2001.02549.x
   Voskaridou E, 2006, HAEMATOLOGICA, V91, P1193
   Wood JC, 2005, BLOOD, V106, P1460, DOI 10.1182/blood 2004 10 3982
NR 50
TC 70
Z9 82
U1 0
U2 16
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390 6078
J9 HAEMATOLOGICA
JI Haematologica
PD DEC
PY 2014
VL 99
IS 12
BP 1876
EP 1884
DI 10.3324/haematol.2014.104463
PG 9
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA AX6EP
UT WOS:000347016400014
PM 25216685
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Salmon Gonzalez, Z
   Anchuelo, J
   Borregan, JC
   del Real, A
   Sanudo, C
   Garcia Unzueta, MT
   Riancho, JA
   Valero, C
AF Salmon Gonzalez, Zaida
   Anchuelo, Javier
   Borregan, Juan C.
   del Real, Alvaro
   Sanudo, Carolina
   Garcia Unzueta, Maria Teresa
   Riancho, Jose A.
   Valero, Carmen
TI Hyperbaric Oxygen Therapy Does Not Have a Negative Impact on Bone
   Signaling Pathways in Humans
SO HEALTHCARE
LA English
DT Article
DE hyperbaric oxygen therapy; osteoprotegerin; RANKL; sclerostin; DKK1;
   HIF 1 alpha
ID SCLEROSTIN EXPRESSION; OSTEOCLAST FORMATION; OXIDATIVE STRESS; HYPOXIA;
   CELLS
AB Introduction: Oxygen is emerging as an important factor in the local regulation of bone remodeling. Some preclinical data suggest that hyperoxia may have deleterious effects on bone cells. However, its clinical relevance is unclear. Hence, we studied the effect of hyperbaric oxygen therapy (HBOT) on serum biomarkers reflecting the status of the Wnt and receptor activator of NF kappa B ligand (RANKL) pathways, two core pathways for bone homeostasis. Materials and methods: This was a prospective study of 20 patients undergoing HBOT (mean age 58 yrs., range 35 82 yrs.) because of complications of radiotherapy or chronic anal fissure. Patients were subjected to HBOT (100% oxygen; 2.4 atmospheres absolute for 90 min). The average number of HBOT sessions was 20 +/  5 (range 8 31). Serum hypoxia inducible factor 1 alpha (HIF1 alpha), osteoprotegerin (OPG), RANKL, and the Wnt inhibitors sclerostin and dickkopf 1 (DKK1) were measured at baseline and after HBOT by using specific immunoassays. Results: HIF 1 alpha in eight patients with measurable serum levels increased from 0.084 (0.098) ng/mL at baseline to 0.146 (0.130) ng/mL after HBOT (p = 0.028). However, HBOT did not induce any significant changes in the serum levels of OPG, RANKL, sclerostin or DKK1. This was independent of the patients' diagnosis, either neoplasia or benign. Conclusion: Despite the potential concerns about hyperoxia, we found no evidence that HBOT has any detrimental effect on bone homeostasis.
C1 [Salmon Gonzalez, Zaida; del Real, Alvaro; Sanudo, Carolina; Riancho, Jose A.; Valero, Carmen] Univ Cantabria, Dept Internal Med, Hosp Univ Marques de Valdecilla, IDIVAL, Santander 39008, Spain.
   [Anchuelo, Javier] Hosp Univ Marques de Valdecilla, Serv Radiat Oncol, Santander 39008, Spain.
   [Borregan, Juan C.] Hosp Univ Marques de Valdecilla, Serv Intens Care, Santander 39008, Spain.
   [Garcia Unzueta, Maria Teresa] Hosp Univ Marques de Valdecilla, Serv Clin Biochem, IDIVAL, Santander 39008, Spain.
C3 Universidad de Cantabria; Hospital Universitario Marques de Valdecilla
   (HUMV); Hospital Universitario Marques de Valdecilla (HUMV); Hospital
   Universitario Marques de Valdecilla (HUMV); Hospital Universitario
   Marques de Valdecilla (HUMV)
RP Valero, C (通讯作者)，Univ Cantabria, Dept Internal Med, Hosp Univ Marques de Valdecilla, IDIVAL, Santander 39008, Spain.
EM zaida.salmon@scsalud.es; javiertomas.anchuelo@scsalud.es;
   juancarlos.rborregan@scsalud.es; alvarodel.real92@gmail.com;
   carolinasanudo@gmail.com; mteresa.garciau@scsalud.es;
   jose.riancho@unican.es; mirvdc@humv.es
RI ; del real, alvaro/AAI 7841 2020
OI Garcia Unzueta, Maria Teresa/0000 0003 2531 3284; Sanudo,
   Carolina/0000 0002 4287 1336; Riancho, Jose A./0000 0003 0691 8755;
   Valero Diaz de Lamadrid, Maria del Carmen/0000 0002 6620 8395; del Real,
   Alvaro/0000 0002 1057 461X; 
FU Instituto de Investigacion Sanitaria Valdecilla (IDIVAL)
FX This research was funded by Instituto de Investigacion Sanitaria
   Valdecilla (IDIVAL).
CR Adamopoulos IE, 2018, CURR OPIN RHEUMATOL, V30, P59, DOI 10.1097/BOR.0000000000000449
   Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Al Hadi H, 2013, J ORTHOP RES, V31, P1839, DOI 10.1002/jor.22443
   Arnett TR, 2010, ARCH BIOCHEM BIOPHYS, V503, P103, DOI 10.1016/j.abb.2010.07.021
   Callaway DA, 2015, J BONE MINER METAB, V33, P359, DOI 10.1007/s00774 015 0656 4
   Ceponis P, 2017, ORAL DIS, V23, P141, DOI 10.1111/odi.12489
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021 9681(87)90171 8
   Delgado Calle J, 2017, BONE, V96, P29, DOI 10.1016/j.bone.2016.10.007
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Fabre S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9113439
   Fratantonio D, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010458
   Genetos DC, 2010, J CELL BIOCHEM, V110, P457, DOI 10.1002/jcb.22559
   Hannah SS, 2021, J CELL PHYSIOL, V236, P721, DOI 10.1002/jcp.29921
   Janjic K, 2018, BMC ORAL HEALTH, V18, DOI 10.1186/s12903 018 0492 8
   Kenkre JS, 2018, ANN CLIN BIOCHEM, V55, P308, DOI 10.1177/0004563218759371
   Kobayashi Y, 2016, J BIOCHEM, V159, P387, DOI 10.1093/jb/mvv124
   Lin SS, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471 2474 15 56
   Maeda K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225525
   Matsumoto T, 2021, J BONE MINER METAB, V39, P91, DOI 10.1007/s00774 020 01153 7
   Memar MY, 2019, BIOMED PHARMACOTHER, V109, P440, DOI 10.1016/j.biopha.2018.10.142
   Mulawarmanti Dian, 2020, Eur J Dent, V14, P404, DOI 10.1055/s 0040 1712072
   Ortega MA, 2021, MEDICINA LITHUANIA, V57, DOI 10.3390/medicina57090864
   Paderno E, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18062888
   Robling AG, 2020, ANNU REV PHYSIOL, V82, P485, DOI 10.1146/annurev physiol 021119 034332
   Salmón González Z, 2020, REV OSTEOPOR METAB M, V12, P28, DOI [10.4321/S1889 836X2020000100005, 10.4321/s1889 836x2020000100005]
   Schipani E, 2009, J BONE MINER RES, V24, P1347, DOI [10.1359/JBMR.090602, 10.1359/jbmr.090602]
   Schupbach D, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115491
   Silva ML, 2017, CLIN ORAL INVEST, V21, P199, DOI 10.1007/s00784 016 1778 3
   Stegen S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 04679 7
   Takemura A, 2020, J BONE MINER METAB, V38, P631, DOI 10.1007/s00774 020 01100 6
   Tang CY, 2021, PLOS GENET, V17, DOI 10.1371/journal.pgen.1009233
   Utting JC, 2010, CELL BIOCHEM FUNCT, V28, P374, DOI 10.1002/cbf.1660
   Ververidis AN, 2020, J ORTHOP, V22, P29, DOI 10.1016/j.jor.2020.03.062
   Vezzani G, 2017, ACTA MEDICA MEDITERR, V33, P801, DOI 10.19193/0393 6384_2017_5_118
   Vezzani G, 2017, J ENZYM INHIB MED CH, V32, P707, DOI 10.1080/14756366.2017.1302440
   Watson EC, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031559
   Weivoda MM, 2017, BONE, V96, P45, DOI 10.1016/j.bone.2016.11.024
   Xu YY, 2021, ONCOGENE, V40, P1231, DOI 10.1038/s41388 020 01590 8
   Yasuda H, 2021, J BONE MINER METAB, V39, P2, DOI 10.1007/s00774 020 01175 1
   Yellowley CE, 2019, CURR OSTEOPOROS REP, V17, P26, DOI 10.1007/s11914 019 00500 6
   Yu XJ, 2015, INT J CLIN EXP PATHO, V8, P12929
NR 41
TC 5
Z9 5
U1 0
U2 2
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 2227 9032
J9 HEALTHCARE BASEL
JI Healthcare
PD DEC
PY 2021
VL 9
IS 12
AR 1714
DI 10.3390/healthcare9121714
PG 7
WC Health Care Sciences & Services; Health Policy & Services
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services
GA YC0ZR
UT WOS:000739428700001
PM 34946440
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU López Alvarez, M
   López Puente, V
   Rodríguez Valencia, C
   Angelomé, PC
   Liz Marzán, LM
   Serra, J
   Pastoriza Santos, I
   González, P
AF Lopez Alvarez, Miriam
   Lopez Puente, Vanesa
   Rodriguez Valencia, Cosme
   Angelome, Paula C.
   Liz Marzan, Luis M.
   Serra, Julia
   Pastoriza Santos, Isabel
   Gonzalez, Pio
TI Osteogenic effects of simvastatin loaded mesoporous titania thin films
SO BIOMEDICAL MATERIALS
LA English
DT Article
DE simvastatin; mesoporous titania; thin films; osteogenic activity; drug
   delivery
ID DELIVERY SYSTEM; BONE FORMATION; TIO2; COATINGS; DIFFERENTIATION;
   OSTEOPOROSIS; STATINS; DOSAGE
AB The use of statins in the field of bone regeneration is under current investigation due to the existing demand for non toxic anabolic agents capable of enhancing bone formation in cases of substantial loss. Simvastatin, a coenzyme currently prescribed in clinics to inhibit cholesterol biosynthesis, has been proven to promote osteogenic differentiation by stimulating bone formation and inhibiting osteoclasts activity. We present the loading of simvastatin in mesoporous TiO2 thin films toward combining the pro osteogenic properties of this molecule with the demonstrated bioactivity of titania. TiO2 thin films processing and characterization were carried out, as well as evaluation of MC3T3 E1 pre osteoblasts viability when directly incubated with different concentrations of simvastatin, followed by the analysis of osteogenic activity promoted by simvastatin upon loading in the thin films. The accessible porosity of 36% quantified on the 95 +/  5 nm thick mesoporous thin films, together with pore diameters of 5.5 nm, necks between pores of 2.8 nm and interpore distances of 12 +/  2 nm allow the loading of the simvastatin molecule, as confirmed by FTIR spectroscopy. Simvastatin was found to promote MC3T3 E1 pre osteoblasts viability at concentrations <= 0.01 g l( 1), with a cytotoxicity threshold of 0.05 g l( 1). We additionally found that film loadings with 0.001 g l( 1) simvastatin promotes statistically higher MC3T3 E1 pre osteoblast proliferation whereas a higher concentration of 0.01 g l( 1) leads to statistically higher osteogenic activity (ALP synthesis), after 21 days of incubation, as compared to unloaded films. These results demonstrate the potential of simvastatin local administration based on bioactive mesoporous thin films to promote pro osteogenic properties. By focusing this strategy on the coating of metallic prostheses, the supply of simvastatin to the target tissue can be favored and risks of systemic side effects will be reduced while enhancing the osteointegration of the implants.
C1 [Lopez Alvarez, Miriam; Rodriguez Valencia, Cosme; Serra, Julia; Gonzalez, Pio] Univ Vigo, IISGS, New Mat Grp, Appl Phys Dept, Vigo, Spain.
   [Lopez Puente, Vanesa; Pastoriza Santos, Isabel] Univ Vigo, CINBIO, Dept Quim Fis, E 36310 Vigo, Spain.
   [Angelome, Paula C.] Consejo Nacl Invest Cient & Tecn, Comis Nacl Energia Atom, Gerencia Quim, Ctr Atom Constituyentes, Av Gral Paz 1499,B1650KNA, Buenos Aires, DF, Argentina.
   [Liz Marzan, Luis M.] CIC biomaGUNE, Paseo Miramon 182, E 20014 Donostia San Sebastian, Spain.
   [Liz Marzan, Luis M.] Ikerbasque Basque Fdn Sci, E 48013 Bilbao, Spain.
   [Liz Marzan, Luis M.] CIBER BBN, CIBER Bioingn Biomat & Nanomed, E 20014 Donostia San Sebastian, Spain.
C3 Universidade de Vigo; Universidade de Vigo; CINBIO; Consejo Nacional de
   Investigaciones Cientificas y Tecnicas (CONICET); Comision Nacional de
   Energia Atomica (CNEA); Centro Atomico Constituyentes; CIC biomaGUNE;
   Basque Foundation for Science; CIBER   Centro de Investigacion Biomedica
   en Red; CIBERBBN
RP López Alvarez, M (通讯作者)，Univ Vigo, IISGS, New Mat Grp, Appl Phys Dept, Vigo, Spain.
EM miriammsd@uvigo.es; vanelope@uvigo.es; cosme@uvigo.es;
   angelome@cnea.gov.ar; llizmarzan@cicbiomagune.es; jserra@uvigo.es;
   pastoriza@uvigo.es; pglez@uvigo.es
RI Angelomé, Paula/AAI 3964 2021; Santos, Isabel/D 4015 2013;
   pastoriza santos, isabel/D 4015 2013; Liz Marzán, Luis/B 8910 2011
OI pastoriza santos, isabel/0000 0002 1091 1364; Lopez Alvarez,
   Miriam/0000 0003 0118 7412; , IIS Galicia Sur/0000 0003 3812 7413
FU Xunta de Galicia [GRC2013 008]; Ministerio de Economia y Competitividad
   (MINECO) [MAT2016 77809 R]; BIOCAPS [n 316265]; Spanish MINECO FPI
   [n 316265]; ANPCyT [PICT 2012 0111]
FX This work was partially funded by Xunta de Galicia GRC2013 008 and by
   the Ministerio de Economia y Competitividad (MINECO, Grant
   MAT2016 77809 R). M Lopez Alvarez and V Lopez Puente thank funding from
   FP7/REFPOT 2012 2013.1 (n 316265) BIOCAPS and Spanish MINECO FPI
   scholarship, respectively. PCA acknowledges the financial support of
   ANPCyT (PICT 2012 0111) Technical staff of CACTI (University of Vigo) is
   gratefully acknowledged.
CR Allon N, 2012, J CONTROL RELEASE, V160, P217, DOI 10.1016/j.jconrel.2011.10.033
   Angelomé PC, 2007, J PHYS CHEM C, V111, P10886, DOI 10.1021/jp069020z
   Angelomé PC, 2005, CHEM MATER, V17, P322, DOI 10.1021/cm048559b
   Bellino MG, 2013, BIOMATER SCI UK, V1, P186, DOI 10.1039/c2bm00136e
   Boissiere C, 2005, LANGMUIR, V21, P12362, DOI 10.1021/la050981z
   Brinker CJ, 1999, ADV MATER, V11, P579, DOI 10.1002/(SICI)1521 4095(199905)11:7<579::AID ADMA579>3.0.CO;2 R
   Crepaldi EL, 2003, J AM CHEM SOC, V125, P9770, DOI 10.1021/ja030070g
   Galli S, 2014, ACTA BIOMATER, V10, P5193, DOI 10.1016/j.actbio.2014.08.011
   Gertler G, 2010, LANGMUIR, V26, P6457, DOI 10.1021/la903490v
   Harmankaya N, 2013, ACTA BIOMATER, V9, P7064, DOI 10.1016/j.actbio.2013.02.040
   Kanis JA, 2013, OSTEOPOROSIS INT, V24, P23, DOI 10.1007/s00198 012 2074 y
   Karlsson J, 2015, INT J NANOMED, V10, P4425, DOI 10.2147/IJN.S83005
   Karlsson J, 2015, J MATER SCI MATER M, V26, DOI 10.1007/s10856 014 5337 7
   Karlsson J, 2014, NANO LETT, V14, P4220, DOI [10.1021/nl1501564f, 10.1021/nl501564f]
   Kheirallah M, 2016, J ORAL MAX SURG MED, V28, P205, DOI 10.1016/j.ajoms.2015.10.005
   Ledeti I, 2015, J THERM ANAL CALORIM, V121, P1093, DOI 10.1007/s10973 015 4832 5
   Liu H, 2016, BIOFABRICATION, V8, DOI 10.1088/1758 5090/8/4/045012
   Maeda T, 2001, BIOCHEM BIOPH RES CO, V280, P874, DOI 10.1006/bbrc.2000.4232
   McMaster WA, 2012, ACS APPL MATER INTER, V4, P4717, DOI 10.1021/am301093k
   Meretoja VV, 2007, TISSUE ENG, V13, P855, DOI 10.1089/ten.2006.0234
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Pullisaar H, 2014, BIOCHEM BIOPH RES CO, V447, P139, DOI 10.1016/j.bbrc.2014.03.133
   Sanchez C, 2008, CHEM MATER, V20, P682, DOI 10.1021/cm702100t
   Sayar F, 2016, ORAL DIS, V22, P775, DOI 10.1111/odi.12545
   Sendyk DI, 2016, J ORAL REHABIL, V43, P873, DOI 10.1111/joor.12438
   Socrates G., 2007, INFRARED RAMAN CHARA, DOI DOI 10.1021/JA0153520
   Soler Illia GJAA, 2012, NANOSCALE, V4, P2549, DOI 10.1039/c2nr11817c
   Violi IL, 2012, ACS APPL MATER INTER, V4, P4320, DOI 10.1021/am300990p
   Wang XD, 2013, MATERIALS, V6, P2819, DOI 10.3390/ma6072819
   Xia W, 2012, J BIOMED MATER RES B, V100B, P82, DOI 10.1002/jbm.b.31925
   Yin H, 2012, EUR J PHARMACOL, V674, P200, DOI 10.1016/j.ejphar.2011.11.024
NR 31
TC 14
Z9 14
U1 0
U2 39
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 1748 6041
EI 1748 605X
J9 BIOMED MATER
JI Biomed. Mater.
PD MAR
PY 2018
VL 13
IS 2
AR 025017
DI 10.1088/1748 605X/aa95f1
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA FU7RQ
UT WOS:000424050800002
PM 29068320
OA Green Published
DA 2025 08 17
ER

PT J
AU Sundelacruz, S
   Levin, M
   Kaplan, DL
AF Sundelacruz, Sarah
   Levin, Michael
   Kaplan, David L.
TI Depolarization Alters Phenotype, Maintains Plasticity of
   Predifferentiated Mesenchymal Stem Cells
SO TISSUE ENGINEERING PART A
LA English
DT Article
ID FIBROBLAST GROWTH FACTOR; HUMAN MYOBLAST DIFFERENTIATION; K ATP
   CHANNELS; ZEBRAFISH HEART REGENERATION; BONE MORPHOGENETIC PROTEINS;
   CORNEAL ENDOTHELIAL CELLS; MARROW STROMAL CELLS; IN VITRO; OSTEOGENIC
   DIFFERENTIATION; NEUROBLASTOMA CELLS
AB Although adult stem cell transplantation has been implemented as a therapy for tissue repair, it is limited by the availability of functional adult stem cells. A potential approach to generate stem and progenitor cells may be to modulate the differentiated status of somatic cells. Therefore, there is a need for a better understanding of how the differentiated phenotype of mature cells is regulated. We hypothesize that bioelectric signaling plays an important role in the maintenance of the differentiated state, as it is a functional regulator of the differentiation process in various cells and tissues. In this study, we asked whether the mature phenotype of osteoblasts and adipocytes derived from human mesenchymal stem cells (hMSCs) could be altered by modulation of their membrane potential. hMSC derived osteoblasts and adipocytes were depolarized by treatment with ouabain, a Na+/K+ ATPase inhibitor, or by treatment with high concentrations of extracellular K+. To characterize the effect of voltage modulation on the differentiated state, the depolarized cells were evaluated for (1) the loss of differentiation markers; (2) the up regulation of stemness markers and stem properties; and (3) differences in gene expression profiles in response to voltage modulation. hMSC derived osteoblasts and adipocytes exhibited significant down regulation of bone and fat tissue markers in response to depolarization, despite the presence of differentiation inducing soluble factors, suggesting that bioelectric signaling overrides biochemical signaling in the maintenance of cell state. Suppression of the osteoblast or adipocyte phenotype was not accompanied by up regulation of genes associated with the stem state. Thus, depolarization does not activate the stem cell genetic signature and, therefore, does not induce a full reprogramming event. However, after transdifferentiating the depolarized cells to evaluate for multi lineage potential, depolarized osteoblasts demonstrated improved ability to achieve correct adipocyte morphology compared with nondepolarized osteoblasts. The present study thus demonstrates that depolarization reduces the differentiated phenotype of hMSC derived cells and improves their transdifferentiation capacity, but does not restore a stem like genetic profile. Through global transcript profiling of depolarized osteoblasts, we identified pathways that may mediate the effects of voltage signaling on cell state, which will require a detailed mechanistic inquiry in future studies.
C1 [Sundelacruz, Sarah; Kaplan, David L.] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA.
   [Levin, Michael] Tufts Univ, Dept Biol, Medford, MA 02155 USA.
   [Levin, Michael] Tufts Univ, Ctr Regenerat & Dev Biol, Medford, MA 02155 USA.
C3 Tufts University; Tufts University; Tufts University
RP Kaplan, DL (通讯作者)，Tufts Univ, Dept Biomed Engn, 4 Colby St, Medford, MA 02155 USA.
EM david.kaplan@tufts.edu
RI ; Levin, Michael/A 5918 2011
OI Kaplan, David/0000 0002 9245 7774; Levin, Michael/0000 0001 7292 8084;
   Li, pengcheng/0009 0004 6334 051X
FU NSF; NIH through the Tissue Engineering Resource Center [P41 EB002520,
   R01 AR005593, R01 AR061988]
FX The authors thank the Tufts Center for Neuroscience Research (P30
   NS047243) and the Yale Center for Genome Analysis for assistance with
   microarray experiments. S.S. thanks the NSF for funding through the
   Graduate Research Fellowship Program. The authors also thank the NIH for
   support through the Tissue Engineering Resource Center (P41 EB002520),
   R01 AR005593, and R01 AR061988.
CR Abdallah BM, 2008, GENE THER, V15, P109, DOI 10.1038/sj.gt.3303067
   Adams DS, 2007, DEVELOPMENT, V134, P1323, DOI 10.1242/dev.02812
   Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Altizer AM, 2002, J EXP ZOOL, V293, P467, DOI 10.1002/jez.10141
   An P, 2007, PLOS BIOL, V5, P263, DOI 10.1371/journal.pbio.0050036
   Arcangeli A, 1999, J NEUROBIOL, V40, P214
   Arcangeli A, 1998, BIOCHEM BIOPH RES CO, V244, P706, DOI 10.1006/bbrc.1998.8319
   Arcangeli A, 1997, EUR J NEUROSCI, V9, P2596, DOI 10.1111/j.1460 9568.1997.tb01689.x
   Arcangeli A, 1995, J PHYSIOL LONDON, V489, P455, DOI 10.1113/jphysiol.1995.sp021065
   Arcangeli A, 2006, TRENDS CELL BIOL, V16, P631, DOI 10.1016/j.tcb.2006.10.003
   Barry FP, 2004, INT J BIOCHEM CELL B, V36, P568, DOI 10.1016/j.biocel.2003.11.001
   Beane WS, 2011, CHEM BIOL, V18, P77, DOI 10.1016/j.chembiol.2010.11.012
   Bentzon JF, 2005, BIOCHEM BIOPH RES CO, V330, P633, DOI 10.1016/j.bbrc.2005.03.072
   BERESFORD JN, 1992, J CELL SCI, V102, P341
   Blackiston DJ, 2009, CELL CYCLE, V8, P3527, DOI 10.4161/cc.8.21.9888
   Bonab MM, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471 2121 7 14
   Boutillier AL, 1999, EUR J NEUROSCI, V11, P441, DOI 10.1046/j.1460 9568.1999.00451.x
   Bowers RR, 2007, CELL CYCLE, V6, P385, DOI 10.4161/cc.6.4.3804
   Bowers RR, 2006, P NATL ACAD SCI USA, V103, P13022, DOI 10.1073/pnas.0605789103
   BURKHARDT R, 1987, BONE, V8, P157, DOI 10.1016/8756 3282(87)90015 9
   Celil AB, 2005, J BIOL CHEM, V280, P31353, DOI 10.1074/jbc.M503845200
   Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295
   Chen ZL, 2007, ANNU REV NEUROSCI, V30, P209, DOI 10.1146/annurev.neuro.30.051606.094337
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Chifflet S, 2005, AM J PHYSIOL CELL PH, V288, pC1420, DOI 10.1152/ajpcell.00259.2004
   Chifflet S, 2003, EXP CELL RES, V282, P1, DOI 10.1006/excr.2002.5664
   Chifflet S, 2012, INT J CELL BIOL
   Collard JF, 2011, BIOELECTROMAGNETICS, V32, P28, DOI 10.1002/bem.20608
   Davis MJ, 2002, CELL BIOCHEM BIOPHYS, V36, P41, DOI 10.1385/CBB:36:1:41
   De A, 2003, BRAIN RES, V981, P133, DOI 10.1016/S0006 8993(03)02997 4
   Diehlmann A, 2011, TISSUE CELL, V43, P331, DOI 10.1016/j.tice.2011.06.004
   Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224
   Fischer Lougheed J, 2001, J CELL BIOL, V153, P677, DOI 10.1083/jcb.153.4.677
   François S, 2006, STEM CELLS, V24, P1020, DOI 10.1634/stemcells.2005 0260
   Gao JZ, 2001, CELLS TISSUES ORGANS, V169, P12, DOI 10.1159/000047856
   Gentleman R, 2004, COMPSTAT 2004: PROCEEDINGS IN COMPUTATIONAL STATISTICS, P171
   Gregory CA, 2005, ANN NY ACAD SCI, V1049, P97, DOI 10.1196/annals.1334.010
   Hanada K, 1997, J BONE MINER RES, V12, P1606, DOI 10.1359/jbmr.1997.12.10.1606
   Hartmann C, 2006, TRENDS CELL BIOL, V16, P151, DOI 10.1016/j.tcb.2006.01.001
   Hata K, 2003, MOL BIOL CELL, V14, P545, DOI 10.1091/mbc.E02 06 0356
   Hinard V, 2008, DEVELOPMENT, V135, P859, DOI 10.1242/dev.011387
   Hinsenkamp M, 2011, INT ORTHOP, V35, P1577, DOI 10.1007/s00264 011 1215 9
   Hullinger TG, 2001, EXP CELL RES, V262, P69, DOI 10.1006/excr.2000.5074
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Jenkins LS, 1996, DEV BIOL, V178, P251, DOI 10.1006/dbio.1996.0216
   Jopling C, 2011, NAT REV MOL CELL BIO, V12, P79, DOI 10.1038/nrm3043
   Jopling C, 2010, NATURE, V464, P606, DOI 10.1038/nature08899
   Juretic N, 2006, AM J PHYSIOL CELL PH, V290, pC1428, DOI 10.1152/ajpcell.00449.2005
   Kang Q, 2009, STEM CELLS DEV, V18, P545, DOI 10.1089/scd.2008.0130
   Kikuchi K, 2010, NATURE, V464, P601, DOI 10.1038/nature08804
   Knopf F, 2011, DEV CELL, V20, P713, DOI 10.1016/j.devcel.2011.04.014
   Koch H, 2005, STEM CELLS DEV, V14, P621, DOI 10.1089/scd.2005.14.621
   Koller H, 1996, BRAIN, V119, P2021, DOI 10.1093/brain/119.6.2021
   Konig S, 2004, J BIOL CHEM, V279, P28187, DOI 10.1074/jbc.M313932200
   Konig S, 2006, DEVELOPMENT, V133, P3107, DOI 10.1242/dev.02479
   Kragl M, 2009, NATURE, V460, P60, DOI 10.1038/nature08152
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lecka Czernik B, 2002, ENDOCRINOLOGY, V143, P2376, DOI 10.1210/en.143.6.2376
   Lecka Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097 4644(19990901)74:3<357::AID JCB5>3.0.CO;2 7
   Lee JA, 2007, PLOS BIOL, V5, P281, DOI 10.1371/journal.pbio.0050040
   Levin M, 2007, TRENDS CELL BIOL, V17, P261, DOI 10.1016/j.tcb.2007.04.007
   Levin M, 2012, BIOESSAYS, V34, P205, DOI 10.1002/bies.201100136
   Levin M, 2011, BIOL EFF ELECTROMAGN, P39
   Levin M, 2009, SEMIN CELL DEV BIOL, V20, P543, DOI 10.1016/j.semcdb.2009.04.013
   Lin SM, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkm1075
   Liu F, 2008, J BONE MINER METAB, V26, P312, DOI 10.1007/s00774 007 0842 0
   Liu JH, 1998, J PHYSIOL LONDON, V510, P467, DOI 10.1111/j.1469 7793.1998.467bk.x
   Liu QH, 2009, P NATL ACAD SCI USA, V106, P11418, DOI 10.1073/pnas.0813307106
   Liu Y, 2011, STEM CELLS, V29, P2077, DOI 10.1002/stem.764
   Mahaut Smith MP, 2008, TRENDS PHARMACOL SCI, V29, P421, DOI 10.1016/j.tips.2008.05.007
   Martherus RSRM, 2010, PHYSIOL GENOMICS, V42A, P283, DOI 10.1152/physiolgenomics.00182.2009
   Mauney JR, 2007, BIOMATERIALS, V28, P5280, DOI 10.1016/j.biomaterials.2007.08.017
   Meinel L, 2005, BONE, V37, P688, DOI 10.1016/j.bone.2005.06.010
   Meinel L, 2006, BIOMATERIALS, V27, P4993, DOI 10.1016/j.biomaterials.2006.05.021
   Miki T, 2005, J MOL CELL CARDIOL, V38, P917, DOI 10.1016/j.yjmcc.2004.11.019
   Mirsky R, 2008, J PERIPHER NERV SYST, V13, P122, DOI 10.1111/j.1529 8027.2008.00168.x
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Neubauer M, 2005, TISSUE ENG, V11, P1840, DOI 10.1089/ten.2005.11.1840
   Neubauer M, 2004, FEBS LETT, V577, P277, DOI 10.1016/j.febslet.2004.10.020
   Ng SY, 2010, J CELL PHYSIOL, V224, P165, DOI 10.1002/jcp.22113
   Nichols CG, 2006, NATURE, V440, P470, DOI 10.1038/nature04711
   Nin V, 2009, CELL MOTIL CYTOSKEL, V66, P1087, DOI 10.1002/cm.20416
   Orlic D, 2002, CIRC RES, V91, P1092, DOI 10.1161/01.RES.0000046045.00846.B0
   Pai VP, 2012, DEVELOPMENT, V139, P313, DOI 10.1242/dev.073759
   Panáková D, 2010, NATURE, V466, P874, DOI 10.1038/nature09249
   Phinney DG, 1999, J CELL BIOCHEM, V75, P424, DOI 10.1002/(SICI)1097 4644(19991201)75:3<424::AID JCB8>3.0.CO;2 8
   PITARU S, 1993, J BONE MINER RES, V8, P919
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Ponce ML, 2008, J CELL BIOCHEM, V104, P1342, DOI 10.1002/jcb.21711
   Rajnicek AM, 2006, J CELL SCI, V119, P1723, DOI 10.1242/jcs.02896
   Salem HK, 2010, STEM CELLS, V28, P585, DOI 10.1002/stem.269
   Scavo LM, 2004, J CLIN ENDOCR METAB, V89, P3543, DOI 10.1210/jc.2003 031682
   Schilling T, 2008, J CELL BIOCHEM, V103, P413, DOI 10.1002/jcb.21415
   Schilling T, 2007, MOL CELL ENDOCRINOL, V271, P1, DOI 10.1016/j.mce.2007.03.004
   Siddappa R, 2007, J ORTHOP RES, V25, P1029, DOI 10.1002/jor.20402
   Smyth G. K., 2004, Statistical Applications in Genetics and Molecular Biology, V3, P1, DOI [DOI 10.2202/1544 6115.1027, 10.2202/1544 6115.1027]
   Sollazzo V, 2010, CLIN ORTHOP RELAT R, V468, P2260, DOI 10.1007/s11999 010 1341 5
   Song L, 2004, FASEB J, V18, P980, DOI 10.1096/fj.03 1100fje
   Song L, 2006, STEM CELLS, V24, P1707, DOI 10.1634/stemcells.2005 0604
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sundelacruz S, 2009, STEM CELL REV REP, V5, P231, DOI 10.1007/s12015 009 9080 2
   Sundelacruz S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003737
   Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800
   Suzawa M, 1999, ENDOCRINOLOGY, V140, P2125, DOI 10.1210/en.140.5.2125
   Takada I, 2007, NAT CELL BIOL, V9, P1273, DOI 10.1038/ncb1647
   Tanaka EM, 1997, J CELL BIOL, V136, P155, DOI 10.1083/jcb.136.1.155
   Thomas T, 1999, ENDOCRINOLOGY, V140, P5036, DOI 10.1210/en.140.11.5036
   Tseng AS, 2010, J NEUROSCI, V30, P13192, DOI 10.1523/JNEUROSCI.3315 10.2010
   van Vliet P, 2010, STEM CELL REV REP, V6, P178, DOI 10.1007/s12015 010 9142 5
   Vandenberg LN, 2011, DEV DYNAM, V240, P1889, DOI 10.1002/dvdy.22685
   Wagner W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002213
   Zingman LV, 2007, J APPL PHYSIOL, V103, P1888, DOI 10.1152/japplphysiol.00747.2007
NR 112
TC 76
Z9 86
U1 0
U2 25
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3341
EI 1937 335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD SEP
PY 2013
VL 19
IS 17 18
BP 1889
EP 1908
DI 10.1089/ten.tea.2012.0425.rev
PG 20
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA 190ES
UT WOS:000322322600002
PM 23738690
OA Green Published
DA 2025 08 17
ER

PT J
AU Räikkönen, J
   Taskinen, M
   Dunford, JE
   Mönkkönen, H
   Auriola, S
   Mönkkönen, J
AF Raikkonen, Johanna
   Taskinen, Markku
   Dunford, James E.
   Monkkonen, Hannu
   Auriola, Seppo
   Monkkonen, Jukka
TI Correlation between time dependent inhibition of human farnesyl
   pyrophosphate synthase and blockade of mevalonate pathway by
   nitrogen containing bisphosphonates in cultured cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Apppl; Bisphosphonate; Bisphosphonate analog; Farnesyl pyrophosphate
   synthase; Isopentenyl pyrophosphate; Isomerization constant
ID ATP ANALOG FORMATION; ZOLEDRONIC ACID; IN VIVO; DIPHOSPHATE SYNTHASE;
   ISOPENTENYL PYROPHOSPHATE; BREAST CANCER; BONE; OSTEOPOROSIS; ISOMERASE;
   THERAPY
AB A class of drugs successfully used for treatment of metabolic bone diseases is the nitrogen containing bis phosphonates (N BPs), which act by inhibiting the vital enzyme, farnesyl pyrophosphate synthase (FPPS), of the mevalonate pathway. Inhibition of FPPS by N BPs results in the intracellular accumulation of isopentenyl pyrophosphate (IPP) and consequently induces the biosynthesis of a cytotoxic ATP analog (Apppl). Previous cell free data has reported that N BPs inhibit FPPS by time dependent manner as a result of the conformational change. This associated conformational change can be measured as an isomerization constant (K(isom)) and reflects the binding differences of the N BPs to FPPS. In the present study, we tested the biological relevance of the calculated K(isom), values of zoledronic acid, risedronate and five experimental N BP analogs in the cell culture model. We used IPP/Apppl formation as a surrogate marker for blocking of FPPS in the mevalonate pathway.
   As a result, a correlation between the time dependent inhibition of FPPS and IPP/Apppl formation by N BPs was observed. This outcome indicates that the time dependent inhibition of FPPS enzyme is a biologically significant mechanism and further supports the use of the K(isom) calculations for evaluation of the overall potency of the novel FPPS inhibitors. Additionally, data illustrates that IPP/Apppl analysis is a useful method to monitor the intracellular action of drugs and drug candidates based on FPPS inhibition. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Raikkonen, Johanna; Taskinen, Markku; Monkkonen, Hannu; Auriola, Seppo; Monkkonen, Jukka] Univ Eastern Finland, Sch Pharm, Fac Hlth Sci, FIN 70211 Kuopio, Finland.
   [Raikkonen, Johanna; Taskinen, Markku; Monkkonen, Hannu; Auriola, Seppo; Monkkonen, Jukka] Bioctr Kuopio, Kuopio, Finland.
   [Dunford, James E.] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Botnar Res Ctr, Inst Musculoskeletal Sci,Nuffield Orthopaed Ctr, Oxford OX3 7LD, England.
C3 University of Eastern Finland; University of Oxford; Nuffield
   Orthopaedic Centre
RP Räikkönen, J (通讯作者)，Univ Eastern Finland, Sch Pharm, Fac Hlth Sci, Yliopistonranta 1C,POB 1627, FIN 70211 Kuopio, Finland.
EM johanna.raikkonen@uef.fi
OI Dunford, James/0000 0002 9932 4042
FU Academy of Finland; Graduate School in Pharmaceutical Research; Finnish
   Cultural Foundation
FX This work was supported by grants from the Academy of Finland, the
   Graduate School in Pharmaceutical Research, and the Finnish Cultural
   Foundation. The authors thank Procter & Gamble Pharmaceuticals and
   Novartis Pharma AG (Switzerland) for their kind gifts of risedronate and
   NE compounds, and zoledronate, respectively.
CR Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140 6736(02)08827 X
   Diel Ingo J., 2000, Cancer, V88, P3080, DOI 10.1002/1097 0142(20000615)88:12+<3080::AID CNCR27>3.0.CO;2 W
   Dunford JE, 2008, J MED CHEM, V51, P2187, DOI 10.1021/jm7015733
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Hahn FM, 1996, ARCH BIOCHEM BIOPHYS, V332, P30, DOI 10.1006/abbi.1996.0312
   Jauhiainen M, 2009, J CHROMATOGR B, V877, P2967, DOI 10.1016/j.jchromb.2009.07.010
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Mitrofan LM, 2009, BONE, V45, P1153, DOI 10.1016/j.bone.2009.08.010
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   Mönkkönen H, 2003, EUR J PHARM SCI, V19, P23, DOI 10.1016/S0928 0987(03)00039 3
   Mönkkönen H, 2008, ANTI CANCER DRUG, V19, P391, DOI 10.1097/CAD.0b013e3282f632bf
   Mönkkönen H, 2007, LIFE SCI, V81, P1066, DOI 10.1016/j.lfs.2007.08.007
   Räikkönen J, 2010, BIOCHEM PHARMACOL, V79, P777, DOI 10.1016/j.bcp.2009.10.003
   Räikkönen J, 2009, BRIT J PHARMACOL, V157, P427, DOI 10.1111/j.1476 5381.2009.00160.x
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Roux C, 1999, DRUGS, V58, P823, DOI 10.2165/00003495 199958050 00005
   SCHLOSS JV, 1988, ACCOUNTS CHEM RES, V21, P348, DOI 10.1021/ar00153a005
   Stresing V, 2007, CANCER LETT, V257, P16, DOI 10.1016/j.canlet.2007.07.007
   Thompson K, 2002, BIOCHEM BIOPH RES CO, V290, P869, DOI 10.1006/bbrc.2001.6289
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
NR 24
TC 16
Z9 18
U1 0
U2 19
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD APR 22
PY 2011
VL 407
IS 4
BP 663
EP 667
DI 10.1016/j.bbrc.2011.03.070
PG 5
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 759KI
UT WOS:000290240500007
PM 21420384
DA 2025 08 17
ER

PT J
AU Zhang, N
   Gui, YY
   Qiu, XM
   Tang, W
   Li, LS
   Gober, HJ
   Li, DJ
   Wang, L
AF Zhang, Na
   Gui, Yuyan
   Qiu, Xuemin
   Tang, Wei
   Li, Lisha
   Gober, Hans Juergen
   Li, Dajin
   Wang, Ling
TI DHEA prevents bone loss by suppressing the expansion of CD<SUP>4+</SUP>
   T cells and TNFa production in the OVX mouse model for postmenopausal
   osteoporosis
SO BIOSCIENCE TRENDS
LA English
DT Article
DE Dehydroepiandrosterone; postmenopausal osteoporosis; CD4(+) T cells;
   TNF alpha
ID ESTROGEN DEFICIENCY; DEHYDROEPIANDROSTERONE SULFATE; KEY MECHANISM;
   EXPRESSION; OSTEOCLASTOGENESIS; METABOLISM; OSTEOBLAST; RECEPTOR;
   HORMONE; OSTEOPROTEGERIN
AB Recent studies have suggested that dehydroepiandrosterone (DHEA) might serve as a form of immunomodulatory therapy for postmenopausal osteoporosis (PMO). The current study investigated the effects of DHEA administration on ovariectomy (OVX) induced bone loss and its corresponding immunological changes. Adult OVX mice were treated with DHEA or 17 beta estradiol (E2) for 12 weeks, with or without the aromatase inhibitor letrozole. DHEA improved bone mass after OVX and displayed action like that of E2 with regard to decreasing osteoclast related parameters. DHEA also suppressed an OVX induced increase in CD4(+) T cell subsets and TNF alpha production. However, DHEA elevated serum E2 levels to a lesser extent than E2. Although letrozole decreased serum E2 levels in OVX mice treated with DHEA, it did not alter DHEA's effects on corresponding immunological changes due to OVX. In conclusion, DHEA may prevent bone loss by suppressing the OVX induced expansion of CD4(+) T cells and TNF a production in mice, independent of E2.
C1 [Zhang, Na; Gui, Yuyan; Qiu, Xuemin; Li, Lisha; Li, Dajin; Wang, Ling] Fudan Univ, Shanghai Med Coll, Lab Reprod Immunol, Hosp & Inst Obstet & Gynecol,IBS, Shanghai, Peoples R China.
   [Zhang, Na; Gui, Yuyan; Qiu, Xuemin; Li, Lisha; Li, Dajin; Wang, Ling] Fudan Univ, Acad Integrat Med, Shanghai, Peoples R China.
   [Zhang, Na; Gui, Yuyan; Qiu, Xuemin; Li, Lisha; Wang, Ling] Shanghai Key Lab Female Reprod Endocrine Related, Shanghai, Peoples R China.
   [Tang, Wei] Univ Tokyo, Dept Surg, Grad Sch Med, Tokyo, Japan.
   [Gober, Hans Juergen] Wagner Jauregg Hosp, Dept Pharm, Linz, Austria.
   [Gober, Hans Juergen] Childrens Hosp, Linz, Austria.
C3 Fudan University; Fudan University; Shanghai Academy of Science &
   Technology; University of Tokyo; Kepler University Hospital; Kepler
   University Hospital
RP Wang, L (通讯作者)，Fudan Univ, Obstet & Gynecol Hosp, 413 Zhaozhou Rd, Shanghai 200011, Peoples R China.
EM Dr.wangling@fudan.edu.cn
RI tang, wei/HZH 5205 2023; Gui, Yuyan/KIE 1380 2024
OI Zhang, Na/0000 0002 5510 5702
FU National Natural Science Foundation of China [31571196, 30801502,
   81401171]; Science and Technology Commission of Shanghai Municipality
   YIXUEYINGDAO project [15401932200]; FY JSPS Postdoctoral Fellowship for
   Foreign Researchers [P08471]; Shanghai Pujiang Program [11PJ1401900];
   Development Project of Shanghai Peak Disciplines Integrated Chinese and
   Western Medicine [20150407]; Program for Outstanding Medical Leaders;
   Grants in Aid for Scientific Research [26462037] Funding Source: KAKEN
FX This work was supported by the National Natural Science Foundation of
   China (grant no. 31571196 to Ling Wang), the Science and Technology
   Commission of Shanghai Municipality 2015 YIXUEYINGDAO project (grant no.
   15401932200 to Ling Wang), the FY2008 JSPS Postdoctoral Fellowship for
   Foreign Researchers (P08471 to Ling Wang), the National Natural Science
   Foundation of China (grant no. 30801502 to Ling Wang), the Shanghai
   Pujiang Program (grant no. 11PJ1401900 to Ling Wang), the National
   Natural Science Foundation of China (grant no. 81401171 to Xue Min Qiu),
   the Development Project of Shanghai Peak Disciplines Integrated Chinese
   and Western Medicine (grant no. 20150407), and the Program for
   Outstanding Medical Leaders (to Da Jin Li).
CR Abdallah BM, 2011, J BONE MINER RES, V26, P1457, DOI 10.1002/jbmr.346
   Al Banna N, 2014, MICROVASC RES, V95, P82, DOI 10.1016/j.mvr.2014.07.010
   Brazao V, 2010, IMMUNOBIOLOGY, V215, P427, DOI 10.1016/j.imbio.2009.05.005
   CASSON PR, 1993, AM J OBSTET GYNECOL, V169, P1536, DOI 10.1016/0002 9378(93)90431 H
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   Clarke BL, 2002, CALCIFIED TISSUE INT, V70, P137, DOI 10.1007/s00223 001 1072 4
   D'Amelio P, 2008, BONE, V43, P92, DOI 10.1016/j.bone.2008.02.017
   Fan XL, 2015, CELL MOL BIOL, V61, P13
   Genazzani AD, 2007, DRUG AGING, V24, P173, DOI 10.2165/00002512 200724030 00001
   Guerrini MM, 2014, ARCH BIOCHEM BIOPHYS, V561, P118, DOI 10.1016/j.abb.2014.06.003
   Gui YY, 2015, BIOSCI TRENDS, V9, P169, DOI 10.5582/bst.2015.01011
   Jahn MP, 2011, STEROIDS, V76, P564, DOI 10.1016/j.steroids.2011.02.006
   Kim HR, 2014, ARTHRITIS RHEUMATOL, V66, P538, DOI 10.1002/art.38286
   Li FJ, 2013, J NUTR BIOCHEM, V24, P1112, DOI 10.1016/j.jnutbio.2012.08.010
   Li JY, 2011, P NATL ACAD SCI USA, V108, P768, DOI 10.1073/pnas.1013492108
   Lichte P, 2014, EUR J MED RES, V19, DOI 10.1186/2047 783X 19 27
   Magyar Z, 2011, GERONTOLOGY, V57, P343, DOI 10.1159/000321385
   Mannic T, 2015, INT J ENDOCRINOL MET, V13, DOI 10.5812/ijem.24660
   Matuszewska A, 2014, POSTEP HIG MED DOSW, V68, P145, DOI 10.5604/17322693.1088339
   Moynihan JA, 1998, CELL IMMUNOL, V184, P58, DOI 10.1006/cimm.1998.1259
   Nadkarni S, 2013, CURR OPIN PHARMACOL, V13, P576, DOI 10.1016/j.coph.2013.05.007
   NAWATA H, 1995, J STEROID BIOCHEM, V53, P165, DOI 10.1016/0960 0760(95)00031 T
   Ostrowska Z, 2012, POSTEP HIG MED DOSW, V66, P655, DOI 10.5604/17322693.1009971
   Park J, 2014, HORM METAB RES, V46, P651, DOI 10.1055/s 0034 1374630
   Pinto A, 2015, BRIT J PHARMACOL, V172, P2918, DOI 10.1111/bph.13097
   Prall SP, 2015, AM J HUM BIOL, V27, P877, DOI 10.1002/ajhb.22724
   Pratschke S, 2014, J SURG RES, V189, P117, DOI 10.1016/j.jss.2014.02.002
   Qiu XM, 2015, BIOSCI TRENDS, V9, P307, DOI 10.5582/bst.2015.01073
   Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698
   Sah C, 2013, KOREAN J UROL, V54, P199, DOI 10.4111/kju.2013.54.3.199
   Samaras N, 2013, REJUV RES, V16, P285, DOI 10.1089/rej.2013.1425
   Samaras N, 2013, MATURITAS, V74, P213, DOI 10.1016/j.maturitas.2012.11.009
   Stein NC, 2008, J BONE MINER RES, V23, P750, DOI 10.1359/JBMR.080203
   Traish AM, 2011, J SEX MED, V8, P2960, DOI 10.1111/j.1743 6109.2011.02523.x
   TURNER RT, 1990, AM J PHYSIOL, V258, pE673, DOI 10.1152/ajpendo.1990.258.4.E673
   Tyagi AM, 2012, OSTEOPOROSIS INT, V23, P1151, DOI 10.1007/s00198 011 1650 x
   Tyagi AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021216
   Wang L, 2009, OSTEOPOROSIS INT, V20, P79, DOI 10.1007/s00198 008 0631 1
   Wang L, 2007, J MOL ENDOCRINOL, V38, P467, DOI 10.1677/jme.1.02173
   Wang L, 2011, ATHEROSCLEROSIS, V214, P47, DOI 10.1016/j.atherosclerosis.2010.07.043
   Wang YD, 2012, HORM METAB RES, V44, P494, DOI 10.1055/s 0032 1311567
   Wang YD, 2012, CHINESE MED J PEKING, V125, P1230, DOI 10.3760/cma.j.issn.0366 6999.2012.07.008
   Weitzmann MN, 2007, ANN NY ACAD SCI, V1116, P360, DOI 10.1196/annals.1402.068
   Weitzmann MN, 2006, ANN NY ACAD SCI, V1068, P256, DOI 10.1196/annals.1346.030
   Yang JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056585
   Zallone A, 2006, ANN NY ACAD SCI, V1068, P173, DOI 10.1196/annals.1346.019
   Zhao BH, 2009, NAT MED, V15, P1066, DOI 10.1038/nm.2007
   Zhou X, 2013, AM J MED GENET A, V161A, P983, DOI 10.1002/ajmg.a.35824
NR 48
TC 15
Z9 18
U1 0
U2 39
PU IRCA BSSA
PI TOKYO
PA PEARL CITY KOISHIKAWA 603, 2 4 5 KASUGA, BUNKYO KU, TOKYO, 112 0003,
   JAPAN
SN 1881 7815
EI 1881 7823
J9 BIOSCI TRENDS
JI BioSci. Trends
PD AUG
PY 2016
VL 10
IS 4
BP 277
EP 287
DI 10.5582/bst.2016.01081
PG 11
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA DX9XF
UT WOS:000384749600005
PM 27464762
OA Bronze
DA 2025 08 17
ER

PT J
AU Hao, J
   Bei, JX
   Li, ZH
   Han, MY
   Ma, BY
   Ma, PY
   Zhou, XH
AF Hao, Jian
   Bei, Jiaxin
   Li, Zhenhan
   Han, Mingyuan
   Ma, Boyuan
   Ma, Pengyi
   Zhou, Xianhu
TI Qing`e Pill Inhibits Osteoblast Ferroptosis via ATM
   Serine/Threonine Kinase (ATM) and the PI3K/AKT Pathway in Primary
   Osteoporosis
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE osteoporosis; PI3K; AKT pathway; ATM; ferroptosis; network analysis;
   Qing'e Pill
ID EXERTS ESTROGENIC ACTIVITIES; WATER EXTRACT; FORMULA; PHARMACOLOGY;
   DATABASE; DAMAGE
AB Osteoporosis (OP) is an aging related disease that is the main etiology of fragility fracture. Qing'e Pill (QEP) is a mixture of traditional Chinese medicine (TCM) consisting of Eucommia ulmoides Oliv., Psoralea corylifolia L., Juglans regia L., and Allium sativum L. QEP has an anti osteoporosis function, but the underlying mechanism remains unclear. In this study, online databases were employed to determine the chemical compounds of QEP and potential target genes in osteoporosis. Potential pathways associated with genes were defined by Gene Ontology (GO) and Kyoto Encyclopaedia of Genes and Genomes (KEGG) databases. A compound target disease network was constructed. Hub genes screened through Cytoscape were intersected with the FerrDB database. The potential key genes were validated in HFOB 1.19 cells, and rat models were ovariectomized through Western blot, RT qPCR, ELISA, HE staining, immunohistochemistry, and immunofluorescence analyses. The intersection targets of QEP and osteoporosis contained 121 proteins, whereas the target pathway network included 156 pathways. We filtered five genes that stood out in the network analysis for experimental verification. The experiments validated that QEP exerted therapeutic effects on osteoporosis by inhibiting ferroptosis and promoting cell survival via the PI3K/AKT pathway and ATM. In conclusion, combining the application of network analysis and experimental verification may provide an efficient method to validate the molecular mechanism of QEP on osteoporosis.
C1 [Hao, Jian; Han, Mingyuan; Ma, Boyuan; Zhou, Xianhu] Ningbo Univ, Med Sch, Affiliated Hosp, Orthoped Dept, Ningbo, Peoples R China.
   [Bei, Jiaxin] Guangzhou Med Univ, Affiliated Hosp 2, Dept Minimally Invas Intervent Radiol, Lab Intervent Radiol, Guangzhou, Peoples R China.
   [Bei, Jiaxin] Guangzhou Med Univ, Affiliated Hosp 2, Dept Radiol, Guangzhou, Peoples R China.
   [Li, Zhenhan] Wannan Med Coll, Sch Clin, Wuhu, Peoples R China.
   [Ma, Pengyi] Tianjin Med Univ, Grad Sch, Dept Orthopaed, Tianjin, Peoples R China.
C3 Ningbo University; Guangzhou Medical University; Guangzhou Medical
   University; Wannan Medical College; Tianjin Medical University
RP Hao, J; Zhou, XH (通讯作者)，Ningbo Univ, Med Sch, Affiliated Hosp, Orthoped Dept, Ningbo, Peoples R China.
EM hao.jian@mayo.edu; zhouxianhu@nbu.edu.cn
RI Zhou, Xianhu/AGY 2369 2022; 马, 博渊/AAB 4364 2022; Hao,
   Jian/AGY 2303 2022; li, zhenhan/HKM 6439 2023
OI han, mingyuan/0000 0001 6311 7327; Bei, Jiaxin/0000 0003 4108 3749;
   zhou, xianhu/0009 0002 5420 0190; 
FU National Natural Science Foundation of China [82172409]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 82172409).
CR Almalki SG, 2016, DIFFERENTIATION, V92, P41, DOI 10.1016/j.diff.2016.02.005
   Barshir R, 2021, J MOL BIOL, V433, DOI 10.1016/j.jmb.2021.166913
   Chen M, 2019, MOLECULES, V24, DOI 10.3390/molecules24213875
   Chen PH, 2020, BIOLOGY BASEL, V9, DOI 10.3390/biology9080187
   Chen PH, 2020, CELL DEATH DIFFER, V27, P1008, DOI 10.1038/s41418 019 0393 7
   Fujiki K, 2019, CELL DEATH DIFFER, V26, P2371, DOI 10.1038/s41418 019 0307 8
   Gu XY, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 92489 1
   Guo W, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01185
   He JB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01344
   Heinrich M, 2020, J ETHNOPHARMACOL, V246, DOI 10.1016/j.jep.2019.112230
   Hou JX, 2020, J ANAL METHODS CHEM, V2020, DOI 10.1155/2020/8832736
   Li CG, 2017, CHIN J INTEGR MED, V23, P183, DOI 10.1007/s11655 016 2407 3
   Li M, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01023
   Li XL, 2019, J BONE MINER METAB, V37, P224, DOI 10.1007/s00774 018 0924 1
   Lu JL, 2018, MOLECULES, V23, DOI 10.3390/molecules23123321
   Lu JS, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 52513 x
   Luo MY, 2018, CELL DEATH DIFFER, V25, P1457, DOI 10.1038/s41418 017 0053 8
   Luo TT, 2020, CHIN J INTEGR MED, V26, P72, DOI 10.1007/s11655 019 3064 0
   Ma HD, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/9067610
   Maciejczyk M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02322
   Park E, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2064 5
   Piñero J, 2020, NUCLEIC ACIDS RES, V48, pD845, DOI 10.1093/nar/gkz1021
   Presa FB, 2018, MAR DRUGS, V16, DOI 10.3390/md16040135
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shuai B, 2019, CHIN J INTEGR MED, V25, P270, DOI 10.1007/s11655 016 2604 0
   Sui XB, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01371
   Sun L, 2022, BIOENGINEERED, V13, P48, DOI 10.1080/21655979.2021.2004980
   Sun P, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/2532081
   Tian Q, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1295382
   Wang XD, 2022, BIOL TRACE ELEM RES, V200, P298, DOI 10.1007/s12011 021 02627 z
   Wang YH, 2020, EXP THER MED, V20, P3185, DOI 10.3892/etm.2020.9045
   Wong KY, 2021, J ETHNOPHARMACOL, V275, DOI 10.1016/j.jep.2021.114096
   Wong MS, 2020, HANDB EXP PHARMACOL, V262, P499, DOI 10.1007/164_2019_322
   Xie Y, 2016, CELL DEATH DIFFER, V23, P369, DOI 10.1038/cdd.2015.158
   Xiong JL, 2022, J ETHNOPHARMACOL, V283, DOI 10.1016/j.jep.2021.114735
   Yang RZ, 2021, J CELL PHYSIOL, V236, P6691, DOI 10.1002/jcp.30331
   Yang YP, 2015, J HUAZHONG U SCI MED, V35, P525, DOI 10.1007/s11596 015 1464 8
   Yi JM, 2020, P NATL ACAD SCI USA, V117, P31189, DOI 10.1073/pnas.2017152117
   Zhang ND, 2016, J ETHNOPHARMACOL, V189, P61, DOI 10.1016/j.jep.2016.05.025
   Zhang YX, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.693079
   Zhao FJ, 2021, AGING US, V13, P6945, DOI 10.18632/aging.202552
   Zhao Y, 2021, J ETHNOPHARMACOL, V268, DOI 10.1016/j.jep.2020.113644
   Zhou LP, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.817146
   Zhou N, 2020, DATABASE OXFORD, DOI 10.1093/database/baaa021
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09234 6
NR 46
TC 37
Z9 46
U1 5
U2 53
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUL 5
PY 2022
VL 13
AR 902102
DI 10.3389/fphar.2022.902102
PG 27
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 3C6ZC
UT WOS:000828768900001
PM 35865965
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Niemann, T
   Joneleit, J
   Storm, J
   Nacke, T
   Wähnert, D
   Kaltschmidt, C
   Vordemvenne, T
   Kaltschmidt, B
AF Niemann, Tarek
   Joneleit, Jonas
   Storm, Jonathan
   Nacke, Tom
   Waehnert, Dirk
   Kaltschmidt, Christian
   Vordemvenne, Thomas
   Kaltschmidt, Barbara
TI Analyzing Sex Specific Dimorphism in Human Skeletal Stem Cells
SO CELLS
LA English
DT Article
DE skeletal stem cells; sex dimorphism; osteogenic differentiation;
   inflammation; proliferation; NF kappa B
ID NF KAPPA B; OSTEOGENIC DIFFERENTIATION; NEURAL CREST; OSTEOBLAST
   DIFFERENTIATION; BONE; ESTROGEN; CULTURE; GENDER; IDENTIFICATION;
   OSTEOPOROSIS
AB Sex related differences are a current topic in contemporary science. In addition to hormonal regulation, cell autonomous mechanisms are important in bone homeostasis and regeneration. In this study, human skeletal stem cells (SSCs) from female and male adults were cultured and analyzed with immunological assays and osteogenic differentiation assessments. Female SSCs exhibited a mean doubling time of 100.6 h, whereas male SSCs displayed a mean doubling time of 168.0 h. Immunophenotyping revealed the expression of the stem cell markers Nestin, CD133, and CD164, accompanied by the neural crest marker SOX9. Furthermore, multiparameter flow cytometric analyses revealed a substantial population of multipotent SSCs, comprising up to 80% in both sexes. An analysis of the osteogenic differentiation potential demonstrated a strong mineralization in both male and female SSCs under physiological conditions. Recognizing the prevailing association of bone diseases with inflammatory processes, we also analyzed the osteogenic potential of SSCs from both sexes under pro inflammatory conditions. Upon TNF alpha and IL 1 beta treatment, we observed no sexual dimorphism on osteogenesis. In summary, we demonstrated the successful isolation and characterization of SSCs capable of rapid osteogenic differentiation. Taken together, in vitro cultured SSCs might be a suitable model to study sexual dimorphisms and develop drugs for degenerative bone diseases.
C1 [Niemann, Tarek; Joneleit, Jonas; Nacke, Tom; Kaltschmidt, Barbara] Bielefeld Univ, Mol Neurobiol, Univ Str 25, D 33615 Bielefeld, Germany.
   [Niemann, Tarek; Storm, Jonathan; Waehnert, Dirk; Kaltschmidt, Christian; Vordemvenne, Thomas; Kaltschmidt, Barbara] Forschungsverbund Biomed Bielefeld FBMB eV, D 33615 Bielefeld, Germany.
   [Storm, Jonathan; Kaltschmidt, Christian; Kaltschmidt, Barbara] Bielefeld Univ, Dept Cell Biol, Univ Str 25, D 33615 Bielefeld, Germany.
   [Waehnert, Dirk; Vordemvenne, Thomas] Univ Hosp OWL Bielefeld Univ, Protestant Hosp Bethel Fdn, Dept Trauma & Orthoped Surg, Campus Bielefeld Bethel,Burgsteig 13, D 33617 Bielefeld, Germany.
C3 University of Bielefeld; University of Bielefeld
RP Niemann, T (通讯作者)，Bielefeld Univ, Mol Neurobiol, Univ Str 25, D 33615 Bielefeld, Germany.; Niemann, T (通讯作者)，Forschungsverbund Biomed Bielefeld FBMB eV, D 33615 Bielefeld, Germany.
EM tarek.niemann@uni bielefeld.de; jonas.joneleit@uni bielefeld.de;
   jonathan.storm@uni bielefeld.de; tom.nacke@uni bielefeld.de;
   dirk.waehnert@evkb.de; c.kaltschmidt@uni bielefeld.de;
   thomas.vordemvenne@evkb.de; barbara.kaltschmidt@uni bielefeld.de
RI Wähnert, Dirk/IYJ 4259 2023; Vordemvenne, Thomas/KBA 3201 2024
FU Protestant Hospital of Bethel Foundation, University Hospital OWL of
   Bielefeld University; University of Bielefeld; Bethel Foundation
FX We thank the University of Bielefeld for supporting the study and the
   protestant Hospital of Bethel Foundation for financing T.N. (Tarek
   Niemann) and J.S. Figure S1 and Figure 3E and the graphical abstract
   were created with BioRender.com (accessed on 14 October 2023).
CR Ambrosi TH, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00189
   Andrew TW, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 34063 5
   Ansari S, 2022, ACS OMEGA, V7, P12724, DOI 10.1021/acsomega.1c07225
   BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496
   Bianco P, 2015, DEVELOPMENT, V142, P1023, DOI 10.1242/dev.102210
   Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606
   Calis M, 2014, PLAST RECONSTR SURG, V133, p499E, DOI 10.1097/PRS.0000000000000056
   Chan CKF, 2018, CELL, V175, P43, DOI 10.1016/j.cell.2018.07.029
   Chan CKF, 2015, CELL, V160, P285, DOI 10.1016/j.cell.2014.12.002
   Chen Q, 2014, STEM CELLS, V32, P327, DOI 10.1002/stem.1567
   Crisostomo PR, 2007, SURGERY, V142, P215, DOI 10.1016/j.surg.2007.04.013
   Dale E, 2006, ADV PHYSIOL EDUC, V30, P152, DOI 10.1152/advan.00065.2006
   De Martinis M, 2021, WORLD J MENS HEALTH, V39, P750, DOI 10.5534/wjmh.200099
   Debnath S, 2018, NATURE, V562, P133, DOI 10.1038/s41586 018 0554 8
   Dy P, 2012, DEV CELL, V22, P597, DOI 10.1016/j.devcel.2011.12.024
   Farrugia Mark, 2016, J Clin Transl Res, V2, P84
   Fickert S, 2011, J BONE MINER METAB, V29, P224, DOI 10.1007/s00774 010 0215 y
   Ganguly K, 2023, ADV HEALTHC MATER, V12, DOI 10.1002/adhm.202202163
   Gavali S, 2019, BBA MOL CELL RES, V1866, P1498, DOI 10.1016/j.bbamcr.2019.06.014
   Giefing Kröll C, 2015, AGING CELL, V14, P309, DOI 10.1111/acel.12326
   Gordon CM, 2017, J PEDIATR US, V180, P261, DOI 10.1016/j.jpeds.2016.09.056
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Greiner JFW, 2019, FEBS LETT, V593, P3338, DOI 10.1002/1873 3468.13606
   Greiner JFW, 2019, NANOMED NANOTECHNOL, V17, P319, DOI 10.1016/j.nano.2019.01.018
   Hauser S, 2012, STEM CELLS DEV, V21, P742, DOI 10.1089/scd.2011.0419
   Hong L, 2006, TISSUE ENG, V12, P2747, DOI 10.1089/ten.2006.12.2747
   Hong L, 2009, J STEROID BIOCHEM, V114, P180, DOI 10.1016/j.jsbmb.2009.02.001
   Hoover MY, 2023, NAT PROTOC, V18, P2256, DOI 10.1038/s41596 023 00836 5
   Ji Meng Xia, 2015, Chronic Dis Transl Med, V1, P9, DOI 10.1016/j.cdtm.2015.02.006
   Kaltschmidt C, 2021, CELLS BASEL, V10, DOI 10.3390/cells10082042
   Karadjian M, 2020, CELLS BASEL, V9, DOI 10.3390/cells9040918
   Kawane T, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 31853 0
   KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Korzynska A, 2008, BIOCYBERN BIOMED ENG, V28, P75
   Kurapaty SS, 2022, CURR REV MUSCULOSKE, V15, P651, DOI 10.1007/s12178 022 09803 1
   Lane JM, 2006, ORTHOP CLIN N AM, V37, P601, DOI 10.1016/j.ocl.2006.09.002
   Lee HJ, 2021, MEDICINA LITHUANIA, V57, DOI 10.3390/medicina57060520
   Leskelä HV, 2003, BIOCHEM BIOPH RES CO, V311, P1008, DOI 10.1016/j.bbrc.2003.10.095
   Li Y, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt515
   Liu QY, 2012, STEM CELL TRANSL MED, V1, P266, DOI 10.5966/sctm.2011 0042
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Löfman O, 2000, J CLIN DENSITOM, V3, P177, DOI 10.1385/JCD:3:2:177
   Lorenzo J, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092086
   Lysdahl H, 2013, STEM CELL REV REP, V9, P132, DOI 10.1007/s12015 012 9417 0
   Matsushita Y, 2021, BIOESSAYS, V43, DOI 10.1002/bies.202000202
   Matsushita Y, 2020, CURR OSTEOPOROS REP, V18, P189, DOI 10.1007/s11914 020 00572 9
   McPhee C, 2022, J WOMENS HEALTH, V31, P1671, DOI 10.1089/jwh.2022.0361
   Mo QY, 2022, HUM CELL, V35, P957, DOI 10.1007/s13577 022 00711 7
   Mödder UI, 2008, J CELL BIOCHEM, V103, P393, DOI 10.1002/jcb.21423
   Mollentze Jamie, 2021, Stem Cells Int, V2021, P9919361, DOI 10.1155/2021/9919361
   Moller AMJ, 2020, BONE RES, V8, DOI 10.1038/s41413 020 0102 7
   Mun SH, 2021, J BONE MINER RES, V36, P1104, DOI 10.1002/jbmr.4270
   Naganathan V, 2003, OSTEOPOROSIS INT, V14, P564, DOI 10.1007/s00198 003 1422 3
   Noirrit Esclassan E, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041568
   O'Connor MI, 2007, J AM ACAD ORTHOP SUR, V15, pS22, DOI 10.5435/00124635 200700001 00007
   Ono N, 2019, CURR TOP DEV BIOL, V133, P1, DOI 10.1016/bs.ctdb.2019.01.006
   Pacifici R, 1996, J BONE MINER RES, V11, P1043
   Paolella F, 2019, J BIOMED MATER RES A, V107, P2774, DOI 10.1002/jbm.a.36780
   Park SS, 2015, BONE, V76, P169, DOI 10.1016/j.bone.2015.03.001
   Pesce V., 2016, Italian Journal of Gender Specific Medicine, V2, P141, DOI 10.1723/2696.27567
   Pierret C, 2006, STEM CELLS DEV, V15, P286, DOI 10.1089/scd.2006.15.286
   Rodan GA, 1998, P NATL ACAD SCI USA, V95, P13361, DOI 10.1073/pnas.95.23.13361
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Saidenberg Kermanac'h N, 2004, JOINT BONE SPINE, V71, P9, DOI 10.1016/S1297 319X(03)00131 3
   Salari N, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02772 0
   Siegel G, 2013, BMC MED, V11, DOI 10.1186/1741 7015 11 146
   Su J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071333
   Taneja V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01931
   Unnanuntana A, 2010, J BONE JOINT SURG AM, V92A, P743, DOI 10.2106/JBJS.I.00919
   Wang Liang, 2015, Chinese Medical Sciences Journal, V30, P108
   Wu YJ, 2009, STEM CELLS DEV, V18, P1127, DOI 10.1089/scd.2008.0338
   Xie L, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/762098
   Yamada T, 2022, STEM CELL REP, V17, P1576, DOI 10.1016/j.stemcr.2022.06.001
   Yun AJ, 2004, MED HYPOTHESES, V63, P532, DOI 10.1016/S0306 9877(03)00326 8
   Zaim M, 2012, ANN HEMATOL, V91, P1175, DOI 10.1007/s00277 012 1438 x
   Zhao ZD, 2020, ELIFE, V9, DOI 10.7554/eLife.61965
NR 78
TC 2
Z9 2
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD DEC
PY 2023
VL 12
IS 23
AR 2683
DI 10.3390/cells12232683
PG 20
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA AH1Z4
UT WOS:001117495900001
PM 38067111
OA Green Published
DA 2025 08 17
ER

PT J
AU Diomede, F
   Zini, N
   Gatta, V
   Fulle, S
   Merciaro, I
   D'Aurora, M
   La Rovere, RML
   Traini, T
   Pizzicannella, J
   Ballerini, P
   Caputi, S
   Piattelli, A
   Trubiani, O
AF Diomede, F.
   Zini, N.
   Gatta, V.
   Fulle, S.
   Merciaro, I.
   D'Aurora, M.
   La Rovere, R. M. L.
   Traini, T.
   Pizzicannella, J.
   Ballerini, P.
   Caputi, S.
   Piattelli, A.
   Trubiani, O.
TI HUMAN PERIODONTAL LIGAMENT STEM CELLS CULTURED ONTO CORTICO CANCELLOUS
   SCAFFOLD DRIVE BONE REGENERATIVE PROCESS
SO EUROPEAN CELLS & MATERIALS
LA English
DT Article
DE Stem cells   osteogenesis; dental tissue (periodontal ligament);
   biomaterials   scaffolds; dental   regenerative repair; tissue
   engineering/regenerative medicine; biomaterials   biocompatibility (in
   vivo)
ID PARATHYROID HORMONE; STROMAL CELLS; ALVEOLAR BONE; OSTEOBLASTS;
   EXPRESSION; BIOMATERIALS; CARTILAGE; DISEASE; ASSAY
AB The purpose of this work was to test, in vitro and in vivo, a new tissue engineered construct constituted by porcine cortico cancellous scaffold (Osteobiol Dual Block) (DB) and xeno free ex vivo culture of human Periodontal Ligament Stem Cells (hPDLSCs). hPDLSCs cultured in xeno free media formulation preserved the stem cells' morphological features, the expression of stemness and pluripotency markers, and their ability to differentiate into mesenchymal lineage. Transmission electron microscopy analysis suggested that after one week of culture, both noninduced and osteogenic differentiation induced cells joined and grew on DB secreting extracellular matrix (ECM) that in osteogenic induced samples was hierarchically assembled in fibrils. Quantitative RT PCR (qRT PCR) showed the upregulation of key genes involved in the bone differentiation pathway in both differentiated and undifferentiated hPDLSCs cultured with DB (hPDLSCs/DB). Functional studies revealed a significant increased response of calcium transients in the presence of DB, both in undifferentiated and differentiated cells stimulated with calcitonin and parathormone, suggesting that the biomaterial could drive the osteogenic differentiation process of hPDLSCs. These data were confirmed by the increase of gene expression of L type voltage dependent Ca2+ (VDCCL), subunits alpha 1C and alpha 2D1 in undifferentiated cells in the presence of DB. In vivo implantation of the hPDLSCs/DB living construct in the mouse calvaria evidenced a precocious osteointegration and vascularisation process. Our results suggest consideration of DB as a biocompatible, osteoinductive and osteoconductive biomaterial, making it a promising tool to regulate cell activities in biological environments and for a potential use in the development of new custom made tissue engineering.
C1 [Diomede, F.; Merciaro, I.; Traini, T.; Pizzicannella, J.; Caputi, S.; Piattelli, A.; Trubiani, O.] Univ G DAnnunzio, Dept Med Oral & Biotechnol Sci, Via Vestini 31, I 66100 Chieti, Italy.
   [Diomede, F.; Merciaro, I.; Trubiani, O.] Univ G DAnnunzio, Lab Stem Cells & Regenerat Med, I 6610 Chieti, Italy.
   [Zini, N.] CNR, Natl Res Council Italy, IGM, Bologna, Italy.
   [Zini, N.] IOR, SC Lab Musculosckeletal Cell Biol, Bologna, Italy.
   [Gatta, V.; D'Aurora, M.; Ballerini, P.] Univ G DAnnunzio, Dept Psychol Hlth & Terr Sci, Chieti, Italy.
   [Fulle, S.; La Rovere, R. M. L.] Univ G DAnnunzio, Dept Neurosci Imaging & Clin Sci, Chieti, Italy.
   [Pizzicannella, J.] Osped San Pio, Lanciano Vasto Chieti ASL02, Vasto, CH, Italy.
C3 G d'Annunzio University of Chieti Pescara; G d'Annunzio University of
   Chieti Pescara; Consiglio Nazionale delle Ricerche (CNR); G d'Annunzio
   University of Chieti Pescara; G d'Annunzio University of Chieti Pescara
RP Trubiani, O (通讯作者)，Univ G DAnnunzio, Dept Med Oral & Biotechnol Sci, Via Vestini 31, I 66100 Chieti, Italy.; Trubiani, O (通讯作者)，Univ G DAnnunzio, Lab Stem Cells & Regenerat Med, I 6610 Chieti, Italy.
EM trubiani@unich.it
RI Ballerini, Patrizia/AHI 0938 2022; Traini, Tonino/M 3514 2017; Merciaro,
   Ilaria/AAQ 4025 2020; ZINI, NICOLETTA/C 7544 2019; D'Aurora,
   Marco/AAN 1865 2020; Diomede, Francesca/AAL 6840 2020; Traini,
   Tonino/AFQ 6844 2022; Gatta, Valentina/G 5765 2014; Fulle,
   Stefania/F 3328 2013
OI Ballerini, Patrizia/0000 0002 3911 2101; ZINI,
   NICOLETTA/0000 0002 4442 7079; DIOMEDE, Francesca/0000 0002 0384 6509;
   GATTA, Valentina/0000 0002 9999 5823; D'Aurora,
   Marco/0000 0003 1194 5299; Pizzicannella, Jacopo/0000 0003 3318 3758;
   Traini, Tonino/0000 0002 0265 8709; Maria Laura,
   Rita/0000 0002 6543 9829; Fulle, Stefania/0000 0003 4557 9127
FU OT ex 60 % University of Chieti fund; Ministry of Education, University
   and Research (M.I.U.R.), Rome, Italy [PRIN 20102ZLNJ5]
FX This work has been supported from OT ex 60 % University of Chieti fund,
   and partly by PRIN 20102ZLNJ5 "Stem cells and 3D scaffolds: a novel
   construct in bone regeneration" financed by the Ministry of Education,
   University and Research (M.I.U.R.), Rome, Italy.
CR Amini Ami R, 2011, J Long Term Eff Med Implants, V21, P93
   [Anonymous], CLIN PERIODONTOLOGY
   [Anonymous], INJURY S2
   Banfi A, 2000, EXP HEMATOL, V28, P707, DOI 10.1016/S0301 472X(00)00160 0
   Baroli B, 2009, J PHARM SCI US, V98, P1317, DOI 10.1002/jps.21528
   Bergh JJ, 2006, AM J PHYSIOL CELL PH, V290, pC822, DOI 10.1152/ajpcell.00403.2005
   Candeliere GA, 2001, BONE, V28, P351, DOI 10.1016/S8756 3282(01)00410 0
   Chase LG, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt8
   Chen NX, 2000, AM J PHYSIOL CELL PH, V278, pC989, DOI 10.1152/ajpcell.2000.278.5.C989
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Diomede F, 2014, INT ENDOD J, V47, P864, DOI 10.1111/iej.12230
   Egusa H, 2012, J PROSTHODONT RES, V56, P151, DOI 10.1016/j.jpor.2012.06.001
   Eleuterio E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071101
   Greenblatt MB, 2013, ANNU REV CELL DEV BI, V29, P63, DOI 10.1146/annurev cellbio 101512 122347
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Holzwarth JM, 2011, BIOMATERIALS, V32, P9622, DOI 10.1016/j.biomaterials.2011.09.009
   Manescu A, 2016, J PERIODONTAL RES, V51, P112, DOI 10.1111/jre.12289
   Minear S, 2010, J BONE MINER RES, V25, P1196, DOI 10.1002/jbmr.29
   Nanci A, 2006, PERIODONTOL 2000, V40, P11, DOI 10.1111/j.1600 0757.2005.00141.x
   Qin L, 2004, TRENDS ENDOCRIN MET, V15, P60, DOI 10.1016/j.tem.2004.01.006
   Reddi AH, 2000, TISSUE ENG, V6, P351, DOI 10.1089/107632700418074
   Rose FRAJ, 2002, BIOCHEM BIOPH RES CO, V292, P1, DOI 10.1006/bbrc.2002.6519
   Salvadè A, 2007, CYTOTHERAPY, V9, P427, DOI 10.1080/14653240701341995
   Seo BM, 2005, J DENT RES, V84, P907, DOI 10.1177/154405910508401007
   Sodek J, 2000, PERIODONTOL 2000, V24, P99, DOI 10.1034/j.1600 0757.2000.2240106.x
   SUGIMOTO T, 1993, HORM METAB RES, V25, P608, DOI 10.1055/s 2007 1002189
   Temenoff JS, 2000, BIOMATERIALS, V21, P431, DOI 10.1016/S0142 9612(99)00213 6
   Trubiani O, 2008, J BIOMED MATER RES A, V87A, P986, DOI 10.1002/jbm.a.31837
   Trubiani O, 2008, J CELL PHYSIOL, V214, P706, DOI 10.1002/jcp.21266
   Trubiani O, 2016, CELL SIGNAL, V28, P1631, DOI 10.1016/j.cellsig.2016.07.012
   Trubiani O, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 015 0253 4
   Trubiani O, 2015, TISSUE ENG PART C ME, V21, P52, DOI [10.1089/ten.tec.2014.0024, 10.1089/ten.TEC.2014.0024]
   Trubiani O, 2010, EUR CELLS MATER, V20, P72
   Villa I, 2003, AM J PHYSIOL ENDOC M, V284, pE627, DOI 10.1152/ajpendo.00307.2002
   Wu XW, 2007, ANN NY ACAD SCI, V1116, P29, DOI 10.1196/annals.1402.053
   Zhu WT, 2015, J TRANSL MED, V13, DOI 10.1186/s12967 015 0719 2
   Zwingenberger S, 2014, TISSUE ENG PT A, V20, P810, DOI 10.1089/ten.TEA.2013.0222
NR 37
TC 46
Z9 47
U1 0
U2 14
PU AO RESEARCH INSTITUTE DAVOS ARI
PI DAVOS
PA CLAVADELERSTRASSE 8, DAVOS, CH 7270, SWITZERLAND
SN 1473 2262
J9 EUR CELLS MATER
JI Eur. Cells Mater.
PD JUL DEC
PY 2016
VL 32
BP 181
EP 201
DI 10.22203/eCM.v032a12
PG 21
WC Cell & Tissue Engineering; Engineering, Biomedical; Materials Science,
   Biomaterials; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science; Orthopedics
GA EJ3OC
UT WOS:000393120500012
PM 27633707
OA Green Submitted, Bronze
DA 2025 08 17
ER

PT J
AU Hauber, AB
   Arellano, J
   Qian, Y
   González, JM
   Posner, JD
   Mohamed, AF
   Gatta, F
   Tombal, B
   Body, JJ
AF Hauber, A. Brett
   Arellano, Jorge
   Qian, Yi
   Gonzalez, Juan Marcos
   Posner, Joshua D.
   Mohamed, Ateesha F.
   Gatta, Francesca
   Tombal, Bertrand
   Body, Jean Jacques
TI Patient Preferences for Treatments to Delay Bone Metastases
SO PROSTATE
LA English
DT Article
DE bone pain; discrete choice experiment; osteonecrosis of the jaw (ONJ);
   prostate cancer; skeletal related events (SREs); time tradeoff
ID CONJOINT ANALYSIS APPLICATIONS; PROSTATE CANCER; FREE SURVIVAL;
   DENOSUMAB; WILLINGNESS; THERAPIES; PHASE 3; EVENTS; HEALTH; MEN
AB BACKGROUND. Most patients with advanced prostate cancer (PCa) develop bone metastases (BM) and present with bone complications like fracture. Bone targeted agents that prevent metastasis induced bone complications can cause adverse events. Understanding how patients view treatment options may optimize care. This study aimed to quantify how PCa patients value a hypothetical treatment that delays BM but can cause osteonecrosis of the jaw (ONJ). The study also assessed the value patients place on avoiding metastasis induced bone complications versus increased survival.
   METHODS. PCa patients from the United Kingdom (n = 201) and Sweden (n = 200) on androgen deprivation therapy or hormone therapy for > 3 years completed a 10 question discrete choice experiment survey examining whether patients would accept a BM delaying treatment. Two time tradeoff questions assessed patients' willingness to tradeoff between survival and bone complications. Percentages of patients choosing treatment were summarized by levels of treatment efficacy and ONJ risk. Odds ratios from a logit model were used to evaluate how patient and medication characteristics affected treatment choice. Proportions of patients choosing each tradeoff scenario were calculated.
   RESULTS. A majority of patients accepted treatment at the lowest benefit level (5 month BM delay) and highest risk level (9% ONJ risk). PCa symptoms and prior treatment affected patient preferences. Nearly 80% of patients would tradeoff at least 3 months of survival to avoid bone complications.
   CONCLUSIONS. PCa patients in the UK and Sweden may value a medication that delays BM, despite the risk of ONJ. Furthermore, patients were willing to tradeoff up to 5 months of survival for prevention of bone complications. (C) 2014 Wiley Periodicals, Inc.
C1 [Hauber, A. Brett; Gonzalez, Juan Marcos; Posner, Joshua D.; Mohamed, Ateesha F.] RTI Hlth Solut, Res Triangle Pk, NC 27709 USA.
   [Arellano, Jorge; Qian, Yi] Amgen Inc, Global Hlth Econ, Thousand Oaks, CA 91320 USA.
   [Gatta, Francesca] Amgen Europe GmbH, Global Hlth Econ, Zug, Switzerland.
   [Tombal, Bertrand] Clin Univ St Luc, Inst Rech Clin, B 1200 Brussels, Belgium.
   [Body, Jean Jacques] Univ Libre Bruxelles, CHU Brugmann, Brussels, Belgium.
C3 Research Triangle Institute; Amgen; Amgen; AMGEN Europe; Universite
   Catholique Louvain; Cliniques Universitaires Saint Luc; Universite Libre
   de Bruxelles
RP Hauber, AB (通讯作者)，RTI Hlth Solut, 200 Pk Off Dr,POB 12194, Res Triangle Pk, NC 27709 USA.
EM abhauber@rti.org
RI ; Body, Jean Jacques/G 9785 2015; qian, yi/HZH 4175 2023; GONZALEZ,
   Juan/KSL 6454 2024
OI Gonzalez, Juan Marcos/0000 0002 5386 0907; TOMBAL,
   Bertrand/0000 0002 0093 8408; Hauber, Brett/0000 0003 3129 7268
FU Amgen Inc.; Bayer; Amgen; Ferring; Sanofi Ayentis; Mediyation; Astellas;
   Novartis
FX The study was conducted by RTI Health Solutions and funded by Amgen Inc.
   Bertrand Tombal, MD, PhD, is a member of a standing advisory committee
   or council, and has received consulting fees and research grants from
   Bayer, Amgen, Ferring, Sanofi Ayentis, Mediyation, and Astellas. Jean
   Jacques Body, MD, PhD, has received lecture and consulting fees from
   Amgen Inc. and Novartis.
CR [Anonymous], 2012, IARC CANC BASE
   Blinman P, 2012, ANN ONCOL, V23, P1104, DOI 10.1093/annonc/mdr559
   Bridges JFP, 2011, VALUE HEALTH, V14, P403, DOI 10.1016/j.jval.2010.11.013
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Clines Gregory A., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000616
   de Bekker Grob EW, 2013, BRIT J CANCER, V109, P633, DOI 10.1038/bjc.2013.370
   El Amm J, 2013, PROSTATE CANCER, V2013, DOI 10.1155/2013/210686
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Hauber AB, 2013, OSTEOARTHR CARTILAGE, V21, P289, DOI 10.1016/j.joca.2012.11.007
   Hoffman Censits J, 2013, SEMIN ONCOL, V40, P361, DOI 10.1053/j.seminoncol.2013.04.015
   Johnson FR, 2013, VALUE HEALTH, V16, P3, DOI 10.1016/j.jval.2012.08.2223
   LAMOTHE F, 1986, J NATL MED ASSOC, V78, P1083
   Lipton A, 2012, EXPERT REV CLIN PHAR, V5, P359, DOI [10.1586/ecp.12.35, 10.1586/ECP.12.35]
   MacVicar GR, 2013, CURR OPIN ONCOL, V25, P252, DOI 10.1097/CCO.0b013e32835ff161
   Marshall D, 2010, PATIENT, V3, P249, DOI 10.2165/11539650 000000000 00000
   Marta Pedroso C, 2007, ECOL ECON, V62, P388, DOI 10.1016/j.ecolecon.2007.02.005
   Mohamed AF, 2011, PHARMACOECONOMICS, V29, P977, DOI 10.2165/11593370 000000000 00000
   Nelson JB, 2008, CANCER AM CANCER SOC, V113, P2478, DOI 10.1002/cncr.23864
   Nielsen JS, 2011, RESOUR ENERGY ECON, V33, P119, DOI 10.1016/j.reseneeco.2010.01.006
   Orme BryanK., 2006, GETTING STARTED CONJ
   Amaral TMS, 2012, PROSTATE CANCER, V2012, DOI 10.1155/2012/327253
   Sartor O, 2013, ONCOLOGIST, V18, P549, DOI 10.1634/theoncologist.2013 0027
   Sharifi N, 2005, JAMA J AM MED ASSOC, V294, P238, DOI 10.1001/jama.294.2.238
   Smith MR, 2013, J CLIN ONCOL, V31, P3800, DOI 10.1200/JCO.2012.44.6716
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
NR 25
TC 21
Z9 21
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0270 4137
EI 1097 0045
J9 PROSTATE
JI Prostate
PD NOV
PY 2014
VL 74
IS 15
BP 1488
EP 1497
DI 10.1002/pros.22865
PG 10
WC Endocrinology & Metabolism; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Urology & Nephrology
GA AS1OT
UT WOS:000344050800004
PM 25132622
DA 2025 08 17
ER

PT J
AU Zhang, Y
   He, Y
   Zong, Y
   Guo, JZ
   Sun, L
   Ma, YB
   Dong, W
   Gui, L
AF Zhang, Ying
   He, Ying
   Zong, Yi
   Guo, Jiazhi
   Sun, Lin
   Ma, Yunbing
   Dong, Wei
   Gui, Li
TI 17β estradiol attenuates homocysteine induced oxidative stress and
   inflammatory response as well as MAPKs cascade via activating PI3 K/Akt
   signal transduction pathway in Raw 264.7 cells
SO ACTA BIOCHIMICA ET BIOPHYSICA SINICA
LA English
DT Article
DE 17 beta estradiol; homocysteine; reactive oxygen species; MAPKs;
   PI3 K/Akt
ID BONE MINERAL DENSITY; VERTEBRAL FRACTURE RISK; KAPPA B PATHWAYS;
   POSTMENOPAUSAL WOMEN; OSTEOCLAST DIFFERENTIATION; COX 2 EXPRESSION;
   RAW264.7 CELLS; OSTEOPOROSIS; ESTROGEN; MARKERS
AB Oxidative stress, inflammatory response, and mitogen activated protein kinases (MAPKs) cascade are significant pathogenic factors of osteoporosis. It has been reported that elevated homocysteine (Hcy) may activate oxidative stress and reduce bone mineral density in post menopausal osteoporosis. Moreover, hormone replacement therapy has been widely used in clinic to prevent and treat post menopausal women with osteoporosis and osteoporotic fracture, but the molecular mechanisms and relevant signal transduction pathways underlying the action of Hcy remain unclear. In this study, we investigated the effects of 17 beta estradiol (17 beta E 2) on the Hcy induced oxidative stress, inflammatory response and MAPKs cascade, as well as the underlying signal transduction pathway in murine Raw 264.7 cells. The reactive oxygen species (ROS) was assessed by fluorospectrophotometry. The proinflammatory cytokines tumor necrosis factor alpha (TNF alpha) and interleukin (IL) 1 beta were analyzed by double immunofluorescence labeling and reverse transcriptase polymerase chain reaction assay, respectively. Furthermore, phosphorylation levels of MAPKs cascade were measured by western blot analysis. A specific phosphatidylinositol 3 kinase (PI3 K) inhibitor, Wortmannin (1 mu M) was employed to determine whether PI3 K/Akt signaling pathway mediated the 17 beta E 2's effect on Raw 264.7 cells. 17 beta E 2 markedly decreased the ROS production induced by Hcy, the expression of TNF alpha and IL 1 beta at protein and mRNA levels, and down regulated the phosphorylation of MAPKs (ERK1/2, JNK and p38). These suppressing effects of 17 beta E 2 on Hcy induced changes were reversed by pretreatment with PI3 K inhibitor Wortmannin. The results indicate that 17 beta estradiol may attenuate Hcy induced oxidative stress, inflammatory response and up regulation of MAPKs in Raw 264.7 cells via PI3 K/Akt signal transduction pathway.
C1 [Zhang, Ying] Kunming Med Univ, Basic Med Sch, Dept Pathophysiol, Kunming 650500, Peoples R China.
   [He, Ying; Zong, Yi; Guo, Jiazhi] Kunming Med Univ, Basic Med Sch, Dept Anat, Kunming 650500, Peoples R China.
   [Sun, Lin] Kunming Med Univ, Affiliated Hosp 2, Dept Cardiol, Kunming 650101, Peoples R China.
   [Ma, Yunbing; Gui, Li] Third Peoples Hosp Yunnan Prov, Dept Endocrinol, Kunming 650011, Peoples R China.
   [Dong, Wei] Yunnan Tradit Chinese Med Coll, Affiliated Hosp 3, Dept Orthoped, Kunming 650031, Peoples R China.
C3 Kunming Medical University; Kunming Medical University; Kunming Medical
   University; Yunnan University of Chinese Medicine
RP Dong, W (通讯作者)，Yunnan Tradit Chinese Med Coll, Affiliated Hosp 3, Dept Orthoped, Kunming 650031, Peoples R China.
EM dongwei310@126.com; guili0527@126.com
RI gui, li/GQQ 2739 2022; dong, wei/KVA 6898 2024; Ma, Yunbing/I 3799 2014
FU National Natural Science Foundation of China [81460173, 81260061,
   81260297]; Yunnan Applied Basic Research Projects Joint Special Project
   [2012FB013, 2013FB101]; Key Project of Yunnan Provincial Education
   Commission [2014Z128]
FX This work was supported by the grants from the National Natural Science
   Foundation of China (Nos. 81460173, 81260061 and 81260297), the Yunnan
   Applied Basic Research Projects Joint Special Project (Nos. 2012FB013
   and 2013FB101), and the Key Project of Yunnan Provincial Education
   Commission (No. 2014Z128).
CR Aksamitiene E, 2012, BIOCHEM SOC T, V40, P139, DOI 10.1042/BST20110609
   [Anonymous], 2009, J CLIN ENDOCR METAB, V94, P1207, DOI 10.1210/jc.2008 1777
   [Anonymous], SCIENTIFICA CAIRO
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Cagnacci A, 2003, BONE, V33, P956, DOI 10.1016/j.bone.2003.07.001
   Cauley JA, 2003, JAMA J AM MED ASSOC, V290, P1729, DOI 10.1001/jama.290.13.1729
   de Souza JAC, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/650812
   Cicek M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017522
   Claes L, 2009, CALCIFIED TISSUE INT, V85, P17, DOI 10.1007/s00223 009 9262 6
   Clowes JA, 2009, OSTEOPOROSIS INT, V20, P761, DOI 10.1007/s00198 008 0731 y
   da Cunha AA, 2010, METAB BRAIN DIS, V25, P199, DOI 10.1007/s11011 010 9188 8
   Dai JN, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0021891, 10.1371/journal.pone.0028903]
   Dent Paul, 2014, Cancer Biol Ther, V15, P245, DOI 10.4161/cbt.27541
   Duan XH, 2013, PHARM BIOL, V51, P433, DOI 10.3109/13880209.2012.738332
   El Maghraoui A, 2012, J CLIN DENSITOM, V15, P328, DOI 10.1016/j.jocd.2011.12.001
   Feng D, 2011, INFLAMM RES, V60, P817, DOI 10.1007/s00011 011 0337 2
   Gallagher JC, 2002, J CLIN ENDOCR METAB, V87, P4914, DOI 10.1210/jc.2002 020727
   Gerdhem P, 2007, J BONE MINER RES, V22, P127, DOI 10.1359/JBMR.061003
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   Herrmann M, 2009, BONE, V44, P467, DOI 10.1016/j.bone.2008.10.051
   Hou GQ, 2013, INT J MOL MED, V32, P503, DOI 10.3892/ijmm.2013.1406
   Kameda Y, 2013, J BONE MINER RES, V28, P2463, DOI 10.1002/jbmr.1989
   Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615
   Koh JM, 2006, J BONE MINER RES, V21, P1003, DOI 10.1359/JBMR.060406
   Kuroda T, 2013, CALCIFIED TISSUE INT, V93, P269, DOI 10.1007/s00223 013 9754 2
   Kyriakis JM, 2012, PHYSIOL REV, V92, P689, DOI 10.1152/physrev.00028.2011
   Lee BJ, 2012, NUTRITION, V28, P767, DOI 10.1016/j.nut.2011.11.008
   Lee SH, 2010, MOVEMENT DISORD, V25, P332, DOI 10.1002/mds.22866
   Lee SJ, 2012, TOXICOL APPL PHARM, V260, P89, DOI 10.1016/j.taap.2012.01.026
   Lee YS, 2013, FREE RADICAL RES, V47, P422, DOI 10.3109/10715762.2013.784965
   Li DZ, 2014, J BONE MINER METAB, V32, P494, DOI 10.1007/s00774 013 0530 1
   Li XQ, 2009, INT IMMUNOPHARMACOL, V9, P1032, DOI 10.1016/j.intimp.2009.04.010
   Lin MC, 2013, PEPTIDES, V40, P42, DOI 10.1016/j.peptides.2012.11.010
   Looker AC, 1997, J BONE MINER RES, V12, P1761, DOI 10.1359/jbmr.1997.12.11.1761
   Luo CY, 2011, CELL MOL IMMUNOL, V8, P50, DOI 10.1038/cmi.2010.54
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Miyauchi Y, 2013, P NATL ACAD SCI USA, V110, P16568, DOI 10.1073/pnas.1308755110
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   MUDD SH, 1985, AM J HUM GENET, V37, P1
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   Selhub J, 1999, ANNU REV NUTR, V19, P217, DOI 10.1146/annurev.nutr.19.1.217
   Shastry S, 2009, J INFLAMM LOND, V6, DOI 10.1186/1476 9255 6 27
   Silverman SL, 2012, OSTEOPOROSIS INT, V23, P351, DOI 10.1007/s00198 011 1691 1
   Silverman SL, 2008, J BONE MINER RES, V23, P1923, DOI 10.1359/JBMR.080710
   Syed F, 2005, BIOCHEM BIOPH RES CO, V328, P688, DOI 10.1016/j.bbrc.2004.11.097
   Thaler R, 2011, J BIOL CHEM, V286, P5578, DOI 10.1074/jbc.M110.166181
   Vijayan V, 2013, FREE RADICAL BIO MED, V61, P72, DOI 10.1016/j.freeradbiomed.2013.03.004
   Wang DJ, 2012, CELL BIOL INT, V36, P511, DOI 10.1042/CBI20110235
   White Jill, 2012, Biomed Sci Instrum, V48, P478
   Yan TT, 2010, CLIN EXP PHARMACOL P, V37, P1071, DOI 10.1111/j.1440 1681.2010.05438.x
   Yang J, 2012, BONE, V51, P376, DOI 10.1016/j.bone.2012.05.024
   Yilmaz N, 2009, AGING CLIN EXP RES, V21, P353
   Yin H, 2012, EUR J PHARMACOL, V674, P200, DOI 10.1016/j.ejphar.2011.11.024
   Zong Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044107
NR 54
TC 23
Z9 25
U1 0
U2 23
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1672 9145
EI 1745 7270
J9 ACTA BIOCH BIOPH SIN
JI Acta Biochim. Biophys. Sin.
PD FEB
PY 2015
VL 47
IS 2
BP 65
EP 72
DI 10.1093/abbs/gmu124
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA CB2EE
UT WOS:000349438700001
PM 25605419
DA 2025 08 17
ER

PT J
AU Mutyaba, PL
   Belkin, NS
   Lopas, L
   Gray, CF
   Dopkin, D
   Hankenson, KD
   Ahn, J
AF Mutyaba, Patricia L.
   Belkin, Nicole S.
   Lopas, Luke
   Gray, Chancellor F.
   Dopkin, Derek
   Hankenson, Kurt D.
   Ahn, Jaimo
TI Notch Signaling in Mesenchymal Stem Cells Harvested From Geriatric Mice
SO JOURNAL OF ORTHOPAEDIC TRAUMA
LA English
DT Article
DE bone; mesenchymal stem cell; notch; mouse
ID DIFFERENTIATION; AGE; REPAIR
AB Objectives:
   Morbidity associated with geriatric fractures may be attributed, in part, to compromised mesenchymal stem cell (MSC) function within the fracture callus. The Notch signaling pathway is important for the healing of nonskeletal tissues in an age dependent manner, but the effect of Notch on age dependent fracture healing and MSC dysfunction has not been substantiated. The objective of this study was to examine Notch signaling in MSCs obtained from young and geriatric mice.
   Methods:
   Marrow derived MSCs were harvested from the femora of 5  and 25 month old C57BL/6 mice. We assessed in vivo MSC number using CFU F, proliferation using an Alamar Blue assay, osteoblast differentiation by Alizarin Red S staining, and adipogenic differentiation using Oil Red O staining. Notch receptor and ligand expression was assessed using quantitative PCR, and Notch signaling was assessed by evaluating Notch target gene expression (Hey and HES) under basal conditions and when cells were plated to Jagged 1 ligand.
   Results:
   MSC from geriatric mice exhibit reduced MSC number (CFU F), proliferation, adipogenesis, and inconsistent osteogenesis. The highest expressed Notch receptor is Notch 2, and the highest expressed ligand is Jagged 1, but there were no differences in ligand and receptor gene expression between young and old MSCs. Interestingly, geriatric MSCs show decreased basal Notch signaling activity but are fully responsive to Jagged 1 stimulation.
   Conclusions:
   These data suggest that therapeutic targeting of Notch signaling should be explored in clinical therapies to improve geriatric fracture healing.
C1 [Mutyaba, Patricia L.; Belkin, Nicole S.; Lopas, Luke; Gray, Chancellor F.; Hankenson, Kurt D.; Ahn, Jaimo] Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, Philadelphia, PA 19104 USA.
   [Mutyaba, Patricia L.; Dopkin, Derek; Hankenson, Kurt D.] Univ Penn, Sch Vet Med, New Bolton Ctr, Dept Clin Studies, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; University of Pennsylvania
RP Ahn, J (通讯作者)，Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, 2 Silverstein,3400 Spruce St, Philadelphia, PA 19104 USA.
EM jaimo.ahn@uphs.upenn.edu
RI ; Ahn, Jaimo/KVZ 0734 2024; Hankenson, Kurt/ABI 1547 2020
OI Hankenson, Kurt/0000 0001 6361 143X; Ahn, Jaimo/0000 0001 8151 9987;
   Lopas, Luke/0000 0002 4735 2818; 
FU NIH [R03 AG040670]; American Geriatric Association
FX K. D. Hankenson is the cofounder of Skelegen Inc. J. Ahn is a consultant
   for Synthes, Merck, and U&I Corp. K. D. Hankenson and J. Ahn jointly
   received funding for these studies from NIH R03 AG040670 (NIA GEMSSTAR)
   and a matching Jahnigen grant from the American Geriatric Association.
   The remaining authors report no conflicts of interest.
CR BAK B, 1989, CALCIFIED TISSUE INT, V45, P292, DOI 10.1007/BF02556022
   Cauley JA, 2000, OSTEOPOROSIS INT, V11, P556, DOI 10.1007/s001980070075
   Conboy IM, 2003, SCIENCE, V302, P1575, DOI 10.1126/science.1087573
   Coutu DL, 2011, AGING US, V3, P920, DOI 10.18632/aging.100369
   Dishowitz MI, 2013, J BIOMED MATER RES A, DOI [10.1002/jbm.a.34825, DOI 10.1002/JBM.A.34825.PMID:23775982]
   Dishowitz MI, 2012, J ORTHOP RES, V30, P296, DOI 10.1002/jor.21518
   Engin FZ, 2008, NAT MED, V14, P299, DOI 10.1038/nm1712
   Fiúza UM, 2007, J ENDOCRINOL, V194, P459, DOI 10.1677/JOE 07 0242
   Gruber R, 2006, EXP GERONTOL, V41, P1080, DOI 10.1016/j.exger.2006.09.008
   Hankenson KD, 2000, J BONE MINER RES, V15, P851, DOI 10.1359/jbmr.2000.15.5.851
   Hilton MJ, 2008, NAT MED, V14, P306, DOI 10.1038/nm1716
   Karagiannides I, 2001, AM J PHYSIOL REG I, V280, pR1772, DOI 10.1152/ajpregu.2001.280.6.R1772
   KIRKLAND JL, 1990, AM J PHYSIOL, V258, pC206, DOI 10.1152/ajpcell.1990.258.2.C206
   Lu CY, 2005, J ORTHOP RES, V23, P1300, DOI 10.1016/j.orthres.2005.04.003
   Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474 9728.2004.00127.x
   Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood 2007 02 069716
   QUARTO R, 1995, CALCIFIED TISSUE INT, V56, P123, DOI 10.1007/BF00296343
   Shitaye H, 2009, T ORTH RES SOC
   Zhu FC, 2013, STEM CELLS, V31, P1181, DOI 10.1002/stem.1353
NR 19
TC 18
Z9 18
U1 0
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106 3621 USA
SN 0890 5339
EI 1531 2291
J9 J ORTHOP TRAUMA
JI J. Orthop. Trauma
PD APR
PY 2014
VL 28
SU 1
BP S20
EP S23
DI 10.1097/BOT.0000000000000064
PG 4
WC Orthopedics; Sport Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Sport Sciences
GA AE0RX
UT WOS:000333675000006
PM 24378431
OA Bronze
DA 2025 08 17
ER

PT J
AU Yu, XJ
   Zheng, FJ
   Shang, WZ
   Du, YM
   Zhen, JZ
   Mao, Y
   Zhang, SY
AF Yu, Xijiao
   Zheng, Fuju
   Shang, Wenzhi
   Du, Yanmei
   Zhen, Jinze
   Mao, Yi
   Zhang, Shanyong
TI Isorhamnetin 3 O neohesperidoside promotes the resorption of
   crown covered bone during tooth eruption by osteoclastogenesis
SO SCIENTIFIC REPORTS
LA English
DT Article
ID DENTAL FOLLICLE CELLS; ISORHAMNETIN 3 O NEOHESPERIDOSIDE; ACTIVATION;
   DIAGNOSIS; JNK
AB Delayed resorption of crown covered bone is a critical cause of delayed tooth eruption. Traditional herbal medicines may be good auxiliary treatments to promote the resorption of crown covered bone. This study was carried out to analyse the effect of isorhamnetin 3 O neohesperidoside on receptor activator of nuclear factor kB ligand (RANKL) induced osteoclastogenesis in vitro and resorption of the crown covered bone of the lower first molars in mice in vivo. Isorhamnetin 3 O neohesperidoside promoted osteoclastogenesis and the bone resorption of mouse bone marrow macrophages (BMMs) and upregulated mRNA expression of the osteoclast specific genes cathepsin K (CTSK), vacuolar type H +  ATPase d2(V ATPase d2), tartrate resistant acid phosphatase (TRAP) and nuclear factor of activated T cells cytoplasmic 1 (NFATc1). NFATc1, p38 and AKT signalling was obviously activated by isorhamnetin 3 O neohesperidoside in osteoclastogenesis. Isorhamnetin 3 O neohesperidoside aggravated resorption of crown covered bone in vivo. In brief, isorhamnetin 3 O neohesperidoside might be a candidate adjuvant therapy for delayed intraosseous eruption.
C1 [Yu, Xijiao; Zhen, Jinze; Mao, Yi; Zhang, Shanyong] Shanghai Jiao Tong Univ, Peoples Hosp 9, Coll Stomatol, Dept Oral Surg,Sch Med,Shanghai Key Lab Stomatol, Shanghai, Peoples R China.
   [Yu, Xijiao; Zhen, Jinze; Mao, Yi; Zhang, Shanyong] Shanghai Res Inst Stomatol, Shanghai, Peoples R China.
   [Yu, Xijiao; Zheng, Fuju; Shang, Wenzhi; Du, Yanmei] Jinan Stomatol Hosp, Dept Endodont, Jinan 250001, Shandong, Peoples R China.
C3 Shanghai Jiao Tong University
RP Zhen, JZ; Mao, Y; Zhang, SY (通讯作者)，Shanghai Jiao Tong Univ, Peoples Hosp 9, Coll Stomatol, Dept Oral Surg,Sch Med,Shanghai Key Lab Stomatol, Shanghai, Peoples R China.; Zhen, JZ; Mao, Y; Zhang, SY (通讯作者)，Shanghai Res Inst Stomatol, Shanghai, Peoples R China.
EM zhenlich@163.com; maoyi1994@126.com; zhangshanyong@126.com
RI YU, XIJIAO/KFA 3924 2024
OI Zhen, Jinze/0009 0009 0393 3440
FU China Postdoctoral Science Foundation [2019M651537]; Clinical medicine
   science and technology innovation plan of Jinan [201907099]; Research
   Fund of Medicine and Engineering of Shanghai Jiao Tong University
   [ZH2018ZDA13]; Innovation Fund of Translational Medicine of Shanghai
   Jiao Tong University School of Medicine [TM201812]
FX This work was supported by China Postdoctoral Science Foundation
   (2019M651537) and Clinical medicine science and technology innovation
   plan of Jinan (201907099) given to Y.X.J. as well as Research Fund of
   Medicine and Engineering of Shanghai Jiao Tong University (ZH2018ZDA13);
   Innovation Fund of Translational Medicine of Shanghai Jiao Tong
   University School of Medicine (TM201812) given to Z.S.Y.
CR Ahmad I, 2017, INT J ESTHET DENT, V12, P352
   Bouhlel I, 2009, DRUG CHEM TOXICOL, V32, P258, DOI 10.1080/01480540902882192
   Cao SL, 2015, J CHROMATOGR SCI, V53, P866, DOI 10.1093/chromsci/bmu132
   Chen Xiao, 2018, Cell Physiol Biochem, V51, P2858, DOI 10.1159/000496039
   Chen XW, 2019, J CELL PHYSIOL, V234, P20944, DOI 10.1002/jcp.28699
   Chen XZ, 2019, EXP CELL RES, V382, DOI 10.1016/j.yexcr.2019.06.015
   Du LY, 2017, J CHROMATOGR SCI, V55, P243, DOI 10.1093/chromsci/bmw176
   Gaêta Araujo H, 2019, ANGLE ORTHOD, V89, P781, DOI 10.2319/090518 651.1
   Ge J, 2015, J DENT RES, V94, P936, DOI 10.1177/0022034515578908
   Han YJ, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0019 6
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Isawa M, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 56151 1
   Jacobs SG, 2000, AM J ORTHOD DENTOFAC, V118, P439, DOI 10.1067/mod.2000.108782
   Jiang H, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 38711 7
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   la Monaca G, 2019, AM J ORTHOD DENTOFAC, V156, P355, DOI 10.1016/j.ajodo.2018.09.020
   Li ZK, 2018, CALCIFIED TISSUE INT, V103, P324, DOI 10.1007/s00223 018 0425 1
   Liu SJ, 2013, CHIN J NAT MEDICINES, V11, P572, DOI [10.3724/SP.J.1009.2013.00572, 10.1016/S1875 5364(13)60103 X]
   Liu Y, 2018, ORAL DIS, V24, P1270, DOI 10.1111/odi.12900
   MARKS SC, 1984, ARCH ORAL BIOL, V29, P311, DOI 10.1016/0003 9969(84)90105 5
   Oralová V, 2014, CONNECT TISSUE RES, V55, P357, DOI 10.3109/03008207.2014.951441
   Pajevic PD, 2019, BONE, V119, P13, DOI 10.1016/j.bone.2018.02.012
   Park JY, 2016, BIOMOL THER, V24, P610, DOI 10.4062/biomolther.2016.026
   Park JY, 2016, DRUG DEVELOP RES, V77, P143, DOI 10.1002/ddr.21301
   Russo R, 2019, CELLS BASEL, V8, DOI 10.3390/cells8020131
   Sajnani AK, 2015, J INVESTIG CLIN DENT, V6, DOI 10.1111/jicd.12067
   Song MK, 2018, J CELL MOL MED, V22, P849, DOI 10.1111/jcmm.13370
   Sun HY, 2015, CELL TISSUE RES, V362, P399, DOI 10.1007/s00441 015 2214 8
   Suri L, 2004, AM J ORTHOD DENTOFAC, V126, P432, DOI 10.1016/j.ajodo.2003.10.031
   Suzuki T, 2004, J BONE MINER METAB, V22, P185, DOI 10.1007/s00774 003 0481 z
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Wang HT, 2020, EUR J PHARM SCI, V144, DOI 10.1016/j.ejps.2020.105214
   Wang Q, 2019, MOL BIOL REP, V46, P3073, DOI 10.1007/s11033 019 04745 3
   Wang XP, 2013, J DENT RES, V92, P212, DOI 10.1177/0022034512474469
   Wang YX, 2019, J CELL PHYSIOL, V234, P10432, DOI 10.1002/jcp.27711
   Wise GE, 2008, J DENT RES, V87, P414, DOI 10.1177/154405910808700509
   Wu MR, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 13015 6
   Yu XJ, 2019, J MOL HISTOL, V50, P427, DOI 10.1007/s10735 019 09838 8
   Yu XJ, 2019, J MOL HISTOL, V50, P35, DOI 10.1007/s10735 018 9805 0
   Yu XJ, 2019, J PERIODONTAL RES, V54, P180, DOI 10.1111/jre.12618
   Zeng GY, 2020, NAT PROD RES, V34, P1041, DOI 10.1080/14786419.2018.1539979
   Zhou T, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/9159605
NR 42
TC 4
Z9 6
U1 0
U2 18
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD MAR 20
PY 2020
VL 10
IS 1
AR 5172
DI 10.1038/s41598 020 62107 7
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA NF6PI
UT WOS:000563417100010
PM 32198458
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Li, JY
   Chen, XD
   Ren, L
   Chen, XJ
   Wu, T
   Wang, Y
   Ren, XY
   Cheng, B
   Xia, J
AF Li, Jiayan
   Chen, Xiaodan
   Ren, Lin
   Chen, Xijuan
   Wu, Tong
   Wang, Yun
   Ren, Xianyue
   Cheng, Bin
   Xia, Juan
TI Type H vessel/platelet derived growth factor receptor β<SUP>+</SUP>
   perivascular cell disintegration is involved in vascular injury and bone
   loss in radiation induced bone damage
SO CELL PROLIFERATION
LA English
DT Article
ID MESENCHYMAL STEM CELLS; ENDOTHELIUM DAMAGE; PROGENITOR CELLS; PERICYTE
   LOSS; MARROW; PDGF; ANGIOGENESIS; REGENERATION; OSTEOGENESIS; MICE
AB Collapse of the microvascular system is a prerequisite for radiation induced bone loss. Since type H vessels, a specific bone vessel subtype surrounded by platelet derived growth factor receptor beta(+) (PDGFR beta(+)) perivascular cells (PVCs), has been recently identified to couple angiogenesis and osteogenesis, we hypothesize that type H vessel injury initiates PDGFR beta(+) PVC dysfunction, which contributes to the abnormal angiogenesis and osteogenesis after irradiation. In this study, we found that radiation led to the decrease of both type H endothelial cell (EC) and PDGFR beta(+) PVC numbers. Remarkably, results from lineage tracing showed that PDGFR beta(+) PVCs detached from microvessels and converted the lineage commitment from osteoblasts to adipocytes, leading to vascular injury and bone loss after irradiation. These phenotype transitions above were further verified to be associated with the decrease in hypoxia inducible factor 1 alpha (HIF 1 alpha)/PDGF BB/PDGFR beta signalling between type H ECs and PDGFR beta(+) PVCs. Pharmacological blockade of HIF 1 alpha/PDGF BB/PDGFR beta signalling induced a phenotype similar to radiation induced bone damage, while the rescue of this signalling significantly alleviated radiation induced bone injury. Our findings show that the decrease in HIF 1 alpha/PDGF BB/PDGFR beta signalling between type H ECs and PDGFR beta(+) PVCs after irradiation affects the homeostasis of EC PVC coupling and plays a part in vascular damage and bone loss, which has broad implications for effective translational therapies.
C1 [Li, Jiayan; Chen, Xiaodan; Ren, Lin; Chen, Xijuan; Wu, Tong; Wang, Yun; Ren, Xianyue; Cheng, Bin; Xia, Juan] Sun Yat Sen Univ, Hosp Stomatol, Guangzhou, Peoples R China.
   [Li, Jiayan; Chen, Xiaodan; Ren, Lin; Chen, Xijuan; Wu, Tong; Wang, Yun; Ren, Xianyue; Cheng, Bin; Xia, Juan] Sun Yat Sen Univ, Guangdong Prov Key Lab Stomatol, Guangzhou, Peoples R China.
   [Li, Jiayan; Chen, Xiaodan; Ren, Lin; Chen, Xijuan; Wu, Tong; Wang, Yun; Ren, Xianyue; Cheng, Bin; Xia, Juan] Sun Yat Sen Univ, Guanghua Sch Stomatol, Guangzhou, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University
RP Cheng, B; Xia, J (通讯作者)，Sun Yat Sen Univ, Hosp Stomatol, Guangzhou, Peoples R China.; Cheng, B; Xia, J (通讯作者)，Sun Yat Sen Univ, Guangdong Prov Key Lab Stomatol, Guangzhou, Peoples R China.; Cheng, B; Xia, J (通讯作者)，Sun Yat Sen Univ, Guanghua Sch Stomatol, Guangzhou, Peoples R China.
EM chengbin@mail.sysu.edu.cn; xiajuan@mail.sysu.edu.cn
RI Yang, Hongyan/IZQ 2790 2023; Bin, CHENG/KFQ 9943 2024; Chen,
   Xiaodan/AAE 8515 2022; wu, tong/ITV 6896 2023
FU National Natural Science Foundation of China [81870769, 81900976,
   82170960]; Science and Technology Planning Project of Guangzhou, China
   [202206080009]
FX National Natural Science Foundation of China, Grant/Award Numbers:
   81870769, 81900976, 82170960; Science and Technology Planning Project of
   Guangzhou, China, Grant/Award Number: 202206080009
CR Agas D, 2015, CYTOKINE GROWTH F R, V26, P347, DOI 10.1016/j.cytogfr.2014.12.004
   Aguilera KY, 2014, CELL MOL LIFE SCI, V71, P299, DOI 10.1007/s00018 013 1432 z
   Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708
   Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001
   Avolio E, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI152308
   Baselet B, 2019, CELL MOL LIFE SCI, V76, P699, DOI 10.1007/s00018 018 2956 z
   Bell RD, 2010, NEURON, V68, P409, DOI 10.1016/j.neuron.2010.09.043
   Bianco P, 2014, ANNU REV CELL DEV BI, V30, P677, DOI 10.1146/annurev cellbio 100913 013132
   Böhm AM, 2019, DEV CELL, V51, P236, DOI 10.1016/j.devcel.2019.08.013
   Cao X, 2011, P NATL ACAD SCI USA, V108, P1609, DOI 10.1073/pnas.1015350108
   Caplan AI, 2011, J ORTHOP RES, V29, P1795, DOI 10.1002/jor.21462
   Chen M, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00138 0
   Chen Q, 2019, CELL STEM CELL, V25, P768, DOI 10.1016/j.stem.2019.10.006
   Costa S, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00587
   Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003
   D'Oronzo S, 2015, CANCER TREAT REV, V41, P798, DOI 10.1016/j.ctrv.2015.09.003
   Daneman R, 2010, NATURE, V468, P562, DOI 10.1038/nature09513
   De Ruysscher D, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572 019 0064 5
   Dubrac A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05926 7
   Gillman CE, 2021, MAT SCI ENG C MATER, V130, DOI 10.1016/j.msec.2021.112466
   Guo J, 2020, FREE RADICAL BIO MED, V160, P447, DOI 10.1016/j.freeradbiomed.2020.08.015
   Hassanshahi M, 2017, ANGIOGENESIS, V20, P427, DOI 10.1007/s10456 017 9577 2
   Heldin CH, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478 811X 11 97
   Holden P, 2019, TISSUE ENG PART B RE, V25, P461, DOI [10.1089/ten.TEB.2019.0111, 10.1089/ten.teb.2019.0111]
   Jin YQ, 2014, TISSUE ENG PT A, V20, P3303, DOI [10.1089/ten.tea.2013.0556, 10.1089/ten.TEA.2013.0556]
   Kemp SS, 2020, ARTERIOSCL THROM VAS, V40, P2632, DOI 10.1161/ATVBAHA.120.314948
   Kim G, 2018, CYTOTHERAPY, V20, P1013, DOI 10.1016/j.jcyt.2018.06.008
   Kusumbe AP, 2016, NATURE, V532, P380, DOI 10.1038/nature17638
   Kusumbe AP, 2015, NAT PROTOC, V10, P1904, DOI 10.1038/nprot.2015.125
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Langen UH, 2017, NAT CELL BIOL, V19, P189, DOI 10.1038/ncb3476
   LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875
   Li H, 2021, J DENT RES, V100, P983, DOI 10.1177/00220345211002120
   Li XQ, 2020, BLOOD, V136, P2691, DOI 10.1182/blood.2020006321
   Li ZY, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.670813
   Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242
   Mäe MA, 2021, CIRC RES, V128, pE46, DOI 10.1161/CIRCRESAHA.120.317473
   Murray IR, 2014, CELL MOL LIFE SCI, V71, P1353, DOI 10.1007/s00018 013 1462 6
   Nikolakopoulou AM, 2019, NAT NEUROSCI, V22, P1089, DOI 10.1038/s41593 019 0434 z
   Olson LE, 2011, DEV CELL, V20, P815, DOI 10.1016/j.devcel.2011.04.019
   Onogi Y, 2017, DIABETES, V66, P1008, DOI 10.2337/db16 0881
   Pacheco R, 2013, CURR OSTEOPOROS REP, V11, P299, DOI 10.1007/s11914 013 0174 z
   Papadopoulos N, 2018, MOL ASPECTS MED, V62, P75, DOI 10.1016/j.mam.2017.11.007
   Park DY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15296
   Peng Y, 2020, THERANOSTICS, V10, P426, DOI 10.7150/thno.34126
   Rafii S, 2016, NATURE, V529, P316, DOI 10.1038/nature17040
   Ramasamy SK, 2016, ANNU REV CELL DEV BI, V32, P649, DOI 10.1146/annurev cellbio 111315 124936
   Regan JN, 2014, P NATL ACAD SCI USA, V111, P8673, DOI 10.1073/pnas.1324290111
   Roig EM, 2019, CELLS BASEL, V8, DOI 10.3390/cells8010045
   Romeo SG, 2019, NAT CELL BIOL, V21, P430, DOI 10.1038/s41556 019 0304 7
   Santhanam L, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI147116
   Sims NA, 2020, ANNU REV PHYSIOL, V82, P507, DOI 10.1146/annurev physiol 021119 034425
   Singh A, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125679
   Spencer JA, 2014, NATURE, V508, P269, DOI 10.1038/nature13034
   Strojan P, 2017, CANCER TREAT REV, V59, P79, DOI 10.1016/j.ctrv.2017.07.003
   Su WP, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.135446
   Sun CY, 2020, CELL STEM CELL, V26, P707, DOI 10.1016/j.stem.2020.03.004
   Supakul S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051079
   Török O, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2016587118
   Tomlinson RE, 2013, BONE RES, V1, P311, DOI 10.4248/BR201304002
   Venkatesulu BP, 2018, JACC BASIC TRANSL SC, V3, P563, DOI 10.1016/j.jacbts.2018.01.014
   Vitzthum LK, 2020, INT J RADIAT ONCOL, V106, P485, DOI 10.1016/j.ijrobp.2019.10.006
   Wang M, 2020, THERANOSTICS, V10, P12144, DOI 10.7150/thno.48562
   Wijerathne H, 2021, RADIOTHER ONCOL, V158, P21, DOI 10.1016/j.radonc.2021.02.007
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Xu J, 2012, J DENT RES, V91, P702, DOI 10.1177/0022034512448661
   Xu LS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179323
   Zhang J, 2022, ADV MATER, V34, DOI 10.1002/adma.202202044
   Zhu SP, 2020, THERANOSTICS, V10, P5957, DOI 10.7150/thno.45422
NR 69
TC 6
Z9 9
U1 6
U2 33
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0960 7722
EI 1365 2184
J9 CELL PROLIFERAT
JI Cell Prolif.
PD JUL
PY 2023
VL 56
IS 7
DI 10.1111/cpr.13406
EA JAN 2023
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA L5KM2
UT WOS:000919915100001
PM 36694343
OA gold
DA 2025 08 17
ER

PT J
AU Xiong, Y
   Chen, L
   Yan, CC
   Zhou, W
   Yu, T
   Sun, Y
   Cao, FQ
   Xue, H
   Hu, YQ
   Chen, D
   Mi, BB
   Liu, GH
AF Xiong, Yuan
   Chen, Lang
   Yan, Chenchen
   Zhou, Wu
   Yu, Tao
   Sun, Yun
   Cao, Faqi
   Xue, Hang
   Hu, Yiqiang
   Chen, Dong
   Mi, Bobin
   Liu, Guohui
TI 被撤回的出版物: M2 Macrophagy derived exosomal miRNA 5106 induces bone
   mesenchymal stem cells towards osteoblastic fate by targeting
   salt inducible kinase 2 and 3
SO JOURNAL OF NANOBIOTECHNOLOGY
LA English
DT Article; Retracted Publication
DE Exosome; MiR 5106; Osteoblast; Fracture; SIK2; SIK3
ID DIFFERENTIATION
AB Background Osteoblast differentiation is a vital process for fracture healing, and exosomes are nanosized membrane vesicles that can deliver therapeutic drugs easily and safely. Macrophages participate in the regulation of various biological processes in vivo, and macrophage derived exosomes (MD Exos) have recently been a topic of increasing research interest. However, few study has explored the link between MD Exos and osteoblast differentiation. Herein, we sought to identify miRNAs differentially expressed between M1 and M2 macrophage derived exosomes, and to evaluate their roles in the context of osteoblast differentiation. Results We found that microRNA 5106 (miR 5106) was significantly overexpressed in M2 macrophage derived exosomes (M2D Exos), while its expression was decreased in M1 macrophage derived exosomes (M1D Exos), and we found that this exosomal miRNA can induce bone mesenchymal stem cell (BMSC) osteogenic differentiation via directly targeting the Salt inducible kinase 2 and 3 (SIK2 and SIK3) genes. In addition, the local injection of both a miR 5106 agonist or M2D Exos to fracture sites was sufficient to accelerate healing in vivo. Conclusions Our study demonstrates that miR 5106 is highly enriched in M2D Exos, and that it can be transferred to BMSCs wherein it targets SIK2 and SIK3 genes to promote osteoblast differentiation.
C1 [Xiong, Yuan; Chen, Lang; Yan, Chenchen; Zhou, Wu; Cao, Faqi; Xue, Hang; Hu, Yiqiang; Chen, Dong; Mi, Bobin; Liu, Guohui] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Orthopaed, Wuhan 430022, Peoples R China.
   [Yu, Tao] Tongji Univ, Tongji Hosp, Dept Orthoped Surg, Sch Med, Shanghai 200065, Peoples R China.
   [Sun, Yun] Huazhong Univ Sci & Technol, Dept Neurosurg, Union Hosp, Tongji Med Coll, Wuhan 430022, Peoples R China.
C3 Huazhong University of Science & Technology; Tongji University; Huazhong
   University of Science & Technology
RP Mi, BB; Liu, GH (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Orthopaed, Wuhan 430022, Peoples R China.
EM mibobin@hust.edu.cn; liuguohui@hust.edu.cn
RI Xiong, Yuan/AAQ 3642 2021; Mi, Bobin/LTD 1938 2024; Yan,
   chenchen/HJY 0642 2023; chou, wu/AAI 1145 2019
OI Mi, Bobin/0000 0002 6994 4363; Xiong, Yuan/0000 0003 1090 9288
FU National Science Foundation of China [81772345]; National Health
   Commission of the People's Republic of China [ZX 01 018,
   ZX 01 C2016153]; Ministry of Science and Technology of the People's
   Republic of China [2018YFC2001502, 2018YFB1105705]; Health Commission of
   Hubei Province [WJ2019Z009]; Wuhan Science and Technology Bureau
   [2017060201010192]
FX This study was supported by the National Science Foundation of China
   (No. 81772345), National Health Commission of the People's Republic of
   China (No. ZX 01 018, ZX 01 C2016153), Ministry of Science and
   Technology of the People's Republic of China (No.2018YFC2001502,
   2018YFB1105705), Health Commission of Hubei Province (No. WJ2019Z009),
   Wuhan Science and Technology Bureau (No. 2017060201010192).
CR Ageta H, 2019, CELL MOL LIFE SCI, V76, P4829, DOI 10.1007/s00018 019 03246 7
   Alexander KA, 2011, J BONE MINER RES, V26, P1517, DOI 10.1002/jbmr.354
   Bian HJ, 2016, MOL METAB, V5, P970, DOI 10.1016/j.molmet.2016.08.012
   Chang B, 2018, ACS APPL MATER INTER, V10, P33022, DOI 10.1021/acsami.8b11449
   Cheng M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 08895 7
   Claes L, 2012, NAT REV RHEUMATOL, V8, P133, DOI 10.1038/nrrheum.2012.1
   Darling NJ, 2017, BIOCHEM J, V474, P521, DOI 10.1042/BCJ20160646
   Frank AC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 08989 2
   Kim KI, 2014, BIOMATERIALS, V35, P4792, DOI 10.1016/j.biomaterials.2014.02.048
   Kim MK, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1915 4
   Lewis JM, 2018, ACS NANO, V12, P3311, DOI 10.1021/acsnano.7b08199
   Li CJ, 2018, J CLIN INVEST, V128, P5251, DOI 10.1172/JCI99044
   Li CJ, 2015, J CLIN INVEST, V125, P1509, DOI 10.1172/JCI77716
   Li Y, 2019, MOL THER NUCL ACIDS, V17, P590, DOI 10.1016/j.omtn.2019.06.023
   Lin CJ, 2019, THERANOSTICS, V9, P3780, DOI 10.7150/thno.34493
   Lombardi MS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185426
   Ma QL, 2018, BIOMATERIALS, V154, P234, DOI 10.1016/j.biomaterials.2017.11.003
   Milovanovic P, 2017, SMALL, V13, DOI 10.1002/smll.201602215
   Nishimori S, 2019, J CLIN INVEST, V129, P5187, DOI 10.1172/JCI130126
   Parihar A, 2010, J INNATE IMMUN, V2, P204, DOI 10.1159/000296507
   Park JE, 2004, AM J SURG, V187, p11S, DOI 10.1016/S0002 9610(03)00296 4
   Pegtel DM, 2019, ANNU REV BIOCHEM, V88, P487, DOI 10.1146/annurev biochem 013118 111902
   Qiao L, 2019, J CLIN INVEST, V129, P2237, DOI 10.1172/JCI123135
   Ramanathan S, 2019, J EXTRACELL VESICLES, V8, DOI 10.1080/20013078.2019.1650595
   Ren ZW, 2017, BIOFABRICATION, V9, DOI 10.1088/1758 5090/aa747f
   Ricarte FR, 2018, J BIOL CHEM, V293, P20200, DOI 10.1074/jbc.RA118.004751
   Sawada N, 2014, CELL METAB, V19, P246, DOI 10.1016/j.cmet.2013.12.014
   Schlundt C, 2018, BONE, V106, P78, DOI 10.1016/j.bone.2015.10.019
   Schmidt Bleek K, 2014, EXPERT OPIN BIOL TH, V14, P247, DOI 10.1517/14712598.2014.857653
   Su T, 2019, ACS NANO, V13, P2450, DOI 10.1021/acsnano.8b09375
   Thomou T, 2017, NATURE, V542, P450, DOI 10.1038/nature21365
   Vi L, 2015, J BONE MINER RES, V30, P1090, DOI 10.1002/jbmr.2422
   Xiong Y, 2019, MOL THER NUCL ACIDS, V17, P223, DOI 10.1016/j.omtn.2019.06.001
   Yu YL, 2019, CELL METAB, V29, P966, DOI 10.1016/j.cmet.2019.01.016
   Yuan ZH, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1803 y
   Zhang XN, 2019, MOL CANCER, V18, DOI 10.1186/s12943 019 0959 5
NR 36
TC 127
Z9 136
U1 1
U2 71
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477 3155
J9 J NANOBIOTECHNOL
JI J. Nanobiotechnol.
PD APR 28
PY 2020
VL 18
IS 1
AR 66
DI 10.1186/s12951 020 00622 5
PG 16
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Science & Technology   Other
   Topics
GA LL1DP
UT WOS:000531296000002
PM 32345321
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Liu, MF
   Tian, SP
   Liu, YH
   Gao, F
   Yin, QS
AF Liu, Mingfa
   Tian, Shaopeng
   Liu, Yuanhang
   Gao, Feng
   Yin, Qingshui
TI Inhibition of curcumin on proliferation and invasion in giant cell tumor
   of bone (GCTB) by targeting STAT3
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Giant cell tumor of bone; STAT3; curcumin; proliferation; invasion
ID COLON CANCER CELLS; EXPRESSION; DENOSUMAB; ACTIVATION; APOPTOSIS;
   DIFFERENTIATION; HYPOCALCEMIA; INVOLVEMENT; METASTASIS; CYTOKINE
AB Objectives: To investigate the effects of curcumin on the proliferation and invasion in cells of giant cell tumor of bone (GCTB) by targeting the signal transducer and activator transcription factor 3 (STAT3), in order to supply treatments and preventions on GCTB with new drugs and relative mechanisms. Methods: GCTB cells were collected from resection tissues of four patients with GCTB. GCTB cells were treated by curcumin. STAT3 was one of the genes influencing invasion of osteolytic tumor, so we silenced STAT3 by small interfering RNA (siRNA) and detected by Western Blot (WB). Cell counting kit 8 (CCK 8) and Transwell system were used for detecting GCTB cell proliferation and invasion. Results: Curcumin (31.5 nM) was treated on GCTB cells for 24 h. There was significant difference before (case 1, 0.685 +/  0.026; case 2, 0.731 +/  0.030; case 3, 0.728 +/  0.019; case 4, 0.634 +/  0.015) and after (case 1, 0.160 +/  0.008; case 2, 0.769 +/  0.014; case 3, 0.743 +/  0.026; case 4, 0.750 +/  0.018) curcumin treatment (P<0.01). After silencing STAT3, there was no significance before (case 1, 0.738 +/  0.021; case 2, 0.769 +/  0.014; case 3, 0.743 +/  0.026; case 4, 0.750 +/  0.018) and after (case 1, 0.704 +/  0.010; case 2, 0.720 +/  0.015; case 3, 0.714 +/  0.022; case 4, 0.729 +/  0.013) curcumin treatment. Conclusions: Curcumin inhibits the proliferation and invasion in GCTB by targeting STAT3. STAT3 might be the new therapeutic target for treating GCTB metastasis.
C1 [Liu, Mingfa; Yin, Qingshui] Southern Med Univ, Guangzhou 510515, Guangdong, Peoples R China.
   [Liu, Mingfa; Tian, Shaopeng; Liu, Yuanhang; Gao, Feng] First Hosp Huhehaote, Dept Emergency Surg, Hohhot 010010, Inner Mongolia, Peoples R China.
   [Yin, Qingshui] Southern Med Univ, Gen Hosp Guangzhou Mil Command, Orthoped Hosp, Dept Orthoped,Guangdong Key Lab Orthoped Technol, 111 Liuhua Rd, Guangzhou 510010, Guangdong, Peoples R China.
C3 Southern Medical University   China; Southern Theater Command General
   Hospital; Southern Medical University   China
RP Yin, QS (通讯作者)，Southern Med Univ, Gen Hosp Guangzhou Mil Command, Orthoped Hosp, Dept Orthoped,Guangdong Key Lab Orthoped Technol, 111 Liuhua Rd, Guangzhou 510010, Guangdong, Peoples R China.
EM nanyiyinqingshui@163.com
RI Yin, Qing/HNC 6727 2023
CR Asok M, 2002, ONCOGENE, V21, P8852
   Bertoni F, 2003, SKELETAL RADIOL, V32, P143, DOI 10.1007/s00256 002 0550 8
   Brodowicz T, 2015, FUTURE ONCOL, V11, P1881, DOI [10.2217/FON.15.94, 10.2217/fon.15.94]
   Bromberg J, 2009, CANCER CELL, V15, P79, DOI 10.1016/j.ccr.2009.01.009
   Carroll RE, 2011, CANCER PREV RES, V4, P354, DOI 10.1158/1940 6207.CAPR 10 0098
   Cheng AL, 2001, ANTICANCER RES, V21, P2895
   Collett GP, 2004, CARCINOGENESIS, V25, P2183, DOI 10.1093/carcin/bgh233
   Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630
   EMURA I, 1986, ACTA PATHOL JAPON, V36, P691
   Fornasier VL, 2014, HUM PATHOL, V17, P302
   Forsyth RG, 2009, J BONE MINER RES, V24, P70, DOI [10.1359/jbmr.080905, 10.1359/JBMR.080905]
   Gao B, 2001, FEBS LETT, V488, P179, DOI 10.1016/S0014 5793(00)02430 3
   Garcia RA, 2011, SEMIN DIAGN PATHOL, V28, P73, DOI 10.1053/j.semdp.2011.02.013
   GOLDRING SR, 1987, J CLIN INVEST, V79, P483, DOI 10.1172/JCI112838
   Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551
   Houchins JP, 2006, J BONE MINER RES, V21, P1339
   Huang L, 2004, BONE, V34, P393, DOI 10.1016/j.bone.2003.10.013
   HUTTER RVP, 1962, CANCER AM CANCER SOC, V15, P653, DOI 10.1002/1097 0142(196207/08)15:4<653::AID CNCR2820150402>3.0.CO;2 M
   Ikesue H, 2014, ANN PHARMACOTHER, V48, P1159, DOI 10.1177/1060028014539919
   Kim KC, 2010, KOREAN J PHYSIOL PHA, V14, P391, DOI 10.4196/kjpp.2010.14.6.391
   Klampfer L, 2006, CURR CANCER DRUG TAR, V6, P107, DOI 10.2174/156800906776056491
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee YK, 2009, ANN NY ACAD SCI, V1171, P489, DOI 10.1111/j.1749 6632.2009.04699.x
   Lewin J, 2013, DRUG TODAY, V49, P693, DOI 10.1358/dot.2013.49.11.2064725
   McGough RL, 2005, CLIN ORTHOP RELAT R, P116, DOI 10.1097/01.blo.0000180055.769669.08
   Milacic V, 2008, CANCER RES, V68, P7283, DOI 10.1158/0008 5472.CAN 07 6246
   Mohankumar K, 2015, BIOMED PHARMACOTHER, V74, P178, DOI 10.1016/j.biopha.2015.07.024
   Mudduluru G, 2011, BIOSCIENCE REP, V31, P185, DOI 10.1042/BSR20100065
   Nishimura M, 2005, J ORTHOP RES, V23, P979, DOI 10.1016/j.orthres.2005.01.004
   Rabelink NM, 2011, BONE, V48, pS242, DOI 10.1016/j.bone.2011.03.585
   Robinson D, 2002, PATHOBIOLOGY, V70, P333, DOI 10.1159/000071273
   Shishodia S, 2005, BIOCHEM PHARMACOL, V70, P700, DOI 10.1016/j.bcp.2005.04.043
   Singh AS, 2015, BIOL TARGETS THER, V9, P69, DOI 10.2147/BTT.S57359
   Smyth B, 2016, INTERN MED J, V46, P360, DOI 10.1111/imj.13001
   Thomas DM, 2009, CURR OPIN ONCOL, V21, P338, DOI 10.1097/CCO.0b013e32832c951d
   Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995
   ZHENG MH, 1994, AM J PATHOL, V145, P1095
NR 37
TC 1
Z9 1
U1 0
U2 3
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940 5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2016
VL 9
IS 11
BP 21474
EP 21481
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA EG7UD
UT WOS:000391260800106
DA 2025 08 17
ER

PT J
AU Kato, H
   Ochiai Shino, H
   Onodera, S
   Saito, A
   Shibahara, T
   Azuma, T
AF Kato, Hiroshi
   Ochiai Shino, Hiromi
   Onodera, Shoko
   Saito, Akiko
   Shibahara, Takahiko
   Azuma, Toshifumi
TI Promoting effect of 1,25(OH)2 vitamin D3 in
   osteogenic differentiation from induced pluripotent stem cells to
   osteocyte like cells
SO OPEN BIOLOGY
LA English
DT Article
DE induced pluripotent stem cells; vitamin D; osteoblasts; osteocytes; drug
   assessment
ID OSTEOBLAST DIFFERENTIATION; BIOCHEMICAL MARKERS; BONE TURNOVER;
   OSTEOPOROSIS; MECHANISMS; WOMEN; OSTEONECROSIS; ALENDRONATE; EXPRESSION;
   FRACTURE
AB We recently reported a new method to purify the induced pluripotent stem (iPS) derived osteoprogenitors (iPSop). In this paper, we optimized the procedure and characterized cells at each process step. We observed that 10 days of treatment with FGF 2, IGF 1 and TGF beta (FIT) resulted in early phase osteoblasts and 14 days of treatment resulted in late phase osteoblasts. We found that treatment with 1,25(OH)(2) vitamin D 3 increased expression of osteocalcin and decreased expression of tissue non specific alkaline phosphatase and runt related transcription factor 2 (RUNX2) in iPSop day14 cells (cells treated with FIT for 14 days). Therefore, iPSop day14 cells were promoted to mature osteoblasts by 1,25(OH)(2) vitamin D 3 treatment. In addition, we found that 1,25(OH)(2) vitamin D 3 treatment for 14 days enhanced not only mineralization but also expression of osteocyte markers, including dentin matrix protein 1 and fibroblast growth factor 23, in iPSop cells. Therefore, 1,25(OH)(2) vitamin D 3 is a potent promoter of osteoblast osteocyte transition. The results of this study suggest that it is possible to evaluate both early and late phase osteoblasts and to apply cells to drug screening for anabolic drugs that stimulate bone formation.
C1 [Kato, Hiroshi; Shibahara, Takahiko] Tokyo Dent Coll, Dept Oral & Maxillofacial Surg, Tokyo, Japan.
   [Ochiai Shino, Hiromi; Onodera, Shoko; Saito, Akiko; Azuma, Toshifumi] Tokyo Dent Coll, Dept Biochem, Tokyo, Japan.
C3 Tokyo Dental College; Tokyo Dental College
RP Azuma, T (通讯作者)，Tokyo Dent Coll, Dept Biochem, Tokyo, Japan.
EM tazuma@tdc.ac.jp
RI AZUMA, TOSHIFUMI/HTQ 4727 2023
OI Onodera, Shoko/0000 0003 0673 3400
FU JSPS KAKENHI [25462900, 25861761, 26861686, 26861560]; Grants in Aid for
   Scientific Research [26861560, 25861761, 25462900, 26861686] Funding
   Source: KAKEN
FX This work was supported by JSPS KAKENHI (C) grant no. 25462900 and by
   JSPS KAKENHI for young scientist (B) grant nos. 25861761, 26861686 and
   26861560.
CR Bilousova G, 2011, STEM CELLS, V29, P206, DOI 10.1002/stem.566
   Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184
   Das S, 2013, DRUG DES DEV THER, V7, P435, DOI 10.2147/DDDT.S31504
   Ebert AD, 2010, NAT REV DRUG DISCOV, V9, P1, DOI 10.1038/nrd3000
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Geng S, 2013, METABOLISM, V62, P768, DOI 10.1016/j.metabol.2013.01.003
   Gupta Swati, 2013, Natl J Maxillofac Surg, V4, P151, DOI 10.4103/0975 5950.127643
   Iki M, 2004, OSTEOPOROSIS INT, V15, P981, DOI 10.1007/s00198 004 1634 1
   Inoue H, 2011, CLIN PHARMACOL THER, V89, P655, DOI 10.1038/clpt.2011.38
   Inoue H, 2014, EMBO J, V33, P409, DOI 10.1002/embj.201387098
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kondo T, 2013, CELL STEM CELL, V12, P487, DOI 10.1016/j.stem.2013.01.009
   Li F, 2010, J CELL BIOCHEM, V109, P643, DOI 10.1002/jcb.22440
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   McClung MR, 2014, NEW ENGL J MED, V370, P1664, DOI 10.1056/NEJMc1402396
   Nordin BEC, 2004, AM J CLIN NUTR, V80, P998, DOI 10.1093/ajcn/80.4.998
   Ochiai H, 2012, J BIOL CHEM, V287, P22654, DOI 10.1074/jbc.M111.279091
   Ochiai Shino H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099534
   Pajevic PD, 2013, ENDOCRINOL METAB, V28, P255, DOI 10.3803/EnM.2013.28.4.255
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Saito A, 2013, FASEB J, V27, P2165, DOI 10.1096/fj.12 221432
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Sharma D, 2013, VASC CELL, V5, DOI 10.1186/2045 824X 5 1
   Tashiro K, 2009, STEM CELLS, V27, P1802, DOI 10.1002/stem.108
   van Dinther M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062295
   van Driel M, 2004, CURR PHARM DESIGN, V10, P2535
   Woeckel VJ, 2013, GENE, V512, P438, DOI 10.1016/j.gene.2012.07.051
   Yahata N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025788
   Yoshimura N, 1999, CALCIFIED TISSUE INT, V65, P198
   Yoshimura N, 2010, INT J EPIDEMIOL, V39, P988, DOI 10.1093/ije/dyp276
   Yoshimura N, 2009, J BONE MINER METAB, V27, P620, DOI 10.1007/s00774 009 0080 8
   Zhou SH, 2010, ENDOCRINOLOGY, V151, P14, DOI 10.1210/en.2009 0969
NR 36
TC 49
Z9 51
U1 0
U2 21
PU ROYAL SOC
PI LONDON
PA 6 9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
EI 2046 2441
J9 OPEN BIOL
JI Open Biol
PD FEB
PY 2015
VL 5
IS 2
AR 140201
DI 10.1098/rsob.140201
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA CE6BV
UT WOS:000351921700003
PM 25652541
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Pelosi, M
   Lazzarano, S
   Thoms, BL
   Murphy, CL
AF Pelosi, Michele
   Lazzarano, Stefano
   Thoms, Brendan L.
   Murphy, Chris L.
TI Parathyroid hormone related protein is induced by hypoxia and promotes
   expression of the differentiated phenotype of human articular
   chondrocytes
SO CLINICAL SCIENCE
LA English
DT Article
DE articular cartilage; chondrocytes; collagen type II; alpha 1 (COL2A1);
   hypoxia; parathyroid hormone related protein (PTHrP); sex determining
   region on the Y chromosome box 9 (SOX9)
ID GROWTH PLATE; OXYGEN TENSION; CARTILAGE; SOX9; PEPTIDE; PTHRP;
   TRANSCRIPTION; INHIBITION; PHYSIOLOGY; TARGET
AB PTHrP (parathyroid hormone related protein) is crucial for normal cartilage development and long bone growth and acts to delay chondrocyte hypertrophy and terminal differentiation in the growth plate. After growth plate closure adult HACs (human articular chondrocytes) still produce PTHrR suggesting a possible role for this factor in the permanent articular cartilage. However, the expression regulation and function of PTHrP in the permanent articular cartilage is unknown. Human articular cartilage is an avascular tissue and functions in a hypoxic environment. The resident chondrocytes have adapted to hypoxia and use it to drive their tissue specific functions. In the present study, we explored directly in normal articular chondrocytes isolated from a range of human donors the effect of hypoxia on PTHrP expression and whether PTHrP can regulate the expression of the permanent articular chondrocyte phenotype. We show that in HACs PTHrP is up regulated by hypoxia in a HIF (hypoxia inducible factor) 1 alpha and HIF 2 alpha dependent manner. Using recombinant PTHrP, siRNA mediated depletion of endogenous PTHrP and by blocking signalling through its receptor [PTHR1 (PTHrP receptor 1)], we show that hypoxia induced PTHrP is a positive regulator of the key cartilage transcription factor SOX9 [SRY (sex determining region on the Y chromosome) box 9], leading to increased COL2A1 (collagen type II, alpha 1) expression. Our findings thus identify PTHrP as a potential factor for cartilage repair therapies through its ability to promote the differentiated HAC phenotype.
C1 [Pelosi, Michele; Lazzarano, Stefano; Thoms, Brendan L.; Murphy, Chris L.] Univ Oxford, Kennedy Inst Rheumatol, London W6 8LH, England.
C3 University of Oxford; Kennedy Institute for Rheumatology
RP Murphy, CL (通讯作者)，Univ Oxford, Kennedy Inst Rheumatol, 65 Aspenlea Rd, London W6 8LH, England.
EM chris.murphy@kennedy.ox.ac.uk
RI Lazzarano, Stefano/ABG 1261 2021
OI Lazzarano, Stefano/0000 0001 8562 9825
FU Kennedy Institute of Rheumatology Trust, U.K.; Arthritis Research, U.K.
FX This work was funded by The Kennedy Institute of Rheumatology Trust,
   U.K. and Arthritis Research, U.K.
CR Amano K, 2009, MOL BIOL CELL, V20, P4541, DOI 10.1091/mbc.E09 03 0227
   Broadus AE, 2007, ANN NY ACAD SCI, V1116, P65, DOI 10.1196/annals.1402.061
   BURTIS WJ, 1987, J BIOL CHEM, V262, P7151
   Chen XS, 2008, ARTHRITIS RHEUM US, V58, P3788, DOI 10.1002/art.23985
   Correa D, 2010, DEV CELL, V19, P533, DOI 10.1016/j.devcel.2010.09.008
   Domm C, 2004, TISSUE ENG, V10, P1796, DOI 10.1089/ten.2004.10.1796
   FALCHUK KH, 1970, AM J MED, V49, P223, DOI 10.1016/S0002 9343(70)80078 X
   Fischer J, 2010, ARTHRITIS RHEUM US, V62, P2696, DOI 10.1002/art.27565
   Gibson JS, 2008, PFLUG ARCH EUR J PHY, V455, P563, DOI 10.1007/s00424 007 0310 7
   Hirai T, 2011, P NATL ACAD SCI USA, V108, P191, DOI 10.1073/pnas.1005011108
   Huang WD, 2001, P NATL ACAD SCI USA, V98, P160, DOI 10.1073/pnas.011393998
   Kronenberg HM, 2006, ANN NY ACAD SCI, V1068, P1, DOI 10.1196/annals.1346.002
   Kudo S, 2011, OSTEOARTHR CARTILAGE, V19, P886, DOI 10.1016/j.joca.2011.04.007
   Lafont JE, 2008, J BIOL CHEM, V283, P4778, DOI 10.1074/jbc.M707729200
   Lafont JE, 2007, ARTHRITIS RHEUM, V56, P3297, DOI 10.1002/art.22878
   Lefebvre V, 1998, MATRIX BIOL, V16, P529
   Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336
   Li TF, 2004, EXP CELL RES, V299, P128, DOI 10.1016/j.yexcr.2004.05.025
   López Fraga M, 2009, BIODRUGS, V23, P305, DOI 10.2165/11318190 000000000 00000
   LUNDOLESEN K, 1970, ARTHRITIS RHEUM US, V13, P769, DOI 10.1002/art.1780130606
   Macica C, 2011, ARTHRITIS RHEUM US, V63, P3333, DOI 10.1002/art.30515
   Manisterski M, 2010, CELL CYCLE, V9, P3723, DOI 10.4161/cc.9.18.12931
   Martinez Sanchez A, 2012, J BIOL CHEM, V287, P916, DOI 10.1074/jbc.M111.302430
   Murphy CL, 2001, TISSUE ENG, V7, P791, DOI 10.1089/107632701753337735
   Murphy CL, 2004, J CELL PHYSIOL, V199, P451, DOI 10.1002/jcp.10481
   Poole AR, 2001, CLIN ORTHOP RELAT R, pS26, DOI 10.1097/00003086 200110001 00004
   Schipani E, 1997, P NATL ACAD SCI USA, V94, P13689, DOI 10.1073/pnas.94.25.13689
   Schipani E, 2001, GENE DEV, V15, P2865
   Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021
   SILVER IA, 1975, PHILOS T ROY SOC B, V271, P261, DOI 10.1098/rstb.1975.0050
   Strewler GJ, 2000, NEW ENGL J MED, V342, P177, DOI 10.1056/NEJM200001203420306
   Tew SR, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2311
   Thoms BL, 2013, ARTHRITIS RHEUM US, V65, P1302, DOI 10.1002/art.37867
   Thoms BL, 2010, J BIOL CHEM, V285, P20472, DOI 10.1074/jbc.M110.115238
   VONDERMARK K, 1977, NATURE, V267, P531, DOI 10.1038/267531a0
NR 35
TC 13
Z9 15
U1 0
U2 18
PU PORTLAND PRESS LTD
PI LONDON
PA 5TH FLR, 90 HIGH HOLBORN, LONDON WC1V 6LJ, ENGLAND
SN 0143 5221
EI 1470 8736
J9 CLIN SCI
JI Clin. Sci.
PD NOV
PY 2013
VL 125
IS 9 10
BP 461
EP 470
DI 10.1042/CS20120610
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 228ZP
UT WOS:000325231900006
PM 23662774
DA 2025 08 17
ER

PT J
AU Kostenuik, P
   Mirza, FM
AF Kostenuik, Paul
   Mirza, Faisal M.
TI Fracture healing physiology and the quest for therapies for delayed
   healing and nonunion
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE fracture healing; osteogenesis; chondrogenesis; delayed union; nonunion
   fracture
ID HORMONE RELATED PEPTIDE; BONE MORPHOGENETIC PROTEIN 2;
   FIBROBLAST GROWTH FACTOR; OPEN TIBIAL FRACTURES; PARATHYROID HORMONE;
   POSTMENOPAUSAL WOMEN; DOUBLE BLIND; COMPARTMENT SYNDROME; MINERAL
   DENSITY; OSTEOTOMY MODEL
AB Delayed healing and nonunion of fractures represent enormous burdens to patients and healthcare systems. There are currently no approved pharmacological agents for the treatment of established nonunions, or for the acceleration of fracture healing, and no pharmacological agents are approved for promoting the healing of closed fractures. Yet several pharmacologic agents have the potential to enhance some aspects of fracture healing. In preclinical studies, various agents working across a broad spectrum of molecular pathways can produce larger, denser and stronger fracture calluses. However, untreated control animals in most of these studies also demonstrate robust structural and biomechanical healing, leaving unclear how these interventions might alter the healing of recalcitrant fractures in humans. This review describes the physiology of fracture healing, with a focus on aspects of natural repair that may be pharmacologically augmented to prevent or treat delayed or nonunion fractures (collectively referred to as DNFs). The agents covered in this review include recombinant BMPs, PTH/PTHrP receptor agonists, activators of Wnt/ catenin signaling, and recombinant FGF 2. Agents from these therapeutic classes have undergone extensive preclinical testing and progressed to clinical fracture healing trials. Each can promote bone formation, which is important for the stability of bridged calluses, and some but not all can also promote cartilage formation, which may be critical for the initial bridging and subsequent stabilization of fractures. Appropriately timed stimulation of chondrogenesis and osteogenesis in the fracture callus may be a more effective approach for preventing or treating DNFs compared with stimulation of osteogenesis alone. (c) 2016 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 35:213 223, 2017.
C1 [Kostenuik, Paul] Univ Michigan, Sch Dent, Phylon Pharma Serv, Newbury Pk, CA USA.
   [Mirza, Faisal M.] OrthoSynthesis Inc, San Jose, CA USA.
RP Kostenuik, P (通讯作者)，Univ Michigan, Sch Dent, Phylon Pharma Serv, Newbury Pk, CA USA.
EM paulkost@umich.edu
OI Mirza, Faisal/0000 0003 2937 3700
FU Radius Health
FX Grant sponsor: Radius Health.
CR Agholme F, 2011, ACTA ORTHOP, V82, P125, DOI [10.3109/17453674.2011.572252, 10.3109/17453674.2011.625539]
   Agholme F, 2011, BONE, V48, P988, DOI 10.1016/j.bone.2011.02.008
   Alaee F, 2014, J ORTHOP RES, V32, P197, DOI 10.1002/jor.22498
   Alkhiary YM, 2005, J BONE JOINT SURG AM, V87A, P731, DOI 10.2106/JBJS.D.02115
   Amizuka N, 1996, DEV BIOL, V175, P166, DOI 10.1006/dbio.1996.0104
   AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611
   ANDREW JG, 1993, CALCIFIED TISSUE INT, V52, P74, DOI 10.1007/BF00308311
   [Anonymous], J ORTHOP SURG RES
   Aro HT, 2011, J BONE JOINT SURG AM, V93A, P801, DOI 10.2106/JBJS.I.01763
   Aspenberg P, 2010, J BONE MINER RES, V25, P404, DOI 10.1359/jbmr.090731
   Bahney CS, 2014, J BONE MINER RES, V29, P1269, DOI 10.1002/jbmr.2148
   Bais M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005393
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115
   Borges JLC, 2013, ARQ BRAS ENDOCRINOL, V57, P153, DOI 10.1590/S0004 27302013000200010
   Bostrom MPG, 2000, BONE, V26, P437, DOI 10.1016/S8756 3282(00)00251 9
   Carragee EJ, 2011, SPINE J, V11, P471, DOI 10.1016/j.spinee.2011.04.023
   Chan FKW, 2003, J CLIN ENDOCR METAB, V88, P3155, DOI 10.1210/jc.2002 021388
   Chouinard L, 2014, J BONE MINER RES, V29, pS468
   COURTBROWN C, 1987, ACTA ORTHOP SCAND, V58, P249, DOI 10.3109/17453678709146477
   Cupp ME, 2013, J PHARMACOL EXP THER, V345, P404, DOI 10.1124/jpet.112.199752
   Dent Acosta Ricardo E, 2012, J Bone Joint Surg Am, V94 Suppl 1, P39, DOI 10.2106/JBJS.L.00194
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Epari DR, 2006, BONE, V38, P864, DOI 10.1016/j.bone.2005.10.023
   Feng G, 2015, INT IMMUNOPHARMACOL, V24, P7, DOI 10.1016/j.intimp.2014.11.010
   Florio M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11505
   Friedlaender GE, 2001, J BONE JOINT SURG AM, V83A, pS151
   Gerstenfeld LC, 2009, J BONE MINER RES, V24, P196, DOI 10.1359/JBMR.081113
   Giannoudis PV, 2000, J BONE JOINT SURG BR, V82B, P655, DOI 10.1302/0301 620X.82B5.9899
   Govender S, 2002, J BONE JOINT SURG AM, V84A, P2123, DOI 10.2106/00004623 200212000 00001
   GUSTILO RB, 1984, J TRAUMA, V24, P742, DOI 10.1097/00005373 198408000 00009
   Hadjiargyrou M, 2002, J BIOL CHEM, V277, P30177, DOI 10.1074/jbc.M203171200
   Hak DJ, 2014, INJURY, V45, pS3, DOI 10.1016/j.injury.2014.04.002
   Hausman MR, 2001, BONE, V29, P560, DOI 10.1016/S8756 3282(01)00608 1
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Huang Y, 2012, J ORTHOP RES, V30, P304, DOI 10.1002/jor.21505
   Intini G, 2015, BONE, V75, P151, DOI 10.1016/j.bone.2015.01.008
   IWASAKI M, 1994, J BONE MINER RES, V9, P1195
   JIRARATTANAPHOCHAI K, 1993, CLIN ORTHOP RELAT R, P366
   Johansson T, 2016, ACTA ORTHOP, V87, P79, DOI 10.3109/17453674.2015.1073050
   Kakar S, 2007, J BONE MINER RES, V22, P1903, DOI 10.1359/JBMR.070724
   Kanakaris NK, 2007, INJURY, V38, pS77, DOI 10.1016/S0020 1383(07)80012 X
   Kartsogiannis V, 1997, BONE, V21, P385, DOI 10.1016/S8756 3282(97)00180 4
   Kawaguchi H, 2001, J CLIN ENDOCR METAB, V86, P875, DOI 10.1210/jc.86.2.875
   Kawaguchi H, 2010, J BONE MINER RES, V25, P2459, DOI 10.1002/jbmr.146
   Kayal RA, 2007, J BONE MINER RES, V22, P560, DOI 10.1359/JBMR.070115
   Ke HZ, 2012, ENDOCR REV, V33, P747, DOI 10.1210/er.2011 1060
   Kokubu T, 2003, J ORTHOP RES, V21, P503, DOI 10.1016/S0736 0266(02)00209 7
   Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657
   Leder BZ, 2015, J CLIN ENDOCR METAB, V100, P697, DOI 10.1210/jc.2014 3718
   LENEHAN TM, 1985, J ORTHOP RES, V3, P499, DOI 10.1002/jor.1100030413
   Li CY, 2011, BONE, V49, P1178, DOI 10.1016/j.bone.2011.08.012
   Li X., 2011, MATRIX, V1, P1
   Lienau J, 2009, J ORTHOP RES, V27, P1133, DOI 10.1002/jor.20870
   Liu AL, 2015, CALCIFIED TISSUE INT, V97, P581, DOI 10.1007/s00223 015 0041 2
   Lozano D, 2009, ENDOCRINOLOGY, V150, P2027, DOI 10.1210/en.2008 1108
   Lu CY, 2007, J ORTHOP RES, V25, P51, DOI 10.1002/jor.20264
   Lu CY, 2010, J ORTHOP RES, V28, P687, DOI 10.1002/jor.21033
   Lyon T, 2013, J BONE JOINT SURG AM, V95A, P2088, DOI 10.2106/JBJS.L.01545
   Marsh D, 1998, CLIN ORTHOP RELAT R, pS22
   Martin TJ, 2005, J CLIN INVEST, V115, P2322, DOI 10.1172/JCI26239
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   McDonald MM, 2013, J BONE MINER RES, V28, P1550, DOI 10.1002/jbmr.1889
   Reverte MM, 2011, INJURY, V42, P1402, DOI 10.1016/j.injury.2011.09.007
   Meyer RA, 2001, J ORTHOP RES, V19, P428, DOI 10.1016/S0736 0266(00)90034 2
   Miao DS, 2002, J CLIN INVEST, V109, P1173, DOI 10.1172/JCI200214817
   Miao DS, 2004, ENDOCRINOLOGY, V145, P2046, DOI 10.1210/en.2003 1097
   Minear S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000231
   Monroe DG, 2012, GENE, V492, P1, DOI 10.1016/j.gene.2011.10.044
   Morse A, 2015, BONE, V71, P155, DOI 10.1016/j.bone.2014.10.018
   MOSEKILDE L, 1993, BONE, V14, P19, DOI 10.1016/8756 3282(93)90251 5
   Naik AA, 2009, J BONE MINER RES, V24, P251, DOI [10.1359/jbmr.081002, 10.1359/JBMR.081002]
   Nakazawa T, 2005, BONE, V37, P711, DOI 10.1016/j.bone.2005.06.013
   Okazaki K, 2003, J ORTHOPAED RES, V21, P511, DOI 10.1016/S0736 0266(02)00161 4
   Ominsky MS, 2011, J BONE MINER RES, V26, P1012, DOI 10.1002/jbmr.307
   Ong KL, 2010, SPINE, V35, P1794, DOI 10.1097/BRS.0b013e3181ecf6e4
   Oteo Alvaro A., 2010, Journal of shoulder and elbow surgery / American Shoulder and Elbow Surgeons ... [et al.], V19, pe22, DOI [DOI 10.1016/J.JSE.2010.05.005, 10.1016/j.jse.2010.05.005]
   Peichl P, 2011, J BONE JOINT SURG AM, V93A, P1583, DOI 10.2106/JBJS.J.01379
   Pountos I, 2013, INJURY, V44, P1725, DOI 10.1016/j.injury.2013.09.009
   Power RA, 2004, OSTEOPOROSIS INT, V15, P716, DOI 10.1007/s00198 004 1595 4
   Raschke M, 2007, EUR J ENDOCRINOL, V156, P341, DOI 10.1530/EJE 06 0598
   Reinke S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004754
   Ren YX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023060
   Schottel PC, 2015, J BONE JOINT SURG AM, V97A, P1406, DOI 10.2106/JBJS.N.01090
   Shimoaka T, 2004, J BIOL CHEM, V279, P15314, DOI 10.1074/jbc.M312525200
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Suen PK, 2014, J ORTHOP RES, V32, P997, DOI 10.1002/jor.22636
   Susperregui ARG, 2008, J CELL PHYSIOL, V216, P144, DOI 10.1002/jcp.21389
   Tägil M, 2010, BONE, V46, P852, DOI 10.1016/j.bone.2009.11.009
   Taylor S, 2016, BONE, V84, P148, DOI 10.1016/j.bone.2015.12.013
   Tsukazaki T, 1996, J ENDOCRINOL, V150, P359, DOI 10.1677/joe.0.1500359
   Tzioupis C, 2007, INJURY, V38, pS3, DOI 10.1016/S0020 1383(07)80003 9
   Uemura T, 2015, ORTHOPEDICS, V38, pE733, DOI 10.3928/01477447 20150804 90
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   Virk MS, 2013, J BONE JOINT SURG AM, V95A, P694, DOI 10.2106/JBJS.L.00285
   WALSH CA, 1995, J BONE MINER RES, V10, P17
   WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220
   Wang MN, 2015, BONE, V81, P104, DOI 10.1016/j.bone.2015.07.008
   Wang MN, 2014, J ANAT, V225, P71, DOI 10.1111/joa.12184
   Wang YH, 2013, CLIN EXP PHARMACOL P, V40, P715, DOI 10.1111/1440 1681.12161
   Waters RV, 2000, ACTA ORTHOP SCAND, V71, P316, DOI 10.1080/000164700317411951
   WEIR EC, 1992, CALCIFIED TISSUE INT, V51, P30, DOI 10.1007/BF00296214
   Westgeest J, 2016, J ORTHOP TRAUMA, V30, P149, DOI 10.1097/BOT.0000000000000488
   WROBLEWSKI J, 1995, J BONE MINER RES, V10, P735
   Yu YY, 2010, BONE, V47, P65, DOI 10.1016/j.bone.2010.03.012
   Zerega B, 1999, J BONE MINER RES, V14, P1281, DOI 10.1359/jbmr.1999.14.8.1281
NR 107
TC 131
Z9 148
U1 7
U2 42
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD FEB
PY 2017
VL 35
IS 2
BP 213
EP 223
DI 10.1002/jor.23460
PG 11
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA EK5RA
UT WOS:000393982300001
PM 27743449
OA Green Submitted, Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Diaz Borjon, A
   Seyler, TM
   Chen, NL
   Lim, SS
AF Diaz Borjon, Alejandro
   Seyler, Thorsten M.
   Chen, Natasha L.
   Lim, S. Sam
TI Bisphosphonate associated arthritis
SO JCR JOURNAL OF CLINICAL RHEUMATOLOGY
LA English
DT Article
DE bisphosphonates; acute phase response; arthritis; breast carcinoma;
   proinflammatory cytokine; adverse effect
ID ACUTE PHASE RESPONSE; IN VITRO; RHEUMATOID ARTHRITIS; OSTEONECROSIS;
   IBANDRONATE; ALENDRONATE; ALPHA
AB We present a case of arthritis apparently induced by the administration of intravenous bisphosphonates in a 51 year old white woman with metastatic breast carcinoma. She presented with bilateral knee pain and effusions on 2 separate occasions after receiving aminobisphosphonates. Synovial fluid analysis was negative for infection. metastasis, or crystals. Her symptoms resolved after the medication was discontinued and recurred after the patient was rechallenged with a medication from the same drug class. The administration of aminobisphosphonates has been associated with an acute phase response in several in vivo studies. The mechanism of action is thought to be that aminobisphosphonates transiently stimulate the production of proinflammatory cytokines such as interleukin 1, interleukin 6, and tumor necrosis factor alpha. Rheumatologists should be aware of this possible cause of arthropathy.
C1 Emory Univ, Sch Med, Dept Med, Div Rheumatol, Atlanta, GA 30303 USA.
C3 Emory University
RP Diaz Borjon, A (通讯作者)，Emory Univ, Sch Med, Dept Med, Div Rheumatol, 49 Jesse Hill Jr Dr SE, Atlanta, GA 30303 USA.
EM adiazbo@emory.edu
RI ; Seyler, Thorsten/JXN 8196 2024
OI Seyler, Thorsten/0000 0003 1157 132X; 
CR ADAMI S, 1987, CALCIFIED TISSUE INT, V41, P326, DOI 10.1007/BF02556671
   Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   BJORKENGREN AG, 1990, AM J ROENTGENOL, V154, P331
   Dicuonzo G, 2003, J INTERF CYTOK RES, V23, P649, DOI 10.1089/107999003322558782
   Durie BGM, 2005, NEW ENGL J MED, V353, P99
   Gerster JC, 2004, J RHEUMATOL, V31, P829
   Lippi G, 1998, CLIN CHIM ACTA, V271, P79, DOI 10.1016/S0009 8981(97)00212 X
   Mönkkönen J, 1998, LIFE SCI, V62, pPL95, DOI 10.1016/S0024 3205(97)01178 8
   Pietschmann P, 1998, CALCIFIED TISSUE INT, V63, P325, DOI 10.1007/s002239900535
   RALSTON SH, 1989, ANN RHEUM DIS, V48, P396, DOI 10.1136/ard.48.5.396
   Richards PJ, 1999, RHEUMATOLOGY, V38, P984, DOI 10.1093/rheumatology/38.10.984
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Sauty A, 1996, BONE, V18, P133, DOI 10.1016/8756 3282(95)00448 3
   Thiebaud D, 1997, CALCIFIED TISSUE INT, V61, P386, DOI 10.1007/s002239900353
   Valleala H, 2001, INFLAMM RES, V50, P598, DOI 10.1007/PL00000240
   Van Offel JF, 2001, CLIN EXP RHEUMATOL, V19, P13
   Zysk SP, 2003, INFLAMM RES, V52, P221, DOI 10.1007/s000110300075
NR 17
TC 15
Z9 17
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1076 1608
EI 1536 7355
J9 JCR J CLIN RHEUMATOL
JI JCR J. Clin. Rheumatol.
PD JUN
PY 2006
VL 12
IS 3
BP 131
EP 133
DI 10.1097/01.rhu.0000221796.06383.4e
PG 3
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 051CO
UT WOS:000238138300007
PM 16755241
DA 2025 08 17
ER

PT J
AU Teixeira, MZ
AF Teixeira, Marcus Zulian
TI Antiresorptive drugs (bisphosphonates), atypical fractures and rebound
   effect: new evidence of similitude
SO HOMEOPATHY
LA English
DT Article
DE Homeopathy; Osteoporosis; Bisphosphonates; Fracture; Atypical; Law of
   similars; Secondary effect; Rebound effect; Paradoxical reaction
ID SUPPRESSED BONE TURNOVER; FEMORAL SHAFT FRACTURES; LONG TERM
   ALENDRONATE; MINERALIZATION DENSITY DISTRIBUTION; DIAPHYSEAL FEMUR
   FRACTURES; UK PRIMARY CARE; POSTMENOPAUSAL WOMEN; MICRODAMAGE
   ACCUMULATION; HIP FRACTURE; BIOMECHANICAL PROPERTIES
AB Background: Homeopathy is based on treatment by similitude ('like cures like') administering to sick individuals substances that cause similar symptoms in healthy individuals, employing the secondary and paradoxical action of the organism as therapeutic response. This vital or homeostatic reaction of the organism can be scientifically explained by the rebound effect of drugs, resulting in worsening of symptoms after suspension of treatment. Bisphosphonates (BPs) reduce 'typical' fractures in patients with osteoporosis, but recent studies report 'atypical' fractures of the femur after stopping the BPs, a rebound effect may be the causal mechanism.
   Method: Review of the literature concerning the relationship between atypical femoral fractures and antiresorptive drugs (bisphosphonates), identifying the pathogenesis of this adverse event.
   Results: Several studies have described multiple cases of 'atypical' low impact subtrochanteric stress fractures or complete fractures of the femur. These fractures are often bilateral, preceded by pain in the affected thigh, may have a typical X ray appearance, and may delayed healing. Rebound of osteoclastic activity after suspension of antiresorptive drugs is a plausible mechanism to explain this phenomenon.
   Conclusion: As for other classes of drugs, the rebound effect of antiresorptive drugs supports Hahnemann's similitude principle (primary action of the drugs followed by secondary and opposite action of the organism), and clarifies this 'unresolved' issue. Unfortunately, the rebound effect is little discussed among health professionals, depriving them of important knowledge ensure safe management of drugs. Homeopathy (2012) 101, 231 242.
C1 [Teixeira, Marcus Zulian] Univ Sao Paulo, Fac Med, Dept Internal Med, Sao Paulo, Brazil.
C3 Universidade de Sao Paulo
RP Teixeira, MZ (通讯作者)，Hosp Clin FMUSP, Serv Clin Med Geral, Av Dr Eneas de Carvalho Aguiar 255,4 Andar,Bloco, BR 05403000 Sao Paulo, Brazil.
EM marcus@homeozulian.med.br
RI Teixeira, Marcus Zulian/A 7294 2008; Teixeira, Marcus/A 7294 2008
OI Teixeira, Marcus Zulian/0000 0002 3338 8588; 
CR ABRAHAMSEN B, 2010, 37 EUR S CALC TISS E
   Abrahamsen B, 2010, J CLIN ENDOCR METAB, V95, P5258, DOI 10.1210/jc.2010 1571
   Abrahamsen B, 2009, J BONE MINER RES, V24, P1095, DOI [10.1359/JBMR.081247, 10.1359/jbmr.081247]
   Agarwal S, 2010, ACTA ORTHOP BELG, V76, P567
   Akkus O, 2003, J BONE MINER RES, V18, P1012, DOI 10.1359/jbmr.2003.18.6.1012
   Allen MR, 2009, J ORAL MAXIL SURG, V67, P61, DOI 10.1016/j.joms.2009.01.007
   [Anonymous], 2010, US FOOD DRUG ADM ONG
   [Anonymous], 2008, WEBSTERS NEW WORLD M, V3rd
   Black DM, 2010, NEW ENGL J MED, V362, P1761, DOI 10.1056/NEJMoa1001086
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Boivin G, 2002, CONNECT TISSUE RES, V43, P535, DOI 10.1080/03008200290000934
   Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010 1502
   Boonen S, 2012, J BONE MINER RES, V27, P963, DOI 10.1002/jbmr.1570
   Brown JE, 2005, JNCI J NATL CANCER I, V97, P59, DOI 10.1093/jnci/dji002
   Brozoski MA, 2012, REV BRAS REUMATOL, V52, P260
   Chavassieux PM, 2000, J BONE MINER RES, V15, P754, DOI 10.1359/jbmr.2000.15.4.754
   Chavassieux PM, 1997, J CLIN INVEST, V100, P1475, DOI 10.1172/JCI119668
   Cheung Ralph K. H., 2007, Hong Kong Medical Journal, V13, P485
   CHRISTIANSEN C, 1981, LANCET, V1, P459
   Ciarelli TE, 2003, BONE, V32, P311, DOI 10.1016/S8756 3282(02)00975 4
   Cosman F, 2009, ENDOCR PRACT, V15, P483, DOI 10.4158/EP08306.ORR1
   Cremers SCLM, 2005, CLIN PHARMACOKINET, V44, P551, DOI 10.2165/00003088 200544060 00001
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Demiralp B, 2007, ARCH ORTHOP TRAUM SU, V127, P597, DOI 10.1007/s00402 007 0373 0
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Eisman JA, 2011, J BONE MINER RES, V26, P242, DOI 10.1002/jbmr.212
   Ekström W, 2009, INJURY, V40, P371, DOI 10.1016/j.injury.2008.09.010
   Eriksen EF, 2002, BONE, V31, P620, DOI 10.1016/S8756 3282(02)00869 4
   Fujikawa Y, 1996, ENDOCRINOLOGY, V137, P4058, DOI 10.1210/en.137.9.4058
   Gallagher JC, 2002, J CLIN ENDOCR METAB, V87, P4914, DOI 10.1210/jc.2002 020727
   Rodríguez LAG, 2011, BMJ BRIT MED J, V343, DOI 10.1136/bmj.d4094
   Rodríguez LAG, 2011, NEUROLOGY, V76, P740, DOI 10.1212/WNL.0b013e31820d62b5
   Gibson MV, 2008, GERIATRICS, V63, P21
   Girgis CM, 2010, NEW ENGL J MED, V362, P1848, DOI 10.1056/NEJMc0910389
   Giusti A, 2010, BONE, V47, P169, DOI 10.1016/j.bone.2010.05.019
   Goh SK, 2007, J BONE JOINT SURG BR, V89B, P349, DOI 10.1302/0301 620X.89B3.18146
   Greenspan SL, 2002, ANN INTERN MED, V137, P875, DOI 10.7326/0003 4819 137 11 200212030 00008
   Haentjens P, 2010, ANN INTERN MED, V152, P380, DOI 10.7326/0003 4819 152 6 201003160 00008
   HAHNEMANN S, 1991, ORGANON MED
   Haleem S, 2008, INJURY, V39, P1157, DOI 10.1016/j.injury.2008.03.022
   Heiss G, 2008, JAMA J AM MED ASSOC, V299, P1036, DOI 10.1001/jama.299.9.1036
   Hernandez CJ, 2008, BONE, V42, P1014, DOI 10.1016/j.bone.2008.02.001
   Hirano T, 2000, BONE, V27, P13, DOI 10.1016/S8756 3282(00)00284 2
   HODDING GC, 1980, WESTERN J MED, V133, P383
   Husada G, 2005, EUR J TRAUMA, V35, P68
   Ioannidis G, 2009, CAN MED ASSOC J, V181, P265, DOI 10.1503/cmaj.081720
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   KELLY MP, 2010, ASBMR 2010 ANN M TOR
   Kitano M, 2005, J BONE MINER METAB, V23, P48, DOI 10.1007/s00774 004 0540 0
   Kumm DA, 1997, J ARTHROPLASTY, V12, P580, DOI 10.1016/S0883 5403(97)90184 4
   Lenart BA, 2009, OSTEOPOROSIS INT, V20, P1353, DOI 10.1007/s00198 008 0805 x
   Li J, 2001, CALCIFIED TISSUE INT, V69, P281, DOI 10.1007/s002230010036
   Mashiba T, 2000, J BONE MINER RES, V15, P613, DOI 10.1359/jbmr.2000.15.4.613
   Mashiba T, 2001, BONE, V28, P524, DOI 10.1016/S8756 3282(01)00414 8
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   Miller PD, 2011, J CLIN ENDOCR METAB, V96, P394, DOI 10.1210/jc.2010 1805
   National Institute for Health and Clinical Excellence, 2010, FIN APPR DET AL ET R
   Neviaser AS, 2008, J ORTHOP TRAUMA, V22, P346, DOI 10.1097/BOT.0b013e318172841c
   Nieves JW, 2010, OSTEOPOROSIS INT, V21, P399, DOI 10.1007/s00198 009 0962 6
   Nieves Jeri W, 2010, Curr Osteoporos Rep, V8, P34, DOI 10.1007/s11914 010 0007 2
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Oivin G, 2008, J BONE MINER RES, V23, pS10
   Oniani T N, 1988, Neurosci Behav Physiol, V18, P301, DOI 10.1007/BF01185522
   Papaioannou A, 2009, OSTEOPOROSIS INT, V20, P703, DOI 10.1007/s00198 008 0743 7
   Papapoulos S, 2010, J BONE MINER RES  S1, V25, pS1
   Papapoulos S.E., 2008, Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Bisphosphonates for Postmenopausal Osteoporosis, V7th, P237
   Papapoulos SE, 2008, BEST PRACT RES CL EN, V22, P831, DOI 10.1016/j.beem.2008.07.001
   Park Wyllie LY, 2011, JAMA J AM MED ASSOC, V305, P783, DOI 10.1001/jama.2011.190
   Reidenberg MM, 2011, J PHARMACOL EXP THER, V339, P324, DOI 10.1124/jpet.111.183285
   Rizzoli R, 2011, OSTEOPOROSIS INT, V22, P373, DOI 10.1007/s00198 010 1453 5
   Roschger P, 2010, J BONE MINER RES, V25, P48, DOI 10.1359/jbmr.090702
   Rosen HN, 2000, CALCIFIED TISSUE INT, V66, P100, DOI 10.1007/PL00005830
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Salminen S, 1997, J TRAUMA, V43, P117, DOI 10.1097/00005373 199707000 00027
   Sayed Noor AS, 2009, CLIN ORTHOP RELAT R, V467, P1921, DOI 10.1007/s11999 009 0725 x
   Schilcher J, 2011, NEW ENGL J MED, V364, P1728, DOI 10.1056/NEJMoa1010650
   Schneider JP, 2009, GERIATRICS US, V64, P18
   Schneider JP, 2006, GERIATRICS, V61, P31
   Schuiling KD, 2011, J MIDWIFERY WOM HEAL, V56, P615, DOI 10.1111/j.1542 2011.2011.00135.x
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Somford MP, 2009, J BONE MINER RES, V24, P1736, DOI [10.1359/jbmr.090408, 10.1359/JBMR.090408]
   Teixeira M Z, 1999, Br Homeopath J, V88, P112
   Teixeira MZ, 2006, HOMEOPATHY, V95, P229, DOI 10.1016/j.homp.2006.06.004
   Teixeira MZ, 2007, HOMEOPATHY, V96, P135, DOI 10.1016/j.homp.2007.02.001
   Teixeira MZ, 2007, HOMEOPATHY, V96, P67, DOI 10.1016/j.homp.2006.11.009
   Teixeira MZ, 2011, HOMEOPATHY, V100, P244, DOI 10.1016/j.homp.2011.01.002
   Teixeira MZ, 2011, HOMEOPATHY, V100, P148, DOI 10.1016/j.homp.2011.05.003
   Teixeira MZ, 2010, HOMEOPATHY, V99, P255, DOI 10.1016/j.homp.2010.01.001
   Teixeira MZ, 2009, HOMEOPATHY, V98, P114, DOI 10.1016/j.homp.2009.02.004
   Teixeira MZ, 2010, NEW HOMEOPATHIC MED, V3
   TEIXEIRA MZ, 1998, SEMELHANTE CURA SEME
   Teixeira MZ, 2012, INT J HIGH DILUTION, V11, P69
   VESTERGAARD P, 2010, ASBMR 2010 ANN M TOR
   Visekruna M, 2008, J CLIN ENDOCR METAB, V93, P2948, DOI 10.1210/jc.2007 2803
   Wang Z, 2011, J BONE MINER RES, V26, P553, DOI 10.1002/jbmr.233
   Watts NB, 2010, J CLIN ENDOCR METAB, V95, P1555, DOI 10.1210/jc.2009 1947
   Wells G, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004523.pub3
   Wells GA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003376.pub3
   Wells GA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001155.pub2
   Whitaker M, 2012, NEW ENGL J MED, V366, P2048, DOI 10.1056/NEJMp1202619
   Wolfe RM, 1997, AM FAM PHYSICIAN, V56, P455
   World Health Organization, 2002, SAF MON MED PROD
   Yates J, 2004, OBSTET GYNECOL, V103, P440, DOI 10.1097/01.AOG.0000114986.14806.37
   Zhang J, 2011, RHEUM DIS CLIN N AM, V37, P387, DOI 10.1016/j.rdc.2011.08.001
   Zoehrer R, 2006, J BONE MINER RES, V21, P1106, DOI 10.1359/JBMR.060401
NR 105
TC 13
Z9 13
U1 0
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1475 4916
EI 1476 4245
J9 HOMEOPATHY
JI Homeopathy
PD OCT
PY 2012
VL 101
IS 4
BP 231
EP 242
DI 10.1016/j.homp.2012.07.001
PG 12
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA 035GL
UT WOS:000310931300008
PM 23089219
DA 2025 08 17
ER

PT J
AU Saarinen, TT
   Arikoski, P
   Holmberg, C
   Rönnholm, K
AF Saarinen, Tuure T.
   Arikoski, Pekka
   Holmberg, Christer
   Roennholm, Kai
TI Intermittent or daily administration of 1 alpha calcidol for
   nephrectomised infants on peritoneal dialysis?
SO PEDIATRIC NEPHROLOGY
LA English
DT Article
DE growth; children; vitamin D analogue treatment; parathyroid hormone
   (PTH); congenital nephrosis; end stage renal failure
ID CHRONIC RENAL FAILURE; CONGENITAL NEPHROTIC SYNDROME; SECONDARY
   HYPERPARATHYROIDISM; PARATHYROID HORMONE; CALCITRIOL THERAPY;
   BONE DISEASE; INTRAVENOUS CALCITRIOL; PEDIATRIC PATIENTS; PROSPECTIVE
   TRIAL; IMPROVES GROWTH
AB Secondary hyperparathyroidism and renal osteodystrophy are major problems in patients with end stage renal failure and may result in poor growth in children on dialysis. Whether vitamin D sterols should be given intermittently or daily remains a controversial issue. We studied 16 bilaterally nephrectomised infants with congenital nephrosis of the Finnish type (median age 0.54 years), all on peritoneal dialysis. Nine of them were receiving intermittent 1 alpha calcidol therapy and seven daily 1 alpha calcidol therapy. The target serum parathyroid hormone (PTH) level was 2 3 times the upper limit of normal (ULN). There were no statistically significant differences in PTH values between the groups (1.7 times vs 0.5 times the ULN at 3 months and 3.1 times vs 3.4 times the ULN at 6 months, respectively). The required weekly doses of 1 alpha calcidol were low, and there were no significant differences between the intermittent and daily groups (0.06 mu g/kg vs 0.04 mu g/kg at 3 months and 0.09 mu g/kg vs 0.05 mu g/kg at 6 months, respectively). The infants on intermittent 1 alpha calcidol showed significant catch up growth during dialysis after nephrectomy relative to the infants on daily 1 alpha calcidol ( 1.6 SD to  0.7 SD vs  1.4 SD to  1.0 SD, respectively; P < 0.05). Our results indicate that either intermittent or daily vitamin D analogue therapy, if started early, will prevent secondary hyperparathyroidism equally well in children on peritoneal dialysis (PD), but intermittent therapy might be more favourable for growth.
C1 Univ Helsinki, Hosp Children & Adolescents, Dept Paediat Nephrol & Transplantat, FIN 00290 Helsinki, Finland.
   Univ Kuopio, Kuopio Univ Hosp, Dept Paediat, Kuopio, Finland.
C3 University of Helsinki; Kuopio University Hospital; University of
   Eastern Finland; University of Eastern Finland Hospital
RP Saarinen, TT (通讯作者)，Univ Helsinki, Hosp Children & Adolescents, Dept Paediat Nephrol & Transplantat, Stenbackinkatu 11, FIN 00290 Helsinki, Finland.
EM tuure.saarinen@helsinki.fi
OI Saarinen, Tuure/0000 0002 7508 4849
CR AlaHouhala M, 1995, PEDIATR NEPHROL, V9, P737, DOI 10.1007/BF00868726
   ANTIKAINEN M, 1992, CLIN NEPHROL, V38, P254
   ANTIKAINEN M, 1993, PEDIATR NEPHROL, V7, P428, DOI 10.1007/BF00857558
   Ardissino G, 2000, PEDIATR NEPHROL, V14, P664, DOI 10.1007/s004670000365
   Avila Díaz M, 2006, PERITON DIALYSIS INT, V26, P78
   Drüeke TB, 1999, AM J MED SCI, V317, P383, DOI 10.1016/S0002 9629(15)40551 8
   Felsenfeld AJ, 1997, J AM SOC NEPHROL, V8, P993
   Fivush BA, 1998, PEDIATR NEPHROL, V12, P328, DOI 10.1007/s004670050462
   Fournier A, 1995, NEPHROL DIAL TRANSPL, V10, P2376, DOI 10.1093/ndt/10.12.2376
   GOODMAN WG, 1994, KIDNEY INT, V46, P1160, DOI 10.1038/ki.1994.380
   GUNNESSHEY M, 1984, METAB BONE DIS RELAT, V5, P177, DOI 10.1016/0221 8747(84)90026 2
   HERRMANN P, 1994, NEPHRON, V67, P48, DOI 10.1159/000187887
   HOLMBERG C, 1995, PEDIATR NEPHROL, V9, P87, DOI 10.1007/BF00858984
   Hölttä T, 2000, PEDIATR NEPHROL, V14, P889
   Hölttä T, 2000, NEPHROL DIAL TRANSPL, V15, P1438, DOI 10.1093/ndt/15.9.1438
   Holtta TM, 1997, PERITON DIALYSIS INT, V17, P573
   HUTTUNEN NP, 1976, ARCH DIS CHILD, V51, P344, DOI 10.1136/adc.51.5.344
   Klaus G, 2006, PEDIATR NEPHROL, V21, P151, DOI 10.1007/s00467 005 2082 7
   KLAUS G, 1991, PEDIATR NEPHROL, V5, P461, DOI 10.1007/BF01453682
   Kuizon BD, 1998, KIDNEY INT, V53, P205, DOI 10.1046/j.1523 1755.1998.00724.x
   Kuizon BD, 1998, MINER ELECTROL METAB, V24, P290, DOI 10.1159/000057384
   Kuizon BD, 1999, J BONE MINER RES, V14, P1680, DOI 10.1359/jbmr.1999.14.10.1680
   Levine BS, 1996, J AM SOC NEPHROL, V7, P488
   Mehls O, 2000, PEDIATR NEPHROL, V14, P658, DOI 10.1007/s004670000346
   Panichi V, 1998, CLIN NEPHROL, V49, P245
   QUARLES LD, 1994, KIDNEY INT, V45, P1710, DOI 10.1038/ki.1994.223
   RIDGEN SP, 1996, PEDIATR NEPHROL, V10, P653
   SALUSKY IB, 1988, KIDNEY INT, V33, P975, DOI 10.1038/ki.1988.96
   Salusky IB, 1996, PEDIATR NEPHROL, V10, P651, DOI 10.1007/s004670050183
   Sanchez CP, 2005, J AM SOC NEPHROL, V16, P929, DOI 10.1681/ASN.2003100878
   Schmitt CP, 2003, PEDIATR NEPHROL, V18, P440, DOI 10.1007/s00467 003 1091 7
   Schmitt CP, 2000, KIDNEY INT, V57, P1484, DOI 10.1046/j.1523 1755.2000.00993.x
   SHERRARD DJ, 1993, KIDNEY INT, V43, P436, DOI 10.1038/ki.1993.64
   TAM CS, 1982, ENDOCRINOLOGY, V110, P506, DOI 10.1210/endo 110 2 506
   Waller S, 2003, PEDIATR NEPHROL, V18, P1236, DOI 10.1007/s00467 003 1284 0
   WANG M, 1995, AM J KIDNEY DIS, V26, P836, DOI 10.1016/0272 6386(95)90453 0
   Yalcinkaya F, 1997, PEDIATR NEPHROL, V11, P350, DOI 10.1007/s004670050294
NR 37
TC 3
Z9 3
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0931 041X
J9 PEDIATR NEPHROL
JI Pediatr. Nephrol.
PD NOV
PY 2007
VL 22
IS 11
BP 1931
EP 1938
DI 10.1007/s00467 007 0592 1
PG 8
WC Pediatrics; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pediatrics; Urology & Nephrology
GA 215OX
UT WOS:000249820000015
PM 17851700
DA 2025 08 17
ER

PT J
AU Lin, H
   Shi, FL
   Jiang, SS
   Wang, YY
   Zou, JR
   Ying, Y
   Huang, DQ
   Luo, LY
   Yan, XH
   Luo, ZJ
AF Lin, Hui
   Shi, Fuli
   Jiang, Shanshan
   Wang, Yuanyuan
   Zou, Junrong
   Ying, Ying
   Huang, Deqiang
   Luo, Lingyu
   Yan, Xiaohua
   Luo, Zhijun
TI Metformin attenuates trauma induced heterotopic ossification via
   inhibition of Bone Morphogenetic Protein signalling
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE AMP&#8208; activated protein kinase; BMP signalling pathway; metformin;
   trauma&#8208; induced heterotopic ossification
ID ANTIDIABETIC DRUG; FRACTURE RISK; TGF BETA; IN VIVO; AMPK; GLUCOSE;
   PREVENTS; DIFFERENTIATION; ROSIGLITAZONE; METABOLISM
AB AMP activated protein kinase (AMPK) is an intracellular sensor of energy homoeostasis that is activated under energy stress and suppressed in energy surplus. AMPK activation leads to inhibition of anabolic processes that consume ATP. Osteogenic differentiation is a process that highly demands ATP during which AMPK is inhibited. The bone morphogenetic proteins (BMPs) signalling pathway plays an essential role in osteogenic differentiation. The present study examines the inhibitory effect of metformin on BMP signalling, osteogenic differentiation and trauma induced heterotopic ossification. Our results showed that metformin inhibited Smad1/5 phosphorylation induced by BMP6 in osteoblast MC3T3 E1 cells, concurrent with up regulation of Smad6, and this effect was attenuated by knockdown of Smad6. Furthermore, we found that metformin suppressed ALP activity and mineralization of the cells, an event that was attenuated by the dominant negative mutant of AMPK and mimicked by its constitutively active mutant. Finally, administration of metformin prevented the trauma induced heterotopic ossification in mice. In conjuncture, AMPK activity and Smad6 and Smurf1 expression were enhanced by metformin treatment in the muscle of injured area, concurrently with the reduction of ALK2. Collectively, our study suggests that metformin prevents heterotopic ossification via activation of AMPK and subsequent up regulation of Smad6. Therefore, metformin could be a potential therapeutic drug for heterotopic ossification induced by traumatic injury.
C1 [Lin, Hui; Shi, Fuli; Zou, Junrong; Ying, Ying; Luo, Zhijun] Nanchang Univ, Sch Basic Med Sci, Queen Mary Sch, Jiangxi Prov Key Lab Tumor Pathogenesis & Mol Pat, Nanchang, Jiangxi, Peoples R China.
   [Lin, Hui; Shi, Fuli; Zou, Junrong; Ying, Ying; Luo, Zhijun] Nanchang Univ, Sch Basic Med Sci, Queen Mary Sch, Dept Pathophysiol, Nanchang, Jiangxi, Peoples R China.
   [Jiang, Shanshan] Shaanxi Prov Peoples Hosp, Inst Hematol Res, Xian, Peoples R China.
   [Wang, Yuanyuan] Zhengzhou Univ, Affiliated Hosp 1, Clin Syst Biol Lab, Zhengzhou, Peoples R China.
   [Huang, Deqiang; Luo, Lingyu] Nanchang Univ, Res Inst Digest Dis, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China.
   [Yan, Xiaohua] Nanchang Univ, Inst Basic Biomed Sci, Sch Basic Med Sci, Nanchang, Jiangxi, Peoples R China.
   [Yan, Xiaohua] Nanchang Univ, Dept Biochem & Mol Biol, Sch Basic Med Sci, Nanchang, Jiangxi, Peoples R China.
C3 Nanchang University; Nanchang University; Xi'an Medical University;
   Zhengzhou University; Nanchang University; Nanchang University; Nanchang
   University
RP Luo, ZJ (通讯作者)，Nanchang Univ, Queen Mary Sch, Nanchang, Jiangxi, Peoples R China.
EM zluo559914@ncu.edu.cn
RI Zou, Junrong/AGF 6491 2022; Luo, Zhijun/AAE 9302 2019; Jiang,
   Shanshan/G 8731 2017; Yan, Xiaohua/J 4922 2015; luo, ling/MIO 2796 2025
OI Lin, Hui/0000 0003 0343 1757; Yan, Xiaohua/0000 0002 7528 5771; LUO,
   ZHIJUN/0000 0001 8105 5289; 
FU National Natural Science Foundation of China [81572753, 31660332,
   31900852, 81560299]; Nature Science Foundation of Jiangxi Province
   [2018BAB215012, 20192ACB21026, 20171BCB23086]
FX National Natural Science Foundation of China, Grant/Award Number:
   81572753, 31660332, 31900852 and 81560299; Nature Science Foundation of
   Jiangxi Province, Grant/Award Number: 2018BAB215012, 20192ACB21026 and
   20171BCB23086
CR Agarwal S, 2017, MOL THER, V25, P1974, DOI 10.1016/j.ymthe.2017.01.008
   Agarwal S, 2016, P NATL ACAD SCI USA, V113, pE338, DOI 10.1073/pnas.1515397113
   Bahrambeigi S, 2019, BIOMED PHARMACOTHER, V109, P1593, DOI 10.1016/j.biopha.2018.11.032
   Barzilai N, 2016, CELL METAB, V23, P1060, DOI 10.1016/j.cmet.2016.05.011
   Chen JQ, 2018, BONE RES, V6, DOI 10.1038/s41413 017 0004 5
   Cholok D, 2018, BONE, V109, P12, DOI 10.1016/j.bone.2017.09.019
   Colhoun HM, 2012, DIABETOLOGIA, V55, P2929, DOI 10.1007/s00125 012 2668 0
   Davis EL, 2016, J ORTHOP RES, V34, P1894, DOI 10.1002/jor.23216
   Endo H, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 28074 w
   Foretz M, 2014, CELL METAB, V20, P953, DOI 10.1016/j.cmet.2014.09.018
   Goodman AG, 2007, J VIROL, V81, P2221, DOI 10.1128/JVI.02151 06
   Gugala Z, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00408
   Hardie DG, 2016, TRENDS CELL BIOL, V26, P190, DOI 10.1016/j.tcb.2015.10.013
   Haupt J, 2019, MOL BIOL CELL, V30, P17, DOI 10.1091/mbc.E18 05 0311
   He H, 2015, CANCER J, V21, P70, DOI 10.1097/PPO.0000000000000103
   Hino K, 2018, STEM CELL REP, V11, P1106, DOI 10.1016/j.stemcr.2018.10.007
   Jackuliak P, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/820615
   Jang WG, 2011, BONE, V48, P885, DOI 10.1016/j.bone.2010.12.003
   Jeyabalan J, 2013, OSTEOPOROSIS INT, V24, P2659, DOI 10.1007/s00198 013 2371 0
   Kan C, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 018 1107 7
   Kan C, 2018, BONE, V109, P43, DOI 10.1016/j.bone.2017.04.014
   Kasai T, 2009, J CELL PHYSIOL, V221, P740, DOI 10.1002/jcp.21917
   Kraft CT, 2016, J TRAUMA ACUTE CARE, V80, P156, DOI 10.1097/TA.0000000000000883
   La Fontaine J, 2016, J FOOT ANKLE SURG, V55, P955, DOI 10.1053/j.jfas.2016.04.012
   Lees Shepard JB, 2018, BONE, V109, P178, DOI 10.1016/j.bone.2018.01.029
   Li Y, 2018, INT J MOL MED, V41, P2535, DOI 10.3892/ijmm.2018.3498
   Lin H, 2017, BBA MOL CELL RES, V1864, P2369, DOI 10.1016/j.bbamcr.2017.08.009
   Lin H, 2015, MOL PHARMACOL, V88, P1062, DOI 10.1124/mol.115.099549
   Lin SC, 2018, CELL METAB, V27, P299, DOI 10.1016/j.cmet.2017.10.009
   Luo ZJ, 2010, FUTURE ONCOL, V6, P457, DOI [10.2217/fon.09.174, 10.2217/FON.09.174]
   Macfarlane RJ, 2008, EXPERT OPIN PHARMACO, V9, P767, DOI 10.1517/14656566.9.5.767
   Meier C, 2016, BONE, V82, P93, DOI 10.1016/j.bone.2015.04.026
   Melton LJ, 2008, J BONE MINER RES, V23, P1334, DOI 10.1359/JBMR.080323
   Miyazawa K, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022095
   Mobasheri Ali, 2012, Front Endocrinol (Lausanne), V3, P153, DOI 10.3389/fendo.2012.00153
   Monami M, 2008, DIABETES CARE, V31, P199, DOI 10.2337/dc07 1736
   Morizane Y, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.199398
   Ortega N, 2010, DIS MODEL MECH, V3, P224, DOI 10.1242/dmm.004226
   Paschou SA, 2019, MINERVA ENDOCRINOL, V44, P333, DOI 10.23736/S0391 1977.19.03040 2
   Peterson JR, 2015, JOVE J VIS EXP, DOI 10.3791/52880
   Peterson JR, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008810
   Peterson JR, 2013, BONE, V54, P28, DOI 10.1016/j.bone.2013.01.002
   Qureshi AT, 2017, AM J PATHOL, V187, P2536, DOI 10.1016/j.ajpath.2017.07.010
   Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5
   Rodenberg E, 2011, TISSUE ENG PT A, V17, P2487, DOI [10.1089/ten.tea.2011.0007, 10.1089/ten.TEA.2011.0007]
   Roessler PP, 2019, Z ORTHOP UNFALLCHIR, V157, P301, DOI 10.1055/a 0732 5946
   She DM, 2018, BONE, V109, P101, DOI 10.1016/j.bone.2017.11.016
   Molinuevo MS, 2010, J BONE MINER RES, V25, P211, DOI 10.1359/jbmr.090732
   Stage TB, 2018, BONE, V112, P35, DOI 10.1016/j.bone.2018.04.004
   Steinberg GR, 2019, NAT REV DRUG DISCOV, V18, P527, DOI 10.1038/s41573 019 0019 2
   Vestergaard P, 2009, CALCIFIED TISSUE INT, V84, P45, DOI 10.1007/s00223 008 9195 5
   Wang XY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 017 0014 7
   Wei JW, 2015, CELL, V161, P1576, DOI 10.1016/j.cell.2015.05.029
   Wu JH, 2019, J CELL BIOCHEM, V120, P12108, DOI 10.1002/jcb.28710
   Xi G, 2019, J CELL PHYSIOL, V234, P23232, DOI 10.1002/jcp.28890
   Xu RS, 2018, BONE, V109, P134, DOI 10.1016/j.bone.2017.08.025
   Yan XH, 2009, ACTA BIOCH BIOPH SIN, V41, P263, DOI 10.1093/abbs/gmp018
   Yu PB, 2008, NAT MED, V14, P1363, DOI 10.1038/nm.1888
   Zhang CS, 2017, NATURE, V548, P112, DOI 10.1038/nature23275
   Zhang ZY, 2015, J IMMUNOL, V195, P2452, DOI 10.4049/jimmunol.1500944
NR 60
TC 12
Z9 12
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD DEC
PY 2020
VL 24
IS 24
BP 14491
EP 14501
DI 10.1111/jcmm.16076
EA NOV 2020
PG 11
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA PB5LZ
UT WOS:000587738900001
PM 33169942
OA Green Published
DA 2025 08 17
ER

PT J
AU Fan, CM
   Cool, JC
   Scherer, MA
   Foster, BK
   Shandala, T
   Tapp, H
   Xian, CJ
AF Fan, Chiaming
   Cool, Johanna C.
   Scherer, Michaela A.
   Foster, Bruce K.
   Shandala, Tetyana
   Tapp, Heather
   Xian, Cory J.
TI Damaging effects of chronic low dose methotrexate usage on primary bone
   formation in young rats and potential protective effects of folinic acid
   supplementary treatment
SO BONE
LA English
DT Article
DE Methotrexate chemotherapy; Growth Plate; Folinic acid; Osteogenesis;
   Osteoclast precursor; Osteoclastogenesis; Bone marrow osteoprogenitor
   cells
ID LONG TERM SURVIVORS; RHEUMATOID ARTHRITIS; OSTEOCLAST PRECURSORS;
   MINERAL DENSITY; CHEMOTHERAPY; GROWTH; MECHANISMS; MARROW; EXPRESSION;
   OSTEOPENIA
AB Methotrexate (MTX) is a most commonly used anti metabolite in cancer treatment and as an anti rheumatic drug. While MTX chemotherapy at a high dose is known to cause bone growth defects in growing bones, effects of its chronic use at a low dose on growing skeleton remain less clear. Here, we examined effects on bone growth of long term MTX chemotherapy at a low dose ill Young rats, and potential protective effects of supplementary treatment with antidote folinic acid (given ip at 1 mg/kg 6 h after MTX). After two cycles of 5 once daily MTX injections (at 0,75 mg/kg, 5 days on/9 days off/5 days on), histological analysis showed that MTX at this dose caused significant reduction in heights of growth plate and primary spongiosa bone on day 22 compared to controls (P<0.05). In contrast, a similar dosing regimen but at a lower dose (0.4 mg/kg) Caused only slight or no reduction in heights of both regions. However, after the induction phase at this 0.4 mg/kg dosing, continued use of MTX at a low dose (once weekly at 0.2 mg/kg) caused a reduction in primary spongiosa height and bone volume on weeks 9 and 14, which was associated with all increased osteoclast formation and their bone Surface density as well as a decreased osteoblast bone surface density in the primary spongiosa. Folinic acid supplementation was shown able to prevent the MTX effects in the primary spongiosa. These results suggest that acute use of MTX can damage growth plate and primary bone at a high dose, but not at a low close. However, long term use of MTX at a low dose can reduce primary bone formation probably due to decreased osteoblastic function but increased osteoclastic formation and function, and supplementary treatment with folinic acid may be potentially useful in protecting bone growth during long term low dose MTX chemotherapy. Crown Copyright (C) 2008 Published by Elsevier Inc. All rights reserved.
C1 [Fan, Chiaming; Scherer, Michaela A.; Shandala, Tetyana; Xian, Cory J.] Univ S Australia, Sansom Inst, Adelaide, SA 5001, Australia.
   [Fan, Chiaming; Scherer, Michaela A.; Shandala, Tetyana; Xian, Cory J.] Univ S Australia, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia.
   [Fan, Chiaming; Cool, Johanna C.; Scherer, Michaela A.; Foster, Bruce K.; Xian, Cory J.] Womens & Childrens Hosp, Dept Orthopaed Surg, Adelaide, SA, Australia.
   [Fan, Chiaming; Foster, Bruce K.; Xian, Cory J.] Univ Adelaide, Discipline Paediat, Adelaide, SA, Australia.
   [Tapp, Heather] Womens & Childrens Hosp, Dept Haematol & Oncol, Adelaide, SA, Australia.
   [Xian, Cory J.] Womens & Childrens Hlth Res Inst, Adelaide, SA, Australia.
C3 University of South Australia; University of South Australia; Women's &
   Children's Hospital; University of Adelaide; Women's & Children's
   Hospital; Women's & Children's Hospital; Women's & Children's Health
   Research Institute
RP Xian, CJ (通讯作者)，Univ S Australia, Sansom Inst, City E Campus,GPO Box 2471, Adelaide, SA 5001, Australia.
EM cory.xiang@unisa.edu.au
RI Shandala, Tetyana/A 1386 2011; Xian, Cory/D 2646 2009; Signorelli,
   Christina/I 1983 2018
OI Xian, Cory/0000 0002 8467 2845; Scherer, Michaela/0000 0001 7867 6498
FU The Bone Growth Foundation; Women's and Children's Hospital Foundation;
   NHMRC Australia; The University of Adelaide
FX This project was funded in part by The Bone Growth Foundation (to BKF
   and CJX), Women's and Children's Hospital Foundation (to CJX and BKF),
   NHMRC Australia (to CJX and BKF), and a PhD Scholarship from the Faculty
   of Health Sciences of The University of Adelaide (South Australia) (to
   CMF).
CR Banfi A, 2001, CANCER, V92, P2419, DOI 10.1002/1097 0142(20011101)92:9<2419::AID CNCR1591>3.0.CO;2 K
   Bianchi ML, 1999, OSTEOPOROSIS INT, V10, P20, DOI 10.1007/s001980050189
   Borchers AT, 2004, SEMIN ARTHRITIS RHEU, V34, P465, DOI 10.1016/j.semarthrit.2003.12.003
   Byers RJ, 1997, J CLIN PATHOL, V50, P760, DOI 10.1136/jcp.50.9.760
   Carbone LD, 1999, CALCIFIED TISSUE INT, V64, P100, DOI 10.1007/s002239900585
   Cohen IJ, 2007, MED HYPOTHESES, V68, P1147, DOI 10.1016/j.mehy.2006.04.074
   Cronstein BN, 2005, PHARMACOL REV, V57, P163, DOI 10.1124/pr.57.2.3
   Cutolo M, 2001, ANN RHEUM DIS, V60, P729, DOI 10.1136/ard.60.8.729
   Darst M, 2004, J IMMUNOL, V172, P6330, DOI 10.4049/jimmunol.172.10.6330
   Davies JH, 2004, CLIN ENDOCRINOL, V60, P358, DOI 10.1111/j.1365 2265.2003.01986.x
   Davies JH, 2002, BONE, V31, P319, DOI 10.1016/S8756 3282(02)00822 0
   Elliot KJ, 2004, RHEUMATOLOGY, V43, P1226, DOI 10.1093/rheumatology/keh296
   Groninger E, 2004, CRIT REV ONCOL HEMAT, V52, P173, DOI 10.1016/j.critrevonc.2004.08.007
   Holzer G, 2003, J BONE JOINT SURG BR, V85B, P231, DOI 10.1302/0301 620X.85B2.13257
   Humphrey MB, 2004, J BONE MINER RES, V19, P224, DOI 10.1359/JBMR.0301234
   HUNZIKER EB, 1989, J PHYSIOL LONDON, V414, P55, DOI 10.1113/jphysiol.1989.sp017676
   IANOTTI JP, 1990, ORTHOP CLIN N AM, V21, P1
   IGBAL MP, 1999, CLIN EXP RHEUMATOL, V17, P627
   MANDEL K, 2004, CLIN ENDOCRINOL OXF, P1215
   MAY KP, 1994, ARTHRITIS RHEUM, V37, P201, DOI 10.1002/art.1780370208
   Minaur NJ, 2002, RHEUMATOLOGY, V41, P714
   Morigi M, 2004, J AM SOC NEPHROL, V15, P1794, DOI 10.1097/01.ASN.0000128974.07460.34
   SCHNABEL A, 1994, SEMIN ARTHRITIS RHEU, V23, P310, DOI 10.1016/0049 0172(94)90027 2
   SCHRIOCK EA, 1991, J CLIN ONCOL, V9, P400, DOI 10.1200/JCO.1991.9.3.400
   Shahin AA, 2001, Z RHEUMATOL, V60, P63, DOI 10.1007/s003930170075
   Sosin M, 2003, BRIT MED J, V326, P266, DOI 10.1136/bmj.326.7383.266
   Väänänen K, 2005, ADV DRUG DELIVER REV, V57, P959, DOI 10.1016/j.addr.2004.12.018
   WHEELER DL, 1995, BONE, V16, P215, DOI 10.1016/8756 3282(94)00032 U
   Whittle SL, 2004, RHEUMATOLOGY, V43, P267, DOI 10.1093/rheumatology/keh088
   WOLFE F, 1990, J RHEUMATOL, V17, P994
   Xian C. J., 2003, Current Pharmaceutical Biotechnology, V4, P260, DOI 10.2174/1389201033489793
   Xian CJ, 2008, J CELL PHYSIOL, V214, P777, DOI 10.1002/jcp.21274
   Xian CJ, 2007, BONE, V41, P842, DOI 10.1016/j.bone.2007.07.021
   Xian CJ, 2006, J CELL BIOCHEM, V99, P1688, DOI 10.1002/jcb.20889
   Xing LP, 2005, IMMUNOL REV, V208, P19, DOI 10.1111/j.0105 2896.2005.00336.x
   Yao SM, 2006, ARCH ORAL BIOL, V51, P596, DOI 10.1016/j.archoralbio.2005.12.006
   Yao ZQ, 2006, J BIOL CHEM, V281, P11846, DOI 10.1074/jbc.M512624200
NR 37
TC 61
Z9 62
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JAN
PY 2009
VL 44
IS 1
BP 61
EP 70
DI 10.1016/j.bone.2008.09.014
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 395TV
UT WOS:000262547300008
PM 18976724
DA 2025 08 17
ER

PT J
AU He, P
   Zhao, YB
   Wang, B
   Liu, GY
   Zhang, L
   Li, M
   Xu, B
   Cai, WH
   Chu, CL
   Cong, Y
AF He, Peng
   Zhao, Yanbin
   Wang, Bin
   Liu, Guoyin
   Zhang, Lei
   Li, Mei
   Xu, Bin
   Cai, Weihua
   Chu, Chenglin
   Cong, Yu
TI A biodegradable magnesium phosphate cement incorporating chitosan and
   rhBMP 2 designed for bone defect repair
SO JOURNAL OF ORTHOPAEDIC TRANSLATION
LA English
DT Article
ID OSTEOGENIC DIFFERENTIATION; CELL ADHESION; SCAFFOLDS
AB Background: The repair of bone defects has always been a significant challenge in clinical medicine. To address this challenge, doctors often utilize autologous bone grafts, allogeneic bone grafts and artificial bone substitutes. However, the former two methods may result in additional trauma and complications, while allogeneic bone grafts carry the risks of immune rejection and disease transmission. Magnesium phosphate cement (MPC), as a artificial bone substitutes, has been a potential biomaterial for repairing bone defects, but its clinical application is limited by insufficient mechanical strength and poor osteoinductive activity. Methods: In this study, the cement liquid phase base on rhBMP 2 and chitosan solution into MPC were obtained and investigated. After mixing with a cement liquid, the structural and phase composition, morphology, chemical structure, setting time, compressive strength, degradation behavior, solubility, and cellular responses and bone regeneration in response to CHI rhBMP2 MPC were investigated in vitro and in vivo. Results: After the chemical component modification, CHI rhBMP2 MPC possessed controllable degradation rate, moderate setting time, appropriate cuing temperature, good injectability, and improved initial strength. In vitro tests showed that the CHIrhBMP2 MPC could promote cell proliferation and adhesion, as well as that contribute to osteoblast differentiation and mineralization. In addition, cement materials were implanted into the rabbit femoral condyles for in vivo osseointegration evaluation. The results displayed that more new bone grew around CHI rhBMP2 MPC, verifying improved osseointegration capacity. Transcriptome analysis revealed that focal adhesion, Forkhead box O(FoxO) signaling pathway and P13K/AKT signaling pathway were may involved in CHI rhBMP2 MPC induced new bone formation. Conclusion: This work provides a new strategy for the rational design of potential bone repair candidate materials.
C1 [He, Peng; Wang, Bin; Liu, Guoyin; Zhang, Lei; Xu, Bin; Cong, Yu] Nanjing Univ, Jinling Hosp, Affiliated Hosp, Dept Orthoped,Med Sch, Nanjing 211166, Peoples R China.
   [Zhao, Yanbin; Chu, Chenglin] Southeast Univ, Sch Mat Sci & Engn, Nanjing 211189, Peoples R China.
   [Zhao, Yanbin; Chu, Chenglin] Southeast Univ, Jiangsu Key Lab Adv Met Mat, Nanjing 211189, Peoples R China.
   [Li, Mei] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Med Res Ctr, Dept Orthoped, Guangzhou 510080, Peoples R China.
   [Cai, Weihua] Nanjing Med Univ, Affiliated Hosp 1, Dept Orthoped, Nanjing 210029, Peoples R China.
C3 Nanjing University; Southeast University   China; Southeast University  
   China; Guangdong Academy of Medical Sciences & Guangdong General
   Hospital; Southern Medical University   China; Nanjing Medical
   University
RP Cong, Y (通讯作者)，Nanjing Univ, Jinling Hosp, Affiliated Hosp, Dept Orthoped,Med Sch, Nanjing 211166, Peoples R China.; Chu, CL (通讯作者)，Southeast Univ, Sch Mat Sci & Engn, Nanjing 211189, Peoples R China.; Chu, CL (通讯作者)，Southeast Univ, Jiangsu Key Lab Adv Met Mat, Nanjing 211189, Peoples R China.; Cai, WH (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Dept Orthoped, Nanjing 210029, Peoples R China.
EM caiwhspine@sina.com; clchu@seu.edu.cn; congyu122@126.com
RI ; Li, Mei/KRQ 7982 2024; Cai, Weihua/P 4592 2014; Zhang,
   Lei/JMC 7194 2023; Liu, Guoyin/H 3663 2011
OI he, peng/0009 0000 8555 3410; Liu, Guoyin/0000 0001 5570 4564; Li,
   Mei/0000 0002 9265 8541
FU National Natural Science Foundation of China [52171236, 51971062,
   82102547]; Open Research Fund of Jiangsu Key Laboratory for Advanced
   Metallic Mate rials, Southeast University [AMM2021A01]; General Fund of
   Scientific Research Project of Jiangsu Provincial Health Commission
   [H2019022]
FX This research was financially supported by National Natural Science
   Foundation of China (No. 52171236, 51971062, 82102547) , Open Research
   Fund of Jiangsu Key Laboratory for Advanced Metallic Mate rials,
   Southeast University (No. AMM2021A01) and General Fund of Scientific
   Research Project of Jiangsu Provincial Health Commission (No. H2019022)
   .
CR Adhikari U, 2016, BIOACT MATER, V1, P132, DOI 10.1016/j.bioactmat.2016.11.003
   Ahmed MM, 2023, BIOMED PHARMACOTHER, V164, DOI 10.1016/j.biopha.2023.114943
   Arkin VH, 2021, ACS OMEGA, V6, P2477, DOI 10.1021/acsomega.0c03927
   Baldwin P, 2019, J ORTHOP TRAUMA, V33, P203, DOI 10.1097/BOT.0000000000001420
   Betz RR, 2002, ORTHOPEDICS, V25, pS561
   Campana V, 2014, J MATER SCI MATER M, V25, P2445, DOI 10.1007/s10856 014 5240 2
   Cui JB, 2022, BIO MED MATER ENG, V33, P465, DOI 10.3233/BME 211377
   Cui X, 2021, BIOACT MATER, V6, P3801, DOI 10.1016/j.bioactmat.2021.03.028
   Dadsetan M, 2015, ACTA BIOMATER, V18, P9, DOI 10.1016/j.actbio.2014.12.024
   de Klerk E, 2015, TRENDS GENET, V31, P128, DOI 10.1016/j.tig.2015.01.001
   Delgado Calle J, 2022, PHYSIOL REV, V102, DOI 10.1152/physrev.00043.2020
   Demir Oguz Ö, 2023, BIOACT MATER, V19, P217, DOI 10.1016/j.bioactmat.2022.04.007
   Fang BD, 2023, CERAM INT, V49, P4001, DOI 10.1016/j.ceramint.2022.11.078
   Gillman CE, 2021, MAT SCI ENG C MATER, V130, DOI 10.1016/j.msec.2021.112466
   Gong CT, 2021, REGEN BIOMATER, V8, DOI 10.1093/rb/rbaa048
   Gu X, 2022, J MATER CHEM B, V10, P2097, DOI 10.1039/d1tb02836g
   Han S, 2021, BIOMATERIALS, V272, DOI 10.1016/j.biomaterials.2021.120785
   Haque MA, 2019, CONSTR BUILD MATER, V211, P885, DOI 10.1016/j.conbuildmat.2019.03.304
   Jeong J, 2019, BIOMATER RES, V23, DOI 10.1186/s40824 018 0149 3
   Kaiser F, 2022, ACTA BIOMATER, V145, P358, DOI 10.1016/j.actbio.2022.04.019
   Kanter B, 2014, ACTA BIOMATER, V10, P3279, DOI 10.1016/j.actbio.2014.04.020
   Khalili AA, 2015, INT J MOL SCI, V16, P18149, DOI 10.3390/ijms160818149
   Komori T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207513
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Liu DC, 2023, J FUNCT BIOMATER, V14, DOI 10.3390/jfb14030134
   Liu WJ, 2015, ACTA BIOMATER, V21, P217, DOI 10.1016/j.actbio.2015.04.012
   Lv SC, 2022, MATERIALS, V15, DOI 10.3390/ma15062293
   Marupanthorn K, 2017, INT J MOL MED, V39, P654, DOI 10.3892/ijmm.2017.2872
   Nabiyouni M, 2018, ACTA BIOMATER, V66, P23, DOI 10.1016/j.actbio.2017.11.033
   Ostrowski N, 2016, ACS BIOMATER SCI ENG, V2, P1067, DOI 10.1021/acsbiomaterials.6b00056
   Peng H, 2024, Mater Today Chem, V38
   Pylostomou A, 2023, BIOMATER ADV, V148, DOI 10.1016/j.bioadv.2023.213367
   Rico Llanos GA, 2021, POLYMERS BASEL, V13, DOI 10.3390/polym13040599
   Roseti L, 2017, MAT SCI ENG C MATER, V78, P1246, DOI 10.1016/j.msec.2017.05.017
   Salhotra A, 2020, NAT REV MOL CELL BIO, V21, P696, DOI 10.1038/s41580 020 00279 w
   Sarian MN, 2022, BIOACT MATER, V12, P42, DOI 10.1016/j.bioactmat.2021.10.034
   Sato T, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 17099 3
   Shan ZM, 2022, J ORTHOP TRANSL, V36, P184, DOI 10.1016/j.jot.2022.09.013
   Shi YB, 2021, BIOMED MATER, V16, DOI 10.1088/1748 605X/abf5c4
   Szczesny G, 2022, MATERIALS, V15, DOI 10.3390/ma15103622
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Valtanen RS, 2021, INJURY, V52, pS72, DOI 10.1016/j.injury.2020.07.040
   Vimalraj S, 2020, GENE, V754, DOI 10.1016/j.gene.2020.144855
   Wei XH, 2023, BIOACT MATER, V20, P16, DOI 10.1016/j.bioactmat.2022.05.011
   Wickström SA, 2018, CURR OPIN CELL BIOL, V54, P89, DOI 10.1016/j.ceb.2018.05.003
   Wong SK, 2021, POLYMERS BASEL, V13, DOI 10.3390/polym13183075
   Yu L, 2023, BIOACT MATER, V20, P598, DOI 10.1016/j.bioactmat.2022.06.017
   Zhang D, 2022, Chem Eng J, P437
   Zhang JT, 2014, ACTA BIOMATER, V10, P1035, DOI 10.1016/j.actbio.2013.11.001
   Zhang WT, 2022, J ORTHOP TRANSL, V33, P41, DOI 10.1016/j.jot.2022.01.002
   Zhang YX, 2022, J ORTHOP TRANSL, V33, P13, DOI 10.1016/j.jot.2021.11.005
   Zhao SJ, 2020, THERANOSTICS, V10, P17, DOI 10.7150/thno.36930
   Zhao YN, 2021, MATER DESIGN, V200, DOI 10.1016/j.matdes.2021.109466
   Zhao YY, 2022, BIOMATERIALS, V288, DOI 10.1016/j.biomaterials.2022.121684
NR 54
TC 8
Z9 9
U1 9
U2 20
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2214 031X
J9 J ORTHOP TRANSL
JI J. Orthop. Transl.
PD NOV
PY 2024
VL 49
BP 167
EP 180
DI 10.1016/j.jot.2024.08.004
EA OCT 2024
PG 14
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA J3X9E
UT WOS:001336438000001
PM 39483125
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Chen, JG
   Xu, XM
   Fan, MY
AF Chen, Jianguo
   Xu, Xiaoming
   Fan, Mingyu
TI Inhibition of mitochondrial translation selectively targets osteosarcoma
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Tigecycline; Mitochondrial translation; Osteosarcoma; EF Tu
ID ANTIBIOTIC DRUG TIGECYCLINE; CELL LINES; CARCINOMA; CANCER
AB The unique dependence of cancer cells on mitochondrial metabolism has been exploited therapeutically in various cancers but not osteosarcoma. In this work, we demonstrate that inhibition of mitochondria! translation is effective and selective in targeting osteosarcoma. We firstly showed that tigecycline at pharmacological achievable concentrations inhibited growth and induced apoptosis of multiple osteosarcoma cell lines while sparing normal osteoblast cells. Similarly, tigecycline at effective doses that delayed osteosarcoma growth did not cause significant toxicity to mice. We next showed that tigecycline specifically inhibits mitochondrial translation, resulting in defective mitochondrial respiration in both osteosarcoma and normal osteoblast cells. We further confirm mitochondrial respiration as the target of tigecycline using three independent approaches. In addition, we demonstrate that compared to normal osteoblasts, osteosarcoma cells have higher mitochondrial biogenesis. We finally show that specific inhibition of mitochondrial translation via EF Tu depletion produces the similar anti osteosarcoma effects of tigecycline. Our work highlights the therapeutic value of targeting mitochondrial metabolism in osteosarcoma and tigecycline as a useful addition to the treatment of osteosarcoma. (C) 2019 Elsevier Inc. All rights reserved.
C1 [Chen, Jianguo] Yangtze Univ, Clin Med Coll 2, Jingzhou Cent Hosp, Dept Pediat Surg, Jingzhou, Peoples R China.
   [Xu, Xiaoming] Yangtze Univ, Clin Med Coll 2, Jingzhou Cent Hosp, Dept Orthoped Surg, Jingzhou, Peoples R China.
   [Fan, Mingyu] Wuhan Univ, Tongren Hosp, Wuhan Hosp 3, Dept Orthoped, 241 Pengliuyang Rd, Wuhan 430060, Hubei, Peoples R China.
C3 Yangtze University; Yangtze University; Wuhan University
RP Fan, MY (通讯作者)，Wuhan Univ, Tongren Hosp, Wuhan Hosp 3, Dept Orthoped, 241 Pengliuyang Rd, Wuhan 430060, Hubei, Peoples R China.
EM fanmywuhansyy@163.com
RI Chen, Jianguo/AFZ 9932 2022; Fan, Mingyu/ISS 3132 2023
FU Yangtze University [201601616]
FX This work was supported by a research grant provided by Yangtze
   University (201601616).
CR Abarrategi A, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/3631764
   Allison Daniel C., 2012, Sarcoma, V2012, P704872, DOI 10.1155/2012/704872
   Angulo P, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045 016 0373 z
   Baumhoer D, 2018, PATHOLOGE, V39, P139, DOI 10.1007/s00292 017 0365 y
   Botter SM, 2014, CURR OPIN PHARMACOL, V16, P15, DOI 10.1016/j.coph.2014.02.002
   Caro P, 2012, CANCER CELL, V22, P547, DOI 10.1016/j.ccr.2012.08.014
   Chen JG, 2018, BIOCHEM BIOPH RES CO, V506, P604, DOI 10.1016/j.bbrc.2018.10.124
   D'Andrea A, 2016, ONCOTARGET, V7, P72415, DOI 10.18632/oncotarget.11719
   Fan J, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.65
   Fu XD, 2017, AM J CANCER RES, V7, P2395
   Hashiguchi K, 2009, METHODS MOL BIOL, V554, P383, DOI 10.1007/978 1 59745 521 3_23
   Hu HR, 2016, ONCOTARGET, V7, P3171, DOI 10.18632/oncotarget.6419
   Jackson M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209489
   Järas M, 2011, CANCER CELL, V20, P555, DOI 10.1016/j.ccr.2011.10.028
   Jaffe Norman, 2013, Sarcoma, V2013, P203531, DOI 10.1155/2013/203531
   Jia XF, 2016, FUND CLIN PHARMACOL, V30, P297, DOI 10.1111/fcp.12199
   Lagadinou ED, 2013, CELL STEM CELL, V12, P329, DOI 10.1016/j.stem.2012.12.013
   Li H, 2015, BIOCHEM BIOPH RES CO, V467, P14, DOI 10.1016/j.bbrc.2015.09.140
   Loureiro R, 2013, RECENT PATENTS ENDOC, V7, P102, DOI 10.2174/18722148113079990006
   Mohseny AB, 2011, LAB INVEST, V91, P1195, DOI 10.1038/labinvest.2011.72
   Olson MW, 2006, ANTIMICROB AGENTS CH, V50, P2156, DOI 10.1128/AAC.01499 05
   Rodvold KA, 2006, J ANTIMICROB CHEMOTH, V58, P1221, DOI 10.1093/jac/dkl403
   Rose WE, 2006, PHARMACOTHERAPY, V26, P1099, DOI 10.1592/phco.26.8.1099
   Skrtic M, 2011, CANCER CELL, V20, P674, DOI 10.1016/j.ccr.2011.10.015
   Stein GE, 2006, CLIN INFECT DIS, V43, P518, DOI 10.1086/505494
   Tam EWY, 2008, NEUROPEDIATRICS, V39, P328, DOI 10.1055/s 0029 1202287
   Tan J, 2017, BIOCHEM BIOPH RES CO, V483, P17, DOI 10.1016/j.bbrc.2017.01.021
   Vandecasteele S. J., 2018, CLIN MICROBIOL INFEC, V24
   Wang B, 2017, BIOCHEM BIOPH RES CO, V490, P767, DOI 10.1016/j.bbrc.2017.06.115
   Weinberg SE, 2015, NAT CHEM BIOL, V11, P9, DOI 10.1038/nchembio.1712
   Xing JL, 2008, JNCI J NATL CANCER I, V100, P1104, DOI 10.1093/jnci/djn213
   Yang R, 2016, MOL CANCER THER, V15, P421, DOI 10.1158/1535 7163.MCT 15 0709
   Yu M, 2016, BIOCHEM BIOPH RES CO, V471, P639, DOI 10.1016/j.bbrc.2016.02.072
NR 33
TC 8
Z9 10
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUN 12
PY 2019
VL 515
IS 1
BP 9
EP 15
DI 10.1016/j.bbrc.2019.05.070
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA ID5SY
UT WOS:000471737500002
PM 31118131
DA 2025 08 17
ER

PT J
AU Khan, M
   Parshad, S
   Naimi, MF
   Sidhu, AK
   Lyons, F
   Hardisty, MR
   Whyne, CM
   Smoragiewicz, M
   Phillips, CM
   Briones, J
   Emmenegger, U
AF Khan, Maira
   Parshad, Shruti
   Naimi, Mahdi F.
   Sidhu, Amanjot K.
   Lyons, Frank
   Hardisty, Michael R.
   Whyne, Cari M.
   Smoragiewicz, Martin
   Phillips, Cameron M.
   Briones, Juan
   Emmenegger, Urban
TI Sarcopenia in Men With Bone Predominant Metastatic Castration Resistant
   Prostate Cancer Undergoing Ra 223 Therapy
SO CLINICAL GENITOURINARY CANCER
LA English
DT Article
DE Prostate cancer; Radium 223; Sarcopenia; Osteoporosis; Denosumab
ID BODY COMPOSITION; RADIUM 223; ONTARIO
AB There are complex interactions between bone and skeletal muscle. However, the prevention and treatment of treatment induced osteosarcopenia in men with metastatic castration resistant prostate cancer focuses predominantly on bone health. In a single center cohort of 52 patients we demonstrate that bone targeted Radium 223 therapy does not accelerate sarcopenia, but baseline sarcopenia is associated with poor survival in such patients. Introduction: Osteosarcopenia is the progressive loss of musculoskeletal structure and functionality, contributing to disability and mortality. Despite complex interactions between bone and muscle, osteosarcopenia prevention and treat ment in men with metastatic castration resistant prostate cancer (mCRPC) focuses predominantly on bone health. It is unknown whether Radium 223 (Ra 223) therapy affects sarcopenia. Methods: We identified 52 patients with mCRPC who had received Ra 223 and had a baseline plus & GE;1 follow up abdominopelvic CT scan. The total contour area (TCA) and averaged Hounsfield units (HU) of the left and right psoas muscles were obtained at the inferior L3 endplate, and the psoas muscle index (PMI) was calculated therefrom. Intrapatient musculoskeletal changes were analyzed across various time points. Results: TCA and PMI gradually declined over the study period ( P = .002, P = .003, respectively), but Ra 223 therapy did not accelerate sarcopenia, nor the decline of HU compared to the pre Ra 223 period. The median overall survival of patients with baseline sarcopenia was numerically worse (14.93 vs. 23.23 months, HR 0.612, P = .198). Conclusions: Ra 223 does not accelerate sarcopenia. Thus, worsening muscle parameters in men with mCRPC undergoing Ra 223 therapy are attributable to other factors. Further research is needed to determine whether baseline sarcopenia predicts poor overall survival in such patients.
C1 [Khan, Maira; Parshad, Shruti; Naimi, Mahdi F.; Sidhu, Amanjot K.; Briones, Juan; Emmenegger, Urban] Sunnybrook Res Inst, Odette Canc Ctr, Toronto, ON, Canada.
   [Lyons, Frank] Mater Univ Hosp, Dept Orthopaed Surg, Dublin, Ireland.
   [Lyons, Frank] Univ Coll Dublin, Sch Med, Dublin, Ireland.
   [Hardisty, Michael R.; Whyne, Cari M.] Univ Toronto, Dept Surg, Toronto, ON, Canada.
   [Whyne, Cari M.; Emmenegger, Urban] Univ Toronto, Inst Med Sci, Toronto, ON, Canada.
   [Smoragiewicz, Martin; Emmenegger, Urban] Univ Toronto, Dept Med, Toronto, ON, Canada.
   [Phillips, Cameron M.] McMaster Univ, Dept Med, Hamilton, ON, Canada.
   [Phillips, Cameron M.] Niagara Hlth Syst, Dept Med Oncol, St Catharines, ON, Canada.
   [Emmenegger, Urban] Univ Toronto, Odette Canc Ctr, Dept Med, Div Med Oncol, Sunnybrook Hlth Sci Ctr T2 054,2075 Bayview Ave, Toronto, ON M4N3M5, Canada.
C3 University of Toronto; Sunnybrook Health Science Center; Sunnybrook
   Research Institute; Mater Misericordiae University Hospital; University
   College Dublin; University of Toronto; University of Toronto; University
   of Toronto; McMaster University; University of Toronto
RP Emmenegger, U (通讯作者)，Univ Toronto, Odette Canc Ctr, Dept Med, Div Med Oncol, Sunnybrook Hlth Sci Ctr T2 054,2075 Bayview Ave, Toronto, ON M4N3M5, Canada.
EM urban.emmenegger@sunnybrook.ca
RI Smoragiewicz, Martin/AAL 2876 2020; Khan, Maira/NES 7874 2025
OI Smoragiewicz, Martin/0000 0002 4934 6323; Briones Carvajal,
   Juan/0000 0003 4373 0014
FU Joseph and Silvana Melara Cancer Fund , Toronto, Ontario, Canada
FX This research project was made possible by the generous financial
   support of the Joseph and Silvana Melara Cancer Fund , Toronto, Ontario,
   Canada.
CR Alibhai SMH, 2017, CLIN ONCOL UK, V29, P348, DOI 10.1016/j.clon.2017.01.007
   Bauer J, 2019, J CACHEXIA SARCOPENI, V10, P956, DOI 10.1002/jcsm.12483
   Body JJ, 2015, NAT REV UROL, V12, P340, DOI 10.1038/nrurol.2015.90
   Bonnet N, 2019, J CLIN INVEST, V129, P3214, DOI 10.1172/JCI125915
   Chakedis J, 2018, J GASTROINTEST SURG, V22, P1697, DOI 10.1007/s11605 018 3802 1
   Cheng S, 2019, CANCER MANAG RES, V11, P9307, DOI 10.2147/CMAR.S213051
   Coleman R, 2020, ANN ONCOL, V31, P1650, DOI 10.1016/j.annonc.2020.07.019
   Cruz Jentoft AJ, 2010, AGE AGEING, V39, P412, DOI 10.1093/ageing/afq034
   Cushen SJ, 2016, CLIN NUTR ESPEN, V13, pE39, DOI 10.1016/j.clnesp.2016.04.001
   Dennison EM, 2017, NAT REV RHEUMATOL, V13, P340, DOI 10.1038/nrrheum.2017.60
   Ebadi M, 2018, J CACHEXIA SARCOPENI, V9, P1053, DOI 10.1002/jcsm.12349
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Ikeda T, 2020, JPN J CLIN ONCOL, V50, P933, DOI 10.1093/jjco/hyaa045
   Iwamoto H, 2021, IN VIVO, V35, P1703, DOI 10.21873/invivo.12430
   Kirk B, 2020, J CACHEXIA SARCOPENI, V11, P609, DOI 10.1002/jcsm.12567
   Kurumisawa S, 2019, J ARTIF ORGANS, V22, P214, DOI 10.1007/s10047 019 01108 4
   Mourtzakis M, 2008, APPL PHYSIOL NUTR ME, V33, P997, DOI 10.1139/H08 075
   Ohtaka A, 2019, PROSTATE INT, V7, P9, DOI 10.1016/j.prnil.2018.04.002
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Pezaro C, 2013, BRIT J CANCER, V109, P325, DOI 10.1038/bjc.2013.340
   Phu S, 2019, J AM GERIATR SOC, V67, P2660, DOI 10.1111/jgs.16165
   Ryan AM, 2019, NUTRITION, V67 68, DOI 10.1016/j.nut.2019.06.020
   Sartor O, 2018, NEW ENGL J MED, V378, P645, DOI 10.1056/NEJMra1701695
   Smith M, 2019, LANCET ONCOL, V20, P408, DOI 10.1016/S1470 2045(18)30860 X
   Stangl Kremser J, 2020, PROSTATE CANCER P D, V23, P309, DOI 10.1038/s41391 019 0186 6
   Suominen MI, 2017, CLIN CANCER RES, V23, P4335, DOI 10.1158/1078 0432.CCR 16 2955
NR 26
TC 4
Z9 4
U1 1
U2 2
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219 3931 USA
SN 1558 7673
EI 1938 0682
J9 CLIN GENITOURIN CANC
JI Clin. Genitourin. Cancer
PD AUG
PY 2023
VL 21
IS 4
DI 10.1016/j.clgc.2023.01.009
EA JUL 2023
PG 9
WC Oncology; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Urology & Nephrology
GA P0EY0
UT WOS:001047468700001
PM 36849325
DA 2025 08 17
ER

PT J
AU Garthe, TL
   Jacob, L
   Kostev, K
AF Garthe, Tilman L.
   Jacob, Louis
   Kostev, Karel
TI Association between corticosteroid therapy and diagnosis of
   non traumatic rotator cuff tear or rupture in patients followed in
   orthopedic practices in Germany
SO INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
DE corticosteroids; rotator cuff tear; tendinopathy; retrospective study
ID TENDON RUPTURE; INJECTIONS; TENDINOPATHY; MECHANISMS; STRENGTH; TIME
AB Aims: The purpose of this case control study was to examine the association between oral and injected corticosteroids (CS) and subsequent non traumatic rotator cuff tear or rupture (nt RCT or RCR) in orthopedic practices in Germany. Materials and methods: Patients diagnosed with nt RCT or RCR between January 2017 and December 2019 (index date) were included in the study after applying inclusion and exclusion criteria. Controls without nt RCT or RCR were matched using propensity scores based on age, sex, observation time prior to the index date (years), and diseases of the musculoskeletal system and connective tissue. Results: A total of 10,986 patients were included in each group. For both oral and injected CS, we found a significant association with nt RCT or RCR, whereby oral CS had a stronger impact (OR (oral): 1.71 (95% CI: 1.52   1.93) vs. OR (injected): 1.42 (95% CI: 1.28   1.58)). For oral CS, this association was largely unaffected by differences in total doses or latencies between therapy end and index date. Within the group who received injected CS, shorter latencies and total doses of 20 mg or more led to higher odds of nt RCT or RCR. Varying CS had a different impact on rotator cuff tendons. Non steroidal anti inflammatory drugs (NSAIDs) were not associated with nt RCT or RCR at all. Conclusion: Oral and injected CS were associated with nt RCT or RCR in patients treated in orthopedic practices in Germany, while analgesics such as NSAIDs were not.
C1 [Garthe, Tilman L.] Goethe Univ, Fac Med, Frankfurt, Germany.
   [Jacob, Louis] Ctr Invest Biomed Red Salud Mental CIBERSAM, Res & Dev Unit, Parc Sanitari St Joan de Deu, Barcelona, Spain.
   [Jacob, Louis] Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid, Spain.
   [Jacob, Louis] Univ Versailles St Quentin Yvelines, Fac Med, Montigny Le Bretonneux, France.
   [Kostev, Karel] IQVIA, Epidemiol, Frankfurt, Germany.
C3 Goethe University Frankfurt; CIBER   Centro de Investigacion Biomedica
   en Red; CIBERSAM; CIBER   Centro de Investigacion Biomedica en Red;
   CIBERSAM; Universite Paris Saclay; IQVIA
RP Kostev, K (通讯作者)，IQVIA, Epidemiol, Main Airport Ctr, Unterschweinstiege 2 14, D 60549 Frankfurt, Germany.
EM Karel.Kostev@iqvia.com
RI Jacob, Louis/AAL 3956 2020; Kostev, Karel/S 4755 2019
OI Kostev, Karel/0000 0002 2124 7227
CR Blanco I, 2005, DRUG SAFETY, V28, P633, DOI 10.2165/00002018 200528070 00005
   Chechick A, 1982, Br J Sports Med, V16, P89
   Chen SK, 2009, ARCH ORTHOP TRAUM SU, V129, P369, DOI 10.1007/s00402 008 0655 1
   Coombes BK, 2010, LANCET, V376, P1751, DOI 10.1016/S0140 6736(10)61160 9
   Dean BJF, 2012, BONE JOINT RES, V1, P158, DOI 10.1302/2046 3758.17.2000115
   Dean BJF, 2014, BRIT J SPORT MED, V48, P1620, DOI 10.1136/bjsports 2013 093178
   Dolkart O, 2017, J SHOULDER ELB SURG, V26, P1789, DOI 10.1016/j.jse.2017.05.013
   FORD LT, 1979, SOUTH MED J, V72, P827, DOI 10.1097/00007611 197907000 00019
   Ghellioni Gustavo Vinícius, 2015, Rev. bras. ortop., V50, P260, DOI 10.1016/j.rboe.2015.05.002
   Harada Y, 2014, BONE JOINT RES, V3, P328, DOI 10.1302/2046 3758.312.2000321
   Haussler B, VERBRAUCH CORTICOSTE
   Jo CH, 2017, AM J SPORT MED, V45, P1141, DOI 10.1177/0363546516681294
   Khan KM, 2002, BRIT MED J, V324, P626, DOI 10.1136/bmj.324.7338.626
   Kirchgesner T, 2014, JOINT BONE SPINE, V81, P485, DOI 10.1016/j.jbspin.2014.03.022
   Leong Hio Teng, 2019, J Rehabil Med, V51, P627, DOI 10.2340/16501977 2598
   Lin MT, 2019, ARCH PHYS MED REHAB, V100, P336, DOI 10.1016/j.apmr.2018.06.028
   Liu DR, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710 1492 9 30
   MADSBAD S, 1980, GUT, V21, P52, DOI 10.1136/gut.21.1.52
   Maman E, 2016, AM J SPORT MED, V44, P177, DOI 10.1177/0363546515591266
   Mikolyzk DK, 2009, J BONE JOINT SURG AM, V91A, P1172, DOI 10.2106/JBJS.H.00191
   Morales DR, 2019, CLIN DRUG INVEST, V39, P205, DOI 10.1007/s40261 018 0729 y
   Ramírez JP, 2019, CONNECT TISSUE RES, V60, P283, DOI 10.1080/03008207.2018.1501040
   Puzzitiello Richard N, 2020, Arthrosc Sports Med Rehabil, V2, pe161, DOI 10.1016/j.asmr.2020.01.002
   Ramamoorthy S, 2016, RHEUM DIS CLIN N AM, V42, P15, DOI 10.1016/j.rdc.2015.08.002
   Rathmann W, 2018, INT J CLIN PHARM TH, V56, P459, DOI 10.5414/CP203320
   Schäcke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163 7258(02)00297 8
   Smith AG, 1999, BRIT J SPORT MED, V33, P423, DOI 10.1136/bjsm.33.6.423
   Tashjian RZ, 2012, CLIN SPORT MED, V31, P589, DOI 10.1016/j.csm.2012.07.001
   Wise BL, 2012, AM J MED, V125, DOI 10.1016/j.amjmed.2012.05.027
   Yamamoto A, 2010, J SHOULDER ELB SURG, V19, P116, DOI 10.1016/j.jse.2009.04.006
   Zaid MB, 2019, J SHOULDER ELB SURG, V28, P2457, DOI 10.1016/j.jse.2019.05.008
NR 31
TC 0
Z9 0
U1 1
U2 2
PU DUSTRI VERLAG DR KARL FEISTLE
PI DEISENHOFEN MUENCHEN
PA BAHNHOFSTRASSE 9 POSTFACH 49, D 82032 DEISENHOFEN MUENCHEN, GERMANY
SN 0946 1965
J9 INT J CLIN PHARM TH
JI Int. J. Clin. Pharmacol. Ther.
PD NOV
PY 2021
VL 59
IS 11
BP 713
EP 720
DI 10.5414/CP204074
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA WG4MT
UT WOS:000706969300003
PM 34423772
DA 2025 08 17
ER

PT J
AU Mascarenhas, JV
   Jude, EB
AF Mascarenhas, Janice V.
   Jude, Edward B.
TI Pathogenesis and Medical Management of Diabetic Charcot Neuroarthropathy
SO MEDICAL CLINICS OF NORTH AMERICA
LA English
DT Article
DE Charcot neuroarthropathy; Diabetic neuropathy; Total contact cast;
   Bisphosphonates (BPPs); Calcitonin; RANKL pathway
ID BONE MINERAL DENSITY; RHEUMATOID ARTHRITIS; END PRODUCTS; DOUBLE BLIND;
   CONTROLLED TRIAL; ARTHROPATHY; FOOT; BISPHOSPHONATES; METHOTREXATE;
   ANKLE
AB The Charcot foot is an acute clinical emergency that warrants immediate management in order to prevent irreversible joint destruction. Offloading remains the mainstay of treatment of Charcot foot; however, adjunctive therapy with antiresorptive agents may facilitate retardation and early recovery from the inflammatory destructive process. This article discusses the medical management of the ever challenging complication affecting the diabetic foot.
C1 [Mascarenhas, Janice V.] St Johns Natl Acad Hlth Sci, Dept Endocrinol, Bangalore 560034, Karnataka, India.
   [Jude, Edward B.] Tameside Hosp NHS Fdn Trust, Ashton Under Lyne OL6 9RW, Lancs, England.
C3 St. John's National Academy of Health Sciences
RP Jude, EB (通讯作者)，Tameside Hosp NHS Fdn Trust, Fountain St, Ashton Under Lyne OL6 9RW, Lancs, England.
EM Edward.Jude@tgh.nhs.uk
OI MASCARENHAS, JANICE/0000 0001 9443 3517
CR Alikhani M, 2007, BONE, V40, P345, DOI 10.1016/j.bone.2006.09.011
   Anderson John J, 2004, J Foot Ankle Surg, V43, P285, DOI 10.1053/j.jfas.2004.07.005
   Armstrong DG, 1997, J REHABIL RES DEV, V34, P317
   Armstrong DG, 1998, J BONE JOINT SURG AM, V80A, P365, DOI 10.2106/00004623 199803000 00009
   Baumhauer JF, 2006, FOOT ANKLE INT, V27, P797, DOI 10.1177/107110070602701007
   Bem R, 2006, DIABETES CARE, V29, P1392, DOI 10.2337/dc06 0376
   BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315
   CAVANAGH PR, 1991, DIABETES CARE, V14, P750, DOI 10.2337/diacare.14.8.750
   Chantelau E, 2006, HORM METAB RES, V38, P361, DOI 10.1055/s 2006 944525
   Cohen SB, 2004, ANN RHEUM DIS, V63, P1062, DOI 10.1136/ard.2003.016014
   Cohen SB, 2008, ARTHRITIS RHEUM, V58, P1299, DOI 10.1002/art.23417
   Collin Osdoby P, 2000, J BONE MINER RES, V15, P474, DOI 10.1359/jbmr.2000.15.3.474
   Demer LL, 2004, J AM COLL CARDIOL, V44, P1977, DOI 10.1016/j.jacc.2004.08.032
   Dinarello CA, 2011, J INTERN MED, V269, P16, DOI 10.1111/j.1365 2796.2010.02313.x
   Feng Y, 1997, LIFE SCI, V61, pPL281, DOI 10.1016/S0024 3205(97)00866 7
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Foltz Kelley D, 2004, J Foot Ankle Surg, V43, P87, DOI 10.1053/j.jfas.2004.01.001
   Frykberg RG, 2010, DIABETIC CHARCOT FOO, P93
   Frykberg Robert G, 2006, J Foot Ankle Surg, V45, pS1
   Giurini J M, 1994, Clin Podiatr Med Surg, V11, P271
   Gough A, 1997, DIABETIC MED, V14, P527, DOI 10.1002/(SICI)1096 9136(199707)14:7<527::AID DIA404>3.3.CO;2 H
   Grant W P, 1997, J Foot Ankle Surg, V36, P272
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9 90004 3
   Hetland ML, 2010, ARTHRITIS RHEUM US, V62, P22, DOI 10.1002/art.27227
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Hofbauer LC, 2007, J BONE MINER RES, V22, P1317, DOI 10.1359/JBMR.070510
   Hoff AO, 2006, J CLIN ONCOL, V24, p475S
   Itzstein Cecile, 2011, Small GTPases, V2, P117
   Jeffcoate WJ, 2005, LANCET, V366, P2058, DOI 10.1016/S0140 6736(05)67029 8
   Jirkovská A, 2001, DIABETIC MED, V18, P495, DOI 10.1046/j.1464 5491.2001.00511.x
   Johnson JE, 1998, J BONE JOINT SURG AM, V80A, P1700, DOI 10.2106/00004623 199811000 00019
   Jude EB, 2001, DIABETOLOGIA, V44, P2032, DOI 10.1007/s001250100008
   KAPURNIOTU A, 1995, J MED CHEM, V38, P836, DOI 10.1021/jm00005a011
   Keystone EC, 2004, ARTHRITIS RHEUM, V50, P1400, DOI 10.1002/art.20217
   Kimmerle R, 2007, EXP CLIN ENDOCR DIAB, V115, P360, DOI 10.1055/s 2007 970578
   Kume S, 2005, J BONE MINER RES, V20, P1647, DOI 10.1359/JBMR.050514
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202
   MANGAN DF, 1991, J IMMUNOL, V146, P1541
   Matricali GA, 2007, TRANSPLANTATION, V83, P245, DOI 10.1097/01.tp.0000244730.95416.c6
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   MCCONKEY DJ, 1989, J IMMUNOL, V143, P1801
   Monnier VM, 1996, DIABETES, V45, pS67, DOI 10.2337/diab.45.3.S67
   Offley SC, 2005, J BONE MINER RES, V20, P257, DOI 10.1359/JBMR.041108
   Pinzur MS, 2007, FOOT ANKLE INT, V28, P952, DOI 10.3113/FAI.2007.0952
   Pitocco D, 2005, DIABETES CARE, V28, P1214, DOI 10.2337/diacare.28.5.1214
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Sanders LJ., 1991, HIGH RISK FOOT DIABE, V5th, P297
   Saunders L. J., 1991, DIABETES, V40, p529A
   Schlossbauer T, 2008, EUR J MED RES, V13, P409
   SCHWEITZER DH, 1995, J BONE MINER RES, V10, P956
   Scott DL, 2006, NEW ENGL J MED, V355, P704, DOI 10.1056/NEJMct055183
   SELBY PL, 1994, DIABETIC MED, V11, P28, DOI 10.1111/j.1464 5491.1994.tb00225.x
   SINHA S, 1972, MEDICINE, V51, P191, DOI 10.1097/00005792 197205000 00006
   Thomas CC, 1966, CHARCOT JOINTS
   Trepman E, 2005, FOOT ANKLE INT, V26, P46
   Turner C H, 1998, J Orthop Sci, V3, P346, DOI 10.1007/s007760050064
   van der Heijde D, 2006, ARTHRITIS RHEUM US, V54, P1063, DOI 10.1002/art.21655
   Zaidi M, 2002, BONE, V30, P655, DOI 10.1016/S8756 3282(02)00688 9
NR 59
TC 15
Z9 17
U1 0
U2 15
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0025 7125
EI 1557 9859
J9 MED CLIN N AM
JI Med. Clin. N. Am.
PD SEP
PY 2013
VL 97
IS 5
BP 857
EP +
DI 10.1016/j.mcna.2013.05.002
PG 17
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 232TA
UT WOS:000325516100008
PM 23992897
DA 2025 08 17
ER

PT J
AU Zahoor, M
   Westhrin, M
   Aass, KR
   Moen, SH
   Misund, K
   Psonka Antonczyk, KM
   Giliberto, M
   Buene, G
   Sundan, A
   Waage, A
   Sponaas, AM
   Standal, T
AF Zahoor, Muhammad
   Westhrin, Marita
   Aass, Kristin Roseth
   Moen, Siv Helen
   Misund, Kristine
   Psonka Antonczyk, Katarzyna Maria
   Giliberto, Mariaserena
   Buene, Glenn
   Sundan, Anders
   Waage, Anders
   Sponaas, Anne Marit
   Standal, Therese
TI Hypoxia promotes IL 32 expression in myeloma cells, and high expression
   is associated with poor survival and bone loss
SO BLOOD ADVANCES
LA English
DT Article
ID MULTIPLE MYELOMA; UNCONVENTIONAL SECRETION; DRUG RESISTANCE; EXOSOMES;
   MARROW; ANGIOGENESIS; INTERLEUKIN 32; PATHWAY; DIFFERENTIATION;
   PATHOGENESIS
AB Multiple myeloma (MM) is a hematologic cancer characterized by expansion of malignant plasma cells in the bone marrow. Most patients develop an osteolytic bone disease, largely caused by increased osteoclastogenesis. The myeloma bone marrow is hypoxic, and hypoxia may contribute to MM disease progression, including bone loss. Here we identified interleukin 32 (IL 32) as a novel inflammatory cytokine expressed by a subset of primary MM cells and MM cell lines. We found that high IL 32 gene expression in plasma cells correlated with inferior survival in MM and that IL 32 gene expression was higher in patients with bone disease compared with those without. IL 32 was secreted from MM cells in extracellular vesicles (EVs), and those EVs, as well as recombinant human IL 32, promoted osteoclast differentiation both in vitro and in vivo. The osteoclast promoting activity of the EVs was IL 32 dependent. Hypoxia increased plasma cell IL 32 messenger RNA and protein levels in a hypoxia inducible factor 1 alpha dependent manner, and high expression of IL 32 was associated with a hypoxic signature in patient samples, suggesting that hypoxia may promote expression of IL 32 in MM cells. Taken together, our results indicate that targeting IL 32 might be beneficial in the treatment of MM bone disease in a subset of patients.
C1 [Zahoor, Muhammad; Aass, Kristin Roseth; Giliberto, Mariaserena; Sundan, Anders; Standal, Therese] Norwegian Univ Sci & Technol, Ctr Mol Inflammat Res, Trondheim, Norway.
   [Westhrin, Marita; Moen, Siv Helen; Misund, Kristine; Buene, Glenn; Sundan, Anders; Waage, Anders; Sponaas, Anne Marit; Standal, Therese] Norwegian Univ Sci & Technol, Dept Clin & Mol Med, Trondheim, Norway.
   [Aass, Kristin Roseth; Waage, Anders; Standal, Therese] St Olavs Hosp, Dept Hematol, Trondheim, Norway.
   [Psonka Antonczyk, Katarzyna Maria] Norwegian Univ Sci & Technol, Dept Phys, Biophys & Med Technol, Trondheim, Norway.
C3 Norwegian University of Science & Technology (NTNU); Norwegian
   University of Science & Technology (NTNU); Norwegian University of
   Science & Technology (NTNU); Norwegian University of Science &
   Technology (NTNU)
RP Standal, T (通讯作者)，Norwegian Univ Sci & Technol NTNU, Ctr Mol Inflammat Res, Dept Canc Res & Mol Med, MTFS, Olav Kyrresgt 9, N 7489 Trondheim, Norway.
EM therese.standal@ntnu.no
OI Standal, Therese/0000 0003 3314 8522; Westhrin,
   Marita/0000 0001 6932 2102
FU Faculty of Medicine at NTNU; Central Norway Regional Health Authority;
   Research Council of Norway [245963/F50]; Norwegian Cancer Society
   [4500930]; Kristian Gerhard Jebsen Foundation [SKGJ MED 007]; Norwegian
   Research Council [223255, 193072]; Liaison Committee for Education,
   Research and Innovation in Central Norway [90061000, 90171600]
FX The authors thank Berit Stordal, Hanne Hella, Lill Anny Gunnes Groseth,
   Solveig Kvam, and Linh Hoang for technical assistance and Miriam
   Giambelluca for making the summary figure. The confocal imaging services
   provided by the Cellular and Molecular Imaging Core Facility (CMIC),
   Norwegian University of Science and Technology (NTNU). CMIC is funded by
   the Faculty of Medicine at NTNU and Central Norway Regional Health
   Authority. The Research Council of Norway is acknowledged for the
   support to the Norwegian Micro  and Nano Fabrication Facility (NorFab;
   project #245963/F50).This work was supported by funds from the Norwegian
   Cancer Society (#4500930), the Kristian Gerhard Jebsen Foundation
   (#SKGJ MED 007), the Norwegian Research Council (#223255 and #193072),
   and the Liaison Committee for Education, Research and Innovation in
   Central Norway (#90061000 and #90171600).
CR Abdeen A, 2016, NEPHROL DIAL TRANSPL, V31, P1623, DOI 10.1093/ndt/gfw033
   Azab AK, 2012, BLOOD, V119, P5782, DOI 10.1182/blood 2011 09 380410
   Baietti MF, 2012, NAT CELL BIOL, V14, P677, DOI 10.1038/ncb2502
   Baranowska K, 2016, ONCOTARGET, V7, P70845, DOI 10.18632/oncotarget.12226
   Becker A, 2016, CANCER CELL, V30, P836, DOI 10.1016/j.ccell.2016.10.009
   Bianchi G, 2015, BLOOD, V125, P3049, DOI 10.1182/blood 2014 11 568881
   Bosch S, 2016, SCI REP UK, V6, DOI 10.1038/srep36162
   Boyiadzis M, 2017, LEUKEMIA, V31, P1259, DOI 10.1038/leu.2017.91
   Choi JD, 2009, IMMUNOLOGY, V126, P535, DOI 10.1111/j.1365 2567.2008.02917.x
   Colla S, 2010, LEUKEMIA, V24, P1967, DOI 10.1038/leu.2010.193
   Giatromanolaki A, 2010, ANTICANCER RES, V30, P2831
   Harre U, 2012, J CLIN INVEST, V122, P1791, DOI 10.1172/JCI60975
   Hasegawa H, 2011, CYTOKINE, V53, P74, DOI 10.1016/j.cyto.2010.09.002
   Heinhuis B, 2011, P NATL ACAD SCI USA, V108, P4962, DOI 10.1073/pnas.1016005108
   Holien T, 2012, LEUKEMIA, V26, P1073, DOI 10.1038/leu.2011.263
   Hu JS, 2012, DIS MODEL MECH, V5, P763, DOI 10.1242/dmm.008961
   Hu JS, 2010, BLOOD, V116, P1524, DOI 10.1182/blood 2010 02 269126
   Johnson RW, 2014, J BONE MINER RES, V29, P1492, DOI 10.1002/jbmr.2159
   Joosten LAB, 2013, CELL MOL LIFE SCI, V70, P3883, DOI 10.1007/s00018 013 1301 9
   Kim SH, 2005, IMMUNITY, V22, P131, DOI 10.1016/j.immuni.2004.12.003
   Kim YG, 2010, ARTHRITIS RHEUM US, V62, P515, DOI 10.1002/art.27197
   Kowal J, 2016, P NATL ACAD SCI USA, V113, pE968, DOI 10.1073/pnas.1521230113
   Lessnick SL, 2002, CANCER CELL, V1, P393, DOI 10.1016/S1535 6108(02)00056 9
   Lötvall J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.26913
   Mabilleau G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004173
   Maiso P, 2015, CANCER RES, V75, P2071, DOI 10.1158/0008 5472.CAN 14 3400
   Martin SK, 2011, LEUKEMIA, V25, P1533, DOI 10.1038/leu.2011.122
   Moen SH, 2016, IMMUN INFLAMM DIS, V4, P327, DOI 10.1002/iid3.117
   Monteleone M, 2015, CYTOKINE, V74, P213, DOI 10.1016/j.cyto.2015.03.022
   Park JS, 2015, CANCER LETT, V356, P800, DOI 10.1016/j.canlet.2014.10.030
   Raimondi L, 2015, ONCOTARGET, V6, P13772, DOI 10.18632/oncotarget.3830
   Rankin EB, 2016, SCIENCE, V352, P175, DOI 10.1126/science.aaf4405
   Ribeiro Dias F, 2017, J LEUKOCYTE BIOL, V101, P39, DOI [10.1189/jlb.4RU0416 175RR, 10.1189/jlb.4ru0416 175rr]
   Roccaro AM, 2013, J CLIN INVEST, V123, P1542, DOI 10.1172/JCI66517
   Roodman GD, 2010, J CELL BIOCHEM, V109, P283, DOI 10.1002/jcb.22403
   Spencer JA, 2014, NATURE, V508, P269, DOI 10.1038/nature13034
   Storti P, 2013, LEUKEMIA, V27, P1697, DOI 10.1038/leu.2013.24
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Umezu T, 2014, BLOOD, V124, P3748, DOI 10.1182/blood 2014 05 576116
   van't Hof RJ, 2012, METHODS MOL BIOL, V816, P537, DOI 10.1007/978 1 61779 415 5_33
   Wang JH, 2016, J PATHOL, V239, P162, DOI 10.1002/path.4712
   Wang JH, 2014, BLOOD, V124, P555, DOI 10.1182/blood 2014 03 562439
   Westhrin M, 2015, HAEMATOLOGICA, V100, pE511, DOI 10.3324/haematol.2015.124511
   Witwer KW, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20360
   Yáñez Mó M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066
   Zhang J, 2009, CANCER RES, V69, P5082, DOI 10.1158/0008 5472.CAN 08 4603
   Zhang M, 2013, SCIENCE, V340, P559, DOI 10.1126/science.1234740
NR 47
TC 53
Z9 59
U1 0
U2 10
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 2473 9529
EI 2473 9537
J9 BLOOD ADV
JI Blood Adv.
PD DEC 26
PY 2017
VL 1
IS 27
BP 2656
EP 2666
DI 10.1182/bloodadvances.2017010801
PG 11
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA FQ0AW
UT WOS:000418012500001
PM 29296919
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU LaBranche, TP
   Jesson, MI
   Radi, ZA
   Storer, CE
   Guzova, JA
   Bonar, SL
   Thompson, JM
   Happa, FA
   Stewart, ZS
   Zhan, YT
   Bollinger, CS
   Bansal, PN
   Wellen, JW
   Wilkie, DP
   Bailey, SA
   Symanowicz, PT
   Hegen, M
   Head, RD
   Kishore, N
   Mbalaviele, G
   Meyer, DM
AF LaBranche, Timothy P.
   Jesson, Michael I.
   Radi, Zaher A.
   Storer, Chad E.
   Guzova, Julia A.
   Bonar, Sheri L.
   Thompson, Janice M.
   Happa, Fernando A.
   Stewart, Zachary S.
   Zhan, Yutian
   Bollinger, Chris S.
   Bansal, Prashant N.
   Wellen, Jeremy W.
   Wilkie, Dean P.
   Bailey, Steven A.
   Symanowicz, Peter T.
   Hegen, Martin
   Head, Richard D.
   Kishore, Nandini
   Mbalaviele, Gabriel
   Meyer, Debra M.
TI JAK inhibition with tofacitinib suppresses arthritic joint structural
   damage through decreased RANKL production
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID RECEPTOR TYPE I; LYMPHOCYTE DERIVED CYTOKINES; RHEUMATOID ARTHRITIS;
   ANIMAL MODELS; COMBINATION BENEFIT; ADJUVANT ARTHRITIS; KINASE
   INHIBITOR; BONE MASS; CP 690,550; CELLS
AB Objective The mechanistic link between Janus kinase (JAK) signaling and structural damage to arthritic joints in rheumatoid arthritis (RA) is poorly understood. This study was undertaken to investigate how selective inhibition of JAK with tofacitinib (CP 690,550) affects osteoclast mediated bone resorption in a rat adjuvant induced arthritis (AIA) model, as well as human T lymphocyte RANKL production and human osteoclast differentiation and function.
   Methods Hind paw edema, inflammatory cell infiltration, and osteoclast mediated bone resorption in rat AIA were assessed using plethysmography, histopathologic analysis, and immunohistochemistry; plasma and hind paw tissue levels of cytokines and chemokines (including RANKL) were also assessed. In vitro RANKL production by activated human T lymphocytes was evaluated by immunoassay, while human osteoclast differentiation and function were assessed via quantitative tartrate resistant acid phosphatase staining and degradation of human bone collagen, respectively.
   Results Edema, inflammation, and osteoclast mediated bone resorption in rats with AIA were dramatically reduced after 7 days of treatment with the JAK inhibitor, which correlated with reduced numbers of CD68/ED 1+, CD3+, and RANKL+ cells in the paws; interleukin 6 (transcript and protein) levels were rapidly reduced in paw tissue within 4 hours of the first dose, whereas it took 4 7 days of therapy for RANKL levels to decrease. Tofacitinib did not impact human osteoclast differentiation or function, but did decrease human T lymphocyte RANKL production in a concentration dependent manner.
   Conclusion These results suggest that the JAK inhibitor tofacitinib suppresses osteoclast mediated structural damage to arthritic joints, and this effect is secondary to decreased RANKL production.
C1 [LaBranche, Timothy P.; Jesson, Michael I.; Radi, Zaher A.; Storer, Chad E.; Guzova, Julia A.; Bonar, Sheri L.; Thompson, Janice M.; Happa, Fernando A.; Stewart, Zachary S.; Zhan, Yutian; Bollinger, Chris S.; Bansal, Prashant N.; Wellen, Jeremy W.; Wilkie, Dean P.; Bailey, Steven A.; Symanowicz, Peter T.; Hegen, Martin; Head, Richard D.; Kishore, Nandini; Mbalaviele, Gabriel; Meyer, Debra M.] Pfizer Worldwide Res & Dev, Cambridge, MA 02140 USA.
C3 Pfizer; Pfizer USA
RP LaBranche, TP (通讯作者)，Pfizer Worldwide Res & Dev, 35 Cambridge Pk Dr, Cambridge, MA 02140 USA.
EM timothy.labranche@pfizer.com
RI Storer, Chad/GZM 2678 2022; Radi, Zaher/AAB 7851 2021
OI Storer, Chad/0000 0002 0139 0819; 
FU Pfizer Worldwide Research and Development
FX Supported by Pfizer Worldwide Research and Development.
CR Bendele A, 1999, TOXICOL PATHOL, V27, P134, DOI 10.1177/019262339902700125
   Bendele AM, 1999, INFLAMM RES, V48, P453, DOI 10.1007/s000110050486
   Bendele AM, 2000, ARTHRITIS RHEUM US, V43, P2648, DOI 10.1002/1529 0131(200012)43:12<2648::AID ANR4>3.0.CO;2 M
   Blair HC, 2004, HISTOL HISTOPATHOL, V19, P189, DOI 10.14670/HH 19.189
   Borie DC, 2004, TRENDS MOL MED, V10, P532, DOI 10.1016/j.molmed.2004.09.007
   Changelian PS, 2003, SCIENCE, V302, P875, DOI 10.1126/science.1087061
   Christodoulou C, 2006, CLIN EXP MED, V6, P13, DOI 10.1007/s10238 006 0088 5
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   DAMOISEAUX JGMC, 1994, IMMUNOLOGY, V83, P140
   Djaafar S, 2010, ARTHRITIS RHEUM US, V62, P3300, DOI 10.1002/art.27645
   Flanagan ME, 2010, J MED CHEM, V53, P8468, DOI 10.1021/jm1004286
   Ghoreschi K, 2011, J IMMUNOL, V186, P4234, DOI 10.4049/jimmunol.1003668
   Haringman JJ, 2005, ANN RHEUM DIS, V64, P834, DOI 10.1136/ard.2004.029751
   Hashizume M, 2008, RHEUMATOLOGY, V47, P1635, DOI 10.1093/rheumatology/ken363
   Hegen M, 2008, ANN RHEUM DIS, V67, P1505, DOI 10.1136/ard.2007.076430
   Horwood N, 2008, AUTOIMMUNITY, V41, P230, DOI 10.1080/08916930701694766
   Karaman MW, 2008, NAT BIOTECHNOL, V26, P127, DOI 10.1038/nbt1358
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kremer JM, 2009, ARTHRITIS RHEUM US, V60, P1895, DOI 10.1002/art.24567
   Kwok SK, 2012, ARTHRITIS RHEUM US, V64, P740, DOI 10.1002/art.33390
   LaBranche TP, 2010, AM J PATHOL, V177, P1388, DOI 10.2353/ajpath.2010.100195
   Lin TH, 2010, ARTHRITIS RHEUM US, V62, P2283, DOI 10.1002/art.27536
   Magari K, 2003, J RHEUMATOL, V30, P2193
   Marshak DR, 2007, METH MOL B, V356, P121
   Mbalaviele G, 2006, J PHARMACOL EXP THER, V317, P1044, DOI 10.1124/jpet.105.100362
   McComb J, 1999, J RHEUMATOL, V26, P1347
   Meyer DM, 2010, J INFLAMM LOND, V7, DOI 10.1186/1476 9255 7 41
   Milici AJ, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2365
   NICOLLS MR, 1993, TRANSPLANTATION, V55, P459, DOI 10.1097/00007890 199303000 00001
   O'Shea JJ, 2004, ANN RHEUM DIS, V63, P67, DOI 10.1136/ard.2004.028290
   O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092 8674(02)00701 8
   Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092 8674(00)81167 8
   Pesu M, 2005, IMMUNOL REV, V203, P127, DOI 10.1111/j.0105 2896.2005.00220.x
   Poubelle PE, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2137
   Radi ZA, 2009, PATHOBIOLOGY, V76, P199, DOI 10.1159/000218336
   Skerry TM, 2003, CELL BIOCHEM FUNCT, V21, P223, DOI 10.1002/cbf.1077
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Tanaka Y, 2011, ARTHRIT CARE RES, V63, P1150, DOI 10.1002/acr.20494
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   van der Heijde D, 2011, ARTHRITIS RHEUM US, V63, pS1017
   Weitzmann MN, 2000, BLOOD, V96, P1873, DOI 10.1182/blood.V96.5.1873.h8001873_1873_1878
   West K, 2009, CURR OPIN INVEST DR, V10, P491
   Wijbrandts CA, 2007, ARTHRITIS RHEUM, V56, P3869, DOI 10.1002/art.22964
   Wong PKK, 2006, ARTHRITIS RHEUM US, V54, P158, DOI 10.1002/art.21537
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yeo L, 2011, ANN RHEUM DIS, V70, P2022, DOI 10.1136/ard.2011.153312
NR 46
TC 115
Z9 119
U1 2
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0004 3591
EI 1529 0131
J9 ARTHRITIS RHEUM US
JI Arthritis Rheum.
PD NOV
PY 2012
VL 64
IS 11
BP 3531
EP 3542
DI 10.1002/art.34649
PG 12
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 030CC
UT WOS:000310544500007
PM 22899318
DA 2025 08 17
ER

PT J
AU Wang, RK
   Pi, ZL
   Zhu, X
   Wang, XZ
   Zhang, H
   Ji, F
   Tang, H
AF Wang, Renkai
   Pi, Zhilong
   Zhu, Xiang
   Wang, Xinzhe
   Zhang, Hao
   Ji, Fang
   Tang, Hao
TI Nicorandil based hydrogel promotes bone defect reconstruction by
   targeting Hmox1
SO COLLOIDS AND SURFACES B BIOINTERFACES
LA English
DT Article
DE Nicorandil; Hydrogel; Bone defect; Angiogenesis; Hmox1
ID ACTIVATION; REPAIR; CELLS
AB Background: The local use of drugs to promote bone healing is still difficult to apply clinically. We aimed to construct a nicorandil based hydrogel to promote local bone healing by promoting angiogenesis and inhibiting osteoclastogenesis. Results: In this study, we constructed a nicorandil based hydrogel and used it to intervene in bone repair during bone defect reconstruction. The results showed that the nicorandil based hydrogel significantly inhibited osteoclast differentiation and promoted angiogenesis in vitro. Furthermore, bone formation was significantly promoted by the use of a nicorandil based hydrogel. Mechanistically, Hmox1 was directly targeted by nicorandil, and overexpression of Hmox1 was found to promote bone defect reconstruction. Conclusion: Our study provides a fresh perspective and a potential therapeutic approach for the use of local nicorandil based hydrogels to improve bone defect reconstruction.
C1 [Wang, Renkai; Zhu, Xiang; Wang, Xinzhe; Zhang, Hao; Tang, Hao] Naval Mil Med Univ, Changhai Hosp, Dept Orthopaed, 168 Changhai Rd, Shanghai, Peoples R China.
   [Wang, Renkai; Pi, Zhilong] Hosp Orthopaed, Gen Hosp Southern Theater Command PLA, Key Lab Trauma & Tissue Repair Trop Area PLA, Guangdong Key Lab Orthopaed Technol & Implant Mat, 111 Liuhua Rd, Guangzhou 510010, Guangdong, Peoples R China.
   [Ji, Fang] Shanghai Jiao Tong Univ, Peoples Hosp 9, Dept Orthoped, 639 Mfg Bur Rd, Shanghai, Peoples R China.
C3 Naval Medical University; Southern Theater Command General Hospital;
   Shanghai Jiao Tong University
RP Zhang, H; Tang, H (通讯作者)，Naval Mil Med Univ, Changhai Hosp, Dept Orthopaed, 168 Changhai Rd, Shanghai, Peoples R China.; Ji, F (通讯作者)，Shanghai Jiao Tong Univ, Peoples Hosp 9, Dept Orthoped, 639 Mfg Bur Rd, Shanghai, Peoples R China.
EM zhanghsmmu@126.com; doctorjif@126.com; tanghao1978@163.com
OI Tang, Hao/0000 0003 1709 5889
FU National Science Fund Project [82172431]; Guangzhou Science and
   Technology Project [2024A03J0690]
FX The work is supported by the National Science Fund Project (No.
   82172431) and the Guangzhou Science and Technology Project
   (2024A03J0690) .
CR Agarwal R, 2015, ADV DRUG DELIVER REV, V94, P53, DOI 10.1016/j.addr.2015.03.013
   El Rashidy AA, 2017, ACTA BIOMATER, V62, P1, DOI 10.1016/j.actbio.2017.08.030
   Iwaki F, 2016, EUR J PHARMACOL, V793, P14, DOI 10.1016/j.ejphar.2016.10.034
   Li BF, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.627718
   Linderman SW, 2015, ACTA BIOMATER, V23, P229, DOI 10.1016/j.actbio.2015.05.002
   Markl D, 2017, PHARM RES DORDR, V34, P890, DOI 10.1007/s11095 017 2129 z
   Seliktar D, 2012, SCIENCE, V336, P1124, DOI 10.1126/science.1214804
   ShamsEldeen AM, 2022, FRONT PHYSIOL, V13, DOI 10.3389/fphys.2022.934597
   Shi WP, 2024, REGEN THER, V25, P174, DOI 10.1016/j.reth.2023.12.010
   Sun JY, 2012, NATURE, V489, P133, DOI 10.1038/nature11409
   Sun LH, 2023, ORTHOP SURG, V15, P3026, DOI 10.1111/os.13884
   Wang RK, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2377 4
   Wu Y, 2017, J CELL MOL MED, V21, P609, DOI 10.1111/jcmm.13006
   Wu YB, 2016, BIOMATERIALS, V104, P18, DOI 10.1016/j.biomaterials.2016.07.011
   Xu SG, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.726361
   Yin XF, 2017, MAT SCI ENG C MATER, V78, P452, DOI 10.1016/j.msec.2017.04.028
   Zhang FY, 2017, MOL IMMUNOL, V88, P69, DOI 10.1016/j.molimm.2017.06.019
   Zhang H, 2023, BIOACT MATER, V23, P156, DOI 10.1016/j.bioactmat.2022.10.028
   Zhang H, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.666140
   Zhao CF, 2014, CLIN ORTHOP RELAT R, V472, P2569, DOI 10.1007/s11999 014 3690 y
   Zhao FJ, 2024, ADV HEALTHC MATER, V13, DOI 10.1002/adhm.202303532
NR 21
TC 0
Z9 0
U1 3
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0927 7765
EI 1873 4367
J9 COLLOID SURFACE B
JI Colloid Surf. B Biointerfaces
PD JAN
PY 2025
VL 245
AR 114299
DI 10.1016/j.colsurfb.2024.114299
EA OCT 2024
PG 9
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Chemistry; Materials Science
GA I7C4V
UT WOS:001331798700001
PM 39378704
DA 2025 08 17
ER

PT J
AU Simon, JA
AF Simon, James A.
TI Are All Bisphosphonates the Same? Potential Reasons for Clinical
   Differences: A Perspective
SO JOURNAL OF WOMENS HEALTH
LA English
DT Article
ID NITROGEN CONTAINING BISPHOSPHONATES; FRACTURE INTERVENTION TRIAL;
   RANDOMIZED CONTROLLED TRIAL; MONTHLY ORAL IBANDRONATE; BONE MINERAL
   DENSITY; POSTMENOPAUSAL OSTEOPOROSIS; VERTEBRAL FRACTURES; NONVERTEBRAL
   FRACTURES; ZOLEDRONIC ACID; ALENDRONATE THERAPY
AB Bisphosphonates are first line treatment for postmenopausal osteoporosis and women with low bone mass and risk factors for fracture. These agents are often perceived as having equivalent effectiveness and safety and are even used interchangeably by some practitioners. Research suggests, however, that differences between them are meaningful to the patient and clinician. Data from randomized controlled trials and observational database studies have demonstrated variations between bisphosphonates in the scope of fracture protection, such as vertebral and nonvertebral, as well as the speed of onset of this antifracture effect. It has been proposed that unique properties of each compound related to their mechanisms of action could explain, at least in part, differences observed in clinical outcomes. Although the bisphosphonates share a similar core structure, they also contain two side chains or groups, R1 and R2, attached to the central carbon atom. All bisphosphonates approved by the FDA for postmenopausal osteoporosis contain a hydroxyl side group at position R1, increasing their binding to bone and distinguishing them from earlier bisphosphonates not approved for this clinical use. Differences in the physicochemical and biological properties of the approved bisphosphonates are due to differences in the R2 side group. The presence of nitrogen and its orientation within the R2 side chain can influence each bisphosphonate's overall potency. For the physician to optimally determine the bisphosphonate that best suits an individual patient, it is important that they are aware of the differences between them.
C1 [Simon, James A.] George Washington Univ, Sch Med, Dept Obstet & Gynecol, Washington, DC USA.
C3 George Washington University
RP Simon, JA (通讯作者)，1850 M St NW,Suite 450, Washington, DC 20036 USA.
EM jsimon@jamesasimonmd.com
FU BioSante; Boehringer Ingelheim (Ingelheim, Germany); FemmePharma (Wayne,
   PA); GlaxoSmithKline; Nanma/Tripharma/Trinity; Novartis (Basel,
   Switzerland); Procter & Gamble (Cincinnati, OH); QuatRx Pharmaceuticals;
   Teva Pharmaceuticals Ltd.
FX J.A.S. received editorial/writing support in the preparation of this
   article from the Alliance for Better Bone Health (Procter & Gamble
   Pharmaceuticals and sanofi aventis US, Inc.). Betty Thompson, Ph.D.,
   from Excerpta Medica provided editorial and writing assistance. J.A.S.
   has received grant/research support from BioSante, Boehringer Ingelheim
   (Ingelheim, Germany), FemmePharma (Wayne, PA), GlaxoSmithKline,
   Nanma/Tripharma/Trinity, Novartis (Basel, Switzerland), Procter & Gamble
   (Cincinnati, OH), QuatRx Pharmaceuticals, and Teva Pharmaceuticals Ltd.
CR [Anonymous], BONE
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Bonnick S, 2006, J CLIN ENDOCR METAB, V91, P2631, DOI 10.1210/jc.2005 2602
   Boonen S, 2005, OSTEOPOROSIS INT, V16, P1291, DOI 10.1007/s00198 005 1945 x
   Boonen S, 2008, J CLIN ENDOCR METAB, V93, P852, DOI 10.1210/jc.2007 0711
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   CHRISCHILLES EA, 1991, ARCH INTERN MED, V151, P2026, DOI 10.1001/archinte.151.10.2026
   Cosman F, 2008, OSTEOPOROSIS INT, V19, P529, DOI 10.1007/s00198 007 0475 0
   Cranney A, 2009, OSTEOPOROSIS INT, V20, P291, DOI 10.1007/s00198 008 0653 8
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   Dowd R, 2000, OSTEOPOROSIS INT, V11, P533, DOI 10.1007/s001980070097
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   Felsenberg D, 2005, BONE, V37, P651, DOI 10.1016/j.bone.2005.05.004
   Follet H, 2007, BONE, V40, P1172, DOI 10.1016/j.bone.2006.12.052
   Goh SK, 2007, J BONE JOINT SURG BR, V89B, P349, DOI 10.1302/0301 620X.89B3.18146
   Harrington JT, 2004, CALCIFIED TISSUE INT, V74, P129, DOI 10.1007/s00223 003 0042 4
   Harris ST, 2009, BONE, V44, P758, DOI 10.1016/j.bone.2009.01.002
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Harris ST, 2008, CURR MED RES OPIN, V24, P237, DOI 10.1185/030079908X253717
   Henneman ZJ, 2008, J BIOMED MATER RES A, V85A, P993, DOI 10.1002/jbm.a.31599
   HLATKY MA, 1984, STAT MED, V3, P375, DOI 10.1002/sim.4780030415
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kwek EBK, 2008, INJURY, V39, P224, DOI 10.1016/j.injury.2007.08.036
   Lindsay R, 2001, JAMA J AM MED ASSOC, V285, P320, DOI 10.1001/jama.285.3.320
   LINDSAY R, 2005, J BONE MINER RES  S1, V20, pM293
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   Miller PD, 2008, J CLIN ENDOCR METAB, V93, P3785, DOI 10.1210/jc.2008 0353
   Miller PD, 2008, CURR MED RES OPIN, V24, P207, DOI 10.1185/030079908X253889
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   *NAT OST FDN, FAST FACTS OST 2008
   Pasco JA, 2005, OSTEOPOROSIS INT, V16, P2046, DOI 10.1007/s00198 005 1997 y
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   Reid DM, 2009, LANCET, V373, P1253, DOI 10.1016/S0140 6736(09)60250 6
   Rosen CJ, 2005, J BONE MINER RES, V20, P141, DOI 10.1359/jbmr.2005.20.1.141
   Roux C, 2004, CURR MED RES OPIN, V20, P433, DOI 10.1185/030079903125003125
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   SAYEEDNOOR AS, 2009, CLIN ORTHOP RELAT R, V467, P1291
   Silverman SL, 2007, OSTEOPOROSIS INT, V18, P25, DOI 10.1007/s00198 006 0274 z
   Silverman SL, 2009, AM J MED, V122, P114, DOI 10.1016/j.amjmed.2008.09.030
   Watts Nelson B, 2004, J Manag Care Pharm, V10, P142
   Wigderowitz CA, 2000, J BONE JOINT SURG BR, V82B, P87, DOI 10.1302/0301 620X.82B1.9528
NR 50
TC 6
Z9 10
U1 0
U2 4
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540 9996
J9 J WOMENS HEALTH
JI J. Womens Health
PD APR
PY 2010
VL 19
IS 4
BP 719
EP 727
DI 10.1089/jwh.2008.1196
PG 9
WC Public, Environmental & Occupational Health; Medicine, General &
   Internal; Obstetrics & Gynecology; Women's Studies
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health; General & Internal
   Medicine; Obstetrics & Gynecology; Women's Studies
GA 587XS
UT WOS:000277030400011
PM 20201704
DA 2025 08 17
ER

PT J
AU Hu, Y
   Chen, Y
   Douglas, L
   Li, S
AF Hu, Y.
   Chen, Y.
   Douglas, L.
   Li, S.
TI β Catenin is essential for survival of leukemic stem cells insensitive
   to kinase inhibition in mice with BCR ABL induced chronic myeloid
   leukemia
SO LEUKEMIA
LA English
DT Article
DE leukemic stem cells; beta catenin; CML; BCR ABL; drug resistance
ID GRANULOCYTE MACROPHAGE PROGENITORS; TYROSINE KINASE; INTERFERON ALPHA;
   CHRONIC PHASE; IMATINIB; ACTIVATION; BCR/ABL; STI571; CYTARABINE;
   RESISTANCE
AB Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) induced by the BCR ABL oncogene is believed to be developed from leukemic stem cells (LSCs), and we have previously shown in mice that LSCs for CML express the same cell surface markers that are also expressed on normal hematopoietic stem cells (HSCs). Although the inhibition of BCR ABL kinase activity by imatinib is highly effective in treating human Ph+ CML in chronic phase, it is difficult to achieve molecular remission of the disease, suggesting that LSCs remain in patients. In this study, we find that following imatinib treatment, LSCs not only remained but also accumulated increasingly in bone marrow of CML mice. This insensitivity of LSCs to imatinib was not because of the lack of BCR ABL kinase inhibition by imatinib, and proliferating leukemic cells derived from LSCs were still sensitive to growth inhibition by imatinib. These results identify an LSC survival pathway that is not inhibited by imatinib. Furthermore, we show that beta catenin in the Wnt signaling pathway is essential for survival and self renewal of LSCs, providing a new strategy for targeting these cells.
C1 [Hu, Y.; Chen, Y.; Douglas, L.; Li, S.] Univ Massachusetts, Sch Med, Dept Med, Div Hematol Oncol, Worcester, MA 01605 USA.
C3 University of Massachusetts System; University of Massachusetts
   Worcester
RP Li, S (通讯作者)，Univ Massachusetts, Sch Med, Dept Med, Div Hematol Oncol, Lazare Res Bldg 315,364 Plantat St, Worcester, MA 01605 USA.
EM Shaoguang.Li@umassmed.edu
RI ; chen, yaoyu/A 4236 2011
OI Hu, Yiguo/0000 0002 3973 2140; 
FU Leukemia and Lymphoma Society; National Institutes of Health
   [R01 CA114199, R01 CA122142]
FX We thank Stephen B Sampson for critical reading of the manuscript, and
   Patricia Cherry for the secretarial assistance. This work is supported
   by the grants from the Leukemia and Lymphoma Society and the National
   Institutes of Health (R01 CA114199, R01 CA122142) to SL. SL is a Scholar
   of the Leukemia and Lymphoma Society.
CR Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599
   Brault V, 2001, DEVELOPMENT, V128, P1253
   Coluccia AML, 2007, EMBO J, V26, P1456, DOI 10.1038/sj.emboj.7601485
   Domen J, 2000, J EXP MED, V192, P1707, DOI 10.1084/jem.192.12.1707
   Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401
   Drummond MW, 2003, LEUKEMIA, V17, P463, DOI 10.1038/sj.leu.2402814
   Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319
   Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343
   Hu YG, 2006, P NATL ACAD SCI USA, V103, P16870, DOI 10.1073/pnas.0606509103
   Hughes TP, 2003, NEW ENGL J MED, V349, P1423, DOI 10.1056/NEJMoa030513
   Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258
   Kondo M, 2003, ANNU REV IMMUNOL, V21, P759, DOI 10.1146/annurev.immunol.21.120601.141007
   Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784
   Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572
   Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399
   Li SG, 2001, EMBO J, V20, P6793, DOI 10.1093/emboj/20.23.6793
   Lin F, 2003, BLOOD, V102, P1143, DOI 10.1182/blood 2002 12 3916
   Manz MG, 2002, P NATL ACAD SCI USA, V99, P11872, DOI 10.1073/pnas.172384399
   Marley SB, 2000, EXP HEMATOL, V28, P551, DOI 10.1016/S0301 472X(00)00142 9
   Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427
   Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787
   O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457
   Orkin SH, 2002, NAT IMMUNOL, V3, P323, DOI 10.1038/ni0402 323
   Rask K, 2003, BRIT J CANCER, V89, P1298, DOI 10.1038/sj.bjc.6601265
   Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593
   Roumiantsev S, 2001, BLOOD, V97, P4, DOI 10.1182/blood.V97.1.4
   Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790
   Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535 6108(02)00096 X
   Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480
   Uchida N, 1998, P NATL ACAD SCI USA, V95, P11939, DOI 10.1073/pnas.95.20.11939
   Uematsu K, 2003, ONCOGENE, V22, P7218, DOI 10.1038/sj.onc.1206817
   Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611
   Wolff NC, 2001, BLOOD, V98, P2808, DOI 10.1182/blood.V98.9.2808
   Zhao C, 2007, CANCER CELL, V12, P528, DOI 10.1016/j.ccr.2007.11.003
NR 34
TC 155
Z9 172
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887 6924
EI 1476 5551
J9 LEUKEMIA
JI Leukemia
PD JAN
PY 2009
VL 23
IS 1
BP 109
EP 116
DI 10.1038/leu.2008.262
PG 8
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Hematology
GA 394TL
UT WOS:000262470700013
PM 18818703
DA 2025 08 17
ER

PT J
AU Zhu, Y
   Shi, Q
   Peng, Q
   Gao, Y
   Yang, T
   Cheng, Y
   Wang, H
   Luo, YT
   Huang, AL
   He, TC
   Fan, JM
AF Zhu, Ying
   Shi, Qiong
   Peng, Qi
   Gao, Yue
   Yang, Ting
   Cheng, Yu
   Wang, Hao
   Luo, Yetao
   Huang, Ailong
   He, Tong Chuan
   Fan, Jiaming
TI A simplified 3D liver microsphere tissue culture model for hepatic cell
   signaling and drug induced hepatotoxicity studies
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE primary liver tissue culture; exogenous investigation; hepatotoxicity
   prediction
ID BONE MORPHOGENETIC PROTEINS; MESENCHYMAL STEM CELLS; IN VITRO SYSTEMS;
   OSTEOGENIC DIFFERENTIATION; OSTEOBLAST DIFFERENTIATION; PRIMARY
   HEPATOCYTES; GROWTH; GENE; MECHANISMS; EXPRESSION
AB Although a number of experimental models have been developed for liver research, each has its own advantages and disadvantages. The present study attempted to develop a simple and effective 3 dimensional mouse liver microsphere tissue culture (LMTC) model in vitro for the analysis of hepatic functions. Hepatic characteristics and potential applications of this model were compared with that of mouse model in vivo and mouse primary hepatocytes in vitro. Using freshly perfused mouse liver tissue passed through 80 mesh sift strainer (sift80), it was demonstrated that under the optimal culture conditions, the sift80 microsphere tissue cultured in 2% bovine calf serum medium remained viable with marked proliferating cell nuclear antigen and anti Myc proto oncogene protein expression, exhibited normal hepatic functions including indocyanine green (ICG) uptake/release and periodic acid Schiff staining, and expressed hepatocyte specific genes for up to 2 weeks. The microsphere tissue was responsive to bone morphogenic protein 9 (BMP9) stimulation leading to upregulation of downstream targets of BMP9 signaling. Furthermore, 3 commonly used liver damaging drugs were indicated to effectively inhibit hepatic ICG uptake, and induce the expression of hepatotoxicity associated genes. Therefore, this simplified LMTC model may be a useful in vitro tissue culture model to investigate drug induced liver injury and metabolism, and hepatocyte based cell singling.
C1 [Zhu, Ying; Shi, Qiong; Peng, Qi; Gao, Yue; Yang, Ting; Cheng, Yu; Wang, Hao; Fan, Jiaming] Chongqing Med Univ, Sch Lab Med, Minist Educ, Key Lab Diagnost Med, 1 Med Coll Rd, Chongqing 400016, Peoples R China.
   [Luo, Yetao] Chongqing Med Univ, Sch Publ Hlth & Management, Dept Biostat, Chongqing 400016, Peoples R China.
   [Huang, Ailong] Chongqing Med Univ, Affiliated Hosp 2, Key Lab Mol Biol Infect Dis, Inst Viral Hepatitis,Minist Educ China,Dept Infec, Chongqing 400037, Peoples R China.
   [He, Tong Chuan] Univ Chicago, Med Ctr, Dept Orthoped Surg & Rehabil Med, Mol Oncol Lab, Chicago, IL 60637 USA.
C3 Chongqing Medical University; Chongqing Medical University; Chongqing
   Medical University; University of Chicago; University of Chicago Medical
   Center
RP Fan, JM (通讯作者)，Chongqing Med Univ, Sch Lab Med, Minist Educ, Key Lab Diagnost Med, 1 Med Coll Rd, Chongqing 400016, Peoples R China.
EM fanjiaming1988@cqmu.edu.cn
FU 2017 Chongqing Postdoctoral Innovation Talent Support Program; China
   Postdoctoral Research Fund [2018M643426]; National Key Research and
   Development Program of China [2016YFC1000803, 2011CB707906]; Mabel Green
   Myers Research Endowment Fund; University of Chicago Orthopaedic Surgery
   Alumni Fund
FX The present study was supported in part by research grants from the 2017
   Chongqing Postdoctoral Innovation Talent Support Program (JMF), the
   China Postdoctoral Research Fund (grant no. 2018M643426 to JMF) and the
   National Key Research and Development Program of China (grant nos.
   2016YFC1000803 and 2011CB707906). TCH was also supported by the Mabel
   Green Myers Research Endowment Fund and The University of Chicago
   Orthopaedic Surgery Alumni Fund.
CR Bale SS, 2016, TISSUE ENG PART B RE, V22, P383, DOI 10.1089/ten.teb.2016.0031
   Bale SS, 2015, TISSUE ENG PART C ME, V21, P413, DOI [10.1089/ten.TEC.2014.0152, 10.1089/ten.tec.2014.0152]
   Bale SS, 2014, EXP BIOL MED, V239, P1180, DOI 10.1177/1535370214531872
   Beckwitt CH, 2018, EXP CELL RES, V363, P15, DOI 10.1016/j.yexcr.2017.12.023
   Bhakuni GS, 2016, INFLAMM RES, V65, P13, DOI 10.1007/s00011 015 0883 0
   Bhushan A, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt377
   Bi Y, 2013, BRAZ J MED BIOL RES, V46, P559, DOI 10.1590/1414 431X20132455
   Bi Y, 2014, CELL PHYSIOL BIOCHEM, V34, P1318, DOI 10.1159/000366340
   Bi Y, 2010, DEV GROWTH DIFFER, V52, P419, DOI 10.1111/j.1440 169X.2010.01182.x
   Bi Y, 2009, J CELL BIOCHEM, V108, P295, DOI 10.1002/jcb.22254
   Cabral F, 2018, JOVE J VIS EXP, DOI 10.3791/56993
   Chen LA, 2010, J BONE MINER RES, V25, P2447, DOI 10.1002/jbmr.133
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Choi WM, 2019, MOL CELLS, V42, P45, DOI 10.14348/molcells.2018.0330
   Clark M, 2018, REGUL TOXICOL PHARM, V96, P94, DOI 10.1016/j.yrtph.2018.04.018
   Cogger VC, 2015, JOVE J VIS EXP, DOI 10.3791/52698
   Cui J, 2019, LAB INVEST, V99, P58, DOI 10.1038/s41374 018 0087 7
   Desmettre T, 1999, J FR OPHTALMOL, V22, P1003
   Fan JM, 2017, ONCOTARGET, V8, P27105, DOI 10.18632/oncotarget.15637
   Gao YH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082436
   Gebhardt R, 2003, DRUG METAB REV, V35, P145, DOI 10.1081/DMR 120023684
   Godoy P, 2013, ARCH TOXICOL, V87, P1315, DOI 10.1007/s00204 013 1078 5
   Granhall C, 2002, XENOBIOTICA, V32, P985, DOI 10.1080/0049825021000012646
   Groneberg DA, 2002, TOXICOL PATHOL, V30, P394, DOI 10.1080/01926230252929972
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   Houston JB, 1997, DRUG METAB REV, V29, P891, DOI 10.3109/03602539709002237
   Huang EY, 2012, J BONE MINER RES, V27, P1566, DOI 10.1002/jbmr.1622
   Huang JY, 2009, LIVER INT, V29, P1569, DOI 10.1111/j.1478 3231.2009.02111.x
   Hughes DJ, 2017, EXP BIOL MED, V242, P1593, DOI 10.1177/1535370217708976
   Jaeschke H, 2002, TOXICOL SCI, V65, P166, DOI 10.1093/toxsci/65.2.166
   Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   Kang Q, 2009, STEM CELLS DEV, V18, P545, DOI 10.1089/scd.2008.0130
   Kaplowitz N, 2005, NAT REV DRUG DISCOV, V4, P489, DOI 10.1038/nrd1750
   Kegel V, 2016, JOVE J VIS EXP, DOI 10.3791/53069
   Khetani SR, 2008, NAT BIOTECHNOL, V26, P120, DOI 10.1038/nbt1361
   Kim DS, 2017, HEPATOLOGY, V66, P1662, DOI 10.1002/hep.29324
   Kong YH, 2013, CELL PHYSIOL BIOCHEM, V32, P1187, DOI 10.1159/000354518
   Lamplot JD, 2013, AM J STEM CELLS, V2, P1
   Lee CS, 2017, GENES DIS, V4, P43, DOI 10.1016/j.gendis.2017.04.001
   Li RD, 2014, CURR CANCER DRUG TAR, V14, P274, DOI 10.2174/1568009614666140305105805
   Li RF, 2016, INT J MED SCI, V13, P8, DOI 10.7150/ijms.13333
   Liao JY, 2017, CELL PHYSIOL BIOCHEM, V41, P1905, DOI 10.1159/000471945
   Liao Z, 2015, CURR CANCER DRUG TAR, V15, P726, DOI 10.2174/1568009615666150629132157
   Liu J, 2017, METHODS MOL BIOL, V1540, P249, DOI 10.1007/978 1 4939 6700 1_21
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luo J, 2007, NAT PROTOC, V2, P1236, DOI 10.1038/nprot.2007.135
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Luther G, 2011, CURR GENE THER, V11, P229
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   Maes M, 2016, TOXICOL APPL PHARM, V290, P86, DOI 10.1016/j.taap.2015.11.016
   May JE, 2009, BRIT J BIOMED SCI, V66, P160, DOI 10.1080/09674845.2009.11730265
   Mederacke I, 2015, NAT PROTOC, V10, P305, DOI 10.1038/nprot.2015.017
   National Research Council, 2011, GUIDE CARE USE LAB A, DOI [10.17226/12910, DOI 10.17226/12910]
   Nikoozad Z, 2014, IRAN J BASIC MED SCI, V17, P27
   Njoku DB, 2014, INT J MOL SCI, V15, P6990, DOI 10.3390/ijms15046990
   Olson H, 2000, REGUL TOXICOL PHARM, V32, P56, DOI 10.1006/rtph.2000.1399
   OMURA T, 1964, J BIOL CHEM, V239, P2370
   Pandit A., 2012, Journal of Applied Pharmaceutical Science, V2, P233, DOI DOI 10.7324/JAPS.2012.2541
   Peng Y, 2004, J BIOL CHEM, V279, P32941, DOI 10.1074/jbc.M403344200
   Peng Y, 2003, J CELL BIOCHEM, V90, P1149, DOI 10.1002/jcb.10744
   Perwitasari DA, 2015, DRUG METAB REV, V47, P222, DOI 10.3109/03602532.2014.984070
   Ramappa V, 2013, J CLIN EXP HEPATOL, V3, P37, DOI 10.1016/j.jceh.2012.12.001
   Rebelo SP, 2017, J TISSUE ENG REGEN M, V11, P2034, DOI 10.1002/term.2099
   Riccalton Banks L, 2003, TISSUE ENG, V9, P401, DOI 10.1089/107632703322066589
   Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091 679X(08)61797 5
   Shu Y, 2018, J CELL BIOCHEM, V119, P8872, DOI 10.1002/jcb.27140
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   Si Tayeb K, 2010, DEV CELL, V18, P175, DOI 10.1016/j.devcel.2010.01.011
   Soldatow VY, 2013, TOXICOL RES UK, V2, P23, DOI 10.1039/c2tx20051a
   Thapa BR, 2007, INDIAN J PEDIATR, V74, P663, DOI 10.1007/s12098 007 0118 7
   Vorrink SU, 2018, TOXICOL SCI, V163, P655, DOI 10.1093/toxsci/kfy058
   Wagner Eric R., 2011, Sarcoma, V2011, P325238, DOI 10.1155/2011/325238
   Wang N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097316
   Wang RN, 2014, GENES DIS, V1, P87, DOI 10.1016/j.gendis.2014.07.005
   Wang XJ, 2014, J BIOMED MATER RES A, V102, P1017, DOI 10.1002/jbm.a.34764
   Ware BR, 2017, TRENDS BIOTECHNOL, V35, P172, DOI 10.1016/j.tibtech.2016.08.001
   Wu N, 2014, GENE THER, V21, P629, DOI 10.1038/gt.2014.40
   Yan ZJ, 2015, CELLS TISSUES ORGANS, V201, P38, DOI 10.1159/000439268
   Yu XY, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 29417 3
   Yu XY, 2018, CELL PHYSIOL BIOCHEM, V47, P957, DOI 10.1159/000490140
   Zelepukin IV, 2019, NANOTECHNOLOGY, V30, DOI 10.1088/1361 6528/aafa3a
   Zhang Q, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132666
   Zhao C, 2018, ACS BIOMATER SCI ENG, V4, P2943, DOI 10.1021/acsbiomaterials.8b00179
   Zhao C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092908
   Zhou L, 2002, BIOTECHNIQUES, V33, P1126, DOI 10.2144/02335dd07
NR 85
TC 10
Z9 10
U1 1
U2 21
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
EI 1791 244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD NOV
PY 2019
VL 44
IS 5
BP 1653
EP 1666
DI 10.3892/ijmm.2019.4321
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA JE2TM
UT WOS:000490547400006
PM 31485603
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Shi, LP
   Zhou, J
   Zhao, SP
   Wu, YW
AF Shi Li Ping
   Zhou Jian
   Zhao Su Ping
   Wu You Wei
TI Curcumin and Risendronate/hydroxyapatite co loaded lipid polymer
   nanoparticle to enhance the therapeutic efficacy in osteoporosis
SO RESEARCH JOURNAL OF BIOTECHNOLOGY
LA English
DT Article
DE Steoporosis; osteoblast cell; curcumin; hydroxyapatite; risendronate
ID TARGETED DRUG DELIVERY; BONE; RISEDRONATE; MICROSPHERES
AB In this study, a unique lipid polymer nanoparticle loaded with dual drug (CUM and RSN) was formulated to treat osteoporosis. For this purpose, PEG lecithin coated PLGA NP (LCRHP NPs) was prepared by nanoprecipitation method. The main aim was to increase the stability, sustained release and internalization of nanoformulations in the osteoblast cells. The particles were nanosized indicating its suitability for bone applications. Morphology was investigated by the SEM which showed clear spherical shaped NPs with size less than 200 nm to treat the micropores in the bone. Both the drugs were released in a sustained manner from the nanoparticles throughout the study period.
   Moreover, a typical biphasic release pattern was observed which could be attributed to the presence of drug on the outer surface as well as on the inner core. Initial fast release of drug will enhance the treatment while slow release from core will maintain the drug reservoir effect in the bone site. Consistently, nanoparticle showed superior killing property and uptake in HFOb 1.19 cells. Most importantly, RSN HA in the lipid polymer showed strong affinity towards the HA further enhancing the therapeutic efficacy in osteoporosis.
C1 [Shi Li Ping; Zhou Jian; Zhao Su Ping; Wu You Wei] Shaanxi Prov Peoples Hosp, Dept Gastroenterol 2, Xian, Shaanxi, Peoples R China.
C3 Xi'an Medical University
RP Wu, YW (通讯作者)，Shaanxi Prov Peoples Hosp, Dept Gastroenterol 2, Xian, Shaanxi, Peoples R China.
EM wuyouwei0906@hotmail.com
FU Shaanxi Provincial People's Hospital, Shaanxi, China
FX The study was funded from the research grant of Shaanxi Provincial
   People's Hospital, Shaanxi, China.
CR Brock Garry R, 2015, Bone Rep, V2, P8
   Chan JM, 2009, BIOMATERIALS, V30, P1627, DOI 10.1016/j.biomaterials.2008.12.013
   Chan WH, 2006, FOOD CHEM TOXICOL, V44, P1362, DOI 10.1016/j.fct.2006.03.001
   Cong YY, 2015, J BIOMAT SCI POLYM E, V26, P629, DOI 10.1080/09205063.2015.1053170
   Fazil M, 2016, DRUG DELIV, V23, P2428, DOI 10.3109/10717544.2014.1002947
   Folwarczna J., 2013, NUTR DIET MENOPAUSE, V3, P165, DOI [DOI 10.1007/978 1 62703 373 213, 10.1007/978 1 62703 373 2_13, DOI 10.1007/978 1 62703 373 2_13]
   Kwak HB, 2009, BIOL PHARM BULL, V32, P1193, DOI 10.1248/bpb.32.1193
   Li L, 2014, INT J NANOMED, V9, P1083, DOI 10.2147/IJN.S59779
   Matthew T.D., 2015, CLIN THER, V37, P1837
   Nasr M, 2011, EUR J PHARM BIOPHARM, V79, P601, DOI 10.1016/j.ejpb.2011.07.010
   Ramasamy T, 2015, CHEM COMMUN, V51, P5758, DOI 10.1039/c5cc00482a
   Ramasamy T, 2013, DRUG DELIV, V20, P65, DOI 10.3109/10717544.2012.762434
   Rawat P, 2015, PHARM RES DORDR, V32, P3149, DOI 10.1007/s11095 015 1692 4
   Ruttala HB, 2015, COLLOID SURFACE B, V128, P419, DOI 10.1016/j.colsurfb.2015.02.040
   Shi XT, 2009, PHARM RES DORDR, V26, P422, DOI 10.1007/s11095 008 9759 0
   Wang D, 2003, BIOCONJUGATE CHEM, V14, P853, DOI 10.1021/bc034090j
   Yewle JN, 2011, BIOCONJUGATE CHEM, V22, P2496, DOI 10.1021/bc2003132
NR 17
TC 3
Z9 3
U1 1
U2 22
PU RESEARCH JOURNAL BIOTECHNOLOGY
PI INDORE
PA SECTOR A 80, SCHEME NO 54, VIJAY NAGAR, A B ROAD, INDORE, 452 010 MP,
   INDIA
SN 2278 4535
J9 RES J BIOTECHNOL
JI Res. J. Biotechnol.
PD DEC
PY 2016
VL 11
IS 12
BP 1
EP 7
PG 7
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology
GA EE0BX
UT WOS:000389239600001
DA 2025 08 17
ER

PT J
AU Li, ZH
   Li, C
   Szajnman, SH
   Rodriguez, JB
   Moreno, SNJ
AF Li, Zhu Hong
   Li, Catherine
   Szajnman, Sergio H.
   Rodriguez, Juan B.
   Moreno, Silvia N. J.
TI Synergistic Activity between Statins and Bisphosphonates against Acute
   Experimental Toxoplasmosis
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
DE bisphosphonate; statins; synergy; Toxoplasma gondii; isoprenoids
ID DIPHOSPHATE SYNTHASE; TRYPANOSOMA CRUZI; GONDII; APICOPLAST; DESIGN;
   GROWTH; ENZYME
AB Bisphosphonates are widely used for the treatment of bone disorders. These drugs also inhibit the growth of a variety of protozoan parasites, such as Toxoplasma gondii, the etiologic agent of toxoplasmosis. The target of the most potent bisphosphonates is the isoprenoid biosynthesis pathway enzyme farnesyl diphosphate synthase (FPPS). Based on our previous work on the inhibitory effect of sulfur containing linear bisphosphonates against T. gondii, we investigated the potential synergistic interaction between one of these derivatives, 1 [(n heptylthio) ethyl] 1,1 bisphosphonate (C7S), and statins, which are potent inhibitors of the host 3 hydroxy 3 methyl glutaryl coenzyme A reductase (3 HMG CoA reductase). C7S showed high activity against the T. gondii bifunctional farnesyl diphosphate (FPP)/geranylgeranyl diphosphate (GGPP) synthase (TgFPPS), which catalyzes the formation of FPP and GGPP (50% inhibitory concentration [IC50] = 31 +/  0.01 nM [mean +/  standard deviation]), and modest effect against the human FPPS (IC50 = 1.3 +/  0.5 mu M). We tested combinations of C7S with statins against the in vitro replication of T. gondii. We also treated mice infected with a lethal dose of T. gondii with similar combinations. We found strong synergistic activities when using low doses of C7S, which were stronger in vivo than when tested in vitro. We also investigated the synergism of several commercially available bisphosphonates with statins both in vitro and in vivo. Our results provide evidence that it is possible to develop drug combinations that act synergistically by inhibiting host and parasite enzymes in vitro and in vivo.
C1 [Li, Zhu Hong; Li, Catherine; Moreno, Silvia N. J.] Univ Georgia, Ctr Trop & Emerging Global Dis, Athens, GA 30602 USA.
   [Li, Zhu Hong; Li, Catherine; Moreno, Silvia N. J.] Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA.
   [Szajnman, Sergio H.; Rodriguez, Juan B.] Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Organ, Buenos Aires, DF, Argentina.
   [Szajnman, Sergio H.; Rodriguez, Juan B.] Univ Buenos Aires, Fac Ciencias Exactas & Nat, CONICET, UMYMFOR, Buenos Aires, DF, Argentina.
C3 University System of Georgia; University of Georgia; University System
   of Georgia; University of Georgia; University of Buenos Aires;
   University of Buenos Aires; Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET)
RP Moreno, SNJ (通讯作者)，Univ Georgia, Ctr Trop & Emerging Global Dis, Athens, GA 30602 USA.; Moreno, SNJ (通讯作者)，Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA.
EM smoreno@uga.edu
RI ; Szajnman, Sergio/AFM 1606 2022
OI Szajnman, Sergio Hernan/0000 0001 6989 4768; 
FU U.S. National Institutes of Health [AI 102254]; National Research
   Council of Argentina [PIP 0797]; ANPCyT [0457]; Universidad de Buenos
   Aires [20020130100223BA]
FX This work was supported by grants from the U.S. National Institutes of
   Health, to S.N.J.M. (AI 102254), and the National Research Council of
   Argentina (grant number PIP 0797), ANPCyT (grant number PICT 2012
   #0457), and the Universidad de Buenos Aires (grant number
   20020130100223BA) to J.B.R.
CR [Anonymous], 2005, PHYS DESK REF, P2585
   Rodriguez JB, 2012, EXPERT OPIN THER PAT, V22, P311, DOI 10.1517/13543776.2012.668886
   BERENBAUM MC, 1978, J INFECT DIS, V137, P122, DOI 10.1093/infdis/137.2.122
   Blader IJ, 2001, J BIOL CHEM, V276, P24223, DOI 10.1074/jbc.M100951200
   Chou T.C., 2005, CompuSyn for drug combinations: PC software and user's guide: A computer program for quantitation of synergism and antagonism in drug combinations, and the determination of IC50 and ED50 and LD50 values
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065 2571(84)90007 4
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Derouin F, 2001, Curr Opin Investig Drugs, V2, P1368
   Docampo Roberto, 2001, Current Drug Targets   Infectious Disorders, V1, P51, DOI 10.2174/1568005013343191
   Doggett JS, 2012, P NATL ACAD SCI USA, V109, P15936, DOI 10.1073/pnas.1208069109
   Dyer O, 2015, BMJ BRIT MED J, V351, DOI 10.1136/bmj.h6472
   Holland GN, 2004, AM J OPHTHALMOL, V137, P1, DOI 10.1016/j.ajo.2003.10.032
   ISRAELSKI DM, 1993, CLIN INFECT DIS, V17, pS423, DOI 10.1093/clinids/17.Supplement_2.S423
   Li Y, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005511
   Li ZH, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003665
   Li ZH, 2012, BIOCHEMISTRY US, V51, P7533, DOI 10.1021/bi3005335
   Liñares GEG, 2006, CURR MED CHEM, V13, P335, DOI 10.2174/092986706775476043
   Ling Y, 2007, J BIOL CHEM, V282, P30804, DOI 10.1074/jbc.M703178200
   LUFT BJ, 1993, NEW ENGL J MED, V329, P995, DOI 10.1056/NEJM199309303291403
   Martin MB, 1999, BIOCHEM BIOPH RES CO, V263, P754, DOI 10.1006/bbrc.1999.1404
   Martin MB, 2001, J MED CHEM, V44, P909, DOI 10.1021/jm0002578
   Miller K, 2009, ANGEW CHEM INT EDIT, V48, P2949, DOI 10.1002/anie.200805133
   Nair SC, 2011, J EXP MED, V208, P1547, DOI 10.1084/jem.20110039
   Neville AJ, 2015, ANTIMICROB AGENTS CH, V59, P7161, DOI 10.1128/AAC.02009 15
   Oldfield E, 2010, ACCOUNTS CHEM RES, V43, P1216, DOI 10.1021/ar100026v
   Pillai S.K., 2005, Antibiotics in laboratory medicine
   Recher M, 2013, EUR J MED CHEM, V60, P431, DOI 10.1016/j.ejmech.2012.12.015
   Reddy R, 2008, CHEMMEDCHEM, V3, P1863, DOI 10.1002/cmdc.200800255
   Rodan GA, 1998, ANNU REV PHARMACOL, V38, P375, DOI 10.1146/annurev.pharmtox.38.1.375
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sanders JM, 2004, J MED CHEM, V47, P375, DOI 10.1021/jm0303709
   Seeber F, 2010, INT REV CEL MOL BIO, V281, P161, DOI 10.1016/S1937 6448(10)81005 6
   Urbina JA, 1999, J BIOL CHEM, V274, P33609, DOI 10.1074/jbc.274.47.33609
   van Dooren GG, 2008, P NATL ACAD SCI USA, V105, P13574, DOI 10.1073/pnas.0803862105
   Wei HX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138204
   Wiesner J, 2008, CURR PHARM DESIGN, V14, P855, DOI 10.2174/138161208784041105
   WONG SY, 1994, CLIN INFECT DIS, V18, P853, DOI 10.1093/clinids/18.6.853
   Zhang YH, 2009, J AM CHEM SOC, V131, P5153, DOI 10.1021/ja808285e
NR 38
TC 22
Z9 26
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036 2904 USA
SN 0066 4804
EI 1098 6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD AUG
PY 2017
VL 61
IS 8
AR e02628 16
DI 10.1128/AAC.02628 16
PG 10
WC Microbiology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Microbiology; Pharmacology & Pharmacy
GA FB6NJ
UT WOS:000406259400095
PM 28559264
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Locker, M
   Bitard, J
   Collet, C
   Poliard, A
   Mutel, V
   Launay, JM
   Kellermann, O
AF Locker, M
   Bitard, J
   Collet, C
   Poliard, A
   Mutel, V
   Launay, JM
   Kellermann, O
TI Stepwise control of osteogenic differentiation by 5 HT2B
   receptor signaling:: Nitric oxide production and phospholipase A2
   activation
SO CELLULAR SIGNALLING
LA English
DT Article
DE 5 HT2B receptor; osteogenic differentiation; PLA2; NO; COX/PGE2; bone
   mineralization
ID SEROTONIN 2B RECEPTOR; MESOBLASTIC CELL LINE; OSTEOBLAST LIKE CELLS;
   BONE RESORPTION; CHONDROGENIC DIFFERENTIATION; CRANIOFACIAL
   MORPHOGENESIS; MOUSE TERATOCARCINOMA; SYNTHASE ISOFORMS; GROWTH FACTOR;
   NEURAL CREST
AB During development, antagonists of 5 HT2 receptor subtypes cause morphological defects of mesodermal and neural crest derivatives including the craniofacial skeleton. We used an inducible mesoblastic cell line, Cl, able to fully convert into osteocytes within 12 days, to assess the involvement of 5 HT2 receptors during osteogenic differentiation. On day 5 of the osteogenic program, immediately before matrix mineralization, the cells selectively implement 5 HT2B receptors (5 HT2BR) which remain functional until terminal differentiation. In 5 HT depleted medium, the receptor exhibits a constitutive activity leading to basal nitric oxide (NO) release and phospholipase A2 (PLA2)dependent arachidonic acid (AA) production. Blockade of this intrinsic activity affects the efficiency of mineralization by decreasing calcium incorporation within the matrix by 40%. Optimal bone matrix mineralization involves both NO and PLA2 signaling pathways. Moreover, between day 5 and day 10, at the beginning of mineral deposition, the 5 HT2BR promotes prostaglandin E2 production through AA dependent cyclooxygenase (COX) activation. From day 10 onwards, when Cl osteoblasts undergo conversion into osteocyte like cells, COX activity is quenched. Altogether these observations indicate that the 5 HT2BR contributes in an autocrine manner to osteogenic differentiation and highlight a switch in the downstream targets of the receptor at the terminal stage of the program. Finally, in addition to its autocrine function, the 5 HT2BR responds to 5 HT by increasing NO production and AA release. These findings raise concern regarding the use of 5HT(2B)R related drugs that may interfere with bone metabolism in physiological or pathological situations. (c) 2005 Elsevier Inc. All rights reserved.
C1 CNRS, UPR 1983, Inst Andre Lwoff, F 94801 Villejuif, France.
   Inst Pasteur, Dept Biol Cellulaire & Infect, Paris, France.
   Hop Lariboisiere, Serv Biochim, F 75475 Paris, France.
   F Hoffmann La Roche & Co Ltd, Pharma Res Dept, CH 4070 Basel, Switzerland.
C3 Centre National de la Recherche Scientifique (CNRS); Pasteur Network;
   Universite Paris Cite; Institut Pasteur Paris; Universite Paris Cite;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Lariboisiere Fernand Widal   APHP; Roche Holding
RP CNRS, UPR 1983, Inst Andre Lwoff, 7 Rue Guy Moquet,BP8, F 94801 Villejuif, France.
EM mlocker@vjf.cnrs.fr; jbitard@vjf.cnrs.fr;
   corinne.collet@lrb.ap hop paris.fr; apoliard@vjf.cnrs.fr;
   Vincent.Mutel@addexpharma.com; jean marie.launay@lrb.ap hop paris.fr;
   okellerm@vjf.cnrs.fr
RI ; Locker, Morgane/LIF 6504 2024
OI collet, corinne/0000 0001 6990 863X; 
CR Aguirre J, 2001, AM J PATHOL, V158, P247, DOI 10.1016/S0002 9440(10)63963 6
   [Anonymous], 2002, PRINCIPLES BONE BIOL
   Armour KE, 2001, ENDOCRINOLOGY, V142, P760, DOI 10.1210/en.142.2.760
   Armour KE, 1999, J BONE MINER RES, V14, P2137, DOI 10.1359/jbmr.1999.14.12.2137
   Battaglino R, 2004, J BONE MINER RES, V19, P1420, DOI 10.1359/JBMR.040606
   Bingham CO, 2002, J RHEUMATOL, V29, P3
   Bliziotes MM, 2001, BONE, V29, P477, DOI 10.1016/S8756 3282(01)00593 2
   Bonventre JV, 2004, TRENDS IMMUNOL, V25, P116, DOI 10.1016/j.it.2004.01.006
   BUCCARON MH, 1990, P NATL ACAD SCI USA, V87, P1922, DOI 10.1073/pnas.87.5.1922
   Buznikov GA, 2001, CELL TISSUE RES, V305, P177, DOI 10.1007/s004410100408
   Chen QR, 1997, J BIOL CHEM, V272, P5952, DOI 10.1074/jbc.272.9.5952
   Choi DS, 1997, DEVELOPMENT, V124, P1745
   COX DA, 1995, J PHARMACOL EXP THER, V272, P143
   Cussac D, 2002, N S ARCH PHARMACOL, V365, P242, DOI 10.1007/s00210 001 0505 y
   ELLIS ES, 1995, BRIT J PHARMACOL, V114, P400, DOI 10.1111/j.1476 5381.1995.tb13240.x
   Gaspar P, 2003, NAT REV NEUROSCI, V4, P1002, DOI 10.1038/nrn1256
   Gerstenfeld LC, 2003, J ORTHOP RES, V21, P670, DOI 10.1016/S0736 0266(03)00003 2
   GLENNON RA, 1988, J MED CHEM, V31, P5, DOI 10.1021/jm00396a003
   GODDARD DH, 1992, CYTOKINE, V4, P377, DOI 10.1016/1043 4666(92)90081 2
   Helfrich MH, 1997, J BONE MINER RES, V12, P1108, DOI 10.1359/jbmr.1997.12.7.1108
   Hoyer D, 2002, PHARMACOL BIOCHEM BE, V71, P533, DOI 10.1016/S0091 3057(01)00746 8
   Jerman JC, 2001, EUR J PHARMACOL, V414, P23, DOI 10.1016/S0014 2999(01)00775 0
   Kanai AJ, 2001, P NATL ACAD SCI USA, V98, P14126, DOI 10.1073/pnas.241380298
   Karsenty G, 1999, GENE DEV, V13, P3037, DOI 10.1101/gad.13.23.3037
   KAWAGUCHI H, 1995, CLIN ORTHOP RELAT R, P36
   Kellermann O, 1996, BRIT J PHARMACOL, V118, P1161, DOI 10.1111/j.1476 5381.1996.tb15519.x
   KELLERMANN O, 1990, J CELL BIOL, V110, P123, DOI 10.1083/jcb.110.1.123
   Lauder J.M., 1988, Progress in Brain Research, V73, P365, DOI DOI 10.1096/fj.08 117697
   LAUDER JM, 1981, DEV NEUROSCI BASEL, V4, P291, DOI 10.1159/000112768
   Lauder JM, 2000, INT J DEV NEUROSCI, V18, P653, DOI 10.1016/S0736 5748(00)00032 0
   Launay JM, 1996, J BIOL CHEM, V271, P3141, DOI 10.1074/jbc.271.6.3141
   LEDOUARIN NM, 1993, DEV BIOL, V159, P24, DOI 10.1006/dbio.1993.1219
   Locker M, 2004, J BONE MINER RES, V19, P100, DOI 10.1359/JBMR.0301206
   LORIC S, 1995, MOL PHARMACOL, V47, P458
   MacPherson H, 1999, BONE, V24, P179, DOI 10.1016/S8756 3282(98)00173 2
   MALINSKI T, 1992, NATURE, V358, P676, DOI 10.1038/358676a0
   Manivet P, 2000, J BIOL CHEM, V275, P9324, DOI 10.1074/jbc.275.13.9324
   MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160 5402(85)90034 8
   Miyaura C, 2003, J EXP MED, V197, P1303, DOI 10.1084/jem.20030015
   Nebigil CG, 2000, P NATL ACAD SCI USA, V97, P9508, DOI 10.1073/pnas.97.17.9508
   POLIARD A, 1995, J CELL BIOL, V130, P1461, DOI 10.1083/jcb.130.6.1461
   POLIARD A, 1993, J CELL SCI, V106, P503
   Poliard A, 1999, EXP CELL RES, V253, P385, DOI 10.1006/excr.1999.4704
   Porter RHP, 1999, BRIT J PHARMACOL, V128, P13, DOI 10.1038/sj.bjp.0702751
   Raisz LG, 1999, CLIN CHEM, V45, P1353
   RALSTON SH, 1995, J BONE MINER RES, V10, P1040
   RALSTON SH, 1994, ENDOCRINOLOGY, V135, P330, DOI 10.1210/en.135.1.330
   Raymond JR, 2001, PHARMACOL THERAPEUT, V92, P179, DOI 10.1016/S0163 7258(01)00169 3
   SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471 4159.1990.tb08813.x
   SHUEY DL, 1993, ANAT EMBRYOL, V187, P75
   SHUEY DL, 1992, TERATOLOGY, V46, P367, DOI 10.1002/tera.1420460407
   Spencer GJ, 2004, FEBS LETT, V559, P6, DOI 10.1016/S0014 5793(04)00053 5
   STRINGA E, 1995, BONE, V16, P663, DOI 10.1016/8756 3282(95)00100 R
   TAM PPL, 1994, ANAT EMBRYOL, V189, P275
   Tournois C, 1998, J BIOL CHEM, V273, P17498, DOI 10.1074/jbc.273.28.17498
   van't Hof RJ, 2001, IMMUNOLOGY, V103, P255, DOI 10.1046/j.1365 2567.2001.01261.x
   VENEMA RC, 1994, BBA GENE STRUCT EXPR, V1218, P413, DOI 10.1016/0167 4781(94)90195 3
   Westbroek I, 2001, J BIOL CHEM, V276, P28961, DOI 10.1074/jbc.M101824200
   WILINSON LO, 1991, SEROTONIN RECEPTOR S, P147
   YAVARONE MS, 1993, PLACENTA, V14, P149, DOI 10.1016/S0143 4004(05)80257 7
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 61
TC 32
Z9 38
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0898 6568
EI 1873 3913
J9 CELL SIGNAL
JI Cell. Signal.
PD MAY
PY 2006
VL 18
IS 5
BP 628
EP 639
DI 10.1016/j.cellsig.2005.06.006
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 011FP
UT WOS:000235253800006
PM 16014328
DA 2025 08 17
ER

PT J
AU Jiao, YR
   Chen, CL
   Hu, XJ
   Feng, X
   Shi, ZQ
   Cao, J
   Li, Q
   Zhu, YK
AF Jiao, Yurui
   Chen, Chenglong
   Hu, Xijian
   Feng, Xu
   Shi, Zhenqi
   Cao, Jie
   Li, Qing
   Zhu, Yikun
TI Niclosamide and its derivative DK 520 inhibit RANKL induced
   osteoclastogenesis
SO FEBS OPEN BIO
LA English
DT Article
DE differentiation; DK 520; Niclosamide; osteoclast; RANKL
ID NF KAPPA B; DC STAMP; TRANSCRIPTION FACTOR; CELL FUSION; BONE TURNOVER;
   C FOS; DIFFERENTIATION; MOLECULE; PU.1; PHOSPHORYLATION
AB Niclosamide is a potent inhibitor of osteoclastogenesis and bone remodeling. DK 520 is an acyl derivative of Niclosamide and significantly increased both the plasma concentration and the duration of exposure of Niclosamide when dosed orally. However, at present the effect of DK 520 on osteoclastogenesis has not been reported. Here, we investigated whether DK 520 can regulate receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclastogenesis of bone marrow macrophages (BMMs)in vitro. Following induction of BMMs with RANKL for three days, we detected differentiated osteoclasts with typical morphology and high levels of tartrate resistant acid phosphatase (TRAP), RANKL, and cathepsin K (CTSK) expression. Treatment with either Niclosamide or DK 520 did not affect the viability of osteoclast precursors (OCPs), but significantly inhibited RANKL induced transdifferentiation of macrophages into OCPs, particularly in the early stage of osteoclastogenesis. Both Niclosamide and DK 520 significantly decreased the relative levels of transcription factor PU.1 mRNA transcripts and dendritic cell specific transmembrane protein (DC STAMP), but not v ATPasev(0)d(2)protein expression in OCPs. In addition, the inhibitory effect of DK 520 on osteoclastogenesis is realized through impairment of the NF kB (nuclear factor kappa B) and MAPK (mitogen activated protein kinase) signaling pathways. These results demonstrate that DK 520, like Niclosamide, effectively inhibits the early stage of osteoclastogenesis. The findings presented here, together with its increased oral plasma concentrations and bioavailability, suggest that DK 520 may be a promising drug candidate for treatment of osteoclast related diseases.
C1 [Jiao, Yurui; Cao, Jie; Li, Qing; Zhu, Yikun] Shanxi Med Univ, Hosp 2, Dept Endocrinol, 382 Wuyi Rd, Taiyuan 030001, Peoples R China.
   [Chen, Chenglong] Peking Univ, Peoples Hosp, Musculoskeletal Tumor Ctr, Beijing, Peoples R China.
   [Hu, Xijian] Shanxi Med Univ, Hosp 2, Dept Orthoped, Taiyuan, Peoples R China.
   [Feng, Xu; Shi, Zhenqi] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
C3 Shanxi Medical University; Peking University; Shanxi Medical University;
   University of Alabama System; University of Alabama Birmingham
RP Zhu, YK (通讯作者)，Shanxi Med Univ, Hosp 2, Dept Endocrinol, 382 Wuyi Rd, Taiyuan 030001, Peoples R China.
EM zyk1003@sxmu.edu.cn
RI Chen, Chenglong/HJY 3957 2023; zhu, yikun/MEP 2871 2025
OI Jiao, Yurui/0000 0002 1052 0531; Chen, Chenglong/0000 0001 7085 6793;
   Hu, Xijian/0000 0001 5871 4805
FU Shanxi Scholarship Council of China [2017 121]
FX We would like to thank Dr. Chen at Duke University Medical Center for
   kindly providing DK 520. This work was supported by a grant from the
   Research Project Supported by Shanxi Scholarship Council of China
   (Number. 2017 121).
CR Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781
   Boyce BF, 1999, BONE, V25, P137, DOI 10.1016/S8756 3282(99)00105 2
   Boyce BF, 2013, J BONE MINER RES, V28, P711, DOI 10.1002/jbmr.1885
   Chen W, 2013, P NATL ACAD SCI USA, V110, P7294, DOI 10.1073/pnas.1211383110
   Cheon YH, 2016, BIOCHEM BIOPH RES CO, V470, P343, DOI 10.1016/j.bbrc.2016.01.048
   Cosman F, 2015, OSTEOPOROSIS INT, V26, P2045, DOI 10.1007/s00198 015 3037 x
   Courtial N, 2012, FASEB J, V26, P523, DOI 10.1096/fj.11 190850
   Crockett JC, 2011, OSTEOPOROSIS INT, V22, P1, DOI 10.1007/s00198 010 1272 8
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Ding Y, 2017, ORTHOP SURG, V9, P284, DOI 10.1111/os.12338
   Ferrari S, 2014, BEST PRACT RES CL EN, V28, P859, DOI 10.1016/j.beem.2014.08.002
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Frayha GJ, 1997, GEN PHARMACOL VASC S, V28, P273, DOI 10.1016/S0306 3623(96)00149 8
   Hannon RA, 2010, J BONE MINER RES, V25, P463, DOI 10.1359/jbmr.090830
   Hartgers FC, 2000, EUR J IMMUNOL, V30, P3585, DOI 10.1002/1521 4141(200012)30:12<3585::AID IMMU3585>3.0.CO;2 Y
   Hinoi E, 2014, BIOCHEM BIOPH RES CO, V452, P974, DOI 10.1016/j.bbrc.2014.09.022
   Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Ishiyama K, 2015, ALLERGOL INT, V64, P241, DOI 10.1016/j.alit.2015.01.006
   Iwasaki R, 2008, BIOCHEM BIOPH RES CO, V377, P899, DOI 10.1016/j.bbrc.2008.10.076
   JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092 8674(92)90592 Z
   Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Kukita T, 2004, J EXP MED, V200, P941, DOI 10.1084/jem.20040518
   Kyunghee L, 2016, DIFFERENTIATION, V12, P235
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Liu FL, 2017, INT J MED SCI, V14, P840, DOI 10.7150/ijms.19268
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855
   Mook RA, 2015, BIOORGAN MED CHEM, V23, P5829, DOI 10.1016/j.bmc.2015.07.001
   Murphy MG, 2005, J CLIN ENDOCR METAB, V90, P2022, DOI 10.1210/jc.2004 2126
   Osada T, 2011, CANCER RES, V71, P4172, DOI 10.1158/0008 5472.CAN 10 3978
   Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083
   Saginario C, 1995, P NATL ACAD SCI USA, V92, P12210, DOI 10.1073/pnas.92.26.12210
   Saginario C, 1998, MOL CELL BIOL, V18, P6213, DOI 10.1128/MCB.18.11.6213
   Scott EW, 1997, IMMUNITY, V6, P437, DOI 10.1016/S1074 7613(00)80287 3
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201
   So H, 2003, J BIOL CHEM, V278, P24209, DOI 10.1074/jbc.M302940200
   Sotornik Ivo, 2016, Vnitr Lek, V62 Suppl 6, P84
   Suen PK, 2016, J ORTHOP TRANSL, V4, P1, DOI 10.1016/j.jot.2015.08.004
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1857
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092 8674(95)90506 5
   Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   WEINBACH EC, 1969, NATURE, V221, P1016, DOI 10.1038/2211016a0
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yagi M, 2006, J BONE MINER METAB, V24, P355, DOI 10.1007/s00774 006 0697 9
   Yu MX, 2014, BIOCHEM BIOPH RES CO, V447, P364, DOI 10.1016/j.bbrc.2014.04.009
   Zhang CC, 2014, J CELL PHYSIOL, V229, P1330, DOI 10.1002/jcp.24553
NR 53
TC 4
Z9 5
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2211 5463
J9 FEBS OPEN BIO
JI FEBS Open Bio
PD AUG
PY 2020
VL 10
IS 8
BP 1685
EP 1697
DI 10.1002/2211 5463.12921
EA JUL 2020
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA MT2HO
UT WOS:000550932100001
PM 32602250
OA Green Published
DA 2025 08 17
ER

PT J
AU Huang, XY
   Lan, YH
   Shen, JH
   Zhao, XM
   Zhou, YY
   Wu, WZ
   Mao, JJ
   Wu, YZ
   Xie, ZJ
   Chen, Z
AF Huang, Xiaoyuan
   Lan, Yanhua
   Shen, Jiahui
   Zhao, Xiaomin
   Zhou, Yanyan
   Wu, Wenzhi
   Mao, Jiajie
   Wu, Yuzhu
   Xie, Zhijian
   Chen, Zhuo
TI M2 macrophages secrete glutamate containing extracellular vesicles to
   alleviate osteoporosis by reshaping osteoclast precursor fate
SO MOLECULAR THERAPY
LA English
DT Article
ID METABOLIC REGULATION; DIFFERENTIATION; POLARIZATION; ACTIVATION; CELLS
AB Osteoclast precursors (OCPs) are thought to commit to osteoclast differentiation, which is accelerated by aging related chronic inflammation, thereby leading to osteoporosis. However, whether the fate of OCPs can be reshaped to transition into other cell lineages is unknown. Here, we showed that M2 macrophage derived extracellular vesicles (M2 EVs) could reprogram OCPs to downregulate osteoclast specific gene expression and convert OCPs to M2 macrophage like lineage cells, which reshaped the fate of OCPs by delivering the molecular metabolite glutamate. Upon delivery of glutamate, glutamine metabolism in OCPs was markedly enhanced, resulting in the increased production of a ketoglutarate (aKG), which participates in Jmjd3 dependent epigenetic reprogramming, causing M2 like macrophage differentiation. Thus, we revealed a novel transformation of OCPs into M2 like macrophages via M2 EVs initiated metabolic reprogramming and epigenetic modification. Our findings suggest that M2 EVs can reestablish the balance between osteoclasts and M2 macrophages, alleviate the symptoms of bone loss, and constitute a new approach for bone targeted therapy to treat osteoporosis.
C1 [Huang, Xiaoyuan; Lan, Yanhua; Shen, Jiahui; Zhao, Xiaomin; Zhou, Yanyan; Wu, Wenzhi; Mao, Jiajie; Wu, Yuzhu; Xie, Zhijian; Chen, Zhuo] Zhejiang Univ, Stomatol Hosp, Canc Ctr, Sch Med,Zhejiang Prov Clin Res Ctr Oral Dis,Sch St, Hangzhou 310006, Peoples R China.
   [Zhao, Xiaomin] Fudan Univ, Shanghai Pudong Hosp, Pudong Med Ctr, Dept Stomatol, 2800 Gongwei Rd, Shanghai 201399, Peoples R China.
C3 Zhejiang University; Fudan University
RP Xie, ZJ; Chen, Z (通讯作者)，Zhejiang Univ, Stomatol Hosp, Canc Ctr, Sch Med,Zhejiang Prov Clin Res Ctr Oral Dis,Sch St, Hangzhou 310006, Peoples R China.
EM xzj66@zju.edu.cn; zoechen@zju.edu.cn
RI ; shen, jiahui/NKO 7629 2025; Chen, Zhi/V 2214 2017; Lan,
   Yanhua/GWC 3664 2022
OI Chen, Zhuo/0000 0001 8247 7387; Wu, Wenzhi/0009 0001 6912 1623; 
FU National Natural Science Foundation of China [82270964]; Zhejiang Basic
   Public Welfare Research Project [Y24H140003]
FX This work was supported by the National Natural Science Foundation of
   China (grant no. 82270964) and the Zhejiang Basic Public Welfare
   Research Project (no. Y24H140003) . The in vivo study was approved by
   the Ethics Committee for Animal Research at Zhejiang University (ethics
   approval no. ZJU20220173) . All of the procedures were con ducted in
   accordance with the standard guidelines and the Declaration of Helsinki.
CR Ambrosi TH, 2021, NATURE, V597, P256, DOI 10.1038/s41586 021 03795 7
   Anesi A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194925
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Buccitelli C, 2020, NAT REV GENET, V21, P630, DOI 10.1038/s41576 020 0258 4
   Busse E, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 52921 z
   Chen F, 2019, NAT CELL BIOL, V21, P498, DOI 10.1038/s41556 019 0299 0
   Chen QT, 2022, NAT METAB, V4, P1306, DOI 10.1038/s42255 022 00642 5
   Chen XT, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 022 01314 y
   Cioni B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 18313 y
   Clement E, 2020, EMBO J, V39, DOI 10.15252/embj.2019102525
   Coppé JP, 2010, ANNU REV PATHOL MECH, V5, P99, DOI 10.1146/annurev pathol 121808 102144
   Dai EY, 2020, AUTOPHAGY, V16, P2069, DOI 10.1080/15548627.2020.1714209
   Duque G, 2008, J AM GERIATR SOC, V56, P935, DOI 10.1111/j.1532 5415.2008.01764.x
   Gao S, 2014, EXP BIOL MED, V239, P366, DOI 10.1177/1535370213518169
   Goddard ME, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00247
   Hayashi M, 2012, NATURE, V485, P69, DOI 10.1038/nature11000
   Huang WJ, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202009189
   Ikeda G, 2021, J AM COLL CARDIOL, V77, P1073, DOI 10.1016/j.jacc.2020.12.060
   Indo Y, 2013, J BONE MINER RES, V28, P2392, DOI 10.1002/jbmr.1976
   Ishii M, 2009, BLOOD, V114, P3244, DOI 10.1182/blood 2009 04 217620
   JESSERER H, 1953, Z Rheumaforsch, V12, P261
   Kim H, 2019, ADV SCI, V6, DOI 10.1002/advs.201900513
   Kim JM, 2007, CELL PHYSIOL BIOCHEM, V20, P935, DOI 10.1159/000110454
   Kronstadt SM, 2023, CYTOTHERAPY, V25, P387, DOI 10.1016/j.jcyt.2022.12.002
   Lan YH, 2022, BIOACT MATER, V17, P457, DOI 10.1016/j.bioactmat.2022.01.019
   Lan YH, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.583234
   Lee S, 2021, BONE, V145, DOI 10.1016/j.bone.2020.115836
   Lemma S, 2016, INT J BIOCHEM CELL B, V79, P168, DOI 10.1016/j.biocel.2016.08.034
   Li ZY, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.680328
   Liang WQ, 2022, NATURE AGING, V2, P906, DOI 10.1038/s43587 022 00285 x
   Lin Xinyao, 2023, Nat Commun, V14, P7424, DOI 10.1038/s41467 023 43307 x
   Liu F, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1447 y
   Liu PS, 2017, NAT IMMUNOL, V18, P985, DOI 10.1038/ni.3796
   Liu XS, 2012, J BONE MINER RES, V27, P263, DOI 10.1002/jbmr.562
   Ma LW, 2016, AGING DIS, V7, P254, DOI 10.14336/AD.2016.0118
   Man K, 2017, IMMUNITY, V47, P1129, DOI 10.1016/j.immuni.2017.11.021
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   McDonough MA, 2010, CURR OPIN STRUC BIOL, V20, P659, DOI 10.1016/j.sbi.2010.08.006
   Milbank E, 2021, NAT METAB, V3, P1415, DOI 10.1038/s42255 021 00467 8
   Morrissey SM, 2021, CELL METAB, V33, P2040, DOI 10.1016/j.cmet.2021.09.002
   Park Min KH, 2019, SEMIN IMMUNOPATHOL, V41, P565, DOI 10.1007/s00281 019 00757 0
   Saito H, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 08778 x
   Shen L, 2021, CELL METAB, V33, P971, DOI 10.1016/j.cmet.2021.03.006
   Tai TW, 2017, SCI REP UK, V7, DOI 10.1038/srep44245
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Thery Clotilde, 2011, F1000 Biol Rep, V3, P15, DOI 10.3410/B3 15
   Tian H, 2022, SMALL METHODS, V6, DOI 10.1002/smtd.202200130
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   van Gastel N, 2021, NAT METAB, V3, P11, DOI 10.1038/s42255 020 00321 3
   Wang J, 2020, J CELL MOL MED, V24, P2294, DOI 10.1111/jcmm.14912
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Xiong Y, 2023, ADV MATER, V35, DOI 10.1002/adma.202212300
   Xiong Y, 2022, MILITARY MED RES, V9, DOI 10.1186/s40779 022 00426 8
   Xiong Y, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951 020 00622 5
   Yasui T, 2011, J BONE MINER RES, V26, P2665, DOI 10.1002/jbmr.464
   Ye SQ, 2016, INT J BIOL SCI, V12, P1488, DOI 10.7150/ijbs.15583
   Yu YL, 2019, CELL METAB, V29, P966, DOI 10.1016/j.cmet.2019.01.016
   Zhang GS, 2020, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12030
   Zhao SJ, 2020, THERANOSTICS, V10, P17, DOI 10.7150/thno.36930
NR 59
TC 9
Z9 10
U1 5
U2 38
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1525 0016
EI 1525 0024
J9 MOL THER
JI Mol. Ther.
PD APR 3
PY 2024
VL 32
IS 4
BP 1158
EP 1177
DI 10.1016/j.ymthe.2024.02.005
EA APR 2024
PG 20
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA QY6O0
UT WOS:001224470300001
PM 38332583
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Shao, J
   Xu, XY
   Li, GS
   Zhang, W
   Qi, J
   Wang, JS
   Cai, M
   Cui, L
   Zhang, LF
   Zhao, Q
   Deng, LF
AF Shao Jin
   Xu Xiangyang
   Li Guosong
   Zhang Wei
   Qi Jin
   Wang Jinshen
   Cai Ming
   Cui Lun
   Zhang Lianfang
   Zhao Qiang
   Deng Lianfu
TI Inhibitory effects of pharmacological doses of dexamethasone on
   mineralization of mesenchymal progenitor cells in vitro
SO PHARMAZIE
LA English
DT Article
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; OSTEOBLAST DIFFERENTIATION;
   GENE EXPRESSION; BONE FORMATION; CBFA1; OSTEOGENESIS; CORTISOL; ROB C26;
   OSTERIX; GROWTH
AB Dexamethasone (Dex), a synthetic glucocorticoid, has a clinical adverse effect on bone acquisition and metabolism at pharmacological doses. To investigate the underlying mechanisms of Dex induced bone loss, we employed calvaria derived mesenchymal progenitor cells (MPCs) to examine the effects of Dex on their osteoblast lineage commitment and mineralization function. MPCs were cultured up to 28 days in the presence or absence of pharmacological doses of Dex. Alkaline phosphatase (ALP) and von Kossa histochemical staining showed that Dex decreased ALP activity and mineralized nodule formation. In addition, Dex treatment led to inhibition of cell proliferation and a decrease of cell numbers as assessed by BrdU incorporation and MTT methods, while it increased apoptosis as shown by flow cytometry of annexin V stained cells These effects were associated with a marked reduction of secreted lGF I levels as indicated by ELISA quantification, raising the possibility that Dex decreased proliferation and promoted apoptosis of MPCs through the inhibition of lGF I secretion. To further define the effect of Dex on osteoblast lineage commitment, Runx2 and Osx, the key transcription regulators of osteogenesis, were determined at both mRNA and protein levels. Interestingly, no effects were observed on mRNA and protein expression of Osx, while the mRNA and protein levels of Runx2 were inhibited by Dex treatment Taken together, the inhibition of the expression of IGF I and Runx2 by Dex in this in vitro system may account for the impaired MCP proliferation, osteoblastic differentiation and mineralized matrix deposition. These findings and the in vitro MCP system developed will facilitate further mechanistic studies of glucocorticoid induced bone loss.
C1 [Shao Jin; Xu Xiangyang; Li Guosong; Zhang Wei; Qi Jin; Wang Jinshen; Cai Ming; Cui Lun; Zhang Lianfang; Zhao Qiang; Deng Lianfu] Shanghai Jiao Tong Univ, Shanghai Inst Traumatol & Orthoped, Dept Orthopaed, Ruijin Hosp,Sch Med, Shanghai 200025, Peoples R China.
C3 Shanghai Jiao Tong University
RP Deng, LF (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Inst Traumatol & Orthoped, Dept Orthopaed, Ruijin Hosp,Sch Med, Shanghai 200025, Peoples R China.
EM denglianfu@126.com
RI Zhang, Wei/HOF 7252 2023; Cai, Ming/AAX 2275 2020; zhao,
   qiang/GWC 1298 2022
FU NSFC [30672145, 30872641]; Shanghai Science and Technology Commission
   [06DZ22020, 07DZ22008]
FX This work was supported by art NSFC grant (No. 30672145 and 30872641),
   Shanghai Science and Technology Commission project (No 06DZ22020 and
   07DZ22008)
CR Avram D, 2008, CELL PHYSIOL BIOCHEM, V21, P455, DOI 10.1159/000129638
   Buranasinsup S, 2006, DEV GROWTH DIFFER, V48, P263, DOI 10.1111/j.1440 169x.2006.00864.x
   Canalis Ernesto, 2005, Curr Osteoporos Rep, V3, P98, DOI 10.1007/s11914 005 0017 7
   Chen TL, 2004, BONE, V35, P83, DOI 10.1016/j.bone.2004.03.019
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Eijken M, 2006, MOL CELL ENDOCRINOL, V248, P87, DOI 10.1016/j.mce.2005.11.034
   Haasper C, 2008, Z ORTHOP UNFALLCHIR, V146, P636, DOI 10.1055/s 2008 1038578
   Hayashi K, 2009, BIOCHEM BIOPH RES CO, V379, P261, DOI 10.1016/j.bbrc.2008.12.035
   Hong D, 2008, J STEROID BIOCHEM, V111, P164, DOI 10.1016/j.jsbmb.2008.06.015
   Igarashi M, 2004, J MOL HISTOL, V35, P3, DOI 10.1023/B:HIJO.0000020883.33256.fe
   Ishida Y, 1998, J BONE MINER RES, V13, P1822, DOI 10.1359/jbmr.1998.13.12.1822
   Ito S, 2007, BONE, V40, P84, DOI 10.1016/j.bone.2006.07.012
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Lafage Proust MH, 2003, JOINT BONE SPINE, V70, P109, DOI 10.1016/S1297 319X(03)00016 2
   Leclerc N, 2004, J MOL ENDOCRINOL, V33, P175, DOI 10.1677/jme.0.0330175
   Li XD, 2005, OSTEOPOROSIS INT, V16, P101, DOI 10.1007/s00198 004 1649 7
   MacRae VE, 2007, GROWTH HORM IGF RES, V17, P435, DOI 10.1016/j.ghir.2007.05.002
   Mikami Y, 2008, CELL BIOL INT, V32, P239, DOI 10.1016/j.cellbi.2007.08.033
   Mikami Y, 2007, BIOCHEM BIOPH RES CO, V362, P368, DOI 10.1016/j.bbrc.2007.07.192
   Mori K, 1999, ARTERIOSCL THROM VAS, V19, P2112, DOI 10.1161/01.ATV.19.9.2112
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   PARTRIDGE NC, 1981, ENDOCRINOLOGY, V108, P213, DOI 10.1210/endo 108 1 213
   Pereira RC, 2002, BONE, V30, P685, DOI 10.1016/S8756 3282(02)00687 7
   Pereira RMR, 2001, BONE, V28, P484, DOI 10.1016/S8756 3282(01)00422 7
   Scutt A, 1996, CALCIFIED TISSUE INT, V59, P154, DOI 10.1007/s002239900102
   Sivagurunathan S, 2005, J BONE MINER RES, V20, P390, DOI 10.1359/JBMR.041233
NR 27
TC 6
Z9 8
U1 0
U2 12
PU GOVI VERLAG  PHARMAZEUTISCHER VERLAG GMBH
PI ESCHBORN
PA PHARMAZEUTISCCARL MANNICH STR 26, D 65760 ESCHBORN, GERMANY
SN 0031 7144
J9 PHARMAZIE
JI Pharmazie
PD OCT
PY 2009
VL 64
IS 10
BP 674
EP 679
DI 10.1691/ph.2009.9561
PG 6
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Chemistry
GA 512TD
UT WOS:000271272600010
PM 19947171
DA 2025 08 17
ER

PT J
AU Sarathy, AP
   Bourgeois, SL Jr
   Goodell, GG
AF Sarathy, AP
   Bourgeois, SL Jr
   Goodell, GG
TI Bisphosphonate associated osteonecrosis of the jaws and endodontic
   treatment: Two case reports
SO JOURNAL OF ENDODONTICS
LA English
DT Article
DE bisphosphonates; osteonecrosis; jaws; endodontics; pamidronate;
   zoledronate; alendronate
ID NECROSIS; BONE
AB Bisphosphonates are commonly used in the management of bone diseases, such as osteoporosis and Paget's disease, and to prevent bone complications and to treat malignant hypercalcemia in certain types of cancer. Although this class of drugs has clear evidence of medical efficacy, there are an increasing number of reports of bisphosphonate associated osteonecrosis of the jaws that have substantial implications for the patient and for the treating dentist. This case report reviews proposed possible mechanisms of bisphosphonate associated osteonecrosis of the jaws and describes two case reports where nonsurgical and surgical root canal treatments were precipitating factors. Recommendations for prevention and treatment of the disease follow. Thorough history taking and timely consultation with the patient's oral surgeon and oncologist are emphasized.
C1 USN, Postgrad Sch, NNMC, Bethesda, MD 20084 USA.
   USN, Natl Med Ctr, Bethesda, MD 20084 USA.
C3 United States Department of Defense; United States Navy; Walter Reed
   National Military Medical Center; United States Department of Defense;
   United States Navy
RP Goodell, GG (通讯作者)，12214 Hollow Tree Lane, Fairfax, VA 22030 USA.
EM gggoodell@bethesda.med.navy.mil
CR [Anonymous], HARRISONS PRINCIPLES
   Bagan JV, 2005, J ORAL PATHOL MED, V34, P120, DOI 10.1111/j.1600 0714.2004.00269.x
   Durie BGM, 2005, NEW ENGL J MED, V353, P99
   ESTILO CL, 2005, ORAL SURG ORAL MED O, V97, P449
   *FDA, 2004, FDA PAT SAF NEWS SHO
   Greenberg MS, 2004, ORAL SURG ORAL MED O, V98, P259, DOI 10.1016/j.tripleo.2004.08.001
   Lipton A, 2001, SEMIN ONCOL, V28, P1
   Maerevoet M, 2005, NEW ENGL J MED, V353, P100
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Melo Maico D, 2005, J Can Dent Assoc, V71, P111
   Migliorati CA, 2005, CANCER, V104, P83, DOI 10.1002/cncr.21130
   Migliorati CA, 2005, ORAL SURG ORAL MED O, V99, P135, DOI 10.1016/j.tripleo.2004.10.001
   *NOV PHARM CORP, 2005, IMP DRUG PREC DENT H
   Robinson NA, 2004, ANN ACAD MED SINGAP, V33, P48
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Sanna G, 2005, ANN ONCOL, V16, P1207, DOI 10.1093/annonc/mdi206
   Santini D, 2002, CLIN CANCER RES, V8, P1080
   Woo SB, 2005, NEW ENGL J MED, V353, P100
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
NR 19
TC 44
Z9 52
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0099 2399
EI 1878 3554
J9 J ENDODONT
JI J. Endod.
PD OCT
PY 2005
VL 31
IS 10
BP 759
EP 763
DI 10.1097/01.don.0000182737.09980.2c
PG 5
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 969EC
UT WOS:000232215200012
PM 16186759
DA 2025 08 17
ER

PT J
AU De Ugarte, L
   Yoskovitz, G
   Balcells, S
   Güerri Fernández, R
   Martinez Diaz, S
   Mellibovsky, L
   Urreizti, R
   Nogués, X
   Grinberg, D
   García Giralt, N
   Díez Pérez, A
AF De Ugarte, Laura
   Yoskovitz, Guy
   Balcells, Susana
   Gueerri Fernandez, Robert
   Martinez Diaz, Santos
   Mellibovsky, Leonardo
   Urreizti, Roser
   Nogues, Xavier
   Grinberg, Daniel
   Garcia Giralt, Natalia
   Diez Perez, Adolfo
TI MiRNA profiling of whole trabecular bone: identification of
   osteoporosis related changes in MiRNAs in human hip bones
SO BMC MEDICAL GENOMICS
LA English
DT Article
DE Osteoporosis; microRNAs; Osteoblast; Fracture; Epigenetic regulation
ID CELLS; EXPRESSION; DIFFERENTIATION; TRANSCRIPTION; HOMEOSTASIS;
   MICRORNAS; CARTILAGE; DISEASE; MIR 483; GENE
AB Background: MicroRNAs (miRNAs) are important regulators of gene expression, with documented roles in bone metabolism and osteoporosis, suggesting potential therapeutic targets. Our aim was to identify miRNAs differentially expressed in fractured vs nonfractured bones. Additionally, we performed a miRNA profiling of primary osteoblasts to assess the origin of these differentially expressed miRNAs.
   Methods: Total RNA was extracted from (a) fresh femoral neck trabecular bone from women undergoing hip replacement due to either osteoporotic fracture (OP group, n = 6) or osteoarthritis in the absence of osteoporosis (Control group, n = 6), matching the two groups by age and body mass index, and (b) primary osteoblasts obtained from knee replacement due to osteoarthritis (n = 4). Samples were hybridized to a microRNA array containing more than 1900 miRNAs. Principal component analysis (PCA) plots and heat map hierarchical clustering were performed. For comparison of expression levels, the threshold was set at log fold change > 1.5 and a p value < 0.05 (corrected for multiple testing).
   Results: Both PCA and heat map analyses showed that the samples clustered according to the presence or absence of fracture. Overall, 790 and 315 different miRNAs were detected in fresh bone samples and in primary osteoblasts, respectively, 293 of which were common to both groups. A subset of 82 miRNAs was differentially expressed (p < 0.05) between osteoporotic and control osteoarthritic samples. The eight miRNAs with the lowest p values (and for which a validated miRNA qPCR assay was available) were assayed, and two were confirmed: miR 320a and miR 483 5p. Both were over expressed in the osteoporotic samples and expressed in primary osteoblasts. miR 320a is known to target CTNNB1 and predicted to regulate RUNX2 and LEPR, while miR 483 5p down regulates IGF2. We observed a reduction trend for this target gene in the osteoporotic bone.
   Conclusions: We identified two osteoblast miRNAs over expressed in osteoporotic fractures, which opens novel prospects for research and therapy.
C1 [De Ugarte, Laura; Yoskovitz, Guy; Gueerri Fernandez, Robert; Mellibovsky, Leonardo; Nogues, Xavier; Garcia Giralt, Natalia; Diez Perez, Adolfo] IMIM Hosp del Mar Med Res Inst, Musculoskeletal Res Grp, ISCIII, Red Temat Invest Cooperat Envejecimiento & Fragil, Barcelona, Spain.
   [Balcells, Susana; Urreizti, Roser; Grinberg, Daniel] Univ Barcelona, CIBERER, Dept Genet, ISCIII,IBUB, Barcelona, Spain.
   [Gueerri Fernandez, Robert; Mellibovsky, Leonardo; Nogues, Xavier; Diez Perez, Adolfo] Univ Autonoma Barcelona, Hosp del Mar, Internal Med Dept, E 08193 Barcelona, Spain.
   [Martinez Diaz, Santos] Univ Autonoma Barcelona, Hosp del Mar, Orthopaed Surg & Traumatol Dept, E 08193 Barcelona, Spain.
C3 Instituto de Salud Carlos III; Hospital del Mar Research Institute;
   Hospital del Mar; CIBER   Centro de Investigacion Biomedica en Red;
   CIBERER; Instituto de Salud Carlos III; University of Barcelona;
   Hospital del Mar Research Institute; Hospital del Mar; Autonomous
   University of Barcelona; Hospital del Mar Research Institute; Hospital
   del Mar; Autonomous University of Barcelona
RP García Giralt, N (通讯作者)，IMIM Hosp del Mar Med Res Inst, Musculoskeletal Res Grp, ISCIII, Red Temat Invest Cooperat Envejecimiento & Fragil, Barcelona, Spain.
EM ngarcia@imim.es
RI Garcia Giralt, Natalia/AAA 7588 2021; Guerri Fernandez,
   Robert/I 1306 2013; Mellibovsky, Leonardo/IRG 7294 2023; Urreizti,
   Roser/M 6402 2014; Grinberg, Daniel/F 3641 2010; Balcells,
   Susana/C 5222 2017
OI Guerri Fernandez, Robert/0000 0002 9794 9161; Diez Perez,
   Adolfo/0000 0001 8162 0209; Mellibovsky, Leonardo/0009 0001 7921 8840;
   Nogues, Xavier/0000 0002 5537 1859; Urreizti, Roser/0000 0003 3617 7134;
   Nogues, Xavier/0000 0001 8201 9933; Grinberg,
   Daniel/0000 0001 9859 2590; Balcells, Susana/0000 0003 1211 1907;
   Garcia Giralt, Natalia/0000 0001 6507 0147
FU FIS [PI10/01537]; Red Tematica de Investigacion Cooperativa en
   Envejecimiento y Fragilidad (RETICEF) (Carlos III Health Institute,
   Science and Innovation Ministry); FEDER funds; Science and Innovation
   Ministry [SAF2011 25431, PIB2010AR 00473]; Centro de Investigacion
   Biomedica en Red de Enfermedades Raras (CIBERER, an initiative of
   ISCIII); Generalitat de Catalunya (DIUE) [2009 SGR 818, 2009 SGR 971]
FX This work was supported by grant FIS PI10/01537 and the Red Tematica de
   Investigacion Cooperativa en Envejecimiento y Fragilidad (RETICEF)
   (Carlos III Health Institute, Science and Innovation Ministry), and
   FEDER funds. Grant SAF2011 25431 and PIB2010AR 00473 (Science and
   Innovation Ministry), and the support from the Centro de Investigacion
   Biomedica en Red de Enfermedades Raras (CIBERER, an initiative of
   ISCIII) are also acknowledged. Grants from the Generalitat de Catalunya
   (DIUE; 2009 SGR 818, 2009 SGR 971) also supported this work.
CR Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Cai YH, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756 3305 6 356
   Dai N, 2013, NEOPLASMA, V60, P384, DOI 10.4149/neo_2013_050
   Díaz Prado S, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471 2474 13 144
   Garmilla Ezquerra P, 2015, CALCIFIED TISSUE INT, V96, P30, DOI 10.1007/s00223 014 9935 7
   Gong JY, 2012, CANCER SCI, V103, P645, DOI 10.1111/j.1349 7006.2012.02207.x
   Gordeladze JO, 2010, ILAR J, V51, P42, DOI 10.1093/ilar.51.1.42
   Guo L, 2011, EXP HEMATOL, V39, P608, DOI 10.1016/j.exphem.2011.01.011
   Hamam D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.462
   Kapinas K, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3325
   Kim DH, 2008, P NATL ACAD SCI USA, V105, P16230, DOI 10.1073/pnas.0808830105
   Lei SF, 2011, J BONE MINER RES, V26, P72, DOI 10.1002/jbmr.186
   Li H, 2009, J CLIN INVEST, V119, P3666, DOI 10.1172/JCI39832
   Lian JB, 2012, NAT REV ENDOCRINOL, V8, P212, DOI 10.1038/nrendo.2011.234
   Liu MZ, 2013, GENE DEV, V27, P2543, DOI 10.1101/gad.224170.113
   Ma N, 2011, MOL CELL ENDOCRINOL, V333, P96, DOI 10.1016/j.mce.2010.11.027
   Minuto F, 2005, J ENDOCRINOL INVEST, V28, P1
   Patterson EE, 2011, CANCER AM CANCER SOC, V117, P1630, DOI 10.1002/cncr.25724
   Qi YB, 2013, INT J BIOL MACROMOL, V61, P43, DOI 10.1016/j.ijbiomac.2013.06.006
   Ritchie ME, 2007, BIOINFORMATICS, V23, P2700, DOI 10.1093/bioinformatics/btm412
   Seeliger C., 2014, J Bone Miner Res
   Sun JY, 2012, BIOCHEM BIOPH RES CO, V420, P787, DOI 10.1016/j.bbrc.2012.03.075
   Taipaleenmäki H, 2012, EUR J ENDOCRINOL, V166, P359, DOI 10.1530/EJE 11 0646
   van Wijnen AJ, 2013, CURR OSTEOPOROS REP, V11, P72, DOI 10.1007/s11914 013 0143 6
   Vlachos IS, 2012, NUCLEIC ACIDS RES, V40, pW498, DOI 10.1093/nar/gks494
   Yu FC, 2011, BIOSCI TRENDS, V5, P46, DOI 10.5582/bst.2011.v5.2.46
   Yu XT, 2013, TUMOR BIOL, V34, P3501, DOI 10.1007/s13277 013 0928 3
   Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028
   Zuntini M, 2010, CLIN GENET, V78, P507, DOI 10.1111/j.1399 0004.2010.01490.x
NR 30
TC 81
Z9 87
U1 0
U2 14
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1755 8794
J9 BMC MED GENOMICS
JI BMC Med. Genomics
PD NOV 10
PY 2015
VL 8
AR 75
DI 10.1186/s12920 015 0149 2
PG 11
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA CW8ZZ
UT WOS:000365289400001
PM 26555194
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Warden, SJ
   Komatsu, DB
   Rydberg, J
   Bond, JL
   Hassett, SM
AF Warden, Stuart J.
   Komatsu, David B.
   Rydberg, Johanna
   Bond, Julie L.
   Hassett, Sean M.
TI Recombinant human parathyroid hormone (PTH 1 34) and low intensity
   pulsed ultrasound have contrasting additive effects during fracture
   healing
SO BONE
LA English
DT Article
DE Animal model; Orthopedics; Physical therapy; Teriparatide; Ultrasound
   therapy
ID AGGRECAN GENE EXPRESSION; HUMAN PARATHYROID HORMONE (1 34); THERAPEUTIC
   ULTRASOUND; BONE FORMATION; CORTICAL BONE; IN VIVO; TRABECULAR BONE; AKT
   PATHWAY; REPAIR; MODEL
AB Fracture healing is thought to be naturally optimized; however, recent evidence indicates that it may be manipulated to occur at a faster rate. This has implications for the duration of morbidity associated with bone injuries. Two interventions found to accelerate fracture healing processes are recombinant human parathyroid hormone [1 34] (PTH) and low intensity pulsed ultrasound (LIPUS). This study aimed to investigate the individual and combined effects of PTH and LIPUS on fracture healing. Bilateral midshaft femur fractures were created in Sprague Dawley rats, and the animals treated 7 days/week with PTH (10 mu g/kg) or a vehicle solution. Each animal also had one fracture treated for 20 min/day with active LIPUS (spatial averaged, temporal averaged intensity I(SATA)]= 100 mW/cm(2)) and the contralateral fracture treated with inactive LIPUS (placebo). Femurs were harvested 35 days following injury to permit micro computed tomography, mechanical property and histological assessments of the fracture calluses. There were no interactions between PTH and LIPUS indicating that their effects were additive rather than synergistic. These additive effects were contrasting with LIPUS primarily increasing total callus volume (TV) without influencing bone mineral content (BMC), and PTH having the opposite effect of increasing BMC without influencing TV. As a consequence of the effect of LIPUS on TV but not BMC, it decreased volumetric bone mineral density (vBMD) resulting in a less mature callus. The decreased maturity and persistence of cartilage at the fracture site when harvested offset any beneficial mechanical effects of the increased callus size with LIPUS. In contrast, the effect of PTH on callus BMC but not TV resulted in increased callus vBMD and a more mature callus. This resulted in PTH increasing fracture site mechanical strength and stiffness. These data suggest that PTH may have utility in the treatment of acute bone fractures, whereas LIPUS at an I(SATA) Of 100 mW/cm(2) does not appear to be indicated in the management of closed, diaphyseal fractures. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Warden, Stuart J.; Komatsu, David B.; Rydberg, Johanna; Bond, Julie L.; Hassett, Sean M.] Indiana Univ, Dept Phys Therapy, Sch Hlth & Rehabil Sci, Indianapolis, IN 46202 USA.
   [Warden, Stuart J.] Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
   [Komatsu, David B.] InMot Musculoskeletal Inst, Biolog & Biomat Lab, Memphis, TN USA.
C3 Indiana University System; Indiana University Indianapolis; Indiana
   University System; Indiana University Indianapolis
RP Warden, SJ (通讯作者)，Indiana Univ, Dept Phys Therapy, Sch Hlth & Rehabil Sci, Indianapolis, IN 46202 USA.
EM stwarden@iupui.edu
RI Komatsu, David/AAE 3282 2019; Warden, Stuart/C 5287 2012
OI Warden, Stuart/0000 0002 6415 4936; 
CR Alkhiary YM, 2005, J BONE JOINT SURG AM, V87A, P731, DOI 10.2106/JBJS.D.02115
   Andreassen TT, 2004, CALCIFIED TISSUE INT, V74, P351, DOI 10.1007/s00223 003 0093 6
   Andreassen TT, 1999, J BONE MINER RES, V14, P960, DOI 10.1359/jbmr.1999.14.6.960
   Azuma Y, 2001, J BONE MINER RES, V16, P671, DOI 10.1359/jbmr.2001.16.4.671
   Barnes GL, 2008, J BONE JOINT SURG AM, V90A, P120, DOI 10.2106/JBJS.G.01443
   BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115
   Busse JW, 2004, ARCH PHYS MED REHAB, V85, P1653, DOI 10.1016/j.apmr.2003.12.040
   Chalidis B, 2007, EXPERT OPIN INV DRUG, V16, P441, DOI 10.1517/13543784.16.4.441
   Chang WHS, 2002, BIOELECTROMAGNETICS, V23, P256, DOI 10.1002/bem.10009
   Choi BH, 2007, P I MECH ENG H, V221, P527, DOI 10.1243/09544119JEIM201
   Chow JWM, 1998, AM J PHYSIOL ENDOC M, V274, pE146, DOI 10.1152/ajpendo.1998.274.1.E146
   Dyson M, 1983, Ultrasound Med Biol, VSuppl 2, P61
   Frolik CA, 2003, BONE, V33, P372, DOI 10.1016/S8756 3282(03)00202 3
   Frolik CA, 1999, J BONE MINER RES, V14, P163, DOI 10.1359/jbmr.1999.14.2.163
   Gardner MJ, 2007, J ORTHOP RES, V25, P1474, DOI 10.1002/jor.20427
   Gerstenfeld LC, 2005, J BONE MINER RES, V20, P1715, DOI 10.1359/JBMR.050702
   Hagino H, 2001, J BONE MINER METAB, V19, P244, DOI 10.1007/s007740170027
   HECKMAN JD, 1994, J BONE JOINT SURG AM, V76A, P26, DOI 10.2106/00004623 199401000 00004
   Holzer G, 1999, CLIN ORTHOP RELAT R, P258, DOI 10.1097/00003086 199909000 00033
   Hu ZP, 2006, INT J PHARMACEUT, V317, P144, DOI 10.1016/j.ijpharm.2006.03.005
   Kaback LA, 2008, J CELL BIOCHEM, V105, P219, DOI 10.1002/jcb.21816
   Kaiser E, 2001, J CELL BIOCHEM, V83, P617, DOI 10.1002/jcb.1256
   Kakar S, 2007, J BONE MINER RES, V22, P1903, DOI 10.1359/JBMR.070724
   Kim CH, 2003, J BONE MINER RES, V18, P2116, DOI 10.1359/jbmr.2003.18.12.2116
   Komatsubara S, 2005, BONE, V36, P678, DOI 10.1016/j.bone.2005.02.002
   Korstjens CM, 2008, MED BIOL ENG COMPUT, V46, P1263, DOI 10.1007/s11517 008 0409 9
   Kristiansen TK, 1997, J BONE JOINT SURG AM, V79A, P961, DOI 10.2106/00004623 199707000 00002
   Li J, 2003, ENDOCRINOLOGY, V144, P1226, DOI 10.1210/en.2002 220821
   Li J, 2007, J ORTHOP RES, V25, P1559, DOI 10.1002/jor.20461
   Lindsay R, 2007, J BONE MINER RES, V22, P495, DOI 10.1359/JBMR.070104
   Ma YF, 1999, J BONE MINER RES, V14, P439, DOI 10.1359/jbmr.1999.14.3.439
   Manabe T, 2007, BONE, V40, P1475, DOI 10.1016/j.bone.2007.01.015
   Mayr E, 2000, Handchir Mikrochir Plast Chir, V32, P115, DOI 10.1055/s 2000 19253
   Mayr E, 2000, ARCH ORTHOP TRAUM SU, V120, P1
   Nakajima A, 2002, J BONE MINER RES, V17, P2038, DOI 10.1359/jbmr.2002.17.11.2038
   Nakazawa T, 2005, BONE, V37, P711, DOI 10.1016/j.bone.2005.06.013
   Naruse K, 2000, BIOCHEM BIOPH RES CO, V268, P216, DOI 10.1006/bbrc.2000.2094
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nolte PA, 2001, J TRAUMA, V51, P693, DOI 10.1097/00005373 200110000 00012
   Parvizi J, 1999, J ORTHOPAED RES, V17, P488, DOI 10.1002/jor.1100170405
   Pilla A A, 1990, J Orthop Trauma, V4, P246, DOI 10.1097/00005131 199004030 00002
   REEVE J, 1980, BMJ BRIT MED J, V280, P1340, DOI 10.1136/bmj.280.6228.1340
   Sato M, 1997, ENDOCRINOLOGY, V138, P4330, DOI 10.1210/en.138.10.4330
   Sato M, 1998, ENDOCRINOLOGY, V139, P4642, DOI 10.1210/en.139.11.4642
   Skripitz R, 2004, ACTA ORTHOP SCAND, V75, P654, DOI 10.1080/00016470410004012
   Sugiyama T, 2008, BONE, V43, P238, DOI 10.1016/j.bone.2008.04.012
   Takeuchi R, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2451
   Takikawa S, 2001, J ULTRAS MED, V20, P197, DOI 10.7863/jum.2001.20.3.197
   Tang CH, 2006, MOL PHARMACOL, V69, P2047, DOI 10.1124/mol.105.022160
   Turner C.H., 2001, EXPT TECHNIQUES BONE
   WANG SJ, 1994, J ORTHOP RES, V12, P40, DOI 10.1002/jor.1100120106
   Warden SJ, 2003, SPORTS MED, V33, P95, DOI 10.2165/00007256 200333020 00002
   Warden SJ, 2002, ULTRASOUND MED BIOL, V28, P1075, DOI 10.1016/S0301 5629(02)00552 5
   Warden SJ, 2001, BIOCHEM BIOPH RES CO, V286, P443, DOI 10.1006/bbrc.2001.5412
   Warden SJ, 2000, CALCIFIED TISSUE INT, V66, P157, DOI 10.1007/s002230010031
   Warden SJ, 2006, PHYS THER, V86, P1118, DOI 10.1093/ptj/86.8.1118
   WILTINK A, 1995, ULTRASOUND MED BIOL, V21, P121, DOI 10.1016/0301 5629(94)00092 1
   Yamamoto T, 2007, BONE, V40, P354, DOI 10.1016/j.bone.2006.09.002
   Yang KH, 1996, J ORTHOP RES, V14, P802, DOI 10.1002/jor.1100140518
   Zorlu U, 1998, AM J PHYS MED REHAB, V77, P427, DOI 10.1097/00002060 199809000 00013
NR 60
TC 58
Z9 64
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
J9 BONE
JI Bone
PD MAR
PY 2009
VL 44
IS 3
BP 485
EP 494
DI 10.1016/j.bone.2008.11.007
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 414WI
UT WOS:000263895500015
PM 19071238
DA 2025 08 17
ER

PT J
AU Bubpamala, T
   Promoppatum, P
   Pholpabu, P
AF Bubpamala, Theeraporn
   Promoppatum, Patcharapit
   Pholpabu, Pitirat
TI Drug Releasing Tannic Acid Mediated Adhesive PEG Hydrogel for Porous
   Titanium Implants
SO ACS OMEGA
LA English
DT Article
ID SCAFFOLDS
AB Porous titanium implants are commonly utilized for orthopedic surgery because they can mimic the mechanical properties and porous structure of human bone. However, the bioinertness of titanium (Ti) has been reported to obstruct biointegration processes, resulting in slower bone repair. Here, we propose a localized drug delivery system on Ti surfaces using adhesive hydrogel to enhance biological Ti interactions. The hydrogel was fabricated from polyethylene glycol (PEG), which was cross linked by the complex of tannic acid (TA) and 1,4 phenylenediboronic acid (PDBA) and stabilized by bovine serum albumin (BSA). The hydrogel was formed and attached to a Ti plate to investigate stability, biodegradability, controlled drug release, and biocompatibility. The stability and biodegradability of the hydrogel could be tuned by adjusting the concentrations of BSA and TA. The hydrogel lasted and remained adhered to the Ti surface after being submerged in PBS for at least 15 days. The controlled release of strontium ranelate (SrRan) and the release mechanism depended on the amount of TA since it was found to govern the hydrogel integrity and pore size. Additionally, in vitro biocompatibility was validated using L929 fibroblast and MC3T3 E1 osteoblast cells that showed greater than 70% viability. The adhesive hydrogel was further studied by injecting it into a 3D printed Ti scaffold that contained a porous structure mimicking natural human bone. The hydrogel completely filled and adhered to the inner porous structure of the scaffold. The biodegradation and drug release of the hydrogel in the scaffold occurred at a slower rate, suggesting sustainable drug release that is suitable for bone cell regeneration. The overall results in biodegradability, controlled drug release, and biocompatibility demonstrate the great potential of the drug releasing TA mediated adhesive PEG hydrogel as a Ti enhancing biomaterial that supports osseointegration.
C1 [Bubpamala, Theeraporn; Pholpabu, Pitirat] King Mongkuts Univ Technol Thonburi, Fac Engn, Biol Engn Program, Bangkok 10140, Thailand.
   [Promoppatum, Patcharapit] King Mongkuts Univ Technol Thonburi, Fac Engn, Dept Mech Engn, Bangkok 10140, Thailand.
C3 King Mongkuts University of Technology Thonburi; King Mongkuts
   University of Technology Thonburi
RP Pholpabu, P (通讯作者)，King Mongkuts Univ Technol Thonburi, Fac Engn, Biol Engn Program, Bangkok 10140, Thailand.
EM pitirat.pho@mail.kmutt.ac.th
RI Pholpabu, Pitirat/AAW 6263 2020; Promoppatum, Patcharapit/AAX 3316 2021
FU King Mongkut's University of Technology Thonburi [FRB650048/0164];
   Thailand Science Research and Innovation (TSRI) Basic Research Fund;
   Research Strengthening Project of the Faculty of Engineering, King
   Mongkut's University of Technology Thonburi; King Mongkut's University
   of Technology Thonburi
FX This research project was supported by Thailand Science Research and
   Innovation (TSRI) Basic Research Fund: Fiscal year 2022 under project
   number FRB650048/0164, the Research Strengthening Project of the Faculty
   of Engineering, King Mongkut's University of Technology Thonburi, and
   the Petchra Pra Jom Klao Ph.D. Research Scholarship from King Mongkut's
   University of Technology Thonburi (to T.B.).
CR Agarwal R, 2015, ADV DRUG DELIVER REV, V94, P53, DOI 10.1016/j.addr.2015.03.013
   [Anonymous], 2023, StatPearls
   Bekale L, 2015, COLLOID SURFACE B, V130, P141, DOI 10.1016/j.colsurfb.2015.03.045
   Bubpamala T, 2019, P PUR APPL CHEM INT, pPO1
   Bubpamala T, 2020, ACS OMEGA, V5, P19437, DOI 10.1021/acsomega.0c01393
   Cambre JN, 2011, POLYMER, V52, P4631, DOI 10.1016/j.polymer.2011.07.057
   Chen C, 2022, RSC ADV, V12, P7689, DOI 10.1039/d1ra07657d
   Chen KW, 2021, ACS APPL MATER INTER, V13, P9748, DOI 10.1021/acsami.1c00637
   Cheng XJ, 2020, CHINESE CHEM LETT, V31, P869, DOI 10.1016/j.cclet.2019.07.013
   Chiang CW, 2021, INT J NANOMED, V16, P4209, DOI 10.2147/IJN.S274461
   Comyn J., 1985, POLYM PERMEABILITY, P11, DOI DOI 10.1007/978 94 009 4858 7_2
   Crank J., 1979, The Mathematics of Diffusion
   Geng HM, 2020, ACS APPL BIO MATER, V3, P1258, DOI 10.1021/acsabm.9b01138
   Ghasemian M, 2023, BIOMED PHARMACOTHER, V166, DOI 10.1016/j.biopha.2023.115328
   He H, 2023, SCI ADV, V9, DOI 10.1126/sciadv.adf3887
   He LH, 2011, CHEM COMMUN, V47, P7497, DOI 10.1039/c1cc11928a
   Huang ZJ, 2018, BIOMATER SCI UK, V6, P2487, DOI 10.1039/c8bm00453f
   Jing J, 2019, ACS BIOMATER SCI ENG, V5, P4601, DOI 10.1021/acsbiomaterials.9b00604
   KORSMEYER RW, 1983, INT J PHARMACEUT, V15, P25, DOI 10.1016/0378 5173(83)90064 9
   Li JP, 2016, J TRANSL MED, V14, DOI 10.1186/s12967 016 1028 0
   Li X, 2022, BIOMATERIALS, V287, DOI 10.1016/j.biomaterials.2022.121683
   Liu Y, 2020, J BIOMED MATER RES A, V108, P470, DOI 10.1002/jbm.a.36829
   Lu RF, 2020, FRONT CHEM, V8, DOI 10.3389/fchem.2020.583484
   Malizos K, 2017, J ORTHOP TRAUMATOL, V18, P159, DOI 10.1007/s10195 017 0442 2
   Marx D, 2020, BONE REP, V12, DOI 10.1016/j.bonr.2020.100273
   Mello Machado RC, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 94886 y
   Montanari E, 2016, MACROMOL BIOSCI, V16, P1815, DOI 10.1002/mabi.201600311
   PEPPAS NA, 1985, PHARM ACTA HELV, V60, P110
   Poltue T, 2021, INT J MECH SCI, V211, DOI 10.1016/j.ijmecsci.2021.106762
   Romano C L, 2017, J Bone Jt Infect, V2, P63, DOI 10.7150/jbji.17705
   Romano Carlo Luca, 2016, J Bone Jt Infect, V1, P34, DOI 10.7150/jbji.15986
   Steffi C, 2019, POLYMERS BASEL, V11, DOI 10.3390/polym11081256
   Suneetha M, 2019, ACS OMEGA, V4, P12647, DOI 10.1021/acsomega.9b01302
   Wang MO, 2013, BIOMACROMOLECULES, V14, P1321, DOI 10.1021/bm301962f
   Wang YP, 2022, REGEN BIOMATER, V9, DOI 10.1093/rb/rbac003
   Wang YL, 2016, CLIN IMPLANT DENT R, V18, P618, DOI 10.1111/cid.12343
   Wind MM, 1996, PROG ORG COAT, V28, P239, DOI 10.1016/0300 9440(95)00601 X
   Yang SF, 2001, TISSUE ENG, V7, P679, DOI 10.1089/107632701753337645
   Yang WJ, 2015, POLYM CHEM UK, V6, P7027, DOI 10.1039/c5py00936g
   Zhang BJ, 2020, ACTA BIOMATER, V114, P431, DOI 10.1016/j.actbio.2020.07.024
   Zhang Y, 2010, AAPS J, V12, P263, DOI 10.1208/s12248 010 9185 1
NR 41
TC 7
Z9 8
U1 8
U2 27
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2470 1343
J9 ACS OMEGA
JI ACS Omega
PD DEC 19
PY 2023
VL 9
IS 1
BP 887
EP 895
DI 10.1021/acsomega.3c06966
PG 9
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA EM9Q2
UT WOS:001139464100001
PM 38222498
OA gold
DA 2025 08 17
ER

PT J
AU Yu, DD
   Mu, S
   Zhao, DY
   Wang, GB
   Chen, ZG
   Ren, HF
   Fu, Q
AF Yu, Dongdong
   Mu, Shuai
   Zhao, Danyang
   Wang, Guangbin
   Chen, Zhiguang
   Ren, Hongfei
   Fu, Qin
TI Puerarin attenuates glucocorticoid induced apoptosis of hFOB1.19 cells
   through the JNK  and Akt mediated mitochondrial apoptotic pathways
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE puerarin; apoptosis; osteoporosis; AKT; c Jun N terminal kinase
ID OSTEOBLASTIC MC3T3 E1 CELLS; STRESS INDUCED APOPTOSIS; INDUCED
   OSTEOPOROSIS; IN VIVO; SIGNALING PATHWAYS; STIMULATES PROLIFERATION;
   OXIDATIVE STRESS; BONE FORMATION; UP REGULATION; DIFFERENTIATION
AB Puerarin is an active component of Pueraria lobata, which is a commonly used Chinese herbal medicine for the treatment of osteoporosis. The present study aimed to evaluate the osteoprotective effect of puerarin on glucocorticoid (GC) induced apoptosis of osteoblasts in vitro. The effects of puerarin on dexamethasone (DEX) induced cell apoptosis were assessed using enzyme linked immunosorbent assay and a terminal deoxynucleotidyl transferase dUTP nick end labeling assay, and found that the viability of hFOB1.19 cells was significantly increased following exposure to between 10( 6) and 10( 10) M puerarin, with a maximal anti apoptotic effect at a concentration of 10( 8) M. In addition, compared with the control group, puerarin upregulated the transcription and protein levels of B cell lymphoma 2 and downregulated B cell associated X protein in the hFOB1.19 cells. Puerarin attenuated the DEX induced release of cytochrome c and cleavage of caspase 3, and treatment with puerarin inhibited the c Jun N terminal kinase (JNK) pathway and activated the phosphoinositide 3 kinase (PI3K)/Akt pathway in the hFOB1.19 cells. Furthermore, the Akt inhibitor, LY294002, partly eliminated the protective effect of puerarin on DEX induced apoptosis, and puerarin combined with the JNK inhibitor, SP600125, suppressed DEX induced apoptosis to a lesser extent than in the cells treated with SP600125 alone. These results suggested that the JNK and PI3K/Akt signaling pathways mediate the inhibitory effects of puerarin on apoptosis in the hFOB1.19 cells. In conclusion, puerarin prevented DEX induced apoptosis of hFOB1.19 cells via inhibition of the JNK pathway and activation of the PI3K/Akt signaling pathway in the cells, dependent on the mitochondrial apoptotic pathway. These results support puerarin as a promising target in the treatment of GC induced osteoporosis.
C1 [Yu, Dongdong; Mu, Shuai; Zhao, Danyang; Wang, Guangbin; Chen, Zhiguang; Ren, Hongfei; Fu, Qin] China Med Univ, Shengjing Hosp, Dept Orthoped Surg, Liaoning 110004, Peoples R China.
C3 China Medical University
RP Fu, Q (通讯作者)，China Med Univ, Shengjing Hosp, Dept Orthoped Surg, Liaoning 110004, Peoples R China.
EM qinfucmu@163.com
FU National Natural Science Foundation of China [81370981, 81200714]
FX This study was supported by grants from the National Natural Science
   Foundation of China (grant. nos. 81370981 and 81200714).
CR Abud HE, 2004, CELL DEATH DIFFER, V11, P797, DOI 10.1038/sj.cdd.4401455
   Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322
   Beavan S, 2001, J BONE MINER RES, V16, P1496, DOI 10.1359/jbmr.2001.16.8.1496
   Bost F, 2005, BIOCHIMIE, V87, P51, DOI 10.1016/j.biochi.2004.10.018
   Canalis E, 1996, J CLIN ENDOCR METAB, V81, P3441, DOI 10.1210/jc.81.10.3441
   Cantrell DA, 2001, J CELL SCI, V114, P1439
   Cao XH, 2010, CHEM BIOL INTERACT, V183, P357, DOI 10.1016/j.cbi.2009.11.027
   Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007
   Choi EM, 2009, TOXICOL IN VITRO, V23, P862, DOI 10.1016/j.tiv.2009.05.005
   Chua CC, 2003, BBA MOL CELL RES, V1642, P79, DOI 10.1016/S0167 4889(03)00100 9
   Cui RR, 2010, AMINO ACIDS, V39, P1193, DOI 10.1007/s00726 010 0555 x
   Díaz Montero CM, 2006, EUR J CANCER, V42, P1491, DOI 10.1016/j.ejca.2006.03.007
   Dong LP, 1998, ACTA PHARMACOL SIN, V19, P339
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Feng RJ, 2013, CELL BIOCHEM BIOPHYS, V67, P189, DOI 10.1007/s12013 013 9533 8
   Gohel A, 1999, ENDOCRINOLOGY, V140, P5339, DOI 10.1210/en.140.11.5339
   Gu YX, 2013, J BIOMED MATER RES A, V101, P748, DOI 10.1002/jbm.a.34377
   Guerra MC, 2000, LIFE SCI, V67, P2997, DOI 10.1016/S0024 3205(00)00885 7
   Guo CR, 2014, ENVIRON TOXICOL PHAR, V37, P37, DOI 10.1016/j.etap.2013.11.009
   Guo DG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091354
   Habata Y, 1999, BBA MOL CELL RES, V1452, P25, DOI 10.1016/S0167 4889(99)00114 7
   Han Jiang quan, 2012, Zhongguo Zhong Xi Yi Jie He Za Zhi, V32, P1069
   Huang F, 2012, BIOCHIMIE, V94, P1143, DOI 10.1016/j.biochi.2012.01.018
   Hwang YP, 2008, TOXICOL APPL PHARM, V233, P371, DOI 10.1016/j.taap.2008.09.006
   Kim BJ, 2012, BONE, V51, P431, DOI 10.1016/j.bone.2012.06.015
   Kim H, 2005, NEUROL RES, V27, P287, DOI 10.1179/016164105X25234
   Kim SW, 2005, BONE, V37, P359, DOI 10.1016/j.bone.2005.04.020
   Kitamura T, 2004, INT J CANCER, V109, P576, DOI 10.1002/ijc.20012
   Kitase Y, 2010, J BONE MINER RES, V25, P2381, DOI 10.1002/jbmr.168
   Li JM, 2010, EUR J PHARMACOL, V649, P195, DOI 10.1016/j.ejphar.2010.09.045
   Liang D, 2013, CELL SIGNAL, V25, P1126, DOI 10.1016/j.cellsig.2013.02.003
   Liang QH, 2013, TOXICOL APPL PHARM, V272, P591, DOI 10.1016/j.taap.2013.07.018
   Liu CM, 2012, TOXICOL APPL PHARM, V258, P330, DOI 10.1016/j.taap.2011.11.015
   Liu CM, 2012, EXP TOXICOL PATHOL, V64, P575, DOI 10.1016/j.etp.2010.11.016
   Liu LJ, 2013, INT J ENDOCRINOL, V2013, DOI 10.1155/2013/786574
   Liu Y, 2004, J BONE MINER RES, V19, P479, DOI 10.1359/JBMR.0301242
   Manelli F, 2000, TRENDS ENDOCRIN MET, V11, P79, DOI 10.1016/S1043 2760(00)00234 4
   Matsuguchi T, 2009, J BONE MINER RES, V24, P398, DOI 10.1359/JBMR.081107
   Michihara S, 2012, J NUTR SCI VITAMINOL, V58, P202, DOI 10.3177/jnsv.58.202
   Quintavalle C, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.38
   Seibel MJ, 2013, LANCET DIABETES ENDO, V1, P59, DOI 10.1016/S2213 8587(13)70045 7
   Shi Rui li, 2003, Yaoxue Xuebao, V38, P103
   Tamura Y, 2004, BIOMED PHARMACOTHER, V58, P500, DOI 10.1016/j.biopha.2004.08.018
   Tang SY, 2007, PEPTIDES, V28, P708, DOI 10.1016/j.peptides.2006.10.005
   Tiyasatkulkovit W, 2012, PHYTOMEDICINE, V19, P1147, DOI 10.1016/j.phymed.2012.07.010
   Urasopon N, 2008, MATURITAS, V59, P137, DOI 10.1016/j.maturitas.2008.01.001
   van Brussel MS, 2009, EXPERT OPIN PHARMACO, V10, P997, DOI [10.1517/14656560902868225 , 10.1517/14656560902868225]
   Wang G, 2011, NEUROSCI LETT, V487, P88, DOI 10.1016/j.neulet.2010.10.002
   Wang Q, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004196.pub2
   Wang Y, 2013, PHYTOMEDICINE, V20, P787, DOI 10.1016/j.phymed.2013.03.005
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Widlak P, 2000, ACTA BIOCHIM POL, V47, P1037
   Wong R, 2007, OSTEOARTHR CARTILAGE, V15, P894, DOI 10.1016/j.joca.2007.02.009
   Wu L, 2007, PHYTOMEDICINE, V14, P652, DOI 10.1016/j.phymed.2007.07.060
   Xie H, 2008, AMINO ACIDS, V35, P419, DOI 10.1007/s00726 007 0598 9
   Xie H, 2010, AMINO ACIDS, V38, P1145, DOI 10.1007/s00726 009 0325 9
   Yan XT, 2014, FOOD CHEM, V156, P408, DOI 10.1016/j.foodchem.2014.01.078
   Zhang HY, 2011, EXP GERONTOL, V46, P30, DOI 10.1016/j.exger.2010.09.013
   Zhang MY, 2012, CHIN J INTEGR MED, V18, P276, DOI 10.1007/s11655 012 1056 4
   Zhu LH, 2010, FREE RADICAL BIO MED, V48, P471, DOI 10.1016/j.freeradbiomed.2009.10.040
   Zhu X, 2013, AMINO ACIDS, V44, P961, DOI 10.1007/s00726 012 1425 5
NR 61
TC 18
Z9 23
U1 0
U2 16
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
EI 1791 244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD AUG
PY 2015
VL 36
IS 2
BP 345
EP 354
DI 10.3892/ijmm.2015.2258
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA CN8GE
UT WOS:000358677000003
PM 26101183
OA Green Submitted, Green Accepted, hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Jung, GY
   Park, YJ
   Han, JS
AF Jung, Gil Yong
   Park, Yoon Jeong
   Han, Jung Suk
TI Mediation of Rac1 Activation by Kindlin 2: An Essential Function in
   Osteoblast Adhesion, Spreading, and Proliferation
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE KINDLIN 2; OSTEOBLAST; INTEGRIN; Rac1
ID TRANSCRIPTION FACTOR; RHO GTPASES; INTEGRINS; KINASE; AP 1;
   ORGANIZATION; EXPRESSION; INHIBITOR; BINDING; DESIGN
AB Kindlins are focal adhesion proteins that regulate integrin signaling. Although integrin activation is critical for bone development, little is known about the expression and role of kindlins in osteoblasts. We therefore investigated the function of kindlin 2 in osteoblast adhesion, spreading, and proliferation using small interfering RNA. In MC3T3 E1 cells, only kindlin 2 is highly expressed and localizes to focal adhesion. We found that kindlin 2 was involved in integrin activation in MC3T3 E1 cells and that kindlin 2 knockdown osteoblasts resulted in diminished cell adhesion, spreading, and proliferation. In this process, kindlin 2 knockdown impaired transient Rac1 activation, influencing Akt activation and AP 1 activity. In agreement with these data, pharmacological inhibition of Rac1 reduced MC3T3 E1 cell adhesion, spreading, and proliferation. Overall, these findings demonstrated that kindlin 2 governs Rac1 activation, which controls osteoblast function. Our findings provide the first insights concerning the function of kindlin 2 in osteoblast, and suggest that kindlin 2 is a critical mediator for osteoblast physiology. J. Cell. Biochem. 112: 2541 2548, 2011. (C) 2011 Wiley Liss, Inc.
C1 [Han, Jung Suk] Seoul Natl Univ, Dept Prosthodont, Seoul 110749, South Korea.
   [Jung, Gil Yong; Park, Yoon Jeong] Seoul Natl Univ, Interdisciplinary Program Bioengn, Seoul 152742, South Korea.
   [Park, Yoon Jeong] Sch Dent, Dept Craniomaxilofacial Reconstruct Sci, Seoul 110749, South Korea.
   [Han, Jung Suk] Seoul Natl Univ, Dent Res Ctr, Sch Dent, Seoul 110749, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU)
RP Han, JS (通讯作者)，Seoul Natl Univ, Dept Prosthodont, Seoul 110749, South Korea.
EM proshan@snu.ac.kr
RI Han, Jung Suk/D 5783 2012
FU Korea Science and Engineering Foundation [R01 2007 000 10977 0,
   M10528010004 06N2801 00410]
FX Grant sponsor: Korea Science and Engineering Foundation; Grant numbers:
   R01 2007 000 10977 0, M10528010004 06N2801 00410.
CR An ZW, 2010, INT J CANCER, V127, P1999, DOI 10.1002/ijc.25223
   Cowles EA, 2000, J BIOMED MATER RES, V52, P725, DOI 10.1002/1097 4636(20001215)52:4<725::AID JBM18>3.0.CO;2 O
   Danen EHJ, 2002, J CELL BIOL, V159, P1071, DOI 10.1083/jcb.200205014
   Dowling JJ, 2008, CIRC RES, V102, P423, DOI 10.1161/CIRCRESAHA.107.161489
   Dowling JJ, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471 2121 9 36
   Engers R, 2006, FEBS J, V273, P4754, DOI 10.1111/j.1742 4658.2006.05476.x
   Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101
   Genot E, 1998, ONCOGENE, V17, P1731, DOI 10.1038/sj.onc.1202101
   Hall A, 2005, BIOCHEM SOC T, V33, P891, DOI 10.1042/BST0330891
   Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632
   Harburger DS, 2009, J BIOL CHEM, V284, P11485, DOI 10.1074/jbc.M809233200
   Has C, 2009, AM J PATHOL, V175, P1442, DOI 10.2353/ajpath.2009.090203
   He YH, 2011, J INVEST DERMATOL, V131, P245, DOI 10.1038/jid.2010.273
   Huveneers S, 2009, J CELL SCI, V122, P1059, DOI 10.1242/jcs.039446
   Legate KR, 2009, J CELL SCI, V122, P187, DOI 10.1242/jcs.041624
   Liu WF, 2007, CIRC RES, V101, pE44, DOI 10.1161/CIRCRESAHA.107.158329
   Malinin NL, 2010, BLOOD, V115, P4011, DOI 10.1182/blood 2009 10 239269
   Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087
   Meves A, 2009, TRENDS CELL BIOL, V19, P504, DOI 10.1016/j.tcb.2009.07.006
   Miao H, 2002, J CELL SCI, V115, P2199
   Montanez E, 2008, GENE DEV, V22, P1325, DOI 10.1101/gad.469408
   Nassar N, 2006, CURR TOP MED CHEM, V6, P1109, DOI 10.2174/156802606777812095
   Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863
   Schneider GB, 2001, J DENT RES, V80, P1540, DOI 10.1177/00220345010800061201
   Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968 0004(00)01605 4
   Shattil SJ, 2010, NAT REV MOL CELL BIO, V11, P288, DOI 10.1038/nrm2871
   Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383
   Siebers MC, 2005, BIOMATERIALS, V26, P137, DOI 10.1016/j.biomaterials.2004.02.021
   Sundberg LJ, 2003, J BIOL CHEM, V278, P29783, DOI 10.1074/jbc.M303771200
   Troussard AA, 1999, MOL CELL BIOL, V19, P7420
   Tu YZ, 2003, CELL, V113, P37, DOI 10.1016/S0092 8674(03)00163 6
   Ussar S, 2006, EXP CELL RES, V312, P3142, DOI 10.1016/j.yexcr.2006.06.030
NR 32
TC 20
Z9 28
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD SEP
PY 2011
VL 112
IS 9
BP 2541
EP 2548
DI 10.1002/jcb.23178
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 818QN
UT WOS:000294769500037
PM 21590706
DA 2025 08 17
ER

PT J
AU Dean, T
   Vilardaga, JP
   Potts, JT
   Gardella, TJ
AF Dean, Thomas
   Vilardaga, Jean Pierre
   Potts, John T., Jr.
   Gardella, Thomas J.
TI Altered selectivity of parathyroid hormone (PTH) and PTH Related protein
   (PTHrP) for distinct conformations of the PTH/PTHrP receptor
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID OSTEOBLAST DERIVED PTHRP; LIGAND BINDING; TYPE 1 RECEPTOR; ANABOLIC
   AGENT; PEPTIDE; AGONIST; SWITCH; IDENTIFICATION; ACTIVATION; SEQUENCES
AB PTH and PTHrP use the same G protein coupled receptor, the PTH/PTHrP receptor (PTHR), to mediate their distinct biological actions. The extent to which the mechanisms by which the two ligands bind to the PTHR differ is unclear. We examined this question using several pharmacological and biophysical approaches. Kinetic dissociation and equilibrium binding assays revealed that the binding of [I 125] PTHrP(1 36) to the PTHR was more sensitive to GTP gamma S (added to functionally uncouple PTHR G protein complexes) than was the binding of [I 125] PTH(1 34) (similar to 75% maximal inhibition vs. similar to 20%). Fluorescence resonance energy transfer based kinetic analyses revealed that PTHrP(1 36) bound to the PTHR more slowly and dissociated from it more rapidly than did PTH(1 34). The cAMP signaling response capacity of PTHrP(1 36) in cells decayed more rapidly than did that of PTH(1 34) (t(1/2) = similar to 1 vs. similar to 2 h). Divergent residue 5 in the ligand, IIe in PTH and His in PTHrP, was identified as a key determinant of the altered receptor interaction responses exhibited by the two peptides. We conclude that whereas PTH and PTHrP bind similarly to the G protein coupled PTHR conformation (RG), PTH has a greater capacity to bind to the G protein uncoupled conformation (R 0) and, hence, can produce cumulatively greater signaling responses (via R(0  >)RG isomerization) than can PTHrP. Such conformational selectivity may relate to the distinct modes by which PTH and PTHrP act biologically, endocrine vs. paracrine, and may help explain reported differences in the effects that the ligands have on calcium and bone metabolism when administered to humans.
C1 [Dean, Thomas; Vilardaga, Jean Pierre; Potts, John T., Jr.; Gardella, Thomas J.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
   [Vilardaga, Jean Pierre] Massachusetts Gen Hosp, Program Membrane Biol, Boston, MA 02114 USA.
   Harvard Univ, Sch Med, Boston, MA 02114 USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Harvard University; Harvard University Medical
   Affiliates; Massachusetts General Hospital; Harvard University; Harvard
   Medical School
RP Gardella, TJ (通讯作者)，Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
EM Gardella@helix.mgh.harvard.edu
OI Vilardaga, Jean Pierre/0000 0002 1217 1435
FU NIDDK NIH HHS [DK 11794, P01 DK011794] Funding Source: Medline
CR ABOUSAMRA AB, 1989, ENDOCRINOLOGY, V125, P2215, DOI 10.1210/endo 125 4 2215
   Behar V, 1996, ENDOCRINOLOGY, V137, P4217, DOI 10.1210/en.137.10.4217
   Berlot CH, 2002, J BIOL CHEM, V277, P21080, DOI 10.1074/jbc.M201330200
   Bisello A, 2002, J BIOL CHEM, V277, P38524, DOI 10.1074/jbc.M202544200
   Castro M, 2005, P NATL ACAD SCI USA, V102, P16084, DOI 10.1073/pnas.0503942102
   Castro M, 2002, ENDOCRINOLOGY, V143, P3854, DOI 10.1210/en.2002 220232
   CAULFIELD MP, 1990, ENDOCRINOLOGY, V127, P83, DOI 10.1210/endo 127 1 83
   Chauvin S, 2002, MOL ENDOCRINOL, V16, P2720, DOI 10.1210/me.2002 0049
   Chen XS, 2006, J BONE MINER RES, V21, P113, DOI 10.1359/JBMR.051005
   Dean T, 2006, MOL ENDOCRINOL, V20, P931, DOI 10.1210/me.2005 0349
   Dean T, 2006, J BIOL CHEM, V281, P32485, DOI 10.1074/JBC.M606179200
   DELEAN A, 1980, J BIOL CHEM, V255, P7108
   Gardella TJ, 1996, J BIOL CHEM, V271, P19888, DOI 10.1074/jbc.271.33.19888
   GARDELLA TJ, 1995, J BIOL CHEM, V270, P6584, DOI 10.1074/jbc.270.12.6584
   Gensure RC, 2005, BIOCHEM BIOPH RES CO, V328, P666, DOI 10.1016/j.bbrc.2004.11.069
   Heck M, 2001, J BIOL CHEM, V276, P10000, DOI 10.1074/jbc.M009475200
   Hilton JM, 2000, J ENDOCRINOL, V166, P213, DOI 10.1677/joe.0.1660213
   Hoare SRJ, 2003, PEPTIDES, V24, P1881, DOI 10.1016/j.peptides.2003.09.002
   Hoare SRJ, 1999, J PHARMACOL EXP THER, V289, P1323
   Hoare SRJ, 2001, J BIOL CHEM, V276, P7741, DOI 10.1074/jbc.M009395200
   Horwitz MJ, 2006, OSTEOPOROSIS INT, V17, P225, DOI 10.1007/s00198 005 1976 3
   Horwitz MJ, 2003, J CLIN ENDOCR METAB, V88, P569, DOI 10.1210/jc.2002 021122
   Horwitz MJ, 2005, J BONE MINER RES, V20, P1792, DOI 10.1359/JBMR.050602
   Kenakin T, 2004, TRENDS PHARMACOL SCI, V25, P186, DOI 10.1016/j.tips.2004.02.012
   Kronenberg HM, 2006, ANN NY ACAD SCI, V1068, P1, DOI 10.1196/annals.1346.002
   MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo 107 5 1494
   Martin TJ, 2005, J CLIN INVEST, V115, P2322, DOI 10.1172/JCI26239
   Miao DS, 2005, J CLIN INVEST, V115, P2402, DOI 10.1172/JCI24918
   Nagai S, 2007, J BONE MINER RES, V22, pS53
   Okazaki M, 2007, J BONE MINER RES, V22, pS54
   POST SR, 1992, J BIOL CHEM, V267, P25776
   Rodbell M, 1997, ADV ENZYME REGUL, V37, P427, DOI 10.1016/S0065 2571(96)00020 9
   Shimizu M, 2001, ENDOCRINOLOGY, V142, P3068, DOI 10.1210/en.142.7.3068
   Shimizu N, 2005, J BIOL CHEM, V280, P1797, DOI 10.1074/jbc.M408270200
   Shimizu N, 2001, J BIOL CHEM, V276, P49003, DOI 10.1074/jbc.M106827200
   Takasu H, 1999, J BONE MINER RES, V14, P11, DOI 10.1359/jbmr.1999.14.1.11
   Tashjian AH, 2006, J BONE MINER RES, V21, P354, DOI 10.1359/JBMR.051023
   Tawfeek HA, 1999, J BONE MINER RES, V14, pS542
   Tawfeek HAW, 2002, MOL ENDOCRINOL, V16, P1, DOI 10.1210/me.16.1.1
   Vilardaga JP, 2003, NAT BIOTECHNOL, V21, P807, DOI 10.1038/nbt838
   Wittelsberger A, 2006, BIOCHEMISTRY US, V45, P2027, DOI 10.1021/bi051833a
   YAMAMOTO I, 1988, ENDOCRINOLOGY, V122, P1208, DOI 10.1210/endo 122 4 1208
NR 42
TC 164
Z9 201
U1 1
U2 11
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0888 8809
EI 1944 9917
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD JAN
PY 2008
VL 22
IS 1
BP 156
EP 166
DI 10.1210/me.2007 0274
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 246FZ
UT WOS:000251994200016
PM 17872377
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Paramasivam, S
   Perumal, SS
AF Paramasivam, Sivasakthi
   Perumal, Senthamil Selvan
TI In Silico Rationalization for Leads from Oldenlandia
   umbellata L. to Inhibit Multiple Molecular Targets Regulating
   Osteoporosis
SO PHARMACOGNOSY MAGAZINE
LA English
DT Article
DE Deacetylasperuloside; docking; in silico; molecular dynamics simulation;
   osteoporosis; Oldenlandia umbellata
ID DRUG DISCOVERY; DIFFERENTIATION; VISUALIZATION; PREDICTION; PROGRAM;
   VITRO
AB Background: Osteoporosis is a chronic metabolic bone disease caused due to the dysregulation in the functioning of osteoblast and osteoclast cells leading to increased bone resorption predominantly in postmenopausal women and the elderly, thereby affecting a significant global population.Purpose :The present study aims to computationally screen the phytochemical constituents of Oldenlandia umbellata Linn against the unique molecular therapeutic targets of osteoporosis and validate the results using Molecular Dynamics (MD) Simulation.Methods: The molecular docking analysis of the selected phytoconstituents against the molecular targets were performed using AutoDock 4.2.6   AutoDock Tools 1.5.6. In addition, the drug likeliness, ADME, bioactivity, and toxicity were predicted using Molinspiration ADMELAB2.0, ProTox II and Orisis DataWarrior online tools. Molecular Dynamic Simulation studies were performed using WebGRO macromolecular simulation server.Results :Molecular docking results and data analysis revealed that deacetylasperuloside possesses good drug likeness, ADME properties, and bioactive scores and did not indicate any toxicity compared to other phytochemicals exhibiting binding energies below  8.00 Kcal/mol against the targets. Together, the study emphasized that deacetylasperuloside could bind with the molecular targets of osteoporosis, and the lead is a potential therapeutic candidate for osteoporosis treatment. Further, molecular dynamic simulation analysis for 100 ns revealed that the ligand protein complexes, including glycogen synthase kinase 3 beta (GSK3 beta) deacetylasperuloside and cathepsin K (CTSK) deacetylasperuloside complexes, were stable and highly compact assessed from their trajectories. Hence, it can be emphasized that deacetylasperuloside could be a potential therapeutic molecule that could inhibit the targets, including GSK3 beta and CTSK.Conclusion: Oldenlandia umbellata L. is a potential candidate for identifying therapeutic leads for osteoporosis treatment. Further, in vitro and in vivo studies are needed as an output of this research to evaluate its therapeutic efficacy.
C1 [Paramasivam, Sivasakthi; Perumal, Senthamil Selvan] Anna Univ, Univ Coll Engn, Dept Pharmaceut Technol, BIT Campus, Tiruchirappalli, Tamil Nadu, India.
   [Perumal, Senthamil Selvan] Anna Univ, Univ Coll Engn, Dept Pharmaceut Technol, BIT Campus, Tiruchirappalli 620024, Tamil Nadu, India.
C3 Anna University; Anna University of Technology Tiruchirappalli; Anna
   University; Anna University of Technology Tiruchirappalli
RP Perumal, SS (通讯作者)，Anna Univ, Univ Coll Engn, Dept Pharmaceut Technol, BIT Campus, Tiruchirappalli 620024, Tamil Nadu, India.
EM senthamil77@gmail.com
RI ; Paramasivam, Sivasakthi/JBS 2575 2023
OI Perumal, Senthamil Selvan/0000 0003 1747 490X; 
CR Abraham Mark James, 2015, SoftwareX, V1 2, P19, DOI 10.1016/j.softx.2015.06.001
   Ali P, 2012, MED CHEM RES, V21, P157, DOI 10.1007/s00044 010 9505 0
   Amjadi Moheb F, 2019, J CELL PHYSIOL, V234, P14641, DOI 10.1002/jcp.28207
   Durán Iturbide NA, 2020, ACS OMEGA, V5, P16076, DOI 10.1021/acsomega.0c01581
   Arun P., 2010, J Pharm Sci Technol, V2, P198
   Banerjee P, 2018, NUCLEIC ACIDS RES, V46, pW257, DOI 10.1093/nar/gky318
   Chau JFL, 2009, HISTOL HISTOPATHOL, V24, P1593, DOI 10.14670/HH 24.1593
   Cheng L, 2018, AM J TRANSL RES, V10, P1457
   Dai R, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00433
   Daina A, 2017, SCI REP UK, V7, DOI 10.1038/srep42717
   Ghose AK, 1998, J PHYS CHEM A, V102, P3762, DOI 10.1021/jp980230o
   Gyori DS, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00507
   Husain A, 2016, SAUDI PHARM J, V24, P104, DOI 10.1016/j.jsps.2015.02.008
   Jing YK, 2015, FUTURE MED CHEM, V7, P571, DOI 10.4155/fmc.15.18
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169 409X(96)00423 1
   Mahibalan S., 2008, NPAIJ, V4, P184
   Mahibalan S, 2016, MED CHEM RES, V25, P466, DOI 10.1007/s00044 015 1500 z
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Mun SH, 2020, EXP MOL MED, V52, P1239
   Nakamura I, 2007, J BONE MINER METAB, V25, P337, DOI 10.1007/s00774 007 0773 9
   Noh JY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207623
   Padhy I., 2014, INT J PHARM HEAL RES, V2, P12
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Saad FA, 2020, ANN NY ACAD SCI, V1462, P37, DOI 10.1111/nyas.14231
   Sander T, 2015, J CHEM INF MODEL, V55, P460, DOI 10.1021/ci500588j
   Saraswathy G., 2008, PHARMACOLOGYONLINE, V3, P253
   Sharan K, 2009, CURR MED CHEM, V16, P1138, DOI 10.2174/092986709787581806
   Sivapraksam S.S.K., 2014, INT J PHARM SCI REV, V26, P320
   Somnath D.E., 2014, INT J PHARM PHARM SC, V6, P94
   Sun LX, 2018, CHEMMEDCHEM, V13, P572, DOI 10.1002/cmdc.201700582
   Sun P, 2020, DRUG DES DEV THER, V14, P4189, DOI 10.2147/DDDT.S275128
   Suvarna V, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00981
   Tian W, 2018, NUCLEIC ACIDS RES, V46, pW363, DOI 10.1093/nar/gky473
   vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047
   Walsh MC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00511
   Wang XD, 2019, MOL MED, V25, DOI 10.1186/s10020 019 0107 0
   Xiong GL, 2021, NUCLEIC ACIDS RES, V49, pW5, DOI 10.1093/nar/gkab255
   Yoganarasimhan S N., 2000, Medicinal plants of India Tamilnadu
   Zhang ZP, 2018, ACTA PHARM SIN B, V8, P721, DOI 10.1016/j.apsb.2018.04.003
NR 40
TC 3
Z9 3
U1 0
U2 2
PU SAGE PUBLICATIONS INDIA  PVT LTD
PI NEW DELHI
PA B 1 I 1 MOHAN CO OPERATIVE INDUSTRIAL AREA, MATHURA RD, POST BAG NO 7,
   NEW DELHI 110 044, INDIA
SN 0973 1296
EI 0976 4062
J9 PHARMACOGN MAG
JI Pharmacogn. Mag.
PD MAR
PY 2024
VL 20
IS 1
BP 146
EP 158
DI 10.1177/09731296231196189
EA OCT 2023
PG 13
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GK2C3
UT WOS:001085769600001
OA hybrid
DA 2025 08 17
ER

PT J
AU Ge, YM
   Wang, K
   Li, HL
   Tian, Y
   Wu, YT
   Lin, ZW
   Lin, YY
   Wang, YS
   Zhang, JR
   Tang, B
AF Ge, Yongmei
   Wang, Kui
   Li, Huili
   Tian, Ye
   Wu, Yutong
   Lin, Zhaowei
   Lin, Yangyang
   Wang, Yansong
   Zhang, Jiarong
   Tang, Bin
TI An Mg MOFs based multifunctional medicine for the treatment of
   osteoporotic pain
SO MATERIALS SCIENCE & ENGINEERING C MATERIALS FOR BIOLOGICAL APPLICATIONS
LA English
DT Article
DE Pain; Osteoporosis; Bone formation; Inflammation; Ketoprofen; Mg MOF 74
ID MAGNESIUM; KETOPROFEN; MECHANISMS; OSTEOBLAST; CELL
AB Bone pain is the primary problem for patients with osteoporosis. Ketoprofen is clinically used to treat osteoporotic pain, while long term oral administration of ketoprofen can cause some side effects. In addition, osteoporosis is also accompanied by bone mass loss and inflammation. In this study, we designed a multifunctional drug (Ket@Mg MOF 74) adopted Mg MOF 74 to load ketoprofen to treat osteoporotic pain, bone loss and inflammation comprehensively. Mg MOF 74 was prepared, and the physicochemical characterization proved that it had excellent physical and chemical stability. Ket@Mg MOF 74 was synthesized by post synthetic modification method and a high loading rate of ketoprofen was confirmed. Drug release and ion release experiments indicated Ket@Mg MOF 74 had a good controlled release of ketoprofen and Mg in solution. Cell experiments in vitro proved the compound drug could significantly reduce the expression of pain related genes of cyclooxygenase 2 (COX2), obviously up regulated the expression of osteogenic cytokines and remarkably downregulated the secretion of pro inflammatory factors. Therefore, Ket@Mg MOF 74 is believed a promising painkiller for osteoporotic bone pain, with the function of anti inflammatory and promoting bone formation.
C1 [Ge, Yongmei] Harbin Inst Technol, Harbin 150001, Heilongjiang, Peoples R China.
   [Ge, Yongmei; Wang, Kui; Wu, Yutong; Wang, Yansong; Zhang, Jiarong; Tang, Bin] Southern Univ Sci & Technol, Dept Biomed Engn, Shenzhen 518055, Guangdong, Peoples R China.
   [Wang, Kui; Tian, Ye] Univ Hong Kong, Dept Mech Engn, Pokfulam, Hong Kong, Peoples R China.
   [Li, Huili] Southern Univ Sci & Technol, Dept Mat Sci & Engn, Shenzhen 518055, Guangdong, Peoples R China.
   [Lin, Zhaowei] Southern Med Univ, Zhujiang Hosp, Dept Orthopaed, Guangzhou 510282, Guangdong, Peoples R China.
   [Lin, Yangyang] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Rehabil Med, Guangzhou 510655, Guangdong, Peoples R China.
C3 Harbin Institute of Technology; Southern University of Science &
   Technology; University of Hong Kong; Southern University of Science &
   Technology; Southern Medical University   China; Sun Yat Sen University
RP Tang, B (通讯作者)，Southern Univ Sci & Technol, Dept Biomed Engn, Shenzhen 518055, Guangdong, Peoples R China.
EM tangb@sustech.edu.cn
RI Tang, Bin/HCH 5552 2022; 田, 野/HTS 2047 2023; WANG, kui/C 7396 2018
OI Tang, Bin/0000 0001 9676 984X; Wang, Kui/0000 0002 5764 1445; 
FU National Key Research and Development Program of China [2019YFA0906004];
   National Foundation of Science and Technology [11872200]; Guangdong
   Foundation of Science and Technology [2017B030301018]; Shenzhen Science
   and Technology Innovation Committee [JSGG20200225151916021]
FX This study is financially supported by National Key Research and
   Development Program of China Grants (2019YFA0906004), the National
   Foundation of Science and Technology (Project No. 11872200), Guangdong
   Foundation of Science and Technology (Project No. 2017B030301018),
   Shenzhen Science and Technology Innovation Committee (Project No.
   JSGG20200225151916021).
CR An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Anneken JH, 2013, J NEUROIMMUNE PHARM, V8, P58, DOI 10.1007/s11481 012 9420 x
   Atzeni F, 2021, PAIN THER, V10, P577, DOI 10.1007/s40122 021 00250 3
   Bao ZB, 2011, J COLLOID INTERF SCI, V353, P549, DOI 10.1016/j.jcis.2010.09.065
   Cai W, 2019, ADV SCI, V6, DOI 10.1002/advs.201801526
   Castellsague J, 2012, DRUG SAFETY, V35, P1127, DOI 10.2165/11633470 000000000 00000
   Chakraborty A, 2014, APL MATER, V2, DOI 10.1063/1.4902816
   Cheng WR, 2019, NAT ENERGY, V4, P115, DOI 10.1038/s41560 018 0308 8
   Chesi A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09302 x
   Curry SJ, 2018, JAMA J AM MED ASSOC, V319, P2521, DOI 10.1001/jama.2018.7498
   Díaz García M, 2014, CRYST GROWTH DES, V14, P2479, DOI 10.1021/cg500190h
   Dong R, 2018, NAT MATER, V17, P1027, DOI 10.1038/s41563 018 0189 z
   Fajar JK, 2017, J TAIBAH UNIV MED SC, V12, P212, DOI 10.1016/j.jtumed.2016.07.010
   Hu JQ, 2021, J SOLID STATE CHEM, V294, DOI 10.1016/j.jssc.2020.121853
   Inoue K, 2018, NAT REV NEUROSCI, V19, P138, DOI 10.1038/nrn.2018.2
   Kang NH, 2020, PFLUG ARCH EUR J PHY, V472, P583, DOI 10.1007/s00424 020 02380 7
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P801, DOI [10.1007/s00198 018 4704 5, 10.1007/s00198 020 05303 5, 10.1007/s00223 018 00512 x]
   Kany S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236008
   Li Z, 2020, MICROPOR MESOPOR MAT, V294, DOI 10.1016/j.micromeso.2019.109835
   Li Z, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 54147 5
   Li Z, 2020, CHEMMEDCHEM, V15, P13, DOI 10.1002/cmdc.201900546
   Li Z, 2019, COLLOID SURFACE B, V178, P1, DOI 10.1016/j.colsurfb.2019.02.027
   Lin JS, 2021, RSC ADV, V11, P21414, DOI 10.1039/d1ra02873a
   Liu Q, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.601224
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020
   Lu KD, 2018, ADV MATER, V30, DOI 10.1002/adma.201707634
   Mederle OA, 2018, CLIN INTERV AGING, V13, P1383, DOI 10.2147/CIA.S170111
   Mennillo E, 2018, ENVIRON TOXICOL PHAR, V59, P199, DOI 10.1016/j.etap.2018.03.018
   Mennillo E, 2018, ENVIRON TOXICOL CHEM, V37, P201, DOI 10.1002/etc.3943
   Morris JA, 2019, NAT GENET, V51, P258, DOI 10.1038/s41588 018 0302 x
   O'Grady S, 2019, SCI REP UK, V9, DOI 10.1038/s41598 018 36496 9
   Oliveira CB, 2021, EMERG MED J, V38, P59, DOI 10.1136/emermed 2020 209588
   Qiao XR, 2020, INT J NANOMED, V15, P7185, DOI 10.2147/IJN.S239550
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Romero Muñiz C, 2020, ACS APPL MATER INTER, V12, P54980, DOI 10.1021/acsami.0c16629
   Sarzi Puttini P, 2013, CLIN EXP RHEUMATOL, V31, P731
   Schnabel J, 2020, CHEMNANOMAT, V6, P1229, DOI 10.1002/cnma.202000221
   Song YC, 2020, CHEMMEDCHEM, V15, P416, DOI 10.1002/cmdc.201900664
   Sun L, 2020, REGEN BIOMATER, V7, P391, DOI 10.1093/rb/rbaa010
   Venkatraman SK, 2020, J BIOMED MATER RES A, V108, P1546, DOI 10.1002/jbm.a.36925
   Wang CG, 2019, EXP MOL PATHOL, V107, P77, DOI 10.1016/j.yexmp.2019.01.012
   Wang XN, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 71564 z
   Xie SZ, 2020, ACS APPL MATER INTER, V12, P48476, DOI 10.1021/acsami.0c11035
   Yadav PS, 2013, SAUDI PHARM J, V21, P77, DOI 10.1016/j.jsps.2011.12.007
   Yu L, 2020, INT J BIOL MACROMOL, V160, P101, DOI 10.1016/j.ijbiomac.2020.05.161
   Yuan S, 2018, ADV MATER, V30, DOI 10.1002/adma.201704303
   Zhang XZ, 2017, ACTA BIOMATER, V63, P369, DOI 10.1016/j.actbio.2017.08.051
   Zhao DW, 2017, BIOMATERIALS, V112, P287, DOI 10.1016/j.biomaterials.2016.10.017
   Zhou WH, 2021, BIOMATER SCI UK, V9, P807, DOI 10.1039/d0bm01584a
   Zhu SA, 2019, J CLIN INVEST, V129, P1076, DOI 10.1172/JCI121561
   Zhu ZJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023554
NR 51
TC 29
Z9 34
U1 17
U2 206
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928 4931
EI 1873 0191
J9 MAT SCI ENG C MATER
JI Mater. Sci. Eng. C Mater. Biol. Appl.
PD OCT
PY 2021
VL 129
AR 112386
DI 10.1016/j.msec.2021.112386
EA SEP 2021
PG 8
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA WA3BI
UT WOS:000702764200001
PM 34579905
OA Bronze
DA 2025 08 17
ER

PT J
AU Hasmim, M
   Bieler, G
   Rüegg, C
AF Hasmim, M.
   Bieler, G.
   Rueegg, C.
TI Zoledronate inhibits endothelial cell adhesion, migration and survival
   through the suppression of multiple, prenylation dependent signaling
   pathways
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Article
DE angiogenesis; bisphosphonate; mevalonate; signaling; tumor necrosis
   factor
ID TUMOR NECROSIS FACTOR; BREAST CANCER PATIENTS; BISPHOSPHONATES INHIBIT;
   ANGIOGENIC FACTORS; KINASE; ACID; JNK; ACTIVATION; PHOSPHORYLATION;
   ISOPRENYLATION
AB Background: Recent evidence indicates that zoledronate, a nitrogen containing bisphosphonate used to treat conditions of increased bone resorption, may have anti angiogenic activity. The endothelial cells signaling events modulated by zoledronate remain largely elusive. Objectives: The aim of this work was to identify signaling events suppressed by zoledronate in endothelial cells and responsible for some of its biological effects. Methods: Human umbilical vein endothelial cells (HUVEC) were exposed to zoledronate, isoprenoid analogs (i.e. farnesol and geranylgeraniol) and various inhibitors of signaling, and the effect on adhesion, survival, migration, actin cytoskeleton and signaling events characterized. Results: Zoledronate reduced Ras prenylation, Ras and RhoA translocation to the membrane, and sustained ERK1/2 phosphorylation and tumor necrosis factor (TNF) induced JNK phosphorylation. Isoprenoid analogs attenuated zoledronate effects on HUVEC adhesion, actin stress fibers and focal adhesions, migration and survival. Isoprenoid analogs also restored Ras prenylation, RhoA translocation to the membrane, sustained FAK and ERK1/2 phosphorylation and prevented suppression of protein kinase B (PKB) and JNK phosphorylation in HUVEC exposed to TNF in the presence of zoledronate. Pharmacological inhibition of Rock, a RhoA target mediating actin fiber formation, phosphatidylinositol 3 kinase, an activator of PKB, MEK1/2, an activator of ERK1/2, and JNK, recapitulated individual zoledronate effects, consistent with the involvement of these molecules and pathways and their inhibition in the zoledronate effects. Conclusions: This work has demonstrated that zoledronate inhibits HUVEC adhesion, survival, migration and actin stress fiber formation by interfering with protein prenylation and has identified ERK1/2, JNK, Rock, FAK and PKB as kinases affected by zoledronate in a prenylation dependent manner.
C1 Lausanne Canc Ctr, Ctr Pluridisciplinaire Onco, Div Expt Oncol, Epalinges, Switzerland.
   Swiss Inst Expt Canc Res, NCCR Mol Oncol, CH 1066 Epalinges, Switzerland.
C3 Swiss Institute Experimental Cancer Research
RP Rüegg, C (通讯作者)，CePO, 155 Chemin Boveresses, CH 1066 Epalinges, Switzerland.
EM curzio.ruegg@isrec.ch
OI Hasmim, Meriem/0000 0002 7920 2443
CR Bezzi M, 2003, J BIOL CHEM, V278, P43603, DOI 10.1074/jbc.M308114200
   Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006
   Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097 2765(05)00076 6
   Caraglia M, 2005, CURR DRUG TARGETS, V6, P301, DOI 10.2174/1389450053765833
   Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945
   Crick DC, 1997, BIOCHEM BIOPH RES CO, V237, P483, DOI 10.1006/bbrc.1997.7145
   Etienne Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148
   Ferretti G, 2005, ONCOLOGY BASEL, V69, P35, DOI 10.1159/000087286
   Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
   Fournier P, 2002, CANCER RES, V62, P6538
   Galetic I, 1999, PHARMACOL THERAPEUT, V82, P409, DOI 10.1016/S0163 7258(98)00071 0
   Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087
   Graves DT, 2003, J PERIODONTOL, V74, P391, DOI 10.1902/jop.2003.74.3.391
   Hasmim M, 2005, THROMB HAEMOSTASIS, V94, P1060, DOI 10.1160/TH05 02 0108
   Holstein SA, 2002, J BIOL CHEM, V277, P10678, DOI 10.1074/jbc.M111369200
   Homsy JG, 2006, DEV DYNAM, V235, P427, DOI 10.1002/dvdy.20649
   Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745
   Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682
   Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893 901.2001
   Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097 2765(04)00153 4
   Migliorati CA, 2006, LANCET ONCOL, V7, P508, DOI 10.1016/S1470 2045(06)70726 4
   Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877
   Reszka AA, 2001, MOL PHARMACOL, V59, P193, DOI 10.1124/mol.59.2.193
   Reuther Madrid JY, 2002, MOL CELL BIOL, V22, P8175, DOI 10.1128/MCB.22.23.8175 8183.2002
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Santini D, 2003, CLIN CANCER RES, V9, P2893
   Santini D, 2002, CLIN CANCER RES, V8, P1080
   Schaller MD, 2001, BBA MOL CELL RES, V1540, P1, DOI 10.1016/S0167 4889(01)00123 9
   Senaratne SG, 2002, BRIT J CANCER, V86, P1479, DOI 10.1038/sj.bjc.6600297
   Uyen HD, 2002, J CELL SCI, V115, P3073
   Vincenzi B, 2005, J INTERF CYTOK RES, V25, P144, DOI 10.1089/jir.2005.25.144
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325
   Zhao XX, 2002, J BIOL CHEM, V277, P25385, DOI 10.1074/jbc.M203630200
NR 36
TC 79
Z9 92
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1538 7933
EI 1538 7836
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD JAN
PY 2007
VL 5
IS 1
BP 166
EP 173
DI 10.1111/j.1538 7836.2006.02259.x
PG 8
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology; Cardiovascular System & Cardiology
GA 116WP
UT WOS:000242834800024
PM 17059425
OA Bronze
DA 2025 08 17
ER

PT J
AU Chen, W
   Yang, SY
   Abe, Y
   Li, M
   Wang, YC
   Shao, JZ
   Li, E
   Li, YP
AF Chen, Wei
   Yang, Shuying
   Abe, Yoke
   Li, Ming
   Wang, Yucheng
   Shao, Jianzhong
   Li, En
   Li, Yi Ping
TI Novel pycnodysostosis mouse model uncovers cathepsin K function as a
   potential regulator of osteoclast apoptosis and senescence
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID MOLECULAR CLONING; TARGETED DISRUPTION; CYSTEINE PROTEASE;
   BONE RESORPTION; MICE; OSTEOPETROSIS; EXPRESSION; CELLS; DEFICIENT;
   PATHWAYS
AB Pycnodysostosis is a genetic bone disease featuring the unique bone homeostasis disorders of osteolysis and osteopetrosis in the same organism. The pathomechanism for pycnodysostosis has been largely unknown due to the unavailability of a pycnodysostosis mouse model with all the traits of the disease. We generated cathepsin K /  mouse strains in the 129/Sv and C57BL/6J backgrounds and found that, only in the 129/Sv background, cathepsin K /  mice exhibit many characteristics of the human pycnodysostosis like phenotype. Our data indicated that 129/Sv cathepsin K /  osteoclasts (OCs) lacked normal apoptosis and senescence and exhibited over growth both in vitro and in vivo. These abnormalities resulted in an unusually high OC number, which is consistent with a recent case study of human pycnodysostosis. Our results show that cathepsin K function has different effects around the skeleton due to site specific variations in bone homeostasis, such as phenotypes of osteopetrosis in tibiae and osteolysis in calvariae as a result of cathepsin K mutation. Our data demonstrated that the expression levels of p19, p53 and p21 were significantly reduced in 129/Sv cathepsin K /  OCs and forced expression of cathepsin K in pre OCs induced premature senescence and increased expression of p19, p53 and p21. This is the first evidence that cathepsin K plays a key role in OC apoptosis and senescence, revealing the importance of OC senescence in bone homeostasis. The finding of this novel cathepsin K function provides insight into the pathomechanism of pycnodysostosis and may provide new drug targets for diseases involved in OC related abnormal bone homeostasis.
C1 Forsyth Inst, Dept Cytokine Biol, Boston, MA 02115 USA.
   Harvard Univ, Sch Dent Med, Harvard Forsyth Dept Oral Biol, Boston, MA 02115 USA.
   Zhejiang Univ, Life Sci Coll, Hangzhou 310027, Peoples R China.
   Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp,Cardiovasc Res Ctr, Charlestown, MA 02129 USA.
C3 Harvard University; Harvard University Medical Affiliates; Forsyth
   Institute; Harvard University; Harvard School of Dental Medicine;
   Zhejiang University; Harvard University; Harvard University Medical
   Affiliates; Massachusetts General Hospital
RP Li, YP (通讯作者)，Forsyth Inst, Dept Cytokine Biol, 140 Fenway, Boston, MA 02115 USA.
EM ypli@forsyth.org
RI Li, Yi Ping/ABF 9245 2020; Shao, Zongze/T 6682 2017; li,
   en/HPH 8812 2023; Yang, Shuying/G 4599 2011
FU NIAMS NIH HHS [AR 44741, R01 AR048133, R01 AR044741, AR 48133 01]
   Funding Source: Medline; NIA NIH HHS [R01 AG048388] Funding Source:
   Medline; NIDCR NIH HHS [R03 DE016857] Funding Source: Medline
CR Beamer W. G., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P225
   Ben Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013
   BROMME D, 1995, BIOL CHEM H S, V376, P379, DOI 10.1515/bchm3.1995.376.6.379
   Bühling F, 2002, DEV DYNAM, V225, P14, DOI 10.1002/dvdy.10134
   Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003
   Chen H., 1998, THUNDERBIRD INT BUSI, V40, P13, DOI DOI 10.1002/TIE.4270400104
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   EDELSON JG, 1992, CLIN ORTHOP RELAT R, P263
   Everts V, 1999, FASEB J, V13, P1219, DOI 10.1096/fasebj.13.10.1219
   EVERTS V, 1985, CALCIFIED TISSUE INT, V37, P25, DOI 10.1007/BF02557674
   Fratzl Zelman N, 2004, J CLIN ENDOCR METAB, V89, P1538, DOI 10.1210/jc.2003 031055
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Godat E, 2004, BIOCHEM J, V383, P501, DOI 10.1042/BJ20040864
   Goulet B, 2004, MOL CELL, V14, P207, DOI 10.1016/S1097 2765(04)00209 6
   Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654
   Helfrich MH, 2003, MICROSC RES TECHNIQ, V61, P514, DOI 10.1002/jemt.10375
   Ho N, 1999, J BONE MINER RES, V14, P1649, DOI 10.1359/jbmr.1999.14.10.1649
   Imbronito AV, 2002, BIOMATERIALS, V23, P4079, DOI 10.1016/S0142 9612(02)00145 X
   INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013
   Johnson MR, 1996, GENOME RES, V6, P1050, DOI 10.1101/gr.6.11.1050
   KAMEDA T, 1995, BIOCHEM BIOPH RES CO, V207, P753, DOI 10.1006/bbrc.1995.1251
   Kiviranta R, 2005, BONE, V36, P159, DOI 10.1016/j.bone.2004.09.020
   LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293
   Lange AW, 2006, DEV BIOL, V292, P407, DOI 10.1016/j.ydbio.2006.01.017
   Li CY, 2006, J BONE MINER RES, V21, P865, DOI 10.1359/JBMR.060313
   LI E, 1992, CELL, V69, P915, DOI 10.1016/0092 8674(92)90611 F
   LI YP, 1993, MOL CELL BIOL, V13, P3714, DOI 10.1128/MCB.13.6.3714
   Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563
   LI YP, 1995, J BONE MINER RES, V10, P1197
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298
   Motyckova Gabriela, 2002, Current Molecular Medicine (Hilversum), V2, P407, DOI 10.2174/1566524023362401
   Pritchard CA, 1996, CURR BIOL, V6, P614, DOI 10.1016/S0960 9822(02)00548 1
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   SHI GP, 1995, FEBS LETT, V357, P129, DOI 10.1016/0014 5793(94)01349 6
   Singh Arvind Rup, 2004, Indian Journal of Pediatrics, V71, P453, DOI 10.1007/BF02725641
   SMITHIES O, 1993, TRENDS GENET, V9, P112, DOI 10.1016/0168 9525(93)90204 U
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Steingrimsson E, 2002, P NATL ACAD SCI USA, V99, P4477, DOI 10.1073/pnas.072071099
   TEZUKA K, 1994, J BIOL CHEM, V269, P1106
   Varela I, 2005, NATURE, V437, P564, DOI 10.1038/nature04019
   Wang Q, 2003, J CELL BIOL, V160, P565, DOI 10.1083/jcb.200207036
   Weilbaecher KN, 2001, MOL CELL, V8, P749, DOI 10.1016/S1097 2765(01)00360 4
   Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097 2765(00)00109 X
NR 45
TC 100
Z9 110
U1 0
U2 13
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964 6906
EI 1460 2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD FEB 15
PY 2007
VL 16
IS 4
BP 410
EP 423
DI 10.1093/hmg/ddl474
PG 14
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 135AO
UT WOS:000244126400006
PM 17210673
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Wang, TY
   Qiao, H
   Zhai, ZJ
   Zhang, J
   Tu, JW
   Zheng, XY
   Qian, ND
   Zhou, H
   Lu, EY
   Tang, TT
AF Wang, Tingyu
   Qiao, Han
   Zhai, Zanjing
   Zhang, Jun
   Tu, Jinwen
   Zheng, Xinyi
   Qian, Niandong
   Zhou, Hong
   Lu, Eryi
   Tang, Tingting
TI 被撤回的出版物: Plumbagin Ameliorates Collagen Induced Arthritis by Regulating
   Treg/Th17 Cell Imbalances and Suppressing Osteoclastogenesis (Retracted
   Article)
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article; Retracted Publication
DE inflammation; plumbagin; arthritis; Th17 cells; osteoclast
ID BREAST CANCER CELLS; FACTOR KAPPA B; T CELLS; CYTOKINE; BONE;
   INHIBITION; ACTIVATION; INDUCTION; DIFFERENTIATION; INTERLEUKIN 17
AB Objective: Plumbago zeylanica L. (with plumbagin as its active ingredients) has been used for centuries to treat conditions such as joint swelling, fractures, and bacterial infections, suggesting that it possesses anti inflammatory and immunosuppressive properties. In the present study, we evaluated the potential anti arthritic activity and related mechanisms of plumbagin.
   Methods: Collagen induced arthritis (CIA) was initiated in Wistar rats with collagen type II. Plumbagin (2 and 6 mg/kg) was orally administered to rats with CIA from day 12 to day 32 post immunization. The effects of plumbagin on arthritis progression were assessed by paw swelling, clinical scoring, and histologic analysis. The percentage of Treg and Th17 were defined by flow cytometry or immunofluorescence (IF) staining. Bone erosion and resorption were assessed by micro CT and histomorphometric analysis. Osteoclast differentiation was further determined by in vitro osteoclastogenesis assay. The molecular docking assay was used to determine the potential binding site of plumbagin.
   Results: Treatment with plumbagin significantly inhibited arthritis development, as well as suppressed the local and systemic inflammation. Plumbagin reciprocally regulated pro inflammatory Th17 cell and immunosuppressive Treg cell populations. In addition, plumbagin protected inflammation induced bone loss by inhibiting osteoclast formation and activity. Plumbagin markedly suppressed RANKL stimulated osteoclast specific gene expression by repressing NF kappa B signaling activation and MAP kinase phosphorylation. Further study via molecular docking assay demonstrated that plumbagin bound to MET169 of JNK kinase and LYS138 and SER183 of p38 kinase.
   Conclusion: Plumbagin not only attenuates the immune induced arthritis by inhibiting inflammation, but also protects bone erosion by directly inhibiting osteoclast formation and activity. These data suggest plumbagin is a promising new candidate drug for treating inflammatory joint diseases.
C1 [Wang, Tingyu] Shanghai Jiao Tong Univ, Shanghai Ninth Peoples Hosp, Sch Med, Dept Pharm, Shanghai, Peoples R China.
   [Qiao, Han; Zhai, Zanjing; Tang, Tingting] Shanghai Jiao Tong Univ, Shanghai Ninth Peoples Hosp, Sch Med, Dept Orthopaed Surg,Shanghai Key Lab Orthopaed Im, Shanghai, Peoples R China.
   [Zhang, Jun] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA.
   [Tu, Jinwen; Zhou, Hong] Univ Sydney, ANZAC Res Inst, Bone Res Program, Sydney, NSW, Australia.
   [Zheng, Xinyi; Lu, Eryi] Shanghai Jiao Tong Univ, Shanghai Renji Hosp, Sch Med, Dept Stomatol, Shanghai, Peoples R China.
   [Qian, Niandong] Shanghai Inst Traumatol & Orthopaed, Dept Orthopaed Surg, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; University
   of Texas System; UTMD Anderson Cancer Center; University of Sydney;
   ANZAC Research Institute; Shanghai Jiao Tong University
RP Wang, TY (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Ninth Peoples Hosp, Sch Med, Dept Pharm, Shanghai, Peoples R China.; Tang, TT (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Ninth Peoples Hosp, Sch Med, Dept Orthopaed Surg,Shanghai Key Lab Orthopaed Im, Shanghai, Peoples R China.; Lu, EY (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Renji Hosp, Sch Med, Dept Stomatol, Shanghai, Peoples R China.
EM drtywang@163.com; lueryi222@126.com; ttt@sjtu.edu.cn
RI Zhang, Jun/U 2902 2018; zhang, xuyang/GQH 3712 2022
OI Zhang, Jun/0000 0001 6990 5324; Zhou, Hong/0000 0001 5899 9660; Lu,
   Eryi/0000 0002 0045 2571; 
FU National Natural Science Foundation of China (NSFC) [81874011, 81572104,
   81301531]; Shanghai Municipal Science and Commission [18140903502]
FX This work was supported by National Natural Science Foundation of China
   (NSFC) (grant # 81874011, 81572104, and 81301531) to TW. This work was
   also partially supported by the Innovation Grant from Shanghai Municipal
   Science and Commission (grant #18140903502) to TW.
CR Adamopoulos IE, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2936
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Bae KJ, 2016, BIOCHEM BIOPH RES CO, V473, P272, DOI 10.1016/j.bbrc.2016.03.092
   Cao DJ, 2004, ARTHRITIS RES THER, V6, pR335, DOI 10.1186/ar1192
   Chabaud M, 1999, ARTHRITIS RHEUM US, V42, P963, DOI 10.1002/1529 0131(199905)42:5<963::AID ANR15>3.0.CO;2 E
   Chabaud M, 2001, ARTHRITIS RES, V3, P168, DOI 10.1186/ar294
   Checker R, 2010, J CELL BIOCHEM, V110, P1082, DOI 10.1002/jcb.22620
   Checker R, 2009, INT IMMUNOPHARMACOL, V9, P949, DOI 10.1016/j.intimp.2009.03.022
   Cooles FAH, 2013, CURR RHEUMATOL REP, V15, DOI 10.1007/s11926 013 0352 0
   Eastaff Leung N, 2010, J CLIN IMMUNOL, V30, P80, DOI 10.1007/s10875 009 9345 1
   Felcenloben I, 2015, IMMUNOTHERAPY UK, V7, P215, DOI [10.2217/imt.14.121, 10.2217/IMT.14.121]
   Katayama M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062231
   Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432
   Lamontain V, 2019, CELL MOL IMMUNOL, V16, P65, DOI 10.1038/cmi.2017.138
   Luo P, 2010, J PHARMACOL EXP THER, V335, P735, DOI 10.1124/jpet.110.170852
   Metawi SA, 2011, CLIN RHEUMATOL, V30, P1201, DOI 10.1007/s10067 011 1737 y
   Moon SJ, 2014, ARTHRITIS RHEUMATOL, V66, P874, DOI 10.1002/art.38310
   Nair RS, 2016, SCI REP UK, V6, DOI 10.1038/srep26631
   Nakae S, 2003, J IMMUNOL, V171, P6173, DOI 10.4049/jimmunol.171.11.6173
   Picerno V, 2015, CLIN EXP RHEUMATOL, V33, P551
   Pöllinger B, 2011, J IMMUNOL, V186, P2602, DOI 10.4049/jimmunol.1003370
   Poosarla A, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472 6882 11 114
   Qiao H, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.11
   Qiao H, 2015, ACTA PHARMACOL SIN, V36, P1085, DOI 10.1038/aps.2015.42
   Sadik CD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026342
   Sandur SK, 2006, J BIOL CHEM, V281, P17023, DOI 10.1074/jbc.M601595200
   Sheeja E, 2010, PHARM BIOL, V48, P381, DOI 10.3109/13880200903156424
   Sitara D, 2010, IMMUNOL REV, V233, P286, DOI 10.1111/j.0105 2896.2009.00849.x
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Wang L, 2018, CELL MOL IMMUNOL, V15, P685, DOI 10.1038/cmi.2017.20
   Wang TY, 2015, KOREAN J PHYSIOL PHA, V19, P83, DOI 10.4196/kjpp.2015.19.2.83
   Wang TY, 2014, FOOD CHEM TOXICOL, V64, P177, DOI 10.1016/j.fct.2013.11.027
   Wu HJ, 2010, IMMUNITY, V32, P815, DOI 10.1016/j.immuni.2010.06.001
   Xiao F, 2015, EXP CELL RES, V330, P91, DOI 10.1016/j.yexcr.2014.07.005
   Yan W, 2013, BONE RES, V1, P362, DOI 10.4248/BR201304007
   Yan W, 2014, ACTA PHARMACOL SIN, V35, P124, DOI 10.1038/aps.2013.152
NR 36
TC 15
Z9 17
U1 2
U2 20
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JAN 8
PY 2019
VL 9
AR 3102
DI 10.3389/fimmu.2018.03102
PG 14
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA HG6YP
UT WOS:000455134700001
PM 30671063
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Coloma, PM
   de Ridder, M
   Bezemer, I
   Herings, RMC
   Gini, R
   Pecchioli, S
   Scotti, L
   Rijnbeek, P
   Mosseveld, M
   van der Lei, J
   Trifirò, G
   Sturkenboom, M
AF Coloma, P. M.
   de Ridder, M.
   Bezemer, I.
   Herings, R. M. C.
   Gini, R.
   Pecchioli, S.
   Scotti, L.
   Rijnbeek, P.
   Mosseveld, M.
   van der Lei, J.
   Trifiro, G.
   Sturkenboom, M.
CA EU ADR Consortium
TI Risk of cardiac valvulopathy with use of bisphosphonates: a
   population based, multi country case control study
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Bisphosphonates; Cardiac valve disorders; Cardiac valve regurgitation;
   Drug induced valvular heart disease; Drug induced valvulopathy
ID VALVULAR HEART DISEASE; METHYSERGIDE THERAPY; VALVE REGURGITATION;
   OSTEOPOROSIS; COHORT
AB Analyses of healthcare data from 30 million individuals in three countries showed that current use of bisphosphonates may be associated with a small increased risk of cardiac valvulopathy (vs. those not exposed within the previous year), although confounding cannot be entirely ruled out. The observed tendency for decreased valvulopathy risk with cumulative duration of bisphosphonate use > 6 months may even indicate a protective effect with prolonged use. Further studies are still needed to evaluate whether bisphosphonates increase or decrease the risk of valvulopathy.
   A signal of cardiac valve disorders with use of bisphosphonates was identified in the literature and EudraVigilance database, which contains reports of suspected adverse drug reactions from worldwide sources. The aim of this study was to evaluate the association using population based healthcare data.
   This was a case control study among users of bisphosphonates and other drugs for osteoporosis in six healthcare databases covering over 30 million individuals in Italy, Netherlands and the UK from 1996 to 2012. Prescriptions/dispensations were used to assess drug exposure. Newly diagnosed cases of cardiac valvulopathy were identified via disease codes/free text search. Controls were matched to each case by age, sex, database and index date. Adjusted odds ratios (ORs) were estimated using conditional logistic regression for the pooled data and meta analysis of individual database risk estimates.
   A small but statistically significant association was found between exposure to bisphosphonates as a class and risk of valvulopathy. Overall risk was 18 % higher (95 % CI 12 23 %) in those currently exposed to any bisphosphonate (mainly alendronate and risedronate) vs. those not exposed within the previous year. Risk of valve regurgitation was 14 % higher (95 % CI 7 22 %). Decreased valvulopathy risk was observed with longer cumulative duration of bisphosphonate use, compared to use of less than 6 months. Meta analyses of database specific estimates confirmed results from pooled analyses.
   The observed increased risks of cardiac valvulopathy with bisphosphonate use, although statistically significant, were quite small and unlikely to be clinically significant. Further studies are still needed to evaluate whether bisphosphonates increase or decrease the risk of valvulopathy and to investigate possible mechanisms for the association.
C1 [Coloma, P. M.; de Ridder, M.; Rijnbeek, P.; Mosseveld, M.; van der Lei, J.; Trifiro, G.; Sturkenboom, M.] Erasmus MC Univ, Dept Med Informat, Med Ctr Rotterdam, NL 3000 CA Rotterdam, Netherlands.
   [Bezemer, I.; Herings, R. M. C.] PHARMO Inst NV, NL 3528 AE Utrecht, Netherlands.
   [Gini, R.] Agenzia Reg Sanita Toscana, I 50141 Florence, Italy.
   [Pecchioli, S.] Soc Italiana Med Gen, I 50141 Florence, Italy.
   [Scotti, L.] Univ Milano Bicocca, I 20126 Milan, Italy.
   [Trifiro, G.] Univ Messina, Dept Clin & Expt Med, I 98122 Messina, Italy.
C3 Erasmus University Rotterdam; Erasmus MC; University of Milano Bicocca;
   University of Messina
RP Coloma, PM (通讯作者)，Erasmus MC Univ, Dept Med Informat, Med Ctr Rotterdam, NL 3000 CA Rotterdam, Netherlands.
EM p.coloma@erasmusmc.nl
RI ; Gini, Rosa/HKN 4067 2023; Scotti, Lorenza/AAB 9544 2019; Trifiro,
   Gianluca/K 9744 2016; Herings, Ron/AAE 4096 2021
OI Mosseveld, Mees/0000 0001 9301 8565; Sturkenboom,
   Miriam/0000 0003 1360 2388; Gini, Rosa/0000 0002 6250 877X; 
CR Aksoy O, 2012, J AM COLL CARDIOL, V59, P1452, DOI 10.1016/j.jacc.2012.01.024
   Andrejak M, 2013, ARCH CARDIOVASC DIS, V106, P333, DOI 10.1016/j.acvd.2013.02.003
   [Anonymous], 2013, EUDRAVIGILANCE HUM A
   Barchielli A, 2007, INT J CARDIOL, V114, P57, DOI 10.1016/j.ijcard.2006.01.006
   Bevilacqua M, 2005, LUPUS, V14, P773, DOI 10.1191/0961203305lu2219oa
   Bhattacharyya S, 2009, LANCET, V374, P577, DOI 10.1016/S0140 6736(09)60252 X
   Bunch TJ, 2009, AM J CARDIOL, V103, P824, DOI 10.1016/j.amjcard.2008.11.037
   Camm AJ, 2010, CLIN THER, V32, P426, DOI 10.1016/j.clinthera.2010.03.014
   Coloma PM, 2012, PHARMACOEPIDEM DR S, V21, P611, DOI 10.1002/pds.3197
   Coloma PM, 2011, PHARMACOEPIDEM DR S, V20, P1, DOI 10.1002/pds.2053
   Corrao G, 2008, ANN ONCOL, V19, P150, DOI 10.1093/annonc/mdm404
   Corvol JC, 2007, ARCH NEUROL CHICAGO, V64, P1721, DOI 10.1001/archneur.64.12.1721
   Cosyns B, 2013, HEART, V99, P7, DOI 10.1136/heartjnl 2012 302239
   d'Arcy JL, 2011, HEART, V97, P91, DOI 10.1136/hrt.2010.205096
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Dweck MR, 2012, J AM COLL CARDIOL, V60, P1027, DOI 10.1016/j.jacc.2012.04.048
   Elmariah S, 2010, CARDIOLOGY, V117, P229, DOI 10.1159/000322902
   Elmariah S, 2010, J AM COLL CARDIOL, V56, P1752, DOI 10.1016/j.jacc.2010.05.050
   Fiore C E, 2009, J Endocrinol Invest, V32, P38
   Gardin JM, 2000, JAMA J AM MED ASSOC, V283, P1703, DOI 10.1001/jama.283.13.1703
   Goettsch WG, 2007, PHARMACOEPIDEM DR S, V16, P166, DOI 10.1002/pds.1245
   GRAHAM JR, 1967, AM J MED SCI, V254, P1
   GRAHAM JR, 1966, NEW ENGL J MED, V274, P359, DOI 10.1056/NEJM196602172740701
   Grove EL, 2013, J INTERN MED, V274, P342, DOI 10.1111/joim.12087
   Gueffet JP, 2010, ARCH CARDIOVASC DIS, V103, P342, DOI 10.1016/j.acvd.2009.09.015
   Jick H, 1998, NEW ENGL J MED, V339, P719, DOI 10.1056/NEJM199809103391102
   Le Ven F, 2011, EUR J ECHOCARDIOGR, V12, P265, DOI 10.1093/ejechocard/jeq172
   Mazzaglia G, 2005, J HYPERTENS, V23, P2093, DOI 10.1097/01.hjh.0000186832.41125.8a
   MISCH KA, 1974, BRIT MED J, V2, P365, DOI 10.1136/bmj.2.5915.365
   Mohler ER, 1999, J HEART VALVE DIS, V8, P254
   O'Connell MB, 2006, J MANAGE CARE PHARM, V12, pS10, DOI 10.18553/jmcp.2006.12.S6 A.S10
   O'Connell MB, 2006, J MANAG CARE PHAR SA, V12, pS26
   Persy V, 2009, TRENDS MOL MED, V15, P405, DOI 10.1016/j.molmed.2009.07.001
   Reynolds K, 2013, OSTEOPOROSIS INT, V24, P2509, DOI 10.1007/s00198 013 2326 5
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Schade R, 2007, NEW ENGL J MED, V356, P29, DOI 10.1056/NEJMoa062222
   Seghatol FF, 2002, CURR OPIN CARDIOL, V17, P486, DOI 10.1097/00001573 200209000 00007
   Smeeth L, 2009, BRIT J CLIN PHARMACO, V67, P99, DOI 10.1111/j.1365 2125.2008.03308.x
   Trifirò G, 2012, DRUG SAFETY, V35, P159, DOI 10.2165/11594940 000000000 00000
   Vieira Helena Parente, 2013, Int Arch Med, V6, P24, DOI 10.1186/1755 7682 6 24
   Vlug AE, 1999, METHOD INFORM MED, V38, P339
NR 41
TC 8
Z9 7
U1 0
U2 3
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD MAY
PY 2016
VL 27
IS 5
BP 1857
EP 1867
DI 10.1007/s00198 015 3441 2
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DJ9WU
UT WOS:000374564800020
PM 26694594
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Hirohata, S
   Tomita, T
   Yoshikawa, H
   Kyogoku, M
AF Hirohata, Shunsei
   Tomita, Tetsuya
   Yoshikawa, Hideki
   Kyogoku, Masahisa
TI TNF inhibitors induce discoid fibrosis in the sublining layers of the
   synovium with degeneration of synoviocytes in rheumatoid arthritis
SO RHEUMATOLOGY INTERNATIONAL
LA English
DT Article
DE Infliximab; Etanercept; Synovium; Histology; Fibrosis; Osteoclast
ID NECROSIS FACTOR ALPHA; BONE MARROW; ENDOTHELIAL CELLS; DENDRITIC CELLS;
   ANGIOGENESIS; MECHANISMS; THERAPY
AB We determined the characteristic features of synovial tissues of rheumatoid arthritis (RA) patients treated by TNF inhibitors in order to delineate their mechanism of action. Synovial tissues were obtained during the joint surgical operations from 12 RA patients who had been treated with TNF inhibitors in addition to disease modifying antirheumatic drugs (DMARDs) for at least 5 months (5 25 months) (RA TNFinh), and from 12 RA patients who had been treated with DMARDs alone (RA DMARD), and were evaluated under light microscopy. There were no significant differences in disease duration, serum CRP levels, DAS28, Steinbrocker's stages on X ray and treatment regimen except for TNF inhibitors between RA TNFinh and RA DMARD. The most prominent changes in the synovium from RA TNFinh were discoid fibrosis in the subliming layers of the synovium with degeneration and detachment of synoviocytes and marked decrease in vasculatures. There was no significant difference in these synovial features between RA patients with infliximab and those with etanercept. Interestingly, appearance of osteoclasts was observed in RA TNFinh (3 out of 12 patients) and in RA DMARD (1 out of 12 patients). These results indicate that not only infliximab, but etanercept might have direct actions on synovial cells in the deep lining layers of the synovium, leading to the discoid fibrosis thereof. Moreover, the data confirm that the deep lining or sublining layers of the synovium are the most important portions that steer the disease process of RA synovitis.
C1 [Hirohata, Shunsei] Kitasato Univ, Sch Med, Dept Rheumatol & Infect Dis, Minami Ku, Sagamihara, Kanagawa 2520374, Japan.
   [Tomita, Tetsuya; Yoshikawa, Hideki] Osaka Univ, Sch Med, Suita, Osaka 5650871, Japan.
   [Kyogoku, Masahisa] Tohoku Univ, Dept Pathol, Sch Med, Sendai, Miyagi 9808575, Japan.
C3 Kitasato University; University of Osaka; Tohoku University
RP Hirohata, S (通讯作者)，Kitasato Univ, Sch Med, Dept Rheumatol & Infect Dis, Minami Ku, 1 15 1 Kitasato, Sagamihara, Kanagawa 2520374, Japan.
EM shunsei_tenpoint@yahoo.co.jp
FU Eisai Co., Tokyo; Mitsubishi Tanabe Pharma Co., Tokyo; Takeda
   Pharmaceutical Co., Tokyo Japan; Grants in Aid for Scientific Research
   [22591685, 23591447] Funding Source: KAKEN
FX This work was supported by grants from Eisai Co., Tokyo, Mitsubishi
   Tanabe Pharma Co., Tokyo, and Takeda Pharmaceutical Co., Tokyo Japan.
CR ARNETT FC, 1988, ARTHRITIS RHEUM US, V31, P315, DOI 10.1002/art.1780310302
   BURMESTER GR, 1983, RHEUMATOL INT, V3, P173, DOI 10.1007/BF00541597
   Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163
   Firestein GS, 1996, ARTHRITIS RHEUM, V39, P1781, DOI 10.1002/art.1780391103
   HIROHATA KAZUSHI, 1964, KOBE J MED SCI, V10, P195
   Hirohata S, 1999, LANCET, V353, P1331, DOI 10.1016/S0140 6736(98)05912 1
   Hirohata S, 2004, ARTHRITIS RHEUM US, V50, P3888, DOI 10.1002/art.20729
   Hirohata S, 2001, J LEUKOCYTE BIOL, V70, P413
   Hirohata S, 2011, CLIN IMMUNOL, V140, P276, DOI 10.1016/j.clim.2011.04.008
   Izquierdo E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008131
   Koch AE, 1998, ARTHRITIS RHEUM US, V41, P951, DOI 10.1002/1529 0131(199806)41:6<951::AID ART2>3.0.CO;2 D
   Kyogoku M, 1992, Nihon Rinsho, V50, P483
   LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0
   Maini Ravinder N, 2002, Arthritis Res, V4 Suppl 2, pS22, DOI 10.1186/ar549
   Mitoma H, 2008, ARTHRITIS RHEUM US, V58, P1248, DOI 10.1002/art.23447
   Sainson RCA, 2008, BLOOD, V111, P4997, DOI 10.1182/blood 2007 08 108597
   Tak PP., 2000, RHEUMATOID ARTHRITIS, P55
   Takita Chikahiro, 2005, Mod Rheumatol, V15, P97, DOI 10.1007/s10165 004 0373 7
   Tejima S, 2012, P JPN SOC IMMUNOL, V41, P156
   THOMAS R, 1994, J IMMUNOL, V152, P2613
   Tracey D, 2008, PHARMACOL THERAPEUT, V117, P244, DOI 10.1016/j.pharmthera.2007.10.001
   Varani K, 2010, BRIT J PHARMACOL, V160, P101, DOI 10.1111/j.1476 5381.2010.00667.x
NR 22
TC 5
Z9 9
U1 0
U2 5
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 0172 8172
EI 1437 160X
J9 RHEUMATOL INT
JI Rheumatol. Int.
PD OCT
PY 2013
VL 33
IS 10
BP 2473
EP 2481
DI 10.1007/s00296 013 2743 y
PG 9
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 223RC
UT WOS:000324824500003
PM 23575549
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Sorrell, FJ
   Szklarz, M
   Azeez, KRA
   Elkins, JM
   Knapp, S
AF Sorrell, Fiona J.
   Szklarz, Marta
   Azeez, Kamal R. Abdul
   Elkins, Jon M.
   Knapp, Stefan
TI Family wide Structural Analysis of Human Numb Associated Protein Kinases
SO STRUCTURE
LA English
DT Article
ID ADAPTER ASSOCIATED KINASE; INHIBITOR AZD7762; AAK1; CHECKPOINT;
   IDENTIFICATION; ACTIVATION; MECHANISM; ENDOCYTOSIS; SELECTIVITY;
   ABROGATION
AB The highly diverse Numb associated kinase (NAK) family has been linked to broad cellular functions including receptor mediated endocytosis, Notch pathway modulation, osteoblast differentiation, and dendrite morphogenesis. Consequently, NAK kinases play a key role in a diverse range of diseases from Parkinson's and prostate cancer to HIV. Due to the plasticity of this kinase family, NAK kinases are often inhibited by approved or investigational drugs and have been associated with side effects, but they are also potential drug targets. The presence of cysteine residues in some NAK family members provides the possibility for selective targeting via covalent inhibition. Here we report the first high resolution structures of kinases AAK1 and BIKE in complex with two drug candidates. The presented data allow a comprehensive structural characterization of the NAK kinase family and provide the basis for rational design of selective NAK inhibitors.
C1 [Sorrell, Fiona J.; Szklarz, Marta; Azeez, Kamal R. Abdul; Elkins, Jon M.; Knapp, Stefan] Univ Oxford, Nuffield Dept Clin Med, Struct Genom Consortium, Old Rd Campus,Roosevelt Dr, Oxford OX3 7DQ, England.
   [Sorrell, Fiona J.; Szklarz, Marta; Azeez, Kamal R. Abdul; Elkins, Jon M.; Knapp, Stefan] Univ Oxford, Target Discovery Inst, Old Rd Campus,Roosevelt Dr, Oxford OX3 7DQ, England.
   [Knapp, Stefan] Goethe Univ Frankfurt, Inst Pharmaceut Chem, Buchmann Inst Life Sci Campus Riedberg, D 60438 Frankfurt, Germany.
C3 University of Oxford; University of Oxford; Goethe University Frankfurt
RP Knapp, S (通讯作者)，Univ Oxford, Nuffield Dept Clin Med, Struct Genom Consortium, Old Rd Campus,Roosevelt Dr, Oxford OX3 7DQ, England.; Knapp, S (通讯作者)，Univ Oxford, Target Discovery Inst, Old Rd Campus,Roosevelt Dr, Oxford OX3 7DQ, England.; Knapp, S (通讯作者)，Goethe Univ Frankfurt, Inst Pharmaceut Chem, Buchmann Inst Life Sci Campus Riedberg, D 60438 Frankfurt, Germany.
EM knapp@pharmchem.uni frankfurt.de
RI Knapp, Stefan/AAG 2347 2019
OI Elkins, Jon/0000 0003 2858 8929; Knapp, Stefan/0000 0001 5995 6494;
   Sorrell, Fiona/0000 0001 9211 5590
FU SGC; AbbVie; Bayer; Boehringer Ingelheim; Canada Foundation for
   Innovation; Canadian Institutes for Health Research; Genome Canada;
   GlaxoSmithKline; Janssen; Lilly Canada; Novartis Research Foundation;
   Ontario Ministry of Economic Development and Innovation; Pfizer; Takeda;
   Wellcome Trust [092809/Z/10/Z]
FX We thank the Diamond Light Source for assistance with crystallographic
   data collection. The authors are grateful for financial support by the
   SGC, a registered charity (number 1097737) that receives funds from
   AbbVie, Bayer, Boehringer Ingelheim, the Canada Foundation for
   Innovation, the Canadian Institutes for Health Research, Genome Canada,
   GlaxoSmithKline, Janssen, Lilly Canada, the Novartis Research
   Foundation, the Ontario Ministry of Economic Development and Innovation,
   Pfizer, Takeda, and the Wellcome Trust (092809/Z/10/Z).
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Ashwell S, 2008, EXPERT OPIN INV DRUG, V17, P1331, DOI [10.1517/13543784.17.9.1331, 10.1517/13543784.17.9.1331 ]
   Beilina A, 2014, P NATL ACAD SCI USA, V111, P2626, DOI 10.1073/pnas.1318306111
   Borner GHH, 2012, J CELL BIOL, V197, P141, DOI 10.1083/jcb.201111049
   Brown PH, 2006, BIOPHYS J, V90, P4651, DOI 10.1529/biophysj.106.081372
   Cai Z, 2009, MOL CELL, V35, P818, DOI 10.1016/j.molcel.2009.09.007
   Chaikuad A, 2014, BIOCHEM J, V459, P59, DOI 10.1042/BJ20131399
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Conner SD, 2003, J CELL BIOL, V162, P773, DOI 10.1083/jcb.200304069
   Conner SD, 2003, TRAFFIC, V4, P885, DOI 10.1046/j.1398 9219.2003.0142.x
   Conner SD, 2002, J CELL BIOL, V156, P921, DOI 10.1083/jcb.200108123
   Cowtan K, 2006, ACTA CRYSTALLOGR D, V62, P1002, DOI 10.1107/S0907444906022116
   Dawson MA, 2010, BRIT J HAEMATOL, V150, P46, DOI 10.1111/j.1365 2141.2010.08175.x
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Eswaran J, 2008, STRUCTURE, V16, P115, DOI 10.1016/j.str.2007.10.026
   Fedorov O, 2012, METHODS MOL BIOL, V795, P109, DOI 10.1007/978 1 61779 337 0_7
   Gao YH, 2013, BIOCHEM J, V451, P313, DOI 10.1042/BJ20121418
   Grabauskiene S, 2014, J SURG RES, V187, P6, DOI 10.1016/j.jss.2013.12.016
   Gupta Rossi N, 2011, J BIOL CHEM, V286, P18720, DOI 10.1074/jbc.M110.190769
   Jackson AP, 2003, J CELL BIOL, V163, P231, DOI 10.1083/jcb.200304079
   Kooistra AJ, 2016, NUCLEIC ACIDS RES, V44, pD365, DOI 10.1093/nar/gkv1082
   Kornev AP, 2010, BBA PROTEINS PROTEOM, V1804, P440, DOI 10.1016/j.bbapap.2009.10.017
   Krieger JR, 2013, MOL CELL PROTEOMICS, V12, P499, DOI 10.1074/mcp.M112.020768
   Kuai LT, 2011, CHEM BIOL, V18, P891, DOI 10.1016/j.chembiol.2011.03.017
   Landau HJ, 2012, MOL CANCER THER, V11, P1781, DOI 10.1158/1535 7163.MCT 11 0949
   Leslie AGW, 2007, NATO SCI SER II MATH, V245, P41, DOI 10.1007/978 1 4020 6316 9_4
   Liu HP, 2009, J CLIN LAB ANAL, V23, P362, DOI 10.1002/jcla.20344
   Longenecker KL, 2001, ACTA CRYSTALLOGR D, V57, P679, DOI 10.1107/S0907444901003122
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Morgan MA, 2010, CANCER RES, V70, P4972, DOI 10.1158/0008 5472.CAN 09 3573
   Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255
   Neveu G, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002845
   Norman P, 2014, EXPERT OPIN INV DRUG, V23, P1067, DOI 10.1517/13543784.2014.918604
   Ohori M, 2007, BIOCHEM BIOPH RES CO, V353, P633, DOI 10.1016/j.bbrc.2006.12.083
   Pardanani A, 2009, LEUKEMIA, V23, P1441, DOI 10.1038/leu.2009.50
   Perrett RM, 2015, MOL CELL NEUROSCI, V66, P21, DOI 10.1016/j.mcn.2015.02.009
   Sakurai MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100124
   Shi BX, 2014, INT J MOL SCI, V15, P22918, DOI 10.3390/ijms151222918
   Smythe E, 2003, EMBO REP, V4, P246, DOI 10.1038/sj.embor.embor776
   Sorensen EB, 2008, TRAFFIC, V9, P1791, DOI 10.1111/j.1600 0854.2008.00790.x
   Stairs DB, 2005, TRANSGENIC RES, V14, P919, DOI 10.1007/s11248 005 1806 6
   Susa M, 2010, MOL CANCER THER, V9, P3342, DOI 10.1158/1535 7163.MCT 10 0637
   Tabara H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026034
   Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419
   Ultanir SK, 2012, NEURON, V73, P1127, DOI 10.1016/j.neuron.2012.01.019
   van Vollenhoven RF, 2013, CURR OPIN RHEUMATOL, V25, P391, DOI 10.1097/BOR.0b013e32835fd828
   Wang G, 2012, PROG NEUROBIOL, V98, P207, DOI 10.1016/j.pneurobio.2012.06.003
   Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749
   Wu JQ, 2013, ACS CHEM BIOL, V8, P643, DOI 10.1021/cb3005897
   Zabludoff SD, 2008, MOL CANCER THER, V7, P2955, DOI 10.1158/1535 7163.MCT 08 0492
   Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559
   Zhang KYJ, 1997, METHOD ENZYMOL, V277, P53, DOI 10.1016/S0076 6879(97)77006 X
   Zhou HL, 2008, CELL HOST MICROBE, V4, P495, DOI 10.1016/j.chom.2008.10.004
NR 53
TC 104
Z9 110
U1 0
U2 17
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0969 2126
EI 1878 4186
J9 STRUCTURE
JI Structure
PD MAR 1
PY 2016
VL 24
IS 3
BP 401
EP 411
DI 10.1016/j.str.2015.12.015
PG 11
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA DI5VJ
UT WOS:000373568300008
PM 26853940
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Weidauer, E
   Yasuda, Y
   Biswal, BK
   Cherny, M
   James, MNG
   Brömme, D
AF Weidauer, Enrico
   Yasuda, Yoshiyuki
   Biswal, Bichitra K.
   Cherny, Maia
   James, Michael N. G.
   Bromme, Dieter
TI Effects of disease modifying anti rheumatic drugs (DMARDs) on the
   activities of rheumatoid arthritis associated cathepsins K and S
SO BIOLOGICAL CHEMISTRY
LA English
DT Article
DE cathepsin K; cathepsin S; cysteine protease inhibitor; gold; rheumatoid
   arthritis
ID LYSOSOMAL CYSTEINE PROTEASES; BONE RESORPTION; CLASS II; COLLAGEN; GOLD;
   OSTEOCLASTS; INHIBITION; PYCNODYSOSTOSIS; LOCALIZATION; PHAGOCYTOSIS
AB Rheumatoid arthritis is an inflammatory and disabling joint disease affecting 0.5 1.5% of the population. Although various anti inflammatory (NSAIDs) and disease modifying (DMARDs) drugs are in clinical use, their precise mechanisms of action are not always defined. In this report, we discuss the effects of widely used DMARDs such as gold derivatives and chloroquine on cathepsins K and S, which have been implicated as critical mediators of inflammation and joint erosion in rheumatoid arthritis. We demonstrate that clinically potent gold derivatives inhibit cathepsins K and S in in vitro and cell based assays. An X ray analysis of the gold thiomalate/cathepsin K complex reveals that the inhibitor is bound to the active site cysteine residue of the protease. Chloroquine, a lysosomotropic agent of lower clinical potency than gold derivatives, inhibits neutral pH labile cathepsins intracellularly, but does not affect the neutral pH stable cathepsin S. The potent inhibition of cathepsins implicated in the pathogenesis of rheumatoid arthritis by gold derivatives may explain the therapeutic efficacy of these drugs.
C1 CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA.
   Univ Alberta, Dept Biochem, CIHR Grp Prot Struct & Funct, Edmonton, AB T6G 2H7, Canada.
C3 Icahn School of Medicine at Mount Sinai; City University of New York
   (CUNY) System; University of Alberta
RP Brömme, D (通讯作者)，CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA.
EM dbromme@interchange.ubc.ca
OI Biswal, Bichitra/0000 0002 5927 3244
FU NIAMS NIH HHS [AR46182] Funding Source: Medline
CR BAICI A, 1984, BIOCHEM PHARMACOL, V33, P1859, DOI 10.1016/0006 2952(84)90540 9
   Barrera P, 1996, SEMIN ARTHRITIS RHEU, V25, P234, DOI 10.1016/S0049 0172(96)80035 7
   BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189
   Bau R, 1998, J AM CHEM SOC, V120, P9380, DOI 10.1021/ja9819763
   Brömme D, 2004, METHODS, V32, P199, DOI 10.1016/S1046 2023(03)00212 3
   Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126
   BROMME D, 1995, BIOL CHEM H S, V376, P379, DOI 10.1515/bchm3.1995.376.6.379
   Brune K, 2003, INFLAMMATION AND RHEUMATIC DISEASES: THE MOLECULAR BASIS OF NOVEL THERAPIES, P69
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254
   Chircorian A, 2004, BIOORG MED CHEM LETT, V14, P5113, DOI 10.1016/j.bmcl.2004.07.073
   Conaghan Philip G., 1995, Current Opinion in Rheumatology, V7, P167, DOI 10.1097/00002281 199505000 00003
   DENZIN LK, 1994, IMMUNITY, V1, P595, DOI 10.1016/1074 7613(94)90049 3
   Doan T, 2005, J CLIN PHARMACOL, V45, P751, DOI 10.1177/0091270005277938
   ESSER RE, 1993, J RHEUMATOL, V20, P1176
   ESSER RE, 1994, ARTHRITIS RHEUM, V37, P236, DOI 10.1002/art.1780370213
   EVERTS V, 1985, CALCIFIED TISSUE INT, V37, P25, DOI 10.1007/BF02557674
   Everts V, 1996, HISTOCHEM J, V28, P229, DOI 10.1007/BF02409011
   Everts V, 2003, CALCIFIED TISSUE INT, V73, P380, DOI 10.1007/s00223 002 2092 4
   FELSON DT, 1990, ARTHRITIS RHEUM US, V33, P1449, DOI 10.1002/art.1780331001
   FRASER TN, 1945, ANN RHEUM DIS, V4, P71, DOI 10.1136/ard.4.4.71
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Gunatilleke SS, 2006, J MED CHEM, V49, P3933, DOI 10.1021/jm060158f
   Hall TJ, 1996, INFLAMM RES, V45, P230, DOI 10.1007/BF02259608
   Hou WS, 2002, ARTHRITIS RHEUM, V46, P663, DOI 10.1002/art.10114
   Hou WS, 2001, AM J PATHOL, V159, P2167, DOI 10.1016/S0002 9440(10)63068 4
   KIRSCHKE H, 1989, BIOCHEM J, V264, P467, DOI 10.1042/bj2640467
   KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Nakagawa TY, 1999, IMMUNITY, V10, P207, DOI 10.1016/S1074 7613(00)80021 7
   PALMER JT, 1995, J MED CHEM, V38, P3193, DOI 10.1021/jm00017a002
   Punturieri A, 2000, J EXP MED, V192, P789, DOI 10.1084/jem.192.6.789
   Rau R, 1997, BRIT J RHEUMATOL, V36, P345
   Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074 7613(00)80249 6
   Sanders M, 2000, J RHEUMATOL, V27, P523
   Sfikakis PP, 1996, CLIN IMMUNOL IMMUNOP, V79, P43, DOI 10.1006/clin.1996.0049
   Simon LS, 2000, RHEUMATOLOGY, V39, P36, DOI 10.1093/oxfordjournals.rheumatology.a031493
   Xia LH, 1999, BIOL CHEM, V380, P679, DOI 10.1515/BC.1999.084
   Yamashita Masamichi, 2003, Current Drug Targets   Inflammation and Allergy, V2, P216, DOI 10.2174/1568010033484142
   Yasuda Y, 2005, ADV DRUG DELIVER REV, V57, P973, DOI 10.1016/j.addr.2004.12.013
NR 39
TC 51
Z9 55
U1 0
U2 16
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D 10785 BERLIN, GERMANY
SN 1431 6730
EI 1437 4315
J9 BIOL CHEM
JI Biol. Chem.
PD MAR
PY 2007
VL 388
IS 3
BP 331
EP 336
DI 10.1515/BC.2007.037
PG 6
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 145EE
UT WOS:000244847300010
PM 17338641
DA 2025 08 17
ER

PT J
AU Son, JH
   Park, BS
   Kim, IR
   Sung, IY
   Cho, YC
   Kim, JS
   Kim, YD
AF Son, Jang Ho
   Park, Bong Soo
   Kim, In Ryoung
   Sung, Iel Yong
   Cho, Yeong Cheol
   Kim, Jung Soo
   Kim, Yong Deok
TI A novel combination treatment to stimulate bone healing and regeneration
   under hypoxic conditions: photobiomodulation and melatonin
SO LASERS IN MEDICAL SCIENCE
LA English
DT Article
DE Bone; Differentiation; Receptor; Cytokines; Cell membrane
ID PROMOTES OSTEOBLAST DIFFERENTIATION; INTENSITY LASER IRRADIATION;
   MESENCHYMAL STEM CELLS; PROTEIN KINASE D; PROLIFERATION; ACTIVATION;
   RECEPTORS; RADIATION; THERAPY; MITOCHONDRIA
AB Melatonin has anabolic effects on the bone, even under hypoxia, and laser irradiation has been shown to improve osteoblastic differentiation. The aim of this study was to investigate whether laser irradiation and melatonin would have synergistic effects on osteoblastic differentiation and mineralization under hypoxic conditions. MC3T3 E1 cells were exposed to 1% oxygen tension for the hypoxia condition. The cells were divided into four groups: G1 osteoblast differentiation medium only (as the hypoxic condition), G2 treatment with 50 mu M melatonin only, G3 laser irradiation (808 nm, 80 mW, GaAlAs diode) only, and G4 treatment with 50 mu M melatonin and laser irradiation (808 nm, 80 mW, GaAlAs diode). Immunoblotting showed that osterix expression was markedly increased in the melatonin treated and laser irradiated cells at 48 and 72 h. In addition, alkaline phosphatase activity significantly increased and continued to rise throughout the experiment. Alizarin Red staining showed markedly increased mineralized nodules as compared with only melatonin treated or laser irradiated cells at day 7, which significantly increased by day 14. Moreover, when melatonin treated cells were laser irradiated, the differentiation and mineralization of cells were found to involve p38 MAPK and PRKD1 signaling mechanisms. However, the enhanced effects of laser irradiation with melatonin were markedly inhibited when the cells were treated with luzindole, a selective melatonin receptor antagonist. Therefore, we concluded that laser irradiation could promote the effect of melatonin on the differentiation and mineralization of MC3T3 E1 cells under hypoxic conditions, and that this process is mediated through melatonin 1/2 receptors and PKRD/p38 signaling pathways.
C1 [Son, Jang Ho; Sung, Iel Yong; Cho, Yeong Cheol; Kim, Jung Soo] Univ Ulsan, Coll Med, Dept Oral & Maxillofacial Surg, Ulsan Univ Hosp, Ulsan, South Korea.
   [Park, Bong Soo; Kim, In Ryoung] Pusan Natl Univ, Sch Dent, Dept Oral Anat, Yangsan, South Korea.
   [Kim, Yong Deok] Pusan Natl Univ, Sch Dent, Dept Oral & Maxillofacial Surg, Yangsan, South Korea.
   [Kim, Yong Deok] Pusan Natl Univ, Dent Hosp, Dent Res Inst, Yangsan, South Korea.
   [Kim, Yong Deok] Pusan Natl Univ, Dent Hosp, Inst Translat Dent Sci, Yangsan, South Korea.
   [Kim, Yong Deok] Pusan Natl Univ, Dent Hosp, Dept Oral & Maxillofacial Surg, Yangsan 626770, Kyoungnam, South Korea.
C3 University of Ulsan; Ulsan University Hospital; Pusan National
   University; Pusan National University Hospital; Pusan National
   University; Pusan National University Hospital; Pusan National
   University; Pusan National University Hospital; Pusan National
   University; Pusan National University Hospital; Pusan National
   University; Pusan National University Hospital
RP Kim, YD (通讯作者)，Pusan Natl Univ, Sch Dent, Dept Oral & Maxillofacial Surg, Yangsan, South Korea.; Kim, YD (通讯作者)，Pusan Natl Univ, Dent Hosp, Dent Res Inst, Yangsan, South Korea.; Kim, YD (通讯作者)，Pusan Natl Univ, Dent Hosp, Inst Translat Dent Sci, Yangsan, South Korea.; Kim, YD (通讯作者)，Pusan Natl Univ, Dent Hosp, Dept Oral & Maxillofacial Surg, Yangsan 626770, Kyoungnam, South Korea.
EM ydkimdds@pusan.ac.kr
RI Kim, In Ryoung/AGF 2385 2022; Kim, YongDeok/JLM 4590 2023
FU National Research Foundation of Korea [NRF2015R1D1A3A01016667]
FX This study was supported by the National Research Foundation of Korea
   (NRF2015R1D1A3A01016667).
CR Aleksic V, 2010, LASER MED SCI, V25, P559, DOI 10.1007/s10103 010 0761 5
   AlGhamdi KM, 2012, LASER MED SCI, V27, P237, DOI 10.1007/s10103 011 0885 2
   Amstrup AK, 2013, OSTEOPOROSIS INT, V24, P2919, DOI 10.1007/s00198 013 2404 8
   Bilezikian J.P., 2008, Principles of Bone Biology
   Celil AB, 2005, J BIOL CHEM, V280, P31353, DOI 10.1074/jbc.M503845200
   Cipolla Neto J, 2014, J PINEAL RES, V56, P371, DOI 10.1111/jpi.12137
   Cury V, 2013, J PHOTOCH PHOTOBIO B, V125, P164, DOI 10.1016/j.jphotobiol.2013.06.004
   Cuschieri J, 2005, CRIT CARE MED, V33, pS417, DOI 10.1097/01.CCM.0000191714.39495.A6
   Dröge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001
   Ekmekcioglu C, 2006, BIOMED PHARMACOTHER, V60, P97, DOI 10.1016/j.biopha.2006.01.002
   Gao XJ, 2009, J BIOMED SCI, V16, DOI 10.1186/1423 0127 16 4
   Karu TI, 2004, PHOTOCH PHOTOBIO SCI, V3, P211, DOI 10.1039/b306126d
   Khadra M, 2005, BIOMATERIALS, V26, P3503, DOI 10.1016/j.biomaterials.2004.09.033
   Kimira Y, 2014, BIOCHEM BIOPH RES CO, V453, P498, DOI 10.1016/j.bbrc.2014.09.121
   Komarova SV, 2000, AM J PHYSIOL CELL PH, V279, pC1220, DOI 10.1152/ajpcell.2000.279.4.C1220
   Kujawa J, 2004, J CLIN LASER MED SUR, V22, P111, DOI 10.1089/104454704774076163
   Kujawa J, 2014, LASER MED SCI, V29, P1663, DOI 10.1007/s10103 014 1571 y
   Kushibiki T, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/974864
   Laakso L, 1993, Aust J Physiother, V39, P95, DOI 10.1016/S0004 9514(14)60473 6
   Lemonnier J, 2004, J BIOL CHEM, V279, P259, DOI 10.1074/jbc.M308665200
   Liu JB, 2016, ANNU REV PHARMACOL, V56, P361, DOI 10.1146/annurev pharmtox 010814 124742
   López A, 2009, J PINEAL RES, V46, P188, DOI 10.1111/j.1600 079X.2008.00647.x
   Migliario M, 2014, LASER MED SCI, V29, P1463, DOI 10.1007/s10103 014 1556 x
   Miyata H, 2006, INT ENDOD J, V39, P238, DOI 10.1111/j.1365 2591.2006.01080.x
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nishio Y, 2006, GENE, V372, P62, DOI 10.1016/j.gene.2005.12.022
   Nissan J, 2006, J ORAL REHABIL, V33, P619, DOI 10.1111/j.1365 2842.2006.01601.x
   Oliveira DAAP, 2008, PHOTOMED LASER SURG, V26, P401, DOI 10.1089/pho.2007.2101
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   Radio NM, 2006, J PINEAL RES, V40, P332, DOI 10.1111/j.1600 079X.2006.00318.x
   Reiter RJ, 2000, NEWS PHYSIOL SCI, V15, P246
   Rola P, 2014, ADV CLIN EXP MED, V23, P835, DOI 10.17219/acem/37263
   Roth JA, 1999, J BIOL CHEM, V274, P22041, DOI 10.1074/jbc.274.31.22041
   Saygun I, 2012, PHOTOMED LASER SURG, V30, P149, DOI 10.1089/pho.2011.3079
   Semenza GL, 2009, PHYSIOLOGY, V24, P97, DOI 10.1152/physiol.00045.2008
   Shimizu N, 2007, LASER SURG MED, V39, P551, DOI 10.1002/lsm.20521
   Silva AN, 2002, J CLIN LASER MED SUR, V20, P83, DOI 10.1089/104454702753768061
   Son JH, 2014, J PINEAL RES, V57, P385, DOI 10.1111/jpi.12177
   Stehle JH, 2011, J PINEAL RES, V51, P17, DOI 10.1111/j.1600 079X.2011.00856.x
   Taylor CT, 2008, BIOCHEM J, V409, P19, DOI 10.1042/BJ20071249
   Theodoro LH, 2006, J PERIODONTAL RES, V41, P381, DOI 10.1111/j.1600 0765.2005.00846.x
   Wu SN, 2009, J CELL PHYSIOL, V218, P603, DOI 10.1002/jcp.21636
   Yilmaz S, 2006, TOXICOLOGY, V222, P1, DOI 10.1016/j.tox.2006.02.008
   Zhang L, 2014, ADV MECH ENG, DOI 10.1155/2014/371673
NR 44
TC 19
Z9 21
U1 0
U2 15
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268 8921
EI 1435 604X
J9 LASER MED SCI
JI Lasers Med. Sci.
PD APR
PY 2017
VL 32
IS 3
BP 533
EP 541
DI 10.1007/s10103 017 2145 6
PG 9
WC Engineering, Biomedical; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Surgery
GA ER3RU
UT WOS:000398716200006
PM 28091848
DA 2025 08 17
ER

PT J
AU Subia, B
   Dey, T
   Sharma, S
   Kundu, SC
AF Subia, Bano
   Dey, Tuli
   Sharma, Shaily
   Kundu, Subhas C.
TI Target Specific Delivery of Anticancer Drug in Silk Fibroin Based 3D
   Distribution Model of Bone Breast Cancer Cells
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE silk fibroin; 3D in vitro model; coculture; drug delivery; bone
   metastasis
ID IN VITRO; TUMOR MODEL; STEM CELLS; CULTURE; VIVO; NANOPARTICLES;
   COMBINATION; SCAFFOLD; PROTEIN; SYSTEM
AB To avoid the indiscriminating action of anti cancer drugs, the cancer cell specific targeting of drug molecule becomes a preferred choice for the treatment. The successful screening of the drug molecules in 2D culture system requires further validation. The failure of target specific drug in animal model raises the issue of creating a platform in between the in vitro (2D) and in vivo animal testing. The metastatic breast cancer cells migrate and settle at different sites such as bone tissue. This work evaluates the in vitro 3D model of the breast cancer and bone cells to understand the cellular interactions in the presence of a targeted anticancer drug delivery system. The silk fibroin based cytocompatible 3D scaffold is used as in vitro 3D distribution model. Human breast adenocarcinoma and osteoblast like cells are cocultured to evaluate the efficiency of doxorubicin loaded folic acid conjugated silk fibroin nanoparticle as drug delivery system. Decreasing population of the cancer cells, which lower the levels of vascular endothelial growth factors, glucose consumption, and lactate production are observed in the drug treated coculture constructs. The drug treated constructs do not show any major impact on bone mineralization. The diminished expression of osteogenic markers such as osteocalcein and alkaline phosphatase are recorded. The result indicates that this type of silk based 3D in vitro coculture model may be utilized as a bridge between the traditional 2D and animal model system to evaluate the new drug molecule (s) or to reassay the known drug molecules or to develop target specific drug in cancer research.
C1 [Subia, Bano; Dey, Tuli; Sharma, Shaily; Kundu, Subhas C.] Indian Inst Technol, Dept Biotechnol, Kharagpur 721302, W Bengal, India.
C3 Indian Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT)   Kharagpur
RP Kundu, SC (通讯作者)，Indian Inst Technol, Dept Biotechnol, Kharagpur 721302, W Bengal, India.
EM kundu@hijli.iitkgp.ernet.in
RI Kundu, Subhas C/AAC 1317 2020
OI Dey, Tuli/0000 0003 0413 0729; Kundu, Subhas C./0000 0002 7170 2291
FU Indian Council of Medical Research and Department of Biotechnology,
   Govt. of India
FX This work is financially supported by the Indian Council of Medical
   Research and Department of Biotechnology, Govt. of India.
CR Baker E. L., 2010, BIOPHYS J, V99
   Birgersdotter A, 2005, SEMIN CANCER BIOL, V15, P405, DOI 10.1016/j.semcancer.2005.06.009
   Chen MW, 2012, INT J NANOMED, V7, P4285, DOI 10.2147/IJN.S33083
   Dhiman HK, 2005, BIOMATERIALS, V26, P979, DOI 10.1016/j.biomaterials.2004.04.012
   Du CL, 2013, BIOMATERIALS, V34, P3087, DOI 10.1016/j.biomaterials.2013.01.041
   Dunne LW, 2014, BIOMATERIALS, V35, P4940, DOI 10.1016/j.biomaterials.2014.03.003
   El Dakdouki MH, 2014, ACS APPL MATER INTER, V6, P697, DOI 10.1021/am404946v
   Fantozzi A, 2014, CANCER RES, V74, P1566, DOI 10.1158/0008 5472.CAN 13 1641
   Fischbach C, 2007, NAT METHODS, V4, P855, DOI 10.1038/NMETH1085
   Gao W, 2013, BIOMATERIALS, V34, P4137, DOI 10.1016/j.biomaterials.2013.02.014
   Godugu C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053708
   Gupta V, 2011, ANN BIOMED ENG, V39, P2374, DOI 10.1007/s10439 011 0335 0
   Horning JL, 2008, MOL PHARMACEUT, V5, P849, DOI 10.1021/mp800047v
   Huang Wei Chih, 2012, Int J Bioinform Res Appl, V8, P192, DOI 10.1504/IJBRA.2012.048965
   Johnson A. W., 2011, ANTICANCER RES, V31, P3237
   Kim JB, 2005, SEMIN CANCER BIOL, V15, P365, DOI 10.1016/j.semcancer.2005.05.002
   Kleinman HK, 2005, SEMIN CANCER BIOL, V15, P378, DOI 10.1016/j.semcancer.2005.05.004
   Lee ES, 2005, J CONTROL RELEASE, V103, P405, DOI 10.1016/j.jconrel.2004.12.018
   Lescarbeau RM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040372
   Ma J, 2008, MOL CANCER THER, V7, P3670, DOI 10.1158/1535 7163.MCT 08 0715
   Ma L, 2012, BIOMATERIALS, V33, P4353, DOI 10.1016/j.biomaterials.2012.02.054
   Magnusson P, 1998, CLIN CHEM, V44, P1621
   Mandal BB, 2008, BIOTECHNOL BIOENG, V100, P1237, DOI 10.1002/bit.21835
   Mandal BB, 2009, ACTA BIOMATER, V5, P2579, DOI 10.1016/j.actbio.2009.02.033
   Marlow R, 2013, CANCER RES, V73, P6886, DOI 10.1158/0008 5472.CAN 13 0991
   McKnight AL, 2002, AM J ROENTGENOL, V178, DOI 10.2214/ajr.178.6.1781411
   Nyga A, 2011, J CELL COMMUN SIGNAL, V5, P239, DOI 10.1007/s12079 011 0132 4
   Paulos CM, 2004, MOL PHARMACOL, V66, P1406, DOI 10.1124/mol.104.003723
   Provenzale JM, 2009, AM J NEURORADIOL, V30, P1293, DOI 10.3174/ajnr.A1590
   Ricketts KPM, 2014, SMALL, V10, P3954, DOI 10.1002/smll.201400194
   Sarkar B, 2009, CHEM REV, V109, P3200, DOI 10.1021/cr9000397
   She WC, 2013, BIOMATERIALS, V34, P2252, DOI 10.1016/j.biomaterials.2012.12.017
   Shin C. S., 2013, MOL PHARM, V10, P102
   Shinoda T, 1998, J PHARM SCI, V87, P1521, DOI 10.1021/js980215v
   Sieh S., 2014, BONE S, VS8, P756
   Sieh S, 2014, BONE, V63, P121, DOI 10.1016/j.bone.2014.02.001
   Song H., 2013, BIOMED RES INT, V723, P158
   Subia B, 2013, NANOTECHNOLOGY, V24, DOI 10.1088/0957 4484/24/3/035103
   Subia B, 2014, INTEGR BIOL UK, V6, P203, DOI 10.1039/c3ib40184g
   Szot CS, 2011, BIOMATERIALS, V32, P7905, DOI 10.1016/j.biomaterials.2011.07.001
   Talukdar S, 2013, ADV FUNCT MATER, V23, P5249, DOI 10.1002/adfm.201300312
   Talukdar S, 2012, ADV FUNCT MATER, V22, P4778, DOI 10.1002/adfm.201200375
   Talukdar S, 2011, BIOMATERIALS, V32, P2149, DOI 10.1016/j.biomaterials.2010.11.052
   Wang NN, 2010, NEPHRON EXP NEPHROL, V115, pE60, DOI 10.1159/000313831
   Weigelt B, 2008, SEMIN CANCER BIOL, V18, P311, DOI 10.1016/j.semcancer.2008.03.013
   Xu S, 2013, ADV DRUG DELIVER REV, V65, P121, DOI 10.1016/j.addr.2012.09.041
   Yang S. J., 2010, J BIOCONJUGATE CHEM, V21, P667
   Yoo HS, 2004, J CONTROL RELEASE, V96, P273, DOI 10.1016/j.jconrel.2004.02.003
   Zhang M, 2013, INT J BIOMATER, V2013, DOI 10.1155/2013/396056
   Zhang Y, 2011, SMALL, V7, P3261, DOI 10.1002/smll.201100597
   Zhao Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.60
   Zhao Y, 2014, BIOFABRICATION, V6, DOI 10.1088/1758 5082/6/3/035001
   Zwicke GL, 2012, NANO REV EXP, V3, DOI 10.3402/nano.v3i0.18496
NR 53
TC 70
Z9 77
U1 1
U2 95
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
EI 1944 8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD FEB 4
PY 2015
VL 7
IS 4
BP 2269
EP 2279
DI 10.1021/am506094c
PG 11
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA CA7ZW
UT WOS:000349137300018
PM 25557227
DA 2025 08 17
ER

EF